Inclusion NCT03931772 0 9 O
Criteria NCT03931772 10 18 O
: NCT03931772 19 20 O

- NCT03931772 24 25 O
18 NCT03931772 27 29 B-Eq-Comparison
years NCT03931772 30 35 I-Eq-Comparison
or NCT03931772 36 38 I-Eq-Comparison
older NCT03931772 39 44 I-Eq-Comparison

- NCT03931772 47 48 O
Able NCT03931772 50 54 O
to NCT03931772 55 57 O
read NCT03931772 58 62 O
and NCT03931772 63 66 O
understand NCT03931772 67 77 O
English NCT03931772 78 85 O

- NCT03931772 88 89 O
Desire NCT03931772 91 97 B-Assertion___Assertion-Type-Value:intention
to NCT03931772 98 100 I-Assertion___Assertion-Type-Value:intention
quit NCT03931772 101 105 B-Condition
smoking NCT03931772 106 113 I-Condition
( NCT03931772 114 115 O
specifically NCT03931772 116 128 O
, NCT03931772 129 130 O
report NCT03931772 131 137 O
a NCT03931772 138 139 O
motivation NCT03931772 140 150 B-Modifier
of NCT03931772 151 153 O
≥ NCT03931772 154 155 B-Eq-Comparison
5 NCT03931772 156 157 I-Eq-Comparison
out NCT03931772 158 161 I-Eq-Comparison
of NCT03931772 162 164 I-Eq-Comparison
10 NCT03931772 165 167 I-Eq-Comparison
to NCT03931772 168 170 O
quit NCT03931772 171 175 B-Condition|Observation
smoking NCT03931772 176 183 I-Condition|Observation
on NCT03931772 184 186 O
a NCT03931772 187 188 O
10 NCT03931772 189 191 O
- NCT03931772 192 193 O
point NCT03931772 194 199 O
Likert NCT03931772 200 206 O
- NCT03931772 207 208 O
type NCT03931772 209 213 O
scale NCT03931772 214 219 O
) NCT03931772 220 221 O

- NCT03931772 225 226 O
Having NCT03931772 228 234 O
access NCT03931772 235 241 O
to NCT03931772 242 244 O
wireless NCT03931772 245 253 O
internet NCT03931772 254 262 O
connection NCT03931772 263 273 O
or NCT03931772 274 276 O
mobile NCT03931772 277 283 O
data NCT03931772 284 288 O

- NCT03931772 291 292 O
Reporting NCT03931772 294 303 O
being NCT03931772 304 309 O
a NCT03931772 310 311 O
daily NCT03931772 312 317 B-Eq-Comparison
smoker NCT03931772 318 324 B-Condition
for NCT03931772 325 328 O
at NCT03931772 329 331 B-Eq-Comparison
least NCT03931772 332 337 I-Eq-Comparison
one NCT03931772 338 341 I-Eq-Comparison
year NCT03931772 342 346 I-Eq-Comparison
, NCT03931772 347 348 O
smoking NCT03931772 349 356 B-Condition|Observation
an NCT03931772 357 359 O
average NCT03931772 360 367 B-Eq-Comparison
≥ NCT03931772 368 369 I-Eq-Comparison
5 NCT03931772 370 371 I-Eq-Comparison
cigarettes NCT03931772 372 382 I-Eq-Comparison
per NCT03931772 383 386 I-Eq-Comparison
day NCT03931772 387 390 I-Eq-Comparison

Exclusion NCT03931772 391 400 O
Criteria NCT03931772 401 409 O
: NCT03931772 410 411 O

- NCT03931772 415 416 O
Meeting NCT03931772 418 425 O
criteria NCT03931772 426 434 O
for NCT03931772 435 438 O
drug NCT03931772 439 443 B-Condition
abuse NCT03931772 444 449 I-Condition
of NCT03931772 450 452 O
depressants NCT03931772 453 464 B-Drug
, NCT03931772 465 466 O
dissociative NCT03931772 467 479 B-Drug
anesthetics NCT03931772 480 491 I-Drug
, NCT03931772 492 493 O
hallucinogens NCT03931772 494 507 B-Drug
, NCT03931772 508 509 O
opioids NCT03931772 510 517 B-Drug
, NCT03931772 518 519 O
cocaine NCT03931772 520 527 B-Drug
, NCT03931772 528 529 O
or NCT03931772 530 532 O
amphetamine NCT03931772 533 544 B-Drug
within NCT03931772 545 551 B-Eq-Comparison
the NCT03931772 552 555 I-Eq-Comparison
last NCT03931772 556 560 I-Eq-Comparison
3 NCT03931772 561 562 I-Eq-Comparison
months NCT03931772 563 569 I-Eq-Comparison
. NCT03931772 570 571 O

- NCT03931772 575 576 O
Severe NCT03931772 578 584 O
psychiatric NCT03931772 585 596 B-Modifier
or NCT03931772 597 599 B-Or
structural NCT03931772 600 610 B-Modifier
brain NCT03931772 611 616 B-Condition
disease NCT03931772 617 624 I-Condition
( NCT03931772 625 626 O
i. NCT03931772 627 629 O
e. NCT03931772 630 632 O
psychosis NCT03931772 634 643 B-Condition
, NCT03931772 644 645 O
stroke NCT03931772 646 652 B-Condition
with NCT03931772 653 657 B-And
functional NCT03931772 658 668 B-Condition
impairment NCT03931772 669 679 I-Condition
, NCT03931772 680 681 O
dementia NCT03931772 682 690 B-Condition
) NCT03931772 691 692 O
or NCT03931772 693 695 B-Or
[ NCT03931772 696 697 O
current NCT03931772 698 705 B-Eq-Comparison
/ NCT03931772 706 707 B-Or
recent NCT03931772 708 714 B-Eq-Comparison
risk NCT03931772 715 719 B-Condition
to NCT03931772 720 722 I-Condition
self NCT03931772 723 727 I-Condition
. NCT03931772 727 728 O
Indicated NCT03931772 730 739 O
by NCT03931772 740 742 O
denial NCT03931772 743 749 O
of NCT03931772 750 752 O
question NCT03931772 753 761 O
pertaining NCT03931772 762 772 O
to NCT03931772 773 775 O
inpatient NCT03931772 776 785 B-Encounter
hospitalization NCT03931772 786 801 I-Encounter

- NCT03931772 804 805 O
Hearing NCT03931772 807 814 B-Condition
impairment NCT03931772 815 825 I-Condition
that NCT03931772 826 830 O
would NCT03931772 831 836 B-Assertion___Assertion-Type-Value:hypothetical
impede NCT03931772 837 843 O
ability NCT03931772 844 851 O
to NCT03931772 852 854 O
listen NCT03931772 855 861 O
the NCT03931772 862 865 O
auditory NCT03931772 866 874 B-Modifier
intervention NCT03931772 875 887 B-Study

- NCT03931772 890 891 O
Major NCT03931772 893 898 O
illnesses NCT03931772 899 908 B-Condition
impacting NCT03931772 909 918 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03931772 919 922 O
study NCT03931772 923 928 B-Study
results NCT03931772 929 936 O

- NCT03931772 939 940 O
Currently NCT03931772 942 951 B-Eq-Comparison
taking NCT03931772 952 958 I-Eq-Comparison
Wellbutrin NCT03931772 959 969 B-Drug
, NCT03931772 970 971 O
Chantix NCT03931772 972 979 B-Drug
, NCT03931772 980 981 O
or NCT03931772 982 984 B-Or
other NCT03931772 985 990 O
pharmacological NCT03931772 991 1006 O
smoking NCT03931772 1007 1014 B-Drug
cessation NCT03931772 1015 1024 I-Drug
aids NCT03931772 1025 1029 I-Drug
that NCT03931772 1030 1034 O
could NCT03931772 1035 1040 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03931772 1041 1049 O
results NCT03931772 1050 1057 O
of NCT03931772 1058 1060 O
the NCT03931772 1061 1064 O
study NCT03931772 1065 1070 B-Study

Inclusion NCT03931941 0 9 O
Criteria NCT03931941 10 18 O
: NCT03931941 19 20 O

1 NCT03931941 24 25 O
. NCT03931941 25 26 O
≥ NCT03931941 28 29 B-Eq-Comparison
18 NCT03931941 30 32 I-Eq-Comparison
years NCT03931941 33 38 I-Eq-Comparison
old NCT03931941 39 42 B-Age
. NCT03931941 43 44 O

2 NCT03931941 48 49 O
. NCT03931941 49 50 O
Medical NCT03931941 52 59 O
record NCT03931941 60 66 O
documentation NCT03931941 67 80 O
of NCT03931941 81 83 O
either NCT03931941 84 90 O
: NCT03931941 91 92 O
a NCT03931941 93 94 O
) NCT03931941 95 96 O
recurrent NCT03931941 97 106 B-Modifier
CDI NCT03931941 107 110 B-Condition
per NCT03931941 111 114 O
the NCT03931941 115 118 O
study NCT03931941 119 124 O
definition NCT03931941 125 135 O
, NCT03931941 136 137 O
that NCT03931941 138 142 O
includes NCT03931941 143 151 O
at NCT03931941 152 154 B-Eq-Comparison
least NCT03931941 155 160 I-Eq-Comparison
one NCT03931941 161 164 I-Eq-Comparison
recurrence NCT03931941 165 175 B-Coreference
after NCT03931941 176 181 B-Temporal-Connection___Temporal-Connection-Type-Value:after
a NCT03931941 182 183 O
primary NCT03931941 184 191 O
episode NCT03931941 192 199 B-Coreference
and NCT03931941 200 203 O
has NCT03931941 204 207 O
completed NCT03931941 208 217 O
at NCT03931941 218 220 B-Eq-Comparison
least NCT03931941 221 226 I-Eq-Comparison
one NCT03931941 227 230 I-Eq-Comparison
round NCT03931941 231 236 O
of NCT03931941 237 239 O
standard NCT03931941 240 248 O
- NCT03931941 249 250 O
of NCT03931941 251 253 O
- NCT03931941 254 255 O
care NCT03931941 256 260 O
oral NCT03931941 261 265 B-Procedure
antibiotic NCT03931941 266 276 I-Procedure
therapy NCT03931941 277 284 I-Procedure
, NCT03931941 285 286 O
b NCT03931941 287 288 O
) NCT03931941 289 290 O
or NCT03931941 291 293 B-Or
has NCT03931941 294 297 O
had NCT03931941 298 301 O
at NCT03931941 302 304 B-Eq-Comparison
least NCT03931941 305 310 I-Eq-Comparison
two NCT03931941 311 314 I-Eq-Comparison
episodes NCT03931941 315 323 O
of NCT03931941 324 326 O
severe NCT03931941 327 333 O
CDI NCT03931941 334 337 B-Condition
resulting NCT03931941 338 347 O
in NCT03931941 348 350 O
hospitalization NCT03931941 351 366 B-Encounter
. NCT03931941 367 368 O

3 NCT03931941 372 373 O
. NCT03931941 373 374 O
A NCT03931941 376 377 O
positive NCT03931941 378 386 O
stool NCT03931941 387 392 B-Observation
test NCT03931941 393 397 I-Observation
for NCT03931941 398 401 O
the NCT03931941 402 405 O
presence NCT03931941 406 414 O
of NCT03931941 415 417 O
toxigenic NCT03931941 418 427 B-Organism
C. NCT03931941 428 430 I-Organism
difficile NCT03931941 432 441 I-Organism
or NCT03931941 442 444 B-Or
C. NCT03931941 445 447 O
difficile NCT03931941 449 458 O
toxin NCT03931941 459 464 I-Organism
within NCT03931941 465 471 B-Eq-Comparison
30 NCT03931941 472 474 I-Eq-Comparison
days NCT03931941 475 479 I-Eq-Comparison
prior NCT03931941 480 485 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03931941 486 488 I-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03931941 489 491 O
on NCT03931941 492 494 O
the NCT03931941 495 498 O
date NCT03931941 499 503 O
of NCT03931941 504 506 O
enrollment NCT03931941 507 517 B-Study
. NCT03931941 518 519 O

4 NCT03931941 523 524 O
. NCT03931941 524 525 O
Is NCT03931941 527 529 O
currently NCT03931941 530 539 B-Eq-Comparison
taking NCT03931941 540 546 O
or NCT03931941 547 549 B-Or
was NCT03931941 550 553 O
just NCT03931941 554 558 B-Eq-Comparison
prescribed NCT03931941 559 569 O
antibiotics NCT03931941 570 581 B-Drug
to NCT03931941 582 584 O
control NCT03931941 585 592 O
CDI NCT03931941 593 596 B-Condition
related NCT03931941 597 604 O
diarrhea NCT03931941 605 613 B-Condition
at NCT03931941 614 616 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03931941 617 620 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03931941 621 625 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03931941 626 628 O
enrollment NCT03931941 629 639 B-Study
. NCT03931941 640 641 O

[ NCT03931941 644 645 O
Note NCT03931941 646 650 O
: NCT03931941 651 652 O
Subject NCT03931941 653 660 O
's NCT03931941 660 662 O
CDI NCT03931941 663 666 B-Condition
diarrhea NCT03931941 667 675 B-Condition
must NCT03931941 676 680 O
be NCT03931941 681 683 O
controlled NCT03931941 684 694 O
( NCT03931941 695 696 O
< NCT03931941 698 699 B-Eq-Comparison
3 NCT03931941 700 701 I-Eq-Comparison
unformed NCT03931941 702 710 I-Eq-Comparison
/ NCT03931941 711 712 I-Eq-Comparison
loose NCT03931941 713 718 I-Eq-Comparison
stools NCT03931941 719 725 I-Eq-Comparison
/ NCT03931941 726 727 I-Eq-Comparison
day NCT03931941 728 731 I-Eq-Comparison
) NCT03931941 732 733 O
while NCT03931941 734 739 B-Temporal-Connection___Temporal-Connection-Type-Value:during

taking NCT03931941 740 746 B-Eq-Comparison
antibiotics NCT03931941 747 758 B-Drug
during NCT03931941 759 765 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03931941 766 775 B-Study
. NCT03931941 775 776 O
] NCT03931941 777 778 O

Exclusion NCT03931941 780 789 O
Criteria NCT03931941 790 798 O
: NCT03931941 799 800 O

1 NCT03931941 804 805 O
. NCT03931941 805 806 O
Has NCT03931941 808 811 O
continued NCT03931941 812 821 O
CDI NCT03931941 822 825 B-Condition
diarrhea NCT03931941 826 834 B-Condition
despite NCT03931941 835 842 O
being NCT03931941 843 848 O
on NCT03931941 849 851 O
a NCT03931941 852 853 O
course NCT03931941 854 860 O
of NCT03931941 861 863 O
antibiotics NCT03931941 864 875 B-Drug
prescribed NCT03931941 876 886 O
for NCT03931941 887 890 O
CDI NCT03931941 891 894 B-Condition
treatment NCT03931941 895 904 O
. NCT03931941 905 906 O

2 NCT03931941 910 911 O
. NCT03931941 911 912 O
Requires NCT03931941 914 922 B-Assertion___Assertion-Type-Value:hypothetical
systemic NCT03931941 923 931 O
antibiotic NCT03931941 932 942 B-Procedure
therapy NCT03931941 943 950 I-Procedure
for NCT03931941 951 954 O
a NCT03931941 955 956 O
condition NCT03931941 957 966 B-Condition
other NCT03931941 967 972 B-Exception
than NCT03931941 973 977 I-Exception
CDI NCT03931941 978 981 B-Condition
. NCT03931941 982 983 O

3 NCT03931941 987 988 O
. NCT03931941 988 989 O
Fecal NCT03931941 991 996 B-Procedure
microbiota NCT03931941 997 1007 I-Procedure
transplant NCT03931941 1008 1018 I-Procedure
( NCT03931941 1019 1020 O
FMT NCT03931941 1021 1024 B-Procedure
) NCT03931941 1025 1026 O
within NCT03931941 1027 1033 B-Eq-Comparison
the NCT03931941 1034 1037 I-Eq-Comparison
past NCT03931941 1038 1042 I-Eq-Comparison
6 NCT03931941 1043 1044 I-Eq-Comparison
months NCT03931941 1045 1051 I-Eq-Comparison
. NCT03931941 1052 1053 O

4 NCT03931941 1057 1058 O
. NCT03931941 1058 1059 O
FMT NCT03931941 1061 1064 B-Procedure
with NCT03931941 1065 1069 B-And
an NCT03931941 1070 1072 O
associated NCT03931941 1073 1083 O
serious NCT03931941 1084 1091 O
adverse NCT03931941 1092 1099 B-Observation
event NCT03931941 1100 1105 I-Observation
related NCT03931941 1106 1113 O
to NCT03931941 1114 1116 O
the NCT03931941 1117 1120 O
FMT NCT03931941 1121 1124 B-Procedure
product NCT03931941 1125 1132 O
or NCT03931941 1133 1135 B-Or
procedure NCT03931941 1136 1145 B-Procedure
. NCT03931941 1146 1147 O

5 NCT03931941 1151 1152 O
. NCT03931941 1152 1153 O
Bezlotoxumab NCT03931941 1155 1167 B-Drug
( NCT03931941 1168 1169 O
CDI NCT03931941 1170 1173 B-Condition
monoclonal NCT03931941 1174 1184 B-Drug
antibodies NCT03931941 1185 1195 I-Drug
) NCT03931941 1196 1197 O
if NCT03931941 1198 1200 O
received NCT03931941 1201 1209 B-Eq-Comparison
within NCT03931941 1210 1216 B-Eq-Comparison
the NCT03931941 1217 1220 I-Eq-Comparison
last NCT03931941 1221 1225 I-Eq-Comparison
year NCT03931941 1226 1230 I-Eq-Comparison
. NCT03931941 1231 1232 O

6 NCT03931941 1236 1237 O
. NCT03931941 1237 1238 O
CD4 NCT03931941 1240 1243 B-Observation
count NCT03931941 1244 1249 I-Observation
< NCT03931941 1250 1251 B-Eq-Comparison
200 NCT03931941 1252 1255 I-Eq-Comparison
/ NCT03931941 1256 1257 I-Eq-Comparison
mm3 NCT03931941 1258 1261 I-Eq-Comparison
during NCT03931941 1262 1268 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03931941 1269 1278 B-Study
. NCT03931941 1279 1280 O

7 NCT03931941 1284 1285 O
. NCT03931941 1285 1286 O
An NCT03931941 1288 1290 O
absolute NCT03931941 1291 1299 B-Observation
neutrophil NCT03931941 1300 1310 I-Observation
count NCT03931941 1311 1316 I-Observation
of NCT03931941 1317 1319 O
< NCT03931941 1320 1321 B-Eq-Comparison
1000 NCT03931941 1322 1326 I-Eq-Comparison
cells NCT03931941 1327 1332 O
/ NCT03931941 1333 1334 O
µL NCT03931941 1335 1337 O
during NCT03931941 1338 1344 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03931941 1345 1354 B-Study
. NCT03931941 1355 1356 O

8 NCT03931941 1360 1361 O
. NCT03931941 1361 1362 O
Pregnant NCT03931941 1364 1372 B-Condition
, NCT03931941 1373 1374 O
breastfeeding NCT03931941 1375 1388 B-Condition
, NCT03931941 1389 1390 O
or NCT03931941 1391 1393 B-Or
intends NCT03931941 1394 1401 B-Assertion___Assertion-Type-Value:intention
to NCT03931941 1402 1404 I-Assertion___Assertion-Type-Value:intention
become NCT03931941 1405 1411 O
pregnant NCT03931941 1412 1420 B-Condition
during NCT03931941 1421 1427 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03931941 1428 1433 B-Study
participation NCT03931941 1434 1447 O
. NCT03931941 1447 1448 O

Inclusion NCT03930108 0 9 O
Criteria NCT03930108 10 18 O
: NCT03930108 19 20 O

- NCT03930108 24 25 O
adult NCT03930108 27 32 O
patients NCT03930108 33 41 O
( NCT03930108 42 43 O
age NCT03930108 44 47 B-Age
18 NCT03930108 48 50 B-Eq-Comparison
and NCT03930108 51 54 I-Eq-Comparison
above NCT03930108 55 60 I-Eq-Comparison
) NCT03930108 61 62 O
who NCT03930108 63 66 O
admitted NCT03930108 67 75 B-Encounter
to NCT03930108 76 78 O
burn NCT03930108 79 83 O
unit NCT03930108 84 88 O
during NCT03930108 89 95 B-Temporal-Connection___Temporal-Connection-Type-Value:during
sampling NCT03930108 96 104 B-Study
period NCT03930108 105 111 O

Exclusion NCT03930108 112 121 O
Criteria NCT03930108 122 130 O
: NCT03930108 131 132 O

- NCT03930108 136 137 O
patients NCT03930108 139 147 O
discharged NCT03930108 148 158 B-Encounter
or NCT03930108 159 161 B-Or
deceased NCT03930108 162 170 B-Death
less NCT03930108 171 175 B-Eq-Comparison
than NCT03930108 176 180 I-Eq-Comparison
24 NCT03930108 181 183 I-Eq-Comparison
hours NCT03930108 184 189 I-Eq-Comparison
of NCT03930108 190 192 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03930108 193 202 B-Encounter

- NCT03930108 205 206 O
patients NCT03930108 208 216 O
referred NCT03930108 217 225 B-Encounter
to NCT03930108 226 228 O
other NCT03930108 229 234 B-Other
hospital NCT03930108 235 243 O
within NCT03930108 244 250 B-Eq-Comparison
30 NCT03930108 251 253 I-Eq-Comparison
days NCT03930108 254 258 I-Eq-Comparison
admission NCT03930108 259 268 B-Encounter

Inclusion NCT03930134 0 9 O
Criteria NCT03930134 10 18 O
: NCT03930134 19 20 O

- NCT03930134 24 25 O
singleton NCT03930134 27 36 B-Modifier
pregnancy NCT03930134 37 46 B-Condition

- NCT03930134 49 50 O
Cicatricial NCT03930134 52 63 B-Condition
uterus NCT03930134 64 70 I-Condition
with NCT03930134 71 75 B-And
contraindication NCT03930134 76 92 B-Contraindication
to NCT03930134 93 95 O
vaginal NCT03930134 96 103 B-Procedure
delivery NCT03930134 104 112 I-Procedure
( NCT03930134 113 114 O
uterus NCT03930134 115 121 B-Condition
bi NCT03930134 122 124 B-Modifier
or NCT03930134 125 127 B-Or
multi NCT03930134 128 133 B-Modifier
- NCT03930134 134 135 I-Modifier
cicatricial NCT03930134 136 147 I-Modifier
, NCT03930134 148 149 O
corporal NCT03930134 150 158 B-Condition
uterine NCT03930134 159 166 I-Condition
scar NCT03930134 167 171 I-Condition
, NCT03930134 172 173 O
intra NCT03930134 174 179 B-Procedure
- NCT03930134 180 181 I-Procedure
mural NCT03930134 182 187 I-Procedure
myomectomy NCT03930134 188 198 I-Procedure
, NCT03930134 199 200 O
dystocic NCT03930134 201 209 B-Condition
presentation NCT03930134 210 222 I-Condition
) NCT03930134 223 224 O

- NCT03930134 228 229 O
Fetal NCT03930134 231 236 B-Condition
macrosomia NCT03930134 237 247 I-Condition
with NCT03930134 248 252 B-And
a NCT03930134 253 254 O
weight NCT03930134 255 261 B-Observation
greater NCT03930134 262 269 B-Eq-Comparison
than NCT03930134 270 274 I-Eq-Comparison
4 NCT03930134 275 276 I-Eq-Comparison
Kg NCT03930134 277 279 O

- NCT03930134 282 283 O
Placenta NCT03930134 285 293 B-Condition
previa NCT03930134 294 300 I-Condition

Exclusion NCT03930134 301 310 O
Criteria NCT03930134 311 319 O
: NCT03930134 320 321 O

- NCT03930134 325 326 O
Patients NCT03930134 328 336 O
who NCT03930134 337 340 O
refuse NCT03930134 341 347 O
to NCT03930134 348 350 O
participate NCT03930134 351 362 O
in NCT03930134 363 365 O
the NCT03930134 366 369 O
study NCT03930134 370 375 B-Study

- NCT03930134 378 379 O
prenatally NCT03930134 381 391 O
diagnosed NCT03930134 392 401 O
fetal NCT03930134 402 407 B-Condition
pathology NCT03930134 408 417 I-Condition
( NCT03930134 418 419 O
intrauterine NCT03930134 420 432 B-Condition
growth NCT03930134 433 439 I-Condition
restriction NCT03930134 440 451 I-Condition
, NCT03930134 452 453 O
malformation NCT03930134 454 466 B-Condition
, NCT03930134 467 468 O
genetics NCT03930134 469 477 B-Condition
disorders NCT03930134 478 487 I-Condition
) NCT03930134 488 489 O

- NCT03930134 493 494 O
adherent NCT03930134 496 504 B-Condition
placenta NCT03930134 505 513 I-Condition
, NCT03930134 514 515 O
an NCT03930134 516 518 O
adnexal NCT03930134 519 526 B-Condition
mass NCT03930134 527 531 I-Condition
or NCT03930134 532 534 B-Or
a NCT03930134 535 536 O
myoma NCT03930134 537 542 B-Condition
at NCT03930134 543 545 I-Condition
the NCT03930134 546 549 I-Condition
lower NCT03930134 550 555 I-Condition
uterine NCT03930134 556 563 I-Condition
segment NCT03930134 564 571 I-Condition

- NCT03930134 574 575 O
Cesarean NCT03930134 577 585 B-Procedure
section NCT03930134 586 593 I-Procedure
in NCT03930134 594 596 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03930134 597 598 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
context NCT03930134 599 606 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
of NCT03930134 607 609 O
medical NCT03930134 610 617 B-Modifier
or NCT03930134 618 620 B-Or
obstetrical NCT03930134 621 632 B-Modifier
emergency NCT03930134 633 642 B-Observation

- NCT03930134 645 646 O
Caesarean NCT03930134 648 657 B-Procedure
section NCT03930134 658 665 I-Procedure
with NCT03930134 666 670 B-And
a NCT03930134 671 672 O
high NCT03930134 673 677 O
risk NCT03930134 678 682 B-Risk
of NCT03930134 683 685 O
bleeding NCT03930134 686 694 B-Condition

Inclusion NCT03932045 0 9 O
Criteria NCT03932045 10 18 O
: NCT03932045 19 20 O

1 NCT03932045 24 25 O
. NCT03932045 25 26 O
Individuals NCT03932045 28 39 O
who NCT03932045 40 43 O
desire NCT03932045 44 50 B-Assertion___Assertion-Type-Value:intention
an NCT03932045 51 53 O
improvement NCT03932045 54 65 O
in NCT03932045 66 68 O
the NCT03932045 69 72 O
appearance NCT03932045 73 83 B-Observation
of NCT03932045 84 86 I-Observation
the NCT03932045 87 90 I-Observation
nasolabial NCT03932045 91 101 I-Observation
fold NCT03932045 102 106 I-Observation
on NCT03932045 107 109 O
both NCT03932045 110 114 O
sides NCT03932045 115 120 O
of NCT03932045 121 123 O
the NCT03932045 124 127 O
face NCT03932045 128 132 O
and NCT03932045 133 136 B-And
who NCT03932045 137 140 O
have NCT03932045 141 145 O
a NCT03932045 146 147 O
score NCT03932045 148 153 B-Eq-Comparison
of NCT03932045 154 156 I-Eq-Comparison
3 NCT03932045 157 158 I-Eq-Comparison
or NCT03932045 159 161 I-Eq-Comparison
4 NCT03932045 162 163 I-Eq-Comparison
on NCT03932045 164 166 O
the NCT03932045 167 170 O
Wrinkle NCT03932045 171 178 B-Observation
Severity NCT03932045 179 187 I-Observation
Rating NCT03932045 188 194 I-Observation
Scale NCT03932045 195 200 I-Observation
( NCT03932045 201 202 O
WSRS NCT03932045 203 207 B-Observation
) NCT03932045 208 209 O

2 NCT03932045 213 214 O
. NCT03932045 214 215 O
Individuals NCT03932045 217 228 O
who NCT03932045 229 232 O
have NCT03932045 233 237 O
consented NCT03932045 238 247 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03932045 248 250 I-Assertion___Assertion-Type-Value:hypothetical
abstain NCT03932045 251 258 B-Negation
from NCT03932045 259 263 I-Negation
any NCT03932045 264 267 O
other NCT03932045 268 273 O
dermatological NCT03932045 274 288 B-Procedure
procedures NCT03932045 289 299 I-Procedure
or NCT03932045 300 302 B-Or
treatments NCT03932045 303 313 B-Procedure
, NCT03932045 314 315 O
including NCT03932045 316 325 O
treatments NCT03932045 326 336 O
for NCT03932045 337 340 O
wrinkle NCT03932045 341 348 B-Procedure
reduction NCT03932045 349 358 I-Procedure
in NCT03932045 359 361 O
the NCT03932045 362 365 O
facial NCT03932045 366 372 O
area NCT03932045 373 377 O
, NCT03932045 378 379 O
during NCT03932045 380 386 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03932045 387 390 O
duration NCT03932045 391 399 O
of NCT03932045 400 402 O
this NCT03932045 403 407 O
study NCT03932045 408 413 B-Study
. NCT03932045 414 415 O

Exclusion NCT03932045 417 426 O
Criteria NCT03932045 427 435 O
: NCT03932045 436 437 O

1 NCT03932045 441 442 O
. NCT03932045 442 443 O
Administered NCT03932045 445 457 B-Eq-Comparison
an NCT03932045 458 460 O
anticoagulant NCT03932045 461 474 B-Drug
( NCT03932045 475 476 O
with NCT03932045 477 481 O
the NCT03932045 482 485 O
exception NCT03932045 486 495 B-Exception
of NCT03932045 496 498 O
low NCT03932045 499 502 B-Eq-Comparison
dosage NCT03932045 503 509 O
aspirin NCT03932045 510 517 B-Drug
( NCT03932045 518 519 O
100 NCT03932045 520 523 B-Eq-Comparison
mg NCT03932045 524 526 I-Eq-Comparison
, NCT03932045 527 528 I-Eq-Comparison
up NCT03932045 529 531 I-Eq-Comparison
to NCT03932045 532 534 I-Eq-Comparison
300 NCT03932045 535 538 I-Eq-Comparison
mg NCT03932045 539 541 I-Eq-Comparison
/ NCT03932045 542 543 I-Eq-Comparison
day NCT03932045 544 547 I-Eq-Comparison
) NCT03932045 548 549 O
) NCT03932045 551 552 O
within NCT03932045 553 559 B-Eq-Comparison
2 NCT03932045 560 561 I-Eq-Comparison
weeks NCT03932045 562 567 I-Eq-Comparison
of NCT03932045 568 570 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 571 574 O
date NCT03932045 575 579 O
of NCT03932045 580 582 O
the NCT03932045 583 586 O
screening NCT03932045 587 596 B-Study

2 NCT03932045 599 600 O
. NCT03932045 600 601 O
Administered NCT03932045 603 615 B-Eq-Comparison
Vitamin NCT03932045 616 623 B-Drug
E NCT03932045 624 625 I-Drug
or NCT03932045 626 628 B-Or
non NCT03932045 629 632 B-Drug
- NCT03932045 633 634 I-Drug
steroidal NCT03932045 635 644 I-Drug
anti NCT03932045 645 649 I-Drug
- NCT03932045 650 651 I-Drug
inflammatory NCT03932045 652 664 I-Drug
drugs NCT03932045 665 670 I-Drug
or NCT03932045 671 673 B-Or
Collagen NCT03932045 674 682 B-Drug
within NCT03932045 683 689 B-Eq-Comparison
1 NCT03932045 690 691 I-Eq-Comparison
week NCT03932045 692 696 I-Eq-Comparison
of NCT03932045 697 699 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 700 703 O
date NCT03932045 704 708 O
of NCT03932045 709 711 O
the NCT03932045 712 715 O
screening NCT03932045 716 725 B-Study
, NCT03932045 726 727 O
or NCT03932045 728 730 O
who NCT03932045 731 734 O
require NCT03932045 735 742 B-Assertion___Assertion-Type-Value:hypothetical
these NCT03932045 743 748 B-Coreference
during NCT03932045 749 755 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03932045 756 759 O
period NCT03932045 760 766 O
of NCT03932045 767 769 O
the NCT03932045 770 773 O
study NCT03932045 774 779 B-Study

3 NCT03932045 782 783 O
. NCT03932045 783 784 O
History NCT03932045 786 793 B-Eq-Comparison
of NCT03932045 794 796 O
bleeding NCT03932045 797 805 B-Condition
disorder NCT03932045 806 814 I-Condition
in NCT03932045 815 817 O
past NCT03932045 818 822 B-Eq-Comparison
or NCT03932045 823 825 B-Or
present NCT03932045 826 833 B-Eq-Comparison

4 NCT03932045 836 837 O
. NCT03932045 837 838 O
Received NCT03932045 840 848 B-Eq-Comparison
deep NCT03932045 849 853 B-Procedure
- NCT03932045 854 855 I-Procedure
peeling NCT03932045 856 863 I-Procedure
, NCT03932045 864 865 O
skin NCT03932045 866 870 B-Procedure
regeneration NCT03932045 871 883 I-Procedure
, NCT03932045 884 885 O
plastic NCT03932045 886 893 B-Procedure
surgery NCT03932045 894 901 I-Procedure
( NCT03932045 902 903 O
including NCT03932045 904 913 O
botulinum NCT03932045 914 923 B-Procedure
toxin NCT03932045 924 929 I-Procedure
injection NCT03932045 930 939 I-Procedure
) NCT03932045 940 941 O
, NCT03932045 943 944 O
wrinkle NCT03932045 945 952 B-Procedure
improvement NCT03932045 953 964 I-Procedure
or NCT03932045 965 967 B-Or
acne NCT03932045 968 972 B-Procedure
scar NCT03932045 973 977 I-Procedure
treatment NCT03932045 978 987 I-Procedure
in NCT03932045 988 990 O
the NCT03932045 991 994 O
facial NCT03932045 995 1001 O
area NCT03932045 1002 1006 O
within NCT03932045 1007 1013 B-Eq-Comparison
24 NCT03932045 1014 1016 I-Eq-Comparison
weeks NCT03932045 1017 1022 I-Eq-Comparison
of NCT03932045 1023 1025 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 1026 1029 O
date NCT03932045 1030 1034 O
of NCT03932045 1035 1037 O
the NCT03932045 1038 1041 O
screening NCT03932045 1042 1051 B-Study

5 NCT03932045 1054 1055 O
. NCT03932045 1055 1056 O
Administered NCT03932045 1058 1070 B-Eq-Comparison
an NCT03932045 1071 1073 O
hyaluronic NCT03932045 1074 1084 B-Drug
acid NCT03932045 1085 1089 I-Drug
filler NCT03932045 1090 1096 I-Drug
within NCT03932045 1097 1103 B-Eq-Comparison
24 NCT03932045 1104 1106 I-Eq-Comparison
weeks NCT03932045 1107 1112 I-Eq-Comparison
of NCT03932045 1113 1115 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03932045 1116 1119 O
date NCT03932045 1120 1124 O
of NCT03932045 1125 1127 O
the NCT03932045 1128 1131 O
screening NCT03932045 1132 1141 B-Study


Inclusion NCT03934346 0 9 O
Criteria NCT03934346 10 18 O
: NCT03934346 19 20 O

- NCT03934346 24 25 O
Apparently NCT03934346 27 37 B-Assertion___Assertion-Type-Value:possible
healthy NCT03934346 38 45 B-Condition
men NCT03934346 46 49 O

- NCT03934346 52 53 O
Body NCT03934346 55 59 B-Observation
mass NCT03934346 60 64 I-Observation
index NCT03934346 65 70 I-Observation
between NCT03934346 71 78 B-Eq-Comparison
18 NCT03934346 79 81 I-Eq-Comparison
and NCT03934346 82 85 I-Eq-Comparison
30 NCT03934346 86 88 I-Eq-Comparison
kg NCT03934346 89 91 I-Eq-Comparison
/ NCT03934346 92 93 I-Eq-Comparison
m2 NCT03934346 94 96 I-Eq-Comparison

- NCT03934346 99 100 O
Willing NCT03934346 102 109 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03934346 110 112 I-Assertion___Assertion-Type-Value:hypothetical
eat NCT03934346 113 116 B-Observation
only NCT03934346 117 121 O
the NCT03934346 122 125 O
foods NCT03934346 126 131 O
provided NCT03934346 132 140 O
by NCT03934346 141 143 O
the NCT03934346 144 147 O
study NCT03934346 148 153 B-Study
for NCT03934346 154 157 O
a NCT03934346 158 159 O
2 NCT03934346 160 161 B-Eq-Comparison
week NCT03934346 162 166 I-Eq-Comparison
period NCT03934346 167 173 O

Exclusion NCT03934346 174 183 O
Criteria NCT03934346 184 192 O
: NCT03934346 193 194 O

- NCT03934346 198 199 O
Those NCT03934346 201 206 O
reporting NCT03934346 207 216 O
any NCT03934346 217 220 O
chronic NCT03934346 221 228 B-Modifier
or NCT03934346 229 231 B-Or
acute NCT03934346 232 237 O
diseases NCT03934346 238 246 B-Condition
, NCT03934346 247 248 O
food NCT03934346 249 253 O
allergies NCT03934346 254 263 B-Allergy
, NCT03934346 264 265 O
smoking NCT03934346 266 273 B-Modifier
or NCT03934346 274 276 B-Or
alcohol NCT03934346 277 284 B-Modifier
abuse NCT03934346 285 290 B-Condition

- NCT03934346 293 294 O
Use NCT03934346 296 299 B-Eq-Comparison
of NCT03934346 300 302 O
illicit NCT03934346 303 310 B-Drug
drugs NCT03934346 311 316 I-Drug
; NCT03934346 316 317 O
regular NCT03934346 318 325 O
consumption NCT03934346 326 337 O
of NCT03934346 338 340 O
medications NCT03934346 341 352 B-Drug
, NCT03934346 353 354 O
micronutrient NCT03934346 355 368 B-Drug
supplements NCT03934346 369 380 I-Drug
, NCT03934346 381 382 O
or NCT03934346 383 385 B-Or
both NCT03934346 386 390 B-Coreference

- NCT03934346 393 394 O
Vegetarians NCT03934346 396 407 B-Condition
, NCT03934346 408 409 O
or NCT03934346 410 412 B-Or
those NCT03934346 413 418 O
unable NCT03934346 419 425 B-Condition
to NCT03934346 426 428 I-Condition
eat NCT03934346 429 432 I-Condition
meat NCT03934346 433 437 I-Condition
, NCT03934346 438 439 O
are NCT03934346 440 443 O
also NCT03934346 444 448 O
excluded NCT03934346 449 457 O
since NCT03934346 458 463 O
the NCT03934346 464 467 O
foods NCT03934346 468 473 O
for NCT03934346 474 477 O
the NCT03934346 478 481 O
study NCT03934346 482 487 O
contain NCT03934346 488 495 O
meat NCT03934346 496 500 O

- NCT03934346 503 504 O
Unable NCT03934346 506 512 B-Negation
to NCT03934346 513 515 O
refrain NCT03934346 516 523 B-Negation
from NCT03934346 524 528 O
taking NCT03934346 529 535 B-Eq-Comparison
medications NCT03934346 536 547 B-Drug
during NCT03934346 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03934346 555 558 O
study NCT03934346 559 564 B-Study
period NCT03934346 565 571 O

Inclusion NCT03930849 0 9 O
Criteria NCT03930849 10 18 O
: NCT03930849 19 20 O

VA NCT03930849 22 24 O
Patient NCT03930849 25 32 O

- NCT03930849 35 36 O
Diagnosed NCT03930849 38 47 O
with NCT03930849 48 52 O
depression NCT03930849 53 63 B-Condition

- NCT03930849 66 67 O
Initiating NCT03930849 69 79 B-Eq-Comparison
or NCT03930849 80 82 B-Or
changing NCT03930849 83 91 O
to NCT03930849 92 94 O
a NCT03930849 95 96 O
new NCT03930849 97 100 O
antidepressant NCT03930849 101 115 B-Drug
medication NCT03930849 116 126 I-Drug

- NCT03930849 129 130 O
Cell NCT03930849 132 136 O
phone NCT03930849 137 142 O
with NCT03930849 143 147 O
text NCT03930849 148 152 O
messaging NCT03930849 153 162 O
capabilities NCT03930849 163 175 O

- NCT03930849 178 179 O
Registered NCT03930849 181 191 O
with NCT03930849 192 196 O
My NCT03930849 197 199 O
HealtheVet NCT03930849 200 210 O

- NCT03930849 213 214 O
Follow NCT03930849 216 222 B-Encounter
- NCT03930849 223 224 I-Encounter
up NCT03930849 225 227 I-Encounter
appointment NCT03930849 228 239 I-Encounter
with NCT03930849 240 244 O
their NCT03930849 245 250 O
provider NCT03930849 251 259 B-Provider
in NCT03930849 260 262 O
the NCT03930849 263 266 O
next NCT03930849 267 271 B-Eq-Comparison
12 NCT03930849 272 274 I-Eq-Comparison
weeks NCT03930849 275 280 I-Eq-Comparison

- NCT03930849 283 284 O
Internet NCT03930849 286 294 O
access NCT03930849 295 301 O

- NCT03930849 304 305 O
English NCT03930849 307 314 O
speaking NCT03930849 315 323 O
VA NCT03930849 324 326 O
Providers NCT03930849 327 336 B-Provider
: NCT03930849 337 338 O
provide NCT03930849 339 346 O
care NCT03930849 347 351 O
to NCT03930849 352 354 O
a NCT03930849 355 356 O
study NCT03930849 357 362 B-Study
participant NCT03930849 363 374 O

Exclusion NCT03930849 375 384 O
Criteria NCT03930849 385 393 O
: NCT03930849 394 395 O

- NCT03930849 399 400 O
Lack NCT03930849 402 406 O
of NCT03930849 407 409 O
cell NCT03930849 410 414 O
phone NCT03930849 415 420 O
access NCT03930849 421 427 O
/ NCT03930849 428 429 O
willingness NCT03930849 430 441 O
to NCT03930849 442 444 O
receive NCT03930849 445 452 O
text NCT03930849 453 457 O
messages NCT03930849 458 466 O

- NCT03930849 469 470 O
Diagnosis NCT03930849 472 481 O
of NCT03930849 482 484 O
cognitive NCT03930849 485 494 B-Condition
disorders NCT03930849 495 504 I-Condition
, NCT03930849 505 506 O
psychotic NCT03930849 507 516 B-Condition
disorders NCT03930849 517 526 I-Condition
, NCT03930849 527 528 O
bipolar NCT03930849 529 536 B-Condition
disorder NCT03930849 537 545 I-Condition
, NCT03930849 546 547 O
or NCT03930849 548 550 B-Or
active NCT03930849 551 557 B-Eq-Comparison
substance NCT03930849 558 567 B-Condition
abuse NCT03930849 568 573 I-Condition
. NCT03930849 573 574 O

Inclusion NCT03934385 0 9 O
Criteria NCT03934385 10 18 O
: NCT03934385 19 20 O

- NCT03934385 24 25 O
English NCT03934385 27 34 O
- NCT03934385 35 36 O
speaking NCT03934385 37 45 O

- NCT03934385 48 49 O
Elevated NCT03934385 51 59 O
score NCT03934385 60 65 O
on NCT03934385 66 68 O
Spider NCT03934385 69 75 B-Observation
Phobia NCT03934385 76 82 I-Observation
Questionnaire NCT03934385 83 96 I-Observation
( NCT03934385 97 98 O
SPQ NCT03934385 99 102 B-Observation
) NCT03934385 103 104 O

Exclusion NCT03934385 106 115 O
Criteria NCT03934385 116 124 O
: NCT03934385 125 126 O

- NCT03934385 130 131 O
Severe NCT03934385 133 139 O
allergies NCT03934385 140 149 B-Allergy
to NCT03934385 150 152 O
bees NCT03934385 153 157 O
/ NCT03934385 158 159 B-Or
spiders NCT03934385 160 167 O
/ NCT03934385 168 169 B-Or
insects NCT03934385 170 177 O

Inclusion NCT03934554 0 9 O
Criteria NCT03934554 10 18 O
: NCT03934554 19 20 O

- NCT03934554 24 25 O
Dialysis NCT03934554 27 35 B-Procedure
or NCT03934554 36 38 B-Or
non NCT03934554 39 42 B-Negation
- NCT03934554 43 44 O
dialysis NCT03934554 45 53 B-Procedure
patients NCT03934554 54 62 O
with NCT03934554 63 67 B-And
chronic NCT03934554 68 75 B-Condition
renal NCT03934554 76 81 I-Condition
insufficiency NCT03934554 82 95 I-Condition
with NCT03934554 96 100 B-And
a NCT03934554 101 102 O
GFR NCT03934554 103 106 B-Observation
< NCT03934554 107 108 B-Eq-Comparison
20 NCT03934554 109 111 I-Eq-Comparison
ml NCT03934554 112 114 I-Eq-Comparison
/ NCT03934554 115 116 I-Eq-Comparison
min NCT03934554 117 120 I-Eq-Comparison
eligible NCT03934554 121 129 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03934554 130 133 O
transplant NCT03934554 134 144 B-Procedure

- NCT03934554 147 148 O
Patient NCT03934554 150 157 O
wishing NCT03934554 158 165 B-Assertion___Assertion-Type-Value:intention
to NCT03934554 166 168 I-Assertion___Assertion-Type-Value:intention
start NCT03934554 169 174 O
the NCT03934554 175 178 O
registration NCT03934554 179 191 O
process NCT03934554 192 199 O
at NCT03934554 200 202 O
the NCT03934554 203 206 O
transplant NCT03934554 207 217 B-Procedure

- NCT03934554 220 221 O
Patient NCT03934554 223 230 O
giving NCT03934554 231 237 O
consent NCT03934554 238 245 O
for NCT03934554 246 249 O
the NCT03934554 250 253 O
transmission NCT03934554 254 266 O
of NCT03934554 267 269 O
his NCT03934554 270 273 O
data NCT03934554 274 278 O
via NCT03934554 279 282 O
an NCT03934554 283 285 O
electronic NCT03934554 286 296 O
platform NCT03934554 297 305 O

Exclusion NCT03934554 306 315 O
Criteria NCT03934554 316 324 O
: NCT03934554 325 326 O

- NCT03934554 330 331 O
Patient NCT03934554 333 340 O
already NCT03934554 341 348 O
enrolled NCT03934554 349 357 O

- NCT03934554 360 361 O
Patient NCT03934554 363 370 O
having NCT03934554 371 377 B-Eq-Comparison
a NCT03934554 378 379 O
pathology NCT03934554 380 389 B-Condition
with NCT03934554 390 394 B-And
a NCT03934554 395 396 O
life NCT03934554 397 401 B-Observation
expectancy NCT03934554 402 412 I-Observation
of NCT03934554 413 415 O
less NCT03934554 416 420 B-Eq-Comparison
than NCT03934554 421 425 I-Eq-Comparison
two NCT03934554 426 429 I-Eq-Comparison
years NCT03934554 430 435 I-Eq-Comparison

- NCT03934554 438 439 O
Patient NCT03934554 441 448 O
with NCT03934554 449 453 O
serious NCT03934554 454 461 O
psychiatric NCT03934554 462 473 B-Condition
disorders NCT03934554 474 483 I-Condition
, NCT03934554 484 485 O
or NCT03934554 486 488 B-Or
dementia NCT03934554 489 497 B-Condition
. NCT03934554 497 498 O

Inclusion NCT03930901 0 9 O
Criteria NCT03930901 10 18 O
: NCT03930901 19 20 O

- NCT03930901 24 25 O
Grade NCT03930901 27 32 O
2 NCT03930901 33 34 O
- NCT03930901 35 36 O
6 NCT03930901 37 38 O

- NCT03930901 42 43 O
Orang NCT03930901 45 50 O
Asli NCT03930901 51 55 O
ethnicity NCT03930901 56 65 O

- NCT03930901 68 69 O
Schools NCT03930901 71 78 O
exclusively NCT03930901 79 90 O
for NCT03930901 91 94 O
Orang NCT03930901 95 100 O
Asli NCT03930901 101 105 O

Exclusion NCT03930901 106 115 O
Criteria NCT03930901 116 124 O
: NCT03930901 125 126 O

- NCT03930901 130 131 O
Grade NCT03930901 133 138 O
1 NCT03930901 139 140 O

- NCT03930901 144 145 O
Chronic NCT03930901 147 154 B-Modifier
sever NCT03930901 155 160 B-Condition
diseases NCT03930901 161 169 I-Condition

- NCT03930901 172 173 O
no NCT03930901 175 177 O
consent NCT03930901 178 185 O

- NCT03930901 188 189 O
schools NCT03930901 191 198 O
for NCT03930901 199 202 O
mixed NCT03930901 203 208 O
population NCT03930901 209 219 O
groups NCT03930901 220 226 O

Inclusion NCT03930524 0 9 O
Criteria NCT03930524 10 18 O
: NCT03930524 19 20 O

- NCT03930524 24 25 O
Incoming NCT03930524 27 35 O
college NCT03930524 36 43 O
students NCT03930524 44 52 O
aged NCT03930524 53 57 B-Age
18 NCT03930524 58 60 B-Eq-Comparison
- NCT03930524 61 62 I-Eq-Comparison
21 NCT03930524 63 65 O
at NCT03930524 66 68 O
the NCT03930524 69 72 O
University NCT03930524 73 83 O
of NCT03930524 84 86 O
Minnesota NCT03930524 87 96 O
will NCT03930524 97 101 O
be NCT03930524 102 104 O
eligible NCT03930524 105 113 O
and NCT03930524 114 117 O
randomly NCT03930524 118 126 O
selected NCT03930524 127 135 O
for NCT03930524 136 139 O
participation NCT03930524 140 153 O
. NCT03930524 154 155 O

Exclusion NCT03930524 157 166 O
Criteria NCT03930524 167 175 O
: NCT03930524 176 177 O

- NCT03930524 181 182 O
None NCT03930524 184 188 O

Inclusion NCT03931148 0 9 O
Criteria NCT03931148 10 18 O
: NCT03931148 19 20 O

- NCT03931148 24 25 O
French NCT03931148 27 33 O
speaker NCT03931148 34 41 O

- NCT03931148 44 45 O
Recent NCT03931148 47 53 B-Eq-Comparison
diagnosis NCT03931148 54 63 O
of NCT03931148 64 66 O
neurocognitive NCT03931148 67 81 B-Condition
disorder NCT03931148 82 90 I-Condition

- NCT03931148 93 94 O
Agreed NCT03931148 96 102 O
with NCT03931148 103 107 O
the NCT03931148 108 111 O
study NCT03931148 112 117 O

Exclusion NCT03931148 118 127 O
Criteria NCT03931148 128 136 O
: NCT03931148 137 138 O

- NCT03931148 142 143 O
Delirium NCT03931148 145 153 B-Condition

- NCT03931148 156 157 O
Major NCT03931148 159 164 O
depressive NCT03931148 165 175 B-Condition
symptoms NCT03931148 176 184 B-Assertion___Assertion-Type-Value:possible

- NCT03931148 187 188 O
MRI NCT03931148 190 193 B-Procedure
contraindication NCT03931148 194 210 B-Contraindication

Inclusion NCT03930121 0 9 O
Criteria NCT03930121 10 18 O
: NCT03930121 19 20 O

- NCT03930121 24 25 O
left NCT03930121 27 31 B-Modifier
- NCT03930121 32 33 I-Modifier
hemisphere NCT03930121 34 44 I-Modifier
cortical NCT03930121 45 53 I-Modifier
or NCT03930121 54 56 B-Or
subcortical NCT03930121 57 68 B-Modifier
stroke NCT03930121 69 75 B-Condition
with NCT03930121 76 80 B-And
first NCT03930121 81 86 B-Eq-Comparison
- NCT03930121 87 88 I-Eq-Comparison
ever NCT03930121 89 93 I-Eq-Comparison
aphasic NCT03930121 94 101 B-Condition
symptoms NCT03930121 102 110 B-Assertion___Assertion-Type-Value:possible

- NCT03930121 113 114 O
at NCT03930121 116 118 B-Eq-Comparison
least NCT03930121 119 124 I-Eq-Comparison
6 NCT03930121 125 126 I-Eq-Comparison
months NCT03930121 127 133 I-Eq-Comparison
post NCT03930121 134 138 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03930121 139 140 O
onset NCT03930121 141 146 B-Eq-Comparison
of NCT03930121 147 149 O
stroke NCT03930121 150 156 B-Condition
; NCT03930121 156 157 O

- NCT03930121 160 161 O
aphasia NCT03930121 163 170 B-Condition
, NCT03930121 171 172 O
as NCT03930121 173 175 O
determined NCT03930121 176 186 O
by NCT03930121 187 189 O
the NCT03930121 190 193 O
Aachen NCT03930121 194 200 B-Observation
Aphasia NCT03930121 201 208 I-Observation
Test NCT03930121 209 213 I-Observation
( NCT03930121 214 215 O
AAT NCT03930121 216 219 B-Observation
) NCT03930121 220 221 O
; NCT03930121 222 223 O

- NCT03930121 226 227 O
13 NCT03930121 229 231 B-Eq-Comparison
moderate NCT03930121 232 240 O
- NCT03930121 241 242 O
to NCT03930121 243 245 B-Or
- NCT03930121 246 247 O
severe NCT03930121 248 254 O
word NCT03930121 255 259 B-Condition
finding NCT03930121 260 267 I-Condition
difficulties NCT03930121 268 280 I-Condition
( NCT03930121 281 282 O
maximum NCT03930121 283 290 B-Eq-Comparison
of NCT03930121 291 293 I-Eq-Comparison
60 NCT03930121 294 296 I-Eq-Comparison
% NCT03930121 297 298 I-Eq-Comparison
correct NCT03930121 299 306 O
items NCT03930121 307 312 O
on NCT03930121 313 315 O
a NCT03930121 316 317 O
computerized NCT03930121 318 330 B-Observation
naming NCT03930121 331 337 I-Observation
task NCT03930121 338 342 I-Observation
at NCT03930121 343 345 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03930121 346 354 B-Study
) NCT03930121 355 356 O
; NCT03930121 357 358 O

- NCT03930121 361 362 O
at NCT03930121 364 366 B-Eq-Comparison
least NCT03930121 367 372 I-Eq-Comparison
1 NCT03930121 373 374 I-Eq-Comparison
correct NCT03930121 375 382 I-Eq-Comparison
reaction NCT03930121 383 391 I-Eq-Comparison
on NCT03930121 392 394 O
the NCT03930121 395 398 O
first NCT03930121 399 404 O
part NCT03930121 405 409 O
of NCT03930121 410 412 O
the NCT03930121 413 416 O
AAT NCT03930121 417 420 B-Observation
subscale NCT03930121 421 429 I-Observation
Token NCT03930121 430 435 I-Observation
Test NCT03930121 436 440 I-Observation
( NCT03930121 441 442 O
ensuring NCT03930121 443 451 O
basic NCT03930121 452 457 O
comprehension NCT03930121 458 471 O
skills NCT03930121 472 478 O
) NCT03930121 479 480 O
; NCT03930121 481 482 O

- NCT03930121 485 486 O
at NCT03930121 488 490 B-Eq-Comparison
least NCT03930121 491 496 I-Eq-Comparison
1 NCT03930121 497 498 I-Eq-Comparison
point NCT03930121 499 504 I-Eq-Comparison
on NCT03930121 505 507 O
the NCT03930121 508 511 O
communicative NCT03930121 512 525 O
task NCT03930121 526 530 O
of NCT03930121 531 533 O
the NCT03930121 534 537 O
AAT NCT03930121 538 541 B-Observation
subscale NCT03930121 542 550 I-Observation
Spontaneous NCT03930121 551 562 I-Observation
Speech NCT03930121 563 569 I-Observation
( NCT03930121 570 571 O
ensuring NCT03930121 572 580 O
basic NCT03930121 581 586 O
communication NCT03930121 587 600 O
abilities NCT03930121 601 610 O
) NCT03930121 611 612 O
; NCT03930121 613 614 O

- NCT03930121 617 618 O
German NCT03930121 620 626 O
as NCT03930121 627 629 O
first NCT03930121 630 635 O
language NCT03930121 636 644 O
; NCT03930121 644 645 O

- NCT03930121 648 649 O
intact NCT03930121 651 657 B-Modifier
left NCT03930121 658 662 B-Condition
- NCT03930121 663 664 I-Condition
hemisphere NCT03930121 665 675 I-Condition
" NCT03930121 676 677 I-Condition
hand NCT03930121 677 681 I-Condition
knob NCT03930121 682 686 I-Condition
" NCT03930121 686 687 I-Condition
without NCT03930121 688 695 B-Negation
right NCT03930121 696 701 B-Modifier
prefrontal NCT03930121 702 712 B-Condition
lesions NCT03930121 713 720 I-Condition
for NCT03930121 721 724 B-Assertion___Assertion-Type-Value:hypothetical
placement NCT03930121 725 734 B-Procedure
of NCT03930121 735 737 I-Procedure
tDCS NCT03930121 738 742 I-Procedure
electrodes NCT03930121 743 753 I-Procedure
, NCT03930121 754 755 O
as NCT03930121 756 758 O
confirmed NCT03930121 759 768 O
by NCT03930121 769 771 O
magnetic NCT03930121 772 780 B-Procedure
resonance NCT03930121 781 790 I-Procedure
imaging NCT03930121 791 798 I-Procedure
or NCT03930121 799 801 B-Or
computer NCT03930121 802 810 B-Procedure
tomography NCT03930121 811 821 I-Procedure
scans NCT03930121 822 827 I-Procedure
. NCT03930121 828 829 O

Exclusion NCT03930121 831 840 O
Criteria NCT03930121 841 849 O
: NCT03930121 850 851 O

- NCT03930121 855 856 O
contraindications NCT03930121 858 875 B-Contraindication
for NCT03930121 876 879 O
tDCS NCT03930121 880 884 B-Procedure
( NCT03930121 885 886 O
e. NCT03930121 887 889 O
g. NCT03930121 890 892 O
, NCT03930121 893 894 O
cardiac NCT03930121 895 902 B-Condition
pacemaker NCT03930121 903 912 I-Condition
, NCT03930121 913 914 O
history NCT03930121 915 922 B-Eq-Comparison
of NCT03930121 923 925 O
seizures NCT03930121 926 934 B-Condition
, NCT03930121 935 936 O
implanted NCT03930121 937 946 B-Condition
metal NCT03930121 947 952 I-Condition
inside NCT03930121 953 959 I-Condition
the NCT03930121 960 963 I-Condition
head NCT03930121 964 968 I-Condition
) NCT03930121 969 970 O
; NCT03930121 971 972 O

- NCT03930121 975 976 O
more NCT03930121 978 982 B-Eq-Comparison
than NCT03930121 983 987 I-Eq-Comparison
one NCT03930121 988 991 I-Eq-Comparison
clinically NCT03930121 992 1002 B-Modifier
apparent NCT03930121 1003 1011 I-Modifier
stroke NCT03930121 1012 1018 B-Condition
with NCT03930121 1019 1023 B-And
aphasic NCT03930121 1024 1031 B-Condition
symptoms NCT03930121 1032 1040 B-Assertion___Assertion-Type-Value:possible
; NCT03930121 1040 1041 O

- NCT03930121 1044 1045 O
other NCT03930121 1047 1052 O
severe NCT03930121 1053 1059 O
neurological NCT03930121 1060 1072 B-Condition
diseases NCT03930121 1073 1081 I-Condition
( NCT03930121 1082 1083 O
e. NCT03930121 1084 1086 O
g. NCT03930121 1087 1089 O
, NCT03930121 1090 1091 O
epilepsy NCT03930121 1092 1100 B-Condition
, NCT03930121 1101 1102 O
brain NCT03930121 1103 1108 B-Condition
tumor NCT03930121 1109 1114 I-Condition
, NCT03930121 1115 1116 O
and NCT03930121 1117 1120 B-And
subdural NCT03930121 1121 1129 B-Condition
hematoma NCT03930121 1130 1138 I-Condition
) NCT03930121 1139 1140 O
; NCT03930121 1141 1142 O

- NCT03930121 1145 1146 O
history NCT03930121 1148 1155 B-Eq-Comparison
of NCT03930121 1156 1158 O
severe NCT03930121 1159 1165 O
alcohol NCT03930121 1166 1173 B-Modifier
or NCT03930121 1174 1176 B-Or
drug NCT03930121 1177 1181 B-Modifier
abuse NCT03930121 1182 1187 B-Condition
; NCT03930121 1187 1188 O

- NCT03930121 1191 1192 O
current NCT03930121 1194 1201 B-Eq-Comparison
severe NCT03930121 1202 1208 O
depression NCT03930121 1209 1219 B-Condition
; NCT03930121 1219 1220 O

- NCT03930121 1223 1224 O
current NCT03930121 1226 1233 B-Eq-Comparison
psychosis NCT03930121 1234 1243 B-Condition
or NCT03930121 1244 1246 B-Or
other NCT03930121 1247 1252 O
relevant NCT03930121 1253 1261 O
psychiatric NCT03930121 1262 1273 B-Condition
condition NCT03930121 1274 1283 I-Condition
; NCT03930121 1283 1284 O

- NCT03930121 1287 1288 O
very NCT03930121 1290 1294 O
severe NCT03930121 1295 1301 O
apraxia NCT03930121 1302 1309 B-Condition
of NCT03930121 1310 1312 I-Condition
speech NCT03930121 1313 1319 I-Condition
, NCT03930121 1320 1321 O
as NCT03930121 1322 1324 O
revealed NCT03930121 1325 1333 O
by NCT03930121 1334 1336 O
Hierarchical NCT03930121 1337 1349 B-Observation
Word NCT03930121 1350 1354 I-Observation
Lists NCT03930121 1355 1360 I-Observation
; NCT03930121 1360 1361 O

- NCT03930121 1364 1365 O
severe NCT03930121 1367 1373 O
non NCT03930121 1374 1377 B-Condition
- NCT03930121 1378 1379 I-Condition
verbal NCT03930121 1380 1386 I-Condition
cognitive NCT03930121 1387 1396 I-Condition
deficits NCT03930121 1397 1405 I-Condition
, NCT03930121 1406 1407 O
as NCT03930121 1408 1410 O
indicated NCT03930121 1411 1420 O
by NCT03930121 1421 1423 O
the NCT03930121 1424 1427 O
Corsi NCT03930121 1428 1433 B-Observation
Block NCT03930121 1434 1439 I-Observation
- NCT03930121 1440 1441 I-Observation
Tapping NCT03930121 1442 1449 I-Observation
Task NCT03930121 1450 1454 I-Observation
; NCT03930121 1454 1455 O

- NCT03930121 1458 1459 O
severe NCT03930121 1461 1467 O
uncontrolled NCT03930121 1468 1480 B-Modifier
medical NCT03930121 1481 1488 B-Condition
problems NCT03930121 1489 1497 I-Condition
; NCT03930121 1497 1498 O

- NCT03930121 1501 1502 O
severely NCT03930121 1504 1512 O
impaired NCT03930121 1513 1521 B-Condition
vision NCT03930121 1522 1528 B-Modifier
or NCT03930121 1529 1531 B-Or
hearing NCT03930121 1532 1539 B-Modifier
that NCT03930121 1540 1544 O
prevents NCT03930121 1545 1553 O
patients NCT03930121 1554 1562 O
from NCT03930121 1563 1567 O
engaging NCT03930121 1568 1576 O
in NCT03930121 1577 1579 O
intensive NCT03930121 1580 1589 O
SLT NCT03930121 1590 1593 O
; NCT03930121 1593 1594 O

- NCT03930121 1597 1598 O
changes NCT03930121 1600 1607 O
in NCT03930121 1608 1610 O
centrally NCT03930121 1611 1620 B-Drug
active NCT03930121 1621 1627 I-Drug
drugs NCT03930121 1628 1633 I-Drug
within NCT03930121 1634 1640 B-Eq-Comparison
2 NCT03930121 1641 1642 I-Eq-Comparison
weeks NCT03930121 1643 1648 I-Eq-Comparison
prior NCT03930121 1649 1654 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03930121 1655 1657 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03930121 1658 1663 B-Study
inclusion NCT03930121 1664 1673 O
. NCT03930121 1673 1674 O

Inclusion NCT03934151 0 9 O
Criteria NCT03934151 10 18 O
: NCT03934151 19 20 O

- NCT03934151 24 25 O
Patients NCT03934151 27 35 O
and NCT03934151 36 39 O
/ NCT03934151 40 41 O
or NCT03934151 42 44 O
legal NCT03934151 45 50 O
guardians NCT03934151 51 60 O
exhaustively NCT03934151 61 73 O
informed NCT03934151 74 82 O
by NCT03934151 83 85 O
the NCT03934151 86 89 O
investigator NCT03934151 90 102 O
, NCT03934151 103 104 O
and NCT03934151 105 108 O
who NCT03934151 109 112 O
have NCT03934151 113 117 O
voluntarily NCT03934151 118 129 O
provided NCT03934151 130 138 O
written NCT03934151 139 146 O
informed NCT03934151 147 155 O
consent NCT03934151 156 163 O
or NCT03934151 164 166 O
, NCT03934151 167 168 O
when NCT03934151 169 173 O
unable NCT03934151 174 180 O
to NCT03934151 181 183 O
read NCT03934151 184 188 O
and NCT03934151 189 192 O
/ NCT03934151 193 194 O
or NCT03934151 195 197 O
write NCT03934151 198 203 O
, NCT03934151 204 205 O
verbal NCT03934151 206 212 O
consent NCT03934151 213 220 O
put NCT03934151 221 224 O
into NCT03934151 225 229 O
writing NCT03934151 230 237 O
by NCT03934151 238 240 O
a NCT03934151 241 242 O
third NCT03934151 243 248 O
person NCT03934151 249 255 O

- NCT03934151 258 259 O
Patients NCT03934151 261 269 O
who NCT03934151 270 273 O
underwent NCT03934151 274 283 B-Eq-Comparison
elective NCT03934151 284 292 O
laparoscopic NCT03934151 293 305 B-Modifier
or NCT03934151 306 308 B-Or
video NCT03934151 309 314 B-Modifier
assisted NCT03934151 315 323 I-Modifier
right NCT03934151 324 329 B-Procedure
hemicolectomy NCT03934151 330 343 I-Procedure
at NCT03934151 344 346 O
U. NCT03934151 347 349 O
O. NCT03934151 350 352 O
General NCT03934151 354 361 B-Modifier
and NCT03934151 362 365 B-Or
Thoracic NCT03934151 366 374 B-Modifier
Surgery NCT03934151 375 382 B-Procedure
for NCT03934151 383 386 O
malignant NCT03934151 387 396 B-Modifier
or NCT03934151 397 399 B-Or
bening NCT03934151 400 406 B-Modifier
pathology NCT03934151 407 416 B-Condition
. NCT03934151 417 418 O

- NCT03934151 422 423 O
Patients NCT03934151 425 433 O
who NCT03934151 434 437 O
had NCT03934151 438 441 O
prior NCT03934151 442 447 B-Eq-Comparison
chemotherapy NCT03934151 448 460 B-Procedure
and NCT03934151 461 464 B-Or
radiotherapy NCT03934151 465 477 B-Procedure

Exclusion NCT03934151 478 487 O
Criteria NCT03934151 488 496 O
: NCT03934151 497 498 O

- NCT03934151 502 503 O
Patients NCT03934151 505 513 O
operated NCT03934151 514 522 B-Procedure
in NCT03934151 523 525 B-Temporal-Connection___Temporal-Connection-Type-Value:during
emergency NCT03934151 526 535 B-Encounter

- NCT03934151 538 539 O
Pregnant NCT03934151 541 549 B-Condition
women NCT03934151 550 555 O

- NCT03934151 558 559 O
Right NCT03934151 561 566 B-Procedure
laparotomic NCT03934151 567 578 I-Procedure
hemicolectomy NCT03934151 579 592 I-Procedure

- NCT03934151 595 596 O
BMI NCT03934151 598 601 B-Observation
> NCT03934151 602 603 B-Eq-Comparison
35 NCT03934151 604 606 I-Eq-Comparison

Inclusion NCT03932929 0 9 O
Criteria NCT03932929 10 18 O
: NCT03932929 19 20 O

- NCT03932929 24 25 O
over NCT03932929 27 31 B-Eq-Comparison
18 NCT03932929 32 34 I-Eq-Comparison
years NCT03932929 35 40 I-Eq-Comparison
old NCT03932929 41 44 B-Age

- NCT03932929 47 48 O
good NCT03932929 50 54 B-Condition
oral NCT03932929 55 59 I-Condition
hygiene NCT03932929 60 67 I-Condition

- NCT03932929 70 71 O
available NCT03932929 73 82 O
for NCT03932929 83 86 O
recall NCT03932929 87 93 O

- NCT03932929 96 97 O
at NCT03932929 99 101 B-Eq-Comparison
least NCT03932929 102 107 I-Eq-Comparison
20 NCT03932929 108 110 I-Eq-Comparison
teeth NCT03932929 111 116 B-Condition
under NCT03932929 117 122 I-Condition
occlusion NCT03932929 123 132 I-Condition

- NCT03932929 135 136 O
the NCT03932929 138 141 O
presence NCT03932929 142 150 O
of NCT03932929 151 153 O
at NCT03932929 154 156 B-Eq-Comparison
least NCT03932929 157 162 I-Eq-Comparison
three NCT03932929 163 168 I-Eq-Comparison
non NCT03932929 169 172 B-Negation
- NCT03932929 173 174 O
carious NCT03932929 175 182 B-Modifier
cervical NCT03932929 183 191 B-Condition
lesions NCT03932929 192 199 I-Condition

Exclusion NCT03932929 200 209 O
Criteria NCT03932929 210 218 O
: NCT03932929 219 220 O

- NCT03932929 224 225 O
poor NCT03932929 227 231 B-Condition
oral NCT03932929 232 236 I-Condition
hygiene NCT03932929 237 244 I-Condition

- NCT03932929 247 248 O
bruxism NCT03932929 250 257 B-Condition
habits NCT03932929 258 264 I-Condition

- NCT03932929 267 268 O
severe NCT03932929 270 276 O
or NCT03932929 277 279 B-Or
chronic NCT03932929 280 287 B-Modifier
periodontitis NCT03932929 288 301 B-Condition

- NCT03932929 304 305 O
If NCT03932929 307 309 O
the NCT03932929 310 313 O
teeth NCT03932929 314 319 O
selected NCT03932929 320 328 O
for NCT03932929 329 332 O
study NCT03932929 333 338 O
, NCT03932929 339 340 O
were NCT03932929 341 345 O
nonvital NCT03932929 346 354 O
, NCT03932929 355 356 O
or NCT03932929 357 359 O
had NCT03932929 360 363 O
any NCT03932929 364 367 O
restorations NCT03932929 368 380 O
on NCT03932929 381 383 O
other NCT03932929 384 389 O
surfaces NCT03932929 390 398 O
were NCT03932929 399 403 O
not NCT03932929 404 407 O
included NCT03932929 408 416 O
. NCT03932929 416 417 O

Inclusion NCT03931616 0 9 O
Criteria NCT03931616 10 18 O
: NCT03931616 19 20 O

1 NCT03931616 24 25 O
. NCT03931616 25 26 O
Suspected NCT03931616 28 37 B-Assertion___Assertion-Type-Value:possible
acute NCT03931616 38 43 O
stroke NCT03931616 44 50 B-Condition
according NCT03931616 51 60 O
to NCT03931616 61 63 O
the NCT03931616 64 67 O
dispatcher NCT03931616 68 78 O
stroke NCT03931616 79 85 O
identification NCT03931616 86 100 O
algorithm NCT03931616 101 110 O
during NCT03931616 111 117 O
STEMO NCT03931616 118 123 O
hours NCT03931616 124 129 O
( NCT03931616 130 131 O
7 NCT03931616 132 133 O
am NCT03931616 134 136 O
- NCT03931616 137 138 O
11 NCT03931616 139 141 O
pm NCT03931616 142 144 O
, NCT03931616 145 146 O
Monday NCT03931616 147 153 O
- NCT03931616 154 155 O
Sunday NCT03931616 156 162 O
) NCT03931616 163 164 O
and NCT03931616 165 168 O
within NCT03931616 169 175 O
the NCT03931616 176 179 O
STEMO NCT03931616 180 185 O
catchment NCT03931616 186 195 O
area NCT03931616 196 200 O
Inclusion NCT03931616 201 210 O
criteria NCT03931616 211 219 O
for NCT03931616 220 223 O
primary NCT03931616 224 231 O
study NCT03931616 232 237 O
population NCT03931616 238 248 O
: NCT03931616 249 250 O

2 NCT03931616 254 255 O
. NCT03931616 255 256 O
Final NCT03931616 258 263 O
diagnosis NCT03931616 264 273 O
of NCT03931616 274 276 O
ischemic NCT03931616 277 285 B-Condition
stroke NCT03931616 286 292 I-Condition
( NCT03931616 293 294 O
ICD NCT03931616 295 298 O
10 NCT03931616 299 301 O
: NCT03931616 302 303 O
I63 NCT03931616 304 307 O
) NCT03931616 308 309 O
or NCT03931616 310 312 B-Or
TIA NCT03931616 313 316 B-Condition
( NCT03931616 317 318 O
Transient NCT03931616 319 328 B-Condition
Ischemic NCT03931616 329 337 I-Condition
Attack NCT03931616 338 344 I-Condition
, NCT03931616 345 346 O
ICD NCT03931616 347 350 O
10 NCT03931616 351 353 O
: NCT03931616 354 355 O
G45 NCT03931616 356 359 O
except NCT03931616 360 366 B-Exception
G45.4 NCT03931616 367 372 B-Condition
) NCT03931616 373 374 O

3 NCT03931616 378 379 O
. NCT03931616 379 380 O
Confirmed NCT03931616 382 391 O
onset NCT03931616 392 397 B-Observation
- NCT03931616 398 399 I-Observation
to NCT03931616 400 402 I-Observation
- NCT03931616 403 404 I-Observation
alarm NCT03931616 405 410 I-Observation
time NCT03931616 411 415 I-Observation
≤ NCT03931616 416 417 B-Eq-Comparison
4 NCT03931616 418 419 I-Eq-Comparison
hours NCT03931616 420 425 I-Eq-Comparison
at NCT03931616 426 428 O
dispatch NCT03931616 429 437 O

4 NCT03931616 440 441 O
. NCT03931616 441 442 O
Pre NCT03931616 444 447 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03931616 448 449 O
stroke NCT03931616 450 456 B-Condition
modified NCT03931616 457 465 B-Observation
Rankin NCT03931616 466 472 I-Observation
scale NCT03931616 473 478 I-Observation
≤ NCT03931616 479 480 B-Eq-Comparison
3 NCT03931616 481 482 I-Eq-Comparison
( NCT03931616 483 484 O
being NCT03931616 485 490 O
able NCT03931616 491 495 B-Condition
to NCT03931616 496 498 I-Condition
ambulate NCT03931616 499 507 I-Condition
, NCT03931616 508 509 O
in NCT03931616 510 512 O
routine NCT03931616 513 520 O
clinical NCT03931616 521 529 O
care NCT03931616 530 534 O
, NCT03931616 535 536 O
patients NCT03931616 537 545 O
with NCT03931616 546 550 O
mRS NCT03931616 551 554 B-Observation
up NCT03931616 555 557 B-Eq-Comparison
to NCT03931616 558 560 I-Eq-Comparison
3 NCT03931616 561 562 I-Eq-Comparison
are NCT03931616 563 566 O
usually NCT03931616 567 574 O
deemed NCT03931616 575 581 O
suitable NCT03931616 582 590 O
for NCT03931616 591 594 O
tissue NCT03931616 595 601 O
plasminogen NCT03931616 602 613 O
activator NCT03931616 614 623 O
treatment NCT03931616 624 633 O
) NCT03931616 634 635 O

Exclusion NCT03931616 637 646 O
Criteria NCT03931616 647 655 O
: NCT03931616 656 657 O

1 NCT03931616 661 662 O
. NCT03931616 662 663 O
Remission NCT03931616 665 674 O
of NCT03931616 675 677 O
disabling NCT03931616 678 687 B-Condition
symptoms NCT03931616 688 696 B-Assertion___Assertion-Type-Value:possible
until NCT03931616 697 702 O
arrival NCT03931616 703 710 O
of NCT03931616 711 713 O
emergency NCT03931616 714 723 O
medical NCT03931616 724 731 O
service NCT03931616 732 739 O

2 NCT03931616 742 743 O
. NCT03931616 743 744 O
Malignant NCT03931616 746 755 B-Modifier
or NCT03931616 756 758 B-Or
other NCT03931616 759 764 B-Modifier
severe NCT03931616 765 771 O
primary NCT03931616 772 779 B-Condition
disease NCT03931616 780 787 I-Condition
with NCT03931616 788 792 B-And
life NCT03931616 793 797 B-Observation
expectancy NCT03931616 798 808 I-Observation
< NCT03931616 809 810 B-Eq-Comparison
1 NCT03931616 811 812 I-Eq-Comparison
year NCT03931616 813 817 I-Eq-Comparison
Additional NCT03931616 818 828 O
exclusion NCT03931616 829 838 O
criteria NCT03931616 839 847 O
for NCT03931616 848 851 O
primary NCT03931616 852 859 O
study NCT03931616 860 865 O
population NCT03931616 866 876 O
: NCT03931616 877 878 O

3 NCT03931616 882 883 O
. NCT03931616 883 884 O
Major NCT03931616 886 891 O
surgery NCT03931616 892 899 B-Procedure
within NCT03931616 900 906 B-Eq-Comparison
4 NCT03931616 907 908 I-Eq-Comparison
weeks NCT03931616 909 914 I-Eq-Comparison
before NCT03931616 915 921 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03931616 922 927 B-Study
inclusion NCT03931616 928 937 O

4 NCT03931616 940 941 O
. NCT03931616 941 942 O
Confirmed NCT03931616 944 953 O
stroke NCT03931616 954 960 B-Condition
within NCT03931616 961 967 B-Eq-Comparison
3 NCT03931616 968 969 I-Eq-Comparison
months NCT03931616 970 976 I-Eq-Comparison
before NCT03931616 977 983 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03931616 984 989 B-Study
inclusion NCT03931616 990 999 I-Study

5 NCT03931616 1002 1003 O
. NCT03931616 1003 1004 O
Absolute NCT03931616 1006 1014 O
contraindications NCT03931616 1015 1032 B-Contraindication
for NCT03931616 1033 1036 O
thrombolysis NCT03931616 1037 1049 B-Procedure
AND NCT03931616 1050 1053 B-And
thrombectomy NCT03931616 1054 1066 B-Procedure

Inclusion NCT03934008 0 9 O
Criteria NCT03934008 10 18 O
( NCT03934008 19 20 O
primary NCT03934008 21 28 O
outcome NCT03934008 29 36 O
) NCT03934008 37 38 O
: NCT03934008 40 41 O

- NCT03934008 45 46 O
Patients NCT03934008 48 56 O
0 NCT03934008 57 58 B-Eq-Comparison
- NCT03934008 59 60 I-Eq-Comparison
6 NCT03934008 61 62 I-Eq-Comparison
years NCT03934008 63 68 I-Eq-Comparison
of NCT03934008 69 71 O
age NCT03934008 72 75 B-Age

- NCT03934008 78 79 O
Seen NCT03934008 81 85 B-Encounter
in NCT03934008 86 88 O
the NCT03934008 89 92 O
Rocking NCT03934008 93 100 O
Horse NCT03934008 101 106 O
Community NCT03934008 107 116 O
Center NCT03934008 117 123 O
by NCT03934008 124 126 O
a NCT03934008 127 128 O
pediatric NCT03934008 129 138 B-Provider
provider NCT03934008 139 147 I-Provider
during NCT03934008 148 154 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03934008 155 158 O
baseline NCT03934008 159 167 B-Study
or NCT03934008 168 170 B-Or
study NCT03934008 171 176 B-Study
period NCT03934008 177 183 O

Inclusion NCT03934008 184 193 O
Criteria NCT03934008 194 202 O
( NCT03934008 203 204 O
secondary NCT03934008 205 214 O
parental NCT03934008 215 223 O
health NCT03934008 224 230 O
belief NCT03934008 231 237 O
outcomes NCT03934008 238 246 O
) NCT03934008 247 248 O
: NCT03934008 250 251 O

- NCT03934008 255 256 O
Parents NCT03934008 258 265 B-Family-Member___Family-Member-Type:parent
/ NCT03934008 266 267 O
caregivers NCT03934008 268 278 O
( NCT03934008 279 280 O
1 NCT03934008 281 282 O
) NCT03934008 283 284 O
≥ NCT03934008 285 286 B-Eq-Comparison
18 NCT03934008 287 289 I-Eq-Comparison
years NCT03934008 290 295 I-Eq-Comparison
old NCT03934008 296 299 B-Age

- NCT03934008 302 303 O
Read NCT03934008 305 309 O
English NCT03934008 310 317 O

- NCT03934008 320 321 O
Have NCT03934008 323 327 O
at NCT03934008 328 330 B-Eq-Comparison
least NCT03934008 331 336 I-Eq-Comparison
one NCT03934008 337 340 I-Eq-Comparison
child NCT03934008 341 346 O
≤ NCT03934008 347 348 B-Eq-Comparison
6 NCT03934008 349 350 I-Eq-Comparison
years NCT03934008 351 356 I-Eq-Comparison
of NCT03934008 357 359 O
age NCT03934008 360 363 B-Age

Inclusion NCT03934008 364 373 O
Criteria NCT03934008 374 382 O
( NCT03934008 383 384 O
secondary NCT03934008 385 394 O
provider NCT03934008 395 403 O
outcomes NCT03934008 404 412 O
) NCT03934008 413 414 O
: NCT03934008 416 417 O
All NCT03934008 418 421 O
providers NCT03934008 422 431 O
who NCT03934008 432 435 O
interact NCT03934008 436 444 O
with NCT03934008 445 449 O
pediatric NCT03934008 450 459 O

patients NCT03934008 460 468 O
in NCT03934008 469 471 O
the NCT03934008 472 475 O
Rocking NCT03934008 476 483 O
Horse NCT03934008 484 489 O
Community NCT03934008 490 499 O
Center NCT03934008 500 506 O
who NCT03934008 507 510 O

- NCT03934008 513 514 O
Complete NCT03934008 516 524 O
the NCT03934008 525 528 O
training NCT03934008 529 537 O
and NCT03934008 538 541 O

- NCT03934008 544 545 O
Implement NCT03934008 547 556 O
the NCT03934008 557 560 O
MOTIVE NCT03934008 561 567 O
tool NCT03934008 568 572 O
in NCT03934008 573 575 O
practice NCT03934008 576 584 O

Inclusion NCT03934034 0 9 O
Criteria NCT03934034 10 18 O
: NCT03934034 19 20 O

1 NCT03934034 24 25 O
. NCT03934034 25 26 O
Clinical NCT03934034 28 36 O
diagnosis NCT03934034 37 46 O
of NCT03934034 47 49 O
NTM NCT03934034 50 53 B-Condition
pulmonary NCT03934034 54 63 I-Condition
disease NCT03934034 64 71 I-Condition
. NCT03934034 72 73 O

2 NCT03934034 77 78 O
. NCT03934034 78 79 O
The NCT03934034 81 84 O
causative NCT03934034 85 94 B-Organism
agent NCT03934034 95 100 I-Organism
of NCT03934034 101 103 O
NTM NCT03934034 104 107 B-Condition
pulmonary NCT03934034 108 117 I-Condition
disease NCT03934034 118 125 I-Condition
includes NCT03934034 126 134 O
: NCT03934034 135 136 O
M. NCT03934034 137 139 B-Organism
avium NCT03934034 141 146 I-Organism
complex NCT03934034 147 154 I-Organism
, NCT03934034 155 156 O
or NCT03934034 157 159 B-Or
M. NCT03934034 160 162 O
abscessus NCT03934034 164 173 I-Organism
subspecies NCT03934034 174 184 I-Organism
abscessus NCT03934034 185 194 O
, NCT03934034 195 196 O
or NCT03934034 197 199 B-Or
M. NCT03934034 200 202 O
abscessus NCT03934034 204 213 O
subspecies NCT03934034 214 224 O
massiliense NCT03934034 225 236 I-Organism
, NCT03934034 237 238 O
or NCT03934034 239 241 B-Or
M. NCT03934034 242 244 O
kansasii NCT03934034 246 254 I-Organism
. NCT03934034 255 256 O

3 NCT03934034 260 261 O
. NCT03934034 261 262 O
Patients NCT03934034 264 272 O
who NCT03934034 273 276 O
starts NCT03934034 277 283 O
new NCT03934034 284 287 B-Eq-Comparison
treatment NCT03934034 288 297 B-Procedure
( NCT03934034 298 299 O
those NCT03934034 300 305 O
who NCT03934034 306 309 O
have NCT03934034 310 314 O
previous NCT03934034 315 323 B-Eq-Comparison
history NCT03934034 324 331 I-Eq-Comparison
of NCT03934034 332 334 O
treatment NCT03934034 335 344 B-Procedure
are NCT03934034 345 348 O
eligible NCT03934034 349 357 O
) NCT03934034 358 359 O

Exclusion NCT03934034 361 370 O
Criteria NCT03934034 371 379 O

1 NCT03934034 382 383 O
. NCT03934034 383 384 O
Patients NCT03934034 386 394 O
who NCT03934034 395 398 O
have NCT03934034 399 403 O
been NCT03934034 404 408 O
treated NCT03934034 409 416 B-Procedure
for NCT03934034 417 420 O
more NCT03934034 421 425 B-Eq-Comparison
than NCT03934034 426 430 I-Eq-Comparison
4 NCT03934034 431 432 I-Eq-Comparison
weeks NCT03934034 433 438 I-Eq-Comparison
. NCT03934034 439 440 O

2 NCT03934034 444 445 O
. NCT03934034 445 446 O
The NCT03934034 448 451 O
causative NCT03934034 452 461 B-Organism
agent NCT03934034 462 467 I-Organism
of NCT03934034 468 470 O
NTM NCT03934034 471 474 B-Condition
pulmonary NCT03934034 475 484 I-Condition
disease NCT03934034 485 492 I-Condition
is NCT03934034 493 495 O
none NCT03934034 496 500 B-Negation
of NCT03934034 501 503 I-Negation
M. NCT03934034 504 506 O
avium NCT03934034 508 513 O
complex NCT03934034 514 521 O
, NCT03934034 522 523 O
M. NCT03934034 524 526 O
abscessus NCT03934034 528 537 O
subspecies NCT03934034 538 548 O
abscessus NCT03934034 549 558 O
, NCT03934034 559 560 O
M. NCT03934034 561 563 O
abscessus NCT03934034 565 574 O
subspecies NCT03934034 575 585 O
massiliense NCT03934034 586 597 O
, NCT03934034 598 599 O
or NCT03934034 600 602 B-Or
M. NCT03934034 603 605 O
kansasii NCT03934034 607 615 O
. NCT03934034 615 616 O

Inclusion NCT03934593 0 9 O
Criteria NCT03934593 10 18 O
: NCT03934593 19 20 O

- NCT03934593 24 25 O
Church NCT03934593 27 33 O
eligibility NCT03934593 34 45 O
: NCT03934593 46 47 O
[ NCT03934593 48 49 O
Churches NCT03934593 50 58 O
must NCT03934593 59 63 O
be NCT03934593 64 66 O
predominantly NCT03934593 67 80 O
Hispanics NCT03934593 81 90 O
( NCT03934593 91 92 O
60 NCT03934593 93 95 O
% NCT03934593 96 97 O
) NCT03934593 99 100 O
with NCT03934593 101 105 O
at NCT03934593 106 108 B-Eq-Comparison
least NCT03934593 109 114 I-Eq-Comparison
20 NCT03934593 115 117 I-Eq-Comparison
adult NCT03934593 118 123 I-Eq-Comparison
congregants NCT03934593 124 135 O
with NCT03934593 136 140 B-And
T2D NCT03934593 141 144 B-Condition
willing NCT03934593 145 152 O
to NCT03934593 153 155 O
participate NCT03934593 156 167 O
in NCT03934593 168 170 O
the NCT03934593 171 174 O
study NCT03934593 175 180 O
. NCT03934593 180 181 O
The NCT03934593 183 186 O
rationale NCT03934593 187 196 O
for NCT03934593 197 200 O
20 NCT03934593 201 203 O
diabetic NCT03934593 204 212 O
voluntary NCT03934593 213 222 O
participants NCT03934593 223 235 O
per NCT03934593 236 239 O
church NCT03934593 240 246 O
is NCT03934593 247 249 O
based NCT03934593 250 255 O
on NCT03934593 256 258 O
the NCT03934593 259 262 O
Stanford NCT03934593 263 271 O
requirement NCT03934593 272 283 O
of NCT03934593 284 286 O

12 NCT03934593 292 294 O
- NCT03934593 295 296 O
16 NCT03934593 297 299 O
participants NCT03934593 300 312 O
allowed NCT03934593 313 320 O
per NCT03934593 321 324 O
support NCT03934593 325 332 O
group NCT03934593 333 338 O
and NCT03934593 339 342 O
with NCT03934593 343 347 O
an NCT03934593 348 350 O
anticipated NCT03934593 351 362 O
25 NCT03934593 363 365 O
% NCT03934593 366 367 O
attrition NCT03934593 368 377 O
. NCT03934593 377 378 O
] NCT03934593 379 380 O

- NCT03934593 384 385 O
Participants NCT03934593 387 399 O
' NCT03934593 399 400 O
eligibility NCT03934593 401 412 O
: NCT03934593 413 414 O
Participants NCT03934593 415 427 O
will NCT03934593 428 432 O
be NCT03934593 433 435 O
adults NCT03934593 436 442 O
age NCT03934593 443 446 B-Age
21 NCT03934593 447 449 B-Eq-Comparison
and NCT03934593 450 453 I-Eq-Comparison
above NCT03934593 454 459 I-Eq-Comparison
that NCT03934593 460 464 O
have NCT03934593 465 469 B-And
been NCT03934593 470 474 I-And
diagnosed NCT03934593 475 484 O
with NCT03934593 485 489 O
T2D NCT03934593 490 493 B-Condition
. NCT03934593 494 495 O

Exclusion NCT03934593 497 506 O
Criteria NCT03934593 507 515 O
: NCT03934593 516 517 O

- NCT03934593 521 522 O
Children NCT03934593 524 532 O
, NCT03934593 533 534 O
adults NCT03934593 535 541 O
under NCT03934593 542 547 B-Eq-Comparison
21 NCT03934593 548 550 I-Eq-Comparison
years NCT03934593 551 556 I-Eq-Comparison
of NCT03934593 557 559 O
age NCT03934593 560 563 B-Age
, NCT03934593 564 565 O
and NCT03934593 566 569 B-And
pregnant NCT03934593 570 578 B-Condition
women NCT03934593 579 584 O

Inclusion NCT03934424 0 9 O
Criteria NCT03934424 10 18 O
: NCT03934424 19 20 O

- NCT03934424 24 25 O
Generally NCT03934424 27 36 O
healthy NCT03934424 37 44 B-Condition
individuals NCT03934424 45 56 O
aged NCT03934424 57 61 B-Age
from NCT03934424 62 66 O
18 NCT03934424 67 69 B-Eq-Comparison
to NCT03934424 70 72 I-Eq-Comparison
55 NCT03934424 73 75 I-Eq-Comparison
years NCT03934424 76 81 I-Eq-Comparison

- NCT03934424 84 85 O
BMI NCT03934424 87 90 B-Observation
25 NCT03934424 91 93 B-Eq-Comparison
- NCT03934424 94 95 I-Eq-Comparison
35 NCT03934424 96 98 I-Eq-Comparison
kg NCT03934424 99 101 I-Eq-Comparison
/ NCT03934424 102 103 I-Eq-Comparison
m2 NCT03934424 104 106 I-Eq-Comparison
will NCT03934424 107 111 O
be NCT03934424 112 114 O
recruited NCT03934424 115 124 O

Exclusion NCT03934424 125 134 O
Criteria NCT03934424 135 143 O
: NCT03934424 144 145 O

- NCT03934424 149 150 O
Being NCT03934424 152 157 B-Eq-Comparison
on NCT03934424 158 160 O
a NCT03934424 161 162 O
weight NCT03934424 163 169 B-Modifier
- NCT03934424 170 171 I-Modifier
loss NCT03934424 172 176 I-Modifier
or NCT03934424 177 179 B-Or
special NCT03934424 180 187 B-Modifier
diet NCT03934424 188 192 B-Procedure

- NCT03934424 195 196 O
Taking NCT03934424 198 204 B-Eq-Comparison
any NCT03934424 205 208 O
medications NCT03934424 209 220 B-Drug
or NCT03934424 221 223 B-Or
drugs NCT03934424 224 229 B-Drug
known NCT03934424 230 235 O
to NCT03934424 236 238 O
affect NCT03934424 239 245 O
appetite NCT03934424 246 254 B-Condition

- NCT03934424 257 258 O
Have NCT03934424 260 264 O
serious NCT03934424 265 272 O
claustrophobia NCT03934424 273 287 B-Condition
. NCT03934424 288 289 O

- NCT03934424 293 294 O
Individuals NCT03934424 296 307 O
with NCT03934424 308 312 O
mental NCT03934424 313 319 B-Condition
disorders NCT03934424 320 329 I-Condition
( NCT03934424 330 331 O
self NCT03934424 332 336 B-Assertion___Assertion-Type-Value:possible
- NCT03934424 337 338 I-Assertion___Assertion-Type-Value:possible
report NCT03934424 339 345 I-Assertion___Assertion-Type-Value:possible
) NCT03934424 346 347 O
will NCT03934424 348 352 O
be NCT03934424 353 355 O
excluded NCT03934424 356 364 B-Negation
. NCT03934424 365 366 O

- NCT03934424 370 371 O
Due NCT03934424 373 376 O
to NCT03934424 377 379 O
MRI NCT03934424 380 383 B-Procedure
, NCT03934424 384 385 O
any NCT03934424 386 389 O
individuals NCT03934424 390 401 O
with NCT03934424 402 406 O
metallic NCT03934424 407 415 B-Condition
objects NCT03934424 416 423 I-Condition
in NCT03934424 424 426 I-Condition
their NCT03934424 427 432 I-Condition
body NCT03934424 433 437 I-Condition
, NCT03934424 438 439 O
including NCT03934424 440 449 O
surgical NCT03934424 450 458 B-Condition
staples NCT03934424 459 466 I-Condition
left NCT03934424 467 471 I-Condition
in NCT03934424 472 474 I-Condition
the NCT03934424 475 478 I-Condition
body NCT03934424 479 483 I-Condition
following NCT03934424 484 493 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03934424 494 501 B-Procedure
, NCT03934424 502 503 O
middle NCT03934424 504 510 B-Condition
ear NCT03934424 511 514 I-Condition
prosthesis NCT03934424 515 525 I-Condition
, NCT03934424 526 527 O
permanent NCT03934424 528 537 B-Condition
eye NCT03934424 538 541 I-Condition
liner NCT03934424 542 547 I-Condition
, NCT03934424 548 549 O
metal NCT03934424 550 555 B-Condition
foreign NCT03934424 556 563 I-Condition
objects NCT03934424 564 571 I-Condition
lodged NCT03934424 572 578 I-Condition
inside NCT03934424 579 585 I-Condition
the NCT03934424 586 589 I-Condition
eye NCT03934424 590 593 I-Condition
, NCT03934424 594 595 O
heart NCT03934424 596 601 B-Condition
pacemakers NCT03934424 602 612 I-Condition
, NCT03934424 613 614 O
and NCT03934424 615 618 B-Or
/ NCT03934424 619 620 I-Or
or NCT03934424 621 623 I-Or
pins NCT03934424 624 628 B-Condition
inside NCT03934424 629 635 I-Condition
the NCT03934424 636 639 O
knee NCT03934424 640 644 B-Modifier
or NCT03934424 645 647 B-Or
other NCT03934424 648 653 B-Modifier
joints NCT03934424 654 660 I-Modifier
or NCT03934424 661 663 B-Or
who NCT03934424 664 667 O
are NCT03934424 668 671 O
pregnant NCT03934424 672 680 B-Condition
or NCT03934424 681 683 B-Or
could NCT03934424 684 689 B-Assertion___Assertion-Type-Value:possible
be NCT03934424 690 692 I-Assertion___Assertion-Type-Value:possible
pregnant NCT03934424 693 701 B-Condition
( NCT03934424 702 703 O
assessed NCT03934424 704 712 O
through NCT03934424 713 720 O
a NCT03934424 721 722 O
urine NCT03934424 723 728 B-Observation
pregnancy NCT03934424 729 738 I-Observation
test NCT03934424 739 743 I-Observation
for NCT03934424 744 747 O
women NCT03934424 748 753 O
) NCT03934424 754 755 O
will NCT03934424 756 760 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03934424 761 763 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03934424 764 772 B-Negation
from NCT03934424 773 777 O
this NCT03934424 778 782 O
study NCT03934424 783 788 B-Study
because NCT03934424 789 796 O
of NCT03934424 797 799 O
the NCT03934424 800 803 O
risk NCT03934424 804 808 B-Risk
associated NCT03934424 809 819 O
with NCT03934424 820 824 O
the NCT03934424 825 828 O
MRI NCT03934424 829 832 B-Procedure
scanner NCT03934424 833 840 O
. NCT03934424 840 841 O

Inclusion NCT03862404 0 9 O
Criteria NCT03862404 10 18 O
: NCT03862404 19 20 O

- NCT03862404 24 25 O
Male NCT03862404 27 31 O
and NCT03862404 32 35 B-Or
Female NCT03862404 36 42 O
, NCT03862404 43 44 O
between NCT03862404 45 52 B-Eq-Comparison
18 NCT03862404 53 55 I-Eq-Comparison
and NCT03862404 56 59 I-Eq-Comparison
80 NCT03862404 60 62 I-Eq-Comparison
years NCT03862404 63 68 I-Age|Eq-Comparison
, NCT03862404 69 70 O
ASA NCT03862404 71 74 B-Condition
1 NCT03862404 75 76 B-Eq-Comparison
- NCT03862404 77 78 I-Eq-Comparison
3 NCT03862404 79 80 O
, NCT03862404 81 82 O
Scheduled NCT03862404 83 92 B-Eq-Comparison
for NCT03862404 93 96 O
open NCT03862404 97 101 B-Modifier
thoracotomy NCT03862404 102 113 B-Procedure

Exclusion NCT03862404 114 123 O
Criteria NCT03862404 124 132 O
: NCT03862404 133 134 O

- NCT03862404 138 139 O
ASA NCT03862404 141 144 B-Condition
> NCT03862404 145 146 B-Eq-Comparison
3 NCT03862404 147 148 I-Eq-Comparison
, NCT03862404 149 150 O
morbid NCT03862404 151 157 B-Condition
obesity NCT03862404 158 165 I-Condition
BMI NCT03862404 166 169 B-Observation
> NCT03862404 170 171 B-Eq-Comparison
40 NCT03862404 172 174 I-Eq-Comparison
, NCT03862404 175 176 O
Previous NCT03862404 177 185 B-Eq-Comparison
cardiac NCT03862404 186 193 B-Modifier
or NCT03862404 194 196 B-Or
ipsilateral NCT03862404 197 208 B-Modifier
thoracic NCT03862404 209 217 B-Procedure
surgery NCT03862404 218 225 I-Procedure
, NCT03862404 226 227 O
Renal NCT03862404 228 233 B-Modifier
or NCT03862404 234 236 B-Or
hepatic NCT03862404 237 244 B-Modifier
failure NCT03862404 245 252 B-Condition
, NCT03862404 253 254 O
anemia NCT03862404 255 261 B-Condition
, NCT03862404 262 263 O
allergy NCT03862404 264 271 B-Allergy
to NCT03862404 272 274 O
local NCT03862404 275 280 B-Procedure
anesthetics NCT03862404 281 292 I-Procedure
, NCT03862404 293 294 O
contraindications NCT03862404 295 312 B-Contraindication
to NCT03862404 313 315 O
receive NCT03862404 316 323 O
regional NCT03862404 324 332 B-Procedure
anesthesia NCT03862404 333 343 I-Procedure
, NCT03862404 344 345 O
patient NCT03862404 346 353 O
refusal NCT03862404 354 361 O
, NCT03862404 362 363 O
reiteration NCT03862404 364 375 B-Observation
due NCT03862404 376 379 O
to NCT03862404 380 382 O
complication NCT03862404 383 395 B-Condition

Inclusion NCT03861858 0 9 O
Criteria NCT03861858 10 18 O
: NCT03861858 19 20 O

- NCT03861858 24 25 O
Age NCT03861858 27 30 B-Age
13 NCT03861858 31 33 B-Eq-Comparison
- NCT03861858 34 35 I-Eq-Comparison
17 NCT03861858 36 38 I-Eq-Comparison
years NCT03861858 39 44 I-Eq-Comparison
or NCT03861858 45 47 B-Or
18 NCT03861858 48 50 B-Eq-Comparison
- NCT03861858 51 52 I-Eq-Comparison
20 NCT03861858 53 55 O
if NCT03861858 56 58 O
still NCT03861858 59 64 O
living NCT03861858 65 71 O
at NCT03861858 72 74 O
home NCT03861858 75 79 O
with NCT03861858 80 84 O
parent NCT03861858 85 91 O
. NCT03861858 92 93 O

- NCT03861858 97 98 O
Agreement NCT03861858 100 109 O
of NCT03861858 110 112 O
at NCT03861858 113 115 B-Eq-Comparison
least NCT03861858 116 121 I-Eq-Comparison
one NCT03861858 122 125 I-Eq-Comparison
responsible NCT03861858 126 137 O
adult NCT03861858 138 143 O
parent NCT03861858 144 150 B-Family-Member___Family-Member-Type:parent
/ NCT03861858 151 152 O
caregiver NCT03861858 153 162 O
to NCT03861858 163 165 O
participate NCT03861858 166 177 O
in NCT03861858 178 180 O
treatment NCT03861858 181 190 B-Procedure
. NCT03861858 191 192 O

- NCT03861858 196 197 O
Agreement NCT03861858 199 208 O
to NCT03861858 209 211 O
take NCT03861858 212 216 O
part NCT03861858 217 221 O
in NCT03861858 222 224 O
assessments NCT03861858 225 236 O
, NCT03861858 237 238 O
videotaping NCT03861858 239 250 O
/ NCT03861858 251 252 O
audiotaping NCT03861858 253 264 O
and NCT03861858 265 268 O
coding NCT03861858 269 275 O
of NCT03861858 276 278 O
their NCT03861858 279 284 O
sessions NCT03861858 285 293 O
by NCT03861858 294 296 O
research NCT03861858 297 305 O
personnel NCT03861858 306 315 O
. NCT03861858 316 317 O

- NCT03861858 321 322 O
Agreement NCT03861858 324 333 O
to NCT03861858 334 336 O
pay NCT03861858 337 340 O
for NCT03861858 341 344 O
mental NCT03861858 345 351 O
health NCT03861858 352 358 O
services NCT03861858 359 367 O
at NCT03861858 368 370 O
the NCT03861858 371 374 O
DBT NCT03861858 375 378 O
- NCT03861858 379 380 O
RU NCT03861858 381 383 O
on NCT03861858 384 386 O
a NCT03861858 387 388 O
sliding NCT03861858 389 396 O
scale NCT03861858 397 402 O
, NCT03861858 403 404 O
and NCT03861858 405 408 O
to NCT03861858 409 411 O
participate NCT03861858 412 423 O
in NCT03861858 424 426 O
research NCT03861858 427 435 O
assessments NCT03861858 436 447 O
as NCT03861858 448 450 O
volunteers NCT03861858 451 461 O
. NCT03861858 462 463 O

- NCT03861858 467 468 O
Residence NCT03861858 470 479 O
within NCT03861858 480 486 O
commuting NCT03861858 487 496 B-Observation
distance NCT03861858 497 505 I-Observation
of NCT03861858 506 508 O
clinic NCT03861858 509 515 O
( NCT03861858 516 517 O
< NCT03861858 519 520 B-Eq-Comparison
45 NCT03861858 521 523 I-Eq-Comparison
minutes NCT03861858 524 531 I-Eq-Comparison
) NCT03861858 532 533 O
. NCT03861858 535 536 O

- NCT03861858 540 541 O
Agreement NCT03861858 543 552 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861858 553 555 O
discontinue NCT03861858 556 567 B-Negation
other NCT03861858 568 573 O
forms NCT03861858 574 579 O
of NCT03861858 580 582 O
talk NCT03861858 583 587 B-Procedure
therapy NCT03861858 588 595 I-Procedure
for NCT03861858 596 599 B-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03861858 600 608 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03861858 609 611 O
DBT NCT03861858 612 615 B-Procedure
program NCT03861858 616 623 I-Procedure
( NCT03861858 624 625 O
does NCT03861858 626 630 B-Exception
not NCT03861858 631 634 I-Exception
refer NCT03861858 635 640 I-Exception
to NCT03861858 641 643 I-Exception
AA NCT03861858 644 646 B-Modifier
/ NCT03861858 647 648 B-Or
NA NCT03861858 649 651 B-Modifier
programs NCT03861858 652 660 B-Procedure
or NCT03861858 661 663 B-Or
psychotropic NCT03861858 664 676 B-Drug
medication NCT03861858 677 687 I-Drug
management NCT03861858 688 698 B-Procedure
) NCT03861858 699 700 O
. NCT03861858 702 703 O

- NCT03861858 707 708 O
Exhibits NCT03861858 710 718 O
dysregulation NCT03861858 719 732 B-Condition
within NCT03861858 733 739 B-Eq-Comparison
the NCT03861858 740 743 I-Eq-Comparison
past NCT03861858 744 748 I-Eq-Comparison
six NCT03861858 749 752 I-Eq-Comparison
months NCT03861858 753 759 I-Eq-Comparison
as NCT03861858 760 762 O
evidenced NCT03861858 763 772 O
by NCT03861858 773 775 O
1 NCT03861858 776 777 O
) NCT03861858 778 779 O
intentional NCT03861858 780 791 B-Modifier
self NCT03861858 792 796 B-Condition
- NCT03861858 797 798 I-Condition
injury NCT03861858 799 805 I-Condition
and NCT03861858 806 809 B-Or
/ NCT03861858 810 811 I-Or
or NCT03861858 812 814 I-Or
suicide NCT03861858 815 822 B-Condition
attempt NCT03861858 823 830 I-Condition
and NCT03861858 831 834 B-Or
/ NCT03861858 835 836 I-Or
or NCT03861858 837 839 I-Or
2 NCT03861858 840 841 O
) NCT03861858 842 843 O
substance NCT03861858 844 853 B-Condition
use NCT03861858 854 857 I-Condition
disorder NCT03861858 858 866 I-Condition
. NCT03861858 867 868 O

- NCT03861858 872 873 O
Meets NCT03861858 875 880 O
two NCT03861858 881 884 B-Eq-Comparison
additional NCT03861858 885 895 O
criteria NCT03861858 896 904 O
for NCT03861858 905 908 O
borderline NCT03861858 909 919 B-Condition
personality NCT03861858 920 931 I-Condition
disorder NCT03861858 932 940 I-Condition
( NCT03861858 941 942 O
BPD NCT03861858 943 946 B-Condition
) NCT03861858 947 948 O
. NCT03861858 950 951 O

Exclusion NCT03861858 953 962 O
Criteria NCT03861858 963 971 O
: NCT03861858 972 973 O

- NCT03861858 977 978 O
Clients NCT03861858 980 987 O
who NCT03861858 988 991 O
need NCT03861858 992 996 B-Assertion___Assertion-Type-Value:hypothetical
mental NCT03861858 997 1003 B-Procedure
health NCT03861858 1004 1010 I-Procedure
services NCT03861858 1011 1019 I-Procedure
not NCT03861858 1020 1023 B-Negation
available NCT03861858 1024 1033 O
at NCT03861858 1034 1036 O
the NCT03861858 1037 1040 O
DBT NCT03861858 1041 1044 O
- NCT03861858 1045 1046 O
RU NCT03861858 1047 1049 O
, NCT03861858 1050 1051 O
such NCT03861858 1052 1056 O
as NCT03861858 1057 1059 O
treatment NCT03861858 1060 1069 B-Procedure
for NCT03861858 1070 1073 O
schizophrenia NCT03861858 1074 1087 B-Condition
or NCT03861858 1088 1090 B-Or
life NCT03861858 1091 1095 B-Death|Risk
- NCT03861858 1096 1097 I-Death|Risk
threatening NCT03861858 1098 1109 I-Death|Risk
anorexia NCT03861858 1110 1118 B-Condition
, NCT03861858 1119 1120 O
or NCT03861858 1121 1123 B-Or
who NCT03861858 1124 1127 O
are NCT03861858 1128 1131 O
currently NCT03861858 1132 1141 B-Eq-Comparison
obtaining NCT03861858 1142 1151 O
optimum NCT03861858 1152 1159 O
professional NCT03861858 1160 1172 B-Procedure
treatment NCT03861858 1173 1182 I-Procedure
that NCT03861858 1183 1187 O
should NCT03861858 1188 1194 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03861858 1195 1198 B-Negation
be NCT03861858 1199 1201 O
ended NCT03861858 1202 1207 B-Negation
. NCT03861858 1208 1209 O

- NCT03861858 1213 1214 O
Non NCT03861858 1216 1219 B-Negation
- NCT03861858 1220 1221 O
English NCT03861858 1222 1229 O
speaking NCT03861858 1230 1238 O
. NCT03861858 1239 1240 O

- NCT03861858 1244 1245 O
IQ NCT03861858 1247 1249 B-Observation
< NCT03861858 1250 1251 B-Eq-Comparison
70 NCT03861858 1252 1254 I-Eq-Comparison
. NCT03861858 1254 1255 O

- NCT03861858 1259 1260 O
Unable NCT03861858 1262 1268 O
to NCT03861858 1269 1271 O
understand NCT03861858 1272 1282 O
research NCT03861858 1283 1291 O
consent NCT03861858 1292 1299 O
forms NCT03861858 1300 1305 O
. NCT03861858 1306 1307 O

- NCT03861858 1311 1312 O
Court NCT03861858 1314 1319 B-Observation
- NCT03861858 1320 1321 I-Observation
ordered NCT03861858 1322 1329 I-Observation
to NCT03861858 1330 1332 O
participate NCT03861858 1333 1344 O
in NCT03861858 1345 1347 O
treatment NCT03861858 1348 1357 B-Procedure
. NCT03861858 1357 1358 O

Inclusion NCT03869021 0 9 O
Criteria NCT03869021 10 18 O
: NCT03869021 19 20 O

1 NCT03869021 24 25 O
. NCT03869021 25 26 O
Patients NCT03869021 28 36 O
free NCT03869021 37 41 B-Negation
from NCT03869021 42 46 I-Negation
any NCT03869021 47 50 O
disease NCT03869021 51 58 B-Condition
affecting NCT03869021 59 68 B-Modifier
bone NCT03869021 69 73 I-Modifier
formation NCT03869021 74 83 I-Modifier
of NCT03869021 84 86 O
both NCT03869021 87 91 O
sexes NCT03869021 92 97 O
was NCT03869021 98 101 O
included NCT03869021 102 110 O
in NCT03869021 111 113 O
the NCT03869021 114 117 O
study NCT03869021 118 123 O
. NCT03869021 124 125 O

2 NCT03869021 129 130 O
. NCT03869021 130 131 O
Patients NCT03869021 133 141 O
younger NCT03869021 142 149 B-Eq-Comparison
than NCT03869021 150 154 I-Eq-Comparison
25 NCT03869021 155 157 I-Eq-Comparison
years NCT03869021 158 163 I-Eq-Comparison
old NCT03869021 164 167 B-Age
. NCT03869021 168 169 O

3 NCT03869021 173 174 O
. NCT03869021 174 175 O
Patients NCT03869021 177 185 O
included NCT03869021 186 194 O
in NCT03869021 195 197 O
the NCT03869021 198 201 O
study NCT03869021 202 207 O
were NCT03869021 208 212 O
hemifacial NCT03869021 213 223 B-Condition
microsomia NCT03869021 224 234 I-Condition

4 NCT03869021 237 238 O
. NCT03869021 238 239 O
Distraction NCT03869021 241 252 B-Observation
range NCT03869021 253 258 I-Observation
was NCT03869021 259 262 O
between NCT03869021 263 270 O
15 NCT03869021 271 273 B-Eq-Comparison
- NCT03869021 274 275 I-Eq-Comparison
20 NCT03869021 276 278 I-Eq-Comparison
mm NCT03869021 279 281 I-Eq-Comparison
. NCT03869021 282 283 O

Exclusion NCT03869021 285 294 O
Criteria NCT03869021 295 303 O
: NCT03869021 304 305 O

1 NCT03869021 309 310 O
. NCT03869021 310 311 O
The NCT03869021 313 316 O
presence NCT03869021 317 325 B-Eq-Comparison
of NCT03869021 326 328 O
uncontrolled NCT03869021 329 341 B-Modifier
systemic NCT03869021 342 350 I-Modifier
disease NCT03869021 351 358 B-Condition
. NCT03869021 359 360 O

2 NCT03869021 364 365 O
. NCT03869021 365 366 O
Previous NCT03869021 368 376 B-Eq-Comparison
radiotherapy NCT03869021 377 389 B-Procedure
on NCT03869021 390 392 O
head NCT03869021 393 397 B-Modifier
and NCT03869021 398 401 B-Or
neck NCT03869021 402 406 B-Modifier
region NCT03869021 407 413 I-Modifier
. NCT03869021 414 415 O

3 NCT03869021 419 420 O
. NCT03869021 420 421 O
Chemotherapy NCT03869021 423 435 B-Procedure
within NCT03869021 436 442 B-Eq-Comparison
the NCT03869021 443 446 I-Eq-Comparison
past NCT03869021 447 451 I-Eq-Comparison
12 NCT03869021 452 454 I-Eq-Comparison
- NCT03869021 455 456 I-Eq-Comparison
month NCT03869021 457 462 I-Eq-Comparison
period NCT03869021 463 469 O
. NCT03869021 470 471 O

4 NCT03869021 475 476 O
. NCT03869021 476 477 O
An NCT03869021 479 481 O
active NCT03869021 482 488 B-Eq-Comparison
infection NCT03869021 489 498 B-Condition
at NCT03869021 499 501 O
the NCT03869021 502 505 O
distraction NCT03869021 506 517 B-Modifier
site NCT03869021 518 522 I-Modifier
. NCT03869021 522 523 O

Inclusion NCT03864263 0 9 O
Criteria NCT03864263 10 18 O
: NCT03864263 19 20 O

- NCT03864263 24 25 O
The NCT03864263 27 30 O
father NCT03864263 31 37 B-Family-Member___Family-Member-Type:father
or NCT03864263 38 40 B-Or
( NCT03864263 41 42 I-Or
and NCT03864263 43 46 I-Or
) NCT03864263 47 48 I-Or
mother NCT03864263 49 55 B-Family-Member___Family-Member-Type:mother
is NCT03864263 56 58 O
HBV NCT03864263 59 62 B-Condition
- NCT03864263 63 64 I-Condition
infected NCT03864263 65 73 I-Condition
( NCT03864263 74 75 O
pre NCT03864263 76 79 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03864263 80 81 O
pregnancy NCT03864263 82 91 B-Condition
or NCT03864263 92 94 B-Or
present NCT03864263 95 102 B-Eq-Comparison
) NCT03864263 103 104 O
； NCT03864263 105 106 O

- NCT03864263 109 110 O
Children NCT03864263 112 120 B-Family-Member___Family-Member-Type:child
is NCT03864263 121 123 O
vaccinated NCT03864263 124 134 B-Immunization
with NCT03864263 135 139 O
hepatitis NCT03864263 140 149 O
B NCT03864263 150 151 O
vaccine NCT03864263 152 159 O
after NCT03864263 160 165 B-Temporal-Connection___Temporal-Connection-Type-Value:after
birth NCT03864263 166 171 B-Birth
; NCT03864263 171 172 O

Exclusion NCT03864263 173 182 O
Criteria NCT03864263 183 191 O
: NCT03864263 192 193 O

- NCT03864263 197 198 O
Children NCT03864263 200 208 B-Family-Member___Family-Member-Type:child
with NCT03864263 209 213 O
HBV NCT03864263 214 217 B-Condition
infection NCT03864263 218 227 I-Condition
; NCT03864263 227 228 O

- NCT03864263 231 232 O
Participants NCT03864263 234 246 O
agreed NCT03864263 247 253 O
to NCT03864263 254 256 O
undergo NCT03864263 257 264 O
clinical NCT03864263 265 273 O
follow NCT03864263 274 280 O
- NCT03864263 281 282 O
up NCT03864263 283 285 O
studies NCT03864263 286 293 O
. NCT03864263 293 294 O

Inclusion NCT03862612 0 9 O
Criteria NCT03862612 10 18 O
: NCT03862612 19 20 O

- NCT03862612 24 25 O
Male NCT03862612 27 31 O
and NCT03862612 32 35 B-Or
Female NCT03862612 36 42 O
participants NCT03862612 43 55 O
providing NCT03862612 56 65 O
written NCT03862612 66 73 O
informed NCT03862612 74 82 O
consent NCT03862612 83 90 O
, NCT03862612 91 92 O

- NCT03862612 96 97 O
ASA NCT03862612 99 102 B-Condition
grade NCT03862612 103 108 B-Eq-Comparison
1 NCT03862612 109 110 I-Eq-Comparison
- NCT03862612 111 112 I-Eq-Comparison
4 NCT03862612 113 114 I-Eq-Comparison
, NCT03862612 115 116 O

- NCT03862612 121 122 O
aged NCT03862612 124 128 B-Age
over NCT03862612 129 133 B-Eq-Comparison
18 NCT03862612 134 136 I-Eq-Comparison

- NCT03862612 140 141 O
undergoing NCT03862612 143 153 B-Eq-Comparison
a NCT03862612 154 155 O
VATS NCT03862612 156 160 B-Procedure
procedure NCT03862612 161 170 I-Procedure
under NCT03862612 171 176 O
General NCT03862612 177 184 B-Procedure
Anaesthesia NCT03862612 185 196 I-Procedure

Exclusion NCT03862612 197 206 O
Criteria NCT03862612 207 215 O
: NCT03862612 216 217 O

- NCT03862612 221 222 O
Absence NCT03862612 224 231 O
of NCT03862612 232 234 O
informed NCT03862612 235 243 O
written NCT03862612 244 251 O
consent NCT03862612 252 259 O
, NCT03862612 260 261 O

- NCT03862612 265 266 O
pre NCT03862612 268 271 B-Eq-Comparison
existing NCT03862612 272 280 I-Eq-Comparison
infection NCT03862612 281 290 B-Condition
at NCT03862612 291 293 O
block NCT03862612 294 299 B-Modifier
site NCT03862612 300 304 I-Modifier
, NCT03862612 305 306 O
- NCT03862612 308 309 O

- NCT03862612 313 314 O
severe NCT03862612 316 322 O
coagulopathy NCT03862612 323 335 B-Condition
, NCT03862612 336 337 O

- NCT03862612 341 342 O
allergy NCT03862612 344 351 B-Allergy
to NCT03862612 352 354 O
local NCT03862612 355 360 B-Procedure
anaesthesia NCT03862612 361 372 I-Procedure
, NCT03862612 373 374 O

- NCT03862612 378 379 O
pre NCT03862612 381 384 B-Eq-Comparison
existing NCT03862612 385 393 I-Eq-Comparison
neurological NCT03862612 394 406 B-Condition
deficit NCT03862612 407 414 I-Condition
, NCT03862612 415 416 O

- NCT03862612 420 421 O
previous NCT03862612 423 431 B-Eq-Comparison
history NCT03862612 432 439 I-Eq-Comparison
of NCT03862612 440 442 O
opiate NCT03862612 443 449 B-Condition
abuse NCT03862612 450 455 I-Condition
, NCT03862612 456 457 O

- NCT03862612 461 462 O
pre NCT03862612 464 467 B-Eq-Comparison
existing NCT03862612 468 476 I-Eq-Comparison
chronic NCT03862612 477 484 B-Modifier
pain NCT03862612 485 489 B-Condition
condition NCT03862612 490 499 I-Condition
, NCT03862612 500 501 O

- NCT03862612 505 506 O
pre NCT03862612 508 511 B-Eq-Comparison
- NCT03862612 512 513 I-Eq-Comparison
existing NCT03862612 514 522 I-Eq-Comparison
dementia NCT03862612 523 531 B-Condition
[ NCT03862612 532 533 O
because NCT03862612 534 541 O
of NCT03862612 542 544 O
need NCT03862612 545 549 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862612 550 552 I-Assertion___Assertion-Type-Value:hypothetical
co NCT03862612 553 555 O
- NCT03862612 556 557 O
operate NCT03862612 558 565 O
in NCT03862612 566 568 O
completing NCT03862612 569 579 O
QoR NCT03862612 580 583 B-Observation
- NCT03862612 584 585 I-Observation
15 NCT03862612 586 588 I-Observation
score NCT03862612 589 594 I-Observation
day NCT03862612 595 598 B-Eq-Comparison
after NCT03862612 599 604 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03862612 605 612 B-Procedure
] NCT03862612 613 614 O
. NCT03862612 615 616 O

Inclusion NCT03866460 0 9 O
Criteria NCT03866460 10 18 O
: NCT03866460 19 20 O

- NCT03866460 24 25 O
Signed NCT03866460 27 33 O
informed NCT03866460 34 42 O
consent NCT03866460 43 50 O
indicating NCT03866460 51 61 O
awareness NCT03866460 62 71 O
of NCT03866460 72 74 O
the NCT03866460 75 78 O
investigational NCT03866460 79 94 O
nature NCT03866460 95 101 O
of NCT03866460 102 104 O
the NCT03866460 105 108 O
protocol NCT03866460 109 117 O
. NCT03866460 118 119 O

- NCT03866460 123 124 O
Children NCT03866460 126 134 O
with NCT03866460 135 139 B-And
RB NCT03866460 140 142 B-Condition
aged NCT03866460 143 147 B-Age
3 NCT03866460 148 149 B-Eq-Comparison
months NCT03866460 150 156 I-Eq-Comparison
and NCT03866460 157 160 I-Eq-Comparison
older NCT03866460 161 166 I-Eq-Comparison
who NCT03866460 167 170 B-And
are NCT03866460 171 174 O
scheduled NCT03866460 175 184 B-Eq-Comparison
to NCT03866460 185 187 O
receive NCT03866460 188 195 O
their NCT03866460 196 201 O
first NCT03866460 202 207 B-Eq-Comparison
dose NCT03866460 208 212 O
of NCT03866460 213 215 O
IA NCT03866460 216 218 B-Drug
carboplatin NCT03866460 219 230 I-Drug
chemotherapy NCT03866460 231 243 B-Procedure
. NCT03866460 244 245 O

- NCT03866460 254 255 O
Retinoblastoma NCT03866460 257 271 B-Condition
is NCT03866460 272 274 O
rarely NCT03866460 275 281 O
seen NCT03866460 282 286 O
in NCT03866460 287 289 O
children NCT03866460 290 298 O
over NCT03866460 299 303 B-Eq-Comparison
8 NCT03866460 304 305 I-Eq-Comparison
years NCT03866460 306 311 I-Eq-Comparison
old NCT03866460 312 315 I-Eq-Comparison
, NCT03866460 316 317 O
however NCT03866460 318 325 O
we NCT03866460 326 328 O
will NCT03866460 329 333 O
not NCT03866460 334 337 O
include NCT03866460 338 345 O
an NCT03866460 346 348 O
upper NCT03866460 349 354 O
age NCT03866460 355 358 O
range NCT03866460 359 364 O
so NCT03866460 365 367 O
as NCT03866460 368 370 O
not NCT03866460 371 374 O
to NCT03866460 375 377 O
exclude NCT03866460 378 385 O
any NCT03866460 386 389 O
possible NCT03866460 390 398 O
participants NCT03866460 399 411 O

Exclusion NCT03866460 412 421 O
Criteria NCT03866460 422 430 O
: NCT03866460 431 432 O

- NCT03866460 436 437 O
Children NCT03866460 439 447 O
with NCT03866460 448 452 B-And
known NCT03866460 453 458 O
and NCT03866460 459 462 O
documented NCT03866460 463 473 O
preexisting NCT03866460 474 485 B-Eq-Comparison
hearing NCT03866460 486 493 B-Condition
loss NCT03866460 494 498 I-Condition
. NCT03866460 498 499 O

Inclusion NCT03863444 0 9 O
Criteria NCT03863444 10 18 O
: NCT03863444 19 20 O

- NCT03863444 24 25 O
( NCT03863444 27 28 O
1 NCT03863444 29 30 O
) NCT03863444 31 32 O
gestational NCT03863444 33 44 B-Observation
age NCT03863444 45 48 I-Observation
35 NCT03863444 49 51 B-Eq-Comparison
to NCT03863444 52 54 I-Eq-Comparison
39 NCT03863444 55 57 I-Eq-Comparison
weeks NCT03863444 58 63 I-Eq-Comparison

- NCT03863444 66 67 O
( NCT03863444 69 70 O
2 NCT03863444 71 72 O
) NCT03863444 73 74 O
adults NCT03863444 75 81 O

- NCT03863444 84 85 O
( NCT03863444 87 88 O
3 NCT03863444 89 90 O
) NCT03863444 91 92 O
primipara NCT03863444 93 102 B-Condition
and NCT03863444 103 106 B-And
their NCT03863444 107 112 O
spouses NCT03863444 113 120 B-Family-Member___Family-Member-Type:spouse

- NCT03863444 123 124 O
( NCT03863444 126 127 O
4 NCT03863444 128 129 O
) NCT03863444 130 131 O
having NCT03863444 132 138 B-Eq-Comparison
routine NCT03863444 139 146 O
prenatal NCT03863444 147 155 B-Modifier
visits NCT03863444 156 162 B-Encounter
and NCT03863444 163 166 B-And
plan NCT03863444 167 171 B-Assertion___Assertion-Type-Value:intention
to NCT03863444 172 174 O
have NCT03863444 175 179 O
the NCT03863444 180 183 O
birth NCT03863444 184 189 B-Birth
in NCT03863444 190 192 O
the NCT03863444 193 196 O
medical NCT03863444 197 204 O
center NCT03863444 205 211 O

- NCT03863444 214 215 O
( NCT03863444 217 218 O
5 NCT03863444 219 220 O
) NCT03863444 221 222 O
able NCT03863444 223 227 O
to NCT03863444 228 230 O
communicate NCT03863444 231 242 O
with NCT03863444 243 247 O
Mandarin NCT03863444 248 256 O
or NCT03863444 257 259 B-Or
Taiwanese NCT03863444 260 269 O

- NCT03863444 272 273 O
( NCT03863444 275 276 O
6 NCT03863444 277 278 O
) NCT03863444 279 280 O
willing NCT03863444 281 288 O
to NCT03863444 289 291 O
participate NCT03863444 292 303 O
in NCT03863444 304 306 O
this NCT03863444 307 311 O
study NCT03863444 312 317 O
and NCT03863444 318 321 O
give NCT03863444 322 326 O
written NCT03863444 327 334 O
inform NCT03863444 335 341 O
- NCT03863444 342 343 O
consent NCT03863444 344 351 O
forms NCT03863444 352 357 O

Exclusion NCT03863444 358 367 O
Criteria NCT03863444 368 376 O
: NCT03863444 377 378 O

- NCT03863444 382 383 O
( NCT03863444 385 386 O
1 NCT03863444 387 388 O
) NCT03863444 389 390 O
having NCT03863444 391 397 O
fetus NCT03863444 398 403 B-Condition
with NCT03863444 404 408 O
abnormality NCT03863444 409 420 O

- NCT03863444 423 424 O
( NCT03863444 426 427 O
2 NCT03863444 428 429 O
) NCT03863444 430 431 O
high NCT03863444 432 436 O
- NCT03863444 437 438 O
risk NCT03863444 439 443 B-Risk
pregnancy NCT03863444 444 453 B-Condition

- NCT03863444 456 457 O
( NCT03863444 459 460 O
3 NCT03863444 461 462 O
) NCT03863444 463 464 O
can NCT03863444 465 468 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03863444 468 471 I-Assertion___Assertion-Type-Value:hypothetical|Negation
room NCT03863444 472 476 B-Observation
- NCT03863444 477 478 I-Observation
in NCT03863444 479 481 I-Observation
due NCT03863444 482 485 O
to NCT03863444 486 488 O
newborn NCT03863444 489 496 B-Family-Member___Family-Member-Type:child
's NCT03863444 496 498 O
medical NCT03863444 499 506 B-Condition
conditions NCT03863444 507 517 I-Condition

Inclusion NCT03864471 0 9 O
Criteria NCT03864471 10 18 O
: NCT03864471 19 20 O

- NCT03864471 24 25 O
lived NCT03864471 27 32 O
in NCT03864471 33 35 O
the NCT03864471 36 39 O
community NCT03864471 40 49 O
at NCT03864471 50 52 B-Eq-Comparison
least NCT03864471 53 58 I-Eq-Comparison
three NCT03864471 59 64 I-Eq-Comparison
months NCT03864471 65 71 I-Eq-Comparison

- NCT03864471 74 75 O
over NCT03864471 77 81 B-Eq-Comparison
65 NCT03864471 82 84 I-Eq-Comparison
years NCT03864471 85 90 I-Eq-Comparison
old NCT03864471 91 94 B-Age

- NCT03864471 97 98 O
fluently NCT03864471 100 108 O
communicated NCT03864471 109 121 O
in NCT03864471 122 124 O
Mandarin NCT03864471 125 133 O
or NCT03864471 134 136 B-Or
Taiwanese NCT03864471 137 146 O

- NCT03864471 149 150 O
screened NCT03864471 152 160 O
by NCT03864471 161 163 O
the NCT03864471 164 167 O
High NCT03864471 168 172 B-Observation
- NCT03864471 173 174 I-Observation
need NCT03864471 175 179 I-Observation
Community NCT03864471 180 189 I-Observation
Older NCT03864471 190 195 I-Observation
Adults NCT03864471 196 202 I-Observation
Screening NCT03864471 203 212 I-Observation
Scale NCT03864471 213 218 I-Observation
( NCT03864471 219 220 O
HCOASS NCT03864471 221 227 B-Observation
) NCT03864471 228 229 O
as NCT03864471 230 232 O
high NCT03864471 233 237 B-Condition
- NCT03864471 238 239 I-Condition
need NCT03864471 240 244 I-Condition
older NCT03864471 245 250 O
adults NCT03864471 251 257 O

Exclusion NCT03864471 258 267 O
Criteria NCT03864471 268 276 O
: NCT03864471 277 278 O

- NCT03864471 282 283 O
diagnosed NCT03864471 285 294 O
as NCT03864471 295 297 O
dementia NCT03864471 298 306 B-Condition

Inclusion NCT03862014 0 9 O
Criteria NCT03862014 10 18 O
: NCT03862014 19 20 O

- NCT03862014 24 25 O
Patients NCT03862014 27 35 O
and NCT03862014 36 39 O
parents NCT03862014 40 47 B-Family-Member
of NCT03862014 48 50 O
the NCT03862014 51 54 O
patients NCT03862014 55 63 O
who NCT03862014 64 67 O
accept NCT03862014 68 74 O
to NCT03862014 75 77 O
participate NCT03862014 78 89 O
and NCT03862014 90 93 O
sign NCT03862014 94 98 O
the NCT03862014 99 102 O
informed NCT03862014 103 111 O
consent NCT03862014 112 119 O

- NCT03862014 122 123 O
Patients NCT03862014 125 133 O
whose NCT03862014 134 139 O
molar NCT03862014 140 145 B-Modifier
teeth NCT03862014 146 151 I-Modifier
are NCT03862014 152 155 O
diagnosed NCT03862014 156 165 O
as NCT03862014 166 168 O
molar NCT03862014 169 174 B-Condition
incisor NCT03862014 175 182 I-Condition
hypomineralization NCT03862014 183 201 I-Condition
by NCT03862014 202 204 O
EAPD NCT03862014 205 209 O

- NCT03862014 212 213 O
Teeth NCT03862014 215 220 B-Modifier
that NCT03862014 221 225 I-Modifier
are NCT03862014 226 229 O
fully NCT03862014 230 235 B-Condition
erupted NCT03862014 236 243 I-Condition

- NCT03862014 246 247 O
Patients NCT03862014 249 257 O
who NCT03862014 258 261 O
have NCT03862014 262 266 O
at NCT03862014 267 269 B-Eq-Comparison
least NCT03862014 270 275 I-Eq-Comparison
two NCT03862014 276 279 I-Eq-Comparison
permanent NCT03862014 280 289 B-Modifier
first NCT03862014 290 295 I-Modifier
molars NCT03862014 296 302 B-Condition
that NCT03862014 303 307 O
need NCT03862014 308 312 B-Assertion___Assertion-Type-Value:hypothetical
fissure NCT03862014 313 320 B-Procedure
sealant NCT03862014 321 328 I-Procedure

- NCT03862014 331 332 O
Teeth NCT03862014 334 339 B-Modifier
that NCT03862014 340 344 O
have NCT03862014 345 349 O
white NCT03862014 350 355 B-Modifier
- NCT03862014 356 357 I-Modifier
yellow NCT03862014 358 364 I-Modifier
- NCT03862014 365 366 I-Modifier
brown NCT03862014 367 372 I-Modifier
discoloration NCT03862014 373 386 B-Condition
that NCT03862014 387 391 O
indicate NCT03862014 392 400 O
high NCT03862014 401 405 O
- NCT03862014 406 407 O
caries NCT03862014 408 414 B-Condition
risk NCT03862014 415 419 B-Risk

Exclusion NCT03862014 420 429 O
Criteria NCT03862014 430 438 O
: NCT03862014 439 440 O

- NCT03862014 444 445 O
Teeth NCT03862014 447 452 B-Condition
that NCT03862014 453 457 O
are NCT03862014 458 461 O
previously NCT03862014 462 472 B-Eq-Comparison
restored NCT03862014 473 481 B-Procedure
or NCT03862014 482 484 B-Or
have NCT03862014 485 489 O
caries NCT03862014 490 496 B-Condition

- NCT03862014 499 500 O
Patients NCT03862014 502 510 O
who NCT03862014 511 514 O
have NCT03862014 515 519 O
orthodontic NCT03862014 520 531 B-Procedure
treatment NCT03862014 532 541 I-Procedure

- NCT03862014 544 545 O
Patients NCT03862014 547 555 O
who NCT03862014 556 559 O
are NCT03862014 560 563 O
not NCT03862014 564 567 B-Assertion___Assertion-Type-Value:hypothetical|Negation
cooperative NCT03862014 568 579 O
for NCT03862014 580 583 O
the NCT03862014 584 587 O
dental NCT03862014 588 594 B-Procedure
procedure NCT03862014 595 604 I-Procedure

- NCT03862014 607 608 O
Teeth NCT03862014 610 615 B-Modifier
that NCT03862014 616 620 O
have NCT03862014 621 625 O
dental NCT03862014 626 632 B-Condition
flourosis NCT03862014 633 642 I-Condition
or NCT03862014 643 645 B-Or
enamel NCT03862014 646 652 B-Condition
malformation NCT03862014 653 665 I-Condition
according NCT03862014 666 675 O
to NCT03862014 676 678 O
the NCT03862014 679 682 O
specific NCT03862014 683 691 O
syndromes NCT03862014 692 701 O

Inclusion NCT03869814 0 9 O
Criteria NCT03869814 10 18 O
: NCT03869814 19 20 O

1 NCT03869814 24 25 O
. NCT03869814 25 26 O
Age NCT03869814 28 31 B-Age
greater NCT03869814 32 39 B-Eq-Comparison
than NCT03869814 40 44 I-Eq-Comparison
or NCT03869814 45 47 I-Eq-Comparison
equal NCT03869814 48 53 I-Eq-Comparison
to NCT03869814 54 56 I-Eq-Comparison
21 NCT03869814 57 59 I-Eq-Comparison
years NCT03869814 60 65 I-Eq-Comparison
old NCT03869814 66 69 O

2 NCT03869814 72 73 O
. NCT03869814 73 74 O
Clinical NCT03869814 76 84 O
suspicion NCT03869814 85 94 B-Assertion___Assertion-Type-Value:possible
of NCT03869814 95 97 O
malignancy NCT03869814 98 108 B-Condition
based NCT03869814 109 114 O
on NCT03869814 115 117 O
signs NCT03869814 118 123 B-Assertion___Assertion-Type-Value:possible
, NCT03869814 124 125 O
symptoms NCT03869814 126 134 B-Assertion___Assertion-Type-Value:possible
, NCT03869814 135 136 O
imaging NCT03869814 137 144 B-Procedure
studies NCT03869814 145 152 I-Procedure
, NCT03869814 153 154 O
and NCT03869814 155 158 B-Or
/ NCT03869814 159 160 I-Or
or NCT03869814 161 163 I-Or
non NCT03869814 164 167 B-Negation
- NCT03869814 168 169 O
surgical NCT03869814 170 178 B-Modifier
biopsies NCT03869814 179 187 B-Procedure
of NCT03869814 188 190 O
any NCT03869814 191 194 O
of NCT03869814 195 197 O
the NCT03869814 198 201 O
following NCT03869814 202 211 O
cancer NCT03869814 212 218 B-Condition
types NCT03869814 219 224 O
: NCT03869814 225 226 O
bladder NCT03869814 227 234 B-Modifier
, NCT03869814 235 236 O
breast NCT03869814 237 243 B-Modifier
, NCT03869814 244 245 O
colorectal NCT03869814 246 256 B-Modifier
, NCT03869814 257 258 O
kidney NCT03869814 259 265 B-Modifier
, NCT03869814 266 267 O
liver NCT03869814 268 273 B-Modifier
, NCT03869814 274 275 O
lung NCT03869814 276 280 B-Modifier
, NCT03869814 281 282 O
pancreas NCT03869814 283 291 B-Modifier
or NCT03869814 292 294 B-Or
prostate NCT03869814 295 303 B-Modifier
. NCT03869814 304 305 O

3 NCT03869814 309 310 O
. NCT03869814 310 311 O
Candidate NCT03869814 313 322 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869814 323 326 I-Assertion___Assertion-Type-Value:hypothetical
subsequent NCT03869814 327 337 O
medical NCT03869814 338 345 B-Modifier
and NCT03869814 346 349 B-Or
/ NCT03869814 350 351 I-Or
or NCT03869814 352 354 I-Or
surgical NCT03869814 355 363 B-Modifier
work NCT03869814 364 368 B-Procedure
- NCT03869814 369 370 I-Procedure
up NCT03869814 371 373 I-Procedure
to NCT03869814 374 376 O
complete NCT03869814 377 385 O
organ NCT03869814 386 391 B-Modifier
- NCT03869814 392 393 I-Modifier
specific NCT03869814 394 402 I-Modifier
cancer NCT03869814 403 409 B-Condition
diagnosis NCT03869814 410 419 O
inclusive NCT03869814 420 429 O
of NCT03869814 430 432 O
pathologic NCT03869814 433 443 B-Procedure
staging NCT03869814 444 451 I-Procedure
as NCT03869814 452 454 O
specified NCT03869814 455 464 O
by NCT03869814 465 467 O
the NCT03869814 468 471 O
College NCT03869814 472 479 O
of NCT03869814 480 482 O
American NCT03869814 483 491 O
Pathology NCT03869814 492 501 O
( NCT03869814 502 503 O
CAP NCT03869814 504 507 O
) NCT03869814 508 509 O
. NCT03869814 511 512 O

4 NCT03869814 516 517 O
. NCT03869814 517 518 O
Provision NCT03869814 520 529 O
of NCT03869814 530 532 O
informed NCT03869814 533 541 O
consent NCT03869814 542 549 O
. NCT03869814 550 551 O

Exclusion NCT03869814 553 562 O
Criteria NCT03869814 563 571 O
: NCT03869814 572 573 O

1 NCT03869814 577 578 O
. NCT03869814 578 579 O
Age NCT03869814 581 584 B-Age
less NCT03869814 585 589 B-Eq-Comparison
than NCT03869814 590 594 I-Eq-Comparison
21 NCT03869814 595 597 I-Eq-Comparison
years NCT03869814 598 603 I-Eq-Comparison
old NCT03869814 604 607 O

2 NCT03869814 610 611 O
. NCT03869814 611 612 O
Any NCT03869814 614 617 O
prior NCT03869814 618 623 B-Eq-Comparison
cancer NCT03869814 624 630 B-Condition
diagnosis NCT03869814 631 640 O
, NCT03869814 641 642 O
without NCT03869814 643 650 B-Negation
or NCT03869814 651 653 B-Or
with NCT03869814 654 658 B-And
any NCT03869814 659 662 O
treatment NCT03869814 663 672 B-Procedure
( NCT03869814 673 674 O
e. NCT03869814 675 677 O
g. NCT03869814 678 680 O
, NCT03869814 681 682 O
medical NCT03869814 683 690 B-Modifier
, NCT03869814 691 692 O
surgical NCT03869814 693 701 B-Modifier
, NCT03869814 702 703 O
or NCT03869814 704 706 B-Or
radiation NCT03869814 707 716 B-Modifier
oncology NCT03869814 717 725 I-Modifier
) NCT03869814 726 727 O
within NCT03869814 728 734 B-Eq-Comparison
prior NCT03869814 735 740 I-Eq-Comparison
six NCT03869814 741 744 I-Eq-Comparison
months NCT03869814 745 751 I-Eq-Comparison
. NCT03869814 752 753 O

3 NCT03869814 757 758 O
. NCT03869814 758 759 O
Any NCT03869814 761 764 O
surgery NCT03869814 765 772 B-Procedure
, NCT03869814 773 774 O
i. NCT03869814 775 777 O
e. NCT03869814 778 780 O
, NCT03869814 781 782 O
invasive NCT03869814 783 791 B-Procedure
procedure NCT03869814 792 801 I-Procedure
performed NCT03869814 802 811 O
in NCT03869814 812 814 O
the NCT03869814 815 818 O
operating NCT03869814 819 828 O
room NCT03869814 829 833 O
with NCT03869814 834 838 O
any NCT03869814 839 842 O
level NCT03869814 843 848 O
of NCT03869814 849 851 O
anesthesia NCT03869814 852 862 B-Procedure
, NCT03869814 863 864 O
within NCT03869814 865 871 B-Eq-Comparison
prior NCT03869814 872 877 I-Eq-Comparison
month NCT03869814 878 883 I-Eq-Comparison
. NCT03869814 884 885 O

4 NCT03869814 889 890 O
. NCT03869814 890 891 O
Any NCT03869814 893 896 O
non NCT03869814 897 900 B-Negation
- NCT03869814 901 902 O
cancer NCT03869814 903 909 B-Condition
systemic NCT03869814 910 918 B-Procedure
therapy NCT03869814 919 926 I-Procedure
associated NCT03869814 927 937 O
with NCT03869814 938 942 O
molecularly NCT03869814 943 954 B-Modifier
targeted NCT03869814 955 963 I-Modifier
immune NCT03869814 964 970 B-Procedure
modulation NCT03869814 971 981 I-Procedure
, NCT03869814 982 983 O
e. NCT03869814 984 986 O
g. NCT03869814 987 989 O
, NCT03869814 990 991 O
monoclonal NCT03869814 992 1002 B-Procedure
antibodies NCT03869814 1003 1013 I-Procedure
. NCT03869814 1014 1015 O

5 NCT03869814 1019 1020 O
. NCT03869814 1020 1021 O
Any NCT03869814 1023 1026 O
concurrent NCT03869814 1027 1037 B-Modifier
or NCT03869814 1038 1040 B-Or
prior NCT03869814 1041 1046 B-Eq-Comparison
pregnancy NCT03869814 1047 1056 B-Condition
within NCT03869814 1057 1063 B-Eq-Comparison
previous NCT03869814 1064 1072 I-Eq-Comparison
twelve NCT03869814 1073 1079 I-Eq-Comparison
months NCT03869814 1080 1086 I-Eq-Comparison
. NCT03869814 1087 1088 O

6 NCT03869814 1092 1093 O
. NCT03869814 1093 1094 O
Any NCT03869814 1096 1099 O
history NCT03869814 1100 1107 B-Eq-Comparison
of NCT03869814 1108 1110 O
organ NCT03869814 1111 1116 B-Procedure
tissue NCT03869814 1117 1123 I-Procedure
transplantation NCT03869814 1124 1139 I-Procedure

7 NCT03869814 1142 1143 O
. NCT03869814 1143 1144 O
Any NCT03869814 1146 1149 O
history NCT03869814 1150 1157 B-Eq-Comparison
of NCT03869814 1158 1160 O
blood NCT03869814 1161 1166 B-Procedure
product NCT03869814 1167 1174 I-Procedure
transfusion NCT03869814 1175 1186 I-Procedure
within NCT03869814 1187 1193 B-Eq-Comparison
prior NCT03869814 1194 1199 I-Eq-Comparison
month NCT03869814 1200 1205 I-Eq-Comparison
. NCT03869814 1206 1207 O

8 NCT03869814 1211 1212 O
. NCT03869814 1212 1213 O
Any NCT03869814 1215 1218 O
major NCT03869814 1219 1224 O
trauma NCT03869814 1225 1231 B-Condition
within NCT03869814 1232 1238 B-Eq-Comparison
prior NCT03869814 1239 1244 I-Eq-Comparison
six NCT03869814 1245 1248 I-Eq-Comparison
months NCT03869814 1249 1255 I-Eq-Comparison
, NCT03869814 1256 1257 O
e. NCT03869814 1258 1260 O
g. NCT03869814 1261 1263 O
, NCT03869814 1264 1265 O
burn NCT03869814 1266 1270 B-Condition
injury NCT03869814 1271 1277 I-Condition
, NCT03869814 1278 1279 O
extremity NCT03869814 1280 1289 B-Condition
crush NCT03869814 1290 1295 I-Condition
injury NCT03869814 1296 1302 I-Condition
, NCT03869814 1303 1304 O
motor NCT03869814 1305 1310 B-Condition
vehicle NCT03869814 1311 1318 I-Condition
accident NCT03869814 1319 1327 I-Condition
, NCT03869814 1328 1329 O
etc NCT03869814 1330 1333 O
. NCT03869814 1334 1335 O

9 NCT03869814 1339 1340 O
. NCT03869814 1340 1341 O
Unable NCT03869814 1343 1349 O
to NCT03869814 1350 1352 O
provide NCT03869814 1353 1360 O
informed NCT03869814 1361 1369 O
consent NCT03869814 1370 1377 O
. NCT03869814 1377 1378 O

Inclusion NCT03865784 0 9 O
Criteria NCT03865784 10 18 O
: NCT03865784 19 20 O

- NCT03865784 24 25 O
Federated NCT03865784 27 36 B-Observation
boxers NCT03865784 37 43 I-Observation

- NCT03865784 46 47 O
Over NCT03865784 49 53 B-Eq-Comparison
18 NCT03865784 54 56 I-Eq-Comparison
years NCT03865784 57 62 I-Age|Eq-Comparison

- NCT03865784 65 66 O
Male NCT03865784 68 72 O

- NCT03865784 75 76 O
With NCT03865784 78 82 O
non NCT03865784 83 86 B-Negation
- NCT03865784 87 88 O
specific NCT03865784 89 97 B-Modifier
back NCT03865784 98 102 B-Condition
pain NCT03865784 103 107 I-Condition
that NCT03865784 108 112 O
does NCT03865784 113 117 O
not NCT03865784 118 121 O
incapacitate NCT03865784 122 134 O
them NCT03865784 135 139 O
for NCT03865784 140 143 O
the NCT03865784 144 147 O
realization NCT03865784 148 159 O
of NCT03865784 160 162 O
their NCT03865784 163 168 O
sport NCT03865784 169 174 O
or NCT03865784 175 177 O
work NCT03865784 178 182 O
activity NCT03865784 183 191 O
. NCT03865784 192 193 O

Exclusion NCT03865784 195 204 O
Criteria NCT03865784 205 213 O
: NCT03865784 214 215 O

- NCT03865784 219 220 O
Federated NCT03865784 222 231 B-Observation
boxers NCT03865784 232 238 I-Observation
with NCT03865784 239 243 B-And
lumbar NCT03865784 244 250 B-Modifier
injury NCT03865784 251 257 B-Condition
with NCT03865784 258 262 O
medical NCT03865784 263 270 O
diagnosis NCT03865784 271 280 O

- NCT03865784 283 284 O
Who NCT03865784 286 289 O
are NCT03865784 290 293 B-Eq-Comparison
or NCT03865784 294 296 B-Or
have NCT03865784 297 301 B-Eq-Comparison
been NCT03865784 302 306 I-Eq-Comparison
treated NCT03865784 307 314 B-Procedure
by NCT03865784 315 317 O
pharmacological NCT03865784 318 333 B-Procedure
or NCT03865784 334 336 B-Or
physiotherapy NCT03865784 337 350 B-Procedure
in NCT03865784 351 353 O
the NCT03865784 354 357 O
last NCT03865784 358 362 B-Eq-Comparison
6 NCT03865784 363 364 I-Eq-Comparison
months NCT03865784 365 371 I-Eq-Comparison

- NCT03865784 374 375 O
Presenting NCT03865784 377 387 O
allergies NCT03865784 388 397 B-Allergy
or NCT03865784 398 400 B-Or
alterations NCT03865784 401 412 B-Condition
of NCT03865784 413 415 O
the NCT03865784 416 419 O
skin NCT03865784 420 424 B-Modifier

- NCT03865784 427 428 O
Not NCT03865784 430 433 O
sign NCT03865784 434 438 O
the NCT03865784 439 442 O
informed NCT03865784 443 451 O
consent NCT03865784 452 459 O
document NCT03865784 460 468 O
. NCT03865784 468 469 O

Inclusion NCT03863652 0 9 O
Criteria NCT03863652 10 18 O
: NCT03863652 19 20 O

- NCT03863652 24 25 O
Patients NCT03863652 27 35 O
≥ NCT03863652 36 37 B-Eq-Comparison
18 NCT03863652 38 40 I-Eq-Comparison
years NCT03863652 41 46 I-Eq-Comparison
old NCT03863652 47 50 B-Age
requiring NCT03863652 51 60 B-Assertion___Assertion-Type-Value:hypothetical
PCI NCT03863652 61 64 B-Procedure

- NCT03863652 67 68 O
Patients NCT03863652 70 78 O
who NCT03863652 79 82 O
are NCT03863652 83 86 O
palpable NCT03863652 87 95 B-Condition
distal NCT03863652 96 102 I-Condition
radial NCT03863652 103 109 I-Condition
arter NCT03863652 110 115 I-Condition

- NCT03863652 118 119 O
The NCT03863652 121 124 O
decision NCT03863652 125 133 O
to NCT03863652 134 136 O
participate NCT03863652 137 148 O
voluntarily NCT03863652 149 160 O
in NCT03863652 161 163 O
this NCT03863652 164 168 O
study NCT03863652 169 174 O
and NCT03863652 175 178 O
the NCT03863652 179 182 O
written NCT03863652 183 190 O
consent NCT03863652 191 198 O
of NCT03863652 199 201 O
the NCT03863652 202 205 O
patient NCT03863652 206 213 O

Exclusion NCT03863652 214 223 O
Criteria NCT03863652 224 232 O
: NCT03863652 233 234 O

- NCT03863652 238 239 O
Patients NCT03863652 241 249 O
who NCT03863652 250 253 O
are NCT03863652 254 257 O
not NCT03863652 258 261 B-Negation
palpable NCT03863652 262 270 B-Condition
distal NCT03863652 271 277 I-Condition
radial NCT03863652 278 284 I-Condition
artery NCT03863652 285 291 I-Condition

- NCT03863652 294 295 O
Female NCT03863652 297 303 O
of NCT03863652 304 306 B-And
childbearing NCT03863652 307 319 B-Condition
potential NCT03863652 320 329 I-Condition
, NCT03863652 330 331 O
who NCT03863652 332 335 B-And
possibly NCT03863652 336 344 B-Assertion___Assertion-Type-Value:intention
plans NCT03863652 345 350 I-Assertion___Assertion-Type-Value:intention
to NCT03863652 351 353 O
become NCT03863652 354 360 O
pregnant NCT03863652 361 369 B-Condition
any NCT03863652 370 373 B-Eq-Comparison
time NCT03863652 374 378 I-Eq-Comparison
after NCT03863652 379 384 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03863652 385 395 O
into NCT03863652 396 400 O
this NCT03863652 401 405 O
study NCT03863652 406 411 B-Study
. NCT03863652 412 413 O

- NCT03863652 417 418 O
Patients NCT03863652 420 428 O
who NCT03863652 429 432 O
are NCT03863652 433 436 O
not NCT03863652 437 440 O
appropriate NCT03863652 441 452 O
for NCT03863652 453 456 O
this NCT03863652 457 461 O
study NCT03863652 462 467 O

Inclusion NCT03860415 0 9 O
Criteria NCT03860415 10 18 O
: NCT03860415 19 20 O

- NCT03860415 24 25 O
Chronic NCT03860415 27 34 B-Modifier
( NCT03860415 35 36 O
more NCT03860415 37 41 B-Eq-Comparison
than NCT03860415 42 46 I-Eq-Comparison
three NCT03860415 47 52 I-Eq-Comparison
months NCT03860415 53 59 I-Eq-Comparison
) NCT03860415 60 61 O
ESBL NCT03860415 62 66 B-Condition
colonization NCT03860415 67 79 I-Condition
of NCT03860415 80 82 O
the NCT03860415 83 86 O
same NCT03860415 87 91 O
strain NCT03860415 92 98 O
as NCT03860415 99 101 O
determined NCT03860415 102 112 O
by NCT03860415 113 115 O

- NCT03860415 118 119 O
species NCT03860415 121 128 B-Observation
, NCT03860415 129 130 O
phenotype NCT03860415 131 140 B-Condition
and NCT03860415 141 144 O
antibiogram NCT03860415 145 156 B-Procedure
. NCT03860415 157 158 O

- NCT03860415 162 163 O
Patients NCT03860415 165 173 O
must NCT03860415 174 178 O
be NCT03860415 179 181 O
able NCT03860415 182 186 O
to NCT03860415 187 189 O
swallow NCT03860415 190 197 O
sachets NCT03860415 198 205 O
. NCT03860415 206 207 O

- NCT03860415 211 212 O
Must NCT03860415 214 218 O
be NCT03860415 219 221 O
able NCT03860415 222 226 O
to NCT03860415 227 229 O
speak NCT03860415 230 235 O
and NCT03860415 236 239 O
understand NCT03860415 240 250 O
Swedish NCT03860415 251 258 O
. NCT03860415 259 260 O

- NCT03860415 264 265 O
Must NCT03860415 267 271 O
have NCT03860415 272 276 O
a NCT03860415 277 278 O
permanent NCT03860415 279 288 O
residence NCT03860415 289 298 O
in NCT03860415 299 301 O
Sweden NCT03860415 302 308 O
. NCT03860415 309 310 O

- NCT03860415 314 315 O
Must NCT03860415 317 321 O
be NCT03860415 322 324 O
able NCT03860415 325 329 O
to NCT03860415 330 332 O
sign NCT03860415 333 337 O
informed NCT03860415 338 346 O
consent NCT03860415 347 354 O
in NCT03860415 355 357 O
Swedish NCT03860415 358 365 O
. NCT03860415 366 367 O

Exclusion NCT03860415 369 378 O
Criteria NCT03860415 379 387 O
: NCT03860415 388 389 O

- NCT03860415 393 394 O
Immunosuppression NCT03860415 396 413 B-Procedure
( NCT03860415 414 415 O
i. NCT03860415 416 418 O
e. NCT03860415 419 421 O
chemotheraphy NCT03860415 423 436 B-Procedure
, NCT03860415 437 438 O
treatment NCT03860415 439 448 B-Procedure
with NCT03860415 449 453 I-Procedure
TNF NCT03860415 454 457 I-Procedure
- NCT03860415 458 459 I-Procedure
alpha NCT03860415 460 465 I-Procedure
- NCT03860415 466 467 I-Procedure
inhibitors NCT03860415 468 478 I-Procedure
) NCT03860415 479 480 O
. NCT03860415 482 483 O

- NCT03860415 487 488 O
In NCT03860415 490 492 O
patient NCT03860415 493 500 O
care NCT03860415 501 505 O
. NCT03860415 506 507 O

- NCT03860415 511 512 O
immunodeficiency NCT03860415 514 530 B-Condition

- NCT03860415 533 534 O
psychiatric NCT03860415 536 547 B-Condition
disorder NCT03860415 548 556 I-Condition

- NCT03860415 559 560 O
alcohol NCT03860415 562 569 B-Modifier
or NCT03860415 570 572 B-Or
substance NCT03860415 573 582 B-Modifier
abuse NCT03860415 583 588 B-Condition

- NCT03860415 591 592 O
dementia NCT03860415 594 602 B-Condition

- NCT03860415 605 606 O
Invasive NCT03860415 608 616 B-Procedure
catheters NCT03860415 617 626 I-Procedure
. NCT03860415 626 627 O

Inclusion NCT03866070 0 9 O
Criteria NCT03866070 10 18 O
: NCT03866070 19 20 O

- NCT03866070 24 25 O
Female NCT03866070 27 33 O

- NCT03866070 36 37 O
Handball NCT03866070 39 47 B-Observation
players NCT03866070 48 55 I-Observation
federated NCT03866070 56 65 O
in NCT03866070 66 68 O
the NCT03866070 69 72 O
Madrid NCT03866070 73 79 O
Handball NCT03866070 80 88 O
Federation NCT03866070 89 99 O

- NCT03866070 102 103 O
With NCT03866070 105 109 O
an NCT03866070 110 112 O
age NCT03866070 113 116 B-Age
range NCT03866070 117 122 O
between NCT03866070 123 130 B-Eq-Comparison
18 NCT03866070 131 133 I-Eq-Comparison
and NCT03866070 134 137 I-Eq-Comparison
37 NCT03866070 138 140 I-Eq-Comparison
years NCT03866070 141 146 I-Eq-Comparison

- NCT03866070 149 150 O
More NCT03866070 152 156 B-Eq-Comparison
than NCT03866070 157 161 I-Eq-Comparison
2 NCT03866070 162 163 I-Eq-Comparison
years NCT03866070 164 169 I-Eq-Comparison
of NCT03866070 170 172 O
handball NCT03866070 173 181 B-Observation
sports NCT03866070 182 188 I-Observation

- NCT03866070 191 192 O
Currently NCT03866070 194 203 O
participate NCT03866070 204 215 O
in NCT03866070 216 218 O
amateur NCT03866070 219 226 O
competitions NCT03866070 227 239 O
of NCT03866070 240 242 O
First NCT03866070 243 248 O
National NCT03866070 249 257 O
Women NCT03866070 258 263 O
's NCT03866070 263 265 O
category NCT03866070 266 274 O
. NCT03866070 275 276 O

Exclusion NCT03866070 278 287 O
Criteria NCT03866070 288 296 O
: NCT03866070 297 298 O

- NCT03866070 302 303 O
Have NCT03866070 305 309 O
suffered NCT03866070 310 318 B-Eq-Comparison
a NCT03866070 319 320 O
shoulder NCT03866070 321 329 B-Modifier
injury NCT03866070 330 336 B-Condition
in NCT03866070 337 339 O
the NCT03866070 340 343 O
last NCT03866070 344 348 B-Eq-Comparison
six NCT03866070 349 352 I-Eq-Comparison
months NCT03866070 353 359 I-Eq-Comparison

- NCT03866070 362 363 O
Who NCT03866070 365 368 O
are NCT03866070 369 372 O
currently NCT03866070 373 382 B-Eq-Comparison
doing NCT03866070 383 388 O
some NCT03866070 389 393 O
physiotherapy NCT03866070 394 407 B-Procedure
treatment NCT03866070 408 417 I-Procedure

- NCT03866070 420 421 O
Who NCT03866070 423 426 O
fail NCT03866070 427 431 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866070 432 434 I-Assertion___Assertion-Type-Value:hypothetical|Negation
participate NCT03866070 435 446 O
in NCT03866070 447 449 O
the NCT03866070 450 453 O
established NCT03866070 454 465 O
intervention NCT03866070 466 478 B-Procedure
and NCT03866070 479 482 B-And
evaluation NCT03866070 483 493 B-Procedure
sessions NCT03866070 494 502 O

- NCT03866070 505 506 O
Refusing NCT03866070 508 516 O
to NCT03866070 517 519 O
sign NCT03866070 520 524 O
the NCT03866070 525 528 O
informed NCT03866070 529 537 O
consent NCT03866070 538 545 O
document NCT03866070 546 554 O
. NCT03866070 554 555 O

Inclusion NCT03863691 0 9 O
Criteria NCT03863691 10 18 O
: NCT03863691 19 20 O

- NCT03863691 24 25 O
Common NCT03863691 27 33 O
European NCT03863691 34 42 O
Framework NCT03863691 43 52 O
of NCT03863691 53 55 O
Reference NCT03863691 56 65 O
for NCT03863691 66 69 O
Languages NCT03863691 70 79 O
level NCT03863691 80 85 O
B2 NCT03863691 86 88 O
in NCT03863691 89 91 O
German NCT03863691 92 98 O
language NCT03863691 99 107 O
. NCT03863691 108 109 O

- NCT03863691 113 114 O
Consent NCT03863691 116 123 O
ability NCT03863691 124 131 O
for NCT03863691 132 135 O
all NCT03863691 136 139 O
relevant NCT03863691 140 148 O
aspects NCT03863691 149 156 O
of NCT03863691 157 159 O
the NCT03863691 160 163 O
experiment NCT03863691 164 174 O
. NCT03863691 175 176 O

Exclusion NCT03863691 178 187 O
Criteria NCT03863691 188 196 O
: NCT03863691 197 198 O

- NCT03863691 202 203 O
Amisulpride NCT03863691 205 216 B-Drug
allergy NCT03863691 217 224 B-Allergy
. NCT03863691 225 226 O

- NCT03863691 230 231 O
Allergy NCT03863691 233 240 B-Allergy
to NCT03863691 241 243 O
other NCT03863691 244 249 O
components NCT03863691 250 260 B-Drug
of NCT03863691 261 263 I-Drug
amisulpride NCT03863691 264 275 I-Drug
/ NCT03863691 276 277 B-Or
placebo NCT03863691 278 285 B-Drug
capsules NCT03863691 286 294 I-Drug
like NCT03863691 295 299 O
lactose NCT03863691 300 307 B-Drug
. NCT03863691 308 309 O

- NCT03863691 313 314 O
Daily NCT03863691 316 321 B-Eq-Comparison
intake NCT03863691 322 328 O
of NCT03863691 329 331 O
other NCT03863691 332 337 B-Other
medication NCT03863691 338 348 B-Drug
including NCT03863691 349 358 O
contraceptives NCT03863691 359 373 B-Drug
. NCT03863691 374 375 O

- NCT03863691 379 380 O
Tendency NCT03863691 382 390 B-Modifier
to NCT03863691 391 393 O
seizures NCT03863691 394 402 B-Condition
. NCT03863691 403 404 O

- NCT03863691 408 409 O
Diagnosis NCT03863691 411 420 O
of NCT03863691 421 423 O
cancer NCT03863691 424 430 B-Condition
especially NCT03863691 431 441 O
pheochromocytoma NCT03863691 442 458 B-Condition
, NCT03863691 459 460 O
prolactinoma NCT03863691 461 473 B-Condition
, NCT03863691 474 475 O
or NCT03863691 476 478 O
breast NCT03863691 479 485 B-Modifier
cancer NCT03863691 486 492 B-Condition
. NCT03863691 493 494 O

- NCT03863691 498 499 O
Kidney NCT03863691 501 507 B-Condition
dysfunction NCT03863691 508 519 I-Condition
: NCT03863691 520 521 O
creatinine NCT03863691 522 532 B-Observation
clearance NCT03863691 533 542 I-Observation
below NCT03863691 543 548 B-Eq-Comparison
10 NCT03863691 549 551 I-Eq-Comparison
ml NCT03863691 552 554 I-Eq-Comparison
per NCT03863691 555 558 I-Eq-Comparison
minute NCT03863691 559 565 I-Eq-Comparison
. NCT03863691 566 567 O

- NCT03863691 571 572 O
High NCT03863691 574 578 O
risk NCT03863691 579 583 B-Risk
for NCT03863691 584 587 O
stroke NCT03863691 588 594 B-Condition
or NCT03863691 595 597 B-Or
thrombosis NCT03863691 598 608 B-Condition
. NCT03863691 609 610 O

- NCT03863691 614 615 O
Known NCT03863691 617 622 O
prolongation NCT03863691 623 635 B-Condition
of NCT03863691 636 638 I-Condition
the NCT03863691 639 642 I-Condition
QT NCT03863691 643 645 I-Condition
interval NCT03863691 646 654 I-Condition
, NCT03863691 655 656 O

- NCT03863691 660 661 O
Any NCT03863691 663 666 O
substantial NCT03863691 667 678 O
medical NCT03863691 679 686 B-Condition
condition NCT03863691 687 696 I-Condition
that NCT03863691 697 701 O
is NCT03863691 702 704 O
capable NCT03863691 705 712 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863691 713 715 I-Assertion___Assertion-Type-Value:hypothetical
reducing NCT03863691 716 724 O
the NCT03863691 725 728 O
volunteers NCT03863691 729 739 O
ability NCT03863691 740 747 O
to NCT03863691 748 750 O
participate NCT03863691 751 762 O
at NCT03863691 763 765 O
the NCT03863691 766 769 O
study NCT03863691 770 775 B-Study
. NCT03863691 776 777 O

- NCT03863691 781 782 O
Suicidal NCT03863691 784 792 B-Condition
thoughts NCT03863691 793 801 I-Condition
or NCT03863691 802 804 B-Or
suicide NCT03863691 805 812 B-Condition
attempts NCT03863691 813 821 I-Condition
in NCT03863691 822 824 O
the NCT03863691 825 828 O
past NCT03863691 829 833 B-Eq-Comparison
or NCT03863691 834 836 B-Or
at NCT03863691 837 839 O
present NCT03863691 840 847 B-Eq-Comparison
. NCT03863691 848 849 O

- NCT03863691 853 854 O
Substantial NCT03863691 856 867 O
mental NCT03863691 868 874 B-Condition
disorders NCT03863691 875 884 I-Condition
especially NCT03863691 885 895 O
schizophrenia NCT03863691 896 909 B-Condition
, NCT03863691 910 911 O
bipolar NCT03863691 912 919 B-Condition
disorder NCT03863691 920 928 I-Condition
, NCT03863691 929 930 O
drug NCT03863691 931 935 B-Condition
abuse NCT03863691 936 941 I-Condition
, NCT03863691 942 943 O
or NCT03863691 944 946 B-Or
personality NCT03863691 947 958 B-Condition
disorders NCT03863691 959 968 I-Condition
. NCT03863691 969 970 O

- NCT03863691 974 975 O
Pregnancy NCT03863691 977 986 B-Condition
or NCT03863691 987 989 B-Or
breastfeeding NCT03863691 990 1003 B-Condition
. NCT03863691 1003 1004 O

Inclusion NCT03861910 0 9 O
Criteria NCT03861910 10 18 O
: NCT03861910 19 20 O

- NCT03861910 24 25 O
age NCT03861910 27 30 B-Age
1 NCT03861910 31 32 B-Eq-Comparison
- NCT03861910 33 34 I-Eq-Comparison
12 NCT03861910 35 37 I-Eq-Comparison
months NCT03861910 38 44 I-Eq-Comparison

- NCT03861910 47 48 O
IgE NCT03861910 50 53 B-Modifier
- NCT03861910 54 55 I-Modifier
mediated NCT03861910 56 64 I-Modifier
CMA NCT03861910 65 68 B-Condition

Exclusion NCT03861910 69 78 O
Criteria NCT03861910 79 87 O
: NCT03861910 88 89 O

- NCT03861910 93 94 O
cow NCT03861910 96 99 B-Drug
's NCT03861910 99 101 I-Drug
milk NCT03861910 102 106 I-Drug
protein NCT03861910 107 114 I-Drug
- NCT03861910 115 116 O
induced NCT03861910 117 124 O
anaphylaxis NCT03861910 125 136 B-Condition
, NCT03861910 137 138 O

- NCT03861910 142 143 O
food NCT03861910 145 149 B-Drug
protein NCT03861910 150 157 I-Drug
induced NCT03861910 158 165 O
enterocolitis NCT03861910 166 179 B-Condition
syndrome NCT03861910 180 188 I-Condition
, NCT03861910 189 190 O

- NCT03861910 194 195 O
other NCT03861910 197 202 B-Other
food NCT03861910 203 207 O
allergies NCT03861910 208 217 B-Allergy
, NCT03861910 218 219 O

- NCT03861910 223 224 O
other NCT03861910 226 231 B-Other
allergic NCT03861910 232 240 B-Condition
diseases NCT03861910 241 249 I-Condition
, NCT03861910 250 251 O

- NCT03861910 255 256 O
non NCT03861910 258 261 B-Negation
- NCT03861910 262 263 O
CMA NCT03861910 264 267 B-Modifier
- NCT03861910 268 269 I-Modifier
related NCT03861910 270 277 I-Modifier
atopic NCT03861910 278 284 B-Condition
eczema NCT03861910 285 291 I-Condition
, NCT03861910 292 293 O

- NCT03861910 297 298 O
eosinophilic NCT03861910 300 312 B-Condition
disorders NCT03861910 313 322 I-Condition
of NCT03861910 323 325 O
the NCT03861910 326 329 O
gastrointestinal NCT03861910 330 346 B-Modifier
tract NCT03861910 347 352 I-Modifier
, NCT03861910 353 354 O

- NCT03861910 358 359 O
chronic NCT03861910 361 368 B-Modifier
systemic NCT03861910 369 377 I-Modifier
diseases NCT03861910 378 386 B-Condition
, NCT03861910 387 388 O

- NCT03861910 392 393 O
congenital NCT03861910 395 405 B-Modifier
cardiac NCT03861910 406 413 B-Condition
defects NCT03861910 414 421 I-Condition
, NCT03861910 422 423 O

- NCT03861910 427 428 O
active NCT03861910 430 436 B-Eq-Comparison
tuberculosis NCT03861910 437 449 B-Condition
, NCT03861910 450 451 O

- NCT03861910 455 456 O
autoimmune NCT03861910 458 468 B-Condition
diseases NCT03861910 469 477 I-Condition
, NCT03861910 478 479 O

- NCT03861910 483 484 O
immunodeficiency NCT03861910 486 502 B-Condition
, NCT03861910 503 504 O

- NCT03861910 508 509 O
chronic NCT03861910 511 518 B-Modifier
inflammatory NCT03861910 519 531 B-Condition
bowel NCT03861910 532 537 I-Condition
diseases NCT03861910 538 546 I-Condition
, NCT03861910 547 548 O

- NCT03861910 552 553 O
celiac NCT03861910 555 561 B-Condition
disease NCT03861910 562 569 I-Condition
, NCT03861910 570 571 O

- NCT03861910 575 576 O
cystic NCT03861910 578 584 B-Condition
fibrosis NCT03861910 585 593 I-Condition
, NCT03861910 594 595 O

- NCT03861910 599 600 O
metabolic NCT03861910 602 611 B-Condition
diseases NCT03861910 612 620 I-Condition
, NCT03861910 621 622 O

- NCT03861910 626 627 O
malignancy NCT03861910 629 639 B-Condition
, NCT03861910 640 641 O

- NCT03861910 645 646 O
chronic NCT03861910 648 655 B-Modifier
pulmonary NCT03861910 656 665 B-Condition
diseases NCT03861910 666 674 I-Condition
, NCT03861910 675 676 O

- NCT03861910 680 681 O
malformations NCT03861910 683 696 B-Condition
of NCT03861910 697 699 O
the NCT03861910 700 703 O
gastrointestinal NCT03861910 704 720 B-Modifier
and NCT03861910 721 724 B-Or
/ NCT03861910 725 726 I-Or
or NCT03861910 727 729 I-Or
respiratory NCT03861910 730 741 B-Modifier
tract NCT03861910 742 747 I-Modifier
, NCT03861910 748 749 O

- NCT03861910 753 754 O
administration NCT03861910 756 770 O
of NCT03861910 771 773 O
prebiotics NCT03861910 774 784 B-Drug
or NCT03861910 785 787 B-Or
probiotics NCT03861910 788 798 B-Drug
during NCT03861910 799 805 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861910 806 809 O
4 NCT03861910 810 811 B-Eq-Comparison
weeks NCT03861910 812 817 I-Eq-Comparison
before NCT03861910 818 824 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03861910 825 834 B-Study
. NCT03861910 834 835 O

Inclusion NCT03863860 0 9 O
Criteria NCT03863860 10 18 O
: NCT03863860 19 20 O

1 NCT03863860 24 25 O
. NCT03863860 25 26 O
Histologically NCT03863860 28 42 B-Procedure
diagnosed NCT03863860 43 52 O
high NCT03863860 53 57 O
- NCT03863860 58 59 I-Eq-Comparison
grade NCT03863860 60 65 O
serous NCT03863860 66 72 B-Modifier
or NCT03863860 73 75 B-Or
endometrioid NCT03863860 76 88 B-Modifier
ovarian NCT03863860 89 96 I-Modifier
cancer NCT03863860 97 103 B-Condition
( NCT03863860 104 105 B-Eq-Comparison
including NCT03863860 106 115 O
primary NCT03863860 116 123 B-Modifier
peritoneal NCT03863860 124 134 I-Modifier
and NCT03863860 135 138 B-Or
fallopian NCT03863860 139 148 B-Modifier
tube NCT03863860 149 153 I-Modifier
cancer NCT03863860 154 160 B-Condition
) NCT03863860 161 162 O

2 NCT03863860 166 167 O
. NCT03863860 167 168 O
Completion NCT03863860 170 180 O
of NCT03863860 181 183 O
≥ NCT03863860 184 185 B-Eq-Comparison
2 NCT03863860 186 187 I-Eq-Comparison
previous NCT03863860 188 196 B-Eq-Comparison
platinum NCT03863860 197 205 B-Procedure
- NCT03863860 206 207 I-Procedure
containing NCT03863860 208 218 I-Procedure
regimens NCT03863860 219 227 I-Procedure

3 NCT03863860 230 231 O
. NCT03863860 231 232 O
Complete NCT03863860 234 242 B-Condition
response NCT03863860 243 251 I-Condition
( NCT03863860 252 253 O
CR NCT03863860 254 256 B-Condition
) NCT03863860 257 258 O
or NCT03863860 259 261 B-Or
partial NCT03863860 262 269 B-Condition
response NCT03863860 270 278 I-Condition
( NCT03863860 279 280 O
PR NCT03863860 281 283 B-Condition
) NCT03863860 284 285 O
achieved NCT03863860 286 294 O
with NCT03863860 295 299 O
last NCT03863860 300 304 B-Eq-Comparison
platinum NCT03863860 305 313 B-Modifier
- NCT03863860 314 315 I-Modifier
based NCT03863860 316 321 I-Modifier
chemotherapy NCT03863860 322 334 B-Procedure
regimen NCT03863860 335 342 I-Procedure
as NCT03863860 343 345 O
determined NCT03863860 346 356 O
by NCT03863860 357 359 O
investigator NCT03863860 360 372 O

4 NCT03863860 375 376 O
. NCT03863860 376 377 O
Ability NCT03863860 379 386 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863860 387 389 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03863860 390 392 O
randomized NCT03863860 393 403 O
≤ NCT03863860 404 405 B-Eq-Comparison
8 NCT03863860 406 407 I-Eq-Comparison
weeks NCT03863860 408 413 I-Eq-Comparison
after NCT03863860 414 419 B-Temporal-Connection___Temporal-Connection-Type-Value:after
last NCT03863860 420 424 B-Eq-Comparison
dose NCT03863860 425 429 O
of NCT03863860 430 432 O
platinum NCT03863860 433 441 B-Procedure

Exclusion NCT03863860 442 451 O
Criteria NCT03863860 452 460 O
: NCT03863860 461 462 O

1 NCT03863860 466 467 O
. NCT03863860 467 468 O
Prior NCT03863860 470 475 B-Eq-Comparison
treatment NCT03863860 476 485 B-Procedure
with NCT03863860 486 490 O
a NCT03863860 491 492 O
poly NCT03863860 493 497 B-Drug
( NCT03863860 498 499 I-Drug
ADP NCT03863860 500 503 I-Drug
- NCT03863860 504 505 I-Drug
ribose NCT03863860 506 512 I-Drug
) NCT03863860 513 514 I-Drug
polymerase NCT03863860 515 525 I-Drug
( NCT03863860 526 527 O
PARP NCT03863860 528 532 B-Drug
) NCT03863860 533 534 O
inhibitor NCT03863860 535 544 B-Modifier

2 NCT03863860 547 548 O
. NCT03863860 548 549 O
Patients NCT03863860 551 559 O
who NCT03863860 560 563 O
have NCT03863860 564 568 O
received NCT03863860 569 577 O
other NCT03863860 578 583 B-Other
study NCT03863860 584 589 B-Study
drug NCT03863860 590 594 B-Drug
treatment NCT03863860 595 604 B-Procedure
within NCT03863860 605 611 B-Eq-Comparison
4 NCT03863860 612 613 I-Eq-Comparison
weeks NCT03863860 614 619 I-Eq-Comparison
prior NCT03863860 620 625 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863860 626 628 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863860 629 632 O
first NCT03863860 633 638 B-Eq-Comparison
administration NCT03863860 639 653 O
( NCT03863860 654 655 O
< NCT03863860 657 658 I-Eq-Comparison
5 NCT03863860 659 660 I-Eq-Comparison
elimination NCT03863860 661 672 I-Eq-Comparison
half NCT03863860 673 677 I-Eq-Comparison
- NCT03863860 678 679 O
lives NCT03863860 680 685 I-Eq-Comparison
of NCT03863860 686 688 O
the NCT03863860 689 692 O
study NCT03863860 693 698 B-Study
drug NCT03863860 699 703 B-Drug
molecular NCT03863860 704 713 B-Modifier
targeted NCT03863860 714 722 I-Modifier
anti NCT03863860 723 727 O
- NCT03863860 728 729 O
cancer NCT03863860 730 736 B-Condition
drugs NCT03863860 737 742 B-Drug
) NCT03863860 743 744 O
. NCT03863860 746 747 O

3 NCT03863860 751 752 O
. NCT03863860 752 753 O
Patients NCT03863860 755 763 O
with NCT03863860 764 768 O
clinical NCT03863860 769 777 O
symptoms NCT03863860 778 786 B-Assertion___Assertion-Type-Value:possible
of NCT03863860 787 789 O
cancer NCT03863860 790 796 B-Condition
ascites NCT03863860 797 804 I-Condition
, NCT03863860 805 806 O
pleural NCT03863860 807 814 B-Condition
effusion NCT03863860 815 823 I-Condition
, NCT03863860 824 825 O
who NCT03863860 826 829 B-And
need NCT03863860 830 834 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863860 835 837 O
drainage NCT03863860 838 846 B-Procedure
, NCT03863860 847 848 O
or NCT03863860 849 851 B-Or
who NCT03863860 852 855 O
have NCT03863860 856 860 O
undergone NCT03863860 861 870 B-Eq-Comparison
ascites NCT03863860 871 878 B-Procedure
drainage NCT03863860 879 887 I-Procedure
within NCT03863860 888 894 B-Eq-Comparison
2 NCT03863860 895 896 I-Eq-Comparison
months NCT03863860 897 903 I-Eq-Comparison
prior NCT03863860 904 909 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863860 910 912 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863860 913 916 O
first NCT03863860 917 922 B-Eq-Comparison
administration NCT03863860 923 937 B-Drug
. NCT03863860 937 938 O

Inclusion NCT03867409 0 9 O
Criteria NCT03867409 10 18 O
: NCT03867409 19 20 O

- NCT03867409 24 25 O
reside NCT03867409 27 33 O
within NCT03867409 34 40 O
the NCT03867409 41 44 O
United NCT03867409 45 51 O
States NCT03867409 52 58 O
but NCT03867409 59 62 B-Exception
outside NCT03867409 63 70 I-Exception
of NCT03867409 71 73 O
Florida NCT03867409 74 81 O

- NCT03867409 84 85 O
speak NCT03867409 87 92 O
English NCT03867409 93 100 O

- NCT03867409 103 104 O
are NCT03867409 106 109 O
of NCT03867409 110 112 O
either NCT03867409 113 119 O
black NCT03867409 120 125 O
or NCT03867409 126 128 B-Or
white NCT03867409 129 134 O
racial NCT03867409 135 141 O
background NCT03867409 142 152 O
. NCT03867409 153 154 O

- NCT03867409 158 159 O
are NCT03867409 161 164 O
out NCT03867409 165 168 O
- NCT03867409 169 170 O
of NCT03867409 171 173 O
- NCT03867409 174 175 O
guidelines NCT03867409 176 186 O
for NCT03867409 187 190 O
colorectal NCT03867409 191 201 B-Procedure
cancer NCT03867409 202 208 I-Procedure
screening NCT03867409 209 218 I-Procedure
( NCT03867409 219 220 O
> NCT03867409 222 223 B-Eq-Comparison
10 NCT03867409 224 226 I-Eq-Comparison
years NCT03867409 227 232 I-Eq-Comparison
for NCT03867409 233 236 O
colonoscopy NCT03867409 237 248 B-Procedure
, NCT03867409 249 250 O
> NCT03867409 251 252 B-Eq-Comparison
3 NCT03867409 253 254 I-Eq-Comparison
years NCT03867409 255 260 I-Eq-Comparison
for NCT03867409 261 264 O
Cologuard NCT03867409 265 274 B-Procedure
, NCT03867409 275 276 O
> NCT03867409 277 278 B-Eq-Comparison
1 NCT03867409 279 280 I-Eq-Comparison
year NCT03867409 281 285 I-Eq-Comparison
for NCT03867409 286 289 O
fecal NCT03867409 290 295 B-Procedure
immunochemical NCT03867409 296 310 I-Procedure
test NCT03867409 311 315 I-Procedure
) NCT03867409 316 317 O

Exclusion NCT03867409 319 328 O
Criteria NCT03867409 329 337 O
: NCT03867409 338 339 O

- NCT03867409 343 344 O
does NCT03867409 346 350 O
not NCT03867409 351 354 O
meet NCT03867409 355 359 O
the NCT03867409 360 363 O
above NCT03867409 364 369 O
criteria NCT03867409 370 378 O

Inclusion NCT03869424 0 9 O
Criteria NCT03869424 10 18 O
: NCT03869424 19 20 O

- NCT03869424 24 25 O
healthy NCT03869424 27 34 B-Condition
volunteers NCT03869424 35 45 O

- NCT03869424 48 49 O
fluent NCT03869424 51 57 O
in NCT03869424 58 60 O
German NCT03869424 61 67 O
language NCT03869424 68 76 O

Exclusion NCT03869424 77 86 O
Criteria NCT03869424 87 95 O
: NCT03869424 96 97 O

- NCT03869424 101 102 O
mental NCT03869424 104 110 B-Condition
disorders NCT03869424 111 120 I-Condition

- NCT03869424 123 124 O
allergic NCT03869424 126 134 B-Allergy
to NCT03869424 135 137 O
capsaicin NCT03869424 138 147 B-Drug

- NCT03869424 150 151 O
allergic NCT03869424 153 161 B-Allergy
to NCT03869424 162 164 O
sesame NCT03869424 165 171 B-Drug
oil NCT03869424 172 175 I-Drug

- NCT03869424 178 179 O
intake NCT03869424 181 187 O
of NCT03869424 188 190 O
psychopharmacological NCT03869424 191 212 B-Drug
drugs NCT03869424 213 218 I-Drug
in NCT03869424 219 221 O
the NCT03869424 222 225 O
last NCT03869424 226 230 B-Eq-Comparison
four NCT03869424 231 235 I-Eq-Comparison
weeks NCT03869424 236 241 I-Eq-Comparison

- NCT03869424 244 245 O
intake NCT03869424 247 253 O
of NCT03869424 254 256 O
illegal NCT03869424 257 264 B-Modifier
drugs NCT03869424 265 270 B-Drug
in NCT03869424 271 273 O
the NCT03869424 274 277 O
last NCT03869424 278 282 B-Eq-Comparison
two NCT03869424 283 286 I-Eq-Comparison
weeks NCT03869424 287 292 I-Eq-Comparison

- NCT03869424 295 296 O
consumption NCT03869424 298 309 O
of NCT03869424 310 312 O
alcohol NCT03869424 313 320 B-Drug
in NCT03869424 321 323 O
the NCT03869424 324 327 O
last NCT03869424 328 332 B-Eq-Comparison
twelve NCT03869424 333 339 I-Eq-Comparison
hours NCT03869424 340 345 I-Eq-Comparison

- NCT03869424 348 349 O
students NCT03869424 351 359 O
in NCT03869424 360 362 O
medicine NCT03869424 363 371 O
, NCT03869424 372 373 O
pharmacy NCT03869424 374 382 O
, NCT03869424 383 384 O
or NCT03869424 385 387 O
psychology NCT03869424 388 398 O

- NCT03869424 401 402 O
completed NCT03869424 404 413 O
studies NCT03869424 414 421 O
in NCT03869424 422 424 O
medicine NCT03869424 425 433 O
, NCT03869424 434 435 O
pharmacy NCT03869424 436 444 O
or NCT03869424 445 447 O
psychology NCT03869424 448 458 O

- NCT03869424 461 462 O
current NCT03869424 464 471 B-Eq-Comparison
pregnancy NCT03869424 472 481 B-Condition
or NCT03869424 482 484 B-Or
lactation NCT03869424 485 494 B-Condition

- NCT03869424 497 498 O
cardio NCT03869424 500 506 B-Condition
vascular NCT03869424 507 515 I-Condition
disease NCT03869424 516 523 I-Condition

- NCT03869424 526 527 O
kidney NCT03869424 529 535 B-Condition
disease NCT03869424 536 543 I-Condition

- NCT03869424 546 547 O
liver NCT03869424 549 554 B-Condition
disease NCT03869424 555 562 I-Condition

Inclusion NCT03861078 0 9 O
Criteria NCT03861078 10 18 O
- NCT03861078 19 20 O
- NCT03861078 22 23 O
Participants NCT03861078 24 36 O
must NCT03861078 37 41 O
be NCT03861078 42 44 O
: NCT03861078 45 46 O

- NCT03861078 50 51 O
Healthy NCT03861078 53 60 B-Condition
( NCT03861078 61 62 O
determined NCT03861078 63 73 O
by NCT03861078 74 76 O
self NCT03861078 77 81 O
- NCT03861078 82 83 O
report NCT03861078 84 90 O
) NCT03861078 91 92 O

- NCT03861078 96 97 O
Between NCT03861078 99 106 O
the NCT03861078 107 110 O
ages NCT03861078 111 115 B-Age
of NCT03861078 116 118 O
18 NCT03861078 119 121 B-Eq-Comparison
- NCT03861078 122 123 I-Eq-Comparison
55 NCT03861078 124 126 I-Eq-Comparison
years NCT03861078 127 132 I-Eq-Comparison
old NCT03861078 133 136 O

- NCT03861078 139 140 O
Current NCT03861078 142 149 B-Eq-Comparison
cigarette NCT03861078 150 159 B-Condition
smokers NCT03861078 160 167 I-Condition

- NCT03861078 170 171 O
Wiling NCT03861078 173 179 O
to NCT03861078 180 182 O
provide NCT03861078 183 190 O
informed NCT03861078 191 199 O
consent NCT03861078 200 207 O

- NCT03861078 210 211 O
Able NCT03861078 213 217 O
to NCT03861078 218 220 O
attend NCT03861078 221 227 O
the NCT03861078 228 231 O
lab NCT03861078 232 235 O
session NCT03861078 236 243 O
and NCT03861078 244 247 O
abstain NCT03861078 248 255 O
from NCT03861078 256 260 O
tobacco NCT03861078 261 268 O
/ NCT03861078 269 270 O
nicotine NCT03861078 271 279 O
products NCT03861078 280 288 O
as NCT03861078 289 291 O
required NCT03861078 292 300 O

- NCT03861078 303 304 O
Agree NCT03861078 306 311 O
to NCT03861078 312 314 O
use NCT03861078 315 318 O
designated NCT03861078 319 329 O
products NCT03861078 330 338 O
according NCT03861078 339 348 O
to NCT03861078 349 351 O
the NCT03861078 352 355 O
study NCT03861078 356 361 O
protocol NCT03861078 362 370 O

Exclusion NCT03861078 371 380 O
Criteria NCT03861078 381 389 O
: NCT03861078 390 391 O

- NCT03861078 395 396 O
Women NCT03861078 398 403 O
if NCT03861078 404 406 O
they NCT03861078 407 411 O
are NCT03861078 412 415 O
breast NCT03861078 416 422 B-Condition
- NCT03861078 423 424 I-Condition
feeding NCT03861078 425 432 I-Condition
or NCT03861078 433 435 B-Or
test NCT03861078 436 440 B-Observation
positive NCT03861078 441 449 O
for NCT03861078 450 453 O
pregnancy NCT03861078 454 463 B-Condition
( NCT03861078 464 465 O
by NCT03861078 466 468 O
urinalysis NCT03861078 469 479 B-Observation
) NCT03861078 480 481 O
at NCT03861078 482 484 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03861078 485 494 B-Study
. NCT03861078 495 496 O

- NCT03861078 500 501 O
Individuals NCT03861078 503 514 O
who NCT03861078 515 518 O
weigh NCT03861078 519 524 B-Observation
less NCT03861078 525 529 B-Eq-Comparison
than NCT03861078 530 534 I-Eq-Comparison
110 NCT03861078 535 538 I-Eq-Comparison
pounds NCT03861078 539 545 I-Eq-Comparison
. NCT03861078 546 547 O

Some NCT03861078 549 553 O
study NCT03861078 554 559 O
details NCT03861078 560 567 O
about NCT03861078 568 573 O
the NCT03861078 574 577 O
eligibility NCT03861078 578 589 O
criteria NCT03861078 590 598 O
are NCT03861078 599 602 O
purposely NCT03861078 603 612 O
omitted NCT03861078 613 620 O
at NCT03861078 621 623 O
this NCT03861078 624 628 O
time NCT03861078 629 633 O
to NCT03861078 634 636 O
preserve NCT03861078 637 645 O
scientific NCT03861078 646 656 O
integrity NCT03861078 657 666 O
. NCT03861078 666 667 O
Full NCT03861078 669 673 O
details NCT03861078 674 681 O
will NCT03861078 682 686 O
be NCT03861078 687 689 O
posted NCT03861078 690 696 O
at NCT03861078 697 699 O
the NCT03861078 700 703 O
conclusion NCT03861078 704 714 O
of NCT03861078 715 717 O
the NCT03861078 718 721 O
study NCT03861078 722 727 O
. NCT03861078 728 729 O


Inclusion NCT03860428 0 9 O
Criteria NCT03860428 10 18 O
: NCT03860428 19 20 O

- NCT03860428 24 25 O
Gestational NCT03860428 27 38 B-Observation
age NCT03860428 39 42 I-Observation
< NCT03860428 43 44 B-Eq-Comparison
32 NCT03860428 45 47 I-Eq-Comparison
weeks NCT03860428 48 53 I-Eq-Comparison

- NCT03860428 56 57 O
Birthweight NCT03860428 59 70 B-Observation
< NCT03860428 71 72 B-Eq-Comparison
1500 NCT03860428 73 77 I-Eq-Comparison
g NCT03860428 78 79 I-Eq-Comparison

- NCT03860428 82 83 O
Age NCT03860428 85 88 B-Age
less NCT03860428 89 93 B-Eq-Comparison
than NCT03860428 94 98 I-Eq-Comparison
72 NCT03860428 99 101 I-Eq-Comparison
hours NCT03860428 102 107 I-Eq-Comparison

- NCT03860428 110 111 O
PDA NCT03860428 113 116 B-Condition
diameter NCT03860428 117 125 B-Observation
> NCT03860428 126 127 B-Eq-Comparison
1.5 NCT03860428 128 131 I-Eq-Comparison
mm NCT03860428 132 134 I-Eq-Comparison

- NCT03860428 137 138 O
Signed NCT03860428 140 146 O
informed NCT03860428 147 155 O
consent NCT03860428 156 163 O
obtained NCT03860428 164 172 O
from NCT03860428 173 177 O
both NCT03860428 178 182 O
parents NCT03860428 183 190 O

Exclusion NCT03860428 191 200 O
Criteria NCT03860428 201 209 O
: NCT03860428 210 211 O

- NCT03860428 215 216 O
Birthweight NCT03860428 218 229 B-Observation
≥ NCT03860428 230 231 B-Eq-Comparison
1500 NCT03860428 232 236 I-Eq-Comparison
g NCT03860428 237 238 I-Eq-Comparison
and NCT03860428 239 242 B-Or
/ NCT03860428 243 244 I-Or
or NCT03860428 245 247 I-Or
gestation NCT03860428 248 257 B-Observation
age NCT03860428 258 261 I-Observation
≥ NCT03860428 262 263 B-Eq-Comparison
32 NCT03860428 264 266 I-Eq-Comparison
weeks NCT03860428 267 272 I-Eq-Comparison

- NCT03860428 275 276 O
Lack NCT03860428 278 282 O
of NCT03860428 283 285 O
informed NCT03860428 286 294 O
consent NCT03860428 295 302 O
of NCT03860428 303 305 O
the NCT03860428 306 309 O
parents NCT03860428 310 317 O

- NCT03860428 320 321 O
Congenital NCT03860428 323 333 B-Condition
heart NCT03860428 334 339 I-Condition
defect NCT03860428 340 346 I-Condition
, NCT03860428 347 348 O
other NCT03860428 349 354 B-Exception
than NCT03860428 355 359 I-Exception
PDA NCT03860428 360 363 B-Condition
and NCT03860428 364 367 B-Or
/ NCT03860428 368 369 I-Or
or NCT03860428 370 372 I-Or
patent NCT03860428 373 379 B-Condition
foramen NCT03860428 380 387 I-Condition
ovale NCT03860428 388 393 I-Condition
( NCT03860428 394 395 O
PFO NCT03860428 396 399 B-Condition
) NCT03860428 400 401 O

- NCT03860428 405 406 O
The NCT03860428 408 411 O
presence NCT03860428 412 420 O
of NCT03860428 421 423 O
a NCT03860428 424 425 O
clinically NCT03860428 426 436 O
apparent NCT03860428 437 445 O
hemorrhagic NCT03860428 446 457 B-Condition
syndrome NCT03860428 458 466 I-Condition

- NCT03860428 469 470 O
Any NCT03860428 472 475 O
intraventricular NCT03860428 476 492 B-Condition
hemorrhage NCT03860428 493 503 I-Condition
( NCT03860428 504 505 O
IVH NCT03860428 506 509 B-Condition
) NCT03860428 510 511 O
in NCT03860428 512 514 B-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03860428 515 518 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
first NCT03860428 519 524 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
48 NCT03860428 525 527 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
hours NCT03860428 528 533 I-Eq-Comparison|Temporal-Connection___Temporal-Connection-Type-Value:after
or NCT03860428 534 536 B-Or
IVH NCT03860428 537 540 B-Condition
grade NCT03860428 541 546 B-Eq-Comparison
3 NCT03860428 547 548 I-Eq-Comparison
- NCT03860428 549 550 I-Eq-Comparison
4 NCT03860428 551 552 I-Eq-Comparison

- NCT03860428 556 557 O
A NCT03860428 559 560 O
platelet NCT03860428 561 569 B-Observation
count NCT03860428 570 575 I-Observation
of NCT03860428 576 578 O
< NCT03860428 579 580 B-Eq-Comparison
50 NCT03860428 581 583 I-Eq-Comparison
, NCT03860428 584 585 O
000 NCT03860428 586 589 O
/ NCT03860428 590 591 O
mm3 NCT03860428 592 595 O

- NCT03860428 598 599 O
A NCT03860428 601 602 O
serum NCT03860428 603 608 B-Observation
creatinine NCT03860428 609 619 I-Observation
concentration NCT03860428 620 633 I-Observation
of NCT03860428 634 636 O
> NCT03860428 637 638 B-Eq-Comparison
110 NCT03860428 639 642 I-Eq-Comparison
μmol NCT03860428 643 647 I-Eq-Comparison
/ NCT03860428 648 649 I-Eq-Comparison
L NCT03860428 650 651 I-Eq-Comparison

- NCT03860428 654 655 O
Oliguria NCT03860428 657 665 B-Condition|Observation
< NCT03860428 666 667 B-Eq-Comparison
1 NCT03860428 668 669 I-Eq-Comparison
ml NCT03860428 670 672 I-Eq-Comparison
/ NCT03860428 673 674 I-Eq-Comparison
kg NCT03860428 675 677 I-Eq-Comparison
/ NCT03860428 678 679 I-Eq-Comparison
h NCT03860428 680 681 I-Eq-Comparison

- NCT03860428 684 685 O
Suspected NCT03860428 687 696 B-Assertion___Assertion-Type-Value:possible
/ NCT03860428 697 698 I-Assertion___Assertion-Type-Value:possible
apparent NCT03860428 699 707 I-Assertion___Assertion-Type-Value:possible
NEC NCT03860428 708 711 B-Condition

- NCT03860428 714 715 O
Suspected NCT03860428 717 726 B-Assertion___Assertion-Type-Value:possible
/ NCT03860428 727 728 I-Assertion___Assertion-Type-Value:possible
apparent NCT03860428 729 737 I-Assertion___Assertion-Type-Value:possible
lung NCT03860428 738 742 B-Condition
hypoplasia NCT03860428 743 753 I-Condition

Inclusion NCT03865550 0 9 O
Criteria NCT03865550 10 18 O
: NCT03865550 19 20 O

- NCT03865550 24 25 O
18 NCT03865550 27 29 B-Eq-Comparison
- NCT03865550 30 31 I-Eq-Comparison
85 NCT03865550 32 34 I-Eq-Comparison
years NCT03865550 35 40 I-Eq-Comparison
of NCT03865550 41 43 O
age NCT03865550 44 47 B-Age

- NCT03865550 50 51 O
ASA NCT03865550 53 56 B-Condition
I NCT03865550 57 58 B-Eq-Comparison
- NCT03865550 59 60 I-Eq-Comparison
IV NCT03865550 61 63 I-Eq-Comparison

- NCT03865550 66 67 O
Undergoing NCT03865550 69 79 B-Eq-Comparison
primary NCT03865550 80 87 B-Modifier
unilateral NCT03865550 88 98 I-Modifier
elective NCT03865550 99 107 I-Modifier
total NCT03865550 108 113 B-Procedure
knee NCT03865550 114 118 I-Procedure
arthroplasty NCT03865550 119 131 I-Procedure
with NCT03865550 132 136 O
spinal NCT03865550 137 143 B-Procedure
anesthesia NCT03865550 144 154 I-Procedure

Exclusion NCT03865550 155 164 O
Criteria NCT03865550 165 173 O
: NCT03865550 174 175 O

- NCT03865550 179 180 O
BMI NCT03865550 182 185 B-Observation
over NCT03865550 186 190 B-Eq-Comparison
40 NCT03865550 191 193 I-Eq-Comparison
* NCT03865550 194 195 O

- NCT03865550 198 199 O
Contraindication NCT03865550 201 217 B-Contraindication
or NCT03865550 218 220 B-Or
allergy NCT03865550 221 228 B-Allergy
to NCT03865550 229 231 O
opioid NCT03865550 232 238 B-Drug
pain NCT03865550 239 243 I-Drug
medication NCT03865550 244 254 I-Drug
or NCT03865550 255 257 B-Or
ketamine NCT03865550 258 266 B-Drug
* NCT03865550 266 267 O

- NCT03865550 270 271 O
Daily NCT03865550 273 278 B-Eq-Comparison
opioid NCT03865550 279 285 B-Drug
use NCT03865550 286 289 O
for NCT03865550 290 293 O
pain NCT03865550 294 298 B-Condition
control NCT03865550 299 306 O
before NCT03865550 307 313 B-Temporal-Connection
surgery NCT03865550 314 321 B-Procedure
in NCT03865550 322 324 B-Eq-Comparison
excess NCT03865550 325 331 I-Eq-Comparison
of NCT03865550 332 334 I-Eq-Comparison
systemic NCT03865550 335 343 I-Eq-Comparison
morphine NCT03865550 344 352 I-Eq-Comparison
equivalent NCT03865550 353 363 I-Eq-Comparison
to NCT03865550 364 366 I-Eq-Comparison
10 NCT03865550 367 369 I-Eq-Comparison
mg NCT03865550 370 372 I-Eq-Comparison
* NCT03865550 372 373 O

- NCT03865550 376 377 O
Ejection NCT03865550 379 387 B-Observation
fraction NCT03865550 388 396 I-Observation
( NCT03865550 397 398 O
EF NCT03865550 399 401 B-Observation
) NCT03865550 402 403 O
less NCT03865550 404 408 B-Eq-Comparison
than NCT03865550 409 413 I-Eq-Comparison
30 NCT03865550 414 416 I-Eq-Comparison
% NCT03865550 417 418 I-Eq-Comparison

- NCT03865550 422 423 O
Creatinine NCT03865550 425 435 B-Observation
clearance NCT03865550 436 445 I-Observation
less NCT03865550 446 450 B-Eq-Comparison
than NCT03865550 451 455 I-Eq-Comparison
30 NCT03865550 456 458 I-Eq-Comparison
mL NCT03865550 459 461 I-Eq-Comparison
/ NCT03865550 462 463 I-Eq-Comparison
min NCT03865550 464 467 I-Eq-Comparison
* NCT03865550 467 468 O

- NCT03865550 471 472 O
History NCT03865550 474 481 B-Eq-Comparison
of NCT03865550 482 484 O
chronic NCT03865550 485 492 B-Modifier
liver NCT03865550 493 498 B-Condition
failure NCT03865550 499 506 I-Condition

- NCT03865550 509 510 O
Desire NCT03865550 512 518 B-Assertion___Assertion-Type-Value:intention
for NCT03865550 519 522 I-Assertion___Assertion-Type-Value:intention
nerve NCT03865550 523 528 B-Procedure
block NCT03865550 529 534 I-Procedure
or NCT03865550 535 537 B-Or
general NCT03865550 538 545 B-Procedure
anesthesia NCT03865550 546 556 I-Procedure

- NCT03865550 559 560 O
Any NCT03865550 562 565 O
neurologic NCT03865550 566 576 B-Modifier
or NCT03865550 577 579 B-Or
psychiatric NCT03865550 580 591 B-Modifier
disorder NCT03865550 592 600 B-Condition
( NCT03865550 601 602 O
including NCT03865550 603 612 O
bipolar NCT03865550 613 620 B-Condition
disorder NCT03865550 621 629 I-Condition
, NCT03865550 630 631 O
post NCT03865550 632 636 B-Condition
traumatic NCT03865550 637 646 I-Condition
stress NCT03865550 647 653 I-Condition
disorder NCT03865550 654 662 I-Condition
, NCT03865550 663 664 O
schizophrenia NCT03865550 665 678 B-Condition
) NCT03865550 679 680 O

- NCT03865550 684 685 O
Prior NCT03865550 687 692 B-Eq-Comparison
surgery NCT03865550 693 700 B-Procedure
on NCT03865550 701 703 O
ipsilateral NCT03865550 704 715 B-Modifier
knee NCT03865550 716 720 I-Modifier
within NCT03865550 721 727 B-Eq-Comparison
the NCT03865550 728 731 I-Eq-Comparison
last NCT03865550 732 736 I-Eq-Comparison
6 NCT03865550 737 738 I-Eq-Comparison
months NCT03865550 739 745 I-Eq-Comparison

- NCT03865550 748 749 O
Alcohol NCT03865550 751 758 B-Condition
abuse NCT03865550 759 764 I-Condition

Inclusion NCT03869801 0 9 O
Criteria NCT03869801 10 18 O
: NCT03869801 19 20 O

- NCT03869801 24 25 O
Elective NCT03869801 27 35 B-Modifier
laparoscopic NCT03869801 36 48 B-Procedure
Cholecystectomy NCT03869801 49 64 I-Procedure
, NCT03869801 65 66 O
ASA NCT03869801 67 70 B-Condition
status NCT03869801 71 77 O
1 NCT03869801 78 79 B-Eq-Comparison
- NCT03869801 80 81 I-Eq-Comparison
2 NCT03869801 82 83 O

Exclusion NCT03869801 85 94 O
Criteria NCT03869801 95 103 O
: NCT03869801 104 105 O

- NCT03869801 109 110 O
Patient NCT03869801 112 119 O
refusal NCT03869801 120 127 O
Contraindications NCT03869801 128 145 B-Contraindication
to NCT03869801 146 148 O
regional NCT03869801 149 157 B-Procedure
anesthesia NCT03869801 158 168 I-Procedure
Known NCT03869801 169 174 O
allergy NCT03869801 175 182 B-Allergy
to NCT03869801 183 185 O
local NCT03869801 186 191 B-Drug
anesthetics NCT03869801 192 203 I-Drug
Bleeding NCT03869801 204 212 B-Condition
diathesis NCT03869801 213 222 B-Condition
Use NCT03869801 223 226 O
of NCT03869801 227 229 O
any NCT03869801 230 233 O
anti NCT03869801 234 238 B-Drug
- NCT03869801 239 240 I-Drug
coagulants NCT03869801 241 251 I-Drug
Inability NCT03869801 252 261 O
to NCT03869801 262 264 O
provide NCT03869801 265 272 O
informed NCT03869801 273 281 O
consent NCT03869801 282 289 O
Severe NCT03869801 290 296 O
kidney NCT03869801 297 303 B-Modifier
or NCT03869801 304 306 B-Or
liver NCT03869801 307 312 B-Modifier
disease NCT03869801 313 320 B-Condition
Inability NCT03869801 321 330 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869801 331 333 O
operate NCT03869801 334 341 B-Procedure
PCA NCT03869801 342 345 I-Procedure
system NCT03869801 346 352 O
Patient NCT03869801 353 360 O
with NCT03869801 361 365 O
psychiatric NCT03869801 366 377 B-Condition
disorders NCT03869801 378 387 I-Condition

Inclusion NCT03867838 0 9 O
Criteria NCT03867838 10 18 O
: NCT03867838 19 20 O

- NCT03867838 24 25 O
greater NCT03867838 27 34 B-Eq-Comparison
than NCT03867838 35 39 I-Eq-Comparison
6 NCT03867838 40 41 I-Eq-Comparison
months NCT03867838 42 48 I-Eq-Comparison
post NCT03867838 49 53 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03867838 54 55 O
stroke NCT03867838 56 62 B-Condition

- NCT03867838 65 66 O
passive NCT03867838 68 75 B-Condition|Observation
abduction NCT03867838 76 85 I-Condition|Observation
to NCT03867838 86 88 O
90 NCT03867838 89 91 B-Eq-Comparison
degrees NCT03867838 92 99 I-Eq-Comparison
at NCT03867838 100 102 O
shoulder NCT03867838 103 111 B-Modifier

- NCT03867838 114 115 O
reduced NCT03867838 117 124 O
active NCT03867838 125 131 B-Eq-Comparison
( NCT03867838 132 133 O
retro NCT03867838 134 139 B-Modifier
) NCT03867838 140 141 O
flexion NCT03867838 142 149 B-Condition
/ NCT03867838 150 151 B-Or
extension NCT03867838 152 161 B-Condition
at NCT03867838 162 164 O
shoulder NCT03867838 165 173 B-Modifier
when NCT03867838 174 178 O
abducted NCT03867838 179 187 B-Observation
to NCT03867838 188 190 O
90 NCT03867838 191 193 B-Eq-Comparison
degrees NCT03867838 194 201 I-Eq-Comparison

- NCT03867838 204 205 O
reduced NCT03867838 207 214 O
active NCT03867838 215 221 B-Eq-Comparison
flexion NCT03867838 222 229 B-Condition
/ NCT03867838 230 231 B-Or
extension NCT03867838 232 241 B-Condition
at NCT03867838 242 244 O
elbow NCT03867838 245 250 B-Modifier

Exclusion NCT03867838 251 260 O
Criteria NCT03867838 261 269 O
: NCT03867838 270 271 O

- NCT03867838 275 276 O
unable NCT03867838 278 284 O
to NCT03867838 285 287 O
give NCT03867838 288 292 O
informed NCT03867838 293 301 O
consent NCT03867838 302 309 O

- NCT03867838 312 313 O
unable NCT03867838 315 321 O
to NCT03867838 322 324 O
comprehend NCT03867838 325 335 O
and NCT03867838 336 339 O
follow NCT03867838 340 346 O
instructions NCT03867838 347 359 O

- NCT03867838 362 363 O
have NCT03867838 365 369 O
a NCT03867838 370 371 O
condition NCT03867838 372 381 B-Condition
( NCT03867838 382 383 O
other NCT03867838 384 389 B-Exception
than NCT03867838 390 394 I-Exception
stroke NCT03867838 395 401 B-Condition
) NCT03867838 402 403 O
affecting NCT03867838 404 413 O
sensorimotor NCT03867838 414 426 B-Condition
function NCT03867838 427 435 I-Condition

- NCT03867838 438 439 O
show NCT03867838 441 445 O
evidence NCT03867838 446 454 O
of NCT03867838 455 457 O
unilateral NCT03867838 458 468 B-Modifier
spatial NCT03867838 469 476 B-Condition
neglect NCT03867838 477 484 I-Condition

- NCT03867838 487 488 O
unable NCT03867838 490 496 B-Negation
to NCT03867838 497 499 O
sit NCT03867838 500 503 B-Condition
in NCT03867838 504 506 B-Modifier
a NCT03867838 507 508 I-Modifier
chair NCT03867838 509 514 I-Modifier
without NCT03867838 515 522 B-Negation
armrests NCT03867838 523 531 B-Modifier
for NCT03867838 532 535 O
2 NCT03867838 536 537 B-Eq-Comparison
hours NCT03867838 538 543 I-Eq-Comparison

Inclusion NCT03864302 0 9 O
Criteria NCT03864302 10 18 O
: NCT03864302 19 20 O

- NCT03864302 24 25 O
Doctors NCT03864302 27 34 B-Provider

- NCT03864302 37 38 O
Informed NCT03864302 40 48 O
written NCT03864302 49 56 O
consent NCT03864302 57 64 O
. NCT03864302 65 66 O

- NCT03864302 70 71 O
Four NCT03864302 73 77 B-Eq-Comparison
video NCT03864302 78 83 O
- NCT03864302 84 85 O
recordings NCT03864302 86 96 O
of NCT03864302 97 99 O
TURBs NCT03864302 100 105 B-Procedure
. NCT03864302 106 107 O

Exclusion NCT03864302 109 118 O
Criteria NCT03864302 119 127 O
: NCT03864302 128 129 O

- NCT03864302 133 134 O
Not NCT03864302 136 139 B-Negation
providing NCT03864302 140 149 O
four NCT03864302 150 154 B-Eq-Comparison
video NCT03864302 155 160 O
recordings NCT03864302 161 171 O
of NCT03864302 172 174 O
TURB NCT03864302 175 179 B-Procedure
procedures NCT03864302 180 190 I-Procedure

- NCT03864302 193 194 O
Simulation NCT03864302 196 206 B-Procedure
- NCT03864302 207 208 I-Procedure
based NCT03864302 209 214 I-Procedure
training NCT03864302 215 223 I-Procedure
course NCT03864302 224 230 O
in NCT03864302 231 233 O
TURB NCT03864302 234 238 B-Procedure
within NCT03864302 239 245 B-Eq-Comparison
6 NCT03864302 246 247 I-Eq-Comparison
months NCT03864302 248 254 I-Eq-Comparison

- NCT03864302 257 258 O
No NCT03864302 260 262 O
consent NCT03864302 263 270 O

Inclusion NCT03862001 0 9 O
Criteria NCT03862001 10 18 O
: NCT03862001 19 20 O

- NCT03862001 24 25 O
age NCT03862001 27 30 B-Age
55 NCT03862001 31 33 B-Eq-Comparison
- NCT03862001 34 35 I-Eq-Comparison
80 NCT03862001 36 38 O

- NCT03862001 42 43 O
smoked NCT03862001 45 51 B-Condition|Observation
at NCT03862001 52 54 B-Eq-Comparison
least NCT03862001 55 60 I-Eq-Comparison
30 NCT03862001 61 63 I-Eq-Comparison
pack NCT03862001 64 68 I-Eq-Comparison
- NCT03862001 69 70 I-Eq-Comparison
years NCT03862001 71 76 I-Eq-Comparison
in NCT03862001 77 79 I-Eq-Comparison
lifetime NCT03862001 80 88 I-Eq-Comparison

- NCT03862001 91 92 O
if NCT03862001 94 96 O
former NCT03862001 97 103 B-Eq-Comparison
smoker NCT03862001 104 110 B-Condition
, NCT03862001 111 112 O
quit NCT03862001 113 117 B-Negation
smoking NCT03862001 118 125 B-Condition
within NCT03862001 126 132 B-Eq-Comparison
the NCT03862001 133 136 I-Eq-Comparison
last NCT03862001 137 141 I-Eq-Comparison
15 NCT03862001 142 144 I-Eq-Comparison
years NCT03862001 145 150 I-Eq-Comparison

- NCT03862001 153 154 O
English NCT03862001 156 163 O
speaker NCT03862001 164 171 O

- NCT03862001 174 175 O
no NCT03862001 177 179 B-Negation
prior NCT03862001 180 185 B-Eq-Comparison
history NCT03862001 186 193 I-Eq-Comparison
of NCT03862001 194 196 O
lung NCT03862001 197 201 B-Modifier
cancer NCT03862001 202 208 B-Condition

- NCT03862001 211 212 O
did NCT03862001 214 217 O
not NCT03862001 218 221 B-Negation
have NCT03862001 222 226 O
a NCT03862001 227 228 O
lung NCT03862001 229 233 B-Modifier
cancer NCT03862001 234 240 B-Condition
screening NCT03862001 241 250 B-Procedure
test NCT03862001 251 255 I-Procedure
within NCT03862001 256 262 B-Eq-Comparison
the NCT03862001 263 266 I-Eq-Comparison
last NCT03862001 267 271 I-Eq-Comparison
year NCT03862001 272 276 I-Eq-Comparison

- NCT03862001 279 280 O
PCP NCT03862001 282 285 O
does NCT03862001 286 290 O
not NCT03862001 291 294 O
object NCT03862001 295 301 O
to NCT03862001 302 304 O
patient NCT03862001 305 312 O
's NCT03862001 312 314 O
participation NCT03862001 315 328 O

- NCT03862001 331 332 O
have NCT03862001 334 338 O
a NCT03862001 339 340 O
scheduled NCT03862001 341 350 B-Eq-Comparison
visit NCT03862001 351 356 B-Encounter
at NCT03862001 357 359 O
University NCT03862001 360 370 O
of NCT03862001 371 373 O
California NCT03862001 374 384 O
, NCT03862001 385 386 O
San NCT03862001 387 390 O
Francisco NCT03862001 391 400 O
( NCT03862001 401 402 O
UCSF NCT03862001 403 407 O
) NCT03862001 408 409 O
internal NCT03862001 410 418 O
medicine NCT03862001 419 427 O
clinics NCT03862001 428 435 O
. NCT03862001 436 437 O

Exclusion NCT03862001 439 448 O
Criteria NCT03862001 449 457 O
: NCT03862001 458 459 O

- NCT03862001 463 464 O
speaking NCT03862001 466 474 O
a NCT03862001 475 476 O
language NCT03862001 477 485 O
other NCT03862001 486 491 B-Negation
than NCT03862001 492 496 I-Negation
English NCT03862001 497 504 O

- NCT03862001 507 508 O
has NCT03862001 510 513 O
a NCT03862001 514 515 O
history NCT03862001 516 523 B-Eq-Comparison
of NCT03862001 524 526 O
lung NCT03862001 527 531 B-Modifier
cancer NCT03862001 532 538 B-Condition

- NCT03862001 541 542 O
had NCT03862001 544 547 B-Eq-Comparison
a NCT03862001 548 549 O
lung NCT03862001 550 554 B-Modifier
cancer NCT03862001 555 561 B-Condition
screening NCT03862001 562 571 B-Procedure
test NCT03862001 572 576 I-Procedure
within NCT03862001 577 583 B-Eq-Comparison
the NCT03862001 584 587 I-Eq-Comparison
last NCT03862001 588 592 I-Eq-Comparison
year NCT03862001 593 597 I-Eq-Comparison

- NCT03862001 600 601 O
PCP NCT03862001 603 606 O
objects NCT03862001 607 614 O
to NCT03862001 615 617 O
patient NCT03862001 618 625 O
's NCT03862001 625 627 O
participation NCT03862001 628 641 O
. NCT03862001 641 642 O

Inclusion NCT03861520 0 9 O
Criteria NCT03861520 10 18 O
: NCT03861520 19 20 O

1 NCT03861520 24 25 O
. NCT03861520 25 26 O
pregnant NCT03861520 28 36 B-Condition
woman NCT03861520 37 42 O
between NCT03861520 43 50 B-Eq-Comparison
( NCT03861520 51 52 I-Eq-Comparison
16 NCT03861520 53 55 I-Eq-Comparison
- NCT03861520 56 57 I-Eq-Comparison
24 NCT03861520 58 60 I-Eq-Comparison
) NCT03861520 61 62 I-Eq-Comparison
weeks NCT03861520 63 68 I-Eq-Comparison
of NCT03861520 69 71 O
gestation NCT03861520 72 81 B-Observation
. NCT03861520 82 83 O

2 NCT03861520 87 88 O
. NCT03861520 88 89 O
singelton NCT03861520 91 100 B-Modifier
pregnancy NCT03861520 101 110 B-Condition
. NCT03861520 111 112 O

Exclusion NCT03861520 114 123 O
Criteria NCT03861520 124 132 O
: NCT03861520 133 134 O

1 NCT03861520 138 139 O
. NCT03861520 139 140 O
Multiple NCT03861520 142 150 B-Eq-Comparison
pregnancies NCT03861520 151 162 B-Condition
. NCT03861520 163 164 O

2 NCT03861520 168 169 O
. NCT03861520 169 170 O
Mental NCT03861520 172 178 B-Condition
condition NCT03861520 179 188 I-Condition
rendering NCT03861520 189 198 O
the NCT03861520 199 202 O
patients NCT03861520 203 211 O
unable NCT03861520 212 218 B-Condition
to NCT03861520 219 221 I-Condition
understand NCT03861520 222 232 I-Condition
the NCT03861520 233 236 O
nature NCT03861520 237 243 O
and NCT03861520 244 247 O
scope NCT03861520 248 253 O
of NCT03861520 254 256 O
the NCT03861520 257 260 O
study NCT03861520 261 266 B-Study
. NCT03861520 266 267 O

Inclusion NCT03864289 0 9 O
Criteria NCT03864289 10 18 O
: NCT03864289 19 20 O

- NCT03864289 24 25 O
Children NCT03864289 27 35 O
with NCT03864289 36 40 B-And
ASD NCT03864289 41 44 B-Condition
or NCT03864289 45 47 B-Or
high NCT03864289 48 52 O
risk NCT03864289 53 57 B-Risk
for NCT03864289 58 61 O
autism NCT03864289 62 68 B-Condition
; NCT03864289 68 69 O

- NCT03864289 72 73 O
Han NCT03864289 75 78 O
ethic NCT03864289 79 84 O
; NCT03864289 84 85 O

- NCT03864289 88 89 O
Parents NCT03864289 91 98 B-Family-Member___Family-Member-Type:parent
were NCT03864289 99 103 O
at NCT03864289 104 106 B-Eq-Comparison
least NCT03864289 107 112 I-Eq-Comparison
middle NCT03864289 113 119 B-Observation
school NCT03864289 120 126 I-Observation
educated NCT03864289 127 135 I-Observation
, NCT03864289 136 137 O
and NCT03864289 138 141 B-And
agreed NCT03864289 142 148 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864289 149 151 I-Assertion___Assertion-Type-Value:hypothetical
do NCT03864289 152 154 O
at NCT03864289 155 157 B-Eq-Comparison
least NCT03864289 158 163 I-Eq-Comparison
20 NCT03864289 164 166 I-Eq-Comparison
hours NCT03864289 167 172 I-Eq-Comparison
per NCT03864289 173 176 I-Eq-Comparison
week NCT03864289 177 181 I-Eq-Comparison
of NCT03864289 182 184 O
planned NCT03864289 185 192 B-Eq-Comparison
practice NCT03864289 193 201 B-Observation
activities NCT03864289 202 212 I-Observation
with NCT03864289 213 217 O
the NCT03864289 218 221 O
child NCT03864289 222 227 O
in NCT03864289 228 230 O
daily NCT03864289 231 236 O
life NCT03864289 237 241 O
. NCT03864289 242 243 O

Exclusion NCT03864289 245 254 O
Criteria NCT03864289 255 263 O
: NCT03864289 264 265 O

- NCT03864289 269 270 O
Children NCT03864289 272 280 O
with NCT03864289 281 285 B-And
Syndromic NCT03864289 286 295 B-Modifier
ASD NCT03864289 296 299 B-Condition
caused NCT03864289 300 306 O
by NCT03864289 307 309 O
known NCT03864289 310 315 O
genetic NCT03864289 316 323 B-Condition
defects NCT03864289 324 331 I-Condition
or NCT03864289 332 334 B-Or
inherited NCT03864289 335 344 B-Modifier
metabolic NCT03864289 345 354 B-Condition
diseases NCT03864289 355 363 I-Condition
, NCT03864289 364 365 O
such NCT03864289 366 370 O
as NCT03864289 371 373 O
Rett NCT03864289 374 378 B-Condition
Syndrome NCT03864289 379 387 I-Condition
, NCT03864289 388 389 O
Fragile NCT03864289 390 397 B-Condition
X NCT03864289 398 399 I-Condition
Syndrome NCT03864289 400 408 I-Condition
, NCT03864289 409 410 O
Angelman NCT03864289 411 419 B-Condition
Syndrome NCT03864289 420 428 I-Condition
, NCT03864289 429 430 O
Prader NCT03864289 431 437 B-Condition
- NCT03864289 438 439 I-Condition
Willi NCT03864289 440 445 I-Condition
Syndrome NCT03864289 446 454 I-Condition
, NCT03864289 455 456 O
tuberous NCT03864289 457 465 B-Condition
sclerosis NCT03864289 466 475 I-Condition
; NCT03864289 475 476 O

- NCT03864289 479 480 O
Visual NCT03864289 482 488 B-Modifier
, NCT03864289 489 490 O
auditory NCT03864289 491 499 B-Modifier
and NCT03864289 500 503 B-Or
physical NCT03864289 504 512 B-Modifier
disabilities NCT03864289 513 525 B-Condition
; NCT03864289 525 526 O

- NCT03864289 529 530 O
Complication NCT03864289 532 544 O
with NCT03864289 545 549 O
other NCT03864289 550 555 B-Other
serious NCT03864289 556 563 O
chronic NCT03864289 564 571 B-Condition
diseases NCT03864289 572 580 I-Condition
, NCT03864289 581 582 O
such NCT03864289 583 587 O
as NCT03864289 588 590 O
liver NCT03864289 591 596 B-Modifier
and NCT03864289 597 600 B-Or
kidney NCT03864289 601 607 B-Modifier
failure NCT03864289 608 615 B-Condition
, NCT03864289 616 617 O
connective NCT03864289 618 628 B-Condition
tissue NCT03864289 629 635 I-Condition
diseases NCT03864289 636 644 I-Condition
, NCT03864289 645 646 O
tumors NCT03864289 647 653 B-Condition
. NCT03864289 653 654 O

Inclusion NCT03862820 0 9 O
Criteria NCT03862820 10 18 O
: NCT03862820 19 20 O

Pregnant NCT03862820 22 30 B-Condition
women NCT03862820 31 36 O
in NCT03862820 37 39 O
third NCT03862820 40 45 B-Condition
trimester NCT03862820 46 55 I-Condition
planned NCT03862820 56 63 B-Eq-Comparison
to NCT03862820 64 66 O
undergo NCT03862820 67 74 O
elective NCT03862820 75 83 B-Procedure
cesarean NCT03862820 84 92 I-Procedure
section NCT03862820 93 100 I-Procedure

Exclusion NCT03862820 101 110 O
Criteria NCT03862820 111 119 O
: NCT03862820 120 121 O

Primary NCT03862820 123 130 B-Modifier
elective NCT03862820 131 139 I-Modifier
cesarean NCT03862820 140 148 B-Procedure
section NCT03862820 149 156 I-Procedure
. NCT03862820 156 157 O

Inclusion NCT03864276 0 9 O
Criteria NCT03864276 10 18 O
: NCT03864276 19 20 O

- NCT03864276 24 25 O
patients NCT03864276 27 35 O
with NCT03864276 36 40 O
liver NCT03864276 41 46 B-Condition
cirrhosis NCT03864276 47 56 I-Condition
who NCT03864276 57 60 B-And
will NCT03864276 61 65 O
undergo NCT03864276 66 73 O
planned NCT03864276 74 81 B-Eq-Comparison
liver NCT03864276 82 87 B-Procedure
transplantation NCT03864276 88 103 I-Procedure

Exclusion NCT03864276 104 113 O
Criteria NCT03864276 114 122 O
: NCT03864276 123 124 O

- NCT03864276 128 129 O
1 NCT03864276 131 132 O
. NCT03864276 132 133 O
emergent NCT03864276 135 143 B-Modifier
liver NCT03864276 144 149 B-Procedure
transplantation NCT03864276 150 165 I-Procedure

- NCT03864276 168 169 O
2 NCT03864276 171 172 O
. NCT03864276 172 173 O
unstable NCT03864276 175 183 O
angina NCT03864276 184 190 B-Condition

- NCT03864276 193 194 O
3 NCT03864276 196 197 O
. NCT03864276 197 198 O
recent NCT03864276 200 206 B-Eq-Comparison
MI NCT03864276 207 209 B-Condition
( NCT03864276 210 211 O
Myocardial NCT03864276 212 222 B-Condition
Infarction NCT03864276 223 233 I-Condition
) NCT03864276 234 235 O

- NCT03864276 239 240 O
4 NCT03864276 242 243 O
. NCT03864276 243 244 O
uncontrolled NCT03864276 246 258 B-Modifier
hypertension NCT03864276 259 271 B-Condition
( NCT03864276 272 273 O
diastolic NCT03864276 274 283 B-Observation
BP NCT03864276 284 286 I-Observation
> NCT03864276 287 288 B-Eq-Comparison
110 NCT03864276 289 292 I-Eq-Comparison
mmHg NCT03864276 293 297 O
) NCT03864276 298 299 O

- NCT03864276 303 304 O
5 NCT03864276 306 307 O
. NCT03864276 307 308 O
implantable NCT03864276 310 321 B-Procedure
cardiac NCT03864276 322 329 I-Procedure
defibrillator NCT03864276 330 343 I-Procedure

- NCT03864276 346 347 O
6 NCT03864276 349 350 O
. NCT03864276 350 351 O
severe NCT03864276 353 359 O
obesity NCT03864276 360 367 B-Condition
( NCT03864276 368 369 O
BMI NCT03864276 370 373 B-Observation
> NCT03864276 374 375 B-Eq-Comparison
30 NCT03864276 376 378 I-Eq-Comparison
kg NCT03864276 379 381 O
/ NCT03864276 382 383 O
m2 NCT03864276 384 386 O
) NCT03864276 387 388 O

- NCT03864276 392 393 O
7 NCT03864276 395 396 O
. NCT03864276 396 397 O
allergy NCT03864276 399 406 B-Allergy
to NCT03864276 407 409 O
propofol NCT03864276 410 418 B-Drug

Inclusion NCT03864510 0 9 O
Criteria NCT03864510 10 18 O
: NCT03864510 19 20 O

- NCT03864510 24 25 O
Diabetes NCT03864510 27 35 B-Condition
type NCT03864510 36 40 B-Modifier
2 NCT03864510 41 42 I-Modifier

- NCT03864510 46 47 O
Age NCT03864510 49 52 B-Age
35 NCT03864510 53 55 B-Eq-Comparison
- NCT03864510 56 57 I-Eq-Comparison
75 NCT03864510 58 60 I-Eq-Comparison
year NCT03864510 61 65 I-Eq-Comparison

Exclusion NCT03864510 66 75 O
Criteria NCT03864510 76 84 O
: NCT03864510 85 86 O

- NCT03864510 90 91 O
Contraindication NCT03864510 93 109 B-Contraindication
to NCT03864510 110 112 O
MR NCT03864510 113 115 B-Procedure

- NCT03864510 118 119 O
Alcohol NCT03864510 121 128 B-Condition
dependance NCT03864510 129 139 I-Condition

- NCT03864510 142 143 O
Previously NCT03864510 145 155 B-Eq-Comparison
diagnosed NCT03864510 156 165 O
liver NCT03864510 166 171 B-Condition
cirrhosis NCT03864510 172 181 I-Condition

- NCT03864510 184 185 O
Previously NCT03864510 187 197 B-Eq-Comparison
known NCT03864510 198 203 O
liver NCT03864510 204 209 B-Condition
disease NCT03864510 210 217 I-Condition
( NCT03864510 218 219 O
other NCT03864510 220 225 B-Exception
than NCT03864510 226 230 I-Exception
fatty NCT03864510 231 236 B-Condition
liver NCT03864510 237 242 I-Condition
) NCT03864510 243 244 O

Inclusion NCT03861468 0 9 O
Criteria NCT03861468 10 18 O
: NCT03861468 19 20 O

- NCT03861468 24 25 O
Patients NCT03861468 27 35 O
aged NCT03861468 36 40 B-Age
from NCT03861468 41 45 O
18 NCT03861468 46 48 B-Eq-Comparison
to NCT03861468 49 51 I-Eq-Comparison
80 NCT03861468 52 54 I-Eq-Comparison
years NCT03861468 55 60 I-Eq-Comparison

- NCT03861468 63 64 O
Obese NCT03861468 66 71 B-Condition
( NCT03861468 72 73 O
BMI NCT03861468 74 77 B-Observation
≥ NCT03861468 78 79 B-Eq-Comparison
30 NCT03861468 80 82 I-Eq-Comparison
kg NCT03861468 83 85 O
/ NCT03861468 86 87 O
m² NCT03861468 88 90 O
) NCT03861468 91 92 O

- NCT03861468 96 97 O
Referred NCT03861468 99 107 B-Encounter
by NCT03861468 108 110 O
GPs NCT03861468 111 114 B-Provider
to NCT03861468 115 117 O
the NCT03861468 118 121 O
medical NCT03861468 122 129 O
analysis NCT03861468 130 138 O
laboratory NCT03861468 139 149 O
for NCT03861468 150 153 O
usual NCT03861468 154 159 O
biological NCT03861468 160 170 B-Observation
assessment NCT03861468 171 181 I-Observation

- NCT03861468 184 185 O
Patients NCT03861468 187 195 O
with NCT03861468 196 200 O
no NCT03861468 201 203 B-Negation
respiratory NCT03861468 204 215 B-Condition
follow NCT03861468 216 222 B-Encounter
- NCT03861468 223 224 I-Encounter
up NCT03861468 225 227 I-Encounter
already NCT03861468 228 235 B-Eq-Comparison
in NCT03861468 236 238 O
place NCT03861468 239 244 O

- NCT03861468 247 248 O
Bicarbonate NCT03861468 250 261 B-Observation
- NCT03861468 262 263 I-Observation
Concentration NCT03861468 264 277 I-Observation
≥ NCT03861468 278 279 B-Eq-Comparison
27 NCT03861468 280 282 I-Eq-Comparison
mmol NCT03861468 283 287 I-Eq-Comparison
/ NCT03861468 288 289 I-Eq-Comparison
L NCT03861468 290 291 I-Eq-Comparison

- NCT03861468 294 295 O
STOP NCT03861468 297 301 B-Observation
- NCT03861468 302 303 I-Observation
BANG NCT03861468 304 308 I-Observation
score NCT03861468 309 314 O
≥ NCT03861468 315 316 B-Eq-Comparison
3 NCT03861468 317 318 I-Eq-Comparison

Exclusion NCT03861468 320 329 O
Criteria NCT03861468 330 338 O
: NCT03861468 339 340 O

- NCT03861468 344 345 O
Acute NCT03861468 347 352 O
disease NCT03861468 353 360 B-Condition
or NCT03861468 361 363 B-Or
recently NCT03861468 364 372 B-Eq-Comparison
diagnosed NCT03861468 373 382 O
chronic NCT03861468 383 390 B-Modifier
disease NCT03861468 391 398 B-Condition
( NCT03861468 399 400 O
< NCT03861468 402 403 B-Eq-Comparison
2 NCT03861468 404 405 I-Eq-Comparison
months NCT03861468 406 412 I-Eq-Comparison
) NCT03861468 413 414 O

- NCT03861468 418 419 O
Hospitalization NCT03861468 421 436 B-Encounter
for NCT03861468 437 440 O
respiratory NCT03861468 441 452 B-Modifier
, NCT03861468 453 454 O
metabolic NCT03861468 455 464 B-Modifier
or NCT03861468 465 467 B-Or
cardiovascular NCT03861468 468 482 B-Modifier
event NCT03861468 483 488 B-Condition
( NCT03861468 489 490 O
< NCT03861468 492 493 B-Eq-Comparison
2 NCT03861468 494 495 I-Eq-Comparison
months NCT03861468 496 502 I-Eq-Comparison
) NCT03861468 503 504 O

- NCT03861468 508 509 O
Renal NCT03861468 511 516 B-Condition
insufficiency NCT03861468 517 530 I-Condition
stage NCT03861468 531 536 B-Eq-Comparison
4 NCT03861468 537 538 I-Eq-Comparison
or NCT03861468 539 541 I-Eq-Comparison
5 NCT03861468 542 543 I-Eq-Comparison
, NCT03861468 544 545 O
or NCT03861468 546 548 B-Or
autoimmune NCT03861468 549 559 B-Condition
disease NCT03861468 560 567 I-Condition
, NCT03861468 568 569 O
or NCT03861468 570 572 B-Or
viral NCT03861468 573 578 B-Condition
hepatitis NCT03861468 579 588 I-Condition
, NCT03861468 589 590 O
or NCT03861468 591 593 B-Or
cirrhosis NCT03861468 594 603 B-Condition

- NCT03861468 606 607 O
Pregnant NCT03861468 609 617 B-Condition
women NCT03861468 618 623 O

- NCT03861468 626 627 O
Patients NCT03861468 629 637 O
already NCT03861468 638 645 O
included NCT03861468 646 654 O
in NCT03861468 655 657 O
an NCT03861468 658 660 O
interventional NCT03861468 661 675 B-Study
study NCT03861468 676 681 I-Study
( NCT03861468 682 683 O
end NCT03861468 684 687 O
of NCT03861468 688 690 O
the NCT03861468 691 694 O
study NCT03861468 695 700 B-Study
< NCT03861468 701 702 B-Eq-Comparison
1 NCT03861468 703 704 I-Eq-Comparison
month NCT03861468 705 710 I-Eq-Comparison
) NCT03861468 711 712 O

Inclusion NCT03867019 0 9 O
Criteria NCT03867019 10 18 O
: NCT03867019 19 20 O

Subjects NCT03867019 22 30 O
with NCT03867019 31 35 O
BPPV NCT03867019 36 40 B-Condition
- NCT03867019 41 42 O
Patients NCT03867019 43 51 O
diagnosed NCT03867019 52 61 O
with NCT03867019 62 66 O
BPPV NCT03867019 67 71 B-Condition
, NCT03867019 72 73 O
who NCT03867019 74 77 O
meet NCT03867019 78 82 O
the NCT03867019 83 86 B-Criteria-Count
following NCT03867019 87 96 I-Criteria-Count
criteria NCT03867019 97 105 I-Criteria-Count
: NCT03867019 106 107 O

1 NCT03867019 111 112 O
. NCT03867019 112 113 O
Main NCT03867019 115 119 O
complain NCT03867019 120 128 O
of NCT03867019 129 131 O
spinning NCT03867019 132 140 B-Condition
sensation NCT03867019 141 150 I-Condition
( NCT03867019 151 152 O
Vertigo NCT03867019 153 160 B-Condition
) NCT03867019 161 162 O
when NCT03867019 163 167 O
changes NCT03867019 168 175 O
are NCT03867019 176 179 O
made NCT03867019 180 184 O
in NCT03867019 185 187 O
head NCT03867019 188 192 O
position NCT03867019 193 201 O
relative NCT03867019 202 210 O
to NCT03867019 211 213 O
gravity NCT03867019 214 221 O
( NCT03867019 222 223 O
such NCT03867019 224 228 O
as NCT03867019 229 231 O
when NCT03867019 232 236 O
moving NCT03867019 237 243 O
from NCT03867019 244 248 O
sitting NCT03867019 249 256 O
to NCT03867019 257 259 O
lying NCT03867019 260 265 O
down NCT03867019 266 270 O
or NCT03867019 271 273 O
rolling NCT03867019 274 281 O
in NCT03867019 282 284 O
bed NCT03867019 285 288 O
, NCT03867019 289 290 O
bending NCT03867019 291 298 O
over NCT03867019 299 303 O
etc NCT03867019 304 307 O
. NCT03867019 307 308 O
) NCT03867019 309 310 O

2 NCT03867019 314 315 O
. NCT03867019 315 316 O
Positive NCT03867019 318 326 O
Dix NCT03867019 327 330 B-Observation
- NCT03867019 331 332 I-Observation
Hallpike NCT03867019 333 341 I-Observation
/ NCT03867019 342 343 I-Observation
Supine NCT03867019 344 350 I-Observation
Roll NCT03867019 351 355 I-Observation
Test NCT03867019 356 360 I-Observation
, NCT03867019 361 362 O
confirmed NCT03867019 363 372 O
by NCT03867019 373 375 O
presence NCT03867019 376 384 O
of NCT03867019 385 387 O
nystagmus NCT03867019 388 397 B-Condition
. NCT03867019 398 399 O

Subjects NCT03867019 401 409 O
without NCT03867019 410 417 B-Negation
BPPV NCT03867019 418 422 B-Condition
( NCT03867019 423 424 O
Control NCT03867019 425 432 O
group NCT03867019 433 438 O
) NCT03867019 439 440 O
: NCT03867019 442 443 O

Subjects NCT03867019 445 453 O
who NCT03867019 454 457 O
do NCT03867019 458 460 O
not NCT03867019 461 464 B-Negation
suffer NCT03867019 465 471 O
from NCT03867019 472 476 O
dizziness NCT03867019 477 486 B-Condition
/ NCT03867019 487 488 O
spinning NCT03867019 489 497 B-Condition
sensation NCT03867019 498 507 I-Condition
( NCT03867019 508 509 O
Vertigo NCT03867019 510 517 B-Condition
) NCT03867019 518 519 O
. NCT03867019 521 522 O

Exclusion NCT03867019 524 533 O
Criteria NCT03867019 534 542 O
: NCT03867019 543 544 O

- NCT03867019 548 549 O
Suffering NCT03867019 551 560 O
from NCT03867019 561 565 O
pain NCT03867019 566 570 B-Condition
in NCT03867019 571 573 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867019 574 577 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03867019 578 581 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867019 582 584 I-Temporal-Connection___Temporal-Connection-Type-Value:during
assessment NCT03867019 585 595 B-Study
. NCT03867019 596 597 O

- NCT03867019 601 602 O
Postural NCT03867019 604 612 B-Modifier
Hypotension NCT03867019 613 624 B-Condition
. NCT03867019 625 626 O

- NCT03867019 630 631 O
Familial NCT03867019 633 641 B-Condition
Dysautonomia NCT03867019 642 654 I-Condition
. NCT03867019 655 656 O

- NCT03867019 660 661 O
Diabetic NCT03867019 663 671 B-Condition
Neuropathy NCT03867019 672 682 I-Condition
. NCT03867019 683 684 O

- NCT03867019 688 689 O
History NCT03867019 691 698 B-Eq-Comparison
of NCT03867019 699 701 O
Whiplash NCT03867019 702 710 B-Condition
or NCT03867019 711 713 B-Or
Traumatic NCT03867019 714 723 B-Condition
Brain NCT03867019 724 729 I-Condition
Injury NCT03867019 730 736 I-Condition
( NCT03867019 737 738 O
TBI NCT03867019 739 742 B-Condition
) NCT03867019 743 744 O
in NCT03867019 745 747 O
the NCT03867019 748 751 O
last NCT03867019 752 756 B-Eq-Comparison
year NCT03867019 757 761 I-Eq-Comparison
. NCT03867019 762 763 O

- NCT03867019 767 768 O
History NCT03867019 770 777 B-Eq-Comparison
of NCT03867019 778 780 O
Stroke NCT03867019 781 787 B-Condition
( NCT03867019 788 789 O
CVA NCT03867019 790 793 B-Condition
) NCT03867019 794 795 O
, NCT03867019 797 798 O
Multiple NCT03867019 799 807 B-Condition
Sclerosis NCT03867019 808 817 I-Condition
( NCT03867019 818 819 O
MS NCT03867019 820 822 B-Condition
) NCT03867019 823 824 O
or NCT03867019 825 827 B-Or
Central NCT03867019 828 835 B-Condition
Positional NCT03867019 836 846 I-Condition
Vertigo NCT03867019 847 854 I-Condition
. NCT03867019 855 856 O

- NCT03867019 860 861 O
Coronary NCT03867019 863 871 B-Condition
Heart NCT03867019 872 877 I-Condition
Disease NCT03867019 878 885 I-Condition
( NCT03867019 886 887 O
CHD NCT03867019 888 891 B-Condition
) NCT03867019 892 893 O
, NCT03867019 895 896 O
Cardiac NCT03867019 897 904 B-Condition
Heart NCT03867019 905 910 I-Condition
Failure NCT03867019 911 918 I-Condition
( NCT03867019 919 920 O
CHF NCT03867019 921 924 B-Condition
) NCT03867019 925 926 O
, NCT03867019 928 929 O
Cardiac NCT03867019 930 937 B-Condition
arrhythmias NCT03867019 938 949 I-Condition
, NCT03867019 950 951 O
Vertebrobasilar NCT03867019 952 967 B-Condition
Insufficiency NCT03867019 968 981 I-Condition
( NCT03867019 982 983 O
VBI NCT03867019 984 987 B-Condition
) NCT03867019 988 989 O
. NCT03867019 991 992 O

- NCT03867019 996 997 O
Under NCT03867019 999 1004 O
treatment NCT03867019 1005 1014 B-Procedure
of NCT03867019 1015 1017 O
Beta NCT03867019 1018 1022 B-Drug
- NCT03867019 1023 1024 I-Drug
Blockers NCT03867019 1025 1033 I-Drug
. NCT03867019 1034 1035 O

- NCT03867019 1039 1040 O
Anxiety NCT03867019 1042 1049 B-Condition
Disorders NCT03867019 1050 1059 I-Condition
. NCT03867019 1060 1061 O

- NCT03867019 1065 1066 O
Vestibular NCT03867019 1068 1078 B-Condition
Migraine NCT03867019 1079 1087 I-Condition
, NCT03867019 1088 1089 O
Vestibular NCT03867019 1090 1100 B-Condition
Neuritis NCT03867019 1101 1109 I-Condition
, NCT03867019 1110 1111 O
Menier NCT03867019 1112 1118 B-Condition
's NCT03867019 1118 1120 I-Condition
Disease NCT03867019 1121 1128 I-Condition
, NCT03867019 1129 1130 O
Perilymphatic NCT03867019 1131 1144 B-Condition
Fistula NCT03867019 1145 1152 I-Condition
, NCT03867019 1153 1154 O
Superior NCT03867019 1155 1163 B-Condition
Canal NCT03867019 1164 1169 I-Condition
Dehiscence NCT03867019 1170 1180 I-Condition
Syndrome NCT03867019 1181 1189 I-Condition
. NCT03867019 1190 1191 O

- NCT03867019 1195 1196 O
Medical NCT03867019 1198 1205 B-Condition
conditions NCT03867019 1206 1216 I-Condition
with NCT03867019 1217 1221 O
high NCT03867019 1222 1226 O
risk NCT03867019 1227 1231 B-Risk
of NCT03867019 1232 1234 O
subluxation NCT03867019 1235 1246 B-Condition
/ NCT03867019 1247 1248 B-Or
dislocation NCT03867019 1249 1260 B-Condition
of NCT03867019 1261 1263 O
the NCT03867019 1264 1267 O
Atlanto NCT03867019 1268 1275 B-Modifier
- NCT03867019 1276 1277 I-Modifier
axial NCT03867019 1278 1283 I-Modifier
joint NCT03867019 1284 1289 I-Modifier
. NCT03867019 1290 1291 O

- NCT03867019 1295 1296 O
Health NCT03867019 1298 1304 B-Provider
professionals NCT03867019 1305 1318 I-Provider
who NCT03867019 1319 1322 O
are NCT03867019 1323 1326 O
specialized NCT03867019 1327 1338 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867019 1339 1341 I-Assertion___Assertion-Type-Value:hypothetical
treat NCT03867019 1342 1347 B-Procedure
Vestibular NCT03867019 1348 1358 B-Condition
disorders NCT03867019 1359 1368 I-Condition
( NCT03867019 1369 1370 O
such NCT03867019 1371 1375 O
as NCT03867019 1376 1378 O
Vestibular NCT03867019 1379 1389 B-Provider
physiotherapists NCT03867019 1390 1406 I-Provider
) NCT03867019 1407 1408 O

Inclusion NCT03869008 0 9 O
Criteria NCT03869008 10 18 O
: NCT03869008 19 20 O

• NCT03869008 22 23 O
Clinical NCT03869008 24 32 O
Diagnosis NCT03869008 33 42 O
of NCT03869008 43 45 O
Primary NCT03869008 46 53 B-Condition
Raynaud NCT03869008 54 61 I-Condition
's NCT03869008 61 63 I-Condition
Phenomenon NCT03869008 64 74 I-Condition

Exclusion NCT03869008 75 84 O
Criteria NCT03869008 85 93 O
: NCT03869008 94 95 O

- NCT03869008 99 100 O
Less NCT03869008 102 106 B-Eq-Comparison
than NCT03869008 107 111 I-Eq-Comparison
18 NCT03869008 112 114 I-Eq-Comparison
years NCT03869008 115 120 I-Eq-Comparison
of NCT03869008 121 123 O
age NCT03869008 124 127 B-Age

- NCT03869008 130 131 O
Pregnant NCT03869008 133 141 B-Condition
women NCT03869008 142 147 O

- NCT03869008 150 151 O
Current NCT03869008 153 160 B-Eq-Comparison
smokers NCT03869008 161 168 B-Condition

- NCT03869008 171 172 O
Have NCT03869008 174 178 O
Digital NCT03869008 179 186 B-Modifier
ulcers NCT03869008 187 193 B-Condition

- NCT03869008 196 197 O
Diagnosed NCT03869008 199 208 O
Pulmonary NCT03869008 209 218 B-Condition
hypertension NCT03869008 219 231 I-Condition

- NCT03869008 234 235 O
Currently NCT03869008 237 246 B-Eq-Comparison
on NCT03869008 247 249 O
vasodilators NCT03869008 250 262 B-Drug
( NCT03869008 263 264 O
i. NCT03869008 265 267 O
e. NCT03869008 268 270 O
Phosphodiesterase NCT03869008 272 289 B-Drug
type NCT03869008 290 294 I-Drug
5 NCT03869008 295 296 I-Drug
inhibitors NCT03869008 297 307 I-Drug
, NCT03869008 308 309 O
prostacyclin NCT03869008 310 322 B-Drug
, NCT03869008 323 324 O
nitroglycerine NCT03869008 325 339 B-Drug
, NCT03869008 340 341 O
or NCT03869008 342 344 B-Or
other NCT03869008 345 350 B-Other
nitric NCT03869008 351 357 B-Drug
oxide NCT03869008 358 363 I-Drug
derivatives NCT03869008 364 375 I-Drug
) NCT03869008 376 377 O

- NCT03869008 381 382 O
Currently NCT03869008 384 393 B-Eq-Comparison
on NCT03869008 394 396 O
Calcium NCT03869008 397 404 B-Drug
Channel NCT03869008 405 412 I-Drug
Blockers NCT03869008 413 421 I-Drug

Inclusion NCT03860038 0 9 O
criteria NCT03860038 10 18 O
: NCT03860038 19 20 O

1 NCT03860038 24 25 O
. NCT03860038 25 26 O
Age NCT03860038 28 31 B-Age
≥ NCT03860038 32 33 B-Eq-Comparison
18 NCT03860038 34 36 I-Eq-Comparison
, NCT03860038 37 38 O
male NCT03860038 39 43 O
or NCT03860038 44 46 B-Or
female NCT03860038 47 53 O
; NCT03860038 53 54 O

2 NCT03860038 57 58 O
. NCT03860038 58 59 O
Subject NCT03860038 61 68 O
must NCT03860038 69 73 O
have NCT03860038 74 78 O
had NCT03860038 79 82 O
documented NCT03860038 83 93 O
MM NCT03860038 94 96 B-Condition
; NCT03860038 96 97 O

3 NCT03860038 100 101 O
. NCT03860038 101 102 O
At NCT03860038 104 106 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03860038 107 116 B-Study
phase NCT03860038 117 122 O
, NCT03860038 123 124 O
subject NCT03860038 125 132 O
must NCT03860038 133 137 O
have NCT03860038 138 142 O
measurable NCT03860038 143 153 B-Assertion___Assertion-Type-Value:hypothetical
disease NCT03860038 154 161 B-Condition
; NCT03860038 161 162 O

4 NCT03860038 165 166 O
. NCT03860038 166 167 O
Subject NCT03860038 169 176 O
is NCT03860038 177 179 O
in NCT03860038 180 182 O
a NCT03860038 183 184 O
state NCT03860038 185 190 O
of NCT03860038 191 193 O
progressive NCT03860038 194 205 B-Condition
disease NCT03860038 206 213 I-Condition
( NCT03860038 214 215 O
PD NCT03860038 216 218 B-Condition
) NCT03860038 219 220 O
; NCT03860038 221 222 O

5 NCT03860038 225 226 O
. NCT03860038 226 227 O
Subject NCT03860038 229 236 O
must NCT03860038 237 241 O
have NCT03860038 242 246 O
life NCT03860038 247 251 B-Observation
expectancy NCT03860038 252 262 I-Observation
of NCT03860038 263 265 O
no NCT03860038 266 268 B-Eq-Comparison
less NCT03860038 269 273 I-Eq-Comparison
than NCT03860038 274 278 I-Eq-Comparison
6 NCT03860038 279 280 I-Eq-Comparison
months NCT03860038 281 287 I-Eq-Comparison
; NCT03860038 287 288 O

6 NCT03860038 291 292 O
. NCT03860038 292 293 O
Subject NCT03860038 295 302 O
must NCT03860038 303 307 O
have NCT03860038 308 312 O
an NCT03860038 313 315 O
ECOG NCT03860038 316 320 B-Observation
( NCT03860038 321 322 O
Eastern NCT03860038 323 330 B-Observation
Cooperative NCT03860038 331 342 I-Observation
Oncology NCT03860038 343 351 I-Observation
Group NCT03860038 352 357 I-Observation
) NCT03860038 358 359 O
performance NCT03860038 360 371 O
status NCT03860038 372 378 O
score NCT03860038 379 384 O
of NCT03860038 385 387 O
0 NCT03860038 388 389 B-Eq-Comparison
~ NCT03860038 390 391 I-Eq-Comparison
2 NCT03860038 392 393 I-Eq-Comparison
; NCT03860038 394 395 O

Exclusion NCT03860038 396 405 O
criteria NCT03860038 406 414 O
: NCT03860038 415 416 O

1 NCT03860038 420 421 O
. NCT03860038 421 422 O
Subject NCT03860038 424 431 O
has NCT03860038 432 435 O
received NCT03860038 436 444 O
anti NCT03860038 445 449 B-Drug
- NCT03860038 450 451 I-Drug
CD38 NCT03860038 452 456 I-Drug
monoclonal NCT03860038 457 467 I-Drug
antibody NCT03860038 468 476 I-Drug
treatment NCT03860038 477 486 I-Drug
previously NCT03860038 487 497 B-Eq-Comparison
; NCT03860038 497 498 O

2 NCT03860038 501 502 O
. NCT03860038 502 503 O
Subject NCT03860038 505 512 O
has NCT03860038 513 516 O
received NCT03860038 517 525 O
CAR NCT03860038 526 529 B-Procedure
- NCT03860038 530 531 I-Procedure
T NCT03860038 532 533 I-Procedure
cell NCT03860038 534 538 I-Procedure
therapy NCT03860038 539 546 I-Procedure
previously NCT03860038 547 557 B-Eq-Comparison
; NCT03860038 557 558 O

3 NCT03860038 561 562 O
. NCT03860038 562 563 O
Subject NCT03860038 565 572 O
has NCT03860038 573 576 O
previously NCT03860038 577 587 B-Eq-Comparison
received NCT03860038 588 596 O
allogenic NCT03860038 597 606 B-Modifier
stem NCT03860038 607 611 B-Procedure
cell NCT03860038 612 616 I-Procedure
transplant NCT03860038 617 627 I-Procedure
, NCT03860038 628 629 O
or NCT03860038 630 632 B-Or
subject NCT03860038 633 640 O
has NCT03860038 641 644 O
received NCT03860038 645 653 O
autologous NCT03860038 654 664 B-Modifier
stem NCT03860038 665 669 B-Procedure
cell NCT03860038 670 674 I-Procedure
transplant NCT03860038 675 685 I-Procedure
within NCT03860038 686 692 B-Eq-Comparison
3 NCT03860038 693 694 I-Eq-Comparison
months NCT03860038 695 701 I-Eq-Comparison
before NCT03860038 702 708 B-Temporal-Connection___Temporal-Connection-Type-Value:before
administration NCT03860038 709 723 O
of NCT03860038 724 726 O
the NCT03860038 727 730 O
study NCT03860038 731 736 B-Study
agent NCT03860038 737 742 B-Drug
; NCT03860038 742 743 O

4 NCT03860038 746 747 O
. NCT03860038 747 748 O
Primary NCT03860038 750 757 B-Modifier
refractory NCT03860038 758 768 I-Modifier
multiple NCT03860038 769 777 I-Modifier
myeloma NCT03860038 778 785 B-Condition
( NCT03860038 786 787 O
subject NCT03860038 788 795 O
failed NCT03860038 796 802 O
to NCT03860038 803 805 O
generate NCT03860038 806 814 O
any NCT03860038 815 818 O
minimal NCT03860038 819 826 O
response NCT03860038 827 835 O
or NCT03860038 836 838 O
any NCT03860038 839 842 O
degree NCT03860038 843 849 O
of NCT03860038 850 852 O
response NCT03860038 853 861 O
to NCT03860038 862 864 O
any NCT03860038 865 868 O
therapy NCT03860038 869 876 B-Procedure
) NCT03860038 877 878 O
; NCT03860038 879 880 O

5 NCT03860038 883 884 O
. NCT03860038 884 885 O
Subject NCT03860038 887 894 O
has NCT03860038 895 898 O
received NCT03860038 899 907 O
anti NCT03860038 908 912 B-Procedure
- NCT03860038 913 914 I-Procedure
myeloma NCT03860038 915 922 I-Procedure
treatment NCT03860038 923 932 I-Procedure
( NCT03860038 933 934 O
radiotherapy NCT03860038 935 947 B-Procedure
is NCT03860038 948 950 O
excluded NCT03860038 951 959 B-Exception
) NCT03860038 960 961 O
within NCT03860038 962 968 B-Eq-Comparison
4 NCT03860038 969 970 I-Eq-Comparison
weeks NCT03860038 971 976 I-Eq-Comparison
or NCT03860038 977 979 B-Or
5 NCT03860038 980 981 B-Eq-Comparison
PK NCT03860038 982 984 I-Eq-Comparison
half NCT03860038 985 989 I-Eq-Comparison
- NCT03860038 990 991 I-Eq-Comparison
lives NCT03860038 992 997 I-Eq-Comparison
of NCT03860038 998 1000 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860038 1001 1004 O
treatment NCT03860038 1005 1014 B-Procedure
, NCT03860038 1015 1016 O
whichever NCT03860038 1017 1026 O
longer NCT03860038 1027 1033 O
, NCT03860038 1034 1035 O
before NCT03860038 1036 1042 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860038 1043 1046 O
first NCT03860038 1047 1052 B-Eq-Comparison
study NCT03860038 1053 1058 B-Study
agent NCT03860038 1059 1064 B-Drug
administration NCT03860038 1065 1079 O
. NCT03860038 1079 1080 O

Inclusion NCT03869593 0 9 O
Criteria NCT03869593 10 18 O
: NCT03869593 19 20 O

- NCT03869593 24 25 O
Patient NCT03869593 27 34 O
with NCT03869593 35 39 O
S. NCT03869593 40 42 B-Organism
aureus NCT03869593 44 50 I-Organism
or NCT03869593 51 53 B-Or
E. NCT03869593 54 56 B-Organism
coli NCT03869593 58 62 I-Organism
bacteriostatic NCT03869593 63 77 B-Condition
bacteremia NCT03869593 78 88 I-Condition
defined NCT03869593 89 96 O
by NCT03869593 97 99 O
at NCT03869593 100 102 B-Eq-Comparison
least NCT03869593 103 108 I-Eq-Comparison
one NCT03869593 109 112 I-Eq-Comparison
positive NCT03869593 113 121 O
blood NCT03869593 122 127 B-Observation
culture NCT03869593 128 135 I-Observation
bottle NCT03869593 136 142 O

- NCT03869593 145 146 O
Patient NCT03869593 148 155 O
requiring NCT03869593 156 165 O
a NCT03869593 166 167 O
blood NCT03869593 168 173 B-Observation
test NCT03869593 174 178 I-Observation
as NCT03869593 179 181 O
part NCT03869593 182 186 O
of NCT03869593 187 189 O
his NCT03869593 190 193 O
bacteremia NCT03869593 194 204 B-Condition

- NCT03869593 207 208 O
not NCT03869593 210 213 B-Negation
subject NCT03869593 214 221 O
to NCT03869593 222 224 O
a NCT03869593 225 226 O
judicial NCT03869593 227 235 B-Observation
protection NCT03869593 236 246 I-Observation
measure NCT03869593 247 254 O

- NCT03869593 257 258 O
Signature NCT03869593 260 269 O
of NCT03869593 270 272 O
the NCT03869593 273 276 O
non NCT03869593 277 280 O
- NCT03869593 281 282 O
opposition NCT03869593 283 293 O
of NCT03869593 294 296 O
consent NCT03869593 297 304 O
( NCT03869593 305 306 O
for NCT03869593 307 310 O
minor NCT03869593 311 316 O
patients NCT03869593 317 325 O
signed NCT03869593 326 332 O
by NCT03869593 333 335 O
one NCT03869593 336 339 O
of NCT03869593 340 342 O
the NCT03869593 343 346 O
parents NCT03869593 347 354 O
or NCT03869593 355 357 O
the NCT03869593 358 361 O
representative NCT03869593 362 376 O
of NCT03869593 377 379 O
the NCT03869593 380 383 O
parental NCT03869593 384 392 O
authority NCT03869593 393 402 O
) NCT03869593 403 404 O

- NCT03869593 408 409 O
Affiliation NCT03869593 411 422 O
to NCT03869593 423 425 O
social NCT03869593 426 432 O
security NCT03869593 433 441 O

Exclusion NCT03869593 442 451 O
Criteria NCT03869593 452 460 O
: NCT03869593 461 462 O

- NCT03869593 466 467 O
Immunocompromised NCT03869593 469 486 B-Condition
patient NCT03869593 487 494 O
defined NCT03869593 495 502 O
by NCT03869593 503 505 O
: NCT03869593 506 507 O

- NCT03869593 516 517 O
current NCT03869593 519 526 B-Eq-Comparison
immunosuppressive NCT03869593 527 544 B-Procedure
therapies NCT03869593 545 554 I-Procedure
: NCT03869593 555 556 O
corticosteroids NCT03869593 557 572 B-Drug
, NCT03869593 573 574 O
chemotherapy NCT03869593 575 587 B-Procedure
, NCT03869593 588 589 O
biotherapy NCT03869593 590 600 B-Procedure

- NCT03869593 608 609 O
solid NCT03869593 611 616 B-Procedure
organ NCT03869593 617 622 I-Procedure
transplant NCT03869593 623 633 I-Procedure
patient NCT03869593 634 641 O
or NCT03869593 642 644 B-Or
hematopoietic NCT03869593 645 658 B-Modifier
stem NCT03869593 659 663 B-Procedure
cell NCT03869593 664 668 I-Procedure
transplant NCT03869593 669 679 I-Procedure

- NCT03869593 687 688 O
chemotherapy NCT03869593 690 702 B-Procedure
- NCT03869593 703 704 O
induced NCT03869593 705 712 O
neutropenia NCT03869593 713 724 B-Condition

- NCT03869593 732 733 O
Congenital NCT03869593 735 745 B-Modifier
immune NCT03869593 746 752 B-Condition
deficiency NCT03869593 753 763 I-Condition

- NCT03869593 766 767 O
bacteremia NCT03869593 769 779 B-Condition
related NCT03869593 780 787 O
to NCT03869593 788 790 O
a NCT03869593 791 792 O
peripheral NCT03869593 793 803 B-Modifier
or NCT03869593 804 806 B-Or
central NCT03869593 807 814 B-Modifier
catheter NCT03869593 815 823 B-Procedure

- NCT03869593 826 827 O
Urinary NCT03869593 829 836 B-Condition
obstruction NCT03869593 837 848 I-Condition
not NCT03869593 849 852 B-Negation
lifted NCT03869593 853 859 B-Procedure
within NCT03869593 860 866 B-Eq-Comparison
the NCT03869593 867 870 I-Eq-Comparison
first NCT03869593 871 876 I-Eq-Comparison
24 NCT03869593 877 879 I-Eq-Comparison
hours NCT03869593 880 885 I-Eq-Comparison
of NCT03869593 886 888 O
management NCT03869593 889 899 O

- NCT03869593 902 903 O
Intra NCT03869593 905 910 B-Modifier
- NCT03869593 911 912 I-Modifier
abdominal NCT03869593 913 922 I-Modifier
infection NCT03869593 923 932 B-Condition
collected NCT03869593 933 942 O
undrained NCT03869593 943 952 B-Procedure
in NCT03869593 953 955 B-Eq-Comparison
the NCT03869593 956 959 I-Eq-Comparison
first NCT03869593 960 965 I-Eq-Comparison
24 NCT03869593 966 968 I-Eq-Comparison
hours NCT03869593 969 974 I-Eq-Comparison
of NCT03869593 975 977 O
management NCT03869593 978 988 O

- NCT03869593 991 992 O
primary NCT03869593 994 1001 B-Modifier
infectious NCT03869593 1002 1012 B-Condition
focus NCT03869593 1013 1018 O
represented NCT03869593 1019 1030 O
by NCT03869593 1031 1033 O
mechanically NCT03869593 1034 1046 B-Procedure
ventilated NCT03869593 1047 1057 I-Procedure
pneumonia NCT03869593 1058 1067 B-Condition

- NCT03869593 1070 1071 O
Pregnant NCT03869593 1073 1081 B-Condition
or NCT03869593 1082 1084 B-Or
lactating NCT03869593 1085 1094 B-Condition
woman NCT03869593 1095 1100 O

Inclusion NCT03866850 0 9 O
Criteria NCT03866850 10 18 O
: NCT03866850 19 20 O

- NCT03866850 24 25 O
Cochlear NCT03866850 27 35 B-Modifier
Nucleus NCT03866850 36 43 I-Modifier
cochlear NCT03866850 44 52 B-Procedure
implant NCT03866850 53 60 I-Procedure
users NCT03866850 61 66 O
or NCT03866850 67 69 B-Or
Advanced NCT03866850 70 78 B-Modifier
Bionics NCT03866850 79 86 I-Modifier
cochlear NCT03866850 87 95 B-Procedure
implant NCT03866850 96 103 I-Procedure
users NCT03866850 104 109 O

- NCT03866850 112 113 O
Native NCT03866850 115 121 O
speakers NCT03866850 122 130 O
of NCT03866850 131 133 O
English NCT03866850 134 141 O

- NCT03866850 144 145 O
Early NCT03866850 147 152 B-Modifier
onset NCT03866850 153 158 B-Eq-Comparison
of NCT03866850 159 161 O
deafness NCT03866850 162 170 B-Condition
( NCT03866850 171 172 O
< NCT03866850 174 175 B-Eq-Comparison
3 NCT03866850 176 177 I-Eq-Comparison
years NCT03866850 178 183 I-Eq-Comparison
of NCT03866850 184 186 O
age NCT03866850 187 190 B-Age
) NCT03866850 191 192 O
; NCT03866850 193 194 O
no NCT03866850 195 197 O
requirement NCT03866850 198 209 O
for NCT03866850 210 213 O
age NCT03866850 214 217 O
at NCT03866850 218 220 O
implantation NCT03866850 221 233 B-Procedure

- NCT03866850 236 237 O
Late NCT03866850 239 243 B-Modifier
onset NCT03866850 244 249 B-Eq-Comparison
of NCT03866850 250 252 O
deafness NCT03866850 253 261 B-Condition
( NCT03866850 262 263 O
> NCT03866850 265 266 B-Eq-Comparison
3 NCT03866850 267 268 I-Eq-Comparison
years NCT03866850 269 274 I-Eq-Comparison
of NCT03866850 275 277 O
age NCT03866850 278 281 B-Age
) NCT03866850 282 283 O
; NCT03866850 284 285 O
matched NCT03866850 286 293 O
in NCT03866850 294 296 O
duration NCT03866850 297 305 O
of NCT03866850 306 308 O
deafness NCT03866850 309 317 O
to NCT03866850 318 320 O
the NCT03866850 321 324 O
early NCT03866850 325 330 O
onset NCT03866850 331 336 O
group NCT03866850 337 342 O

- NCT03866850 345 346 O
Has NCT03866850 348 351 O
had NCT03866850 352 355 O
device NCT03866850 356 362 O
experience NCT03866850 363 373 O
for NCT03866850 374 377 O
at NCT03866850 378 380 O
least NCT03866850 381 386 O
one NCT03866850 387 390 O
year NCT03866850 391 395 O

- NCT03866850 398 399 O
Can NCT03866850 401 404 O
be NCT03866850 405 407 O
child NCT03866850 408 413 O
or NCT03866850 414 416 B-Or
adult NCT03866850 417 422 O
at NCT03866850 423 425 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866850 426 429 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866850 430 434 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866850 435 437 O
enrollment NCT03866850 438 448 B-Study

Exclusion NCT03866850 449 458 O
Criteria NCT03866850 459 467 O
: NCT03866850 468 469 O

- NCT03866850 473 474 O
None NCT03866850 476 480 O

Inclusion NCT03865381 0 9 O
Criteria NCT03865381 10 18 O
: NCT03865381 19 20 O

- NCT03865381 24 25 O
Male NCT03865381 27 31 O
and NCT03865381 32 35 B-Or
Female NCT03865381 36 42 O
; NCT03865381 42 43 O
18 NCT03865381 44 46 B-Eq-Comparison
years NCT03865381 47 52 I-Eq-Comparison
of NCT03865381 53 55 I-Eq-Comparison
age NCT03865381 56 59 I-Eq-Comparison
or NCT03865381 60 62 I-Eq-Comparison
older NCT03865381 63 68 I-Eq-Comparison

- NCT03865381 71 72 O
Confirmed NCT03865381 74 83 O
diagnosis NCT03865381 84 93 O
of NCT03865381 94 96 O
Type NCT03865381 97 101 B-Modifier
2 NCT03865381 102 103 I-Modifier
diabetes NCT03865381 104 112 B-Condition
mellitus NCT03865381 113 121 I-Condition

- NCT03865381 124 125 O
Willing NCT03865381 127 134 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865381 135 137 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03865381 138 141 O
CGM NCT03865381 142 145 B-Procedure
and NCT03865381 146 149 B-Or
BGM NCT03865381 150 153 B-Procedure

- NCT03865381 156 157 O
A1c NCT03865381 159 162 B-Observation
result NCT03865381 163 169 O
≥ NCT03865381 170 171 B-Eq-Comparison
8.0 NCT03865381 172 175 I-Eq-Comparison
% NCT03865381 176 177 I-Eq-Comparison
and NCT03865381 178 181 B-And
≤ NCT03865381 182 183 B-Eq-Comparison
12.0 NCT03865381 184 188 I-Eq-Comparison
% NCT03865381 189 190 I-Eq-Comparison

- NCT03865381 194 195 O
Receive NCT03865381 197 204 B-Eq-Comparison
their NCT03865381 205 210 O
diabetes NCT03865381 211 219 B-Condition
care NCT03865381 220 224 B-Procedure
from NCT03865381 225 229 O
Premier NCT03865381 230 237 O
Medical NCT03865381 238 245 O
Associates NCT03865381 246 256 O
or NCT03865381 257 259 B-Or
the NCT03865381 260 263 O
Palo NCT03865381 264 268 O
Alto NCT03865381 269 273 O
Medical NCT03865381 274 281 O
Foundation NCT03865381 282 292 O

- NCT03865381 295 296 O
Own NCT03865381 298 301 O
a NCT03865381 302 303 O
Smartphone NCT03865381 304 314 O
with NCT03865381 315 319 O
a NCT03865381 320 321 O
data NCT03865381 322 326 O
plan NCT03865381 327 331 O
and NCT03865381 332 335 O
be NCT03865381 336 338 O
the NCT03865381 339 342 O
primary NCT03865381 343 350 O
user NCT03865381 351 355 O
of NCT03865381 356 358 O
that NCT03865381 359 363 O
smartphone NCT03865381 364 374 O

- NCT03865381 377 378 O
Smartphone NCT03865381 380 390 O
must NCT03865381 391 395 O
use NCT03865381 396 399 O
a NCT03865381 400 401 O
supported NCT03865381 402 411 O
Android NCT03865381 412 419 O
OS NCT03865381 420 422 O
or NCT03865381 423 425 O
iOS NCT03865381 426 429 O

Exclusion NCT03865381 430 439 O
Criteria NCT03865381 440 448 O
: NCT03865381 449 450 O

- NCT03865381 454 455 O
Pregnant NCT03865381 457 465 B-Condition
or NCT03865381 466 468 B-Or
breastfeeding NCT03865381 469 482 B-Condition

- NCT03865381 485 486 O
Use NCT03865381 488 491 O
of NCT03865381 492 494 O
an NCT03865381 495 497 O
insulin NCT03865381 498 505 B-Procedure
pump NCT03865381 506 510 I-Procedure

- NCT03865381 513 514 O
Any NCT03865381 516 519 O
condition NCT03865381 520 529 B-Condition
or NCT03865381 530 532 B-Or
situation NCT03865381 533 542 B-Condition
that NCT03865381 543 547 O
the NCT03865381 548 551 O
Sponsor NCT03865381 552 559 O
or NCT03865381 560 562 O
Investigator NCT03865381 563 575 O
determines NCT03865381 576 586 O
as NCT03865381 587 589 O
inappropriate NCT03865381 590 603 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03865381 604 607 O
study NCT03865381 608 613 B-Study
inclusion NCT03865381 614 623 O

Inclusion NCT03867227 0 9 O
Criteria NCT03867227 10 18 O
: NCT03867227 19 20 O

- NCT03867227 24 25 O
Patient NCT03867227 27 34 O
with NCT03867227 35 39 O
paroxysmal NCT03867227 40 50 B-Modifier
/ NCT03867227 51 52 B-Or
persistent NCT03867227 53 63 B-Modifier
/ NCT03867227 64 65 B-Or
permanent NCT03867227 66 75 B-Modifier
atrial NCT03867227 76 82 B-Condition
fibrillation NCT03867227 83 95 I-Condition

- NCT03867227 98 99 O
CHA2DS2VASc NCT03867227 101 112 B-Observation
score NCT03867227 113 118 O
≥ NCT03867227 119 120 B-Eq-Comparison
2 NCT03867227 121 122 I-Eq-Comparison
for NCT03867227 123 126 O
male NCT03867227 127 131 O
and NCT03867227 132 135 B-And
≥ NCT03867227 136 137 B-Eq-Comparison
3 NCT03867227 138 139 I-Eq-Comparison
for NCT03867227 140 143 O
female NCT03867227 144 150 O

- NCT03867227 153 154 O
Without NCT03867227 156 163 B-Negation
contraindications NCT03867227 164 181 B-Contraindication
to NCT03867227 182 184 O
anticoagulation NCT03867227 185 200 B-Procedure
therapy NCT03867227 201 208 I-Procedure

Exclusion NCT03867227 209 218 O
Criteria NCT03867227 219 227 O
: NCT03867227 228 229 O

- NCT03867227 233 234 O
LAA NCT03867227 236 239 B-Modifier
thrombosis NCT03867227 240 250 B-Condition

- NCT03867227 253 254 O
mechanical NCT03867227 256 266 B-Procedure
prosthetic NCT03867227 267 277 I-Procedure
heart NCT03867227 278 283 I-Procedure
valve NCT03867227 284 289 I-Procedure

- NCT03867227 292 293 O
moderate NCT03867227 295 303 O
or NCT03867227 304 306 B-Or
severe NCT03867227 307 313 O
mitral NCT03867227 314 320 B-Condition
valve NCT03867227 321 326 I-Condition
stenosis NCT03867227 327 335 I-Condition

Inclusion NCT03861130 0 9 O
Criteria NCT03861130 10 18 O
: NCT03861130 19 20 O

- NCT03861130 24 25 O
Affected NCT03861130 27 35 O
children NCT03861130 36 44 O
will NCT03861130 45 49 O
be NCT03861130 50 52 O
recruited NCT03861130 53 62 O
if NCT03861130 63 65 O
the NCT03861130 66 69 O
treating NCT03861130 70 78 B-Procedure
clinician NCT03861130 79 88 B-Provider
has NCT03861130 89 92 O
made NCT03861130 93 97 O
a NCT03861130 98 99 O
diagnosis NCT03861130 100 109 O
of NCT03861130 110 112 O
possible NCT03861130 113 121 B-Assertion___Assertion-Type-Value:possible
Kawasaki NCT03861130 122 130 B-Condition
disease NCT03861130 131 138 I-Condition
( NCT03861130 139 140 O
even NCT03861130 141 145 O
if NCT03861130 146 148 O
they NCT03861130 149 153 O
do NCT03861130 154 156 O
not NCT03861130 157 160 O
fulfil NCT03861130 161 167 O
the NCT03861130 168 171 O
criteria NCT03861130 172 180 O
below NCT03861130 181 186 O
for NCT03861130 187 190 O
Kawasaki NCT03861130 191 199 B-Condition
disease NCT03861130 200 207 I-Condition
) NCT03861130 208 209 O
. NCT03861130 211 212 O

The NCT03861130 214 217 O
current NCT03861130 218 225 O
standard NCT03861130 226 234 O
diagnostic NCT03861130 235 245 O
criteria NCT03861130 246 254 O
for NCT03861130 255 258 O
KD NCT03861130 259 261 B-Condition
( NCT03861130 262 263 O
Circulation NCT03861130 264 275 O
2001 NCT03861130 276 280 O
103 NCT03861130 281 284 O
335 NCT03861130 285 288 O
- NCT03861130 289 290 O
336 NCT03861130 291 294 O
doi NCT03861130 295 298 O
: NCT03861130 299 300 O
10.1161 NCT03861130 301 308 O
/ NCT03861130 309 310 O
01 NCT03861130 311 313 O
. NCT03861130 313 314 O
CIR NCT03861130 315 318 O
103.2.335 NCT03861130 319 328 O
) NCT03861130 329 330 O
are NCT03861130 331 334 O
: NCT03861130 335 336 O

The NCT03861130 338 341 O
presence NCT03861130 342 350 O
of NCT03861130 351 353 O
fever NCT03861130 354 359 B-Condition
for NCT03861130 360 363 O
at NCT03861130 364 366 B-Eq-Comparison
least NCT03861130 367 372 I-Eq-Comparison
five NCT03861130 373 377 I-Eq-Comparison
days NCT03861130 378 382 I-Eq-Comparison
plus NCT03861130 383 387 B-And
four NCT03861130 388 392 B-Eq-Comparison
of NCT03861130 393 395 O
the NCT03861130 396 399 B-Criteria-Count
following NCT03861130 400 409 I-Criteria-Count
criteria NCT03861130 410 418 I-Criteria-Count
: NCT03861130 419 420 O

1 NCT03861130 424 425 I-Eq-Comparison
. NCT03861130 425 426 O
Changes NCT03861130 428 435 O
in NCT03861130 436 438 O
the NCT03861130 439 442 O
peripheral NCT03861130 443 453 B-Condition
extremities NCT03861130 454 465 I-Condition
Acute NCT03861130 466 471 O
: NCT03861130 472 473 O
erythema NCT03861130 474 482 B-Condition
and NCT03861130 483 486 B-Or
oedema NCT03861130 487 493 B-Condition
of NCT03861130 494 496 O
hands NCT03861130 497 502 B-Modifier
and NCT03861130 503 506 B-Or
feet NCT03861130 507 511 B-Modifier
Convalescent NCT03861130 512 524 B-Modifier
: NCT03861130 525 526 O
membranous NCT03861130 527 537 B-Condition
desquamation NCT03861130 538 550 I-Condition
of NCT03861130 551 553 O
fingertips NCT03861130 554 564 B-Modifier

2 NCT03861130 567 568 O
. NCT03861130 568 569 O
Polymorphous NCT03861130 571 583 B-Condition
exanthema NCT03861130 584 593 I-Condition

3 NCT03861130 596 597 O
. NCT03861130 597 598 O
Bilateral NCT03861130 600 609 B-Modifier
painless NCT03861130 610 618 I-Modifier
bulbar NCT03861130 619 625 B-Condition
conjunctival NCT03861130 626 638 I-Condition
injection NCT03861130 639 648 I-Condition
without NCT03861130 649 656 B-Negation
exudate NCT03861130 657 664 B-Modifier

4 NCT03861130 667 668 O
. NCT03861130 668 669 O
Changes NCT03861130 671 678 O
in NCT03861130 679 681 O
lips NCT03861130 682 686 B-Modifier
and NCT03861130 687 690 B-Or
oral NCT03861130 691 695 B-Modifier
cavity NCT03861130 696 702 B-Condition
: NCT03861130 703 704 O
erythema NCT03861130 705 713 B-Condition
and NCT03861130 714 717 B-Or
cracking NCT03861130 718 726 B-Condition
of NCT03861130 727 729 I-Condition
lips NCT03861130 730 734 I-Condition
, NCT03861130 735 736 O
strawberry NCT03861130 737 747 B-Condition
tongue NCT03861130 748 754 I-Condition
, NCT03861130 755 756 O
diffuse NCT03861130 757 764 B-Condition
injection NCT03861130 765 774 I-Condition
of NCT03861130 775 777 O
oral NCT03861130 778 782 B-Modifier
and NCT03861130 783 786 B-Or
pharyngeal NCT03861130 787 797 B-Modifier
mucosae NCT03861130 798 805 I-Modifier

5 NCT03861130 808 809 O
. NCT03861130 809 810 O
Cervical NCT03861130 812 820 B-Condition
lymphadenopathy NCT03861130 821 836 I-Condition
( NCT03861130 837 838 O
> NCT03861130 840 841 B-Eq-Comparison
1.5 NCT03861130 842 845 O
cm NCT03861130 846 848 O
diameter NCT03861130 849 857 B-Observation
) NCT03861130 858 859 O
, NCT03861130 861 862 O
usually NCT03861130 863 870 O
unilateral NCT03861130 871 881 O
Patients NCT03861130 882 890 O
meeting NCT03861130 891 898 O
not NCT03861130 899 902 O
all NCT03861130 903 906 O
of NCT03861130 907 909 O
these NCT03861130 910 915 O
criteria NCT03861130 916 924 O
may NCT03861130 925 928 O
meet NCT03861130 929 933 O
the NCT03861130 934 937 O
criteria NCT03861130 938 946 O
for NCT03861130 947 950 O
atypical NCT03861130 951 959 O
Kawasaki NCT03861130 960 968 B-Condition
disease NCT03861130 969 976 I-Condition
, NCT03861130 977 978 O
ie NCT03861130 979 981 O
. NCT03861130 981 982 O
if NCT03861130 984 986 O
they NCT03861130 987 991 O
have NCT03861130 992 996 O
fever NCT03861130 997 1002 B-Condition
and NCT03861130 1003 1006 B-And
two NCT03861130 1007 1010 O
or NCT03861130 1011 1013 O
three NCT03861130 1014 1019 O
of NCT03861130 1020 1022 O
the NCT03861130 1023 1026 O
above NCT03861130 1027 1032 O
criteria NCT03861130 1033 1041 O
and NCT03861130 1042 1045 O
elevation NCT03861130 1046 1055 O
of NCT03861130 1056 1058 O
CRP NCT03861130 1059 1062 B-Condition
or NCT03861130 1063 1065 B-Or
echocardiographic NCT03861130 1066 1083 B-Observation
evidence NCT03861130 1084 1092 I-Observation
of NCT03861130 1093 1095 O
coronary NCT03861130 1096 1104 B-Condition
artery NCT03861130 1105 1111 I-Condition
dilatation NCT03861130 1112 1122 I-Condition
. NCT03861130 1123 1124 O

Parents NCT03861130 1126 1133 B-Family-Member___Family-Member-Type:parent
of NCT03861130 1134 1136 O
affected NCT03861130 1137 1145 O
child NCT03861130 1146 1151 O
must NCT03861130 1152 1156 O
be NCT03861130 1157 1159 O
biological NCT03861130 1160 1170 O
parents NCT03861130 1171 1178 O
. NCT03861130 1179 1180 O

Exclusion NCT03861130 1182 1191 O
Criteria NCT03861130 1192 1200 O
: NCT03861130 1201 1202 O

- NCT03861130 1206 1207 O
children NCT03861130 1209 1217 B-Family-Member___Family-Member-Type:child
who NCT03861130 1218 1221 O
do NCT03861130 1222 1224 O
not NCT03861130 1225 1228 B-Negation
have NCT03861130 1229 1233 O
a NCT03861130 1234 1235 O
diagnosis NCT03861130 1236 1245 O
of NCT03861130 1246 1248 O
possible NCT03861130 1249 1257 B-Assertion___Assertion-Type-Value:possible
Kawasaki NCT03861130 1258 1266 B-Condition
disease NCT03861130 1267 1274 I-Condition


Inclusion NCT03865342 0 9 O
criteria NCT03865342 10 18 O
: NCT03865342 19 20 O

- NCT03865342 24 25 O
English NCT03865342 27 34 O
- NCT03865342 35 36 O
speaking NCT03865342 37 45 O

- NCT03865342 48 49 O
18 NCT03865342 51 53 B-Eq-Comparison
years NCT03865342 54 59 I-Eq-Comparison
of NCT03865342 60 62 I-Eq-Comparison
age NCT03865342 63 66 I-Eq-Comparison
and NCT03865342 67 70 I-Eq-Comparison
older NCT03865342 71 76 I-Eq-Comparison

- NCT03865342 79 80 O
Referral NCT03865342 82 90 B-Encounter
from NCT03865342 91 95 O
the NCT03865342 96 99 O
patient NCT03865342 100 107 O
's NCT03865342 107 109 O
physician NCT03865342 110 119 B-Provider

- NCT03865342 122 123 O
Hemoglobin NCT03865342 125 135 B-Observation
A1C NCT03865342 136 139 I-Observation
: NCT03865342 140 141 O
5.7 NCT03865342 142 145 B-Eq-Comparison
- NCT03865342 146 147 I-Eq-Comparison
6.4 NCT03865342 148 151 I-Eq-Comparison
within NCT03865342 152 158 B-Eq-Comparison
the NCT03865342 159 162 I-Eq-Comparison
3 NCT03865342 163 164 I-Eq-Comparison
months NCT03865342 165 171 I-Eq-Comparison
prior NCT03865342 172 177 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865342 178 180 O
enrollment NCT03865342 181 191 B-Study

- NCT03865342 194 195 O
Own NCT03865342 197 200 O
a NCT03865342 201 202 O
smartphone NCT03865342 203 213 O
( NCT03865342 214 215 O
Apple NCT03865342 216 221 O
or NCT03865342 222 224 O
Android NCT03865342 225 232 O
) NCT03865342 233 234 O

Exclusion NCT03865342 236 245 O
criteria NCT03865342 246 254 O
: NCT03865342 255 256 O

- NCT03865342 260 261 O
Recent NCT03865342 263 269 B-Eq-Comparison
weight NCT03865342 270 276 B-Condition|Observation
loss NCT03865342 277 281 I-Condition|Observation
( NCT03865342 282 283 O
by NCT03865342 284 286 O
patient NCT03865342 287 294 O
report NCT03865342 295 301 O
, NCT03865342 302 303 O
> NCT03865342 304 305 B-Eq-Comparison
5 NCT03865342 306 307 I-Eq-Comparison
lbs NCT03865342 308 311 I-Eq-Comparison
in NCT03865342 312 314 B-Eq-Comparison
the NCT03865342 315 318 I-Eq-Comparison
6 NCT03865342 319 320 I-Eq-Comparison
months NCT03865342 321 327 I-Eq-Comparison
preceding NCT03865342 328 337 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03865342 338 348 B-Study
visit NCT03865342 349 354 O
) NCT03865342 355 356 O

- NCT03865342 360 361 O
previous NCT03865342 363 371 B-Eq-Comparison
diagnosis NCT03865342 372 381 O
of NCT03865342 382 384 O
type NCT03865342 385 389 B-Modifier
1 NCT03865342 390 391 I-Modifier
or NCT03865342 392 394 B-Or
type NCT03865342 395 399 B-Modifier
2 NCT03865342 400 401 I-Modifier
diabetes NCT03865342 402 410 B-Condition

- NCT03865342 413 414 O
serious NCT03865342 416 423 O
or NCT03865342 424 426 B-Or
persistent NCT03865342 427 437 B-Modifier
mental NCT03865342 438 444 B-Condition
illnesses NCT03865342 445 454 I-Condition

- NCT03865342 457 458 O
more NCT03865342 460 464 B-Eq-Comparison
than NCT03865342 465 469 I-Eq-Comparison
72 NCT03865342 470 472 I-Eq-Comparison
hours NCT03865342 473 478 I-Eq-Comparison
of NCT03865342 479 481 O
hospitalization NCT03865342 482 497 B-Encounter
in NCT03865342 498 500 B-Eq-Comparison
the NCT03865342 501 504 I-Eq-Comparison
last NCT03865342 505 509 I-Eq-Comparison
30 NCT03865342 510 512 I-Eq-Comparison
days NCT03865342 513 517 I-Eq-Comparison

- NCT03865342 520 521 O
Enrollment NCT03865342 523 533 O
in NCT03865342 534 536 O
a NCT03865342 537 538 O
structured NCT03865342 539 549 O
weight NCT03865342 550 556 B-Procedure
- NCT03865342 557 558 I-Procedure
loss NCT03865342 559 563 I-Procedure
program NCT03865342 564 571 I-Procedure
currently NCT03865342 572 581 B-Eq-Comparison
or NCT03865342 582 584 B-Or
within NCT03865342 585 591 B-Eq-Comparison
the NCT03865342 592 595 I-Eq-Comparison
1 NCT03865342 596 597 I-Eq-Comparison
month NCT03865342 598 603 I-Eq-Comparison
preceding NCT03865342 604 613 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03865342 614 619 B-Study
enrollment NCT03865342 620 630 O

- NCT03865342 633 634 O
Pregnant NCT03865342 636 644 B-Condition

- NCT03865342 647 648 O
Currently NCT03865342 650 659 B-Eq-Comparison
nursing NCT03865342 660 667 B-Condition

- NCT03865342 670 671 O
Have NCT03865342 673 677 O
given NCT03865342 678 683 B-Condition
birth NCT03865342 684 689 I-Condition
within NCT03865342 690 696 B-Eq-Comparison
the NCT03865342 697 700 I-Eq-Comparison
past NCT03865342 701 705 I-Eq-Comparison
3 NCT03865342 706 707 I-Eq-Comparison
months NCT03865342 708 714 I-Eq-Comparison

- NCT03865342 717 718 O
Has NCT03865342 720 723 O
been NCT03865342 724 728 O
discouraged NCT03865342 729 740 B-Assertion___Assertion-Type-Value:hypothetical|Negation
by NCT03865342 741 743 O
a NCT03865342 744 745 O
physician NCT03865342 746 755 B-Provider
to NCT03865342 756 758 O
enroll NCT03865342 759 765 O
in NCT03865342 766 768 O
a NCT03865342 769 770 O
DPP NCT03865342 771 774 B-Procedure
program NCT03865342 775 782 I-Procedure

Inclusion NCT03863678 0 9 O
Criteria NCT03863678 10 18 O
: NCT03863678 19 20 O

- NCT03863678 24 25 O
First NCT03863678 27 32 B-Eq-Comparison
time NCT03863678 33 37 I-Eq-Comparison
stroke NCT03863678 38 44 B-Condition
, NCT03863678 45 46 O

- NCT03863678 50 51 O
Patients NCT03863678 53 61 O
who NCT03863678 62 65 O
has NCT03863678 66 69 O
spasticity NCT03863678 70 80 B-Condition
due NCT03863678 81 84 O
to NCT03863678 85 87 O
stroke NCT03863678 88 94 B-Condition
, NCT03863678 95 96 O

- NCT03863678 100 101 O
At NCT03863678 103 105 B-Eq-Comparison
least NCT03863678 106 111 I-Eq-Comparison
6 NCT03863678 112 113 I-Eq-Comparison
months NCT03863678 114 120 I-Eq-Comparison
after NCT03863678 121 126 B-Temporal-Connection___Temporal-Connection-Type-Value:after
stroke NCT03863678 127 133 B-Condition
, NCT03863678 134 135 O

- NCT03863678 139 140 O
Individuals NCT03863678 142 153 O
between NCT03863678 154 161 B-Eq-Comparison
the NCT03863678 162 165 I-Eq-Comparison
ages NCT03863678 166 170 I-Age|Eq-Comparison
of NCT03863678 171 173 I-Eq-Comparison
18 NCT03863678 174 176 I-Eq-Comparison
- NCT03863678 177 178 I-Eq-Comparison
75 NCT03863678 179 181 I-Eq-Comparison
will NCT03863678 182 186 O
be NCT03863678 187 189 O
included NCT03863678 190 198 O
in NCT03863678 199 201 O
the NCT03863678 202 205 O
study NCT03863678 206 211 B-Study
. NCT03863678 212 213 O

Exclusion NCT03863678 215 224 O
Criteria NCT03863678 225 233 O
: NCT03863678 234 235 O

- NCT03863678 239 240 O
Any NCT03863678 242 245 O
contraindication NCT03863678 246 262 B-Contraindication
for NCT03863678 263 266 O
dry NCT03863678 267 270 B-Procedure
needling NCT03863678 271 279 I-Procedure
( NCT03863678 280 281 O
eg NCT03863678 282 284 O
, NCT03863678 285 286 O
anticoagulants NCT03863678 287 301 B-Drug
, NCT03863678 302 303 O
infections NCT03863678 304 314 B-Condition
, NCT03863678 315 316 O
bleeding NCT03863678 317 325 B-Condition
, NCT03863678 326 327 O
etc NCT03863678 328 331 O
. NCT03863678 331 332 O
) NCT03863678 333 334 O
, NCT03863678 336 337 O

- NCT03863678 341 342 O
Having NCT03863678 344 350 B-Eq-Comparison
diabetes NCT03863678 351 359 B-Condition
, NCT03863678 360 361 O

- NCT03863678 365 366 O
Having NCT03863678 368 374 B-Eq-Comparison
cardiovascular NCT03863678 375 389 B-Condition
diseases NCT03863678 390 398 I-Condition
, NCT03863678 399 400 O

- NCT03863678 404 405 O
Having NCT03863678 407 413 B-Eq-Comparison
any NCT03863678 414 417 O
other NCT03863678 418 423 B-Other
neurological NCT03863678 424 436 B-Condition
problems NCT03863678 437 445 I-Condition
, NCT03863678 446 447 O

- NCT03863678 451 452 O
Application NCT03863678 454 465 O
of NCT03863678 466 468 O
Botox NCT03863678 469 474 B-Procedure
within NCT03863678 475 481 B-Eq-Comparison
6 NCT03863678 482 483 I-Eq-Comparison
months NCT03863678 484 490 I-Eq-Comparison
prior NCT03863678 491 496 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863678 497 499 O
the NCT03863678 500 503 O
study NCT03863678 504 509 B-Study
, NCT03863678 510 511 O

- NCT03863678 515 516 O
Individuals NCT03863678 518 529 O
included NCT03863678 530 538 O
in NCT03863678 539 541 O
another NCT03863678 542 549 B-Other
treatment NCT03863678 550 559 B-Procedure
program NCT03863678 560 567 I-Procedure
will NCT03863678 568 572 O
not NCT03863678 573 576 B-Negation
be NCT03863678 577 579 O
included NCT03863678 580 588 O
in NCT03863678 589 591 O
the NCT03863678 592 595 O
study NCT03863678 596 601 B-Study
. NCT03863678 601 602 O

Inclusion NCT03867344 0 9 O
Criteria NCT03867344 10 18 O
: NCT03867344 19 20 O

- NCT03867344 24 25 O
Healthy NCT03867344 27 34 B-Condition
volunteers NCT03867344 35 45 O

- NCT03867344 48 49 O
Males NCT03867344 51 56 O
and NCT03867344 57 60 B-Or
Females NCT03867344 61 68 O
age NCT03867344 69 72 B-Age
18 NCT03867344 73 75 B-Eq-Comparison
to NCT03867344 76 78 I-Eq-Comparison
45 NCT03867344 79 81 I-Eq-Comparison
years NCT03867344 82 87 I-Eq-Comparison

- NCT03867344 90 91 O
BMI NCT03867344 93 96 B-Observation
18 NCT03867344 97 99 B-Eq-Comparison
- NCT03867344 100 101 I-Eq-Comparison
30 NCT03867344 102 104 I-Eq-Comparison
kg NCT03867344 105 107 I-Eq-Comparison
/ NCT03867344 108 109 I-Eq-Comparison
m2 NCT03867344 110 112 I-Eq-Comparison

Exclusion NCT03867344 113 122 O
Criteria NCT03867344 123 131 O
: NCT03867344 132 133 O

- NCT03867344 137 138 O
Pregnancy NCT03867344 140 149 B-Condition

- NCT03867344 152 153 O
Lactation NCT03867344 155 164 B-Condition

- NCT03867344 167 168 O
Menopause NCT03867344 170 179 B-Condition

- NCT03867344 182 183 O
Any NCT03867344 185 188 O
medical NCT03867344 189 196 B-Condition
condition NCT03867344 197 206 I-Condition

- NCT03867344 209 210 O
Current NCT03867344 212 219 B-Eq-Comparison
or NCT03867344 220 222 B-Or
prior NCT03867344 223 228 B-Eq-Comparison
alcohol NCT03867344 229 236 B-Modifier
or NCT03867344 237 239 B-Or
drug NCT03867344 240 244 B-Modifier
abuse NCT03867344 245 250 B-Condition

- NCT03867344 253 254 O
Active NCT03867344 256 262 B-Eq-Comparison
tobacco NCT03867344 263 270 B-Condition
use NCT03867344 271 274 I-Condition

- NCT03867344 277 278 O
Abnormal NCT03867344 280 288 O
ECG NCT03867344 289 292 B-Procedure

- NCT03867344 295 296 O
In NCT03867344 298 300 O
all NCT03867344 301 304 O
subjects NCT03867344 305 313 O
, NCT03867344 314 315 O
any NCT03867344 316 319 O
individuals NCT03867344 320 331 O
on NCT03867344 332 334 O
oral NCT03867344 335 339 B-Modifier
, NCT03867344 340 341 O
injected NCT03867344 342 350 B-Modifier
, NCT03867344 351 352 O
inhaled NCT03867344 353 360 B-Modifier
or NCT03867344 361 363 B-Or
topical NCT03867344 364 371 B-Modifier
corticosteroids NCT03867344 372 387 B-Drug
within NCT03867344 388 394 B-Eq-Comparison
the NCT03867344 395 398 I-Eq-Comparison
last NCT03867344 399 403 I-Eq-Comparison
year NCT03867344 404 408 I-Eq-Comparison
or NCT03867344 409 411 B-Or
oral NCT03867344 412 416 O
contraceptives NCT03867344 417 431 B-Drug
within NCT03867344 432 438 B-Eq-Comparison
the NCT03867344 439 442 I-Eq-Comparison
past NCT03867344 443 447 I-Eq-Comparison
3 NCT03867344 448 449 I-Eq-Comparison
months NCT03867344 450 456 I-Eq-Comparison
will NCT03867344 457 461 O
be NCT03867344 462 464 O
excluded NCT03867344 465 473 B-Negation
. NCT03867344 474 475 O

- NCT03867344 479 480 O
Use NCT03867344 482 485 O
of NCT03867344 486 488 O
medications NCT03867344 489 500 B-Drug

- NCT03867344 503 504 O
Serum NCT03867344 506 511 B-Observation
potassium NCT03867344 512 521 I-Observation
> NCT03867344 522 523 B-Eq-Comparison
5.0 NCT03867344 524 527 I-Eq-Comparison
mmol NCT03867344 528 532 I-Eq-Comparison
/ NCT03867344 533 534 I-Eq-Comparison
L NCT03867344 535 536 I-Eq-Comparison

- NCT03867344 539 540 O
Estimated NCT03867344 542 551 B-Observation
GFR NCT03867344 552 555 I-Observation
< NCT03867344 556 557 B-Eq-Comparison
60 NCT03867344 558 560 I-Eq-Comparison
mL NCT03867344 561 563 I-Eq-Comparison
/ NCT03867344 564 565 I-Eq-Comparison
min NCT03867344 566 569 I-Eq-Comparison
/ NCT03867344 570 571 I-Eq-Comparison
1.73 NCT03867344 572 576 I-Eq-Comparison
m2 NCT03867344 577 579 I-Eq-Comparison

- NCT03867344 582 583 O
Hemoglobin NCT03867344 585 595 B-Observation
A1c NCT03867344 596 599 I-Observation
≥ NCT03867344 600 601 B-Eq-Comparison
6.5 NCT03867344 602 605 I-Eq-Comparison
% NCT03867344 606 607 I-Eq-Comparison

- NCT03867344 611 612 O
LDL NCT03867344 614 617 B-Observation
> NCT03867344 618 619 B-Eq-Comparison
130 NCT03867344 620 623 I-Eq-Comparison
mg NCT03867344 624 626 I-Eq-Comparison
/ NCT03867344 627 628 I-Eq-Comparison
dL NCT03867344 629 631 I-Eq-Comparison
; NCT03867344 631 632 O
Triglycerides NCT03867344 633 646 B-Observation
> NCT03867344 647 648 B-Eq-Comparison
150 NCT03867344 649 652 I-Eq-Comparison
mg NCT03867344 653 655 I-Eq-Comparison
/ NCT03867344 656 657 I-Eq-Comparison
dL NCT03867344 658 660 I-Eq-Comparison

- NCT03867344 663 664 O
Patient NCT03867344 666 673 B-Observation
Health NCT03867344 674 680 I-Observation
Questionnaire NCT03867344 681 694 I-Observation
( NCT03867344 695 696 O
PHQ9 NCT03867344 697 701 B-Observation
) NCT03867344 702 703 O
for NCT03867344 704 707 O
depression NCT03867344 708 718 O
score NCT03867344 719 724 O
≥ NCT03867344 725 726 B-Eq-Comparison
15 NCT03867344 727 729 I-Eq-Comparison

- NCT03867344 733 734 O
GAD NCT03867344 736 739 B-Observation
- NCT03867344 740 741 I-Observation
73 NCT03867344 742 744 I-Observation
Questionnaire NCT03867344 745 758 I-Observation
for NCT03867344 759 762 O
anxiety NCT03867344 763 770 O
score NCT03867344 771 776 O
≥ NCT03867344 777 778 B-Eq-Comparison
10 NCT03867344 779 781 I-Eq-Comparison

- NCT03867344 785 786 O
Primary NCT03867344 788 795 B-Modifier
Care NCT03867344 796 800 I-Modifier
PTSD NCT03867344 801 805 B-Condition
Screen NCT03867344 806 812 B-Procedure
for NCT03867344 813 816 O
DSM NCT03867344 817 820 O
- NCT03867344 821 822 O
5 NCT03867344 823 824 O
for NCT03867344 825 828 O
post NCT03867344 829 833 B-Observation
- NCT03867344 834 835 I-Observation
traumatic NCT03867344 836 845 I-Observation
stress NCT03867344 846 852 I-Observation
disorder NCT03867344 853 861 I-Observation
score NCT03867344 862 867 I-Observation
≥ NCT03867344 868 869 B-Eq-Comparison
10 NCT03867344 870 872 I-Eq-Comparison

- NCT03867344 876 877 O
Blood NCT03867344 879 884 B-Observation
pressure NCT03867344 885 893 I-Observation
systolic NCT03867344 894 902 I-Observation
≥ NCT03867344 903 904 B-Eq-Comparison
140 NCT03867344 905 908 I-Eq-Comparison
or NCT03867344 909 911 B-Or
< NCT03867344 912 913 B-Eq-Comparison
100 NCT03867344 914 917 I-Eq-Comparison
mmHg NCT03867344 918 922 I-Eq-Comparison
; NCT03867344 922 923 O
Blood NCT03867344 924 929 B-Observation
pressure NCT03867344 930 938 I-Observation
diastolic NCT03867344 939 948 I-Observation
> NCT03867344 949 950 B-Eq-Comparison
90 NCT03867344 951 953 I-Eq-Comparison
mmHg NCT03867344 954 958 I-Eq-Comparison

- NCT03867344 961 962 O
Metal NCT03867344 964 969 B-Condition
in NCT03867344 970 972 I-Condition
the NCT03867344 973 976 I-Condition
body NCT03867344 977 981 I-Condition
including NCT03867344 982 991 O
: NCT03867344 992 993 O
cardiac NCT03867344 994 1001 B-Procedure
pacemakers NCT03867344 1002 1012 I-Procedure
, NCT03867344 1013 1014 O
stents NCT03867344 1015 1021 B-Procedure
, NCT03867344 1022 1023 O
artificial NCT03867344 1024 1034 B-Procedure
heart NCT03867344 1035 1040 I-Procedure
valves NCT03867344 1041 1047 I-Procedure
, NCT03867344 1048 1049 O
artificial NCT03867344 1050 1060 B-Procedure
limbs NCT03867344 1061 1066 B-Modifier
or NCT03867344 1067 1069 B-Or
hands NCT03867344 1070 1075 B-Modifier
, NCT03867344 1076 1077 O
brain NCT03867344 1078 1083 B-Procedure
stimulator NCT03867344 1084 1094 I-Procedure
devices NCT03867344 1095 1102 I-Procedure
, NCT03867344 1103 1104 O
implanted NCT03867344 1105 1114 B-Procedure
drug NCT03867344 1115 1119 I-Procedure
pumps NCT03867344 1120 1125 I-Procedure
, NCT03867344 1126 1127 O
ear NCT03867344 1128 1131 B-Procedure
implants NCT03867344 1132 1140 I-Procedure
, NCT03867344 1141 1142 O
eye NCT03867344 1143 1146 B-Procedure
implants NCT03867344 1147 1155 I-Procedure
or NCT03867344 1156 1158 B-Or
known NCT03867344 1159 1164 O
metal NCT03867344 1165 1170 B-Condition
fragments NCT03867344 1171 1180 I-Condition
in NCT03867344 1181 1183 O
eyes NCT03867344 1184 1188 B-Modifier
, NCT03867344 1189 1190 O
exposure NCT03867344 1191 1199 B-Condition
to NCT03867344 1200 1202 O
shrapnel NCT03867344 1203 1211 B-Modifier
or NCT03867344 1212 1214 B-Or
metal NCT03867344 1215 1220 B-Modifier
filings NCT03867344 1221 1228 I-Modifier
( NCT03867344 1229 1230 O
wounded NCT03867344 1231 1238 B-Condition
in NCT03867344 1239 1241 I-Condition
military NCT03867344 1242 1250 I-Condition
combat NCT03867344 1251 1257 I-Condition
, NCT03867344 1258 1259 O
sheet NCT03867344 1260 1265 B-Observation
metal NCT03867344 1266 1271 I-Observation
workers NCT03867344 1272 1279 I-Observation
, NCT03867344 1280 1281 O
welders NCT03867344 1282 1289 B-Observation
, NCT03867344 1290 1291 O
and NCT03867344 1292 1295 O
others NCT03867344 1296 1302 O
) NCT03867344 1303 1304 O
, NCT03867344 1306 1307 O
other NCT03867344 1308 1313 B-Other
metallic NCT03867344 1314 1322 B-Procedure
surgical NCT03867344 1323 1331 I-Procedure
hardware NCT03867344 1332 1340 I-Procedure
in NCT03867344 1341 1343 O
vital NCT03867344 1344 1349 B-Modifier
areas NCT03867344 1350 1355 I-Modifier
, NCT03867344 1356 1357 O
certain NCT03867344 1358 1365 O
tattoos NCT03867344 1366 1373 B-Condition
with NCT03867344 1374 1378 O
metallic NCT03867344 1379 1387 B-Modifier
ink NCT03867344 1388 1391 I-Modifier
, NCT03867344 1392 1393 O
certain NCT03867344 1394 1401 O
transdermal NCT03867344 1402 1413 B-Procedure
medication NCT03867344 1414 1424 I-Procedure
patches NCT03867344 1425 1432 I-Procedure
, NCT03867344 1433 1434 O
and NCT03867344 1435 1438 B-Or
metal NCT03867344 1439 1444 B-Procedure
- NCT03867344 1445 1446 I-Procedure
containing NCT03867344 1447 1457 I-Procedure
IUDs NCT03867344 1458 1462 I-Procedure

Inclusion NCT03867422 0 9 O
Criteria NCT03867422 10 18 O
: NCT03867422 19 20 O

- NCT03867422 24 25 O
more NCT03867422 27 31 B-Eq-Comparison
or NCT03867422 32 34 I-Eq-Comparison
equal NCT03867422 35 40 I-Eq-Comparison
18 NCT03867422 41 43 I-Eq-Comparison
years NCT03867422 44 49 I-Eq-Comparison
- NCT03867422 50 51 O
old NCT03867422 52 55 B-Age
and NCT03867422 56 59 B-And
less NCT03867422 60 64 B-Eq-Comparison
or NCT03867422 65 67 I-Eq-Comparison
equal NCT03867422 68 73 I-Eq-Comparison
45 NCT03867422 74 76 I-Eq-Comparison
years NCT03867422 77 82 I-Eq-Comparison
- NCT03867422 83 84 O
old NCT03867422 85 88 B-Age

- NCT03867422 91 92 O
no NCT03867422 94 96 B-Negation
known NCT03867422 97 102 O
hearing NCT03867422 103 110 B-Condition
problem NCT03867422 111 118 I-Condition

Exclusion NCT03867422 119 128 O
Criteria NCT03867422 129 137 O
: NCT03867422 138 139 O

- NCT03867422 143 144 O
professional NCT03867422 146 158 B-Observation
musician NCT03867422 159 167 I-Observation

- NCT03867422 170 171 O
history NCT03867422 173 180 B-Eq-Comparison
of NCT03867422 181 183 O
neurologic NCT03867422 184 194 B-Modifier
, NCT03867422 195 196 O
psychiatric NCT03867422 197 208 B-Modifier
or NCT03867422 209 211 O
cadiologic NCT03867422 212 222 B-Modifier
disease NCT03867422 223 230 B-Condition

- NCT03867422 233 234 O
treatment NCT03867422 236 245 B-Procedure
which NCT03867422 246 251 O
could NCT03867422 252 257 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03867422 258 264 O
parameters NCT03867422 265 275 B-Observation
of NCT03867422 276 278 O
brain NCT03867422 279 284 B-Modifier
tissue NCT03867422 285 291 I-Modifier
pulsatility NCT03867422 292 303 I-Modifier
and NCT03867422 304 307 O
peripheral NCT03867422 308 318 B-Modifier
nervous NCT03867422 319 326 I-Modifier
system NCT03867422 327 333 I-Modifier

- NCT03867422 336 337 O
opposition NCT03867422 339 349 O
to NCT03867422 350 352 O
use NCT03867422 353 356 O
the NCT03867422 357 360 O
data NCT03867422 361 365 O

Inclusion NCT03861286 0 9 O
Criteria NCT03861286 10 18 O
: NCT03861286 19 20 O

1 NCT03861286 24 25 O
. NCT03861286 25 26 O
Patients NCT03861286 28 36 O
undergoing NCT03861286 37 47 B-Eq-Comparison
first NCT03861286 48 53 B-Eq-Comparison
time NCT03861286 54 58 I-Eq-Comparison
cardiopulmonary NCT03861286 59 74 B-Procedure
bypass NCT03861286 75 81 I-Procedure
surgery NCT03861286 82 89 I-Procedure
for NCT03861286 90 93 O
correction NCT03861286 94 104 O
of NCT03861286 105 107 O
atrial NCT03861286 108 114 B-Condition
septal NCT03861286 115 121 I-Condition
defects NCT03861286 122 129 I-Condition
or NCT03861286 130 132 B-Or
tissue NCT03861286 133 139 B-Procedure
mitral NCT03861286 140 146 I-Procedure
valve NCT03861286 147 152 I-Procedure
repair NCT03861286 153 159 I-Procedure

2 NCT03861286 162 163 O
. NCT03861286 163 164 O
Receiving NCT03861286 166 175 B-Eq-Comparison
intravenous NCT03861286 176 187 B-Modifier
Heparin NCT03861286 188 195 B-Drug
for NCT03861286 196 199 O
cardiopulmonary NCT03861286 200 215 B-Procedure
bypass NCT03861286 216 222 I-Procedure

Exclusion NCT03861286 223 232 O
Criteria NCT03861286 233 241 O
: NCT03861286 242 243 O

- NCT03861286 247 248 O
Concomitant NCT03861286 250 261 B-Modifier
Aortic NCT03861286 262 268 B-Condition
Stenosis NCT03861286 269 277 I-Condition
which NCT03861286 278 283 O
is NCT03861286 284 286 O
associated NCT03861286 287 297 O
with NCT03861286 298 302 O
an NCT03861286 303 305 O
acquired NCT03861286 306 314 B-Condition
von NCT03861286 315 318 I-Condition
Willebrand NCT03861286 319 329 I-Condition
Syndrome NCT03861286 330 338 I-Condition
( NCT03861286 339 340 O
aVWS NCT03861286 341 345 B-Condition
) NCT03861286 346 347 O

- NCT03861286 351 352 O
Patients NCT03861286 354 362 O
with NCT03861286 363 367 O
a NCT03861286 368 369 O
baseline NCT03861286 370 378 O
platelet NCT03861286 379 387 B-Observation
count NCT03861286 388 393 I-Observation
of NCT03861286 394 396 O
< NCT03861286 397 398 B-Eq-Comparison
100 NCT03861286 399 402 I-Eq-Comparison
x109 NCT03861286 403 407 I-Eq-Comparison
/ NCT03861286 408 409 I-Eq-Comparison
L NCT03861286 410 411 I-Eq-Comparison

- NCT03861286 414 415 O
Patients NCT03861286 417 425 O
with NCT03861286 426 430 O
a NCT03861286 431 432 O
known NCT03861286 433 438 O
coagulation NCT03861286 439 450 B-Condition
factor NCT03861286 451 457 I-Condition
deficiency NCT03861286 458 468 I-Condition
or NCT03861286 469 471 B-Or
platelet NCT03861286 472 480 B-Condition
function NCT03861286 481 489 I-Condition
disorder NCT03861286 490 498 I-Condition

- NCT03861286 501 502 O
Patients NCT03861286 504 512 O
receiving NCT03861286 513 522 B-Eq-Comparison
heparin NCT03861286 523 530 B-Procedure
therapy NCT03861286 531 538 I-Procedure
prior NCT03861286 539 544 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861286 545 547 I-Temporal-Connection___Temporal-Connection-Type-Value:before
CPB NCT03861286 548 551 B-Procedure
within NCT03861286 552 558 B-Eq-Comparison
last NCT03861286 559 563 I-Eq-Comparison
7 NCT03861286 564 565 I-Eq-Comparison
days NCT03861286 566 570 I-Eq-Comparison

Inclusion NCT03864315 0 9 O
Criteria NCT03864315 10 18 O
: NCT03864315 19 20 O

1 NCT03864315 24 25 O
. NCT03864315 25 26 O
20 NCT03864315 28 30 B-Eq-Comparison
- NCT03864315 31 32 I-Eq-Comparison
75 NCT03864315 33 35 I-Eq-Comparison
years NCT03864315 36 41 I-Eq-Comparison
old NCT03864315 42 45 B-Age

2 NCT03864315 48 49 O
. NCT03864315 49 50 O
With NCT03864315 52 56 O
skin NCT03864315 57 61 B-Condition
type NCT03864315 62 66 I-Condition
Ⅲ NCT03864315 67 68 B-Eq-Comparison
or NCT03864315 69 71 I-Eq-Comparison
Ⅳ NCT03864315 72 73 I-Eq-Comparison

3 NCT03864315 76 77 O
. NCT03864315 77 78 O
With NCT03864315 80 84 O
Vitiligo NCT03864315 85 93 B-Condition

4 NCT03864315 96 97 O
. NCT03864315 97 98 O
Can NCT03864315 100 103 O
read NCT03864315 104 108 O
the NCT03864315 109 112 O
informed NCT03864315 113 121 O
consent NCT03864315 122 129 O
form NCT03864315 130 134 O

5 NCT03864315 137 138 O
. NCT03864315 138 139 O
Can NCT03864315 141 144 O
continue NCT03864315 145 153 O
the NCT03864315 154 157 O
original NCT03864315 158 166 O
treatments NCT03864315 167 177 O

Exclusion NCT03864315 178 187 O
Criteria NCT03864315 188 196 O
: NCT03864315 197 198 O

1 NCT03864315 202 203 O
. NCT03864315 203 204 O
With NCT03864315 206 210 O
segmental NCT03864315 211 220 B-Modifier
vitiligo NCT03864315 221 229 B-Condition
. NCT03864315 230 231 O

2 NCT03864315 235 236 O
. NCT03864315 236 237 O
Have NCT03864315 239 243 O
joined NCT03864315 244 250 O
other NCT03864315 251 256 B-Other
clinical NCT03864315 257 265 B-Study
trials NCT03864315 266 272 I-Study

Inclusion NCT03865745 0 9 O
Criteria NCT03865745 10 18 O
: NCT03865745 19 20 O

1 NCT03865745 24 25 O
. NCT03865745 25 26 O
Age NCT03865745 28 31 B-Age
of NCT03865745 32 34 O
40 NCT03865745 35 37 B-Eq-Comparison
~ NCT03865745 38 39 I-Eq-Comparison
75 NCT03865745 40 42 I-Eq-Comparison
men NCT03865745 43 46 O
and NCT03865745 47 50 B-Or
women NCT03865745 51 56 O

2 NCT03865745 59 60 O
. NCT03865745 60 61 O
Those NCT03865745 63 68 O
who NCT03865745 69 72 O
visited NCT03865745 73 80 B-Encounter
the NCT03865745 81 84 O
menopausal NCT03865745 85 95 O
clinic NCT03865745 96 102 O
with NCT03865745 103 107 B-And
complaints NCT03865745 108 118 O
of NCT03865745 119 121 O
climacteric NCT03865745 122 133 B-Condition
symptoms NCT03865745 134 142 B-Assertion___Assertion-Type-Value:possible
due NCT03865745 143 146 O
to NCT03865745 147 149 O
functional NCT03865745 150 160 O
deterioration NCT03865745 161 174 B-Condition
of NCT03865745 175 177 I-Condition
various NCT03865745 178 185 I-Condition
organs NCT03865745 186 192 I-Condition
such NCT03865745 193 197 O
as NCT03865745 198 200 O
fatigue NCT03865745 201 208 B-Condition
, NCT03865745 209 210 O
helplessness NCT03865745 211 223 B-Condition

3 NCT03865745 226 227 O
. NCT03865745 227 228 O
Those NCT03865745 230 235 O
who NCT03865745 236 239 O
have NCT03865745 240 244 O
agreed NCT03865745 245 251 O
to NCT03865745 252 254 O
voluntarily NCT03865745 255 266 O
decide NCT03865745 267 273 O
to NCT03865745 274 276 O
participate NCT03865745 277 288 O
and NCT03865745 289 292 O
observe NCT03865745 293 300 O
the NCT03865745 301 304 O
instructions NCT03865745 305 317 O
after NCT03865745 318 323 O
hearing NCT03865745 324 331 O
the NCT03865745 332 335 O
detailed NCT03865745 336 344 O
explanation NCT03865745 345 356 O
of NCT03865745 357 359 O
this NCT03865745 360 364 O
human NCT03865745 365 370 O
body NCT03865745 371 375 O
application NCT03865745 376 387 O
test NCT03865745 388 392 O

Exclusion NCT03865745 393 402 O
Criteria NCT03865745 403 411 O
: NCT03865745 412 413 O

1 NCT03865745 417 418 O
. NCT03865745 418 419 O
Those NCT03865745 421 426 O
who NCT03865745 427 430 O
have NCT03865745 431 435 O
suspected NCT03865745 436 445 B-Assertion___Assertion-Type-Value:possible
symptoms NCT03865745 446 454 I-Assertion___Assertion-Type-Value:possible
of NCT03865745 455 457 O
acute NCT03865745 458 463 O
disease NCT03865745 464 471 B-Condition
( NCT03865745 472 473 O
severe NCT03865745 474 480 O
infectious NCT03865745 481 491 B-Condition
disease NCT03865745 492 499 I-Condition
, NCT03865745 500 501 O
severe NCT03865745 502 508 O
trauma NCT03865745 509 515 B-Condition
, NCT03865745 516 517 O
severe NCT03865745 518 524 O
diarrhea NCT03865745 525 533 B-Condition
, NCT03865745 534 535 O
vomiting NCT03865745 536 544 B-Condition
, NCT03865745 545 546 O
etc NCT03865745 547 550 O
. NCT03865745 550 551 O
) NCT03865745 552 553 O

2 NCT03865745 557 558 O
. NCT03865745 558 559 O
Patients NCT03865745 561 569 O
with NCT03865745 570 574 O
a NCT03865745 575 576 O
history NCT03865745 577 584 B-Eq-Comparison
of NCT03865745 585 587 O
antibiotic NCT03865745 588 598 B-Drug
treatment NCT03865745 599 608 B-Procedure
for NCT03865745 609 612 O
more NCT03865745 613 617 B-Eq-Comparison
than NCT03865745 618 622 I-Eq-Comparison
1 NCT03865745 623 624 I-Eq-Comparison
month NCT03865745 625 630 I-Eq-Comparison
within NCT03865745 631 637 B-Eq-Comparison
the NCT03865745 638 641 I-Eq-Comparison
last NCT03865745 642 646 I-Eq-Comparison
6 NCT03865745 647 648 I-Eq-Comparison
months NCT03865745 649 655 I-Eq-Comparison

3 NCT03865745 663 664 O
. NCT03865745 664 665 O
Those NCT03865745 667 672 O
who NCT03865745 673 676 O
have NCT03865745 677 681 O
gastrointestinal NCT03865745 682 698 B-Condition
diseases NCT03865745 699 707 I-Condition
( NCT03865745 708 709 O
inflammatory NCT03865745 710 722 B-Condition
growth NCT03865745 723 729 I-Condition
disease NCT03865745 730 737 I-Condition
, NCT03865745 738 739 O
active NCT03865745 740 746 B-Condition
peptic NCT03865745 747 753 I-Condition
ulcer NCT03865745 754 759 I-Condition
, NCT03865745 760 761 O
etc NCT03865745 762 765 O
. NCT03865745 765 766 O
) NCT03865745 767 768 O
or NCT03865745 769 771 B-Or
gastrointestinal NCT03865745 772 788 B-Procedure
surgery NCT03865745 789 796 I-Procedure
( NCT03865745 797 798 O
except NCT03865745 799 805 B-Exception
for NCT03865745 806 809 O
simple NCT03865745 810 816 B-Modifier
appendectomy NCT03865745 817 829 B-Procedure
or NCT03865745 830 832 B-Or
hernia NCT03865745 833 839 B-Procedure
surgery NCT03865745 840 847 I-Procedure
) NCT03865745 848 849 O

4 NCT03865745 853 854 O
. NCT03865745 854 855 O
Those NCT03865745 857 862 O
taking NCT03865745 863 869 B-Eq-Comparison
health NCT03865745 870 876 B-Drug
functional NCT03865745 877 887 I-Drug
foods NCT03865745 888 893 I-Drug
, NCT03865745 894 895 O
lactic NCT03865745 896 902 B-Drug
acid NCT03865745 903 907 I-Drug
bacteria NCT03865745 908 916 I-Drug
, NCT03865745 917 918 O
and NCT03865745 919 922 B-Or
red NCT03865745 923 926 B-Drug
ginseng NCT03865745 927 934 I-Drug
extracts NCT03865745 935 943 I-Drug
for NCT03865745 944 947 O
the NCT03865745 948 951 O
past NCT03865745 952 956 B-Eq-Comparison
year NCT03865745 957 961 I-Eq-Comparison

5 NCT03865745 964 965 O
. NCT03865745 965 966 O
Those NCT03865745 968 973 O
who NCT03865745 974 977 O
are NCT03865745 978 981 O
currently NCT03865745 982 991 B-Eq-Comparison
participating NCT03865745 992 1005 O
in NCT03865745 1006 1008 O
other NCT03865745 1009 1014 B-Other
clinical NCT03865745 1015 1023 B-Study
studies NCT03865745 1024 1031 I-Study
or NCT03865745 1032 1034 B-Or
human NCT03865745 1035 1040 B-Study
trials NCT03865745 1041 1047 I-Study
, NCT03865745 1048 1049 O
or NCT03865745 1050 1052 B-Or
participating NCT03865745 1053 1066 O
in NCT03865745 1067 1069 O
clinical NCT03865745 1070 1078 B-Study
trials NCT03865745 1079 1085 I-Study
or NCT03865745 1086 1088 B-Or
human NCT03865745 1089 1094 B-Study
application NCT03865745 1095 1106 I-Study
tests NCT03865745 1107 1112 I-Study
within NCT03865745 1113 1119 B-Eq-Comparison
the NCT03865745 1120 1123 I-Eq-Comparison
past NCT03865745 1124 1128 I-Eq-Comparison
month NCT03865745 1129 1134 I-Eq-Comparison


Inclusion NCT03863730 0 9 O
Criteria NCT03863730 10 18 O
: NCT03863730 19 20 O

- NCT03863730 24 25 O
Prior NCT03863730 27 32 B-Eq-Comparison
or NCT03863730 33 35 B-Or
ongoing NCT03863730 36 43 B-Eq-Comparison
harmful NCT03863730 44 51 O
alcohol NCT03863730 52 59 B-Drug
intake NCT03863730 60 66 O
defined NCT03863730 67 74 O
as NCT03863730 75 77 O
an NCT03863730 78 80 O
average NCT03863730 81 88 O
of NCT03863730 89 91 O
≥ NCT03863730 92 93 B-Eq-Comparison
24 NCT03863730 94 96 I-Eq-Comparison
g NCT03863730 97 98 I-Eq-Comparison
alcohol NCT03863730 99 106 I-Eq-Comparison
/ NCT03863730 107 108 I-Eq-Comparison
day NCT03863730 109 112 I-Eq-Comparison
for NCT03863730 113 116 O
women NCT03863730 117 122 O
and NCT03863730 123 126 O
≥ NCT03863730 127 128 B-Eq-Comparison
36 NCT03863730 129 131 I-Eq-Comparison
g NCT03863730 132 133 I-Eq-Comparison
/ NCT03863730 134 135 I-Eq-Comparison
d NCT03863730 136 137 I-Eq-Comparison
for NCT03863730 138 141 O
men NCT03863730 142 145 O
for NCT03863730 146 149 O
≥ NCT03863730 150 151 B-Eq-Comparison
5 NCT03863730 152 153 I-Eq-Comparison
year NCT03863730 154 158 I-Eq-Comparison
. NCT03863730 159 160 O

- NCT03863730 169 170 O
Outpatients NCT03863730 172 183 B-Encounter
with NCT03863730 184 188 B-And
compensated NCT03863730 189 200 B-Modifier
advanced NCT03863730 201 209 I-Modifier
chronic NCT03863730 210 217 I-Modifier
alcohol NCT03863730 218 225 B-Drug
- NCT03863730 226 227 O
related NCT03863730 228 235 O
liver NCT03863730 236 241 B-Condition
disease NCT03863730 242 249 I-Condition
, NCT03863730 250 251 O
defined NCT03863730 252 259 O
as NCT03863730 260 262 O
stable NCT03863730 263 269 O
patients NCT03863730 270 278 O
with NCT03863730 279 283 O
: NCT03863730 284 285 O

1 NCT03863730 299 300 O
. NCT03863730 300 301 O
liver NCT03863730 303 308 B-Condition
stiffness NCT03863730 309 318 I-Condition
≥ NCT03863730 319 320 B-Eq-Comparison
15 NCT03863730 321 323 I-Eq-Comparison
kPa NCT03863730 324 327 B-Observation
and NCT03863730 328 331 B-And
asymptomatic NCT03863730 332 344 B-Condition
and NCT03863730 345 348 B-Or
/ NCT03863730 349 350 I-Or
or NCT03863730 351 353 I-Or

2 NCT03863730 366 367 O
. NCT03863730 367 368 O
New NCT03863730 370 373 B-Eq-Comparison
liver NCT03863730 374 379 B-Procedure
biopsy NCT03863730 380 386 I-Procedure
( NCT03863730 387 388 O
< NCT03863730 390 391 B-Eq-Comparison
6 NCT03863730 392 393 I-Eq-Comparison
months NCT03863730 394 400 O
) NCT03863730 401 402 O
with NCT03863730 403 407 B-And
at NCT03863730 408 410 B-Eq-Comparison
least NCT03863730 411 416 I-Eq-Comparison
F3 NCT03863730 417 419 I-Eq-Comparison
fibrosis NCT03863730 420 428 B-Condition
( NCT03863730 429 430 O
kleiner NCT03863730 431 438 B-Modifier
) NCT03863730 439 440 O
and NCT03863730 441 444 B-Or
/ NCT03863730 445 446 I-Or
or NCT03863730 447 449 I-Or

3 NCT03863730 462 463 O
. NCT03863730 463 464 O
Liver NCT03863730 466 471 B-Procedure
biopsy NCT03863730 472 478 I-Procedure
older NCT03863730 479 484 B-Eq-Comparison
that NCT03863730 485 489 I-Eq-Comparison
6 NCT03863730 490 491 I-Eq-Comparison
months NCT03863730 492 498 I-Eq-Comparison
with NCT03863730 499 503 B-And
liver NCT03863730 504 509 B-Condition
stiffness NCT03863730 510 519 I-Condition
≥ NCT03863730 520 521 B-Eq-Comparison
10 NCT03863730 522 524 I-Eq-Comparison
kPa NCT03863730 525 528 B-Observation

- NCT03863730 536 537 O
Understand NCT03863730 539 549 O
and NCT03863730 550 553 O
speak NCT03863730 554 559 O
Danish NCT03863730 560 566 O
written NCT03863730 567 574 O
and NCT03863730 575 578 O
orally NCT03863730 579 585 O

- NCT03863730 593 594 O
Informed NCT03863730 596 604 O
consent NCT03863730 605 612 O

Exclusion NCT03863730 613 622 O
Criteria NCT03863730 623 631 O
: NCT03863730 632 633 O

- NCT03863730 637 638 O
Hospitalised NCT03863730 640 652 B-Encounter

- NCT03863730 655 656 O
Moderete NCT03863730 658 666 O
or NCT03863730 667 669 B-Or
severe NCT03863730 670 676 O
Ascites NCT03863730 677 684 B-Condition
, NCT03863730 685 686 O
determined NCT03863730 687 697 O
from NCT03863730 698 702 O
imaging NCT03863730 703 710 B-Procedure
diagnostics NCT03863730 711 722 I-Procedure

- NCT03863730 725 726 O
High NCT03863730 728 732 O
- NCT03863730 733 734 O
risk NCT03863730 735 739 B-Risk
varices NCT03863730 740 747 B-Condition
needing NCT03863730 748 755 B-Assertion___Assertion-Type-Value:hypothetical
interventional NCT03863730 756 770 B-Procedure
treatment NCT03863730 771 780 I-Procedure
( NCT03863730 781 782 O
endoscopy NCT03863730 783 792 B-Procedure
, NCT03863730 793 794 O
TIPS NCT03863730 795 799 B-Procedure
) NCT03863730 800 801 O

- NCT03863730 805 806 O
Child NCT03863730 808 813 O
- NCT03863730 814 815 O
Pugh NCT03863730 816 820 O
C NCT03863730 821 822 O
score NCT03863730 823 828 O

- NCT03863730 831 832 O
MELD NCT03863730 834 838 B-Observation
- NCT03863730 839 840 I-Observation
Na NCT03863730 841 843 I-Observation
≥ NCT03863730 844 845 B-Eq-Comparison
15 NCT03863730 846 848 I-Eq-Comparison

- NCT03863730 852 853 O
Lactose NCT03863730 855 862 B-Condition
intolerance NCT03863730 863 874 I-Condition

- NCT03863730 877 878 O
Coeliac NCT03863730 880 887 B-Condition
disease NCT03863730 888 895 I-Condition

- NCT03863730 898 899 O
Irritable NCT03863730 901 910 B-Condition
bowel NCT03863730 911 916 I-Condition
syndrome NCT03863730 917 925 I-Condition
defined NCT03863730 926 933 O
by NCT03863730 934 936 O
ROME NCT03863730 937 941 O
III NCT03863730 942 945 O
criteria NCT03863730 946 954 O

- NCT03863730 957 958 O
Antibiotic NCT03863730 960 970 B-Drug
treatment NCT03863730 971 980 B-Procedure
the NCT03863730 981 984 O
prior NCT03863730 985 990 B-Eq-Comparison
3 NCT03863730 991 992 I-Eq-Comparison
months NCT03863730 993 999 I-Eq-Comparison

- NCT03863730 1002 1003 O
Treatment NCT03863730 1005 1014 B-Procedure
with NCT03863730 1015 1019 O
nutritional NCT03863730 1020 1031 B-Drug
drinks NCT03863730 1032 1038 I-Drug
, NCT03863730 1039 1040 O
probiotics NCT03863730 1041 1051 B-Drug
or NCT03863730 1052 1054 B-Or
prebiotics NCT03863730 1055 1065 B-Drug
within NCT03863730 1066 1072 B-Eq-Comparison
the NCT03863730 1073 1076 I-Eq-Comparison
last NCT03863730 1077 1081 I-Eq-Comparison
3 NCT03863730 1082 1083 I-Eq-Comparison
months NCT03863730 1084 1090 I-Eq-Comparison

- NCT03863730 1093 1094 O
The NCT03863730 1096 1099 O
investigator NCT03863730 1100 1112 O
judge NCT03863730 1113 1118 O
that NCT03863730 1119 1123 O
the NCT03863730 1124 1127 O
patient NCT03863730 1128 1135 O
would NCT03863730 1136 1141 O
not NCT03863730 1142 1145 O
be NCT03863730 1146 1148 O
compliant NCT03863730 1149 1158 O
with NCT03863730 1159 1163 O
trial NCT03863730 1164 1169 O
medicine NCT03863730 1170 1178 O

- NCT03863730 1181 1182 O
Pregnancy NCT03863730 1184 1193 B-Condition

- NCT03863730 1196 1197 O
Known NCT03863730 1199 1204 O
liver NCT03863730 1205 1210 B-Condition
disease NCT03863730 1211 1218 I-Condition
other NCT03863730 1219 1224 B-Exception
than NCT03863730 1225 1229 O
alcoholic NCT03863730 1230 1239 B-Condition
, NCT03863730 1240 1241 O
of NCT03863730 1242 1244 O
any NCT03863730 1245 1248 O
aetiology NCT03863730 1249 1258 O

- NCT03863730 1261 1262 O
Severe NCT03863730 1264 1270 O
malnutrition NCT03863730 1271 1283 B-Condition

- NCT03863730 1286 1287 O
Malignancy NCT03863730 1289 1299 B-Condition
- NCT03863730 1300 1301 O
except NCT03863730 1302 1308 B-Exception
spino NCT03863730 1309 1314 B-Condition
- NCT03863730 1315 1316 I-Condition
or NCT03863730 1317 1319 I-Condition
basocellular NCT03863730 1320 1332 I-Condition
skin NCT03863730 1333 1337 I-Condition
cancer NCT03863730 1338 1344 I-Condition
. NCT03863730 1344 1345 O
Patients NCT03863730 1347 1355 O
with NCT03863730 1356 1360 O
prior NCT03863730 1361 1366 B-Eq-Comparison
malignant NCT03863730 1367 1376 B-Condition
disease NCT03863730 1377 1384 I-Condition
are NCT03863730 1385 1388 O
allowed NCT03863730 1389 1396 O
if NCT03863730 1397 1399 O
cancer NCT03863730 1400 1406 B-Condition
- NCT03863730 1407 1408 O
free NCT03863730 1409 1413 B-Negation
for NCT03863730 1414 1417 O
at NCT03863730 1418 1420 B-Eq-Comparison
least NCT03863730 1421 1426 I-Eq-Comparison
one NCT03863730 1427 1430 I-Eq-Comparison
year NCT03863730 1431 1435 I-Eq-Comparison

- NCT03863730 1438 1439 O
Recent NCT03863730 1441 1447 B-Eq-Comparison
infectious NCT03863730 1448 1458 B-Modifier
gastroenteritis NCT03863730 1459 1474 B-Condition
( NCT03863730 1475 1476 O
for NCT03863730 1477 1480 O
the NCT03863730 1481 1484 O
last NCT03863730 1485 1489 B-Eq-Comparison
6 NCT03863730 1490 1491 I-Eq-Comparison
weeks NCT03863730 1492 1497 I-Eq-Comparison
) NCT03863730 1498 1499 O

Inclusion NCT03865355 0 9 O
Criteria NCT03865355 10 18 O
: NCT03865355 19 20 O

1 NCT03865355 24 25 O
. NCT03865355 25 26 O
All NCT03865355 28 31 O
patients NCT03865355 32 40 O
with NCT03865355 41 45 O
suspected NCT03865355 46 55 B-Assertion___Assertion-Type-Value:possible
newly NCT03865355 56 61 B-Eq-Comparison
diagnosed NCT03865355 62 71 O
glioma NCT03865355 72 78 B-Condition
( NCT03865355 79 80 O
grade NCT03865355 81 86 B-Eq-Comparison
I NCT03865355 87 88 I-Eq-Comparison
, NCT03865355 89 90 I-Eq-Comparison
II NCT03865355 91 93 I-Eq-Comparison
, NCT03865355 94 95 I-Eq-Comparison
III NCT03865355 96 99 I-Eq-Comparison
or NCT03865355 100 102 B-Or
glioblastoma NCT03865355 103 115 B-Condition
) NCT03865355 116 117 O
with NCT03865355 118 122 B-And
planned NCT03865355 123 130 B-Eq-Comparison
surgical NCT03865355 131 139 B-Procedure
intervention NCT03865355 140 152 I-Procedure
( NCT03865355 153 154 O
resection NCT03865355 155 164 B-Procedure
or NCT03865355 165 167 B-Or
biopsy NCT03865355 168 174 B-Procedure
) NCT03865355 175 176 O
. NCT03865355 178 179 O

2 NCT03865355 183 184 O
. NCT03865355 184 185 O
Patient NCT03865355 187 194 O
aged NCT03865355 195 199 B-Age
18 NCT03865355 200 202 B-Eq-Comparison
years NCT03865355 203 208 I-Eq-Comparison
or NCT03865355 209 211 I-Eq-Comparison
older NCT03865355 212 217 I-Eq-Comparison

3 NCT03865355 220 221 O
. NCT03865355 221 222 O
Patients NCT03865355 224 232 O
have NCT03865355 233 237 O
to NCT03865355 238 240 O
be NCT03865355 241 243 O
able NCT03865355 244 248 O
to NCT03865355 249 251 O
give NCT03865355 252 256 O
informed NCT03865355 257 265 O
consent NCT03865355 266 273 O

Exclusion NCT03865355 274 283 O
Criteria NCT03865355 284 292 O
: NCT03865355 293 294 O

1 NCT03865355 298 299 O
. NCT03865355 299 300 O
Prior NCT03865355 302 307 B-Eq-Comparison
Radiotherapy NCT03865355 308 320 B-Procedure
to NCT03865355 321 323 O
the NCT03865355 324 327 O
central NCT03865355 328 335 B-Modifier
nervous NCT03865355 336 343 I-Modifier
system NCT03865355 344 350 I-Modifier

2 NCT03865355 353 354 O
. NCT03865355 354 355 O
Prior NCT03865355 357 362 B-Eq-Comparison
Chemotherapy NCT03865355 363 375 B-Procedure
within NCT03865355 376 382 B-Eq-Comparison
the NCT03865355 383 386 I-Eq-Comparison
last NCT03865355 387 391 I-Eq-Comparison
5 NCT03865355 392 393 I-Eq-Comparison
years NCT03865355 394 399 I-Eq-Comparison

3 NCT03865355 402 403 O
. NCT03865355 403 404 O
Any NCT03865355 406 409 O
prior NCT03865355 410 415 B-Eq-Comparison
central NCT03865355 416 423 B-Modifier
nervous NCT03865355 424 431 I-Modifier
system NCT03865355 432 438 I-Modifier
malignancy NCT03865355 439 449 B-Condition

4 NCT03865355 452 453 O
. NCT03865355 453 454 O
Any NCT03865355 456 459 O
surgery NCT03865355 460 467 B-Procedure
during NCT03865355 468 474 B-Temporal-Connection___Temporal-Connection-Type-Value:during
last NCT03865355 475 479 B-Eq-Comparison
6 NCT03865355 480 481 I-Eq-Comparison
month NCT03865355 482 487 I-Eq-Comparison

Inclusion NCT03865433 0 9 O
Criteria NCT03865433 10 18 O
: NCT03865433 19 20 O

1 NCT03865433 24 25 O
. NCT03865433 25 26 O
are NCT03865433 28 31 O
aged NCT03865433 32 36 B-Age
13 NCT03865433 37 39 B-Eq-Comparison
- NCT03865433 40 41 I-Eq-Comparison
17 NCT03865433 42 44 I-Eq-Comparison
, NCT03865433 45 46 I-Eq-Comparison
years NCT03865433 47 52 I-Eq-Comparison
and NCT03865433 53 56 B-And
a NCT03865433 57 58 O
high NCT03865433 59 63 O
school NCT03865433 64 70 O
student NCT03865433 71 78 O
- NCT03865433 79 80 O
athlete NCT03865433 81 88 O
who NCT03865433 89 92 O
attends NCT03865433 93 100 O
school NCT03865433 101 107 O
where NCT03865433 108 113 O
an NCT03865433 114 116 O
athletic NCT03865433 117 125 O
trainer NCT03865433 126 133 O
can NCT03865433 134 137 O
supervise NCT03865433 138 147 O
the NCT03865433 148 151 O
exercise NCT03865433 152 160 O
protocol NCT03865433 161 169 O
; NCT03865433 169 170 O

2 NCT03865433 173 174 O
. NCT03865433 174 175 O
have NCT03865433 177 181 O
sustained NCT03865433 182 191 O
a NCT03865433 192 193 O
concussion NCT03865433 194 204 B-Condition
within NCT03865433 205 211 B-Eq-Comparison
2 NCT03865433 212 213 I-Eq-Comparison
- NCT03865433 214 215 I-Eq-Comparison
7 NCT03865433 216 217 I-Eq-Comparison
days NCT03865433 218 222 I-Eq-Comparison
of NCT03865433 223 225 B-Temporal-Connection___Temporal-Connection-Type-Value:before
clinic NCT03865433 226 232 B-Encounter
presentation NCT03865433 233 245 I-Encounter
and NCT03865433 246 249 O
diagnosed NCT03865433 250 259 O
by NCT03865433 260 262 O
a NCT03865433 263 264 O
study NCT03865433 265 270 B-Study
physician NCT03865433 271 280 B-Provider
; NCT03865433 280 281 O

3 NCT03865433 284 285 O
. NCT03865433 285 286 O
demonstrate NCT03865433 288 299 O
symptom NCT03865433 300 307 O
exacerbation NCT03865433 308 320 O
during NCT03865433 321 327 O
a NCT03865433 328 329 O
graded NCT03865433 330 336 O
treadmill NCT03865433 337 346 O
exercise NCT03865433 347 355 O
test NCT03865433 356 360 O
and NCT03865433 361 364 O
can NCT03865433 365 368 O
not NCT03865433 368 371 O
complete NCT03865433 372 380 O
the NCT03865433 381 384 O
test NCT03865433 385 389 O
; NCT03865433 389 390 O

4 NCT03865433 393 394 O
. NCT03865433 394 395 O
are NCT03865433 397 400 O
currently NCT03865433 401 410 O
participating NCT03865433 411 424 O
in NCT03865433 425 427 O
a NCT03865433 428 429 O
school NCT03865433 430 436 O
or NCT03865433 437 439 O
club NCT03865433 440 444 O
sport NCT03865433 445 450 O
; NCT03865433 450 451 O

5 NCT03865433 454 455 O
. NCT03865433 455 456 O
are NCT03865433 458 461 O
English NCT03865433 462 469 O
speaking NCT03865433 470 478 O
and NCT03865433 479 482 O
capable NCT03865433 483 490 O
of NCT03865433 491 493 O
giving NCT03865433 494 500 O
assent NCT03865433 501 507 O

Exclusion NCT03865433 508 517 O
Criteria NCT03865433 518 526 O
: NCT03865433 527 528 O

1 NCT03865433 532 533 O
. NCT03865433 533 534 O
have NCT03865433 536 540 O
a NCT03865433 541 542 O
reported NCT03865433 543 551 O
history NCT03865433 552 559 B-Eq-Comparison
of NCT03865433 560 562 O
neurological NCT03865433 563 575 B-Condition
condition NCT03865433 576 585 I-Condition
or NCT03865433 586 588 B-Or
disorder NCT03865433 589 597 B-Condition
including NCT03865433 598 607 O
but NCT03865433 608 611 O
not NCT03865433 612 615 O
limited NCT03865433 616 623 O
to NCT03865433 624 626 O
brain NCT03865433 627 632 B-Procedure
surgery NCT03865433 633 640 I-Procedure
, NCT03865433 641 642 O
special NCT03865433 643 650 B-Procedure
education NCT03865433 651 660 I-Procedure
, NCT03865433 661 662 O
seizure NCT03865433 663 670 B-Condition
disorder NCT03865433 671 679 I-Condition
, NCT03865433 680 681 O
speech NCT03865433 682 688 B-Condition
pathology NCT03865433 689 698 I-Condition
, NCT03865433 699 700 O
previous NCT03865433 701 709 B-Eq-Comparison
diagnosis NCT03865433 710 719 O
of NCT03865433 720 722 O
Post NCT03865433 723 727 B-Condition
- NCT03865433 728 729 I-Condition
Concussion NCT03865433 730 740 I-Condition
Syndrome NCT03865433 741 749 I-Condition
( NCT03865433 750 751 O
PCS NCT03865433 752 755 B-Condition
) NCT03865433 756 757 O
, NCT03865433 759 760 O

2 NCT03865433 764 765 O
. NCT03865433 765 766 O
are NCT03865433 768 771 O
unwilling NCT03865433 772 781 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 782 784 O
exercise NCT03865433 785 793 B-Observation
, NCT03865433 794 795 O

3 NCT03865433 799 800 O
. NCT03865433 800 801 O
have NCT03865433 803 807 O
focal NCT03865433 808 813 B-Condition
neurologic NCT03865433 814 824 I-Condition
deficit NCT03865433 825 832 I-Condition
that NCT03865433 833 837 O
would NCT03865433 838 843 O
represent NCT03865433 844 853 O
risk NCT03865433 854 858 B-Risk
for NCT03865433 859 862 O
walking NCT03865433 863 870 B-Observation
/ NCT03865433 871 872 B-Or
running NCT03865433 873 880 B-Observation
on NCT03865433 881 883 O
treadmill NCT03865433 884 893 B-Modifier
, NCT03865433 894 895 O

4 NCT03865433 899 900 O
. NCT03865433 900 901 O
exhibit NCT03865433 903 910 O
an NCT03865433 911 913 O
inability NCT03865433 914 923 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 924 926 O
exercise NCT03865433 927 935 B-Observation
due NCT03865433 936 939 O
to NCT03865433 940 942 O
injury NCT03865433 943 949 B-Condition
, NCT03865433 950 951 O
known NCT03865433 952 957 O
heart NCT03865433 958 963 B-Condition
disease NCT03865433 964 971 I-Condition
, NCT03865433 972 973 O
or NCT03865433 974 976 B-Or
increased NCT03865433 977 986 O
cardiac NCT03865433 987 994 B-Condition
risk NCT03865433 995 999 B-Risk
, NCT03865433 1000 1001 O

5 NCT03865433 1005 1006 O
. NCT03865433 1006 1007 O
have NCT03865433 1009 1013 O
experienced NCT03865433 1014 1025 O
more NCT03865433 1026 1030 B-Eq-Comparison
than NCT03865433 1031 1035 I-Eq-Comparison
3 NCT03865433 1036 1037 I-Eq-Comparison
previous NCT03865433 1038 1046 B-Eq-Comparison
concussions NCT03865433 1047 1058 B-Condition
, NCT03865433 1059 1060 O

6 NCT03865433 1064 1065 O
. NCT03865433 1065 1066 O
have NCT03865433 1068 1072 O
suffered NCT03865433 1073 1081 B-Eq-Comparison
a NCT03865433 1082 1083 O
substantial NCT03865433 1084 1095 O
comorbidity NCT03865433 1096 1107 B-Condition
( NCT03865433 1108 1109 O
eg NCT03865433 1110 1112 O
, NCT03865433 1113 1114 O
cervical NCT03865433 1115 1123 B-Condition
injury NCT03865433 1124 1130 I-Condition
) NCT03865433 1131 1132 O
, NCT03865433 1134 1135 O

7 NCT03865433 1139 1140 O
. NCT03865433 1140 1141 O
currently NCT03865433 1143 1152 B-Eq-Comparison
taking NCT03865433 1153 1159 I-Eq-Comparison
β NCT03865433 1160 1161 B-Drug
- NCT03865433 1162 1163 I-Drug
blockers NCT03865433 1164 1172 I-Drug
, NCT03865433 1173 1174 O
calcium NCT03865433 1175 1182 B-Drug
channel NCT03865433 1183 1190 I-Drug
blockers NCT03865433 1191 1199 I-Drug
, NCT03865433 1200 1201 O
or NCT03865433 1202 1204 B-Or
prophylactic NCT03865433 1205 1217 B-Drug
headache NCT03865433 1218 1226 I-Drug
medications NCT03865433 1227 1238 I-Drug
( NCT03865433 1239 1240 O
e. NCT03865433 1241 1243 O
g. NCT03865433 1244 1246 O
, NCT03865433 1247 1248 O
amitriptyline NCT03865433 1249 1262 B-Drug
, NCT03865433 1263 1264 O
topiramate NCT03865433 1265 1275 B-Drug
) NCT03865433 1276 1277 O
, NCT03865433 1279 1280 O
or NCT03865433 1281 1283 B-Or

8 NCT03865433 1286 1287 O
. NCT03865433 1287 1288 O
have NCT03865433 1290 1294 O
a NCT03865433 1295 1296 O
resting NCT03865433 1297 1304 B-Modifier
blood NCT03865433 1305 1310 B-Observation
pressure NCT03865433 1311 1319 I-Observation
of NCT03865433 1320 1322 O
> NCT03865433 1323 1324 B-Eq-Comparison
140 NCT03865433 1325 1328 I-Eq-Comparison
/ NCT03865433 1329 1330 O
90 NCT03865433 1331 1333 O
. NCT03865433 1333 1334 O

9 NCT03865433 1338 1339 O
. NCT03865433 1339 1340 O
If NCT03865433 1342 1344 O
the NCT03865433 1345 1348 O
potential NCT03865433 1349 1358 O
participant NCT03865433 1359 1370 O
or NCT03865433 1371 1373 O
parent NCT03865433 1374 1380 O
/ NCT03865433 1381 1382 O
guardian NCT03865433 1383 1391 O
is NCT03865433 1392 1394 O
unable NCT03865433 1395 1401 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865433 1402 1404 O
fully NCT03865433 1405 1410 O
understand NCT03865433 1411 1421 O
the NCT03865433 1422 1425 O
study NCT03865433 1426 1431 B-Study
protocol NCT03865433 1432 1440 O
or NCT03865433 1441 1443 B-Or
study NCT03865433 1444 1449 B-Study
risks NCT03865433 1450 1455 B-Risk
due NCT03865433 1456 1459 O
to NCT03865433 1460 1462 O
injury NCT03865433 1463 1469 B-Condition
or NCT03865433 1470 1472 B-Or
developmental NCT03865433 1473 1486 B-Condition
delay NCT03865433 1487 1492 I-Condition
, NCT03865433 1493 1494 O
the NCT03865433 1495 1498 O
potential NCT03865433 1499 1508 O
participant NCT03865433 1509 1520 O
will NCT03865433 1521 1525 O
be NCT03865433 1526 1528 O
excluded NCT03865433 1529 1537 B-Negation
from NCT03865433 1538 1542 O
the NCT03865433 1543 1546 O
study NCT03865433 1547 1552 B-Study
. NCT03865433 1552 1553 O

Inclusion NCT03868670 0 9 O
Criteria NCT03868670 10 18 O
: NCT03868670 19 20 O

- NCT03868670 24 25 O
BMI NCT03868670 27 30 B-Observation
45 NCT03868670 31 33 B-Eq-Comparison
- NCT03868670 34 35 I-Eq-Comparison
60 NCT03868670 36 38 I-Eq-Comparison
kg NCT03868670 39 41 I-Eq-Comparison
/ NCT03868670 42 43 I-Eq-Comparison
m2 NCT03868670 44 46 I-Eq-Comparison

- NCT03868670 49 50 O
Failure NCT03868670 52 59 O
of NCT03868670 60 62 O
at NCT03868670 63 65 B-Eq-Comparison
least NCT03868670 66 71 I-Eq-Comparison
one NCT03868670 72 75 I-Eq-Comparison
weight NCT03868670 76 82 B-Drug
loss NCT03868670 83 87 I-Drug
medication NCT03868670 88 98 I-Drug

- NCT03868670 101 102 O
Previous NCT03868670 104 112 B-Eq-Comparison
Gastric NCT03868670 113 120 B-Procedure
Bypass NCT03868670 121 127 I-Procedure
Surgery NCT03868670 128 135 I-Procedure
lead NCT03868670 136 140 O
to NCT03868670 141 143 O
less NCT03868670 144 148 B-Eq-Comparison
than NCT03868670 149 153 I-Eq-Comparison
50 NCT03868670 154 156 I-Eq-Comparison
% NCT03868670 157 158 I-Eq-Comparison
of NCT03868670 159 161 O
excess NCT03868670 162 168 B-Observation
weight NCT03868670 169 175 I-Observation
lost NCT03868670 176 180 O
by NCT03868670 181 183 O
2 NCT03868670 184 185 B-Eq-Comparison
years NCT03868670 186 191 I-Eq-Comparison
after NCT03868670 192 197 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03868670 198 205 B-Coreference

- NCT03868670 208 209 O
Significant NCT03868670 211 222 O
Loss NCT03868670 223 227 B-Condition
of NCT03868670 228 230 I-Condition
Control NCT03868670 231 238 I-Condition
over NCT03868670 239 243 O
eating NCT03868670 244 250 B-Modifier

- NCT03868670 253 254 O
Subject NCT03868670 256 263 O
is NCT03868670 264 266 O
able NCT03868670 267 271 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 272 274 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03868670 275 281 O
all NCT03868670 282 285 O
scheduled NCT03868670 286 295 B-Eq-Comparison
clinic NCT03868670 296 302 B-Encounter
appointments NCT03868670 303 315 I-Encounter
on NCT03868670 316 318 O
their NCT03868670 319 324 O
own NCT03868670 325 328 O
or NCT03868670 329 331 O
with NCT03868670 332 336 O
a NCT03868670 337 338 O
caregiver NCT03868670 339 348 O
. NCT03868670 349 350 O

- NCT03868670 354 355 O
Premenopausal NCT03868670 357 370 B-Condition
women NCT03868670 371 376 O
must NCT03868670 377 381 O
agree NCT03868670 382 387 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 388 390 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03868670 391 394 O
acceptable NCT03868670 395 405 O
methods NCT03868670 406 413 O
of NCT03868670 414 416 O
birth NCT03868670 417 422 B-Procedure
control NCT03868670 423 430 I-Procedure
. NCT03868670 431 432 O

- NCT03868670 436 437 O
Participants NCT03868670 439 451 O
provide NCT03868670 452 459 O
voluntary NCT03868670 460 469 O
, NCT03868670 470 471 O
decisionally NCT03868670 472 484 O
capable NCT03868670 485 492 O
, NCT03868670 493 494 O
and NCT03868670 495 498 O
appropriately NCT03868670 499 512 O
informed NCT03868670 513 521 O
consent NCT03868670 522 529 O
. NCT03868670 530 531 O

- NCT03868670 535 536 O
Subject NCT03868670 538 545 O
is NCT03868670 546 548 O
able NCT03868670 549 553 O
to NCT03868670 554 556 O
comply NCT03868670 557 563 O
w NCT03868670 564 565 O
/ NCT03868670 566 567 O
all NCT03868670 568 571 O
testing NCT03868670 572 579 O
and NCT03868670 580 583 O
follow NCT03868670 584 590 O
- NCT03868670 591 592 O
up NCT03868670 593 595 O
requirements NCT03868670 596 608 O
defined NCT03868670 609 616 O
by NCT03868670 617 619 O
the NCT03868670 620 623 O
study NCT03868670 624 629 O
protocol NCT03868670 630 638 O
. NCT03868670 639 640 O

- NCT03868670 644 645 O
Participant NCT03868670 647 658 O
has NCT03868670 659 662 O
no NCT03868670 663 665 B-Negation
immediate NCT03868670 666 675 O
plan NCT03868670 676 680 B-Assertion___Assertion-Type-Value:intention
for NCT03868670 681 684 O
relocation NCT03868670 685 695 B-Observation
beyond NCT03868670 696 702 B-Eq-Comparison
6 NCT03868670 703 704 I-Eq-Comparison
hours NCT03868670 705 710 I-Eq-Comparison
of NCT03868670 711 713 O
the NCT03868670 714 717 O
study NCT03868670 718 723 B-Study
site NCT03868670 724 728 O
. NCT03868670 729 730 O

- NCT03868670 734 735 O
Proficiency NCT03868670 737 748 O
with NCT03868670 749 753 O
the NCT03868670 754 757 O
English NCT03868670 758 765 O
language NCT03868670 766 774 O
. NCT03868670 775 776 O

Exclusion NCT03868670 778 787 O
Criteria NCT03868670 788 796 O
: NCT03868670 797 798 O

- NCT03868670 802 803 O
Subject NCT03868670 805 812 O
has NCT03868670 813 816 O
an NCT03868670 817 819 O
implanted NCT03868670 820 829 B-Procedure
medical NCT03868670 830 837 I-Procedure
device NCT03868670 838 844 I-Procedure
that NCT03868670 845 849 O
delivers NCT03868670 850 858 O
electrical NCT03868670 859 869 B-Procedure
energy NCT03868670 870 876 I-Procedure
to NCT03868670 877 879 O
the NCT03868670 880 883 O
brain NCT03868670 884 889 B-Modifier
. NCT03868670 890 891 O

- NCT03868670 895 896 O
Subject NCT03868670 898 905 O
has NCT03868670 906 909 O
an NCT03868670 910 912 O
implantable NCT03868670 913 924 B-Procedure
cardiac NCT03868670 925 932 I-Procedure
pacemaker NCT03868670 933 942 I-Procedure
, NCT03868670 943 944 O
defibrillator NCT03868670 945 958 B-Procedure
, NCT03868670 959 960 O
or NCT03868670 961 963 B-Or
neurostimulator NCT03868670 964 979 B-Procedure
. NCT03868670 980 981 O

- NCT03868670 985 986 O
Subject NCT03868670 988 995 O
is NCT03868670 996 998 O
likely NCT03868670 999 1005 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868670 1006 1008 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03868670 1009 1016 O
repeat NCT03868670 1017 1023 B-Modifier
MR NCT03868670 1024 1026 B-Procedure
imaging NCT03868670 1027 1034 I-Procedure
after NCT03868670 1035 1040 B-Temporal-Connection___Temporal-Connection-Type-Value:after
implant NCT03868670 1041 1048 B-Procedure
of NCT03868670 1049 1051 I-Procedure
the NCT03868670 1052 1055 I-Procedure
RNS NCT03868670 1056 1059 I-Procedure
Neurostimulator NCT03868670 1060 1075 B-Modifier
and NCT03868670 1076 1079 B-Or
Leads NCT03868670 1080 1085 B-Modifier
. NCT03868670 1086 1087 O

- NCT03868670 1091 1092 O
Subject NCT03868670 1094 1101 O
is NCT03868670 1102 1104 O
unable NCT03868670 1105 1111 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868670 1112 1114 O
fit NCT03868670 1115 1118 O
into NCT03868670 1119 1123 O
CT NCT03868670 1124 1126 B-Procedure
scanner NCT03868670 1127 1134 I-Procedure
( NCT03868670 1135 1136 O
500 NCT03868670 1137 1140 B-Eq-Comparison
lb NCT03868670 1141 1143 I-Eq-Comparison
upper NCT03868670 1144 1149 I-Eq-Comparison
weight NCT03868670 1150 1156 B-Observation
limit NCT03868670 1157 1162 O
for NCT03868670 1163 1166 O
CT NCT03868670 1167 1169 B-Procedure
scanner NCT03868670 1170 1177 I-Procedure
) NCT03868670 1178 1179 O
. NCT03868670 1181 1182 O

- NCT03868670 1186 1187 O
Inability NCT03868670 1189 1198 O
to NCT03868670 1199 1201 O
provide NCT03868670 1202 1209 O
informed NCT03868670 1210 1218 O
consent NCT03868670 1219 1226 O
to NCT03868670 1227 1229 O
treatment NCT03868670 1230 1239 O
. NCT03868670 1239 1240 O

Inclusion NCT03865368 0 9 O
Criteria NCT03865368 10 18 O
: NCT03865368 19 20 O

- NCT03865368 24 25 O
Individuals NCT03865368 27 38 O
between NCT03865368 39 46 B-Eq-Comparison
age NCT03865368 47 50 I-Eq-Comparison
18 NCT03865368 51 53 I-Eq-Comparison
- NCT03865368 54 55 I-Eq-Comparison
65 NCT03865368 56 58 I-Eq-Comparison
with NCT03865368 59 63 B-And
Body NCT03865368 64 68 B-Observation
Mass NCT03865368 69 73 I-Observation
Index NCT03865368 74 79 I-Observation
( NCT03865368 80 81 O
BMI NCT03865368 82 85 B-Observation
) NCT03865368 86 87 O
of NCT03865368 88 90 O
> NCT03865368 91 92 B-Eq-Comparison
29.9 NCT03865368 93 97 I-Eq-Comparison
kg NCT03865368 98 100 I-Eq-Comparison
/ NCT03865368 101 102 I-Eq-Comparison
m2 NCT03865368 103 105 I-Eq-Comparison

Exclusion NCT03865368 106 115 O
Criteria NCT03865368 116 124 O
: NCT03865368 125 126 O

- NCT03865368 130 131 O
Unstable NCT03865368 133 141 O
hypertensive NCT03865368 142 154 B-Condition
patients NCT03865368 155 163 O

- NCT03865368 166 167 O
History NCT03865368 169 176 B-Eq-Comparison
of NCT03865368 177 179 O
cardiovascular NCT03865368 180 194 B-Modifier
, NCT03865368 195 196 O
neurologic NCT03865368 197 207 B-Modifier
, NCT03865368 208 209 O
or NCT03865368 210 212 B-Or
orthopedic NCT03865368 213 223 B-Modifier
diseases NCT03865368 224 232 B-Condition
, NCT03865368 233 234 O

- NCT03865368 238 239 O
Presence NCT03865368 241 249 O
of NCT03865368 250 252 O
knee NCT03865368 253 257 B-Procedure
prosthesis NCT03865368 258 268 I-Procedure
, NCT03865368 269 270 O
hip NCT03865368 271 274 B-Procedure
replacement NCT03865368 275 286 I-Procedure

- NCT03865368 289 290 O
Chronic NCT03865368 292 299 B-Modifier
inflammatory NCT03865368 300 312 B-Condition
disease NCT03865368 313 320 I-Condition
, NCT03865368 321 322 O

- NCT03865368 326 327 O
Anti NCT03865368 329 333 B-Procedure
- NCT03865368 334 335 I-Procedure
inflammatory NCT03865368 336 348 I-Procedure
treatment NCT03865368 349 358 I-Procedure

- NCT03865368 361 362 O
Cognitive NCT03865368 364 373 B-Condition
impairments NCT03865368 374 385 I-Condition

- NCT03865368 388 389 O
Pregnancy NCT03865368 391 400 B-Condition
. NCT03865368 400 401 O

Inclusion NCT03863080 0 9 O
Criteria NCT03863080 10 18 O
: NCT03863080 19 20 O

1 NCT03863080 24 25 O
. NCT03863080 25 26 O
Male NCT03863080 28 32 O
or NCT03863080 33 35 B-Or
female NCT03863080 36 42 O
≥ NCT03863080 43 44 B-Eq-Comparison
18 NCT03863080 45 47 I-Eq-Comparison
years NCT03863080 48 53 I-Eq-Comparison
of NCT03863080 54 56 O
age NCT03863080 57 60 B-Age
. NCT03863080 61 62 O

2 NCT03863080 66 67 O
. NCT03863080 67 68 O
Myasthenia NCT03863080 70 80 B-Condition
Gravis NCT03863080 81 87 I-Condition
Foundation NCT03863080 88 98 I-Condition
of NCT03863080 99 101 I-Condition
America NCT03863080 102 109 I-Condition
( NCT03863080 110 111 O
MGFA NCT03863080 112 116 B-Condition
) NCT03863080 117 118 O
Class NCT03863080 119 124 B-Eq-Comparison
II NCT03863080 125 127 I-Eq-Comparison
- NCT03863080 128 129 I-Eq-Comparison
IVa NCT03863080 130 133 I-Eq-Comparison
and NCT03863080 134 137 B-And
likely NCT03863080 138 144 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03863080 145 148 B-Negation
in NCT03863080 149 151 O
need NCT03863080 152 156 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863080 157 159 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03863080 160 161 O
respirator NCT03863080 162 172 B-Procedure
for NCT03863080 173 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863080 177 180 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03863080 181 189 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863080 190 192 O
the NCT03863080 193 196 O
study NCT03863080 197 202 B-Study
as NCT03863080 203 205 O
judged NCT03863080 206 212 O
by NCT03863080 213 215 O
the NCT03863080 216 219 O
Investigator NCT03863080 220 232 O
. NCT03863080 233 234 O

3 NCT03863080 238 239 O
. NCT03863080 239 240 O
QMG NCT03863080 242 245 B-Observation
score NCT03863080 246 251 O
≥ NCT03863080 252 253 B-Eq-Comparison
12 NCT03863080 254 256 I-Eq-Comparison
at NCT03863080 257 259 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03863080 260 269 B-Study
and NCT03863080 270 273 B-And
Baseline NCT03863080 274 282 B-Study
. NCT03863080 283 284 O

Other NCT03863080 286 291 O
, NCT03863080 292 293 O
more NCT03863080 294 298 O
specific NCT03863080 299 307 O
inclusion NCT03863080 308 317 O
criteria NCT03863080 318 326 O
are NCT03863080 327 330 O
defined NCT03863080 331 338 O
in NCT03863080 339 341 O
the NCT03863080 342 345 O
protocol NCT03863080 346 354 O
. NCT03863080 355 356 O

Exclusion NCT03863080 358 367 O
Criteria NCT03863080 368 376 O
: NCT03863080 377 378 O

1 NCT03863080 382 383 O
. NCT03863080 383 384 O
Use NCT03863080 386 389 O
of NCT03863080 390 392 O
rituximab NCT03863080 393 402 B-Drug
, NCT03863080 403 404 O
belimumab NCT03863080 405 414 B-Drug
, NCT03863080 415 416 O
eculizumab NCT03863080 417 427 B-Drug
or NCT03863080 428 430 B-Or
any NCT03863080 431 434 O
monoclonal NCT03863080 435 445 B-Drug
antibody NCT03863080 446 454 I-Drug
for NCT03863080 455 458 O
immunomodulation NCT03863080 459 475 B-Procedure
within NCT03863080 476 482 B-Eq-Comparison
6 NCT03863080 483 484 I-Eq-Comparison
months NCT03863080 485 491 I-Eq-Comparison
prior NCT03863080 492 497 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863080 498 500 O
first NCT03863080 501 506 B-Eq-Comparison
dosing NCT03863080 507 513 B-Procedure
. NCT03863080 514 515 O

2 NCT03863080 519 520 O
. NCT03863080 520 521 O
Immunoglobulins NCT03863080 523 538 B-Drug
given NCT03863080 539 544 O
by NCT03863080 545 547 O
SC NCT03863080 548 550 B-Modifier
, NCT03863080 551 552 O
IV NCT03863080 553 555 B-Modifier
( NCT03863080 556 557 O
IVIG NCT03863080 558 562 B-Modifier
) NCT03863080 563 564 O
, NCT03863080 566 567 O
or NCT03863080 568 570 B-Or
intramuscular NCT03863080 571 584 B-Modifier
route NCT03863080 585 590 I-Modifier
, NCT03863080 591 592 O
or NCT03863080 593 595 B-Or
plasmapheresis NCT03863080 596 610 B-Procedure
/ NCT03863080 611 612 O
plasma NCT03863080 613 619 B-Procedure
exchange NCT03863080 620 628 I-Procedure
( NCT03863080 629 630 O
PE NCT03863080 631 633 B-Procedure
) NCT03863080 634 635 O
within NCT03863080 636 642 B-Eq-Comparison
4 NCT03863080 643 644 I-Eq-Comparison
weeks NCT03863080 645 650 I-Eq-Comparison
before NCT03863080 651 657 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Screening NCT03863080 658 667 B-Study
. NCT03863080 668 669 O

3 NCT03863080 673 674 O
. NCT03863080 674 675 O
Thymectomy NCT03863080 677 687 B-Procedure
performed NCT03863080 688 697 O
< NCT03863080 698 699 B-Eq-Comparison
12 NCT03863080 700 702 I-Eq-Comparison
months NCT03863080 703 709 I-Eq-Comparison
prior NCT03863080 710 715 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863080 716 718 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03863080 719 728 B-Study
. NCT03863080 729 730 O

4 NCT03863080 734 735 O
. NCT03863080 735 736 O
Total NCT03863080 738 743 B-Observation
IgG NCT03863080 744 747 I-Observation
level NCT03863080 748 753 O
< NCT03863080 754 755 B-Eq-Comparison
6 NCT03863080 756 757 I-Eq-Comparison
g NCT03863080 758 759 I-Eq-Comparison
/ NCT03863080 760 761 I-Eq-Comparison
L NCT03863080 762 763 I-Eq-Comparison
( NCT03863080 764 765 O
at NCT03863080 766 768 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863080 769 778 B-Study
) NCT03863080 779 780 O
. NCT03863080 782 783 O

5 NCT03863080 787 788 O
. NCT03863080 788 789 O
Absolute NCT03863080 791 799 B-Observation
neutrophil NCT03863080 800 810 I-Observation
count NCT03863080 811 816 I-Observation
< NCT03863080 817 818 B-Eq-Comparison
1500 NCT03863080 819 823 I-Eq-Comparison
cells NCT03863080 824 829 I-Eq-Comparison
/ NCT03863080 830 831 I-Eq-Comparison
mm3 NCT03863080 832 835 I-Eq-Comparison
( NCT03863080 836 837 O
at NCT03863080 838 840 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863080 841 850 B-Study
) NCT03863080 851 852 O
. NCT03863080 854 855 O

Other NCT03863080 857 862 O
, NCT03863080 863 864 O
more NCT03863080 865 869 O
specific NCT03863080 870 878 O
exclusion NCT03863080 879 888 O
criteria NCT03863080 889 897 O
are NCT03863080 898 901 O
defined NCT03863080 902 909 O
in NCT03863080 910 912 O
the NCT03863080 913 916 O
protocol NCT03863080 917 925 O

Inclusion NCT03861442 0 9 O
Criteria NCT03861442 10 18 O
: NCT03861442 19 20 O

- NCT03861442 24 25 O
A NCT03861442 27 28 O
minimum NCT03861442 29 36 B-Eq-Comparison
of NCT03861442 37 39 I-Eq-Comparison
18 NCT03861442 40 42 I-Eq-Comparison
years NCT03861442 43 48 I-Eq-Comparison
old NCT03861442 49 52 B-Age

- NCT03861442 55 56 O
Experienced NCT03861442 58 69 O
user NCT03861442 70 74 O
( NCT03861442 75 76 O
≥ NCT03861442 78 79 B-Eq-Comparison
6 NCT03861442 80 81 I-Eq-Comparison
months NCT03861442 82 88 I-Eq-Comparison
) NCT03861442 89 90 O
of NCT03861442 91 93 O
a NCT03861442 94 95 O
MED NCT03861442 96 99 B-Procedure
- NCT03861442 100 101 I-Procedure
EL NCT03861442 102 104 I-Procedure
cochlear NCT03861442 105 113 I-Procedure
implant NCT03861442 114 121 I-Procedure
( NCT03861442 122 123 O
CI NCT03861442 124 126 B-Modifier
; NCT03861442 126 127 O
C40 NCT03861442 128 131 B-Modifier
+ NCT03861442 132 133 I-Modifier
and NCT03861442 134 137 O
later NCT03861442 138 143 O
model NCT03861442 144 149 O
) NCT03861442 150 151 O

- NCT03861442 155 156 O
Experienced NCT03861442 158 169 O
user NCT03861442 170 174 O
of NCT03861442 175 177 O
a NCT03861442 178 179 O
MED NCT03861442 180 183 B-Procedure
- NCT03861442 184 185 I-Procedure
EL NCT03861442 186 188 I-Procedure
SONNET NCT03861442 189 195 I-Procedure
audio NCT03861442 196 201 I-Procedure
processor NCT03861442 202 211 I-Procedure
( NCT03861442 212 213 O
≥ NCT03861442 215 216 B-Eq-Comparison
6 NCT03861442 217 218 I-Eq-Comparison
months NCT03861442 219 225 I-Eq-Comparison
) NCT03861442 226 227 O

- NCT03861442 231 232 O
Post NCT03861442 234 238 B-Modifier
- NCT03861442 239 240 I-Modifier
lingual NCT03861442 241 248 I-Modifier
onset NCT03861442 249 254 B-Eq-Comparison
of NCT03861442 255 257 O
bilateral NCT03861442 258 267 B-Modifier
severe NCT03861442 268 274 B-Eq-Comparison
to NCT03861442 275 277 I-Eq-Comparison
profound NCT03861442 278 286 I-Eq-Comparison
sensory NCT03861442 287 294 B-Condition
- NCT03861442 295 296 I-Condition
neural NCT03861442 297 303 I-Condition
hearing NCT03861442 304 311 I-Condition
loss NCT03861442 312 316 I-Condition

- NCT03861442 319 320 O
Unilateral NCT03861442 322 332 B-Procedure
CI NCT03861442 333 335 I-Procedure
user NCT03861442 336 340 O

- NCT03861442 343 344 O
A NCT03861442 346 347 O
minimum NCT03861442 348 355 B-Eq-Comparison
of NCT03861442 356 358 I-Eq-Comparison
10 NCT03861442 359 361 I-Eq-Comparison
active NCT03861442 362 368 B-Eq-Comparison
electrodes NCT03861442 369 379 B-Procedure

- NCT03861442 382 383 O
A NCT03861442 385 386 O
minimum NCT03861442 387 394 B-Eq-Comparison
of NCT03861442 395 397 I-Eq-Comparison
40 NCT03861442 398 400 I-Eq-Comparison
% NCT03861442 401 402 I-Eq-Comparison
speech NCT03861442 403 409 B-Modifier
recognition NCT03861442 410 421 I-Modifier
in NCT03861442 422 424 O
the NCT03861442 425 428 O
Freiburg NCT03861442 429 437 B-Observation
Monosyllables NCT03861442 438 451 I-Observation
test NCT03861442 452 456 I-Observation
in NCT03861442 457 459 O
quiet NCT03861442 460 465 B-Modifier
at NCT03861442 466 468 I-Modifier
65 NCT03861442 469 471 I-Modifier
dB NCT03861442 472 474 I-Modifier
sound NCT03861442 475 480 I-Modifier
pressure NCT03861442 481 489 I-Modifier
level NCT03861442 490 495 I-Modifier
( NCT03861442 496 497 O
SPL NCT03861442 498 501 B-Modifier
; NCT03861442 501 502 O
at NCT03861442 503 505 O
the NCT03861442 506 509 O
last NCT03861442 510 514 B-Eq-Comparison
time NCT03861442 515 519 I-Eq-Comparison
tested NCT03861442 520 526 O
) NCT03861442 527 528 O

- NCT03861442 532 533 O
Fluent NCT03861442 535 541 O
in NCT03861442 542 544 O
German NCT03861442 545 551 O
( NCT03861442 552 553 O
the NCT03861442 554 557 O
language NCT03861442 558 566 O
of NCT03861442 567 569 O
the NCT03861442 570 573 O
test NCT03861442 574 578 O
centre NCT03861442 579 585 O
) NCT03861442 586 587 O

- NCT03861442 591 592 O
Signed NCT03861442 594 600 O
and NCT03861442 601 604 O
dated NCT03861442 605 610 O
Informed NCT03861442 611 619 O
Consent NCT03861442 620 627 O
Form NCT03861442 628 632 O
before NCT03861442 633 639 O
the NCT03861442 640 643 O
start NCT03861442 644 649 O
of NCT03861442 650 652 O
any NCT03861442 653 656 O
study NCT03861442 657 662 O
- NCT03861442 663 664 O
specific NCT03861442 665 673 O
procedure NCT03861442 674 683 O
. NCT03861442 684 685 O

Exclusion NCT03861442 687 696 O
Criteria NCT03861442 697 705 O
: NCT03861442 706 707 O

- NCT03861442 711 712 O
Lack NCT03861442 714 718 O
of NCT03861442 719 721 O
compliance NCT03861442 722 732 O
with NCT03861442 733 737 O
any NCT03861442 738 741 O
inclusion NCT03861442 742 751 O
criteria NCT03861442 752 760 O

- NCT03861442 763 764 O
CI NCT03861442 766 768 B-Procedure
user NCT03861442 769 773 O
with NCT03861442 774 778 B-And
contralateral NCT03861442 779 792 B-Condition
hearing NCT03861442 793 800 I-Condition
equal NCT03861442 801 806 B-Eq-Comparison
to NCT03861442 807 809 I-Eq-Comparison
or NCT03861442 810 812 I-Eq-Comparison
better NCT03861442 813 819 I-Eq-Comparison
than NCT03861442 820 824 I-Eq-Comparison
60 NCT03861442 825 827 I-Eq-Comparison
dB NCT03861442 828 830 I-Eq-Comparison
( NCT03861442 831 832 O
PTA NCT03861442 833 836 B-Observation
measured NCT03861442 837 845 O
at NCT03861442 846 848 O
500 NCT03861442 849 852 B-Eq-Comparison
, NCT03861442 853 854 I-Eq-Comparison
1000 NCT03861442 855 859 I-Eq-Comparison
, NCT03861442 860 861 I-Eq-Comparison
and NCT03861442 862 865 I-Eq-Comparison
2000 NCT03861442 866 870 I-Eq-Comparison
Hz NCT03861442 871 873 I-Eq-Comparison
) NCT03861442 874 875 O

- NCT03861442 882 883 O
User NCT03861442 885 889 O
with NCT03861442 890 894 O
electric NCT03861442 895 903 B-Procedure
- NCT03861442 904 905 I-Procedure
acoustic NCT03861442 906 914 I-Procedure
stimulation NCT03861442 915 926 I-Procedure
( NCT03861442 927 928 O
EAS NCT03861442 929 932 B-Procedure
; NCT03861442 932 933 O
user NCT03861442 934 938 O
of NCT03861442 939 941 O
an NCT03861442 942 944 O
EAS NCT03861442 945 948 B-Procedure
audio NCT03861442 949 954 I-Procedure
processor NCT03861442 955 964 I-Procedure
) NCT03861442 965 966 O

- NCT03861442 970 971 O
Implanted NCT03861442 973 982 B-Procedure
with NCT03861442 983 987 O
C40 NCT03861442 988 991 B-Modifier
X NCT03861442 992 993 I-Modifier
and NCT03861442 994 997 B-Or
C40 NCT03861442 998 1001 B-Modifier
C NCT03861442 1002 1003 I-Modifier

- NCT03861442 1006 1007 O
Implanted NCT03861442 1009 1018 B-Procedure
with NCT03861442 1019 1023 O
an NCT03861442 1024 1026 O
Auditory NCT03861442 1027 1035 B-Modifier
Brainstem NCT03861442 1036 1045 I-Modifier
Implant NCT03861442 1046 1053 I-Modifier
or NCT03861442 1054 1056 B-Or
Split NCT03861442 1057 1062 B-Modifier
electrode NCT03861442 1063 1072 I-Modifier
array NCT03861442 1073 1078 I-Modifier

- NCT03861442 1081 1082 O
Known NCT03861442 1084 1089 O
allergic NCT03861442 1090 1098 B-Allergy
reactions NCT03861442 1099 1108 O
to NCT03861442 1109 1111 O
components NCT03861442 1112 1122 O
of NCT03861442 1123 1125 O
the NCT03861442 1126 1129 O
investigational NCT03861442 1130 1145 B-Study
medical NCT03861442 1146 1153 B-Procedure
device NCT03861442 1154 1160 I-Procedure

- NCT03861442 1163 1164 O
Unstable NCT03861442 1166 1174 O
psychological NCT03861442 1175 1188 B-Condition
status NCT03861442 1189 1195 I-Condition

- NCT03861442 1198 1199 O
Anything NCT03861442 1201 1209 O
that NCT03861442 1210 1214 O
, NCT03861442 1215 1216 O
in NCT03861442 1217 1219 O
the NCT03861442 1220 1223 O
opinion NCT03861442 1224 1231 O
of NCT03861442 1232 1234 O
the NCT03861442 1235 1238 O
Investigator NCT03861442 1239 1251 O
, NCT03861442 1252 1253 O
would NCT03861442 1254 1259 B-Assertion___Assertion-Type-Value:hypothetical
place NCT03861442 1260 1265 O
the NCT03861442 1266 1269 O
subject NCT03861442 1270 1277 O
at NCT03861442 1278 1280 O
increased NCT03861442 1281 1290 O
risk NCT03861442 1291 1295 B-Risk
or NCT03861442 1296 1298 B-Or
preclude NCT03861442 1299 1307 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03861442 1308 1311 O
subject NCT03861442 1312 1319 O
's NCT03861442 1319 1321 O
full NCT03861442 1322 1326 O
compliance NCT03861442 1327 1337 O
with NCT03861442 1338 1342 O
or NCT03861442 1343 1345 O
completion NCT03861442 1346 1356 O
of NCT03861442 1357 1359 O
the NCT03861442 1360 1363 O
study NCT03861442 1364 1369 B-Study


Inclusion NCT03860012 0 9 O
Criteria NCT03860012 10 18 O
: NCT03860012 19 20 O

1 NCT03860012 24 25 O
. NCT03860012 25 26 O
inflammatory NCT03860012 28 40 B-Condition
bowel NCT03860012 41 46 I-Condition
disease NCT03860012 47 54 I-Condition

2 NCT03860012 57 58 O
. NCT03860012 58 59 O
on NCT03860012 61 63 B-Eq-Comparison
methotrexate NCT03860012 64 76 B-Drug
at NCT03860012 77 79 O
appropriate NCT03860012 80 91 O
dosing NCT03860012 92 98 O

3 NCT03860012 101 102 O
. NCT03860012 102 103 O
normal NCT03860012 105 111 O
folate NCT03860012 112 118 B-Observation
levels NCT03860012 119 125 I-Observation
at NCT03860012 126 128 O
onset NCT03860012 129 134 B-Eq-Comparison
of NCT03860012 135 137 O
study NCT03860012 138 143 B-Study

4 NCT03860012 146 147 O
. NCT03860012 147 148 O
treatment NCT03860012 150 159 B-Procedure
with NCT03860012 160 164 O
folic NCT03860012 165 170 B-Drug
acid NCT03860012 171 175 I-Drug

5 NCT03860012 178 179 O
. NCT03860012 179 180 O
ages NCT03860012 182 186 B-Age
2 NCT03860012 187 188 B-Eq-Comparison
- NCT03860012 189 190 I-Eq-Comparison
21 NCT03860012 191 193 I-Eq-Comparison
years NCT03860012 194 199 I-Eq-Comparison

Exclusion NCT03860012 200 209 O
Criteria NCT03860012 210 218 O
: NCT03860012 219 220 O

1 NCT03860012 224 225 O
. NCT03860012 225 226 O
abnormal NCT03860012 228 236 O
folate NCT03860012 237 243 B-Observation
levels NCT03860012 244 250 I-Observation

2 NCT03860012 253 254 O
. NCT03860012 254 255 O
age NCT03860012 257 260 B-Age
> NCT03860012 261 262 B-Eq-Comparison
21 NCT03860012 263 265 I-Eq-Comparison
or NCT03860012 266 268 B-Or
less NCT03860012 269 273 B-Eq-Comparison
than NCT03860012 274 278 I-Eq-Comparison
2 NCT03860012 279 280 I-Eq-Comparison

Inclusion NCT03866265 0 9 O
Criteria NCT03866265 10 18 O
: NCT03866265 19 20 O

- NCT03866265 24 25 O
The NCT03866265 27 30 O
selection NCT03866265 31 40 O
criteria NCT03866265 41 49 O
of NCT03866265 50 52 O
the NCT03866265 53 56 O
subjects NCT03866265 57 65 O
will NCT03866265 66 70 O
be NCT03866265 71 73 O
as NCT03866265 74 76 O
follows NCT03866265 77 84 O
: NCT03866265 85 86 O

1 NCT03866265 95 96 O
. NCT03866265 96 97 O
they NCT03866265 99 103 O
need NCT03866265 104 108 O
to NCT03866265 109 111 O
be NCT03866265 112 114 O
off NCT03866265 115 118 B-Negation
medication NCT03866265 119 129 B-Drug
and NCT03866265 130 133 B-And
off NCT03866265 134 137 B-Negation
intake NCT03866265 138 144 O
of NCT03866265 145 147 O
dietary NCT03866265 148 155 B-Drug
supplements NCT03866265 156 167 I-Drug

2 NCT03866265 175 176 O
. NCT03866265 176 177 O
they NCT03866265 179 183 O
need NCT03866265 184 188 O
to NCT03866265 189 191 O
have NCT03866265 192 196 O
no NCT03866265 197 199 B-Negation
blood NCT03866265 200 205 B-Condition
clotting NCT03866265 206 214 I-Condition
disorders NCT03866265 215 224 I-Condition
or NCT03866265 225 227 B-Or
dyslipidaemia NCT03866265 228 241 B-Condition
and NCT03866265 242 245 B-And

Exclusion NCT03866265 246 255 O
Criteria NCT03866265 256 264 O
: NCT03866265 265 266 O

Subjects NCT03866265 268 276 O
with NCT03866265 277 281 O
clotting NCT03866265 282 290 B-Condition
disorders NCT03866265 291 300 I-Condition
, NCT03866265 301 302 O
dyslipidemia NCT03866265 303 315 B-Condition
or NCT03866265 316 318 B-Or
being NCT03866265 319 324 O
on NCT03866265 325 327 B-Eq-Comparison
medication NCT03866265 328 338 B-Drug
( NCT03866265 339 340 O
i. NCT03866265 341 343 O
e. NCT03866265 344 346 O
statins NCT03866265 348 355 B-Drug
) NCT03866265 356 357 O
or NCT03866265 358 360 B-Or
other NCT03866265 361 366 B-Other
supplements NCT03866265 367 378 B-Drug
during NCT03866265 379 385 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866265 386 389 O
study NCT03866265 390 395 B-Study
will NCT03866265 396 400 O
be NCT03866265 401 403 O
excluded NCT03866265 404 412 B-Negation
. NCT03866265 413 414 O


Inclusion NCT03862573 0 9 O
Criteria NCT03862573 10 18 O
: NCT03862573 19 20 O

1 NCT03862573 24 25 O
. NCT03862573 25 26 O
Children NCT03862573 28 36 O
age NCT03862573 37 40 B-Age
4 NCT03862573 41 42 B-Eq-Comparison
to NCT03862573 43 45 I-Eq-Comparison
< NCT03862573 46 47 I-Eq-Comparison
17 NCT03862573 48 50 I-Eq-Comparison
years NCT03862573 51 56 I-Eq-Comparison

2 NCT03862573 59 60 O
. NCT03862573 60 61 O
Arriving NCT03862573 63 71 B-Encounter
to NCT03862573 72 74 O
the NCT03862573 75 78 O
UBC NCT03862573 79 82 O
dentistry NCT03862573 83 92 O
clinic NCT03862573 93 99 O
and NCT03862573 100 103 B-And
need NCT03862573 104 108 B-Assertion___Assertion-Type-Value:hypothetical
dental NCT03862573 109 115 B-Procedure
assessment NCT03862573 116 126 B-Modifier
/ NCT03862573 127 128 B-Or
procedures NCT03862573 129 139 B-Modifier

3 NCT03862573 142 143 O
. NCT03862573 143 144 O
Parents NCT03862573 146 153 O
will NCT03862573 154 158 O
sign NCT03862573 159 163 O
a NCT03862573 164 165 O
consent NCT03862573 166 173 O
form NCT03862573 174 178 O
and NCT03862573 179 182 O
children NCT03862573 183 191 O
will NCT03862573 192 196 O
sign NCT03862573 197 201 O
an NCT03862573 202 204 O
assent NCT03862573 205 211 O
form NCT03862573 212 216 O

Exclusion NCT03862573 217 226 O
Criteria NCT03862573 227 235 O
: NCT03862573 236 237 O

1 NCT03862573 241 242 O
. NCT03862573 242 243 O
Children NCT03862573 245 253 O
with NCT03862573 254 258 B-And
conditions NCT03862573 259 269 B-Condition
that NCT03862573 270 274 O
may NCT03862573 275 278 B-Assertion___Assertion-Type-Value:hypothetical
prohibit NCT03862573 279 287 B-Negation
participation NCT03862573 288 301 O
or NCT03862573 302 304 O
evaluation NCT03862573 305 315 O
of NCT03862573 316 318 O
the NCT03862573 319 322 O
procedure NCT03862573 323 332 B-Procedure
( NCT03862573 333 334 O
such NCT03862573 335 339 O
as NCT03862573 340 342 O
developmental NCT03862573 343 356 B-Condition
delay NCT03862573 357 362 I-Condition
, NCT03862573 363 364 O
autism NCT03862573 365 371 B-Condition
, NCT03862573 372 373 O
challenging NCT03862573 374 385 B-Condition
communication NCT03862573 386 399 I-Condition
) NCT03862573 400 401 O

2 NCT03862573 405 406 O
. NCT03862573 406 407 O
Facial NCT03862573 409 415 B-Condition
features NCT03862573 416 424 I-Condition
prohibiting NCT03862573 425 436 B-Assertion___Assertion-Type-Value:hypothetical|Negation
wearing NCT03862573 437 444 B-Observation
the NCT03862573 445 448 O
VR NCT03862573 449 451 B-Modifier
goggles NCT03862573 452 459 I-Modifier

3 NCT03862573 462 463 O
. NCT03862573 463 464 O
Children NCT03862573 466 474 O
needing NCT03862573 475 482 B-Assertion___Assertion-Type-Value:hypothetical
sedation NCT03862573 483 491 B-Procedure
that NCT03862573 492 496 O
includes NCT03862573 497 505 O
inhalation NCT03862573 506 516 B-Procedure
via NCT03862573 517 520 I-Procedure
a NCT03862573 521 522 I-Procedure
mask NCT03862573 523 527 I-Procedure
( NCT03862573 528 529 O
N2O NCT03862573 530 533 B-Procedure
) NCT03862573 534 535 O
or NCT03862573 536 538 B-Or
IV NCT03862573 539 541 B-Modifier
/ NCT03862573 542 543 B-Or
IM NCT03862573 544 546 B-Modifier
sedation NCT03862573 547 555 B-Procedure

Inclusion NCT03860402 0 9 O
Criteria NCT03860402 10 18 O
: NCT03860402 19 20 O

- NCT03860402 24 25 O
Among NCT03860402 27 32 O
the NCT03860402 33 36 O
pregnant NCT03860402 37 45 B-Condition
women NCT03860402 46 51 O
who NCT03860402 52 55 B-And
were NCT03860402 56 60 O
administered NCT03860402 61 73 B-Eq-Comparison
cesarean NCT03860402 74 82 B-Procedure
section NCT03860402 83 90 I-Procedure
in NCT03860402 91 93 O
this NCT03860402 94 98 O
study NCT03860402 99 104 B-Study
, NCT03860402 105 106 O
those NCT03860402 107 112 O
who NCT03860402 113 116 O
agreed NCT03860402 117 123 O
to NCT03860402 124 126 O
participate NCT03860402 127 138 O
in NCT03860402 139 141 O
this NCT03860402 142 146 O
study NCT03860402 147 152 O
. NCT03860402 153 154 O

Exclusion NCT03860402 156 165 O
Criteria NCT03860402 166 174 O
: NCT03860402 175 176 O

- NCT03860402 180 181 O
Fetal NCT03860402 183 188 B-Condition
distress NCT03860402 189 197 I-Condition
requiring NCT03860402 198 207 B-Assertion___Assertion-Type-Value:hypothetical
fast NCT03860402 208 212 B-Modifier
delivery NCT03860402 213 221 B-Procedure
. NCT03860402 222 223 O

- NCT03860402 227 228 O
Patients NCT03860402 230 238 O
with NCT03860402 239 243 O
hypersensitivity NCT03860402 244 260 B-Condition
, NCT03860402 261 262 O
allergic NCT03860402 263 271 B-Allergy
response NCT03860402 272 280 B-Condition
, NCT03860402 281 282 O
resistance NCT03860402 283 293 B-Condition
to NCT03860402 294 296 O
the NCT03860402 297 300 O
drugs NCT03860402 301 306 B-Drug
used NCT03860402 307 311 O
in NCT03860402 312 314 O
this NCT03860402 315 319 O
study NCT03860402 320 325 B-Study
( NCT03860402 326 327 O
fentanyl NCT03860402 328 336 B-Drug
, NCT03860402 337 338 O
ropivacaine NCT03860402 339 350 B-Drug
, NCT03860402 351 352 O
lidocaine NCT03860402 353 362 B-Drug
) NCT03860402 363 364 O
. NCT03860402 366 367 O

- NCT03860402 371 372 O
Patients NCT03860402 374 382 O
who NCT03860402 383 386 O
is NCT03860402 387 389 O
not NCT03860402 390 393 B-Negation
possible NCT03860402 394 402 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860402 403 406 O
regional NCT03860402 407 415 B-Procedure
anesthesia NCT03860402 416 426 I-Procedure

- NCT03860402 429 430 O
Patients NCT03860402 432 440 O
who NCT03860402 441 444 O
refused NCT03860402 445 452 O
to NCT03860402 453 455 O
participate NCT03860402 456 467 O
in NCT03860402 468 470 O
this NCT03860402 471 475 O
study NCT03860402 476 481 O
. NCT03860402 482 483 O

- NCT03860402 487 488 O
Patients NCT03860402 490 498 O
who NCT03860402 499 502 O
can NCT03860402 503 506 O
not NCT03860402 506 509 O
read NCT03860402 510 514 O
or NCT03860402 515 517 O
understand NCT03860402 518 528 O
the NCT03860402 529 532 O
agreement NCT03860402 533 542 O
. NCT03860402 543 544 O

- NCT03860402 548 549 O
Patients NCT03860402 551 559 O
whose NCT03860402 560 565 O
weight NCT03860402 566 572 B-Observation
is NCT03860402 573 575 O
less NCT03860402 576 580 B-Eq-Comparison
than NCT03860402 581 585 I-Eq-Comparison
50 NCT03860402 586 588 I-Eq-Comparison
kg NCT03860402 589 591 O
or NCT03860402 592 594 B-Or
exceeds NCT03860402 595 602 B-Eq-Comparison
100 NCT03860402 603 606 I-Eq-Comparison
kg NCT03860402 607 609 I-Eq-Comparison
. NCT03860402 609 610 O

Inclusion NCT03861494 0 9 O
Criteria NCT03861494 10 18 O
: NCT03861494 19 20 O

- NCT03861494 24 25 O
patients NCT03861494 27 35 O
hospitalized NCT03861494 36 48 B-Encounter
with NCT03861494 49 53 B-And
primary NCT03861494 54 61 O
diagnosis NCT03861494 62 71 O
of NCT03861494 72 74 O
acute NCT03861494 75 80 O
or NCT03861494 81 83 B-Or
subacute NCT03861494 84 92 O
ischemic NCT03861494 93 101 B-Condition
cerebral NCT03861494 102 110 I-Condition
infarction NCT03861494 111 121 I-Condition

- NCT03861494 124 125 O
18 NCT03861494 127 129 B-Eq-Comparison
years NCT03861494 130 135 I-Eq-Comparison
of NCT03861494 136 138 I-Eq-Comparison
age NCT03861494 139 142 I-Eq-Comparison
or NCT03861494 143 145 I-Eq-Comparison
older NCT03861494 146 151 I-Eq-Comparison

- NCT03861494 154 155 O
English NCT03861494 157 164 O
speaking NCT03861494 165 173 O

- NCT03861494 176 177 O
admitted NCT03861494 179 187 B-Encounter
to NCT03861494 188 190 O
hospital NCT03861494 191 199 O
Sunday NCT03861494 200 206 B-Eq-Comparison
through NCT03861494 207 214 I-Eq-Comparison
Thursday NCT03861494 215 223 I-Eq-Comparison

- NCT03861494 226 227 O
patient NCT03861494 229 236 O
or NCT03861494 237 239 O
responsible NCT03861494 240 251 O
primary NCT03861494 252 259 O
caregiver NCT03861494 260 269 O
able NCT03861494 270 274 O
to NCT03861494 275 277 O
understand NCT03861494 278 288 O
and NCT03861494 289 292 O
provide NCT03861494 293 300 O
informed NCT03861494 301 309 O
consent NCT03861494 310 317 O

- NCT03861494 320 321 O
prognosis NCT03861494 323 332 B-Condition
for NCT03861494 333 336 I-Condition
survival NCT03861494 337 345 I-Condition
greater NCT03861494 346 353 B-Eq-Comparison
than NCT03861494 354 358 I-Eq-Comparison
6 NCT03861494 359 360 I-Eq-Comparison
months NCT03861494 361 367 I-Eq-Comparison

- NCT03861494 370 371 O
one NCT03861494 373 376 B-Eq-Comparison
or NCT03861494 377 379 I-Eq-Comparison
more NCT03861494 380 384 I-Eq-Comparison
vascular NCT03861494 385 393 B-Condition
risk NCT03861494 394 398 B-Risk
factors NCT03861494 399 406 I-Risk
( NCT03861494 407 408 O
HTN NCT03861494 409 412 B-Condition
, NCT03861494 413 414 O
DLP NCT03861494 415 418 B-Condition
, NCT03861494 419 420 O
current NCT03861494 421 428 B-Condition
smoker NCT03861494 429 435 I-Condition
, NCT03861494 436 437 O
DM NCT03861494 438 440 B-Condition
, NCT03861494 441 442 O
obesity NCT03861494 443 450 B-Condition
) NCT03861494 451 452 O

- NCT03861494 456 457 O
live NCT03861494 459 463 O
in NCT03861494 464 466 O
NWA NCT03861494 467 470 O
area NCT03861494 471 475 O
( NCT03861494 476 477 O
Benton NCT03861494 478 484 O
, NCT03861494 485 486 O
Boone NCT03861494 487 492 O
, NCT03861494 493 494 O
Carroll NCT03861494 495 502 O
, NCT03861494 503 504 O
Madison NCT03861494 505 512 O
, NCT03861494 513 514 O
and NCT03861494 515 518 O
Washington NCT03861494 519 529 O
counties NCT03861494 530 538 O
) NCT03861494 539 540 O
, NCT03861494 542 543 O

- NCT03861494 547 548 O
have NCT03861494 550 554 O
a NCT03861494 555 556 O
working NCT03861494 557 564 O
phone NCT03861494 565 570 O
. NCT03861494 571 572 O

Exclusion NCT03861494 574 583 O
Criteria NCT03861494 584 592 O
: NCT03861494 593 594 O

- NCT03861494 598 599 O
admitted NCT03861494 601 609 B-Encounter
with NCT03861494 610 614 B-And
transient NCT03861494 615 624 B-Condition
ischemic NCT03861494 625 633 I-Condition
attack NCT03861494 634 640 I-Condition

- NCT03861494 643 644 O
admitted NCT03861494 646 654 B-Encounter
with NCT03861494 655 659 B-And
an NCT03861494 660 662 O
intracerebral NCT03861494 663 676 B-Condition
hemorrhage NCT03861494 677 687 I-Condition

- NCT03861494 690 691 O
experience NCT03861494 693 703 O
an NCT03861494 704 706 O
in NCT03861494 707 709 O
- NCT03861494 710 711 O
hospital NCT03861494 712 720 O
ischemic NCT03861494 721 729 B-Condition
cerebral NCT03861494 730 738 I-Condition
infarction NCT03861494 739 749 I-Condition

- NCT03861494 752 753 O
hospital NCT03861494 755 763 O
to NCT03861494 764 766 O
hospital NCT03861494 767 775 O
transfer NCT03861494 776 784 B-Encounter
patients NCT03861494 785 793 O

- NCT03861494 796 797 O
nursing NCT03861494 799 806 O
home NCT03861494 807 811 O
as NCT03861494 812 814 O
primary NCT03861494 815 822 O
residence NCT03861494 823 832 O
before NCT03861494 833 839 B-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03861494 840 842 B-Or
after NCT03861494 843 848 B-Temporal-Connection___Temporal-Connection-Type-Value:after
discharge NCT03861494 849 858 B-Encounter

- NCT03861494 861 862 O
hospice NCT03861494 864 871 B-Condition

- NCT03861494 874 875 O
inability NCT03861494 877 886 B-Condition
to NCT03861494 887 889 I-Condition
comply NCT03861494 890 896 I-Condition
with NCT03861494 897 901 O
post NCT03861494 902 906 B-Temporal-Connection___Temporal-Connection-Type-Value:after
discharge NCT03861494 907 916 B-Encounter
follow NCT03861494 917 923 B-Encounter
up NCT03861494 924 926 I-Encounter

Inclusion NCT03861325 0 9 O
Criteria NCT03861325 10 18 O
: NCT03861325 19 20 O

- NCT03861325 24 25 O
The NCT03861325 27 30 O
patient NCT03861325 31 38 O
or NCT03861325 39 41 O
his NCT03861325 42 45 O
/ NCT03861325 46 47 O
her NCT03861325 48 51 O
representative NCT03861325 52 66 O
has NCT03861325 67 70 O
been NCT03861325 71 75 O
informed NCT03861325 76 84 O
about NCT03861325 85 90 O
the NCT03861325 91 94 O
implementation NCT03861325 95 109 O
of NCT03861325 110 112 O
the NCT03861325 113 116 O
study NCT03861325 117 122 O
, NCT03861325 123 124 O
its NCT03861325 125 128 O
objectives NCT03861325 129 139 O
, NCT03861325 140 141 O
its NCT03861325 142 145 O
constraints NCT03861325 146 157 O
, NCT03861325 158 159 O
the NCT03861325 160 163 O
rights NCT03861325 164 170 O
of NCT03861325 171 173 O
the NCT03861325 174 177 O
patient NCT03861325 178 185 O
and NCT03861325 186 189 O
must NCT03861325 190 194 O
have NCT03861325 195 199 O
received NCT03861325 200 208 O
the NCT03861325 209 212 O
newsletter NCT03861325 213 223 O
and NCT03861325 224 227 O
no NCT03861325 228 230 O
opposition NCT03861325 231 241 O
of NCT03861325 242 244 O
the NCT03861325 245 248 O
study NCT03861325 249 254 O
. NCT03861325 255 256 O

- NCT03861325 260 261 O
The NCT03861325 263 266 O
patient NCT03861325 267 274 O
must NCT03861325 275 279 O
be NCT03861325 280 282 O
an NCT03861325 283 285 O
affiliate NCT03861325 286 295 O
or NCT03861325 296 298 O
beneficiary NCT03861325 299 310 O
of NCT03861325 311 313 O
a NCT03861325 314 315 O
health NCT03861325 316 322 O
insurance NCT03861325 323 332 O
plan NCT03861325 333 337 O
. NCT03861325 338 339 O

- NCT03861325 343 344 O
The NCT03861325 346 349 O
patient NCT03861325 350 357 O
is NCT03861325 358 360 O
at NCT03861325 361 363 B-Eq-Comparison
least NCT03861325 364 369 I-Eq-Comparison
18 NCT03861325 370 372 I-Eq-Comparison
years NCT03861325 373 378 I-Eq-Comparison
old NCT03861325 379 382 B-Age
. NCT03861325 383 384 O

- NCT03861325 388 389 O
The NCT03861325 391 394 O
patient NCT03861325 395 402 O
has NCT03861325 403 406 O
septic NCT03861325 407 413 B-Condition
shock NCT03861325 414 419 I-Condition
as NCT03861325 420 422 O
defined NCT03861325 423 430 O
by NCT03861325 431 433 O
the NCT03861325 434 437 O
3 NCT03861325 438 439 O
rd NCT03861325 440 442 O
International NCT03861325 443 456 O
Conference NCT03861325 457 467 O
for NCT03861325 468 471 O
the NCT03861325 472 475 O
definition NCT03861325 476 486 O
of NCT03861325 487 489 O
sepsis NCT03861325 490 496 O
and NCT03861325 497 500 O
septic NCT03861325 501 507 O
shock NCT03861325 508 513 O

Exclusion NCT03861325 514 523 O
Criteria NCT03861325 524 532 O
: NCT03861325 533 534 O

- NCT03861325 538 539 O
The NCT03861325 541 544 O
patient NCT03861325 545 552 O
is NCT03861325 553 555 O
in NCT03861325 556 558 O
an NCT03861325 559 561 O
exclusion NCT03861325 562 571 O
period NCT03861325 572 578 O
determined NCT03861325 579 589 O
by NCT03861325 590 592 O
a NCT03861325 593 594 O
previous NCT03861325 595 603 O
study NCT03861325 604 609 O

- NCT03861325 612 613 O
The NCT03861325 615 618 O
patient NCT03861325 619 626 O
is NCT03861325 627 629 O
under NCT03861325 630 635 O
guardianship NCT03861325 636 648 O
, NCT03861325 649 650 O
under NCT03861325 651 656 O
guardianship NCT03861325 657 669 O
, NCT03861325 670 671 O
or NCT03861325 672 674 O
under NCT03861325 675 680 O
the NCT03861325 681 684 O
protection NCT03861325 685 695 O
of NCT03861325 696 698 O
justice NCT03861325 699 706 O

- NCT03861325 709 710 O
The NCT03861325 712 715 O
patient NCT03861325 716 723 O
has NCT03861325 724 727 O
already NCT03861325 728 735 O
participated NCT03861325 736 748 O
in NCT03861325 749 751 O
this NCT03861325 752 756 O
study NCT03861325 757 762 O

- NCT03861325 765 766 O
The NCT03861325 768 771 O
patient NCT03861325 772 779 O
or NCT03861325 780 782 O
his NCT03861325 783 786 O
/ NCT03861325 787 788 O
her NCT03861325 789 792 O
representative NCT03861325 793 807 O
refuses NCT03861325 808 815 O
to NCT03861325 816 818 O
participate NCT03861325 819 830 O
in NCT03861325 831 833 O
the NCT03861325 834 837 O
study NCT03861325 838 843 O

- NCT03861325 846 847 O
The NCT03861325 849 852 O
patient NCT03861325 853 860 O
is NCT03861325 861 863 O
pregnant NCT03861325 864 872 B-Condition
, NCT03861325 873 874 O
parturient NCT03861325 875 885 B-Condition
or NCT03861325 886 888 B-Or
is NCT03861325 889 891 O
breastfeeding NCT03861325 892 905 B-Condition

- NCT03861325 908 909 O
The NCT03861325 911 914 O
patient NCT03861325 915 922 O
is NCT03861325 923 925 O
a NCT03861325 926 927 O
minor NCT03861325 928 933 O

- NCT03861325 936 937 O
The NCT03861325 939 942 O
patient NCT03861325 943 950 O
is NCT03861325 951 953 O
in NCT03861325 954 956 O
therapeutic NCT03861325 957 968 B-Condition
limitation NCT03861325 969 979 I-Condition
or NCT03861325 980 982 B-Or
moribund NCT03861325 983 991 B-Condition

- NCT03861325 994 995 O
The NCT03861325 997 1000 O
patient NCT03861325 1001 1008 O
has NCT03861325 1009 1012 B-Eq-Comparison
undergone NCT03861325 1013 1022 I-Eq-Comparison
or NCT03861325 1023 1025 B-Or
is NCT03861325 1026 1028 B-Eq-Comparison
going NCT03861325 1029 1034 I-Eq-Comparison
to NCT03861325 1035 1037 I-Eq-Comparison
have NCT03861325 1038 1042 I-Eq-Comparison
scheduled NCT03861325 1043 1052 B-Modifier
or NCT03861325 1053 1055 B-Or
emergency NCT03861325 1056 1065 B-Encounter
digestive NCT03861325 1066 1075 B-Procedure
surgery NCT03861325 1076 1083 I-Procedure

- NCT03861325 1086 1087 O
The NCT03861325 1089 1092 O
patient NCT03861325 1093 1100 O
is NCT03861325 1101 1103 O
HIV NCT03861325 1104 1107 B-Condition
- NCT03861325 1108 1109 O
positive NCT03861325 1110 1118 O

- NCT03861325 1121 1122 O
The NCT03861325 1124 1127 O
patient NCT03861325 1128 1135 O
has NCT03861325 1136 1139 O
Child NCT03861325 1140 1145 B-Modifier
C NCT03861325 1146 1147 I-Modifier
cirrhosis NCT03861325 1148 1157 B-Condition

- NCT03861325 1160 1161 O
The NCT03861325 1163 1166 O
patient NCT03861325 1167 1174 O
has NCT03861325 1175 1178 O
progressive NCT03861325 1179 1190 B-Modifier
digestive NCT03861325 1191 1200 B-Condition
neoplasia NCT03861325 1201 1210 I-Condition
, NCT03861325 1211 1212 O
digestive NCT03861325 1213 1222 B-Condition
lymphoma NCT03861325 1223 1231 I-Condition
, NCT03861325 1232 1233 O
chronic NCT03861325 1234 1241 B-Modifier
inflammatory NCT03861325 1242 1254 B-Condition
bowel NCT03861325 1255 1260 I-Condition
disease NCT03861325 1261 1268 I-Condition
( NCT03861325 1269 1270 O
Crohn NCT03861325 1271 1276 B-Condition
's NCT03861325 1276 1278 I-Condition
disease NCT03861325 1279 1286 I-Condition
. NCT03861325 1287 1288 O
. NCT03861325 1289 1290 O
. NCT03861325 1291 1292 O
) NCT03861325 1293 1294 O
. NCT03861325 1295 1296 O

Inclusion NCT03867032 0 9 O
Criteria NCT03867032 10 18 O
: NCT03867032 19 20 O

- NCT03867032 24 25 O
Native NCT03867032 27 33 O
speakers NCT03867032 34 42 O
of NCT03867032 43 45 O
English NCT03867032 46 53 O

- NCT03867032 56 57 O
Cochlear NCT03867032 59 67 B-Procedure
Nucleus NCT03867032 68 75 I-Procedure
cochlear NCT03867032 76 84 I-Procedure
implant NCT03867032 85 92 I-Procedure
users NCT03867032 93 98 O
or NCT03867032 99 101 B-Or
Advanced NCT03867032 102 110 B-Procedure
Bionics NCT03867032 111 118 I-Procedure
users NCT03867032 119 124 O

- NCT03867032 127 128 O
Postlingually NCT03867032 130 143 B-Modifier
deafened NCT03867032 144 152 B-Condition

- NCT03867032 155 156 O
Has NCT03867032 158 161 O
had NCT03867032 162 165 O
device NCT03867032 166 172 B-Procedure
experience NCT03867032 173 183 O
for NCT03867032 184 187 O
at NCT03867032 188 190 B-Eq-Comparison
least NCT03867032 191 196 I-Eq-Comparison
one NCT03867032 197 200 I-Eq-Comparison
year NCT03867032 201 205 I-Eq-Comparison

- NCT03867032 208 209 O
Can NCT03867032 211 214 O
be NCT03867032 215 217 O
child NCT03867032 218 223 O
or NCT03867032 224 226 B-Or
adult NCT03867032 227 232 O
at NCT03867032 233 235 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867032 236 239 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867032 240 244 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867032 245 247 O
enrollment NCT03867032 248 258 B-Study

Exclusion NCT03867032 259 268 O
Criteria NCT03867032 269 277 O
: NCT03867032 278 279 O

- NCT03867032 283 284 O
None NCT03867032 286 290 O

Inclusion NCT03862638 0 9 O
Criteria NCT03862638 10 18 O
: NCT03862638 19 20 O

- NCT03862638 24 25 O
Meeting NCT03862638 27 34 O
the NCT03862638 35 38 O
diagnostic NCT03862638 39 49 O
criteria NCT03862638 50 58 O
of NCT03862638 59 61 O
CTTH NCT03862638 62 66 B-Condition
in NCT03862638 67 69 O
the NCT03862638 70 73 O
international NCT03862638 74 87 O
classification NCT03862638 88 102 O
of NCT03862638 103 105 O
headache NCT03862638 106 114 O
disorders NCT03862638 115 124 O
, NCT03862638 125 126 O
3 NCT03862638 127 128 O
rd NCT03862638 129 131 O
edition NCT03862638 132 139 O
( NCT03862638 140 141 O
beta NCT03862638 142 146 O
version NCT03862638 147 154 O
) NCT03862638 155 156 O
( NCT03862638 157 158 O
ICHD NCT03862638 159 163 O
- NCT03862638 164 165 O
III NCT03862638 166 169 O
beta NCT03862638 170 174 O
) NCT03862638 175 176 O
; NCT03862638 177 178 O

- NCT03862638 181 182 O
Aged NCT03862638 184 188 B-Age
18 NCT03862638 189 191 B-Eq-Comparison
- NCT03862638 192 193 I-Eq-Comparison
55 NCT03862638 194 196 I-Eq-Comparison
years NCT03862638 197 202 I-Eq-Comparison
; NCT03862638 202 203 O

- NCT03862638 206 207 O
Having NCT03862638 209 215 O
the NCT03862638 216 219 O
ability NCT03862638 220 227 O
of NCT03862638 228 230 O
understanding NCT03862638 231 244 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03862638 245 248 B-And
completing NCT03862638 249 259 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03862638 260 263 O
headache NCT03862638 264 272 B-Observation
dairy NCT03862638 273 278 I-Observation
; NCT03862638 278 279 O

- NCT03862638 282 283 O
Provide NCT03862638 285 292 O
written NCT03862638 293 300 O
informed NCT03862638 301 309 O
consent NCT03862638 310 317 O
. NCT03862638 318 319 O

Exclusion NCT03862638 321 330 O
Criteria NCT03862638 331 339 O
: NCT03862638 340 341 O

- NCT03862638 345 346 O
No NCT03862638 348 350 B-Negation
headache NCT03862638 351 359 B-Condition
during NCT03862638 360 366 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862638 367 370 O
pervious NCT03862638 371 379 B-Eq-Comparison
3 NCT03862638 380 381 I-Eq-Comparison
months NCT03862638 382 388 I-Eq-Comparison
; NCT03862638 388 389 O

- NCT03862638 392 393 O
Taking NCT03862638 395 401 O
any NCT03862638 402 405 O
prophylactic NCT03862638 406 418 B-Drug
medication NCT03862638 419 429 I-Drug
during NCT03862638 430 436 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862638 437 440 O
previous NCT03862638 441 449 B-Eq-Comparison
one NCT03862638 450 453 I-Eq-Comparison
month NCT03862638 454 459 I-Eq-Comparison
; NCT03862638 459 460 O

- NCT03862638 463 464 O
Secondary NCT03862638 466 475 B-Modifier
headache NCT03862638 476 484 B-Condition
or NCT03862638 485 487 B-Or
any NCT03862638 488 491 O
systematic NCT03862638 492 502 B-Modifier
cause NCT03862638 503 508 B-Condition

- NCT03862638 511 512 O
Having NCT03862638 514 520 O
serious NCT03862638 521 528 O
conditions NCT03862638 529 539 B-Condition
of NCT03862638 540 542 O
the NCT03862638 543 546 O
heart NCT03862638 547 552 B-Modifier
, NCT03862638 553 554 O
liver NCT03862638 555 560 B-Modifier
, NCT03862638 561 562 O
kidney NCT03862638 563 569 B-Modifier
or NCT03862638 570 572 B-Or
other NCT03862638 573 578 B-Other
organs NCT03862638 579 585 B-Modifier
; NCT03862638 585 586 O

- NCT03862638 589 590 O
In NCT03862638 592 594 O
pregnancy NCT03862638 595 604 B-Condition
or NCT03862638 605 607 B-Or
lactation NCT03862638 608 617 B-Condition
, NCT03862638 618 619 O
or NCT03862638 620 622 B-Or
planning NCT03862638 623 631 B-Assertion___Assertion-Type-Value:intention
to NCT03862638 632 634 O
be NCT03862638 635 637 O
pregnant NCT03862638 638 646 B-Condition
in NCT03862638 647 649 O
6 NCT03862638 650 651 B-Eq-Comparison
months NCT03862638 652 658 I-Eq-Comparison
; NCT03862638 658 659 O

- NCT03862638 662 663 O
Drug NCT03862638 665 669 B-Modifier
and NCT03862638 670 673 B-Or
Substance NCT03862638 674 683 B-Modifier
abuse NCT03862638 684 689 B-Condition

- NCT03862638 692 693 O
Diagnosed NCT03862638 695 704 O
psychiatric NCT03862638 705 716 B-Condition
condition NCT03862638 717 726 I-Condition

- NCT03862638 729 730 O
Taking NCT03862638 732 738 B-Eq-Comparison
any NCT03862638 739 742 O
other NCT03862638 743 748 B-Other
complementary NCT03862638 749 762 B-Modifier
and NCT03862638 763 766 B-Or
alternative NCT03862638 767 778 B-Modifier
medicines NCT03862638 779 788 B-Drug

- NCT03862638 791 792 O
Practicing NCT03862638 794 804 O
yoga NCT03862638 805 809 B-Observation
of NCT03862638 810 812 O
any NCT03862638 813 816 O
kind NCT03862638 817 821 O
in NCT03862638 822 824 O
last NCT03862638 825 829 B-Eq-Comparison
three NCT03862638 830 835 I-Eq-Comparison
months NCT03862638 836 842 I-Eq-Comparison

Inclusion NCT03864705 0 9 O
Criteria NCT03864705 10 18 O
: NCT03864705 19 20 O

- NCT03864705 24 25 O
Type NCT03864705 27 31 B-Modifier
2 NCT03864705 32 33 I-Modifier
diabetes NCT03864705 34 42 B-Condition
mellitus NCT03864705 43 51 I-Condition
on NCT03864705 52 54 O
metformin NCT03864705 55 64 B-Drug
therapy NCT03864705 65 72 B-Procedure
for NCT03864705 73 76 O
at NCT03864705 77 79 B-Eq-Comparison
least NCT03864705 80 85 I-Eq-Comparison
3 NCT03864705 86 87 I-Eq-Comparison
months NCT03864705 88 94 I-Eq-Comparison

Exclusion NCT03864705 95 104 O
Criteria NCT03864705 105 113 O
: NCT03864705 114 115 O

- NCT03864705 118 119 O

Inclusion NCT03868891 0 9 O
Criteria NCT03868891 10 18 O
: NCT03868891 19 20 O

- NCT03868891 24 25 O
6 NCT03868891 27 28 B-Eq-Comparison
- NCT03868891 29 30 I-Eq-Comparison
17 NCT03868891 31 33 I-Eq-Comparison
years NCT03868891 34 39 I-Eq-Comparison
old NCT03868891 40 43 B-Age

- NCT03868891 46 47 O
Otherwise NCT03868891 49 58 O
healthy NCT03868891 59 66 B-Condition

- NCT03868891 69 70 O
Currently NCT03868891 72 81 B-Eq-Comparison
have NCT03868891 82 86 O
unilateral NCT03868891 87 97 B-Modifier
or NCT03868891 98 100 B-Or
bilateral NCT03868891 101 110 B-Modifier
ventilation NCT03868891 111 122 B-Procedure
tube NCT03868891 123 127 I-Procedure
( NCT03868891 128 129 O
s NCT03868891 130 131 O
) NCT03868891 132 133 O
( NCT03868891 134 135 O
VTs NCT03868891 136 139 B-Procedure
) NCT03868891 140 141 O
inserted NCT03868891 142 150 B-Modifier
for NCT03868891 151 154 O
otitis NCT03868891 155 161 B-Condition
media NCT03868891 162 167 I-Condition
with NCT03868891 168 172 I-Condition
effusion NCT03868891 173 181 I-Condition
( NCT03868891 182 183 O
OME NCT03868891 184 187 B-Condition
) NCT03868891 188 189 O
or NCT03868891 190 192 B-Or
tympanic NCT03868891 193 201 B-Procedure
membrane NCT03868891 202 210 I-Procedure
retraction NCT03868891 211 221 I-Procedure
/ NCT03868891 222 223 B-Or
retraction NCT03868891 224 234 B-Procedure
pocket NCT03868891 235 241 I-Procedure
( NCT03868891 242 243 O
TM NCT03868891 244 246 B-Procedure
- NCT03868891 247 248 I-Procedure
R NCT03868891 249 250 I-Procedure
/ NCT03868891 251 252 I-Procedure
RP NCT03868891 253 255 I-Procedure
) NCT03868891 256 257 O
or NCT03868891 258 260 B-Or
a NCT03868891 261 262 O
TM NCT03868891 263 265 B-Condition
perforation NCT03868891 266 277 I-Condition
after NCT03868891 278 283 B-Temporal-Connection___Temporal-Connection-Type-Value:after
extrusion NCT03868891 284 293 B-Procedure
of NCT03868891 294 296 I-Procedure
a NCT03868891 297 298 I-Procedure
VT NCT03868891 299 301 I-Procedure

- NCT03868891 304 305 O
History NCT03868891 307 314 B-Eq-Comparison
of NCT03868891 315 317 O
at NCT03868891 318 320 B-Eq-Comparison
least NCT03868891 321 326 I-Eq-Comparison
2 NCT03868891 327 328 I-Eq-Comparison
sets NCT03868891 329 333 I-Eq-Comparison
of NCT03868891 334 336 O
VT NCT03868891 337 339 B-Procedure
insertions NCT03868891 340 350 I-Procedure
in NCT03868891 351 353 O
the NCT03868891 354 357 O
past NCT03868891 358 362 B-Eq-Comparison

- NCT03868891 365 366 O
Eustachian NCT03868891 368 378 B-Observation
tube NCT03868891 379 383 I-Observation
( NCT03868891 384 385 O
ET NCT03868891 386 388 B-Observation
) NCT03868891 389 390 O
function NCT03868891 391 399 B-Modifier
( NCT03868891 400 401 O
ETF NCT03868891 402 405 B-Observation
) NCT03868891 406 407 O
tests NCT03868891 408 413 O
showing NCT03868891 414 421 O
an NCT03868891 422 424 O
active NCT03868891 425 431 B-Eq-Comparison
muscular NCT03868891 432 440 B-Modifier
pattern NCT03868891 441 448 I-Modifier
of NCT03868891 449 451 O
Eustachian NCT03868891 452 462 B-Condition
tube NCT03868891 463 467 I-Condition
dysfunction NCT03868891 468 479 I-Condition

- NCT03868891 482 483 O
Tubomanometry NCT03868891 485 498 B-Observation
test NCT03868891 499 503 I-Observation
results NCT03868891 504 511 O
showing NCT03868891 512 519 O
evidence NCT03868891 520 528 O
of NCT03868891 529 531 O
velopharyngeal NCT03868891 532 546 B-Condition
dysfunction NCT03868891 547 558 I-Condition
during NCT03868891 559 565 B-Temporal-Connection___Temporal-Connection-Type-Value:during
swallowing NCT03868891 566 576 B-Observation

- NCT03868891 579 580 O
Cleft NCT03868891 582 587 B-Condition
palate NCT03868891 588 594 I-Condition
( NCT03868891 595 596 O
CP NCT03868891 597 599 B-Condition
) NCT03868891 600 601 O
cohort NCT03868891 602 608 O
: NCT03868891 609 610 O
non NCT03868891 611 614 B-Negation
- NCT03868891 615 616 O
syndromic NCT03868891 617 626 B-Condition
; NCT03868891 626 627 O
prior NCT03868891 628 633 B-Eq-Comparison
Furlow NCT03868891 634 640 B-Procedure
palatoplasty NCT03868891 641 653 I-Procedure
without NCT03868891 654 661 B-Negation
complications NCT03868891 662 675 B-Condition
or NCT03868891 676 678 B-Or
need NCT03868891 679 683 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868891 684 687 I-Assertion___Assertion-Type-Value:hypothetical
revision NCT03868891 688 696 B-Procedure

- NCT03868891 699 700 O
Non NCT03868891 702 705 B-Negation
- NCT03868891 706 707 O
CP NCT03868891 708 710 B-Condition
cohort NCT03868891 711 717 O
: NCT03868891 718 719 O
have NCT03868891 720 724 O
had NCT03868891 725 728 O
prior NCT03868891 729 734 B-Eq-Comparison
adenoidectomy NCT03868891 735 748 B-Procedure

Exclusion NCT03868891 749 758 O
Criteria NCT03868891 759 767 O
: NCT03868891 768 769 O

- NCT03868891 773 774 O
Concurrent NCT03868891 776 786 B-Eq-Comparison
or NCT03868891 787 789 B-Or
past NCT03868891 790 794 B-Eq-Comparison
diagnosis NCT03868891 795 804 O
of NCT03868891 805 807 O
cancer NCT03868891 808 814 B-Condition
or NCT03868891 815 817 B-Or
history NCT03868891 818 825 B-Eq-Comparison
of NCT03868891 826 828 O
radiation NCT03868891 829 838 B-Procedure

- NCT03868891 841 842 O
Have NCT03868891 844 848 B-Eq-Comparison
or NCT03868891 849 851 B-Or
had NCT03868891 852 855 B-Eq-Comparison
vestibular NCT03868891 856 866 B-Condition
pathology NCT03868891 867 876 I-Condition
, NCT03868891 877 878 O
cranial NCT03868891 879 886 B-Modifier
base NCT03868891 887 891 I-Modifier
surgery NCT03868891 892 899 B-Procedure
or NCT03868891 900 902 B-Or
ossicular NCT03868891 903 912 B-Modifier
chain NCT03868891 913 918 B-Procedure
reconstruction NCT03868891 919 933 I-Procedure

- NCT03868891 936 937 O
Craniofacial NCT03868891 939 951 B-Condition
dysmorphology NCT03868891 952 965 I-Condition
( NCT03868891 966 967 O
other NCT03868891 968 973 B-Exception
than NCT03868891 974 978 I-Exception
non NCT03868891 979 982 B-Negation
- NCT03868891 983 984 O
syndromic NCT03868891 985 994 B-Modifier
CP NCT03868891 995 997 B-Condition
with NCT03868891 998 1002 B-And
or NCT03868891 1003 1005 B-Or
without NCT03868891 1006 1013 B-Negation
cleft NCT03868891 1014 1019 B-Condition
lip NCT03868891 1020 1023 I-Condition
in NCT03868891 1024 1026 O
the NCT03868891 1027 1030 O
CP NCT03868891 1031 1033 B-Condition
cohort NCT03868891 1034 1040 O
) NCT03868891 1041 1042 O
or NCT03868891 1043 1045 B-Or
other NCT03868891 1046 1051 B-Other
syndrome NCT03868891 1052 1060 B-Condition

- NCT03868891 1063 1064 O
A NCT03868891 1066 1067 O
non NCT03868891 1068 1071 B-Negation
- NCT03868891 1072 1073 O
patent NCT03868891 1074 1080 B-Modifier
nasal NCT03868891 1081 1086 B-Condition
cavity NCT03868891 1087 1093 I-Condition

- NCT03868891 1096 1097 O
Patulous NCT03868891 1099 1107 B-Condition
ET NCT03868891 1108 1110 I-Condition
or NCT03868891 1111 1113 B-Or
pathologically NCT03868891 1114 1128 B-Condition
low NCT03868891 1129 1132 I-Condition
ET NCT03868891 1133 1135 I-Condition
opening NCT03868891 1136 1143 B-Modifier
or NCT03868891 1144 1146 B-Or
closing NCT03868891 1147 1154 B-Modifier
pressures NCT03868891 1155 1164 I-Modifier

- NCT03868891 1167 1168 O
Pregnancy NCT03868891 1170 1179 B-Condition

- NCT03868891 1182 1183 O
Unable NCT03868891 1185 1191 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868891 1192 1194 B-Or
unwilling NCT03868891 1195 1204 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868891 1205 1207 O
perform NCT03868891 1208 1215 O
the NCT03868891 1216 1219 O
tests NCT03868891 1220 1225 B-Observation
and NCT03868891 1226 1229 B-Or
exercises NCT03868891 1230 1239 B-Observation
outlined NCT03868891 1240 1248 O
in NCT03868891 1249 1251 O
the NCT03868891 1252 1255 O
study NCT03868891 1256 1261 B-Study

Inclusion NCT03867552 0 9 O
Criteria NCT03867552 10 18 O
: NCT03867552 19 20 O

- NCT03867552 24 25 O
Woman NCT03867552 27 32 O
≥ NCT03867552 33 34 B-Eq-Comparison
18 NCT03867552 35 37 I-Eq-Comparison
years NCT03867552 38 43 I-Eq-Comparison
old NCT03867552 44 47 B-Age

- NCT03867552 50 51 O
undergoing NCT03867552 53 63 B-Eq-Comparison
laparoscopic NCT03867552 64 76 B-Procedure
surgery NCT03867552 77 84 I-Procedure
for NCT03867552 85 88 O
endometriosis NCT03867552 89 102 B-Condition
, NCT03867552 103 104 O
uterine NCT03867552 105 112 B-Condition
myoma NCT03867552 113 118 I-Condition
's NCT03867552 118 120 I-Condition
, NCT03867552 121 122 O
hysterectomy NCT03867552 123 135 B-Procedure
or NCT03867552 136 138 B-Or
colpopexy NCT03867552 139 148 B-Procedure
. NCT03867552 149 150 O

Exclusion NCT03867552 152 161 O
Criteria NCT03867552 162 170 O
: NCT03867552 171 172 O

- NCT03867552 176 177 O
Women NCT03867552 179 184 O
< NCT03867552 185 186 B-Eq-Comparison
18 NCT03867552 187 189 I-Eq-Comparison
years NCT03867552 190 195 I-Eq-Comparison
old NCT03867552 196 199 B-Age

- NCT03867552 202 203 O
Males NCT03867552 205 210 O

- NCT03867552 213 214 O
Pregnancy NCT03867552 216 225 B-Condition

- NCT03867552 228 229 O
Conditions NCT03867552 231 241 B-Condition
associated NCT03867552 242 252 O
with NCT03867552 253 257 O
chronic NCT03867552 258 265 B-Modifier
pain NCT03867552 266 270 B-Condition
, NCT03867552 271 272 O
such NCT03867552 273 277 O
as NCT03867552 278 280 O
peripheral NCT03867552 281 291 B-Condition
neuropathy NCT03867552 292 302 I-Condition
, NCT03867552 303 304 O
pathology NCT03867552 305 314 B-Condition
of NCT03867552 315 317 O
the NCT03867552 318 321 O
vertebral NCT03867552 322 331 B-Modifier
column NCT03867552 332 338 I-Modifier
and NCT03867552 339 342 B-Or
osteo NCT03867552 343 348 B-Condition
- NCT03867552 349 350 I-Condition
articular NCT03867552 351 360 I-Condition
disease NCT03867552 361 368 I-Condition
. NCT03867552 369 370 O

- NCT03867552 374 375 O
Conditions NCT03867552 377 387 B-Condition
causing NCT03867552 388 395 O
acute NCT03867552 396 401 O
pain NCT03867552 402 406 B-Condition
e. NCT03867552 407 409 O
g. NCT03867552 410 412 O
abdominal NCT03867552 414 423 B-Modifier
trauma NCT03867552 424 430 B-Condition

Inclusion NCT03868852 0 9 O
Criteria NCT03868852 10 18 O
: NCT03868852 19 20 O

- NCT03868852 24 25 O
Patients NCT03868852 27 35 O
must NCT03868852 36 40 O
be NCT03868852 41 43 O
≥ NCT03868852 44 45 B-Eq-Comparison
3 NCT03868852 46 47 I-Eq-Comparison
and NCT03868852 48 51 B-And
≤ NCT03868852 52 53 B-Eq-Comparison
18 NCT03868852 54 56 I-Eq-Comparison
years NCT03868852 57 62 I-Eq-Comparison
of NCT03868852 63 65 O
age NCT03868852 66 69 B-Age
. NCT03868852 70 71 O

- NCT03868852 75 76 O
The NCT03868852 78 81 O
predicted NCT03868852 82 91 B-Observation
survival NCT03868852 92 100 I-Observation
period NCT03868852 101 107 O
is NCT03868852 108 110 O
more NCT03868852 111 115 B-Eq-Comparison
than NCT03868852 116 120 I-Eq-Comparison
3 NCT03868852 121 122 I-Eq-Comparison
months NCT03868852 123 129 I-Eq-Comparison
. NCT03868852 130 131 O

- NCT03868852 135 136 O
According NCT03868852 138 147 O
to NCT03868852 148 150 O
RECIST NCT03868852 151 157 O
version NCT03868852 158 165 O
1.1 NCT03868852 166 169 O
, NCT03868852 170 171 O
there NCT03868852 172 177 O
is NCT03868852 178 180 O
at NCT03868852 181 183 B-Eq-Comparison
least NCT03868852 184 189 I-Eq-Comparison
one NCT03868852 190 193 I-Eq-Comparison
measurable NCT03868852 194 204 O
lesion NCT03868852 205 211 B-Condition
. NCT03868852 212 213 O

- NCT03868852 217 218 O
Post NCT03868852 220 224 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03868852 225 234 B-Procedure
pathological NCT03868852 235 247 B-Condition
stage NCT03868852 248 253 I-Condition
was NCT03868852 254 257 O
group NCT03868852 258 263 B-Eq-Comparison
II NCT03868852 264 266 I-Eq-Comparison
- NCT03868852 267 268 I-Eq-Comparison
IV NCT03868852 269 271 I-Eq-Comparison
. NCT03868852 272 273 O

- NCT03868852 277 278 O
Patients NCT03868852 280 288 O
have NCT03868852 289 293 O
not NCT03868852 294 297 B-Negation
received NCT03868852 298 306 B-Eq-Comparison
radiotherapy NCT03868852 307 319 B-Procedure
before NCT03868852 320 326 B-Eq-Comparison
, NCT03868852 327 328 O
and NCT03868852 329 332 B-And
can NCT03868852 333 336 B-Assertion___Assertion-Type-Value:hypothetical
accept NCT03868852 337 343 I-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03868852 344 356 B-Procedure
and NCT03868852 357 360 B-Or
surgical NCT03868852 361 369 B-Procedure
treatment NCT03868852 370 379 I-Procedure
. NCT03868852 380 381 O

- NCT03868852 385 386 O
No NCT03868852 388 390 B-Negation
other NCT03868852 391 396 B-Other
anticancer NCT03868852 397 407 B-Procedure
therapy NCT03868852 408 415 I-Procedure
should NCT03868852 416 422 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03868852 423 425 I-Assertion___Assertion-Type-Value:hypothetical
used NCT03868852 426 430 O
during NCT03868852 431 437 B-Temporal-Connection___Temporal-Connection-Type-Value:during
radiotherapy NCT03868852 438 450 B-Procedure
. NCT03868852 451 452 O

- NCT03868852 456 457 O
The NCT03868852 459 462 O
main NCT03868852 463 467 B-Condition
organs NCT03868852 468 474 I-Condition
are NCT03868852 475 478 O
functioning NCT03868852 479 490 O
normally NCT03868852 491 499 O
, NCT03868852 500 501 O
which NCT03868852 502 507 O
meets NCT03868852 508 513 O
the NCT03868852 514 517 B-Criteria-Count
following NCT03868852 518 527 I-Criteria-Count
criteria NCT03868852 528 536 I-Criteria-Count
: NCT03868852 537 538 O

1 NCT03868852 547 548 O
. NCT03868852 548 549 O
Blood NCT03868852 551 556 B-Procedure
routine NCT03868852 557 564 I-Procedure
examination NCT03868852 565 576 I-Procedure
standards NCT03868852 577 586 O
should NCT03868852 587 593 O
be NCT03868852 594 596 O
met NCT03868852 597 600 O
: NCT03868852 601 602 O
( NCT03868852 603 604 O
no NCT03868852 605 607 B-Negation
blood NCT03868852 608 613 B-Procedure
transfusion NCT03868852 614 625 I-Procedure
within NCT03868852 626 632 B-Eq-Comparison
14 NCT03868852 633 635 I-Eq-Comparison
days NCT03868852 636 640 I-Eq-Comparison
) NCT03868852 641 642 O
A. NCT03868852 643 645 O
HB NCT03868852 647 649 B-Observation
> NCT03868852 650 651 B-Eq-Comparison
90 NCT03868852 652 654 I-Eq-Comparison
g NCT03868852 655 656 I-Eq-Comparison
/ NCT03868852 657 658 I-Eq-Comparison
L NCT03868852 659 660 I-Eq-Comparison
; NCT03868852 660 661 O
B. NCT03868852 662 664 O
ANC NCT03868852 666 669 B-Observation
> NCT03868852 670 671 B-Eq-Comparison
1.5 NCT03868852 672 675 I-Eq-Comparison
* NCT03868852 676 677 I-Eq-Comparison
109 NCT03868852 678 681 I-Eq-Comparison
/ NCT03868852 682 683 I-Eq-Comparison
L NCT03868852 684 685 I-Eq-Comparison
; NCT03868852 685 686 O
C. NCT03868852 687 689 O
PLT NCT03868852 691 694 B-Observation
> NCT03868852 695 696 B-Eq-Comparison
80 NCT03868852 697 699 I-Eq-Comparison
* NCT03868852 700 701 I-Eq-Comparison
109 NCT03868852 702 705 I-Eq-Comparison
/ NCT03868852 706 707 I-Eq-Comparison
L NCT03868852 708 709 I-Eq-Comparison

2 NCT03868852 717 718 O
. NCT03868852 718 719 O
Biochemical NCT03868852 721 732 B-Observation
tests NCT03868852 733 738 I-Observation
should NCT03868852 739 745 O
meet NCT03868852 746 750 O
the NCT03868852 751 754 B-Criteria-Count
following NCT03868852 755 764 I-Criteria-Count
criteria NCT03868852 765 773 I-Criteria-Count
: NCT03868852 774 775 O

A. NCT03868852 777 779 O
BIL NCT03868852 781 784 B-Observation
< NCT03868852 785 786 B-Eq-Comparison
1.25 NCT03868852 787 791 I-Eq-Comparison
times NCT03868852 792 797 I-Eq-Comparison
normal NCT03868852 798 804 I-Eq-Comparison
upper NCT03868852 805 810 I-Eq-Comparison
limit NCT03868852 811 816 I-Eq-Comparison
( NCT03868852 817 818 O
ULN NCT03868852 819 822 O
) NCT03868852 823 824 O
; NCT03868852 825 826 O
B. NCT03868852 827 829 O
ALT NCT03868852 831 834 B-Observation
and NCT03868852 835 838 B-And
AST NCT03868852 839 842 B-Observation
< NCT03868852 843 844 B-Eq-Comparison
2.5 NCT03868852 845 848 I-Eq-Comparison
ULN NCT03868852 849 852 I-Eq-Comparison
; NCT03868852 852 853 O
C. NCT03868852 854 856 O
Serum NCT03868852 858 863 B-Observation
Cr NCT03868852 864 866 I-Observation
< NCT03868852 867 868 B-Eq-Comparison
1 NCT03868852 869 870 I-Eq-Comparison
ULN NCT03868852 871 874 I-Eq-Comparison
, NCT03868852 875 876 O
endogenous NCT03868852 877 887 B-Observation
creatinine NCT03868852 888 898 I-Observation
clearance NCT03868852 899 908 I-Observation
> NCT03868852 909 910 B-Eq-Comparison
50 NCT03868852 911 913 I-Eq-Comparison
ml NCT03868852 914 916 I-Eq-Comparison
/ NCT03868852 917 918 I-Eq-Comparison
min NCT03868852 919 922 I-Eq-Comparison

- NCT03868852 925 926 O
Subjects NCT03868852 928 936 O
volunteered NCT03868852 937 948 O
to NCT03868852 949 951 O
participate NCT03868852 952 963 O
in NCT03868852 964 966 O
this NCT03868852 967 971 O
study NCT03868852 972 977 O
, NCT03868852 978 979 O
patients NCT03868852 980 988 O
or NCT03868852 989 991 O
legal NCT03868852 992 997 O
guardians NCT03868852 998 1007 O
signed NCT03868852 1008 1014 O
informed NCT03868852 1015 1023 O
consent NCT03868852 1024 1031 O
through NCT03868852 1032 1039 O
patient NCT03868852 1040 1047 O
consent NCT03868852 1048 1055 O
, NCT03868852 1056 1057 O
good NCT03868852 1058 1062 O
compliance NCT03868852 1063 1073 O
, NCT03868852 1074 1075 O
with NCT03868852 1076 1080 O
follow NCT03868852 1081 1087 O
- NCT03868852 1088 1089 O
up NCT03868852 1090 1092 O
. NCT03868852 1093 1094 O

- NCT03868852 1098 1099 O
Doctors NCT03868852 1101 1108 O
believe NCT03868852 1109 1116 O
that NCT03868852 1117 1121 O
treatment NCT03868852 1122 1131 O
can NCT03868852 1132 1135 O
benefit NCT03868852 1136 1143 O
patients NCT03868852 1144 1152 O
. NCT03868852 1153 1154 O


Inclusion NCT03869580 0 9 O
Criteria NCT03869580 10 18 O
: NCT03869580 19 20 O

- NCT03869580 24 25 O
Patients NCT03869580 27 35 O
with NCT03869580 36 40 O
a NCT03869580 41 42 O
double NCT03869580 43 49 B-Procedure
- NCT03869580 50 51 I-Procedure
J NCT03869580 52 53 I-Procedure
stent NCT03869580 54 59 I-Procedure
placement NCT03869580 60 69 B-Modifier
or NCT03869580 70 72 B-Or
change NCT03869580 73 79 B-Modifier
in NCT03869580 80 82 O
the NCT03869580 83 86 O
hospital NCT03869580 87 95 O

Exclusion NCT03869580 96 105 O
Criteria NCT03869580 106 114 O
: NCT03869580 115 116 O

- NCT03869580 120 121 O
renal NCT03869580 123 128 B-Modifier
transplants NCT03869580 129 140 B-Procedure
less NCT03869580 141 145 B-Eq-Comparison
than NCT03869580 146 150 I-Eq-Comparison
one NCT03869580 151 154 I-Eq-Comparison
year NCT03869580 155 159 I-Eq-Comparison
old NCT03869580 160 163 O

Inclusion NCT03867591 0 9 O
Criteria NCT03867591 10 18 O
: NCT03867591 19 20 O

- NCT03867591 24 25 O
Able NCT03867591 27 31 O
to NCT03867591 32 34 O
provide NCT03867591 35 42 O
written NCT03867591 43 50 O
informed NCT03867591 51 59 O
consent NCT03867591 60 67 O
in NCT03867591 68 70 O
English NCT03867591 71 78 O
. NCT03867591 79 80 O

- NCT03867591 84 85 O
Willing NCT03867591 87 94 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 95 97 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03867591 98 102 O
height NCT03867591 103 109 B-Observation
and NCT03867591 110 113 B-Or
weight NCT03867591 114 120 B-Observation
measured NCT03867591 121 129 O
and NCT03867591 130 133 O
provide NCT03867591 134 141 O
demographic NCT03867591 142 153 O
information NCT03867591 154 165 O
( NCT03867591 166 167 O
e. NCT03867591 168 170 O
g. NCT03867591 171 173 O
age NCT03867591 175 178 O
, NCT03867591 179 180 O
race NCT03867591 181 185 O
, NCT03867591 186 187 O
sex NCT03867591 188 191 O
) NCT03867591 192 193 O

- NCT03867591 197 198 O
Experience NCT03867591 200 210 O
heartburn NCT03867591 211 220 B-Condition
symptoms NCT03867591 221 229 B-Assertion___Assertion-Type-Value:possible
at NCT03867591 230 232 B-Eq-Comparison
least NCT03867591 233 238 I-Eq-Comparison
2 NCT03867591 239 240 I-Eq-Comparison
days NCT03867591 241 245 I-Eq-Comparison
a NCT03867591 246 247 I-Eq-Comparison
week NCT03867591 248 252 I-Eq-Comparison
during NCT03867591 253 259 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 260 263 O
past NCT03867591 264 268 B-Eq-Comparison
3 NCT03867591 269 270 I-Eq-Comparison
months NCT03867591 271 277 I-Eq-Comparison
. NCT03867591 278 279 O

- NCT03867591 283 284 O
Use NCT03867591 286 289 B-Eq-Comparison
OTC NCT03867591 290 293 B-Drug
product NCT03867591 294 301 I-Drug
( NCT03867591 302 303 O
s NCT03867591 304 305 O
) NCT03867591 306 307 O
, NCT03867591 309 310 O
supplements NCT03867591 311 322 B-Drug
, NCT03867591 323 324 O
or NCT03867591 325 327 B-Or
dietary NCT03867591 328 335 B-Drug
manipulation NCT03867591 336 348 I-Drug
to NCT03867591 349 351 O
relieve NCT03867591 352 359 O
heartburn NCT03867591 360 369 B-Condition
symptoms NCT03867591 370 378 B-Assertion___Assertion-Type-Value:possible
in NCT03867591 379 381 O
the NCT03867591 382 385 O
last NCT03867591 386 390 B-Eq-Comparison
3 NCT03867591 391 392 I-Eq-Comparison
months NCT03867591 393 399 I-Eq-Comparison
. NCT03867591 400 401 O

- NCT03867591 405 406 O
Willing NCT03867591 408 415 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 416 418 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03867591 419 423 O
the NCT03867591 424 427 O
study NCT03867591 428 433 B-Study
soy NCT03867591 434 437 B-Drug
supplement NCT03867591 438 448 I-Drug
before NCT03867591 449 455 B-Temporal-Connection___Temporal-Connection-Type-Value:before
resorting NCT03867591 456 465 O
to NCT03867591 466 468 O
OTC NCT03867591 469 472 B-Drug
product NCT03867591 473 480 I-Drug
( NCT03867591 481 482 O
s NCT03867591 483 484 O
) NCT03867591 485 486 O
to NCT03867591 487 489 O
control NCT03867591 490 497 O
heartburn NCT03867591 498 507 B-Condition
symptoms NCT03867591 508 516 B-Assertion___Assertion-Type-Value:possible
. NCT03867591 517 518 O

- NCT03867591 522 523 O
Willing NCT03867591 525 532 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 533 535 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03867591 536 544 O
questionnaires NCT03867591 545 559 B-Observation
, NCT03867591 560 561 O
records NCT03867591 562 569 B-Observation
, NCT03867591 570 571 O
and NCT03867591 572 575 B-Or
diaries NCT03867591 576 583 B-Observation
associated NCT03867591 584 594 O
with NCT03867591 595 599 O
the NCT03867591 600 603 O
study NCT03867591 604 609 B-Study
and NCT03867591 610 613 O
to NCT03867591 614 616 O
complete NCT03867591 617 625 O
all NCT03867591 626 629 O
clinical NCT03867591 630 638 B-Encounter
visits NCT03867591 639 645 I-Encounter
. NCT03867591 646 647 O

- NCT03867591 651 652 O
Willing NCT03867591 654 661 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867591 662 664 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03867591 665 672 O
information NCT03867591 673 684 O
about NCT03867591 685 690 O
dietary NCT03867591 691 698 B-Observation
intake NCT03867591 699 705 I-Observation
; NCT03867591 705 706 O
3 NCT03867591 707 708 B-Eq-Comparison
- NCT03867591 709 710 I-Eq-Comparison
day NCT03867591 711 714 I-Eq-Comparison
online NCT03867591 715 721 I-Eq-Comparison
24 NCT03867591 722 724 I-Eq-Comparison
- NCT03867591 725 726 I-Eq-Comparison
hr NCT03867591 727 729 I-Eq-Comparison
recalls NCT03867591 730 737 B-Observation
during NCT03867591 738 744 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03867591 745 753 B-Study
, NCT03867591 754 755 O
intervention NCT03867591 756 768 B-Procedure
, NCT03867591 769 770 O
and NCT03867591 771 774 B-And
washout NCT03867591 775 782 B-Procedure
. NCT03867591 783 784 O

- NCT03867591 788 789 O
Willing NCT03867591 791 798 O
and NCT03867591 799 802 O
able NCT03867591 803 807 O
to NCT03867591 808 810 O
provide NCT03867591 811 818 O
a NCT03867591 819 820 O
valid NCT03867591 821 826 O
social NCT03867591 827 833 O
security NCT03867591 834 842 O
for NCT03867591 843 846 O
study NCT03867591 847 852 O
payment NCT03867591 853 860 O
purposes NCT03867591 861 869 O
. NCT03867591 870 871 O

Exclusion NCT03867591 873 882 O
Criteria NCT03867591 883 891 O
: NCT03867591 892 893 O

- NCT03867591 897 898 O
Do NCT03867591 900 902 O
not NCT03867591 903 906 O
meet NCT03867591 907 911 O
the NCT03867591 912 915 O
above NCT03867591 916 921 O
criteria NCT03867591 922 930 O
. NCT03867591 931 932 O

- NCT03867591 936 937 O
Soy NCT03867591 939 942 O
allergy NCT03867591 943 950 B-Allergy

- NCT03867591 953 954 O
Severe NCT03867591 956 962 O
heartburn NCT03867591 963 972 B-Condition
problem NCT03867591 973 980 I-Condition
( NCT03867591 981 982 O
can NCT03867591 983 986 O
not NCT03867591 986 989 O
be NCT03867591 990 992 O
ignored NCT03867591 993 1000 O
and NCT03867591 1001 1004 O
often NCT03867591 1005 1010 B-Assertion___Assertion-Type-Value:hypothetical
limits NCT03867591 1011 1017 O
your NCT03867591 1018 1022 O
concentration NCT03867591 1023 1036 B-Condition
on NCT03867591 1037 1039 O
daily NCT03867591 1040 1045 B-Eq-Comparison
activities NCT03867591 1046 1056 O
) NCT03867591 1057 1058 O
during NCT03867591 1059 1065 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 1066 1069 O
last NCT03867591 1070 1074 B-Eq-Comparison
week NCT03867591 1075 1079 I-Eq-Comparison

- NCT03867591 1082 1083 O
Diagnosed NCT03867591 1085 1094 B-Coreference
or NCT03867591 1095 1097 B-Or
currently NCT03867591 1098 1107 B-Eq-Comparison
being NCT03867591 1108 1113 I-Eq-Comparison
treated NCT03867591 1114 1121 B-Procedure
for NCT03867591 1122 1125 O
any NCT03867591 1126 1129 O
gastrointestinal NCT03867591 1130 1146 B-Condition
diseases NCT03867591 1147 1155 I-Condition
including NCT03867591 1156 1165 O
GERD NCT03867591 1166 1170 B-Condition
, NCT03867591 1171 1172 O
gastric NCT03867591 1173 1180 B-Condition
ulcers NCT03867591 1181 1187 I-Condition
, NCT03867591 1188 1189 O
Crohn NCT03867591 1190 1195 B-Condition
's NCT03867591 1195 1197 I-Condition
, NCT03867591 1198 1199 O
celiac NCT03867591 1200 1206 B-Condition
, NCT03867591 1207 1208 O
ulcerative NCT03867591 1209 1219 B-Condition
colitis NCT03867591 1220 1227 I-Condition
, NCT03867591 1228 1229 O
etc NCT03867591 1230 1233 O
. NCT03867591 1234 1235 O

- NCT03867591 1239 1240 O
Self NCT03867591 1242 1246 O
- NCT03867591 1247 1248 O
disclosed NCT03867591 1249 1258 O
as NCT03867591 1259 1261 O
pregnant NCT03867591 1262 1270 B-Condition
or NCT03867591 1271 1273 B-Or
breast NCT03867591 1274 1280 B-Condition
- NCT03867591 1281 1282 I-Condition
feeding NCT03867591 1283 1290 I-Condition
or NCT03867591 1291 1293 B-Or
planning NCT03867591 1294 1302 B-Assertion___Assertion-Type-Value:intention
on NCT03867591 1303 1305 O
becoming NCT03867591 1306 1314 O
pregnant NCT03867591 1315 1323 B-Condition
during NCT03867591 1324 1330 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867591 1331 1334 O
study NCT03867591 1335 1340 B-Study
duration NCT03867591 1341 1349 O
. NCT03867591 1350 1351 O

- NCT03867591 1355 1356 O
Currently NCT03867591 1358 1367 B-Eq-Comparison
participating NCT03867591 1368 1381 O
in NCT03867591 1382 1384 O
another NCT03867591 1385 1392 B-Other
clinical NCT03867591 1393 1401 O
study NCT03867591 1402 1407 B-Study
. NCT03867591 1407 1408 O

Inclusion NCT03863522 0 9 O
Criteria NCT03863522 10 18 O
: NCT03863522 19 20 O

- NCT03863522 24 25 O
Patient NCT03863522 27 34 O
must NCT03863522 35 39 O
be NCT03863522 40 42 O
female NCT03863522 43 49 O

- NCT03863522 52 53 O
Patient NCT03863522 55 62 O
must NCT03863522 63 67 O
be NCT03863522 68 70 O
18 NCT03863522 71 73 B-Eq-Comparison
years NCT03863522 74 79 I-Eq-Comparison
of NCT03863522 80 82 I-Eq-Comparison
age NCT03863522 83 86 I-Age|Eq-Comparison
or NCT03863522 87 89 I-Eq-Comparison
older NCT03863522 90 95 I-Eq-Comparison

- NCT03863522 98 99 O
Patient NCT03863522 101 108 O
has NCT03863522 109 112 O
been NCT03863522 113 117 O
recommended NCT03863522 118 129 O
for NCT03863522 130 133 O
ultrasound NCT03863522 134 144 B-Procedure
core NCT03863522 145 149 I-Procedure
needle NCT03863522 150 156 I-Procedure
biopsy NCT03863522 157 163 I-Procedure
of NCT03863522 164 166 O
a NCT03863522 167 168 O
suspicious NCT03863522 169 179 B-Assertion___Assertion-Type-Value:possible
breast NCT03863522 180 186 B-Condition
lesion NCT03863522 187 193 I-Condition

Exclusion NCT03863522 194 203 O
Criteria NCT03863522 204 212 O
: NCT03863522 213 214 O

- NCT03863522 218 219 O
Patients NCT03863522 221 229 O
may NCT03863522 230 233 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03863522 234 236 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03863522 237 245 B-Negation
for NCT03863522 246 249 O
any NCT03863522 250 253 O
condition NCT03863522 254 263 B-Condition
that NCT03863522 264 268 O
in NCT03863522 269 271 O
the NCT03863522 272 275 O
opinion NCT03863522 276 283 O
of NCT03863522 284 286 O
the NCT03863522 287 290 O
investigator NCT03863522 291 303 O
may NCT03863522 304 307 O
not NCT03863522 308 311 O
make NCT03863522 312 316 O
it NCT03863522 317 319 O
safe NCT03863522 320 324 O
to NCT03863522 325 327 O
take NCT03863522 328 332 O
part NCT03863522 333 337 O
( NCT03863522 338 339 O
e. NCT03863522 340 342 O
g. NCT03863522 343 345 O
certain NCT03863522 347 354 O
medicines NCT03863522 355 364 B-Drug
) NCT03863522 365 366 O
. NCT03863522 367 368 O

Inclusion NCT03868488 0 9 O
Criteria NCT03868488 10 18 O
: NCT03868488 19 20 O

- NCT03868488 24 25 O
The NCT03868488 27 30 O
scores NCT03868488 31 37 O
of NCT03868488 38 40 O
the NCT03868488 41 44 O
9 NCT03868488 45 46 O
items NCT03868488 47 52 O
of NCT03868488 53 55 O
The NCT03868488 56 59 O
Diagnostic NCT03868488 60 70 O
and NCT03868488 71 74 O
Statistical NCT03868488 75 86 O
Manual NCT03868488 87 93 O
of NCT03868488 94 96 O
Mental NCT03868488 97 103 O
Disorders NCT03868488 104 113 O
, NCT03868488 114 115 O
Fifth NCT03868488 116 121 O
Edition NCT03868488 122 129 O
( NCT03868488 130 131 O
DSM NCT03868488 132 135 O
- NCT03868488 136 137 O
5 NCT03868488 138 139 O
) NCT03868488 140 141 O
recommended NCT03868488 142 153 O
diagnosis NCT03868488 154 163 O
for NCT03868488 164 167 O
Internet NCT03868488 168 176 B-Condition
gaming NCT03868488 177 183 I-Condition
disorder NCT03868488 184 192 I-Condition
≥ NCT03868488 193 194 B-Eq-Comparison
5 NCT03868488 195 196 I-Eq-Comparison
. NCT03868488 196 197 O

- NCT03868488 201 202 O
Engagement NCT03868488 204 214 B-Observation
in NCT03868488 215 217 I-Observation
popular NCT03868488 218 225 I-Observation
Internet NCT03868488 226 234 I-Observation
games NCT03868488 235 240 I-Observation
( NCT03868488 241 242 O
e. NCT03868488 243 245 O
g. NCT03868488 246 248 O
Arena NCT03868488 250 255 O
of NCT03868488 256 258 O
Valor NCT03868488 259 264 O
, NCT03868488 265 266 O
League NCT03868488 267 273 O
of NCT03868488 274 276 O
Legends NCT03868488 277 284 O
and NCT03868488 285 288 O
Player NCT03868488 289 295 O
Unknown NCT03868488 296 303 O
's NCT03868488 303 305 O
Battle NCT03868488 306 312 O
Grounds NCT03868488 313 320 O
) NCT03868488 321 322 O
for NCT03868488 323 326 O
over NCT03868488 327 331 B-Eq-Comparison
20 NCT03868488 332 334 I-Eq-Comparison
hours NCT03868488 335 340 I-Eq-Comparison
per NCT03868488 341 344 I-Eq-Comparison
week NCT03868488 345 349 I-Eq-Comparison
for NCT03868488 350 353 O
a NCT03868488 354 355 O
minimum NCT03868488 356 363 B-Eq-Comparison
of NCT03868488 364 366 I-Eq-Comparison
12 NCT03868488 367 369 I-Eq-Comparison
months NCT03868488 370 376 I-Eq-Comparison
. NCT03868488 377 378 O

- NCT03868488 382 383 O
The NCT03868488 385 388 O
scores NCT03868488 389 395 O
of NCT03868488 396 398 O
the NCT03868488 399 402 O
Young NCT03868488 403 408 B-Observation
- NCT03868488 409 410 I-Observation
Internet NCT03868488 411 419 I-Observation
Addiction NCT03868488 420 429 I-Observation
Test NCT03868488 430 434 I-Observation
( NCT03868488 435 436 O
Y NCT03868488 437 438 B-Observation
- NCT03868488 439 440 I-Observation
IAT NCT03868488 441 444 I-Observation
) NCT03868488 445 446 O
≥ NCT03868488 447 448 B-Eq-Comparison
50 NCT03868488 449 451 I-Eq-Comparison

Exclusion NCT03868488 453 462 O
Criteria NCT03868488 463 471 O
: NCT03868488 472 473 O

- NCT03868488 477 478 O
Current NCT03868488 480 487 B-Eq-Comparison
or NCT03868488 488 490 B-Or
history NCT03868488 491 498 B-Eq-Comparison
of NCT03868488 499 501 O
use NCT03868488 502 505 O
of NCT03868488 506 508 O
illegal NCT03868488 509 516 B-Drug
substances NCT03868488 517 527 I-Drug
and NCT03868488 528 531 B-Or
gambling NCT03868488 532 540 B-Observation
; NCT03868488 540 541 O

- NCT03868488 544 545 O
Current NCT03868488 547 554 B-Eq-Comparison
or NCT03868488 555 557 B-Or
history NCT03868488 558 565 B-Eq-Comparison
of NCT03868488 566 568 O
psychiatric NCT03868488 569 580 B-Modifier
or NCT03868488 581 583 B-Or
neurological NCT03868488 584 596 B-Modifier
illness NCT03868488 597 604 B-Condition
; NCT03868488 604 605 O

- NCT03868488 608 609 O
Current NCT03868488 611 618 B-Eq-Comparison
use NCT03868488 619 622 O
of NCT03868488 623 625 O
psychotropic NCT03868488 626 638 B-Drug
medications NCT03868488 639 650 I-Drug
. NCT03868488 651 652 O


Inclusion NCT03866499 0 9 O
Criteria NCT03866499 10 18 O
: NCT03866499 19 20 O

- NCT03866499 24 25 O
Histologically NCT03866499 27 41 B-Procedure
or NCT03866499 42 44 B-Or
cytologically NCT03866499 45 58 B-Procedure
confirmed NCT03866499 59 68 O
non NCT03866499 69 72 B-Negation
- NCT03866499 73 74 O
small NCT03866499 75 80 B-Modifier
cell NCT03866499 81 85 I-Modifier
lung NCT03866499 86 90 I-Modifier
cancer NCT03866499 91 97 B-Condition
. NCT03866499 98 99 O

- NCT03866499 103 104 O
The NCT03866499 106 109 O
ECOG NCT03866499 110 114 B-Observation
score NCT03866499 115 120 O
of NCT03866499 121 123 O
performance NCT03866499 124 135 O
status NCT03866499 136 142 O
is NCT03866499 143 145 O
0 NCT03866499 146 147 B-Eq-Comparison
- NCT03866499 148 149 I-Eq-Comparison
1 NCT03866499 150 151 O
. NCT03866499 151 152 O

- NCT03866499 156 157 O
Locally NCT03866499 159 166 B-Modifier
advanced NCT03866499 167 175 I-Modifier
or NCT03866499 176 178 B-Or
recurrent NCT03866499 179 188 B-Modifier
metastatic NCT03866499 189 199 I-Modifier
NSCLC NCT03866499 200 205 B-Condition
that NCT03866499 206 210 O
has NCT03866499 211 214 O
never NCT03866499 215 220 B-Negation
received NCT03866499 221 229 B-Eq-Comparison
systemic NCT03866499 230 238 B-Procedure
treatment NCT03866499 239 248 I-Procedure
. NCT03866499 249 250 O

- NCT03866499 254 255 O
According NCT03866499 257 266 O
to NCT03866499 267 269 O
RECIST1.1 NCT03866499 270 279 O
criteria NCT03866499 280 288 O
, NCT03866499 289 290 O
there NCT03866499 291 296 O
is NCT03866499 297 299 O
at NCT03866499 300 302 B-Eq-Comparison
least NCT03866499 303 308 I-Eq-Comparison
1 NCT03866499 309 310 I-Eq-Comparison
measurable NCT03866499 311 321 O
lesion NCT03866499 322 328 B-Condition
that NCT03866499 329 333 O
has NCT03866499 334 337 O
not NCT03866499 338 341 B-Negation
been NCT03866499 342 346 O
previously NCT03866499 347 357 B-Eq-Comparison
irradiated NCT03866499 358 368 B-Procedure
. NCT03866499 369 370 O

- NCT03866499 374 375 O
Prior NCT03866499 377 382 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866499 383 385 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866499 386 396 B-Study
, NCT03866499 397 398 O
a NCT03866499 399 400 O
central NCT03866499 401 408 O
laboratory NCT03866499 409 419 B-Observation
testing NCT03866499 420 427 I-Observation
report NCT03866499 428 434 O
has NCT03866499 435 438 O
confirmed NCT03866499 439 448 O
that NCT03866499 449 453 O
the NCT03866499 454 457 O
tumor NCT03866499 458 463 B-Condition
has NCT03866499 464 467 O
one NCT03866499 468 471 B-Eq-Comparison
of NCT03866499 472 474 I-Eq-Comparison
two NCT03866499 475 478 I-Eq-Comparison
common NCT03866499 479 485 B-Condition
EGFR NCT03866499 486 490 I-Condition
mutations NCT03866499 491 500 I-Condition
positive NCT03866499 501 509 O
that NCT03866499 510 514 O
are NCT03866499 515 518 O
sensitive NCT03866499 519 528 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866499 529 531 I-Assertion___Assertion-Type-Value:hypothetical
EGFR NCT03866499 532 536 B-Procedure
- NCT03866499 537 538 I-Procedure
TKI NCT03866499 539 542 I-Procedure
therapy NCT03866499 543 550 I-Procedure
, NCT03866499 551 552 O
accompanied NCT03866499 553 564 O
with NCT03866499 565 569 B-And
or NCT03866499 570 572 B-Or
not NCT03866499 573 576 B-Negation
accompanied NCT03866499 577 588 O
with NCT03866499 589 593 O
other NCT03866499 594 599 B-Other
EGFR NCT03866499 600 604 B-Condition
mutation NCT03866499 605 613 I-Condition
, NCT03866499 614 615 O
with NCT03866499 616 620 O
the NCT03866499 621 624 O
exception NCT03866499 625 634 B-Exception
of NCT03866499 635 637 O
exon NCT03866499 638 642 B-Condition
20 NCT03866499 643 645 I-Condition
insertion NCT03866499 646 655 I-Condition
. NCT03866499 656 657 O

Exclusion NCT03866499 659 668 O
Criteria NCT03866499 669 677 O
: NCT03866499 678 679 O

- NCT03866499 683 684 O
Previously NCT03866499 686 696 B-Eq-Comparison
received NCT03866499 697 705 I-Eq-Comparison
systemic NCT03866499 706 714 B-Modifier
treatment NCT03866499 715 724 B-Procedure
for NCT03866499 725 728 O
locally NCT03866499 729 736 B-Modifier
advanced NCT03866499 737 745 I-Modifier
or NCT03866499 746 748 B-Or
recurrent NCT03866499 749 758 B-Modifier
metastatic NCT03866499 759 769 I-Modifier
cancer NCT03866499 770 776 B-Condition
. NCT03866499 777 778 O

- NCT03866499 782 783 O
Primary NCT03866499 785 792 B-Modifier
T790 NCT03866499 793 797 B-Condition
M NCT03866499 798 799 I-Condition
mutation NCT03866499 800 808 I-Condition
- NCT03866499 809 810 O
positive NCT03866499 811 819 O
patient NCT03866499 820 827 O
. NCT03866499 828 829 O

- NCT03866499 833 834 O
Previous NCT03866499 836 844 B-Eq-Comparison
interstitial NCT03866499 845 857 B-Condition
lung NCT03866499 858 862 I-Condition
disease NCT03866499 863 870 I-Condition
, NCT03866499 871 872 O
drug NCT03866499 873 877 B-Drug
- NCT03866499 878 879 O
induced NCT03866499 880 887 O
interstitial NCT03866499 888 900 B-Condition
lung NCT03866499 901 905 I-Condition
disease NCT03866499 906 913 I-Condition
, NCT03866499 914 915 O
radiation NCT03866499 916 925 B-Condition
pneumonia NCT03866499 926 935 I-Condition
requiring NCT03866499 936 945 B-Assertion___Assertion-Type-Value:hypothetical
hormonal NCT03866499 946 954 B-Procedure
therapy NCT03866499 955 962 I-Procedure
, NCT03866499 963 964 O
or NCT03866499 965 967 B-Or
any NCT03866499 968 971 O
clinically NCT03866499 972 982 O
proven NCT03866499 983 989 O
active NCT03866499 990 996 B-Eq-Comparison
interstitial NCT03866499 997 1009 B-Condition
lung NCT03866499 1010 1014 I-Condition
disease NCT03866499 1015 1022 I-Condition
. NCT03866499 1023 1024 O

- NCT03866499 1028 1029 O
Known NCT03866499 1031 1036 O
active NCT03866499 1037 1043 B-Eq-Comparison
infections NCT03866499 1044 1054 B-Condition
such NCT03866499 1055 1059 O
as NCT03866499 1060 1062 O
hepatitis NCT03866499 1063 1072 B-Condition
B NCT03866499 1073 1074 I-Condition
, NCT03866499 1075 1076 O
hepatitis NCT03866499 1077 1086 B-Condition
C NCT03866499 1087 1088 I-Condition
, NCT03866499 1089 1090 O
and NCT03866499 1091 1094 B-Or
human NCT03866499 1095 1100 B-Condition
immunodeficiency NCT03866499 1101 1117 I-Condition
virus NCT03866499 1118 1123 I-Condition
. NCT03866499 1124 1125 O

- NCT03866499 1129 1130 O
Local NCT03866499 1132 1137 B-Modifier
radiation NCT03866499 1138 1147 B-Procedure
therapy NCT03866499 1148 1155 I-Procedure
is NCT03866499 1156 1158 O
carried NCT03866499 1159 1166 B-Eq-Comparison
out NCT03866499 1167 1170 I-Eq-Comparison
within NCT03866499 1171 1177 B-Eq-Comparison
1 NCT03866499 1178 1179 I-Eq-Comparison
week NCT03866499 1180 1184 I-Eq-Comparison
; NCT03866499 1184 1185 O
more NCT03866499 1186 1190 B-Eq-Comparison
than NCT03866499 1191 1195 I-Eq-Comparison
30 NCT03866499 1196 1198 I-Eq-Comparison
% NCT03866499 1199 1200 I-Eq-Comparison
bone NCT03866499 1201 1205 B-Procedure
marrow NCT03866499 1206 1212 I-Procedure
radiation NCT03866499 1213 1222 I-Procedure
therapy NCT03866499 1223 1230 I-Procedure
or NCT03866499 1231 1233 B-Or
extensive NCT03866499 1234 1243 O
radiation NCT03866499 1244 1253 B-Procedure
therapy NCT03866499 1254 1261 I-Procedure
is NCT03866499 1262 1264 O
performed NCT03866499 1265 1274 O
within NCT03866499 1275 1281 B-Eq-Comparison
4 NCT03866499 1282 1283 I-Eq-Comparison
weeks NCT03866499 1284 1289 I-Eq-Comparison
. NCT03866499 1290 1291 O

- NCT03866499 1295 1296 O
≤ NCT03866499 1298 1299 B-Eq-Comparison
4 NCT03866499 1300 1301 I-Eq-Comparison
weeks NCT03866499 1302 1307 I-Eq-Comparison
from NCT03866499 1308 1312 B-Temporal-Connection___Temporal-Connection-Type-Value:after
major NCT03866499 1313 1318 O
surgery NCT03866499 1319 1326 B-Procedure
or NCT03866499 1327 1329 B-Or
≤ NCT03866499 1330 1331 B-Eq-Comparison
2 NCT03866499 1332 1333 I-Eq-Comparison
weeks NCT03866499 1334 1339 I-Eq-Comparison
from NCT03866499 1340 1344 B-Temporal-Connection___Temporal-Connection-Type-Value:after
minor NCT03866499 1345 1350 O
surgery NCT03866499 1351 1358 B-Procedure
. NCT03866499 1358 1359 O

Inclusion NCT03866512 0 9 O
Criteria NCT03866512 10 18 O
: NCT03866512 19 20 O

- NCT03866512 24 25 O
Males NCT03866512 27 32 O
and NCT03866512 33 36 B-Or
females NCT03866512 37 44 O
18 NCT03866512 45 47 B-Eq-Comparison
- NCT03866512 48 49 I-Eq-Comparison
40 NCT03866512 50 52 I-Eq-Comparison
years NCT03866512 53 58 I-Eq-Comparison
of NCT03866512 59 61 O
age NCT03866512 62 65 B-Age

- NCT03866512 68 69 O
Body NCT03866512 71 75 B-Observation
mass NCT03866512 76 80 I-Observation
index NCT03866512 81 86 I-Observation
between NCT03866512 87 94 B-Eq-Comparison
18 NCT03866512 95 97 I-Eq-Comparison
and NCT03866512 98 101 I-Eq-Comparison
27 NCT03866512 102 104 I-Eq-Comparison

Exclusion NCT03866512 106 115 O
Criteria NCT03866512 116 124 O
: NCT03866512 125 126 O

- NCT03866512 130 131 O
Any NCT03866512 133 136 O
diagnosed NCT03866512 137 146 O
metabolic NCT03866512 147 156 B-Condition
impairment NCT03866512 157 167 I-Condition
( NCT03866512 168 169 O
e. NCT03866512 170 172 O
g. NCT03866512 173 175 O
type NCT03866512 177 181 B-Modifier
1 NCT03866512 182 183 I-Modifier
or NCT03866512 184 186 B-Or
2 NCT03866512 187 188 B-Modifier
diabetes NCT03866512 189 197 B-Condition
) NCT03866512 198 199 O

- NCT03866512 203 204 O
Any NCT03866512 206 209 O
diagnosed NCT03866512 210 219 O
cardiovascular NCT03866512 220 234 B-Condition
disease NCT03866512 235 242 I-Condition

- NCT03866512 245 246 O
Hypertension NCT03866512 248 260 B-Condition
( NCT03866512 261 262 O
≥ NCT03866512 264 265 B-Eq-Comparison
140 NCT03866512 266 269 I-Eq-Comparison
mmHg NCT03866512 270 274 I-Eq-Comparison
systolic NCT03866512 275 283 B-Observation
and NCT03866512 284 287 B-Or
/ NCT03866512 288 289 I-Or
or NCT03866512 290 292 I-Or
≥ NCT03866512 293 294 B-Eq-Comparison
90 NCT03866512 295 297 I-Eq-Comparison
mmHg NCT03866512 298 302 I-Eq-Comparison
diastolic NCT03866512 303 312 B-Observation
) NCT03866512 313 314 O

- NCT03866512 318 319 O
Chronic NCT03866512 321 328 B-Modifier
use NCT03866512 329 332 O
of NCT03866512 333 335 O
any NCT03866512 336 339 O
prescribed NCT03866512 340 350 B-Modifier
or NCT03866512 351 353 B-Or
over NCT03866512 354 358 B-Modifier
the NCT03866512 359 362 I-Modifier
counter NCT03866512 363 370 I-Modifier
pharmaceuticals NCT03866512 371 386 B-Drug
( NCT03866512 387 388 O
excluding NCT03866512 389 398 B-Exception
oral NCT03866512 399 403 B-Drug
contraceptives NCT03866512 404 418 I-Drug
and NCT03866512 419 422 B-Or
contraceptive NCT03866512 423 436 B-Procedure
devices NCT03866512 437 444 I-Procedure
) NCT03866512 445 446 O

- NCT03866512 450 451 O
Regular NCT03866512 453 460 B-Eq-Comparison
use NCT03866512 461 464 O
of NCT03866512 465 467 O
nutritional NCT03866512 468 479 B-Drug
supplements NCT03866512 480 491 I-Drug

- NCT03866512 494 495 O
Metallic NCT03866512 497 505 B-Procedure
implants NCT03866512 506 514 I-Procedure

- NCT03866512 517 518 O
A NCT03866512 520 521 O
personal NCT03866512 522 530 B-Family-Member___Family-Member-Type:patient
or NCT03866512 531 533 B-Or
family NCT03866512 534 540 B-Family-Member
history NCT03866512 541 548 I-Family-Member
of NCT03866512 549 551 O
thrombosis NCT03866512 552 562 B-Condition
, NCT03866512 563 564 O
epilepsy NCT03866512 565 573 B-Condition
, NCT03866512 574 575 O
seizures NCT03866512 576 584 B-Condition
or NCT03866512 585 587 B-Or
schizophrenia NCT03866512 588 601 B-Condition

- NCT03866512 604 605 O
Any NCT03866512 607 610 O
previous NCT03866512 611 619 B-Eq-Comparison
motor NCT03866512 620 625 B-Condition
disorders NCT03866512 626 635 I-Condition

- NCT03866512 638 639 O
Any NCT03866512 641 644 O
known NCT03866512 645 650 O
disorders NCT03866512 651 660 B-Condition
in NCT03866512 661 663 I-Condition
lipid NCT03866512 664 669 I-Condition
metabolism NCT03866512 670 680 I-Condition

- NCT03866512 683 684 O
Any NCT03866512 686 689 O
known NCT03866512 690 695 O
disorders NCT03866512 696 705 B-Condition
in NCT03866512 706 708 I-Condition
muscle NCT03866512 709 715 I-Condition
metabolism NCT03866512 716 726 I-Condition

- NCT03866512 729 730 O
Known NCT03866512 732 737 O
allergy NCT03866512 738 745 B-Allergy
for NCT03866512 746 749 O
Acipimox NCT03866512 750 758 B-Drug
, NCT03866512 759 760 O
beta NCT03866512 761 765 B-Drug
agonist NCT03866512 766 773 I-Drug
, NCT03866512 774 775 O
or NCT03866512 776 778 B-Or
other NCT03866512 779 784 B-Other
substances NCT03866512 785 795 B-Drug
in NCT03866512 796 798 I-Drug
the NCT03866512 799 802 I-Drug
tablets NCT03866512 803 810 I-Drug

- NCT03866512 813 814 O
Known NCT03866512 816 821 O
sensitivity NCT03866512 822 833 B-Condition
for NCT03866512 834 837 O
sympathomimetic NCT03866512 838 853 B-Drug
drugs NCT03866512 854 859 I-Drug

- NCT03866512 862 863 O
Known NCT03866512 865 870 O
hypokalaemia NCT03866512 871 883 B-Condition

- NCT03866512 886 887 O
Presence NCT03866512 889 897 B-Eq-Comparison
of NCT03866512 898 900 O
an NCT03866512 901 903 O
ulcer NCT03866512 904 909 B-Condition
in NCT03866512 910 912 O
the NCT03866512 913 916 O
stomach NCT03866512 917 924 B-Modifier
or NCT03866512 925 927 B-Or
gut NCT03866512 928 931 B-Modifier
and NCT03866512 932 935 B-Or
/ NCT03866512 936 937 I-Or
or NCT03866512 938 940 I-Or
strong NCT03866512 941 947 O
history NCT03866512 948 955 B-Eq-Comparison
of NCT03866512 956 958 O
indigestion NCT03866512 959 970 B-Condition

- NCT03866512 973 974 O
Known NCT03866512 976 981 O
severe NCT03866512 982 988 O
kidney NCT03866512 989 995 B-Condition
problems NCT03866512 996 1004 I-Condition

- NCT03866512 1007 1008 O
Pregnancy NCT03866512 1010 1019 B-Condition

- NCT03866512 1022 1023 O
Unable NCT03866512 1025 1031 O
to NCT03866512 1032 1034 O
give NCT03866512 1035 1039 O
consent NCT03866512 1040 1047 O

Inclusion NCT03867630 0 9 O
Criteria NCT03867630 10 18 O
: NCT03867630 19 20 O

- NCT03867630 24 25 O
20 NCT03867630 27 29 B-Eq-Comparison
to NCT03867630 30 32 I-Eq-Comparison
80 NCT03867630 33 35 I-Eq-Comparison
years NCT03867630 36 41 I-Eq-Comparison
old NCT03867630 42 45 B-Age

- NCT03867630 48 49 O
Patients NCT03867630 51 59 O
with NCT03867630 60 64 O
a NCT03867630 65 66 O
herniated NCT03867630 67 76 B-Condition
disc NCT03867630 77 81 I-Condition
, NCT03867630 82 83 O
spinal NCT03867630 84 90 B-Condition
stenosis NCT03867630 91 99 I-Condition

- NCT03867630 102 103 O
Patients NCT03867630 105 113 O
with NCT03867630 114 118 O
chronic NCT03867630 119 126 B-Modifier
low NCT03867630 127 130 I-Modifier
back NCT03867630 131 135 I-Modifier
pain NCT03867630 136 140 B-Condition
and NCT03867630 141 144 B-Or
lower NCT03867630 145 150 B-Modifier
extremity NCT03867630 151 160 I-Modifier
pain NCT03867630 161 165 B-Condition
who NCT03867630 166 169 B-And
did NCT03867630 170 173 O
not NCT03867630 174 177 O
respond NCT03867630 178 185 O
to NCT03867630 186 188 O
lumbar NCT03867630 189 195 B-Modifier
epidural NCT03867630 196 204 B-Procedure
steroid NCT03867630 205 212 I-Procedure
injections NCT03867630 213 223 I-Procedure

- NCT03867630 226 227 O
Patients NCT03867630 229 237 O
who NCT03867630 238 241 O
are NCT03867630 242 245 O
performed NCT03867630 246 255 B-Eq-Comparison
percutaneous NCT03867630 256 268 B-Procedure
epidural NCT03867630 269 277 I-Procedure
neuroplasty NCT03867630 278 289 I-Procedure
with NCT03867630 290 294 O
wire NCT03867630 295 299 B-Procedure
type NCT03867630 300 304 I-Procedure
catheter NCT03867630 305 313 I-Procedure
. NCT03867630 314 315 O

Exclusion NCT03867630 317 326 O
Criteria NCT03867630 327 335 O
: NCT03867630 336 337 O

- NCT03867630 341 342 O
Incomplete NCT03867630 344 354 O
medical NCT03867630 355 362 O
record NCT03867630 363 369 O

- NCT03867630 372 373 O
Contraindication NCT03867630 375 391 B-Contraindication
to NCT03867630 392 394 O
percutaneous NCT03867630 395 407 B-Procedure
epidural NCT03867630 408 416 I-Procedure
neuroplasty NCT03867630 417 428 I-Procedure

Inclusion NCT03861533 0 9 O
Criteria NCT03861533 10 18 O
: NCT03861533 19 20 O

1 NCT03861533 24 25 O
. NCT03861533 25 26 O
Adults NCT03861533 28 34 O
≥ NCT03861533 35 36 B-Eq-Comparison
18 NCT03861533 37 39 I-Eq-Comparison
years NCT03861533 40 45 I-Eq-Comparison
old NCT03861533 46 49 B-Age

2 NCT03861533 52 53 O
. NCT03861533 53 54 O
High NCT03861533 56 60 O
risk NCT03861533 61 65 B-Risk
for NCT03861533 66 69 O
cardiovascular NCT03861533 70 84 B-Condition
morbidity NCT03861533 85 94 I-Condition
and NCT03861533 95 98 B-Or
mortality NCT03861533 99 108 B-Death
such NCT03861533 109 113 O
as NCT03861533 114 116 O
prior NCT03861533 117 122 B-Eq-Comparison
history NCT03861533 123 130 I-Eq-Comparison
of NCT03861533 131 133 O
clinical NCT03861533 134 142 B-Modifier
cardiovascular NCT03861533 143 157 B-Condition
disease NCT03861533 158 165 I-Condition
and NCT03861533 166 169 B-Or
/ NCT03861533 170 171 I-Or
or NCT03861533 172 174 I-Or
history NCT03861533 175 182 B-Eq-Comparison
of NCT03861533 183 185 O
familial NCT03861533 186 194 B-Modifier
hypercholesterolemia NCT03861533 195 215 B-Condition

3 NCT03861533 218 219 O
. NCT03861533 219 220 O
LDL NCT03861533 222 225 B-Observation
- NCT03861533 226 227 I-Observation
C NCT03861533 228 229 I-Observation
within NCT03861533 230 236 B-Eq-Comparison
the NCT03861533 237 240 I-Eq-Comparison
past NCT03861533 241 245 I-Eq-Comparison
6 NCT03861533 246 247 I-Eq-Comparison
months NCT03861533 248 254 I-Eq-Comparison
above NCT03861533 255 260 B-Eq-Comparison
recommended NCT03861533 261 272 I-Eq-Comparison
level NCT03861533 273 278 I-Eq-Comparison
despite NCT03861533 279 286 B-And
maximal NCT03861533 287 294 B-Modifier
tolerated NCT03861533 295 304 I-Modifier
statin NCT03861533 305 311 B-Procedure
therapy NCT03861533 312 319 I-Procedure
± NCT03861533 320 321 O
ezetimibe NCT03861533 322 331 B-Drug
for NCT03861533 332 335 O
the NCT03861533 336 339 B-Eq-Comparison
past NCT03861533 340 344 I-Eq-Comparison
3 NCT03861533 345 346 I-Eq-Comparison
months NCT03861533 347 353 I-Eq-Comparison
. NCT03861533 354 355 O

Exclusion NCT03861533 357 366 O
Criteria NCT03861533 367 375 O
: NCT03861533 376 377 O

1 NCT03861533 381 382 O
. NCT03861533 382 383 O
Current NCT03861533 385 392 B-Eq-Comparison
treatment NCT03861533 393 402 B-Procedure
with NCT03861533 403 407 O
PCSK9 NCT03861533 408 413 B-Drug
inhibitor NCT03861533 414 423 I-Drug

2 NCT03861533 426 427 O
. NCT03861533 427 428 O
Current NCT03861533 430 437 B-Eq-Comparison
participation NCT03861533 438 451 O
in NCT03861533 452 454 O
investigational NCT03861533 455 470 O
study NCT03861533 471 476 B-Study

3 NCT03861533 479 480 O
. NCT03861533 480 481 O
Prior NCT03861533 483 488 O
participation NCT03861533 489 502 O
in NCT03861533 503 505 O
the NCT03861533 506 509 O
GOAL NCT03861533 510 514 O
program NCT03861533 515 522 O

Inclusion NCT03865966 0 9 O
Criteria NCT03865966 10 18 O
: NCT03865966 19 20 O

- NCT03865966 24 25 O
Patients NCT03865966 27 35 O
with NCT03865966 36 40 O
end NCT03865966 41 44 B-Modifier
- NCT03865966 45 46 I-Modifier
stage NCT03865966 47 52 I-Modifier
liver NCT03865966 53 58 B-Condition
disease NCT03865966 59 66 I-Condition
who NCT03865966 67 70 B-And
require NCT03865966 71 78 B-Assertion___Assertion-Type-Value:hypothetical
liver NCT03865966 79 84 B-Procedure
transplantation NCT03865966 85 100 I-Procedure

Exclusion NCT03865966 101 110 O
Criteria NCT03865966 111 119 O
: NCT03865966 120 121 O

- NCT03865966 125 126 O
Children NCT03865966 128 136 O
without NCT03865966 137 144 B-Negation
liver NCT03865966 145 150 B-Procedure
transplantation NCT03865966 151 166 I-Procedure
refer NCT03865966 167 172 O
to NCT03865966 173 175 O
children NCT03865966 176 184 O
; NCT03865966 184 185 O

- NCT03865966 188 189 O
Children NCT03865966 191 199 O
who NCT03865966 200 203 O
are NCT03865966 204 207 O
unwilling NCT03865966 208 217 O
to NCT03865966 218 220 O
participate NCT03865966 221 232 O
; NCT03865966 232 233 O

Inclusion NCT03864107 0 9 O
Criteria NCT03864107 10 18 O
: NCT03864107 19 20 O

- NCT03864107 24 25 O
Men NCT03864107 27 30 O
and NCT03864107 31 34 B-Or
women NCT03864107 35 40 O
aged NCT03864107 41 45 B-Age
18 NCT03864107 46 48 B-Eq-Comparison
- NCT03864107 49 50 I-Eq-Comparison
70 NCT03864107 51 53 I-Eq-Comparison
years NCT03864107 54 59 I-Eq-Comparison

- NCT03864107 62 63 O
BMI NCT03864107 65 68 B-Observation
18.5 NCT03864107 69 73 B-Eq-Comparison
- NCT03864107 74 75 I-Eq-Comparison
50 NCT03864107 76 78 I-Eq-Comparison
kg NCT03864107 79 81 I-Eq-Comparison
/ NCT03864107 82 83 I-Eq-Comparison
m2 NCT03864107 84 86 I-Eq-Comparison

- NCT03864107 89 90 O
Not NCT03864107 92 95 B-Negation
taking NCT03864107 96 102 B-Eq-Comparison
antibiotics NCT03864107 103 114 B-Drug
and NCT03864107 115 118 B-Or
antimicrobial NCT03864107 119 132 B-Drug
drugs NCT03864107 133 138 I-Drug
for NCT03864107 139 142 O
at NCT03864107 143 145 B-Eq-Comparison
least NCT03864107 146 151 I-Eq-Comparison
three NCT03864107 152 157 I-Eq-Comparison
months NCT03864107 158 164 I-Eq-Comparison

- NCT03864107 167 168 O
Both NCT03864107 170 174 O
physically NCT03864107 175 185 B-Observation
active NCT03864107 186 192 I-Observation
and NCT03864107 193 196 B-Or
sedentary NCT03864107 197 206 B-Observation
individuals NCT03864107 207 218 O
will NCT03864107 219 223 O
be NCT03864107 224 226 O
eligible NCT03864107 227 235 O
to NCT03864107 236 238 O
take NCT03864107 239 243 O
part NCT03864107 244 248 O
in NCT03864107 249 251 O
the NCT03864107 252 255 O
study NCT03864107 256 261 B-Study

- NCT03864107 264 265 O
Weight NCT03864107 267 273 B-Observation
stable NCT03864107 274 280 O
( NCT03864107 281 282 O
± NCT03864107 284 285 B-Eq-Comparison
5 NCT03864107 286 287 I-Eq-Comparison
kg NCT03864107 288 290 I-Eq-Comparison
) NCT03864107 291 292 O
for NCT03864107 293 296 O
at NCT03864107 297 299 B-Eq-Comparison
least NCT03864107 300 305 I-Eq-Comparison
6 NCT03864107 306 307 I-Eq-Comparison
months NCT03864107 308 314 I-Eq-Comparison

Excusion NCT03864107 315 323 O
Criteria NCT03864107 324 332 O
: NCT03864107 333 334 O

- NCT03864107 338 339 O
No NCT03864107 341 343 B-Negation
cardiometabolic NCT03864107 344 359 B-Condition
( NCT03864107 360 361 O
e. NCT03864107 362 364 O
g. NCT03864107 365 367 O
heart NCT03864107 369 374 B-Condition
disease NCT03864107 375 382 I-Condition
, NCT03864107 383 384 O
high NCT03864107 385 389 O
blood NCT03864107 390 395 B-Condition
pressure NCT03864107 396 404 I-Condition
) NCT03864107 405 406 O
or NCT03864107 407 409 B-Or
inflammatory NCT03864107 410 422 B-Modifier
illness NCT03864107 423 430 B-Condition

- NCT03864107 433 434 O
Smokers NCT03864107 436 443 B-Condition
( NCT03864107 444 445 O
including NCT03864107 446 455 O
the NCT03864107 456 459 O
use NCT03864107 460 463 O
of NCT03864107 464 466 O
vaporisers NCT03864107 467 477 B-Drug
and NCT03864107 478 481 B-Or
e NCT03864107 482 483 B-Drug
- NCT03864107 484 485 I-Drug
cigarettes NCT03864107 486 496 I-Drug
) NCT03864107 497 498 O

- NCT03864107 502 503 O
Taking NCT03864107 505 511 B-Eq-Comparison
anti NCT03864107 512 516 B-Drug
- NCT03864107 517 518 I-Drug
inflammatory NCT03864107 519 531 I-Drug
drugs NCT03864107 532 537 I-Drug
( NCT03864107 538 539 O
excluding NCT03864107 540 549 B-Exception
aspirin NCT03864107 550 557 B-Drug
) NCT03864107 558 559 O

Inclusion NCT03865225 0 9 O
Criteria NCT03865225 10 18 O
: NCT03865225 19 20 O

- NCT03865225 24 25 O
male NCT03865225 27 31 O
and NCT03865225 32 35 B-Or
female NCT03865225 36 42 O
subjects NCT03865225 43 51 O
aged NCT03865225 52 56 B-Age
between NCT03865225 57 64 B-Eq-Comparison
18 NCT03865225 65 67 I-Eq-Comparison
and NCT03865225 68 71 I-Eq-Comparison
90 NCT03865225 72 74 I-Eq-Comparison

- NCT03865225 78 79 O
written NCT03865225 81 88 O
and NCT03865225 89 92 O
oral NCT03865225 93 97 O
informed NCT03865225 98 106 O
consent NCT03865225 107 114 O

- NCT03865225 117 118 O
evidence NCT03865225 120 128 O
of NCT03865225 129 131 O
an NCT03865225 132 134 O
ischaemic NCT03865225 135 144 B-Condition
lesion NCT03865225 145 151 I-Condition
on NCT03865225 152 154 O
cranial NCT03865225 155 162 B-Procedure
computed NCT03865225 163 171 I-Procedure
tomography NCT03865225 172 182 I-Procedure
scan NCT03865225 183 187 I-Procedure
or NCT03865225 188 190 B-Or
magnetic NCT03865225 191 199 B-Procedure
resonance NCT03865225 200 209 I-Procedure
imaging NCT03865225 210 217 I-Procedure

Exclusion NCT03865225 218 227 O
Criteria NCT03865225 228 236 O
: NCT03865225 237 238 O

- NCT03865225 242 243 O
intake NCT03865225 245 251 O
of NCT03865225 252 254 O
any NCT03865225 255 258 O
tricyclic NCT03865225 259 268 B-Drug
antidepressant NCT03865225 269 283 I-Drug
within NCT03865225 284 290 B-Eq-Comparison
the NCT03865225 291 294 I-Eq-Comparison
last NCT03865225 295 299 I-Eq-Comparison
14 NCT03865225 300 302 I-Eq-Comparison
days NCT03865225 303 307 I-Eq-Comparison

- NCT03865225 310 311 O
atrial NCT03865225 313 319 B-Condition
fibrillation NCT03865225 320 332 I-Condition

- NCT03865225 335 336 O
prior NCT03865225 338 343 B-Eq-Comparison
diagnosed NCT03865225 344 353 O
autonomic NCT03865225 354 363 B-Condition
neuropathy NCT03865225 364 374 I-Condition

- NCT03865225 377 378 O
malignant NCT03865225 380 389 B-Condition
cerebral NCT03865225 390 398 I-Condition
infarct NCT03865225 399 406 I-Condition
or NCT03865225 407 409 B-Or
indication NCT03865225 410 420 B-Indication
for NCT03865225 421 424 O
treatment NCT03865225 425 434 B-Procedure
at NCT03865225 435 437 O
intensive NCT03865225 438 447 O
care NCT03865225 448 452 O
unit NCT03865225 453 457 O

- NCT03865225 460 461 O
aphasia NCT03865225 463 470 B-Condition
or NCT03865225 471 473 B-Or
cognitive NCT03865225 474 483 B-Condition
deficit NCT03865225 484 491 I-Condition
with NCT03865225 492 496 O
resulted NCT03865225 497 505 O
inability NCT03865225 506 515 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865225 516 518 O
participate NCT03865225 519 530 O
in NCT03865225 531 533 O
Heart NCT03865225 534 539 B-Modifier
rate NCT03865225 540 544 I-Modifier
variability NCT03865225 545 556 I-Modifier
- NCT03865225 557 558 O
biofeedback NCT03865225 559 570 B-Procedure
training NCT03865225 571 579 I-Procedure

- NCT03865225 582 583 O
respiratory NCT03865225 585 596 B-Condition
insufficiency NCT03865225 597 610 I-Condition

- NCT03865225 613 614 O
blindness NCT03865225 616 625 B-Condition
, NCT03865225 626 627 O
deafness NCT03865225 628 636 B-Condition
or NCT03865225 637 639 B-Or
other NCT03865225 640 645 B-Other
physical NCT03865225 646 654 B-Condition
limitations NCT03865225 655 666 I-Condition
with NCT03865225 667 671 O
resulted NCT03865225 672 680 O
inability NCT03865225 681 690 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865225 691 693 O
participate NCT03865225 694 705 O
in NCT03865225 706 708 O
heart NCT03865225 709 714 B-Modifier
rate NCT03865225 715 719 I-Modifier
variability NCT03865225 720 731 I-Modifier
- NCT03865225 732 733 O
biofeedback NCT03865225 734 745 B-Procedure
training NCT03865225 746 754 I-Procedure

Inclusion NCT03863873 0 9 O
Criteria NCT03863873 10 18 O
: NCT03863873 19 20 O

- NCT03863873 24 25 O
Patients NCT03863873 27 35 O
with NCT03863873 36 40 O
mild NCT03863873 41 45 B-Eq-Comparison
- NCT03863873 46 47 I-Eq-Comparison
to NCT03863873 48 50 I-Eq-Comparison
- NCT03863873 51 52 I-Eq-Comparison
moderate NCT03863873 53 61 I-Eq-Comparison
idiopathic NCT03863873 62 72 B-Modifier
CTS NCT03863873 73 76 B-Condition
with NCT03863873 77 81 O
clinical NCT03863873 82 90 B-Condition
manifestations NCT03863873 91 105 I-Condition
failed NCT03863873 106 112 O
to NCT03863873 113 115 O
respond NCT03863873 116 123 O
to NCT03863873 124 126 O
conservative NCT03863873 127 139 B-Procedure
treatment NCT03863873 140 149 I-Procedure
( NCT03863873 150 151 O
such NCT03863873 152 156 O
as NCT03863873 157 159 O
splint NCT03863873 160 166 B-Procedure
, NCT03863873 167 168 O
medications NCT03863873 169 180 B-Drug
, NCT03863873 181 182 O
Physical NCT03863873 183 191 B-Procedure
therapy NCT03863873 192 199 I-Procedure
) NCT03863873 200 201 O
for NCT03863873 202 205 O
at NCT03863873 206 208 B-Eq-Comparison
least NCT03863873 209 214 I-Eq-Comparison
3 NCT03863873 215 216 I-Eq-Comparison
months NCT03863873 217 223 I-Eq-Comparison
and NCT03863873 224 227 B-And
they NCT03863873 228 232 O
were NCT03863873 233 237 O
diagnosed NCT03863873 238 247 O
by NCT03863873 248 250 O
electrophysiological NCT03863873 251 271 B-Procedure
study NCT03863873 272 277 I-Procedure
and NCT03863873 278 281 B-Or
musculoskeletal NCT03863873 282 297 B-Modifier
ultrasound NCT03863873 298 308 B-Procedure
. NCT03863873 309 310 O

Exclusion NCT03863873 312 321 O
Criteria NCT03863873 322 330 O
: NCT03863873 331 332 O

- NCT03863873 336 337 O
Diabetes NCT03863873 339 347 B-Condition

- NCT03863873 350 351 O
Hypothyroidism NCT03863873 353 367 B-Condition

- NCT03863873 370 371 O
Rheumatoid NCT03863873 373 383 B-Condition
arthritis NCT03863873 384 393 I-Condition

- NCT03863873 396 397 O
Previous NCT03863873 399 407 B-Eq-Comparison
carpal NCT03863873 408 414 B-Procedure
tunnel NCT03863873 415 421 I-Procedure
decompressive NCT03863873 422 435 I-Procedure
surgery NCT03863873 436 443 I-Procedure

- NCT03863873 446 447 O
Cervical NCT03863873 449 457 B-Condition
radiculopathy NCT03863873 458 471 I-Condition
, NCT03863873 472 473 O
polyneuropathy NCT03863873 474 488 B-Condition
, NCT03863873 489 490 O
brachial NCT03863873 491 499 B-Condition
plexopathy NCT03863873 500 510 I-Condition
, NCT03863873 511 512 O
traumatic NCT03863873 513 522 B-Condition
nerve NCT03863873 523 528 I-Condition
injury NCT03863873 529 535 I-Condition
, NCT03863873 536 537 O
thoracic NCT03863873 538 546 B-Condition
outlet NCT03863873 547 553 I-Condition
syndrome NCT03863873 554 562 I-Condition

- NCT03863873 565 566 O
Previous NCT03863873 568 576 B-Eq-Comparison
corticosteroid NCT03863873 577 591 B-Procedure
injection NCT03863873 592 601 I-Procedure
into NCT03863873 602 606 O
the NCT03863873 607 610 O
carpal NCT03863873 611 617 B-Modifier
tunnel NCT03863873 618 624 I-Modifier
in NCT03863873 625 627 O
the NCT03863873 628 631 O
preceding NCT03863873 632 641 B-Eq-Comparison
4 NCT03863873 642 643 I-Eq-Comparison
weeks NCT03863873 644 649 I-Eq-Comparison

- NCT03863873 652 653 O
Anemia NCT03863873 655 661 B-Condition
( NCT03863873 662 663 O
hemoglobin NCT03863873 664 674 B-Observation
< NCT03863873 675 676 B-Eq-Comparison
10 NCT03863873 677 679 I-Eq-Comparison
gm NCT03863873 680 682 I-Eq-Comparison
% NCT03863873 683 684 I-Eq-Comparison
) NCT03863873 686 687 O

- NCT03863873 691 692 O
Coagulopathy NCT03863873 694 706 B-Condition

- NCT03863873 709 710 O
Pregnancy NCT03863873 712 721 B-Condition

Inclusion NCT03867396 0 9 O
Criteria NCT03867396 10 18 O
* NCT03867396 18 19 O
: NCT03867396 20 21 O

- NCT03867396 25 26 O
An NCT03867396 28 30 O
Advanced NCT03867396 31 39 B-Procedure
Bionics NCT03867396 40 47 I-Procedure
cochlear NCT03867396 48 56 I-Procedure
implant NCT03867396 57 64 I-Procedure
recipient NCT03867396 65 74 O
with NCT03867396 75 79 O
at NCT03867396 80 82 B-Eq-Comparison
least NCT03867396 83 88 I-Eq-Comparison
12 NCT03867396 89 91 I-Eq-Comparison
months NCT03867396 92 98 I-Eq-Comparison
of NCT03867396 99 101 O
listening NCT03867396 102 111 O
experience NCT03867396 112 122 O

- NCT03867396 125 126 O
Low NCT03867396 128 131 B-Observation
frequency NCT03867396 132 141 I-Observation
Pure NCT03867396 142 146 I-Observation
Tone NCT03867396 147 151 I-Observation
Audiometry NCT03867396 152 162 I-Observation
( NCT03867396 163 164 O
PTA NCT03867396 165 168 B-Observation
) NCT03867396 169 170 O

Exclusion NCT03867396 172 181 O
Criteria NCT03867396 182 190 O
* NCT03867396 190 191 O
: NCT03867396 192 193 O

- NCT03867396 197 198 O
Non NCT03867396 200 203 B-Negation
- NCT03867396 204 205 O
English NCT03867396 206 213 O
speakers NCT03867396 214 222 O

- NCT03867396 230 231 O
Additional NCT03867396 233 243 O
Inclusion NCT03867396 244 253 O
and NCT03867396 254 257 O
Exclusion NCT03867396 258 267 O
criteria NCT03867396 268 276 O
apply NCT03867396 277 282 O

Inclusion NCT03865797 0 9 O
Criteria NCT03865797 10 18 O
: NCT03865797 19 20 O

- NCT03865797 24 25 O
Rugby NCT03865797 27 32 B-Observation
players NCT03865797 33 40 I-Observation

- NCT03865797 43 44 O
Both NCT03865797 46 50 O
gender NCT03865797 51 57 O

- NCT03865797 60 61 O
From NCT03865797 63 67 B-Eq-Comparison
18 NCT03865797 68 70 I-Eq-Comparison
to NCT03865797 71 73 I-Eq-Comparison
40 NCT03865797 74 76 I-Eq-Comparison
years NCT03865797 77 82 I-Eq-Comparison
old NCT03865797 83 86 B-Age

- NCT03865797 89 90 O
Federated NCT03865797 92 101 O
. NCT03865797 102 103 O

Exclusion NCT03865797 105 114 O
Criteria NCT03865797 115 123 O
: NCT03865797 124 125 O

- NCT03865797 129 130 O
At NCT03865797 132 134 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865797 135 138 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865797 139 143 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865797 144 146 O
the NCT03865797 147 150 O
study NCT03865797 151 156 B-Study
, NCT03865797 157 158 O
they NCT03865797 159 163 O
present NCT03865797 164 171 O
an NCT03865797 172 174 O
injury NCT03865797 175 181 B-Condition
that NCT03865797 182 186 O
prevents NCT03865797 187 195 B-Assertion___Assertion-Type-Value:hypothetical|Negation
them NCT03865797 196 200 O
from NCT03865797 201 205 O
carrying NCT03865797 206 214 O
out NCT03865797 215 218 O
the NCT03865797 219 222 O
proposed NCT03865797 223 231 O
intervention NCT03865797 232 244 B-Procedure

- NCT03865797 247 248 O
Included NCT03865797 250 258 O
in NCT03865797 259 261 O
a NCT03865797 262 263 O
personal NCT03865797 264 272 B-Observation
training NCT03865797 273 281 I-Observation
regime NCT03865797 282 288 I-Observation

- NCT03865797 291 292 O
With NCT03865797 294 298 O
musculoskeletal NCT03865797 299 314 B-Modifier
injuries NCT03865797 315 323 B-Condition
in NCT03865797 324 326 O
the NCT03865797 327 330 O
ankle NCT03865797 331 336 B-Modifier
in NCT03865797 337 339 O
the NCT03865797 340 343 O
last NCT03865797 344 348 B-Eq-Comparison
3 NCT03865797 349 350 I-Eq-Comparison
months NCT03865797 351 357 I-Eq-Comparison

- NCT03865797 360 361 O
Not NCT03865797 363 366 O
sign NCT03865797 367 371 O
the NCT03865797 372 375 O
informed NCT03865797 376 384 O
consent NCT03865797 385 392 O
document NCT03865797 393 401 O
. NCT03865797 401 402 O

Inclusion NCT03863457 0 9 O
Criteria NCT03863457 10 18 O
: NCT03863457 19 20 O

- NCT03863457 24 25 O
Participants NCT03863457 27 39 O
will NCT03863457 40 44 O
be NCT03863457 45 47 O
≥ NCT03863457 48 49 B-Eq-Comparison
18 NCT03863457 50 52 I-Eq-Comparison
years NCT03863457 53 58 I-Eq-Comparison
of NCT03863457 59 61 O
age NCT03863457 62 65 B-Age

- NCT03863457 68 69 O
Known NCT03863457 71 76 B-Modifier
or NCT03863457 77 79 B-Or
suspected NCT03863457 80 89 B-Assertion___Assertion-Type-Value:possible
primary NCT03863457 90 97 B-Modifier
or NCT03863457 98 100 B-Or
metastatic NCT03863457 101 111 B-Modifier
breast NCT03863457 112 118 I-Modifier
cancer NCT03863457 119 125 B-Condition
. NCT03863457 126 127 O

- NCT03863457 131 132 O
At NCT03863457 134 136 B-Eq-Comparison
least NCT03863457 137 142 I-Eq-Comparison
one NCT03863457 143 146 I-Eq-Comparison
lesion NCT03863457 147 153 B-Condition|Observation
≥ NCT03863457 154 155 B-Eq-Comparison
1.5 NCT03863457 156 159 I-Eq-Comparison
cm NCT03863457 160 162 I-Eq-Comparison
that NCT03863457 163 167 O
is NCT03863457 168 170 O
seen NCT03863457 171 175 O
on NCT03863457 176 178 O
standard NCT03863457 179 187 B-Procedure
imaging NCT03863457 188 195 I-Procedure
( NCT03863457 196 197 O
e. NCT03863457 198 200 O
g. NCT03863457 201 203 O
CT NCT03863457 205 207 B-Procedure
, NCT03863457 208 209 O
MRI NCT03863457 210 213 B-Procedure
, NCT03863457 214 215 O
mammogram NCT03863457 216 225 B-Procedure
, NCT03863457 226 227 O
ultrasound NCT03863457 228 238 B-Procedure
, NCT03863457 239 240 O
FDG NCT03863457 241 244 B-Procedure
- NCT03863457 245 246 I-Procedure
PET NCT03863457 247 250 I-Procedure
/ NCT03863457 251 252 B-Or
CT NCT03863457 253 255 B-Procedure
) NCT03863457 256 257 O
. NCT03863457 258 259 O
Only NCT03863457 261 265 B-Eq-Comparison
one NCT03863457 266 269 I-Eq-Comparison
type NCT03863457 270 274 O
of NCT03863457 275 277 O
imaging NCT03863457 278 285 B-Procedure
is NCT03863457 286 288 O
required NCT03863457 289 297 O
to NCT03863457 298 300 O
show NCT03863457 301 305 O
a NCT03863457 306 307 O
lesion NCT03863457 308 314 B-Condition
. NCT03863457 315 316 O

- NCT03863457 320 321 O
Participants NCT03863457 323 335 O
must NCT03863457 336 340 O
be NCT03863457 341 343 O
informed NCT03863457 344 352 O
of NCT03863457 353 355 O
the NCT03863457 356 359 O
investigational NCT03863457 360 375 O
nature NCT03863457 376 382 O
of NCT03863457 383 385 O
this NCT03863457 386 390 O
study NCT03863457 391 396 O
and NCT03863457 397 400 O
be NCT03863457 401 403 O
willing NCT03863457 404 411 O
to NCT03863457 412 414 O
provide NCT03863457 415 422 O
written NCT03863457 423 430 O
informed NCT03863457 431 439 O
consent NCT03863457 440 447 O
and NCT03863457 448 451 O
participate NCT03863457 452 463 O
in NCT03863457 464 466 O
this NCT03863457 467 471 O
study NCT03863457 472 477 O
in NCT03863457 478 480 O
accordance NCT03863457 481 491 O
with NCT03863457 492 496 O
institutional NCT03863457 497 510 O
and NCT03863457 511 514 O
federal NCT03863457 515 522 O
guidelines NCT03863457 523 533 O
prior NCT03863457 534 539 O
to NCT03863457 540 542 O
study NCT03863457 543 548 O
- NCT03863457 549 550 O
specific NCT03863457 551 559 O
procedures NCT03863457 560 570 O
. NCT03863457 571 572 O

Exclusion NCT03863457 574 583 O
Criteria NCT03863457 584 592 O
: NCT03863457 593 594 O

- NCT03863457 598 599 O
Females NCT03863457 601 608 O
who NCT03863457 609 612 B-And
are NCT03863457 613 616 O
pregnant NCT03863457 617 625 B-Condition
or NCT03863457 626 628 B-Or
breast NCT03863457 629 635 B-Condition
feeding NCT03863457 636 643 I-Condition
at NCT03863457 644 646 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863457 647 650 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03863457 651 655 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863457 656 658 O
screening NCT03863457 659 668 B-Study
; NCT03863457 668 669 O
a NCT03863457 670 671 O
urine NCT03863457 672 677 B-Observation
pregnancy NCT03863457 678 687 I-Observation
test NCT03863457 688 692 I-Observation
will NCT03863457 693 697 O
be NCT03863457 698 700 O
performed NCT03863457 701 710 O
in NCT03863457 711 713 O
women NCT03863457 714 719 O
of NCT03863457 720 722 B-And
child NCT03863457 723 728 B-Condition
- NCT03863457 729 730 I-Condition
bearing NCT03863457 731 738 I-Condition
potential NCT03863457 739 748 I-Condition
at NCT03863457 749 751 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03863457 752 761 B-Study
. NCT03863457 762 763 O

- NCT03863457 767 768 O
Inability NCT03863457 770 779 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863457 780 782 O
tolerate NCT03863457 783 791 O
imaging NCT03863457 792 799 B-Procedure
procedures NCT03863457 800 810 I-Procedure
in NCT03863457 811 813 O
the NCT03863457 814 817 O
opinion NCT03863457 818 825 O
of NCT03863457 826 828 O
an NCT03863457 829 831 O
investigator NCT03863457 832 844 O
or NCT03863457 845 847 O
treating NCT03863457 848 856 O
physician NCT03863457 857 866 O
. NCT03863457 867 868 O

- NCT03863457 872 873 O
Any NCT03863457 875 878 O
current NCT03863457 879 886 B-Eq-Comparison
medical NCT03863457 887 894 B-Condition
condition NCT03863457 895 904 I-Condition
, NCT03863457 905 906 O
illness NCT03863457 907 914 B-Condition
, NCT03863457 915 916 O
or NCT03863457 917 919 B-Or
disorder NCT03863457 920 928 B-Condition
, NCT03863457 929 930 O
as NCT03863457 931 933 O
assessed NCT03863457 934 942 O
by NCT03863457 943 945 O
medical NCT03863457 946 953 O
record NCT03863457 954 960 O
review NCT03863457 961 967 O
and NCT03863457 968 971 O
/ NCT03863457 972 973 O
or NCT03863457 974 976 O
self NCT03863457 977 981 O
- NCT03863457 982 983 O
reported NCT03863457 984 992 O
, NCT03863457 993 994 O
that NCT03863457 995 999 O
is NCT03863457 1000 1002 O
considered NCT03863457 1003 1013 O
by NCT03863457 1014 1016 O
a NCT03863457 1017 1018 O
physician NCT03863457 1019 1028 O
investigator NCT03863457 1029 1041 O
to NCT03863457 1042 1044 O
be NCT03863457 1045 1047 O
a NCT03863457 1048 1049 O
condition NCT03863457 1050 1059 B-Condition
that NCT03863457 1060 1064 O
could NCT03863457 1065 1070 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03863457 1071 1081 O
participant NCT03863457 1082 1093 O
safety NCT03863457 1094 1100 O
or NCT03863457 1101 1103 O
successful NCT03863457 1104 1114 O
participation NCT03863457 1115 1128 O
in NCT03863457 1129 1131 O
the NCT03863457 1132 1135 O
study NCT03863457 1136 1141 B-Study
. NCT03863457 1141 1142 O

Inclusion NCT03860610 0 9 O
Criteria NCT03860610 10 18 O
: NCT03860610 19 20 O

- NCT03860610 24 25 O
Patients NCT03860610 27 35 O
with NCT03860610 36 40 O
an NCT03860610 41 43 O
unilateral NCT03860610 44 54 B-Modifier
THA NCT03860610 55 58 B-Procedure
or NCT03860610 59 61 B-Or
TKA NCT03860610 62 65 B-Procedure
, NCT03860610 66 67 O
which NCT03860610 68 73 O
they NCT03860610 74 78 O
received NCT03860610 79 87 B-Eq-Comparison
for NCT03860610 88 91 O
the NCT03860610 92 95 O
treatment NCT03860610 96 105 B-Procedure
of NCT03860610 106 108 O
osteoarthritis NCT03860610 109 123 B-Condition
( NCT03860610 124 125 O
Patient NCT03860610 126 133 O
groups NCT03860610 134 140 O
1 NCT03860610 141 142 O
+ NCT03860610 143 144 O
2 NCT03860610 145 146 O
) NCT03860610 147 148 O

- NCT03860610 152 153 O
Patients NCT03860610 155 163 O
diagnosed NCT03860610 164 173 O
with NCT03860610 174 178 O
unilateral NCT03860610 179 189 B-Modifier
OA NCT03860610 190 192 B-Condition
of NCT03860610 193 195 O
the NCT03860610 196 199 O
knee NCT03860610 200 204 B-Modifier
or NCT03860610 205 207 B-Or
hip NCT03860610 208 211 B-Modifier
planned NCT03860610 212 219 B-Eq-Comparison
for NCT03860610 220 223 O
a NCT03860610 224 225 O
treatment NCT03860610 226 235 B-Procedure
with NCT03860610 236 240 O
THA NCT03860610 241 244 B-Procedure
or NCT03860610 245 247 B-Or
TKA NCT03860610 248 251 B-Procedure
( NCT03860610 252 253 O
Patient NCT03860610 254 261 O
groups NCT03860610 262 268 O
3 NCT03860610 269 270 O
+ NCT03860610 271 272 O
4 NCT03860610 273 274 O
) NCT03860610 275 276 O

- NCT03860610 280 281 O
Age NCT03860610 283 286 B-Age
≥ NCT03860610 287 288 B-Eq-Comparison
30 NCT03860610 289 291 I-Eq-Comparison
years NCT03860610 292 297 I-Eq-Comparison
( NCT03860610 298 299 O
Healthy NCT03860610 300 307 B-Condition
control NCT03860610 308 315 O
group NCT03860610 316 321 O
) NCT03860610 322 323 O

Exclusion NCT03860610 325 334 O
Criteria NCT03860610 335 343 O
: NCT03860610 344 345 O

- NCT03860610 349 350 O
Body NCT03860610 352 356 B-Observation
mass NCT03860610 357 361 I-Observation
index NCT03860610 362 367 I-Observation
> NCT03860610 368 369 B-Eq-Comparison
35 NCT03860610 370 372 I-Eq-Comparison
kg NCT03860610 373 375 O
/ NCT03860610 376 377 O
m2 NCT03860610 378 380 O

- NCT03860610 383 384 O
Use NCT03860610 386 389 O
of NCT03860610 390 392 O
walking NCT03860610 393 400 B-Procedure
aids NCT03860610 401 405 I-Procedure

- NCT03860610 408 409 O
Neuromuscular NCT03860610 411 424 B-Condition
disorders NCT03860610 425 434 I-Condition
affecting NCT03860610 435 444 O
gait NCT03860610 445 449 B-Condition

- NCT03860610 452 453 O
Inability NCT03860610 455 464 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860610 465 467 O
follow NCT03860610 468 474 O
procedures NCT03860610 475 485 B-Procedure
due NCT03860610 486 489 O
to NCT03860610 490 492 O
psychological NCT03860610 493 506 B-Condition
disorders NCT03860610 507 516 I-Condition
or NCT03860610 517 519 B-Or
dementia NCT03860610 520 528 B-Condition

- NCT03860610 531 532 O
Diagnosed NCT03860610 534 543 O
hip NCT03860610 544 547 B-Modifier
or NCT03860610 548 550 O
knee NCT03860610 551 555 B-Modifier
OA NCT03860610 556 558 B-Condition
( NCT03860610 559 560 O
Healthy NCT03860610 561 568 B-Condition
control NCT03860610 569 576 O
group NCT03860610 577 582 O
) NCT03860610 583 584 O

- NCT03860610 588 589 O
Current NCT03860610 591 598 B-Eq-Comparison
pain NCT03860610 599 603 B-Condition
in NCT03860610 604 606 O
the NCT03860610 607 610 O
lower NCT03860610 611 616 B-Modifier
extremities NCT03860610 617 628 I-Modifier
or NCT03860610 629 631 B-Or
lower NCT03860610 632 637 B-Modifier
back NCT03860610 638 642 I-Modifier
( NCT03860610 643 644 O
Healthy NCT03860610 645 652 B-Condition
control NCT03860610 653 660 O
group NCT03860610 661 666 O
) NCT03860610 667 668 O

- NCT03860610 672 673 O
Rheumatoid NCT03860610 675 685 B-Condition
Arthritis NCT03860610 686 695 I-Condition
( NCT03860610 696 697 O
Healthy NCT03860610 698 705 B-Condition
control NCT03860610 706 713 O
group NCT03860610 714 719 O
) NCT03860610 720 721 O

- NCT03860610 725 726 O
Previous NCT03860610 728 736 B-Eq-Comparison
corrective NCT03860610 737 747 B-Procedure
osteotomy NCT03860610 748 757 I-Procedure
( NCT03860610 758 759 O
Healthy NCT03860610 760 767 B-Condition
control NCT03860610 768 775 O
group NCT03860610 776 781 O
) NCT03860610 782 783 O

- NCT03860610 787 788 O
Regular NCT03860610 790 797 O
intake NCT03860610 798 804 O
of NCT03860610 805 807 O
pain NCT03860610 808 812 B-Drug
medication NCT03860610 813 823 I-Drug
( NCT03860610 824 825 O
more NCT03860610 826 830 B-Eq-Comparison
than NCT03860610 831 835 I-Eq-Comparison
4 NCT03860610 836 837 I-Eq-Comparison
times NCT03860610 838 843 I-Eq-Comparison
per NCT03860610 844 847 I-Eq-Comparison
week NCT03860610 848 852 I-Eq-Comparison
) NCT03860610 853 854 O
( NCT03860610 855 856 O
Healthy NCT03860610 857 864 B-Condition
control NCT03860610 865 872 O
group NCT03860610 873 878 O
) NCT03860610 879 880 O

Inclusion NCT03863912 0 9 O
Criteria NCT03863912 10 18 O
: NCT03863912 19 20 O

- NCT03863912 24 25 O
planned NCT03863912 27 34 B-Eq-Comparison
6 NCT03863912 35 36 I-Eq-Comparison
cycles NCT03863912 37 43 I-Eq-Comparison
of NCT03863912 44 46 O
chemotherapy NCT03863912 47 59 B-Procedure
with NCT03863912 60 64 O
carboplatin NCT03863912 65 76 B-Drug
/ NCT03863912 77 78 B-Or
paclitaxel NCT03863912 79 89 B-Drug
or NCT03863912 90 92 B-Or
carboplatin NCT03863912 93 104 B-Drug
/ NCT03863912 105 106 B-Or
pegylated NCT03863912 107 116 B-Drug
liposomal NCT03863912 117 126 I-Drug
doxorubicin NCT03863912 127 138 I-Drug

- NCT03863912 141 142 O
Age NCT03863912 144 147 B-Age
> NCT03863912 148 149 B-Eq-Comparison
18 NCT03863912 150 152 I-Eq-Comparison
years NCT03863912 153 158 I-Eq-Comparison

Exclusion NCT03863912 159 168 O
Criteria NCT03863912 169 177 O
: NCT03863912 178 179 O

- NCT03863912 183 184 O
inadequate NCT03863912 186 196 B-Negation
knowledge NCT03863912 197 206 O
of NCT03863912 207 209 O
the NCT03863912 210 213 O
German NCT03863912 214 220 O
language NCT03863912 221 229 O

Inclusion NCT03861650 0 9 O
Criteria NCT03861650 10 18 O
: NCT03861650 19 20 O

1 NCT03861650 24 25 O
. NCT03861650 25 26 O
Patients NCT03861650 28 36 O
free NCT03861650 37 41 B-Negation
from NCT03861650 42 46 I-Negation
any NCT03861650 47 50 O
disease NCT03861650 51 58 B-Condition
affecting NCT03861650 59 68 O
bone NCT03861650 69 73 B-Condition
formation NCT03861650 74 83 I-Condition
of NCT03861650 84 86 O
both NCT03861650 87 91 O
sexes NCT03861650 92 97 O
was NCT03861650 98 101 O
included NCT03861650 102 110 O
in NCT03861650 111 113 O
the NCT03861650 114 117 O
study NCT03861650 118 123 O
. NCT03861650 124 125 O

2 NCT03861650 129 130 O
. NCT03861650 130 131 O
Patients NCT03861650 133 141 O
younger NCT03861650 142 149 B-Eq-Comparison
than NCT03861650 150 154 I-Eq-Comparison
25 NCT03861650 155 157 I-Eq-Comparison
years NCT03861650 158 163 I-Eq-Comparison
old NCT03861650 164 167 B-Age
. NCT03861650 168 169 O

3 NCT03861650 173 174 O
. NCT03861650 174 175 O
Patients NCT03861650 177 185 O
included NCT03861650 186 194 O
in NCT03861650 195 197 O
the NCT03861650 198 201 O
study NCT03861650 202 207 B-Study
were NCT03861650 208 212 O
post NCT03861650 213 217 B-Condition
traumatic NCT03861650 218 227 I-Condition
patients NCT03861650 228 236 O
, NCT03861650 237 238 O
hemifacial NCT03861650 239 249 B-Condition
microsomia NCT03861650 250 260 I-Condition
, NCT03861650 261 262 O
Treacher NCT03861650 263 271 B-Condition
Collins NCT03861650 272 279 I-Condition
and NCT03861650 280 283 B-Or
post NCT03861650 284 288 B-Condition
ankylotic NCT03861650 289 298 I-Condition
mandibular NCT03861650 299 309 I-Condition
deformity NCT03861650 310 319 I-Condition
. NCT03861650 320 321 O

4 NCT03861650 325 326 O
. NCT03861650 326 327 O
Distraction NCT03861650 329 340 B-Observation
range NCT03861650 341 346 I-Observation
was NCT03861650 347 350 O
between NCT03861650 351 358 B-Eq-Comparison
15 NCT03861650 359 361 I-Eq-Comparison
- NCT03861650 362 363 I-Eq-Comparison
20 NCT03861650 364 366 I-Eq-Comparison
mm NCT03861650 367 369 I-Eq-Comparison
. NCT03861650 370 371 O

Exclusion NCT03861650 373 382 O
Criteria NCT03861650 383 391 O
: NCT03861650 392 393 O

1 NCT03861650 397 398 O
. NCT03861650 398 399 O
The NCT03861650 401 404 O
presence NCT03861650 405 413 O
of NCT03861650 414 416 O
uncontrolled NCT03861650 417 429 B-Modifier
systemic NCT03861650 430 438 I-Modifier
disease NCT03861650 439 446 B-Condition
. NCT03861650 447 448 O

2 NCT03861650 452 453 O
. NCT03861650 453 454 O
Previous NCT03861650 456 464 B-Eq-Comparison
radiotherapy NCT03861650 465 477 B-Procedure
on NCT03861650 478 480 O
head NCT03861650 481 485 B-Modifier
and NCT03861650 486 489 B-Or
neck NCT03861650 490 494 B-Modifier
region NCT03861650 495 501 O
. NCT03861650 502 503 O

3 NCT03861650 507 508 O
. NCT03861650 508 509 O
Chemotherapy NCT03861650 511 523 B-Procedure
within NCT03861650 524 530 B-Eq-Comparison
the NCT03861650 531 534 I-Eq-Comparison
past NCT03861650 535 539 I-Eq-Comparison
12 NCT03861650 540 542 I-Eq-Comparison
- NCT03861650 543 544 I-Eq-Comparison
month NCT03861650 545 550 I-Eq-Comparison
period NCT03861650 551 557 O
. NCT03861650 558 559 O

4 NCT03861650 563 564 O
. NCT03861650 564 565 O
An NCT03861650 567 569 O
active NCT03861650 570 576 B-Eq-Comparison
infection NCT03861650 577 586 B-Condition
at NCT03861650 587 589 O
the NCT03861650 590 593 O
distraction NCT03861650 594 605 B-Modifier
site NCT03861650 606 610 I-Modifier
. NCT03861650 610 611 O

Inclusion NCT03862417 0 9 O
Criteria NCT03862417 10 18 O
: NCT03862417 19 20 O

- NCT03862417 24 25 O
Adults NCT03862417 27 33 O
over NCT03862417 34 38 B-Eq-Comparison
50 NCT03862417 39 41 I-Eq-Comparison
years NCT03862417 42 47 I-Eq-Comparison
old NCT03862417 48 51 B-Age
with NCT03862417 52 56 B-And
degenerative NCT03862417 57 69 B-Condition
scoliosis NCT03862417 70 79 I-Condition
( NCT03862417 80 81 O
n NCT03862417 82 83 O
= NCT03862417 84 85 O
20 NCT03862417 86 88 O
) NCT03862417 89 90 O
with NCT03862417 91 95 B-And
pain NCT03862417 96 100 B-Condition|Observation
( NCT03862417 101 102 O
> NCT03862417 104 105 B-Eq-Comparison
2 NCT03862417 106 107 I-Eq-Comparison
/ NCT03862417 108 109 O
10 NCT03862417 110 112 O
) NCT03862417 113 114 O
. NCT03862417 115 116 O
Other NCT03862417 118 123 O
inclusion NCT03862417 124 133 O
criteria NCT03862417 134 142 O
are NCT03862417 143 146 O
: NCT03862417 147 148 O
( NCT03862417 149 150 O
1 NCT03862417 151 152 O
) NCT03862417 153 154 O
curves NCT03862417 155 161 B-Observation
15 NCT03862417 162 164 B-Eq-Comparison
° NCT03862417 165 166 I-Eq-Comparison
- NCT03862417 167 168 I-Eq-Comparison
45 NCT03862417 169 171 I-Eq-Comparison
° NCT03862417 172 173 I-Eq-Comparison
. NCT03862417 174 175 O

Exclusion NCT03862417 177 186 O
Criteria NCT03862417 187 195 O
: NCT03862417 196 197 O

- NCT03862417 201 202 O
Curves NCT03862417 204 210 B-Observation
over NCT03862417 211 215 B-Eq-Comparison
50 NCT03862417 216 218 I-Eq-Comparison
° NCT03862417 219 220 I-Eq-Comparison
are NCT03862417 221 224 O
surgical NCT03862417 225 233 B-Procedure
candidates NCT03862417 234 244 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03862417 245 246 O
and NCT03862417 247 250 O
will NCT03862417 251 255 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862417 256 258 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03862417 259 267 B-Negation
. NCT03862417 267 268 O
Patients NCT03862417 270 278 O
who NCT03862417 279 282 O
have NCT03862417 283 287 O
had NCT03862417 288 291 B-Eq-Comparison
cortisone NCT03862417 292 301 B-Drug
or NCT03862417 302 304 B-Or
anesthetic NCT03862417 305 315 B-Drug
injections NCT03862417 316 326 B-Procedure
within NCT03862417 327 333 B-Eq-Comparison
the NCT03862417 334 337 I-Eq-Comparison
last NCT03862417 338 342 I-Eq-Comparison
3 NCT03862417 343 344 I-Eq-Comparison
months NCT03862417 345 351 I-Eq-Comparison
, NCT03862417 352 353 O
surgery NCT03862417 354 361 B-Procedure
or NCT03862417 362 364 B-Or
presenting NCT03862417 365 375 O
contra NCT03862417 376 382 B-Contraindication
- NCT03862417 383 384 I-Contraindication
indications NCT03862417 385 396 I-Contraindication
to NCT03862417 397 399 O
exercises NCT03862417 400 409 B-Observation
( NCT03862417 410 411 O
fractures NCT03862417 412 421 B-Condition
, NCT03862417 422 423 O
cancer NCT03862417 424 430 B-Condition
, NCT03862417 431 432 O
severe NCT03862417 433 439 O
cardio NCT03862417 440 446 B-Condition
- NCT03862417 447 448 I-Condition
vascular NCT03862417 449 457 I-Condition
co NCT03862417 458 460 I-Condition
- NCT03862417 461 462 I-Condition
morbidities NCT03862417 463 474 I-Condition
, NCT03862417 475 476 O
or NCT03862417 477 479 B-Or
osteopenia NCT03862417 480 490 B-Condition
) NCT03862417 491 492 O
will NCT03862417 493 497 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862417 498 500 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03862417 501 509 B-Negation
. NCT03862417 509 510 O

Inclusion NCT03868930 0 9 O
Criteria NCT03868930 10 18 O
: NCT03868930 19 20 O

- NCT03868930 24 25 O
Post NCT03868930 27 31 B-Modifier
- NCT03868930 32 33 I-Modifier
9 NCT03868930 34 35 I-Modifier
/ NCT03868930 36 37 I-Modifier
11 NCT03868930 38 40 I-Modifier
Veterans NCT03868930 41 49 B-Observation
who NCT03868930 50 53 B-And
report NCT03868930 54 60 O
some NCT03868930 61 65 O
reintegration NCT03868930 66 79 B-Modifier
, NCT03868930 80 81 O
readjustment NCT03868930 82 94 B-Modifier
, NCT03868930 95 96 O
or NCT03868930 97 99 B-Or
anger NCT03868930 100 105 B-Modifier
difficulty NCT03868930 106 116 B-Condition

- NCT03868930 124 125 O
i. NCT03868930 127 129 O
e. NCT03868930 130 132 O
, NCT03868930 133 134 O
Veterans NCT03868930 135 143 B-Observation
who NCT03868930 144 147 B-And
report NCT03868930 148 154 O
" NCT03868930 155 156 O
some NCT03868930 156 160 B-Modifier
difficulty NCT03868930 161 171 I-Modifier
" NCT03868930 171 172 O
( NCT03868930 173 174 O
Likert NCT03868930 175 181 O
rating NCT03868930 182 188 O
) NCT03868930 189 190 O
on NCT03868930 191 193 O
at NCT03868930 194 196 B-Eq-Comparison
least NCT03868930 197 202 I-Eq-Comparison
one NCT03868930 203 206 I-Eq-Comparison
of NCT03868930 207 209 O
the NCT03868930 210 213 O
primary NCT03868930 214 221 B-Observation
measures NCT03868930 222 230 I-Observation
: NCT03868930 231 232 O
M2CQ NCT03868930 233 237 B-Observation
; NCT03868930 237 238 O
PDRI NCT03868930 239 243 B-Observation
; NCT03868930 243 244 O
STAXI NCT03868930 245 250 B-Observation
- NCT03868930 251 252 I-Observation
2 NCT03868930 253 254 I-Observation

- NCT03868930 258 259 O
18 NCT03868930 261 263 B-Eq-Comparison
- NCT03868930 264 265 I-Eq-Comparison
65 NCT03868930 266 268 I-Eq-Comparison
years NCT03868930 269 274 I-Eq-Comparison
old NCT03868930 275 278 B-Age
( NCT03868930 279 280 O
to NCT03868930 281 283 O
avoid NCT03868930 284 289 O
outcomes NCT03868930 290 298 O
being NCT03868930 299 304 O
affected NCT03868930 305 313 O
by NCT03868930 314 316 O
aging NCT03868930 317 322 O
) NCT03868930 323 324 O

- NCT03868930 328 329 O
English NCT03868930 331 338 O
- NCT03868930 339 340 O
speaking NCT03868930 341 349 O
( NCT03868930 350 351 O
sessions NCT03868930 352 360 O
will NCT03868930 361 365 O
be NCT03868930 366 368 O
conducted NCT03868930 369 378 O
in NCT03868930 379 381 O
English NCT03868930 382 389 O
) NCT03868930 390 391 O

- NCT03868930 395 396 O
Agreeing NCT03868930 398 406 O
to NCT03868930 407 409 O
participate NCT03868930 410 421 O

- NCT03868930 429 430 O
i. NCT03868930 432 434 O
e. NCT03868930 435 437 O
, NCT03868930 438 439 O
completion NCT03868930 440 450 O
of NCT03868930 451 453 O
ICF NCT03868930 454 457 B-Observation
/ NCT03868930 458 459 B-Or
HIPAA NCT03868930 460 465 B-Observation

Exclusion NCT03868930 466 475 O
Criteria NCT03868930 476 484 O
: NCT03868930 485 486 O

- NCT03868930 490 491 O
schizophreniform NCT03868930 493 509 B-Condition
disorder NCT03868930 510 518 I-Condition
/ NCT03868930 519 520 B-Or
active NCT03868930 521 527 B-Eq-Comparison
psychosis NCT03868930 528 537 B-Condition

- NCT03868930 540 541 O
bipolar NCT03868930 543 550 B-Condition
disorder NCT03868930 551 559 I-Condition

- NCT03868930 562 563 O
active NCT03868930 565 571 B-Eq-Comparison
suicidality NCT03868930 572 583 B-Condition
/ NCT03868930 584 585 B-Or
homicidality NCT03868930 586 598 B-Condition
requiring NCT03868930 599 608 B-Assertion___Assertion-Type-Value:hypothetical
crisis NCT03868930 609 615 B-Procedure
intervention NCT03868930 616 628 I-Procedure

- NCT03868930 631 632 O
other NCT03868930 634 639 B-Other
severe NCT03868930 640 646 O
psychiatric NCT03868930 647 658 B-Condition
disorders NCT03868930 659 668 I-Condition
prohibiting NCT03868930 669 680 B-Assertion___Assertion-Type-Value:hypothetical|Negation
appropriate NCT03868930 681 692 O
group NCT03868930 693 698 B-Procedure
participation NCT03868930 699 712 I-Procedure

- NCT03868930 715 716 O
neurological NCT03868930 718 730 B-Condition
diagnosis NCT03868930 731 740 O
prohibiting NCT03868930 741 752 B-Assertion___Assertion-Type-Value:hypothetical|Negation
appropriate NCT03868930 753 764 O
group NCT03868930 765 770 B-Procedure
participation NCT03868930 771 784 I-Procedure
( NCT03868930 785 786 O
excluding NCT03868930 787 796 B-Exception
TBI NCT03868930 797 800 B-Condition
) NCT03868930 801 802 O

- NCT03868930 806 807 O
current NCT03868930 809 816 B-Eq-Comparison
substance NCT03868930 817 826 B-Condition
dependence NCT03868930 827 837 I-Condition

- NCT03868930 840 841 O
current NCT03868930 843 850 B-Eq-Comparison
participation NCT03868930 851 864 O
in NCT03868930 865 867 O
any NCT03868930 868 871 O
other NCT03868930 872 877 B-Other
form NCT03868930 878 882 O
of NCT03868930 883 885 O
active NCT03868930 886 892 B-Eq-Comparison
behavioral NCT03868930 893 903 B-Procedure
therapy NCT03868930 904 911 I-Procedure
at NCT03868930 912 914 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868930 915 918 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03868930 919 923 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03868930 924 926 O
enrollment NCT03868930 927 937 B-Study

- NCT03868930 945 946 O
e. NCT03868930 948 950 O
g. NCT03868930 951 953 O
, NCT03868930 954 955 O
Cognitive NCT03868930 956 965 B-Procedure
Processing NCT03868930 966 976 I-Procedure
Therapy NCT03868930 977 984 I-Procedure
, NCT03868930 985 986 O
cognitive NCT03868930 987 996 B-Procedure
rehabilitation NCT03868930 997 1011 I-Procedure
for NCT03868930 1012 1015 O
mTBI NCT03868930 1016 1020 B-Condition
, NCT03868930 1021 1022 O
or NCT03868930 1023 1025 B-Or
other NCT03868930 1026 1031 B-Other
psychotherapy NCT03868930 1032 1045 B-Procedure

Inclusion NCT03864887 0 9 O
Criteria NCT03864887 10 18 O
: NCT03864887 19 20 O

- NCT03864887 24 25 O
Patients NCT03864887 27 35 O
who NCT03864887 36 39 O
have NCT03864887 40 44 O
had NCT03864887 45 48 B-Eq-Comparison
brain NCT03864887 49 54 B-Condition
death NCT03864887 55 60 I-Condition
or NCT03864887 61 63 B-Or
serious NCT03864887 64 71 O
brain NCT03864887 72 77 B-Modifier
trauma NCT03864887 78 84 B-Condition
. NCT03864887 85 86 O

- NCT03864887 90 91 O
Healthy NCT03864887 93 100 B-Condition
people NCT03864887 101 107 O
who NCT03864887 108 111 B-And
are NCT03864887 112 115 O
interested NCT03864887 116 126 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03864887 127 129 I-Assertion___Assertion-Type-Value:hypothetical
optical NCT03864887 130 137 B-Procedure
assessment NCT03864887 138 148 I-Procedure
of NCT03864887 149 151 O
hemodynamic NCT03864887 152 163 B-Observation
parameters NCT03864887 164 174 I-Observation

Exclusion NCT03864887 175 184 O
Criteria NCT03864887 185 193 O
: NCT03864887 194 195 O

- NCT03864887 199 200 O
Patients NCT03864887 202 210 O
who NCT03864887 211 214 O
are NCT03864887 215 218 O
in NCT03864887 219 221 O
pregnancy NCT03864887 222 231 B-Condition
or NCT03864887 232 234 B-Or
have NCT03864887 235 239 O
plan NCT03864887 240 244 B-Assertion___Assertion-Type-Value:intention
to NCT03864887 245 247 I-Assertion___Assertion-Type-Value:intention
conception NCT03864887 248 258 B-Condition
. NCT03864887 259 260 O

- NCT03864887 264 265 O
Patients NCT03864887 267 275 O
who NCT03864887 276 279 O
have NCT03864887 280 284 O
vertebra NCT03864887 285 293 B-Procedure
surgery NCT03864887 294 301 I-Procedure
or NCT03864887 302 304 B-Or
have NCT03864887 305 309 O
plan NCT03864887 310 314 B-Assertion___Assertion-Type-Value:intention
of NCT03864887 315 317 I-Assertion___Assertion-Type-Value:intention
surgery NCT03864887 318 325 B-Procedure
. NCT03864887 326 327 O

- NCT03864887 331 332 O
Patients NCT03864887 334 342 O
who NCT03864887 343 346 O
are NCT03864887 347 350 O
inappropriate NCT03864887 351 364 O
to NCT03864887 365 367 O
join NCT03864887 368 372 O
this NCT03864887 373 377 O
trial NCT03864887 378 383 O
judged NCT03864887 384 390 O
by NCT03864887 391 393 O
the NCT03864887 394 397 O
radiologists NCT03864887 398 410 O
or NCT03864887 411 413 O
specialists NCT03864887 414 425 O
. NCT03864887 426 427 O

- NCT03864887 436 437 O
AIDS NCT03864887 439 443 B-Condition
, NCT03864887 444 445 O
Active NCT03864887 446 452 B-Eq-Comparison
Hepatitis NCT03864887 453 462 B-Condition
, NCT03864887 463 464 O
Tuberculosis NCT03864887 465 477 B-Condition
, NCT03864887 478 479 O
Syphilis NCT03864887 480 488 B-Condition

- NCT03864887 496 497 O
Patients NCT03864887 499 507 O
who NCT03864887 508 511 O
regularly NCT03864887 512 521 B-Eq-Comparison
take NCT03864887 522 526 I-Eq-Comparison
anticoagulants NCT03864887 527 541 B-Drug
, NCT03864887 542 543 O
antiplatelet NCT03864887 544 556 B-Drug
drugs NCT03864887 557 562 I-Drug

Inclusion NCT03860363 0 9 O
Criteria NCT03860363 10 18 O
: NCT03860363 19 20 O

- NCT03860363 24 25 O
Adult NCT03860363 27 32 O
( NCT03860363 33 34 O
age NCT03860363 35 38 B-Age
≥ NCT03860363 39 40 B-Eq-Comparison
18 NCT03860363 41 43 I-Eq-Comparison
) NCT03860363 44 45 O

- NCT03860363 49 50 O
Patient NCT03860363 52 59 O
undergoing NCT03860363 60 70 B-Eq-Comparison
non NCT03860363 71 74 B-Negation
- NCT03860363 75 76 O
emergent NCT03860363 77 85 B-Modifier
cardiac NCT03860363 86 93 B-Procedure
surgery NCT03860363 94 101 I-Procedure

- NCT03860363 104 105 O
Anticipated NCT03860363 107 118 B-Assertion___Assertion-Type-Value:possible
requirement NCT03860363 119 130 O
for NCT03860363 131 134 O
mediastinal NCT03860363 135 146 B-Procedure
chest NCT03860363 147 152 I-Procedure
tube NCT03860363 153 157 I-Procedure
drainage NCT03860363 158 166 I-Procedure

Exclusion NCT03860363 167 176 O
Criteria NCT03860363 177 185 O
: NCT03860363 186 187 O

- NCT03860363 191 192 O
Emergency NCT03860363 194 203 B-Modifier
surgery NCT03860363 204 211 B-Procedure

- NCT03860363 214 215 O
Re NCT03860363 217 219 B-Modifier
- NCT03860363 220 221 I-Modifier
do NCT03860363 222 224 I-Modifier
surgery NCT03860363 225 232 B-Procedure

- NCT03860363 235 236 O
Prior NCT03860363 238 243 B-Eq-Comparison
cardiac NCT03860363 244 251 B-Procedure
surgery NCT03860363 252 259 I-Procedure

- NCT03860363 262 263 O
Congenital NCT03860363 265 275 B-Modifier
cardiac NCT03860363 276 283 B-Condition
disease NCT03860363 284 291 I-Condition
or NCT03860363 292 294 B-Or
deformation NCT03860363 295 306 B-Condition

- NCT03860363 309 310 O
Transplant NCT03860363 312 322 B-Procedure
surgery NCT03860363 323 330 I-Procedure

- NCT03860363 333 334 O
Ventricular NCT03860363 336 347 B-Procedure
Assist NCT03860363 348 354 I-Procedure
Device NCT03860363 355 361 I-Procedure
Surgery NCT03860363 362 369 I-Procedure

- NCT03860363 372 373 O
Suspected NCT03860363 375 384 B-Assertion___Assertion-Type-Value:possible
pulmonary NCT03860363 385 394 B-Condition
air NCT03860363 395 398 I-Condition
leak NCT03860363 399 403 I-Condition

- NCT03860363 406 407 O
Atrial NCT03860363 409 415 B-Condition
fibrillation NCT03860363 416 428 I-Condition

- NCT03860363 431 432 O
In NCT03860363 434 436 O
the NCT03860363 437 440 O
opinion NCT03860363 441 448 O
of NCT03860363 449 451 O
the NCT03860363 452 455 O
investigator NCT03860363 456 468 O
the NCT03860363 469 472 O
patient NCT03860363 473 480 O
is NCT03860363 481 483 O
unsuitable NCT03860363 484 494 O
for NCT03860363 495 498 O
the NCT03860363 499 502 O
study NCT03860363 503 508 O
for NCT03860363 509 512 O
any NCT03860363 513 516 O
other NCT03860363 517 522 O
legitimate NCT03860363 523 533 O
reason NCT03860363 534 540 O
including NCT03860363 541 550 O
incarceration NCT03860363 551 564 O
, NCT03860363 565 566 O
pre NCT03860363 567 570 B-Eq-Comparison
- NCT03860363 571 572 I-Eq-Comparison
existing NCT03860363 573 581 I-Eq-Comparison
medical NCT03860363 582 589 B-Modifier
or NCT03860363 590 592 O
psychiatric NCT03860363 593 604 B-Modifier
condition NCT03860363 605 614 B-Condition
, NCT03860363 615 616 O
or NCT03860363 617 619 B-Or
interfering NCT03860363 620 631 O
medications NCT03860363 632 643 B-Drug

- NCT03860363 646 647 O
Known NCT03860363 649 654 O
previous NCT03860363 655 663 B-Eq-Comparison
or NCT03860363 664 666 B-Or
concurrent NCT03860363 667 677 B-Modifier
enrollment NCT03860363 678 688 O
in NCT03860363 689 691 O
a NCT03860363 692 693 O
clinical NCT03860363 694 702 B-Study
trial NCT03860363 703 708 I-Study
that NCT03860363 709 713 O
, NCT03860363 714 715 O
in NCT03860363 716 718 O
the NCT03860363 719 722 O
opinion NCT03860363 723 730 O
of NCT03860363 731 733 O
the NCT03860363 734 737 O
investigator NCT03860363 738 750 O
, NCT03860363 751 752 O
might NCT03860363 753 758 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860363 759 768 O
with NCT03860363 769 773 O
the NCT03860363 774 777 O
objectives NCT03860363 778 788 O
of NCT03860363 789 791 O
this NCT03860363 792 796 O
clinical NCT03860363 797 805 B-Study
trial NCT03860363 806 811 I-Study

- NCT03860363 814 815 O
Pregnancy NCT03860363 817 826 B-Condition

Inclusion NCT03862560 0 9 O
Criteria NCT03862560 10 18 O
: NCT03862560 19 20 O

- NCT03862560 24 25 O
Caucasian NCT03862560 27 36 O
, NCT03862560 37 38 O
Healthy NCT03862560 39 46 B-Condition
participant NCT03862560 47 58 O
, NCT03862560 59 60 O
from NCT03862560 61 65 O
12 NCT03862560 66 68 B-Eq-Comparison
to NCT03862560 69 71 I-Eq-Comparison
20 NCT03862560 72 74 I-Eq-Comparison
years NCT03862560 75 80 I-Eq-Comparison
old NCT03862560 81 84 B-Age
, NCT03862560 85 86 O
with NCT03862560 87 91 B-And
a NCT03862560 92 93 O
history NCT03862560 94 101 B-Eq-Comparison
of NCT03862560 102 104 O
training NCT03862560 105 113 B-Observation
at NCT03862560 114 116 B-Eq-Comparison
least NCT03862560 117 122 I-Eq-Comparison
3 NCT03862560 123 124 I-Eq-Comparison
years NCT03862560 125 130 I-Eq-Comparison
. NCT03862560 131 132 O

Exclusion NCT03862560 134 143 O
Criteria NCT03862560 144 152 O
: NCT03862560 153 154 O

- NCT03862560 158 159 O
Non NCT03862560 161 164 B-Negation
- NCT03862560 165 166 O
caucasian NCT03862560 167 176 O
, NCT03862560 177 178 O
injury NCT03862560 179 185 B-Condition
. NCT03862560 185 186 O

Inclusion NCT03868267 0 9 O
Criteria NCT03868267 10 18 O
: NCT03868267 19 20 O

- NCT03868267 24 25 O
adult NCT03868267 27 32 O
patients NCT03868267 33 41 O
( NCT03868267 42 43 O
≥ NCT03868267 45 46 B-Eq-Comparison
18 NCT03868267 47 49 I-Eq-Comparison
years NCT03868267 50 55 I-Eq-Comparison
of NCT03868267 56 58 O
age NCT03868267 59 62 B-Age
) NCT03868267 63 64 O
who NCT03868267 65 68 B-And
are NCT03868267 69 72 O
undergoing NCT03868267 73 83 B-Eq-Comparison
esophago NCT03868267 84 92 B-Procedure
- NCT03868267 93 94 I-Procedure
gastro NCT03868267 95 101 I-Procedure
duodenoscopy NCT03868267 102 114 I-Procedure
( NCT03868267 115 116 O
EGD NCT03868267 117 120 B-Procedure
) NCT03868267 121 122 O
for NCT03868267 123 126 O
any NCT03868267 127 130 O
reason NCT03868267 131 137 O
and NCT03868267 138 141 B-And
are NCT03868267 142 145 O
consenting NCT03868267 146 156 O
to NCT03868267 157 159 O
be NCT03868267 160 162 O
enrolled NCT03868267 163 171 O
in NCT03868267 172 174 O
the NCT03868267 175 178 O
study NCT03868267 179 184 B-Study
during NCT03868267 185 191 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868267 192 195 O
study NCT03868267 196 201 B-Study
period NCT03868267 202 208 O
. NCT03868267 209 210 O

Exclusion NCT03868267 212 221 O
Criteria NCT03868267 222 230 O
: NCT03868267 231 232 O

- NCT03868267 236 237 O
the NCT03868267 239 242 O
patients NCT03868267 243 251 O
who NCT03868267 252 255 O
can NCT03868267 256 259 B-Negation
not NCT03868267 259 262 I-Negation
speak NCT03868267 263 268 O
English NCT03868267 269 276 O
in NCT03868267 277 279 O
Canada NCT03868267 280 286 O
, NCT03868267 287 288 O
who NCT03868267 289 292 B-And
can NCT03868267 293 296 B-Negation
not NCT03868267 296 299 I-Negation
speak NCT03868267 300 305 O
Japanese NCT03868267 306 314 O
in NCT03868267 315 317 O
Japan NCT03868267 318 323 O
, NCT03868267 324 325 O
and NCT03868267 326 329 B-Or
can NCT03868267 330 333 B-Negation
not NCT03868267 333 336 I-Negation
speak NCT03868267 337 342 O
Persian NCT03868267 343 350 O
in NCT03868267 351 353 O
Iran NCT03868267 354 358 O
. NCT03868267 358 359 O

Inclusion NCT03866538 0 9 O
Criteria NCT03866538 10 18 O

- NCT03866538 21 22 O
Patients NCT03866538 24 32 O
will NCT03866538 33 37 O
be NCT03866538 38 40 O
recruited NCT03866538 41 50 O
from NCT03866538 51 55 O
the NCT03866538 56 59 O
Division NCT03866538 60 68 O
of NCT03866538 69 71 O
Gastroenterology NCT03866538 72 88 O
and NCT03866538 89 92 O
Hepatology NCT03866538 93 103 O
and NCT03866538 104 107 O
the NCT03866538 108 111 O
Mayo NCT03866538 112 116 O
Clinic NCT03866538 117 123 O
in NCT03866538 124 126 O
Rochester NCT03866538 127 136 O
, NCT03866538 137 138 O
MN NCT03866538 139 141 O
. NCT03866538 142 143 O

- NCT03866538 147 148 O
Adult NCT03866538 150 155 O
patients NCT03866538 156 164 O
with NCT03866538 165 169 B-And
immune NCT03866538 170 176 B-Condition
mediated NCT03866538 177 185 I-Condition
enteropathies NCT03866538 186 199 I-Condition
who NCT03866538 200 203 B-And
have NCT03866538 204 208 O
had NCT03866538 209 212 O
improvement NCT03866538 213 224 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03866538 225 227 I-Assertion___Assertion-Type-Value:hypothetical
symptoms NCT03866538 228 236 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03866538 237 240 B-Or
histology NCT03866538 241 250 B-Procedure
on NCT03866538 251 253 B-Eq-Comparison
oral NCT03866538 254 258 B-Procedure
budesonide NCT03866538 259 269 I-Procedure
therapy NCT03866538 270 277 I-Procedure
. NCT03866538 278 279 O

Exclusion NCT03866538 281 290 O
Criteria NCT03866538 291 299 O

- NCT03866538 302 303 O
Age NCT03866538 305 308 B-Age
< NCT03866538 309 310 B-Eq-Comparison
18 NCT03866538 311 313 I-Eq-Comparison
years NCT03866538 314 319 I-Eq-Comparison

- NCT03866538 322 323 O
Positive NCT03866538 325 333 O
stool NCT03866538 334 339 B-Observation
gluten NCT03866538 340 346 I-Observation
testing NCT03866538 347 354 I-Observation
in NCT03866538 355 357 O
patients NCT03866538 358 366 O
with NCT03866538 367 371 B-And
refractory NCT03866538 372 382 B-Condition
celiac NCT03866538 383 389 I-Condition
disease NCT03866538 390 397 I-Condition

- NCT03866538 400 401 O
Small NCT03866538 403 408 B-Condition
bowel NCT03866538 409 414 I-Condition
malignancy NCT03866538 415 425 I-Condition
or NCT03866538 426 428 B-Or
history NCT03866538 429 436 B-Eq-Comparison
of NCT03866538 437 439 O
small NCT03866538 440 445 B-Condition
bowel NCT03866538 446 451 I-Condition
malignancy NCT03866538 452 462 I-Condition

- NCT03866538 465 466 O
Refractory NCT03866538 468 478 B-Condition
celiac NCT03866538 479 485 I-Condition
disease NCT03866538 486 493 I-Condition
type NCT03866538 494 498 B-Modifier
2 NCT03866538 499 500 I-Modifier

- NCT03866538 504 505 O
Post NCT03866538 507 511 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03866538 512 513 O
transplant NCT03866538 514 524 B-Procedure
lymphoproliferative NCT03866538 525 544 B-Condition
disorder NCT03866538 545 553 I-Condition
associated NCT03866538 554 564 O
enteropathy NCT03866538 565 576 B-Condition

- NCT03866538 579 580 O
No NCT03866538 582 584 B-Negation
prior NCT03866538 585 590 B-Eq-Comparison
improvement NCT03866538 591 602 B-Assertion___Assertion-Type-Value:hypothetical
in NCT03866538 603 605 I-Assertion___Assertion-Type-Value:hypothetical
symptoms NCT03866538 606 614 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03866538 615 618 B-Or
histology NCT03866538 619 628 B-Procedure
with NCT03866538 629 633 B-And
budesonide NCT03866538 634 644 B-Procedure
therapy NCT03866538 645 652 I-Procedure

- NCT03866538 655 656 O
Discontinuation NCT03866538 658 673 B-Negation
of NCT03866538 674 676 O
budesonide NCT03866538 677 687 B-Procedure
therapy NCT03866538 688 695 I-Procedure
prior NCT03866538 696 701 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866538 702 704 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866538 705 708 O
trial NCT03866538 709 714 B-Study

- NCT03866538 717 718 O
Other NCT03866538 720 725 B-Other
concurrent NCT03866538 726 736 B-Modifier
systemic NCT03866538 737 745 I-Modifier
corticosteroids NCT03866538 746 761 B-Drug

- NCT03866538 764 765 O
Other NCT03866538 767 772 B-Other
immune NCT03866538 773 779 B-Drug
mediating NCT03866538 780 789 I-Drug
medications NCT03866538 790 801 I-Drug
, NCT03866538 802 803 O
for NCT03866538 804 807 O
example NCT03866538 808 815 O
but NCT03866538 816 819 O
not NCT03866538 820 823 O
limited NCT03866538 824 831 O
to NCT03866538 832 834 O
azathioprine NCT03866538 835 847 B-Drug
, NCT03866538 848 849 O
6 NCT03866538 850 851 B-Drug
- NCT03866538 852 853 I-Drug
mercaptopurine NCT03866538 854 868 I-Drug
, NCT03866538 869 870 O
cyclosporine NCT03866538 871 883 B-Drug
, NCT03866538 884 885 O
methotrexate NCT03866538 886 898 B-Drug
, NCT03866538 899 900 O
anti NCT03866538 901 905 B-Drug
- NCT03866538 906 907 I-Drug
TNF NCT03866538 908 911 I-Drug
monoclonal NCT03866538 912 922 I-Drug
antibodies NCT03866538 923 933 I-Drug
, NCT03866538 934 935 O
alpha NCT03866538 936 941 B-Drug
- NCT03866538 942 943 I-Drug
4 NCT03866538 944 945 I-Drug
beta NCT03866538 946 950 I-Drug
- NCT03866538 951 952 I-Drug
7 NCT03866538 953 954 I-Drug
integrin NCT03866538 955 963 I-Drug
inhibiting NCT03866538 964 974 I-Drug
monoclonal NCT03866538 975 985 I-Drug
antibody NCT03866538 986 994 I-Drug
, NCT03866538 995 996 O
interleukin NCT03866538 997 1008 B-Drug
12 NCT03866538 1009 1011 I-Drug
/ NCT03866538 1012 1013 I-Drug
23 NCT03866538 1014 1016 I-Drug
inhibiting NCT03866538 1017 1027 I-Drug
monoclonal NCT03866538 1028 1038 I-Drug
antibody NCT03866538 1039 1047 I-Drug
, NCT03866538 1048 1049 O
JAK NCT03866538 1050 1053 B-Drug
inhibitors NCT03866538 1054 1064 I-Drug
. NCT03866538 1065 1066 O


Inclusion NCT03869151 0 9 O
Criteria NCT03869151 10 18 O
: NCT03869151 19 20 O

Patients NCT03869151 22 30 O
with NCT03869151 31 35 O
child NCT03869151 36 41 B-Modifier
A NCT03869151 42 43 I-Modifier
Hepatocellular NCT03869151 44 58 I-Modifier
carcinoma NCT03869151 59 68 B-Condition
. NCT03869151 69 70 O

Exclusion NCT03869151 72 81 O
Criteria NCT03869151 82 90 O
: NCT03869151 91 92 O

- NCT03869151 96 97 O
Patients NCT03869151 99 107 O
with NCT03869151 108 112 O
child NCT03869151 113 118 B-Modifier
C NCT03869151 119 120 I-Modifier
Hepatocellular NCT03869151 121 135 I-Modifier
carcinoma NCT03869151 136 145 B-Condition
. NCT03869151 146 147 O

- NCT03869151 151 152 O
Patients NCT03869151 154 162 O
with NCT03869151 163 167 O
heart NCT03869151 168 173 B-Condition
failure NCT03869151 174 181 I-Condition

Inclusion NCT03869970 0 9 O
Criteria NCT03869970 10 18 O
: NCT03869970 19 20 O

- NCT03869970 24 25 O
Diagnosis NCT03869970 27 36 O
of NCT03869970 37 39 O
mTBI NCT03869970 40 44 B-Condition
in NCT03869970 45 47 O
the NCT03869970 48 51 O
past NCT03869970 52 56 B-Eq-Comparison
48 NCT03869970 57 59 I-Eq-Comparison
hours NCT03869970 60 65 I-Eq-Comparison

Exclusion NCT03869970 66 75 O
Criteria NCT03869970 76 84 O
: NCT03869970 85 86 O

- NCT03869970 90 91 O
Patients NCT03869970 93 101 O
having NCT03869970 102 108 O
conditions NCT03869970 109 119 B-Condition
otherwise NCT03869970 120 129 O
which NCT03869970 130 135 O
limit NCT03869970 136 141 O
physical NCT03869970 142 150 B-Observation
activity NCT03869970 151 159 I-Observation
or NCT03869970 160 162 B-Or
neurocognitive NCT03869970 163 177 B-Modifier
assessment NCT03869970 178 188 B-Procedure

- NCT03869970 191 192 O
Do NCT03869970 194 196 O
not NCT03869970 197 200 O
have NCT03869970 201 205 O
a NCT03869970 206 207 O
smart NCT03869970 208 213 O
phone NCT03869970 214 219 O

- NCT03869970 222 223 O
History NCT03869970 225 232 B-Eq-Comparison
of NCT03869970 233 235 I-Eq-Comparison
past NCT03869970 236 240 I-Eq-Comparison
moderate NCT03869970 241 249 O
/ NCT03869970 250 251 B-Or
severe NCT03869970 252 258 O
TBI NCT03869970 259 262 B-Condition
, NCT03869970 263 264 O

- NCT03869970 268 269 O
Substance NCT03869970 271 280 B-Condition
abuse NCT03869970 281 286 I-Condition
, NCT03869970 287 288 O

- NCT03869970 292 293 O
Major NCT03869970 295 300 O
psychiatric NCT03869970 301 312 B-Condition
condition NCT03869970 313 322 I-Condition
, NCT03869970 323 324 O

- NCT03869970 328 329 O
Vestibular NCT03869970 331 341 B-Condition
disorder NCT03869970 342 350 I-Condition
, NCT03869970 351 352 O

- NCT03869970 356 357 O
Cardiac NCT03869970 359 366 B-Condition
condition NCT03869970 367 376 I-Condition
, NCT03869970 377 378 O

- NCT03869970 382 383 O
Unable NCT03869970 385 391 O
to NCT03869970 392 394 O
provide NCT03869970 395 402 O
consent NCT03869970 403 410 O
/ NCT03869970 411 412 O
assent NCT03869970 413 419 O

Inclusion NCT03865186 0 9 O
Criteria NCT03865186 10 18 O
: NCT03865186 19 20 O

- NCT03865186 24 25 O
Clinical NCT03865186 27 35 O
diagnosis NCT03865186 36 45 O
of NCT03865186 46 48 O
schizophrenia NCT03865186 49 62 B-Condition
according NCT03865186 63 72 O
to NCT03865186 73 75 O
DSM NCT03865186 76 79 O
- NCT03865186 80 81 O
IV NCT03865186 82 84 O

- NCT03865186 87 88 O
over NCT03865186 90 94 B-Eq-Comparison
the NCT03865186 95 98 I-Eq-Comparison
age NCT03865186 99 102 I-Eq-Comparison
of NCT03865186 103 105 I-Eq-Comparison
18 NCT03865186 106 108 I-Eq-Comparison

Exclusion NCT03865186 110 119 O
Criteria NCT03865186 120 128 O
: NCT03865186 129 130 O

- NCT03865186 134 135 O
having NCT03865186 137 143 B-Eq-Comparison
cominication NCT03865186 144 156 B-Condition
problems NCT03865186 157 165 I-Condition

- NCT03865186 168 169 O
having NCT03865186 171 177 B-Eq-Comparison
another NCT03865186 178 185 B-Other
psychiatric NCT03865186 186 197 B-Condition
disease NCT03865186 198 205 I-Condition

Inclusion NCT03865810 0 9 O
Criteria NCT03865810 10 18 O
: NCT03865810 19 20 O

- NCT03865810 24 25 O
All NCT03865810 27 30 O
patients NCT03865810 31 39 O
over NCT03865810 40 44 B-Eq-Comparison
18 NCT03865810 45 47 I-Eq-Comparison
years NCT03865810 48 53 I-Eq-Comparison
of NCT03865810 54 56 O
age NCT03865810 57 60 B-Age
undergoing NCT03865810 61 71 B-Eq-Comparison
gastric NCT03865810 72 79 B-Procedure
resection NCT03865810 80 89 I-Procedure
surgery NCT03865810 90 97 I-Procedure
due NCT03865810 98 101 O
to NCT03865810 102 104 O
cancer NCT03865810 105 111 B-Condition
within NCT03865810 112 118 B-And
or NCT03865810 119 121 B-Or
not NCT03865810 122 125 B-Negation
of NCT03865810 126 128 O
an NCT03865810 129 131 O
intensified NCT03865810 132 143 B-Modifier
recovery NCT03865810 144 152 B-Procedure
program NCT03865810 153 160 I-Procedure
( NCT03865810 161 162 O
ERAS NCT03865810 163 167 B-Procedure
) NCT03865810 168 169 O
with NCT03865810 170 174 O
any NCT03865810 175 178 O
level NCT03865810 179 184 O
of NCT03865810 185 187 O
compliance NCT03865810 188 198 O
with NCT03865810 199 203 O
the NCT03865810 204 207 O
protocol NCT03865810 208 216 O
( NCT03865810 217 218 O
from NCT03865810 219 223 O
0 NCT03865810 224 225 B-Eq-Comparison
- NCT03865810 226 227 I-Eq-Comparison
100 NCT03865810 228 231 I-Eq-Comparison
% NCT03865810 232 233 I-Eq-Comparison
) NCT03865810 235 236 O
. NCT03865810 238 239 O

Exclusion NCT03865810 241 250 O
Criteria NCT03865810 251 259 O
: NCT03865810 260 261 O

- NCT03865810 265 266 O
Patients NCT03865810 268 276 O
undergoing NCT03865810 277 287 B-Eq-Comparison
emergency NCT03865810 288 297 B-Modifier
surgery NCT03865810 298 305 B-Procedure

- NCT03865810 313 314 O
Endoscopic NCT03865810 316 326 B-Procedure
procedures NCT03865810 327 337 I-Procedure

- NCT03865810 345 346 O
Non NCT03865810 348 351 B-Negation
- NCT03865810 352 353 O
oncological NCT03865810 354 365 B-Procedure
gastric NCT03865810 366 373 I-Procedure
surgery NCT03865810 374 381 I-Procedure

- NCT03865810 389 390 O
Patients NCT03865810 392 400 O
who NCT03865810 401 404 O
refuse NCT03865810 405 411 O
to NCT03865810 412 414 O
participate NCT03865810 415 426 O

Inclusion NCT03868449 0 9 O
Criteria NCT03868449 10 18 O
: NCT03868449 19 20 O

- NCT03868449 24 25 O
patients NCT03868449 27 35 O
with NCT03868449 36 40 O
common NCT03868449 41 47 B-Modifier
hand NCT03868449 48 52 I-Modifier
conditions NCT03868449 53 63 B-Condition

Exclusion NCT03868449 64 73 O
Criteria NCT03868449 74 82 O
: NCT03868449 83 84 O

- NCT03868449 87 88 O

Inclusion NCT03868878 0 9 O
Criteria NCT03868878 10 18 O
: NCT03868878 19 20 O

- NCT03868878 24 25 O
age NCT03868878 27 30 B-Age
greater NCT03868878 31 38 B-Eq-Comparison
than NCT03868878 39 43 I-Eq-Comparison
60 NCT03868878 44 46 I-Eq-Comparison
years NCT03868878 47 52 I-Eq-Comparison
; NCT03868878 52 53 O

- NCT03868878 56 57 O
is NCT03868878 59 61 O
not NCT03868878 62 65 B-Negation
engaged NCT03868878 66 73 O
in NCT03868878 74 76 O
physical NCT03868878 77 85 B-Observation
exercise NCT03868878 86 94 I-Observation
programs NCT03868878 95 103 O
for NCT03868878 104 107 O
at NCT03868878 108 110 B-Eq-Comparison
least NCT03868878 111 116 I-Eq-Comparison
one NCT03868878 117 120 I-Eq-Comparison
year NCT03868878 121 125 I-Eq-Comparison
; NCT03868878 125 126 O

- NCT03868878 129 130 O
do NCT03868878 132 134 O
not NCT03868878 135 138 B-Negation
present NCT03868878 139 146 O
severe NCT03868878 147 153 O
cardiovascular NCT03868878 154 168 B-Condition
disease NCT03868878 169 176 I-Condition
, NCT03868878 177 178 O
kidney NCT03868878 179 185 B-Condition
disease NCT03868878 186 193 I-Condition
, NCT03868878 194 195 O
liver NCT03868878 196 201 B-Condition
disease NCT03868878 202 209 I-Condition
or NCT03868878 210 212 B-Or
limiting NCT03868878 213 221 B-Modifier
cognitive NCT03868878 222 231 I-Modifier
or NCT03868878 232 234 B-Or
neuromuscular NCT03868878 235 248 B-Modifier
disease NCT03868878 249 256 B-Condition
and NCT03868878 257 260 B-And
; NCT03868878 260 261 O

- NCT03868878 264 265 O
does NCT03868878 267 271 O
not NCT03868878 272 275 B-Negation
present NCT03868878 276 283 O
visual NCT03868878 284 290 B-Modifier
or NCT03868878 291 293 B-Or
auditory NCT03868878 294 302 B-Modifier
inability NCT03868878 303 312 B-Condition
. NCT03868878 313 314 O

Exclusion NCT03868878 316 325 O
Criteria NCT03868878 326 334 O
: NCT03868878 335 336 O

- NCT03868878 340 341 O
failing NCT03868878 343 350 B-Negation
to NCT03868878 351 353 O
perform NCT03868878 354 361 O
any NCT03868878 362 365 O
of NCT03868878 366 368 O
the NCT03868878 369 372 O
evaluations NCT03868878 373 384 B-Study
suggested NCT03868878 385 394 O
during NCT03868878 395 401 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868878 402 405 O
intervention NCT03868878 406 418 B-Study
protocol NCT03868878 419 427 O
and NCT03868878 428 431 B-And
; NCT03868878 431 432 O

- NCT03868878 435 436 O
absence NCT03868878 438 445 B-Negation
in NCT03868878 446 448 O
five NCT03868878 449 453 B-Eq-Comparison
or NCT03868878 454 456 I-Eq-Comparison
more NCT03868878 457 461 I-Eq-Comparison
Capoeira NCT03868878 462 470 B-Procedure
training NCT03868878 471 479 I-Procedure
sessions NCT03868878 480 488 I-Procedure
. NCT03868878 488 489 O

Inclusion NCT03868111 0 9 O
Criteria NCT03868111 10 18 O
: NCT03868111 19 20 O

- NCT03868111 24 25 O
Patients NCT03868111 27 35 O
aged NCT03868111 36 40 B-Age
between NCT03868111 41 48 B-Eq-Comparison
19 NCT03868111 49 51 I-Eq-Comparison
and NCT03868111 52 55 I-Eq-Comparison
65 NCT03868111 56 58 I-Eq-Comparison
years NCT03868111 59 64 I-Eq-Comparison

- NCT03868111 67 68 O
Patients NCT03868111 70 78 O
with NCT03868111 79 83 O
American NCT03868111 84 92 B-Condition
Society NCT03868111 93 100 I-Condition
of NCT03868111 101 103 I-Condition
Anesthesiologists NCT03868111 104 121 I-Condition
physical NCT03868111 122 130 O
status NCT03868111 131 137 O
I NCT03868111 138 139 B-Eq-Comparison
or NCT03868111 140 142 I-Eq-Comparison
II NCT03868111 143 145 I-Eq-Comparison

- NCT03868111 148 149 O
Patients NCT03868111 151 159 O
scheduled NCT03868111 160 169 B-Eq-Comparison
for NCT03868111 170 173 O
elective NCT03868111 174 182 B-Modifier
laparoscopic NCT03868111 183 195 B-Procedure
cholecystectomy NCT03868111 196 211 I-Procedure
under NCT03868111 212 217 O
balanced NCT03868111 218 226 O
general NCT03868111 227 234 B-Procedure
anesthesia NCT03868111 235 245 I-Procedure
for NCT03868111 246 249 O
benign NCT03868111 250 256 B-Condition
cholecystic NCT03868111 257 268 I-Condition
diseases NCT03868111 269 277 I-Condition

- NCT03868111 280 281 O
Patients NCT03868111 283 291 O
obtaining NCT03868111 292 301 O
written NCT03868111 302 309 O
informed NCT03868111 310 318 O
consent NCT03868111 319 326 O

Exclusion NCT03868111 327 336 O
Criteria NCT03868111 337 345 O
: NCT03868111 346 347 O

- NCT03868111 351 352 O
Patients NCT03868111 354 362 O
with NCT03868111 363 367 O
asthma NCT03868111 368 374 B-Condition
or NCT03868111 375 377 B-Or
hypertension NCT03868111 378 390 B-Condition

- NCT03868111 393 394 O
Patients NCT03868111 396 404 O
with NCT03868111 405 409 O
an NCT03868111 410 412 O
inability NCT03868111 413 422 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868111 423 425 O
express NCT03868111 426 433 O
their NCT03868111 434 439 O
pain NCT03868111 440 444 B-Condition
accurately NCT03868111 445 455 O

- NCT03868111 458 459 O
Patients NCT03868111 461 469 O
with NCT03868111 470 474 O
an NCT03868111 475 477 O
inability NCT03868111 478 487 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 488 490 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03868111 491 501 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03868111 502 505 O
pain NCT03868111 506 510 B-Observation
scale NCT03868111 511 516 I-Observation

- NCT03868111 519 520 O
Patients NCT03868111 522 530 O
with NCT03868111 531 535 O
chronic NCT03868111 536 543 B-Modifier
abdominal NCT03868111 544 553 I-Modifier
pain NCT03868111 554 558 B-Condition
or NCT03868111 559 561 B-Or
chronic NCT03868111 562 569 B-Modifier
pain NCT03868111 570 574 B-Condition
syndrome NCT03868111 575 583 I-Condition

- NCT03868111 586 587 O
Patients NCT03868111 589 597 O
who NCT03868111 598 601 O
required NCT03868111 602 610 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 611 613 I-Assertion___Assertion-Type-Value:hypothetical
convert NCT03868111 614 621 O
to NCT03868111 622 624 O
laparotomy NCT03868111 625 635 B-Procedure
from NCT03868111 636 640 O
laparoscopic NCT03868111 641 653 B-Procedure
surgery NCT03868111 654 661 I-Procedure

- NCT03868111 664 665 O
Patients NCT03868111 667 675 O
who NCT03868111 676 679 O
required NCT03868111 680 688 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868111 689 691 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03868111 692 699 O
incidental NCT03868111 700 710 B-Modifier
lower NCT03868111 711 716 I-Modifier
abdominal NCT03868111 717 726 B-Procedure
procedures NCT03868111 727 737 I-Procedure
owing NCT03868111 738 743 O
to NCT03868111 744 746 O
adhesion NCT03868111 747 755 B-Condition
, NCT03868111 756 757 O
injury NCT03868111 758 764 B-Condition
, NCT03868111 765 766 O
or NCT03868111 767 769 B-Or
other NCT03868111 770 775 B-Other
incidental NCT03868111 776 786 B-Condition
findings NCT03868111 787 795 I-Condition
at NCT03868111 796 798 O
the NCT03868111 799 802 O
lower NCT03868111 803 808 B-Modifier
abdominal NCT03868111 809 818 I-Modifier
cavity NCT03868111 819 825 I-Modifier

- NCT03868111 828 829 O
Patients NCT03868111 831 839 O
with NCT03868111 840 844 O
a NCT03868111 845 846 O
history NCT03868111 847 854 B-Eq-Comparison
of NCT03868111 855 857 O
drug NCT03868111 858 862 B-Modifier
or NCT03868111 863 865 B-Or
alcohol NCT03868111 866 873 B-Modifier
abuse NCT03868111 874 879 B-Condition

- NCT03868111 882 883 O
Pregnant NCT03868111 885 893 B-Condition
women NCT03868111 894 899 O

Patient NCT03869541 0 7 O
participants NCT03869541 8 20 O
: NCT03869541 21 22 O

Inclusion NCT03869541 24 33 O
Criteria NCT03869541 34 42 O
: NCT03869541 43 44 O

- NCT03869541 48 49 O
Patients NCT03869541 51 59 O
admitted NCT03869541 60 68 B-Encounter
to NCT03869541 69 71 O
the NCT03869541 72 75 O
ICU NCT03869541 76 79 O
who NCT03869541 80 83 B-And
are NCT03869541 84 87 O
receiving NCT03869541 88 97 B-Eq-Comparison
vasoactive NCT03869541 98 108 B-Drug
drugs NCT03869541 109 114 I-Drug
. NCT03869541 115 116 O

- NCT03869541 120 121 O
Age NCT03869541 123 126 B-Age
greater NCT03869541 127 134 B-Eq-Comparison
than NCT03869541 135 139 I-Eq-Comparison
or NCT03869541 140 142 I-Eq-Comparison
equal NCT03869541 143 148 I-Eq-Comparison
to NCT03869541 149 151 I-Eq-Comparison
18 NCT03869541 152 154 I-Eq-Comparison
years NCT03869541 155 160 I-Eq-Comparison
old NCT03869541 161 164 O
. NCT03869541 165 166 O

- NCT03869541 170 171 O
Expected NCT03869541 173 181 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869541 182 184 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03869541 185 191 O
admitted NCT03869541 192 200 B-Encounter
to NCT03869541 201 203 O
the NCT03869541 204 207 O
ICU NCT03869541 208 211 O
for NCT03869541 212 215 O
at NCT03869541 216 218 B-Eq-Comparison
least NCT03869541 219 224 I-Eq-Comparison
24 NCT03869541 225 227 I-Eq-Comparison
hours NCT03869541 228 233 I-Eq-Comparison
post NCT03869541 234 238 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03869541 239 240 O
enrolment NCT03869541 241 250 B-Study
. NCT03869541 251 252 O

Exclusion NCT03869541 254 263 O
Criteria NCT03869541 264 272 O
: NCT03869541 273 274 O

- NCT03869541 278 279 O
Any NCT03869541 281 284 O
patient NCT03869541 285 292 O
who NCT03869541 293 296 O
is NCT03869541 297 299 O
expected NCT03869541 300 308 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869541 309 311 I-Assertion___Assertion-Type-Value:hypothetical
die NCT03869541 312 315 B-Death
imminently NCT03869541 316 326 B-Modifier
, NCT03869541 327 328 O
as NCT03869541 329 331 O
per NCT03869541 332 335 O
clinical NCT03869541 336 344 O
opinion NCT03869541 345 352 O
. NCT03869541 353 354 O

- NCT03869541 358 359 O
Any NCT03869541 361 364 O
patient NCT03869541 365 372 O
where NCT03869541 373 378 O
mobilization NCT03869541 379 391 B-Procedure
is NCT03869541 392 394 O
contraindicated NCT03869541 395 410 B-Contraindication
by NCT03869541 411 413 O
the NCT03869541 414 417 O
nature NCT03869541 418 424 O
of NCT03869541 425 427 O
their NCT03869541 428 433 O
existing NCT03869541 434 442 B-Eq-Comparison
injuries NCT03869541 443 451 B-Condition
. NCT03869541 452 453 O

- NCT03869541 457 458 O
Where NCT03869541 460 465 O
it NCT03869541 466 468 O
is NCT03869541 469 471 O
clear NCT03869541 472 477 O
from NCT03869541 478 482 O
the NCT03869541 483 486 O
medical NCT03869541 487 494 O
records NCT03869541 495 502 O
that NCT03869541 503 507 O
participants NCT03869541 508 520 O
are NCT03869541 521 524 O
prisoners NCT03869541 525 534 B-Observation
or NCT03869541 535 537 B-Or
offenders NCT03869541 538 547 O
on NCT03869541 548 550 B-Observation
probation NCT03869541 551 560 I-Observation
. NCT03869541 561 562 O

- NCT03869541 566 567 O
Patients NCT03869541 569 577 O
with NCT03869541 578 582 O
neuromuscular NCT03869541 583 596 B-Condition
disease NCT03869541 597 604 I-Condition
or NCT03869541 605 607 B-Or
acute NCT03869541 608 613 O
brain NCT03869541 614 619 B-Modifier
injury NCT03869541 620 626 B-Condition
or NCT03869541 627 629 B-Or
spinal NCT03869541 630 636 B-Modifier
cord NCT03869541 637 641 I-Modifier
injury NCT03869541 642 648 B-Condition
. NCT03869541 649 650 O

- NCT03869541 654 655 O
If NCT03869541 657 659 O
the NCT03869541 660 663 O
patient NCT03869541 664 671 O
and NCT03869541 672 675 O
/ NCT03869541 676 677 O
or NCT03869541 678 680 O
their NCT03869541 681 686 O
consultee NCT03869541 687 696 O
is NCT03869541 697 699 O
unable NCT03869541 700 706 B-Negation
to NCT03869541 707 709 O
speak NCT03869541 710 715 O
English NCT03869541 716 723 O
. NCT03869541 724 725 O

Clinicians NCT03869541 727 737 O
participating NCT03869541 738 751 O
in NCT03869541 752 754 O
a NCT03869541 755 756 O
survey NCT03869541 757 763 O
on NCT03869541 764 766 O
hypothetical NCT03869541 767 779 O
randomization NCT03869541 780 793 O
of NCT03869541 794 796 O
patient NCT03869541 797 804 O
participants NCT03869541 805 817 O
: NCT03869541 818 819 O

Inclusion NCT03869541 821 830 O
criteria NCT03869541 831 839 O
: NCT03869541 840 841 O

- NCT03869541 845 846 O
Clinicians NCT03869541 848 858 O
who NCT03869541 859 862 O
work NCT03869541 863 867 O
in NCT03869541 868 870 O
the NCT03869541 871 874 O
intensive NCT03869541 875 884 O
care NCT03869541 885 889 O
unit NCT03869541 890 894 O
where NCT03869541 895 900 O
a NCT03869541 901 902 O
patient NCT03869541 903 910 O
participant NCT03869541 911 922 O
has NCT03869541 923 926 B-Eq-Comparison
been NCT03869541 927 931 I-Eq-Comparison
admitted NCT03869541 932 940 B-Encounter
. NCT03869541 941 942 O

Exclusion NCT03869541 944 953 O
criteria NCT03869541 954 962 O
: NCT03869541 963 964 O

- NCT03869541 968 969 O
None NCT03869541 971 975 O
. NCT03869541 976 977 O

Clinician NCT03869541 979 988 O
participants NCT03869541 989 1001 O
in NCT03869541 1002 1004 O
the NCT03869541 1005 1008 O
survey NCT03869541 1009 1015 O
on NCT03869541 1016 1018 O
the NCT03869541 1019 1022 O
feasibility NCT03869541 1023 1034 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03869541 1035 1037 O
the NCT03869541 1038 1041 O
ICU NCT03869541 1042 1045 O
physical NCT03869541 1046 1054 B-Procedure
rehabilitation NCT03869541 1055 1069 I-Procedure
adverse NCT03869541 1070 1077 O
event NCT03869541 1078 1083 O
tool NCT03869541 1084 1088 O
: NCT03869541 1089 1090 O

Inclusion NCT03869541 1092 1101 O
criteria NCT03869541 1102 1110 O
: NCT03869541 1111 1112 O

- NCT03869541 1116 1117 O
An NCT03869541 1119 1121 O
ICU NCT03869541 1122 1125 O
clinician NCT03869541 1126 1135 O
at NCT03869541 1136 1138 O
the NCT03869541 1139 1142 O
research NCT03869541 1143 1151 O
site NCT03869541 1152 1156 O
. NCT03869541 1157 1158 O

- NCT03869541 1162 1163 O
Has NCT03869541 1165 1168 O
used NCT03869541 1169 1173 O
the NCT03869541 1174 1177 O
ICU NCT03869541 1178 1181 O
physical NCT03869541 1182 1190 B-Observation
rehabilitation NCT03869541 1191 1205 I-Observation
adverse NCT03869541 1206 1213 I-Observation
event NCT03869541 1214 1219 I-Observation
tool NCT03869541 1220 1224 I-Observation
as NCT03869541 1225 1227 O
part NCT03869541 1228 1232 O
of NCT03869541 1233 1235 O
this NCT03869541 1236 1240 O
research NCT03869541 1241 1249 O
study NCT03869541 1250 1255 B-Study
. NCT03869541 1256 1257 O

Exclusion NCT03869541 1259 1268 O
criteria NCT03869541 1269 1277 O
: NCT03869541 1278 1279 O

- NCT03869541 1283 1284 O
None NCT03869541 1286 1290 O
. NCT03869541 1291 1292 O


Inclusion NCT03868176 0 9 O
Criteria NCT03868176 10 18 O
: NCT03868176 19 20 O

- NCT03868176 24 25 O
Patient NCT03868176 27 34 O
with NCT03868176 35 39 O
germ NCT03868176 40 44 B-Modifier
cell NCT03868176 45 49 I-Modifier
tumor NCT03868176 50 55 B-Condition
. NCT03868176 56 57 O

- NCT03868176 61 62 O
Patient NCT03868176 64 71 O
with NCT03868176 72 76 O
a NCT03868176 77 78 O
mobile NCT03868176 79 85 O
phone NCT03868176 86 91 O
. NCT03868176 92 93 O

- NCT03868176 97 98 O
Patient NCT03868176 100 107 O
on NCT03868176 108 110 B-Eq-Comparison
surveillance NCT03868176 111 123 B-Procedure
. NCT03868176 124 125 O

Exclusion NCT03868176 127 136 O
Criteria NCT03868176 137 145 O
: NCT03868176 146 147 O

- NCT03868176 151 152 O
Testicular NCT03868176 154 164 B-Modifier
cancer NCT03868176 165 171 B-Condition
without NCT03868176 172 179 B-Negation
germ NCT03868176 180 184 B-Modifier
cell NCT03868176 185 189 I-Modifier
component NCT03868176 190 199 I-Modifier
. NCT03868176 200 201 O

- NCT03868176 205 206 O
Prior NCT03868176 208 213 B-Eq-Comparison
history NCT03868176 214 221 I-Eq-Comparison
of NCT03868176 222 224 O
other NCT03868176 225 230 B-Other
malignancy NCT03868176 231 241 B-Condition
except NCT03868176 242 248 B-Exception
for NCT03868176 249 252 O
: NCT03868176 253 254 O
cutaneous NCT03868176 255 264 B-Condition
cancers NCT03868176 265 272 I-Condition
excluding NCT03868176 273 282 B-Exception
melanoma NCT03868176 283 291 B-Condition
, NCT03868176 292 293 O
superficial NCT03868176 294 305 B-Modifier
bladder NCT03868176 306 313 I-Modifier
tumor NCT03868176 314 319 B-Condition
, NCT03868176 320 321 O
localized NCT03868176 322 331 B-Modifier
prostate NCT03868176 332 340 I-Modifier
cancer NCT03868176 341 347 B-Condition
with NCT03868176 348 352 B-And
undetectable NCT03868176 353 365 O
PSA NCT03868176 366 369 B-Observation
. NCT03868176 370 371 O

- NCT03868176 375 376 O
Cognitive NCT03868176 378 387 B-Condition
condition NCT03868176 388 397 I-Condition
that NCT03868176 398 402 O
would NCT03868176 403 408 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03868176 409 417 B-Negation
patient NCT03868176 418 425 O
's NCT03868176 425 427 O
understanding NCT03868176 428 441 O
and NCT03868176 442 445 O
completion NCT03868176 446 456 O
of NCT03868176 457 459 O
study NCT03868176 460 465 B-Study
procedures NCT03868176 466 476 B-Procedure
. NCT03868176 476 477 O

Inclusion NCT03864016 0 9 O
Criteria NCT03864016 10 18 O
: NCT03864016 19 20 O

- NCT03864016 24 25 O
Person NCT03864016 27 33 O
who NCT03864016 34 37 O
has NCT03864016 38 41 O
given NCT03864016 42 47 O
written NCT03864016 48 55 O
consent NCT03864016 56 63 O

- NCT03864016 66 67 O
Adult NCT03864016 69 74 O
patient NCT03864016 75 82 O

- NCT03864016 85 86 O
Patient NCT03864016 88 95 O
undergoing NCT03864016 96 106 B-Eq-Comparison
coronary NCT03864016 107 115 B-Procedure
artery NCT03864016 116 122 I-Procedure
bypass NCT03864016 123 129 I-Procedure
surgery NCT03864016 130 137 I-Procedure
with NCT03864016 138 142 O
CEC NCT03864016 143 146 B-Procedure
, NCT03864016 147 148 O
with NCT03864016 149 153 B-And
or NCT03864016 154 156 B-Or
without NCT03864016 157 164 B-Negation
valve NCT03864016 165 170 B-Procedure
surgery NCT03864016 171 178 I-Procedure
, NCT03864016 179 180 O
by NCT03864016 181 183 O
sternotomy NCT03864016 184 194 B-Procedure
. NCT03864016 195 196 O

- NCT03864016 200 201 O
ASA NCT03864016 203 206 B-Condition
< NCT03864016 207 208 B-Eq-Comparison
4 NCT03864016 209 210 I-Eq-Comparison
. NCT03864016 210 211 O

Exclusion NCT03864016 213 222 O
Criteria NCT03864016 223 231 O
: NCT03864016 232 233 O

- NCT03864016 237 238 O
Person NCT03864016 240 246 O
not NCT03864016 247 250 B-Negation
affiliated NCT03864016 251 261 O
to NCT03864016 262 264 O
the NCT03864016 265 268 O
national NCT03864016 269 277 O
health NCT03864016 278 284 O
insurance NCT03864016 285 294 O
system NCT03864016 295 301 O

- NCT03864016 304 305 O
Person NCT03864016 307 313 O
subject NCT03864016 314 321 O
to NCT03864016 322 324 O
legal NCT03864016 325 330 B-Observation
protection NCT03864016 331 341 I-Observation
( NCT03864016 342 343 O
curatorship NCT03864016 344 355 B-Observation
, NCT03864016 356 357 O
guardianship NCT03864016 358 370 B-Observation
) NCT03864016 371 372 O

- NCT03864016 376 377 O
Person NCT03864016 379 385 O
who NCT03864016 386 389 O
has NCT03864016 390 393 O
been NCT03864016 394 398 O
deemed NCT03864016 399 405 O
mentally NCT03864016 406 414 B-Condition
incompetent NCT03864016 415 426 I-Condition

- NCT03864016 429 430 O
Pregnant NCT03864016 432 440 B-Condition
, NCT03864016 441 442 O
parturient NCT03864016 443 453 B-Condition
or NCT03864016 454 456 B-Or
breastfeeding NCT03864016 457 470 B-Condition
woman NCT03864016 471 476 O

- NCT03864016 479 480 O
Adult NCT03864016 482 487 O
unable NCT03864016 488 494 O
or NCT03864016 495 497 O
unwilling NCT03864016 498 507 O
to NCT03864016 508 510 O
provide NCT03864016 511 518 O
consent NCT03864016 519 526 O

- NCT03864016 529 530 O
Patient NCT03864016 532 539 O
with NCT03864016 540 544 O
pre NCT03864016 545 548 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03864016 549 558 B-Procedure
cognitive NCT03864016 559 568 B-Condition
dysfunction NCT03864016 569 580 I-Condition
( NCT03864016 581 582 O
MMS NCT03864016 583 586 B-Observation
< NCT03864016 587 588 B-Eq-Comparison
13 NCT03864016 589 591 I-Eq-Comparison
) NCT03864016 592 593 O
( NCT03864016 594 595 O
APPENDIX NCT03864016 596 604 O
6 NCT03864016 605 606 O
) NCT03864016 607 608 O
, NCT03864016 610 611 O

- NCT03864016 615 616 O
Patient NCT03864016 618 625 O
with NCT03864016 626 630 O
morphine NCT03864016 631 639 B-Drug
intolerance NCT03864016 640 651 B-Condition
, NCT03864016 652 653 O

- NCT03864016 657 658 O
Patient NCT03864016 660 667 O
on NCT03864016 668 670 B-Eq-Comparison
long NCT03864016 671 675 B-Modifier
- NCT03864016 676 677 I-Modifier
term NCT03864016 678 682 I-Modifier
opioid NCT03864016 683 689 B-Drug
treatment NCT03864016 690 699 B-Procedure
, NCT03864016 700 701 O

- NCT03864016 705 706 O
Emergency NCT03864016 708 717 B-Modifier
surgery NCT03864016 718 725 B-Procedure
, NCT03864016 726 727 O

- NCT03864016 731 732 O
Eye NCT03864016 734 737 B-Condition
disease NCT03864016 738 745 I-Condition
, NCT03864016 746 747 O
corneal NCT03864016 748 755 B-Modifier
injury NCT03864016 756 762 B-Condition
, NCT03864016 763 764 O
or NCT03864016 765 767 B-Or
wearing NCT03864016 768 775 B-Modifier
contact NCT03864016 776 783 B-Procedure
lenses NCT03864016 784 790 I-Procedure
, NCT03864016 791 792 O
a NCT03864016 793 794 O
neurological NCT03864016 795 807 B-Condition
disease NCT03864016 808 815 I-Condition
that NCT03864016 816 820 O
can NCT03864016 821 824 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03864016 825 834 O
the NCT03864016 835 838 O
pupillary NCT03864016 839 848 B-Condition
reflex NCT03864016 849 855 I-Condition
, NCT03864016 856 857 O

- NCT03864016 861 862 O
Refusal NCT03864016 864 871 O
to NCT03864016 872 874 O
participate NCT03864016 875 886 O

Inclusion NCT03867279 0 9 O
Criteria NCT03867279 10 18 O
: NCT03867279 19 20 O

- NCT03867279 24 25 O
From NCT03867279 27 31 O
18 NCT03867279 32 34 B-Eq-Comparison
to NCT03867279 35 37 I-Eq-Comparison
24 NCT03867279 38 40 I-Eq-Comparison
years NCT03867279 41 46 I-Eq-Comparison
old NCT03867279 47 50 B-Age

- NCT03867279 53 54 O
Male NCT03867279 56 60 O

- NCT03867279 63 64 O
That NCT03867279 66 70 O
they NCT03867279 71 75 O
be NCT03867279 76 78 O
weight NCT03867279 79 85 B-Observation
lifters NCT03867279 86 93 I-Observation
with NCT03867279 94 98 O
at NCT03867279 99 101 B-Eq-Comparison
least NCT03867279 102 107 I-Eq-Comparison
one NCT03867279 108 111 I-Eq-Comparison
year NCT03867279 112 116 I-Eq-Comparison
of NCT03867279 117 119 O
experience NCT03867279 120 130 O

- NCT03867279 133 134 O
That NCT03867279 136 140 O
they NCT03867279 141 145 O
do NCT03867279 146 148 O
not NCT03867279 149 152 B-Negation
present NCT03867279 153 160 O
musculoskeletal NCT03867279 161 176 B-Modifier
injury NCT03867279 177 183 B-Condition
or NCT03867279 184 186 B-Or
pathology NCT03867279 187 196 B-Condition
in NCT03867279 197 199 O
the NCT03867279 200 203 O
three NCT03867279 204 209 B-Eq-Comparison
months NCT03867279 210 216 I-Eq-Comparison
prior NCT03867279 217 222 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867279 223 225 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867279 226 229 O
beginning NCT03867279 230 239 O
of NCT03867279 240 242 O
the NCT03867279 243 246 O
study NCT03867279 247 252 B-Study

Exclusion NCT03867279 253 262 O
Criteria NCT03867279 263 271 O
: NCT03867279 272 273 O

- NCT03867279 277 278 O
Can NCT03867279 280 283 O
not NCT03867279 284 287 B-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03867279 288 290 B-Encounter
present NCT03867279 291 298 I-Encounter
during NCT03867279 299 305 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867279 306 309 O
6 NCT03867279 310 311 B-Eq-Comparison
weeks NCT03867279 312 317 I-Eq-Comparison
of NCT03867279 318 320 O
the NCT03867279 321 324 O
intervention NCT03867279 325 337 B-Study
and NCT03867279 338 341 B-And
the NCT03867279 342 345 O
evaluations NCT03867279 346 357 B-Study
will NCT03867279 358 362 O
be NCT03867279 363 365 O
excluded NCT03867279 366 374 B-Negation

- NCT03867279 377 378 O
Under NCT03867279 380 385 B-Eq-Comparison
pharmacological NCT03867279 386 401 B-Procedure
treatment NCT03867279 402 411 I-Procedure

- NCT03867279 414 415 O
Who NCT03867279 417 420 O
are NCT03867279 421 424 O
performing NCT03867279 425 435 O
another NCT03867279 436 443 B-Other
physiotherapy NCT03867279 444 457 B-Procedure
study NCT03867279 458 463 B-Study

- NCT03867279 466 467 O
Not NCT03867279 469 472 O
sign NCT03867279 473 477 O
the NCT03867279 478 481 O
informed NCT03867279 482 490 O
consent NCT03867279 491 498 O
document NCT03867279 499 507 O
. NCT03867279 507 508 O

Inclusion NCT03864770 0 9 O
Criteria NCT03864770 10 18 O
: NCT03864770 19 20 O

1 NCT03864770 24 25 O
. NCT03864770 25 26 O
≥ NCT03864770 28 29 B-Eq-Comparison
20 NCT03864770 30 32 I-Eq-Comparison
y NCT03864770 33 34 I-Eq-Comparison
/ NCT03864770 35 36 I-Eq-Comparison
o NCT03864770 37 38 I-Age|Eq-Comparison
patients NCT03864770 39 47 O
with NCT03864770 48 52 O
NLCs NCT03864770 53 57 B-Condition
: NCT03864770 58 59 O
( NCT03864770 60 61 O
1 NCT03864770 62 63 O
) NCT03864770 64 65 O
4 NCT03864770 66 67 B-Eq-Comparison
times NCT03864770 68 73 I-Eq-Comparison
/ NCT03864770 74 75 I-Eq-Comparison
week NCT03864770 76 80 I-Eq-Comparison
, NCT03864770 81 82 O
last NCT03864770 83 87 B-Eq-Comparison
2 NCT03864770 88 89 I-Eq-Comparison
weeks NCT03864770 90 95 I-Eq-Comparison
; NCT03864770 95 96 O
( NCT03864770 97 98 O
2 NCT03864770 99 100 O
) NCT03864770 101 102 O
Occurred NCT03864770 103 111 O
in NCT03864770 112 114 O
nighttime NCT03864770 115 124 B-Modifier
or NCT03864770 125 127 B-Or
resting NCT03864770 128 135 B-Modifier
time NCT03864770 136 140 I-Modifier
of NCT03864770 141 143 I-Modifier
daytime NCT03864770 144 151 I-Modifier

2 NCT03864770 154 155 O
. NCT03864770 155 156 O
Patients NCT03864770 158 166 O
with NCT03864770 167 171 O
MTrPs NCT03864770 172 177 B-Condition
on NCT03864770 178 180 B-Eq-Comparison
gastrocnemius NCT03864770 181 194 B-Drug
( NCT03864770 195 196 O
According NCT03864770 197 206 O
to NCT03864770 207 209 O
the NCT03864770 210 213 O
diagnostic NCT03864770 214 224 O
criteria NCT03864770 225 233 O
proposed NCT03864770 234 242 O
by NCT03864770 243 245 O
Simons NCT03864770 246 252 B-Provider
& NCT03864770 253 254 I-Provider
Travell NCT03864770 255 262 I-Provider
) NCT03864770 263 264 O

Exclusion NCT03864770 266 275 O
Criteria NCT03864770 276 284 O
: NCT03864770 285 286 O

1 NCT03864770 290 291 O
. NCT03864770 291 292 O
( NCT03864770 294 295 O
1 NCT03864770 296 297 O
) NCT03864770 298 299 O
Taking NCT03864770 300 306 B-Eq-Comparison
medication NCT03864770 307 317 B-Drug
for NCT03864770 318 321 O
leg NCT03864770 322 325 B-Modifier
cramps NCT03864770 326 332 B-Condition
( NCT03864770 333 334 O
eg NCT03864770 335 337 O
. NCT03864770 337 338 O
Quinine NCT03864770 340 347 B-Drug
, NCT03864770 348 349 O
Magnesium NCT03864770 350 359 B-Drug
oxide NCT03864770 360 365 I-Drug
) NCT03864770 366 367 O
; NCT03864770 368 369 O
( NCT03864770 370 371 O
2 NCT03864770 372 373 O
) NCT03864770 374 375 O
Other NCT03864770 376 381 B-Other
drugs NCT03864770 382 387 B-Drug
that NCT03864770 388 392 O
affect NCT03864770 393 399 O
research NCT03864770 400 408 O
and NCT03864770 409 412 O
evaluation NCT03864770 413 423 B-Study
( NCT03864770 424 425 O
eg NCT03864770 426 428 O
. NCT03864770 428 429 O
diuretics NCT03864770 431 440 B-Drug
, NCT03864770 441 442 O
statins NCT03864770 443 450 B-Drug
, NCT03864770 451 452 O
calcium NCT03864770 453 460 B-Drug
channel NCT03864770 461 468 I-Drug
blockers NCT03864770 469 477 I-Drug
, NCT03864770 478 479 O
anticonvulsants NCT03864770 480 495 B-Drug
) NCT03864770 496 497 O

2 NCT03864770 501 502 O
. NCT03864770 502 503 O
Congenital NCT03864770 505 515 B-Condition
lower NCT03864770 516 521 I-Condition
limb NCT03864770 522 526 I-Condition
musculoskeletal NCT03864770 527 542 I-Condition
diseases NCT03864770 543 551 I-Condition
, NCT03864770 552 553 O
Lower NCT03864770 554 559 B-Modifier
limb NCT03864770 560 564 I-Modifier
or NCT03864770 565 567 B-Or
spine NCT03864770 568 573 B-Modifier
surgery NCT03864770 574 581 B-Procedure

3 NCT03864770 584 585 O
. NCT03864770 585 586 O
Uncommunicated NCT03864770 588 602 B-Condition
or NCT03864770 603 605 B-Or
cognitive NCT03864770 606 615 B-Condition
impaired NCT03864770 616 624 I-Condition

4 NCT03864770 627 628 O
. NCT03864770 628 629 O
Patients NCT03864770 631 639 O
refused NCT03864770 640 647 O
to NCT03864770 648 650 O
be NCT03864770 651 653 O
recruited NCT03864770 654 663 O

Inclusion NCT03868189 0 9 O
Criteria NCT03868189 10 18 O
: NCT03868189 19 20 O

- NCT03868189 24 25 O
Patient NCT03868189 27 34 O
requiring NCT03868189 35 44 B-Assertion___Assertion-Type-Value:hypothetical
an NCT03868189 45 47 O
electroneuromyogram NCT03868189 48 67 B-Procedure
whose NCT03868189 68 73 O
indication NCT03868189 74 84 B-Indication
allows NCT03868189 85 91 O
the NCT03868189 92 95 O
application NCT03868189 96 107 O
of NCT03868189 108 110 O
a NCT03868189 111 112 O
standard NCT03868189 113 121 B-Modifier
protocol NCT03868189 122 130 I-Modifier
of NCT03868189 131 133 O
examination NCT03868189 134 145 B-Procedure
. NCT03868189 146 147 O

- NCT03868189 151 152 O
Patient NCT03868189 154 161 O
that NCT03868189 162 166 O
has NCT03868189 167 170 O
given NCT03868189 171 176 O
his NCT03868189 177 180 O
/ NCT03868189 181 182 O
her NCT03868189 183 186 O
free NCT03868189 187 191 O
and NCT03868189 192 195 O
informed NCT03868189 196 204 O
consent NCT03868189 205 212 O
. NCT03868189 213 214 O

- NCT03868189 218 219 O
Patient NCT03868189 221 228 O
that NCT03868189 229 233 O
signed NCT03868189 234 240 O
the NCT03868189 241 244 O
consent NCT03868189 245 252 O
form NCT03868189 253 257 O
. NCT03868189 258 259 O

- NCT03868189 263 264 O
Patient NCT03868189 266 273 O
with NCT03868189 274 278 O
an NCT03868189 279 281 O
health NCT03868189 282 288 O
insurance NCT03868189 289 298 O
plan NCT03868189 299 303 O
. NCT03868189 304 305 O

- NCT03868189 309 310 O
The NCT03868189 312 315 O
patient NCT03868189 316 323 O
is NCT03868189 324 326 O
at NCT03868189 327 329 B-Eq-Comparison
least NCT03868189 330 335 I-Eq-Comparison
18 NCT03868189 336 338 I-Eq-Comparison
years NCT03868189 339 344 I-Eq-Comparison
old NCT03868189 345 348 B-Age
( NCT03868189 349 350 O
≥ NCT03868189 352 353 O
) NCT03868189 355 356 O
. NCT03868189 358 359 O

- NCT03868189 363 364 O
he NCT03868189 366 368 O
patient NCT03868189 369 376 O
is NCT03868189 377 379 O
under NCT03868189 380 385 B-Eq-Comparison
80 NCT03868189 386 388 I-Eq-Comparison
years NCT03868189 389 394 I-Eq-Comparison
old NCT03868189 395 398 B-Age
( NCT03868189 399 400 O
≤ NCT03868189 402 403 O
) NCT03868189 405 406 O
. NCT03868189 408 409 O

Exclusion NCT03868189 411 420 O
Criteria NCT03868189 421 429 O
: NCT03868189 430 431 O

- NCT03868189 435 436 O
Patient NCT03868189 438 445 O
with NCT03868189 446 450 O
symptoms NCT03868189 451 459 B-Assertion___Assertion-Type-Value:possible
of NCT03868189 460 462 O
neuropathy NCT03868189 463 473 B-Condition
during NCT03868189 474 480 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868189 481 484 O
screening NCT03868189 485 494 B-Study
. NCT03868189 495 496 O

- NCT03868189 500 501 O
Patient NCT03868189 503 510 O
whose NCT03868189 511 516 O
Neurological NCT03868189 517 529 B-Observation
severity NCT03868189 530 538 I-Observation
score NCT03868189 539 544 I-Observation
( NCT03868189 545 546 O
NSS NCT03868189 547 550 B-Observation
) NCT03868189 551 552 O
score NCT03868189 553 558 O
is NCT03868189 559 561 O
≥ NCT03868189 562 563 B-Eq-Comparison
3 NCT03868189 564 565 I-Eq-Comparison
. NCT03868189 565 566 O

- NCT03868189 570 571 O
Patient NCT03868189 573 580 O
whose NCT03868189 581 586 O
neurological NCT03868189 587 599 B-Procedure
examination NCT03868189 600 611 I-Procedure
is NCT03868189 612 614 O
abnormal NCT03868189 615 623 O
and NCT03868189 624 627 B-Or
suggestive NCT03868189 628 638 B-Assertion___Assertion-Type-Value:possible
of NCT03868189 639 641 O
neuropathy NCT03868189 642 652 B-Condition
. NCT03868189 653 654 O

- NCT03868189 658 659 O
Patient NCT03868189 661 668 O
presenting NCT03868189 669 679 O
a NCT03868189 680 681 O
pathology NCT03868189 682 691 B-Condition
that NCT03868189 692 696 O
could NCT03868189 697 702 B-Assertion___Assertion-Type-Value:hypothetical
cause NCT03868189 703 708 O
neuropathy NCT03868189 709 719 B-Condition
( NCT03868189 720 721 O
e. NCT03868189 722 724 O
g. NCT03868189 725 727 O
diabetes NCT03868189 729 737 B-Condition
, NCT03868189 738 739 O
renal NCT03868189 740 745 B-Condition
failure NCT03868189 746 753 I-Condition
, NCT03868189 754 755 O
etc NCT03868189 756 759 O
. NCT03868189 759 760 O
) NCT03868189 761 762 O
. NCT03868189 764 765 O

- NCT03868189 769 770 O
Patient NCT03868189 772 779 O
already NCT03868189 780 787 O
participating NCT03868189 788 801 O
in NCT03868189 802 804 O
a NCT03868189 805 806 O
category NCT03868189 807 815 O
1 NCT03868189 816 817 O
research NCT03868189 818 826 O
study NCT03868189 827 832 O
( NCT03868189 833 834 O
Jardé NCT03868189 835 840 O
law NCT03868189 841 844 O
) NCT03868189 845 846 O
. NCT03868189 848 849 O

- NCT03868189 853 854 O
Patient NCT03868189 856 863 O
in NCT03868189 864 866 O
an NCT03868189 867 869 O
exclusion NCT03868189 870 879 O
period NCT03868189 880 886 O
determined NCT03868189 887 897 O
by NCT03868189 898 900 O
another NCT03868189 901 908 B-Other
study NCT03868189 909 914 B-Study
. NCT03868189 915 916 O

- NCT03868189 920 921 O
Patient NCT03868189 923 930 O
under NCT03868189 931 936 O
the NCT03868189 937 940 O
protection NCT03868189 941 951 B-Observation
of NCT03868189 952 954 I-Observation
justice NCT03868189 955 962 I-Observation
, NCT03868189 963 964 O
under NCT03868189 965 970 B-Observation
guardianship NCT03868189 971 983 I-Observation
or NCT03868189 984 986 B-Or
under NCT03868189 987 992 O
curatorship NCT03868189 993 1004 B-Observation
. NCT03868189 1005 1006 O

- NCT03868189 1010 1011 O
Patient NCT03868189 1013 1020 O
refusing NCT03868189 1021 1029 O
to NCT03868189 1030 1032 O
sign NCT03868189 1033 1037 O
the NCT03868189 1038 1041 O
consent NCT03868189 1042 1049 O
form NCT03868189 1050 1054 O
. NCT03868189 1055 1056 O

- NCT03868189 1060 1061 O
Patient NCT03868189 1063 1070 O
for NCT03868189 1071 1074 O
which NCT03868189 1075 1080 O
it NCT03868189 1081 1083 O
is NCT03868189 1084 1086 O
impossible NCT03868189 1087 1097 O
to NCT03868189 1098 1100 O
provide NCT03868189 1101 1108 O
information NCT03868189 1109 1120 O
about NCT03868189 1121 1126 O
the NCT03868189 1127 1130 O
study NCT03868189 1131 1136 B-Study
. NCT03868189 1137 1138 O

- NCT03868189 1142 1143 O
Pregnant NCT03868189 1145 1153 B-Condition
patient NCT03868189 1154 1161 O
, NCT03868189 1162 1163 O
parturient NCT03868189 1164 1174 B-Condition
, NCT03868189 1175 1176 O
or NCT03868189 1177 1179 B-Or
breastfeeding NCT03868189 1180 1193 B-Condition
. NCT03868189 1193 1194 O

Inclusion NCT03867721 0 9 O
Criteria NCT03867721 10 18 O
: NCT03867721 19 20 O

- NCT03867721 24 25 O
All NCT03867721 27 30 O
individuals NCT03867721 31 42 O
affected NCT03867721 43 51 O
by NCT03867721 52 54 O
NMDs NCT03867721 55 59 B-Condition
attending NCT03867721 60 69 B-Encounter
our NCT03867721 70 73 O
Centre NCT03867721 74 80 O
for NCT03867721 81 84 O
Home NCT03867721 85 89 O
Mechanical NCT03867721 90 100 O
Ventilation NCT03867721 101 112 O
between NCT03867721 113 120 B-Eq-Comparison
January NCT03867721 121 128 I-Eq-Comparison
2015 NCT03867721 129 133 I-Eq-Comparison
and NCT03867721 134 137 I-Eq-Comparison
December NCT03867721 138 146 I-Eq-Comparison
2018 NCT03867721 147 151 I-Eq-Comparison
who NCT03867721 152 155 B-And
required NCT03867721 156 164 O
daytime NCT03867721 165 172 B-Modifier
MPV NCT03867721 173 176 B-Procedure
as NCT03867721 177 179 B-And
an NCT03867721 180 182 I-And
extension NCT03867721 183 192 I-And
of NCT03867721 193 195 I-And
nocturnal NCT03867721 196 205 B-Modifier
NIV NCT03867721 206 209 B-Procedure

Exclusion NCT03867721 210 219 O
Criteria NCT03867721 220 228 O
: NCT03867721 229 230 O

- NCT03867721 234 235 O
Patients NCT03867721 237 245 O
with NCT03867721 246 250 O
no NCT03867721 251 253 B-Negation
need NCT03867721 254 258 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867721 259 262 I-Assertion___Assertion-Type-Value:hypothetical
daytime NCT03867721 263 270 B-Modifier
ventilation NCT03867721 271 282 B-Procedure

- NCT03867721 285 286 O
patients NCT03867721 288 296 O
with NCT03867721 297 301 O
ineffective NCT03867721 302 313 B-Modifier
NIV NCT03867721 314 317 B-Procedure
during NCT03867721 318 324 B-Temporal-Connection___Temporal-Connection-Type-Value:during
sleep NCT03867721 325 330 B-Observation
as NCT03867721 331 333 O
assessed NCT03867721 334 342 O
by NCT03867721 343 345 O
the NCT03867721 346 349 O
measurement NCT03867721 350 361 O
of NCT03867721 362 364 O
TcCO2 NCT03867721 365 370 B-Observation
> NCT03867721 371 372 B-Eq-Comparison
49 NCT03867721 373 375 I-Eq-Comparison
mmHg NCT03867721 376 380 I-Eq-Comparison
( NCT03867721 381 382 O
S NCT03867721 383 384 O
) NCT03867721 385 386 O

- NCT03867721 390 391 O
patients NCT03867721 393 401 O
with NCT03867721 402 406 O
uncontrollable NCT03867721 407 421 B-Modifier
oral NCT03867721 422 426 B-Condition
leaks NCT03867721 427 432 I-Condition
with NCT03867721 433 437 O
MPV NCT03867721 438 441 B-Procedure
or NCT03867721 442 444 B-Or
episode NCT03867721 445 452 O
of NCT03867721 453 455 O
acute NCT03867721 456 461 O
respiratory NCT03867721 462 473 B-Condition
infection NCT03867721 474 483 I-Condition
during NCT03867721 484 490 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867721 491 494 O
trials NCT03867721 495 501 B-Study

Inclusion NCT03860714 0 9 O
Criteria NCT03860714 10 18 O
: NCT03860714 19 20 O

- NCT03860714 24 25 O
Non NCT03860714 27 30 B-Negation
- NCT03860714 31 32 O
cardiac NCT03860714 33 40 B-Modifier
surgery NCT03860714 41 48 B-Procedure
patients NCT03860714 49 57 O
; NCT03860714 57 58 O

- NCT03860714 66 67 O
Age NCT03860714 69 72 B-Age
is NCT03860714 73 75 O
greater NCT03860714 76 83 B-Eq-Comparison
than NCT03860714 84 88 I-Eq-Comparison
or NCT03860714 89 91 I-Eq-Comparison
equal NCT03860714 92 97 I-Eq-Comparison
to NCT03860714 98 100 I-Eq-Comparison
60 NCT03860714 101 103 I-Eq-Comparison
years NCT03860714 104 109 I-Eq-Comparison
old NCT03860714 110 113 O
; NCT03860714 113 114 O
③ NCT03860714 115 116 O
Han NCT03860714 117 120 O
Nationality NCT03860714 121 132 O
, NCT03860714 133 134 O
mother NCT03860714 135 141 O
tongue NCT03860714 142 148 O
is NCT03860714 149 151 O
chinese NCT03860714 152 159 O
; NCT03860714 159 160 O
④ NCT03860714 161 162 O
The NCT03860714 163 166 O
MMSE NCT03860714 167 171 B-Observation
score NCT03860714 172 177 O
: NCT03860714 178 179 O
Illiteracy NCT03860714 180 190 O
is NCT03860714 191 193 O
greater NCT03860714 194 201 B-Eq-Comparison
than NCT03860714 202 206 I-Eq-Comparison
or NCT03860714 207 209 I-Eq-Comparison
equal NCT03860714 210 215 I-Eq-Comparison
to NCT03860714 216 218 I-Eq-Comparison
17 NCT03860714 219 221 I-Eq-Comparison
points NCT03860714 222 228 I-Eq-Comparison
, NCT03860714 229 230 O
primary NCT03860714 231 238 B-Observation
school NCT03860714 239 245 I-Observation
is NCT03860714 246 248 O
greater NCT03860714 249 256 B-Eq-Comparison
than NCT03860714 257 261 I-Eq-Comparison
or NCT03860714 262 264 I-Eq-Comparison
equal NCT03860714 265 270 I-Eq-Comparison
to NCT03860714 271 273 I-Eq-Comparison
20 NCT03860714 274 276 I-Eq-Comparison
points NCT03860714 277 283 I-Eq-Comparison
, NCT03860714 284 285 O
higher NCT03860714 286 292 B-Observation
secondary NCT03860714 293 302 I-Observation
school NCT03860714 303 309 I-Observation
is NCT03860714 310 312 O
more NCT03860714 313 317 B-Eq-Comparison
than NCT03860714 318 322 I-Eq-Comparison
24 NCT03860714 323 325 I-Eq-Comparison
points NCT03860714 326 332 I-Eq-Comparison
; NCT03860714 332 333 O
⑤The NCT03860714 334 338 O
people NCT03860714 339 345 O
signed NCT03860714 346 352 O
informed NCT03860714 353 361 O
consent NCT03860714 362 369 O
. NCT03860714 370 371 O

Exclusion NCT03860714 373 382 O
Criteria NCT03860714 383 391 O
: NCT03860714 392 393 O

- NCT03860714 397 398 O
The NCT03860714 400 403 O
diagnosis NCT03860714 404 413 O
of NCT03860714 414 416 O
pre NCT03860714 417 420 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03860714 421 430 B-Procedure
delirium NCT03860714 431 439 B-Condition
； NCT03860714 439 440 O

- NCT03860714 448 449 O
The NCT03860714 451 454 O
diagnosis NCT03860714 455 464 O
Unstable NCT03860714 465 473 O
hypertension NCT03860714 474 486 B-Condition
（ NCT03860714 487 488 O
Such NCT03860714 489 493 O
as NCT03860714 494 496 O
： NCT03860714 497 498 O
pheochromocytoma NCT03860714 499 515 B-Condition
or NCT03860714 516 518 B-Or
aortic NCT03860714 519 525 B-Condition
dissection NCT03860714 526 536 I-Condition
） NCT03860714 536 537 O
； NCT03860714 537 538 O
③ NCT03860714 539 540 O
Severe NCT03860714 541 547 O
chronic NCT03860714 548 555 B-Modifier
obstructive NCT03860714 556 567 B-Condition
pulmonary NCT03860714 568 577 I-Condition
disease NCT03860714 578 585 I-Condition
or NCT03860714 586 588 B-Or
congestive NCT03860714 589 599 B-Condition
heart NCT03860714 600 605 I-Condition
failure NCT03860714 606 613 I-Condition
； NCT03860714 613 614 O
④ NCT03860714 615 616 O
Severe NCT03860714 617 623 O
liver NCT03860714 624 629 B-Modifier
and NCT03860714 630 633 B-Or
kidney NCT03860714 634 640 B-Modifier
dysfunction NCT03860714 641 652 B-Condition
; NCT03860714 652 653 O

Inclusion NCT03865693 0 9 O
Criteria NCT03865693 10 18 O
: NCT03865693 19 20 O

- NCT03865693 24 25 O
Burn NCT03865693 27 31 B-Condition
patients NCT03865693 32 40 O

- NCT03865693 43 44 O
severe NCT03865693 46 52 O
neuropatic NCT03865693 53 63 B-Modifier
pain NCT03865693 64 68 B-Condition
rated NCT03865693 69 74 O
at NCT03865693 75 77 B-Eq-Comparison
least NCT03865693 78 83 I-Eq-Comparison
5 NCT03865693 84 85 I-Eq-Comparison
on NCT03865693 86 88 O
the NCT03865693 89 92 O
10 NCT03865693 93 95 B-Observation
- NCT03865693 96 97 I-Observation
point NCT03865693 98 103 I-Observation
numerical NCT03865693 104 113 I-Observation
rating NCT03865693 114 120 I-Observation
scale NCT03865693 121 126 I-Observation
( NCT03865693 127 128 O
NRS NCT03865693 129 132 B-Observation
) NCT03865693 133 134 O

Exclusion NCT03865693 136 145 O
Criteria NCT03865693 146 154 O
: NCT03865693 155 156 O

- NCT03865693 160 161 O
cardiac NCT03865693 163 170 B-Condition
arrest NCT03865693 171 177 I-Condition
history NCT03865693 178 185 B-Eq-Comparison

- NCT03865693 188 189 O
history NCT03865693 191 198 B-Eq-Comparison
of NCT03865693 199 201 O
neurologi NCT03865693 202 211 B-Condition
disease NCT03865693 212 219 I-Condition
or NCT03865693 220 222 B-Or
brain NCT03865693 223 228 B-Modifier
surgery NCT03865693 229 236 B-Procedure

- NCT03865693 239 240 O
unstable NCT03865693 242 250 O
heart NCT03865693 251 256 B-Condition
disease NCT03865693 257 264 I-Condition
or NCT03865693 265 267 B-Or
presence NCT03865693 268 276 O
of NCT03865693 277 279 O
a NCT03865693 280 281 O
cardiac NCT03865693 282 289 B-Procedure
pacemaker NCT03865693 290 299 I-Procedure

- NCT03865693 302 303 O
pain NCT03865693 305 309 B-Condition
resulting NCT03865693 310 319 O
from NCT03865693 320 324 O
other NCT03865693 325 330 B-Other
causes NCT03865693 331 337 B-Condition
like NCT03865693 338 342 O
as NCT03865693 343 345 O
neuromuscular NCT03865693 346 359 B-Condition
diseases NCT03865693 360 368 I-Condition

- NCT03865693 371 372 O
psychiatric NCT03865693 374 385 B-Condition
disorder NCT03865693 386 394 I-Condition

- NCT03865693 397 398 O
diabetes NCT03865693 400 408 B-Condition
mellitus NCT03865693 409 417 I-Condition

- NCT03865693 420 421 O
abnormal NCT03865693 423 431 O
renal NCT03865693 432 437 B-Condition
function NCT03865693 438 446 I-Condition

- NCT03865693 449 450 O
contraindication NCT03865693 452 468 B-Contraindication
for NCT03865693 469 472 O
MRI NCT03865693 473 476 B-Procedure
, NCT03865693 477 478 O
or NCT03865693 479 481 B-Or
pregnancy NCT03865693 482 491 B-Condition
. NCT03865693 491 492 O

Inclusion NCT03868956 0 9 O
Criteria NCT03868956 10 18 O
: NCT03868956 19 20 O

- NCT03868956 24 25 O
Age NCT03868956 27 30 B-Age
> NCT03868956 31 32 B-Eq-Comparison
= NCT03868956 34 35 I-Eq-Comparison
18 NCT03868956 36 38 I-Eq-Comparison
years NCT03868956 39 44 I-Eq-Comparison

- NCT03868956 47 48 O
Known NCT03868956 50 55 O
history NCT03868956 56 63 B-Eq-Comparison
of NCT03868956 64 66 O
objectively NCT03868956 67 78 O
documented NCT03868956 79 89 O
deep NCT03868956 90 94 B-Condition
vein NCT03868956 95 99 I-Condition
thrombosis NCT03868956 100 110 I-Condition
of NCT03868956 111 113 O
the NCT03868956 114 117 O
lower NCT03868956 118 123 B-Modifier
limb NCT03868956 124 128 I-Modifier
( NCT03868956 129 130 O
with NCT03868956 131 135 B-And
or NCT03868956 136 138 B-Or
without NCT03868956 139 146 B-Negation
pulmonary NCT03868956 147 156 B-Condition
embolism NCT03868956 157 165 I-Condition
) NCT03868956 166 167 O

- NCT03868956 171 172 O
Out NCT03868956 174 177 B-Encounter
- NCT03868956 178 179 I-Encounter
patients NCT03868956 180 188 I-Encounter
referred NCT03868956 189 197 O
for NCT03868956 198 201 O
clinically NCT03868956 202 212 O
suspected NCT03868956 213 222 B-Assertion___Assertion-Type-Value:possible
acute NCT03868956 223 228 O
recurrent NCT03868956 229 238 B-Modifier
ipsilateral NCT03868956 239 250 I-Modifier
DVT NCT03868956 251 254 B-Condition
of NCT03868956 255 257 O
the NCT03868956 258 261 O
lower NCT03868956 262 267 B-Modifier
limb NCT03868956 268 272 I-Modifier
i. NCT03868956 273 275 O
e. NCT03868956 276 278 O
the NCT03868956 280 283 O
occurrence NCT03868956 284 294 O
of NCT03868956 295 297 O
new NCT03868956 298 301 B-Eq-Comparison
symptoms NCT03868956 302 310 B-Assertion___Assertion-Type-Value:possible
and NCT03868956 311 314 B-And
signs NCT03868956 315 320 B-Assertion___Assertion-Type-Value:possible
of NCT03868956 321 323 O
DVT NCT03868956 324 327 B-Condition
or NCT03868956 328 330 B-Or
the NCT03868956 331 334 O
increase NCT03868956 335 343 O
of NCT03868956 344 346 O
symptoms NCT03868956 347 355 B-Assertion___Assertion-Type-Value:possible
and NCT03868956 356 359 B-And
signs NCT03868956 360 365 B-Assertion___Assertion-Type-Value:possible
in NCT03868956 366 368 O
patients NCT03868956 369 377 O
with NCT03868956 378 382 O
post NCT03868956 383 387 B-Condition
- NCT03868956 388 389 I-Condition
thrombotic NCT03868956 390 400 I-Condition
syndrome NCT03868956 401 409 I-Condition

- NCT03868956 412 413 O
Patients NCT03868956 415 423 O
covered NCT03868956 424 431 O
by NCT03868956 432 434 O
social NCT03868956 435 441 O
security NCT03868956 442 450 O
or NCT03868956 451 453 O
equivalent NCT03868956 454 464 O
regimen NCT03868956 465 472 O

- NCT03868956 475 476 O
Signed NCT03868956 478 484 O
and NCT03868956 485 488 O
dated NCT03868956 489 494 O
informed NCT03868956 495 503 O
consent NCT03868956 504 511 O

Exclusion NCT03868956 512 521 O
Criteria NCT03868956 522 530 O
: NCT03868956 531 532 O

- NCT03868956 536 537 O
Known NCT03868956 539 544 O
current NCT03868956 545 552 B-Eq-Comparison
pregnancy NCT03868956 553 562 B-Condition

- NCT03868956 565 566 O
Any NCT03868956 568 571 O
condition NCT03868956 572 581 B-Condition
, NCT03868956 582 583 O
which NCT03868956 584 589 O
, NCT03868956 590 591 O
in NCT03868956 592 594 O
the NCT03868956 595 598 O
opinion NCT03868956 599 606 O
of NCT03868956 607 609 O
the NCT03868956 610 613 O
investigator NCT03868956 614 626 O
may NCT03868956 627 630 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03868956 631 638 B-Negation
him NCT03868956 639 642 O
from NCT03868956 643 647 O
performing NCT03868956 648 658 O
the NCT03868956 659 662 O
colour NCT03868956 663 669 B-Procedure
doppler NCT03868956 670 677 I-Procedure
ultrasound NCT03868956 678 688 I-Procedure
test NCT03868956 689 693 I-Procedure
( NCT03868956 694 695 O
plaster NCT03868956 696 703 B-Condition
cast NCT03868956 704 708 I-Condition
, NCT03868956 709 710 O
inaccessible NCT03868956 711 723 B-Modifier
vein NCT03868956 724 728 B-Condition
segment NCT03868956 729 736 I-Condition
after NCT03868956 737 742 B-Temporal-Connection___Temporal-Connection-Type-Value:after
abdominal NCT03868956 743 752 B-Modifier
or NCT03868956 753 755 B-Or
pelvic NCT03868956 756 762 B-Modifier
surgery NCT03868956 763 770 B-Procedure
, NCT03868956 771 772 O
or NCT03868956 773 775 B-Or
other NCT03868956 776 781 B-Other
causes NCT03868956 782 788 B-Condition
that NCT03868956 789 793 O
may NCT03868956 794 797 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03868956 798 802 O
to NCT03868956 803 805 O
a NCT03868956 806 807 O
technically NCT03868956 808 819 O
inadequate NCT03868956 820 830 O
CDUS NCT03868956 831 835 O
) NCT03868956 836 837 O

- NCT03868956 841 842 O
Delay NCT03868956 844 849 O
from NCT03868956 850 854 O
onset NCT03868956 855 860 B-Eq-Comparison
of NCT03868956 861 863 O
symptoms NCT03868956 864 872 B-Coreference
to NCT03868956 873 875 B-Temporal-Connection___Temporal-Connection-Type-Value:after
inclusion NCT03868956 876 885 B-Study
of NCT03868956 886 888 O
more NCT03868956 889 893 B-Eq-Comparison
than NCT03868956 894 898 I-Eq-Comparison
10 NCT03868956 899 901 I-Eq-Comparison
days NCT03868956 902 906 I-Eq-Comparison

- NCT03868956 909 910 O
Therapeutic NCT03868956 912 923 B-Procedure
anticoagulation NCT03868956 924 939 I-Procedure
for NCT03868956 940 943 O
more NCT03868956 944 948 B-Eq-Comparison
than NCT03868956 949 953 I-Eq-Comparison
48 NCT03868956 954 956 I-Eq-Comparison
hours NCT03868956 957 962 I-Eq-Comparison
in NCT03868956 963 965 O
the NCT03868956 966 969 O
two NCT03868956 970 973 B-Eq-Comparison
days NCT03868956 974 978 I-Eq-Comparison
prior NCT03868956 979 984 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868956 985 987 I-Temporal-Connection___Temporal-Connection-Type-Value:before
consent NCT03868956 988 995 O

- NCT03868956 998 999 O
Prophylactic NCT03868956 1001 1013 B-Procedure
anticoagulation NCT03868956 1014 1029 I-Procedure
for NCT03868956 1030 1033 O
more NCT03868956 1034 1038 B-Eq-Comparison
than NCT03868956 1039 1043 I-Eq-Comparison
48 NCT03868956 1044 1046 I-Eq-Comparison
hours NCT03868956 1047 1052 I-Eq-Comparison
in NCT03868956 1053 1055 O
the NCT03868956 1056 1059 O
two NCT03868956 1060 1063 B-Eq-Comparison
days NCT03868956 1064 1068 I-Eq-Comparison
prior NCT03868956 1069 1074 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868956 1075 1077 I-Temporal-Connection___Temporal-Connection-Type-Value:before
consent NCT03868956 1078 1085 O

- NCT03868956 1088 1089 O
Clinical NCT03868956 1091 1099 O
symptoms NCT03868956 1100 1108 B-Assertion___Assertion-Type-Value:possible
of NCT03868956 1109 1111 O
pulmonary NCT03868956 1112 1121 B-Condition
embolism NCT03868956 1122 1130 I-Condition

- NCT03868956 1133 1134 O
Life NCT03868956 1136 1140 B-Observation
expectancy NCT03868956 1141 1151 I-Observation
less NCT03868956 1152 1156 B-Eq-Comparison
than NCT03868956 1157 1161 I-Eq-Comparison
3 NCT03868956 1162 1163 I-Eq-Comparison
months NCT03868956 1164 1170 I-Eq-Comparison

- NCT03868956 1173 1174 O
Patient NCT03868956 1176 1183 O
unable NCT03868956 1184 1190 O
to NCT03868956 1191 1193 O
adhere NCT03868956 1194 1200 O
to NCT03868956 1201 1203 O
protocol NCT03868956 1204 1212 O
or NCT03868956 1213 1215 O
follow NCT03868956 1216 1222 O
- NCT03868956 1223 1224 O
up NCT03868956 1225 1227 O
visits NCT03868956 1228 1234 O
and NCT03868956 1235 1238 O
contacts NCT03868956 1239 1247 O

- NCT03868956 1250 1251 O
Participants NCT03868956 1253 1265 O
under NCT03868956 1266 1271 O
legal NCT03868956 1272 1277 B-Observation
guardianship NCT03868956 1278 1290 I-Observation
or NCT03868956 1291 1293 B-Or
incapacitation NCT03868956 1294 1308 B-Condition

- NCT03868956 1311 1312 O
Patient NCT03868956 1314 1321 O
already NCT03868956 1322 1329 B-Eq-Comparison
enrolled NCT03868956 1330 1338 O
in NCT03868956 1339 1341 O
a NCT03868956 1342 1343 O
deep NCT03868956 1344 1348 B-Condition
vein NCT03868956 1349 1353 I-Condition
thrombosis NCT03868956 1354 1364 I-Condition
( NCT03868956 1365 1366 O
DVT NCT03868956 1367 1370 B-Condition
) NCT03868956 1371 1372 O
diagnostic NCT03868956 1373 1383 O
research NCT03868956 1384 1392 B-Study

Inclusion NCT03864822 0 9 O
Criteria NCT03864822 10 18 O
: NCT03864822 19 20 O

- NCT03864822 24 25 O
Otherwise NCT03864822 27 36 O
healthy NCT03864822 37 44 B-Condition
men NCT03864822 45 48 O
and NCT03864822 49 52 B-Or
women NCT03864822 53 58 O

- NCT03864822 61 62 O
Aged NCT03864822 64 68 B-Age
18 NCT03864822 69 71 B-Eq-Comparison
- NCT03864822 72 73 I-Eq-Comparison
60 NCT03864822 74 76 I-Eq-Comparison
years NCT03864822 77 82 I-Eq-Comparison

- NCT03864822 85 86 O
Continuous NCT03864822 88 98 B-Eq-Comparison
pain NCT03864822 99 103 B-Condition
( NCT03864822 104 105 O
> NCT03864822 107 108 B-Eq-Comparison
3 NCT03864822 109 110 I-Eq-Comparison
days NCT03864822 111 115 I-Eq-Comparison
pain NCT03864822 116 120 I-Eq-Comparison
/ NCT03864822 121 122 I-Eq-Comparison
week NCT03864822 123 127 I-Eq-Comparison
) NCT03864822 128 129 O
episode NCT03864822 130 137 O
lasting NCT03864822 138 145 O
at NCT03864822 146 148 B-Eq-Comparison
least NCT03864822 149 154 I-Eq-Comparison
3 NCT03864822 155 156 I-Eq-Comparison
months NCT03864822 157 163 I-Eq-Comparison
, NCT03864822 164 165 O
sufficient NCT03864822 166 176 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864822 177 179 I-Assertion___Assertion-Type-Value:hypothetical
limit NCT03864822 180 185 O
daily NCT03864822 186 191 B-Eq-Comparison
activities NCT03864822 192 202 B-Observation

- NCT03864822 205 206 O
Pain NCT03864822 208 212 B-Condition
in NCT03864822 213 215 O
the NCT03864822 216 219 O
region NCT03864822 220 226 B-Modifier
posteriorly NCT03864822 227 238 I-Modifier
between NCT03864822 239 246 I-Modifier
the NCT03864822 247 250 I-Modifier
inferior NCT03864822 251 259 I-Modifier
border NCT03864822 260 266 I-Modifier
of NCT03864822 267 269 I-Modifier
the NCT03864822 270 273 I-Modifier
12 NCT03864822 274 276 I-Modifier
th NCT03864822 277 279 I-Modifier
rib NCT03864822 280 283 I-Modifier
and NCT03864822 284 287 B-And
the NCT03864822 288 291 O
lower NCT03864822 292 297 B-Modifier
gluteal NCT03864822 298 305 I-Modifier
fold NCT03864822 306 310 I-Modifier
( NCT03864822 311 312 O
low NCT03864822 313 316 B-Modifier
back NCT03864822 317 321 I-Modifier
pain NCT03864822 322 326 B-Condition
) NCT03864822 327 328 O
at NCT03864822 329 331 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864822 332 335 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864822 336 340 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864822 341 343 O
recruitment NCT03864822 344 355 B-Study

- NCT03864822 358 359 O
Able NCT03864822 361 365 O
to NCT03864822 366 368 O
speak NCT03864822 369 374 O
, NCT03864822 375 376 O
read NCT03864822 377 381 O
and NCT03864822 382 385 O
understand NCT03864822 386 396 O
English NCT03864822 397 404 O

Exclusion NCT03864822 405 414 O
Criteria NCT03864822 415 423 O
: NCT03864822 424 425 O

- NCT03864822 429 430 O
Pregnancy NCT03864822 432 441 B-Condition

- NCT03864822 444 445 O
Low NCT03864822 447 450 B-Modifier
back NCT03864822 451 455 I-Modifier
pain NCT03864822 456 460 B-Condition
associated NCT03864822 461 471 O
with NCT03864822 472 476 O
menstruation NCT03864822 477 489 B-Condition

- NCT03864822 492 493 O
Currently NCT03864822 495 504 B-Eq-Comparison
seeking NCT03864822 505 512 B-Assertion___Assertion-Type-Value:intention
active NCT03864822 513 519 B-Eq-Comparison
treatment NCT03864822 520 529 B-Procedure
for NCT03864822 530 533 O
low NCT03864822 534 537 B-Modifier
back NCT03864822 538 542 I-Modifier
pain NCT03864822 543 547 B-Condition

- NCT03864822 550 551 O
Red NCT03864822 553 556 B-Condition
flags NCT03864822 557 562 I-Condition
symptoms NCT03864822 563 571 B-Assertion___Assertion-Type-Value:possible
( NCT03864822 572 573 O
i. NCT03864822 574 576 O
e. NCT03864822 577 579 O
fever NCT03864822 581 586 B-Condition
, NCT03864822 587 588 O
malaise NCT03864822 589 596 B-Condition
, NCT03864822 597 598 O
progressive NCT03864822 599 610 B-Modifier
neurologic NCT03864822 611 621 B-Condition
deficit NCT03864822 622 629 I-Condition
, NCT03864822 630 631 O
significant NCT03864822 632 643 O
trauma NCT03864822 644 650 B-Condition
, NCT03864822 651 652 O
prolonged NCT03864822 653 662 B-Modifier
corticosteroid NCT03864822 663 677 B-Drug
use NCT03864822 678 681 O
or NCT03864822 682 684 B-Or
osteoporosis NCT03864822 685 697 B-Condition
, NCT03864822 698 699 O
pain NCT03864822 700 704 B-Condition
worst NCT03864822 705 710 O
at NCT03864822 711 713 O
night NCT03864822 714 719 B-Modifier
, NCT03864822 720 721 O
urinary NCT03864822 722 729 B-Modifier
or NCT03864822 730 732 B-Or
faecal NCT03864822 733 739 B-Modifier
incontinence NCT03864822 740 752 B-Condition
, NCT03864822 753 754 O
or NCT03864822 755 757 B-Or
unintended NCT03864822 758 768 B-Modifier
weight NCT03864822 769 775 B-Condition
loss NCT03864822 776 780 I-Condition
) NCT03864822 781 782 O

- NCT03864822 786 787 O
Drug NCT03864822 789 793 B-Condition
addiction NCT03864822 794 803 I-Condition
defined NCT03864822 804 811 O
as NCT03864822 812 814 O
the NCT03864822 815 818 O
use NCT03864822 819 822 O
of NCT03864822 823 825 O
cannabis NCT03864822 826 834 B-Drug
, NCT03864822 835 836 O
opioids NCT03864822 837 844 B-Drug
or NCT03864822 845 847 B-Or
other NCT03864822 848 853 B-Other
drugs NCT03864822 854 859 B-Drug

- NCT03864822 862 863 O
Current NCT03864822 865 872 B-Eq-Comparison
or NCT03864822 873 875 B-Or
previous NCT03864822 876 884 B-Eq-Comparison
neurologic NCT03864822 885 895 B-Modifier
, NCT03864822 896 897 O
musculoskeletal NCT03864822 898 913 B-Modifier
, NCT03864822 914 915 O
mental NCT03864822 916 922 B-Modifier
, NCT03864822 923 924 O
or NCT03864822 925 927 B-Or
other NCT03864822 928 933 B-Other
illnesses NCT03864822 934 943 B-Condition
which NCT03864822 944 949 O
may NCT03864822 950 953 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864822 954 960 O
the NCT03864822 961 964 O
trial NCT03864822 965 970 B-Study

- NCT03864822 973 974 O
Current NCT03864822 976 983 B-Eq-Comparison
or NCT03864822 984 986 B-Or
previous NCT03864822 987 995 B-Eq-Comparison
chronic NCT03864822 996 1003 B-Modifier
or NCT03864822 1004 1006 B-Or
recurrent NCT03864822 1007 1016 B-Modifier
pain NCT03864822 1017 1021 B-Condition
condition NCT03864822 1022 1031 I-Condition
other NCT03864822 1032 1037 B-Exception
than NCT03864822 1038 1042 I-Exception
low NCT03864822 1043 1046 B-Modifier
back NCT03864822 1047 1051 I-Modifier
pain NCT03864822 1052 1056 B-Condition

- NCT03864822 1059 1060 O
Current NCT03864822 1062 1069 B-Eq-Comparison
regular NCT03864822 1070 1077 O
use NCT03864822 1078 1081 O
of NCT03864822 1082 1084 O
analgesic NCT03864822 1085 1094 B-Drug
medication NCT03864822 1095 1105 I-Drug
or NCT03864822 1106 1108 B-Or
other NCT03864822 1109 1114 B-Other
medication NCT03864822 1115 1125 B-Drug
which NCT03864822 1126 1131 O
may NCT03864822 1132 1135 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864822 1136 1142 O
the NCT03864822 1143 1146 O
trial NCT03864822 1147 1152 B-Study

- NCT03864822 1155 1156 O
Lack NCT03864822 1158 1162 O
of NCT03864822 1163 1165 O
ability NCT03864822 1166 1173 O
to NCT03864822 1174 1176 O
cooperate NCT03864822 1177 1186 O

Inclusion NCT03862274 0 9 O
Criteria NCT03862274 10 18 O
: NCT03862274 19 20 O

- NCT03862274 24 25 O
Patients NCT03862274 27 35 O
that NCT03862274 36 40 O
have NCT03862274 41 45 O
a NCT03862274 46 47 O
TPP1 NCT03862274 48 52 B-Modifier
enzyme NCT03862274 53 59 B-Condition
deficiency NCT03862274 60 70 I-Condition

- NCT03862274 73 74 O
Patients NCT03862274 76 84 O
have NCT03862274 85 89 O
confirmed NCT03862274 90 99 O
molecular NCT03862274 100 109 B-Procedure
diagnosis NCT03862274 110 119 O
of NCT03862274 120 122 O
pathogenic NCT03862274 123 133 B-Condition
variants NCT03862274 134 142 I-Condition
in NCT03862274 143 145 O
the NCT03862274 146 149 O
TPP1 NCT03862274 150 154 B-Modifier
gene NCT03862274 155 159 I-Modifier

- NCT03862274 162 163 O
Patients NCT03862274 165 173 O
that NCT03862274 174 178 O
are NCT03862274 179 182 O
enrolled NCT03862274 183 191 O
in NCT03862274 192 194 O
post NCT03862274 195 199 O
- NCT03862274 200 201 O
marketing NCT03862274 202 211 O
studies NCT03862274 212 219 O
will NCT03862274 220 224 O
be NCT03862274 225 227 O
allowed NCT03862274 228 235 O
to NCT03862274 236 238 O
enroll NCT03862274 239 245 O
into NCT03862274 246 250 O
the NCT03862274 251 254 O
current NCT03862274 255 262 O
study NCT03862274 263 268 O

Exclusion NCT03862274 269 278 O
Criteria NCT03862274 279 287 O
: NCT03862274 288 289 O

- NCT03862274 293 294 O
Patients NCT03862274 296 304 O
without NCT03862274 305 312 B-Negation
a NCT03862274 313 314 O
diagnosis NCT03862274 315 324 O
of NCT03862274 325 327 O
CLN2 NCT03862274 328 332 B-Condition
and NCT03862274 333 336 B-Or
deficiency NCT03862274 337 347 B-Condition
of NCT03862274 348 350 O
TPP1 NCT03862274 351 355 B-Modifier

- NCT03862274 358 359 O
Patients NCT03862274 361 369 O
that NCT03862274 370 374 O
are NCT03862274 375 378 O
currently NCT03862274 379 388 B-Eq-Comparison
enrolled NCT03862274 389 397 O
as NCT03862274 398 400 O
part NCT03862274 401 405 O
of NCT03862274 406 408 O
a NCT03862274 409 410 O
larger NCT03862274 411 417 O
multi NCT03862274 418 423 O
- NCT03862274 424 425 O
center NCT03862274 426 432 O
clinical NCT03862274 433 441 O
trial NCT03862274 442 447 B-Study

Inclusion NCT03860311 0 9 O
Criteria NCT03860311 10 18 O
: NCT03860311 19 20 O

- NCT03860311 24 25 O
Age NCT03860311 27 30 B-Age
8 NCT03860311 31 32 B-Eq-Comparison
yr NCT03860311 33 35 I-Eq-Comparison
- NCT03860311 36 37 I-Eq-Comparison
18 NCT03860311 38 40 I-Eq-Comparison
yrs NCT03860311 41 44 I-Eq-Comparison

- NCT03860311 47 48 O
Female NCT03860311 50 56 O

- NCT03860311 59 60 O
Likely NCT03860311 62 68 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860311 69 71 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03860311 72 76 O
order NCT03860311 77 82 O
placed NCT03860311 83 89 O
for NCT03860311 90 93 O
transabdominal NCT03860311 94 108 B-Procedure
pelvic NCT03860311 109 115 I-Procedure
ultrasound NCT03860311 116 126 I-Procedure
/ NCT03860311 127 128 B-Or
ovarian NCT03860311 129 136 B-Modifier
ultrasound NCT03860311 137 147 B-Procedure

- NCT03860311 150 151 O
No NCT03860311 153 155 B-Negation
history NCT03860311 156 163 B-Eq-Comparison
of NCT03860311 164 166 O
pelvic NCT03860311 167 173 B-Modifier
or NCT03860311 174 176 B-Or
bladder NCT03860311 177 184 B-Modifier
reconstructive NCT03860311 185 199 B-Procedure
surgery NCT03860311 200 207 I-Procedure

Exclusion NCT03860311 208 217 O
Criteria NCT03860311 218 226 O
: NCT03860311 227 228 O

- NCT03860311 232 233 O
Pregnancy NCT03860311 235 244 B-Condition
( NCT03860311 245 246 O
known NCT03860311 247 252 O
) NCT03860311 253 254 O

- NCT03860311 258 259 O
Critically NCT03860311 261 271 O
ill NCT03860311 272 275 B-Condition
patients NCT03860311 276 284 O

- NCT03860311 287 288 O
Patients NCT03860311 290 298 O
with NCT03860311 299 303 O
known NCT03860311 304 309 O
renal NCT03860311 310 315 B-Modifier
or NCT03860311 316 318 B-Or
genitourinary NCT03860311 319 332 B-Modifier
structural NCT03860311 333 343 I-Modifier
abnormalities NCT03860311 344 357 B-Condition
or NCT03860311 358 360 B-Or
prior NCT03860311 361 366 B-Eq-Comparison
pelvic NCT03860311 367 373 B-Modifier
/ NCT03860311 374 375 B-Or
genitourinary NCT03860311 376 389 B-Modifier
surgery NCT03860311 390 397 B-Procedure

- NCT03860311 400 401 O
Chronic NCT03860311 403 410 B-Modifier
renal NCT03860311 411 416 B-Condition
disease NCT03860311 417 424 I-Condition

- NCT03860311 427 428 O
Patients NCT03860311 430 438 O
presenting NCT03860311 439 449 O
outside NCT03860311 450 457 B-Negation
the NCT03860311 458 461 O
defined NCT03860311 462 469 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03860311 470 479 B-Procedure
windows NCT03860311 480 487 O

Inclusion NCT03868995 0 9 O
Criteria NCT03868995 10 18 O
: NCT03868995 19 20 O

1 NCT03868995 24 25 O
. NCT03868995 25 26 O
20 NCT03868995 28 30 B-Eq-Comparison
- NCT03868995 31 32 I-Eq-Comparison
70 NCT03868995 33 35 O
age NCT03868995 36 39 B-Age

2 NCT03868995 42 43 O
. NCT03868995 43 44 O
Chronic NCT03868995 46 53 B-Modifier
ankle NCT03868995 54 59 I-Modifier
sprain NCT03868995 60 66 B-Condition
more NCT03868995 67 71 B-Eq-Comparison
than NCT03868995 72 76 I-Eq-Comparison
3 NCT03868995 77 78 I-Eq-Comparison
months NCT03868995 79 85 I-Eq-Comparison
with NCT03868995 86 90 B-And
chronic NCT03868995 91 98 B-Modifier
ankle NCT03868995 99 104 I-Modifier
pain NCT03868995 105 109 B-Condition
or NCT03868995 110 112 B-Or
instability NCT03868995 113 124 B-Modifier
sensation NCT03868995 125 134 B-Condition

3 NCT03868995 137 138 O
. NCT03868995 138 139 O
Ultrasound NCT03868995 141 151 B-Procedure
diagnosed NCT03868995 152 161 O
anterior NCT03868995 162 170 B-Modifier
talofibular NCT03868995 171 182 I-Modifier
ligament NCT03868995 183 191 B-Condition
sprain NCT03868995 192 198 I-Condition

Exclusion NCT03868995 199 208 O
Criteria NCT03868995 209 217 O
: NCT03868995 218 219 O

1 NCT03868995 223 224 O
. NCT03868995 224 225 O
Acute NCT03868995 227 232 O
ankle NCT03868995 233 238 B-Modifier
sprain NCT03868995 239 245 B-Condition
less NCT03868995 246 250 B-Eq-Comparison
than NCT03868995 251 255 I-Eq-Comparison
3 NCT03868995 256 257 I-Eq-Comparison
months NCT03868995 258 264 I-Eq-Comparison

2 NCT03868995 267 268 O
. NCT03868995 268 269 O
Lower NCT03868995 271 276 B-Modifier
limb NCT03868995 277 281 I-Modifier
fracture NCT03868995 282 290 B-Condition
history NCT03868995 291 298 B-Eq-Comparison

3 NCT03868995 301 302 O
. NCT03868995 302 303 O
Cognitive NCT03868995 305 314 B-Condition
impairment NCT03868995 315 325 I-Condition

4 NCT03868995 328 329 O
. NCT03868995 329 330 O
Other NCT03868995 332 337 B-Other
neurological NCT03868995 338 350 B-Modifier
or NCT03868995 351 353 B-Or
muscular NCT03868995 354 362 B-Modifier
disorders NCT03868995 363 372 B-Condition

5 NCT03868995 375 376 O
. NCT03868995 376 377 O
Sever NCT03868995 379 384 O
pain NCT03868995 385 389 B-Condition
could NCT03868995 390 395 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03868995 396 399 B-Negation
tolerate NCT03868995 400 408 B-Assertion___Assertion-Type-Value:hypothetical
examination NCT03868995 409 420 B-Procedure

Inclusion NCT03861741 0 9 O
Criteria NCT03861741 10 18 O
: NCT03861741 19 20 O

1 NCT03861741 24 25 O
. NCT03861741 25 26 O
NS NCT03861741 28 30 B-Condition
- NCT03861741 31 32 I-Condition
TAD NCT03861741 33 36 I-Condition
probands NCT03861741 37 45 O
operated NCT03861741 46 54 B-Procedure
on NCT03861741 55 57 O
( NCT03861741 58 59 O
n NCT03861741 60 61 O
= NCT03861741 62 63 O
16 NCT03861741 64 66 O
) NCT03861741 67 68 O
. NCT03861741 70 71 O

2 NCT03861741 75 76 O
. NCT03861741 76 77 O
FDR NCT03861741 79 82 B-Condition
and NCT03861741 83 86 B-Or
SDR NCT03861741 87 90 B-Condition
, NCT03861741 91 92 O
aged NCT03861741 93 97 B-Age
16 NCT03861741 98 100 B-Eq-Comparison
and NCT03861741 101 104 I-Eq-Comparison
above NCT03861741 105 110 I-Eq-Comparison
: NCT03861741 111 112 O

1 NCT03861741 121 122 O
. NCT03861741 122 123 O
At NCT03861741 125 127 B-Eq-Comparison
least NCT03861741 128 133 I-Eq-Comparison
two NCT03861741 134 137 I-Eq-Comparison
relatives NCT03861741 138 147 B-Family-Member
willing NCT03861741 148 155 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861741 156 158 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861741 159 170 O
in NCT03861741 171 173 O
the NCT03861741 174 177 O
screening NCT03861741 178 187 B-Study
programme NCT03861741 188 197 O
. NCT03861741 198 199 O

2 NCT03861741 208 209 O
. NCT03861741 209 210 O
Relatives NCT03861741 212 221 O
able NCT03861741 222 226 O
to NCT03861741 227 229 O
understand NCT03861741 230 240 O
English NCT03861741 241 248 O
. NCT03861741 249 250 O

Exclusion NCT03861741 252 261 O
Criteria NCT03861741 262 270 O
: NCT03861741 271 272 O

1 NCT03861741 276 277 O
. NCT03861741 277 278 O
Probands NCT03861741 280 288 O
with NCT03861741 289 293 O
syndromic NCT03861741 294 303 B-Condition
aortopathies NCT03861741 304 316 I-Condition
, NCT03861741 317 318 O
including NCT03861741 319 328 O
Marfan NCT03861741 329 335 B-Condition
Syndrome NCT03861741 336 344 I-Condition
, NCT03861741 345 346 O
Loeys NCT03861741 347 352 B-Condition
- NCT03861741 353 354 I-Condition
Dietz NCT03861741 355 360 I-Condition
Syndrome NCT03861741 361 369 I-Condition
, NCT03861741 370 371 O
Ehlers NCT03861741 372 378 B-Condition
- NCT03861741 379 380 I-Condition
Danlos NCT03861741 381 387 I-Condition
Syndrome NCT03861741 388 396 I-Condition
, NCT03861741 397 398 O
Shprintzen NCT03861741 399 409 B-Condition
- NCT03861741 410 411 I-Condition
Goldberg NCT03861741 412 420 I-Condition
syndrome NCT03861741 421 429 I-Condition
, NCT03861741 430 431 O
aneurysm NCT03861741 432 440 B-Condition
- NCT03861741 441 442 I-Condition
osteoarthritis NCT03861741 443 457 I-Condition
syndrome NCT03861741 458 466 I-Condition
, NCT03861741 467 468 O
arterial NCT03861741 469 477 B-Condition
tortuosity NCT03861741 478 488 I-Condition
syndrome NCT03861741 489 497 I-Condition
, NCT03861741 498 499 O
and NCT03861741 500 503 B-Or
cutis NCT03861741 504 509 B-Condition
laxa NCT03861741 510 514 I-Condition
syndrome NCT03861741 515 523 I-Condition
. NCT03861741 524 525 O

2 NCT03861741 529 530 O
. NCT03861741 530 531 O
Probands NCT03861741 533 541 O
with NCT03861741 542 546 O
aortic NCT03861741 547 553 B-Condition
lesions NCT03861741 554 561 I-Condition
associated NCT03861741 562 572 O
with NCT03861741 573 577 O
trauma NCT03861741 578 584 B-Condition
and NCT03861741 585 588 B-Or
infections NCT03861741 589 599 B-Condition
. NCT03861741 600 601 O

3 NCT03861741 605 606 O
. NCT03861741 606 607 O
Probands NCT03861741 609 617 O
/ NCT03861741 618 619 O
relatives NCT03861741 620 629 O
unable NCT03861741 630 636 O
to NCT03861741 637 639 O
give NCT03861741 640 644 O
informed NCT03861741 645 653 O
consent NCT03861741 654 661 O

Inclusion NCT03862248 0 9 O
Criteria NCT03862248 10 18 O
: NCT03862248 19 20 O

- NCT03862248 24 25 O
All NCT03862248 27 30 O
newly NCT03862248 31 36 O
registered NCT03862248 37 47 O
patients NCT03862248 48 56 O
with NCT03862248 57 61 O
smear NCT03862248 62 67 B-Modifier
- NCT03862248 68 69 O
positive NCT03862248 70 78 O
recurrent NCT03862248 79 88 B-Modifier
pulmonary NCT03862248 89 98 I-Modifier
TB NCT03862248 99 101 B-Condition

- NCT03862248 104 105 O
Adults NCT03862248 107 113 O
as NCT03862248 114 116 B-Or
well NCT03862248 117 121 I-Or
as NCT03862248 122 124 I-Or
children NCT03862248 125 133 O
( NCT03862248 134 135 O
no NCT03862248 136 138 O
age NCT03862248 139 142 O
limit NCT03862248 143 148 O
) NCT03862248 149 150 O

- NCT03862248 154 155 O
Able NCT03862248 157 161 O
and NCT03862248 162 165 O
willing NCT03862248 166 173 O
to NCT03862248 174 176 O
provide NCT03862248 177 184 O
written NCT03862248 185 192 O
informed NCT03862248 193 201 O
consent NCT03862248 202 209 O

Exclusion NCT03862248 210 219 O
Criteria NCT03862248 220 228 O
: NCT03862248 229 230 O

- NCT03862248 234 235 O
Patients NCT03862248 237 245 O
transferred NCT03862248 246 257 B-Encounter
to NCT03862248 258 260 O
a NCT03862248 261 262 O
health NCT03862248 263 269 O
facility NCT03862248 270 278 O
not NCT03862248 279 282 B-Negation
supported NCT03862248 283 292 B-Assertion___Assertion-Type-Value:hypothetical
by NCT03862248 293 295 I-Assertion___Assertion-Type-Value:hypothetical
Damien NCT03862248 296 302 O
Foundation NCT03862248 303 313 O
will NCT03862248 314 318 O
be NCT03862248 319 321 O
excluded NCT03862248 322 330 O
. NCT03862248 330 331 O
This NCT03862248 333 337 O
includes NCT03862248 338 346 O
patients NCT03862248 347 355 O
diagnosed NCT03862248 356 365 O
with NCT03862248 366 370 O
HIV NCT03862248 371 374 B-Condition
/ NCT03862248 375 376 B-Or
TB NCT03862248 377 379 B-Condition
- NCT03862248 380 381 O
coinfection NCT03862248 382 393 B-Condition
. NCT03862248 393 394 O

Inclusion NCT03862937 0 9 O
Criteria NCT03862937 10 18 O
: NCT03862937 19 20 O

- NCT03862937 24 25 O
Be NCT03862937 27 29 O
60 NCT03862937 30 32 B-Eq-Comparison
or NCT03862937 33 35 I-Eq-Comparison
older NCT03862937 36 41 I-Age|Eq-Comparison
, NCT03862937 42 43 O
and NCT03862937 44 47 O
in NCT03862937 48 50 O
the NCT03862937 51 54 O
case NCT03862937 55 59 O
of NCT03862937 60 62 O
women NCT03862937 63 68 O
, NCT03862937 69 70 O
they NCT03862937 71 75 O
must NCT03862937 76 80 O
be NCT03862937 81 83 O
postmenopausal NCT03862937 84 98 B-Condition
( NCT03862937 99 100 O
interruption NCT03862937 101 113 B-Negation
of NCT03862937 114 116 O
menstruation NCT03862937 117 129 B-Condition
for NCT03862937 130 133 O
more NCT03862937 134 138 B-Eq-Comparison
than NCT03862937 139 143 I-Eq-Comparison
one NCT03862937 144 147 I-Eq-Comparison
year NCT03862937 148 152 I-Eq-Comparison
) NCT03862937 153 154 O
. NCT03862937 156 157 O

- NCT03862937 161 162 O
Have NCT03862937 164 168 O
not NCT03862937 169 172 B-Negation
participated NCT03862937 173 185 O
in NCT03862937 186 188 O
any NCT03862937 189 192 O
systematic NCT03862937 193 203 B-Modifier
exercise NCT03862937 204 212 B-Procedure
program NCT03862937 213 220 I-Procedure
for NCT03862937 221 224 O
at NCT03862937 225 227 B-Eq-Comparison
least NCT03862937 228 233 I-Eq-Comparison
six NCT03862937 234 237 I-Eq-Comparison
months NCT03862937 238 244 I-Eq-Comparison
prior NCT03862937 245 250 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862937 251 253 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862937 254 257 O
start NCT03862937 258 263 O
of NCT03862937 264 266 O
this NCT03862937 267 271 O
project NCT03862937 272 279 B-Study
. NCT03862937 280 281 O

- NCT03862937 285 286 O
To NCT03862937 288 290 O
have NCT03862937 291 295 O
a NCT03862937 296 297 O
body NCT03862937 298 302 B-Observation
mass NCT03862937 303 307 I-Observation
index NCT03862937 308 313 I-Observation
( NCT03862937 314 315 O
BMI NCT03862937 316 319 B-Observation
) NCT03862937 320 321 O
between NCT03862937 322 329 B-Eq-Comparison
22 NCT03862937 330 332 I-Eq-Comparison
and NCT03862937 333 336 I-Eq-Comparison
30 NCT03862937 337 339 I-Eq-Comparison
kg NCT03862937 340 342 I-Eq-Comparison
/ NCT03862937 343 344 I-Eq-Comparison
m2 NCT03862937 345 347 I-Eq-Comparison
. NCT03862937 347 348 O

- NCT03862937 352 353 O
Are NCT03862937 355 358 O
not NCT03862937 359 362 B-Negation
cardiopathic NCT03862937 363 375 B-Condition
, NCT03862937 376 377 O
diabetic NCT03862937 378 386 B-Condition
or NCT03862937 387 389 B-Or
have NCT03862937 390 394 O
any NCT03862937 395 398 O
other NCT03862937 399 404 B-Other
metabolic NCT03862937 405 414 B-Condition
disease NCT03862937 415 422 I-Condition
. NCT03862937 423 424 O

- NCT03862937 428 429 O
Do NCT03862937 431 433 O
not NCT03862937 434 437 B-Negation
present NCT03862937 438 445 O
joint NCT03862937 446 451 B-Condition
problems NCT03862937 452 460 I-Condition
or NCT03862937 461 463 B-Or
any NCT03862937 464 467 O
other NCT03862937 468 473 B-Other
injury NCT03862937 474 480 B-Condition
that NCT03862937 481 485 O
prevents NCT03862937 486 494 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862937 495 498 O
proper NCT03862937 499 505 O
execution NCT03862937 506 515 O
of NCT03862937 516 518 O
the NCT03862937 519 522 O
exercises NCT03862937 523 532 B-Observation
of NCT03862937 533 535 O
the NCT03862937 536 539 O
training NCT03862937 540 548 B-Procedure
routine NCT03862937 549 556 I-Procedure
. NCT03862937 557 558 O

- NCT03862937 562 563 O
Non NCT03862937 565 568 B-Negation
- NCT03862937 569 570 O
smoker NCT03862937 571 577 B-Condition
or NCT03862937 578 580 B-Or
have NCT03862937 581 585 O
quit NCT03862937 586 590 B-Condition
smoking NCT03862937 591 598 I-Condition
for NCT03862937 599 602 O
at NCT03862937 603 605 B-Eq-Comparison
least NCT03862937 606 611 I-Eq-Comparison
five NCT03862937 612 616 I-Eq-Comparison
years NCT03862937 617 622 I-Eq-Comparison
ago NCT03862937 623 626 I-Eq-Comparison
. NCT03862937 627 628 O

- NCT03862937 632 633 O
Release NCT03862937 635 642 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03862937 643 645 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862937 646 649 O
doctor NCT03862937 650 656 O
( NCT03862937 657 658 O
medical NCT03862937 659 666 O
certificate NCT03862937 667 678 O
) NCT03862937 679 680 O
to NCT03862937 681 683 O
perform NCT03862937 684 691 O
the NCT03862937 692 695 O
physical NCT03862937 696 704 B-Observation
exercises NCT03862937 705 714 I-Observation
. NCT03862937 715 716 O

Exclusion NCT03862937 718 727 O
Criteria NCT03862937 728 736 O
: NCT03862937 737 738 O

- NCT03862937 742 743 O
Do NCT03862937 745 747 O
not NCT03862937 748 751 B-Negation
participate NCT03862937 752 763 O
in NCT03862937 764 766 O
at NCT03862937 767 769 B-Eq-Comparison
least NCT03862937 770 775 I-Eq-Comparison
20 NCT03862937 776 778 I-Eq-Comparison
training NCT03862937 779 787 B-Procedure
sessions NCT03862937 788 796 I-Procedure
or NCT03862937 797 799 B-Or
miss NCT03862937 800 804 B-Negation
more NCT03862937 805 809 B-Eq-Comparison
than NCT03862937 810 814 I-Eq-Comparison
three NCT03862937 815 820 I-Eq-Comparison
consecutive NCT03862937 821 832 I-Eq-Comparison
training NCT03862937 833 841 B-Procedure
sessions NCT03862937 842 850 I-Procedure
. NCT03862937 850 851 O

Inclusion NCT03869645 0 9 O
Criteria NCT03869645 10 18 O
: NCT03869645 19 20 O

- NCT03869645 24 25 O
Patients NCT03869645 27 35 O
who NCT03869645 36 39 O
are NCT03869645 40 43 O
> NCT03869645 44 45 B-Eq-Comparison
18 NCT03869645 46 48 I-Eq-Comparison
years NCT03869645 49 54 I-Eq-Comparison
of NCT03869645 55 57 O
age NCT03869645 58 61 B-Age

- NCT03869645 64 65 O
Patients NCT03869645 67 75 O
with NCT03869645 76 80 O
clinical NCT03869645 81 89 B-Assertion___Assertion-Type-Value:possible
signs NCT03869645 90 95 I-Assertion___Assertion-Type-Value:possible
, NCT03869645 96 97 O
symptoms NCT03869645 98 106 B-Assertion___Assertion-Type-Value:possible
and NCT03869645 107 110 B-And
presentation NCT03869645 111 123 B-Assertion___Assertion-Type-Value:possible
consistent NCT03869645 124 134 O
with NCT03869645 135 139 O
acute NCT03869645 140 145 O
thrombosis NCT03869645 146 156 B-Condition
; NCT03869645 156 157 O
onset NCT03869645 158 163 B-Eq-Comparison
of NCT03869645 164 166 O
symptoms NCT03869645 167 175 B-Coreference
< NCT03869645 176 177 B-Eq-Comparison
14 NCT03869645 178 180 I-Eq-Comparison
days NCT03869645 181 185 I-Eq-Comparison

- NCT03869645 188 189 O
Patients NCT03869645 191 199 O
cleared NCT03869645 200 207 B-Assertion___Assertion-Type-Value:hypothetical
medically NCT03869645 208 217 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03869645 218 221 I-Assertion___Assertion-Type-Value:hypothetical
invasive NCT03869645 222 230 B-Procedure
endovenous NCT03869645 231 241 I-Procedure
procedures NCT03869645 242 252 I-Procedure

Exclusion NCT03869645 253 262 O
Criteria NCT03869645 263 271 O
: NCT03869645 272 273 O

- NCT03869645 277 278 O
Patients NCT03869645 280 288 O
with NCT03869645 289 293 O
IVC NCT03869645 294 297 B-Procedure
filter NCT03869645 298 304 I-Procedure
in NCT03869645 305 307 O
area NCT03869645 308 312 B-Modifier
to NCT03869645 313 315 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03869645 316 318 I-Assertion___Assertion-Type-Value:hypothetical
treated NCT03869645 319 326 B-Procedure

- NCT03869645 329 330 O
Patients NCT03869645 332 340 O
who NCT03869645 341 344 O
are NCT03869645 345 348 O
< NCT03869645 349 350 B-Eq-Comparison
18 NCT03869645 351 353 I-Eq-Comparison
years NCT03869645 354 359 I-Eq-Comparison
of NCT03869645 360 362 O
age NCT03869645 363 366 B-Age
. NCT03869645 367 368 O

- NCT03869645 372 373 O
Known NCT03869645 375 380 O
anaphylactic NCT03869645 381 393 B-Condition
reaction NCT03869645 394 402 I-Condition
of NCT03869645 403 405 O
radiographic NCT03869645 406 418 B-Drug
contrast NCT03869645 419 427 I-Drug
agents NCT03869645 428 434 I-Drug
that NCT03869645 435 439 O
can NCT03869645 440 443 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03869645 443 446 I-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03869645 447 449 O
pre NCT03869645 450 453 B-Procedure
- NCT03869645 454 455 I-Procedure
treated NCT03869645 456 463 I-Procedure

- NCT03869645 466 467 O
Imaging NCT03869645 469 476 B-Procedure
evidence NCT03869645 477 485 O
or NCT03869645 486 488 B-Or
other NCT03869645 489 494 B-Other
evidence NCT03869645 495 503 O
that NCT03869645 504 508 O
suggests NCT03869645 509 517 O
the NCT03869645 518 521 O
participant NCT03869645 522 533 O
is NCT03869645 534 536 O
not NCT03869645 537 540 B-Negation
appropriate NCT03869645 541 552 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869645 553 556 O
mechanical NCT03869645 557 567 B-Procedure
thrombectomy NCT03869645 568 580 I-Procedure
intervention NCT03869645 581 593 I-Procedure

- NCT03869645 596 597 O
Female NCT03869645 599 605 O
who NCT03869645 606 609 B-And
is NCT03869645 610 612 O
pregnant NCT03869645 613 621 B-Condition
or NCT03869645 622 624 B-Or
nursing NCT03869645 625 632 B-Condition

- NCT03869645 635 636 O
Concurrent NCT03869645 638 648 B-Modifier
participation NCT03869645 649 662 O
in NCT03869645 663 665 O
another NCT03869645 666 673 B-Other
investigational NCT03869645 674 689 B-Study
drug NCT03869645 690 694 B-Drug
or NCT03869645 695 697 B-Or
device NCT03869645 698 704 B-Procedure
treatment NCT03869645 705 714 I-Procedure
study NCT03869645 715 720 B-Study

Inclusion NCT03865043 0 9 O
criteria NCT03865043 10 18 O
: NCT03865043 19 20 O

- NCT03865043 24 25 O
Patients NCT03865043 27 35 O
undergoing NCT03865043 36 46 B-Eq-Comparison
a NCT03865043 47 48 O
TAVI NCT03865043 49 53 B-Procedure
at NCT03865043 54 56 O
Montpellier NCT03865043 57 68 O
University NCT03865043 69 79 O
Hospital NCT03865043 80 88 O

- NCT03865043 91 92 O
Since NCT03865043 94 99 B-Eq-Comparison
November NCT03865043 100 108 I-Eq-Comparison
2017 NCT03865043 109 113 I-Eq-Comparison

- NCT03865043 117 118 O
With NCT03865043 120 124 O
implantation NCT03865043 125 137 B-Procedure
of NCT03865043 138 140 O
a NCT03865043 141 142 O
COREVALVE NCT03865043 143 152 B-Modifier
or NCT03865043 153 155 B-Or
EDWARDS NCT03865043 156 163 B-Modifier

- NCT03865043 166 167 O
By NCT03865043 169 171 O
femoral NCT03865043 172 179 B-Procedure
approach NCT03865043 180 188 I-Procedure

Exclusion NCT03865043 189 198 O
criteria NCT03865043 199 207 O
: NCT03865043 208 209 O

- NCT03865043 213 214 O
Minor NCT03865043 216 221 O
patient NCT03865043 222 229 O

- NCT03865043 232 233 O
Patient NCT03865043 235 242 O
unable NCT03865043 243 249 O
to NCT03865043 250 252 O
give NCT03865043 253 257 O
consent NCT03865043 258 265 O
for NCT03865043 266 269 O
reasons NCT03865043 270 277 O
of NCT03865043 278 280 O
understanding NCT03865043 281 294 O
or NCT03865043 295 297 O
language NCT03865043 298 306 B-Condition
barrier NCT03865043 307 314 I-Condition

Inclusion NCT03865862 0 9 O
Criteria NCT03865862 10 18 O
: NCT03865862 19 20 O

- NCT03865862 24 25 O
Volleyball NCT03865862 27 37 B-Observation
players NCT03865862 38 45 I-Observation

- NCT03865862 48 49 O
Federated NCT03865862 51 60 O
that NCT03865862 61 65 O
at NCT03865862 66 68 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865862 69 72 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865862 73 77 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865862 78 80 O
the NCT03865862 81 84 O
study NCT03865862 85 90 B-Study
compete NCT03865862 91 98 O
in NCT03865862 99 101 O
clubs NCT03865862 102 107 O
of NCT03865862 108 110 O
the NCT03865862 111 114 O
Community NCT03865862 115 124 O
of NCT03865862 125 127 O
Madrid NCT03865862 128 134 O

- NCT03865862 137 138 O
Over NCT03865862 140 144 B-Eq-Comparison
18 NCT03865862 145 147 I-Eq-Comparison
years NCT03865862 148 153 I-Eq-Comparison
old NCT03865862 154 157 B-Age
. NCT03865862 158 159 O

Exclusion NCT03865862 161 170 O
Criteria NCT03865862 171 179 O
: NCT03865862 180 181 O

- NCT03865862 185 186 O
Present NCT03865862 188 195 O
a NCT03865862 196 197 O
medical NCT03865862 198 205 O
diagnosis NCT03865862 206 215 O
of NCT03865862 216 218 O
injury NCT03865862 219 225 B-Condition
or NCT03865862 226 228 B-Or
illness NCT03865862 229 236 B-Condition

- NCT03865862 239 240 O
Have NCT03865862 242 246 O
suffered NCT03865862 247 255 O
a NCT03865862 256 257 O
knee NCT03865862 258 262 B-Modifier
injury NCT03865862 263 269 B-Condition
in NCT03865862 270 272 O
the NCT03865862 273 276 O
6 NCT03865862 277 278 B-Eq-Comparison
months NCT03865862 279 285 I-Eq-Comparison
prior NCT03865862 286 291 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865862 292 294 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03865862 295 298 O
study NCT03865862 299 304 B-Study

- NCT03865862 307 308 O
Doing NCT03865862 310 315 O
some NCT03865862 316 320 O
pharmacological NCT03865862 321 336 B-Drug
or NCT03865862 337 339 B-Or
physiotherapy NCT03865862 340 353 B-Procedure
treatment NCT03865862 354 363 I-Procedure
external NCT03865862 364 372 B-Other
to NCT03865862 373 375 I-Other
the NCT03865862 376 379 O
study NCT03865862 380 385 B-Study

- NCT03865862 388 389 O
Not NCT03865862 391 394 O
signed NCT03865862 395 401 O
the NCT03865862 402 405 O
informed NCT03865862 406 414 O
consent NCT03865862 415 422 O
document NCT03865862 423 431 O
. NCT03865862 431 432 O

Inclusion NCT03862664 0 9 O
Criteria NCT03862664 10 18 O
: NCT03862664 19 20 O

- NCT03862664 24 25 O
Excellent NCT03862664 27 36 O
general NCT03862664 37 44 O
physical NCT03862664 45 53 B-Modifier
and NCT03862664 54 57 B-And
mental NCT03862664 58 64 B-Modifier
condition NCT03862664 65 74 B-Condition
, NCT03862664 75 76 O

- NCT03862664 80 81 O
Free NCT03862664 83 87 B-Negation
of NCT03862664 88 90 I-Negation
chronic NCT03862664 91 98 B-Modifier
disease NCT03862664 99 106 B-Condition
or NCT03862664 107 109 B-Or

- NCT03862664 112 113 O
Previous NCT03862664 115 123 B-Eq-Comparison
major NCT03862664 124 129 O
abdominal NCT03862664 130 139 B-Procedure
surgery NCT03862664 140 147 I-Procedure
, NCT03862664 148 149 O

- NCT03862664 153 154 O
Body NCT03862664 156 160 B-Observation
mass NCT03862664 161 165 I-Observation
index NCT03862664 166 171 I-Observation
( NCT03862664 172 173 O
BMI NCT03862664 174 177 B-Observation
) NCT03862664 178 179 O
< NCT03862664 180 181 B-Eq-Comparison
28 NCT03862664 182 184 I-Eq-Comparison
, NCT03862664 185 186 O

- NCT03862664 191 192 O
ABO NCT03862664 194 197 B-Observation
blood NCT03862664 198 203 I-Observation
group NCT03862664 204 209 O
identical NCT03862664 210 219 O
to NCT03862664 220 222 O
recipients NCT03862664 223 233 O
and NCT03862664 234 237 B-And

- NCT03862664 240 241 O
Negative NCT03862664 243 251 O
for NCT03862664 252 255 O
hepatitis NCT03862664 256 265 B-Condition
B NCT03862664 266 267 B-Modifier
, NCT03862664 268 269 O
C NCT03862664 270 271 B-Modifier
and NCT03862664 272 275 B-Or
human NCT03862664 276 281 B-Condition
immunodeficiency NCT03862664 282 298 I-Condition
viruses NCT03862664 299 306 I-Condition
( NCT03862664 307 308 O
HIV NCT03862664 309 312 B-Condition
) NCT03862664 313 314 O
. NCT03862664 316 317 O

Exclusion NCT03862664 319 328 O
Criteria NCT03862664 329 337 O
: NCT03862664 338 339 O

- NCT03862664 343 344 O
ASA NCT03862664 346 349 B-Condition
physical NCT03862664 350 358 O
status NCT03862664 359 365 O
> NCT03862664 366 367 B-Eq-Comparison
II NCT03862664 368 370 I-Eq-Comparison
, NCT03862664 371 372 O

- NCT03862664 376 377 O
BMI NCT03862664 379 382 B-Observation
> NCT03862664 383 384 B-Eq-Comparison
28 NCT03862664 385 387 I-Eq-Comparison
, NCT03862664 388 389 O

- NCT03862664 394 395 O
Psychiatric NCT03862664 397 408 B-Modifier
or NCT03862664 409 411 B-Or
mental NCT03862664 412 418 B-Modifier
retardation NCT03862664 419 430 B-Condition
, NCT03862664 431 432 O

- NCT03862664 436 437 O
pregnant NCT03862664 439 447 B-Condition
and NCT03862664 448 451 B-Or
nursing NCT03862664 452 459 B-Condition
women NCT03862664 460 465 O
or NCT03862664 466 468 B-Or

- NCT03862664 471 472 O
Patients NCT03862664 474 482 O
with NCT03862664 483 487 O
significant NCT03862664 488 499 O
laboratory NCT03862664 500 510 B-Observation
abnormalities NCT03862664 511 524 O

Inclusion NCT03867708 0 9 O
Criteria NCT03867708 10 18 O
: NCT03867708 19 20 O

- NCT03867708 24 25 O
Patients NCT03867708 27 35 O
with NCT03867708 36 40 O
suitable NCT03867708 41 49 O
indication NCT03867708 50 60 B-Indication
for NCT03867708 61 64 O
ASD NCT03867708 65 68 B-Condition
closure NCT03867708 69 76 B-Procedure
according NCT03867708 77 86 O
to NCT03867708 87 89 O
recent NCT03867708 90 96 O
guidelines NCT03867708 97 107 O
: NCT03867708 108 109 O

1 NCT03867708 118 119 O
. NCT03867708 119 120 O
Impaired NCT03867708 122 130 B-Condition
functional NCT03867708 131 141 I-Condition
capacity NCT03867708 142 150 I-Condition
. NCT03867708 151 152 O

2 NCT03867708 161 162 O
. NCT03867708 162 163 O
Right NCT03867708 165 170 B-Modifier
atrial NCT03867708 171 177 I-Modifier
and NCT03867708 178 181 B-Or
/ NCT03867708 182 183 I-Or
or NCT03867708 184 186 I-Or
RV NCT03867708 187 189 B-Modifier
enlargement NCT03867708 190 201 B-Condition
. NCT03867708 202 203 O

3 NCT03867708 212 213 O
. NCT03867708 213 214 O
Left NCT03867708 216 220 B-Modifier
- NCT03867708 221 222 I-Modifier
to NCT03867708 223 225 I-Modifier
- NCT03867708 226 227 I-Modifier
right NCT03867708 228 233 I-Modifier
shunt NCT03867708 234 239 B-Condition
with NCT03867708 240 244 B-And
[ NCT03867708 245 246 O
Qp NCT03867708 247 249 B-Observation
: NCT03867708 250 251 I-Observation
Qs NCT03867708 252 254 I-Observation
] NCT03867708 255 256 O
≥ NCT03867708 257 258 B-Eq-Comparison
1.5 NCT03867708 259 262 I-Eq-Comparison
: NCT03867708 263 264 I-Eq-Comparison
1 NCT03867708 265 266 I-Eq-Comparison
. NCT03867708 266 267 O

4 NCT03867708 276 277 O
. NCT03867708 277 278 O
Paradoxical NCT03867708 280 291 B-Condition
embolism NCT03867708 292 300 I-Condition
. NCT03867708 301 302 O

- NCT03867708 306 307 O
Patients NCT03867708 309 317 O
with NCT03867708 318 322 O
isolated NCT03867708 323 331 B-Modifier
secundum NCT03867708 332 340 I-Modifier
ASD NCT03867708 341 344 B-Condition
with NCT03867708 345 349 B-And
sufficient NCT03867708 350 360 O
rims NCT03867708 361 365 B-Observation
suitable NCT03867708 366 374 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867708 375 378 I-Assertion___Assertion-Type-Value:hypothetical
device NCT03867708 379 385 B-Procedure
closure NCT03867708 386 393 I-Procedure
. NCT03867708 394 395 O

Exclusion NCT03867708 397 406 O
Criteria NCT03867708 407 415 O
: NCT03867708 416 417 O

- NCT03867708 421 422 O
Small NCT03867708 424 429 B-Modifier
ASD NCT03867708 430 433 B-Condition
with NCT03867708 434 438 B-And
Qp NCT03867708 439 441 B-Observation
/ NCT03867708 442 443 I-Observation
Qs NCT03867708 444 446 I-Observation
< NCT03867708 447 448 B-Eq-Comparison
1.5 NCT03867708 449 452 I-Eq-Comparison
: NCT03867708 453 454 I-Eq-Comparison
1 NCT03867708 455 456 I-Eq-Comparison
or NCT03867708 457 459 B-Or
no NCT03867708 460 462 B-Negation
signs NCT03867708 463 468 B-Assertion___Assertion-Type-Value:possible
of NCT03867708 469 471 O
RV NCT03867708 472 474 B-Condition
volume NCT03867708 475 481 I-Condition
overload NCT03867708 482 490 I-Condition

- NCT03867708 493 494 O
A NCT03867708 496 497 O
single NCT03867708 498 504 B-Eq-Comparison
defect NCT03867708 505 511 B-Condition|Observation
too NCT03867708 512 515 B-Modifier
large NCT03867708 516 521 I-Modifier
for NCT03867708 522 525 O
closure NCT03867708 526 533 B-Procedure
( NCT03867708 534 535 O
> NCT03867708 537 538 B-Eq-Comparison
38 NCT03867708 539 541 I-Eq-Comparison
mm NCT03867708 542 544 I-Eq-Comparison
) NCT03867708 545 546 O

- NCT03867708 550 551 O
Multiple NCT03867708 553 561 B-Eq-Comparison
ASDs NCT03867708 562 566 B-Condition
unsuitable NCT03867708 567 577 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03867708 578 581 O
percutaneous NCT03867708 582 594 B-Procedure
closure NCT03867708 595 602 I-Procedure
. NCT03867708 603 604 O

- NCT03867708 608 609 O
Anterior NCT03867708 611 619 B-Modifier
, NCT03867708 620 621 O
posterior NCT03867708 622 631 B-Modifier
, NCT03867708 632 633 O
superior NCT03867708 634 642 B-Modifier
, NCT03867708 643 644 O
or NCT03867708 645 647 B-Or
inferior NCT03867708 648 656 B-Modifier
rim NCT03867708 657 660 B-Observation
< NCT03867708 661 662 B-Eq-Comparison
5 NCT03867708 663 664 I-Eq-Comparison
mm NCT03867708 665 667 I-Eq-Comparison
. NCT03867708 668 669 O

- NCT03867708 673 674 O
Abnormal NCT03867708 676 684 O
pulmonary NCT03867708 685 694 B-Condition
venous NCT03867708 695 701 I-Condition
drainage NCT03867708 702 710 I-Condition
. NCT03867708 711 712 O

- NCT03867708 716 717 O
Associated NCT03867708 719 729 O
structural NCT03867708 730 740 B-Modifier
heart NCT03867708 741 746 B-Condition
disease NCT03867708 747 754 I-Condition
requiring NCT03867708 755 764 B-Assertion___Assertion-Type-Value:hypothetical
cardiac NCT03867708 765 772 B-Procedure
surgery NCT03867708 773 780 I-Procedure
. NCT03867708 781 782 O

- NCT03867708 786 787 O
ASD NCT03867708 789 792 B-Condition
with NCT03867708 793 797 B-And
severe NCT03867708 798 804 O
pulmonary NCT03867708 805 814 B-Condition
arterial NCT03867708 815 823 I-Condition
hypertension NCT03867708 824 836 I-Condition
and NCT03867708 837 840 B-And
bidirectional NCT03867708 841 854 B-Modifier
or NCT03867708 855 857 B-Or
right NCT03867708 858 863 B-Modifier
- NCT03867708 864 865 I-Modifier
to NCT03867708 866 868 I-Modifier
- NCT03867708 869 870 I-Modifier
left NCT03867708 871 875 I-Modifier
shunting NCT03867708 876 884 B-Condition
. NCT03867708 885 886 O

- NCT03867708 890 891 O
Intracardiac NCT03867708 893 905 B-Condition
thrombi NCT03867708 906 913 I-Condition
diagnosed NCT03867708 914 923 O
by NCT03867708 924 926 O
echocardiography NCT03867708 927 943 B-Procedure
. NCT03867708 943 944 O

Inclusion NCT03860701 0 9 O
Criteria NCT03860701 10 18 O
: NCT03860701 19 20 O

- NCT03860701 24 25 O
Patients NCT03860701 27 35 O
with NCT03860701 36 40 O
NEC NCT03860701 41 44 B-Condition
( NCT03860701 45 46 O
stages NCT03860701 47 53 B-Eq-Comparison
I NCT03860701 54 55 I-Eq-Comparison
- NCT03860701 56 57 I-Eq-Comparison
III NCT03860701 58 61 I-Eq-Comparison
Bell NCT03860701 62 66 O
's NCT03860701 66 68 O
Classification NCT03860701 69 83 O
) NCT03860701 84 85 O

- NCT03860701 89 90 O
Weight NCT03860701 92 98 B-Observation
greater NCT03860701 99 106 B-Eq-Comparison
or NCT03860701 107 109 I-Eq-Comparison
equal NCT03860701 110 115 I-Eq-Comparison
to NCT03860701 116 118 I-Eq-Comparison
750 NCT03860701 119 122 I-Eq-Comparison
g NCT03860701 123 124 I-Eq-Comparison
. NCT03860701 125 126 I-Eq-Comparison

- NCT03860701 130 131 O
Gestational NCT03860701 133 144 B-Observation
age NCT03860701 145 148 I-Observation
< NCT03860701 149 150 B-Eq-Comparison
36 NCT03860701 151 153 I-Eq-Comparison
weeks NCT03860701 154 159 I-Eq-Comparison
. NCT03860701 160 161 O

- NCT03860701 165 166 O
Patients NCT03860701 168 176 O
whose NCT03860701 177 182 O
parents NCT03860701 183 190 O
consent NCT03860701 191 198 O
to NCT03860701 199 201 O
participate NCT03860701 202 213 O
in NCT03860701 214 216 O
the NCT03860701 217 220 O
study NCT03860701 221 226 O
. NCT03860701 227 228 O

Exclusion NCT03860701 230 239 O
Criteria NCT03860701 240 248 O
: NCT03860701 249 250 O

- NCT03860701 254 255 O
Patients NCT03860701 257 265 O
with NCT03860701 266 270 O
major NCT03860701 271 276 O
congenital NCT03860701 277 287 B-Condition
anomalies NCT03860701 288 297 I-Condition

- NCT03860701 300 301 O
No NCT03860701 303 305 B-Negation
antecedent NCT03860701 306 316 B-Condition
of NCT03860701 317 319 O
limb NCT03860701 320 324 B-Modifier
ischemia NCT03860701 325 333 B-Condition
/ NCT03860701 334 335 B-Or
limb NCT03860701 336 340 B-Modifier
thrombotic NCT03860701 341 351 B-Condition
events NCT03860701 352 358 I-Condition
. NCT03860701 359 360 O

- NCT03860701 364 365 O
No NCT03860701 367 369 B-Negation
antecedent NCT03860701 370 380 B-Condition
diagnosis NCT03860701 381 390 O
of NCT03860701 391 393 O
occlusive NCT03860701 394 403 B-Modifier
arterial NCT03860701 404 412 I-Modifier
or NCT03860701 413 415 B-Or
venous NCT03860701 416 422 B-Modifier
thrombosis NCT03860701 423 433 B-Condition

- NCT03860701 436 437 O
Hemodynamic NCT03860701 439 450 B-Condition
instability NCT03860701 451 462 O

Inclusion NCT03867734 0 9 O
Criteria NCT03867734 10 18 O
: NCT03867734 19 20 O

- NCT03867734 24 25 I-Eq-Comparison
Persons NCT03867734 27 34 O
diagnosed NCT03867734 35 44 O
with NCT03867734 45 49 O
pharyngeal NCT03867734 50 60 B-Modifier
gonorrhea NCT03867734 61 70 B-Condition
or NCT03867734 71 73 B-Or
gonococcal NCT03867734 74 84 B-Modifier
urethritis NCT03867734 85 95 B-Condition
who NCT03867734 96 99 B-And
are NCT03867734 100 103 O
undergoing NCT03867734 104 114 B-Eq-Comparison
pharyngeal NCT03867734 115 125 B-Procedure
gonorrhea NCT03867734 126 135 I-Procedure
testing NCT03867734 136 143 I-Procedure
, NCT03867734 144 145 O
who NCT03867734 146 149 B-And
are NCT03867734 150 153 O
not NCT03867734 154 157 B-Negation
yet NCT03867734 158 161 O
treated NCT03867734 162 169 B-Procedure
. NCT03867734 170 171 O

Exclusion NCT03867734 173 182 O
Criteria NCT03867734 183 191 O
: NCT03867734 192 193 O

- NCT03867734 197 198 O
Age NCT03867734 200 203 B-Age
less NCT03867734 204 208 B-Eq-Comparison
than NCT03867734 209 213 I-Eq-Comparison
16 NCT03867734 214 216 I-Eq-Comparison
years NCT03867734 217 222 I-Eq-Comparison

- NCT03867734 225 226 O
Receipt NCT03867734 228 235 O
of NCT03867734 236 238 O
antibiotics NCT03867734 239 250 B-Drug
in NCT03867734 251 253 O
≤ NCT03867734 254 255 B-Eq-Comparison
30 NCT03867734 256 258 I-Eq-Comparison
days NCT03867734 259 263 I-Eq-Comparison

- NCT03867734 266 267 O
Known NCT03867734 269 274 O
allergy NCT03867734 275 282 B-Allergy
to NCT03867734 283 285 O
aztreonam NCT03867734 286 295 B-Drug

- NCT03867734 298 299 O
History NCT03867734 301 308 B-Eq-Comparison
of NCT03867734 309 311 O
renal NCT03867734 312 317 B-Condition
disease NCT03867734 318 325 I-Condition
( NCT03867734 326 327 O
including NCT03867734 328 337 O
diagnosis NCT03867734 338 347 O
of NCT03867734 348 350 O
solitary NCT03867734 351 359 B-Condition
kidney NCT03867734 360 366 I-Condition
, NCT03867734 367 368 O
chronic NCT03867734 369 376 B-Modifier
renal NCT03867734 377 382 B-Condition
insufficiency NCT03867734 383 396 I-Condition
, NCT03867734 397 398 O
renal NCT03867734 399 404 B-Condition
cell NCT03867734 405 409 I-Condition
carcinoma NCT03867734 410 419 I-Condition
etc NCT03867734 420 423 O
. NCT03867734 423 424 O
) NCT03867734 425 426 O

- NCT03867734 430 431 O
Concurrent NCT03867734 433 443 B-Modifier
infection NCT03867734 444 453 B-Condition
with NCT03867734 454 458 O
syphilis NCT03867734 459 467 B-Condition
or NCT03867734 468 470 B-Or
chlamydia NCT03867734 471 480 B-Condition

- NCT03867734 483 484 O
Pregnancy NCT03867734 486 495 B-Condition
and NCT03867734 496 499 B-Or
/ NCT03867734 500 501 I-Eq-Comparison|Or
or NCT03867734 502 504 I-Or
nursing NCT03867734 505 512 B-Condition

- NCT03867734 515 516 O
Unable NCT03867734 518 524 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03867734 525 527 O
return NCT03867734 528 534 O
for NCT03867734 535 538 O
a NCT03867734 539 540 O
follow NCT03867734 541 547 B-Encounter
- NCT03867734 548 549 I-Encounter
up NCT03867734 550 552 I-Encounter
visit NCT03867734 553 558 I-Encounter
4 NCT03867734 559 560 B-Eq-Comparison
- NCT03867734 561 562 I-Eq-Comparison
7 NCT03867734 563 564 I-Eq-Comparison
days NCT03867734 565 569 I-Eq-Comparison
( NCT03867734 570 571 O
+ NCT03867734 573 574 B-Eq-Comparison
/ NCT03867734 576 577 O
- NCT03867734 579 580 O
1 NCT03867734 581 582 I-Eq-Comparison
day NCT03867734 583 586 I-Eq-Comparison
) NCT03867734 587 588 O
. NCT03867734 590 591 O

- NCT03867734 595 596 O
Study NCT03867734 598 603 O
team NCT03867734 604 608 O
's NCT03867734 608 610 O
discretion NCT03867734 611 621 O

Inclusion NCT03861806 0 9 O
Criteria NCT03861806 10 18 O
: NCT03861806 19 20 O

- NCT03861806 24 25 O
Unilateral NCT03861806 27 37 B-Modifier
ischemic NCT03861806 38 46 I-Modifier
stroke NCT03861806 47 53 B-Condition
with NCT03861806 54 58 B-And
residual NCT03861806 59 67 B-Modifier
arm NCT03861806 68 71 I-Modifier
weakness NCT03861806 72 80 B-Condition
( NCT03861806 81 82 O
Fugl NCT03861806 83 87 B-Observation
- NCT03861806 88 89 I-Observation
Meyer NCT03861806 90 95 I-Observation
Upper NCT03861806 96 101 I-Observation
Limb NCT03861806 102 106 I-Observation
< NCT03861806 107 108 B-Eq-Comparison
60 NCT03861806 109 111 I-Eq-Comparison
) NCT03861806 112 113 O
more NCT03861806 114 118 B-Eq-Comparison
than NCT03861806 119 123 I-Eq-Comparison
6 NCT03861806 124 125 I-Eq-Comparison
months NCT03861806 126 132 I-Eq-Comparison
prior NCT03861806 133 138 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861806 139 141 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03861806 142 152 B-Study
. NCT03861806 153 154 O

- NCT03861806 158 159 O
Ability NCT03861806 161 168 O
to NCT03861806 169 171 O
give NCT03861806 172 176 O
informed NCT03861806 177 185 O
consent NCT03861806 186 193 O
and NCT03861806 194 197 O
understand NCT03861806 198 208 O
the NCT03861806 209 212 O
tasks NCT03861806 213 218 O
involved NCT03861806 219 227 O
. NCT03861806 228 229 O

- NCT03861806 233 234 O
Age NCT03861806 236 239 B-Age
over NCT03861806 240 244 B-Eq-Comparison
18 NCT03861806 245 247 I-Eq-Comparison
years NCT03861806 248 253 I-Eq-Comparison
. NCT03861806 254 255 O

Exclusion NCT03861806 257 266 O
Criteria NCT03861806 267 275 O
: NCT03861806 276 277 O

- NCT03861806 281 282 O
Hemorrhagic NCT03861806 284 295 B-Modifier
Stroke NCT03861806 296 302 B-Condition

- NCT03861806 305 306 O
Contraindications NCT03861806 308 325 B-Contraindication
to NCT03861806 326 328 O
TMS NCT03861806 329 332 B-Drug
: NCT03861806 333 334 O
history NCT03861806 335 342 B-Eq-Comparison
of NCT03861806 343 345 O
seizure NCT03861806 346 353 B-Condition
/ NCT03861806 354 355 B-Or
epilepsy NCT03861806 356 364 B-Condition
, NCT03861806 365 366 O
pacemaker NCT03861806 367 376 B-Procedure
, NCT03861806 377 378 O
other NCT03861806 379 384 B-Other
neurological NCT03861806 385 397 B-Condition
disorders NCT03861806 398 407 I-Condition
, NCT03861806 408 409 O
brain NCT03861806 410 415 B-Procedure
surgery NCT03861806 416 423 I-Procedure
, NCT03861806 424 425 O
metal NCT03861806 426 431 B-Procedure
implant NCT03861806 432 439 B-Modifier
/ NCT03861806 440 441 B-Or
fragment NCT03861806 442 450 B-Modifier
in NCT03861806 451 453 O
the NCT03861806 454 457 O
head NCT03861806 458 462 B-Modifier
, NCT03861806 463 464 O
pregnancy NCT03861806 465 474 B-Condition

- NCT03861806 477 478 O
Taking NCT03861806 480 486 B-Eq-Comparison
medications NCT03861806 487 498 B-Drug
or NCT03861806 499 501 B-Or
substances NCT03861806 502 512 B-Drug
that NCT03861806 513 517 O
are NCT03861806 518 521 O
known NCT03861806 522 527 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861806 528 530 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861806 531 537 O
PAS NCT03861806 538 541 B-Modifier
- NCT03861806 542 543 I-Modifier
induced NCT03861806 544 551 I-Modifier
plasticity NCT03861806 552 562 B-Condition
within NCT03861806 563 569 B-Eq-Comparison
the NCT03861806 570 573 I-Eq-Comparison
past NCT03861806 574 578 I-Eq-Comparison
2 NCT03861806 579 580 I-Eq-Comparison
months NCT03861806 581 587 I-Eq-Comparison
: NCT03861806 588 589 O
selective NCT03861806 590 599 O
serotonin NCT03861806 600 609 B-Drug
reuptake NCT03861806 610 618 I-Drug
inhibitors NCT03861806 619 629 I-Drug
, NCT03861806 630 631 O
dopamine NCT03861806 632 640 B-Drug
, NCT03861806 641 642 O
dopamine NCT03861806 643 651 B-Drug
agonists NCT03861806 652 660 I-Drug
, NCT03861806 661 662 O
haloperidol NCT03861806 663 674 B-Drug
, NCT03861806 675 676 O
lithium NCT03861806 677 684 B-Drug
, NCT03861806 685 686 O
acetylcholinesterase NCT03861806 687 707 B-Drug
inhibitors NCT03861806 708 718 I-Drug
, NCT03861806 719 720 O
beta NCT03861806 721 725 B-Drug
- NCT03861806 726 727 I-Drug
blockers NCT03861806 728 736 I-Drug
, NCT03861806 737 738 O
nimodipine NCT03861806 739 749 B-Drug
, NCT03861806 750 751 O
levetiracetam NCT03861806 752 765 B-Drug
, NCT03861806 766 767 O
ethosuximide NCT03861806 768 780 B-Drug
, NCT03861806 781 782 O
benzodiazepines NCT03861806 783 798 B-Drug
, NCT03861806 799 800 O
baclofen NCT03861806 801 809 B-Drug
, NCT03861806 810 811 O
nicotine NCT03861806 812 820 B-Drug

- NCT03861806 823 824 O
Peripheral NCT03861806 826 836 B-Modifier
neuropathy NCT03861806 837 847 B-Condition
or NCT03861806 848 850 B-Or
history NCT03861806 851 858 B-Eq-Comparison
of NCT03861806 859 861 O
nerve NCT03861806 862 867 B-Modifier
injury NCT03861806 868 874 B-Condition
in NCT03861806 875 877 O
the NCT03861806 878 881 O
paretic NCT03861806 882 889 B-Modifier
upper NCT03861806 890 895 I-Modifier
limb NCT03861806 896 900 I-Modifier
. NCT03861806 901 902 O

- NCT03861806 906 907 O
Social NCT03861806 909 915 B-Modifier
and NCT03861806 916 919 B-Or
/ NCT03861806 920 921 I-Or
or NCT03861806 922 924 I-Or
personal NCT03861806 925 933 B-Modifier
circumstances NCT03861806 934 947 B-Condition
that NCT03861806 948 952 O
interfere NCT03861806 953 962 O
with NCT03861806 963 967 O
ability NCT03861806 968 975 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861806 976 978 I-Assertion___Assertion-Type-Value:hypothetical
return NCT03861806 979 985 O
for NCT03861806 986 989 O
all NCT03861806 990 993 O
study NCT03861806 994 999 B-Study
visits NCT03861806 1000 1006 O
. NCT03861806 1006 1007 O

Inclusion NCT03863977 0 9 O
Criteria NCT03863977 10 18 O
: NCT03863977 19 20 O

- NCT03863977 24 25 O
Patients NCT03863977 27 35 O
' NCT03863977 35 36 O
age NCT03863977 37 40 B-Age
from NCT03863977 41 45 O
18 NCT03863977 46 48 B-Eq-Comparison
to NCT03863977 49 51 I-Eq-Comparison
60 NCT03863977 52 54 I-Eq-Comparison
years NCT03863977 55 60 I-Eq-Comparison
old NCT03863977 61 64 O
, NCT03863977 65 66 O

- NCT03863977 70 71 O
physical NCT03863977 73 81 O
status NCT03863977 82 88 O
ASA NCT03863977 89 92 B-Condition
I NCT03863977 93 94 B-Eq-Comparison
- NCT03863977 95 96 I-Eq-Comparison
II NCT03863977 97 99 I-Eq-Comparison
( NCT03863977 100 101 O
by NCT03863977 102 104 O
the NCT03863977 105 108 O
American NCT03863977 109 117 B-Condition
Society NCT03863977 118 125 I-Condition
of NCT03863977 126 128 I-Condition
Anesthesiologists NCT03863977 129 146 I-Condition
) NCT03863977 147 148 O
, NCT03863977 150 151 O

- NCT03863977 155 156 O
Elective NCT03863977 158 166 B-Modifier
unilateral NCT03863977 167 177 I-Modifier
open NCT03863977 178 182 I-Modifier
inguinal NCT03863977 183 191 B-Procedure
hernia NCT03863977 192 198 I-Procedure
repair NCT03863977 199 205 I-Procedure
, NCT03863977 206 207 O

- NCT03863977 211 212 O
Under NCT03863977 214 219 O
spinal NCT03863977 220 226 B-Procedure
anesthesia NCT03863977 227 237 I-Procedure

Exclusion NCT03863977 238 247 O
Criteria NCT03863977 248 256 O
: NCT03863977 257 258 O

- NCT03863977 262 263 O
age NCT03863977 265 268 B-Age
< NCT03863977 269 270 B-Eq-Comparison
18 NCT03863977 271 273 I-Eq-Comparison
or NCT03863977 274 276 B-Or
> NCT03863977 277 278 B-Eq-Comparison
60 NCT03863977 279 281 I-Eq-Comparison
, NCT03863977 282 283 O

- NCT03863977 288 289 O
American NCT03863977 291 299 B-Condition
society NCT03863977 300 307 I-Condition
of NCT03863977 308 310 I-Condition
anesthesiologist NCT03863977 311 327 I-Condition
( NCT03863977 328 329 O
ASA NCT03863977 330 333 B-Condition
) NCT03863977 334 335 O
class NCT03863977 336 341 B-Eq-Comparison
III NCT03863977 342 345 I-Eq-Comparison
- NCT03863977 346 347 I-Eq-Comparison
IV NCT03863977 348 350 I-Eq-Comparison
, NCT03863977 351 352 O

- NCT03863977 356 357 O
known NCT03863977 359 364 O
allergy NCT03863977 365 372 B-Allergy
to NCT03863977 373 375 O
amino NCT03863977 376 381 B-Drug
amide NCT03863977 382 387 I-Drug
local NCT03863977 388 393 I-Drug
anesthetics NCT03863977 394 405 I-Drug
, NCT03863977 406 407 O

- NCT03863977 411 412 O
skin NCT03863977 414 418 B-Modifier
infection NCT03863977 419 428 B-Condition
and NCT03863977 429 432 B-Or
diseases NCT03863977 433 441 B-Condition
at NCT03863977 442 444 O
site NCT03863977 445 449 B-Modifier
of NCT03863977 450 452 O
injection NCT03863977 453 462 B-Procedure
. NCT03863977 463 464 O

- NCT03863977 468 469 O
coagulation NCT03863977 471 482 B-Condition
disorders NCT03863977 483 492 I-Condition
, NCT03863977 493 494 O

- NCT03863977 498 499 O
patients NCT03863977 501 509 O
with NCT03863977 510 514 O
body NCT03863977 515 519 B-Observation
mass NCT03863977 520 524 I-Observation
index NCT03863977 525 530 I-Observation
( NCT03863977 531 532 O
BMI NCT03863977 533 536 B-Observation
) NCT03863977 537 538 O
> NCT03863977 539 540 B-Eq-Comparison
35 NCT03863977 541 543 I-Eq-Comparison
kg NCT03863977 544 546 I-Eq-Comparison
/ NCT03863977 547 548 I-Eq-Comparison
m2 NCT03863977 549 551 I-Eq-Comparison
, NCT03863977 552 553 O

- NCT03863977 558 559 O
scrotal NCT03863977 561 568 B-Modifier
hernias NCT03863977 569 576 B-Condition
, NCT03863977 577 578 O

For NCT03869255 0 3 O
community NCT03869255 4 13 O
patients NCT03869255 14 22 O
: NCT03869255 23 24 O

Inclusion NCT03869255 26 35 O
Criteria NCT03869255 36 44 O
: NCT03869255 45 46 O

- NCT03869255 50 51 O
the NCT03869255 53 56 O
selection NCT03869255 57 66 B-Assertion___Assertion-Type-Value:hypothetical
criteria NCT03869255 67 75 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03869255 76 79 O
blood NCT03869255 80 85 B-Observation
donation NCT03869255 86 94 I-Observation

- NCT03869255 97 98 O
age NCT03869255 100 103 B-Age
≥ NCT03869255 104 105 B-Eq-Comparison
18 NCT03869255 106 108 I-Eq-Comparison
years NCT03869255 109 114 I-Eq-Comparison
old NCT03869255 115 118 O

- NCT03869255 121 122 O
No NCT03869255 124 126 O
refusal NCT03869255 127 134 O
of NCT03869255 135 137 O
the NCT03869255 138 141 O
person NCT03869255 142 148 O

Exclusion NCT03869255 149 158 O
Criteria NCT03869255 159 167 O
: NCT03869255 168 169 O

- NCT03869255 173 174 O
None NCT03869255 176 180 O

For NCT03869255 181 184 O
hospitalized NCT03869255 185 197 B-Encounter
patients NCT03869255 198 206 O
: NCT03869255 207 208 O

Inclusion NCT03869255 210 219 O
Criteria NCT03869255 220 228 O
: NCT03869255 229 230 O

- NCT03869255 234 235 O
age NCT03869255 237 240 B-Age
≥ NCT03869255 241 242 B-Eq-Comparison
18 NCT03869255 243 245 I-Eq-Comparison
years NCT03869255 246 251 I-Eq-Comparison
old NCT03869255 252 255 O

- NCT03869255 258 259 O
hospitalization NCT03869255 261 276 B-Encounter
in NCT03869255 277 279 O
one NCT03869255 280 283 O
of NCT03869255 284 286 O
the NCT03869255 287 290 O
services NCT03869255 291 299 O
participating NCT03869255 300 313 O
in NCT03869255 314 316 O
the NCT03869255 317 320 O
study NCT03869255 321 326 B-Study

- NCT03869255 329 330 O
no NCT03869255 332 334 O
refusal NCT03869255 335 342 O
of NCT03869255 343 345 O
the NCT03869255 346 349 O
person NCT03869255 350 356 O

Exclusion NCT03869255 357 366 O
Criteria NCT03869255 367 375 O
: NCT03869255 376 377 O

- NCT03869255 381 382 O
None NCT03869255 384 388 O

Inclusion NCT03864003 0 9 O
Criteria NCT03864003 10 18 O
: NCT03864003 19 20 O

- NCT03864003 24 25 O
Bilateral NCT03864003 27 36 B-Modifier
hearing NCT03864003 37 44 B-Condition
loss NCT03864003 45 49 I-Condition
within NCT03864003 50 56 O
the NCT03864003 57 60 O
fitting NCT03864003 61 68 O
range NCT03864003 69 74 O
of NCT03864003 75 77 O
study NCT03864003 78 83 B-Study
hearing NCT03864003 84 91 B-Procedure
aids NCT03864003 92 96 I-Procedure

Exclusion NCT03864003 97 106 O
Criteria NCT03864003 107 115 O
: NCT03864003 116 117 O

- NCT03864003 121 122 O
Medically NCT03864003 124 133 O
unqualified NCT03864003 134 145 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864003 146 148 O
receive NCT03864003 149 156 O
hearing NCT03864003 157 164 B-Procedure
aids NCT03864003 165 169 I-Procedure

- NCT03864003 172 173 O
Current NCT03864003 175 182 B-Eq-Comparison
hearing NCT03864003 183 190 B-Procedure
aid NCT03864003 191 194 I-Procedure
user NCT03864003 195 199 O

- NCT03864003 202 203 O
Cognitively NCT03864003 205 216 B-Condition
impaired NCT03864003 217 225 I-Condition

Inclusion NCT03868163 0 9 O
Criteria NCT03868163 10 18 O
: NCT03868163 19 20 O

- NCT03868163 24 25 O
Treatment NCT03868163 27 36 B-Procedure
- NCT03868163 37 38 O
naïve NCT03868163 39 44 B-Negation
or NCT03868163 45 47 B-Or
- NCT03868163 48 49 O
pegIFN NCT03868163 50 56 B-Drug
( NCT03868163 57 58 O
or NCT03868163 59 61 B-Or
IFN NCT03868163 62 65 B-Drug
) NCT03868163 66 67 O
, NCT03868163 69 70 O
and NCT03868163 71 74 B-Or
/ NCT03868163 75 76 I-Or
or NCT03868163 77 79 I-Or
Ribavirin NCT03868163 80 89 B-Drug
( NCT03868163 90 91 O
RBV NCT03868163 92 95 B-Drug
) NCT03868163 96 97 O
and NCT03868163 98 101 B-Or
/ NCT03868163 102 103 I-Or
or NCT03868163 104 106 I-Or
sofosbuvir NCT03868163 107 117 B-Drug
( NCT03868163 118 119 O
PRS NCT03868163 120 123 B-Drug
) NCT03868163 124 125 O
experienced NCT03868163 126 137 B-Eq-Comparison
with NCT03868163 138 142 B-And
confirmed NCT03868163 143 152 O
CHC NCT03868163 153 156 B-Condition
, NCT03868163 157 158 O
genotypes NCT03868163 159 168 B-Modifier
1 NCT03868163 169 170 B-Modifier
, NCT03868163 171 172 O
2 NCT03868163 173 174 B-Modifier
, NCT03868163 175 176 O
3 NCT03868163 177 178 B-Modifier
, NCT03868163 179 180 O
4 NCT03868163 181 182 B-Modifier
, NCT03868163 183 184 O
5 NCT03868163 185 186 B-Modifier
, NCT03868163 187 188 O
or NCT03868163 189 191 B-Or
6 NCT03868163 192 193 B-Modifier
, NCT03868163 194 195 O
with NCT03868163 196 200 B-And
or NCT03868163 201 203 B-Or
without NCT03868163 204 211 B-Negation
compensated NCT03868163 212 223 B-Modifier
cirrhosis NCT03868163 224 233 B-Condition
, NCT03868163 234 235 O
receiving NCT03868163 236 245 B-Eq-Comparison
combination NCT03868163 246 257 B-Procedure
therapy NCT03868163 258 265 I-Procedure
with NCT03868163 266 270 O
the NCT03868163 271 274 O
all NCT03868163 275 278 O
oral NCT03868163 279 283 B-Drug
GLE NCT03868163 284 287 I-Drug
/ NCT03868163 288 289 B-Or
PIB NCT03868163 290 293 B-Drug
regimen NCT03868163 294 301 O
according NCT03868163 302 311 O
to NCT03868163 312 314 O
standard NCT03868163 315 323 O
of NCT03868163 324 326 O
care NCT03868163 327 331 O
, NCT03868163 332 333 O
international NCT03868163 334 347 O
guidelines NCT03868163 348 358 O
and NCT03868163 359 362 O
in NCT03868163 363 365 O
line NCT03868163 366 370 O
with NCT03868163 371 375 O
the NCT03868163 376 379 O
current NCT03868163 380 387 O
local NCT03868163 388 393 O
label NCT03868163 394 399 O
. NCT03868163 400 401 O

- NCT03868163 405 406 O
May NCT03868163 408 411 O
be NCT03868163 412 414 O
enrolled NCT03868163 415 423 O
up NCT03868163 424 426 B-Eq-Comparison
to NCT03868163 427 429 I-Eq-Comparison
4 NCT03868163 430 431 I-Eq-Comparison
weeks NCT03868163 432 437 I-Eq-Comparison
after NCT03868163 438 443 B-Temporal-Connection___Temporal-Connection-Type-Value:after
treatment NCT03868163 444 453 B-Procedure
initiation NCT03868163 454 464 B-Eq-Comparison
. NCT03868163 465 466 O

- NCT03868163 470 471 O
Patients NCT03868163 473 481 O
must NCT03868163 482 486 O
voluntarily NCT03868163 487 498 O
sign NCT03868163 499 503 O
and NCT03868163 504 507 O
date NCT03868163 508 512 O
Informed NCT03868163 513 521 O
Consent NCT03868163 522 529 O
Form NCT03868163 530 534 O
prior NCT03868163 535 540 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868163 541 543 O
inclusion NCT03868163 544 553 O
into NCT03868163 554 558 O
the NCT03868163 559 562 O
study NCT03868163 563 568 B-Study
. NCT03868163 569 570 O

- NCT03868163 574 575 O
Patient NCT03868163 577 584 O
must NCT03868163 585 589 O
not NCT03868163 590 593 B-Negation
be NCT03868163 594 596 O
participating NCT03868163 597 610 O
or NCT03868163 611 613 O
intending NCT03868163 614 623 O
to NCT03868163 624 626 O
participate NCT03868163 627 638 O
in NCT03868163 639 641 O
a NCT03868163 642 643 O
concurrent NCT03868163 644 654 O
interventional NCT03868163 655 669 O
therapeutic NCT03868163 670 681 B-Procedure
trial NCT03868163 682 687 B-Study
. NCT03868163 688 689 O

Exclusion NCT03868163 691 700 O
Criteria NCT03868163 701 709 O
: NCT03868163 710 711 O

- NCT03868163 715 716 O
None NCT03868163 718 722 O
. NCT03868163 722 723 O

Inclusion NCT03868605 0 9 O
Criteria NCT03868605 10 18 O
: NCT03868605 19 20 O

- NCT03868605 24 25 O
age NCT03868605 27 30 B-Age
≥ NCT03868605 31 32 B-Eq-Comparison
18 NCT03868605 33 35 I-Eq-Comparison
years NCT03868605 36 41 I-Eq-Comparison

- NCT03868605 44 45 O
colorectal NCT03868605 47 57 B-Modifier
lesions NCT03868605 58 65 B-Condition|Observation
of NCT03868605 66 68 O
10 NCT03868605 69 71 B-Eq-Comparison
- NCT03868605 72 73 I-Eq-Comparison
25 NCT03868605 74 76 I-Eq-Comparison
mm NCT03868605 77 79 I-Eq-Comparison
size NCT03868605 80 84 O
with NCT03868605 85 89 B-And
positive NCT03868605 90 98 O
non NCT03868605 99 102 B-Negation
- NCT03868605 103 104 O
lifting NCT03868605 105 112 B-Modifier
sign NCT03868605 113 117 B-Condition

- NCT03868605 120 121 O
signed NCT03868605 123 129 O
informed NCT03868605 130 138 O
consent NCT03868605 139 146 O
with NCT03868605 147 151 O
the NCT03868605 152 155 O
study NCT03868605 156 161 B-Study
and NCT03868605 162 165 O
with NCT03868605 166 170 O
colonoscopy NCT03868605 171 182 B-Procedure

Exclusion NCT03868605 183 192 O
Criteria NCT03868605 193 201 O
: NCT03868605 202 203 O

- NCT03868605 207 208 O
age NCT03868605 210 213 B-Age
< NCT03868605 214 215 B-Eq-Comparison
18 NCT03868605 216 218 I-Eq-Comparison
years NCT03868605 219 224 I-Eq-Comparison

- NCT03868605 227 228 O
lesions NCT03868605 230 237 B-Condition|Observation
> NCT03868605 238 239 B-Eq-Comparison
25 NCT03868605 240 242 I-Eq-Comparison
mm NCT03868605 243 245 I-Eq-Comparison

- NCT03868605 248 249 O
pedunculated NCT03868605 251 263 B-Condition
polyps NCT03868605 264 270 I-Condition

- NCT03868605 273 274 O
colorectal NCT03868605 276 286 B-Condition
stenosis NCT03868605 287 295 I-Condition

- NCT03868605 298 299 O
colonoscopy NCT03868605 301 312 B-Procedure
contraindication NCT03868605 313 329 B-Contraindication

- NCT03868605 332 333 O
severe NCT03868605 335 341 O
acute NCT03868605 342 347 O
inflammatory NCT03868605 348 360 B-Condition
bowel NCT03868605 361 366 I-Condition
disease NCT03868605 367 374 I-Condition

- NCT03868605 377 378 O
severe NCT03868605 380 386 O
comorbidities NCT03868605 387 400 B-Condition

- NCT03868605 403 404 O
patient NCT03868605 406 413 O
not NCT03868605 414 417 O
able NCT03868605 418 422 O
to NCT03868605 423 425 O
sign NCT03868605 426 430 O
the NCT03868605 431 434 O
informed NCT03868605 435 443 O
consent NCT03868605 444 451 O

Inclusion NCT03860259 0 9 O
Criteria NCT03860259 10 18 O
: NCT03860259 19 20 O

1 NCT03860259 24 25 O
. NCT03860259 25 26 O
Subject NCT03860259 28 35 O
is NCT03860259 36 38 O
greater NCT03860259 39 46 B-Eq-Comparison
than NCT03860259 47 51 I-Eq-Comparison
18 NCT03860259 52 54 I-Eq-Comparison
years NCT03860259 55 60 I-Eq-Comparison
of NCT03860259 61 63 O
age NCT03860259 64 67 B-Age

2 NCT03860259 70 71 O
. NCT03860259 71 72 O
Subject NCT03860259 74 81 O
is NCT03860259 82 84 O
willing NCT03860259 85 92 O
and NCT03860259 93 96 O
able NCT03860259 97 101 O
to NCT03860259 102 104 O
provide NCT03860259 105 112 O
informed NCT03860259 113 121 O
consent NCT03860259 122 129 O

3 NCT03860259 132 133 O
. NCT03860259 133 134 O
Subject NCT03860259 136 143 O
is NCT03860259 144 146 O
scheduled NCT03860259 147 156 B-Eq-Comparison
to NCT03860259 157 159 O
undergo NCT03860259 160 167 O
elective NCT03860259 168 176 B-Modifier
rotator NCT03860259 177 184 B-Procedure
cuff NCT03860259 185 189 I-Procedure
surgery NCT03860259 190 197 I-Procedure

4 NCT03860259 200 201 O
. NCT03860259 201 202 O
Subject NCT03860259 204 211 O
has NCT03860259 212 215 O
consented NCT03860259 216 225 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860259 226 228 I-Assertion___Assertion-Type-Value:hypothetical
an NCT03860259 229 231 O
interscalene NCT03860259 232 244 B-Procedure
block NCT03860259 245 250 I-Procedure

Exclusion NCT03860259 251 260 O
Criteria NCT03860259 261 269 O
: NCT03860259 270 271 O

1 NCT03860259 275 276 O
. NCT03860259 276 277 O
Opioid NCT03860259 279 285 B-Condition
dependence NCT03860259 286 296 I-Condition

2 NCT03860259 299 300 O
. NCT03860259 300 301 O
Any NCT03860259 303 306 O
subject NCT03860259 307 314 O
diagnosed NCT03860259 315 324 O
with NCT03860259 325 329 O
a NCT03860259 330 331 O
chronic NCT03860259 332 339 B-Modifier
pain NCT03860259 340 344 B-Condition
condition NCT03860259 345 354 I-Condition
which NCT03860259 355 360 O
daily NCT03860259 361 366 B-Eq-Comparison
opioid NCT03860259 367 373 B-Drug
use NCT03860259 374 377 O
is NCT03860259 378 380 O
needed NCT03860259 381 387 O

3 NCT03860259 390 391 O
. NCT03860259 391 392 O
Anatomical NCT03860259 394 404 B-Condition
malformation NCT03860259 405 417 I-Condition
, NCT03860259 418 419 O
which NCT03860259 420 425 O
in NCT03860259 426 428 O
the NCT03860259 429 432 O
investigator NCT03860259 433 445 O
's NCT03860259 445 447 O
opinion NCT03860259 448 455 O
may NCT03860259 456 459 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860259 460 469 O
with NCT03860259 470 474 O
the NCT03860259 475 478 O
placement NCT03860259 479 488 O
of NCT03860259 489 491 O
the NCT03860259 492 495 O
nerve NCT03860259 496 501 B-Procedure
block NCT03860259 502 507 I-Procedure

4 NCT03860259 510 511 O
. NCT03860259 511 512 O
Raynaud NCT03860259 514 521 B-Condition
's NCT03860259 521 523 I-Condition
disease NCT03860259 524 531 I-Condition
diagnosis NCT03860259 532 541 O

5 NCT03860259 544 545 O
. NCT03860259 545 546 O
Vasculopathy NCT03860259 548 560 B-Condition

6 NCT03860259 563 564 O
. NCT03860259 564 565 O
Patient NCT03860259 567 574 O
refusal NCT03860259 575 582 O

Inclusion NCT03869554 0 9 O
Criteria NCT03869554 10 18 O
: NCT03869554 19 20 O

- NCT03869554 24 25 O
Adult NCT03869554 27 32 O
patient NCT03869554 33 40 O
( NCT03869554 41 42 O
> NCT03869554 44 45 B-Eq-Comparison
18 NCT03869554 46 48 I-Eq-Comparison
years NCT03869554 49 54 I-Eq-Comparison
old NCT03869554 55 58 B-Age
) NCT03869554 59 60 O

- NCT03869554 64 65 O
Obtaining NCT03869554 67 76 O
consent NCT03869554 77 84 O
to NCT03869554 85 87 O
participate NCT03869554 88 99 O
in NCT03869554 100 102 O
the NCT03869554 103 106 O
study NCT03869554 107 112 O

- NCT03869554 115 116 O
Patients NCT03869554 118 126 O
whose NCT03869554 127 132 O
clinical NCT03869554 133 141 O
presentation NCT03869554 142 154 O
meets NCT03869554 155 160 O
at NCT03869554 161 163 B-Eq-Comparison
least NCT03869554 164 169 I-Eq-Comparison
one NCT03869554 170 173 I-Eq-Comparison
of NCT03869554 174 176 O
the NCT03869554 177 180 B-Criteria-Count
following NCT03869554 181 190 I-Criteria-Count
criteria NCT03869554 191 199 I-Criteria-Count
: NCT03869554 200 201 O

- NCT03869554 210 211 O
Undetermined NCT03869554 213 225 B-Modifier
nephropathy NCT03869554 226 237 B-Condition
despite NCT03869554 238 245 B-And
renal NCT03869554 246 251 B-Procedure
biopsy NCT03869554 252 258 I-Procedure
, NCT03869554 259 260 O

- NCT03869554 269 270 O
Nephroangiosclerosis NCT03869554 272 292 B-Condition
as NCT03869554 293 295 O
the NCT03869554 296 299 O
predominant NCT03869554 300 311 B-Modifier
lesion NCT03869554 312 318 B-Condition

- NCT03869554 326 327 O
Chronic NCT03869554 329 336 B-Modifier
tubulointerstitial NCT03869554 337 355 I-Modifier
nephropathy NCT03869554 356 367 B-Condition
, NCT03869554 368 369 O

- NCT03869554 378 379 O
Glomerulosclerosis NCT03869554 381 399 B-Condition
, NCT03869554 400 401 O

- NCT03869554 410 411 O
Segmental NCT03869554 413 422 B-Modifier
and NCT03869554 423 426 B-Or
focal NCT03869554 427 432 B-Modifier
hyalinosis NCT03869554 433 443 B-Condition
. NCT03869554 444 445 O

- NCT03869554 454 455 O
Optically NCT03869554 457 466 O
normal NCT03869554 467 473 O
kidney NCT03869554 474 480 B-Modifier
or NCT03869554 481 483 B-Or
seat NCT03869554 484 488 B-Modifier
of NCT03869554 489 491 I-Modifier
minimal NCT03869554 492 499 I-Modifier
lesions NCT03869554 500 507 B-Condition

Exclusion NCT03869554 508 517 O
Criteria NCT03869554 518 526 O
: NCT03869554 527 528 O

- NCT03869554 532 533 O
Patient NCT03869554 535 542 O
who NCT03869554 543 546 O
has NCT03869554 547 550 O
already NCT03869554 551 558 B-Eq-Comparison
been NCT03869554 559 563 O
screened NCT03869554 564 572 B-Procedure
for NCT03869554 573 576 O
Fabry NCT03869554 577 582 B-Condition
Disease NCT03869554 583 590 I-Condition

- NCT03869554 593 594 O
At NCT03869554 596 598 B-Eq-Comparison
least NCT03869554 599 604 I-Eq-Comparison
one NCT03869554 605 608 I-Eq-Comparison
of NCT03869554 609 611 O
the NCT03869554 612 615 B-Criteria-Count
following NCT03869554 616 625 I-Criteria-Count
criteria NCT03869554 626 634 I-Criteria-Count
: NCT03869554 635 636 O

- NCT03869554 645 646 O
Nephrotic NCT03869554 648 657 B-Condition
syndrome NCT03869554 658 666 I-Condition
and NCT03869554 667 670 B-Or
/ NCT03869554 671 672 I-Or
or NCT03869554 673 675 I-Or
Glomerular NCT03869554 676 686 B-Modifier
nephropathy NCT03869554 687 698 B-Condition

- NCT03869554 706 707 O
Histological NCT03869554 709 721 B-Procedure
diagnosis NCT03869554 722 731 O
of NCT03869554 732 734 O
certain NCT03869554 735 742 O
nephropathies NCT03869554 743 756 B-Condition
( NCT03869554 757 758 O
specific NCT03869554 759 767 O
kidney NCT03869554 768 774 B-Modifier
lesions NCT03869554 775 782 B-Condition
) NCT03869554 783 784 O

Inclusion NCT03865420 0 9 O
Criteria NCT03865420 10 18 O
: NCT03865420 19 20 O

- NCT03865420 24 25 O
Men NCT03865420 27 30 O
or NCT03865420 31 33 B-Or
women NCT03865420 34 39 O
of NCT03865420 40 42 O
any NCT03865420 43 46 O
race NCT03865420 47 51 O
or NCT03865420 52 54 O
ethnicity NCT03865420 55 64 O
aged NCT03865420 65 69 B-Age
18 NCT03865420 70 72 B-Eq-Comparison
or NCT03865420 73 75 I-Eq-Comparison
older NCT03865420 76 81 I-Eq-Comparison

- NCT03865420 84 85 O
No NCT03865420 87 89 B-Negation
symptoms NCT03865420 90 98 B-Assertion___Assertion-Type-Value:possible
of NCT03865420 99 101 O
ALS NCT03865420 102 105 B-Condition
or NCT03865420 106 108 B-Or
fronto NCT03865420 109 115 B-Modifier
- NCT03865420 116 117 I-Modifier
temporal NCT03865420 118 126 I-Modifier
dementia NCT03865420 127 135 B-Condition
at NCT03865420 136 138 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrollment NCT03865420 139 149 B-Study

- NCT03865420 152 153 O
Have NCT03865420 155 159 O
a NCT03865420 160 161 O
first NCT03865420 162 167 B-Family-Member
degree NCT03865420 168 174 I-Family-Member
relative NCT03865420 175 183 I-Family-Member
who NCT03865420 184 187 O
had NCT03865420 188 191 O
an NCT03865420 192 194 O
ALS NCT03865420 195 198 B-Condition
- NCT03865420 199 200 O
spectrum NCT03865420 201 209 O
diagnosis NCT03865420 210 219 O
with NCT03865420 220 224 B-And
a NCT03865420 225 226 O
confirmed NCT03865420 227 236 O
ALS NCT03865420 237 240 B-Condition
- NCT03865420 241 242 I-Condition
spectrum NCT03865420 243 251 I-Condition
gene NCT03865420 252 256 I-Condition
mutation NCT03865420 257 265 I-Condition
; NCT03865420 265 266 O
or NCT03865420 267 269 B-Or
already NCT03865420 270 277 B-Eq-Comparison
have NCT03865420 278 282 O
had NCT03865420 283 286 O
genetic NCT03865420 287 294 B-Procedure
testing NCT03865420 295 302 I-Procedure
and NCT03865420 303 306 B-And
have NCT03865420 307 311 O
tested NCT03865420 312 318 B-Observation
positive NCT03865420 319 327 O
for NCT03865420 328 331 O
an NCT03865420 332 334 O
ALS NCT03865420 335 338 B-Condition
- NCT03865420 339 340 I-Condition
spectrum NCT03865420 341 349 I-Condition
gene NCT03865420 350 354 I-Condition
mutation NCT03865420 355 363 I-Condition
. NCT03865420 364 365 O

- NCT03865420 369 370 O
Willing NCT03865420 372 379 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865420 380 382 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03865420 383 390 O
genetic NCT03865420 391 398 B-Procedure
testing NCT03865420 399 406 I-Procedure
with NCT03865420 407 411 O
option NCT03865420 412 418 O
of NCT03865420 419 421 O
whether NCT03865420 422 429 O
or NCT03865420 430 432 O
not NCT03865420 433 436 O
to NCT03865420 437 439 O
learn NCT03865420 440 445 O
results NCT03865420 446 453 O

- NCT03865420 456 457 O
Willing NCT03865420 459 466 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865420 467 469 I-Assertion___Assertion-Type-Value:hypothetical
travel NCT03865420 470 476 O
to NCT03865420 477 479 O
Columbia NCT03865420 480 488 O
University NCT03865420 489 499 O
Irving NCT03865420 500 506 O
Medical NCT03865420 507 514 O
Center NCT03865420 515 521 O
( NCT03865420 522 523 O
CUIMC NCT03865420 524 529 O
) NCT03865420 530 531 O
every NCT03865420 532 537 B-Eq-Comparison
6 NCT03865420 538 539 I-Eq-Comparison
- NCT03865420 540 541 I-Eq-Comparison
24 NCT03865420 542 544 I-Eq-Comparison
months NCT03865420 545 551 I-Eq-Comparison
for NCT03865420 552 555 O
study NCT03865420 556 561 B-Study
procedures NCT03865420 562 572 O

- NCT03865420 575 576 O
Capable NCT03865420 578 585 O
of NCT03865420 586 588 O
providing NCT03865420 589 598 O
informed NCT03865420 599 607 O
consent NCT03865420 608 615 O
and NCT03865420 616 619 O
following NCT03865420 620 629 O
study NCT03865420 630 635 O
procedures NCT03865420 636 646 O
, NCT03865420 647 648 O
or NCT03865420 649 651 O
has NCT03865420 652 655 O
a NCT03865420 656 657 O
legally NCT03865420 658 665 O
authorized NCT03865420 666 676 O
representative NCT03865420 677 691 O
who NCT03865420 692 695 O
is NCT03865420 696 698 O
able NCT03865420 699 703 O
to NCT03865420 704 706 O
consent NCT03865420 707 714 O
for NCT03865420 715 718 O
the NCT03865420 719 722 O
subject NCT03865420 723 730 O
. NCT03865420 731 732 O

Exclusion NCT03865420 734 743 O
Criteria NCT03865420 744 752 O
: NCT03865420 753 754 O

- NCT03865420 758 759 O
Known NCT03865420 761 766 O
HIV NCT03865420 767 770 B-Condition

- NCT03865420 773 774 O
Known NCT03865420 776 781 O
hepatitis NCT03865420 782 791 B-Condition
B NCT03865420 792 793 I-Condition

- NCT03865420 796 797 O
Known NCT03865420 799 804 O
hepatitis NCT03865420 805 814 B-Condition
C NCT03865420 815 816 I-Condition

Inclusion NCT03863938 0 9 O
Criteria NCT03863938 10 18 O
: NCT03863938 19 20 O

- NCT03863938 24 25 O
Healthy NCT03863938 27 34 B-Condition
adult NCT03863938 35 40 O
males NCT03863938 41 46 O
aged NCT03863938 47 51 B-Age
≥ NCT03863938 52 53 B-Eq-Comparison
19 NCT03863938 54 56 I-Eq-Comparison
years NCT03863938 57 62 I-Eq-Comparison
and NCT03863938 63 66 B-And
≤ NCT03863938 67 68 B-Eq-Comparison
50 NCT03863938 69 71 I-Eq-Comparison
years NCT03863938 72 77 I-Eq-Comparison

- NCT03863938 80 81 O
Body NCT03863938 83 87 B-Observation
weight NCT03863938 88 94 I-Observation
of NCT03863938 95 97 O
≥ NCT03863938 98 99 B-Eq-Comparison
55.0 NCT03863938 100 104 I-Eq-Comparison
kg NCT03863938 105 107 I-Eq-Comparison
and NCT03863938 108 111 B-And
≤ NCT03863938 112 113 B-Eq-Comparison
90.0 NCT03863938 114 118 I-Eq-Comparison
kg NCT03863938 119 121 I-Eq-Comparison
, NCT03863938 122 123 O
with NCT03863938 124 128 B-And
body NCT03863938 129 133 B-Observation
mass NCT03863938 134 138 I-Observation
index NCT03863938 139 144 I-Observation
( NCT03863938 145 146 O
BMI NCT03863938 147 150 B-Observation
) NCT03863938 151 152 O
of NCT03863938 153 155 O
≥ NCT03863938 156 157 B-Eq-Comparison
18.0 NCT03863938 158 162 I-Eq-Comparison
kg NCT03863938 163 165 I-Eq-Comparison
/ NCT03863938 166 167 I-Eq-Comparison
m2 NCT03863938 168 170 I-Eq-Comparison
and NCT03863938 171 174 B-And
≤ NCT03863938 175 176 B-Eq-Comparison
27.0 NCT03863938 177 181 I-Eq-Comparison
kg NCT03863938 182 184 I-Eq-Comparison
/ NCT03863938 185 186 I-Eq-Comparison
m2 NCT03863938 187 189 I-Eq-Comparison
at NCT03863938 190 192 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863938 193 196 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03863938 197 201 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863938 202 204 O
screening NCT03863938 205 214 B-Study

- NCT03863938 217 218 O
Helicobacter NCT03863938 220 232 B-Organism
pylori NCT03863938 233 239 I-Organism
negative NCT03863938 240 248 O

Exclusion NCT03863938 249 258 O
Criteria NCT03863938 259 267 O
: NCT03863938 268 269 O

- NCT03863938 273 274 O
Presence NCT03863938 276 284 B-Eq-Comparison
or NCT03863938 285 287 B-Or
history NCT03863938 288 295 B-Eq-Comparison
of NCT03863938 296 298 O
clinically NCT03863938 299 309 O
significant NCT03863938 310 321 O
diseases NCT03863938 322 330 B-Condition

- NCT03863938 333 334 O
Presence NCT03863938 336 344 B-Eq-Comparison
or NCT03863938 345 347 B-Or
history NCT03863938 348 355 B-Eq-Comparison
of NCT03863938 356 358 O
gastrointestinal NCT03863938 359 375 B-Condition
disorder NCT03863938 376 384 I-Condition
( NCT03863938 385 386 O
gastric NCT03863938 387 394 B-Condition
ulcer NCT03863938 395 400 I-Condition
, NCT03863938 401 402 O
GERD NCT03863938 403 407 B-Condition
, NCT03863938 408 409 O
Crohn NCT03863938 410 415 B-Condition
's NCT03863938 415 417 I-Condition
disease NCT03863938 418 425 I-Condition
, NCT03863938 426 427 O
etc NCT03863938 428 431 O
. NCT03863938 431 432 O
) NCT03863938 433 434 O

- NCT03863938 438 439 O
Hypersensitivity NCT03863938 441 457 B-Condition
to NCT03863938 458 460 O
drugs NCT03863938 461 466 B-Drug
containing NCT03863938 467 477 O
study NCT03863938 478 483 B-Study
drug NCT03863938 484 488 B-Drug
or NCT03863938 489 491 B-Or
proton NCT03863938 492 498 B-Drug
pump NCT03863938 499 503 I-Drug
inhibitor NCT03863938 504 513 I-Drug
and NCT03863938 514 517 B-Or
other NCT03863938 518 523 B-Other
drugs NCT03863938 524 529 B-Drug
( NCT03863938 530 531 O
aspirin NCT03863938 532 539 B-Drug
, NCT03863938 540 541 O
antibiotics NCT03863938 542 553 B-Drug
, NCT03863938 554 555 O
etc NCT03863938 556 559 O
. NCT03863938 559 560 O
) NCT03863938 561 562 O
or NCT03863938 563 565 B-Or
history NCT03863938 566 573 B-Eq-Comparison
of NCT03863938 574 576 O
clinically NCT03863938 577 587 O
significant NCT03863938 588 599 O
hypersensitivity NCT03863938 600 616 B-Condition

- NCT03863938 619 620 O
Serologic NCT03863938 622 631 B-Observation
test NCT03863938 632 636 I-Observation
positive NCT03863938 637 645 O

- NCT03863938 648 649 O
Abnormal NCT03863938 651 659 O
obstacle NCT03863938 660 668 O
to NCT03863938 669 671 O
insertion NCT03863938 672 681 B-Procedure
and NCT03863938 682 685 B-And
maintenance NCT03863938 686 697 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03863938 698 700 O
pH NCT03863938 701 703 B-Procedure
meter NCT03863938 704 709 I-Procedure
catheter NCT03863938 710 718 I-Procedure

- NCT03863938 721 722 O
History NCT03863938 724 731 B-Eq-Comparison
of NCT03863938 732 734 O
drug NCT03863938 735 739 B-Condition
abuse NCT03863938 740 745 I-Condition

- NCT03863938 748 749 O
Excessive NCT03863938 751 760 O
caffeine NCT03863938 761 769 B-Drug
intake NCT03863938 770 776 O
or NCT03863938 777 779 B-Or
persistent NCT03863938 780 790 B-Modifier
alcohol NCT03863938 791 798 B-Drug
intake NCT03863938 799 805 O

- NCT03863938 808 809 O
Not NCT03863938 811 814 B-Negation
use NCT03863938 815 818 O
of NCT03863938 819 821 O
a NCT03863938 822 823 O
medically NCT03863938 824 833 O
acceptable NCT03863938 834 844 O
method NCT03863938 845 851 O
of NCT03863938 852 854 O
contraception NCT03863938 855 868 B-Procedure

Inclusion NCT03863509 0 9 O
Criteria NCT03863509 10 18 O
: NCT03863509 19 20 O

- NCT03863509 24 25 O
able NCT03863509 27 31 O
to NCT03863509 32 34 O
read NCT03863509 35 39 O
and NCT03863509 40 43 O
write NCT03863509 44 49 O
English NCT03863509 50 57 O

- NCT03863509 60 61 O
no NCT03863509 63 65 B-Negation
plans NCT03863509 66 71 B-Assertion___Assertion-Type-Value:intention
to NCT03863509 72 74 O
quit NCT03863509 75 79 B-Negation
smoking NCT03863509 80 87 B-Condition
and NCT03863509 88 91 B-Or
/ NCT03863509 92 93 I-Eq-Comparison|Or
or NCT03863509 94 96 I-Or
e NCT03863509 97 98 B-Drug
- NCT03863509 99 100 I-Drug
cig NCT03863509 101 104 I-Drug
use NCT03863509 105 108 O
in NCT03863509 109 111 O
the NCT03863509 112 115 O
next NCT03863509 116 120 B-Eq-Comparison
month NCT03863509 121 126 I-Eq-Comparison

- NCT03863509 129 130 O
not NCT03863509 132 135 B-Negation
using NCT03863509 136 141 B-Eq-Comparison
cigars NCT03863509 142 148 B-Drug
/ NCT03863509 149 150 B-Or
smokeless NCT03863509 151 160 B-Drug
/ NCT03863509 161 162 B-Or
snus NCT03863509 163 167 B-Drug
tobacco NCT03863509 168 175 I-Drug
> NCT03863509 176 177 B-Eq-Comparison
/ NCT03863509 179 180 O
= NCT03863509 182 183 I-Eq-Comparison
1 NCT03863509 184 185 I-Eq-Comparison
time NCT03863509 186 190 I-Eq-Comparison
per NCT03863509 191 194 I-Eq-Comparison
week NCT03863509 195 199 I-Eq-Comparison

- NCT03863509 202 203 O
having NCT03863509 205 211 O
a NCT03863509 212 213 O
stable NCT03863509 214 220 O
pattern NCT03863509 221 228 O
of NCT03863509 229 231 O
current NCT03863509 232 239 B-Eq-Comparison
product NCT03863509 240 247 B-Drug
use NCT03863509 248 251 I-Drug

- NCT03863509 254 255 O
able NCT03863509 257 261 B-Condition|Observation
to NCT03863509 262 264 I-Condition|Observation
walk NCT03863509 265 269 I-Condition|Observation
at NCT03863509 270 272 B-Eq-Comparison
least NCT03863509 273 278 I-Eq-Comparison
2 NCT03863509 279 280 I-Eq-Comparison
blocks NCT03863509 281 287 I-Eq-Comparison
without NCT03863509 288 295 B-Negation
assistance NCT03863509 296 306 B-Modifier
or NCT03863509 307 309 B-Or
stopping NCT03863509 310 318 B-Modifier

- NCT03863509 321 322 O
Specific NCT03863509 324 332 O
to NCT03863509 333 335 O
Exclusive NCT03863509 336 345 O
Smokers NCT03863509 346 353 B-Condition
: NCT03863509 354 355 O

- NCT03863509 364 365 O
smokes NCT03863509 367 373 B-Condition
daily NCT03863509 374 379 B-Eq-Comparison

- NCT03863509 387 388 O
> NCT03863509 390 391 O
/ NCT03863509 393 394 O
= NCT03863509 396 397 O
5 NCT03863509 398 399 I-Eq-Comparison
cigs NCT03863509 400 404 I-Drug|Eq-Comparison
/ NCT03863509 405 406 O
day NCT03863509 407 410 I-Eq-Comparison
for NCT03863509 411 414 O
last NCT03863509 415 419 B-Eq-Comparison
6 NCT03863509 420 421 I-Eq-Comparison
months NCT03863509 422 428 I-Eq-Comparison

- NCT03863509 436 437 O
< NCT03863509 439 440 B-Eq-Comparison
3 NCT03863509 441 442 I-Eq-Comparison
uses NCT03863509 443 447 O
E NCT03863509 448 449 B-Observation
- NCT03863509 450 451 I-Observation
cigs NCT03863509 452 456 I-Observation
in NCT03863509 457 459 O
lifetime NCT03863509 460 468 B-Eq-Comparison

- NCT03863509 476 477 O
> NCT03863509 479 480 O
/ NCT03863509 482 483 O
= NCT03863509 485 486 O
5 NCT03863509 487 488 O
ppm NCT03863509 489 492 I-Eq-Comparison
carbon NCT03863509 493 499 B-Observation
monoxide NCT03863509 500 508 I-Observation
( NCT03863509 509 510 O
CO NCT03863509 511 513 B-Observation
) NCT03863509 514 515 O

- NCT03863509 524 525 O
Cotinine NCT03863509 527 535 B-Observation
> NCT03863509 536 537 B-Eq-Comparison
100 NCT03863509 538 541 I-Eq-Comparison
ng NCT03863509 542 544 I-Eq-Comparison
/ NCT03863509 545 546 I-Eq-Comparison
ml NCT03863509 547 549 I-Eq-Comparison

- NCT03863509 552 553 O
Specific NCT03863509 555 563 O
to NCT03863509 564 566 O
Exclusive NCT03863509 567 576 O
E NCT03863509 577 578 B-Drug
- NCT03863509 579 580 I-Drug
cig NCT03863509 581 584 I-Drug
users NCT03863509 585 590 O
: NCT03863509 591 592 O

- NCT03863509 601 602 O
< NCT03863509 604 605 O
/ NCT03863509 607 608 O
= NCT03863509 610 611 O
2 NCT03863509 612 613 O
days NCT03863509 614 618 I-Eq-Comparison
per NCT03863509 619 622 O
month NCT03863509 623 628 O
cigarette NCT03863509 629 638 B-Drug
use NCT03863509 639 642 O
for NCT03863509 643 646 O
last NCT03863509 647 651 B-Eq-Comparison
6 NCT03863509 652 653 I-Eq-Comparison
months NCT03863509 654 660 I-Eq-Comparison

- NCT03863509 668 669 O
> NCT03863509 671 672 O
/ NCT03863509 674 675 O
= NCT03863509 677 678 O
5 NCT03863509 679 680 O
days NCT03863509 681 685 O
per NCT03863509 686 689 O
week NCT03863509 690 694 O
E NCT03863509 695 696 B-Drug
- NCT03863509 697 698 I-Drug
cig NCT03863509 699 702 I-Drug
use NCT03863509 703 706 O
for NCT03863509 707 710 O
last NCT03863509 711 715 B-Eq-Comparison
3 NCT03863509 716 717 I-Eq-Comparison
months NCT03863509 718 724 I-Eq-Comparison

- NCT03863509 732 733 O
< NCT03863509 735 736 O
/ NCT03863509 738 739 O
= NCT03863509 741 742 O
4 NCT03863509 743 744 I-Eq-Comparison
ppm NCT03863509 745 748 O
CO NCT03863509 749 751 B-Observation

- NCT03863509 759 760 O
Cotinine NCT03863509 762 770 B-Observation
> NCT03863509 771 772 B-Eq-Comparison
100 NCT03863509 773 776 I-Eq-Comparison
ng NCT03863509 777 779 I-Eq-Comparison
/ NCT03863509 780 781 I-Eq-Comparison
ml NCT03863509 782 784 I-Eq-Comparison

- NCT03863509 787 788 O
Specific NCT03863509 790 798 O
to NCT03863509 799 801 O
Dual NCT03863509 802 806 O
users NCT03863509 807 812 O

- NCT03863509 820 821 O
> NCT03863509 823 824 O
/ NCT03863509 826 827 O
= NCT03863509 829 830 O
5 NCT03863509 831 832 O
cigs NCT03863509 833 837 B-Drug
/ NCT03863509 838 839 O
day NCT03863509 840 843 O
for NCT03863509 844 847 O
last NCT03863509 848 852 B-Eq-Comparison
6 NCT03863509 853 854 I-Eq-Comparison
months NCT03863509 855 861 I-Eq-Comparison

- NCT03863509 869 870 O
> NCT03863509 872 873 O
/ NCT03863509 875 876 O
= NCT03863509 878 879 O
5 NCT03863509 880 881 O
days NCT03863509 882 886 O
per NCT03863509 887 890 O
week NCT03863509 891 895 O
E NCT03863509 896 897 B-Drug
- NCT03863509 898 899 I-Drug
cig NCT03863509 900 903 I-Drug
use NCT03863509 904 907 O
for NCT03863509 908 911 O
last NCT03863509 912 916 B-Eq-Comparison
3 NCT03863509 917 918 I-Eq-Comparison
months NCT03863509 919 925 I-Eq-Comparison

- NCT03863509 933 934 O
> NCT03863509 936 937 O
/ NCT03863509 939 940 O
= NCT03863509 942 943 O
5 NCT03863509 944 945 O
ppm NCT03863509 946 949 O
CO NCT03863509 950 952 B-Observation

- NCT03863509 960 961 O
Continine NCT03863509 963 972 B-Observation
> NCT03863509 973 974 B-Eq-Comparison
100 NCT03863509 975 978 I-Eq-Comparison
ng NCT03863509 979 981 I-Eq-Comparison
/ NCT03863509 982 983 I-Eq-Comparison
ml NCT03863509 984 986 I-Eq-Comparison

- NCT03863509 989 990 O
Specific NCT03863509 992 1000 O
to NCT03863509 1001 1003 O
Never NCT03863509 1004 1009 O
- NCT03863509 1010 1011 O
users NCT03863509 1012 1017 O

- NCT03863509 1025 1026 O
< NCT03863509 1028 1029 B-Eq-Comparison
100 NCT03863509 1030 1033 I-Eq-Comparison
cigarettes NCT03863509 1034 1044 B-Drug
in NCT03863509 1045 1047 O
a NCT03863509 1048 1049 O
lifetime NCT03863509 1050 1058 B-Eq-Comparison
, NCT03863509 1059 1060 O
none NCT03863509 1061 1065 B-Eq-Comparison
for NCT03863509 1066 1069 O
> NCT03863509 1070 1071 B-Eq-Comparison
5 NCT03863509 1072 1073 I-Eq-Comparison
years NCT03863509 1074 1079 I-Eq-Comparison

- NCT03863509 1087 1088 O
< NCT03863509 1090 1091 B-Eq-Comparison
3 NCT03863509 1092 1093 I-Eq-Comparison
E NCT03863509 1094 1095 B-Drug
- NCT03863509 1096 1097 I-Drug
cig NCT03863509 1098 1101 I-Drug
uses NCT03863509 1102 1106 O
in NCT03863509 1107 1109 O
a NCT03863509 1110 1111 O
lifetime NCT03863509 1112 1120 B-Eq-Comparison

- NCT03863509 1128 1129 O
< NCT03863509 1131 1132 O
/ NCT03863509 1134 1135 O
= NCT03863509 1137 1138 O
4 NCT03863509 1139 1140 O
ppm NCT03863509 1141 1144 O
CO NCT03863509 1145 1147 B-Observation

- NCT03863509 1155 1156 O
Continine NCT03863509 1158 1167 B-Observation
< NCT03863509 1168 1169 B-Eq-Comparison
100 NCT03863509 1170 1173 I-Eq-Comparison
ng NCT03863509 1174 1176 I-Eq-Comparison
/ NCT03863509 1177 1178 I-Eq-Comparison
ml NCT03863509 1179 1181 I-Eq-Comparison

Exclusion NCT03863509 1182 1191 O
Criteria NCT03863509 1192 1200 O
: NCT03863509 1201 1202 O

- NCT03863509 1206 1207 O
current NCT03863509 1209 1216 B-Eq-Comparison
use NCT03863509 1217 1220 O
of NCT03863509 1221 1223 O
a NCT03863509 1224 1225 O
smoking NCT03863509 1226 1233 B-Drug
cessation NCT03863509 1234 1243 I-Drug
medication NCT03863509 1244 1254 I-Drug

- NCT03863509 1257 1258 O
women NCT03863509 1260 1265 O
who NCT03863509 1266 1269 B-And
are NCT03863509 1270 1273 O
pregnant NCT03863509 1274 1282 B-Condition
or NCT03863509 1283 1285 B-Or
plan NCT03863509 1286 1290 B-Assertion___Assertion-Type-Value:intention
to NCT03863509 1291 1293 I-Assertion___Assertion-Type-Value:intention
get NCT03863509 1294 1297 O
pregnant NCT03863509 1298 1306 B-Condition
in NCT03863509 1307 1309 O
the NCT03863509 1310 1313 O
coming NCT03863509 1314 1320 B-Eq-Comparison
month NCT03863509 1321 1326 I-Eq-Comparison

- NCT03863509 1329 1330 O
women NCT03863509 1332 1337 O
who NCT03863509 1338 1341 B-And
might NCT03863509 1342 1347 B-Assertion___Assertion-Type-Value:possible
be NCT03863509 1348 1350 I-Assertion___Assertion-Type-Value:possible
pregnant NCT03863509 1351 1359 B-Condition

- NCT03863509 1362 1363 O
incarcerated NCT03863509 1365 1377 B-Observation
individuals NCT03863509 1378 1389 O

- NCT03863509 1392 1393 O
history NCT03863509 1395 1402 B-Eq-Comparison
of NCT03863509 1403 1405 O
sarcoidosis NCT03863509 1406 1417 B-Condition
in NCT03863509 1418 1420 O
past NCT03863509 1421 1425 B-Eq-Comparison
5 NCT03863509 1426 1427 I-Eq-Comparison
years NCT03863509 1428 1433 I-Eq-Comparison
, NCT03863509 1434 1435 O
or NCT03863509 1436 1438 B-Or
active NCT03863509 1439 1445 B-Eq-Comparison
interstitial NCT03863509 1446 1458 B-Modifier
lung NCT03863509 1459 1463 I-Modifier
/ NCT03863509 1464 1465 B-Or
pulmonary NCT03863509 1466 1475 B-Modifier
fibrosis NCT03863509 1476 1484 B-Condition

Inclusion NCT03860766 0 9 O
Criteria NCT03860766 10 18 O
: NCT03860766 19 20 O

- NCT03860766 24 25 O
Handball NCT03860766 27 35 B-Observation
players NCT03860766 36 43 I-Observation
; NCT03860766 43 44 O

- NCT03860766 47 48 O
Healthy NCT03860766 50 57 B-Condition
; NCT03860766 57 58 O

- NCT03860766 61 62 O
Participation NCT03860766 64 77 O
of NCT03860766 78 80 O
at NCT03860766 81 83 B-Eq-Comparison
least NCT03860766 84 89 I-Eq-Comparison
one NCT03860766 90 93 I-Eq-Comparison
official NCT03860766 94 102 B-Observation
match NCT03860766 103 108 I-Observation
in NCT03860766 109 111 O
the NCT03860766 112 115 O
last NCT03860766 116 120 B-Eq-Comparison
year NCT03860766 121 125 I-Eq-Comparison
and NCT03860766 126 129 B-And
attend NCT03860766 130 136 O
70 NCT03860766 137 139 B-Eq-Comparison
% NCT03860766 140 141 I-Eq-Comparison
of NCT03860766 142 144 O
the NCT03860766 145 148 O
team NCT03860766 149 153 B-Observation
's NCT03860766 153 155 I-Observation
activities NCT03860766 156 166 I-Observation
during NCT03860766 167 173 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860766 174 177 O
current NCT03860766 178 185 B-Eq-Comparison
season NCT03860766 186 192 O
. NCT03860766 193 194 O

Exclusion NCT03860766 196 205 O
Criteria NCT03860766 206 214 O
: NCT03860766 215 216 O

- NCT03860766 220 221 O
musculoskeletal NCT03860766 223 238 B-Modifier
injury NCT03860766 239 245 B-Condition
in NCT03860766 246 248 O
the NCT03860766 249 252 O
last NCT03860766 253 257 B-Eq-Comparison
three NCT03860766 258 263 I-Eq-Comparison
months NCT03860766 264 270 I-Eq-Comparison
; NCT03860766 270 271 O

- NCT03860766 274 275 O
cardiovascular NCT03860766 277 291 B-Condition
diseases NCT03860766 292 300 I-Condition
; NCT03860766 300 301 O

- NCT03860766 304 305 O
use NCT03860766 307 310 O
of NCT03860766 311 313 O
anabolic NCT03860766 314 322 B-Modifier
, NCT03860766 323 324 O
anti NCT03860766 325 329 B-Modifier
- NCT03860766 330 331 I-Modifier
inflammatory NCT03860766 332 344 I-Modifier
and NCT03860766 345 348 B-Or
analgesic NCT03860766 349 358 B-Modifier
drugs NCT03860766 359 364 B-Drug
72 NCT03860766 365 367 B-Eq-Comparison
hours NCT03860766 368 373 I-Eq-Comparison
before NCT03860766 374 380 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860766 381 384 O
evaluations NCT03860766 385 396 B-Study
; NCT03860766 396 397 O

- NCT03860766 400 401 O
use NCT03860766 403 406 O
of NCT03860766 407 409 O
alcohol NCT03860766 410 417 B-Drug
and NCT03860766 418 421 B-Or
illicit NCT03860766 422 429 B-Drug
drugs NCT03860766 430 435 I-Drug
during NCT03860766 436 442 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860766 443 446 O
collection NCT03860766 447 457 B-Study
period NCT03860766 458 464 I-Study
; NCT03860766 464 465 O

Inclusion NCT03866317 0 9 O
Criteria NCT03866317 10 18 O
: NCT03866317 19 20 O

1 NCT03866317 24 25 O
. NCT03866317 25 26 O
Male NCT03866317 28 32 O
or NCT03866317 33 35 B-Or
female NCT03866317 36 42 O
subject NCT03866317 43 50 O
18 NCT03866317 51 53 B-Eq-Comparison
years NCT03866317 54 59 I-Eq-Comparison
of NCT03866317 60 62 I-Eq-Comparison
age NCT03866317 63 66 I-Age|Eq-Comparison
or NCT03866317 67 69 I-Eq-Comparison
older NCT03866317 70 75 I-Eq-Comparison

2 NCT03866317 78 79 O
. NCT03866317 79 80 O
Subjects NCT03866317 82 90 O
with NCT03866317 91 95 O
moderate NCT03866317 96 104 B-Eq-Comparison
to NCT03866317 105 107 I-Eq-Comparison
severe NCT03866317 108 114 I-Eq-Comparison
DLE NCT03866317 115 118 B-Condition
with NCT03866317 119 123 B-And
at NCT03866317 124 126 B-Eq-Comparison
least NCT03866317 127 132 I-Eq-Comparison
one NCT03866317 133 136 I-Eq-Comparison
active NCT03866317 137 143 B-Eq-Comparison
discoid NCT03866317 144 151 B-Modifier
target NCT03866317 152 158 I-Modifier
lesion NCT03866317 159 165 B-Condition|Observation
( NCT03866317 166 167 O
0.5 NCT03866317 168 171 B-Eq-Comparison
- NCT03866317 172 173 I-Eq-Comparison
1.0 NCT03866317 174 177 I-Eq-Comparison
cm2 NCT03866317 178 181 I-Eq-Comparison
) NCT03866317 182 183 O
, NCT03866317 185 186 O
with NCT03866317 187 191 B-And
CLASI NCT03866317 192 197 B-Observation
≥ NCT03866317 198 199 B-Eq-Comparison
5 NCT03866317 200 201 I-Eq-Comparison
. NCT03866317 201 202 O

3 NCT03866317 206 207 O
. NCT03866317 207 208 O
Willingness NCT03866317 210 221 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866317 222 224 O
subject NCT03866317 225 232 O
to NCT03866317 233 235 O
follow NCT03866317 236 242 O
all NCT03866317 243 246 O
study NCT03866317 247 252 B-Study
procedures NCT03866317 253 263 B-Procedure

4 NCT03866317 266 267 O
. NCT03866317 267 268 O
Willingness NCT03866317 270 281 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866317 282 284 I-Assertion___Assertion-Type-Value:hypothetical
avoid NCT03866317 285 290 B-Negation
excessive NCT03866317 291 300 O
exposure NCT03866317 301 309 O
of NCT03866317 310 312 O
diseased NCT03866317 313 321 B-Condition
areas NCT03866317 322 327 O
to NCT03866317 328 330 O
natural NCT03866317 331 338 B-Modifier
or NCT03866317 339 341 B-Or
artificial NCT03866317 342 352 B-Modifier
sunlight NCT03866317 353 361 I-Modifier

Exclusion NCT03866317 362 371 O
Criteria NCT03866317 372 380 O
: NCT03866317 381 382 O

1 NCT03866317 386 387 O
. NCT03866317 387 388 O
Pregnancy NCT03866317 390 399 B-Condition
or NCT03866317 400 402 B-Or
breast NCT03866317 403 409 B-Condition
feeding NCT03866317 410 417 I-Condition

2 NCT03866317 420 421 O
. NCT03866317 421 422 O
Any NCT03866317 424 427 O
condition NCT03866317 428 437 B-Condition
or NCT03866317 438 440 B-Or
therapy NCT03866317 441 448 B-Procedure
that NCT03866317 449 453 O
in NCT03866317 454 456 O
the NCT03866317 457 460 O
investigator NCT03866317 461 473 O
's NCT03866317 473 475 O
opinion NCT03866317 476 483 O
may NCT03866317 484 487 B-Assertion___Assertion-Type-Value:hypothetical
pose NCT03866317 488 492 O
a NCT03866317 493 494 O
risk NCT03866317 495 499 B-Risk
to NCT03866317 500 502 O
the NCT03866317 503 506 O
subject NCT03866317 507 514 O
or NCT03866317 515 517 B-Or
that NCT03866317 518 522 O
could NCT03866317 523 528 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03866317 529 538 O
with NCT03866317 539 543 O
any NCT03866317 544 547 O
evaluation NCT03866317 548 558 O
in NCT03866317 559 561 O
the NCT03866317 562 565 O
study NCT03866317 566 571 B-Study

3 NCT03866317 574 575 O
. NCT03866317 575 576 O
Systemic NCT03866317 578 586 B-Modifier
Lupus NCT03866317 587 592 B-Condition
Erythematosus NCT03866317 593 606 I-Condition
( NCT03866317 607 608 O
SLE NCT03866317 609 612 B-Condition
) NCT03866317 613 614 O
as NCT03866317 615 617 O
defined NCT03866317 618 625 O
by NCT03866317 626 628 O
ACR NCT03866317 629 632 O
criteria NCT03866317 633 641 O

4 NCT03866317 644 645 O
. NCT03866317 645 646 O
Known NCT03866317 648 653 O
hypersensitivity NCT03866317 654 670 B-Condition
to NCT03866317 671 673 O
any NCT03866317 674 677 O
of NCT03866317 678 680 O
the NCT03866317 681 684 O
constituents NCT03866317 685 697 B-Coreference
or NCT03866317 698 700 B-Or
excipients NCT03866317 701 711 B-Coreference
of NCT03866317 712 714 O
the NCT03866317 715 718 O
investigational NCT03866317 719 734 B-Study
product NCT03866317 735 742 B-Drug

5 NCT03866317 745 746 O
. NCT03866317 746 747 O
Use NCT03866317 749 752 B-Eq-Comparison
of NCT03866317 753 755 O
any NCT03866317 756 759 O
prescription NCT03866317 760 772 B-Modifier
or NCT03866317 773 775 B-Or
non NCT03866317 776 779 B-Negation
- NCT03866317 780 781 O
prescription NCT03866317 782 794 B-Modifier
medication NCT03866317 795 805 B-Drug
that NCT03866317 806 810 O
could NCT03866317 811 816 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03866317 817 826 O
with NCT03866317 827 831 O
efficacy NCT03866317 832 840 B-Procedure
evaluations NCT03866317 841 852 I-Procedure
in NCT03866317 853 855 O
the NCT03866317 856 859 O
study NCT03866317 860 865 B-Study

6 NCT03866317 868 869 O
. NCT03866317 869 870 O
Change NCT03866317 872 878 O
in NCT03866317 879 881 O
use NCT03866317 882 885 O
of NCT03866317 886 888 O
systemic NCT03866317 889 897 B-Modifier
DLE NCT03866317 898 901 B-Procedure
therapy NCT03866317 902 909 I-Procedure
, NCT03866317 910 911 O
e. NCT03866317 912 914 O
g. NCT03866317 915 917 O
systemic NCT03866317 919 927 B-Drug
corticosteroids NCT03866317 928 943 I-Drug
, NCT03866317 944 945 O
cyclosporine NCT03866317 946 958 B-Drug
A NCT03866317 959 960 I-Drug
, NCT03866317 961 962 O
azathioprine NCT03866317 963 975 B-Drug
, NCT03866317 976 977 O
mycophenolate NCT03866317 978 991 B-Drug
mofetil NCT03866317 992 999 I-Drug
, NCT03866317 1000 1001 O
in NCT03866317 1002 1004 O
the NCT03866317 1005 1008 O
past NCT03866317 1009 1013 B-Eq-Comparison
1 NCT03866317 1014 1015 I-Eq-Comparison
month NCT03866317 1016 1021 I-Eq-Comparison
. NCT03866317 1022 1023 O

7 NCT03866317 1027 1028 O
. NCT03866317 1028 1029 O
Use NCT03866317 1031 1034 B-Eq-Comparison
of NCT03866317 1035 1037 O
systemic NCT03866317 1038 1046 B-Modifier
pain NCT03866317 1047 1051 B-Condition
medications NCT03866317 1052 1063 B-Drug
, NCT03866317 1064 1065 O
e. NCT03866317 1066 1068 O
g. NCT03866317 1069 1071 O
oxycodone NCT03866317 1073 1082 B-Drug
in NCT03866317 1083 1085 O
the NCT03866317 1086 1089 O
past NCT03866317 1090 1094 B-Eq-Comparison
2 NCT03866317 1095 1096 I-Eq-Comparison
weeks NCT03866317 1097 1102 I-Eq-Comparison

8 NCT03866317 1105 1106 O
. NCT03866317 1106 1107 O
Participation NCT03866317 1109 1122 O
in NCT03866317 1123 1125 O
another NCT03866317 1126 1133 B-Other
clinical NCT03866317 1134 1142 O
research NCT03866317 1143 1151 O
study NCT03866317 1152 1157 B-Study
with NCT03866317 1158 1162 B-And
an NCT03866317 1163 1165 O
investigational NCT03866317 1166 1181 B-Study
drug NCT03866317 1182 1186 B-Drug
within NCT03866317 1187 1193 B-Eq-Comparison
4 NCT03866317 1194 1195 I-Eq-Comparison
weeks NCT03866317 1196 1201 I-Eq-Comparison
before NCT03866317 1202 1208 B-Temporal-Connection___Temporal-Connection-Type-Value:before
this NCT03866317 1209 1213 O
study NCT03866317 1214 1219 B-Study

9 NCT03866317 1222 1223 O
. NCT03866317 1223 1224 O
Use NCT03866317 1226 1229 B-Eq-Comparison
of NCT03866317 1230 1232 O
immune NCT03866317 1233 1239 B-Drug
- NCT03866317 1240 1241 I-Drug
suppressant NCT03866317 1242 1253 I-Drug
or NCT03866317 1254 1256 B-Or
other NCT03866317 1257 1262 B-Other
biological NCT03866317 1263 1273 B-Procedure
treatment NCT03866317 1274 1283 I-Procedure

10 NCT03866317 1285 1287 O
. NCT03866317 1287 1288 O
Starting NCT03866317 1290 1298 B-Eq-Comparison
antimalarial NCT03866317 1299 1311 B-Drug
medicine NCT03866317 1312 1320 I-Drug
after NCT03866317 1321 1326 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolling NCT03866317 1327 1336 O
in NCT03866317 1337 1339 O
the NCT03866317 1340 1343 O
study NCT03866317 1344 1349 B-Study
. NCT03866317 1349 1350 O
Subjects NCT03866317 1352 1360 O
who NCT03866317 1361 1364 O
are NCT03866317 1365 1368 O
already NCT03866317 1369 1376 B-Eq-Comparison
on NCT03866317 1377 1379 O
a NCT03866317 1380 1381 O
stable NCT03866317 1382 1388 O
dose NCT03866317 1389 1393 O
of NCT03866317 1394 1396 O
antimalarial NCT03866317 1397 1409 B-Drug
before NCT03866317 1410 1416 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866317 1417 1427 B-Study
, NCT03866317 1428 1429 O
may NCT03866317 1430 1433 O
continue NCT03866317 1434 1442 O
the NCT03866317 1443 1446 O
same NCT03866317 1447 1451 O
dose NCT03866317 1452 1456 O
. NCT03866317 1457 1458 O

11 NCT03866317 1461 1463 O
. NCT03866317 1463 1464 O
An NCT03866317 1466 1468 O
ongoing NCT03866317 1469 1476 B-Eq-Comparison
infection NCT03866317 1477 1486 B-Condition
. NCT03866317 1486 1487 O

Inclusion NCT03863535 0 9 O
Criteria NCT03863535 10 18 O
: NCT03863535 19 20 O

Type NCT03863535 22 26 B-Modifier
II NCT03863535 27 29 I-Modifier
diabetic NCT03863535 30 38 B-Condition
patients NCT03863535 39 47 O
, NCT03863535 48 49 O
18 NCT03863535 50 52 B-Eq-Comparison
years NCT03863535 53 58 I-Eq-Comparison
and NCT03863535 59 62 I-Eq-Comparison
older NCT03863535 63 68 I-Age|Eq-Comparison
, NCT03863535 69 70 O
were NCT03863535 71 75 O
included NCT03863535 76 84 O
if NCT03863535 85 87 O
the NCT03863535 88 91 O
participants NCT03863535 92 104 O
had NCT03863535 105 108 O
: NCT03863535 109 110 O

1 NCT03863535 114 115 O
. NCT03863535 115 116 O
severe NCT03863535 118 124 O
non NCT03863535 125 128 B-Negation
- NCT03863535 129 130 O
PDR NCT03863535 131 134 B-Condition
in NCT03863535 135 137 O
either NCT03863535 138 144 B-Modifier
eyes NCT03863535 145 149 I-Modifier
with NCT03863535 150 154 B-And
/ NCT03863535 155 156 B-Or
without NCT03863535 157 164 B-Negation
diabetic NCT03863535 165 173 B-Condition
macular NCT03863535 174 181 I-Condition
edema NCT03863535 182 187 I-Condition
; NCT03863535 187 188 O

2 NCT03863535 191 192 O
. NCT03863535 192 193 O
ETDRS NCT03863535 195 200 B-Modifier
letters NCT03863535 201 208 I-Modifier
- NCT03863535 209 210 I-Modifier
measured NCT03863535 211 219 I-Modifier
best NCT03863535 220 224 B-Observation
- NCT03863535 225 226 I-Observation
corrected NCT03863535 227 236 I-Observation
visual NCT03863535 237 243 I-Observation
acuity NCT03863535 244 250 I-Observation
( NCT03863535 251 252 O
BCVA NCT03863535 253 257 B-Observation
) NCT03863535 258 259 O
ranging NCT03863535 260 267 O
from NCT03863535 268 272 O
20 NCT03863535 273 275 B-Eq-Comparison
/ NCT03863535 276 277 I-Eq-Comparison
40 NCT03863535 278 280 I-Eq-Comparison
to NCT03863535 281 283 I-Eq-Comparison
20 NCT03863535 284 286 I-Eq-Comparison
/ NCT03863535 287 288 I-Eq-Comparison
320 NCT03863535 289 292 I-Eq-Comparison
Snellen NCT03863535 293 300 B-Modifier
equivalent NCT03863535 301 311 I-Modifier
; NCT03863535 311 312 O

3 NCT03863535 320 321 O
. NCT03863535 321 322 O
no NCT03863535 324 326 B-Negation
previous NCT03863535 327 335 B-Eq-Comparison
treatment NCT03863535 336 345 B-Procedure
( NCT03863535 346 347 O
of NCT03863535 348 350 O
any NCT03863535 351 354 O
type NCT03863535 355 359 O
) NCT03863535 360 361 O
in NCT03863535 362 364 O
either NCT03863535 365 371 B-Modifier
eye NCT03863535 372 375 I-Modifier
. NCT03863535 376 377 O

Exclusion NCT03863535 379 388 O
Criteria NCT03863535 389 397 O
: NCT03863535 398 399 O

1 NCT03863535 403 404 O
. NCT03863535 404 405 O
history NCT03863535 407 414 B-Eq-Comparison
of NCT03863535 415 417 I-Eq-Comparison
prior NCT03863535 418 423 I-Eq-Comparison
laser NCT03863535 424 429 B-Procedure
treatment NCT03863535 430 439 I-Procedure
or NCT03863535 440 442 B-Or
vitrectomy NCT03863535 443 453 B-Procedure
in NCT03863535 454 456 O
the NCT03863535 457 460 O
study NCT03863535 461 466 B-Study
eye NCT03863535 467 470 B-Modifier
; NCT03863535 470 471 O

2 NCT03863535 474 475 O
. NCT03863535 475 476 O
history NCT03863535 478 485 B-Eq-Comparison
of NCT03863535 486 488 O
thromboembolic NCT03863535 489 503 B-Condition
event NCT03863535 504 509 I-Condition
- NCT03863535 510 511 O
including NCT03863535 512 521 O
myocardial NCT03863535 522 532 B-Condition
infarction NCT03863535 533 543 I-Condition
or NCT03863535 544 546 B-Or
cerebral NCT03863535 547 555 B-Condition
vascular NCT03863535 556 564 I-Condition
accident NCT03863535 565 573 I-Condition
; NCT03863535 573 574 O

3 NCT03863535 577 578 O
. NCT03863535 578 579 O
major NCT03863535 581 586 O
surgery NCT03863535 587 594 B-Procedure
within NCT03863535 595 601 B-Eq-Comparison
the NCT03863535 602 605 I-Eq-Comparison
prior NCT03863535 606 611 I-Eq-Comparison
6 NCT03863535 612 613 I-Eq-Comparison
months NCT03863535 614 620 I-Eq-Comparison
or NCT03863535 621 623 B-Or
planned NCT03863535 624 631 B-Eq-Comparison
within NCT03863535 632 638 I-Eq-Comparison
the NCT03863535 639 642 I-Eq-Comparison
next NCT03863535 643 647 I-Eq-Comparison
28 NCT03863535 648 650 I-Eq-Comparison
days NCT03863535 651 655 I-Eq-Comparison
; NCT03863535 655 656 O

4 NCT03863535 659 660 O
. NCT03863535 660 661 O
history NCT03863535 663 670 B-Eq-Comparison
of NCT03863535 671 673 O
glaucoma NCT03863535 674 682 B-Condition
or NCT03863535 683 685 B-Or
ocular NCT03863535 686 692 B-Modifier
hypertension NCT03863535 693 705 B-Condition
; NCT03863535 705 706 O

5 NCT03863535 709 710 O
. NCT03863535 710 711 O
loss NCT03863535 713 717 B-Condition
of NCT03863535 718 720 I-Condition
vision NCT03863535 721 727 I-Condition
as NCT03863535 728 730 O
a NCT03863535 731 732 O
result NCT03863535 733 739 O
of NCT03863535 740 742 O
other NCT03863535 743 748 B-Other
causes NCT03863535 749 755 B-Condition
; NCT03863535 755 756 O

6 NCT03863535 759 760 O
. NCT03863535 760 761 O
history NCT03863535 763 770 B-Eq-Comparison
of NCT03863535 771 773 O
systemic NCT03863535 774 782 B-Modifier
corticosteroid NCT03863535 783 797 B-Procedure
therapy NCT03863535 798 805 I-Procedure
within NCT03863535 806 812 B-Eq-Comparison
the NCT03863535 813 816 I-Eq-Comparison
last NCT03863535 817 821 I-Eq-Comparison
3 NCT03863535 822 823 I-Eq-Comparison
months NCT03863535 824 830 I-Eq-Comparison
; NCT03863535 830 831 O

7 NCT03863535 834 835 O
. NCT03863535 835 836 O
severe NCT03863535 838 844 O
systemic NCT03863535 845 853 B-Modifier
disease NCT03863535 854 861 B-Condition
other NCT03863535 862 867 B-Exception
than NCT03863535 868 872 I-Exception
diabetes NCT03863535 873 881 B-Condition
mellitus NCT03863535 882 890 I-Condition
; NCT03863535 890 891 O

8 NCT03863535 894 895 O
. NCT03863535 895 896 O
known NCT03863535 898 903 O
coagulation NCT03863535 904 915 B-Condition
abnormalities NCT03863535 916 929 O
or NCT03863535 930 932 B-Or
current NCT03863535 933 940 B-Eq-Comparison
use NCT03863535 941 944 O
of NCT03863535 945 947 O
anticoagulative NCT03863535 948 963 B-Drug
medication NCT03863535 964 974 I-Drug
other NCT03863535 975 980 B-Exception
than NCT03863535 981 985 I-Exception
aspirin NCT03863535 986 993 B-Drug

9 NCT03863535 996 997 O
. NCT03863535 997 998 O
any NCT03863535 1000 1003 O
condition NCT03863535 1004 1013 B-Condition
that NCT03863535 1014 1018 O
could NCT03863535 1019 1024 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03863535 1025 1031 O
followup NCT03863535 1032 1040 B-Encounter
or NCT03863535 1041 1043 B-Or
documentation NCT03863535 1044 1057 B-Observation
( NCT03863535 1058 1059 O
including NCT03863535 1060 1069 O
preretinal NCT03863535 1070 1080 B-Modifier
or NCT03863535 1081 1083 B-Or
vitreous NCT03863535 1084 1092 B-Modifier
hemorrhage NCT03863535 1093 1103 B-Condition
) NCT03863535 1104 1105 O
. NCT03863535 1107 1108 O


Inclusion NCT03868306 0 9 O
Criteria NCT03868306 10 18 O
: NCT03868306 19 20 O

- NCT03868306 24 25 O
All NCT03868306 27 30 O
patients NCT03868306 31 39 O
with NCT03868306 40 44 O
microcytic NCT03868306 45 55 B-Condition
hypochromic NCT03868306 56 67 I-Condition
anemia NCT03868306 68 74 I-Condition
( NCT03868306 75 76 O
according NCT03868306 77 86 O
to NCT03868306 87 89 O
WHO NCT03868306 90 93 O
, NCT03868306 94 95 O
MCV NCT03868306 96 99 B-Observation
less NCT03868306 100 104 B-Eq-Comparison
than NCT03868306 105 109 I-Eq-Comparison
80 NCT03868306 110 112 I-Eq-Comparison
fl NCT03868306 113 115 I-Eq-Comparison
and NCT03868306 116 119 B-And
HB NCT03868306 120 122 B-Observation
level NCT03868306 123 128 O
below NCT03868306 129 134 B-Eq-Comparison
the NCT03868306 135 138 I-Eq-Comparison
lower NCT03868306 139 144 I-Eq-Comparison
limit NCT03868306 145 150 I-Eq-Comparison
of NCT03868306 151 153 I-Eq-Comparison
normal NCT03868306 154 160 I-Eq-Comparison
value NCT03868306 161 166 I-Eq-Comparison
specified NCT03868306 167 176 O
by NCT03868306 177 179 O
age NCT03868306 180 183 O
and NCT03868306 184 187 O
gender NCT03868306 188 194 O
. NCT03868306 196 197 O

Exclusion NCT03868306 199 208 O
Criteria NCT03868306 209 217 O
: NCT03868306 218 219 O

- NCT03868306 223 224 O
Beta NCT03868306 226 230 B-Condition
thalassemia NCT03868306 231 242 I-Condition
major NCT03868306 243 248 I-Condition
patients NCT03868306 249 257 O
. NCT03868306 259 260 O

- NCT03868306 264 265 O
Chronic NCT03868306 267 274 B-Modifier
diseases NCT03868306 275 283 B-Condition
or NCT03868306 284 286 B-Or
infections NCT03868306 287 297 B-Condition
. NCT03868306 299 300 O

- NCT03868306 304 305 O
Lead NCT03868306 307 311 B-Condition
poisoning NCT03868306 312 321 I-Condition
. NCT03868306 323 324 O

- NCT03868306 328 329 O
Sideroblastic NCT03868306 331 344 B-Condition
anaemia NCT03868306 345 352 I-Condition
. NCT03868306 353 354 O

Inclusion NCT03867747 0 9 O
Criteria NCT03867747 10 18 O
: NCT03867747 19 20 O

- NCT03867747 24 25 O
Patients NCT03867747 27 35 O
with NCT03867747 36 40 O
structural NCT03867747 41 51 B-Modifier
heart NCT03867747 52 57 B-Condition
disease NCT03867747 58 65 I-Condition
and NCT03867747 66 69 B-Or
implantable NCT03867747 70 81 B-Procedure
cardioverter NCT03867747 82 94 I-Procedure
defibrillator NCT03867747 95 108 I-Procedure
( NCT03867747 109 110 O
ICD NCT03867747 111 114 B-Procedure
) NCT03867747 115 116 O

- NCT03867747 120 121 O
Age NCT03867747 123 126 B-Age
> NCT03867747 127 128 B-Eq-Comparison
18 NCT03867747 129 131 I-Eq-Comparison
years NCT03867747 132 137 I-Eq-Comparison

- NCT03867747 140 141 O
either NCT03867747 143 149 O

1 NCT03867747 157 158 O
. NCT03867747 158 159 O
Recurring NCT03867747 161 170 B-Modifier
symptomatic NCT03867747 171 182 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 183 194 B-Condition
ventricular NCT03867747 195 206 I-Condition
tachycardia NCT03867747 207 218 I-Condition
that NCT03867747 219 223 O
requires NCT03867747 224 232 B-Assertion___Assertion-Type-Value:hypothetical
ICD NCT03867747 233 236 B-Procedure
intervention NCT03867747 237 249 I-Procedure
( NCT03867747 250 251 O
e. NCT03867747 252 254 O
g. NCT03867747 255 257 O
shock NCT03867747 259 264 B-Modifier
or NCT03867747 265 267 B-Or
anti NCT03867747 268 272 B-Negation
- NCT03867747 273 274 O
tachycardia NCT03867747 275 286 B-Modifier
stimulation NCT03867747 287 298 B-Procedure
) NCT03867747 299 300 O
. NCT03867747 301 302 O
At NCT03867747 304 306 B-Eq-Comparison
least NCT03867747 307 312 I-Eq-Comparison
3 NCT03867747 313 314 I-Eq-Comparison
episodes NCT03867747 315 323 B-Coreference
within NCT03867747 324 330 B-Eq-Comparison
the NCT03867747 331 334 I-Eq-Comparison
3 NCT03867747 335 336 I-Eq-Comparison
months NCT03867747 337 343 I-Eq-Comparison
prior NCT03867747 344 349 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867747 350 352 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03867747 353 362 B-Study
or NCT03867747 363 365 B-Or

2 NCT03867747 373 374 O
. NCT03867747 374 375 O
induction NCT03867747 377 386 B-Procedure
of NCT03867747 387 389 O
symptomatic NCT03867747 390 401 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 402 413 B-Condition
ventricular NCT03867747 414 425 I-Condition
tachycardia NCT03867747 426 437 I-Condition
that NCT03867747 438 442 O
requires NCT03867747 443 451 B-Assertion___Assertion-Type-Value:hypothetical
ICD NCT03867747 452 455 B-Procedure
intervention NCT03867747 456 468 I-Procedure
( NCT03867747 469 470 O
e. NCT03867747 471 473 O
g. NCT03867747 474 476 O
shock NCT03867747 478 483 B-Modifier
or NCT03867747 484 486 B-Or
anti NCT03867747 487 491 B-Negation
- NCT03867747 492 493 O
tachycardia NCT03867747 494 505 B-Modifier
stimulation NCT03867747 506 517 B-Procedure
) NCT03867747 518 519 O
. NCT03867747 520 521 O
Induction NCT03867747 523 532 B-Procedure
triggered NCT03867747 533 542 O
by NCT03867747 543 545 O
ICD NCT03867747 546 549 B-Procedure
or NCT03867747 550 552 B-Or
during NCT03867747 553 559 B-Temporal-Connection___Temporal-Connection-Type-Value:during
electrophysiology NCT03867747 560 577 B-Procedure
studies NCT03867747 578 585 I-Procedure
( NCT03867747 586 587 O
EPS NCT03867747 588 591 B-Procedure
) NCT03867747 592 593 O
or NCT03867747 594 596 B-Or
both NCT03867747 597 601 B-Modifier
, NCT03867747 602 603 O
a NCT03867747 604 605 O
) NCT03867747 606 607 O
and NCT03867747 608 611 O
b NCT03867747 612 613 O
) NCT03867747 614 615 O

- NCT03867747 619 620 O
Refractory NCT03867747 622 632 B-Condition
to NCT03867747 633 635 O
antiarrhythmic NCT03867747 636 650 B-Procedure
combination NCT03867747 651 662 I-Procedure
therapy NCT03867747 663 670 I-Procedure

- NCT03867747 673 674 O
Beside NCT03867747 676 682 O
the NCT03867747 683 686 O
cardiac NCT03867747 687 694 B-Condition
conditions NCT03867747 695 705 I-Condition
: NCT03867747 706 707 O
No NCT03867747 708 710 B-Negation
competing NCT03867747 711 720 O
illness NCT03867747 721 728 B-Condition
that NCT03867747 729 733 O
would NCT03867747 734 739 B-Assertion___Assertion-Type-Value:hypothetical
additionally NCT03867747 740 752 O
limit NCT03867747 753 758 O
the NCT03867747 759 762 O
life NCT03867747 763 767 B-Observation
expectancy NCT03867747 768 778 I-Observation
to NCT03867747 779 781 O
less NCT03867747 782 786 B-Eq-Comparison
than NCT03867747 787 791 I-Eq-Comparison
6 NCT03867747 792 793 I-Eq-Comparison
months NCT03867747 794 800 I-Eq-Comparison

- NCT03867747 803 804 O
No NCT03867747 806 808 B-Negation
prior NCT03867747 809 814 B-Eq-Comparison
radiation NCT03867747 815 824 B-Procedure
therapy NCT03867747 825 832 I-Procedure
in NCT03867747 833 835 O
the NCT03867747 836 839 O
thorax NCT03867747 840 846 B-Modifier
area NCT03867747 847 851 I-Modifier

- NCT03867747 854 855 O
No NCT03867747 857 859 B-Negation
pregnancy NCT03867747 860 869 B-Condition
and NCT03867747 870 873 B-And
no NCT03867747 874 876 B-Negation
active NCT03867747 877 883 B-Eq-Comparison
breastfeeding NCT03867747 884 897 B-Condition

- NCT03867747 900 901 O
Ability NCT03867747 903 910 O
to NCT03867747 911 913 O
consent NCT03867747 914 921 O
and NCT03867747 922 925 O
consent NCT03867747 926 933 O
to NCT03867747 934 936 O
study NCT03867747 937 942 O
participation NCT03867747 943 956 O

Exclusion NCT03867747 957 966 O
Criteria NCT03867747 967 975 O
: NCT03867747 976 977 O

- NCT03867747 981 982 O
ICD NCT03867747 984 987 B-Condition
electrode NCT03867747 988 997 I-Condition
malfunction NCT03867747 998 1009 I-Condition
of NCT03867747 1010 1012 O
ICD NCT03867747 1013 1016 B-Procedure
readings NCT03867747 1017 1025 O
outside NCT03867747 1026 1033 O
reference NCT03867747 1034 1043 O
range NCT03867747 1044 1049 O

- NCT03867747 1052 1053 O
Lack NCT03867747 1055 1059 B-Negation
of NCT03867747 1060 1062 O
evidence NCT03867747 1063 1071 O
of NCT03867747 1072 1074 O
a NCT03867747 1075 1076 O
myocardial NCT03867747 1077 1087 B-Condition
scar NCT03867747 1088 1092 I-Condition
( NCT03867747 1093 1094 O
Computer NCT03867747 1095 1103 B-Procedure
tomography NCT03867747 1104 1114 I-Procedure
or NCT03867747 1115 1117 B-Or
magnetic NCT03867747 1118 1126 B-Procedure
resonance NCT03867747 1127 1136 I-Procedure
tomography NCT03867747 1137 1147 I-Procedure
for NCT03867747 1148 1151 O
MRI NCT03867747 1152 1155 B-Procedure
- NCT03867747 1156 1157 O
capable NCT03867747 1158 1165 O
ICD NCT03867747 1166 1169 B-Procedure
aggregates NCT03867747 1170 1180 I-Procedure
or NCT03867747 1181 1183 B-Or
electrophysiological NCT03867747 1184 1204 B-Observation
measurement NCT03867747 1205 1216 I-Observation
) NCT03867747 1217 1218 O

- NCT03867747 1222 1223 O
No NCT03867747 1225 1227 B-Negation
possible NCT03867747 1228 1236 B-Assertion___Assertion-Type-Value:hypothetical
induction NCT03867747 1237 1246 B-Procedure
of NCT03867747 1247 1249 O
symptomatic NCT03867747 1250 1261 B-Assertion___Assertion-Type-Value:possible
monomorphic NCT03867747 1262 1273 B-Modifier
ventricular NCT03867747 1274 1285 B-Condition
tachycardia NCT03867747 1286 1297 I-Condition
non NCT03867747 1298 1301 B-Negation
- NCT03867747 1302 1303 O
persistent NCT03867747 1304 1314 B-Modifier
or NCT03867747 1315 1317 B-Or
persistent NCT03867747 1318 1328 B-Modifier
with NCT03867747 1329 1333 O
delivery NCT03867747 1334 1342 O
of NCT03867747 1343 1345 O
ICD NCT03867747 1346 1349 B-Procedure
therapies NCT03867747 1350 1359 I-Procedure
such NCT03867747 1360 1364 O
as NCT03867747 1365 1367 O
antitachycardic NCT03867747 1368 1383 B-Procedure
pacing NCT03867747 1384 1390 I-Procedure
or NCT03867747 1391 1393 B-Or
shock NCT03867747 1394 1399 B-Procedure

- NCT03867747 1402 1403 O
Contraindication NCT03867747 1405 1421 B-Contraindication
to NCT03867747 1422 1424 O
radiosurgery NCT03867747 1425 1437 B-Procedure
( NCT03867747 1438 1439 O
e. NCT03867747 1440 1442 O
g. NCT03867747 1443 1445 O
precise NCT03867747 1447 1454 O
target NCT03867747 1455 1461 B-Observation
volume NCT03867747 1462 1468 I-Observation
definition NCT03867747 1469 1479 I-Observation
not NCT03867747 1480 1483 B-Negation
possible NCT03867747 1484 1492 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03867747 1493 1496 O
to NCT03867747 1497 1499 O
image NCT03867747 1500 1505 B-Observation
artifacts NCT03867747 1506 1515 I-Observation
created NCT03867747 1516 1523 O
from NCT03867747 1524 1528 O
a NCT03867747 1529 1530 O
left NCT03867747 1531 1535 B-Procedure
ventricular NCT03867747 1536 1547 I-Procedure
assist NCT03867747 1548 1554 I-Procedure
device NCT03867747 1555 1561 I-Procedure
[ NCT03867747 1562 1563 O
LVAD NCT03867747 1564 1568 B-Procedure
] NCT03867747 1569 1570 O
) NCT03867747 1572 1573 O

- NCT03867747 1577 1578 O
Inability NCT03867747 1580 1589 O
to NCT03867747 1590 1592 O
consent NCT03867747 1593 1600 O
or NCT03867747 1601 1603 O
missing NCT03867747 1604 1611 O
or NCT03867747 1612 1614 O
withdrawn NCT03867747 1615 1624 O
consent NCT03867747 1625 1632 O

Inclusion NCT03865030 0 9 O
Criteria NCT03865030 10 18 O
: NCT03865030 19 20 O

- NCT03865030 24 25 O
Psoriatic NCT03865030 27 36 B-Condition
patients NCT03865030 37 45 O
that NCT03865030 46 50 O
are NCT03865030 51 54 O
treated NCT03865030 55 62 B-Procedure
in NCT03865030 63 65 O
our NCT03865030 66 69 O
institute NCT03865030 70 79 O
. NCT03865030 80 81 O

Exclusion NCT03865030 83 92 O
Criteria NCT03865030 93 101 O
: NCT03865030 102 103 O

- NCT03865030 107 108 O
Patients NCT03865030 110 118 O
suffering NCT03865030 119 128 O
from NCT03865030 129 133 O
cardiovascular NCT03865030 134 148 B-Condition
diseases NCT03865030 149 157 I-Condition
( NCT03865030 158 159 O
peripheral NCT03865030 160 170 B-Condition
vascular NCT03865030 171 179 I-Condition
disease NCT03865030 180 187 I-Condition
, NCT03865030 188 189 O
congestive NCT03865030 190 200 B-Condition
heart NCT03865030 201 206 I-Condition
failure NCT03865030 207 214 I-Condition
, NCT03865030 215 216 O
status NCT03865030 217 223 O
post NCT03865030 224 228 B-Temporal-Connection___Temporal-Connection-Type-Value:after
cerebrovascular NCT03865030 229 244 B-Condition
accident NCT03865030 245 253 I-Condition
) NCT03865030 254 255 O
. NCT03865030 257 258 O

- NCT03865030 262 263 O
Conditions NCT03865030 265 275 B-Condition
that NCT03865030 276 280 O
are NCT03865030 281 284 O
harmful NCT03865030 285 292 B-Condition
to NCT03865030 293 295 I-Condition
the NCT03865030 296 299 I-Condition
inner NCT03865030 300 305 I-Condition
ear NCT03865030 306 309 I-Condition
( NCT03865030 310 311 O
chronic NCT03865030 312 319 B-Modifier
renal NCT03865030 320 325 B-Condition
failure NCT03865030 326 333 I-Condition
, NCT03865030 334 335 O
history NCT03865030 336 343 B-Eq-Comparison
of NCT03865030 344 346 O
noise NCT03865030 347 352 B-Condition
exposure NCT03865030 353 361 I-Condition
, NCT03865030 362 363 O
usage NCT03865030 364 369 O
of NCT03865030 370 372 O
ototoxic NCT03865030 373 381 B-Drug
drugs NCT03865030 382 387 I-Drug
, NCT03865030 388 389 O
chronic NCT03865030 390 397 B-Modifier
otitis NCT03865030 398 404 B-Condition
media NCT03865030 405 410 I-Condition
, NCT03865030 411 412 O
ear NCT03865030 413 416 B-Procedure
surgery NCT03865030 417 424 I-Procedure
in NCT03865030 425 427 O
the NCT03865030 428 431 O
past NCT03865030 432 436 B-Eq-Comparison
, NCT03865030 437 438 O
significant NCT03865030 439 450 O
head NCT03865030 451 455 B-Modifier
trauma NCT03865030 456 462 B-Condition
in NCT03865030 463 465 O
the NCT03865030 466 469 O
past NCT03865030 470 474 B-Eq-Comparison
, NCT03865030 475 476 O
ear NCT03865030 477 480 B-Condition
drum NCT03865030 481 485 I-Condition
perforation NCT03865030 486 497 I-Condition
) NCT03865030 498 499 O
. NCT03865030 501 502 O

- NCT03865030 506 507 O
participant NCT03865030 509 520 O
that NCT03865030 521 525 O
complains NCT03865030 526 535 O
of NCT03865030 536 538 O
vertigo NCT03865030 539 546 B-Condition
/ NCT03865030 547 548 B-Or
dizziness NCT03865030 549 558 B-Condition
/ NCT03865030 559 560 B-Or
unsteadiness NCT03865030 561 573 B-Condition
. NCT03865030 574 575 O

- NCT03865030 579 580 O
Participant NCT03865030 582 593 O
who NCT03865030 594 597 O
is NCT03865030 598 600 O
/ NCT03865030 601 602 O
was NCT03865030 603 606 O
suffering NCT03865030 607 616 O
from NCT03865030 617 621 O
known NCT03865030 622 627 O
inner NCT03865030 628 633 B-Condition
ear NCT03865030 634 637 I-Condition
disease NCT03865030 638 645 I-Condition
: NCT03865030 646 647 O
meniere NCT03865030 648 655 B-Condition
disease NCT03865030 656 663 I-Condition
, NCT03865030 664 665 O
acoustic NCT03865030 666 674 B-Condition
neurinoma NCT03865030 675 684 I-Condition
, NCT03865030 685 686 O
vestibular NCT03865030 687 697 B-Condition
neuronitis NCT03865030 698 708 I-Condition
. NCT03865030 708 709 O

Inclusion NCT03868514 0 9 O
Criteria NCT03868514 10 18 O
: NCT03868514 19 20 O

Age NCT03868514 22 25 B-Age
[ NCT03868514 26 27 O
≥ NCT03868514 29 30 B-Eq-Comparison
18 NCT03868514 31 33 I-Eq-Comparison
] NCT03868514 34 35 O

Indications NCT03868514 37 48 B-Indication
of NCT03868514 49 51 O
breast NCT03868514 52 58 B-Procedure
reconstruction NCT03868514 59 73 I-Procedure
: NCT03868514 74 75 O
histologically NCT03868514 76 90 B-Procedure
confirmed NCT03868514 91 100 O
breast NCT03868514 101 107 B-Modifier
cancer NCT03868514 108 114 B-Condition
, NCT03868514 115 116 O
precancerous NCT03868514 117 129 B-Modifier
lesions NCT03868514 130 137 B-Condition
( NCT03868514 138 139 O
DCIS NCT03868514 140 144 B-Condition
, NCT03868514 145 146 O
LCIS NCT03868514 147 151 B-Condition
) NCT03868514 152 153 O
, NCT03868514 155 156 O
mutation NCT03868514 157 165 B-Condition
carrier NCT03868514 166 173 I-Condition
with NCT03868514 174 178 B-And
increased NCT03868514 179 188 O
breast NCT03868514 189 195 B-Modifier
cancer NCT03868514 196 202 B-Condition
risk NCT03868514 203 207 B-Risk
, NCT03868514 208 209 O
strong NCT03868514 210 216 O
family NCT03868514 217 223 B-Family-Member
history NCT03868514 224 231 I-Family-Member
( NCT03868514 232 233 O
lifetime NCT03868514 234 242 O
risk NCT03868514 243 247 B-Risk
> NCT03868514 248 249 B-Eq-Comparison
15 NCT03868514 250 252 I-Eq-Comparison
% NCT03868514 253 254 I-Eq-Comparison
) NCT03868514 256 257 O

The NCT03868514 259 262 O
patient NCT03868514 263 270 O
is NCT03868514 271 273 O
capable NCT03868514 274 281 O
to NCT03868514 282 284 O
realise NCT03868514 285 292 O
the NCT03868514 293 296 O
nature NCT03868514 297 303 O
, NCT03868514 304 305 O
aims NCT03868514 306 310 O
and NCT03868514 311 314 O
possible NCT03868514 315 323 O
consequences NCT03868514 324 336 O
of NCT03868514 337 339 O
the NCT03868514 340 343 O
clinical NCT03868514 344 352 O
trial NCT03868514 353 358 O
( NCT03868514 359 360 O
MPG NCT03868514 361 364 O
§ NCT03868514 365 366 O
20.2.1 NCT03868514 366 372 O
) NCT03868514 373 374 O

Patient NCT03868514 376 383 O
information NCT03868514 384 395 O
has NCT03868514 396 399 O
been NCT03868514 400 404 O
provided NCT03868514 405 413 O
and NCT03868514 414 417 O
all NCT03868514 418 421 O
written NCT03868514 422 429 O
consents NCT03868514 430 438 O
of NCT03868514 439 441 O
the NCT03868514 442 445 O
patient NCT03868514 446 453 O
are NCT03868514 454 457 O
available NCT03868514 458 467 O

Exclusion NCT03868514 468 477 O
Criteria NCT03868514 478 486 O
: NCT03868514 487 488 O

Metastatic NCT03868514 490 500 B-Modifier
breast NCT03868514 501 507 I-Modifier
cancer NCT03868514 508 514 B-Condition

Patient NCT03868514 515 522 O
with NCT03868514 523 527 O
known NCT03868514 528 533 O
contraindications NCT03868514 534 551 B-Contraindication
against NCT03868514 552 559 O
mesh NCT03868514 560 564 B-Modifier
- NCT03868514 565 566 I-Modifier
assisted NCT03868514 567 575 I-Modifier
or NCT03868514 576 578 B-Or
plastic NCT03868514 579 586 B-Modifier
- NCT03868514 587 588 I-Modifier
reconstructive NCT03868514 589 603 I-Modifier
breast NCT03868514 604 610 B-Procedure
surgery NCT03868514 611 618 I-Procedure
according NCT03868514 619 628 O
to NCT03868514 629 631 O
the NCT03868514 632 635 O
instruction NCT03868514 636 647 O
for NCT03868514 648 651 O
use NCT03868514 652 655 O

Patient NCT03868514 656 663 O
is NCT03868514 664 666 O
kept NCT03868514 667 671 O
in NCT03868514 672 674 O
an NCT03868514 675 677 O
institution NCT03868514 678 689 B-Observation
under NCT03868514 690 695 I-Observation
judicial NCT03868514 696 704 I-Observation
or NCT03868514 705 707 O
official NCT03868514 708 716 O
orders NCT03868514 717 723 O
( NCT03868514 724 725 O
MPG NCT03868514 726 729 O
§ NCT03868514 730 731 O
20.3 NCT03868514 731 735 O
) NCT03868514 736 737 O

Participate NCT03868514 739 750 O
in NCT03868514 751 753 O
another NCT03868514 754 761 B-Other
operative NCT03868514 762 771 B-Procedure
clinical NCT03868514 772 780 B-Study
trial NCT03868514 781 786 I-Study
, NCT03868514 787 788 O
if NCT03868514 789 791 O
it NCT03868514 792 794 O
relates NCT03868514 795 802 O
to NCT03868514 803 805 O
the NCT03868514 806 809 O
area NCT03868514 810 814 O
of NCT03868514 815 817 O
reconstructive NCT03868514 818 832 B-Procedure
breast NCT03868514 833 839 I-Procedure
surgery NCT03868514 840 847 I-Procedure
and NCT03868514 848 851 B-Or
/ NCT03868514 852 853 I-Or
or NCT03868514 854 856 I-Or
influences NCT03868514 857 867 O
the NCT03868514 868 871 O
primary NCT03868514 872 879 O
endpoint NCT03868514 880 888 O
of NCT03868514 889 891 O
the NCT03868514 892 895 O
clinical NCT03868514 896 904 O
trial NCT03868514 905 910 B-Study


Inclusion NCT03863327 0 9 O
Criteria NCT03863327 10 18 O
: NCT03863327 19 20 O

- NCT03863327 24 25 O
Recorded NCT03863327 27 35 B-Eq-Comparison
EKG NCT03863327 36 39 B-Procedure
prior NCT03863327 40 45 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863327 46 48 I-Temporal-Connection___Temporal-Connection-Type-Value:before
cardiac NCT03863327 49 56 B-Procedure
catheterization NCT03863327 57 72 I-Procedure

Exclusion NCT03863327 73 82 O
Criteria NCT03863327 83 91 O
: NCT03863327 92 93 O

- NCT03863327 97 98 O
Absence NCT03863327 100 107 B-Negation
of NCT03863327 108 110 O
documented NCT03863327 111 121 O
EKG NCT03863327 122 125 B-Procedure
prior NCT03863327 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863327 132 134 I-Temporal-Connection___Temporal-Connection-Type-Value:before
cardiac NCT03863327 135 142 B-Procedure
catheterization NCT03863327 143 158 I-Procedure

Inclusion NCT03863496 0 9 O
Criteria NCT03863496 10 18 O
: NCT03863496 19 20 O

- NCT03863496 24 25 O
Signed NCT03863496 27 33 O
and NCT03863496 34 37 O
dated NCT03863496 38 43 O
informed NCT03863496 44 52 O
consent NCT03863496 53 60 O
for NCT03863496 61 64 O
participation NCT03863496 65 78 O
in NCT03863496 79 81 O
the NCT03863496 82 85 O
study NCT03863496 86 91 O
( NCT03863496 92 93 O
separate NCT03863496 94 102 O
informed NCT03863496 103 111 O
consents NCT03863496 112 120 O
for NCT03863496 121 124 O
child NCT03863496 125 130 B-Family-Member___Family-Member-Type:child
and NCT03863496 131 134 B-Or
parents NCT03863496 135 142 B-Family-Member___Family-Member-Type:parent
/ NCT03863496 143 144 O
caregivers NCT03863496 145 155 O
) NCT03863496 156 157 O
, NCT03863496 159 160 O
obtained NCT03863496 161 169 O
before NCT03863496 170 176 B-Temporal-Connection___Temporal-Connection-Type-Value:before
conducting NCT03863496 177 187 O
any NCT03863496 188 191 O
study NCT03863496 192 197 B-Study
procedures NCT03863496 198 208 B-Procedure

- NCT03863496 211 212 O
Verified NCT03863496 214 222 O
and NCT03863496 223 226 O
documented NCT03863496 227 237 O
diagnosis NCT03863496 238 247 O
( NCT03863496 248 249 O
neuromuscular NCT03863496 250 263 B-Condition
desease NCT03863496 264 271 I-Condition
, NCT03863496 272 273 O
NMD NCT03863496 274 277 B-Condition
) NCT03863496 278 279 O
with NCT03863496 280 284 O
the NCT03863496 285 288 O
results NCT03863496 289 296 O
of NCT03863496 297 299 O
neurologic NCT03863496 300 310 B-Procedure
examination NCT03863496 311 322 I-Procedure

- NCT03863496 325 326 O
Deformity NCT03863496 328 337 B-Condition
of NCT03863496 338 340 O
thoracic NCT03863496 341 349 B-Modifier
and NCT03863496 350 353 B-Or
/ NCT03863496 354 355 I-Or
or NCT03863496 356 358 I-Or
lumbar NCT03863496 359 365 B-Modifier
spine NCT03863496 366 371 I-Modifier
associated NCT03863496 372 382 O
with NCT03863496 383 387 O
NMD NCT03863496 388 391 B-Condition
, NCT03863496 392 393 O
which NCT03863496 394 399 O
requires NCT03863496 400 408 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03863496 409 417 B-Procedure
intervention NCT03863496 418 430 I-Procedure

Exclusion NCT03863496 431 440 O
Criteria NCT03863496 441 449 O
: NCT03863496 450 451 O

- NCT03863496 455 456 O
Patient NCT03863496 458 465 O
unwillingness NCT03863496 466 479 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03863496 480 482 B-Or
inability NCT03863496 483 492 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863496 493 495 O
follow NCT03863496 496 502 O
study NCT03863496 503 508 B-Study
procedures NCT03863496 509 519 B-Procedure

- NCT03863496 522 523 O
Absence NCT03863496 525 532 O
of NCT03863496 533 535 O
signed NCT03863496 536 542 O
and NCT03863496 543 546 O
dated NCT03863496 547 552 O
informed NCT03863496 553 561 O
consent NCT03863496 562 569 O
for NCT03863496 570 573 O
participation NCT03863496 574 587 O
in NCT03863496 588 590 O
the NCT03863496 591 594 O
study NCT03863496 595 600 O
( NCT03863496 601 602 O
as NCT03863496 603 605 O
for NCT03863496 606 609 O
child NCT03863496 610 615 B-Family-Member___Family-Member-Type:child
and NCT03863496 616 619 B-Or
for NCT03863496 620 623 O
parents NCT03863496 624 631 B-Family-Member___Family-Member-Type:parent
/ NCT03863496 632 633 O
caregivers NCT03863496 634 644 O
) NCT03863496 645 646 O

- NCT03863496 650 651 O
Patient NCT03863496 653 660 O
participation NCT03863496 661 674 O
in NCT03863496 675 677 O
another NCT03863496 678 685 B-Other
clinical NCT03863496 686 694 O
study NCT03863496 695 700 B-Study
, NCT03863496 701 702 O
which NCT03863496 703 708 O
can NCT03863496 709 712 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03863496 713 722 O
the NCT03863496 723 726 O
results NCT03863496 727 734 O
of NCT03863496 735 737 O
this NCT03863496 738 742 O
study NCT03863496 743 748 B-Study

- NCT03863496 751 752 O
Left NCT03863496 754 758 B-Observation
ventricle NCT03863496 759 768 I-Observation
ejection NCT03863496 769 777 I-Observation
fraction NCT03863496 778 786 I-Observation
less NCT03863496 787 791 B-Eq-Comparison
than NCT03863496 792 796 I-Eq-Comparison
40 NCT03863496 797 799 I-Eq-Comparison
% NCT03863496 800 801 I-Eq-Comparison
by NCT03863496 802 804 O
echocardiography NCT03863496 805 821 B-Procedure

- NCT03863496 824 825 O
FEV NCT03863496 827 830 B-Observation
> NCT03863496 831 832 B-Eq-Comparison
20 NCT03863496 833 835 I-Eq-Comparison

- NCT03863496 839 840 O
Life NCT03863496 842 846 B-Observation
expectancy NCT03863496 847 857 I-Observation
< NCT03863496 858 859 B-Eq-Comparison
12 NCT03863496 860 862 I-Eq-Comparison
months NCT03863496 863 869 I-Eq-Comparison

- NCT03863496 872 873 O
Liver NCT03863496 875 880 B-Condition
insufficiency NCT03863496 881 894 I-Condition
: NCT03863496 895 896 O
ALT NCT03863496 897 900 B-Observation
, NCT03863496 901 902 O
AST NCT03863496 903 906 B-Observation
and NCT03863496 907 910 B-Or
total NCT03863496 911 916 B-Observation
bilirubin NCT03863496 917 926 I-Observation
twice NCT03863496 927 932 B-Eq-Comparison
higher NCT03863496 933 939 I-Eq-Comparison
than NCT03863496 940 944 I-Eq-Comparison
normal NCT03863496 945 951 I-Eq-Comparison

- NCT03863496 954 955 O
Kidney NCT03863496 957 963 B-Condition
insufficiency NCT03863496 964 977 I-Condition
( NCT03863496 978 979 O
creatinine NCT03863496 980 990 B-Observation
clearance NCT03863496 991 1000 I-Observation
< NCT03863496 1001 1002 B-Eq-Comparison
60 NCT03863496 1003 1005 I-Eq-Comparison
ml NCT03863496 1006 1008 I-Eq-Comparison
/ NCT03863496 1009 1010 I-Eq-Comparison
min NCT03863496 1011 1014 I-Eq-Comparison
) NCT03863496 1015 1016 O

- NCT03863496 1020 1021 O
Concomitant NCT03863496 1023 1034 B-Modifier
diseases NCT03863496 1035 1043 B-Condition
, NCT03863496 1044 1045 O
which NCT03863496 1046 1051 O
preclude NCT03863496 1052 1060 B-Assertion___Assertion-Type-Value:hypothetical|Negation
patient NCT03863496 1061 1068 O
participation NCT03863496 1069 1082 O
in NCT03863496 1083 1085 O
this NCT03863496 1086 1090 O
study NCT03863496 1091 1096 B-Study
according NCT03863496 1097 1106 O
to NCT03863496 1107 1109 O
doctor NCT03863496 1110 1116 O
's NCT03863496 1116 1118 O
opinion NCT03863496 1119 1126 O

Inclusion NCT03866707 0 9 O
Criteria NCT03866707 10 18 O
: NCT03866707 19 20 O

- NCT03866707 24 25 O
Childhood NCT03866707 27 36 O
cancer NCT03866707 37 43 B-Condition
survivors NCT03866707 44 53 O
age NCT03866707 54 57 B-Age
1 NCT03866707 58 59 B-Eq-Comparison
- NCT03866707 60 61 I-Eq-Comparison
18 NCT03866707 62 64 I-Eq-Comparison
years NCT03866707 65 70 I-Eq-Comparison
old NCT03866707 71 74 O
who NCT03866707 75 78 B-And
received NCT03866707 79 87 B-Eq-Comparison
intensive NCT03866707 88 97 O
treatment NCT03866707 98 107 B-Procedure
which NCT03866707 108 113 O
included NCT03866707 114 122 O
anthracycline NCT03866707 123 136 B-Drug
and NCT03866707 137 140 B-Or
/ NCT03866707 141 142 I-Or
or NCT03866707 143 145 I-Or
alkylating NCT03866707 146 156 B-Drug
agent NCT03866707 157 162 I-Drug
chemotherapy NCT03866707 163 175 B-Procedure
. NCT03866707 176 177 O

- NCT03866707 181 182 O
Diseases NCT03866707 184 192 B-Condition
which NCT03866707 193 198 O
will NCT03866707 199 203 O
be NCT03866707 204 206 O
eligible NCT03866707 207 215 O
include NCT03866707 216 223 O
, NCT03866707 224 225 O
high NCT03866707 226 230 O
risk NCT03866707 231 235 B-Risk
or NCT03866707 236 238 B-Or
very NCT03866707 239 243 O
high NCT03866707 244 248 O
risk NCT03866707 249 253 B-Risk
acute NCT03866707 254 259 O
lymphoblastic NCT03866707 260 273 B-Condition
leukemia NCT03866707 274 282 I-Condition
, NCT03866707 283 284 O
acute NCT03866707 285 290 O
myeloid NCT03866707 291 298 B-Condition
leukemia NCT03866707 299 307 I-Condition
, NCT03866707 308 309 O
Hodgkin NCT03866707 310 317 B-Condition
lymphoma NCT03866707 318 326 I-Condition
, NCT03866707 327 328 O
non NCT03866707 329 332 B-Negation
- NCT03866707 333 334 O
Hodgkin NCT03866707 335 342 B-Modifier
lymphoma NCT03866707 343 351 B-Condition
, NCT03866707 352 353 O
sarcomas NCT03866707 354 362 B-Condition
. NCT03866707 363 364 O

Healthy NCT03866707 366 373 B-Condition
controls NCT03866707 374 382 O
: NCT03866707 383 384 O

• NCT03866707 386 387 O
Healthy NCT03866707 388 395 B-Condition
controls NCT03866707 396 404 O
are NCT03866707 405 408 O
defined NCT03866707 409 416 O
as NCT03866707 417 419 O
children NCT03866707 420 428 O
ages NCT03866707 429 433 B-Age
1 NCT03866707 434 435 B-Eq-Comparison
- NCT03866707 436 437 I-Eq-Comparison
18 NCT03866707 438 440 I-Eq-Comparison
years NCT03866707 441 446 I-Eq-Comparison
old NCT03866707 447 450 O
who NCT03866707 451 454 B-And
are NCT03866707 455 458 O
free NCT03866707 459 463 B-Negation
from NCT03866707 464 468 I-Negation
diseases NCT03866707 469 477 B-Condition
or NCT03866707 478 480 B-Or
medical NCT03866707 481 488 B-Condition
conditions NCT03866707 489 499 I-Condition
that NCT03866707 500 504 O
might NCT03866707 505 510 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03866707 511 513 I-Assertion___Assertion-Type-Value:hypothetical
affected NCT03866707 514 522 O
by NCT03866707 523 525 O
or NCT03866707 526 528 B-Or
have NCT03866707 529 533 O
an NCT03866707 534 536 O
impact NCT03866707 537 543 O
on NCT03866707 544 546 O
this NCT03866707 547 551 O
research NCT03866707 552 560 O
study NCT03866707 561 566 B-Study
. NCT03866707 566 567 O
Healthy NCT03866707 569 576 B-Condition
controls NCT03866707 577 585 O
will NCT03866707 586 590 O
be NCT03866707 591 593 O
matched NCT03866707 594 601 O
with NCT03866707 602 606 O
patients NCT03866707 607 615 O
for NCT03866707 616 619 O
age NCT03866707 620 623 O
, NCT03866707 624 625 O
sex NCT03866707 626 629 O
, NCT03866707 630 631 O
ethnicity NCT03866707 632 641 O
, NCT03866707 642 643 O
geographic NCT03866707 644 654 O
region NCT03866707 655 661 O
, NCT03866707 662 663 O
and NCT03866707 664 667 O
tanner NCT03866707 668 674 O
stage NCT03866707 675 680 O
, NCT03866707 681 682 O
since NCT03866707 683 688 O
it NCT03866707 689 691 O
is NCT03866707 692 694 O
known NCT03866707 695 700 O
that NCT03866707 701 705 O
these NCT03866707 706 711 O
factors NCT03866707 712 719 O
can NCT03866707 720 723 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03866707 724 730 O
the NCT03866707 731 734 O
epigenetic NCT03866707 735 745 B-Observation
signature NCT03866707 746 755 I-Observation
of NCT03866707 756 758 O
an NCT03866707 759 761 O
individual NCT03866707 762 772 O
. NCT03866707 772 773 O
Controls NCT03866707 775 783 O
will NCT03866707 784 788 O
already NCT03866707 789 796 O
be NCT03866707 797 799 O
having NCT03866707 800 806 O
blood NCT03866707 807 812 B-Observation
drawn NCT03866707 813 818 O
as NCT03866707 819 821 O
part NCT03866707 822 826 O
of NCT03866707 827 829 O
their NCT03866707 830 835 O
routine NCT03866707 836 843 B-Procedure
care NCT03866707 844 848 I-Procedure
. NCT03866707 849 850 O

Exclusion NCT03866707 852 861 O
Criteria NCT03866707 862 870 O
: NCT03866707 871 872 O

Cancer NCT03866707 874 880 B-Condition
survivors NCT03866707 881 890 O
: NCT03866707 891 892 O

• NCT03866707 894 895 O
Patients NCT03866707 896 904 O
who NCT03866707 905 908 O
have NCT03866707 909 913 O
received NCT03866707 914 922 B-Eq-Comparison
a NCT03866707 923 924 O
bone NCT03866707 925 929 B-Procedure
marrow NCT03866707 930 936 I-Procedure
transplant NCT03866707 937 947 I-Procedure
will NCT03866707 948 952 O
not NCT03866707 953 956 B-Negation
be NCT03866707 957 959 O
eligible NCT03866707 960 968 O
. NCT03866707 969 970 O

Healthy NCT03866707 972 979 B-Condition
controls NCT03866707 980 988 O
: NCT03866707 989 990 O

• NCT03866707 992 993 O
Age NCT03866707 994 997 O
, NCT03866707 998 999 O
sex NCT03866707 1000 1003 O
, NCT03866707 1004 1005 O
ethnicity NCT03866707 1006 1015 O
, NCT03866707 1016 1017 O
geographic NCT03866707 1018 1028 O
region NCT03866707 1029 1035 O
, NCT03866707 1036 1037 O
and NCT03866707 1038 1041 O
tanner NCT03866707 1042 1048 O
stage NCT03866707 1049 1054 O
matched NCT03866707 1055 1062 O
controls NCT03866707 1063 1071 O
with NCT03866707 1072 1076 O
any NCT03866707 1077 1080 O
acute NCT03866707 1081 1086 O
or NCT03866707 1087 1089 B-Or
chronic NCT03866707 1090 1097 B-Modifier
disease NCT03866707 1098 1105 B-Condition
will NCT03866707 1106 1110 O
be NCT03866707 1111 1113 O
excluded NCT03866707 1114 1122 B-Negation
. NCT03866707 1123 1124 O


Inclusion NCT03860376 0 9 O
Criteria NCT03860376 10 18 O
: NCT03860376 19 20 O

- NCT03860376 24 25 O
Patients NCT03860376 27 35 O
aged NCT03860376 36 40 B-Age
21 NCT03860376 41 43 B-Eq-Comparison
years NCT03860376 44 49 I-Eq-Comparison
or NCT03860376 50 52 I-Eq-Comparison
younger NCT03860376 53 60 I-Eq-Comparison
at NCT03860376 61 63 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860376 64 67 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03860376 68 72 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860376 73 75 O
enrollment NCT03860376 76 86 B-Study
on NCT03860376 87 89 O
this NCT03860376 90 94 O
study NCT03860376 95 100 O
of NCT03860376 101 103 O
any NCT03860376 104 107 O
gender NCT03860376 108 114 O
, NCT03860376 115 116 O
race NCT03860376 117 121 O
or NCT03860376 122 124 O
ethnicity NCT03860376 125 134 O
. NCT03860376 135 136 O

- NCT03860376 145 146 O
Subjects NCT03860376 148 156 O
with NCT03860376 157 161 O
suspected NCT03860376 162 171 B-Assertion___Assertion-Type-Value:possible
or NCT03860376 172 174 B-Or
confirmed NCT03860376 175 184 B-Modifier
diagnosis NCT03860376 185 194 O
of NCT03860376 195 197 O
recurrent NCT03860376 198 207 B-Modifier
or NCT03860376 208 210 B-Or
refractory NCT03860376 211 221 B-Modifier
cancer NCT03860376 222 228 B-Condition

- NCT03860376 236 237 O
Subjects NCT03860376 239 247 O
who NCT03860376 248 251 O
are NCT03860376 252 255 O
scheduled NCT03860376 256 265 B-Eq-Comparison
for NCT03860376 266 269 O
or NCT03860376 270 272 B-Or
have NCT03860376 273 277 O
recently NCT03860376 278 286 B-Eq-Comparison
had NCT03860376 287 290 O
biopsy NCT03860376 291 297 B-Procedure
or NCT03860376 298 300 B-Or
tumor NCT03860376 301 306 B-Condition
excised NCT03860376 307 314 B-Procedure
( NCT03860376 315 316 O
solid NCT03860376 317 322 B-Modifier
tumors NCT03860376 323 329 B-Condition
) NCT03860376 330 331 O
or NCT03860376 332 334 B-Or
bone NCT03860376 335 339 B-Modifier
marrow NCT03860376 340 346 I-Modifier
aspirate NCT03860376 347 355 B-Procedure
( NCT03860376 356 357 O
blood NCT03860376 358 363 B-Modifier
cancers NCT03860376 364 371 B-Condition
) NCT03860376 372 373 O

- NCT03860376 382 383 O
Subjects NCT03860376 385 393 O
willing NCT03860376 394 401 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860376 402 404 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03860376 405 409 O
a NCT03860376 410 411 O
blood NCT03860376 412 417 B-Observation
draw NCT03860376 418 422 I-Observation
or NCT03860376 423 425 B-Or
buccal NCT03860376 426 432 B-Procedure
swab NCT03860376 433 437 I-Procedure
done NCT03860376 438 442 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860376 443 446 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03860376 447 450 O
purposes NCT03860376 451 459 O
of NCT03860376 460 462 O
genetic NCT03860376 463 470 B-Procedure
testing NCT03860376 471 478 I-Procedure

- NCT03860376 486 487 O
Subjects NCT03860376 489 497 O
or NCT03860376 498 500 O
their NCT03860376 501 506 O
parents NCT03860376 507 514 O
or NCT03860376 515 517 O
legal NCT03860376 518 523 O
guardians NCT03860376 524 533 O
willing NCT03860376 534 541 O
to NCT03860376 542 544 O
sign NCT03860376 545 549 O
informed NCT03860376 550 558 O
consent NCT03860376 559 566 O

- NCT03860376 574 575 O
Subjects NCT03860376 577 585 O
aged NCT03860376 586 590 B-Age
7 NCT03860376 591 592 B-Eq-Comparison
to NCT03860376 593 595 I-Eq-Comparison
17 NCT03860376 596 598 I-Eq-Comparison
willing NCT03860376 599 606 O
to NCT03860376 607 609 O
sign NCT03860376 610 614 O
assent NCT03860376 615 621 O

Exclusion NCT03860376 622 631 O
Criteria NCT03860376 632 640 O
: NCT03860376 641 642 O

- NCT03860376 646 647 O
Subjects NCT03860376 649 657 O
who NCT03860376 658 661 O
do NCT03860376 662 664 O
not NCT03860376 665 668 B-Negation
have NCT03860376 669 673 O
malignant NCT03860376 674 683 B-Condition
tissue NCT03860376 684 690 I-Condition
available NCT03860376 691 700 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03860376 701 704 B-Or
accessible NCT03860376 705 715 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03860376 718 719 O
The NCT03860376 721 724 O
amount NCT03860376 725 731 O
of NCT03860376 732 734 O
excised NCT03860376 735 742 B-Procedure
malignant NCT03860376 743 752 B-Condition
tissue NCT03860376 753 759 I-Condition
is NCT03860376 760 762 O
not NCT03860376 763 766 B-Negation
sufficient NCT03860376 767 777 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860376 778 781 O
the NCT03860376 782 785 O
ex NCT03860376 786 788 B-Modifier
vivo NCT03860376 789 793 I-Modifier
drug NCT03860376 794 798 B-Procedure
testing NCT03860376 799 806 I-Procedure
and NCT03860376 807 810 B-Or
/ NCT03860376 811 812 I-Or
or NCT03860376 813 815 I-Or
genetic NCT03860376 816 823 B-Procedure
profiling NCT03860376 824 833 I-Procedure
. NCT03860376 834 835 O

- NCT03860376 839 840 O
Patients NCT03860376 842 850 O
with NCT03860376 851 855 O
newly NCT03860376 856 861 B-Eq-Comparison
diagnosed NCT03860376 862 871 O
tumors NCT03860376 872 878 B-Condition
and NCT03860376 879 882 B-Or
tumors NCT03860376 883 889 B-Condition
that NCT03860376 890 894 O
have NCT03860376 895 899 O
high NCT03860376 900 904 O
( NCT03860376 905 906 O
> NCT03860376 908 909 B-Eq-Comparison
90 NCT03860376 910 912 I-Eq-Comparison
% NCT03860376 913 914 I-Eq-Comparison
) NCT03860376 916 917 O
cure NCT03860376 918 922 B-Observation
rate NCT03860376 923 927 I-Observation
with NCT03860376 928 932 O
safe NCT03860376 933 937 B-Modifier
standard NCT03860376 938 946 B-Procedure
therapy NCT03860376 947 954 I-Procedure
. NCT03860376 954 955 O

Inclusion NCT03869346 0 9 O
Criteria NCT03869346 10 18 O
: NCT03869346 19 20 O

- NCT03869346 24 25 O
American NCT03869346 27 35 B-Condition
Society NCT03869346 36 43 I-Condition
of NCT03869346 44 46 I-Condition
Anesthesiologists NCT03869346 47 64 I-Condition
GradeⅠ NCT03869346 65 71 B-Eq-Comparison
－ NCT03869346 72 73 I-Eq-Comparison
II NCT03869346 74 76 I-Eq-Comparison
, NCT03869346 77 78 O
Patients NCT03869346 79 87 O
undergo NCT03869346 88 95 B-Eq-Comparison
elective NCT03869346 96 104 B-Modifier
surgery NCT03869346 105 112 B-Procedure
for NCT03869346 113 116 O
benign NCT03869346 117 123 B-Modifier
Reproductive NCT03869346 124 136 B-Condition
diseases NCT03869346 137 145 I-Condition
( NCT03869346 146 147 O
including NCT03869346 148 157 O
laparoscopic NCT03869346 158 170 B-Procedure
ovarian NCT03869346 171 178 I-Procedure
cyst NCT03869346 179 183 I-Procedure
removal NCT03869346 184 191 I-Procedure
, NCT03869346 192 193 O
laparoscopic NCT03869346 194 206 B-Procedure
tubal NCT03869346 207 212 I-Procedure
ligation NCT03869346 213 221 I-Procedure
, NCT03869346 222 223 O
laparoscopic NCT03869346 224 236 B-Procedure
tubal NCT03869346 237 242 I-Procedure
drainage NCT03869346 243 251 I-Procedure
, NCT03869346 252 253 O
laparoscopic NCT03869346 254 266 B-Procedure
salpingoplasty NCT03869346 267 281 I-Procedure
, NCT03869346 282 283 O
etc NCT03869346 284 287 O
. NCT03869346 287 288 O
) NCT03869346 289 290 O
or NCT03869346 291 293 B-Or
breast NCT03869346 294 300 B-Condition
disease NCT03869346 301 308 I-Condition
. NCT03869346 309 310 O

- NCT03869346 314 315 O
Aged NCT03869346 317 321 B-Age
18 NCT03869346 322 324 B-Eq-Comparison
- NCT03869346 325 326 I-Eq-Comparison
45 NCT03869346 327 329 I-Eq-Comparison
years NCT03869346 330 335 I-Eq-Comparison

- NCT03869346 338 339 O
Body NCT03869346 341 345 B-Observation
Mass NCT03869346 346 350 I-Observation
Index NCT03869346 351 356 I-Observation
18 NCT03869346 357 359 B-Eq-Comparison
- NCT03869346 360 361 I-Eq-Comparison
25 NCT03869346 362 364 I-Eq-Comparison
kg NCT03869346 365 367 I-Eq-Comparison
/ NCT03869346 368 369 I-Eq-Comparison
m2 NCT03869346 370 372 I-Eq-Comparison
, NCT03869346 373 374 O
body NCT03869346 376 380 B-Observation
weight NCT03869346 381 387 I-Observation
40 NCT03869346 388 390 B-Eq-Comparison
- NCT03869346 391 392 I-Eq-Comparison
65 NCT03869346 393 395 I-Eq-Comparison
kilograms NCT03869346 396 405 I-Eq-Comparison

- NCT03869346 408 409 O
Agreed NCT03869346 411 417 O
to NCT03869346 418 420 O
participate NCT03869346 421 432 O
the NCT03869346 433 436 O
research NCT03869346 437 445 O

Exclusion NCT03869346 446 455 O
Criteria NCT03869346 456 464 O
: NCT03869346 465 466 O

- NCT03869346 470 471 O
Difficult NCT03869346 473 482 B-Condition
airway NCT03869346 483 489 I-Condition

- NCT03869346 492 493 O
upper NCT03869346 495 500 B-Condition
respiratory NCT03869346 501 512 I-Condition
tract NCT03869346 513 518 I-Condition
infection NCT03869346 519 528 I-Condition
within NCT03869346 529 535 B-Eq-Comparison
2 NCT03869346 536 537 I-Eq-Comparison
weeks NCT03869346 538 543 I-Eq-Comparison

- NCT03869346 546 547 O
history NCT03869346 549 556 B-Eq-Comparison
of NCT03869346 557 559 O
allergy NCT03869346 560 567 B-Allergy
or NCT03869346 568 570 B-Or
long NCT03869346 571 575 B-Modifier
- NCT03869346 576 577 I-Modifier
term NCT03869346 578 582 I-Modifier
use NCT03869346 583 586 O
of NCT03869346 587 589 O
propofol NCT03869346 590 598 B-Drug
and NCT03869346 599 602 B-Or
opioids NCT03869346 603 610 B-Drug

- NCT03869346 613 614 O
self NCT03869346 616 620 B-Observation
- NCT03869346 621 622 I-Observation
rating NCT03869346 623 629 I-Observation
anxiety NCT03869346 630 637 I-Observation
scale NCT03869346 638 643 I-Observation
before NCT03869346 644 650 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operation NCT03869346 651 660 B-Procedure
indicates NCT03869346 661 670 O
anxiety NCT03869346 671 678 B-Condition

- NCT03869346 681 682 O
pregnancy NCT03869346 684 693 B-Condition
or NCT03869346 694 696 B-Or
lactation NCT03869346 697 706 B-Condition
. NCT03869346 706 707 O

Inclusion NCT03860389 0 9 O
Criteria NCT03860389 10 18 O
: NCT03860389 19 20 O

- NCT03860389 24 25 O
Diagnosis NCT03860389 27 36 O
of NCT03860389 37 39 O
autism NCT03860389 40 46 B-Condition
spectrum NCT03860389 47 55 I-Condition
disorder NCT03860389 56 64 I-Condition

Exclusion NCT03860389 65 74 O
Criteria NCT03860389 75 83 O
: NCT03860389 84 85 O

- NCT03860389 89 90 O
Any NCT03860389 92 95 O
medical NCT03860389 96 103 B-Condition
condition NCT03860389 104 113 I-Condition
which NCT03860389 114 119 O
excludes NCT03860389 120 128 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03860389 129 132 O
child NCT03860389 133 138 B-Family-Member___Family-Member-Type:child
from NCT03860389 139 143 O
partaking NCT03860389 144 153 O
in NCT03860389 154 156 O
exercise NCT03860389 157 165 B-Observation

Inclusion NCT03868475 0 9 O
Criteria NCT03868475 10 18 O
: NCT03868475 19 20 O

- NCT03868475 24 25 O
Women NCT03868475 27 32 O
over NCT03868475 33 37 B-Eq-Comparison
age NCT03868475 38 41 I-Age|Eq-Comparison
18 NCT03868475 42 44 I-Eq-Comparison
with NCT03868475 45 49 B-And
a NCT03868475 50 51 O
core NCT03868475 52 56 B-Modifier
biopsy NCT03868475 57 63 B-Procedure
proven NCT03868475 64 70 O
borderline NCT03868475 71 81 B-Modifier
or NCT03868475 82 84 B-Or
high NCT03868475 85 89 O
- NCT03868475 90 91 O
risk NCT03868475 92 96 B-Risk
breast NCT03868475 97 103 B-Condition
lesion NCT03868475 104 110 I-Condition
that NCT03868475 111 115 O
requires NCT03868475 116 124 B-Assertion___Assertion-Type-Value:hypothetical
further NCT03868475 125 132 O
excision NCT03868475 133 141 B-Procedure
for NCT03868475 142 145 O
management NCT03868475 146 156 O
based NCT03868475 157 162 O
on NCT03868475 163 165 O
the NCT03868475 166 169 O
surgeon NCT03868475 170 177 B-Provider
's NCT03868475 177 179 O
assessment NCT03868475 180 190 O

- NCT03868475 193 194 O
Informed NCT03868475 196 204 O
consent NCT03868475 205 212 O
must NCT03868475 213 217 O
be NCT03868475 218 220 O
obtained NCT03868475 221 229 O
. NCT03868475 230 231 O

Exclusion NCT03868475 233 242 O
Criteria NCT03868475 243 251 O
: NCT03868475 252 253 O

- NCT03868475 257 258 O
Women NCT03868475 260 265 O
who NCT03868475 266 269 B-And
are NCT03868475 270 273 O
considered NCT03868475 274 284 O
high NCT03868475 285 289 O
- NCT03868475 290 291 O
risk NCT03868475 292 296 B-Risk
based NCT03868475 297 302 O
on NCT03868475 303 305 O
a NCT03868475 306 307 O
greater NCT03868475 308 315 B-Eq-Comparison
than NCT03868475 316 320 I-Eq-Comparison
25 NCT03868475 321 323 I-Eq-Comparison
% NCT03868475 324 325 I-Eq-Comparison
lifetime NCT03868475 326 334 O
risk NCT03868475 335 339 B-Risk
of NCT03868475 340 342 O
breast NCT03868475 343 349 B-Modifier
cancer NCT03868475 350 356 B-Condition
as NCT03868475 357 359 O
per NCT03868475 360 363 O
the NCT03868475 364 367 O
IBIS NCT03868475 368 372 O
( NCT03868475 373 374 O
International NCT03868475 375 388 O
Breast NCT03868475 389 395 O
Cancer NCT03868475 396 402 O
Intervention NCT03868475 403 415 O
Study NCT03868475 416 421 O
) NCT03868475 422 423 O
Breast NCT03868475 424 430 B-Observation
Cancer NCT03868475 431 437 I-Observation
Risk NCT03868475 438 442 I-Observation
Evaluation NCT03868475 443 453 I-Observation
Tool NCT03868475 454 458 I-Observation

- NCT03868475 461 462 O
Pathology NCT03868475 464 473 B-Condition
that NCT03868475 474 478 O
is NCT03868475 479 481 O
felt NCT03868475 482 486 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868475 487 489 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868475 490 492 O
discordant NCT03868475 493 503 B-Modifier
with NCT03868475 504 508 O
imaging NCT03868475 509 516 B-Procedure

- NCT03868475 519 520 O
Extensive NCT03868475 522 531 O
calcifications NCT03868475 532 546 B-Condition|Observation
extending NCT03868475 547 556 O
more NCT03868475 557 561 B-Eq-Comparison
than NCT03868475 562 566 I-Eq-Comparison
20 NCT03868475 567 569 I-Eq-Comparison
mm NCT03868475 570 572 I-Eq-Comparison
and NCT03868475 573 576 B-Or
/ NCT03868475 577 578 I-Or
or NCT03868475 579 581 I-Or
masses NCT03868475 582 588 B-Condition|Observation
greater NCT03868475 589 596 B-Eq-Comparison
than NCT03868475 597 601 I-Eq-Comparison
30 NCT03868475 602 604 I-Eq-Comparison
mm NCT03868475 605 607 I-Eq-Comparison

- NCT03868475 610 611 O
The NCT03868475 613 616 O
following NCT03868475 617 626 O
lesions NCT03868475 627 634 B-Condition
will NCT03868475 635 639 O
be NCT03868475 640 642 O
excluded NCT03868475 643 651 B-Negation
based NCT03868475 652 657 O
on NCT03868475 658 660 O
their NCT03868475 661 666 O
increased NCT03868475 667 676 O
risk NCT03868475 677 681 B-Risk
of NCT03868475 682 684 O
upstaging NCT03868475 685 694 B-Condition
; NCT03868475 694 695 O
lesions NCT03868475 696 703 B-Condition
( NCT03868475 704 705 O
other NCT03868475 706 711 B-Exception
than NCT03868475 712 716 I-Exception
fibroadenomas NCT03868475 717 730 B-Condition
, NCT03868475 731 732 O
phyllodes NCT03868475 733 742 B-Condition
and NCT03868475 743 746 B-Or
papillomas NCT03868475 747 757 B-Condition
) NCT03868475 758 759 O
that NCT03868475 760 764 O
are NCT03868475 765 768 O
associated NCT03868475 769 779 O
with NCT03868475 780 784 O
a NCT03868475 785 786 O
palpable NCT03868475 787 795 B-Condition
mass NCT03868475 796 800 I-Condition
, NCT03868475 801 802 O
ADH NCT03868475 803 806 B-Condition
( NCT03868475 807 808 O
atypical NCT03868475 809 817 B-Condition
ductal NCT03868475 818 824 I-Condition
hyperplasia NCT03868475 825 836 I-Condition
) NCT03868475 837 838 O
with NCT03868475 839 843 B-And
high NCT03868475 844 848 O
- NCT03868475 849 850 O
risk NCT03868475 851 855 B-Risk
features NCT03868475 856 864 B-Condition
( NCT03868475 865 866 O
ADH NCT03868475 867 870 B-Condition
with NCT03868475 871 875 B-And
zonal NCT03868475 876 881 B-Condition
necrosis NCT03868475 882 890 I-Condition
, NCT03868475 891 892 O
significant NCT03868475 893 904 O
cytological NCT03868475 905 916 B-Condition
atypia NCT03868475 917 923 I-Condition
or NCT03868475 924 926 B-Or
more NCT03868475 927 931 B-Eq-Comparison
than NCT03868475 932 936 I-Eq-Comparison
2 NCT03868475 937 938 I-Eq-Comparison
foci NCT03868475 939 943 B-Condition
) NCT03868475 944 945 O
, NCT03868475 947 948 O
LCIS NCT03868475 949 953 B-Condition
( NCT03868475 954 955 O
lobular NCT03868475 956 963 B-Modifier
carcinoma NCT03868475 964 973 B-Condition
in NCT03868475 974 976 B-Modifier
situ NCT03868475 977 981 I-Modifier
) NCT03868475 982 983 O
with NCT03868475 984 988 B-And
high NCT03868475 989 993 O
- NCT03868475 994 995 O
risk NCT03868475 996 1000 B-Risk
features NCT03868475 1001 1009 B-Condition
( NCT03868475 1010 1011 O
associated NCT03868475 1012 1022 O
with NCT03868475 1023 1027 O
ADH NCT03868475 1028 1031 B-Condition
, NCT03868475 1032 1033 O
pleomorphic NCT03868475 1034 1045 B-Condition
LCIS NCT03868475 1046 1050 I-Condition
, NCT03868475 1051 1052 O
zonal NCT03868475 1053 1058 B-Condition
necrosis NCT03868475 1059 1067 I-Condition
and NCT03868475 1068 1071 B-Or
> NCT03868475 1072 1073 B-Eq-Comparison
4 NCT03868475 1074 1075 I-Eq-Comparison
foci NCT03868475 1076 1080 B-Condition
) NCT03868475 1081 1082 O
or NCT03868475 1083 1085 B-Or
discordant NCT03868475 1086 1096 B-Modifier
with NCT03868475 1097 1101 O
imaging NCT03868475 1102 1109 B-Procedure
, NCT03868475 1110 1111 O
papilloma NCT03868475 1112 1121 B-Condition
with NCT03868475 1122 1126 O
atypia NCT03868475 1127 1133 B-Modifier
, NCT03868475 1134 1135 O
and NCT03868475 1136 1139 B-Or
spindle NCT03868475 1140 1147 B-Modifier
cell NCT03868475 1148 1152 I-Modifier
lesion NCT03868475 1153 1159 B-Condition
( NCT03868475 1160 1161 O
especially NCT03868475 1162 1172 O
if NCT03868475 1173 1175 O
there NCT03868475 1176 1181 O
is NCT03868475 1182 1184 O
atypia NCT03868475 1185 1191 B-Modifier
) NCT03868475 1192 1193 O
. NCT03868475 1195 1196 O

- NCT03868475 1200 1201 O
Lesions NCT03868475 1203 1210 B-Condition
that NCT03868475 1211 1215 O
are NCT03868475 1216 1219 O
suspicious NCT03868475 1220 1230 B-Assertion___Assertion-Type-Value:possible
for NCT03868475 1231 1234 O
borderline NCT03868475 1235 1245 B-Modifier
or NCT03868475 1246 1248 B-Or
malignant NCT03868475 1249 1258 B-Modifier
Phyllodes NCT03868475 1259 1268 B-Condition
, NCT03868475 1269 1270 O
DCIS NCT03868475 1271 1275 B-Condition
( NCT03868475 1276 1277 O
ductal NCT03868475 1278 1284 B-Condition
carcinoma NCT03868475 1285 1294 I-Condition
in NCT03868475 1295 1297 B-Modifier
situ NCT03868475 1298 1302 I-Modifier
) NCT03868475 1303 1304 O
, NCT03868475 1306 1307 O
invasive NCT03868475 1308 1316 B-Modifier
mammary NCT03868475 1317 1324 I-Modifier
carcinoma NCT03868475 1325 1334 B-Condition
, NCT03868475 1335 1336 O
or NCT03868475 1337 1339 B-Or
encapsulated NCT03868475 1340 1352 B-Modifier
papillary NCT03868475 1353 1362 I-Modifier
carcinoma NCT03868475 1363 1372 B-Condition

- NCT03868475 1375 1376 O
Any NCT03868475 1378 1381 O
lesion NCT03868475 1382 1388 B-Condition
that NCT03868475 1389 1393 O
either NCT03868475 1394 1400 O
the NCT03868475 1401 1404 O
radiologist NCT03868475 1405 1416 B-Provider
, NCT03868475 1417 1418 O
pathologist NCT03868475 1419 1430 B-Provider
or NCT03868475 1431 1433 B-Or
surgeon NCT03868475 1434 1441 B-Provider
feels NCT03868475 1442 1447 O
is NCT03868475 1448 1450 O
not NCT03868475 1451 1454 B-Negation
amenable NCT03868475 1455 1463 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868475 1464 1466 O
VAPE NCT03868475 1467 1471 B-Procedure
or NCT03868475 1472 1474 B-Or
surgical NCT03868475 1475 1483 B-Procedure
excision NCT03868475 1484 1492 I-Procedure

Inclusion NCT03867292 0 9 O
Criteria NCT03867292 10 18 O
: NCT03867292 19 20 O

- NCT03867292 24 25 O
Padel NCT03867292 27 32 B-Observation
players NCT03867292 33 40 I-Observation

- NCT03867292 43 44 O
With NCT03867292 46 50 O
federal NCT03867292 51 58 O
sheet NCT03867292 59 64 O

- NCT03867292 67 68 O
Male NCT03867292 70 74 O

- NCT03867292 77 78 O
Over NCT03867292 80 84 B-Eq-Comparison
18 NCT03867292 85 87 I-Eq-Comparison
years NCT03867292 88 93 I-Age|Eq-Comparison

- NCT03867292 96 97 O
Currently NCT03867292 99 108 O
participate NCT03867292 109 120 O
in NCT03867292 121 123 O
regional NCT03867292 124 132 O
and NCT03867292 133 136 O
/ NCT03867292 137 138 O
or NCT03867292 139 141 O
national NCT03867292 142 150 O
competitions NCT03867292 151 163 O

Exclusion NCT03867292 164 173 O
Criteria NCT03867292 174 182 O
: NCT03867292 183 184 O

- NCT03867292 188 189 O
Present NCT03867292 191 198 O
a NCT03867292 199 200 O
medical NCT03867292 201 208 O
diagnosis NCT03867292 209 218 O
of NCT03867292 219 221 O
musculoskeletal NCT03867292 222 237 B-Modifier
pathology NCT03867292 238 247 B-Condition

- NCT03867292 250 251 O
Not NCT03867292 253 256 O
signed NCT03867292 257 263 O
the NCT03867292 264 267 O
informed NCT03867292 268 276 O
consent NCT03867292 277 284 O
document NCT03867292 285 293 O
. NCT03867292 293 294 O

Inclusion NCT03865056 0 9 O
Criteria NCT03865056 10 18 O
: NCT03865056 19 20 O

1 NCT03865056 24 25 O
. NCT03865056 25 26 O
Hypoxemia NCT03865056 28 37 B-Condition
defined NCT03865056 38 45 O
by NCT03865056 46 48 O
a NCT03865056 49 50 O
ratio NCT03865056 51 56 O
of NCT03865056 57 59 O
the NCT03865056 60 63 O
partial NCT03865056 64 71 B-Observation
pressure NCT03865056 72 80 I-Observation
of NCT03865056 81 83 I-Observation
arterial NCT03865056 84 92 I-Observation
oxygen NCT03865056 93 99 I-Observation
to NCT03865056 100 102 I-Observation
the NCT03865056 103 106 I-Observation
fraction NCT03865056 107 115 I-Observation
of NCT03865056 116 118 I-Observation
inspired NCT03865056 119 127 I-Observation
oxygen NCT03865056 128 134 I-Observation
( NCT03865056 135 136 O
PaO2 NCT03865056 137 141 B-Observation
: NCT03865056 142 143 I-Observation
FiO2 NCT03865056 144 148 I-Observation
) NCT03865056 149 150 O
≤ NCT03865056 151 152 B-Eq-Comparison
300 NCT03865056 153 156 I-Eq-Comparison
while NCT03865056 157 162 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865056 163 166 O
patient NCT03865056 167 174 O
is NCT03865056 175 177 O
breathing NCT03865056 178 187 B-Observation
oxygen NCT03865056 188 194 I-Observation
through NCT03865056 195 202 O
NHF NCT03865056 203 206 B-Procedure
for NCT03865056 207 210 O
at NCT03865056 211 213 B-Eq-Comparison
least NCT03865056 214 219 I-Eq-Comparison
15 NCT03865056 220 222 I-Eq-Comparison
minutes NCT03865056 223 230 I-Eq-Comparison
; NCT03865056 230 231 O

2 NCT03865056 234 235 O
. NCT03865056 235 236 O
Respiratory NCT03865056 238 249 B-Observation
rate NCT03865056 250 254 I-Observation
> NCT03865056 255 256 B-Eq-Comparison
25 NCT03865056 257 259 I-Eq-Comparison
breaths NCT03865056 260 267 I-Eq-Comparison
/ NCT03865056 268 269 I-Eq-Comparison
minute NCT03865056 270 276 I-Eq-Comparison
; NCT03865056 276 277 O

3 NCT03865056 280 281 O
. NCT03865056 281 282 O
Partial NCT03865056 284 291 B-Observation
pressure NCT03865056 292 300 I-Observation
of NCT03865056 301 303 I-Observation
arterial NCT03865056 304 312 I-Observation
carbon NCT03865056 313 319 I-Observation
dioxide NCT03865056 320 327 I-Observation
( NCT03865056 328 329 O
PaCO2 NCT03865056 330 335 B-Observation
) NCT03865056 336 337 O
≤ NCT03865056 338 339 B-Eq-Comparison
45 NCT03865056 340 342 I-Eq-Comparison
mmHg NCT03865056 343 347 I-Eq-Comparison
; NCT03865056 347 348 O

4 NCT03865056 351 352 O
. NCT03865056 352 353 O
Absence NCT03865056 355 362 B-Negation
of NCT03865056 363 365 O
clinical NCT03865056 366 374 O
history NCT03865056 375 382 B-Eq-Comparison
of NCT03865056 383 385 O
underlying NCT03865056 386 396 O
chronic NCT03865056 397 404 B-Modifier
respiratory NCT03865056 405 416 B-Condition
failure NCT03865056 417 424 I-Condition
. NCT03865056 425 426 O

Exclusion NCT03865056 428 437 O
Criteria NCT03865056 438 446 O
: NCT03865056 447 448 O

1 NCT03865056 452 453 O
. NCT03865056 453 454 O
Lack NCT03865056 456 460 O
of NCT03865056 461 463 O
consent NCT03865056 464 471 O
; NCT03865056 471 472 O

2 NCT03865056 475 476 O
. NCT03865056 476 477 O
Age NCT03865056 479 482 B-Age
< NCT03865056 483 484 B-Eq-Comparison
18 NCT03865056 485 487 I-Eq-Comparison
years NCT03865056 488 493 I-Eq-Comparison
; NCT03865056 493 494 O

3 NCT03865056 497 498 O
. NCT03865056 498 499 O
Invasive NCT03865056 501 509 B-Modifier
mechanical NCT03865056 510 520 B-Procedure
ventilation NCT03865056 521 532 I-Procedure
for NCT03865056 533 536 O
> NCT03865056 537 538 B-Eq-Comparison
48 NCT03865056 539 541 I-Eq-Comparison
hours NCT03865056 542 547 I-Eq-Comparison
in NCT03865056 548 550 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865056 551 554 I-Temporal-Connection___Temporal-Connection-Type-Value:during
same NCT03865056 555 559 I-Temporal-Connection___Temporal-Connection-Type-Value:during
hospital NCT03865056 560 568 O
admission NCT03865056 569 578 B-Encounter

4 NCT03865056 581 582 O
. NCT03865056 582 583 O
Immediate NCT03865056 585 594 O
need NCT03865056 595 599 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865056 600 603 I-Assertion___Assertion-Type-Value:hypothetical
intubation NCT03865056 604 614 B-Procedure
; NCT03865056 614 615 O

5 NCT03865056 618 619 O
. NCT03865056 619 620 O
Previous NCT03865056 622 630 B-Eq-Comparison
inclusion NCT03865056 631 640 O
in NCT03865056 641 643 O
the NCT03865056 644 647 O
present NCT03865056 648 655 O
study NCT03865056 656 661 B-Study
; NCT03865056 661 662 O

6 NCT03865056 665 666 O
. NCT03865056 666 667 O
Systolic NCT03865056 669 677 B-Observation
arterial NCT03865056 678 686 I-Observation
pressure NCT03865056 687 695 I-Observation
< NCT03865056 696 697 B-Eq-Comparison
90 NCT03865056 698 700 I-Eq-Comparison
mmHg NCT03865056 701 705 I-Eq-Comparison
after NCT03865056 706 711 B-Temporal-Connection___Temporal-Connection-Type-Value:after
optimal NCT03865056 712 719 B-Modifier
fluid NCT03865056 720 725 B-Procedure
therapy NCT03865056 726 733 I-Procedure
; NCT03865056 733 734 O

7 NCT03865056 737 738 O
. NCT03865056 738 739 O
Cardiogenic NCT03865056 741 752 B-Condition
pulmonary NCT03865056 753 762 I-Condition
edema NCT03865056 763 768 I-Condition
; NCT03865056 768 769 O

8 NCT03865056 772 773 O
. NCT03865056 773 774 O
Glasgow NCT03865056 776 783 B-Observation
Coma NCT03865056 784 788 I-Observation
Scale NCT03865056 789 794 I-Observation
< NCT03865056 795 796 B-Eq-Comparison
12 NCT03865056 797 799 I-Eq-Comparison
; NCT03865056 800 801 O

9 NCT03865056 804 805 O
. NCT03865056 805 806 O
Imminent NCT03865056 808 816 B-Risk
death NCT03865056 817 822 B-Death
; NCT03865056 822 823 O

10 NCT03865056 825 827 O
. NCT03865056 827 828 O
Contraindications NCT03865056 830 847 B-Contraindication
to NCT03865056 848 850 O
noninvasive NCT03865056 851 862 B-Procedure
ventilation NCT03865056 863 874 I-Procedure
; NCT03865056 874 875 O

11 NCT03865056 877 879 O
. NCT03865056 879 880 O
Tracheostomy NCT03865056 882 894 B-Procedure
. NCT03865056 894 895 O

Inclusion NCT03868228 0 9 O
Criteria NCT03868228 10 18 O
: NCT03868228 19 20 O

1 NCT03868228 24 25 O
. NCT03868228 25 26 O
Patients NCT03868228 28 36 O
with NCT03868228 37 41 O
CPM NCT03868228 42 45 B-Condition
with NCT03868228 46 50 B-And
expected NCT03868228 51 59 B-Modifier
life NCT03868228 60 64 B-Observation
expectancy NCT03868228 65 75 I-Observation
of NCT03868228 76 78 O
> NCT03868228 79 80 B-Eq-Comparison
6 NCT03868228 81 82 I-Eq-Comparison
months NCT03868228 83 89 I-Eq-Comparison
. NCT03868228 90 91 O

2 NCT03868228 95 96 O
. NCT03868228 96 97 O
ECOG NCT03868228 99 103 B-Observation
Scale NCT03868228 104 109 I-Observation
of NCT03868228 110 112 I-Observation
Performance NCT03868228 113 124 I-Observation
Status NCT03868228 125 131 I-Observation
( NCT03868228 132 133 O
PS NCT03868228 134 136 B-Observation
) NCT03868228 137 138 O
scores NCT03868228 139 145 B-Eq-Comparison
0 NCT03868228 146 147 I-Eq-Comparison
or NCT03868228 148 150 I-Eq-Comparison
1 NCT03868228 151 152 I-Eq-Comparison
. NCT03868228 152 153 O

3 NCT03868228 157 158 O
. NCT03868228 158 159 O
15 NCT03868228 161 163 O
mile NCT03868228 164 168 O
catchment NCT03868228 169 178 O
area NCT03868228 179 183 O
to NCT03868228 184 186 B-Assertion___Assertion-Type-Value:hypothetical
facilitate NCT03868228 187 197 I-Assertion___Assertion-Type-Value:hypothetical
overseeing NCT03868228 198 208 O
systemic NCT03868228 209 217 B-Modifier
chemotherapy NCT03868228 218 230 B-Procedure
administration NCT03868228 231 245 O

4 NCT03868228 248 249 O
. NCT03868228 249 250 O
Concomitant NCT03868228 252 263 B-Modifier
systemic NCT03868228 264 272 I-Modifier
chemotherapy NCT03868228 273 285 B-Procedure
regimens NCT03868228 286 294 O
with NCT03868228 295 299 O
FOLFIRI NCT03868228 300 307 B-Drug
, NCT03868228 308 309 O
FOLFOX NCT03868228 310 316 B-Drug
, NCT03868228 317 318 O
Mitomycin NCT03868228 319 328 B-Drug
C NCT03868228 329 330 I-Drug
& NCT03868228 331 332 B-Or

Fluorouracil NCT03868228 338 350 B-Drug
, NCT03868228 351 352 O
Capecitabine NCT03868228 353 365 B-Drug
( NCT03868228 366 367 O
excluding NCT03868228 368 377 B-Exception
Lonsurf NCT03868228 378 385 B-Drug
) NCT03868228 386 387 O
or NCT03868228 388 390 B-Or
without NCT03868228 391 398 B-Negation
systemic NCT03868228 399 407 B-Modifier
chemotherapy NCT03868228 408 420 B-Procedure
if NCT03868228 421 423 O
no NCT03868228 424 426 B-Negation
systemic NCT03868228 427 435 B-Modifier
options NCT03868228 436 443 O
available NCT03868228 444 453 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868228 454 456 O
patient NCT03868228 457 464 O

5 NCT03868228 467 468 O
. NCT03868228 468 469 O
Neutrophil NCT03868228 471 481 B-Observation
count NCT03868228 482 487 I-Observation
on NCT03868228 488 490 B-Temporal-Connection___Temporal-Connection-Type-Value:during
or NCT03868228 491 493 B-Or
just NCT03868228 494 498 O
before NCT03868228 499 505 B-Temporal-Connection___Temporal-Connection-Type-Value:before
chemotherapy NCT03868228 506 518 B-Procedure
due NCT03868228 519 522 O
date NCT03868228 523 527 O
of NCT03868228 528 530 O
> NCT03868228 531 532 B-Eq-Comparison
1.5 NCT03868228 533 536 I-Eq-Comparison

Exclusion NCT03868228 538 547 O
Criteria NCT03868228 548 556 O
: NCT03868228 557 558 O

1 NCT03868228 562 563 O
. NCT03868228 563 564 O
Age NCT03868228 566 569 B-Age
< NCT03868228 570 571 B-Eq-Comparison
18 NCT03868228 572 574 I-Eq-Comparison

2 NCT03868228 578 579 O
. NCT03868228 579 580 O
MDT NCT03868228 582 585 B-Condition
decision NCT03868228 586 594 O
that NCT03868228 595 599 O
patient NCT03868228 600 607 O
not NCT03868228 608 611 B-Negation
suitable NCT03868228 612 620 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868228 621 624 O
PIPAC NCT03868228 625 630 B-Procedure

3 NCT03868228 633 634 O
. NCT03868228 634 635 O
Decision NCT03868228 637 645 O
by NCT03868228 646 648 O
Pre NCT03868228 649 652 B-Procedure
operative NCT03868228 653 662 I-Procedure
Assessment NCT03868228 663 673 I-Procedure
Department NCT03868228 674 684 O
or NCT03868228 685 687 B-Or
Consultant NCT03868228 688 698 B-Modifier
Anaesthetist NCT03868228 699 711 B-Provider
that NCT03868228 712 716 O
patient NCT03868228 717 724 O
not NCT03868228 725 728 B-Negation
fit NCT03868228 729 732 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868228 733 736 I-Assertion___Assertion-Type-Value:hypothetical
general NCT03868228 737 744 B-Procedure
anaesthesia NCT03868228 745 756 I-Procedure
and NCT03868228 757 760 B-Or
/ NCT03868228 761 762 I-Or
or NCT03868228 763 765 I-Or
laparoscopy NCT03868228 766 777 B-Procedure

4 NCT03868228 780 781 O
. NCT03868228 781 782 O
Clinically NCT03868228 784 794 O
evident NCT03868228 795 802 B-Condition
gross NCT03868228 803 808 I-Condition
ascites NCT03868228 809 816 I-Condition

5 NCT03868228 819 820 O
. NCT03868228 820 821 O
Bowel NCT03868228 823 828 B-Condition
obstruction NCT03868228 829 840 I-Condition

6 NCT03868228 843 844 O
. NCT03868228 844 845 O
Bevacizumab NCT03868228 847 858 B-Drug
as NCT03868228 859 861 O
part NCT03868228 862 866 O
of NCT03868228 867 869 O
systemic NCT03868228 870 878 B-Modifier
chemotherapy NCT03868228 879 891 B-Procedure
regime NCT03868228 892 898 O
- NCT03868228 899 900 O
time NCT03868228 901 905 O
from NCT03868228 906 910 O
chemotherapy NCT03868228 911 923 B-Procedure
to NCT03868228 924 926 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03868228 927 934 B-Procedure
would NCT03868228 935 940 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03868228 941 943 I-Assertion___Assertion-Type-Value:hypothetical
too NCT03868228 944 947 O
long NCT03868228 948 952 O
for NCT03868228 953 956 O
PIPAC NCT03868228 957 962 B-Procedure
to NCT03868228 963 965 O
be NCT03868228 966 968 O
feasible NCT03868228 969 977 O

7 NCT03868228 980 981 O
. NCT03868228 981 982 O
Previous NCT03868228 984 992 B-Eq-Comparison
bone NCT03868228 993 997 B-Condition
marrow NCT03868228 998 1004 I-Condition
suppression NCT03868228 1005 1016 I-Condition
due NCT03868228 1017 1020 O
to NCT03868228 1021 1023 O
chemotherapy NCT03868228 1024 1036 B-Procedure
given NCT03868228 1037 1042 O
risk NCT03868228 1043 1047 B-Risk
of NCT03868228 1048 1050 O
post NCT03868228 1051 1055 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03868228 1056 1057 O
operative NCT03868228 1058 1067 B-Procedure
neutropenia NCT03868228 1068 1079 B-Condition

Key NCT03866577 0 3 O
Criteria NCT03866577 4 12 O
for NCT03866577 13 16 O
Healthy NCT03866577 17 24 B-Condition
Volunteers NCT03866577 25 35 O
: NCT03866577 36 37 O
Subject NCT03866577 38 45 O
must NCT03866577 46 50 O
be NCT03866577 51 53 O
between NCT03866577 54 61 B-Eq-Comparison
the NCT03866577 62 65 I-Eq-Comparison
ages NCT03866577 66 70 I-Age|Eq-Comparison
of NCT03866577 71 73 I-Eq-Comparison
18 NCT03866577 74 76 I-Eq-Comparison
and NCT03866577 77 80 I-Eq-Comparison
55 NCT03866577 81 83 I-Eq-Comparison
years NCT03866577 84 89 I-Eq-Comparison
; NCT03866577 89 90 O

healthy NCT03866577 91 98 B-Condition
as NCT03866577 99 101 O
indicated NCT03866577 102 111 O
by NCT03866577 112 114 O
medical NCT03866577 115 122 B-Procedure
history NCT03866577 123 130 I-Procedure
, NCT03866577 131 132 O
physical NCT03866577 133 141 B-Procedure
examination NCT03866577 142 153 I-Procedure
, NCT03866577 154 155 O
vital NCT03866577 156 161 B-Observation
signs NCT03866577 162 167 I-Observation
, NCT03866577 168 169 O
clinical NCT03866577 170 178 O
laboratory NCT03866577 179 189 B-Observation
tests NCT03866577 190 195 I-Observation
, NCT03866577 196 197 O
and NCT03866577 198 201 B-Or
12 NCT03866577 202 204 B-Procedure
- NCT03866577 205 206 I-Procedure
lead NCT03866577 207 211 I-Procedure
electrocardiogram NCT03866577 212 229 I-Procedure
, NCT03866577 230 231 O
and NCT03866577 232 235 B-And
all NCT03866577 236 239 O
abnormal NCT03866577 240 248 O
findings NCT03866577 249 257 B-Condition
are NCT03866577 258 261 O
assessed NCT03866577 262 270 O
as NCT03866577 271 273 O
not NCT03866577 274 277 B-Negation
clinically NCT03866577 278 288 O
significant NCT03866577 289 300 O
by NCT03866577 301 303 O
the NCT03866577 304 307 O
Investigator NCT03866577 308 320 O
; NCT03866577 320 321 O
not NCT03866577 322 325 B-Negation
pregnant NCT03866577 326 334 B-Condition
or NCT03866577 335 337 B-Or
breastfeeding NCT03866577 338 351 B-Condition
; NCT03866577 351 352 O
and NCT03866577 353 356 B-And
no NCT03866577 357 359 B-Negation
other NCT03866577 360 365 B-Other
clinically NCT03866577 366 376 O
relevant NCT03866577 377 385 O
abnormalities NCT03866577 386 399 B-Condition
currently NCT03866577 400 409 B-Eq-Comparison
or NCT03866577 410 412 B-Or
in NCT03866577 413 415 O
their NCT03866577 416 421 O
history NCT03866577 422 429 B-Eq-Comparison
that NCT03866577 430 434 O
the NCT03866577 435 438 O
Investigator NCT03866577 439 451 O
would NCT03866577 452 457 O
deem NCT03866577 458 462 O
them NCT03866577 463 467 O
ineligible NCT03866577 468 478 O
to NCT03866577 479 481 O
participate NCT03866577 482 493 O
. NCT03866577 494 495 O

Key NCT03866577 497 500 O
Criteria NCT03866577 501 509 O
for NCT03866577 510 513 O
Immune NCT03866577 514 520 B-Condition
Thrombocytopenic NCT03866577 521 537 I-Condition
Purpura NCT03866577 538 545 I-Condition
( NCT03866577 546 547 O
ITP NCT03866577 548 551 B-Condition
) NCT03866577 552 553 O
Patients NCT03866577 554 562 O
: NCT03866577 563 564 O
Patient NCT03866577 565 572 O
must NCT03866577 573 577 O
be NCT03866577 578 580 O
between NCT03866577 581 588 B-Eq-Comparison
the NCT03866577 589 592 I-Eq-Comparison
ages NCT03866577 593 597 I-Age|Eq-Comparison
of NCT03866577 598 600 I-Eq-Comparison
18 NCT03866577 601 603 I-Eq-Comparison
to NCT03866577 604 606 I-Eq-Comparison
64 NCT03866577 607 609 I-Eq-Comparison
years NCT03866577 610 615 I-Eq-Comparison
and NCT03866577 616 619 B-And
diagnosed NCT03866577 620 629 O
with NCT03866577 630 634 O
ITP NCT03866577 635 638 B-Condition
at NCT03866577 639 641 B-Eq-Comparison
least NCT03866577 642 647 I-Eq-Comparison
3 NCT03866577 648 649 I-Eq-Comparison
months NCT03866577 650 656 I-Eq-Comparison
prior NCT03866577 657 662 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866577 663 665 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03866577 666 675 B-Study
, NCT03866577 676 677 O
stable NCT03866577 678 684 O
maintenance NCT03866577 685 696 B-Procedure
therapy NCT03866577 697 704 I-Procedure
for NCT03866577 705 708 O
at NCT03866577 709 711 B-Eq-Comparison
least NCT03866577 712 717 I-Eq-Comparison
4 NCT03866577 718 719 I-Eq-Comparison
weeks NCT03866577 720 725 I-Eq-Comparison
prior NCT03866577 726 731 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866577 732 734 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866577 735 738 O
first NCT03866577 739 744 B-Eq-Comparison
study NCT03866577 745 750 B-Study
visit NCT03866577 751 756 O
, NCT03866577 757 758 O
not NCT03866577 759 762 B-Negation
pregnant NCT03866577 763 771 B-Condition
or NCT03866577 772 774 B-Or
breastfeeding NCT03866577 775 788 B-Condition
, NCT03866577 789 790 O
and NCT03866577 791 794 B-And
no NCT03866577 795 797 B-Negation
other NCT03866577 798 803 B-Other
clinically NCT03866577 804 814 O
relevant NCT03866577 815 823 O
abnormalities NCT03866577 824 837 B-Condition
currently NCT03866577 838 847 B-Eq-Comparison
or NCT03866577 848 850 B-Or
in NCT03866577 851 853 O
their NCT03866577 854 859 O
history NCT03866577 860 867 B-Eq-Comparison
that NCT03866577 868 872 O
the NCT03866577 873 876 O
Investigator NCT03866577 877 889 O
would NCT03866577 890 895 O
deem NCT03866577 896 900 O
them NCT03866577 901 905 O
ineligible NCT03866577 906 916 O
to NCT03866577 917 919 O
participate NCT03866577 920 931 O
. NCT03866577 932 933 O


Inclusion NCT03865095 0 9 O
Criteria NCT03865095 10 18 O
: NCT03865095 19 20 O

- NCT03865095 24 25 O
age NCT03865095 27 30 B-Age
≥ NCT03865095 31 32 B-Eq-Comparison
18 NCT03865095 33 35 I-Eq-Comparison
years NCT03865095 36 41 I-Eq-Comparison

- NCT03865095 44 45 O
mechanical NCT03865095 47 57 B-Procedure
ventilation NCT03865095 58 69 I-Procedure
expected NCT03865095 70 78 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865095 79 82 O
at NCT03865095 83 85 B-Eq-Comparison
least NCT03865095 86 91 I-Eq-Comparison
48 NCT03865095 92 94 I-Eq-Comparison
hours NCT03865095 95 100 I-Eq-Comparison

Exclusion NCT03865095 101 110 O
Criteria NCT03865095 111 119 O
: NCT03865095 120 121 O

- NCT03865095 125 126 O
Clinical NCT03865095 128 136 B-Observation
Frailty NCT03865095 137 144 I-Observation
Score NCT03865095 145 150 I-Observation
above NCT03865095 151 156 B-Eq-Comparison
7 NCT03865095 157 158 I-Eq-Comparison
prior NCT03865095 159 164 B-Eq-Comparison
admission NCT03865095 165 174 B-Encounter

- NCT03865095 177 178 O
neuromuscular NCT03865095 180 193 B-Condition
disease NCT03865095 194 201 I-Condition
in NCT03865095 202 204 O
previous NCT03865095 205 213 B-Eq-Comparison
medical NCT03865095 214 221 I-Eq-Comparison
history NCT03865095 222 229 I-Eq-Comparison

- NCT03865095 232 233 O
amputated NCT03865095 235 244 B-Condition
lower NCT03865095 245 250 B-Modifier
extremities NCT03865095 251 262 I-Modifier

- NCT03865095 265 266 O
trauma NCT03865095 268 274 B-Condition
of NCT03865095 275 277 O
lower NCT03865095 278 283 B-Modifier
extremities NCT03865095 284 295 I-Modifier
involving NCT03865095 296 305 I-Modifier
tights NCT03865095 306 312 I-Modifier

- NCT03865095 315 316 O
age NCT03865095 318 321 B-Age
under NCT03865095 322 327 B-Eq-Comparison
18 NCT03865095 328 330 I-Eq-Comparison
years NCT03865095 331 336 I-Eq-Comparison

- NCT03865095 339 340 O
inability NCT03865095 342 351 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865095 352 354 O
perform NCT03865095 355 362 O
ultrasound NCT03865095 363 373 B-Procedure
examination NCT03865095 374 385 I-Procedure

- NCT03865095 388 389 O
death NCT03865095 391 396 B-Death
or NCT03865095 397 399 B-Or
discharge NCT03865095 400 409 B-Encounter
prior NCT03865095 410 415 B-Temporal-Connection___Temporal-Connection-Type-Value:before
completion NCT03865095 416 426 O
of NCT03865095 427 429 O
protocol NCT03865095 430 438 B-Study

- NCT03865095 441 442 O
full NCT03865095 444 448 B-Procedure
verticalization NCT03865095 449 464 I-Procedure
prior NCT03865095 465 470 B-Temporal-Connection___Temporal-Connection-Type-Value:before
completion NCT03865095 471 481 O
of NCT03865095 482 484 O
protocol NCT03865095 485 493 B-Study

Inclusion NCT03867682 0 9 O
Criteria NCT03867682 10 18 O
: NCT03867682 19 20 O

1 NCT03867682 24 25 O
. NCT03867682 25 26 O
Refractory NCT03867682 28 38 B-Modifier
or NCT03867682 39 41 B-Or
relapsed NCT03867682 42 50 B-Modifier
AML NCT03867682 51 54 B-Condition
which NCT03867682 55 60 O
will NCT03867682 61 65 O
include NCT03867682 66 73 O
: NCT03867682 74 75 O

1 NCT03867682 84 85 O
. NCT03867682 85 86 O
Refractory NCT03867682 88 98 B-Condition
disease NCT03867682 99 106 I-Condition
will NCT03867682 107 111 O
be NCT03867682 112 114 O
defined NCT03867682 115 122 O
as NCT03867682 123 125 O
at NCT03867682 126 128 B-Eq-Comparison
least NCT03867682 129 134 I-Eq-Comparison
1 NCT03867682 135 136 I-Eq-Comparison
prior NCT03867682 137 142 B-Eq-Comparison
treatment NCT03867682 143 152 B-Procedure
with NCT03867682 153 157 B-And
no NCT03867682 158 160 B-Negation
remission NCT03867682 161 170 B-Condition
. NCT03867682 171 172 O

2 NCT03867682 181 182 O
. NCT03867682 182 183 O
Relapsed NCT03867682 185 193 B-Condition
disease NCT03867682 194 201 I-Condition
will NCT03867682 202 206 O
be NCT03867682 207 209 O
defined NCT03867682 210 217 O
as NCT03867682 218 220 O
5 NCT03867682 221 222 B-Eq-Comparison
% NCT03867682 223 224 I-Eq-Comparison
or NCT03867682 225 227 I-Eq-Comparison
more NCT03867682 228 232 I-Eq-Comparison
blasts NCT03867682 233 239 B-Observation
in NCT03867682 240 242 I-Observation
bone NCT03867682 243 247 I-Observation
marrow NCT03867682 248 254 I-Observation
seen NCT03867682 255 259 O
after NCT03867682 260 265 B-Temporal-Connection___Temporal-Connection-Type-Value:after
remission NCT03867682 266 275 B-Condition
. NCT03867682 276 277 O

3 NCT03867682 286 287 O
. NCT03867682 287 288 O
Patients NCT03867682 290 298 O
with NCT03867682 299 303 O
AML NCT03867682 304 307 B-Condition
arising NCT03867682 308 315 O
from NCT03867682 316 320 O
myelodysplastic NCT03867682 321 336 B-Condition
syndromes NCT03867682 337 346 I-Condition
( NCT03867682 347 348 O
including NCT03867682 349 358 O
CMML NCT03867682 359 363 B-Condition
) NCT03867682 364 365 O
or NCT03867682 366 368 B-Or
myeloproliferative NCT03867682 369 387 B-Condition
neoplasms NCT03867682 388 397 I-Condition
( NCT03867682 398 399 O
secondary NCT03867682 400 409 B-Modifier
AML NCT03867682 410 413 B-Condition
, NCT03867682 414 415 O
ts NCT03867682 416 418 B-Condition
- NCT03867682 419 420 I-Condition
AML NCT03867682 421 424 I-Condition
) NCT03867682 425 426 O
are NCT03867682 427 430 O
also NCT03867682 431 435 O
eligible NCT03867682 436 444 O
. NCT03867682 445 446 O

2 NCT03867682 450 451 O
. NCT03867682 451 452 O
Circulating NCT03867682 454 465 B-Observation
blast NCT03867682 466 471 I-Observation
count NCT03867682 472 477 I-Observation
≤ NCT03867682 478 479 B-Eq-Comparison
200 NCT03867682 480 483 I-Eq-Comparison
/ NCT03867682 484 485 I-Eq-Comparison
μL NCT03867682 486 488 I-Eq-Comparison
within NCT03867682 489 495 B-Eq-Comparison
10 NCT03867682 496 498 I-Eq-Comparison
days NCT03867682 499 503 I-Eq-Comparison
prior NCT03867682 504 509 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867682 510 512 I-Temporal-Connection___Temporal-Connection-Type-Value:before
first NCT03867682 513 518 B-Eq-Comparison
cycle NCT03867682 519 524 O
of NCT03867682 525 527 O
treatment NCT03867682 528 537 B-Procedure
. NCT03867682 537 538 O
Hydroxyurea NCT03867682 540 551 B-Drug
should NCT03867682 552 558 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867682 559 561 I-Assertion___Assertion-Type-Value:hypothetical
used NCT03867682 562 566 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867682 567 569 O
keep NCT03867682 570 574 O
the NCT03867682 575 578 O
peripheral NCT03867682 579 589 B-Observation
blast NCT03867682 590 595 I-Observation
count NCT03867682 596 601 I-Observation
≤ NCT03867682 602 603 B-Eq-Comparison
200 NCT03867682 604 607 I-Eq-Comparison
/ NCT03867682 608 609 I-Eq-Comparison
μL NCT03867682 610 612 I-Eq-Comparison
until NCT03867682 613 618 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867682 619 622 O
first NCT03867682 623 628 B-Eq-Comparison
day NCT03867682 629 632 I-Eq-Comparison
of NCT03867682 633 635 O
protocol NCT03867682 636 644 O
treatment NCT03867682 645 654 B-Procedure
, NCT03867682 655 656 O
to NCT03867682 657 659 O
the NCT03867682 660 663 O
extent NCT03867682 664 670 O
that NCT03867682 671 675 O
this NCT03867682 676 680 O
is NCT03867682 681 683 O
possible NCT03867682 684 692 O

3 NCT03867682 695 696 O
. NCT03867682 696 697 O
ECOG NCT03867682 699 703 B-Observation
≤ NCT03867682 704 705 B-Eq-Comparison
2 NCT03867682 706 707 I-Eq-Comparison

4 NCT03867682 711 712 O
. NCT03867682 712 713 O
Estimated NCT03867682 715 724 B-Observation
creatinine NCT03867682 725 735 I-Observation
clearance NCT03867682 736 745 I-Observation
≥ NCT03867682 746 747 B-Eq-Comparison
50 NCT03867682 748 750 I-Eq-Comparison
mL NCT03867682 751 753 I-Eq-Comparison
/ NCT03867682 754 755 I-Eq-Comparison
min NCT03867682 756 759 I-Eq-Comparison

5 NCT03867682 762 763 O
. NCT03867682 763 764 O
AST NCT03867682 766 769 B-Observation
and NCT03867682 770 773 B-And
ALT NCT03867682 774 777 B-Observation
≤ NCT03867682 778 779 B-Eq-Comparison
3.0 NCT03867682 780 783 I-Eq-Comparison
x NCT03867682 784 785 I-Eq-Comparison
ULN NCT03867682 786 789 I-Eq-Comparison

6 NCT03867682 792 793 O
. NCT03867682 793 794 O
Bilirubin NCT03867682 796 805 B-Observation
≤ NCT03867682 806 807 B-Eq-Comparison
3.0 NCT03867682 808 811 I-Eq-Comparison
x NCT03867682 812 813 I-Eq-Comparison
ULN NCT03867682 814 817 I-Eq-Comparison

Exclusion NCT03867682 818 827 O
Criteria NCT03867682 828 836 O
: NCT03867682 837 838 O

1 NCT03867682 842 843 O
. NCT03867682 843 844 O
Active NCT03867682 846 852 B-Eq-Comparison
CNS NCT03867682 853 856 B-Modifier
Leukemia NCT03867682 857 865 B-Condition
. NCT03867682 866 867 O

2 NCT03867682 871 872 O
. NCT03867682 872 873 O
Known NCT03867682 875 880 O
HIV NCT03867682 881 884 B-Condition
infection NCT03867682 885 894 I-Condition
or NCT03867682 895 897 B-Or
known NCT03867682 898 903 O
hepatitis NCT03867682 904 913 B-Modifier
B NCT03867682 914 915 I-Modifier
or NCT03867682 916 918 B-Or
hepatitis NCT03867682 919 928 B-Modifier
C NCT03867682 929 930 I-Modifier
infection NCT03867682 931 940 B-Condition
( NCT03867682 941 942 O
with NCT03867682 943 947 O
a NCT03867682 948 949 O
detectable NCT03867682 950 960 O
viral NCT03867682 961 966 B-Observation
load NCT03867682 967 971 I-Observation
) NCT03867682 972 973 O
. NCT03867682 975 976 O

3 NCT03867682 980 981 O
. NCT03867682 981 982 O
Participant NCT03867682 984 995 O
has NCT03867682 996 999 O
received NCT03867682 1000 1008 B-Eq-Comparison
strong NCT03867682 1009 1015 O
and NCT03867682 1016 1019 B-Or
/ NCT03867682 1020 1021 I-Or
or NCT03867682 1022 1024 I-Or
moderate NCT03867682 1025 1033 O
CYP3A NCT03867682 1034 1039 B-Drug
inducers NCT03867682 1040 1048 I-Drug
within NCT03867682 1049 1055 B-Eq-Comparison
7 NCT03867682 1056 1057 I-Eq-Comparison
days NCT03867682 1058 1062 I-Eq-Comparison
prior NCT03867682 1063 1068 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867682 1069 1071 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867682 1072 1075 O
initiation NCT03867682 1076 1086 B-Eq-Comparison
of NCT03867682 1087 1089 O
study NCT03867682 1090 1095 B-Study
treatment NCT03867682 1096 1105 B-Procedure
. NCT03867682 1106 1107 O

4 NCT03867682 1111 1112 O
. NCT03867682 1112 1113 O
Have NCT03867682 1115 1119 O
received NCT03867682 1120 1128 B-Eq-Comparison
prior NCT03867682 1129 1134 I-Eq-Comparison
radiation NCT03867682 1135 1144 B-Procedure
to NCT03867682 1145 1147 O
maximally NCT03867682 1148 1157 B-Modifier
tolerated NCT03867682 1158 1167 I-Modifier
levels NCT03867682 1168 1174 I-Modifier
to NCT03867682 1175 1177 O
any NCT03867682 1178 1181 O
critical NCT03867682 1182 1190 O
normal NCT03867682 1191 1197 O
organ NCT03867682 1198 1203 B-Modifier
. NCT03867682 1204 1205 O

5 NCT03867682 1209 1210 O
. NCT03867682 1210 1211 O
Clinically NCT03867682 1213 1223 O
significant NCT03867682 1224 1235 O
cardiac NCT03867682 1236 1243 B-Condition
disease NCT03867682 1244 1251 I-Condition
. NCT03867682 1252 1253 O

6 NCT03867682 1257 1258 O
. NCT03867682 1258 1259 O
Active NCT03867682 1261 1267 B-Eq-Comparison
, NCT03867682 1268 1269 O
uncontrolled NCT03867682 1270 1282 B-Modifier
serious NCT03867682 1283 1290 O
infection NCT03867682 1291 1300 B-Condition
. NCT03867682 1301 1302 O

7 NCT03867682 1306 1307 O
. NCT03867682 1307 1308 O
Have NCT03867682 1310 1314 O
other NCT03867682 1315 1320 B-Other
non NCT03867682 1321 1324 B-Negation
- NCT03867682 1325 1326 O
myeloid NCT03867682 1327 1334 B-Modifier
malignancy NCT03867682 1335 1345 B-Condition
within NCT03867682 1346 1352 B-Eq-Comparison
2 NCT03867682 1353 1354 I-Eq-Comparison
years NCT03867682 1355 1360 I-Eq-Comparison
of NCT03867682 1361 1363 B-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03867682 1364 1369 B-Study
( NCT03867682 1370 1371 O
with NCT03867682 1372 1376 O
exceptions NCT03867682 1377 1387 O
) NCT03867682 1388 1389 O
. NCT03867682 1391 1392 O

8 NCT03867682 1396 1397 O
. NCT03867682 1397 1398 O
Psychiatric NCT03867682 1400 1411 B-Condition
disorder NCT03867682 1412 1420 I-Condition
that NCT03867682 1421 1425 O
would NCT03867682 1426 1431 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03867682 1432 1440 B-Negation
study NCT03867682 1441 1446 B-Study
participation NCT03867682 1447 1460 O

9 NCT03867682 1463 1464 O
. NCT03867682 1464 1465 O
Previous NCT03867682 1467 1475 B-Eq-Comparison
solid NCT03867682 1476 1481 B-Modifier
organ NCT03867682 1482 1487 B-Procedure
transplant NCT03867682 1488 1498 I-Procedure
( NCT03867682 1499 1500 O
prior NCT03867682 1501 1506 B-Eq-Comparison
treatment NCT03867682 1507 1516 B-Procedure
with NCT03867682 1517 1521 O
SCT NCT03867682 1522 1525 B-Procedure
is NCT03867682 1526 1528 O
allowed NCT03867682 1529 1536 O
but NCT03867682 1537 1540 B-And
not NCT03867682 1541 1544 B-Negation
if NCT03867682 1545 1547 O
patient NCT03867682 1548 1555 O
has NCT03867682 1556 1559 O
GVHD NCT03867682 1560 1564 B-Condition
or NCT03867682 1565 1567 B-Or
is NCT03867682 1568 1570 O
still NCT03867682 1571 1576 O
receiving NCT03867682 1577 1586 B-Eq-Comparison
immunosuppression NCT03867682 1587 1604 B-Procedure
/ NCT03867682 1605 1606 B-Or
GVHD NCT03867682 1607 1611 B-Procedure
therapy NCT03867682 1612 1619 I-Procedure
) NCT03867682 1620 1621 O
. NCT03867682 1622 1623 O

Inclusion NCT03861754 0 9 O
Criteria NCT03861754 10 18 O
: NCT03861754 19 20 O

- NCT03861754 24 25 O
Body NCT03861754 27 31 B-Observation
mass NCT03861754 32 36 I-Observation
Index NCT03861754 37 42 I-Observation
> NCT03861754 43 44 B-Eq-Comparison
30 NCT03861754 45 47 I-Eq-Comparison

- NCT03861754 51 52 O
Age NCT03861754 54 57 B-Age
18 NCT03861754 58 60 B-Eq-Comparison
- NCT03861754 61 62 I-Eq-Comparison
64 NCT03861754 63 65 O

Exclusion NCT03861754 67 76 O
Criteria NCT03861754 77 85 O
: NCT03861754 86 87 O

- NCT03861754 91 92 O
Pregnancy NCT03861754 94 103 B-Condition

- NCT03861754 106 107 O
Health NCT03861754 109 115 B-Condition
reasons NCT03861754 116 123 I-Condition
preventing NCT03861754 124 134 B-Assertion___Assertion-Type-Value:hypothetical|Negation
exercise NCT03861754 135 143 B-Observation
and NCT03861754 144 147 B-Or
exercise NCT03861754 148 156 B-Procedure
test NCT03861754 157 161 I-Procedure

- NCT03861754 164 165 O
Medication NCT03861754 167 177 B-Drug
preventing NCT03861754 178 188 B-Assertion___Assertion-Type-Value:hypothetical|Negation
exercise NCT03861754 189 197 B-Observation
and NCT03861754 198 201 B-Or
exercise NCT03861754 202 210 B-Procedure
test NCT03861754 211 215 I-Procedure

- NCT03861754 218 219 O
Previously NCT03861754 221 231 B-Eq-Comparison
diagnosed NCT03861754 232 241 O
diabetes NCT03861754 242 250 B-Condition

Inclusion NCT03862261 0 9 O
Criteria NCT03862261 10 18 O
: NCT03862261 19 20 O

- NCT03862261 24 25 O
Children NCT03862261 27 35 O
< NCT03862261 36 37 B-Eq-Comparison
5 NCT03862261 38 39 I-Eq-Comparison
years NCT03862261 40 45 I-Eq-Comparison
old NCT03862261 46 49 B-Age
. NCT03862261 50 51 O

- NCT03862261 55 56 O
Presumptive NCT03862261 58 69 B-Assertion___Assertion-Type-Value:possible
pulmonary NCT03862261 70 79 B-Modifier
or NCT03862261 80 82 B-Or
extra NCT03862261 83 88 B-Modifier
- NCT03862261 89 90 I-Modifier
pulmonary NCT03862261 91 100 I-Modifier
TB NCT03862261 101 103 B-Condition
case NCT03862261 104 108 O
: NCT03862261 109 110 O
symptoms NCT03862261 111 119 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 120 122 B-Or
clinical NCT03862261 123 131 O
signs NCT03862261 132 137 B-Assertion___Assertion-Type-Value:possible
suggestive NCT03862261 138 148 B-Assertion___Assertion-Type-Value:possible
of NCT03862261 149 151 O
active NCT03862261 152 158 B-Eq-Comparison
TB NCT03862261 159 161 B-Condition
disease NCT03862261 162 169 I-Condition
. NCT03862261 170 171 O

- NCT03862261 175 176 O
Other NCT03862261 178 183 B-Other
infectious NCT03862261 184 194 B-Condition
diseases NCT03862261 195 203 I-Condition
are NCT03862261 204 207 O
not NCT03862261 208 211 B-Negation
suspected NCT03862261 212 221 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 222 224 B-Or
have NCT03862261 225 229 O
already NCT03862261 230 237 O
been NCT03862261 238 242 O
ruled NCT03862261 243 248 O
out NCT03862261 249 252 O
. NCT03862261 253 254 O

- NCT03862261 258 259 O
Commitment NCT03862261 261 271 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862261 272 274 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03862261 275 279 O
treatment NCT03862261 280 289 B-Procedure
in NCT03862261 290 292 O
the NCT03862261 293 296 O
clinic NCT03862261 297 303 O
of NCT03862261 304 306 O
enrolment NCT03862261 307 316 O
or NCT03862261 317 319 B-Or
another NCT03862261 320 327 O
INPUT NCT03862261 328 333 O
study NCT03862261 334 339 B-Study
site NCT03862261 340 344 O
. NCT03862261 345 346 O

- NCT03862261 350 351 O
Parental NCT03862261 353 361 B-Family-Member___Family-Member-Type:parent
/ NCT03862261 362 363 O
caregiver NCT03862261 364 373 O
consent NCT03862261 374 381 O
for NCT03862261 382 385 O
the NCT03862261 386 389 O
child NCT03862261 390 395 B-Family-Member___Family-Member-Type:child
to NCT03862261 396 398 O
participate NCT03862261 399 410 O
in NCT03862261 411 413 O
the NCT03862261 414 417 O
study NCT03862261 418 423 B-Study
. NCT03862261 424 425 O

Exclusion NCT03862261 427 436 O
Criteria NCT03862261 437 445 O
: NCT03862261 446 447 O

- NCT03862261 451 452 O
Children NCT03862261 454 462 O
who NCT03862261 463 466 B-And
are NCT03862261 467 470 O
TB NCT03862261 471 473 B-Condition
contacts NCT03862261 474 482 O
but NCT03862261 483 486 B-And
without NCT03862261 487 494 B-Negation
symptoms NCT03862261 495 503 B-Assertion___Assertion-Type-Value:possible
or NCT03862261 504 506 B-Or
signs NCT03862261 507 512 B-Assertion___Assertion-Type-Value:possible
of NCT03862261 513 515 O
active NCT03862261 516 522 B-Eq-Comparison
TB NCT03862261 523 525 B-Condition

Inclusion NCT03861637 0 9 O
Criteria NCT03861637 10 18 O
: NCT03861637 19 20 O

- NCT03861637 24 25 O
Patients NCT03861637 27 35 O
who NCT03861637 36 39 O
fulfilled NCT03861637 40 49 O
the NCT03861637 50 53 O
following NCT03861637 54 63 O
criteria NCT03861637 64 72 O
were NCT03861637 73 77 O
included NCT03861637 78 86 O
in NCT03861637 87 89 O
the NCT03861637 90 93 O
study NCT03861637 94 99 O
: NCT03861637 100 101 O

- NCT03861637 105 106 O
Adult NCT03861637 108 113 O
renal NCT03861637 114 119 B-Procedure
transplant NCT03861637 120 130 I-Procedure
patients NCT03861637 131 139 O
( NCT03861637 140 141 O
≥ NCT03861637 143 144 B-Eq-Comparison
21 NCT03861637 145 147 I-Eq-Comparison
years NCT03861637 148 153 I-Age|Eq-Comparison
) NCT03861637 154 155 O
, NCT03861637 157 158 O

- NCT03861637 162 163 O
Informed NCT03861637 165 173 O
consent NCT03861637 174 181 O
, NCT03861637 182 183 O

- NCT03861637 187 188 O
Stable NCT03861637 190 196 O
maintenance NCT03861637 197 208 O
subcutaneous NCT03861637 209 221 B-Modifier
ESA NCT03861637 222 225 B-Procedure
therapy NCT03861637 226 233 I-Procedure
with NCT03861637 234 238 O
constant NCT03861637 239 247 O
dose NCT03861637 248 252 O
interval NCT03861637 253 261 O
during NCT03861637 262 268 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861637 269 272 O
last NCT03861637 273 277 B-Eq-Comparison
2 NCT03861637 278 279 I-Eq-Comparison
months NCT03861637 280 286 I-Eq-Comparison
, NCT03861637 287 288 O

- NCT03861637 292 293 O
Haemoglobin NCT03861637 295 306 B-Observation
( NCT03861637 307 308 O
Hb NCT03861637 309 311 B-Observation
) NCT03861637 312 313 O
≥ NCT03861637 314 315 B-Eq-Comparison
10 NCT03861637 316 318 I-Eq-Comparison
mg NCT03861637 319 321 I-Eq-Comparison
/ NCT03861637 322 323 I-Eq-Comparison
dL NCT03861637 324 326 I-Eq-Comparison
( NCT03861637 327 328 O
Hct NCT03861637 329 332 B-Observation
32 NCT03861637 333 335 B-Eq-Comparison
% NCT03861637 336 337 I-Eq-Comparison
) NCT03861637 339 340 O
, NCT03861637 342 343 O

- NCT03861637 347 348 O
Transferrin NCT03861637 350 361 B-Observation
saturation NCT03861637 362 372 I-Observation
( NCT03861637 373 374 O
TSAT NCT03861637 375 379 B-Observation
) NCT03861637 380 381 O
≥ NCT03861637 382 383 B-Eq-Comparison
20 NCT03861637 384 386 I-Eq-Comparison
% NCT03861637 387 388 I-Eq-Comparison
( NCT03861637 389 390 O
during NCT03861637 391 397 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861637 398 401 O
screening NCT03861637 402 411 B-Study
phase NCT03861637 412 417 O
) NCT03861637 418 419 O
, NCT03861637 421 422 O

- NCT03861637 426 427 O
and NCT03861637 429 432 B-And
serum NCT03861637 433 438 B-Observation
ferritin NCT03861637 439 447 I-Observation
≥ NCT03861637 448 449 B-Eq-Comparison
100 NCT03861637 450 453 I-Eq-Comparison
ng NCT03861637 454 456 I-Eq-Comparison
/ NCT03861637 457 458 I-Eq-Comparison
mL NCT03861637 459 461 I-Eq-Comparison

Exclusion NCT03861637 462 471 O
Criteria NCT03861637 472 480 O
: NCT03861637 481 482 O

We NCT03861637 484 486 O
excluded NCT03861637 487 495 O
patients NCT03861637 496 504 O
with NCT03861637 505 509 O
the NCT03861637 510 513 O
following NCT03861637 514 523 O
criteria NCT03861637 524 532 O
: NCT03861637 533 534 O

- NCT03861637 538 539 O
Acute NCT03861637 541 546 O
or NCT03861637 547 549 B-Or
chronic NCT03861637 550 557 B-Modifier
bleeding NCT03861637 558 566 B-Condition
, NCT03861637 567 568 O
or NCT03861637 569 571 B-Or
erythrocyte NCT03861637 572 583 B-Procedure
transfusion NCT03861637 584 595 I-Procedure
, NCT03861637 596 597 O
within NCT03861637 598 604 B-Eq-Comparison
the NCT03861637 605 608 I-Eq-Comparison
preceding NCT03861637 609 618 I-Eq-Comparison
8 NCT03861637 619 620 I-Eq-Comparison
weeks NCT03861637 621 626 I-Eq-Comparison
. NCT03861637 626 627 O
change NCT03861637 629 635 O
in NCT03861637 636 638 O
Hb NCT03861637 639 641 B-Observation
level NCT03861637 642 647 O
≥ NCT03861637 648 649 B-Eq-Comparison
2 NCT03861637 650 651 I-Eq-Comparison
g NCT03861637 652 653 I-Eq-Comparison
/ NCT03861637 654 655 I-Eq-Comparison
dL NCT03861637 656 658 I-Eq-Comparison
during NCT03861637 659 665 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03861637 666 675 B-Study
phase NCT03861637 676 681 O
, NCT03861637 682 683 O

- NCT03861637 687 688 O
Hemolytic NCT03861637 690 699 B-Condition
anemia NCT03861637 700 706 I-Condition
, NCT03861637 707 708 O

- NCT03861637 712 713 O
Recent NCT03861637 715 721 B-Eq-Comparison
infection NCT03861637 722 731 B-Condition
or NCT03861637 732 734 B-Or
rejection NCT03861637 735 744 B-Condition
, NCT03861637 745 746 O

- NCT03861637 750 751 O
Diastolic NCT03861637 753 762 B-Observation
blood NCT03861637 763 768 I-Observation
pressure NCT03861637 769 777 I-Observation
> NCT03861637 778 779 O
100 NCT03861637 780 783 B-Eq-Comparison
mmHg NCT03861637 784 788 I-Eq-Comparison
or NCT03861637 789 791 B-Or
discontinuation NCT03861637 792 807 B-Negation
of NCT03861637 808 810 O
ESA NCT03861637 811 814 B-Procedure
due NCT03861637 815 818 O
to NCT03861637 819 821 O
hypertension NCT03861637 822 834 B-Condition
in NCT03861637 835 837 O
the NCT03861637 838 841 O
6 NCT03861637 842 843 B-Eq-Comparison
months NCT03861637 844 850 I-Eq-Comparison
prior NCT03861637 851 856 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03861637 857 859 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03861637 860 865 B-Study
, NCT03861637 866 867 O

- NCT03861637 871 872 O
Vitamin NCT03861637 874 881 B-Modifier
B12 NCT03861637 882 885 I-Modifier
or NCT03861637 886 888 B-Or
folic NCT03861637 889 894 B-Modifier
acid NCT03861637 895 899 I-Modifier
deficiency NCT03861637 900 910 B-Condition
, NCT03861637 911 912 O

- NCT03861637 916 917 O
Uncontrolled NCT03861637 919 931 B-Modifier
or NCT03861637 932 934 B-Or
secondary NCT03861637 935 944 B-Modifier
hyperparathyroidism NCT03861637 945 964 B-Condition
, NCT03861637 965 966 O

- NCT03861637 970 971 O
Acute NCT03861637 973 978 O
or NCT03861637 979 981 B-Or
chronic NCT03861637 982 989 B-Modifier
systemic NCT03861637 990 998 B-Condition
inflammatory NCT03861637 999 1011 I-Condition
disease NCT03861637 1012 1019 I-Condition
and NCT03861637 1020 1023 B-Or
/ NCT03861637 1024 1025 I-Or
or NCT03861637 1026 1028 I-Or
C NCT03861637 1029 1030 B-Observation
- NCT03861637 1031 1032 I-Observation
reactive NCT03861637 1033 1041 I-Observation
protein NCT03861637 1042 1049 I-Observation
( NCT03861637 1050 1051 O
CRP NCT03861637 1052 1055 B-Observation
) NCT03861637 1056 1057 O
> NCT03861637 1058 1059 B-Eq-Comparison
30 NCT03861637 1060 1062 I-Eq-Comparison
mg NCT03861637 1063 1065 I-Eq-Comparison
/ NCT03861637 1066 1067 I-Eq-Comparison
L NCT03861637 1068 1069 I-Eq-Comparison
, NCT03861637 1070 1071 O

- NCT03861637 1075 1076 O
Hemodialysis NCT03861637 1078 1090 B-Procedure
due NCT03861637 1091 1094 O
to NCT03861637 1095 1097 O
failure NCT03861637 1098 1105 B-Modifier
of NCT03861637 1106 1108 O
a NCT03861637 1109 1110 O
kidney NCT03861637 1111 1117 B-Procedure
transplant NCT03861637 1118 1128 I-Procedure
, NCT03861637 1129 1130 O

- NCT03861637 1134 1135 O
and NCT03861637 1137 1140 B-Or
malignancy NCT03861637 1141 1151 B-Condition


Inclusion NCT03864029 0 9 O
Criteria NCT03864029 10 18 O
: NCT03864029 19 20 O

- NCT03864029 24 25 O
Willing NCT03864029 27 34 O
and NCT03864029 35 38 O
able NCT03864029 39 43 O
to NCT03864029 44 46 O
provide NCT03864029 47 54 O
informed NCT03864029 55 63 O
consent NCT03864029 64 71 O
( NCT03864029 72 73 O
unless NCT03864029 74 80 O
exemption NCT03864029 81 90 O
of NCT03864029 91 93 O
obtaining NCT03864029 94 103 O
consent NCT03864029 104 111 O
is NCT03864029 112 114 O
obtained NCT03864029 115 123 O
as NCT03864029 124 126 O
per NCT03864029 127 130 O
local NCT03864029 131 136 O
regulation NCT03864029 137 147 O
) NCT03864029 148 149 O
. NCT03864029 150 151 O
Assent NCT03864029 153 159 O
( NCT03864029 160 161 O
if NCT03864029 162 164 O
required NCT03864029 165 173 O
defined NCT03864029 174 181 O
by NCT03864029 182 184 O
local NCT03864029 185 190 O
regulation NCT03864029 191 201 O
and NCT03864029 202 205 O
requirement NCT03864029 206 217 O
) NCT03864029 218 219 O
should NCT03864029 220 226 O
also NCT03864029 227 231 O
be NCT03864029 232 234 O
obtained NCT03864029 235 243 O
from NCT03864029 244 248 O
the NCT03864029 249 252 O
subject NCT03864029 253 260 O
and NCT03864029 261 264 O
the NCT03864029 265 268 O
legal NCT03864029 269 274 O
authorized NCT03864029 275 285 O
representative NCT03864029 286 300 O
. NCT03864029 301 302 O

- NCT03864029 306 307 O
Diagnosed NCT03864029 309 318 O
with NCT03864029 319 323 O
BH4 NCT03864029 324 327 B-Condition
deficiency NCT03864029 328 338 I-Condition
per NCT03864029 339 342 O
local NCT03864029 343 348 O
practice NCT03864029 349 357 O
. NCT03864029 358 359 O

- NCT03864029 363 364 O
KUVAN NCT03864029 366 371 B-Drug
® NCT03864029 371 372 O
was NCT03864029 373 376 O
taken NCT03864029 377 382 O
at NCT03864029 383 385 B-Eq-Comparison
least NCT03864029 386 391 I-Eq-Comparison
1 NCT03864029 392 393 I-Eq-Comparison
dose NCT03864029 394 398 I-Eq-Comparison
to NCT03864029 399 401 O
treat NCT03864029 402 407 O
HPA NCT03864029 408 411 B-Condition
caused NCT03864029 412 418 O
by NCT03864029 419 421 O
BH4 NCT03864029 422 425 B-Condition
deficiency NCT03864029 426 436 I-Condition
during NCT03864029 437 443 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864029 444 447 O
period NCT03864029 448 454 O
of NCT03864029 455 457 O
observation NCT03864029 458 469 B-Study
. NCT03864029 470 471 O

- NCT03864029 475 476 O
Baseline NCT03864029 478 486 O
Phe NCT03864029 487 490 B-Observation
concentration NCT03864029 491 504 I-Observation
≥ NCT03864029 505 506 B-Eq-Comparison
450 NCT03864029 507 510 I-Eq-Comparison
µmol NCT03864029 511 515 I-Eq-Comparison
/ NCT03864029 516 517 I-Eq-Comparison
L NCT03864029 518 519 I-Eq-Comparison

Exclusion NCT03864029 520 529 O
Criteria NCT03864029 530 538 O
: NCT03864029 539 540 O

- NCT03864029 544 545 O
Subject NCT03864029 547 554 O
diagnosed NCT03864029 555 564 O
to NCT03864029 565 567 O
have NCT03864029 568 572 O
Phenylketonuria NCT03864029 573 588 B-Condition
( NCT03864029 589 590 O
PKU NCT03864029 591 594 B-Condition
) NCT03864029 595 596 O

- NCT03864029 600 601 O
Has NCT03864029 603 606 O
any NCT03864029 607 610 O
condition NCT03864029 611 620 B-Condition
that NCT03864029 621 625 O
, NCT03864029 626 627 O
in NCT03864029 628 630 O
the NCT03864029 631 634 O
view NCT03864029 635 639 O
of NCT03864029 640 642 O
the NCT03864029 643 646 O
Investigator NCT03864029 647 659 O
, NCT03864029 660 661 O
the NCT03864029 662 665 O
medical NCT03864029 666 673 O
record NCT03864029 674 680 O
of NCT03864029 681 683 O
the NCT03864029 684 687 O
subject NCT03864029 688 695 O
in NCT03864029 696 698 O
the NCT03864029 699 702 O
duration NCT03864029 703 711 O
of NCT03864029 712 714 O
observation NCT03864029 715 726 O
is NCT03864029 727 729 O
not NCT03864029 730 733 B-Negation
reliable NCT03864029 734 742 O
, NCT03864029 743 744 O
or NCT03864029 745 747 O
not NCT03864029 748 751 O
accessible NCT03864029 752 762 O
. NCT03864029 762 763 O

Inclusion NCT03869294 0 9 O
Criteria NCT03869294 10 18 O
: NCT03869294 19 20 O

- NCT03869294 24 25 O
1 NCT03869294 27 28 O
. NCT03869294 28 29 O
Histologically NCT03869294 30 44 B-Procedure
confirmed NCT03869294 45 54 O
pancreatic NCT03869294 55 65 B-Condition
adenocarcinoma NCT03869294 66 80 I-Condition
2 NCT03869294 81 82 O
. NCT03869294 82 83 O
Locally NCT03869294 84 91 B-Modifier
advanced NCT03869294 92 100 I-Modifier
or NCT03869294 101 103 B-Or
metastatic NCT03869294 104 114 B-Modifier
PC NCT03869294 115 117 B-Condition
3 NCT03869294 118 119 O
. NCT03869294 119 120 O
Chemotherapy NCT03869294 121 133 B-Procedure
- NCT03869294 134 135 O
naïve NCT03869294 136 141 B-Negation
4 NCT03869294 142 143 O
. NCT03869294 143 144 O
ECOG NCT03869294 145 149 B-Observation
performance NCT03869294 150 161 I-Observation
status NCT03869294 162 168 I-Observation
of NCT03869294 169 171 O
0 NCT03869294 172 173 B-Eq-Comparison
or NCT03869294 174 176 I-Eq-Comparison
1 NCT03869294 177 178 I-Eq-Comparison
5 NCT03869294 179 180 O
. NCT03869294 180 181 O
An NCT03869294 183 185 O
adequate NCT03869294 186 194 O
bone NCT03869294 195 199 B-Modifier
marrow NCT03869294 200 206 I-Modifier
, NCT03869294 207 208 O
liver NCT03869294 209 214 B-Modifier
function NCT03869294 215 223 B-Condition
and NCT03869294 224 227 B-And
kidney NCT03869294 228 234 B-Modifier
function NCT03869294 235 243 B-Condition

Exclusion NCT03869294 244 253 O
Criteria NCT03869294 254 262 O
: NCT03869294 263 264 O

- NCT03869294 268 269 O
1 NCT03869294 271 272 O
. NCT03869294 272 273 O
Age NCT03869294 274 277 B-Age
≥ NCT03869294 278 279 B-Eq-Comparison
80 NCT03869294 280 282 I-Eq-Comparison
years NCT03869294 283 288 I-Eq-Comparison
2 NCT03869294 289 290 O
. NCT03869294 290 291 O
Brain NCT03869294 292 297 B-Modifier
metastasis NCT03869294 298 308 B-Condition
3 NCT03869294 309 310 O
. NCT03869294 310 311 O
With NCT03869294 312 316 O
other NCT03869294 317 322 B-Other
malignancies NCT03869294 323 335 B-Condition
4 NCT03869294 336 337 O
. NCT03869294 337 338 O
Chronic NCT03869294 339 346 B-Modifier
diarrhea NCT03869294 347 355 B-Condition
, NCT03869294 356 357 O
cardiac NCT03869294 358 365 B-Condition
disease NCT03869294 366 373 I-Condition
, NCT03869294 374 375 O
pregnancy NCT03869294 376 385 B-Condition
or NCT03869294 386 388 B-Or
breast NCT03869294 389 395 B-Condition
feeding NCT03869294 396 403 I-Condition

Inclusion NCT03863236 0 9 O
Criteria NCT03863236 10 18 O
: NCT03863236 19 20 O

- NCT03863236 24 25 O
18 NCT03863236 27 29 B-Eq-Comparison
years NCT03863236 30 35 I-Eq-Comparison
or NCT03863236 36 38 I-Eq-Comparison
older NCT03863236 39 44 I-Age|Eq-Comparison

- NCT03863236 47 48 O
Primary NCT03863236 50 57 B-Modifier
colon NCT03863236 58 63 I-Modifier
adenocarcinoma NCT03863236 64 78 B-Condition

- NCT03863236 81 82 O
Curative NCT03863236 84 92 B-Procedure
operation NCT03863236 93 102 I-Procedure
is NCT03863236 103 105 O
possible NCT03863236 106 114 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03863236 117 118 O
Patient NCT03863236 120 127 O
has NCT03863236 128 131 O
a NCT03863236 132 133 O
life NCT03863236 134 138 B-Observation
expectancy NCT03863236 139 149 I-Observation
of NCT03863236 150 152 O
at NCT03863236 153 155 B-Eq-Comparison
least NCT03863236 156 161 I-Eq-Comparison
12 NCT03863236 162 164 I-Eq-Comparison
months NCT03863236 165 171 I-Eq-Comparison

- NCT03863236 174 175 O
Patient NCT03863236 177 184 O
signs NCT03863236 185 190 O
the NCT03863236 191 194 O
informed NCT03863236 195 203 O
consent NCT03863236 204 211 O
and NCT03863236 212 215 O
agrees NCT03863236 216 222 O
to NCT03863236 223 225 O
attend NCT03863236 226 232 O
all NCT03863236 233 236 O
study NCT03863236 237 242 O
visits NCT03863236 243 249 O

Exclusion NCT03863236 250 259 O
Criteria NCT03863236 260 268 O
: NCT03863236 269 270 O

- NCT03863236 274 275 O
Recurrent NCT03863236 277 286 B-Modifier
colon NCT03863236 287 292 I-Modifier
adenocarcinoma NCT03863236 293 307 B-Condition

- NCT03863236 310 311 O
Metastatic NCT03863236 313 323 B-Condition
disease NCT03863236 324 331 I-Condition

- NCT03863236 334 335 O
Cancer NCT03863236 337 343 B-Condition
that NCT03863236 344 348 O
will NCT03863236 349 353 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03863236 354 361 I-Assertion___Assertion-Type-Value:hypothetical
multiorgan NCT03863236 362 372 B-Procedure
resection NCT03863236 373 382 I-Procedure

- NCT03863236 385 386 O
Pregnant NCT03863236 388 396 B-Condition
or NCT03863236 397 399 B-Or
suspected NCT03863236 400 409 B-Assertion___Assertion-Type-Value:possible
pregnancy NCT03863236 410 419 B-Condition

- NCT03863236 422 423 O
Patient NCT03863236 425 432 O
with NCT03863236 433 437 O
a NCT03863236 438 439 O
comorbid NCT03863236 440 448 B-Condition
illness NCT03863236 449 456 I-Condition
or NCT03863236 457 459 B-Or
condition NCT03863236 460 469 B-Condition
that NCT03863236 470 474 O
would NCT03863236 475 480 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03863236 481 489 B-Negation
the NCT03863236 490 493 O
use NCT03863236 494 497 O
of NCT03863236 498 500 O
surgery NCT03863236 501 508 B-Procedure
( NCT03863236 509 510 O
ASA NCT03863236 511 514 B-Condition
5 NCT03863236 515 516 B-Eq-Comparison
) NCT03863236 517 518 O
. NCT03863236 520 521 O

- NCT03863236 525 526 O
Patients NCT03863236 528 536 O
with NCT03863236 537 541 O
concurrent NCT03863236 542 552 B-Modifier
or NCT03863236 553 555 B-Or
previous NCT03863236 556 564 B-Eq-Comparison
malignant NCT03863236 565 574 B-Condition
tumors NCT03863236 575 581 I-Condition
within NCT03863236 582 588 B-Eq-Comparison
5 NCT03863236 589 590 I-Eq-Comparison
years NCT03863236 591 596 I-Eq-Comparison
before NCT03863236 597 603 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03863236 604 607 O
study NCT03863236 608 613 B-Study
enrollment NCT03863236 614 624 O

- NCT03863236 627 628 O
Patient NCT03863236 630 637 O
undergoing NCT03863236 638 648 B-Eq-Comparison
emergency NCT03863236 649 658 B-Modifier
procedures NCT03863236 659 669 B-Procedure

- NCT03863236 672 673 O
Dialysis NCT03863236 675 683 B-Procedure

- NCT03863236 686 687 O
Liver NCT03863236 689 694 B-Condition
dysfunction NCT03863236 695 706 I-Condition
, NCT03863236 707 708 O
child NCT03863236 709 714 B-Condition
pugh NCT03863236 715 719 I-Condition
B NCT03863236 720 721 B-Eq-Comparison
or NCT03863236 722 724 I-Eq-Comparison
worse NCT03863236 725 730 I-Eq-Comparison

- NCT03863236 733 734 O
NRS NCT03863236 736 739 B-Observation
score NCT03863236 740 745 B-Eq-Comparison
< NCT03863236 746 747 I-Eq-Comparison
2 NCT03863236 748 749 I-Eq-Comparison
or NCT03863236 750 752 B-Or
> NCT03863236 753 754 B-Eq-Comparison
5 NCT03863236 755 756 I-Eq-Comparison

- NCT03863236 760 761 O
BMI NCT03863236 763 766 B-Observation
under NCT03863236 767 772 B-Eq-Comparison
18.5 NCT03863236 773 777 I-Eq-Comparison

- NCT03863236 781 782 O
Weight NCT03863236 784 790 B-Observation
loss NCT03863236 791 795 I-Observation
15 NCT03863236 796 798 B-Eq-Comparison
% NCT03863236 799 800 I-Eq-Comparison
or NCT03863236 801 803 I-Eq-Comparison
more NCT03863236 804 808 I-Eq-Comparison
past NCT03863236 809 813 B-Eq-Comparison
6 NCT03863236 814 815 I-Eq-Comparison
months NCT03863236 816 822 I-Eq-Comparison

- NCT03863236 825 826 O
Serum NCT03863236 828 833 B-Observation
albumin NCT03863236 834 841 I-Observation
less NCT03863236 842 846 B-Eq-Comparison
than NCT03863236 847 851 I-Eq-Comparison
30 NCT03863236 852 854 I-Eq-Comparison
without NCT03863236 855 862 B-Negation
liver NCT03863236 863 868 B-Modifier
or NCT03863236 869 871 B-Or
renal NCT03863236 872 877 B-Modifier
dysfunction NCT03863236 878 889 B-Condition

- NCT03863236 892 893 O
Chronic NCT03863236 895 902 B-Condition
malnutrition NCT03863236 903 915 I-Condition
: NCT03863236 916 917 O
short NCT03863236 918 923 B-Condition
bowel NCT03863236 924 929 I-Condition
syndrome NCT03863236 930 938 I-Condition
, NCT03863236 939 940 O
previous NCT03863236 941 949 B-Eq-Comparison
gastrectomy NCT03863236 950 961 B-Condition
, NCT03863236 962 963 O
pancreatic NCT03863236 964 974 B-Condition
dysfunction NCT03863236 975 986 I-Condition

- NCT03863236 989 990 O
Language NCT03863236 992 1000 B-Condition
barrier NCT03863236 1001 1008 I-Condition
or NCT03863236 1009 1011 O
other NCT03863236 1012 1017 O
reasons NCT03863236 1018 1025 O
why NCT03863236 1026 1029 O
informed NCT03863236 1030 1038 O
consent NCT03863236 1039 1046 O
is NCT03863236 1047 1049 O
not NCT03863236 1050 1053 O
possible NCT03863236 1054 1062 O

Inclusion NCT03865121 0 9 O
criteria NCT03865121 10 18 O
: NCT03865121 19 20 O

- NCT03865121 24 25 O
Subjects NCT03865121 27 35 O
over NCT03865121 36 40 B-Eq-Comparison
60 NCT03865121 41 43 I-Eq-Comparison
years NCT03865121 44 49 I-Eq-Comparison
of NCT03865121 50 52 O
age NCT03865121 53 56 B-Age
with NCT03865121 57 61 B-And
a NCT03865121 62 63 O
clinical NCT03865121 64 72 O
diagnosis NCT03865121 73 82 O
of NCT03865121 83 85 O
Parkinson NCT03865121 86 95 B-Condition
's NCT03865121 95 97 I-Condition
disease NCT03865121 98 105 I-Condition

- NCT03865121 108 109 O
Stages NCT03865121 111 117 O
of NCT03865121 118 120 O
the NCT03865121 121 124 B-Coreference
disease NCT03865121 125 132 I-Coreference
2 NCT03865121 133 134 B-Eq-Comparison
- NCT03865121 135 136 I-Eq-Comparison
3 NCT03865121 137 138 I-Eq-Comparison
of NCT03865121 139 141 O
Hoehn NCT03865121 142 147 B-Modifier
and NCT03865121 148 151 I-Modifier
Yahr NCT03865121 152 156 I-Modifier

- NCT03865121 159 160 O
Not NCT03865121 162 165 B-Negation
exposed NCT03865121 166 173 B-Condition
to NCT03865121 174 176 I-Condition
tobacco NCT03865121 177 184 I-Condition
during NCT03865121 185 191 B-Temporal-Connection___Temporal-Connection-Type-Value:during
any NCT03865121 192 195 B-Eq-Comparison
stage NCT03865121 196 201 I-Eq-Comparison
of NCT03865121 202 204 I-Eq-Comparison
their NCT03865121 205 210 I-Eq-Comparison
life NCT03865121 211 215 I-Eq-Comparison

- NCT03865121 218 219 O
No NCT03865121 221 223 B-Negation
history NCT03865121 224 231 B-Eq-Comparison
of NCT03865121 232 234 O
lung NCT03865121 235 239 B-Condition
diseases NCT03865121 240 248 I-Condition

- NCT03865121 251 252 O
No NCT03865121 254 256 B-Negation
laboratory NCT03865121 257 267 B-Observation
abnormalities NCT03865121 268 281 O

- NCT03865121 284 285 O
No NCT03865121 287 289 B-Negation
history NCT03865121 290 297 B-Eq-Comparison
of NCT03865121 298 300 O
adverse NCT03865121 301 308 B-Condition
reactions NCT03865121 309 318 I-Condition
to NCT03865121 319 321 O
nicotine NCT03865121 322 330 B-Drug

- NCT03865121 333 334 O
Able NCT03865121 336 340 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865121 341 343 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03865121 344 347 O
nicotine NCT03865121 348 356 B-Drug
nasal NCT03865121 357 362 I-Drug
spray NCT03865121 363 368 I-Drug

- NCT03865121 371 372 O
Residents NCT03865121 374 383 O
of NCT03865121 384 386 O
Mexico NCT03865121 387 393 O
City NCT03865121 394 398 O
able NCT03865121 399 403 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865121 404 406 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03865121 407 413 O
for NCT03865121 414 417 O
evaluations NCT03865121 418 429 B-Study

- NCT03865121 432 433 O
Under NCT03865121 435 440 B-Eq-Comparison
current NCT03865121 441 448 I-Eq-Comparison
treatment NCT03865121 449 458 B-Procedure
with NCT03865121 459 463 O
levodopa NCT03865121 464 472 B-Drug
at NCT03865121 473 475 O
a NCT03865121 476 477 O
stable NCT03865121 478 484 O
dose NCT03865121 485 489 O

- NCT03865121 492 493 O
Not NCT03865121 495 498 B-Negation
currently NCT03865121 499 508 B-Eq-Comparison
receiving NCT03865121 509 518 I-Eq-Comparison
a NCT03865121 519 520 O
monoamine NCT03865121 521 530 B-Drug
oxidase NCT03865121 531 538 I-Drug
inhibitor NCT03865121 539 548 I-Drug
treatment NCT03865121 549 558 B-Procedure

Exclusion NCT03865121 559 568 O
Criteria NCT03865121 569 577 O

- NCT03865121 580 581 O
Unable NCT03865121 583 589 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865121 590 592 O
complete NCT03865121 593 601 O
follow NCT03865121 602 608 B-Encounter
- NCT03865121 609 610 I-Encounter
up NCT03865121 611 613 I-Encounter
protocol NCT03865121 614 622 O

- NCT03865121 625 626 O
Drug NCT03865121 628 632 B-Drug
adverse NCT03865121 633 640 B-Condition
reaction NCT03865121 641 649 I-Condition

- NCT03865121 652 653 O
Death NCT03865121 655 660 B-Death

Inclusion NCT03867656 0 9 O
Criteria NCT03867656 10 18 O
: NCT03867656 19 20 O

- NCT03867656 24 25 O
Male NCT03867656 27 31 O

- NCT03867656 34 35 O
Age NCT03867656 37 40 B-Age
25 NCT03867656 41 43 B-Eq-Comparison
to NCT03867656 44 46 I-Eq-Comparison
65 NCT03867656 47 49 I-Eq-Comparison
years NCT03867656 50 55 I-Eq-Comparison
old NCT03867656 56 59 O
. NCT03867656 60 61 O

- NCT03867656 65 66 O
Type NCT03867656 68 72 B-Modifier
2 NCT03867656 73 74 I-Modifier
diabetes NCT03867656 75 83 B-Condition
. NCT03867656 84 85 O

- NCT03867656 89 90 O
In NCT03867656 92 94 O
Metformin NCT03867656 95 104 B-Drug
or NCT03867656 105 107 B-Or
sulfonylureas NCT03867656 108 121 B-Drug

Exclusion NCT03867656 122 131 O
Criteria NCT03867656 132 140 O
: NCT03867656 141 142 O

- NCT03867656 146 147 O
Treatment NCT03867656 149 158 B-Procedure
with NCT03867656 159 163 O
other NCT03867656 164 169 B-Other
antidiabetics NCT03867656 170 183 B-Drug

- NCT03867656 186 187 O
Osteopososis NCT03867656 189 201 B-Condition
or NCT03867656 202 204 B-Or
gastrointestinal NCT03867656 205 221 B-Modifier
disease NCT03867656 222 229 B-Condition

- NCT03867656 232 233 O
Smoking NCT03867656 235 242 B-Condition

- NCT03867656 245 246 O
Long NCT03867656 248 252 B-Modifier
term NCT03867656 253 257 I-Modifier
steroid NCT03867656 258 265 B-Drug
treatment NCT03867656 266 275 B-Procedure

- NCT03867656 278 279 O
Weight NCT03867656 281 287 B-Observation
change NCT03867656 288 294 O
more NCT03867656 295 299 B-Eq-Comparison
than NCT03867656 300 304 I-Eq-Comparison
3 NCT03867656 305 306 I-Eq-Comparison
kg NCT03867656 307 309 I-Eq-Comparison
within NCT03867656 310 316 B-Eq-Comparison
the NCT03867656 317 320 I-Eq-Comparison
last NCT03867656 321 325 I-Eq-Comparison
3 NCT03867656 326 327 I-Eq-Comparison
months NCT03867656 328 334 I-Eq-Comparison
. NCT03867656 335 336 O

- NCT03867656 340 341 O
Overweight NCT03867656 343 353 B-Condition
or NCT03867656 354 356 B-Or
intestinal NCT03867656 357 367 B-Modifier
surgery NCT03867656 368 375 B-Procedure

Inclusion NCT03863418 0 9 O
Criteria NCT03863418 10 18 O
: NCT03863418 19 20 O

- NCT03863418 24 25 O
Children NCT03863418 27 35 O
aged NCT03863418 36 40 B-Age
6 NCT03863418 41 42 B-Eq-Comparison
- NCT03863418 43 44 I-Eq-Comparison
36 NCT03863418 45 47 I-Eq-Comparison
months NCT03863418 48 54 I-Eq-Comparison

- NCT03863418 57 58 O
diagnosis NCT03863418 60 69 O
of NCT03863418 70 72 O
Atopic NCT03863418 73 79 B-Condition
Dermatitis NCT03863418 80 90 I-Condition
according NCT03863418 91 100 O
to NCT03863418 101 103 O
SCORAD NCT03863418 104 110 B-Observation
index NCT03863418 111 116 I-Observation

Exclusion NCT03863418 117 126 O
Criteria NCT03863418 127 135 O

- NCT03863418 138 139 O
Age NCT03863418 141 144 B-Age
< NCT03863418 145 146 B-Eq-Comparison
6 NCT03863418 147 148 I-Eq-Comparison
months NCT03863418 149 155 I-Eq-Comparison

- NCT03863418 158 159 O
age NCT03863418 161 164 B-Age
> NCT03863418 165 166 B-Eq-Comparison
36 NCT03863418 167 169 I-Eq-Comparison
months NCT03863418 170 176 I-Eq-Comparison
, NCT03863418 177 178 O

- NCT03863418 182 183 O
skin NCT03863418 185 189 B-Modifier
infections NCT03863418 190 200 B-Condition
, NCT03863418 201 202 O

- NCT03863418 206 207 O
ichthyosis NCT03863418 209 219 B-Condition
, NCT03863418 220 221 O

- NCT03863418 225 226 O
food NCT03863418 228 232 O
allergies NCT03863418 233 242 B-Allergy
, NCT03863418 243 244 O

- NCT03863418 248 249 O
other NCT03863418 251 256 B-Other
allergic NCT03863418 257 265 B-Condition
diseases NCT03863418 266 274 I-Condition
, NCT03863418 275 276 O

- NCT03863418 280 281 O
chronic NCT03863418 283 290 B-Modifier
systemic NCT03863418 291 299 I-Modifier
diseases NCT03863418 300 308 B-Condition
, NCT03863418 309 310 O

- NCT03863418 314 315 O
congenital NCT03863418 317 327 B-Condition
cardiac NCT03863418 328 335 I-Condition
defects NCT03863418 336 343 I-Condition
, NCT03863418 344 345 O

- NCT03863418 349 350 O
active NCT03863418 352 358 B-Eq-Comparison
tuberculosis NCT03863418 359 371 B-Condition
, NCT03863418 372 373 O

- NCT03863418 377 378 O
autoimmune NCT03863418 380 390 B-Condition
diseases NCT03863418 391 399 I-Condition
, NCT03863418 400 401 O

- NCT03863418 405 406 O
immunodeficiency NCT03863418 408 424 B-Condition
, NCT03863418 425 426 O

- NCT03863418 430 431 O
chronic NCT03863418 433 440 B-Modifier
inflammatory NCT03863418 441 453 B-Condition
bowel NCT03863418 454 459 I-Condition
diseases NCT03863418 460 468 I-Condition
, NCT03863418 469 470 O

- NCT03863418 474 475 O
celiac NCT03863418 477 483 B-Condition
disease NCT03863418 484 491 I-Condition
, NCT03863418 492 493 O

- NCT03863418 497 498 O
cystic NCT03863418 500 506 B-Condition
fibrosis NCT03863418 507 515 I-Condition
, NCT03863418 516 517 O

- NCT03863418 521 522 O
metabolic NCT03863418 524 533 B-Condition
diseases NCT03863418 534 542 I-Condition
, NCT03863418 543 544 O

- NCT03863418 548 549 O
malignancy NCT03863418 551 561 B-Condition
, NCT03863418 562 563 O

- NCT03863418 567 568 O
chronic NCT03863418 570 577 B-Modifier
pulmonary NCT03863418 578 587 B-Condition
diseases NCT03863418 588 596 I-Condition
, NCT03863418 597 598 O

- NCT03863418 602 603 O
malformations NCT03863418 605 618 B-Condition
of NCT03863418 619 621 O
the NCT03863418 622 625 O
gastrointestinal NCT03863418 626 642 B-Modifier
and NCT03863418 643 646 B-Or
/ NCT03863418 647 648 I-Or
or NCT03863418 649 651 I-Or
respiratory NCT03863418 652 663 B-Modifier
tract NCT03863418 664 669 I-Modifier
, NCT03863418 670 671 O

- NCT03863418 675 676 O
administration NCT03863418 678 692 O
of NCT03863418 693 695 O
prebiotics NCT03863418 696 706 B-Drug
/ NCT03863418 707 708 B-Or
probiotics NCT03863418 709 719 B-Drug
/ NCT03863418 720 721 B-Or
symbiotic NCT03863418 722 731 B-Modifier
/ NCT03863418 732 733 B-Or
systemic NCT03863418 734 742 B-Modifier
immunomodulators NCT03863418 743 759 B-Drug
during NCT03863418 760 766 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863418 767 770 O
4 NCT03863418 771 772 B-Eq-Comparison
weeks NCT03863418 773 778 I-Eq-Comparison
before NCT03863418 779 785 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03863418 786 795 B-Study
, NCT03863418 796 797 O

- NCT03863418 801 802 O
treatments NCT03863418 804 814 B-Procedure
with NCT03863418 815 819 O
topical NCT03863418 820 827 B-Drug
immunomodulators NCT03863418 828 844 I-Drug
( NCT03863418 845 846 O
Tacrolimus NCT03863418 847 857 B-Drug
or NCT03863418 858 860 B-Or
Pimecrolimus NCT03863418 861 873 B-Drug
) NCT03863418 874 875 O
over NCT03863418 876 880 B-Eq-Comparison
the NCT03863418 881 884 I-Eq-Comparison
three NCT03863418 885 890 I-Eq-Comparison
months NCT03863418 891 897 I-Eq-Comparison
prior NCT03863418 898 903 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863418 904 906 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03863418 907 916 B-Study
; NCT03863418 916 917 O

- NCT03863418 920 921 O
use NCT03863418 923 926 O
of NCT03863418 927 929 O
corticosteroids NCT03863418 930 945 B-Drug
or NCT03863418 946 948 B-Or
calcineurin NCT03863418 949 960 B-Drug
antagonists NCT03863418 961 972 I-Drug
or NCT03863418 973 975 B-Or
phototherapy NCT03863418 976 988 B-Procedure
in NCT03863418 989 991 O
the NCT03863418 992 995 O
previous NCT03863418 996 1004 B-Eq-Comparison
4 NCT03863418 1005 1006 I-Eq-Comparison
weeks NCT03863418 1007 1012 I-Eq-Comparison
, NCT03863418 1013 1014 O

- NCT03863418 1018 1019 O
use NCT03863418 1021 1024 O
of NCT03863418 1025 1027 O
systemic NCT03863418 1028 1036 B-Modifier
antibiotics NCT03863418 1037 1048 B-Drug
or NCT03863418 1049 1051 B-Or
anti NCT03863418 1052 1056 O
- NCT03863418 1057 1058 O
mycotic NCT03863418 1059 1066 B-Condition
drugs NCT03863418 1067 1072 B-Drug
during NCT03863418 1073 1079 B-Temporal-Connection___Temporal-Connection-Type-Value:during
4 NCT03863418 1080 1081 B-Eq-Comparison
weeks NCT03863418 1082 1087 I-Eq-Comparison
before NCT03863418 1088 1094 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03863418 1095 1100 B-Study
entry NCT03863418 1101 1106 O
; NCT03863418 1106 1107 O

- NCT03863418 1110 1111 O
investigator NCT03863418 1113 1125 O
's NCT03863418 1125 1127 O
uncertainty NCT03863418 1128 1139 O
about NCT03863418 1140 1145 O
the NCT03863418 1146 1149 O
willingness NCT03863418 1150 1161 O
or NCT03863418 1162 1164 O
ability NCT03863418 1165 1172 O
of NCT03863418 1173 1175 O
the NCT03863418 1176 1179 O
subject NCT03863418 1180 1187 O
to NCT03863418 1188 1190 O
comply NCT03863418 1191 1197 O
with NCT03863418 1198 1202 O
the NCT03863418 1203 1206 O
protocol NCT03863418 1207 1215 O
requirements NCT03863418 1216 1228 O
; NCT03863418 1228 1229 O

- NCT03863418 1232 1233 O
participation NCT03863418 1235 1248 O
in NCT03863418 1249 1251 O
any NCT03863418 1252 1255 O
other NCT03863418 1256 1261 B-Other
studies NCT03863418 1262 1269 B-Study
involving NCT03863418 1270 1279 O
investigational NCT03863418 1280 1295 B-Study
or NCT03863418 1296 1298 B-Or
marketed NCT03863418 1299 1307 B-Modifier
products NCT03863418 1308 1316 B-Drug
concomitantly NCT03863418 1317 1330 B-Modifier
or NCT03863418 1331 1333 B-Or
within NCT03863418 1334 1340 B-Eq-Comparison
two NCT03863418 1341 1344 I-Eq-Comparison
weeks NCT03863418 1345 1350 I-Eq-Comparison
prior NCT03863418 1351 1356 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863418 1357 1359 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03863418 1360 1365 O
into NCT03863418 1366 1370 O
the NCT03863418 1371 1374 O
study NCT03863418 1375 1380 B-Study
; NCT03863418 1380 1381 O

- NCT03863418 1384 1385 O
hypersensitivity NCT03863418 1387 1403 B-Condition
to NCT03863418 1404 1406 O
components NCT03863418 1407 1417 O
contained NCT03863418 1418 1427 O
in NCT03863418 1428 1430 O
study NCT03863418 1431 1436 B-Study
product NCT03863418 1437 1444 B-Drug
. NCT03863418 1444 1445 O

Inclusion NCT03867695 0 9 O
criteria NCT03867695 10 18 O
: NCT03867695 19 20 O

- NCT03867695 24 25 O
All NCT03867695 27 30 O
patients NCT03867695 31 39 O
undergoing NCT03867695 40 50 B-Eq-Comparison
lobectomy NCT03867695 51 60 B-Procedure
VATS NCT03867695 61 65 I-Procedure

- NCT03867695 68 69 O
Older NCT03867695 71 76 B-Age
> NCT03867695 77 78 B-Eq-Comparison
18 NCT03867695 79 81 I-Eq-Comparison
years NCT03867695 82 87 I-Eq-Comparison

- NCT03867695 90 91 O
Patients NCT03867695 93 101 O
who NCT03867695 102 105 O
meet NCT03867695 106 110 O
criteria NCT03867695 111 119 O
of NCT03867695 120 122 O
ASA NCT03867695 123 126 B-Condition
1 NCT03867695 127 128 B-Eq-Comparison
to NCT03867695 129 131 I-Eq-Comparison
3 NCT03867695 132 133 I-Eq-Comparison
class NCT03867695 134 139 I-Eq-Comparison

Exclusion NCT03867695 140 149 O
criteria NCT03867695 150 158 O
: NCT03867695 159 160 O

- NCT03867695 164 165 O
Patient NCT03867695 167 174 O
's NCT03867695 174 176 O
refusal NCT03867695 177 184 O
to NCT03867695 185 187 O
participate NCT03867695 188 199 O
in NCT03867695 200 202 O
the NCT03867695 203 206 O
study NCT03867695 207 212 O

- NCT03867695 215 216 O
Psychiatric NCT03867695 218 229 B-Condition
disorder NCT03867695 230 238 I-Condition
( NCT03867695 239 240 O
impossibility NCT03867695 241 254 O
to NCT03867695 255 257 O
collect NCT03867695 258 265 O
the NCT03867695 266 269 O
informed NCT03867695 270 278 O
consent NCT03867695 279 286 O
) NCT03867695 287 288 O

- NCT03867695 292 293 O
Patient NCT03867695 295 302 O
under NCT03867695 303 308 O
juridical NCT03867695 309 318 B-Observation
protection NCT03867695 319 329 I-Observation

- NCT03867695 332 333 O
On NCT03867695 335 337 O
going NCT03867695 338 343 O
an NCT03867695 344 346 O
other NCT03867695 347 352 B-Other
study NCT03867695 353 358 B-Study

- NCT03867695 361 362 O
Non NCT03867695 364 367 B-Negation
balanced NCT03867695 368 376 B-Modifier
epilepsy NCT03867695 377 385 B-Condition

- NCT03867695 388 389 O
3 NCT03867695 391 392 B-Eq-Comparison
grade NCT03867695 393 398 I-Eq-Comparison
auriculo NCT03867695 399 407 B-Modifier
- NCT03867695 408 409 I-Modifier
ventricular NCT03867695 410 421 I-Modifier
heart NCT03867695 422 427 B-Condition
block NCT03867695 428 433 I-Condition
without NCT03867695 434 441 B-Negation
pacing NCT03867695 442 448 B-Modifier

- NCT03867695 451 452 O
Severe NCT03867695 454 460 O
hepatocellular NCT03867695 461 475 B-Condition
insufficiency NCT03867695 476 489 I-Condition

- NCT03867695 492 493 O
Anti NCT03867695 495 499 B-Procedure
arrhythmic NCT03867695 500 510 I-Procedure
treatment NCT03867695 511 520 I-Procedure
: NCT03867695 521 522 O
class NCT03867695 523 528 B-Eq-Comparison
III NCT03867695 529 532 I-Eq-Comparison
of NCT03867695 533 535 O
the NCT03867695 536 539 O
Vaughan NCT03867695 540 547 B-Modifier
William NCT03867695 548 555 I-Modifier
's NCT03867695 555 557 I-Modifier
classification NCT03867695 558 572 I-Modifier

- NCT03867695 575 576 O
Pregnant NCT03867695 578 586 B-Condition
patient NCT03867695 587 594 O
or NCT03867695 595 597 B-Or
/ NCT03867695 598 599 I-Or
and NCT03867695 600 603 I-Or
breastfeeding NCT03867695 604 617 B-Condition

- NCT03867695 620 621 O
History NCT03867695 623 630 B-Eq-Comparison
of NCT03867695 631 633 O
opioid NCT03867695 634 640 B-Condition
abuse NCT03867695 641 646 I-Condition

- NCT03867695 649 650 O
Allergy NCT03867695 652 659 B-Allergy
to NCT03867695 660 662 O
local NCT03867695 663 668 B-Drug
anesthetic NCT03867695 669 679 I-Drug
drug NCT03867695 680 684 I-Drug
or NCT03867695 685 687 B-Or
opioids NCT03867695 688 695 B-Drug

Inclusion NCT03860688 0 9 O
Criteria NCT03860688 10 18 O
: NCT03860688 19 20 O

- NCT03860688 24 25 O
Men NCT03860688 27 30 O
and NCT03860688 31 34 B-Or
women NCT03860688 35 40 O
, NCT03860688 41 42 O
aged NCT03860688 43 47 B-Age
18 NCT03860688 48 50 B-Eq-Comparison
to NCT03860688 51 53 I-Eq-Comparison
60 NCT03860688 54 56 I-Eq-Comparison
years NCT03860688 57 62 I-Eq-Comparison
. NCT03860688 63 64 O

- NCT03860688 68 69 O
Body NCT03860688 71 75 B-Observation
mass NCT03860688 76 80 I-Observation
index NCT03860688 81 86 I-Observation
20 NCT03860688 87 89 B-Eq-Comparison
to NCT03860688 90 92 I-Eq-Comparison
27 NCT03860688 93 95 I-Eq-Comparison
kg NCT03860688 96 98 I-Eq-Comparison
/ NCT03860688 99 100 I-Eq-Comparison
m2 NCT03860688 101 103 I-Eq-Comparison

Exclusion NCT03860688 104 113 O
Criteria NCT03860688 114 122 O
: NCT03860688 123 124 O

1 NCT03860688 128 129 O
. NCT03860688 129 130 O
Patients NCT03860688 132 140 O
with NCT03860688 141 145 O
active NCT03860688 146 152 B-Eq-Comparison
inflammatory NCT03860688 153 165 B-Condition
bowel NCT03860688 166 171 I-Condition
disease NCT03860688 172 179 I-Condition

2 NCT03860688 182 183 O
. NCT03860688 183 184 O
Patients NCT03860688 186 194 O
with NCT03860688 195 199 O
pre NCT03860688 200 203 B-Eq-Comparison
- NCT03860688 204 205 I-Eq-Comparison
existing NCT03860688 206 214 I-Eq-Comparison
Celiac NCT03860688 215 221 B-Condition
disease NCT03860688 222 229 I-Condition
, NCT03860688 230 231 O
exocrine NCT03860688 232 240 B-Condition
pancreatic NCT03860688 241 251 I-Condition
insufficiency NCT03860688 252 265 I-Condition
or NCT03860688 266 268 B-Or
small NCT03860688 269 274 B-Condition
bowel NCT03860688 275 280 I-Condition
malabsorption NCT03860688 281 294 I-Condition

3 NCT03860688 297 298 O
. NCT03860688 298 299 O
Patients NCT03860688 301 309 O
with NCT03860688 310 314 O
active NCT03860688 315 321 B-Eq-Comparison
bowel NCT03860688 322 327 B-Condition
malignancy NCT03860688 328 338 I-Condition

4 NCT03860688 341 342 O
. NCT03860688 342 343 O
Patients NCT03860688 345 353 O
with NCT03860688 354 358 O
diabetes NCT03860688 359 367 B-Condition
mellitus NCT03860688 368 376 I-Condition
or NCT03860688 377 379 B-Or
known NCT03860688 380 385 B-Modifier
/ NCT03860688 386 387 B-Or
suspected NCT03860688 388 397 B-Assertion___Assertion-Type-Value:possible
motility NCT03860688 398 406 B-Condition
disorders NCT03860688 407 416 I-Condition
of NCT03860688 417 419 O
the NCT03860688 420 423 O
gut NCT03860688 424 427 B-Modifier

5 NCT03860688 430 431 O
. NCT03860688 431 432 O
Patients NCT03860688 434 442 O
with NCT03860688 443 447 O
decompensated NCT03860688 448 461 B-Modifier
liver NCT03860688 462 467 B-Condition
disease NCT03860688 468 475 I-Condition

6 NCT03860688 478 479 O
. NCT03860688 479 480 O
Patients NCT03860688 482 490 O
on NCT03860688 491 493 B-Eq-Comparison
ezetimibe NCT03860688 494 503 B-Drug
or NCT03860688 504 506 B-Or
bile NCT03860688 507 511 B-Drug
acid NCT03860688 512 516 I-Drug
sequestrants NCT03860688 517 529 I-Drug

7 NCT03860688 532 533 O
. NCT03860688 533 534 O
Patients NCT03860688 536 544 O
who NCT03860688 545 548 O
are NCT03860688 549 552 B-Eq-Comparison
pregnant NCT03860688 553 561 B-Condition
or NCT03860688 562 564 B-Or
breastfeeding NCT03860688 565 578 B-Condition
. NCT03860688 579 580 O

8 NCT03860688 584 585 O
. NCT03860688 585 586 O
Patients NCT03860688 588 596 O
with NCT03860688 597 601 O
renal NCT03860688 602 607 B-Condition
disease NCT03860688 608 615 I-Condition
. NCT03860688 616 617 O

9 NCT03860688 621 622 O
. NCT03860688 622 623 O
Patients NCT03860688 625 633 O
on NCT03860688 634 636 B-Eq-Comparison
benzodiazepine NCT03860688 637 651 B-Drug
. NCT03860688 652 653 O

10 NCT03860688 656 658 O
. NCT03860688 658 659 O
Unstable NCT03860688 661 669 O
cardiac NCT03860688 670 677 B-Modifier
or NCT03860688 678 680 B-Or
respiratory NCT03860688 681 692 B-Modifier
disease NCT03860688 693 700 B-Condition

11 NCT03860688 702 704 O
. NCT03860688 704 705 O
Any NCT03860688 707 710 O
changes NCT03860688 711 718 O
to NCT03860688 719 721 O
medication NCT03860688 722 732 B-Drug
in NCT03860688 733 735 O
the NCT03860688 736 739 O
preceding NCT03860688 740 749 B-Eq-Comparison
month NCT03860688 750 755 I-Eq-Comparison

12 NCT03860688 757 759 O
. NCT03860688 759 760 O
Patients NCT03860688 762 770 O
with NCT03860688 771 775 O
hypersensitive NCT03860688 776 790 B-Condition
to NCT03860688 791 793 O
Revestive NCT03860688 794 803 B-Drug
or NCT03860688 804 806 B-Or
any NCT03860688 807 810 O
ingredient NCT03860688 811 821 B-Coreference
, NCT03860688 822 823 O
active NCT03860688 824 830 B-Eq-Comparison
or NCT03860688 831 833 B-Or
a NCT03860688 834 835 O
history NCT03860688 836 843 B-Eq-Comparison
of NCT03860688 844 846 O
the NCT03860688 847 850 B-Coreference
drug NCT03860688 851 855 I-Coreference
within NCT03860688 856 862 B-Eq-Comparison
the NCT03860688 863 866 I-Eq-Comparison
last NCT03860688 867 871 I-Eq-Comparison
5 NCT03860688 872 873 I-Eq-Comparison
years NCT03860688 874 879 I-Eq-Comparison

13 NCT03860688 881 883 O
. NCT03860688 883 884 O
Patients NCT03860688 886 894 O
with NCT03860688 895 899 O
GI NCT03860688 900 902 B-Condition
malignancy NCT03860688 903 913 I-Condition
( NCT03860688 914 915 O
GI NCT03860688 916 918 B-Modifier
tract NCT03860688 919 924 I-Modifier
, NCT03860688 925 926 O
hepatobiliary NCT03860688 927 940 B-Modifier
, NCT03860688 941 942 O
pancreatic NCT03860688 943 953 B-Modifier
) NCT03860688 954 955 O

Inclusion NCT03869684 0 9 O
Criteria NCT03869684 10 18 O
: NCT03869684 19 20 O

- NCT03869684 24 25 O
Must NCT03869684 27 31 O
agree NCT03869684 32 37 O
to NCT03869684 38 40 O
sign NCT03869684 41 45 O
informed NCT03869684 46 54 O
consent NCT03869684 55 62 O
form NCT03869684 63 67 O
, NCT03869684 68 69 O
and NCT03869684 70 73 O
to NCT03869684 74 76 O
comply NCT03869684 77 83 O
with NCT03869684 84 88 O
protocol NCT03869684 89 97 O
requirements NCT03869684 98 110 O
, NCT03869684 111 112 O
including NCT03869684 113 122 O
study NCT03869684 123 128 O
visits NCT03869684 129 135 O
. NCT03869684 136 137 O

- NCT03869684 141 142 O
Must NCT03869684 144 148 O
have NCT03869684 149 153 O
clear NCT03869684 154 159 B-Modifier
optic NCT03869684 160 165 B-Observation
media NCT03869684 166 171 I-Observation
in NCT03869684 172 174 O
the NCT03869684 175 178 O
study NCT03869684 179 184 B-Study
eye NCT03869684 185 188 B-Modifier
that NCT03869684 189 193 O
is NCT03869684 194 196 O
capable NCT03869684 197 204 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03869684 205 207 I-Assertion___Assertion-Type-Value:hypothetical
producing NCT03869684 208 217 O
high NCT03869684 218 222 B-Modifier
- NCT03869684 223 224 I-Modifier
quality NCT03869684 225 232 I-Modifier
fundus NCT03869684 233 239 B-Observation
images NCT03869684 240 246 I-Observation
. NCT03869684 247 248 O

Exclusion NCT03869684 250 259 O
Criteria NCT03869684 260 268 O
: NCT03869684 269 270 O

- NCT03869684 274 275 O
Has NCT03869684 277 280 O
active NCT03869684 281 287 B-Eq-Comparison
CNV NCT03869684 288 291 B-Condition
due NCT03869684 292 295 O
to NCT03869684 296 298 O
causes NCT03869684 299 305 B-Condition
other NCT03869684 306 311 B-Exception
than NCT03869684 312 316 I-Exception
AMD NCT03869684 317 320 B-Condition
in NCT03869684 321 323 O
the NCT03869684 324 327 O
study NCT03869684 328 333 B-Study
eye NCT03869684 334 337 B-Modifier
. NCT03869684 338 339 O

- NCT03869684 343 344 O
Has NCT03869684 346 349 O
retinal NCT03869684 350 357 B-Condition
vascular NCT03869684 358 366 I-Condition
disease NCT03869684 367 374 I-Condition
or NCT03869684 375 377 B-Or
retinal NCT03869684 378 385 B-Condition
degeneration NCT03869684 386 398 I-Condition
other NCT03869684 399 404 B-Exception
than NCT03869684 405 409 I-Exception
AMD NCT03869684 410 413 B-Condition
in NCT03869684 414 416 O
the NCT03869684 417 420 O
study NCT03869684 421 426 B-Study
eye NCT03869684 427 430 B-Modifier
. NCT03869684 431 432 O

- NCT03869684 436 437 O
Has NCT03869684 439 442 O
had NCT03869684 443 446 B-Eq-Comparison
intraocular NCT03869684 447 458 B-Procedure
surgery NCT03869684 459 466 I-Procedure
, NCT03869684 467 468 O
cataract NCT03869684 469 477 B-Procedure
surgery NCT03869684 478 485 I-Procedure
or NCT03869684 486 488 B-Or
LASIK NCT03869684 489 494 B-Procedure
surgery NCT03869684 495 502 I-Procedure
on NCT03869684 503 505 O
the NCT03869684 506 509 O
study NCT03869684 510 515 B-Study
eye NCT03869684 516 519 B-Modifier
within NCT03869684 520 526 B-Eq-Comparison
90 NCT03869684 527 529 I-Eq-Comparison
days NCT03869684 530 534 I-Eq-Comparison
prior NCT03869684 535 540 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 541 543 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 544 547 O
study NCT03869684 548 553 B-Study
. NCT03869684 553 554 O

- NCT03869684 563 564 O
Has NCT03869684 566 569 O
had NCT03869684 570 573 O
yttrium NCT03869684 574 581 B-Procedure
aluminum NCT03869684 582 590 I-Procedure
garnet NCT03869684 591 597 I-Procedure
( NCT03869684 598 599 O
YAG NCT03869684 600 603 B-Procedure
) NCT03869684 604 605 O
laser NCT03869684 606 611 B-Procedure
capsulotomy NCT03869684 612 623 I-Procedure
on NCT03869684 624 626 O
the NCT03869684 627 630 O
study NCT03869684 631 636 B-Study
eye NCT03869684 637 640 B-Modifier
within NCT03869684 641 647 B-Eq-Comparison
30 NCT03869684 648 650 I-Eq-Comparison
days NCT03869684 651 655 I-Eq-Comparison
prior NCT03869684 656 661 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 662 664 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 665 668 O
study NCT03869684 669 674 B-Study
. NCT03869684 675 676 O

- NCT03869684 680 681 O
Has NCT03869684 683 686 O
active NCT03869684 687 693 B-Eq-Comparison
inflammation NCT03869684 694 706 B-Condition
, NCT03869684 707 708 O
infection NCT03869684 709 718 B-Condition
, NCT03869684 719 720 O
or NCT03869684 721 723 B-Or
other NCT03869684 724 729 B-Other
severe NCT03869684 730 736 O
ocular NCT03869684 737 743 B-Condition
disease NCT03869684 744 751 I-Condition
in NCT03869684 752 754 O
either NCT03869684 755 761 B-Modifier
eye NCT03869684 762 765 I-Modifier
. NCT03869684 766 767 O

- NCT03869684 771 772 O
Has NCT03869684 774 777 O
aphakia NCT03869684 778 785 B-Condition
in NCT03869684 786 788 O
the NCT03869684 789 792 O
study NCT03869684 793 798 B-Study
eye NCT03869684 799 802 B-Modifier
. NCT03869684 803 804 O

- NCT03869684 808 809 O
Has NCT03869684 811 814 O
uncontrolled NCT03869684 815 827 B-Modifier
glaucoma NCT03869684 828 836 B-Condition
or NCT03869684 837 839 B-Or
a NCT03869684 840 841 O
history NCT03869684 842 849 B-Eq-Comparison
of NCT03869684 850 852 I-Eq-Comparison
previous NCT03869684 853 861 I-Eq-Comparison
glaucoma NCT03869684 862 870 B-Procedure
filter NCT03869684 871 877 I-Procedure
surgery NCT03869684 878 885 I-Procedure
in NCT03869684 886 888 O
either NCT03869684 889 895 B-Modifier
eye NCT03869684 896 899 I-Modifier
. NCT03869684 900 901 O

- NCT03869684 905 906 O
Is NCT03869684 908 910 O
a NCT03869684 911 912 O
contact NCT03869684 913 920 B-Procedure
lens NCT03869684 921 925 I-Procedure
wearer NCT03869684 926 932 O
and NCT03869684 933 936 B-And
is NCT03869684 937 939 O
unable NCT03869684 940 946 B-Negation
to NCT03869684 947 949 O
discontinue NCT03869684 950 961 B-Assertion___Assertion-Type-Value:hypothetical|Negation
their NCT03869684 962 967 O
use NCT03869684 968 971 O
in NCT03869684 972 974 O
both NCT03869684 975 979 B-Modifier
eyes NCT03869684 980 984 I-Modifier
for NCT03869684 985 988 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869684 989 992 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03869684 993 1001 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03869684 1002 1004 O
the NCT03869684 1005 1008 O
study NCT03869684 1009 1014 B-Study
. NCT03869684 1015 1016 O

- NCT03869684 1020 1021 O
Has NCT03869684 1023 1026 O
a NCT03869684 1027 1028 O
serious NCT03869684 1029 1036 O
allergy NCT03869684 1037 1044 B-Allergy
to NCT03869684 1045 1047 O
, NCT03869684 1048 1049 O
or NCT03869684 1050 1052 B-Or
experienced NCT03869684 1053 1064 O
a NCT03869684 1065 1066 O
prior NCT03869684 1067 1072 B-Eq-Comparison
significant NCT03869684 1073 1084 O
adverse NCT03869684 1085 1092 B-Condition
reaction NCT03869684 1093 1101 I-Condition
to NCT03869684 1102 1104 O
fluorescein NCT03869684 1105 1116 B-Procedure
angiography NCT03869684 1117 1128 I-Procedure
( NCT03869684 1129 1130 O
FA NCT03869684 1131 1133 B-Procedure
) NCT03869684 1134 1135 O
or NCT03869684 1136 1138 B-Or
indocyanine NCT03869684 1139 1150 B-Procedure
green NCT03869684 1151 1156 I-Procedure
angiography NCT03869684 1157 1168 I-Procedure
( NCT03869684 1169 1170 O
ICGA NCT03869684 1171 1175 B-Procedure
) NCT03869684 1176 1177 O
. NCT03869684 1179 1180 O

- NCT03869684 1184 1185 O
Has NCT03869684 1187 1190 O
participated NCT03869684 1191 1203 O
in NCT03869684 1204 1206 O
any NCT03869684 1207 1210 O
other NCT03869684 1211 1216 B-Other
clinical NCT03869684 1217 1225 B-Study
trial NCT03869684 1226 1231 I-Study
and NCT03869684 1232 1235 B-Or
/ NCT03869684 1236 1237 I-Or
or NCT03869684 1238 1240 I-Or
has NCT03869684 1241 1244 O
taken NCT03869684 1245 1250 O
any NCT03869684 1251 1254 O
investigational NCT03869684 1255 1270 B-Study
drug NCT03869684 1271 1275 B-Drug
or NCT03869684 1276 1278 B-Or
product NCT03869684 1279 1286 B-Drug
within NCT03869684 1287 1293 B-Eq-Comparison
90 NCT03869684 1294 1296 I-Eq-Comparison
days NCT03869684 1297 1301 I-Eq-Comparison
prior NCT03869684 1302 1307 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869684 1308 1310 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869684 1311 1314 O
study NCT03869684 1315 1320 B-Study
. NCT03869684 1321 1322 O

Other NCT03869684 1324 1329 O
protocol NCT03869684 1330 1338 O
- NCT03869684 1339 1340 O
defined NCT03869684 1341 1348 O
inclusion NCT03869684 1349 1358 O
/ NCT03869684 1359 1360 O
exclusion NCT03869684 1361 1370 O
criteria NCT03869684 1371 1379 O
could NCT03869684 1380 1385 O
apply NCT03869684 1386 1391 O
. NCT03869684 1392 1393 O


Inclusion NCT03865914 0 9 O
Criteria NCT03865914 10 18 O
: NCT03865914 19 20 O

- NCT03865914 24 25 O
Age NCT03865914 27 30 B-Age
≥ NCT03865914 31 32 B-Eq-Comparison
18 NCT03865914 33 35 I-Eq-Comparison
, NCT03865914 36 37 O
male NCT03865914 38 42 O
or NCT03865914 43 45 B-Or
female NCT03865914 46 52 O

- NCT03865914 55 56 O
Clinical NCT03865914 58 66 O
diagnosed NCT03865914 67 76 O
as NCT03865914 77 79 O
type NCT03865914 80 84 B-Modifier
2 NCT03865914 85 86 I-Modifier
diabetes NCT03865914 87 95 B-Condition
mellitus NCT03865914 96 104 I-Condition

- NCT03865914 107 108 O
The NCT03865914 110 113 O
presence NCT03865914 114 122 O
of NCT03865914 123 125 O
renal NCT03865914 126 131 B-Condition
impairment NCT03865914 132 142 I-Condition
including NCT03865914 143 152 O
: NCT03865914 153 154 O
microalbuminuria NCT03865914 155 171 B-Condition
or NCT03865914 172 174 B-Or
overt NCT03865914 175 180 B-Modifier
proteinuria NCT03865914 181 192 B-Condition
or NCT03865914 193 195 B-Or
renal NCT03865914 196 201 B-Modifier
insufficiency NCT03865914 202 215 B-Condition

- NCT03865914 218 219 O
The NCT03865914 221 224 O
renal NCT03865914 225 230 B-Modifier
biopsy NCT03865914 231 237 B-Procedure
was NCT03865914 238 241 O
performed NCT03865914 242 251 O
with NCT03865914 252 256 O
complete NCT03865914 257 265 O
renal NCT03865914 266 271 B-Condition
pathological NCT03865914 272 284 I-Condition
diagnosis NCT03865914 285 294 O

- NCT03865914 297 298 O
Obtaining NCT03865914 300 309 O
the NCT03865914 310 313 O
signed NCT03865914 314 320 O
informed NCT03865914 321 329 O
consent NCT03865914 330 337 O
from NCT03865914 338 342 O
patients NCT03865914 343 351 O

Exclusion NCT03865914 352 361 O
Criteria NCT03865914 362 370 O
: NCT03865914 371 372 O

- NCT03865914 376 377 O
The NCT03865914 379 382 O
history NCT03865914 383 390 B-Eq-Comparison
of NCT03865914 391 393 O
the NCT03865914 394 397 B-Coreference
disease NCT03865914 398 405 I-Coreference
was NCT03865914 406 409 O
not NCT03865914 410 413 B-Assertion___Assertion-Type-Value:hypothetical|Negation
complete NCT03865914 414 422 I-Assertion___Assertion-Type-Value:hypothetical|Negation

- NCT03865914 425 426 O
Clinical NCT03865914 428 436 O
diagnosed NCT03865914 437 446 O
as NCT03865914 447 449 O
other NCT03865914 450 455 B-Other
secondary NCT03865914 456 465 B-Modifier
renal NCT03865914 466 471 B-Condition
diseases NCT03865914 472 480 I-Condition

- NCT03865914 483 484 O
Patients NCT03865914 486 494 O
with NCT03865914 495 499 O
hereditary NCT03865914 500 510 B-Modifier
kidney NCT03865914 511 517 B-Condition
disease NCT03865914 518 525 I-Condition

- NCT03865914 528 529 O
Autoimmune NCT03865914 531 541 B-Condition
diseases NCT03865914 542 550 I-Condition

- NCT03865914 553 554 O
Patients NCT03865914 556 564 O
with NCT03865914 565 569 O
malignant NCT03865914 570 579 B-Condition
tumor NCT03865914 580 585 I-Condition
were NCT03865914 586 590 B-And
expected NCT03865914 591 599 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865914 600 602 I-Assertion___Assertion-Type-Value:hypothetical
survive NCT03865914 603 610 B-Death
less NCT03865914 611 615 B-Eq-Comparison
than NCT03865914 616 620 I-Eq-Comparison
6 NCT03865914 621 622 I-Eq-Comparison
months NCT03865914 623 629 I-Eq-Comparison

- NCT03865914 632 633 O
Pregnancy NCT03865914 635 644 B-Condition
and NCT03865914 645 648 B-Or
lactation NCT03865914 649 658 B-Condition

Inclusion NCT03863626 0 9 O
Criteria NCT03863626 10 18 O
: NCT03863626 19 20 O

- NCT03863626 24 25 O
Age NCT03863626 27 30 B-Age
more NCT03863626 31 35 B-Eq-Comparison
than NCT03863626 36 40 I-Eq-Comparison
18 NCT03863626 41 43 I-Eq-Comparison
years NCT03863626 44 49 I-Eq-Comparison
. NCT03863626 50 51 O

- NCT03863626 55 56 O
Chronic NCT03863626 58 65 B-Modifier
heart NCT03863626 66 71 B-Condition
failure NCT03863626 72 79 I-Condition
prior NCT03863626 80 85 B-Eq-Comparison
diagnosis NCT03863626 86 95 O
, NCT03863626 96 97 O
based NCT03863626 98 103 O
on NCT03863626 104 106 O
signs NCT03863626 107 112 B-Assertion___Assertion-Type-Value:possible
and NCT03863626 113 116 B-Or
or NCT03863626 117 119 I-Or
symptoms NCT03863626 120 128 B-Assertion___Assertion-Type-Value:possible
of NCT03863626 129 131 O
heart NCT03863626 132 137 B-Condition
failure NCT03863626 138 145 I-Condition
, NCT03863626 146 147 O
presenting NCT03863626 148 158 O
with NCT03863626 159 163 O
acute NCT03863626 164 169 O
decompensation NCT03863626 170 184 B-Condition
as NCT03863626 185 187 O
judged NCT03863626 188 194 O
by NCT03863626 195 197 O
the NCT03863626 198 201 O
physician NCT03863626 202 211 B-Provider
to NCT03863626 212 214 O
require NCT03863626 215 222 B-Assertion___Assertion-Type-Value:hypothetical
hospitalization NCT03863626 223 238 B-Encounter
for NCT03863626 239 242 O
IV NCT03863626 243 245 B-Drug
diuretics NCT03863626 246 255 I-Drug

Exclusion NCT03863626 256 265 O
Criteria NCT03863626 266 274 O
: NCT03863626 275 276 O

- NCT03863626 280 281 O
Refusal NCT03863626 283 290 O
to NCT03863626 291 293 O
participate NCT03863626 294 305 O
in NCT03863626 306 308 O
the NCT03863626 309 312 O
study NCT03863626 313 318 O
. NCT03863626 319 320 O

- NCT03863626 324 325 O
Allergy NCT03863626 327 334 B-Allergy
to NCT03863626 335 337 O
IV NCT03863626 338 340 B-Drug
frusemide NCT03863626 341 350 I-Drug
. NCT03863626 351 352 O

- NCT03863626 356 357 O
Severe NCT03863626 359 365 O
renal NCT03863626 366 371 B-Condition
impairment NCT03863626 372 382 I-Condition
defined NCT03863626 383 390 O
as NCT03863626 391 393 O
eGFR NCT03863626 394 398 B-Observation
< NCT03863626 399 400 B-Eq-Comparison
30 NCT03863626 401 403 I-Eq-Comparison
ml NCT03863626 404 406 I-Eq-Comparison
/ NCT03863626 407 408 I-Eq-Comparison
m NCT03863626 409 410 I-Eq-Comparison
. NCT03863626 411 412 O

- NCT03863626 416 417 O
Cardiogenic NCT03863626 419 430 B-Condition
shock NCT03863626 431 436 I-Condition
or NCT03863626 437 439 B-Or
hemodynamic NCT03863626 440 451 B-Condition
instability NCT03863626 452 463 O
judged NCT03863626 464 470 O
by NCT03863626 471 473 O
the NCT03863626 474 477 O
treating NCT03863626 478 486 O
physician NCT03863626 487 496 O
to NCT03863626 497 499 O
be NCT03863626 500 502 O
unsuitable NCT03863626 503 513 O
to NCT03863626 514 516 O
participate NCT03863626 517 528 O
. NCT03863626 528 529 O

Inclusion NCT03863197 0 9 O
Criteria NCT03863197 10 18 O
: NCT03863197 19 20 O

- NCT03863197 24 25 O
Confirmed NCT03863197 27 36 O
diagnosis NCT03863197 37 46 O
of NCT03863197 47 49 O
SCP NCT03863197 50 53 B-Condition

- NCT03863197 56 57 O
Aged NCT03863197 59 63 B-Age
5 NCT03863197 64 65 B-Eq-Comparison
- NCT03863197 66 67 I-Eq-Comparison
12 NCT03863197 68 70 I-Eq-Comparison
years NCT03863197 71 76 I-Eq-Comparison

- NCT03863197 79 80 O
GMFCS NCT03863197 82 87 B-Observation
levels NCT03863197 88 94 B-Eq-Comparison
I NCT03863197 95 96 I-Eq-Comparison
- NCT03863197 97 98 I-Eq-Comparison
III NCT03863197 99 102 I-Eq-Comparison
( NCT03863197 103 104 O
GMFCS NCT03863197 105 110 B-Observation
= NCT03863197 111 112 B-Eq-Comparison
Gross NCT03863197 113 118 B-Observation
Motor NCT03863197 119 124 I-Observation
Function NCT03863197 125 133 I-Observation
Classification NCT03863197 134 148 I-Observation
Score NCT03863197 149 154 I-Observation
, NCT03863197 155 156 O
expressing NCT03863197 157 167 O
the NCT03863197 168 171 O
overall NCT03863197 172 179 O
functional NCT03863197 180 190 B-Condition
level NCT03863197 191 196 I-Condition
of NCT03863197 197 199 I-Condition
impairment NCT03863197 200 210 I-Condition
) NCT03863197 211 212 O

- NCT03863197 216 217 O
Sufficient NCT03863197 219 229 B-Assertion___Assertion-Type-Value:hypothetical
cooperation NCT03863197 230 241 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03863197 242 244 O
comprehend NCT03863197 245 255 O
and NCT03863197 256 259 O
complete NCT03863197 260 268 O
the NCT03863197 269 272 O
test NCT03863197 273 277 B-Procedure
procedure NCT03863197 278 287 I-Procedure

Exclusion NCT03863197 288 297 O
Criteria NCT03863197 298 306 O
: NCT03863197 307 308 O

- NCT03863197 312 313 O
Non NCT03863197 315 318 B-Negation
- NCT03863197 319 320 O
ambulatory NCT03863197 321 331 B-Condition

- NCT03863197 334 335 O
Botulinum NCT03863197 337 346 B-Drug
toxin NCT03863197 347 352 I-Drug
A NCT03863197 353 354 I-Drug
injections NCT03863197 355 365 B-Procedure
six NCT03863197 366 369 B-Eq-Comparison
months NCT03863197 370 376 I-Eq-Comparison
prior NCT03863197 377 382 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863197 383 385 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03863197 386 396 B-Study

- NCT03863197 399 400 O
Lower NCT03863197 402 407 B-Modifier
limb NCT03863197 408 412 I-Modifier
surgery NCT03863197 413 420 B-Procedure
two NCT03863197 421 424 B-Eq-Comparison
years NCT03863197 425 430 I-Eq-Comparison
prior NCT03863197 431 436 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863197 437 439 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03863197 440 450 B-Study

- NCT03863197 453 454 O
Presence NCT03863197 456 464 O
of NCT03863197 465 467 O
ataxia NCT03863197 468 474 B-Condition
or NCT03863197 475 477 B-Or
dystonia NCT03863197 478 486 B-Condition

- NCT03863197 489 490 O
Cognitive NCT03863197 492 501 B-Condition
problems NCT03863197 502 510 I-Condition
that NCT03863197 511 515 O
impede NCT03863197 516 522 O
measurements NCT03863197 523 535 B-Observation

- NCT03863197 538 539 O
Severe NCT03863197 541 547 O
co NCT03863197 548 550 B-Condition
- NCT03863197 551 552 I-Condition
morbidities NCT03863197 553 564 I-Condition
( NCT03863197 565 566 O
severe NCT03863197 567 573 O
epilepsy NCT03863197 574 582 B-Condition
, NCT03863197 583 584 O
non NCT03863197 585 588 B-Modifier
- NCT03863197 589 590 I-Modifier
correctable NCT03863197 591 602 I-Modifier
visual NCT03863197 603 609 B-Condition
impairment NCT03863197 610 620 I-Condition
, NCT03863197 621 622 O
autism NCT03863197 623 629 B-Condition
spectrum NCT03863197 630 638 I-Condition
disorders NCT03863197 639 648 I-Condition
, NCT03863197 649 650 O
mental NCT03863197 651 657 B-Condition
problems NCT03863197 658 666 I-Condition
that NCT03863197 667 671 O
prevent NCT03863197 672 679 B-Assertion___Assertion-Type-Value:hypothetical|Negation
comprehensiveness NCT03863197 680 697 O
of NCT03863197 698 700 O
the NCT03863197 701 704 O
tasks NCT03863197 705 710 B-Procedure
) NCT03863197 711 712 O

Inclusion NCT03864809 0 9 O
Criteria NCT03864809 10 18 O
: NCT03864809 19 20 O

- NCT03864809 23 24 O
patients NCT03864809 25 33 O
with NCT03864809 34 38 O
Psoriasis NCT03864809 39 48 B-Condition
and NCT03864809 49 52 B-Or
Patients NCT03864809 53 61 O
with NCT03864809 62 66 O
A NCT03864809 67 68 O
topic NCT03864809 69 74 B-Condition
dermatitis NCT03864809 75 85 I-Condition

Exclusion NCT03864809 86 95 O
Criteria NCT03864809 96 104 O
: NCT03864809 105 106 O

- NCT03864809 110 111 O
All NCT03864809 113 116 O
patient NCT03864809 117 124 O
have NCT03864809 125 129 O
another NCT03864809 130 137 B-Other
dermatological NCT03864809 138 152 B-Condition
disease NCT03864809 153 160 I-Condition

Inclusion NCT03868969 0 9 O
Criteria NCT03868969 10 18 O
: NCT03868969 19 20 O

- NCT03868969 24 25 O
clinical NCT03868969 27 35 O
suspicion NCT03868969 36 45 B-Assertion___Assertion-Type-Value:possible
of NCT03868969 46 48 O
urinary NCT03868969 49 56 B-Condition
tract NCT03868969 57 62 I-Condition
infection NCT03868969 63 72 I-Condition
( NCT03868969 73 74 O
UTI NCT03868969 75 78 B-Condition
) NCT03868969 79 80 O
defined NCT03868969 81 88 O
by NCT03868969 89 91 O
the NCT03868969 92 95 O
presence NCT03868969 96 104 O
of NCT03868969 105 107 O
at NCT03868969 108 110 B-Eq-Comparison
least NCT03868969 111 116 I-Eq-Comparison
one NCT03868969 117 120 I-Eq-Comparison
of NCT03868969 121 123 B-Criteria-Count
these NCT03868969 124 129 I-Criteria-Count
signs NCT03868969 130 135 I-Criteria-Count
: NCT03868969 136 137 O
fever NCT03868969 138 143 B-Condition|Observation
> NCT03868969 144 145 B-Eq-Comparison
38 NCT03868969 146 148 I-Eq-Comparison
° NCT03868969 149 150 I-Eq-Comparison
C NCT03868969 150 151 I-Eq-Comparison
and NCT03868969 152 155 B-Or
/ NCT03868969 156 157 I-Or
or NCT03868969 158 160 I-Or
sus NCT03868969 161 164 B-Modifier
- NCT03868969 165 166 I-Modifier
pubic NCT03868969 167 172 I-Modifier
pain NCT03868969 173 177 B-Condition
and NCT03868969 178 181 B-Or
/ NCT03868969 182 183 I-Or
or NCT03868969 184 186 I-Or
dysuria NCT03868969 187 194 B-Condition
and NCT03868969 195 198 B-Or
/ NCT03868969 199 200 I-Or
or NCT03868969 201 203 I-Or
pollakiuria NCT03868969 204 215 B-Condition
and NCT03868969 216 219 B-Or
/ NCT03868969 220 221 I-Or
or NCT03868969 222 224 I-Or
urinary NCT03868969 225 232 B-Modifier
burns NCT03868969 233 238 B-Condition
and NCT03868969 239 242 B-Or
/ NCT03868969 243 244 I-Or
or NCT03868969 245 247 I-Or
macroscopic NCT03868969 248 259 B-Modifier
hematuria NCT03868969 260 269 B-Condition
and NCT03868969 270 273 B-Or
/ NCT03868969 274 275 I-Or
or NCT03868969 276 278 I-Or
acute NCT03868969 279 284 O
urinary NCT03868969 285 292 B-Condition
retention NCT03868969 293 302 I-Condition
and NCT03868969 303 306 B-Or
/ NCT03868969 307 308 I-Or
or NCT03868969 309 311 I-Or
pain NCT03868969 312 316 B-Condition
with NCT03868969 317 321 O
the NCT03868969 322 325 O
rectal NCT03868969 326 332 B-Procedure
examination NCT03868969 333 344 I-Procedure
and NCT03868969 345 348 B-Or
/ NCT03868969 349 350 I-Or
or NCT03868969 351 353 I-Or
confusion NCT03868969 354 363 B-Condition

- NCT03868969 366 367 O
And NCT03868969 369 372 B-And
urinary NCT03868969 373 380 B-Observation
analysis NCT03868969 381 389 I-Observation
with NCT03868969 390 394 O
leukocyturia NCT03868969 395 407 B-Condition|Observation
> NCT03868969 408 409 B-Eq-Comparison
10 NCT03868969 410 412 I-Eq-Comparison
/ NCT03868969 413 414 I-Eq-Comparison
mm3 NCT03868969 415 418 I-Eq-Comparison
, NCT03868969 419 420 O
bacteriuria NCT03868969 421 432 B-Condition|Observation
> NCT03868969 433 434 B-Eq-Comparison
10 NCT03868969 435 437 I-Eq-Comparison
^3 NCT03868969 438 440 I-Eq-Comparison
CFU NCT03868969 441 444 I-Eq-Comparison
/ NCT03868969 445 446 I-Eq-Comparison
mL NCT03868969 447 449 I-Eq-Comparison
with NCT03868969 450 454 B-And
ESBL NCT03868969 455 459 B-Modifier
producing NCT03868969 460 469 I-Modifier
enterobacteriaceae NCT03868969 470 488 B-Condition
and NCT03868969 489 492 B-And
resistance NCT03868969 493 503 B-Condition
associated NCT03868969 504 514 O
with NCT03868969 515 519 O
fluoroquinolones NCT03868969 520 536 B-Drug
( NCT03868969 537 538 O
FQ NCT03868969 539 541 B-Drug
) NCT03868969 542 543 O
and NCT03868969 544 547 B-Or
cotrimoxazole NCT03868969 548 561 B-Drug
( NCT03868969 562 563 O
CTX NCT03868969 564 567 B-Drug
) NCT03868969 568 569 O
but NCT03868969 570 573 B-And
sensitive NCT03868969 574 583 B-Condition
to NCT03868969 584 586 O
fosfomycin NCT03868969 587 597 B-Drug
. NCT03868969 598 599 O

Exclusion NCT03868969 601 610 O
Criteria NCT03868969 611 619 O
: NCT03868969 620 621 O

- NCT03868969 625 626 O
allergy NCT03868969 628 635 B-Allergy
to NCT03868969 636 638 O
fosfomycin NCT03868969 639 649 B-Drug
and NCT03868969 650 653 B-Or
/ NCT03868969 654 655 I-Or
or NCT03868969 656 658 I-Or
trometamol NCT03868969 659 669 B-Drug

- NCT03868969 672 673 O
Presence NCT03868969 675 683 O
of NCT03868969 684 686 O
material NCT03868969 687 695 B-Condition
in NCT03868969 696 698 O
the NCT03868969 699 702 O
urinary NCT03868969 703 710 B-Modifier
tract NCT03868969 711 716 I-Modifier

- NCT03868969 719 720 O
Severe NCT03868969 722 728 O
immunosuppression NCT03868969 729 746 B-Condition

- NCT03868969 749 750 O
Chronic NCT03868969 752 759 B-Modifier
prostatitis NCT03868969 760 771 B-Condition

- NCT03868969 774 775 O
Prostate NCT03868969 777 785 B-Condition
abscess NCT03868969 786 793 I-Condition

- NCT03868969 796 797 O
Acute NCT03868969 799 804 O
pyelonephritis NCT03868969 805 819 B-Condition

- NCT03868969 822 823 O
Hemodynamic NCT03868969 825 836 B-Condition
instability NCT03868969 837 848 O

- NCT03868969 851 852 O
Chronic NCT03868969 854 861 B-Condition
renal NCT03868969 862 867 I-Condition
failure NCT03868969 868 875 I-Condition
( NCT03868969 876 877 O
clearance NCT03868969 878 887 B-Observation
< NCT03868969 888 889 B-Eq-Comparison
60 NCT03868969 890 892 I-Eq-Comparison
mL NCT03868969 893 895 I-Eq-Comparison
/ NCT03868969 896 897 I-Eq-Comparison
min NCT03868969 898 901 I-Eq-Comparison
) NCT03868969 902 903 O

- NCT03868969 907 908 O
Prior NCT03868969 910 915 B-Eq-Comparison
antibiotic NCT03868969 916 926 B-Procedure
therapy NCT03868969 927 934 I-Procedure
, NCT03868969 935 936 O
with NCT03868969 937 941 B-And
an NCT03868969 942 944 O
antibiotic NCT03868969 945 955 B-Drug
sensitive NCT03868969 956 965 B-Condition
on NCT03868969 966 968 O
the NCT03868969 969 972 O
antibiotic NCT03868969 973 983 B-Observation
susceptibility NCT03868969 984 998 I-Observation
test NCT03868969 999 1003 I-Observation
except NCT03868969 1004 1010 B-Exception
: NCT03868969 1011 1012 O
amoxicillin NCT03868969 1013 1024 B-Drug
- NCT03868969 1025 1026 B-Or
clavulanic NCT03868969 1027 1037 B-Drug
acid NCT03868969 1038 1042 I-Drug
, NCT03868969 1043 1044 O
cefixime NCT03868969 1045 1053 B-Drug
, NCT03868969 1054 1055 O
nitrofurantoin NCT03868969 1056 1070 B-Drug
. NCT03868969 1071 1072 O

- NCT03868969 1076 1077 O
Co NCT03868969 1079 1081 O
- NCT03868969 1082 1083 O
treatment NCT03868969 1084 1093 B-Procedure
with NCT03868969 1094 1098 O
metoclopramide NCT03868969 1099 1113 B-Drug

Inclusion NCT03864835 0 9 O
Criteria NCT03864835 10 18 O

•Enrollment NCT03864835 19 30 O
and NCT03864835 31 34 O
completion NCT03864835 35 45 O
of NCT03864835 46 48 O
IRB NCT03864835 49 52 O
study NCT03864835 53 58 O
# NCT03864835 59 60 O
00011797 NCT03864835 61 69 O

Exclusion NCT03864835 71 80 O
Criteria NCT03864835 81 89 O

- NCT03864835 92 93 O
Inability NCT03864835 95 104 O
to NCT03864835 105 107 O
provide NCT03864835 108 115 O
informed NCT03864835 116 124 O
consent NCT03864835 125 132 O

- NCT03864835 135 136 O
Institutionalized NCT03864835 138 155 B-Observation
/ NCT03864835 156 157 B-Or
prisoner NCT03864835 158 166 B-Observation

- NCT03864835 169 170 O
Non NCT03864835 172 175 B-Negation
- NCT03864835 176 177 O
English NCT03864835 178 185 O
- NCT03864835 186 187 O
speaking NCT03864835 188 196 O
patients NCT03864835 197 205 O
due NCT03864835 206 209 O
to NCT03864835 210 212 O
unavailability NCT03864835 213 227 O
of NCT03864835 228 230 O
translators NCT03864835 231 242 O
for NCT03864835 243 246 O
all NCT03864835 247 250 O
visits NCT03864835 251 257 O
/ NCT03864835 258 259 O
sessions NCT03864835 260 268 O

Inclusion NCT03866005 0 9 O
Criteria NCT03866005 10 18 O
: NCT03866005 19 20 O

- NCT03866005 24 25 O
Diagnosed NCT03866005 27 36 O
diabetes NCT03866005 37 45 B-Condition
mellitus NCT03866005 46 54 I-Condition
and NCT03866005 55 58 B-And
treatment NCT03866005 59 68 B-Procedure
- NCT03866005 69 70 O
naïve NCT03866005 71 76 B-Negation
CI NCT03866005 77 79 B-Condition
- NCT03866005 80 81 I-Condition
DME NCT03866005 82 85 I-Condition
requiring NCT03866005 86 95 B-Assertion___Assertion-Type-Value:hypothetical
anti NCT03866005 96 100 O
- NCT03866005 101 102 O
VEGF NCT03866005 103 107 B-Condition
therapy NCT03866005 108 115 B-Procedure
per NCT03866005 116 119 O
retinal NCT03866005 120 127 B-Provider
specialist NCT03866005 128 138 I-Provider
's NCT03866005 138 140 O
customary NCT03866005 141 150 O
treatment NCT03866005 151 160 B-Procedure
regimen NCT03866005 161 168 O
will NCT03866005 169 173 O
be NCT03866005 174 176 O
recruited NCT03866005 177 186 O
to NCT03866005 187 189 O
participate NCT03866005 190 201 O
in NCT03866005 202 204 O
the NCT03866005 205 208 O
study NCT03866005 209 214 B-Study
. NCT03866005 214 215 O
CI NCT03866005 217 219 B-Condition
- NCT03866005 220 221 I-Condition
DME NCT03866005 222 225 I-Condition
will NCT03866005 226 230 O
be NCT03866005 231 233 O
defined NCT03866005 234 241 O
as NCT03866005 242 244 O
a NCT03866005 245 246 O
central NCT03866005 247 254 B-Observation
subfield NCT03866005 255 263 I-Observation
thickness NCT03866005 264 273 I-Observation
( NCT03866005 274 275 O
CST NCT03866005 276 279 B-Observation
) NCT03866005 280 281 O
> NCT03866005 282 283 B-Eq-Comparison
300 NCT03866005 284 287 I-Eq-Comparison
microns NCT03866005 288 295 I-Eq-Comparison
on NCT03866005 296 298 O
spectral NCT03866005 299 307 B-Modifier
domain NCT03866005 308 314 I-Modifier
optical NCT03866005 315 322 B-Procedure
coherence NCT03866005 323 332 I-Procedure
tomography NCT03866005 333 343 I-Procedure
( NCT03866005 344 345 O
SD NCT03866005 346 348 B-Procedure
- NCT03866005 349 350 I-Procedure
OCT NCT03866005 351 354 I-Procedure
) NCT03866005 355 356 O
or NCT03866005 357 359 B-Or
CST NCT03866005 360 363 B-Observation
> NCT03866005 364 365 B-Eq-Comparison
250 NCT03866005 366 369 I-Eq-Comparison
microns NCT03866005 370 377 I-Eq-Comparison
with NCT03866005 378 382 B-And
definite NCT03866005 383 391 O
intra NCT03866005 392 397 B-Modifier
- NCT03866005 398 399 I-Modifier
retinal NCT03866005 400 407 I-Modifier
cystic NCT03866005 408 414 B-Condition
fluid NCT03866005 415 420 I-Condition
accumulation NCT03866005 421 433 I-Condition
. NCT03866005 433 434 O
Additional NCT03866005 436 446 O
inclusion NCT03866005 447 456 O
criteria NCT03866005 457 465 O
are NCT03866005 466 469 O
age NCT03866005 470 473 B-Age
> NCT03866005 474 475 B-Eq-Comparison
18 NCT03866005 476 478 I-Eq-Comparison
years NCT03866005 479 484 I-Eq-Comparison
, NCT03866005 485 486 O
and NCT03866005 487 490 O
ability NCT03866005 491 498 O
to NCT03866005 499 501 O
give NCT03866005 502 506 O
informed NCT03866005 507 515 O
consent NCT03866005 516 523 O
. NCT03866005 524 525 O

Exclusion NCT03866005 527 536 O
Criteria NCT03866005 537 545 O
: NCT03866005 546 547 O

- NCT03866005 551 552 O
Age NCT03866005 554 557 B-Age
< NCT03866005 558 559 B-Eq-Comparison
18 NCT03866005 560 562 I-Eq-Comparison
years NCT03866005 563 568 I-Eq-Comparison
, NCT03866005 569 570 O
inability NCT03866005 571 580 O
to NCT03866005 581 583 O
give NCT03866005 584 588 O
informed NCT03866005 589 597 O
consent NCT03866005 598 605 O
, NCT03866005 606 607 O
evidence NCT03866005 608 616 O
of NCT03866005 617 619 O
proliferative NCT03866005 620 633 B-Condition
diabetic NCT03866005 634 642 I-Condition
retinopathy NCT03866005 643 654 I-Condition
, NCT03866005 655 656 O
evidence NCT03866005 657 665 O
of NCT03866005 666 668 O
other NCT03866005 669 674 B-Other
serious NCT03866005 675 682 O
ocular NCT03866005 683 689 B-Condition
disease NCT03866005 690 697 I-Condition
( NCT03866005 698 699 O
age NCT03866005 700 703 B-Modifier
- NCT03866005 704 705 I-Modifier
related NCT03866005 706 713 I-Modifier
macular NCT03866005 714 721 B-Condition
degeneration NCT03866005 722 734 I-Condition
, NCT03866005 735 736 O
glaucoma NCT03866005 737 745 B-Condition
, NCT03866005 746 747 O
significant NCT03866005 748 759 O
media NCT03866005 760 765 B-Condition
opacity NCT03866005 766 773 I-Condition
) NCT03866005 774 775 O
, NCT03866005 777 778 O
history NCT03866005 779 786 B-Eq-Comparison
of NCT03866005 787 789 I-Eq-Comparison
previous NCT03866005 790 798 I-Eq-Comparison
intraocular NCT03866005 799 810 B-Procedure
surgery NCT03866005 811 818 I-Procedure
, NCT03866005 819 820 O
including NCT03866005 821 830 O
macular NCT03866005 831 838 B-Modifier
or NCT03866005 839 841 B-Or
panretinal NCT03866005 842 852 B-Modifier
photocoagulation NCT03866005 853 869 B-Procedure
( NCT03866005 870 871 O
except NCT03866005 872 878 B-Exception
uncomplicated NCT03866005 879 892 B-Modifier
cataract NCT03866005 893 901 I-Modifier
or NCT03866005 902 904 B-Or
keratorefractive NCT03866005 905 921 B-Modifier
surgery NCT03866005 922 929 B-Procedure
more NCT03866005 930 934 B-Eq-Comparison
than NCT03866005 935 939 I-Eq-Comparison
6 NCT03866005 940 941 I-Eq-Comparison
months NCT03866005 942 948 I-Eq-Comparison
prior NCT03866005 949 954 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866005 955 957 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866005 958 968 B-Study
) NCT03866005 969 970 O
, NCT03866005 972 973 O
pregnant NCT03866005 974 982 B-Condition
and NCT03866005 983 986 B-Or
nursing NCT03866005 987 994 B-Condition
women NCT03866005 995 1000 O
, NCT03866005 1001 1002 O
known NCT03866005 1003 1008 O
sensitivity NCT03866005 1009 1020 B-Condition
to NCT03866005 1021 1023 O
any NCT03866005 1024 1027 O
of NCT03866005 1028 1030 O
the NCT03866005 1031 1034 O
supplement NCT03866005 1035 1045 B-Drug
ingredients NCT03866005 1046 1057 I-Drug
. NCT03866005 1057 1058 O

Inclusion NCT03868982 0 9 O
Criteria NCT03868982 10 18 O
: NCT03868982 19 20 O

- NCT03868982 24 25 O
Diagnosis NCT03868982 27 36 O
of NCT03868982 37 39 O
ARDS NCT03868982 40 44 B-Condition
by NCT03868982 45 47 O
Berlin NCT03868982 48 54 O
definition NCT03868982 55 65 O

- NCT03868982 68 69 O
P NCT03868982 71 72 B-Observation
/ NCT03868982 73 74 I-Observation
F NCT03868982 75 76 I-Observation
ratio NCT03868982 77 82 I-Observation
between NCT03868982 83 90 B-Eq-Comparison
100 NCT03868982 91 94 I-Eq-Comparison
- NCT03868982 95 96 I-Eq-Comparison
300 NCT03868982 97 100 I-Eq-Comparison

- NCT03868982 104 105 O
Completed NCT03868982 107 116 O
the NCT03868982 117 120 O
case NCT03868982 121 125 O
enrollement NCT03868982 126 137 B-Study
within NCT03868982 138 144 B-Eq-Comparison
48 NCT03868982 145 147 I-Eq-Comparison
hours NCT03868982 148 153 I-Eq-Comparison

Exclusion NCT03868982 154 163 O
Criteria NCT03868982 164 172 O
: NCT03868982 173 174 O

- NCT03868982 178 179 O
Less NCT03868982 181 185 B-Eq-Comparison
than NCT03868982 186 190 I-Eq-Comparison
18 NCT03868982 191 193 I-Eq-Comparison
years NCT03868982 194 199 I-Eq-Comparison
old NCT03868982 200 203 B-Age

- NCT03868982 206 207 O
Pregnancy NCT03868982 209 218 B-Condition

- NCT03868982 221 222 O
Participants NCT03868982 224 236 O
with NCT03868982 237 241 O
tracheostomy NCT03868982 242 254 B-Procedure

- NCT03868982 257 258 O
Unable NCT03868982 260 266 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868982 267 269 O
insert NCT03868982 270 276 O
the NCT03868982 277 280 O
NG NCT03868982 281 283 B-Procedure
- NCT03868982 284 285 I-Procedure
tube NCT03868982 286 290 I-Procedure

Inclusion NCT03865524 0 9 O
Criteria NCT03865524 10 18 O
: NCT03865524 19 20 O

- NCT03865524 24 25 O
Men NCT03865524 27 30 O
and NCT03865524 31 34 B-Or
women NCT03865524 35 40 O
over NCT03865524 41 45 B-Eq-Comparison
18 NCT03865524 46 48 I-Eq-Comparison
years NCT03865524 49 54 I-Eq-Comparison
old NCT03865524 55 58 B-Age
. NCT03865524 59 60 O

- NCT03865524 64 65 O
Written NCT03865524 67 74 O
informed NCT03865524 75 83 O
consent NCT03865524 84 91 O
according NCT03865524 92 101 O
to NCT03865524 102 104 O
ICH NCT03865524 105 108 O
/ NCT03865524 109 110 O
GCP NCT03865524 111 114 O
and NCT03865524 115 118 O
Spanish NCT03865524 119 126 O
legislation NCT03865524 127 138 O
, NCT03865524 139 140 O
obtained NCT03865524 141 149 O
before NCT03865524 150 156 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03865524 157 160 O
study NCT03865524 161 166 B-Study
procedure NCT03865524 167 176 O
. NCT03865524 177 178 O

- NCT03865524 182 183 O
Patient NCT03865524 185 192 O
with NCT03865524 193 197 O
a NCT03865524 198 199 O
BMI NCT03865524 200 203 B-Observation
equal NCT03865524 204 209 B-Eq-Comparison
to NCT03865524 210 212 I-Eq-Comparison
or NCT03865524 213 215 I-Eq-Comparison
greater NCT03865524 216 223 I-Eq-Comparison
than NCT03865524 224 228 I-Eq-Comparison
30 NCT03865524 229 231 I-Eq-Comparison
Kg NCT03865524 232 234 I-Eq-Comparison
/ NCT03865524 235 236 I-Eq-Comparison
m2 NCT03865524 237 239 I-Eq-Comparison

- NCT03865524 242 243 O
Patients NCT03865524 245 253 O
with NCT03865524 254 258 O
clinical NCT03865524 259 267 B-Modifier
and NCT03865524 268 271 B-Or
radiological NCT03865524 272 284 B-Procedure
criteria NCT03865524 285 293 O
of NCT03865524 294 296 O
knee NCT03865524 297 301 B-Modifier
osteoarthritis NCT03865524 302 316 B-Condition
. NCT03865524 317 318 O

- NCT03865524 322 323 O
Patients NCT03865524 325 333 O
with NCT03865524 334 338 O
indication NCT03865524 339 349 B-Indication
for NCT03865524 350 353 O
primary NCT03865524 354 361 B-Modifier
TKA NCT03865524 362 365 B-Condition
according NCT03865524 366 375 O
to NCT03865524 376 378 O
medical NCT03865524 379 386 O
criteria NCT03865524 387 395 O
. NCT03865524 396 397 O

Exclusion NCT03865524 399 408 O
Criteria NCT03865524 409 417 O
: NCT03865524 418 419 O

- NCT03865524 423 424 O
Pregnancy NCT03865524 426 435 B-Condition
or NCT03865524 436 438 B-Or
lactation NCT03865524 439 448 B-Condition
. NCT03865524 449 450 O

- NCT03865524 454 455 O
Inability NCT03865524 457 466 O
to NCT03865524 467 469 O
give NCT03865524 470 474 O
informed NCT03865524 475 483 O
consent NCT03865524 484 491 O
in NCT03865524 492 494 O
the NCT03865524 495 498 O
absence NCT03865524 499 506 O
of NCT03865524 507 509 O
a NCT03865524 510 511 O
legal NCT03865524 512 517 O
representative NCT03865524 518 532 O
. NCT03865524 533 534 O

- NCT03865524 538 539 O
Subjects NCT03865524 541 549 O
that NCT03865524 550 554 O
are NCT03865524 555 558 O
participating NCT03865524 559 572 B-Eq-Comparison
in NCT03865524 573 575 O
a NCT03865524 576 577 O
study NCT03865524 578 583 B-Study
with NCT03865524 584 588 O
medicines NCT03865524 589 598 B-Drug
or NCT03865524 599 601 B-Or
other NCT03865524 602 607 B-Other
medical NCT03865524 608 615 B-Procedure
devices NCT03865524 616 623 I-Procedure
. NCT03865524 624 625 O

- NCT03865524 629 630 O
Those NCT03865524 632 637 O
who NCT03865524 638 641 O
show NCT03865524 642 646 O
inability NCT03865524 647 656 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865524 657 659 O
follow NCT03865524 660 666 O
the NCT03865524 667 670 O
instructions NCT03865524 671 683 O
or NCT03865524 684 686 O
collaborate NCT03865524 687 698 O
during NCT03865524 699 705 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865524 706 709 O
development NCT03865524 710 721 O
of NCT03865524 722 724 O
the NCT03865524 725 728 O
study NCT03865524 729 734 B-Study
. NCT03865524 735 736 O

- NCT03865524 740 741 O
If NCT03865524 743 745 O
in NCT03865524 746 748 O
the NCT03865524 749 752 O
opinion NCT03865524 753 760 O
of NCT03865524 761 763 O
the NCT03865524 764 767 O
researcher NCT03865524 768 778 O
there NCT03865524 779 784 O
are NCT03865524 785 788 O
findings NCT03865524 789 797 O
in NCT03865524 798 800 O
the NCT03865524 801 804 O
physical NCT03865524 805 813 B-Procedure
examination NCT03865524 814 825 I-Procedure
, NCT03865524 826 827 O
abnormalities NCT03865524 828 841 B-Condition
in NCT03865524 842 844 O
the NCT03865524 845 848 O
results NCT03865524 849 856 O
of NCT03865524 857 859 O
the NCT03865524 860 863 O
clinical NCT03865524 864 872 O
analyzes NCT03865524 873 881 O
or NCT03865524 882 884 B-Or
other NCT03865524 885 890 O
medical NCT03865524 891 898 O
, NCT03865524 899 900 O
social NCT03865524 901 907 B-Modifier
or NCT03865524 908 910 B-Or
psychosocial NCT03865524 911 923 B-Modifier
factors NCT03865524 924 931 B-Condition
that NCT03865524 932 936 O
could NCT03865524 937 942 B-Assertion___Assertion-Type-Value:hypothetical
have NCT03865524 943 947 O
a NCT03865524 948 949 O
negative NCT03865524 950 958 O
influence NCT03865524 959 968 O

- NCT03865524 971 972 O
Having NCT03865524 974 980 O
had NCT03865524 981 984 O
a NCT03865524 985 986 O
previous NCT03865524 987 995 B-Eq-Comparison
surgical NCT03865524 996 1004 B-Procedure
procedure NCT03865524 1005 1014 I-Procedure
on NCT03865524 1015 1017 B-Modifier
or NCT03865524 1018 1020 B-Or
around NCT03865524 1021 1027 B-Modifier
the NCT03865524 1028 1031 I-Modifier
knee NCT03865524 1032 1036 I-Modifier
in NCT03865524 1037 1039 O
the NCT03865524 1040 1043 O
last NCT03865524 1044 1048 B-Eq-Comparison
12 NCT03865524 1049 1051 I-Eq-Comparison
months NCT03865524 1052 1058 I-Eq-Comparison
( NCT03865524 1059 1060 O
such NCT03865524 1061 1065 O
as NCT03865524 1066 1068 O
proximal NCT03865524 1069 1077 B-Procedure
tibial NCT03865524 1078 1084 I-Procedure
osteotomy NCT03865524 1085 1094 I-Procedure
, NCT03865524 1095 1096 O
femoral NCT03865524 1097 1104 B-Procedure
osteotomy NCT03865524 1105 1114 I-Procedure
, NCT03865524 1115 1116 O
open NCT03865524 1117 1121 B-Procedure
reduction NCT03865524 1122 1131 I-Procedure
and NCT03865524 1132 1135 B-Or
internal NCT03865524 1136 1144 B-Procedure
fixation NCT03865524 1145 1153 I-Procedure
for NCT03865524 1154 1157 O
a NCT03865524 1158 1159 O
fracture NCT03865524 1160 1168 B-Condition
, NCT03865524 1169 1170 O
patellectomy NCT03865524 1171 1183 B-Procedure
or NCT03865524 1184 1186 B-Or
patellar NCT03865524 1187 1195 B-Procedure
realignment NCT03865524 1196 1207 I-Procedure
) NCT03865524 1208 1209 O
. NCT03865524 1211 1212 O

- NCT03865524 1216 1217 O
Need NCT03865524 1219 1223 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03865524 1224 1225 O
simultaneous NCT03865524 1226 1238 B-Modifier
bilateral NCT03865524 1239 1248 I-Modifier
TKA NCT03865524 1249 1252 B-Procedure
. NCT03865524 1253 1254 O

- NCT03865524 1258 1259 O
Have NCT03865524 1261 1265 O
a NCT03865524 1266 1267 O
varus NCT03865524 1268 1273 B-Observation
angle NCT03865524 1274 1279 I-Observation
or NCT03865524 1280 1282 B-Or
valgus NCT03865524 1283 1289 B-Observation
≥ NCT03865524 1290 1291 B-Eq-Comparison
15 NCT03865524 1292 1294 I-Eq-Comparison
° NCT03865524 1295 1296 I-Eq-Comparison
. NCT03865524 1297 1298 O

- NCT03865524 1302 1303 O
Total NCT03865524 1305 1310 B-Procedure
revision NCT03865524 1311 1319 I-Procedure
knee NCT03865524 1320 1324 I-Procedure
arthroplasty NCT03865524 1325 1337 I-Procedure
. NCT03865524 1337 1338 O

Inclusion NCT03867864 0 9 O
Criteria NCT03867864 10 18 O
: NCT03867864 19 20 O

- NCT03867864 24 25 O
Registered NCT03867864 27 37 O
nurses NCT03867864 38 44 B-Provider
, NCT03867864 45 46 O
working NCT03867864 47 54 O
in NCT03867864 55 57 O
intensive NCT03867864 58 67 O
care NCT03867864 68 72 O
units NCT03867864 73 78 O
( NCT03867864 79 80 O
ICU NCT03867864 81 84 O
) NCT03867864 85 86 O
or NCT03867864 87 89 B-Or
department NCT03867864 90 100 O
of NCT03867864 101 103 O
emergency NCT03867864 104 113 O
( NCT03867864 114 115 O
ED NCT03867864 116 118 O
) NCT03867864 119 120 O
. NCT03867864 122 123 O

- NCT03867864 127 128 O
The NCT03867864 130 133 O
frequency NCT03867864 134 143 O
of NCT03867864 144 146 O
headaches NCT03867864 147 156 B-Condition
more NCT03867864 157 161 B-Eq-Comparison
than NCT03867864 162 166 I-Eq-Comparison
three NCT03867864 167 172 I-Eq-Comparison
times NCT03867864 173 178 I-Eq-Comparison
per NCT03867864 179 182 I-Eq-Comparison
month NCT03867864 183 188 I-Eq-Comparison
. NCT03867864 189 190 O

- NCT03867864 194 195 O
The NCT03867864 197 200 O
type NCT03867864 201 205 O
of NCT03867864 206 208 O
headache NCT03867864 209 217 B-Condition
is NCT03867864 218 220 O
migraine NCT03867864 221 229 B-Condition
or NCT03867864 230 232 B-Or
frequent NCT03867864 233 241 B-Modifier
episodic NCT03867864 242 250 I-Modifier
tension NCT03867864 251 258 I-Modifier
- NCT03867864 259 260 I-Modifier
type NCT03867864 261 265 I-Modifier
headache NCT03867864 266 274 B-Condition
, NCT03867864 275 276 O
which NCT03867864 277 282 O
is NCT03867864 283 285 O
defined NCT03867864 286 293 O
by NCT03867864 294 296 O
the NCT03867864 297 300 O
Headache NCT03867864 301 309 O
Classification NCT03867864 310 324 O
Committee NCT03867864 325 334 O
of NCT03867864 335 337 O
the NCT03867864 338 341 O
International NCT03867864 342 355 O
Headache NCT03867864 356 364 O
Society NCT03867864 365 372 O
. NCT03867864 372 373 O
If NCT03867864 375 377 O
the NCT03867864 378 381 O
symptoms NCT03867864 382 390 B-Assertion___Assertion-Type-Value:possible
of NCT03867864 391 393 O
a NCT03867864 394 395 O
headache NCT03867864 396 404 B-Condition
can NCT03867864 405 408 O
not NCT03867864 408 411 O
be NCT03867864 412 414 O
defined NCT03867864 415 422 O
, NCT03867864 423 424 O
the NCT03867864 425 428 O
investigator NCT03867864 429 441 O
will NCT03867864 442 446 B-Assertion___Assertion-Type-Value:hypothetical
refer NCT03867864 447 452 B-Encounter
the NCT03867864 453 456 O
potential NCT03867864 457 466 O
participant NCT03867864 467 478 O
to NCT03867864 479 481 O
a NCT03867864 482 483 O
neurologist NCT03867864 484 495 B-Provider
for NCT03867864 496 499 O
further NCT03867864 500 507 O
diagnosis NCT03867864 508 517 O
. NCT03867864 518 519 O

Exclusion NCT03867864 521 530 O
Criteria NCT03867864 531 539 O
: NCT03867864 540 541 O

- NCT03867864 545 546 O
Current NCT03867864 548 555 B-Eq-Comparison
user NCT03867864 556 560 O
of NCT03867864 561 563 O
other NCT03867864 564 569 B-Other
kinds NCT03867864 570 575 O
of NCT03867864 576 578 O
essential NCT03867864 579 588 B-Drug
oils NCT03867864 589 593 I-Drug
( NCT03867864 594 595 O
e. NCT03867864 596 598 O
g. NCT03867864 599 601 O
, NCT03867864 602 603 O
the NCT03867864 604 607 O
external NCT03867864 608 616 B-Modifier
application NCT03867864 617 628 I-Modifier
on NCT03867864 629 631 I-Modifier
skin NCT03867864 632 636 I-Modifier
, NCT03867864 637 638 O
sniffing NCT03867864 639 647 B-Modifier
) NCT03867864 648 649 O
, NCT03867864 651 652 O
and NCT03867864 653 656 B-And
do NCT03867864 657 659 O
not NCT03867864 660 663 B-Negation
willing NCT03867864 664 671 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867864 672 674 I-Assertion___Assertion-Type-Value:hypothetical
temporarily NCT03867864 675 686 O
suspend NCT03867864 687 694 B-Negation
for NCT03867864 695 698 O
nine NCT03867864 699 703 B-Eq-Comparison
weeks NCT03867864 704 709 I-Eq-Comparison
. NCT03867864 710 711 O

- NCT03867864 715 716 O
Having NCT03867864 718 724 O
sensitive NCT03867864 725 734 B-Condition
responses NCT03867864 735 744 I-Condition
to NCT03867864 745 747 O
the NCT03867864 748 751 O
essential NCT03867864 752 761 B-Drug
oil NCT03867864 762 765 I-Drug
. NCT03867864 766 767 O

- NCT03867864 771 772 O
Pregnancy NCT03867864 774 783 B-Condition
or NCT03867864 784 786 B-Or
preparing NCT03867864 787 796 B-Assertion___Assertion-Type-Value:intention
for NCT03867864 797 800 O
pregnancy NCT03867864 801 810 B-Condition
. NCT03867864 811 812 O

- NCT03867864 816 817 O
Breastfeeding NCT03867864 819 832 B-Condition
. NCT03867864 833 834 O

- NCT03867864 838 839 O
The NCT03867864 841 844 O
type NCT03867864 845 849 O
of NCT03867864 850 852 O
headache NCT03867864 853 861 B-Condition
was NCT03867864 862 865 O
neither NCT03867864 866 873 B-Negation
migraine NCT03867864 874 882 B-Condition
nor NCT03867864 883 886 B-Negation
frequent NCT03867864 887 895 B-Modifier
episodic NCT03867864 896 904 I-Modifier
tension NCT03867864 905 912 I-Modifier
- NCT03867864 913 914 I-Modifier
type NCT03867864 915 919 I-Modifier
headache NCT03867864 920 928 B-Condition
after NCT03867864 929 934 B-Temporal-Connection___Temporal-Connection-Type-Value:after
diagnosed NCT03867864 935 944 B-Coreference
by NCT03867864 945 947 O
the NCT03867864 948 951 O
neurologist NCT03867864 952 963 B-Provider
. NCT03867864 964 965 O

- NCT03867864 969 970 O
With NCT03867864 972 976 O
hepatic NCT03867864 977 984 B-Modifier
or NCT03867864 985 987 B-Or
renal NCT03867864 988 993 B-Modifier
diseases NCT03867864 994 1002 B-Condition
. NCT03867864 1003 1004 O

- NCT03867864 1008 1009 O
taking NCT03867864 1011 1017 B-Eq-Comparison
medicine NCT03867864 1018 1026 B-Drug
for NCT03867864 1027 1030 O
long NCT03867864 1031 1035 B-Modifier
- NCT03867864 1036 1037 I-Modifier
term NCT03867864 1038 1042 I-Modifier
( NCT03867864 1043 1044 O
such NCT03867864 1045 1049 O
as NCT03867864 1050 1052 O
Aspirin NCT03867864 1053 1060 B-Drug
, NCT03867864 1061 1062 O
anti NCT03867864 1063 1067 B-Drug
- NCT03867864 1068 1069 I-Drug
coagulant NCT03867864 1070 1079 I-Drug
, NCT03867864 1080 1081 O
medication NCT03867864 1082 1092 B-Drug
for NCT03867864 1093 1096 O
mental NCT03867864 1097 1103 B-Condition
disorders NCT03867864 1104 1113 I-Condition
, NCT03867864 1114 1115 O
contraceptives NCT03867864 1116 1130 B-Drug
, NCT03867864 1131 1132 O
etc NCT03867864 1133 1136 O
. NCT03867864 1136 1137 O
) NCT03867864 1138 1139 O
. NCT03867864 1140 1141 O

Inclusion NCT03865901 0 9 O
Criteria NCT03865901 10 18 O
: NCT03865901 19 20 O

1 NCT03865901 24 25 O
. NCT03865901 25 26 O
Women NCT03865901 28 33 O
18 NCT03865901 34 36 B-Eq-Comparison
years NCT03865901 37 42 I-Eq-Comparison
of NCT03865901 43 45 I-Eq-Comparison
age NCT03865901 46 49 I-Age|Eq-Comparison
or NCT03865901 50 52 I-Eq-Comparison
older NCT03865901 53 58 I-Eq-Comparison
at NCT03865901 59 61 B-Temporal-Connection___Temporal-Connection-Type-Value:during
enrollment NCT03865901 62 72 B-Study

2 NCT03865901 75 76 O
. NCT03865901 76 77 O
Has NCT03865901 79 82 O
an NCT03865901 83 85 O
established NCT03865901 86 97 O
viable NCT03865901 98 104 B-Modifier
singleton NCT03865901 105 114 I-Modifier
pregnancy NCT03865901 115 124 B-Condition

3 NCT03865901 127 128 O
. NCT03865901 128 129 O
Is NCT03865901 131 133 O
recommended NCT03865901 134 145 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865901 146 149 I-Assertion___Assertion-Type-Value:hypothetical
routine NCT03865901 150 157 O
GDM NCT03865901 158 161 B-Procedure
screening NCT03865901 162 171 I-Procedure
between NCT03865901 172 179 B-Eq-Comparison
24 NCT03865901 180 182 I-Eq-Comparison
- NCT03865901 183 184 I-Eq-Comparison
28 NCT03865901 185 187 I-Eq-Comparison
weeks NCT03865901 188 193 I-Eq-Comparison
gestation NCT03865901 194 203 B-Observation

4 NCT03865901 206 207 O
. NCT03865901 207 208 O
Has NCT03865901 210 213 O
confirmed NCT03865901 214 223 O
gestational NCT03865901 224 235 B-Observation
age NCT03865901 236 239 I-Observation
of NCT03865901 240 242 O
24 NCT03865901 243 245 B-Eq-Comparison
- NCT03865901 246 247 I-Eq-Comparison
28 NCT03865901 248 250 I-Eq-Comparison
weeks NCT03865901 251 256 I-Eq-Comparison
at NCT03865901 257 259 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865901 260 263 O
Screening NCT03865901 264 273 B-Study
Visit NCT03865901 274 279 O

5 NCT03865901 282 283 O
. NCT03865901 283 284 O
Is NCT03865901 286 288 O
willing NCT03865901 289 296 O
and NCT03865901 297 300 O
able NCT03865901 301 305 O
to NCT03865901 306 308 O
provide NCT03865901 309 316 O
documentation NCT03865901 317 330 O
of NCT03865901 331 333 O
informed NCT03865901 334 342 O
consent NCT03865901 343 350 O

Exclusion NCT03865901 351 360 O
Criteria NCT03865901 361 369 O
: NCT03865901 370 371 O

1 NCT03865901 375 376 O
. NCT03865901 376 377 O
Has NCT03865901 379 382 O
diabetes NCT03865901 383 391 B-Condition
before NCT03865901 392 398 B-Temporal-Connection___Temporal-Connection-Type-Value:before
pregnancy NCT03865901 399 408 B-Condition
or NCT03865901 409 411 B-Or
has NCT03865901 412 415 O
already NCT03865901 416 423 B-Eq-Comparison
been NCT03865901 424 428 O
diagnosed NCT03865901 429 438 O
with NCT03865901 439 443 O
GDM NCT03865901 444 447 B-Condition

2 NCT03865901 450 451 O
. NCT03865901 451 452 O
Has NCT03865901 454 457 O
contraindications NCT03865901 458 475 B-Contraindication
for NCT03865901 476 479 O
drinking NCT03865901 480 488 B-Modifier
oral NCT03865901 489 493 I-Modifier
glucose NCT03865901 494 501 B-Drug
solution NCT03865901 502 510 O
up NCT03865901 511 513 B-Eq-Comparison
to NCT03865901 514 516 I-Eq-Comparison
100 NCT03865901 517 520 I-Eq-Comparison
g NCT03865901 521 522 I-Eq-Comparison
of NCT03865901 523 525 I-Eq-Comparison
sugar NCT03865901 526 531 I-Eq-Comparison

3 NCT03865901 534 535 B-Eq-Comparison
. NCT03865901 535 536 O
Is NCT03865901 538 540 O
taking NCT03865901 541 547 B-Eq-Comparison
metformin NCT03865901 548 557 B-Drug
for NCT03865901 558 561 O
any NCT03865901 562 565 O
reason NCT03865901 566 572 O

4 NCT03865901 575 576 O
. NCT03865901 576 577 O
Has NCT03865901 579 582 O
any NCT03865901 583 586 O
concomitant NCT03865901 587 598 B-Modifier
illness NCT03865901 599 606 B-Condition
, NCT03865901 607 608 O
disease NCT03865901 609 616 B-Condition
or NCT03865901 617 619 B-Or
condition NCT03865901 620 629 B-Condition
that NCT03865901 630 634 O
, NCT03865901 635 636 O
in NCT03865901 637 639 O
the NCT03865901 640 643 O
clinical NCT03865901 644 652 O
judgment NCT03865901 653 661 O
of NCT03865901 662 664 O
the NCT03865901 665 668 O
investigator NCT03865901 669 681 O
, NCT03865901 682 683 O
is NCT03865901 684 686 O
likely NCT03865901 687 693 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865901 694 696 O
prevent NCT03865901 697 704 O
the NCT03865901 705 708 O
subject NCT03865901 709 716 O
from NCT03865901 717 721 O
complying NCT03865901 722 731 O
with NCT03865901 732 736 O
any NCT03865901 737 740 O
aspect NCT03865901 741 747 O
of NCT03865901 748 750 O
the NCT03865901 751 754 O
protocol NCT03865901 755 763 B-Study
, NCT03865901 764 765 O
or NCT03865901 766 768 B-Or
that NCT03865901 769 773 O
may NCT03865901 774 777 O
put NCT03865901 778 781 O
the NCT03865901 782 785 O
subject NCT03865901 786 793 O
at NCT03865901 794 796 O
unacceptable NCT03865901 797 809 O
risk NCT03865901 810 814 B-Risk

Inclusion NCT03860662 0 9 O
Criteria NCT03860662 10 18 O
: NCT03860662 19 20 O

- NCT03860662 24 25 O
Being NCT03860662 27 32 O
between NCT03860662 33 40 B-Eq-Comparison
the NCT03860662 41 44 I-Eq-Comparison
ages NCT03860662 45 49 I-Age|Eq-Comparison
of NCT03860662 50 52 I-Eq-Comparison
18 NCT03860662 53 55 I-Eq-Comparison
- NCT03860662 56 57 I-Eq-Comparison
60 NCT03860662 58 60 O

- NCT03860662 64 65 O
To NCT03860662 67 69 O
accept NCT03860662 70 76 O
voluntary NCT03860662 77 86 O
participation NCT03860662 87 100 O
in NCT03860662 101 103 O
the NCT03860662 104 107 O
study NCT03860662 108 113 O

- NCT03860662 116 117 O
Spastic NCT03860662 119 126 B-Condition
Hemiplegia NCT03860662 127 137 I-Condition
( NCT03860662 138 139 O
Modified NCT03860662 140 148 B-Observation
Ashworth NCT03860662 149 157 I-Observation
Scale NCT03860662 158 163 I-Observation
2 NCT03860662 164 165 B-Eq-Comparison
and NCT03860662 166 169 I-Eq-Comparison
above NCT03860662 170 175 I-Eq-Comparison
) NCT03860662 176 177 O

Exclusion NCT03860662 179 188 O
Criteria NCT03860662 189 197 O
: NCT03860662 198 199 O

- NCT03860662 203 204 O
Pregnant NCT03860662 206 214 B-Condition
women NCT03860662 215 220 O
, NCT03860662 221 222 O
breastfeeding NCT03860662 223 236 B-Condition
and NCT03860662 237 240 B-And
younger NCT03860662 241 248 B-Eq-Comparison
than NCT03860662 249 253 I-Eq-Comparison
18 NCT03860662 254 256 I-Eq-Comparison
years NCT03860662 257 262 I-Age|Eq-Comparison

- NCT03860662 265 266 O
To NCT03860662 268 270 O
have NCT03860662 271 275 O
medication NCT03860662 276 286 B-Drug
and NCT03860662 287 290 B-Or
substance NCT03860662 291 300 B-Condition
use NCT03860662 301 304 I-Condition
causing NCT03860662 305 312 O
neuropathy NCT03860662 313 323 B-Condition
in NCT03860662 324 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860662 327 330 O
history NCT03860662 331 338 B-Eq-Comparison
of NCT03860662 339 341 O
the NCT03860662 342 345 O
disease NCT03860662 346 353 B-Condition
and NCT03860662 354 357 B-Or
/ NCT03860662 358 359 I-Or
or NCT03860662 360 362 I-Or
neuropathy NCT03860662 363 373 B-Condition

- NCT03860662 376 377 O
Companies NCT03860662 379 388 O
that NCT03860662 389 393 O
have NCT03860662 394 398 O
received NCT03860662 399 407 B-Eq-Comparison
botulinum NCT03860662 408 417 B-Procedure
toxin NCT03860662 418 423 I-Procedure
injection NCT03860662 424 433 I-Procedure
therapy NCT03860662 434 441 I-Procedure
and NCT03860662 442 445 B-Or
/ NCT03860662 446 447 I-Or
or NCT03860662 448 450 I-Or
oral NCT03860662 451 455 B-Modifier
antispastic NCT03860662 456 467 B-Procedure
therapy NCT03860662 468 475 I-Procedure
within NCT03860662 476 482 B-Eq-Comparison
the NCT03860662 483 486 I-Eq-Comparison
last NCT03860662 487 491 I-Eq-Comparison
6 NCT03860662 492 493 I-Eq-Comparison
months NCT03860662 494 500 I-Eq-Comparison

- NCT03860662 503 504 O
Have NCT03860662 506 510 O
a NCT03860662 511 512 O
history NCT03860662 513 520 B-Eq-Comparison
of NCT03860662 521 523 O
allergies NCT03860662 524 533 B-Allergy
and NCT03860662 534 537 B-Or
hypersensitivity NCT03860662 538 554 B-Condition
to NCT03860662 555 557 O
usability NCT03860662 558 567 B-Modifier
drug NCT03860662 568 572 B-Drug

- NCT03860662 575 576 O
Injection NCT03860662 578 587 B-Procedure
treatment NCT03860662 588 597 I-Procedure
planned NCT03860662 598 605 B-Eq-Comparison
purification NCT03860662 606 618 B-Procedure
hematoma NCT03860662 619 627 I-Procedure
, NCT03860662 628 629 O
cleaning NCT03860662 630 638 B-Modifier
or NCT03860662 639 641 B-Or
skin NCT03860662 642 646 B-Modifier
lesion NCT03860662 647 653 B-Condition
to NCT03860662 654 656 O
be NCT03860662 657 659 O

Inclusion NCT03866213 0 9 O
Criteria NCT03866213 10 18 O
: NCT03866213 19 20 O

- NCT03866213 24 25 O
The NCT03866213 27 30 O
patient NCT03866213 31 38 O
is NCT03866213 39 41 O
currently NCT03866213 42 51 B-Eq-Comparison
being NCT03866213 52 57 O
treated NCT03866213 58 65 B-Procedure
at NCT03866213 66 68 O
Queen NCT03866213 69 74 O
Elizabeth NCT03866213 75 84 O
Central NCT03866213 85 92 O
Hospital NCT03866213 93 101 O
or NCT03866213 102 104 B-Or
Kamuzu NCT03866213 105 111 O
Central NCT03866213 112 119 O
Hospital NCT03866213 120 128 O
in NCT03866213 129 131 O
the NCT03866213 132 135 O
neonatal NCT03866213 136 144 O
ward NCT03866213 145 149 O
. NCT03866213 150 151 O

- NCT03866213 155 156 O
The NCT03866213 158 161 O
patient NCT03866213 162 169 O
is NCT03866213 170 172 O
less NCT03866213 173 177 B-Eq-Comparison
than NCT03866213 178 182 I-Eq-Comparison
28 NCT03866213 183 185 I-Eq-Comparison
days NCT03866213 186 190 I-Eq-Comparison
old NCT03866213 191 194 B-Age
( NCT03866213 195 196 O
neonate NCT03866213 197 204 O
) NCT03866213 205 206 O
. NCT03866213 208 209 O

- NCT03866213 213 214 O
The NCT03866213 216 219 O
patient NCT03866213 220 227 O
is NCT03866213 228 230 O
deemed NCT03866213 231 237 O
to NCT03866213 238 240 O
be NCT03866213 241 243 O
at NCT03866213 244 246 O
risk NCT03866213 247 251 B-Risk
for NCT03866213 252 255 O
jaundice NCT03866213 256 264 B-Condition
or NCT03866213 265 267 B-Or
the NCT03866213 268 271 O
patient NCT03866213 272 279 O
is NCT03866213 280 282 O
undergoing NCT03866213 283 293 B-Eq-Comparison
blue NCT03866213 294 298 B-Modifier
light NCT03866213 299 304 I-Modifier
phototherapy NCT03866213 305 317 B-Procedure
for NCT03866213 318 321 O
treatment NCT03866213 322 331 B-Procedure
of NCT03866213 332 334 O
jaundice NCT03866213 335 343 B-Condition
. NCT03866213 344 345 O

- NCT03866213 349 350 O
The NCT03866213 352 355 O
patient NCT03866213 356 363 O
's NCT03866213 363 365 O
parent NCT03866213 366 372 B-Family-Member___Family-Member-Type:parent
or NCT03866213 373 375 O
guardian NCT03866213 376 384 O
has NCT03866213 385 388 O
provided NCT03866213 389 397 O
informed NCT03866213 398 406 O
consent NCT03866213 407 414 O
for NCT03866213 415 418 O
their NCT03866213 419 424 O
child NCT03866213 425 430 B-Family-Member___Family-Member-Type:child
to NCT03866213 431 433 O
participate NCT03866213 434 445 O
. NCT03866213 446 447 O

Exclusion NCT03866213 449 458 O
Criteria NCT03866213 459 467 O
: NCT03866213 468 469 O

- NCT03866213 473 474 O
Parent NCT03866213 476 482 O
or NCT03866213 483 485 O
guardian NCT03866213 486 494 O
is NCT03866213 495 497 O
unable NCT03866213 498 504 O
or NCT03866213 505 507 O
unwilling NCT03866213 508 517 O
to NCT03866213 518 520 O
provide NCT03866213 521 528 O
informed NCT03866213 529 537 O
consent NCT03866213 538 545 O
. NCT03866213 546 547 O

- NCT03866213 551 552 O
The NCT03866213 554 557 O
patient NCT03866213 558 565 O
is NCT03866213 566 568 O
unable NCT03866213 569 575 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866213 576 578 O
receive NCT03866213 579 586 O
a NCT03866213 587 588 O
blood NCT03866213 589 594 B-Observation
draw NCT03866213 595 599 I-Observation
/ NCT03866213 600 601 B-Or
heel NCT03866213 602 606 B-Observation
stick NCT03866213 607 612 I-Observation
as NCT03866213 613 615 O
determined NCT03866213 616 626 O
by NCT03866213 627 629 O
their NCT03866213 630 635 O
clinician NCT03866213 636 645 O
. NCT03866213 645 646 O

Inclusion NCT03865732 0 9 O
Criteria NCT03865732 10 18 O
: NCT03865732 19 20 O

- NCT03865732 24 25 O
Molecular NCT03865732 27 36 B-Procedure
confirmation NCT03865732 37 49 O
of NCT03865732 50 52 O
a NCT03865732 53 54 O
pathogenic NCT03865732 55 65 B-Modifier
or NCT03865732 66 68 B-Or
likely NCT03865732 69 75 B-Assertion___Assertion-Type-Value:possible
pathogenic NCT03865732 76 86 B-Modifier
PCDH19 NCT03865732 87 93 B-Condition
variant NCT03865732 94 101 I-Condition

- NCT03865732 104 105 O
Failure NCT03865732 107 114 B-Negation
to NCT03865732 115 117 O
control NCT03865732 118 125 O
seizures NCT03865732 126 134 B-Condition
despite NCT03865732 135 142 B-And
2 NCT03865732 143 144 B-Eq-Comparison
or NCT03865732 145 147 I-Eq-Comparison
more NCT03865732 148 152 I-Eq-Comparison
anti NCT03865732 153 157 O
- NCT03865732 158 159 O
seizure NCT03865732 160 167 B-Condition
medications NCT03865732 168 179 B-Drug

- NCT03865732 182 183 O
12 NCT03865732 185 187 B-Eq-Comparison
seizures NCT03865732 188 196 B-Condition
over NCT03865732 197 201 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03865732 202 203 O
12 NCT03865732 204 206 B-Eq-Comparison
- NCT03865732 207 208 I-Eq-Comparison
week NCT03865732 209 213 I-Eq-Comparison
period NCT03865732 214 220 I-Eq-Comparison
of NCT03865732 221 223 O
primary NCT03865732 224 231 B-Condition
seizure NCT03865732 232 239 I-Condition
types NCT03865732 240 245 O
prior NCT03865732 246 251 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 252 254 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 255 264 B-Study

- NCT03865732 267 268 O
On NCT03865732 270 272 B-Eq-Comparison
a NCT03865732 273 274 O
stable NCT03865732 275 281 O
regimen NCT03865732 282 289 O
of NCT03865732 290 292 O
anti NCT03865732 293 297 O
- NCT03865732 298 299 O
seizure NCT03865732 300 307 B-Condition
treatments NCT03865732 308 318 B-Procedure
( NCT03865732 319 320 O
Vagus NCT03865732 321 326 B-Procedure
nerve NCT03865732 327 332 I-Procedure
stimulator NCT03865732 333 343 I-Procedure
, NCT03865732 344 345 O
ketogenic NCT03865732 346 355 B-Observation
diet NCT03865732 356 360 I-Observation
, NCT03865732 361 362 O
and NCT03865732 363 366 B-Or
modified NCT03865732 367 375 B-Modifier
Atkins NCT03865732 376 382 B-Observation
diet NCT03865732 383 387 I-Observation
should NCT03865732 388 394 O
be NCT03865732 395 397 O
unchanged NCT03865732 398 407 O
for NCT03865732 408 411 O
3 NCT03865732 412 413 B-Eq-Comparison
months NCT03865732 414 420 I-Eq-Comparison
prior NCT03865732 421 426 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 427 429 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 430 439 B-Study
) NCT03865732 440 441 O

Exclusion NCT03865732 443 452 O
Criteria NCT03865732 453 461 O
: NCT03865732 462 463 O

- NCT03865732 467 468 O
Previous NCT03865732 470 478 B-Eq-Comparison
exposure NCT03865732 479 487 O
to NCT03865732 488 490 O
ganaxolone NCT03865732 491 501 B-Drug

- NCT03865732 504 505 O
> NCT03865732 507 508 B-Eq-Comparison
8 NCT03865732 509 510 I-Eq-Comparison
consecutive NCT03865732 511 522 I-Eq-Comparison
weeks NCT03865732 523 528 I-Eq-Comparison
of NCT03865732 529 531 O
seizure NCT03865732 532 539 B-Condition
freedom NCT03865732 540 547 B-Negation
during NCT03865732 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865732 555 558 O
12 NCT03865732 559 561 B-Eq-Comparison
weeks NCT03865732 562 567 I-Eq-Comparison
prior NCT03865732 568 573 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 574 576 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 577 586 B-Study

- NCT03865732 589 590 O
Concurrent NCT03865732 592 602 B-Modifier
use NCT03865732 603 606 O
of NCT03865732 607 609 O
strong NCT03865732 610 616 B-Drug
inducers NCT03865732 617 625 I-Drug
or NCT03865732 626 628 B-Or
inhibitors NCT03865732 629 639 B-Drug
of NCT03865732 640 642 O
CYP3A4 NCT03865732 643 649 B-Modifier
/ NCT03865732 650 651 B-Or
5 NCT03865732 652 653 B-Modifier
/ NCT03865732 654 655 B-Or
7 NCT03865732 656 657 B-Modifier
is NCT03865732 658 660 O
not NCT03865732 661 664 B-Negation
permitted NCT03865732 665 674 O

- NCT03865732 677 678 O
Use NCT03865732 680 683 B-Eq-Comparison
of NCT03865732 684 686 O
tetrahydrocannabinol NCT03865732 687 707 B-Drug
( NCT03865732 708 709 O
THC NCT03865732 710 713 B-Drug
) NCT03865732 714 715 O
or NCT03865732 716 718 B-Or
non NCT03865732 719 722 B-Modifier
- NCT03865732 723 724 I-Modifier
approved NCT03865732 725 733 I-Modifier
cannabidiol NCT03865732 734 745 B-Drug
( NCT03865732 746 747 O
CBD NCT03865732 748 751 B-Drug
) NCT03865732 752 753 O
is NCT03865732 754 756 O
prohibited NCT03865732 757 767 B-Negation
during NCT03865732 768 774 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865732 775 778 O
double NCT03865732 779 785 B-Modifier
- NCT03865732 786 787 I-Modifier
blind NCT03865732 788 793 I-Modifier
phase NCT03865732 794 799 O

- NCT03865732 802 803 O
Exposure NCT03865732 805 813 O
to NCT03865732 814 816 O
any NCT03865732 817 820 O
other NCT03865732 821 826 B-Other
investigational NCT03865732 827 842 B-Study
drug NCT03865732 843 847 B-Drug
within NCT03865732 848 854 B-Eq-Comparison
30 NCT03865732 855 857 I-Eq-Comparison
days NCT03865732 858 862 I-Eq-Comparison
or NCT03865732 863 865 B-Or
fewer NCT03865732 866 871 B-Eq-Comparison
than NCT03865732 872 876 I-Eq-Comparison
5 NCT03865732 877 878 I-Eq-Comparison
half NCT03865732 879 883 I-Eq-Comparison
- NCT03865732 884 885 I-Eq-Comparison
lives NCT03865732 886 891 I-Eq-Comparison
prior NCT03865732 892 897 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865732 898 900 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865732 901 910 B-Study

Inclusion NCT03867643 0 9 O
Criteria NCT03867643 10 18 O
: NCT03867643 19 20 O

- NCT03867643 24 25 O
Children NCT03867643 27 35 O
who NCT03867643 36 39 O
are NCT03867643 40 43 O
6 NCT03867643 44 45 B-Eq-Comparison
- NCT03867643 46 47 I-Eq-Comparison
12 NCT03867643 48 50 I-Eq-Comparison
years NCT03867643 51 56 I-Eq-Comparison
old NCT03867643 57 60 B-Age
， NCT03867643 61 62 O
in NCT03867643 63 65 O
Chongqing NCT03867643 66 75 O

- NCT03867643 78 79 O
After NCT03867643 81 86 B-Temporal-Connection___Temporal-Connection-Type-Value:after
birth NCT03867643 87 92 B-Birth
, NCT03867643 93 94 O
three NCT03867643 95 100 B-Eq-Comparison
injections NCT03867643 101 111 B-Procedure
of NCT03867643 112 114 O
Hep NCT03867643 115 118 B-Drug
B NCT03867643 119 120 I-Drug
were NCT03867643 121 125 O
inoculated NCT03867643 126 136 O
in NCT03867643 137 139 O
time NCT03867643 140 144 O
according NCT03867643 145 154 O
to NCT03867643 155 157 O
the NCT03867643 158 161 O
procedure NCT03867643 162 171 O
of NCT03867643 172 174 O
0 NCT03867643 175 176 B-Eq-Comparison
, NCT03867643 177 178 I-Eq-Comparison
1 NCT03867643 179 180 I-Eq-Comparison
and NCT03867643 181 184 I-Eq-Comparison
6 NCT03867643 185 186 I-Eq-Comparison
months NCT03867643 187 193 I-Eq-Comparison
（ NCT03867643 194 195 O
The NCT03867643 196 199 O
vaccination NCT03867643 200 211 O
certificate NCT03867643 212 223 O
record NCT03867643 224 230 O
） NCT03867643 230 231 O

- NCT03867643 234 235 O
No NCT03867643 237 239 B-Negation
HBV NCT03867643 240 243 B-Immunization
booster NCT03867643 244 251 I-Immunization
vaccine NCT03867643 252 259 I-Immunization
given NCT03867643 260 265 O
since NCT03867643 266 271 B-Temporal-Connection___Temporal-Connection-Type-Value:after
primary NCT03867643 272 279 B-Modifier
HBV NCT03867643 280 283 B-Immunization
immunization NCT03867643 284 296 I-Immunization

- NCT03867643 299 300 O
Children NCT03867643 302 310 O
or NCT03867643 311 313 B-Or
guardian NCT03867643 314 322 B-Family-Member___Family-Member-Type:parent
knew NCT03867643 323 327 O
and NCT03867643 328 331 O
agreed NCT03867643 332 338 O
to NCT03867643 339 341 O
accept NCT03867643 342 348 O
the NCT03867643 349 352 O
study NCT03867643 353 358 B-Study

- NCT03867643 361 362 O
Follow NCT03867643 364 370 B-Encounter
- NCT03867643 371 372 I-Encounter
up NCT03867643 373 375 I-Encounter
study NCT03867643 376 381 B-Study
and NCT03867643 382 385 B-And
blood NCT03867643 386 391 B-Observation
collection NCT03867643 392 402 I-Observation
after NCT03867643 403 408 B-Temporal-Connection___Temporal-Connection-Type-Value:after
vaccination NCT03867643 409 420 B-Immunization
can NCT03867643 421 424 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867643 425 427 I-Assertion___Assertion-Type-Value:hypothetical
accepted NCT03867643 428 436 O

Exclusion NCT03867643 437 446 O
Criteria NCT03867643 447 455 O
: NCT03867643 456 457 O

- NCT03867643 461 462 O
Unwilling NCT03867643 464 473 O
or NCT03867643 474 476 O
impossible NCT03867643 477 487 O
to NCT03867643 488 490 O
participate NCT03867643 491 502 O
in NCT03867643 503 505 O
this NCT03867643 506 510 O
research NCT03867643 511 519 O
project NCT03867643 520 527 O
; NCT03867643 527 528 O

- NCT03867643 531 532 O
Have NCT03867643 534 538 O
a NCT03867643 539 540 O
history NCT03867643 541 548 B-Eq-Comparison
of NCT03867643 549 551 O
allergy NCT03867643 552 559 B-Allergy
or NCT03867643 560 562 B-Or
have NCT03867643 563 567 O
had NCT03867643 568 571 O
a NCT03867643 572 573 O
serious NCT03867643 574 581 O
vaccine NCT03867643 582 589 B-Immunization
reaction NCT03867643 590 598 B-Condition

- NCT03867643 601 602 O
Have NCT03867643 604 608 O
immune NCT03867643 609 615 B-Condition
impairment NCT03867643 616 626 I-Condition
diseases NCT03867643 627 635 I-Condition
and NCT03867643 636 639 B-Or
appear NCT03867643 640 646 B-Assertion___Assertion-Type-Value:possible
immune NCT03867643 647 653 B-Condition
impairment NCT03867643 654 664 I-Condition
; NCT03867643 664 665 O

- NCT03867643 668 669 O
Immunosuppressive NCT03867643 671 688 B-Procedure
treatment NCT03867643 689 698 I-Procedure
, NCT03867643 699 700 O
receive NCT03867643 701 708 O
any NCT03867643 709 712 O
injection NCT03867643 713 722 B-Modifier
or NCT03867643 723 725 B-Or
oral NCT03867643 726 730 B-Modifier
administration NCT03867643 731 745 I-Modifier
of NCT03867643 746 748 O
cortisone NCT03867643 749 758 B-Drug
or NCT03867643 759 761 B-Or
cancer NCT03867643 762 768 B-Condition
chemotherapy NCT03867643 769 781 B-Procedure
; NCT03867643 781 782 O

- NCT03867643 785 786 O
Any NCT03867643 788 791 O
kind NCT03867643 792 796 O
of NCT03867643 797 799 O
vaccine NCT03867643 800 807 B-Immunization
or NCT03867643 808 810 B-Or
any NCT03867643 811 814 O
kind NCT03867643 815 819 O
of NCT03867643 820 822 O
observation NCT03867643 823 834 B-Study
drug NCT03867643 835 839 B-Drug
has NCT03867643 840 843 O
been NCT03867643 844 848 O
vaccinated NCT03867643 849 859 B-Immunization
in NCT03867643 860 862 O
the NCT03867643 863 866 O
past NCT03867643 867 871 B-Eq-Comparison
four NCT03867643 872 876 I-Eq-Comparison
weeks NCT03867643 877 882 I-Eq-Comparison
; NCT03867643 882 883 O

- NCT03867643 886 887 O
Any NCT03867643 889 892 O
acute NCT03867643 893 898 O
disease NCT03867643 899 906 B-Condition
or NCT03867643 907 909 B-Or
other NCT03867643 910 915 B-Other
infection NCT03867643 916 925 B-Condition
requiring NCT03867643 926 935 O
antibiotic NCT03867643 936 946 B-Drug
or NCT03867643 947 949 B-Or
antiviral NCT03867643 950 959 B-Drug
treatment NCT03867643 960 969 B-Procedure
in NCT03867643 970 972 O
the NCT03867643 973 976 O
past NCT03867643 977 981 B-Eq-Comparison
four NCT03867643 982 986 I-Eq-Comparison
weeks NCT03867643 987 992 I-Eq-Comparison
; NCT03867643 992 993 O

- NCT03867643 996 997 O
Fever NCT03867643 999 1004 B-Condition
symptoms NCT03867643 1005 1013 B-Assertion___Assertion-Type-Value:possible
occurred NCT03867643 1014 1022 O
in NCT03867643 1023 1025 O
the NCT03867643 1026 1029 O
past NCT03867643 1030 1034 B-Eq-Comparison
week NCT03867643 1035 1039 I-Eq-Comparison
( NCT03867643 1040 1041 O
axillary NCT03867643 1042 1050 B-Modifier
temperature NCT03867643 1051 1062 B-Observation
≥ NCT03867643 1063 1064 B-Eq-Comparison
38 NCT03867643 1065 1067 I-Eq-Comparison
℃ NCT03867643 1068 1069 I-Eq-Comparison
) NCT03867643 1070 1071 O

- NCT03867643 1075 1076 O
Blood NCT03867643 1078 1083 B-Procedure
transfusion NCT03867643 1084 1095 I-Procedure
experience NCT03867643 1096 1106 O
; NCT03867643 1106 1107 O

- NCT03867643 1110 1111 O
Has NCT03867643 1113 1116 O
a NCT03867643 1117 1118 O
history NCT03867643 1119 1126 B-Eq-Comparison
of NCT03867643 1127 1129 O
more NCT03867643 1130 1134 O
serious NCT03867643 1135 1142 O
infectious NCT03867643 1143 1153 B-Condition
diseases NCT03867643 1154 1162 I-Condition
( NCT03867643 1163 1164 O
five NCT03867643 1165 1169 O
types NCT03867643 1170 1175 O
of NCT03867643 1176 1178 O
hepatitis NCT03867643 1179 1188 B-Condition
, NCT03867643 1189 1190 O
AIDS NCT03867643 1191 1195 B-Condition
, NCT03867643 1196 1197 O
syphilis NCT03867643 1198 1206 B-Condition
, NCT03867643 1207 1208 O
gonorrhea NCT03867643 1209 1218 B-Condition
, NCT03867643 1219 1220 O
etc NCT03867643 1221 1224 O
. NCT03867643 1224 1225 O
) NCT03867643 1227 1228 O
; NCT03867643 1229 1230 O

- NCT03867643 1233 1234 O
Hepatitis NCT03867643 1236 1245 B-Condition
B NCT03867643 1246 1247 I-Condition
infection NCT03867643 1248 1257 B-Modifier
or NCT03867643 1258 1260 B-Or
carriers NCT03867643 1261 1269 B-Modifier
( NCT03867643 1270 1271 O
lineal NCT03867643 1272 1278 O
relationship NCT03867643 1279 1291 O
) NCT03867643 1292 1293 O
; NCT03867643 1294 1295 O

- NCT03867643 1298 1299 O
Abnormal NCT03867643 1301 1309 O
physical NCT03867643 1310 1318 B-Procedure
examination NCT03867643 1319 1330 I-Procedure

Inclusion NCT03863431 0 9 O
Criteria NCT03863431 10 18 O
: NCT03863431 19 20 O

- NCT03863431 24 25 O
18 NCT03863431 27 29 B-Eq-Comparison
- NCT03863431 30 31 I-Eq-Comparison
40 NCT03863431 32 34 I-Eq-Comparison
years NCT03863431 35 40 I-Age|Eq-Comparison

- NCT03863431 43 44 O
BMI NCT03863431 46 49 B-Observation
= NCT03863431 50 51 B-Eq-Comparison
18.5 NCT03863431 52 56 I-Eq-Comparison
- NCT03863431 57 58 I-Eq-Comparison
29.9 NCT03863431 59 63 I-Eq-Comparison
kg NCT03863431 64 66 I-Eq-Comparison
/ NCT03863431 67 68 I-Eq-Comparison
m2 NCT03863431 69 71 I-Eq-Comparison

- NCT03863431 74 75 O
Male NCT03863431 77 81 O
or NCT03863431 82 84 B-Or
female NCT03863431 85 91 O

- NCT03863431 94 95 O
Physically NCT03863431 97 107 B-Observation
active NCT03863431 108 114 I-Observation
( NCT03863431 115 116 O
> NCT03863431 118 119 B-Eq-Comparison
3 NCT03863431 120 121 I-Eq-Comparison
x NCT03863431 122 123 O
30 NCT03863431 124 126 B-Eq-Comparison
min NCT03863431 127 130 I-Eq-Comparison
moderate NCT03863431 131 139 I-Eq-Comparison
exercise NCT03863431 140 148 I-Eq-Comparison
per NCT03863431 149 152 I-Eq-Comparison
week NCT03863431 153 157 I-Eq-Comparison
) NCT03863431 158 159 O

- NCT03863431 163 164 O
Non NCT03863431 166 169 B-Negation
- NCT03863431 170 171 O
smoker NCT03863431 172 178 B-Condition
( NCT03863431 179 180 O
including NCT03863431 181 190 O
the NCT03863431 191 194 O
use NCT03863431 195 198 O
of NCT03863431 199 201 O
vaporisers NCT03863431 202 212 B-Drug
and NCT03863431 213 216 B-Or
e NCT03863431 217 218 B-Drug
- NCT03863431 219 220 I-Drug
cigarettes NCT03863431 221 231 I-Drug
) NCT03863431 232 233 O

- NCT03863431 237 238 O
Healthy NCT03863431 240 247 B-Condition
( NCT03863431 248 249 O
determined NCT03863431 250 260 O
by NCT03863431 261 263 O
the NCT03863431 264 267 O
School NCT03863431 268 274 B-Observation
's NCT03863431 274 276 I-Observation
standard NCT03863431 277 285 I-Observation
health NCT03863431 286 292 I-Observation
questionnaire NCT03863431 293 306 I-Observation
) NCT03863431 307 308 O

- NCT03863431 312 313 O
No NCT03863431 315 317 B-Negation
cardiometabolic NCT03863431 318 333 B-Modifier
or NCT03863431 334 336 B-Or
inflammatory NCT03863431 337 349 B-Modifier
illness NCT03863431 350 357 B-Condition

Exclusion NCT03863431 358 367 O
Criteria NCT03863431 368 376 O
: NCT03863431 377 378 O

- NCT03863431 382 383 O
Outside NCT03863431 385 392 O
of NCT03863431 393 395 O
age NCT03863431 396 399 O
- NCT03863431 400 401 O
range NCT03863431 402 407 O

- NCT03863431 410 411 O
Outside NCT03863431 413 420 B-Negation
BMI NCT03863431 421 424 B-Observation
range NCT03863431 425 430 B-Eq-Comparison

- NCT03863431 433 434 O
Inactive NCT03863431 436 444 B-Observation
( NCT03863431 445 446 O
< NCT03863431 448 449 B-Eq-Comparison
3 NCT03863431 450 451 I-Eq-Comparison
x NCT03863431 452 453 O
30 NCT03863431 454 456 B-Eq-Comparison
min NCT03863431 457 460 I-Eq-Comparison
moderate NCT03863431 461 469 I-Eq-Comparison
exercise NCT03863431 470 478 I-Eq-Comparison
per NCT03863431 479 482 I-Eq-Comparison
week NCT03863431 483 487 I-Eq-Comparison
) NCT03863431 488 489 O

- NCT03863431 493 494 O
Smoker NCT03863431 496 502 B-Condition

- NCT03863431 505 506 O
Taking NCT03863431 508 514 B-Eq-Comparison
medication NCT03863431 515 525 B-Drug

- NCT03863431 528 529 O
History NCT03863431 531 538 B-Eq-Comparison
of NCT03863431 539 541 O
cardiometabolic NCT03863431 542 557 B-Modifier
or NCT03863431 558 560 B-Or
inflammatory NCT03863431 561 573 B-Modifier
illness NCT03863431 574 581 B-Condition

- NCT03863431 584 585 O
Vegetarian NCT03863431 587 597 B-Condition
/ NCT03863431 598 599 B-Or
vegan NCT03863431 600 605 B-Condition
( NCT03863431 606 607 O
as NCT03863431 608 610 O
the NCT03863431 611 614 O
high NCT03863431 615 619 O
- NCT03863431 620 621 O
fat NCT03863431 622 625 O
diet NCT03863431 626 630 O
is NCT03863431 631 633 O
based NCT03863431 634 639 O
on NCT03863431 640 642 O
animal NCT03863431 643 649 O
fats NCT03863431 650 654 O
) NCT03863431 655 656 O

- NCT03863431 660 661 O
Other NCT03863431 663 668 B-Other
dietary NCT03863431 669 676 B-Condition
restrictions NCT03863431 677 689 I-Condition
which NCT03863431 690 695 O
prevent NCT03863431 696 703 B-Negation
consumption NCT03863431 704 715 O
of NCT03863431 716 718 O
the NCT03863431 719 722 O
experimental NCT03863431 723 735 B-Procedure
diet NCT03863431 736 740 I-Procedure

- NCT03863431 743 744 O
Consumption NCT03863431 746 757 O
of NCT03863431 758 760 O
probiotics NCT03863431 761 771 B-Drug
within NCT03863431 772 778 B-Eq-Comparison
last NCT03863431 779 783 I-Eq-Comparison
3 NCT03863431 784 785 I-Eq-Comparison
months NCT03863431 786 792 I-Eq-Comparison
( NCT03863431 793 794 O
these NCT03863431 795 800 O
influence NCT03863431 801 810 O
the NCT03863431 811 814 O
gut NCT03863431 815 818 O
microbiota NCT03863431 819 829 O
) NCT03863431 830 831 O

- NCT03863431 835 836 O
Participation NCT03863431 838 851 O
in NCT03863431 852 854 O
another NCT03863431 855 862 B-Other
clinical NCT03863431 863 871 B-Study
trial NCT03863431 872 877 I-Study

- NCT03863431 880 881 O
Those NCT03863431 883 888 O
with NCT03863431 889 893 O
known NCT03863431 894 899 B-Modifier
or NCT03863431 900 902 B-Or
suspected NCT03863431 903 912 B-Assertion___Assertion-Type-Value:possible
food NCT03863431 913 917 B-Condition
intolerances NCT03863431 918 930 I-Condition
, NCT03863431 931 932 O
allergies NCT03863431 933 942 B-Allergy
or NCT03863431 943 945 B-Or
hypersensitivity NCT03863431 946 962 B-Condition

- NCT03863431 965 966 O
Women NCT03863431 968 973 O
who NCT03863431 974 977 B-And
are NCT03863431 978 981 O
known NCT03863431 982 987 O
to NCT03863431 988 990 O
be NCT03863431 991 993 O
pregnant NCT03863431 994 1002 B-Condition
or NCT03863431 1003 1005 B-Or
who NCT03863431 1006 1009 O
are NCT03863431 1010 1013 O
intending NCT03863431 1014 1023 B-Assertion___Assertion-Type-Value:intention
to NCT03863431 1024 1026 I-Assertion___Assertion-Type-Value:intention
become NCT03863431 1027 1033 O
pregnant NCT03863431 1034 1042 B-Condition
over NCT03863431 1043 1047 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863431 1048 1051 I-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03863431 1052 1058 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863431 1059 1061 O
the NCT03863431 1062 1065 O
study NCT03863431 1066 1071 B-Study

Inclusion NCT03865875 0 9 O
Criteria NCT03865875 10 18 O

- NCT03865875 21 22 O
Adults NCT03865875 24 30 O
age NCT03865875 31 34 B-Age
18 NCT03865875 35 37 B-Eq-Comparison
years NCT03865875 38 43 I-Eq-Comparison
or NCT03865875 44 46 I-Eq-Comparison
older NCT03865875 47 52 I-Eq-Comparison
. NCT03865875 53 54 O

- NCT03865875 58 59 O
Diagnosed NCT03865875 61 70 O
within NCT03865875 71 77 B-Eq-Comparison
8 NCT03865875 78 79 I-Eq-Comparison
weeks NCT03865875 80 85 I-Eq-Comparison
with NCT03865875 86 90 O
upfront NCT03865875 91 98 O
resectable NCT03865875 99 109 B-Modifier
, NCT03865875 110 111 O
borderline NCT03865875 112 122 B-Modifier
resectable NCT03865875 123 133 I-Modifier
, NCT03865875 134 135 O
or NCT03865875 136 138 B-Or
locally NCT03865875 139 146 B-Modifier
advanced NCT03865875 147 155 I-Modifier
unresectable NCT03865875 156 168 I-Modifier
PDAC NCT03865875 169 173 B-Condition
as NCT03865875 174 176 O
defined NCT03865875 177 184 O
by NCT03865875 185 187 O
the NCT03865875 188 191 O
National NCT03865875 192 200 O
Comprehensive NCT03865875 201 214 O
Cancer NCT03865875 215 221 O
Network NCT03865875 222 229 O
( NCT03865875 230 231 O
NCCN NCT03865875 232 236 O
) NCT03865875 237 238 O
. NCT03865875 240 241 O

- NCT03865875 245 246 O
Planning NCT03865875 248 256 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 257 259 O
undergo NCT03865875 260 267 O
TNT NCT03865875 268 271 B-Procedure
at NCT03865875 272 274 O
MGH NCT03865875 275 278 O
. NCT03865875 279 280 O

- NCT03865875 284 285 O
Planning NCT03865875 287 295 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 296 298 O
receive NCT03865875 299 306 O
modified NCT03865875 307 315 B-Modifier
FOLFIRINOX NCT03865875 316 326 B-Drug
for NCT03865875 327 330 O
neoadjuvant NCT03865875 331 342 B-Modifier
chemotherapy NCT03865875 343 355 B-Procedure
. NCT03865875 356 357 O

- NCT03865875 361 362 O
Planning NCT03865875 364 372 B-Assertion___Assertion-Type-Value:intention
to NCT03865875 373 375 O
undergo NCT03865875 376 383 O
surgical NCT03865875 384 392 B-Procedure
resection NCT03865875 393 402 I-Procedure
of NCT03865875 403 405 O
PDAC NCT03865875 406 410 B-Condition
at NCT03865875 411 413 O
MGH NCT03865875 414 417 O
. NCT03865875 418 419 O

- NCT03865875 423 424 O
Verbal NCT03865875 426 432 O
fluency NCT03865875 433 440 O
in NCT03865875 441 443 O
English NCT03865875 444 451 O
. NCT03865875 452 453 O

Exclusion NCT03865875 455 464 O
Criteria NCT03865875 465 473 O

- NCT03865875 476 477 O
Metastatic NCT03865875 479 489 B-Condition
disease NCT03865875 490 497 I-Condition
. NCT03865875 498 499 O

- NCT03865875 503 504 O
Previous NCT03865875 506 514 B-Eq-Comparison
treatment NCT03865875 515 524 B-Procedure
for NCT03865875 525 528 O
pancreas NCT03865875 529 537 B-Modifier
adenocarcinoma NCT03865875 538 552 B-Condition
and NCT03865875 553 556 B-And
no NCT03865875 557 559 B-Negation
prior NCT03865875 560 565 B-Eq-Comparison
therapy NCT03865875 566 573 B-Procedure
for NCT03865875 574 577 O
any NCT03865875 578 581 O
cancer NCT03865875 582 588 B-Condition
within NCT03865875 589 595 B-Eq-Comparison
5 NCT03865875 596 597 I-Eq-Comparison
years NCT03865875 598 603 I-Eq-Comparison
. NCT03865875 604 605 O

- NCT03865875 609 610 O
Known NCT03865875 612 617 O
history NCT03865875 618 625 B-Eq-Comparison
of NCT03865875 626 628 O
cognitive NCT03865875 629 638 B-Modifier
or NCT03865875 639 641 B-Or
psychologic NCT03865875 642 653 B-Modifier
impairment NCT03865875 654 664 B-Condition
. NCT03865875 665 666 O

- NCT03865875 670 671 O
Known NCT03865875 673 678 O
history NCT03865875 679 686 B-Eq-Comparison
of NCT03865875 687 689 O
physical NCT03865875 690 698 B-Condition
impairment NCT03865875 699 709 I-Condition
such NCT03865875 710 714 O
as NCT03865875 715 717 O
immobility NCT03865875 718 728 B-Condition
, NCT03865875 729 730 O
use NCT03865875 731 734 O
of NCT03865875 735 737 O
walking NCT03865875 738 745 B-Procedure
aids NCT03865875 746 750 I-Procedure
, NCT03865875 751 752 O
or NCT03865875 753 755 B-Or
required NCT03865875 756 764 O
wheelchair NCT03865875 765 775 B-Procedure
use NCT03865875 776 779 I-Procedure
. NCT03865875 780 781 O

- NCT03865875 785 786 O
Known NCT03865875 788 793 O
history NCT03865875 794 801 B-Eq-Comparison
of NCT03865875 802 804 O
the NCT03865875 805 808 O
following NCT03865875 809 818 O
orthopedic NCT03865875 819 829 B-Condition
comorbidities NCT03865875 830 843 I-Condition
: NCT03865875 844 845 O
advanced NCT03865875 846 854 O
osteoarthritis NCT03865875 855 869 B-Condition
or NCT03865875 870 872 B-Or
rheumatoid NCT03865875 873 883 B-Modifier
arthritis NCT03865875 884 893 B-Condition
, NCT03865875 894 895 O
mobility NCT03865875 896 904 B-Modifier
- NCT03865875 905 906 I-Modifier
limiting NCT03865875 907 915 I-Modifier
amputations NCT03865875 916 927 B-Condition
, NCT03865875 928 929 O
orthopedic NCT03865875 930 940 B-Modifier
injuries NCT03865875 941 949 B-Condition
, NCT03865875 950 951 O
or NCT03865875 952 954 B-Or
widespread NCT03865875 955 965 O
chronic NCT03865875 966 973 B-Modifier
pain NCT03865875 974 978 B-Condition
( NCT03865875 979 980 O
e. NCT03865875 981 983 O
g. NCT03865875 984 986 O
fibromyalgia NCT03865875 988 1000 B-Condition
) NCT03865875 1001 1002 O
. NCT03865875 1004 1005 O

- NCT03865875 1009 1010 O
Known NCT03865875 1012 1017 O
history NCT03865875 1018 1025 B-Eq-Comparison
of NCT03865875 1026 1028 O
the NCT03865875 1029 1032 O
following NCT03865875 1033 1042 O
pulmonary NCT03865875 1043 1052 B-Modifier
comorbidities NCT03865875 1053 1066 B-Condition
: NCT03865875 1067 1068 O
severe NCT03865875 1069 1075 O
chronic NCT03865875 1076 1083 B-Modifier
obstructive NCT03865875 1084 1095 B-Condition
pulmonary NCT03865875 1096 1105 I-Condition
disease NCT03865875 1106 1113 I-Condition
( NCT03865875 1114 1115 O
COPD NCT03865875 1116 1120 B-Condition
) NCT03865875 1121 1122 O
defined NCT03865875 1123 1130 O
as NCT03865875 1131 1133 O
FEV1 NCT03865875 1134 1138 B-Observation
≤ NCT03865875 1139 1140 B-Eq-Comparison
50 NCT03865875 1141 1143 I-Eq-Comparison
% NCT03865875 1144 1145 I-Eq-Comparison
, NCT03865875 1147 1148 O
emphysema NCT03865875 1149 1158 B-Condition
, NCT03865875 1159 1160 O
interstitial NCT03865875 1161 1173 B-Condition
lung NCT03865875 1174 1178 I-Condition
disease NCT03865875 1179 1186 I-Condition
, NCT03865875 1187 1188 O
and NCT03865875 1189 1192 B-Or
/ NCT03865875 1193 1194 I-Or
or NCT03865875 1195 1197 I-Or
use NCT03865875 1198 1201 O
of NCT03865875 1202 1204 O
supplemental NCT03865875 1205 1217 B-Procedure
oxygen NCT03865875 1218 1224 I-Procedure
. NCT03865875 1225 1226 O

- NCT03865875 1230 1231 O
Known NCT03865875 1233 1238 O
history NCT03865875 1239 1246 B-Eq-Comparison
of NCT03865875 1247 1249 O
the NCT03865875 1250 1253 O
following NCT03865875 1254 1263 O
cardiovascular NCT03865875 1264 1278 B-Condition
comorbidities NCT03865875 1279 1292 I-Condition
: NCT03865875 1293 1294 O
uncontrolled NCT03865875 1295 1307 B-Modifier
hypertension NCT03865875 1308 1320 B-Condition
, NCT03865875 1321 1322 O
severe NCT03865875 1323 1329 O
congestive NCT03865875 1330 1340 B-Condition
heart NCT03865875 1341 1346 I-Condition
failure NCT03865875 1347 1354 I-Condition
( NCT03865875 1355 1356 O
NYHA NCT03865875 1357 1361 B-Condition
Class NCT03865875 1362 1367 B-Eq-Comparison
IV NCT03865875 1368 1370 I-Eq-Comparison
) NCT03865875 1371 1372 O
, NCT03865875 1374 1375 O
and NCT03865875 1376 1379 B-Or
/ NCT03865875 1380 1381 I-Or
or NCT03865875 1382 1384 I-Or
myocardial NCT03865875 1385 1395 B-Condition
infarction NCT03865875 1396 1406 I-Condition
within NCT03865875 1407 1413 B-Eq-Comparison
the NCT03865875 1414 1417 I-Eq-Comparison
last NCT03865875 1418 1422 I-Eq-Comparison
6 NCT03865875 1423 1424 I-Eq-Comparison
months NCT03865875 1425 1431 I-Eq-Comparison
. NCT03865875 1432 1433 O

- NCT03865875 1437 1438 O
Inability NCT03865875 1440 1449 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865875 1450 1452 O
tolerate NCT03865875 1453 1461 O
diet NCT03865875 1462 1466 B-Observation
through NCT03865875 1467 1474 O
routine NCT03865875 1475 1482 O
oral NCT03865875 1483 1487 B-Modifier
routes NCT03865875 1488 1494 I-Modifier
and NCT03865875 1495 1498 B-Or
/ NCT03865875 1499 1500 I-Or
or NCT03865875 1501 1503 I-Or
patients NCT03865875 1504 1512 O
with NCT03865875 1513 1517 O
strict NCT03865875 1518 1524 O
nutritional NCT03865875 1525 1536 B-Condition
restrictions NCT03865875 1537 1549 I-Condition
, NCT03865875 1550 1551 O
allergies NCT03865875 1552 1561 B-Allergy
, NCT03865875 1562 1563 O
and NCT03865875 1564 1567 B-Or
/ NCT03865875 1568 1569 I-Or
or NCT03865875 1570 1572 I-Or
dietary NCT03865875 1573 1580 B-Observation
preferences NCT03865875 1581 1592 I-Observation
. NCT03865875 1592 1593 O

Inclusion NCT03860064 0 9 O
Criteria NCT03860064 10 18 O
: NCT03860064 19 20 O

- NCT03860064 24 25 O
18 NCT03860064 27 29 B-Eq-Comparison
- NCT03860064 30 31 I-Eq-Comparison
35 NCT03860064 32 34 I-Eq-Comparison
- NCT03860064 35 36 I-Eq-Comparison
year NCT03860064 37 41 I-Eq-Comparison
- NCT03860064 42 43 O
old NCT03860064 44 47 B-Age
women NCT03860064 48 53 O

- NCT03860064 56 57 O
BMI NCT03860064 59 62 B-Observation
: NCT03860064 63 64 O
> NCT03860064 65 66 B-Eq-Comparison
18 NCT03860064 67 69 I-Eq-Comparison
and NCT03860064 70 73 B-And
< NCT03860064 74 75 B-Eq-Comparison
30 NCT03860064 76 78 I-Eq-Comparison
kg NCT03860064 79 81 I-Eq-Comparison
/ NCT03860064 82 83 I-Eq-Comparison
m2 NCT03860064 84 86 I-Eq-Comparison

- NCT03860064 89 90 O
Normal NCT03860064 92 98 O
female NCT03860064 99 105 B-Modifier
karyotype NCT03860064 106 115 B-Condition

- NCT03860064 118 119 O
Normal NCT03860064 121 127 O
uterus NCT03860064 128 134 B-Condition
and NCT03860064 135 138 B-And
ovaries NCT03860064 139 146 B-Condition
at NCT03860064 147 149 B-Temporal-Connection___Temporal-Connection-Type-Value:during
transvaginal NCT03860064 150 162 B-Procedure
ultrasound NCT03860064 163 173 I-Procedure

Exclusion NCT03860064 174 183 O
Criteria NCT03860064 184 192 O
: NCT03860064 193 194 O

- NCT03860064 198 199 O
> NCT03860064 201 202 B-Eq-Comparison
35 NCT03860064 203 205 I-Eq-Comparison
years NCT03860064 206 211 I-Age|Eq-Comparison

- NCT03860064 214 215 O
PCO NCT03860064 217 220 B-Condition
syndrome NCT03860064 221 229 I-Condition
carriers NCT03860064 230 238 O

- NCT03860064 241 242 O
Null NCT03860064 244 248 B-Modifier
follicle NCT03860064 249 257 B-Condition
aspiration NCT03860064 258 268 I-Condition

- NCT03860064 271 272 O
History NCT03860064 274 281 B-Eq-Comparison
of NCT03860064 282 284 O
chemotherapy NCT03860064 285 297 B-Procedure
or NCT03860064 298 300 B-Or
radiotherapy NCT03860064 301 313 B-Procedure

Inclusion NCT03865108 0 9 O
Criteria NCT03865108 10 18 O
: NCT03865108 19 20 O

- NCT03865108 24 25 O
Singleton NCT03865108 27 36 B-Modifier
gestation NCT03865108 37 46 B-Condition
. NCT03865108 47 48 O

- NCT03865108 57 58 O
Twin NCT03865108 60 64 B-Modifier
gestation NCT03865108 65 74 B-Condition
reduced NCT03865108 75 82 O
to NCT03865108 83 85 O
singleton NCT03865108 86 95 B-Modifier
either NCT03865108 96 102 O
spontaneously NCT03865108 103 116 B-Modifier
or NCT03865108 117 119 B-Or
therapeutically NCT03865108 120 135 B-Procedure
, NCT03865108 136 137 O
is NCT03865108 138 140 O
not NCT03865108 141 144 B-Negation
eligible NCT03865108 145 153 O
unless NCT03865108 154 160 B-Exception
the NCT03865108 161 164 B-Coreference
reduction NCT03865108 165 174 I-Coreference
occurred NCT03865108 175 183 O
before NCT03865108 184 190 B-Temporal-Connection___Temporal-Connection-Type-Value:before
13 NCT03865108 191 193 B-Eq-Comparison
weeks NCT03865108 194 199 I-Eq-Comparison
6 NCT03865108 200 201 I-Eq-Comparison
days NCT03865108 202 206 I-Eq-Comparison
project NCT03865108 207 214 O
gestational NCT03865108 215 226 B-Observation
age NCT03865108 227 230 I-Observation
. NCT03865108 231 232 O

- NCT03865108 241 242 O
Higher NCT03865108 244 250 B-Modifier
order NCT03865108 251 256 I-Modifier
multifetal NCT03865108 257 267 I-Modifier
gestations NCT03865108 268 278 B-Condition
reduced NCT03865108 279 286 O
to NCT03865108 287 289 O
singletons NCT03865108 290 300 B-Modifier
are NCT03865108 301 304 O
not NCT03865108 305 308 B-Negation
eligible NCT03865108 309 317 O
. NCT03865108 318 319 O

- NCT03865108 323 324 O
Gestational NCT03865108 326 337 B-Observation
age NCT03865108 338 341 I-Observation
at NCT03865108 342 344 B-Temporal-Connection___Temporal-Connection-Type-Value:during
randomization NCT03865108 345 358 B-Study
between NCT03865108 359 366 B-Eq-Comparison
16 NCT03865108 367 369 I-Eq-Comparison
weeks NCT03865108 370 375 I-Eq-Comparison
0 NCT03865108 376 377 I-Eq-Comparison
days NCT03865108 378 382 I-Eq-Comparison
and NCT03865108 383 386 B-And
23 NCT03865108 387 389 B-Eq-Comparison
weeks NCT03865108 390 395 I-Eq-Comparison
6 NCT03865108 396 397 I-Eq-Comparison
days NCT03865108 398 402 I-Eq-Comparison
based NCT03865108 403 408 O
on NCT03865108 409 411 O
clinical NCT03865108 412 420 O
information NCT03865108 421 432 O
and NCT03865108 433 436 O
evaluation NCT03865108 437 447 O
of NCT03865108 448 450 O
the NCT03865108 451 454 O
earliest NCT03865108 455 463 B-Eq-Comparison
ultrasound NCT03865108 464 474 B-Procedure
as NCT03865108 475 477 O
described NCT03865108 478 487 O
in NCT03865108 488 490 O
Gestational NCT03865108 491 502 B-Observation
Age NCT03865108 503 506 I-Observation
. NCT03865108 507 508 O

- NCT03865108 512 513 O
Cervical NCT03865108 515 523 B-Observation
length NCT03865108 524 530 I-Observation
on NCT03865108 531 533 O
transvaginal NCT03865108 534 546 B-Procedure
examination NCT03865108 547 558 I-Procedure
of NCT03865108 559 561 O
less NCT03865108 562 566 B-Eq-Comparison
than NCT03865108 567 571 I-Eq-Comparison
or NCT03865108 572 574 I-Eq-Comparison
equal NCT03865108 575 580 I-Eq-Comparison
to NCT03865108 581 583 I-Eq-Comparison
20 NCT03865108 584 586 I-Eq-Comparison
mm NCT03865108 587 589 I-Eq-Comparison
within NCT03865108 590 596 B-Eq-Comparison
10 NCT03865108 597 599 I-Eq-Comparison
days NCT03865108 600 604 I-Eq-Comparison
prior NCT03865108 605 610 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865108 611 613 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03865108 614 627 O
by NCT03865108 628 630 O
a NCT03865108 631 632 O
study NCT03865108 633 638 B-Study
certified NCT03865108 639 648 O
sonographer NCT03865108 649 660 B-Provider
. NCT03865108 660 661 O
There NCT03865108 663 668 O
is NCT03865108 669 671 O
no NCT03865108 672 674 B-Negation
lower NCT03865108 675 680 O
cervical NCT03865108 681 689 B-Observation
length NCT03865108 690 696 I-Observation
threshold NCT03865108 697 706 O
. NCT03865108 707 708 O

Exclusion NCT03865108 710 719 O
Criteria NCT03865108 720 728 O
: NCT03865108 729 730 O

- NCT03865108 734 735 O
Women NCT03865108 737 742 O
who NCT03865108 743 746 B-And
are NCT03865108 747 750 O
ineligible NCT03865108 751 761 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865108 762 765 O
the NCT03865108 766 769 O
TOPS NCT03865108 770 774 O
trial NCT03865108 775 780 O
. NCT03865108 780 781 O

Inclusion NCT03865134 0 9 O
Criteria NCT03865134 10 18 O
: NCT03865134 19 20 O

- NCT03865134 24 25 O
Age NCT03865134 27 30 B-Age
range NCT03865134 31 36 O
between NCT03865134 37 44 B-Eq-Comparison
2 NCT03865134 45 46 I-Eq-Comparison
- NCT03865134 47 48 I-Eq-Comparison
6 NCT03865134 49 50 I-Eq-Comparison
years NCT03865134 51 56 I-Eq-Comparison
of NCT03865134 57 59 O
age NCT03865134 60 63 O

- NCT03865134 66 67 O
Gestational NCT03865134 69 80 B-Observation
age NCT03865134 81 84 I-Observation
range NCT03865134 85 90 O
26 NCT03865134 91 93 B-Eq-Comparison
- NCT03865134 94 95 I-Eq-Comparison
34 NCT03865134 96 98 O
. NCT03865134 98 99 O
be NCT03865134 101 103 O
between NCT03865134 104 111 B-Eq-Comparison
weeks NCT03865134 112 117 I-Eq-Comparison

- NCT03865134 120 121 O
To NCT03865134 123 125 O
be NCT03865134 126 128 O
diagnosed NCT03865134 129 138 O
with NCT03865134 139 143 O
retinopathy NCT03865134 144 155 B-Condition
of NCT03865134 156 158 I-Condition
prematurity NCT03865134 159 170 I-Condition

- NCT03865134 173 174 O
Neurological NCT03865134 176 188 B-Modifier
, NCT03865134 189 190 O
hereditary NCT03865134 191 201 B-Modifier
and NCT03865134 202 205 B-Or
not NCT03865134 206 209 B-Negation
having NCT03865134 210 216 O
metabolic NCT03865134 217 226 B-Modifier
disease NCT03865134 227 234 B-Condition

- NCT03865134 237 238 O
Compliance NCT03865134 240 250 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03865134 251 255 I-Assertion___Assertion-Type-Value:hypothetical
visual NCT03865134 256 262 B-Procedure
examinations NCT03865134 263 275 I-Procedure
and NCT03865134 276 279 B-Or
physiotherapy NCT03865134 280 293 B-Procedure
evaluations NCT03865134 294 305 I-Procedure

- NCT03865134 308 309 O
To NCT03865134 311 313 O
be NCT03865134 314 316 O
children NCT03865134 317 325 O
and NCT03865134 326 329 O
parents NCT03865134 330 337 O
who NCT03865134 338 341 O
agree NCT03865134 342 347 O
to NCT03865134 348 350 O
participate NCT03865134 351 362 O
in NCT03865134 363 365 O
the NCT03865134 366 369 O
study NCT03865134 370 375 O

Exclusion NCT03865134 376 385 O
Criteria NCT03865134 386 394 O
: NCT03865134 395 396 O

- NCT03865134 400 401 O
To NCT03865134 403 405 O
be NCT03865134 406 408 O
a NCT03865134 409 410 O
child NCT03865134 411 416 O
who NCT03865134 417 420 B-And
does NCT03865134 421 425 O
not NCT03865134 426 429 B-Negation
comply NCT03865134 430 436 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03865134 437 441 I-Assertion___Assertion-Type-Value:hypothetical
Optical NCT03865134 442 449 B-Procedure
Kohlerans NCT03865134 450 459 I-Procedure
Tomography NCT03865134 460 470 I-Procedure
( NCT03865134 471 472 O
OCT NCT03865134 473 476 B-Procedure
) NCT03865134 477 478 O

- NCT03865134 482 483 O
Not NCT03865134 485 488 B-Negation
participating NCT03865134 489 502 B-Eq-Comparison
in NCT03865134 503 505 O
one NCT03865134 506 509 B-Eq-Comparison
or NCT03865134 510 512 I-Eq-Comparison
more NCT03865134 513 517 I-Eq-Comparison
of NCT03865134 518 520 O
the NCT03865134 521 524 O
eye NCT03865134 525 528 B-Procedure
examination NCT03865134 529 540 I-Procedure
or NCT03865134 541 543 B-Or
physiotherapy NCT03865134 544 557 B-Procedure
assessments NCT03865134 558 569 I-Procedure

- NCT03865134 572 573 O
Being NCT03865134 575 580 O
children NCT03865134 581 589 O
and NCT03865134 590 593 B-Or
parents NCT03865134 594 601 B-Family-Member___Family-Member-Type:parent
who NCT03865134 602 605 O
do NCT03865134 606 608 O
not NCT03865134 609 612 B-Negation
agree NCT03865134 613 618 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865134 619 621 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03865134 622 633 O
in NCT03865134 634 636 O
the NCT03865134 637 640 O
study NCT03865134 641 646 B-Study

Inclusion NCT03863223 0 9 O
Criteria NCT03863223 10 18 O
: NCT03863223 19 20 O

1 NCT03863223 24 25 O
. NCT03863223 25 26 O
HER2 NCT03863223 28 32 B-Modifier
positive NCT03863223 33 41 O
recurrent NCT03863223 42 51 B-Modifier
or NCT03863223 52 54 B-Or
metastasis NCT03863223 55 65 B-Modifier
breast NCT03863223 66 72 I-Modifier
cancer NCT03863223 73 79 B-Condition
. NCT03863223 80 81 O

2 NCT03863223 85 86 O
. NCT03863223 86 87 O
Patients NCT03863223 89 97 O
with NCT03863223 98 102 O
measurable NCT03863223 103 113 B-Modifier
disease NCT03863223 114 121 B-Condition
are NCT03863223 122 125 O
eligible NCT03863223 126 134 O
. NCT03863223 135 136 O

3 NCT03863223 140 141 O
. NCT03863223 141 142 O
Eastern NCT03863223 144 151 B-Observation
Cooperative NCT03863223 152 163 I-Observation
Oncology NCT03863223 164 172 I-Observation
Group NCT03863223 173 178 I-Observation
( NCT03863223 179 180 O
ECOG NCT03863223 181 185 B-Observation
) NCT03863223 186 187 O
performance NCT03863223 188 199 O
status NCT03863223 200 206 O
0 NCT03863223 207 208 B-Eq-Comparison
or NCT03863223 209 211 I-Eq-Comparison
1 NCT03863223 212 213 I-Eq-Comparison
. NCT03863223 213 214 O

4 NCT03863223 218 219 O
. NCT03863223 219 220 O
Adequate NCT03863223 222 230 O
organ NCT03863223 231 236 B-Condition
function NCT03863223 237 245 I-Condition
. NCT03863223 246 247 O

5 NCT03863223 251 252 O
. NCT03863223 252 253 O
Signed NCT03863223 255 261 O
, NCT03863223 262 263 O
written NCT03863223 264 271 O
inform NCT03863223 272 278 O
consent NCT03863223 279 286 O
obtained NCT03863223 287 295 O
prior NCT03863223 296 301 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863223 302 304 I-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03863223 305 308 O
study NCT03863223 309 314 B-Study
procedure NCT03863223 315 324 O
. NCT03863223 325 326 O

Exclusion NCT03863223 328 337 O
Criteria NCT03863223 338 346 O
: NCT03863223 347 348 O

1 NCT03863223 352 353 O
. NCT03863223 353 354 O
History NCT03863223 356 363 B-Eq-Comparison
of NCT03863223 364 366 O
anti NCT03863223 367 371 O
- NCT03863223 372 373 O
cancer NCT03863223 374 380 B-Condition
therapy NCT03863223 381 388 B-Procedure
for NCT03863223 389 392 O
MBC NCT03863223 393 396 B-Condition
（ NCT03863223 397 398 O
with NCT03863223 399 403 O
the NCT03863223 404 407 O
exception NCT03863223 408 417 B-Exception
of NCT03863223 418 420 O
one NCT03863223 421 424 B-Eq-Comparison
prior NCT03863223 425 430 B-Eq-Comparison
hormonal NCT03863223 431 439 B-Procedure
regimen NCT03863223 440 447 I-Procedure
for NCT03863223 448 451 O
MBC NCT03863223 452 455 B-Condition
） NCT03863223 455 456 O
. NCT03863223 457 458 O

2 NCT03863223 462 463 O
. NCT03863223 463 464 O
History NCT03863223 466 473 B-Eq-Comparison
of NCT03863223 474 476 O
HER NCT03863223 477 480 B-Modifier
tyrosine NCT03863223 481 489 B-Drug
kinase NCT03863223 490 496 I-Drug
inhibitors NCT03863223 497 507 I-Drug
or NCT03863223 508 510 B-Or
monoclonal NCT03863223 511 521 B-Drug
antibody NCT03863223 522 530 I-Drug
for NCT03863223 531 534 O
breast NCT03863223 535 541 B-Modifier
cancer NCT03863223 542 548 B-Condition
in NCT03863223 549 551 O
any NCT03863223 552 555 O
treatment NCT03863223 556 565 B-Procedure
setting NCT03863223 566 573 O
， NCT03863223 574 575 O
except NCT03863223 576 582 B-Exception
trastuzumab NCT03863223 583 594 B-Drug
used NCT03863223 595 599 O
in NCT03863223 600 602 O
the NCT03863223 603 606 O
neo NCT03863223 607 610 B-Modifier
- NCT03863223 611 612 I-Modifier
adjuvant NCT03863223 613 621 I-Modifier
or NCT03863223 622 624 B-Or
adjuvant NCT03863223 625 633 B-Modifier
setting NCT03863223 634 641 O
. NCT03863223 642 643 O

3 NCT03863223 647 648 O
. NCT03863223 648 649 O
Assessed NCT03863223 651 659 O
by NCT03863223 660 662 O
the NCT03863223 663 666 O
investigator NCT03863223 667 679 O
to NCT03863223 680 682 O
be NCT03863223 683 685 O
unable NCT03863223 686 692 B-Assertion___Assertion-Type-Value:hypothetical|Negation
receive NCT03863223 693 700 O
systemic NCT03863223 701 709 B-Modifier
chemotherapy NCT03863223 710 722 B-Procedure
. NCT03863223 723 724 O

4 NCT03863223 728 729 O
. NCT03863223 729 730 O
History NCT03863223 732 739 B-Eq-Comparison
of NCT03863223 740 742 O
other NCT03863223 743 748 B-Other
malignancy NCT03863223 749 759 B-Condition
within NCT03863223 760 766 B-Eq-Comparison
the NCT03863223 767 770 I-Eq-Comparison
last NCT03863223 771 775 I-Eq-Comparison
5 NCT03863223 776 777 I-Eq-Comparison
years NCT03863223 778 783 I-Eq-Comparison
， NCT03863223 784 785 O
except NCT03863223 786 792 B-Exception
for NCT03863223 793 796 O
carcinoma NCT03863223 797 806 B-Condition
in NCT03863223 807 809 O
situ NCT03863223 810 814 B-Modifier
of NCT03863223 815 817 I-Modifier
cervix NCT03863223 818 824 I-Modifier
， NCT03863223 825 826 O
basal NCT03863223 827 832 B-Modifier
cell NCT03863223 833 837 I-Modifier
carcinoma NCT03863223 838 847 I-Modifier
or NCT03863223 848 850 B-Or
squamous NCT03863223 851 859 B-Modifier
cell NCT03863223 860 864 I-Modifier
carcinoma NCT03863223 865 874 B-Condition
of NCT03863223 875 877 O
the NCT03863223 878 881 O
skin NCT03863223 882 886 B-Modifier
that NCT03863223 887 891 O
has NCT03863223 892 895 O
been NCT03863223 896 900 O
previously NCT03863223 901 911 B-Eq-Comparison
treated NCT03863223 912 919 B-Procedure
with NCT03863223 920 924 O
curative NCT03863223 925 933 B-Modifier
intent NCT03863223 934 940 I-Modifier
. NCT03863223 941 942 O

5 NCT03863223 946 947 O
. NCT03863223 947 948 O
Pregnant NCT03863223 950 958 B-Condition
or NCT03863223 959 961 B-Or
lactating NCT03863223 962 971 B-Condition
women NCT03863223 972 977 O
， NCT03863223 978 979 O
or NCT03863223 980 982 B-Or
for NCT03863223 983 986 O
women NCT03863223 987 992 O
of NCT03863223 993 995 O
childbearing NCT03863223 996 1008 B-Condition
potential NCT03863223 1009 1018 B-Assertion___Assertion-Type-Value:hypothetical
unwilling NCT03863223 1019 1028 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863223 1029 1031 I-Assertion___Assertion-Type-Value:hypothetical|Negation
use NCT03863223 1032 1035 O
a NCT03863223 1036 1037 O
highly NCT03863223 1038 1044 B-Modifier
- NCT03863223 1045 1046 I-Modifier
effective NCT03863223 1047 1056 I-Modifier
contraception NCT03863223 1057 1070 B-Procedure
during NCT03863223 1071 1077 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03863223 1078 1080 O
the NCT03863223 1081 1084 O
study NCT03863223 1085 1090 B-Study
treatment NCT03863223 1091 1100 B-Procedure
and NCT03863223 1101 1104 B-And
for NCT03863223 1105 1108 O
at NCT03863223 1109 1111 B-Eq-Comparison
least NCT03863223 1112 1117 I-Eq-Comparison
7 NCT03863223 1118 1119 I-Eq-Comparison
months NCT03863223 1120 1126 I-Eq-Comparison
after NCT03863223 1127 1132 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03863223 1133 1136 O
last NCT03863223 1137 1141 B-Eq-Comparison
dose NCT03863223 1142 1146 O
of NCT03863223 1147 1149 O
study NCT03863223 1150 1155 B-Study
treatment NCT03863223 1156 1165 B-Procedure
. NCT03863223 1165 1166 O

Inclusion NCT03867045 0 9 O
Criteria NCT03867045 10 18 O
: NCT03867045 19 20 O

Patients NCT03867045 22 30 O
> NCT03867045 31 32 B-Eq-Comparison
18 NCT03867045 33 35 I-Eq-Comparison
years NCT03867045 36 41 I-Eq-Comparison
of NCT03867045 42 44 O
age NCT03867045 45 48 B-Age
Patients NCT03867045 49 57 O
planning NCT03867045 58 66 B-Assertion___Assertion-Type-Value:intention
to NCT03867045 67 69 O
start NCT03867045 70 75 B-Eq-Comparison
treatment NCT03867045 76 85 B-Procedure
with NCT03867045 86 90 O
cabozantinib NCT03867045 91 103 B-Procedure
therapy NCT03867045 104 111 I-Procedure
for NCT03867045 112 115 O
renal NCT03867045 116 121 B-Modifier
cancer NCT03867045 122 128 B-Condition
. NCT03867045 129 130 O

Technology NCT03867045 132 142 O
requirement NCT03867045 143 154 O
: NCT03867045 155 156 O
The NCT03867045 157 160 O
patient NCT03867045 161 168 O
will NCT03867045 169 173 O
need NCT03867045 174 178 O
to NCT03867045 179 181 O
have NCT03867045 182 186 O
home NCT03867045 187 191 O
wireless NCT03867045 192 200 O
internet NCT03867045 201 209 O
access NCT03867045 210 216 O
for NCT03867045 217 220 O
use NCT03867045 221 224 O
of NCT03867045 225 227 O
the NCT03867045 228 231 O
software NCT03867045 232 240 O
and NCT03867045 241 244 O
technology NCT03867045 245 255 O
in NCT03867045 256 258 O
this NCT03867045 259 263 O
study NCT03867045 264 269 O
. NCT03867045 269 270 O
The NCT03867045 272 275 O
patient NCT03867045 276 283 O
will NCT03867045 284 288 O
need NCT03867045 289 293 O
to NCT03867045 294 296 O
already NCT03867045 297 304 O
have NCT03867045 305 309 O
or NCT03867045 310 312 O
be NCT03867045 313 315 O
willing NCT03867045 316 323 O
to NCT03867045 324 326 O
set NCT03867045 327 330 O
up NCT03867045 331 333 O
a NCT03867045 334 335 O
Duke NCT03867045 336 340 O
MyChart NCT03867045 341 348 O
account NCT03867045 349 356 O
. NCT03867045 357 358 O

Exclusion NCT03867045 360 369 O
Criteria NCT03867045 370 378 O
: NCT03867045 379 380 O

Non NCT03867045 382 385 B-Negation
- NCT03867045 386 387 O
English NCT03867045 388 395 O
Speaking NCT03867045 396 404 O
. NCT03867045 404 405 O
Any NCT03867045 407 410 O
patient NCT03867045 411 418 O
who NCT03867045 419 422 O
is NCT03867045 423 425 O
not NCT03867045 426 429 O
able NCT03867045 430 434 O
to NCT03867045 435 437 O
comprehend NCT03867045 438 448 O
and NCT03867045 449 452 O
operate NCT03867045 453 460 O
the NCT03867045 461 464 O
technology NCT03867045 465 475 O
at NCT03867045 476 478 O
the NCT03867045 479 482 O
discretion NCT03867045 483 493 O
of NCT03867045 494 496 O
the NCT03867045 497 500 O
enrolling NCT03867045 501 510 O
provider NCT03867045 511 519 O
. NCT03867045 520 521 O


Inclusion NCT03869281 0 9 O
Criteria NCT03869281 10 18 O
( NCT03869281 19 20 O
PTA NCT03869281 21 24 O
group NCT03869281 25 30 O
) NCT03869281 31 32 O

- NCT03869281 36 37 O
T1D NCT03869281 39 42 B-Condition
patients NCT03869281 43 51 O
who NCT03869281 52 55 B-And
received NCT03869281 56 64 B-Eq-Comparison
their NCT03869281 65 70 O
first NCT03869281 71 76 B-Eq-Comparison
PTA NCT03869281 77 80 B-Procedure
, NCT03869281 81 82 O
or NCT03869281 83 85 B-Or
second NCT03869281 86 92 B-Eq-Comparison
PTA NCT03869281 93 96 B-Procedure
only NCT03869281 97 101 B-And
if NCT03869281 102 104 I-And
their NCT03869281 105 110 O
first NCT03869281 111 116 B-Eq-Comparison
graft NCT03869281 117 122 B-Procedure
was NCT03869281 123 126 O
explanted NCT03869281 127 136 O
within NCT03869281 137 143 B-Eq-Comparison
a NCT03869281 144 145 I-Eq-Comparison
week NCT03869281 146 150 I-Eq-Comparison
, NCT03869281 151 152 O
between NCT03869281 153 160 B-Eq-Comparison
2 NCT03869281 161 162 I-Eq-Comparison
January NCT03869281 163 170 I-Eq-Comparison
2005 NCT03869281 171 175 I-Eq-Comparison
and NCT03869281 176 179 I-Eq-Comparison
31 NCT03869281 180 182 I-Eq-Comparison
December NCT03869281 183 191 I-Eq-Comparison
2017 NCT03869281 192 196 I-Eq-Comparison

- NCT03869281 200 201 O
age NCT03869281 203 206 B-Age
≥ NCT03869281 207 208 B-Eq-Comparison
18 NCT03869281 209 211 I-Eq-Comparison
and NCT03869281 212 215 B-And
< NCT03869281 216 217 B-Eq-Comparison
65 NCT03869281 218 220 I-Eq-Comparison
years NCT03869281 221 226 I-Eq-Comparison

- NCT03869281 229 230 O
willingness NCT03869281 232 243 O
to NCT03869281 244 246 O
participate NCT03869281 247 258 O
in NCT03869281 259 261 O
this NCT03869281 262 266 O
observational NCT03869281 267 280 O
study NCT03869281 281 286 O

Inclusion NCT03869281 287 296 O
Criteria NCT03869281 297 305 O
( NCT03869281 306 307 O
control NCT03869281 308 315 O
group NCT03869281 316 321 O
) NCT03869281 322 323 O

- NCT03869281 327 328 O
Type NCT03869281 330 334 B-Modifier
1 NCT03869281 335 336 I-Modifier
diabetes NCT03869281 337 345 B-Condition

- NCT03869281 348 349 O
age NCT03869281 351 354 B-Age
≥ NCT03869281 355 356 B-Eq-Comparison
18 NCT03869281 357 359 I-Eq-Comparison
years NCT03869281 360 365 I-Eq-Comparison
and NCT03869281 366 369 B-And
< NCT03869281 370 371 B-Eq-Comparison
65 NCT03869281 372 374 I-Eq-Comparison
years NCT03869281 375 380 I-Eq-Comparison

- NCT03869281 383 384 O
willingness NCT03869281 386 397 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869281 398 400 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03869281 401 412 O
in NCT03869281 413 415 O
this NCT03869281 416 420 O
observational NCT03869281 421 434 O
study NCT03869281 435 440 B-Study

- NCT03869281 443 444 O
minimum NCT03869281 446 453 O
disease NCT03869281 454 461 B-Condition
duration NCT03869281 462 470 O
of NCT03869281 471 473 O
5 NCT03869281 474 475 B-Eq-Comparison
years NCT03869281 476 481 I-Eq-Comparison

- NCT03869281 484 485 O
brittle NCT03869281 487 494 B-Condition
diabetes NCT03869281 495 503 I-Condition
, NCT03869281 504 505 O
as NCT03869281 506 508 O
defined NCT03869281 509 516 O
by NCT03869281 517 519 O
the NCT03869281 520 523 O
occurrence NCT03869281 524 534 O
of NCT03869281 535 537 O
frequent NCT03869281 538 546 B-Modifier
acute NCT03869281 547 552 O
complications NCT03869281 553 566 B-Condition
( NCT03869281 567 568 O
ketoacidosis NCT03869281 569 581 B-Condition
or NCT03869281 582 584 B-Or
severe NCT03869281 585 591 O
hypoglycaemic NCT03869281 592 605 B-Condition
episodes NCT03869281 606 614 O
requiring NCT03869281 615 624 O
third NCT03869281 625 630 B-Procedure
- NCT03869281 631 632 I-Procedure
part NCT03869281 633 637 I-Procedure
assistance NCT03869281 638 648 I-Procedure
or NCT03869281 649 651 B-Or
unawareness NCT03869281 652 663 B-Condition
despite NCT03869281 664 671 B-And
well NCT03869281 672 676 O
- NCT03869281 677 678 O
conducted NCT03869281 679 688 O
intensive NCT03869281 689 698 O
insulin NCT03869281 699 706 B-Procedure
therapy NCT03869281 707 714 I-Procedure
) NCT03869281 715 716 O

- NCT03869281 720 721 O
presence NCT03869281 723 731 O
of NCT03869281 732 734 O
at NCT03869281 735 737 B-Eq-Comparison
least NCT03869281 738 743 I-Eq-Comparison
one NCT03869281 744 747 I-Eq-Comparison
diabetes NCT03869281 748 756 B-Condition
- NCT03869281 757 758 O
related NCT03869281 759 766 O
complication NCT03869281 767 779 B-Condition
( NCT03869281 780 781 O
either NCT03869281 782 788 O
neuropathy NCT03869281 789 799 B-Condition
, NCT03869281 800 801 O
retinopathy NCT03869281 802 813 B-Condition
, NCT03869281 814 815 O
subclinical NCT03869281 816 827 B-Modifier
nephropathy NCT03869281 828 839 B-Condition
) NCT03869281 840 841 O
. NCT03869281 843 844 O

Exclusion NCT03869281 846 855 O
Criteria NCT03869281 856 864 O
( NCT03869281 865 866 O
both NCT03869281 867 871 O
groups NCT03869281 872 878 O
) NCT03869281 879 880 O

- NCT03869281 884 885 O
conditions NCT03869281 887 897 B-Condition
other NCT03869281 898 903 B-Exception
than NCT03869281 904 908 I-Exception
T1D NCT03869281 909 912 B-Condition
known NCT03869281 913 918 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869281 919 921 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869281 922 928 O
bone NCT03869281 929 933 B-Condition
health NCT03869281 934 940 I-Condition
( NCT03869281 941 942 O
i. NCT03869281 943 945 O
e. NCT03869281 946 948 O
, NCT03869281 949 950 O
non NCT03869281 951 954 B-Negation
- NCT03869281 955 956 O
compensated NCT03869281 957 968 B-Modifier
hypothyroidism NCT03869281 969 983 B-Condition
, NCT03869281 984 985 O
hyperthyroidism NCT03869281 986 1001 B-Condition
, NCT03869281 1002 1003 O
hyperparathyroidism NCT03869281 1004 1023 B-Condition
, NCT03869281 1024 1025 O
inflammatory NCT03869281 1026 1038 B-Condition
bowel NCT03869281 1039 1044 I-Condition
disease NCT03869281 1045 1052 I-Condition
, NCT03869281 1053 1054 O
malignancy NCT03869281 1055 1065 B-Condition
, NCT03869281 1066 1067 O
rheumatoid NCT03869281 1068 1078 B-Condition
arthritis NCT03869281 1079 1088 I-Condition
, NCT03869281 1089 1090 O
hypogonadism NCT03869281 1091 1103 B-Condition
, NCT03869281 1104 1105 O
severe NCT03869281 1106 1112 O
chronic NCT03869281 1113 1120 B-Modifier
obstructive NCT03869281 1121 1132 B-Condition
pulmonary NCT03869281 1133 1142 I-Condition
disease NCT03869281 1143 1150 I-Condition
, NCT03869281 1151 1152 O
hepatic NCT03869281 1153 1160 B-Condition
insufficiency NCT03869281 1161 1174 I-Condition
, NCT03869281 1175 1176 O
alcohol NCT03869281 1177 1184 B-Observation
intake NCT03869281 1185 1191 I-Observation
≥ NCT03869281 1192 1193 B-Eq-Comparison
3 NCT03869281 1194 1195 I-Eq-Comparison
units NCT03869281 1196 1201 I-Eq-Comparison
/ NCT03869281 1202 1203 I-Eq-Comparison
day NCT03869281 1204 1207 I-Eq-Comparison
) NCT03869281 1208 1209 O
, NCT03869281 1211 1212 O

- NCT03869281 1216 1217 O
use NCT03869281 1219 1222 B-Eq-Comparison
of NCT03869281 1223 1225 O
drugs NCT03869281 1226 1231 B-Drug
that NCT03869281 1232 1236 O
can NCT03869281 1237 1240 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869281 1241 1247 O
bone NCT03869281 1248 1252 B-Condition
metabolism NCT03869281 1253 1263 I-Condition
( NCT03869281 1264 1265 O
e. NCT03869281 1266 1268 O
g. NCT03869281 1269 1271 O
, NCT03869281 1272 1273 O
bisphosphonates NCT03869281 1274 1289 B-Drug
, NCT03869281 1290 1291 O
anticonvulsants NCT03869281 1292 1307 B-Drug
, NCT03869281 1308 1309 O
hormone NCT03869281 1310 1317 B-Procedure
replacement NCT03869281 1318 1329 I-Procedure
therapy NCT03869281 1330 1337 I-Procedure
) NCT03869281 1338 1339 O
other NCT03869281 1340 1345 B-Exception
than NCT03869281 1346 1350 I-Exception
glucocorticoids NCT03869281 1351 1366 B-Drug
and NCT03869281 1367 1370 B-Or
immunosuppressants NCT03869281 1371 1389 B-Drug

- NCT03869281 1392 1393 O
recipients NCT03869281 1395 1405 O
of NCT03869281 1406 1408 O
simultaneous NCT03869281 1409 1421 B-Modifier
pancreas NCT03869281 1422 1430 B-Procedure
kidney NCT03869281 1431 1437 I-Procedure
transplantation NCT03869281 1438 1453 I-Procedure
, NCT03869281 1454 1455 O
pancreatic NCT03869281 1456 1466 B-Procedure
islet NCT03869281 1467 1472 I-Procedure
transplantation NCT03869281 1473 1488 I-Procedure
, NCT03869281 1489 1490 O
multiple NCT03869281 1491 1499 B-Modifier
PTAs NCT03869281 1500 1504 B-Procedure
, NCT03869281 1505 1506 O
other NCT03869281 1507 1512 B-Other
transplants NCT03869281 1513 1524 B-Procedure

- NCT03869281 1527 1528 O
BMI NCT03869281 1530 1533 B-Observation
< NCT03869281 1534 1535 B-Eq-Comparison
18.5 NCT03869281 1536 1540 I-Eq-Comparison
or NCT03869281 1541 1543 B-Or
≥ NCT03869281 1544 1545 B-Eq-Comparison
30 NCT03869281 1546 1548 I-Eq-Comparison
kg NCT03869281 1549 1551 I-Eq-Comparison
/ NCT03869281 1552 1553 I-Eq-Comparison
m2 NCT03869281 1554 1556 I-Eq-Comparison

Inclusion NCT03866824 0 9 O
Criteria NCT03866824 10 18 O
: NCT03866824 19 20 O

Men NCT03866824 22 25 O
and NCT03866824 26 29 B-Or
women NCT03866824 30 35 O
aged NCT03866824 36 40 B-Age
20 NCT03866824 41 43 B-Eq-Comparison
to NCT03866824 44 46 I-Eq-Comparison
80 NCT03866824 47 49 I-Eq-Comparison

- NCT03866824 53 54 O
MDD NCT03866824 56 59 B-Condition
diagnosis NCT03866824 60 69 O
objected NCT03866824 70 78 O
to NCT03866824 79 81 O
MRI NCT03866824 82 85 B-Procedure
( NCT03866824 86 87 O
grade NCT03866824 88 93 B-Eq-Comparison
II NCT03866824 94 96 I-Eq-Comparison
/ NCT03866824 97 98 I-Eq-Comparison
III NCT03866824 99 102 I-Eq-Comparison
) NCT03866824 103 104 O

- NCT03866824 108 109 O
Joint NCT03866824 111 116 B-Modifier
pain NCT03866824 117 121 B-Condition
for NCT03866824 122 125 O
more NCT03866824 126 130 B-Eq-Comparison
than NCT03866824 131 135 I-Eq-Comparison
3 NCT03866824 136 137 I-Eq-Comparison
month NCT03866824 138 143 I-Eq-Comparison

- NCT03866824 146 147 O
Absence NCT03866824 149 156 B-Negation
of NCT03866824 157 159 O
bone NCT03866824 160 164 B-Modifier
lesion NCT03866824 165 171 B-Condition
or NCT03866824 172 174 B-Or
moderate NCT03866824 175 183 O
knee NCT03866824 184 188 B-Modifier
osteoarthritis NCT03866824 189 203 B-Condition
stage NCT03866824 204 209 B-Eq-Comparison
< NCT03866824 210 211 I-Eq-Comparison
2 NCT03866824 212 213 I-Eq-Comparison
on NCT03866824 214 216 O
the NCT03866824 217 220 O
Kellgren NCT03866824 221 229 B-Observation
Laurence NCT03866824 230 238 I-Observation
scale NCT03866824 239 244 I-Observation
( NCT03866824 245 246 O
objectified NCT03866824 247 258 O
on NCT03866824 259 261 O
radiography NCT03866824 262 273 B-Procedure
in NCT03866824 274 276 O
schuss NCT03866824 277 283 B-Modifier
) NCT03866824 284 285 O
in NCT03866824 286 288 O
the NCT03866824 289 292 O
6 NCT03866824 293 294 B-Eq-Comparison
months NCT03866824 295 301 I-Eq-Comparison
prior NCT03866824 302 307 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866824 308 310 I-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03866824 311 320 B-Study

- NCT03866824 323 324 O
Axial NCT03866824 326 331 B-Condition|Observation
deformity NCT03866824 332 341 I-Condition|Observation
of NCT03866824 342 344 O
the NCT03866824 345 348 O
lower NCT03866824 349 354 B-Modifier
limbs NCT03866824 355 360 I-Modifier
less NCT03866824 361 365 B-Eq-Comparison
than NCT03866824 366 370 I-Eq-Comparison
or NCT03866824 371 373 I-Eq-Comparison
equal NCT03866824 374 379 I-Eq-Comparison
to NCT03866824 380 382 I-Eq-Comparison
5 NCT03866824 383 384 I-Eq-Comparison
° NCT03866824 385 386 I-Eq-Comparison

- NCT03866824 389 390 O
Signed NCT03866824 392 398 O
consent NCT03866824 399 406 O
signed NCT03866824 407 413 O
by NCT03866824 414 416 O
the NCT03866824 417 420 O
patient NCT03866824 421 428 O

- NCT03866824 431 432 O
Ability NCT03866824 434 441 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866824 442 444 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03866824 445 452 O
procedures NCT03866824 453 463 B-Procedure
as NCT03866824 464 466 O
part NCT03866824 467 471 O
of NCT03866824 472 474 O
the NCT03866824 475 478 O
follow NCT03866824 479 485 B-Encounter
- NCT03866824 486 487 I-Encounter
up NCT03866824 488 490 I-Encounter
( NCT03866824 491 492 O
walk NCT03866824 493 497 B-Observation
50 NCT03866824 498 500 B-Eq-Comparison
steps NCT03866824 501 506 I-Eq-Comparison
on NCT03866824 507 509 O
a NCT03866824 510 511 O
flat NCT03866824 512 516 B-Modifier
surface NCT03866824 517 524 I-Modifier
and NCT03866824 525 528 B-Or
up NCT03866824 529 531 B-Modifier
/ NCT03866824 532 533 B-Or
down NCT03866824 534 538 B-Modifier
stairs NCT03866824 539 545 I-Modifier
) NCT03866824 546 547 O
. NCT03866824 549 550 O

- NCT03866824 554 555 O
Be NCT03866824 557 559 O
affiliated NCT03866824 560 570 O
to NCT03866824 571 573 O
a NCT03866824 574 575 O
health NCT03866824 576 582 O
insurance NCT03866824 583 592 O
scheme NCT03866824 593 599 O

Exclusion NCT03866824 600 609 O
Criteria NCT03866824 610 618 O
: NCT03866824 619 620 O

- NCT03866824 624 625 O
Axial NCT03866824 627 632 B-Condition|Observation
deformity NCT03866824 633 642 I-Condition|Observation
> NCT03866824 643 644 B-Eq-Comparison
5 NCT03866824 645 646 I-Eq-Comparison
° NCT03866824 647 648 I-Eq-Comparison

- NCT03866824 651 652 O
Ligament NCT03866824 654 662 B-Condition
instability NCT03866824 663 674 I-Condition

- NCT03866824 677 678 O
Major NCT03866824 680 685 O
injuries NCT03866824 686 694 B-Condition
or NCT03866824 695 697 B-Or
surgery NCT03866824 698 705 B-Procedure
of NCT03866824 706 708 O
the NCT03866824 709 712 O
target NCT03866824 713 719 B-Modifier
knee NCT03866824 720 724 I-Modifier
or NCT03866824 725 727 B-Or
lateral NCT03866824 728 735 B-Modifier
contralateral NCT03866824 736 749 I-Modifier
knee NCT03866824 750 754 I-Modifier
in NCT03866824 755 757 O
the NCT03866824 758 761 O
12 NCT03866824 762 764 B-Eq-Comparison
months NCT03866824 765 771 I-Eq-Comparison
preceding NCT03866824 772 781 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866824 782 785 O
inclusion NCT03866824 786 795 B-Study
visit NCT03866824 796 801 O

- NCT03866824 804 805 O
Ligament NCT03866824 807 815 B-Procedure
reconstruction NCT03866824 816 830 I-Procedure
in NCT03866824 831 833 O
the NCT03866824 834 837 O
12 NCT03866824 838 840 B-Eq-Comparison
months NCT03866824 841 847 I-Eq-Comparison
prior NCT03866824 848 853 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866824 854 856 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866824 857 860 O
inclusion NCT03866824 861 870 B-Study
visit NCT03866824 871 876 O

- NCT03866824 879 880 O
Need NCT03866824 882 886 O
a NCT03866824 887 888 O
cane NCT03866824 889 893 B-Modifier
or NCT03866824 894 896 B-Or
assistance NCT03866824 897 907 B-Modifier
to NCT03866824 908 910 O
move NCT03866824 911 915 B-Condition

- NCT03866824 918 919 O
BMI NCT03866824 921 924 B-Observation
> NCT03866824 925 926 B-Eq-Comparison
35 NCT03866824 927 929 I-Eq-Comparison

- NCT03866824 933 934 O
Thrombocytopenia NCT03866824 936 952 B-Condition|Observation
< NCT03866824 953 954 B-Eq-Comparison
150 NCT03866824 955 958 I-Eq-Comparison
G NCT03866824 959 960 I-Eq-Comparison
/ NCT03866824 961 962 I-Eq-Comparison
L NCT03866824 963 964 I-Eq-Comparison

- NCT03866824 967 968 O
Thrombocytosis NCT03866824 970 984 B-Condition|Observation
> NCT03866824 985 986 B-Eq-Comparison
450 NCT03866824 987 990 I-Eq-Comparison
G NCT03866824 991 992 I-Eq-Comparison
/ NCT03866824 993 994 I-Eq-Comparison
L NCT03866824 995 996 I-Eq-Comparison

Inclusion NCT03866603 0 9 O
Criteria NCT03866603 10 18 O
: NCT03866603 19 20 O

- NCT03866603 24 25 O
Informed NCT03866603 27 35 O
consent NCT03866603 36 43 O
is NCT03866603 44 46 O
obtained NCT03866603 47 55 O
from NCT03866603 56 60 O
the NCT03866603 61 64 O
participant NCT03866603 65 76 O
. NCT03866603 77 78 O

- NCT03866603 82 83 O
The NCT03866603 85 88 O
participant NCT03866603 89 100 O
is NCT03866603 101 103 O
clinically NCT03866603 104 114 O
diagnosed NCT03866603 115 124 O
with NCT03866603 125 129 O
Parkinson NCT03866603 130 139 B-Condition
's NCT03866603 139 141 I-Condition
disease NCT03866603 142 149 I-Condition
or NCT03866603 150 152 B-Or
the NCT03866603 153 156 O
individual NCT03866603 157 167 O
is NCT03866603 168 170 O
a NCT03866603 171 172 O
family NCT03866603 173 179 B-Family-Member
member NCT03866603 180 186 I-Family-Member
of NCT03866603 187 189 O
a NCT03866603 190 191 O
participant NCT03866603 192 203 O
with NCT03866603 204 208 O
LRRK2 NCT03866603 209 214 B-Modifier
parkinsonism NCT03866603 215 227 B-Condition
or NCT03866603 228 230 B-Or
is NCT03866603 231 233 O
a NCT03866603 234 235 O
member NCT03866603 236 242 O
of NCT03866603 243 245 O
a NCT03866603 246 247 O
high NCT03866603 248 252 O
risk NCT03866603 253 257 B-Risk
population NCT03866603 258 268 O
with NCT03866603 269 273 O
an NCT03866603 274 276 O
early NCT03866603 277 282 B-Modifier
PD NCT03866603 283 285 B-Condition
onset NCT03866603 286 291 B-Eq-Comparison
. NCT03866603 292 293 O

- NCT03866603 297 298 O
The NCT03866603 300 303 O
participant NCT03866603 304 315 O
is NCT03866603 316 318 O
equal NCT03866603 319 324 B-Eq-Comparison
to NCT03866603 325 327 I-Eq-Comparison
or NCT03866603 328 330 I-Eq-Comparison
older NCT03866603 331 336 I-Eq-Comparison
than NCT03866603 337 341 I-Eq-Comparison
18 NCT03866603 342 344 I-Eq-Comparison
years NCT03866603 345 350 I-Eq-Comparison
old NCT03866603 351 354 B-Age
. NCT03866603 355 356 O

Exclusion NCT03866603 358 367 O
Criteria NCT03866603 368 376 O
: NCT03866603 377 378 O

- NCT03866603 382 383 O
Inability NCT03866603 385 394 O
to NCT03866603 395 397 O
provide NCT03866603 398 405 O
informed NCT03866603 406 414 O
consent NCT03866603 415 422 O
. NCT03866603 423 424 O

- NCT03866603 428 429 O
The NCT03866603 431 434 O
participant NCT03866603 435 446 O
is NCT03866603 447 449 O
not NCT03866603 450 453 B-Negation
suffering NCT03866603 454 463 O
from NCT03866603 464 468 O
Parkinson NCT03866603 469 478 B-Condition
's NCT03866603 478 480 I-Condition
disease NCT03866603 481 488 I-Condition
or NCT03866603 489 491 B-Or
the NCT03866603 492 495 O
individual NCT03866603 496 506 O
is NCT03866603 507 509 O
not NCT03866603 510 513 B-Negation
a NCT03866603 514 515 O
family NCT03866603 516 522 B-Family-Member
member NCT03866603 523 529 I-Family-Member
of NCT03866603 530 532 O
a NCT03866603 533 534 O
participant NCT03866603 535 546 O
with NCT03866603 547 551 O
LRRK2 NCT03866603 552 557 B-Modifier
parkinsonism NCT03866603 558 570 B-Condition
or NCT03866603 571 573 B-Or
is NCT03866603 574 576 O
not NCT03866603 577 580 B-Negation
a NCT03866603 581 582 O
member NCT03866603 583 589 O
of NCT03866603 590 592 O
a NCT03866603 593 594 O
high NCT03866603 595 599 O
risk NCT03866603 600 604 B-Risk
population NCT03866603 605 615 O
. NCT03866603 616 617 O

- NCT03866603 621 622 O
The NCT03866603 624 627 O
participant NCT03866603 628 639 O
is NCT03866603 640 642 O
younger NCT03866603 643 650 B-Eq-Comparison
than NCT03866603 651 655 I-Eq-Comparison
18 NCT03866603 656 658 I-Eq-Comparison
years NCT03866603 659 664 I-Eq-Comparison
old NCT03866603 665 668 B-Age
. NCT03866603 669 670 O

- NCT03866603 674 675 O
Previously NCT03866603 677 687 B-Eq-Comparison
enrolled NCT03866603 688 696 O
in NCT03866603 697 699 O
the NCT03866603 700 703 O
study NCT03866603 704 709 B-Study
. NCT03866603 710 711 O

- NCT03866603 715 716 O
Participant NCT03866603 718 729 O
in NCT03866603 730 732 B-Observation
custody NCT03866603 733 740 I-Observation
. NCT03866603 740 741 O

Inclusion NCT03866941 0 9 O
Criteria NCT03866941 10 18 O
: NCT03866941 19 20 O

1 NCT03866941 24 25 O
. NCT03866941 25 26 O
All NCT03866941 28 31 O
the NCT03866941 32 35 O
cases NCT03866941 36 41 O
with NCT03866941 42 46 O
the NCT03866941 47 50 O
primary NCT03866941 51 58 O
diagnosis NCT03866941 59 68 O
of NCT03866941 69 71 O
acute NCT03866941 72 77 O
or NCT03866941 78 80 B-Or
chronic NCT03866941 81 88 B-Modifier
synthetic NCT03866941 89 98 B-Condition
cannabinoids NCT03866941 99 111 I-Condition
toxicity NCT03866941 112 120 I-Condition
will NCT03866941 121 125 O
be NCT03866941 126 128 O
included NCT03866941 129 137 O
in NCT03866941 138 140 O
the NCT03866941 141 144 O
study NCT03866941 145 150 B-Study
. NCT03866941 151 152 O

2 NCT03866941 156 157 O
. NCT03866941 157 158 O
Willing NCT03866941 160 167 O
and NCT03866941 168 171 O
able NCT03866941 172 176 O
to NCT03866941 177 179 O
comply NCT03866941 180 186 O
with NCT03866941 187 191 O
the NCT03866941 192 195 O
study NCT03866941 196 201 O
procedures NCT03866941 202 212 O
and NCT03866941 213 216 O
provide NCT03866941 217 224 O
written NCT03866941 225 232 O
informed NCT03866941 233 241 O
consent NCT03866941 242 249 O
to NCT03866941 250 252 O
participate NCT03866941 253 264 O
in NCT03866941 265 267 O
the NCT03866941 268 271 O
study NCT03866941 272 277 B-Study
. NCT03866941 278 279 O

Exclusion NCT03866941 281 290 O
Criteria NCT03866941 291 299 O
: NCT03866941 300 301 O

- NCT03866941 305 306 O
1 NCT03866941 308 309 O
- NCT03866941 310 311 O
Patients NCT03866941 312 320 O
with NCT03866941 321 325 O
a NCT03866941 326 327 O
history NCT03866941 328 335 B-Eq-Comparison
of NCT03866941 336 338 O
any NCT03866941 339 342 O
chronic NCT03866941 343 350 B-Modifier
disease NCT03866941 351 358 B-Condition
( NCT03866941 359 360 O
renal NCT03866941 361 366 B-Modifier
and NCT03866941 367 370 B-Or
hepatic NCT03866941 371 378 B-Modifier
) NCT03866941 379 380 O
. NCT03866941 381 382 O
2 NCT03866941 384 385 O
- NCT03866941 386 387 O
Patients NCT03866941 388 396 O
refuse NCT03866941 397 403 O
to NCT03866941 404 406 O
participate NCT03866941 407 418 O
in NCT03866941 419 421 O
the NCT03866941 422 425 O
study NCT03866941 426 431 O
. NCT03866941 431 432 O
3 NCT03866941 434 435 O
- NCT03866941 436 437 O
Abuse NCT03866941 438 443 B-Condition
to NCT03866941 444 446 O
other NCT03866941 447 452 B-Other
drugs NCT03866941 453 458 B-Drug
. NCT03866941 458 459 O

Inclusion NCT03864159 0 9 O
Criteria NCT03864159 10 18 O
: NCT03864159 19 20 O

- NCT03864159 24 25 O
Age NCT03864159 27 30 B-Age
between NCT03864159 31 38 B-Eq-Comparison
18 NCT03864159 39 41 I-Eq-Comparison
to NCT03864159 42 44 I-Eq-Comparison
25 NCT03864159 45 47 I-Eq-Comparison
years NCT03864159 48 53 I-Eq-Comparison

- NCT03864159 56 57 O
Amateur NCT03864159 59 66 B-Observation
basketball NCT03864159 67 77 I-Observation
players NCT03864159 78 85 I-Observation

- NCT03864159 88 89 O
Belong NCT03864159 91 97 O
to NCT03864159 98 100 O
the NCT03864159 101 104 O
Celeste NCT03864159 105 112 O
club NCT03864159 113 117 O

- NCT03864159 120 121 O
Not NCT03864159 123 126 B-Negation
having NCT03864159 127 133 O
any NCT03864159 134 137 O
injury NCT03864159 138 144 B-Condition
to NCT03864159 145 147 O
the NCT03864159 148 151 O
hamstring NCT03864159 152 161 B-Modifier
musculature NCT03864159 162 173 I-Modifier
at NCT03864159 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864159 177 180 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864159 181 185 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864159 186 188 O
the NCT03864159 189 192 O
study NCT03864159 193 198 B-Study

Exclusion NCT03864159 199 208 O
Criteria NCT03864159 209 217 O
: NCT03864159 218 219 O

- NCT03864159 223 224 O
At NCT03864159 226 228 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864159 229 232 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864159 233 237 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864159 238 240 O
the NCT03864159 241 244 O
study NCT03864159 245 250 B-Study
they NCT03864159 251 255 O
are NCT03864159 256 259 O
included NCT03864159 260 268 O
in NCT03864159 269 271 O
a NCT03864159 272 273 O
program NCT03864159 274 281 B-Procedure
of NCT03864159 282 284 I-Procedure
individualized NCT03864159 285 299 I-Procedure
strength NCT03864159 300 308 I-Procedure
training NCT03864159 309 317 I-Procedure
in NCT03864159 318 320 O
lower NCT03864159 321 326 B-Modifier
limbs NCT03864159 327 332 I-Modifier

- NCT03864159 335 336 O
Subjects NCT03864159 338 346 O
with NCT03864159 347 351 O
alterations NCT03864159 352 363 B-Condition
in NCT03864159 364 366 O
venous NCT03864159 367 373 B-Modifier
return NCT03864159 374 380 I-Modifier
or NCT03864159 381 383 B-Or
congenital NCT03864159 384 394 B-Modifier
coagulopathies NCT03864159 395 409 B-Condition

- NCT03864159 412 413 O
Subjects NCT03864159 415 423 O
who NCT03864159 424 427 O
present NCT03864159 428 435 O
hypermobility NCT03864159 436 449 B-Condition

- NCT03864159 452 453 O
Not NCT03864159 455 458 O
signed NCT03864159 459 465 O
the NCT03864159 466 469 O
informed NCT03864159 470 478 O
consent NCT03864159 479 486 O
document NCT03864159 487 495 O

Inclusion NCT03866772 0 9 O
Criteria NCT03866772 10 18 O
: NCT03866772 19 20 O

- NCT03866772 24 25 O
unfavourable NCT03866772 27 39 B-Condition
cervix NCT03866772 40 46 I-Condition
( NCT03866772 47 48 O
Bishop NCT03866772 49 55 B-Observation
score NCT03866772 56 61 I-Observation
≤ NCT03866772 62 63 B-Eq-Comparison
4 NCT03866772 64 65 I-Eq-Comparison
) NCT03866772 66 67 O
, NCT03866772 69 70 O

- NCT03866772 74 75 O
indication NCT03866772 77 87 B-Indication
for NCT03866772 88 91 O
induction NCT03866772 92 101 B-Procedure
of NCT03866772 102 104 I-Procedure
labor NCT03866772 105 110 I-Procedure
( NCT03866772 111 112 O
medical NCT03866772 113 120 B-Modifier
or NCT03866772 121 123 B-Or
obstetrical NCT03866772 124 135 B-Modifier
) NCT03866772 136 137 O
, NCT03866772 139 140 O

- NCT03866772 144 145 O
37 NCT03866772 147 149 B-Eq-Comparison
completed NCT03866772 150 159 O
gestational NCT03866772 160 171 B-Observation
weeks NCT03866772 172 177 O
, NCT03866772 178 179 O

- NCT03866772 183 184 O
vertex NCT03866772 186 192 B-Condition
presentation NCT03866772 193 205 I-Condition
, NCT03866772 206 207 O

- NCT03866772 211 212 O
singleton NCT03866772 214 223 B-Modifier
pregnancy NCT03866772 224 233 B-Condition

- NCT03866772 236 237 O
intact NCT03866772 239 245 B-Condition
membranes NCT03866772 246 255 I-Condition
. NCT03866772 256 257 O

Exclusion NCT03866772 259 268 O
Criteria NCT03866772 269 277 O
: NCT03866772 278 279 O

- NCT03866772 283 284 O
previous NCT03866772 286 294 B-Eq-Comparison
cesarean NCT03866772 295 303 B-Procedure
delivery NCT03866772 304 312 I-Procedure

- NCT03866772 315 316 O
previous NCT03866772 318 326 B-Eq-Comparison
uterine NCT03866772 327 334 B-Procedure
surgery NCT03866772 335 342 I-Procedure
( NCT03866772 343 344 O
eg NCT03866772 345 347 O
: NCT03866772 348 349 O
myomectomy NCT03866772 350 360 B-Procedure
) NCT03866772 361 362 O

- NCT03866772 366 367 O
noncephalic NCT03866772 369 380 B-Condition
presentation NCT03866772 381 393 I-Condition

- NCT03866772 396 397 O
multiple NCT03866772 399 407 B-Eq-Comparison
pregnancy NCT03866772 408 417 B-Condition

- NCT03866772 420 421 O
pre NCT03866772 423 426 B-Condition
- NCT03866772 427 428 I-Condition
eclampsia NCT03866772 429 438 I-Condition
with NCT03866772 439 443 O
severe NCT03866772 444 450 O
features NCT03866772 451 459 B-Modifier

- NCT03866772 462 463 O
oligohydramnios NCT03866772 465 480 B-Condition
( NCT03866772 481 482 O
Maximal NCT03866772 483 490 B-Observation
vertical NCT03866772 491 499 I-Observation
pocket NCT03866772 500 506 I-Observation
≤ NCT03866772 507 508 B-Eq-Comparison
2 NCT03866772 509 510 I-Eq-Comparison
) NCT03866772 511 512 O

- NCT03866772 516 517 O
estimated NCT03866772 519 528 B-Modifier
fetal NCT03866772 529 534 B-Family-Member___Family-Member-Type:child
weight NCT03866772 535 541 B-Observation
< NCT03866772 542 543 B-Eq-Comparison
10 NCT03866772 544 546 I-Eq-Comparison
% NCT03866772 547 548 I-Eq-Comparison
percentile NCT03866772 549 559 I-Eq-Comparison

- NCT03866772 562 563 O
any NCT03866772 565 568 O
contraindication NCT03866772 569 585 B-Contraindication
to NCT03866772 586 588 O
Vaginal NCT03866772 589 596 B-Procedure
delivery NCT03866772 597 605 I-Procedure

Inclusion NCT03866564 0 9 O
Criteria NCT03866564 10 18 O
: NCT03866564 19 20 O

- NCT03866564 24 25 O
Age NCT03866564 27 30 B-Age
24 NCT03866564 31 33 B-Eq-Comparison
- NCT03866564 34 35 I-Eq-Comparison
55 NCT03866564 36 38 O

- NCT03866564 42 43 O
Former NCT03866564 45 51 B-Eq-Comparison
professional NCT03866564 52 64 B-Observation
football NCT03866564 65 73 I-Observation
play NCT03866564 74 78 I-Observation
from NCT03866564 79 83 O
1960 NCT03866564 84 88 B-Eq-Comparison
to NCT03866564 89 91 I-Eq-Comparison
present NCT03866564 92 99 I-Eq-Comparison
. NCT03866564 100 101 O

- NCT03866564 105 106 O
Prior NCT03866564 108 113 B-Eq-Comparison
completed NCT03866564 114 123 O
the NCT03866564 124 127 O
first NCT03866564 128 133 B-Eq-Comparison
Health NCT03866564 134 140 B-Observation
and NCT03866564 141 144 I-Observation
Wellness NCT03866564 145 153 I-Observation
Questionnaire NCT03866564 154 167 I-Observation
( NCT03866564 168 169 O
Q1 NCT03866564 170 172 B-Observation
) NCT03866564 173 174 O

- NCT03866564 178 179 O
" NCT03866564 181 182 O
Healthy NCT03866564 182 189 O
" NCT03866564 189 190 O
subjects NCT03866564 191 199 O
: NCT03866564 200 201 O
ability NCT03866564 202 209 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866564 210 212 I-Assertion___Assertion-Type-Value:hypothetical
give NCT03866564 213 217 O
informed NCT03866564 218 226 O
consent NCT03866564 227 234 O
, NCT03866564 235 236 O
comply NCT03866564 237 243 O
with NCT03866564 244 248 O
study NCT03866564 249 254 O
procedures NCT03866564 255 265 O
, NCT03866564 266 267 O
and NCT03866564 268 271 O
have NCT03866564 272 276 O
a NCT03866564 277 278 O
Telephone NCT03866564 279 288 B-Observation
- NCT03866564 289 290 I-Observation
Montreal NCT03866564 291 299 I-Observation
Cognitive NCT03866564 300 309 I-Observation
Assessment NCT03866564 310 320 I-Observation
( NCT03866564 321 322 O
T NCT03866564 323 324 B-Observation
- NCT03866564 325 326 I-Observation
MoCA NCT03866564 327 331 I-Observation
) NCT03866564 332 333 O
score NCT03866564 334 339 O
of NCT03866564 340 342 O
> NCT03866564 343 344 B-Eq-Comparison
20 NCT03866564 345 347 I-Eq-Comparison
. NCT03866564 347 348 O

- NCT03866564 352 353 O
" NCT03866564 355 356 O
Afflicted NCT03866564 356 365 O
" NCT03866564 365 366 O
participants NCT03866564 367 379 O
: NCT03866564 380 381 O
must NCT03866564 382 386 O
meet NCT03866564 387 391 O
criteria NCT03866564 392 400 O
for NCT03866564 401 404 O
at NCT03866564 405 407 B-Eq-Comparison
least NCT03866564 408 413 I-Eq-Comparison
one NCT03866564 414 417 I-Eq-Comparison
of NCT03866564 418 420 O
the NCT03866564 421 424 B-Criteria-Count
following NCT03866564 425 434 I-Criteria-Count
subjective NCT03866564 435 445 B-Condition
afflictions NCT03866564 446 457 I-Condition
based NCT03866564 458 463 O
on NCT03866564 464 466 O
Q1 NCT03866564 467 469 B-Observation
responses NCT03866564 470 479 O
: NCT03866564 480 481 O
1 NCT03866564 482 483 O
) NCT03866564 484 485 O
Cardiovascular NCT03866564 486 500 B-Condition
Dysfunction NCT03866564 501 512 I-Condition
, NCT03866564 513 514 O
2 NCT03866564 515 516 O
) NCT03866564 517 518 O
Neurocognitive NCT03866564 519 533 B-Condition
Disease NCT03866564 534 541 I-Condition
, NCT03866564 542 543 O
3 NCT03866564 544 545 O
) NCT03866564 546 547 O
Chronic NCT03866564 548 555 B-Modifier
Pain NCT03866564 556 560 B-Condition
, NCT03866564 561 562 O
and NCT03866564 563 566 O
/ NCT03866564 567 568 O
or NCT03866564 569 571 O
4 NCT03866564 572 573 O
) NCT03866564 574 575 O
Sleep NCT03866564 576 581 B-Condition
Apnea NCT03866564 582 587 I-Condition

- NCT03866564 590 591 O
" NCT03866564 593 594 O
Afflicted NCT03866564 594 603 O
" NCT03866564 603 604 O
participants NCT03866564 605 617 O
must NCT03866564 618 622 O
be NCT03866564 623 625 O
able NCT03866564 626 630 O
to NCT03866564 631 633 O
give NCT03866564 634 638 O
informed NCT03866564 639 647 O
consent NCT03866564 648 655 O
or NCT03866564 656 658 O
have NCT03866564 659 663 O
a NCT03866564 664 665 O
legal NCT03866564 666 671 O
guardian NCT03866564 672 680 O
present NCT03866564 681 688 O
to NCT03866564 689 691 O
provide NCT03866564 692 699 O
informed NCT03866564 700 708 O
consent NCT03866564 709 716 O
( NCT03866564 717 718 O
if NCT03866564 719 721 O
participants NCT03866564 722 734 O
demonstrate NCT03866564 735 746 O
on NCT03866564 747 749 O
T NCT03866564 750 751 B-Observation
- NCT03866564 752 753 I-Observation
MoCA NCT03866564 754 758 I-Observation
score NCT03866564 759 764 B-Eq-Comparison
< NCT03866564 765 766 I-Eq-Comparison
19 NCT03866564 767 769 I-Eq-Comparison
) NCT03866564 770 771 O
and NCT03866564 772 775 O
to NCT03866564 776 778 O
comply NCT03866564 779 785 O
with NCT03866564 786 790 O
study NCT03866564 791 796 O
procedures NCT03866564 797 807 O
. NCT03866564 808 809 O

Exclusion NCT03866564 811 820 O
Criteria NCT03866564 821 829 O
: NCT03866564 830 831 O

- NCT03866564 835 836 O
Prior NCT03866564 838 843 B-Eq-Comparison
metallic NCT03866564 844 852 B-Procedure
device NCT03866564 853 859 I-Procedure
implants NCT03866564 860 868 I-Procedure
such NCT03866564 869 873 O
as NCT03866564 874 876 O
cardiac NCT03866564 877 884 B-Procedure
pacemakers NCT03866564 885 895 I-Procedure
/ NCT03866564 896 897 B-Or
defibrillators NCT03866564 898 912 B-Procedure
or NCT03866564 913 915 B-Or
perfusion NCT03866564 916 925 B-Procedure
pumps NCT03866564 926 931 I-Procedure
that NCT03866564 932 936 O
can NCT03866564 937 940 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03866564 940 943 I-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03866564 944 946 O
removed NCT03866564 947 954 B-Negation
. NCT03866564 955 956 O

- NCT03866564 960 961 O
Ferromagnetic NCT03866564 963 976 B-Procedure
implants NCT03866564 977 985 I-Procedure
or NCT03866564 986 988 B-Or
objects NCT03866564 989 996 B-Procedure
that NCT03866564 997 1001 O
can NCT03866564 1002 1005 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03866564 1005 1008 I-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03866564 1009 1011 O
removed NCT03866564 1012 1019 B-Negation
such NCT03866564 1020 1024 O
as NCT03866564 1025 1027 O
aneurysm NCT03866564 1028 1036 B-Procedure
clips NCT03866564 1037 1042 I-Procedure
, NCT03866564 1043 1044 O
surgical NCT03866564 1045 1053 B-Procedure
clips NCT03866564 1054 1059 I-Procedure
, NCT03866564 1060 1061 O
prostheses NCT03866564 1062 1072 B-Procedure
, NCT03866564 1073 1074 O
artificial NCT03866564 1075 1085 B-Procedure
hearts NCT03866564 1086 1092 I-Procedure
, NCT03866564 1093 1094 O
valves NCT03866564 1095 1101 B-Procedure
with NCT03866564 1102 1106 O
steel NCT03866564 1107 1112 B-Modifier
parts NCT03866564 1113 1118 I-Modifier
, NCT03866564 1119 1120 O
metal NCT03866564 1121 1126 B-Condition
fragments NCT03866564 1127 1136 I-Condition
, NCT03866564 1137 1138 O
shrapnel NCT03866564 1139 1147 B-Condition
, NCT03866564 1148 1149 O
tattoos NCT03866564 1150 1157 B-Condition
near NCT03866564 1158 1162 B-Modifier
the NCT03866564 1163 1166 I-Modifier
eye NCT03866564 1167 1170 I-Modifier
, NCT03866564 1171 1172 O
or NCT03866564 1173 1175 B-Or
steel NCT03866564 1176 1181 B-Procedure
implants NCT03866564 1182 1190 B-Modifier
or NCT03866564 1191 1193 B-Or
jewelry NCT03866564 1194 1201 B-Modifier

- NCT03866564 1204 1205 O
Body NCT03866564 1207 1211 B-Observation
weight NCT03866564 1212 1218 I-Observation
> NCT03866564 1219 1220 B-Eq-Comparison
450 NCT03866564 1221 1224 I-Eq-Comparison
lbs NCT03866564 1225 1228 I-Eq-Comparison

- NCT03866564 1231 1232 O
Inability NCT03866564 1234 1243 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866564 1244 1246 O
complete NCT03866564 1247 1255 O
the NCT03866564 1256 1259 O
telephone NCT03866564 1260 1269 B-Procedure
screener NCT03866564 1270 1278 I-Procedure

- NCT03866564 1281 1282 O
Low NCT03866564 1284 1287 O
T NCT03866564 1288 1289 B-Observation
- NCT03866564 1290 1291 I-Observation
MoCA NCT03866564 1292 1296 I-Observation
score NCT03866564 1297 1302 O
( NCT03866564 1303 1304 O
< NCT03866564 1306 1307 B-Eq-Comparison
20 NCT03866564 1308 1310 I-Eq-Comparison
) NCT03866564 1311 1312 O
and NCT03866564 1313 1316 O
absence NCT03866564 1317 1324 O
of NCT03866564 1325 1327 O
an NCT03866564 1328 1330 O
available NCT03866564 1331 1340 O
legal NCT03866564 1341 1346 O
guardian NCT03866564 1347 1355 O
who NCT03866564 1356 1359 O
can NCT03866564 1360 1363 O
accompany NCT03866564 1364 1373 O
the NCT03866564 1374 1377 O
participant NCT03866564 1378 1389 O
through NCT03866564 1390 1397 O
all NCT03866564 1398 1401 O
phases NCT03866564 1402 1408 O
of NCT03866564 1409 1411 O
the NCT03866564 1412 1415 O
study NCT03866564 1416 1421 B-Study
. NCT03866564 1422 1423 O

- NCT03866564 1427 1428 O
Significant NCT03866564 1430 1441 O
behavioral NCT03866564 1442 1452 B-Modifier
or NCT03866564 1453 1455 B-Or
functional NCT03866564 1456 1466 B-Modifier
disability NCT03866564 1467 1477 B-Condition
due NCT03866564 1478 1481 O
to NCT03866564 1482 1484 O
cognitive NCT03866564 1485 1494 B-Condition
impairment NCT03866564 1495 1505 I-Condition

Inclusion NCT03869125 0 9 O
Criteria NCT03869125 10 18 O
: NCT03869125 19 20 O

- NCT03869125 24 25 O
Obstructive NCT03869125 27 38 B-Condition
sleep NCT03869125 39 44 I-Condition
apnoea NCT03869125 45 51 I-Condition
syndrome NCT03869125 52 60 I-Condition

Exclusion NCT03869125 61 70 O
Criteria NCT03869125 71 79 O
: NCT03869125 80 81 O

- NCT03869125 85 86 O
Non NCT03869125 88 91 B-Assertion___Assertion-Type-Value:hypothetical
- NCT03869125 92 93 I-Assertion___Assertion-Type-Value:hypothetical
compliance NCT03869125 94 104 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03869125 105 107 O
patients NCT03869125 108 116 O
with NCT03869125 117 121 O
blood NCT03869125 122 127 B-Procedure
pressure NCT03869125 128 136 I-Procedure
monitoring NCT03869125 137 147 I-Procedure

Inclusion NCT03864367 0 9 O
Criteria NCT03864367 10 18 O
: NCT03864367 19 20 O

- NCT03864367 24 25 O
55 NCT03864367 27 29 B-Eq-Comparison
and NCT03864367 30 33 I-Eq-Comparison
older NCT03864367 34 39 I-Age|Eq-Comparison

- NCT03864367 42 43 O
distal NCT03864367 45 51 B-Modifier
femur NCT03864367 52 57 I-Modifier
fracture NCT03864367 58 66 B-Condition

- NCT03864367 69 70 O
able NCT03864367 72 76 B-Condition
to NCT03864367 77 79 I-Condition
walk NCT03864367 80 84 I-Condition
prior NCT03864367 85 90 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864367 91 93 I-Temporal-Connection___Temporal-Connection-Type-Value:before
fracture NCT03864367 94 102 B-Condition

Exclusion NCT03864367 103 112 O
Criteria NCT03864367 113 121 O
: NCT03864367 122 123 O

- NCT03864367 127 128 O
patients NCT03864367 130 138 O
unable NCT03864367 139 145 B-Condition
to NCT03864367 146 148 I-Condition
walk NCT03864367 149 153 I-Condition
without NCT03864367 154 161 B-Negation
any NCT03864367 162 165 O
assistive NCT03864367 166 175 B-Procedure
devices NCT03864367 176 183 I-Procedure
post NCT03864367 184 188 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864367 189 190 O
injury NCT03864367 191 197 B-Condition

- NCT03864367 200 201 O
patients NCT03864367 203 211 O
too NCT03864367 212 215 B-Assertion___Assertion-Type-Value:hypothetical|Negation
medically NCT03864367 216 225 B-Condition
unstable NCT03864367 226 234 O
to NCT03864367 235 237 O
participate NCT03864367 238 249 O
in NCT03864367 250 252 O
physical NCT03864367 253 261 B-Procedure
therapy NCT03864367 262 269 I-Procedure

Inclusion NCT03863795 0 9 O
Criteria NCT03863795 10 18 O
: NCT03863795 19 20 O

- NCT03863795 24 25 O
United NCT03863795 27 33 O
States NCT03863795 34 40 O
( NCT03863795 41 42 O
US NCT03863795 43 45 O
) NCT03863795 46 47 O
adult NCT03863795 48 53 O
smokers NCT03863795 54 61 B-Condition
. NCT03863795 62 63 O

Smokers NCT03863795 65 72 B-Condition
recruited NCT03863795 73 82 O
through NCT03863795 83 90 O
Amazon NCT03863795 91 97 O
Mechanical NCT03863795 98 108 O
Turk NCT03863795 109 113 O

Inclusion NCT03866161 0 9 O
Criteria NCT03866161 10 18 O
: NCT03866161 19 20 O

- NCT03866161 24 25 O
Newly NCT03866161 27 32 B-Eq-Comparison
diagnosed NCT03866161 33 42 O
obstructive NCT03866161 43 54 B-Condition
sleep NCT03866161 55 60 I-Condition
apnea NCT03866161 61 66 I-Condition
indicated NCT03866161 67 76 B-Indication
for NCT03866161 77 80 O
positive NCT03866161 81 89 O
airway NCT03866161 90 96 B-Procedure
pressure NCT03866161 97 105 I-Procedure
therapy NCT03866161 106 113 I-Procedure
, NCT03866161 114 115 O
i. NCT03866161 116 118 O
e. NCT03866161 119 121 O
Apnea NCT03866161 123 128 B-Observation
- NCT03866161 129 130 I-Observation
Hypopnea NCT03866161 131 139 I-Observation
index NCT03866161 140 145 I-Observation
AHI NCT03866161 146 149 B-Observation
> NCT03866161 150 151 B-Eq-Comparison
15 NCT03866161 152 154 I-Eq-Comparison

Exclusion NCT03866161 156 165 O
Criteria NCT03866161 166 174 O
: NCT03866161 175 176 O

- NCT03866161 180 181 O
Psychiatric NCT03866161 183 194 B-Procedure
treatment NCT03866161 195 204 I-Procedure

- NCT03866161 207 208 O
Treatment NCT03866161 210 219 B-Procedure
with NCT03866161 220 224 O
psychoactive NCT03866161 225 237 B-Drug
drugs NCT03866161 238 243 I-Drug

Inclusion NCT03863743 0 9 O
Criteria NCT03863743 10 18 O
: NCT03863743 19 20 O

- NCT03863743 24 25 O
ASA NCT03863743 27 30 B-Condition
grade NCT03863743 31 36 B-Eq-Comparison
I NCT03863743 37 38 I-Eq-Comparison
- NCT03863743 39 40 I-Eq-Comparison
III NCT03863743 41 44 I-Eq-Comparison

- NCT03863743 47 48 O
BMI NCT03863743 50 53 B-Observation
under NCT03863743 54 59 B-Eq-Comparison
36 NCT03863743 60 62 I-Eq-Comparison
kg NCT03863743 63 65 I-Eq-Comparison
/ NCT03863743 66 67 I-Eq-Comparison
m^2 NCT03863743 68 71 I-Eq-Comparison

- NCT03863743 75 76 O
Scheduled NCT03863743 78 87 B-Eq-Comparison
surgery NCT03863743 88 95 B-Procedure
for NCT03863743 96 99 O
primary NCT03863743 100 107 B-Modifier
total NCT03863743 108 113 B-Modifier
hip NCT03863743 114 117 I-Modifier
or NCT03863743 118 120 B-Or
knee NCT03863743 121 125 B-Modifier
replacement NCT03863743 126 137 B-Procedure

- NCT03863743 140 141 O
Age NCT03863743 143 146 B-Age
18 NCT03863743 147 149 B-Eq-Comparison
+ NCT03863743 150 151 I-Eq-Comparison
years NCT03863743 152 157 I-Eq-Comparison

Exclusion NCT03863743 158 167 O
Criteria NCT03863743 168 176 O
: NCT03863743 177 178 O

- NCT03863743 182 183 O
Contraindications NCT03863743 185 202 B-Contraindication
or NCT03863743 203 205 B-Or
failure NCT03863743 206 213 B-Modifier
of NCT03863743 214 216 O
neuraxial NCT03863743 217 226 B-Procedure
anesthesia NCT03863743 227 237 I-Procedure

- NCT03863743 240 241 O
Patients NCT03863743 243 251 O
must NCT03863743 252 256 O
not NCT03863743 257 260 B-Negation
be NCT03863743 261 263 O
outpatient NCT03863743 264 274 B-Encounter
total NCT03863743 275 280 B-Modifier
hip NCT03863743 281 284 I-Modifier
or NCT03863743 285 287 B-Or
knee NCT03863743 288 292 B-Modifier
procedure NCT03863743 293 302 B-Procedure

- NCT03863743 305 306 O
Known NCT03863743 308 313 O
intercurrent NCT03863743 314 326 B-Modifier
UTI NCT03863743 327 330 B-Condition
, NCT03863743 331 332 O
incontinence NCT03863743 333 345 B-Condition
, NCT03863743 346 347 O
or NCT03863743 348 350 B-Or
urinary NCT03863743 351 358 B-Condition
retention NCT03863743 359 368 I-Condition
not NCT03863743 369 372 B-Negation
addressed NCT03863743 373 382 O
by NCT03863743 383 385 O
pre NCT03863743 386 389 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863743 390 391 O
operative NCT03863743 392 401 B-Procedure
urologic NCT03863743 402 410 B-Procedure
consultation NCT03863743 411 423 B-Modifier
and NCT03863743 424 427 B-Or
correction NCT03863743 428 438 B-Modifier

- NCT03863743 441 442 O
Pregnancy NCT03863743 444 453 B-Condition

- NCT03863743 456 457 O
Current NCT03863743 459 466 B-Eq-Comparison
nicotine NCT03863743 467 475 B-Drug
, NCT03863743 476 477 O
alcohol NCT03863743 478 485 B-Modifier
or NCT03863743 486 488 B-Or
drug NCT03863743 489 493 B-Modifier
abusers NCT03863743 494 501 B-Condition

- NCT03863743 504 505 O
Pre NCT03863743 507 510 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863743 511 512 O
operative NCT03863743 513 522 B-Procedure
narcotic NCT03863743 523 531 B-Drug
use NCT03863743 532 535 O
( NCT03863743 536 537 O
any NCT03863743 538 541 O
narcotic NCT03863743 542 550 B-Drug
consumption NCT03863743 551 562 O
within NCT03863743 563 569 B-Eq-Comparison
3 NCT03863743 570 571 I-Eq-Comparison
days NCT03863743 572 576 I-Eq-Comparison
prior NCT03863743 577 582 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863743 583 585 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03863743 586 593 B-Procedure
) NCT03863743 594 595 O

- NCT03863743 599 600 O
Post NCT03863743 602 606 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03863743 607 608 O
operative NCT03863743 609 618 B-Procedure
parenteral NCT03863743 619 629 B-Modifier
narcotic NCT03863743 630 638 B-Drug
administration NCT03863743 639 653 O

- NCT03863743 656 657 O
Allergy NCT03863743 659 666 B-Allergy
or NCT03863743 667 669 B-Or
intolerance NCT03863743 670 681 B-Condition
to NCT03863743 682 684 O
liposomal NCT03863743 685 694 B-Drug
bupivacaine NCT03863743 695 706 B-Drug
, NCT03863743 707 708 O
bupivacaine NCT03863743 709 720 B-Drug
, NCT03863743 721 722 O
celecoxib NCT03863743 723 732 B-Drug
, NCT03863743 733 734 O
dexamethasone NCT03863743 735 748 B-Drug
and NCT03863743 749 752 B-Or
/ NCT03863743 753 754 I-Or
or NCT03863743 755 757 I-Or
pregabalin NCT03863743 758 768 B-Drug

Minimum NCT03862105 0 7 B-Eq-Comparison
Age NCT03862105 8 11 I-Eq-Comparison
: NCT03862105 12 13 I-Eq-Comparison
18 NCT03862105 14 16 I-Eq-Comparison
Years NCT03862105 17 22 I-Eq-Comparison
Maximum NCT03862105 23 30 B-Eq-Comparison
Age NCT03862105 31 34 I-Eq-Comparison
: NCT03862105 35 36 I-Eq-Comparison
99 NCT03862105 37 39 I-Eq-Comparison
Years NCT03862105 40 45 I-Eq-Comparison
Sex NCT03862105 46 49 O
: NCT03862105 50 51 O
All NCT03862105 52 55 O
Gender NCT03862105 56 62 O
Based NCT03862105 63 68 O
: NCT03862105 69 70 O
No NCT03862105 71 73 O

Criteria NCT03862105 74 82 O
: NCT03862105 83 84 O
Inclusion NCT03862105 85 94 O
Criteria NCT03862105 95 103 O
: NCT03862105 104 105 O

- NCT03862105 109 110 O
Male NCT03862105 112 116 O
or NCT03862105 117 119 B-Or
female NCT03862105 120 126 O
patients NCT03862105 127 135 O
with NCT03862105 136 140 B-And
invasive NCT03862105 141 149 B-Modifier
bladder NCT03862105 150 157 I-Modifier
cancer NCT03862105 158 164 B-Condition
scheduled NCT03862105 165 174 B-Eq-Comparison
for NCT03862105 175 178 O
radical NCT03862105 179 186 B-Procedure
cystectomy NCT03862105 187 197 I-Procedure
at NCT03862105 198 200 O
UNC NCT03862105 201 204 O
within NCT03862105 205 211 B-Eq-Comparison
the NCT03862105 212 215 I-Eq-Comparison
next NCT03862105 216 220 I-Eq-Comparison
30 NCT03862105 221 223 I-Eq-Comparison
days NCT03862105 224 228 I-Eq-Comparison

- NCT03862105 231 232 O
English NCT03862105 234 241 O
- NCT03862105 242 243 O
speaking NCT03862105 244 252 O

- NCT03862105 255 256 O
Ability NCT03862105 258 265 O
to NCT03862105 266 268 O
access NCT03862105 269 275 O
the NCT03862105 276 279 O
Internet NCT03862105 280 288 O
( NCT03862105 289 290 O
either NCT03862105 291 297 O
themselves NCT03862105 298 308 O
or NCT03862105 309 311 O
with NCT03862105 312 316 O
assistance NCT03862105 317 327 O
from NCT03862105 328 332 O
their NCT03862105 333 338 O
caregiver NCT03862105 339 348 O
) NCT03862105 349 350 O

- NCT03862105 354 355 O
Ability NCT03862105 357 364 O
to NCT03862105 365 367 O
read NCT03862105 368 372 O

- NCT03862105 375 376 O
Ability NCT03862105 378 385 O
to NCT03862105 386 388 O
provide NCT03862105 389 396 O
informed NCT03862105 397 405 O
consent NCT03862105 406 413 O
. NCT03862105 414 415 O

Exclusion NCT03862105 417 426 O
Criteria NCT03862105 427 435 O
: NCT03862105 436 437 O

- NCT03862105 441 442 O
Inability NCT03862105 444 453 O
to NCT03862105 454 456 O
read NCT03862105 457 461 O

- NCT03862105 464 465 O
Inability NCT03862105 467 476 O
to NCT03862105 477 479 O
provide NCT03862105 480 487 O
informed NCT03862105 488 496 O
consent NCT03862105 497 504 O

- NCT03862105 507 508 O
Severe NCT03862105 510 516 O
psychiatric NCT03862105 517 528 B-Condition
illness NCT03862105 529 536 I-Condition

- NCT03862105 539 540 O
Cystectomy NCT03862105 542 552 B-Procedure
surgery NCT03862105 553 560 I-Procedure
without NCT03862105 561 568 B-Negation
cancer NCT03862105 569 575 B-Condition
diagnosis NCT03862105 576 585 O

- NCT03862105 588 589 O
Non NCT03862105 591 594 B-Negation
- NCT03862105 595 596 O
English NCT03862105 597 604 O
speaking NCT03862105 605 613 O

Inclusion NCT03862677 0 9 O
Criteria NCT03862677 10 18 O
: NCT03862677 19 20 O

- NCT03862677 24 25 O
Patients NCT03862677 27 35 O
with NCT03862677 36 40 O
( NCT03862677 41 42 O
suspicion NCT03862677 43 52 B-Assertion___Assertion-Type-Value:possible
of NCT03862677 53 55 O
) NCT03862677 56 57 O
primary NCT03862677 58 65 B-Modifier
or NCT03862677 66 68 B-Or
recurrent NCT03862677 69 78 B-Modifier
EOC NCT03862677 79 82 B-Condition
with NCT03862677 83 87 B-And
an NCT03862677 88 90 O
indication NCT03862677 91 101 B-Indication
for NCT03862677 102 105 O
surgery NCT03862677 106 113 B-Procedure
, NCT03862677 114 115 O
chemotherapy NCT03862677 116 128 B-Procedure
and NCT03862677 129 132 B-Or
/ NCT03862677 133 134 I-Or
or NCT03862677 135 137 I-Or
immunotherapy NCT03862677 138 151 B-Procedure
. NCT03862677 152 153 O

- NCT03862677 157 158 O
Age NCT03862677 160 163 B-Age
≥ NCT03862677 164 165 B-Eq-Comparison
18 NCT03862677 166 168 I-Eq-Comparison
years NCT03862677 169 174 I-Eq-Comparison
. NCT03862677 175 176 O

- NCT03862677 180 181 O
WHO NCT03862677 183 186 B-Observation
performance NCT03862677 187 198 I-Observation
status NCT03862677 199 205 I-Observation
0 NCT03862677 206 207 B-Eq-Comparison
- NCT03862677 208 209 I-Eq-Comparison
2 NCT03862677 210 211 O
. NCT03862677 211 212 O

- NCT03862677 216 217 O
Accessible NCT03862677 219 229 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03862677 230 233 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03862677 234 243 B-Procedure
and NCT03862677 244 247 B-And
follow NCT03862677 248 254 B-Encounter
- NCT03862677 255 256 I-Encounter
up NCT03862677 257 259 I-Encounter
. NCT03862677 260 261 O

- NCT03862677 265 266 O
Written NCT03862677 268 275 O
informed NCT03862677 276 284 O
consent NCT03862677 285 292 O
. NCT03862677 293 294 O

Exclusion NCT03862677 296 305 O
Criteria NCT03862677 306 314 O
: NCT03862677 315 316 O

- NCT03862677 320 321 O
Other NCT03862677 323 328 B-Other
active NCT03862677 329 335 B-Eq-Comparison
malignancy NCT03862677 336 346 B-Condition
in NCT03862677 347 349 O
past NCT03862677 350 354 B-Eq-Comparison
5 NCT03862677 355 356 I-Eq-Comparison
years NCT03862677 357 362 I-Eq-Comparison
prior NCT03862677 363 368 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862677 369 371 I-Temporal-Connection___Temporal-Connection-Type-Value:before
entry NCT03862677 372 377 O
into NCT03862677 378 382 O
the NCT03862677 383 386 O
study NCT03862677 387 392 B-Study
, NCT03862677 393 394 O
except NCT03862677 395 401 B-Exception
for NCT03862677 402 405 O
treated NCT03862677 406 413 B-Procedure
non NCT03862677 414 417 B-Negation
- NCT03862677 418 419 O
melanoma NCT03862677 420 428 B-Modifier
skin NCT03862677 429 433 I-Modifier
cancer NCT03862677 434 440 B-Condition
. NCT03862677 441 442 O

- NCT03862677 446 447 O
Any NCT03862677 449 452 O
known NCT03862677 453 458 O
severe NCT03862677 459 465 O
infection NCT03862677 466 475 B-Condition
like NCT03862677 476 480 O
HIV NCT03862677 481 484 B-Condition
, NCT03862677 485 486 O
hepatitis NCT03862677 487 496 B-Condition
A NCT03862677 497 498 B-Modifier
, NCT03862677 499 500 O
B NCT03862677 501 502 B-Modifier
and NCT03862677 503 506 B-Or
C NCT03862677 507 508 B-Modifier
. NCT03862677 509 510 O

- NCT03862677 514 515 O
Receiving NCT03862677 517 526 B-Eq-Comparison
immune NCT03862677 527 533 B-Procedure
suppressive NCT03862677 534 545 I-Procedure
treatment NCT03862677 546 555 I-Procedure
. NCT03862677 556 557 O

- NCT03862677 561 562 O
Medical NCT03862677 564 571 B-Modifier
or NCT03862677 572 574 B-Or
psychological NCT03862677 575 588 B-Modifier
condition NCT03862677 589 598 B-Condition
which NCT03862677 599 604 O
in NCT03862677 605 607 O
the NCT03862677 608 611 O
opinion NCT03862677 612 619 O
of NCT03862677 620 622 O
the NCT03862677 623 626 O
investigator NCT03862677 627 639 O
would NCT03862677 640 645 O
not NCT03862677 646 649 B-Assertion___Assertion-Type-Value:hypothetical|Negation
permit NCT03862677 650 656 O
the NCT03862677 657 660 O
patient NCT03862677 661 668 O
to NCT03862677 669 671 O
complete NCT03862677 672 680 O
the NCT03862677 681 684 O
study NCT03862677 685 690 B-Study
or NCT03862677 691 693 O
sign NCT03862677 694 698 O
meaningful NCT03862677 699 709 O
informed NCT03862677 710 718 O
consent NCT03862677 719 726 O
. NCT03862677 726 727 O

Inclusion NCT03860909 0 9 O
Criteria NCT03860909 10 18 O
: NCT03860909 19 20 O

- NCT03860909 24 25 O
Female NCT03860909 27 33 O
patients NCT03860909 34 42 O
who NCT03860909 43 46 B-And
have NCT03860909 47 51 O
symptoms NCT03860909 52 60 B-Assertion___Assertion-Type-Value:possible
consistent NCT03860909 61 71 O
with NCT03860909 72 76 O
endometriosis NCT03860909 77 90 B-Condition
such NCT03860909 91 95 O
as NCT03860909 96 98 O
pelvic NCT03860909 99 105 B-Modifier
pain NCT03860909 106 110 B-Condition
, NCT03860909 111 112 O
dysmenorrhea NCT03860909 113 125 B-Condition
, NCT03860909 126 127 O
deep NCT03860909 128 132 B-Condition
dyspareunia NCT03860909 133 144 I-Condition
, NCT03860909 145 146 O
and NCT03860909 147 150 B-Or
infertility NCT03860909 151 162 B-Condition

Exclusion NCT03860909 163 172 O
Criteria NCT03860909 173 181 O
: NCT03860909 182 183 O

- NCT03860909 187 188 O
The NCT03860909 190 193 O
common NCT03860909 194 200 O
contraindication NCT03860909 201 217 B-Contraindication
to NCT03860909 218 220 O
MRI NCT03860909 221 224 B-Procedure
, NCT03860909 225 226 O
peacemaker NCT03860909 227 237 B-Procedure
, NCT03860909 238 239 O
metallic NCT03860909 240 248 B-Condition
foreign NCT03860909 249 256 I-Condition
bodies NCT03860909 257 263 I-Condition
, NCT03860909 264 265 O
and NCT03860909 266 269 B-Or
claustrophobia NCT03860909 270 284 B-Condition

Inclusion NCT03869905 0 9 O
Criteria NCT03869905 10 18 O
: NCT03869905 19 20 O

- NCT03869905 24 25 O
Ulcerative NCT03869905 27 37 B-Condition
colitis NCT03869905 38 45 I-Condition
with NCT03869905 46 50 O
confirmed NCT03869905 51 60 O
diagnosis NCT03869905 61 70 O
by NCT03869905 71 73 O
histology NCT03869905 74 83 B-Procedure
and NCT03869905 84 87 B-Or
endoscopy NCT03869905 88 97 B-Procedure
AND NCT03869905 98 101 B-And
in NCT03869905 102 104 O
stable NCT03869905 105 111 O
remission NCT03869905 112 121 B-Condition
for NCT03869905 122 125 O
3 NCT03869905 126 127 B-Eq-Comparison
months NCT03869905 128 134 I-Eq-Comparison
or NCT03869905 135 137 I-Eq-Comparison
more NCT03869905 138 142 I-Eq-Comparison
without NCT03869905 143 150 B-Negation
therapy NCT03869905 151 158 B-Procedure
or NCT03869905 159 161 B-Or
with NCT03869905 162 166 B-And
a NCT03869905 167 168 O
maintenance NCT03869905 169 180 B-Procedure
therapy NCT03869905 181 188 I-Procedure
( NCT03869905 189 190 O
except NCT03869905 191 197 B-Exception
steroids NCT03869905 198 206 B-Drug
and NCT03869905 207 210 B-Or
antibiotics NCT03869905 211 222 B-Drug
for NCT03869905 223 226 O
3 NCT03869905 227 228 B-Eq-Comparison
months NCT03869905 229 235 I-Eq-Comparison
) NCT03869905 236 237 O

- NCT03869905 241 242 O
A NCT03869905 244 245 O
negative NCT03869905 246 254 O
pregnancy NCT03869905 255 264 B-Observation
test NCT03869905 265 269 I-Observation

Exclusion NCT03869905 270 279 O
Criteria NCT03869905 280 288 O
: NCT03869905 289 290 O

- NCT03869905 294 295 O
No NCT03869905 297 299 B-Negation
history NCT03869905 300 307 B-Eq-Comparison
or NCT03869905 308 310 O
diagnosis NCT03869905 311 320 O
of NCT03869905 321 323 O
any NCT03869905 324 327 O
of NCT03869905 328 330 O
the NCT03869905 331 334 O
following NCT03869905 335 344 O
conditions NCT03869905 345 355 B-Condition
: NCT03869905 356 357 O
Chron NCT03869905 358 363 B-Condition
's NCT03869905 363 365 I-Condition
disease NCT03869905 366 373 I-Condition
, NCT03869905 374 375 O
bleeding NCT03869905 376 384 B-Condition
disorders NCT03869905 385 394 I-Condition
, NCT03869905 395 396 O
gastrointestinal NCT03869905 397 413 B-Modifier
or NCT03869905 414 416 B-Or
colonic NCT03869905 417 424 B-Modifier
malignancy NCT03869905 425 435 B-Condition
, NCT03869905 436 437 O
Kidney NCT03869905 438 444 B-Condition
disease NCT03869905 445 452 I-Condition
, NCT03869905 453 454 O
including NCT03869905 455 464 O
kidney NCT03869905 465 471 B-Condition
" NCT03869905 472 473 I-Condition
stones NCT03869905 473 479 I-Condition
" NCT03869905 479 480 I-Condition
or NCT03869905 481 483 B-Or
hypercalcemia NCT03869905 484 497 B-Condition
, NCT03869905 498 499 O
Coagulopathy NCT03869905 500 512 B-Condition
/ NCT03869905 513 514 B-Or
hereditary NCT03869905 515 525 B-Modifier
hemorrhagic NCT03869905 526 537 B-Condition
disorders NCT03869905 538 547 I-Condition
/ NCT03869905 548 549 O
or NCT03869905 550 552 B-Or
receiving NCT03869905 553 562 B-Eq-Comparison
therapeutic NCT03869905 563 574 B-Procedure
doses NCT03869905 575 580 O
of NCT03869905 581 583 O
Coumadin NCT03869905 584 592 B-Drug
or NCT03869905 593 595 B-Or
heparin NCT03869905 596 603 B-Drug
. NCT03869905 604 605 O

- NCT03869905 609 610 O
Ingested NCT03869905 612 620 B-Eq-Comparison
certain NCT03869905 621 628 O
medications NCT03869905 629 640 B-Drug
( NCT03869905 641 642 O
Calcium NCT03869905 643 650 B-Drug
, NCT03869905 651 652 O
Vitamin NCT03869905 653 660 B-Drug
D NCT03869905 661 662 I-Drug
, NCT03869905 663 664 O
fiber NCT03869905 665 670 B-Drug
supplements NCT03869905 671 682 I-Drug
and NCT03869905 683 686 B-Or
Non NCT03869905 687 690 B-Drug
- NCT03869905 691 692 I-Drug
steroidal NCT03869905 693 702 I-Drug
anti NCT03869905 703 707 I-Drug
- NCT03869905 708 709 I-Drug
inflammatory NCT03869905 710 722 I-Drug
drugs NCT03869905 723 728 I-Drug
- NCT03869905 729 730 O
NSAIDs NCT03869905 731 737 B-Drug
) NCT03869905 738 739 O
within NCT03869905 740 746 B-Eq-Comparison
30 NCT03869905 747 749 I-Eq-Comparison
days NCT03869905 750 754 I-Eq-Comparison
of NCT03869905 755 757 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03869905 758 763 B-Study
start NCT03869905 764 769 B-Eq-Comparison
. NCT03869905 769 770 O

Inclusion NCT03862703 0 9 O
Criteria NCT03862703 10 18 O
: NCT03862703 19 20 O

1 NCT03862703 24 25 O
. NCT03862703 25 26 O
must NCT03862703 28 32 O
be NCT03862703 33 35 O
at NCT03862703 36 38 B-Eq-Comparison
least NCT03862703 39 44 I-Eq-Comparison
18 NCT03862703 45 47 I-Eq-Comparison
years NCT03862703 48 53 I-Eq-Comparison
old NCT03862703 54 57 B-Age
. NCT03862703 58 59 O

2 NCT03862703 63 64 O
. NCT03862703 64 65 O
fulfil NCT03862703 67 73 O
the NCT03862703 74 77 O
DSM NCT03862703 78 81 O
- NCT03862703 82 83 O
5 NCT03862703 84 85 O
PTSD NCT03862703 86 90 B-Condition
diagnosis NCT03862703 91 100 O
criteria NCT03862703 101 109 O
. NCT03862703 110 111 O

3 NCT03862703 115 116 O
. NCT03862703 116 117 O
be NCT03862703 119 121 O
referred NCT03862703 122 130 O
to NCT03862703 131 133 O
PTSD NCT03862703 134 138 B-Condition
care NCT03862703 139 143 B-Procedure
package NCT03862703 144 151 I-Procedure
treatment NCT03862703 152 161 I-Procedure
( NCT03862703 162 163 O
Danske NCT03862703 164 170 O
regioner NCT03862703 171 179 O
, NCT03862703 180 181 O
pakkeforløb NCT03862703 182 193 O
for NCT03862703 194 197 O
PTSD NCT03862703 198 202 O
, NCT03862703 203 204 O
2017 NCT03862703 205 209 O
) NCT03862703 210 211 O

4 NCT03862703 219 220 O
. NCT03862703 220 221 O
have NCT03862703 223 227 O
access NCT03862703 228 234 O
to NCT03862703 235 237 O
a NCT03862703 238 239 O
smartphone NCT03862703 240 250 O
with NCT03862703 251 255 O
iOS NCT03862703 256 259 O
( NCT03862703 260 261 O
version NCT03862703 262 269 O
10 NCT03862703 270 272 O
or NCT03862703 273 275 O
higher NCT03862703 276 282 O
) NCT03862703 283 284 O
or NCT03862703 285 287 O
Android NCT03862703 288 295 O
( NCT03862703 296 297 O
version NCT03862703 298 305 O
5.0.1 NCT03862703 306 311 O
. NCT03862703 311 312 O
or NCT03862703 314 316 O
higher NCT03862703 317 323 O
) NCT03862703 324 325 O

5 NCT03862703 329 330 O
. NCT03862703 330 331 O
provide NCT03862703 333 340 O
informed NCT03862703 341 349 O
consent NCT03862703 350 357 O
. NCT03862703 358 359 O

Exclusion NCT03862703 361 370 O
Criteria NCT03862703 371 379 O
: NCT03862703 380 381 O

1 NCT03862703 385 386 O
. NCT03862703 386 387 O
suicidal NCT03862703 389 397 B-Condition
risk NCT03862703 398 402 B-Risk

2 NCT03862703 405 406 O
. NCT03862703 406 407 O
ongoing NCT03862703 409 416 B-Eq-Comparison
episode NCT03862703 417 424 O
of NCT03862703 425 427 O
bipolar NCT03862703 428 435 B-Condition
disease NCT03862703 436 443 I-Condition
or NCT03862703 444 446 B-Or
psychotic NCT03862703 447 456 B-Condition
disorder NCT03862703 457 465 I-Condition

3 NCT03862703 468 469 O
. NCT03862703 469 470 O
current NCT03862703 472 479 B-Eq-Comparison
abuse NCT03862703 480 485 B-Condition
of NCT03862703 486 488 O
alcohol NCT03862703 489 496 B-Modifier
or NCT03862703 497 499 B-Or
drugs NCT03862703 500 505 B-Modifier

4 NCT03862703 508 509 O
. NCT03862703 509 510 O
inability NCT03862703 512 521 B-Negation
to NCT03862703 522 524 O
understand NCT03862703 525 535 O
and NCT03862703 536 539 O
/ NCT03862703 540 541 O
or NCT03862703 542 544 O
read NCT03862703 545 549 O
Danish NCT03862703 550 556 O

5 NCT03862703 559 560 O
. NCT03862703 560 561 O
concurrent NCT03862703 563 573 B-Modifier
psychiatric NCT03862703 574 585 I-Modifier
or NCT03862703 586 588 B-Or
psychological NCT03862703 589 602 B-Modifier
treatment NCT03862703 603 612 B-Procedure
of NCT03862703 613 615 O
PTSD NCT03862703 616 620 B-Condition
outside NCT03862703 621 628 B-Exception
of NCT03862703 629 631 I-Exception
MHS NCT03862703 632 635 B-Procedure
- NCT03862703 636 637 I-Procedure
CRD NCT03862703 638 641 I-Procedure
. NCT03862703 642 643 O


Inclusion NCT03863353 0 9 O
Criteria NCT03863353 10 18 O
: NCT03863353 19 20 O

- NCT03863353 24 25 O
Undergoing NCT03863353 27 37 B-Eq-Comparison
an NCT03863353 38 40 O
elective NCT03863353 41 49 B-Modifier
surgical NCT03863353 50 58 B-Procedure
procedure NCT03863353 59 68 I-Procedure
for NCT03863353 69 72 O
which NCT03863353 73 78 O
it NCT03863353 79 81 O
is NCT03863353 82 84 O
expected NCT03863353 85 93 B-Assertion___Assertion-Type-Value:hypothetical
they NCT03863353 94 98 I-Assertion___Assertion-Type-Value:hypothetical
will NCT03863353 99 103 O
receive NCT03863353 104 111 O
a NCT03863353 112 113 O
prescription NCT03863353 114 126 B-Modifier
pain NCT03863353 127 131 B-Condition
medicine NCT03863353 132 140 B-Drug
for NCT03863353 141 144 O
management NCT03863353 145 155 O
of NCT03863353 156 158 O
pain NCT03863353 159 163 B-Condition
during NCT03863353 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recovery NCT03863353 171 179 B-Observation
at NCT03863353 180 182 O
home NCT03863353 183 187 O
. NCT03863353 188 189 O

Exclusion NCT03863353 191 200 O
Criteria NCT03863353 201 209 O
: NCT03863353 210 211 O

- NCT03863353 215 216 O
Undergoing NCT03863353 218 228 B-Eq-Comparison
non NCT03863353 229 232 B-Negation
- NCT03863353 233 234 O
elective NCT03863353 235 243 B-Modifier
procedure NCT03863353 244 253 B-Procedure

- NCT03863353 256 257 O
Cognitive NCT03863353 259 268 B-Condition
impairment NCT03863353 269 279 I-Condition
precluding NCT03863353 280 290 B-Assertion___Assertion-Type-Value:hypothetical|Negation
self NCT03863353 291 295 O
- NCT03863353 296 297 O
reporting NCT03863353 298 307 O
of NCT03863353 308 310 O
pain NCT03863353 311 315 B-Condition

- NCT03863353 318 319 O
Hematologic NCT03863353 321 332 B-Modifier
/ NCT03863353 333 334 B-Or
oncologic NCT03863353 335 344 B-Modifier
condition NCT03863353 345 354 B-Condition

- NCT03863353 357 358 O
Liver NCT03863353 360 365 B-Modifier
of NCT03863353 366 368 I-Modifier
kidney NCT03863353 369 375 I-Modifier
conditions NCT03863353 376 386 B-Condition
precluding NCT03863353 387 397 B-Assertion___Assertion-Type-Value:hypothetical|Negation
usual NCT03863353 398 403 O
analgesic NCT03863353 404 413 B-Drug
prescription NCT03863353 414 426 I-Drug
patters NCT03863353 427 434 I-Drug
( NCT03863353 435 436 O
opioid NCT03863353 437 443 B-Drug
plus NCT03863353 444 448 B-And
a NCT03863353 449 450 O
non NCT03863353 451 454 O
- NCT03863353 455 456 O
opioid NCT03863353 457 463 B-Drug
) NCT03863353 464 465 O

- NCT03863353 469 470 O
Use NCT03863353 472 475 B-Eq-Comparison
of NCT03863353 476 478 O
opioids NCT03863353 479 486 B-Drug
for NCT03863353 487 490 O
prolonged NCT03863353 491 500 B-Modifier
pain NCT03863353 501 505 B-Condition
pre NCT03863353 506 509 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863353 510 511 O
operatively NCT03863353 512 523 B-Procedure
( NCT03863353 524 525 O
< NCT03863353 527 528 B-Eq-Comparison
2 NCT03863353 529 530 I-Eq-Comparison
weeks NCT03863353 531 536 I-Eq-Comparison
) NCT03863353 537 538 O

Inclusion NCT03860896 0 9 O
Criteria NCT03860896 10 18 O
: NCT03860896 19 20 O

- NCT03860896 24 25 O
Patients NCT03860896 27 35 O
aged NCT03860896 36 40 B-Age
18 NCT03860896 41 43 B-Eq-Comparison
- NCT03860896 44 45 I-Eq-Comparison
74 NCT03860896 46 48 O
, NCT03860896 49 50 O
receiving NCT03860896 51 60 B-Eq-Comparison
therapy NCT03860896 61 68 B-Procedure
for NCT03860896 69 72 O
active NCT03860896 73 79 B-Eq-Comparison
ulcerative NCT03860896 80 90 B-Condition
colitis NCT03860896 91 98 I-Condition
confirmed NCT03860896 99 108 O
by NCT03860896 109 111 O
Mayo NCT03860896 112 116 B-Observation
Score NCT03860896 117 122 I-Observation
assessment NCT03860896 123 133 I-Observation
, NCT03860896 134 135 O
and NCT03860896 136 139 B-And
evidence NCT03860896 140 148 O
of NCT03860896 149 151 O
colonic NCT03860896 152 159 B-Condition
inflammation NCT03860896 160 172 I-Condition
. NCT03860896 173 174 O

Exclusion NCT03860896 176 185 O
Criteria NCT03860896 186 194 O
: NCT03860896 195 196 O

- NCT03860896 200 201 O
Evidence NCT03860896 203 211 O
of NCT03860896 212 214 O
Crohn NCT03860896 215 220 B-Condition
's NCT03860896 220 222 I-Condition
disease NCT03860896 223 230 I-Condition
, NCT03860896 231 232 O
indeterminate NCT03860896 233 246 B-Condition
colitis NCT03860896 247 254 I-Condition
, NCT03860896 255 256 O
or NCT03860896 257 259 B-Or
presence NCT03860896 260 268 O
of NCT03860896 269 271 O
bacterial NCT03860896 272 281 B-Modifier
or NCT03860896 282 284 B-Or
parasitic NCT03860896 285 294 B-Modifier
infection NCT03860896 295 304 B-Condition
. NCT03860896 305 306 O

- NCT03860896 310 311 O
Patients NCT03860896 313 321 O
receiving NCT03860896 322 331 B-Eq-Comparison
biologic NCT03860896 332 340 B-Drug
agents NCT03860896 341 347 I-Drug
and NCT03860896 348 351 B-Or
experimental NCT03860896 352 364 B-Drug
agents NCT03860896 365 371 I-Drug
are NCT03860896 372 375 O
excluded NCT03860896 376 384 B-Negation
. NCT03860896 384 385 O

Inclusion NCT03862924 0 9 O
Criteria NCT03862924 10 18 O
: NCT03862924 19 20 O

- NCT03862924 24 25 O
diagnosed NCT03862924 27 36 O
with NCT03862924 37 41 O
and NCT03862924 42 45 O
engaged NCT03862924 46 53 O
in NCT03862924 54 56 O
care NCT03862924 57 61 O
for NCT03862924 62 65 O
HIV NCT03862924 66 69 B-Condition
( NCT03862924 70 71 O
defined NCT03862924 72 79 O
as NCT03862924 80 82 O
at NCT03862924 83 85 B-Eq-Comparison
least NCT03862924 86 91 I-Eq-Comparison
one NCT03862924 92 95 I-Eq-Comparison
HIV NCT03862924 96 99 O
clinic NCT03862924 100 106 O
medical NCT03862924 107 114 B-Encounter
appointment NCT03862924 115 126 I-Encounter
within NCT03862924 127 133 B-Eq-Comparison
the NCT03862924 134 137 I-Eq-Comparison
past NCT03862924 138 142 I-Eq-Comparison
six NCT03862924 143 146 I-Eq-Comparison
month NCT03862924 147 152 I-Eq-Comparison
period NCT03862924 153 159 I-Eq-Comparison
) NCT03862924 160 161 O

- NCT03862924 165 166 O
at NCT03862924 168 170 B-Eq-Comparison
least NCT03862924 171 176 I-Eq-Comparison
18 NCT03862924 177 179 I-Eq-Comparison
years NCT03862924 180 185 I-Eq-Comparison
of NCT03862924 186 188 O
age NCT03862924 189 192 B-Age

- NCT03862924 195 196 O
smoke NCT03862924 198 203 B-Condition|Observation
at NCT03862924 204 206 B-Eq-Comparison
least NCT03862924 207 212 I-Eq-Comparison
5 NCT03862924 213 214 I-Eq-Comparison
cigarettes NCT03862924 215 225 I-Eq-Comparison
per NCT03862924 226 229 I-Eq-Comparison
day NCT03862924 230 233 I-Eq-Comparison
for NCT03862924 234 237 O
longer NCT03862924 238 244 B-Eq-Comparison
than NCT03862924 245 249 I-Eq-Comparison
one NCT03862924 250 253 I-Eq-Comparison
year NCT03862924 254 258 I-Eq-Comparison

- NCT03862924 261 262 O
exhaled NCT03862924 264 271 B-Observation
carbon NCT03862924 272 278 I-Observation
monoxide NCT03862924 279 287 I-Observation
( NCT03862924 288 289 O
CO NCT03862924 290 292 B-Observation
) NCT03862924 293 294 O
level NCT03862924 295 300 O
greater NCT03862924 301 308 B-Eq-Comparison
than NCT03862924 309 313 I-Eq-Comparison
5 NCT03862924 314 315 I-Eq-Comparison
at NCT03862924 316 318 O
BL NCT03862924 319 321 B-Modifier

Exclusion NCT03862924 322 331 O
Criteria NCT03862924 332 340 O
: NCT03862924 341 342 O

- NCT03862924 346 347 O
intention NCT03862924 349 358 B-Assertion___Assertion-Type-Value:intention
to NCT03862924 359 361 I-Assertion___Assertion-Type-Value:intention
quit NCT03862924 362 366 B-Condition
smoking NCT03862924 367 374 I-Condition
in NCT03862924 375 377 O
the NCT03862924 378 381 O
next NCT03862924 382 386 B-Eq-Comparison
30 NCT03862924 387 389 I-Eq-Comparison
days NCT03862924 390 394 I-Eq-Comparison

- NCT03862924 397 398 O
currently NCT03862924 400 409 B-Eq-Comparison
using NCT03862924 410 415 I-Eq-Comparison
pharmacotherapy NCT03862924 416 431 B-Procedure
for NCT03862924 432 435 O
smoking NCT03862924 436 443 B-Procedure
cessation NCT03862924 444 453 I-Procedure

- NCT03862924 456 457 O
currently NCT03862924 459 468 B-Eq-Comparison
using NCT03862924 469 474 I-Eq-Comparison
electronic NCT03862924 475 485 B-Modifier
cigarettes NCT03862924 486 496 B-Drug
more NCT03862924 497 501 B-Eq-Comparison
than NCT03862924 502 506 I-Eq-Comparison
2 NCT03862924 507 508 I-Eq-Comparison
days NCT03862924 509 513 I-Eq-Comparison
/ NCT03862924 514 515 I-Eq-Comparison
week NCT03862924 516 520 I-Eq-Comparison

- NCT03862924 523 524 O
unstable NCT03862924 526 534 O
medical NCT03862924 535 542 B-Modifier
or NCT03862924 543 545 B-Or
psychiatric NCT03862924 546 557 B-Modifier
condition NCT03862924 558 567 B-Condition
( NCT03862924 568 569 O
defined NCT03862924 570 577 O
as NCT03862924 578 580 O
hospitalization NCT03862924 581 596 B-Encounter
) NCT03862924 597 598 O

- NCT03862924 602 603 O
medical NCT03862924 605 612 O
contraindications NCT03862924 613 630 B-Contraindication
to NCT03862924 631 633 O
nicotine NCT03862924 634 642 B-Drug
( NCT03862924 643 644 O
unstable NCT03862924 645 653 O
angina NCT03862924 654 660 B-Condition
, NCT03862924 661 662 O
uncontrolled NCT03862924 663 675 B-Modifier
hypertension NCT03862924 676 688 B-Condition
, NCT03862924 689 690 O
or NCT03862924 691 693 B-Or
recent NCT03862924 694 700 B-Eq-Comparison
cardiovascular NCT03862924 701 715 B-Condition
event NCT03862924 716 721 I-Condition
, NCT03862924 722 723 O
including NCT03862924 724 733 O
hospitalization NCT03862924 734 749 B-Encounter
) NCT03862924 750 751 O

- NCT03862924 755 756 O
psychotic NCT03862924 758 767 B-Condition
symptoms NCT03862924 768 776 B-Assertion___Assertion-Type-Value:possible

- NCT03862924 779 780 O
substance NCT03862924 782 791 B-Condition
use NCT03862924 792 795 I-Condition
disorder NCT03862924 796 804 I-Condition
other NCT03862924 805 810 B-Exception
than NCT03862924 811 815 I-Exception
nicotine NCT03862924 816 824 B-Condition
dependence NCT03862924 825 835 I-Condition

- NCT03862924 838 839 O
past NCT03862924 841 845 B-Eq-Comparison
- NCT03862924 846 847 I-Eq-Comparison
month NCT03862924 848 853 I-Eq-Comparison
suicidal NCT03862924 854 862 B-Condition
ideation NCT03862924 863 871 I-Condition
or NCT03862924 872 874 B-Or
past NCT03862924 875 879 B-Eq-Comparison
- NCT03862924 880 881 I-Eq-Comparison
year NCT03862924 882 886 I-Eq-Comparison
suicide NCT03862924 887 894 B-Condition
attempt NCT03862924 895 902 I-Condition

- NCT03862924 905 906 O
pregnant NCT03862924 908 916 B-Condition
or NCT03862924 917 919 B-Or
nursing NCT03862924 920 927 B-Condition
. NCT03862924 927 928 O

Inclusion NCT03861975 0 9 O
Criteria NCT03861975 10 18 O
: NCT03861975 19 20 O

- NCT03861975 24 25 O
Participants NCT03861975 27 39 O
must NCT03861975 40 44 O
have NCT03861975 45 49 O
histologically NCT03861975 50 64 B-Modifier
or NCT03861975 65 67 B-Or
cytologically NCT03861975 68 81 B-Procedure
confirmed NCT03861975 82 91 O
invasive NCT03861975 92 100 B-Modifier
or NCT03861975 101 103 B-Or
in NCT03861975 104 106 B-Modifier
- NCT03861975 107 108 I-Modifier
situ NCT03861975 109 113 I-Modifier
carcinoma NCT03861975 114 123 B-Condition
of NCT03861975 124 126 O
the NCT03861975 127 130 O
breast NCT03861975 131 137 B-Modifier
and NCT03861975 138 141 B-And
will NCT03861975 142 146 B-Eq-Comparison
undergo NCT03861975 147 154 I-Eq-Comparison
unilateral NCT03861975 155 165 B-Modifier
breast NCT03861975 166 172 I-Modifier
cancer NCT03861975 173 179 B-Condition
surgery NCT03861975 180 187 B-Procedure

- NCT03861975 190 191 O
Willingness NCT03861975 193 204 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 205 207 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03861975 208 216 O
SEI NCT03861975 217 220 B-Observation
- NCT03861975 221 222 I-Observation
BCLE NCT03861975 223 227 I-Observation
Questionnaire NCT03861975 228 241 I-Observation

- NCT03861975 244 245 O
Age NCT03861975 247 250 B-Age
> NCT03861975 251 252 B-Eq-Comparison
18 NCT03861975 253 255 I-Eq-Comparison
years NCT03861975 256 261 I-Eq-Comparison
. NCT03861975 262 263 O

- NCT03861975 267 268 O
Ability NCT03861975 270 277 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 278 280 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03861975 281 291 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03861975 292 295 B-And
the NCT03861975 296 299 O
willingness NCT03861975 300 311 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 312 314 O
verbally NCT03861975 315 323 O
consent NCT03861975 324 331 O
to NCT03861975 332 334 O
the NCT03861975 335 338 O
trial NCT03861975 339 344 B-Study

Exclusion NCT03861975 345 354 O
Criteria NCT03861975 355 363 O
: NCT03861975 364 365 O

- NCT03861975 369 370 O
History NCT03861975 372 379 B-Eq-Comparison
of NCT03861975 380 382 O
primary NCT03861975 383 390 B-Modifier
lymphedema NCT03861975 391 401 B-Condition
. NCT03861975 402 403 O

- NCT03861975 407 408 O
Any NCT03861975 410 413 O
patient NCT03861975 414 421 O
with NCT03861975 422 426 O
a NCT03861975 427 428 O
current NCT03861975 429 436 B-Eq-Comparison
case NCT03861975 437 441 O
of NCT03861975 442 444 O
cellulitis NCT03861975 445 455 B-Condition
. NCT03861975 456 457 O

- NCT03861975 461 462 O
Participants NCT03861975 464 476 O
with NCT03861975 477 481 O
known NCT03861975 482 487 O
brain NCT03861975 488 493 B-Modifier
metastases NCT03861975 494 504 B-Condition
should NCT03861975 505 511 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861975 512 514 I-Assertion___Assertion-Type-Value:hypothetical
excluded NCT03861975 515 523 B-Negation
from NCT03861975 524 528 O
this NCT03861975 529 533 O
clinical NCT03861975 534 542 B-Study
trial NCT03861975 543 548 I-Study
because NCT03861975 549 556 O
of NCT03861975 557 559 O
their NCT03861975 560 565 O
poor NCT03861975 566 570 B-Condition
prognosis NCT03861975 571 580 I-Condition
and NCT03861975 581 584 B-And
because NCT03861975 585 592 O
they NCT03861975 593 597 O
often NCT03861975 598 603 B-Assertion___Assertion-Type-Value:hypothetical
develop NCT03861975 604 611 I-Assertion___Assertion-Type-Value:hypothetical
progressive NCT03861975 612 623 B-Modifier
neurologic NCT03861975 624 634 B-Condition
dysfunction NCT03861975 635 646 I-Condition
that NCT03861975 647 651 O
would NCT03861975 652 657 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03861975 658 666 O
the NCT03861975 667 670 O
evaluation NCT03861975 671 681 B-Procedure
of NCT03861975 682 684 O
neurologic NCT03861975 685 695 B-Modifier
and NCT03861975 696 699 B-Or
other NCT03861975 700 705 B-Other
adverse NCT03861975 706 713 B-Condition
events NCT03861975 714 720 I-Condition
. NCT03861975 721 722 O

- NCT03861975 726 727 O
Uncontrolled NCT03861975 729 741 B-Modifier
intercurrent NCT03861975 742 754 B-Condition
illness NCT03861975 755 762 I-Condition
including NCT03861975 763 772 O
, NCT03861975 773 774 O
but NCT03861975 775 778 O
not NCT03861975 779 782 O
limited NCT03861975 783 790 O
to NCT03861975 791 793 O
, NCT03861975 794 795 O
ongoing NCT03861975 796 803 B-Eq-Comparison
or NCT03861975 804 806 B-Or
active NCT03861975 807 813 B-Eq-Comparison
infection NCT03861975 814 823 B-Condition
, NCT03861975 824 825 O
symptomatic NCT03861975 826 837 B-Assertion___Assertion-Type-Value:possible
congestive NCT03861975 838 848 B-Condition
heart NCT03861975 849 854 I-Condition
failure NCT03861975 855 862 I-Condition
, NCT03861975 863 864 O
unstable NCT03861975 865 873 O
angina NCT03861975 874 880 B-Condition
pectoris NCT03861975 881 889 I-Condition
, NCT03861975 890 891 O
cardiac NCT03861975 892 899 B-Condition
arrhythmia NCT03861975 900 910 I-Condition
, NCT03861975 911 912 O
or NCT03861975 913 915 B-Or
psychiatric NCT03861975 916 927 B-Modifier
illness NCT03861975 928 935 B-Condition
/ NCT03861975 936 937 B-Or
social NCT03861975 938 944 B-Observation
situations NCT03861975 945 955 I-Observation
that NCT03861975 956 960 O
would NCT03861975 961 966 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03861975 967 972 O
compliance NCT03861975 973 983 O
with NCT03861975 984 988 O
study NCT03861975 989 994 B-Study
requirements NCT03861975 995 1007 O
. NCT03861975 1008 1009 O

- NCT03861975 1013 1014 O
Participants NCT03861975 1016 1028 O
unable NCT03861975 1029 1035 B-Negation
to NCT03861975 1036 1038 O
abduct NCT03861975 1039 1045 B-Condition
upper NCT03861975 1046 1051 B-Modifier
- NCT03861975 1052 1053 I-Modifier
extremity NCT03861975 1054 1063 I-Modifier
perpendicular NCT03861975 1064 1077 I-Modifier
to NCT03861975 1078 1080 I-Modifier
body NCT03861975 1081 1085 I-Modifier
or NCT03861975 1086 1088 B-Or
to NCT03861975 1089 1091 O
stand NCT03861975 1092 1097 B-Observation
comfortably NCT03861975 1098 1109 O
without NCT03861975 1110 1117 O
aid NCT03861975 1118 1121 O
for NCT03861975 1122 1125 O
several NCT03861975 1126 1133 B-Eq-Comparison
minutes NCT03861975 1134 1141 I-Eq-Comparison
, NCT03861975 1142 1143 O
both NCT03861975 1144 1148 B-Coreference
of NCT03861975 1149 1151 I-Coreference
which NCT03861975 1152 1157 I-Coreference
are NCT03861975 1158 1161 O
necessary NCT03861975 1162 1171 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861975 1172 1174 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03861975 1175 1182 O
a NCT03861975 1183 1184 O
LymphaTech NCT03861975 1185 1195 B-Procedure
Scan NCT03861975 1196 1200 I-Procedure

Inclusion NCT03861949 0 9 O
Criteria NCT03861949 10 18 O
: NCT03861949 19 20 O

- NCT03861949 24 25 O
adult NCT03861949 27 32 O
patients NCT03861949 33 41 O
of NCT03861949 42 44 O
ASA NCT03861949 45 48 B-Condition
physical NCT03861949 49 57 O
status NCT03861949 58 64 B-Eq-Comparison
I NCT03861949 65 66 I-Eq-Comparison
and NCT03861949 67 70 I-Eq-Comparison
II NCT03861949 71 73 I-Eq-Comparison
undergoing NCT03861949 74 84 B-Eq-Comparison
surgery NCT03861949 85 92 B-Procedure
under NCT03861949 93 98 O
general NCT03861949 99 106 B-Procedure
anaesthesia NCT03861949 107 118 I-Procedure

Exclusion NCT03861949 119 128 O
Criteria NCT03861949 129 137 O
: NCT03861949 138 139 O

- NCT03861949 143 144 O
anticipated NCT03861949 146 157 B-Assertion___Assertion-Type-Value:hypothetical
difficult NCT03861949 158 167 B-Modifier
mask NCT03861949 168 172 B-Procedure
ventilation NCT03861949 173 184 I-Procedure
/ NCT03861949 185 186 B-Or
intubation NCT03861949 187 197 B-Procedure

- NCT03861949 200 201 O
individuals NCT03861949 203 214 O
with NCT03861949 215 219 O
significant NCT03861949 220 231 O
cardiorespiratory NCT03861949 232 249 B-Modifier
or NCT03861949 250 252 B-Or
cerebrovascular NCT03861949 253 268 B-Modifier
disease NCT03861949 269 276 B-Condition

- NCT03861949 279 280 O
pregnant NCT03861949 282 290 B-Condition
ladies NCT03861949 291 297 O

- NCT03861949 300 301 O
patient NCT03861949 303 310 O
with NCT03861949 311 315 O
history NCT03861949 316 323 B-Eq-Comparison
of NCT03861949 324 326 O
epilepsy NCT03861949 327 335 B-Condition

- NCT03861949 338 339 O
body NCT03861949 341 345 B-Observation
mass NCT03861949 346 350 I-Observation
index NCT03861949 351 356 I-Observation
> NCT03861949 357 358 B-Eq-Comparison
25 NCT03861949 359 361 I-Eq-Comparison
kg NCT03861949 362 364 I-Eq-Comparison
/ NCT03861949 365 366 I-Eq-Comparison
m2 NCT03861949 367 369 I-Eq-Comparison

- NCT03861949 372 373 O
hemoglobin NCT03861949 375 385 B-Observation
< NCT03861949 386 387 B-Eq-Comparison
8 NCT03861949 388 389 I-Eq-Comparison
gm NCT03861949 390 392 I-Eq-Comparison
/ NCT03861949 393 394 I-Eq-Comparison
dL NCT03861949 395 397 I-Eq-Comparison

- NCT03861949 400 401 O
patients NCT03861949 403 411 O
who NCT03861949 412 415 O
were NCT03861949 416 420 B-Eq-Comparison
non NCT03861949 421 424 B-Negation
- NCT03861949 425 426 O
ambulant NCT03861949 427 435 B-Condition
for NCT03861949 436 439 O
> NCT03861949 440 441 B-Eq-Comparison
24 NCT03861949 442 444 I-Eq-Comparison
h NCT03861949 445 446 I-Eq-Comparison
, NCT03861949 447 448 O
having NCT03861949 449 455 B-And
SpO2 NCT03861949 456 460 B-Observation
< NCT03861949 461 462 B-Eq-Comparison
97 NCT03861949 463 465 I-Eq-Comparison
% NCT03861949 466 467 I-Eq-Comparison
while NCT03861949 468 473 B-Temporal-Connection___Temporal-Connection-Type-Value:during
breathing NCT03861949 474 483 B-Observation
in NCT03861949 484 486 O
room NCT03861949 487 491 B-Modifier
air NCT03861949 492 495 I-Modifier

- NCT03861949 498 499 O
phobia NCT03861949 501 507 B-Condition
to NCT03861949 508 510 O
facemask NCT03861949 511 519 B-Modifier
. NCT03861949 519 520 O

Inclusion NCT03867929 0 9 O
Criteria NCT03867929 10 18 O
: NCT03867929 19 20 O

- NCT03867929 24 25 O
presence NCT03867929 27 35 B-Eq-Comparison
of NCT03867929 36 38 O
erectile NCT03867929 39 47 B-Condition
dysfunction NCT03867929 48 59 I-Condition

Exclusion NCT03867929 60 69 O
Criteria NCT03867929 70 78 O
: NCT03867929 79 80 O

- NCT03867929 84 85 O
Presence NCT03867929 87 95 B-Eq-Comparison
of NCT03867929 96 98 O
uncontrolled NCT03867929 99 111 B-Modifier
diabetes NCT03867929 112 120 B-Condition
mellitus NCT03867929 121 129 I-Condition
, NCT03867929 130 131 O

- NCT03867929 135 136 O
Presence NCT03867929 138 146 B-Eq-Comparison
of NCT03867929 147 149 O
uncontrolled NCT03867929 150 162 B-Modifier
hypertension NCT03867929 163 175 B-Condition
, NCT03867929 176 177 O

- NCT03867929 181 182 O
Presence NCT03867929 184 192 B-Eq-Comparison
of NCT03867929 193 195 O
uncontrolled NCT03867929 196 208 B-Modifier
lipid NCT03867929 209 214 B-Condition
metabolism NCT03867929 215 225 I-Condition
disorders NCT03867929 226 235 I-Condition
, NCT03867929 236 237 O

- NCT03867929 241 242 O
Presence NCT03867929 244 252 B-Eq-Comparison
of NCT03867929 253 255 O
neurological NCT03867929 256 268 B-Condition
diseases NCT03867929 269 277 I-Condition
, NCT03867929 278 279 O

- NCT03867929 283 284 O
Presence NCT03867929 286 294 B-Eq-Comparison
of NCT03867929 295 297 O
heamatological NCT03867929 298 312 B-Condition
diseases NCT03867929 313 321 I-Condition
, NCT03867929 322 323 O

- NCT03867929 327 328 O
Urinary NCT03867929 330 337 B-Condition
tract NCT03867929 338 343 I-Condition
infection NCT03867929 344 353 I-Condition
, NCT03867929 354 355 O

- NCT03867929 359 360 O
Diagnosis NCT03867929 362 371 O
of NCT03867929 372 374 O
any NCT03867929 375 378 O
malignencies NCT03867929 379 391 B-Condition
, NCT03867929 392 393 O

- NCT03867929 397 398 O
Chronic NCT03867929 400 407 B-Modifier
kidney NCT03867929 408 414 B-Condition
failure NCT03867929 415 422 I-Condition
, NCT03867929 423 424 O

- NCT03867929 428 429 O
Presence NCT03867929 431 439 B-Eq-Comparison
of NCT03867929 440 442 O
metabolic NCT03867929 443 452 B-Condition
syndrome NCT03867929 453 461 I-Condition
, NCT03867929 462 463 O

- NCT03867929 467 468 O
Presence NCT03867929 470 478 B-Eq-Comparison
of NCT03867929 479 481 O
psychiatric NCT03867929 482 493 B-Condition
diseases NCT03867929 494 502 I-Condition
and NCT03867929 503 506 B-Or
/ NCT03867929 507 508 I-Or
or NCT03867929 509 511 I-Or
medical NCT03867929 512 519 B-Procedure
treatment NCT03867929 520 529 I-Procedure
, NCT03867929 530 531 O

- NCT03867929 535 536 O
Smoking NCT03867929 538 545 B-Condition
, NCT03867929 546 547 O

- NCT03867929 551 552 O
History NCT03867929 554 561 B-Eq-Comparison
of NCT03867929 562 564 O
pelvic NCT03867929 565 571 B-Procedure
surgery NCT03867929 572 579 I-Procedure
, NCT03867929 580 581 O
cardiac NCT03867929 582 589 B-Procedure
surgery NCT03867929 590 597 I-Procedure
and NCT03867929 598 601 B-Or
pelvic NCT03867929 602 608 B-Modifier
radiotherapy NCT03867929 609 621 B-Procedure

Inclusion NCT03865680 0 9 O
Criteria NCT03865680 10 18 O
: NCT03865680 19 20 O

- NCT03865680 24 25 O
Healthy NCT03865680 27 34 B-Condition
children NCT03865680 35 43 O
with NCT03865680 44 48 B-And
no NCT03865680 49 51 B-Negation
systemic NCT03865680 52 60 B-Modifier
diseases NCT03865680 61 69 B-Condition
. NCT03865680 70 71 O

- NCT03865680 75 76 O
High NCT03865680 78 82 O
caries NCT03865680 83 89 B-Condition
risk NCT03865680 90 94 B-Risk
children NCT03865680 95 103 O
with NCT03865680 104 108 B-And
the NCT03865680 109 112 O
presence NCT03865680 113 121 O
of NCT03865680 122 124 O
at NCT03865680 125 127 B-Eq-Comparison
least NCT03865680 128 133 I-Eq-Comparison
one NCT03865680 134 137 I-Eq-Comparison
visible NCT03865680 138 145 B-Modifier
active NCT03865680 146 152 B-Eq-Comparison
WSL NCT03865680 153 156 B-Condition
in NCT03865680 157 159 O
primary NCT03865680 160 167 B-Modifier
teeth NCT03865680 168 173 I-Modifier
with NCT03865680 174 178 B-And
ICDAS NCT03865680 179 184 B-Observation
II NCT03865680 185 187 I-Observation
score NCT03865680 188 193 I-Observation
of NCT03865680 194 196 O
1 NCT03865680 197 198 B-Eq-Comparison
, NCT03865680 199 200 I-Eq-Comparison
2 NCT03865680 201 202 I-Eq-Comparison
or NCT03865680 203 205 I-Eq-Comparison
3 NCT03865680 206 207 I-Eq-Comparison

- NCT03865680 211 212 O
Completion NCT03865680 214 224 O
of NCT03865680 225 227 O
a NCT03865680 228 229 O
parental NCT03865680 230 238 O
consent NCT03865680 239 246 O
to NCT03865680 247 249 O
participate NCT03865680 250 261 O
in NCT03865680 262 264 O
the NCT03865680 265 268 O
study NCT03865680 269 274 O
. NCT03865680 275 276 O

Exclusion NCT03865680 278 287 O
Criteria NCT03865680 288 296 O
: NCT03865680 297 298 O

- NCT03865680 302 303 O
Selected NCT03865680 305 313 B-Modifier
tooth NCT03865680 314 319 I-Modifier
with NCT03865680 320 324 O
cavitated NCT03865680 325 334 B-Condition
lesion NCT03865680 335 341 I-Condition
. NCT03865680 342 343 O

- NCT03865680 347 348 O
Selected NCT03865680 350 358 B-Modifier
tooth NCT03865680 359 364 I-Modifier
with NCT03865680 365 369 O
enamel NCT03865680 370 376 B-Condition
defects NCT03865680 377 384 I-Condition
. NCT03865680 385 386 O

- NCT03865680 390 391 O
Participants NCT03865680 393 405 O
allergic NCT03865680 406 414 B-Allergy
to NCT03865680 415 417 O
milk NCT03865680 418 422 O
products NCT03865680 423 431 O
. NCT03865680 431 432 O

Inclusion NCT03869086 0 9 O
Criteria NCT03869086 10 18 O
: NCT03869086 19 20 O

- NCT03869086 24 25 O
BMI NCT03869086 27 30 B-Observation
> NCT03869086 31 32 B-Eq-Comparison
= NCT03869086 34 35 I-Eq-Comparison
25 NCT03869086 36 38 I-Eq-Comparison
kg NCT03869086 39 41 I-Eq-Comparison
/ NCT03869086 42 43 I-Eq-Comparison
m2 NCT03869086 44 46 I-Eq-Comparison

- NCT03869086 49 50 O
Adults NCT03869086 52 58 O
aged NCT03869086 59 63 B-Age
50 NCT03869086 64 66 B-Eq-Comparison
- NCT03869086 67 68 I-Eq-Comparison
80 NCT03869086 69 71 I-Eq-Comparison
years NCT03869086 72 77 I-Eq-Comparison
old NCT03869086 78 81 O

- NCT03869086 84 85 O
Successful NCT03869086 87 97 B-Modifier
biochemical NCT03869086 98 109 I-Modifier
, NCT03869086 110 111 O
haematological NCT03869086 112 126 B-Modifier
, NCT03869086 127 128 O
and NCT03869086 129 132 B-Or
urinalysis NCT03869086 133 143 B-Modifier
assessment NCT03869086 144 154 B-Procedure
at NCT03869086 155 157 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03869086 158 167 B-Study

Exclusion NCT03869086 168 177 O
Criteria NCT03869086 178 186 O
: NCT03869086 187 188 O

- NCT03869086 192 193 O
Current NCT03869086 195 202 B-Eq-Comparison
smokers NCT03869086 203 210 B-Condition
, NCT03869086 211 212 O
or NCT03869086 213 215 B-Or
ex NCT03869086 216 218 B-Eq-Comparison
- NCT03869086 219 220 O
smokers NCT03869086 221 228 B-Condition
ceasing NCT03869086 229 236 O
< NCT03869086 237 238 B-Eq-Comparison
6 NCT03869086 239 240 I-Eq-Comparison
months NCT03869086 241 247 I-Eq-Comparison
ago NCT03869086 248 251 I-Eq-Comparison

- NCT03869086 254 255 O
existing NCT03869086 257 265 B-Eq-Comparison
or NCT03869086 266 268 B-Or
significant NCT03869086 269 280 O
past NCT03869086 281 285 B-Eq-Comparison
medical NCT03869086 286 293 I-Eq-Comparison
history NCT03869086 294 301 I-Eq-Comparison
of NCT03869086 302 304 O
vascular NCT03869086 305 313 B-Condition
disease NCT03869086 314 321 I-Condition
or NCT03869086 322 324 B-Or
medical NCT03869086 325 332 O
conditions NCT03869086 333 343 B-Condition
likely NCT03869086 344 350 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 351 353 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03869086 354 360 O
the NCT03869086 361 364 O
study NCT03869086 365 370 B-Study
measures NCT03869086 371 379 O

- NCT03869086 382 383 O
Fructose NCT03869086 385 393 B-Modifier
or NCT03869086 394 396 B-Or
lactose NCT03869086 397 404 B-Modifier
intolerant NCT03869086 405 415 B-Condition
subjects NCT03869086 416 424 O
or NCT03869086 425 427 B-Or
known NCT03869086 428 433 O
allergies NCT03869086 434 443 B-Allergy
to NCT03869086 444 446 O
intervention NCT03869086 447 459 B-Study
treatments NCT03869086 460 470 B-Procedure

- NCT03869086 473 474 O
Those NCT03869086 476 481 O
unprepared NCT03869086 482 492 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 493 495 I-Assertion___Assertion-Type-Value:hypothetical
adhere NCT03869086 496 502 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 503 505 O
dietary NCT03869086 506 513 B-Procedure
instructions NCT03869086 514 526 I-Procedure

- NCT03869086 529 530 O
Parallel NCT03869086 532 540 O
participation NCT03869086 541 554 O
in NCT03869086 555 557 O
another NCT03869086 558 565 B-Other
research NCT03869086 566 574 B-Study
project NCT03869086 575 582 O
involving NCT03869086 583 592 O
dietary NCT03869086 593 600 B-Procedure
intervention NCT03869086 601 613 I-Procedure
and NCT03869086 614 617 B-Or
/ NCT03869086 618 619 I-Or
or NCT03869086 620 622 I-Or
sampling NCT03869086 623 631 B-Procedure
of NCT03869086 632 634 O
biological NCT03869086 635 645 B-Modifier
fluids NCT03869086 646 652 I-Modifier
/ NCT03869086 653 654 B-Or
material NCT03869086 655 663 B-Modifier

- NCT03869086 666 667 O
Those NCT03869086 669 674 O
on NCT03869086 675 677 B-Eq-Comparison
therapeutic NCT03869086 678 689 B-Procedure
diets NCT03869086 690 695 I-Procedure
or NCT03869086 696 698 B-Or
having NCT03869086 699 705 O
experienced NCT03869086 706 717 B-Eq-Comparison
substantial NCT03869086 718 729 O
weight NCT03869086 730 736 B-Condition
loss NCT03869086 737 741 I-Condition
within NCT03869086 742 748 B-Eq-Comparison
2 NCT03869086 749 750 I-Eq-Comparison
months NCT03869086 751 757 I-Eq-Comparison
of NCT03869086 758 760 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03869086 761 770 B-Study
. NCT03869086 771 772 O

- NCT03869086 776 777 O
Those NCT03869086 779 784 O
taking NCT03869086 785 791 B-Eq-Comparison
flavonoid NCT03869086 792 801 B-Drug
, NCT03869086 802 803 O
nitrate NCT03869086 804 811 B-Drug
/ NCT03869086 812 813 B-Or
nitrite NCT03869086 814 821 B-Drug
containing NCT03869086 822 832 I-Drug
or NCT03869086 833 835 B-Or
fish NCT03869086 836 840 B-Modifier
oil NCT03869086 841 844 I-Modifier
containing NCT03869086 845 855 I-Modifier
supplements NCT03869086 856 867 B-Drug
( NCT03869086 868 869 O
and NCT03869086 870 873 B-And
unwilling NCT03869086 874 883 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 884 886 I-Assertion___Assertion-Type-Value:hypothetical
cease NCT03869086 887 892 B-Negation
intake NCT03869086 893 899 B-Coreference
during NCT03869086 900 906 B-Temporal-Connection___Temporal-Connection-Type-Value:during
, NCT03869086 907 908 O
and NCT03869086 909 912 B-And
1 NCT03869086 913 914 B-Eq-Comparison
month NCT03869086 915 920 I-Eq-Comparison
preceding NCT03869086 921 930 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869086 931 934 O
trial NCT03869086 935 940 B-Study
) NCT03869086 941 942 O
or NCT03869086 943 945 B-Or
unwilling NCT03869086 946 955 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869086 956 958 I-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03869086 959 967 O
existing NCT03869086 968 976 B-Eq-Comparison
intake NCT03869086 977 983 O
of NCT03869086 984 986 O
other NCT03869086 987 992 B-Other
supplements NCT03869086 993 1004 B-Drug
. NCT03869086 1005 1006 O

- NCT03869086 1010 1011 O
Prescribed NCT03869086 1013 1023 O
hypoglycaemic NCT03869086 1024 1037 B-Drug
, NCT03869086 1038 1039 O
anti NCT03869086 1040 1044 B-Drug
- NCT03869086 1045 1046 I-Drug
hypertensive NCT03869086 1047 1059 I-Drug
, NCT03869086 1060 1061 O
vasodilator NCT03869086 1062 1073 B-Drug
or NCT03869086 1074 1076 B-Or
hormone NCT03869086 1077 1084 B-Procedure
replacement NCT03869086 1085 1096 I-Procedure
therapy NCT03869086 1097 1104 I-Procedure
( NCT03869086 1105 1106 O
HRT NCT03869086 1107 1110 B-Procedure
) NCT03869086 1111 1112 O
medication NCT03869086 1113 1123 B-Drug
. NCT03869086 1124 1125 O

- NCT03869086 1129 1130 O
Unsatisfactory NCT03869086 1132 1146 O
biochemical NCT03869086 1147 1158 B-Modifier
, NCT03869086 1159 1160 O
haematological NCT03869086 1161 1175 B-Modifier
or NCT03869086 1176 1178 B-Or
urinary NCT03869086 1179 1186 B-Modifier
results NCT03869086 1187 1194 B-Observation
or NCT03869086 1195 1197 B-Or
measurements NCT03869086 1198 1210 B-Observation
considered NCT03869086 1211 1221 O
to NCT03869086 1222 1224 O
be NCT03869086 1225 1227 O
counter NCT03869086 1228 1235 O
indicative NCT03869086 1236 1246 O
for NCT03869086 1247 1250 O
the NCT03869086 1251 1254 O
study NCT03869086 1255 1260 B-Study

- NCT03869086 1263 1264 O
Undiagnosed NCT03869086 1266 1277 B-Modifier
hypertension NCT03869086 1278 1290 B-Condition|Observation
( NCT03869086 1291 1292 O
elicited NCT03869086 1293 1301 O
at NCT03869086 1302 1304 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03869086 1305 1314 B-Study
; NCT03869086 1314 1315 O
i. NCT03869086 1316 1318 O
e. NCT03869086 1319 1321 O
≥ NCT03869086 1323 1324 B-Eq-Comparison
180 NCT03869086 1325 1328 I-Eq-Comparison
/ NCT03869086 1329 1330 I-Eq-Comparison
110 NCT03869086 1331 1334 I-Eq-Comparison
mmHg NCT03869086 1335 1339 I-Eq-Comparison
) NCT03869086 1340 1341 O
at NCT03869086 1342 1344 O
a NCT03869086 1345 1346 O
level NCT03869086 1347 1352 O
requiring NCT03869086 1353 1362 B-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03869086 1363 1372 O
referral NCT03869086 1373 1381 O
back NCT03869086 1382 1386 O
to NCT03869086 1387 1389 O
general NCT03869086 1390 1397 B-Provider
practitioner NCT03869086 1398 1410 I-Provider
for NCT03869086 1411 1414 O
follow NCT03869086 1415 1421 B-Encounter
- NCT03869086 1422 1423 I-Encounter
up NCT03869086 1424 1426 I-Encounter

Inclusion NCT03864549 0 9 O
Criteria NCT03864549 10 18 O
: NCT03864549 19 20 O

- NCT03864549 24 25 O
Pregnant NCT03864549 27 35 B-Condition
women NCT03864549 36 41 O
who NCT03864549 42 45 B-And
were NCT03864549 46 50 O
diagnosed NCT03864549 51 60 O
with NCT03864549 61 65 O
GDM NCT03864549 66 69 B-Condition
from NCT03864549 70 74 B-Temporal-Connection___Temporal-Connection-Type-Value:during
13 NCT03864549 75 77 B-Eq-Comparison
to NCT03864549 78 80 I-Eq-Comparison
32.6 NCT03864549 81 85 I-Eq-Comparison
gestational NCT03864549 86 97 B-Observation
weeks NCT03864549 98 103 O

- NCT03864549 106 107 O
18 NCT03864549 109 111 B-Eq-Comparison
years NCT03864549 112 117 I-Eq-Comparison
old NCT03864549 118 121 I-Eq-Comparison
and NCT03864549 122 125 I-Eq-Comparison
older NCT03864549 126 131 I-Age|Eq-Comparison

- NCT03864549 134 135 O
Singleton NCT03864549 137 146 B-Modifier
pregnancy NCT03864549 147 156 B-Condition

Exclusion NCT03864549 157 166 O
Criteria NCT03864549 167 175 O
: NCT03864549 176 177 O

- NCT03864549 181 182 O
Women NCT03864549 184 189 O
with NCT03864549 190 194 B-And
pre NCT03864549 195 198 B-Modifier
- NCT03864549 199 200 I-Modifier
gestational NCT03864549 201 212 I-Modifier
diabetes NCT03864549 213 221 B-Condition
mellitus NCT03864549 222 230 I-Condition

- NCT03864549 233 234 O
GDM NCT03864549 236 239 B-Condition
diagnosed NCT03864549 240 249 O
≥ NCT03864549 250 251 B-Eq-Comparison
33 NCT03864549 252 254 I-Eq-Comparison
gestational NCT03864549 255 266 B-Observation
weeks NCT03864549 267 272 O

- NCT03864549 275 276 O
Women NCT03864549 278 283 O
using NCT03864549 284 289 B-Eq-Comparison
prophylactic NCT03864549 290 302 B-Procedure
antimicrobial NCT03864549 303 316 I-Procedure
treatment NCT03864549 317 326 I-Procedure

- NCT03864549 329 330 O
Immunocompromised NCT03864549 332 349 B-Condition
women NCT03864549 350 355 O

- NCT03864549 358 359 O
Multiple NCT03864549 361 369 B-Eq-Comparison
pregnancy NCT03864549 370 379 B-Condition

- NCT03864549 382 383 O
Women NCT03864549 385 390 O
taking NCT03864549 391 397 B-Eq-Comparison
oral NCT03864549 398 402 B-Modifier
probiotic NCT03864549 403 412 B-Drug
products NCT03864549 413 421 I-Drug
who NCT03864549 422 425 B-And
refuse NCT03864549 426 432 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864549 433 435 I-Assertion___Assertion-Type-Value:hypothetical
stop NCT03864549 436 440 B-Negation
the NCT03864549 441 444 B-Coreference
consumption NCT03864549 445 456 I-Coreference
( NCT03864549 457 458 O
food NCT03864549 459 463 B-Modifier
- NCT03864549 464 465 I-Modifier
containing NCT03864549 466 476 I-Modifier
probiotics NCT03864549 477 487 B-Drug
is NCT03864549 488 490 B-Exception
not NCT03864549 491 494 I-Exception
considered NCT03864549 495 505 I-Exception
an NCT03864549 506 508 I-Exception
exclusion NCT03864549 509 518 I-Exception
criterion NCT03864549 519 528 I-Exception
) NCT03864549 529 530 O
. NCT03864549 531 532 O

Inclusion NCT03869723 0 9 O
Criteria NCT03869723 10 18 O
: NCT03869723 19 20 O

- NCT03869723 24 25 O
Patients NCT03869723 27 35 O
who NCT03869723 36 39 O
underwent NCT03869723 40 49 B-Eq-Comparison
fibula NCT03869723 50 56 B-Procedure
free NCT03869723 57 61 I-Procedure
flap NCT03869723 62 66 I-Procedure
for NCT03869723 67 70 O
mandibular NCT03869723 71 81 B-Procedure
reconstruction NCT03869723 82 96 I-Procedure

- NCT03869723 99 100 O
Patient NCT03869723 102 109 O
≥ NCT03869723 110 111 B-Eq-Comparison
18 NCT03869723 112 114 I-Eq-Comparison
years NCT03869723 115 120 I-Eq-Comparison
old NCT03869723 121 124 B-Age

- NCT03869723 127 128 O
patient NCT03869723 130 137 O
alive NCT03869723 138 143 B-Death|Negation
6 NCT03869723 144 145 B-Eq-Comparison
months NCT03869723 146 152 I-Eq-Comparison
after NCT03869723 153 158 B-Temporal-Connection___Temporal-Connection-Type-Value:after
completion NCT03869723 159 169 O
of NCT03869723 170 172 O
treatment NCT03869723 173 182 B-Procedure

Exclusion NCT03869723 183 192 O
Criteria NCT03869723 193 201 O
: NCT03869723 202 203 O

- NCT03869723 207 208 O
Patient NCT03869723 210 217 O
without NCT03869723 218 225 B-Negation
post NCT03869723 226 230 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03869723 231 232 O
operative NCT03869723 233 242 B-Procedure
scan NCT03869723 243 247 B-Procedure
evaluation NCT03869723 248 258 I-Procedure

- NCT03869723 261 262 O
Patient NCT03869723 264 271 O
with NCT03869723 272 276 O
a NCT03869723 277 278 O
chirurgical NCT03869723 279 290 B-Procedure
contraindication NCT03869723 291 307 B-Contraindication

- NCT03869723 310 311 O
Pregnant NCT03869723 313 321 B-Condition
or NCT03869723 322 324 B-Or
nursing NCT03869723 325 332 B-Condition
woman NCT03869723 333 338 O

- NCT03869723 341 342 O
Adult NCT03869723 344 349 O
requiring NCT03869723 350 359 B-Observation
protection NCT03869723 360 370 I-Observation
( NCT03869723 371 372 O
guardianship NCT03869723 373 385 B-Observation
, NCT03869723 386 387 O
supervision NCT03869723 388 399 B-Observation
) NCT03869723 400 401 O

Inclusion NCT03861182 0 9 O
Criteria NCT03861182 10 18 O
: NCT03861182 19 20 O

Adult NCT03861182 22 27 O
Healthy NCT03861182 28 35 B-Condition
Volunteers NCT03861182 36 46 O
: NCT03861182 47 48 O

- NCT03861182 51 52 O
Over NCT03861182 53 57 B-Eq-Comparison
18 NCT03861182 58 60 I-Eq-Comparison
years NCT03861182 61 66 I-Eq-Comparison
of NCT03861182 67 69 O
age NCT03861182 70 73 B-Age

Neonates NCT03861182 74 82 B-Condition
: NCT03861182 83 84 O

- NCT03861182 88 89 O
Aged NCT03861182 91 95 B-Age
between NCT03861182 96 103 B-Eq-Comparison
1 NCT03861182 104 105 I-Eq-Comparison
h NCT03861182 106 107 I-Eq-Comparison
of NCT03861182 108 110 I-Eq-Comparison
life NCT03861182 111 115 I-Eq-Comparison
and NCT03861182 116 119 I-Eq-Comparison
28 NCT03861182 120 122 I-Eq-Comparison
days NCT03861182 123 127 I-Eq-Comparison
of NCT03861182 128 130 O
life NCT03861182 131 135 O

- NCT03861182 138 139 O
Born NCT03861182 141 145 B-Birth
beyond NCT03861182 146 152 B-Eq-Comparison
33 NCT03861182 153 155 I-Eq-Comparison
Week NCT03861182 156 160 I-Eq-Comparison
of NCT03861182 161 163 B-Temporal-Connection___Temporal-Connection-Type-Value:after
Amenorrhea NCT03861182 164 174 B-Condition
+ NCT03861182 175 176 B-Temporal-Connection___Temporal-Connection-Type-Value:after
1 NCT03861182 177 178 B-Eq-Comparison
day NCT03861182 179 182 I-Eq-Comparison
and NCT03861182 183 186 B-And
2 NCT03861182 187 188 B-Eq-Comparison
kg NCT03861182 189 191 I-Eq-Comparison
of NCT03861182 192 194 O
birth NCT03861182 195 200 B-Observation
weight NCT03861182 201 207 I-Observation

- NCT03861182 210 211 O
Hospitalized NCT03861182 213 225 B-Encounter
in NCT03861182 226 228 O
the NCT03861182 229 232 O
medical NCT03861182 233 240 O
- NCT03861182 241 242 O
surgical NCT03861182 243 251 O
centre NCT03861182 252 258 O
of NCT03861182 259 261 O
Pediatrics NCT03861182 262 272 O
of NCT03861182 273 275 O
the NCT03861182 276 279 O
hospital NCT03861182 280 288 O
of NCT03861182 289 291 O
Strasbourg NCT03861182 292 302 O

- NCT03861182 305 306 O
For NCT03861182 308 311 O
whom NCT03861182 312 316 O
a NCT03861182 317 318 O
blood NCT03861182 319 324 B-Observation
sample NCT03861182 325 331 I-Observation
was NCT03861182 332 335 O
prescribed NCT03861182 336 346 O
as NCT03861182 347 349 O
part NCT03861182 350 354 O
of NCT03861182 355 357 O
their NCT03861182 358 363 O
routine NCT03861182 364 371 O
care NCT03861182 372 376 O

Exclusion NCT03861182 377 386 O
Criteria NCT03861182 387 395 O
: NCT03861182 396 397 O

Adult NCT03861182 399 404 O
Healthy NCT03861182 405 412 B-Condition
Volunteers NCT03861182 413 423 O
: NCT03861182 424 425 O

- NCT03861182 429 430 O
Systemic NCT03861182 432 440 B-Modifier
inflammatory NCT03861182 441 453 B-Condition
disease NCT03861182 454 461 I-Condition

- NCT03861182 464 465 O
Transient NCT03861182 467 476 B-Condition
inflammatory NCT03861182 477 489 I-Condition
state NCT03861182 490 495 I-Condition

- NCT03861182 498 499 O
Any NCT03861182 501 504 O
drug NCT03861182 505 509 B-Drug
that NCT03861182 510 514 O
modifies NCT03861182 515 523 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03861182 524 527 O
coagulation NCT03861182 528 539 B-Condition
cascade NCT03861182 540 547 I-Condition
during NCT03861182 548 554 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861182 555 558 O
48 NCT03861182 559 561 B-Eq-Comparison
h NCT03861182 562 563 I-Eq-Comparison
preceding NCT03861182 564 573 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861182 574 577 O
sampling NCT03861182 578 586 B-Study

Neonates NCT03861182 587 595 O
: NCT03861182 596 597 O

- NCT03861182 601 602 O
Risk NCT03861182 604 608 B-Risk
of NCT03861182 609 611 O
anemia NCT03861182 612 618 B-Condition|Observation
< NCT03861182 619 620 B-Eq-Comparison
7 NCT03861182 621 622 I-Eq-Comparison
g NCT03861182 623 624 I-Eq-Comparison
/ NCT03861182 625 626 I-Eq-Comparison
DL NCT03861182 627 629 I-Eq-Comparison

- NCT03861182 632 633 O
Current NCT03861182 635 642 B-Eq-Comparison
anticoagulant NCT03861182 643 656 B-Drug
treatment NCT03861182 657 666 B-Procedure

Inclusion NCT03866148 0 9 O
Criteria NCT03866148 10 18 O
: NCT03866148 19 20 O

- NCT03866148 24 25 O
Patients NCT03866148 27 35 O
with NCT03866148 36 40 O
moderate NCT03866148 41 49 B-Eq-Comparison
to NCT03866148 50 52 I-Eq-Comparison
severe NCT03866148 53 59 I-Eq-Comparison
sleep NCT03866148 60 65 B-Condition
apnoea NCT03866148 66 72 I-Condition
who NCT03866148 73 76 B-And
require NCT03866148 77 84 B-Assertion___Assertion-Type-Value:hypothetical
CPAP NCT03866148 85 89 B-Procedure
as NCT03866148 90 92 O
standard NCT03866148 93 101 B-Procedure
care NCT03866148 102 106 I-Procedure
( NCT03866148 107 108 O
AHI NCT03866148 109 112 B-Observation
> NCT03866148 113 114 B-Eq-Comparison
15 NCT03866148 115 117 I-Eq-Comparison
) NCT03866148 118 119 O

- NCT03866148 123 124 O
Patients NCT03866148 126 134 O
between NCT03866148 135 142 B-Eq-Comparison
the NCT03866148 143 146 I-Eq-Comparison
age NCT03866148 147 150 I-Age|Eq-Comparison
of NCT03866148 151 153 I-Eq-Comparison
18 NCT03866148 154 156 I-Eq-Comparison
and NCT03866148 157 160 I-Eq-Comparison
75 NCT03866148 161 163 I-Eq-Comparison

Exclusion NCT03866148 165 174 O
Criteria NCT03866148 175 183 O
: NCT03866148 184 185 O

- NCT03866148 189 190 O
Patients NCT03866148 192 200 O
with NCT03866148 201 205 O
a NCT03866148 206 207 O
diagnosis NCT03866148 208 217 O
of NCT03866148 218 220 O
atrial NCT03866148 221 227 B-Condition
fibrillation NCT03866148 228 240 I-Condition
( NCT03866148 241 242 O
AF NCT03866148 243 245 B-Condition
) NCT03866148 246 247 O
, NCT03866148 249 250 O
atrial NCT03866148 251 257 B-Condition
flutter NCT03866148 258 265 I-Condition
and NCT03866148 266 269 B-Or
/ NCT03866148 270 271 I-Or
or NCT03866148 272 274 I-Or
ventricular NCT03866148 275 286 B-Condition
tachycardia NCT03866148 287 298 I-Condition
( NCT03866148 299 300 O
VT NCT03866148 301 303 B-Condition
) NCT03866148 304 305 O

- NCT03866148 309 310 O
Patients NCT03866148 312 320 O
with NCT03866148 321 325 O
an NCT03866148 326 328 O
ILR NCT03866148 329 332 B-Procedure
already NCT03866148 333 340 B-Eq-Comparison
in NCT03866148 341 343 B-Modifier
- NCT03866148 344 345 I-Modifier
situ NCT03866148 346 350 I-Modifier
or NCT03866148 351 353 B-Or
an NCT03866148 354 356 O
established NCT03866148 357 368 O
indication NCT03866148 369 379 B-Indication
for NCT03866148 380 383 O
ILR NCT03866148 384 387 B-Procedure

- NCT03866148 390 391 O
Patients NCT03866148 393 401 O
with NCT03866148 402 406 O
a NCT03866148 407 408 O
palliative NCT03866148 409 419 B-Condition
diagnosis NCT03866148 420 429 O
i. NCT03866148 430 432 O
e. NCT03866148 433 435 O
life NCT03866148 437 441 B-Observation
expectancy NCT03866148 442 452 I-Observation
less NCT03866148 453 457 B-Eq-Comparison
than NCT03866148 458 462 I-Eq-Comparison
3 NCT03866148 463 464 I-Eq-Comparison
years NCT03866148 465 470 I-Eq-Comparison

- NCT03866148 473 474 O
Patients NCT03866148 476 484 O
who NCT03866148 485 488 O
lack NCT03866148 489 493 B-Condition
capacity NCT03866148 494 502 I-Condition

Inclusion NCT03863756 0 9 O
Criteria NCT03863756 10 18 O
: NCT03863756 19 20 O

- NCT03863756 24 25 O
Patients NCT03863756 27 35 O
with NCT03863756 36 40 O
Spondyloarthritis NCT03863756 41 58 B-Condition
( NCT03863756 59 60 O
SpA NCT03863756 61 64 B-Condition
) NCT03863756 65 66 O
meeting NCT03863756 67 74 O
the NCT03863756 75 78 O
criteria NCT03863756 79 87 O
of NCT03863756 88 90 O
Amor NCT03863756 91 95 O
and NCT03863756 96 99 O
/ NCT03863756 100 101 O
or NCT03863756 102 104 O
Assessement NCT03863756 105 116 O
of NCT03863756 117 119 O
spondyloarthritis NCT03863756 120 137 O
International NCT03863756 138 151 O
Society NCT03863756 152 159 O
( NCT03863756 160 161 O
ASAS NCT03863756 162 166 O
) NCT03863756 167 168 O

- NCT03863756 172 173 O
Indication NCT03863756 175 185 B-Indication
of NCT03863756 186 188 O
standard NCT03863756 189 197 B-Procedure
radiography NCT03863756 198 209 I-Procedure
for NCT03863756 210 213 O
the NCT03863756 214 217 O
follow NCT03863756 218 224 B-Encounter
- NCT03863756 225 226 I-Encounter
up NCT03863756 227 229 I-Encounter
of NCT03863756 230 232 O
the NCT03863756 233 236 O
patients NCT03863756 237 245 O
. NCT03863756 246 247 O

Exclusion NCT03863756 249 258 O
Criteria NCT03863756 259 267 O
: NCT03863756 268 269 O

- NCT03863756 273 274 O
the NCT03863756 276 279 O
presence NCT03863756 280 288 O
of NCT03863756 289 291 O
a NCT03863756 292 293 O
contraindication NCT03863756 294 310 B-Contraindication
to NCT03863756 311 313 O
the NCT03863756 314 317 O
performance NCT03863756 318 329 O
of NCT03863756 330 332 O
conventional NCT03863756 333 345 B-Procedure
radiography NCT03863756 346 357 I-Procedure
( NCT03863756 358 359 O
CR NCT03863756 360 362 B-Procedure
) NCT03863756 363 364 O
or NCT03863756 365 367 B-Or
EOS NCT03863756 368 371 B-Procedure
imaging NCT03863756 372 379 I-Procedure

- NCT03863756 382 383 O
any NCT03863756 385 388 O
disease NCT03863756 389 396 B-Condition
affecting NCT03863756 397 406 O
cognition NCT03863756 407 416 B-Condition

- NCT03863756 419 420 O
Patients NCT03863756 422 430 O
who NCT03863756 431 434 O
have NCT03863756 435 439 O
had NCT03863756 440 443 B-Eq-Comparison
surgery NCT03863756 444 451 B-Procedure
on NCT03863756 452 454 O
the NCT03863756 455 458 O
spine NCT03863756 459 464 B-Modifier
and NCT03863756 465 468 B-Or
/ NCT03863756 469 470 I-Or
or NCT03863756 471 473 I-Or
hip NCT03863756 474 477 B-Modifier
. NCT03863756 477 478 O

Inclusion NCT03864991 0 9 O
Criteria NCT03864991 10 18 O
: NCT03864991 19 20 O

- NCT03864991 24 25 O
Patient NCT03864991 27 34 O
diagnosed NCT03864991 35 44 O
with NCT03864991 45 49 O
T1D NCT03864991 50 53 B-Condition
> NCT03864991 54 55 B-Eq-Comparison
6 NCT03864991 56 57 I-Eq-Comparison
months NCT03864991 58 64 I-Eq-Comparison

- NCT03864991 67 68 O
Patient NCT03864991 70 77 O
's NCT03864991 77 79 O
age NCT03864991 80 83 B-Age
≥ NCT03864991 84 85 B-Eq-Comparison
15 NCT03864991 86 88 I-Eq-Comparison
years NCT03864991 89 94 I-Eq-Comparison

- NCT03864991 97 98 O
Patient NCT03864991 100 107 O
or NCT03864991 108 110 O
any NCT03864991 111 114 O
one NCT03864991 115 118 O
of NCT03864991 119 121 O
the NCT03864991 122 125 O
family NCT03864991 126 132 B-Family-Member
member NCT03864991 133 139 I-Family-Member
like NCT03864991 140 144 O
father NCT03864991 145 151 B-Family-Member___Family-Member-Type:father
, NCT03864991 152 153 O
mother NCT03864991 154 160 B-Family-Member___Family-Member-Type:parent
or NCT03864991 161 163 B-Or
sibling NCT03864991 164 171 B-Family-Member___Family-Member-Type:sibling
using NCT03864991 172 177 B-Eq-Comparison
smart NCT03864991 178 183 O
phone NCT03864991 184 189 O
. NCT03864991 190 191 O

- NCT03864991 195 196 O
Patient NCT03864991 198 205 O
or NCT03864991 206 208 O
any NCT03864991 209 212 O
one NCT03864991 213 216 O
of NCT03864991 217 219 O
the NCT03864991 220 223 O
family NCT03864991 224 230 B-Family-Member
member NCT03864991 231 237 I-Family-Member
know NCT03864991 238 242 O
how NCT03864991 243 246 O
to NCT03864991 247 249 O
use NCT03864991 250 253 O
( NCT03864991 254 255 O
receive NCT03864991 256 263 O
calls NCT03864991 264 269 O
or NCT03864991 270 272 O
read NCT03864991 273 277 O
text NCT03864991 278 282 O
message NCT03864991 283 290 O
) NCT03864991 291 292 O
a NCT03864991 293 294 O
smart NCT03864991 295 300 O
phone NCT03864991 301 306 O
. NCT03864991 307 308 O

Exclusion NCT03864991 310 319 O
Criteria NCT03864991 320 328 O
: NCT03864991 329 330 O

- NCT03864991 334 335 O
Patient NCT03864991 337 344 O
on NCT03864991 345 347 B-Eq-Comparison
insulin NCT03864991 348 355 B-Drug
pump NCT03864991 356 360 B-Modifier

- NCT03864991 363 364 O
Pregnant NCT03864991 366 374 B-Condition
females NCT03864991 375 382 O
, NCT03864991 383 384 O

- NCT03864991 388 389 O
Patient NCT03864991 391 398 O
with NCT03864991 399 403 O
neurodevelopmental NCT03864991 404 422 B-Condition
delay NCT03864991 423 428 I-Condition
or NCT03864991 429 431 B-Or
thalassemia NCT03864991 432 443 B-Condition

- NCT03864991 446 447 O
Patient NCT03864991 449 456 O
currently NCT03864991 457 466 B-Eq-Comparison
using NCT03864991 467 472 O
any NCT03864991 473 476 O
kind NCT03864991 477 481 O
of NCT03864991 482 484 O
authentic NCT03864991 485 494 O
e NCT03864991 495 496 B-Procedure
- NCT03864991 497 498 I-Procedure
device NCT03864991 499 505 I-Procedure
for NCT03864991 506 509 O
step NCT03864991 510 514 B-Observation
count NCT03864991 515 520 I-Observation
or NCT03864991 521 523 B-Or
physical NCT03864991 524 532 B-Observation
activity NCT03864991 533 541 I-Observation
. NCT03864991 541 542 O

Inclusion NCT03867240 0 9 O
Criteria NCT03867240 10 18 O
: NCT03867240 19 20 O

- NCT03867240 24 25 O
Be NCT03867240 27 29 O
aged NCT03867240 30 34 B-Age
10 NCT03867240 35 37 B-Eq-Comparison
- NCT03867240 38 39 I-Eq-Comparison
18 NCT03867240 40 42 I-Eq-Comparison
years NCT03867240 43 48 I-Eq-Comparison
at NCT03867240 49 51 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867240 52 55 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867240 56 60 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867240 61 63 O
surgery NCT03867240 64 71 B-Procedure

- NCT03867240 74 75 O
Have NCT03867240 77 81 O
a NCT03867240 82 83 O
diagnosis NCT03867240 84 93 O
of NCT03867240 94 96 O
idiopathic NCT03867240 97 107 B-Condition
scoliosis NCT03867240 108 117 I-Condition
and NCT03867240 118 121 B-Or
/ NCT03867240 122 123 I-Or
or NCT03867240 124 126 I-Or
kyphosis NCT03867240 127 135 B-Condition

- NCT03867240 138 139 O
Be NCT03867240 141 143 O
undergoing NCT03867240 144 154 B-Eq-Comparison
elective NCT03867240 155 163 B-Modifier
posterior NCT03867240 164 173 B-Procedure
spinal NCT03867240 174 180 I-Procedure
fusion NCT03867240 181 187 I-Procedure

- NCT03867240 190 191 O
Have NCT03867240 193 197 O
only NCT03867240 198 202 O
mild NCT03867240 203 207 O
systemic NCT03867240 208 216 B-Condition
disease NCT03867240 217 224 I-Condition

Exclusion NCT03867240 225 234 O
Criteria NCT03867240 235 243 O
: NCT03867240 244 245 O

- NCT03867240 249 250 O
A NCT03867240 252 253 O
diagnosis NCT03867240 254 263 O
of NCT03867240 264 266 O
neuromuscular NCT03867240 267 280 B-Condition
scoliosis NCT03867240 281 290 I-Condition
and NCT03867240 291 294 B-Or
/ NCT03867240 295 296 I-Or
or NCT03867240 297 299 I-Or
kyphosis NCT03867240 300 308 B-Condition

- NCT03867240 311 312 O
A NCT03867240 314 315 O
diagnosis NCT03867240 316 325 O
of NCT03867240 326 328 O
chronic NCT03867240 329 336 B-Modifier
pain NCT03867240 337 341 B-Condition

- NCT03867240 344 345 O
Used NCT03867240 347 351 B-Eq-Comparison
opioids NCT03867240 352 359 B-Drug
in NCT03867240 360 362 O
the NCT03867240 363 366 O
past NCT03867240 367 371 B-Eq-Comparison
6 NCT03867240 372 373 I-Eq-Comparison
months NCT03867240 374 380 I-Eq-Comparison

- NCT03867240 383 384 O
Developmental NCT03867240 386 399 B-Condition
delay NCT03867240 400 405 I-Condition

- NCT03867240 408 409 O
Liver NCT03867240 411 416 B-Modifier
or NCT03867240 417 419 B-Or
kidney NCT03867240 420 426 B-Modifier
disease NCT03867240 427 434 B-Condition

- NCT03867240 437 438 O
Obstructive NCT03867240 440 451 B-Condition
sleep NCT03867240 452 457 I-Condition
apnea NCT03867240 458 463 I-Condition

- NCT03867240 466 467 O
Body NCT03867240 469 473 B-Observation
mass NCT03867240 474 478 I-Observation
index NCT03867240 479 484 I-Observation
> NCT03867240 485 486 B-Eq-Comparison
40 NCT03867240 487 489 I-Eq-Comparison

- NCT03867240 493 494 O
Be NCT03867240 496 498 O
pregnant NCT03867240 499 507 B-Condition
or NCT03867240 508 510 B-Or
breastfeeding NCT03867240 511 524 B-Condition

Inclusion NCT03867526 0 9 O
Criteria NCT03867526 10 18 O
: NCT03867526 19 20 O

- NCT03867526 24 25 O
Informed NCT03867526 27 35 O
consent NCT03867526 36 43 O
will NCT03867526 44 48 O
be NCT03867526 49 51 O
obtained NCT03867526 52 60 O
from NCT03867526 61 65 O
the NCT03867526 66 69 O
patient NCT03867526 70 77 O
or NCT03867526 78 80 O
the NCT03867526 81 84 O
parents NCT03867526 85 92 B-Family-Member___Family-Member-Type:parent
before NCT03867526 93 99 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03867526 100 103 O
study NCT03867526 104 109 B-Study
related NCT03867526 110 117 O
procedures NCT03867526 118 128 B-Procedure
. NCT03867526 129 130 O

- NCT03867526 134 135 O
Patients NCT03867526 137 145 O
of NCT03867526 146 148 O
both NCT03867526 149 153 O
genders NCT03867526 154 161 O
older NCT03867526 162 167 I-Eq-Comparison
than NCT03867526 168 172 I-Eq-Comparison
6 NCT03867526 173 174 I-Eq-Comparison
months NCT03867526 175 181 I-Eq-Comparison
and NCT03867526 182 185 B-And
younger NCT03867526 186 193 B-Eq-Comparison
than NCT03867526 194 198 I-Eq-Comparison
80 NCT03867526 199 201 I-Eq-Comparison
years NCT03867526 202 207 I-Eq-Comparison

- NCT03867526 210 211 O
The NCT03867526 213 216 O
patient NCT03867526 217 224 O
has NCT03867526 225 228 O
a NCT03867526 229 230 O
diagnosis NCT03867526 231 240 O
of NCT03867526 241 243 O
Wilson NCT03867526 244 250 B-Condition
dis NCT03867526 251 254 I-Condition
- NCT03867526 255 256 I-Condition
ease NCT03867526 257 261 I-Condition

Exclusion NCT03867526 262 271 O
Criteria NCT03867526 272 280 O
: NCT03867526 281 282 O

- NCT03867526 286 287 O
No NCT03867526 289 291 O
Informed NCT03867526 292 300 O
consent NCT03867526 301 308 O
from NCT03867526 309 313 O
the NCT03867526 314 317 O
patient NCT03867526 318 325 O
or NCT03867526 326 328 O
the NCT03867526 329 332 O
parents NCT03867526 333 340 B-Family-Member___Family-Member-Type:parent
before NCT03867526 341 347 B-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03867526 348 351 O
study NCT03867526 352 357 B-Study
related NCT03867526 358 365 O
procedures NCT03867526 366 376 B-Procedure

- NCT03867526 379 380 O
Patients NCT03867526 382 390 O
of NCT03867526 391 393 O
both NCT03867526 394 398 O
genders NCT03867526 399 406 O
younger NCT03867526 407 414 B-Eq-Comparison
than NCT03867526 415 419 I-Eq-Comparison
6 NCT03867526 420 421 I-Eq-Comparison
months NCT03867526 422 428 I-Eq-Comparison
and NCT03867526 429 432 B-And
older NCT03867526 433 438 I-Eq-Comparison
than NCT03867526 439 443 I-Eq-Comparison
80 NCT03867526 444 446 I-Eq-Comparison
years NCT03867526 447 452 I-Eq-Comparison

- NCT03867526 455 456 O
No NCT03867526 458 460 B-Negation
diagnosis NCT03867526 461 470 O
of NCT03867526 471 473 O
Wilson NCT03867526 474 480 B-Condition
disease NCT03867526 481 488 I-Condition

Inclusion NCT03868826 0 9 O
Criteria NCT03868826 10 18 O
: NCT03868826 19 20 O

- NCT03868826 24 25 O
Patients NCT03868826 27 35 O
eligible NCT03868826 36 44 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868826 45 48 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03868826 49 58 B-Procedure
of NCT03868826 59 61 O
hamstring NCT03868826 62 71 B-Condition
avulsion NCT03868826 72 80 I-Condition

Exclusion NCT03868826 81 90 O
Criteria NCT03868826 91 99 O
: NCT03868826 100 101 O

- NCT03868826 105 106 O
Conditions NCT03868826 108 118 B-Condition
that NCT03868826 119 123 O
contraindicate NCT03868826 124 138 B-Contraindication
muscle NCT03868826 139 145 B-Procedure
strength NCT03868826 146 154 I-Procedure
testing NCT03868826 155 162 I-Procedure
e. NCT03868826 163 165 O
g. NCT03868826 166 168 O
cancer NCT03868826 170 176 B-Condition
and NCT03868826 177 180 B-Or
neurological NCT03868826 181 193 B-Condition
conditions NCT03868826 194 204 I-Condition

- NCT03868826 207 208 O
Patients NCT03868826 210 218 O
that NCT03868826 219 223 O
do NCT03868826 224 226 O
not NCT03868826 227 230 B-Negation
speak NCT03868826 231 236 O
or NCT03868826 237 239 O
understand NCT03868826 240 250 O
Danish NCT03868826 251 257 O

Inclusion NCT03866837 0 9 O
Criteria NCT03866837 10 18 O
: NCT03866837 19 20 O

- NCT03866837 24 25 O
vaginal NCT03866837 27 34 B-Procedure
delivery NCT03866837 35 43 I-Procedure

- NCT03866837 46 47 O
an NCT03866837 49 51 O
infant NCT03866837 52 58 B-Family-Member___Family-Member-Type:child
age NCT03866837 59 62 I-Eq-Comparison
of NCT03866837 63 65 I-Eq-Comparison
6 NCT03866837 66 67 I-Eq-Comparison
months NCT03866837 68 74 I-Eq-Comparison
( NCT03866837 75 76 O
± NCT03866837 78 79 B-Eq-Comparison
3 NCT03866837 80 81 I-Eq-Comparison
weeks NCT03866837 82 87 I-Eq-Comparison
) NCT03866837 88 89 O

- NCT03866837 93 94 O
mother NCT03866837 96 102 B-Family-Member___Family-Member-Type:mother
≥ NCT03866837 103 104 B-Eq-Comparison
15 NCT03866837 105 107 I-Eq-Comparison
years NCT03866837 108 113 I-Eq-Comparison
of NCT03866837 114 116 O
age NCT03866837 117 120 B-Age

- NCT03866837 123 124 O
infant NCT03866837 126 132 O
still NCT03866837 133 138 O
breastfeeding NCT03866837 139 152 B-Condition

- NCT03866837 155 156 O
anticipated NCT03866837 158 169 O
residence NCT03866837 170 179 O
in NCT03866837 180 182 O
the NCT03866837 183 186 O
area NCT03866837 187 191 O
for NCT03866837 192 195 O
the NCT03866837 196 199 O
study NCT03866837 200 205 B-Study
duration NCT03866837 206 214 O
. NCT03866837 215 216 O

Exclusion NCT03866837 218 227 O
Criteria NCT03866837 228 236 O
: NCT03866837 237 238 O

- NCT03866837 242 243 O
inability NCT03866837 245 254 O
to NCT03866837 255 257 O
provide NCT03866837 258 265 O
informed NCT03866837 266 274 O
consent NCT03866837 275 282 O

- NCT03866837 285 286 O
hemoglobin NCT03866837 288 298 B-Observation
< NCT03866837 299 300 B-Eq-Comparison
70 NCT03866837 301 303 I-Eq-Comparison
g NCT03866837 304 305 I-Eq-Comparison
/ NCT03866837 306 307 I-Eq-Comparison
L NCT03866837 308 309 I-Eq-Comparison

- NCT03866837 312 313 O
Z NCT03866837 315 316 B-Observation
scores NCT03866837 317 323 I-Observation
for NCT03866837 324 327 I-Observation
weight NCT03866837 328 334 I-Observation
- NCT03866837 335 336 I-Observation
for NCT03866837 337 340 I-Observation
- NCT03866837 341 342 I-Observation
age NCT03866837 343 346 I-Observation
( NCT03866837 347 348 O
WAZ NCT03866837 349 352 B-Observation
) NCT03866837 353 354 O
or NCT03866837 355 357 B-Or
weight NCT03866837 358 364 B-Observation
- NCT03866837 365 366 I-Observation
for NCT03866837 367 370 I-Observation
- NCT03866837 371 372 I-Observation
height NCT03866837 373 379 I-Observation
( NCT03866837 380 381 O
WHZ NCT03866837 382 385 B-Observation
) NCT03866837 386 387 O
< NCT03866837 388 389 B-Eq-Comparison
3 NCT03866837 390 391 I-Eq-Comparison
, NCT03866837 392 393 O

- NCT03866837 398 399 O
any NCT03866837 401 404 O
maternal NCT03866837 405 413 B-Family-Member___Family-Member-Type:mother
or NCT03866837 414 416 B-Or
infant NCT03866837 417 423 B-Family-Member___Family-Member-Type:child
chronic NCT03866837 424 431 B-Modifier
illness NCT03866837 432 439 B-Condition

- NCT03866837 442 443 O
administration NCT03866837 445 459 O
of NCT03866837 460 462 O
any NCT03866837 463 466 O
infant NCT03866837 467 473 B-Family-Member___Family-Member-Type:child
vitamin NCT03866837 474 481 B-Modifier
or NCT03866837 482 484 B-Or
mineral NCT03866837 485 492 B-Modifier
supplements NCT03866837 493 504 B-Drug
for NCT03866837 505 508 O
the NCT03866837 509 512 O
past NCT03866837 513 517 B-Eq-Comparison
2 NCT03866837 518 519 I-Eq-Comparison
months NCT03866837 520 526 I-Eq-Comparison

- NCT03866837 529 530 O
any NCT03866837 532 535 O
history NCT03866837 536 543 B-Eq-Comparison
of NCT03866837 544 546 O
infant NCT03866837 547 553 B-Family-Member___Family-Member-Type:child
antibiotic NCT03866837 554 564 B-Drug
treatment NCT03866837 565 574 B-Procedure
. NCT03866837 574 575 O

Inclusion NCT03864952 0 9 O
Criteria NCT03864952 10 18 O
: NCT03864952 19 20 O

- NCT03864952 24 25 O
three NCT03864952 27 32 B-Eq-Comparison
months NCT03864952 33 39 I-Eq-Comparison
before NCT03864952 40 46 I-Eq-Comparison
, NCT03864952 47 48 O
having NCT03864952 49 55 O
been NCT03864952 56 60 O
infected NCT03864952 61 69 B-Condition
with NCT03864952 70 74 O
a NCT03864952 75 76 O
documented NCT03864952 77 87 O
pathogen NCT03864952 88 96 B-Condition

- NCT03864952 99 100 O
this NCT03864952 102 106 B-Coreference
infection NCT03864952 107 116 I-Coreference
must NCT03864952 117 121 O
have NCT03864952 122 126 O
been NCT03864952 127 131 O
clinically NCT03864952 132 142 O
obvious NCT03864952 143 150 O

- NCT03864952 153 154 O
the NCT03864952 156 159 O
patient NCT03864952 160 167 O
must NCT03864952 168 172 O
have NCT03864952 173 177 O
dental NCT03864952 178 184 B-Condition
calculus NCT03864952 185 193 I-Condition

Exclusion NCT03864952 194 203 O
Criteria NCT03864952 204 212 O
: NCT03864952 213 214 O

- NCT03864952 218 219 O
to NCT03864952 221 223 O
be NCT03864952 224 226 O
under NCT03864952 227 232 B-Eq-Comparison
18 NCT03864952 233 235 I-Eq-Comparison
years NCT03864952 236 241 I-Eq-Comparison
old NCT03864952 242 245 B-Age

- NCT03864952 248 249 O
to NCT03864952 251 253 O
be NCT03864952 254 256 O
incapable NCT03864952 257 266 O
to NCT03864952 267 269 O
consenting NCT03864952 270 280 O

- NCT03864952 283 284 O
a NCT03864952 286 287 O
tartar NCT03864952 288 294 B-Procedure
removal NCT03864952 295 302 I-Procedure
since NCT03864952 303 308 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03864952 309 312 B-Coreference
infection NCT03864952 313 322 I-Coreference

Inclusion NCT03869047 0 9 O
Criteria NCT03869047 10 18 O
: NCT03869047 19 20 O

- NCT03869047 24 25 O
physical NCT03869047 27 35 O
status NCT03869047 36 42 O
American NCT03869047 43 51 B-Condition
Society NCT03869047 52 59 I-Condition
of NCT03869047 60 62 I-Condition
Anesthesiologist NCT03869047 63 79 I-Condition
( NCT03869047 80 81 O
ASA NCT03869047 82 85 B-Condition
) NCT03869047 86 87 O
I NCT03869047 88 89 B-Eq-Comparison
or NCT03869047 90 92 I-Eq-Comparison
II NCT03869047 93 95 I-Eq-Comparison

Exclusion NCT03869047 96 105 O
Criteria NCT03869047 106 114 O
: NCT03869047 115 116 O

- NCT03869047 120 121 O
Patients NCT03869047 123 131 O
refusal NCT03869047 132 139 O

- NCT03869047 142 143 O
A NCT03869047 145 146 O
body NCT03869047 147 151 B-Observation
mass NCT03869047 152 156 I-Observation
index NCT03869047 157 162 I-Observation
( NCT03869047 163 164 O
BMI NCT03869047 165 168 B-Observation
) NCT03869047 169 170 O
> NCT03869047 171 172 B-Eq-Comparison
30 NCT03869047 173 175 I-Eq-Comparison
kg NCT03869047 176 178 I-Eq-Comparison
/ NCT03869047 179 180 I-Eq-Comparison
m2 NCT03869047 181 183 I-Eq-Comparison

- NCT03869047 186 187 O
ASA NCT03869047 189 192 B-Condition
physical NCT03869047 193 201 O
status NCT03869047 202 208 O
> NCT03869047 209 210 B-Eq-Comparison
II NCT03869047 211 213 I-Eq-Comparison

- NCT03869047 216 217 O
major NCT03869047 219 224 O
illnesses NCT03869047 225 234 B-Condition
( NCT03869047 235 236 O
e. NCT03869047 237 239 O
g. NCT03869047 240 242 O
, NCT03869047 243 244 O
cardiac NCT03869047 245 252 B-Modifier
, NCT03869047 253 254 O
respiratory NCT03869047 255 266 B-Modifier
, NCT03869047 267 268 O
renal NCT03869047 269 274 B-Modifier
, NCT03869047 275 276 O
hepatic NCT03869047 277 284 B-Modifier
or NCT03869047 285 287 B-Or
neurological NCT03869047 288 300 B-Modifier
) NCT03869047 301 302 O

- NCT03869047 306 307 O
Coagulation NCT03869047 309 320 B-Condition
abnormalities NCT03869047 321 334 O

- NCT03869047 337 338 O
Infection NCT03869047 340 349 B-Condition
at NCT03869047 350 352 O
the NCT03869047 353 356 O
injection NCT03869047 357 366 B-Procedure
site NCT03869047 367 371 B-Modifier

- NCT03869047 374 375 O
Allergy NCT03869047 377 384 B-Allergy
or NCT03869047 385 387 B-Or
contraindications NCT03869047 388 405 B-Contraindication
to NCT03869047 406 408 O
the NCT03869047 409 412 O
drugs NCT03869047 413 418 B-Drug
used NCT03869047 419 423 O
in NCT03869047 424 426 O
the NCT03869047 427 430 O
study NCT03869047 431 436 B-Study

- NCT03869047 439 440 O
History NCT03869047 442 449 B-Eq-Comparison
of NCT03869047 450 452 O
drug NCT03869047 453 457 B-Condition
addiction NCT03869047 458 467 I-Condition
or NCT03869047 468 470 B-Or
alcohol NCT03869047 471 478 B-Condition
abuse NCT03869047 479 484 I-Condition

- NCT03869047 487 488 O
A NCT03869047 490 491 O
psychiatric NCT03869047 492 503 B-Condition
illness NCT03869047 504 511 I-Condition
, NCT03869047 512 513 O
or NCT03869047 514 516 B-Or
mental NCT03869047 517 523 B-Condition
retardation NCT03869047 524 535 I-Condition
interfering NCT03869047 536 547 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03869047 548 552 O
the NCT03869047 553 556 O
evaluation NCT03869047 557 567 O
of NCT03869047 568 570 O
pain NCT03869047 571 575 B-Observation
scores NCT03869047 576 582 I-Observation
or NCT03869047 583 585 B-Or
PCA NCT03869047 586 589 B-Procedure
programs NCT03869047 590 598 I-Procedure
. NCT03869047 599 600 O

Inclusion NCT03865641 0 9 O
Criteria NCT03865641 10 18 O
: NCT03865641 19 20 O

- NCT03865641 24 25 O
The NCT03865641 27 30 O
patients NCT03865641 31 39 O
' NCT03865641 39 40 O
burn NCT03865641 41 45 B-Condition
scars NCT03865641 46 51 I-Condition
had NCT03865641 52 55 O
re NCT03865641 56 58 B-Modifier
- NCT03865641 59 60 I-Modifier
epithelialized NCT03865641 61 75 I-Modifier
after NCT03865641 76 81 B-Temporal-Connection___Temporal-Connection-Type-Value:after
aseptic NCT03865641 82 89 B-Procedure
care NCT03865641 90 94 I-Procedure
or NCT03865641 95 97 B-Or
skin NCT03865641 98 102 B-Procedure
graft NCT03865641 103 108 I-Procedure
. NCT03865641 108 109 O
We NCT03865641 111 113 O
included NCT03865641 114 122 O
patients NCT03865641 123 131 O
aged NCT03865641 132 136 B-Age
≥ NCT03865641 137 138 B-Eq-Comparison
18 NCT03865641 139 141 I-Eq-Comparison
years NCT03865641 142 147 I-Eq-Comparison
with NCT03865641 148 152 B-And
a NCT03865641 153 154 O
deep NCT03865641 155 159 B-Modifier
partial NCT03865641 160 167 I-Modifier
- NCT03865641 168 169 I-Modifier
thickness NCT03865641 170 179 I-Modifier
( NCT03865641 180 181 O
second NCT03865641 182 188 B-Modifier
- NCT03865641 189 190 I-Modifier
degree NCT03865641 191 197 I-Modifier
) NCT03865641 198 199 O
burn NCT03865641 200 204 B-Condition
or NCT03865641 205 207 B-Or
a NCT03865641 208 209 O
full NCT03865641 210 214 B-Modifier
thickness NCT03865641 215 224 I-Modifier
( NCT03865641 225 226 O
third NCT03865641 227 232 B-Modifier
- NCT03865641 233 234 I-Modifier
degree NCT03865641 235 241 I-Modifier
) NCT03865641 242 243 O
burn NCT03865641 244 248 B-Condition
to NCT03865641 249 251 O
their NCT03865641 252 257 O
hands NCT03865641 258 263 B-Modifier
, NCT03865641 264 265 O
with NCT03865641 266 270 B-And
joint NCT03865641 271 276 B-Condition
contracture NCT03865641 277 288 I-Condition
( NCT03865641 289 290 O
hand NCT03865641 291 295 B-Modifier
and NCT03865641 296 299 B-Or
wrist NCT03865641 300 305 B-Modifier
) NCT03865641 306 307 O
, NCT03865641 309 310 O
having NCT03865641 311 317 B-And
been NCT03865641 318 322 I-And
transferred NCT03865641 323 334 B-Encounter
to NCT03865641 335 337 O
the NCT03865641 338 341 O
rehabilitation NCT03865641 342 356 O
department NCT03865641 357 367 O
after NCT03865641 368 373 B-Temporal-Connection___Temporal-Connection-Type-Value:after
acute NCT03865641 374 379 O
burn NCT03865641 380 384 B-Condition
treatment NCT03865641 385 394 B-Procedure
, NCT03865641 395 396 O
and NCT03865641 397 400 O
less NCT03865641 401 405 B-Eq-Comparison
than NCT03865641 406 410 I-Eq-Comparison
6 NCT03865641 411 412 I-Eq-Comparison
months NCT03865641 413 419 I-Eq-Comparison
since NCT03865641 420 425 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865641 426 429 O
onset NCT03865641 430 435 B-Eq-Comparison
of NCT03865641 436 438 O
the NCT03865641 439 442 O
burn NCT03865641 443 447 B-Modifier
injury NCT03865641 448 454 B-Condition
. NCT03865641 455 456 O

Exclusion NCT03865641 458 467 O
Criteria NCT03865641 468 476 O
: NCT03865641 477 478 O

- NCT03865641 482 483 O
patients NCT03865641 485 493 O
who NCT03865641 494 497 O
had NCT03865641 498 501 O
fourth NCT03865641 502 508 B-Modifier
- NCT03865641 509 510 I-Modifier
degree NCT03865641 511 517 I-Modifier
burns NCT03865641 518 523 B-Condition
( NCT03865641 524 525 O
involving NCT03865641 526 535 O
muscles NCT03865641 536 543 B-Modifier
, NCT03865641 544 545 O
tendons NCT03865641 546 553 B-Modifier
, NCT03865641 554 555 O
and NCT03865641 556 559 B-Or
bone NCT03865641 560 564 B-Modifier
injuries NCT03865641 565 573 B-Condition
) NCT03865641 574 575 O
, NCT03865641 577 578 O
musculoskeletal NCT03865641 579 594 B-Condition
diseases NCT03865641 595 603 I-Condition
( NCT03865641 604 605 O
fracture NCT03865641 606 614 B-Condition
, NCT03865641 615 616 O
amputation NCT03865641 617 627 B-Condition
, NCT03865641 628 629 O
rheumatoid NCT03865641 630 640 B-Condition
arthritis NCT03865641 641 650 I-Condition
, NCT03865641 651 652 O
and NCT03865641 653 656 B-Or
degenerative NCT03865641 657 669 B-Condition
joint NCT03865641 670 675 I-Condition
diseases NCT03865641 676 684 I-Condition
) NCT03865641 685 686 O
in NCT03865641 687 689 O
the NCT03865641 690 693 O
burned NCT03865641 694 700 B-Modifier
hand NCT03865641 701 705 I-Modifier
, NCT03865641 706 707 O
or NCT03865641 708 710 B-Or
neurological NCT03865641 711 723 B-Condition
diseases NCT03865641 724 732 I-Condition
( NCT03865641 733 734 O
such NCT03865641 735 739 O
as NCT03865641 740 742 O
peripheral NCT03865641 743 753 B-Condition
nerve NCT03865641 754 759 I-Condition
disorders NCT03865641 760 769 I-Condition
) NCT03865641 770 771 O
, NCT03865641 773 774 O
preexisting NCT03865641 775 786 B-Eq-Comparison
physical NCT03865641 787 795 B-Modifier
and NCT03865641 796 799 B-Or
psychologic NCT03865641 800 811 B-Modifier
disability NCT03865641 812 822 B-Condition
( NCT03865641 823 824 O
severe NCT03865641 825 831 O
aphasia NCT03865641 832 839 B-Condition
and NCT03865641 840 843 B-Or
cognitive NCT03865641 844 853 B-Condition
impairment NCT03865641 854 864 I-Condition
that NCT03865641 865 869 O
could NCT03865641 870 875 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03865641 876 885 O
the NCT03865641 886 889 O
intervention NCT03865641 890 902 B-Study
) NCT03865641 903 904 O
, NCT03865641 906 907 O
and NCT03865641 908 911 B-Or
severe NCT03865641 912 918 O
pain NCT03865641 919 923 B-Condition
impeding NCT03865641 924 932 O
hand NCT03865641 933 937 B-Procedure
rehabilitation NCT03865641 938 952 I-Procedure
. NCT03865641 952 953 O

Inclusion NCT03868371 0 9 O
Criteria NCT03868371 10 18 O
: NCT03868371 19 20 O

- NCT03868371 24 25 O
≥ NCT03868371 27 28 B-Eq-Comparison
18 NCT03868371 29 31 I-Eq-Comparison
years NCT03868371 32 37 I-Eq-Comparison
of NCT03868371 38 40 O
age NCT03868371 41 44 B-Age

- NCT03868371 47 48 O
Currently NCT03868371 50 59 B-Eq-Comparison
treated NCT03868371 60 67 B-Procedure
with NCT03868371 68 72 O
peritoneal NCT03868371 73 83 B-Procedure
dialysis NCT03868371 84 92 I-Procedure
( NCT03868371 93 94 O
APD NCT03868371 95 98 B-Procedure
or NCT03868371 99 101 B-Or
CAPD NCT03868371 102 106 B-Procedure
) NCT03868371 107 108 O

- NCT03868371 112 113 O
Serum NCT03868371 115 120 B-Observation
ionized NCT03868371 121 128 I-Observation
calcium NCT03868371 129 136 I-Observation
between NCT03868371 137 144 B-Eq-Comparison
1.10 NCT03868371 145 149 I-Eq-Comparison
and NCT03868371 150 153 I-Eq-Comparison
1.40 NCT03868371 154 158 I-Eq-Comparison
mmol NCT03868371 159 163 I-Eq-Comparison
/ NCT03868371 164 165 I-Eq-Comparison
L NCT03868371 166 167 I-Eq-Comparison
for NCT03868371 168 171 O
> NCT03868371 172 173 B-Eq-Comparison
3 NCT03868371 174 175 I-Eq-Comparison
months NCT03868371 176 182 I-Eq-Comparison

- NCT03868371 185 186 O
Plasma NCT03868371 188 194 B-Observation
phosphate NCT03868371 195 204 I-Observation
between NCT03868371 205 212 B-Eq-Comparison
0.7 NCT03868371 213 216 I-Eq-Comparison
and NCT03868371 217 220 I-Eq-Comparison
3.0 NCT03868371 221 224 I-Eq-Comparison
mmol NCT03868371 225 229 I-Eq-Comparison
/ NCT03868371 230 231 I-Eq-Comparison
L NCT03868371 232 233 I-Eq-Comparison
for NCT03868371 234 237 O
> NCT03868371 238 239 B-Eq-Comparison
3 NCT03868371 240 241 I-Eq-Comparison
months NCT03868371 242 248 I-Eq-Comparison

Exclusion NCT03868371 249 258 O
Criteria NCT03868371 259 267 O
: NCT03868371 268 269 O

- NCT03868371 273 274 O
Earlier NCT03868371 276 283 B-Eq-Comparison
parathyroidectomized NCT03868371 284 304 B-Condition

- NCT03868371 307 308 O
Other NCT03868371 310 315 B-Other
conditions NCT03868371 316 326 B-Condition
, NCT03868371 327 328 O
which NCT03868371 329 334 O
hinders NCT03868371 335 342 O
the NCT03868371 343 346 O
participation NCT03868371 347 360 O
in NCT03868371 361 363 O
the NCT03868371 364 367 O
trial NCT03868371 368 373 B-Study

Inclusion NCT03867903 0 9 O
Criteria NCT03867903 10 18 O
: NCT03867903 19 20 O

- NCT03867903 24 25 O
Study NCT03867903 27 32 O
participants NCT03867903 33 45 O
will NCT03867903 46 50 O
be NCT03867903 51 53 O
infants NCT03867903 54 61 B-Family-Member___Family-Member-Type:child
( NCT03867903 62 63 O
and NCT03867903 64 67 B-Or
their NCT03867903 68 73 O
parents NCT03867903 74 81 B-Family-Member___Family-Member-Type:parent
) NCT03867903 82 83 O
who NCT03867903 84 87 O
have NCT03867903 88 92 O
undergone NCT03867903 93 102 B-Eq-Comparison
cardiac NCT03867903 103 110 B-Procedure
surgery NCT03867903 111 118 I-Procedure
at NCT03867903 119 121 O
Children NCT03867903 122 130 O
's NCT03867903 130 132 O
Mercy NCT03867903 133 138 O
Kansas NCT03867903 139 145 O
City NCT03867903 146 150 O
in NCT03867903 151 153 O
the NCT03867903 154 157 O
first NCT03867903 158 163 B-Eq-Comparison
six NCT03867903 164 167 I-Eq-Comparison
weeks NCT03867903 168 173 I-Eq-Comparison
of NCT03867903 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:after
life NCT03867903 177 181 B-Birth
and NCT03867903 182 185 B-And
are NCT03867903 186 189 O
currently NCT03867903 190 199 B-Eq-Comparison
less NCT03867903 200 204 B-Eq-Comparison
than NCT03867903 205 209 I-Eq-Comparison
18 NCT03867903 210 212 I-Eq-Comparison
months NCT03867903 213 219 I-Eq-Comparison
of NCT03867903 220 222 O
age NCT03867903 223 226 B-Age
at NCT03867903 227 229 O
the NCT03867903 230 233 O
time NCT03867903 234 238 O
of NCT03867903 239 241 O
being NCT03867903 242 247 O
approached NCT03867903 248 258 O
for NCT03867903 259 262 O
participation NCT03867903 263 276 O
in NCT03867903 277 279 O
this NCT03867903 280 284 O
study NCT03867903 285 290 B-Study
. NCT03867903 291 292 O

Exclusion NCT03867903 294 303 O
Criteria NCT03867903 304 312 O
: NCT03867903 313 314 O

- NCT03867903 318 319 O
• NCT03867903 321 322 O
Families NCT03867903 323 331 O
without NCT03867903 332 339 O
access NCT03867903 340 346 O
to NCT03867903 347 349 O
a NCT03867903 350 351 O
personal NCT03867903 352 360 O
device NCT03867903 361 367 O
for NCT03867903 368 371 O
download NCT03867903 372 380 O
( NCT03867903 381 382 O
no NCT03867903 383 385 O
devices NCT03867903 386 393 O
will NCT03867903 394 398 O
be NCT03867903 399 401 O
provided NCT03867903 402 410 O
) NCT03867903 411 412 O

- NCT03867903 421 422 O
Children NCT03867903 424 432 B-Family-Member___Family-Member-Type:child
who NCT03867903 433 436 O
are NCT03867903 437 440 O
deceased NCT03867903 441 449 B-Death
prior NCT03867903 450 455 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867903 456 458 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867903 459 462 O
family NCT03867903 463 469 O
being NCT03867903 470 475 O
approached NCT03867903 476 486 O
for NCT03867903 487 490 O
study NCT03867903 491 496 B-Study
participation NCT03867903 497 510 O

- NCT03867903 518 519 O
Neonates NCT03867903 521 529 B-Family-Member___Family-Member-Type:child
that NCT03867903 530 534 O
are NCT03867903 535 538 O
considered NCT03867903 539 549 O
non NCT03867903 550 553 B-Condition
- NCT03867903 554 555 I-Condition
viable NCT03867903 556 562 I-Condition
, NCT03867903 563 564 O
or NCT03867903 565 567 B-Or
have NCT03867903 568 572 O
the NCT03867903 573 576 O
potential NCT03867903 577 586 B-Risk
to NCT03867903 587 589 O
be NCT03867903 590 592 O
non NCT03867903 593 596 B-Condition
- NCT03867903 597 598 I-Condition
viable NCT03867903 599 605 I-Condition

- NCT03867903 613 614 O
Spanish NCT03867903 616 623 O
- NCT03867903 624 625 O
only NCT03867903 626 630 O
speaking NCT03867903 631 639 O
families NCT03867903 640 648 O

Exclude NCT03867903 649 656 O
special NCT03867903 657 664 O
populations NCT03867903 665 676 O
: NCT03867903 677 678 O

• NCT03867903 680 681 O
Wards NCT03867903 682 687 B-Observation
of NCT03867903 688 690 I-Observation
the NCT03867903 691 694 I-Observation
state NCT03867903 695 700 I-Observation

Inclusion NCT03860922 0 9 O
Criteria NCT03860922 10 18 O
: NCT03860922 19 20 O

- NCT03860922 24 25 O
patients NCT03860922 27 35 O
in NCT03860922 36 38 O
different NCT03860922 39 48 O
age NCT03860922 49 52 O
groups NCT03860922 53 59 O
and NCT03860922 60 63 O
both NCT03860922 64 68 O
sex NCT03860922 69 72 O
referred NCT03860922 73 81 O
from NCT03860922 82 86 O
orthopedic NCT03860922 87 97 O
outpatient NCT03860922 98 108 B-Encounter
clinic NCT03860922 109 115 O
with NCT03860922 116 120 B-And
chronic NCT03860922 121 128 B-Modifier
ankle NCT03860922 129 134 I-Modifier
pain NCT03860922 135 139 B-Condition
and NCT03860922 140 143 B-And
suspected NCT03860922 144 153 B-Assertion___Assertion-Type-Value:possible
clinically NCT03860922 154 164 O
to NCT03860922 165 167 O
have NCT03860922 168 172 O
impingement NCT03860922 173 184 B-Condition
syndrome NCT03860922 185 193 I-Condition
. NCT03860922 194 195 O

Exclusion NCT03860922 197 206 O
Criteria NCT03860922 207 215 O
: NCT03860922 216 217 O

1 NCT03860922 221 222 O
. NCT03860922 222 223 O
Inflammatory NCT03860922 225 237 B-Condition
arthritis NCT03860922 238 247 I-Condition
of NCT03860922 248 250 O
ankle NCT03860922 251 256 B-Modifier
joint NCT03860922 257 262 I-Modifier
, NCT03860922 263 264 O
infection NCT03860922 265 274 B-Condition
in NCT03860922 275 277 O
ankle NCT03860922 278 283 B-Modifier
joint NCT03860922 284 289 I-Modifier
, NCT03860922 290 291 O
neoplasm NCT03860922 292 300 B-Modifier
around NCT03860922 301 307 B-Modifier
ankle NCT03860922 308 313 I-Modifier
joint NCT03860922 314 319 I-Modifier
. NCT03860922 320 321 O

2 NCT03860922 325 326 O
. NCT03860922 326 327 O
Patients NCT03860922 329 337 O
with NCT03860922 338 342 O
contraindications NCT03860922 343 360 B-Contraindication
for NCT03860922 361 364 O
MRI NCT03860922 365 368 B-Procedure
, NCT03860922 369 370 O
e. NCT03860922 371 373 O
g. NCT03860922 374 376 O
an NCT03860922 378 380 O
implanted NCT03860922 381 390 B-Procedure
magnetic NCT03860922 391 399 I-Procedure
device NCT03860922 400 406 I-Procedure
, NCT03860922 407 408 O
pacemakers NCT03860922 409 419 B-Procedure
or NCT03860922 420 422 B-Or
claustrophobia NCT03860922 423 437 B-Condition
. NCT03860922 437 438 O

Inclusion NCT03868774 0 9 O
Criteria NCT03868774 10 18 O
: NCT03868774 19 20 O

1 NCT03868774 24 25 O
. NCT03868774 25 26 O
Moderate NCT03868774 28 36 B-Eq-Comparison
- NCT03868774 37 38 I-Eq-Comparison
severe NCT03868774 39 45 I-Eq-Comparison
uni NCT03868774 46 49 B-Modifier
- NCT03868774 50 51 I-Modifier
and NCT03868774 52 55 B-Or
bipolar NCT03868774 56 63 B-Modifier
depression NCT03868774 64 74 B-Condition
according NCT03868774 75 84 O
to NCT03868774 85 87 O
the NCT03868774 88 91 O
International NCT03868774 92 105 O
Classification NCT03868774 106 120 O
of NCT03868774 121 123 O
Diseases NCT03868774 124 132 O
( NCT03868774 133 134 O
ICD NCT03868774 135 138 O
- NCT03868774 139 140 O
10 NCT03868774 141 143 O
) NCT03868774 144 145 O

2 NCT03868774 149 150 O
. NCT03868774 150 151 O
A NCT03868774 153 154 O
Hamilton NCT03868774 155 163 B-Observation
scale NCT03868774 164 169 I-Observation
score NCT03868774 170 175 O
( NCT03868774 176 177 O
HDS NCT03868774 178 181 B-Observation
- NCT03868774 182 183 I-Observation
17 NCT03868774 184 186 I-Observation
) NCT03868774 187 188 O
of NCT03868774 189 191 O
≥ NCT03868774 192 193 B-Eq-Comparison
18 NCT03868774 194 196 I-Eq-Comparison
and NCT03868774 197 200 B-Or
/ NCT03868774 201 202 I-Or
or NCT03868774 203 205 I-Or
a NCT03868774 206 207 O
sub NCT03868774 208 211 B-Observation
- NCT03868774 212 213 I-Observation
scale NCT03868774 214 219 I-Observation
( NCT03868774 220 221 O
HDSS NCT03868774 222 226 B-Observation
) NCT03868774 227 228 O
score NCT03868774 229 234 O
of NCT03868774 235 237 O
≥ NCT03868774 238 239 B-Eq-Comparison
9 NCT03868774 240 241 I-Eq-Comparison
within NCT03868774 242 248 B-Eq-Comparison
24 NCT03868774 249 251 I-Eq-Comparison
- NCT03868774 252 253 I-Eq-Comparison
48 NCT03868774 254 256 I-Eq-Comparison
hours NCT03868774 257 262 I-Eq-Comparison
before NCT03868774 263 269 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03868774 270 273 O
first NCT03868774 274 279 B-Eq-Comparison
treatment NCT03868774 280 289 B-Procedure

Exclusion NCT03868774 290 299 O
Criteria NCT03868774 300 308 O
: NCT03868774 309 310 O

1 NCT03868774 314 315 O
. NCT03868774 315 316 O
Organic NCT03868774 318 325 B-Modifier
brain NCT03868774 326 331 B-Condition
disease NCT03868774 332 339 I-Condition
. NCT03868774 340 341 O

2 NCT03868774 345 346 O
. NCT03868774 346 347 O
Epileptic NCT03868774 349 358 B-Condition
seizure NCT03868774 359 366 I-Condition
< NCT03868774 367 368 B-Eq-Comparison
2 NCT03868774 369 370 I-Eq-Comparison
years NCT03868774 371 376 I-Eq-Comparison

3 NCT03868774 379 380 O
. NCT03868774 380 381 O
Patients NCT03868774 383 391 O
with NCT03868774 392 396 O
implanted NCT03868774 397 406 B-Procedure
metal NCT03868774 407 412 I-Procedure
parts NCT03868774 413 418 I-Procedure
in NCT03868774 419 421 O
the NCT03868774 422 425 O
brain NCT03868774 426 431 B-Modifier
or NCT03868774 432 434 B-Or
chest NCT03868774 435 440 B-Modifier

4 NCT03868774 443 444 O
. NCT03868774 444 445 O
Patients NCT03868774 447 455 O
with NCT03868774 456 460 O
pacemaker NCT03868774 461 470 B-Procedure

5 NCT03868774 473 474 O
. NCT03868774 474 475 O
Medical NCT03868774 477 484 O
diseases NCT03868774 485 493 B-Condition
with NCT03868774 494 498 O
cerebral NCT03868774 499 507 B-Condition
impact NCT03868774 508 514 O

6 NCT03868774 517 518 O
. NCT03868774 518 519 O
Serious NCT03868774 521 528 O
suicidal NCT03868774 529 537 B-Condition
danger NCT03868774 538 544 B-Risk


Inclusion NCT03861988 0 9 O
Criteria NCT03861988 10 18 O
: NCT03861988 19 20 O

- NCT03861988 24 25 O
Patient NCT03861988 27 34 O
presenting NCT03861988 35 45 O
for NCT03861988 46 49 O
primary NCT03861988 50 57 B-Modifier
total NCT03861988 58 63 B-Procedure
joint NCT03861988 64 69 I-Procedure
arthroplasty NCT03861988 70 82 I-Procedure

- NCT03861988 85 86 O
Major NCT03861988 88 93 O
Depressive NCT03861988 94 104 B-Condition
Disorder NCT03861988 105 113 I-Condition

Exclusion NCT03861988 114 123 O
Criteria NCT03861988 124 132 O
: NCT03861988 133 134 O

- NCT03861988 138 139 O
Pregnant NCT03861988 141 149 B-Condition
of NCT03861988 150 152 O
breastfeeding NCT03861988 153 166 B-Condition
women NCT03861988 167 172 O

Inclusion NCT03864172 0 9 O
Criteria NCT03864172 10 18 O

- NCT03864172 21 22 O
Screened NCT03864172 24 32 O
to NCT03864172 33 35 O
be NCT03864172 36 38 O
generally NCT03864172 39 48 O
healthy NCT03864172 49 56 B-Condition
as NCT03864172 57 59 O
determined NCT03864172 60 70 O
by NCT03864172 71 73 O
standard NCT03864172 74 82 B-Procedure
medical NCT03864172 83 90 I-Procedure
assessment NCT03864172 91 101 I-Procedure
on NCT03864172 102 104 O
physical NCT03864172 105 113 B-Modifier
and NCT03864172 114 117 B-Or
mental NCT03864172 118 124 B-Modifier
health NCT03864172 125 131 I-Modifier

- NCT03864172 134 135 O
Tanner NCT03864172 137 143 B-Condition
stage NCT03864172 144 149 B-Eq-Comparison
2 NCT03864172 150 151 I-Eq-Comparison
based NCT03864172 152 157 O
on NCT03864172 158 160 O
breast NCT03864172 161 167 B-Condition
development NCT03864172 168 179 I-Condition
for NCT03864172 180 183 O
girls NCT03864172 184 189 O
, NCT03864172 190 191 O
and NCT03864172 192 195 B-Or
pubic NCT03864172 196 201 B-Condition
hair NCT03864172 202 206 I-Condition
in NCT03864172 207 209 O
boys NCT03864172 210 214 O
. NCT03864172 214 215 O
Girls NCT03864172 217 222 O
will NCT03864172 223 227 O
have NCT03864172 228 232 O
to NCT03864172 233 235 O
be NCT03864172 236 238 O
premenarcheal NCT03864172 239 252 B-Condition

- NCT03864172 255 256 O
Having NCT03864172 258 264 O
obtained NCT03864172 265 273 O
his NCT03864172 274 277 O
/ NCT03864172 278 279 O
her NCT03864172 280 283 O
informed NCT03864172 284 292 O
consent NCT03864172 293 300 O
and NCT03864172 301 304 O
parents NCT03864172 305 312 O
or NCT03864172 313 315 O
legal NCT03864172 316 321 O
guardians NCT03864172 322 331 O
consent NCT03864172 332 339 O

Exclusion NCT03864172 340 349 O
Criteria NCT03864172 350 358 O
: NCT03864172 359 360 O

- NCT03864172 364 365 O
History NCT03864172 367 374 B-Eq-Comparison
of NCT03864172 375 377 O
serious NCT03864172 378 385 O
medical NCT03864172 386 393 B-Condition
conditions NCT03864172 394 404 I-Condition
such NCT03864172 405 409 O
as NCT03864172 410 412 O
intestinal NCT03864172 413 423 B-Modifier
or NCT03864172 424 426 B-Or
severe NCT03864172 427 433 O
metabolic NCT03864172 434 443 B-Condition
diseases NCT03864172 444 452 I-Condition
, NCT03864172 453 454 O
disorders NCT03864172 455 464 B-Condition
such NCT03864172 465 469 O
as NCT03864172 470 472 O
diabetes NCT03864172 473 481 B-Condition
, NCT03864172 482 483 O
renal NCT03864172 484 489 B-Modifier
, NCT03864172 490 491 O
hepatic NCT03864172 492 499 B-Modifier
or NCT03864172 500 502 B-Or
pancreatic NCT03864172 503 513 B-Modifier
diseases NCT03864172 514 522 B-Condition
, NCT03864172 523 524 O
disorders NCT03864172 525 534 B-Condition
, NCT03864172 535 536 O
ulcer NCT03864172 537 542 B-Condition
, NCT03864172 543 544 O
hyperthyroidism NCT03864172 545 560 B-Condition
, NCT03864172 561 562 O
malignance NCT03864172 563 573 B-Condition
, NCT03864172 574 575 O
chronic NCT03864172 576 583 B-Modifier
malnutrition NCT03864172 584 596 B-Condition
, NCT03864172 597 598 O
anaemia NCT03864172 599 606 B-Condition

- NCT03864172 609 610 O
History NCT03864172 612 619 B-Eq-Comparison
or NCT03864172 620 622 B-Or
on NCT03864172 623 625 B-Eq-Comparison
therapy NCT03864172 626 633 B-Procedure
with NCT03864172 634 638 O
medication NCT03864172 639 649 B-Drug
known NCT03864172 650 655 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864172 656 658 I-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864172 659 668 O
with NCT03864172 669 673 O
bone NCT03864172 674 678 B-Condition
metabolism NCT03864172 679 689 I-Condition
such NCT03864172 690 694 O
as NCT03864172 695 697 O
steroids NCT03864172 698 706 B-Drug
, NCT03864172 707 708 O
hormones NCT03864172 709 717 B-Drug
, NCT03864172 718 719 O
diuretics NCT03864172 720 729 B-Drug
, NCT03864172 730 731 O
cortisone NCT03864172 732 741 B-Drug
or NCT03864172 742 744 B-Or
anti NCT03864172 745 749 O
- NCT03864172 750 751 O
seizure NCT03864172 752 759 B-Condition
medication NCT03864172 760 770 B-Drug

- NCT03864172 773 774 O
Taking NCT03864172 776 782 B-Eq-Comparison
regularly NCT03864172 783 792 O
any NCT03864172 793 796 O
nutritional NCT03864172 797 808 B-Drug
supplements NCT03864172 809 820 I-Drug
and NCT03864172 821 824 B-And
unwilling NCT03864172 825 834 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864172 835 837 O
stop NCT03864172 838 842 B-Negation
for NCT03864172 843 846 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864172 847 850 I-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03864172 851 856 B-Study

Inclusion NCT03864614 0 9 O
Criteria NCT03864614 10 18 O
: NCT03864614 19 20 O

1 NCT03864614 24 25 O
. NCT03864614 25 26 O
Subject NCT03864614 28 35 O
has NCT03864614 36 39 O
a NCT03864614 40 41 O
diagnosis NCT03864614 42 51 O
of NCT03864614 52 54 O
MDD NCT03864614 55 58 B-Condition
as NCT03864614 59 61 O
diagnosed NCT03864614 62 71 O
by NCT03864614 72 74 O
SCID NCT03864614 75 79 O
- NCT03864614 80 81 O
5 NCT03864614 82 83 O
- NCT03864614 84 85 O
CT NCT03864614 86 88 O
, NCT03864614 89 90 O
with NCT03864614 91 95 B-And
symptoms NCT03864614 96 104 B-Coreference
that NCT03864614 105 109 O
have NCT03864614 110 114 O
been NCT03864614 115 119 O
present NCT03864614 120 127 O
for NCT03864614 128 131 O
at NCT03864614 132 134 B-Eq-Comparison
least NCT03864614 135 140 I-Eq-Comparison
a NCT03864614 141 142 I-Eq-Comparison
4 NCT03864614 143 144 I-Eq-Comparison
- NCT03864614 145 146 I-Eq-Comparison
week NCT03864614 147 151 I-Eq-Comparison
period NCT03864614 152 158 O
. NCT03864614 159 160 O

2 NCT03864614 164 165 O
. NCT03864614 165 166 O
Subject NCT03864614 168 175 O
is NCT03864614 176 178 O
in NCT03864614 179 181 O
good NCT03864614 182 186 B-Condition
physical NCT03864614 187 195 I-Condition
health NCT03864614 196 202 I-Condition
and NCT03864614 203 206 B-And
has NCT03864614 207 210 O
no NCT03864614 211 213 B-Negation
clinically NCT03864614 214 224 O
significant NCT03864614 225 236 O
findings NCT03864614 237 245 B-Condition
, NCT03864614 246 247 O
as NCT03864614 248 250 O
determined NCT03864614 251 261 O
by NCT03864614 262 264 O
the NCT03864614 265 268 O
Investigator NCT03864614 269 281 O
, NCT03864614 282 283 O
on NCT03864614 284 286 O
physical NCT03864614 287 295 B-Procedure
examination NCT03864614 296 307 I-Procedure
, NCT03864614 308 309 O
12 NCT03864614 310 312 B-Procedure
- NCT03864614 313 314 I-Procedure
lead NCT03864614 315 319 I-Procedure
ECG NCT03864614 320 323 I-Procedure
, NCT03864614 324 325 O
or NCT03864614 326 328 B-Or
clinical NCT03864614 329 337 O
laboratory NCT03864614 338 348 B-Observation
tests NCT03864614 349 354 I-Observation
. NCT03864614 355 356 O

Exclusion NCT03864614 358 367 O
Criteria NCT03864614 368 376 O
: NCT03864614 377 378 O

1 NCT03864614 382 383 O
. NCT03864614 383 384 O
Subject NCT03864614 386 393 O
has NCT03864614 394 397 O
attempted NCT03864614 398 407 B-Condition
suicide NCT03864614 408 415 I-Condition
associated NCT03864614 416 426 B-Temporal-Connection___Temporal-Connection-Type-Value:during
with NCT03864614 427 431 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864614 432 435 O
current NCT03864614 436 443 B-Eq-Comparison
episode NCT03864614 444 451 O
of NCT03864614 452 454 O
MDD NCT03864614 455 458 B-Condition
. NCT03864614 459 460 O

2 NCT03864614 464 465 O
. NCT03864614 465 466 O
Subject NCT03864614 468 475 O
has NCT03864614 476 479 O
a NCT03864614 480 481 O
medical NCT03864614 482 489 O
history NCT03864614 490 497 B-Eq-Comparison
of NCT03864614 498 500 O
bipolar NCT03864614 501 508 B-Condition
disorder NCT03864614 509 517 I-Condition
, NCT03864614 518 519 O
schizophrenia NCT03864614 520 533 B-Condition
, NCT03864614 534 535 O
and NCT03864614 536 539 B-Or
/ NCT03864614 540 541 I-Or
or NCT03864614 542 544 I-Or
schizoaffective NCT03864614 545 560 B-Condition
disorder NCT03864614 561 569 I-Condition
. NCT03864614 570 571 O

3 NCT03864614 575 576 O
. NCT03864614 576 577 O
Subject NCT03864614 579 586 O
has NCT03864614 587 590 O
had NCT03864614 591 594 B-Eq-Comparison
vagus NCT03864614 595 600 B-Procedure
nerve NCT03864614 601 606 I-Procedure
stimulation NCT03864614 607 618 I-Procedure
, NCT03864614 619 620 O
electroconvulsive NCT03864614 621 638 B-Procedure
therapy NCT03864614 639 646 I-Procedure
, NCT03864614 647 648 O
or NCT03864614 649 651 B-Or
has NCT03864614 652 655 O
taken NCT03864614 656 661 B-Eq-Comparison
ketamine NCT03864614 662 670 B-Drug
( NCT03864614 671 672 O
including NCT03864614 673 682 O
esketamine NCT03864614 683 693 B-Drug
) NCT03864614 694 695 O
within NCT03864614 696 702 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864614 703 706 I-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03864614 707 714 B-Eq-Comparison
major NCT03864614 715 720 O
depressive NCT03864614 721 731 B-Condition
episode NCT03864614 732 739 I-Condition
. NCT03864614 739 740 O

Inclusion NCT03861585 0 9 O
Criteria NCT03861585 10 18 O
: NCT03861585 19 20 O

- NCT03861585 24 25 O
Children NCT03861585 27 35 O
between NCT03861585 36 43 B-Eq-Comparison
7 NCT03861585 44 45 I-Eq-Comparison
and NCT03861585 46 49 I-Eq-Comparison
12 NCT03861585 50 52 I-Eq-Comparison
years NCT03861585 53 58 I-Eq-Comparison
old NCT03861585 59 62 B-Age
… NCT03861585 62 63 O
…… NCT03861585 63 65 O
…… NCT03861585 65 67 O
…… NCT03861585 67 69 O
…… NCT03861585 69 71 O
…… NCT03861585 71 73 O
. NCT03861585 74 75 O

- NCT03861585 79 80 O
Normal NCT03861585 82 88 O
or NCT03861585 89 91 B-Or
corrected NCT03861585 92 101 B-Modifier
visual NCT03861585 102 108 B-Condition
acuity NCT03861585 109 115 I-Condition
… NCT03861585 116 117 O
… NCT03861585 117 118 O
… NCT03861585 118 119 O
… NCT03861585 119 120 O
…… NCT03861585 120 122 O
…… NCT03861585 122 124 O
…… NCT03861585 124 126 O
…… NCT03861585 126 128 O
. NCT03861585 129 130 O

- NCT03861585 134 135 O
ADHD NCT03861585 137 141 B-Condition
diagnostic NCT03861585 142 152 O
given NCT03861585 153 158 O
by NCT03861585 159 161 O
a NCT03861585 162 163 O
doctor NCT03861585 164 170 O
according NCT03861585 171 180 O
to NCT03861585 181 183 O
DSM NCT03861585 184 187 O
5 NCT03861585 188 189 O
criteria NCT03861585 190 198 O
( NCT03861585 199 200 O
Diagnostic NCT03861585 201 211 O
and NCT03861585 212 215 O
Statistical NCT03861585 216 227 O
Manual NCT03861585 228 234 O
of NCT03861585 235 237 O
Mental NCT03861585 238 244 O
Disorders NCT03861585 245 254 O
) NCT03861585 255 256 O

- NCT03861585 260 261 O
Free NCT03861585 263 267 B-Negation
from NCT03861585 268 272 I-Negation
drug NCT03861585 273 277 B-Drug
treatment NCT03861585 278 287 B-Procedure
until NCT03861585 288 293 B-Eq-Comparison
24 NCT03861585 294 296 I-Eq-Comparison
hours NCT03861585 297 302 I-Eq-Comparison
before NCT03861585 303 309 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861585 310 313 O
experiment NCT03861585 314 324 B-Study
session NCT03861585 325 332 O
… NCT03861585 332 333 O
…… NCT03861585 333 335 O
…… NCT03861585 335 337 O
…… NCT03861585 337 339 O
…… NCT03861585 339 341 O
. NCT03861585 342 343 O

- NCT03861585 347 348 O
Affiliation NCT03861585 350 361 O
to NCT03861585 362 364 O
a NCT03861585 365 366 O
social NCT03861585 367 373 O
security NCT03861585 374 382 O
system NCT03861585 383 389 O
…… NCT03861585 389 391 O
…… NCT03861585 391 393 O
…… NCT03861585 393 395 O
…… NCT03861585 395 397 O
. NCT03861585 398 399 O

- NCT03861585 403 404 O
Signature NCT03861585 406 415 O
of NCT03861585 416 418 O
the NCT03861585 419 422 O
authorization NCT03861585 423 436 O
documents NCT03861585 437 446 O
from NCT03861585 447 451 O
one NCT03861585 452 455 O
parent NCT03861585 456 462 O
or NCT03861585 463 465 O
the NCT03861585 466 469 O
holder NCT03861585 470 476 O
of NCT03861585 477 479 O
parental NCT03861585 480 488 O
authority NCT03861585 489 498 O

Exclusion NCT03861585 499 508 O
Criteria NCT03861585 509 517 O
: NCT03861585 518 519 O

- NCT03861585 522 523 O
History NCT03861585 524 531 B-Eq-Comparison
of NCT03861585 532 534 O
neurological NCT03861585 535 547 B-Condition
troubles NCT03861585 548 556 I-Condition
, NCT03861585 557 558 O
dysphasia NCT03861585 559 568 B-Condition
, NCT03861585 569 570 O
autistic NCT03861585 571 579 B-Condition
spectrum NCT03861585 580 588 I-Condition
disorder NCT03861585 589 597 I-Condition
, NCT03861585 598 599 O
intellectual NCT03861585 600 612 B-Condition
disabilities NCT03861585 613 625 I-Condition


Inclusion NCT03863392 0 9 O
Criteria NCT03863392 10 18 O
: NCT03863392 19 20 O

- NCT03863392 24 25 O
Primigravida NCT03863392 27 39 B-Condition
or NCT03863392 40 42 B-Or
Primipara NCT03863392 43 52 B-Condition

- NCT03863392 55 56 O
Pregnancy NCT03863392 58 67 B-Condition
between NCT03863392 68 75 B-Eq-Comparison
36 NCT03863392 76 78 I-Eq-Comparison
and NCT03863392 79 82 I-Eq-Comparison
42 NCT03863392 83 85 I-Eq-Comparison
weeks NCT03863392 86 91 I-Eq-Comparison
of NCT03863392 92 94 O
gestation NCT03863392 95 104 B-Observation
. NCT03863392 105 106 O

- NCT03863392 110 111 O
A NCT03863392 113 114 O
live NCT03863392 115 119 B-Modifier
singleton NCT03863392 120 129 B-Condition
fetus NCT03863392 130 135 I-Condition
in NCT03863392 136 138 O
cephalic NCT03863392 139 147 B-Modifier
presentation NCT03863392 148 160 I-Modifier
. NCT03863392 161 162 O

- NCT03863392 166 167 O
No NCT03863392 169 171 B-Negation
history NCT03863392 172 179 B-Eq-Comparison
of NCT03863392 180 182 O
uterine NCT03863392 183 190 B-Procedure
surgery NCT03863392 191 198 I-Procedure
. NCT03863392 199 200 O

- NCT03863392 204 205 O
Clinically NCT03863392 207 217 O
adequate NCT03863392 218 226 O
pelvis NCT03863392 227 233 B-Condition
. NCT03863392 234 235 O

- NCT03863392 239 240 O
Modified NCT03863392 242 250 B-Modifier
Bishop NCT03863392 251 257 B-Observation
's NCT03863392 257 259 I-Observation
score NCT03863392 260 265 I-Observation
< NCT03863392 266 267 B-Eq-Comparison
5 NCT03863392 268 269 I-Eq-Comparison
. NCT03863392 269 270 O

- NCT03863392 274 275 O
Reactive NCT03863392 277 285 O
Non NCT03863392 286 289 B-Procedure
stress NCT03863392 290 296 I-Procedure
test NCT03863392 297 301 I-Procedure
( NCT03863392 302 303 O
NST NCT03863392 304 307 B-Procedure
) NCT03863392 308 309 O
. NCT03863392 311 312 O

Exclusion NCT03863392 314 323 O
Criteria NCT03863392 324 332 O
: NCT03863392 333 334 O

- NCT03863392 338 339 O
•Known NCT03863392 341 347 O
hypersensitivity NCT03863392 348 364 B-Condition
or NCT03863392 365 367 B-Or
contraindications NCT03863392 368 385 B-Contraindication
to NCT03863392 386 388 O
oral NCT03863392 389 393 B-Modifier
misoprostol NCT03863392 394 405 B-Drug
( NCT03863392 406 407 O
uterine NCT03863392 408 415 B-Procedure
surgery NCT03863392 416 423 I-Procedure
) NCT03863392 424 425 O
. NCT03863392 427 428 O

- NCT03863392 437 438 O
Any NCT03863392 440 443 O
antenatal NCT03863392 444 453 B-Modifier
medical NCT03863392 454 461 O
complications NCT03863392 462 475 B-Condition
. NCT03863392 476 477 O

- NCT03863392 486 487 O
A NCT03863392 489 490 O
situation NCT03863392 491 500 B-Condition
requiring NCT03863392 501 510 B-Assertion___Assertion-Type-Value:hypothetical
LSCS NCT03863392 511 515 B-Procedure
( NCT03863392 516 517 O
Maternal NCT03863392 518 526 B-Modifier
or NCT03863392 527 529 B-Or
Fetal NCT03863392 530 535 B-Modifier
) NCT03863392 536 537 O
e. NCT03863392 538 540 O
g NCT03863392 541 542 O
: NCT03863392 543 544 O
fetal NCT03863392 545 550 B-Condition
distress NCT03863392 551 559 I-Condition

- NCT03863392 567 568 O
Non NCT03863392 570 573 O
- NCT03863392 574 575 O
reactive NCT03863392 576 584 O
NST NCT03863392 585 588 B-Procedure
. NCT03863392 589 590 O

- NCT03863392 599 600 O
Patient NCT03863392 602 609 O
's NCT03863392 609 611 O
refusal NCT03863392 612 619 O
to NCT03863392 620 622 O
give NCT03863392 623 627 O
consent NCT03863392 628 635 O

Inclusion NCT03860857 0 9 O
Criteria NCT03860857 10 18 O
: NCT03860857 19 20 O

1 NCT03860857 24 25 O
. NCT03860857 25 26 O
Between NCT03860857 28 35 B-Eq-Comparison
the NCT03860857 36 39 I-Eq-Comparison
ages NCT03860857 40 44 I-Age|Eq-Comparison
of NCT03860857 45 47 I-Eq-Comparison
60 NCT03860857 48 50 I-Eq-Comparison
and NCT03860857 51 54 I-Eq-Comparison
85 NCT03860857 55 57 I-Eq-Comparison
; NCT03860857 58 59 O

2 NCT03860857 62 63 O
. NCT03860857 63 64 O
Speaks NCT03860857 66 72 O
fluent NCT03860857 73 79 O
English NCT03860857 80 87 O
; NCT03860857 87 88 O

3 NCT03860857 91 92 O
. NCT03860857 92 93 O
Visual NCT03860857 95 101 B-Modifier
and NCT03860857 102 105 B-And
auditory NCT03860857 106 114 B-Modifier
acuity NCT03860857 115 121 B-Condition
adequate NCT03860857 122 130 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03860857 131 134 I-Assertion___Assertion-Type-Value:hypothetical
neuropsychological NCT03860857 135 153 B-Modifier
and NCT03860857 154 157 B-And
computerized NCT03860857 158 170 B-Modifier
testing NCT03860857 171 178 B-Procedure
; NCT03860857 178 179 O

4 NCT03860857 182 183 O
. NCT03860857 183 184 O
Good NCT03860857 186 190 O
general NCT03860857 191 198 B-Condition
health NCT03860857 199 205 I-Condition
with NCT03860857 206 210 B-And
no NCT03860857 211 213 B-Negation
disease NCT03860857 214 221 B-Condition
( NCT03860857 222 223 O
s NCT03860857 224 225 O
) NCT03860857 226 227 O
expected NCT03860857 228 236 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860857 237 239 I-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860857 240 249 O
with NCT03860857 250 254 O
the NCT03860857 255 258 O
study NCT03860857 259 264 B-Study
; NCT03860857 264 265 O

5 NCT03860857 268 269 O
. NCT03860857 269 270 O
Willing NCT03860857 272 279 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03860857 280 283 B-And
able NCT03860857 284 288 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860857 289 291 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03860857 292 303 O
for NCT03860857 304 307 O
the NCT03860857 308 311 O
duration NCT03860857 312 320 O
of NCT03860857 321 323 O
the NCT03860857 324 327 O
study NCT03860857 328 333 B-Study
and NCT03860857 334 337 B-And
in NCT03860857 338 340 O
all NCT03860857 341 344 O
study NCT03860857 345 350 B-Study
procedures NCT03860857 351 361 B-Procedure
including NCT03860857 362 371 O
MRI NCT03860857 372 375 B-Procedure
and NCT03860857 376 379 B-Or
PET NCT03860857 380 383 B-Procedure
; NCT03860857 383 384 O

6 NCT03860857 387 388 O
. NCT03860857 388 389 O
Normal NCT03860857 391 397 O
cognition NCT03860857 398 407 B-Condition
defined NCT03860857 408 415 O
as NCT03860857 416 418 O
a NCT03860857 419 420 O
Clinical NCT03860857 421 429 B-Observation
Dementia NCT03860857 430 438 I-Observation
Rating NCT03860857 439 445 I-Observation
of NCT03860857 446 448 O
0 NCT03860857 449 450 B-Eq-Comparison
and NCT03860857 451 454 B-And
a NCT03860857 455 456 O
Mini NCT03860857 457 461 B-Observation
- NCT03860857 462 463 I-Observation
Mental NCT03860857 464 470 I-Observation
State NCT03860857 471 476 I-Observation
Examination NCT03860857 477 488 I-Observation
score NCT03860857 489 494 B-Eq-Comparison
of NCT03860857 495 497 I-Eq-Comparison
27 NCT03860857 498 500 I-Eq-Comparison
or NCT03860857 501 503 I-Eq-Comparison
higher NCT03860857 504 510 I-Eq-Comparison
. NCT03860857 511 512 O

Exclusion NCT03860857 514 523 O
Criteria NCT03860857 524 532 O
: NCT03860857 533 534 O

1 NCT03860857 538 539 O
. NCT03860857 539 540 O
Significant NCT03860857 542 553 O
co NCT03860857 554 556 B-Modifier
- NCT03860857 557 558 I-Modifier
morbid NCT03860857 559 565 I-Modifier
neurologic NCT03860857 566 576 B-Condition
disease NCT03860857 577 584 I-Condition
such NCT03860857 585 589 O
as NCT03860857 590 592 O
Parkinson NCT03860857 593 602 B-Condition
's NCT03860857 602 604 I-Condition
disease NCT03860857 605 612 I-Condition
, NCT03860857 613 614 O
multiple NCT03860857 615 623 B-Condition
sclerosis NCT03860857 624 633 I-Condition
, NCT03860857 634 635 O
brain NCT03860857 636 641 B-Condition
cyst NCT03860857 642 646 I-Condition
, NCT03860857 647 648 O
tumor NCT03860857 649 654 B-Condition
or NCT03860857 655 657 B-Or
aneurysm NCT03860857 658 666 B-Condition
; NCT03860857 666 667 O

2 NCT03860857 670 671 O
. NCT03860857 671 672 O
Major NCT03860857 674 679 O
health NCT03860857 680 686 B-Condition
conditions NCT03860857 687 697 I-Condition
such NCT03860857 698 702 O
as NCT03860857 703 705 O
uncontrolled NCT03860857 706 718 B-Modifier
diabetes NCT03860857 719 727 B-Condition
mellitus NCT03860857 728 736 I-Condition
, NCT03860857 737 738 O
uncontrolled NCT03860857 739 751 B-Modifier
hypertension NCT03860857 752 764 B-Condition
, NCT03860857 765 766 O
nutritional NCT03860857 767 778 B-Condition
deficiency NCT03860857 779 789 I-Condition
or NCT03860857 790 792 B-Or
uncontrolled NCT03860857 793 805 B-Modifier
thyroid NCT03860857 806 813 B-Condition
disease NCT03860857 814 821 I-Condition
; NCT03860857 821 822 O

3 NCT03860857 825 826 O
. NCT03860857 826 827 O
Significant NCT03860857 829 840 O
psychiatric NCT03860857 841 852 B-Condition
disorders NCT03860857 853 862 I-Condition
such NCT03860857 863 867 O
as NCT03860857 868 870 O
schizophrenia NCT03860857 871 884 B-Condition
, NCT03860857 885 886 O
bipolar NCT03860857 887 894 B-Condition
disorder NCT03860857 895 903 I-Condition
, NCT03860857 904 905 O
anxiety NCT03860857 906 913 B-Condition
disorder NCT03860857 914 922 I-Condition
, NCT03860857 923 924 O
major NCT03860857 925 930 O
depressive NCT03860857 931 941 B-Condition
disorder NCT03860857 942 950 I-Condition
, NCT03860857 951 952 O
or NCT03860857 953 955 B-Or
attention NCT03860857 956 965 B-Condition
- NCT03860857 966 967 I-Condition
deficit NCT03860857 968 975 I-Condition
hyperactivity NCT03860857 976 989 I-Condition
disorder NCT03860857 990 998 I-Condition
; NCT03860857 998 999 O

4 NCT03860857 1002 1003 O
. NCT03860857 1003 1004 O
ADRC NCT03860857 1006 1010 O
consensus NCT03860857 1011 1020 O
diagnosis NCT03860857 1021 1030 O
of NCT03860857 1031 1033 O
dementia NCT03860857 1034 1042 B-Condition
or NCT03860857 1043 1045 B-Or
mild NCT03860857 1046 1050 O
cognitive NCT03860857 1051 1060 B-Condition
impairment NCT03860857 1061 1071 I-Condition
; NCT03860857 1071 1072 O

5 NCT03860857 1075 1076 O
. NCT03860857 1076 1077 O
Cognitive NCT03860857 1079 1088 B-Condition
impairment NCT03860857 1089 1099 I-Condition
when NCT03860857 1100 1104 O
tested NCT03860857 1105 1111 O
at NCT03860857 1112 1114 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860857 1115 1123 B-Study
( NCT03860857 1124 1125 O
defined NCT03860857 1126 1133 O
as NCT03860857 1134 1136 O
a NCT03860857 1137 1138 O
score NCT03860857 1139 1144 O
on NCT03860857 1145 1147 O
any NCT03860857 1148 1151 O
neuropsychological NCT03860857 1152 1170 B-Observation
test NCT03860857 1171 1175 I-Observation
of NCT03860857 1176 1178 O
1.5 NCT03860857 1179 1182 B-Eq-Comparison
SDs NCT03860857 1183 1186 I-Eq-Comparison
or NCT03860857 1187 1189 I-Eq-Comparison
more NCT03860857 1190 1194 I-Eq-Comparison
outside NCT03860857 1195 1202 B-Modifier
the NCT03860857 1203 1206 I-Modifier
age NCT03860857 1207 1210 I-Modifier
norm NCT03860857 1211 1215 I-Modifier
) NCT03860857 1216 1217 O
; NCT03860857 1218 1219 O

6 NCT03860857 1222 1223 O
. NCT03860857 1223 1224 O
Alcohol NCT03860857 1226 1233 B-Modifier
or NCT03860857 1234 1236 B-Or
substance NCT03860857 1237 1246 B-Modifier
abuse NCT03860857 1247 1252 B-Condition
or NCT03860857 1253 1255 B-Or
dependence NCT03860857 1256 1266 B-Condition
within NCT03860857 1267 1273 B-Eq-Comparison
the NCT03860857 1274 1277 I-Eq-Comparison
past NCT03860857 1278 1282 I-Eq-Comparison
2 NCT03860857 1283 1284 I-Eq-Comparison
years NCT03860857 1285 1290 I-Eq-Comparison
( NCT03860857 1291 1292 O
DSM NCT03860857 1293 1296 O
- NCT03860857 1297 1298 O
IV NCT03860857 1299 1301 O
criteria NCT03860857 1302 1310 O
) NCT03860857 1311 1312 O
; NCT03860857 1313 1314 O

7 NCT03860857 1317 1318 O
. NCT03860857 1318 1319 O
MRI NCT03860857 1321 1324 B-Procedure
contraindications NCT03860857 1325 1342 B-Contraindication
, NCT03860857 1343 1344 O
e. NCT03860857 1345 1347 O
g. NCT03860857 1348 1350 O
pacemakers NCT03860857 1352 1362 B-Procedure
, NCT03860857 1363 1364 O
aneurysm NCT03860857 1365 1373 B-Procedure
clips NCT03860857 1374 1379 I-Procedure
, NCT03860857 1380 1381 O
artificial NCT03860857 1382 1392 B-Procedure
heart NCT03860857 1393 1398 I-Procedure
valves NCT03860857 1399 1405 I-Procedure
, NCT03860857 1406 1407 O
ear NCT03860857 1408 1411 B-Procedure
implants NCT03860857 1412 1420 I-Procedure
, NCT03860857 1421 1422 O
metal NCT03860857 1423 1428 B-Condition
fragments NCT03860857 1429 1438 I-Condition
or NCT03860857 1439 1441 B-Or
foreign NCT03860857 1442 1449 B-Modifier
objects NCT03860857 1450 1457 B-Condition
in NCT03860857 1458 1460 O
the NCT03860857 1461 1464 O
eyes NCT03860857 1465 1469 B-Modifier
, NCT03860857 1470 1471 O
skin NCT03860857 1472 1476 B-Modifier
or NCT03860857 1477 1479 B-Or
body NCT03860857 1480 1484 B-Modifier
. NCT03860857 1484 1485 O
Females NCT03860857 1487 1494 O
who NCT03860857 1495 1498 B-And
are NCT03860857 1499 1502 O
pregnant NCT03860857 1503 1511 B-Condition
or NCT03860857 1512 1514 B-Or
trying NCT03860857 1515 1521 B-Assertion___Assertion-Type-Value:intention
to NCT03860857 1522 1524 I-Assertion___Assertion-Type-Value:intention
get NCT03860857 1525 1528 O
pregnant NCT03860857 1529 1537 B-Condition
are NCT03860857 1538 1541 O
also NCT03860857 1542 1546 O
excluded NCT03860857 1547 1555 B-Negation
; NCT03860857 1555 1556 O

8 NCT03860857 1559 1560 O
. NCT03860857 1560 1561 O
PET NCT03860857 1563 1566 B-Procedure
contraindications NCT03860857 1567 1584 B-Contraindication
, NCT03860857 1585 1586 O
e. NCT03860857 1587 1589 O
g. NCT03860857 1590 1592 O
significant NCT03860857 1594 1605 O
prior NCT03860857 1606 1611 B-Eq-Comparison
radiation NCT03860857 1612 1621 B-Condition
exposure NCT03860857 1622 1630 I-Condition
and NCT03860857 1631 1634 B-Or
pregnancy NCT03860857 1635 1644 B-Condition
. NCT03860857 1644 1645 O

Inclusion NCT03861546 0 9 O
Criteria NCT03861546 10 18 O
: NCT03861546 19 20 O

1 NCT03861546 24 25 O
. NCT03861546 25 26 O
age NCT03861546 28 31 B-Age
> NCT03861546 32 33 B-Eq-Comparison
18 NCT03861546 34 36 I-Eq-Comparison
years NCT03861546 37 42 I-Eq-Comparison
; NCT03861546 42 43 O

2 NCT03861546 46 47 O
. NCT03861546 47 48 O
confirmed NCT03861546 50 59 O
diagnosis NCT03861546 60 69 O
of NCT03861546 70 72 O
prediabetes NCT03861546 73 84 B-Condition
or NCT03861546 85 87 B-Or
T2D NCT03861546 88 91 B-Condition
( NCT03861546 92 93 O
documented NCT03861546 94 104 O
A1c NCT03861546 105 108 B-Observation
of NCT03861546 109 111 O
≥ NCT03861546 112 113 B-Eq-Comparison
5.7 NCT03861546 114 117 I-Eq-Comparison
% NCT03861546 118 119 I-Eq-Comparison
, NCT03861546 121 122 O
2 NCT03861546 123 124 B-Observation
- NCT03861546 125 126 I-Observation
hour NCT03861546 127 131 I-Observation
post NCT03861546 132 136 I-Observation
- NCT03861546 137 138 I-Observation
load NCT03861546 139 143 I-Observation
glucose NCT03861546 144 151 I-Observation
of NCT03861546 152 154 O
> NCT03861546 155 156 B-Eq-Comparison
140 NCT03861546 157 160 I-Eq-Comparison
, NCT03861546 161 162 O
or NCT03861546 163 165 B-Or
FBG NCT03861546 166 169 B-Observation
of NCT03861546 170 172 O
> NCT03861546 173 174 B-Eq-Comparison
100 NCT03861546 175 178 I-Eq-Comparison
) NCT03861546 179 180 O
; NCT03861546 181 182 O

3 NCT03861546 185 186 O
. NCT03861546 186 187 O
a NCT03861546 189 190 O
family NCT03861546 191 197 B-Family-Member___Family-Member-Type:parent
member NCT03861546 198 204 O
or NCT03861546 205 207 O
peer NCT03861546 208 212 O
willing NCT03861546 213 220 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861546 221 223 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861546 224 235 O
and NCT03861546 236 239 O
attend NCT03861546 240 246 O
all NCT03861546 247 250 O
sessions NCT03861546 251 259 B-Procedure
as NCT03861546 260 262 O
a NCT03861546 263 264 O
social NCT03861546 265 271 O
influencer NCT03861546 272 282 O
; NCT03861546 282 283 O

4 NCT03861546 286 287 O
. NCT03861546 287 288 O
proficiency NCT03861546 290 301 O
in NCT03861546 302 304 O
English NCT03861546 305 312 O
of NCT03861546 313 315 O
at NCT03861546 316 318 B-Eq-Comparison
least NCT03861546 319 324 I-Eq-Comparison
one NCT03861546 325 328 I-Eq-Comparison
member NCT03861546 329 335 O
of NCT03861546 336 338 O
each NCT03861546 339 343 O
dyad NCT03861546 344 348 O
, NCT03861546 349 350 O

5 NCT03861546 354 355 O
. NCT03861546 355 356 O
willingness NCT03861546 358 369 O
to NCT03861546 370 372 O
provide NCT03861546 373 380 O
written NCT03861546 381 388 O
consent NCT03861546 389 396 O
. NCT03861546 397 398 O

Exclusion NCT03861546 400 409 O
Criteria NCT03861546 410 418 O
: NCT03861546 419 420 O

1 NCT03861546 424 425 O
. NCT03861546 425 426 O
type NCT03861546 428 432 B-Modifier
1 NCT03861546 433 434 I-Modifier
diabetes NCT03861546 435 443 B-Condition
or NCT03861546 444 446 B-Or
diabetes NCT03861546 447 455 B-Condition
secondary NCT03861546 456 465 B-Modifier
to NCT03861546 466 468 O
other NCT03861546 469 474 B-Other
conditions NCT03861546 475 485 B-Condition
( NCT03861546 486 487 O
e. NCT03861546 488 490 O
g. NCT03861546 491 493 O
steroid NCT03861546 495 502 B-Drug
- NCT03861546 503 504 O
induced NCT03861546 505 512 B-Modifier
, NCT03861546 513 514 O
pancreatic NCT03861546 515 525 B-Modifier
insufficiency NCT03861546 526 539 B-Condition
, NCT03861546 540 541 O
or NCT03861546 542 544 B-Or
chemotherapy NCT03861546 545 557 B-Procedure
- NCT03861546 558 559 O
induced NCT03861546 560 567 B-Modifier
) NCT03861546 568 569 O
; NCT03861546 570 571 O

2 NCT03861546 574 575 O
. NCT03861546 575 576 O
malignancy NCT03861546 578 588 B-Condition
or NCT03861546 589 591 B-Or
life NCT03861546 592 596 B-Death|Risk
- NCT03861546 597 598 I-Death|Risk
threatening NCT03861546 599 610 I-Death|Risk
illness NCT03861546 611 618 B-Condition
with NCT03861546 619 623 B-And
life NCT03861546 624 628 B-Observation
expectancy NCT03861546 629 639 I-Observation
of NCT03861546 640 642 O
< NCT03861546 643 644 B-Eq-Comparison
5 NCT03861546 645 646 I-Eq-Comparison
years NCT03861546 647 652 I-Eq-Comparison
; NCT03861546 652 653 O

3 NCT03861546 656 657 O
. NCT03861546 657 658 O
end NCT03861546 660 663 B-Modifier
- NCT03861546 664 665 I-Modifier
stage NCT03861546 666 671 I-Modifier
disease NCT03861546 672 679 B-Condition
or NCT03861546 680 682 B-Or
serious NCT03861546 683 690 O
illness NCT03861546 691 698 B-Condition
that NCT03861546 699 703 O
prohibits NCT03861546 704 713 B-Assertion___Assertion-Type-Value:hypothetical|Negation
participation NCT03861546 714 727 B-Study
( NCT03861546 728 729 O
e. NCT03861546 730 732 O
g. NCT03861546 733 735 O
end NCT03861546 737 740 B-Modifier
- NCT03861546 741 742 I-Modifier
stage NCT03861546 743 748 I-Modifier
renal NCT03861546 749 754 B-Condition
disease NCT03861546 755 762 I-Condition
or NCT03861546 763 765 B-Or
class NCT03861546 766 771 B-Eq-Comparison
IV NCT03861546 772 774 I-Eq-Comparison
congestive NCT03861546 775 785 B-Condition
heart NCT03861546 786 791 I-Condition
failure NCT03861546 792 799 I-Condition
) NCT03861546 800 801 O
; NCT03861546 802 803 O

4 NCT03861546 806 807 O
. NCT03861546 807 808 O
inability NCT03861546 810 819 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861546 820 822 O
perform NCT03861546 823 830 O
unsupervised NCT03861546 831 843 B-Modifier
physical NCT03861546 844 852 B-Observation
activity NCT03861546 853 861 I-Observation
; NCT03861546 861 862 O

5 NCT03861546 865 866 O
. NCT03861546 866 867 O
pregnancy NCT03861546 869 878 B-Condition
; NCT03861546 878 879 O

6 NCT03861546 882 883 O
. NCT03861546 883 884 O
diagnosed NCT03861546 886 895 O
cognitive NCT03861546 896 905 B-Condition
deficits NCT03861546 906 914 I-Condition
or NCT03861546 915 917 B-Or
limited NCT03861546 918 925 O
decision NCT03861546 926 934 B-Condition
- NCT03861546 935 936 I-Condition
making NCT03861546 937 943 I-Condition
capacity NCT03861546 944 952 I-Condition
; NCT03861546 952 953 O

7 NCT03861546 956 957 O
. NCT03861546 957 958 O
alcohol NCT03861546 960 967 B-Modifier
or NCT03861546 968 970 B-Or
substance NCT03861546 971 980 B-Modifier
abuse NCT03861546 981 986 B-Condition
; NCT03861546 986 987 O

8 NCT03861546 990 991 O
. NCT03861546 991 992 O
homelessness NCT03861546 994 1006 B-Condition
or NCT03861546 1007 1009 B-Or
no NCT03861546 1010 1012 B-Negation
fixed NCT03861546 1013 1018 O
address NCT03861546 1019 1026 O
. NCT03861546 1026 1027 O

Inclusion NCT03863379 0 9 O
Criteria NCT03863379 10 18 O
: NCT03863379 19 20 O

Persons NCT03863379 22 29 O
with NCT03863379 30 34 O

- NCT03863379 37 38 O
stroke NCT03863379 40 46 B-Condition
/ NCT03863379 47 48 B-Or
cerebrovascular NCT03863379 49 64 B-Condition
disease NCT03863379 65 72 I-Condition

- NCT03863379 75 76 O
traumatic NCT03863379 78 87 B-Condition
brain NCT03863379 88 93 I-Condition
injury NCT03863379 94 100 I-Condition

- NCT03863379 103 104 O
multiple NCT03863379 106 114 B-Condition
sclerosis NCT03863379 115 124 I-Condition

- NCT03863379 127 128 O
spinal NCT03863379 130 136 B-Modifier
cord NCT03863379 137 141 I-Modifier
injuries NCT03863379 142 150 B-Condition
( NCT03863379 151 152 O
including NCT03863379 153 162 O
spinal NCT03863379 163 169 B-Modifier
cord NCT03863379 170 174 I-Modifier
lesions NCT03863379 175 182 B-Condition
i. NCT03863379 183 185 O
e. NCT03863379 186 188 O
myelopathies NCT03863379 190 202 B-Condition
etc NCT03863379 203 206 O
. NCT03863379 206 207 O
) NCT03863379 208 209 O

Exclusion NCT03863379 211 220 O
Criteria NCT03863379 221 229 O
: NCT03863379 230 231 O

Persons NCT03863379 233 240 O
with NCT03863379 241 245 O

- NCT03863379 248 249 O
heterotopic NCT03863379 251 262 B-Condition
ossifications NCT03863379 263 276 I-Condition
, NCT03863379 277 278 O

- NCT03863379 282 283 O
chronic NCT03863379 285 292 B-Modifier
administration NCT03863379 293 307 O
of NCT03863379 308 310 O
drugs NCT03863379 311 316 B-Drug
, NCT03863379 317 318 O
which NCT03863379 319 324 O
promote NCT03863379 325 332 O
fat NCT03863379 333 336 B-Condition
increase NCT03863379 337 345 O

- NCT03863379 348 349 O
chronic NCT03863379 351 358 B-Modifier
administration NCT03863379 359 373 O
of NCT03863379 374 376 O
drugs NCT03863379 377 382 B-Drug
, NCT03863379 383 384 O
which NCT03863379 385 390 O
promote NCT03863379 391 398 O
bone NCT03863379 399 403 B-Modifier
or NCT03863379 404 406 B-Or
muscle NCT03863379 407 413 B-Modifier
loss NCT03863379 414 418 B-Condition

- NCT03863379 421 422 O
co NCT03863379 424 426 B-Modifier
- NCT03863379 427 428 I-Modifier
existing NCT03863379 429 437 I-Modifier
other NCT03863379 438 443 B-Other
diseases NCT03863379 444 452 B-Condition
such NCT03863379 453 457 O
as NCT03863379 458 460 O
: NCT03863379 461 462 O
endocrinopathies NCT03863379 463 479 B-Condition
, NCT03863379 480 481 O
muscular NCT03863379 482 490 B-Condition
dystrophies NCT03863379 491 502 I-Condition
, NCT03863379 503 504 O
non NCT03863379 505 508 B-Negation
- NCT03863379 509 510 O
alcoholic NCT03863379 511 520 B-Modifier
fatty NCT03863379 521 526 B-Condition
liver NCT03863379 527 532 I-Condition
disease NCT03863379 533 540 I-Condition
. NCT03863379 540 541 O

Inclusion NCT03861208 0 9 O
Criteria NCT03861208 10 18 O
: NCT03861208 19 20 O

- NCT03861208 24 25 O
healthy NCT03861208 27 34 B-Condition
children NCT03861208 35 43 O

Exclusion NCT03861208 44 53 O
Criteria NCT03861208 54 62 O
: NCT03861208 63 64 O

- NCT03861208 68 69 O
no NCT03861208 71 73 B-Negation
food NCT03861208 74 78 O
allergies NCT03861208 79 88 B-Allergy

- NCT03861208 91 92 O
no NCT03861208 94 96 B-Negation
medications NCT03861208 97 108 B-Drug
that NCT03861208 109 113 O
affect NCT03861208 114 120 B-Assertion___Assertion-Type-Value:hypothetical
behavior NCT03861208 121 129 B-Condition
/ NCT03861208 130 131 B-Or
learning NCT03861208 132 140 B-Condition
/ NCT03861208 141 142 B-Or
appetite NCT03861208 143 151 B-Condition

Inclusion NCT03860116 0 9 O
Criteria NCT03860116 10 18 O
: NCT03860116 19 20 O

- NCT03860116 24 25 O
1 NCT03860116 27 28 O
. NCT03860116 28 29 O
diagnosed NCT03860116 31 40 O
as NCT03860116 41 43 O
HIV NCT03860116 44 47 B-Condition
positive NCT03860116 48 56 O
; NCT03860116 56 57 O

- NCT03860116 60 61 O
2 NCT03860116 63 64 O
. NCT03860116 64 65 O
initiate NCT03860116 67 75 B-Eq-Comparison
antiretroviral NCT03860116 76 90 B-Procedure
therapy NCT03860116 91 98 I-Procedure
on NCT03860116 99 101 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860116 102 105 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03860116 106 109 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860116 110 112 O
recruitment NCT03860116 113 124 B-Study
; NCT03860116 124 125 O

- NCT03860116 128 129 O
3 NCT03860116 131 132 O
. NCT03860116 132 133 O
was NCT03860116 135 138 O
infected NCT03860116 139 147 B-Condition
through NCT03860116 148 155 O
male NCT03860116 156 160 B-Modifier
same NCT03860116 161 165 B-Condition
- NCT03860116 166 167 I-Condition
sex NCT03860116 168 171 I-Condition
behavior NCT03860116 172 180 I-Condition
; NCT03860116 180 181 O

- NCT03860116 184 185 O
4 NCT03860116 187 188 O
. NCT03860116 188 189 O
has NCT03860116 191 194 O
access NCT03860116 195 201 O
to NCT03860116 202 204 O
internet NCT03860116 205 213 O
on NCT03860116 214 216 O
a NCT03860116 217 218 O
personal NCT03860116 219 227 O
mobile NCT03860116 228 234 O
phone NCT03860116 235 240 O
; NCT03860116 240 241 O

- NCT03860116 244 245 O
5 NCT03860116 247 248 O
. NCT03860116 248 249 O
has NCT03860116 251 254 O
a NCT03860116 255 256 O
Wechat NCT03860116 257 263 O
account NCT03860116 264 271 O
and NCT03860116 272 275 O
use NCT03860116 276 279 O
it NCT03860116 280 282 O
daily NCT03860116 283 288 O
; NCT03860116 288 289 O

- NCT03860116 292 293 O
6 NCT03860116 295 296 O
. NCT03860116 296 297 O
willing NCT03860116 299 306 O
to NCT03860116 307 309 O
provide NCT03860116 310 317 O
written NCT03860116 318 325 O
informed NCT03860116 326 334 O
consent NCT03860116 335 342 O
; NCT03860116 342 343 O

Exclusion NCT03860116 344 353 O
Criteria NCT03860116 354 362 O
: NCT03860116 363 364 O

- NCT03860116 368 369 O
1 NCT03860116 371 372 O
. NCT03860116 372 373 O
under NCT03860116 375 380 O
severe NCT03860116 381 387 O
physical NCT03860116 388 396 B-Modifier
or NCT03860116 397 399 B-Or
mental NCT03860116 400 406 B-Modifier
condition NCT03860116 407 416 B-Condition
which NCT03860116 417 422 O
precludes NCT03860116 423 432 B-Assertion___Assertion-Type-Value:hypothetical|Negation
study NCT03860116 433 438 B-Study
participation NCT03860116 439 452 O
; NCT03860116 452 453 O

- NCT03860116 456 457 O
2 NCT03860116 459 460 O
. NCT03860116 460 461 O
being NCT03860116 463 468 B-Eq-Comparison
an NCT03860116 469 471 O
inpatient NCT03860116 472 481 B-Encounter
of NCT03860116 482 484 O
the NCT03860116 485 488 O
hospital NCT03860116 489 497 O
; NCT03860116 497 498 O

Inclusion NCT03862846 0 9 O
Criteria NCT03862846 10 18 O
: NCT03862846 19 20 O

- NCT03862846 24 25 O
Subjects NCT03862846 27 35 O
must NCT03862846 36 40 O
give NCT03862846 41 45 O
written NCT03862846 46 53 O
, NCT03862846 54 55 O
signed NCT03862846 56 62 O
and NCT03862846 63 66 O
dated NCT03862846 67 72 O
informed NCT03862846 73 81 O
consent NCT03862846 82 89 O

- NCT03862846 92 93 O
Confirmed NCT03862846 95 104 O
diagnosis NCT03862846 105 114 O
of NCT03862846 115 117 O
PMM NCT03862846 118 121 B-Condition
according NCT03862846 122 131 O
to NCT03862846 132 134 O
the NCT03862846 135 138 O
2016 NCT03862846 139 143 O
Rome NCT03862846 144 148 O
Consensus NCT03862846 149 158 O
recommendations NCT03862846 159 174 O

- NCT03862846 177 178 O
Confirmed NCT03862846 180 189 O
mitochondrial NCT03862846 190 203 B-Condition
mutation NCT03862846 204 212 I-Condition
with NCT03862846 213 217 B-And
evidence NCT03862846 218 226 O
of NCT03862846 227 229 O
myopathy NCT03862846 230 238 B-Condition

- NCT03862846 241 242 O
Able NCT03862846 244 248 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862846 249 251 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03862846 252 258 O
on NCT03862846 259 261 O
stable NCT03862846 262 268 O
medication NCT03862846 269 279 B-Drug
throughout NCT03862846 280 290 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862846 291 294 O
study NCT03862846 295 300 B-Study

Exclusion NCT03862846 301 310 O
Criteria NCT03862846 311 319 O
: NCT03862846 320 321 O

- NCT03862846 325 326 O
Documented NCT03862846 328 338 O
evidence NCT03862846 339 347 O
of NCT03862846 348 350 O
ongoing NCT03862846 351 358 B-Eq-Comparison
rhabdomyolysis NCT03862846 359 373 B-Condition

- NCT03862846 376 377 O
Subjects NCT03862846 379 387 O
with NCT03862846 388 392 O
motor NCT03862846 393 398 B-Condition
abnormalities NCT03862846 399 412 I-Condition
other NCT03862846 413 418 B-Exception
than NCT03862846 419 423 I-Exception
related NCT03862846 424 431 O
to NCT03862846 432 434 O
mitochondrial NCT03862846 435 448 B-Condition
disease NCT03862846 449 456 I-Condition

- NCT03862846 459 460 O
Treatment NCT03862846 462 471 B-Procedure
with NCT03862846 472 476 O
an NCT03862846 477 479 O
investigational NCT03862846 480 495 B-Study
drug NCT03862846 496 500 B-Drug
within NCT03862846 501 507 B-Eq-Comparison
3 NCT03862846 508 509 I-Eq-Comparison
months NCT03862846 510 516 I-Eq-Comparison
prior NCT03862846 517 522 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862846 523 525 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Day NCT03862846 526 529 B-Study
1 NCT03862846 530 531 O

- NCT03862846 535 536 O
Hospitalised NCT03862846 538 550 B-Encounter
within NCT03862846 551 557 B-Eq-Comparison
3 NCT03862846 558 559 I-Eq-Comparison
months NCT03862846 560 566 I-Eq-Comparison
prior NCT03862846 567 572 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862846 573 575 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03862846 576 585 B-Study
for NCT03862846 586 589 O
any NCT03862846 590 593 O
major NCT03862846 594 599 O
medical NCT03862846 600 607 B-Condition
condition NCT03862846 608 617 I-Condition

- NCT03862846 620 621 O
Pregnant NCT03862846 623 631 B-Condition
or NCT03862846 632 634 B-Or
nursing NCT03862846 635 642 B-Condition
females NCT03862846 643 650 O

Inclusion NCT03867916 0 9 O
Criteria NCT03867916 10 18 O
: NCT03867916 19 20 O

- NCT03867916 24 25 O
FOR NCT03867916 27 30 O
INTERVIEWS NCT03867916 31 41 O
AND NCT03867916 42 45 O
FOCUS NCT03867916 46 51 O
GROUPS NCT03867916 52 58 O
: NCT03867916 59 60 O
Cancer NCT03867916 61 67 B-Condition
patients NCT03867916 68 76 O
: NCT03867916 77 78 O
Self NCT03867916 79 83 O
- NCT03867916 84 85 O
identifies NCT03867916 86 96 O
as NCT03867916 97 99 O
Asian NCT03867916 100 105 O
American NCT03867916 106 114 O
, NCT03867916 115 116 O
lives NCT03867916 117 122 O
in NCT03867916 123 125 O
San NCT03867916 126 129 O
Francisco NCT03867916 130 139 O
, NCT03867916 140 141 O
speaks NCT03867916 142 148 O
English NCT03867916 149 156 O
, NCT03867916 157 158 O
Mandarin NCT03867916 159 167 O
, NCT03867916 168 169 O
Cantonese NCT03867916 170 179 O
, NCT03867916 180 181 O
or NCT03867916 182 184 B-Or
Vietnamese NCT03867916 185 195 O
, NCT03867916 196 197 O
has NCT03867916 198 201 O
a NCT03867916 202 203 O
history NCT03867916 204 211 B-Eq-Comparison
of NCT03867916 212 214 O
cancer NCT03867916 215 221 B-Condition
of NCT03867916 222 224 O
any NCT03867916 225 228 O
kind NCT03867916 229 233 O

- NCT03867916 236 237 O
FOR NCT03867916 239 242 O
INTERVIEWS NCT03867916 243 253 O
AND NCT03867916 254 257 O
FOCUS NCT03867916 258 263 O
GROUPS NCT03867916 264 270 O
: NCT03867916 271 272 O
Caregivers NCT03867916 273 283 O
: NCT03867916 284 285 O
any NCT03867916 286 289 O
person NCT03867916 290 296 O
who NCT03867916 297 300 O
has NCT03867916 301 304 O
provided NCT03867916 305 313 O
care NCT03867916 314 318 O
to NCT03867916 319 321 O
an NCT03867916 322 324 O
Asian NCT03867916 325 330 O
American NCT03867916 331 339 O
cancer NCT03867916 340 346 B-Condition
patient NCT03867916 347 354 O

- NCT03867916 357 358 O
FOR NCT03867916 360 363 O
INTERVIEWS NCT03867916 364 374 O
AND NCT03867916 375 378 O
FOCUS NCT03867916 379 384 O
GROUPS NCT03867916 385 391 O
: NCT03867916 392 393 O
Health NCT03867916 394 400 O
professionals NCT03867916 401 414 O
: NCT03867916 415 416 O
physicians NCT03867916 417 427 B-Provider
and NCT03867916 428 431 O
other NCT03867916 432 437 O
health NCT03867916 438 444 B-Provider
professionals NCT03867916 445 458 I-Provider
who NCT03867916 459 462 O
provide NCT03867916 463 470 O
care NCT03867916 471 475 O
to NCT03867916 476 478 O
Asian NCT03867916 479 484 O
American NCT03867916 485 493 O
patients NCT03867916 494 502 O
with NCT03867916 503 507 B-And
cancer NCT03867916 508 514 B-Condition

- NCT03867916 517 518 O
FOR NCT03867916 520 523 O
PILOT NCT03867916 524 529 O
AND NCT03867916 530 533 O
FULL NCT03867916 534 538 O
IMPLEMENTATION NCT03867916 539 553 O
: NCT03867916 554 555 O
Self NCT03867916 556 560 O
- NCT03867916 561 562 O
identifies NCT03867916 563 573 O
as NCT03867916 574 576 O
Asian NCT03867916 577 582 O
American NCT03867916 583 591 O
, NCT03867916 592 593 O
lives NCT03867916 594 599 O
in NCT03867916 600 602 O
San NCT03867916 603 606 O
Francisco NCT03867916 607 616 O
, NCT03867916 617 618 O
speaks NCT03867916 619 625 O
English NCT03867916 626 633 O
, NCT03867916 634 635 O
Mandarin NCT03867916 636 644 O
, NCT03867916 645 646 O
Cantonese NCT03867916 647 656 O
, NCT03867916 657 658 O
or NCT03867916 659 661 B-Or
Vietnamese NCT03867916 662 672 O
, NCT03867916 673 674 O
has NCT03867916 675 678 O
stage NCT03867916 679 684 B-Eq-Comparison
I NCT03867916 685 686 I-Eq-Comparison
- NCT03867916 687 688 I-Eq-Comparison
III NCT03867916 689 692 I-Eq-Comparison
colorectal NCT03867916 693 703 B-Modifier
, NCT03867916 704 705 O
lung NCT03867916 706 710 B-Modifier
, NCT03867916 711 712 O
or NCT03867916 713 715 B-Or
liver NCT03867916 716 721 B-Modifier
cancer NCT03867916 722 728 B-Condition
, NCT03867916 729 730 O
has NCT03867916 731 734 O
not NCT03867916 735 738 B-Negation
yet NCT03867916 739 742 O
undergone NCT03867916 743 752 B-Eq-Comparison
treatment NCT03867916 753 762 B-Procedure

- NCT03867916 765 766 O
FOR NCT03867916 768 771 O
PILOT NCT03867916 772 777 O
AND NCT03867916 778 781 O
FULL NCT03867916 782 786 O
IMPLEMENTATION NCT03867916 787 801 O
: NCT03867916 802 803 O
Is NCT03867916 804 806 O
willing NCT03867916 807 814 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867916 815 817 I-Assertion___Assertion-Type-Value:hypothetical
stay NCT03867916 818 822 O
in NCT03867916 823 825 O
the NCT03867916 826 829 O
study NCT03867916 830 835 B-Study
for NCT03867916 836 839 O
six NCT03867916 840 843 B-Eq-Comparison
months NCT03867916 844 850 I-Eq-Comparison

Exclusion NCT03867916 851 860 O
Criteria NCT03867916 861 869 O
: NCT03867916 870 871 O

- NCT03867916 875 876 O
Any NCT03867916 878 881 O
medical NCT03867916 882 889 B-Modifier
or NCT03867916 890 892 B-Or
psychological NCT03867916 893 906 B-Modifier
conditions NCT03867916 907 917 B-Condition
precluding NCT03867916 918 928 O
informed NCT03867916 929 937 O
consent NCT03867916 938 945 O

Inclusion NCT03864562 0 9 O
Criteria NCT03864562 10 18 O
: NCT03864562 19 20 O

- NCT03864562 24 25 O
White NCT03864562 27 32 O
European NCT03864562 33 41 O
or NCT03864562 42 44 B-Or
black NCT03864562 45 50 O
African NCT03864562 51 58 O
/ NCT03864562 59 60 B-Or
Caribbean NCT03864562 61 70 O
heritage NCT03864562 71 79 O

- NCT03864562 82 83 O
BMI NCT03864562 85 88 B-Observation
> NCT03864562 89 90 B-Eq-Comparison
18 NCT03864562 91 93 I-Eq-Comparison
kg NCT03864562 94 96 I-Eq-Comparison
/ NCT03864562 97 98 I-Eq-Comparison
m2 NCT03864562 99 101 I-Eq-Comparison

- NCT03864562 104 105 O
Ability NCT03864562 107 114 O
to NCT03864562 115 117 O
give NCT03864562 118 122 O
written NCT03864562 123 130 O
informed NCT03864562 131 139 O
consent NCT03864562 140 147 O

- NCT03864562 150 151 O
English NCT03864562 153 160 O
speaking NCT03864562 161 169 O

Exclusion NCT03864562 170 179 O
Criteria NCT03864562 180 188 O
: NCT03864562 189 190 O

- NCT03864562 194 195 O
Any NCT03864562 197 200 O
significant NCT03864562 201 212 O
medical NCT03864562 213 220 B-Condition
condition NCT03864562 221 230 I-Condition

- NCT03864562 233 234 O
Uncontrolled NCT03864562 236 248 B-Modifier
hypertension NCT03864562 249 261 B-Condition

- NCT03864562 264 265 O
Alcohol NCT03864562 267 274 B-Observation
consumption NCT03864562 275 286 I-Observation
> NCT03864562 287 288 O
14 NCT03864562 289 291 B-Eq-Comparison
units NCT03864562 292 297 I-Eq-Comparison
/ NCT03864562 298 299 I-Eq-Comparison
week NCT03864562 300 304 I-Eq-Comparison

- NCT03864562 307 308 O
Random NCT03864562 310 316 B-Modifier
blood NCT03864562 317 322 B-Observation
Glucose NCT03864562 323 330 I-Observation
concentration NCT03864562 331 344 I-Observation
above NCT03864562 345 350 B-Eq-Comparison
7.8 NCT03864562 351 354 I-Eq-Comparison
mmol NCT03864562 355 359 I-Eq-Comparison
/ NCT03864562 360 361 I-Eq-Comparison
l NCT03864562 362 363 I-Eq-Comparison

- NCT03864562 366 367 O
Hemoglobin NCT03864562 369 379 B-Observation
A1c NCT03864562 380 383 I-Observation
( NCT03864562 384 385 O
HbA1c NCT03864562 386 391 B-Observation
) NCT03864562 392 393 O
> NCT03864562 394 395 O
47 NCT03864562 396 398 B-Eq-Comparison
mmol NCT03864562 399 403 I-Eq-Comparison
/ NCT03864562 404 405 I-Eq-Comparison
mol NCT03864562 406 409 I-Eq-Comparison
( NCT03864562 410 411 O
> NCT03864562 413 414 B-Eq-Comparison
6.4 NCT03864562 415 418 I-Eq-Comparison
% NCT03864562 419 420 I-Eq-Comparison
) NCT03864562 422 423 O

- NCT03864562 427 428 O
Use NCT03864562 430 433 B-Eq-Comparison
of NCT03864562 434 436 O
regular NCT03864562 437 444 O
medication NCT03864562 445 455 B-Drug
, NCT03864562 456 457 O
( NCT03864562 458 459 O
oral NCT03864562 460 464 B-Drug
contraceptive NCT03864562 465 478 I-Drug
pill NCT03864562 479 483 I-Drug
or NCT03864562 484 486 B-Or
antihypertensive NCT03864562 487 503 B-Drug
medication NCT03864562 504 514 I-Drug
are NCT03864562 515 518 O
acceptable NCT03864562 519 529 B-Exception
if NCT03864562 530 532 I-Exception
use NCT03864562 533 536 O
has NCT03864562 537 540 O
been NCT03864562 541 545 O
for NCT03864562 546 549 O
> NCT03864562 550 551 B-Eq-Comparison
6 NCT03864562 552 553 I-Eq-Comparison
months NCT03864562 554 560 I-Eq-Comparison
) NCT03864562 561 562 O

- NCT03864562 566 567 O
History NCT03864562 569 576 B-Eq-Comparison
of NCT03864562 577 579 O
Irritable NCT03864562 580 589 B-Condition
Bowel NCT03864562 590 595 I-Condition
Syndrome NCT03864562 596 604 I-Condition
, NCT03864562 605 606 O
food NCT03864562 607 611 B-Condition
intolerances NCT03864562 612 624 I-Condition
or NCT03864562 625 627 B-Or
any NCT03864562 628 631 O
gastrointestinal NCT03864562 632 648 B-Condition
disorders NCT03864562 649 658 I-Condition

- NCT03864562 661 662 O
Previous NCT03864562 664 672 B-Eq-Comparison
bariatric NCT03864562 673 682 B-Procedure
surgery NCT03864562 683 690 I-Procedure
, NCT03864562 691 692 O
or NCT03864562 693 695 B-Or
gastrointestinal NCT03864562 696 712 B-Procedure
surgery NCT03864562 713 720 I-Procedure
which NCT03864562 721 726 O
may NCT03864562 727 730 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864562 731 737 O
normal NCT03864562 738 744 O
function NCT03864562 745 753 B-Condition
( NCT03864562 754 755 O
e. NCT03864562 756 758 O
g. NCT03864562 759 761 O
bowel NCT03864562 763 768 B-Procedure
resection NCT03864562 769 778 I-Procedure
) NCT03864562 779 780 O

Inclusion NCT03868358 0 9 O
Criteria NCT03868358 10 18 O
: NCT03868358 19 20 O

- NCT03868358 24 25 O
Patients NCT03868358 27 35 O
met NCT03868358 36 39 O
diagnostic NCT03868358 40 50 O
criteria NCT03868358 51 59 O
for NCT03868358 60 63 O
schizophrenia NCT03868358 64 77 B-Condition
or NCT03868358 78 80 B-Or
schizoaffective NCT03868358 81 96 B-Condition
disorder NCT03868358 97 105 I-Condition
using NCT03868358 106 111 O
the NCT03868358 112 115 O
Structural NCT03868358 116 126 O
Clinical NCT03868358 127 135 O
Interview NCT03868358 136 145 O
for NCT03868358 146 149 O
Diagnostic NCT03868358 150 160 O
and NCT03868358 161 164 O
Statistical NCT03868358 165 176 O
Manual NCT03868358 177 183 O
Diploma NCT03868358 184 191 O
in NCT03868358 192 194 O
Social NCT03868358 195 201 O
Medicine NCT03868358 202 210 O
( NCT03868358 211 212 O
DSM NCT03868358 213 216 O
) NCT03868358 217 218 O
- NCT03868358 220 221 O
IV NCT03868358 222 224 O
( NCT03868358 225 226 O
SCID NCT03868358 227 231 O
, NCT03868358 232 233 O
Version NCT03868358 234 241 O
2.0 NCT03868358 242 245 O
) NCT03868358 246 247 O
. NCT03868358 249 250 O

- NCT03868358 254 255 O
Patients NCT03868358 257 265 O
remain NCT03868358 266 272 O
their NCT03868358 273 278 O
psychotropic NCT03868358 279 291 B-Drug
medication NCT03868358 292 302 I-Drug
at NCT03868358 303 305 O
steady NCT03868358 306 312 O
dosages NCT03868358 313 320 O
for NCT03868358 321 324 O
at NCT03868358 325 327 B-Eq-Comparison
least NCT03868358 328 333 I-Eq-Comparison
4 NCT03868358 334 335 I-Eq-Comparison
weeks NCT03868358 336 341 I-Eq-Comparison
prior NCT03868358 342 347 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868358 348 350 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03868358 351 356 B-Study
entry NCT03868358 357 362 O
and NCT03868358 363 366 B-And
for NCT03868358 367 370 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868358 371 374 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03868358 375 383 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03868358 384 386 O
the NCT03868358 387 390 O
trial NCT03868358 391 396 B-Study
. NCT03868358 397 398 O

- NCT03868358 402 403 O
Verbal NCT03868358 405 411 B-Observation
intelligence NCT03868358 412 424 I-Observation
quotient NCT03868358 425 433 I-Observation
> NCT03868358 434 435 B-Eq-Comparison
85 NCT03868358 436 438 I-Eq-Comparison
as NCT03868358 439 441 O
measured NCT03868358 442 450 O
by NCT03868358 451 453 O
using NCT03868358 454 459 O
a NCT03868358 460 461 O
Chinese NCT03868358 462 469 B-Modifier
version NCT03868358 470 477 I-Modifier
of NCT03868358 478 480 O
the NCT03868358 481 484 O
National NCT03868358 485 493 B-Observation
Adult NCT03868358 494 499 I-Observation
Reading NCT03868358 500 507 I-Observation
Test NCT03868358 508 512 I-Observation
. NCT03868358 513 514 O

Exclusion NCT03868358 516 525 O
Criteria NCT03868358 526 534 O
: NCT03868358 535 536 O

- NCT03868358 540 541 O
History NCT03868358 543 550 B-Eq-Comparison
of NCT03868358 551 553 O
significant NCT03868358 554 565 O
head NCT03868358 566 570 B-Modifier
trauma NCT03868358 571 577 B-Condition
or NCT03868358 578 580 B-Or
neurological NCT03868358 581 593 B-Condition
disorders NCT03868358 594 603 I-Condition

- NCT03868358 606 607 O
Alcohol NCT03868358 609 616 B-Modifier
or NCT03868358 617 619 B-Or
drug NCT03868358 620 624 B-Modifier
abuse NCT03868358 625 630 B-Condition
Focal NCT03868358 631 636 B-Condition
brain NCT03868358 637 642 I-Condition
lesions NCT03868358 643 650 I-Condition
on NCT03868358 651 653 O
T1 NCT03868358 654 656 B-Modifier
- NCT03868358 657 658 O
or NCT03868358 659 661 B-Or
T2 NCT03868358 662 664 B-Modifier
- NCT03868358 665 666 I-Modifier
weighted NCT03868358 667 675 I-Modifier
fluid NCT03868358 676 681 B-Modifier
- NCT03868358 682 683 I-Modifier
attenuated NCT03868358 684 694 I-Modifier
inversion NCT03868358 695 704 I-Modifier
- NCT03868358 705 706 I-Modifier
recovery NCT03868358 707 715 I-Modifier
magnetic NCT03868358 716 724 B-Procedure
resonance NCT03868358 725 734 I-Procedure
images NCT03868358 735 741 I-Procedure

- NCT03868358 744 745 O
a NCT03868358 747 748 O
prior NCT03868358 749 754 B-Eq-Comparison
history NCT03868358 755 762 I-Eq-Comparison
of NCT03868358 763 765 O
a NCT03868358 766 767 O
seizure NCT03868358 768 775 B-Condition
not NCT03868358 776 779 B-Negation
induced NCT03868358 780 787 O
by NCT03868358 788 790 O
drug NCT03868358 791 795 B-Condition
withdrawal NCT03868358 796 806 I-Condition
, NCT03868358 807 808 O
first NCT03868358 809 814 B-Modifier
degree NCT03868358 815 821 I-Modifier
relative NCT03868358 822 830 B-Family-Member
with NCT03868358 831 835 O
epilepsy NCT03868358 836 844 B-Condition
, NCT03868358 845 846 O
significant NCT03868358 847 858 O
neurological NCT03868358 859 871 B-Condition
illness NCT03868358 872 879 I-Condition
or NCT03868358 880 882 B-Or
head NCT03868358 883 887 B-Modifier
trauma NCT03868358 888 894 B-Condition
, NCT03868358 895 896 O
endocrine NCT03868358 897 906 B-Condition
disease NCT03868358 907 914 I-Condition
, NCT03868358 915 916 O
such NCT03868358 917 921 O
as NCT03868358 922 924 O
thyroid NCT03868358 925 932 B-Condition
disease NCT03868358 933 940 I-Condition
, NCT03868358 941 942 O
significant NCT03868358 943 954 O
unstable NCT03868358 955 963 O
medical NCT03868358 964 971 B-Condition
condition NCT03868358 972 981 I-Condition
, NCT03868358 982 983 O
recent NCT03868358 984 990 B-Eq-Comparison
aggression NCT03868358 991 1001 B-Condition
or NCT03868358 1002 1004 B-Or
other NCT03868358 1005 1010 B-Other
forms NCT03868358 1011 1016 O
of NCT03868358 1017 1019 O
behavioral NCT03868358 1020 1030 B-Condition
dyscontrol NCT03868358 1031 1041 I-Condition

- NCT03868358 1044 1045 O
left NCT03868358 1047 1051 B-Condition
- NCT03868358 1052 1053 I-Condition
handedness NCT03868358 1054 1064 I-Condition
, NCT03868358 1065 1066 O
pregnancy NCT03868358 1067 1076 B-Condition

- NCT03868358 1079 1080 O
estimated NCT03868358 1082 1091 B-Observation
intelligence NCT03868358 1092 1104 I-Observation
quotient NCT03868358 1105 1113 I-Observation
< NCT03868358 1114 1115 B-Eq-Comparison
80 NCT03868358 1116 1118 I-Eq-Comparison

- NCT03868358 1122 1123 O
current NCT03868358 1125 1132 B-Eq-Comparison
alcohol NCT03868358 1133 1140 B-Modifier
or NCT03868358 1141 1143 B-Or
drug NCT03868358 1144 1148 B-Modifier
abuse NCT03868358 1149 1154 B-Condition

- NCT03868358 1157 1158 O
inability NCT03868358 1160 1169 O
to NCT03868358 1170 1172 O
provide NCT03868358 1173 1180 O
informed NCT03868358 1181 1189 O
consent NCT03868358 1190 1197 O
. NCT03868358 1198 1199 O

- NCT03868358 1203 1204 O
Hamilton NCT03868358 1206 1214 B-Observation
Anxiety NCT03868358 1215 1222 I-Observation
Rating NCT03868358 1223 1229 I-Observation
Scale NCT03868358 1230 1235 I-Observation
or NCT03868358 1236 1238 B-Or
the NCT03868358 1239 1242 O
Hamilton NCT03868358 1243 1251 B-Observation
Depression NCT03868358 1252 1262 I-Observation
Rating NCT03868358 1263 1269 I-Observation
Scale NCT03868358 1270 1275 I-Observation
score NCT03868358 1276 1281 B-Eq-Comparison
> NCT03868358 1282 1283 I-Eq-Comparison
10 NCT03868358 1284 1286 I-Eq-Comparison

Inclusion NCT03861195 0 9 O
Criteria NCT03861195 10 18 O
: NCT03861195 19 20 O

- NCT03861195 24 25 O
age NCT03861195 27 30 B-Age
≥ NCT03861195 31 32 B-Eq-Comparison
18 NCT03861195 33 35 I-Eq-Comparison
years NCT03861195 36 41 I-Eq-Comparison

- NCT03861195 44 45 O
BMI NCT03861195 47 50 B-Observation
≤ NCT03861195 51 52 B-Eq-Comparison
40 NCT03861195 53 55 I-Eq-Comparison
kg NCT03861195 56 58 I-Eq-Comparison
/ NCT03861195 59 60 I-Eq-Comparison
m2 NCT03861195 61 63 I-Eq-Comparison

- NCT03861195 66 67 O
indication NCT03861195 69 79 B-Indication
for NCT03861195 80 83 O
hysterectomy NCT03861195 84 96 B-Procedure
for NCT03861195 97 100 O
benign NCT03861195 101 107 B-Condition
disease NCT03861195 108 115 I-Condition
or NCT03861195 116 118 B-Or
prophylactic NCT03861195 119 131 B-Procedure
surgery NCT03861195 132 139 I-Procedure
due NCT03861195 140 143 O
to NCT03861195 144 146 O
hereditary NCT03861195 147 157 B-Modifier
cancer NCT03861195 158 164 B-Condition

- NCT03861195 167 168 O
indication NCT03861195 170 180 B-Indication
for NCT03861195 181 184 O
radical NCT03861195 185 192 B-Procedure
hysterectomy NCT03861195 193 205 I-Procedure
and NCT03861195 206 209 B-Or
/ NCT03861195 210 211 I-Or
or NCT03861195 212 214 I-Or
pelvic NCT03861195 215 221 B-Modifier
- NCT03861195 222 223 O
/ NCT03861195 225 226 B-Or
para NCT03861195 227 231 B-Modifier
- NCT03861195 232 233 I-Modifier
aortic NCT03861195 234 240 I-Modifier
( NCT03861195 241 242 O
sentinel NCT03861195 243 251 B-Modifier
- NCT03861195 252 253 I-Modifier
node NCT03861195 254 258 I-Modifier
) NCT03861195 259 260 O
lymphadenectomy NCT03861195 261 276 B-Procedure
for NCT03861195 277 280 O
cervical NCT03861195 281 289 B-Modifier
cancer NCT03861195 290 296 B-Condition

- NCT03861195 299 300 O
indication NCT03861195 302 312 B-Indication
for NCT03861195 313 316 O
modified NCT03861195 317 325 B-Modifier
radical NCT03861195 326 333 I-Modifier
hysterectomy NCT03861195 334 346 B-Procedure
and NCT03861195 347 350 B-Or
/ NCT03861195 351 352 I-Or
or NCT03861195 353 355 I-Or
pelvic NCT03861195 356 362 B-Modifier
- NCT03861195 363 364 O
/ NCT03861195 366 367 B-Or
para NCT03861195 368 372 B-Modifier
- NCT03861195 373 374 I-Modifier
aortic NCT03861195 375 381 I-Modifier
( NCT03861195 382 383 O
sentinel NCT03861195 384 392 B-Modifier
- NCT03861195 393 394 I-Modifier
node NCT03861195 395 399 I-Modifier
) NCT03861195 400 401 O
lymphadenectomy NCT03861195 402 417 B-Procedure
for NCT03861195 418 421 O
endometrial NCT03861195 422 433 B-Modifier
cancer NCT03861195 434 440 B-Condition

- NCT03861195 443 444 O
size NCT03861195 446 450 B-Observation
of NCT03861195 451 453 O
uterus NCT03861195 454 460 B-Modifier
and NCT03861195 461 464 B-Or
vagina NCT03861195 465 471 B-Modifier
allows NCT03861195 472 478 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861195 479 482 I-Assertion___Assertion-Type-Value:hypothetical
retrieval NCT03861195 483 492 B-Procedure
by NCT03861195 493 495 O
the NCT03861195 496 499 O
vaginal NCT03861195 500 507 B-Modifier
route NCT03861195 508 513 I-Modifier
in NCT03861195 514 516 O
cancer NCT03861195 517 523 B-Condition
patients NCT03861195 524 532 O

- NCT03861195 535 536 O
written NCT03861195 538 545 O
informed NCT03861195 546 554 O
consent NCT03861195 555 562 O

Exclusion NCT03861195 563 572 O
Criteria NCT03861195 573 581 O
: NCT03861195 582 583 O

- NCT03861195 587 588 O
known NCT03861195 590 595 O
extensive NCT03861195 596 605 O
intra NCT03861195 606 611 B-Modifier
- NCT03861195 612 613 I-Modifier
abdominal NCT03861195 614 623 I-Modifier
adhesions NCT03861195 624 633 B-Condition

- NCT03861195 636 637 O
anaesthesiological NCT03861195 639 657 B-Modifier
contraindications NCT03861195 658 675 B-Contraindication
to NCT03861195 676 678 O
laparoscopy NCT03861195 679 690 B-Procedure

- NCT03861195 693 694 O
women NCT03861195 696 701 O
with NCT03861195 702 706 B-And
pacemaker NCT03861195 707 716 B-Procedure
or NCT03861195 717 719 B-Or
other NCT03861195 720 725 B-Other
implants NCT03861195 726 734 B-Procedure
where NCT03861195 735 740 B-And
electrosurgery NCT03861195 741 755 B-Procedure
is NCT03861195 756 758 O
to NCT03861195 759 761 B-Contraindication
be NCT03861195 762 764 I-Contraindication
avoided NCT03861195 765 772 I-Contraindication

- NCT03861195 775 776 O
women NCT03861195 778 783 O
with NCT03861195 784 788 B-And
known NCT03861195 789 794 O
defects NCT03861195 795 802 B-Condition
of NCT03861195 803 805 I-Condition
the NCT03861195 806 809 I-Condition
hemostasis NCT03861195 810 820 I-Condition

- NCT03861195 823 824 O
pregnancy NCT03861195 826 835 B-Condition

- NCT03861195 838 839 O
other NCT03861195 841 846 B-Other
internal NCT03861195 847 855 B-Modifier
or NCT03861195 856 858 B-Or
anatomical NCT03861195 859 869 B-Modifier
criteria NCT03861195 870 878 B-Condition
that NCT03861195 879 883 O
preclude NCT03861195 884 892 B-Assertion___Assertion-Type-Value:hypothetical|Negation
a NCT03861195 893 894 O
minimal NCT03861195 895 902 B-Procedure
invasive NCT03861195 903 911 I-Procedure
approach NCT03861195 912 920 I-Procedure

- NCT03861195 923 924 O
inability NCT03861195 926 935 O
to NCT03861195 936 938 O
understand NCT03861195 939 949 O
patient NCT03861195 950 957 O
information NCT03861195 958 969 O

Inclusion NCT03861156 0 9 O
Criteria NCT03861156 10 18 O
: NCT03861156 19 20 O

- NCT03861156 24 25 O
Aged NCT03861156 27 31 B-Age
at NCT03861156 32 34 B-Eq-Comparison
least NCT03861156 35 40 I-Eq-Comparison
18 NCT03861156 41 43 I-Eq-Comparison
years NCT03861156 44 49 I-Eq-Comparison
. NCT03861156 50 51 O

- NCT03861156 55 56 O
Histologically NCT03861156 58 72 B-Modifier
or NCT03861156 73 75 B-Or
cytologically NCT03861156 76 89 B-Procedure
proven NCT03861156 90 96 O
diagnosis NCT03861156 97 106 O
of NCT03861156 107 109 O
NSCLC NCT03861156 110 115 B-Condition
that NCT03861156 116 120 O
is NCT03861156 121 123 O
locally NCT03861156 124 131 B-Modifier
advanced NCT03861156 132 140 I-Modifier
or NCT03861156 141 143 B-Or
metastatic NCT03861156 144 154 B-Modifier
. NCT03861156 155 156 O

- NCT03861156 160 161 O
Radiological NCT03861156 163 175 B-Procedure
documentation NCT03861156 176 189 O
of NCT03861156 190 192 O
disease NCT03861156 193 200 B-Condition
progression NCT03861156 201 212 I-Condition
while NCT03861156 213 218 B-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03861156 219 221 O
a NCT03861156 222 223 O
previous NCT03861156 224 232 B-Eq-Comparison
continuous NCT03861156 233 243 B-Modifier
treatment NCT03861156 244 253 B-Procedure
with NCT03861156 254 258 O
an NCT03861156 259 261 O
first NCT03861156 262 267 B-Modifier
or NCT03861156 268 270 B-Or
second NCT03861156 271 277 B-Modifier
generation NCT03861156 278 288 I-Modifier
of NCT03861156 289 291 O
EGFR NCT03861156 292 296 B-Drug
TKI NCT03861156 297 300 I-Drug
e. NCT03861156 301 303 O
g. NCT03861156 304 306 O
gefitinib NCT03861156 308 317 B-Drug
or NCT03861156 318 320 B-Or
erlotinib NCT03861156 321 330 B-Drug
. NCT03861156 331 332 O

- NCT03861156 336 337 O
patients NCT03861156 339 347 O
must NCT03861156 348 352 O
also NCT03861156 353 357 O
have NCT03861156 358 362 O
confirmation NCT03861156 363 375 O
of NCT03861156 376 378 O
tumour NCT03861156 379 385 B-Condition
T790 NCT03861156 386 390 I-Condition
M NCT03861156 391 392 I-Condition
mutation NCT03861156 393 401 I-Condition
status NCT03861156 402 408 O
( NCT03861156 409 410 O
confirmed NCT03861156 411 420 O
positive NCT03861156 421 429 O
) NCT03861156 430 431 O
after NCT03861156 432 437 B-Temporal-Connection___Temporal-Connection-Type-Value:after
disease NCT03861156 438 445 B-Condition
progression NCT03861156 446 457 I-Condition
on NCT03861156 458 460 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 461 464 O
prior NCT03861156 465 470 B-Eq-Comparison
EGFR NCT03861156 471 475 B-Drug
TKI NCT03861156 476 479 I-Drug
. NCT03861156 480 481 O

- NCT03861156 485 486 O
Eastern NCT03861156 488 495 B-Observation
cooperative NCT03861156 496 507 I-Observation
oncology NCT03861156 508 516 I-Observation
group NCT03861156 517 522 I-Observation
performance NCT03861156 523 534 I-Observation
status NCT03861156 535 541 I-Observation
( NCT03861156 542 543 O
ECOG NCT03861156 544 548 B-Observation
PS NCT03861156 549 551 O
) NCT03861156 552 553 O
of NCT03861156 554 556 O
0 NCT03861156 557 558 B-Eq-Comparison
- NCT03861156 559 560 I-Eq-Comparison
1 NCT03861156 561 562 O
. NCT03861156 562 563 O

- NCT03861156 567 568 O
a NCT03861156 570 571 O
minimum NCT03861156 572 579 O
life NCT03861156 580 584 B-Observation
expectancy NCT03861156 585 595 I-Observation
of NCT03861156 596 598 O
12 NCT03861156 599 601 B-Eq-Comparison
weeks NCT03861156 602 607 I-Eq-Comparison
. NCT03861156 608 609 O

- NCT03861156 613 614 O
At NCT03861156 616 618 B-Eq-Comparison
least NCT03861156 619 624 I-Eq-Comparison
one NCT03861156 625 628 I-Eq-Comparison
lesion NCT03861156 629 635 B-Condition
, NCT03861156 636 637 O
not NCT03861156 638 641 B-Negation
previously NCT03861156 642 652 B-Eq-Comparison
irradiated NCT03861156 653 663 B-Procedure
during NCT03861156 664 670 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 671 674 O
study NCT03861156 675 680 B-Study
screening NCT03861156 681 690 O
period NCT03861156 691 697 O
, NCT03861156 698 699 O
that NCT03861156 700 704 B-And
can NCT03861156 705 708 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861156 709 711 I-Assertion___Assertion-Type-Value:hypothetical
accurately NCT03861156 712 722 O
measured NCT03861156 723 731 B-Observation
at NCT03861156 732 734 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03861156 735 743 B-Study
according NCT03861156 744 753 O
to NCT03861156 754 756 O
RECIST NCT03861156 757 763 O
1.1 NCT03861156 764 767 O
. NCT03861156 767 768 O

- NCT03861156 772 773 O
Agree NCT03861156 775 780 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861156 781 783 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03861156 784 787 O
routine NCT03861156 788 795 O
adequate NCT03861156 796 804 O
and NCT03861156 805 808 O
effective NCT03861156 809 818 O
contraceptive NCT03861156 819 832 B-Procedure
measures NCT03861156 833 841 O
during NCT03861156 842 848 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 849 852 O
entire NCT03861156 853 859 O
study NCT03861156 860 865 B-Study
period NCT03861156 866 872 O
and NCT03861156 873 876 B-And
within NCT03861156 877 883 B-Eq-Comparison
6 NCT03861156 884 885 I-Eq-Comparison
weeks NCT03861156 886 891 I-Eq-Comparison
after NCT03861156 892 897 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03861156 898 901 O
last NCT03861156 902 906 B-Eq-Comparison
dose NCT03861156 907 911 O
pre NCT03861156 912 915 B-Condition
- NCT03861156 916 917 I-Condition
menopausal NCT03861156 918 928 I-Condition
fertility NCT03861156 929 938 I-Condition
possible NCT03861156 939 947 O
; NCT03861156 947 948 O
Female NCT03861156 949 955 O
patients NCT03861156 956 964 O
need NCT03861156 965 969 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861156 970 972 I-Assertion___Assertion-Type-Value:hypothetical
exclude NCT03861156 973 980 B-Negation
pregnancy NCT03861156 981 990 B-Condition
( NCT03861156 991 992 O
ie NCT03861156 993 995 O
negative NCT03861156 996 1004 O
pregnancy NCT03861156 1005 1014 B-Observation
test NCT03861156 1015 1019 I-Observation
) NCT03861156 1020 1021 O
and NCT03861156 1022 1025 B-Or
in NCT03861156 1026 1028 O
non NCT03861156 1029 1032 B-Negation
- NCT03861156 1033 1034 O
lactation NCT03861156 1035 1044 B-Condition
period NCT03861156 1045 1051 O
. NCT03861156 1052 1053 O

Exclusion NCT03861156 1055 1064 O
Criteria NCT03861156 1065 1073 O
: NCT03861156 1074 1075 O

- NCT03861156 1079 1080 O
Treatment NCT03861156 1082 1091 B-Procedure
with NCT03861156 1092 1096 O
a NCT03861156 1097 1098 O
first NCT03861156 1099 1104 B-Modifier
or NCT03861156 1105 1107 B-Or
second NCT03861156 1108 1114 B-Modifier
generation NCT03861156 1115 1125 I-Modifier
of NCT03861156 1126 1128 O
EGFR NCT03861156 1129 1133 B-Drug
- NCT03861156 1134 1135 I-Drug
TKI NCT03861156 1136 1139 I-Drug
within NCT03861156 1140 1146 B-Eq-Comparison
7 NCT03861156 1147 1148 I-Eq-Comparison
days NCT03861156 1149 1153 I-Eq-Comparison
of NCT03861156 1154 1156 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03861156 1157 1162 B-Study
entry NCT03861156 1163 1168 O
; NCT03861156 1168 1169 O
previous NCT03861156 1170 1178 B-Eq-Comparison
treatment NCT03861156 1179 1188 B-Procedure
with NCT03861156 1189 1193 O
a NCT03861156 1194 1195 O
third NCT03861156 1196 1201 B-Modifier
generation NCT03861156 1202 1212 I-Modifier
of NCT03861156 1213 1215 O
EGFR NCT03861156 1216 1220 B-Drug
- NCT03861156 1221 1222 I-Drug
TKI NCT03861156 1223 1226 I-Drug
. NCT03861156 1227 1228 O

- NCT03861156 1232 1233 O
Unresolved NCT03861156 1235 1245 B-Eq-Comparison
toxicities NCT03861156 1246 1256 B-Condition
from NCT03861156 1257 1261 O
prior NCT03861156 1262 1267 B-Eq-Comparison
therapy NCT03861156 1268 1275 B-Procedure
. NCT03861156 1276 1277 O

- NCT03861156 1281 1282 O
Unstable NCT03861156 1284 1292 O
spinal NCT03861156 1293 1299 B-Condition
cord NCT03861156 1300 1304 I-Condition
compression NCT03861156 1305 1316 I-Condition
/ NCT03861156 1317 1318 B-Or
brain NCT03861156 1319 1324 B-Modifier
metastases NCT03861156 1325 1335 B-Condition
. NCT03861156 1336 1337 O

- NCT03861156 1341 1342 O
Severe NCT03861156 1344 1350 O
/ NCT03861156 1351 1352 B-Or
uncontrolled NCT03861156 1353 1365 B-Modifier
systemic NCT03861156 1366 1374 I-Modifier
diseases NCT03861156 1375 1383 B-Condition
, NCT03861156 1384 1385 O
including NCT03861156 1386 1395 O
uncontrolled NCT03861156 1396 1408 B-Modifier
hypertension NCT03861156 1409 1421 B-Condition
, NCT03861156 1422 1423 O
bleeding NCT03861156 1424 1432 B-Condition
diatheses NCT03861156 1433 1442 I-Condition
or NCT03861156 1443 1445 B-Or
infection NCT03861156 1446 1455 B-Condition
. NCT03861156 1456 1457 O

- NCT03861156 1461 1462 O
QTcF NCT03861156 1464 1468 B-Observation
> NCT03861156 1469 1470 B-Eq-Comparison
470 NCT03861156 1471 1474 I-Eq-Comparison
msec NCT03861156 1475 1479 I-Eq-Comparison
during NCT03861156 1480 1486 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861156 1487 1490 O
screening NCT03861156 1491 1500 B-Study
period NCT03861156 1501 1507 O
. NCT03861156 1508 1509 O

- NCT03861156 1513 1514 O
Severe NCT03861156 1516 1522 O
respiratory NCT03861156 1523 1534 B-Condition
diseases NCT03861156 1535 1543 I-Condition
such NCT03861156 1544 1548 O
as NCT03861156 1549 1551 O
interstitial NCT03861156 1552 1564 B-Condition
lung NCT03861156 1565 1569 I-Condition
disease NCT03861156 1570 1577 I-Condition
, NCT03861156 1578 1579 O
severe NCT03861156 1580 1586 O
asthma NCT03861156 1587 1593 B-Condition
, NCT03861156 1594 1595 O
pulmonary NCT03861156 1596 1605 B-Condition
embolism NCT03861156 1606 1614 I-Condition
, NCT03861156 1615 1616 O
etc NCT03861156 1617 1620 O
. NCT03861156 1621 1622 O

- NCT03861156 1626 1627 O
previous NCT03861156 1629 1637 B-Eq-Comparison
treatment NCT03861156 1638 1647 B-Procedure
with NCT03861156 1648 1652 O
2 NCT03861156 1653 1654 B-Eq-Comparison
or NCT03861156 1655 1657 I-Eq-Comparison
more NCT03861156 1658 1662 I-Eq-Comparison
lines NCT03861156 1663 1668 O
of NCT03861156 1669 1671 O
Chemotherapy NCT03861156 1672 1684 B-Procedure
or NCT03861156 1685 1687 B-Or
immunotherapy NCT03861156 1688 1701 B-Procedure
. NCT03861156 1701 1702 O

Inclusion NCT03861624 0 9 O
Criteria NCT03861624 10 18 O
: NCT03861624 19 20 O

1 NCT03861624 24 25 O
. NCT03861624 25 26 O
Skeletal NCT03861624 28 36 B-Condition
maturity NCT03861624 37 45 I-Condition

2 NCT03861624 48 49 O
. NCT03861624 49 50 O
AO NCT03861624 52 54 B-Eq-Comparison
/ NCT03861624 55 56 I-Eq-Comparison
OTA NCT03861624 57 60 I-Eq-Comparison
42 NCT03861624 61 63 I-Eq-Comparison
open NCT03861624 64 68 B-Modifier
tibia NCT03861624 69 74 I-Modifier
fractures NCT03861624 75 84 B-Condition

3 NCT03861624 87 88 O
. NCT03861624 88 89 O
Wound NCT03861624 91 96 B-Condition
primarily NCT03861624 97 106 B-Modifier
closeable NCT03861624 107 116 I-Modifier
( NCT03861624 117 118 O
no NCT03861624 119 121 B-Negation
flap NCT03861624 122 126 B-Modifier
or NCT03861624 127 129 B-Or
delay NCT03861624 130 135 B-Modifier
in NCT03861624 136 138 O
closure NCT03861624 139 146 B-Procedure
due NCT03861624 147 150 O
to NCT03861624 151 153 O
contamination NCT03861624 154 167 B-Condition
needed NCT03861624 168 174 O
) NCT03861624 175 176 O

4 NCT03861624 180 181 O
. NCT03861624 181 182 O
Palpable NCT03861624 184 192 B-Modifier
pedal NCT03861624 193 198 B-Observation
pulses NCT03861624 199 205 I-Observation
( NCT03861624 206 207 O
no NCT03861624 208 210 B-Negation
vascular NCT03861624 211 219 B-Condition
injury NCT03861624 220 226 I-Condition
sustained NCT03861624 227 236 O
) NCT03861624 237 238 O

5 NCT03861624 242 243 O
. NCT03861624 243 244 O
Presentation NCT03861624 246 258 O
within NCT03861624 259 265 B-Eq-Comparison
24 NCT03861624 266 268 I-Eq-Comparison
hours NCT03861624 269 274 I-Eq-Comparison
from NCT03861624 275 279 B-Temporal-Connection___Temporal-Connection-Type-Value:after
injury NCT03861624 280 286 B-Condition

Exclusion NCT03861624 287 296 O
Criteria NCT03861624 297 305 O
: NCT03861624 306 307 O

1 NCT03861624 311 312 O
. NCT03861624 312 313 O
Current NCT03861624 315 322 B-Eq-Comparison
injury NCT03861624 323 329 B-Condition
is NCT03861624 330 332 O
a NCT03861624 333 334 O
pathologic NCT03861624 335 345 B-Modifier
fracture NCT03861624 346 354 B-Condition

2 NCT03861624 357 358 O
. NCT03861624 358 359 O
Sustained NCT03861624 361 370 O
bilateral NCT03861624 371 380 B-Modifier
tibia NCT03861624 381 386 I-Modifier
fracture NCT03861624 387 395 B-Condition

3 NCT03861624 398 399 O
. NCT03861624 399 400 O
Sustained NCT03861624 402 411 O
comminuted NCT03861624 412 422 B-Modifier
femur NCT03861624 423 428 I-Modifier
fracture NCT03861624 429 437 B-Condition

4 NCT03861624 440 441 O
. NCT03861624 441 442 O
Sustained NCT03861624 444 453 O
severe NCT03861624 454 460 O
Traumatic NCT03861624 461 470 B-Condition
Brain NCT03861624 471 476 I-Condition
Injury NCT03861624 477 483 I-Condition
( NCT03861624 484 485 O
GCS NCT03861624 486 489 B-Observation
< NCT03861624 490 491 B-Eq-Comparison
12 NCT03861624 492 494 I-Eq-Comparison
) NCT03861624 495 496 O
* NCT03861624 497 498 O
* NCT03861624 498 499 O
* NCT03861624 499 500 O

5 NCT03861624 503 504 O
. NCT03861624 504 505 O
Sustained NCT03861624 507 516 O
severe NCT03861624 517 523 O
spinal NCT03861624 524 530 B-Modifier
cord NCT03861624 531 535 I-Modifier
injury NCT03861624 536 542 B-Condition
( NCT03861624 543 544 O
lower NCT03861624 545 550 B-Modifier
extremity NCT03861624 551 560 I-Modifier
paresis NCT03861624 561 568 B-Condition
/ NCT03861624 569 570 B-Or
paralysis NCT03861624 571 580 B-Condition
) NCT03861624 581 582 O

6 NCT03861624 586 587 O
. NCT03861624 587 588 O
Sustained NCT03861624 590 599 O
severe NCT03861624 600 606 O
burns NCT03861624 607 612 B-Condition
( NCT03861624 613 614 O
> NCT03861624 616 617 B-Eq-Comparison
10 NCT03861624 618 620 I-Eq-Comparison
% NCT03861624 621 622 I-Eq-Comparison
total NCT03861624 623 628 B-Observation
body NCT03861624 629 633 I-Observation
surface NCT03861624 634 641 I-Observation
area NCT03861624 642 646 I-Observation
( NCT03861624 647 648 O
TBSA NCT03861624 649 653 B-Observation
) NCT03861624 654 655 O
or NCT03861624 656 658 B-Or
> NCT03861624 659 660 B-Eq-Comparison
5 NCT03861624 661 662 I-Eq-Comparison
% NCT03861624 663 664 I-Eq-Comparison
TBSA NCT03861624 665 669 I-Eq-Comparison|Observation
with NCT03861624 670 674 B-And
full NCT03861624 675 679 B-Modifier
thickness NCT03861624 680 689 I-Modifier
or NCT03861624 690 692 B-Or
circumferential NCT03861624 693 708 B-Modifier
injury NCT03861624 709 715 B-Condition
) NCT03861624 716 717 O

7 NCT03861624 721 722 O
. NCT03861624 722 723 O
Prior NCT03861624 725 730 B-Eq-Comparison
ipsilateral NCT03861624 731 742 B-Modifier
leg NCT03861624 743 746 I-Modifier
injury NCT03861624 747 753 B-Condition
requiring NCT03861624 754 763 B-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03861624 764 771 B-Procedure

8 NCT03861624 774 775 O
. NCT03861624 775 776 O
Prior NCT03861624 778 783 B-Eq-Comparison
or NCT03861624 784 786 B-Or
current NCT03861624 787 794 B-Eq-Comparison
lower NCT03861624 795 800 B-Modifier
limb NCT03861624 801 805 I-Modifier
deformity NCT03861624 806 815 B-Condition
or NCT03861624 816 818 B-Or
abnormality NCT03861624 819 830 B-Condition

9 NCT03861624 833 834 O
. NCT03861624 834 835 O
Unable NCT03861624 837 843 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861624 844 846 O
complete NCT03861624 847 855 O
follow NCT03861624 856 862 B-Encounter
- NCT03861624 863 864 I-Encounter
up NCT03861624 865 867 I-Encounter
visits NCT03861624 868 874 I-Encounter

Inclusion NCT03863769 0 9 O
Criteria NCT03863769 10 18 O
: NCT03863769 19 20 O

- NCT03863769 24 25 O
Age NCT03863769 27 30 B-Age
greater NCT03863769 31 38 B-Eq-Comparison
than NCT03863769 39 43 I-Eq-Comparison
48 NCT03863769 44 46 I-Eq-Comparison
years NCT03863769 47 52 I-Eq-Comparison
old NCT03863769 53 56 O

- NCT03863769 59 60 O
Patient NCT03863769 62 69 O
has NCT03863769 70 73 O
leg NCT03863769 74 77 B-Modifier
or NCT03863769 78 80 B-Or
buttock NCT03863769 81 88 B-Modifier
pain NCT03863769 89 93 B-Condition
while NCT03863769 94 99 O
walking NCT03863769 100 107 B-Observation

- NCT03863769 110 111 O
Patient NCT03863769 113 120 O
feels NCT03863769 121 126 O
relief NCT03863769 127 133 O
of NCT03863769 134 136 O
symptoms NCT03863769 137 145 B-Coreference
with NCT03863769 146 150 O
bending NCT03863769 151 158 O
( NCT03863769 159 160 O
flexing NCT03863769 161 168 O
) NCT03863769 169 170 O
forward NCT03863769 171 178 O

- NCT03863769 181 182 O
Patient NCT03863769 184 191 O
feels NCT03863769 192 197 O
relief NCT03863769 198 204 O
when NCT03863769 205 209 O
using NCT03863769 210 215 O
a NCT03863769 216 217 O
shopping NCT03863769 218 226 O
cart NCT03863769 227 231 O
of NCT03863769 232 234 O
bicycle NCT03863769 235 242 O

- NCT03863769 245 246 O
Patient NCT03863769 248 255 O
has NCT03863769 256 259 O
motor NCT03863769 260 265 B-Modifier
or NCT03863769 266 268 B-Or
sensory NCT03863769 269 276 B-Modifier
disturbance NCT03863769 277 288 B-Condition
while NCT03863769 289 294 O
walking NCT03863769 295 302 B-Observation

- NCT03863769 305 306 O
Patient NCT03863769 308 315 O
has NCT03863769 316 319 O
normal NCT03863769 320 326 O
and NCT03863769 327 330 B-And
symmetrical NCT03863769 331 342 B-Modifier
foot NCT03863769 343 347 B-Observation
pulses NCT03863769 348 354 I-Observation

- NCT03863769 357 358 O
Patient NCT03863769 360 367 O
has NCT03863769 368 371 O
lower NCT03863769 372 377 B-Modifier
extremity NCT03863769 378 387 I-Modifier
weakness NCT03863769 388 396 B-Condition

- NCT03863769 399 400 O
Patient NCT03863769 402 409 O
has NCT03863769 410 413 O
low NCT03863769 414 417 B-Modifier
back NCT03863769 418 422 I-Modifier
pain NCT03863769 423 427 B-Condition

- NCT03863769 430 431 O
Duration NCT03863769 433 441 O
of NCT03863769 442 444 O
symptoms NCT03863769 445 453 B-Coreference
and NCT03863769 454 457 I-Coreference
signs NCT03863769 458 463 I-Coreference
for NCT03863769 464 467 O
more NCT03863769 468 472 B-Eq-Comparison
than NCT03863769 473 477 I-Eq-Comparison
1 NCT03863769 478 479 I-Eq-Comparison
month NCT03863769 480 485 I-Eq-Comparison

- NCT03863769 488 489 O
Able NCT03863769 491 495 B-Condition
to NCT03863769 496 498 I-Condition
stand NCT03863769 499 504 B-Modifier
and NCT03863769 505 508 B-And
walk NCT03863769 509 513 B-Modifier
without NCT03863769 514 521 B-Negation
assistive NCT03863769 522 531 B-Procedure
devices NCT03863769 532 539 I-Procedure
for NCT03863769 540 543 O
at NCT03863769 544 546 B-Eq-Comparison
least NCT03863769 547 552 I-Eq-Comparison
20 NCT03863769 553 555 I-Eq-Comparison
minutes NCT03863769 556 563 I-Eq-Comparison

- NCT03863769 566 567 O
Able NCT03863769 569 573 O
to NCT03863769 574 576 O
give NCT03863769 577 581 O
written NCT03863769 582 589 O
informed NCT03863769 590 598 O
consent NCT03863769 599 606 O
and NCT03863769 607 610 O
complete NCT03863769 611 619 O
interviews NCT03863769 620 630 O
and NCT03863769 631 634 O
questionnaires NCT03863769 635 649 O
in NCT03863769 650 652 O
English NCT03863769 653 660 O

Exclusion NCT03863769 661 670 O
Criteria NCT03863769 671 679 O
: NCT03863769 680 681 O

- NCT03863769 685 686 O
Complicated NCT03863769 688 699 O
spinal NCT03863769 700 706 B-Modifier
pain NCT03863769 707 711 B-Condition
due NCT03863769 712 715 O
to NCT03863769 716 718 O
fracture NCT03863769 719 727 B-Condition
, NCT03863769 728 729 O
tumor NCT03863769 730 735 B-Condition
, NCT03863769 736 737 O
infection NCT03863769 738 747 B-Condition
, NCT03863769 748 749 O
or NCT03863769 750 752 B-Or
severe NCT03863769 753 759 O
spondyloarthropathy NCT03863769 760 779 B-Condition

- NCT03863769 782 783 O
Has NCT03863769 785 788 O
other NCT03863769 789 794 B-Other
severe NCT03863769 795 801 O
co NCT03863769 802 804 B-Condition
- NCT03863769 805 806 I-Condition
morbidities NCT03863769 807 818 I-Condition
, NCT03863769 819 820 O
including NCT03863769 821 830 O
progressive NCT03863769 831 842 B-Modifier
neurological NCT03863769 843 855 B-Condition
deficit NCT03863769 856 863 I-Condition

- NCT03863769 866 867 O
Other NCT03863769 869 874 B-Other
serious NCT03863769 875 882 O
pathologies NCT03863769 883 894 B-Condition
of NCT03863769 895 897 O
the NCT03863769 898 901 O
locomotor NCT03863769 902 911 B-Modifier
system NCT03863769 912 918 I-Modifier

- NCT03863769 921 922 O
No NCT03863769 924 926 O
correspondence NCT03863769 927 941 O
availability NCT03863769 942 954 O
through NCT03863769 955 962 O
email NCT03863769 963 968 O

- NCT03863769 971 972 O
Inability NCT03863769 974 983 B-Negation
to NCT03863769 984 986 O
read NCT03863769 987 991 O
/ NCT03863769 992 993 O
comprehend NCT03863769 994 1004 O
English NCT03863769 1005 1012 O

- NCT03863769 1015 1016 O
Compensation NCT03863769 1018 1030 O
or NCT03863769 1031 1033 O
seeking NCT03863769 1034 1041 O
compensation NCT03863769 1042 1054 O
from NCT03863769 1055 1059 O
a NCT03863769 1060 1061 O
third NCT03863769 1062 1067 O
- NCT03863769 1068 1069 O
party NCT03863769 1070 1075 O
liability NCT03863769 1076 1085 O
or NCT03863769 1086 1088 O
workers NCT03863769 1089 1096 O
' NCT03863769 1096 1097 O
compensation NCT03863769 1098 1110 O

- NCT03863769 1113 1114 O
Previous NCT03863769 1116 1124 B-Eq-Comparison
spinal NCT03863769 1125 1131 B-Procedure
manipulation NCT03863769 1132 1144 I-Procedure
within NCT03863769 1145 1151 B-Eq-Comparison
the NCT03863769 1152 1155 I-Eq-Comparison
past NCT03863769 1156 1160 I-Eq-Comparison
month NCT03863769 1161 1166 I-Eq-Comparison

Inclusion NCT03866200 0 9 O
Criteria NCT03866200 10 18 O
: NCT03866200 19 20 O

- NCT03866200 24 25 O
The NCT03866200 27 30 O
diagnosis NCT03866200 31 40 O
of NCT03866200 41 43 O
pseudoachondroplasia NCT03866200 44 64 B-Condition
is NCT03866200 65 67 O
based NCT03866200 68 73 O
on NCT03866200 74 76 O
clinical NCT03866200 77 85 B-Procedure
assessment NCT03866200 86 96 I-Procedure
either NCT03866200 97 103 O
in NCT03866200 104 106 B-Modifier
person NCT03866200 107 113 I-Modifier
or NCT03866200 114 116 B-Or
by NCT03866200 117 119 O
photographic NCT03866200 120 132 B-Modifier
review NCT03866200 133 139 I-Modifier
by NCT03866200 140 142 O
skeletal NCT03866200 143 151 B-Provider
dysplasia NCT03866200 152 161 I-Provider
specialist NCT03866200 162 172 I-Provider
( NCT03866200 173 174 O
JTH NCT03866200 175 178 O
) NCT03866200 179 180 O
, NCT03866200 182 183 O

- NCT03866200 187 188 O
Healthy NCT03866200 190 197 B-Condition
beyond NCT03866200 198 204 B-Exception
pseudoachondroplasia NCT03866200 205 225 B-Condition
associated NCT03866200 226 236 O
complications NCT03866200 237 250 B-Condition
, NCT03866200 251 252 O

Exclusion NCT03866200 254 263 O
Criteria NCT03866200 264 272 O
: NCT03866200 273 274 O

- NCT03866200 278 279 O
Current NCT03866200 281 288 B-Eq-Comparison
use NCT03866200 289 292 O
of NCT03866200 293 295 O
resveratrol NCT03866200 296 307 B-Drug

- NCT03866200 310 311 O
Current NCT03866200 313 320 B-Eq-Comparison
use NCT03866200 321 324 O
of NCT03866200 325 327 O
blood NCT03866200 328 333 B-Drug
thinners NCT03866200 334 342 I-Drug
, NCT03866200 343 344 O
lovastatin NCT03866200 345 355 B-Drug
, NCT03866200 356 357 O
ketoconazole NCT03866200 358 370 B-Drug
, NCT03866200 371 372 O
itraconazole NCT03866200 373 385 B-Drug
, NCT03866200 386 387 O
fexofenadine NCT03866200 388 400 B-Drug
and NCT03866200 401 404 B-Or
triazolam NCT03866200 405 414 B-Drug
. NCT03866200 415 416 O

- NCT03866200 420 421 O
Other NCT03866200 423 428 B-Other
non NCT03866200 429 432 B-Negation
- NCT03866200 433 434 O
pseudoachondroplasia NCT03866200 435 455 B-Condition
related NCT03866200 456 463 O
health NCT03866200 464 470 B-Condition
conditions NCT03866200 471 481 I-Condition
, NCT03866200 482 483 O
e. NCT03866200 484 486 O
g. NCT03866200 487 489 O
cancers NCT03866200 491 498 B-Condition
. NCT03866200 499 500 O

- NCT03866200 504 505 O
Pregnancy NCT03866200 507 516 B-Condition
or NCT03866200 517 519 B-Or
breastfeeding NCT03866200 520 533 B-Condition
. NCT03866200 533 534 O
Women NCT03866200 536 541 O
must NCT03866200 542 546 O
use NCT03866200 547 550 O
adequate NCT03866200 551 559 O
contraception NCT03866200 560 573 B-Procedure
during NCT03866200 574 580 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866200 581 584 O
study NCT03866200 585 590 B-Study
. NCT03866200 591 592 O

- NCT03866200 596 597 O
Participation NCT03866200 599 612 O
in NCT03866200 613 615 O
another NCT03866200 616 623 B-Other
clinical NCT03866200 624 632 O
study NCT03866200 633 638 B-Study
and NCT03866200 639 642 B-Or
/ NCT03866200 643 644 I-Or
or NCT03866200 645 647 I-Or
using NCT03866200 648 653 B-Eq-Comparison
investigational NCT03866200 654 669 B-Drug
agents NCT03866200 670 676 I-Drug
. NCT03866200 677 678 O

- NCT03866200 682 683 O
Use NCT03866200 685 688 B-Eq-Comparison
of NCT03866200 689 691 O
Non NCT03866200 692 695 B-Drug
- NCT03866200 696 697 I-Drug
steroid NCT03866200 698 705 I-Drug
anti NCT03866200 706 710 I-Drug
- NCT03866200 711 712 I-Drug
inflammatory NCT03866200 713 725 I-Drug
( NCT03866200 726 727 O
NSAIDs NCT03866200 728 734 B-Drug
) NCT03866200 735 736 O
or NCT03866200 737 739 B-Or
aspirin NCT03866200 740 747 B-Drug
. NCT03866200 748 749 O

- NCT03866200 753 754 O
Current NCT03866200 756 763 B-Eq-Comparison
use NCT03866200 764 767 O
of NCT03866200 768 770 O
Alfentanil NCT03866200 771 781 B-Drug
, NCT03866200 782 783 O
Cyclosporine NCT03866200 784 796 B-Drug
, NCT03866200 797 798 O
Dihydroergotamine NCT03866200 799 816 B-Drug
, NCT03866200 817 818 O
Dofetilide NCT03866200 819 829 B-Drug
, NCT03866200 830 831 O
Ergotamine NCT03866200 832 842 B-Drug
, NCT03866200 843 844 O
Fentanyl NCT03866200 845 853 B-Drug
, NCT03866200 854 855 O
Flibanserin NCT03866200 856 867 B-Drug
, NCT03866200 868 869 O
Oxycodone NCT03866200 870 879 B-Drug
, NCT03866200 880 881 O
Pimavanserin NCT03866200 882 894 B-Drug
, NCT03866200 895 896 O
Pimozide NCT03866200 897 905 B-Drug
, NCT03866200 906 907 O
Quinidine NCT03866200 908 917 B-Drug
, NCT03866200 918 919 O
Saquinavir NCT03866200 920 930 B-Drug
, NCT03866200 931 932 O
Sirolimus NCT03866200 933 942 B-Drug
, NCT03866200 943 944 O
Tacrolimus NCT03866200 945 955 B-Drug
, NCT03866200 956 957 O
Temsirolimus NCT03866200 958 970 B-Drug
, NCT03866200 971 972 O
Theophylline NCT03866200 973 985 B-Drug
, NCT03866200 986 987 O
Tizanidine NCT03866200 988 998 B-Drug
, NCT03866200 999 1000 O
Thioridazine NCT03866200 1001 1013 B-Drug
, NCT03866200 1014 1015 O
Fosphenytoin NCT03866200 1016 1028 B-Drug
, NCT03866200 1029 1030 O
Phenytoin NCT03866200 1031 1040 B-Drug
or NCT03866200 1041 1043 B-Or
Warfarin NCT03866200 1044 1052 B-Drug
. NCT03866200 1053 1054 O

- NCT03866200 1058 1059 O
Baseline NCT03866200 1061 1069 O
level NCT03866200 1070 1075 O
of NCT03866200 1076 1078 O
pain NCT03866200 1079 1083 B-Condition|Observation
of NCT03866200 1084 1086 O
2 NCT03866200 1087 1088 B-Eq-Comparison
or NCT03866200 1089 1091 I-Eq-Comparison
higher NCT03866200 1092 1098 I-Eq-Comparison
on NCT03866200 1099 1101 O
10 NCT03866200 1102 1104 B-Modifier
point NCT03866200 1105 1110 I-Modifier
scale NCT03866200 1111 1116 I-Modifier
. NCT03866200 1117 1118 O

- NCT03866200 1122 1123 O
Platelet NCT03866200 1125 1133 B-Observation
count NCT03866200 1134 1139 I-Observation
below NCT03866200 1140 1145 B-Eq-Comparison
50 NCT03866200 1146 1148 I-Eq-Comparison
, NCT03866200 1149 1150 I-Eq-Comparison
000 NCT03866200 1151 1154 I-Eq-Comparison
per NCT03866200 1155 1158 I-Eq-Comparison
ul NCT03866200 1159 1161 I-Eq-Comparison
on NCT03866200 1162 1164 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03866200 1165 1173 B-Study
complete NCT03866200 1174 1182 B-Observation
blood NCT03866200 1183 1188 I-Observation
count NCT03866200 1189 1194 I-Observation
( NCT03866200 1195 1196 O
CBC NCT03866200 1197 1200 B-Observation
) NCT03866200 1201 1202 O
. NCT03866200 1203 1204 O

Inclusion NCT03862066 0 9 O
Criteria NCT03862066 10 18 O
: NCT03862066 19 20 O

- NCT03862066 24 25 O
Newly NCT03862066 27 32 B-Eq-Comparison
diagnosed NCT03862066 33 42 O
histologically NCT03862066 43 57 O
proven NCT03862066 58 64 O
locoregional NCT03862066 65 77 B-Modifier
oral NCT03862066 78 82 I-Modifier
squamous NCT03862066 83 91 I-Modifier
cell NCT03862066 92 96 I-Modifier
carcinoma NCT03862066 97 106 B-Condition
( NCT03862066 107 108 O
OSCC NCT03862066 109 113 B-Condition
) NCT03862066 114 115 O
without NCT03862066 116 123 B-Negation
evidence NCT03862066 124 132 O
of NCT03862066 133 135 O
distant NCT03862066 136 143 B-Modifier
metastases NCT03862066 144 154 B-Condition
. NCT03862066 154 155 O
OSCC NCT03862066 157 161 B-Condition
includes NCT03862066 162 170 O
the NCT03862066 171 174 O
subsites NCT03862066 175 183 B-Modifier
of NCT03862066 184 186 I-Modifier
oral NCT03862066 187 191 I-Modifier
tongue NCT03862066 192 198 I-Modifier
, NCT03862066 199 200 O
floor NCT03862066 201 206 B-Modifier
of NCT03862066 207 209 I-Modifier
mouth NCT03862066 210 215 I-Modifier
, NCT03862066 216 217 O
gingiva NCT03862066 218 225 B-Modifier
, NCT03862066 226 227 O
retromolar NCT03862066 228 238 B-Modifier
trigone NCT03862066 239 246 I-Modifier
and NCT03862066 247 250 B-Or
buccal NCT03862066 251 257 B-Modifier
mucosa NCT03862066 258 264 I-Modifier
OR NCT03862066 265 267 B-Or
Recurrent NCT03862066 268 277 B-Modifier
or NCT03862066 278 280 B-Or
persistent NCT03862066 281 291 B-Modifier
histologically NCT03862066 292 306 O
proven NCT03862066 307 313 O
locoregional NCT03862066 314 326 B-Modifier
OSCC NCT03862066 327 331 B-Condition
that NCT03862066 332 336 O
was NCT03862066 337 340 O
initially NCT03862066 341 350 B-Eq-Comparison
treated NCT03862066 351 358 B-Procedure
with NCT03862066 359 363 O
surgery NCT03862066 364 371 B-Procedure
alone NCT03862066 372 377 O
. NCT03862066 378 379 O

- NCT03862066 383 384 O
must NCT03862066 386 390 O
be NCT03862066 391 393 O
eligible NCT03862066 394 402 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03862066 403 406 I-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03862066 407 415 B-Procedure
resection NCT03862066 416 425 I-Procedure

- NCT03862066 428 429 O
greater NCT03862066 431 438 B-Eq-Comparison
than NCT03862066 439 443 I-Eq-Comparison
18 NCT03862066 444 446 I-Eq-Comparison
years NCT03862066 447 452 I-Eq-Comparison
of NCT03862066 453 455 O
age NCT03862066 456 459 B-Age

Exclusion NCT03862066 460 469 O
Criteria NCT03862066 470 478 O
: NCT03862066 479 480 O

- NCT03862066 484 485 O
prior NCT03862066 487 492 B-Eq-Comparison
immunotherapy NCT03862066 493 506 B-Procedure
or NCT03862066 507 509 B-Or
treatment NCT03862066 510 519 B-Procedure
with NCT03862066 520 524 O
another NCT03862066 525 532 B-Other
anti NCT03862066 533 537 B-Drug
PD NCT03862066 538 540 I-Drug
- NCT03862066 541 542 I-Drug
1 NCT03862066 543 544 I-Drug
agent NCT03862066 545 550 I-Drug
besides NCT03862066 551 558 B-Exception
nivolumab NCT03862066 559 568 B-Drug

- NCT03862066 571 572 O
prior NCT03862066 574 579 B-Eq-Comparison
chemotherapy NCT03862066 580 592 B-Procedure
including NCT03862066 593 602 O
cetuximab NCT03862066 603 612 B-Drug
or NCT03862066 613 615 B-Or
radiation NCT03862066 616 625 B-Procedure
therapy NCT03862066 626 633 I-Procedure

- NCT03862066 636 637 O
concomitant NCT03862066 639 650 B-Modifier
malignancies NCT03862066 651 663 B-Condition
except NCT03862066 664 670 B-Exception
cutaneous NCT03862066 671 680 B-Modifier
squamous NCT03862066 681 689 I-Modifier
cell NCT03862066 690 694 I-Modifier
carcinoma NCT03862066 695 704 B-Condition
or NCT03862066 705 707 B-Or
basal NCT03862066 708 713 B-Modifier
cell NCT03862066 714 718 I-Modifier
carcinoma NCT03862066 719 728 B-Condition

- NCT03862066 731 732 O
unresectable NCT03862066 734 746 B-Modifier
primary NCT03862066 747 754 I-Modifier
tumor NCT03862066 755 760 B-Condition
or NCT03862066 761 763 B-Or
regional NCT03862066 764 772 B-Condition
disease NCT03862066 773 780 I-Condition
or NCT03862066 781 783 B-Or
distant NCT03862066 784 791 B-Modifier
metastases NCT03862066 792 802 B-Condition


Inclusion NCT03860103 0 9 O
Criteria NCT03860103 10 18 O
: NCT03860103 19 20 O

- NCT03860103 24 25 O
Patient NCT03860103 27 34 O
who NCT03860103 35 38 O
accepted NCT03860103 39 47 O
to NCT03860103 48 50 O
participate NCT03860103 51 62 O
in NCT03860103 63 65 O
the NCT03860103 66 69 O
study NCT03860103 70 75 O

- NCT03860103 78 79 O
Woman NCT03860103 81 86 O
over NCT03860103 87 91 B-Eq-Comparison
18 NCT03860103 92 94 I-Eq-Comparison
years NCT03860103 95 100 I-Eq-Comparison
old NCT03860103 101 104 B-Age

- NCT03860103 107 108 O
Affiliated NCT03860103 110 120 O
to NCT03860103 121 123 O
a NCT03860103 124 125 O
social NCT03860103 126 132 O
security NCT03860103 133 141 O
scheme NCT03860103 142 148 O

- NCT03860103 151 152 O
Mono NCT03860103 154 158 B-Modifier
- NCT03860103 159 160 I-Modifier
fetal NCT03860103 161 166 I-Modifier
pregnancy NCT03860103 167 176 B-Condition

- NCT03860103 179 180 O
Patients NCT03860103 182 190 O
with NCT03860103 191 195 O
normal NCT03860103 196 202 O
pregnancy NCT03860103 203 212 B-Condition
between NCT03860103 213 220 B-Eq-Comparison
11 NCT03860103 221 223 I-Eq-Comparison
and NCT03860103 224 227 I-Eq-Comparison
42 NCT03860103 228 230 I-Eq-Comparison
weeks NCT03860103 231 236 I-Eq-Comparison
of NCT03860103 237 239 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03860103 240 250 B-Condition

- NCT03860103 253 254 O
Patients NCT03860103 256 264 O
hospitalized NCT03860103 265 277 B-Encounter
for NCT03860103 278 281 O
preeclampsia NCT03860103 282 294 B-Condition
and NCT03860103 295 298 B-Or
/ NCT03860103 299 300 I-Or
or NCT03860103 301 303 I-Or
intrauterine NCT03860103 304 316 B-Condition
growth NCT03860103 317 323 I-Condition
retardation NCT03860103 324 335 I-Condition
, NCT03860103 336 337 O
beyond NCT03860103 338 344 B-Eq-Comparison
20 NCT03860103 345 347 I-Eq-Comparison
weeks NCT03860103 348 353 I-Eq-Comparison
of NCT03860103 354 356 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03860103 357 367 B-Condition

Exclusion NCT03860103 368 377 O
Criteria NCT03860103 378 386 O
: NCT03860103 387 388 O

- NCT03860103 392 393 O
Minors NCT03860103 395 401 O
, NCT03860103 402 403 O
adults NCT03860103 404 410 O
under NCT03860103 411 416 B-Observation
guardianship NCT03860103 417 429 I-Observation
, NCT03860103 430 431 O
protected NCT03860103 432 441 B-Observation
persons NCT03860103 442 449 I-Observation

- NCT03860103 452 453 O
Not NCT03860103 455 458 O
affiliated NCT03860103 459 469 O
to NCT03860103 470 472 O
a NCT03860103 473 474 O
social NCT03860103 475 481 O
security NCT03860103 482 490 O
scheme NCT03860103 491 497 O

- NCT03860103 500 501 O
Multiple NCT03860103 503 511 B-Eq-Comparison
pregnancy NCT03860103 512 521 B-Condition

Inclusion NCT03861221 0 9 O
Criteria NCT03861221 10 18 O
: NCT03861221 19 20 O

- NCT03861221 24 25 O
Female NCT03861221 27 33 O
, NCT03861221 34 35 O
older NCT03861221 36 41 I-Eq-Comparison
than NCT03861221 42 46 I-Eq-Comparison
35 NCT03861221 47 49 I-Eq-Comparison
years NCT03861221 50 55 I-Eq-Comparison
. NCT03861221 55 56 O
Already NCT03861221 58 65 B-Eq-Comparison
have NCT03861221 66 70 O
mammography NCT03861221 71 82 B-Procedure
, NCT03861221 83 84 O
or NCT03861221 85 87 B-Or
other NCT03861221 88 93 B-Other
standard NCT03861221 94 102 B-Procedure
exams NCT03861221 103 108 I-Procedure
( NCT03861221 109 110 O
ultrasound NCT03861221 111 121 B-Procedure
, NCT03861221 122 123 O
MRI NCT03861221 124 127 B-Procedure
, NCT03861221 128 129 O
etc NCT03861221 130 133 O
) NCT03861221 134 135 O
. NCT03861221 136 137 O
Could NCT03861221 139 144 B-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861221 145 156 O
this NCT03861221 157 161 O
trial NCT03861221 162 167 B-Study
within NCT03861221 168 174 B-Eq-Comparison
2 NCT03861221 175 176 I-Eq-Comparison
weeks NCT03861221 177 182 I-Eq-Comparison
after NCT03861221 183 188 B-Temporal-Connection___Temporal-Connection-Type-Value:after
mammography NCT03861221 189 200 B-Procedure
. NCT03861221 200 201 O
Have NCT03861221 203 207 O
the NCT03861221 208 211 O
ability NCT03861221 212 219 O
of NCT03861221 220 222 O
consent NCT03861221 223 230 O
inform NCT03861221 231 237 O
. NCT03861221 238 239 O

Exclusion NCT03861221 241 250 O
Criteria NCT03861221 251 259 O
: NCT03861221 260 261 O

- NCT03861221 265 266 O
During NCT03861221 268 274 O
pregnancy NCT03861221 275 284 B-Condition
or NCT03861221 285 287 B-Or
lactation NCT03861221 288 297 B-Condition
period NCT03861221 298 304 O
. NCT03861221 304 305 O
Patients NCT03861221 307 315 O
that NCT03861221 316 320 O
may NCT03861221 321 324 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03861221 325 328 B-Negation
be NCT03861221 329 331 O
capable NCT03861221 332 339 B-Observation
of NCT03861221 340 342 I-Observation
prone NCT03861221 343 348 I-Observation
position NCT03861221 349 357 I-Observation
, NCT03861221 358 359 O
such NCT03861221 360 364 O
as NCT03861221 365 367 O
patients NCT03861221 368 376 O
with NCT03861221 377 381 O
scapulohumeral NCT03861221 382 396 B-Condition
periarthritis NCT03861221 397 410 I-Condition
, NCT03861221 411 412 O
cardiac NCT03861221 413 420 B-Procedure
pacemaker NCT03861221 421 430 I-Procedure
or NCT03861221 431 433 B-Or
have NCT03861221 434 438 O
recent NCT03861221 439 445 B-Eq-Comparison
cardiac NCT03861221 446 453 B-Procedure
surgery NCT03861221 454 461 I-Procedure
. NCT03861221 462 463 O

Lymphoma NCT03861221 465 473 B-Condition
patients NCT03861221 474 482 O
that NCT03861221 483 487 O
under NCT03861221 488 493 B-Eq-Comparison
therapy NCT03861221 494 501 B-Procedure
. NCT03861221 501 502 O
Severe NCT03861221 504 510 O
scoliosis NCT03861221 511 520 B-Condition
. NCT03861221 520 521 O

Inclusion NCT03867877 0 9 O
Criteria NCT03867877 10 18 O
: NCT03867877 19 20 O

- NCT03867877 24 25 O
Hoehn NCT03867877 27 32 B-Condition
& NCT03867877 33 34 I-Condition
Yahr NCT03867877 35 39 I-Condition
Classification NCT03867877 40 54 I-Condition
of NCT03867877 55 57 I-Condition
Disability NCT03867877 58 68 I-Condition
, NCT03867877 69 70 O
stage NCT03867877 71 76 B-Eq-Comparison
1 NCT03867877 77 78 I-Eq-Comparison
- NCT03867877 79 80 I-Eq-Comparison
3 NCT03867877 81 82 O

- NCT03867877 86 87 O
can NCT03867877 89 92 B-Condition|Observation
ambulate NCT03867877 93 101 I-Condition|Observation
with NCT03867877 102 106 B-And
or NCT03867877 107 109 B-Or
without NCT03867877 110 117 B-Negation
an NCT03867877 118 120 O
assistive NCT03867877 121 130 B-Procedure
device NCT03867877 131 137 I-Procedure
for NCT03867877 138 141 O
at NCT03867877 142 144 B-Eq-Comparison
least NCT03867877 145 150 I-Eq-Comparison
50 NCT03867877 151 153 I-Eq-Comparison
feet NCT03867877 154 158 I-Eq-Comparison

- NCT03867877 161 162 O
able NCT03867877 164 168 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867877 169 171 I-Assertion___Assertion-Type-Value:hypothetical
get NCT03867877 172 175 B-Observation
up NCT03867877 176 178 I-Observation
and NCT03867877 179 182 I-Observation
down NCT03867877 183 187 I-Observation
from NCT03867877 188 192 I-Observation
the NCT03867877 193 196 I-Observation
floor NCT03867877 197 202 I-Observation
with NCT03867877 203 207 O
minimal NCT03867877 208 215 B-Modifier
assistance NCT03867877 216 226 I-Modifier

- NCT03867877 229 230 O
has NCT03867877 232 235 O
a NCT03867877 236 237 O
score NCT03867877 238 243 O
of NCT03867877 244 246 O
24 NCT03867877 247 249 B-Eq-Comparison
or NCT03867877 250 252 I-Eq-Comparison
above NCT03867877 253 258 I-Eq-Comparison
on NCT03867877 259 261 O
the NCT03867877 262 265 O
Folstein NCT03867877 266 274 B-Observation
Mini NCT03867877 275 279 I-Observation
- NCT03867877 280 281 I-Observation
Mental NCT03867877 282 288 I-Observation
State NCT03867877 289 294 I-Observation
Exam NCT03867877 295 299 I-Observation

Exclusion NCT03867877 300 309 O
Criteria NCT03867877 310 318 O
: NCT03867877 319 320 O

- NCT03867877 324 325 O
Greater NCT03867877 327 334 B-Eq-Comparison
than NCT03867877 335 339 I-Eq-Comparison
Stage NCT03867877 340 345 I-Eq-Comparison
3 NCT03867877 346 347 I-Eq-Comparison
on NCT03867877 348 350 O
the NCT03867877 351 354 O
Hoehn NCT03867877 355 360 B-Condition
& NCT03867877 361 362 I-Condition
Yahr NCT03867877 363 367 I-Condition
Classification NCT03867877 368 382 I-Condition
of NCT03867877 383 385 I-Condition
Disability NCT03867877 386 396 I-Condition

- NCT03867877 399 400 O
decline NCT03867877 402 409 O
in NCT03867877 410 412 O
immune NCT03867877 413 419 B-Condition
function NCT03867877 420 428 I-Condition
such NCT03867877 429 433 O
as NCT03867877 434 436 O
pneumonia NCT03867877 437 446 B-Condition
or NCT03867877 447 449 B-Or
systemic NCT03867877 450 458 B-Modifier
infection NCT03867877 459 468 B-Condition

- NCT03867877 471 472 O
progressive NCT03867877 474 485 B-Condition
degenerative NCT03867877 486 498 I-Condition
disease NCT03867877 499 506 I-Condition
besides NCT03867877 507 514 B-Exception
PD NCT03867877 515 517 B-Condition

- NCT03867877 520 521 O
spinal NCT03867877 523 529 B-Procedure
fusion NCT03867877 530 536 I-Procedure
or NCT03867877 537 539 B-Or
other NCT03867877 540 545 B-Other
orthopedic NCT03867877 546 556 B-Procedure
surgery NCT03867877 557 564 I-Procedure
in NCT03867877 565 567 O
the NCT03867877 568 571 O
past NCT03867877 572 576 B-Eq-Comparison
six NCT03867877 577 580 I-Eq-Comparison
months NCT03867877 581 587 I-Eq-Comparison

- NCT03867877 590 591 O
mental NCT03867877 593 599 B-Condition
disease NCT03867877 600 607 I-Condition
/ NCT03867877 608 609 B-Or
psychosis NCT03867877 610 619 B-Condition
such NCT03867877 620 624 O
as NCT03867877 625 627 O
dementia NCT03867877 628 636 B-Condition

- NCT03867877 639 640 O
greater NCT03867877 642 649 B-Eq-Comparison
than NCT03867877 650 654 I-Eq-Comparison
minimal NCT03867877 655 662 B-Observation
assistance NCT03867877 663 673 I-Observation
required NCT03867877 674 682 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867877 683 686 O
gait NCT03867877 687 691 B-Modifier
and NCT03867877 692 695 B-And
transfers NCT03867877 696 705 B-Modifier

- NCT03867877 708 709 O
inability NCT03867877 711 720 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03867877 721 723 O
make NCT03867877 724 728 O
regular NCT03867877 729 736 O
time NCT03867877 737 741 O
commitments NCT03867877 742 753 O
to NCT03867877 754 756 O
the NCT03867877 757 760 O
scheduled NCT03867877 761 770 B-Eq-Comparison
training NCT03867877 771 779 B-Procedure
sessions NCT03867877 780 788 I-Procedure

- NCT03867877 791 792 O
participation NCT03867877 794 807 O
in NCT03867877 808 810 O
resistance NCT03867877 811 821 B-Observation
training NCT03867877 822 830 I-Observation
on NCT03867877 831 833 O
a NCT03867877 834 835 O
regular NCT03867877 836 843 O
basis NCT03867877 844 849 O
within NCT03867877 850 856 B-Eq-Comparison
the NCT03867877 857 860 I-Eq-Comparison
past NCT03867877 861 865 I-Eq-Comparison
six NCT03867877 866 869 I-Eq-Comparison
months NCT03867877 870 876 I-Eq-Comparison

- NCT03867877 879 880 O
inability NCT03867877 882 891 O
to NCT03867877 892 894 O
provide NCT03867877 895 902 O
consent NCT03867877 903 910 O

- NCT03867877 913 914 O
pregnancy NCT03867877 916 925 B-Condition

- NCT03867877 928 929 O
a NCT03867877 931 932 O
prisoner NCT03867877 933 941 B-Observation

Inclusion NCT03860467 0 9 O
Criteria NCT03860467 10 18 O
: NCT03860467 19 20 O

- NCT03860467 24 25 O
admitted NCT03860467 27 35 B-Encounter
to NCT03860467 36 38 O
the NCT03860467 39 42 O
ICU NCT03860467 43 46 O
at NCT03860467 47 49 O
the NCT03860467 50 53 O
University NCT03860467 54 64 O
Hospital NCT03860467 65 73 O
Basel NCT03860467 74 79 O

- NCT03860467 82 83 O
suffered NCT03860467 85 93 O
from NCT03860467 94 98 O
one NCT03860467 99 102 B-Eq-Comparison
or NCT03860467 103 105 I-Eq-Comparison
more NCT03860467 106 110 I-Eq-Comparison
epileptic NCT03860467 111 120 B-Condition
seizures NCT03860467 121 129 I-Condition
( NCT03860467 130 131 O
detected NCT03860467 132 140 O
clinically NCT03860467 141 151 B-Modifier
and NCT03860467 152 155 B-Or
/ NCT03860467 156 157 I-Or
or NCT03860467 158 160 I-Or
by NCT03860467 161 163 O
EEG NCT03860467 164 167 B-Procedure
) NCT03860467 168 169 O
during NCT03860467 170 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03860467 177 182 O
ICU NCT03860467 183 186 O
- NCT03860467 187 188 O
stay NCT03860467 189 193 B-Encounter

Exclusion NCT03860467 194 203 O
Criteria NCT03860467 204 212 O
: NCT03860467 213 214 O

- NCT03860467 218 219 O
patients NCT03860467 221 229 O
with NCT03860467 230 234 O
epileptic NCT03860467 235 244 B-Condition
seizures NCT03860467 245 253 I-Condition
transforming NCT03860467 254 266 O
into NCT03860467 267 271 O
Status NCT03860467 272 278 B-Condition
epilepticus NCT03860467 279 290 I-Condition
( NCT03860467 291 292 O
SE NCT03860467 293 295 B-Condition
) NCT03860467 296 297 O

Inclusion NCT03865251 0 9 O
Criteria NCT03865251 10 18 O
: NCT03865251 19 20 O

- NCT03865251 24 25 O
Undertake NCT03865251 27 36 B-Eq-Comparison
regular NCT03865251 37 44 B-Modifier
exercise NCT03865251 45 53 B-Observation
at NCT03865251 54 56 B-Eq-Comparison
least NCT03865251 57 62 I-Eq-Comparison
3 NCT03865251 63 64 I-Eq-Comparison
times NCT03865251 65 70 I-Eq-Comparison
a NCT03865251 71 72 I-Eq-Comparison
week NCT03865251 73 77 I-Eq-Comparison
with NCT03865251 78 82 O
accumulation NCT03865251 83 95 O
of NCT03865251 96 98 O
150 NCT03865251 99 102 B-Eq-Comparison
min NCT03865251 103 106 I-Eq-Comparison
per NCT03865251 107 110 I-Eq-Comparison
week NCT03865251 111 115 I-Eq-Comparison

- NCT03865251 118 119 O
Age NCT03865251 121 124 B-Age
between NCT03865251 125 132 B-Eq-Comparison
20 NCT03865251 133 135 I-Eq-Comparison
and NCT03865251 136 139 I-Eq-Comparison
30 NCT03865251 140 142 I-Eq-Comparison
years NCT03865251 143 148 I-Eq-Comparison
old NCT03865251 149 152 O

Exclusion NCT03865251 153 162 O
Criteria NCT03865251 163 171 O
: NCT03865251 172 173 O

- NCT03865251 177 178 O
History NCT03865251 180 187 B-Eq-Comparison
of NCT03865251 188 190 O
severe NCT03865251 191 197 O
neuromuscular NCT03865251 198 211 B-Modifier
injury NCT03865251 212 218 B-Condition

- NCT03865251 221 222 O
Current NCT03865251 224 231 B-Eq-Comparison
lower NCT03865251 232 237 B-Modifier
extremity NCT03865251 238 247 I-Modifier
injury NCT03865251 248 254 B-Condition

- NCT03865251 257 258 O
Current NCT03865251 260 267 B-Eq-Comparison
neurological NCT03865251 268 280 B-Condition
diseases NCT03865251 281 289 I-Condition

Inclusion NCT03865537 0 9 O
Criteria NCT03865537 10 18 O
: NCT03865537 19 20 O

- NCT03865537 24 25 O
Any NCT03865537 27 30 O
patient NCT03865537 31 38 O
≥ NCT03865537 39 40 B-Eq-Comparison
18 NCT03865537 41 43 I-Age|Eq-Comparison
who NCT03865537 44 47 B-And
presents NCT03865537 48 56 B-Eq-Comparison
for NCT03865537 57 60 I-Eq-Comparison
a NCT03865537 61 62 O
colonoscopy NCT03865537 63 74 B-Procedure
and NCT03865537 75 78 B-And
who NCT03865537 79 82 O
does NCT03865537 83 87 O
not NCT03865537 88 91 B-Negation
have NCT03865537 92 96 O
criteria NCT03865537 97 105 B-Condition
for NCT03865537 106 109 O
exclusion NCT03865537 110 119 B-Negation

- NCT03865537 122 123 O
Patients NCT03865537 125 133 O
with NCT03865537 134 138 O
a NCT03865537 139 140 O
≥ NCT03865537 141 142 B-Eq-Comparison
20 NCT03865537 143 145 I-Eq-Comparison
mm NCT03865537 146 148 I-Eq-Comparison
non NCT03865537 149 152 B-Negation
- NCT03865537 153 154 O
pedunculated NCT03865537 155 167 B-Modifier
colorectal NCT03865537 168 178 B-Modifier
polyp NCT03865537 179 184 B-Condition|Observation

Exclusion NCT03865537 185 194 O
Criteria NCT03865537 195 203 O
: NCT03865537 204 205 O

- NCT03865537 209 210 O
Pedunculated NCT03865537 212 224 B-Modifier
polyps NCT03865537 225 231 B-Condition
( NCT03865537 232 233 O
as NCT03865537 234 236 O
defined NCT03865537 237 244 O
by NCT03865537 245 247 O
Paris NCT03865537 248 253 O
Classification NCT03865537 254 268 O
type NCT03865537 269 273 O
Ip NCT03865537 274 276 O
) NCT03865537 277 278 O

- NCT03865537 282 283 O
Suspected NCT03865537 285 294 B-Assertion___Assertion-Type-Value:possible
adenocarcinoma NCT03865537 295 309 B-Condition
with NCT03865537 310 314 O
deep NCT03865537 315 319 B-Modifier
submucosal NCT03865537 320 330 I-Modifier
invasion NCT03865537 331 339 I-Modifier

- NCT03865537 342 343 O
Patients NCT03865537 345 353 O
with NCT03865537 354 358 O
ulcerated NCT03865537 359 368 B-Modifier
depressed NCT03865537 369 378 I-Modifier
lesions NCT03865537 379 386 B-Condition
( NCT03865537 387 388 O
as NCT03865537 389 391 O
defined NCT03865537 392 399 O
by NCT03865537 400 402 O
Paris NCT03865537 403 408 O
Classification NCT03865537 409 423 O
type NCT03865537 424 428 O
III NCT03865537 429 432 O
) NCT03865537 433 434 O
or NCT03865537 435 437 B-Or
confirmed NCT03865537 438 447 O
adenocarcinoma NCT03865537 448 462 B-Condition

- NCT03865537 465 466 O
Patients NCT03865537 468 476 O
with NCT03865537 477 481 O
inflammatory NCT03865537 482 494 B-Condition
bowel NCT03865537 495 500 I-Condition
disease NCT03865537 501 508 I-Condition

- NCT03865537 511 512 O
Patients NCT03865537 514 522 O
who NCT03865537 523 526 O
are NCT03865537 527 530 O
receiving NCT03865537 531 540 B-Eq-Comparison
an NCT03865537 541 543 O
emergency NCT03865537 544 553 B-Modifier
colonoscopy NCT03865537 554 565 B-Procedure

- NCT03865537 568 569 O
Poor NCT03865537 571 575 B-Condition
general NCT03865537 576 583 I-Condition
health NCT03865537 584 590 I-Condition
( NCT03865537 591 592 O
ASA NCT03865537 593 596 B-Condition
class NCT03865537 597 602 O
> NCT03865537 603 604 B-Eq-Comparison
3 NCT03865537 605 606 I-Eq-Comparison
) NCT03865537 607 608 O

- NCT03865537 612 613 O
Patients NCT03865537 615 623 O
with NCT03865537 624 628 O
coagulopathy NCT03865537 629 641 B-Condition
with NCT03865537 642 646 B-And
an NCT03865537 647 649 O
elevated NCT03865537 650 658 O
INR NCT03865537 659 662 B-Observation
≥ NCT03865537 663 664 B-Eq-Comparison
1.5 NCT03865537 665 668 I-Eq-Comparison
, NCT03865537 669 670 O
or NCT03865537 671 673 B-Or
platelets NCT03865537 674 683 B-Observation
< NCT03865537 684 685 B-Eq-Comparison
50 NCT03865537 686 688 I-Eq-Comparison

- NCT03865537 692 693 O
Inadequate NCT03865537 695 705 B-Condition
bowel NCT03865537 706 711 I-Condition
preparation NCT03865537 712 723 I-Condition
( NCT03865537 724 725 O
Boston NCT03865537 726 732 B-Observation
Bowel NCT03865537 733 738 I-Observation
Prep NCT03865537 739 743 I-Observation
Scale NCT03865537 744 749 I-Observation
, NCT03865537 750 751 O
total NCT03865537 752 757 O
score NCT03865537 758 763 O
≤ NCT03865537 764 765 B-Eq-Comparison
2 NCT03865537 766 767 I-Eq-Comparison
) NCT03865537 768 769 O

- NCT03865537 773 774 O
Pregnancy NCT03865537 776 785 B-Condition


Inclusion NCT03868761 0 9 O
Criteria NCT03868761 10 18 O
: NCT03868761 19 20 O

1 NCT03868761 24 25 O
. NCT03868761 25 26 O
Males NCT03868761 28 33 O
& NCT03868761 34 35 B-Or
females NCT03868761 36 43 O
aged NCT03868761 44 48 B-Age
13 NCT03868761 49 51 B-Eq-Comparison
- NCT03868761 52 53 I-Eq-Comparison
17 NCT03868761 54 56 I-Eq-Comparison
years NCT03868761 57 62 I-Eq-Comparison
directly NCT03868761 63 71 O
impacted NCT03868761 72 80 O
by NCT03868761 81 83 O
the NCT03868761 84 87 O
2017 NCT03868761 88 92 O
wildfires NCT03868761 93 102 O
having NCT03868761 103 109 O
lost NCT03868761 110 114 B-Observation
their NCT03868761 115 120 I-Observation
home NCT03868761 121 125 I-Observation
or NCT03868761 126 128 B-Or
been NCT03868761 129 133 O
temporarily NCT03868761 134 145 B-Observation
displaced NCT03868761 146 155 I-Observation

2 NCT03868761 158 159 O
. NCT03868761 159 160 O
Screen NCT03868761 162 168 O
positive NCT03868761 169 177 O
for NCT03868761 178 181 O
PTSD NCT03868761 182 186 B-Condition
( NCT03868761 187 188 O
Child NCT03868761 189 194 B-Observation
Trauma NCT03868761 195 201 I-Observation
Screening NCT03868761 202 211 I-Observation
Questionnaire NCT03868761 212 225 I-Observation
= NCT03868761 226 227 B-Eq-Comparison
5 NCT03868761 228 229 I-Eq-Comparison
or NCT03868761 230 232 I-Eq-Comparison
higher NCT03868761 233 239 I-Eq-Comparison
) NCT03868761 240 241 O

3 NCT03868761 245 246 O
. NCT03868761 246 247 O
Have NCT03868761 249 253 O
regular NCT03868761 254 261 O
access NCT03868761 262 268 O
to NCT03868761 269 271 O
a NCT03868761 272 273 O
smart NCT03868761 274 279 O
phone NCT03868761 280 285 O
and NCT03868761 286 289 O
a NCT03868761 290 291 O
computer NCT03868761 292 300 O

4 NCT03868761 303 304 O
. NCT03868761 304 305 O
Have NCT03868761 307 311 O
a NCT03868761 312 313 O
personal NCT03868761 314 322 O
email NCT03868761 323 328 O
address NCT03868761 329 336 O

5 NCT03868761 339 340 O
. NCT03868761 340 341 O
Speak NCT03868761 343 348 O
and NCT03868761 349 352 O
read NCT03868761 353 357 O
English NCT03868761 358 365 O
fluently NCT03868761 366 374 O

6 NCT03868761 377 378 O
. NCT03868761 378 379 O
Have NCT03868761 381 385 O
parental NCT03868761 386 394 O
consent NCT03868761 395 402 O

Exclusion NCT03868761 403 412 O
Criteria NCT03868761 413 421 O
: NCT03868761 422 423 O

1 NCT03868761 427 428 O
. NCT03868761 428 429 O
A NCT03868761 431 432 O
positive NCT03868761 433 441 O
self NCT03868761 442 446 O
- NCT03868761 447 448 O
reported NCT03868761 449 457 O
history NCT03868761 458 465 B-Eq-Comparison
of NCT03868761 466 468 O
psychosis NCT03868761 469 478 B-Condition
, NCT03868761 479 480 O
bipolar NCT03868761 481 488 B-Condition
, NCT03868761 489 490 O
or NCT03868761 491 493 B-Or
schizophrenia NCT03868761 494 507 B-Condition

2 NCT03868761 510 511 O
. NCT03868761 511 512 O
Serious NCT03868761 514 521 O
self NCT03868761 522 526 O
- NCT03868761 527 528 O
reported NCT03868761 529 537 O
physical NCT03868761 538 546 B-Condition
health NCT03868761 547 553 I-Condition
concerns NCT03868761 554 562 I-Condition
necessitating NCT03868761 563 576 B-Assertion___Assertion-Type-Value:hypothetical
surgery NCT03868761 577 584 B-Procedure
or NCT03868761 585 587 B-Or
with NCT03868761 588 592 O
prognosis NCT03868761 593 602 B-Observation
< NCT03868761 603 604 B-Eq-Comparison
6 NCT03868761 605 606 I-Eq-Comparison
months NCT03868761 607 613 I-Eq-Comparison

3 NCT03868761 621 622 O
. NCT03868761 622 623 O
A NCT03868761 625 626 O
positive NCT03868761 627 635 O
screen NCT03868761 636 642 O
for NCT03868761 643 646 O
a NCT03868761 647 648 O
current NCT03868761 649 656 B-Eq-Comparison
Substance NCT03868761 657 666 B-Condition
User NCT03868761 667 671 I-Condition
Disorder NCT03868761 672 680 I-Condition
( NCT03868761 681 682 O
CRAFFT NCT03868761 683 689 B-Observation
= NCT03868761 690 691 B-Eq-Comparison
2 NCT03868761 692 693 I-Eq-Comparison
or NCT03868761 694 696 I-Eq-Comparison
higher NCT03868761 697 703 I-Eq-Comparison
) NCT03868761 704 705 O

4 NCT03868761 709 710 O
. NCT03868761 710 711 O
Current NCT03868761 713 720 B-Eq-Comparison
self NCT03868761 721 725 O
- NCT03868761 726 727 O
reported NCT03868761 728 736 O
suicidal NCT03868761 737 745 B-Condition
ideation NCT03868761 746 754 I-Condition

5 NCT03868761 757 758 O
. NCT03868761 758 759 O
Self NCT03868761 761 765 O
- NCT03868761 766 767 O
reported NCT03868761 768 776 O
pregnancy NCT03868761 777 786 B-Condition

6 NCT03868761 789 790 O
. NCT03868761 790 791 O
Self NCT03868761 793 797 O
- NCT03868761 798 799 O
reported NCT03868761 800 808 O
less NCT03868761 809 813 B-Eq-Comparison
than NCT03868761 814 818 I-Eq-Comparison
four NCT03868761 819 823 I-Eq-Comparison
weeks NCT03868761 824 829 I-Eq-Comparison
of NCT03868761 830 832 O
stable NCT03868761 833 839 O
prescription NCT03868761 840 852 O
medication NCT03868761 853 863 B-Drug
for NCT03868761 864 867 O
anxiety NCT03868761 868 875 B-Condition
, NCT03868761 876 877 O
anti NCT03868761 878 882 B-Drug
- NCT03868761 883 884 I-Drug
depressant NCT03868761 885 895 I-Drug
, NCT03868761 896 897 O
and NCT03868761 898 901 B-Or
sleep NCT03868761 902 907 B-Condition
promoting NCT03868761 908 917 O
medications NCT03868761 918 929 B-Drug
prior NCT03868761 930 935 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868761 936 938 O
the NCT03868761 939 942 O
screening NCT03868761 943 952 B-Study
assessment NCT03868761 953 963 B-Procedure


Inclusion NCT03861962 0 9 O
Criteria NCT03861962 10 18 O
: NCT03861962 19 20 O

- NCT03861962 24 25 O
patients NCT03861962 27 35 O
( NCT03861962 36 37 O
adults NCT03861962 38 44 O
and NCT03861962 45 48 B-Or
children NCT03861962 49 57 O
) NCT03861962 58 59 O

- NCT03861962 63 64 O
patients NCT03861962 66 74 O
recipients NCT03861962 75 85 O
in NCT03861962 86 88 O
France NCT03861962 89 95 O
from NCT03861962 96 100 O
2008 NCT03861962 101 105 B-Eq-Comparison
to NCT03861962 106 108 I-Eq-Comparison
2015 NCT03861962 109 113 I-Eq-Comparison
of NCT03861962 114 116 O
a NCT03861962 117 118 O
first NCT03861962 119 124 B-Eq-Comparison
kidney NCT03861962 125 131 B-Modifier
transplant NCT03861962 132 142 B-Procedure
/ NCT03861962 143 144 B-Or
heart NCT03861962 145 150 B-Modifier
/ NCT03861962 151 152 B-Or
lung NCT03861962 153 157 B-Modifier
/ NCT03861962 158 159 B-Or
liver NCT03861962 160 165 B-Modifier
donor NCT03861962 166 171 I-Modifier
living NCT03861962 172 178 B-Death|Negation
or NCT03861962 179 181 B-Or
deceased NCT03861962 182 190 B-Death
, NCT03861962 191 192 O
non NCT03861962 193 196 B-Negation
- NCT03861962 197 198 O
immunized NCT03861962 199 208 B-Immunization
anti NCT03861962 209 213 O
- NCT03861962 214 215 O
HLA NCT03861962 216 219 B-Condition
before NCT03861962 220 226 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03861962 227 230 O
transplant NCT03861962 231 241 B-Coreference|Procedure

- NCT03861962 244 245 O
patients NCT03861962 247 255 O
having NCT03861962 256 262 O
preserved NCT03861962 263 272 O
their NCT03861962 273 278 O
graft NCT03861962 279 284 B-Procedure
> NCT03861962 285 286 B-Eq-Comparison
2 NCT03861962 287 288 I-Eq-Comparison
years NCT03861962 289 294 I-Eq-Comparison

- NCT03861962 297 298 O
having NCT03861962 300 306 O
agreed NCT03861962 307 313 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861962 314 316 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03861962 317 320 O
use NCT03861962 321 324 O
for NCT03861962 325 328 O
research NCT03861962 329 337 O
purposes NCT03861962 338 346 O
in NCT03861962 347 349 O
transplantation NCT03861962 350 365 B-Procedure
of NCT03861962 366 368 O
the NCT03861962 369 372 O
remains NCT03861962 373 380 O
of NCT03861962 381 383 O
the NCT03861962 384 387 O
DNA NCT03861962 388 391 B-Observation
and NCT03861962 392 395 B-And
serum NCT03861962 396 401 B-Observation
samples NCT03861962 402 409 I-Observation
taken NCT03861962 410 415 O
as NCT03861962 416 418 O
part NCT03861962 419 423 O
of NCT03861962 424 426 O
the NCT03861962 427 430 O
care NCT03861962 431 435 O
of NCT03861962 436 438 O
which NCT03861962 439 444 O
the NCT03861962 445 448 O
remains NCT03861962 449 456 O
are NCT03861962 457 460 O
available NCT03861962 461 470 O

Exclusion NCT03861962 471 480 O
Criteria NCT03861962 481 489 O
: NCT03861962 490 491 O

- NCT03861962 495 496 O
no NCT03861962 498 500 O
inclusion NCT03861962 501 510 O
if NCT03861962 511 513 O
one NCT03861962 514 517 O
of NCT03861962 518 520 O
the NCT03861962 521 524 O
inclusion NCT03861962 525 534 O
criteria NCT03861962 535 543 O
is NCT03861962 544 546 O
not NCT03861962 547 550 O
met NCT03861962 551 554 O

Inclusion NCT03864198 0 9 O
Criteria NCT03864198 10 18 O
: NCT03864198 19 20 O

- NCT03864198 24 25 O
male NCT03864198 27 31 O
18 NCT03864198 32 34 B-Eq-Comparison
- NCT03864198 35 36 I-Eq-Comparison
50 NCT03864198 37 39 I-Eq-Comparison
years NCT03864198 40 45 I-Age|Eq-Comparison

- NCT03864198 48 49 O
oligozoospermia NCT03864198 51 66 B-Condition
: NCT03864198 67 68 O
< NCT03864198 69 70 B-Eq-Comparison
5 NCT03864198 71 72 I-Eq-Comparison
million NCT03864198 73 80 I-Eq-Comparison
spermatozoa NCT03864198 81 92 I-Eq-Comparison|Observation
/ NCT03864198 93 94 I-Eq-Comparison
mL NCT03864198 95 97 I-Eq-Comparison
; NCT03864198 97 98 O

- NCT03864198 101 102 O
asthenozoospermia NCT03864198 104 121 B-Condition
: NCT03864198 122 123 O
< NCT03864198 124 125 B-Eq-Comparison
32 NCT03864198 126 128 I-Eq-Comparison
% NCT03864198 129 130 I-Eq-Comparison
progressive NCT03864198 131 142 B-Observation
motile NCT03864198 143 149 I-Observation
spermatozoa NCT03864198 150 161 I-Observation
; NCT03864198 161 162 O

- NCT03864198 165 166 O
teratozoospermia NCT03864198 168 184 B-Condition
: NCT03864198 185 186 O
< NCT03864198 187 188 B-Eq-Comparison
4 NCT03864198 189 190 I-Eq-Comparison
% NCT03864198 191 192 I-Eq-Comparison
normal NCT03864198 193 199 O
forms NCT03864198 200 205 B-Observation
. NCT03864198 206 207 O

Exclusion NCT03864198 209 218 O
Criteria NCT03864198 219 227 O
: NCT03864198 228 229 O

- NCT03864198 233 234 O
azoospermia NCT03864198 236 247 B-Condition

- NCT03864198 250 251 O
smoke NCT03864198 253 258 B-Condition

- NCT03864198 261 262 O
use NCT03864198 264 267 B-Eq-Comparison
drugs NCT03864198 268 273 B-Drug

- NCT03864198 276 277 O
use NCT03864198 279 282 B-Eq-Comparison
drugs NCT03864198 283 288 B-Drug
with NCT03864198 289 293 B-And
proven NCT03864198 294 300 O
fertility NCT03864198 301 310 B-Condition
toxicity NCT03864198 311 319 I-Condition

- NCT03864198 322 323 O
exposition NCT03864198 325 335 O
to NCT03864198 336 338 O
any NCT03864198 339 342 O
environmental NCT03864198 343 356 B-Modifier
or NCT03864198 357 359 B-Or
occupational NCT03864198 360 372 B-Modifier
toxic NCT03864198 373 378 I-Modifier
substances NCT03864198 379 389 B-Drug

- NCT03864198 392 393 O
exposition NCT03864198 395 405 O
to NCT03864198 406 408 O
radiation NCT03864198 409 418 B-Procedure
or NCT03864198 419 421 B-Or
heat NCT03864198 422 426 B-Modifier

- NCT03864198 429 430 O
orchitis NCT03864198 432 440 B-Condition
secondary NCT03864198 441 450 B-Modifier
to NCT03864198 451 453 O
mumps NCT03864198 454 459 B-Condition

- NCT03864198 462 463 O
sexually NCT03864198 465 473 B-Condition
transmitted NCT03864198 474 485 I-Condition
diseases NCT03864198 486 494 I-Condition

- NCT03864198 497 498 O
history NCT03864198 500 507 B-Eq-Comparison
of NCT03864198 508 510 O
cryptorchidism NCT03864198 511 525 B-Condition

- NCT03864198 528 529 O
previous NCT03864198 531 539 B-Eq-Comparison
testicular NCT03864198 540 550 B-Procedure
torsion NCT03864198 551 558 I-Procedure

- NCT03864198 561 562 O
genitourinary NCT03864198 564 577 B-Condition
anomalies NCT03864198 578 587 I-Condition

- NCT03864198 590 591 O
alterations NCT03864198 593 604 B-Procedure
of NCT03864198 605 607 O
the NCT03864198 608 611 O
epididymis NCT03864198 612 622 B-Modifier
or NCT03864198 623 625 B-Or
deferens NCT03864198 626 634 B-Modifier

- NCT03864198 637 638 O
inguinal NCT03864198 640 648 B-Procedure
surgery NCT03864198 649 656 I-Procedure

Inclusion NCT03868631 0 9 O
Criteria NCT03868631 10 18 O
: NCT03868631 19 20 O

- NCT03868631 24 25 O
non NCT03868631 27 30 B-Negation
- NCT03868631 31 32 O
smoking NCT03868631 33 40 B-Condition

- NCT03868631 43 44 O
body NCT03868631 46 50 B-Observation
mass NCT03868631 51 55 I-Observation
index NCT03868631 56 61 I-Observation
( NCT03868631 62 63 O
BMI NCT03868631 64 67 B-Observation
) NCT03868631 68 69 O
18.5 NCT03868631 70 74 B-Eq-Comparison
- NCT03868631 75 76 I-Eq-Comparison
24.9 NCT03868631 77 81 I-Eq-Comparison

- NCT03868631 85 86 O
recreationally NCT03868631 88 102 B-Observation
active NCT03868631 103 109 B-Eq-Comparison

Exclusion NCT03868631 110 119 O
Criteria NCT03868631 120 128 O
: NCT03868631 129 130 O

- NCT03868631 134 135 O
participated NCT03868631 137 149 O
in NCT03868631 150 152 O
structured NCT03868631 153 163 B-Modifier
weight NCT03868631 164 170 B-Observation
training NCT03868631 171 179 I-Observation
during NCT03868631 180 186 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868631 187 190 O
previous NCT03868631 191 199 B-Eq-Comparison
12 NCT03868631 200 202 I-Eq-Comparison
month NCT03868631 203 208 I-Eq-Comparison

- NCT03868631 211 212 O
vegetarian NCT03868631 214 224 B-Condition
or NCT03868631 225 227 B-Or
vegan NCT03868631 228 233 B-Condition

- NCT03868631 236 237 O
presence NCT03868631 239 247 O
of NCT03868631 248 250 O
chronic NCT03868631 251 258 B-Modifier
disease NCT03868631 259 266 B-Condition

- NCT03868631 269 270 O
pregnant NCT03868631 272 280 B-Condition
, NCT03868631 281 282 O
postpartum NCT03868631 283 293 B-Condition
up NCT03868631 294 296 B-Eq-Comparison
to NCT03868631 297 299 I-Eq-Comparison
six NCT03868631 300 303 I-Eq-Comparison
months NCT03868631 304 310 I-Eq-Comparison
, NCT03868631 311 312 O
lactating NCT03868631 313 322 B-Condition
, NCT03868631 323 324 O
or NCT03868631 325 327 B-Or
intention NCT03868631 328 337 B-Assertion___Assertion-Type-Value:intention
to NCT03868631 338 340 I-Assertion___Assertion-Type-Value:intention
become NCT03868631 341 347 O
pregnant NCT03868631 348 356 B-Condition

- NCT03868631 359 360 O
allergy NCT03868631 362 369 B-Allergy
to NCT03868631 370 372 O
whey NCT03868631 373 377 O
or NCT03868631 378 380 B-Or
soy NCT03868631 381 384 O

- NCT03868631 387 388 O
changes NCT03868631 390 397 O
in NCT03868631 398 400 O
body NCT03868631 401 405 B-Observation
weight NCT03868631 406 412 I-Observation
more NCT03868631 413 417 B-Eq-Comparison
than NCT03868631 418 422 I-Eq-Comparison
10 NCT03868631 423 425 I-Eq-Comparison
pounds NCT03868631 426 432 I-Eq-Comparison
in NCT03868631 433 435 O
the NCT03868631 436 439 O
past NCT03868631 440 444 B-Eq-Comparison
three NCT03868631 445 450 I-Eq-Comparison
months NCT03868631 451 457 I-Eq-Comparison

Inclusion NCT03865329 0 9 O
Criteria NCT03865329 10 18 O

- NCT03865329 21 22 O
COPD NCT03865329 24 28 B-Condition
related NCT03865329 29 36 O
hospitalization NCT03865329 37 52 B-Encounter
and NCT03865329 53 56 B-And
eligible NCT03865329 57 65 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865329 66 69 O
PR NCT03865329 70 72 B-Procedure

- NCT03865329 75 76 O
Exclusion NCT03865329 78 87 O
Criteria NCT03865329 88 96 O

- NCT03865329 99 100 O
Inability NCT03865329 102 111 B-Condition
to NCT03865329 112 114 I-Condition
walk NCT03865329 115 119 I-Condition
( NCT03865329 120 121 O
orthopedic NCT03865329 122 132 B-Modifier
- NCT03865329 133 134 B-Or
neurologic NCT03865329 135 145 B-Modifier
problems NCT03865329 146 154 B-Condition
or NCT03865329 155 157 B-Or
confined NCT03865329 158 166 B-Condition
to NCT03865329 167 169 I-Condition
bed NCT03865329 170 173 I-Condition
) NCT03865329 174 175 O

Inclusion NCT03865498 0 9 O
Criteria NCT03865498 10 18 O
: NCT03865498 19 20 O

- NCT03865498 24 25 O
18 NCT03865498 27 29 B-Eq-Comparison
years NCT03865498 30 35 I-Eq-Comparison
of NCT03865498 36 38 I-Eq-Comparison
age NCT03865498 39 42 I-Age|Eq-Comparison
or NCT03865498 43 45 I-Eq-Comparison
older NCT03865498 46 51 I-Eq-Comparison

- NCT03865498 54 55 O
Black NCT03865498 57 62 O
or NCT03865498 63 65 B-Or
Hispanic NCT03865498 66 74 O
, NCT03865498 75 76 O
living NCT03865498 77 83 O
in NCT03865498 84 86 O
the NCT03865498 87 90 O
U. NCT03865498 91 93 O
S. NCT03865498 94 96 O
including NCT03865498 98 107 O
the NCT03865498 108 111 O
U. NCT03865498 112 114 O
S. NCT03865498 115 117 O
territories NCT03865498 119 130 O

- NCT03865498 133 134 O
a NCT03865498 136 137 O
dementia NCT03865498 138 146 B-Condition
caregiver NCT03865498 147 156 B-Family-Member___Family-Member-Type:parent
with NCT03865498 157 161 O
any NCT03865498 162 165 O
duration NCT03865498 166 174 O
, NCT03865498 175 176 O
able NCT03865498 177 181 O
to NCT03865498 182 184 O
speak NCT03865498 185 190 O
English NCT03865498 191 198 O
or NCT03865498 199 201 B-Or
Spanish NCT03865498 202 209 O
/ NCT03865498 210 211 O
bilingual NCT03865498 212 221 O

- NCT03865498 224 225 O
must NCT03865498 227 231 O
agree NCT03865498 232 237 O
to NCT03865498 238 240 O
terms NCT03865498 241 246 O
of NCT03865498 247 249 O
conditions NCT03865498 250 260 O
of NCT03865498 261 263 O
use NCT03865498 264 267 O
and NCT03865498 268 271 O
privacy NCT03865498 272 279 O
policy NCT03865498 280 286 O
and NCT03865498 287 290 O
rules NCT03865498 291 296 O
of NCT03865498 297 299 O
one NCT03865498 300 303 O
of NCT03865498 304 306 O
the NCT03865498 307 310 O
two NCT03865498 311 314 O
dementia NCT03865498 315 323 O
caregiver NCT03865498 324 333 O
network NCT03865498 334 341 O
( NCT03865498 342 343 O
Hispanic NCT03865498 344 352 O
@dcnh NCT03865498 353 358 O
, NCT03865498 359 360 O
Black NCT03865498 361 366 O
@dcnaab NCT03865498 367 374 O
) NCT03865498 375 376 O
, NCT03865498 378 379 O
the NCT03865498 380 383 O
Twitter NCT03865498 384 391 O
user NCT03865498 392 396 O
agreement NCT03865498 397 406 O
of NCT03865498 407 409 O
the NCT03865498 410 413 O
terms NCT03865498 414 419 O
of NCT03865498 420 422 O
service NCT03865498 423 430 O
, NCT03865498 431 432 O
Twitter NCT03865498 433 440 O
privacy NCT03865498 441 448 O
policy NCT03865498 449 455 O
and NCT03865498 456 459 O
Twitter NCT03865498 460 467 O
rules NCT03865498 468 473 O
including NCT03865498 474 483 O
intellectual NCT03865498 484 496 O
property NCT03865498 497 505 O
, NCT03865498 506 507 O
violence NCT03865498 508 516 B-Condition
, NCT03865498 517 518 O
misconduct NCT03865498 519 529 B-Condition
, NCT03865498 530 531 O
abuse NCT03865498 532 537 B-Condition
behavior NCT03865498 538 546 I-Condition
, NCT03865498 547 548 O
private NCT03865498 549 556 O
information NCT03865498 557 568 O
and NCT03865498 569 572 O
spam NCT03865498 573 577 O
and NCT03865498 578 581 O
security NCT03865498 582 590 O

- NCT03865498 593 594 O
use NCT03865498 596 599 O
a NCT03865498 600 601 O
smartphone NCT03865498 602 612 O
or NCT03865498 613 615 O
a NCT03865498 616 617 O
feature NCT03865498 618 625 O
phone NCT03865498 626 631 O
( NCT03865498 632 633 O
i. NCT03865498 634 636 O
e. NCT03865498 637 639 O
, NCT03865498 640 641 O
a NCT03865498 642 643 O
cell NCT03865498 644 648 O
phone NCT03865498 649 654 O
with NCT03865498 655 659 O
text NCT03865498 660 664 O
messaging NCT03865498 665 674 O
) NCT03865498 675 676 O

Exclusion NCT03865498 678 687 O
Criteria NCT03865498 688 696 O
: NCT03865498 697 698 O

- NCT03865498 702 703 O
do NCT03865498 705 707 O
not NCT03865498 708 711 O
have NCT03865498 712 716 O
de NCT03865498 717 719 O
- NCT03865498 720 721 O
identified NCT03865498 722 732 O
Twitter NCT03865498 733 740 O
account NCT03865498 741 748 O
, NCT03865498 749 750 O
children NCT03865498 751 759 O
, NCT03865498 760 761 O
not NCT03865498 762 765 B-Negation
a NCT03865498 766 767 O
dementia NCT03865498 768 776 B-Condition
family NCT03865498 777 783 B-Family-Member___Family-Member-Type:parent
caregiver NCT03865498 784 793 I-Family-Member___Family-Member-Type:parent

Inclusion NCT03860090 0 9 O
Criteria NCT03860090 10 18 O
: NCT03860090 19 20 O

- NCT03860090 24 25 O
Patients NCT03860090 27 35 O
with NCT03860090 36 40 O
a NCT03860090 41 42 O
endovenous NCT03860090 43 53 B-Procedure
pacemaker NCT03860090 54 63 I-Procedure
or NCT03860090 64 66 B-Or
defibrillator NCT03860090 67 80 B-Procedure
indication NCT03860090 81 91 B-Indication
. NCT03860090 92 93 O

Exclusion NCT03860090 95 104 O
Criteria NCT03860090 105 113 O
: NCT03860090 114 115 O

- NCT03860090 119 120 O
Pre NCT03860090 122 125 B-Eq-Comparison
- NCT03860090 126 127 I-Eq-Comparison
existing NCT03860090 128 136 I-Eq-Comparison
ipsilateral NCT03860090 137 148 B-Procedure
pacing NCT03860090 149 155 I-Procedure
electrode NCT03860090 156 165 I-Procedure
. NCT03860090 166 167 O

- NCT03860090 171 172 O
Previous NCT03860090 174 182 B-Eq-Comparison
ipsilateral NCT03860090 183 194 B-Condition
lymphadenectomy NCT03860090 195 210 I-Condition
. NCT03860090 211 212 O

- NCT03860090 216 217 O
Indication NCT03860090 219 229 B-Indication
of NCT03860090 230 232 O
cardiac NCT03860090 233 240 B-Procedure
resynchronization NCT03860090 241 258 I-Procedure
therapy NCT03860090 259 266 I-Procedure
. NCT03860090 266 267 O

For NCT03869671 0 3 O
all NCT03869671 4 7 O
phases NCT03869671 8 14 O
: NCT03869671 15 16 O

Inclusion NCT03869671 18 27 O
Criteria NCT03869671 28 36 O
: NCT03869671 37 38 O

- NCT03869671 42 43 O
An NCT03869671 45 47 O
adult NCT03869671 48 53 O
PWID NCT03869671 54 58 B-Condition

- NCT03869671 61 62 O
Self NCT03869671 64 68 O
report NCT03869671 69 75 O
of NCT03869671 76 78 O
any NCT03869671 79 82 O
high NCT03869671 83 87 O
risk NCT03869671 88 92 B-Risk
behaviors NCT03869671 93 102 I-Risk
for NCT03869671 103 106 O
HIV NCT03869671 107 110 B-Condition
( NCT03869671 111 112 O
past NCT03869671 113 117 B-Eq-Comparison
- NCT03869671 118 119 I-Eq-Comparison
month NCT03869671 120 125 I-Eq-Comparison
receptive NCT03869671 126 135 B-Modifier
syringe NCT03869671 136 143 B-Condition
sharing NCT03869671 144 151 I-Condition
, NCT03869671 152 153 O
transactional NCT03869671 154 167 B-Condition
sex NCT03869671 168 171 I-Condition
, NCT03869671 172 173 O
condomless NCT03869671 174 184 B-Modifier
sex NCT03869671 185 188 B-Condition
with NCT03869671 189 193 O
an NCT03869671 194 196 O
HIV NCT03869671 197 200 B-Modifier
- NCT03869671 201 202 I-Modifier
infected NCT03869671 203 211 I-Modifier
or NCT03869671 212 214 B-Or
unknown NCT03869671 215 222 B-Modifier
status NCT03869671 223 229 I-Modifier
partner NCT03869671 230 237 I-Modifier
) NCT03869671 238 239 O

Exclusion NCT03869671 241 250 O
Criteria NCT03869671 251 259 O
: NCT03869671 260 261 O

- NCT03869671 265 266 O
Unable NCT03869671 268 274 O
or NCT03869671 275 277 O
unwilling NCT03869671 278 287 O
to NCT03869671 288 290 O
provide NCT03869671 291 298 O
informed NCT03869671 299 307 O
consent NCT03869671 308 315 O

For NCT03869671 316 319 O
Phase NCT03869671 320 325 O
3 NCT03869671 326 327 O
( NCT03869671 328 329 O
the NCT03869671 330 333 O
RCT NCT03869671 334 337 O
pilot NCT03869671 338 343 O
) NCT03869671 344 345 O
: NCT03869671 347 348 O

Inclusion NCT03869671 350 359 O
Criteria NCT03869671 360 368 O
: NCT03869671 369 370 O

- NCT03869671 374 375 O
Clinically NCT03869671 377 387 O
eligible NCT03869671 388 396 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869671 397 400 I-Assertion___Assertion-Type-Value:hypothetical
PrEP NCT03869671 401 405 B-Procedure
( NCT03869671 406 407 O
confirmed NCT03869671 408 417 O
HIV NCT03869671 418 421 B-Condition
- NCT03869671 422 423 O
uninfected NCT03869671 424 434 B-Negation
status NCT03869671 435 441 O
, NCT03869671 442 443 O
adequate NCT03869671 444 452 O
renal NCT03869671 453 458 B-Observation
function NCT03869671 459 467 I-Observation
[ NCT03869671 468 469 O
estimated NCT03869671 470 479 B-Observation
creatinine NCT03869671 480 490 I-Observation
clearance NCT03869671 491 500 I-Observation
≥ NCT03869671 501 502 B-Eq-Comparison
60 NCT03869671 503 505 I-Eq-Comparison
ml NCT03869671 506 508 I-Eq-Comparison
/ NCT03869671 509 510 I-Eq-Comparison
min NCT03869671 511 514 I-Eq-Comparison
] NCT03869671 515 516 O
, NCT03869671 518 519 O
and NCT03869671 520 523 B-And
documented NCT03869671 524 534 O
hepatitis NCT03869671 535 544 B-Condition
B NCT03869671 545 546 I-Condition
virus NCT03869671 547 552 I-Condition
[ NCT03869671 553 554 O
HBV NCT03869671 555 558 B-Condition
] NCT03869671 559 560 O
status NCT03869671 561 567 O
) NCT03869671 568 569 O

Inclusion NCT03864341 0 9 O
Criteria NCT03864341 10 18 O
: NCT03864341 19 20 O

- NCT03864341 24 25 O
Be NCT03864341 27 29 O
a NCT03864341 30 31 O
patient NCT03864341 32 39 O
in NCT03864341 40 42 O
the NCT03864341 43 46 O
Bellevue NCT03864341 47 55 O
Hospital NCT03864341 56 64 O
Center NCT03864341 65 71 O
ED NCT03864341 72 74 O
. NCT03864341 75 76 O

- NCT03864341 80 81 O
Be NCT03864341 83 85 O
≥ NCT03864341 86 87 B-Eq-Comparison
18 NCT03864341 88 90 I-Eq-Comparison
years NCT03864341 91 96 I-Eq-Comparison
old NCT03864341 97 100 B-Age
. NCT03864341 101 102 O

- NCT03864341 106 107 O
Screen NCT03864341 109 115 O
positive NCT03864341 116 124 O
for NCT03864341 125 128 O
homelessness NCT03864341 129 141 B-Condition
risk NCT03864341 142 146 B-Risk
using NCT03864341 147 152 O
a NCT03864341 153 154 O
homelessness NCT03864341 155 167 B-Observation
risk NCT03864341 168 172 I-Observation
screening NCT03864341 173 182 I-Observation
tool NCT03864341 183 187 I-Observation
( NCT03864341 188 189 O
HRST NCT03864341 190 194 B-Observation
) NCT03864341 195 196 O
. NCT03864341 198 199 O

- NCT03864341 203 204 O
Screen NCT03864341 206 212 O
positive NCT03864341 213 221 O
for NCT03864341 222 225 O
unhealthy NCT03864341 226 235 O
alcohol NCT03864341 236 243 B-Modifier
or NCT03864341 244 246 B-Or
drug NCT03864341 247 251 B-Modifier
use NCT03864341 252 255 B-Condition
. NCT03864341 256 257 O

- NCT03864341 261 262 O
Able NCT03864341 264 268 O
to NCT03864341 269 271 O
provide NCT03864341 272 279 O
consent NCT03864341 280 287 O
. NCT03864341 288 289 O

Exclusion NCT03864341 291 300 O
Criteria NCT03864341 301 309 O
: NCT03864341 310 311 O

- NCT03864341 315 316 O
Medically NCT03864341 318 327 B-Modifier
( NCT03864341 328 329 O
e. NCT03864341 330 332 O
g. NCT03864341 333 335 O
, NCT03864341 336 337 O
critically NCT03864341 338 348 B-Condition
ill NCT03864341 349 352 I-Condition
) NCT03864341 353 354 O
or NCT03864341 355 357 B-Or
psychiatrically NCT03864341 358 373 B-Modifier
unstable NCT03864341 374 382 B-Condition
. NCT03864341 383 384 O

- NCT03864341 388 389 O
Unable NCT03864341 391 397 O
to NCT03864341 398 400 O
provide NCT03864341 401 408 O
informed NCT03864341 409 417 O
consent NCT03864341 418 425 O
for NCT03864341 426 429 O
other NCT03864341 430 435 O
reason NCT03864341 436 442 O
( NCT03864341 443 444 O
e. NCT03864341 445 447 O
g. NCT03864341 448 450 O
, NCT03864341 451 452 O
cognitive NCT03864341 453 462 B-Condition
deficit NCT03864341 463 470 I-Condition
, NCT03864341 471 472 O
profound NCT03864341 473 481 B-Condition
intoxication NCT03864341 482 494 I-Condition
) NCT03864341 495 496 O
. NCT03864341 498 499 O

- NCT03864341 503 504 O
Incarcerated NCT03864341 506 518 B-Observation
or NCT03864341 519 521 B-Or
in NCT03864341 522 524 O
police NCT03864341 525 531 B-Observation
custody NCT03864341 532 539 I-Observation
. NCT03864341 540 541 O

- NCT03864341 545 546 O
Unable NCT03864341 548 554 B-Negation
to NCT03864341 555 557 O
understand NCT03864341 558 568 O
and NCT03864341 569 572 O
speak NCT03864341 573 578 O
English NCT03864341 579 586 O
. NCT03864341 587 588 O

- NCT03864341 592 593 O
Lives NCT03864341 595 600 O
outside NCT03864341 601 608 B-Negation
NYC NCT03864341 609 612 O
and NCT03864341 613 616 B-Or
/ NCT03864341 617 618 I-Or
or NCT03864341 619 621 I-Or
can NCT03864341 622 625 B-Negation
not NCT03864341 625 628 I-Negation
give NCT03864341 629 633 O
a NCT03864341 634 635 O
NYC NCT03864341 636 639 O
ZIP NCT03864341 640 643 O
code NCT03864341 644 648 O
. NCT03864341 649 650 O

- NCT03864341 654 655 O
Already NCT03864341 657 664 O
homeless NCT03864341 665 673 B-Condition
( NCT03864341 674 675 O
residing NCT03864341 676 684 O
in NCT03864341 685 687 O
a NCT03864341 688 689 O
shelter NCT03864341 690 697 O
or NCT03864341 698 700 B-Or
on NCT03864341 701 703 O
the NCT03864341 704 707 O
streets NCT03864341 708 715 O
) NCT03864341 716 717 O
. NCT03864341 719 720 O

- NCT03864341 724 725 O
Does NCT03864341 727 731 O
not NCT03864341 732 735 O
have NCT03864341 736 740 O
a NCT03864341 741 742 O
telephone NCT03864341 743 752 O
where NCT03864341 753 758 O
can NCT03864341 759 762 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864341 763 765 I-Assertion___Assertion-Type-Value:hypothetical
reached NCT03864341 766 773 O
for NCT03864341 774 777 O
follow NCT03864341 778 784 B-Encounter
- NCT03864341 785 786 I-Encounter
up NCT03864341 787 789 I-Encounter
. NCT03864341 790 791 O

- NCT03864341 795 796 O
Has NCT03864341 798 801 O
already NCT03864341 802 809 B-Eq-Comparison
received NCT03864341 810 818 I-Eq-Comparison
specialized NCT03864341 819 830 O
peer NCT03864341 831 835 B-Modifier
navigator NCT03864341 836 845 I-Modifier
/ NCT03864341 846 847 B-Or
addiction NCT03864341 848 857 B-Modifier
social NCT03864341 858 864 B-Procedure
worker NCT03864341 865 871 I-Procedure
services NCT03864341 872 880 I-Procedure
during NCT03864341 881 887 B-Temporal-Connection___Temporal-Connection-Type-Value:during
current NCT03864341 888 895 O
ED NCT03864341 896 898 B-Encounter
visit NCT03864341 899 904 I-Encounter
. NCT03864341 905 906 O

- NCT03864341 910 911 O
Has NCT03864341 913 916 O
already NCT03864341 917 924 B-Eq-Comparison
participated NCT03864341 925 937 I-Eq-Comparison
in NCT03864341 938 940 O
the NCT03864341 941 944 O
study NCT03864341 945 950 B-Study
. NCT03864341 950 951 O

Inclusion NCT03867890 0 9 O
Criteria NCT03867890 10 18 O
: NCT03867890 19 20 O

- NCT03867890 24 25 O
walk NCT03867890 27 31 B-Observation
or NCT03867890 32 34 B-Or
run NCT03867890 35 38 B-Observation
at NCT03867890 39 41 B-Eq-Comparison
least NCT03867890 42 47 I-Eq-Comparison
10 NCT03867890 48 50 I-Eq-Comparison
kilometres NCT03867890 51 61 I-Eq-Comparison
per NCT03867890 62 65 I-Eq-Comparison
week NCT03867890 66 70 I-Eq-Comparison

- NCT03867890 73 74 O
maintain NCT03867890 76 84 B-Observation
a NCT03867890 85 86 O
minimal NCT03867890 87 94 B-Eq-Comparison
distance NCT03867890 95 103 I-Eq-Comparison
of NCT03867890 104 106 I-Eq-Comparison
ten NCT03867890 107 110 I-Eq-Comparison
kilometres NCT03867890 111 121 I-Eq-Comparison
per NCT03867890 122 125 I-Eq-Comparison
week NCT03867890 126 130 I-Eq-Comparison
, NCT03867890 131 132 O
for NCT03867890 133 136 O
a NCT03867890 137 138 O
period NCT03867890 139 145 O
of NCT03867890 146 148 O
24 NCT03867890 149 151 B-Eq-Comparison
weeks NCT03867890 152 157 I-Eq-Comparison

- NCT03867890 160 161 O
wear NCT03867890 163 167 B-Observation
one NCT03867890 168 171 B-Eq-Comparison
and NCT03867890 172 175 B-And
the NCT03867890 176 179 O
same NCT03867890 180 184 B-Modifier
pair NCT03867890 185 189 I-Modifier
of NCT03867890 190 192 I-Modifier
shoes NCT03867890 193 198 I-Modifier
during NCT03867890 199 205 B-Temporal-Connection___Temporal-Connection-Type-Value:during
walking NCT03867890 206 213 B-Observation
/ NCT03867890 214 215 B-Or
running NCT03867890 216 223 B-Observation
activities NCT03867890 224 234 O
during NCT03867890 235 241 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03867890 242 246 O
period NCT03867890 247 253 O

Exclusion NCT03867890 254 263 O
Criteria NCT03867890 264 272 O
: NCT03867890 273 274 O

- NCT03867890 278 279 O
systemic NCT03867890 281 289 B-Condition
disease NCT03867890 290 297 I-Condition
, NCT03867890 298 299 O
cardiac NCT03867890 300 307 B-Condition
problems NCT03867890 308 316 I-Condition
or NCT03867890 317 319 B-Or
diabetes NCT03867890 320 328 B-Condition

- NCT03867890 331 332 O
complaints NCT03867890 334 344 B-Condition
at NCT03867890 345 347 O
the NCT03867890 348 351 O
lower NCT03867890 352 357 B-Modifier
extremities NCT03867890 358 369 I-Modifier
in NCT03867890 370 372 O
the NCT03867890 373 376 O
last NCT03867890 377 381 B-Eq-Comparison
two NCT03867890 382 385 I-Eq-Comparison
weeks NCT03867890 386 391 I-Eq-Comparison
, NCT03867890 392 393 O

- NCT03867890 397 398 O
surgery NCT03867890 400 407 B-Procedure
at NCT03867890 408 410 O
the NCT03867890 411 414 O
lower NCT03867890 415 420 B-Modifier
extremities NCT03867890 421 432 I-Modifier
in NCT03867890 433 435 O
the NCT03867890 436 439 O
last NCT03867890 440 444 B-Eq-Comparison
three NCT03867890 445 450 I-Eq-Comparison
years NCT03867890 451 456 I-Eq-Comparison

Inclusion NCT03860480 0 9 O
Criteria NCT03860480 10 18 O
: NCT03860480 19 20 O

• NCT03860480 22 23 O
Patients NCT03860480 24 32 O
> NCT03860480 33 34 B-Eq-Comparison
18 NCT03860480 35 37 I-Eq-Comparison
years NCT03860480 38 43 I-Eq-Comparison
old NCT03860480 44 47 B-Age
with NCT03860480 48 52 B-And
to NCT03860480 53 55 O
ASA NCT03860480 56 59 B-Condition
status NCT03860480 60 66 O
I NCT03860480 67 68 B-Eq-Comparison
- NCT03860480 69 70 I-Eq-Comparison
III NCT03860480 71 74 I-Eq-Comparison
, NCT03860480 75 76 O
undergoing NCT03860480 77 87 B-Eq-Comparison
VATS NCT03860480 88 92 B-Procedure
for NCT03860480 93 96 O
lobectomy NCT03860480 97 106 B-Procedure
or NCT03860480 107 109 B-Or
wedge NCT03860480 110 115 B-Procedure
. NCT03860480 116 117 O

Non NCT03860480 119 122 O
- NCT03860480 123 124 O
inclusion NCT03860480 125 134 O
Criteria NCT03860480 135 143 O
: NCT03860480 144 145 O

- NCT03860480 149 150 O
< NCT03860480 152 153 B-Eq-Comparison
18 NCT03860480 154 156 I-Eq-Comparison
years NCT03860480 157 162 I-Eq-Comparison
old NCT03860480 163 166 B-Age

- NCT03860480 169 170 O
BMI NCT03860480 172 175 B-Observation
> NCT03860480 176 177 B-Eq-Comparison
35 NCT03860480 178 180 I-Eq-Comparison

- NCT03860480 184 185 O
Chronic NCT03860480 187 194 B-Modifier
pain NCT03860480 195 199 B-Condition
history NCT03860480 200 207 B-Eq-Comparison
with NCT03860480 208 212 B-And
regular NCT03860480 213 220 O
opioid NCT03860480 221 227 B-Drug
and NCT03860480 228 231 B-Or
/ NCT03860480 232 233 I-Or
or NCT03860480 234 236 I-Or
gabapentinoids NCT03860480 237 251 B-Drug
use NCT03860480 252 255 O
during NCT03860480 256 262 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860480 263 266 O
2 NCT03860480 267 268 B-Eq-Comparison
weeks NCT03860480 269 274 I-Eq-Comparison
before NCT03860480 275 281 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03860480 282 289 B-Procedure

- NCT03860480 292 293 O
Regular NCT03860480 295 302 B-Eq-Comparison
marijuana NCT03860480 303 312 B-Drug
use NCT03860480 313 316 O

- NCT03860480 319 320 O
History NCT03860480 322 329 B-Eq-Comparison
of NCT03860480 330 332 O
thoracic NCT03860480 333 341 B-Procedure
surgery NCT03860480 342 349 I-Procedure
on NCT03860480 350 352 O
the NCT03860480 353 356 O
operated NCT03860480 357 365 B-Modifier
side NCT03860480 366 370 I-Modifier

- NCT03860480 373 374 O
Epidural NCT03860480 376 384 B-Procedure
analgesia NCT03860480 385 394 I-Procedure
preferred NCT03860480 395 404 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03860480 405 408 O
to NCT03860480 409 411 O
an NCT03860480 412 414 O
anticipated NCT03860480 415 426 B-Assertion___Assertion-Type-Value:hypothetical
high NCT03860480 427 431 O
risk NCT03860480 432 436 B-Risk
of NCT03860480 437 439 O
conversion NCT03860480 440 450 B-Modifier
to NCT03860480 451 453 O
thoracotomy NCT03860480 454 465 B-Procedure

- NCT03860480 468 469 O
Unable NCT03860480 471 477 B-Condition
to NCT03860480 478 480 I-Condition
communicate NCT03860480 481 492 I-Condition
with NCT03860480 493 497 O
the NCT03860480 498 501 O
investigators NCT03860480 502 515 O

- NCT03860480 518 519 O
Receiving NCT03860480 521 530 B-Eq-Comparison
anticoagulation NCT03860480 531 546 B-Procedure
or NCT03860480 547 549 B-Or
experiencing NCT03860480 550 562 B-Eq-Comparison
any NCT03860480 563 566 O
bleeding NCT03860480 567 575 B-Condition
disorder NCT03860480 576 584 I-Condition

- NCT03860480 587 588 O
Surgery NCT03860480 590 597 B-Procedure
for NCT03860480 598 601 O
empyema NCT03860480 602 609 B-Condition
and NCT03860480 610 613 B-Or
sympathectomy NCT03860480 614 627 B-Procedure

- NCT03860480 630 631 O
Known NCT03860480 633 638 O
allergy NCT03860480 639 646 B-Allergy
to NCT03860480 647 649 O
local NCT03860480 650 655 B-Procedure
anesthetics NCT03860480 656 667 I-Procedure
, NCT03860480 668 669 O
fentanyl NCT03860480 670 678 B-Drug
or NCT03860480 679 681 B-Or
hydromorphone NCT03860480 682 695 B-Drug

- NCT03860480 698 699 O
Active NCT03860480 701 707 B-Eq-Comparison
infection NCT03860480 708 717 B-Condition
at NCT03860480 718 720 O
injection NCT03860480 721 730 B-Modifier
sites NCT03860480 731 736 I-Modifier

- NCT03860480 739 740 O
Preexisting NCT03860480 742 753 B-Eq-Comparison
neurological NCT03860480 754 766 B-Condition
deficit NCT03860480 767 774 I-Condition
or NCT03860480 775 777 B-Or
psychiatric NCT03860480 778 789 B-Condition
illness NCT03860480 790 797 I-Condition

- NCT03860480 800 801 O
Severe NCT03860480 803 809 O
cardiovascular NCT03860480 810 824 B-Condition
disease NCT03860480 825 832 I-Condition

- NCT03860480 835 836 O
Liver NCT03860480 838 843 B-Condition
failure NCT03860480 844 851 I-Condition

- NCT03860480 854 855 O
Renal NCT03860480 857 862 B-Condition
failure NCT03860480 863 870 I-Condition
( NCT03860480 871 872 O
estimated NCT03860480 873 882 B-Observation
glomerular NCT03860480 883 893 I-Observation
filtration NCT03860480 894 904 I-Observation
rate NCT03860480 905 909 I-Observation
< NCT03860480 910 911 B-Eq-Comparison
15 NCT03860480 912 914 I-Eq-Comparison
mL NCT03860480 915 917 I-Eq-Comparison
/ NCT03860480 918 919 I-Eq-Comparison
min NCT03860480 920 923 I-Eq-Comparison
/ NCT03860480 924 925 I-Eq-Comparison
1.73 NCT03860480 926 930 I-Eq-Comparison
m2 NCT03860480 931 933 I-Eq-Comparison
) NCT03860480 934 935 O

- NCT03860480 939 940 O
Pregnancy NCT03860480 942 951 B-Condition

Exclusion NCT03860480 952 961 O
Criteria NCT03860480 962 970 O
: NCT03860480 971 972 O

- NCT03860480 976 977 O
Peri NCT03860480 979 983 B-Temporal-Connection___Temporal-Connection-Type-Value:during
operative NCT03860480 984 993 B-Procedure
conversion NCT03860480 994 1004 B-Modifier
to NCT03860480 1005 1007 O
thoracotomy NCT03860480 1008 1019 B-Procedure

- NCT03860480 1022 1023 O
Severe NCT03860480 1025 1031 O
intra NCT03860480 1032 1037 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03860480 1038 1039 I-Temporal-Connection___Temporal-Connection-Type-Value:during
or NCT03860480 1040 1042 B-Or
post NCT03860480 1043 1047 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03860480 1048 1057 B-Procedure
bleeding NCT03860480 1058 1066 B-Condition

- NCT03860480 1069 1070 O
Patients NCT03860480 1072 1080 O
requiring NCT03860480 1081 1090 B-Assertion___Assertion-Type-Value:hypothetical
post NCT03860480 1091 1095 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03860480 1096 1105 B-Procedure
mechanical NCT03860480 1106 1116 B-Procedure
ventilation NCT03860480 1117 1128 I-Procedure

- NCT03860480 1131 1132 O
Technical NCT03860480 1134 1143 O
inability NCT03860480 1144 1153 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860480 1154 1156 O
proceed NCT03860480 1157 1164 O
with NCT03860480 1165 1169 O
the NCT03860480 1170 1173 O
blocks NCT03860480 1174 1180 O

Inclusion NCT03868787 0 9 O
Criteria NCT03868787 10 18 O
: NCT03868787 19 20 O

1 NCT03868787 24 25 O
. NCT03868787 25 26 O
Women NCT03868787 28 33 O
≥ NCT03868787 34 35 B-Eq-Comparison
18 NCT03868787 36 38 I-Eq-Comparison
years NCT03868787 39 44 I-Eq-Comparison
of NCT03868787 45 47 O
age NCT03868787 48 51 B-Age

2 NCT03868787 54 55 O
. NCT03868787 55 56 O
Gestational NCT03868787 58 69 B-Observation
age NCT03868787 70 73 I-Observation
between NCT03868787 74 81 B-Eq-Comparison
14 NCT03868787 82 84 I-Eq-Comparison
weeks NCT03868787 85 90 I-Eq-Comparison
and NCT03868787 91 94 I-Eq-Comparison
23 NCT03868787 95 97 I-Eq-Comparison
weeks NCT03868787 98 103 I-Eq-Comparison
6 NCT03868787 104 105 I-Eq-Comparison
days NCT03868787 106 110 I-Eq-Comparison

3 NCT03868787 113 114 O
. NCT03868787 114 115 O
Willing NCT03868787 117 124 O
and NCT03868787 125 128 O
able NCT03868787 129 133 O
to NCT03868787 134 136 O
sign NCT03868787 137 141 O
an NCT03868787 142 144 O
informed NCT03868787 145 153 O
consent NCT03868787 154 161 O
in NCT03868787 162 164 O
English NCT03868787 165 172 O

4 NCT03868787 175 176 O
. NCT03868787 176 177 O
No NCT03868787 179 181 B-Negation
contraindications NCT03868787 182 199 B-Contraindication
to NCT03868787 200 202 O
TENS NCT03868787 203 207 B-Procedure

Exclusion NCT03868787 208 217 O
Criteria NCT03868787 218 226 O
: NCT03868787 227 228 O

1 NCT03868787 232 233 O
. NCT03868787 233 234 O
Incarceration NCT03868787 236 249 B-Observation

2 NCT03868787 252 253 O
. NCT03868787 253 254 O
Preterm NCT03868787 256 263 B-Condition
Premature NCT03868787 264 273 I-Condition
Rupture NCT03868787 274 281 I-Condition
of NCT03868787 282 284 O
Membranes NCT03868787 285 294 B-Modifier
or NCT03868787 295 297 B-Or
evidence NCT03868787 298 306 O
of NCT03868787 307 309 O
intra NCT03868787 310 315 B-Modifier
- NCT03868787 316 317 I-Modifier
amniotic NCT03868787 318 326 I-Modifier
infection NCT03868787 327 336 B-Condition

3 NCT03868787 339 340 O
. NCT03868787 340 341 O
Presence NCT03868787 343 351 O
of NCT03868787 352 354 O
implanted NCT03868787 355 364 B-Procedure
cardiac NCT03868787 365 372 I-Procedure
device NCT03868787 373 379 I-Procedure

4 NCT03868787 382 383 O
. NCT03868787 383 384 O
Lack NCT03868787 386 390 B-Negation
of NCT03868787 391 393 O
sensation NCT03868787 394 403 B-Condition
to NCT03868787 404 406 I-Condition
touch NCT03868787 407 412 I-Condition
on NCT03868787 413 415 O
area NCT03868787 416 420 B-Modifier
of NCT03868787 421 423 O
electrode NCT03868787 424 433 B-Procedure
placement NCT03868787 434 443 I-Procedure

5 NCT03868787 446 447 O
. NCT03868787 447 448 O
Prior NCT03868787 450 455 B-Eq-Comparison
TENS NCT03868787 456 460 B-Procedure
use NCT03868787 461 464 O

6 NCT03868787 467 468 O
. NCT03868787 468 469 O
Opioid NCT03868787 471 477 B-Condition
dependence NCT03868787 478 488 I-Condition

Inclusion NCT03860324 0 9 O
Criteria NCT03860324 10 18 O
: NCT03860324 19 20 O

- NCT03860324 24 25 O
Surgical NCT03860324 27 35 O
plan NCT03860324 36 40 B-Eq-Comparison
for NCT03860324 41 44 I-Eq-Comparison
total NCT03860324 45 50 B-Procedure
hip NCT03860324 51 54 I-Procedure
replacement NCT03860324 55 66 I-Procedure

- NCT03860324 69 70 O
Signing NCT03860324 72 79 O
of NCT03860324 80 82 O
consent NCT03860324 83 90 O
form NCT03860324 91 95 O
to NCT03860324 96 98 O
participate NCT03860324 99 110 O
in NCT03860324 111 113 O
the NCT03860324 114 117 O
study NCT03860324 118 123 O

Exclusion NCT03860324 124 133 O
Criteria NCT03860324 134 142 O
: NCT03860324 143 144 O

- NCT03860324 148 149 O
Patient NCT03860324 151 158 O
refusal NCT03860324 159 166 O

- NCT03860324 169 170 O
BMI NCT03860324 172 175 B-Observation
> NCT03860324 176 177 B-Eq-Comparison
40 NCT03860324 178 180 I-Eq-Comparison
kg NCT03860324 181 183 I-Eq-Comparison
/ NCT03860324 184 185 I-Eq-Comparison
m2 NCT03860324 186 188 I-Eq-Comparison

- NCT03860324 191 192 O
Surgical NCT03860324 194 202 O
plan NCT03860324 203 207 B-Eq-Comparison
for NCT03860324 208 211 I-Eq-Comparison
revision NCT03860324 212 220 B-Modifier
of NCT03860324 221 223 O
hip NCT03860324 224 227 B-Procedure
replacement NCT03860324 228 239 I-Procedure

- NCT03860324 242 243 O
Patient NCT03860324 245 252 O
unable NCT03860324 253 259 B-Negation
to NCT03860324 260 262 O
quantify NCT03860324 263 271 O
pain NCT03860324 272 276 B-Condition|Observation
level NCT03860324 277 282 O

- NCT03860324 285 286 O
Chronic NCT03860324 288 295 B-Modifier
kidney NCT03860324 296 302 B-Condition
disease NCT03860324 303 310 I-Condition
with NCT03860324 311 315 B-And
a NCT03860324 316 317 O
Glomerular NCT03860324 318 328 B-Observation
Filtration NCT03860324 329 339 I-Observation
Rate NCT03860324 340 344 I-Observation
< NCT03860324 345 346 B-Eq-Comparison
50 NCT03860324 347 349 I-Eq-Comparison
ml NCT03860324 350 352 I-Eq-Comparison
/ NCT03860324 353 354 I-Eq-Comparison
min NCT03860324 355 358 I-Eq-Comparison

- NCT03860324 361 362 O
Previously NCT03860324 364 374 B-Eq-Comparison
medicated NCT03860324 375 384 B-Procedure
with NCT03860324 385 389 O
opioids NCT03860324 390 397 B-Drug

- NCT03860324 400 401 O
Patient NCT03860324 403 410 O
unable NCT03860324 411 417 B-Negation
to NCT03860324 418 420 O
perform NCT03860324 421 428 O
the NCT03860324 429 432 B-Coreference
surgery NCT03860324 433 440 I-Coreference|Procedure
with NCT03860324 441 445 O
spinal NCT03860324 446 452 B-Procedure
block NCT03860324 453 458 I-Procedure

- NCT03860324 461 462 O
Allergy NCT03860324 464 471 B-Allergy
to NCT03860324 472 474 O
local NCT03860324 475 480 B-Procedure
anesthetics NCT03860324 481 492 I-Procedure

- NCT03860324 495 496 O
Infection NCT03860324 498 507 B-Condition
in NCT03860324 508 510 O
the NCT03860324 511 514 O
site NCT03860324 515 519 B-Modifier
of NCT03860324 520 522 O
the NCT03860324 523 526 O
Erector NCT03860324 527 534 B-Modifier
Spinae NCT03860324 535 541 I-Modifier
Plane NCT03860324 542 547 I-Modifier
or NCT03860324 548 550 B-Or
Fascia NCT03860324 551 557 B-Modifier
Iliaca NCT03860324 558 564 I-Modifier
block NCT03860324 565 570 I-Modifier

- NCT03860324 573 574 O
Allergy NCT03860324 576 583 B-Allergy
or NCT03860324 584 586 B-Or
contraindication NCT03860324 587 603 B-Contraindication
to NCT03860324 604 606 O
the NCT03860324 607 610 O
use NCT03860324 611 614 O
of NCT03860324 615 617 O
morphine NCT03860324 618 626 B-Drug

Inclusion NCT03863639 0 9 O
Criteria NCT03863639 10 18 O
: NCT03863639 19 20 O
Severe NCT03863639 21 27 O
Pre NCT03863639 28 31 B-Condition
- NCT03863639 32 33 I-Condition
Eclampsia NCT03863639 34 43 I-Condition
defined NCT03863639 44 51 O
by NCT03863639 52 54 O

- NCT03863639 57 58 O
Symptoms NCT03863639 60 68 B-Assertion___Assertion-Type-Value:possible
of NCT03863639 69 71 O
central NCT03863639 72 79 B-Condition
nervous NCT03863639 80 87 I-Condition
system NCT03863639 88 94 I-Condition
dysfunction NCT03863639 95 106 I-Condition
( NCT03863639 107 108 O
New NCT03863639 109 112 B-Eq-Comparison
onset NCT03863639 113 118 I-Eq-Comparison
cerebral NCT03863639 119 127 B-Modifier
or NCT03863639 128 130 B-Or
visual NCT03863639 131 137 B-Modifier
disturbance NCT03863639 138 149 B-Condition
, NCT03863639 150 151 O
such NCT03863639 152 156 O
as NCT03863639 157 159 O
: NCT03863639 160 161 O
Photopsia NCT03863639 162 171 B-Condition
, NCT03863639 172 173 O
scotomata NCT03863639 174 183 B-Condition
, NCT03863639 184 185 O
cortical NCT03863639 186 194 B-Condition
blindness NCT03863639 195 204 I-Condition
, NCT03863639 205 206 O
retinal NCT03863639 207 214 B-Condition
vasospasm NCT03863639 215 224 I-Condition
) NCT03863639 225 226 O

- NCT03863639 230 231 O
Severe NCT03863639 233 239 O
headache NCT03863639 240 248 B-Condition
( NCT03863639 249 250 O
ie NCT03863639 251 253 O
, NCT03863639 254 255 O
incapacitating NCT03863639 256 270 B-Condition
, NCT03863639 271 272 O
" NCT03863639 273 274 O
the NCT03863639 274 277 O
worst NCT03863639 278 283 O
headache NCT03863639 284 292 B-Condition
I NCT03863639 293 294 O
've NCT03863639 294 297 O
ever NCT03863639 298 302 O
had NCT03863639 303 306 O
" NCT03863639 306 307 O
) NCT03863639 308 309 O
or NCT03863639 310 312 B-Or
headache NCT03863639 313 321 B-Condition
that NCT03863639 322 326 O
persists NCT03863639 327 335 B-Modifier
and NCT03863639 336 339 B-And
progresses NCT03863639 340 350 B-Modifier
despite NCT03863639 351 358 O
analgesic NCT03863639 359 368 B-Procedure
therapy NCT03863639 369 376 I-Procedure

- NCT03863639 379 380 O
Altered NCT03863639 382 389 B-Condition
mental NCT03863639 390 396 I-Condition
status NCT03863639 397 403 I-Condition

- NCT03863639 406 407 O
Hepatic NCT03863639 409 416 B-Condition
abnormality NCT03863639 417 428 O
( NCT03863639 429 430 O
Severe NCT03863639 431 437 O
persistent NCT03863639 438 448 B-Modifier
right NCT03863639 449 454 I-Modifier
upper NCT03863639 455 460 B-Modifier
quadrant NCT03863639 461 469 I-Modifier
or NCT03863639 470 472 B-Or
epigastric NCT03863639 473 483 B-Modifier
pain NCT03863639 484 488 B-Condition
unresponsive NCT03863639 489 501 O
to NCT03863639 502 504 O
medication NCT03863639 505 515 B-Drug
and NCT03863639 516 519 B-And
not NCT03863639 520 523 B-Negation
accounted NCT03863639 524 533 O
for NCT03863639 534 537 O
by NCT03863639 538 540 O
an NCT03863639 541 543 O
alternative NCT03863639 544 555 B-Other
diagnosis NCT03863639 556 565 B-Condition
or NCT03863639 566 568 B-Or
serum NCT03863639 569 574 B-Observation
transaminase NCT03863639 575 587 I-Observation
concentration NCT03863639 588 601 I-Observation
≥ NCT03863639 602 603 B-Eq-Comparison
twice NCT03863639 604 609 I-Eq-Comparison
normal NCT03863639 610 616 I-Eq-Comparison
, NCT03863639 617 618 O
or NCT03863639 619 621 O
both NCT03863639 622 626 O
) NCT03863639 627 628 O

- NCT03863639 632 633 O
Severe NCT03863639 635 641 O
blood NCT03863639 642 647 B-Observation
pressure NCT03863639 648 656 I-Observation
elevation NCT03863639 657 666 O
( NCT03863639 667 668 O
Systolic NCT03863639 669 677 B-Observation
blood NCT03863639 678 683 I-Observation
pressure NCT03863639 684 692 I-Observation
≥ NCT03863639 693 694 B-Eq-Comparison
160 NCT03863639 695 698 I-Eq-Comparison
mmHg NCT03863639 699 703 I-Eq-Comparison
or NCT03863639 704 706 B-Or
diastolic NCT03863639 707 716 B-Observation
blood NCT03863639 717 722 I-Observation
pressure NCT03863639 723 731 I-Observation
≥ NCT03863639 732 733 B-Eq-Comparison
110 NCT03863639 734 737 I-Eq-Comparison
mmHg NCT03863639 738 742 I-Eq-Comparison
on NCT03863639 743 745 O
two NCT03863639 746 749 B-Eq-Comparison
occasions NCT03863639 750 759 I-Eq-Comparison
at NCT03863639 760 762 B-Eq-Comparison
least NCT03863639 763 768 I-Eq-Comparison
four NCT03863639 769 773 I-Eq-Comparison
hours NCT03863639 774 779 I-Eq-Comparison
apart NCT03863639 780 785 I-Eq-Comparison
while NCT03863639 786 791 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863639 792 795 I-Temporal-Connection___Temporal-Connection-Type-Value:during
patient NCT03863639 796 803 I-Temporal-Connection___Temporal-Connection-Type-Value:during
is NCT03863639 804 806 I-Temporal-Connection___Temporal-Connection-Type-Value:during
on NCT03863639 807 809 I-Temporal-Connection___Temporal-Connection-Type-Value:during
bedrest NCT03863639 810 817 B-Encounter
( NCT03863639 818 819 O
unless NCT03863639 820 826 B-Exception
the NCT03863639 827 830 O
patient NCT03863639 831 838 O
is NCT03863639 839 841 O
on NCT03863639 842 844 O
antihypertensive NCT03863639 845 861 B-Procedure
therapy NCT03863639 862 869 I-Procedure
) NCT03863639 870 871 O
) NCT03863639 873 874 O

- NCT03863639 878 879 O
Thrombocytopenia NCT03863639 881 897 B-Condition
( NCT03863639 898 899 O
< NCT03863639 901 902 B-Eq-Comparison
100 NCT03863639 903 906 I-Eq-Comparison
, NCT03863639 907 908 I-Eq-Comparison
000 NCT03863639 909 912 I-Eq-Comparison
platelets NCT03863639 913 922 I-Eq-Comparison|Observation
/ NCT03863639 923 924 I-Eq-Comparison
microL NCT03863639 925 931 I-Eq-Comparison
) NCT03863639 932 933 O

- NCT03863639 937 938 O
Renal NCT03863639 940 945 B-Condition
abnormality NCT03863639 946 957 O
( NCT03863639 958 959 O
Progressive NCT03863639 960 971 B-Condition
renal NCT03863639 972 977 I-Condition
insufficiency NCT03863639 978 991 I-Condition
( NCT03863639 992 993 O
serum NCT03863639 994 999 B-Observation
creatinine NCT03863639 1000 1010 I-Observation
> NCT03863639 1011 1012 B-Eq-Comparison
1.1 NCT03863639 1013 1016 I-Eq-Comparison
mg NCT03863639 1017 1019 I-Eq-Comparison
/ NCT03863639 1020 1021 I-Eq-Comparison
dL NCT03863639 1022 1024 I-Eq-Comparison
or NCT03863639 1025 1027 B-Or
doubling NCT03863639 1028 1036 B-Eq-Comparison
of NCT03863639 1037 1039 O
serum NCT03863639 1040 1045 B-Observation
creatinine NCT03863639 1046 1056 I-Observation
concentration NCT03863639 1057 1070 I-Observation
in NCT03863639 1071 1073 B-And
the NCT03863639 1074 1077 I-And
absence NCT03863639 1078 1085 B-Negation
of NCT03863639 1086 1088 O
other NCT03863639 1089 1094 B-Other
renal NCT03863639 1095 1100 B-Condition
disease NCT03863639 1101 1108 I-Condition
) NCT03863639 1109 1110 O
) NCT03863639 1112 1113 O

- NCT03863639 1117 1118 O
Pulmonary NCT03863639 1120 1129 B-Condition
edema NCT03863639 1130 1135 I-Condition

15 NCT03863639 1141 1143 O
English NCT03863639 1144 1151 O
- NCT03863639 1152 1153 O
speaking NCT03863639 1154 1162 O
pregnant NCT03863639 1163 1171 B-Condition
controls NCT03863639 1172 1180 O
with NCT03863639 1181 1185 B-And
uncomplicated NCT03863639 1186 1199 B-Modifier
pregnancy NCT03863639 1200 1209 B-Condition
matched NCT03863639 1210 1217 O
by NCT03863639 1218 1220 O
age NCT03863639 1221 1224 O
and NCT03863639 1225 1228 O
gestational NCT03863639 1229 1240 B-Observation
age NCT03863639 1241 1244 I-Observation
will NCT03863639 1245 1249 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03863639 1250 1252 I-Assertion___Assertion-Type-Value:hypothetical
enrolled NCT03863639 1253 1261 B-Study
from NCT03863639 1262 1266 O
the NCT03863639 1267 1270 O
antenatal NCT03863639 1271 1280 O
clinic NCT03863639 1281 1287 O
or NCT03863639 1288 1290 B-Or
the NCT03863639 1291 1294 O
labor NCT03863639 1295 1300 O
ward NCT03863639 1301 1305 O
. NCT03863639 1306 1307 O

Exclusion NCT03863639 1309 1318 O
Criteria NCT03863639 1319 1327 O
: NCT03863639 1328 1329 O

- NCT03863639 1333 1334 O
History NCT03863639 1336 1343 B-Eq-Comparison
of NCT03863639 1344 1346 O
symptomatic NCT03863639 1347 1358 B-Assertion___Assertion-Type-Value:possible
cerebrovascular NCT03863639 1359 1374 B-Condition
disease NCT03863639 1375 1382 I-Condition
with NCT03863639 1383 1387 B-And
substantial NCT03863639 1388 1399 O
residual NCT03863639 1400 1408 B-Condition
deficit NCT03863639 1409 1416 I-Condition

- NCT03863639 1419 1420 O
History NCT03863639 1422 1429 B-Eq-Comparison
of NCT03863639 1430 1432 O
alcoholism NCT03863639 1433 1443 B-Condition

- NCT03863639 1446 1447 O
History NCT03863639 1449 1456 B-Eq-Comparison
of NCT03863639 1457 1459 O
psychiatric NCT03863639 1460 1471 B-Condition
illness NCT03863639 1472 1479 I-Condition

- NCT03863639 1482 1483 O
History NCT03863639 1485 1492 B-Eq-Comparison
of NCT03863639 1493 1495 O
claustrophobia NCT03863639 1496 1510 B-Condition

- NCT03863639 1513 1514 O
Renal NCT03863639 1516 1521 B-Condition
failure NCT03863639 1522 1529 I-Condition
( NCT03863639 1530 1531 O
creatinine NCT03863639 1532 1542 B-Observation
> NCT03863639 1543 1544 B-Eq-Comparison
2.0 NCT03863639 1545 1548 I-Eq-Comparison
mg NCT03863639 1549 1551 I-Eq-Comparison
/ NCT03863639 1552 1553 I-Eq-Comparison
dl NCT03863639 1554 1556 I-Eq-Comparison
) NCT03863639 1557 1558 O

- NCT03863639 1562 1563 O
Patients NCT03863639 1565 1573 O
with NCT03863639 1574 1578 O
less NCT03863639 1579 1583 B-Eq-Comparison
than NCT03863639 1584 1588 I-Eq-Comparison
a NCT03863639 1589 1590 I-Eq-Comparison
7 NCT03863639 1591 1592 I-Eq-Comparison
th NCT03863639 1593 1595 I-Eq-Comparison
grade NCT03863639 1596 1601 I-Eq-Comparison
education NCT03863639 1602 1611 B-Observation
or NCT03863639 1612 1614 B-Or
unable NCT03863639 1615 1621 B-Condition
to NCT03863639 1622 1624 I-Condition
read NCT03863639 1625 1629 I-Condition
and NCT03863639 1630 1633 O
thus NCT03863639 1634 1638 O
unable NCT03863639 1639 1645 B-Assertion___Assertion-Type-Value:hypothetical|Negation
complete NCT03863639 1646 1654 O
the NCT03863639 1655 1658 O
neuropsychological NCT03863639 1659 1677 B-Procedure
testing NCT03863639 1678 1685 I-Procedure

- NCT03863639 1688 1689 O
Patients NCT03863639 1691 1699 O
with NCT03863639 1700 1704 O
bodily NCT03863639 1705 1711 B-Procedure
implants NCT03863639 1712 1720 I-Procedure
unsafe NCT03863639 1721 1727 B-Contraindication
for NCT03863639 1728 1731 O
MRI NCT03863639 1732 1735 B-Procedure
use NCT03863639 1736 1739 O

Inclusion NCT03867305 0 9 O
Criteria NCT03867305 10 18 O
: NCT03867305 19 20 O

- NCT03867305 24 25 O
Patient NCT03867305 27 34 O
requiring NCT03867305 35 44 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03867305 45 46 O
first NCT03867305 47 52 B-Eq-Comparison
total NCT03867305 53 58 B-Procedure
knee NCT03867305 59 63 I-Procedure
prosthesis NCT03867305 64 74 I-Procedure
( NCT03867305 75 76 O
scheduled NCT03867305 77 86 B-Eq-Comparison
between NCT03867305 87 94 I-Eq-Comparison
Tuesday NCT03867305 95 102 I-Eq-Comparison
and NCT03867305 103 106 I-Eq-Comparison
Friday NCT03867305 107 113 I-Eq-Comparison
) NCT03867305 114 115 O
. NCT03867305 117 118 O

- NCT03867305 122 123 O
Patient NCT03867305 125 132 O
that NCT03867305 133 137 O
has NCT03867305 138 141 O
given NCT03867305 142 147 O
his NCT03867305 148 151 O
/ NCT03867305 152 153 O
her NCT03867305 154 157 O
free NCT03867305 158 162 O
and NCT03867305 163 166 O
informed NCT03867305 167 175 O
consent NCT03867305 176 183 O
and NCT03867305 184 187 O
signed NCT03867305 188 194 O
the NCT03867305 195 198 O
consent NCT03867305 199 206 O
form NCT03867305 207 211 O
. NCT03867305 212 213 O

- NCT03867305 217 218 O
The NCT03867305 220 223 O
patient NCT03867305 224 231 O
must NCT03867305 232 236 O
be NCT03867305 237 239 O
a NCT03867305 240 241 O
member NCT03867305 242 248 O
or NCT03867305 249 251 O
beneficiary NCT03867305 252 263 O
of NCT03867305 264 266 O
a NCT03867305 267 268 O
health NCT03867305 269 275 O
insurance NCT03867305 276 285 O
plan NCT03867305 286 290 O

- NCT03867305 293 294 O
The NCT03867305 296 299 O
patient NCT03867305 300 307 O
is NCT03867305 308 310 O
at NCT03867305 311 313 B-Eq-Comparison
least NCT03867305 314 319 I-Eq-Comparison
18 NCT03867305 320 322 I-Eq-Comparison
years NCT03867305 323 328 I-Eq-Comparison
old NCT03867305 329 332 B-Age
( NCT03867305 333 334 O
≥ NCT03867305 336 337 O
) NCT03867305 339 340 O
and NCT03867305 341 344 B-And
under NCT03867305 345 350 B-Eq-Comparison
90 NCT03867305 351 353 I-Eq-Comparison
years NCT03867305 354 359 I-Eq-Comparison
old NCT03867305 360 363 O
( NCT03867305 364 365 O
< NCT03867305 367 368 O
) NCT03867305 370 371 O
. NCT03867305 373 374 O

Exclusion NCT03867305 376 385 O
Criteria NCT03867305 386 394 O
: NCT03867305 395 396 O

- NCT03867305 400 401 O
The NCT03867305 403 406 O
subject NCT03867305 407 414 O
is NCT03867305 415 417 O
in NCT03867305 418 420 O
a NCT03867305 421 422 O
period NCT03867305 423 429 O
of NCT03867305 430 432 O
exclusion NCT03867305 433 442 O
determined NCT03867305 443 453 O
by NCT03867305 454 456 O
a NCT03867305 457 458 O
previous NCT03867305 459 467 B-Eq-Comparison
study NCT03867305 468 473 B-Study
( NCT03867305 474 475 O
therapeutic NCT03867305 476 487 B-Procedure
study NCT03867305 488 493 B-Study
) NCT03867305 494 495 O

- NCT03867305 499 500 O
The NCT03867305 502 505 O
subject NCT03867305 506 513 O
refuses NCT03867305 514 521 O
to NCT03867305 522 524 O
sign NCT03867305 525 529 O
the NCT03867305 530 533 O
consent NCT03867305 534 541 O

- NCT03867305 544 545 O
It NCT03867305 547 549 O
is NCT03867305 550 552 O
impossible NCT03867305 553 563 O
to NCT03867305 564 566 O
give NCT03867305 567 571 O
the NCT03867305 572 575 O
subject NCT03867305 576 583 O
informed NCT03867305 584 592 O
information NCT03867305 593 604 O

- NCT03867305 607 608 O
The NCT03867305 610 613 O
patient NCT03867305 614 621 O
is NCT03867305 622 624 O
under NCT03867305 625 630 B-Observation
safeguard NCT03867305 631 640 I-Observation
of NCT03867305 641 643 I-Observation
justice NCT03867305 644 651 I-Observation
or NCT03867305 652 654 B-Or
state NCT03867305 655 660 B-Observation
guardianship NCT03867305 661 673 I-Observation

- NCT03867305 676 677 O
The NCT03867305 679 682 O
patient NCT03867305 683 690 O
is NCT03867305 691 693 O
pregnant NCT03867305 694 702 B-Condition
or NCT03867305 703 705 B-Or
breastfeeding NCT03867305 706 719 B-Condition

- NCT03867305 722 723 O
The NCT03867305 725 728 O
patient NCT03867305 729 736 O
is NCT03867305 737 739 O
allergic NCT03867305 740 748 B-Allergy
to NCT03867305 749 751 O
latex NCT03867305 752 757 O
bandages NCT03867305 758 766 O
. NCT03867305 767 768 O

- NCT03867305 772 773 O
The NCT03867305 775 778 O
subject NCT03867305 779 786 O
has NCT03867305 787 790 O
contralateral NCT03867305 791 804 B-Condition
amputation NCT03867305 805 815 I-Condition
, NCT03867305 816 817 O
pressure NCT03867305 818 826 B-Condition
ulcers NCT03867305 827 833 I-Condition
, NCT03867305 834 835 O
severe NCT03867305 836 842 O
Obstructive NCT03867305 843 854 B-Condition
Arteriopathy NCT03867305 855 867 I-Condition
of NCT03867305 868 870 O
Lower NCT03867305 871 876 B-Modifier
Limbs NCT03867305 877 882 I-Modifier
, NCT03867305 883 884 O
lymphoedema NCT03867305 885 896 B-Modifier
or NCT03867305 897 899 B-Or
thromboembolic NCT03867305 900 914 B-Condition
event NCT03867305 915 920 I-Condition
of NCT03867305 921 923 O
the NCT03867305 924 927 O
lower NCT03867305 928 933 B-Modifier
limb NCT03867305 934 938 I-Modifier
( NCT03867305 939 940 O
ipsilateral NCT03867305 941 952 B-Modifier
and NCT03867305 953 956 B-Or
/ NCT03867305 957 958 I-Or
or NCT03867305 959 961 I-Or
contralateral NCT03867305 962 975 B-Modifier
/ NCT03867305 976 977 B-Or
superficial NCT03867305 978 989 B-Modifier
or NCT03867305 990 992 B-Or
deep NCT03867305 993 997 B-Modifier
or NCT03867305 998 1000 B-Or
detected NCT03867305 1001 1009 O
by NCT03867305 1010 1012 O
post NCT03867305 1013 1017 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03867305 1018 1027 B-Procedure
Doppler NCT03867305 1028 1035 B-Procedure
) NCT03867305 1036 1037 O
. NCT03867305 1039 1040 O

- NCT03867305 1044 1045 O
The NCT03867305 1047 1050 O
subject NCT03867305 1051 1058 O
has NCT03867305 1059 1062 O
chronic NCT03867305 1063 1070 B-Modifier
or NCT03867305 1071 1073 B-Or
active NCT03867305 1074 1080 B-Eq-Comparison
wounds NCT03867305 1081 1087 B-Condition
or NCT03867305 1088 1090 B-Or
any NCT03867305 1091 1094 O
cause NCT03867305 1095 1100 B-Condition
that NCT03867305 1101 1105 O
hinders NCT03867305 1106 1113 B-Assertion___Assertion-Type-Value:hypothetical
normal NCT03867305 1114 1120 O
rehabilitation NCT03867305 1121 1135 B-Procedure
or NCT03867305 1136 1138 B-Or
the NCT03867305 1139 1142 O
application NCT03867305 1143 1154 O
of NCT03867305 1155 1157 O
a NCT03867305 1158 1159 O
bandage NCT03867305 1160 1167 B-Procedure
. NCT03867305 1168 1169 O

- NCT03867305 1173 1174 O
patient NCT03867305 1176 1183 O
with NCT03867305 1184 1188 O
a NCT03867305 1189 1190 O
stroke NCT03867305 1191 1197 B-Condition
/ NCT03867305 1198 1199 B-Or
Disabling NCT03867305 1200 1209 B-Modifier
Neurological NCT03867305 1210 1222 B-Condition
Pathology NCT03867305 1223 1232 I-Condition
, NCT03867305 1233 1234 O
Chronic NCT03867305 1235 1242 B-Modifier
Immunological NCT03867305 1243 1256 B-Condition
Pathology NCT03867305 1257 1266 I-Condition
/ NCT03867305 1267 1268 B-Or
Systemic NCT03867305 1269 1277 B-Modifier
Disease NCT03867305 1278 1285 B-Condition
. NCT03867305 1286 1287 O

- NCT03867305 1291 1292 O
patient NCT03867305 1294 1301 O
with NCT03867305 1302 1306 O
Hepatic NCT03867305 1307 1314 B-Condition
insufficiency NCT03867305 1315 1328 I-Condition
. NCT03867305 1329 1330 O

- NCT03867305 1334 1335 O
patient NCT03867305 1337 1344 O
with NCT03867305 1345 1349 O
Venous NCT03867305 1350 1356 B-Condition
insufficiency NCT03867305 1357 1370 I-Condition
( NCT03867305 1371 1372 O
stages NCT03867305 1373 1379 B-Eq-Comparison
3 NCT03867305 1380 1381 I-Eq-Comparison
and NCT03867305 1382 1385 I-Eq-Comparison
4 NCT03867305 1386 1387 I-Eq-Comparison
) NCT03867305 1388 1389 O
. NCT03867305 1391 1392 O

- NCT03867305 1396 1397 O
The NCT03867305 1399 1402 O
patient NCT03867305 1403 1410 O
is NCT03867305 1411 1413 O
on NCT03867305 1414 1416 B-Eq-Comparison
dialysis NCT03867305 1417 1425 B-Procedure
. NCT03867305 1426 1427 O

- NCT03867305 1431 1432 O
The NCT03867305 1434 1437 O
subject NCT03867305 1438 1445 O
has NCT03867305 1446 1449 O
cognitive NCT03867305 1450 1459 B-Modifier
or NCT03867305 1460 1462 B-Or
behavioral NCT03867305 1463 1473 B-Modifier
disorders NCT03867305 1474 1483 B-Condition
( NCT03867305 1484 1485 O
Parkinson NCT03867305 1486 1495 B-Condition
's NCT03867305 1495 1497 I-Condition
disease NCT03867305 1498 1505 I-Condition
, NCT03867305 1506 1507 O
cerebellar NCT03867305 1508 1518 B-Condition
syndrome NCT03867305 1519 1527 I-Condition
, NCT03867305 1528 1529 O
opposition NCT03867305 1530 1540 B-Condition
, NCT03867305 1541 1542 O
agitation NCT03867305 1543 1552 B-Condition
, NCT03867305 1553 1554 O
dementia NCT03867305 1555 1563 B-Condition
) NCT03867305 1564 1565 O
. NCT03867305 1567 1568 O

- NCT03867305 1572 1573 O
The NCT03867305 1575 1578 O
subject NCT03867305 1579 1586 O
has NCT03867305 1587 1590 O
a NCT03867305 1591 1592 O
history NCT03867305 1593 1600 B-Eq-Comparison
of NCT03867305 1601 1603 O
knee NCT03867305 1604 1608 B-Procedure
surgery NCT03867305 1609 1616 I-Procedure
. NCT03867305 1616 1617 O

Inclusion NCT03864354 0 9 O
Criteria NCT03864354 10 18 O
: NCT03864354 19 20 O

- NCT03864354 24 25 O
18 NCT03864354 27 29 B-Eq-Comparison
years NCT03864354 30 35 I-Eq-Comparison
of NCT03864354 36 38 I-Eq-Comparison
age NCT03864354 39 42 I-Age|Eq-Comparison
or NCT03864354 43 45 I-Eq-Comparison
older NCT03864354 46 51 I-Eq-Comparison

- NCT03864354 54 55 O
previously NCT03864354 57 67 B-Eq-Comparison
diagnosed NCT03864354 68 77 O
with NCT03864354 78 82 O
asthma NCT03864354 83 89 B-Condition

Exclusion NCT03864354 90 99 O
Criteria NCT03864354 100 108 O
: NCT03864354 109 110 O

- NCT03864354 114 115 O
Current NCT03864354 117 124 B-Eq-Comparison
smoker NCT03864354 125 131 B-Condition

- NCT03864354 134 135 O
Diagnosed NCT03864354 137 146 O
with NCT03864354 147 151 O
any NCT03864354 152 155 O
other NCT03864354 156 161 B-Other
respiratory NCT03864354 162 173 B-Condition
disease NCT03864354 174 181 I-Condition
besides NCT03864354 182 189 B-Exception
asthma NCT03864354 190 196 B-Condition

- NCT03864354 199 200 O
Receiving NCT03864354 202 211 B-Eq-Comparison
OMM NCT03864354 212 215 B-Drug
from NCT03864354 216 220 O
a NCT03864354 221 222 O
licensed NCT03864354 223 231 O
physician NCT03864354 232 241 B-Provider
, NCT03864354 242 243 O
chiropractic NCT03864354 244 256 B-Procedure
treatment NCT03864354 257 266 I-Procedure
, NCT03864354 267 268 O
or NCT03864354 269 271 B-Or
massage NCT03864354 272 279 B-Procedure
therapy NCT03864354 280 287 I-Procedure
for NCT03864354 288 291 O
30 NCT03864354 292 294 B-Eq-Comparison
days NCT03864354 295 299 I-Eq-Comparison
prior NCT03864354 300 305 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864354 306 308 I-Temporal-Connection___Temporal-Connection-Type-Value:before
and NCT03864354 309 312 B-Or
during NCT03864354 313 319 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864354 320 323 O
study NCT03864354 324 329 B-Study

Inclusion NCT03864432 0 9 O
Criteria NCT03864432 10 18 O
: NCT03864432 19 20 O

- NCT03864432 24 25 O
Healthy NCT03864432 27 34 B-Condition
male NCT03864432 35 39 O
and NCT03864432 40 43 B-Or
female NCT03864432 44 50 O
subjects NCT03864432 51 59 O
( NCT03864432 60 61 O
aged NCT03864432 62 66 B-Age
19 NCT03864432 67 69 B-Eq-Comparison
~ NCT03864432 70 71 I-Eq-Comparison
45 NCT03864432 72 74 I-Eq-Comparison
years NCT03864432 75 80 I-Eq-Comparison
at NCT03864432 81 83 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864432 84 87 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864432 88 92 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864432 93 95 O
screening NCT03864432 96 105 B-Study
) NCT03864432 106 107 O

- NCT03864432 111 112 O
Subjects NCT03864432 114 122 O
weighing NCT03864432 123 131 B-Observation
between NCT03864432 132 139 B-Eq-Comparison
50 NCT03864432 140 142 I-Eq-Comparison
kg NCT03864432 143 145 I-Eq-Comparison
( NCT03864432 146 147 I-Eq-Comparison
inclusive NCT03864432 148 157 I-Eq-Comparison
) NCT03864432 158 159 I-Eq-Comparison
and NCT03864432 160 163 I-Eq-Comparison
90 NCT03864432 164 166 I-Eq-Comparison
kg NCT03864432 167 169 I-Eq-Comparison
( NCT03864432 170 171 O
exclusive NCT03864432 172 181 O
) NCT03864432 182 183 O
, NCT03864432 185 186 O
and NCT03864432 187 190 B-And
having NCT03864432 191 197 O
a NCT03864432 198 199 O
body NCT03864432 200 204 B-Observation
mass NCT03864432 205 209 I-Observation
index NCT03864432 210 215 I-Observation
( NCT03864432 216 217 O
BMI NCT03864432 218 221 B-Observation
) NCT03864432 222 223 O
of NCT03864432 224 226 O
17.1 NCT03864432 227 231 B-Eq-Comparison
～ NCT03864432 232 233 I-Eq-Comparison
25.8 NCT03864432 233 237 I-Eq-Comparison
( NCT03864432 238 239 O
inclusive NCT03864432 240 249 O
of NCT03864432 250 252 O
limits NCT03864432 253 259 O
) NCT03864432 260 261 O
. NCT03864432 263 264 O

- NCT03864432 268 269 O
Subjects NCT03864432 271 279 O
with NCT03864432 280 284 O
a NCT03864432 285 286 O
fasting NCT03864432 287 294 B-Observation
plasma NCT03864432 295 301 I-Observation
glucose NCT03864432 302 309 I-Observation
( NCT03864432 310 311 O
FPG NCT03864432 312 315 B-Observation
) NCT03864432 316 317 O
of NCT03864432 318 320 O
70 NCT03864432 321 323 B-Eq-Comparison
～ NCT03864432 324 325 I-Eq-Comparison
110 NCT03864432 325 328 I-Eq-Comparison
mg NCT03864432 329 331 I-Eq-Comparison
/ NCT03864432 332 333 I-Eq-Comparison
dL NCT03864432 334 336 I-Eq-Comparison
( NCT03864432 337 338 O
inclusive NCT03864432 339 348 O
of NCT03864432 349 351 O
limits NCT03864432 352 358 O
) NCT03864432 359 360 O
at NCT03864432 361 363 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864432 364 367 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03864432 368 372 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03864432 373 375 O
screening NCT03864432 376 385 B-Study

- NCT03864432 388 389 O
Subjects NCT03864432 391 399 O
who NCT03864432 400 403 O
are NCT03864432 404 407 O
willing NCT03864432 408 415 O
to NCT03864432 416 418 O
participate NCT03864432 419 430 O
in NCT03864432 431 433 O
the NCT03864432 434 437 O
entire NCT03864432 438 444 O
study NCT03864432 445 450 O
cycle NCT03864432 451 456 O
and NCT03864432 457 460 O
comply NCT03864432 461 467 O
with NCT03864432 468 472 O
the NCT03864432 473 476 O
study NCT03864432 477 482 O
protocol NCT03864432 483 491 O
( NCT03864432 492 493 O
including NCT03864432 494 503 O
contraception NCT03864432 504 517 O
) NCT03864432 518 519 O
. NCT03864432 520 521 O
Subjects NCT03864432 523 531 O
who NCT03864432 532 535 O
can NCT03864432 536 539 O
sign NCT03864432 540 544 O
the NCT03864432 545 548 O
written NCT03864432 549 556 O
Informed NCT03864432 557 565 O
Consent NCT03864432 566 573 O
Form NCT03864432 574 578 O
after NCT03864432 579 584 O
being NCT03864432 585 590 O
informed NCT03864432 591 599 O
of NCT03864432 600 602 O
the NCT03864432 603 606 O
study NCT03864432 607 612 O
procedures NCT03864432 613 623 O
. NCT03864432 624 625 O

Exclusion NCT03864432 627 636 O
Criteria NCT03864432 637 645 O
: NCT03864432 646 647 O

- NCT03864432 651 652 O
Those NCT03864432 654 659 O
with NCT03864432 660 664 O
a NCT03864432 665 666 O
history NCT03864432 667 674 B-Eq-Comparison
of NCT03864432 675 677 O
allergies NCT03864432 678 687 B-Allergy
including NCT03864432 688 697 O
drug NCT03864432 698 702 B-Drug
allergies NCT03864432 703 712 B-Allergy
( NCT03864432 713 714 O
aspirin NCT03864432 715 722 B-Drug
, NCT03864432 723 724 O
antibiotics NCT03864432 725 736 B-Drug
, NCT03864432 737 738 O
etc NCT03864432 739 742 O
. NCT03864432 742 743 O
) NCT03864432 744 745 O
, NCT03864432 747 748 O
or NCT03864432 749 751 B-Or
other NCT03864432 752 757 B-Other
clinically NCT03864432 758 768 O
significant NCT03864432 769 780 O
allergies NCT03864432 781 790 B-Allergy
. NCT03864432 791 792 O

- NCT03864432 796 797 O
Those NCT03864432 799 804 O
with NCT03864432 805 809 O
diseases NCT03864432 810 818 B-Condition
of NCT03864432 819 821 O
the NCT03864432 822 825 O
liver NCT03864432 826 831 B-Modifier
( NCT03864432 832 833 O
including NCT03864432 834 843 O
carriers NCT03864432 844 852 O
of NCT03864432 853 855 O
hepatitis NCT03864432 856 865 B-Condition
virus NCT03864432 866 871 I-Condition
) NCT03864432 872 873 O
, NCT03864432 875 876 O
kidney NCT03864432 877 883 B-Modifier
, NCT03864432 884 885 O
respiratory NCT03864432 886 897 B-Modifier
system NCT03864432 898 904 I-Modifier
, NCT03864432 905 906 O
endocrine NCT03864432 907 916 B-Modifier
system NCT03864432 917 923 I-Modifier
, NCT03864432 924 925 O
nervous NCT03864432 926 933 B-Modifier
system NCT03864432 934 940 I-Modifier
or NCT03864432 941 943 B-Or
immune NCT03864432 944 950 B-Modifier
system NCT03864432 951 957 I-Modifier
. NCT03864432 957 958 O
Those NCT03864432 960 965 O
with NCT03864432 966 970 O
a NCT03864432 971 972 O
medical NCT03864432 973 980 O
history NCT03864432 981 988 B-Eq-Comparison
of NCT03864432 989 991 O
hematology NCT03864432 992 1002 B-Modifier
/ NCT03864432 1003 1004 B-Or
oncology NCT03864432 1005 1013 B-Modifier
, NCT03864432 1014 1015 O
psychiatry NCT03864432 1016 1026 B-Modifier
or NCT03864432 1027 1029 B-Or
cardiovascular NCT03864432 1030 1044 B-Modifier
diseases NCT03864432 1045 1053 B-Condition
. NCT03864432 1054 1055 O

- NCT03864432 1059 1060 O
Those NCT03864432 1062 1067 O
with NCT03864432 1068 1072 O
a NCT03864432 1073 1074 O
medical NCT03864432 1075 1082 O
history NCT03864432 1083 1090 B-Eq-Comparison
of NCT03864432 1091 1093 O
gastrointestinal NCT03864432 1094 1110 B-Condition
diseases NCT03864432 1111 1119 I-Condition
( NCT03864432 1120 1121 O
ulcers NCT03864432 1122 1128 B-Condition
, NCT03864432 1129 1130 O
Crohn NCT03864432 1131 1136 B-Condition
's NCT03864432 1136 1138 I-Condition
disease NCT03864432 1139 1146 I-Condition
, NCT03864432 1147 1148 O
etc NCT03864432 1149 1152 O
. NCT03864432 1152 1153 O
) NCT03864432 1154 1155 O
or NCT03864432 1156 1158 B-Or
surgery NCT03864432 1159 1166 B-Procedure
( NCT03864432 1167 1168 O
excluding NCT03864432 1169 1178 B-Exception
simple NCT03864432 1179 1185 B-Modifier
appendectomy NCT03864432 1186 1198 B-Procedure
or NCT03864432 1199 1201 B-Or
hernia NCT03864432 1202 1208 B-Procedure
repair NCT03864432 1209 1215 I-Procedure
) NCT03864432 1216 1217 O
, NCT03864432 1219 1220 O
and NCT03864432 1221 1224 O
these NCT03864432 1225 1230 O
situations NCT03864432 1231 1241 O
can NCT03864432 1242 1245 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03864432 1246 1252 O
the NCT03864432 1253 1256 O
absorption NCT03864432 1257 1267 B-Condition
of NCT03864432 1268 1270 O
the NCT03864432 1271 1274 O
study NCT03864432 1275 1280 B-Study
drug NCT03864432 1281 1285 B-Drug
. NCT03864432 1285 1286 O

Inclusion NCT03868397 0 9 O
Criteria NCT03868397 10 18 O
: NCT03868397 19 20 O

- NCT03868397 24 25 O
older NCT03868397 27 32 I-Eq-Comparison
than NCT03868397 33 37 I-Eq-Comparison
18 NCT03868397 38 40 I-Eq-Comparison
years NCT03868397 41 46 I-Eq-Comparison

- NCT03868397 49 50 O
And NCT03868397 52 55 O
signed NCT03868397 56 62 O
informed NCT03868397 63 71 O
consent NCT03868397 72 79 O

- NCT03868397 82 83 O
And NCT03868397 85 88 O
planned NCT03868397 89 96 B-Eq-Comparison
either NCT03868397 97 103 O
a NCT03868397 104 105 O
) NCT03868397 106 107 O
liver NCT03868397 108 113 B-Procedure
transplantation NCT03868397 114 129 I-Procedure
as NCT03868397 130 132 O
a NCT03868397 133 134 O
recipient NCT03868397 135 144 B-Modifier
; NCT03868397 144 145 O
or NCT03868397 146 148 B-Or
b NCT03868397 149 150 O
) NCT03868397 151 152 O
liver NCT03868397 153 158 B-Procedure
transplantation NCT03868397 159 174 I-Procedure
as NCT03868397 175 177 O
a NCT03868397 178 179 O
donor NCT03868397 180 185 B-Modifier

Exclusion NCT03868397 186 195 O
Criteria NCT03868397 196 204 O
: NCT03868397 205 206 O

- NCT03868397 210 211 O
any NCT03868397 213 216 O
absolute NCT03868397 217 225 O
/ NCT03868397 226 227 O
relative NCT03868397 228 236 O
contraindication NCT03868397 237 253 B-Contraindication
of NCT03868397 254 256 O
contrast NCT03868397 257 265 B-Modifier
- NCT03868397 266 267 I-Modifier
enhanced NCT03868397 268 276 I-Modifier
MRI NCT03868397 277 280 B-Procedure

Inclusion NCT03869710 0 9 O
Criteria NCT03869710 10 18 O
: NCT03869710 19 20 O

- NCT03869710 24 25 O
Chronic NCT03869710 27 34 B-Modifier
neck NCT03869710 35 39 I-Modifier
pain NCT03869710 40 44 B-Condition

- NCT03869710 47 48 O
Chronic NCT03869710 50 57 B-Modifier
head NCT03869710 58 62 I-Modifier
pain NCT03869710 63 67 B-Condition

Exclusion NCT03869710 68 77 O
Criteria NCT03869710 78 86 O
: NCT03869710 87 88 O

- NCT03869710 92 93 O
previous NCT03869710 95 103 B-Eq-Comparison
surgery NCT03869710 104 111 B-Procedure
of NCT03869710 112 114 O
neck NCT03869710 115 119 B-Modifier
and NCT03869710 120 123 B-Or
head NCT03869710 124 128 B-Modifier

- NCT03869710 131 132 O
Body NCT03869710 134 138 B-Observation
Mass NCT03869710 139 143 I-Observation
Index NCT03869710 144 149 I-Observation
> NCT03869710 150 151 B-Eq-Comparison
39 NCT03869710 152 154 I-Eq-Comparison
, NCT03869710 155 156 I-Eq-Comparison
99 NCT03869710 157 159 I-Eq-Comparison

- NCT03869710 163 164 O
politrauma NCT03869710 166 176 B-Condition
patients NCT03869710 177 185 O

- NCT03869710 188 189 O
pregnancy NCT03869710 191 200 B-Condition

- NCT03869710 203 204 O
neck NCT03869710 206 210 B-Modifier
and NCT03869710 211 214 B-Or
head NCT03869710 215 219 B-Modifier
infections NCT03869710 220 230 B-Condition

Inclusion NCT03864744 0 9 O
Criteria NCT03864744 10 18 O
: NCT03864744 19 20 O

- NCT03864744 24 25 O
Subject NCT03864744 27 34 O
scheduled NCT03864744 35 44 B-Eq-Comparison
for NCT03864744 45 48 O
total NCT03864744 49 54 B-Procedure
pancreatectomy NCT03864744 55 69 I-Procedure
or NCT03864744 70 72 B-Or
pancreaticoduodenectomy NCT03864744 73 96 B-Procedure

- NCT03864744 99 100 O
Informed NCT03864744 102 110 O
consent NCT03864744 111 118 O
signed NCT03864744 119 125 O
prior NCT03864744 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03864744 132 134 I-Temporal-Connection___Temporal-Connection-Type-Value:before
any NCT03864744 135 138 O
study NCT03864744 139 144 B-Study
- NCT03864744 145 146 O
related NCT03864744 147 154 O
procedure NCT03864744 155 164 B-Procedure

Exclusion NCT03864744 165 174 O
Criteria NCT03864744 175 183 O
: NCT03864744 184 185 O

- NCT03864744 189 190 O
Known NCT03864744 192 197 O
liver NCT03864744 198 203 B-Condition
disease NCT03864744 204 211 I-Condition
before NCT03864744 212 218 B-Temporal-Connection___Temporal-Connection-Type-Value:before
total NCT03864744 219 224 B-Procedure
pancreatectomy NCT03864744 225 239 I-Procedure
or NCT03864744 240 242 B-Or
pancreaticoduodenectomy NCT03864744 243 266 B-Procedure
( NCT03864744 267 268 O
excluding NCT03864744 269 278 B-Exception
NAFLD NCT03864744 279 284 B-Condition
) NCT03864744 285 286 O

- NCT03864744 290 291 O
Severe NCT03864744 293 299 O
co NCT03864744 300 302 B-Condition
- NCT03864744 303 304 I-Condition
morbid NCT03864744 305 311 I-Condition
disease NCT03864744 312 319 I-Condition
( NCT03864744 320 321 O
besides NCT03864744 322 329 B-Exception
from NCT03864744 330 334 O
the NCT03864744 335 338 O
indication NCT03864744 339 349 B-Indication
for NCT03864744 350 353 O
the NCT03864744 354 357 O
pancreas NCT03864744 358 366 B-Procedure
surgery NCT03864744 367 374 I-Procedure
) NCT03864744 375 376 O

- NCT03864744 380 381 O
Pregnancy NCT03864744 383 392 B-Condition

- NCT03864744 395 396 O
Any NCT03864744 398 401 O
condition NCT03864744 402 411 B-Condition
that NCT03864744 412 416 O
the NCT03864744 417 420 O
investigator NCT03864744 421 433 O
feels NCT03864744 434 439 O
would NCT03864744 440 445 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864744 446 455 O
with NCT03864744 456 460 O
the NCT03864744 461 464 O
safety NCT03864744 465 471 O
of NCT03864744 472 474 O
the NCT03864744 475 478 O
trial NCT03864744 479 484 B-Study
participation NCT03864744 485 498 O
or NCT03864744 499 501 O
the NCT03864744 502 505 O
safety NCT03864744 506 512 O
of NCT03864744 513 515 O
the NCT03864744 516 519 O
subject NCT03864744 520 527 O

- NCT03864744 530 531 O
Metastatic NCT03864744 533 543 B-Condition
disease NCT03864744 544 551 I-Condition

Percutaneous NCT03864744 552 564 B-Modifier
liver NCT03864744 565 570 B-Procedure
biopsy NCT03864744 571 577 I-Procedure
exclusion NCT03864744 578 587 O
criteria NCT03864744 588 596 O
( NCT03864744 597 598 O
to NCT03864744 599 601 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864744 602 604 I-Assertion___Assertion-Type-Value:hypothetical
evaluated NCT03864744 605 614 B-Procedure
before NCT03864744 615 621 B-Temporal-Connection___Temporal-Connection-Type-Value:before
last NCT03864744 622 626 B-Eq-Comparison
visit NCT03864744 627 632 B-Encounter
) NCT03864744 633 634 O

- NCT03864744 638 639 O
MR NCT03864744 641 643 B-Procedure
spectroscopy NCT03864744 644 656 I-Procedure
demonstrating NCT03864744 657 670 O
lipid NCT03864744 671 676 B-Observation
content NCT03864744 677 684 I-Observation
< NCT03864744 685 686 B-Eq-Comparison
2 NCT03864744 687 688 I-Eq-Comparison
% NCT03864744 689 690 I-Eq-Comparison

- NCT03864744 694 695 O
Haemoglobin NCT03864744 697 708 B-Observation
< NCT03864744 709 710 B-Eq-Comparison
6 NCT03864744 711 712 I-Eq-Comparison
mmol NCT03864744 713 717 I-Eq-Comparison
/ NCT03864744 718 719 I-Eq-Comparison
L NCT03864744 720 721 I-Eq-Comparison

- NCT03864744 724 725 O
INR NCT03864744 727 730 B-Observation
> NCT03864744 731 732 B-Eq-Comparison
1.5 NCT03864744 733 736 I-Eq-Comparison

- NCT03864744 740 741 O
Trombocytes NCT03864744 743 754 B-Observation
< NCT03864744 755 756 B-Eq-Comparison
40 NCT03864744 757 759 I-Eq-Comparison
× NCT03864744 760 761 I-Eq-Comparison
109 NCT03864744 762 765 I-Eq-Comparison
/ NCT03864744 766 767 I-Eq-Comparison
L NCT03864744 768 769 I-Eq-Comparison

- NCT03864744 772 773 O
Skin NCT03864744 775 779 B-Modifier
infection NCT03864744 780 789 B-Condition
in NCT03864744 790 792 O
area NCT03864744 793 797 B-Modifier
where NCT03864744 798 803 O
biopsy NCT03864744 804 810 B-Procedure
will NCT03864744 811 815 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864744 816 818 I-Assertion___Assertion-Type-Value:hypothetical
sampled NCT03864744 819 826 O

Inclusion NCT03868618 0 9 O
Criteria NCT03868618 10 18 O
: NCT03868618 19 20 O

- NCT03868618 24 25 O
Body NCT03868618 27 31 B-Observation
mass NCT03868618 32 36 I-Observation
index NCT03868618 37 42 I-Observation
( NCT03868618 43 44 O
BMI NCT03868618 45 48 B-Observation
) NCT03868618 49 50 O
limitations NCT03868618 51 62 B-Modifier

- NCT03868618 65 66 O
Likely NCT03868618 68 74 B-Assertion___Assertion-Type-Value:possible
suffer NCT03868618 75 81 O
from NCT03868618 82 86 O
moderate NCT03868618 87 95 B-Eq-Comparison
to NCT03868618 96 98 I-Eq-Comparison
severe NCT03868618 99 105 I-Eq-Comparison
OSA NCT03868618 106 109 B-Condition
based NCT03868618 110 115 O
on NCT03868618 116 118 O
history NCT03868618 119 126 B-Eq-Comparison
and NCT03868618 127 130 B-Or
physical NCT03868618 131 139 B-Procedure

- NCT03868618 142 143 O
Has NCT03868618 145 148 O
either NCT03868618 149 155 O
not NCT03868618 156 159 B-Negation
tolerated NCT03868618 160 169 B-Assertion___Assertion-Type-Value:hypothetical
, NCT03868618 170 171 O
has NCT03868618 172 175 O
failed NCT03868618 176 182 O
or NCT03868618 183 185 O
refused NCT03868618 186 193 O
positive NCT03868618 194 202 B-Procedure
airway NCT03868618 203 209 I-Procedure
pressure NCT03868618 210 218 I-Procedure
( NCT03868618 219 220 O
PAP NCT03868618 221 224 B-Procedure
) NCT03868618 225 226 O
treatments NCT03868618 227 237 B-Procedure

- NCT03868618 240 241 O
Willing NCT03868618 243 250 O
and NCT03868618 251 254 O
capable NCT03868618 255 262 O
of NCT03868618 263 265 O
providing NCT03868618 266 275 O
informed NCT03868618 276 284 O
consent NCT03868618 285 292 O

Exclusion NCT03868618 293 302 O
Criteria NCT03868618 303 311 O
: NCT03868618 312 313 O

- NCT03868618 317 318 O
Inadequately NCT03868618 320 332 B-Modifier
treated NCT03868618 333 340 B-Procedure
sleep NCT03868618 341 346 B-Condition
disorders NCT03868618 347 356 I-Condition
other NCT03868618 357 362 B-Exception
than NCT03868618 363 367 I-Exception
OSA NCT03868618 368 371 B-Condition

- NCT03868618 374 375 O
Significant NCT03868618 377 388 O
co NCT03868618 389 391 B-Condition
- NCT03868618 392 393 I-Condition
morbidities NCT03868618 394 405 I-Condition
that NCT03868618 406 410 O
contraindicates NCT03868618 411 426 B-Contraindication
surgery NCT03868618 427 434 B-Procedure
or NCT03868618 435 437 B-Or
general NCT03868618 438 445 B-Procedure
anesthesia NCT03868618 446 456 I-Procedure

Inclusion NCT03866421 0 9 O
Criteria NCT03866421 10 18 O
( NCT03866421 19 20 O
kidney NCT03866421 21 27 B-Procedure
transplanted NCT03866421 28 40 I-Procedure
patients NCT03866421 41 49 O
) NCT03866421 50 51 O
: NCT03866421 53 54 O

- NCT03866421 58 59 O
Outpatient NCT03866421 61 71 B-Encounter
at NCT03866421 72 74 O
the NCT03866421 75 78 O
department NCT03866421 79 89 O
of NCT03866421 90 92 O
nephrology NCT03866421 93 103 O
at NCT03866421 104 106 O
either NCT03866421 107 113 O
Rigshospitalet NCT03866421 114 128 O
or NCT03866421 129 131 B-Or
Herlev NCT03866421 132 138 O
Hospital NCT03866421 139 147 O
scheduled NCT03866421 148 157 B-Eq-Comparison
for NCT03866421 158 161 O
a NCT03866421 162 163 O
kidney NCT03866421 164 170 B-Procedure
transplantation NCT03866421 171 186 I-Procedure
with NCT03866421 187 191 O
a NCT03866421 192 193 O
living NCT03866421 194 200 B-Observation
donor NCT03866421 201 206 I-Observation

- NCT03866421 209 210 O
Impaired NCT03866421 212 220 B-Condition
glucose NCT03866421 221 228 I-Condition
tolerance NCT03866421 229 238 I-Condition
: NCT03866421 239 240 O
fasting NCT03866421 241 248 B-Modifier
glucose NCT03866421 249 256 B-Observation
concentration NCT03866421 257 270 I-Observation
< NCT03866421 271 272 B-Eq-Comparison
7 NCT03866421 273 274 I-Eq-Comparison
, NCT03866421 275 276 I-Eq-Comparison
0 NCT03866421 277 278 I-Eq-Comparison
mmol NCT03866421 279 283 I-Eq-Comparison
/ NCT03866421 284 285 I-Eq-Comparison
l NCT03866421 286 287 I-Eq-Comparison
and NCT03866421 288 291 B-And
a NCT03866421 292 293 O
2 NCT03866421 294 295 B-Observation
- NCT03866421 296 297 I-Observation
hour NCT03866421 298 302 I-Observation
glucose NCT03866421 303 310 I-Observation
load NCT03866421 311 315 I-Observation
≥ NCT03866421 316 317 B-Eq-Comparison
7 NCT03866421 318 319 I-Eq-Comparison
, NCT03866421 320 321 I-Eq-Comparison
8 NCT03866421 322 323 I-Eq-Comparison
mmol NCT03866421 324 328 I-Eq-Comparison
/ NCT03866421 329 330 I-Eq-Comparison
l NCT03866421 331 332 I-Eq-Comparison
and NCT03866421 333 336 B-And
< NCT03866421 337 338 B-Eq-Comparison
11 NCT03866421 339 341 I-Eq-Comparison
, NCT03866421 342 343 I-Eq-Comparison
1 NCT03866421 344 345 I-Eq-Comparison
mmol NCT03866421 346 350 I-Eq-Comparison
/ NCT03866421 351 352 I-Eq-Comparison
l NCT03866421 353 354 I-Eq-Comparison
OR NCT03866421 355 357 B-Or
Impaired NCT03866421 358 366 B-Condition
fasting NCT03866421 367 374 I-Condition
glycaemia NCT03866421 375 384 I-Condition
: NCT03866421 385 386 O
Fasting NCT03866421 387 394 B-Modifier
blood NCT03866421 395 400 B-Observation
glucose NCT03866421 401 408 I-Observation
≥ NCT03866421 409 410 B-Eq-Comparison
6 NCT03866421 411 412 I-Eq-Comparison
, NCT03866421 413 414 I-Eq-Comparison
1 NCT03866421 415 416 I-Eq-Comparison
mmol NCT03866421 417 421 I-Eq-Comparison
/ NCT03866421 422 423 I-Eq-Comparison
l NCT03866421 424 425 I-Eq-Comparison
and NCT03866421 426 429 B-And
< NCT03866421 430 431 B-Eq-Comparison
7 NCT03866421 432 433 I-Eq-Comparison
, NCT03866421 434 435 I-Eq-Comparison
0 NCT03866421 436 437 I-Eq-Comparison
mmol NCT03866421 438 442 I-Eq-Comparison
/ NCT03866421 443 444 I-Eq-Comparison
l NCT03866421 445 446 I-Eq-Comparison
and NCT03866421 447 450 B-And
a NCT03866421 451 452 O
2 NCT03866421 453 454 B-Observation
- NCT03866421 455 456 I-Observation
hour NCT03866421 457 461 I-Observation
glucose NCT03866421 462 469 I-Observation
load NCT03866421 470 474 I-Observation
< NCT03866421 475 476 B-Eq-Comparison
7 NCT03866421 477 478 I-Eq-Comparison
, NCT03866421 479 480 I-Eq-Comparison
8 NCT03866421 481 482 I-Eq-Comparison
mmol NCT03866421 483 487 I-Eq-Comparison
/ NCT03866421 488 489 I-Eq-Comparison
l NCT03866421 490 491 I-Eq-Comparison
OR NCT03866421 492 494 B-Or
Normal NCT03866421 495 501 O
glucose NCT03866421 502 509 B-Condition
tolerance NCT03866421 510 519 I-Condition
: NCT03866421 520 521 O
fasting NCT03866421 522 529 B-Modifier
glucose NCT03866421 530 537 B-Observation
concentration NCT03866421 538 551 I-Observation
< NCT03866421 552 553 B-Eq-Comparison
6 NCT03866421 554 555 I-Eq-Comparison
, NCT03866421 556 557 I-Eq-Comparison
1 NCT03866421 558 559 I-Eq-Comparison
mmol NCT03866421 560 564 I-Eq-Comparison
/ NCT03866421 565 566 I-Eq-Comparison
l NCT03866421 567 568 I-Eq-Comparison
and NCT03866421 569 572 B-And
a NCT03866421 573 574 O
2 NCT03866421 575 576 B-Observation
- NCT03866421 577 578 I-Observation
hour NCT03866421 579 583 I-Observation
glucose NCT03866421 584 591 I-Observation
load NCT03866421 592 596 I-Observation
< NCT03866421 597 598 B-Eq-Comparison
7 NCT03866421 599 600 I-Eq-Comparison
, NCT03866421 601 602 I-Eq-Comparison
8 NCT03866421 603 604 I-Eq-Comparison
mmol NCT03866421 605 609 I-Eq-Comparison
/ NCT03866421 610 611 I-Eq-Comparison
l NCT03866421 612 613 I-Eq-Comparison
. NCT03866421 614 615 O

Inclusion NCT03866421 617 626 O
criteria NCT03866421 627 635 O
( NCT03866421 636 637 O
control NCT03866421 638 645 O
group NCT03866421 646 651 O
) NCT03866421 652 653 O
: NCT03866421 655 656 O

- NCT03866421 660 661 O
Normal NCT03866421 663 669 O
kidney NCT03866421 670 676 B-Condition
function NCT03866421 677 685 I-Condition

- NCT03866421 688 689 O
Normal NCT03866421 691 697 O
glucose NCT03866421 698 705 B-Condition
tolerance NCT03866421 706 715 I-Condition

Exclusion NCT03866421 716 725 O
Criteria NCT03866421 726 734 O
: NCT03866421 735 736 O

- NCT03866421 740 741 O
End NCT03866421 743 746 B-Modifier
stage NCT03866421 747 752 I-Modifier
liver NCT03866421 753 758 B-Condition
disease NCT03866421 759 766 I-Condition
as NCT03866421 767 769 O
diagnosed NCT03866421 770 779 O
by NCT03866421 780 782 O
MELD NCT03866421 783 787 O
( NCT03866421 788 789 O
model NCT03866421 790 795 O
for NCT03866421 796 799 O
end NCT03866421 800 803 O
stage NCT03866421 804 809 O
liver NCT03866421 810 815 O
disease NCT03866421 816 823 O
) NCT03866421 824 825 O
criteria NCT03866421 826 834 O
OR NCT03866421 835 837 B-Or

- NCT03866421 840 841 O
At NCT03866421 843 845 O
the NCT03866421 846 849 O
waiting NCT03866421 850 857 B-Assertion___Assertion-Type-Value:hypothetical
list NCT03866421 858 862 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03866421 863 866 O
liver NCT03866421 867 872 B-Procedure
transplantation NCT03866421 873 888 I-Procedure
OR NCT03866421 889 891 B-Or

- NCT03866421 894 895 O
Daily NCT03866421 897 902 B-Eq-Comparison
alcohol NCT03866421 903 910 B-Observation
intake NCT03866421 911 917 I-Observation
above NCT03866421 918 923 B-Eq-Comparison
20 NCT03866421 924 926 I-Eq-Comparison
g NCT03866421 927 928 I-Eq-Comparison
and NCT03866421 929 932 B-And
30 NCT03866421 933 935 B-Eq-Comparison
g NCT03866421 936 937 I-Eq-Comparison
for NCT03866421 938 941 O
women NCT03866421 942 947 O
and NCT03866421 948 951 B-Or
men NCT03866421 952 955 O
respectively NCT03866421 956 968 O
OR NCT03866421 969 971 B-Or

- NCT03866421 974 975 O
Known NCT03866421 977 982 O
hepatitis NCT03866421 983 992 B-Condition
A NCT03866421 993 994 B-Modifier
, NCT03866421 995 996 O
B NCT03866421 997 998 B-Modifier
or NCT03866421 999 1001 B-Or
C NCT03866421 1002 1003 B-Modifier
or NCT03866421 1004 1006 B-Or
hepatocellular NCT03866421 1007 1021 B-Modifier
carcinoma NCT03866421 1022 1031 B-Condition
or NCT03866421 1032 1034 B-Or
other NCT03866421 1035 1040 B-Other
known NCT03866421 1041 1046 O
liver NCT03866421 1047 1052 B-Condition
disease NCT03866421 1053 1060 I-Condition
OR NCT03866421 1061 1063 B-Or

- NCT03866421 1066 1067 O
Pregnancy NCT03866421 1069 1078 B-Condition
OR NCT03866421 1079 1081 B-Or

- NCT03866421 1084 1085 O
Weight NCT03866421 1087 1093 B-Observation
> NCT03866421 1094 1095 B-Eq-Comparison
130 NCT03866421 1096 1099 I-Eq-Comparison
kg NCT03866421 1100 1102 I-Eq-Comparison
OR NCT03866421 1103 1105 B-Or

- NCT03866421 1108 1109 O
Implanted NCT03866421 1111 1120 B-Procedure
pacemaker NCT03866421 1121 1130 I-Procedure

Inclusion NCT03863821 0 9 O
Criteria NCT03863821 10 18 O
: NCT03863821 19 20 O

- NCT03863821 24 25 O
Mild NCT03863821 27 31 O
COPD NCT03863821 32 36 B-Condition
with NCT03863821 37 41 B-And
performed NCT03863821 42 51 O
pulmonary NCT03863821 52 61 B-Observation
function NCT03863821 62 70 I-Observation
test NCT03863821 71 75 I-Observation

Exclusion NCT03863821 76 85 O
Criteria NCT03863821 86 94 O
: NCT03863821 95 96 O

- NCT03863821 100 101 O
Left NCT03863821 103 107 B-Modifier
- NCT03863821 108 109 I-Modifier
side NCT03863821 110 114 I-Modifier
heart NCT03863821 115 120 B-Condition
failure NCT03863821 121 128 I-Condition

- NCT03863821 131 132 O
COPD NCT03863821 134 138 B-Condition
exacerbation NCT03863821 139 151 O
within NCT03863821 152 158 B-Eq-Comparison
3 NCT03863821 159 160 I-Eq-Comparison
month NCT03863821 161 166 I-Eq-Comparison

- NCT03863821 169 170 O
Diagnosed NCT03863821 172 181 O
neuromuscular NCT03863821 182 195 B-Condition
disease NCT03863821 196 203 I-Condition

- NCT03863821 206 207 O
Unable NCT03863821 209 215 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863821 216 218 O
perform NCT03863821 219 226 O
6 NCT03863821 227 228 B-Observation
- NCT03863821 229 230 I-Observation
MWT NCT03863821 231 234 I-Observation

Inclusion NCT03865277 0 9 O
Criteria NCT03865277 10 18 O
: NCT03865277 19 20 O

- NCT03865277 24 25 O
Age NCT03865277 27 30 B-Age
: NCT03865277 31 32 O
older NCT03865277 33 38 B-Eq-Comparison
than NCT03865277 39 43 I-Eq-Comparison
18 NCT03865277 44 46 I-Eq-Comparison
years NCT03865277 47 52 I-Eq-Comparison

- NCT03865277 55 56 O
WHO NCT03865277 58 61 O
( NCT03865277 62 63 O
ECOG NCT03865277 64 68 B-Observation
) NCT03865277 69 70 O
performance NCT03865277 71 82 O
status NCT03865277 83 89 O
0 NCT03865277 90 91 B-Eq-Comparison
- NCT03865277 92 93 I-Eq-Comparison
2 NCT03865277 94 95 O

- NCT03865277 99 100 O
Histological NCT03865277 102 114 O
proven NCT03865277 115 121 O
HNSCC NCT03865277 122 127 B-Condition

- NCT03865277 130 131 O
HPV NCT03865277 133 136 B-Condition
negative NCT03865277 137 145 O
tumors NCT03865277 146 152 B-Modifier
or NCT03865277 153 155 B-Or
HPV NCT03865277 156 159 B-Condition
positive NCT03865277 160 168 O
tumors NCT03865277 169 175 B-Modifier

- NCT03865277 178 179 O
Stage NCT03865277 181 186 B-Eq-Comparison
III NCT03865277 187 190 I-Eq-Comparison
, NCT03865277 191 192 O
IVA NCT03865277 193 196 B-Modifier
or NCT03865277 197 199 B-Or
IVB NCT03865277 200 203 B-Modifier
HNSCC NCT03865277 204 209 B-Condition
according NCT03865277 210 219 O
to NCT03865277 220 222 O
UICC NCT03865277 223 227 O
and NCT03865277 228 231 O
AJCC NCT03865277 232 236 O
guidelines NCT03865277 237 247 O

- NCT03865277 250 251 O
Tumor NCT03865277 253 258 B-Condition
classified NCT03865277 259 269 O
as NCT03865277 270 272 O
irresectable NCT03865277 273 285 B-Modifier
or NCT03865277 286 288 B-Or
patient NCT03865277 289 296 O
inoperable NCT03865277 297 307 B-Modifier
or NCT03865277 308 310 B-Or
patient NCT03865277 311 318 O
refused NCT03865277 319 326 B-Assertion___Assertion-Type-Value:hypothetical|Negation
surgery NCT03865277 327 334 B-Procedure

- NCT03865277 337 338 O
Tumor NCT03865277 340 345 B-Condition
extension NCT03865277 346 355 B-Modifier
and NCT03865277 356 359 B-And
localization NCT03865277 360 372 B-Modifier
suitable NCT03865277 373 381 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865277 382 385 I-Assertion___Assertion-Type-Value:hypothetical
radiochemotherapy NCT03865277 386 403 B-Procedure
with NCT03865277 404 408 O
curative NCT03865277 409 417 O
intent NCT03865277 418 424 O

- NCT03865277 427 428 O
Simultaneous NCT03865277 430 442 B-Modifier
standard NCT03865277 443 451 I-Modifier
chemotherapy NCT03865277 452 464 B-Procedure
with NCT03865277 465 469 O
cisplatin NCT03865277 470 479 B-Drug
applicable NCT03865277 480 490 B-Assertion___Assertion-Type-Value:hypothetical
( NCT03865277 491 492 O
no NCT03865277 493 495 B-Negation
contra NCT03865277 496 502 B-Contraindication
- NCT03865277 503 504 I-Contraindication
indications NCT03865277 505 516 I-Contraindication
) NCT03865277 517 518 O

- NCT03865277 522 523 O
Dental NCT03865277 525 531 B-Procedure
examination NCT03865277 532 543 B-Modifier
and NCT03865277 544 547 B-And
- NCT03865277 548 549 O
treatment NCT03865277 550 559 B-Modifier
before NCT03865277 560 566 B-Temporal-Connection___Temporal-Connection-Type-Value:before
start NCT03865277 567 572 B-Eq-Comparison
of NCT03865277 573 575 O
therapy NCT03865277 576 583 B-Procedure

- NCT03865277 586 587 O
For NCT03865277 589 592 O
women NCT03865277 593 598 O
with NCT03865277 599 603 B-And
childbearing NCT03865277 604 616 B-Condition
potential NCT03865277 617 626 I-Condition
and NCT03865277 627 630 B-Or
men NCT03865277 631 634 O
in NCT03865277 635 637 B-And
reproductive NCT03865277 638 650 B-Condition
ages NCT03865277 651 655 I-Condition
adequate NCT03865277 656 664 O
contraception NCT03865277 665 678 B-Procedure
. NCT03865277 679 680 O

- NCT03865277 684 685 O
Ability NCT03865277 687 694 O
of NCT03865277 695 697 O
subject NCT03865277 698 705 O
to NCT03865277 706 708 O
understand NCT03865277 709 719 O
character NCT03865277 720 729 O
and NCT03865277 730 733 O
individual NCT03865277 734 744 O
consequences NCT03865277 745 757 O
of NCT03865277 758 760 O
the NCT03865277 761 764 O
clinical NCT03865277 765 773 O
trial NCT03865277 774 779 O

- NCT03865277 782 783 O
Written NCT03865277 785 792 O
informed NCT03865277 793 801 O
consent NCT03865277 802 809 O
( NCT03865277 810 811 O
must NCT03865277 812 816 O
be NCT03865277 817 819 O
available NCT03865277 820 829 O
before NCT03865277 830 836 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03865277 837 846 O
in NCT03865277 847 849 O
the NCT03865277 850 853 O
trial NCT03865277 854 859 B-Study
) NCT03865277 860 861 O

Exclusion NCT03865277 863 872 O
Criteria NCT03865277 873 881 O
: NCT03865277 882 883 O

- NCT03865277 887 888 O
Refusal NCT03865277 890 897 O
of NCT03865277 898 900 O
the NCT03865277 901 904 O
patients NCT03865277 905 913 O
to NCT03865277 914 916 O
take NCT03865277 917 921 O
part NCT03865277 922 926 O
in NCT03865277 927 929 O
the NCT03865277 930 933 O
trial NCT03865277 934 939 O

- NCT03865277 942 943 O
Presence NCT03865277 945 953 B-Eq-Comparison
of NCT03865277 954 956 O
distant NCT03865277 957 964 B-Modifier
metastases NCT03865277 965 975 B-Condition
( NCT03865277 976 977 O
UICC NCT03865277 978 982 B-Condition
stage NCT03865277 983 988 B-Eq-Comparison
IVC NCT03865277 989 992 I-Eq-Comparison
) NCT03865277 993 994 O

- NCT03865277 998 999 O
Previous NCT03865277 1001 1009 B-Eq-Comparison
radiotherapy NCT03865277 1010 1022 B-Procedure
in NCT03865277 1023 1025 O
the NCT03865277 1026 1029 O
head NCT03865277 1030 1034 B-Modifier
and NCT03865277 1035 1038 B-Or
neck NCT03865277 1039 1043 B-Modifier
region NCT03865277 1044 1050 O

- NCT03865277 1053 1054 O
Second NCT03865277 1056 1062 B-Eq-Comparison
malignancy NCT03865277 1063 1073 B-Condition
that NCT03865277 1074 1078 O
is NCT03865277 1079 1081 O
likely NCT03865277 1082 1088 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865277 1089 1091 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03865277 1092 1099 O
treatment NCT03865277 1100 1109 B-Procedure
during NCT03865277 1110 1116 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865277 1117 1120 O
trial NCT03865277 1121 1126 B-Study
intervention NCT03865277 1127 1139 I-Study
or NCT03865277 1140 1142 B-Or
follow NCT03865277 1143 1149 B-Encounter
- NCT03865277 1150 1151 I-Encounter
up NCT03865277 1152 1154 I-Encounter
period NCT03865277 1155 1161 O
or NCT03865277 1162 1164 O
that NCT03865277 1165 1169 O
, NCT03865277 1170 1171 O
in NCT03865277 1172 1174 O
the NCT03865277 1175 1178 O
opinion NCT03865277 1179 1186 O
of NCT03865277 1187 1189 O
the NCT03865277 1190 1193 O
physician NCT03865277 1194 1203 O
, NCT03865277 1204 1205 O
has NCT03865277 1206 1209 O
a NCT03865277 1210 1211 O
considerable NCT03865277 1212 1224 O
risk NCT03865277 1225 1229 B-Risk
of NCT03865277 1230 1232 O
recurrence NCT03865277 1233 1243 B-Modifier
or NCT03865277 1244 1246 B-Or
metastases NCT03865277 1247 1257 B-Condition
within NCT03865277 1258 1264 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865277 1265 1268 O
follow NCT03865277 1269 1275 B-Encounter
- NCT03865277 1276 1277 I-Encounter
up NCT03865277 1278 1280 I-Encounter
period NCT03865277 1281 1287 O

- NCT03865277 1290 1291 O
Serious NCT03865277 1293 1300 O
disease NCT03865277 1301 1308 B-Condition
or NCT03865277 1309 1311 B-Or
medical NCT03865277 1312 1319 B-Condition
condition NCT03865277 1320 1329 I-Condition
with NCT03865277 1330 1334 B-And
life NCT03865277 1335 1339 B-Observation
expectancy NCT03865277 1340 1350 I-Observation
of NCT03865277 1351 1353 O
less NCT03865277 1354 1358 B-Eq-Comparison
than NCT03865277 1359 1363 I-Eq-Comparison
one NCT03865277 1364 1367 I-Eq-Comparison
year NCT03865277 1368 1372 I-Eq-Comparison

- NCT03865277 1375 1376 O
Participation NCT03865277 1378 1391 O
in NCT03865277 1392 1394 O
competing NCT03865277 1395 1404 B-Other
interventional NCT03865277 1405 1419 B-Study
trial NCT03865277 1420 1425 I-Study
on NCT03865277 1426 1428 O
cancer NCT03865277 1429 1435 B-Condition
treatment NCT03865277 1436 1445 B-Procedure

- NCT03865277 1448 1449 O
Patients NCT03865277 1451 1459 O
who NCT03865277 1460 1463 O
are NCT03865277 1464 1467 O
not NCT03865277 1468 1471 B-Contraindication
suitable NCT03865277 1472 1480 I-Contraindication
for NCT03865277 1481 1484 O
radiochemotherapy NCT03865277 1485 1502 B-Procedure

- NCT03865277 1505 1506 O
Pregnant NCT03865277 1508 1516 B-Condition
or NCT03865277 1517 1519 B-Or
lactating NCT03865277 1520 1529 B-Condition
women NCT03865277 1530 1535 O

- NCT03865277 1538 1539 O
Patients NCT03865277 1541 1549 O
not NCT03865277 1550 1553 B-Negation
able NCT03865277 1554 1558 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865277 1559 1561 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03865277 1562 1572 O
the NCT03865277 1573 1576 O
character NCT03865277 1577 1586 O
and NCT03865277 1587 1590 O
individual NCT03865277 1591 1601 O
consequences NCT03865277 1602 1614 B-Risk
of NCT03865277 1615 1617 O
the NCT03865277 1618 1621 O
trial NCT03865277 1622 1627 B-Study

- NCT03865277 1630 1631 O
Nasopharyngeal NCT03865277 1633 1647 B-Condition
Carcinomas NCT03865277 1648 1658 I-Condition

Inclusion NCT03866018 0 9 O
Criteria NCT03866018 10 18 O
: NCT03866018 19 20 O

- NCT03866018 24 25 O
Male NCT03866018 27 31 O
or NCT03866018 32 34 B-Or
Female NCT03866018 35 41 O
≥ NCT03866018 42 43 B-Eq-Comparison
60 NCT03866018 44 46 I-Eq-Comparison
years NCT03866018 47 52 I-Eq-Comparison
old NCT03866018 53 56 B-Age

- NCT03866018 59 60 O
MMSE NCT03866018 62 66 B-Observation
score NCT03866018 67 72 O
between NCT03866018 73 80 B-Eq-Comparison
4 NCT03866018 81 82 I-Eq-Comparison
and NCT03866018 83 86 I-Eq-Comparison
26 NCT03866018 87 89 I-Eq-Comparison
/ NCT03866018 90 91 I-Eq-Comparison
30 NCT03866018 92 94 I-Eq-Comparison

- NCT03866018 98 99 O
Diagnosis NCT03866018 101 110 O
of NCT03866018 111 113 O
minor NCT03866018 114 119 B-Eq-Comparison
to NCT03866018 120 122 I-Eq-Comparison
major NCT03866018 123 128 I-Eq-Comparison
NeuroCognitive NCT03866018 129 143 B-Condition
Disorder NCT03866018 144 152 I-Condition
of NCT03866018 153 155 O
the NCT03866018 156 159 O
Alzheimer NCT03866018 160 169 B-Condition
type NCT03866018 170 174 O
or NCT03866018 175 177 B-Or
multiple NCT03866018 178 186 B-Eq-Comparison
etiology NCT03866018 187 195 B-Condition
; NCT03866018 195 196 O

- NCT03866018 199 200 O
Subject NCT03866018 202 209 O
without NCT03866018 210 217 B-Negation
a NCT03866018 218 219 O
major NCT03866018 220 225 O
hearing NCT03866018 226 233 B-Modifier
or NCT03866018 234 236 B-Or
visual NCT03866018 237 243 B-Modifier
impairment NCT03866018 244 254 B-Condition
; NCT03866018 254 255 O

- NCT03866018 258 259 O
Subject NCT03866018 261 268 O
not NCT03866018 269 272 B-Negation
presenting NCT03866018 273 283 O
any NCT03866018 284 287 O
contraindications NCT03866018 288 305 B-Contraindication
to NCT03866018 306 308 O
the NCT03866018 309 312 O
practice NCT03866018 313 321 O
of NCT03866018 322 324 O
adapted NCT03866018 325 332 O
physical NCT03866018 333 341 B-Observation
activity NCT03866018 342 350 I-Observation
; NCT03866018 350 351 O

- NCT03866018 354 355 O
Subject NCT03866018 357 364 O
affiliated NCT03866018 365 375 O
to NCT03866018 376 378 O
Social NCT03866018 379 385 O
Security NCT03866018 386 394 O
System NCT03866018 395 401 O
; NCT03866018 401 402 O

- NCT03866018 405 406 O
Signing NCT03866018 408 415 O
informed NCT03866018 416 424 O
consent NCT03866018 425 432 O

Exclusion NCT03866018 433 442 O
Criteria NCT03866018 443 451 O
: NCT03866018 452 453 O

- NCT03866018 457 458 O
< NCT03866018 460 461 B-Eq-Comparison
60 NCT03866018 462 464 I-Eq-Comparison
years NCT03866018 465 470 I-Age|Eq-Comparison

- NCT03866018 473 474 O
Medical NCT03866018 476 483 O
indications NCT03866018 484 495 O
: NCT03866018 496 497 O
Recent NCT03866018 498 504 B-Eq-Comparison
or NCT03866018 505 507 B-Or
unstable NCT03866018 508 516 O
cardiovascular NCT03866018 517 531 B-Condition
events NCT03866018 532 538 I-Condition
: NCT03866018 539 540 O
ECG NCT03866018 541 544 B-Procedure
changes NCT03866018 545 552 O
, NCT03866018 553 554 O
unstable NCT03866018 555 563 O
angina NCT03866018 564 570 B-Condition
, NCT03866018 571 572 O
uncontrolled NCT03866018 573 585 B-Modifier
arrhythmia NCT03866018 586 596 B-Condition
, NCT03866018 597 598 O
3 NCT03866018 599 600 B-Modifier
rd NCT03866018 601 603 I-Modifier
degree NCT03866018 604 610 I-Modifier
BAV NCT03866018 611 614 B-Condition
, NCT03866018 615 616 O
acute NCT03866018 617 622 O
heart NCT03866018 623 628 B-Condition
failure NCT03866018 629 636 I-Condition
. NCT03866018 637 638 O

- NCT03866018 642 643 O
MMSE NCT03866018 645 649 B-Observation
score NCT03866018 650 655 B-Eq-Comparison
< NCT03866018 656 657 I-Eq-Comparison
4 NCT03866018 658 659 I-Eq-Comparison

- NCT03866018 663 664 O
Subject NCT03866018 666 673 O
already NCT03866018 674 681 B-Eq-Comparison
engaged NCT03866018 682 689 O
in NCT03866018 690 692 O
appropriate NCT03866018 693 704 O
physical NCT03866018 705 713 B-Observation
activity NCT03866018 714 722 I-Observation

- NCT03866018 725 726 O
Subject NCT03866018 728 735 O
with NCT03866018 736 740 O
a NCT03866018 741 742 O
perceptual NCT03866018 743 753 B-Condition
disorder NCT03866018 754 762 I-Condition
( NCT03866018 763 764 O
AMD NCT03866018 765 768 B-Condition
, NCT03866018 769 770 O
deafness NCT03866018 771 779 B-Condition
. NCT03866018 779 780 O
. NCT03866018 781 782 O
. NCT03866018 783 784 O
) NCT03866018 785 786 O

- NCT03866018 790 791 O
Subject NCT03866018 793 800 O
with NCT03866018 801 805 O
a NCT03866018 806 807 O
motor NCT03866018 808 813 B-Condition
disability NCT03866018 814 824 I-Condition

- NCT03866018 827 828 O
Subject NCT03866018 830 837 O
under NCT03866018 838 843 B-Observation
guardianship NCT03866018 844 856 I-Observation
, NCT03866018 857 858 O
curatorship NCT03866018 859 870 B-Observation
or NCT03866018 871 873 B-Or
safeguard NCT03866018 874 883 B-Observation
of NCT03866018 884 886 I-Observation
justice NCT03866018 887 894 I-Observation

- NCT03866018 897 898 O
Persons NCT03866018 900 907 O
deprived NCT03866018 908 916 B-Observation
of NCT03866018 917 919 I-Observation
their NCT03866018 920 925 I-Observation
liberty NCT03866018 926 933 I-Observation
( NCT03866018 934 935 O
administrative NCT03866018 936 950 B-Modifier
or NCT03866018 951 953 B-Or
judicial NCT03866018 954 962 B-Modifier
) NCT03866018 963 964 O

Inclusion NCT03867474 0 9 O
Criteria NCT03867474 10 18 O
: NCT03867474 19 20 O

- NCT03867474 24 25 O
Inclusion NCT03867474 27 36 O
criteria NCT03867474 37 45 O
for NCT03867474 46 49 O
study NCT03867474 50 55 O
participants NCT03867474 56 68 O
include NCT03867474 69 76 O
: NCT03867474 77 78 O
( NCT03867474 79 80 O
1 NCT03867474 81 82 O
) NCT03867474 83 84 O
age NCT03867474 85 88 B-Age
≥ NCT03867474 89 90 B-Eq-Comparison
60 NCT03867474 91 93 I-Eq-Comparison
years NCT03867474 94 99 I-Eq-Comparison
; NCT03867474 99 100 O
( NCT03867474 101 102 O
2 NCT03867474 103 104 O
) NCT03867474 105 106 O
English NCT03867474 107 114 O
fluency NCT03867474 115 122 O
; NCT03867474 122 123 O
( NCT03867474 124 125 O
3 NCT03867474 126 127 O
) NCT03867474 128 129 O
living NCT03867474 130 136 B-Observation
independently NCT03867474 137 150 I-Observation
in NCT03867474 151 153 O
the NCT03867474 154 157 O
community NCT03867474 158 167 O
; NCT03867474 167 168 O
( NCT03867474 169 170 O
4 NCT03867474 171 172 O
) NCT03867474 173 174 O
self NCT03867474 175 179 O
- NCT03867474 180 181 O
reported NCT03867474 182 190 O
demographic NCT03867474 191 202 O
information NCT03867474 203 214 O
that NCT03867474 215 219 O
includes NCT03867474 220 228 O
either NCT03867474 229 235 O
the NCT03867474 236 239 O
label NCT03867474 240 245 O
of NCT03867474 246 248 O
SCD NCT03867474 249 252 B-Condition
or NCT03867474 253 255 B-Or
MCI NCT03867474 256 259 B-Condition

Exclusion NCT03867474 260 269 O
Criteria NCT03867474 270 278 O
: NCT03867474 279 280 O

- NCT03867474 284 285 O
( NCT03867474 287 288 O
1 NCT03867474 289 290 O
) NCT03867474 291 292 O
history NCT03867474 293 300 B-Eq-Comparison
of NCT03867474 301 303 I-Eq-Comparison
prior NCT03867474 304 309 I-Eq-Comparison
participation NCT03867474 310 323 O
in NCT03867474 324 326 O
any NCT03867474 327 330 O
MBSR NCT03867474 331 335 B-Modifier
or NCT03867474 336 338 B-Or
other NCT03867474 339 344 B-Other
mindfulness NCT03867474 345 356 B-Modifier
- NCT03867474 357 358 I-Modifier
based NCT03867474 359 364 I-Modifier
interventions NCT03867474 365 378 B-Procedure
, NCT03867474 379 380 O
or NCT03867474 381 383 B-Or
participation NCT03867474 384 397 O
in NCT03867474 398 400 O
regular NCT03867474 401 408 O
( NCT03867474 409 410 O
weekly NCT03867474 411 417 B-Eq-Comparison
) NCT03867474 418 419 O
mindfulness NCT03867474 420 431 B-Modifier
or NCT03867474 432 434 B-Or
yoga NCT03867474 435 439 B-Modifier
practice NCT03867474 440 448 B-Observation
; NCT03867474 448 449 O
( NCT03867474 450 451 O
2 NCT03867474 452 453 O
) NCT03867474 454 455 O
low NCT03867474 456 459 O
mood NCT03867474 460 464 B-Condition
as NCT03867474 465 467 O
indicated NCT03867474 468 477 O
by NCT03867474 478 480 O
a NCT03867474 481 482 O
5 NCT03867474 483 484 B-Eq-Comparison
or NCT03867474 485 487 I-Eq-Comparison
greater NCT03867474 488 495 I-Eq-Comparison
on NCT03867474 496 498 O
the NCT03867474 499 502 O
Geriatric NCT03867474 503 512 B-Observation
Depression NCT03867474 513 523 I-Observation
Scale NCT03867474 524 529 I-Observation
( NCT03867474 530 531 O
GDS NCT03867474 532 535 B-Observation
) NCT03867474 536 537 O
( NCT03867474 538 539 O
3 NCT03867474 540 541 O
) NCT03867474 542 543 O
alcoholism NCT03867474 544 554 B-Condition
and NCT03867474 555 558 B-Or
/ NCT03867474 559 560 I-Or
or NCT03867474 561 563 I-Or
other NCT03867474 564 569 B-Other
substance NCT03867474 570 579 B-Condition
abuse NCT03867474 580 585 I-Condition
defined NCT03867474 586 593 O
in NCT03867474 594 596 O
the NCT03867474 597 600 O
Diagnostic NCT03867474 601 611 O
and NCT03867474 612 615 O
Statistical NCT03867474 616 627 O
Manual NCT03867474 628 634 O
of NCT03867474 635 637 O
Mental NCT03867474 638 644 O
Disorders NCT03867474 645 654 O
, NCT03867474 655 656 O
Fifth NCT03867474 657 662 O
Edition NCT03867474 663 670 O
( NCT03867474 671 672 O
DSM NCT03867474 673 676 O
- NCT03867474 677 678 O
V NCT03867474 679 680 O
) NCT03867474 681 682 O
( NCT03867474 683 684 O
American NCT03867474 685 693 O
Psychiatric NCT03867474 694 705 O
Association NCT03867474 706 717 O
, NCT03867474 718 719 O
2013 NCT03867474 720 724 O
; NCT03867474 725 726 O
Kiefer NCT03867474 727 733 O
, NCT03867474 734 735 O
Israel NCT03867474 736 742 O
, NCT03867474 743 744 O
& NCT03867474 745 746 O
Martino NCT03867474 747 754 O
, NCT03867474 755 756 O
2016 NCT03867474 757 761 O
) NCT03867474 762 763 O
; NCT03867474 764 765 O
( NCT03867474 766 767 O
4 NCT03867474 768 769 O
) NCT03867474 770 771 O
Montreal NCT03867474 772 780 B-Observation
Cognitive NCT03867474 781 790 I-Observation
Assessment NCT03867474 791 801 I-Observation
( NCT03867474 802 803 O
MoCA NCT03867474 804 808 B-Observation
) NCT03867474 809 810 O
of NCT03867474 811 813 O
23 NCT03867474 814 816 O
( NCT03867474 817 818 O
+ NCT03867474 820 821 O
/ NCT03867474 823 824 O
- NCT03867474 826 827 O
4 NCT03867474 828 829 O
) NCT03867474 830 831 O
( NCT03867474 832 833 O
Clarnette NCT03867474 834 843 O
, NCT03867474 844 845 O
O'Caoimh NCT03867474 846 854 O
, NCT03867474 855 856 O
Antony NCT03867474 857 863 O
, NCT03867474 864 865 O
Svendrovski NCT03867474 866 877 O
, NCT03867474 878 879 O
& NCT03867474 880 881 O
Molloy NCT03867474 882 888 O
, NCT03867474 889 890 O
2017 NCT03867474 891 895 O
; NCT03867474 896 897 O
O'Caoimh NCT03867474 898 906 O
, NCT03867474 907 908 O
Timmons NCT03867474 909 916 O
, NCT03867474 917 918 O
& NCT03867474 919 920 O
Molloy NCT03867474 921 927 O
, NCT03867474 928 929 O
2016 NCT03867474 930 934 O
) NCT03867474 935 936 O
or NCT03867474 937 939 O
under NCT03867474 940 945 O
; NCT03867474 945 946 O
and NCT03867474 947 950 O
( NCT03867474 951 952 O
5 NCT03867474 953 954 O
) NCT03867474 955 956 O
if NCT03867474 957 959 O
participating NCT03867474 960 973 O
in NCT03867474 974 976 O
other NCT03867474 977 982 O
concurrent NCT03867474 983 993 B-Modifier
group NCT03867474 994 999 B-Procedure
( NCT03867474 1000 1001 O
s NCT03867474 1002 1003 O
) NCT03867474 1004 1005 O
e. NCT03867474 1006 1008 O
g. NCT03867474 1009 1011 O
cognitive NCT03867474 1013 1022 B-Procedure
behavioural NCT03867474 1023 1034 I-Procedure
therapy NCT03867474 1035 1042 I-Procedure
( NCT03867474 1043 1044 O
CBT NCT03867474 1045 1048 B-Procedure
) NCT03867474 1049 1050 O
or NCT03867474 1051 1053 B-Or
memory NCT03867474 1054 1060 B-Procedure
training NCT03867474 1061 1069 I-Procedure
programs NCT03867474 1070 1078 I-Procedure
in NCT03867474 1079 1081 O
the NCT03867474 1082 1085 O
community NCT03867474 1086 1095 O
, NCT03867474 1096 1097 O
while NCT03867474 1098 1103 B-Temporal-Connection___Temporal-Connection-Type-Value:during
in NCT03867474 1104 1106 O
the NCT03867474 1107 1110 O
study NCT03867474 1111 1116 B-Study
. NCT03867474 1117 1118 O


Inclusion NCT03864380 0 9 O
Criteria NCT03864380 10 18 O
: NCT03864380 19 20 O

- NCT03864380 24 25 O
Person NCT03864380 27 33 O
registered NCT03864380 34 44 O
at NCT03864380 45 47 O
the NCT03864380 48 51 O
2019 NCT03864380 52 56 O
Paris NCT03864380 57 62 O
Marathon NCT03864380 63 71 O

Exclusion NCT03864380 72 81 O
Criteria NCT03864380 82 90 O
: NCT03864380 91 92 O

- NCT03864380 96 97 O
Ophthalmological NCT03864380 99 115 B-Condition
disorders NCT03864380 116 125 I-Condition
making NCT03864380 126 132 O
access NCT03864380 133 139 B-Observation
to NCT03864380 140 142 O
the NCT03864380 143 146 O
fundus NCT03864380 147 153 B-Modifier
impossible NCT03864380 154 164 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03864380 165 168 O
both NCT03864380 169 173 B-Modifier
eyes NCT03864380 174 178 I-Modifier

Inclusion NCT03860870 0 9 O
Criteria NCT03860870 10 18 O
: NCT03860870 19 20 O

- NCT03860870 24 25 O
Healthy NCT03860870 27 34 B-Condition

- NCT03860870 37 38 O
Male NCT03860870 40 44 O

- NCT03860870 47 48 O
18 NCT03860870 50 52 B-Eq-Comparison
- NCT03860870 53 54 I-Eq-Comparison
40 NCT03860870 55 57 I-Eq-Comparison
years NCT03860870 58 63 I-Eq-Comparison
of NCT03860870 64 66 O
age NCT03860870 67 70 B-Age

- NCT03860870 73 74 O
No NCT03860870 76 78 B-Negation
known NCT03860870 79 84 O
contraindications NCT03860870 85 102 B-Contraindication
for NCT03860870 103 106 O
anabolic NCT03860870 107 115 B-Drug
drugs NCT03860870 116 121 I-Drug
( NCT03860870 122 123 O
e. NCT03860870 124 126 O
g. NCT03860870 127 129 O
cancer NCT03860870 131 137 B-Condition
) NCT03860870 138 139 O

Exclusion NCT03860870 141 150 O
Criteria NCT03860870 151 159 O
: NCT03860870 160 161 O

- NCT03860870 165 166 O
Abnormal NCT03860870 168 176 O
ECG NCT03860870 177 180 B-Procedure

- NCT03860870 183 184 O
Steroid NCT03860870 186 193 B-Condition
abuse NCT03860870 194 199 I-Condition

- NCT03860870 202 203 O
Ongoing NCT03860870 205 212 B-Eq-Comparison
use NCT03860870 213 216 O
of NCT03860870 217 219 O
prescription NCT03860870 220 232 B-Drug
medication NCT03860870 233 243 I-Drug

- NCT03860870 246 247 O
heavy NCT03860870 249 254 O
resistance NCT03860870 255 265 B-Observation
training NCT03860870 266 274 I-Observation
more NCT03860870 275 279 B-Eq-Comparison
than NCT03860870 280 284 I-Eq-Comparison
2 NCT03860870 285 286 I-Eq-Comparison
times NCT03860870 287 292 I-Eq-Comparison
weekly NCT03860870 293 299 I-Eq-Comparison

- NCT03860870 302 303 O
Disease NCT03860870 305 312 B-Condition
deemed NCT03860870 313 319 O
by NCT03860870 320 322 O
the NCT03860870 323 326 O
MD NCT03860870 327 329 O
to NCT03860870 330 332 O
infer NCT03860870 333 338 O
a NCT03860870 339 340 O
risk NCT03860870 341 345 B-Risk
to NCT03860870 346 348 O
participate NCT03860870 349 360 O
in NCT03860870 361 363 O
the NCT03860870 364 367 O
trial NCT03860870 368 373 B-Study

Inclusion NCT03868592 0 9 O
Criteria NCT03868592 10 18 O
: NCT03868592 19 20 O

- NCT03868592 24 25 O
BMI NCT03868592 27 30 B-Observation
40 NCT03868592 31 33 B-Eq-Comparison
- NCT03868592 34 35 I-Eq-Comparison
50 NCT03868592 36 38 I-Eq-Comparison
kg NCT03868592 39 41 I-Eq-Comparison
/ NCT03868592 42 43 I-Eq-Comparison
m2 NCT03868592 44 46 I-Eq-Comparison
. NCT03868592 46 47 O

- NCT03868592 51 52 O
Mo NCT03868592 54 56 O
active NCT03868592 57 63 B-Eq-Comparison
physical NCT03868592 64 72 B-Condition
illness NCT03868592 73 80 I-Condition
that NCT03868592 81 85 O
would NCT03868592 86 91 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03868592 92 101 O
with NCT03868592 102 106 O
mobility NCT03868592 107 115 B-Condition
or NCT03868592 116 118 B-Or
weight NCT03868592 119 125 B-Condition
loss NCT03868592 126 130 I-Condition
after NCT03868592 131 136 B-Temporal-Connection___Temporal-Connection-Type-Value:after
bariatric NCT03868592 137 146 B-Procedure
surgery NCT03868592 147 154 I-Procedure

Exclusion NCT03868592 155 164 O
Criteria NCT03868592 165 173 O
: NCT03868592 174 175 O

- NCT03868592 179 180 O
Type NCT03868592 182 186 B-Modifier
1 NCT03868592 187 188 I-Modifier
or NCT03868592 189 191 B-Or
Type NCT03868592 192 196 B-Modifier
2 NCT03868592 197 198 I-Modifier
Diabetes NCT03868592 199 207 B-Condition
diagnosis NCT03868592 208 217 O
or NCT03868592 218 220 B-Or
fasting NCT03868592 221 228 B-Modifier
plasma NCT03868592 229 235 B-Observation
glucose NCT03868592 236 243 I-Observation
≥ NCT03868592 244 245 B-Eq-Comparison
126 NCT03868592 246 249 I-Eq-Comparison
mg NCT03868592 250 252 I-Eq-Comparison
/ NCT03868592 253 254 I-Eq-Comparison
dL NCT03868592 255 257 I-Eq-Comparison

- NCT03868592 260 261 O
Active NCT03868592 263 269 B-Eq-Comparison
coronary NCT03868592 270 278 B-Condition
artery NCT03868592 279 285 I-Condition
disease NCT03868592 286 293 I-Condition

- NCT03868592 296 297 O
Participation NCT03868592 299 312 O
in NCT03868592 313 315 O
structured NCT03868592 316 326 B-Observation
exercise NCT03868592 327 335 I-Observation
( NCT03868592 336 337 O
> NCT03868592 339 340 B-Eq-Comparison
2 NCT03868592 341 342 I-Eq-Comparison
times NCT03868592 343 348 I-Eq-Comparison
per NCT03868592 349 352 I-Eq-Comparison
week NCT03868592 353 357 I-Eq-Comparison
for NCT03868592 358 361 O
30 NCT03868592 362 364 B-Eq-Comparison
minutes NCT03868592 365 372 I-Eq-Comparison
or NCT03868592 373 375 I-Eq-Comparison
longer NCT03868592 376 382 I-Eq-Comparison
) NCT03868592 383 384 O

- NCT03868592 388 389 O
Smoking NCT03868592 391 398 B-Condition

- NCT03868592 401 402 O
Medications NCT03868592 404 415 B-Drug
known NCT03868592 416 421 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868592 422 424 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03868592 425 431 O
adipose NCT03868592 432 439 B-Condition
tissue NCT03868592 440 446 I-Condition
metabolism NCT03868592 447 457 I-Condition
( NCT03868592 458 459 O
e. NCT03868592 460 462 O
g. NCT03868592 463 465 O
, NCT03868592 466 467 O
beta NCT03868592 468 472 B-Drug
blockers NCT03868592 473 481 I-Drug
, NCT03868592 482 483 O
corticosteroids NCT03868592 484 499 B-Drug
) NCT03868592 500 501 O

- NCT03868592 505 506 O
Renal NCT03868592 508 513 B-Condition
insufficiency NCT03868592 514 527 I-Condition
( NCT03868592 528 529 O
serum NCT03868592 530 535 B-Observation
creatinine NCT03868592 536 546 I-Observation
> NCT03868592 547 548 B-Eq-Comparison
1.5 NCT03868592 549 552 I-Eq-Comparison
mg NCT03868592 553 555 I-Eq-Comparison
/ NCT03868592 556 557 I-Eq-Comparison
dl NCT03868592 558 560 I-Eq-Comparison
) NCT03868592 561 562 O

- NCT03868592 566 567 O
Chronic NCT03868592 569 576 B-Modifier
active NCT03868592 577 583 B-Eq-Comparison
liver NCT03868592 584 589 B-Condition
disease NCT03868592 590 597 I-Condition
( NCT03868592 598 599 O
Bilirubin NCT03868592 600 609 B-Observation
> NCT03868592 610 611 B-Eq-Comparison
17 NCT03868592 612 614 I-Eq-Comparison
mmol NCT03868592 615 619 I-Eq-Comparison
/ NCT03868592 620 621 I-Eq-Comparison
L NCT03868592 622 623 I-Eq-Comparison
, NCT03868592 624 625 O
AST NCT03868592 626 629 B-Observation
> NCT03868592 630 631 B-Eq-Comparison
144 NCT03868592 632 635 I-Eq-Comparison
IU NCT03868592 636 638 I-Eq-Comparison
/ NCT03868592 639 640 I-Eq-Comparison
L NCT03868592 641 642 I-Eq-Comparison
, NCT03868592 643 644 O
or NCT03868592 645 647 B-Or
ALT NCT03868592 648 651 B-Observation
> NCT03868592 652 653 B-Eq-Comparison
165 NCT03868592 654 657 I-Eq-Comparison
IU NCT03868592 658 660 I-Eq-Comparison
/ NCT03868592 661 662 I-Eq-Comparison
L NCT03868592 663 664 I-Eq-Comparison
) NCT03868592 665 666 O

- NCT03868592 670 671 O
Pregnancy NCT03868592 673 682 B-Condition
or NCT03868592 683 685 B-Or
breastfeeding NCT03868592 686 699 B-Condition
. NCT03868592 699 700 O

Inclusion NCT03866226 0 9 O
Criteria NCT03866226 10 18 O
: NCT03866226 19 20 O

1 NCT03866226 24 25 O
. NCT03866226 25 26 O
Signed NCT03866226 28 34 O
written NCT03866226 35 42 O
informed NCT03866226 43 51 O
consent NCT03866226 52 59 O

2 NCT03866226 62 63 O
. NCT03866226 63 64 O
Age NCT03866226 66 69 B-Age
18 NCT03866226 70 72 B-Eq-Comparison
- NCT03866226 73 74 I-Eq-Comparison
80 NCT03866226 75 77 I-Eq-Comparison
years NCT03866226 78 83 I-Eq-Comparison

3 NCT03866226 86 87 O
. NCT03866226 87 88 O
Capable NCT03866226 90 97 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866226 98 100 I-Assertion___Assertion-Type-Value:hypothetical
understanding NCT03866226 101 114 O
the NCT03866226 115 118 O
test NCT03866226 119 123 B-Procedure
and NCT03866226 124 127 B-And
cooperating NCT03866226 128 139 O
with NCT03866226 140 144 O
the NCT03866226 145 148 O
questionnaire NCT03866226 149 162 B-Observation
. NCT03866226 163 164 O

Exclusion NCT03866226 166 175 O
Criteria NCT03866226 176 184 O
: NCT03866226 185 186 O

1 NCT03866226 190 191 O
. NCT03866226 191 192 O
History NCT03866226 194 201 B-Eq-Comparison
of NCT03866226 202 204 O
psychosis NCT03866226 205 214 B-Condition
, NCT03866226 215 216 O
including NCT03866226 217 226 O
schizophrenia NCT03866226 227 240 B-Condition
, NCT03866226 241 242 O
bipolar NCT03866226 243 250 B-Condition
disorder NCT03866226 251 259 I-Condition
, NCT03866226 260 261 O
depression NCT03866226 262 272 B-Condition
, NCT03866226 273 274 O
anxiety NCT03866226 275 282 B-Condition
, NCT03866226 283 284 O
obsessive NCT03866226 285 294 B-Condition
- NCT03866226 295 296 I-Condition
compulsive NCT03866226 297 307 I-Condition
disorder NCT03866226 308 316 I-Condition
, NCT03866226 317 318 O
phobia NCT03866226 319 325 B-Condition
, NCT03866226 326 327 O
somatoform NCT03866226 328 338 B-Condition
disorder NCT03866226 339 347 I-Condition
, NCT03866226 348 349 O
stress NCT03866226 350 356 B-Condition
- NCT03866226 357 358 I-Condition
related NCT03866226 359 366 I-Condition
disorders NCT03866226 367 376 I-Condition

2 NCT03866226 379 380 O
. NCT03866226 380 381 O
History NCT03866226 383 390 B-Eq-Comparison
of NCT03866226 391 393 O
insomnia NCT03866226 394 402 B-Condition
, NCT03866226 403 404 O
currently NCT03866226 405 414 B-Eq-Comparison
with NCT03866226 415 419 O
medication NCT03866226 420 430 B-Drug

3 NCT03866226 433 434 O
. NCT03866226 434 435 O
History NCT03866226 437 444 B-Eq-Comparison
of NCT03866226 445 447 O
obstructive NCT03866226 448 459 B-Condition
sleep NCT03866226 460 465 I-Condition
apnea NCT03866226 466 471 I-Condition
( NCT03866226 472 473 O
OSA NCT03866226 474 477 B-Condition
) NCT03866226 478 479 O

4 NCT03866226 483 484 O
. NCT03866226 484 485 O
History NCT03866226 487 494 B-Eq-Comparison
of NCT03866226 495 497 O
other NCT03866226 498 503 B-Other
sleep NCT03866226 504 509 B-Condition
disorders NCT03866226 510 519 I-Condition
, NCT03866226 520 521 O
including NCT03866226 522 531 O
narcolepsy NCT03866226 532 542 B-Condition
/ NCT03866226 543 544 B-Or
hypersomnias NCT03866226 545 557 B-Condition
, NCT03866226 558 559 O
circadian NCT03866226 560 569 B-Condition
rhythm NCT03866226 570 576 I-Condition
sleep NCT03866226 577 582 I-Condition
disorder NCT03866226 583 591 I-Condition
, NCT03866226 592 593 O
parasomnias NCT03866226 594 605 B-Condition
, NCT03866226 606 607 O
sleep NCT03866226 608 613 B-Modifier
- NCT03866226 614 615 I-Modifier
related NCT03866226 616 623 I-Modifier
dyskinesia NCT03866226 624 634 B-Condition

5 NCT03866226 637 638 O
. NCT03866226 638 639 O
History NCT03866226 641 648 B-Eq-Comparison
of NCT03866226 649 651 O
heart NCT03866226 652 657 B-Condition
failure NCT03866226 658 665 I-Condition
, NCT03866226 666 667 O
that NCT03866226 668 672 O
is NCT03866226 673 675 O
New NCT03866226 676 679 B-Condition
York NCT03866226 680 684 I-Condition
heart NCT03866226 685 690 I-Condition
association NCT03866226 691 702 I-Condition
( NCT03866226 703 704 O
NYHA NCT03866226 705 709 B-Condition
) NCT03866226 710 711 O
Class NCT03866226 712 717 B-Eq-Comparison
Ⅲ NCT03866226 718 719 I-Eq-Comparison
- NCT03866226 720 721 I-Eq-Comparison
Ⅳ NCT03866226 722 723 I-Eq-Comparison

6 NCT03866226 726 727 O
. NCT03866226 727 728 O
History NCT03866226 730 737 B-Eq-Comparison
of NCT03866226 738 740 O
atrial NCT03866226 741 747 B-Condition
fibrillation NCT03866226 748 760 I-Condition
and NCT03866226 761 764 B-Or
frequent NCT03866226 765 773 O
atrial NCT03866226 774 780 B-Modifier
or NCT03866226 781 783 B-Or
ventricular NCT03866226 784 795 B-Modifier
extrasystoles NCT03866226 796 809 B-Condition

7 NCT03866226 812 813 O
. NCT03866226 813 814 O
Ongoing NCT03866226 816 823 B-Eq-Comparison
substance NCT03866226 824 833 B-Modifier
or NCT03866226 834 836 B-Or
alcohol NCT03866226 837 844 B-Modifier
abuse NCT03866226 845 850 B-Condition

8 NCT03866226 853 854 O
. NCT03866226 854 855 O
Currently NCT03866226 857 866 B-Eq-Comparison
receiving NCT03866226 867 876 I-Eq-Comparison
sedative NCT03866226 877 885 B-Drug
hypnotic NCT03866226 886 894 I-Drug
medication NCT03866226 895 905 I-Drug
within NCT03866226 906 912 B-Eq-Comparison
1 NCT03866226 913 914 I-Eq-Comparison
week NCT03866226 915 919 I-Eq-Comparison

9 NCT03866226 922 923 O
. NCT03866226 923 924 O
Pregnant NCT03866226 926 934 B-Condition
women NCT03866226 935 940 O

10 NCT03866226 942 944 O
. NCT03866226 944 945 O
Ongoing NCT03866226 947 954 B-Eq-Comparison
involvement NCT03866226 955 966 O
in NCT03866226 967 969 O
night NCT03866226 970 975 B-Observation
- NCT03866226 976 977 I-Observation
shift NCT03866226 978 983 I-Observation
work NCT03866226 984 988 I-Observation
( NCT03866226 989 990 O
22 NCT03866226 991 993 B-Eq-Comparison
: NCT03866226 994 995 I-Eq-Comparison
00 NCT03866226 996 998 I-Eq-Comparison
- NCT03866226 999 1000 I-Eq-Comparison
6 NCT03866226 1001 1002 I-Eq-Comparison
: NCT03866226 1003 1004 I-Eq-Comparison
00 NCT03866226 1005 1007 I-Eq-Comparison
) NCT03866226 1008 1009 O
within NCT03866226 1010 1016 B-Eq-Comparison
1 NCT03866226 1017 1018 I-Eq-Comparison
week NCT03866226 1019 1023 I-Eq-Comparison

11 NCT03866226 1025 1027 O
. NCT03866226 1027 1028 O
Ongoing NCT03866226 1030 1037 O
need NCT03866226 1038 1042 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866226 1043 1045 I-Assertion___Assertion-Type-Value:hypothetical
care NCT03866226 1046 1050 B-Procedure
of NCT03866226 1051 1053 O
families NCT03866226 1054 1062 B-Family-Member
at NCT03866226 1063 1065 I-Family-Member
home NCT03866226 1066 1070 I-Family-Member
that NCT03866226 1071 1075 O
wake NCT03866226 1076 1080 B-Condition
during NCT03866226 1081 1087 I-Condition
the NCT03866226 1088 1091 I-Condition
night NCT03866226 1092 1097 I-Condition
within NCT03866226 1098 1104 B-Eq-Comparison
1 NCT03866226 1105 1106 I-Eq-Comparison
week NCT03866226 1107 1111 I-Eq-Comparison

12 NCT03866226 1113 1115 O
. NCT03866226 1115 1116 O
Incomprehensible NCT03866226 1118 1134 O
or NCT03866226 1135 1137 O
unwilling NCT03866226 1138 1147 O
to NCT03866226 1148 1150 O
fill NCT03866226 1151 1155 O
in NCT03866226 1156 1158 O
informed NCT03866226 1159 1167 O
consent NCT03866226 1168 1175 O
or NCT03866226 1176 1178 O
questionnaire NCT03866226 1179 1192 O

Inclusion NCT03868579 0 9 O
Criteria NCT03868579 10 18 O
: NCT03868579 19 20 O

- NCT03868579 24 25 O
Patients NCT03868579 27 35 O
who NCT03868579 36 39 O
will NCT03868579 40 44 B-Eq-Comparison
undergo NCT03868579 45 52 I-Eq-Comparison
pleuroscopy NCT03868579 53 64 B-Procedure
with NCT03868579 65 69 O
biopsy NCT03868579 70 76 B-Procedure

Exclusion NCT03868579 77 86 O
Criteria NCT03868579 87 95 O
: NCT03868579 96 97 O

- NCT03868579 101 102 O
Patients NCT03868579 104 112 O
with NCT03868579 113 117 O
known NCT03868579 118 123 O
malignant NCT03868579 124 133 B-Modifier
pleural NCT03868579 134 141 B-Condition
effusion NCT03868579 142 150 I-Condition

- NCT03868579 153 154 O
Inability NCT03868579 156 165 O
or NCT03868579 166 168 O
unwillingness NCT03868579 169 182 O
to NCT03868579 183 185 O
give NCT03868579 186 190 O
informed NCT03868579 191 199 O
consent NCT03868579 200 207 O

Resident NCT03861429 0 8 O
Inclusion NCT03861429 9 18 O
Criteria NCT03861429 19 27 O
: NCT03861429 28 29 O

- NCT03861429 33 34 O
Identified NCT03861429 36 46 O
as NCT03861429 47 49 O
having NCT03861429 50 56 O
Alzheimer NCT03861429 57 66 B-Condition
's NCT03861429 66 68 I-Condition
or NCT03861429 69 71 B-Or
related NCT03861429 72 79 O
dementia NCT03861429 80 88 B-Condition

- NCT03861429 91 92 O
Mild NCT03861429 94 98 B-Eq-Comparison
to NCT03861429 99 101 I-Eq-Comparison
moderate NCT03861429 102 110 I-Eq-Comparison
cognitive NCT03861429 111 120 B-Condition
impairment NCT03861429 121 131 I-Condition
( NCT03861429 132 133 O
BIMS NCT03861429 134 138 B-Observation
= NCT03861429 139 140 B-Eq-Comparison
8 NCT03861429 141 142 I-Eq-Comparison
- NCT03861429 143 144 I-Eq-Comparison
15 NCT03861429 145 147 O
, NCT03861429 148 149 O
( NCT03861429 150 151 O
MDS NCT03861429 152 155 O
C0500 NCT03861429 156 161 O
) NCT03861429 162 163 O
( NCT03861429 164 165 O
nursing NCT03861429 166 173 O
home NCT03861429 174 178 O
residents NCT03861429 179 188 O
only NCT03861429 189 193 O
) NCT03861429 194 195 O

- NCT03861429 199 200 O
Makes NCT03861429 202 207 B-Observation
Self NCT03861429 208 212 I-Observation
Understood NCT03861429 213 223 I-Observation
= NCT03861429 224 225 B-Eq-Comparison
< NCT03861429 226 227 I-Eq-Comparison
1 NCT03861429 228 229 I-Eq-Comparison
( NCT03861429 230 231 O
MDS NCT03861429 232 235 O
B0700 NCT03861429 236 241 O
) NCT03861429 242 243 O
/ NCT03861429 245 246 O
present NCT03861429 247 254 O
in NCT03861429 255 257 O
medical NCT03861429 258 265 O
record NCT03861429 266 272 O

- NCT03861429 275 276 O
Understood NCT03861429 278 288 B-Observation
By NCT03861429 289 291 I-Observation
Others NCT03861429 292 298 I-Observation
= NCT03861429 299 300 B-Eq-Comparison
< NCT03861429 301 302 I-Eq-Comparison
1 NCT03861429 303 304 I-Eq-Comparison
( NCT03861429 305 306 O
MDS NCT03861429 307 310 O
B0800 NCT03861429 311 316 O
) NCT03861429 317 318 O
/ NCT03861429 320 321 O
present NCT03861429 322 329 O
in NCT03861429 330 332 O
medical NCT03861429 333 340 O
record NCT03861429 341 347 O

- NCT03861429 350 351 O
Reside NCT03861429 353 359 B-Encounter
at NCT03861429 360 362 O
the NCT03861429 363 366 O
facility NCT03861429 367 375 O
at NCT03861429 376 378 B-Eq-Comparison
least NCT03861429 379 384 I-Eq-Comparison
2 NCT03861429 385 386 I-Eq-Comparison
weeks NCT03861429 387 392 I-Eq-Comparison
identified NCT03861429 393 403 O
as NCT03861429 404 406 O
a NCT03861429 407 408 O
long NCT03861429 409 413 B-Observation
- NCT03861429 414 415 I-Observation
term NCT03861429 416 420 I-Observation
resident NCT03861429 421 429 I-Observation

- NCT03861429 432 433 O
Age NCT03861429 435 438 B-Age
> NCT03861429 439 440 B-Eq-Comparison
65 NCT03861429 441 443 I-Eq-Comparison
years NCT03861429 444 449 I-Eq-Comparison

- NCT03861429 452 453 O
Speaks NCT03861429 455 461 O
English NCT03861429 462 469 O

Family NCT03861429 470 476 O
Inclusion NCT03861429 477 486 O
Criteria NCT03861429 487 495 O
: NCT03861429 496 497 O

- NCT03861429 501 502 O
Speaks NCT03861429 504 510 O
English NCT03861429 511 518 O

- NCT03861429 521 522 O
Willing NCT03861429 524 531 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03861429 532 535 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03861429 536 540 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 541 543 I-Assertion___Assertion-Type-Value:hypothetical
watch NCT03861429 544 549 O
the NCT03861429 550 553 O
videos NCT03861429 554 560 O

- NCT03861429 563 564 O
Willing NCT03861429 566 573 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 574 576 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03861429 577 585 O
short NCT03861429 586 591 B-Observation
surveys NCT03861429 592 599 I-Observation
. NCT03861429 599 600 O
Being NCT03861429 602 607 O
unable NCT03861429 608 614 O
to NCT03861429 615 617 O
attend NCT03861429 618 624 O
care NCT03861429 625 629 O
conference NCT03861429 630 640 O
to NCT03861429 641 643 O
view NCT03861429 644 648 O
the NCT03861429 649 652 O
video NCT03861429 653 658 O
( NCT03861429 659 660 O
e. NCT03861429 661 663 O
g. NCT03861429 664 666 O
due NCT03861429 668 671 O
to NCT03861429 672 674 O
distance NCT03861429 675 683 O
) NCT03861429 684 685 O
will NCT03861429 686 690 O
not NCT03861429 691 694 O
exclude NCT03861429 695 702 O
family NCT03861429 703 709 O
from NCT03861429 710 714 O
participating NCT03861429 715 728 O
. NCT03861429 729 730 O

Staff NCT03861429 732 737 O
Inclusion NCT03861429 738 747 O
Criteria NCT03861429 748 756 O
: NCT03861429 757 758 O

- NCT03861429 762 763 O
Speaks NCT03861429 765 771 O
English NCT03861429 772 779 O

- NCT03861429 782 783 O
Willing NCT03861429 785 792 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 793 795 I-Assertion___Assertion-Type-Value:hypothetical
watch NCT03861429 796 801 O
the NCT03861429 802 805 O
videos NCT03861429 806 812 O

- NCT03861429 815 816 O
Willing NCT03861429 818 825 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861429 826 828 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03861429 829 837 O
short NCT03861429 838 843 O
surveys NCT03861429 844 851 O

Resident NCT03861429 852 860 O
Exclusion NCT03861429 861 870 O
Criteria NCT03861429 871 879 O
: NCT03861429 880 881 O

- NCT03861429 885 886 O
Limited NCT03861429 888 895 O
communication NCT03861429 896 909 B-Condition
capacity NCT03861429 910 918 I-Condition
( NCT03861429 919 920 O
e. NCT03861429 921 923 O
g. NCT03861429 924 926 O
aphasia NCT03861429 928 935 B-Condition
) NCT03861429 936 937 O

- NCT03861429 941 942 O
Comatose NCT03861429 944 952 B-Condition

- NCT03861429 955 956 O
Cognitively NCT03861429 958 969 B-Condition
intact NCT03861429 970 976 I-Condition

- NCT03861429 979 980 O
Severe NCT03861429 982 988 O
cognitive NCT03861429 989 998 B-Condition
impairment NCT03861429 999 1009 I-Condition

Inclusion NCT03867058 0 9 O
Criteria NCT03867058 10 18 O
: NCT03867058 19 20 O

- NCT03867058 24 25 O
Native NCT03867058 27 33 O
speakers NCT03867058 34 42 O
of NCT03867058 43 45 O
English NCT03867058 46 53 O

- NCT03867058 56 57 O
Cochlear NCT03867058 59 67 B-Procedure
Nucleus NCT03867058 68 75 I-Procedure
cochlear NCT03867058 76 84 I-Procedure
implant NCT03867058 85 92 I-Procedure
users NCT03867058 93 98 O
or NCT03867058 99 101 B-Or
Advanced NCT03867058 102 110 B-Procedure
Bionics NCT03867058 111 118 I-Procedure
users NCT03867058 119 124 O

- NCT03867058 127 128 O
Postlingually NCT03867058 130 143 B-Modifier
deafened NCT03867058 144 152 B-Condition

- NCT03867058 155 156 O
Has NCT03867058 158 161 O
had NCT03867058 162 165 O
device NCT03867058 166 172 B-Procedure
experience NCT03867058 173 183 O
for NCT03867058 184 187 O
at NCT03867058 188 190 B-Eq-Comparison
least NCT03867058 191 196 I-Eq-Comparison
one NCT03867058 197 200 I-Eq-Comparison
year NCT03867058 201 205 I-Eq-Comparison

- NCT03867058 208 209 O
Can NCT03867058 211 214 O
be NCT03867058 215 217 O
child NCT03867058 218 223 O
or NCT03867058 224 226 B-Or
adult NCT03867058 227 232 O
at NCT03867058 233 235 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867058 236 239 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867058 240 244 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867058 245 247 O
enrollment NCT03867058 248 258 B-Study

Exclusion NCT03867058 259 268 O
Criteria NCT03867058 269 277 O
: NCT03867058 278 279 O

- NCT03867058 283 284 O
None NCT03867058 286 290 O

Inclusion NCT03868800 0 9 O
Criteria NCT03868800 10 18 O
: NCT03868800 19 20 O

- NCT03868800 24 25 O
Estimated NCT03868800 27 36 B-Observation
glomerular NCT03868800 37 47 I-Observation
filtration NCT03868800 48 58 I-Observation
rate NCT03868800 59 63 I-Observation
below NCT03868800 64 69 B-Eq-Comparison
20 NCT03868800 70 72 I-Eq-Comparison
ml NCT03868800 73 75 I-Eq-Comparison
/ NCT03868800 76 77 I-Eq-Comparison
min NCT03868800 78 81 I-Eq-Comparison

- NCT03868800 84 85 O
A NCT03868800 87 88 O
clinical NCT03868800 89 97 O
judgement NCT03868800 98 107 O
made NCT03868800 108 112 O
by NCT03868800 113 115 O
the NCT03868800 116 119 O
contact NCT03868800 120 127 O
nurse NCT03868800 128 133 O
and NCT03868800 134 137 O
the NCT03868800 138 141 O
contact NCT03868800 142 149 O
physician NCT03868800 150 159 O

Exclusion NCT03868800 160 169 O
Criteria NCT03868800 170 178 O
: NCT03868800 179 180 O

- NCT03868800 184 185 O
Conservative NCT03868800 187 199 B-Procedure
care NCT03868800 200 204 I-Procedure

- NCT03868800 207 208 O
A NCT03868800 210 211 O
set NCT03868800 212 215 B-Eq-Comparison
date NCT03868800 216 220 I-Eq-Comparison
for NCT03868800 221 224 O
a NCT03868800 225 226 O
transplantation NCT03868800 227 242 B-Procedure
with NCT03868800 243 247 O
a NCT03868800 248 249 O
living NCT03868800 250 256 B-Modifier
donor NCT03868800 257 262 I-Modifier

- NCT03868800 265 266 O
Not NCT03868800 268 271 B-Negation
able NCT03868800 272 276 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868800 277 279 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868800 280 291 B-Study
due NCT03868800 292 295 O
to NCT03868800 296 298 O
cognitive NCT03868800 299 308 B-Condition
impairment NCT03868800 309 319 I-Condition

Inclusion NCT03866811 0 9 O
Criteria NCT03866811 10 18 O
: NCT03866811 19 20 O

- NCT03866811 24 25 O
female NCT03866811 27 33 O
emergency NCT03866811 34 43 B-Encounter
department NCT03866811 44 54 I-Encounter
patient NCT03866811 55 62 O

- NCT03866811 65 66 O
age NCT03866811 68 71 B-Age
14 NCT03866811 72 74 B-Eq-Comparison
- NCT03866811 75 76 I-Eq-Comparison
19 NCT03866811 77 79 I-Eq-Comparison
years NCT03866811 80 85 I-Eq-Comparison

- NCT03866811 88 89 O
sexually NCT03866811 91 99 B-Condition
active NCT03866811 100 106 I-Condition
with NCT03866811 107 111 B-Modifier
males NCT03866811 112 117 I-Modifier
in NCT03866811 118 120 O
the NCT03866811 121 124 O
past NCT03866811 125 129 B-Eq-Comparison
3 NCT03866811 130 131 I-Eq-Comparison
months NCT03866811 132 138 I-Eq-Comparison

Exclusion NCT03866811 139 148 O
Criteria NCT03866811 149 157 O
: NCT03866811 158 159 O

- NCT03866811 163 164 O
currently NCT03866811 166 175 B-Eq-Comparison
using NCT03866811 176 181 I-Eq-Comparison
any NCT03866811 182 185 O
effective NCT03866811 186 195 O
form NCT03866811 196 200 O
of NCT03866811 201 203 O
contraception NCT03866811 204 217 B-Procedure

- NCT03866811 220 221 O
do NCT03866811 223 225 O
not NCT03866811 226 229 O
own NCT03866811 230 233 O
a NCT03866811 234 235 O
mobile NCT03866811 236 242 O
phone NCT03866811 243 248 O
with NCT03866811 249 253 O
texting NCT03866811 254 261 O

- NCT03866811 264 265 O
are NCT03866811 267 270 B-Eq-Comparison
pregnant NCT03866811 271 279 B-Condition

- NCT03866811 282 283 O
are NCT03866811 285 288 B-Eq-Comparison
too NCT03866811 289 292 O
ill NCT03866811 293 296 B-Condition
for NCT03866811 297 300 O
participation NCT03866811 301 314 O
per NCT03866811 315 318 O
the NCT03866811 319 322 O
attending NCT03866811 323 332 B-Provider
physician NCT03866811 333 342 I-Provider

- NCT03866811 345 346 O
are NCT03866811 348 351 B-Eq-Comparison
cognitively NCT03866811 352 363 B-Condition
impaired NCT03866811 364 372 I-Condition

- NCT03866811 375 376 O
do NCT03866811 378 380 O
not NCT03866811 381 384 B-Negation
live NCT03866811 385 389 O
locally NCT03866811 390 397 O

- NCT03866811 400 401 O
do NCT03866811 403 405 O
not NCT03866811 406 409 B-Negation
speak NCT03866811 410 415 O
English NCT03866811 416 423 O

- NCT03866811 426 427 O
want NCT03866811 429 433 B-Assertion___Assertion-Type-Value:intention
to NCT03866811 434 436 I-Assertion___Assertion-Type-Value:intention
" NCT03866811 437 438 O
become NCT03866811 438 444 O
pregnant NCT03866811 445 453 B-Condition
in NCT03866811 454 456 O
the NCT03866811 457 460 O
next NCT03866811 461 465 B-Eq-Comparison
year NCT03866811 466 470 I-Eq-Comparison
" NCT03866811 470 471 O

Inclusion NCT03865459 0 9 O
Criteria NCT03865459 10 18 O
: NCT03865459 19 20 O

- NCT03865459 24 25 O
age NCT03865459 27 30 B-Age
> NCT03865459 31 32 B-Eq-Comparison
18 NCT03865459 33 35 I-Eq-Comparison
years NCT03865459 36 41 I-Eq-Comparison

- NCT03865459 44 45 O
female NCT03865459 47 53 O
gender NCT03865459 54 60 O

- NCT03865459 63 64 O
rigid NCT03865459 66 71 B-Modifier
cystoscopy NCT03865459 72 82 B-Procedure
for NCT03865459 83 86 O
the NCT03865459 87 90 O
first NCT03865459 91 96 B-Eq-Comparison
time NCT03865459 97 101 I-Eq-Comparison

Exclusion NCT03865459 102 111 O
Criteria NCT03865459 112 120 O
: NCT03865459 121 122 O

- NCT03865459 126 127 O
presence NCT03865459 129 137 O
of NCT03865459 138 140 O
any NCT03865459 141 144 O
contraindication NCT03865459 145 161 B-Contraindication
for NCT03865459 162 165 O
cystoscopy NCT03865459 166 176 B-Procedure
( NCT03865459 177 178 O
such NCT03865459 179 183 O
as NCT03865459 184 186 O
lidocaine NCT03865459 187 196 B-Drug
allergy NCT03865459 197 204 B-Allergy
, NCT03865459 205 206 O
urinary NCT03865459 207 214 B-Condition
tract NCT03865459 215 220 I-Condition
infection NCT03865459 221 230 I-Condition
, NCT03865459 231 232 O
and NCT03865459 233 236 B-Or
urethra NCT03865459 237 244 B-Modifier
- NCT03865459 245 246 O
related NCT03865459 247 254 O
anatomical NCT03865459 255 265 B-Condition
disorders NCT03865459 266 275 I-Condition
) NCT03865459 276 277 O

- NCT03865459 281 282 O
any NCT03865459 284 287 O
analgesic NCT03865459 288 297 B-Drug
used NCT03865459 298 302 O
24 NCT03865459 303 305 B-Eq-Comparison
hours NCT03865459 306 311 I-Eq-Comparison
before NCT03865459 312 318 B-Temporal-Connection___Temporal-Connection-Type-Value:before
cystoscopy NCT03865459 319 329 B-Procedure

- NCT03865459 332 333 O
manipulations NCT03865459 335 348 B-Procedure
such NCT03865459 349 353 O
as NCT03865459 354 356 O
Double NCT03865459 357 363 B-Procedure
- NCT03865459 364 365 I-Procedure
J NCT03865459 366 367 I-Procedure
stent NCT03865459 368 373 I-Procedure
placement NCT03865459 374 383 B-Modifier
or NCT03865459 384 386 B-Or
removal NCT03865459 387 394 B-Modifier
, NCT03865459 395 396 O
and NCT03865459 397 400 B-Or
/ NCT03865459 401 402 I-Or
or NCT03865459 403 405 I-Or
bladder NCT03865459 406 413 B-Modifier
biopsy NCT03865459 414 420 B-Procedure
. NCT03865459 420 421 O

Inclusion NCT03865303 0 9 O
Criteria NCT03865303 10 18 O

- NCT03865303 21 22 O
For NCT03865303 24 27 O
EMR NCT03865303 28 31 O
review NCT03865303 32 38 O
all NCT03865303 39 42 O
adults NCT03865303 43 49 O
admitted NCT03865303 50 58 B-Encounter
to NCT03865303 59 61 O
the NCT03865303 62 65 O
hospital NCT03865303 66 74 O
ages NCT03865303 75 79 B-Age
18 NCT03865303 80 82 B-Eq-Comparison
and NCT03865303 83 86 I-Eq-Comparison
older NCT03865303 87 92 I-Eq-Comparison
with NCT03865303 93 97 O
research NCT03865303 98 106 O
authorization NCT03865303 107 120 O

- NCT03865303 123 124 O
For NCT03865303 126 129 O
survey NCT03865303 130 136 O
- NCT03865303 137 138 O
clinicians NCT03865303 139 149 O
including NCT03865303 150 159 O
physicians NCT03865303 160 170 B-Provider
, NCT03865303 171 172 O
advanced NCT03865303 173 181 B-Provider
care NCT03865303 182 186 I-Provider
practitioners NCT03865303 187 200 I-Provider

- NCT03865303 203 204 O
For NCT03865303 206 209 O
focus NCT03865303 210 215 O
groups NCT03865303 216 222 O
and NCT03865303 223 226 O
interviews NCT03865303 227 237 O
- NCT03865303 238 239 O
clinicians NCT03865303 240 250 O
including NCT03865303 251 260 O
physicians NCT03865303 261 271 B-Provider
, NCT03865303 272 273 O
advanced NCT03865303 274 282 B-Provider
care NCT03865303 283 287 I-Provider
practitioners NCT03865303 288 301 I-Provider

Exclusion NCT03865303 302 311 O
Criteria NCT03865303 312 320 O

- NCT03865303 323 324 O
Age NCT03865303 326 329 B-Age
< NCT03865303 330 331 B-Eq-Comparison
18 NCT03865303 332 334 I-Eq-Comparison
years NCT03865303 335 340 I-Eq-Comparison
old NCT03865303 341 344 O

- NCT03865303 347 348 O
No NCT03865303 350 352 O
research NCT03865303 353 361 O
authorization NCT03865303 362 375 O

- NCT03865303 378 379 O
Refusal NCT03865303 381 388 O
to NCT03865303 389 391 O
give NCT03865303 392 396 O
consent NCT03865303 397 404 O

Inclusion NCT03867266 0 9 O
criteria NCT03867266 10 18 O
: NCT03867266 19 20 O

- NCT03867266 24 25 O
paroxysmal NCT03867266 27 37 B-Modifier
, NCT03867266 38 39 O
persistent NCT03867266 40 50 B-Modifier
and NCT03867266 51 54 B-Or
/ NCT03867266 55 56 I-Or
or NCT03867266 57 59 I-Or
long NCT03867266 60 64 B-Modifier
standing NCT03867266 65 73 I-Modifier
atrial NCT03867266 74 80 B-Condition
flutter NCT03867266 81 88 I-Condition
even NCT03867266 89 93 O
in NCT03867266 94 96 O
the NCT03867266 97 100 O
presence NCT03867266 101 109 O
of NCT03867266 110 112 O
structural NCT03867266 113 123 B-Modifier
heart NCT03867266 124 129 B-Condition
disease NCT03867266 130 137 I-Condition

- NCT03867266 140 141 O
Informed NCT03867266 143 151 O
consent NCT03867266 152 159 O
form NCT03867266 160 164 O

- NCT03867266 167 168 O
Age NCT03867266 170 173 B-Age
equal NCT03867266 174 179 B-Eq-Comparison
or NCT03867266 180 182 I-Eq-Comparison
above NCT03867266 183 188 I-Eq-Comparison
18 NCT03867266 189 191 I-Eq-Comparison
years NCT03867266 192 197 I-Eq-Comparison

- NCT03867266 200 201 O
Skilled NCT03867266 203 210 O
and NCT03867266 211 214 O
willing NCT03867266 215 222 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867266 223 225 I-Assertion___Assertion-Type-Value:hypothetical
comply NCT03867266 226 232 O
with NCT03867266 233 237 O
all NCT03867266 238 241 O
tests NCT03867266 242 247 B-Procedure
and NCT03867266 248 251 B-And
follow NCT03867266 252 258 B-Encounter
up NCT03867266 259 261 I-Encounter
requirements NCT03867266 262 274 O

- NCT03867266 277 278 O
Patients NCT03867266 280 288 O
that NCT03867266 289 293 O
, NCT03867266 294 295 O
in NCT03867266 296 298 O
the NCT03867266 299 302 O
context NCT03867266 303 310 O
of NCT03867266 311 313 O
ablation NCT03867266 314 322 B-Procedure
for NCT03867266 323 326 O
fibrillation NCT03867266 327 339 B-Condition
atrial NCT03867266 340 346 I-Condition
, NCT03867266 347 348 O
should NCT03867266 349 355 B-Assertion___Assertion-Type-Value:hypothetical
also NCT03867266 356 360 O
undergo NCT03867266 361 368 O
to NCT03867266 369 371 O
typical NCT03867266 372 379 B-Modifier
flutter NCT03867266 380 387 B-Procedure
ablation NCT03867266 388 396 I-Procedure
: NCT03867266 397 398 O
in NCT03867266 399 401 O
this NCT03867266 402 406 O
case NCT03867266 407 411 O
the NCT03867266 412 415 O
data NCT03867266 416 420 O
collected NCT03867266 421 430 O
will NCT03867266 431 435 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867266 436 438 I-Assertion___Assertion-Type-Value:hypothetical
those NCT03867266 439 444 O
related NCT03867266 445 452 O
to NCT03867266 453 455 O
typical NCT03867266 456 463 O
flutter NCT03867266 464 471 B-Procedure
ablation NCT03867266 472 480 I-Procedure
. NCT03867266 481 482 O

Exclusion NCT03867266 484 493 O
Criteria NCT03867266 494 502 O
: NCT03867266 503 504 O

- NCT03867266 508 509 O
Previous NCT03867266 511 519 B-Eq-Comparison
ablation NCT03867266 520 528 B-Procedure
for NCT03867266 529 532 O
atrial NCT03867266 533 539 B-Condition
flutter NCT03867266 540 547 I-Condition

- NCT03867266 550 551 O
Atrial NCT03867266 553 559 B-Condition
flutter NCT03867266 560 567 I-Condition
secondary NCT03867266 568 577 B-Modifier
to NCT03867266 578 580 O
electrolyte NCT03867266 581 592 B-Condition
imbalance NCT03867266 593 602 I-Condition
, NCT03867266 603 604 O
thyroid NCT03867266 605 612 B-Condition
disease NCT03867266 613 620 I-Condition
or NCT03867266 621 623 B-Or
to NCT03867266 624 626 O
a NCT03867266 627 628 O
reversible NCT03867266 629 639 B-Modifier
or NCT03867266 640 642 B-Or
non NCT03867266 643 646 B-Negation
- NCT03867266 647 648 O
cardiac NCT03867266 649 656 B-Modifier
cause NCT03867266 657 662 B-Condition

- NCT03867266 665 666 O
severe NCT03867266 668 674 O
anemia NCT03867266 675 681 B-Condition
, NCT03867266 682 683 O

- NCT03867266 687 688 O
sepsis NCT03867266 690 696 B-Condition
in NCT03867266 697 699 B-Eq-Comparison
progress NCT03867266 700 708 I-Eq-Comparison

- NCT03867266 711 712 O
Bypass NCT03867266 714 720 B-Procedure
procedure NCT03867266 721 730 I-Procedure
with NCT03867266 731 735 O
coronary NCT03867266 736 744 B-Modifier
arterial NCT03867266 745 753 I-Modifier
artery NCT03867266 754 760 I-Modifier
in NCT03867266 761 763 O
the NCT03867266 764 767 O
last NCT03867266 768 772 B-Eq-Comparison
three NCT03867266 773 778 I-Eq-Comparison
months NCT03867266 779 785 I-Eq-Comparison

- NCT03867266 788 789 O
Pending NCT03867266 791 798 B-Eq-Comparison
cardiac NCT03867266 799 806 B-Procedure
transplantation NCT03867266 807 822 I-Procedure
or NCT03867266 823 825 B-Or
other NCT03867266 826 831 B-Other
cardiac NCT03867266 832 839 B-Procedure
surgery NCT03867266 840 847 I-Procedure

- NCT03867266 850 851 O
Pregnant NCT03867266 853 861 B-Condition
or NCT03867266 862 864 B-Or
breastfeeding NCT03867266 865 878 B-Condition
women NCT03867266 879 884 O

- NCT03867266 887 888 O
Acute NCT03867266 890 895 O
disease NCT03867266 896 903 B-Condition
or NCT03867266 904 906 B-Or
active NCT03867266 907 913 B-Eq-Comparison
systemic NCT03867266 914 922 B-Modifier
infection NCT03867266 923 932 B-Condition
or NCT03867266 933 935 B-Or
sepsis NCT03867266 936 942 B-Condition

- NCT03867266 945 946 O
Documented NCT03867266 948 958 O
left NCT03867266 959 963 B-Modifier
atrial NCT03867266 964 970 B-Condition
thrombus NCT03867266 971 979 I-Condition

- NCT03867266 982 983 O
Unstable NCT03867266 985 993 O
angina NCT03867266 994 1000 B-Condition

- NCT03867266 1003 1004 O
Uncontrolled NCT03867266 1006 1018 B-Modifier
heart NCT03867266 1019 1024 B-Condition
failure NCT03867266 1025 1032 I-Condition

- NCT03867266 1035 1036 O
Life NCT03867266 1038 1042 B-Observation
expectancy NCT03867266 1043 1053 I-Observation
of NCT03867266 1054 1056 O
less NCT03867266 1057 1061 B-Eq-Comparison
than NCT03867266 1062 1066 I-Eq-Comparison
12 NCT03867266 1067 1069 I-Eq-Comparison
months NCT03867266 1070 1076 I-Eq-Comparison

- NCT03867266 1079 1080 O
Registration NCT03867266 1082 1094 O
in NCT03867266 1095 1097 O
any NCT03867266 1098 1101 O
other NCT03867266 1102 1107 B-Other
study NCT03867266 1108 1113 B-Study
evaluating NCT03867266 1114 1124 O
another NCT03867266 1125 1132 B-Other
device NCT03867266 1133 1139 B-Procedure
or NCT03867266 1140 1142 B-Or
medication NCT03867266 1143 1153 B-Drug

- NCT03867266 1156 1157 O
Presence NCT03867266 1159 1167 O
of NCT03867266 1168 1170 O
intramural NCT03867266 1171 1181 B-Condition
thrombi NCT03867266 1182 1189 I-Condition
, NCT03867266 1190 1191 O
tumor NCT03867266 1192 1197 B-Condition
or NCT03867266 1198 1200 B-Or
other NCT03867266 1201 1206 B-Other
anomalies NCT03867266 1207 1216 B-Condition
that NCT03867266 1217 1221 O
preclude NCT03867266 1222 1230 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03867266 1231 1234 O
introduction NCT03867266 1235 1247 O
of NCT03867266 1248 1250 O
the NCT03867266 1251 1254 O
catheter NCT03867266 1255 1263 B-Procedure
into NCT03867266 1264 1268 O
the NCT03867266 1269 1272 O
vein NCT03867266 1273 1277 B-Modifier
system NCT03867266 1278 1284 I-Modifier

Inclusion NCT03867500 0 9 O
criteria NCT03867500 10 18 O
: NCT03867500 19 20 O

- NCT03867500 24 25 O
Women NCT03867500 27 32 O
and NCT03867500 33 36 B-Or
Men NCT03867500 37 40 O
( NCT03867500 41 42 O
Women NCT03867500 43 48 O
premenopausal NCT03867500 49 62 B-Condition
) NCT03867500 63 64 O

- NCT03867500 68 69 O
BMI NCT03867500 71 74 B-Observation
29 NCT03867500 75 77 B-Eq-Comparison
- NCT03867500 78 79 I-Eq-Comparison
37 NCT03867500 80 82 O

- NCT03867500 86 87 O
Weight NCT03867500 89 95 B-Observation
stable NCT03867500 96 102 O

- NCT03867500 105 106 O
Not NCT03867500 108 111 B-Negation
pregnant NCT03867500 112 120 B-Condition
/ NCT03867500 121 122 B-Or
nursing NCT03867500 123 130 B-Condition

Exclusion NCT03867500 131 140 O
criteria NCT03867500 141 149 O
: NCT03867500 150 151 O

- NCT03867500 155 156 O
Ischemic NCT03867500 158 166 B-Condition
heart NCT03867500 167 172 I-Condition
disease NCT03867500 173 180 I-Condition

- NCT03867500 183 184 O
Atherosclerotic NCT03867500 186 201 B-Condition
valvular NCT03867500 202 210 I-Condition
disease NCT03867500 211 218 I-Condition

- NCT03867500 221 222 O
Smokers NCT03867500 224 231 B-Condition|Observation
( NCT03867500 232 233 O
> NCT03867500 235 236 B-Eq-Comparison
20 NCT03867500 237 239 I-Eq-Comparison
cigarettes NCT03867500 240 250 I-Eq-Comparison
per NCT03867500 251 254 I-Eq-Comparison
week NCT03867500 255 259 I-Eq-Comparison
) NCT03867500 260 261 O

- NCT03867500 265 266 O
Bilateral NCT03867500 268 277 B-Modifier
oophorectomy NCT03867500 278 290 B-Procedure

- NCT03867500 293 294 O
Concomitant NCT03867500 296 307 B-Modifier
use NCT03867500 308 311 O
of NCT03867500 312 314 O
medications NCT03867500 315 326 B-Drug
that NCT03867500 327 331 O
can NCT03867500 332 335 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03867500 336 341 O
serum NCT03867500 342 347 B-Observation
lipid NCT03867500 348 353 I-Observation
profile NCT03867500 354 361 I-Observation
: NCT03867500 362 363 O

- NCT03867500 372 373 O
High NCT03867500 375 379 O
dose NCT03867500 380 384 O
fish NCT03867500 385 389 B-Drug
oil NCT03867500 390 393 I-Drug
( NCT03867500 394 395 O
> NCT03867500 397 398 B-Eq-Comparison
3 NCT03867500 399 400 I-Eq-Comparison
g NCT03867500 401 402 I-Eq-Comparison
per NCT03867500 403 406 I-Eq-Comparison
day NCT03867500 407 410 I-Eq-Comparison
) NCT03867500 411 412 O
, NCT03867500 414 415 O

- NCT03867500 424 425 O
STATINS NCT03867500 427 434 B-Drug
( NCT03867500 435 436 O
if NCT03867500 437 439 O
yes NCT03867500 440 443 O
hold NCT03867500 444 448 B-Eq-Comparison
for NCT03867500 449 452 I-Eq-Comparison
6 NCT03867500 453 454 I-Eq-Comparison
weeks NCT03867500 455 460 I-Eq-Comparison
and NCT03867500 461 464 O
receive NCT03867500 465 472 O
PCP NCT03867500 473 476 B-Provider
's NCT03867500 476 478 O
approval NCT03867500 479 487 B-Observation
) NCT03867500 488 489 O
, NCT03867500 491 492 O

- NCT03867500 501 502 O
Niacin NCT03867500 504 510 B-Drug

- NCT03867500 518 519 O
Fibrates NCT03867500 521 529 B-Drug

- NCT03867500 537 538 O
thiazolidinediones NCT03867500 540 558 B-Drug

- NCT03867500 566 567 O
Beta NCT03867500 569 573 B-Drug
- NCT03867500 574 575 I-Drug
blockers NCT03867500 576 584 I-Drug

- NCT03867500 592 593 O
Atypical NCT03867500 595 603 B-Modifier
antipsychotics NCT03867500 604 618 B-Drug

- NCT03867500 621 622 O
Lidocaine NCT03867500 624 633 B-Drug
or NCT03867500 634 636 B-Or
Niacin NCT03867500 637 643 B-Drug
/ NCT03867500 644 645 B-Or
Niaspan NCT03867500 646 653 B-Drug
allergy NCT03867500 654 661 B-Allergy

- NCT03867500 664 665 O
Subjects NCT03867500 667 675 O
with NCT03867500 676 680 O
1.5 NCT03867500 681 684 B-Eq-Comparison
times NCT03867500 685 690 I-Eq-Comparison
upper NCT03867500 691 696 I-Eq-Comparison
limit NCT03867500 697 702 I-Eq-Comparison
of NCT03867500 703 705 I-Eq-Comparison
normal NCT03867500 706 712 I-Eq-Comparison
of NCT03867500 713 715 O
serum NCT03867500 716 721 B-Observation
creatinine NCT03867500 722 732 I-Observation
, NCT03867500 733 734 O
Alkaline NCT03867500 735 743 B-Observation
phosphatase NCT03867500 744 755 I-Observation
, NCT03867500 756 757 O
Aspartate NCT03867500 758 767 B-Observation
aminotransferase NCT03867500 768 784 I-Observation
( NCT03867500 785 786 O
AST NCT03867500 787 790 B-Observation
) NCT03867500 791 792 O
, NCT03867500 794 795 O
Alanine NCT03867500 796 803 B-Observation
aminotransferase NCT03867500 804 820 I-Observation
( NCT03867500 821 822 O
ALT NCT03867500 823 826 B-Observation
) NCT03867500 827 828 O
unless NCT03867500 829 835 B-Exception
participant NCT03867500 836 847 O
has NCT03867500 848 851 O
fatty NCT03867500 852 857 B-Condition
liver NCT03867500 858 863 I-Condition
disease NCT03867500 864 871 I-Condition
, NCT03867500 872 873 O
Total NCT03867500 874 879 B-Observation
bilirubin NCT03867500 880 889 I-Observation
( NCT03867500 890 891 O
unless NCT03867500 892 898 B-Exception
the NCT03867500 899 902 O
patient NCT03867500 903 910 O
has NCT03867500 911 914 O
documented NCT03867500 915 925 O
Gilbert NCT03867500 926 933 B-Condition
's NCT03867500 933 935 I-Condition
syndrome NCT03867500 936 944 I-Condition
) NCT03867500 945 946 O

Inclusion NCT03865316 0 9 O
Criteria NCT03865316 10 18 O
: NCT03865316 19 20 O

- NCT03865316 24 25 O
Patients NCT03865316 27 35 O
18 NCT03865316 36 38 B-Eq-Comparison
years NCT03865316 39 44 I-Eq-Comparison
old NCT03865316 45 48 I-Age|Eq-Comparison
and NCT03865316 49 52 I-Eq-Comparison
older NCT03865316 53 58 I-Eq-Comparison
at NCT03865316 59 61 O
the NCT03865316 62 65 O
time NCT03865316 66 70 O
of NCT03865316 71 73 O
consent NCT03865316 74 81 O
. NCT03865316 82 83 O

- NCT03865316 87 88 O
ASA NCT03865316 90 93 B-Condition
status NCT03865316 94 100 O
I NCT03865316 101 102 B-Eq-Comparison
, NCT03865316 103 104 I-Eq-Comparison
II NCT03865316 105 107 I-Eq-Comparison
, NCT03865316 108 109 I-Eq-Comparison
or NCT03865316 110 112 I-Eq-Comparison
III NCT03865316 113 116 I-Eq-Comparison
. NCT03865316 117 118 O

- NCT03865316 122 123 O
English NCT03865316 125 132 O
- NCT03865316 133 134 O
speaking NCT03865316 135 143 O
subjects NCT03865316 144 152 O
. NCT03865316 153 154 O

- NCT03865316 158 159 O
Scheduled NCT03865316 161 170 B-Eq-Comparison
for NCT03865316 171 174 O
surgical NCT03865316 175 183 B-Modifier
and NCT03865316 184 187 B-Or
non NCT03865316 188 191 B-Negation
- NCT03865316 192 193 O
surgical NCT03865316 194 202 B-Modifier
procedures NCT03865316 203 213 B-Procedure
scheduled NCT03865316 214 223 B-Eq-Comparison
under NCT03865316 224 229 O
general NCT03865316 230 237 B-Procedure
anesthesia NCT03865316 238 248 I-Procedure
( NCT03865316 249 250 O
Common NCT03865316 251 257 B-Coreference
procedures NCT03865316 258 268 I-Coreference
include NCT03865316 269 276 O
but NCT03865316 277 280 O
are NCT03865316 281 284 O
not NCT03865316 285 288 O
restricted NCT03865316 289 299 O
to NCT03865316 300 302 O
tonsillectomy NCT03865316 303 316 B-Procedure
, NCT03865316 317 318 O
adenoidectomy NCT03865316 319 332 B-Procedure
, NCT03865316 333 334 O
urological NCT03865316 335 345 B-Procedure
procedures NCT03865316 346 356 I-Procedure
, NCT03865316 357 358 O
dental NCT03865316 359 365 B-Procedure
rehabilitation NCT03865316 366 380 I-Procedure
, NCT03865316 381 382 O
orthopedic NCT03865316 383 393 B-Procedure
procedures NCT03865316 394 404 I-Procedure
, NCT03865316 405 406 O
biopsies NCT03865316 407 415 B-Procedure
, NCT03865316 416 417 O
audiogram NCT03865316 418 427 B-Procedure
, NCT03865316 428 429 O
nuclear NCT03865316 430 437 B-Procedure
scans NCT03865316 438 443 I-Procedure
, NCT03865316 444 445 O
gastroscopy NCT03865316 446 457 B-Procedure
, NCT03865316 458 459 O
colonoscopy NCT03865316 460 471 B-Procedure
, NCT03865316 472 473 O
etc NCT03865316 474 477 O
. NCT03865316 477 478 O
) NCT03865316 479 480 O
. NCT03865316 482 483 O

Exclusion NCT03865316 485 494 O
Criteria NCT03865316 495 503 O
: NCT03865316 504 505 O

- NCT03865316 509 510 O
Any NCT03865316 512 515 O
deformities NCT03865316 516 527 B-Condition
or NCT03865316 528 530 B-Or
devices NCT03865316 531 538 B-Procedure
that NCT03865316 539 543 O
may NCT03865316 544 547 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03865316 548 555 B-Negation
application NCT03865316 556 567 O
of NCT03865316 568 570 O
EEG NCT03865316 571 574 B-Procedure
Sensor NCT03865316 575 581 I-Procedure
to NCT03865316 582 584 O
forehead NCT03865316 585 593 B-Modifier
with NCT03865316 594 598 O
a NCT03865316 599 600 O
proper NCT03865316 601 607 O
fit NCT03865316 608 611 O
. NCT03865316 612 613 O

- NCT03865316 617 618 O
Subjects NCT03865316 620 628 O
who NCT03865316 629 632 O
are NCT03865316 633 636 O
developmentally NCT03865316 637 652 B-Condition
delayed NCT03865316 653 660 I-Condition
. NCT03865316 661 662 O

- NCT03865316 666 667 O
Subjects NCT03865316 669 677 O
deemed NCT03865316 678 684 O
not NCT03865316 685 688 B-Assertion___Assertion-Type-Value:hypothetical|Negation
suitable NCT03865316 689 697 I-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03865316 698 701 O
study NCT03865316 702 707 B-Study
at NCT03865316 708 710 O
the NCT03865316 711 714 O
discretion NCT03865316 715 725 O
of NCT03865316 726 728 O
the NCT03865316 729 732 O
investigator NCT03865316 733 745 O
. NCT03865316 745 746 O

Inclusion NCT03863015 0 9 O
Criteria NCT03863015 10 18 O
: NCT03863015 19 20 O

Each NCT03863015 22 26 O
of NCT03863015 27 29 O
the NCT03863015 30 33 O
following NCT03863015 34 43 O
criteria NCT03863015 44 52 O
must NCT03863015 53 57 O
be NCT03863015 58 60 O
fulfilled NCT03863015 61 70 O
for NCT03863015 71 74 O
a NCT03863015 75 76 O
subject NCT03863015 77 84 O
to NCT03863015 85 87 O
be NCT03863015 88 90 O
eligible NCT03863015 91 99 O
: NCT03863015 100 101 O

1 NCT03863015 105 106 O
. NCT03863015 106 107 O
Age NCT03863015 109 112 B-Age
≥ NCT03863015 113 114 B-Eq-Comparison
18 NCT03863015 115 117 I-Eq-Comparison
years NCT03863015 118 123 I-Eq-Comparison

2 NCT03863015 126 127 O
. NCT03863015 127 128 O
OHCA NCT03863015 130 134 B-Condition
of NCT03863015 135 137 O
a NCT03863015 138 139 O
presumed NCT03863015 140 148 O
cardiac NCT03863015 149 156 B-Condition
cause NCT03863015 157 162 I-Condition

3 NCT03863015 165 166 O
. NCT03863015 166 167 O
Unconsciousness NCT03863015 169 184 B-Condition
upon NCT03863015 185 189 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 190 199 B-Encounter
, NCT03863015 200 201 O
i. NCT03863015 202 204 O
e. NCT03863015 205 207 O
a NCT03863015 209 210 O
GCS NCT03863015 211 214 B-Observation
< NCT03863015 215 216 B-Eq-Comparison
9 NCT03863015 217 218 I-Eq-Comparison

4 NCT03863015 222 223 O
. NCT03863015 223 224 O
Sustained NCT03863015 226 235 O
ROSC NCT03863015 236 240 B-Condition
for NCT03863015 241 244 O
more NCT03863015 245 249 B-Eq-Comparison
than NCT03863015 250 254 I-Eq-Comparison
20 NCT03863015 255 257 I-Eq-Comparison
minutes NCT03863015 258 265 I-Eq-Comparison

Exclusion NCT03863015 266 275 O
Criteria NCT03863015 276 284 O
: NCT03863015 285 286 O

None NCT03863015 288 292 O
of NCT03863015 293 295 O
the NCT03863015 296 299 O
following NCT03863015 300 309 O
criteria NCT03863015 310 318 O
must NCT03863015 319 323 O
be NCT03863015 324 326 O
fulfilled NCT03863015 327 336 O
for NCT03863015 337 340 O
a NCT03863015 341 342 O
subject NCT03863015 343 350 O
to NCT03863015 351 353 O
be NCT03863015 354 356 O
eligible NCT03863015 357 365 O
: NCT03863015 366 367 O

1 NCT03863015 371 372 O
. NCT03863015 372 373 O
Consciousness NCT03863015 375 388 B-Condition
upon NCT03863015 389 393 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 394 403 B-Encounter
, NCT03863015 404 405 O
i. NCT03863015 406 408 O
e. NCT03863015 409 411 O
a NCT03863015 413 414 O
GCS NCT03863015 415 418 B-Observation
≥ NCT03863015 419 420 B-Eq-Comparison
9 NCT03863015 421 422 I-Eq-Comparison

2 NCT03863015 426 427 O
. NCT03863015 427 428 O
Presumed NCT03863015 430 438 O
non NCT03863015 439 442 B-Negation
- NCT03863015 443 444 O
cardiac NCT03863015 445 452 B-Modifier
cause NCT03863015 453 458 O
of NCT03863015 459 461 O
arrest NCT03863015 462 468 B-Condition

3 NCT03863015 471 472 O
. NCT03863015 472 473 O
Unwitnessed NCT03863015 475 486 B-Condition
asystole NCT03863015 487 495 I-Condition

4 NCT03863015 498 499 O
. NCT03863015 499 500 O
Suspected NCT03863015 502 511 B-Assertion___Assertion-Type-Value:possible
or NCT03863015 512 514 B-Or
confirmed NCT03863015 515 524 B-Modifier
intracranial NCT03863015 525 537 B-Condition
bleeding NCT03863015 538 546 I-Condition
or NCT03863015 547 549 B-Or
stroke NCT03863015 550 556 B-Condition

5 NCT03863015 559 560 O
. NCT03863015 560 561 O
Pregnancy NCT03863015 563 572 B-Condition
, NCT03863015 573 574 O
or NCT03863015 575 577 B-Or
females NCT03863015 578 585 O
in NCT03863015 586 588 O
fertile NCT03863015 589 596 B-Condition
age NCT03863015 597 600 I-Condition
, NCT03863015 601 602 O
unless NCT03863015 603 609 B-Or
a NCT03863015 610 611 O
negative NCT03863015 612 620 O
serum NCT03863015 621 626 B-Observation
HCG NCT03863015 627 630 I-Observation
can NCT03863015 631 634 B-Assertion___Assertion-Type-Value:hypothetical
rule NCT03863015 635 639 I-Assertion___Assertion-Type-Value:hypothetical
out NCT03863015 640 643 I-Assertion___Assertion-Type-Value:hypothetical
pregnancy NCT03863015 644 653 B-Condition
within NCT03863015 654 660 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863015 661 664 O
inclusion NCT03863015 665 674 B-Study
window NCT03863015 675 681 I-Study
. NCT03863015 682 683 O

6 NCT03863015 687 688 O
. NCT03863015 688 689 O
Temperature NCT03863015 691 702 B-Observation
on NCT03863015 703 705 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03863015 706 715 B-Encounter
< NCT03863015 716 717 B-Eq-Comparison
30 NCT03863015 718 720 I-Eq-Comparison
° NCT03863015 721 722 I-Eq-Comparison
C NCT03863015 722 723 I-Eq-Comparison

7 NCT03863015 726 727 O
. NCT03863015 727 728 O
Persistent NCT03863015 730 740 B-Modifier
cardiogenic NCT03863015 741 752 B-Condition
shock NCT03863015 753 758 I-Condition
* NCT03863015 758 759 O
that NCT03863015 760 764 O
is NCT03863015 765 767 O
not NCT03863015 768 771 B-Negation
reversed NCT03863015 772 780 B-Modifier
within NCT03863015 781 787 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863015 788 791 O
inclusion NCT03863015 792 801 B-Study
window NCT03863015 802 808 I-Study

8 NCT03863015 811 812 O
. NCT03863015 812 813 O
Known NCT03863015 815 820 O
disease NCT03863015 821 828 B-Condition
making NCT03863015 829 835 O
180 NCT03863015 836 839 B-Eq-Comparison
day NCT03863015 840 843 I-Eq-Comparison
survival NCT03863015 844 852 B-Death|Risk
unlikely NCT03863015 853 861 I-Death|Risk

9 NCT03863015 864 865 O
. NCT03863015 865 866 O
Known NCT03863015 868 873 O
limitations NCT03863015 874 885 B-Assertion___Assertion-Type-Value:hypothetical|Negation
in NCT03863015 886 888 O
therapy NCT03863015 889 896 B-Procedure

10 NCT03863015 898 900 O
. NCT03863015 900 901 O
Known NCT03863015 903 908 O
pre NCT03863015 909 912 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03863015 913 914 O
arrest NCT03863015 915 921 B-Condition
Cerebral NCT03863015 922 930 B-Observation
Performance NCT03863015 931 942 I-Observation
Category NCT03863015 943 951 I-Observation
of NCT03863015 952 954 O
3 NCT03863015 955 956 B-Eq-Comparison
to NCT03863015 957 959 I-Eq-Comparison
4 NCT03863015 960 961 I-Eq-Comparison

11 NCT03863015 964 966 O
. NCT03863015 966 967 O
> NCT03863015 969 970 B-Eq-Comparison
240 NCT03863015 971 974 I-Eq-Comparison
minutes NCT03863015 975 982 I-Eq-Comparison
from NCT03863015 983 987 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ROSC NCT03863015 988 992 B-Observation
to NCT03863015 993 995 O
randomization NCT03863015 996 1009 B-Study

Inclusion NCT03860246 0 9 O
Criteria NCT03860246 10 18 O
: NCT03860246 19 20 O

Nursing NCT03860246 22 29 O
home NCT03860246 30 34 O
residents NCT03860246 35 44 O
with NCT03860246 45 49 O
≥ NCT03860246 50 51 B-Eq-Comparison
2 NCT03860246 52 53 I-Eq-Comparison
of NCT03860246 54 56 O
the NCT03860246 57 60 B-Criteria-Count
following NCT03860246 61 70 I-Criteria-Count
risk NCT03860246 71 75 B-Risk
factors NCT03860246 76 83 I-Risk
for NCT03860246 84 87 O
atrial NCT03860246 88 94 B-Condition
fibrillation NCT03860246 95 107 I-Condition
: NCT03860246 108 109 O

- NCT03860246 113 114 O
age NCT03860246 116 119 B-Age
≥ NCT03860246 120 121 B-Eq-Comparison
75 NCT03860246 122 124 I-Eq-Comparison
years NCT03860246 125 130 I-Eq-Comparison

- NCT03860246 133 134 O
female NCT03860246 136 142 O
sex NCT03860246 143 146 O

- NCT03860246 149 150 O
obstructive NCT03860246 152 163 B-Condition
sleep NCT03860246 164 169 I-Condition
apnea NCT03860246 170 175 I-Condition

- NCT03860246 178 179 O
peripheral NCT03860246 181 191 B-Condition
vascular NCT03860246 192 200 I-Condition
disease NCT03860246 201 208 I-Condition

- NCT03860246 211 212 O
diabetes NCT03860246 214 222 B-Condition
mellitus NCT03860246 223 231 I-Condition

- NCT03860246 234 235 O
obesity NCT03860246 237 244 B-Condition
( NCT03860246 245 246 O
body NCT03860246 247 251 B-Observation
mass NCT03860246 252 256 I-Observation
index NCT03860246 257 262 I-Observation
[ NCT03860246 263 264 O
BMI NCT03860246 265 268 B-Observation
] NCT03860246 269 270 O
> NCT03860246 271 272 B-Eq-Comparison
30 NCT03860246 273 275 I-Eq-Comparison
kg NCT03860246 276 278 I-Eq-Comparison
/ NCT03860246 279 280 I-Eq-Comparison
m2 NCT03860246 281 283 I-Eq-Comparison
) NCT03860246 284 285 O

- NCT03860246 289 290 O
hypertension NCT03860246 292 304 B-Condition

- NCT03860246 307 308 O
congestive NCT03860246 310 320 B-Condition
heart NCT03860246 321 326 I-Condition
failure NCT03860246 327 334 I-Condition

Exclusion NCT03860246 335 344 O
Criteria NCT03860246 345 353 O
: NCT03860246 354 355 O

- NCT03860246 359 360 O
prior NCT03860246 362 367 B-Eq-Comparison
diagnosis NCT03860246 368 377 O
of NCT03860246 378 380 O
AF NCT03860246 381 383 B-Condition

- NCT03860246 386 387 O
continuous NCT03860246 389 399 B-Modifier
rhythm NCT03860246 400 406 B-Procedure
monitoring NCT03860246 407 417 I-Procedure
over NCT03860246 418 422 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860246 423 426 O
past NCT03860246 427 431 B-Eq-Comparison
year NCT03860246 432 436 I-Eq-Comparison

- NCT03860246 439 440 O
pacemaker NCT03860246 442 451 B-Procedure
or NCT03860246 452 454 B-Or
implantable NCT03860246 455 466 B-Procedure
cardioverter NCT03860246 467 479 I-Procedure
defibrillator NCT03860246 480 493 I-Procedure
in NCT03860246 494 496 B-Modifier
situ NCT03860246 497 501 I-Modifier

Inclusion NCT03861819 0 9 O
Criteria NCT03861819 10 18 O
: NCT03861819 19 20 O

- NCT03861819 24 25 O
Ages NCT03861819 27 31 B-Age
18 NCT03861819 32 34 B-Eq-Comparison
- NCT03861819 35 36 I-Eq-Comparison
59 NCT03861819 37 39 O

- NCT03861819 43 44 O
Histologically NCT03861819 46 60 O
confirmed NCT03861819 61 70 O
nonalcoholic NCT03861819 71 83 B-Condition
steatohepatitis NCT03861819 84 99 I-Condition
and NCT03861819 100 103 B-Or
fibrosis NCT03861819 104 112 B-Condition
( NCT03861819 113 114 O
stage NCT03861819 115 120 B-Eq-Comparison
1 NCT03861819 121 122 I-Eq-Comparison
- NCT03861819 123 124 I-Eq-Comparison
3 NCT03861819 125 126 I-Eq-Comparison
) NCT03861819 127 128 O
from NCT03861819 129 133 O
liver NCT03861819 134 139 B-Procedure
biopsy NCT03861819 140 146 I-Procedure

- NCT03861819 149 150 O
Able NCT03861819 152 156 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861819 157 159 I-Assertion___Assertion-Type-Value:hypothetical
row NCT03861819 160 163 O
on NCT03861819 164 166 O
an NCT03861819 167 169 O
indoor NCT03861819 170 176 B-Observation
rowing NCT03861819 177 183 I-Observation
apparatus NCT03861819 184 193 I-Observation

- NCT03861819 196 197 O
Not NCT03861819 199 202 B-Negation
participating NCT03861819 203 216 O
in NCT03861819 217 219 O
regular NCT03861819 220 227 O
physical NCT03861819 228 236 B-Observation
exercise NCT03861819 237 245 I-Observation
( NCT03861819 246 247 O
more NCT03861819 248 252 B-Eq-Comparison
than NCT03861819 253 257 I-Eq-Comparison
60 NCT03861819 258 260 I-Eq-Comparison
minutes NCT03861819 261 268 I-Eq-Comparison
of NCT03861819 269 271 O
moderate NCT03861819 272 280 O
intensity NCT03861819 281 290 O
or NCT03861819 291 293 B-Or
30 NCT03861819 294 296 B-Eq-Comparison
minutes NCT03861819 297 304 I-Eq-Comparison
of NCT03861819 305 307 O
vigorous NCT03861819 308 316 O
intensity NCT03861819 317 326 O
exercise NCT03861819 327 335 B-Observation
per NCT03861819 336 339 B-Eq-Comparison
week NCT03861819 340 344 I-Eq-Comparison
) NCT03861819 345 346 O

- NCT03861819 350 351 O
Not NCT03861819 353 356 B-Negation
actively NCT03861819 357 365 O
trying NCT03861819 366 372 B-Assertion___Assertion-Type-Value:intention
to NCT03861819 373 375 I-Assertion___Assertion-Type-Value:intention
lose NCT03861819 376 380 B-Condition
weight NCT03861819 381 387 I-Condition
through NCT03861819 388 395 O
a NCT03861819 396 397 O
dietary NCT03861819 398 405 B-Observation
approach NCT03861819 406 414 I-Observation

- NCT03861819 417 418 O
No NCT03861819 420 422 B-Negation
absolute NCT03861819 423 431 O
contra NCT03861819 432 438 B-Contraindication
- NCT03861819 439 440 I-Contraindication
indications NCT03861819 441 452 I-Contraindication
to NCT03861819 453 455 O
exercise NCT03861819 456 464 B-Observation
: NCT03861819 465 466 O
recent NCT03861819 467 473 B-Eq-Comparison
( NCT03861819 474 475 O
< NCT03861819 477 478 B-Eq-Comparison
6 NCT03861819 479 480 I-Eq-Comparison
months NCT03861819 481 487 I-Eq-Comparison
) NCT03861819 488 489 O
acute NCT03861819 490 495 O
cardiac NCT03861819 496 503 B-Condition
event NCT03861819 504 509 I-Condition
unstable NCT03861819 510 518 O
angina NCT03861819 519 525 B-Condition
, NCT03861819 526 527 O
uncontrolled NCT03861819 528 540 B-Modifier
dysrhythmias NCT03861819 541 553 B-Condition
causing NCT03861819 554 561 O
symptoms NCT03861819 562 570 B-Assertion___Assertion-Type-Value:possible
or NCT03861819 571 573 B-Or
hemodynamic NCT03861819 574 585 B-Modifier
compromise NCT03861819 586 596 B-Condition
, NCT03861819 597 598 O
symptomatic NCT03861819 599 610 B-Assertion___Assertion-Type-Value:possible
aortic NCT03861819 611 617 B-Condition
stenosis NCT03861819 618 626 I-Condition
, NCT03861819 627 628 O
uncontrolled NCT03861819 629 641 B-Modifier
symptomatic NCT03861819 642 653 B-Assertion___Assertion-Type-Value:possible
heart NCT03861819 654 659 B-Condition
failure NCT03861819 660 667 I-Condition
, NCT03861819 668 669 O
acute NCT03861819 670 675 O
pulmonary NCT03861819 676 685 B-Condition
embolus NCT03861819 686 693 I-Condition
, NCT03861819 694 695 O
acute NCT03861819 696 701 O
myocarditis NCT03861819 702 713 B-Condition
or NCT03861819 714 716 B-Or
pericarditis NCT03861819 717 729 B-Condition
, NCT03861819 730 731 O
suspected NCT03861819 732 741 B-Assertion___Assertion-Type-Value:possible
or NCT03861819 742 744 B-Or
known NCT03861819 745 750 O
dissecting NCT03861819 751 761 B-Condition
aneurism NCT03861819 762 770 I-Condition
and NCT03861819 771 774 B-Or
acute NCT03861819 775 780 O
systemic NCT03861819 781 789 B-Modifier
infection NCT03861819 790 799 B-Condition

- NCT03861819 802 803 O
No NCT03861819 805 807 B-Negation
other NCT03861819 808 813 B-Other
form NCT03861819 814 818 O
of NCT03861819 819 821 O
chronic NCT03861819 822 829 B-Modifier
liver NCT03861819 830 835 B-Condition
disease NCT03861819 836 843 I-Condition
( NCT03861819 844 845 O
as NCT03861819 846 848 O
confirmed NCT03861819 849 858 O
by NCT03861819 859 861 O
serology NCT03861819 862 870 B-Procedure
and NCT03861819 871 874 B-Or
histology NCT03861819 875 884 B-Procedure
) NCT03861819 885 886 O

- NCT03861819 890 891 O
No NCT03861819 893 895 B-Negation
liver NCT03861819 896 901 B-Condition
cirrhosis NCT03861819 902 911 I-Condition
( NCT03861819 912 913 O
stage NCT03861819 914 919 B-Eq-Comparison
4 NCT03861819 920 921 I-Eq-Comparison
fibrosis NCT03861819 922 930 B-Condition
on NCT03861819 931 933 O
liver NCT03861819 934 939 B-Procedure
biopsy NCT03861819 940 946 I-Procedure
) NCT03861819 947 948 O
or NCT03861819 949 951 B-Or
a NCT03861819 952 953 O
clinical NCT03861819 954 962 O
diagnosis NCT03861819 963 972 O
of NCT03861819 973 975 O
cirrhosis NCT03861819 976 985 B-Condition
as NCT03861819 986 988 O
ascertained NCT03861819 989 1000 O
by NCT03861819 1001 1003 O
a NCT03861819 1004 1005 O
hepatologist NCT03861819 1006 1018 B-Provider

- NCT03861819 1021 1022 O
No NCT03861819 1024 1026 B-Negation
coronary NCT03861819 1027 1035 B-Condition
artery NCT03861819 1036 1042 I-Condition
disease NCT03861819 1043 1050 I-Condition
or NCT03861819 1051 1053 B-Or
chronic NCT03861819 1054 1061 B-Modifier
obstructive NCT03861819 1062 1073 B-Condition
pulmonary NCT03861819 1074 1083 I-Condition
disease NCT03861819 1084 1091 I-Condition
. NCT03861819 1092 1093 O

- NCT03861819 1097 1098 O
No NCT03861819 1100 1102 B-Negation
diagnosis NCT03861819 1103 1112 O
of NCT03861819 1113 1115 O
malignancy NCT03861819 1116 1126 B-Condition
( NCT03861819 1127 1128 O
except NCT03861819 1129 1135 B-Exception
non NCT03861819 1136 1139 B-Negation
- NCT03861819 1140 1141 O
melanoma NCT03861819 1142 1150 B-Modifier
skin NCT03861819 1151 1155 B-Modifier
cancer NCT03861819 1156 1162 B-Condition
) NCT03861819 1163 1164 O

- NCT03861819 1168 1169 O
No NCT03861819 1171 1173 B-Negation
past NCT03861819 1174 1178 B-Eq-Comparison
or NCT03861819 1179 1181 B-Or
present NCT03861819 1182 1189 B-Eq-Comparison
history NCT03861819 1190 1197 I-Eq-Comparison
of NCT03861819 1198 1200 O
portal NCT03861819 1201 1207 B-Condition
hypertension NCT03861819 1208 1220 I-Condition
( NCT03861819 1221 1222 O
esophageal NCT03861819 1223 1233 B-Modifier
varices NCT03861819 1234 1241 B-Condition
, NCT03861819 1242 1243 O
ascites NCT03861819 1244 1251 B-Condition
, NCT03861819 1252 1253 O
hepatic NCT03861819 1254 1261 B-Condition
encephalopathy NCT03861819 1262 1276 I-Condition
) NCT03861819 1277 1278 O

- NCT03861819 1282 1283 O
No NCT03861819 1285 1287 B-Negation
use NCT03861819 1288 1291 O
of NCT03861819 1292 1294 O
immunosuppression NCT03861819 1295 1312 B-Drug
or NCT03861819 1313 1315 B-Or
chronic NCT03861819 1316 1323 B-Modifier
nonsteroidal NCT03861819 1324 1336 B-Drug
anti NCT03861819 1337 1341 I-Drug
- NCT03861819 1342 1343 I-Drug
inflammatory NCT03861819 1344 1356 I-Drug
medication NCT03861819 1357 1367 I-Drug

- NCT03861819 1370 1371 O
No NCT03861819 1373 1375 B-Eq-Comparison
more NCT03861819 1376 1380 I-Eq-Comparison
than NCT03861819 1381 1385 I-Eq-Comparison
14 NCT03861819 1386 1388 I-Eq-Comparison
drinks NCT03861819 1389 1395 I-Eq-Comparison|Observation
per NCT03861819 1396 1399 I-Eq-Comparison
week NCT03861819 1400 1404 I-Eq-Comparison
( NCT03861819 1405 1406 O
if NCT03861819 1407 1409 O
male NCT03861819 1410 1414 O
) NCT03861819 1415 1416 O
or NCT03861819 1417 1419 B-Or
7 NCT03861819 1420 1421 B-Eq-Comparison
drinks NCT03861819 1422 1428 I-Eq-Comparison|Observation
a NCT03861819 1429 1430 I-Eq-Comparison
week NCT03861819 1431 1435 I-Eq-Comparison
( NCT03861819 1436 1437 O
if NCT03861819 1438 1440 O
female NCT03861819 1441 1447 O
) NCT03861819 1448 1449 O
in NCT03861819 1450 1452 O
the NCT03861819 1453 1456 O
last NCT03861819 1457 1461 B-Eq-Comparison
2 NCT03861819 1462 1463 I-Eq-Comparison
years NCT03861819 1464 1469 I-Eq-Comparison

- NCT03861819 1472 1473 O
Cognitively NCT03861819 1475 1486 O
able NCT03861819 1487 1491 O
to NCT03861819 1492 1494 O
provide NCT03861819 1495 1502 O
consent NCT03861819 1503 1510 O

- NCT03861819 1513 1514 O
Able NCT03861819 1516 1520 O
to NCT03861819 1521 1523 O
read NCT03861819 1524 1528 O
, NCT03861819 1529 1530 O
write NCT03861819 1531 1536 O
, NCT03861819 1537 1538 O
and NCT03861819 1539 1542 O
understand NCT03861819 1543 1553 O
English NCT03861819 1554 1561 O

- NCT03861819 1564 1565 O
Transportation NCT03861819 1567 1581 O
to NCT03861819 1582 1584 O
the NCT03861819 1585 1588 O
exercise NCT03861819 1589 1597 O
and NCT03861819 1598 1601 O
testing NCT03861819 1602 1609 O
facility NCT03861819 1610 1618 O

Inclusion NCT03867071 0 9 O
Criteria NCT03867071 10 18 O
: NCT03867071 19 20 O

- NCT03867071 24 25 O
Patients NCT03867071 27 35 O
between NCT03867071 36 43 B-Eq-Comparison
18 NCT03867071 44 46 I-Eq-Comparison
to NCT03867071 47 49 I-Eq-Comparison
65 NCT03867071 50 52 I-Eq-Comparison
years NCT03867071 53 58 I-Eq-Comparison
old NCT03867071 59 62 B-Age

- NCT03867071 65 66 O
Patient NCT03867071 68 75 O
with NCT03867071 76 80 O
an NCT03867071 81 83 O
ASA NCT03867071 84 87 B-Condition
1 NCT03867071 88 89 B-Eq-Comparison
or NCT03867071 90 92 I-Eq-Comparison
2 NCT03867071 93 94 I-Eq-Comparison
( NCT03867071 95 96 O
ASA NCT03867071 97 100 O
1 NCT03867071 101 102 O
corresponding NCT03867071 103 116 O
to NCT03867071 117 119 O
a NCT03867071 120 121 O
patient NCT03867071 122 129 O
in NCT03867071 130 132 O
perfect NCT03867071 133 140 O
health NCT03867071 141 147 O
and NCT03867071 148 151 O
ASA NCT03867071 152 155 O
2 NCT03867071 156 157 O
to NCT03867071 158 160 O
a NCT03867071 161 162 O
patient NCT03867071 163 170 O
with NCT03867071 171 175 O
moderate NCT03867071 176 184 O
involvement NCT03867071 185 196 O
and NCT03867071 197 200 O
well NCT03867071 201 205 O
controlled NCT03867071 206 216 O
organ NCT03867071 217 222 O
function NCT03867071 223 231 O
) NCT03867071 232 233 O

- NCT03867071 237 238 O
patient NCT03867071 240 247 O
presenting NCT03867071 248 258 O
at NCT03867071 259 261 B-Eq-Comparison
least NCT03867071 262 267 I-Eq-Comparison
one NCT03867071 268 271 I-Eq-Comparison
of NCT03867071 272 274 O
the NCT03867071 275 278 B-Criteria-Count
following NCT03867071 279 288 I-Criteria-Count
fractures NCT03867071 289 298 B-Condition
: NCT03867071 299 300 O
Basin NCT03867071 301 306 B-Modifier
and NCT03867071 307 310 B-Or
/ NCT03867071 311 312 I-Or
or NCT03867071 313 315 I-Or
femur NCT03867071 316 321 B-Modifier
with NCT03867071 322 326 O
surgical NCT03867071 327 335 B-Procedure
indication NCT03867071 336 346 B-Indication
, NCT03867071 347 348 O
associated NCT03867071 349 359 O
or NCT03867071 360 362 O
not NCT03867071 363 366 O
with NCT03867071 367 371 O
other NCT03867071 372 377 B-Other
fractures NCT03867071 378 387 B-Condition
. NCT03867071 388 389 O

- NCT03867071 393 394 O
patient NCT03867071 396 403 O
with NCT03867071 404 408 O
hemoglobin NCT03867071 409 419 B-Observation
between NCT03867071 420 427 B-Eq-Comparison
9 NCT03867071 428 429 I-Eq-Comparison
and NCT03867071 430 433 I-Eq-Comparison
13 NCT03867071 434 436 I-Eq-Comparison
g NCT03867071 437 438 I-Eq-Comparison
/ NCT03867071 439 440 I-Eq-Comparison
dl NCT03867071 441 443 I-Eq-Comparison
at NCT03867071 444 446 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867071 447 450 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03867071 451 455 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03867071 456 458 O
admission NCT03867071 459 468 B-Encounter
on NCT03867071 469 471 O
trauma NCT03867071 472 478 O
department NCT03867071 479 489 O

Exclusion NCT03867071 490 499 O
Criteria NCT03867071 500 508 O
: NCT03867071 509 510 O

- NCT03867071 514 515 O
patient NCT03867071 517 524 O
with NCT03867071 525 529 O
contraindication NCT03867071 530 546 B-Contraindication
to NCT03867071 547 549 O
synthetic NCT03867071 550 559 B-Procedure
erythropoietin NCT03867071 560 574 I-Procedure

- NCT03867071 577 578 O
Patient NCT03867071 580 587 O
with NCT03867071 588 592 O
intravenous NCT03867071 593 604 B-Procedure
iron NCT03867071 605 609 I-Procedure
contraindication NCT03867071 610 626 B-Contraindication

- NCT03867071 629 630 O
pregnant NCT03867071 632 640 B-Condition
patient NCT03867071 641 648 O
or NCT03867071 649 651 B-Or
with NCT03867071 652 656 O
a NCT03867071 657 658 O
risk NCT03867071 659 663 B-Risk
of NCT03867071 664 666 O
pregnancy NCT03867071 667 676 B-Condition

- NCT03867071 679 680 O
patient NCT03867071 682 689 O
who NCT03867071 690 693 O
has NCT03867071 694 697 O
not NCT03867071 698 701 O
given NCT03867071 702 707 O
his NCT03867071 708 711 O
consent NCT03867071 712 719 O
or NCT03867071 720 722 O
does NCT03867071 723 727 O
not NCT03867071 728 731 O
understand NCT03867071 732 742 O
the NCT03867071 743 746 O
protocol NCT03867071 747 755 O

- NCT03867071 758 759 O
Patient NCT03867071 761 768 O
with NCT03867071 769 773 O
hemodynamic NCT03867071 774 785 B-Condition
instability NCT03867071 786 797 O

- NCT03867071 800 801 O
patient NCT03867071 803 810 O
participating NCT03867071 811 824 O
in NCT03867071 825 827 O
another NCT03867071 828 835 B-Other
research NCT03867071 836 844 B-Study
protocol NCT03867071 845 853 I-Study
for NCT03867071 854 857 O
less NCT03867071 858 862 B-Eq-Comparison
than NCT03867071 863 867 I-Eq-Comparison
3 NCT03867071 868 869 I-Eq-Comparison
months NCT03867071 870 876 I-Eq-Comparison
. NCT03867071 877 878 O


Inclusion NCT03862690 0 9 O
Criteria NCT03862690 10 18 O
: NCT03862690 19 20 O

- NCT03862690 24 25 O
Signed NCT03862690 27 33 O
consent NCT03862690 34 41 O
obtained NCT03862690 42 50 O
before NCT03862690 51 57 O
any NCT03862690 58 61 O
study NCT03862690 62 67 O
- NCT03862690 68 69 O
related NCT03862690 70 77 O
activities NCT03862690 78 88 O
( NCT03862690 89 90 O
study NCT03862690 91 96 O
- NCT03862690 97 98 O
related NCT03862690 99 106 O
activities NCT03862690 107 117 O
are NCT03862690 118 121 O
any NCT03862690 122 125 O
procedure NCT03862690 126 135 O
related NCT03862690 136 143 O
to NCT03862690 144 146 O
recording NCT03862690 147 156 O
of NCT03862690 157 159 O
data NCT03862690 160 164 O
according NCT03862690 165 174 O
to NCT03862690 175 177 O
the NCT03862690 178 181 O
protocol NCT03862690 182 190 O
) NCT03862690 191 192 O

- NCT03862690 196 197 O
The NCT03862690 199 202 O
decision NCT03862690 203 211 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862690 212 214 I-Assertion___Assertion-Type-Value:hypothetical
initiate NCT03862690 215 223 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03862690 224 233 B-Procedure
with NCT03862690 234 238 O
commercially NCT03862690 239 251 O
available NCT03862690 252 261 O
NovoMix NCT03862690 262 269 B-Drug
® NCT03862690 269 270 I-Drug
30 NCT03862690 271 273 I-Drug
has NCT03862690 274 277 O
been NCT03862690 278 282 O
made NCT03862690 283 287 O
by NCT03862690 288 290 O
the NCT03862690 291 294 O
patient NCT03862690 295 302 O
and NCT03862690 303 306 O
the NCT03862690 307 310 O
treating NCT03862690 311 319 O
physician NCT03862690 320 329 O
before NCT03862690 330 336 O
and NCT03862690 337 340 O
independently NCT03862690 341 354 O
from NCT03862690 355 359 O
the NCT03862690 360 363 O
decision NCT03862690 364 372 O
to NCT03862690 373 375 O
include NCT03862690 376 383 O
the NCT03862690 384 387 O
patient NCT03862690 388 395 O
in NCT03862690 396 398 O
this NCT03862690 399 403 O
study NCT03862690 404 409 O

- NCT03862690 412 413 O
Male NCT03862690 415 419 O
or NCT03862690 420 422 B-Or
female NCT03862690 423 429 O
, NCT03862690 430 431 O
greater NCT03862690 432 439 B-Eq-Comparison
than NCT03862690 440 444 I-Eq-Comparison
or NCT03862690 445 447 I-Eq-Comparison
equal NCT03862690 448 453 I-Eq-Comparison
to NCT03862690 454 456 I-Eq-Comparison
19 NCT03862690 457 459 I-Eq-Comparison
years NCT03862690 460 465 I-Age|Eq-Comparison
at NCT03862690 466 468 O
the NCT03862690 469 472 O
time NCT03862690 473 477 O
of NCT03862690 478 480 O
signing NCT03862690 481 488 O
informed NCT03862690 489 497 O
consent NCT03862690 498 505 O

- NCT03862690 508 509 O
Diagnosed NCT03862690 511 520 O
with NCT03862690 521 525 O
type NCT03862690 526 530 B-Modifier
2 NCT03862690 531 532 I-Modifier
diabetes NCT03862690 533 541 B-Condition
and NCT03862690 542 545 B-And
treated NCT03862690 546 553 B-Procedure
with NCT03862690 554 558 O
basal NCT03862690 559 564 B-Drug
insulin NCT03862690 565 572 I-Drug
plus NCT03862690 573 577 O
1 NCT03862690 578 579 B-Eq-Comparison
- NCT03862690 580 581 I-Eq-Comparison
3 NCT03862690 582 583 I-Eq-Comparison
bolus NCT03862690 584 589 I-Eq-Comparison
insulin NCT03862690 590 597 I-Eq-Comparison
injections NCT03862690 598 608 I-Eq-Comparison
per NCT03862690 609 612 I-Eq-Comparison
day NCT03862690 613 616 I-Eq-Comparison
for NCT03862690 617 620 O
at NCT03862690 621 623 B-Eq-Comparison
least NCT03862690 624 629 I-Eq-Comparison
24 NCT03862690 630 632 I-Eq-Comparison
weeks NCT03862690 633 638 I-Eq-Comparison
prior NCT03862690 639 644 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 645 647 I-Temporal-Connection___Temporal-Connection-Type-Value:before
informed NCT03862690 648 656 O
consent NCT03862690 657 664 O

- NCT03862690 667 668 O
Available NCT03862690 670 679 O
and NCT03862690 680 683 O
documented NCT03862690 684 694 O
HbA1c NCT03862690 695 700 B-Observation
value NCT03862690 701 706 O
less NCT03862690 707 711 B-Eq-Comparison
than NCT03862690 712 716 I-Eq-Comparison
or NCT03862690 717 719 I-Eq-Comparison
equal NCT03862690 720 725 I-Eq-Comparison
to NCT03862690 726 728 I-Eq-Comparison
12 NCT03862690 729 731 I-Eq-Comparison
weeks NCT03862690 732 737 I-Eq-Comparison
prior NCT03862690 738 743 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 744 746 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03862690 747 757 B-Eq-Comparison
of NCT03862690 758 760 O
NovoMix NCT03862690 761 768 B-Drug
® NCT03862690 768 769 I-Drug
30 NCT03862690 770 772 I-Drug
treatment NCT03862690 773 782 B-Procedure

Exclusion NCT03862690 783 792 O
Criteria NCT03862690 793 801 O
: NCT03862690 802 803 O

- NCT03862690 807 808 O
Previous NCT03862690 810 818 B-Eq-Comparison
participation NCT03862690 819 832 O
in NCT03862690 833 835 O
this NCT03862690 836 840 O
study NCT03862690 841 846 B-Study
. NCT03862690 846 847 O
Participation NCT03862690 849 862 O
is NCT03862690 863 865 O
defined NCT03862690 866 873 O
as NCT03862690 874 876 O
having NCT03862690 877 883 O
given NCT03862690 884 889 O
informed NCT03862690 890 898 O
consent NCT03862690 899 906 O
in NCT03862690 907 909 O
this NCT03862690 910 914 O
study NCT03862690 915 920 O

- NCT03862690 923 924 O
Mental NCT03862690 926 932 B-Condition
incapacity NCT03862690 933 943 I-Condition
, NCT03862690 944 945 O
unwillingness NCT03862690 946 959 B-Modifier
or NCT03862690 960 962 B-Or
language NCT03862690 963 971 B-Condition
barriers NCT03862690 972 980 I-Condition
precluding NCT03862690 981 991 O
adequate NCT03862690 992 1000 O
understanding NCT03862690 1001 1014 O
or NCT03862690 1015 1017 O
cooperation NCT03862690 1018 1029 O

- NCT03862690 1032 1033 O
Participation NCT03862690 1035 1048 O
in NCT03862690 1049 1051 O
any NCT03862690 1052 1055 O
clinical NCT03862690 1056 1064 B-Study
trial NCT03862690 1065 1070 I-Study
of NCT03862690 1071 1073 O
an NCT03862690 1074 1076 O
approved NCT03862690 1077 1085 O
or NCT03862690 1086 1088 B-Or
non NCT03862690 1089 1092 O
- NCT03862690 1093 1094 O
approved NCT03862690 1095 1103 O
investigational NCT03862690 1104 1119 B-Study
medicinal NCT03862690 1120 1129 B-Drug
product NCT03862690 1130 1137 I-Drug
within NCT03862690 1138 1144 B-Eq-Comparison
24 NCT03862690 1145 1147 I-Eq-Comparison
weeks NCT03862690 1148 1153 I-Eq-Comparison
prior NCT03862690 1154 1159 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862690 1160 1162 I-Temporal-Connection___Temporal-Connection-Type-Value:before
initiation NCT03862690 1163 1173 B-Eq-Comparison
of NCT03862690 1174 1176 O
NovoMix NCT03862690 1177 1184 B-Drug
® NCT03862690 1184 1185 I-Drug
30 NCT03862690 1186 1188 I-Drug
treatment NCT03862690 1189 1198 B-Procedure
. NCT03862690 1198 1199 O
Clinical NCT03862690 1201 1209 O
trials NCT03862690 1210 1216 O
do NCT03862690 1217 1219 O
not NCT03862690 1220 1223 O
include NCT03862690 1224 1231 O
non NCT03862690 1232 1235 O
- NCT03862690 1236 1237 O
interventional NCT03862690 1238 1252 O
studies NCT03862690 1253 1260 O

- NCT03862690 1263 1264 O
Hypersensitivity NCT03862690 1266 1282 B-Condition
to NCT03862690 1283 1285 O
NovoMix NCT03862690 1286 1293 B-Drug
® NCT03862690 1293 1294 I-Drug
30 NCT03862690 1295 1297 I-Drug
or NCT03862690 1298 1300 B-Or
to NCT03862690 1301 1303 O
any NCT03862690 1304 1307 O
of NCT03862690 1308 1310 O
the NCT03862690 1311 1314 O
excipients NCT03862690 1315 1325 B-Coreference

- NCT03862690 1328 1329 O
Pregnancy NCT03862690 1331 1340 B-Condition
or NCT03862690 1341 1343 B-Or
intention NCT03862690 1344 1353 B-Assertion___Assertion-Type-Value:intention
of NCT03862690 1354 1356 O
becoming NCT03862690 1357 1365 O
pregnant NCT03862690 1366 1374 B-Condition

Inclusion NCT03865706 0 9 O
Criteria NCT03865706 10 18 O
: NCT03865706 19 20 O

1 NCT03865706 24 25 O
. NCT03865706 25 26 O
Hospitalized NCT03865706 28 40 B-Encounter
in NCT03865706 41 43 O
an NCT03865706 44 46 O
eligible NCT03865706 47 55 B-Assertion___Assertion-Type-Value:hypothetical
medical NCT03865706 56 63 O
ICU NCT03865706 64 67 O

2 NCT03865706 70 71 O
. NCT03865706 71 72 O
Age NCT03865706 74 77 B-Age
≥ NCT03865706 78 79 B-Eq-Comparison
18 NCT03865706 80 82 I-Eq-Comparison
years NCT03865706 83 88 I-Eq-Comparison
old NCT03865706 89 92 O
at NCT03865706 93 95 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865706 96 99 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865706 100 104 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865706 105 107 O
hospitalization NCT03865706 108 123 B-Encounter

3 NCT03865706 126 127 O
. NCT03865706 127 128 O
With NCT03865706 130 134 O
sepsis NCT03865706 135 141 B-Condition
as NCT03865706 142 144 O
defined NCT03865706 145 152 O
by NCT03865706 153 155 O
the NCT03865706 156 159 O
Sepsis NCT03865706 160 166 O
- NCT03865706 167 168 O
3 NCT03865706 169 170 O
( NCT03865706 171 172 O
2016 NCT03865706 173 177 O
) NCT03865706 178 179 O
consensus NCT03865706 180 189 O
as NCT03865706 190 192 O
a NCT03865706 193 194 O
known NCT03865706 195 200 B-Modifier
or NCT03865706 201 203 B-Or
suspected NCT03865706 204 213 B-Assertion___Assertion-Type-Value:possible
infection NCT03865706 214 223 B-Condition
with NCT03865706 224 228 B-And
a NCT03865706 229 230 O
SOFA NCT03865706 231 235 B-Observation
score NCT03865706 236 241 I-Observation
of NCT03865706 242 244 O
≥ NCT03865706 245 246 B-Eq-Comparison
2 NCT03865706 247 248 I-Eq-Comparison
points NCT03865706 249 255 I-Eq-Comparison
above NCT03865706 256 261 I-Eq-Comparison
baseline NCT03865706 262 270 I-Eq-Comparison

4 NCT03865706 273 274 O
. NCT03865706 274 275 O
Received NCT03865706 277 285 B-Eq-Comparison
broad NCT03865706 286 291 B-Modifier
- NCT03865706 292 293 I-Modifier
spectrum NCT03865706 294 302 I-Modifier
antibiotics NCT03865706 303 314 B-Drug
within NCT03865706 315 321 B-Eq-Comparison
the NCT03865706 322 325 I-Eq-Comparison
last NCT03865706 326 330 I-Eq-Comparison
24 NCT03865706 331 333 I-Eq-Comparison
hours NCT03865706 334 339 I-Eq-Comparison
or NCT03865706 340 342 B-Or
ordered NCT03865706 343 350 B-Coreference
and NCT03865706 351 354 O
pending NCT03865706 355 362 B-Assertion___Assertion-Type-Value:hypothetical
administration NCT03865706 363 377 I-Assertion___Assertion-Type-Value:hypothetical

5 NCT03865706 380 381 O
. NCT03865706 381 382 O
Able NCT03865706 384 388 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03865706 389 391 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03865706 392 400 O
enrollment NCT03865706 401 411 B-Study
within NCT03865706 412 418 B-Eq-Comparison
4 NCT03865706 419 420 I-Eq-Comparison
hours NCT03865706 421 426 I-Eq-Comparison
of NCT03865706 427 429 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ICU NCT03865706 430 433 O
admission NCT03865706 434 443 B-Encounter
for NCT03865706 444 447 O
administration NCT03865706 448 462 O
of NCT03865706 463 465 O
the NCT03865706 466 469 O
intervention NCT03865706 470 482 B-Study
within NCT03865706 483 489 B-Eq-Comparison
6 NCT03865706 490 491 I-Eq-Comparison
hours NCT03865706 492 497 I-Eq-Comparison
of NCT03865706 498 500 B-Temporal-Connection___Temporal-Connection-Type-Value:after
ICU NCT03865706 501 504 O
admission NCT03865706 505 514 B-Encounter

Exclusion NCT03865706 515 524 O
Criteria NCT03865706 525 533 O
: NCT03865706 534 535 O

1 NCT03865706 539 540 O
. NCT03865706 540 541 O
Inability NCT03865706 543 552 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03865706 553 555 O
receive NCT03865706 556 563 O
oral NCT03865706 564 568 B-Modifier
or NCT03865706 569 571 B-Or
enteric NCT03865706 572 579 B-Modifier
fluids NCT03865706 580 586 B-Procedure

2 NCT03865706 589 590 O
. NCT03865706 590 591 O
Inulin NCT03865706 593 599 B-Drug
allergy NCT03865706 600 607 B-Allergy

3 NCT03865706 610 611 O
. NCT03865706 611 612 O
Hyponatremia NCT03865706 614 626 B-Condition
( NCT03865706 627 628 O
serum NCT03865706 629 634 B-Observation
sodium NCT03865706 635 641 I-Observation
≤ NCT03865706 642 643 B-Eq-Comparison
128 NCT03865706 644 647 I-Eq-Comparison
mEq NCT03865706 648 651 I-Eq-Comparison
/ NCT03865706 652 653 I-Eq-Comparison
L NCT03865706 654 655 I-Eq-Comparison
) NCT03865706 656 657 O

4 NCT03865706 661 662 O
. NCT03865706 662 663 O
Immunosuppression NCT03865706 665 682 B-Condition
, NCT03865706 683 684 O
defined NCT03865706 685 692 O
as NCT03865706 693 695 O
history NCT03865706 696 703 B-Eq-Comparison
of NCT03865706 704 706 O
solid NCT03865706 707 712 B-Procedure
organ NCT03865706 713 718 I-Procedure
transplant NCT03865706 719 729 I-Procedure
or NCT03865706 730 732 B-Or
as NCT03865706 733 735 O
receipt NCT03865706 736 743 B-Eq-Comparison
of NCT03865706 744 746 O
ablative NCT03865706 747 755 B-Procedure
chemotherapy NCT03865706 756 768 I-Procedure
, NCT03865706 769 770 O
steroids NCT03865706 771 779 B-Drug
at NCT03865706 780 782 O
the NCT03865706 783 786 O
equivalent NCT03865706 787 797 O
of NCT03865706 798 800 O
≥ NCT03865706 801 802 B-Eq-Comparison
5 NCT03865706 803 804 I-Eq-Comparison
mg NCT03865706 805 807 I-Eq-Comparison
/ NCT03865706 808 809 I-Eq-Comparison
day NCT03865706 810 813 I-Eq-Comparison
prednisone NCT03865706 814 824 B-Drug
, NCT03865706 825 826 O
antimetabolites NCT03865706 827 842 B-Drug
, NCT03865706 843 844 O
anti NCT03865706 845 849 B-Drug
- NCT03865706 850 851 I-Drug
TNFα NCT03865706 852 856 I-Drug
agents NCT03865706 857 863 I-Drug
, NCT03865706 864 865 O
calcineurin NCT03865706 866 877 B-Drug
inhibitors NCT03865706 878 888 I-Drug
, NCT03865706 889 890 O
or NCT03865706 891 893 B-Or
mycophenolate NCT03865706 894 907 B-Drug

5 NCT03865706 910 911 O
. NCT03865706 911 912 O
Surgery NCT03865706 914 921 B-Procedure
involving NCT03865706 922 931 O
the NCT03865706 932 935 O
intestinal NCT03865706 936 946 B-Modifier
lumen NCT03865706 947 952 I-Modifier
within NCT03865706 953 959 B-Eq-Comparison
30 NCT03865706 960 962 I-Eq-Comparison
days NCT03865706 963 967 I-Eq-Comparison
or NCT03865706 968 970 B-Or
known NCT03865706 971 976 O
intestinal NCT03865706 977 987 B-Condition
strictures NCT03865706 988 998 I-Condition

6 NCT03865706 1001 1002 O
. NCT03865706 1002 1003 O
Do NCT03865706 1005 1007 B-Observation
Not NCT03865706 1008 1011 I-Observation
Resuscitate NCT03865706 1012 1023 I-Observation
( NCT03865706 1024 1025 O
DNR NCT03865706 1026 1029 B-Observation
) NCT03865706 1030 1031 O
or NCT03865706 1032 1034 B-Or
Do NCT03865706 1035 1037 B-Observation
Not NCT03865706 1038 1041 I-Observation
Intubate NCT03865706 1042 1050 I-Observation
( NCT03865706 1051 1052 O
DNI NCT03865706 1053 1056 B-Observation
) NCT03865706 1057 1058 O
status NCT03865706 1059 1065 O
, NCT03865706 1066 1067 O
or NCT03865706 1068 1070 B-Or
" NCT03865706 1071 1072 O
no NCT03865706 1072 1074 B-Observation
escalation NCT03865706 1075 1085 I-Observation
of NCT03865706 1086 1088 I-Observation
care NCT03865706 1089 1093 I-Observation
" NCT03865706 1093 1094 O
orders NCT03865706 1095 1101 O

7 NCT03865706 1104 1105 O
. NCT03865706 1105 1106 O
Lack NCT03865706 1108 1112 O
capacity NCT03865706 1113 1121 O
for NCT03865706 1122 1125 O
consent NCT03865706 1126 1133 O
and NCT03865706 1134 1137 O
no NCT03865706 1138 1140 O
appropriate NCT03865706 1141 1152 O
Legally NCT03865706 1153 1160 O
Authorized NCT03865706 1161 1171 O
Representative NCT03865706 1172 1186 O
( NCT03865706 1187 1188 O
LAR NCT03865706 1189 1192 O
) NCT03865706 1193 1194 O


Inclusion NCT03863405 0 9 O
Criteria NCT03863405 10 18 O
: NCT03863405 19 20 O

- NCT03863405 24 25 I-Observation
Patients NCT03863405 27 35 O
older NCT03863405 36 41 I-Eq-Comparison
than NCT03863405 42 46 I-Eq-Comparison
18 NCT03863405 47 49 I-Eq-Comparison
years NCT03863405 50 55 I-Eq-Comparison
( NCT03863405 56 57 O
of NCT03863405 58 60 O
both NCT03863405 61 65 O
sexes NCT03863405 66 71 O
) NCT03863405 72 73 O
diagnosed NCT03863405 74 83 O
with NCT03863405 84 88 O
rheumatoid NCT03863405 89 99 B-Condition
arthritis NCT03863405 100 109 I-Condition
according NCT03863405 110 119 O
to NCT03863405 120 122 O
ACR NCT03863405 123 126 O
/ NCT03863405 127 128 O
EULAR NCT03863405 129 134 O
2010 NCT03863405 135 139 O
criteria NCT03863405 140 148 O
. NCT03863405 150 151 I-Observation

- NCT03863405 155 156 O
Patients NCT03863405 158 166 O
with NCT03863405 167 171 O
moderate NCT03863405 172 180 B-Eq-Comparison
to NCT03863405 181 183 I-Eq-Comparison
high NCT03863405 184 188 I-Eq-Comparison
disease NCT03863405 189 196 B-Condition
activity NCT03863405 197 205 I-Condition
( NCT03863405 206 207 O
DAS NCT03863405 208 211 B-Observation
- NCT03863405 212 213 O
28 NCT03863405 214 216 I-Observation
. NCT03863405 217 218 O
score NCT03863405 220 225 I-Observation
greater NCT03863405 226 233 B-Eq-Comparison
than NCT03863405 234 238 I-Eq-Comparison
3.2 NCT03863405 239 242 I-Eq-Comparison
) NCT03863405 243 244 O

- NCT03863405 248 249 O
Patients NCT03863405 251 259 O
received NCT03863405 260 268 B-Eq-Comparison
the NCT03863405 269 272 O
standard NCT03863405 273 281 B-Procedure
therapy NCT03863405 282 289 I-Procedure
( NCT03863405 290 291 O
i. NCT03863405 292 294 O
e. NCT03863405 295 297 O
one NCT03863405 299 302 B-Eq-Comparison
or NCT03863405 303 305 I-Eq-Comparison
more NCT03863405 306 310 I-Eq-Comparison
conventional NCT03863405 311 323 O
DMARDs NCT03863405 324 330 B-Drug
) NCT03863405 331 332 O
for NCT03863405 333 336 O
at NCT03863405 337 339 B-Eq-Comparison
least NCT03863405 340 345 I-Eq-Comparison
three NCT03863405 346 351 I-Eq-Comparison
months NCT03863405 352 358 I-Eq-Comparison
. NCT03863405 359 360 O

Exclusion NCT03863405 362 371 O
Criteria NCT03863405 372 380 O
: NCT03863405 381 382 O

- NCT03863405 386 387 O
Known NCT03863405 389 394 O
hypersensitivity NCT03863405 395 411 B-Condition
to NCT03863405 412 414 O
metformin NCT03863405 415 424 B-Drug
. NCT03863405 425 426 O

- NCT03863405 430 431 O
Patients NCT03863405 433 441 O
who NCT03863405 442 445 O
have NCT03863405 446 450 O
a NCT03863405 451 452 O
prior NCT03863405 453 458 B-Eq-Comparison
diagnosis NCT03863405 459 468 O
with NCT03863405 469 473 O
diabetes NCT03863405 474 482 B-Condition
mellitus NCT03863405 483 491 I-Condition
. NCT03863405 492 493 O

- NCT03863405 497 498 O
Patients NCT03863405 500 508 O
receive NCT03863405 509 516 B-Eq-Comparison
metformin NCT03863405 517 526 B-Drug
for NCT03863405 527 530 O
any NCT03863405 531 534 O
other NCT03863405 535 540 B-Other
indications NCT03863405 541 552 B-Indication
. NCT03863405 553 554 O

- NCT03863405 558 559 O
Patients NCT03863405 561 569 O
with NCT03863405 570 574 O
congestive NCT03863405 575 585 B-Condition
heart NCT03863405 586 591 I-Condition
failure NCT03863405 592 599 I-Condition
. NCT03863405 600 601 O

- NCT03863405 605 606 O
Patients NCT03863405 608 616 O
with NCT03863405 617 621 O
a NCT03863405 622 623 O
history NCT03863405 624 631 B-Eq-Comparison
of NCT03863405 632 634 O
myocardial NCT03863405 635 645 B-Condition
infarction NCT03863405 646 656 I-Condition
. NCT03863405 657 658 O

- NCT03863405 662 663 O
Patients NCT03863405 665 673 O
with NCT03863405 674 678 O
severe NCT03863405 679 685 O
anemia NCT03863405 686 692 B-Condition
. NCT03863405 693 694 O

- NCT03863405 698 699 O
Patients NCT03863405 701 709 O
with NCT03863405 710 714 O
active NCT03863405 715 721 B-Eq-Comparison
infections NCT03863405 722 732 B-Condition
or NCT03863405 733 735 B-Or
other NCT03863405 736 741 B-Other
inflammatory NCT03863405 742 754 B-Condition
diseases NCT03863405 755 763 I-Condition
. NCT03863405 764 765 O

- NCT03863405 769 770 O
Patients NCT03863405 772 780 O
receiving NCT03863405 781 790 B-Eq-Comparison
biological NCT03863405 791 801 B-Procedure
therapy NCT03863405 802 809 I-Procedure
. NCT03863405 810 811 O

- NCT03863405 815 816 O
Pregnancy NCT03863405 818 827 B-Condition
or NCT03863405 828 830 B-Or
lactation NCT03863405 831 840 B-Condition
. NCT03863405 841 842 O

- NCT03863405 846 847 O
Patients NCT03863405 849 857 O
with NCT03863405 858 862 O
impaired NCT03863405 863 871 B-Condition
liver NCT03863405 872 877 I-Condition
functions NCT03863405 878 887 I-Condition
. NCT03863405 888 889 O

- NCT03863405 893 894 O
Patients NCT03863405 896 904 O
with NCT03863405 905 909 O
impaired NCT03863405 910 918 B-Condition
kidney NCT03863405 919 925 I-Condition
functions NCT03863405 926 935 I-Condition
( NCT03863405 936 937 O
serum NCT03863405 938 943 B-Observation
creatinine NCT03863405 944 954 I-Observation
concentrations NCT03863405 955 969 I-Observation
≥ NCT03863405 970 971 B-Eq-Comparison
1.5 NCT03863405 972 975 I-Eq-Comparison
and NCT03863405 976 979 B-Or
≥ NCT03863405 980 981 B-Eq-Comparison
1.4 NCT03863405 982 985 I-Eq-Comparison
mg NCT03863405 986 988 I-Eq-Comparison
/ NCT03863405 989 990 I-Eq-Comparison
dL NCT03863405 991 993 I-Eq-Comparison
in NCT03863405 994 996 O
males NCT03863405 997 1002 O
and NCT03863405 1003 1006 B-Or
females NCT03863405 1007 1014 O
respectively NCT03863405 1015 1027 O
) NCT03863405 1028 1029 O
. NCT03863405 1031 1032 O

- NCT03863405 1036 1037 O
Patients NCT03863405 1039 1047 O
with NCT03863405 1048 1052 O
malignancies NCT03863405 1053 1065 B-Condition
. NCT03863405 1065 1066 O

Inclusion NCT03868020 0 9 O
Criteria NCT03868020 10 18 O
: NCT03868020 19 20 O

- NCT03868020 24 25 O
Adults NCT03868020 27 33 O
with NCT03868020 34 38 B-And
biopsy NCT03868020 39 45 B-Procedure
proven NCT03868020 46 52 O
metastatic NCT03868020 53 63 B-Modifier
cervical NCT03868020 64 72 I-Modifier
nodal NCT03868020 73 78 I-Modifier
squamous NCT03868020 79 87 I-Modifier
cell NCT03868020 88 92 I-Modifier
carcinoma NCT03868020 93 102 B-Condition

- NCT03868020 105 106 O
CT NCT03868020 108 110 B-Procedure
of NCT03868020 111 113 O
the NCT03868020 114 117 O
neck NCT03868020 118 122 B-Modifier
with NCT03868020 123 127 B-And
contrast NCT03868020 128 136 B-Modifier
that NCT03868020 137 141 O
does NCT03868020 142 146 O
not NCT03868020 147 150 B-Negation
confidently NCT03868020 151 162 O
identify NCT03868020 163 171 O
a NCT03868020 172 173 O
primary NCT03868020 174 181 B-Modifier
oropharyngeal NCT03868020 182 195 I-Modifier
site NCT03868020 196 200 I-Modifier
of NCT03868020 201 203 O
disease NCT03868020 204 211 B-Coreference

- NCT03868020 214 215 O
Planned NCT03868020 217 224 B-Eq-Comparison
standard NCT03868020 225 233 O
of NCT03868020 234 236 O
care NCT03868020 237 241 O
18 NCT03868020 242 244 B-Modifier
F NCT03868020 245 246 I-Modifier
- NCT03868020 247 248 I-Modifier
FDG NCT03868020 249 252 I-Modifier
PET NCT03868020 253 256 B-Procedure
CT NCT03868020 257 259 I-Procedure
examination NCT03868020 260 271 I-Procedure

- NCT03868020 274 275 O
Planned NCT03868020 277 284 B-Eq-Comparison
standard NCT03868020 285 293 O
of NCT03868020 294 296 O
care NCT03868020 297 301 B-Procedure
exam NCT03868020 302 306 I-Procedure
under NCT03868020 307 312 O
anesthesia NCT03868020 313 323 B-Procedure
with NCT03868020 324 328 B-And
oropharyngeal NCT03868020 329 342 B-Procedure
surgical NCT03868020 343 351 I-Procedure
biopsy NCT03868020 352 358 I-Procedure

Exclusion NCT03868020 359 368 O
Criteria NCT03868020 369 377 O
: NCT03868020 378 379 O

- NCT03868020 383 384 O
Pregnant NCT03868020 386 394 B-Condition
women NCT03868020 395 400 O

- NCT03868020 403 404 O
Known NCT03868020 406 411 O
allergy NCT03868020 412 419 B-Allergy
to NCT03868020 420 422 O
FDG NCT03868020 423 426 B-Drug
, NCT03868020 427 428 O
fluciclovine NCT03868020 429 441 B-Drug
, NCT03868020 442 443 O
or NCT03868020 444 446 B-Or
iodine NCT03868020 447 453 B-Modifier
- NCT03868020 454 455 I-Modifier
based NCT03868020 456 461 I-Modifier
contrast NCT03868020 462 470 B-Drug
agents NCT03868020 471 477 I-Drug

- NCT03868020 480 481 O
Severe NCT03868020 483 489 O
renal NCT03868020 490 495 B-Condition
dysfunction NCT03868020 496 507 I-Condition
( NCT03868020 508 509 O
glomerular NCT03868020 510 520 B-Observation
filtrate NCT03868020 521 529 I-Observation
rate NCT03868020 530 534 I-Observation
[ NCT03868020 535 536 O
within NCT03868020 537 543 B-Eq-Comparison
30 NCT03868020 544 546 I-Eq-Comparison
days NCT03868020 547 551 I-Eq-Comparison
] NCT03868020 552 553 O
less NCT03868020 554 558 B-Eq-Comparison
than NCT03868020 559 563 I-Eq-Comparison
30 NCT03868020 564 566 I-Eq-Comparison
) NCT03868020 567 568 O

- NCT03868020 572 573 O
Inability NCT03868020 575 584 B-Condition
to NCT03868020 585 587 I-Condition
tolerate NCT03868020 588 596 I-Condition
lying NCT03868020 597 602 I-Condition
supine NCT03868020 603 609 I-Condition
, NCT03868020 610 611 O
relatively NCT03868020 612 622 B-Modifier
motionless NCT03868020 623 633 I-Modifier
for NCT03868020 634 637 O
up NCT03868020 638 640 B-Eq-Comparison
to NCT03868020 641 643 I-Eq-Comparison
1 NCT03868020 644 645 I-Eq-Comparison
hour NCT03868020 646 650 I-Eq-Comparison

Inclusion NCT03863613 0 9 O
Criteria NCT03863613 10 18 O
: NCT03863613 19 20 O

- NCT03863613 24 25 O
Women NCT03863613 27 32 O
with NCT03863613 33 37 B-And
a NCT03863613 38 39 O
twin NCT03863613 40 44 B-Modifier
pregnancy NCT03863613 45 54 B-Condition
( NCT03863613 55 56 O
mono NCT03863613 57 61 B-Modifier
- NCT03863613 62 63 I-Modifier
and NCT03863613 64 67 B-Or
di NCT03863613 68 70 B-Modifier
- NCT03863613 71 72 I-Modifier
chorionic NCT03863613 73 82 I-Modifier
) NCT03863613 83 84 O

- NCT03863613 88 89 O
16 NCT03863613 91 93 B-Eq-Comparison
0 NCT03863613 94 95 I-Eq-Comparison
/ NCT03863613 96 97 I-Eq-Comparison
7 NCT03863613 98 99 I-Eq-Comparison
to NCT03863613 100 102 I-Eq-Comparison
22 NCT03863613 103 105 I-Eq-Comparison
0 NCT03863613 106 107 I-Eq-Comparison
/ NCT03863613 108 109 I-Eq-Comparison
7 NCT03863613 110 111 I-Eq-Comparison
weeks NCT03863613 112 117 I-Eq-Comparison
of NCT03863613 118 120 O
gestation NCT03863613 121 130 B-Observation

- NCT03863613 133 134 O
Maternal NCT03863613 136 144 O
age NCT03863613 145 148 B-Age
≥ NCT03863613 149 150 B-Eq-Comparison
18 NCT03863613 151 153 I-Eq-Comparison
yrs NCT03863613 154 157 I-Eq-Comparison

- NCT03863613 160 161 O
Cervical NCT03863613 163 171 B-Observation
length NCT03863613 172 178 I-Observation
≤ NCT03863613 179 180 B-Eq-Comparison
28 NCT03863613 181 183 I-Eq-Comparison
mm NCT03863613 184 186 I-Eq-Comparison

- NCT03863613 189 190 O
Informed NCT03863613 192 200 O
consent NCT03863613 201 208 O

- NCT03863613 211 212 O
Not NCT03863613 214 217 B-Negation
participating NCT03863613 218 231 O
in NCT03863613 232 234 O
another NCT03863613 235 242 B-Other
preterm NCT03863613 243 250 B-Modifier
birth NCT03863613 251 256 B-Birth
study NCT03863613 257 262 B-Study
at NCT03863613 263 265 O
the NCT03863613 266 269 O
same NCT03863613 270 274 O
time NCT03863613 275 279 O

Exclusion NCT03863613 280 289 O
Criteria NCT03863613 290 298 O
: NCT03863613 299 300 O

- NCT03863613 304 305 O
Uterine NCT03863613 307 314 B-Condition
anomalies NCT03863613 315 324 I-Condition

- NCT03863613 327 328 O
Cervical NCT03863613 330 338 B-Condition
dilation NCT03863613 339 347 I-Condition
with NCT03863613 348 352 B-And
visible NCT03863613 353 360 O
amniotic NCT03863613 361 369 B-Condition
membranes NCT03863613 370 379 I-Condition
or NCT03863613 380 382 B-Or
amniotic NCT03863613 383 391 B-Condition
membranes NCT03863613 392 401 I-Condition
prolapsed NCT03863613 402 411 I-Condition
into NCT03863613 412 416 B-Modifier
the NCT03863613 417 420 I-Modifier
vagina NCT03863613 421 427 I-Modifier

- NCT03863613 430 431 O
Twin NCT03863613 433 437 B-Modifier
- NCT03863613 438 439 I-Modifier
to NCT03863613 440 442 I-Modifier
- NCT03863613 443 444 I-Modifier
twin NCT03863613 445 449 I-Modifier
transfusion NCT03863613 450 461 B-Condition
syndrome NCT03863613 462 470 I-Condition

- NCT03863613 473 474 O
Stillbirth NCT03863613 476 486 B-Condition
or NCT03863613 487 489 B-Or
major NCT03863613 490 495 O
congenital NCT03863613 496 506 B-Condition
abnormalities NCT03863613 507 520 I-Condition
in NCT03863613 521 523 O
any NCT03863613 524 527 O
of NCT03863613 528 530 O
the NCT03863613 531 534 O
fetus NCT03863613 535 540 B-Modifier

- NCT03863613 543 544 O
Severe NCT03863613 546 552 O
vaginal NCT03863613 553 560 B-Condition
discharge NCT03863613 561 570 I-Condition

- NCT03863613 573 574 O
Acute NCT03863613 576 581 O
vaginitis NCT03863613 582 591 B-Condition
or NCT03863613 592 594 B-Or
cervicitis NCT03863613 595 605 B-Condition

- NCT03863613 608 609 O
Vaginal NCT03863613 611 618 B-Modifier
bleeding NCT03863613 619 627 B-Condition

- NCT03863613 630 631 O
Placental NCT03863613 633 642 B-Condition
preavia NCT03863613 643 650 I-Condition

- NCT03863613 653 654 O
Vasa NCT03863613 656 660 B-Condition
preavia NCT03863613 661 668 I-Condition

- NCT03863613 671 672 O
Premature NCT03863613 674 683 B-Modifier
rupture NCT03863613 684 691 B-Condition
of NCT03863613 692 694 I-Condition
membranes NCT03863613 695 704 I-Condition

- NCT03863613 707 708 O
Premature NCT03863613 710 719 B-Modifier
labor NCT03863613 720 725 B-Condition
with NCT03863613 726 730 B-And
/ NCT03863613 731 732 B-Or
without NCT03863613 733 740 B-Negation
ruptured NCT03863613 741 749 B-Condition
membrane NCT03863613 750 758 I-Condition

- NCT03863613 761 762 O
Suspicion NCT03863613 764 773 B-Assertion___Assertion-Type-Value:possible
of NCT03863613 774 776 O
chorioamnionitis NCT03863613 777 793 B-Condition

- NCT03863613 796 797 O
Cerclage NCT03863613 799 807 B-Condition
in NCT03863613 808 810 I-Condition
place NCT03863613 811 816 I-Condition
or NCT03863613 817 819 B-Or
unable NCT03863613 820 826 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863613 827 829 O
undergo NCT03863613 830 837 O
cervical NCT03863613 838 846 B-Procedure
cerclage NCT03863613 847 855 B-Modifier
or NCT03863613 856 858 B-Or
pessary NCT03863613 859 866 B-Modifier

Inclusion NCT03867461 0 9 O
Criteria NCT03867461 10 18 O
: NCT03867461 19 20 O

- NCT03867461 24 25 O
Adults NCT03867461 27 33 O
determined NCT03867461 34 44 O
to NCT03867461 45 47 O
be NCT03867461 48 50 O
candidates NCT03867461 51 61 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867461 62 65 I-Assertion___Assertion-Type-Value:hypothetical
venous NCT03867461 66 72 B-Procedure
sinus NCT03867461 73 78 I-Procedure
stenting NCT03867461 79 87 I-Procedure

Inclusion NCT03866031 0 9 O
Criteria NCT03866031 10 18 O
: NCT03866031 19 20 O

1 NCT03866031 24 25 O
. NCT03866031 25 26 O
the NCT03866031 28 31 O
patient NCT03866031 32 39 O
should NCT03866031 40 46 O
be NCT03866031 47 49 O
completely NCT03866031 50 60 O
edentulous NCT03866031 61 71 B-Condition
for NCT03866031 72 75 O
at NCT03866031 76 78 B-Eq-Comparison
least NCT03866031 79 84 I-Eq-Comparison
6 NCT03866031 85 86 I-Eq-Comparison
months NCT03866031 87 93 I-Eq-Comparison
. NCT03866031 94 95 O

2 NCT03866031 99 100 O
. NCT03866031 100 101 O
first NCT03866031 103 108 O
class NCT03866031 109 114 O
jaw NCT03866031 115 118 O
relation NCT03866031 119 127 O
. NCT03866031 128 129 O

3 NCT03866031 133 134 O
. NCT03866031 134 135 O
adequate NCT03866031 137 145 O
bone NCT03866031 146 150 B-Condition|Observation
for NCT03866031 151 154 O
an NCT03866031 155 157 O
implant NCT03866031 158 165 B-Procedure
length NCT03866031 166 172 B-Modifier
of NCT03866031 173 175 O
at NCT03866031 176 178 B-Eq-Comparison
least NCT03866031 179 184 I-Eq-Comparison
10 NCT03866031 185 187 I-Eq-Comparison
mm NCT03866031 188 190 I-Eq-Comparison
and NCT03866031 191 194 B-And
diameter NCT03866031 195 203 B-Modifier
of NCT03866031 204 206 O
at NCT03866031 207 209 B-Eq-Comparison
least NCT03866031 210 215 I-Eq-Comparison
2.75 NCT03866031 216 220 I-Eq-Comparison
mm NCT03866031 221 223 I-Eq-Comparison
. NCT03866031 224 225 O

4 NCT03866031 229 230 O
. NCT03866031 230 231 O
the NCT03866031 233 236 O
patients NCT03866031 237 245 O
should NCT03866031 246 252 O
be NCT03866031 253 255 O
able NCT03866031 256 260 O
to NCT03866031 261 263 O
speak NCT03866031 264 269 O
and NCT03866031 270 273 O
write NCT03866031 274 279 O
in NCT03866031 280 282 O
arabic NCT03866031 283 289 O
. NCT03866031 290 291 O

Exclusion NCT03866031 293 302 O
Criteria NCT03866031 303 311 O
: NCT03866031 312 313 O

1 NCT03866031 315 316 O
) NCT03866031 317 318 O
patients NCT03866031 319 327 O
who NCT03866031 328 331 O
received NCT03866031 332 340 B-Eq-Comparison
radiotherapy NCT03866031 341 353 B-Procedure
to NCT03866031 354 356 O
the NCT03866031 357 360 O
head NCT03866031 361 365 B-Modifier
or NCT03866031 366 368 B-Or
neck NCT03866031 369 373 B-Modifier
region NCT03866031 374 380 O
for NCT03866031 381 384 O
tumors NCT03866031 385 391 B-Condition
. NCT03866031 391 392 O
( NCT03866031 394 395 O
2 NCT03866031 396 397 O
) NCT03866031 398 399 O
a NCT03866031 400 401 O
history NCT03866031 402 409 B-Eq-Comparison
of NCT03866031 410 412 O
chemotherapy NCT03866031 413 425 B-Procedure
. NCT03866031 425 426 O
( NCT03866031 428 429 O
3 NCT03866031 430 431 O
) NCT03866031 432 433 O
patients NCT03866031 434 442 O
on NCT03866031 443 445 B-Eq-Comparison
long NCT03866031 446 450 B-Modifier
- NCT03866031 451 452 I-Modifier
term NCT03866031 453 457 I-Modifier
steroids NCT03866031 458 466 B-Drug
, NCT03866031 467 468 O
or NCT03866031 469 471 B-Or
bisphosphonates NCT03866031 472 487 B-Drug
. NCT03866031 487 488 O
( NCT03866031 490 491 O
4 NCT03866031 492 493 O
) NCT03866031 494 495 O
heavy NCT03866031 496 501 O
smokers NCT03866031 502 509 B-Condition
. NCT03866031 510 511 O

( NCT03866031 514 515 O
5 NCT03866031 516 517 O
) NCT03866031 518 519 O
patients NCT03866031 520 528 O
with NCT03866031 529 533 O
physical NCT03866031 534 542 B-Modifier
and NCT03866031 543 546 B-Or
mental NCT03866031 547 553 B-Modifier
dis NCT03866031 554 557 B-Condition
- NCT03866031 558 559 I-Condition
abilities NCT03866031 560 569 I-Condition
that NCT03866031 570 574 O
interfere NCT03866031 575 584 O
with NCT03866031 585 589 O
the NCT03866031 590 593 O
maintenance NCT03866031 594 605 O
of NCT03866031 606 608 O
implants NCT03866031 609 617 B-Procedure
. NCT03866031 618 619 O

( NCT03866031 622 623 O
6 NCT03866031 624 625 O
) NCT03866031 626 627 O
uncontrolled NCT03866031 628 640 B-Modifier
systematic NCT03866031 641 651 I-Modifier
disease NCT03866031 652 659 B-Condition
that NCT03866031 660 664 O
could NCT03866031 665 670 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03866031 671 681 O
implant NCT03866031 682 689 B-Procedure
surgery NCT03866031 690 697 I-Procedure
. NCT03866031 697 698 O
( NCT03866031 700 701 O
7 NCT03866031 702 703 O
) NCT03866031 704 705 O
extreme NCT03866031 706 713 O
bruxism NCT03866031 714 721 B-Condition
. NCT03866031 721 722 O
( NCT03866031 724 725 O
8 NCT03866031 726 727 O
) NCT03866031 728 729 O
infectious NCT03866031 730 740 B-Condition
disease NCT03866031 741 748 I-Condition
. NCT03866031 748 749 O
( NCT03866031 751 752 O
9 NCT03866031 753 754 O
) NCT03866031 755 756 O
temporomandibular NCT03866031 757 774 B-Condition
joint NCT03866031 775 780 I-Condition
dysfunction NCT03866031 781 792 I-Condition
. NCT03866031 793 794 O


Inclusion NCT03860454 0 9 O
Criteria NCT03860454 10 18 O
: NCT03860454 19 20 O

- NCT03860454 24 25 O
LMNA NCT03860454 27 31 B-Condition
+ NCT03860454 32 33 O
cases NCT03860454 34 39 O
with NCT03860454 40 44 B-And
pathogenic NCT03860454 45 55 B-Condition
LMNA NCT03860454 56 60 I-Condition
mutations NCT03860454 61 70 I-Condition
for NCT03860454 71 74 O
LMNA NCT03860454 75 79 B-Condition
+ NCT03860454 80 81 O
and NCT03860454 82 85 B-Or
heart NCT03860454 86 91 B-Observation
myocardial NCT03860454 92 102 I-Observation
samples NCT03860454 103 110 I-Observation
from NCT03860454 111 115 O
the NCT03860454 116 119 O
explanted NCT03860454 120 129 B-Modifier
hearts NCT03860454 130 136 I-Modifier
of NCT03860454 137 139 O
LMNA NCT03860454 140 144 B-Condition
+ NCT03860454 145 146 O
patients NCT03860454 147 155 O
who NCT03860454 156 159 B-And
are NCT03860454 160 163 O
scheduled NCT03860454 164 173 B-Eq-Comparison
to NCT03860454 174 176 I-Eq-Comparison
undergo NCT03860454 177 184 I-Eq-Comparison
clinically NCT03860454 185 195 O
indicated NCT03860454 196 205 B-Indication
heart NCT03860454 206 211 B-Procedure
transplantation NCT03860454 212 227 I-Procedure
at NCT03860454 228 230 O
the NCT03860454 231 234 O
Papworth NCT03860454 235 243 O
Hospital NCT03860454 244 252 O
NHS NCT03860454 253 256 O
Trust NCT03860454 257 262 O
. NCT03860454 263 264 O

- NCT03860454 268 269 O
DCMWT NCT03860454 271 276 B-Condition
cases NCT03860454 277 282 O
: NCT03860454 283 284 O
patients NCT03860454 285 293 O
with NCT03860454 294 298 O
heart NCT03860454 299 304 B-Condition
muscle NCT03860454 305 311 I-Condition
failure NCT03860454 312 319 I-Condition
but NCT03860454 320 323 B-And
with NCT03860454 324 328 O
wild NCT03860454 329 333 B-Modifier
- NCT03860454 334 335 I-Modifier
type NCT03860454 336 340 I-Modifier
lamin NCT03860454 341 346 B-Condition
gene NCT03860454 347 351 I-Condition
. NCT03860454 351 352 O
Heart NCT03860454 354 359 B-Observation
myocardial NCT03860454 360 370 I-Observation
samples NCT03860454 371 378 I-Observation
from NCT03860454 379 383 O
the NCT03860454 384 387 O
explanted NCT03860454 388 397 B-Modifier
hearts NCT03860454 398 404 I-Modifier
of NCT03860454 405 407 O
DCMWT NCT03860454 408 413 B-Condition
patients NCT03860454 414 422 O
who NCT03860454 423 426 B-And
are NCT03860454 427 430 O
scheduled NCT03860454 431 440 B-Eq-Comparison
to NCT03860454 441 443 O
undergo NCT03860454 444 451 O
clinically NCT03860454 452 462 O
indicated NCT03860454 463 472 B-Indication
heart NCT03860454 473 478 B-Procedure
transplantation NCT03860454 479 494 I-Procedure
at NCT03860454 495 497 O
the NCT03860454 498 501 O
Papworth NCT03860454 502 510 O
Hospital NCT03860454 511 519 O
NHS NCT03860454 520 523 O
Trust NCT03860454 524 529 O
. NCT03860454 530 531 O

- NCT03860454 535 536 O
HV NCT03860454 538 540 O
( NCT03860454 541 542 O
controls NCT03860454 543 551 O
) NCT03860454 552 553 O
: NCT03860454 555 556 O
matched NCT03860454 557 564 O
to NCT03860454 565 567 O
cases NCT03860454 568 573 O
. NCT03860454 574 575 O

Exclusion NCT03860454 577 586 O
Criteria NCT03860454 587 595 O
: NCT03860454 596 597 O

- NCT03860454 601 602 O
Needle NCT03860454 604 610 B-Condition
- NCT03860454 611 612 I-Condition
phobia NCT03860454 613 619 I-Condition
that NCT03860454 620 624 O
would NCT03860454 625 630 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03860454 631 639 B-Negation
blood NCT03860454 640 645 B-Procedure
- NCT03860454 646 647 I-Procedure
letting NCT03860454 648 655 I-Procedure

- NCT03860454 658 659 O
Participants NCT03860454 661 673 O
unwilling NCT03860454 674 683 O
to NCT03860454 684 686 O
consent NCT03860454 687 694 O

- NCT03860454 697 698 O
Patients NCT03860454 700 708 O
that NCT03860454 709 713 O
have NCT03860454 714 718 O
a NCT03860454 719 720 O
conventional NCT03860454 721 733 O
contraindication NCT03860454 734 750 B-Contraindication
for NCT03860454 751 754 O
cardiac NCT03860454 755 762 B-Procedure
magnetic NCT03860454 763 771 I-Procedure
resonance NCT03860454 772 781 I-Procedure
imaging NCT03860454 782 789 I-Procedure
( NCT03860454 790 791 O
MRI NCT03860454 792 795 B-Procedure
) NCT03860454 796 797 O
. NCT03860454 799 800 O

- NCT03860454 804 805 O
Patients NCT03860454 807 815 O
that NCT03860454 816 820 O
have NCT03860454 821 825 O
had NCT03860454 826 829 O
a NCT03860454 830 831 O
blood NCT03860454 832 837 B-Procedure
transfusion NCT03860454 838 849 I-Procedure
within NCT03860454 850 856 B-Eq-Comparison
the NCT03860454 857 860 I-Eq-Comparison
last NCT03860454 861 865 I-Eq-Comparison
month NCT03860454 866 871 I-Eq-Comparison
and NCT03860454 872 875 B-Or
patients NCT03860454 876 884 O
having NCT03860454 885 891 B-Eq-Comparison
haemodialysis NCT03860454 892 905 B-Procedure
will NCT03860454 906 910 O
be NCT03860454 911 913 O
excluded NCT03860454 914 922 B-Negation
. NCT03860454 922 923 O

Inclusion NCT03869515 0 9 O
Criteria NCT03869515 10 18 O
: NCT03869515 19 20 O

- NCT03869515 24 25 O
The NCT03869515 27 30 O
chILD NCT03869515 31 36 B-Condition
syndrome NCT03869515 37 45 I-Condition
exists NCT03869515 46 52 O
when NCT03869515 53 57 O
a NCT03869515 58 59 O
child NCT03869515 60 65 B-Family-Member___Family-Member-Type:child
with NCT03869515 66 70 O
DLD NCT03869515 71 74 B-Condition
has NCT03869515 75 78 O
had NCT03869515 79 82 O
the NCT03869515 83 86 O
common NCT03869515 87 93 O
causes NCT03869515 94 100 B-Condition
of NCT03869515 101 103 O
DLD NCT03869515 104 107 B-Condition
excluded NCT03869515 108 116 B-Negation
as NCT03869515 117 119 O
the NCT03869515 120 123 O
primary NCT03869515 124 131 O
diagnosis NCT03869515 132 141 O
and NCT03869515 142 145 B-And
has NCT03869515 146 149 O
at NCT03869515 150 152 B-Eq-Comparison
least NCT03869515 153 158 I-Eq-Comparison
three NCT03869515 159 164 I-Eq-Comparison
of NCT03869515 165 167 B-Criteria-Count
the NCT03869515 168 171 I-Criteria-Count
following NCT03869515 172 181 I-Criteria-Count
four NCT03869515 182 186 B-Eq-Comparison
criteria NCT03869515 187 195 O
: NCT03869515 196 197 O
( NCT03869515 198 199 O
1 NCT03869515 200 201 O
) NCT03869515 202 203 O
respiratory NCT03869515 204 215 B-Condition
symptoms NCT03869515 216 224 B-Assertion___Assertion-Type-Value:possible
( NCT03869515 225 226 O
e. NCT03869515 227 229 O
g. NCT03869515 230 232 O
, NCT03869515 233 234 O
cough NCT03869515 235 240 B-Condition
, NCT03869515 241 242 O
rapid NCT03869515 243 248 B-Modifier
and NCT03869515 249 252 B-Or
/ NCT03869515 253 254 I-Or
or NCT03869515 255 257 I-Or
difficult NCT03869515 258 267 B-Modifier
breathing NCT03869515 268 277 B-Condition
, NCT03869515 278 279 O
or NCT03869515 280 282 B-Or
exercise NCT03869515 283 291 B-Condition
intolerance NCT03869515 292 303 I-Condition
) NCT03869515 304 305 O
; NCT03869515 306 307 O
( NCT03869515 308 309 O
2 NCT03869515 310 311 O
) NCT03869515 312 313 O
respiratory NCT03869515 314 325 B-Condition
signs NCT03869515 326 331 B-Assertion___Assertion-Type-Value:possible
( NCT03869515 332 333 O
e. NCT03869515 334 336 O
g. NCT03869515 337 339 O
, NCT03869515 340 341 O
resting NCT03869515 342 349 B-Condition
tachypnea NCT03869515 350 359 I-Condition
, NCT03869515 360 361 O
adventitious NCT03869515 362 374 B-Condition
sounds NCT03869515 375 381 I-Condition
, NCT03869515 382 383 O
retractions NCT03869515 384 395 B-Condition
, NCT03869515 396 397 O
digital NCT03869515 398 405 B-Condition
clubbing NCT03869515 406 414 I-Condition
, NCT03869515 415 416 O
failure NCT03869515 417 424 B-Condition
to NCT03869515 425 427 I-Condition
thrive NCT03869515 428 434 I-Condition
, NCT03869515 435 436 O
or NCT03869515 437 439 B-Or
respiratory NCT03869515 440 451 B-Condition
fail NCT03869515 452 456 I-Condition
- NCT03869515 457 458 I-Condition
ure NCT03869515 459 462 I-Condition
) NCT03869515 463 464 O
; NCT03869515 465 466 O
( NCT03869515 467 468 O
3 NCT03869515 469 470 O
) NCT03869515 471 472 O
hypoxemia NCT03869515 473 482 B-Condition
; NCT03869515 482 483 O
and NCT03869515 484 487 O
( NCT03869515 488 489 O
4 NCT03869515 490 491 O
) NCT03869515 492 493 O
diffuse NCT03869515 494 501 B-Condition
abnormalities NCT03869515 502 515 I-Condition
on NCT03869515 516 518 O
CXR NCT03869515 519 522 B-Procedure
or NCT03869515 523 525 B-Or
a NCT03869515 526 527 O
CT NCT03869515 528 530 B-Procedure
scan NCT03869515 531 535 I-Procedure
. NCT03869515 536 537 O

Exclusion NCT03869515 539 548 O
Criteria NCT03869515 549 557 O
: NCT03869515 558 559 O

- NCT03869515 563 564 O
These NCT03869515 566 571 O
include NCT03869515 572 579 O
cystic NCT03869515 580 586 B-Condition
fibrosis NCT03869515 587 595 I-Condition
, NCT03869515 596 597 O
congenital NCT03869515 598 608 B-Modifier
or NCT03869515 609 611 B-Or
acquired NCT03869515 612 620 B-Modifier
immunodeficiency NCT03869515 621 637 B-Condition
, NCT03869515 638 639 O
congenital NCT03869515 640 650 B-Condition
heart NCT03869515 651 656 I-Condition
disease NCT03869515 657 664 I-Condition
, NCT03869515 665 666 O
bronchopulmonary NCT03869515 667 683 B-Condition
dysplasia NCT03869515 684 693 I-Condition
, NCT03869515 694 695 O
pulmonary NCT03869515 696 705 B-Condition
infection NCT03869515 706 715 I-Condition
, NCT03869515 716 717 O
primary NCT03869515 718 725 B-Modifier
ciliary NCT03869515 726 733 I-Modifier
dyskinesia NCT03869515 734 744 B-Condition
presenting NCT03869515 745 755 O
with NCT03869515 756 760 O
newborn NCT03869515 761 768 B-Condition
respiratory NCT03869515 769 780 I-Condition
distress NCT03869515 781 789 I-Condition
and NCT03869515 790 793 B-Or
recurrent NCT03869515 794 803 B-Modifier
aspiration NCT03869515 804 814 B-Condition
. NCT03869515 814 815 O

Inclusion NCT03864757 0 9 O
Criteria NCT03864757 10 18 O
: NCT03864757 19 20 O

- NCT03864757 24 25 O
Male NCT03864757 27 31 O
and NCT03864757 32 35 B-Or
female NCT03864757 36 42 O
patients NCT03864757 43 51 O
between NCT03864757 52 59 B-Eq-Comparison
18 NCT03864757 60 62 I-Eq-Comparison
and NCT03864757 63 66 I-Eq-Comparison
80 NCT03864757 67 69 I-Eq-Comparison
years NCT03864757 70 75 I-Age|Eq-Comparison

- NCT03864757 78 79 O
Diagnosed NCT03864757 81 90 O
with NCT03864757 91 95 O
permanent NCT03864757 96 105 B-Modifier
UVFP NCT03864757 106 110 B-Condition
and NCT03864757 111 114 B-And
insufficient NCT03864757 115 127 B-Modifier
glottal NCT03864757 128 135 B-Condition
closure NCT03864757 136 143 I-Condition
and NCT03864757 144 147 B-And
planned NCT03864757 148 155 B-Eq-Comparison
type NCT03864757 156 160 B-Modifier
I NCT03864757 161 162 I-Modifier
thyroplasty NCT03864757 163 174 B-Procedure
with NCT03864757 175 179 O
conventional NCT03864757 180 192 B-Procedure
implant NCT03864757 193 200 I-Procedure

- NCT03864757 203 204 O
Ability NCT03864757 206 213 O
to NCT03864757 214 216 O
co NCT03864757 217 219 O
- NCT03864757 220 221 O
operate NCT03864757 222 229 O
with NCT03864757 230 234 O
the NCT03864757 235 238 O
investigator NCT03864757 239 251 O
and NCT03864757 252 255 O
to NCT03864757 256 258 O
comply NCT03864757 259 265 O
with NCT03864757 266 270 O
the NCT03864757 271 274 O
requirements NCT03864757 275 287 O
of NCT03864757 288 290 O
the NCT03864757 291 294 O
entire NCT03864757 295 301 O
study NCT03864757 302 307 O

Exclusion NCT03864757 308 317 O
Criteria NCT03864757 318 326 O
: NCT03864757 327 328 O

- NCT03864757 332 333 O
Any NCT03864757 335 338 O
other NCT03864757 339 344 B-Other
significant NCT03864757 345 356 O
disease NCT03864757 357 364 B-Condition
or NCT03864757 365 367 B-Or
disorder NCT03864757 368 376 B-Condition
which NCT03864757 377 382 O
, NCT03864757 383 384 O
in NCT03864757 385 387 O
the NCT03864757 388 391 O
opinion NCT03864757 392 399 O
of NCT03864757 400 402 O
the NCT03864757 403 406 O
investigator NCT03864757 407 419 O
, NCT03864757 420 421 O
may NCT03864757 422 425 B-Assertion___Assertion-Type-Value:hypothetical
either NCT03864757 426 432 O
put NCT03864757 433 436 O
the NCT03864757 437 440 O
participant NCT03864757 441 452 O
at NCT03864757 453 455 O
risk NCT03864757 456 460 B-Risk
because NCT03864757 461 468 O
of NCT03864757 469 471 O
participation NCT03864757 472 485 O
in NCT03864757 486 488 O
the NCT03864757 489 492 O
clinical NCT03864757 493 501 O
investigation NCT03864757 502 515 O
may NCT03864757 516 519 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03864757 520 529 O
the NCT03864757 530 533 O
result NCT03864757 534 540 O
of NCT03864757 541 543 O
the NCT03864757 544 547 O
clinical NCT03864757 548 556 O
investigation NCT03864757 557 570 O
, NCT03864757 571 572 O
or NCT03864757 573 575 O
the NCT03864757 576 579 O
participant NCT03864757 580 591 O
's NCT03864757 591 593 O
ability NCT03864757 594 601 O
to NCT03864757 602 604 O
participate NCT03864757 605 616 O
in NCT03864757 617 619 O
the NCT03864757 620 623 O
clinical NCT03864757 624 632 O
investigation NCT03864757 633 646 B-Study

- NCT03864757 649 650 O
Scheduled NCT03864757 652 661 B-Eq-Comparison
elective NCT03864757 662 670 B-Modifier
surgery NCT03864757 671 678 B-Procedure
or NCT03864757 679 681 B-Or
other NCT03864757 682 687 B-Other
procedures NCT03864757 688 698 B-Procedure
requiring NCT03864757 699 708 O
general NCT03864757 709 716 B-Procedure
anaesthesia NCT03864757 717 728 I-Procedure
during NCT03864757 729 735 B-Temporal-Connection___Temporal-Connection-Type-Value:during
clinical NCT03864757 736 744 O
investigation NCT03864757 745 758 B-Study

- NCT03864757 761 762 O
Had NCT03864757 764 767 O
medialization NCT03864757 768 781 B-Procedure
thyroplasty NCT03864757 782 793 I-Procedure
before NCT03864757 794 800 B-Eq-Comparison

- NCT03864757 803 804 O
Had NCT03864757 806 809 O
injection NCT03864757 810 819 B-Modifier
medialization NCT03864757 820 833 B-Procedure
laryngoplasty NCT03864757 834 847 I-Procedure
in NCT03864757 848 850 O
the NCT03864757 851 854 O
past NCT03864757 855 859 B-Eq-Comparison
two NCT03864757 860 863 I-Eq-Comparison
years NCT03864757 864 869 I-Eq-Comparison
. NCT03864757 870 871 O

- NCT03864757 875 876 O
Presence NCT03864757 878 886 O
of NCT03864757 887 889 O
structural NCT03864757 890 900 B-Modifier
vocal NCT03864757 901 906 I-Modifier
fold NCT03864757 907 911 I-Modifier
lesions NCT03864757 912 919 B-Condition
such NCT03864757 920 924 O
as NCT03864757 925 927 O
polyp NCT03864757 928 933 B-Condition
or NCT03864757 934 936 B-Or
nodules NCT03864757 937 944 B-Condition

- NCT03864757 947 948 O
Status NCT03864757 950 956 O
post NCT03864757 957 961 B-Temporal-Connection___Temporal-Connection-Type-Value:after
total NCT03864757 962 967 B-Procedure
cordectomy NCT03864757 968 978 I-Procedure

- NCT03864757 981 982 O
Previous NCT03864757 984 992 B-Eq-Comparison
laryngeal NCT03864757 993 1002 B-Procedure
framework NCT03864757 1003 1012 I-Procedure
surgery NCT03864757 1013 1020 I-Procedure
( NCT03864757 1021 1022 O
any NCT03864757 1023 1026 O
type NCT03864757 1027 1031 O
of NCT03864757 1032 1034 O
thyroplasty NCT03864757 1035 1046 B-Procedure
, NCT03864757 1047 1048 O
arytenoid NCT03864757 1049 1058 B-Procedure
adduction NCT03864757 1059 1068 I-Procedure
) NCT03864757 1069 1070 O

- NCT03864757 1074 1075 O
Significant NCT03864757 1077 1088 O
non NCT03864757 1089 1092 B-Negation
- NCT03864757 1093 1094 O
laryngeal NCT03864757 1095 1104 B-Modifier
speech NCT03864757 1105 1111 B-Modifier
abnormality NCT03864757 1112 1123 B-Condition
( NCT03864757 1124 1125 O
severe NCT03864757 1126 1132 O
dysarthria NCT03864757 1133 1143 B-Condition
determined NCT03864757 1144 1154 O
by NCT03864757 1155 1157 O
a NCT03864757 1158 1159 O
panel NCT03864757 1160 1165 O
of NCT03864757 1166 1168 O
trained NCT03864757 1169 1176 O
speech NCT03864757 1177 1183 B-Provider
therapists NCT03864757 1184 1194 I-Provider
) NCT03864757 1195 1196 O

- NCT03864757 1200 1201 O
Severe NCT03864757 1203 1209 O
coagulopathy NCT03864757 1210 1222 B-Condition

Inclusion NCT03862326 0 9 O
Criteria NCT03862326 10 18 O
: NCT03862326 19 20 O

Diaper NCT03862326 22 28 O
grant NCT03862326 29 34 O

- NCT03862326 37 38 O
Urinary NCT03862326 40 47 B-Condition
incontinency NCT03862326 48 60 I-Condition

- NCT03862326 64 65 O
Living NCT03862326 67 73 O
in NCT03862326 74 76 O
own NCT03862326 77 80 O
home NCT03862326 81 85 O
in NCT03862326 86 88 O
Aalborg NCT03862326 89 96 O
Municipality NCT03862326 97 109 O

Exclusion NCT03862326 110 119 O
Criteria NCT03862326 120 128 O
: NCT03862326 129 130 O

- NCT03862326 134 135 O
Dementia NCT03862326 137 145 O

- NCT03862326 149 150 O
Inability NCT03862326 152 161 O
to NCT03862326 162 164 O
transport NCT03862326 165 174 O
herself NCT03862326 175 182 O
to NCT03862326 183 185 O
the NCT03862326 186 189 O
training NCT03862326 190 198 O
facility NCT03862326 199 207 O

- NCT03862326 211 212 O
neurological NCT03862326 214 226 B-Condition
diseases NCT03862326 227 235 I-Condition

- NCT03862326 239 240 O
inability NCT03862326 242 251 B-Negation
to NCT03862326 252 254 O
understand NCT03862326 255 265 O
Danish NCT03862326 266 272 O
or NCT03862326 273 275 O
bring NCT03862326 276 281 O
a NCT03862326 282 283 O
translator NCT03862326 284 294 O


Inclusion NCT03863951 0 9 O
Criteria NCT03863951 10 18 O
: NCT03863951 19 20 O

- NCT03863951 24 25 O
diagnosed NCT03863951 27 36 O
with NCT03863951 37 41 O
the NCT03863951 42 45 O
first NCT03863951 46 51 B-Eq-Comparison
ever NCT03863951 52 56 I-Eq-Comparison
acute NCT03863951 57 62 O
ischemic NCT03863951 63 71 B-Modifier
stroke NCT03863951 72 78 B-Condition
occurring NCT03863951 79 88 O
within NCT03863951 89 95 B-Eq-Comparison
2 NCT03863951 96 97 I-Eq-Comparison
weeks NCT03863951 98 103 I-Eq-Comparison
and NCT03863951 104 107 O
were NCT03863951 108 112 O
confirmed NCT03863951 113 122 O
by NCT03863951 123 125 O
CT NCT03863951 126 128 B-Procedure
or NCT03863951 129 131 B-Or
MRI NCT03863951 132 135 B-Procedure
, NCT03863951 136 137 O

- NCT03863951 141 142 O
has NCT03863951 144 147 O
no NCT03863951 148 150 B-Negation
history NCT03863951 151 158 B-Eq-Comparison
of NCT03863951 159 161 O
depression NCT03863951 162 172 B-Condition
or NCT03863951 173 175 B-Or
use NCT03863951 176 179 O
of NCT03863951 180 182 O
antidepressants NCT03863951 183 198 B-Drug
or NCT03863951 199 201 B-Or
antipsychotics NCT03863951 202 216 B-Drug
, NCT03863951 217 218 O

- NCT03863951 222 223 O
were NCT03863951 225 229 O
competent NCT03863951 230 239 O
to NCT03863951 240 242 O
consent NCT03863951 243 250 O
to NCT03863951 251 253 O
take NCT03863951 254 258 O
part NCT03863951 259 263 O
in NCT03863951 264 266 O
this NCT03863951 267 271 O
research NCT03863951 272 280 O
. NCT03863951 281 282 O

Exclusion NCT03863951 284 293 O
Criteria NCT03863951 294 302 O
: NCT03863951 303 304 O

- NCT03863951 308 309 O
significant NCT03863951 311 322 O
acute NCT03863951 323 328 O
or NCT03863951 329 331 B-Or
severe NCT03863951 332 338 O
illness NCT03863951 339 346 B-Condition
such NCT03863951 347 351 O
as NCT03863951 352 354 O
infection NCT03863951 355 364 B-Condition
, NCT03863951 365 366 O
heart NCT03863951 367 372 B-Condition
failure NCT03863951 373 380 I-Condition
and NCT03863951 381 384 B-Or
tumor NCT03863951 385 390 B-Condition
, NCT03863951 391 392 O

- NCT03863951 396 397 O
previous NCT03863951 399 407 B-Eq-Comparison
diagnosis NCT03863951 408 417 O
of NCT03863951 418 420 O
depression NCT03863951 421 431 B-Condition
or NCT03863951 432 434 B-Or
other NCT03863951 435 440 B-Other
mental NCT03863951 441 447 B-Condition
disorder NCT03863951 448 456 I-Condition
or NCT03863951 457 459 B-Or
who NCT03863951 460 463 O
had NCT03863951 464 467 O
recently NCT03863951 468 476 B-Eq-Comparison
accepted NCT03863951 477 485 O
antidepressants NCT03863951 486 501 B-Drug
or NCT03863951 502 504 B-Or
antipsychotics NCT03863951 505 519 B-Drug
, NCT03863951 520 521 O

- NCT03863951 525 526 O
antibiotics NCT03863951 528 539 B-Drug
in NCT03863951 540 542 O
the NCT03863951 543 546 O
last NCT03863951 547 551 B-Eq-Comparison
two NCT03863951 552 555 I-Eq-Comparison
weeks NCT03863951 556 561 I-Eq-Comparison
, NCT03863951 562 563 O

- NCT03863951 567 568 O
severe NCT03863951 570 576 O
aphasia NCT03863951 577 584 B-Condition
or NCT03863951 585 587 B-Or
dysarthria NCT03863951 588 598 B-Condition
, NCT03863951 599 600 O
irritable NCT03863951 601 610 B-Condition
bowel NCT03863951 611 616 I-Condition
syndrome NCT03863951 617 625 I-Condition
, NCT03863951 626 627 O
asthma NCT03863951 628 634 B-Condition
, NCT03863951 635 636 O
and NCT03863951 637 640 B-Or
pregnant NCT03863951 641 649 B-Condition
or NCT03863951 650 652 B-Or
lactating NCT03863951 653 662 B-Condition
women NCT03863951 663 668 O
, NCT03863951 669 670 O

- NCT03863951 674 675 O
a NCT03863951 677 678 O
previous NCT03863951 679 687 B-Eq-Comparison
history NCT03863951 688 695 I-Eq-Comparison
of NCT03863951 696 698 O
neurological NCT03863951 699 711 B-Condition
illness NCT03863951 712 719 I-Condition
including NCT03863951 720 729 O
AD NCT03863951 730 732 B-Condition
and NCT03863951 733 736 B-Or
PD NCT03863951 737 739 B-Condition
， NCT03863951 740 741 O

- NCT03863951 745 746 O
Inflammatory NCT03863951 748 760 B-Condition
bowel NCT03863951 761 766 I-Condition
disease NCT03863951 767 774 I-Condition
， NCT03863951 775 776 O

Inclusion NCT03863548 0 9 O
Criteria NCT03863548 10 18 O
: NCT03863548 19 20 O

- NCT03863548 24 25 O
person NCT03863548 27 33 O
who NCT03863548 34 37 O
has NCT03863548 38 41 O
expressed NCT03863548 42 51 O
willingness NCT03863548 52 63 O
to NCT03863548 64 66 O
participate NCT03863548 67 78 O

- NCT03863548 81 82 O
person NCT03863548 84 90 O
over NCT03863548 91 95 B-Eq-Comparison
18 NCT03863548 96 98 I-Eq-Comparison
years NCT03863548 99 104 I-Eq-Comparison
of NCT03863548 105 107 O
age NCT03863548 108 111 B-Age

- NCT03863548 114 115 O
person NCT03863548 117 123 O
with NCT03863548 124 128 O
a NCT03863548 129 130 O
retinal NCT03863548 131 138 B-Condition
- NCT03863548 139 140 I-Condition
vitreous NCT03863548 141 149 I-Condition
condition NCT03863548 150 159 I-Condition
requiring NCT03863548 160 169 B-Assertion___Assertion-Type-Value:hypothetical
scheduled NCT03863548 170 179 B-Eq-Comparison
surgery NCT03863548 180 187 B-Procedure
( NCT03863548 188 189 O
epi NCT03863548 190 193 B-Procedure
- NCT03863548 194 195 I-Procedure
retinal NCT03863548 196 203 I-Procedure
membrane NCT03863548 204 212 I-Procedure
surgery NCT03863548 213 220 I-Procedure
, NCT03863548 221 222 O
vitreous NCT03863548 223 231 B-Procedure
traction NCT03863548 232 240 I-Procedure
surgery NCT03863548 241 248 I-Procedure
, NCT03863548 249 250 O
macular NCT03863548 251 258 B-Procedure
hole NCT03863548 259 263 I-Procedure
surgery NCT03863548 264 271 I-Procedure
) NCT03863548 272 273 O
. NCT03863548 275 276 O

Exclusion NCT03863548 278 287 O
Criteria NCT03863548 288 296 O
: NCT03863548 297 298 O

- NCT03863548 302 303 O
person NCT03863548 305 311 O
subject NCT03863548 312 319 O
to NCT03863548 320 322 O
legal NCT03863548 323 328 B-Observation
protection NCT03863548 329 339 I-Observation
( NCT03863548 340 341 O
curatorship NCT03863548 342 353 O
, NCT03863548 354 355 O
guardianship NCT03863548 356 368 O
) NCT03863548 369 370 O

- NCT03863548 374 375 O
person NCT03863548 377 383 O
deemed NCT03863548 384 390 O
mentally NCT03863548 391 399 B-Condition
incompetent NCT03863548 400 411 I-Condition

- NCT03863548 414 415 O
pregnant NCT03863548 417 425 B-Condition
, NCT03863548 426 427 O
parturient NCT03863548 428 438 B-Condition
or NCT03863548 439 441 B-Or
breastfeeding NCT03863548 442 455 B-Condition
woman NCT03863548 456 461 O

- NCT03863548 464 465 O
adult NCT03863548 467 472 O
unwilling NCT03863548 473 482 O
or NCT03863548 483 485 O
unable NCT03863548 486 492 O
to NCT03863548 493 495 O
consent NCT03863548 496 503 O

- NCT03863548 506 507 O
patient NCT03863548 509 516 O
who NCT03863548 517 520 O
has NCT03863548 521 524 O
already NCT03863548 525 532 B-Eq-Comparison
participated NCT03863548 533 545 I-Eq-Comparison
in NCT03863548 546 548 O
the NCT03863548 549 552 O
study NCT03863548 553 558 B-Study

- NCT03863548 561 562 O
person NCT03863548 564 570 O
with NCT03863548 571 575 O
a NCT03863548 576 577 O
physical NCT03863548 578 586 B-Modifier
or NCT03863548 587 589 B-Or
mental NCT03863548 590 596 B-Modifier
disability NCT03863548 597 607 B-Condition
that NCT03863548 608 612 O
does NCT03863548 613 617 O
not NCT03863548 618 621 B-Negation
allow NCT03863548 622 627 O
participation NCT03863548 628 641 O
. NCT03863548 642 643 O

- NCT03863548 647 648 O
a NCT03863548 650 651 O
person NCT03863548 652 658 O
who NCT03863548 659 662 O
has NCT03863548 663 666 O
participated NCT03863548 667 679 O
in NCT03863548 680 682 O
any NCT03863548 683 686 O
study NCT03863548 687 692 B-Study
of NCT03863548 693 695 O
an NCT03863548 696 698 O
experimental NCT03863548 699 711 O
medical NCT03863548 712 719 O
product NCT03863548 720 727 B-Drug
within NCT03863548 728 734 B-Eq-Comparison
the NCT03863548 735 738 I-Eq-Comparison
previous NCT03863548 739 747 I-Eq-Comparison
3 NCT03863548 748 749 I-Eq-Comparison
months NCT03863548 750 756 I-Eq-Comparison

- NCT03863548 759 760 O
person NCT03863548 762 768 O
who NCT03863548 769 772 O
experiences NCT03863548 773 784 O
any NCT03863548 785 788 O
of NCT03863548 789 791 O
the NCT03863548 792 795 B-Criteria-Count
following NCT03863548 796 805 I-Criteria-Count
during NCT03863548 806 812 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863548 813 816 O
ophthalmological NCT03863548 817 833 B-Procedure
examination NCT03863548 834 845 I-Procedure
: NCT03863548 846 847 O

- NCT03863548 856 857 O
severe NCT03863548 859 865 O
or NCT03863548 866 868 B-Or
proliferating NCT03863548 869 882 B-Modifier
diabetic NCT03863548 883 891 B-Condition
retinopathy NCT03863548 892 903 I-Condition

- NCT03863548 911 912 O
intra NCT03863548 914 919 B-Modifier
- NCT03863548 920 921 I-Modifier
vitreal NCT03863548 922 929 I-Modifier
hemorrhage NCT03863548 930 940 B-Condition

- NCT03863548 948 949 O
tractional NCT03863548 951 961 B-Condition
retinal NCT03863548 962 969 I-Condition
detachment NCT03863548 970 980 I-Condition

- NCT03863548 988 989 O
subretinal NCT03863548 991 1001 B-Modifier
or NCT03863548 1002 1004 B-Or
retrohyaloidal NCT03863548 1005 1019 B-Modifier
hematoma NCT03863548 1020 1028 B-Condition
. NCT03863548 1028 1029 O

Inclusion NCT03866356 0 9 O
Criteria NCT03866356 10 18 O
: NCT03866356 19 20 O

- NCT03866356 24 25 O
The NCT03866356 27 30 O
inclusion NCT03866356 31 40 O
criteria NCT03866356 41 49 O
were NCT03866356 50 54 O
being NCT03866356 55 60 O
female NCT03866356 61 67 O
, NCT03866356 68 69 O
≥ NCT03866356 70 71 B-Eq-Comparison
18 NCT03866356 72 74 I-Eq-Comparison
years NCT03866356 75 80 I-Age|Eq-Comparison
, NCT03866356 81 82 O
having NCT03866356 83 89 B-And
an NCT03866356 90 92 O
initial NCT03866356 93 100 B-Eq-Comparison
diagnosis NCT03866356 101 110 O
of NCT03866356 111 113 O
SI NCT03866356 114 116 B-Condition
, NCT03866356 117 118 O
being NCT03866356 119 124 O
literate NCT03866356 125 133 B-Condition
, NCT03866356 134 135 O
having NCT03866356 136 142 O
no NCT03866356 143 145 B-Negation
sensory NCT03866356 146 153 B-Condition
disorder NCT03866356 154 162 I-Condition
affecting NCT03866356 163 172 O
communication NCT03866356 173 186 B-Condition
, NCT03866356 187 188 O
and NCT03866356 189 192 O
agreeing NCT03866356 193 201 O
to NCT03866356 202 204 O
participate NCT03866356 205 216 O
in NCT03866356 217 219 O
the NCT03866356 220 223 O
research NCT03866356 224 232 O

Exclusion NCT03866356 233 242 O
Criteria NCT03866356 243 251 O
: NCT03866356 252 253 O

- NCT03866356 257 258 O
The NCT03866356 260 263 O
exclusion NCT03866356 264 273 O
criteria NCT03866356 274 282 O
were NCT03866356 283 287 O
pregnancy NCT03866356 288 297 B-Condition
, NCT03866356 298 299 O
presence NCT03866356 300 308 O
of NCT03866356 309 311 O
a NCT03866356 312 313 O
urinary NCT03866356 314 321 B-Condition
tract NCT03866356 322 327 I-Condition
infection NCT03866356 328 337 I-Condition
and NCT03866356 338 341 B-Or
previous NCT03866356 342 350 B-Eq-Comparison
treatment NCT03866356 351 360 B-Procedure
for NCT03866356 361 364 O
SI NCT03866356 365 367 B-Condition
. NCT03866356 367 368 O
The NCT03866356 370 373 O
removal NCT03866356 374 381 O
criteria NCT03866356 382 390 O
were NCT03866356 391 395 O
patient NCT03866356 396 403 O
non NCT03866356 404 407 O
- NCT03866356 408 409 O
compliance NCT03866356 410 420 O
with NCT03866356 421 425 O
the NCT03866356 426 429 O
protocol NCT03866356 430 438 O
, NCT03866356 439 440 O
failure NCT03866356 441 448 O
in NCT03866356 449 451 O
contacting NCT03866356 452 462 O
the NCT03866356 463 466 O
patient NCT03866356 467 474 O
and NCT03866356 475 478 O
the NCT03866356 479 482 O
patient NCT03866356 483 490 O
's NCT03866356 490 492 O
wish NCT03866356 493 497 O
to NCT03866356 498 500 O
withdraw NCT03866356 501 509 O
from NCT03866356 510 514 O
the NCT03866356 515 518 O
study NCT03866356 519 524 O
. NCT03866356 524 525 O

Inclusion NCT03862118 0 9 O
Criteria NCT03862118 10 18 O
: NCT03862118 19 20 O

- NCT03862118 24 25 O
•Both NCT03862118 27 32 O
sexes NCT03862118 33 38 O
will NCT03862118 39 43 O
be NCT03862118 44 46 O
included NCT03862118 47 55 O
. NCT03862118 56 57 O

- NCT03862118 66 67 O
Age NCT03862118 69 72 B-Age
( NCT03862118 73 74 O
20 NCT03862118 75 77 B-Eq-Comparison
- NCT03862118 78 79 I-Eq-Comparison
50 NCT03862118 80 82 O
) NCT03862118 83 84 O

- NCT03862118 93 94 O
Patient NCT03862118 96 103 O
with NCT03862118 104 108 O
Fitzpatrick NCT03862118 109 120 B-Condition
skin NCT03862118 121 125 I-Condition
types NCT03862118 126 131 B-Eq-Comparison
III NCT03862118 132 135 I-Eq-Comparison
- NCT03862118 136 137 I-Eq-Comparison
IV NCT03862118 138 140 I-Eq-Comparison

Exclusion NCT03862118 141 150 O
Criteria NCT03862118 151 159 O
: NCT03862118 160 161 O

- NCT03862118 165 166 O
• NCT03862118 168 169 O
Patients NCT03862118 170 178 O
with NCT03862118 179 183 O
known NCT03862118 184 189 O
platelet NCT03862118 190 198 B-Condition
dysfunction NCT03862118 199 210 I-Condition
syndrome NCT03862118 211 219 I-Condition
, NCT03862118 220 221 O
critical NCT03862118 222 230 O
thrombocytopenia NCT03862118 231 247 B-Condition
( NCT03862118 248 249 O
< NCT03862118 251 252 B-Eq-Comparison
50 NCT03862118 253 255 I-Eq-Comparison
, NCT03862118 256 257 I-Eq-Comparison
000 NCT03862118 258 261 I-Eq-Comparison
/ NCT03862118 262 263 I-Eq-Comparison
ul NCT03862118 264 266 I-Eq-Comparison
) NCT03862118 267 268 O
, NCT03862118 270 271 O
any NCT03862118 272 275 O
hemodynamic NCT03862118 276 287 B-Condition
instability NCT03862118 288 299 I-Condition
. NCT03862118 300 301 O

- NCT03862118 310 311 O
Patients NCT03862118 313 321 O
with NCT03862118 322 326 O
chronic NCT03862118 327 334 B-Modifier
medical NCT03862118 335 342 B-Condition
illness NCT03862118 343 350 I-Condition
( NCT03862118 351 352 O
e. NCT03862118 353 355 O
g. NCT03862118 356 358 O
diabetes NCT03862118 360 368 B-Condition
, NCT03862118 369 370 O
chronic NCT03862118 371 378 B-Modifier
infections NCT03862118 379 389 B-Condition
, NCT03862118 390 391 O
and NCT03862118 392 395 B-Or
blood NCT03862118 396 401 B-Modifier
dyscrasias NCT03862118 402 412 B-Condition
) NCT03862118 413 414 O
. NCT03862118 416 417 O

- NCT03862118 426 427 O
Patients NCT03862118 429 437 O
with NCT03862118 438 442 O
local NCT03862118 443 448 B-Modifier
inflammatory NCT03862118 449 461 I-Modifier
skin NCT03862118 462 466 B-Condition
disorders NCT03862118 467 476 I-Condition
or NCT03862118 477 479 B-Or
active NCT03862118 480 486 B-Eq-Comparison
herpes NCT03862118 487 493 B-Condition
infection NCT03862118 494 503 I-Condition
at NCT03862118 504 506 O
the NCT03862118 507 510 O
site NCT03862118 511 515 B-Modifier
of NCT03862118 516 518 O
the NCT03862118 519 522 O
procedure NCT03862118 523 532 B-Procedure
. NCT03862118 533 534 O

- NCT03862118 543 544 O
Patients NCT03862118 546 554 O
on NCT03862118 555 557 B-Eq-Comparison
consistent NCT03862118 558 568 O
use NCT03862118 569 572 O
of NCT03862118 573 575 O
anti NCT03862118 576 580 B-Drug
- NCT03862118 581 582 I-Drug
coagulants NCT03862118 583 593 I-Drug
or NCT03862118 594 596 B-Or
non NCT03862118 597 600 B-Drug
- NCT03862118 601 602 I-Drug
steroidal NCT03862118 603 612 I-Drug
anti NCT03862118 613 617 I-Drug
- NCT03862118 618 619 I-Drug
inflammatory NCT03862118 620 632 I-Drug
drugs NCT03862118 633 638 I-Drug
( NCT03862118 639 640 O
NSAID NCT03862118 641 646 B-Drug
) NCT03862118 647 648 O
within NCT03862118 649 655 B-Eq-Comparison
48 NCT03862118 656 658 I-Eq-Comparison
hours NCT03862118 659 664 I-Eq-Comparison
of NCT03862118 665 667 B-Temporal-Connection___Temporal-Connection-Type-Value:before
procedure NCT03862118 668 677 B-Procedure
. NCT03862118 678 679 O

- NCT03862118 688 689 O
Haemoglobin NCT03862118 691 702 B-Observation
level NCT03862118 703 708 O
< NCT03862118 709 710 B-Eq-Comparison
10 NCT03862118 711 713 I-Eq-Comparison
g NCT03862118 714 715 I-Eq-Comparison
/ NCT03862118 716 717 I-Eq-Comparison
dl NCT03862118 718 720 I-Eq-Comparison
were NCT03862118 721 725 O
also NCT03862118 726 730 O
excluded NCT03862118 731 739 B-Negation
. NCT03862118 740 741 O

- NCT03862118 750 751 O
Patients NCT03862118 753 761 O
with NCT03862118 762 766 O
cancer NCT03862118 767 773 B-Condition
- NCT03862118 774 775 O
especially NCT03862118 776 786 O
hematopoietic NCT03862118 787 800 B-Modifier
or NCT03862118 801 803 B-Or
of NCT03862118 804 806 O
bone NCT03862118 807 811 B-Modifier
. NCT03862118 812 813 O

- NCT03862118 822 823 O
Pregnant NCT03862118 825 833 B-Condition
females NCT03862118 834 841 O
. NCT03862118 842 843 O

- NCT03862118 852 853 O
Patients NCT03862118 855 863 O
with NCT03862118 864 868 O
corticosteroids NCT03862118 869 884 B-Drug
injection NCT03862118 885 894 O
at NCT03862118 895 897 O
treatment NCT03862118 898 907 B-Procedure
site NCT03862118 908 912 O
within NCT03862118 913 919 B-Eq-Comparison
1 NCT03862118 920 921 I-Eq-Comparison
month NCT03862118 922 927 I-Eq-Comparison
or NCT03862118 928 930 B-Or
systemic NCT03862118 931 939 B-Modifier
use NCT03862118 940 943 O
of NCT03862118 944 946 O
corticosteroids NCT03862118 947 962 B-Drug
within NCT03862118 963 969 B-Eq-Comparison
2 NCT03862118 970 971 I-Eq-Comparison
weeks NCT03862118 972 977 I-Eq-Comparison
. NCT03862118 977 978 O

Inclusion NCT03861377 0 9 O
Criteria NCT03861377 10 18 O
: NCT03861377 19 20 O

- NCT03861377 24 25 O
Gynecological NCT03861377 27 40 B-Procedure
procedure NCT03861377 41 50 I-Procedure

- NCT03861377 53 54 O
Age NCT03861377 56 59 B-Age
18 NCT03861377 60 62 B-Eq-Comparison
- NCT03861377 63 64 I-Eq-Comparison
50 NCT03861377 65 67 I-Eq-Comparison
years NCT03861377 68 73 I-Eq-Comparison

- NCT03861377 76 77 O
General NCT03861377 79 86 B-Procedure
anesthesia NCT03861377 87 97 I-Procedure
planned NCT03861377 98 105 B-Eq-Comparison

- NCT03861377 108 109 O
Systolic NCT03861377 111 119 B-Observation
blood NCT03861377 120 125 I-Observation
pressure NCT03861377 126 134 I-Observation
< NCT03861377 135 136 B-Eq-Comparison
150 NCT03861377 137 140 I-Eq-Comparison
mmHg NCT03861377 141 145 I-Eq-Comparison
, NCT03861377 146 147 O
HR NCT03861377 148 150 B-Observation
< NCT03861377 151 152 B-Eq-Comparison
100 NCT03861377 153 156 I-Eq-Comparison
beats NCT03861377 157 162 I-Eq-Comparison
/ NCT03861377 163 164 I-Eq-Comparison
min NCT03861377 165 168 I-Eq-Comparison

Exclusion NCT03861377 169 178 O
Criteria NCT03861377 179 187 O
: NCT03861377 188 189 O

- NCT03861377 193 194 O
Pre NCT03861377 196 199 B-Eq-Comparison
- NCT03861377 200 201 I-Eq-Comparison
existing NCT03861377 202 210 I-Eq-Comparison
hypertension NCT03861377 211 223 B-Condition

- NCT03861377 226 227 O
Diabetes NCT03861377 229 237 B-Condition

- NCT03861377 240 241 O
Ischemic NCT03861377 243 251 B-Modifier
heart NCT03861377 252 257 B-Condition
disease NCT03861377 258 265 I-Condition
or NCT03861377 266 268 B-Or
cerebrovascular NCT03861377 269 284 B-Condition
disease NCT03861377 285 292 I-Condition

- NCT03861377 295 296 O
Heart NCT03861377 298 303 B-Condition
valve NCT03861377 304 309 I-Condition
disease NCT03861377 310 317 I-Condition

- NCT03861377 320 321 O
Verified NCT03861377 323 331 O
cardiac NCT03861377 332 339 B-Condition
arrhythmia NCT03861377 340 350 I-Condition
other NCT03861377 351 356 B-Exception
than NCT03861377 357 361 I-Exception
extrasystoles NCT03861377 362 375 B-Condition

- NCT03861377 378 379 O
Verified NCT03861377 381 389 O
anaemia NCT03861377 390 397 B-Condition
with NCT03861377 398 402 B-And
hemoglobin NCT03861377 403 413 B-Observation
level NCT03861377 414 419 O
below NCT03861377 420 425 B-Eq-Comparison
9.0 NCT03861377 426 429 I-Eq-Comparison
gr NCT03861377 430 432 I-Eq-Comparison
/ NCT03861377 433 434 I-Eq-Comparison
dl NCT03861377 435 437 I-Eq-Comparison
. NCT03861377 438 439 O

- NCT03861377 443 444 O
Kidney NCT03861377 446 452 B-Modifier
or NCT03861377 453 455 B-Or
hepatic NCT03861377 456 463 B-Modifier
disease NCT03861377 464 471 B-Condition

- NCT03861377 474 475 O
Hypersensitivity NCT03861377 477 493 B-Condition
for NCT03861377 494 497 O
propofol NCT03861377 498 506 B-Drug
, NCT03861377 507 508 O
soya NCT03861377 509 513 B-Modifier
, NCT03861377 514 515 O
eggs NCT03861377 516 520 B-Modifier
or NCT03861377 521 523 B-Or
peanuts NCT03861377 524 531 B-Modifier

- NCT03861377 534 535 O
Pregnancy NCT03861377 537 546 B-Condition

- NCT03861377 549 550 O
Poor NCT03861377 552 556 B-Condition
health NCT03861377 557 563 I-Condition
state NCT03861377 564 569 O

- NCT03861377 572 573 O
Illicit NCT03861377 575 582 B-Condition
substance NCT03861377 583 592 I-Condition
use NCT03861377 593 596 I-Condition

- NCT03861377 599 600 O
BMI NCT03861377 602 605 B-Observation
< NCT03861377 606 607 B-Eq-Comparison
20 NCT03861377 608 610 I-Eq-Comparison
or NCT03861377 611 613 B-Or
> NCT03861377 614 615 B-Eq-Comparison
35 NCT03861377 616 618 I-Eq-Comparison
kg NCT03861377 619 621 I-Eq-Comparison
/ NCT03861377 622 623 I-Eq-Comparison
m2 NCT03861377 624 626 I-Eq-Comparison

Inclusion NCT03869918 0 9 O
Criteria NCT03869918 10 18 O
: NCT03869918 19 20 O

1 NCT03869918 24 25 O
. NCT03869918 25 26 O
female NCT03869918 28 34 O

2 NCT03869918 37 38 O
. NCT03869918 38 39 O
age NCT03869918 41 44 B-Age
60 NCT03869918 45 47 B-Eq-Comparison
+ NCT03869918 48 49 I-Eq-Comparison
years NCT03869918 50 55 I-Eq-Comparison

3 NCT03869918 58 59 O
. NCT03869918 59 60 O
community NCT03869918 62 71 O
dwelling NCT03869918 72 80 O

4 NCT03869918 83 84 O
. NCT03869918 84 85 O
Moderate NCT03869918 87 95 B-Eq-Comparison
to NCT03869918 96 98 I-Eq-Comparison
severe NCT03869918 99 105 I-Eq-Comparison
UUI NCT03869918 106 109 B-Condition
( NCT03869918 110 111 O
as NCT03869918 112 114 O
measured NCT03869918 115 123 O
by NCT03869918 124 126 O
International NCT03869918 127 140 B-Observation
Consultation NCT03869918 141 153 I-Observation
on NCT03869918 154 156 I-Observation
Incontinence NCT03869918 157 169 I-Observation
Questionnaire NCT03869918 170 183 I-Observation
Short NCT03869918 184 189 I-Observation
Form NCT03869918 190 194 I-Observation
) NCT03869918 195 196 O

5 NCT03869918 200 201 O
. NCT03869918 201 202 O
low NCT03869918 204 207 O
physical NCT03869918 208 216 B-Observation
activity NCT03869918 217 225 I-Observation
( NCT03869918 226 227 O
Physical NCT03869918 228 236 B-Observation
Activity NCT03869918 237 245 I-Observation
Staging NCT03869918 246 253 I-Observation
questionnaire NCT03869918 254 267 I-Observation
) NCT03869918 268 269 O

6 NCT03869918 273 274 O
. NCT03869918 274 275 O
cognitively NCT03869918 277 288 B-Condition
able NCT03869918 289 293 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869918 294 296 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03869918 297 305 O
the NCT03869918 306 309 O
study NCT03869918 310 315 B-Study
( NCT03869918 316 317 O
in NCT03869918 318 320 O
opinion NCT03869918 321 328 O
of NCT03869918 329 331 O
the NCT03869918 332 335 O
referring NCT03869918 336 345 O
provider NCT03869918 346 354 O
) NCT03869918 355 356 O
Women NCT03869918 357 362 O
currently NCT03869918 363 372 B-Eq-Comparison
on NCT03869918 373 375 O
anti NCT03869918 376 380 B-Drug
- NCT03869918 381 382 I-Drug
cholinergic NCT03869918 383 394 I-Drug
medication NCT03869918 395 405 I-Drug
for NCT03869918 406 409 O
urinary NCT03869918 410 417 B-Condition
incontinence NCT03869918 418 430 I-Condition
will NCT03869918 431 435 O
be NCT03869918 436 438 O
allowed NCT03869918 439 446 O
if NCT03869918 447 449 O
they NCT03869918 450 454 O
meet NCT03869918 455 459 O
the NCT03869918 460 463 O
above NCT03869918 464 469 O
criteria NCT03869918 470 478 O
. NCT03869918 479 480 O

Exclusion NCT03869918 482 491 O
Criteria NCT03869918 492 500 O
: NCT03869918 501 502 O

1 NCT03869918 506 507 O
. NCT03869918 507 508 O
cognitive NCT03869918 510 519 B-Condition
impairment NCT03869918 520 530 I-Condition
( NCT03869918 531 532 O
in NCT03869918 533 535 O
opinion NCT03869918 536 543 O
of NCT03869918 544 546 O
the NCT03869918 547 550 O
referring NCT03869918 551 560 O
provider NCT03869918 561 569 O
) NCT03869918 570 571 O

2 NCT03869918 575 576 O
. NCT03869918 576 577 O
unable NCT03869918 579 585 O
to NCT03869918 586 588 O
provide NCT03869918 589 596 O
informed NCT03869918 597 605 O
consent NCT03869918 606 613 O
or NCT03869918 614 616 O
communicate NCT03869918 617 628 O
in NCT03869918 629 631 O
English NCT03869918 632 639 O

3 NCT03869918 642 643 O
. NCT03869918 643 644 O
desire NCT03869918 646 652 B-Assertion___Assertion-Type-Value:intention
for NCT03869918 653 656 I-Assertion___Assertion-Type-Value:intention
surgical NCT03869918 657 665 B-Procedure
management NCT03869918 666 676 I-Procedure

4 NCT03869918 679 680 O
. NCT03869918 680 681 O
osteoporosis NCT03869918 683 695 B-Condition

5 NCT03869918 698 699 O
. NCT03869918 699 700 O
lack NCT03869918 702 706 O
of NCT03869918 707 709 O
medical NCT03869918 710 717 O
clearance NCT03869918 718 727 O
from NCT03869918 728 732 O
the NCT03869918 733 736 O
physician NCT03869918 737 746 B-Provider
. NCT03869918 746 747 O

Inclusion NCT03868384 0 9 O
Criteria NCT03868384 10 18 O
: NCT03868384 19 20 O

- NCT03868384 24 25 O
Patients NCT03868384 27 35 O
with NCT03868384 36 40 O
hypertension NCT03868384 41 53 B-Condition
and NCT03868384 54 57 B-And
taking NCT03868384 58 64 B-Eq-Comparison
antihypertensive NCT03868384 65 81 B-Drug
drugs NCT03868384 82 87 I-Drug
more NCT03868384 88 92 B-Eq-Comparison
than NCT03868384 93 97 I-Eq-Comparison
1 NCT03868384 98 99 I-Eq-Comparison
year NCT03868384 100 104 I-Eq-Comparison

Exclusion NCT03868384 105 114 O
Criteria NCT03868384 115 123 O
: NCT03868384 124 125 O

- NCT03868384 129 130 O
Secondary NCT03868384 132 141 B-Modifier
hypertension NCT03868384 142 154 B-Condition

- NCT03868384 157 158 O
Hypertensive NCT03868384 160 172 B-Condition
emergency NCT03868384 173 182 B-Encounter
and NCT03868384 183 186 B-Or
urgency NCT03868384 187 194 B-Encounter

- NCT03868384 197 198 O
Severe NCT03868384 200 206 O
heart NCT03868384 207 212 B-Condition
failure NCT03868384 213 220 I-Condition
( NCT03868384 221 222 O
NYHA NCT03868384 223 227 B-Condition
III NCT03868384 228 231 B-Eq-Comparison
and NCT03868384 232 235 I-Eq-Comparison
IV NCT03868384 236 238 I-Eq-Comparison
) NCT03868384 239 240 O

- NCT03868384 244 245 O
Angina NCT03868384 247 253 B-Condition
with NCT03868384 254 258 O
6 NCT03868384 259 260 B-Eq-Comparison
months NCT03868384 261 267 I-Eq-Comparison

- NCT03868384 270 271 O
Myocardial NCT03868384 273 283 B-Condition
infarction NCT03868384 284 294 I-Condition
within NCT03868384 295 301 B-Eq-Comparison
6 NCT03868384 302 303 I-Eq-Comparison
months NCT03868384 304 310 I-Eq-Comparison

- NCT03868384 313 314 O
Peripheral NCT03868384 316 326 B-Condition
artery NCT03868384 327 333 I-Condition
disease NCT03868384 334 341 I-Condition
within NCT03868384 342 348 B-Eq-Comparison
6 NCT03868384 349 350 I-Eq-Comparison
months NCT03868384 351 357 I-Eq-Comparison

- NCT03868384 360 361 O
Significant NCT03868384 363 374 O
arrhythmia NCT03868384 375 385 B-Condition
( NCT03868384 386 387 O
i. NCT03868384 388 390 O
e. NCT03868384 391 393 O
ventricular NCT03868384 395 406 B-Condition
tachycardia NCT03868384 407 418 I-Condition
and NCT03868384 419 422 B-Or
fibrillation NCT03868384 423 435 B-Condition
, NCT03868384 436 437 O
atrial NCT03868384 438 444 B-Condition
fibrillation NCT03868384 445 457 I-Condition
, NCT03868384 458 459 O
atrial NCT03868384 460 466 B-Condition
flutter NCT03868384 467 474 I-Condition
) NCT03868384 475 476 O

- NCT03868384 480 481 O
Pregnancy NCT03868384 483 492 B-Condition

- NCT03868384 495 496 O
Night NCT03868384 498 503 B-Observation
labor NCT03868384 504 509 I-Observation
, NCT03868384 510 511 O
shift NCT03868384 512 517 B-Observation
worker NCT03868384 518 524 I-Observation

- NCT03868384 527 528 O
Those NCT03868384 530 535 O
who NCT03868384 536 539 O
are NCT03868384 540 543 O
currently NCT03868384 544 553 B-Eq-Comparison
participating NCT03868384 554 567 O
in NCT03868384 568 570 O
other NCT03868384 571 576 B-Other
clinical NCT03868384 577 585 O
studies NCT03868384 586 593 B-Study

- NCT03868384 596 597 O
Those NCT03868384 599 604 O
who NCT03868384 605 608 O
have NCT03868384 609 613 O
taken NCT03868384 614 619 B-Eq-Comparison
other NCT03868384 620 625 B-Other
clinical NCT03868384 626 634 B-Study
trial NCT03868384 635 640 I-Study
drugs NCT03868384 641 646 B-Drug
within NCT03868384 647 653 B-Eq-Comparison
the NCT03868384 654 657 I-Eq-Comparison
past NCT03868384 658 662 I-Eq-Comparison
month NCT03868384 663 668 I-Eq-Comparison

- NCT03868384 671 672 O
According NCT03868384 674 683 O
to NCT03868384 684 686 O
the NCT03868384 687 690 O
opinion NCT03868384 691 698 O
of NCT03868384 699 701 O
the NCT03868384 702 705 O
researcher NCT03868384 706 716 O
, NCT03868384 717 718 O
those NCT03868384 719 724 O
who NCT03868384 725 728 O
have NCT03868384 729 733 O
or NCT03868384 734 736 O
may NCT03868384 737 740 B-Assertion___Assertion-Type-Value:possible
have NCT03868384 741 745 I-Assertion___Assertion-Type-Value:possible
a NCT03868384 746 747 O
disease NCT03868384 748 755 B-Condition
that NCT03868384 756 760 O
may NCT03868384 761 764 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03868384 765 774 O
with NCT03868384 775 779 O
the NCT03868384 780 783 O
completion NCT03868384 784 794 O
of NCT03868384 795 797 O
the NCT03868384 798 801 O
study NCT03868384 802 807 B-Study

- NCT03868384 810 811 O
History NCT03868384 813 820 B-Eq-Comparison
of NCT03868384 821 823 O
drug NCT03868384 824 828 B-Modifier
or NCT03868384 829 831 B-Or
alcohol NCT03868384 832 839 B-Modifier
dependence NCT03868384 840 850 B-Condition
within NCT03868384 851 857 B-Eq-Comparison
6 NCT03868384 858 859 I-Eq-Comparison
months NCT03868384 860 866 I-Eq-Comparison

Inclusion NCT03861559 0 9 O
Criteria NCT03861559 10 18 O
: NCT03861559 19 20 O

- NCT03861559 24 25 O
Has NCT03861559 27 30 O
a NCT03861559 31 32 O
2 NCT03861559 33 34 B-Eq-Comparison
- NCT03861559 35 36 I-Eq-Comparison
year NCT03861559 37 41 I-Eq-Comparison
history NCT03861559 42 49 I-Eq-Comparison
of NCT03861559 50 52 O
seasonal NCT03861559 53 61 O
allergic NCT03861559 62 70 B-Condition
rhinitis NCT03861559 71 79 I-Condition

- NCT03861559 82 83 O
Has NCT03861559 85 88 O
a NCT03861559 89 90 O
positive NCT03861559 91 99 O
skin NCT03861559 100 104 B-Observation
test NCT03861559 105 109 I-Observation
response NCT03861559 110 118 O
to NCT03861559 119 121 O
a NCT03861559 122 123 O
local NCT03861559 124 129 O
seasonal NCT03861559 130 138 O
allergen NCT03861559 139 147 B-Drug
( NCT03861559 148 149 O
current NCT03861559 150 157 B-Eq-Comparison
, NCT03861559 158 159 O
or NCT03861559 160 162 B-Or
performed NCT03861559 163 172 O
in NCT03861559 173 175 O
investigator NCT03861559 176 188 O
's NCT03861559 188 190 O
office NCT03861559 191 197 O
within NCT03861559 198 204 B-Eq-Comparison
the NCT03861559 205 208 I-Eq-Comparison
past NCT03861559 209 213 I-Eq-Comparison
year NCT03861559 214 218 I-Eq-Comparison
) NCT03861559 219 220 O

- NCT03861559 224 225 O
Is NCT03861559 227 229 O
in NCT03861559 230 232 O
good NCT03861559 233 237 B-Condition
health NCT03861559 238 244 I-Condition
and NCT03861559 245 248 B-And
free NCT03861559 249 253 B-Negation
of NCT03861559 254 256 I-Negation
any NCT03861559 257 260 O
unstable NCT03861559 261 269 O
, NCT03861559 270 271 O
clinically NCT03861559 272 282 O
- NCT03861559 283 284 O
significant NCT03861559 285 296 O
disease NCT03861559 297 304 B-Condition
, NCT03861559 305 306 O
other NCT03861559 307 312 B-Exception
than NCT03861559 313 317 I-Exception
allergic NCT03861559 318 326 B-Condition
rhinitis NCT03861559 327 335 I-Condition
, NCT03861559 336 337 O
that NCT03861559 338 342 O
would NCT03861559 343 348 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 349 358 O
with NCT03861559 359 363 O
the NCT03861559 364 367 O
study NCT03861559 368 373 B-Study
schedule NCT03861559 374 382 O
or NCT03861559 383 385 O
evaluation NCT03861559 386 396 O
of NCT03861559 397 399 O
seasonal NCT03861559 400 408 O
allergic NCT03861559 409 417 B-Condition
rhinitis NCT03861559 418 426 I-Condition

Exclusion NCT03861559 427 436 O
Criteria NCT03861559 437 445 O
: NCT03861559 446 447 O

- NCT03861559 451 452 O
Women NCT03861559 454 459 O
who NCT03861559 460 463 B-And
are NCT03861559 464 467 O
pregnant NCT03861559 468 476 B-Condition
or NCT03861559 477 479 B-Or
breastfeeding NCT03861559 480 493 B-Condition

- NCT03861559 496 497 O
Women NCT03861559 499 504 O
of NCT03861559 505 507 B-And
childbearing NCT03861559 508 520 B-Condition
potential NCT03861559 521 530 I-Condition
who NCT03861559 531 534 B-And
are NCT03861559 535 538 O
not NCT03861559 539 542 B-Negation
using NCT03861559 543 548 B-Eq-Comparison
an NCT03861559 549 551 O
acceptable NCT03861559 552 562 O
form NCT03861559 563 567 O
of NCT03861559 568 570 O
birth NCT03861559 571 576 B-Procedure
control NCT03861559 577 584 I-Procedure

- NCT03861559 587 588 O
Has NCT03861559 590 593 O
asthma NCT03861559 594 600 B-Condition
that NCT03861559 601 605 O
requires NCT03861559 606 614 B-Assertion___Assertion-Type-Value:hypothetical
therapy NCT03861559 615 622 B-Procedure
with NCT03861559 623 627 O
inhaled NCT03861559 628 635 B-Modifier
or NCT03861559 636 638 B-Or
systemic NCT03861559 639 647 B-Modifier
corticosteroids NCT03861559 648 663 B-Drug
, NCT03861559 664 665 O
cromolyn NCT03861559 666 674 B-Drug
, NCT03861559 675 676 O
or NCT03861559 677 679 B-Or
nedocromil NCT03861559 680 690 B-Drug

- NCT03861559 693 694 O
Has NCT03861559 696 699 O
significant NCT03861559 700 711 O
renal NCT03861559 712 717 B-Modifier
, NCT03861559 718 719 O
hepatic NCT03861559 720 727 B-Modifier
, NCT03861559 728 729 O
neurologic NCT03861559 730 740 B-Modifier
, NCT03861559 741 742 O
cardiovascular NCT03861559 743 757 B-Modifier
, NCT03861559 758 759 O
hematologic NCT03861559 760 771 B-Modifier
, NCT03861559 772 773 O
metabolic NCT03861559 774 783 B-Modifier
, NCT03861559 784 785 O
cerebrovascular NCT03861559 786 801 B-Modifier
, NCT03861559 802 803 O
respiratory NCT03861559 804 815 B-Modifier
, NCT03861559 816 817 O
gastrointestinal NCT03861559 818 834 B-Modifier
, NCT03861559 835 836 O
or NCT03861559 837 839 B-Or
other NCT03861559 840 845 B-Other
significant NCT03861559 846 857 O
medical NCT03861559 858 865 B-Condition
illness NCT03861559 866 873 I-Condition
or NCT03861559 874 876 B-Or
disorder NCT03861559 877 885 B-Condition
which NCT03861559 886 891 O
, NCT03861559 892 893 O
in NCT03861559 894 896 O
the NCT03861559 897 900 O
judgment NCT03861559 901 909 O
of NCT03861559 910 912 O
the NCT03861559 913 916 O
investigator NCT03861559 917 929 O
, NCT03861559 930 931 O
could NCT03861559 932 937 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 938 947 O
with NCT03861559 948 952 O
the NCT03861559 953 956 O
study NCT03861559 957 962 B-Study
, NCT03861559 963 964 O
or NCT03861559 965 967 B-Or
required NCT03861559 968 976 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03861559 977 986 B-Procedure
which NCT03861559 987 992 O
might NCT03861559 993 998 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861559 999 1008 O
with NCT03861559 1009 1013 O
the NCT03861559 1014 1017 O
study NCT03861559 1018 1023 B-Study

- NCT03861559 1026 1027 O
Is NCT03861559 1029 1031 O
on NCT03861559 1032 1034 B-Eq-Comparison
immunotherapy NCT03861559 1035 1048 B-Procedure
with NCT03861559 1049 1053 O
the NCT03861559 1054 1057 O
exception NCT03861559 1058 1067 B-Exception
of NCT03861559 1068 1070 O
maintenance NCT03861559 1071 1082 B-Procedure
therapy NCT03861559 1083 1090 I-Procedure

- NCT03861559 1093 1094 O
Has NCT03861559 1096 1099 O
a NCT03861559 1100 1101 O
clinically NCT03861559 1102 1112 O
significant NCT03861559 1113 1124 O
upper NCT03861559 1125 1130 B-Modifier
respiratory NCT03861559 1131 1142 I-Modifier
or NCT03861559 1143 1145 B-Or
sinus NCT03861559 1146 1151 B-Modifier
infection NCT03861559 1152 1161 B-Condition

- NCT03861559 1164 1165 O
Has NCT03861559 1167 1170 O
used NCT03861559 1171 1175 B-Eq-Comparison
an NCT03861559 1176 1178 O
investigational NCT03861559 1179 1194 B-Study
drug NCT03861559 1195 1199 B-Drug
within NCT03861559 1200 1206 B-Eq-Comparison
the NCT03861559 1207 1210 I-Eq-Comparison
previous NCT03861559 1211 1219 I-Eq-Comparison
30 NCT03861559 1220 1222 I-Eq-Comparison
days NCT03861559 1223 1227 I-Eq-Comparison

- NCT03861559 1230 1231 O
Has NCT03861559 1233 1236 O
nasal NCT03861559 1237 1242 B-Modifier
structural NCT03861559 1243 1253 I-Modifier
abnormalities NCT03861559 1254 1267 B-Condition
, NCT03861559 1268 1269 O
including NCT03861559 1270 1279 O
large NCT03861559 1280 1285 B-Modifier
nasal NCT03861559 1286 1291 B-Condition
polyps NCT03861559 1292 1298 I-Condition
and NCT03861559 1299 1302 B-Or
marked NCT03861559 1303 1309 O
septal NCT03861559 1310 1316 B-Condition
deviation NCT03861559 1317 1326 I-Condition
, NCT03861559 1327 1328 O
that NCT03861559 1329 1333 O
significantly NCT03861559 1334 1347 O
interfere NCT03861559 1348 1357 O
with NCT03861559 1358 1362 O
nasal NCT03861559 1363 1368 B-Condition
air NCT03861559 1369 1372 I-Condition
flow NCT03861559 1373 1377 I-Condition

- NCT03861559 1380 1381 O
Has NCT03861559 1383 1386 O
a NCT03861559 1387 1388 O
history NCT03861559 1389 1396 B-Eq-Comparison
of NCT03861559 1397 1399 O
multiple NCT03861559 1400 1408 B-Eq-Comparison
drug NCT03861559 1409 1413 B-Drug
allergies NCT03861559 1414 1423 B-Allergy
or NCT03861559 1424 1426 B-Or
an NCT03861559 1427 1429 O
allergy NCT03861559 1430 1437 B-Allergy
to NCT03861559 1438 1440 O
antihistamines NCT03861559 1441 1455 B-Drug
or NCT03861559 1456 1458 B-Or
corticoids NCT03861559 1459 1469 B-Drug

- NCT03861559 1472 1473 O
Has NCT03861559 1475 1478 O
dependence NCT03861559 1479 1489 O
upon NCT03861559 1490 1494 O
nasal NCT03861559 1495 1500 B-Modifier
, NCT03861559 1501 1502 O
oral NCT03861559 1503 1507 B-Modifier
or NCT03861559 1508 1510 B-Or
ocular NCT03861559 1511 1517 B-Modifier
decongestants NCT03861559 1518 1531 B-Drug
, NCT03861559 1532 1533 O
or NCT03861559 1534 1536 B-Or
nasal NCT03861559 1537 1542 B-Drug
topical NCT03861559 1543 1550 I-Drug
antihistamines NCT03861559 1551 1565 I-Drug
, NCT03861559 1566 1567 O
in NCT03861559 1568 1570 O
the NCT03861559 1571 1574 O
opinion NCT03861559 1575 1582 O
of NCT03861559 1583 1585 O
the NCT03861559 1586 1589 O
investigator NCT03861559 1590 1602 O

- NCT03861559 1605 1606 O
Has NCT03861559 1608 1611 O
rhinitis NCT03861559 1612 1620 B-Condition
medicamentosa NCT03861559 1621 1634 I-Condition

- NCT03861559 1637 1638 O
Is NCT03861559 1640 1642 O
using NCT03861559 1643 1648 B-Eq-Comparison
of NCT03861559 1649 1651 O
any NCT03861559 1652 1655 O
chronic NCT03861559 1656 1663 B-Modifier
medication NCT03861559 1664 1674 B-Drug
which NCT03861559 1675 1680 O
could NCT03861559 1681 1686 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861559 1687 1693 O
the NCT03861559 1694 1697 O
course NCT03861559 1698 1704 O
of NCT03861559 1705 1707 O
seasonal NCT03861559 1708 1716 O
allergic NCT03861559 1717 1725 B-Condition
rhinitis NCT03861559 1726 1734 I-Condition

Inclusion NCT03863366 0 9 O
Criteria NCT03863366 10 18 O
: NCT03863366 19 20 O

- NCT03863366 24 25 O
Male NCT03863366 27 31 O
or NCT03863366 32 34 B-Or
female NCT03863366 35 41 O

- NCT03863366 44 45 O
Aged NCT03863366 47 51 B-Age
18 NCT03863366 52 54 B-Eq-Comparison
- NCT03863366 55 56 I-Eq-Comparison
40 NCT03863366 57 59 I-Eq-Comparison
years NCT03863366 60 65 I-Eq-Comparison

- NCT03863366 68 69 O
Willing NCT03863366 71 78 O
and NCT03863366 79 82 O
able NCT03863366 83 87 O
to NCT03863366 88 90 O
give NCT03863366 91 95 O
informed NCT03863366 96 104 O
consent NCT03863366 105 112 O
for NCT03863366 113 116 O
participation NCT03863366 117 130 O
in NCT03863366 131 133 O
the NCT03863366 134 137 O
study NCT03863366 138 143 O

- NCT03863366 146 147 O
Sufficiently NCT03863366 149 161 O
fluent NCT03863366 162 168 O
English NCT03863366 169 176 O
to NCT03863366 177 179 O
understand NCT03863366 180 190 O
and NCT03863366 191 194 O
complete NCT03863366 195 203 O
the NCT03863366 204 207 O
task NCT03863366 208 212 O

Exclusion NCT03863366 213 222 O
Criteria NCT03863366 223 231 O
: NCT03863366 232 233 O

- NCT03863366 237 238 O
Current NCT03863366 240 247 B-Eq-Comparison
usage NCT03863366 248 253 O
of NCT03863366 254 256 O
psychoactive NCT03863366 257 269 B-Drug
medication NCT03863366 270 280 I-Drug
( NCT03863366 281 282 O
except NCT03863366 283 289 B-Exception
the NCT03863366 290 293 O
contraceptive NCT03863366 294 307 B-Drug
pill NCT03863366 308 312 I-Drug
, NCT03863366 313 314 O
the NCT03863366 315 318 O
Depo NCT03863366 319 323 B-Drug
- NCT03863366 324 325 I-Drug
Provera NCT03863366 326 333 I-Drug
injection NCT03863366 334 343 O
or NCT03863366 344 346 B-Or
the NCT03863366 347 350 O
progesterone NCT03863366 351 363 B-Procedure
implant NCT03863366 364 371 I-Procedure
) NCT03863366 372 373 O

- NCT03863366 377 378 O
Any NCT03863366 380 383 O
past NCT03863366 384 388 B-Eq-Comparison
or NCT03863366 389 391 B-Or
current NCT03863366 392 399 B-Eq-Comparison
Axis NCT03863366 400 404 B-Modifier
1 NCT03863366 405 406 I-Modifier
DSM NCT03863366 407 410 I-Modifier
- NCT03863366 411 412 I-Modifier
IV NCT03863366 413 415 I-Modifier
psychiatric NCT03863366 416 427 B-Condition
disorder NCT03863366 428 436 I-Condition

- NCT03863366 439 440 O
Significant NCT03863366 442 453 O
medical NCT03863366 454 461 B-Condition
condition NCT03863366 462 471 I-Condition

- NCT03863366 474 475 O
Current NCT03863366 477 484 B-Eq-Comparison
or NCT03863366 485 487 B-Or
past NCT03863366 488 492 B-Eq-Comparison
gastro NCT03863366 493 499 B-Modifier
- NCT03863366 500 501 I-Modifier
intestinal NCT03863366 502 512 I-Modifier
disorder NCT03863366 513 521 B-Condition
or NCT03863366 522 524 B-Or
irritable NCT03863366 525 534 B-Condition
bowel NCT03863366 535 540 I-Condition
syndrome NCT03863366 541 549 I-Condition

- NCT03863366 552 553 O
Current NCT03863366 555 562 B-Eq-Comparison
pregnancy NCT03863366 563 572 B-Condition
or NCT03863366 573 575 B-Or
breastfeeding NCT03863366 576 589 B-Condition

- NCT03863366 592 593 O
Known NCT03863366 595 600 O
lactate NCT03863366 601 608 B-Condition
deficiency NCT03863366 609 619 I-Condition
or NCT03863366 620 622 B-Or
any NCT03863366 623 626 O
other NCT03863366 627 632 B-Other
problem NCT03863366 633 640 B-Condition
absorbing NCT03863366 641 650 I-Condition
lactose NCT03863366 651 658 B-Modifier
, NCT03863366 659 660 O
galactose NCT03863366 661 670 B-Modifier
or NCT03863366 671 673 B-Or
glucose NCT03863366 674 681 B-Modifier

- NCT03863366 684 685 O
Current NCT03863366 687 694 B-Eq-Comparison
or NCT03863366 695 697 B-Or
past NCT03863366 698 702 B-Eq-Comparison
history NCT03863366 703 710 I-Eq-Comparison
of NCT03863366 711 713 O
drug NCT03863366 714 718 B-Modifier
or NCT03863366 719 721 B-Or
alcohol NCT03863366 722 729 B-Modifier
dependency NCT03863366 730 740 B-Condition

- NCT03863366 743 744 O
Participation NCT03863366 746 759 O
in NCT03863366 760 762 O
a NCT03863366 763 764 O
psychological NCT03863366 765 778 B-Modifier
or NCT03863366 779 781 B-Or
medical NCT03863366 782 789 B-Modifier
study NCT03863366 790 795 B-Study
involving NCT03863366 796 805 O
the NCT03863366 806 809 O
use NCT03863366 810 813 O
of NCT03863366 814 816 O
medication NCT03863366 817 827 B-Drug
within NCT03863366 828 834 B-Eq-Comparison
the NCT03863366 835 838 I-Eq-Comparison
last NCT03863366 839 843 I-Eq-Comparison
3 NCT03863366 844 845 I-Eq-Comparison
months NCT03863366 846 852 I-Eq-Comparison

- NCT03863366 855 856 O
Previous NCT03863366 858 866 B-Eq-Comparison
participation NCT03863366 867 880 O
in NCT03863366 881 883 O
a NCT03863366 884 885 O
study NCT03863366 886 891 B-Study
using NCT03863366 892 897 O
the NCT03863366 898 901 O
same NCT03863366 902 906 B-Modifier
, NCT03863366 907 908 O
or NCT03863366 909 911 B-Or
similar NCT03863366 912 919 B-Modifier
, NCT03863366 920 921 O
emotional NCT03863366 922 931 B-Procedure
processing NCT03863366 932 942 I-Procedure
tasks NCT03863366 943 948 I-Procedure

- NCT03863366 951 952 O
Smoker NCT03863366 954 960 B-Condition|Observation
> NCT03863366 961 962 B-Eq-Comparison
5 NCT03863366 963 964 I-Eq-Comparison
cigarettes NCT03863366 965 975 I-Eq-Comparison
per NCT03863366 976 979 I-Eq-Comparison
day NCT03863366 980 983 I-Eq-Comparison

- NCT03863366 986 987 O
Typically NCT03863366 989 998 O
drinks NCT03863366 999 1005 B-Observation
> NCT03863366 1006 1007 B-Eq-Comparison
6 NCT03863366 1008 1009 I-Eq-Comparison
caffeinated NCT03863366 1010 1021 I-Eq-Comparison
drinks NCT03863366 1022 1028 I-Eq-Comparison
per NCT03863366 1029 1032 I-Eq-Comparison
day NCT03863366 1033 1036 I-Eq-Comparison

Inclusion NCT03862534 0 9 O
Criteria NCT03862534 10 18 O
: NCT03862534 19 20 O

- NCT03862534 24 25 O
Age NCT03862534 27 30 B-Age
≥ NCT03862534 31 32 B-Eq-Comparison
18 NCT03862534 33 35 I-Eq-Comparison
years NCT03862534 36 41 I-Eq-Comparison

- NCT03862534 44 45 O
No NCT03862534 47 49 B-Negation
systemic NCT03862534 50 58 B-Modifier
diseases NCT03862534 59 67 B-Condition
or NCT03862534 68 70 B-Or
pregnancy NCT03862534 71 80 B-Condition
. NCT03862534 81 82 O

- NCT03862534 86 87 O
Self NCT03862534 89 93 O
- NCT03862534 94 95 O
reported NCT03862534 96 104 O
smoking NCT03862534 105 112 B-Condition|Observation
≤ NCT03862534 113 114 B-Eq-Comparison
10 NCT03862534 115 117 I-Eq-Comparison
cigarettes NCT03862534 118 128 I-Eq-Comparison
/ NCT03862534 129 130 I-Eq-Comparison
day NCT03862534 131 134 I-Eq-Comparison
. NCT03862534 135 136 O

- NCT03862534 140 141 O
Full NCT03862534 143 147 B-Observation
- NCT03862534 148 149 I-Observation
mouth NCT03862534 150 155 I-Observation
plaque NCT03862534 156 162 I-Observation
score NCT03862534 163 168 I-Observation
( NCT03862534 169 170 O
FMPS NCT03862534 171 175 B-Observation
) NCT03862534 176 177 O
and NCT03862534 178 181 B-And
full NCT03862534 182 186 B-Observation
- NCT03862534 187 188 I-Observation
mouth NCT03862534 189 194 I-Observation
bleeding NCT03862534 195 203 I-Observation
score NCT03862534 204 209 I-Observation
( NCT03862534 210 211 O
FMBS NCT03862534 212 216 B-Observation
) NCT03862534 217 218 O
≤ NCT03862534 219 220 B-Eq-Comparison
10 NCT03862534 221 223 I-Eq-Comparison
% NCT03862534 224 225 I-Eq-Comparison
( NCT03862534 226 227 O
measured NCT03862534 228 236 O
at NCT03862534 237 239 O
four NCT03862534 240 244 B-Eq-Comparison
sites NCT03862534 245 250 I-Eq-Comparison
per NCT03862534 251 254 I-Eq-Comparison
tooth NCT03862534 255 260 I-Eq-Comparison
) NCT03862534 261 262 O
. NCT03862534 264 265 O

- NCT03862534 269 270 O
Presence NCT03862534 272 280 O
of NCT03862534 281 283 O
single NCT03862534 284 290 B-Eq-Comparison
RT1 NCT03862534 291 294 B-Modifier
buccal NCT03862534 295 301 I-Modifier
gingival NCT03862534 302 310 B-Condition|Observation
recessions NCT03862534 311 321 I-Condition|Observation
≥ NCT03862534 322 323 B-Eq-Comparison
2 NCT03862534 324 325 I-Eq-Comparison
mm NCT03862534 326 328 I-Eq-Comparison
of NCT03862534 329 331 O
depth NCT03862534 332 337 O
located NCT03862534 338 345 O
in NCT03862534 346 348 O
the NCT03862534 349 352 O
anterior NCT03862534 353 361 B-Modifier
area NCT03862534 362 366 I-Modifier
of NCT03862534 367 369 O
the NCT03862534 370 373 O
upper NCT03862534 374 379 B-Modifier
jaw NCT03862534 380 383 I-Modifier
( NCT03862534 384 385 O
central NCT03862534 386 393 B-Modifier
and NCT03862534 394 397 B-Or
lateral NCT03862534 398 405 B-Modifier
incisors NCT03862534 406 414 I-Modifier
, NCT03862534 415 416 O
canine NCT03862534 417 423 B-Modifier
, NCT03862534 424 425 O
first NCT03862534 426 431 B-Modifier
and NCT03862534 432 435 I-Modifier
second NCT03862534 436 442 I-Modifier
pre NCT03862534 443 446 I-Modifier
- NCT03862534 447 448 I-Modifier
molars NCT03862534 449 455 I-Modifier
, NCT03862534 456 457 O
first NCT03862534 458 463 B-Modifier
molar NCT03862534 464 469 I-Modifier
) NCT03862534 470 471 O
and NCT03862534 472 475 O
associated NCT03862534 476 486 O
with NCT03862534 487 491 O
aesthetic NCT03862534 492 501 B-Condition
complains NCT03862534 502 511 I-Condition
and NCT03862534 512 515 O
or NCT03862534 516 518 B-Or
dental NCT03862534 519 525 B-Condition
sensitivity NCT03862534 526 537 I-Condition
. NCT03862534 538 539 O

- NCT03862534 543 544 O
Presence NCT03862534 546 554 O
of NCT03862534 555 557 O
NCCL NCT03862534 558 562 B-Condition
associated NCT03862534 563 573 O
with NCT03862534 574 578 O
recession NCT03862534 579 588 B-Condition

- NCT03862534 591 592 O
No NCT03862534 594 596 B-Negation
history NCT03862534 597 604 B-Eq-Comparison
of NCT03862534 605 607 O
mucogingival NCT03862534 608 620 B-Modifier
or NCT03862534 621 623 B-Or
periodontal NCT03862534 624 635 B-Modifier
surgery NCT03862534 636 643 B-Procedure
at NCT03862534 644 646 O
experimental NCT03862534 647 659 B-Modifier
sites NCT03862534 660 665 I-Modifier
. NCT03862534 666 667 O

Exclusion NCT03862534 669 678 O
Criteria NCT03862534 679 687 O
: NCT03862534 688 689 O

- NCT03862534 693 694 O
Prosthetic NCT03862534 696 706 B-Condition
crown NCT03862534 707 712 I-Condition
at NCT03862534 713 715 O
experimental NCT03862534 716 728 B-Modifier
teeth NCT03862534 729 734 I-Modifier
. NCT03862534 735 736 O

- NCT03862534 740 741 O
Gingival NCT03862534 743 751 B-Condition
recessions NCT03862534 752 762 I-Condition
presenting NCT03862534 763 773 O
minimal NCT03862534 774 781 O
amount NCT03862534 782 788 O
( NCT03862534 789 790 O
< NCT03862534 792 793 B-Eq-Comparison
1 NCT03862534 794 795 I-Eq-Comparison
mm NCT03862534 796 798 I-Eq-Comparison
) NCT03862534 799 800 O
of NCT03862534 801 803 O
apico NCT03862534 804 809 B-Condition|Observation
- NCT03862534 810 811 I-Condition|Observation
coronal NCT03862534 812 819 I-Condition|Observation
keratinized NCT03862534 820 831 I-Condition|Observation
tissue NCT03862534 832 838 I-Condition|Observation
( NCT03862534 839 840 O
KT NCT03862534 841 843 B-Condition
) NCT03862534 844 845 O
extension NCT03862534 846 855 O
apical NCT03862534 856 862 B-Modifier
to NCT03862534 863 865 I-Modifier
recession NCT03862534 866 875 I-Modifier
area NCT03862534 876 880 I-Modifier
. NCT03862534 880 881 O

Inclusion NCT03869307 0 9 O
Criteria NCT03869307 10 18 O
: NCT03869307 19 20 O

- NCT03869307 24 25 O
Men NCT03869307 27 30 O
and NCT03869307 31 34 B-Or
women NCT03869307 35 40 O
aged NCT03869307 41 45 B-Age
18 NCT03869307 46 48 B-Eq-Comparison
- NCT03869307 49 50 I-Eq-Comparison
65 NCT03869307 51 53 I-Eq-Comparison

- NCT03869307 57 58 O
Generalized NCT03869307 60 71 B-Modifier
HSD NCT03869307 72 75 B-Condition
( NCT03869307 76 77 O
G NCT03869307 78 79 B-Condition
- NCT03869307 80 81 I-Condition
HSD NCT03869307 82 85 I-Condition
) NCT03869307 86 87 O
defined NCT03869307 88 95 O
with NCT03869307 96 100 O
Beighton NCT03869307 101 109 B-Observation
score NCT03869307 110 115 I-Observation
cut NCT03869307 116 119 O
- NCT03869307 120 121 O
off NCT03869307 122 125 O
≥ NCT03869307 126 127 B-Eq-Comparison
5 NCT03869307 128 129 I-Eq-Comparison
for NCT03869307 130 133 O
women NCT03869307 134 139 O
up NCT03869307 140 142 B-Eq-Comparison
to NCT03869307 143 145 I-Eq-Comparison
the NCT03869307 146 149 I-Eq-Comparison
age NCT03869307 150 153 I-Age|Eq-Comparison
of NCT03869307 154 156 I-Eq-Comparison
50 NCT03869307 157 159 I-Eq-Comparison
years NCT03869307 160 165 I-Eq-Comparison
and NCT03869307 166 169 B-Or
≥ NCT03869307 170 171 B-Eq-Comparison
4 NCT03869307 172 173 I-Eq-Comparison
for NCT03869307 174 177 O
those NCT03869307 178 183 B-Coreference
above NCT03869307 184 189 B-Eq-Comparison
50 NCT03869307 190 192 I-Eq-Comparison
years NCT03869307 193 198 I-Age|Eq-Comparison
and NCT03869307 199 202 B-Or
all NCT03869307 203 206 O
men NCT03869307 207 210 O
, NCT03869307 211 212 O
or NCT03869307 213 215 B-Or
Historical NCT03869307 216 226 B-Modifier
HSD NCT03869307 227 230 B-Condition
( NCT03869307 231 232 O
H NCT03869307 233 234 B-Condition
- NCT03869307 235 236 I-Condition
HSD NCT03869307 237 240 I-Condition
) NCT03869307 241 242 O
if NCT03869307 243 245 O
the NCT03869307 246 249 O
Beighton NCT03869307 250 258 B-Observation
score NCT03869307 259 264 I-Observation
was NCT03869307 265 268 O
1 NCT03869307 269 270 B-Eq-Comparison
point NCT03869307 271 276 I-Eq-Comparison
below NCT03869307 277 282 I-Eq-Comparison
the NCT03869307 283 286 I-Eq-Comparison
age NCT03869307 287 290 I-Eq-Comparison
and NCT03869307 291 294 I-Eq-Comparison
sex NCT03869307 295 298 I-Eq-Comparison
- NCT03869307 299 300 I-Eq-Comparison
specific NCT03869307 301 309 I-Eq-Comparison
cut NCT03869307 310 313 I-Eq-Comparison
- NCT03869307 314 315 I-Eq-Comparison
off NCT03869307 316 319 I-Eq-Comparison
AND NCT03869307 320 323 B-And
the NCT03869307 324 327 O
five NCT03869307 328 332 B-Observation
- NCT03869307 333 334 I-Observation
part NCT03869307 335 339 I-Observation
questionnaire NCT03869307 340 353 I-Observation
( NCT03869307 354 355 O
5 NCT03869307 356 357 B-Observation
PQ NCT03869307 358 360 I-Observation
) NCT03869307 361 362 O
was NCT03869307 363 366 O
positive NCT03869307 367 375 O
( NCT03869307 376 377 O
= NCT03869307 379 380 O
at NCT03869307 381 383 B-Eq-Comparison
least NCT03869307 384 389 I-Eq-Comparison
two NCT03869307 390 393 I-Eq-Comparison
positive NCT03869307 394 402 I-Eq-Comparison
items NCT03869307 403 408 I-Eq-Comparison
) NCT03869307 409 410 O
. NCT03869307 412 413 O

- NCT03869307 417 418 O
Present NCT03869307 420 427 O
with NCT03869307 428 432 O
one NCT03869307 433 436 B-Eq-Comparison
or NCT03869307 437 439 I-Eq-Comparison
more NCT03869307 440 444 I-Eq-Comparison
secondary NCT03869307 445 454 B-Modifier
symptomatic NCT03869307 455 466 B-Assertion___Assertion-Type-Value:possible
musculoskeletal NCT03869307 467 482 B-Condition
manifestations NCT03869307 483 497 I-Condition
, NCT03869307 498 499 O
defined NCT03869307 500 507 O
as NCT03869307 508 510 O
either NCT03869307 511 517 O

1 NCT03869307 525 526 O
. NCT03869307 526 527 O
musculoskeletal NCT03869307 529 544 B-Modifier
pain NCT03869307 545 549 B-Condition
in NCT03869307 550 552 O
minimum NCT03869307 553 560 B-Eq-Comparison
one NCT03869307 561 564 I-Eq-Comparison
shoulder NCT03869307 565 573 B-Modifier
for NCT03869307 574 577 O
at NCT03869307 578 580 B-Eq-Comparison
least NCT03869307 581 586 I-Eq-Comparison
three NCT03869307 587 592 I-Eq-Comparison
months NCT03869307 593 599 I-Eq-Comparison
and NCT03869307 600 603 B-Or
/ NCT03869307 604 605 I-Or
or NCT03869307 606 608 I-Or

2 NCT03869307 616 617 O
. NCT03869307 617 618 O
recurrent NCT03869307 620 629 B-Modifier
joint NCT03869307 630 635 I-Modifier
dislocations NCT03869307 636 648 B-Condition
or NCT03869307 649 651 B-Or
joint NCT03869307 652 657 B-Modifier
instability NCT03869307 658 669 B-Condition
without NCT03869307 670 677 B-Negation
a NCT03869307 678 679 O
reported NCT03869307 680 688 O
history NCT03869307 689 696 B-Eq-Comparison
of NCT03869307 697 699 O
trauma NCT03869307 700 706 B-Condition
defined NCT03869307 707 714 O
as NCT03869307 715 717 O
either NCT03869307 718 724 O
a NCT03869307 725 726 O
) NCT03869307 727 728 O
minimum NCT03869307 729 736 B-Eq-Comparison
three NCT03869307 737 742 I-Eq-Comparison
atraumatic NCT03869307 743 753 B-Modifier
dislocations NCT03869307 754 766 B-Condition
in NCT03869307 767 769 O
same NCT03869307 770 774 B-Modifier
shoulder NCT03869307 775 783 I-Modifier
, NCT03869307 784 785 O
b NCT03869307 786 787 O
) NCT03869307 788 789 O
minimum NCT03869307 790 797 B-Eq-Comparison
two NCT03869307 798 801 I-Eq-Comparison
atraumatic NCT03869307 802 812 B-Modifier
dislocations NCT03869307 813 825 B-Condition
in NCT03869307 826 828 O
two NCT03869307 829 832 B-Modifier
different NCT03869307 833 842 I-Modifier
joints NCT03869307 843 849 I-Modifier
( NCT03869307 850 851 O
minimum NCT03869307 852 859 B-Eq-Comparison
one NCT03869307 860 863 I-Eq-Comparison
in NCT03869307 864 866 O
the NCT03869307 867 870 O
shoulder NCT03869307 871 879 B-Modifier
) NCT03869307 880 881 O
occurring NCT03869307 882 891 O
at NCT03869307 892 894 O
different NCT03869307 895 904 O
times NCT03869307 905 910 O
, NCT03869307 911 912 O
or NCT03869307 913 915 B-Or
c NCT03869307 916 917 O
) NCT03869307 918 919 O
medical NCT03869307 920 927 O
confirmation NCT03869307 928 940 O
of NCT03869307 941 943 O
joint NCT03869307 944 949 B-Modifier
instability NCT03869307 950 961 B-Condition
in NCT03869307 962 964 O
minimum NCT03869307 965 972 B-Eq-Comparison
two NCT03869307 973 976 I-Eq-Comparison
joints NCT03869307 977 983 I-Eq-Comparison
( NCT03869307 984 985 O
minimum NCT03869307 986 993 B-Eq-Comparison
one NCT03869307 994 997 B-Eq-Comparison|Modifier
in NCT03869307 998 1000 I-Modifier
the NCT03869307 1001 1004 I-Modifier
shoulder NCT03869307 1005 1013 I-Modifier
) NCT03869307 1014 1015 O
not NCT03869307 1016 1019 B-Negation
related NCT03869307 1020 1027 O
to NCT03869307 1028 1030 O
trauma NCT03869307 1031 1037 B-Condition
. NCT03869307 1038 1039 O

Exclusion NCT03869307 1041 1050 O
Criteria NCT03869307 1051 1059 O
: NCT03869307 1060 1061 O

- NCT03869307 1065 1066 O
Clinically NCT03869307 1068 1078 O
suspected NCT03869307 1079 1088 B-Assertion___Assertion-Type-Value:possible
referred NCT03869307 1089 1097 O
pain NCT03869307 1098 1102 B-Condition
from NCT03869307 1103 1107 O
the NCT03869307 1108 1111 O
cervical NCT03869307 1112 1120 B-Modifier
spine NCT03869307 1121 1126 I-Modifier

- NCT03869307 1129 1130 O
Systemic NCT03869307 1132 1140 B-Modifier
inflammatory NCT03869307 1141 1153 B-Condition
rheumatic NCT03869307 1154 1163 I-Condition
diseases NCT03869307 1164 1172 I-Condition

- NCT03869307 1175 1176 O
Connective NCT03869307 1178 1188 B-Condition
tissue NCT03869307 1189 1195 I-Condition
diseases NCT03869307 1196 1204 I-Condition
( NCT03869307 1205 1206 O
e. NCT03869307 1207 1209 O
g. NCT03869307 1210 1212 O
Marfans NCT03869307 1214 1221 B-Condition
, NCT03869307 1222 1223 O
Stickler NCT03869307 1224 1232 B-Condition
's NCT03869307 1232 1234 I-Condition
or NCT03869307 1235 1237 B-Or
Loeys NCT03869307 1238 1243 B-Condition
Dietz NCT03869307 1244 1249 I-Condition
syndromes NCT03869307 1250 1259 I-Condition
, NCT03869307 1260 1261 O
Ehlers NCT03869307 1262 1268 B-Condition
- NCT03869307 1269 1270 I-Condition
Danlos NCT03869307 1271 1277 I-Condition
Syndromes NCT03869307 1278 1287 I-Condition
except NCT03869307 1288 1294 B-Exception
hypermobile NCT03869307 1295 1306 B-Modifier
type NCT03869307 1307 1311 I-Modifier
) NCT03869307 1312 1313 O

- NCT03869307 1317 1318 O
Neurological NCT03869307 1320 1332 B-Condition
diseases NCT03869307 1333 1341 I-Condition

- NCT03869307 1344 1345 O
Pregnancy NCT03869307 1347 1356 B-Condition
or NCT03869307 1357 1359 B-Or
childbirth NCT03869307 1360 1370 B-Condition
within NCT03869307 1371 1377 B-Eq-Comparison
the NCT03869307 1378 1381 I-Eq-Comparison
past NCT03869307 1382 1386 I-Eq-Comparison
year NCT03869307 1387 1391 I-Eq-Comparison
or NCT03869307 1392 1394 B-Or
planning NCT03869307 1395 1403 B-Assertion___Assertion-Type-Value:intention
to NCT03869307 1404 1406 I-Assertion___Assertion-Type-Value:intention
get NCT03869307 1407 1410 O
pregnant NCT03869307 1411 1419 B-Condition
during NCT03869307 1420 1426 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869307 1427 1430 O
study NCT03869307 1431 1436 B-Study
period NCT03869307 1437 1443 O

- NCT03869307 1446 1447 O
Shoulder NCT03869307 1449 1457 B-Modifier
surgery NCT03869307 1458 1465 B-Procedure
within NCT03869307 1466 1472 B-Eq-Comparison
the NCT03869307 1473 1476 I-Eq-Comparison
past NCT03869307 1477 1481 I-Eq-Comparison
year NCT03869307 1482 1486 I-Eq-Comparison

- NCT03869307 1489 1490 O
Steroid NCT03869307 1492 1499 B-Procedure
injection NCT03869307 1500 1509 I-Procedure
in NCT03869307 1510 1512 O
the NCT03869307 1513 1516 O
affected NCT03869307 1517 1525 B-Modifier
shoulder NCT03869307 1526 1534 I-Modifier
within NCT03869307 1535 1541 B-Eq-Comparison
three NCT03869307 1542 1547 I-Eq-Comparison
months NCT03869307 1548 1554 I-Eq-Comparison

- NCT03869307 1557 1558 O
Inability NCT03869307 1560 1569 B-Negation
to NCT03869307 1570 1572 O
speak NCT03869307 1573 1578 O
and NCT03869307 1579 1582 O
understand NCT03869307 1583 1593 O
Danish NCT03869307 1594 1600 O
. NCT03869307 1601 1602 O

- NCT03869307 1606 1607 O
Unable NCT03869307 1609 1615 O
to NCT03869307 1616 1618 O
comply NCT03869307 1619 1625 O
with NCT03869307 1626 1630 O
protocol NCT03869307 1631 1639 O

Inclusion NCT03863158 0 9 O
Criteria NCT03863158 10 18 O
: NCT03863158 19 20 O

- NCT03863158 24 25 O
Patients NCT03863158 27 35 O
presenting NCT03863158 36 46 O
acute NCT03863158 47 52 O
myocardial NCT03863158 53 63 B-Condition
infarction NCT03863158 64 74 I-Condition
with NCT03863158 75 79 B-And
hemodynamic NCT03863158 80 91 B-Condition
stability NCT03863158 92 101 O
at NCT03863158 102 104 O
the NCT03863158 105 108 O
diagnosis NCT03863158 109 118 O

- NCT03863158 121 122 O
Patients NCT03863158 124 132 O
undergoing NCT03863158 133 143 B-Eq-Comparison
coronary NCT03863158 144 152 B-Procedure
artery NCT03863158 153 159 I-Procedure
bypass NCT03863158 160 166 I-Procedure
in NCT03863158 167 169 O
Dijon NCT03863158 170 175 O
University NCT03863158 176 186 O
hospital NCT03863158 187 195 O

Exclusion NCT03863158 196 205 O
Criteria NCT03863158 206 214 O
: NCT03863158 215 216 O

- NCT03863158 220 221 O
Patients NCT03863158 223 231 O
with NCT03863158 232 236 O
Acute NCT03863158 237 242 O
pulmonary NCT03863158 243 252 B-Condition
oedema NCT03863158 253 259 I-Condition

- NCT03863158 262 263 O
Patients NCT03863158 265 273 O
with NCT03863158 274 278 O
cardiorespiratory NCT03863158 279 296 B-Condition
arrest NCT03863158 297 303 I-Condition
before NCT03863158 304 310 B-Temporal-Connection___Temporal-Connection-Type-Value:before
coronary NCT03863158 311 319 B-Procedure
angiography NCT03863158 320 331 I-Procedure

- NCT03863158 334 335 O
hemodynamically NCT03863158 337 352 B-Condition
unstable NCT03863158 353 361 O
patient NCT03863158 362 369 O
at NCT03863158 370 372 O
diagnosis NCT03863158 373 382 O

- NCT03863158 385 386 O
patients NCT03863158 388 396 O
requiring NCT03863158 397 406 B-Assertion___Assertion-Type-Value:hypothetical
combined NCT03863158 407 415 B-Modifier
surgery NCT03863158 416 423 B-Procedure

- NCT03863158 426 427 O
patients NCT03863158 429 437 O
with NCT03863158 438 442 O
unstable NCT03863158 443 451 O
angina NCT03863158 452 458 B-Condition

Inclusion NCT03866746 0 9 O
Criteria NCT03866746 10 18 O
: NCT03866746 19 20 O

- NCT03866746 24 25 O
older NCT03866746 27 32 B-Eq-Comparison
than NCT03866746 33 37 I-Eq-Comparison
18 NCT03866746 38 40 I-Eq-Comparison
years NCT03866746 41 46 I-Eq-Comparison
old NCT03866746 47 50 B-Age

- NCT03866746 53 54 O
diagnosed NCT03866746 56 65 O
with NCT03866746 66 70 O
DME NCT03866746 71 74 B-Condition
with NCT03866746 75 79 B-And
central NCT03866746 80 87 B-Observation
macular NCT03866746 88 95 I-Observation
thickness NCT03866746 96 105 I-Observation
( NCT03866746 106 107 O
CMT NCT03866746 108 111 B-Observation
) NCT03866746 112 113 O
more NCT03866746 114 118 B-Eq-Comparison
than NCT03866746 119 123 I-Eq-Comparison
250 NCT03866746 124 127 I-Eq-Comparison
µm NCT03866746 128 130 I-Eq-Comparison
measured NCT03866746 131 139 O
by NCT03866746 140 142 O
OCT NCT03866746 143 146 B-Procedure

- NCT03866746 149 150 O
best NCT03866746 152 156 B-Observation
corrected NCT03866746 157 166 I-Observation
visual NCT03866746 167 173 I-Observation
acuity NCT03866746 174 180 I-Observation
( NCT03866746 181 182 O
BCVA NCT03866746 183 187 B-Observation
) NCT03866746 188 189 O
between NCT03866746 190 197 B-Eq-Comparison
20 NCT03866746 198 200 I-Eq-Comparison
/ NCT03866746 201 202 I-Eq-Comparison
400 NCT03866746 203 206 I-Eq-Comparison
and NCT03866746 207 210 I-Eq-Comparison
20 NCT03866746 211 213 I-Eq-Comparison
/ NCT03866746 214 215 I-Eq-Comparison
40 NCT03866746 216 218 I-Eq-Comparison
. NCT03866746 218 219 O

Exclusion NCT03866746 221 230 O
Criteria NCT03866746 231 239 O
: NCT03866746 240 241 O

- NCT03866746 245 246 O
patients NCT03866746 248 256 O
with NCT03866746 257 261 O
intra NCT03866746 262 267 B-Modifier
- NCT03866746 268 269 I-Modifier
ocular NCT03866746 270 276 I-Modifier
surgery NCT03866746 277 284 B-Procedure
as NCT03866746 285 287 O
cataract NCT03866746 288 296 B-Procedure
surgery NCT03866746 297 304 I-Procedure
within NCT03866746 305 311 B-Eq-Comparison
6 NCT03866746 312 313 I-Eq-Comparison
months NCT03866746 314 320 I-Eq-Comparison

- NCT03866746 323 324 O
prior NCT03866746 326 331 B-Eq-Comparison
intravitreal NCT03866746 332 344 B-Procedure
injection NCT03866746 345 354 I-Procedure
of NCT03866746 355 357 O
any NCT03866746 358 361 O
drug NCT03866746 362 366 B-Drug
within NCT03866746 367 373 B-Eq-Comparison
the NCT03866746 374 377 I-Eq-Comparison
preceding NCT03866746 378 387 I-Eq-Comparison
6 NCT03866746 388 389 I-Eq-Comparison
months NCT03866746 390 396 I-Eq-Comparison

- NCT03866746 399 400 O
panretinal NCT03866746 402 412 B-Procedure
photocoagulation NCT03866746 413 429 I-Procedure
( NCT03866746 430 431 O
PRP NCT03866746 432 435 B-Procedure
) NCT03866746 436 437 O
within NCT03866746 438 444 B-Eq-Comparison
the NCT03866746 445 448 I-Eq-Comparison
former NCT03866746 449 455 I-Eq-Comparison
4 NCT03866746 456 457 I-Eq-Comparison
months NCT03866746 458 464 I-Eq-Comparison
. NCT03866746 465 466 O

- NCT03866746 470 471 O
Patients NCT03866746 473 481 O
with NCT03866746 482 486 O
previous NCT03866746 487 495 B-Eq-Comparison
macular NCT03866746 496 503 B-Procedure
laser NCT03866746 504 509 I-Procedure

- NCT03866746 512 513 O
patients NCT03866746 515 523 O
with NCT03866746 524 528 O
vitreo NCT03866746 529 535 B-Condition
- NCT03866746 536 537 I-Condition
macular NCT03866746 538 545 I-Condition
traction NCT03866746 546 554 I-Condition
( NCT03866746 555 556 O
VMT NCT03866746 557 560 B-Condition
) NCT03866746 561 562 O
syndrome NCT03866746 563 571 B-Modifier

- NCT03866746 574 575 O
severe NCT03866746 577 583 O
glaucoma NCT03866746 584 592 B-Condition

- NCT03866746 595 596 O
other NCT03866746 598 603 B-Other
retinal NCT03866746 604 611 B-Condition
vascular NCT03866746 612 620 I-Condition
diseases NCT03866746 621 629 I-Condition

- NCT03866746 632 633 O
conditions NCT03866746 635 645 B-Condition
that NCT03866746 646 650 O
impede NCT03866746 651 657 O
the NCT03866746 658 661 O
OCT NCT03866746 662 665 B-Procedure
interpretation NCT03866746 666 680 B-Modifier

Inclusion NCT03860337 0 9 O
Criteria NCT03860337 10 18 O
: NCT03860337 19 20 O

- NCT03860337 23 24 O

Exclusion NCT03860337 26 35 O
Criteria NCT03860337 36 44 O
: NCT03860337 45 46 O

- NCT03860337 50 51 O
pregnant NCT03860337 53 61 B-Condition
or NCT03860337 62 64 B-Or
lactating NCT03860337 65 74 B-Condition
. NCT03860337 74 75 O

Inclusion NCT03862508 0 9 O
Criteria NCT03862508 10 18 O
: NCT03862508 19 20 O

- NCT03862508 24 25 O
Height NCT03862508 27 33 B-Observation
jumpers NCT03862508 34 41 I-Observation

- NCT03862508 44 45 O
Age NCT03862508 47 50 B-Age
between NCT03862508 51 58 B-Eq-Comparison
18 NCT03862508 59 61 I-Eq-Comparison
and NCT03862508 62 65 I-Eq-Comparison
40 NCT03862508 66 68 I-Eq-Comparison
years NCT03862508 69 74 I-Eq-Comparison

- NCT03862508 77 78 O
Currently NCT03862508 80 89 O
participate NCT03862508 90 101 O
in NCT03862508 102 104 O
the NCT03862508 105 108 O
competitive NCT03862508 109 120 O
field NCT03862508 121 126 O

Exclusion NCT03862508 127 136 O
Criteria NCT03862508 137 145 O
: NCT03862508 146 147 O

- NCT03862508 151 152 O
Present NCT03862508 154 161 O
medical NCT03862508 162 169 O
diagnosis NCT03862508 170 179 O
of NCT03862508 180 182 O
musculoskeletal NCT03862508 183 198 B-Modifier
pathology NCT03862508 199 208 B-Condition

- NCT03862508 211 212 O
Who NCT03862508 214 217 O
have NCT03862508 218 222 O
not NCT03862508 223 226 B-Negation
had NCT03862508 227 230 O
musculoskeletal NCT03862508 231 246 B-Modifier
injuries NCT03862508 247 255 B-Condition
in NCT03862508 256 258 O
the NCT03862508 259 262 O
last NCT03862508 263 267 B-Eq-Comparison
month NCT03862508 268 273 I-Eq-Comparison

- NCT03862508 276 277 O
Not NCT03862508 279 282 O
signed NCT03862508 283 289 O
the NCT03862508 290 293 O
informed NCT03862508 294 302 O
consent NCT03862508 303 310 O
document NCT03862508 311 319 O
. NCT03862508 319 320 O

Inclusion NCT03860493 0 9 O
Criteria NCT03860493 10 18 O
: NCT03860493 19 20 O

1 NCT03860493 24 25 O
. NCT03860493 25 26 O
Patients NCT03860493 28 36 O
of NCT03860493 37 39 O
both NCT03860493 40 44 O
genders NCT03860493 45 52 O

2 NCT03860493 55 56 O
. NCT03860493 56 57 O
Minimum NCT03860493 59 66 O
age NCT03860493 67 70 B-Age
: NCT03860493 71 72 O
18 NCT03860493 73 75 B-Eq-Comparison
years NCT03860493 76 81 I-Eq-Comparison
old NCT03860493 82 85 O

3 NCT03860493 88 89 O
. NCT03860493 89 90 O
Spoken NCT03860493 92 98 O
and NCT03860493 99 102 O
written NCT03860493 103 110 O
command NCT03860493 111 118 O
of NCT03860493 119 121 O
the NCT03860493 122 125 O
language NCT03860493 126 134 O
spoken NCT03860493 135 141 O
in NCT03860493 142 144 O
the NCT03860493 145 148 O
country NCT03860493 149 156 O
's NCT03860493 156 158 O
center NCT03860493 159 165 O

4 NCT03860493 168 169 O
. NCT03860493 169 170 O
Ability NCT03860493 172 179 O
to NCT03860493 180 182 O
understand NCT03860493 183 193 O
and NCT03860493 194 197 O
follow NCT03860493 198 204 O
the NCT03860493 205 208 O
study NCT03860493 209 214 O
procedures NCT03860493 215 225 O
and NCT03860493 226 229 O
sign NCT03860493 230 234 O
the NCT03860493 235 238 O
informed NCT03860493 239 247 O
consent NCT03860493 248 255 O

5 NCT03860493 258 259 O
. NCT03860493 259 260 O
open NCT03860493 262 266 B-Modifier
surgical NCT03860493 267 275 B-Procedure
porcedures NCT03860493 276 286 I-Procedure

Exclusion NCT03860493 287 296 O
Criteria NCT03860493 297 305 O
: NCT03860493 306 307 O

1 NCT03860493 311 312 O
. NCT03860493 312 313 O
Known NCT03860493 315 320 O
allergies NCT03860493 321 330 B-Allergy
to NCT03860493 331 333 O
iodides NCT03860493 334 341 B-Drug

2 NCT03860493 344 345 O
. NCT03860493 345 346 O
Known NCT03860493 348 353 O
history NCT03860493 354 361 B-Eq-Comparison
of NCT03860493 362 364 O
coagulopathy NCT03860493 365 377 B-Condition

3 NCT03860493 380 381 O
. NCT03860493 381 382 O
Women NCT03860493 384 389 O
who NCT03860493 390 393 B-And
are NCT03860493 394 397 O
pregnant NCT03860493 398 406 B-Condition
or NCT03860493 407 409 B-Or
breastfeeding NCT03860493 410 423 B-Condition
, NCT03860493 424 425 O
or NCT03860493 426 428 B-Or
for NCT03860493 429 432 O
whom NCT03860493 433 437 O
possibility NCT03860493 438 449 B-Assertion___Assertion-Type-Value:possible
of NCT03860493 450 452 O
pregnancy NCT03860493 453 462 B-Condition
was NCT03860493 463 466 O
not NCT03860493 467 470 O
ruled NCT03860493 471 476 O
out NCT03860493 477 480 O

Inclusion NCT03863171 0 9 O
Criteria NCT03863171 10 18 O
: NCT03863171 19 20 O

- NCT03863171 24 25 O
Ocular NCT03863171 27 33 B-Condition
ischemia NCT03863171 34 42 I-Condition
syndrome NCT03863171 43 51 I-Condition
group NCT03863171 52 57 O
: NCT03863171 58 59 O
Patients NCT03863171 60 68 O
diagnosed NCT03863171 69 78 O
with NCT03863171 79 83 O
ocular NCT03863171 84 90 B-Condition
ischemia NCT03863171 91 99 I-Condition
syndrome NCT03863171 100 108 I-Condition
; NCT03863171 108 109 O

- NCT03863171 112 113 O
Age NCT03863171 115 118 B-Modifier
- NCT03863171 119 120 I-Modifier
related NCT03863171 121 128 I-Modifier
macular NCT03863171 129 136 B-Condition
degeneration NCT03863171 137 149 I-Condition
group NCT03863171 150 155 O
( NCT03863171 156 157 O
Control NCT03863171 158 165 O
group NCT03863171 166 171 O
) NCT03863171 172 173 O
: NCT03863171 175 176 O
Patients NCT03863171 177 185 O
diagnosed NCT03863171 186 195 O
with NCT03863171 196 200 O
age NCT03863171 201 204 B-Modifier
- NCT03863171 205 206 I-Modifier
related NCT03863171 207 214 I-Modifier
macular NCT03863171 215 222 B-Condition
degeneration NCT03863171 223 235 I-Condition
; NCT03863171 235 236 O

- NCT03863171 239 240 O
Age NCT03863171 242 245 B-Age
: NCT03863171 246 247 O
50 NCT03863171 248 250 B-Eq-Comparison
- NCT03863171 251 252 I-Eq-Comparison
80 NCT03863171 253 255 I-Eq-Comparison
years NCT03863171 256 261 I-Eq-Comparison
; NCT03863171 261 262 O

- NCT03863171 265 266 O
Sex NCT03863171 268 271 O
: NCT03863171 272 273 O
all NCT03863171 274 277 O
; NCT03863171 277 278 O

- NCT03863171 281 282 O
Patients NCT03863171 284 292 O
signed NCT03863171 293 299 O
written NCT03863171 300 307 O
informed NCT03863171 308 316 O
consent NCT03863171 317 324 O
. NCT03863171 325 326 O

Exclusion NCT03863171 328 337 O
Criteria NCT03863171 338 346 O
: NCT03863171 347 348 O

- NCT03863171 352 353 O
Fundus NCT03863171 355 361 B-Procedure
fluorescein NCT03863171 362 373 I-Procedure
angiography NCT03863171 374 385 I-Procedure
( NCT03863171 386 387 O
FFA NCT03863171 388 391 B-Procedure
) NCT03863171 392 393 O
clear NCT03863171 394 399 O
images NCT03863171 400 406 O
can NCT03863171 407 410 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03863171 410 413 I-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03863171 414 416 I-Assertion___Assertion-Type-Value:hypothetical|Negation
obtained NCT03863171 417 425 I-Assertion___Assertion-Type-Value:hypothetical|Negation
due NCT03863171 426 429 O
to NCT03863171 430 432 O
refractive NCT03863171 433 443 B-Condition
media NCT03863171 444 449 I-Condition
problems NCT03863171 450 458 I-Condition
( NCT03863171 459 460 O
such NCT03863171 461 465 O
as NCT03863171 466 468 O
corneal NCT03863171 469 476 B-Condition
leukoplakia NCT03863171 477 488 I-Condition
, NCT03863171 489 490 O
severe NCT03863171 491 497 O
cataract NCT03863171 498 506 B-Condition
, NCT03863171 507 508 O
vitreous NCT03863171 509 517 B-Condition
hemorrhage NCT03863171 518 528 I-Condition
, NCT03863171 529 530 O
etc NCT03863171 531 534 O
. NCT03863171 534 535 O
) NCT03863171 536 537 O
; NCT03863171 538 539 O

- NCT03863171 542 543 O
Patients NCT03863171 545 553 O
with NCT03863171 554 558 O
contraindications NCT03863171 559 576 B-Contraindication
for NCT03863171 577 580 O
FFA NCT03863171 581 584 B-Procedure
; NCT03863171 584 585 O

- NCT03863171 588 589 O
Patients NCT03863171 591 599 O
was NCT03863171 600 603 O
unable NCT03863171 604 610 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03863171 611 613 O
perform NCT03863171 614 621 O
magnetic NCT03863171 622 630 B-Procedure
resonance NCT03863171 631 640 I-Procedure
rmaging NCT03863171 641 648 I-Procedure
( NCT03863171 649 650 O
MRI NCT03863171 651 654 B-Procedure
) NCT03863171 655 656 O
test NCT03863171 657 661 O
; NCT03863171 661 662 O

- NCT03863171 665 666 O
Patients NCT03863171 668 676 O
with NCT03863171 677 681 O
history NCT03863171 682 689 B-Eq-Comparison
of NCT03863171 690 692 O
bleeding NCT03863171 693 701 B-Condition
and NCT03863171 702 705 B-Or
cerebral NCT03863171 706 714 B-Condition
infarction NCT03863171 715 725 I-Condition
; NCT03863171 725 726 O

- NCT03863171 729 730 O
Patients NCT03863171 732 740 O
with NCT03863171 741 745 O
a NCT03863171 746 747 O
history NCT03863171 748 755 B-Eq-Comparison
of NCT03863171 756 758 O
surgery NCT03863171 759 766 B-Procedure
within NCT03863171 767 773 B-Eq-Comparison
3 NCT03863171 774 775 I-Eq-Comparison
months NCT03863171 776 782 I-Eq-Comparison
; NCT03863171 782 783 O

- NCT03863171 786 787 O
Patients NCT03863171 789 797 O
who NCT03863171 798 801 O
had NCT03863171 802 805 O
participated NCT03863171 806 818 O
in NCT03863171 819 821 O
other NCT03863171 822 827 B-Other
clinical NCT03863171 828 836 B-Study
trials NCT03863171 837 843 I-Study
within NCT03863171 844 850 B-Eq-Comparison
3 NCT03863171 851 852 I-Eq-Comparison
months NCT03863171 853 859 I-Eq-Comparison
; NCT03863171 859 860 O

- NCT03863171 863 864 O
Patients NCT03863171 866 874 O
who NCT03863171 875 878 O
disagree NCT03863171 879 887 O
and NCT03863171 888 891 O
refuse NCT03863171 892 898 O
to NCT03863171 899 901 O
participate NCT03863171 902 913 O
in NCT03863171 914 916 O
the NCT03863171 917 920 O
trial NCT03863171 921 926 O
. NCT03863171 926 927 O

Inclusion NCT03862521 0 9 O
criteria NCT03862521 10 18 O

- NCT03862521 21 22 O
Prepubertal NCT03862521 24 35 B-Condition
children NCT03862521 36 44 O
2 NCT03862521 45 46 B-Eq-Comparison
to NCT03862521 47 49 I-Eq-Comparison
< NCT03862521 50 51 I-Eq-Comparison
12 NCT03862521 52 54 I-Eq-Comparison
years NCT03862521 55 60 I-Eq-Comparison
old NCT03862521 61 64 B-Age
( NCT03862521 65 66 O
i. NCT03862521 67 69 O
e. NCT03862521 70 72 O
, NCT03862521 73 74 O
before NCT03862521 75 81 O
12 NCT03862521 82 84 O
th NCT03862521 85 87 O
birthday NCT03862521 88 96 O
) NCT03862521 97 98 O

- NCT03862521 102 103 O
Type NCT03862521 105 109 B-Modifier
1 NCT03862521 110 111 I-Modifier
diabetes NCT03862521 112 120 B-Condition
for NCT03862521 121 124 O
at NCT03862521 125 127 B-Eq-Comparison
least NCT03862521 128 133 I-Eq-Comparison
6 NCT03862521 134 135 I-Eq-Comparison
months NCT03862521 136 142 I-Eq-Comparison

- NCT03862521 145 146 O
Patients NCT03862521 148 156 O
must NCT03862521 157 161 O
be NCT03862521 162 164 O
using NCT03862521 165 170 B-Eq-Comparison
insulin NCT03862521 171 178 B-Procedure
pump NCT03862521 179 183 I-Procedure
therapy NCT03862521 184 191 I-Procedure

- NCT03862521 194 195 O
Not NCT03862521 197 200 B-Negation
presently NCT03862521 201 210 B-Eq-Comparison
on NCT03862521 211 213 O
low NCT03862521 214 217 O
carbohydrate NCT03862521 218 230 B-Modifier
diet NCT03862521 231 235 B-Observation

Exclusion NCT03862521 236 245 O
criteria NCT03862521 246 254 O

- NCT03862521 257 258 O
On NCT03862521 260 262 B-Eq-Comparison
low NCT03862521 263 266 O
or NCT03862521 267 269 B-Or
very NCT03862521 270 274 O
low NCT03862521 275 278 O
carbohydrate NCT03862521 279 291 B-Modifier
diet NCT03862521 292 296 B-Observation

- NCT03862521 299 300 O
History NCT03862521 302 309 B-Eq-Comparison
of NCT03862521 310 312 O
endocrine NCT03862521 313 322 B-Modifier
or NCT03862521 323 325 B-Or
metabolic NCT03862521 326 335 B-Modifier
disorder NCT03862521 336 344 B-Condition
that NCT03862521 345 349 O
could NCT03862521 350 355 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03862521 356 362 O
counter NCT03862521 363 370 B-Condition
- NCT03862521 371 372 I-Condition
regulation NCT03862521 373 383 I-Condition
( NCT03862521 384 385 O
well NCT03862521 386 390 O
- NCT03862521 391 392 O
controlled NCT03862521 393 403 O
hypothyroidism NCT03862521 404 418 B-Condition
is NCT03862521 419 421 O
acceptable NCT03862521 422 432 O
if NCT03862521 433 435 O
on NCT03862521 436 438 B-Eq-Comparison
stable NCT03862521 439 445 O
dose NCT03862521 446 450 O
of NCT03862521 451 453 O
l NCT03862521 454 455 B-Drug
- NCT03862521 456 457 I-Drug
thyroxine NCT03862521 458 467 I-Drug
for NCT03862521 468 471 O
≥ NCT03862521 472 473 B-Eq-Comparison
3 NCT03862521 474 475 I-Eq-Comparison
months NCT03862521 476 482 I-Eq-Comparison
) NCT03862521 483 484 O

- NCT03862521 488 489 O
History NCT03862521 491 498 B-Eq-Comparison
of NCT03862521 499 501 O
metabolic NCT03862521 502 511 B-Condition
disorder NCT03862521 512 520 I-Condition
affection NCT03862521 521 530 O
lipid NCT03862521 531 536 B-Condition
metabolism NCT03862521 537 547 I-Condition

- NCT03862521 550 551 O
Severe NCT03862521 553 559 O
hypoglycemic NCT03862521 560 572 B-Condition
event NCT03862521 573 578 I-Condition
in NCT03862521 579 581 O
past NCT03862521 582 586 B-Eq-Comparison
3 NCT03862521 587 588 I-Eq-Comparison
months NCT03862521 589 595 I-Eq-Comparison

Inclusion NCT03862092 0 9 O
Criteria NCT03862092 10 18 O
: NCT03862092 19 20 O

- NCT03862092 24 25 O
Patients NCT03862092 27 35 O
aged NCT03862092 36 40 B-Age
≥ NCT03862092 41 42 B-Eq-Comparison
18 NCT03862092 43 45 I-Eq-Comparison
, NCT03862092 46 47 O
and NCT03862092 48 51 B-Or
< NCT03862092 52 53 B-Eq-Comparison
80 NCT03862092 54 56 I-Eq-Comparison
years NCT03862092 57 62 I-Eq-Comparison

- NCT03862092 65 66 O
ER NCT03862092 68 70 B-Encounter
- NCT03862092 71 72 I-Encounter
visit NCT03862092 73 78 I-Encounter
patients NCT03862092 79 87 O
with NCT03862092 88 92 B-And
acute NCT03862092 93 98 O
abdominal NCT03862092 99 108 B-Modifier
pain NCT03862092 109 113 B-Condition

- NCT03862092 121 122 O
NRS NCT03862092 124 127 B-Observation
≥ NCT03862092 128 129 B-Eq-Comparison
6 NCT03862092 130 131 I-Eq-Comparison

- NCT03862092 140 141 O
Unresponsive NCT03862092 143 155 B-Condition
to NCT03862092 156 158 O
gastrointestinal NCT03862092 159 175 B-Drug
motility NCT03862092 176 184 I-Drug
drug NCT03862092 185 189 I-Drug
, NCT03862092 190 191 O
antacid NCT03862092 192 199 B-Drug

Exclusion NCT03862092 200 209 O
Criteria NCT03862092 210 218 O
: NCT03862092 219 220 O

- NCT03862092 224 225 O
Unwilling NCT03862092 227 236 O
or NCT03862092 237 239 O
unable NCT03862092 240 246 O
to NCT03862092 247 249 O
give NCT03862092 250 254 O
informed NCT03862092 255 263 O
consent NCT03862092 264 271 O

- NCT03862092 274 275 O
Patients NCT03862092 277 285 O
who NCT03862092 286 289 O
take NCT03862092 290 294 B-Eq-Comparison
antiviral NCT03862092 295 304 B-Drug
agents NCT03862092 305 311 I-Drug
( NCT03862092 312 313 O
acyclovir NCT03862092 314 323 B-Drug
, NCT03862092 324 325 O
valacyclovir NCT03862092 326 338 B-Drug
, NCT03862092 339 340 O
famciclovir NCT03862092 341 352 B-Drug
, NCT03862092 353 354 O
ganciclovir NCT03862092 355 366 B-Drug
, NCT03862092 367 368 O
valganciclovir NCT03862092 369 383 B-Drug
, NCT03862092 384 385 O
foscarnet NCT03862092 386 395 B-Drug
. NCT03862092 395 396 O
. NCT03862092 397 398 O
. NCT03862092 399 400 O
) NCT03862092 401 402 O

- NCT03862092 406 407 O
Patients NCT03862092 409 417 O
complaining NCT03862092 418 429 O
abdominal NCT03862092 430 439 B-Modifier
pain NCT03862092 440 444 B-Condition
with NCT03862092 445 449 B-And
NRS NCT03862092 450 453 B-Observation
≤ NCT03862092 454 455 B-Eq-Comparison
5 NCT03862092 456 457 I-Eq-Comparison
or NCT03862092 458 460 B-Or
improved NCT03862092 461 469 O
symptom NCT03862092 470 477 B-Condition
by NCT03862092 478 480 O
gastrointestinal NCT03862092 481 497 B-Drug
motility NCT03862092 498 506 I-Drug
drug NCT03862092 507 511 I-Drug
, NCT03862092 512 513 O
antacid NCT03862092 514 521 B-Drug

Inclusion NCT03869879 0 9 O
Criteria NCT03869879 10 18 O
: NCT03869879 19 20 O

- NCT03869879 24 25 O
60 NCT03869879 27 29 B-Eq-Comparison
- NCT03869879 30 31 I-Eq-Comparison
89 NCT03869879 32 34 I-Eq-Comparison
years NCT03869879 35 40 I-Eq-Comparison
old NCT03869879 41 44 B-Age

- NCT03869879 47 48 O
gait NCT03869879 50 54 B-Condition
disturbances NCT03869879 55 67 I-Condition
requiring NCT03869879 68 77 B-Assertion___Assertion-Type-Value:hypothetical
physical NCT03869879 78 86 B-Procedure
therapy NCT03869879 87 94 I-Procedure

Exclusion NCT03869879 95 104 O
Criteria NCT03869879 105 113 O
: NCT03869879 114 115 O

- NCT03869879 119 120 O
unable NCT03869879 122 128 O
to NCT03869879 129 131 O
follow NCT03869879 132 138 O
instructions NCT03869879 139 151 O
( NCT03869879 152 153 O
up NCT03869879 154 156 O
to NCT03869879 157 159 O
the NCT03869879 160 163 O
practitioner NCT03869879 164 176 O
's NCT03869879 176 178 O
judgement NCT03869879 179 188 O
) NCT03869879 189 190 O

Inclusion NCT03862079 0 9 O
Criteria NCT03862079 10 18 O
: NCT03862079 19 20 O

- NCT03862079 24 25 O
Patients NCT03862079 27 35 O
who NCT03862079 36 39 O
are NCT03862079 40 43 O
day NCT03862079 44 47 B-Eq-Comparison
- NCT03862079 48 49 I-Eq-Comparison
10 NCT03862079 50 52 I-Eq-Comparison
pre NCT03862079 53 56 I-Eq-Comparison
- NCT03862079 57 58 I-Eq-Comparison
to NCT03862079 59 61 I-Eq-Comparison
day NCT03862079 62 65 I-Eq-Comparison
+ NCT03862079 66 67 I-Eq-Comparison
30 NCT03862079 68 70 I-Eq-Comparison
post NCT03862079 71 75 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862079 76 77 O
allogeneic NCT03862079 78 88 B-Procedure
hematopoietic NCT03862079 89 102 I-Procedure
cell NCT03862079 103 107 I-Procedure
transplant NCT03862079 108 118 I-Procedure
( NCT03862079 119 120 O
AHCT NCT03862079 121 125 B-Procedure
) NCT03862079 126 127 O
from NCT03862079 128 132 O
any NCT03862079 133 136 O
donor NCT03862079 137 142 B-Modifier
or NCT03862079 143 145 B-Or
graft NCT03862079 146 151 B-Modifier
source NCT03862079 152 158 I-Modifier
and NCT03862079 159 162 B-And
for NCT03862079 163 166 O
any NCT03862079 167 170 O
conditioning NCT03862079 171 183 B-Procedure
regimen NCT03862079 184 191 I-Procedure

- NCT03862079 194 195 O
Patients NCT03862079 197 205 O
who NCT03862079 206 209 O
have NCT03862079 210 214 O
received NCT03862079 215 223 B-Eq-Comparison
treatment NCT03862079 224 233 B-Procedure
with NCT03862079 234 238 O
meropenem NCT03862079 239 248 B-Drug
or NCT03862079 249 251 B-Or
piperacillin NCT03862079 252 264 B-Drug
- NCT03862079 265 266 I-Drug
tazobactam NCT03862079 267 277 I-Drug
( NCT03862079 278 279 O
pip NCT03862079 280 283 B-Drug
- NCT03862079 284 285 I-Drug
tazo NCT03862079 286 290 I-Drug
) NCT03862079 291 292 O
intravenously NCT03862079 293 306 B-Modifier
( NCT03862079 307 308 O
IV NCT03862079 309 311 B-Modifier
) NCT03862079 312 313 O
( NCT03862079 314 315 O
of NCT03862079 316 318 O
at NCT03862079 319 321 B-Eq-Comparison
least NCT03862079 322 327 I-Eq-Comparison
24 NCT03862079 328 330 I-Eq-Comparison
hours NCT03862079 331 336 I-Eq-Comparison
duration NCT03862079 337 345 I-Eq-Comparison
) NCT03862079 346 347 O
in NCT03862079 348 350 O
past NCT03862079 351 355 B-Eq-Comparison
7 NCT03862079 356 357 I-Eq-Comparison
days NCT03862079 358 362 I-Eq-Comparison

- NCT03862079 365 366 O
Controlled NCT03862079 368 378 B-Modifier
infection NCT03862079 379 388 B-Condition
defined NCT03862079 389 396 O
as NCT03862079 397 399 O
hemodynamically NCT03862079 400 415 B-Condition
stable NCT03862079 416 422 O
and NCT03862079 423 426 B-And
not NCT03862079 427 430 B-Negation
requiring NCT03862079 431 440 B-Assertion___Assertion-Type-Value:hypothetical
supplemental NCT03862079 441 453 B-Observation|Procedure
oxygen NCT03862079 454 460 I-Observation|Procedure
of NCT03862079 461 463 O
more NCT03862079 464 468 B-Eq-Comparison
than NCT03862079 469 473 I-Eq-Comparison
2 NCT03862079 474 475 I-Eq-Comparison
liters NCT03862079 476 482 I-Eq-Comparison
via NCT03862079 483 486 I-Eq-Comparison
nasal NCT03862079 487 492 B-Modifier
cannula NCT03862079 493 500 I-Modifier

- NCT03862079 503 504 O
Patients NCT03862079 506 514 O
who NCT03862079 515 518 O
are NCT03862079 519 522 O
able NCT03862079 523 527 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862079 528 530 I-Assertion___Assertion-Type-Value:hypothetical
take NCT03862079 531 535 O
oral NCT03862079 536 540 B-Drug
medications NCT03862079 541 552 I-Drug
in NCT03862079 553 555 O
suspension NCT03862079 556 566 B-Modifier
form NCT03862079 567 571 I-Modifier

- NCT03862079 574 575 O
Patients NCT03862079 577 585 O
who NCT03862079 586 589 O
are NCT03862079 590 593 O
able NCT03862079 594 598 O
to NCT03862079 599 601 O
provide NCT03862079 602 609 O
informed NCT03862079 610 618 O
consent NCT03862079 619 626 O
( NCT03862079 627 628 O
IC NCT03862079 629 631 O
) NCT03862079 632 633 O
and NCT03862079 634 637 O
comply NCT03862079 638 644 O
with NCT03862079 645 649 O
all NCT03862079 650 653 O
study NCT03862079 654 659 O
visits NCT03862079 660 666 O
and NCT03862079 667 670 O
procedures NCT03862079 671 681 O

Exclusion NCT03862079 682 691 O
Criteria NCT03862079 692 700 O
: NCT03862079 701 702 O

- NCT03862079 706 707 O
Patients NCT03862079 709 717 O
who NCT03862079 718 721 O
are NCT03862079 722 725 O
anticipated NCT03862079 726 737 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862079 738 740 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03862079 741 748 O
continued NCT03862079 749 758 O
broad NCT03862079 759 764 B-Modifier
spectrum NCT03862079 765 773 I-Modifier
antibiotics NCT03862079 774 785 B-Drug
with NCT03862079 786 790 B-And
meropenem NCT03862079 791 800 B-Drug
or NCT03862079 801 803 B-Or
pip NCT03862079 804 807 B-Drug
- NCT03862079 808 809 I-Drug
tazo NCT03862079 810 814 I-Drug
IV NCT03862079 815 817 B-Modifier
for NCT03862079 818 821 O
> NCT03862079 822 823 B-Eq-Comparison
96 NCT03862079 824 826 I-Eq-Comparison
hours NCT03862079 827 832 I-Eq-Comparison
post NCT03862079 833 837 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862079 838 839 O
engraftment NCT03862079 840 851 B-Procedure
such NCT03862079 852 856 O
as NCT03862079 857 859 O
for NCT03862079 860 863 O
known NCT03862079 864 869 O
, NCT03862079 870 871 O
documented NCT03862079 872 882 O
infections NCT03862079 883 893 B-Condition
necessitating NCT03862079 894 907 B-Assertion___Assertion-Type-Value:hypothetical
prolonged NCT03862079 908 917 O
treatment NCT03862079 918 927 B-Procedure

- NCT03862079 930 931 O
Patients NCT03862079 933 941 O
with NCT03862079 942 946 O
a NCT03862079 947 948 O
prior NCT03862079 949 954 B-Eq-Comparison
documented NCT03862079 955 965 O
infection NCT03862079 966 975 B-Condition
with NCT03862079 976 980 O
mycormycetes NCT03862079 981 993 B-Organism

- NCT03862079 996 997 O
Patients NCT03862079 999 1007 O
who NCT03862079 1008 1011 O
are NCT03862079 1012 1015 O
greater NCT03862079 1016 1023 B-Eq-Comparison
than NCT03862079 1024 1028 I-Eq-Comparison
2 NCT03862079 1029 1030 I-Eq-Comparison
days NCT03862079 1031 1035 I-Eq-Comparison
from NCT03862079 1036 1040 B-Temporal-Connection___Temporal-Connection-Type-Value:after
time NCT03862079 1041 1045 O
of NCT03862079 1046 1048 O
neutrophil NCT03862079 1049 1059 B-Procedure
engraftment NCT03862079 1060 1071 I-Procedure
post NCT03862079 1072 1076 B-Temporal-Connection___Temporal-Connection-Type-Value:after
AHCT NCT03862079 1077 1081 B-Procedure

- NCT03862079 1084 1085 O
Patients NCT03862079 1087 1095 O
with NCT03862079 1096 1100 O
active NCT03862079 1101 1107 B-Eq-Comparison
enteric NCT03862079 1108 1115 B-Modifier
infections NCT03862079 1116 1126 B-Condition

- NCT03862079 1129 1130 O
Patients NCT03862079 1132 1140 O
with NCT03862079 1141 1145 O
acute NCT03862079 1146 1151 O
GVHD NCT03862079 1152 1156 B-Condition
> NCT03862079 1157 1158 O
= NCT03862079 1160 1161 I-Eq-Comparison
grade NCT03862079 1162 1167 I-Eq-Comparison
II NCT03862079 1168 1170 I-Eq-Comparison

- NCT03862079 1173 1174 O
Patients NCT03862079 1176 1184 O
unwilling NCT03862079 1185 1194 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03862079 1195 1197 B-Or
unable NCT03862079 1198 1204 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862079 1205 1207 O
undergo NCT03862079 1208 1215 O
the NCT03862079 1216 1219 O
FMT NCT03862079 1220 1223 B-Procedure
via NCT03862079 1224 1227 O
retention NCT03862079 1228 1237 B-Procedure
enema NCT03862079 1238 1243 I-Procedure
procedure NCT03862079 1244 1253 I-Procedure

- NCT03862079 1256 1257 O
Patients NCT03862079 1259 1267 O
who NCT03862079 1268 1271 O
have NCT03862079 1272 1276 O
received NCT03862079 1277 1285 B-Eq-Comparison
treatment NCT03862079 1286 1295 B-Procedure
with NCT03862079 1296 1300 O
an NCT03862079 1301 1303 O
investigational NCT03862079 1304 1319 B-Study
agent NCT03862079 1320 1325 B-Drug
within NCT03862079 1326 1332 B-Eq-Comparison
2 NCT03862079 1333 1334 I-Eq-Comparison
weeks NCT03862079 1335 1340 I-Eq-Comparison
of NCT03862079 1341 1343 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03862079 1344 1354 B-Study

- NCT03862079 1357 1358 O
Patients NCT03862079 1360 1368 O
unable NCT03862079 1369 1375 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862079 1376 1378 I-Assertion___Assertion-Type-Value:hypothetical|Negation
tolerate NCT03862079 1379 1387 I-Assertion___Assertion-Type-Value:hypothetical|Negation
oral NCT03862079 1388 1392 B-Procedure
decontamination NCT03862079 1393 1408 I-Procedure
regimen NCT03862079 1409 1416 O
of NCT03862079 1417 1419 O
pip NCT03862079 1420 1423 B-Drug
- NCT03862079 1424 1425 I-Drug
tazo NCT03862079 1426 1430 I-Drug
and NCT03862079 1431 1434 B-Or
nystatin NCT03862079 1435 1443 B-Drug
due NCT03862079 1444 1447 O
to NCT03862079 1448 1450 O
prior NCT03862079 1451 1456 B-Eq-Comparison
allergy NCT03862079 1457 1464 B-Allergy
or NCT03862079 1465 1467 B-Or
intolerance NCT03862079 1468 1479 B-Condition
of NCT03862079 1480 1482 O
these NCT03862079 1483 1488 B-Coreference
medications NCT03862079 1489 1500 I-Coreference

- NCT03862079 1503 1504 O
Patients NCT03862079 1506 1514 O
with NCT03862079 1515 1519 O
any NCT03862079 1520 1523 O
medical NCT03862079 1524 1531 B-Modifier
or NCT03862079 1532 1534 B-Or
psychological NCT03862079 1535 1548 B-Modifier
condition NCT03862079 1549 1558 B-Condition
that NCT03862079 1559 1563 O
, NCT03862079 1564 1565 O
in NCT03862079 1566 1568 O
the NCT03862079 1569 1572 O
opinion NCT03862079 1573 1580 O
of NCT03862079 1581 1583 O
the NCT03862079 1584 1587 O
investigator NCT03862079 1588 1600 O
, NCT03862079 1601 1602 O
might NCT03862079 1603 1608 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03862079 1609 1618 O
with NCT03862079 1619 1623 O
the NCT03862079 1624 1627 O
subject NCT03862079 1628 1635 O
's NCT03862079 1635 1637 O
participation NCT03862079 1638 1651 O
in NCT03862079 1652 1654 O
the NCT03862079 1655 1658 O
trial NCT03862079 1659 1664 B-Study
, NCT03862079 1665 1666 O
pose NCT03862079 1667 1671 O
any NCT03862079 1672 1675 O
additional NCT03862079 1676 1686 O
risk NCT03862079 1687 1691 B-Risk
for NCT03862079 1692 1695 O
the NCT03862079 1696 1699 O
subject NCT03862079 1700 1707 O
, NCT03862079 1708 1709 O
or NCT03862079 1710 1712 B-Or
confound NCT03862079 1713 1721 O
the NCT03862079 1722 1725 O
assessments NCT03862079 1726 1737 O
of NCT03862079 1738 1740 O
the NCT03862079 1741 1744 O
subject NCT03862079 1745 1752 O

Inclusion NCT03863561 0 9 O
Criteria NCT03863561 10 18 O
: NCT03863561 19 20 O

- NCT03863561 24 25 O
Diagnosis NCT03863561 27 36 O
of NCT03863561 37 39 O
type NCT03863561 40 44 B-Modifier
1 NCT03863561 45 46 I-Modifier
or NCT03863561 47 49 B-Or
type NCT03863561 50 54 B-Modifier
2 NCT03863561 55 56 I-Modifier
diabetes NCT03863561 57 65 B-Condition

- NCT03863561 68 69 O
Age NCT03863561 71 74 B-Age
≥ NCT03863561 75 76 B-Eq-Comparison
18 NCT03863561 77 79 I-Eq-Comparison
years NCT03863561 80 85 I-Eq-Comparison

- NCT03863561 88 89 O
Ability NCT03863561 91 98 O
to NCT03863561 99 101 O
read NCT03863561 102 106 O
English NCT03863561 107 114 O

- NCT03863561 117 118 O
Duration NCT03863561 120 128 O
of NCT03863561 129 131 O
diabetes NCT03863561 132 140 B-Condition
≥ NCT03863561 141 142 B-Eq-Comparison
6 NCT03863561 143 144 I-Eq-Comparison
months NCT03863561 145 151 I-Eq-Comparison
( NCT03863561 152 153 O
DSME NCT03863561 154 158 O
cohort NCT03863561 159 165 O
only NCT03863561 166 170 O
) NCT03863561 171 172 O

- NCT03863561 176 177 O
A1C NCT03863561 179 182 B-Observation
≥ NCT03863561 183 184 B-Eq-Comparison
8.0 NCT03863561 185 188 I-Eq-Comparison
% NCT03863561 189 190 I-Eq-Comparison
( NCT03863561 191 192 O
DSME NCT03863561 193 197 O
cohort NCT03863561 198 204 O
only NCT03863561 205 209 O
) NCT03863561 210 211 O

Exclusion NCT03863561 213 222 O
Criteria NCT03863561 223 231 O
: NCT03863561 232 233 O

- NCT03863561 236 237 O

Inclusion NCT03862131 0 9 O
Criteria NCT03862131 10 18 O
: NCT03862131 19 20 O

- NCT03862131 24 25 O
Participant NCT03862131 27 38 O
in NCT03862131 39 41 O
the NCT03862131 42 45 O
SURVIVE NCT03862131 46 53 O
registry NCT03862131 54 62 O

- NCT03862131 65 66 O
Signed NCT03862131 68 74 O
informed NCT03862131 75 83 O
consent NCT03862131 84 91 O
form NCT03862131 92 96 O
for NCT03862131 97 100 O
PROACT NCT03862131 101 107 O

- NCT03862131 110 111 O
Histological NCT03862131 113 125 O
diagnosis NCT03862131 126 135 O
of NCT03862131 136 138 O
early NCT03862131 139 144 B-Modifier
or NCT03862131 145 147 B-Or
metastatic NCT03862131 148 158 B-Modifier
breast NCT03862131 159 165 I-Modifier
cancer NCT03862131 166 172 B-Condition
, NCT03862131 173 174 O
lymphoma NCT03862131 175 183 B-Condition
, NCT03862131 184 185 O
sarcoma NCT03862131 186 193 B-Condition
, NCT03862131 194 195 O
leukemia NCT03862131 196 204 B-Condition
, NCT03862131 205 206 O
myeloma NCT03862131 207 214 B-Condition
, NCT03862131 215 216 O
or NCT03862131 217 219 B-Or
lung NCT03862131 220 224 B-Modifier
cancer NCT03862131 225 231 B-Condition
( NCT03862131 232 233 O
patients NCT03862131 234 242 O
with NCT03862131 243 247 O
treated NCT03862131 248 255 B-Procedure
and NCT03862131 256 259 B-And
clinically NCT03862131 260 270 O
stable NCT03862131 271 277 O
brain NCT03862131 278 283 B-Modifier
metastasis NCT03862131 284 294 B-Condition
are NCT03862131 295 298 O
acceptable NCT03862131 299 309 O
) NCT03862131 310 311 O

- NCT03862131 315 316 O
Scheduled NCT03862131 318 327 B-Eq-Comparison
to NCT03862131 328 330 O
receive NCT03862131 331 338 O
anti NCT03862131 339 343 O
- NCT03862131 344 345 O
cancer NCT03862131 346 352 B-Condition
therapy NCT03862131 353 360 B-Procedure
( NCT03862131 361 362 O
radiation NCT03862131 363 372 B-Procedure
therapy NCT03862131 373 380 I-Procedure
is NCT03862131 381 383 O
permitted NCT03862131 384 393 O
) NCT03862131 394 395 O

Exclusion NCT03862131 397 406 O
Criteria NCT03862131 407 415 O
: NCT03862131 416 417 O

- NCT03862131 421 422 O
Contraindication NCT03862131 424 440 B-Contraindication
to NCT03862131 441 443 O
magnetic NCT03862131 444 452 B-Procedure
resonance NCT03862131 453 462 I-Procedure
imaging NCT03862131 463 470 I-Procedure
( NCT03862131 471 472 O
MRI NCT03862131 473 476 B-Procedure
) NCT03862131 477 478 O

- NCT03862131 482 483 O
Unable NCT03862131 485 491 O
to NCT03862131 492 494 O
comply NCT03862131 495 501 O
with NCT03862131 502 506 O
study NCT03862131 507 512 O
investigations NCT03862131 513 527 O
( NCT03862131 528 529 O
in NCT03862131 530 532 O
the NCT03862131 533 536 O
judgment NCT03862131 537 545 O
of NCT03862131 546 548 O
the NCT03862131 549 552 O
investigator NCT03862131 553 565 O
) NCT03862131 566 567 O

- NCT03862131 571 572 O
Life NCT03862131 574 578 B-Observation
expectancy NCT03862131 579 589 I-Observation
less NCT03862131 590 594 B-Eq-Comparison
than NCT03862131 595 599 I-Eq-Comparison
1 NCT03862131 600 601 I-Eq-Comparison
year NCT03862131 602 606 I-Eq-Comparison

Inclusion NCT03864965 0 9 O
Criteria NCT03864965 10 18 O
: NCT03864965 19 20 O

- NCT03864965 24 25 O
Patients NCT03864965 27 35 O
having NCT03864965 36 42 O
mild NCT03864965 43 47 O
cognitive NCT03864965 48 57 B-Condition
impairment NCT03864965 58 68 I-Condition
( NCT03864965 69 70 O
MCI NCT03864965 71 74 B-Condition
) NCT03864965 75 76 O
or NCT03864965 77 79 B-Or
very NCT03864965 80 84 O
mild NCT03864965 85 89 B-Eq-Comparison
to NCT03864965 90 92 I-Eq-Comparison
mild NCT03864965 93 97 I-Eq-Comparison
dementia NCT03864965 98 106 B-Condition
( NCT03864965 107 108 O
CDR NCT03864965 109 112 B-Observation
0.5 NCT03864965 113 116 B-Eq-Comparison
- NCT03864965 117 118 I-Eq-Comparison
1 NCT03864965 119 120 I-Eq-Comparison
) NCT03864965 121 122 O
. NCT03864965 124 125 O

Exclusion NCT03864965 127 136 O
Criteria NCT03864965 137 145 O
: NCT03864965 146 147 O

- NCT03864965 151 152 O
Patients NCT03864965 154 162 O
with NCT03864965 163 167 O
moderate NCT03864965 168 176 B-Eq-Comparison
to NCT03864965 177 179 I-Eq-Comparison
severe NCT03864965 180 186 I-Eq-Comparison
dementia NCT03864965 187 195 B-Condition
( NCT03864965 196 197 O
CDR NCT03864965 198 201 B-Observation
2 NCT03864965 202 203 B-Eq-Comparison
- NCT03864965 204 205 I-Eq-Comparison
3 NCT03864965 206 207 I-Eq-Comparison
) NCT03864965 208 209 O
. NCT03864965 211 212 O


Inclusion NCT03862482 0 9 O
Criteria NCT03862482 10 18 O
: NCT03862482 19 20 O

- NCT03862482 24 25 O
non NCT03862482 27 30 B-Negation
- NCT03862482 31 32 O
smoker NCT03862482 33 39 B-Condition

- NCT03862482 42 43 O
no NCT03862482 45 47 B-Negation
temporomandibular NCT03862482 48 65 B-Condition
joint NCT03862482 66 71 I-Condition
( NCT03862482 72 73 O
TMJ NCT03862482 74 77 B-Condition
) NCT03862482 78 79 O
disorder NCT03862482 80 88 B-Modifier
or NCT03862482 89 91 B-Or
facial NCT03862482 92 98 B-Modifier
pain NCT03862482 99 103 B-Condition

- NCT03862482 106 107 O
having NCT03862482 109 115 O
partcipated NCT03862482 116 127 O
in NCT03862482 128 130 O
the NCT03862482 131 134 O
original NCT03862482 135 143 O
study NCT03862482 144 149 B-Study
( NCT03862482 150 151 O
1993 NCT03862482 152 156 B-Eq-Comparison
- NCT03862482 157 158 I-Eq-Comparison
1996 NCT03862482 159 163 I-Eq-Comparison
) NCT03862482 164 165 O
at NCT03862482 166 168 O
which NCT03862482 169 174 O
time NCT03862482 175 179 O
the NCT03862482 180 183 O
mnimum NCT03862482 184 190 O
participate NCT03862482 191 202 O
age NCT03862482 203 206 B-Age
was NCT03862482 207 210 O
25 NCT03862482 211 213 B-Eq-Comparison
years NCT03862482 214 219 I-Eq-Comparison
and NCT03862482 220 223 B-And
the NCT03862482 224 227 O
maximum NCT03862482 228 235 B-Eq-Comparison
56 NCT03862482 236 238 I-Eq-Comparison
years NCT03862482 239 244 I-Eq-Comparison
. NCT03862482 245 246 O

Exclusion NCT03862482 248 257 O
Criteria NCT03862482 258 266 O
: NCT03862482 267 268 O

- NCT03862482 272 273 O
refusal NCT03862482 275 282 O
to NCT03862482 283 285 O
sign NCT03862482 286 290 O
informed NCT03862482 291 299 O
consent NCT03862482 300 307 O
documents NCT03862482 308 317 O
. NCT03862482 317 318 O

Inclusion NCT03862469 0 9 O
Criteria NCT03862469 10 18 O
: NCT03862469 19 20 O

- NCT03862469 24 25 O
Female NCT03862469 27 33 O

- NCT03862469 36 37 O
Aged NCT03862469 39 43 B-Age
18 NCT03862469 44 46 B-Eq-Comparison
- NCT03862469 47 48 I-Eq-Comparison
35 NCT03862469 49 51 I-Eq-Comparison
years NCT03862469 52 57 I-Eq-Comparison
, NCT03862469 58 59 O
established NCT03862469 60 71 O
by NCT03862469 72 74 O
visual NCT03862469 75 81 B-Procedure
inspection NCT03862469 82 92 I-Procedure
of NCT03862469 93 95 O
a NCT03862469 96 97 O
government NCT03862469 98 108 O
- NCT03862469 109 110 O
issued NCT03862469 111 117 O
ID NCT03862469 118 120 O

- NCT03862469 123 124 O
Average NCT03862469 126 133 O
menstrual NCT03862469 134 143 B-Observation
cycle NCT03862469 144 149 I-Observation
21 NCT03862469 150 152 B-Eq-Comparison
- NCT03862469 153 154 I-Eq-Comparison
35 NCT03862469 155 157 I-Eq-Comparison
days NCT03862469 158 162 I-Eq-Comparison

- NCT03862469 165 166 O
Access NCT03862469 168 174 O
to NCT03862469 175 177 O
smartphone NCT03862469 178 188 O
with NCT03862469 189 193 O
working NCT03862469 194 201 O
camera NCT03862469 202 208 O
for NCT03862469 209 212 O
daily NCT03862469 213 218 O
use NCT03862469 219 222 O
of NCT03862469 223 225 O
the NCT03862469 226 229 O
PreMom NCT03862469 230 236 O
application NCT03862469 237 248 O

Exclusion NCT03862469 249 258 O
Criteria NCT03862469 259 267 O
: NCT03862469 268 269 O

- NCT03862469 273 274 O
Lifetime NCT03862469 276 284 O
DSM NCT03862469 285 288 B-Condition
- NCT03862469 289 290 I-Condition
5 NCT03862469 291 292 I-Condition
Axis NCT03862469 293 297 I-Condition
1 NCT03862469 298 299 I-Condition
disorder NCT03862469 300 308 I-Condition
( NCT03862469 309 310 O
except NCT03862469 311 317 B-Exception
anxiety NCT03862469 318 325 B-Condition
and NCT03862469 326 329 B-Or
depression NCT03862469 330 340 B-Condition
) NCT03862469 341 342 O
, NCT03862469 344 345 O
as NCT03862469 346 348 O
documented NCT03862469 349 359 O
in NCT03862469 360 362 O
the NCT03862469 363 366 O
Mental NCT03862469 367 373 B-Procedure
Health NCT03862469 374 380 I-Procedure
Interview NCT03862469 381 390 I-Procedure

- NCT03862469 393 394 O
Current NCT03862469 396 403 B-Eq-Comparison
DSM NCT03862469 404 407 B-Condition
- NCT03862469 408 409 I-Condition
5 NCT03862469 410 411 I-Condition
Axis NCT03862469 412 416 I-Condition
depressive NCT03862469 417 427 I-Condition
or NCT03862469 428 430 B-Or
anxiety NCT03862469 431 438 B-Condition
disorder NCT03862469 439 447 I-Condition
, NCT03862469 448 449 O
as NCT03862469 450 452 O
documented NCT03862469 453 463 O
in NCT03862469 464 466 O
the NCT03862469 467 470 O
Mental NCT03862469 471 477 B-Procedure
Health NCT03862469 478 484 I-Procedure
Interview NCT03862469 485 494 I-Procedure

- NCT03862469 497 498 O
Positive NCT03862469 500 508 O
urine NCT03862469 509 514 B-Observation
drug NCT03862469 515 519 I-Observation
screen NCT03862469 520 526 I-Observation
test NCT03862469 527 531 I-Observation

- NCT03862469 534 535 O
Breath NCT03862469 537 543 B-Observation
alcohol NCT03862469 544 551 I-Observation
concentration NCT03862469 552 565 I-Observation
> NCT03862469 566 567 B-Eq-Comparison
0.00 NCT03862469 568 572 I-Eq-Comparison
% NCT03862469 573 574 I-Eq-Comparison

- NCT03862469 578 579 O
Self NCT03862469 581 585 O
- NCT03862469 586 587 O
reported NCT03862469 588 596 O
smoker NCT03862469 597 603 B-Condition
or NCT03862469 604 606 B-Or
carbon NCT03862469 607 613 B-Observation
monoxide NCT03862469 614 622 I-Observation
concentration NCT03862469 623 636 I-Observation
≥ NCT03862469 637 638 B-Eq-Comparison
6 NCT03862469 639 640 I-Eq-Comparison
ppm NCT03862469 641 644 I-Eq-Comparison

- NCT03862469 647 648 O
Irregular NCT03862469 650 659 B-Condition
menstrual NCT03862469 660 669 I-Condition
cycle NCT03862469 670 675 I-Condition

- NCT03862469 678 679 O
Current NCT03862469 681 688 B-Eq-Comparison
pregnancy NCT03862469 689 698 B-Condition
( NCT03862469 699 700 O
urine NCT03862469 701 706 B-Observation
test NCT03862469 707 711 I-Observation
- NCT03862469 712 713 O
verified NCT03862469 714 722 O
) NCT03862469 723 724 O
or NCT03862469 725 727 B-Or
lactation NCT03862469 728 737 B-Condition
, NCT03862469 738 739 O
or NCT03862469 740 742 B-Or
a NCT03862469 743 744 O
plan NCT03862469 745 749 B-Assertion___Assertion-Type-Value:intention
to NCT03862469 750 752 I-Assertion___Assertion-Type-Value:intention
become NCT03862469 753 759 O
pregnant NCT03862469 760 768 B-Condition

- NCT03862469 771 772 O
Moderate NCT03862469 774 782 B-Eq-Comparison
or NCT03862469 783 785 I-Eq-Comparison
high NCT03862469 786 790 I-Eq-Comparison
suicide NCT03862469 791 798 B-Condition
risk NCT03862469 799 803 B-Risk

- NCT03862469 806 807 O
Shipley NCT03862469 809 816 B-Observation
IQ NCT03862469 817 819 I-Observation
( NCT03862469 820 821 O
vocabulary NCT03862469 822 832 B-Observation
standard NCT03862469 833 841 I-Observation
score NCT03862469 842 847 I-Observation
) NCT03862469 848 849 O
> NCT03862469 850 851 B-Eq-Comparison
80 NCT03862469 852 854 I-Eq-Comparison

- NCT03862469 858 859 O
Prescription NCT03862469 861 873 O
medications NCT03862469 874 885 B-Drug

Inclusion NCT03869528 0 9 O
Criteria NCT03869528 10 18 O
: NCT03869528 19 20 O

- NCT03869528 24 25 O
All NCT03869528 27 30 O
adults NCT03869528 31 37 O
≥ NCT03869528 38 39 B-Eq-Comparison
18 NCT03869528 40 42 I-Eq-Comparison
yrs NCT03869528 43 46 I-Eq-Comparison
of NCT03869528 47 49 O
age NCT03869528 50 53 B-Age
undergoing NCT03869528 54 64 B-Eq-Comparison
flexible NCT03869528 65 73 B-Modifier
bronchoscopy NCT03869528 74 86 B-Procedure

Exclusion NCT03869528 87 96 O
Criteria NCT03869528 97 105 O
: NCT03869528 106 107 O

- NCT03869528 111 112 O
Uncontrolled NCT03869528 114 126 B-Modifier
hypertension NCT03869528 127 139 B-Condition
Systolic NCT03869528 140 148 B-Observation
Blood NCT03869528 149 154 I-Observation
Pressure NCT03869528 155 163 I-Observation
> NCT03869528 164 165 B-Eq-Comparison
180 NCT03869528 166 169 I-Eq-Comparison
mm NCT03869528 170 172 I-Eq-Comparison
Hg NCT03869528 173 175 I-Eq-Comparison

- NCT03869528 178 179 O
Symptomatic NCT03869528 181 192 B-Assertion___Assertion-Type-Value:possible
coronary NCT03869528 193 201 B-Condition
artery NCT03869528 202 208 I-Condition
disease NCT03869528 209 216 I-Condition

- NCT03869528 219 220 O
Pregnancy NCT03869528 222 231 B-Condition

- NCT03869528 234 235 O
Not NCT03869528 237 240 O
giving NCT03869528 241 247 O
informed NCT03869528 248 256 O
consent NCT03869528 257 264 O
for NCT03869528 265 268 O
the NCT03869528 269 272 B-Coreference
procedure NCT03869528 273 282 I-Coreference

- NCT03869528 285 286 O
Hypoxemia NCT03869528 288 297 B-Condition
( NCT03869528 298 299 O
oxygen NCT03869528 300 306 B-Observation
saturation NCT03869528 307 317 I-Observation
[ NCT03869528 318 319 O
by NCT03869528 320 322 O
pulse NCT03869528 323 328 B-Procedure
oximetry NCT03869528 329 337 I-Procedure
] NCT03869528 338 339 O
< NCT03869528 340 341 B-Eq-Comparison
92 NCT03869528 342 344 I-Eq-Comparison
% NCT03869528 345 346 I-Eq-Comparison
with NCT03869528 347 351 B-And
Fio2 NCT03869528 352 356 B-Observation
of NCT03869528 357 359 O
≥ NCT03869528 360 361 B-Eq-Comparison
0.3 NCT03869528 362 365 I-Eq-Comparison

- NCT03869528 369 370 O
Bronchoscopy NCT03869528 372 384 B-Procedure
performed NCT03869528 385 394 O
through NCT03869528 395 402 O
an NCT03869528 403 405 O
artificial NCT03869528 406 416 B-Procedure
airway NCT03869528 417 423 I-Procedure

Inclusion NCT03868150 0 9 O
Criteria NCT03868150 10 18 O
: NCT03868150 19 20 O

- NCT03868150 24 25 O
Patients NCT03868150 27 35 O
scheduled NCT03868150 36 45 B-Eq-Comparison
for NCT03868150 46 49 O
first NCT03868150 50 55 B-Eq-Comparison
- NCT03868150 56 57 I-Eq-Comparison
time NCT03868150 58 62 I-Eq-Comparison
non NCT03868150 63 66 B-Negation
- NCT03868150 67 68 O
emergent NCT03868150 69 77 B-Modifier
open NCT03868150 78 82 B-Procedure
- NCT03868150 83 84 I-Procedure
heart NCT03868150 85 90 I-Procedure
surgery NCT03868150 91 98 I-Procedure
for NCT03868150 99 102 O
coronary NCT03868150 103 111 B-Procedure
artery NCT03868150 112 118 I-Procedure
bypass NCT03868150 119 125 I-Procedure
graft NCT03868150 126 131 I-Procedure
( NCT03868150 132 133 O
CABG NCT03868150 134 138 B-Procedure
) NCT03868150 139 140 O
revascularization NCT03868150 141 158 B-Modifier
, NCT03868150 159 160 O
valvular NCT03868150 161 169 B-Procedure
repair NCT03868150 170 176 B-Modifier
or NCT03868150 177 179 B-Or
replacement NCT03868150 180 191 B-Modifier
, NCT03868150 192 193 O
combined NCT03868150 194 202 B-Modifier
CABG NCT03868150 203 207 B-Procedure
with NCT03868150 208 212 B-And
valve NCT03868150 213 218 B-Procedure
repair NCT03868150 219 225 B-Modifier
or NCT03868150 226 228 B-Or
replacement NCT03868150 229 240 B-Modifier
, NCT03868150 241 242 O
or NCT03868150 243 245 B-Or
valve NCT03868150 246 251 B-Procedure
sparing NCT03868150 252 259 I-Procedure
aortic NCT03868150 260 266 I-Procedure
root NCT03868150 267 271 I-Procedure
repair NCT03868150 272 278 I-Procedure

- NCT03868150 281 282 O
Normal NCT03868150 284 290 O
sinus NCT03868150 291 296 B-Condition
rhythm NCT03868150 297 303 I-Condition

- NCT03868150 306 307 O
No NCT03868150 309 311 B-Negation
documented NCT03868150 312 322 O
history NCT03868150 323 330 B-Eq-Comparison
of NCT03868150 331 333 O
atrial NCT03868150 334 340 B-Condition
fibrillation NCT03868150 341 353 I-Condition

Exclusion NCT03868150 354 363 O
Criteria NCT03868150 364 372 O
: NCT03868150 373 374 O

- NCT03868150 378 379 O
Prior NCT03868150 381 386 B-Eq-Comparison
surgical NCT03868150 387 395 B-Procedure
procedures NCT03868150 396 406 I-Procedure
involving NCT03868150 407 416 O
heart NCT03868150 417 422 B-Procedure
surgery NCT03868150 423 430 I-Procedure
and NCT03868150 431 434 B-Or
cardiopulmonary NCT03868150 435 450 B-Procedure
bypass NCT03868150 451 457 I-Procedure

- NCT03868150 460 461 O
Any NCT03868150 463 466 O
prior NCT03868150 467 472 B-Eq-Comparison
documented NCT03868150 473 483 O
history NCT03868150 484 491 B-Eq-Comparison
of NCT03868150 492 494 O
atrial NCT03868150 495 501 B-Condition
fibrillation NCT03868150 502 514 I-Condition
, NCT03868150 515 516 O
atrial NCT03868150 517 523 B-Condition
flutter NCT03868150 524 531 I-Condition
or NCT03868150 532 534 B-Or
atrial NCT03868150 535 541 B-Condition
tachycardia NCT03868150 542 553 I-Condition
lasting NCT03868150 554 561 O
longer NCT03868150 562 568 B-Eq-Comparison
than NCT03868150 569 573 I-Eq-Comparison
30 NCT03868150 574 576 I-Eq-Comparison
seconds NCT03868150 577 584 I-Eq-Comparison

- NCT03868150 587 588 O
Prior NCT03868150 590 595 B-Eq-Comparison
history NCT03868150 596 603 I-Eq-Comparison
of NCT03868150 604 606 O
Amiodarone NCT03868150 607 617 B-Drug
treatment NCT03868150 618 627 B-Procedure
for NCT03868150 628 631 O
the NCT03868150 632 635 O
management NCT03868150 636 646 O
of NCT03868150 647 649 O
supraventricular NCT03868150 650 666 B-Modifier
tachy NCT03868150 667 672 B-Condition
- NCT03868150 673 674 I-Condition
arrhythmias NCT03868150 675 686 I-Condition

- NCT03868150 689 690 O
Patients NCT03868150 692 700 O
requiring NCT03868150 701 710 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03868150 711 719 B-Procedure
treatment NCT03868150 720 729 I-Procedure
of NCT03868150 730 732 O
atrial NCT03868150 733 739 B-Condition
arrhythmias NCT03868150 740 751 I-Condition
such NCT03868150 752 756 O
as NCT03868150 757 759 O
pulmonary NCT03868150 760 769 B-Procedure
vein NCT03868150 770 774 I-Procedure
isolation NCT03868150 775 784 I-Procedure
or NCT03868150 785 787 B-Or
Maze NCT03868150 788 792 B-Procedure
procedure NCT03868150 793 802 I-Procedure
. NCT03868150 802 803 O

Inclusion NCT03867539 0 9 O
Criteria NCT03867539 10 18 O
: NCT03867539 19 20 O

- NCT03867539 24 25 O
carpal NCT03867539 27 33 B-Condition
tunnel NCT03867539 34 40 I-Condition
syndrome NCT03867539 41 49 I-Condition
diagnosed NCT03867539 50 59 O
either NCT03867539 60 66 O
by NCT03867539 67 69 O
physical NCT03867539 70 78 B-Procedure
exam NCT03867539 79 83 I-Procedure
or NCT03867539 84 86 B-Or
EMG NCT03867539 87 90 B-Procedure

- NCT03867539 93 94 O
age NCT03867539 96 99 B-Age
> NCT03867539 100 101 B-Eq-Comparison
18 NCT03867539 102 104 I-Eq-Comparison
. NCT03867539 104 105 O

Exclusion NCT03867539 107 116 O
Criteria NCT03867539 117 125 O
: NCT03867539 126 127 O

- NCT03867539 131 132 O
allergy NCT03867539 134 141 B-Allergy
to NCT03867539 142 144 O
bupivacaine NCT03867539 145 156 B-Drug

- NCT03867539 159 160 O
pre NCT03867539 162 165 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03867539 166 167 O
operative NCT03867539 168 177 B-Procedure
opioid NCT03867539 178 184 B-Drug
usage NCT03867539 185 190 O
within NCT03867539 191 197 B-Eq-Comparison
the NCT03867539 198 201 I-Eq-Comparison
last NCT03867539 202 206 I-Eq-Comparison
six NCT03867539 207 210 I-Eq-Comparison
months NCT03867539 211 217 I-Eq-Comparison

- NCT03867539 220 221 O
patients NCT03867539 223 231 O
allergic NCT03867539 232 240 B-Allergy
to NCT03867539 241 243 O
Percocet NCT03867539 244 252 B-Drug
or NCT03867539 253 255 B-Or
acetaminophen NCT03867539 256 269 B-Drug

- NCT03867539 272 273 O
patients NCT03867539 275 283 O
taking NCT03867539 284 290 B-Eq-Comparison
tricyclic NCT03867539 291 300 B-Drug
antidepressants NCT03867539 301 316 I-Drug
( NCT03867539 317 318 O
interaction NCT03867539 319 330 O
with NCT03867539 331 335 O
bupivacaine NCT03867539 336 347 B-Drug
) NCT03867539 348 349 O

- NCT03867539 353 354 O
vulnerable NCT03867539 356 366 B-Observation
populations NCT03867539 367 378 I-Observation
( NCT03867539 379 380 O
prisoners NCT03867539 381 390 B-Observation
or NCT03867539 391 393 B-Or
pregnant NCT03867539 394 402 B-Condition
women NCT03867539 403 408 O
) NCT03867539 409 410 O

Inclusion NCT03862287 0 9 O
Criteria NCT03862287 10 18 O
: NCT03862287 19 20 O

- NCT03862287 24 25 O
ASA NCT03862287 27 30 B-Condition
I NCT03862287 31 32 B-Eq-Comparison
- NCT03862287 33 34 I-Eq-Comparison
III NCT03862287 35 38 I-Eq-Comparison
male NCT03862287 39 43 O
and NCT03862287 44 47 B-Or
female NCT03862287 48 54 O
patients NCT03862287 55 63 O
aged NCT03862287 64 68 B-Age
between NCT03862287 69 76 B-Eq-Comparison
18 NCT03862287 77 79 I-Eq-Comparison
to NCT03862287 80 82 I-Eq-Comparison
80 NCT03862287 83 85 I-Eq-Comparison
years NCT03862287 86 91 I-Eq-Comparison
old NCT03862287 92 95 O
, NCT03862287 96 97 O
who NCT03862287 98 101 B-And
will NCT03862287 102 106 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03862287 107 114 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03862287 115 121 B-Procedure
anesthesia NCT03862287 122 132 I-Procedure
for NCT03862287 133 136 O
surgeries NCT03862287 137 146 B-Procedure
lasting NCT03862287 147 154 O
less NCT03862287 155 159 B-Eq-Comparison
than NCT03862287 160 164 I-Eq-Comparison
one NCT03862287 165 168 I-Eq-Comparison
hour NCT03862287 169 173 I-Eq-Comparison
. NCT03862287 174 175 O

Exclusion NCT03862287 177 186 O
Criteria NCT03862287 187 195 O
: NCT03862287 196 197 O

- NCT03862287 201 202 O
Patients NCT03862287 204 212 O
younger NCT03862287 213 220 B-Eq-Comparison
than NCT03862287 221 225 I-Eq-Comparison
18 NCT03862287 226 228 I-Eq-Comparison
years NCT03862287 229 234 I-Eq-Comparison
old NCT03862287 235 238 B-Age
. NCT03862287 239 240 O

- NCT03862287 244 245 O
ASA NCT03862287 247 250 B-Condition
physical NCT03862287 251 259 O
status NCT03862287 260 266 O
> NCT03862287 267 268 B-Eq-Comparison
3 NCT03862287 269 270 I-Eq-Comparison
. NCT03862287 270 271 O

- NCT03862287 275 276 O
Immunosuppression NCT03862287 278 295 B-Condition
or NCT03862287 296 298 B-Or
high NCT03862287 299 303 O
risk NCT03862287 304 308 B-Risk
of NCT03862287 309 311 O
infection NCT03862287 312 321 B-Condition
. NCT03862287 322 323 O

- NCT03862287 327 328 O
Contraindications NCT03862287 330 347 B-Contraindication
to NCT03862287 348 350 O
receiving NCT03862287 351 360 O
spinal NCT03862287 361 367 B-Procedure
anesthesia NCT03862287 368 378 I-Procedure
( NCT03862287 379 380 O
e. NCT03862287 381 383 O
g. NCT03862287 384 386 O
coagulation NCT03862287 388 399 B-Condition
impairment NCT03862287 400 410 I-Condition
) NCT03862287 411 412 O
. NCT03862287 414 415 O

- NCT03862287 419 420 O
Patients NCT03862287 422 430 O
with NCT03862287 431 435 O
psychosis NCT03862287 436 445 B-Condition

- NCT03862287 448 449 O
Patients NCT03862287 451 459 O
with NCT03862287 460 464 O
preexisting NCT03862287 465 476 B-Eq-Comparison
back NCT03862287 477 481 B-Condition
pain NCT03862287 482 486 I-Condition
. NCT03862287 487 488 O

- NCT03862287 492 493 O
Patients NCT03862287 495 503 O
with NCT03862287 504 508 O
cognitive NCT03862287 509 518 B-Condition
impairment NCT03862287 519 529 I-Condition

- NCT03862287 532 533 O
Allergies NCT03862287 535 544 B-Allergy
to NCT03862287 545 547 O
local NCT03862287 548 553 B-Procedure
anesthetics NCT03862287 554 565 I-Procedure
, NCT03862287 566 567 O
analgesics NCT03862287 568 578 B-Drug
or NCT03862287 579 581 B-Or
any NCT03862287 582 585 O
medication NCT03862287 586 596 B-Drug
used NCT03862287 597 601 O
in NCT03862287 602 604 O
the NCT03862287 605 608 O
study NCT03862287 609 614 B-Study
. NCT03862287 615 616 O

- NCT03862287 620 621 O
Patients NCT03862287 623 631 O
with NCT03862287 632 636 O
chronic NCT03862287 637 644 B-Modifier
regular NCT03862287 645 652 B-Eq-Comparison
opioid NCT03862287 653 659 B-Drug
usage NCT03862287 660 665 O

- NCT03862287 668 669 O
Presence NCT03862287 671 679 O
of NCT03862287 680 682 O
preexisting NCT03862287 683 694 B-Eq-Comparison
neurological NCT03862287 695 707 B-Condition
symptoms NCT03862287 708 716 B-Assertion___Assertion-Type-Value:possible
. NCT03862287 716 717 O

Inclusion NCT03863600 0 9 O
Criteria NCT03863600 10 18 O
: NCT03863600 19 20 O

- NCT03863600 24 25 O
Residing NCT03863600 27 35 O
in NCT03863600 36 38 O
rural NCT03863600 39 44 O
village NCT03863600 45 52 O

- NCT03863600 55 56 O
Registered NCT03863600 58 68 O
for NCT03863600 69 72 O
pregnancy NCT03863600 73 82 B-Condition
care NCT03863600 83 87 B-Procedure
at NCT03863600 88 90 O
the NCT03863600 91 94 O
villages NCT03863600 95 103 O
governmental NCT03863600 104 116 O
clinic NCT03863600 117 123 O

- NCT03863600 126 127 O
With NCT03863600 129 133 O
singleton NCT03863600 134 143 B-Modifier
pregnancy NCT03863600 144 153 B-Condition

- NCT03863600 156 157 O
Gave NCT03863600 159 163 B-Eq-Comparison
birth NCT03863600 164 169 B-Birth
the NCT03863600 170 173 O
last NCT03863600 174 178 B-Eq-Comparison
one NCT03863600 179 182 I-Eq-Comparison
to NCT03863600 183 185 I-Eq-Comparison
six NCT03863600 186 189 I-Eq-Comparison
month NCT03863600 190 195 I-Eq-Comparison

Exclusion NCT03863600 196 205 O
Criteria NCT03863600 206 214 O
: NCT03863600 215 216 O

- NCT03863600 220 221 O
Residing NCT03863600 223 231 O
in NCT03863600 232 234 O
urban NCT03863600 235 240 O
areas NCT03863600 241 246 O

- NCT03863600 249 250 O
With NCT03863600 252 256 O
multiple NCT03863600 257 265 B-Eq-Comparison
pregnancy NCT03863600 266 275 B-Condition

- NCT03863600 278 279 O
Not NCT03863600 281 284 B-Negation
registered NCT03863600 285 295 O
for NCT03863600 296 299 O
antenatal NCT03863600 300 309 B-Procedure
care NCT03863600 310 314 I-Procedure
at NCT03863600 315 317 O
the NCT03863600 318 321 O
local NCT03863600 322 327 O
governmental NCT03863600 328 340 O
clinic NCT03863600 341 347 O

Inclusion NCT03868033 0 9 O
Criteria NCT03868033 10 18 O
: NCT03868033 19 20 O

1 NCT03868033 24 25 O
. NCT03868033 25 26 O
Postmenopausal NCT03868033 28 42 B-Condition
women NCT03868033 43 48 O

2 NCT03868033 51 52 O
. NCT03868033 52 53 O
Men NCT03868033 55 58 O
> NCT03868033 59 60 B-Eq-Comparison
50 NCT03868033 61 63 I-Eq-Comparison
- NCT03868033 64 65 I-Eq-Comparison
year NCT03868033 66 70 I-Eq-Comparison
- NCT03868033 71 72 O
old NCT03868033 73 76 B-Age

3 NCT03868033 79 80 O
. NCT03868033 80 81 O
After NCT03868033 83 88 B-Eq-Comparison
Denosumab NCT03868033 89 98 B-Drug
treatment NCT03868033 99 108 B-Procedure
≥ NCT03868033 109 110 B-Eq-Comparison
2 NCT03868033 111 112 I-Eq-Comparison
years NCT03868033 113 118 I-Eq-Comparison
due NCT03868033 119 122 O
to NCT03868033 123 125 O
osteoporosis NCT03868033 126 138 B-Condition

Exclusion NCT03868033 139 148 O
Criteria NCT03868033 149 157 O
: NCT03868033 158 159 O

1 NCT03868033 163 164 O
. NCT03868033 164 165 O
secondary NCT03868033 167 176 B-Modifier
osteoporosis NCT03868033 177 189 B-Condition

2 NCT03868033 192 193 O
. NCT03868033 193 194 O
metabolic NCT03868033 196 205 B-Condition
bone NCT03868033 206 210 I-Condition
disease NCT03868033 211 218 I-Condition

3 NCT03868033 221 222 O
. NCT03868033 222 223 O
cancer NCT03868033 225 231 B-Condition
history NCT03868033 232 239 B-Eq-Comparison

4 NCT03868033 242 243 O
. NCT03868033 243 244 O
continuous NCT03868033 246 256 B-Eq-Comparison
steroid NCT03868033 257 264 B-Procedure
therapy NCT03868033 265 272 I-Procedure

5 NCT03868033 275 276 O
. NCT03868033 276 277 O
hormone NCT03868033 279 286 B-Procedure
replacement NCT03868033 287 298 I-Procedure
therapy NCT03868033 299 306 I-Procedure

6 NCT03868033 309 310 O
. NCT03868033 310 311 O
ever NCT03868033 313 317 B-Eq-Comparison
used NCT03868033 318 322 O
any NCT03868033 323 326 O
other NCT03868033 327 332 B-Other
kind NCT03868033 333 337 O
of NCT03868033 338 340 O
anti NCT03868033 341 345 B-Procedure
- NCT03868033 346 347 I-Procedure
resorptive NCT03868033 348 358 I-Procedure
treatment NCT03868033 359 368 I-Procedure

6 NCT03868033 371 372 O
. NCT03868033 372 373 O
estimated NCT03868033 375 384 B-Observation
Glomerular NCT03868033 385 395 I-Observation
filtration NCT03868033 396 406 I-Observation
rate NCT03868033 407 411 I-Observation
< NCT03868033 412 413 B-Eq-Comparison
35 NCT03868033 414 416 I-Eq-Comparison
mL NCT03868033 417 419 I-Eq-Comparison
/ NCT03868033 420 421 I-Eq-Comparison
min NCT03868033 422 425 I-Eq-Comparison

7 NCT03868033 429 430 O
. NCT03868033 430 431 O
allergy NCT03868033 433 440 B-Allergy
to NCT03868033 441 443 O
Zoledronic NCT03868033 444 454 B-Drug
acid NCT03868033 455 459 I-Drug

8 NCT03868033 462 463 O
. NCT03868033 463 464 O
hypocalcaemia NCT03868033 466 479 B-Condition

9 NCT03868033 483 484 O
. NCT03868033 484 485 O
any NCT03868033 487 490 O
contraindications NCT03868033 491 508 B-Contraindication
to NCT03868033 509 511 O
use NCT03868033 512 515 O
Zoledronic NCT03868033 516 526 B-Drug
acid NCT03868033 527 531 I-Drug


Inclusion NCT03869463 0 9 O
Criteria NCT03869463 10 18 O
: NCT03869463 19 20 O

1 NCT03869463 24 25 O
. NCT03869463 25 26 O
Age NCT03869463 28 31 B-Age
18 NCT03869463 32 34 B-Eq-Comparison
- NCT03869463 35 36 I-Eq-Comparison
29 NCT03869463 37 39 O
. NCT03869463 39 40 O

2 NCT03869463 44 45 O
. NCT03869463 45 46 O
Current NCT03869463 48 55 B-Eq-Comparison
diagnosis NCT03869463 56 65 O
of NCT03869463 66 68 O
MDD NCT03869463 69 72 B-Condition
/ NCT03869463 73 74 B-Or
persistent NCT03869463 75 85 B-Modifier
depressive NCT03869463 86 96 B-Condition
disorder NCT03869463 97 105 I-Condition
or NCT03869463 106 108 B-Or
HDRS NCT03869463 109 113 B-Observation
greater NCT03869463 114 121 B-Eq-Comparison
than NCT03869463 122 126 I-Eq-Comparison
or NCT03869463 127 129 I-Eq-Comparison
equal NCT03869463 130 135 I-Eq-Comparison
to NCT03869463 136 138 I-Eq-Comparison
12 NCT03869463 139 141 I-Eq-Comparison
. NCT03869463 141 142 O
3 NCT03869463 144 145 O
. NCT03869463 145 146 O
Daily NCT03869463 148 153 O
access NCT03869463 154 160 O
to NCT03869463 161 163 O
smartphone NCT03869463 164 174 O
or NCT03869463 175 177 O
tablet NCT03869463 178 184 O
with NCT03869463 185 189 O
internet NCT03869463 190 198 O
connection NCT03869463 199 209 O
for NCT03869463 210 213 O
the NCT03869463 214 217 O
study NCT03869463 218 223 O
duration NCT03869463 224 232 O
. NCT03869463 233 234 O

4 NCT03869463 236 237 O
. NCT03869463 237 238 O
Willing NCT03869463 240 247 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03869463 248 251 B-And
able NCT03869463 252 256 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869463 257 259 I-Assertion___Assertion-Type-Value:hypothetical
complete NCT03869463 260 268 O
MRI NCT03869463 269 272 B-Procedure
, NCT03869463 273 274 O
mood NCT03869463 275 279 B-Modifier
, NCT03869463 280 281 O
and NCT03869463 282 285 B-Or
neuropsychological NCT03869463 286 304 B-Modifier
testing NCT03869463 305 312 B-Procedure
. NCT03869463 312 313 O
5 NCT03869463 315 316 O
. NCT03869463 316 317 O
IQ NCT03869463 319 321 B-Observation
> NCT03869463 322 323 B-Eq-Comparison
85 NCT03869463 324 326 I-Eq-Comparison
. NCT03869463 326 327 O

Exclusion NCT03869463 329 338 O
Criteria NCT03869463 339 347 O
: NCT03869463 348 349 O

1 NCT03869463 353 354 O
. NCT03869463 354 355 O
Lacks NCT03869463 357 362 O
English NCT03869463 363 370 O
- NCT03869463 371 372 O
speaking NCT03869463 373 381 O
ability NCT03869463 382 389 O
as NCT03869463 390 392 O
determined NCT03869463 393 403 O
by NCT03869463 404 406 O
self NCT03869463 407 411 O
- NCT03869463 412 413 O
report NCT03869463 414 420 O
and NCT03869463 421 424 O
clinical NCT03869463 425 433 O
evaluation NCT03869463 434 444 O
. NCT03869463 445 446 O

2 NCT03869463 450 451 O
. NCT03869463 451 452 O
Evidence NCT03869463 454 462 O
of NCT03869463 463 465 O
schizophrenia NCT03869463 466 479 B-Condition
, NCT03869463 480 481 O
schizoaffective NCT03869463 482 497 B-Condition
disorder NCT03869463 498 506 I-Condition
, NCT03869463 507 508 O
psychosis NCT03869463 509 518 B-Condition
, NCT03869463 519 520 O
bipolar NCT03869463 521 528 B-Condition
I NCT03869463 529 530 B-Eq-Comparison
and NCT03869463 531 534 I-Eq-Comparison
II NCT03869463 535 537 I-Eq-Comparison
disorder NCT03869463 538 546 B-Modifier
. NCT03869463 547 548 O

3 NCT03869463 552 553 O
. NCT03869463 553 554 O
Active NCT03869463 556 562 B-Eq-Comparison
suicidal NCT03869463 563 571 B-Condition
ideation NCT03869463 572 580 I-Condition
, NCT03869463 581 582 O
intent NCT03869463 583 589 B-Assertion___Assertion-Type-Value:intention
, NCT03869463 590 591 O
or NCT03869463 592 594 B-Or
plan NCT03869463 595 599 B-Assertion___Assertion-Type-Value:intention
, NCT03869463 600 601 O
or NCT03869463 602 604 B-Or
past NCT03869463 605 609 B-Eq-Comparison
attempt NCT03869463 610 617 B-Coreference
within NCT03869463 618 624 B-Eq-Comparison
1 NCT03869463 625 626 I-Eq-Comparison
year NCT03869463 627 631 I-Eq-Comparison
. NCT03869463 632 633 O

4 NCT03869463 637 638 O
. NCT03869463 638 639 O
Severe NCT03869463 641 647 O
depression NCT03869463 648 658 B-Condition
( NCT03869463 659 660 O
HDRS NCT03869463 661 665 B-Observation
> NCT03869463 666 667 B-Eq-Comparison
30 NCT03869463 668 670 I-Eq-Comparison
) NCT03869463 671 672 O
. NCT03869463 674 675 O

5 NCT03869463 679 680 O
. NCT03869463 680 681 O
Neurological NCT03869463 683 695 B-Condition
disorder NCT03869463 696 704 I-Condition
( NCT03869463 705 706 O
epilepsy NCT03869463 707 715 B-Condition
, NCT03869463 716 717 O
multiple NCT03869463 718 726 B-Condition
sclerosis NCT03869463 727 736 I-Condition
, NCT03869463 737 738 O
traumatic NCT03869463 739 748 B-Condition
brain NCT03869463 749 754 I-Condition
injury NCT03869463 755 761 I-Condition
, NCT03869463 762 763 O
clinical NCT03869463 764 772 B-Modifier
stroke NCT03869463 773 779 B-Condition
) NCT03869463 780 781 O
. NCT03869463 783 784 O

6 NCT03869463 788 789 O
. NCT03869463 789 790 O
Use NCT03869463 792 795 B-Eq-Comparison
of NCT03869463 796 798 O
medications NCT03869463 799 810 B-Drug
known NCT03869463 811 816 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869463 817 819 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03869463 820 824 I-Assertion___Assertion-Type-Value:hypothetical
negative NCT03869463 825 833 O
impact NCT03869463 834 840 O
on NCT03869463 841 843 O
cognition NCT03869463 844 853 B-Condition
( NCT03869463 854 855 O
benzodiazepines NCT03869463 856 871 B-Drug
and NCT03869463 872 875 B-Or
lorazepam NCT03869463 876 885 B-Drug
equivalents NCT03869463 886 897 O
> NCT03869463 898 899 B-Eq-Comparison
1 NCT03869463 900 901 I-Eq-Comparison
mg NCT03869463 902 904 I-Eq-Comparison
daily NCT03869463 905 910 I-Eq-Comparison
, NCT03869463 911 912 O
narcotics NCT03869463 913 922 B-Drug
, NCT03869463 923 924 O
anticholinergics NCT03869463 925 941 B-Drug
) NCT03869463 942 943 O
. NCT03869463 945 946 O

7 NCT03869463 950 951 O
. NCT03869463 951 952 O
History NCT03869463 954 961 B-Eq-Comparison
of NCT03869463 962 964 O
alcohol NCT03869463 965 972 B-Modifier
or NCT03869463 973 975 B-Or
drug NCT03869463 976 980 B-Modifier
abuse NCT03869463 981 986 B-Condition
or NCT03869463 987 989 B-Or
dependence NCT03869463 990 1000 B-Modifier
within NCT03869463 1001 1007 B-Eq-Comparison
past NCT03869463 1008 1012 I-Eq-Comparison
year NCT03869463 1013 1017 I-Eq-Comparison
. NCT03869463 1018 1019 O

8 NCT03869463 1023 1024 O
. NCT03869463 1024 1025 O
Acute NCT03869463 1027 1032 O
, NCT03869463 1033 1034 O
severe NCT03869463 1035 1041 O
, NCT03869463 1042 1043 O
unstable NCT03869463 1044 1052 O
medical NCT03869463 1053 1060 B-Condition
illness NCT03869463 1061 1068 I-Condition
. NCT03869463 1068 1069 O
For NCT03869463 1071 1074 O
cancer NCT03869463 1075 1081 B-Condition
, NCT03869463 1082 1083 O
acutely NCT03869463 1084 1091 O
ill NCT03869463 1092 1095 B-Condition
patients NCT03869463 1096 1104 O
( NCT03869463 1105 1106 O
including NCT03869463 1107 1116 O
those NCT03869463 1117 1122 O
with NCT03869463 1123 1127 O
metastases NCT03869463 1128 1138 B-Condition
) NCT03869463 1139 1140 O
are NCT03869463 1141 1144 O
excluded NCT03869463 1145 1153 B-Negation
, NCT03869463 1154 1155 O
but NCT03869463 1156 1159 O
past NCT03869463 1160 1164 B-Eq-Comparison
history NCT03869463 1165 1172 I-Eq-Comparison
of NCT03869463 1173 1175 O
successfully NCT03869463 1176 1188 O
treated NCT03869463 1189 1196 B-Procedure
cancer NCT03869463 1197 1203 B-Condition
does NCT03869463 1204 1208 O
not NCT03869463 1209 1212 B-Negation
result NCT03869463 1213 1219 O
in NCT03869463 1220 1222 O
exclusion NCT03869463 1223 1232 B-Negation
. NCT03869463 1233 1234 O

9 NCT03869463 1238 1239 O
. NCT03869463 1239 1240 O
Regular NCT03869463 1242 1249 O
online NCT03869463 1250 1256 B-Modifier
brain NCT03869463 1257 1262 I-Modifier
training NCT03869463 1263 1271 B-Observation
or NCT03869463 1272 1274 B-Or
regular NCT03869463 1275 1282 O
player NCT03869463 1283 1289 O
of NCT03869463 1290 1292 O
non NCT03869463 1293 1296 B-Negation
- NCT03869463 1297 1298 O
fluency NCT03869463 1299 1306 B-Modifier
verbal NCT03869463 1307 1313 B-Observation
games NCT03869463 1314 1319 I-Observation
, NCT03869463 1320 1321 O
defined NCT03869463 1322 1329 O
as NCT03869463 1330 1332 O
doing NCT03869463 1333 1338 O
these NCT03869463 1339 1344 B-Coreference
procedures NCT03869463 1345 1355 I-Coreference
at NCT03869463 1356 1358 O
a NCT03869463 1359 1360 O
frequency NCT03869463 1361 1370 O
of NCT03869463 1371 1373 O
twice NCT03869463 1374 1379 B-Eq-Comparison
weekly NCT03869463 1380 1386 I-Eq-Comparison
or NCT03869463 1387 1389 I-Eq-Comparison
greater NCT03869463 1390 1397 I-Eq-Comparison
during NCT03869463 1398 1404 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869463 1405 1408 O
year NCT03869463 1409 1413 B-Eq-Comparison
prior NCT03869463 1414 1419 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03869463 1420 1422 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03869463 1423 1432 B-Study
. NCT03869463 1432 1433 O

Inclusion NCT03861598 0 9 O
Criteria NCT03861598 10 18 O
: NCT03861598 19 20 O

- NCT03861598 24 25 O
Grade NCT03861598 27 32 B-Eq-Comparison
IV NCT03861598 33 35 I-Eq-Comparison
Glioblastoma NCT03861598 36 48 B-Condition
, NCT03861598 49 50 O
receiving NCT03861598 51 60 B-Eq-Comparison
chemotherapy NCT03861598 61 73 B-Procedure
with NCT03861598 74 78 O
or NCT03861598 79 81 B-Or
without NCT03861598 82 89 B-Negation
TTfields NCT03861598 90 98 B-Drug
. NCT03861598 99 100 O

- NCT03861598 104 105 O
Progressive NCT03861598 107 118 B-Modifier
or NCT03861598 119 121 B-Or
recurrent NCT03861598 122 131 B-Modifier
disease NCT03861598 132 139 B-Condition
requiring NCT03861598 140 149 B-Assertion___Assertion-Type-Value:hypothetical
second NCT03861598 150 156 B-Procedure
line NCT03861598 157 161 I-Procedure
treatment NCT03861598 162 171 I-Procedure

- NCT03861598 174 175 O
evidence NCT03861598 177 185 O
of NCT03861598 186 188 O
progression NCT03861598 189 200 B-Condition
of NCT03861598 201 203 I-Condition
disease NCT03861598 204 211 I-Condition
by NCT03861598 212 214 O
brain NCT03861598 215 220 B-Procedure
MRI NCT03861598 221 224 I-Procedure
and NCT03861598 225 228 B-And
are NCT03861598 229 232 O
planned NCT03861598 233 240 B-Eq-Comparison
to NCT03861598 241 243 O
receive NCT03861598 244 251 O
chemotherapy NCT03861598 252 264 B-Procedure

Exclusion NCT03861598 265 274 O
Criteria NCT03861598 275 283 O
: NCT03861598 284 285 O

- NCT03861598 289 290 O
Current NCT03861598 292 299 B-Eq-Comparison
use NCT03861598 300 303 O
of NCT03861598 304 306 O
another NCT03861598 307 314 B-Other
beta NCT03861598 315 319 B-Drug
blocker NCT03861598 320 327 I-Drug
that NCT03861598 328 332 O
can NCT03861598 333 336 B-Assertion___Assertion-Type-Value:hypothetical|Negation
not NCT03861598 336 339 I-Assertion___Assertion-Type-Value:hypothetical|Negation
be NCT03861598 340 342 O
switched NCT03861598 343 351 O
to NCT03861598 352 354 O
carvedilol NCT03861598 355 365 B-Drug
at NCT03861598 366 368 O
the NCT03861598 369 372 O
onset NCT03861598 373 378 B-Eq-Comparison
of NCT03861598 379 381 O
the NCT03861598 382 385 O
trial NCT03861598 386 391 B-Study
. NCT03861598 392 393 O

- NCT03861598 397 398 O
Systolic NCT03861598 400 408 B-Observation
blood NCT03861598 409 414 I-Observation
pressure NCT03861598 415 423 I-Observation
< NCT03861598 424 425 B-Eq-Comparison
90 NCT03861598 426 428 I-Eq-Comparison
mmHg NCT03861598 429 433 I-Eq-Comparison
and NCT03861598 434 437 B-Or
/ NCT03861598 438 439 I-Or
or NCT03861598 440 442 I-Or
heart NCT03861598 443 448 B-Observation
rate NCT03861598 449 453 I-Observation
< NCT03861598 454 455 B-Eq-Comparison
60 NCT03861598 456 458 I-Eq-Comparison
bpm NCT03861598 459 462 I-Eq-Comparison
without NCT03861598 463 470 B-Negation
hypertensive NCT03861598 471 483 B-Condition
medications NCT03861598 484 495 B-Drug

- NCT03861598 498 499 O
Allergy NCT03861598 501 508 B-Allergy
to NCT03861598 509 511 O
beta NCT03861598 512 516 B-Drug
blockers NCT03861598 517 525 I-Drug

- NCT03861598 528 529 O
Severe NCT03861598 531 537 O
or NCT03861598 538 540 B-Or
uncontrolled NCT03861598 541 553 B-Modifier
asthma NCT03861598 554 560 B-Condition
or NCT03861598 561 563 B-Or
COPD NCT03861598 564 568 B-Condition
( NCT03861598 569 570 O
chronic NCT03861598 571 578 B-Condition
obstructive NCT03861598 579 590 I-Condition
pulmonary NCT03861598 591 600 I-Condition
disease NCT03861598 601 608 I-Condition
) NCT03861598 609 610 O

Inclusion NCT03861104 0 9 O
Criteria NCT03861104 10 18 O
: NCT03861104 19 20 O

- NCT03861104 24 25 O
patients NCT03861104 27 35 O
who NCT03861104 36 39 O
will NCT03861104 40 44 B-Eq-Comparison
undergo NCT03861104 45 52 I-Eq-Comparison
septoplasty NCT03861104 53 64 B-Procedure
/ NCT03861104 65 66 B-Or
septorhinoplasty NCT03861104 67 83 B-Procedure
procedures NCT03861104 84 94 I-Procedure

- NCT03861104 97 98 O
patients NCT03861104 100 108 O
who NCT03861104 109 112 O
will NCT03861104 113 117 B-Eq-Comparison
receive NCT03861104 118 125 I-Eq-Comparison
nasal NCT03861104 126 131 B-Procedure
packing NCT03861104 132 139 I-Procedure
at NCT03861104 140 142 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03861104 143 148 O
septoplasty NCT03861104 149 160 B-Procedure
septorhinoplasty NCT03861104 161 177 I-Procedure
procedures NCT03861104 178 188 I-Procedure

Exclusion NCT03861104 189 198 O
Criteria NCT03861104 199 207 O
: NCT03861104 208 209 O

- NCT03861104 213 214 O
patients NCT03861104 216 224 O
who NCT03861104 225 228 O
will NCT03861104 229 233 O
not NCT03861104 234 237 B-Negation
want NCT03861104 238 242 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861104 243 245 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03861104 246 257 O
to NCT03861104 258 260 O
the NCT03861104 261 264 O
study NCT03861104 265 270 B-Study

- NCT03861104 273 274 O
revision NCT03861104 276 284 B-Modifier
surgeries NCT03861104 285 294 B-Procedure

- NCT03861104 297 298 O
if NCT03861104 300 302 O
the NCT03861104 303 306 O
patient NCT03861104 307 314 O
is NCT03861104 315 317 O
taking NCT03861104 318 324 B-Eq-Comparison
antidepressants NCT03861104 325 340 B-Drug
during NCT03861104 341 347 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03861104 348 351 O
last NCT03861104 352 356 B-Eq-Comparison
6 NCT03861104 357 358 I-Eq-Comparison
months NCT03861104 359 365 I-Eq-Comparison

- NCT03861104 368 369 O
if NCT03861104 371 373 O
the NCT03861104 374 377 O
patient NCT03861104 378 385 O
has NCT03861104 386 389 O
a NCT03861104 390 391 O
history NCT03861104 392 399 B-Eq-Comparison
of NCT03861104 400 402 O
a NCT03861104 403 404 O
disease NCT03861104 405 412 B-Condition
that NCT03861104 413 417 O
can NCT03861104 418 421 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03861104 422 428 O
anxiety NCT03861104 429 436 B-Condition
levels NCT03861104 437 443 O

- NCT03861104 446 447 O
if NCT03861104 449 451 O
patient NCT03861104 452 459 O
wants NCT03861104 460 465 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861104 466 468 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03861104 469 471 O
excluded NCT03861104 472 480 B-Negation
from NCT03861104 481 485 O
the NCT03861104 486 489 O
study NCT03861104 490 495 B-Study

Inclusion NCT03861676 0 9 O
Criteria NCT03861676 10 18 O
: NCT03861676 19 20 O

- NCT03861676 24 25 O
Adenocarcinoma NCT03861676 27 41 B-Condition
of NCT03861676 42 44 O
the NCT03861676 45 48 O
prostate NCT03861676 49 57 B-Modifier

- NCT03861676 60 61 O
Performance NCT03861676 63 74 B-Observation
Status NCT03861676 75 81 I-Observation
< NCT03861676 82 83 B-Eq-Comparison
2 NCT03861676 84 85 I-Eq-Comparison

- NCT03861676 89 90 O
Clinical NCT03861676 92 100 B-Coreference
stages NCT03861676 101 107 I-Coreference
( NCT03861676 108 109 O
not NCT03861676 110 113 B-Negation
radiographic NCT03861676 114 126 B-Modifier
stage NCT03861676 127 132 I-Modifier
) NCT03861676 133 134 O
T1c NCT03861676 135 138 B-Eq-Comparison
- NCT03861676 139 140 I-Eq-Comparison
T2a NCT03861676 141 144 I-Eq-Comparison
, NCT03861676 145 146 I-Eq-Comparison
Nx NCT03861676 147 149 I-Eq-Comparison
or NCT03861676 150 152 B-Or
N0 NCT03861676 153 155 B-Eq-Comparison
, NCT03861676 156 157 I-Eq-Comparison
Mx NCT03861676 158 160 I-Eq-Comparison
or NCT03861676 161 163 B-Or
M0 NCT03861676 164 166 B-Eq-Comparison

- NCT03861676 169 170 O
Gleason NCT03861676 172 179 B-Observation
6 NCT03861676 180 181 B-Eq-Comparison
- NCT03861676 182 183 I-Eq-Comparison
7 NCT03861676 184 185 I-Eq-Comparison
cancer NCT03861676 186 192 B-Condition

- NCT03861676 195 196 O
Prostate NCT03861676 198 206 B-Observation
volume NCT03861676 207 213 I-Observation
< NCT03861676 214 215 B-Eq-Comparison
60 NCT03861676 216 218 I-Eq-Comparison
cc NCT03861676 219 221 I-Eq-Comparison
( NCT03861676 222 223 O
if NCT03861676 224 226 O
MRI NCT03861676 227 230 B-Procedure
and NCT03861676 231 234 B-And
TRUS NCT03861676 235 239 B-Procedure
have NCT03861676 240 244 O
conflicting NCT03861676 245 256 O
values NCT03861676 257 263 O
, NCT03861676 264 265 O
then NCT03861676 266 270 O
MRI NCT03861676 271 274 B-Procedure
value NCT03861676 275 280 O
will NCT03861676 281 285 O
be NCT03861676 286 288 O
utilized NCT03861676 289 297 O
) NCT03861676 298 299 O

- NCT03861676 303 304 O
International NCT03861676 306 319 B-Observation
Prostate NCT03861676 320 328 I-Observation
symptom NCT03861676 329 336 I-Observation
score NCT03861676 337 342 I-Observation
( NCT03861676 343 344 O
IPSS NCT03861676 345 349 B-Observation
) NCT03861676 350 351 O
20 NCT03861676 352 354 B-Eq-Comparison
or NCT03861676 355 357 I-Eq-Comparison
less NCT03861676 358 362 I-Eq-Comparison

- NCT03861676 365 366 O
Ability NCT03861676 368 375 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861676 376 378 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03861676 379 386 O
DCF NCT03861676 387 390 B-Procedure
- NCT03861676 391 392 I-Procedure
Pyl NCT03861676 393 396 I-Procedure
PSMA NCT03861676 397 401 I-Procedure
PET NCT03861676 402 405 I-Procedure
as NCT03861676 406 408 O
part NCT03861676 409 413 O
of NCT03861676 414 416 O
pretreatment NCT03861676 417 429 O
staging NCT03861676 430 437 O

- NCT03861676 440 441 O
Signed NCT03861676 443 449 O
study NCT03861676 450 455 O
- NCT03861676 456 457 O
specific NCT03861676 458 466 O
consent NCT03861676 467 474 O
form NCT03861676 475 479 O
prior NCT03861676 480 485 O
to NCT03861676 486 488 O
registration NCT03861676 489 501 O

Exclusion NCT03861676 502 511 O
Criteria NCT03861676 512 520 O
: NCT03861676 521 522 O

- NCT03861676 526 527 O
Prior NCT03861676 529 534 B-Eq-Comparison
history NCT03861676 535 542 I-Eq-Comparison
of NCT03861676 543 545 O
pelvic NCT03861676 546 552 B-Modifier
radiation NCT03861676 553 562 B-Procedure
therapy NCT03861676 563 570 I-Procedure

- NCT03861676 573 574 O
Major NCT03861676 576 581 O
medical NCT03861676 582 589 B-Modifier
or NCT03861676 590 592 B-Or
psychiatric NCT03861676 593 604 B-Modifier
illness NCT03861676 605 612 B-Condition
which NCT03861676 613 618 O
, NCT03861676 619 620 O
in NCT03861676 621 623 O
the NCT03861676 624 627 O
investigator NCT03861676 628 640 O
's NCT03861676 640 642 O
opinion NCT03861676 643 650 O
, NCT03861676 651 652 O
would NCT03861676 653 658 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03861676 659 666 B-Negation
completion NCT03861676 667 677 O
of NCT03861676 678 680 O
treatment NCT03861676 681 690 B-Procedure
and NCT03861676 691 694 B-And
would NCT03861676 695 700 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03861676 701 710 O
with NCT03861676 711 715 O
follow NCT03861676 716 722 B-Encounter
up NCT03861676 723 725 I-Encounter
. NCT03861676 726 727 O

- NCT03861676 731 732 O
Implanted NCT03861676 734 743 B-Procedure
device NCT03861676 744 750 B-Modifier
or NCT03861676 751 753 B-Or
apparatus NCT03861676 754 763 B-Modifier
which NCT03861676 764 769 O
obstruct NCT03861676 770 778 B-Assertion___Assertion-Type-Value:hypothetical|Negation
visibility NCT03861676 779 789 O
of NCT03861676 790 792 O
the NCT03861676 793 796 O
implanted NCT03861676 797 806 B-Modifier
sources NCT03861676 807 814 I-Modifier
on NCT03861676 815 817 O
fluoroscopy NCT03861676 818 829 B-Procedure

- NCT03861676 832 833 O
Metallic NCT03861676 835 843 B-Procedure
implants NCT03861676 844 852 I-Procedure
, NCT03861676 853 854 O
claustrophobia NCT03861676 855 869 B-Condition
not NCT03861676 870 873 B-Negation
amenable NCT03861676 874 882 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03861676 883 885 O
medication NCT03861676 886 896 B-Drug
, NCT03861676 897 898 O
or NCT03861676 899 901 B-Or
known NCT03861676 902 907 O
contraindications NCT03861676 908 925 B-Contraindication
to NCT03861676 926 928 O
undergoing NCT03861676 929 939 O
MR NCT03861676 940 942 B-Procedure
scanning NCT03861676 943 951 I-Procedure

- NCT03861676 954 955 O
History NCT03861676 957 964 B-Eq-Comparison
of NCT03861676 965 967 O
other NCT03861676 968 973 B-Other
malignancy NCT03861676 974 984 B-Condition
diagnosed NCT03861676 985 994 O
within NCT03861676 995 1001 B-Eq-Comparison
the NCT03861676 1002 1005 I-Eq-Comparison
past NCT03861676 1006 1010 I-Eq-Comparison
3 NCT03861676 1011 1012 I-Eq-Comparison
years NCT03861676 1013 1018 I-Eq-Comparison

Inclusion NCT03864068 0 9 O
Criteria NCT03864068 10 18 O
: NCT03864068 19 20 O

- NCT03864068 24 25 O
Women NCT03864068 27 32 O
with NCT03864068 33 37 B-And
chronic NCT03864068 38 45 B-Modifier
anovulation NCT03864068 46 57 B-Condition
or NCT03864068 58 60 B-Or
oligomenorrhea NCT03864068 61 75 B-Condition
defined NCT03864068 76 83 O
as NCT03864068 84 86 O
spontaneous NCT03864068 87 98 B-Condition
intermenstrual NCT03864068 99 113 I-Condition
periods NCT03864068 114 121 I-Condition
of NCT03864068 122 124 O
greater NCT03864068 125 132 B-Eq-Comparison
than NCT03864068 133 137 I-Eq-Comparison
or NCT03864068 138 140 I-Eq-Comparison
equal NCT03864068 141 146 I-Eq-Comparison
to NCT03864068 147 149 I-Eq-Comparison
45 NCT03864068 150 152 I-Eq-Comparison
days NCT03864068 153 157 I-Eq-Comparison
or NCT03864068 158 160 B-Or
a NCT03864068 161 162 O
total NCT03864068 163 168 O
of NCT03864068 169 171 O
less NCT03864068 172 176 B-Eq-Comparison
than NCT03864068 177 181 I-Eq-Comparison
or NCT03864068 182 184 I-Eq-Comparison
equal NCT03864068 185 190 I-Eq-Comparison
to NCT03864068 191 193 I-Eq-Comparison
8 NCT03864068 194 195 I-Eq-Comparison
menses NCT03864068 196 202 B-Observation
per NCT03864068 203 206 O
year NCT03864068 207 211 O
. NCT03864068 212 213 O

- NCT03864068 217 218 O
Women NCT03864068 220 225 O
with NCT03864068 226 230 B-And
Hyperandrogenism NCT03864068 231 247 B-Condition
defined NCT03864068 248 255 O
as NCT03864068 256 258 O
a NCT03864068 259 260 O
total NCT03864068 261 266 B-Observation
testosterone NCT03864068 267 279 I-Observation
greater NCT03864068 280 287 B-Eq-Comparison
than NCT03864068 288 292 I-Eq-Comparison
50 NCT03864068 293 295 I-Eq-Comparison
ng NCT03864068 296 298 I-Eq-Comparison
/ NCT03864068 299 300 I-Eq-Comparison
dL NCT03864068 301 303 I-Eq-Comparison
or NCT03864068 304 306 B-Or
a NCT03864068 307 308 O
free NCT03864068 309 313 B-Observation
androgen NCT03864068 314 322 I-Observation
index NCT03864068 323 328 I-Observation
greater NCT03864068 329 336 B-Eq-Comparison
than NCT03864068 337 341 I-Eq-Comparison
10 NCT03864068 342 344 I-Eq-Comparison
. NCT03864068 344 345 O

- NCT03864068 349 350 O
Women NCT03864068 352 357 O
with NCT03864068 358 362 B-And
Polycystic NCT03864068 363 373 B-Condition
Ovaries NCT03864068 374 381 I-Condition
on NCT03864068 382 384 O
Ultrasound NCT03864068 385 395 B-Procedure
defined NCT03864068 396 403 O
as NCT03864068 404 406 O
either NCT03864068 407 413 B-Eq-Comparison
12 NCT03864068 414 416 I-Eq-Comparison
or NCT03864068 417 419 I-Eq-Comparison
more NCT03864068 420 424 I-Eq-Comparison
follicles NCT03864068 425 434 B-Observation
measuring NCT03864068 435 444 I-Observation
2 NCT03864068 445 446 B-Eq-Comparison
- NCT03864068 447 448 I-Eq-Comparison
9 NCT03864068 449 450 I-Eq-Comparison
mm NCT03864068 451 453 I-Eq-Comparison
in NCT03864068 454 456 O
diameter NCT03864068 457 465 B-Modifier
or NCT03864068 466 468 B-Or
increased NCT03864068 469 478 O
ovarian NCT03864068 479 486 B-Observation
volume NCT03864068 487 493 I-Observation
greater NCT03864068 494 501 B-Eq-Comparison
than NCT03864068 502 506 I-Eq-Comparison
10 NCT03864068 507 509 I-Eq-Comparison
cm NCT03864068 510 512 I-Eq-Comparison
. NCT03864068 513 514 O

Exclusion NCT03864068 516 525 O
Criteria NCT03864068 526 534 O
: NCT03864068 535 536 O

- NCT03864068 540 541 O
Women NCT03864068 543 548 O
with NCT03864068 549 553 B-And
Hyperprolactinemia NCT03864068 554 572 B-Condition
defined NCT03864068 573 580 O
as NCT03864068 581 583 O
2 NCT03864068 584 585 B-Eq-Comparison
prolactin NCT03864068 586 595 B-Observation
levels NCT03864068 596 602 I-Observation
at NCT03864068 603 605 B-Eq-Comparison
least NCT03864068 606 611 I-Eq-Comparison
one NCT03864068 612 615 I-Eq-Comparison
week NCT03864068 616 620 I-Eq-Comparison
apart NCT03864068 621 626 O
greater NCT03864068 627 634 B-Eq-Comparison
than NCT03864068 635 639 I-Eq-Comparison
30 NCT03864068 640 642 I-Eq-Comparison
ng NCT03864068 643 645 I-Eq-Comparison
/ NCT03864068 646 647 I-Eq-Comparison
mL NCT03864068 648 650 I-Eq-Comparison
. NCT03864068 651 652 O

- NCT03864068 656 657 O
Women NCT03864068 659 664 O
with NCT03864068 665 669 B-And
known NCT03864068 670 675 O
21 NCT03864068 676 678 B-Condition
- NCT03864068 679 680 I-Condition
hydroxylase NCT03864068 681 692 I-Condition
deficiency NCT03864068 693 703 I-Condition
or NCT03864068 704 706 B-Or
other NCT03864068 707 712 B-Other
enzyme NCT03864068 713 719 B-Condition
deficiency NCT03864068 720 730 I-Condition
leading NCT03864068 731 738 O
to NCT03864068 739 741 O
the NCT03864068 742 745 O
congenital NCT03864068 746 756 B-Condition
adrenal NCT03864068 757 764 I-Condition
hyperplasia NCT03864068 765 776 I-Condition
. NCT03864068 777 778 O

- NCT03864068 782 783 O
Women NCT03864068 785 790 O
with NCT03864068 791 795 B-And
elevated NCT03864068 796 804 O
FSH NCT03864068 805 808 B-Observation
levels NCT03864068 809 815 I-Observation
greater NCT03864068 816 823 B-Eq-Comparison
than NCT03864068 824 828 I-Eq-Comparison
10 NCT03864068 829 831 I-Eq-Comparison
mIU NCT03864068 832 835 I-Eq-Comparison
/ NCT03864068 836 837 I-Eq-Comparison
mL NCT03864068 838 840 I-Eq-Comparison
. NCT03864068 841 842 I-Eq-Comparison

- NCT03864068 846 847 O
Women NCT03864068 849 854 O
with NCT03864068 855 859 B-And
uncorrected NCT03864068 860 871 B-Modifier
thyroid NCT03864068 872 879 B-Condition
disease NCT03864068 880 887 I-Condition
as NCT03864068 888 890 O
per NCT03864068 891 894 O
ASRM NCT03864068 895 899 O
guidelines NCT03864068 900 910 O
for NCT03864068 911 914 O
nonpregnant NCT03864068 915 926 O
subjects NCT03864068 927 935 O
( NCT03864068 936 937 O
TSH NCT03864068 938 941 B-Observation
less NCT03864068 942 946 B-Eq-Comparison
than NCT03864068 947 951 I-Eq-Comparison
0.45 NCT03864068 952 956 I-Eq-Comparison
mIU NCT03864068 957 960 I-Eq-Comparison
/ NCT03864068 961 962 I-Eq-Comparison
mL NCT03864068 963 965 I-Eq-Comparison
or NCT03864068 966 968 B-Or
greater NCT03864068 969 976 B-Eq-Comparison
than NCT03864068 977 981 I-Eq-Comparison
4.5 NCT03864068 982 985 I-Eq-Comparison
MIU NCT03864068 986 989 I-Eq-Comparison
/ NCT03864068 990 991 I-Eq-Comparison
mL NCT03864068 992 994 I-Eq-Comparison
) NCT03864068 995 996 O
. NCT03864068 998 999 O

- NCT03864068 1003 1004 O
Women NCT03864068 1006 1011 O
with NCT03864068 1012 1016 B-And
a NCT03864068 1017 1018 O
suspected NCT03864068 1019 1028 B-Assertion___Assertion-Type-Value:possible
adrenal NCT03864068 1029 1036 B-Modifier
or NCT03864068 1037 1039 B-Or
ovarian NCT03864068 1040 1047 B-Modifier
tumor NCT03864068 1048 1053 B-Condition
secreting NCT03864068 1054 1063 B-Modifier
androgens NCT03864068 1064 1073 I-Modifier

- NCT03864068 1076 1077 O
Women NCT03864068 1079 1084 O
with NCT03864068 1085 1089 B-And
Cushing NCT03864068 1090 1097 B-Condition
's NCT03864068 1097 1099 I-Condition
syndrome NCT03864068 1100 1108 I-Condition

- NCT03864068 1111 1112 O
Women NCT03864068 1114 1119 O
on NCT03864068 1120 1122 B-Eq-Comparison
confounding NCT03864068 1123 1134 O
medications NCT03864068 1135 1146 B-Drug
which NCT03864068 1147 1152 O
affect NCT03864068 1153 1159 B-Assertion___Assertion-Type-Value:hypothetical
ovarian NCT03864068 1160 1167 B-Condition
function NCT03864068 1168 1176 I-Condition
including NCT03864068 1177 1186 O
metformin NCT03864068 1187 1196 B-Drug
, NCT03864068 1197 1198 O
hormonal NCT03864068 1199 1207 B-Drug
contraceptives NCT03864068 1208 1222 I-Drug
or NCT03864068 1223 1225 B-Or
other NCT03864068 1226 1231 B-Other
medications NCT03864068 1232 1243 B-Drug
for NCT03864068 1244 1247 O
type NCT03864068 1248 1252 B-Condition
2 NCT03864068 1253 1254 I-Condition
diabetes NCT03864068 1255 1263 I-Condition

- NCT03864068 1266 1267 O
Women NCT03864068 1269 1274 O
with NCT03864068 1275 1279 B-And
medical NCT03864068 1280 1287 B-Condition
conditions NCT03864068 1288 1298 I-Condition
that NCT03864068 1299 1303 O
are NCT03864068 1304 1307 O
contraindications NCT03864068 1308 1325 B-Contraindication
to NCT03864068 1326 1328 O
OTC NCT03864068 1329 1332 B-Drug
inositol NCT03864068 1333 1341 I-Drug
or NCT03864068 1342 1344 B-Or
previous NCT03864068 1345 1353 B-Eq-Comparison
allergic NCT03864068 1354 1362 B-Allergy
reactions NCT03864068 1363 1372 O
to NCT03864068 1373 1375 O
the NCT03864068 1376 1379 O
supplement NCT03864068 1380 1390 B-Drug
or NCT03864068 1391 1393 B-Or
to NCT03864068 1394 1396 O
the NCT03864068 1397 1400 O
placebo NCT03864068 1401 1408 B-Drug
maltodextrin NCT03864068 1409 1421 I-Drug
or NCT03864068 1422 1424 B-Or
inulin NCT03864068 1425 1431 B-Drug
. NCT03864068 1431 1432 O

Patient NCT03869216 0 7 O
Inclusion NCT03869216 8 17 O
Criteria NCT03869216 18 26 O
: NCT03869216 27 28 O

- NCT03869216 32 33 O
Receiving NCT03869216 35 44 B-Eq-Comparison
care NCT03869216 45 49 B-Procedure
at NCT03869216 50 52 O
the NCT03869216 53 56 O
clinical NCT03869216 57 65 O
sites NCT03869216 66 71 O

- NCT03869216 74 75 O
Identify NCT03869216 77 85 O
as NCT03869216 86 88 O
African NCT03869216 89 96 O
American NCT03869216 97 105 O
male NCT03869216 106 110 O

- NCT03869216 113 114 O
Ages NCT03869216 116 120 B-Age
40 NCT03869216 121 123 B-Eq-Comparison
- NCT03869216 124 125 I-Eq-Comparison
69 NCT03869216 126 128 I-Eq-Comparison
years NCT03869216 129 134 I-Eq-Comparison
old NCT03869216 135 138 O

- NCT03869216 141 142 O
Provider NCT03869216 144 152 O
- NCT03869216 153 154 O
estimated NCT03869216 155 164 O
life NCT03869216 165 169 B-Observation
expectancy NCT03869216 170 180 I-Observation
of NCT03869216 181 183 O
at NCT03869216 184 186 B-Eq-Comparison
least NCT03869216 187 192 I-Eq-Comparison
10 NCT03869216 193 195 I-Eq-Comparison
years NCT03869216 196 201 I-Eq-Comparison

Patient NCT03869216 202 209 O
Exclusion NCT03869216 210 219 O
Criteria NCT03869216 220 228 O
: NCT03869216 229 230 O

- NCT03869216 234 235 O
Personal NCT03869216 237 245 O
history NCT03869216 246 253 B-Eq-Comparison
of NCT03869216 254 256 O
prostate NCT03869216 257 265 B-Modifier
cancer NCT03869216 266 272 B-Condition
at NCT03869216 273 275 O
the NCT03869216 276 279 O
time NCT03869216 280 284 O
of NCT03869216 285 287 O
consent NCT03869216 288 295 O

- NCT03869216 298 299 O
Cognitive NCT03869216 301 310 B-Condition
impairment NCT03869216 311 321 I-Condition
that NCT03869216 322 326 O
would NCT03869216 327 332 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03869216 333 342 O
with NCT03869216 343 347 O
participation NCT03869216 348 361 O
in NCT03869216 362 364 O
the NCT03869216 365 368 O
study NCT03869216 369 374 B-Study

- NCT03869216 377 378 O
Unable NCT03869216 380 386 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869216 387 389 O
complete NCT03869216 390 398 O
any NCT03869216 399 402 O
aspect NCT03869216 403 409 O
of NCT03869216 410 412 O
the NCT03869216 413 416 O
intervention NCT03869216 417 429 B-Study
within NCT03869216 430 436 O
the NCT03869216 437 440 O
specified NCT03869216 441 450 O
time NCT03869216 451 455 O
limit NCT03869216 456 461 O

Inclusion NCT03861845 0 9 O
Criteria NCT03861845 10 18 O
: NCT03861845 19 20 O

- NCT03861845 24 25 O
18 NCT03861845 27 29 B-Eq-Comparison
years NCT03861845 30 35 I-Eq-Comparison
of NCT03861845 36 38 I-Eq-Comparison
age NCT03861845 39 42 I-Age|Eq-Comparison
or NCT03861845 43 45 I-Eq-Comparison
older NCT03861845 46 51 I-Eq-Comparison

- NCT03861845 54 55 O
speak NCT03861845 57 62 O
English NCT03861845 63 70 O

- NCT03861845 73 74 O
be NCT03861845 76 78 O
prescribed NCT03861845 79 89 O
to NCT03861845 90 92 O
take NCT03861845 93 97 O
two NCT03861845 98 101 B-Eq-Comparison
or NCT03861845 102 104 I-Eq-Comparison
more NCT03861845 105 109 I-Eq-Comparison
medications NCT03861845 110 121 B-Drug
per NCT03861845 122 125 O
day NCT03861845 126 129 B-Eq-Comparison
, NCT03861845 130 131 O
and NCT03861845 132 135 B-And
manage NCT03861845 136 142 B-Assertion___Assertion-Type-Value:hypothetical
their NCT03861845 143 148 I-Assertion___Assertion-Type-Value:hypothetical
own NCT03861845 149 152 O
medications NCT03861845 153 164 B-Drug
. NCT03861845 165 166 O

Exclusion NCT03861845 168 177 O
Criteria NCT03861845 178 186 O
: NCT03861845 187 188 O

- NCT03861845 192 193 O
have NCT03861845 195 199 O
a NCT03861845 200 201 O
significant NCT03861845 202 213 O
cognitive NCT03861845 214 223 B-Condition
impairment NCT03861845 224 234 I-Condition

- NCT03861845 237 238 O
unwilling NCT03861845 240 249 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861845 250 252 O
use NCT03861845 253 256 O
a NCT03861845 257 258 O
novel NCT03861845 259 264 B-Procedure
pillbox NCT03861845 265 272 I-Procedure

- NCT03861845 275 276 O
unable NCT03861845 278 284 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03861845 285 287 O
meet NCT03861845 288 292 O
with NCT03861845 293 297 O
the NCT03861845 298 301 O
research NCT03861845 302 310 B-Study
team NCT03861845 311 315 I-Study

Inclusion NCT03860597 0 9 O
Criteria NCT03860597 10 18 O
: NCT03860597 19 20 O

- NCT03860597 24 25 O
diagnosis NCT03860597 27 36 O
of NCT03860597 37 39 O
schizophrenia NCT03860597 40 53 B-Condition
OR NCT03860597 54 56 B-Or
schizoaffective NCT03860597 57 72 B-Condition
- NCT03860597 73 74 I-Condition
depressed NCT03860597 75 84 I-Condition
OR NCT03860597 85 87 B-Or
healthy NCT03860597 88 95 B-Condition
subjects NCT03860597 96 104 O

- NCT03860597 107 108 O
ages NCT03860597 110 114 B-Age
18 NCT03860597 115 117 B-Eq-Comparison
- NCT03860597 118 119 I-Eq-Comparison
50 NCT03860597 120 122 I-Eq-Comparison
for NCT03860597 123 126 O
all NCT03860597 127 130 O
subjects NCT03860597 131 139 O

- NCT03860597 142 143 O
double NCT03860597 145 151 B-Modifier
barrier NCT03860597 152 159 I-Modifier
contraception NCT03860597 160 173 B-Procedure
for NCT03860597 174 177 O
all NCT03860597 178 181 O
subjects NCT03860597 182 190 O

- NCT03860597 193 194 O
not NCT03860597 196 199 B-Negation
pregnant NCT03860597 200 208 B-Condition
for NCT03860597 209 212 O
all NCT03860597 213 216 O
subjects NCT03860597 217 225 O

Exclusion NCT03860597 226 235 O
Criteria NCT03860597 236 244 O
: NCT03860597 245 246 O

- NCT03860597 250 251 O
DSM NCT03860597 253 256 B-Condition
- NCT03860597 257 258 I-Condition
IV NCT03860597 259 261 I-Condition
Axis NCT03860597 262 266 I-Condition
I NCT03860597 267 268 B-Eq-Comparison
or NCT03860597 269 271 I-Eq-Comparison
II NCT03860597 272 274 I-Eq-Comparison
Diagnosis NCT03860597 275 284 O
for NCT03860597 285 288 O
for NCT03860597 289 292 O
healthy NCT03860597 293 300 B-Condition
subjects NCT03860597 301 309 O

- NCT03860597 312 313 O
MEM NCT03860597 315 318 B-Condition
or NCT03860597 319 321 B-Or
amantadine NCT03860597 322 332 B-Drug
for NCT03860597 333 336 O
patients NCT03860597 337 345 O

- NCT03860597 348 349 O
current NCT03860597 351 358 B-Eq-Comparison
substance NCT03860597 359 368 B-Condition
abuse NCT03860597 369 374 I-Condition
for NCT03860597 375 378 O
all NCT03860597 379 382 O
subjects NCT03860597 383 391 O

- NCT03860597 394 395 O
current NCT03860597 397 404 B-Eq-Comparison
recreational NCT03860597 405 417 B-Condition
drug NCT03860597 418 422 I-Condition
use NCT03860597 423 426 I-Condition
for NCT03860597 427 430 O
all NCT03860597 431 434 O
subjects NCT03860597 435 443 O

- NCT03860597 446 447 O
history NCT03860597 449 456 B-Eq-Comparison
of NCT03860597 457 459 O
other NCT03860597 460 465 B-Other
significant NCT03860597 466 477 O
medical NCT03860597 478 485 B-Condition
illness NCT03860597 486 493 I-Condition
( NCT03860597 494 495 O
e. NCT03860597 496 498 O
g. NCT03860597 499 501 O
cancer NCT03860597 503 509 B-Condition
, NCT03860597 510 511 O
diabetes NCT03860597 512 520 B-Condition
, NCT03860597 521 522 O
heart NCT03860597 523 528 B-Condition
disease NCT03860597 529 536 I-Condition
, NCT03860597 537 538 O
HIV NCT03860597 539 542 B-Condition
, NCT03860597 543 544 O
seizures NCT03860597 545 553 B-Condition
) NCT03860597 554 555 O
for NCT03860597 556 559 O
all NCT03860597 560 563 O
subjects NCT03860597 564 572 O

- NCT03860597 575 576 O
open NCT03860597 578 582 B-Modifier
head NCT03860597 583 587 I-Modifier
injury NCT03860597 588 594 B-Condition
or NCT03860597 595 597 B-Or
closed NCT03860597 598 604 B-Modifier
head NCT03860597 605 609 I-Modifier
injury NCT03860597 610 616 B-Condition
with NCT03860597 617 621 B-And
loss NCT03860597 622 626 B-Condition
of NCT03860597 627 629 I-Condition
consciousness NCT03860597 630 643 I-Condition
> NCT03860597 644 645 B-Eq-Comparison
1 NCT03860597 646 647 I-Eq-Comparison
min NCT03860597 648 651 I-Eq-Comparison
for NCT03860597 652 655 O
all NCT03860597 656 659 O
subjects NCT03860597 660 668 O

- NCT03860597 671 672 O
hearing NCT03860597 674 681 B-Modifier
or NCT03860597 682 684 B-Or
visual NCT03860597 685 691 B-Modifier
impairment NCT03860597 692 702 B-Condition
for NCT03860597 703 706 O
all NCT03860597 707 710 O
subjects NCT03860597 711 719 O

- NCT03860597 722 723 O
pregnancy NCT03860597 725 734 B-Condition
for NCT03860597 735 738 O
all NCT03860597 739 742 O
subjects NCT03860597 743 751 O

- NCT03860597 754 755 O
dementia NCT03860597 757 765 B-Condition
for NCT03860597 766 769 O
all NCT03860597 770 773 O
subjects NCT03860597 774 782 O

- NCT03860597 785 786 O
mental NCT03860597 788 794 B-Condition
retardation NCT03860597 795 806 I-Condition
for NCT03860597 807 810 O
all NCT03860597 811 814 O
subjects NCT03860597 815 823 O

Inclusion NCT03861689 0 9 O
Criteria NCT03861689 10 18 O
: NCT03861689 19 20 O

- NCT03861689 24 25 O
Age NCT03861689 27 30 B-Age
≥ NCT03861689 31 32 B-Eq-Comparison
18 NCT03861689 33 35 I-Eq-Comparison
years NCT03861689 36 41 I-Eq-Comparison
old NCT03861689 42 45 O

- NCT03861689 48 49 O
Confirmed NCT03861689 51 60 O
diagnosis NCT03861689 61 70 O
of NCT03861689 71 73 O
perianal NCT03861689 74 82 B-Modifier
Crohn NCT03861689 83 88 B-Condition
's NCT03861689 88 90 I-Condition
disease NCT03861689 91 98 I-Condition

- NCT03861689 101 102 O
On NCT03861689 104 106 B-Eq-Comparison
biologics NCT03861689 107 116 B-Drug
or NCT03861689 117 119 B-Or
will NCT03861689 120 124 B-Eq-Comparison
start NCT03861689 125 130 I-Eq-Comparison
biologics NCT03861689 131 140 B-Drug

Exclusion NCT03861689 141 150 O
Criteria NCT03861689 151 159 O
: NCT03861689 160 161 O

- NCT03861689 165 166 O
Patients NCT03861689 168 176 O
who NCT03861689 177 180 O
have NCT03861689 181 185 O
perianal NCT03861689 186 194 B-Condition
fistula NCT03861689 195 202 I-Condition
due NCT03861689 203 206 O
to NCT03861689 207 209 O
causes NCT03861689 210 216 B-Condition
other NCT03861689 217 222 B-Exception
than NCT03861689 223 227 I-Exception
Crohn NCT03861689 228 233 B-Condition
's NCT03861689 233 235 I-Condition
disease NCT03861689 236 243 I-Condition

- NCT03861689 246 247 O
Fistulation NCT03861689 249 260 B-Condition
into NCT03861689 261 265 O
other NCT03861689 266 271 B-Other
organs NCT03861689 272 278 B-Modifier
, NCT03861689 279 280 O
including NCT03861689 281 290 O
bladder NCT03861689 291 298 B-Modifier
and NCT03861689 299 302 B-Or
intestine NCT03861689 303 312 B-Modifier

- NCT03861689 315 316 O
Patients NCT03861689 318 326 O
who NCT03861689 327 330 O
have NCT03861689 331 335 O
allergic NCT03861689 336 344 B-Allergy
reaction NCT03861689 345 353 B-Modifier
/ NCT03861689 354 355 B-Or
contraindications NCT03861689 356 373 B-Contraindication
to NCT03861689 374 376 O
anti NCT03861689 377 381 B-Drug
- NCT03861689 382 383 I-Drug
TNF NCT03861689 384 387 I-Drug

- NCT03861689 390 391 O
Patients NCT03861689 393 401 O
who NCT03861689 402 405 O
have NCT03861689 406 410 O
active NCT03861689 411 417 B-Eq-Comparison
cancer NCT03861689 418 424 B-Condition

- NCT03861689 427 428 O
Patients NCT03861689 430 438 O
who NCT03861689 439 442 O
have NCT03861689 443 447 O
contraindications NCT03861689 448 465 B-Contraindication
for NCT03861689 466 469 O
MRI NCT03861689 470 473 B-Procedure

- NCT03861689 476 477 O
Known NCT03861689 479 484 O
pregnancy NCT03861689 485 494 B-Condition

For NCT03861689 495 498 O
patients NCT03861689 499 507 O
who NCT03861689 508 511 O
refuse NCT03861689 512 518 O
to NCT03861689 519 521 O
participate NCT03861689 522 533 O
in NCT03861689 534 536 O
the NCT03861689 537 540 O
tight NCT03861689 541 546 O
monitoring NCT03861689 547 557 O
arm NCT03861689 558 561 O
, NCT03861689 562 563 O
they NCT03861689 564 568 O
will NCT03861689 569 573 O
be NCT03861689 574 576 O
consented NCT03861689 577 586 O
and NCT03861689 587 590 O
recruited NCT03861689 591 600 O
to NCT03861689 601 603 O
the NCT03861689 604 607 O
control NCT03861689 608 615 B-Procedure
arm NCT03861689 616 619 I-Procedure
for NCT03861689 620 623 O
comparison NCT03861689 624 634 O
. NCT03861689 635 636 O


Inclusion NCT03865160 0 9 O
Criteria NCT03865160 10 18 O
: NCT03865160 19 20 O

- NCT03865160 24 25 O
Children NCT03865160 27 35 O
aged NCT03865160 36 40 B-Age
6 NCT03865160 41 42 B-Eq-Comparison
- NCT03865160 43 44 I-Eq-Comparison
11 NCT03865160 45 47 I-Eq-Comparison
years NCT03865160 48 53 I-Eq-Comparison
with NCT03865160 54 58 B-And
- NCT03865160 59 60 B-Eq-Comparison
1 NCT03865160 61 62 I-Eq-Comparison
- NCT03865160 63 64 I-Eq-Comparison
to NCT03865160 65 67 I-Eq-Comparison
- NCT03865160 68 69 I-Eq-Comparison
10 NCT03865160 70 72 I-Eq-Comparison
diopters NCT03865160 73 81 I-Eq-Comparison
( NCT03865160 82 83 O
D NCT03865160 84 85 O
) NCT03865160 86 87 O
myopia NCT03865160 88 94 B-Condition|Observation

Exclusion NCT03865160 95 104 O
Criteria NCT03865160 105 113 O
: NCT03865160 114 115 O

- NCT03865160 119 120 O
Any NCT03865160 122 125 O
organic NCT03865160 126 133 B-Condition
eye NCT03865160 134 137 I-Condition
disease NCT03865160 138 145 I-Condition
, NCT03865160 146 147 O
strabismus NCT03865160 148 158 B-Condition
, NCT03865160 159 160 O
astigmatism NCT03865160 161 172 B-Condition
and NCT03865160 173 176 B-Or
/ NCT03865160 177 178 I-Or
or NCT03865160 179 181 I-Or
anisometropia NCT03865160 182 195 B-Condition|Observation
> NCT03865160 196 197 B-Eq-Comparison
1.5 NCT03865160 198 201 I-Eq-Comparison
D NCT03865160 202 203 I-Eq-Comparison
, NCT03865160 204 205 O
prematurity NCT03865160 206 217 B-Condition
, NCT03865160 218 219 O
use NCT03865160 220 223 B-Eq-Comparison
of NCT03865160 224 226 O
mono NCT03865160 227 231 B-Modifier
- NCT03865160 232 233 I-Modifier
/ NCT03865160 234 235 B-Or
multifocal NCT03865160 236 246 B-Modifier
contact NCT03865160 247 254 B-Procedure
lenses NCT03865160 255 261 I-Procedure
, NCT03865160 262 263 O
pre NCT03865160 264 267 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03865160 268 269 O
treatment NCT03865160 270 279 B-Procedure
with NCT03865160 280 284 O
atropine NCT03865160 285 293 B-Drug

Inclusion NCT03861312 0 9 O
Criteria NCT03861312 10 18 O
: NCT03861312 19 20 O

- NCT03861312 24 25 O
The NCT03861312 27 30 O
inclusion NCT03861312 31 40 O
criteria NCT03861312 41 49 O
were NCT03861312 50 54 O
as NCT03861312 55 57 O
follows NCT03861312 58 65 O
: NCT03861312 66 67 O
a NCT03861312 68 69 O
) NCT03861312 70 71 O
men NCT03861312 72 75 O
and NCT03861312 76 79 B-Or
women NCT03861312 80 85 O
aged NCT03861312 86 90 B-Age
between NCT03861312 91 98 B-Eq-Comparison
18 NCT03861312 99 101 I-Eq-Comparison
- NCT03861312 102 103 I-Eq-Comparison
and NCT03861312 104 107 I-Eq-Comparison
65 NCT03861312 108 110 I-Eq-Comparison
- NCT03861312 111 112 I-Eq-Comparison
years NCT03861312 113 118 I-Eq-Comparison
b NCT03861312 119 120 O
) NCT03861312 121 122 O
medical NCT03861312 123 130 O
diagnosis NCT03861312 131 140 O
of NCT03861312 141 143 O
Non NCT03861312 144 147 B-Modifier
- NCT03861312 148 149 I-Modifier
Specific NCT03861312 150 158 I-Modifier
Chronic NCT03861312 159 166 B-Modifier
Neck NCT03861312 167 171 I-Modifier
Pain NCT03861312 172 176 B-Condition
with NCT03861312 177 181 B-And
more NCT03861312 182 186 B-Eq-Comparison
than NCT03861312 187 191 I-Eq-Comparison
6 NCT03861312 192 193 I-Eq-Comparison
months NCT03861312 194 200 I-Eq-Comparison
of NCT03861312 201 203 O
evolution NCT03861312 204 213 O
of NCT03861312 214 216 O
neck NCT03861312 217 221 B-Modifier
pain NCT03861312 222 226 B-Condition
. NCT03861312 227 228 O

Exclusion NCT03861312 230 239 O
Criteria NCT03861312 240 248 O
: NCT03861312 249 250 O

- NCT03861312 254 255 O
Exclusion NCT03861312 257 266 O
criteria NCT03861312 267 275 O
included NCT03861312 276 284 O
the NCT03861312 285 288 O
following NCT03861312 289 298 O
: NCT03861312 299 300 O
a NCT03861312 301 302 O
) NCT03861312 303 304 O
patients NCT03861312 305 313 O
with NCT03861312 314 318 O
rheumatic NCT03861312 319 328 B-Condition
diseases NCT03861312 329 337 I-Condition
, NCT03861312 338 339 O
cervical NCT03861312 340 348 B-Condition
hernia NCT03861312 349 355 I-Condition
, NCT03861312 356 357 O
cervical NCT03861312 358 366 B-Condition
whiplash NCT03861312 367 375 I-Condition
syndrome NCT03861312 376 384 I-Condition
, NCT03861312 385 386 O
neck NCT03861312 387 391 B-Modifier
surgeries NCT03861312 392 401 B-Procedure
or NCT03861312 402 404 B-Or
history NCT03861312 405 412 B-Eq-Comparison
of NCT03861312 413 415 O
arthrodesis NCT03861312 416 427 B-Procedure
, NCT03861312 428 429 O
b NCT03861312 430 431 O
) NCT03861312 432 433 O
systemic NCT03861312 434 442 B-Modifier
diseases NCT03861312 443 451 B-Condition
, NCT03861312 452 453 O
c NCT03861312 454 455 O
) NCT03861312 456 457 O
vision NCT03861312 458 464 B-Modifier
, NCT03861312 465 466 O
hearing NCT03861312 467 474 B-Modifier
or NCT03861312 475 477 B-Or
vestibular NCT03861312 478 488 B-Modifier
problems NCT03861312 489 497 B-Condition
, NCT03861312 498 499 O
d NCT03861312 500 501 O
) NCT03861312 502 503 O
Severe NCT03861312 504 510 O
trauma NCT03861312 511 517 B-Condition
or NCT03861312 518 520 B-Or
traffic NCT03861312 521 528 B-Condition
accident NCT03861312 529 537 I-Condition
which NCT03861312 538 543 O
has NCT03861312 544 547 O
had NCT03861312 548 551 O
an NCT03861312 552 554 O
impact NCT03861312 555 561 O
on NCT03861312 562 564 O
the NCT03861312 565 568 O
cervical NCT03861312 569 577 B-Modifier
area NCT03861312 578 582 I-Modifier
. NCT03861312 582 583 O

Inclusion NCT03869996 0 9 O
Criteria NCT03869996 10 18 O
: NCT03869996 19 20 O

- NCT03869996 24 25 O
patients NCT03869996 27 35 O
affected NCT03869996 36 44 O
by NCT03869996 45 47 O
knee NCT03869996 48 52 B-Modifier
osteoarthritis NCT03869996 53 67 B-Condition
, NCT03869996 68 69 O
eligible NCT03869996 70 78 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869996 79 82 I-Assertion___Assertion-Type-Value:hypothetical
primary NCT03869996 83 90 B-Modifier
total NCT03869996 91 96 B-Procedure
knee NCT03869996 97 101 I-Procedure
arthroplasty NCT03869996 102 114 I-Procedure

- NCT03869996 117 118 O
BMI NCT03869996 120 123 B-Observation
< NCT03869996 124 125 B-Eq-Comparison
32 NCT03869996 126 128 I-Eq-Comparison

- NCT03869996 132 133 O
Time NCT03869996 135 139 B-Observation
up NCT03869996 140 142 I-Observation
ang NCT03869996 143 146 I-Observation
go NCT03869996 147 149 I-Observation
test NCT03869996 150 154 I-Observation
< NCT03869996 155 156 O
/ NCT03869996 158 159 I-Eq-Comparison
= NCT03869996 161 162 I-Eq-Comparison
12 NCT03869996 163 165 I-Eq-Comparison
seconds NCT03869996 166 173 I-Eq-Comparison

- NCT03869996 176 177 O
American NCT03869996 179 187 B-Condition
Society NCT03869996 188 195 I-Condition
of NCT03869996 196 198 I-Condition
Anesthesiologists NCT03869996 199 216 I-Condition
physical NCT03869996 217 225 O
status NCT03869996 226 232 O
classification NCT03869996 233 247 O
system NCT03869996 248 254 O
( NCT03869996 255 256 O
ASA NCT03869996 257 260 B-Condition
) NCT03869996 261 262 O
< NCT03869996 263 264 O
/ NCT03869996 266 267 O
= NCT03869996 269 270 O
2 NCT03869996 271 272 I-Eq-Comparison

- NCT03869996 276 277 O
pre NCT03869996 279 282 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03869996 283 292 B-Procedure
hemoglobin NCT03869996 293 303 B-Observation
( NCT03869996 304 305 O
HB NCT03869996 306 308 B-Observation
) NCT03869996 309 310 O
> NCT03869996 311 312 B-Eq-Comparison
13 NCT03869996 313 315 I-Eq-Comparison
g NCT03869996 316 317 I-Eq-Comparison
/ NCT03869996 318 319 I-Eq-Comparison
dl NCT03869996 320 322 I-Eq-Comparison

- NCT03869996 325 326 O
patients NCT03869996 328 336 O
eligible NCT03869996 337 345 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869996 346 349 I-Assertion___Assertion-Type-Value:hypothetical
spinal NCT03869996 350 356 B-Procedure
anesthesia NCT03869996 357 367 I-Procedure

- NCT03869996 370 371 O
presence NCT03869996 373 381 O
of NCT03869996 382 384 O
a NCT03869996 385 386 O
care NCT03869996 387 391 O
- NCT03869996 392 393 O
giver NCT03869996 394 399 O

Exclusion NCT03869996 400 409 O
Criteria NCT03869996 410 418 O
: NCT03869996 419 420 O

- NCT03869996 424 425 O
psychiatric NCT03869996 427 438 B-Condition
diseases NCT03869996 439 447 I-Condition

- NCT03869996 450 451 O
pre NCT03869996 453 456 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03869996 457 466 B-Procedure
use NCT03869996 467 470 O
of NCT03869996 471 473 O
crutches NCT03869996 474 482 B-Procedure

- NCT03869996 485 486 O
ASA NCT03869996 488 491 B-Condition
> NCT03869996 492 493 B-Eq-Comparison
3 NCT03869996 494 495 I-Eq-Comparison

- NCT03869996 499 500 O
pre NCT03869996 502 505 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03869996 506 515 B-Procedure
HB NCT03869996 516 518 B-Observation
< NCT03869996 519 520 B-Eq-Comparison
13 NCT03869996 521 523 I-Eq-Comparison
g NCT03869996 524 525 I-Eq-Comparison
/ NCT03869996 526 527 I-Eq-Comparison
dl NCT03869996 528 530 I-Eq-Comparison

Inclusion NCT03864874 0 9 O
Criteria NCT03864874 10 18 O
: NCT03864874 19 20 O

- NCT03864874 24 25 O
Patient NCT03864874 27 34 O
candidate NCT03864874 35 44 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864874 45 47 I-Assertion___Assertion-Type-Value:hypothetical
pulmonary NCT03864874 48 57 B-Procedure
metastasectomy NCT03864874 58 72 I-Procedure
with NCT03864874 73 77 O
curative NCT03864874 78 86 B-Modifier
intent NCT03864874 87 93 I-Modifier
by NCT03864874 94 96 O
mean NCT03864874 97 101 O
of NCT03864874 102 104 O
both NCT03864874 105 109 O
major NCT03864874 110 115 O
anatomical NCT03864874 116 126 B-Modifier
or NCT03864874 127 129 B-Or
limited NCT03864874 130 137 B-Modifier
resection NCT03864874 138 147 B-Procedure
; NCT03864874 147 148 O

- NCT03864874 151 152 O
Age NCT03864874 154 157 B-Age
> NCT03864874 158 159 B-Eq-Comparison
18 NCT03864874 160 162 I-Eq-Comparison
years NCT03864874 163 168 I-Eq-Comparison
. NCT03864874 169 170 O

Exclusion NCT03864874 172 181 O
Criteria NCT03864874 182 190 O
: NCT03864874 191 192 O

- NCT03864874 196 197 O
Patients NCT03864874 199 207 O
with NCT03864874 208 212 O
widespread NCT03864874 213 223 O
metastatic NCT03864874 224 234 B-Condition
disease NCT03864874 235 242 I-Condition
where NCT03864874 243 248 O
surgical NCT03864874 249 257 B-Procedure
resection NCT03864874 258 267 I-Procedure
is NCT03864874 268 270 B-Assertion___Assertion-Type-Value:hypothetical
performed NCT03864874 271 280 I-Assertion___Assertion-Type-Value:hypothetical
only NCT03864874 281 285 O
for NCT03864874 286 289 O
diagnostic NCT03864874 290 300 O
purposes NCT03864874 301 309 O
; NCT03864874 309 310 O

- NCT03864874 313 314 O
History NCT03864874 316 323 B-Eq-Comparison
of NCT03864874 324 326 I-Eq-Comparison
previous NCT03864874 327 335 I-Eq-Comparison
intrapleural NCT03864874 336 348 B-Procedure
talc NCT03864874 349 353 I-Procedure
injection NCT03864874 354 363 I-Procedure
; NCT03864874 363 364 O

- NCT03864874 367 368 O
Any NCT03864874 370 373 O
anatomical NCT03864874 374 384 B-Modifier
or NCT03864874 385 387 B-Or
pathological NCT03864874 388 400 B-Modifier
condition NCT03864874 401 410 B-Condition
( NCT03864874 411 412 O
eg NCT03864874 413 415 O
. NCT03864874 415 416 O
diffuse NCT03864874 418 425 B-Condition
adhesions NCT03864874 426 435 I-Condition
, NCT03864874 436 437 O
severe NCT03864874 438 444 O
emphysema NCT03864874 445 454 B-Condition
) NCT03864874 455 456 O
that NCT03864874 457 461 O
may NCT03864874 462 465 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864874 466 475 O
with NCT03864874 476 480 O
execution NCT03864874 481 490 O
of NCT03864874 491 493 O
ultrasonographic NCT03864874 494 510 B-Procedure
investigation NCT03864874 511 524 I-Procedure
; NCT03864874 524 525 O

- NCT03864874 528 529 O
Incomplete NCT03864874 531 541 B-Modifier
lung NCT03864874 542 546 B-Condition
exclusion NCT03864874 547 556 I-Condition
during NCT03864874 557 563 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgical NCT03864874 564 572 B-Procedure
procedure NCT03864874 573 582 I-Procedure
. NCT03864874 582 583 O

Inclusion NCT03869411 0 9 O
Criteria NCT03869411 10 18 O
: NCT03869411 19 20 O

- NCT03869411 24 25 O
Diabetes NCT03869411 27 35 O
group NCT03869411 36 41 O
: NCT03869411 42 43 O
1 NCT03869411 44 45 O
) NCT03869411 46 47 O
Age NCT03869411 48 51 B-Age
between NCT03869411 52 59 B-Eq-Comparison
30 NCT03869411 60 62 I-Eq-Comparison
- NCT03869411 63 64 I-Eq-Comparison
70 NCT03869411 65 67 I-Eq-Comparison
years NCT03869411 68 73 I-Eq-Comparison
of NCT03869411 74 76 O
old NCT03869411 77 80 O
, NCT03869411 81 82 O
2 NCT03869411 83 84 O
) NCT03869411 85 86 O
type NCT03869411 87 91 B-Modifier
2 NCT03869411 92 93 I-Modifier
diabetes NCT03869411 94 102 B-Condition
. NCT03869411 103 104 O

- NCT03869411 108 109 O
Healthy NCT03869411 111 118 B-Condition
control NCT03869411 119 126 O
group NCT03869411 127 132 O
: NCT03869411 133 134 O
1 NCT03869411 135 136 O
) NCT03869411 137 138 O
Age NCT03869411 139 142 B-Age
between NCT03869411 143 150 B-Eq-Comparison
30 NCT03869411 151 153 I-Eq-Comparison
- NCT03869411 154 155 I-Eq-Comparison
70 NCT03869411 156 158 I-Eq-Comparison
years NCT03869411 159 164 I-Eq-Comparison
of NCT03869411 165 167 O
old NCT03869411 168 171 O
, NCT03869411 172 173 O
2 NCT03869411 174 175 O
) NCT03869411 176 177 O
without NCT03869411 178 185 B-Negation
diabetes NCT03869411 186 194 B-Condition

Exclusion NCT03869411 195 204 O
Criteria NCT03869411 205 213 O
: NCT03869411 214 215 O

- NCT03869411 219 220 O
history NCT03869411 222 229 B-Eq-Comparison
of NCT03869411 230 232 O
moderate NCT03869411 233 241 B-Eq-Comparison
- NCT03869411 242 243 I-Eq-Comparison
severe NCT03869411 244 250 I-Eq-Comparison
somatic NCT03869411 251 258 B-Modifier
or NCT03869411 259 261 B-Or
autonomic NCT03869411 262 271 B-Modifier
neuropathy NCT03869411 272 282 B-Condition
, NCT03869411 283 284 O
cardiovascular NCT03869411 285 299 B-Condition
disease NCT03869411 300 307 I-Condition
, NCT03869411 308 309 O
preproliferative NCT03869411 310 326 B-Modifier
or NCT03869411 327 329 B-Or
proliferative NCT03869411 330 343 B-Modifier
retinopathy NCT03869411 344 355 B-Condition
, NCT03869411 356 357 O
and NCT03869411 358 361 B-Or
chronic NCT03869411 362 369 B-Modifier
renal NCT03869411 370 375 B-Condition
failure NCT03869411 376 383 I-Condition

- NCT03869411 386 387 O
unable NCT03869411 389 395 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03869411 396 398 O
perform NCT03869411 399 406 O
the NCT03869411 407 410 O
programs NCT03869411 411 419 B-Procedure
or NCT03869411 420 422 B-Or
assessments NCT03869411 423 434 B-Procedure

- NCT03869411 437 438 O
other NCT03869411 440 445 B-Other
systematic NCT03869411 446 456 B-Modifier
diseases NCT03869411 457 465 B-Condition

1 NCT03866044 0 1 O
. NCT03866044 1 2 O
Parkinson NCT03866044 4 13 B-Condition
's NCT03866044 13 15 I-Condition
Disease NCT03866044 16 23 I-Condition
( NCT03866044 24 25 O
PD NCT03866044 26 28 B-Condition
) NCT03866044 29 30 O
group NCT03866044 31 36 O
Inclusion NCT03866044 37 46 O
criteria NCT03866044 47 55 O
: NCT03866044 56 57 O

- NCT03866044 66 67 O
Aged NCT03866044 69 73 B-Age
18 NCT03866044 74 76 B-Eq-Comparison
or NCT03866044 77 79 I-Eq-Comparison
more NCT03866044 80 84 I-Eq-Comparison
. NCT03866044 85 86 O

- NCT03866044 95 96 O
Clinically NCT03866044 98 108 O
established NCT03866044 109 120 B-Modifier
or NCT03866044 121 123 B-Or
probable NCT03866044 124 132 B-Assertion___Assertion-Type-Value:possible
PD NCT03866044 133 135 B-Condition
according NCT03866044 136 145 O
to NCT03866044 146 148 O
the NCT03866044 149 152 O
Movement NCT03866044 153 161 O
Disorder NCT03866044 162 170 O
Society NCT03866044 171 178 O
Clinical NCT03866044 179 187 O
Diagnostic NCT03866044 188 198 O
Criteria NCT03866044 199 207 O
for NCT03866044 208 211 O
Parkinson NCT03866044 212 221 O
's NCT03866044 221 223 O
Disease NCT03866044 224 231 O

- NCT03866044 239 240 O
Signed NCT03866044 242 248 O
informed NCT03866044 249 257 O
consent NCT03866044 258 265 O
Exclusion NCT03866044 266 275 O
criteria NCT03866044 276 284 O
: NCT03866044 285 286 O

- NCT03866044 295 296 O
Pregnancy NCT03866044 298 307 B-Condition
or NCT03866044 308 310 B-Or
breastfeeding NCT03866044 311 324 B-Condition

- NCT03866044 332 333 O
History NCT03866044 335 342 B-Eq-Comparison
of NCT03866044 343 345 O
other NCT03866044 346 351 B-Other
neurologic NCT03866044 352 362 B-Modifier
or NCT03866044 363 365 B-Or
psychiatric NCT03866044 366 377 B-Modifier
disease NCT03866044 378 385 B-Condition

- NCT03866044 393 394 O
Pacemaker NCT03866044 396 405 B-Procedure
or NCT03866044 406 408 B-Or
other NCT03866044 409 414 B-Other
implanted NCT03866044 415 424 B-Procedure
electronic NCT03866044 425 435 I-Procedure
devices NCT03866044 436 443 I-Procedure

- NCT03866044 451 452 O
Claustrophobia NCT03866044 454 468 B-Condition

2 NCT03866044 471 472 O
. NCT03866044 472 473 O
Healthy NCT03866044 475 482 B-Condition
participants NCT03866044 483 495 O
age NCT03866044 496 499 O
- NCT03866044 500 501 O
and NCT03866044 502 505 O
sex NCT03866044 506 509 O
- NCT03866044 510 511 O
matched NCT03866044 512 519 O
to NCT03866044 520 522 O
the NCT03866044 523 526 O
PD NCT03866044 527 529 B-Condition
group NCT03866044 530 535 O
: NCT03866044 536 537 O

Inclusion NCT03866044 539 548 O
criteria NCT03866044 549 557 O
: NCT03866044 558 559 O

- NCT03866044 563 564 O
Age NCT03866044 566 569 O
- NCT03866044 570 571 O
and NCT03866044 572 575 O
sex NCT03866044 576 579 O
- NCT03866044 580 581 O
matched NCT03866044 582 589 O
to NCT03866044 590 592 O
PD NCT03866044 593 595 B-Condition
group NCT03866044 596 601 O
( NCT03866044 602 603 O
aged NCT03866044 604 608 B-Age
18 NCT03866044 609 611 B-Eq-Comparison
or NCT03866044 612 614 I-Eq-Comparison
more NCT03866044 615 619 I-Eq-Comparison
) NCT03866044 620 621 O

- NCT03866044 625 626 O
Signed NCT03866044 628 634 O
informed NCT03866044 635 643 O
consent NCT03866044 644 651 O

Exclusion NCT03866044 652 661 O
criteria NCT03866044 662 670 O
: NCT03866044 671 672 O

- NCT03866044 676 677 O
Pregnancy NCT03866044 679 688 B-Condition
or NCT03866044 689 691 B-Or
breastfeeding NCT03866044 692 705 B-Condition

- NCT03866044 708 709 O
History NCT03866044 711 718 B-Eq-Comparison
of NCT03866044 719 721 O
neurologic NCT03866044 722 732 B-Modifier
or NCT03866044 733 735 B-Or
psychiatric NCT03866044 736 747 B-Modifier
disease NCT03866044 748 755 B-Condition

- NCT03866044 758 759 O
Pacemaker NCT03866044 761 770 B-Procedure
or NCT03866044 771 773 B-Or
other NCT03866044 774 779 B-Other
implanted NCT03866044 780 789 B-Procedure
electronic NCT03866044 790 800 I-Procedure
devices NCT03866044 801 808 I-Procedure

- NCT03866044 811 812 O
Claustrophobia NCT03866044 814 828 B-Condition

Inclusion NCT03864653 0 9 O
Criteria NCT03864653 10 18 O
: NCT03864653 19 20 O

- NCT03864653 24 25 O
Currently NCT03864653 27 36 B-Eq-Comparison
enrolled NCT03864653 37 45 O
within NCT03864653 46 52 O
the NCT03864653 53 56 O
" NCT03864653 57 58 O
Getting NCT03864653 58 65 O
Off NCT03864653 66 69 O
" NCT03864653 69 70 O
( NCT03864653 71 72 O
AKA NCT03864653 73 76 O
, NCT03864653 77 78 O
" NCT03864653 79 80 O
Friends NCT03864653 80 87 O
Getting NCT03864653 88 95 O
Off NCT03864653 96 99 O
" NCT03864653 99 100 O
) NCT03864653 101 102 O
outpatient NCT03864653 103 113 B-Encounter
methamphetamine NCT03864653 114 129 B-Drug
treatment NCT03864653 130 139 B-Procedure
program NCT03864653 140 147 I-Procedure
at NCT03864653 148 150 O
Friends NCT03864653 151 158 O
Community NCT03864653 159 168 O
Center NCT03864653 169 175 O
, NCT03864653 176 177 O
Los NCT03864653 178 181 O
Angeles NCT03864653 182 189 O
, NCT03864653 190 191 O
CA NCT03864653 192 194 O
, NCT03864653 195 196 O
USA NCT03864653 197 200 O
. NCT03864653 201 202 O

- NCT03864653 206 207 O
and NCT03864653 209 212 B-And
; NCT03864653 212 213 O
within NCT03864653 214 220 B-Eq-Comparison
two NCT03864653 221 224 I-Eq-Comparison
weeks NCT03864653 225 230 I-Eq-Comparison
of NCT03864653 231 233 B-Temporal-Connection___Temporal-Connection-Type-Value:before
initial NCT03864653 234 241 B-Eq-Comparison
enrollment NCT03864653 242 252 B-Study
into NCT03864653 253 257 O
the NCT03864653 258 261 O
" NCT03864653 262 263 O
Getting NCT03864653 263 270 O
Off NCT03864653 271 274 O
" NCT03864653 274 275 O
program NCT03864653 276 283 B-Procedure
. NCT03864653 284 285 O

Exclusion NCT03864653 287 296 O
Criteria NCT03864653 297 305 O
: NCT03864653 306 307 O

- NCT03864653 311 312 O
Not NCT03864653 314 317 B-Negation
currently NCT03864653 318 327 B-Eq-Comparison
enrolled NCT03864653 328 336 B-Study
within NCT03864653 337 343 O
the NCT03864653 344 347 O
" NCT03864653 348 349 O
Getting NCT03864653 349 356 O
Off NCT03864653 357 360 O
" NCT03864653 360 361 O
program NCT03864653 362 369 B-Procedure
. NCT03864653 370 371 O

- NCT03864653 375 376 O
or NCT03864653 378 380 B-Or
; NCT03864653 380 381 O
more NCT03864653 382 386 B-Eq-Comparison
than NCT03864653 387 391 I-Eq-Comparison
two NCT03864653 392 395 I-Eq-Comparison
weeks NCT03864653 396 401 I-Eq-Comparison
post NCT03864653 402 406 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864653 407 408 O
enrollment NCT03864653 409 419 B-Study
in NCT03864653 420 422 O
the NCT03864653 423 426 O
" NCT03864653 427 428 O
Getting NCT03864653 428 435 O
Off NCT03864653 436 439 O
" NCT03864653 439 440 O
program NCT03864653 441 448 B-Procedure
. NCT03864653 448 449 O

Inclusion NCT03861065 0 9 O
Criteria NCT03861065 10 18 O
: NCT03861065 19 20 O

- NCT03861065 24 25 O
Patients NCT03861065 27 35 O
with NCT03861065 36 40 O
high NCT03861065 41 45 O
risk NCT03861065 46 50 B-Risk
class NCT03861065 51 56 B-Eq-Comparison
II NCT03861065 57 59 I-Eq-Comparison
, NCT03861065 60 61 I-Eq-Comparison
class NCT03861065 62 67 I-Eq-Comparison
III NCT03861065 68 71 I-Eq-Comparison
, NCT03861065 72 73 O
class NCT03861065 74 79 B-Eq-Comparison
IV NCT03861065 80 82 I-Eq-Comparison
abdominal NCT03861065 83 92 B-Modifier
wounds NCT03861065 93 99 B-Condition

- NCT03861065 102 103 O
Undergoing NCT03861065 105 115 B-Eq-Comparison
laparotomy NCT03861065 116 126 B-Procedure
for NCT03861065 127 130 O
gynecologic NCT03861065 131 142 B-Condition
related NCT03861065 143 150 I-Condition
disorders NCT03861065 151 160 I-Condition

- NCT03861065 163 164 O
Patients NCT03861065 166 174 O
undergoing NCT03861065 175 185 B-Eq-Comparison
laparotomy NCT03861065 186 196 B-Procedure
for NCT03861065 197 200 O
both NCT03861065 201 205 O
benign NCT03861065 206 212 B-Modifier
and NCT03861065 213 216 B-Or
malignant NCT03861065 217 226 B-Modifier
diagnoses NCT03861065 227 236 B-Condition
will NCT03861065 237 241 O
be NCT03861065 242 244 O
included NCT03861065 245 253 O
in NCT03861065 254 256 O
this NCT03861065 257 261 O
study NCT03861065 262 267 B-Study

Exclusion NCT03861065 268 277 O
Criteria NCT03861065 278 286 O
: NCT03861065 287 288 O

- NCT03861065 292 293 O
Pregnancy NCT03861065 295 304 B-Condition

- NCT03861065 307 308 O
Allergy NCT03861065 310 317 B-Allergy
to NCT03861065 318 320 O
triclosan NCT03861065 321 330 B-Drug

- NCT03861065 333 334 O
Patients NCT03861065 336 344 O
undergoing NCT03861065 345 355 B-Eq-Comparison
HIPEC NCT03861065 356 361 B-Procedure

Inclusion NCT03866291 0 9 O
Criteria NCT03866291 10 18 O
: NCT03866291 19 20 O

- NCT03866291 24 25 O
Travellers NCT03866291 27 37 B-Modifier
diarrhoea NCT03866291 38 47 B-Condition

- NCT03866291 50 51 O
foreign NCT03866291 53 60 O
traveller NCT03866291 61 70 O

Exclusion NCT03866291 71 80 O
Criteria NCT03866291 81 89 O
: NCT03866291 90 91 O

- NCT03866291 95 96 O
foreign NCT03866291 98 105 O
traveller NCT03866291 106 115 O
but NCT03866291 116 119 B-And
no NCT03866291 120 122 B-Negation
symptoms NCT03866291 123 131 B-Coreference

Inclusion NCT03867825 0 9 O
Criteria NCT03867825 10 18 O
: NCT03867825 19 20 O

- NCT03867825 24 25 O
Newborn NCT03867825 27 34 O
infants NCT03867825 35 42 O

Exclusion NCT03867825 43 52 O
Criteria NCT03867825 53 61 O
: NCT03867825 62 63 O

- NCT03867825 67 68 O
Infants NCT03867825 70 77 O
> NCT03867825 78 79 B-Eq-Comparison
1 NCT03867825 80 81 I-Eq-Comparison
month NCT03867825 82 87 I-Eq-Comparison
of NCT03867825 88 90 O
age NCT03867825 91 94 B-Age

Inclusion NCT03868280 0 9 O
Criteria NCT03868280 10 18 O
: NCT03868280 19 20 O

- NCT03868280 24 25 O
Mid NCT03868280 27 30 B-Modifier
shaft NCT03868280 31 36 I-Modifier
or NCT03868280 37 39 B-Or
subtrochanteric NCT03868280 40 55 B-Modifier
femur NCT03868280 56 61 I-Modifier
fracture NCT03868280 62 70 B-Condition
appropriate NCT03868280 71 82 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868280 83 86 O
antegrade NCT03868280 87 96 B-Procedure
fixation NCT03868280 97 105 I-Procedure

- NCT03868280 108 109 O
Surgeon NCT03868280 111 118 B-Provider
agreement NCT03868280 119 128 O
for NCT03868280 129 132 O
participation NCT03868280 133 146 O
in NCT03868280 147 149 O
study NCT03868280 150 155 B-Study

- NCT03868280 158 159 O
Ability NCT03868280 161 168 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868280 169 171 I-Assertion___Assertion-Type-Value:hypothetical
obtain NCT03868280 172 178 O
peri NCT03868280 179 183 B-Procedure
operative NCT03868280 184 193 I-Procedure
imaging NCT03868280 194 201 I-Procedure
( NCT03868280 202 203 O
CT NCT03868280 204 206 B-Procedure
scans NCT03868280 207 212 I-Procedure
) NCT03868280 213 214 O

- NCT03868280 218 219 O
Provision NCT03868280 221 230 O
of NCT03868280 231 233 O
informed NCT03868280 234 242 O
consent NCT03868280 243 250 O

Exclusion NCT03868280 251 260 O
Criteria NCT03868280 261 269 O
: NCT03868280 270 271 O

- NCT03868280 275 276 O
Inability NCT03868280 278 287 O
to NCT03868280 288 290 O
provide NCT03868280 291 298 O
informed NCT03868280 299 307 O
consent NCT03868280 308 315 O
( NCT03868280 316 317 O
e. NCT03868280 318 320 O
g. NCT03868280 321 323 O
cognitive NCT03868280 325 334 B-Condition
disability NCT03868280 335 345 I-Condition
, NCT03868280 346 347 O
language NCT03868280 348 356 B-Condition
barrier NCT03868280 357 364 I-Condition
) NCT03868280 365 366 O

- NCT03868280 370 371 O
Bilateral NCT03868280 373 382 B-Modifier
Femoral NCT03868280 383 390 I-Modifier
Fractures NCT03868280 391 400 B-Condition

- NCT03868280 403 404 O
Inability NCT03868280 406 415 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868280 416 418 B-Or
lack NCT03868280 419 423 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03868280 424 426 I-Assertion___Assertion-Type-Value:hypothetical|Negation
willingness NCT03868280 427 438 I-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868280 439 441 O
attend NCT03868280 442 448 O
follow NCT03868280 449 455 B-Encounter
up NCT03868280 456 458 I-Encounter

- NCT03868280 461 462 O
Ipsilateral NCT03868280 464 475 B-Modifier
tibial NCT03868280 476 482 B-Condition
fracture NCT03868280 483 491 I-Condition

- NCT03868280 494 495 O
Ipsilateral NCT03868280 497 508 B-Modifier
femoral NCT03868280 509 516 I-Modifier
neck NCT03868280 517 521 I-Modifier
fracture NCT03868280 522 530 B-Condition

- NCT03868280 533 534 O
Ipsilateral NCT03868280 536 547 B-Modifier
acetabular NCT03868280 548 558 I-Modifier
fracture NCT03868280 559 567 B-Condition

- NCT03868280 570 571 O
Pregnant NCT03868280 573 581 B-Condition
or NCT03868280 582 584 B-Or
breastfeeding NCT03868280 585 598 B-Condition

- NCT03868280 601 602 O
Contraindications NCT03868280 604 621 B-Contraindication
to NCT03868280 622 624 O
CT NCT03868280 625 627 B-Procedure
imaging NCT03868280 628 635 I-Procedure
including NCT03868280 636 645 O
impaired NCT03868280 646 654 B-Condition
kidney NCT03868280 655 661 I-Condition
/ NCT03868280 662 663 B-Or
liver NCT03868280 664 669 B-Condition
function NCT03868280 670 678 I-Condition
, NCT03868280 679 680 O
or NCT03868280 681 683 B-Or
lack NCT03868280 684 688 O
of NCT03868280 689 691 O
timely NCT03868280 692 698 O
availability NCT03868280 699 711 O

- NCT03868280 714 715 O
Periprosthetic NCT03868280 717 731 B-Modifier
fracture NCT03868280 732 740 B-Condition

- NCT03868280 743 744 O
Pathologic NCT03868280 746 756 B-Modifier
fracture NCT03868280 757 765 B-Condition

- NCT03868280 768 769 O
Significant NCT03868280 771 782 O
delirium NCT03868280 783 791 B-Condition
or NCT03868280 792 794 B-Or
dementia NCT03868280 795 803 B-Condition

Inclusion NCT03860623 0 9 O
Criteria NCT03860623 10 18 O
: NCT03860623 19 20 O

- NCT03860623 24 25 O
BMI NCT03860623 27 30 B-Observation
30 NCT03860623 31 33 B-Eq-Comparison
- NCT03860623 34 35 I-Eq-Comparison
40 NCT03860623 36 38 I-Eq-Comparison
kg NCT03860623 39 41 I-Eq-Comparison
/ NCT03860623 42 43 I-Eq-Comparison
m2 NCT03860623 44 46 I-Eq-Comparison

- NCT03860623 49 50 O
BMI NCT03860623 52 55 B-Observation
18 NCT03860623 56 58 B-Eq-Comparison
- NCT03860623 59 60 I-Eq-Comparison
25 NCT03860623 61 63 I-Eq-Comparison
kg NCT03860623 64 66 I-Eq-Comparison
/ NCT03860623 67 68 I-Eq-Comparison
m2 NCT03860623 69 71 I-Eq-Comparison
; NCT03860623 71 72 O
those NCT03860623 73 78 O
with NCT03860623 79 83 O
BMI NCT03860623 84 87 B-Observation
up NCT03860623 88 90 B-Eq-Comparison
to NCT03860623 91 93 I-Eq-Comparison
28 NCT03860623 94 96 I-Eq-Comparison
kg NCT03860623 97 99 I-Eq-Comparison
/ NCT03860623 100 101 I-Eq-Comparison
m2 NCT03860623 102 104 I-Eq-Comparison
will NCT03860623 105 109 O
be NCT03860623 110 112 O
included NCT03860623 113 121 O
if NCT03860623 122 124 O
waist NCT03860623 125 130 B-Observation
circumference NCT03860623 131 144 I-Observation
is NCT03860623 145 147 O
< NCT03860623 148 149 B-Eq-Comparison
96 NCT03860623 150 152 I-Eq-Comparison
cm NCT03860623 153 155 O
. NCT03860623 156 157 O

- NCT03860623 161 162 O
Males NCT03860623 164 169 O

- NCT03860623 172 173 O
Aged NCT03860623 175 179 B-Age
18 NCT03860623 180 182 B-Eq-Comparison
- NCT03860623 183 184 I-Eq-Comparison
60 NCT03860623 185 187 I-Eq-Comparison
yrs NCT03860623 188 191 I-Eq-Comparison

Exclusion NCT03860623 192 201 O
Criteria NCT03860623 202 210 O
: NCT03860623 211 212 O

- NCT03860623 216 217 O
Acute NCT03860623 219 224 O
illness NCT03860623 225 232 B-Condition
in NCT03860623 233 235 O
the NCT03860623 236 239 O
preceding NCT03860623 240 249 B-Eq-Comparison
6 NCT03860623 250 251 I-Eq-Comparison
weeks NCT03860623 252 257 I-Eq-Comparison

- NCT03860623 260 261 O
Taking NCT03860623 263 269 B-Eq-Comparison
regular NCT03860623 270 277 O
medication NCT03860623 278 288 B-Drug

- NCT03860623 291 292 O
History NCT03860623 294 301 B-Eq-Comparison
of NCT03860623 302 304 O
deep NCT03860623 305 309 B-Condition
vein NCT03860623 310 314 I-Condition
thrombosis NCT03860623 315 325 I-Condition
or NCT03860623 326 328 B-Or
clotting NCT03860623 329 337 B-Condition
disorders NCT03860623 338 347 I-Condition

- NCT03860623 350 351 O
Hypertension NCT03860623 353 365 B-Condition

- NCT03860623 368 369 O
Diabetes NCT03860623 371 379 B-Condition

- NCT03860623 382 383 O
Any NCT03860623 385 388 O
clinically NCT03860623 389 399 O
significant NCT03860623 400 411 O
findings NCT03860623 412 420 B-Condition
at NCT03860623 421 423 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03860623 424 433 B-Study

- NCT03860623 436 437 O
History NCT03860623 439 446 B-Eq-Comparison
of NCT03860623 447 449 O
substance NCT03860623 450 459 B-Condition
abuse NCT03860623 460 465 I-Condition

- NCT03860623 468 469 O
Demonstrating NCT03860623 471 484 O
factors NCT03860623 485 492 B-Condition
precluding NCT03860623 493 503 B-Contraindication
safe NCT03860623 504 508 O
MRI NCT03860623 509 512 B-Procedure

- NCT03860623 515 516 O
History NCT03860623 518 525 B-Eq-Comparison
of NCT03860623 526 528 O
gastrointestinal NCT03860623 529 545 B-Condition
motility NCT03860623 546 554 I-Condition
disorders NCT03860623 555 564 I-Condition
( NCT03860623 565 566 O
e. NCT03860623 567 569 O
g. NCT03860623 570 572 O
gastroesophageal NCT03860623 574 590 B-Condition
reflux NCT03860623 591 597 I-Condition
disease NCT03860623 598 605 I-Condition
- NCT03860623 606 607 O
irritable NCT03860623 608 617 B-Condition
bowel NCT03860623 618 623 I-Condition
syndrome NCT03860623 624 632 I-Condition
, NCT03860623 633 634 O
gastroparesis NCT03860623 635 648 B-Condition
, NCT03860623 649 650 O
sphincter NCT03860623 651 660 B-Condition
of NCT03860623 661 663 I-Condition
Oddi NCT03860623 664 668 I-Condition
dysfunction NCT03860623 669 680 I-Condition
, NCT03860623 681 682 O
etc NCT03860623 683 686 O
. NCT03860623 686 687 O
) NCT03860623 688 689 O

- NCT03860623 693 694 O
Previous NCT03860623 696 704 B-Eq-Comparison
thoracic NCT03860623 705 713 B-Modifier
or NCT03860623 714 716 B-Or
abdominal NCT03860623 717 726 B-Modifier
surgery NCT03860623 727 734 B-Procedure
. NCT03860623 735 736 O

- NCT03860623 740 741 O
Those NCT03860623 743 748 O
who NCT03860623 749 752 O
report NCT03860623 753 759 O
having NCT03860623 760 766 O
≤ NCT03860623 767 768 B-Eq-Comparison
3 NCT03860623 769 770 I-Eq-Comparison
bowel NCT03860623 771 776 B-Observation
movements NCT03860623 777 786 I-Observation
/ NCT03860623 787 788 O
week NCT03860623 789 793 O
or NCT03860623 794 796 B-Or
> NCT03860623 797 798 B-Eq-Comparison
2 NCT03860623 799 800 I-Eq-Comparison
/ NCT03860623 801 802 I-Eq-Comparison
day NCT03860623 803 806 I-Eq-Comparison
. NCT03860623 806 807 O

Inclusion NCT03866252 0 9 O
Criteria NCT03866252 10 18 O
: NCT03866252 19 20 O

- NCT03866252 24 25 O
Major NCT03866252 27 32 O
Depressive NCT03866252 33 43 B-Condition
Disorder NCT03866252 44 52 I-Condition
according NCT03866252 53 62 O
to NCT03866252 63 65 O
Diagnostic NCT03866252 66 76 O
and NCT03866252 77 80 O
Statistical NCT03866252 81 92 O
Manual NCT03866252 93 99 O
of NCT03866252 100 102 O
Mental NCT03866252 103 109 O
Disorders NCT03866252 110 119 O
( NCT03866252 120 121 O
DSM NCT03866252 122 125 O
- NCT03866252 126 127 O
V NCT03866252 128 129 O
) NCT03866252 130 131 O

- NCT03866252 135 136 O
> NCT03866252 138 139 B-Eq-Comparison
25 NCT03866252 140 142 I-Eq-Comparison
years NCT03866252 143 148 I-Age|Eq-Comparison

- NCT03866252 151 152 O
Sufficient NCT03866252 154 164 O
understanding NCT03866252 165 178 O
of NCT03866252 179 181 O
the NCT03866252 182 185 O
German NCT03866252 186 192 O
language NCT03866252 193 201 O

Exclusion NCT03866252 202 211 O
Criteria NCT03866252 212 220 O
: NCT03866252 221 222 O

- NCT03866252 226 227 O
< NCT03866252 229 230 B-Eq-Comparison
25 NCT03866252 231 233 I-Eq-Comparison
years NCT03866252 234 239 I-Age|Eq-Comparison

- NCT03866252 242 243 O
Concomitant NCT03866252 245 256 O
diagnosis NCT03866252 257 266 O
of NCT03866252 267 269 O
past NCT03866252 270 274 B-Eq-Comparison
or NCT03866252 275 277 B-Or
present NCT03866252 278 285 B-Eq-Comparison
psychotic NCT03866252 286 295 B-Condition
disorder NCT03866252 296 304 I-Condition

- NCT03866252 307 308 O
Concomitant NCT03866252 310 321 O
diagnosis NCT03866252 322 331 O
of NCT03866252 332 334 O
past NCT03866252 335 339 B-Eq-Comparison
or NCT03866252 340 342 B-Or
present NCT03866252 343 350 B-Eq-Comparison
bipolar NCT03866252 351 358 B-Condition
disorder NCT03866252 359 367 I-Condition

- NCT03866252 370 371 O
First NCT03866252 373 378 B-Family-Member
degree NCT03866252 379 385 I-Family-Member
relative NCT03866252 386 394 I-Family-Member
with NCT03866252 395 399 O
a NCT03866252 400 401 O
psychotic NCT03866252 402 411 B-Condition
disorder NCT03866252 412 420 I-Condition

- NCT03866252 423 424 O
Unable NCT03866252 426 432 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03866252 433 435 B-Or
unwilling NCT03866252 436 445 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866252 446 448 O
discontinue NCT03866252 449 460 B-Negation
antidepressant NCT03866252 461 475 B-Drug
medication NCT03866252 476 486 I-Drug

- NCT03866252 489 490 O
Pregnancy NCT03866252 492 501 B-Condition
or NCT03866252 502 504 B-Or
breastfeeding NCT03866252 505 518 B-Condition

- NCT03866252 521 522 O
Known NCT03866252 524 529 O
hypersensitivity NCT03866252 530 546 B-Condition
to NCT03866252 547 549 O
LSD NCT03866252 550 553 B-Drug

- NCT03866252 556 557 O
Somatic NCT03866252 559 566 B-Condition
disorders NCT03866252 567 576 I-Condition
including NCT03866252 577 586 O
central NCT03866252 587 594 B-Condition
nervous NCT03866252 595 602 I-Condition
system NCT03866252 603 609 I-Condition
( NCT03866252 610 611 O
CNS NCT03866252 612 615 B-Condition
) NCT03866252 616 617 O
involvement NCT03866252 618 629 B-Modifier

- NCT03866252 632 633 O
Known NCT03866252 635 640 O
or NCT03866252 641 643 B-Or
suspected NCT03866252 644 653 B-Assertion___Assertion-Type-Value:possible
non NCT03866252 654 657 B-Negation
- NCT03866252 658 659 O
compliance NCT03866252 660 670 B-Modifier
, NCT03866252 671 672 O
drug NCT03866252 673 677 B-Modifier
or NCT03866252 678 680 B-Or
alcohol NCT03866252 681 688 B-Modifier
abuse NCT03866252 689 694 B-Condition

- NCT03866252 697 698 O
Metal NCT03866252 700 705 B-Procedure
implants NCT03866252 706 714 I-Procedure

- NCT03866252 717 718 O
Weight NCT03866252 720 726 B-Observation
< NCT03866252 727 728 B-Eq-Comparison
42 NCT03866252 729 731 I-Eq-Comparison
kg NCT03866252 732 734 I-Eq-Comparison

- NCT03866252 737 738 O
Suicide NCT03866252 740 747 B-Condition
risk NCT03866252 748 752 B-Risk
or NCT03866252 753 755 B-Or
very NCT03866252 756 760 O
likely NCT03866252 761 767 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866252 768 770 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03866252 771 778 O
psychiatric NCT03866252 779 790 B-Condition
hospitalisation NCT03866252 791 806 B-Encounter

Inclusion NCT03863470 0 9 O
Criteria NCT03863470 10 18 O
: NCT03863470 19 20 O

- NCT03863470 24 25 O
Age NCT03863470 27 30 B-Age
≥ NCT03863470 31 32 B-Eq-Comparison
18 NCT03863470 33 35 I-Eq-Comparison
years NCT03863470 36 41 I-Eq-Comparison
old NCT03863470 42 45 O
; NCT03863470 45 46 O
AND NCT03863470 47 50 B-And

- NCT03863470 53 54 O
Admission NCT03863470 56 65 B-Encounter
to NCT03863470 66 68 O
1 NCT03863470 69 70 O
of NCT03863470 71 73 O
12 NCT03863470 74 76 O
participating NCT03863470 77 90 O
ICUs NCT03863470 91 95 O
; NCT03863470 95 96 O
AND NCT03863470 97 100 B-And

- NCT03863470 103 104 O
Continuous NCT03863470 106 116 B-Modifier
mechanical NCT03863470 117 127 B-Procedure
ventilation NCT03863470 128 139 I-Procedure
for NCT03863470 140 143 O
≥ NCT03863470 144 145 B-Eq-Comparison
48 NCT03863470 146 148 I-Eq-Comparison
hours NCT03863470 149 154 I-Eq-Comparison
( NCT03863470 155 156 O
without NCT03863470 157 164 B-Modifier
interruption NCT03863470 165 177 I-Modifier
) NCT03863470 178 179 O
; NCT03863470 180 181 O
AND NCT03863470 182 185 B-And

- NCT03863470 188 189 O
Baseline NCT03863470 191 199 O
independent NCT03863470 200 211 B-Condition
ambulatory NCT03863470 212 222 I-Condition
status NCT03863470 223 229 O

Exclusion NCT03863470 230 239 O
Criteria NCT03863470 240 248 O
: NCT03863470 249 250 O

- NCT03863470 254 255 O
Admitting NCT03863470 257 266 O
diagnosis NCT03863470 267 276 O
of NCT03863470 277 279 O
any NCT03863470 280 283 O
of NCT03863470 284 286 O
the NCT03863470 287 290 B-Criteria-Count
following NCT03863470 291 300 I-Criteria-Count
conditions NCT03863470 301 311 I-Criteria-Count
: NCT03863470 312 313 O

- NCT03863470 322 323 O
Cardiopulmonary NCT03863470 325 340 B-Condition
arrest NCT03863470 341 347 I-Condition

- NCT03863470 355 356 O
Raised NCT03863470 358 364 O
intracranial NCT03863470 365 377 B-Condition
pressure NCT03863470 378 386 I-Condition

- NCT03863470 394 395 O
Acute NCT03863470 397 402 O
neurological NCT03863470 403 415 B-Modifier
admission NCT03863470 416 425 O
diagnosis NCT03863470 426 435 B-Condition

- NCT03863470 443 444 O
Subarachnoid NCT03863470 446 458 B-Condition
hemorrhage NCT03863470 459 469 I-Condition

- NCT03863470 477 478 O
Ischemic NCT03863470 480 488 B-Modifier
stroke NCT03863470 489 495 B-Condition

Inclusion NCT03862183 0 9 O
Criteria NCT03862183 10 18 O
: NCT03862183 19 20 O

1 NCT03862183 24 25 O
. NCT03862183 25 26 O
Outpatients NCT03862183 28 39 B-Encounter
from NCT03862183 40 44 O
departments NCT03862183 45 56 O
of NCT03862183 57 59 O
Cardiology NCT03862183 60 70 B-Provider
, NCT03862183 71 72 O
Endocrinology NCT03862183 73 86 B-Provider
, NCT03862183 87 88 O
Nephrology NCT03862183 89 99 B-Provider
, NCT03862183 100 101 O
Neurology NCT03862183 102 111 B-Provider
, NCT03862183 112 113 O
Geriatrics NCT03862183 114 124 B-Provider
or NCT03862183 125 127 B-Or
General NCT03862183 128 135 B-Provider
Internal NCT03862183 136 144 I-Provider
Medicine NCT03862183 145 153 I-Provider
. NCT03862183 154 155 O

2 NCT03862183 159 160 O
. NCT03862183 160 161 O
Diagnosed NCT03862183 163 172 O
as NCT03862183 173 175 O
hypertension NCT03862183 176 188 B-Condition
. NCT03862183 188 189 O
Diagnostic NCT03862183 191 201 O
criteria NCT03862183 202 210 O
: NCT03862183 211 212 O
1 NCT03862183 213 214 O
) NCT03862183 215 216 O
The NCT03862183 217 220 O
office NCT03862183 221 227 O
BP NCT03862183 228 230 B-Observation
measured NCT03862183 231 239 O
at NCT03862183 240 242 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862183 243 246 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03862183 247 250 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862183 251 253 O
visit NCT03862183 254 259 B-Encounter
and NCT03862183 260 263 O
at NCT03862183 264 266 B-Eq-Comparison
least NCT03862183 267 272 I-Eq-Comparison
one NCT03862183 273 276 I-Eq-Comparison
time NCT03862183 277 281 I-Eq-Comparison
before NCT03862183 282 288 B-Temporal-Connection___Temporal-Connection-Type-Value:before
that NCT03862183 289 293 O
day NCT03862183 294 297 O
were NCT03862183 298 302 O
above NCT03862183 303 308 B-Eq-Comparison
the NCT03862183 309 312 I-Eq-Comparison
cut NCT03862183 313 316 I-Eq-Comparison
- NCT03862183 317 318 I-Eq-Comparison
off NCT03862183 319 322 I-Eq-Comparison
values NCT03862183 323 329 I-Eq-Comparison
( NCT03862183 330 331 O
≥ NCT03862183 332 333 B-Eq-Comparison
140 NCT03862183 334 337 I-Eq-Comparison
mmHg NCT03862183 338 342 I-Eq-Comparison
SBP NCT03862183 343 346 I-Eq-Comparison|Observation
and NCT03862183 347 350 B-Or
/ NCT03862183 351 352 I-Or
or NCT03862183 353 355 I-Or
≥ NCT03862183 356 357 B-Eq-Comparison
90 NCT03862183 358 360 I-Eq-Comparison
mmHg NCT03862183 361 365 I-Eq-Comparison
DBP NCT03862183 366 369 I-Eq-Comparison|Observation
) NCT03862183 370 371 O
; NCT03862183 372 373 O
2 NCT03862183 374 375 O
) NCT03862183 376 377 O
for NCT03862183 378 381 O
patients NCT03862183 382 390 O
with NCT03862183 391 395 O
normal NCT03862183 396 402 O
BP NCT03862183 403 405 B-Observation
at NCT03862183 406 408 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862183 409 412 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03862183 413 416 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862183 417 419 O
visit NCT03862183 420 425 B-Encounter
, NCT03862183 426 427 O
they NCT03862183 428 432 O
should NCT03862183 433 439 O
have NCT03862183 440 444 O
already NCT03862183 445 452 O
been NCT03862183 453 457 O
given NCT03862183 458 463 B-Eq-Comparison
pre NCT03862183 464 467 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862183 468 469 O
treatment NCT03862183 470 479 B-Procedure
with NCT03862183 480 484 O
antihypertensive NCT03862183 485 501 B-Drug
drugs NCT03862183 502 507 I-Drug
≥ NCT03862183 508 509 B-Eq-Comparison
2 NCT03862183 510 511 I-Eq-Comparison
weeks NCT03862183 512 517 I-Eq-Comparison
. NCT03862183 518 519 O

3 NCT03862183 523 524 O
. NCT03862183 524 525 O
Voluntary NCT03862183 527 536 O
participation NCT03862183 537 550 O
. NCT03862183 551 552 O

Exclusion NCT03862183 554 563 O
Criteria NCT03862183 564 572 O
: NCT03862183 573 574 O

1 NCT03862183 578 579 O
. NCT03862183 579 580 O
Patients NCT03862183 582 590 O
aged NCT03862183 591 595 B-Age
< NCT03862183 596 597 B-Eq-Comparison
18 NCT03862183 598 600 I-Eq-Comparison
years NCT03862183 601 606 I-Eq-Comparison
old NCT03862183 607 610 O
. NCT03862183 611 612 O

2 NCT03862183 616 617 O
. NCT03862183 617 618 O
Patients NCT03862183 620 628 O
without NCT03862183 629 636 B-Negation
a NCT03862183 637 638 O
definite NCT03862183 639 647 O
diagnosis NCT03862183 648 657 O
of NCT03862183 658 660 O
hypertension NCT03862183 661 673 B-Condition
（ NCT03862183 674 675 O
for NCT03862183 676 679 O
instance NCT03862183 680 688 O
, NCT03862183 689 690 O
if NCT03862183 691 693 O
the NCT03862183 694 697 O
patient NCT03862183 698 705 O
has NCT03862183 706 709 O
been NCT03862183 710 714 O
taking NCT03862183 715 721 B-Eq-Comparison
antihypertensive NCT03862183 722 738 B-Drug
drugs NCT03862183 739 744 I-Drug
irregularly NCT03862183 745 756 O
, NCT03862183 757 758 O
it NCT03862183 759 761 O
is NCT03862183 762 764 O
difficult NCT03862183 765 774 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862183 775 777 I-Assertion___Assertion-Type-Value:hypothetical
confirm NCT03862183 778 785 O
the NCT03862183 786 789 O
diagnosis NCT03862183 790 799 O
of NCT03862183 800 802 O
hypertension NCT03862183 803 815 B-Condition
） NCT03862183 815 816 O
. NCT03862183 817 818 O

3 NCT03862183 822 823 O
. NCT03862183 823 824 O
Patients NCT03862183 826 834 O
with NCT03862183 835 839 O
a NCT03862183 840 841 O
definite NCT03862183 842 850 O
diagnosis NCT03862183 851 860 O
of NCT03862183 861 863 O
secondary NCT03862183 864 873 B-Modifier
hypertension NCT03862183 874 886 B-Condition
. NCT03862183 887 888 O

4 NCT03862183 892 893 O
. NCT03862183 893 894 O
Patients NCT03862183 896 904 O
are NCT03862183 905 908 O
diagnosed NCT03862183 909 918 O
dyslipidemia NCT03862183 919 931 B-Condition
with NCT03862183 932 936 O
clear NCT03862183 937 942 O
cause NCT03862183 943 948 B-Condition
, NCT03862183 949 950 O
such NCT03862183 951 955 O
as NCT03862183 956 958 O
nephrotic NCT03862183 959 968 B-Condition
syndrome NCT03862183 969 977 I-Condition
, NCT03862183 978 979 O
severe NCT03862183 980 986 O
hypothyroidism NCT03862183 987 1001 B-Condition
, NCT03862183 1002 1003 O
terminal NCT03862183 1004 1012 B-Eq-Comparison
stage NCT03862183 1013 1018 I-Eq-Comparison
of NCT03862183 1019 1021 O
malignancy NCT03862183 1022 1032 B-Condition
, NCT03862183 1033 1034 O
etc NCT03862183 1035 1038 O
. NCT03862183 1039 1040 O

5 NCT03862183 1044 1045 O
. NCT03862183 1045 1046 O
Patients NCT03862183 1048 1056 O
are NCT03862183 1057 1060 O
diagnosed NCT03862183 1061 1070 O
end NCT03862183 1071 1074 B-Eq-Comparison
- NCT03862183 1075 1076 I-Eq-Comparison
stage NCT03862183 1077 1082 I-Eq-Comparison
renal NCT03862183 1083 1088 B-Condition
disease NCT03862183 1089 1096 I-Condition
, NCT03862183 1097 1098 O
hemodialysis NCT03862183 1099 1111 B-Procedure
, NCT03862183 1112 1113 O
and NCT03862183 1114 1117 B-Or
peritoneal NCT03862183 1118 1128 B-Procedure
dialysis NCT03862183 1129 1137 I-Procedure
patients NCT03862183 1138 1146 O
. NCT03862183 1147 1148 O

6 NCT03862183 1152 1153 O
. NCT03862183 1153 1154 O
Patients NCT03862183 1156 1164 O
diagnosed NCT03862183 1165 1174 O
with NCT03862183 1175 1179 O
mental NCT03862183 1180 1186 B-Condition
abnormalities NCT03862183 1187 1200 I-Condition
who NCT03862183 1201 1204 B-And
are NCT03862183 1205 1208 O
unable NCT03862183 1209 1215 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862183 1216 1218 O
complete NCT03862183 1219 1227 O
the NCT03862183 1228 1231 O
questionnaire NCT03862183 1232 1245 B-Observation
. NCT03862183 1246 1247 O

7 NCT03862183 1251 1252 O
. NCT03862183 1252 1253 O
Patients NCT03862183 1255 1263 O
have NCT03862183 1264 1268 O
once NCT03862183 1269 1273 O
participated NCT03862183 1274 1286 B-Eq-Comparison
in NCT03862183 1287 1289 O
this NCT03862183 1290 1294 O
research NCT03862183 1295 1303 B-Study
during NCT03862183 1304 1310 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03862183 1311 1315 O
study NCT03862183 1316 1321 B-Study
cycle NCT03862183 1322 1327 O
（ NCT03862183 1328 1329 O
to NCT03862183 1330 1332 O
avoid NCT03862183 1333 1338 O
repeated NCT03862183 1339 1347 O
participation NCT03862183 1348 1361 O
） NCT03862183 1361 1362 O
. NCT03862183 1362 1363 O

Inclusion NCT03860025 0 9 O
Criteria NCT03860025 10 18 O
: NCT03860025 19 20 O

- NCT03860025 24 25 O
patients NCT03860025 27 35 O
with NCT03860025 36 40 O
one NCT03860025 41 44 B-Eq-Comparison
or NCT03860025 45 47 I-Eq-Comparison
more NCT03860025 48 52 I-Eq-Comparison
events NCT03860025 53 59 O
of NCT03860025 60 62 O
hip NCT03860025 63 66 B-Condition
dislocation NCT03860025 67 78 I-Condition
after NCT03860025 79 84 B-Temporal-Connection___Temporal-Connection-Type-Value:after
a NCT03860025 85 86 O
primary NCT03860025 87 94 B-Modifier
THA NCT03860025 95 98 B-Procedure

- NCT03860025 101 102 O
controls NCT03860025 104 112 O
with NCT03860025 113 117 O
a NCT03860025 118 119 O
primary NCT03860025 120 127 B-Modifier
THA NCT03860025 128 131 B-Procedure
without NCT03860025 132 139 B-Negation
events NCT03860025 140 146 O
of NCT03860025 147 149 O
hip NCT03860025 150 153 B-Condition
dislocation NCT03860025 154 165 I-Condition

Exclusion NCT03860025 166 175 O
Criteria NCT03860025 176 184 O
: NCT03860025 185 186 O

- NCT03860025 189 190 O

Inclusion NCT03863262 0 9 O
Criteria NCT03863262 10 18 O
: NCT03863262 19 20 O

- NCT03863262 24 25 O
Registered NCT03863262 27 37 O
patients NCT03863262 38 46 O
at NCT03863262 47 49 O
Eric NCT03863262 50 54 O
Williams NCT03863262 55 63 O
Medical NCT03863262 64 71 O
Sciences NCT03863262 72 80 O
Complex NCT03863262 81 88 O
in NCT03863262 89 91 O
any NCT03863262 92 95 O
of NCT03863262 96 98 O
the NCT03863262 99 102 O
cardiology NCT03863262 103 113 O
outpatient NCT03863262 114 124 O
clinics NCT03863262 125 132 O
. NCT03863262 132 133 O
This NCT03863262 135 139 O
was NCT03863262 140 143 O
confirmed NCT03863262 144 153 O
by NCT03863262 154 156 O
matching NCT03863262 157 165 O
patients NCT03863262 166 174 O
with NCT03863262 175 179 O
their NCT03863262 180 185 O
registration NCT03863262 186 198 O
numbers NCT03863262 199 206 O
on NCT03863262 207 209 O
the NCT03863262 210 213 O
cardiology NCT03863262 214 224 O
outpatient NCT03863262 225 235 O
clinic NCT03863262 236 242 O
appointment NCT03863262 243 254 O
listings NCT03863262 255 263 O
. NCT03863262 263 264 O
These NCT03863262 266 271 O
lists NCT03863262 272 277 O
are NCT03863262 278 281 O
made NCT03863262 282 286 O
prior NCT03863262 287 292 O
to NCT03863262 293 295 O
each NCT03863262 296 300 O
cardiology NCT03863262 301 311 O
clinic NCT03863262 312 318 O
that NCT03863262 319 323 O
is NCT03863262 324 326 O
scheduled NCT03863262 327 336 O
every NCT03863262 337 342 O
week NCT03863262 343 347 O
on NCT03863262 348 350 O
Mondays NCT03863262 351 358 O
, NCT03863262 359 360 O
Tuesdays NCT03863262 361 369 O
, NCT03863262 370 371 O
Wednesdays NCT03863262 372 382 O
, NCT03863262 383 384 O
Thursdays NCT03863262 385 394 O
and NCT03863262 395 398 O
Fridays NCT03863262 399 406 O
. NCT03863262 407 408 O

- NCT03863262 412 413 O
Patients NCT03863262 415 423 O
who NCT03863262 424 427 O
were NCT03863262 428 432 B-Eq-Comparison
18 NCT03863262 433 435 I-Eq-Comparison
years NCT03863262 436 441 I-Eq-Comparison
old NCT03863262 442 445 B-Age

Exclusion NCT03863262 446 455 O
Criteria NCT03863262 456 464 O
: NCT03863262 465 466 O

- NCT03863262 470 471 O
Patients NCT03863262 473 481 O
less NCT03863262 482 486 B-Eq-Comparison
than NCT03863262 487 491 I-Eq-Comparison
18 NCT03863262 492 494 I-Eq-Comparison
years NCT03863262 495 500 I-Eq-Comparison
old NCT03863262 501 504 B-Age

- NCT03863262 507 508 O
Those NCT03863262 510 515 O
who NCT03863262 516 519 O
did NCT03863262 520 523 O
not NCT03863262 524 527 O
give NCT03863262 528 532 O
informed NCT03863262 533 541 O
consent NCT03863262 542 549 O
to NCT03863262 550 552 O
participate NCT03863262 553 564 O
in NCT03863262 565 567 O
the NCT03863262 568 571 O
study NCT03863262 572 577 O

- NCT03863262 580 581 O
Patients NCT03863262 583 591 O
who NCT03863262 592 595 O
were NCT03863262 596 600 O
not NCT03863262 601 604 B-Negation
registered NCT03863262 605 615 O
patients NCT03863262 616 624 O
of NCT03863262 625 627 O
the NCT03863262 628 631 O
cardiology NCT03863262 632 642 O
outpatient NCT03863262 643 653 O
clinics NCT03863262 654 661 O
at NCT03863262 662 664 O
Eric NCT03863262 665 669 O
Williams NCT03863262 670 678 O
Medical NCT03863262 679 686 O
Sciences NCT03863262 687 695 O
Complex NCT03863262 696 703 O
along NCT03863262 704 709 O

- NCT03863262 712 713 O
Patients NCT03863262 715 723 O
who NCT03863262 724 727 O
were NCT03863262 728 732 O
acutely NCT03863262 733 740 O
unwell NCT03863262 741 747 B-Condition
requiring NCT03863262 748 757 B-Assertion___Assertion-Type-Value:hypothetical
hospital NCT03863262 758 766 O
admission NCT03863262 767 776 B-Encounter

Inclusion NCT03866681 0 9 O
Criteria NCT03866681 10 18 O
: NCT03866681 19 20 O

- NCT03866681 24 25 O
age NCT03866681 27 30 B-Age
18 NCT03866681 31 33 B-Eq-Comparison
- NCT03866681 34 35 I-Eq-Comparison
70 NCT03866681 36 38 I-Eq-Comparison
years NCT03866681 39 44 I-Eq-Comparison

- NCT03866681 47 48 O
diagnosed NCT03866681 50 59 O
with NCT03866681 60 64 O
PNH NCT03866681 65 68 B-Condition
and NCT03866681 69 72 B-And
no NCT03866681 73 75 B-Negation
thrombosis NCT03866681 76 86 B-Condition

- NCT03866681 89 90 O
ineffective NCT03866681 92 103 B-Modifier
, NCT03866681 104 105 O
relapsed NCT03866681 106 114 B-Modifier
or NCT03866681 115 117 B-Or
intolerant NCT03866681 118 128 B-Condition
to NCT03866681 129 131 O
conventional NCT03866681 132 144 B-Procedure
treatment NCT03866681 145 154 I-Procedure
( NCT03866681 155 156 O
eg NCT03866681 157 159 O
glucocorticoids NCT03866681 160 175 B-Drug
, NCT03866681 176 177 O
• NCT03866681 178 179 O
• NCT03866681 180 181 O
iron NCT03866681 182 186 B-Drug
, NCT03866681 187 188 O
folic NCT03866681 189 194 B-Drug
acid NCT03866681 195 199 I-Drug
, NCT03866681 200 201 O
androgen NCT03866681 202 210 B-Drug
, NCT03866681 211 212 O
etc NCT03866681 213 216 O
. NCT03866681 216 217 O
) NCT03866681 218 219 O

- NCT03866681 223 224 O
not NCT03866681 226 229 B-Negation
available NCT03866681 230 239 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03866681 240 243 O
hematopoietic NCT03866681 244 257 B-Procedure
stem NCT03866681 258 262 I-Procedure
cell NCT03866681 263 267 I-Procedure
transplantation NCT03866681 268 283 I-Procedure

- NCT03866681 286 287 O
ECOG NCT03866681 289 293 B-Observation
≤ NCT03866681 294 295 B-Eq-Comparison
2 NCT03866681 296 297 I-Eq-Comparison

- NCT03866681 301 302 O
agreed NCT03866681 304 310 O
to NCT03866681 311 313 O
sign NCT03866681 314 318 O
the NCT03866681 319 322 O
consent NCT03866681 323 330 O
forms NCT03866681 331 336 O

Exclusion NCT03866681 337 346 O
Criteria NCT03866681 347 355 O
: NCT03866681 356 357 O

- NCT03866681 361 362 O
severe NCT03866681 364 370 O
heart NCT03866681 371 376 B-Modifier
, NCT03866681 377 378 O
liver NCT03866681 379 384 B-Modifier
and NCT03866681 385 388 B-Or
kidney NCT03866681 389 395 B-Modifier
dysfunction NCT03866681 396 407 B-Condition

- NCT03866681 410 411 O
combined NCT03866681 413 421 O
with NCT03866681 422 426 O
thrombotic NCT03866681 427 437 B-Modifier
complications NCT03866681 438 451 B-Condition

- NCT03866681 454 455 O
people NCT03866681 457 463 O
who NCT03866681 464 467 O
are NCT03866681 468 471 O
pregnant NCT03866681 472 480 B-Condition
and NCT03866681 481 484 B-Or
breastfeeding NCT03866681 485 498 B-Condition

- NCT03866681 501 502 O
history NCT03866681 504 511 B-Eq-Comparison
of NCT03866681 512 514 O
other NCT03866681 515 520 B-Other
immunosuppressive NCT03866681 521 538 B-Drug
agents NCT03866681 539 545 I-Drug
in NCT03866681 546 548 O
recent NCT03866681 549 555 B-Eq-Comparison
3 NCT03866681 556 557 I-Eq-Comparison
months NCT03866681 558 564 I-Eq-Comparison

- NCT03866681 567 568 O
Patients NCT03866681 570 578 O
who NCT03866681 579 582 O
are NCT03866681 583 586 O
not NCT03866681 587 590 B-Negation
eligible NCT03866681 591 599 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03866681 600 602 O
participate NCT03866681 603 614 O
in NCT03866681 615 617 O
this NCT03866681 618 622 O
trial NCT03866681 623 628 O
due NCT03866681 629 632 O
to NCT03866681 633 635 O
any NCT03866681 636 639 O
reason NCT03866681 640 646 O
based NCT03866681 647 652 O
• NCT03866681 653 654 O
• NCT03866681 655 656 O
• NCT03866681 657 658 O
on NCT03866681 659 661 O
the NCT03866681 662 665 O
consideration NCT03866681 666 679 O
of NCT03866681 680 682 O
investigator NCT03866681 683 695 O

Inclusion NCT03864900 0 9 O
Criteria NCT03864900 10 18 O
: NCT03864900 19 20 O

1 NCT03864900 24 25 O
. NCT03864900 25 26 O
≥ NCT03864900 28 29 B-Eq-Comparison
20 NCT03864900 30 32 I-Eq-Comparison
years NCT03864900 33 38 I-Eq-Comparison
of NCT03864900 39 41 O
age NCT03864900 42 45 B-Age

2 NCT03864900 48 49 O
. NCT03864900 49 50 O
fluent NCT03864900 52 58 O
in NCT03864900 59 61 O
Mandarin NCT03864900 62 70 O
or NCT03864900 71 73 B-Or
Taiwanese NCT03864900 74 83 O

3 NCT03864900 86 87 O
. NCT03864900 87 88 O
diagnosed NCT03864900 90 99 O
with NCT03864900 100 104 O
AF NCT03864900 105 107 B-Condition

4 NCT03864900 110 111 O
. NCT03864900 111 112 O
treated NCT03864900 114 121 B-Procedure
with NCT03864900 122 126 O
warfarin NCT03864900 127 135 B-Drug
or NCT03864900 136 138 B-Or
NOACs NCT03864900 139 144 B-Drug
for NCT03864900 145 148 O
anticoagulation NCT03864900 149 164 B-Procedure
. NCT03864900 165 166 O

Exclusion NCT03864900 168 177 O
Criteria NCT03864900 178 186 O
: NCT03864900 187 188 O

1 NCT03864900 192 193 O
. NCT03864900 193 194 O
diagnosed NCT03864900 196 205 O
with NCT03864900 206 210 O
psychological NCT03864900 211 224 B-Condition
diseases NCT03864900 225 233 I-Condition

2 NCT03864900 236 237 O
. NCT03864900 237 238 O
diagnosed NCT03864900 240 249 O
with NCT03864900 250 254 O
uncontrolled NCT03864900 255 267 B-Modifier
hypertension NCT03864900 268 280 B-Condition

3 NCT03864900 283 284 O
. NCT03864900 284 285 O
diagnosed NCT03864900 287 296 O
with NCT03864900 297 301 O
the NCT03864900 302 305 O
New NCT03864900 306 309 B-Condition
York NCT03864900 310 314 I-Condition
Heart NCT03864900 315 320 I-Condition
Association NCT03864900 321 332 I-Condition
( NCT03864900 333 334 O
NYHA NCT03864900 335 339 B-Condition
) NCT03864900 340 341 O
grade NCT03864900 342 347 B-Eq-Comparison
VI NCT03864900 348 350 I-Eq-Comparison
heart NCT03864900 351 356 B-Condition
failure NCT03864900 357 364 I-Condition

4 NCT03864900 367 368 O
. NCT03864900 368 369 O
implanted NCT03864900 371 380 O
with NCT03864900 381 385 O
a NCT03864900 386 387 O
cardiac NCT03864900 388 395 B-Procedure
pacemaker NCT03864900 396 405 I-Procedure

5 NCT03864900 408 409 O
. NCT03864900 409 410 O
had NCT03864900 412 415 O
a NCT03864900 416 417 O
cardiac NCT03864900 418 425 B-Procedure
surgery NCT03864900 426 433 I-Procedure
in NCT03864900 434 436 O
the NCT03864900 437 440 O
past NCT03864900 441 445 B-Eq-Comparison
three NCT03864900 446 451 I-Eq-Comparison
months NCT03864900 452 458 I-Eq-Comparison

6 NCT03864900 461 462 O
. NCT03864900 462 463 O
hospitalized NCT03864900 465 477 B-Encounter
for NCT03864900 478 481 O
AF NCT03864900 482 484 B-Condition
in NCT03864900 485 487 O
the NCT03864900 488 491 O
past NCT03864900 492 496 B-Eq-Comparison
three NCT03864900 497 502 I-Eq-Comparison
months NCT03864900 503 509 I-Eq-Comparison
. NCT03864900 509 510 O

Inclusion NCT03866642 0 9 O
Criteria NCT03866642 10 18 O
: NCT03866642 19 20 O

- NCT03866642 24 25 O
Ankle NCT03866642 27 32 B-Modifier
arthritis NCT03866642 33 42 B-Condition
treated NCT03866642 43 50 O
with NCT03866642 51 55 O
Cadence NCT03866642 56 63 B-Modifier
Total NCT03866642 64 69 B-Procedure
Ankle NCT03866642 70 75 I-Procedure
Replacement NCT03866642 76 87 I-Procedure
system NCT03866642 88 94 I-Procedure

Exclusion NCT03866642 95 104 O
Criteria NCT03866642 105 113 O
: NCT03866642 114 115 O

- NCT03866642 119 120 O
Under NCT03866642 122 127 B-Eq-Comparison
18 NCT03866642 128 130 I-Eq-Comparison
years NCT03866642 131 136 I-Eq-Comparison
of NCT03866642 137 139 O
age NCT03866642 140 143 B-Age

Inclusion NCT03860233 0 9 O
Criteria NCT03860233 10 18 O
: NCT03860233 19 20 O

- NCT03860233 24 25 O
Men NCT03860233 27 30 O
or NCT03860233 31 33 B-Or
women NCT03860233 34 39 O
18 NCT03860233 40 42 B-Eq-Comparison
years NCT03860233 43 48 I-Eq-Comparison
of NCT03860233 49 51 I-Eq-Comparison
age NCT03860233 52 55 I-Age|Eq-Comparison
or NCT03860233 56 58 I-Eq-Comparison
older NCT03860233 59 64 I-Eq-Comparison
. NCT03860233 65 66 O

Exclusion NCT03860233 68 77 O
Criteria NCT03860233 78 86 O
: NCT03860233 87 88 O

- NCT03860233 92 93 O
subjects NCT03860233 95 103 O
not NCT03860233 104 107 B-Negation
willing NCT03860233 108 115 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860233 116 118 I-Assertion___Assertion-Type-Value:hypothetical
or NCT03860233 119 121 B-Or
otherwise NCT03860233 122 131 O
unable NCT03860233 132 138 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860233 139 141 O
use NCT03860233 142 145 O
CPAP NCT03860233 146 150 B-Procedure
for NCT03860233 151 154 O
treatment NCT03860233 155 164 B-Procedure
of NCT03860233 165 167 O
OSA NCT03860233 168 171 B-Condition
. NCT03860233 172 173 O

- NCT03860233 177 178 O
Presence NCT03860233 180 188 O
of NCT03860233 189 191 O
other NCT03860233 192 197 B-Other
sleep NCT03860233 198 203 B-Condition
disorders NCT03860233 204 213 I-Condition

- NCT03860233 216 217 O
Pregnant NCT03860233 219 227 B-Condition
or NCT03860233 228 230 B-Or
breastfeeding NCT03860233 231 244 B-Condition
women NCT03860233 245 250 O

- NCT03860233 253 254 O
Women NCT03860233 256 261 O
of NCT03860233 262 264 B-And
child NCT03860233 265 270 B-Condition
- NCT03860233 271 272 I-Condition
bearing NCT03860233 273 280 I-Condition
age NCT03860233 281 284 I-Condition
( NCT03860233 285 286 O
WOCBA NCT03860233 287 292 B-Condition
) NCT03860233 293 294 O
not NCT03860233 295 298 B-Negation
willing NCT03860233 299 306 B-Assertion___Assertion-Type-Value:hypothetical
or NCT03860233 307 309 B-Or
unable NCT03860233 310 316 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03860233 317 319 O
use NCT03860233 320 323 O
an NCT03860233 324 326 O
accepted NCT03860233 327 335 O
method NCT03860233 336 342 B-Procedure
to NCT03860233 343 345 O
avoid NCT03860233 346 351 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03860233 352 361 B-Condition
for NCT03860233 362 365 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860233 366 369 I-Temporal-Connection___Temporal-Connection-Type-Value:during
entire NCT03860233 370 376 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03860233 377 385 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03860233 386 388 O
the NCT03860233 389 392 O
study NCT03860233 393 398 B-Study

- NCT03860233 401 402 O
Prisoners NCT03860233 404 413 B-Observation
or NCT03860233 414 416 B-Or
subjects NCT03860233 417 425 O
who NCT03860233 426 429 O
are NCT03860233 430 433 O
involuntarily NCT03860233 434 447 B-Observation
incarcerated NCT03860233 448 460 I-Observation

- NCT03860233 463 464 O
Subjects NCT03860233 466 474 O
who NCT03860233 475 478 O
are NCT03860233 479 482 O
compulsorily NCT03860233 483 495 B-Observation
detain NCT03860233 496 502 I-Observation
or NCT03860233 503 505 B-Or
treatment NCT03860233 506 515 B-Procedure
of NCT03860233 516 518 O
either NCT03860233 519 525 O
a NCT03860233 526 527 O
psychiatric NCT03860233 528 539 B-Modifier
or NCT03860233 540 542 B-Or
physical NCT03860233 543 551 B-Modifier
( NCT03860233 552 553 O
i. NCT03860233 554 556 O
e. NCT03860233 557 559 O
infectious NCT03860233 561 571 B-Condition
disease NCT03860233 572 579 I-Condition
) NCT03860233 580 581 O
illness NCT03860233 582 589 B-Condition

- NCT03860233 592 593 O
Patients NCT03860233 595 603 O
unable NCT03860233 604 610 O
to NCT03860233 611 613 O
give NCT03860233 614 618 O
consent NCT03860233 619 626 O
because NCT03860233 627 634 O
of NCT03860233 635 637 O
a NCT03860233 638 639 O
language NCT03860233 640 648 B-Condition
barrier NCT03860233 649 656 I-Condition
, NCT03860233 657 658 O
or NCT03860233 659 661 O
other NCT03860233 662 667 O
reason NCT03860233 668 674 O
. NCT03860233 674 675 O

Inclusion NCT03864055 0 9 O
Criteria NCT03864055 10 18 O
: NCT03864055 19 20 O

- NCT03864055 24 25 O
age NCT03864055 27 30 B-Age
of NCT03864055 31 33 O
18 NCT03864055 34 36 B-Eq-Comparison
years NCT03864055 37 42 I-Eq-Comparison
or NCT03864055 43 45 I-Eq-Comparison
younger NCT03864055 46 53 I-Eq-Comparison

- NCT03864055 56 57 O
both NCT03864055 59 63 O
sexes NCT03864055 64 69 O
are NCT03864055 70 73 O
included NCT03864055 74 82 O

- NCT03864055 85 86 O
a NCT03864055 88 89 O
clinical NCT03864055 90 98 B-Modifier
or NCT03864055 99 101 B-Or
radiological NCT03864055 102 114 B-Procedure
finding NCT03864055 115 122 O
of NCT03864055 123 125 O
mastoiditis NCT03864055 126 137 B-Condition
in NCT03864055 138 140 O
the NCT03864055 141 144 O
patient NCT03864055 145 152 O
's NCT03864055 152 154 O
file NCT03864055 155 159 O

- NCT03864055 162 163 O
Documentation NCT03864055 165 178 O
of NCT03864055 179 181 O
CSVT NCT03864055 182 186 B-Condition
in NCT03864055 187 189 O
an NCT03864055 190 192 O
imaging NCT03864055 193 200 B-Procedure
study NCT03864055 201 206 I-Procedure
, NCT03864055 207 208 O
either NCT03864055 209 215 O
CT NCT03864055 216 218 B-Procedure
or NCT03864055 219 221 B-Or
MRI NCT03864055 222 225 B-Procedure
. NCT03864055 226 227 O

Patient NCT03864055 229 236 O
's NCT03864055 236 238 O
exclusion NCT03864055 239 248 O
criteria NCT03864055 249 257 O

- NCT03864055 260 261 O
age NCT03864055 263 266 B-Age
above NCT03864055 267 272 B-Eq-Comparison
18 NCT03864055 273 275 I-Eq-Comparison
years NCT03864055 276 281 I-Eq-Comparison

- NCT03864055 284 285 O
lack NCT03864055 287 291 B-Negation
of NCT03864055 292 294 I-Negation
a NCT03864055 295 296 O
clinical NCT03864055 297 305 B-Modifier
or NCT03864055 306 308 B-Or
radiological NCT03864055 309 321 B-Procedure
finding NCT03864055 322 329 O
of NCT03864055 330 332 O
mastoiditis NCT03864055 333 344 B-Condition
in NCT03864055 345 347 O
the NCT03864055 348 351 O
patient NCT03864055 352 359 O
's NCT03864055 359 361 O
file NCT03864055 362 366 O

- NCT03864055 369 370 O
Lack NCT03864055 372 376 B-Negation
of NCT03864055 377 379 O
documentation NCT03864055 380 393 O
of NCT03864055 394 396 O
CSVT NCT03864055 397 401 B-Condition
in NCT03864055 402 404 O
an NCT03864055 405 407 O
imaging NCT03864055 408 415 B-Procedure
study NCT03864055 416 421 I-Procedure
, NCT03864055 422 423 O
either NCT03864055 424 430 O
CT NCT03864055 431 433 B-Procedure
or NCT03864055 434 436 B-Or
MRI NCT03864055 437 440 B-Procedure
. NCT03864055 441 442 O

- NCT03864055 446 447 O
previous NCT03864055 449 457 B-Eq-Comparison
unprovoked NCT03864055 458 468 B-Modifier
venous NCT03864055 469 475 B-Condition
thromboembolism NCT03864055 476 491 I-Condition
event NCT03864055 492 497 O
. NCT03864055 497 498 O

Inclusion NCT03869203 0 9 O
Criteria NCT03869203 10 18 O
: NCT03869203 19 20 O

- NCT03869203 24 25 O
1 NCT03869203 27 28 O
. NCT03869203 28 29 O
elective NCT03869203 31 39 B-Modifier
total NCT03869203 40 45 B-Procedure
knee NCT03869203 46 50 I-Procedure
arthroplasty NCT03869203 51 63 I-Procedure
for NCT03869203 64 67 O
degenerative NCT03869203 68 80 B-Modifier
osteoarthritis NCT03869203 81 95 B-Condition

- NCT03869203 98 99 O
2 NCT03869203 101 102 O
. NCT03869203 102 103 O
elective NCT03869203 105 113 B-Modifier
total NCT03869203 114 119 B-Procedure
hip NCT03869203 120 123 I-Procedure
arthroplasty NCT03869203 124 136 I-Procedure
for NCT03869203 137 140 O
osteoarthritis NCT03869203 141 155 B-Condition
of NCT03869203 156 158 O
osteonecrosis NCT03869203 159 172 B-Condition
of NCT03869203 173 175 I-Condition
femoral NCT03869203 176 183 I-Condition
head NCT03869203 184 188 I-Condition

Exclusion NCT03869203 189 198 O
Criteria NCT03869203 199 207 O
: NCT03869203 208 209 O

- NCT03869203 213 214 O
1 NCT03869203 216 217 O
. NCT03869203 217 218 O
ASA NCT03869203 220 223 B-Condition
class NCT03869203 224 229 B-Eq-Comparison
> NCT03869203 230 231 I-Eq-Comparison
3 NCT03869203 232 233 I-Eq-Comparison

- NCT03869203 237 238 O
2 NCT03869203 240 241 O
. NCT03869203 241 242 O
severe NCT03869203 244 250 O
medical NCT03869203 251 258 B-Condition
comorbidities NCT03869203 259 272 I-Condition

- NCT03869203 275 276 O
3 NCT03869203 278 279 O
. NCT03869203 279 280 O
inflammatory NCT03869203 282 294 B-Condition
arthritis NCT03869203 295 304 I-Condition
including NCT03869203 305 314 O
rheumatoid NCT03869203 315 325 B-Condition
arthritis NCT03869203 326 335 I-Condition

- NCT03869203 338 339 O
4 NCT03869203 341 342 O
. NCT03869203 342 343 O
severe NCT03869203 345 351 O
instability NCT03869203 352 363 B-Condition
of NCT03869203 364 366 O
knee NCT03869203 367 371 B-Modifier
or NCT03869203 372 374 B-Or
hip NCT03869203 375 378 B-Modifier

- NCT03869203 381 382 O
5 NCT03869203 384 385 O
. NCT03869203 385 386 O
revision NCT03869203 388 396 B-Modifier
surgery NCT03869203 397 404 B-Procedure

Inclusion NCT03869502 0 9 O
Criteria NCT03869502 10 18 O
: NCT03869502 19 20 O

- NCT03869502 24 25 O
Age NCT03869502 27 30 B-Age
> NCT03869502 31 32 B-Eq-Comparison
18 NCT03869502 33 35 I-Eq-Comparison
years NCT03869502 36 41 I-Eq-Comparison

- NCT03869502 44 45 O
Diagnosis NCT03869502 47 56 O
of NCT03869502 57 59 O
BCR‐ABL NCT03869502 60 67 B-Condition
positive NCT03869502 68 76 O
CML NCT03869502 77 80 B-Modifier
blast NCT03869502 81 86 I-Modifier
crisis NCT03869502 87 93 I-Modifier
according NCT03869502 94 103 O
to NCT03869502 104 106 O
the NCT03869502 107 110 O
WHO NCT03869502 111 114 O
criteria NCT03869502 115 123 O
: NCT03869502 124 125 O

- NCT03869502 134 135 O
Blasts NCT03869502 137 143 B-Observation
20 NCT03869502 144 146 B-Eq-Comparison
% NCT03869502 147 148 I-Eq-Comparison
or NCT03869502 149 151 I-Eq-Comparison
more NCT03869502 152 156 I-Eq-Comparison
of NCT03869502 157 159 O
peripheral NCT03869502 160 170 B-Modifier
blood NCT03869502 171 176 I-Modifier
white NCT03869502 177 182 I-Modifier
cells NCT03869502 183 188 I-Modifier
or NCT03869502 189 191 B-Or
bone NCT03869502 192 196 B-Modifier
marrow NCT03869502 197 203 I-Modifier
cells NCT03869502 204 209 I-Modifier
or NCT03869502 210 212 B-Or

- NCT03869502 220 221 O
Extramedullary NCT03869502 223 237 B-Modifier
blast NCT03869502 238 243 B-Condition
proliferation NCT03869502 244 257 I-Condition
or NCT03869502 258 260 B-Or

- NCT03869502 268 269 O
Large NCT03869502 271 276 B-Modifier
foci NCT03869502 277 281 I-Modifier
or NCT03869502 282 284 B-Or
clusters NCT03869502 285 293 B-Modifier
of NCT03869502 294 296 O
blasts NCT03869502 297 303 B-Condition
in NCT03869502 304 306 O
bone NCT03869502 307 311 B-Procedure
marrow NCT03869502 312 318 I-Procedure
biopsy NCT03869502 319 325 I-Procedure

Exclusion NCT03869502 326 335 O
Criteria NCT03869502 336 344 O
: NCT03869502 345 346 O

- NCT03869502 350 351 O
Lack NCT03869502 353 357 O
of NCT03869502 358 360 O
informed NCT03869502 361 369 O
consent NCT03869502 370 377 O

Inclusion NCT03862443 0 9 O
Criteria NCT03862443 10 18 O
for NCT03862443 19 22 O
Parent NCT03862443 23 29 O
/ NCT03862443 30 31 O
Caregiver NCT03862443 32 41 O
: NCT03862443 42 43 O

- NCT03862443 47 48 O
Provide NCT03862443 50 57 O
signed NCT03862443 58 64 O
and NCT03862443 65 68 O
dated NCT03862443 69 74 O
informed NCT03862443 75 83 O
consent NCT03862443 84 91 O
form NCT03862443 92 96 O
in NCT03862443 97 99 O
English NCT03862443 100 107 O
or NCT03862443 108 110 B-Or
Spanish NCT03862443 111 118 O
. NCT03862443 119 120 O

- NCT03862443 124 125 O
Agree NCT03862443 127 132 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862443 133 135 O
comply NCT03862443 136 142 O
with NCT03862443 143 147 O
all NCT03862443 148 151 O
study NCT03862443 152 157 B-Study
procedures NCT03862443 158 168 O
and NCT03862443 169 172 O
be NCT03862443 173 175 B-Assertion___Assertion-Type-Value:hypothetical
available NCT03862443 176 185 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03862443 186 189 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862443 190 193 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03862443 194 202 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862443 203 205 O
the NCT03862443 206 209 O
study NCT03862443 210 215 B-Study
visit NCT03862443 216 221 O
. NCT03862443 222 223 O

- NCT03862443 227 228 O
Male NCT03862443 230 234 O
or NCT03862443 235 237 B-Or
female NCT03862443 238 244 O
, NCT03862443 245 246 O
aged NCT03862443 247 251 B-Age
18 NCT03862443 252 254 B-Eq-Comparison
and NCT03862443 255 258 I-Eq-Comparison
older NCT03862443 259 264 I-Eq-Comparison
. NCT03862443 265 266 O

- NCT03862443 270 271 O
Speak NCT03862443 273 278 O
, NCT03862443 279 280 O
read NCT03862443 281 285 O
, NCT03862443 286 287 O
and NCT03862443 288 291 O
write NCT03862443 292 297 O
either NCT03862443 298 304 O
English NCT03862443 305 312 O
or NCT03862443 313 315 B-Or
Spanish NCT03862443 316 323 O
. NCT03862443 324 325 O

- NCT03862443 329 330 O
Be NCT03862443 332 334 O
a NCT03862443 335 336 O
parent NCT03862443 337 343 B-Family-Member___Family-Member-Type:parent
or NCT03862443 344 346 B-Or
caregiver NCT03862443 347 356 B-Family-Member___Family-Member-Type:parent
of NCT03862443 357 359 O
a NCT03862443 360 361 O
child NCT03862443 362 367 B-Family-Member___Family-Member-Type:child
at NCT03862443 368 370 B-Eq-Comparison
least NCT03862443 371 376 I-Eq-Comparison
6 NCT03862443 377 378 I-Eq-Comparison
months NCT03862443 379 385 I-Eq-Comparison
old NCT03862443 386 389 B-Age
but NCT03862443 390 393 B-And
less NCT03862443 394 398 B-Eq-Comparison
than NCT03862443 399 403 I-Eq-Comparison
3.5 NCT03862443 404 407 I-Eq-Comparison
years NCT03862443 408 413 I-Eq-Comparison
( NCT03862443 414 415 O
42 NCT03862443 416 418 B-Eq-Comparison
months NCT03862443 419 425 I-Eq-Comparison
) NCT03862443 426 427 O
, NCT03862443 429 430 O
with NCT03862443 431 435 B-And
at NCT03862443 436 438 B-Eq-Comparison
least NCT03862443 439 444 I-Eq-Comparison
2 NCT03862443 445 446 I-Eq-Comparison
fully NCT03862443 447 452 B-Modifier
erupted NCT03862443 453 460 I-Modifier
teeth NCT03862443 461 466 B-Condition
and NCT03862443 467 470 O
enrolled NCT03862443 471 479 O
in NCT03862443 480 482 O
, NCT03862443 483 484 O
or NCT03862443 485 487 O
waitlisted NCT03862443 488 498 O
for NCT03862443 499 502 O
, NCT03862443 503 504 O
one NCT03862443 505 508 O
of NCT03862443 509 511 O
the NCT03862443 512 515 O
three NCT03862443 516 521 O
participating NCT03862443 522 535 O
Los NCT03862443 536 539 O
Angeles NCT03862443 540 547 O
County NCT03862443 548 554 O
EHS NCT03862443 555 558 O
home NCT03862443 559 563 O
visit NCT03862443 564 569 O
programs NCT03862443 570 578 O
. NCT03862443 579 580 O

- NCT03862443 584 585 O
Not NCT03862443 587 590 B-Negation
be NCT03862443 591 593 O
planning NCT03862443 594 602 B-Assertion___Assertion-Type-Value:intention
to NCT03862443 603 605 I-Assertion___Assertion-Type-Value:intention
move NCT03862443 606 610 B-Observation
residence NCT03862443 611 620 O
for NCT03862443 621 624 O
the NCT03862443 625 628 O
next NCT03862443 629 633 B-Eq-Comparison
6 NCT03862443 634 635 I-Eq-Comparison
months NCT03862443 636 642 I-Eq-Comparison
outside NCT03862443 643 650 B-Negation
the NCT03862443 651 654 O
greater NCT03862443 655 662 O
Los NCT03862443 663 666 O
Angeles NCT03862443 667 674 O
area NCT03862443 675 679 O
. NCT03862443 680 681 O

- NCT03862443 685 686 O
Own NCT03862443 688 691 O
a NCT03862443 692 693 O
smartphone NCT03862443 694 704 O
with NCT03862443 705 709 O
the NCT03862443 710 713 O
Google NCT03862443 714 720 O
Play NCT03862443 721 725 O
or NCT03862443 726 728 O
iTunes NCT03862443 729 735 O
store NCT03862443 736 741 O
and NCT03862443 742 745 O
be NCT03862443 746 748 O
willing NCT03862443 749 756 O
to NCT03862443 757 759 O
download NCT03862443 760 768 O
the NCT03862443 769 772 O
smart NCT03862443 773 778 O
powered NCT03862443 779 786 O
TB NCT03862443 787 789 O
app NCT03862443 790 793 O

- NCT03862443 796 797 O
Be NCT03862443 799 801 O
willing NCT03862443 802 809 O
to NCT03862443 810 812 O
be NCT03862443 813 815 O
contacted NCT03862443 816 825 O
via NCT03862443 826 829 O
text NCT03862443 830 834 O
- NCT03862443 835 836 O
messaging NCT03862443 837 846 O
( NCT03862443 847 848 O
SMS NCT03862443 849 852 O
) NCT03862443 853 854 O
for NCT03862443 855 858 O
study NCT03862443 859 864 B-Study
related NCT03862443 865 872 O
notifications NCT03862443 873 886 O
, NCT03862443 887 888 O
such NCT03862443 889 893 O
as NCT03862443 894 896 O
incentives NCT03862443 897 907 O
earned NCT03862443 908 914 O
or NCT03862443 915 917 O
reminders NCT03862443 918 927 O
to NCT03862443 928 930 O
sync NCT03862443 931 935 O
the NCT03862443 936 939 O
TB NCT03862443 940 942 O

Exclusion NCT03862443 943 952 O
Criteria NCT03862443 953 961 O
: NCT03862443 962 963 O

- NCT03862443 967 968 O
Known NCT03862443 970 975 O
allergic NCT03862443 976 984 B-Allergy
reaction NCT03862443 985 993 O
to NCT03862443 994 996 O
components NCT03862443 997 1007 O
of NCT03862443 1008 1010 O
the NCT03862443 1011 1014 O
study NCT03862443 1015 1020 B-Study
product NCT03862443 1021 1028 B-Drug
( NCT03862443 1029 1030 I-Drug
s NCT03862443 1031 1032 I-Drug
) NCT03862443 1033 1034 I-Drug
. NCT03862443 1036 1037 O

- NCT03862443 1041 1042 O
Uncooperative NCT03862443 1044 1057 B-Condition
or NCT03862443 1058 1060 B-Or
behaviorally NCT03862443 1061 1073 B-Condition
unsuited NCT03862443 1074 1082 I-Condition
( NCT03862443 1083 1084 O
assessed NCT03862443 1085 1093 O
during NCT03862443 1094 1100 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03862443 1101 1102 O
TB NCT03862443 1103 1105 B-Procedure
prophylaxis NCT03862443 1106 1117 I-Procedure
at NCT03862443 1118 1120 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862443 1121 1124 O
initial NCT03862443 1125 1132 B-Eq-Comparison
baseline NCT03862443 1133 1141 B-Study
study NCT03862443 1142 1147 I-Study
visit NCT03862443 1148 1153 O
) NCT03862443 1154 1155 O
. NCT03862443 1157 1158 O

- NCT03862443 1162 1163 O
A NCT03862443 1165 1166 O
sibling NCT03862443 1167 1174 B-Family-Member___Family-Member-Type:sibling
of NCT03862443 1175 1177 O
a NCT03862443 1178 1179 O
child NCT03862443 1180 1185 B-Family-Member___Family-Member-Type:child
already NCT03862443 1186 1193 O
enrolled NCT03862443 1194 1202 O
in NCT03862443 1203 1205 O
the NCT03862443 1206 1209 O
study NCT03862443 1210 1215 B-Study
( NCT03862443 1216 1217 O
the NCT03862443 1218 1221 O
family NCT03862443 1222 1228 O
's NCT03862443 1228 1230 O
oldest NCT03862443 1231 1237 O
child NCT03862443 1238 1243 O
in NCT03862443 1244 1246 O
the NCT03862443 1247 1250 O
eligible NCT03862443 1251 1259 O
age NCT03862443 1260 1263 O
range NCT03862443 1264 1269 O
will NCT03862443 1270 1274 O
be NCT03862443 1275 1277 O
the NCT03862443 1278 1281 O
study NCT03862443 1282 1287 O
child NCT03862443 1288 1293 O
) NCT03862443 1294 1295 O
. NCT03862443 1297 1298 O

- NCT03862443 1302 1303 O
Enrolled NCT03862443 1305 1313 O
in NCT03862443 1314 1316 O
foster NCT03862443 1317 1323 B-Observation
care NCT03862443 1324 1328 I-Observation
. NCT03862443 1329 1330 O

- NCT03862443 1334 1335 O
Anything NCT03862443 1337 1345 B-Condition
else NCT03862443 1346 1350 I-Condition
that NCT03862443 1351 1355 O
would NCT03862443 1356 1361 B-Assertion___Assertion-Type-Value:hypothetical
place NCT03862443 1362 1367 O
him NCT03862443 1368 1371 O
/ NCT03862443 1372 1373 O
her NCT03862443 1374 1377 O
at NCT03862443 1378 1380 O
increased NCT03862443 1381 1390 O
health NCT03862443 1391 1397 O
risk NCT03862443 1398 1402 B-Risk
or NCT03862443 1403 1405 B-Or
preclude NCT03862443 1406 1414 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862443 1415 1418 O
individual NCT03862443 1419 1429 O
's NCT03862443 1429 1431 O
full NCT03862443 1432 1436 O
compliance NCT03862443 1437 1447 O
with NCT03862443 1448 1452 O
or NCT03862443 1453 1455 O
completion NCT03862443 1456 1466 O
of NCT03862443 1467 1469 O
the NCT03862443 1470 1473 O
study NCT03862443 1474 1479 B-Study
. NCT03862443 1479 1480 O

Inclusion NCT03868813 0 9 O
Criteria NCT03868813 10 18 O
: NCT03868813 19 20 O

Health NCT03868813 22 28 O
Coaches NCT03868813 29 36 O
Group NCT03868813 37 42 O
: NCT03868813 43 44 O

( NCT03868813 47 48 O
i NCT03868813 49 50 O
) NCT03868813 51 52 O
age NCT03868813 53 56 B-Age
between NCT03868813 57 64 B-Eq-Comparison
18 NCT03868813 65 67 I-Eq-Comparison
and NCT03868813 68 71 I-Eq-Comparison
80 NCT03868813 72 74 I-Eq-Comparison
years NCT03868813 75 80 I-Eq-Comparison
( NCT03868813 81 82 O
ii NCT03868813 83 85 O
) NCT03868813 86 87 O
fluent NCT03868813 88 94 O
in NCT03868813 95 97 O
English NCT03868813 98 105 O
( NCT03868813 106 107 O
iii NCT03868813 108 111 O
) NCT03868813 112 113 O
work NCT03868813 114 118 O
in NCT03868813 119 121 O
or NCT03868813 122 124 O
carry NCT03868813 125 130 O
expertise NCT03868813 131 140 O
in NCT03868813 141 143 O
physical NCT03868813 144 152 B-Observation
activity NCT03868813 153 161 I-Observation
, NCT03868813 162 163 O
nutrition NCT03868813 164 173 B-Condition
/ NCT03868813 174 175 B-Or
diet NCT03868813 176 180 B-Observation
or NCT03868813 181 183 B-Or
health NCT03868813 184 190 B-Condition
behavior NCT03868813 191 199 I-Condition
. NCT03868813 200 201 O

People NCT03868813 203 209 O
with NCT03868813 210 214 O
Diabetes NCT03868813 215 223 O
Group NCT03868813 224 229 O
( NCT03868813 230 231 O
Patient NCT03868813 232 239 O
/ NCT03868813 240 241 O
Caregiver NCT03868813 242 251 O
Dyads NCT03868813 252 257 O
) NCT03868813 258 259 O
: NCT03868813 261 262 O

( NCT03868813 265 266 O
i NCT03868813 267 268 O
) NCT03868813 269 270 O
age NCT03868813 271 274 B-Age
between NCT03868813 275 282 B-Eq-Comparison
18 NCT03868813 283 285 I-Eq-Comparison
and NCT03868813 286 289 I-Eq-Comparison
80 NCT03868813 290 292 I-Eq-Comparison
years NCT03868813 293 298 I-Eq-Comparison
( NCT03868813 299 300 O
ii NCT03868813 301 303 O
) NCT03868813 304 305 O
fluent NCT03868813 306 312 O
in NCT03868813 313 315 O
English NCT03868813 316 323 O
( NCT03868813 324 325 O
iii NCT03868813 326 329 O
) NCT03868813 330 331 O
have NCT03868813 332 336 O
Type NCT03868813 337 341 B-Modifier
- NCT03868813 342 343 I-Modifier
II NCT03868813 344 346 I-Modifier
diabetes NCT03868813 347 355 B-Condition
. NCT03868813 356 357 O

Exclusion NCT03868813 359 368 O
Criteria NCT03868813 369 377 O
: NCT03868813 378 379 O

None NCT03868813 381 385 O


Inclusion NCT03864224 0 9 O
Criteria NCT03864224 10 18 O
: NCT03864224 19 20 O

- NCT03864224 24 25 O
Patients NCT03864224 27 35 O
must NCT03864224 36 40 O
have NCT03864224 41 45 O
persistent NCT03864224 46 56 B-Modifier
low NCT03864224 57 60 I-Modifier
back NCT03864224 61 65 I-Modifier
pain NCT03864224 66 70 B-Condition
of NCT03864224 71 73 O
at NCT03864224 74 76 B-Eq-Comparison
least NCT03864224 77 82 I-Eq-Comparison
1 NCT03864224 83 84 I-Eq-Comparison
month NCT03864224 85 90 I-Eq-Comparison
's NCT03864224 90 92 O
duration NCT03864224 93 101 O
. NCT03864224 102 103 O

Exclusion NCT03864224 105 114 O
Criteria NCT03864224 115 123 O
: NCT03864224 124 125 O

- NCT03864224 129 130 O
Participating NCT03864224 132 145 O
currently NCT03864224 146 155 B-Eq-Comparison
in NCT03864224 156 158 O
a NCT03864224 159 160 O
supervised NCT03864224 161 171 O
exercise NCT03864224 172 180 B-Modifier
or NCT03864224 181 183 B-Or
rehabilitation NCT03864224 184 198 B-Modifier
program NCT03864224 199 206 B-Procedure
or NCT03864224 207 209 B-Or
enrolled NCT03864224 210 218 O
in NCT03864224 219 221 O
another NCT03864224 222 229 B-Other
interventional NCT03864224 230 244 O
clinical NCT03864224 245 253 B-Study
trial NCT03864224 254 259 I-Study
. NCT03864224 260 261 O

- NCT03864224 265 266 O
Patients NCT03864224 268 276 O
with NCT03864224 277 281 O
nerve NCT03864224 282 287 B-Condition
root NCT03864224 288 292 I-Condition
involvement NCT03864224 293 304 I-Condition
, NCT03864224 305 306 O
suspected NCT03864224 307 316 B-Assertion___Assertion-Type-Value:possible
serious NCT03864224 317 324 O
pathology NCT03864224 325 334 B-Condition
, NCT03864224 335 336 O
unstable NCT03864224 337 345 O
trauma NCT03864224 346 352 B-Condition
to NCT03864224 353 355 O
the NCT03864224 356 359 O
spine NCT03864224 360 365 B-Modifier
, NCT03864224 366 367 O
aspects NCT03864224 368 375 O
of NCT03864224 376 378 O
pregnancy NCT03864224 379 388 B-Condition
or NCT03864224 389 391 B-Or
other NCT03864224 392 397 B-Other
conditions NCT03864224 398 408 B-Condition
that NCT03864224 409 413 O
would NCT03864224 414 419 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03864224 420 427 B-Negation
participation NCT03864224 428 441 O
or NCT03864224 442 444 O
disallow NCT03864224 445 453 O
trial NCT03864224 454 459 B-Study
completion NCT03864224 460 470 O
within NCT03864224 471 477 O
the NCT03864224 478 481 O
prescribed NCT03864224 482 492 O
time NCT03864224 493 497 O
period NCT03864224 498 504 O
. NCT03864224 505 506 O

- NCT03864224 510 511 O
Persons NCT03864224 513 520 O
with NCT03864224 521 525 O
conditions NCT03864224 526 536 B-Condition
that NCT03864224 537 541 O
require NCT03864224 542 549 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03864224 550 551 O
specialist NCT03864224 552 562 B-Provider
consult NCT03864224 563 570 I-Provider
are NCT03864224 571 574 O
suspected NCT03864224 575 584 B-Assertion___Assertion-Type-Value:possible
of NCT03864224 585 587 O
needing NCT03864224 588 595 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03864224 596 597 O
specialist NCT03864224 598 608 B-Provider
consult NCT03864224 609 616 I-Provider
, NCT03864224 617 618 O
or NCT03864224 619 621 B-Or
have NCT03864224 622 626 O
conditions NCT03864224 627 637 B-Condition
that NCT03864224 638 642 O
would NCT03864224 643 648 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03864224 649 651 O
aggravated NCT03864224 652 662 O
or NCT03864224 663 665 B-Or
worsened NCT03864224 666 674 O
if NCT03864224 675 677 O
treated NCT03864224 678 685 B-Procedure
by NCT03864224 686 688 O
the NCT03864224 689 692 O
interventions NCT03864224 693 706 B-Procedure
in NCT03864224 707 709 O
this NCT03864224 710 714 O
study NCT03864224 715 720 B-Study
. NCT03864224 720 721 O

Inclusion NCT03868436 0 9 O
Criteria NCT03868436 10 18 O
: NCT03868436 19 20 O

1 NCT03868436 24 25 O
. NCT03868436 25 26 O
Conscious NCT03868436 28 37 O
adult NCT03868436 38 43 O
patients NCT03868436 44 52 O
: NCT03868436 53 54 O
≥ NCT03868436 55 56 B-Eq-Comparison
18 NCT03868436 57 59 I-Eq-Comparison
years NCT03868436 60 65 I-Eq-Comparison
of NCT03868436 66 68 O
age NCT03868436 69 72 B-Age

2 NCT03868436 75 76 O
. NCT03868436 76 77 O
Moderate NCT03868436 79 87 B-Eq-Comparison
to NCT03868436 88 90 I-Eq-Comparison
severe NCT03868436 91 97 I-Eq-Comparison
pain NCT03868436 98 102 B-Condition
associated NCT03868436 103 113 O
with NCT03868436 114 118 O
trauma NCT03868436 119 125 B-Condition
( NCT03868436 126 127 O
NRS0 NCT03868436 128 132 B-Eq-Comparison|Observation
- NCT03868436 133 134 I-Eq-Comparison|Observation
10 NCT03868436 135 137 I-Eq-Comparison|Observation
≥ NCT03868436 138 139 I-Eq-Comparison
4 NCT03868436 140 141 I-Eq-Comparison
) NCT03868436 142 143 O
which NCT03868436 144 149 O
is NCT03868436 150 152 O
unlikely NCT03868436 153 161 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868436 162 164 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03868436 165 172 O
surgery NCT03868436 173 180 B-Procedure
/ NCT03868436 181 182 B-Or
hospitalization NCT03868436 183 198 B-Encounter
, NCT03868436 199 200 O
such NCT03868436 201 205 O
as NCT03868436 206 208 O

- NCT03868436 216 217 O
Musculoskeletal NCT03868436 219 234 B-Modifier
injuries NCT03868436 235 243 B-Condition
and NCT03868436 244 247 B-Or
physical NCT03868436 248 256 B-Modifier
wounds NCT03868436 257 263 B-Condition

- NCT03868436 271 272 O
Fractures NCT03868436 274 283 B-Condition

- NCT03868436 291 292 O
Lacerations NCT03868436 294 305 B-Condition

- NCT03868436 313 314 O
Burns NCT03868436 316 321 B-Condition

- NCT03868436 329 330 O
Dislocations NCT03868436 332 344 O

- NCT03868436 352 353 O
Contusions NCT03868436 355 365 B-Condition

- NCT03868436 373 374 O
Injury NCT03868436 376 382 B-Condition
due NCT03868436 383 386 O
to NCT03868436 387 389 O
foreign NCT03868436 390 397 B-Condition
bodies NCT03868436 398 404 I-Condition

3 NCT03868436 407 408 O
. NCT03868436 408 409 O
Patient NCT03868436 411 418 O
( NCT03868436 419 420 O
and NCT03868436 421 424 O
/ NCT03868436 425 426 O
or NCT03868436 427 429 O
patient NCT03868436 430 437 O
's NCT03868436 437 439 O
authorized NCT03868436 440 450 O
legal NCT03868436 451 456 O
representative NCT03868436 457 471 O
) NCT03868436 472 473 O
should NCT03868436 474 480 O
understand NCT03868436 481 491 O
the NCT03868436 492 495 O
nature NCT03868436 496 502 O
of NCT03868436 503 505 O
the NCT03868436 506 509 O
study NCT03868436 510 515 O
and NCT03868436 516 519 O
provide NCT03868436 520 527 O
written NCT03868436 528 535 O
informed NCT03868436 536 544 O
consent NCT03868436 545 552 O

4 NCT03868436 555 556 O
. NCT03868436 556 557 O
Patient NCT03868436 559 566 O
is NCT03868436 567 569 O
able NCT03868436 570 574 O
to NCT03868436 575 577 O
follow NCT03868436 578 584 O
all NCT03868436 585 588 O
study NCT03868436 589 594 O
requirements NCT03868436 595 607 O
and NCT03868436 608 611 O
procedures NCT03868436 612 622 O
and NCT03868436 623 626 O
complete NCT03868436 627 635 O
required NCT03868436 636 644 O
questionnaires NCT03868436 645 659 O

Exclusion NCT03868436 660 669 O
Criteria NCT03868436 670 678 O
: NCT03868436 679 680 O

1 NCT03868436 684 685 O
. NCT03868436 685 686 O
Multi NCT03868436 688 693 B-Condition
- NCT03868436 694 695 I-Condition
level NCT03868436 696 701 I-Condition
trauma NCT03868436 702 708 I-Condition

2 NCT03868436 711 712 O
. NCT03868436 712 713 O
Women NCT03868436 715 720 O
of NCT03868436 721 723 B-And
child NCT03868436 724 729 B-Condition
bearing NCT03868436 730 737 I-Condition
potential NCT03868436 738 747 I-Condition
who NCT03868436 748 751 B-And
are NCT03868436 752 755 O
pregnant NCT03868436 756 764 B-Condition
or NCT03868436 765 767 B-Or
peri NCT03868436 768 772 B-Condition
partum NCT03868436 773 779 I-Condition
, NCT03868436 780 781 O
including NCT03868436 782 791 O
labour NCT03868436 792 798 B-Condition

3 NCT03868436 801 802 O
. NCT03868436 802 803 O
An NCT03868436 805 807 O
altered NCT03868436 808 815 B-Condition
level NCT03868436 816 821 I-Condition
of NCT03868436 822 824 I-Condition
consciousness NCT03868436 825 838 I-Condition
, NCT03868436 839 840 O
due NCT03868436 841 844 O
to NCT03868436 845 847 O
any NCT03868436 848 851 O
cause NCT03868436 852 857 B-Condition
, NCT03868436 858 859 O
including NCT03868436 860 869 O
head NCT03868436 870 874 B-Modifier
injury NCT03868436 875 881 B-Condition
, NCT03868436 882 883 O
drugs NCT03868436 884 889 B-Drug
, NCT03868436 890 891 O
or NCT03868436 892 894 B-Or
alcohol NCT03868436 895 902 B-Drug

4 NCT03868436 905 906 O
. NCT03868436 906 907 O
Clinically NCT03868436 909 919 O
significant NCT03868436 920 931 O
renal NCT03868436 932 937 B-Condition
impairment NCT03868436 938 948 I-Condition

5 NCT03868436 951 952 O
. NCT03868436 952 953 O
A NCT03868436 955 956 O
history NCT03868436 957 964 B-Eq-Comparison
of NCT03868436 965 967 O
liver NCT03868436 968 973 B-Condition
dysfunction NCT03868436 974 985 I-Condition
after NCT03868436 986 991 B-Temporal-Connection___Temporal-Connection-Type-Value:after
previous NCT03868436 992 1000 B-Eq-Comparison
MEOF NCT03868436 1001 1005 B-Drug
use NCT03868436 1006 1009 O
or NCT03868436 1010 1012 B-Or
other NCT03868436 1013 1018 B-Other
halogenated NCT03868436 1019 1030 B-Drug
anesthetics NCT03868436 1031 1042 I-Drug

6 NCT03868436 1045 1046 O
. NCT03868436 1046 1047 O
Hypersensitivity NCT03868436 1049 1065 B-Condition
to NCT03868436 1066 1068 O
MEOF NCT03868436 1069 1073 B-Drug
or NCT03868436 1074 1076 B-Or
other NCT03868436 1077 1082 B-Other
halogenated NCT03868436 1083 1094 B-Drug
anesthetics NCT03868436 1095 1106 I-Drug
, NCT03868436 1107 1108 O
or NCT03868436 1109 1111 B-Or
to NCT03868436 1112 1114 O
butylated NCT03868436 1115 1124 B-Drug
hydroxytoluene NCT03868436 1125 1139 I-Drug

7 NCT03868436 1142 1143 O
. NCT03868436 1143 1144 O
Known NCT03868436 1146 1151 O
or NCT03868436 1152 1154 B-Or
genetically NCT03868436 1155 1166 B-Modifier
susceptible NCT03868436 1167 1178 I-Modifier
to NCT03868436 1179 1181 I-Modifier
malignant NCT03868436 1182 1191 I-Modifier
hyperthermia NCT03868436 1192 1204 B-Condition
or NCT03868436 1205 1207 B-Or
a NCT03868436 1208 1209 O
history NCT03868436 1210 1217 B-Eq-Comparison
of NCT03868436 1218 1220 O
severe NCT03868436 1221 1227 O
adverse NCT03868436 1228 1235 B-Condition
reactions NCT03868436 1236 1245 I-Condition
in NCT03868436 1246 1248 O
either NCT03868436 1249 1255 O
patient NCT03868436 1256 1263 B-Family-Member___Family-Member-Type:patient
or NCT03868436 1264 1266 B-Or
relatives NCT03868436 1267 1276 B-Family-Member

8 NCT03868436 1279 1280 O
. NCT03868436 1280 1281 O
Exacerbation NCT03868436 1283 1295 O
of NCT03868436 1296 1298 O
an NCT03868436 1299 1301 O
underlying NCT03868436 1302 1312 B-Condition
condition NCT03868436 1313 1322 I-Condition
( NCT03868436 1323 1324 O
i. NCT03868436 1325 1327 O
e. NCT03868436 1328 1330 O
, NCT03868436 1331 1332 O
chronic NCT03868436 1333 1340 B-Modifier
pain NCT03868436 1341 1345 B-Condition
) NCT03868436 1346 1347 O

9 NCT03868436 1351 1352 O
. NCT03868436 1352 1353 O
Clinically NCT03868436 1355 1365 O
evident NCT03868436 1366 1373 B-Modifier
or NCT03868436 1374 1376 B-Or
potential NCT03868436 1377 1386 B-Assertion___Assertion-Type-Value:hypothetical
hemodynamic NCT03868436 1387 1398 B-Condition
instability NCT03868436 1399 1410 O
as NCT03868436 1411 1413 O
per NCT03868436 1414 1417 O
the NCT03868436 1418 1421 O
opinion NCT03868436 1422 1429 O
of NCT03868436 1430 1432 O
the NCT03868436 1433 1436 O
investigator NCT03868436 1437 1449 O

10 NCT03868436 1451 1453 O
. NCT03868436 1453 1454 O
Clinically NCT03868436 1456 1466 O
evident NCT03868436 1467 1474 O
respiratory NCT03868436 1475 1486 B-Condition
impairment NCT03868436 1487 1497 I-Condition
as NCT03868436 1498 1500 O
per NCT03868436 1501 1504 O
the NCT03868436 1505 1508 O
opinion NCT03868436 1509 1516 O
of NCT03868436 1517 1519 O
the NCT03868436 1520 1523 O
investigator NCT03868436 1524 1536 O

11 NCT03868436 1538 1540 O
. NCT03868436 1540 1541 O
Prior NCT03868436 1543 1548 B-Eq-Comparison
treatment NCT03868436 1549 1558 B-Procedure
with NCT03868436 1559 1563 O
PENTHROX NCT03868436 1564 1572 B-Drug
within NCT03868436 1573 1579 B-Eq-Comparison
3 NCT03868436 1580 1581 I-Eq-Comparison
months NCT03868436 1582 1588 I-Eq-Comparison

Inclusion NCT03869112 0 9 O
Criteria NCT03869112 10 18 O
: NCT03869112 19 20 O

- NCT03869112 24 25 O
Participant NCT03869112 27 38 O
is NCT03869112 39 41 O
willing NCT03869112 42 49 O
and NCT03869112 50 53 O
able NCT03869112 54 58 O
to NCT03869112 59 61 O
give NCT03869112 62 66 O
informed NCT03869112 67 75 O
consent NCT03869112 76 83 O
for NCT03869112 84 87 O
participation NCT03869112 88 101 O
in NCT03869112 102 104 O
the NCT03869112 105 108 O
study NCT03869112 109 114 B-Study

- NCT03869112 117 118 O
Male NCT03869112 120 124 O
or NCT03869112 125 127 B-Or
Female NCT03869112 128 134 O
, NCT03869112 135 136 O
aged NCT03869112 137 141 B-Age
40 NCT03869112 142 144 B-Eq-Comparison
years NCT03869112 145 150 I-Eq-Comparison
to NCT03869112 151 153 I-Eq-Comparison
85 NCT03869112 154 156 I-Eq-Comparison
years NCT03869112 157 162 I-Eq-Comparison
. NCT03869112 163 164 O

- NCT03869112 168 169 O
Diagnosed NCT03869112 171 180 O
with NCT03869112 181 185 O
COPD NCT03869112 186 190 B-Condition

- NCT03869112 193 194 O
Able NCT03869112 196 200 O
( NCT03869112 201 202 O
in NCT03869112 203 205 O
the NCT03869112 206 209 O
Investigators NCT03869112 210 223 O
opinion NCT03869112 224 231 O
) NCT03869112 232 233 O
and NCT03869112 234 237 O
willing NCT03869112 238 245 O
to NCT03869112 246 248 O
comply NCT03869112 249 255 O
with NCT03869112 256 260 O
all NCT03869112 261 264 O
study NCT03869112 265 270 O
requirements NCT03869112 271 283 O
. NCT03869112 284 285 O

- NCT03869112 289 290 O
Participant NCT03869112 292 303 O
is NCT03869112 304 306 O
willing NCT03869112 307 314 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869112 315 317 I-Assertion___Assertion-Type-Value:hypothetical
attend NCT03869112 318 324 O
visits NCT03869112 325 331 B-Encounter
at NCT03869112 332 334 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03869112 335 343 B-Study
and NCT03869112 344 347 B-And
8 NCT03869112 348 349 B-Eq-Comparison
weeks NCT03869112 350 355 I-Eq-Comparison
( NCT03869112 356 357 O
sub NCT03869112 358 361 O
- NCT03869112 362 363 O
group NCT03869112 364 369 O
: NCT03869112 370 371 O
baseline NCT03869112 372 380 O
, NCT03869112 381 382 O
8 NCT03869112 383 384 O
weeks NCT03869112 385 390 O
) NCT03869112 391 392 O

- NCT03869112 400 401 O
Able NCT03869112 403 407 O
to NCT03869112 408 410 O
read NCT03869112 411 415 O
and NCT03869112 416 419 O
understand NCT03869112 420 430 O
English NCT03869112 431 438 O

Exclusion NCT03869112 439 448 O
Criteria NCT03869112 449 457 O
: NCT03869112 458 459 O

- NCT03869112 463 464 O
Age NCT03869112 466 469 B-Age
< NCT03869112 470 471 B-Eq-Comparison
40 NCT03869112 472 474 I-Eq-Comparison

- NCT03869112 478 479 O
Attended NCT03869112 481 489 O
a NCT03869112 490 491 O
pulmonary NCT03869112 492 501 B-Procedure
rehabilitation NCT03869112 502 516 I-Procedure
programme NCT03869112 517 526 O
or NCT03869112 527 529 B-Or
participating NCT03869112 530 543 O
in NCT03869112 544 546 O
a NCT03869112 547 548 O
physical NCT03869112 549 557 B-Procedure
activity NCT03869112 558 566 I-Procedure
intervention NCT03869112 567 579 I-Procedure
study NCT03869112 580 585 B-Study
in NCT03869112 586 588 O
current NCT03869112 589 596 B-Eq-Comparison
time NCT03869112 597 601 I-Eq-Comparison
or NCT03869112 602 604 B-Or
in NCT03869112 605 607 O
the NCT03869112 608 611 O
last NCT03869112 612 616 B-Eq-Comparison
6 NCT03869112 617 618 I-Eq-Comparison
months NCT03869112 619 625 I-Eq-Comparison
. NCT03869112 626 627 O

- NCT03869112 631 632 O
Any NCT03869112 634 637 O
other NCT03869112 638 643 B-Other
significant NCT03869112 644 655 O
diseases NCT03869112 656 664 B-Condition
or NCT03869112 665 667 B-Or
disorders NCT03869112 668 677 B-Condition
that NCT03869112 678 682 O
are NCT03869112 683 686 O
a NCT03869112 687 688 O
contraindication NCT03869112 689 705 B-Contraindication
to NCT03869112 706 708 O
be NCT03869112 709 711 O
enrolled NCT03869112 712 720 O
in NCT03869112 721 723 O
a NCT03869112 724 725 O
pulmonary NCT03869112 726 735 B-Procedure
rehabilitation NCT03869112 736 750 I-Procedure
programme NCT03869112 751 760 O
. NCT03869112 761 762 O


Inclusion NCT03861572 0 9 O
Criteria NCT03861572 10 18 O
: NCT03861572 19 20 O

- NCT03861572 24 25 O
Participants NCT03861572 27 39 O
will NCT03861572 40 44 O
be NCT03861572 45 47 O
male NCT03861572 48 52 O
and NCT03861572 53 56 B-Or
female NCT03861572 57 63 O
subjects NCT03861572 64 72 O
who NCT03861572 73 76 B-And
suffered NCT03861572 77 85 B-Eq-Comparison
total NCT03861572 86 91 B-Modifier
acute NCT03861572 92 97 O
Achilles NCT03861572 98 106 B-Condition
tendon NCT03861572 107 113 I-Condition
rupture NCT03861572 114 121 I-Condition
, NCT03861572 122 123 O
and NCT03861572 124 127 B-And
which NCT03861572 128 133 O
underwent NCT03861572 134 143 B-Eq-Comparison
surgical NCT03861572 144 152 B-Procedure
repair NCT03861572 153 159 I-Procedure
. NCT03861572 159 160 O
In NCT03861572 162 164 O
addition NCT03861572 165 173 O
, NCT03861572 174 175 O
to NCT03861572 176 178 O
participate NCT03861572 179 190 O
in NCT03861572 191 193 O
this NCT03861572 194 198 O
study NCT03861572 199 204 B-Study
all NCT03861572 205 208 O
volunteers NCT03861572 209 219 O
will NCT03861572 220 224 O
need NCT03861572 225 229 O
to NCT03861572 230 232 O
present NCT03861572 233 240 O
medical NCT03861572 241 248 O
and NCT03861572 249 252 O
/ NCT03861572 253 254 O
or NCT03861572 255 257 O
physiotherapeutic NCT03861572 258 275 O
release NCT03861572 276 283 O
for NCT03861572 284 287 O
physical NCT03861572 288 296 O
/ NCT03861572 297 298 O
sports NCT03861572 299 305 O
activities NCT03861572 306 316 O
practice NCT03861572 317 325 O
. NCT03861572 326 327 O

Exclusion NCT03861572 329 338 O
Criteria NCT03861572 339 347 O
: NCT03861572 348 349 O

- NCT03861572 353 354 O
Volunteers NCT03861572 356 366 O
that NCT03861572 367 371 O
did NCT03861572 372 375 O
not NCT03861572 376 379 B-Negation
have NCT03861572 380 384 O
Achilles NCT03861572 385 393 B-Procedure
tendon NCT03861572 394 400 I-Procedure
surgical NCT03861572 401 409 I-Procedure
reconstruction NCT03861572 410 424 I-Procedure
, NCT03861572 425 426 O
that NCT03861572 427 431 O
did NCT03861572 432 435 O
not NCT03861572 436 439 B-Negation
present NCT03861572 440 447 O
medical NCT03861572 448 455 B-Modifier
and NCT03861572 456 459 B-Or
/ NCT03861572 460 461 I-Or
or NCT03861572 462 464 I-Or
physiotherapeutic NCT03861572 465 482 B-Modifier
release NCT03861572 483 490 B-Observation
for NCT03861572 491 494 O
physical NCT03861572 495 503 B-Modifier
/ NCT03861572 504 505 B-Or
sports NCT03861572 506 512 B-Modifier
activities NCT03861572 513 523 I-Modifier
, NCT03861572 524 525 O
who NCT03861572 526 529 B-And
have NCT03861572 530 534 O
participated NCT03861572 535 547 O
in NCT03861572 548 550 O
strength NCT03861572 551 559 B-Procedure
training NCT03861572 560 568 I-Procedure
program NCT03861572 569 576 I-Procedure
for NCT03861572 577 580 O
the NCT03861572 581 584 O
plantar NCT03861572 585 592 B-Modifier
flexors NCT03861572 593 600 I-Modifier
in NCT03861572 601 603 O
the NCT03861572 604 607 O
last NCT03861572 608 612 B-Eq-Comparison
6 NCT03861572 613 614 I-Eq-Comparison
months NCT03861572 615 621 I-Eq-Comparison
, NCT03861572 622 623 O
patients NCT03861572 624 632 O
with NCT03861572 633 637 O
diabetic NCT03861572 638 646 B-Condition
diseases NCT03861572 647 655 I-Condition
, NCT03861572 656 657 O
as NCT03861572 658 660 B-And
well NCT03861572 661 665 I-And
as NCT03861572 666 668 I-And
those NCT03861572 669 674 O
with NCT03861572 675 679 O
difficulty NCT03861572 680 690 B-Assertion___Assertion-Type-Value:hypothetical|Negation
for NCT03861572 691 694 O
understanding NCT03861572 695 708 O
and NCT03861572 709 712 O
/ NCT03861572 713 714 O
or NCT03861572 715 717 O
executing NCT03861572 718 727 O
the NCT03861572 728 731 O
test NCT03861572 732 736 B-Study
and NCT03861572 737 740 O
training NCT03861572 741 749 O
protocols NCT03861572 750 759 O
in NCT03861572 760 762 O
the NCT03861572 763 766 O
isokinetic NCT03861572 767 777 O
dynamometer NCT03861572 778 789 O
will NCT03861572 790 794 O
be NCT03861572 795 797 O
excluded NCT03861572 798 806 O
. NCT03861572 806 807 O

Inclusion NCT03864393 0 9 O
Criteria NCT03864393 10 18 O
: NCT03864393 19 20 O

- NCT03864393 24 25 O
18 NCT03864393 27 29 B-Eq-Comparison
years NCT03864393 30 35 I-Eq-Comparison
of NCT03864393 36 38 I-Eq-Comparison
age NCT03864393 39 42 I-Age|Eq-Comparison
or NCT03864393 43 45 I-Eq-Comparison
older NCT03864393 46 51 I-Eq-Comparison

- NCT03864393 54 55 O
diagnosis NCT03864393 57 66 O
of NCT03864393 67 69 O
idiopathic NCT03864393 70 80 B-Modifier
Parkinson NCT03864393 81 90 B-Condition
's NCT03864393 90 92 I-Condition
Disease NCT03864393 93 100 I-Condition
, NCT03864393 101 102 O
mild NCT03864393 103 107 B-Eq-Comparison
to NCT03864393 108 110 I-Eq-Comparison
moderate NCT03864393 111 119 I-Eq-Comparison
( NCT03864393 120 121 O
Hoehn NCT03864393 122 127 B-Observation
and NCT03864393 128 131 I-Observation
Yahr NCT03864393 132 136 I-Observation
score NCT03864393 137 142 I-Observation
less NCT03864393 143 147 B-Eq-Comparison
than NCT03864393 148 152 I-Eq-Comparison
or NCT03864393 153 155 I-Eq-Comparison
equal NCT03864393 156 161 I-Eq-Comparison
to NCT03864393 162 164 I-Eq-Comparison
3 NCT03864393 165 166 I-Eq-Comparison
) NCT03864393 167 168 O

- NCT03864393 172 173 O
speaks NCT03864393 175 181 O
English NCT03864393 182 189 O

- NCT03864393 192 193 O
able NCT03864393 195 199 B-Condition
to NCT03864393 200 202 I-Condition
ambulate NCT03864393 203 211 I-Condition
without NCT03864393 212 219 B-Negation
requiring NCT03864393 220 229 O
an NCT03864393 230 232 O
assistive NCT03864393 233 242 B-Procedure
device NCT03864393 243 249 I-Procedure

Exclusion NCT03864393 250 259 O
Criteria NCT03864393 260 268 O
: NCT03864393 269 270 O

- NCT03864393 274 275 O
neurological NCT03864393 277 289 B-Condition
disease NCT03864393 290 297 I-Condition
diagnosis NCT03864393 298 307 O
other NCT03864393 308 313 B-Exception
than NCT03864393 314 318 I-Exception
PD NCT03864393 319 321 B-Condition

- NCT03864393 324 325 O
uncontrolled NCT03864393 327 339 B-Modifier
cardiovascular NCT03864393 340 354 B-Modifier
, NCT03864393 355 356 O
pulmonary NCT03864393 357 366 B-Modifier
, NCT03864393 367 368 O
neurological NCT03864393 369 381 B-Modifier
, NCT03864393 382 383 O
or NCT03864393 384 386 B-Or
metabolic NCT03864393 387 396 B-Modifier
disease NCT03864393 397 404 B-Condition
which NCT03864393 405 410 O
may NCT03864393 411 414 B-Assertion___Assertion-Type-Value:hypothetical
impact NCT03864393 415 421 O
the NCT03864393 422 425 O
ability NCT03864393 426 433 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864393 434 436 I-Assertion___Assertion-Type-Value:hypothetical
exercise NCT03864393 437 445 B-Observation
or NCT03864393 446 448 B-Or
in NCT03864393 449 451 O
which NCT03864393 452 457 O
exercise NCT03864393 458 466 B-Observation
is NCT03864393 467 469 O
contraindicated NCT03864393 470 485 B-Contraindication

- NCT03864393 488 489 O
any NCT03864393 491 494 O
medications NCT03864393 495 506 B-Drug
, NCT03864393 507 508 O
such NCT03864393 509 513 O
as NCT03864393 514 516 O
beta NCT03864393 517 521 B-Drug
- NCT03864393 522 523 I-Drug
blockers NCT03864393 524 532 I-Drug
, NCT03864393 533 534 O
that NCT03864393 535 539 O
may NCT03864393 540 543 B-Assertion___Assertion-Type-Value:hypothetical
alter NCT03864393 544 549 O
HR NCT03864393 550 552 B-Observation
or NCT03864393 553 555 B-Or
metabolic NCT03864393 556 565 B-Observation
data NCT03864393 566 570 I-Observation

- NCT03864393 573 574 O
cognitive NCT03864393 576 585 B-Modifier
or NCT03864393 586 588 B-Or
psychiatric NCT03864393 589 600 B-Modifier
impairment NCT03864393 601 611 B-Condition
precluding NCT03864393 612 622 O
informed NCT03864393 623 631 O
consent NCT03864393 632 639 O
or NCT03864393 640 642 O
ability NCT03864393 643 650 O
to NCT03864393 651 653 O
following NCT03864393 654 663 O
instructions NCT03864393 664 676 O

- NCT03864393 679 680 O
mini NCT03864393 682 686 B-Observation
- NCT03864393 687 688 I-Observation
Mental NCT03864393 689 695 I-Observation
State NCT03864393 696 701 I-Observation
Examination NCT03864393 702 713 I-Observation
score NCT03864393 714 719 B-Eq-Comparison
< NCT03864393 720 721 I-Eq-Comparison
24 NCT03864393 722 724 I-Eq-Comparison

- NCT03864393 728 729 O
pregnancy NCT03864393 731 740 B-Condition

Inclusion NCT03866590 0 9 O
Criteria NCT03866590 10 18 O
: NCT03866590 19 20 O

- NCT03866590 24 25 O
Informed NCT03866590 27 35 O
consent NCT03866590 36 43 O
is NCT03866590 44 46 O
obtained NCT03866590 47 55 O
from NCT03866590 56 60 O
the NCT03866590 61 64 O
participant NCT03866590 65 76 O
or NCT03866590 77 79 O
its NCT03866590 80 83 O
legal NCT03866590 84 89 O
representatives NCT03866590 90 105 O

- NCT03866590 108 109 O
The NCT03866590 111 114 O
participant NCT03866590 115 126 O
is NCT03866590 127 129 O
older NCT03866590 130 135 B-Eq-Comparison
than NCT03866590 136 140 I-Eq-Comparison
14 NCT03866590 141 143 I-Eq-Comparison
years NCT03866590 144 149 I-Eq-Comparison
and NCT03866590 150 153 B-And
younger NCT03866590 154 161 B-Eq-Comparison
than NCT03866590 162 166 I-Eq-Comparison
25 NCT03866590 167 169 I-Eq-Comparison
years NCT03866590 170 175 I-Eq-Comparison
old NCT03866590 176 179 B-Age

- NCT03866590 182 183 O
The NCT03866590 185 188 O
patient NCT03866590 189 196 O
exhibits NCT03866590 197 205 O
chronic NCT03866590 206 213 B-Modifier
anaemia NCT03866590 214 221 B-Condition
or NCT03866590 222 224 B-Or
cholelithiasis NCT03866590 225 239 B-Condition
or NCT03866590 240 242 B-Or
cholecystitis NCT03866590 243 256 B-Condition
of NCT03866590 257 259 O
undetermined NCT03866590 260 272 B-Modifier
aetiology NCT03866590 273 282 I-Modifier
or NCT03866590 283 285 B-Or
The NCT03866590 286 289 O
patient NCT03866590 290 297 O
has NCT03866590 298 301 O
a NCT03866590 302 303 O
high NCT03866590 304 308 O
- NCT03866590 309 310 O
grade NCT03866590 311 316 O
PKD NCT03866590 317 320 B-Condition
suspicion NCT03866590 321 330 B-Assertion___Assertion-Type-Value:possible
due NCT03866590 331 334 O
to NCT03866590 335 337 O
any NCT03866590 338 341 O
clinical NCT03866590 342 350 O
item NCT03866590 351 355 O
or NCT03866590 356 358 B-Or
The NCT03866590 359 362 O
patient NCT03866590 363 370 O
is NCT03866590 371 373 O
diagnosed NCT03866590 374 383 O
biochemically NCT03866590 384 397 B-Procedure
and NCT03866590 398 401 B-Or
/ NCT03866590 402 403 I-Or
or NCT03866590 404 406 I-Or
genetically NCT03866590 407 418 B-Procedure
with NCT03866590 419 423 O
PKD NCT03866590 424 427 B-Condition

Exclusion NCT03866590 428 437 O
Criteria NCT03866590 438 446 O
: NCT03866590 447 448 O

- NCT03866590 452 453 O
Inability NCT03866590 455 464 O
to NCT03866590 465 467 O
provide NCT03866590 468 475 O
informed NCT03866590 476 484 O
consent NCT03866590 485 492 O

- NCT03866590 495 496 O
The NCT03866590 498 501 O
patient NCT03866590 502 509 O
does NCT03866590 510 514 O
not NCT03866590 515 518 B-Negation
suffer NCT03866590 519 525 O
from NCT03866590 526 530 O
chronic NCT03866590 531 538 B-Modifier
anaemia NCT03866590 539 546 B-Condition
or NCT03866590 547 549 B-Or
cholelithiasis NCT03866590 550 564 B-Condition
or NCT03866590 565 567 B-Or
cholecystitis NCT03866590 568 581 B-Condition

- NCT03866590 584 585 O
The NCT03866590 587 590 O
aetiology NCT03866590 591 600 O
of NCT03866590 601 603 O
chronic NCT03866590 604 611 B-Modifier
anaemia NCT03866590 612 619 B-Condition
or NCT03866590 620 622 B-Or
cholelithiasis NCT03866590 623 637 B-Condition
or NCT03866590 638 640 B-Or
cholecystitis NCT03866590 641 654 B-Condition
is NCT03866590 655 657 O
determined NCT03866590 658 668 O
and NCT03866590 669 672 O
is NCT03866590 673 675 O
not NCT03866590 676 679 B-Negation
due NCT03866590 680 683 O
to NCT03866590 684 686 O
PKD NCT03866590 687 690 B-Condition

- NCT03866590 693 694 O
The NCT03866590 696 699 O
participant NCT03866590 700 711 O
is NCT03866590 712 714 O
younger NCT03866590 715 722 B-Eq-Comparison
than NCT03866590 723 727 I-Eq-Comparison
14 NCT03866590 728 730 I-Eq-Comparison
years NCT03866590 731 736 I-Eq-Comparison
or NCT03866590 737 739 B-Or
older NCT03866590 740 745 B-Eq-Comparison
than NCT03866590 746 750 I-Eq-Comparison
25 NCT03866590 751 753 I-Eq-Comparison
years NCT03866590 754 759 I-Eq-Comparison
old NCT03866590 760 763 B-Age

- NCT03866590 766 767 O
Previously NCT03866590 769 779 B-Eq-Comparison
enrolled NCT03866590 780 788 O
in NCT03866590 789 791 O
the NCT03866590 792 795 O
study NCT03866590 796 801 B-Study

Inclusion NCT03869476 0 9 O
Criteria NCT03869476 10 18 O
: NCT03869476 19 20 O

- NCT03869476 24 25 O
Adult NCT03869476 27 32 O
( NCT03869476 33 34 O
18 NCT03869476 35 37 B-Eq-Comparison
years NCT03869476 38 43 I-Eq-Comparison
of NCT03869476 44 46 I-Eq-Comparison
age NCT03869476 47 50 I-Age|Eq-Comparison
or NCT03869476 51 53 I-Eq-Comparison
older NCT03869476 54 59 I-Eq-Comparison
) NCT03869476 60 61 O
with NCT03869476 62 66 B-And
the NCT03869476 67 70 O
diagnosis NCT03869476 71 80 O
of NCT03869476 81 83 O
essential NCT03869476 84 93 B-Modifier
thrombocytosis NCT03869476 94 108 B-Condition
, NCT03869476 109 110 O
prefibrotic NCT03869476 111 122 B-Condition
myelofibrosis NCT03869476 123 136 I-Condition
or NCT03869476 137 139 B-Or
overt NCT03869476 140 145 B-Modifier
myelofibrosis NCT03869476 146 159 B-Condition
according NCT03869476 160 169 O
to NCT03869476 170 172 O
WHO NCT03869476 173 176 O
2016 NCT03869476 177 181 O
criteria NCT03869476 182 190 O
; NCT03869476 190 191 O

- NCT03869476 194 195 O
Patient NCT03869476 197 204 O
who NCT03869476 205 208 O
has NCT03869476 209 212 O
not NCT03869476 213 216 B-Negation
received NCT03869476 217 225 B-Eq-Comparison
specific NCT03869476 226 234 O
treatment NCT03869476 235 244 B-Procedure
for NCT03869476 245 248 O
neoplasms NCT03869476 249 258 B-Condition
; NCT03869476 258 259 O

- NCT03869476 262 263 O
Patient NCT03869476 265 272 O
who NCT03869476 273 276 O
has NCT03869476 277 280 O
signed NCT03869476 281 287 O
the NCT03869476 288 291 O
consent NCT03869476 292 299 O
to NCT03869476 300 302 O
participate NCT03869476 303 314 O
in NCT03869476 315 317 O
the NCT03869476 318 321 O
study NCT03869476 322 327 B-Study
; NCT03869476 327 328 O

- NCT03869476 331 332 O
Patient NCT03869476 334 341 O
who NCT03869476 342 345 O
has NCT03869476 346 349 O
consented NCT03869476 350 359 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869476 360 362 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03869476 363 365 O
included NCT03869476 366 374 O
in NCT03869476 375 377 O
the NCT03869476 378 381 O
" NCT03869476 382 383 O
Malignant NCT03869476 383 392 O
Haemopathies NCT03869476 393 405 O
" NCT03869476 405 406 O
collection NCT03869476 407 417 O
at NCT03869476 418 420 O
the NCT03869476 421 424 O
University NCT03869476 425 435 O
Hospital NCT03869476 436 444 O
of NCT03869476 445 447 O
Angers NCT03869476 448 454 O
or NCT03869476 455 457 B-Or
Brest NCT03869476 458 463 O
and NCT03869476 464 467 O
for NCT03869476 468 471 O
whom NCT03869476 472 476 O
the NCT03869476 477 480 O
samples NCT03869476 481 488 O
necessary NCT03869476 489 498 O
for NCT03869476 499 502 O
the NCT03869476 503 506 O
study NCT03869476 507 512 B-Study
are NCT03869476 513 516 O
available NCT03869476 517 526 O
in NCT03869476 527 529 O
the NCT03869476 530 533 O
biocollection NCT03869476 534 547 O
. NCT03869476 548 549 O

Exclusion NCT03869476 551 560 O
Criteria NCT03869476 561 569 O
: NCT03869476 570 571 O

- NCT03869476 575 576 O
Patient NCT03869476 578 585 O
with NCT03869476 586 590 O
another NCT03869476 591 598 B-Other
hematologic NCT03869476 599 610 B-Condition
neoplasm NCT03869476 611 619 I-Condition
or NCT03869476 620 622 B-Or
progressive NCT03869476 623 634 B-Modifier
cancer NCT03869476 635 641 B-Condition
at NCT03869476 642 644 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03869476 645 648 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03869476 649 653 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03869476 654 656 O
diagnosis NCT03869476 657 666 B-Coreference
; NCT03869476 666 667 O

- NCT03869476 670 671 O
Patient NCT03869476 673 680 O
with NCT03869476 681 685 O
a NCT03869476 686 687 O
diagnosis NCT03869476 688 697 O
of NCT03869476 698 700 O
secondary NCT03869476 701 710 B-Modifier
myelofibrosis NCT03869476 711 724 B-Condition
; NCT03869476 724 725 O

- NCT03869476 728 729 O
Pregnant NCT03869476 731 739 B-Condition
or NCT03869476 740 742 B-Or
breastfeeding NCT03869476 743 756 B-Condition
woman NCT03869476 757 762 O
; NCT03869476 762 763 O

- NCT03869476 766 767 O
Person NCT03869476 769 775 O
prived NCT03869476 776 782 B-Observation
of NCT03869476 783 785 I-Observation
liberty NCT03869476 786 793 I-Observation
by NCT03869476 794 796 O
judicial NCT03869476 797 805 O
or NCT03869476 806 808 O
administrative NCT03869476 809 823 O
decision NCT03869476 824 832 O
; NCT03869476 832 833 O

- NCT03869476 836 837 O
Person NCT03869476 839 845 O
subject NCT03869476 846 853 O
to NCT03869476 854 856 O
a NCT03869476 857 858 O
legal NCT03869476 859 864 B-Observation
protection NCT03869476 865 875 I-Observation
measure NCT03869476 876 883 I-Observation
; NCT03869476 883 884 O

Inclusion NCT03869489 0 9 O
Criteria NCT03869489 10 18 O
: NCT03869489 19 20 O

- NCT03869489 24 25 O
Normal NCT03869489 27 33 O
hearing NCT03869489 34 41 B-Condition
and NCT03869489 42 45 B-And
vision NCT03869489 46 52 B-Condition

Exclusion NCT03869489 53 62 O
Criteria NCT03869489 63 71 O
: NCT03869489 72 73 O

- NCT03869489 77 78 O
Left NCT03869489 80 84 B-Condition
- NCT03869489 85 86 I-Condition
handedness NCT03869489 87 97 I-Condition

- NCT03869489 100 101 O
History NCT03869489 103 110 B-Eq-Comparison
of NCT03869489 111 113 O
seizure NCT03869489 114 121 B-Condition
, NCT03869489 122 123 O
head NCT03869489 124 128 B-Modifier
injury NCT03869489 129 135 B-Condition
( NCT03869489 136 137 O
including NCT03869489 138 147 O
neurosurgery NCT03869489 148 160 B-Procedure
) NCT03869489 161 162 O
, NCT03869489 164 165 O
brain NCT03869489 166 171 B-Modifier
injury NCT03869489 172 178 B-Condition
, NCT03869489 179 180 O
diagnosis NCT03869489 181 190 O
or NCT03869489 191 193 B-Or
a NCT03869489 194 195 O
neurological NCT03869489 196 208 B-Modifier
or NCT03869489 209 211 B-Or
psychiatric NCT03869489 212 223 B-Modifier
disorder NCT03869489 224 232 B-Condition
, NCT03869489 233 234 O
metal NCT03869489 235 240 B-Condition
in NCT03869489 241 243 I-Condition
the NCT03869489 244 247 I-Condition
head NCT03869489 248 252 I-Condition
, NCT03869489 253 254 O
sensitive NCT03869489 255 264 B-Condition
scalp NCT03869489 265 270 I-Condition

- NCT03869489 273 274 O
History NCT03869489 276 283 B-Eq-Comparison
of NCT03869489 284 286 O
anxiolytic NCT03869489 287 297 B-Drug
and NCT03869489 298 301 B-Or
/ NCT03869489 302 303 I-Or
or NCT03869489 304 306 I-Or
antidepressant NCT03869489 307 321 B-Drug
medications NCT03869489 322 333 I-Drug

- NCT03869489 336 337 O
Participation NCT03869489 339 352 O
in NCT03869489 353 355 O
Experiment NCT03869489 356 366 B-Study
# NCT03869489 367 368 O
1 NCT03869489 368 369 O
or NCT03869489 370 372 B-Or
Experiment NCT03869489 373 383 B-Study
# NCT03869489 384 385 O
2 NCT03869489 385 386 O
of NCT03869489 387 389 O
the NCT03869489 390 393 O
larger NCT03869489 394 400 O
study NCT03869489 401 406 B-Study

Inclusion NCT03863210 0 9 O
Criteria NCT03863210 10 18 O
: NCT03863210 19 20 O

- NCT03863210 24 25 O
female NCT03863210 27 33 O
sex NCT03863210 34 37 O

- NCT03863210 40 41 O
age NCT03863210 43 46 B-Age
45 NCT03863210 47 49 B-Eq-Comparison
to NCT03863210 50 52 I-Eq-Comparison
60 NCT03863210 53 55 I-Eq-Comparison
years NCT03863210 56 61 I-Eq-Comparison

- NCT03863210 64 65 O
one NCT03863210 67 70 B-Eq-Comparison
or NCT03863210 71 73 I-Eq-Comparison
more NCT03863210 74 78 I-Eq-Comparison
CV NCT03863210 79 81 B-Condition
risk NCT03863210 82 86 B-Risk
factors NCT03863210 87 94 I-Risk
[ NCT03863210 95 96 O
overweight NCT03863210 97 107 B-Condition
or NCT03863210 108 110 B-Or
obesity NCT03863210 111 118 B-Condition
, NCT03863210 119 120 O
i. NCT03863210 121 123 O
e. NCT03863210 125 127 O
body NCT03863210 129 133 B-Observation
mass NCT03863210 134 138 I-Observation
index NCT03863210 139 144 I-Observation
( NCT03863210 145 146 O
BMI NCT03863210 147 150 B-Observation
) NCT03863210 151 152 O
≥ NCT03863210 153 154 B-Eq-Comparison
25 NCT03863210 155 157 I-Eq-Comparison
kg NCT03863210 158 160 I-Eq-Comparison
/ NCT03863210 161 162 I-Eq-Comparison
m2 NCT03863210 163 165 I-Eq-Comparison
, NCT03863210 166 167 O
and NCT03863210 168 171 B-Or
/ NCT03863210 172 173 I-Or
or NCT03863210 174 176 I-Or
central NCT03863210 177 184 B-Modifier
obesity NCT03863210 185 192 B-Condition
- NCT03863210 193 194 O
waist NCT03863210 195 200 B-Observation
circumference NCT03863210 201 214 I-Observation
≥ NCT03863210 215 216 B-Eq-Comparison
88 NCT03863210 217 219 I-Eq-Comparison
cm NCT03863210 220 222 I-Eq-Comparison
, NCT03863210 223 224 O
high NCT03863210 225 229 O
blood NCT03863210 230 235 B-Observation
pressure NCT03863210 236 244 I-Observation
( NCT03863210 245 246 O
systolic NCT03863210 247 255 B-Observation
blood NCT03863210 256 261 I-Observation
pressure NCT03863210 262 270 I-Observation
≥ NCT03863210 271 272 B-Eq-Comparison
140 NCT03863210 273 276 I-Eq-Comparison
mm NCT03863210 277 279 I-Eq-Comparison
Hg NCT03863210 280 282 I-Eq-Comparison
and NCT03863210 283 286 B-Or
/ NCT03863210 287 288 I-Or
or NCT03863210 289 291 I-Or
diastolic NCT03863210 292 301 B-Observation
blood NCT03863210 302 307 I-Observation
pressure NCT03863210 308 316 I-Observation
≥ NCT03863210 317 318 B-Eq-Comparison
90 NCT03863210 319 321 I-Eq-Comparison
mm NCT03863210 322 324 I-Eq-Comparison
Hg NCT03863210 325 327 I-Eq-Comparison
) NCT03863210 328 329 O
, NCT03863210 331 332 O
high NCT03863210 333 337 O
blood NCT03863210 338 343 B-Observation
cholesterol NCT03863210 344 355 I-Observation
( NCT03863210 356 357 O
≥ NCT03863210 359 360 B-Eq-Comparison
5.2 NCT03863210 361 364 I-Eq-Comparison
mmol NCT03863210 365 369 I-Eq-Comparison
/ NCT03863210 370 371 I-Eq-Comparison
L NCT03863210 372 373 I-Eq-Comparison
) NCT03863210 374 375 O
and NCT03863210 376 379 B-And
active NCT03863210 380 386 B-Eq-Comparison
smoking NCT03863210 387 394 B-Condition
] NCT03863210 395 396 O

- NCT03863210 400 401 O
participants NCT03863210 403 415 O
on NCT03863210 416 418 B-Eq-Comparison
antihypertensive NCT03863210 419 435 B-Procedure
therapy NCT03863210 436 443 I-Procedure
were NCT03863210 444 448 O
also NCT03863210 449 453 O
included NCT03863210 454 462 O
in NCT03863210 463 465 O
the NCT03863210 466 469 O
study NCT03863210 470 475 B-Study

Exclusion NCT03863210 476 485 O
Criteria NCT03863210 486 494 O
: NCT03863210 495 496 O

- NCT03863210 500 501 O
current NCT03863210 503 510 B-Eq-Comparison
cardiovascular NCT03863210 511 525 B-Condition
disease NCT03863210 526 533 I-Condition
( NCT03863210 534 535 O
CVD NCT03863210 536 539 B-Condition
) NCT03863210 540 541 O
( NCT03863210 542 543 O
ischemic NCT03863210 544 552 B-Condition
heart NCT03863210 553 558 I-Condition
disease NCT03863210 559 566 I-Condition
, NCT03863210 567 568 O
peripheral NCT03863210 569 579 B-Condition
artery NCT03863210 580 586 I-Condition
disease NCT03863210 587 594 I-Condition
, NCT03863210 595 596 O
and NCT03863210 597 600 B-Or
stroke NCT03863210 601 607 B-Condition
) NCT03863210 608 609 O

- NCT03863210 613 614 O
malignant NCT03863210 616 625 B-Condition
diseases NCT03863210 626 634 I-Condition

- NCT03863210 637 638 O
serious NCT03863210 640 647 O
systemic NCT03863210 648 656 B-Modifier
or NCT03863210 657 659 B-Or
mental NCT03863210 660 666 B-Modifier
diseases NCT03863210 667 675 B-Condition

Inclusion NCT03868345 0 9 O
Criteria NCT03868345 10 18 O
: NCT03868345 19 20 O

1 NCT03868345 24 25 O
. NCT03868345 25 26 O
male NCT03868345 28 32 O
or NCT03868345 33 35 B-Or
female NCT03868345 36 42 O
, NCT03868345 43 44 O
age NCT03868345 45 48 B-Age
21 NCT03868345 49 51 B-Eq-Comparison
or NCT03868345 52 54 I-Eq-Comparison
older NCT03868345 55 60 I-Eq-Comparison
, NCT03868345 61 62 O

2 NCT03868345 66 67 O
. NCT03868345 67 68 O
diagnosed NCT03868345 70 79 O
with NCT03868345 80 84 O
definite NCT03868345 85 93 B-Modifier
, NCT03868345 94 95 O
probable NCT03868345 96 104 B-Assertion___Assertion-Type-Value:possible
, NCT03868345 105 106 O
or NCT03868345 107 109 B-Or
possible NCT03868345 110 118 B-Assertion___Assertion-Type-Value:possible
ALS NCT03868345 119 122 B-Condition
according NCT03868345 123 132 O
to NCT03868345 133 135 O
the NCT03868345 136 139 O
modified NCT03868345 140 148 O
El NCT03868345 149 151 O
Escorial NCT03868345 152 160 O
Criteria NCT03868345 161 169 O
, NCT03868345 170 171 O

3 NCT03868345 175 176 O
. NCT03868345 176 177 O
a NCT03868345 179 180 O
score NCT03868345 181 186 B-Eq-Comparison
of NCT03868345 187 189 I-Eq-Comparison
2 NCT03868345 190 191 I-Eq-Comparison
or NCT03868345 192 194 I-Eq-Comparison
greater NCT03868345 195 202 I-Eq-Comparison
on NCT03868345 203 205 O
the NCT03868345 206 209 O
speech NCT03868345 210 216 B-Observation
question NCT03868345 217 225 I-Observation
of NCT03868345 226 228 I-Observation
the NCT03868345 229 232 I-Observation
ALSFRS NCT03868345 233 239 I-Observation
- NCT03868345 240 241 I-Observation
R NCT03868345 242 243 I-Observation
( NCT03868345 244 245 O
i. NCT03868345 246 248 O
e. NCT03868345 249 251 O
speech NCT03868345 253 259 B-Condition
is NCT03868345 260 262 O
intelligible NCT03868345 263 275 B-Modifier
with NCT03868345 276 280 O
occasional NCT03868345 281 291 B-Modifier
repetition NCT03868345 292 302 I-Modifier
) NCT03868345 303 304 O
, NCT03868345 306 307 O

4 NCT03868345 311 312 O
. NCT03868345 312 313 O
continuous NCT03868345 315 325 O
internet NCT03868345 326 334 O
access NCT03868345 335 341 O
at NCT03868345 342 344 O
home NCT03868345 345 349 O
, NCT03868345 350 351 O

5 NCT03868345 355 356 O
. NCT03868345 356 357 O
willingness NCT03868345 359 370 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03868345 371 374 I-Assertion___Assertion-Type-Value:hypothetical
medical NCT03868345 375 382 I-Assertion___Assertion-Type-Value:hypothetical
ability NCT03868345 383 390 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 391 393 O
comply NCT03868345 394 400 O
with NCT03868345 401 405 O
scheduled NCT03868345 406 415 B-Eq-Comparison
visits NCT03868345 416 422 B-Encounter
and NCT03868345 423 426 B-And
study NCT03868345 427 432 B-Study
procedures NCT03868345 433 443 B-Procedure
, NCT03868345 444 445 O

6 NCT03868345 449 450 O
. NCT03868345 450 451 O
ability NCT03868345 453 460 O
to NCT03868345 461 463 O
understand NCT03868345 464 474 O
the NCT03868345 475 478 O
purpose NCT03868345 479 486 O
and NCT03868345 487 490 O
risks NCT03868345 491 496 O
of NCT03868345 497 499 O
the NCT03868345 500 503 O
study NCT03868345 504 509 O
and NCT03868345 510 513 O
provide NCT03868345 514 521 O
signed NCT03868345 522 528 O
and NCT03868345 529 532 O
dated NCT03868345 533 538 O
informed NCT03868345 539 547 O
consent NCT03868345 548 555 O
and NCT03868345 556 559 O
authorization NCT03868345 560 573 O
to NCT03868345 574 576 O
use NCT03868345 577 580 O
protected NCT03868345 581 590 O
health NCT03868345 591 597 O
information NCT03868345 598 609 O
( NCT03868345 610 611 O
PHI NCT03868345 612 615 O
) NCT03868345 616 617 O
in NCT03868345 618 620 O
accordance NCT03868345 621 631 O
with NCT03868345 632 636 O
national NCT03868345 637 645 O
and NCT03868345 646 649 O
local NCT03868345 650 655 O
subject NCT03868345 656 663 O
privacy NCT03868345 664 671 O
regulations NCT03868345 672 683 O
, NCT03868345 684 685 O

7 NCT03868345 689 690 O
. NCT03868345 690 691 O
geographic NCT03868345 693 703 O
accessibility NCT03868345 704 717 O
to NCT03868345 718 720 O
study NCT03868345 721 726 O
site NCT03868345 727 731 O
, NCT03868345 732 733 O

8 NCT03868345 737 738 O
. NCT03868345 738 739 O
for NCT03868345 741 744 O
the NCT03868345 745 748 O
25 NCT03868345 749 751 O
participants NCT03868345 752 764 O
in NCT03868345 765 767 O
Group NCT03868345 768 773 O
1 NCT03868345 774 775 O
, NCT03868345 776 777 O
NO NCT03868345 778 780 B-Negation
noted NCT03868345 781 786 O
symptoms NCT03868345 787 795 B-Assertion___Assertion-Type-Value:possible
of NCT03868345 796 798 O
frontotemporal NCT03868345 799 813 B-Condition
cognitive NCT03868345 814 823 I-Condition
dysfunction NCT03868345 824 835 I-Condition
, NCT03868345 836 837 O
and NCT03868345 838 841 B-And

9 NCT03868345 844 845 O
. NCT03868345 845 846 O
for NCT03868345 848 851 O
the NCT03868345 852 855 O
25 NCT03868345 856 858 O
participants NCT03868345 859 871 O
in NCT03868345 872 874 O
Group NCT03868345 875 880 O
2 NCT03868345 881 882 O
, NCT03868345 883 884 O
MUST NCT03868345 885 889 O
have NCT03868345 890 894 O
cognitive NCT03868345 895 904 B-Condition
symptoms NCT03868345 905 913 B-Assertion___Assertion-Type-Value:possible
as NCT03868345 914 916 O
noted NCT03868345 917 922 O
either NCT03868345 923 929 O
by NCT03868345 930 932 O
themselves NCT03868345 933 943 O
or NCT03868345 944 946 O
a NCT03868345 947 948 O
caregiver NCT03868345 949 958 O
. NCT03868345 959 960 O

Exclusion NCT03868345 962 971 O
Criteria NCT03868345 972 980 O
: NCT03868345 981 982 O

1 NCT03868345 986 987 O
. NCT03868345 987 988 O
unwilling NCT03868345 990 999 O
or NCT03868345 1000 1002 O
unable NCT03868345 1003 1009 O
to NCT03868345 1010 1012 O
comply NCT03868345 1013 1019 O
with NCT03868345 1020 1024 O
the NCT03868345 1025 1028 O
requirements NCT03868345 1029 1041 O
of NCT03868345 1042 1044 O
this NCT03868345 1045 1049 O
protocol NCT03868345 1050 1058 O
, NCT03868345 1059 1060 O
including NCT03868345 1061 1070 O
the NCT03868345 1071 1074 O
presence NCT03868345 1075 1083 O
of NCT03868345 1084 1086 O
any NCT03868345 1087 1090 O
condition NCT03868345 1091 1100 B-Condition
( NCT03868345 1101 1102 O
physical NCT03868345 1103 1111 B-Modifier
, NCT03868345 1112 1113 O
mental NCT03868345 1114 1120 B-Modifier
, NCT03868345 1121 1122 O
or NCT03868345 1123 1125 B-Or
social NCT03868345 1126 1132 B-Modifier
) NCT03868345 1133 1134 O
that NCT03868345 1135 1139 O
is NCT03868345 1140 1142 O
likely NCT03868345 1143 1149 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 1150 1152 O
affect NCT03868345 1153 1159 O
the NCT03868345 1160 1163 O
participant NCT03868345 1164 1175 O
's NCT03868345 1175 1177 O
ability NCT03868345 1178 1185 O
to NCT03868345 1186 1188 O
comply NCT03868345 1189 1195 O
with NCT03868345 1196 1200 O
the NCT03868345 1201 1204 O
protocol NCT03868345 1205 1213 O
, NCT03868345 1214 1215 O
and NCT03868345 1216 1219 O

2 NCT03868345 1222 1223 O
. NCT03868345 1223 1224 O
any NCT03868345 1226 1229 O
other NCT03868345 1230 1235 O
reasons NCT03868345 1236 1243 O
that NCT03868345 1244 1248 O
, NCT03868345 1249 1250 O
in NCT03868345 1251 1253 O
the NCT03868345 1254 1257 O
opinion NCT03868345 1258 1265 O
of NCT03868345 1266 1268 O
the NCT03868345 1269 1272 O
PI NCT03868345 1273 1275 O
, NCT03868345 1276 1277 O
cause NCT03868345 1278 1283 O
the NCT03868345 1284 1287 O
candidate NCT03868345 1288 1297 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868345 1298 1300 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868345 1301 1303 O
deemed NCT03868345 1304 1310 O
unsuitable NCT03868345 1311 1321 B-Negation
for NCT03868345 1322 1325 O
entry NCT03868345 1326 1331 O
into NCT03868345 1332 1336 O
the NCT03868345 1337 1340 O
study NCT03868345 1341 1346 B-Study
. NCT03868345 1346 1347 O

Inclusion NCT03862898 0 9 O
Criteria NCT03862898 10 18 O
: NCT03862898 19 20 O

- NCT03862898 24 25 O
patients NCT03862898 27 35 O
with NCT03862898 36 40 O
lumbar NCT03862898 41 47 B-Modifier
pain NCT03862898 48 52 B-Condition
present NCT03862898 53 60 O
for NCT03862898 61 64 O
more NCT03862898 65 69 B-Eq-Comparison
than NCT03862898 70 74 I-Eq-Comparison
12 NCT03862898 75 77 I-Eq-Comparison
weeks NCT03862898 78 83 I-Eq-Comparison
, NCT03862898 84 85 O

- NCT03862898 89 90 O
pain NCT03862898 92 96 B-Condition
during NCT03862898 97 103 B-Temporal-Connection___Temporal-Connection-Type-Value:during
changing NCT03862898 104 112 B-Observation
of NCT03862898 113 115 I-Observation
the NCT03862898 116 119 I-Observation
position NCT03862898 120 128 I-Observation
, NCT03862898 129 130 O

- NCT03862898 134 135 O
radicular NCT03862898 137 146 B-Modifier
pain NCT03862898 147 151 B-Condition
. NCT03862898 152 153 O

Exclusion NCT03862898 155 164 O
Criteria NCT03862898 165 173 O
: NCT03862898 174 175 O

- NCT03862898 179 180 O
Cauda NCT03862898 182 187 B-Condition
equina NCT03862898 188 194 I-Condition
syndrome NCT03862898 195 203 I-Condition
, NCT03862898 204 205 O

- NCT03862898 209 210 O
ankylosing NCT03862898 212 222 B-Condition
spondylitis NCT03862898 223 234 I-Condition
, NCT03862898 235 236 O

- NCT03862898 240 241 O
thoracic NCT03862898 243 251 B-Condition
deformities NCT03862898 252 263 I-Condition
( NCT03862898 264 265 O
pectus NCT03862898 266 272 B-Condition
carinatum NCT03862898 273 282 I-Condition
, NCT03862898 283 284 O
excavatum NCT03862898 285 294 B-Condition
) NCT03862898 295 296 O
, NCT03862898 298 299 O

- NCT03862898 303 304 O
spina NCT03862898 306 311 B-Condition
bifida NCT03862898 312 318 I-Condition
, NCT03862898 319 320 O

- NCT03862898 324 325 O
fractures NCT03862898 327 336 B-Condition
, NCT03862898 337 338 O

- NCT03862898 342 343 O
post NCT03862898 345 349 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862898 350 351 O
operative NCT03862898 352 361 B-Procedure
spinal NCT03862898 362 368 B-Condition
conditions NCT03862898 369 379 I-Condition
, NCT03862898 380 381 O

- NCT03862898 385 386 O
diabetes NCT03862898 388 396 B-Condition
, NCT03862898 397 398 O

- NCT03862898 402 403 O
inflammatory NCT03862898 405 417 B-Condition
processes NCT03862898 418 427 I-Condition
, NCT03862898 428 429 O

- NCT03862898 433 434 O
tumors NCT03862898 436 442 B-Condition
, NCT03862898 443 444 O

- NCT03862898 448 449 O
pregnancy NCT03862898 451 460 B-Condition
. NCT03862898 460 461 O

Inclusion NCT03869073 0 9 O
Criteria NCT03869073 10 18 O
: NCT03869073 19 20 O

- NCT03869073 24 25 O
Signed NCT03869073 27 33 O
informed NCT03869073 34 42 O
consent NCT03869073 43 50 O

- NCT03869073 53 54 O
At NCT03869073 56 58 B-Eq-Comparison
least NCT03869073 59 64 I-Eq-Comparison
19 NCT03869073 65 67 I-Eq-Comparison
years NCT03869073 68 73 I-Eq-Comparison
of NCT03869073 74 76 O
age NCT03869073 77 80 B-Age

- NCT03869073 83 84 O
Known NCT03869073 86 91 B-Modifier
or NCT03869073 92 94 B-Or
suspected NCT03869073 95 104 B-Assertion___Assertion-Type-Value:possible
infection NCT03869073 105 114 B-Condition

- NCT03869073 117 118 O
AND NCT03869073 120 123 B-And
one NCT03869073 124 127 B-Eq-Comparison
or NCT03869073 128 130 I-Eq-Comparison
more NCT03869073 131 135 I-Eq-Comparison
of NCT03869073 136 138 O
the NCT03869073 139 142 B-Criteria-Count
following NCT03869073 143 152 I-Criteria-Count
organ NCT03869073 153 158 B-Condition
dysfunctions NCT03869073 159 171 I-Condition
judged NCT03869073 172 178 O
due NCT03869073 179 182 O
to NCT03869073 183 185 O
sepsis NCT03869073 186 192 B-Condition
: NCT03869073 193 194 O

1 NCT03869073 203 204 O
. NCT03869073 204 205 O
Cardiovascular NCT03869073 207 221 B-Modifier
- NCT03869073 222 223 I-Modifier
refractory NCT03869073 224 234 I-Modifier
hypotension NCT03869073 235 246 B-Condition
( NCT03869073 247 248 O
a NCT03869073 249 250 O
systolic NCT03869073 251 259 B-Observation
blood NCT03869073 260 265 I-Observation
pressure NCT03869073 266 274 I-Observation
( NCT03869073 275 276 O
SBP NCT03869073 277 280 B-Observation
) NCT03869073 281 282 O
< NCT03869073 283 284 B-Eq-Comparison
90 NCT03869073 285 287 I-Eq-Comparison
mm NCT03869073 288 290 I-Eq-Comparison
Hg NCT03869073 291 293 I-Eq-Comparison
or NCT03869073 294 296 B-Or
mean NCT03869073 297 301 B-Observation
arterial NCT03869073 302 310 I-Observation
pressure NCT03869073 311 319 I-Observation
( NCT03869073 320 321 O
MAP NCT03869073 322 325 B-Observation
) NCT03869073 326 327 O
< NCT03869073 328 329 B-Eq-Comparison
60 NCT03869073 330 332 I-Eq-Comparison
mm NCT03869073 333 335 I-Eq-Comparison
Hg NCT03869073 336 338 I-Eq-Comparison
despite NCT03869073 339 346 B-And
an NCT03869073 347 349 O
IV NCT03869073 350 352 B-Observation
fluid NCT03869073 353 358 I-Observation
challenge NCT03869073 359 368 I-Observation
of NCT03869073 369 371 O
at NCT03869073 372 374 B-Eq-Comparison
least NCT03869073 375 380 I-Eq-Comparison
30 NCT03869073 381 383 I-Eq-Comparison
ml NCT03869073 384 386 I-Eq-Comparison
/ NCT03869073 387 388 I-Eq-Comparison
kg NCT03869073 389 391 I-Eq-Comparison
fluids NCT03869073 392 398 B-Modifier
) NCT03869073 399 400 O
, NCT03869073 402 403 O
or NCT03869073 404 406 B-Or
use NCT03869073 407 410 O
of NCT03869073 411 413 O
vasopressor NCT03869073 414 425 B-Procedure
( NCT03869073 426 427 I-Procedure
s NCT03869073 428 429 I-Procedure
) NCT03869073 430 431 O
to NCT03869073 432 434 B-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03869073 435 443 I-Assertion___Assertion-Type-Value:hypothetical
SAP NCT03869073 444 447 B-Observation
> NCT03869073 448 449 B-Eq-Comparison
90 NCT03869073 450 452 I-Eq-Comparison
mm NCT03869073 453 455 I-Eq-Comparison
Hg NCT03869073 456 458 I-Eq-Comparison
or NCT03869073 459 461 B-Or
MAP NCT03869073 462 465 B-Observation
> NCT03869073 466 467 B-Eq-Comparison
60 NCT03869073 468 470 I-Eq-Comparison
mm NCT03869073 471 473 I-Eq-Comparison
Hg NCT03869073 474 476 I-Eq-Comparison
, NCT03869073 477 478 O
or NCT03869073 479 481 B-Or
; NCT03869073 481 482 O

2 NCT03869073 490 491 O
. NCT03869073 491 492 O
Respiratory NCT03869073 494 505 B-Condition
: NCT03869073 506 507 O
PaO2 NCT03869073 508 512 B-Observation
/ NCT03869073 513 514 B-Or
FiO2 NCT03869073 515 519 B-Observation
< NCT03869073 520 521 B-Eq-Comparison
300 NCT03869073 522 525 I-Eq-Comparison
or NCT03869073 526 528 B-Or
PaO2 NCT03869073 529 533 B-Observation
/ NCT03869073 534 535 B-Or
FiO2 NCT03869073 536 540 B-Observation
< NCT03869073 541 542 B-Eq-Comparison
200 NCT03869073 543 546 I-Eq-Comparison
if NCT03869073 547 549 O
lung NCT03869073 550 554 B-Modifier
is NCT03869073 555 557 O
the NCT03869073 558 561 O
only NCT03869073 562 566 B-Modifier
organ NCT03869073 567 572 I-Modifier
dysfunction NCT03869073 573 584 B-Condition
or NCT03869073 585 587 B-Or
SaO2 NCT03869073 588 592 B-Observation
: NCT03869073 593 594 B-Or
FiO2 NCT03869073 595 599 B-Observation
150 NCT03869073 600 603 B-Eq-Comparison

Exclusion NCT03869073 605 614 O
Criteria NCT03869073 615 623 O
: NCT03869073 624 625 O

- NCT03869073 629 630 O
Known NCT03869073 632 637 O
pregnancy NCT03869073 638 647 B-Condition

- NCT03869073 650 651 O
Underlying NCT03869073 653 663 O
severe NCT03869073 664 670 O
congestive NCT03869073 671 681 B-Condition
heart NCT03869073 682 687 I-Condition
failure NCT03869073 688 695 I-Condition
( NCT03869073 696 697 O
New NCT03869073 698 701 B-Condition
York NCT03869073 702 706 I-Condition
Heart NCT03869073 707 712 I-Condition
Association NCT03869073 713 724 I-Condition
( NCT03869073 725 726 O
NYHA NCT03869073 727 731 B-Condition
) NCT03869073 732 733 O
IV NCT03869073 734 736 B-Eq-Comparison
) NCT03869073 737 738 O
, NCT03869073 740 741 O
severe NCT03869073 742 748 O
COPD NCT03869073 749 753 B-Condition
( NCT03869073 754 755 O
need NCT03869073 756 760 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869073 761 764 I-Assertion___Assertion-Type-Value:hypothetical
chronic NCT03869073 765 772 B-Procedure
oxygen NCT03869073 773 779 I-Procedure
or NCT03869073 780 782 B-Or
mechanical NCT03869073 783 793 B-Procedure
ventilation NCT03869073 794 805 I-Procedure
) NCT03869073 806 807 O
, NCT03869073 809 810 O
severe NCT03869073 811 817 O
liver NCT03869073 818 823 B-Condition
disease NCT03869073 824 831 I-Condition
( NCT03869073 832 833 O
Child NCT03869073 834 839 B-Condition
- NCT03869073 840 841 I-Condition
Pugh NCT03869073 842 846 I-Condition
Class NCT03869073 847 852 B-Eq-Comparison
C NCT03869073 853 854 I-Eq-Comparison
) NCT03869073 855 856 O
, NCT03869073 858 859 O
cancer NCT03869073 860 866 B-Condition
requiring NCT03869073 867 876 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03869073 877 889 B-Procedure
, NCT03869073 890 891 O
or NCT03869073 892 894 B-Or
transplantation NCT03869073 895 910 B-Procedure
( NCT03869073 911 912 O
bone NCT03869073 913 917 B-Modifier
marrow NCT03869073 918 924 I-Modifier
, NCT03869073 925 926 O
heart NCT03869073 927 932 B-Modifier
, NCT03869073 933 934 O
lung NCT03869073 935 939 B-Modifier
, NCT03869073 940 941 O
liver NCT03869073 942 947 B-Modifier
, NCT03869073 948 949 O
pancreas NCT03869073 950 958 B-Modifier
, NCT03869073 959 960 O
or NCT03869073 961 963 B-Or
small NCT03869073 964 969 B-Modifier
bowel NCT03869073 970 975 I-Modifier
) NCT03869073 976 977 O
in NCT03869073 978 980 O
the NCT03869073 981 984 O
past NCT03869073 985 989 B-Eq-Comparison
6 NCT03869073 990 991 I-Eq-Comparison
months NCT03869073 992 998 I-Eq-Comparison
or NCT03869073 999 1001 B-Or
likely NCT03869073 1002 1008 B-Assertion___Assertion-Type-Value:possible
within NCT03869073 1009 1015 B-Eq-Comparison
the NCT03869073 1016 1019 I-Eq-Comparison
next NCT03869073 1020 1024 I-Eq-Comparison
6 NCT03869073 1025 1026 I-Eq-Comparison
months NCT03869073 1027 1033 I-Eq-Comparison

- NCT03869073 1036 1037 O
Previous NCT03869073 1039 1047 B-Eq-Comparison
episode NCT03869073 1048 1055 O
of NCT03869073 1056 1058 O
sepsis NCT03869073 1059 1065 B-Condition
during NCT03869073 1066 1072 B-Temporal-Connection___Temporal-Connection-Type-Value:during
that NCT03869073 1073 1077 O
hospital NCT03869073 1078 1086 O
admission NCT03869073 1087 1096 B-Encounter

- NCT03869073 1099 1100 O
Absolute NCT03869073 1102 1110 B-Observation
Neutrophil NCT03869073 1111 1121 I-Observation
Count NCT03869073 1122 1127 I-Observation
< NCT03869073 1128 1129 B-Eq-Comparison
500 NCT03869073 1130 1133 I-Eq-Comparison
/ NCT03869073 1134 1135 I-Eq-Comparison
mm³ NCT03869073 1136 1139 I-Eq-Comparison

- NCT03869073 1142 1143 O
CD4 NCT03869073 1145 1148 B-Observation
count NCT03869073 1149 1154 I-Observation
< NCT03869073 1155 1156 B-Eq-Comparison
50 NCT03869073 1157 1159 I-Eq-Comparison
/ NCT03869073 1160 1161 I-Eq-Comparison
mm³ NCT03869073 1162 1165 I-Eq-Comparison

- NCT03869073 1168 1169 O
Treating NCT03869073 1171 1179 O
physician NCT03869073 1180 1189 O
deems NCT03869073 1190 1195 O
aggressive NCT03869073 1196 1206 O
care NCT03869073 1207 1211 B-Procedure
unsuitable NCT03869073 1212 1222 B-Contraindication
( NCT03869073 1223 1224 O
i. NCT03869073 1225 1227 O
e. NCT03869073 1228 1230 O
no NCT03869073 1232 1234 B-Negation
commitment NCT03869073 1235 1245 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869073 1246 1248 I-Assertion___Assertion-Type-Value:hypothetical
active NCT03869073 1249 1255 B-Eq-Comparison
care NCT03869073 1256 1260 B-Procedure
) NCT03869073 1261 1262 O

- NCT03869073 1266 1267 O
Participation NCT03869073 1269 1282 O
in NCT03869073 1283 1285 O
another NCT03869073 1286 1293 B-Other
interventional NCT03869073 1294 1308 O
drug NCT03869073 1309 1313 B-Drug
study NCT03869073 1314 1319 B-Study
within NCT03869073 1320 1326 B-Eq-Comparison
previous NCT03869073 1327 1335 I-Eq-Comparison
1 NCT03869073 1336 1337 I-Eq-Comparison
month NCT03869073 1338 1343 I-Eq-Comparison

- NCT03869073 1346 1347 O
Allergic NCT03869073 1349 1357 B-Allergy
to NCT03869073 1358 1360 O
the NCT03869073 1361 1364 O
study NCT03869073 1365 1370 B-Study
drug NCT03869073 1371 1375 B-Drug
or NCT03869073 1376 1378 B-Or
any NCT03869073 1379 1382 O
of NCT03869073 1383 1385 O
its NCT03869073 1386 1389 B-Coreference
components NCT03869073 1390 1400 I-Coreference

- NCT03869073 1403 1404 O
Lactation NCT03869073 1406 1415 B-Condition

- NCT03869073 1418 1419 O
Have NCT03869073 1421 1425 O
signed NCT03869073 1426 1432 B-Eq-Comparison
a NCT03869073 1433 1434 O
Do NCT03869073 1435 1437 B-Observation
No NCT03869073 1438 1440 I-Observation
Resuscitate NCT03869073 1441 1452 I-Observation
( NCT03869073 1453 1454 O
DNR NCT03869073 1455 1458 B-Observation
) NCT03869073 1459 1460 O
Form NCT03869073 1461 1465 O

Inclusion NCT03864796 0 9 O
Criteria NCT03864796 10 18 O
: NCT03864796 19 20 O

- NCT03864796 24 25 O
newly NCT03864796 27 32 B-Eq-Comparison
diagnosed NCT03864796 33 42 O
primary NCT03864796 43 50 B-Modifier
immune NCT03864796 51 57 I-Modifier
thrombocytopenic NCT03864796 58 74 B-Condition
patients NCT03864796 75 83 O

Exclusion NCT03864796 84 93 O
Criteria NCT03864796 94 102 O
: NCT03864796 103 104 O

- NCT03864796 108 109 O
We NCT03864796 111 113 O
will NCT03864796 114 118 O
exclude NCT03864796 119 126 B-Negation
patients NCT03864796 127 135 O
with NCT03864796 136 140 O
any NCT03864796 141 144 O
other NCT03864796 145 150 B-Other
possible NCT03864796 151 159 B-Assertion___Assertion-Type-Value:possible
cause NCT03864796 160 165 B-Condition
of NCT03864796 166 168 O
thrombocytopenia NCT03864796 169 185 B-Condition
either NCT03864796 186 192 O
immune NCT03864796 193 199 B-Modifier
or NCT03864796 200 202 B-Or
non NCT03864796 203 206 B-Negation
immune NCT03864796 207 213 B-Modifier
as NCT03864796 214 216 O
: NCT03864796 217 218 O

- NCT03864796 222 223 O
Patients NCT03864796 225 233 O
with NCT03864796 234 238 O
diabetes NCT03864796 239 247 B-Condition

- NCT03864796 250 251 O
HCV NCT03864796 253 256 B-Condition

- NCT03864796 259 260 O
other NCT03864796 262 267 B-Other
autoimmune NCT03864796 268 278 B-Condition
disease NCT03864796 279 286 I-Condition
( NCT03864796 287 288 O
as NCT03864796 289 291 O
SLE NCT03864796 292 295 B-Condition
or NCT03864796 296 298 B-Or
RA NCT03864796 299 301 B-Condition
) NCT03864796 302 303 O

- NCT03864796 307 308 O
Chronic NCT03864796 310 317 B-Modifier
Liver NCT03864796 318 323 I-Modifier
or NCT03864796 324 326 B-Or
kidney NCT03864796 327 333 B-Modifier
disease NCT03864796 334 341 B-Condition

Inclusion NCT03862495 0 9 O
Criteria NCT03862495 10 18 O
: NCT03862495 19 20 O

1 NCT03862495 24 25 O
. NCT03862495 25 26 O
pregnant NCT03862495 28 36 B-Condition
women NCT03862495 37 42 O
on NCT03862495 43 45 O
their NCT03862495 46 51 O
first NCT03862495 52 57 B-Eq-Comparison
visit NCT03862495 58 63 B-Encounter
to NCT03862495 64 66 O
the NCT03862495 67 70 O
hospital NCT03862495 71 79 O
( NCT03862495 80 81 O
regardless NCT03862495 82 92 O
of NCT03862495 93 95 O
gestational NCT03862495 96 107 B-Observation
age NCT03862495 108 111 I-Observation
) NCT03862495 112 113 O
; NCT03862495 114 115 O

2 NCT03862495 118 119 O
. NCT03862495 119 120 O
aged NCT03862495 122 126 B-Age
18 NCT03862495 127 129 B-Eq-Comparison
or NCT03862495 130 132 I-Eq-Comparison
above NCT03862495 133 138 I-Eq-Comparison
; NCT03862495 138 139 O

3 NCT03862495 142 143 O
. NCT03862495 143 144 O
agree NCT03862495 146 151 O
to NCT03862495 152 154 O
participate NCT03862495 155 166 O
and NCT03862495 167 170 O
sign NCT03862495 171 175 O
an NCT03862495 176 178 O
informed NCT03862495 179 187 O
consent NCT03862495 188 195 O
. NCT03862495 196 197 O

Exclusion NCT03862495 199 208 O
Criteria NCT03862495 209 217 O
: NCT03862495 218 219 O

1 NCT03862495 223 224 O
. NCT03862495 224 225 O
systemic NCT03862495 227 235 B-Modifier
or NCT03862495 236 238 B-Or
topical NCT03862495 239 246 B-Modifier
vaginal NCT03862495 247 254 I-Modifier
antibiotics NCT03862495 255 266 B-Drug
use NCT03862495 267 270 O
within NCT03862495 271 277 B-Eq-Comparison
2 NCT03862495 278 279 I-Eq-Comparison
weeks NCT03862495 280 285 I-Eq-Comparison
prior NCT03862495 286 291 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862495 292 294 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862495 295 298 O
first NCT03862495 299 304 B-Eq-Comparison
perinatal NCT03862495 305 314 B-Modifier
visit NCT03862495 315 320 B-Encounter
; NCT03862495 320 321 O

2 NCT03862495 324 325 O
. NCT03862495 325 326 O
comorbidities NCT03862495 328 341 B-Condition
that NCT03862495 342 346 O
are NCT03862495 347 350 O
known NCT03862495 351 356 O
to NCT03862495 357 359 O
be NCT03862495 360 362 O
related NCT03862495 363 370 O
to NCT03862495 371 373 O
adverse NCT03862495 374 381 B-Condition
pregnancy NCT03862495 382 391 I-Condition
outcomes NCT03862495 392 400 I-Condition
( NCT03862495 401 402 O
e. NCT03862495 403 405 O
g. NCT03862495 406 408 O
, NCT03862495 409 410 O
diabetes NCT03862495 411 419 B-Condition
and NCT03862495 420 423 B-Or
hypertension NCT03862495 424 436 B-Condition
) NCT03862495 437 438 O
; NCT03862495 439 440 O

3 NCT03862495 443 444 O
. NCT03862495 444 445 O
diagnosed NCT03862495 447 456 O
adverse NCT03862495 457 464 B-Condition
pregnancy NCT03862495 465 474 I-Condition
outcomes NCT03862495 475 483 I-Condition
at NCT03862495 484 486 B-Temporal-Connection___Temporal-Connection-Type-Value:during
recruitment NCT03862495 487 498 B-Study
( NCT03862495 499 500 O
e. NCT03862495 501 503 O
g. NCT03862495 504 506 O
, NCT03862495 507 508 O
stillbirth NCT03862495 509 519 B-Condition
) NCT03862495 520 521 O
; NCT03862495 522 523 O
Women NCT03862495 524 529 O
with NCT03862495 530 534 B-And
a NCT03862495 535 536 O
previous NCT03862495 537 545 B-Eq-Comparison
history NCT03862495 546 553 I-Eq-Comparison
of NCT03862495 554 556 O
CT NCT03862495 557 559 B-Procedure
or NCT03862495 560 562 B-Or
NG NCT03862495 563 565 B-Procedure
and NCT03862495 566 569 B-Or
women NCT03862495 570 575 O
with NCT03862495 576 580 B-And
a NCT03862495 581 582 O
prior NCT03862495 583 588 B-Eq-Comparison
adverse NCT03862495 589 596 B-Condition
outcome NCT03862495 597 604 I-Condition
will NCT03862495 605 609 O
not NCT03862495 610 613 O
be NCT03862495 614 616 O
excluded NCT03862495 617 625 O
. NCT03862495 625 626 O
Instead NCT03862495 628 635 O
, NCT03862495 636 637 O
the NCT03862495 638 641 O
investigators NCT03862495 642 655 O
will NCT03862495 656 660 O
conduct NCT03862495 661 668 O
sub NCT03862495 669 672 O
- NCT03862495 673 674 O
analysis NCT03862495 675 683 O
and NCT03862495 684 687 O
check NCT03862495 688 693 O
whether NCT03862495 694 701 O
the NCT03862495 702 705 O
intervention NCT03862495 706 718 O
has NCT03862495 719 722 O
different NCT03862495 723 732 O
effects NCT03862495 733 740 O
on NCT03862495 741 743 O
different NCT03862495 744 753 O
groups NCT03862495 754 760 O
of NCT03862495 761 763 O
pregnant NCT03862495 764 772 O
women NCT03862495 773 778 O
. NCT03862495 778 779 O

Inclusion NCT03861611 0 9 O
Criteria NCT03861611 10 18 O
: NCT03861611 19 20 O

- NCT03861611 24 25 O
Men NCT03861611 27 30 O
or NCT03861611 31 33 B-Or
women NCT03861611 34 39 O
age NCT03861611 40 43 B-Age
18 NCT03861611 44 46 B-Eq-Comparison
- NCT03861611 47 48 I-Eq-Comparison
64 NCT03861611 49 51 O
. NCT03861611 51 52 O

- NCT03861611 56 57 O
Present NCT03861611 59 66 O
to NCT03861611 67 69 O
ED NCT03861611 70 72 B-Encounter
primary NCT03861611 73 80 O
for NCT03861611 81 84 O
management NCT03861611 85 95 O
of NCT03861611 96 98 O
Low NCT03861611 99 102 B-Condition
Back NCT03861611 103 107 I-Condition
Pain NCT03861611 108 112 I-Condition
( NCT03861611 113 114 O
LBP NCT03861611 115 118 B-Condition
) NCT03861611 119 120 O

- NCT03861611 124 125 O
Functionally NCT03861611 127 139 B-Modifier
impairing NCT03861611 140 149 I-Modifier
back NCT03861611 150 154 B-Condition
pain NCT03861611 155 159 I-Condition
: NCT03861611 160 161 O
A NCT03861611 162 163 O
baseline NCT03861611 164 172 O
score NCT03861611 173 178 O
of NCT03861611 179 181 O
greater NCT03861611 182 189 B-Eq-Comparison
than NCT03861611 190 194 I-Eq-Comparison
5 NCT03861611 195 196 I-Eq-Comparison
on NCT03861611 197 199 O
the NCT03861611 200 203 O
Roland NCT03861611 204 210 B-Observation
- NCT03861611 211 212 I-Observation
Morris NCT03861611 213 219 I-Observation
Disability NCT03861611 220 230 I-Observation
Questionnaire NCT03861611 231 244 I-Observation

- NCT03861611 247 248 O
Musculoskeletal NCT03861611 250 265 B-Condition
etiology NCT03861611 266 274 I-Condition
of NCT03861611 275 277 O
low NCT03861611 278 281 B-Modifier
back NCT03861611 282 286 I-Modifier
. NCT03861611 287 288 O

- NCT03861611 292 293 O
Non NCT03861611 295 298 B-Negation
- NCT03861611 299 300 O
radicular NCT03861611 301 310 B-Modifier
pain NCT03861611 311 315 B-Condition
. NCT03861611 316 317 O

- NCT03861611 321 322 O
Pain NCT03861611 324 328 B-Condition
duration NCT03861611 329 337 O
< NCT03861611 338 339 B-Eq-Comparison
2 NCT03861611 340 341 I-Eq-Comparison
weeks NCT03861611 342 347 I-Eq-Comparison
( NCT03861611 348 349 O
336 NCT03861611 350 353 B-Eq-Comparison
hours NCT03861611 354 359 I-Eq-Comparison
) NCT03861611 360 361 O
. NCT03861611 363 364 O

- NCT03861611 368 369 O
Non NCT03861611 371 374 B-Negation
- NCT03861611 375 376 O
traumatic NCT03861611 377 386 B-Modifier
LBP NCT03861611 387 390 B-Condition

- NCT03861611 393 394 O
Participant NCT03861611 396 407 O
is NCT03861611 408 410 O
to NCT03861611 411 413 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03861611 414 416 I-Assertion___Assertion-Type-Value:hypothetical
discharged NCT03861611 417 427 B-Encounter
home NCT03861611 428 432 O
. NCT03861611 433 434 O

Exclusion NCT03861611 436 445 O
Criteria NCT03861611 446 454 O
: NCT03861611 455 456 O

- NCT03861611 460 461 O
Flank NCT03861611 463 468 B-Modifier
pain NCT03861611 469 473 B-Condition
, NCT03861611 474 475 O
that NCT03861611 476 480 O
is NCT03861611 481 483 O
pain NCT03861611 484 488 B-Condition
originating NCT03861611 489 500 O
from NCT03861611 501 505 O
tissues NCT03861611 506 513 B-Modifier
lateral NCT03861611 514 521 I-Modifier
to NCT03861611 522 524 I-Modifier
the NCT03861611 525 528 I-Modifier
paraspinal NCT03861611 529 539 I-Modifier
muscles NCT03861611 540 547 I-Modifier
. NCT03861611 548 549 O

- NCT03861611 553 554 O
Not NCT03861611 556 559 B-Negation
available NCT03861611 560 569 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861611 570 573 O
follow NCT03861611 574 580 B-Encounter
- NCT03861611 581 582 I-Encounter
up NCT03861611 583 585 I-Encounter

- NCT03861611 588 589 O
Pregnant NCT03861611 591 599 B-Condition

- NCT03861611 602 603 O
Chronic NCT03861611 605 612 B-Modifier
pain NCT03861611 613 617 B-Condition
syndrome NCT03861611 618 626 I-Condition

- NCT03861611 629 630 O
Allergic NCT03861611 632 640 B-Allergy
to NCT03861611 641 643 O
or NCT03861611 644 646 B-Or
intolerant NCT03861611 647 657 B-Condition
of NCT03861611 658 660 O
investigational NCT03861611 661 676 B-Study
medications NCT03861611 677 688 B-Drug

- NCT03861611 691 692 O
Contra NCT03861611 694 700 B-Contraindication
- NCT03861611 701 702 I-Contraindication
indications NCT03861611 703 714 I-Contraindication
to NCT03861611 715 717 O
investigational NCT03861611 718 733 B-Study
medications NCT03861611 734 745 B-Drug

Inclusion NCT03862456 0 9 O
Criteria NCT03862456 10 18 O
: NCT03862456 19 20 O

- NCT03862456 24 25 O
Diagnosis NCT03862456 27 36 O
of NCT03862456 37 39 O
periodontitis NCT03862456 40 53 B-Condition
( NCT03862456 54 55 O
stages NCT03862456 56 62 B-Eq-Comparison
III NCT03862456 63 66 I-Eq-Comparison
or NCT03862456 67 69 I-Eq-Comparison
IV NCT03862456 70 72 I-Eq-Comparison
) NCT03862456 73 74 O
that NCT03862456 75 79 O
may NCT03862456 80 83 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03862456 84 91 I-Assertion___Assertion-Type-Value:hypothetical
periodontal NCT03862456 92 103 B-Procedure
surgery NCT03862456 104 111 I-Procedure

- NCT03862456 114 115 O
Have NCT03862456 117 121 O
at NCT03862456 122 124 B-Eq-Comparison
least NCT03862456 125 130 I-Eq-Comparison
10 NCT03862456 131 133 I-Eq-Comparison
teeth NCT03862456 134 139 B-Condition
in NCT03862456 140 142 O
function NCT03862456 143 151 O
, NCT03862456 152 153 O
excluding NCT03862456 154 163 B-Exception
third NCT03862456 164 169 B-Modifier
molars NCT03862456 170 176 I-Modifier
. NCT03862456 177 178 O

- NCT03862456 182 183 O
Present NCT03862456 185 192 O
locations NCT03862456 193 202 O
with NCT03862456 203 207 O
probing NCT03862456 208 215 B-Observation
depth NCT03862456 216 221 I-Observation
( NCT03862456 222 223 O
PS NCT03862456 224 226 B-Observation
) NCT03862456 227 228 O
> NCT03862456 230 231 B-Eq-Comparison
6 NCT03862456 232 233 I-Eq-Comparison
mm NCT03862456 234 236 I-Eq-Comparison
in NCT03862456 237 239 O
at NCT03862456 240 242 B-Eq-Comparison
least NCT03862456 243 248 I-Eq-Comparison
30 NCT03862456 249 251 I-Eq-Comparison
% NCT03862456 252 253 I-Eq-Comparison
of NCT03862456 254 256 O
the NCT03862456 257 260 O
teeth NCT03862456 261 266 B-Condition
. NCT03862456 267 268 O

- NCT03862456 272 273 O
Present NCT03862456 275 282 O
radiographic NCT03862456 283 295 B-Procedure
evidence NCT03862456 296 304 O
of NCT03862456 305 307 O
moderate NCT03862456 308 316 B-Eq-Comparison
- NCT03862456 317 318 I-Eq-Comparison
severe NCT03862456 319 325 I-Eq-Comparison
bone NCT03862456 326 330 B-Condition|Observation
loss NCT03862456 331 335 I-Condition|Observation
in NCT03862456 336 338 O
at NCT03862456 339 341 B-Eq-Comparison
least NCT03862456 342 347 I-Eq-Comparison
30 NCT03862456 348 350 I-Eq-Comparison
% NCT03862456 351 352 I-Eq-Comparison
of NCT03862456 353 355 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862456 356 359 O
dentition NCT03862456 360 369 B-Procedure
. NCT03862456 370 371 O

- NCT03862456 375 376 O
Detection NCT03862456 378 387 O
of NCT03862456 388 390 O
P. NCT03862456 391 393 B-Organism
gingivalis NCT03862456 395 405 I-Organism
in NCT03862456 406 408 O
subgingival NCT03862456 409 420 B-Observation
samples NCT03862456 421 428 I-Observation
taken NCT03862456 429 434 B-Temporal-Connection___Temporal-Connection-Type-Value:during
at NCT03862456 435 437 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862456 438 441 O
screening NCT03862456 442 451 B-Study
visit NCT03862456 452 457 O
as NCT03862456 458 460 B-And
well NCT03862456 461 465 I-And
as NCT03862456 466 468 I-And
in NCT03862456 469 471 O
the NCT03862456 472 475 O
post NCT03862456 476 480 B-Modifier
- NCT03862456 481 482 I-Modifier
scaling NCT03862456 483 490 I-Modifier
and NCT03862456 491 494 B-Or
root NCT03862456 495 499 B-Modifier
planning NCT03862456 500 508 I-Modifier
visit NCT03862456 509 514 B-Encounter
and NCT03862456 515 518 O
processed NCT03862456 519 528 O
by NCT03862456 529 531 O
culture NCT03862456 532 539 O
. NCT03862456 540 541 O

- NCT03862456 545 546 O
Systemically NCT03862456 548 560 B-Modifier
healthy NCT03862456 561 568 B-Condition
patients NCT03862456 569 577 O
. NCT03862456 578 579 O

Exclusion NCT03862456 581 590 O
Criteria NCT03862456 591 599 O
: NCT03862456 600 601 O

- NCT03862456 605 606 O
Pregnant NCT03862456 608 616 B-Condition
or NCT03862456 617 619 B-Or
lactating NCT03862456 620 629 B-Condition
women NCT03862456 630 635 O
. NCT03862456 636 637 O

- NCT03862456 641 642 O
Presenting NCT03862456 644 654 O
systemic NCT03862456 655 663 B-Modifier
pathology NCT03862456 664 673 B-Condition
and NCT03862456 674 677 B-Or
/ NCT03862456 678 679 I-Or
or NCT03862456 680 682 I-Or
taking NCT03862456 683 689 B-Eq-Comparison
medication NCT03862456 690 700 B-Drug
that NCT03862456 701 705 O
may NCT03862456 706 709 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03862456 710 716 O
the NCT03862456 717 720 O
periodontal NCT03862456 721 732 B-Condition
situation NCT03862456 733 742 I-Condition
and NCT03862456 743 746 B-Or
/ NCT03862456 747 748 I-Or
or NCT03862456 749 751 I-Or
patients NCT03862456 752 760 O
requiring NCT03862456 761 770 B-Assertion___Assertion-Type-Value:hypothetical
antibiotic NCT03862456 771 781 B-Procedure
prophylaxis NCT03862456 782 793 I-Procedure
. NCT03862456 794 795 O

- NCT03862456 799 800 O
Have NCT03862456 802 806 O
received NCT03862456 807 815 B-Eq-Comparison
systemic NCT03862456 816 824 B-Modifier
antimicrobial NCT03862456 825 838 B-Procedure
treatment NCT03862456 839 848 I-Procedure
in NCT03862456 849 851 O
the NCT03862456 852 855 O
previous NCT03862456 856 864 B-Eq-Comparison
6 NCT03862456 865 866 I-Eq-Comparison
months NCT03862456 867 873 I-Eq-Comparison
. NCT03862456 874 875 O

- NCT03862456 879 880 O
Have NCT03862456 882 886 O
received NCT03862456 887 895 B-Eq-Comparison
periodontal NCT03862456 896 907 B-Procedure
treatment NCT03862456 908 917 I-Procedure
in NCT03862456 918 920 O
the NCT03862456 921 924 O
6 NCT03862456 925 926 B-Eq-Comparison
months NCT03862456 927 933 I-Eq-Comparison
prior NCT03862456 934 939 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862456 940 942 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03862456 943 946 O
beginning NCT03862456 947 956 B-Eq-Comparison
of NCT03862456 957 959 O
the NCT03862456 960 963 O
study NCT03862456 964 969 B-Study
. NCT03862456 970 971 O

- NCT03862456 975 976 O
Patients NCT03862456 978 986 O
allergic NCT03862456 987 995 B-Allergy
to NCT03862456 996 998 O
metronidazole NCT03862456 999 1012 B-Drug
, NCT03862456 1013 1014 O
or NCT03862456 1015 1017 B-Or
to NCT03862456 1018 1020 O
any NCT03862456 1021 1024 O
of NCT03862456 1025 1027 O
the NCT03862456 1028 1031 O
components NCT03862456 1032 1042 O
of NCT03862456 1043 1045 O
commercial NCT03862456 1046 1056 B-Coreference
formulations NCT03862456 1057 1069 I-Coreference
thereof NCT03862456 1070 1077 I-Coreference
( NCT03862456 1078 1079 O
Flagyl NCT03862456 1080 1086 B-Drug
® NCT03862456 1086 1087 O
) NCT03862456 1088 1089 O
. NCT03862456 1091 1092 O

- NCT03862456 1096 1097 O
Patients NCT03862456 1099 1107 O
allergic NCT03862456 1108 1116 B-Allergy
to NCT03862456 1117 1119 O
azithromycin NCT03862456 1120 1132 B-Drug
, NCT03862456 1133 1134 O
or NCT03862456 1135 1137 B-Or
to NCT03862456 1138 1140 O
any NCT03862456 1141 1144 O
of NCT03862456 1145 1147 O
the NCT03862456 1148 1151 O
components NCT03862456 1152 1162 O
of NCT03862456 1163 1165 O
commercial NCT03862456 1166 1176 B-Coreference
formulations NCT03862456 1177 1189 I-Coreference
thereof NCT03862456 1190 1197 I-Coreference
( NCT03862456 1198 1199 O
Zithromax NCT03862456 1200 1209 B-Drug
® NCT03862456 1209 1210 O
) NCT03862456 1211 1212 O
. NCT03862456 1214 1215 O

- NCT03862456 1219 1220 O
Patients NCT03862456 1222 1230 O
who NCT03862456 1231 1234 O
refuse NCT03862456 1235 1241 O
to NCT03862456 1242 1244 O
sign NCT03862456 1245 1249 O
the NCT03862456 1250 1253 O
informed NCT03862456 1254 1262 O
consent NCT03862456 1263 1270 O
. NCT03862456 1270 1271 O

Inclusion NCT03867617 0 9 O
Criteria NCT03867617 10 18 O
: NCT03867617 19 20 O

- NCT03867617 24 25 O
Patient NCT03867617 27 34 O
has NCT03867617 35 38 O
provided NCT03867617 39 47 O
written NCT03867617 48 55 O
informed NCT03867617 56 64 O
consent NCT03867617 65 72 O
. NCT03867617 73 74 O

- NCT03867617 78 79 O
Patient NCT03867617 81 88 O
is NCT03867617 89 91 O
18 NCT03867617 92 94 B-Eq-Comparison
years NCT03867617 95 100 I-Eq-Comparison
or NCT03867617 101 103 I-Eq-Comparison
older NCT03867617 104 109 I-Age|Eq-Comparison
. NCT03867617 110 111 O

- NCT03867617 115 116 O
Patient NCT03867617 118 125 O
is NCT03867617 126 128 O
a NCT03867617 129 130 O
planned NCT03867617 131 138 B-Eq-Comparison
recipient NCT03867617 139 148 O
of NCT03867617 149 151 O
a NCT03867617 152 153 O
living NCT03867617 154 160 B-Modifier
donor NCT03867617 161 166 I-Modifier
kidney NCT03867617 167 173 B-Procedure
transplant NCT03867617 174 184 I-Procedure
. NCT03867617 185 186 O

- NCT03867617 190 191 O
Patient NCT03867617 193 200 O
is NCT03867617 201 203 O
a NCT03867617 204 205 O
planned NCT03867617 206 213 B-Eq-Comparison
recipient NCT03867617 214 223 O
of NCT03867617 224 226 O
an NCT03867617 227 229 O
ABO NCT03867617 230 233 B-Modifier
blood NCT03867617 234 239 I-Modifier
group NCT03867617 240 245 I-Modifier
- NCT03867617 246 247 I-Modifier
compatible NCT03867617 248 258 I-Modifier
kidney NCT03867617 259 265 B-Procedure
graft NCT03867617 266 271 I-Procedure
. NCT03867617 272 273 O

- NCT03867617 277 278 O
Patient NCT03867617 280 287 O
is NCT03867617 288 290 O
a NCT03867617 291 292 O
planned NCT03867617 293 300 B-Eq-Comparison
recipient NCT03867617 301 310 O
of NCT03867617 311 313 O
a NCT03867617 314 315 O
kidney NCT03867617 316 322 B-Procedure
graft NCT03867617 323 328 I-Procedure
from NCT03867617 329 333 O
a NCT03867617 334 335 O
donor NCT03867617 336 341 B-Modifier
that NCT03867617 342 346 O
is NCT03867617 347 349 O
not NCT03867617 350 353 B-Negation
HLA NCT03867617 354 357 B-Condition
( NCT03867617 358 359 O
human NCT03867617 360 365 B-Condition
leukocyte NCT03867617 366 375 I-Condition
antigen NCT03867617 376 383 I-Condition
) NCT03867617 384 385 O
- NCT03867617 387 388 O
identical NCT03867617 389 398 B-Modifier
. NCT03867617 399 400 O

- NCT03867617 404 405 O
Patient NCT03867617 407 414 O
is NCT03867617 415 417 O
negative NCT03867617 418 426 O
for NCT03867617 427 430 O
DSA NCT03867617 431 434 B-Condition
( NCT03867617 435 436 O
donor NCT03867617 437 442 B-Condition
- NCT03867617 443 444 I-Condition
specific NCT03867617 445 453 I-Condition
antibodies NCT03867617 454 464 I-Condition
) NCT03867617 465 466 O
. NCT03867617 468 469 O

- NCT03867617 473 474 O
WOCBP NCT03867617 476 481 B-Condition
( NCT03867617 482 483 O
women NCT03867617 484 489 O
of NCT03867617 490 492 B-And
child NCT03867617 493 498 B-Condition
- NCT03867617 499 500 I-Condition
bearing NCT03867617 501 508 I-Condition
potential NCT03867617 509 518 I-Condition
) NCT03867617 519 520 O
must NCT03867617 521 525 O
have NCT03867617 526 530 O
a NCT03867617 531 532 O
negative NCT03867617 533 541 O
pregnancy NCT03867617 542 551 B-Observation
test NCT03867617 552 556 I-Observation
at NCT03867617 557 559 B-Temporal-Connection___Temporal-Connection-Type-Value:during
inclusion NCT03867617 560 569 B-Study
. NCT03867617 570 571 O

- NCT03867617 575 576 O
WOCBP NCT03867617 578 583 B-Condition
must NCT03867617 584 588 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867617 589 591 I-Assertion___Assertion-Type-Value:hypothetical
using NCT03867617 592 597 B-Eq-Comparison
an NCT03867617 598 600 O
adequate NCT03867617 601 609 O
method NCT03867617 610 616 O
of NCT03867617 617 619 O
contraception NCT03867617 620 633 B-Procedure
to NCT03867617 634 636 O
avoid NCT03867617 637 642 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03867617 643 652 B-Condition
throughout NCT03867617 653 663 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867617 664 667 O
study NCT03867617 668 673 B-Study
and NCT03867617 674 677 B-And
for NCT03867617 678 681 O
up NCT03867617 682 684 B-Eq-Comparison
to NCT03867617 685 687 I-Eq-Comparison
12 NCT03867617 688 690 I-Eq-Comparison
weeks NCT03867617 691 696 I-Eq-Comparison
after NCT03867617 697 702 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03867617 703 706 O
study NCT03867617 707 712 B-Study
in NCT03867617 713 715 O
such NCT03867617 716 720 O
a NCT03867617 721 722 O
manner NCT03867617 723 729 O
that NCT03867617 730 734 O
the NCT03867617 735 738 O
risk NCT03867617 739 743 B-Risk
of NCT03867617 744 746 O
pregnancy NCT03867617 747 756 B-Condition
is NCT03867617 757 759 O
minimized NCT03867617 760 769 O
. NCT03867617 770 771 O

Exclusion NCT03867617 773 782 O
Criteria NCT03867617 783 791 O
: NCT03867617 792 793 O

- NCT03867617 797 798 O
Patient NCT03867617 800 807 O
is NCT03867617 808 810 O
EBV NCT03867617 811 814 B-Condition
( NCT03867617 815 816 O
epstein NCT03867617 817 824 B-Condition
barr NCT03867617 825 829 I-Condition
virus NCT03867617 830 835 I-Condition
) NCT03867617 836 837 O
- NCT03867617 839 840 O
negative NCT03867617 841 849 O
on NCT03867617 850 852 O
serology NCT03867617 853 861 B-Observation
. NCT03867617 862 863 O

- NCT03867617 867 868 O
Patient NCT03867617 870 877 O
is NCT03867617 878 880 O
HIV NCT03867617 881 884 B-Condition
- NCT03867617 885 886 O
positive NCT03867617 887 895 O
or NCT03867617 896 898 B-Or
suffering NCT03867617 899 908 B-Eq-Comparison
from NCT03867617 909 913 O
chronic NCT03867617 914 921 B-Modifier
viral NCT03867617 922 927 I-Modifier
hepatitis NCT03867617 928 937 B-Condition
. NCT03867617 938 939 O

- NCT03867617 943 944 O
Patient NCT03867617 946 953 O
is NCT03867617 954 956 O
CMV NCT03867617 957 960 B-Condition
( NCT03867617 961 962 O
cytomegalo NCT03867617 963 973 B-Condition
virus NCT03867617 974 979 I-Condition
) NCT03867617 980 981 O
- NCT03867617 983 984 O
negative NCT03867617 985 993 O
and NCT03867617 994 997 B-And
receiving NCT03867617 998 1007 B-Eq-Comparison
a NCT03867617 1008 1009 O
kidney NCT03867617 1010 1016 B-Modifier
from NCT03867617 1017 1021 O
a NCT03867617 1022 1023 O
CMV NCT03867617 1024 1027 B-Condition
- NCT03867617 1028 1029 O
positive NCT03867617 1030 1038 O
donor NCT03867617 1039 1044 B-Modifier
. NCT03867617 1045 1046 O

- NCT03867617 1050 1051 O
Positive NCT03867617 1053 1061 O
T NCT03867617 1062 1063 B-Observation
- NCT03867617 1064 1065 I-Observation
cell NCT03867617 1066 1070 I-Observation
lymphocytotoxic NCT03867617 1071 1086 I-Observation
cross NCT03867617 1087 1092 I-Observation
match NCT03867617 1093 1098 I-Observation
. NCT03867617 1099 1100 O

- NCT03867617 1104 1105 O
Patient NCT03867617 1107 1114 O
with NCT03867617 1115 1119 O
prior NCT03867617 1120 1125 B-Eq-Comparison
kidney NCT03867617 1126 1132 B-Procedure
transplant NCT03867617 1133 1143 I-Procedure
or NCT03867617 1144 1146 B-Or
non NCT03867617 1147 1150 B-Negation
- NCT03867617 1151 1152 O
renal NCT03867617 1153 1158 B-Modifier
solid NCT03867617 1159 1164 B-Procedure
organ NCT03867617 1165 1170 I-Procedure
transplant NCT03867617 1171 1181 I-Procedure
. NCT03867617 1182 1183 O

- NCT03867617 1187 1188 O
Patient NCT03867617 1190 1197 O
has NCT03867617 1198 1201 O
a NCT03867617 1202 1203 O
known NCT03867617 1204 1209 O
contraindication NCT03867617 1210 1226 B-Contraindication
to NCT03867617 1227 1229 O
any NCT03867617 1230 1233 O
of NCT03867617 1234 1236 O
the NCT03867617 1237 1240 O
protocol NCT03867617 1241 1249 B-Study
- NCT03867617 1250 1251 I-Study
specified NCT03867617 1252 1261 I-Study
treatments NCT03867617 1262 1272 B-Procedure
. NCT03867617 1273 1274 O

- NCT03867617 1278 1279 O
Patient NCT03867617 1281 1288 O
had NCT03867617 1289 1292 O
been NCT03867617 1293 1297 O
diagnosed NCT03867617 1298 1307 O
with NCT03867617 1308 1312 O
a NCT03867617 1313 1314 O
malignancy NCT03867617 1315 1325 B-Condition
within NCT03867617 1326 1332 B-Eq-Comparison
5 NCT03867617 1333 1334 I-Eq-Comparison
years NCT03867617 1335 1340 I-Eq-Comparison
prior NCT03867617 1341 1346 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867617 1347 1349 I-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03867617 1350 1355 B-Study
entry NCT03867617 1356 1361 O
, NCT03867617 1362 1363 O
excluding NCT03867617 1364 1373 B-Exception
non NCT03867617 1374 1377 B-Negation
- NCT03867617 1378 1379 O
metastatic NCT03867617 1380 1390 B-Modifier
basal NCT03867617 1391 1396 I-Modifier
or NCT03867617 1397 1399 B-Or
squamous NCT03867617 1400 1408 B-Modifier
cell NCT03867617 1409 1413 I-Modifier
carcinoma NCT03867617 1414 1423 B-Condition
of NCT03867617 1424 1426 O
the NCT03867617 1427 1430 O
skin NCT03867617 1431 1435 B-Modifier
. NCT03867617 1436 1437 O

- NCT03867617 1441 1442 O
Female NCT03867617 1444 1450 O
patients NCT03867617 1451 1459 O
who NCT03867617 1460 1463 B-And
are NCT03867617 1464 1467 O
breast NCT03867617 1468 1474 B-Condition
- NCT03867617 1475 1476 I-Condition
feeding NCT03867617 1477 1484 I-Condition
. NCT03867617 1485 1486 O

- NCT03867617 1490 1491 O
Female NCT03867617 1493 1499 O
patients NCT03867617 1500 1508 O
with NCT03867617 1509 1513 B-And
a NCT03867617 1514 1515 O
positive NCT03867617 1516 1524 O
pregnancy NCT03867617 1525 1534 B-Observation
test NCT03867617 1535 1539 I-Observation
. NCT03867617 1539 1540 O

Inclusion NCT03869606 0 9 O
Criteria NCT03869606 10 18 O
: NCT03869606 19 20 O

- NCT03869606 24 25 O
Patients NCT03869606 27 35 O
11 NCT03869606 36 38 B-Eq-Comparison
to NCT03869606 39 41 I-Eq-Comparison
no NCT03869606 42 44 I-Eq-Comparison
older NCT03869606 45 50 I-Eq-Comparison
than NCT03869606 51 55 I-Eq-Comparison
17 NCT03869606 56 58 I-Eq-Comparison
years NCT03869606 59 64 I-Eq-Comparison
of NCT03869606 65 67 O
age NCT03869606 68 71 B-Age

Exclusion NCT03869606 72 81 O
Criteria NCT03869606 82 90 O
: NCT03869606 91 92 O

- NCT03869606 96 97 O
severed NCT03869606 99 106 O
developmental NCT03869606 107 120 B-Condition
delay NCT03869606 121 126 I-Condition
, NCT03869606 127 128 O

- NCT03869606 132 133 O
orthopedic NCT03869606 135 145 B-Procedure
patients NCT03869606 146 154 O
with NCT03869606 155 159 B-And
leg NCT03869606 160 163 B-Modifier
injuries NCT03869606 164 172 B-Condition

- NCT03869606 175 176 O
injury NCT03869606 178 184 B-Condition
that NCT03869606 185 189 O
would NCT03869606 190 195 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03869606 196 203 B-Negation
passive NCT03869606 204 211 B-Modifier
leg NCT03869606 212 215 I-Modifier
elevation NCT03869606 216 225 B-Procedure
. NCT03869606 226 227 O

- NCT03869606 231 232 O
severe NCT03869606 234 240 O
aortic NCT03869606 241 247 B-Condition
insufficiency NCT03869606 248 261 I-Condition
, NCT03869606 262 263 O

- NCT03869606 267 268 O
severe NCT03869606 270 276 O
anatomic NCT03869606 277 285 B-Condition
abnormalities NCT03869606 286 299 I-Condition
of NCT03869606 300 302 O
the NCT03869606 303 306 O
thoracic NCT03869606 307 315 B-Modifier
aorta NCT03869606 316 321 I-Modifier

- NCT03869606 324 325 O
patients NCT03869606 327 335 O
with NCT03869606 336 340 O
external NCT03869606 341 349 B-Procedure
cardiac NCT03869606 350 357 I-Procedure
pacemakers NCT03869606 358 368 I-Procedure
. NCT03869606 368 369 O
close NCT03869606 371 376 O

Inclusion NCT03861299 0 9 O
Criteria NCT03861299 10 18 O
: NCT03861299 19 20 O

1 NCT03861299 24 25 O
. NCT03861299 25 26 O
Age NCT03861299 28 31 B-Age
≥ NCT03861299 32 33 B-Eq-Comparison
18 NCT03861299 34 36 I-Eq-Comparison
years NCT03861299 37 42 I-Eq-Comparison
and NCT03861299 43 46 B-And
≤ NCT03861299 47 48 B-Eq-Comparison
90 NCT03861299 49 51 I-Eq-Comparison
years NCT03861299 52 57 I-Eq-Comparison

2 NCT03861299 60 61 O
. NCT03861299 61 62 O
Tumor NCT03861299 64 69 B-Condition
diagnosed NCT03861299 70 79 O
as NCT03861299 80 82 O
Glioblastoma NCT03861299 83 95 B-Modifier
Multiforme NCT03861299 96 106 I-Modifier
on NCT03861299 107 109 O
MRI NCT03861299 110 113 B-Procedure
with NCT03861299 114 118 O
distinct NCT03861299 119 127 B-Modifier
ring NCT03861299 128 132 I-Modifier
- NCT03861299 133 134 I-Modifier
like NCT03861299 135 139 I-Modifier
pattern NCT03861299 140 147 I-Modifier
of NCT03861299 148 150 O
contrast NCT03861299 151 159 B-Procedure
enhancement NCT03861299 160 171 I-Procedure
with NCT03861299 172 176 O
thick NCT03861299 177 182 B-Modifier
irregular NCT03861299 183 192 I-Modifier
walls NCT03861299 193 198 I-Modifier
and NCT03861299 199 202 B-And
a NCT03861299 203 204 O
core NCT03861299 205 209 B-Modifier
area NCT03861299 210 214 I-Modifier
reduced NCT03861299 215 222 I-Modifier
signal NCT03861299 223 229 I-Modifier
suggestive NCT03861299 230 240 B-Assertion___Assertion-Type-Value:possible
of NCT03861299 241 243 O
tumour NCT03861299 244 250 B-Condition
necrosis NCT03861299 251 259 I-Condition
as NCT03861299 260 262 O
assessed NCT03861299 263 271 O
by NCT03861299 272 274 O
the NCT03861299 275 278 O
surgeon NCT03861299 279 286 B-Provider

3 NCT03861299 289 290 O
. NCT03861299 290 291 O
Tumors NCT03861299 293 299 B-Condition
situated NCT03861299 300 308 O
in NCT03861299 309 311 B-Modifier
or NCT03861299 312 314 I-Modifier
near NCT03861299 315 319 I-Modifier
eloquent NCT03861299 320 328 I-Modifier
areas NCT03861299 329 334 I-Modifier
; NCT03861299 334 335 O
motor NCT03861299 336 341 B-Modifier
cortex NCT03861299 342 348 I-Modifier
, NCT03861299 349 350 O
sensory NCT03861299 351 358 B-Modifier
cortex NCT03861299 359 365 I-Modifier
, NCT03861299 366 367 O
subcortical NCT03861299 368 379 B-Modifier
pyramidal NCT03861299 380 389 I-Modifier
tract NCT03861299 390 395 I-Modifier
or NCT03861299 396 398 B-Or
speech NCT03861299 399 405 B-Modifier
areas NCT03861299 406 411 I-Modifier
as NCT03861299 412 414 O
indicated NCT03861299 415 424 O
on NCT03861299 425 427 O
MRI NCT03861299 428 431 B-Procedure
( NCT03861299 432 433 O
Sawaya NCT03861299 434 440 B-Condition
Grading NCT03861299 441 448 B-Eq-Comparison
II NCT03861299 449 451 I-Eq-Comparison
and NCT03861299 452 455 I-Eq-Comparison
II NCT03861299 456 458 I-Eq-Comparison
) NCT03861299 459 460 O

4 NCT03861299 464 465 O
. NCT03861299 465 466 O
The NCT03861299 468 471 O
tumor NCT03861299 472 477 B-Condition
is NCT03861299 478 480 O
suitable NCT03861299 481 489 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861299 490 493 I-Assertion___Assertion-Type-Value:hypothetical
resection NCT03861299 494 503 B-Procedure
( NCT03861299 504 505 O
according NCT03861299 506 515 O
to NCT03861299 516 518 O
neurosurgeon NCT03861299 519 531 B-Provider
) NCT03861299 532 533 O

5 NCT03861299 537 538 O
. NCT03861299 538 539 O
Karnofsky NCT03861299 541 550 B-Observation
performance NCT03861299 551 562 I-Observation
scale NCT03861299 563 568 I-Observation
80 NCT03861299 569 571 B-Eq-Comparison
or NCT03861299 572 574 I-Eq-Comparison
more NCT03861299 575 579 I-Eq-Comparison

6 NCT03861299 582 583 O
. NCT03861299 583 584 O
Written NCT03861299 586 593 O
Informed NCT03861299 594 602 O
consent NCT03861299 603 610 O

Exclusion NCT03861299 611 620 O
Criteria NCT03861299 621 629 O
: NCT03861299 630 631 O

1 NCT03861299 635 636 O
. NCT03861299 636 637 O
Tumors NCT03861299 639 645 B-Condition
of NCT03861299 646 648 O
the NCT03861299 649 652 O
cerebellum NCT03861299 653 663 B-Modifier
, NCT03861299 664 665 O
brain NCT03861299 666 671 B-Modifier
stem NCT03861299 672 676 I-Modifier
or NCT03861299 677 679 B-Or
midline NCT03861299 680 687 B-Modifier

2 NCT03861299 690 691 O
. NCT03861299 691 692 O
Multifocal NCT03861299 694 704 B-Modifier
contrast NCT03861299 705 713 I-Modifier
enhancing NCT03861299 714 723 I-Modifier
lesions NCT03861299 724 731 B-Condition

3 NCT03861299 734 735 O
. NCT03861299 735 736 O
Substantial NCT03861299 738 749 O
non NCT03861299 750 753 B-Modifier
- NCT03861299 754 755 I-Modifier
contrast NCT03861299 756 764 I-Modifier
enhancing NCT03861299 765 774 I-Modifier
tumor NCT03861299 775 780 B-Condition
areas NCT03861299 781 786 O
suggesting NCT03861299 787 797 B-Assertion___Assertion-Type-Value:possible
low NCT03861299 798 801 O
grade NCT03861299 802 807 O
gliomas NCT03861299 808 815 B-Condition
with NCT03861299 816 820 O
malignant NCT03861299 821 830 B-Modifier
transformation NCT03861299 831 845 I-Modifier

4 NCT03861299 848 849 O
. NCT03861299 849 850 O
Medical NCT03861299 852 859 B-Condition
reasons NCT03861299 860 867 I-Condition
precluding NCT03861299 868 878 B-Assertion___Assertion-Type-Value:hypothetical|Negation
MRI NCT03861299 879 882 B-Procedure
( NCT03861299 883 884 O
eg NCT03861299 885 887 O
, NCT03861299 888 889 O
pacemaker NCT03861299 890 899 B-Procedure
) NCT03861299 900 901 O

5 NCT03861299 905 906 O
. NCT03861299 906 907 O
Inability NCT03861299 909 918 O
to NCT03861299 919 921 O
give NCT03861299 922 926 O
consent NCT03861299 927 934 O
because NCT03861299 935 942 O
of NCT03861299 943 945 O
or NCT03861299 946 948 O
language NCT03861299 949 957 B-Condition
barrier NCT03861299 958 965 I-Condition

6 NCT03861299 968 969 O
. NCT03861299 969 970 O
Psychiatric NCT03861299 972 983 B-Condition
history NCT03861299 984 991 B-Eq-Comparison

7 NCT03861299 994 995 O
. NCT03861299 995 996 O
Previous NCT03861299 998 1006 B-Eq-Comparison
brain NCT03861299 1007 1012 B-Modifier
tumour NCT03861299 1013 1019 B-Condition
surgery NCT03861299 1020 1027 B-Procedure

8 NCT03861299 1030 1031 O
. NCT03861299 1031 1032 O
Previous NCT03861299 1034 1042 B-Eq-Comparison
low NCT03861299 1043 1046 O
- NCT03861299 1047 1048 O
grade NCT03861299 1049 1054 O
glioma NCT03861299 1055 1061 B-Condition
. NCT03861299 1062 1063 O

9 NCT03861299 1067 1068 O
. NCT03861299 1068 1069 O
Second NCT03861299 1071 1077 B-Eq-Comparison
primary NCT03861299 1078 1085 B-Modifier
malignancy NCT03861299 1086 1096 B-Condition
within NCT03861299 1097 1103 B-Eq-Comparison
the NCT03861299 1104 1107 I-Eq-Comparison
past NCT03861299 1108 1112 I-Eq-Comparison
5 NCT03861299 1113 1114 I-Eq-Comparison
years NCT03861299 1115 1120 I-Eq-Comparison
with NCT03861299 1121 1125 O
the NCT03861299 1126 1129 O
exception NCT03861299 1130 1139 B-Exception
of NCT03861299 1140 1142 I-Exception
adequately NCT03861299 1143 1153 O
treated NCT03861299 1154 1161 B-Procedure
in NCT03861299 1162 1164 B-Modifier
situ NCT03861299 1165 1169 I-Modifier
carcinoma NCT03861299 1170 1179 B-Condition
of NCT03861299 1180 1182 O
any NCT03861299 1183 1186 B-Modifier
organ NCT03861299 1187 1192 I-Modifier
or NCT03861299 1193 1195 B-Or
basal NCT03861299 1196 1201 B-Modifier
cell NCT03861299 1202 1206 I-Modifier
carcinoma NCT03861299 1207 1216 B-Condition
of NCT03861299 1217 1219 O
the NCT03861299 1220 1223 O
skin NCT03861299 1224 1228 B-Modifier
. NCT03861299 1229 1230 O

10 NCT03861299 1233 1235 O
. NCT03861299 1235 1236 O
Severe NCT03861299 1238 1244 O
aphasia NCT03861299 1245 1252 B-Condition
or NCT03861299 1253 1255 B-Or
dysphasia NCT03861299 1256 1265 B-Condition

Inclusion NCT03864120 0 9 O
Criteria NCT03864120 10 18 O
: NCT03864120 19 20 O

1 NCT03864120 24 25 O
. NCT03864120 25 26 O
Age NCT03864120 28 31 B-Age
> NCT03864120 32 33 B-Eq-Comparison
18 NCT03864120 34 36 I-Eq-Comparison
years NCT03864120 37 42 I-Eq-Comparison

2 NCT03864120 45 46 O
. NCT03864120 46 47 O
on NCT03864120 49 51 B-Eq-Comparison
PD NCT03864120 52 54 B-Condition
treatment NCT03864120 55 64 B-Procedure
for NCT03864120 65 68 O
at NCT03864120 69 71 B-Eq-Comparison
least NCT03864120 72 77 I-Eq-Comparison
one NCT03864120 78 81 I-Eq-Comparison
month NCT03864120 82 87 I-Eq-Comparison

3 NCT03864120 90 91 O
. NCT03864120 91 92 O
signed NCT03864120 94 100 O
the NCT03864120 101 104 O
consent NCT03864120 105 112 O

Exclusion NCT03864120 113 122 O
Criteria NCT03864120 123 131 O
: NCT03864120 132 133 O

1 NCT03864120 137 138 O
. NCT03864120 138 139 O
Peritonitis NCT03864120 141 152 B-Condition
or NCT03864120 153 155 B-Or
recovery NCT03864120 156 164 B-Condition
from NCT03864120 165 169 O
peritonitis NCT03864120 170 181 B-Condition
for NCT03864120 182 185 O
less NCT03864120 186 190 B-Eq-Comparison
than NCT03864120 191 195 I-Eq-Comparison
one NCT03864120 196 199 I-Eq-Comparison
month NCT03864120 200 205 I-Eq-Comparison
. NCT03864120 206 207 O

2 NCT03864120 211 212 O
. NCT03864120 212 213 O
On NCT03864120 215 217 B-Eq-Comparison
any NCT03864120 218 221 O
intra NCT03864120 222 227 B-Modifier
peritoneal NCT03864120 228 238 B-Procedure
treatment NCT03864120 239 248 I-Procedure
apart NCT03864120 249 254 B-Exception
from NCT03864120 255 259 O
peritoneal NCT03864120 260 270 B-Procedure
dialysis NCT03864120 271 279 I-Procedure
. NCT03864120 280 281 O

3 NCT03864120 285 286 O
. NCT03864120 286 287 O
Evidence NCT03864120 289 297 O
of NCT03864120 298 300 O
decompensated NCT03864120 301 314 B-Modifier
liver NCT03864120 315 320 I-Modifier
cirrhosis NCT03864120 321 330 B-Condition
or NCT03864120 331 333 B-Or
heart NCT03864120 334 339 B-Condition
failure NCT03864120 340 347 I-Condition
. NCT03864120 348 349 O

4 NCT03864120 353 354 O
. NCT03864120 354 355 O
Evidence NCT03864120 357 365 O
of NCT03864120 366 368 O
extra NCT03864120 369 374 B-Modifier
peritoneal NCT03864120 375 385 B-Condition
leakage NCT03864120 386 393 I-Condition
, NCT03864120 394 395 O
eg NCT03864120 396 398 O
. NCT03864120 398 399 O
leakage NCT03864120 401 408 B-Condition
to NCT03864120 409 411 O
thoracic NCT03864120 412 420 B-Modifier
cavity NCT03864120 421 427 I-Modifier
, NCT03864120 428 429 O
post NCT03864120 430 434 B-Temporal-Connection___Temporal-Connection-Type-Value:after
peritoneal NCT03864120 435 445 B-Procedure
, NCT03864120 446 447 O
hernia NCT03864120 448 454 B-Condition
. NCT03864120 454 455 O

Inclusion NCT03864861 0 9 O
Criteria NCT03864861 10 18 O
: NCT03864861 19 20 O

- NCT03864861 24 25 O
All NCT03864861 27 30 O
adult NCT03864861 31 36 O
patients NCT03864861 37 45 O
( NCT03864861 46 47 O
aged NCT03864861 48 52 B-Age
≥ NCT03864861 53 54 B-Eq-Comparison
18 NCT03864861 55 57 I-Eq-Comparison
years NCT03864861 58 63 I-Eq-Comparison
) NCT03864861 64 65 O
undergoing NCT03864861 66 76 B-Eq-Comparison
elective NCT03864861 77 85 B-Modifier
bariatric NCT03864861 86 95 B-Procedure
surgery NCT03864861 96 103 I-Procedure
and NCT03864861 104 107 O
by NCT03864861 108 110 O
any NCT03864861 111 114 O
approach NCT03864861 115 123 O
( NCT03864861 124 125 O
Includes NCT03864861 126 134 O
surgery NCT03864861 135 142 B-Procedure
with NCT03864861 143 147 O
laparoscopic NCT03864861 148 160 B-Procedure
, NCT03864861 161 162 O
assisted NCT03864861 163 171 B-Modifier
laparoscopic NCT03864861 172 184 B-Procedure
approach NCT03864861 185 193 I-Procedure
or NCT03864861 194 196 B-Or
open NCT03864861 197 201 B-Procedure
approach NCT03864861 202 210 I-Procedure
) NCT03864861 211 212 O
in NCT03864861 213 215 O
a NCT03864861 216 217 O
participating NCT03864861 218 231 O
hospital NCT03864861 232 240 O
during NCT03864861 241 247 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864861 248 251 O
30 NCT03864861 252 254 B-Eq-Comparison
- NCT03864861 255 256 I-Eq-Comparison
day NCT03864861 257 260 I-Eq-Comparison
cohort NCT03864861 261 267 B-Study
period NCT03864861 268 274 O
with NCT03864861 275 279 B-And
a NCT03864861 280 281 O
planned NCT03864861 282 289 B-Eq-Comparison
overnight NCT03864861 290 299 B-Encounter
stay NCT03864861 300 304 I-Encounter
. NCT03864861 305 306 O

Exclusion NCT03864861 308 317 O
Criteria NCT03864861 318 326 O
: NCT03864861 327 328 O

- NCT03864861 332 333 O
Patients NCT03864861 335 343 O
undergoing NCT03864861 344 354 B-Eq-Comparison
emergency NCT03864861 355 364 B-Modifier
surgery NCT03864861 365 372 B-Procedure

- NCT03864861 380 381 O
Endoscopic NCT03864861 383 393 B-Procedure
procedures NCT03864861 394 404 I-Procedure

- NCT03864861 412 413 O
Patients NCT03864861 415 423 O
under NCT03864861 424 429 B-Eq-Comparison
18 NCT03864861 430 432 I-Eq-Comparison
years NCT03864861 433 438 I-Eq-Comparison
of NCT03864861 439 441 O
age NCT03864861 442 445 B-Age

- NCT03864861 453 454 O
Patients NCT03864861 456 464 O
with NCT03864861 465 469 O
previous NCT03864861 470 478 B-Eq-Comparison
bariatric NCT03864861 479 488 B-Procedure
surgery NCT03864861 489 496 I-Procedure
who NCT03864861 497 500 B-And
undergo NCT03864861 501 508 O
revision NCT03864861 509 517 B-Procedure
surgery NCT03864861 518 525 I-Procedure

- NCT03864861 533 534 O
Patients NCT03864861 536 544 O
who NCT03864861 545 548 O
refuse NCT03864861 549 555 O
to NCT03864861 556 558 O
participate NCT03864861 559 570 O

Inclusion NCT03868137 0 9 O
Criteria NCT03868137 10 18 O
: NCT03868137 19 20 O

- NCT03868137 24 25 O
Age NCT03868137 27 30 B-Age
≥ NCT03868137 31 32 B-Eq-Comparison
18 NCT03868137 33 35 I-Eq-Comparison

- NCT03868137 39 40 O
Female NCT03868137 42 48 O

- NCT03868137 51 52 O
Able NCT03868137 54 58 O
to NCT03868137 59 61 O
provide NCT03868137 62 69 O
informed NCT03868137 70 78 O
consent NCT03868137 79 86 O

- NCT03868137 89 90 O
English NCT03868137 92 99 O
speaking NCT03868137 100 108 O

- NCT03868137 111 112 O
Able NCT03868137 114 118 O
to NCT03868137 119 121 O
provide NCT03868137 122 129 O
telephone NCT03868137 130 139 O
and NCT03868137 140 143 O
address NCT03868137 144 151 O
contact NCT03868137 152 159 O
information NCT03868137 160 171 O

- NCT03868137 174 175 O
Able NCT03868137 177 181 O
and NCT03868137 182 185 O
willing NCT03868137 186 193 O
to NCT03868137 194 196 O
receive NCT03868137 197 204 O
HIPAA NCT03868137 205 210 O
compliant NCT03868137 211 220 O
telephone NCT03868137 221 230 O
texts NCT03868137 231 236 O
and NCT03868137 237 240 O
phone NCT03868137 241 246 O
messages NCT03868137 247 255 O

- NCT03868137 258 259 O
Stable NCT03868137 261 267 O
( NCT03868137 268 269 O
the NCT03868137 270 273 O
same NCT03868137 274 278 O
) NCT03868137 279 280 O
address NCT03868137 281 288 O
and NCT03868137 289 292 O
phone NCT03868137 293 298 O
number NCT03868137 299 305 O
within NCT03868137 306 312 B-Eq-Comparison
the NCT03868137 313 316 I-Eq-Comparison
last NCT03868137 317 321 I-Eq-Comparison
6 NCT03868137 322 323 I-Eq-Comparison
months NCT03868137 324 330 I-Eq-Comparison
. NCT03868137 331 332 O

Exclusion NCT03868137 334 343 O
Criteria NCT03868137 344 352 O
: NCT03868137 353 354 O

- NCT03868137 358 359 O
Contraindications NCT03868137 361 378 B-Contraindication
to NCT03868137 379 381 O
IUD NCT03868137 382 385 B-Procedure
insertion NCT03868137 386 395 I-Procedure
( NCT03868137 396 397 O
active NCT03868137 398 404 B-Eq-Comparison
pelvic NCT03868137 405 411 B-Modifier
infection NCT03868137 412 421 B-Condition
, NCT03868137 422 423 O
current NCT03868137 424 431 B-Eq-Comparison
pregnancy NCT03868137 432 441 B-Condition
) NCT03868137 442 443 O

- NCT03868137 447 448 O
Contraindications NCT03868137 450 467 B-Contraindication
to NCT03868137 468 470 O
NSAIDs NCT03868137 471 477 B-Drug
( NCT03868137 478 479 O
allergy NCT03868137 480 487 B-Allergy
, NCT03868137 488 489 O
history NCT03868137 490 497 B-Eq-Comparison
of NCT03868137 498 500 O
asthma NCT03868137 501 507 B-Condition
, NCT03868137 508 509 O
history NCT03868137 510 517 B-Eq-Comparison
of NCT03868137 518 520 O
aspirin NCT03868137 521 528 B-Drug
allergy NCT03868137 529 536 B-Allergy
, NCT03868137 537 538 O
history NCT03868137 539 546 B-Eq-Comparison
of NCT03868137 547 549 O
kidney NCT03868137 550 556 B-Condition
disease NCT03868137 557 564 I-Condition
, NCT03868137 565 566 O
history NCT03868137 567 574 B-Eq-Comparison
of NCT03868137 575 577 O
stomach NCT03868137 578 585 B-Modifier
ulcer NCT03868137 586 591 B-Condition
, NCT03868137 592 593 O
history NCT03868137 594 601 B-Eq-Comparison
of NCT03868137 602 604 O
active NCT03868137 605 611 B-Eq-Comparison
GI NCT03868137 612 614 B-Modifier
bleeding NCT03868137 615 623 B-Condition
, NCT03868137 624 625 O
history NCT03868137 626 633 B-Eq-Comparison
of NCT03868137 634 636 O
liver NCT03868137 637 642 B-Condition
disease NCT03868137 643 650 I-Condition
) NCT03868137 651 652 O

- NCT03868137 656 657 O
Not NCT03868137 659 662 B-Negation
undergoing NCT03868137 663 673 B-Eq-Comparison
any NCT03868137 674 677 O
other NCT03868137 678 683 B-Other
concurrent NCT03868137 684 694 B-Modifier
office NCT03868137 695 701 I-Modifier
procedures NCT03868137 702 712 B-Procedure

Inclusion NCT03865407 0 9 O
Criteria NCT03865407 10 18 O
: NCT03865407 19 20 O

- NCT03865407 24 25 O
Chronic NCT03865407 27 34 B-Modifier
Kidney NCT03865407 35 41 B-Condition
Disease NCT03865407 42 49 I-Condition
stage NCT03865407 50 55 B-Eq-Comparison
1 NCT03865407 56 57 I-Eq-Comparison
- NCT03865407 58 59 I-Eq-Comparison
5 NCT03865407 60 61 O

- NCT03865407 65 66 O
Hyperuricemic NCT03865407 68 81 B-Condition
( NCT03865407 82 83 O
UA NCT03865407 84 86 B-Observation
> NCT03865407 87 88 B-Eq-Comparison
= NCT03865407 90 91 I-Eq-Comparison
5.5 NCT03865407 92 95 I-Eq-Comparison
mg NCT03865407 96 98 I-Eq-Comparison
/ NCT03865407 99 100 I-Eq-Comparison
dL NCT03865407 101 103 I-Eq-Comparison
) NCT03865407 104 105 O

Exclusion NCT03865407 107 116 O
Criteria NCT03865407 117 125 O
: NCT03865407 126 127 O

- NCT03865407 131 132 O
Contraindication NCT03865407 134 150 B-Contraindication
to NCT03865407 151 153 O
Allopurinol NCT03865407 154 165 B-Drug

- NCT03865407 168 169 O
Elevated NCT03865407 171 179 O
baseline NCT03865407 180 188 O
liver NCT03865407 189 194 B-Observation
function NCT03865407 195 203 I-Observation
tests NCT03865407 204 209 I-Observation

- NCT03865407 212 213 O
Receiving NCT03865407 215 224 B-Eq-Comparison
acute NCT03865407 225 230 O
or NCT03865407 231 233 B-Or
chronic NCT03865407 234 241 B-Modifier
dialysis NCT03865407 242 250 B-Procedure

- NCT03865407 253 254 O
Primary NCT03865407 256 263 B-Modifier
metabolic NCT03865407 264 273 B-Condition
disorder NCT03865407 274 282 I-Condition

- NCT03865407 285 286 O
Sickle NCT03865407 288 294 B-Condition
cell NCT03865407 295 299 I-Condition
disease NCT03865407 300 307 I-Condition

- NCT03865407 310 311 O
Autosomal NCT03865407 313 322 B-Modifier
Dominant NCT03865407 323 331 I-Modifier
Polycystic NCT03865407 332 342 B-Condition
Kidney NCT03865407 343 349 I-Condition
Disease NCT03865407 350 357 I-Condition

- NCT03865407 360 361 O
Cystinosis NCT03865407 363 373 B-Condition

- NCT03865407 376 377 O
Bartter NCT03865407 379 386 B-Modifier
or NCT03865407 387 389 B-Or
Gitelman NCT03865407 390 398 B-Modifier
Disease NCT03865407 399 406 B-Condition

- NCT03865407 409 410 O
Pregnant NCT03865407 412 420 B-Condition
or NCT03865407 421 423 B-Or
nursing NCT03865407 424 431 B-Condition

Inclusion NCT03866668 0 9 O
Criteria NCT03866668 10 18 O
: NCT03866668 19 20 O

- NCT03866668 24 25 O
outpatients NCT03866668 27 38 B-Encounter
2 NCT03866668 39 40 B-Eq-Comparison
to NCT03866668 41 43 I-Eq-Comparison
6 NCT03866668 44 45 I-Eq-Comparison
years NCT03866668 46 51 I-Eq-Comparison
of NCT03866668 52 54 O
age NCT03866668 55 58 B-Age
; NCT03866668 58 59 O

- NCT03866668 62 63 O
males NCT03866668 65 70 O
and NCT03866668 71 74 B-Or
females NCT03866668 75 82 O
who NCT03866668 83 86 B-And
are NCT03866668 87 90 O
physically NCT03866668 91 101 O
healthy NCT03866668 102 109 B-Condition
; NCT03866668 109 110 O

- NCT03866668 113 114 O
diagnosis NCT03866668 116 125 O
of NCT03866668 126 128 O
autism NCT03866668 129 135 B-Condition
spectrum NCT03866668 136 144 I-Condition
disorder NCT03866668 145 153 I-Condition
based NCT03866668 154 159 O
on NCT03866668 160 162 O
clinical NCT03866668 163 171 O
evaluation NCT03866668 172 182 O
and NCT03866668 183 186 O
DSM NCT03866668 187 190 O
- NCT03866668 191 192 O
5 NCT03866668 193 194 O
criteria NCT03866668 195 203 O
, NCT03866668 204 205 O
and NCT03866668 206 209 O
confirmed NCT03866668 210 219 O
using NCT03866668 220 225 O
the NCT03866668 226 229 O
Autism NCT03866668 230 236 O
Diagnostic NCT03866668 237 247 O
Interview NCT03866668 248 257 O
- NCT03866668 258 259 O
Revised NCT03866668 260 267 O
, NCT03866668 268 269 O
and NCT03866668 270 273 O
the NCT03866668 274 277 O
Autism NCT03866668 278 284 O
Diagnostic NCT03866668 285 295 O
Observation NCT03866668 296 307 O
Schedule NCT03866668 308 316 O
; NCT03866668 316 317 O

- NCT03866668 320 321 O
care NCT03866668 323 327 B-Provider
provider NCT03866668 328 336 I-Provider
who NCT03866668 337 340 O
could NCT03866668 341 346 B-Assertion___Assertion-Type-Value:hypothetical
reliably NCT03866668 347 355 O
bring NCT03866668 356 361 O
subject NCT03866668 362 369 O
to NCT03866668 370 372 O
clinic NCT03866668 373 379 O
visits NCT03866668 380 386 B-Encounter
, NCT03866668 387 388 O
could NCT03866668 389 394 B-Assertion___Assertion-Type-Value:hypothetical
provide NCT03866668 395 402 O
trustworthy NCT03866668 403 414 O
ratings NCT03866668 415 422 O
, NCT03866668 423 424 O
and NCT03866668 425 428 O
interacted NCT03866668 429 439 O
with NCT03866668 440 444 O
subject NCT03866668 445 452 O
on NCT03866668 453 455 O
a NCT03866668 456 457 O
regular NCT03866668 458 465 O
basis NCT03866668 466 471 O
; NCT03866668 471 472 O

- NCT03866668 475 476 O
ability NCT03866668 478 485 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03866668 486 488 I-Assertion___Assertion-Type-Value:hypothetical
subject NCT03866668 489 496 O
to NCT03866668 497 499 O
swallow NCT03866668 500 507 O
the NCT03866668 508 511 O
compound NCT03866668 512 520 B-Drug
; NCT03866668 520 521 O

- NCT03866668 524 525 O
stable NCT03866668 527 533 O
concomitant NCT03866668 534 545 B-Modifier
medications NCT03866668 546 557 B-Drug
for NCT03866668 558 561 O
at NCT03866668 562 564 B-Eq-Comparison
least NCT03866668 565 570 I-Eq-Comparison
2 NCT03866668 571 572 I-Eq-Comparison
weeks NCT03866668 573 578 I-Eq-Comparison
( NCT03866668 579 580 O
4 NCT03866668 581 582 B-Eq-Comparison
weeks NCT03866668 583 588 I-Eq-Comparison
if NCT03866668 589 591 O
patient NCT03866668 592 599 O
took NCT03866668 600 604 B-Eq-Comparison
fluoxetine NCT03866668 605 615 B-Drug
) NCT03866668 616 617 O
; NCT03866668 618 619 O

- NCT03866668 622 623 O
no NCT03866668 625 627 B-Negation
planned NCT03866668 628 635 B-Eq-Comparison
changes NCT03866668 636 643 O
in NCT03866668 644 646 O
psychosocial NCT03866668 647 659 B-Procedure
interventions NCT03866668 660 673 I-Procedure
during NCT03866668 674 680 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866668 681 684 O
open NCT03866668 685 689 B-Modifier
- NCT03866668 690 691 I-Modifier
label NCT03866668 692 697 I-Modifier
trial NCT03866668 698 703 B-Study
. NCT03866668 704 705 O

Exclusion NCT03866668 707 716 O
Criteria NCT03866668 717 725 O
: NCT03866668 726 727 O

- NCT03866668 731 732 O
DSM NCT03866668 734 737 O
- NCT03866668 738 739 O
5 NCT03866668 740 741 O
diagnosis NCT03866668 742 751 O
of NCT03866668 752 754 O
schizophrenia NCT03866668 755 768 B-Condition
, NCT03866668 769 770 O
schizoaffective NCT03866668 771 786 B-Condition
disorder NCT03866668 787 795 I-Condition
, NCT03866668 796 797 O
or NCT03866668 798 800 B-Or
psychotic NCT03866668 801 810 B-Condition
disorder NCT03866668 811 819 I-Condition
not NCT03866668 820 823 O
otherwise NCT03866668 824 833 O
specified NCT03866668 834 843 O
; NCT03866668 843 844 O

- NCT03866668 847 848 O
prior NCT03866668 850 855 B-Eq-Comparison
adequate NCT03866668 856 864 O
trial NCT03866668 865 870 B-Study
of NCT03866668 871 873 O
Esomeprazole NCT03866668 874 886 B-Drug
; NCT03866668 886 887 O

- NCT03866668 890 891 O
active NCT03866668 893 899 B-Eq-Comparison
medical NCT03866668 900 907 B-Condition
problems NCT03866668 908 916 I-Condition
such NCT03866668 917 921 O
as NCT03866668 922 924 O
unstable NCT03866668 925 933 O
seizures NCT03866668 934 942 B-Condition
, NCT03866668 943 944 O
or NCT03866668 945 947 B-Or
significant NCT03866668 948 959 O
physical NCT03866668 960 968 B-Condition
illness NCT03866668 969 976 I-Condition
( NCT03866668 977 978 O
e. NCT03866668 979 981 O
g. NCT03866668 982 984 O
, NCT03866668 985 986 O
serious NCT03866668 987 994 O
liver NCT03866668 995 1000 B-Modifier
or NCT03866668 1001 1003 B-Or
renal NCT03866668 1004 1009 B-Modifier
pathology NCT03866668 1010 1019 B-Condition
) NCT03866668 1020 1021 O
. NCT03866668 1022 1023 O

Inclusion NCT03864731 0 9 O
Criteria NCT03864731 10 18 O
: NCT03864731 19 20 O

- NCT03864731 24 25 O
Unilateral NCT03864731 27 37 B-Modifier
and NCT03864731 38 41 B-Or
/ NCT03864731 42 43 I-Or
or NCT03864731 44 46 I-Or
bilateral NCT03864731 47 56 B-Modifier
conductive NCT03864731 57 67 B-Condition
hearing NCT03864731 68 75 I-Condition
loss NCT03864731 76 80 I-Condition
( NCT03864731 81 82 O
CHL NCT03864731 83 86 B-Condition
) NCT03864731 87 88 O

- NCT03864731 92 93 O
Conductive NCT03864731 95 105 B-Modifier
hearing NCT03864731 106 113 B-Condition|Observation
loss NCT03864731 114 118 I-Condition|Observation
> NCT03864731 119 120 B-Eq-Comparison
10 NCT03864731 121 123 I-Eq-Comparison
decibel NCT03864731 124 131 I-Eq-Comparison
on NCT03864731 132 134 O
average NCT03864731 135 142 O

- NCT03864731 145 146 O
Subjective NCT03864731 148 158 O
benefit NCT03864731 159 166 O
from NCT03864731 167 171 O
the NCT03864731 172 175 O
device NCT03864731 176 182 O

- NCT03864731 185 186 O
Subjects NCT03864731 188 196 O
aged NCT03864731 197 201 B-Age
13 NCT03864731 202 204 B-Eq-Comparison
years NCT03864731 205 210 I-Eq-Comparison
or NCT03864731 211 213 I-Eq-Comparison
older NCT03864731 214 219 I-Eq-Comparison

- NCT03864731 222 223 O
Capable NCT03864731 225 232 O
of NCT03864731 233 235 O
the NCT03864731 236 239 O
German NCT03864731 240 246 O
language NCT03864731 247 255 O

- NCT03864731 258 259 O
Willingness NCT03864731 261 272 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03864731 273 276 I-Assertion___Assertion-Type-Value:hypothetical
ability NCT03864731 277 284 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03864731 285 287 O
perform NCT03864731 288 295 O
all NCT03864731 296 299 O
tests NCT03864731 300 305 B-Observation
required NCT03864731 306 314 O
for NCT03864731 315 318 O
the NCT03864731 319 322 O
study NCT03864731 323 328 B-Study

- NCT03864731 331 332 O
Signed NCT03864731 334 340 O
, NCT03864731 341 342 O
and NCT03864731 343 346 O
dated NCT03864731 347 352 O
informed NCT03864731 353 361 O
consent NCT03864731 362 369 O
before NCT03864731 370 376 O
the NCT03864731 377 380 O
start NCT03864731 381 386 O
of NCT03864731 387 389 O
any NCT03864731 390 393 O
study NCT03864731 394 399 B-Study
specific NCT03864731 400 408 O
procedure NCT03864731 409 418 B-Procedure

Exclusion NCT03864731 419 428 O
Criteria NCT03864731 429 437 O
: NCT03864731 438 439 O

- NCT03864731 443 444 O
Pregnancy NCT03864731 446 455 B-Condition
or NCT03864731 456 458 B-Or
breastfeeding NCT03864731 459 472 B-Condition

- NCT03864731 475 476 O
Patient NCT03864731 478 485 O
uses NCT03864731 486 490 O
a NCT03864731 491 492 O
hearing NCT03864731 493 500 B-Condition
aid NCT03864731 501 504 I-Condition
or NCT03864731 505 507 B-Or
plans NCT03864731 508 513 B-Assertion___Assertion-Type-Value:intention
to NCT03864731 514 516 O
acquire NCT03864731 517 524 O
a NCT03864731 525 526 O
hearing NCT03864731 527 534 B-Condition
aid NCT03864731 535 538 I-Condition

- NCT03864731 541 542 O
Patient NCT03864731 544 551 O
is NCT03864731 552 554 O
intolerant NCT03864731 555 565 O
of NCT03864731 566 568 O
the NCT03864731 569 572 O
materials NCT03864731 573 582 O
as NCT03864731 583 585 O
described NCT03864731 586 595 O
by NCT03864731 596 598 O
Manufacturer NCT03864731 599 611 O

- NCT03864731 614 615 O
Patient NCT03864731 617 624 O
presents NCT03864731 625 633 O
with NCT03864731 634 638 O
a NCT03864731 639 640 O
skin NCT03864731 641 645 B-Modifier
or NCT03864731 646 648 B-Or
scalp NCT03864731 649 654 B-Modifier
condition NCT03864731 655 664 B-Condition
that NCT03864731 665 669 O
may NCT03864731 670 673 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03864731 674 682 B-Negation
the NCT03864731 683 686 O
attachment NCT03864731 687 697 B-Procedure
of NCT03864731 698 700 I-Procedure
the NCT03864731 701 704 I-Procedure
adhesive NCT03864731 705 713 I-Procedure
adapter NCT03864731 714 721 I-Procedure
. NCT03864731 722 723 O

- NCT03864731 727 728 O
Patient NCT03864731 730 737 O
can NCT03864731 738 741 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03864731 741 744 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03864731 745 752 O
the NCT03864731 753 756 O
audiological NCT03864731 757 769 B-Procedure
tests NCT03864731 770 775 I-Procedure
or NCT03864731 776 778 B-Or
is NCT03864731 779 781 O
unable NCT03864731 782 788 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864731 789 791 O
fill NCT03864731 792 796 O
out NCT03864731 797 800 O
the NCT03864731 801 804 O
questionnaires NCT03864731 805 819 B-Observation
. NCT03864731 820 821 O

- NCT03864731 825 826 O
Patient NCT03864731 828 835 O
presents NCT03864731 836 844 O
with NCT03864731 845 849 O
retrocochlear NCT03864731 850 863 B-Condition
, NCT03864731 864 865 O
or NCT03864731 866 868 B-Or
central NCT03864731 869 876 B-Modifier
auditory NCT03864731 877 885 B-Condition
disorder NCT03864731 886 894 I-Condition
. NCT03864731 895 896 O

- NCT03864731 900 901 O
any NCT03864731 903 906 O
physical NCT03864731 907 915 B-Modifier
, NCT03864731 916 917 O
psychological NCT03864731 918 931 B-Modifier
, NCT03864731 932 933 O
or NCT03864731 934 936 B-Or
emotional NCT03864731 937 946 B-Modifier
disorder NCT03864731 947 955 B-Condition
that NCT03864731 956 960 O
would NCT03864731 961 966 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03864731 967 976 O
with NCT03864731 977 981 O
the NCT03864731 982 985 O
ability NCT03864731 986 993 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864731 994 996 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03864731 997 1004 O
on NCT03864731 1005 1007 O
test NCT03864731 1008 1012 B-Observation
and NCT03864731 1013 1016 B-Or
rehabilitation NCT03864731 1017 1031 B-Procedure
procedures NCT03864731 1032 1042 I-Procedure

Inclusion NCT03869567 0 9 O
Criteria NCT03869567 10 18 O
: NCT03869567 19 20 O

- NCT03869567 24 25 O
all NCT03869567 27 30 O
patients NCT03869567 31 39 O
with NCT03869567 40 44 O
cerebral NCT03869567 45 53 B-Condition
thrombectomy NCT03869567 54 66 I-Condition

- NCT03869567 69 70 O
Adults NCT03869567 72 78 O

- NCT03869567 81 82 O
Patients NCT03869567 84 92 O
able NCT03869567 93 97 O
to NCT03869567 98 100 O
express NCT03869567 101 108 O
consent NCT03869567 109 116 O

- NCT03869567 119 120 O
Signed NCT03869567 122 128 O
written NCT03869567 129 136 O
informed NCT03869567 137 145 O
consent NCT03869567 146 153 O
form NCT03869567 154 158 O

- NCT03869567 161 162 O
Covered NCT03869567 164 171 O
by NCT03869567 172 174 O
national NCT03869567 175 183 O
health NCT03869567 184 190 O
insurance NCT03869567 191 200 O

Exclusion NCT03869567 201 210 O
Criteria NCT03869567 211 219 O
: NCT03869567 220 221 O

- NCT03869567 225 226 O
minors NCT03869567 228 234 O

- NCT03869567 237 238 O
pregnancy NCT03869567 240 249 B-Condition
or NCT03869567 250 252 B-Or
beast NCT03869567 253 258 B-Condition
feeding NCT03869567 259 266 I-Condition

- NCT03869567 269 270 O
patient NCT03869567 272 279 O
deprived NCT03869567 280 288 B-Observation
of NCT03869567 289 291 I-Observation
liberty NCT03869567 292 299 I-Observation
by NCT03869567 300 302 O
administrative NCT03869567 303 317 O
or NCT03869567 318 320 O
judicial NCT03869567 321 329 O
decision NCT03869567 330 338 O
or NCT03869567 339 341 B-Or
placed NCT03869567 342 348 O
under NCT03869567 349 354 O
judicial NCT03869567 355 363 B-Observation
protection NCT03869567 364 374 I-Observation
( NCT03869567 375 376 O
guardianship NCT03869567 377 389 O
or NCT03869567 390 392 O
supervision NCT03869567 393 404 O
) NCT03869567 405 406 O

- NCT03869567 410 411 O
obstruction NCT03869567 413 424 O
to NCT03869567 425 427 O
participate NCT03869567 428 439 O

- NCT03869567 442 443 O
non NCT03869567 445 448 B-Negation
covered NCT03869567 449 456 O
by NCT03869567 457 459 O
national NCT03869567 460 468 O
health NCT03869567 469 475 O
insurance NCT03869567 476 485 O

Inclusion NCT03864094 0 9 O
Criteria NCT03864094 10 18 O
: NCT03864094 19 20 O

- NCT03864094 24 25 O
Healthy NCT03864094 27 34 B-Condition
women NCT03864094 35 40 O

- NCT03864094 43 44 O
Age NCT03864094 46 49 B-Age
18 NCT03864094 50 52 B-Eq-Comparison
- NCT03864094 53 54 I-Eq-Comparison
50 NCT03864094 55 57 I-Eq-Comparison
years NCT03864094 58 63 I-Eq-Comparison

- NCT03864094 66 67 O
Gynecological NCT03864094 69 82 B-Procedure
procedures NCT03864094 83 93 I-Procedure

- NCT03864094 96 97 O
General NCT03864094 99 106 B-Procedure
anesthesia NCT03864094 107 117 I-Procedure

Exclusion NCT03864094 118 127 O
Criteria NCT03864094 128 136 O
: NCT03864094 137 138 O

- NCT03864094 142 143 O
Pre NCT03864094 145 148 B-Eq-Comparison
- NCT03864094 149 150 I-Eq-Comparison
existing NCT03864094 151 159 I-Eq-Comparison
hypertension NCT03864094 160 172 B-Condition

- NCT03864094 175 176 O
Diabetes NCT03864094 178 186 B-Condition
for NCT03864094 187 190 O
several NCT03864094 191 198 B-Eq-Comparison
years NCT03864094 199 204 I-Eq-Comparison

- NCT03864094 207 208 O
Ischemic NCT03864094 210 218 B-Modifier
heart NCT03864094 219 224 B-Condition
disease NCT03864094 225 232 I-Condition

- NCT03864094 235 236 O
Cerebrovascular NCT03864094 238 253 B-Condition
disease NCT03864094 254 261 I-Condition

- NCT03864094 264 265 O
Heart NCT03864094 267 272 B-Condition
valve NCT03864094 273 278 I-Condition
disease NCT03864094 279 286 I-Condition

- NCT03864094 289 290 O
Verified NCT03864094 292 300 O
cardiac NCT03864094 301 308 B-Condition
arrhythmia NCT03864094 309 319 I-Condition

- NCT03864094 322 323 O
Anaemia NCT03864094 325 332 B-Condition

- NCT03864094 335 336 O
Kidney NCT03864094 338 344 B-Modifier
or NCT03864094 345 347 B-Or
hepatic NCT03864094 348 355 B-Modifier
disease NCT03864094 356 363 B-Condition

- NCT03864094 366 367 O
Hypersensitivity NCT03864094 369 385 B-Condition
for NCT03864094 386 389 O
soya NCT03864094 390 394 B-Modifier
, NCT03864094 395 396 O
eggs NCT03864094 397 401 B-Modifier
or NCT03864094 402 404 B-Or
peanuts NCT03864094 405 412 B-Modifier

- NCT03864094 415 416 O
Pregnancy NCT03864094 418 427 B-Condition

- NCT03864094 430 431 O
Poor NCT03864094 433 437 B-Condition
health NCT03864094 438 444 I-Condition
state NCT03864094 445 450 O

- NCT03864094 453 454 O
Illicit NCT03864094 456 463 B-Condition
substance NCT03864094 464 473 I-Condition
use NCT03864094 474 477 O

- NCT03864094 480 481 O
BMI NCT03864094 483 486 B-Observation
< NCT03864094 487 488 B-Eq-Comparison
20 NCT03864094 489 491 I-Eq-Comparison
or NCT03864094 492 494 B-Or
> NCT03864094 495 496 B-Eq-Comparison
35 NCT03864094 497 499 I-Eq-Comparison
kg NCT03864094 500 502 I-Eq-Comparison
/ NCT03864094 503 504 I-Eq-Comparison
m2 NCT03864094 505 507 I-Eq-Comparison

- NCT03864094 510 511 O
SBP NCT03864094 513 516 B-Observation
> NCT03864094 517 518 B-Eq-Comparison
150 NCT03864094 519 522 I-Eq-Comparison
mmHg NCT03864094 523 527 I-Eq-Comparison

- NCT03864094 530 531 O
HR NCT03864094 533 535 B-Observation
> NCT03864094 536 537 B-Eq-Comparison
100 NCT03864094 538 541 I-Eq-Comparison
beats NCT03864094 542 547 I-Eq-Comparison
/ NCT03864094 548 549 I-Eq-Comparison
min NCT03864094 550 553 I-Eq-Comparison

Inclusion NCT03867760 0 9 O
Criteria NCT03867760 10 18 O
: NCT03867760 19 20 O

- NCT03867760 24 25 O
self NCT03867760 27 31 O
- NCT03867760 32 33 O
reporting NCT03867760 34 43 O
moderate NCT03867760 44 52 B-Eq-Comparison
or NCT03867760 53 55 I-Eq-Comparison
higher NCT03867760 56 62 I-Eq-Comparison
pain NCT03867760 63 67 B-Condition
on NCT03867760 68 70 O
average NCT03867760 71 78 O
during NCT03867760 79 85 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867760 86 89 O
last NCT03867760 90 94 B-Eq-Comparison
week NCT03867760 95 99 I-Eq-Comparison
( NCT03867760 100 101 O
> NCT03867760 103 104 B-Eq-Comparison
3 NCT03867760 105 106 I-Eq-Comparison
on NCT03867760 107 109 O
a NCT03867760 110 111 O
0 NCT03867760 112 113 B-Modifier
- NCT03867760 114 115 I-Modifier
10 NCT03867760 116 118 I-Modifier
pain NCT03867760 119 123 B-Observation
intensity NCT03867760 124 133 I-Observation
numeric NCT03867760 134 141 I-Observation
scale NCT03867760 142 147 I-Observation
) NCT03867760 148 149 O

- NCT03867760 153 154 O
self NCT03867760 156 160 O
- NCT03867760 161 162 O
reporting NCT03867760 163 172 O
experiencing NCT03867760 173 185 O
pain NCT03867760 186 190 B-Condition
at NCT03867760 191 193 B-Eq-Comparison
least NCT03867760 194 199 I-Eq-Comparison
half NCT03867760 200 204 I-Eq-Comparison
of NCT03867760 205 207 I-Eq-Comparison
the NCT03867760 208 211 I-Eq-Comparison
days NCT03867760 212 216 I-Eq-Comparison
in NCT03867760 217 219 O
the NCT03867760 220 223 O
past NCT03867760 224 228 B-Eq-Comparison
4 NCT03867760 229 230 I-Eq-Comparison
weeks NCT03867760 231 236 I-Eq-Comparison

- NCT03867760 239 240 O
self NCT03867760 242 246 O
- NCT03867760 247 248 O
reporting NCT03867760 249 258 O
chronic NCT03867760 259 266 B-Modifier
pain NCT03867760 267 271 B-Condition
related NCT03867760 272 279 O
to NCT03867760 280 282 O
cancer NCT03867760 283 289 B-Condition
or NCT03867760 290 292 B-Or
its NCT03867760 293 296 B-Coreference
treatment NCT03867760 297 306 B-Procedure

- NCT03867760 309 310 O
completed NCT03867760 312 321 B-Eq-Comparison
active NCT03867760 322 328 B-Eq-Comparison
cancer NCT03867760 329 335 B-Condition
treatment NCT03867760 336 345 B-Procedure
other NCT03867760 346 351 B-Exception
than NCT03867760 352 356 I-Exception
maintenance NCT03867760 357 368 B-Procedure
therapy NCT03867760 369 376 I-Procedure

- NCT03867760 379 380 O
being NCT03867760 382 387 O
> NCT03867760 388 389 B-Eq-Comparison
18 NCT03867760 390 392 I-Eq-Comparison
years NCT03867760 393 398 I-Eq-Comparison
of NCT03867760 399 401 O
age NCT03867760 402 405 B-Age

- NCT03867760 408 409 O
functional NCT03867760 411 421 O
fluency NCT03867760 422 429 O
in NCT03867760 430 432 O
English NCT03867760 433 440 O

- NCT03867760 443 444 O
mentally NCT03867760 446 454 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03867760 455 458 I-Assertion___Assertion-Type-Value:hypothetical
physically NCT03867760 459 469 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03867760 470 474 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867760 475 477 O
participate NCT03867760 478 489 O
and NCT03867760 490 493 O
complete NCT03867760 494 502 O
surveys NCT03867760 503 510 B-Observation

Exclusion NCT03867760 511 520 O
Criteria NCT03867760 521 529 O
: NCT03867760 530 531 O

• NCT03867760 533 534 O
has NCT03867760 535 538 O
a NCT03867760 539 540 O
psychiatric NCT03867760 541 552 B-Condition
condition NCT03867760 553 562 I-Condition
or NCT03867760 563 565 B-Or
symptoms NCT03867760 566 574 B-Assertion___Assertion-Type-Value:possible
( NCT03867760 575 576 O
i. NCT03867760 577 579 O
e. NCT03867760 580 582 O
, NCT03867760 583 584 O
diagnosis NCT03867760 585 594 O
of NCT03867760 595 597 O
paranoid NCT03867760 598 606 B-Condition
schizophrenia NCT03867760 607 620 I-Condition
or NCT03867760 621 623 B-Or
active NCT03867760 624 630 B-Eq-Comparison
paranoid NCT03867760 631 639 B-Condition
delusional NCT03867760 640 650 I-Condition
thoughts NCT03867760 651 659 I-Condition
, NCT03867760 660 661 O
as NCT03867760 662 664 O
determined NCT03867760 665 675 O
via NCT03867760 676 679 O
a NCT03867760 680 681 O
telephone NCT03867760 682 691 B-Modifier
or NCT03867760 692 694 B-Or
in NCT03867760 695 697 B-Modifier
- NCT03867760 698 699 I-Modifier
person NCT03867760 700 706 I-Modifier
screening NCT03867760 707 716 B-Procedure
assessment NCT03867760 717 727 I-Procedure
) NCT03867760 728 729 O
that NCT03867760 730 734 O
would NCT03867760 735 740 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03867760 741 750 O
with NCT03867760 751 755 O
study NCT03867760 756 761 B-Study
participation NCT03867760 762 775 O
. NCT03867760 776 777 O

Exclusion NCT03867760 779 788 O
Criteria NCT03867760 789 797 O
for NCT03867760 798 801 O
Optional NCT03867760 802 810 O
EEG NCT03867760 811 814 O
Measurement NCT03867760 815 826 O
: NCT03867760 827 828 O

- NCT03867760 832 833 O
a NCT03867760 835 836 O
history NCT03867760 837 844 B-Eq-Comparison
of NCT03867760 845 847 O
seizure NCT03867760 848 855 B-Condition
condition NCT03867760 856 865 I-Condition
within NCT03867760 866 872 B-Eq-Comparison
the NCT03867760 873 876 I-Eq-Comparison
last NCT03867760 877 881 I-Eq-Comparison
year NCT03867760 882 886 I-Eq-Comparison

- NCT03867760 889 890 O
a NCT03867760 892 893 O
significant NCT03867760 894 905 O
brain NCT03867760 906 911 B-Modifier
injury NCT03867760 912 918 B-Condition
or NCT03867760 919 921 B-Or
skull NCT03867760 922 927 B-Modifier
defect NCT03867760 928 934 B-Condition

- NCT03867760 937 938 O
a NCT03867760 940 941 O
history NCT03867760 942 949 B-Eq-Comparison
of NCT03867760 950 952 O
brain NCT03867760 953 958 B-Modifier
cancer NCT03867760 959 965 B-Condition
. NCT03867760 966 967 O


Inclusion NCT03865836 0 9 O
Criteria NCT03865836 10 18 O
: NCT03865836 19 20 O

1 NCT03865836 24 25 O
. NCT03865836 25 26 O
Subject NCT03865836 28 35 O
must NCT03865836 36 40 O
have NCT03865836 41 45 O
a NCT03865836 46 47 O
diagnosis NCT03865836 48 57 O
of NCT03865836 58 60 O
LOPD NCT03865836 61 65 B-Condition
based NCT03865836 66 71 O
on NCT03865836 72 74 O
documentation NCT03865836 75 88 O
of NCT03865836 89 91 O
one NCT03865836 92 95 B-Eq-Comparison
of NCT03865836 96 98 O
the NCT03865836 99 102 B-Criteria-Count
following NCT03865836 103 112 I-Criteria-Count
: NCT03865836 113 114 O

1 NCT03865836 123 124 O
. NCT03865836 124 125 O
deficiency NCT03865836 127 137 B-Condition
of NCT03865836 138 140 O
GAA NCT03865836 141 144 B-Modifier
enzyme NCT03865836 145 151 I-Modifier

2 NCT03865836 159 160 O
. NCT03865836 160 161 O
GAA NCT03865836 163 166 B-Procedure
genotyping NCT03865836 167 177 I-Procedure

2 NCT03865836 180 181 O
. NCT03865836 181 182 O
Subject NCT03865836 184 191 O
must NCT03865836 192 196 O
provide NCT03865836 197 204 O
signed NCT03865836 205 211 O
informed NCT03865836 212 220 O
consent NCT03865836 221 228 O
prior NCT03865836 229 234 O
to NCT03865836 235 237 O
any NCT03865836 238 241 O
study NCT03865836 242 247 B-Study
- NCT03865836 248 249 O
related NCT03865836 250 257 O
procedures NCT03865836 258 268 B-Procedure
being NCT03865836 269 274 O
performed NCT03865836 275 284 O
. NCT03865836 285 286 O

Exclusion NCT03865836 288 297 O
Criteria NCT03865836 298 306 O
: NCT03865836 307 308 O

1 NCT03865836 312 313 O
. NCT03865836 313 314 O
Subject NCT03865836 316 323 O
is NCT03865836 324 326 O
eligible NCT03865836 327 335 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03865836 336 339 I-Assertion___Assertion-Type-Value:hypothetical
enrollment NCT03865836 340 350 O
in NCT03865836 351 353 O
an NCT03865836 354 356 O
ongoing NCT03865836 357 364 B-Eq-Comparison
clinical NCT03865836 365 373 B-Study
trial NCT03865836 374 379 I-Study
using NCT03865836 380 385 O
ATB200 NCT03865836 386 392 B-Drug
/ NCT03865836 393 394 B-Or
AT2221 NCT03865836 395 401 B-Drug
. NCT03865836 401 402 O

2 NCT03865836 406 407 O
. NCT03865836 407 408 O
Subject NCT03865836 410 417 O
, NCT03865836 418 419 O
if NCT03865836 420 422 O
female NCT03865836 423 429 O
, NCT03865836 430 431 O
is NCT03865836 432 434 O
pregnant NCT03865836 435 443 B-Condition
or NCT03865836 444 446 B-Or
breastfeeding NCT03865836 447 460 B-Condition
at NCT03865836 461 463 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03865836 464 473 B-Study
. NCT03865836 474 475 O

3 NCT03865836 479 480 O
. NCT03865836 480 481 O
Subject NCT03865836 483 490 O
, NCT03865836 491 492 O
whether NCT03865836 493 500 O
male NCT03865836 501 505 O
or NCT03865836 506 508 B-Or
female NCT03865836 509 515 O
, NCT03865836 516 517 O
is NCT03865836 518 520 O
planning NCT03865836 521 529 B-Assertion___Assertion-Type-Value:intention
to NCT03865836 530 532 O
conceive NCT03865836 533 541 B-Condition
a NCT03865836 542 543 I-Condition
child NCT03865836 544 549 I-Condition
during NCT03865836 550 556 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865836 557 560 O
study NCT03865836 561 566 B-Study
. NCT03865836 566 567 O

Inclusion NCT03868241 0 9 O
Criteria NCT03868241 10 18 O
: NCT03868241 19 20 O

- NCT03868241 24 25 O
All NCT03868241 27 30 O
patients NCT03868241 31 39 O
admitted NCT03868241 40 48 B-Encounter
to NCT03868241 49 51 O
the NCT03868241 52 55 O
intensive NCT03868241 56 65 O
care NCT03868241 66 70 O
unit NCT03868241 71 75 O
which NCT03868241 76 81 O
will NCT03868241 82 86 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03868241 87 94 I-Assertion___Assertion-Type-Value:hypothetical
simultaneous NCT03868241 95 107 O
insertion NCT03868241 108 117 B-Procedure
of NCT03868241 118 120 I-Procedure
all NCT03868241 121 124 I-Procedure
three NCT03868241 125 130 I-Procedure
devices NCT03868241 131 138 I-Procedure
( NCT03868241 139 140 O
endotracheal NCT03868241 141 153 B-Procedure
tube NCT03868241 154 158 I-Procedure
, NCT03868241 159 160 O
central NCT03868241 161 168 B-Procedure
venous NCT03868241 169 175 I-Procedure
catheter NCT03868241 176 184 I-Procedure
and NCT03868241 185 188 B-Or
urinary NCT03868241 189 196 B-Procedure
catheter NCT03868241 197 205 I-Procedure
) NCT03868241 206 207 O
due NCT03868241 208 211 O
to NCT03868241 212 214 O
illness NCT03868241 215 222 B-Condition
severity NCT03868241 223 231 O
as NCT03868241 232 234 O
defined NCT03868241 235 242 O
by NCT03868241 243 245 O
the NCT03868241 246 249 O
attending NCT03868241 250 259 B-Provider
physician NCT03868241 260 269 I-Provider
. NCT03868241 270 271 O

Exclusion NCT03868241 273 282 O
Criteria NCT03868241 283 291 O
: NCT03868241 292 293 O

- NCT03868241 297 298 O
Patients NCT03868241 300 308 O
admitted NCT03868241 309 317 B-Encounter
to NCT03868241 318 320 O
the NCT03868241 321 324 O
intensive NCT03868241 325 334 O
care NCT03868241 335 339 O
unit NCT03868241 340 344 O
for NCT03868241 345 348 O
more NCT03868241 349 353 B-Eq-Comparison
than NCT03868241 354 358 I-Eq-Comparison
48 NCT03868241 359 361 I-Eq-Comparison
hours NCT03868241 362 367 I-Eq-Comparison
or NCT03868241 368 370 B-Or
admitted NCT03868241 371 379 B-Encounter
in NCT03868241 380 382 O
the NCT03868241 383 386 O
hospital NCT03868241 387 395 O
for NCT03868241 396 399 O
more NCT03868241 400 404 B-Eq-Comparison
than NCT03868241 405 409 I-Eq-Comparison
seven NCT03868241 410 415 I-Eq-Comparison
days NCT03868241 416 420 I-Eq-Comparison

- NCT03868241 423 424 O
Presence NCT03868241 426 434 O
of NCT03868241 435 437 O
any NCT03868241 438 441 O
of NCT03868241 442 444 O
the NCT03868241 445 448 O
invasive NCT03868241 449 457 B-Procedure
devices NCT03868241 458 465 I-Procedure
( NCT03868241 466 467 O
endotracheal NCT03868241 468 480 B-Procedure
tube NCT03868241 481 485 I-Procedure
, NCT03868241 486 487 O
central NCT03868241 488 495 B-Procedure
venous NCT03868241 496 502 I-Procedure
catheter NCT03868241 503 511 I-Procedure
or NCT03868241 512 514 B-Or
urinary NCT03868241 515 522 B-Procedure
catheters NCT03868241 523 532 I-Procedure
) NCT03868241 533 534 O
before NCT03868241 535 541 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03868241 542 555 B-Study
and NCT03868241 556 559 B-And
absence NCT03868241 560 567 B-Negation
of NCT03868241 568 570 O
the NCT03868241 571 574 O
intention NCT03868241 575 584 B-Assertion___Assertion-Type-Value:intention
to NCT03868241 585 587 O
exchange NCT03868241 588 596 O
the NCT03868241 597 600 O
devices NCT03868241 601 608 B-Coreference
; NCT03868241 608 609 O

- NCT03868241 612 613 O
Previous NCT03868241 615 623 B-Eq-Comparison
use NCT03868241 624 627 O
of NCT03868241 628 630 O
any NCT03868241 631 634 O
type NCT03868241 635 639 O
of NCT03868241 640 642 O
coated NCT03868241 643 649 B-Procedure
devices NCT03868241 650 657 I-Procedure
; NCT03868241 657 658 O

- NCT03868241 661 662 O
Age NCT03868241 664 667 B-Age
< NCT03868241 668 669 B-Eq-Comparison
18 NCT03868241 670 672 I-Eq-Comparison
years NCT03868241 673 678 I-Eq-Comparison
; NCT03868241 678 679 O

- NCT03868241 682 683 O
Known NCT03868241 685 690 O
pregnancy NCT03868241 691 700 B-Condition

- NCT03868241 703 704 O
Known NCT03868241 706 711 O
allergy NCT03868241 712 719 B-Allergy
to NCT03868241 720 722 O
gold NCT03868241 723 727 O
, NCT03868241 728 729 O
silver NCT03868241 730 736 O
and NCT03868241 737 740 B-Or
palladium NCT03868241 741 750 O
; NCT03868241 750 751 O

- NCT03868241 754 755 O
Suspected NCT03868241 757 766 B-Assertion___Assertion-Type-Value:possible
or NCT03868241 767 769 B-Or
confirmed NCT03868241 770 779 B-Modifier
brain NCT03868241 780 785 B-Modifier
death NCT03868241 786 791 B-Death
; NCT03868241 791 792 O

- NCT03868241 795 796 O
Previously NCT03868241 798 808 B-Eq-Comparison
enrolled NCT03868241 809 817 O
in NCT03868241 818 820 O
the NCT03868241 821 824 O
study NCT03868241 825 830 B-Study

Newly NCT03868241 831 836 O
added NCT03868241 837 842 O
exclusion NCT03868241 843 852 O
criteria NCT03868241 853 861 O
in NCT03868241 862 864 O
version NCT03868241 865 872 O
2.0 NCT03868241 873 876 O
: NCT03868241 877 878 O

- NCT03868241 882 883 O
Severe NCT03868241 885 891 O
chronic NCT03868241 892 899 B-Modifier
pulmonary NCT03868241 900 909 B-Condition
obstructive NCT03868241 910 921 I-Condition
disease NCT03868241 922 929 I-Condition
which NCT03868241 930 935 O
may NCT03868241 936 939 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03868241 940 945 O
catheter NCT03868241 946 954 B-Procedure
site NCT03868241 955 959 I-Procedure
selection NCT03868241 960 969 O

- NCT03868241 972 973 O
Previous NCT03868241 975 983 B-Eq-Comparison
irradiation NCT03868241 984 995 B-Procedure
and NCT03868241 996 999 B-Or
/ NCT03868241 1000 1001 I-Or
or NCT03868241 1002 1004 I-Or
thrombosis NCT03868241 1005 1015 B-Condition
in NCT03868241 1016 1018 O
site NCT03868241 1019 1023 B-Modifier
selected NCT03868241 1024 1032 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03868241 1033 1036 I-Assertion___Assertion-Type-Value:hypothetical
catheter NCT03868241 1037 1045 B-Procedure
insertion NCT03868241 1046 1055 I-Procedure

Inclusion NCT03863314 0 9 O
Criteria NCT03863314 10 18 O
: NCT03863314 19 20 O

- NCT03863314 24 25 O
Greater NCT03863314 27 34 B-Eq-Comparison
than NCT03863314 35 39 I-Eq-Comparison
18 NCT03863314 40 42 I-Eq-Comparison
years NCT03863314 43 48 I-Eq-Comparison
of NCT03863314 49 51 O
age NCT03863314 52 55 B-Age

- NCT03863314 58 59 O
Personnel NCT03863314 61 70 O
working NCT03863314 71 78 O
or NCT03863314 79 81 O
volunteering NCT03863314 82 94 O
at NCT03863314 95 97 O
Lucile NCT03863314 98 104 O
Packard NCT03863314 105 112 O
Children NCT03863314 113 121 O
's NCT03863314 121 123 O
Hospital NCT03863314 124 132 O
( NCT03863314 133 134 O
LPCH NCT03863314 135 139 O
) NCT03863314 140 141 O
or NCT03863314 142 144 B-Or
Stanford NCT03863314 145 153 O
Health NCT03863314 154 160 O
Care NCT03863314 161 165 O
( NCT03863314 166 167 O
SHC NCT03863314 168 171 O
) NCT03863314 172 173 O
facilities NCT03863314 174 184 O

Exclusion NCT03863314 185 194 O
Criteria NCT03863314 195 203 O
: NCT03863314 204 205 O

- NCT03863314 209 210 O
Patients NCT03863314 212 220 O
who NCT03863314 221 224 O
do NCT03863314 225 227 O
not NCT03863314 228 231 O
consent NCT03863314 232 239 O

- NCT03863314 242 243 O
Are NCT03863314 245 248 O
currently NCT03863314 249 258 B-Eq-Comparison
taking NCT03863314 259 265 I-Eq-Comparison
beta NCT03863314 266 270 B-Drug
blockers NCT03863314 271 279 I-Drug
or NCT03863314 280 282 B-Or
other NCT03863314 283 288 B-Other
chronotropic NCT03863314 289 301 B-Drug
heart NCT03863314 302 307 I-Drug
medication NCT03863314 308 318 I-Drug
( NCT03863314 319 320 I-Drug
s NCT03863314 321 322 I-Drug
) NCT03863314 323 324 O

- NCT03863314 328 329 O
Have NCT03863314 331 335 O
a NCT03863314 336 337 O
history NCT03863314 338 345 B-Eq-Comparison
of NCT03863314 346 348 O
severe NCT03863314 349 355 O
motion NCT03863314 356 362 B-Condition
sickness NCT03863314 363 371 I-Condition

- NCT03863314 374 375 O
Currently NCT03863314 377 386 B-Eq-Comparison
have NCT03863314 387 391 O
nausea NCT03863314 392 398 B-Condition

- NCT03863314 401 402 O
Currently NCT03863314 404 413 B-Eq-Comparison
experiencing NCT03863314 414 426 O
seizures NCT03863314 427 435 B-Condition

- NCT03863314 438 439 O
Are NCT03863314 441 444 O
clinically NCT03863314 445 455 O
unstable NCT03863314 456 464 O

Inclusion NCT03868527 0 9 O
Criteria NCT03868527 10 18 O
: NCT03868527 19 20 O

- NCT03868527 23 24 O
Patients NCT03868527 25 33 O
followed NCT03868527 34 42 B-Encounter
for NCT03868527 43 46 O
hematological NCT03868527 47 60 B-Condition
diseases NCT03868527 61 69 I-Condition
in NCT03868527 70 72 O
Lyon NCT03868527 73 77 O
Sud NCT03868527 78 81 O
Hospital NCT03868527 82 90 O

Exclusion NCT03868527 91 100 O
Criteria NCT03868527 101 109 O
: NCT03868527 110 111 O

- NCT03868527 114 115 O
Patients NCT03868527 116 124 O
who NCT03868527 125 128 O
does NCT03868527 129 133 B-Negation
n't NCT03868527 133 136 I-Negation
have NCT03868527 137 141 I-Negation
hematological NCT03868527 142 155 B-Condition
diseases NCT03868527 156 164 I-Condition

Inclusion NCT03865771 0 9 O
Criteria NCT03865771 10 18 O
: NCT03865771 19 20 O

Principal NCT03865771 22 31 O
: NCT03865771 32 33 O

- NCT03865771 37 38 O
normal NCT03865771 40 46 O
psychomotor NCT03865771 47 58 B-Condition
development NCT03865771 59 70 I-Condition

- NCT03865771 73 74 O
informed NCT03865771 76 84 O
consent NCT03865771 85 92 O
signed NCT03865771 93 99 O
by NCT03865771 100 102 O
both NCT03865771 103 107 O
parents NCT03865771 108 115 O
and NCT03865771 116 119 O
subject NCT03865771 120 127 O
if NCT03865771 128 130 O
able NCT03865771 131 135 O

- NCT03865771 138 139 O
affiliated NCT03865771 141 151 O
to NCT03865771 152 154 O
social NCT03865771 155 161 O
security NCT03865771 162 170 O
regimen NCT03865771 171 178 O

Specific NCT03865771 179 187 O

Patients NCT03865771 188 196 O
from NCT03865771 197 201 O
" NCT03865771 202 203 O
severe NCT03865771 203 209 O
" NCT03865771 209 210 O
and NCT03865771 211 214 O
" NCT03865771 215 216 O
benign NCT03865771 216 222 O
" NCT03865771 222 223 O
groups NCT03865771 224 230 O
: NCT03865771 231 232 O

- NCT03865771 236 237 O
focal NCT03865771 239 244 B-Modifier
age NCT03865771 245 248 I-Modifier
related NCT03865771 249 256 I-Modifier
epilepsy NCT03865771 257 265 B-Condition
: NCT03865771 266 267 O
BECTS NCT03865771 268 273 B-Condition
, NCT03865771 274 275 O
ABPE NCT03865771 276 280 B-Condition
, NCT03865771 281 282 O
ECSWS NCT03865771 283 288 B-Condition
( NCT03865771 289 290 O
ILAE NCT03865771 291 295 O
criteria NCT03865771 296 304 O
) NCT03865771 305 306 O

- NCT03865771 310 311 O
children NCT03865771 313 321 O
hospitalized NCT03865771 322 334 B-Encounter
for NCT03865771 335 338 B-Temporal-Connection___Temporal-Connection-Type-Value:during
their NCT03865771 339 344 O
follow NCT03865771 345 351 B-Encounter
- NCT03865771 352 353 I-Encounter
up NCT03865771 354 356 I-Encounter

- NCT03865771 359 360 O
normal NCT03865771 362 368 O
neuroimaging NCT03865771 369 381 B-Procedure

Control NCT03865771 382 389 O
group NCT03865771 390 395 O

- NCT03865771 397 398 O
children NCT03865771 399 407 O
hospitalized NCT03865771 408 420 B-Encounter
for NCT03865771 421 424 O
a NCT03865771 425 426 O
non NCT03865771 427 430 B-Negation
neurologic NCT03865771 431 441 B-Condition
disease NCT03865771 442 449 I-Condition

Exclusion NCT03865771 450 459 O
Criteria NCT03865771 460 468 O
: NCT03865771 469 470 O

Principal NCT03865771 472 481 O
: NCT03865771 482 483 O

Psychiatric NCT03865771 485 496 B-Condition
trouble NCT03865771 497 504 I-Condition
( NCT03865771 505 506 O
DSM NCT03865771 507 510 O
V NCT03865771 511 512 O
) NCT03865771 513 514 O
Sensorial NCT03865771 515 524 B-Condition
trouble NCT03865771 525 532 I-Condition
without NCT03865771 533 540 B-Negation
correction NCT03865771 541 551 B-Modifier
Poor NCT03865771 552 556 B-Negation
command NCT03865771 557 564 I-Negation
of NCT03865771 565 567 O
French NCT03865771 568 574 O
language NCT03865771 575 583 O
Minor NCT03865771 584 589 O
under NCT03865771 590 595 O
care NCT03865771 596 600 O

Specific NCT03865771 601 609 O

Patients NCT03865771 610 618 O
from NCT03865771 619 623 O
" NCT03865771 624 625 O
severe NCT03865771 625 631 O
" NCT03865771 631 632 O
and NCT03865771 633 636 O
" NCT03865771 637 638 O
benign NCT03865771 638 644 O
" NCT03865771 644 645 O
groups NCT03865771 646 652 O
: NCT03865771 653 654 O

- NCT03865771 658 659 O
degenerative NCT03865771 661 673 B-Condition
disease NCT03865771 674 681 I-Condition

- NCT03865771 684 685 O
abnormal NCT03865771 687 695 O
neuroimaging NCT03865771 696 708 B-Procedure

- NCT03865771 711 712 O
mental NCT03865771 714 720 B-Condition
deficiency NCT03865771 721 731 I-Condition

Control NCT03865771 732 739 O
group NCT03865771 740 745 O

- NCT03865771 748 749 O
neurologic NCT03865771 751 761 B-Condition
trouble NCT03865771 762 769 I-Condition

- NCT03865771 772 773 O
abnormal NCT03865771 775 783 O
sleep NCT03865771 784 789 B-Procedure
EEG NCT03865771 790 793 I-Procedure

- NCT03865771 796 797 O
intellectual NCT03865771 799 811 B-Condition
deficiency NCT03865771 812 822 I-Condition


Inclusion NCT03862963 0 9 O
Criteria NCT03862963 10 18 O
: NCT03862963 19 20 O

- NCT03862963 24 25 O
Resident NCT03862963 27 35 O
of NCT03862963 36 38 O
the NCT03862963 39 42 O
Republic NCT03862963 43 51 O
of NCT03862963 52 54 O
Marshall NCT03862963 55 63 O
Islands NCT03862963 64 71 O

- NCT03862963 74 75 O
Aged NCT03862963 77 81 B-Age
18 NCT03862963 82 84 B-Eq-Comparison
- NCT03862963 85 86 I-Eq-Comparison
75 NCT03862963 87 89 I-Eq-Comparison
years NCT03862963 90 95 I-Eq-Comparison

- NCT03862963 98 99 O
HbA1c NCT03862963 101 106 B-Observation
≥ NCT03862963 107 108 B-Eq-Comparison
8.0 NCT03862963 109 112 I-Eq-Comparison
% NCT03862963 113 114 I-Eq-Comparison
or NCT03862963 115 117 B-Or
diagnosed NCT03862963 118 127 O
with NCT03862963 128 132 O
T2D NCT03862963 133 136 B-Condition
and NCT03862963 137 140 B-And
taking NCT03862963 141 147 B-Eq-Comparison
diabetes NCT03862963 148 156 B-Condition
medication NCT03862963 157 167 B-Drug

- NCT03862963 170 171 O
Medical NCT03862963 173 180 O
clearance NCT03862963 181 190 O
to NCT03862963 191 193 O
participate NCT03862963 194 205 O
from NCT03862963 206 210 O
Diabetes NCT03862963 211 219 O
Wellness NCT03862963 220 228 O
Center NCT03862963 229 235 O
( NCT03862963 236 237 O
DWC NCT03862963 238 241 O
) NCT03862963 242 243 O
physicians NCT03862963 244 254 B-Provider
. NCT03862963 255 256 O

Exclusion NCT03862963 258 267 O
Criteria NCT03862963 268 276 O
: NCT03862963 277 278 O

- NCT03862963 282 283 O
Recent NCT03862963 285 291 B-Eq-Comparison
( NCT03862963 292 293 O
≤ NCT03862963 295 296 B-Eq-Comparison
3 NCT03862963 297 298 I-Eq-Comparison
months NCT03862963 299 305 I-Eq-Comparison
) NCT03862963 306 307 O
change NCT03862963 308 314 O
in NCT03862963 315 317 O
a NCT03862963 318 319 O
diabetes NCT03862963 320 328 B-Condition
- NCT03862963 329 330 O
related NCT03862963 331 338 O
medication NCT03862963 339 349 B-Drug
dosage NCT03862963 350 356 O

- NCT03862963 359 360 O
A NCT03862963 362 363 O
physical NCT03862963 364 372 B-Modifier
or NCT03862963 373 375 B-Or
medical NCT03862963 376 383 B-Modifier
condition NCT03862963 384 393 B-Condition
that NCT03862963 394 398 O
would NCT03862963 399 404 B-Assertion___Assertion-Type-Value:hypothetical
impede NCT03862963 405 411 O
participation NCT03862963 412 425 O
in NCT03862963 426 428 O
the NCT03862963 429 432 O
lifestyle NCT03862963 433 442 B-Procedure
intervention NCT03862963 443 455 I-Procedure
( NCT03862963 456 457 O
e. NCT03862963 458 460 O
g. NCT03862963 461 463 O
, NCT03862963 464 465 O
wheel NCT03862963 466 471 B-Condition
- NCT03862963 472 473 I-Condition
chair NCT03862963 474 479 I-Condition
bound NCT03862963 480 485 I-Condition
, NCT03862963 486 487 O
unstable NCT03862963 488 496 O
angina NCT03862963 497 503 B-Condition
) NCT03862963 504 505 O

- NCT03862963 509 510 O
Evidence NCT03862963 512 520 O
of NCT03862963 521 523 O
significant NCT03862963 524 535 O
coronary NCT03862963 536 544 B-Condition
heart NCT03862963 545 550 I-Condition
disease NCT03862963 551 558 I-Condition

- NCT03862963 561 562 O
Previous NCT03862963 564 572 B-Eq-Comparison
participation NCT03862963 573 586 O
in NCT03862963 587 589 O
an NCT03862963 590 592 O
intensive NCT03862963 593 602 O
lifestyle NCT03862963 603 612 B-Procedure
intervention NCT03862963 613 625 I-Procedure

Inclusion NCT03864484 0 9 O
Criteria NCT03864484 10 18 O
: NCT03864484 19 20 O

- NCT03864484 24 25 O
40 NCT03864484 27 29 B-Eq-Comparison
years NCT03864484 30 35 I-Eq-Comparison
and NCT03864484 36 39 I-Eq-Comparison
older NCT03864484 40 45 I-Age|Eq-Comparison

- NCT03864484 48 49 O
Males NCT03864484 51 56 O
and NCT03864484 57 60 B-Or
females NCT03864484 61 68 O

- NCT03864484 71 72 O
Center NCT03864484 74 80 B-Observation
for NCT03864484 81 84 I-Observation
Epidemiologic NCT03864484 85 98 I-Observation
Studies NCT03864484 99 106 I-Observation
Depression NCT03864484 107 117 I-Observation
Scale NCT03864484 118 123 I-Observation
score NCT03864484 124 129 B-Eq-Comparison
≥ NCT03864484 130 131 I-Eq-Comparison
16 NCT03864484 132 134 I-Eq-Comparison

- NCT03864484 138 139 O
Mini NCT03864484 141 145 B-Observation
Mental NCT03864484 146 152 I-Observation
State NCT03864484 153 158 I-Observation
Examination NCT03864484 159 170 I-Observation
score NCT03864484 171 176 I-Observation
≥ NCT03864484 177 178 B-Eq-Comparison
24 NCT03864484 179 181 I-Eq-Comparison

- NCT03864484 185 186 O
First NCT03864484 188 193 B-Eq-Comparison
stroke NCT03864484 194 200 B-Condition

- NCT03864484 203 204 O
Native NCT03864484 206 212 O
language NCT03864484 213 221 O
is NCT03864484 222 224 O
Japanese NCT03864484 225 233 O

- NCT03864484 236 237 O
Written NCT03864484 239 246 O
informed NCT03864484 247 255 O
consent NCT03864484 256 263 O
prior NCT03864484 264 269 O
to NCT03864484 270 272 O
participation NCT03864484 273 286 O

Exclusion NCT03864484 287 296 O
Criteria NCT03864484 297 305 O
: NCT03864484 306 307 O

- NCT03864484 311 312 O
Major NCT03864484 314 319 O
depressive NCT03864484 320 330 B-Condition
disorder NCT03864484 331 339 I-Condition
before NCT03864484 340 346 B-Temporal-Connection___Temporal-Connection-Type-Value:before
onset NCT03864484 347 352 B-Eq-Comparison
of NCT03864484 353 355 O
stroke NCT03864484 356 362 B-Condition

- NCT03864484 365 366 O
Bilateral NCT03864484 368 377 B-Modifier
hemiplegia NCT03864484 378 388 B-Condition

- NCT03864484 391 392 O
Vision NCT03864484 394 400 B-Modifier
or NCT03864484 401 403 B-Or
hearing NCT03864484 404 411 B-Modifier
deficits NCT03864484 412 420 B-Condition
that NCT03864484 421 425 O
negatively NCT03864484 426 436 O
impact NCT03864484 437 443 O
everyday NCT03864484 444 452 B-Observation
life NCT03864484 453 457 I-Observation

- NCT03864484 460 461 O
Severe NCT03864484 463 469 O
aphasia NCT03864484 470 477 B-Condition

- NCT03864484 480 481 O
Severe NCT03864484 483 489 O
unilateral NCT03864484 490 500 B-Modifier
spatial NCT03864484 501 508 B-Condition
neglect NCT03864484 509 516 I-Condition

- NCT03864484 519 520 O
Diagnosis NCT03864484 522 531 O
of NCT03864484 532 534 O
neurodegenerative NCT03864484 535 552 B-Condition
disease NCT03864484 553 560 I-Condition
such NCT03864484 561 565 O
as NCT03864484 566 568 O
Parkinson NCT03864484 569 578 B-Condition
's NCT03864484 578 580 I-Condition
disease NCT03864484 581 588 I-Condition
or NCT03864484 589 591 B-Or
multiple NCT03864484 592 600 B-Modifier
system NCT03864484 601 607 I-Modifier
atrophy NCT03864484 608 615 B-Condition

- NCT03864484 618 619 O
Current NCT03864484 621 628 B-Eq-Comparison
life NCT03864484 629 633 B-Death|Risk
- NCT03864484 634 635 I-Death|Risk
threatening NCT03864484 636 647 I-Death|Risk
severe NCT03864484 648 654 O
organ NCT03864484 655 660 B-Condition
failure NCT03864484 661 668 I-Condition
, NCT03864484 669 670 O
musculoskeletal NCT03864484 671 686 B-Condition
disorders NCT03864484 687 696 I-Condition
, NCT03864484 697 698 O
or NCT03864484 699 701 B-Or
cancer NCT03864484 702 708 B-Condition

Inclusion NCT03867370 0 9 O
Criteria NCT03867370 10 18 O
: NCT03867370 19 20 O

1 NCT03867370 24 25 O
. NCT03867370 25 26 O
Confirmed NCT03867370 28 37 O
by NCT03867370 38 40 O
histopathological NCT03867370 41 58 B-Procedure
or NCT03867370 59 61 B-Or
cytological NCT03867370 62 73 B-Procedure
examination NCT03867370 74 85 I-Procedure
; NCT03867370 85 86 O

2 NCT03867370 89 90 O
. NCT03867370 90 91 O
The NCT03867370 93 96 O
criteria NCT03867370 97 105 O
for NCT03867370 106 109 O
resectability NCT03867370 110 123 O
is NCT03867370 124 126 O
met NCT03867370 127 130 O

3 NCT03867370 133 134 O
. NCT03867370 134 135 O
Has NCT03867370 137 140 O
at NCT03867370 141 143 B-Eq-Comparison
least NCT03867370 144 149 I-Eq-Comparison
one NCT03867370 150 153 I-Eq-Comparison
evaluable NCT03867370 154 163 B-Modifier
lesion NCT03867370 164 170 B-Condition
according NCT03867370 171 180 O
to NCT03867370 181 183 O
the NCT03867370 184 187 O
RECIST NCT03867370 188 194 O
1.1 NCT03867370 195 198 O
standard NCT03867370 199 207 O
and NCT03867370 208 211 B-And
has NCT03867370 212 215 O
not NCT03867370 216 219 B-Negation
received NCT03867370 220 228 B-Eq-Comparison
local NCT03867370 229 234 B-Modifier
treatment NCT03867370 235 244 B-Procedure

Exclusion NCT03867370 245 254 O
Criteria NCT03867370 255 263 O
: NCT03867370 264 265 O

1 NCT03867370 269 270 O
. NCT03867370 270 271 O
Patients NCT03867370 273 281 O
who NCT03867370 282 285 O
previously NCT03867370 286 296 B-Eq-Comparison
received NCT03867370 297 305 I-Eq-Comparison
anti NCT03867370 306 310 B-Drug
- NCT03867370 311 312 I-Drug
programmed NCT03867370 313 323 I-Drug
death NCT03867370 324 329 I-Drug
receptor NCT03867370 330 338 I-Drug
- NCT03867370 339 340 I-Drug
1 NCT03867370 341 342 I-Drug
( NCT03867370 343 344 O
PD NCT03867370 345 347 B-Drug
- NCT03867370 348 349 I-Drug
1 NCT03867370 350 351 I-Drug
) NCT03867370 352 353 O
antibody NCT03867370 354 362 B-Modifier
, NCT03867370 363 364 O
anti NCT03867370 365 369 B-Drug
- NCT03867370 370 371 I-Drug
programmed NCT03867370 372 382 I-Drug
death NCT03867370 383 388 I-Drug
ligand NCT03867370 389 395 I-Drug
- NCT03867370 396 397 I-Drug
1 NCT03867370 398 399 I-Drug
( NCT03867370 400 401 O
PD NCT03867370 402 404 B-Drug
- NCT03867370 405 406 I-Drug
L1 NCT03867370 407 409 I-Drug
) NCT03867370 410 411 O
antibody NCT03867370 412 420 B-Modifier
, NCT03867370 421 422 O
anti NCT03867370 423 427 B-Drug
- NCT03867370 428 429 I-Drug
programmed NCT03867370 430 440 I-Drug
death NCT03867370 441 446 I-Drug
ligand NCT03867370 447 453 I-Drug
- NCT03867370 454 455 I-Drug
2 NCT03867370 456 457 I-Drug
( NCT03867370 458 459 O
PD NCT03867370 460 462 B-Drug
- NCT03867370 463 464 I-Drug
L2 NCT03867370 465 467 I-Drug
) NCT03867370 468 469 O
antibody NCT03867370 470 478 B-Modifier
or NCT03867370 479 481 B-Or
anti NCT03867370 482 486 B-Drug
- NCT03867370 487 488 I-Drug
cytotoxic NCT03867370 489 498 I-Drug
T NCT03867370 499 500 I-Drug
lymphocyte NCT03867370 501 511 I-Drug
- NCT03867370 512 513 I-Drug
associated NCT03867370 514 524 I-Drug
antigen NCT03867370 525 532 I-Drug
- NCT03867370 533 534 I-Drug
4 NCT03867370 535 536 I-Drug
( NCT03867370 537 538 O
CTLA NCT03867370 539 543 B-Drug
- NCT03867370 544 545 I-Drug
4 NCT03867370 546 547 I-Drug
) NCT03867370 548 549 O
antibodies NCT03867370 550 560 B-Modifier
, NCT03867370 561 562 O
including NCT03867370 563 572 O
those NCT03867370 573 578 O
who NCT03867370 579 582 O
have NCT03867370 583 587 O
participated NCT03867370 588 600 O
in NCT03867370 601 603 O
a NCT03867370 604 605 O
JS001 NCT03867370 606 611 O
clinical NCT03867370 612 620 O
study NCT03867370 621 626 B-Study
; NCT03867370 626 627 O

2 NCT03867370 630 631 O
. NCT03867370 631 632 O
Patients NCT03867370 634 642 O
who NCT03867370 643 646 O
previously NCT03867370 647 657 B-Eq-Comparison
received NCT03867370 658 666 I-Eq-Comparison
any NCT03867370 667 670 O
TACE NCT03867370 671 675 B-Procedure
, NCT03867370 676 677 O
radiofrequency NCT03867370 678 692 B-Procedure
ablation NCT03867370 693 701 I-Procedure
and NCT03867370 702 705 B-Or
other NCT03867370 706 711 B-Other
liver NCT03867370 712 717 B-Modifier
cancer NCT03867370 718 724 B-Condition
treatments NCT03867370 725 735 B-Procedure
; NCT03867370 735 736 O

3 NCT03867370 739 740 O
. NCT03867370 740 741 O
Patients NCT03867370 743 751 O
with NCT03867370 752 756 O
a NCT03867370 757 758 O
history NCT03867370 759 766 B-Eq-Comparison
of NCT03867370 767 769 O
gastroesophageal NCT03867370 770 786 B-Condition
varices NCT03867370 787 794 I-Condition
or NCT03867370 795 797 B-Or
active NCT03867370 798 804 B-Eq-Comparison
cardia NCT03867370 805 811 B-Condition
ulcers NCT03867370 812 818 I-Condition
associated NCT03867370 819 829 O
with NCT03867370 830 834 O
a NCT03867370 835 836 O
high NCT03867370 837 841 O
risk NCT03867370 842 846 B-Risk
of NCT03867370 847 849 O
bleeding NCT03867370 850 858 B-Condition
; NCT03867370 858 859 O

4 NCT03867370 862 863 O
. NCT03867370 863 864 O
Patients NCT03867370 866 874 O
who NCT03867370 875 878 O
have NCT03867370 879 883 O
upper NCT03867370 884 889 B-Modifier
gastrointestinal NCT03867370 890 906 I-Modifier
hemorrhage NCT03867370 907 917 B-Condition
within NCT03867370 918 924 B-Eq-Comparison
1 NCT03867370 925 926 I-Eq-Comparison
year NCT03867370 927 931 I-Eq-Comparison
; NCT03867370 931 932 O

5 NCT03867370 935 936 O
. NCT03867370 936 937 O
Patients NCT03867370 939 947 O
known NCT03867370 948 953 O
to NCT03867370 954 956 O
have NCT03867370 957 961 O
fibrous NCT03867370 962 969 B-Modifier
layer NCT03867370 970 975 I-Modifier
HCC NCT03867370 976 979 B-Condition
, NCT03867370 980 981 O
sarcomatoid NCT03867370 982 993 B-Modifier
HCC NCT03867370 994 997 B-Condition
or NCT03867370 998 1000 B-Or
mixed NCT03867370 1001 1006 B-Modifier
cholangiocarcinoma NCT03867370 1007 1025 B-Condition
and NCT03867370 1026 1029 B-And
HCC NCT03867370 1030 1033 B-Condition
; NCT03867370 1033 1034 O
Other NCT03867370 1035 1040 O
protocol NCT03867370 1041 1049 O
defined NCT03867370 1050 1057 O
inclusion NCT03867370 1058 1067 O
/ NCT03867370 1068 1069 O
exclusion NCT03867370 1070 1079 O
criteria NCT03867370 1080 1088 O
could NCT03867370 1089 1094 O
apply NCT03867370 1095 1100 O

Inclusion NCT03861715 0 9 O
Criteria NCT03861715 10 18 O
: NCT03861715 19 20 O

- NCT03861715 24 25 O
age NCT03861715 27 30 B-Age
20 NCT03861715 31 33 B-Eq-Comparison
- NCT03861715 34 35 I-Eq-Comparison
34 NCT03861715 36 38 I-Eq-Comparison
years NCT03861715 39 44 I-Eq-Comparison
; NCT03861715 44 45 O

- NCT03861715 48 49 O
body NCT03861715 51 55 B-Observation
mass NCT03861715 56 60 I-Observation
index NCT03861715 61 66 I-Observation
( NCT03861715 67 68 O
BMI NCT03861715 69 72 B-Observation
) NCT03861715 73 74 O
18 NCT03861715 75 77 B-Eq-Comparison
- NCT03861715 78 79 I-Eq-Comparison
29 NCT03861715 80 82 I-Eq-Comparison
kg NCT03861715 83 85 I-Eq-Comparison
/ NCT03861715 86 87 I-Eq-Comparison
m2 NCT03861715 88 90 I-Eq-Comparison
; NCT03861715 90 91 O

- NCT03861715 94 95 O
regular NCT03861715 97 104 O
menstrual NCT03861715 105 114 B-Condition
cycle NCT03861715 115 120 I-Condition
of NCT03861715 121 123 O
26 NCT03861715 124 126 B-Eq-Comparison
- NCT03861715 127 128 I-Eq-Comparison
35 NCT03861715 129 131 O
days NCT03861715 132 136 O
, NCT03861715 137 138 O

- NCT03861715 142 143 O
AMH NCT03861715 145 148 B-Observation
levels NCT03861715 149 155 O
age NCT03861715 156 159 O
appropriate NCT03861715 160 171 O
( NCT03861715 172 173 O
≥ NCT03861715 175 176 B-Eq-Comparison
2.3 NCT03861715 177 180 I-Eq-Comparison
ng NCT03861715 181 183 I-Eq-Comparison
/ NCT03861715 184 185 I-Eq-Comparison
ml NCT03861715 186 188 I-Eq-Comparison
) NCT03861715 189 190 O

- NCT03861715 194 195 O
early NCT03861715 197 202 B-Modifier
follicular NCT03861715 203 213 I-Modifier
- NCT03861715 214 215 I-Modifier
phase NCT03861715 216 221 I-Modifier
serum NCT03861715 222 227 B-Observation
concentration NCT03861715 228 241 I-Observation
of NCT03861715 242 244 I-Observation
FSH NCT03861715 245 248 I-Observation
within NCT03861715 249 255 B-Eq-Comparison
normal NCT03861715 256 262 I-Eq-Comparison
limits NCT03861715 263 269 I-Eq-Comparison
( NCT03861715 270 271 O
1 NCT03861715 272 273 B-Eq-Comparison
- NCT03861715 274 275 I-Eq-Comparison
12 NCT03861715 276 278 I-Eq-Comparison
IU NCT03861715 279 281 I-Eq-Comparison
/ NCT03861715 282 283 I-Eq-Comparison
l NCT03861715 284 285 I-Eq-Comparison
) NCT03861715 286 287 O
. NCT03861715 289 290 O

Exclusion NCT03861715 292 301 O
Criteria NCT03861715 302 310 O
: NCT03861715 311 312 O

- NCT03861715 316 317 O
women NCT03861715 319 324 O
with NCT03861715 325 329 B-And
diabetes NCT03861715 330 338 B-Condition
and NCT03861715 339 342 B-Or
other NCT03861715 343 348 B-Other
metabolic NCT03861715 349 358 B-Condition
disease NCT03861715 359 366 I-Condition

- NCT03861715 369 370 O
women NCT03861715 372 377 O
with NCT03861715 378 382 B-And
hereditary NCT03861715 383 393 B-Modifier
genetic NCT03861715 394 401 B-Condition
diseases NCT03861715 402 410 I-Condition
; NCT03861715 410 411 O

- NCT03861715 414 415 O
women NCT03861715 417 422 O
with NCT03861715 423 427 B-And
heart NCT03861715 428 433 B-Condition
disease NCT03861715 434 441 I-Condition
, NCT03861715 442 443 O
QT NCT03861715 444 446 B-Condition
prolongation NCT03861715 447 459 I-Condition
, NCT03861715 460 461 O
heart NCT03861715 462 467 B-Condition
failure NCT03861715 468 475 I-Condition

- NCT03861715 478 479 O
elevated NCT03861715 481 489 O
liver NCT03861715 490 495 B-Condition
enzymes NCT03861715 496 503 I-Condition
, NCT03861715 504 505 O
liver NCT03861715 506 511 B-Condition
failure NCT03861715 512 519 I-Condition
, NCT03861715 520 521 O
hepatitis NCT03861715 522 531 B-Condition

- NCT03861715 534 535 O
women NCT03861715 537 542 O
with NCT03861715 543 547 B-And
inflammatory NCT03861715 548 560 B-Modifier
or NCT03861715 561 563 B-Or
autoimmune NCT03861715 564 574 B-Modifier
disease NCT03861715 575 582 B-Condition

- NCT03861715 585 586 O
abnormal NCT03861715 588 596 O
karyotype NCT03861715 597 606 B-Condition
; NCT03861715 606 607 O

- NCT03861715 610 611 O
endometriosis NCT03861715 613 626 B-Condition
stage NCT03861715 627 632 B-Eq-Comparison
III NCT03861715 633 636 I-Eq-Comparison
/ NCT03861715 637 638 I-Eq-Comparison
IV NCT03861715 639 641 I-Eq-Comparison
; NCT03861715 641 642 O

- NCT03861715 645 646 O
history NCT03861715 648 655 B-Eq-Comparison
of NCT03861715 656 658 O
recurrent NCT03861715 659 668 B-Condition
miscarriage NCT03861715 669 680 I-Condition
; NCT03861715 680 681 O

- NCT03861715 684 685 O
severe NCT03861715 687 693 O
OHSS NCT03861715 694 698 B-Condition
in NCT03861715 699 701 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03861715 702 703 O
previous NCT03861715 704 712 B-Eq-Comparison
stimulation NCT03861715 713 724 B-Procedure
cycle NCT03861715 725 730 I-Procedure
or NCT03861715 731 733 B-Or
any NCT03861715 734 737 O
contraindication NCT03861715 738 754 B-Contraindication
for NCT03861715 755 758 O
the NCT03861715 759 762 O
use NCT03861715 763 766 O
of NCT03861715 767 769 O
gonadotrophins NCT03861715 770 784 B-Drug
. NCT03861715 784 785 O

Inclusion NCT03866720 0 9 O
Criteria NCT03866720 10 18 O
: NCT03866720 19 20 O

- NCT03866720 24 25 O
Body NCT03866720 27 31 B-Observation
mass NCT03866720 32 36 I-Observation
index NCT03866720 37 42 I-Observation
18.5 NCT03866720 43 47 B-Eq-Comparison
- NCT03866720 48 49 I-Eq-Comparison
29.9 NCT03866720 50 54 I-Eq-Comparison
kg NCT03866720 55 57 I-Eq-Comparison
∙ NCT03866720 58 59 I-Eq-Comparison
m NCT03866720 60 61 I-Eq-Comparison
- NCT03866720 62 63 I-Eq-Comparison
2 NCT03866720 64 65 I-Eq-Comparison

- NCT03866720 69 70 O
Age NCT03866720 72 75 B-Age
18 NCT03866720 76 78 B-Eq-Comparison
- NCT03866720 79 80 I-Eq-Comparison
65 NCT03866720 81 83 I-Eq-Comparison
years NCT03866720 84 89 I-Eq-Comparison

- NCT03866720 92 93 O
Able NCT03866720 95 99 O
and NCT03866720 100 103 O
willing NCT03866720 104 111 O
to NCT03866720 112 114 O
provide NCT03866720 115 122 O
informed NCT03866720 123 131 O
consent NCT03866720 132 139 O
and NCT03866720 140 143 O
safely NCT03866720 144 150 O
comply NCT03866720 151 157 O
with NCT03866720 158 162 O
study NCT03866720 163 168 B-Study
procedures NCT03866720 169 179 B-Procedure

- NCT03866720 182 183 O
Females NCT03866720 185 192 O
to NCT03866720 193 195 B-Assertion___Assertion-Type-Value:hypothetical
maintain NCT03866720 196 204 I-Assertion___Assertion-Type-Value:hypothetical
record NCT03866720 205 211 O
of NCT03866720 212 214 O
regular NCT03866720 215 222 O
menstrual NCT03866720 223 232 B-Procedure
cycle NCT03866720 233 238 I-Procedure
phase NCT03866720 239 244 I-Procedure
or NCT03866720 245 247 B-Or
contraceptive NCT03866720 248 261 B-Procedure
use NCT03866720 262 265 O

- NCT03866720 268 269 O
No NCT03866720 271 273 B-Negation
anticipated NCT03866720 274 285 B-Assertion___Assertion-Type-Value:hypothetical
changes NCT03866720 286 293 O
in NCT03866720 294 296 O
diet NCT03866720 297 301 B-Observation
/ NCT03866720 302 303 B-Or
physical NCT03866720 304 312 B-Observation
activity NCT03866720 313 321 I-Observation
during NCT03866720 322 328 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866720 329 332 O
study NCT03866720 333 338 B-Study
( NCT03866720 339 340 O
e. NCT03866720 341 343 O
g. NCT03866720 344 346 O
holidays NCT03866720 348 356 O
or NCT03866720 357 359 O
diet NCT03866720 360 364 B-Observation
plans NCT03866720 365 370 B-Assertion___Assertion-Type-Value:intention
) NCT03866720 371 372 O

- NCT03866720 376 377 O
Inclusive NCT03866720 379 388 O
to NCT03866720 389 391 O
all NCT03866720 392 395 O
breakfast NCT03866720 396 405 O
habits NCT03866720 406 412 O
( NCT03866720 413 414 O
e. NCT03866720 415 417 O
g. NCT03866720 418 420 O
regular NCT03866720 422 429 O
skipper NCT03866720 430 437 O
/ NCT03866720 438 439 O
consumer NCT03866720 440 448 O
) NCT03866720 449 450 O

Exclusion NCT03866720 452 461 O
Criteria NCT03866720 462 470 O
: NCT03866720 471 472 O

- NCT03866720 476 477 O
Any NCT03866720 479 482 O
reported NCT03866720 483 491 O
condition NCT03866720 492 501 B-Condition
or NCT03866720 502 504 B-Or
behaviour NCT03866720 505 514 B-Condition
deemed NCT03866720 515 521 O
either NCT03866720 522 528 O
to NCT03866720 529 531 O
pose NCT03866720 532 536 O
undue NCT03866720 537 542 O
personal NCT03866720 543 551 O
risk NCT03866720 552 556 B-Risk
to NCT03866720 557 559 O
the NCT03866720 560 563 O
participant NCT03866720 564 575 O
or NCT03866720 576 578 B-Or
introduce NCT03866720 579 588 O
bias NCT03866720 589 593 O

- NCT03866720 596 597 O
Any NCT03866720 599 602 O
diagnosed NCT03866720 603 612 O
metabolic NCT03866720 613 622 B-Condition
disease NCT03866720 623 630 I-Condition
( NCT03866720 631 632 O
e. NCT03866720 633 635 O
g. NCT03866720 636 638 O
type NCT03866720 640 644 B-Modifier
1 NCT03866720 645 646 I-Modifier
or NCT03866720 647 649 B-Or
type NCT03866720 650 654 B-Modifier
2 NCT03866720 655 656 I-Modifier
diabetes NCT03866720 657 665 B-Condition
) NCT03866720 666 667 O

- NCT03866720 671 672 O
Any NCT03866720 674 677 O
reported NCT03866720 678 686 O
use NCT03866720 687 690 O
of NCT03866720 691 693 O
substances NCT03866720 694 704 B-Drug
which NCT03866720 705 710 O
may NCT03866720 711 714 B-Assertion___Assertion-Type-Value:hypothetical
pose NCT03866720 715 719 O
undue NCT03866720 720 725 O
personal NCT03866720 726 734 O
risk NCT03866720 735 739 B-Risk
to NCT03866720 740 742 O
the NCT03866720 743 746 O
participants NCT03866720 747 759 O
or NCT03866720 760 762 B-Or
introduce NCT03866720 763 772 O
bias NCT03866720 773 777 O
into NCT03866720 778 782 O
the NCT03866720 783 786 O
experiment NCT03866720 787 797 B-Study
( NCT03866720 798 799 O
e. NCT03866720 800 802 O
g. NCT03866720 803 805 O
smoking NCT03866720 807 814 B-Condition
/ NCT03866720 815 816 B-Or
substance NCT03866720 817 826 B-Condition
abuse NCT03866720 827 832 I-Condition
) NCT03866720 833 834 O

- NCT03866720 838 839 O
Lifestyle NCT03866720 841 850 O
not NCT03866720 851 854 B-Negation
conforming NCT03866720 855 865 O
to NCT03866720 866 868 O
standard NCT03866720 869 877 O
sleep NCT03866720 878 883 B-Condition
- NCT03866720 884 885 I-Condition
wake NCT03866720 886 890 I-Condition
cycle NCT03866720 891 896 I-Condition
( NCT03866720 897 898 O
e. NCT03866720 899 901 O
g. NCT03866720 902 904 O
shift NCT03866720 906 911 B-Observation
worker NCT03866720 912 918 I-Observation
) NCT03866720 919 920 O

- NCT03866720 924 925 O
Any NCT03866720 927 930 O
reported NCT03866720 931 939 O
recent NCT03866720 940 946 B-Eq-Comparison
( NCT03866720 947 948 O
< NCT03866720 950 951 B-Eq-Comparison
6 NCT03866720 952 953 I-Eq-Comparison
months NCT03866720 954 960 I-Eq-Comparison
) NCT03866720 961 962 O
change NCT03866720 963 969 O
in NCT03866720 970 972 O
body NCT03866720 973 977 B-Observation
mass NCT03866720 978 982 I-Observation
( NCT03866720 983 984 O
± NCT03866720 986 987 B-Eq-Comparison
3 NCT03866720 988 989 I-Eq-Comparison
% NCT03866720 990 991 I-Eq-Comparison
) NCT03866720 993 994 O

Inclusion NCT03864692 0 9 O
Criteria NCT03864692 10 18 O
: NCT03864692 19 20 O

- NCT03864692 24 25 O
singleton NCT03864692 27 36 B-Modifier
parturient NCT03864692 37 47 B-Condition

- NCT03864692 50 51 O
planned NCT03864692 53 60 B-Eq-Comparison
for NCT03864692 61 64 O
elective NCT03864692 65 73 B-Modifier
LSCS NCT03864692 74 78 B-Procedure
under NCT03864692 79 84 O
spinal NCT03864692 85 91 B-Procedure
anesthesia NCT03864692 92 102 I-Procedure

Exclusion NCT03864692 103 112 O
Criteria NCT03864692 113 121 O
: NCT03864692 122 123 O

- NCT03864692 127 128 O
gestational NCT03864692 130 141 B-Observation
age NCT03864692 142 145 I-Observation
< NCT03864692 146 147 B-Eq-Comparison
36 NCT03864692 148 150 I-Eq-Comparison
weeks NCT03864692 151 156 I-Eq-Comparison

- NCT03864692 159 160 O
emergency NCT03864692 162 171 O
cases NCT03864692 172 177 O

- NCT03864692 180 181 O
placenta NCT03864692 183 191 B-Condition
previa NCT03864692 192 198 I-Condition
, NCT03864692 199 200 O
pre NCT03864692 201 204 B-Condition
- NCT03864692 205 206 I-Condition
eclampsia NCT03864692 207 216 I-Condition

- NCT03864692 219 220 O
BMI NCT03864692 222 225 B-Observation
> NCT03864692 226 227 B-Eq-Comparison
40 NCT03864692 228 230 I-Eq-Comparison

- NCT03864692 234 235 O
Reynauld NCT03864692 237 245 B-Condition
disease NCT03864692 246 253 I-Condition

- NCT03864692 256 257 O
patient NCT03864692 259 266 O
refusal NCT03864692 267 274 O

- NCT03864692 277 278 O
cardiovascular NCT03864692 280 294 B-Condition
disease NCT03864692 295 302 I-Condition

Inclusion NCT03868917 0 9 O
Criteria NCT03868917 10 18 O
: NCT03868917 19 20 O

- NCT03868917 24 25 O
Scheduled NCT03868917 27 36 B-Eq-Comparison
for NCT03868917 37 40 O
elective NCT03868917 41 49 B-Modifier
thoracotomy NCT03868917 50 61 B-Procedure

- NCT03868917 64 65 O
ASA NCT03868917 67 70 B-Condition
status NCT03868917 71 77 O
1 NCT03868917 78 79 B-Eq-Comparison
, NCT03868917 80 81 I-Eq-Comparison
2 NCT03868917 82 83 I-Eq-Comparison

Exclusion NCT03868917 85 94 O
Criteria NCT03868917 95 103 O
: NCT03868917 104 105 O

- NCT03868917 109 110 O
Inability NCT03868917 112 121 O
to NCT03868917 122 124 O
provide NCT03868917 125 132 O
adequate NCT03868917 133 141 O
informed NCT03868917 142 150 O
consent NCT03868917 151 158 O

- NCT03868917 161 162 O
Any NCT03868917 164 167 O
contraindication NCT03868917 168 184 B-Contraindication
to NCT03868917 185 187 O
the NCT03868917 188 191 O
placement NCT03868917 192 201 O
of NCT03868917 202 204 O
thoracic NCT03868917 205 213 B-Procedure
paravertebral NCT03868917 214 227 I-Procedure
catheters NCT03868917 228 237 I-Procedure

- NCT03868917 240 241 O
Unstable NCT03868917 243 251 O
vertebral NCT03868917 252 261 B-Modifier
and NCT03868917 262 265 B-Or
transverse NCT03868917 266 276 B-Modifier
process NCT03868917 277 284 I-Modifier
fractures NCT03868917 285 294 B-Condition

- NCT03868917 297 298 O
Any NCT03868917 300 303 O
chronic NCT03868917 304 311 B-Modifier
painful NCT03868917 312 319 B-Condition
conditions NCT03868917 320 330 I-Condition
or NCT03868917 331 333 B-Or
pre NCT03868917 334 337 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03868917 338 347 B-Procedure
opioid NCT03868917 348 354 B-Drug
use NCT03868917 355 358 O
Any NCT03868917 359 362 O
chronic NCT03868917 363 370 B-Modifier
painful NCT03868917 371 378 B-Condition
conditions NCT03868917 379 389 I-Condition
or NCT03868917 390 392 B-Or
pre NCT03868917 393 396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03868917 397 406 B-Procedure
opioid NCT03868917 407 413 B-Drug
use NCT03868917 414 417 O

- NCT03868917 420 421 O
Coagulation NCT03868917 423 434 B-Condition
abnormalities NCT03868917 435 448 I-Condition
or NCT03868917 449 451 B-Or
expectation NCT03868917 452 463 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868917 464 466 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03868917 467 469 O
on NCT03868917 470 472 B-Eq-Comparison
therapeutic NCT03868917 473 484 B-Drug
anticoagulants NCT03868917 485 499 I-Drug
post NCT03868917 500 504 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operatively NCT03868917 505 516 B-Procedure

- NCT03868917 519 520 O
Allergy NCT03868917 522 529 B-Allergy
to NCT03868917 530 532 O
any NCT03868917 533 536 O
of NCT03868917 537 539 O
the NCT03868917 540 543 O
drugs NCT03868917 544 549 B-Drug
/ NCT03868917 550 551 B-Or
agents NCT03868917 552 558 B-Drug
used NCT03868917 559 563 O
in NCT03868917 564 566 O
study NCT03868917 567 572 B-Study
protocol NCT03868917 573 581 O

- NCT03868917 584 585 O
Altered NCT03868917 587 594 B-Condition
mental NCT03868917 595 601 I-Condition
status NCT03868917 602 608 I-Condition
or NCT03868917 609 611 B-Or
emergency NCT03868917 612 621 B-Modifier
surgery NCT03868917 622 629 B-Procedure

- NCT03868917 632 633 O
Comorbid NCT03868917 635 643 B-Condition
conditions NCT03868917 644 654 I-Condition
such NCT03868917 655 659 O
as NCT03868917 660 662 O
sepsis NCT03868917 663 669 B-Condition
, NCT03868917 670 671 O
unstable NCT03868917 672 680 O
angina NCT03868917 681 687 B-Condition
, NCT03868917 688 689 O
congestive NCT03868917 690 700 B-Condition
heart NCT03868917 701 706 I-Condition
failure NCT03868917 707 714 I-Condition

Inclusion NCT03862547 0 9 O
Criteria NCT03862547 10 18 O
: NCT03862547 19 20 O

- NCT03862547 24 25 O
men NCT03862547 27 30 O
with NCT03862547 31 35 B-And
DE NCT03862547 36 38 B-Condition
and NCT03862547 39 42 B-And
metabolic NCT03862547 43 52 B-Condition
syndrome NCT03862547 53 61 I-Condition

Exclusion NCT03862547 62 71 O
Criteria NCT03862547 72 80 O
: NCT03862547 81 82 O

- NCT03862547 86 87 O
men NCT03862547 89 92 O
with NCT03862547 93 97 B-And
DE NCT03862547 98 100 B-Condition
without NCT03862547 101 108 B-Negation
metabolic NCT03862547 109 118 B-Condition
syndrome NCT03862547 119 127 I-Condition

Inclusion NCT03860350 0 9 O
Criteria NCT03860350 10 18 O
: NCT03860350 19 20 O

- NCT03860350 24 25 O
CAC NCT03860350 27 30 B-Observation
score NCT03860350 31 36 I-Observation
> NCT03860350 37 38 B-Eq-Comparison
10 NCT03860350 39 41 I-Eq-Comparison

- NCT03860350 45 46 O
Framingham NCT03860350 48 58 B-Observation
risk NCT03860350 59 63 I-Observation
score NCT03860350 64 69 I-Observation
( NCT03860350 70 71 O
10 NCT03860350 72 74 B-Eq-Comparison
% NCT03860350 75 76 I-Eq-Comparison
or NCT03860350 77 79 I-Eq-Comparison
above NCT03860350 80 85 I-Eq-Comparison
) NCT03860350 86 87 O

- NCT03860350 91 92 O
Subjects NCT03860350 94 102 O
are NCT03860350 103 106 O
required NCT03860350 107 115 O
to NCT03860350 116 118 O
be NCT03860350 119 121 O
on NCT03860350 122 124 O
stable NCT03860350 125 131 O
concomitant NCT03860350 132 143 B-Modifier
medications NCT03860350 144 155 B-Drug
for NCT03860350 156 159 O
at NCT03860350 160 162 B-Eq-Comparison
least NCT03860350 163 168 I-Eq-Comparison
12 NCT03860350 169 171 I-Eq-Comparison
weeks NCT03860350 172 177 I-Eq-Comparison
prior NCT03860350 178 183 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03860350 184 186 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03860350 187 200 B-Study

- NCT03860350 203 204 O
Subjects NCT03860350 206 214 O
with NCT03860350 215 219 O
diabetic NCT03860350 220 228 B-Condition
must NCT03860350 229 233 O
have NCT03860350 234 238 O
HbA1C NCT03860350 239 244 B-Observation
< NCT03860350 245 246 B-Eq-Comparison
8.0 NCT03860350 247 250 I-Eq-Comparison
, NCT03860350 251 252 O
and NCT03860350 253 256 B-And
stable NCT03860350 257 263 O
HbA1C NCT03860350 264 269 B-Observation
level NCT03860350 270 275 O
variation NCT03860350 276 285 B-Modifier
range NCT03860350 286 291 I-Modifier
within NCT03860350 292 298 B-Eq-Comparison
0.5 NCT03860350 299 302 I-Eq-Comparison
% NCT03860350 303 304 I-Eq-Comparison
for NCT03860350 305 308 O
three NCT03860350 309 314 B-Eq-Comparison
months NCT03860350 315 321 I-Eq-Comparison
. NCT03860350 322 323 O

Exclusion NCT03860350 325 334 O
Criteria NCT03860350 335 343 O
: NCT03860350 344 345 O

- NCT03860350 349 350 O
Hypersensitivity NCT03860350 352 368 B-Condition
to NCT03860350 369 371 O
AGE NCT03860350 372 375 B-Procedure
therapy NCT03860350 376 383 I-Procedure
, NCT03860350 384 385 O

- NCT03860350 389 390 O
Unstable NCT03860350 392 400 O
medical NCT03860350 401 408 B-Modifier
, NCT03860350 409 410 O
psychiatric NCT03860350 411 422 B-Modifier
, NCT03860350 423 424 O
or NCT03860350 425 427 B-Or
substance NCT03860350 428 437 B-Modifier
abuse NCT03860350 438 443 I-Modifier
disorder NCT03860350 444 452 B-Condition
that NCT03860350 453 457 O
may NCT03860350 458 461 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03860350 462 471 O
with NCT03860350 472 476 O
continuation NCT03860350 477 489 O
in NCT03860350 490 492 O
the NCT03860350 493 496 O
study NCT03860350 497 502 B-Study
, NCT03860350 503 504 O

- NCT03860350 508 509 O
Weight NCT03860350 511 517 B-Observation
≥ NCT03860350 518 519 B-Eq-Comparison
325 NCT03860350 520 523 I-Eq-Comparison
pounds NCT03860350 524 530 I-Eq-Comparison
, NCT03860350 531 532 O

- NCT03860350 536 537 O
Bleeding NCT03860350 539 547 B-Condition
disorder NCT03860350 548 556 I-Condition
, NCT03860350 557 558 O

- NCT03860350 562 563 O
History NCT03860350 565 572 B-Eq-Comparison
of NCT03860350 573 575 O
myocardial NCT03860350 576 586 B-Condition
infarction NCT03860350 587 597 I-Condition
, NCT03860350 598 599 O

- NCT03860350 603 604 O
Stroke NCT03860350 606 612 B-Condition

- NCT03860350 615 616 O
Life NCT03860350 618 622 B-Death|Risk
- NCT03860350 623 624 I-Death|Risk
threatening NCT03860350 625 636 I-Death|Risk
arrhythmia NCT03860350 637 647 B-Condition
within NCT03860350 648 654 B-Eq-Comparison
prior NCT03860350 655 660 I-Eq-Comparison
6 NCT03860350 661 662 I-Eq-Comparison
months NCT03860350 663 669 I-Eq-Comparison
, NCT03860350 670 671 O

- NCT03860350 675 676 O
Resting NCT03860350 678 685 B-Modifier
hypotension NCT03860350 686 697 B-Condition
( NCT03860350 698 699 O
systolic NCT03860350 700 708 B-Observation
< NCT03860350 709 710 B-Eq-Comparison
90 NCT03860350 711 713 I-Eq-Comparison
mmHg NCT03860350 714 718 I-Eq-Comparison
) NCT03860350 719 720 O
or NCT03860350 721 723 B-Or
hypertension NCT03860350 724 736 B-Condition
( NCT03860350 737 738 O
resting NCT03860350 739 746 B-Modifier
blood NCT03860350 747 752 B-Observation
pressure NCT03860350 753 761 I-Observation
> NCT03860350 762 763 B-Eq-Comparison
170 NCT03860350 764 767 I-Eq-Comparison
/ NCT03860350 768 769 I-Eq-Comparison
110 NCT03860350 770 773 I-Eq-Comparison
) NCT03860350 774 775 O

- NCT03860350 779 780 O
Heart NCT03860350 782 787 B-Condition
failure NCT03860350 788 795 I-Condition
NYHA NCT03860350 796 800 B-Condition
class NCT03860350 801 806 I-Condition
III NCT03860350 807 810 B-Eq-Comparison
or NCT03860350 811 813 I-Eq-Comparison
IV NCT03860350 814 816 I-Eq-Comparison
, NCT03860350 817 818 O

- NCT03860350 822 823 O
History NCT03860350 825 832 B-Eq-Comparison
of NCT03860350 833 835 O
malignancy NCT03860350 836 846 B-Condition
within NCT03860350 847 853 B-Eq-Comparison
the NCT03860350 854 857 I-Eq-Comparison
last NCT03860350 858 862 I-Eq-Comparison
5 NCT03860350 863 864 I-Eq-Comparison
years NCT03860350 865 870 I-Eq-Comparison
( NCT03860350 871 872 O
other NCT03860350 873 878 B-Exception
than NCT03860350 879 883 I-Exception
skin NCT03860350 884 888 B-Modifier
cancer NCT03860350 889 895 B-Condition
) NCT03860350 896 897 O
or NCT03860350 898 900 B-Or
evidence NCT03860350 901 909 O
of NCT03860350 910 912 O
active NCT03860350 913 919 B-Eq-Comparison
cancer NCT03860350 920 926 B-Condition
which NCT03860350 927 932 O
would NCT03860350 933 938 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03860350 939 946 I-Assertion___Assertion-Type-Value:hypothetical
concomitant NCT03860350 947 958 B-Modifier
cancer NCT03860350 959 965 B-Procedure
chemotherapy NCT03860350 966 978 I-Procedure

- NCT03860350 981 982 O
Serum NCT03860350 984 989 B-Observation
creatinine NCT03860350 990 1000 I-Observation
> NCT03860350 1001 1002 B-Eq-Comparison
1.4 NCT03860350 1003 1006 I-Eq-Comparison
mg NCT03860350 1007 1009 I-Eq-Comparison
/ NCT03860350 1010 1011 I-Eq-Comparison
dl NCT03860350 1012 1014 I-Eq-Comparison

- NCT03860350 1017 1018 O
Triglycerides NCT03860350 1020 1033 B-Observation
> NCT03860350 1034 1035 B-Eq-Comparison
400 NCT03860350 1036 1039 I-Eq-Comparison
at NCT03860350 1040 1042 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860350 1043 1051 B-Study
visit NCT03860350 1052 1057 O

- NCT03860350 1060 1061 O
Diabetic NCT03860350 1063 1071 B-Condition
subjects NCT03860350 1072 1080 O
with NCT03860350 1081 1085 O
HbA1C NCT03860350 1086 1091 B-Observation
> NCT03860350 1092 1093 B-Eq-Comparison
8 NCT03860350 1094 1095 I-Eq-Comparison
% NCT03860350 1096 1097 I-Eq-Comparison
, NCT03860350 1099 1100 O

- NCT03860350 1104 1105 O
Drug NCT03860350 1107 1111 B-Modifier
or NCT03860350 1112 1114 B-Or
alcohol NCT03860350 1115 1122 B-Modifier
abuse NCT03860350 1123 1128 B-Condition

- NCT03860350 1131 1132 O
Conditions NCT03860350 1134 1144 B-Condition
interfering NCT03860350 1145 1156 O
with NCT03860350 1157 1161 O
accurate NCT03860350 1162 1170 O
assessment NCT03860350 1171 1181 O
of NCT03860350 1182 1184 O
coronary NCT03860350 1185 1193 B-Condition
calcification NCT03860350 1194 1207 I-Condition
( NCT03860350 1208 1209 O
metal NCT03860350 1210 1215 B-Condition
clips NCT03860350 1216 1221 I-Condition
, NCT03860350 1222 1223 O
bypass NCT03860350 1224 1230 B-Procedure
patients NCT03860350 1231 1239 O
, NCT03860350 1240 1241 O
intracoronary NCT03860350 1242 1255 B-Procedure
stents NCT03860350 1256 1262 I-Procedure
) NCT03860350 1263 1264 O
and NCT03860350 1265 1268 B-Or
drug NCT03860350 1269 1273 B-Condition
absorption NCT03860350 1274 1284 I-Condition
( NCT03860350 1285 1286 O
partial NCT03860350 1287 1294 B-Procedure
ileal NCT03860350 1295 1300 I-Procedure
bypass NCT03860350 1301 1307 I-Procedure
or NCT03860350 1308 1310 B-Or
malabsorption NCT03860350 1311 1324 B-Condition
syndrome NCT03860350 1325 1333 I-Condition
) NCT03860350 1334 1335 O
. NCT03860350 1337 1338 O

- NCT03860350 1342 1343 O
Current NCT03860350 1345 1352 B-Eq-Comparison
use NCT03860350 1353 1356 O
of NCT03860350 1357 1359 O
anticoagulants NCT03860350 1360 1374 B-Drug
( NCT03860350 1375 1376 O
except NCT03860350 1377 1383 B-Exception
for NCT03860350 1384 1387 I-Exception
antiplatelet NCT03860350 1388 1400 B-Drug
agents NCT03860350 1401 1407 I-Drug
) NCT03860350 1408 1409 O

- NCT03860350 1413 1414 O
Chronic NCT03860350 1416 1423 B-Modifier
renal NCT03860350 1424 1429 B-Condition
failure NCT03860350 1430 1437 I-Condition

- NCT03860350 1440 1441 O
Liver NCT03860350 1443 1448 B-Condition
failure NCT03860350 1449 1456 I-Condition

- NCT03860350 1459 1460 O
Hematological NCT03860350 1462 1475 B-Modifier
or NCT03860350 1476 1478 B-Or
biochemical NCT03860350 1479 1490 B-Modifier
values NCT03860350 1491 1497 B-Observation
at NCT03860350 1498 1500 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03860350 1501 1509 B-Study
visit NCT03860350 1510 1515 O
outside NCT03860350 1516 1523 O
the NCT03860350 1524 1527 O
reference NCT03860350 1528 1537 O
ranges NCT03860350 1538 1544 O
considered NCT03860350 1545 1555 O
as NCT03860350 1556 1558 O
clinically NCT03860350 1559 1569 O
significant NCT03860350 1570 1581 O
. NCT03860350 1581 1582 O

Inclusion NCT03862235 0 9 O
Criteria NCT03862235 10 18 O
: NCT03862235 19 20 O

- NCT03862235 24 25 O
Anabolic NCT03862235 27 35 B-Drug
androgenic NCT03862235 36 46 I-Drug
steroids NCT03862235 47 55 I-Drug
users NCT03862235 56 61 O
and NCT03862235 62 65 B-Or
Anabolic NCT03862235 66 74 B-Drug
androgenic NCT03862235 75 85 I-Drug
steroids NCT03862235 86 94 I-Drug
nonusers NCT03862235 95 103 B-Negation
groups NCT03862235 104 110 O
had NCT03862235 111 114 O
been NCT03862235 115 119 O
involved NCT03862235 120 128 O
in NCT03862235 129 131 O
strength NCT03862235 132 140 B-Observation
training NCT03862235 141 149 I-Observation
for NCT03862235 150 153 O
at NCT03862235 154 156 B-Eq-Comparison
least NCT03862235 157 162 I-Eq-Comparison
2 NCT03862235 163 164 I-Eq-Comparison
years NCT03862235 165 170 I-Eq-Comparison
; NCT03862235 170 171 O

- NCT03862235 174 175 O
Anabolic NCT03862235 177 185 B-Drug
androgenic NCT03862235 186 196 I-Drug
steroids NCT03862235 197 205 I-Drug
users NCT03862235 206 211 O
should NCT03862235 212 218 O
be NCT03862235 219 221 O
self NCT03862235 222 226 O
- NCT03862235 227 228 O
administering NCT03862235 229 242 O
anabolic NCT03862235 243 251 B-Drug
androgenic NCT03862235 252 262 I-Drug
steroids NCT03862235 263 271 I-Drug
in NCT03862235 272 274 O
periodic NCT03862235 275 283 O
cycles NCT03862235 284 290 O
lasting NCT03862235 291 298 O
from NCT03862235 299 303 O
8 NCT03862235 304 305 B-Eq-Comparison
to NCT03862235 306 308 I-Eq-Comparison
12 NCT03862235 309 311 I-Eq-Comparison
weeks NCT03862235 312 317 I-Eq-Comparison
for NCT03862235 318 321 O
at NCT03862235 322 324 B-Eq-Comparison
least NCT03862235 325 330 I-Eq-Comparison
2 NCT03862235 331 332 I-Eq-Comparison
years NCT03862235 333 338 I-Eq-Comparison
with NCT03862235 339 343 O
2 NCT03862235 344 345 B-Eq-Comparison
- NCT03862235 346 347 I-Eq-Comparison
4 NCT03862235 348 349 I-Eq-Comparison
cycles NCT03862235 350 356 I-Eq-Comparison
per NCT03862235 357 360 I-Eq-Comparison
year NCT03862235 361 365 I-Eq-Comparison
; NCT03862235 365 366 O

- NCT03862235 369 370 O
All NCT03862235 372 375 O
anabolic NCT03862235 376 384 B-Drug
androgenic NCT03862235 385 395 I-Drug
steroids NCT03862235 396 404 I-Drug
users NCT03862235 405 410 O
were NCT03862235 411 415 O
on NCT03862235 416 418 O
a NCT03862235 419 420 O
cycle NCT03862235 421 426 O
over NCT03862235 427 431 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862235 432 435 I-Temporal-Connection___Temporal-Connection-Type-Value:during
course NCT03862235 436 442 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03862235 443 445 O
the NCT03862235 446 449 O
study NCT03862235 450 455 B-Study
; NCT03862235 455 456 O

- NCT03862235 459 460 O
Sedentary NCT03862235 462 471 O
control NCT03862235 472 479 O
group NCT03862235 480 485 O
: NCT03862235 486 487 O
sedentary NCT03862235 488 497 B-Condition
men NCT03862235 498 501 O
without NCT03862235 502 509 B-Negation
cardiovascular NCT03862235 510 524 B-Condition
disease NCT03862235 525 532 I-Condition
. NCT03862235 533 534 O

Exclusion NCT03862235 536 545 O
Criteria NCT03862235 546 554 O
: NCT03862235 555 556 O

- NCT03862235 560 561 O
Smoking NCT03862235 563 570 B-Condition
; NCT03862235 570 571 O

- NCT03862235 574 575 O
Alcohol NCT03862235 577 584 B-Observation
consumption NCT03862235 585 596 I-Observation
; NCT03862235 596 597 O

- NCT03862235 600 601 O
Use NCT03862235 603 606 O
of NCT03862235 607 609 O
diuretics NCT03862235 610 619 B-Drug
and NCT03862235 620 623 B-Or
/ NCT03862235 624 625 I-Or
or NCT03862235 626 628 I-Or
antihypertensive NCT03862235 629 645 B-Drug
medications NCT03862235 646 657 I-Drug
; NCT03862235 657 658 O

- NCT03862235 661 662 O
Liver NCT03862235 664 669 B-Modifier
and NCT03862235 670 673 B-Or
kidney NCT03862235 674 680 B-Modifier
disease NCT03862235 681 688 B-Condition

Inclusion NCT03862209 0 9 O
Criteria NCT03862209 10 18 O
: NCT03862209 19 20 O

Adults NCT03862209 22 28 O
( NCT03862209 29 30 O
ages NCT03862209 31 35 B-Age
18 NCT03862209 36 38 B-Eq-Comparison
- NCT03862209 39 40 I-Eq-Comparison
65 NCT03862209 41 43 O
) NCT03862209 44 45 O
, NCT03862209 47 48 O
current NCT03862209 49 56 O
service NCT03862209 57 64 O
users NCT03862209 65 70 O
, NCT03862209 71 72 O
with NCT03862209 73 77 B-And
severe NCT03862209 78 84 O
and NCT03862209 85 88 B-Or
enduring NCT03862209 89 97 B-Modifier
mental NCT03862209 98 104 B-Condition
ill NCT03862209 105 108 I-Condition
- NCT03862209 109 110 I-Condition
health NCT03862209 111 117 I-Condition
, NCT03862209 118 119 O
which NCT03862209 120 125 O
, NCT03862209 126 127 O
for NCT03862209 128 131 O
clinical NCT03862209 132 140 O
purposes NCT03862209 141 149 O
, NCT03862209 150 151 O
typically NCT03862209 152 161 O
relates NCT03862209 162 169 O
to NCT03862209 170 172 O
diagnostic NCT03862209 173 183 O
categories NCT03862209 184 194 O
of NCT03862209 195 197 O
bipolar NCT03862209 198 205 B-Condition
disorder NCT03862209 206 214 I-Condition
, NCT03862209 215 216 O
severe NCT03862209 217 223 O
depression NCT03862209 224 234 B-Condition
, NCT03862209 235 236 O
or NCT03862209 237 239 B-Or
schizophrenia NCT03862209 240 253 B-Condition
. NCT03862209 253 254 O
We NCT03862209 256 258 O
use NCT03862209 259 262 O
the NCT03862209 263 266 O
following NCT03862209 267 276 O
definition NCT03862209 277 287 O
for NCT03862209 288 291 O
SMI NCT03862209 292 295 B-Condition
: NCT03862209 296 297 O

- NCT03862209 301 302 O
Presence NCT03862209 304 312 O
of NCT03862209 313 315 O
a NCT03862209 316 317 O
psychiatric NCT03862209 318 329 B-Condition
disorder NCT03862209 330 338 I-Condition
that NCT03862209 339 343 O
requires NCT03862209 344 352 B-Assertion___Assertion-Type-Value:hypothetical
care NCT03862209 353 357 B-Procedure
and NCT03862209 358 361 B-And
treatment NCT03862209 362 371 B-Procedure
( NCT03862209 372 373 O
so NCT03862209 374 376 O
, NCT03862209 377 378 O
they NCT03862209 379 383 O
are NCT03862209 384 387 O
NOT NCT03862209 388 391 B-Negation
in NCT03862209 392 394 O
symptom NCT03862209 395 402 B-Modifier
remission NCT03862209 403 412 I-Modifier
) NCT03862209 413 414 O

- NCT03862209 418 419 O
Has NCT03862209 421 424 O
severe NCT03862209 425 431 O
limitations NCT03862209 432 443 B-Condition
in NCT03862209 444 446 O
social NCT03862209 447 453 B-Modifier
and NCT03862209 454 457 B-And
community NCT03862209 458 467 B-Modifier
functioning NCT03862209 468 479 I-Modifier
( NCT03862209 480 481 O
i. NCT03862209 482 484 O
e. NCT03862209 485 487 O
they NCT03862209 489 493 O
are NCT03862209 494 497 O
not NCT03862209 498 501 B-Negation
in NCT03862209 502 504 O
functional NCT03862209 505 515 B-Modifier
remission NCT03862209 516 525 I-Modifier
) NCT03862209 526 527 O

- NCT03862209 531 532 O
These NCT03862209 534 539 O
problems NCT03862209 540 548 B-Condition
are NCT03862209 549 552 O
not NCT03862209 553 556 B-Negation
transient NCT03862209 557 566 B-Modifier
( NCT03862209 567 568 O
e. NCT03862209 569 571 O
g. NCT03862209 572 574 O
temporary NCT03862209 576 585 B-Modifier
, NCT03862209 586 587 O
one NCT03862209 588 591 B-Modifier
- NCT03862209 592 593 I-Modifier
off NCT03862209 594 597 I-Modifier
) NCT03862209 598 599 O
in NCT03862209 600 602 O
nature NCT03862209 603 609 O
( NCT03862209 610 611 O
They NCT03862209 612 616 O
are NCT03862209 617 620 O
systematic NCT03862209 621 631 B-Modifier
and NCT03862209 632 635 B-And
long NCT03862209 636 640 B-Modifier
- NCT03862209 641 642 I-Modifier
term NCT03862209 643 647 I-Modifier
) NCT03862209 648 649 O

- NCT03862209 653 654 O
Coordinated NCT03862209 656 667 B-Procedure
care NCT03862209 668 672 I-Procedure
provided NCT03862209 673 681 O
by NCT03862209 682 684 O
care NCT03862209 685 689 B-Provider
networks NCT03862209 690 698 I-Provider
or NCT03862209 699 701 B-Or
teams NCT03862209 702 707 B-Provider
is NCT03862209 708 710 O
needed NCT03862209 711 717 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862209 718 720 I-Assertion___Assertion-Type-Value:hypothetical
implement NCT03862209 721 730 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862209 731 734 O
treatment NCT03862209 735 744 B-Procedure
plan NCT03862209 745 749 B-Eq-Comparison

Exclusion NCT03862209 750 759 O
Criteria NCT03862209 760 768 O
: NCT03862209 769 770 O

Exclusion NCT03862209 772 781 O
criteria NCT03862209 782 790 O
at NCT03862209 791 793 O
the NCT03862209 794 797 O
patient NCT03862209 798 805 O
level NCT03862209 806 811 O
includes NCT03862209 812 820 O
patients NCT03862209 821 829 O
who NCT03862209 830 833 O
do NCT03862209 834 836 O
not NCT03862209 837 840 O
consent NCT03862209 841 848 O
to NCT03862209 849 851 O
their NCT03862209 852 857 O
data NCT03862209 858 862 O
being NCT03862209 863 868 O
collected NCT03862209 869 878 O
who NCT03862209 879 882 O
are NCT03862209 883 886 O
part NCT03862209 887 891 O
of NCT03862209 892 894 O
the NCT03862209 895 898 O
intervention NCT03862209 899 911 O
or NCT03862209 912 914 O
control NCT03862209 915 922 O
conditions NCT03862209 923 933 O
, NCT03862209 934 935 O
those NCT03862209 936 941 O
who NCT03862209 942 945 O
are NCT03862209 946 949 O
under NCT03862209 950 955 B-Eq-Comparison
the NCT03862209 956 959 I-Eq-Comparison
age NCT03862209 960 963 I-Eq-Comparison
of NCT03862209 964 966 I-Eq-Comparison
18 NCT03862209 967 969 I-Eq-Comparison
at NCT03862209 970 972 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862209 973 976 I-Temporal-Connection___Temporal-Connection-Type-Value:during
start NCT03862209 977 982 B-Eq-Comparison
of NCT03862209 983 985 O
the NCT03862209 986 989 O
study NCT03862209 990 995 B-Study
. NCT03862209 996 997 O


Inclusion NCT03862976 0 9 O
Criteria NCT03862976 10 18 O
: NCT03862976 19 20 O

- NCT03862976 24 25 O
Women NCT03862976 27 32 O
with NCT03862976 33 37 B-And
singleton NCT03862976 38 47 B-Modifier
gestation NCT03862976 48 57 B-Condition

- NCT03862976 60 61 O
18 NCT03862976 63 65 B-Eq-Comparison
years NCT03862976 66 71 I-Eq-Comparison
to NCT03862976 72 74 I-Eq-Comparison
50 NCT03862976 75 77 I-Eq-Comparison
years NCT03862976 78 83 I-Eq-Comparison

- NCT03862976 86 87 O
High NCT03862976 89 93 O
risk NCT03862976 94 98 B-Risk
pregnancies NCT03862976 99 110 B-Condition
: NCT03862976 111 112 O
DM NCT03862976 113 115 B-Condition
, NCT03862976 116 117 O
or NCT03862976 118 120 B-Or
GDM NCT03862976 121 124 B-Condition
, NCT03862976 125 126 O
or NCT03862976 127 129 B-Or
hypertension NCT03862976 130 142 B-Condition
, NCT03862976 143 144 O
or NCT03862976 145 147 B-Or
preeclampsia NCT03862976 148 160 B-Condition

Exclusion NCT03862976 161 170 O
Criteria NCT03862976 171 179 O
: NCT03862976 180 181 O

- NCT03862976 184 185 O
IUGR NCT03862976 186 190 B-Condition

Inclusion NCT03865758 0 9 O
Criteria NCT03865758 10 18 O
: NCT03865758 19 20 O

- NCT03865758 24 25 O
Probable NCT03865758 27 35 B-Assertion___Assertion-Type-Value:possible
dementia NCT03865758 36 44 B-Condition
indicated NCT03865758 45 54 O
by NCT03865758 55 57 O
prior NCT03865758 58 63 B-Eq-Comparison
diagnosis NCT03865758 64 73 B-Coreference
and NCT03865758 74 77 B-Or
/ NCT03865758 78 79 I-Or
or NCT03865758 80 82 I-Or
a NCT03865758 83 84 O
score NCT03865758 85 90 O
of NCT03865758 91 93 O
23 NCT03865758 94 96 B-Eq-Comparison
or NCT03865758 97 99 I-Eq-Comparison
less NCT03865758 100 104 I-Eq-Comparison
on NCT03865758 105 107 O
the NCT03865758 108 111 O
Brief NCT03865758 112 117 B-Observation
Alzheimer NCT03865758 118 127 I-Observation
Screen NCT03865758 128 134 I-Observation
. NCT03865758 135 136 O

Exclusion NCT03865758 138 147 O
Criteria NCT03865758 148 156 O
: NCT03865758 157 158 O

- NCT03865758 162 163 O
No NCT03865758 165 167 B-Negation
evidence NCT03865758 168 176 O
of NCT03865758 177 179 O
dementia NCT03865758 180 188 B-Condition

Inclusion NCT03862989 0 9 O
Criteria NCT03862989 10 18 O
: NCT03862989 19 20 O

- NCT03862989 24 25 O
post NCT03862989 27 31 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862989 32 33 O
myocardial NCT03862989 34 44 B-Condition
infarction NCT03862989 45 55 I-Condition
ventricular NCT03862989 56 67 B-Condition
tachycardia NCT03862989 68 79 I-Condition
diagnosis NCT03862989 80 89 O

- NCT03862989 92 93 O
scheduled NCT03862989 95 104 B-Eq-Comparison
to NCT03862989 105 107 I-Eq-Comparison
undergo NCT03862989 108 115 I-Eq-Comparison
radiofrequency NCT03862989 116 130 B-Procedure
catheter NCT03862989 131 139 I-Procedure
ablation NCT03862989 140 148 I-Procedure
as NCT03862989 149 151 O
either NCT03862989 152 158 O
emergency NCT03862989 159 168 B-Modifier
or NCT03862989 169 171 B-Or
elective NCT03862989 172 180 B-Modifier
case NCT03862989 181 185 O

Exclusion NCT03862989 186 195 O
Criteria NCT03862989 196 204 O
: NCT03862989 205 206 O

- NCT03862989 210 211 O
Unable NCT03862989 213 219 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 220 222 O
perform NCT03862989 223 230 O
pace NCT03862989 231 235 B-Procedure
mapping NCT03862989 236 243 I-Procedure
during NCT03862989 244 250 B-Temporal-Connection___Temporal-Connection-Type-Value:during
ablation NCT03862989 251 259 B-Procedure
procedure NCT03862989 260 269 I-Procedure

- NCT03862989 272 273 O
Unable NCT03862989 275 281 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 282 284 O
terminate NCT03862989 285 294 B-Condition
VT NCT03862989 295 297 I-Condition
thus NCT03862989 298 302 O
unable NCT03862989 303 309 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03862989 310 312 O
provide NCT03862989 313 320 O
data NCT03862989 321 325 O
regarding NCT03862989 326 335 O
successful NCT03862989 336 346 O
ablation NCT03862989 347 355 B-Procedure
lesion NCT03862989 356 362 I-Procedure
sites NCT03862989 363 368 O

- NCT03862989 371 372 O
Intracardiac NCT03862989 374 386 B-Condition
thrombus NCT03862989 387 395 I-Condition

Inclusion NCT03868254 0 9 O
Criteria NCT03868254 10 18 O
: NCT03868254 19 20 O

- NCT03868254 24 25 O
Eye NCT03868254 27 30 B-Modifier
treated NCT03868254 31 38 B-Procedure
with NCT03868254 39 43 O
XEN NCT03868254 44 47 B-Modifier
45 NCT03868254 48 50 I-Modifier
Gel NCT03868254 51 54 B-Procedure
Stent NCT03868254 55 60 I-Procedure
for NCT03868254 61 64 O
primary NCT03868254 65 72 B-Modifier
open NCT03868254 73 77 I-Modifier
angle NCT03868254 78 83 I-Modifier
glaucoma NCT03868254 84 92 B-Condition
as NCT03868254 93 95 O
a NCT03868254 96 97 O
standalone NCT03868254 98 108 B-Coreference
procedure NCT03868254 109 118 I-Coreference
or NCT03868254 119 121 B-Or
in NCT03868254 122 124 B-Modifier
combination NCT03868254 125 136 I-Modifier
with NCT03868254 137 141 O
phacoemulsification NCT03868254 142 161 B-Procedure

- NCT03868254 164 165 O
XEN NCT03868254 167 170 B-Modifier
45 NCT03868254 171 173 I-Modifier
Gel NCT03868254 174 177 B-Procedure
Stent NCT03868254 178 183 I-Procedure
was NCT03868254 184 187 O
implanted NCT03868254 188 197 O
between NCT03868254 198 205 B-Eq-Comparison
1 NCT03868254 206 207 I-Eq-Comparison
January NCT03868254 208 215 I-Eq-Comparison
2014 NCT03868254 216 220 I-Eq-Comparison
and NCT03868254 221 224 I-Eq-Comparison
1 NCT03868254 225 226 I-Eq-Comparison
October NCT03868254 227 234 I-Eq-Comparison
2015 NCT03868254 235 239 I-Eq-Comparison

Exclusion NCT03868254 241 250 O
Criteria NCT03868254 251 259 O

- NCT03868254 262 263 O
None NCT03868254 265 269 O

Inclusion NCT03865823 0 9 O
Criteria NCT03865823 10 18 O
: NCT03865823 19 20 O

- NCT03865823 24 25 O
Patient NCT03865823 27 34 O
over NCT03865823 35 39 B-Eq-Comparison
the NCT03865823 40 43 I-Eq-Comparison
age NCT03865823 44 47 I-Age|Eq-Comparison
of NCT03865823 48 50 I-Eq-Comparison
18 NCT03865823 51 53 I-Eq-Comparison
, NCT03865823 54 55 O
patient NCT03865823 56 63 O
with NCT03865823 64 68 O
an NCT03865823 69 71 O
anus NCT03865823 72 76 B-Modifier
fistula NCT03865823 77 84 B-Condition
with NCT03865823 85 89 B-And
indication NCT03865823 90 100 B-Indication
for NCT03865823 101 104 O
surgical NCT03865823 105 113 B-Procedure
treatment NCT03865823 114 123 I-Procedure

Exclusion NCT03865823 124 133 O
Criteria NCT03865823 134 142 O
: NCT03865823 143 144 O

- NCT03865823 148 149 O
Cutaneous NCT03865823 151 160 B-Condition
Suppuration NCT03865823 161 172 I-Condition
, NCT03865823 173 174 O
without NCT03865823 175 182 B-Negation
fistula NCT03865823 183 190 B-Condition
( NCT03865823 191 192 O
e. NCT03865823 193 195 O
g. NCT03865823 196 198 O
, NCT03865823 199 200 O
Verneuil NCT03865823 201 209 B-Condition
disease NCT03865823 210 217 I-Condition
, NCT03865823 218 219 O
boil NCT03865823 220 224 B-Condition
) NCT03865823 225 226 O

Inclusion NCT03869957 0 9 O
Criteria NCT03869957 10 18 O
: NCT03869957 19 20 O

- NCT03869957 24 25 O
Patients NCT03869957 27 35 O
admitted NCT03869957 36 44 B-Encounter
in NCT03869957 45 47 O
the NCT03869957 48 51 O
non NCT03869957 52 55 B-Negation
- NCT03869957 56 57 O
critical NCT03869957 58 66 O
areas NCT03869957 67 72 O
of NCT03869957 73 75 O
the NCT03869957 76 79 O
Instituto NCT03869957 80 89 O
Nacional NCT03869957 90 98 O
de NCT03869957 99 101 O
Ciencias NCT03869957 102 110 O
Médicas NCT03869957 111 118 O
y NCT03869957 119 120 O
Nutrición NCT03869957 121 130 O
Salvador NCT03869957 131 139 O
Zubirán NCT03869957 140 147 O
( NCT03869957 148 149 O
INCMNSZ NCT03869957 150 157 O
) NCT03869957 158 159 O
with NCT03869957 160 164 B-And
a NCT03869957 165 166 O
nutritional NCT03869957 167 178 B-Condition
risk NCT03869957 179 183 B-Risk
between NCT03869957 184 191 B-Eq-Comparison
January NCT03869957 192 199 I-Eq-Comparison
2019 NCT03869957 200 204 I-Eq-Comparison
and NCT03869957 205 208 I-Eq-Comparison
July NCT03869957 209 213 I-Eq-Comparison
2020 NCT03869957 214 218 I-Eq-Comparison
will NCT03869957 219 223 O
be NCT03869957 224 226 O
considered NCT03869957 227 237 O
eligible NCT03869957 238 246 O
. NCT03869957 247 248 O

- NCT03869957 252 253 O
Patients NCT03869957 255 263 O
with NCT03869957 264 268 O
recent NCT03869957 269 275 B-Eq-Comparison
diagnosis NCT03869957 276 285 O
of NCT03869957 286 288 O
IF NCT03869957 289 291 B-Condition
type NCT03869957 292 296 B-Modifier
II NCT03869957 297 299 I-Modifier
( NCT03869957 300 301 O
an NCT03869957 302 304 O
evolution NCT03869957 305 314 O
> NCT03869957 315 316 B-Eq-Comparison
28 NCT03869957 317 319 I-Eq-Comparison
days NCT03869957 320 324 I-Eq-Comparison
) NCT03869957 325 326 O
originate NCT03869957 327 336 O
from NCT03869957 337 341 O
various NCT03869957 342 349 O
gastrointestinal NCT03869957 350 366 B-Modifier
or NCT03869957 367 369 B-Or
systemic NCT03869957 370 378 B-Modifier
diseases NCT03869957 379 387 B-Condition
( NCT03869957 388 389 O
short NCT03869957 390 395 B-Modifier
bowel NCT03869957 396 401 I-Modifier
, NCT03869957 402 403 O
intestinal NCT03869957 404 414 B-Modifier
fistula NCT03869957 415 422 I-Modifier
, NCT03869957 423 424 O
intestinal NCT03869957 425 435 B-Modifier
dysmotility NCT03869957 436 447 I-Modifier
, NCT03869957 448 449 O
mechanical NCT03869957 450 460 B-Modifier
obstruction NCT03869957 461 472 I-Modifier
, NCT03869957 473 474 O
and NCT03869957 475 478 B-Or
extensive NCT03869957 479 488 B-Modifier
small NCT03869957 489 494 I-Modifier
bowel NCT03869957 495 500 I-Modifier
mucosal NCT03869957 501 508 I-Modifier
disease NCT03869957 509 516 B-Condition
) NCT03869957 517 518 O
. NCT03869957 519 520 O

Exclusion NCT03869957 527 536 O
Criteria NCT03869957 537 545 O
: NCT03869957 546 547 O

- NCT03869957 551 552 O
Patients NCT03869957 554 562 O
with NCT03869957 563 567 O
contraindications NCT03869957 568 585 B-Contraindication
for NCT03869957 586 589 O
PN NCT03869957 590 592 B-Procedure

- NCT03869957 595 596 O
Patients NCT03869957 598 606 O
with NCT03869957 607 611 O
known NCT03869957 612 617 O
allergies NCT03869957 618 627 B-Allergy
to NCT03869957 628 630 O
the NCT03869957 631 634 O
components NCT03869957 635 645 O
of NCT03869957 646 648 O
the NCT03869957 649 652 O
PN NCT03869957 653 655 B-Procedure
formula NCT03869957 656 663 O

- NCT03869957 666 667 O
Severe NCT03869957 669 675 O
liver NCT03869957 676 681 B-Modifier
or NCT03869957 682 684 B-Or
renal NCT03869957 685 690 B-Modifier
insufficiency NCT03869957 691 704 B-Condition

- NCT03869957 707 708 O
Uncontrolled NCT03869957 710 722 O
diabetes NCT03869957 723 731 B-Condition
mellitus NCT03869957 732 740 I-Condition

- NCT03869957 743 744 O
Certain NCT03869957 746 753 O
acute NCT03869957 754 759 O
and NCT03869957 760 763 B-Or
life NCT03869957 764 768 B-Death|Risk
- NCT03869957 769 770 I-Death|Risk
threatening NCT03869957 771 782 I-Death|Risk
conditions NCT03869957 783 793 B-Condition

- NCT03869957 796 797 O
Immunological NCT03869957 799 812 B-Condition
diseases NCT03869957 813 821 I-Condition
( NCT03869957 822 823 O
such NCT03869957 824 828 O
as NCT03869957 829 831 O
autoimmune NCT03869957 832 842 B-Condition
diseases NCT03869957 843 851 I-Condition
, NCT03869957 852 853 O
human NCT03869957 854 859 B-Condition
immunodeficiency NCT03869957 860 876 I-Condition
virus NCT03869957 877 882 I-Condition
infection NCT03869957 883 892 I-Condition
, NCT03869957 893 894 O
cancer NCT03869957 895 901 B-Condition
, NCT03869957 902 903 O
etc NCT03869957 904 907 O
. NCT03869957 907 908 O
) NCT03869957 909 910 O

- NCT03869957 914 915 O
Those NCT03869957 917 922 O
that NCT03869957 923 927 O
take NCT03869957 928 932 B-Eq-Comparison
immunosuppressant NCT03869957 933 950 B-Drug
medications NCT03869957 951 962 I-Drug

- NCT03869957 965 966 O
Severe NCT03869957 968 974 O
hemorrhagic NCT03869957 975 986 B-Condition
disorders NCT03869957 987 996 I-Condition

- NCT03869957 999 1000 O
Pregnant NCT03869957 1002 1010 B-Condition
or NCT03869957 1011 1013 B-Or
lactating NCT03869957 1014 1023 B-Condition


Inclusion NCT03863249 0 9 O
Criteria NCT03863249 10 18 O
: NCT03863249 19 20 O

1 NCT03863249 24 25 O
. NCT03863249 25 26 O
Subjects NCT03863249 28 36 O
of NCT03863249 37 39 O
40 NCT03863249 40 42 B-Eq-Comparison
- NCT03863249 43 44 I-Eq-Comparison
70 NCT03863249 45 47 I-Eq-Comparison
years NCT03863249 48 53 I-Age|Eq-Comparison
. NCT03863249 54 55 O

2 NCT03863249 59 60 O
. NCT03863249 60 61 O
No NCT03863249 63 65 B-Negation
smokers NCT03863249 66 73 B-Condition
or NCT03863249 74 76 B-Or
smokers NCT03863249 77 84 B-Condition|Observation
of NCT03863249 85 87 O
less NCT03863249 88 92 B-Eq-Comparison
than NCT03863249 93 97 I-Eq-Comparison
10 NCT03863249 98 100 I-Eq-Comparison
cigarettes NCT03863249 101 111 I-Eq-Comparison
a NCT03863249 112 113 I-Eq-Comparison
day NCT03863249 114 117 I-Eq-Comparison
. NCT03863249 118 119 O

3 NCT03863249 123 124 O
. NCT03863249 124 125 O
Patients NCT03863249 127 135 O
with NCT03863249 136 140 O
periodontitis NCT03863249 141 154 B-Condition
stages NCT03863249 155 161 B-Eq-Comparison
III NCT03863249 162 165 I-Eq-Comparison
and NCT03863249 166 169 I-Eq-Comparison
IV NCT03863249 170 172 I-Eq-Comparison
grades NCT03863249 173 179 B-Eq-Comparison
A NCT03863249 180 181 I-Eq-Comparison
- NCT03863249 182 183 I-Eq-Comparison
B NCT03863249 184 185 I-Eq-Comparison
. NCT03863249 186 187 O

4 NCT03863249 191 192 O
. NCT03863249 192 193 O
Presence NCT03863249 195 203 O
of NCT03863249 204 206 O
20 NCT03863249 207 209 B-Eq-Comparison
natural NCT03863249 210 217 B-Modifier
teeth NCT03863249 218 223 B-Condition
, NCT03863249 224 225 O
including NCT03863249 226 235 O
at NCT03863249 236 238 B-Eq-Comparison
least NCT03863249 239 244 I-Eq-Comparison
three NCT03863249 245 250 I-Eq-Comparison
molar NCT03863249 251 256 B-Modifier
teeth NCT03863249 257 262 B-Condition
. NCT03863249 263 264 O

5 NCT03863249 268 269 O
. NCT03863249 269 270 O
Presence NCT03863249 272 280 O
of NCT03863249 281 283 O
at NCT03863249 284 286 B-Eq-Comparison
least NCT03863249 287 292 I-Eq-Comparison
4 NCT03863249 293 294 I-Eq-Comparison
sites NCT03863249 295 300 I-Eq-Comparison
with NCT03863249 301 305 O
at NCT03863249 306 308 B-Eq-Comparison
least NCT03863249 309 314 I-Eq-Comparison
6 NCT03863249 315 316 I-Eq-Comparison
mm NCT03863249 317 319 I-Eq-Comparison
probing NCT03863249 320 327 B-Observation
depth NCT03863249 328 333 I-Observation
. NCT03863249 334 335 O

6 NCT03863249 339 340 O
. NCT03863249 340 341 O
Good NCT03863249 343 347 O
general NCT03863249 348 355 B-Condition
health NCT03863249 356 362 I-Condition

Exclusion NCT03863249 363 372 O
Criteria NCT03863249 373 381 O
: NCT03863249 382 383 O

1 NCT03863249 387 388 O
. NCT03863249 388 389 O
Smokers NCT03863249 391 398 B-Condition|Observation
of NCT03863249 399 401 O
more NCT03863249 402 406 B-Eq-Comparison
than NCT03863249 407 411 I-Eq-Comparison
10 NCT03863249 412 414 I-Eq-Comparison
cigarettes NCT03863249 415 425 I-Eq-Comparison
a NCT03863249 426 427 I-Eq-Comparison
day NCT03863249 428 431 I-Eq-Comparison
. NCT03863249 432 433 O

2 NCT03863249 437 438 O
. NCT03863249 438 439 O
Patients NCT03863249 441 449 O
who NCT03863249 450 453 O
have NCT03863249 454 458 O
received NCT03863249 459 467 B-Eq-Comparison
periodontal NCT03863249 468 479 B-Procedure
treatment NCT03863249 480 489 I-Procedure
in NCT03863249 490 492 O
the NCT03863249 493 496 O
previous NCT03863249 497 505 B-Eq-Comparison
12 NCT03863249 506 508 I-Eq-Comparison
months NCT03863249 509 515 I-Eq-Comparison
. NCT03863249 516 517 O

3 NCT03863249 521 522 O
. NCT03863249 522 523 O
Patients NCT03863249 525 533 O
who NCT03863249 534 537 O
have NCT03863249 538 542 O
used NCT03863249 543 547 B-Eq-Comparison
antibiotics NCT03863249 548 559 B-Drug
in NCT03863249 560 562 O
the NCT03863249 563 566 O
last NCT03863249 567 571 B-Eq-Comparison
6 NCT03863249 572 573 I-Eq-Comparison
months NCT03863249 574 580 I-Eq-Comparison
. NCT03863249 581 582 O

4 NCT03863249 586 587 O
. NCT03863249 587 588 O
Routine NCT03863249 590 597 O
use NCT03863249 598 601 O
of NCT03863249 602 604 O
oral NCT03863249 605 609 B-Drug
antiseptics NCT03863249 610 621 I-Drug
and NCT03863249 622 625 B-Or
/ NCT03863249 626 627 I-Or
or NCT03863249 628 630 I-Or
during NCT03863249 631 637 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863249 638 641 O
previous NCT03863249 642 650 B-Eq-Comparison
3 NCT03863249 651 652 I-Eq-Comparison
months NCT03863249 653 659 I-Eq-Comparison
. NCT03863249 660 661 O

5 NCT03863249 665 666 O
. NCT03863249 666 667 O
Systemic NCT03863249 669 677 B-Modifier
conditions NCT03863249 678 688 B-Condition
that NCT03863249 689 693 O
required NCT03863249 694 702 O
antibiotic NCT03863249 703 713 B-Drug
premedication NCT03863249 714 727 I-Drug
. NCT03863249 728 729 O

6 NCT03863249 733 734 O
. NCT03863249 734 735 O
Women NCT03863249 737 742 O
pregnant NCT03863249 743 751 B-Condition
or NCT03863249 752 754 B-Or
nursing NCT03863249 755 762 B-Condition
. NCT03863249 763 764 O

7 NCT03863249 768 769 O
. NCT03863249 769 770 O
Medications NCT03863249 772 783 B-Drug
that NCT03863249 784 788 O
could NCT03863249 789 794 B-Assertion___Assertion-Type-Value:hypothetical
influence NCT03863249 795 804 O
the NCT03863249 805 808 O
outcome NCT03863249 809 816 O
of NCT03863249 817 819 O
periodontal NCT03863249 820 831 B-Procedure
therapy NCT03863249 832 839 I-Procedure
. NCT03863249 840 841 O

8 NCT03863249 845 846 O
. NCT03863249 846 847 O
Any NCT03863249 849 852 O
known NCT03863249 853 858 O
allergies NCT03863249 859 868 B-Allergy
to NCT03863249 869 871 O
the NCT03863249 872 875 O
test NCT03863249 876 880 B-Study
antimicrobial NCT03863249 881 894 B-Drug
agents NCT03863249 895 901 I-Drug
. NCT03863249 902 903 O

9 NCT03863249 907 908 O
. NCT03863249 908 909 O
Diabetics NCT03863249 911 920 B-Condition
. NCT03863249 920 921 O

Inclusion NCT03862625 0 9 O
Criteria NCT03862625 10 18 O
: NCT03862625 19 20 O

- NCT03862625 24 25 O
the NCT03862625 27 30 O
participant NCT03862625 31 42 O
6 NCT03862625 43 44 B-Eq-Comparison
to NCT03862625 45 47 I-Eq-Comparison
15 NCT03862625 48 50 I-Eq-Comparison
years NCT03862625 51 56 I-Eq-Comparison
of NCT03862625 57 59 O
age NCT03862625 60 63 B-Age
during NCT03862625 64 70 B-Temporal-Connection___Temporal-Connection-Type-Value:during
inclusion NCT03862625 71 80 B-Study

- NCT03862625 83 84 O
the NCT03862625 86 89 O
participant NCT03862625 90 101 O
is NCT03862625 102 104 O
diagnosed NCT03862625 105 114 O
as NCT03862625 115 117 O
cerebral NCT03862625 118 126 B-Condition
palsy NCT03862625 127 132 I-Condition
by NCT03862625 133 135 O
a NCT03862625 136 137 O
specialist NCT03862625 138 148 B-Provider

- NCT03862625 151 152 O
the NCT03862625 154 157 O
participant NCT03862625 158 169 O
's NCT03862625 169 171 O
Cobb NCT03862625 172 176 B-Observation
angle NCT03862625 177 182 I-Observation
is NCT03862625 183 185 O
between NCT03862625 186 193 B-Eq-Comparison
10 NCT03862625 194 196 I-Eq-Comparison
- NCT03862625 197 198 I-Eq-Comparison
40 NCT03862625 199 201 I-Eq-Comparison
degrees NCT03862625 202 209 I-Eq-Comparison
. NCT03862625 209 210 O
( NCT03862625 212 213 O
Cobb NCT03862625 214 218 B-Observation
angle NCT03862625 219 224 I-Observation
above NCT03862625 225 230 B-Eq-Comparison
40 NCT03862625 231 233 I-Eq-Comparison
degrees NCT03862625 234 241 I-Eq-Comparison
and NCT03862625 242 245 B-Or
patients NCT03862625 246 254 O
whose NCT03862625 255 260 O
parents NCT03862625 261 268 B-Family-Member___Family-Member-Type:parent
have NCT03862625 269 273 O
not NCT03862625 274 277 B-Negation
accepted NCT03862625 278 286 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03862625 287 290 O
operation NCT03862625 291 300 B-Procedure
) NCT03862625 301 302 O

- NCT03862625 306 307 O
There NCT03862625 309 314 O
is NCT03862625 315 317 O
no NCT03862625 318 320 B-Negation
history NCT03862625 321 328 B-Eq-Comparison
of NCT03862625 329 331 O
operation NCT03862625 332 341 B-Procedure
due NCT03862625 342 345 O
to NCT03862625 346 348 O
scoliosis NCT03862625 349 358 B-Condition
or NCT03862625 359 361 B-Or
the NCT03862625 362 365 O
decision NCT03862625 366 374 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03862625 375 377 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03862625 378 381 O
operation NCT03862625 382 391 B-Procedure
has NCT03862625 392 395 O
not NCT03862625 396 399 B-Negation
been NCT03862625 400 404 O
accepted NCT03862625 405 413 B-Assertion___Assertion-Type-Value:hypothetical
by NCT03862625 414 416 O
the NCT03862625 417 420 O
patients NCT03862625 421 429 O
and NCT03862625 430 433 O
their NCT03862625 434 439 O
parents NCT03862625 440 447 B-Family-Member___Family-Member-Type:parent

- NCT03862625 450 451 O
the NCT03862625 453 456 O
participant NCT03862625 457 468 O
is NCT03862625 469 471 O
Gross NCT03862625 472 477 B-Observation
Motor NCT03862625 478 483 I-Observation
Function NCT03862625 484 492 I-Observation
Classification NCT03862625 493 507 I-Observation
System NCT03862625 508 514 I-Observation
Level NCT03862625 515 520 O
4 NCT03862625 521 522 B-Eq-Comparison
or NCT03862625 523 525 I-Eq-Comparison
5 NCT03862625 526 527 I-Eq-Comparison

- NCT03862625 531 532 O
Lack NCT03862625 534 538 B-Condition
of NCT03862625 539 541 I-Condition
contracture NCT03862625 542 553 I-Condition
to NCT03862625 554 556 O
prevent NCT03862625 557 564 B-Assertion___Assertion-Type-Value:hypothetical|Negation
sitting NCT03862625 565 572 B-Observation
in NCT03862625 573 575 O
the NCT03862625 576 579 O
lower NCT03862625 580 585 B-Modifier
extremity NCT03862625 586 595 I-Modifier

- NCT03862625 598 599 O
Parents NCT03862625 601 608 O
agree NCT03862625 609 614 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862625 615 617 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03862625 618 629 O
in NCT03862625 630 632 O
the NCT03862625 633 636 O
intensive NCT03862625 637 646 B-Modifier
therapy NCT03862625 647 654 B-Procedure
program NCT03862625 655 662 O
and NCT03862625 663 666 B-And
stop NCT03862625 667 671 B-Negation
the NCT03862625 672 675 O
therapeutic NCT03862625 676 687 B-Procedure
interventions NCT03862625 688 701 I-Procedure
for NCT03862625 702 705 O
scoliosis NCT03862625 706 715 B-Condition
and NCT03862625 716 719 B-Or
lower NCT03862625 720 725 B-Modifier
extremities NCT03862625 726 737 I-Modifier
during NCT03862625 738 744 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862625 745 748 O
3 NCT03862625 749 750 B-Eq-Comparison
- NCT03862625 751 752 I-Eq-Comparison
month NCT03862625 753 758 I-Eq-Comparison
follow NCT03862625 759 765 B-Encounter
- NCT03862625 766 767 I-Encounter
up NCT03862625 768 770 I-Encounter
period NCT03862625 771 777 O

Exclusion NCT03862625 778 787 O
Criteria NCT03862625 788 796 O
: NCT03862625 797 798 O

- NCT03862625 802 803 O
Having NCT03862625 805 811 O
a NCT03862625 812 813 O
history NCT03862625 814 821 B-Eq-Comparison
of NCT03862625 822 824 O
operation NCT03862625 825 834 B-Procedure
due NCT03862625 835 838 O
to NCT03862625 839 841 O
scoliosis NCT03862625 842 851 B-Condition

- NCT03862625 854 855 O
The NCT03862625 857 860 O
deformity NCT03862625 861 870 B-Condition
in NCT03862625 871 873 O
the NCT03862625 874 877 O
spine NCT03862625 878 883 B-Modifier
is NCT03862625 884 886 I-Modifier
rigid NCT03862625 887 892 I-Modifier

- NCT03862625 895 896 O
If NCT03862625 898 900 O
the NCT03862625 901 904 O
curvature NCT03862625 905 914 B-Observation
measured NCT03862625 915 923 O
in NCT03862625 924 926 O
the NCT03862625 927 930 O
spine NCT03862625 931 936 B-Modifier
is NCT03862625 937 939 O
less NCT03862625 940 944 B-Eq-Comparison
than NCT03862625 945 949 I-Eq-Comparison
10 NCT03862625 950 952 I-Eq-Comparison
degrees NCT03862625 953 960 I-Eq-Comparison
or NCT03862625 961 963 B-Or
more NCT03862625 964 968 B-Eq-Comparison
than NCT03862625 969 973 I-Eq-Comparison
40 NCT03862625 974 976 I-Eq-Comparison
degrees NCT03862625 977 984 I-Eq-Comparison
in NCT03862625 985 987 O
the NCT03862625 988 991 O
patients NCT03862625 992 1000 B-And
whose NCT03862625 1001 1006 I-And
operation NCT03862625 1007 1016 B-Procedure
decision NCT03862625 1017 1025 B-Assertion___Assertion-Type-Value:hypothetical
is NCT03862625 1026 1028 I-Assertion___Assertion-Type-Value:hypothetical
accepted NCT03862625 1029 1037 I-Assertion___Assertion-Type-Value:hypothetical
by NCT03862625 1038 1040 O
the NCT03862625 1041 1044 O
family NCT03862625 1045 1051 B-Family-Member

- NCT03862625 1054 1055 O
Having NCT03862625 1057 1063 O
a NCT03862625 1064 1065 O
seating NCT03862625 1066 1073 B-Condition
modification NCT03862625 1074 1086 I-Condition
applied NCT03862625 1087 1094 O
at NCT03862625 1095 1097 B-Eq-Comparison
least NCT03862625 1098 1103 I-Eq-Comparison
1 NCT03862625 1104 1105 I-Eq-Comparison
year NCT03862625 1106 1110 I-Eq-Comparison
before NCT03862625 1111 1117 B-Temporal-Connection___Temporal-Connection-Type-Value:before
being NCT03862625 1118 1123 O
included NCT03862625 1124 1132 O
in NCT03862625 1133 1135 O
the NCT03862625 1136 1139 O
study NCT03862625 1140 1145 B-Study

- NCT03862625 1148 1149 O
Having NCT03862625 1151 1157 O
a NCT03862625 1158 1159 O
spasticity NCT03862625 1160 1170 B-Condition
and NCT03862625 1171 1174 B-Or
contracture NCT03862625 1175 1186 B-Condition
to NCT03862625 1187 1189 O
prevent NCT03862625 1190 1197 B-Assertion___Assertion-Type-Value:hypothetical|Negation
sitting NCT03862625 1198 1205 B-Observation
in NCT03862625 1206 1208 O
the NCT03862625 1209 1212 O
hip NCT03862625 1213 1216 B-Modifier
and NCT03862625 1217 1220 B-And
knee NCT03862625 1221 1225 B-Modifier
joint NCT03862625 1226 1231 I-Modifier

- NCT03862625 1234 1235 O
Having NCT03862625 1237 1243 O
a NCT03862625 1244 1245 O
pressure NCT03862625 1246 1254 B-Condition
ulcer NCT03862625 1255 1260 I-Condition
to NCT03862625 1261 1263 O
prevent NCT03862625 1264 1271 B-Assertion___Assertion-Type-Value:hypothetical|Negation
the NCT03862625 1272 1275 O
patient NCT03862625 1276 1283 O
from NCT03862625 1284 1288 O
sitting NCT03862625 1289 1296 B-Observation

- NCT03862625 1299 1300 O
the NCT03862625 1302 1305 O
participant NCT03862625 1306 1317 O
has NCT03862625 1318 1321 O
comorbidity NCT03862625 1322 1333 B-Condition
that NCT03862625 1334 1338 O
is NCT03862625 1339 1341 O
not NCT03862625 1342 1345 B-Negation
related NCT03862625 1346 1353 O
about NCT03862625 1354 1359 O
cerebral NCT03862625 1360 1368 B-Condition
palsy NCT03862625 1369 1374 I-Condition

- NCT03862625 1377 1378 O
Having NCT03862625 1380 1386 O
epileptic NCT03862625 1387 1396 B-Condition
seizures NCT03862625 1397 1405 I-Condition
not NCT03862625 1406 1409 B-Negation
controlled NCT03862625 1410 1420 O

- NCT03862625 1423 1424 O
Having NCT03862625 1426 1432 O
bone NCT03862625 1433 1437 B-Procedure
operations NCT03862625 1438 1448 I-Procedure
for NCT03862625 1449 1452 O
hip NCT03862625 1453 1456 B-Modifier
joints NCT03862625 1457 1463 I-Modifier

Inclusion NCT03863275 0 9 O
Criteria NCT03863275 10 18 O
: NCT03863275 19 20 O

- NCT03863275 24 25 O
Boys NCT03863275 27 31 O
and NCT03863275 32 35 B-Or
girls NCT03863275 36 41 O
from NCT03863275 42 46 O
7 NCT03863275 47 48 B-Eq-Comparison
to NCT03863275 49 51 I-Eq-Comparison
12 NCT03863275 52 54 I-Eq-Comparison
years NCT03863275 55 60 I-Eq-Comparison
old NCT03863275 61 64 B-Age
with NCT03863275 65 69 B-And
class NCT03863275 70 75 B-Eq-Comparison
II NCT03863275 76 78 I-Eq-Comparison
skeletal NCT03863275 79 87 B-Condition
classification NCT03863275 88 102 I-Condition
attending NCT03863275 103 112 B-Encounter
a NCT03863275 113 114 O
consultation NCT03863275 115 127 O
in NCT03863275 128 130 O
the NCT03863275 131 134 O
dental NCT03863275 135 141 O
clinic NCT03863275 142 148 O
of NCT03863275 149 151 O
the NCT03863275 152 155 O
UNICIEO NCT03863275 156 163 O
foundation NCT03863275 164 174 O
, NCT03863275 175 176 O
to NCT03863275 177 179 B-Eq-Comparison
be NCT03863275 180 182 I-Eq-Comparison
fitted NCT03863275 183 189 O
with NCT03863275 190 194 O
myofunctional NCT03863275 195 208 B-Procedure
apparatus NCT03863275 209 218 I-Procedure
type NCT03863275 219 223 B-Modifier
Sn1 NCT03863275 224 227 I-Modifier

Exclusion NCT03863275 228 237 O
Criteria NCT03863275 238 246 O
: NCT03863275 247 248 O

- NCT03863275 252 253 O
Patients NCT03863275 255 263 O
who NCT03863275 264 267 O
have NCT03863275 268 272 O
had NCT03863275 273 276 O
previous NCT03863275 277 285 B-Eq-Comparison
orthopedic NCT03863275 286 296 B-Procedure
treatment NCT03863275 297 306 I-Procedure

- NCT03863275 309 310 O
Patients NCT03863275 312 320 O
with NCT03863275 321 325 O
signs NCT03863275 326 331 B-Assertion___Assertion-Type-Value:possible
of NCT03863275 332 334 O
condyle NCT03863275 335 342 B-Modifier
injuries NCT03863275 343 351 B-Condition

- NCT03863275 354 355 O
Patients NCT03863275 357 365 O
of NCT03863275 366 368 O
Pierre NCT03863275 369 375 B-Provider
Robin NCT03863275 376 381 I-Provider
or NCT03863275 382 384 B-Or
any NCT03863275 385 388 O
form NCT03863275 389 393 O
of NCT03863275 394 396 O
cleft NCT03863275 397 402 B-Condition

- NCT03863275 405 406 O
Patients NCT03863275 408 416 O
with NCT03863275 417 421 O
syndromes NCT03863275 422 431 B-Condition
that NCT03863275 432 436 O
associate NCT03863275 437 446 O
craniofacial NCT03863275 447 459 B-Condition
anomalies NCT03863275 460 469 I-Condition
and NCT03863275 470 473 B-Or
muscle NCT03863275 474 480 B-Condition
alterations NCT03863275 481 492 I-Condition
. NCT03863275 492 493 O

Inclusion NCT03861884 0 9 O
Criteria NCT03861884 10 18 O
: NCT03861884 19 20 O

1 NCT03861884 24 25 O
. NCT03861884 25 26 O
Ability NCT03861884 28 35 O
to NCT03861884 36 38 O
give NCT03861884 39 43 O
informed NCT03861884 44 52 O
consent NCT03861884 53 60 O
. NCT03861884 61 62 O

2 NCT03861884 66 67 O
. NCT03861884 67 68 O
Either NCT03861884 70 76 O
pathological NCT03861884 77 89 B-Procedure
, NCT03861884 90 91 O
genetic NCT03861884 92 99 B-Procedure
or NCT03861884 100 102 B-Or
imaging NCT03861884 103 110 B-Procedure
biomarker NCT03861884 111 120 O
evidence NCT03861884 121 129 O
to NCT03861884 130 132 O
suggest NCT03861884 133 140 O
Fronto NCT03861884 141 147 B-Condition
- NCT03861884 148 149 I-Condition
temporal NCT03861884 150 158 I-Condition
Lobar NCT03861884 159 164 I-Condition
Degeneration NCT03861884 165 177 I-Condition
, NCT03861884 178 179 O
Alzheimer NCT03861884 180 189 B-Condition
's NCT03861884 189 191 I-Condition
Disease NCT03861884 192 199 I-Condition
or NCT03861884 200 202 B-Or
Vascular NCT03861884 203 211 B-Modifier
Cognitive NCT03861884 212 221 B-Condition
Impairment NCT03861884 222 232 I-Condition
, NCT03861884 233 234 O
or NCT03861884 235 237 O
defined NCT03861884 238 245 O
clinical NCT03861884 246 254 O
diagnoses NCT03861884 255 264 O
. NCT03861884 265 266 O

Exclusion NCT03861884 268 277 O
Criteria NCT03861884 278 286 O
: NCT03861884 287 288 O

1 NCT03861884 292 293 O
. NCT03861884 293 294 O
Lack NCT03861884 296 300 B-Condition
of NCT03861884 301 303 I-Condition
mental NCT03861884 304 310 I-Condition
capacity NCT03861884 311 319 I-Condition
to NCT03861884 320 322 O
consent NCT03861884 323 330 O
to NCT03861884 331 333 O
study NCT03861884 334 339 O
involvement NCT03861884 340 351 O
. NCT03861884 352 353 O

2 NCT03861884 357 358 O
. NCT03861884 358 359 O
Not NCT03861884 361 364 B-Negation
speaking NCT03861884 365 373 O
English NCT03861884 374 381 O
before NCT03861884 382 388 B-Temporal-Connection___Temporal-Connection-Type-Value:before
age NCT03861884 389 392 B-Age
5 NCT03861884 393 394 B-Eq-Comparison
years NCT03861884 395 400 I-Eq-Comparison
. NCT03861884 401 402 O

3 NCT03861884 406 407 O
. NCT03861884 407 408 O
Learning NCT03861884 410 418 B-Condition
disability NCT03861884 419 429 I-Condition
. NCT03861884 430 431 O

4 NCT03861884 435 436 O
. NCT03861884 436 437 O
MRI NCT03861884 439 442 B-Procedure
contraindications NCT03861884 443 460 B-Contraindication

Inclusion NCT03866655 0 9 O
Criteria NCT03866655 10 18 O
: NCT03866655 19 20 O

- NCT03866655 24 25 O
female NCT03866655 27 33 O

- NCT03866655 36 37 O
adult NCT03866655 39 44 O
( NCT03866655 45 46 O
age NCT03866655 47 50 B-Age
18 NCT03866655 51 53 B-Eq-Comparison
years NCT03866655 54 59 I-Eq-Comparison
or NCT03866655 60 62 I-Eq-Comparison
over NCT03866655 63 67 I-Eq-Comparison
) NCT03866655 68 69 O

- NCT03866655 73 74 O
newly NCT03866655 76 81 B-Eq-Comparison
diagnosed NCT03866655 82 91 B-Coreference

- NCT03866655 94 95 O
early NCT03866655 97 102 B-Modifier
breast NCT03866655 103 109 I-Modifier
cancer NCT03866655 110 116 B-Condition

- NCT03866655 119 120 O
first NCT03866655 122 127 B-Eq-Comparison
primary NCT03866655 128 135 B-Modifier
cancer NCT03866655 136 142 B-Condition
diagnosis NCT03866655 143 152 O

- NCT03866655 155 156 O
under NCT03866655 158 163 B-Eq-Comparison
treatment NCT03866655 164 173 B-Procedure
at NCT03866655 174 176 O
one NCT03866655 177 180 O
of NCT03866655 181 183 O
the NCT03866655 184 187 O
participating NCT03866655 188 201 O
sites NCT03866655 202 207 O
. NCT03866655 208 209 O

Exclusion NCT03866655 211 220 O
Criteria NCT03866655 221 229 O
: NCT03866655 230 231 O

- NCT03866655 235 236 O
have NCT03866655 238 242 O
started NCT03866655 243 250 B-Eq-Comparison
anti NCT03866655 251 255 O
- NCT03866655 256 257 O
cancer NCT03866655 258 264 B-Condition
treatment NCT03866655 265 274 B-Procedure

- NCT03866655 277 278 O
private NCT03866655 280 287 O
patients NCT03866655 288 296 O

- NCT03866655 299 300 O
unable NCT03866655 302 308 B-Negation
to NCT03866655 309 311 O
read NCT03866655 312 316 O
or NCT03866655 317 319 O
write NCT03866655 320 325 O
in NCT03866655 326 328 O
English NCT03866655 329 336 O

- NCT03866655 339 340 O
significant NCT03866655 342 353 O
cognitive NCT03866655 354 363 B-Condition
impairment NCT03866655 364 374 I-Condition

- NCT03866655 377 378 O
poor NCT03866655 380 384 B-Condition
mental NCT03866655 385 391 I-Condition
health NCT03866655 392 398 I-Condition

- NCT03866655 401 402 O
do NCT03866655 404 406 O
not NCT03866655 407 410 O
have NCT03866655 411 415 O
access NCT03866655 416 422 O
to NCT03866655 423 425 O
the NCT03866655 426 429 O
internet NCT03866655 430 438 O

- NCT03866655 441 442 O
confirmed NCT03866655 444 453 O
metastatic NCT03866655 454 464 B-Condition
disease NCT03866655 465 472 I-Condition

Inclusion NCT03864718 0 9 O
Criteria NCT03864718 10 18 O
: NCT03864718 19 20 O

- NCT03864718 24 25 O
complex NCT03864718 27 34 B-Modifier
anal NCT03864718 35 39 B-Condition
fistula NCT03864718 40 47 I-Condition
according NCT03864718 48 57 O
to NCT03864718 58 60 O
Parks NCT03864718 61 66 O
classification NCT03864718 67 81 O

Exclusion NCT03864718 82 91 O
Criteria NCT03864718 92 100 O
: NCT03864718 101 102 O

- NCT03864718 106 107 O
Non NCT03864718 109 112 B-Negation
cryptoglandular NCT03864718 113 128 B-Condition
fistulas NCT03864718 129 137 I-Condition

- NCT03864718 140 141 O
acute NCT03864718 143 148 O
sepsis NCT03864718 149 155 B-Condition

- NCT03864718 158 159 O
inflammatory NCT03864718 161 173 B-Condition
bowel NCT03864718 174 179 I-Condition
diseases NCT03864718 180 188 I-Condition

- NCT03864718 191 192 O
simple NCT03864718 194 200 B-Condition
fistulas NCT03864718 201 209 I-Condition
( NCT03864718 210 211 O
defined NCT03864718 212 219 O
as NCT03864718 220 222 O
subcutaneous NCT03864718 223 235 B-Modifier
, NCT03864718 236 237 O
intersphincteric NCT03864718 238 254 B-Modifier
and NCT03864718 255 258 B-Or
low NCT03864718 259 262 B-Modifier
transsphincteric NCT03864718 263 279 I-Modifier
fistula NCT03864718 280 287 B-Condition
) NCT03864718 288 289 O

- NCT03864718 293 294 O
pregnant NCT03864718 296 304 B-Condition
patients NCT03864718 305 313 O

- NCT03864718 316 317 O
ASA NCT03864718 319 322 B-Condition
IV NCT03864718 323 325 B-Eq-Comparison

- NCT03864718 328 329 O
patients NCT03864718 331 339 B-Age
< NCT03864718 340 341 B-Eq-Comparison
18 NCT03864718 342 344 I-Eq-Comparison

- NCT03864718 348 349 O
immunocompromised NCT03864718 351 368 B-Condition

- NCT03864718 371 372 O
patients NCT03864718 374 382 O
who NCT03864718 383 386 O
refused NCT03864718 387 394 O
consent NCT03864718 395 402 O
. NCT03864718 402 403 O

Inclusion NCT03868644 0 9 O
Criteria NCT03868644 10 18 O
: NCT03868644 19 20 O

- NCT03868644 23 24 O
Youth NCT03868644 25 30 O
previously NCT03868644 31 41 B-Eq-Comparison
participated NCT03868644 42 54 O
in NCT03868644 55 57 O
an NCT03868644 58 60 O
earlier NCT03868644 61 68 O
study NCT03868644 69 74 B-Study
by NCT03868644 75 77 O
Duflo NCT03868644 78 83 O
, NCT03868644 84 85 O
Dupas NCT03868644 86 91 O
and NCT03868644 92 95 O
Kremer NCT03868644 96 102 O
in NCT03868644 103 105 O
328 NCT03868644 106 109 O
primary NCT03868644 110 117 O
schools NCT03868644 118 125 O
in NCT03868644 126 128 O
the NCT03868644 129 132 O
same NCT03868644 133 137 O
study NCT03868644 138 143 O
site NCT03868644 144 148 O
in NCT03868644 149 151 O
Western NCT03868644 152 159 O
Province NCT03868644 160 168 O
, NCT03868644 169 170 O
Kenya NCT03868644 171 176 O
who NCT03868644 177 180 O
consent NCT03868644 181 188 O
to NCT03868644 189 191 O

participate NCT03868644 192 203 O
. NCT03868644 204 205 O

Exclusion NCT03868644 207 216 O
Criteria NCT03868644 217 225 O
: NCT03868644 226 227 O

- NCT03868644 230 231 O
Youth NCT03868644 232 237 O
sampled NCT03868644 238 245 O
for NCT03868644 246 249 O
the NCT03868644 250 253 O
study NCT03868644 254 259 O
who NCT03868644 260 263 O
do NCT03868644 264 266 O
not NCT03868644 267 270 O
consent NCT03868644 271 278 O
to NCT03868644 279 281 O
participate NCT03868644 282 293 O
. NCT03868644 293 294 O

Inclusion NCT03863847 0 9 O
Criteria NCT03863847 10 18 O
: NCT03863847 19 20 O

- NCT03863847 24 25 O
Patients NCT03863847 27 35 O
suffering NCT03863847 36 45 O
from NCT03863847 46 50 O
chronic NCT03863847 51 58 B-Modifier
pain NCT03863847 59 63 B-Condition
due NCT03863847 64 67 O
to NCT03863847 68 70 O
tennis NCT03863847 71 77 B-Condition
elbow NCT03863847 78 83 I-Condition
for NCT03863847 84 87 O
at NCT03863847 88 90 B-Eq-Comparison
least NCT03863847 91 96 I-Eq-Comparison
3 NCT03863847 97 98 I-Eq-Comparison
months NCT03863847 99 105 I-Eq-Comparison

- NCT03863847 108 109 O
A NCT03863847 111 112 O
clinical NCT03863847 113 121 O
diagnosis NCT03863847 122 131 O
of NCT03863847 132 134 O
chronic NCT03863847 135 142 B-Modifier
lateral NCT03863847 143 150 B-Condition
epicondylalgia NCT03863847 151 165 I-Condition
, NCT03863847 166 167 O

- NCT03863847 171 172 O
Pain NCT03863847 174 178 B-Condition
associated NCT03863847 179 189 O
with NCT03863847 190 194 O
functional NCT03863847 195 205 B-Observation
activities NCT03863847 206 216 I-Observation
such NCT03863847 217 221 O
as NCT03863847 222 224 O
gripping NCT03863847 225 233 B-Observation
and NCT03863847 234 237 B-Or
pain NCT03863847 238 242 B-Condition
with NCT03863847 243 247 O
resisted NCT03863847 248 256 B-Observation
contraction NCT03863847 257 268 I-Observation
of NCT03863847 269 271 O
the NCT03863847 272 275 O
wrist NCT03863847 276 281 B-Modifier
extensors NCT03863847 282 291 I-Modifier
or NCT03863847 292 294 B-Or
extensor NCT03863847 295 303 B-Modifier
carpi NCT03863847 304 309 I-Modifier
radialis NCT03863847 310 318 B-Condition
brevis NCT03863847 319 325 I-Condition
, NCT03863847 326 327 O
or NCT03863847 328 330 B-Or
with NCT03863847 331 335 O
passive NCT03863847 336 343 B-Observation
stretching NCT03863847 344 354 I-Observation
of NCT03863847 355 357 O
the NCT03863847 358 361 O
wrist NCT03863847 362 367 B-Modifier
extensors NCT03863847 368 377 I-Modifier
. NCT03863847 378 379 O

Exclusion NCT03863847 381 390 O
Criteria NCT03863847 391 399 O
: NCT03863847 400 401 O

- NCT03863847 405 406 O
Clinical NCT03863847 408 416 O
diagnosis NCT03863847 417 426 O
of NCT03863847 427 429 O
chronic NCT03863847 430 437 B-Modifier
lateral NCT03863847 438 445 B-Condition
epicondylalgia NCT03863847 446 460 I-Condition
on NCT03863847 461 463 O
both NCT03863847 464 468 B-Modifier
sides NCT03863847 469 474 I-Modifier
, NCT03863847 475 476 O
cervicothoracic NCT03863847 477 492 B-Modifier
spinal NCT03863847 493 499 I-Modifier
pathology NCT03863847 500 509 B-Condition
, NCT03863847 510 511 O
other NCT03863847 512 517 B-Other
upper NCT03863847 518 523 B-Modifier
limb NCT03863847 524 528 I-Modifier
musculoskeletal NCT03863847 529 544 B-Condition
disorders NCT03863847 545 554 I-Condition
or NCT03863847 555 557 B-Or
neurological NCT03863847 558 570 B-Condition
disorders NCT03863847 571 580 I-Condition

- NCT03863847 583 584 O
Pregnancy NCT03863847 586 595 B-Condition

- NCT03863847 598 599 O
Drug NCT03863847 601 605 B-Condition
addiction NCT03863847 606 615 I-Condition
defined NCT03863847 616 623 O
as NCT03863847 624 626 O
the NCT03863847 627 630 O
use NCT03863847 631 634 O
of NCT03863847 635 637 O
cannabis NCT03863847 638 646 B-Drug
, NCT03863847 647 648 O
opioids NCT03863847 649 656 B-Drug
or NCT03863847 657 659 B-Or
other NCT03863847 660 665 B-Other
drugs NCT03863847 666 671 B-Drug

- NCT03863847 674 675 O
Previous NCT03863847 677 685 B-Eq-Comparison
or NCT03863847 686 688 B-Or
current NCT03863847 689 696 B-Eq-Comparison
neurologic NCT03863847 697 707 B-Modifier
, NCT03863847 708 709 O
musculoskeletal NCT03863847 710 725 B-Modifier
or NCT03863847 726 728 B-Or
mental NCT03863847 729 735 B-Modifier
illnesses NCT03863847 736 745 B-Condition
defined NCT03863847 746 753 O
as NCT03863847 754 756 O
an NCT03863847 757 759 O
on NCT03863847 760 762 B-Eq-Comparison
- NCT03863847 763 764 I-Eq-Comparison
going NCT03863847 765 770 I-Eq-Comparison
systemic NCT03863847 771 779 B-Modifier
condition NCT03863847 780 789 B-Condition

- NCT03863847 792 793 O
Lack NCT03863847 795 799 B-Negation
of NCT03863847 800 802 O
ability NCT03863847 803 810 B-Condition
to NCT03863847 811 813 I-Condition
cooperate NCT03863847 814 823 I-Condition

- NCT03863847 826 827 O
Current NCT03863847 829 836 B-Eq-Comparison
use NCT03863847 837 840 O
of NCT03863847 841 843 O
medications NCT03863847 844 855 B-Drug
that NCT03863847 856 860 O
may NCT03863847 861 864 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03863847 865 871 O
the NCT03863847 872 875 O
trial NCT03863847 876 881 B-Study
e. NCT03863847 882 884 O
g. NCT03863847 885 887 O
analgesics NCT03863847 889 899 B-Drug
, NCT03863847 900 901 O
anti NCT03863847 902 906 B-Drug
- NCT03863847 907 908 I-Drug
inflammatory NCT03863847 909 921 I-Drug
drugs NCT03863847 922 927 I-Drug

- NCT03863847 930 931 O
Consumption NCT03863847 933 944 O
of NCT03863847 945 947 O
alcohol NCT03863847 948 955 B-Drug
, NCT03863847 956 957 O
caffeine NCT03863847 958 966 B-Drug
, NCT03863847 967 968 O
nicotine NCT03863847 969 977 B-Drug
or NCT03863847 978 980 B-Or
painkillers NCT03863847 981 992 B-Drug
throughout NCT03863847 993 1003 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863847 1004 1007 O
study NCT03863847 1008 1013 B-Study
period NCT03863847 1014 1020 O

- NCT03863847 1023 1024 O
Past NCT03863847 1026 1030 B-Eq-Comparison
history NCT03863847 1031 1038 I-Eq-Comparison
of NCT03863847 1039 1041 O
chronic NCT03863847 1042 1049 B-Modifier
pain NCT03863847 1050 1054 B-Condition
, NCT03863847 1055 1056 O
neurological NCT03863847 1057 1069 B-Modifier
or NCT03863847 1070 1072 B-Or
psychiatric NCT03863847 1073 1084 B-Modifier
conditions NCT03863847 1085 1095 B-Condition

- NCT03863847 1098 1099 O
Participation NCT03863847 1101 1114 O
in NCT03863847 1115 1117 O
other NCT03863847 1118 1123 B-Other
pain NCT03863847 1124 1128 B-Condition
trials NCT03863847 1129 1135 B-Study
throughout NCT03863847 1136 1146 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03863847 1147 1150 O
study NCT03863847 1151 1156 B-Study
period NCT03863847 1157 1163 O
and NCT03863847 1164 1167 B-Or
one NCT03863847 1168 1171 B-Eq-Comparison
month NCT03863847 1172 1177 I-Eq-Comparison
prior NCT03863847 1178 1183 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03863847 1184 1186 I-Temporal-Connection___Temporal-Connection-Type-Value:before
participation NCT03863847 1187 1200 B-Study

- NCT03863847 1203 1204 O
Participation NCT03863847 1206 1219 O
in NCT03863847 1220 1222 O
more NCT03863847 1223 1227 B-Eq-Comparison
than NCT03863847 1228 1232 I-Eq-Comparison
two NCT03863847 1233 1236 I-Eq-Comparison
sessions NCT03863847 1237 1245 O
of NCT03863847 1246 1248 O
muscle NCT03863847 1249 1255 B-Observation
training NCT03863847 1256 1264 I-Observation
exercises NCT03863847 1265 1274 B-Eq-Comparison
per NCT03863847 1275 1278 I-Eq-Comparison
week NCT03863847 1279 1283 I-Eq-Comparison
involving NCT03863847 1284 1293 O
the NCT03863847 1294 1297 O
upper NCT03863847 1298 1303 B-Modifier
limb NCT03863847 1304 1308 I-Modifier
and NCT03863847 1309 1312 B-Or
/ NCT03863847 1313 1314 I-Or
or NCT03863847 1315 1317 I-Or
lower NCT03863847 1318 1323 B-Modifier
back NCT03863847 1324 1328 I-Modifier

- NCT03863847 1331 1332 O
Evidence NCT03863847 1334 1342 O
of NCT03863847 1343 1345 O
other NCT03863847 1346 1351 B-Other
sources NCT03863847 1352 1359 O
of NCT03863847 1360 1362 O
elbow NCT03863847 1363 1368 B-Modifier
pain NCT03863847 1369 1373 B-Condition
such NCT03863847 1374 1378 O
as NCT03863847 1379 1381 O
exacerbation NCT03863847 1382 1394 O
of NCT03863847 1395 1397 O
pain NCT03863847 1398 1402 B-Condition
with NCT03863847 1403 1407 O
neck NCT03863847 1408 1412 B-Observation
movement NCT03863847 1413 1421 I-Observation
or NCT03863847 1422 1424 B-Or
manual NCT03863847 1425 1431 B-Modifier
examination NCT03863847 1432 1443 B-Procedure

- NCT03863847 1446 1447 O
Sensory NCT03863847 1449 1456 B-Condition
disturbances NCT03863847 1457 1469 I-Condition

- NCT03863847 1472 1473 O
History NCT03863847 1475 1482 B-Eq-Comparison
of NCT03863847 1483 1485 O
fractures NCT03863847 1486 1495 B-Condition

- NCT03863847 1498 1499 O
Elbow NCT03863847 1501 1506 B-Procedure
surgery NCT03863847 1507 1514 I-Procedure

- NCT03863847 1517 1518 O
Contraindications NCT03863847 1520 1537 B-Contraindication
to NCT03863847 1538 1540 O
the NCT03863847 1541 1544 O
use NCT03863847 1545 1548 O
of NCT03863847 1549 1551 O
TMS NCT03863847 1552 1555 B-Procedure

Inclusion NCT03868735 0 9 O
Criteria NCT03868735 10 18 O
: NCT03868735 19 20 O

- NCT03868735 24 25 O
Orally NCT03868735 27 33 B-Modifier
intubated NCT03868735 34 43 B-Procedure
patient NCT03868735 44 51 O
with NCT03868735 52 56 O
endotracheal NCT03868735 57 69 B-Procedure
tube NCT03868735 70 74 I-Procedure

- NCT03868735 77 78 O
Mechanically NCT03868735 80 92 B-Procedure
ventilated NCT03868735 93 103 I-Procedure
less NCT03868735 104 108 B-Eq-Comparison
than NCT03868735 109 113 I-Eq-Comparison
24 NCT03868735 114 116 I-Eq-Comparison
hours NCT03868735 117 122 I-Eq-Comparison
prior NCT03868735 123 128 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03868735 129 131 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03868735 132 142 B-Study

Exclusion NCT03868735 143 152 O
Criteria NCT03868735 153 161 O
: NCT03868735 162 163 O

- NCT03868735 167 168 O
Less NCT03868735 170 174 B-Eq-Comparison
than NCT03868735 175 179 I-Eq-Comparison
18 NCT03868735 180 182 I-Eq-Comparison
years NCT03868735 183 188 I-Eq-Comparison
old NCT03868735 189 192 B-Age

- NCT03868735 195 196 O
Tracheostomy NCT03868735 198 210 B-Procedure
tube NCT03868735 211 215 I-Procedure

- NCT03868735 218 219 O
Extracorporeal NCT03868735 221 235 B-Procedure
membrane NCT03868735 236 244 I-Procedure
oxygenation NCT03868735 245 256 I-Procedure

- NCT03868735 259 260 O
Transfer NCT03868735 262 270 B-Encounter
from NCT03868735 271 275 O
outside NCT03868735 276 283 B-Other
hospital NCT03868735 284 292 O
with NCT03868735 293 297 B-Temporal-Connection___Temporal-Connection-Type-Value:during
more NCT03868735 298 302 B-Eq-Comparison
than NCT03868735 303 307 I-Eq-Comparison
24 NCT03868735 308 310 I-Eq-Comparison
hours NCT03868735 311 316 I-Eq-Comparison
of NCT03868735 317 319 O
mechanical NCT03868735 320 330 B-Procedure
ventilation NCT03868735 331 342 I-Procedure

Inclusion NCT03869359 0 9 O
Criteria NCT03869359 10 18 O
: NCT03869359 19 20 O

- NCT03869359 24 25 O
Adult NCT03869359 27 32 O
patients NCT03869359 33 41 O
with NCT03869359 42 46 B-And
IBS NCT03869359 47 50 B-Condition
according NCT03869359 51 60 O
to NCT03869359 61 63 O
Rome NCT03869359 64 68 O
IV NCT03869359 69 71 O
criteria NCT03869359 72 80 O

Exclusion NCT03869359 81 90 O
Criteria NCT03869359 91 99 O
: NCT03869359 100 101 O

- NCT03869359 105 106 O
allergy NCT03869359 108 115 B-Allergy
or NCT03869359 116 118 B-Or
documented NCT03869359 119 129 O
intolerance NCT03869359 130 141 B-Condition
to NCT03869359 142 144 O
food NCT03869359 145 149 B-Modifier
, NCT03869359 150 151 O

- NCT03869359 155 156 O
severe NCT03869359 158 164 O
cardiovascular NCT03869359 165 179 B-Modifier
, NCT03869359 180 181 O
hepatic NCT03869359 182 189 B-Modifier
, NCT03869359 190 191 O
neurological NCT03869359 192 204 B-Modifier
or NCT03869359 205 207 B-Or
psychiatric NCT03869359 208 219 B-Modifier
disease NCT03869359 220 227 B-Condition

- NCT03869359 230 231 O
serious NCT03869359 233 240 O
gastrointestinal NCT03869359 241 257 B-Condition
disease NCT03869359 258 265 I-Condition
: NCT03869359 266 267 O
including NCT03869359 268 277 O
celiac NCT03869359 278 284 B-Condition
disease NCT03869359 285 292 I-Condition
and NCT03869359 293 296 B-Or
inflammatory NCT03869359 297 309 B-Condition
bowel NCT03869359 310 315 I-Condition
diseases NCT03869359 316 324 I-Condition
( NCT03869359 325 326 O
IBD NCT03869359 327 330 B-Condition
) NCT03869359 331 332 O
, NCT03869359 334 335 O

- NCT03869359 339 340 O
diabetes NCT03869359 342 350 B-Condition

- NCT03869359 353 354 O
bowel NCT03869359 356 361 B-Condition
dysfunction NCT03869359 362 373 I-Condition
related NCT03869359 374 381 O
to NCT03869359 382 384 O
previous NCT03869359 385 393 B-Eq-Comparison
surgery NCT03869359 394 401 B-Procedure

- NCT03869359 404 405 O
pregnant NCT03869359 407 415 B-Condition
or NCT03869359 416 418 B-Or
lactating NCT03869359 419 428 B-Condition
women NCT03869359 429 434 O

- NCT03869359 437 438 O
usage NCT03869359 440 445 O
of NCT03869359 446 448 O
antibiotics NCT03869359 449 460 B-Drug
within NCT03869359 461 467 B-Eq-Comparison
4 NCT03869359 468 469 I-Eq-Comparison
weeks NCT03869359 470 475 I-Eq-Comparison
before NCT03869359 476 482 B-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03869359 483 492 B-Study

- NCT03869359 495 496 O
strict NCT03869359 498 504 O
avoidance NCT03869359 505 514 O
of NCT03869359 515 517 O
foods NCT03869359 518 523 O

Inclusion NCT03864133 0 9 O
Criteria NCT03864133 10 18 O
: NCT03864133 19 20 O

- NCT03864133 24 25 O
Adults NCT03864133 27 33 O
age NCT03864133 34 37 B-Age
55 NCT03864133 38 40 B-Eq-Comparison
- NCT03864133 41 42 I-Eq-Comparison
90 NCT03864133 43 45 I-Eq-Comparison
years NCT03864133 46 51 I-Eq-Comparison
with NCT03864133 52 56 B-And
visual NCT03864133 57 63 B-Modifier
significant NCT03864133 64 75 O
cataracts NCT03864133 76 85 B-Condition
in NCT03864133 86 88 O
one NCT03864133 89 92 B-Modifier
or NCT03864133 93 95 B-Or
both NCT03864133 96 100 B-Modifier
eyes NCT03864133 101 105 I-Modifier
. NCT03864133 106 107 O

- NCT03864133 111 112 O
Healthy NCT03864133 114 121 B-Condition
individuals NCT03864133 122 133 O
able NCT03864133 134 138 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864133 139 141 I-Assertion___Assertion-Type-Value:hypothetical
tolerate NCT03864133 142 150 O
outpatient NCT03864133 151 161 B-Encounter
cataract NCT03864133 162 170 B-Procedure
surgery NCT03864133 171 178 I-Procedure
under NCT03864133 179 184 O
local NCT03864133 185 190 B-Procedure
anesthesia NCT03864133 191 201 I-Procedure
via NCT03864133 202 205 O
either NCT03864133 206 212 O
phacoemulsification NCT03864133 213 232 B-Procedure
and NCT03864133 233 236 B-Or
/ NCT03864133 237 238 I-Or
or NCT03864133 239 241 I-Or
femtosecond NCT03864133 242 253 B-Modifier
assisted NCT03864133 254 262 I-Modifier
cataract NCT03864133 263 271 B-Procedure
surgery NCT03864133 272 279 I-Procedure
. NCT03864133 279 280 O
Well NCT03864133 282 286 O
- NCT03864133 287 288 O
controlled NCT03864133 289 299 O
diabetes NCT03864133 300 308 B-Condition
, NCT03864133 309 310 O
hypertension NCT03864133 311 323 B-Condition
will NCT03864133 324 328 O
be NCT03864133 329 331 O
included NCT03864133 332 340 O
. NCT03864133 341 342 O

- NCT03864133 346 347 O
Females NCT03864133 349 356 O
of NCT03864133 357 359 O
childbearing NCT03864133 360 372 B-Condition
potential NCT03864133 373 382 B-Assertion___Assertion-Type-Value:hypothetical
must NCT03864133 383 387 O
agree NCT03864133 388 393 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03864133 394 396 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03864133 397 400 O
a NCT03864133 401 402 O
reliable NCT03864133 403 411 O
method NCT03864133 412 418 O
of NCT03864133 419 421 O
birth NCT03864133 422 427 B-Procedure
control NCT03864133 428 435 I-Procedure
while NCT03864133 436 441 B-Temporal-Connection___Temporal-Connection-Type-Value:during
participating NCT03864133 442 455 O
in NCT03864133 456 458 O
this NCT03864133 459 463 O
study NCT03864133 464 469 B-Study
. NCT03864133 469 470 O
Reliable NCT03864133 472 480 O
methods NCT03864133 481 488 O
of NCT03864133 489 491 O
birth NCT03864133 492 497 B-Procedure
control NCT03864133 498 505 I-Procedure
are NCT03864133 506 509 O
: NCT03864133 510 511 O
abstinence NCT03864133 512 522 B-Condition
, NCT03864133 523 524 O
oral NCT03864133 525 529 B-Drug
contraceptives NCT03864133 530 544 I-Drug
, NCT03864133 545 546 O
intrauterine NCT03864133 547 559 B-Procedure
device NCT03864133 560 566 I-Procedure
( NCT03864133 567 568 O
IUD NCT03864133 569 572 B-Procedure
) NCT03864133 573 574 O
, NCT03864133 576 577 O
DepoProvera NCT03864133 578 589 B-Procedure
, NCT03864133 590 591 O
tubal NCT03864133 592 597 B-Procedure
ligation NCT03864133 598 606 I-Procedure
or NCT03864133 607 609 B-Or
vasectomy NCT03864133 610 619 B-Procedure
of NCT03864133 620 622 O
the NCT03864133 623 626 O
partner NCT03864133 627 634 O
( NCT03864133 635 636 O
with NCT03864133 637 641 B-And
confirmed NCT03864133 642 651 O
negative NCT03864133 652 660 O
sperm NCT03864133 661 666 B-Observation
counts NCT03864133 667 673 I-Observation
) NCT03864133 674 675 O
in NCT03864133 676 678 B-And
monogamous NCT03864133 679 689 B-Condition
relationship NCT03864133 690 702 I-Condition
( NCT03864133 703 704 O
same NCT03864133 705 709 O
partner NCT03864133 710 717 O
) NCT03864133 718 719 O
. NCT03864133 720 721 O
An NCT03864133 723 725 O
acceptable NCT03864133 726 736 O
, NCT03864133 737 738 O
although NCT03864133 739 747 O
less NCT03864133 748 752 O
reliable NCT03864133 753 761 O
, NCT03864133 762 763 O
method NCT03864133 764 770 O
involves NCT03864133 771 779 O
the NCT03864133 780 783 O
careful NCT03864133 784 791 O
use NCT03864133 792 795 O
of NCT03864133 796 798 O
condoms NCT03864133 799 806 B-Procedure
and NCT03864133 807 810 B-Or
spermicidal NCT03864133 811 822 B-Procedure
foam NCT03864133 823 827 B-Modifier
or NCT03864133 828 830 B-Or
gel NCT03864133 831 834 B-Modifier
and NCT03864133 835 838 B-Or
/ NCT03864133 839 840 I-Or
or NCT03864133 841 843 I-Or
cervical NCT03864133 844 852 B-Procedure
cap NCT03864133 853 856 B-Modifier
or NCT03864133 857 859 B-Or
sponge NCT03864133 860 866 B-Modifier
. NCT03864133 866 867 O
A NCT03864133 869 870 O
pregnancy NCT03864133 871 880 B-Observation
test NCT03864133 881 885 I-Observation
is NCT03864133 886 888 B-Assertion___Assertion-Type-Value:hypothetical
required NCT03864133 889 897 I-Assertion___Assertion-Type-Value:hypothetical
at NCT03864133 898 900 B-Eq-Comparison
least NCT03864133 901 906 I-Eq-Comparison
10 NCT03864133 907 909 I-Eq-Comparison
days NCT03864133 910 914 I-Eq-Comparison
from NCT03864133 915 919 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03864133 920 923 O
last NCT03864133 924 928 B-Eq-Comparison
normal NCT03864133 929 935 O
menstrual NCT03864133 936 945 B-Condition
period NCT03864133 946 952 I-Condition
, NCT03864133 953 954 O
if NCT03864133 955 957 O
the NCT03864133 958 961 O
patient NCT03864133 962 969 O
is NCT03864133 970 972 O
a NCT03864133 973 974 O
sexually NCT03864133 975 983 B-Condition
active NCT03864133 984 990 I-Condition
female NCT03864133 991 997 O
of NCT03864133 998 1000 B-And
childbearing NCT03864133 1001 1013 B-Condition
potential NCT03864133 1014 1023 I-Condition
. NCT03864133 1024 1025 O

Exclusion NCT03864133 1027 1036 O
Criteria NCT03864133 1037 1045 O
: NCT03864133 1046 1047 O

- NCT03864133 1051 1052 O
Allergy NCT03864133 1054 1061 B-Allergy
to NCT03864133 1062 1064 O
Phenylephrine NCT03864133 1065 1078 B-Drug
or NCT03864133 1079 1081 B-Or
NSAIDs NCT03864133 1082 1088 B-Drug
. NCT03864133 1089 1090 O

- NCT03864133 1094 1095 O
Inability NCT03864133 1097 1106 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864133 1107 1109 O
sit NCT03864133 1110 1113 B-Observation
steady NCT03864133 1114 1120 B-Modifier
and NCT03864133 1121 1124 B-And
upright NCT03864133 1125 1132 B-Modifier
for NCT03864133 1133 1136 O
the NCT03864133 1137 1140 O
Optical NCT03864133 1141 1148 B-Procedure
Coherence NCT03864133 1149 1158 I-Procedure
Tomography NCT03864133 1159 1169 I-Procedure
( NCT03864133 1170 1171 O
OCT NCT03864133 1172 1175 B-Procedure
) NCT03864133 1176 1177 O
. NCT03864133 1179 1180 O

- NCT03864133 1184 1185 O
Complications NCT03864133 1187 1200 B-Condition
during NCT03864133 1201 1207 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgery NCT03864133 1208 1215 B-Procedure
, NCT03864133 1216 1217 O
including NCT03864133 1218 1227 O
posterior NCT03864133 1228 1237 B-Modifier
capsular NCT03864133 1238 1246 B-Condition
rupture NCT03864133 1247 1254 I-Condition
, NCT03864133 1255 1256 O
vitreous NCT03864133 1257 1265 B-Condition
loss NCT03864133 1266 1270 I-Condition
, NCT03864133 1271 1272 O
zonular NCT03864133 1273 1280 B-Procedure
dialysis NCT03864133 1281 1289 I-Procedure
, NCT03864133 1290 1291 O
or NCT03864133 1292 1294 B-Or
iris NCT03864133 1295 1299 B-Modifier
trauma NCT03864133 1300 1306 B-Condition
. NCT03864133 1307 1308 O

- NCT03864133 1312 1313 O
Macular NCT03864133 1315 1322 B-Observation
thickness NCT03864133 1323 1332 I-Observation
above NCT03864133 1333 1338 B-Eq-Comparison
300 NCT03864133 1339 1342 I-Eq-Comparison
microns NCT03864133 1343 1350 I-Eq-Comparison
at NCT03864133 1351 1353 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03864133 1354 1362 B-Study

- NCT03864133 1365 1366 O
Currently NCT03864133 1368 1377 B-Eq-Comparison
taking NCT03864133 1378 1384 I-Eq-Comparison
a NCT03864133 1385 1386 O
prostaglandin NCT03864133 1387 1400 B-Drug
analogue NCT03864133 1401 1409 I-Drug

- NCT03864133 1412 1413 O
Presence NCT03864133 1415 1423 O
of NCT03864133 1424 1426 O
an NCT03864133 1427 1429 O
epiretinal NCT03864133 1430 1440 B-Condition
membrane NCT03864133 1441 1449 I-Condition
on NCT03864133 1450 1452 O
the NCT03864133 1453 1456 O
pre NCT03864133 1457 1460 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03864133 1461 1470 I-Temporal-Connection___Temporal-Connection-Type-Value:before
OCT NCT03864133 1471 1474 B-Procedure
. NCT03864133 1475 1476 O

- NCT03864133 1480 1481 O
Retained NCT03864133 1483 1491 B-Modifier
lens NCT03864133 1492 1496 B-Condition
fragment NCT03864133 1497 1505 I-Condition
post NCT03864133 1506 1510 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03864133 1511 1512 O
operatively NCT03864133 1513 1524 B-Procedure
. NCT03864133 1525 1526 O

- NCT03864133 1530 1531 O
Inability NCT03864133 1533 1542 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03864133 1543 1545 O
return NCT03864133 1546 1552 O
for NCT03864133 1553 1556 O
follow NCT03864133 1557 1563 O
appointments NCT03864133 1564 1576 B-Encounter

- NCT03864133 1579 1580 O
Female NCT03864133 1582 1588 O
patients NCT03864133 1589 1597 O
who NCT03864133 1598 1601 B-And
are NCT03864133 1602 1605 O
pregnant NCT03864133 1606 1614 B-Condition
, NCT03864133 1615 1616 O
lactating NCT03864133 1617 1626 B-Condition
or NCT03864133 1627 1629 B-Or
planning NCT03864133 1630 1638 B-Assertion___Assertion-Type-Value:intention
to NCT03864133 1639 1641 I-Assertion___Assertion-Type-Value:intention
become NCT03864133 1642 1648 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03864133 1649 1657 B-Condition
during NCT03864133 1658 1664 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03864133 1665 1668 O
course NCT03864133 1669 1675 O
of NCT03864133 1676 1678 O
treatment NCT03864133 1679 1688 B-Procedure
. NCT03864133 1688 1689 O

Inclusion NCT03868709 0 9 O
Criteria NCT03868709 10 18 O
: NCT03868709 19 20 O

1 NCT03868709 24 25 O
. NCT03868709 25 26 O
Age NCT03868709 28 31 B-Age
of NCT03868709 32 34 O
50 NCT03868709 35 37 B-Eq-Comparison
years NCT03868709 38 43 I-Eq-Comparison
or NCT03868709 44 46 I-Eq-Comparison
over NCT03868709 47 51 I-Eq-Comparison
; NCT03868709 51 52 O

2 NCT03868709 55 56 O
. NCT03868709 56 57 O
Scheduled NCT03868709 59 68 B-Eq-Comparison
to NCT03868709 69 71 I-Eq-Comparison
undergo NCT03868709 72 79 I-Eq-Comparison
open NCT03868709 80 84 B-Modifier
or NCT03868709 85 87 B-Or
laparoscope NCT03868709 88 99 B-Modifier
assisted NCT03868709 100 108 I-Modifier
upper NCT03868709 109 114 B-Modifier
abdominal NCT03868709 115 124 I-Modifier
or NCT03868709 125 127 B-Or
intrathoracic NCT03868709 128 141 B-Modifier
surgery NCT03868709 142 149 B-Procedure
; NCT03868709 149 150 O

3 NCT03868709 153 154 O
. NCT03868709 154 155 O
The NCT03868709 157 160 O
expected NCT03868709 161 169 B-Assertion___Assertion-Type-Value:hypothetical
duration NCT03868709 170 178 O
of NCT03868709 179 181 O
surgery NCT03868709 182 189 B-Procedure
is NCT03868709 190 192 O
2 NCT03868709 193 194 B-Eq-Comparison
hours NCT03868709 195 200 I-Eq-Comparison
or NCT03868709 201 203 I-Eq-Comparison
longer NCT03868709 204 210 I-Eq-Comparison
; NCT03868709 210 211 O

4 NCT03868709 214 215 O
. NCT03868709 215 216 O
Identified NCT03868709 218 228 O
at NCT03868709 229 231 O
high NCT03868709 232 236 O
risk NCT03868709 237 241 B-Risk
of NCT03868709 242 244 O
PPCs NCT03868709 245 249 B-Condition
according NCT03868709 250 259 O
to NCT03868709 260 262 O
the NCT03868709 263 266 O
ARISCAT NCT03868709 267 274 B-Observation
risk NCT03868709 275 279 I-Observation
score NCT03868709 280 285 I-Observation
( NCT03868709 286 287 O
ARISCAT NCT03868709 288 295 B-Observation
predictive NCT03868709 296 306 I-Observation
score NCT03868709 307 312 B-Eq-Comparison|Observation
≥ NCT03868709 313 314 I-Eq-Comparison
45 NCT03868709 315 317 I-Eq-Comparison
) NCT03868709 318 319 O
. NCT03868709 321 322 O

Exclusion NCT03868709 324 333 O
Criteria NCT03868709 334 342 O
: NCT03868709 343 344 O

1 NCT03868709 348 349 O
. NCT03868709 349 350 O
American NCT03868709 352 360 B-Condition
Society NCT03868709 361 368 I-Condition
of NCT03868709 369 371 I-Condition
Anesthesiologists NCT03868709 372 389 I-Condition
( NCT03868709 390 391 O
ASA NCT03868709 392 395 B-Condition
) NCT03868709 396 397 O
physical NCT03868709 398 406 O
classification NCT03868709 407 421 B-Eq-Comparison
≥ NCT03868709 422 423 I-Eq-Comparison
IV NCT03868709 424 426 I-Eq-Comparison
or NCT03868709 427 429 B-Or
the NCT03868709 430 433 O
expected NCT03868709 434 442 B-Observation
survival NCT03868709 443 451 I-Observation
duration NCT03868709 452 460 O
≤ NCT03868709 461 462 B-Eq-Comparison
24 NCT03868709 463 465 I-Eq-Comparison
h NCT03868709 466 467 I-Eq-Comparison
; NCT03868709 467 468 O

2 NCT03868709 471 472 O
. NCT03868709 472 473 O
Pre NCT03868709 475 478 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03868709 479 488 B-Procedure
history NCT03868709 489 496 B-Eq-Comparison
of NCT03868709 497 499 O
prostatic NCT03868709 500 509 B-Condition
hypertrophy NCT03868709 510 521 I-Condition
or NCT03868709 522 524 B-Or
glaucoma NCT03868709 525 533 B-Condition
; NCT03868709 533 534 O

3 NCT03868709 537 538 O
. NCT03868709 538 539 O
History NCT03868709 541 548 B-Eq-Comparison
of NCT03868709 549 551 O
myocardial NCT03868709 552 562 B-Condition
infarction NCT03868709 563 573 I-Condition
, NCT03868709 574 575 O
severe NCT03868709 576 582 O
heart NCT03868709 583 588 B-Condition
dysfunction NCT03868709 589 600 I-Condition
( NCT03868709 601 602 O
New NCT03868709 603 606 B-Condition
York NCT03868709 607 611 I-Condition
Heart NCT03868709 612 617 I-Condition
Association NCT03868709 618 629 I-Condition
functional NCT03868709 630 640 I-Condition
classification NCT03868709 641 655 B-Eq-Comparison
≥ NCT03868709 656 657 I-Eq-Comparison
3 NCT03868709 658 659 I-Eq-Comparison
) NCT03868709 660 661 O
or NCT03868709 662 664 B-Or
tachyarrhythmia NCT03868709 665 680 B-Condition
within NCT03868709 681 687 B-Eq-Comparison
one NCT03868709 688 691 I-Eq-Comparison
year NCT03868709 692 696 I-Eq-Comparison
; NCT03868709 696 697 O

4 NCT03868709 700 701 O
. NCT03868709 701 702 O
Inhalation NCT03868709 704 714 O
of NCT03868709 715 717 O
β2 NCT03868709 718 720 B-Drug
- NCT03868709 721 722 I-Drug
receptor NCT03868709 723 731 I-Drug
activator NCT03868709 732 741 I-Drug
, NCT03868709 742 743 O
M NCT03868709 744 745 B-Drug
- NCT03868709 746 747 I-Drug
receptor NCT03868709 748 756 I-Drug
blockers NCT03868709 757 765 I-Drug
and NCT03868709 766 769 B-Or
/ NCT03868709 770 771 I-Or
or NCT03868709 772 774 I-Or
glucocorticoids NCT03868709 775 790 B-Drug
within NCT03868709 791 797 B-Eq-Comparison
one NCT03868709 798 801 I-Eq-Comparison
month NCT03868709 802 807 I-Eq-Comparison
before NCT03868709 808 814 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03868709 815 822 B-Procedure
; NCT03868709 822 823 O

5 NCT03868709 826 827 O
. NCT03868709 827 828 O
Severe NCT03868709 830 836 O
renal NCT03868709 837 842 B-Condition
dysfunction NCT03868709 843 854 I-Condition
( NCT03868709 855 856 O
requirement NCT03868709 857 868 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03868709 869 871 O
renal NCT03868709 872 877 B-Procedure
replacement NCT03868709 878 889 I-Procedure
therapy NCT03868709 890 897 I-Procedure
) NCT03868709 898 899 O
or NCT03868709 900 902 B-Or
severe NCT03868709 903 909 O
hepatic NCT03868709 910 917 B-Condition
dysfunction NCT03868709 918 929 I-Condition
( NCT03868709 930 931 O
Child NCT03868709 932 937 B-Observation
- NCT03868709 938 939 I-Observation
Pugh NCT03868709 940 944 I-Observation
grade NCT03868709 945 950 B-Eq-Comparison
C NCT03868709 951 952 I-Eq-Comparison
) NCT03868709 953 954 O
; NCT03868709 955 956 O

6 NCT03868709 959 960 O
. NCT03868709 960 961 O
History NCT03868709 963 970 B-Eq-Comparison
of NCT03868709 971 973 O
acute NCT03868709 974 979 O
stroke NCT03868709 980 986 B-Condition
within NCT03868709 987 993 B-Eq-Comparison
three NCT03868709 994 999 I-Eq-Comparison
months NCT03868709 1000 1006 I-Eq-Comparison
before NCT03868709 1007 1013 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03868709 1014 1021 B-Procedure
; NCT03868709 1021 1022 O

7 NCT03868709 1025 1026 O
. NCT03868709 1026 1027 O
Refuse NCT03868709 1029 1035 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868709 1036 1038 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868709 1039 1050 O
in NCT03868709 1051 1053 O
the NCT03868709 1054 1057 O
study NCT03868709 1058 1063 B-Study
or NCT03868709 1064 1066 B-Or
unable NCT03868709 1067 1073 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868709 1074 1076 O
cooperate NCT03868709 1077 1086 O
with NCT03868709 1087 1091 O
the NCT03868709 1092 1095 O
inhalation NCT03868709 1096 1106 B-Procedure
therapy NCT03868709 1107 1114 I-Procedure
; NCT03868709 1114 1115 O

8 NCT03868709 1118 1119 O
. NCT03868709 1119 1120 O
Participation NCT03868709 1122 1135 O
in NCT03868709 1136 1138 O
other NCT03868709 1139 1144 B-Other
clinical NCT03868709 1145 1153 B-Study
trial NCT03868709 1154 1159 I-Study
during NCT03868709 1160 1166 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868709 1167 1170 O
last NCT03868709 1171 1175 B-Eq-Comparison
month NCT03868709 1176 1181 I-Eq-Comparison
or NCT03868709 1182 1184 B-Or
within NCT03868709 1185 1191 B-Eq-Comparison
the NCT03868709 1192 1195 I-Eq-Comparison
six NCT03868709 1196 1199 I-Eq-Comparison
half NCT03868709 1200 1204 I-Eq-Comparison
- NCT03868709 1205 1206 I-Eq-Comparison
life NCT03868709 1207 1211 I-Eq-Comparison
periods NCT03868709 1212 1219 B-Temporal-Connection___Temporal-Connection-Type-Value:before
of NCT03868709 1220 1222 O
the NCT03868709 1223 1226 O
study NCT03868709 1227 1232 B-Study
drug NCT03868709 1233 1237 B-Drug
used NCT03868709 1238 1242 B-Temporal-Connection___Temporal-Connection-Type-Value:during
in NCT03868709 1243 1245 I-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03868709 1246 1249 O
last NCT03868709 1250 1254 B-Eq-Comparison
trial NCT03868709 1255 1260 B-Study
. NCT03868709 1260 1261 O

Inclusion NCT03860194 0 9 O
Criteria NCT03860194 10 18 O
: NCT03860194 19 20 O

- NCT03860194 24 25 O
Older NCT03860194 27 32 O
adults NCT03860194 33 39 O
( NCT03860194 40 41 O
≥ NCT03860194 43 44 B-Eq-Comparison
65 NCT03860194 45 47 I-Eq-Comparison
years NCT03860194 48 53 I-Age|Eq-Comparison
) NCT03860194 54 55 O

- NCT03860194 59 60 O
Subject NCT03860194 62 69 O
has NCT03860194 70 73 O
lower NCT03860194 74 79 B-Observation
appendicular NCT03860194 80 92 I-Observation
muscle NCT03860194 93 99 I-Observation
mass NCT03860194 100 104 I-Observation
index NCT03860194 105 110 I-Observation
( NCT03860194 111 112 O
AMMI NCT03860194 113 117 B-Observation
) NCT03860194 118 119 O
( NCT03860194 120 121 O
< NCT03860194 123 124 B-Eq-Comparison
7 NCT03860194 125 126 I-Eq-Comparison
kg NCT03860194 127 129 I-Eq-Comparison
/ NCT03860194 130 131 I-Eq-Comparison
m^2 NCT03860194 132 135 I-Eq-Comparison
in NCT03860194 136 138 O
men NCT03860194 139 142 O
; NCT03860194 142 143 O
< NCT03860194 144 145 B-Eq-Comparison
5.7 NCT03860194 146 149 I-Eq-Comparison
kg NCT03860194 150 152 I-Eq-Comparison
/ NCT03860194 153 154 I-Eq-Comparison
m^2 NCT03860194 155 158 I-Eq-Comparison
in NCT03860194 159 161 O
women NCT03860194 162 167 O
) NCT03860194 168 169 O
using NCT03860194 170 175 O
Bioelectrical NCT03860194 176 189 B-Procedure
impedance NCT03860194 190 199 I-Procedure
analysis NCT03860194 200 208 I-Procedure
( NCT03860194 209 210 O
BIA NCT03860194 211 214 O
, NCT03860194 215 216 O
TANITA NCT03860194 217 223 O
BC NCT03860194 224 226 O
- NCT03860194 227 228 O
418 NCT03860194 229 232 O
® NCT03860194 233 234 O
, NCT03860194 235 236 O
Tokyo NCT03860194 237 242 O
, NCT03860194 243 244 O
Japan NCT03860194 245 250 O
) NCT03860194 251 252 O

- NCT03860194 256 257 O
Subject NCT03860194 259 266 O
has NCT03860194 267 270 O
lower NCT03860194 271 276 B-Observation
handgrip NCT03860194 277 285 I-Observation
strength NCT03860194 286 294 I-Observation
( NCT03860194 295 296 O
< NCT03860194 298 299 B-Eq-Comparison
26 NCT03860194 300 302 I-Eq-Comparison
kg NCT03860194 303 305 I-Eq-Comparison
in NCT03860194 306 308 O
men NCT03860194 309 312 O
; NCT03860194 312 313 O
< NCT03860194 314 315 B-Eq-Comparison
18 NCT03860194 316 318 I-Eq-Comparison
kg NCT03860194 319 321 I-Eq-Comparison
in NCT03860194 322 324 O
women NCT03860194 325 330 O
) NCT03860194 331 332 O
using NCT03860194 333 338 O
dynamometer NCT03860194 339 350 B-Procedure
( NCT03860194 351 352 O
CAMRY NCT03860194 353 358 O
® NCT03860194 358 359 O
, NCT03860194 360 361 O
Zhongshan NCT03860194 362 371 O
, NCT03860194 372 373 O
Guangdong NCT03860194 374 383 O
) NCT03860194 384 385 O
or NCT03860194 386 388 B-Or
slowly NCT03860194 389 395 O
gait NCT03860194 396 400 B-Observation
speed NCT03860194 401 406 I-Observation
( NCT03860194 407 408 O
< NCT03860194 410 411 B-Eq-Comparison
1 NCT03860194 412 413 I-Eq-Comparison
m NCT03860194 414 415 I-Eq-Comparison
/ NCT03860194 416 417 I-Eq-Comparison
s NCT03860194 418 419 I-Eq-Comparison
) NCT03860194 420 421 O

Exclusion NCT03860194 423 432 O
Criteria NCT03860194 433 441 O
: NCT03860194 442 443 O

- NCT03860194 447 448 O
Subject NCT03860194 450 457 O
's NCT03860194 457 459 O
life NCT03860194 460 464 B-Observation
expectancy NCT03860194 465 475 I-Observation
was NCT03860194 476 479 O
shorter NCT03860194 480 487 B-Eq-Comparison
than NCT03860194 488 492 I-Eq-Comparison
6 NCT03860194 493 494 I-Eq-Comparison
months NCT03860194 495 501 I-Eq-Comparison

- NCT03860194 504 505 O
Nursing NCT03860194 507 514 O
home NCT03860194 515 519 O
resident NCT03860194 520 528 O

- NCT03860194 531 532 O
Subject NCT03860194 534 541 O
has NCT03860194 542 545 O
the NCT03860194 546 549 O
history NCT03860194 550 557 B-Eq-Comparison
of NCT03860194 558 560 O
kidney NCT03860194 561 567 B-Condition
failure NCT03860194 568 575 I-Condition

- NCT03860194 578 579 O
Subject NCT03860194 581 588 O
has NCT03860194 589 592 O
the NCT03860194 593 596 O
history NCT03860194 597 604 B-Eq-Comparison
of NCT03860194 605 607 O
liver NCT03860194 608 613 B-Condition
failure NCT03860194 614 621 I-Condition

- NCT03860194 624 625 O
Subject NCT03860194 627 634 O
has NCT03860194 635 638 O
the NCT03860194 639 642 O
history NCT03860194 643 650 B-Eq-Comparison
of NCT03860194 651 653 O
diabetes NCT03860194 654 662 B-Condition
mellitus NCT03860194 663 671 I-Condition

- NCT03860194 674 675 O
Subject NCT03860194 677 684 O
has NCT03860194 685 688 O
resistance NCT03860194 689 699 B-Observation
exercise NCT03860194 700 708 I-Observation
habit NCT03860194 709 714 O
. NCT03860194 714 715 O

Inclusion NCT03867604 0 9 O
Criteria NCT03867604 10 18 O
: NCT03867604 19 20 O

- NCT03867604 24 25 O
20 NCT03867604 27 29 B-Eq-Comparison
- NCT03867604 30 31 I-Eq-Comparison
70 NCT03867604 32 34 I-Eq-Comparison
years NCT03867604 35 40 I-Eq-Comparison
old NCT03867604 41 44 B-Age

- NCT03867604 47 48 O
diagnosed NCT03867604 50 59 O
as NCT03867604 60 62 O
a NCT03867604 63 64 O
myofascial NCT03867604 65 75 B-Condition
pain NCT03867604 76 80 I-Condition
syndrome NCT03867604 81 89 I-Condition
at NCT03867604 90 92 O
upper NCT03867604 93 98 B-Modifier
trapezium NCT03867604 99 108 I-Modifier
muscle NCT03867604 109 115 I-Modifier

- NCT03867604 118 119 O
trigger NCT03867604 121 128 B-Condition
point NCT03867604 129 134 I-Condition

- NCT03867604 137 138 O
taut NCT03867604 140 144 B-Condition
band NCT03867604 145 149 I-Condition

- NCT03867604 152 153 O
refer NCT03867604 155 160 O
pain NCT03867604 161 165 B-Condition
while NCT03867604 166 171 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taut NCT03867604 172 176 B-Condition
band NCT03867604 177 181 I-Condition
irritation NCT03867604 182 192 I-Condition

Exclusion NCT03867604 193 202 O
Criteria NCT03867604 203 211 O
: NCT03867604 212 213 O

- NCT03867604 217 218 O
Cognitive NCT03867604 220 229 B-Condition
impairment NCT03867604 230 240 I-Condition
. NCT03867604 241 242 O

- NCT03867604 246 247 O
Post NCT03867604 249 253 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operation NCT03867604 254 263 B-Procedure
at NCT03867604 264 266 O
neck NCT03867604 267 271 B-Modifier
and NCT03867604 272 275 B-Or
shoulder NCT03867604 276 284 B-Modifier
. NCT03867604 285 286 O

- NCT03867604 290 291 O
Nerve NCT03867604 293 298 B-Condition
compression NCT03867604 299 310 I-Condition
at NCT03867604 311 313 O
cervical NCT03867604 314 322 B-Modifier
region NCT03867604 323 329 I-Modifier
. NCT03867604 330 331 O

- NCT03867604 335 336 O
Could NCT03867604 338 343 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03867604 344 347 B-Negation
receive NCT03867604 348 355 O
injection NCT03867604 356 365 B-Procedure
therapy NCT03867604 366 373 I-Procedure
, NCT03867604 374 375 O
history NCT03867604 376 383 B-Eq-Comparison
of NCT03867604 384 386 O
fainting NCT03867604 387 395 B-Condition
during NCT03867604 396 402 B-Temporal-Connection___Temporal-Connection-Type-Value:during
needling NCT03867604 403 411 B-Procedure

Inclusion NCT03861507 0 9 O
Criteria NCT03861507 10 18 O
: NCT03861507 19 20 O

- NCT03861507 24 25 O
Male NCT03861507 27 31 O
, NCT03861507 32 33 O
aged NCT03861507 34 38 B-Age
18 NCT03861507 39 41 B-Eq-Comparison
years NCT03861507 42 47 I-Eq-Comparison
or NCT03861507 48 50 I-Eq-Comparison
older NCT03861507 51 56 I-Eq-Comparison

- NCT03861507 59 60 O
Willing NCT03861507 62 69 O
to NCT03861507 70 72 O
provide NCT03861507 73 80 O
written NCT03861507 81 88 O
consent NCT03861507 89 96 O

- NCT03861507 99 100 O
Pathologically NCT03861507 102 116 B-Procedure
confirmed NCT03861507 117 126 O
prostate NCT03861507 127 135 B-Modifier
cancer NCT03861507 136 142 B-Condition
on NCT03861507 143 145 O
previous NCT03861507 146 154 B-Eq-Comparison
biopsy NCT03861507 155 161 B-Procedure

- NCT03861507 164 165 O
Suitable NCT03861507 167 175 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861507 176 179 I-Assertion___Assertion-Type-Value:hypothetical
and NCT03861507 180 183 O
consenting NCT03861507 184 194 O
to NCT03861507 195 197 O
high NCT03861507 198 202 B-Modifier
- NCT03861507 203 204 I-Modifier
dose NCT03861507 205 209 I-Modifier
- NCT03861507 210 211 I-Modifier
rate NCT03861507 212 216 I-Modifier
brachytherapy NCT03861507 217 230 B-Procedure
for NCT03861507 231 234 O
treatment NCT03861507 235 244 B-Procedure
as NCT03861507 245 247 O
standard NCT03861507 248 256 O
of NCT03861507 257 259 O
care NCT03861507 260 264 O
. NCT03861507 265 266 O

Exclusion NCT03861507 268 277 O
Criteria NCT03861507 278 286 O
: NCT03861507 287 288 O

- NCT03861507 292 293 O
• NCT03861507 295 296 O
Previous NCT03861507 297 305 B-Eq-Comparison
radiotherapy NCT03861507 306 318 B-Procedure
to NCT03861507 319 321 O
the NCT03861507 322 325 O
prostate NCT03861507 326 334 B-Condition

Inclusion NCT03860584 0 9 O
Criteria NCT03860584 10 18 O
: NCT03860584 19 20 O

- NCT03860584 24 25 O
Serum NCT03860584 27 32 B-Observation
Glucose NCT03860584 33 40 I-Observation
100 NCT03860584 41 44 B-Eq-Comparison
- NCT03860584 45 46 I-Eq-Comparison
126 NCT03860584 47 50 I-Eq-Comparison
mg NCT03860584 51 53 I-Eq-Comparison
/ NCT03860584 54 55 I-Eq-Comparison
dl NCT03860584 56 58 I-Eq-Comparison

- NCT03860584 61 62 O
Waist NCT03860584 64 69 B-Observation
C NCT03860584 70 71 I-Observation
> NCT03860584 72 73 B-Eq-Comparison
89 NCT03860584 74 76 I-Eq-Comparison
/ NCT03860584 77 78 I-Eq-Comparison
102 NCT03860584 79 82 I-Eq-Comparison
cm NCT03860584 83 85 I-Eq-Comparison
; NCT03860584 85 86 O
F NCT03860584 87 88 O
/ NCT03860584 89 90 B-Or
M NCT03860584 91 92 O

- NCT03860584 95 96 O
Serum NCT03860584 98 103 B-Observation
HDL NCT03860584 104 107 I-Observation
- NCT03860584 108 109 I-Observation
C NCT03860584 110 111 I-Observation
: NCT03860584 112 113 O
< NCT03860584 114 115 B-Eq-Comparison
50 NCT03860584 116 118 I-Eq-Comparison
/ NCT03860584 119 120 I-Eq-Comparison
40 NCT03860584 121 123 I-Eq-Comparison
mg NCT03860584 124 126 I-Eq-Comparison
/ NCT03860584 127 128 I-Eq-Comparison
dl NCT03860584 129 131 I-Eq-Comparison
; NCT03860584 131 132 O
F NCT03860584 133 134 O
/ NCT03860584 135 136 B-Or
M NCT03860584 137 138 O

- NCT03860584 141 142 O
Serum NCT03860584 144 149 B-Observation
TG NCT03860584 150 152 I-Observation
: NCT03860584 153 154 O
> NCT03860584 155 156 B-Eq-Comparison
150 NCT03860584 157 160 I-Eq-Comparison
mg NCT03860584 161 163 I-Eq-Comparison
/ NCT03860584 164 165 I-Eq-Comparison
dl NCT03860584 166 168 I-Eq-Comparison

- NCT03860584 171 172 O
BP NCT03860584 174 176 B-Observation
> NCT03860584 177 178 B-Eq-Comparison
130 NCT03860584 179 182 I-Eq-Comparison
/ NCT03860584 183 184 I-Eq-Comparison
85 NCT03860584 185 187 I-Eq-Comparison
mmHg NCT03860584 188 192 I-Eq-Comparison

- NCT03860584 195 196 O
Serum NCT03860584 198 203 B-Observation
Endotoxin NCT03860584 204 213 I-Observation
> NCT03860584 214 215 B-Eq-Comparison
25 NCT03860584 216 218 I-Eq-Comparison
EU NCT03860584 219 221 I-Eq-Comparison
/ NCT03860584 222 223 I-Eq-Comparison
ml NCT03860584 224 226 I-Eq-Comparison

Exclusion NCT03860584 227 236 O
Criteria NCT03860584 237 245 O
: NCT03860584 246 247 O

- NCT03860584 251 252 O
Unstable NCT03860584 254 262 O
body NCT03860584 263 267 B-Observation
mass NCT03860584 268 272 I-Observation
( NCT03860584 273 274 O
± NCT03860584 276 277 B-Eq-Comparison
2 NCT03860584 278 279 I-Eq-Comparison
kg NCT03860584 280 282 I-Eq-Comparison
over NCT03860584 283 287 O
prior NCT03860584 288 293 B-Eq-Comparison
3 NCT03860584 294 295 I-Eq-Comparison
- NCT03860584 296 297 I-Eq-Comparison
mo NCT03860584 298 300 I-Eq-Comparison
) NCT03860584 301 302 O

- NCT03860584 306 307 O
Vegetarian NCT03860584 309 319 B-Condition

- NCT03860584 322 323 O
Food NCT03860584 325 329 O
allergies NCT03860584 330 339 B-Allergy
or NCT03860584 340 342 B-Or
lactose NCT03860584 343 350 B-Condition
intolerance NCT03860584 351 362 I-Condition

- NCT03860584 365 366 O
User NCT03860584 368 372 B-Eq-Comparison
of NCT03860584 373 375 O
dietary NCT03860584 376 383 B-Drug
supplements NCT03860584 384 395 I-Drug
or NCT03860584 396 398 B-Or
probiotics NCT03860584 399 409 B-Drug
( NCT03860584 410 411 O
within NCT03860584 412 418 B-Eq-Comparison
past NCT03860584 419 423 I-Eq-Comparison
1 NCT03860584 424 425 I-Eq-Comparison
- NCT03860584 426 427 I-Eq-Comparison
mo NCT03860584 428 430 I-Eq-Comparison
) NCT03860584 431 432 O

- NCT03860584 436 437 O
Pregnancy NCT03860584 439 448 B-Condition
, NCT03860584 449 450 O
lactation NCT03860584 451 460 B-Condition
, NCT03860584 461 462 O
changes NCT03860584 463 470 O
in NCT03860584 471 473 O
birth NCT03860584 474 479 B-Procedure
control NCT03860584 480 487 I-Procedure
( NCT03860584 488 489 O
within NCT03860584 490 496 B-Eq-Comparison
6 NCT03860584 497 498 I-Eq-Comparison
- NCT03860584 499 500 O
mo NCT03860584 501 503 O
) NCT03860584 504 505 O

- NCT03860584 509 510 O
Any NCT03860584 512 515 O
gastrointestinal NCT03860584 516 532 B-Condition
disorders NCT03860584 533 542 I-Condition

- NCT03860584 545 546 O
Chronic NCT03860584 548 555 B-Modifier
diarrhea NCT03860584 556 564 B-Condition

- NCT03860584 567 568 O
Smoker NCT03860584 570 576 B-Condition

- NCT03860584 579 580 O
Excess NCT03860584 582 588 O
alcohol NCT03860584 589 596 B-Observation
( NCT03860584 597 598 O
> NCT03860584 600 601 B-Eq-Comparison
2 NCT03860584 602 603 I-Eq-Comparison
drinks NCT03860584 604 610 I-Eq-Comparison
/ NCT03860584 611 612 I-Eq-Comparison
d NCT03860584 613 614 I-Eq-Comparison
) NCT03860584 615 616 O

- NCT03860584 620 621 O
Excess NCT03860584 623 629 O
aerobic NCT03860584 630 637 B-Observation
exercise NCT03860584 638 646 I-Observation
( NCT03860584 647 648 O
> NCT03860584 650 651 B-Eq-Comparison
5 NCT03860584 652 653 I-Eq-Comparison
h NCT03860584 654 655 I-Eq-Comparison
/ NCT03860584 656 657 I-Eq-Comparison
wk NCT03860584 658 660 I-Eq-Comparison
) NCT03860584 661 662 O

- NCT03860584 666 667 O
Recent NCT03860584 669 675 B-Eq-Comparison
antibiotic NCT03860584 676 686 B-Drug
or NCT03860584 687 689 B-Or
anti NCT03860584 690 694 B-Drug
- NCT03860584 695 696 I-Drug
inflammatory NCT03860584 697 709 I-Drug
agent NCT03860584 710 715 I-Drug
use NCT03860584 716 719 O

- NCT03860584 722 723 O
BP NCT03860584 725 727 B-Observation
> NCT03860584 728 729 B-Eq-Comparison
140 NCT03860584 730 733 I-Eq-Comparison
/ NCT03860584 734 735 I-Eq-Comparison
90 NCT03860584 736 738 I-Eq-Comparison
mmHg NCT03860584 739 743 I-Eq-Comparison

Inclusion NCT03860220 0 9 O
Criteria NCT03860220 10 18 O
: NCT03860220 19 20 O

- NCT03860220 24 25 O
145 NCT03860220 27 30 B-Eq-Comparison
mmHg NCT03860220 31 35 I-Eq-Comparison
≤ NCT03860220 36 37 I-Eq-Comparison
msSBP NCT03860220 38 43 B-Observation
≤ NCT03860220 44 45 B-Eq-Comparison
190 NCT03860220 46 49 I-Eq-Comparison
mmHg NCT03860220 50 54 I-Eq-Comparison

- NCT03860220 57 58 O
Triglycerides NCT03860220 60 73 B-Observation
< NCT03860220 74 75 B-Eq-Comparison
500 NCT03860220 76 79 I-Eq-Comparison
mg NCT03860220 80 82 I-Eq-Comparison
/ NCT03860220 83 84 I-Eq-Comparison
dL NCT03860220 85 87 I-Eq-Comparison

- NCT03860220 90 91 O
LDL NCT03860220 93 96 B-Observation
- NCT03860220 97 98 I-Observation
C NCT03860220 99 100 I-Observation
≤ NCT03860220 101 102 B-Eq-Comparison
250 NCT03860220 103 106 I-Eq-Comparison
mg NCT03860220 107 109 I-Eq-Comparison
/ NCT03860220 110 111 I-Eq-Comparison
dL NCT03860220 112 114 I-Eq-Comparison

Exclusion NCT03860220 115 124 O
Criteria NCT03860220 125 133 O
: NCT03860220 134 135 O

- NCT03860220 139 140 O
sSBP NCT03860220 142 146 B-Observation
≥ NCT03860220 147 148 B-Eq-Comparison
20 NCT03860220 149 151 I-Eq-Comparison
mmHg NCT03860220 152 156 I-Eq-Comparison
and NCT03860220 157 160 B-And
sDBP NCT03860220 161 165 B-Observation
≥ NCT03860220 166 167 B-Eq-Comparison
10 NCT03860220 168 170 I-Eq-Comparison
mmHg NCT03860220 171 175 I-Eq-Comparison

- NCT03860220 178 179 O
symptomatic NCT03860220 181 192 B-Assertion___Assertion-Type-Value:possible
orthostatic NCT03860220 193 204 B-Modifier
hypotension NCT03860220 205 216 B-Condition
and NCT03860220 217 220 B-Or
secondary NCT03860220 221 230 B-Modifier
/ NCT03860220 231 232 B-Or
iatrogenic NCT03860220 233 243 B-Modifier
hypertension NCT03860220 244 256 B-Condition
and NCT03860220 257 260 B-Or
dyslipidemia NCT03860220 261 273 B-Condition

- NCT03860220 276 277 O
history NCT03860220 279 286 B-Eq-Comparison
of NCT03860220 287 289 O
moderate NCT03860220 290 298 B-Eq-Comparison
to NCT03860220 299 301 I-Eq-Comparison
severe NCT03860220 302 308 I-Eq-Comparison
cerebral NCT03860220 309 317 B-Condition
ischemia NCT03860220 318 326 I-Condition
, NCT03860220 327 328 O
cerebral NCT03860220 329 337 B-Condition
hemorrhage NCT03860220 338 348 I-Condition
, NCT03860220 349 350 O
transient NCT03860220 351 360 B-Condition
ischemic NCT03860220 361 369 I-Condition
attack NCT03860220 370 376 I-Condition
, NCT03860220 377 378 O
myocardial NCT03860220 379 389 B-Condition
infarction NCT03860220 390 400 I-Condition
, NCT03860220 401 402 O
or NCT03860220 403 405 B-Or
unstable NCT03860220 406 414 O
angina NCT03860220 415 421 B-Condition
in NCT03860220 422 424 O
the NCT03860220 425 428 O
past NCT03860220 429 433 B-Eq-Comparison
6 NCT03860220 434 435 I-Eq-Comparison
months NCT03860220 436 442 I-Eq-Comparison
; NCT03860220 442 443 O
severe NCT03860220 444 450 O
heart NCT03860220 451 456 B-Condition
failure NCT03860220 457 464 I-Condition
( NCT03860220 465 466 O
New NCT03860220 467 470 B-Condition
York NCT03860220 471 475 I-Condition
Heart NCT03860220 476 481 I-Condition
Association NCT03860220 482 493 I-Condition
functional NCT03860220 494 504 O
class NCT03860220 505 510 B-Eq-Comparison
III NCT03860220 511 514 I-Eq-Comparison
and NCT03860220 515 518 I-Eq-Comparison
IV NCT03860220 519 521 I-Eq-Comparison
) NCT03860220 522 523 O

- NCT03860220 527 528 O
hypersensitivity NCT03860220 530 546 B-Condition
to NCT03860220 547 549 O
telmisartan NCT03860220 550 561 B-Drug
or NCT03860220 562 564 B-Or
rosuvastatin NCT03860220 565 577 B-Drug

- NCT03860220 580 581 O
history NCT03860220 583 590 B-Eq-Comparison
of NCT03860220 591 593 O
angioedema NCT03860220 594 604 B-Condition
after NCT03860220 605 610 B-Temporal-Connection___Temporal-Connection-Type-Value:after
treatment NCT03860220 611 620 B-Procedure
with NCT03860220 621 625 O
angiotensin NCT03860220 626 637 B-Drug
- NCT03860220 638 639 I-Drug
converting NCT03860220 640 650 I-Drug
enzyme NCT03860220 651 657 I-Drug
inhibitors NCT03860220 658 668 I-Drug
or NCT03860220 669 671 B-Or
ARBs NCT03860220 672 676 B-Drug
; NCT03860220 676 677 O
creatinine NCT03860220 678 688 B-Observation
phosphokinase NCT03860220 689 702 I-Observation
levels NCT03860220 703 709 O
≥ NCT03860220 710 711 B-Eq-Comparison
3 NCT03860220 712 713 I-Eq-Comparison
times NCT03860220 714 719 I-Eq-Comparison
the NCT03860220 720 723 I-Eq-Comparison
upper NCT03860220 724 729 I-Eq-Comparison
limit NCT03860220 730 735 I-Eq-Comparison
of NCT03860220 736 738 I-Eq-Comparison
normal NCT03860220 739 745 I-Eq-Comparison

- NCT03860220 748 749 O
estimated NCT03860220 751 760 B-Observation
glomerular NCT03860220 761 771 I-Observation
filtration NCT03860220 772 782 I-Observation
rate NCT03860220 783 787 I-Observation
≤ NCT03860220 788 789 B-Eq-Comparison
30 NCT03860220 790 792 I-Eq-Comparison
mL NCT03860220 793 795 I-Eq-Comparison
/ NCT03860220 796 797 I-Eq-Comparison
min NCT03860220 798 801 I-Eq-Comparison
; NCT03860220 801 802 O
aspartate NCT03860220 803 812 B-Observation
aminotransferase NCT03860220 813 829 I-Observation
and NCT03860220 830 833 B-Or
alanine NCT03860220 834 841 B-Observation
aminotransferase NCT03860220 842 858 I-Observation
levels NCT03860220 859 865 O
≥ NCT03860220 866 867 B-Eq-Comparison
3 NCT03860220 868 869 I-Eq-Comparison
times NCT03860220 870 875 I-Eq-Comparison
the NCT03860220 876 879 I-Eq-Comparison
upper NCT03860220 880 885 I-Eq-Comparison
limit NCT03860220 886 891 I-Eq-Comparison
of NCT03860220 892 894 I-Eq-Comparison
normal NCT03860220 895 901 I-Eq-Comparison

- NCT03860220 904 905 O
potassium NCT03860220 907 916 B-Observation
levels NCT03860220 917 923 O
> NCT03860220 924 925 B-Eq-Comparison
5.5 NCT03860220 926 929 I-Eq-Comparison
mmol NCT03860220 930 934 I-Eq-Comparison
/ NCT03860220 935 936 I-Eq-Comparison
L NCT03860220 937 938 I-Eq-Comparison
; NCT03860220 938 939 O
or NCT03860220 940 942 B-Or
any NCT03860220 943 946 O
diseases NCT03860220 947 955 B-Condition
that NCT03860220 956 960 O
could NCT03860220 961 966 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03860220 967 973 O
the NCT03860220 974 977 O
results NCT03860220 978 985 O
of NCT03860220 986 988 O
the NCT03860220 989 992 O
study NCT03860220 993 998 B-Study
. NCT03860220 998 999 O

Inclusion NCT03866889 0 9 O
Criteria NCT03866889 10 18 O
: NCT03866889 19 20 O

- NCT03866889 24 25 O
Military NCT03866889 27 35 B-Observation
personnel NCT03866889 36 45 I-Observation
belonging NCT03866889 46 55 O
to NCT03866889 56 58 O
the NCT03866889 59 62 O
Military NCT03866889 63 71 B-Modifier
Emergency NCT03866889 72 81 I-Modifier
Unit NCT03866889 82 86 I-Modifier

- NCT03866889 89 90 O
male NCT03866889 92 96 O

- NCT03866889 99 100 O
With NCT03866889 102 106 O
an NCT03866889 107 109 O
age NCT03866889 110 113 B-Age
of NCT03866889 114 116 O
25 NCT03866889 117 119 B-Eq-Comparison
to NCT03866889 120 122 I-Eq-Comparison
45 NCT03866889 123 125 I-Eq-Comparison
years NCT03866889 126 131 I-Eq-Comparison

- NCT03866889 134 135 O
No NCT03866889 137 139 B-Negation
history NCT03866889 140 147 B-Eq-Comparison
of NCT03866889 148 150 O
musculoskeletal NCT03866889 151 166 B-Modifier
injury NCT03866889 167 173 B-Condition
in NCT03866889 174 176 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 177 180 O
3 NCT03866889 181 182 B-Eq-Comparison
months NCT03866889 183 189 I-Eq-Comparison
prior NCT03866889 190 195 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866889 196 198 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03866889 199 202 O
study NCT03866889 203 208 B-Study

Exclusion NCT03866889 209 218 O
Criteria NCT03866889 219 227 O
: NCT03866889 228 229 O

- NCT03866889 233 234 O
Present NCT03866889 236 243 O
a NCT03866889 244 245 O
diagnosis NCT03866889 246 255 O
of NCT03866889 256 258 O
injury NCT03866889 259 265 B-Condition
in NCT03866889 266 268 O
the NCT03866889 269 272 O
period NCT03866889 273 279 O
prior NCT03866889 280 285 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03866889 286 288 I-Temporal-Connection___Temporal-Connection-Type-Value:before
or NCT03866889 289 291 B-Or
during NCT03866889 292 298 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 299 302 O
study NCT03866889 303 308 B-Study

- NCT03866889 311 312 O
Who NCT03866889 314 317 O
are NCT03866889 318 321 O
receiving NCT03866889 322 331 B-Eq-Comparison
a NCT03866889 332 333 O
physiotherapy NCT03866889 334 347 B-Procedure
intervention NCT03866889 348 360 I-Procedure
at NCT03866889 361 363 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866889 364 367 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866889 368 372 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866889 373 375 O
the NCT03866889 376 379 O
study NCT03866889 380 385 B-Study

- NCT03866889 388 389 O
Not NCT03866889 391 394 O
signed NCT03866889 395 401 O
the NCT03866889 402 405 O
informed NCT03866889 406 414 O
consent NCT03866889 415 422 O
document NCT03866889 423 431 O

Inclusion NCT03863067 0 9 O
Criteria NCT03863067 10 18 O
: NCT03863067 19 20 O

- NCT03863067 24 25 O
Patient NCT03863067 27 34 O
with NCT03863067 35 39 O
indication NCT03863067 40 50 B-Indication
for NCT03863067 51 54 O
epiduroscopy NCT03863067 55 67 B-Procedure
in NCT03863067 68 70 O
the NCT03863067 71 74 O
usual NCT03863067 75 80 O
clinical NCT03863067 81 89 O
practice NCT03863067 90 98 O

- NCT03863067 101 102 O
Neurogenic NCT03863067 104 114 B-Condition
claudication NCT03863067 115 127 I-Condition

- NCT03863067 130 131 O
Lumbar NCT03863067 133 139 B-Modifier
pain NCT03863067 140 144 B-Condition
for NCT03863067 145 148 O
more NCT03863067 149 153 B-Eq-Comparison
than NCT03863067 154 158 I-Eq-Comparison
6 NCT03863067 159 160 I-Eq-Comparison
months NCT03863067 161 167 I-Eq-Comparison

- NCT03863067 170 171 O
Numerical NCT03863067 173 182 B-Observation
rating NCT03863067 183 189 I-Observation
scale NCT03863067 190 195 I-Observation
> NCT03863067 196 197 B-Eq-Comparison
6 NCT03863067 198 199 I-Eq-Comparison

- NCT03863067 203 204 O
No NCT03863067 206 208 B-Negation
response NCT03863067 209 217 O
with NCT03863067 218 222 O
medical NCT03863067 223 230 O
treatment NCT03863067 231 240 B-Procedure

- NCT03863067 243 244 O
No NCT03863067 246 248 B-Negation
response NCT03863067 249 257 O
with NCT03863067 258 262 O
other NCT03863067 263 268 B-Other
interventional NCT03863067 269 283 O
treatment NCT03863067 284 293 B-Procedure
: NCT03863067 294 295 O
epidurolysis NCT03863067 296 308 B-Procedure

Exclusion NCT03863067 309 318 O
Criteria NCT03863067 319 327 O
: NCT03863067 328 329 O

- NCT03863067 333 334 O
Psychiatric NCT03863067 336 347 B-Condition
disorders NCT03863067 348 357 I-Condition

- NCT03863067 360 361 O
Opioid NCT03863067 363 369 B-Condition
addiction NCT03863067 370 379 I-Condition

- NCT03863067 382 383 O
Acute NCT03863067 385 390 O
organic NCT03863067 391 398 B-Condition
disease NCT03863067 399 406 I-Condition

- NCT03863067 409 410 O
Severe NCT03863067 412 418 O
chronic NCT03863067 419 426 B-Modifier
organic NCT03863067 427 434 B-Condition
disease NCT03863067 435 442 I-Condition

- NCT03863067 445 446 O
Vasculo NCT03863067 448 455 B-Condition
- NCT03863067 456 457 I-Condition
cerebral NCT03863067 458 466 I-Condition
disease NCT03863067 467 474 I-Condition

- NCT03863067 477 478 O
Coagulation NCT03863067 480 491 B-Condition
alterations NCT03863067 492 503 I-Condition

- NCT03863067 506 507 O
Ofthalmologic NCT03863067 509 522 B-Condition
disease NCT03863067 523 530 I-Condition

- NCT03863067 533 534 O
Allergic NCT03863067 536 544 B-Allergy

- NCT03863067 547 548 O
Infections NCT03863067 550 560 B-Condition

- NCT03863067 563 564 O
Impossibility NCT03863067 566 579 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03863067 580 582 I-Assertion___Assertion-Type-Value:hypothetical
understand NCT03863067 583 593 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03863067 594 597 O
procedure NCT03863067 598 607 B-Procedure

key NCT03867201 0 3 O
inclusion NCT03867201 4 13 O
Criteria NCT03867201 14 22 O
: NCT03867201 23 24 O

1 NCT03867201 28 29 O
. NCT03867201 29 30 O
History NCT03867201 32 39 B-Eq-Comparison
of NCT03867201 40 42 O
at NCT03867201 43 45 B-Eq-Comparison
least NCT03867201 46 51 I-Eq-Comparison
5 NCT03867201 52 53 I-Eq-Comparison
attacks NCT03867201 54 61 O
of NCT03867201 62 64 O
migraine NCT03867201 65 73 B-Condition

2 NCT03867201 76 77 O
. NCT03867201 77 78 O
≥ NCT03867201 80 81 B-Eq-Comparison
15 NCT03867201 82 84 I-Eq-Comparison
headache NCT03867201 85 93 B-Condition
days NCT03867201 94 98 O
of NCT03867201 99 101 B-And
which NCT03867201 102 107 I-And
≥ NCT03867201 108 109 B-Eq-Comparison
8 NCT03867201 110 111 I-Eq-Comparison
headache NCT03867201 112 120 B-Condition
days NCT03867201 121 125 O
meet NCT03867201 126 130 O
criteria NCT03867201 131 139 O
as NCT03867201 140 142 O
migraine NCT03867201 143 151 B-Condition
days NCT03867201 152 156 B-Eq-Comparison
during NCT03867201 157 163 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867201 164 167 O
baseline NCT03867201 168 176 B-Study
period NCT03867201 177 183 O

3 NCT03867201 186 187 O
. NCT03867201 187 188 O
> NCT03867201 190 191 O
= NCT03867201 193 194 O
80 NCT03867201 195 197 O
% NCT03867201 198 199 O
diary NCT03867201 200 205 B-Observation
compliance NCT03867201 206 216 I-Observation
during NCT03867201 217 223 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03867201 224 227 O
baseline NCT03867201 228 236 B-Study
period NCT03867201 237 243 O

Key NCT03867201 244 247 O
exclusion NCT03867201 248 257 O
Criteria NCT03867201 258 266 O
: NCT03867201 267 268 O

1 NCT03867201 272 273 O
. NCT03867201 273 274 O
Older NCT03867201 276 281 B-Eq-Comparison
than NCT03867201 282 286 I-Eq-Comparison
50 NCT03867201 287 289 I-Eq-Comparison
years NCT03867201 290 295 I-Eq-Comparison
of NCT03867201 296 298 O
age NCT03867201 299 302 B-Age
at NCT03867201 303 305 B-Temporal-Connection___Temporal-Connection-Type-Value:during
migraine NCT03867201 306 314 B-Condition
onset NCT03867201 315 320 B-Eq-Comparison

2 NCT03867201 323 324 O
. NCT03867201 324 325 O
History NCT03867201 327 334 B-Eq-Comparison
of NCT03867201 335 337 O
cluster NCT03867201 338 345 B-Modifier
or NCT03867201 346 348 B-Or
hemiplegic NCT03867201 349 359 B-Modifier
headache NCT03867201 360 368 B-Condition

3 NCT03867201 371 372 O
. NCT03867201 372 373 O
Evidence NCT03867201 375 383 O
of NCT03867201 384 386 O
seizure NCT03867201 387 394 B-Condition
or NCT03867201 395 397 B-Or
major NCT03867201 398 403 O
psychiatric NCT03867201 404 415 B-Condition
disorder NCT03867201 416 424 I-Condition

4 NCT03867201 427 428 O
. NCT03867201 428 429 O
Cardiac NCT03867201 431 438 B-Modifier
or NCT03867201 439 441 B-Or
active NCT03867201 442 448 B-Eq-Comparison
hepatic NCT03867201 449 456 B-Condition
disease NCT03867201 457 464 I-Condition

5 NCT03867201 467 468 O
. NCT03867201 468 469 O
Pregnant NCT03867201 471 479 B-Condition
or NCT03867201 480 482 B-Or
nursing NCT03867201 483 490 B-Condition

Inclusion NCT03864913 0 9 O
Criteria NCT03864913 10 18 O
: NCT03864913 19 20 O

- NCT03864913 24 25 O
Testosterone NCT03864913 27 39 B-Condition
naive NCT03864913 40 45 I-Condition

- NCT03864913 48 49 O
Transgender NCT03864913 51 62 O
male NCT03864913 63 67 O

- NCT03864913 70 71 O
14 NCT03864913 73 75 B-Eq-Comparison
- NCT03864913 76 77 I-Eq-Comparison
19 NCT03864913 78 80 I-Eq-Comparison
years NCT03864913 81 86 I-Eq-Comparison
old NCT03864913 87 90 B-Age

Exclusion NCT03864913 91 100 O
Criteria NCT03864913 101 109 O
: NCT03864913 110 111 O

- NCT03864913 115 116 O
Transgender NCT03864913 118 129 O
males NCT03864913 130 135 O
who NCT03864913 136 139 B-And
have NCT03864913 140 144 O
received NCT03864913 145 153 B-Eq-Comparison
testosterone NCT03864913 154 166 B-Procedure
therapy NCT03864913 167 174 I-Procedure
in NCT03864913 175 177 O
the NCT03864913 178 181 O
past NCT03864913 182 186 B-Eq-Comparison

Inclusion NCT03868683 0 9 O
Criteria NCT03868683 10 18 O
: NCT03868683 19 20 O

- NCT03868683 24 25 O
Chinese NCT03868683 27 34 O
ethnicity NCT03868683 35 44 O

- NCT03868683 47 48 O
Age NCT03868683 50 53 B-Age
≥ NCT03868683 54 55 B-Eq-Comparison
21 NCT03868683 56 58 I-Eq-Comparison
and NCT03868683 59 62 B-And
≤ NCT03868683 63 64 B-Eq-Comparison
60 NCT03868683 65 67 I-Eq-Comparison
years NCT03868683 68 73 I-Eq-Comparison

- NCT03868683 76 77 O
Body NCT03868683 79 83 B-Observation
mass NCT03868683 84 88 I-Observation
index NCT03868683 89 94 I-Observation
between NCT03868683 95 102 B-Eq-Comparison
18.5 NCT03868683 103 107 I-Eq-Comparison
to NCT03868683 108 110 I-Eq-Comparison
25 NCT03868683 111 113 I-Eq-Comparison
kg NCT03868683 114 116 I-Eq-Comparison
/ NCT03868683 117 118 I-Eq-Comparison
m2 NCT03868683 119 121 I-Eq-Comparison

- NCT03868683 124 125 O
Normal NCT03868683 127 133 O
blood NCT03868683 134 139 B-Observation
pressure NCT03868683 140 148 I-Observation
< NCT03868683 149 150 B-Eq-Comparison
140 NCT03868683 151 154 I-Eq-Comparison
/ NCT03868683 155 156 I-Eq-Comparison
90 NCT03868683 157 159 I-Eq-Comparison
mmHg NCT03868683 160 164 I-Eq-Comparison

- NCT03868683 167 168 O
Fasting NCT03868683 170 177 B-Modifier
blood NCT03868683 178 183 B-Observation
glucose NCT03868683 184 191 I-Observation
< NCT03868683 192 193 B-Eq-Comparison
6.0 NCT03868683 194 197 I-Eq-Comparison
mmol NCT03868683 198 202 I-Eq-Comparison
/ NCT03868683 203 204 I-Eq-Comparison
L NCT03868683 205 206 I-Eq-Comparison

- NCT03868683 209 210 O
In NCT03868683 212 214 O
general NCT03868683 215 222 O
good NCT03868683 223 227 B-Condition
health NCT03868683 228 234 I-Condition

Exclusion NCT03868683 235 244 O
Criteria NCT03868683 245 253 O
: NCT03868683 254 255 O

- NCT03868683 259 260 O
Current NCT03868683 262 269 B-Eq-Comparison
Smoker NCT03868683 270 276 B-Condition

- NCT03868683 279 280 O
have NCT03868683 282 286 O
any NCT03868683 287 290 O
metabolic NCT03868683 291 300 B-Condition
diseases NCT03868683 301 309 I-Condition
( NCT03868683 310 311 O
such NCT03868683 312 316 O
as NCT03868683 317 319 O
diabetes NCT03868683 320 328 B-Condition
, NCT03868683 329 330 O
hypertension NCT03868683 331 343 B-Condition
etc NCT03868683 344 347 O
) NCT03868683 348 349 O

- NCT03868683 353 354 O
have NCT03868683 356 360 O
known NCT03868683 361 366 O
glucose NCT03868683 367 374 B-Condition
- NCT03868683 375 376 I-Condition
6 NCT03868683 377 378 I-Condition
- NCT03868683 379 380 I-Condition
phosphate NCT03868683 381 390 I-Condition
dehydrogenase NCT03868683 391 404 I-Condition
deficiency NCT03868683 405 415 I-Condition
( NCT03868683 416 417 O
G6PD NCT03868683 418 422 B-Condition
deficiency NCT03868683 423 433 I-Condition
) NCT03868683 434 435 O

- NCT03868683 439 440 O
having NCT03868683 442 448 O
medical NCT03868683 449 456 B-Condition
conditions NCT03868683 457 467 I-Condition
and NCT03868683 468 471 B-Or
/ NCT03868683 472 473 I-Or
or NCT03868683 474 476 I-Or
taking NCT03868683 477 483 B-Eq-Comparison
medications NCT03868683 484 495 B-Drug
known NCT03868683 496 501 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868683 502 504 I-Assertion___Assertion-Type-Value:hypothetical
affect NCT03868683 505 511 O
glycaemia NCT03868683 512 521 B-Condition
( NCT03868683 522 523 O
glucocorticoids NCT03868683 524 539 B-Drug
, NCT03868683 540 541 O
thyroid NCT03868683 542 549 B-Drug
hormones NCT03868683 550 558 I-Drug
, NCT03868683 559 560 O
thiazide NCT03868683 561 569 B-Drug
diuretics NCT03868683 570 579 I-Drug
) NCT03868683 580 581 O

- NCT03868683 585 586 O
have NCT03868683 588 592 O
intolerances NCT03868683 593 605 B-Condition
or NCT03868683 606 608 B-Or
allergies NCT03868683 609 618 B-Allergy
to NCT03868683 619 621 O
any NCT03868683 622 625 O
foods NCT03868683 626 631 O

- NCT03868683 634 635 O
partake NCT03868683 637 644 O
in NCT03868683 645 647 O
sports NCT03868683 648 654 B-Observation
at NCT03868683 655 657 O
the NCT03868683 658 661 O
competitive NCT03868683 662 673 B-Modifier
and NCT03868683 674 677 B-Or
/ NCT03868683 678 679 I-Or
or NCT03868683 680 682 I-Or
endurance NCT03868683 683 692 B-Modifier
levels NCT03868683 693 699 O

- NCT03868683 702 703 O
intentionally NCT03868683 705 718 O
restrict NCT03868683 719 727 B-Negation
food NCT03868683 728 732 B-Condition
intake NCT03868683 733 739 I-Condition

Inclusion NCT03866876 0 9 O
Criteria NCT03866876 10 18 O
: NCT03866876 19 20 O

- NCT03866876 24 25 O
All NCT03866876 27 30 O
birth NCT03866876 31 36 B-Birth
more NCT03866876 37 41 B-Eq-Comparison
than NCT03866876 42 46 I-Eq-Comparison
37 NCT03866876 47 49 I-Eq-Comparison
weeks NCT03866876 50 55 I-Eq-Comparison
of NCT03866876 56 58 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03866876 59 69 B-Condition
at NCT03866876 70 72 O
the NCT03866876 73 76 O
maternity NCT03866876 77 86 O
ward NCT03866876 87 91 O
of NCT03866876 92 94 O
the NCT03866876 95 98 O
hospital NCT03866876 99 107 O
Femme NCT03866876 108 113 O
- NCT03866876 114 115 O
Mère NCT03866876 116 120 O
- NCT03866876 121 122 O
Enfant NCT03866876 123 129 O

- NCT03866876 132 133 O
from NCT03866876 135 139 O
1 NCT03866876 140 141 B-Eq-Comparison
st NCT03866876 142 144 I-Eq-Comparison
of NCT03866876 145 147 I-Eq-Comparison
january NCT03866876 148 155 I-Eq-Comparison
2000 NCT03866876 156 160 I-Eq-Comparison
to NCT03866876 161 163 I-Eq-Comparison
31 NCT03866876 164 166 I-Eq-Comparison
december NCT03866876 167 175 I-Eq-Comparison
2016 NCT03866876 176 180 I-Eq-Comparison

Exclusion NCT03866876 182 191 O
Criteria NCT03866876 192 200 O
: NCT03866876 201 202 O

- NCT03866876 206 207 O
Infants NCT03866876 209 216 O
born NCT03866876 217 221 B-Birth
out NCT03866876 222 225 B-Negation
of NCT03866876 226 228 I-Negation
the NCT03866876 229 232 O
hospital NCT03866876 233 241 O
and NCT03866876 242 245 B-And
secondarily NCT03866876 246 257 B-Encounter
hospitalized NCT03866876 258 270 I-Encounter
in NCT03866876 271 273 O
the NCT03866876 274 277 O
hospital NCT03866876 278 286 O
Femme NCT03866876 287 292 O
- NCT03866876 293 294 O
Mère NCT03866876 295 299 O
- NCT03866876 300 301 O
Enfant NCT03866876 302 308 O

- NCT03866876 311 312 O
Children NCT03866876 314 322 O
with NCT03866876 323 327 B-And
congenital NCT03866876 328 338 B-Condition
anomalies NCT03866876 339 348 I-Condition
or NCT03866876 349 351 B-Or
without NCT03866876 352 359 B-Negation
valid NCT03866876 360 365 O
arterial NCT03866876 366 374 B-Modifier
and NCT03866876 375 378 B-Or
venous NCT03866876 379 385 B-Modifier
umbilical NCT03866876 386 395 B-Observation
cord NCT03866876 396 400 I-Observation
samples NCT03866876 401 408 I-Observation

Inclusion NCT03866447 0 9 O
Criteria NCT03866447 10 18 O
: NCT03866447 19 20 O

1 NCT03866447 24 25 O
. NCT03866447 25 26 O
Patients NCT03866447 28 36 O
with NCT03866447 37 41 O
Acne NCT03866447 42 46 B-Condition
of NCT03866447 47 49 O
any NCT03866447 50 53 O
grade NCT03866447 54 59 O
. NCT03866447 60 61 O

2 NCT03866447 65 66 O
. NCT03866447 66 67 O
Patients NCT03866447 69 77 O
between NCT03866447 78 85 B-Eq-Comparison
18 NCT03866447 86 88 I-Eq-Comparison
and NCT03866447 89 92 I-Eq-Comparison
45 NCT03866447 93 95 I-Eq-Comparison
years NCT03866447 96 101 I-Eq-Comparison
old NCT03866447 102 105 B-Age
. NCT03866447 106 107 O

Exclusion NCT03866447 109 118 O
Criteria NCT03866447 119 127 O
: NCT03866447 128 129 O

1 NCT03866447 133 134 O
. NCT03866447 134 135 O
Patients NCT03866447 137 145 O
below NCT03866447 146 151 B-Eq-Comparison
18 NCT03866447 152 154 I-Eq-Comparison
and NCT03866447 155 158 B-Or
above NCT03866447 159 164 B-Eq-Comparison
45 NCT03866447 165 167 I-Eq-Comparison
years NCT03866447 168 173 I-Age|Eq-Comparison
. NCT03866447 174 175 O

2 NCT03866447 179 180 O
. NCT03866447 180 181 O
Patients NCT03866447 183 191 O
with NCT03866447 192 196 O
any NCT03866447 197 200 O
concomitant NCT03866447 201 212 B-Modifier
Dermatologic NCT03866447 213 225 I-Modifier
or NCT03866447 226 228 B-Or
systemic NCT03866447 229 237 B-Modifier
illness NCT03866447 238 245 B-Condition

3 NCT03866447 248 249 O
. NCT03866447 249 250 O
Patients NCT03866447 252 260 O
on NCT03866447 261 263 O
any NCT03866447 264 267 O
topical NCT03866447 268 275 B-Modifier
or NCT03866447 276 278 B-Or
systemic NCT03866447 279 287 B-Modifier
medication NCT03866447 288 298 B-Drug
within NCT03866447 299 305 B-Eq-Comparison
4 NCT03866447 306 307 I-Eq-Comparison
weeks NCT03866447 308 313 I-Eq-Comparison
before NCT03866447 314 320 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03866447 321 331 B-Study
. NCT03866447 332 333 O

4 NCT03866447 337 338 O
. NCT03866447 338 339 O
Pregnancy NCT03866447 341 350 B-Condition
. NCT03866447 350 351 O

Inclusion NCT03867981 0 9 O
Criteria NCT03867981 10 18 O
: NCT03867981 19 20 O

- NCT03867981 24 25 O
Age NCT03867981 27 30 B-Age
18 NCT03867981 31 33 B-Eq-Comparison
- NCT03867981 34 35 I-Eq-Comparison
70 NCT03867981 36 38 O

- NCT03867981 42 43 O
BMI NCT03867981 45 48 B-Observation
: NCT03867981 49 50 O
25 NCT03867981 51 53 B-Eq-Comparison
- NCT03867981 54 55 I-Eq-Comparison
45 NCT03867981 56 58 I-Eq-Comparison
kg NCT03867981 59 61 I-Eq-Comparison
/ NCT03867981 62 63 I-Eq-Comparison
m2 NCT03867981 64 66 I-Eq-Comparison

- NCT03867981 69 70 O
Regular NCT03867981 72 79 O
internet NCT03867981 80 88 O
access NCT03867981 89 95 O

Exclusion NCT03867981 96 105 O
Criteria NCT03867981 106 114 O
: NCT03867981 115 116 O

- NCT03867981 120 121 O
Currently NCT03867981 123 132 B-Eq-Comparison
pregnant NCT03867981 133 141 B-Condition
, NCT03867981 142 143 O
< NCT03867981 144 145 B-Eq-Comparison
6 NCT03867981 146 147 I-Eq-Comparison
months NCT03867981 148 154 I-Eq-Comparison
post NCT03867981 155 159 B-Condition
- NCT03867981 160 161 I-Condition
partum NCT03867981 162 168 I-Condition
, NCT03867981 169 170 O
nursing NCT03867981 171 178 B-Condition
, NCT03867981 179 180 O
or NCT03867981 181 183 B-Or
planning NCT03867981 184 192 B-Assertion___Assertion-Type-Value:intention
to NCT03867981 193 195 I-Assertion___Assertion-Type-Value:intention
become NCT03867981 196 202 I-Assertion___Assertion-Type-Value:intention
pregnant NCT03867981 203 211 B-Condition
within NCT03867981 212 218 B-Eq-Comparison
the NCT03867981 219 222 I-Eq-Comparison
next NCT03867981 223 227 I-Eq-Comparison
12 NCT03867981 228 230 I-Eq-Comparison
months NCT03867981 231 237 I-Eq-Comparison
. NCT03867981 238 239 O

- NCT03867981 243 244 O
Current NCT03867981 246 253 B-Eq-Comparison
enrollment NCT03867981 254 264 O
in NCT03867981 265 267 O
a NCT03867981 268 269 O
commercial NCT03867981 270 280 B-Modifier
weight NCT03867981 281 287 B-Procedure
loss NCT03867981 288 292 I-Procedure
program NCT03867981 293 300 I-Procedure
or NCT03867981 301 303 B-Or
other NCT03867981 304 309 B-Other
weight NCT03867981 310 316 B-Procedure
loss NCT03867981 317 321 I-Procedure
research NCT03867981 322 330 O
study NCT03867981 331 336 B-Study

- NCT03867981 339 340 O
Currently NCT03867981 342 351 B-Eq-Comparison
taking NCT03867981 352 358 O
weight NCT03867981 359 365 B-Procedure
loss NCT03867981 366 370 I-Procedure
medications NCT03867981 371 382 B-Drug

- NCT03867981 385 386 O
Previously NCT03867981 388 398 B-Eq-Comparison
had NCT03867981 399 402 O
bariatric NCT03867981 403 412 B-Procedure
surgery NCT03867981 413 420 I-Procedure

- NCT03867981 423 424 O
Inability NCT03867981 426 435 B-Condition
to NCT03867981 436 438 I-Condition
walk NCT03867981 439 443 I-Condition
2 NCT03867981 444 445 B-Modifier
blocks NCT03867981 446 452 I-Modifier
without NCT03867981 453 460 I-Modifier
stopping NCT03867981 461 469 I-Modifier

- NCT03867981 472 473 O
Any NCT03867981 475 478 O
medical NCT03867981 479 486 B-Condition
condition NCT03867981 487 496 I-Condition
for NCT03867981 497 500 O
which NCT03867981 501 506 O
weight NCT03867981 507 513 B-Procedure
loss NCT03867981 514 518 I-Procedure
, NCT03867981 519 520 O
dietary NCT03867981 521 528 B-Procedure
restriction NCT03867981 529 540 I-Procedure
, NCT03867981 541 542 O
or NCT03867981 543 545 B-Or
physical NCT03867981 546 554 B-Observation
activity NCT03867981 555 563 I-Observation
is NCT03867981 564 566 O
contraindicated NCT03867981 567 582 B-Contraindication

Inclusion NCT03865628 0 9 O
Criteria NCT03865628 10 18 O
: NCT03865628 19 20 O

- NCT03865628 24 25 O
Singleton NCT03865628 27 36 B-Modifier
pregnancy NCT03865628 37 46 B-Condition

- NCT03865628 49 50 O
Estimation NCT03865628 52 62 O
of NCT03865628 63 65 O
the NCT03865628 66 69 O
fetal NCT03865628 70 75 B-Modifier
weight NCT03865628 76 82 B-Observation
less NCT03865628 83 87 B-Eq-Comparison
than NCT03865628 88 92 I-Eq-Comparison
estimation NCT03865628 93 103 I-Eq-Comparison
the NCT03865628 104 107 I-Eq-Comparison
10 NCT03865628 108 110 I-Eq-Comparison
th NCT03865628 111 113 I-Eq-Comparison
percentile NCT03865628 114 124 I-Eq-Comparison

Exclusion NCT03865628 125 134 O
Criteria NCT03865628 135 143 O
: NCT03865628 144 145 O

- NCT03865628 149 150 O
Refusal NCT03865628 152 159 O
of NCT03865628 160 162 O
parents NCT03865628 163 170 O

- NCT03865628 173 174 O
Fetal NCT03865628 176 181 B-Modifier
and NCT03865628 182 185 B-Or
vascular NCT03865628 186 194 B-Modifier
malformations NCT03865628 195 208 B-Condition

- NCT03865628 211 212 O
Fetal NCT03865628 214 219 B-Condition
anemia NCT03865628 220 226 I-Condition

Inclusions NCT03864536 0 10 O
: NCT03864536 11 12 O

- NCT03864536 16 17 O
Must NCT03864536 19 23 O
be NCT03864536 24 26 O
African NCT03864536 27 34 O
American NCT03864536 35 43 O

- NCT03864536 46 47 O
Must NCT03864536 49 53 O
be NCT03864536 54 56 O
age NCT03864536 57 60 B-Age
50 NCT03864536 61 63 B-Eq-Comparison
to NCT03864536 64 66 I-Eq-Comparison
65 NCT03864536 67 69 I-Eq-Comparison

- NCT03864536 73 74 O
Must NCT03864536 76 80 O
have NCT03864536 81 85 O
a NCT03864536 86 87 O
working NCT03864536 88 95 O
cell NCT03864536 96 100 O
phone NCT03864536 101 106 O
with NCT03864536 107 111 O
unlimited NCT03864536 112 121 O
texting NCT03864536 122 129 O

- NCT03864536 132 133 O
Must NCT03864536 135 139 O
be NCT03864536 140 142 O
ambulatory NCT03864536 143 153 B-Condition

Exclusions NCT03864536 154 164 O
: NCT03864536 165 166 O

- NCT03864536 170 171 O
No NCT03864536 173 175 B-Negation
neurological NCT03864536 176 188 B-Modifier
( NCT03864536 189 190 O
including NCT03864536 191 200 O
dementia NCT03864536 201 209 B-Condition
diagnosis NCT03864536 210 219 O
) NCT03864536 220 221 O
or NCT03864536 222 224 B-Or
severe NCT03864536 225 231 O
psychiatric NCT03864536 232 243 B-Modifier
( NCT03864536 244 245 O
e. NCT03864536 246 248 O
g. NCT03864536 249 251 O
, NCT03864536 252 253 O
schizophrenia NCT03864536 254 267 B-Condition
or NCT03864536 268 270 B-Or
bipolar NCT03864536 271 278 B-Condition
disorder NCT03864536 279 287 I-Condition
) NCT03864536 288 289 O
disorders NCT03864536 290 299 B-Condition

- NCT03864536 302 303 O
No NCT03864536 305 307 B-Negation
insomnia NCT03864536 308 316 B-Condition

- NCT03864536 319 320 O
Telephone NCT03864536 322 331 B-Observation
Interview NCT03864536 332 341 I-Observation
for NCT03864536 342 345 I-Observation
Cognitive NCT03864536 346 355 I-Observation
Status NCT03864536 356 362 I-Observation
( NCT03864536 363 364 O
TICS NCT03864536 365 369 B-Observation
) NCT03864536 370 371 O
score NCT03864536 372 377 O
≤ NCT03864536 378 379 B-Eq-Comparison
20 NCT03864536 380 382 I-Eq-Comparison

Inclusion NCT03867942 0 9 O
Criteria NCT03867942 10 18 O
: NCT03867942 19 20 O

- NCT03867942 24 25 O
Age NCT03867942 27 30 B-Age
: NCT03867942 31 32 O
19 NCT03867942 33 35 B-Eq-Comparison
~ NCT03867942 36 37 I-Eq-Comparison
45 NCT03867942 38 40 I-Eq-Comparison

- NCT03867942 44 45 O
Body NCT03867942 47 51 B-Observation
weight NCT03867942 52 58 I-Observation
: NCT03867942 59 60 O
55 NCT03867942 61 63 B-Eq-Comparison
kg NCT03867942 64 66 I-Eq-Comparison
or NCT03867942 67 69 I-Eq-Comparison
higher NCT03867942 70 76 I-Eq-Comparison
( NCT03867942 77 78 O
female NCT03867942 79 85 O
: NCT03867942 86 87 O
50 NCT03867942 88 90 B-Eq-Comparison
kg NCT03867942 91 93 I-Eq-Comparison
or NCT03867942 94 96 I-Eq-Comparison
higher NCT03867942 97 103 I-Eq-Comparison
) NCT03867942 104 105 O
and NCT03867942 106 109 B-And
BMI NCT03867942 110 113 B-Observation
18 NCT03867942 114 116 B-Eq-Comparison
~ NCT03867942 117 118 I-Eq-Comparison
27 NCT03867942 119 121 I-Eq-Comparison
kg NCT03867942 122 124 I-Eq-Comparison
/ NCT03867942 125 126 I-Eq-Comparison
m2 NCT03867942 127 129 I-Eq-Comparison

- NCT03867942 132 133 O
SBP NCT03867942 135 138 B-Observation
90 NCT03867942 139 141 B-Eq-Comparison
~ NCT03867942 142 143 I-Eq-Comparison
150 NCT03867942 144 147 I-Eq-Comparison
mmHg NCT03867942 148 152 I-Eq-Comparison
, NCT03867942 153 154 O
DBP NCT03867942 155 158 B-Observation
60 NCT03867942 159 161 B-Eq-Comparison
- NCT03867942 162 163 I-Eq-Comparison
95 NCT03867942 164 166 O
mmHg NCT03867942 167 171 O

- NCT03867942 174 175 O
Fasting NCT03867942 177 184 B-Modifier
glucose NCT03867942 185 192 B-Observation
70 NCT03867942 193 195 B-Eq-Comparison
~ NCT03867942 196 197 I-Eq-Comparison
120 NCT03867942 198 201 I-Eq-Comparison
mg NCT03867942 202 204 I-Eq-Comparison
/ NCT03867942 205 206 I-Eq-Comparison
dL NCT03867942 207 209 I-Eq-Comparison

- NCT03867942 212 213 O
Infertility NCT03867942 215 226 B-Condition

1 NCT03867942 234 235 O
. NCT03867942 235 236 O
Surgically NCT03867942 238 248 B-Modifier
infertile NCT03867942 249 258 B-Condition

2 NCT03867942 266 267 O
. NCT03867942 267 268 O
To NCT03867942 270 272 O
prevent NCT03867942 273 280 B-Assertion___Assertion-Type-Value:hypothetical|Negation
pregnancy NCT03867942 281 290 B-Condition
, NCT03867942 291 292 O
participants NCT03867942 293 305 O
who NCT03867942 306 309 O
agreed NCT03867942 310 316 B-Assertion___Assertion-Type-Value:hypothetical
using NCT03867942 317 322 B-Eq-Comparison
2 NCT03867942 323 324 B-Eq-Comparison
or NCT03867942 325 327 I-Eq-Comparison
more NCT03867942 328 332 I-Eq-Comparison
contraceptive NCT03867942 333 346 B-Procedure
methods NCT03867942 347 354 I-Procedure
. NCT03867942 354 355 O
Such NCT03867942 357 361 O
as NCT03867942 362 364 O

- NCT03867942 367 368 O
Barrier NCT03867942 370 377 B-Procedure
methods NCT03867942 378 385 I-Procedure
: NCT03867942 386 387 O
Condom NCT03867942 388 394 B-Procedure
, NCT03867942 395 396 O
Diaphragm NCT03867942 397 406 B-Condition
, NCT03867942 407 408 O
Cervical NCT03867942 409 417 B-Procedure
cap NCT03867942 418 421 I-Procedure
( NCT03867942 422 423 O
Pessary NCT03867942 424 431 B-Procedure
) NCT03867942 432 433 O
, NCT03867942 435 436 O
Spermicide NCT03867942 437 447 B-Procedure

- NCT03867942 450 451 O
Hormonal NCT03867942 453 461 B-Procedure
methods NCT03867942 462 469 I-Procedure
: NCT03867942 470 471 O
Pills NCT03867942 472 477 B-Drug
, NCT03867942 478 479 O
Injection NCT03867942 480 489 B-Procedure
( NCT03867942 490 491 O
Depot NCT03867942 492 497 B-Modifier
) NCT03867942 498 499 O
, NCT03867942 501 502 O
Skin NCT03867942 503 507 B-Procedure
patch NCT03867942 508 513 I-Procedure
, NCT03867942 514 515 O
Hormonal NCT03867942 516 524 B-Procedure
implant NCT03867942 525 532 I-Procedure
( NCT03867942 533 534 O
Implanon NCT03867942 535 543 B-Modifier
) NCT03867942 544 545 O
, NCT03867942 547 548 O
Vaginal NCT03867942 549 556 B-Procedure
ring NCT03867942 557 561 I-Procedure

- NCT03867942 564 565 O
Intrauterine NCT03867942 567 579 B-Procedure
Devices NCT03867942 580 587 I-Procedure
( NCT03867942 588 589 O
IUDs NCT03867942 590 594 B-Procedure
) NCT03867942 595 596 O
: NCT03867942 598 599 O
Cooper NCT03867942 600 606 B-Modifier
IUD NCT03867942 607 610 B-Procedure
( NCT03867942 611 612 O
Loop NCT03867942 613 617 B-Modifier
) NCT03867942 618 619 O
, NCT03867942 621 622 O
Hormonal NCT03867942 623 631 B-Modifier
IUD NCT03867942 632 635 B-Procedure
( NCT03867942 636 637 O
Mirena NCT03867942 638 644 B-Modifier
) NCT03867942 645 646 O

- NCT03867942 650 651 O
Natural NCT03867942 653 660 B-Procedure
methods NCT03867942 661 668 I-Procedure
: NCT03867942 669 670 O
Basic NCT03867942 671 676 B-Modifier
body NCT03867942 677 681 B-Observation
temperature NCT03867942 682 693 I-Observation
, NCT03867942 694 695 O
Ovulation NCT03867942 696 705 B-Condition
period NCT03867942 706 712 I-Condition
, NCT03867942 713 714 O
Coitus NCT03867942 715 721 B-Procedure
interruptus NCT03867942 722 733 I-Procedure
, NCT03867942 734 735 O
Abstinent NCT03867942 736 745 B-Condition

- NCT03867942 748 749 O
People NCT03867942 751 757 O
who NCT03867942 758 761 O
perfectly NCT03867942 762 771 O
understood NCT03867942 772 782 O
clinical NCT03867942 783 791 O
trial NCT03867942 792 797 O
and NCT03867942 798 801 O
independently NCT03867942 802 815 O
decided NCT03867942 816 823 O
to NCT03867942 824 826 O
participate NCT03867942 827 838 O
in NCT03867942 839 841 O
clinical NCT03867942 842 850 O
trial NCT03867942 851 856 O
. NCT03867942 857 858 O

- NCT03867942 862 863 O
People NCT03867942 865 871 O
who NCT03867942 872 875 O
will NCT03867942 876 880 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867942 881 883 I-Assertion___Assertion-Type-Value:hypothetical
able NCT03867942 884 888 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03867942 889 891 O
collect NCT03867942 892 899 O
blood NCT03867942 900 905 B-Observation
sample NCT03867942 906 912 I-Observation
during NCT03867942 913 919 B-Temporal-Connection___Temporal-Connection-Type-Value:during
clinical NCT03867942 920 928 B-Study
trial NCT03867942 929 934 I-Study
period NCT03867942 935 941 O
. NCT03867942 942 943 O

- NCT03867942 947 948 O
People NCT03867942 950 956 O
who NCT03867942 957 960 O
are NCT03867942 961 964 O
suitable NCT03867942 965 973 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03867942 974 976 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03867942 977 988 I-Assertion___Assertion-Type-Value:hypothetical
clinical NCT03867942 989 997 B-Study
trial NCT03867942 998 1003 I-Study
by NCT03867942 1004 1006 O
physical NCT03867942 1007 1015 B-Procedure
examination NCT03867942 1016 1027 I-Procedure
, NCT03867942 1028 1029 O
lab NCT03867942 1030 1033 B-Observation
test NCT03867942 1034 1038 I-Observation
and NCT03867942 1039 1042 B-And
medical NCT03867942 1043 1050 B-Procedure
examination NCT03867942 1051 1062 I-Procedure
by NCT03867942 1063 1065 B-Modifier
interview NCT03867942 1066 1075 I-Modifier
. NCT03867942 1076 1077 O

Exclusion NCT03867942 1079 1088 O
Criteria NCT03867942 1089 1097 O
: NCT03867942 1098 1099 O

- NCT03867942 1103 1104 O
Genetic NCT03867942 1106 1113 B-Condition
problems NCT03867942 1114 1122 I-Condition
such NCT03867942 1123 1127 O
as NCT03867942 1128 1130 O
galactose NCT03867942 1131 1140 B-Condition
intolerance NCT03867942 1141 1152 I-Condition
, NCT03867942 1153 1154 O
Lapp NCT03867942 1155 1159 B-Condition
lacatase NCT03867942 1160 1168 I-Condition
deficiency NCT03867942 1169 1179 I-Condition
, NCT03867942 1180 1181 O
glucose NCT03867942 1182 1189 B-Condition
- NCT03867942 1190 1191 I-Condition
galactose NCT03867942 1192 1201 I-Condition
malabsorption NCT03867942 1202 1215 I-Condition

- NCT03867942 1218 1219 O
Clinically NCT03867942 1221 1231 O
significant NCT03867942 1232 1243 O
disease NCT03867942 1244 1251 B-Condition
such NCT03867942 1252 1256 O
as NCT03867942 1257 1259 O
liver NCT03867942 1260 1265 B-Modifier
, NCT03867942 1266 1267 O
kidney NCT03867942 1268 1274 B-Modifier
, NCT03867942 1275 1276 O
digestive NCT03867942 1277 1286 B-Modifier
, NCT03867942 1287 1288 O
pulmonary NCT03867942 1289 1298 B-Modifier
, NCT03867942 1299 1300 O
endocrine NCT03867942 1301 1310 B-Modifier
system NCT03867942 1311 1317 I-Modifier
, NCT03867942 1318 1319 O
cardiovascular NCT03867942 1320 1334 B-Modifier
disease NCT03867942 1335 1342 B-Condition
etc NCT03867942 1343 1346 O
. NCT03867942 1347 1348 O

- NCT03867942 1352 1353 O
People NCT03867942 1355 1361 O
who NCT03867942 1362 1365 O
have NCT03867942 1366 1370 O
gastrointestinal NCT03867942 1371 1387 B-Condition
disease NCT03867942 1388 1395 I-Condition
or NCT03867942 1396 1398 B-Or
history NCT03867942 1399 1406 B-Eq-Comparison
of NCT03867942 1407 1409 O
surgery NCT03867942 1410 1417 B-Procedure
which NCT03867942 1418 1423 O
would NCT03867942 1424 1429 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03867942 1430 1436 O
absorption NCT03867942 1437 1447 B-Condition
of NCT03867942 1448 1450 O
drug NCT03867942 1451 1455 B-Drug
. NCT03867942 1456 1457 O

- NCT03867942 1461 1462 O
History NCT03867942 1464 1471 B-Eq-Comparison
of NCT03867942 1472 1474 O
clinically NCT03867942 1475 1485 O
significant NCT03867942 1486 1497 O
drug NCT03867942 1498 1502 B-Drug
induced NCT03867942 1503 1510 O
hyper NCT03867942 1511 1516 B-Condition
- NCT03867942 1517 1518 I-Condition
sensitive NCT03867942 1519 1528 I-Condition
reaction NCT03867942 1529 1537 I-Condition
or NCT03867942 1538 1540 B-Or
drug NCT03867942 1541 1545 B-Drug
related NCT03867942 1546 1553 O
muscular NCT03867942 1554 1562 B-Condition
disease NCT03867942 1563 1570 I-Condition

Inclusion NCT03865199 0 9 O
Criteria NCT03865199 10 18 O
: NCT03865199 19 20 O

- NCT03865199 24 25 O
Women NCT03865199 27 32 O
aged NCT03865199 33 37 B-Age
18 NCT03865199 38 40 B-Eq-Comparison
or NCT03865199 41 43 I-Eq-Comparison
older NCT03865199 44 49 I-Eq-Comparison
undergoing NCT03865199 50 60 B-Eq-Comparison
medical NCT03865199 61 68 B-Modifier
or NCT03865199 69 71 B-Or
surgical NCT03865199 72 80 B-Modifier
abortion NCT03865199 81 89 B-Procedure
at NCT03865199 90 92 O
Planned NCT03865199 93 100 O
Parenthood NCT03865199 101 111 O
of NCT03865199 112 114 O
Illinois NCT03865199 115 123 O
( NCT03865199 124 125 O
PPIL NCT03865199 126 130 O
) NCT03865199 131 132 O
will NCT03865199 133 137 O
be NCT03865199 138 140 O
eligible NCT03865199 141 149 O
for NCT03865199 150 153 O
inclusion NCT03865199 154 163 O
. NCT03865199 163 164 O
Inclusion NCT03865199 166 175 O
criteria NCT03865199 176 184 O
include NCT03865199 185 192 O
having NCT03865199 193 199 O
an NCT03865199 200 202 O
intrauterine NCT03865199 203 215 B-Modifier
pregnancy NCT03865199 216 225 B-Condition
, NCT03865199 226 227 O
having NCT03865199 228 234 O
a NCT03865199 235 236 O
smart NCT03865199 237 242 O
phone NCT03865199 243 248 O
to NCT03865199 249 251 O
be NCT03865199 252 254 O
able NCT03865199 255 259 O
to NCT03865199 260 262 O
follow NCT03865199 263 269 O
- NCT03865199 270 271 O
up NCT03865199 272 274 O
by NCT03865199 275 277 O
text NCT03865199 278 282 O
message NCT03865199 283 290 O
2 NCT03865199 291 292 B-Eq-Comparison
- NCT03865199 293 294 I-Eq-Comparison
4 NCT03865199 295 296 I-Eq-Comparison
weeks NCT03865199 297 302 I-Eq-Comparison
after NCT03865199 303 308 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865199 309 312 O
clinic NCT03865199 313 319 B-Encounter
appointment NCT03865199 320 331 I-Encounter
, NCT03865199 332 333 O
having NCT03865199 334 340 O
no NCT03865199 341 343 B-Negation
contraindications NCT03865199 344 361 B-Contraindication
to NCT03865199 362 364 O
an NCT03865199 365 367 O
outpatient NCT03865199 368 378 B-Encounter
medication NCT03865199 379 389 B-Modifier
or NCT03865199 390 392 B-Or
surgical NCT03865199 393 401 B-Modifier
abortion NCT03865199 402 410 B-Procedure
that NCT03865199 411 415 O
same NCT03865199 416 420 O
day NCT03865199 421 424 O
, NCT03865199 425 426 O
and NCT03865199 427 430 O
not NCT03865199 431 434 O
meeting NCT03865199 435 442 O
any NCT03865199 443 446 O
exclusion NCT03865199 447 456 O
criteria NCT03865199 457 465 O
. NCT03865199 466 467 O

Exclusion NCT03865199 469 478 O
Criteria NCT03865199 479 487 O
: NCT03865199 488 489 O

- NCT03865199 493 494 O
Exclusion NCT03865199 496 505 O
criteria NCT03865199 506 514 O
will NCT03865199 515 519 O
include NCT03865199 520 527 O
non NCT03865199 528 531 B-Negation
- NCT03865199 532 533 O
English NCT03865199 534 541 O
speaking NCT03865199 542 550 O
, NCT03865199 551 552 O
no NCT03865199 553 555 O
working NCT03865199 556 563 O
telephone NCT03865199 564 573 O
, NCT03865199 574 575 O
and NCT03865199 576 579 O
less NCT03865199 580 584 B-Eq-Comparison
than NCT03865199 585 589 I-Eq-Comparison
5 NCT03865199 590 591 I-Eq-Comparison
th NCT03865199 592 594 I-Eq-Comparison
grade NCT03865199 595 600 I-Eq-Comparison
education NCT03865199 601 610 B-Observation
level NCT03865199 611 616 I-Observation
. NCT03865199 616 617 O

Inclusion NCT03860142 0 9 O
Criteria NCT03860142 10 18 O
: NCT03860142 19 20 O

- NCT03860142 24 25 O
Children NCT03860142 27 35 O
whose NCT03860142 36 41 B-And
age NCT03860142 42 45 B-Age
≥ NCT03860142 46 47 B-Eq-Comparison
24 NCT03860142 48 50 I-Eq-Comparison
months NCT03860142 51 57 I-Eq-Comparison
and NCT03860142 58 61 B-And
≤ NCT03860142 62 63 B-Eq-Comparison
36 NCT03860142 64 66 I-Eq-Comparison
months NCT03860142 67 73 I-Eq-Comparison

- NCT03860142 76 77 O
Full NCT03860142 79 83 B-Modifier
- NCT03860142 84 85 I-Modifier
term NCT03860142 86 90 I-Modifier
or NCT03860142 91 93 B-Or
prematurely NCT03860142 94 105 B-Modifier
born NCT03860142 106 110 B-Birth
( NCT03860142 111 112 O
< NCT03860142 114 115 B-Eq-Comparison
33 NCT03860142 116 118 I-Eq-Comparison
SA NCT03860142 119 121 B-Observation
) NCT03860142 122 123 O
at NCT03860142 124 126 O
Nice NCT03860142 127 131 O
University NCT03860142 132 142 O
Hospital NCT03860142 143 151 O

Exclusion NCT03860142 152 161 O
Criteria NCT03860142 162 170 O
: NCT03860142 171 172 O

- NCT03860142 176 177 O
Children NCT03860142 179 187 O
with NCT03860142 188 192 B-And
congenital NCT03860142 193 203 B-Condition
pathologies NCT03860142 204 215 I-Condition
( NCT03860142 216 217 O
with NCT03860142 218 222 O
malformations NCT03860142 223 236 B-Condition
in NCT03860142 237 239 O
the NCT03860142 240 243 O
oro NCT03860142 244 247 B-Modifier
- NCT03860142 248 249 I-Modifier
facial NCT03860142 250 256 I-Modifier
sphere NCT03860142 257 263 I-Modifier
) NCT03860142 264 265 O

- NCT03860142 269 270 O
Children NCT03860142 272 280 O
with NCT03860142 281 285 B-And
neurological NCT03860142 286 298 B-Modifier
and NCT03860142 299 302 B-Or
developmental NCT03860142 303 316 B-Modifier
pathologies NCT03860142 317 328 B-Condition
unrelated NCT03860142 329 338 B-Exception
to NCT03860142 339 341 I-Exception
prematurity NCT03860142 342 353 B-Condition

- NCT03860142 356 357 O
Children NCT03860142 359 367 O
with NCT03860142 368 372 B-And
ENT NCT03860142 373 376 B-Condition
deformities NCT03860142 377 388 I-Condition

- NCT03860142 391 392 O
Parental NCT03860142 394 402 B-Family-Member___Family-Member-Type:parent
langage NCT03860142 403 410 B-Condition
barrier NCT03860142 411 418 I-Condition

Inclusion NCT03862755 0 9 O
Criteria NCT03862755 10 18 O
: NCT03862755 19 20 O

- NCT03862755 24 25 O
Lung NCT03862755 27 31 B-Procedure
surgical NCT03862755 32 40 I-Procedure
patients NCT03862755 41 49 O
who NCT03862755 50 53 B-And
were NCT03862755 54 58 O
sent NCT03862755 59 63 B-Encounter
to NCT03862755 64 66 O
thoracic NCT03862755 67 75 B-Modifier
post NCT03862755 76 80 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03862755 81 90 B-Procedure
intensive NCT03862755 91 100 O
care NCT03862755 101 105 O
unit NCT03862755 106 110 O
( NCT03862755 111 112 O
ICU NCT03862755 113 116 O
) NCT03862755 117 118 O
ward NCT03862755 119 123 O
right NCT03862755 124 129 O
after NCT03862755 130 135 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03862755 136 143 B-Procedure
and NCT03862755 144 147 B-And
stayed NCT03862755 148 154 B-Encounter
in NCT03862755 155 157 O
ICU NCT03862755 158 161 O
for NCT03862755 162 165 O
at NCT03862755 166 168 B-Eq-Comparison
least NCT03862755 169 174 I-Eq-Comparison
24 NCT03862755 175 177 I-Eq-Comparison
hours NCT03862755 178 183 I-Eq-Comparison
. NCT03862755 184 185 O

Exclusion NCT03862755 187 196 O
Criteria NCT03862755 197 205 O
: NCT03862755 206 207 O

- NCT03862755 211 212 O
Cases NCT03862755 214 219 O
received NCT03862755 220 228 B-Eq-Comparison
inferior NCT03862755 229 237 B-Procedure
vena NCT03862755 238 242 I-Procedure
filter NCT03862755 243 249 I-Procedure
and NCT03862755 250 253 B-Or
anti NCT03862755 254 258 B-Procedure
- NCT03862755 259 260 I-Procedure
coagulation NCT03862755 261 272 I-Procedure
treatment NCT03862755 273 282 I-Procedure
history NCT03862755 283 290 B-Eq-Comparison
. NCT03862755 290 291 O

Inclusion NCT03862027 0 9 O
Criteria NCT03862027 10 18 O
: NCT03862027 19 20 O

- NCT03862027 24 25 O
Adult NCT03862027 27 32 O
patients NCT03862027 33 41 O
( NCT03862027 42 43 O
age NCT03862027 44 47 B-Age
> NCT03862027 48 49 B-Eq-Comparison
/ NCT03862027 51 52 I-Eq-Comparison
= NCT03862027 54 55 I-Eq-Comparison
18 NCT03862027 56 58 I-Eq-Comparison
) NCT03862027 59 60 O
admitted NCT03862027 61 69 B-Encounter
to NCT03862027 70 72 O
the NCT03862027 73 76 O
Neuro NCT03862027 77 82 O
ICU NCT03862027 83 86 O
of NCT03862027 87 89 O
UNC NCT03862027 90 93 O
Hospital NCT03862027 94 102 O
requiring NCT03862027 103 112 O
mechanical NCT03862027 113 123 B-Procedure
ventilation NCT03862027 124 135 I-Procedure
and NCT03862027 136 139 B-And
with NCT03862027 140 144 O
ICP NCT03862027 145 148 B-Procedure
monitoring NCT03862027 149 159 I-Procedure
in NCT03862027 160 162 O
place NCT03862027 163 168 O
. NCT03862027 169 170 O

Exclusion NCT03862027 172 181 O
Criteria NCT03862027 182 190 O
: NCT03862027 191 192 O

1 NCT03862027 196 197 O
. NCT03862027 197 198 O
Pneumothorax NCT03862027 200 212 B-Condition
or NCT03862027 213 215 B-Or
pneumomediastinum NCT03862027 216 233 B-Condition

2 NCT03862027 236 237 O
. NCT03862027 237 238 O
Life NCT03862027 240 244 B-Observation
expectancy NCT03862027 245 255 I-Observation
< NCT03862027 256 257 B-Eq-Comparison
24 NCT03862027 258 260 I-Eq-Comparison
hours NCT03862027 261 266 I-Eq-Comparison
or NCT03862027 267 269 B-Or
expected NCT03862027 270 278 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03862027 279 281 I-Assertion___Assertion-Type-Value:hypothetical
require NCT03862027 282 289 O
mechanical NCT03862027 290 300 B-Procedure
ventilation NCT03862027 301 312 I-Procedure
for NCT03862027 313 316 O
< NCT03862027 317 318 B-Eq-Comparison
24 NCT03862027 319 321 I-Eq-Comparison
hours NCT03862027 322 327 I-Eq-Comparison

3 NCT03862027 330 331 O
. NCT03862027 331 332 O
Condition NCT03862027 334 343 B-Condition
that NCT03862027 344 348 O
precludes NCT03862027 349 358 B-Assertion___Assertion-Type-Value:hypothetical|Negation
placement NCT03862027 359 368 O
of NCT03862027 369 371 O
an NCT03862027 372 374 O
esophageal NCT03862027 375 385 B-Procedure
balloon NCT03862027 386 393 I-Procedure
[ NCT03862027 394 395 O
esophageal NCT03862027 396 406 B-Modifier
or NCT03862027 407 409 B-Or
nasopharyngeal NCT03862027 410 424 B-Modifier
pathology NCT03862027 425 434 B-Condition
preventing NCT03862027 435 445 B-Assertion___Assertion-Type-Value:hypothetical|Negation
insertion NCT03862027 446 455 O
of NCT03862027 456 458 O
the NCT03862027 459 462 O
esophageal NCT03862027 463 473 B-Procedure
balloon NCT03862027 474 481 I-Procedure
catheter NCT03862027 482 490 I-Procedure
( NCT03862027 491 492 O
esophageal NCT03862027 493 503 B-Condition
ulcerations NCT03862027 504 515 I-Condition
, NCT03862027 516 517 O
tumors NCT03862027 518 524 B-Condition
, NCT03862027 525 526 O
diverticulitis NCT03862027 527 541 B-Condition
, NCT03862027 542 543 O
bleeding NCT03862027 544 552 B-Condition
varices NCT03862027 553 560 I-Condition
or NCT03862027 561 563 B-Or
in NCT03862027 564 566 O
patients NCT03862027 567 575 O
with NCT03862027 576 580 O
sinusitis NCT03862027 581 590 B-Condition
, NCT03862027 591 592 O
epistaxis NCT03862027 593 602 B-Condition
or NCT03862027 603 605 B-Or
recent NCT03862027 606 612 B-Eq-Comparison
nasopharyngeal NCT03862027 613 627 B-Procedure
surgery NCT03862027 628 635 I-Procedure
) NCT03862027 636 637 O
, NCT03862027 639 640 O
severe NCT03862027 641 647 O
thrombocytopenia NCT03862027 648 664 B-Condition
( NCT03862027 665 666 O
platelet NCT03862027 667 675 B-Observation
count NCT03862027 676 681 I-Observation
< NCT03862027 682 683 B-Eq-Comparison
30 NCT03862027 684 686 I-Eq-Comparison
) NCT03862027 687 688 O
or NCT03862027 689 691 B-Or
coagulopathy NCT03862027 692 704 B-Condition
( NCT03862027 705 706 O
INR NCT03862027 707 710 B-Observation
> NCT03862027 711 712 B-Eq-Comparison
3 NCT03862027 713 714 I-Eq-Comparison
or NCT03862027 715 717 B-Or
on NCT03862027 718 720 B-Eq-Comparison
oral NCT03862027 721 725 B-Drug
anticoagulants NCT03862027 726 740 I-Drug
) NCT03862027 741 742 O
. NCT03862027 744 745 O

4 NCT03862027 749 750 O
. NCT03862027 750 751 O
Pre NCT03862027 753 756 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 757 758 O
enrollment NCT03862027 759 769 B-Study
ICP NCT03862027 770 773 B-Observation
> NCT03862027 774 775 B-Eq-Comparison
20 NCT03862027 776 778 I-Eq-Comparison
mm NCT03862027 779 781 I-Eq-Comparison
Hg NCT03862027 782 784 I-Eq-Comparison

5 NCT03862027 787 788 O
. NCT03862027 788 789 O
Pre NCT03862027 791 794 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 795 796 O
enrollment NCT03862027 797 807 B-Study
CPP NCT03862027 808 811 B-Observation
< NCT03862027 812 813 B-Eq-Comparison
60 NCT03862027 814 816 I-Eq-Comparison
mm NCT03862027 817 819 I-Eq-Comparison
Hg NCT03862027 820 822 I-Eq-Comparison

6 NCT03862027 825 826 O
. NCT03862027 826 827 O
Planned NCT03862027 829 836 B-Eq-Comparison
change NCT03862027 837 843 O
in NCT03862027 844 846 O
the NCT03862027 847 850 O
external NCT03862027 851 859 B-Procedure
ventricular NCT03862027 860 871 I-Procedure
drain NCT03862027 872 877 I-Procedure
set NCT03862027 878 881 B-Modifier
point NCT03862027 882 887 I-Modifier
during NCT03862027 888 894 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862027 895 898 O
pre NCT03862027 899 902 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03862027 903 904 O
intervention NCT03862027 905 917 B-Procedure
, NCT03862027 918 919 O
intervention NCT03862027 920 932 B-Procedure
or NCT03862027 933 935 B-Or
post NCT03862027 936 940 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03862027 941 942 O
intervention NCT03862027 943 955 B-Procedure
periods NCT03862027 956 963 O

7 NCT03862027 966 967 O
. NCT03862027 967 968 O
Incarceration NCT03862027 970 983 B-Observation

8 NCT03862027 986 987 O
. NCT03862027 987 988 O
Variation NCT03862027 990 999 O
in NCT03862027 1000 1002 O
ICP NCT03862027 1003 1006 B-Observation
of NCT03862027 1007 1009 O
> NCT03862027 1010 1011 B-Eq-Comparison
2 NCT03862027 1012 1013 I-Eq-Comparison
cm NCT03862027 1014 1016 I-Eq-Comparison
H2O NCT03862027 1017 1020 I-Eq-Comparison
in NCT03862027 1021 1023 O
the NCT03862027 1024 1027 O
hour NCT03862027 1028 1032 B-Eq-Comparison
prior NCT03862027 1033 1038 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03862027 1039 1041 I-Temporal-Connection___Temporal-Connection-Type-Value:before
intervention NCT03862027 1042 1054 B-Procedure
. NCT03862027 1054 1055 O

Subjects NCT03860181 0 8 O
will NCT03860181 9 13 O
be NCT03860181 14 16 O
included NCT03860181 17 25 O
if NCT03860181 26 28 O
: NCT03860181 29 30 O

- NCT03860181 34 35 O
They NCT03860181 37 41 O
are NCT03860181 42 45 O
18 NCT03860181 46 48 B-Eq-Comparison
years NCT03860181 49 54 I-Eq-Comparison
or NCT03860181 55 57 I-Eq-Comparison
older NCT03860181 58 63 I-Age|Eq-Comparison
; NCT03860181 63 64 O

- NCT03860181 67 68 O
They NCT03860181 70 74 O
are NCT03860181 75 78 O
undergoing NCT03860181 79 89 B-Eq-Comparison
primary NCT03860181 90 97 B-Modifier
total NCT03860181 98 103 B-Procedure
shoulder NCT03860181 104 112 I-Procedure
arthroplasty NCT03860181 113 125 I-Procedure
by NCT03860181 126 128 O
the NCT03860181 129 132 O
principal NCT03860181 133 142 O
and NCT03860181 143 146 O
co NCT03860181 147 149 O
- NCT03860181 150 151 O
investigator NCT03860181 152 164 O
. NCT03860181 165 166 O

- NCT03860181 170 171 O
They NCT03860181 173 177 O
are NCT03860181 178 181 O
willing NCT03860181 182 189 O
and NCT03860181 190 193 O
have NCT03860181 194 198 O
the NCT03860181 199 202 O
capacity NCT03860181 203 211 O
to NCT03860181 212 214 O
provide NCT03860181 215 222 O
informed NCT03860181 223 231 O
consent NCT03860181 232 239 O
; NCT03860181 239 240 O

- NCT03860181 243 244 O
They NCT03860181 246 250 O
expect NCT03860181 251 257 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860181 258 260 I-Assertion___Assertion-Type-Value:hypothetical
continue NCT03860181 261 269 O
their NCT03860181 270 275 O
post NCT03860181 276 280 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03860181 281 282 O
operative NCT03860181 283 292 B-Procedure
follow NCT03860181 293 299 B-Encounter
up NCT03860181 300 302 I-Encounter
care NCT03860181 303 307 I-Encounter
with NCT03860181 308 312 O
their NCT03860181 313 318 O
operating NCT03860181 319 328 O
surgeons NCT03860181 329 337 O
at NCT03860181 338 340 O
Medical NCT03860181 341 348 O
University NCT03860181 349 359 O
of NCT03860181 360 362 O
South NCT03860181 363 368 O
Carolina NCT03860181 369 377 O
( NCT03860181 378 379 O
MUSC NCT03860181 380 384 O
) NCT03860181 385 386 O
. NCT03860181 388 389 O

Subjects NCT03860181 391 399 O
will NCT03860181 400 404 O
be NCT03860181 405 407 O
excluded NCT03860181 408 416 O
if NCT03860181 417 419 O
: NCT03860181 420 421 O

- NCT03860181 425 426 O
They NCT03860181 428 432 O
have NCT03860181 433 437 O
a NCT03860181 438 439 O
unique NCT03860181 440 446 O
, NCT03860181 447 448 O
identifying NCT03860181 449 460 O
tattoo NCT03860181 461 467 B-Condition
or NCT03860181 468 470 B-Or
skin NCT03860181 471 475 B-Condition
marking NCT03860181 476 483 I-Condition
within NCT03860181 484 490 B-Eq-Comparison
2 NCT03860181 491 492 I-Eq-Comparison
inches NCT03860181 493 499 I-Eq-Comparison
of NCT03860181 500 502 O
intended NCT03860181 503 511 B-Modifier
site NCT03860181 512 516 I-Modifier
of NCT03860181 517 519 O
surgical NCT03860181 520 528 B-Procedure
incision NCT03860181 529 537 I-Procedure

- NCT03860181 540 541 O
They NCT03860181 543 547 O
self NCT03860181 548 552 O
- NCT03860181 553 554 O
report NCT03860181 555 561 O
a NCT03860181 562 563 O
known NCT03860181 564 569 O
hypersensitivity NCT03860181 570 586 B-Condition
to NCT03860181 587 589 O
cyanoacrylate NCT03860181 590 603 B-Drug
, NCT03860181 604 605 O
formaldehyde NCT03860181 606 618 B-Drug
, NCT03860181 619 620 O
benzalkonium NCT03860181 621 633 B-Drug
chloride NCT03860181 634 642 I-Drug
, NCT03860181 643 644 O
or NCT03860181 645 647 B-Or
pressure NCT03860181 648 656 B-Condition
sensitive NCT03860181 657 666 I-Condition
adhesive NCT03860181 667 675 I-Condition
; NCT03860181 675 676 O

- NCT03860181 679 680 O
They NCT03860181 682 686 O
self NCT03860181 687 691 O
- NCT03860181 692 693 O
report NCT03860181 694 700 O
or NCT03860181 701 703 O
have NCT03860181 704 708 O
a NCT03860181 709 710 O
documented NCT03860181 711 721 O
prior NCT03860181 722 727 B-Eq-Comparison
ipsilateral NCT03860181 728 739 B-Modifier
shoulder NCT03860181 740 748 B-Procedure
arthroplasty NCT03860181 749 761 I-Procedure
or NCT03860181 762 764 B-Or
other NCT03860181 765 770 B-Other
open NCT03860181 771 775 B-Modifier
ispilateral NCT03860181 776 787 I-Modifier
shoulder NCT03860181 788 796 B-Procedure
surgery NCT03860181 797 804 I-Procedure
utilizing NCT03860181 805 814 O
the NCT03860181 815 818 O
delto NCT03860181 819 824 B-Modifier
- NCT03860181 825 826 I-Modifier
pectoral NCT03860181 827 835 I-Modifier
approach NCT03860181 836 844 I-Modifier
; NCT03860181 844 845 O

- NCT03860181 848 849 O
Their NCT03860181 851 856 O
medical NCT03860181 857 864 O
record NCT03860181 865 871 O
shows NCT03860181 872 877 O
that NCT03860181 878 882 O
they NCT03860181 883 887 O
are NCT03860181 888 891 O
HIV NCT03860181 892 895 B-Condition
positive NCT03860181 896 904 O
or NCT03860181 905 907 B-Or
otherwise NCT03860181 908 917 O
immunocompromised NCT03860181 918 935 B-Condition
; NCT03860181 935 936 O

- NCT03860181 939 940 O
Their NCT03860181 942 947 O
medical NCT03860181 948 955 O
record NCT03860181 956 962 O
shows NCT03860181 963 968 O
a NCT03860181 969 970 O
skin NCT03860181 971 975 B-Modifier
abnormality NCT03860181 976 987 B-Condition
or NCT03860181 988 990 B-Or
dermatological NCT03860181 991 1005 B-Condition
condition NCT03860181 1006 1015 I-Condition
which NCT03860181 1016 1021 O
affects NCT03860181 1022 1029 B-Assertion___Assertion-Type-Value:hypothetical
skin NCT03860181 1030 1034 B-Condition
healing NCT03860181 1035 1042 I-Condition
; NCT03860181 1042 1043 O

- NCT03860181 1046 1047 O
They NCT03860181 1049 1053 O
report NCT03860181 1054 1060 O
a NCT03860181 1061 1062 O
personal NCT03860181 1063 1071 B-Family-Member___Family-Member-Type:patient
or NCT03860181 1072 1074 B-Or
family NCT03860181 1075 1081 B-Family-Member
history NCT03860181 1082 1089 I-Family-Member
of NCT03860181 1090 1092 O
significant NCT03860181 1093 1104 O
keloid NCT03860181 1105 1111 B-Modifier
or NCT03860181 1112 1114 B-Or
significant NCT03860181 1115 1126 O
hypertrophic NCT03860181 1127 1139 B-Condition
scar NCT03860181 1140 1144 I-Condition
formations NCT03860181 1145 1155 I-Condition
, NCT03860181 1156 1157 O
or NCT03860181 1158 1160 B-Or
other NCT03860181 1161 1166 B-Other
problems NCT03860181 1167 1175 B-Condition
with NCT03860181 1176 1180 I-Condition
wound NCT03860181 1181 1186 I-Condition
healing NCT03860181 1187 1194 I-Condition
. NCT03860181 1194 1195 O

Inclusion NCT03867188 0 9 O
Criteria NCT03867188 10 18 O
: NCT03867188 19 20 O

- NCT03867188 24 25 O
Patients NCT03867188 27 35 O
with NCT03867188 36 40 O
a NCT03867188 41 42 O
soft NCT03867188 43 47 B-Modifier
tissue NCT03867188 48 54 I-Modifier
sarcoma NCT03867188 55 62 B-Condition
of NCT03867188 63 65 O
the NCT03867188 66 69 O
thigh NCT03867188 70 75 B-Modifier

- NCT03867188 78 79 O
Must NCT03867188 81 85 O
have NCT03867188 86 90 O
sufficient NCT03867188 91 101 O
health NCT03867188 102 108 B-Condition
to NCT03867188 109 111 B-Assertion___Assertion-Type-Value:hypothetical
withstand NCT03867188 112 121 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03867188 122 125 O
physical NCT03867188 126 134 O
demands NCT03867188 135 142 O
of NCT03867188 143 145 O
surgery NCT03867188 146 153 B-Procedure

- NCT03867188 156 157 O
≥ NCT03867188 159 160 B-Eq-Comparison
18 NCT03867188 161 163 I-Eq-Comparison
years NCT03867188 164 169 I-Eq-Comparison
old NCT03867188 170 173 I-Age|Eq-Comparison

- NCT03867188 176 177 O
ECOG NCT03867188 179 183 B-Observation
performance NCT03867188 184 195 I-Observation
status NCT03867188 196 202 I-Observation
of NCT03867188 203 205 O
≤ NCT03867188 206 207 B-Eq-Comparison
2 NCT03867188 208 209 I-Eq-Comparison

- NCT03867188 213 214 O
Ability NCT03867188 216 223 O
to NCT03867188 224 226 O
understand NCT03867188 227 237 O
and NCT03867188 238 241 O
the NCT03867188 242 245 O
willingness NCT03867188 246 257 O
to NCT03867188 258 260 O
sign NCT03867188 261 265 O
an NCT03867188 266 268 O
IRB NCT03867188 269 272 O
- NCT03867188 273 274 O
approved NCT03867188 275 283 O
informed NCT03867188 284 292 O
consent NCT03867188 293 300 O
document NCT03867188 301 309 O
( NCT03867188 310 311 O
either NCT03867188 312 318 O
directly NCT03867188 319 327 O
or NCT03867188 328 330 O
via NCT03867188 331 334 O
a NCT03867188 335 336 O
legally NCT03867188 337 344 O
authorized NCT03867188 345 355 O
representative NCT03867188 356 370 O
) NCT03867188 371 372 O

Exclusion NCT03867188 374 383 O
Criteria NCT03867188 384 392 O
: NCT03867188 393 394 O

- NCT03867188 398 399 O
History NCT03867188 401 408 B-Eq-Comparison
of NCT03867188 409 411 O
clinically NCT03867188 412 422 O
significant NCT03867188 423 434 O
medical NCT03867188 435 442 B-Condition
conditions NCT03867188 443 453 I-Condition
including NCT03867188 454 463 O
: NCT03867188 464 465 O
Cardiovascular NCT03867188 466 480 O
: NCT03867188 481 482 O
Atrial NCT03867188 483 489 B-Condition
Fibrillation NCT03867188 490 502 I-Condition
, NCT03867188 503 504 O
Ventricular NCT03867188 505 516 B-Condition
Fibrillation NCT03867188 517 529 I-Condition
, NCT03867188 530 531 O
Significant NCT03867188 532 543 O
Coronary NCT03867188 544 552 B-Condition
Artery NCT03867188 553 559 I-Condition
Disease NCT03867188 560 567 I-Condition
. NCT03867188 567 568 O
Hepatic NCT03867188 570 577 O
: NCT03867188 578 579 O
Viral NCT03867188 580 585 B-Modifier
or NCT03867188 586 588 B-Or
Autoimmune NCT03867188 589 599 B-Modifier
Hepatitis NCT03867188 600 609 B-Condition
, NCT03867188 610 611 O
Cirrhosis NCT03867188 612 621 B-Condition
of NCT03867188 622 624 O
the NCT03867188 625 628 O
Liver NCT03867188 629 634 B-Modifier
, NCT03867188 635 636 O
Liver NCT03867188 637 642 B-Modifier
Metabolism NCT03867188 643 653 B-Condition
Disorders NCT03867188 654 663 I-Condition
. NCT03867188 663 664 O
Renal NCT03867188 666 671 O
: NCT03867188 672 673 O
Any NCT03867188 674 677 O
form NCT03867188 678 682 O
of NCT03867188 683 685 O
renal NCT03867188 686 691 B-Condition
impairment NCT03867188 692 702 I-Condition
. NCT03867188 702 703 O
EXPAREL NCT03867188 705 712 B-Drug
® NCT03867188 712 713 O
is NCT03867188 714 716 O
cleared NCT03867188 717 724 O
by NCT03867188 725 727 O
the NCT03867188 728 731 O
kidneys NCT03867188 732 739 O
, NCT03867188 740 741 O
thus NCT03867188 742 746 O
any NCT03867188 747 750 O
form NCT03867188 751 755 O
of NCT03867188 756 758 O
renal NCT03867188 759 764 B-Condition
impairment NCT03867188 765 775 I-Condition
could NCT03867188 776 781 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03867188 782 786 O
to NCT03867188 787 789 O
an NCT03867188 790 792 O
adverse NCT03867188 793 800 B-Condition
reaction NCT03867188 801 809 I-Condition
. NCT03867188 810 811 O

- NCT03867188 815 816 O
Medical NCT03867188 818 825 B-Condition
condition NCT03867188 826 835 I-Condition
( NCT03867188 836 837 O
s NCT03867188 838 839 O
) NCT03867188 840 841 O
or NCT03867188 842 844 B-Or
concurrent NCT03867188 845 855 B-Modifier
surgery NCT03867188 856 863 B-Procedure
that NCT03867188 864 868 O
may NCT03867188 869 872 B-Assertion___Assertion-Type-Value:hypothetical
have NCT03867188 873 877 I-Assertion___Assertion-Type-Value:hypothetical
required NCT03867188 878 886 O
analgesic NCT03867188 887 896 B-Procedure
treatment NCT03867188 897 906 I-Procedure
in NCT03867188 907 909 O
the NCT03867188 910 913 O
post NCT03867188 914 918 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03867188 919 928 B-Procedure
period NCT03867188 929 935 O
for NCT03867188 936 939 O
pain NCT03867188 940 944 B-Condition
that NCT03867188 945 949 O
was NCT03867188 950 953 O
not NCT03867188 954 957 B-Negation
strictly NCT03867188 958 966 O
related NCT03867188 967 974 O
to NCT03867188 975 977 O
the NCT03867188 978 981 O
study NCT03867188 982 987 B-Study
surgery NCT03867188 988 995 B-Procedure
. NCT03867188 996 997 O

- NCT03867188 1001 1002 O
Any NCT03867188 1004 1007 O
clinically NCT03867188 1008 1018 O
significant NCT03867188 1019 1030 O
event NCT03867188 1031 1036 B-Observation
or NCT03867188 1037 1039 B-Or
condition NCT03867188 1040 1049 B-Condition
discovered NCT03867188 1050 1060 O
during NCT03867188 1061 1067 B-Temporal-Connection___Temporal-Connection-Type-Value:during
surgery NCT03867188 1068 1075 B-Procedure
that NCT03867188 1076 1080 O
may NCT03867188 1081 1084 O
have NCT03867188 1085 1089 O
complicated NCT03867188 1090 1101 O
the NCT03867188 1102 1105 O
patient NCT03867188 1106 1113 O
's NCT03867188 1113 1115 O
post NCT03867188 1116 1120 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgical NCT03867188 1121 1129 B-Procedure
course NCT03867188 1130 1136 O
such NCT03867188 1137 1141 O
as NCT03867188 1142 1144 O
vascular NCT03867188 1145 1153 B-Modifier
or NCT03867188 1154 1156 B-Or
nerve NCT03867188 1157 1162 B-Modifier
involvement NCT03867188 1163 1174 B-Condition
that NCT03867188 1175 1179 O
was NCT03867188 1180 1183 O
unknown NCT03867188 1184 1191 O
before NCT03867188 1192 1198 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03867188 1199 1206 B-Procedure
. NCT03867188 1207 1208 O

- NCT03867188 1212 1213 O
History NCT03867188 1215 1222 B-Eq-Comparison
of NCT03867188 1223 1225 O
allergic NCT03867188 1226 1234 B-Allergy
reactions NCT03867188 1235 1244 I-Allergy
attributed NCT03867188 1245 1255 O
to NCT03867188 1256 1258 O
compounds NCT03867188 1259 1268 O
of NCT03867188 1269 1271 O
similar NCT03867188 1272 1279 O
chemical NCT03867188 1280 1288 O
or NCT03867188 1289 1291 O
biologic NCT03867188 1292 1300 O
composition NCT03867188 1301 1312 O
to NCT03867188 1313 1315 O
liposomal NCT03867188 1316 1325 B-Drug
bupivacaine NCT03867188 1326 1337 I-Drug
. NCT03867188 1338 1339 O

- NCT03867188 1343 1344 O
Pregnant NCT03867188 1346 1354 B-Condition
women NCT03867188 1355 1360 O
are NCT03867188 1361 1364 O
excluded NCT03867188 1365 1373 B-Negation
from NCT03867188 1374 1378 O
this NCT03867188 1379 1383 O
study NCT03867188 1384 1389 B-Study
because NCT03867188 1390 1397 O
EXPAREL NCT03867188 1398 1405 B-Drug
has NCT03867188 1406 1409 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03867188 1410 1413 I-Assertion___Assertion-Type-Value:hypothetical
potential NCT03867188 1414 1423 I-Assertion___Assertion-Type-Value:hypothetical
for NCT03867188 1424 1427 O
teratogenic NCT03867188 1428 1439 B-Modifier
or NCT03867188 1440 1442 B-Or
abortifacient NCT03867188 1443 1456 B-Modifier
effects NCT03867188 1457 1464 B-Condition
. NCT03867188 1464 1465 O
Because NCT03867188 1467 1474 O
there NCT03867188 1475 1480 O
is NCT03867188 1481 1483 O
an NCT03867188 1484 1486 O
unknown NCT03867188 1487 1494 O
but NCT03867188 1495 1498 O
potential NCT03867188 1499 1508 B-Assertion___Assertion-Type-Value:hypothetical
risk NCT03867188 1509 1513 B-Risk
for NCT03867188 1514 1517 O
adverse NCT03867188 1518 1525 B-Condition
events NCT03867188 1526 1532 I-Condition
in NCT03867188 1533 1535 O
nursing NCT03867188 1536 1543 B-Condition
infants NCT03867188 1544 1551 B-Family-Member___Family-Member-Type:child
secondary NCT03867188 1552 1561 O
to NCT03867188 1562 1564 O
treatment NCT03867188 1565 1574 B-Procedure
of NCT03867188 1575 1577 O
the NCT03867188 1578 1581 O
mother NCT03867188 1582 1588 B-Family-Member___Family-Member-Type:mother
with NCT03867188 1589 1593 O
EXPAREL NCT03867188 1594 1601 B-Drug
, NCT03867188 1602 1603 O
breastfeeding NCT03867188 1604 1617 B-Condition
should NCT03867188 1618 1624 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03867188 1625 1627 I-Assertion___Assertion-Type-Value:hypothetical
discontinued NCT03867188 1628 1640 B-Negation
if NCT03867188 1641 1643 O
the NCT03867188 1644 1647 O
mother NCT03867188 1648 1654 B-Family-Member___Family-Member-Type:mother
is NCT03867188 1655 1657 O
treated NCT03867188 1658 1665 B-Procedure
with NCT03867188 1666 1670 O
EXPAREL NCT03867188 1671 1678 B-Drug
. NCT03867188 1678 1679 O

Inclusion NCT03865953 0 9 O
Criteria NCT03865953 10 18 O
: NCT03865953 19 20 O

1 NCT03865953 24 25 O
. NCT03865953 25 26 O
Clinical NCT03865953 28 36 O
diagnosis NCT03865953 37 46 O
of NCT03865953 47 49 O
post NCT03865953 50 54 B-Condition
herpetic NCT03865953 55 63 I-Condition
neuralgia NCT03865953 64 73 I-Condition
, NCT03865953 74 75 O
with NCT03865953 76 80 B-And
pain NCT03865953 81 85 B-Condition
persisting NCT03865953 86 96 O
for NCT03865953 97 100 O
at NCT03865953 101 103 B-Eq-Comparison
least NCT03865953 104 109 I-Eq-Comparison
3 NCT03865953 110 111 I-Eq-Comparison
months NCT03865953 112 118 I-Eq-Comparison
after NCT03865953 119 124 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03865953 125 128 O
onset NCT03865953 129 134 B-Eq-Comparison
of NCT03865953 135 137 O
herpes NCT03865953 138 144 B-Condition
zoster NCT03865953 145 151 I-Condition
rash NCT03865953 152 156 I-Condition
OR NCT03865953 157 159 B-Or

2 NCT03865953 162 163 O
. NCT03865953 163 164 O
Clinical NCT03865953 166 174 O
diagnosis NCT03865953 175 184 O
of NCT03865953 185 187 O
distal NCT03865953 188 194 B-Modifier
painful NCT03865953 195 202 I-Modifier
polyneuropathy NCT03865953 203 217 B-Condition
due NCT03865953 218 221 O
to NCT03865953 222 224 O
Type NCT03865953 225 229 B-Modifier
I NCT03865953 230 231 I-Modifier
or NCT03865953 232 234 B-Or
Type NCT03865953 235 239 B-Modifier
II NCT03865953 240 242 I-Modifier
diabetes NCT03865953 243 251 B-Condition
mellitus NCT03865953 252 260 I-Condition
with NCT03865953 261 265 B-And
: NCT03865953 266 267 O

1 NCT03865953 276 277 O
. NCT03865953 277 278 O
symmetrical NCT03865953 280 291 B-Modifier
, NCT03865953 292 293 O
bilateral NCT03865953 294 303 B-Modifier
pain NCT03865953 304 308 B-Condition
in NCT03865953 309 311 O
the NCT03865953 312 315 O
lower NCT03865953 316 321 B-Modifier
extremities NCT03865953 322 333 I-Modifier
for NCT03865953 334 337 O
at NCT03865953 338 340 B-Eq-Comparison
least NCT03865953 341 346 I-Eq-Comparison
3 NCT03865953 347 348 I-Eq-Comparison
months NCT03865953 349 355 I-Eq-Comparison
and NCT03865953 356 359 B-And

2 NCT03865953 367 368 O
. NCT03865953 368 369 O
diabetes NCT03865953 371 379 B-Condition
under NCT03865953 380 385 O
control NCT03865953 386 393 O
for NCT03865953 394 397 O
at NCT03865953 398 400 B-Eq-Comparison
least NCT03865953 401 406 I-Eq-Comparison
3 NCT03865953 407 408 I-Eq-Comparison
months NCT03865953 409 415 I-Eq-Comparison
prior NCT03865953 416 421 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865953 422 424 I-Temporal-Connection___Temporal-Connection-Type-Value:before
randomisation NCT03865953 425 438 B-Study
, NCT03865953 439 440 O
as NCT03865953 441 443 O
indicated NCT03865953 444 453 O
by NCT03865953 454 456 O
a NCT03865953 457 458 O
glycated NCT03865953 459 467 B-Observation
haemoglobin NCT03865953 468 479 I-Observation
level NCT03865953 480 485 I-Observation
( NCT03865953 486 487 O
HbA1c NCT03865953 488 493 B-Observation
) NCT03865953 494 495 O
of NCT03865953 496 498 O
≤ NCT03865953 499 500 B-Eq-Comparison
11 NCT03865953 501 503 I-Eq-Comparison
% NCT03865953 504 505 I-Eq-Comparison
( NCT03865953 506 507 O
97 NCT03865953 508 510 B-Eq-Comparison
mmol NCT03865953 511 515 I-Eq-Comparison
/ NCT03865953 516 517 I-Eq-Comparison
mol NCT03865953 518 521 I-Eq-Comparison
) NCT03865953 522 523 O
and NCT03865953 524 527 B-And
on NCT03865953 528 530 O
a NCT03865953 531 532 O
stable NCT03865953 533 539 O
dose NCT03865953 540 544 O
of NCT03865953 545 547 O
insulin NCT03865953 548 555 B-Drug
or NCT03865953 556 558 B-Or
oral NCT03865953 559 563 B-Modifier
diabetic NCT03865953 564 572 B-Condition
medication NCT03865953 573 583 B-Drug
for NCT03865953 584 587 O
3 NCT03865953 588 589 B-Eq-Comparison
months NCT03865953 590 596 I-Eq-Comparison
prior NCT03865953 597 602 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865953 603 605 I-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03865953 606 615 B-Study
, NCT03865953 616 617 O
and NCT03865953 618 621 B-And

3 NCT03865953 629 630 O
. NCT03865953 630 631 O
no NCT03865953 633 635 B-Negation
change NCT03865953 636 642 O
in NCT03865953 643 645 O
diabetic NCT03865953 646 654 B-Condition
medication NCT03865953 655 665 B-Drug
planned NCT03865953 666 673 B-Eq-Comparison
for NCT03865953 674 677 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865953 678 681 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03865953 682 690 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865953 691 693 O
the NCT03865953 694 697 O
study NCT03865953 698 703 B-Study

3 NCT03865953 706 707 O
. NCT03865953 707 708 O
Positive NCT03865953 710 718 O
sensory NCT03865953 719 726 B-Condition
symptoms NCT03865953 727 735 I-Condition
( NCT03865953 736 737 O
mechanical NCT03865953 738 748 B-Modifier
or NCT03865953 749 751 B-Or
thermal NCT03865953 752 759 B-Modifier
) NCT03865953 760 761 O
associated NCT03865953 762 772 O
with NCT03865953 773 777 O
neuropathic NCT03865953 778 789 B-Modifier
pain NCT03865953 790 794 B-Condition
, NCT03865953 795 796 O
confirmed NCT03865953 797 806 O
by NCT03865953 807 809 O
: NCT03865953 810 811 O

1 NCT03865953 820 821 O
. NCT03865953 821 822 O
painDETECT NCT03865953 824 834 B-Observation
questionnaire NCT03865953 835 848 I-Observation
( NCT03865953 849 850 O
PD NCT03865953 851 853 B-Observation
- NCT03865953 854 855 I-Observation
Q NCT03865953 856 857 I-Observation
) NCT03865953 858 859 O
and NCT03865953 860 863 B-And

2 NCT03865953 871 872 O
. NCT03865953 872 873 O
Clinical NCT03865953 875 883 O
assessment NCT03865953 884 894 B-Procedure
, NCT03865953 895 896 O
showing NCT03865953 897 904 O
signs NCT03865953 905 910 B-Assertion___Assertion-Type-Value:possible
of NCT03865953 911 913 I-Assertion___Assertion-Type-Value:possible
neuropathic NCT03865953 914 925 B-Modifier
pain NCT03865953 926 930 B-Condition
in NCT03865953 931 933 B-And
either NCT03865953 934 940 O
a NCT03865953 941 942 O
dermatomal NCT03865953 943 953 B-Modifier
( NCT03865953 954 955 O
PHN NCT03865953 956 959 B-Condition
) NCT03865953 960 961 O
or NCT03865953 962 964 B-Or
distal NCT03865953 965 971 B-Modifier
symmetrical NCT03865953 972 983 B-Condition
distribution NCT03865953 984 996 I-Condition
( NCT03865953 997 998 O
DPN NCT03865953 999 1002 B-Condition
) NCT03865953 1003 1004 O

8 NCT03865953 1006 1007 O
. NCT03865953 1007 1008 O
An NCT03865953 1010 1012 O
average NCT03865953 1013 1020 O
daily NCT03865953 1021 1026 B-Eq-Comparison
pain NCT03865953 1027 1031 B-Observation
score NCT03865953 1032 1037 I-Observation
on NCT03865953 1038 1040 O
the NCT03865953 1041 1044 O
NPRS NCT03865953 1045 1049 B-Observation
of NCT03865953 1050 1052 O
at NCT03865953 1053 1055 B-Eq-Comparison
least NCT03865953 1056 1061 I-Eq-Comparison
4 NCT03865953 1062 1063 I-Eq-Comparison
and NCT03865953 1064 1067 B-And
no NCT03865953 1068 1070 B-Negation
more NCT03865953 1071 1075 B-Eq-Comparison
than NCT03865953 1076 1080 I-Eq-Comparison
8 NCT03865953 1081 1082 I-Eq-Comparison
in NCT03865953 1083 1085 O
the NCT03865953 1086 1089 O
last NCT03865953 1090 1094 O
five NCT03865953 1095 1099 O
diary NCT03865953 1100 1105 O
entries NCT03865953 1106 1113 O
before NCT03865953 1114 1120 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomisation NCT03865953 1121 1134 B-Study

Exclusion NCT03865953 1135 1144 O
Criteria NCT03865953 1145 1153 O
: NCT03865953 1154 1155 O

1 NCT03865953 1159 1160 O
. NCT03865953 1160 1161 O
Presence NCT03865953 1163 1171 O
of NCT03865953 1172 1174 O
moderate NCT03865953 1175 1183 B-Eq-Comparison
to NCT03865953 1184 1186 I-Eq-Comparison
severe NCT03865953 1187 1193 I-Eq-Comparison
pain NCT03865953 1194 1198 B-Condition
from NCT03865953 1199 1203 O
other NCT03865953 1204 1209 B-Other
causes NCT03865953 1210 1216 B-Condition
that NCT03865953 1217 1221 O
may NCT03865953 1222 1225 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03865953 1226 1234 O
assessment NCT03865953 1235 1245 B-Study
or NCT03865953 1246 1248 O
self NCT03865953 1249 1253 O
- NCT03865953 1254 1255 O
evaluation NCT03865953 1256 1266 O
of NCT03865953 1267 1269 O
NP NCT03865953 1270 1272 O
. NCT03865953 1273 1274 O

2 NCT03865953 1278 1279 O
. NCT03865953 1279 1280 O
Subjects NCT03865953 1282 1290 O
with NCT03865953 1291 1295 O
both NCT03865953 1296 1300 O
DPN NCT03865953 1301 1304 B-Condition
and NCT03865953 1305 1308 B-And
PHN NCT03865953 1309 1312 B-Condition


Inclusion NCT03869827 0 9 O
Criteria NCT03869827 10 18 O
: NCT03869827 19 20 O

- NCT03869827 24 25 O
All NCT03869827 27 30 O
birth NCT03869827 31 36 B-Birth
between NCT03869827 37 44 B-Eq-Comparison
24 NCT03869827 45 47 I-Eq-Comparison
+ NCT03869827 48 49 I-Eq-Comparison
0 NCT03869827 50 51 I-Eq-Comparison
weeks NCT03869827 52 57 I-Eq-Comparison
of NCT03869827 58 60 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 61 71 B-Condition
and NCT03869827 72 75 B-And
36 NCT03869827 76 78 B-Eq-Comparison
+ NCT03869827 79 80 I-Eq-Comparison
6 NCT03869827 81 82 I-Eq-Comparison
weeks NCT03869827 83 88 I-Eq-Comparison
of NCT03869827 89 91 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 92 102 B-Condition

- NCT03869827 105 106 O
with NCT03869827 108 112 O
isolated NCT03869827 113 121 B-Modifier
intrauterine NCT03869827 122 134 B-Condition
growth NCT03869827 135 141 I-Condition
restriction NCT03869827 142 153 I-Condition
at NCT03869827 154 156 O
the NCT03869827 157 160 O
maternity NCT03869827 161 170 O
ward NCT03869827 171 175 O
of NCT03869827 176 178 O
the NCT03869827 179 182 O
hospital NCT03869827 183 191 O
Femme NCT03869827 192 197 O
- NCT03869827 198 199 O
Mère NCT03869827 200 204 O
- NCT03869827 205 206 O
Enfant NCT03869827 207 213 O

- NCT03869827 216 217 O
from NCT03869827 219 223 O
1 NCT03869827 224 225 B-Eq-Comparison
st NCT03869827 226 228 I-Eq-Comparison
of NCT03869827 229 231 I-Eq-Comparison
january NCT03869827 232 239 I-Eq-Comparison
2011 NCT03869827 240 244 I-Eq-Comparison
to NCT03869827 245 247 I-Eq-Comparison
31 NCT03869827 248 250 I-Eq-Comparison
december NCT03869827 251 259 I-Eq-Comparison
2016 NCT03869827 260 264 I-Eq-Comparison
. NCT03869827 264 265 O

Inclusion NCT03869827 267 276 O
Criteria NCT03869827 277 285 O
for NCT03869827 286 289 O
control NCT03869827 290 297 O
group NCT03869827 298 303 O
: NCT03869827 304 305 O

- NCT03869827 309 310 O
All NCT03869827 312 315 O
birth NCT03869827 316 321 B-Birth
between NCT03869827 322 329 B-Eq-Comparison
24 NCT03869827 330 332 I-Eq-Comparison
+ NCT03869827 333 334 I-Eq-Comparison
0 NCT03869827 335 336 I-Eq-Comparison
weeks NCT03869827 337 342 I-Eq-Comparison
of NCT03869827 343 345 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 346 356 B-Condition
and NCT03869827 357 360 B-And
36 NCT03869827 361 363 B-Eq-Comparison
+ NCT03869827 364 365 I-Eq-Comparison
6 NCT03869827 366 367 I-Eq-Comparison
weeks NCT03869827 368 373 I-Eq-Comparison
of NCT03869827 374 376 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03869827 377 387 B-Condition

- NCT03869827 390 391 O
without NCT03869827 393 400 B-Negation
isolated NCT03869827 401 409 B-Modifier
intrauterine NCT03869827 410 422 B-Condition
growth NCT03869827 423 429 I-Condition
restriction NCT03869827 430 441 I-Condition
at NCT03869827 442 444 O
the NCT03869827 445 448 O
maternity NCT03869827 449 458 O
ward NCT03869827 459 463 O
of NCT03869827 464 466 O
the NCT03869827 467 470 O
hospital NCT03869827 471 479 O
Femme NCT03869827 480 485 O
- NCT03869827 486 487 O
Mère NCT03869827 488 492 O
- NCT03869827 493 494 O
Enfant NCT03869827 495 501 O

- NCT03869827 504 505 O
from NCT03869827 507 511 O
1 NCT03869827 512 513 B-Eq-Comparison
st NCT03869827 514 516 I-Eq-Comparison
of NCT03869827 517 519 I-Eq-Comparison
january NCT03869827 520 527 I-Eq-Comparison
2011 NCT03869827 528 532 I-Eq-Comparison
to NCT03869827 533 535 I-Eq-Comparison
31 NCT03869827 536 538 I-Eq-Comparison
december NCT03869827 539 547 I-Eq-Comparison
2016 NCT03869827 548 552 I-Eq-Comparison
. NCT03869827 552 553 O

Exclusion NCT03869827 555 564 O
Criteria NCT03869827 565 573 O
: NCT03869827 574 575 O

- NCT03869827 579 580 O
Infants NCT03869827 582 589 O
born NCT03869827 590 594 B-Birth
out NCT03869827 595 598 B-Negation
of NCT03869827 599 601 I-Negation
the NCT03869827 602 605 O
hospital NCT03869827 606 614 O
and NCT03869827 615 618 B-And
secondarily NCT03869827 619 630 B-Encounter
hospitalized NCT03869827 631 643 I-Encounter
in NCT03869827 644 646 O
our NCT03869827 647 650 O
department NCT03869827 651 661 O

- NCT03869827 664 665 O
unaccompanied NCT03869827 667 680 B-Modifier
pregnancies NCT03869827 681 692 B-Condition

- NCT03869827 695 696 O
multiple NCT03869827 698 706 B-Eq-Comparison
pregnancies NCT03869827 707 718 B-Condition

- NCT03869827 721 722 O
children NCT03869827 724 732 O
with NCT03869827 733 737 B-And
malformations NCT03869827 738 751 B-Condition
or NCT03869827 752 754 B-Or
genetic NCT03869827 755 762 B-Condition
abnormalities NCT03869827 763 776 I-Condition
, NCT03869827 777 778 O

- NCT03869827 782 783 O
medical NCT03869827 785 792 B-Procedure
termination NCT03869827 793 804 I-Procedure
of NCT03869827 805 807 I-Procedure
pregnancy NCT03869827 808 817 I-Procedure

- NCT03869827 820 821 O
fetal NCT03869827 823 828 O
deaths NCT03869827 829 835 B-Death
in NCT03869827 836 838 B-Modifier
utero NCT03869827 839 844 I-Modifier

Inclusion NCT03866057 0 9 O
criteria NCT03866057 10 18 O
: NCT03866057 19 20 O

- NCT03866057 24 25 O
age NCT03866057 27 30 B-Age
18 NCT03866057 31 33 B-Eq-Comparison
- NCT03866057 34 35 I-Eq-Comparison
90 NCT03866057 36 38 O

- NCT03866057 42 43 O
acute NCT03866057 45 50 O
ischemic NCT03866057 51 59 B-Modifier
or NCT03866057 60 62 B-Or
hemorrhagic NCT03866057 63 74 B-Modifier
stroke NCT03866057 75 81 B-Condition
( NCT03866057 82 83 O
within NCT03866057 84 90 B-Eq-Comparison
30 NCT03866057 91 93 I-Eq-Comparison
days NCT03866057 94 98 I-Eq-Comparison
) NCT03866057 99 100 O

- NCT03866057 104 105 O
consent NCT03866057 107 114 O
to NCT03866057 115 117 O
participate NCT03866057 118 129 O
and NCT03866057 130 133 O
to NCT03866057 134 136 O
anonymous NCT03866057 137 146 O
processing NCT03866057 147 157 O
of NCT03866057 158 160 O
data NCT03866057 161 165 O
. NCT03866057 166 167 O

Additional NCT03866057 169 179 O
inclusion NCT03866057 180 189 O
criteria NCT03866057 190 198 O
for NCT03866057 199 202 O
Sub NCT03866057 203 206 O
- NCT03866057 207 208 O
project NCT03866057 209 216 O
Neurophysiological NCT03866057 217 235 O
Markers NCT03866057 236 243 O
: NCT03866057 244 245 O

- NCT03866057 248 249 O
signing NCT03866057 250 257 O
of NCT03866057 258 260 O
informed NCT03866057 261 269 O
consent NCT03866057 270 277 O
for NCT03866057 278 281 O
the NCT03866057 282 285 O
participation NCT03866057 286 299 O
in NCT03866057 300 302 O
the NCT03866057 303 306 O
sub NCT03866057 307 310 O
- NCT03866057 311 312 O
project NCT03866057 313 320 O
. NCT03866057 321 322 O

Additional NCT03866057 324 334 O
inclusion NCT03866057 335 344 O
criteria NCT03866057 345 353 O
for NCT03866057 354 357 O
Epigenetic NCT03866057 358 368 O
subproject NCT03866057 369 379 O
: NCT03866057 380 381 O

- NCT03866057 384 385 O
signing NCT03866057 386 393 O
of NCT03866057 394 396 O
informed NCT03866057 397 405 O
consent NCT03866057 406 413 O
for NCT03866057 414 417 O
participation NCT03866057 418 431 O
in NCT03866057 432 434 O
the NCT03866057 435 438 O
subproject NCT03866057 439 449 O
. NCT03866057 450 451 O

Exclusion NCT03866057 453 462 O
Criteria NCT03866057 463 471 O
: NCT03866057 472 473 O

- NCT03866057 476 477 O
Stroke NCT03866057 478 484 B-Condition
occurred NCT03866057 485 493 O
more NCT03866057 494 498 B-Eq-Comparison
than NCT03866057 499 503 I-Eq-Comparison
30 NCT03866057 504 506 I-Eq-Comparison
days NCT03866057 507 511 I-Eq-Comparison
after NCT03866057 512 517 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03866057 518 521 O
transfer NCT03866057 522 530 B-Encounter
to NCT03866057 531 533 O
intensive NCT03866057 534 543 O
rehabilitation NCT03866057 544 558 O

Additional NCT03866057 559 569 O
exclusion NCT03866057 570 579 O
criteria NCT03866057 580 588 O
for NCT03866057 589 592 O
Epigenetic NCT03866057 593 603 O
subproject NCT03866057 604 614 O
( NCT03866057 615 616 O
for NCT03866057 617 620 O
retrospective NCT03866057 621 634 O
analysis NCT03866057 635 643 O
) NCT03866057 644 645 O
: NCT03866057 647 648 O

- NCT03866057 652 653 O
history NCT03866057 655 662 B-Eq-Comparison
of NCT03866057 663 665 O
major NCT03866057 666 671 O
psychiatric NCT03866057 672 683 B-Condition
disorder NCT03866057 684 692 I-Condition
or NCT03866057 693 695 B-Or
recent NCT03866057 696 702 B-Eq-Comparison
exacerbation NCT03866057 703 715 B-Condition

- NCT03866057 718 719 O
global NCT03866057 721 727 B-Condition
aphasia NCT03866057 728 735 I-Condition

- NCT03866057 738 739 O
refusal NCT03866057 741 748 O
of NCT03866057 749 751 O
the NCT03866057 752 755 O
patient NCT03866057 756 763 O
to NCT03866057 764 766 O
participate NCT03866057 767 778 O
in NCT03866057 779 781 O
the NCT03866057 782 785 O
study NCT03866057 786 791 O
. NCT03866057 791 792 O

Inclusion NCT03864640 0 9 O
Criteria NCT03864640 10 18 O
: NCT03864640 19 20 O

- NCT03864640 24 25 O
Adult NCT03864640 27 32 O
patients NCT03864640 33 41 O
with NCT03864640 42 46 B-And
colorectal NCT03864640 47 57 B-Modifier
cancer NCT03864640 58 64 B-Condition
. NCT03864640 65 66 O

Exclusion NCT03864640 68 77 O
Criteria NCT03864640 78 86 O
: NCT03864640 87 88 O

- NCT03864640 92 93 O
Patients NCT03864640 95 103 O
reluctant NCT03864640 104 113 O
to NCT03864640 114 116 O
participate NCT03864640 117 128 O
in NCT03864640 129 131 O
the NCT03864640 132 135 O
study NCT03864640 136 141 O
. NCT03864640 141 142 O

Inclusion NCT03868046 0 9 O
Criteria NCT03868046 10 18 O
: NCT03868046 19 20 O

1 NCT03868046 24 25 O
. NCT03868046 25 26 O
Initiation NCT03868046 28 38 B-Eq-Comparison
of NCT03868046 39 41 O
treatment NCT03868046 42 51 B-Procedure
with NCT03868046 52 56 O
a NCT03868046 57 58 O
single NCT03868046 59 65 B-Eq-Comparison
ICI NCT03868046 66 69 B-Procedure
or NCT03868046 70 72 B-Or
a NCT03868046 73 74 O
combination NCT03868046 75 86 B-Eq-Comparison
of NCT03868046 87 89 O
ICIs NCT03868046 90 94 B-Procedure
. NCT03868046 95 96 O

2 NCT03868046 100 101 O
. NCT03868046 101 102 O
Acceptation NCT03868046 104 115 O
of NCT03868046 116 118 O
an NCT03868046 119 121 O
informed NCT03868046 122 130 O
consent NCT03868046 131 138 O
. NCT03868046 139 140 O

Exclusion NCT03868046 142 151 O
Criteria NCT03868046 152 160 O
: NCT03868046 161 162 O

1 NCT03868046 166 167 O
. NCT03868046 167 168 O
Life NCT03868046 170 174 B-Observation
expectancy NCT03868046 175 185 I-Observation
lower NCT03868046 186 191 B-Eq-Comparison
than NCT03868046 192 196 I-Eq-Comparison
3 NCT03868046 197 198 I-Eq-Comparison
months NCT03868046 199 205 I-Eq-Comparison
from NCT03868046 206 210 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03868046 211 214 O
initiation NCT03868046 215 225 B-Eq-Comparison
of NCT03868046 226 228 O
treatment NCT03868046 229 238 B-Procedure
with NCT03868046 239 243 O
ICIs NCT03868046 244 248 B-Procedure
. NCT03868046 249 250 O

2 NCT03868046 254 255 O
. NCT03868046 255 256 O
Proven NCT03868046 258 264 O
hypersensitivity NCT03868046 265 281 B-Condition
or NCT03868046 282 284 B-Or
previous NCT03868046 285 293 O
allergic NCT03868046 294 302 B-Allergy
anaphylactic NCT03868046 303 315 B-Condition
reaction NCT03868046 316 324 I-Condition
induced NCT03868046 325 332 O
by NCT03868046 333 335 O
a NCT03868046 336 337 O
specific NCT03868046 338 346 O
ICI NCT03868046 347 350 B-Procedure
. NCT03868046 351 352 O

3 NCT03868046 356 357 O
. NCT03868046 357 358 O
Active NCT03868046 360 366 B-Eq-Comparison
autoimmune NCT03868046 367 377 B-Condition
disease NCT03868046 378 385 I-Condition
with NCT03868046 386 390 O
severe NCT03868046 391 397 O
involvement NCT03868046 398 409 O
. NCT03868046 410 411 O

4 NCT03868046 415 416 O
. NCT03868046 416 417 O
Eastern NCT03868046 419 426 B-Observation
Cooperative NCT03868046 427 438 I-Observation
Oncology NCT03868046 439 447 I-Observation
Group NCT03868046 448 453 I-Observation
( NCT03868046 454 455 O
ECOG NCT03868046 456 460 B-Observation
) NCT03868046 461 462 O
performance NCT03868046 463 474 O
status NCT03868046 475 481 O
≥ NCT03868046 482 483 B-Eq-Comparison
3 NCT03868046 484 485 I-Eq-Comparison
. NCT03868046 485 486 O

5 NCT03868046 490 491 O
. NCT03868046 491 492 O
Ongoing NCT03868046 494 501 B-Eq-Comparison
immunosuppressive NCT03868046 502 519 B-Procedure
therapy NCT03868046 520 527 I-Procedure
: NCT03868046 528 529 O
prednisone NCT03868046 530 540 B-Drug
at NCT03868046 541 543 O
doses NCT03868046 544 549 O
> NCT03868046 550 551 B-Eq-Comparison
10 NCT03868046 552 554 I-Eq-Comparison
mg NCT03868046 555 557 I-Eq-Comparison
/ NCT03868046 558 559 I-Eq-Comparison
day NCT03868046 560 563 I-Eq-Comparison
or NCT03868046 564 566 O
equivalent NCT03868046 567 577 O
( NCT03868046 578 579 O
> NCT03868046 581 582 B-Eq-Comparison
1.5 NCT03868046 583 586 I-Eq-Comparison
mg NCT03868046 587 589 I-Eq-Comparison
/ NCT03868046 590 591 I-Eq-Comparison
day NCT03868046 592 595 I-Eq-Comparison
of NCT03868046 596 598 O
dexamethasone NCT03868046 599 612 B-Drug
) NCT03868046 613 614 O
, NCT03868046 616 617 O
and NCT03868046 618 621 B-Or
/ NCT03868046 622 623 I-Or
or NCT03868046 624 626 I-Or
any NCT03868046 627 630 O
dose NCT03868046 631 635 O
of NCT03868046 636 638 O
azathioprine NCT03868046 639 651 B-Drug
, NCT03868046 652 653 O
methotrexate NCT03868046 654 666 B-Drug
, NCT03868046 667 668 O
mycophenolate NCT03868046 669 682 B-Drug
, NCT03868046 683 684 O
cyclophosphamide NCT03868046 685 701 B-Drug
, NCT03868046 702 703 O
leflunomide NCT03868046 704 715 B-Drug
, NCT03868046 716 717 O
rituximab NCT03868046 718 727 B-Drug
, NCT03868046 728 729 O
anti NCT03868046 730 734 B-Drug
- NCT03868046 735 736 I-Drug
tumor NCT03868046 737 742 I-Drug
necrosis NCT03868046 743 751 I-Drug
factor NCT03868046 752 758 I-Drug
drugs NCT03868046 759 764 I-Drug
( NCT03868046 765 766 O
infliximab NCT03868046 767 777 B-Drug
, NCT03868046 778 779 O
etanercept NCT03868046 780 790 B-Drug
, NCT03868046 791 792 O
adalimumab NCT03868046 793 803 B-Drug
, NCT03868046 804 805 O
golimumab NCT03868046 806 815 B-Drug
) NCT03868046 816 817 O
, NCT03868046 819 820 O
belimumab NCT03868046 821 830 B-Drug
and NCT03868046 831 834 B-Or
abatacept NCT03868046 835 844 B-Drug
. NCT03868046 844 845 O

Inclusion NCT03865576 0 9 O
Criteria NCT03865576 10 18 O
: NCT03865576 19 20 O

- NCT03865576 24 25 O
ICU NCT03865576 27 30 B-Encounter
patients NCT03865576 31 39 O
suspected NCT03865576 40 49 B-Assertion___Assertion-Type-Value:possible
of NCT03865576 50 52 O
having NCT03865576 53 59 O
an NCT03865576 60 62 O
abnormality NCT03865576 63 74 O
of NCT03865576 75 77 O
ICP NCT03865576 78 81 B-Condition
undergoing NCT03865576 82 92 B-Eq-Comparison
monitoring NCT03865576 93 103 B-Procedure
with NCT03865576 104 108 O
commercially NCT03865576 109 121 O
- NCT03865576 122 123 O
available NCT03865576 124 133 O
, NCT03865576 134 135 O
FDA NCT03865576 136 139 O
- NCT03865576 140 141 O
approved NCT03865576 142 150 O
instrumentation NCT03865576 151 166 O
. NCT03865576 167 168 O

Exclusion NCT03865576 170 179 O
Criteria NCT03865576 180 188 O
: NCT03865576 189 190 O

History NCT03865576 192 199 B-Eq-Comparison
of NCT03865576 200 202 O
: NCT03865576 203 204 O

- NCT03865576 208 209 O
Glaucoma NCT03865576 211 219 B-Condition
or NCT03865576 220 222 B-Or
optic NCT03865576 223 228 B-Modifier
hypertension NCT03865576 229 241 B-Condition

- NCT03865576 244 245 O
Severe NCT03865576 247 253 O
orbital NCT03865576 254 261 B-Modifier
or NCT03865576 262 264 B-Or
ophthalmic NCT03865576 265 275 B-Modifier
injury NCT03865576 276 282 B-Condition

- NCT03865576 285 286 O
Orbital NCT03865576 288 295 B-Modifier
or NCT03865576 296 298 B-Or
intraocular NCT03865576 299 310 B-Modifier
surgery NCT03865576 311 318 B-Procedure
that NCT03865576 319 323 O
might NCT03865576 324 329 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03865576 330 339 O
with NCT03865576 340 344 O
orbital NCT03865576 345 352 B-Condition
compliance NCT03865576 353 363 I-Condition

- NCT03865576 366 367 O
Congenital NCT03865576 369 379 B-Condition
malformations NCT03865576 380 393 I-Condition
of NCT03865576 394 396 O
the NCT03865576 397 400 O
eye NCT03865576 401 404 B-Modifier
and NCT03865576 405 408 B-Or
/ NCT03865576 409 410 I-Or
or NCT03865576 411 413 I-Or
orbit NCT03865576 414 419 B-Modifier
that NCT03865576 420 424 O
might NCT03865576 425 430 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03865576 431 440 O
with NCT03865576 441 445 O
orbital NCT03865576 446 453 B-Condition
compliance NCT03865576 454 464 I-Condition
or NCT03865576 465 467 B-Or
orbital NCT03865576 468 475 B-Condition
vascular NCT03865576 476 484 I-Condition
anatomy NCT03865576 485 492 I-Condition

Inclusion NCT03861923 0 9 O
Criteria NCT03861923 10 18 O
: NCT03861923 19 20 O

- NCT03861923 24 25 O
Primary NCT03861923 27 34 O
complaint NCT03861923 35 44 O
of NCT03861923 45 47 O
shoulder NCT03861923 48 56 B-Modifier
pain NCT03861923 57 61 B-Condition
and NCT03861923 62 65 B-Or
stiffness NCT03861923 66 75 B-Condition

- NCT03861923 78 79 O
Gradual NCT03861923 81 88 O
onset NCT03861923 89 94 O
of NCT03861923 95 97 O
symptoms NCT03861923 98 106 O

- NCT03861923 109 110 O
Glenohumeral NCT03861923 112 124 B-Observation
passive NCT03861923 125 132 I-Observation
range NCT03861923 133 138 I-Observation
of NCT03861923 139 141 I-Observation
motion NCT03861923 142 148 I-Observation
limited NCT03861923 149 156 O
in NCT03861923 157 159 O
multiple NCT03861923 160 168 B-Modifier
directions NCT03861923 169 179 I-Modifier

- NCT03861923 182 183 O
Glenohumeral NCT03861923 185 197 B-Observation
passive NCT03861923 198 205 I-Observation
range NCT03861923 206 211 I-Observation
of NCT03861923 212 214 I-Observation
motion NCT03861923 215 221 I-Observation
decreases NCT03861923 222 231 O
as NCT03861923 232 234 O
the NCT03861923 235 238 O
humerus NCT03861923 239 246 B-Modifier
is NCT03861923 247 249 O
abducted NCT03861923 250 258 B-Observation
from NCT03861923 259 263 O
45 NCT03861923 264 266 B-Eq-Comparison
degrees NCT03861923 267 274 I-Eq-Comparison
to NCT03861923 275 277 I-Eq-Comparison
90 NCT03861923 278 280 I-Eq-Comparison
degrees NCT03861923 281 288 I-Eq-Comparison

- NCT03861923 291 292 O
Age NCT03861923 294 297 B-Age
18 NCT03861923 298 300 B-Eq-Comparison
to NCT03861923 301 303 I-Eq-Comparison
65 NCT03861923 304 306 I-Eq-Comparison
years NCT03861923 307 312 I-Eq-Comparison

- NCT03861923 315 316 O
Reports NCT03861923 318 325 O
pain NCT03861923 326 330 B-Condition
with NCT03861923 331 335 O
normal NCT03861923 336 342 B-Modifier
activity NCT03861923 343 351 I-Modifier
greater NCT03861923 352 359 B-Eq-Comparison
than NCT03861923 360 364 I-Eq-Comparison
or NCT03861923 365 367 I-Eq-Comparison
equal NCT03861923 368 373 I-Eq-Comparison
to NCT03861923 374 376 I-Eq-Comparison
2 NCT03861923 377 378 I-Eq-Comparison
/ NCT03861923 379 380 I-Eq-Comparison
10 NCT03861923 381 383 I-Eq-Comparison
on NCT03861923 384 386 O
the NCT03861923 387 390 O
numeric NCT03861923 391 398 O
pain NCT03861923 399 403 B-Observation
rating NCT03861923 404 410 I-Observation
scale NCT03861923 411 416 I-Observation

- NCT03861923 419 420 O
Read NCT03861923 422 426 O
and NCT03861923 427 430 O
speak NCT03861923 431 436 O
English NCT03861923 437 444 O

Exclusion NCT03861923 445 454 O
Criteria NCT03861923 455 463 O
: NCT03861923 464 465 O

- NCT03861923 469 470 O
Signs NCT03861923 472 477 B-Assertion___Assertion-Type-Value:possible
or NCT03861923 478 480 I-Assertion___Assertion-Type-Value:possible
symptoms NCT03861923 481 489 I-Assertion___Assertion-Type-Value:possible
of NCT03861923 490 492 O
cervical NCT03861923 493 501 B-Condition
radiculopathy NCT03861923 502 515 I-Condition
, NCT03861923 516 517 O
radiculitis NCT03861923 518 529 B-Condition
, NCT03861923 530 531 O
or NCT03861923 532 534 B-Or
referral NCT03861923 535 543 B-Condition
from NCT03861923 544 548 O
the NCT03861923 549 552 O
cervical NCT03861923 553 561 B-Modifier
spine NCT03861923 562 567 I-Modifier

- NCT03861923 570 571 O
Clinical NCT03861923 573 581 O
evidence NCT03861923 582 590 O
as NCT03861923 591 593 O
determined NCT03861923 594 604 O
in NCT03861923 605 607 O
the NCT03861923 608 611 O
examination NCT03861923 612 623 B-Procedure
of NCT03861923 624 626 O
an NCT03861923 627 629 O
alternative NCT03861923 630 641 B-Other
shoulder NCT03861923 642 650 B-Modifier
diagnosis NCT03861923 651 660 B-Condition

- NCT03861923 663 664 O
Normal NCT03861923 666 672 O
passive NCT03861923 673 680 B-Modifier
shoulder NCT03861923 681 689 I-Modifier
range NCT03861923 690 695 B-Observation
of NCT03861923 696 698 I-Observation
motion NCT03861923 699 705 I-Observation

- NCT03861923 708 709 O
Known NCT03861923 711 716 O
radiographic NCT03861923 717 729 B-Procedure
evidence NCT03861923 730 738 O
of NCT03861923 739 741 O
glenohumeral NCT03861923 742 754 B-Modifier
osteoarthritis NCT03861923 755 769 B-Condition

- NCT03861923 772 773 O
Known NCT03861923 775 780 O
neurologic NCT03861923 781 791 B-Condition
disease NCT03861923 792 799 I-Condition

- NCT03861923 802 803 O
Received NCT03861923 805 813 O
dry NCT03861923 814 817 B-Procedure
needling NCT03861923 818 826 I-Procedure
or NCT03861923 827 829 B-Or
acupuncture NCT03861923 830 841 B-Procedure
within NCT03861923 842 848 B-Eq-Comparison
the NCT03861923 849 852 I-Eq-Comparison
past NCT03861923 853 857 I-Eq-Comparison
6 NCT03861923 858 859 I-Eq-Comparison
months NCT03861923 860 866 I-Eq-Comparison

- NCT03861923 869 870 O
Fear NCT03861923 872 876 B-Condition
of NCT03861923 877 879 I-Condition
needling NCT03861923 880 888 I-Condition

- NCT03861923 891 892 O
Currently NCT03861923 894 903 B-Eq-Comparison
being NCT03861923 904 909 O
treated NCT03861923 910 917 B-Procedure
with NCT03861923 918 922 O
anticoagulant NCT03861923 923 936 B-Drug
medication NCT03861923 937 947 I-Drug

- NCT03861923 950 951 O
Shoulder NCT03861923 953 961 B-Observation
pain NCT03861923 962 966 I-Observation
and NCT03861923 967 970 I-Observation
disability NCT03861923 971 981 I-Observation
index NCT03861923 982 987 I-Observation
( NCT03861923 988 989 O
SPADI NCT03861923 990 995 B-Observation
) NCT03861923 996 997 O
score NCT03861923 998 1003 O
less NCT03861923 1004 1008 B-Eq-Comparison
than NCT03861923 1009 1013 I-Eq-Comparison
10 NCT03861923 1014 1016 I-Eq-Comparison
% NCT03861923 1017 1018 I-Eq-Comparison
or NCT03861923 1019 1021 B-Or
greater NCT03861923 1022 1029 B-Eq-Comparison
than NCT03861923 1030 1034 I-Eq-Comparison
90 NCT03861923 1035 1037 I-Eq-Comparison
% NCT03861923 1038 1039 I-Eq-Comparison

Inclusion NCT03865589 0 9 O
Criteria NCT03865589 10 18 O
: NCT03865589 19 20 O

- NCT03865589 24 25 O
Any NCT03865589 27 30 O
patient NCT03865589 31 38 O
undergoing NCT03865589 39 49 B-Eq-Comparison
a NCT03865589 50 51 O
myeloablative NCT03865589 52 65 B-Procedure
conditioning NCT03865589 66 78 I-Procedure
regimen NCT03865589 79 86 O
for NCT03865589 87 90 O
HCT NCT03865589 91 94 B-Condition
between NCT03865589 95 102 B-Eq-Comparison
4 NCT03865589 103 104 I-Eq-Comparison
/ NCT03865589 105 106 I-Eq-Comparison
1 NCT03865589 107 108 I-Eq-Comparison
/ NCT03865589 109 110 I-Eq-Comparison
2019 NCT03865589 111 115 I-Eq-Comparison
and NCT03865589 116 119 I-Eq-Comparison
12 NCT03865589 120 122 I-Eq-Comparison
/ NCT03865589 123 124 I-Eq-Comparison
31 NCT03865589 125 127 I-Eq-Comparison
/ NCT03865589 128 129 I-Eq-Comparison
2120 NCT03865589 130 134 I-Eq-Comparison
defined NCT03865589 135 142 O
as NCT03865589 143 145 O
one NCT03865589 146 149 B-Eq-Comparison
of NCT03865589 150 152 O
the NCT03865589 153 156 B-Criteria-Count
following NCT03865589 157 166 I-Criteria-Count
: NCT03865589 167 168 O

- NCT03865589 177 178 O
TBI NCT03865589 180 183 B-Observation
> NCT03865589 184 185 B-Eq-Comparison
= NCT03865589 187 188 I-Eq-Comparison
1200 NCT03865589 189 193 I-Eq-Comparison
cGy NCT03865589 194 197 I-Eq-Comparison
( NCT03865589 198 199 O
fractionated NCT03865589 200 212 B-Modifier
) NCT03865589 213 214 O

- NCT03865589 223 224 O
Cyclophosphamide NCT03865589 226 242 B-Drug
+ NCT03865589 243 244 B-And
TBI NCT03865589 245 248 B-Observation
( NCT03865589 249 250 O
> NCT03865589 252 253 B-Eq-Comparison
500 NCT03865589 254 257 I-Eq-Comparison
cGy NCT03865589 258 261 I-Eq-Comparison
( NCT03865589 262 263 O
single NCT03865589 264 270 B-Modifier
) NCT03865589 271 272 O
or NCT03865589 273 275 B-Or
> NCT03865589 276 277 B-Eq-Comparison
800 NCT03865589 278 281 I-Eq-Comparison
cGy NCT03865589 282 285 I-Eq-Comparison
( NCT03865589 286 287 O
fractionated NCT03865589 288 300 B-Modifier
) NCT03865589 301 302 O
) NCT03865589 304 305 O

- NCT03865589 314 315 O
Cyclophosphamide NCT03865589 317 333 B-Drug
+ NCT03865589 334 335 B-And
Etoposide NCT03865589 336 345 B-Drug
+ NCT03865589 346 347 B-And
TBI NCT03865589 348 351 B-Observation
( NCT03865589 352 353 O
> NCT03865589 355 356 B-Eq-Comparison
500 NCT03865589 357 360 I-Eq-Comparison
cGy NCT03865589 361 364 I-Eq-Comparison
( NCT03865589 365 366 O
single NCT03865589 367 373 B-Modifier
) NCT03865589 374 375 O
or NCT03865589 376 378 B-Or
> NCT03865589 379 380 B-Eq-Comparison
800 NCT03865589 381 384 I-Eq-Comparison
cGy NCT03865589 385 388 I-Eq-Comparison
( NCT03865589 389 390 O
fractionated NCT03865589 391 403 B-Modifier
) NCT03865589 404 405 O
) NCT03865589 407 408 O

- NCT03865589 417 418 O
Cyclophosphamide NCT03865589 420 436 B-Drug
+ NCT03865589 437 438 B-And
Thiotepa NCT03865589 439 447 B-Drug
+ NCT03865589 448 449 B-And
TBI NCT03865589 450 453 B-Observation
( NCT03865589 454 455 O
> NCT03865589 457 458 B-Eq-Comparison
500 NCT03865589 459 462 I-Eq-Comparison
cGy NCT03865589 463 466 I-Eq-Comparison
( NCT03865589 467 468 O
single NCT03865589 469 475 B-Modifier
) NCT03865589 476 477 O
or NCT03865589 478 480 B-Or
> NCT03865589 481 482 B-Eq-Comparison
800 NCT03865589 483 486 I-Eq-Comparison
cGy NCT03865589 487 490 I-Eq-Comparison
( NCT03865589 491 492 O
fractionated NCT03865589 493 505 B-Modifier
) NCT03865589 506 507 O
) NCT03865589 509 510 O

- NCT03865589 519 520 O
Busulfan NCT03865589 522 530 B-Drug
( NCT03865589 531 532 O
Total NCT03865589 533 538 O
dose NCT03865589 539 543 O
> NCT03865589 544 545 B-Eq-Comparison
7.2 NCT03865589 546 549 I-Eq-Comparison
mg NCT03865589 550 552 I-Eq-Comparison
/ NCT03865589 553 554 I-Eq-Comparison
kg NCT03865589 555 557 I-Eq-Comparison
IV NCT03865589 558 560 I-Eq-Comparison|Modifier
or NCT03865589 561 563 B-Or
> NCT03865589 564 565 B-Eq-Comparison
9.0 NCT03865589 566 569 I-Eq-Comparison
mg NCT03865589 570 572 O
/ NCT03865589 573 574 O
kg NCT03865589 575 577 O
orally NCT03865589 578 584 B-Modifier
) NCT03865589 585 586 O
+ NCT03865589 587 588 B-And
Cyclophosphamide NCT03865589 589 605 B-Drug

- NCT03865589 613 614 O
Busulfan NCT03865589 616 624 B-Drug
( NCT03865589 625 626 O
Total NCT03865589 627 632 O
dose NCT03865589 633 637 O
> NCT03865589 638 639 B-Eq-Comparison
7.2 NCT03865589 640 643 I-Eq-Comparison
mg NCT03865589 644 646 I-Eq-Comparison
/ NCT03865589 647 648 I-Eq-Comparison
kg NCT03865589 649 651 I-Eq-Comparison
IV NCT03865589 652 654 B-Modifier
or NCT03865589 655 657 B-Or
> NCT03865589 658 659 B-Eq-Comparison
9.0 NCT03865589 660 663 I-Eq-Comparison
mg NCT03865589 664 666 I-Eq-Comparison
/ NCT03865589 667 668 I-Eq-Comparison
kg NCT03865589 669 671 I-Eq-Comparison
orally NCT03865589 672 678 B-Modifier
) NCT03865589 679 680 O
+ NCT03865589 681 682 B-And
Melphalan NCT03865589 683 692 B-Drug

- NCT03865589 700 701 O
Busulfan NCT03865589 703 711 B-Drug
( NCT03865589 712 713 O
Total NCT03865589 714 719 O
dose NCT03865589 720 724 O
> NCT03865589 725 726 B-Eq-Comparison
7.2 NCT03865589 727 730 I-Eq-Comparison
mg NCT03865589 731 733 I-Eq-Comparison
/ NCT03865589 734 735 I-Eq-Comparison
kg NCT03865589 736 738 I-Eq-Comparison
IV NCT03865589 739 741 B-Modifier
or NCT03865589 742 744 B-Or
> NCT03865589 745 746 B-Eq-Comparison
9.0 NCT03865589 747 750 I-Eq-Comparison
mg NCT03865589 751 753 I-Eq-Comparison
/ NCT03865589 754 755 I-Eq-Comparison
kg NCT03865589 756 758 I-Eq-Comparison
orally NCT03865589 759 765 B-Modifier
) NCT03865589 766 767 O
+ NCT03865589 768 769 B-And
Thiotepa NCT03865589 770 778 B-Drug

- NCT03865589 786 787 O
NOTE NCT03865589 789 793 O
: NCT03865589 794 795 O
Busulfan NCT03865589 796 804 B-Drug
cumulative NCT03865589 805 815 B-Observation
plasma NCT03865589 816 822 I-Observation
AUC NCT03865589 823 826 I-Observation
of NCT03865589 827 829 O
> NCT03865589 830 831 B-Eq-Comparison
75 NCT03865589 832 834 I-Eq-Comparison
mg NCT03865589 835 837 I-Eq-Comparison
/ NCT03865589 838 839 I-Eq-Comparison
L NCT03865589 840 841 I-Eq-Comparison
per NCT03865589 842 845 I-Eq-Comparison
hour NCT03865589 846 850 I-Eq-Comparison
or NCT03865589 851 853 B-Or
> NCT03865589 854 855 B-Eq-Comparison
18270 NCT03865589 856 861 I-Eq-Comparison
microMolar NCT03865589 862 872 I-Eq-Comparison
per NCT03865589 873 876 I-Eq-Comparison
minute NCT03865589 877 883 I-Eq-Comparison
could NCT03865589 884 889 O
be NCT03865589 890 892 O
used NCT03865589 893 897 O
in NCT03865589 898 900 O
the NCT03865589 901 904 O
preceding NCT03865589 905 914 O
criteria NCT03865589 915 923 O
in NCT03865589 924 926 O
lieu NCT03865589 927 931 O
of NCT03865589 932 934 O
the NCT03865589 935 938 O
mg NCT03865589 939 941 O
/ NCT03865589 942 943 O
kg NCT03865589 944 946 O
doses NCT03865589 947 952 O
. NCT03865589 953 954 O

OR NCT03865589 956 958 B-Or

2 NCT03865589 959 960 O
. NCT03865589 960 961 O
Any NCT03865589 963 966 O
patient NCT03865589 967 974 O
who NCT03865589 975 978 O
has NCT03865589 979 982 O
a NCT03865589 983 984 O
myeloablative NCT03865589 985 998 B-Procedure
conditioning NCT03865589 999 1011 I-Procedure
regimen NCT03865589 1012 1019 O
( NCT03865589 1020 1021 O
as NCT03865589 1022 1024 O
defined NCT03865589 1025 1032 O
by NCT03865589 1033 1035 O
the NCT03865589 1036 1039 O
local NCT03865589 1040 1045 O
HSCT NCT03865589 1046 1050 O
team NCT03865589 1051 1055 O
) NCT03865589 1056 1057 O
that NCT03865589 1058 1062 O
includes NCT03865589 1063 1071 O
sirolimus NCT03865589 1072 1081 B-Drug
and NCT03865589 1082 1085 B-Or
tacrolimus NCT03865589 1086 1096 B-Drug
for NCT03865589 1097 1100 O
GVHD NCT03865589 1101 1105 B-Condition
prophylaxis NCT03865589 1106 1117 B-Procedure
. NCT03865589 1118 1119 O

OR NCT03865589 1121 1123 B-Or

3 NCT03865589 1124 1125 O
. NCT03865589 1125 1126 O
Any NCT03865589 1128 1131 O
patient NCT03865589 1132 1139 O
who NCT03865589 1140 1143 O
is NCT03865589 1144 1146 O
high NCT03865589 1147 1151 O
risk NCT03865589 1152 1156 B-Risk
for NCT03865589 1157 1160 O
SOS NCT03865589 1161 1164 B-Condition
irrespective NCT03865589 1165 1177 O
of NCT03865589 1178 1180 O
conditioning NCT03865589 1181 1193 O
regimen NCT03865589 1194 1201 O
: NCT03865589 1202 1203 O

Neuroblastoma NCT03865589 1205 1218 B-Condition
, NCT03865589 1219 1220 O
HLH NCT03865589 1221 1224 B-Condition
, NCT03865589 1225 1226 O
Osteopetrosis NCT03865589 1227 1240 B-Condition
, NCT03865589 1241 1242 O
Thalassemia NCT03865589 1243 1254 B-Condition
, NCT03865589 1255 1256 O
treatment NCT03865589 1257 1266 B-Procedure
with NCT03865589 1267 1271 O
inotuzumab NCT03865589 1272 1282 B-Drug
or NCT03865589 1283 1285 B-Or
gemtuzumab NCT03865589 1286 1296 B-Drug
within NCT03865589 1297 1303 B-Eq-Comparison
3 NCT03865589 1304 1305 I-Eq-Comparison
months NCT03865589 1306 1312 I-Eq-Comparison
prior NCT03865589 1313 1318 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03865589 1319 1321 I-Temporal-Connection___Temporal-Connection-Type-Value:before
HSCT NCT03865589 1322 1326 B-Procedure
admission NCT03865589 1327 1336 B-Encounter
, NCT03865589 1337 1338 O
2 NCT03865589 1339 1340 B-Eq-Comparison
nd NCT03865589 1341 1343 I-Eq-Comparison
HSCT NCT03865589 1344 1348 B-Procedure
if NCT03865589 1349 1351 O
it NCT03865589 1352 1354 O
is NCT03865589 1355 1357 O
myeloablative NCT03865589 1358 1371 B-Modifier
and NCT03865589 1372 1375 O
within NCT03865589 1376 1382 B-Eq-Comparison
6 NCT03865589 1383 1384 I-Eq-Comparison
months NCT03865589 1385 1391 I-Eq-Comparison
of NCT03865589 1392 1394 B-Temporal-Connection___Temporal-Connection-Type-Value:before
prior NCT03865589 1395 1400 B-Coreference
, NCT03865589 1401 1402 O
iron NCT03865589 1403 1407 B-Condition
overload NCT03865589 1408 1416 I-Condition
, NCT03865589 1417 1418 O
steatohepatitis NCT03865589 1419 1434 B-Condition
, NCT03865589 1435 1436 O
active NCT03865589 1437 1443 B-Eq-Comparison
inflammatory NCT03865589 1444 1456 B-Modifier
or NCT03865589 1457 1459 B-Or
infection NCT03865589 1460 1469 B-Modifier
hepatitis NCT03865589 1470 1479 B-Condition
or NCT03865589 1480 1482 B-Or
any NCT03865589 1483 1486 O
other NCT03865589 1487 1492 B-Other
condition NCT03865589 1493 1502 B-Condition
which NCT03865589 1503 1508 O
puts NCT03865589 1509 1513 O
the NCT03865589 1514 1517 O
patient NCT03865589 1518 1525 O
at NCT03865589 1526 1528 O
a NCT03865589 1529 1530 O
higher NCT03865589 1531 1537 O
risk NCT03865589 1538 1542 B-Risk
of NCT03865589 1543 1545 O
developing NCT03865589 1546 1556 O
SOS NCT03865589 1557 1560 B-Condition
. NCT03865589 1561 1562 O

Exclusion NCT03865589 1564 1573 O
Criteria NCT03865589 1574 1582 O
: NCT03865589 1583 1584 O

- NCT03865589 1588 1589 O
Any NCT03865589 1591 1594 O
patient NCT03865589 1595 1602 O
who NCT03865589 1603 1606 O
has NCT03865589 1607 1610 O
contraindication NCT03865589 1611 1627 B-Contraindication
to NCT03865589 1628 1630 O
US NCT03865589 1631 1633 B-Procedure
SWE NCT03865589 1634 1637 I-Procedure
( NCT03865589 1638 1639 O
e. NCT03865589 1640 1642 O
g. NCT03865589 1643 1645 O
unable NCT03865589 1647 1653 B-Condition
to NCT03865589 1654 1656 I-Condition
hold NCT03865589 1657 1661 I-Condition
still NCT03865589 1662 1667 I-Condition
) NCT03865589 1668 1669 O


Inclusion NCT03866902 0 9 O
criteria NCT03866902 10 18 O
for NCT03866902 19 22 O
mothers NCT03866902 23 30 B-Family-Member___Family-Member-Type:mother
will NCT03866902 31 35 O
be NCT03866902 36 38 O
: NCT03866902 39 40 O

- NCT03866902 44 45 O
age NCT03866902 47 50 B-Age
18 NCT03866902 51 53 B-Eq-Comparison
years NCT03866902 54 59 I-Eq-Comparison
or NCT03866902 60 62 I-Eq-Comparison
older NCT03866902 63 68 I-Eq-Comparison

- NCT03866902 71 72 O
self NCT03866902 74 78 O
- NCT03866902 79 80 O
identification NCT03866902 81 95 O
as NCT03866902 96 98 O
Hispanic NCT03866902 99 107 O

- NCT03866902 110 111 O
limited NCT03866902 113 120 B-Negation
English NCT03866902 121 128 O
proficiency NCT03866902 129 140 O
; NCT03866902 140 141 O
little NCT03866902 142 148 B-Negation
acculturation NCT03866902 149 162 B-Observation
, NCT03866902 163 164 O
as NCT03866902 165 167 O
measured NCT03866902 168 176 O
by NCT03866902 177 179 O
the NCT03866902 180 183 O
Short NCT03866902 184 189 B-Observation
Acculturation NCT03866902 190 203 I-Observation
Scale NCT03866902 204 209 I-Observation
for NCT03866902 210 213 I-Observation
Hispanics NCT03866902 214 223 I-Observation
with NCT03866902 224 228 O
a NCT03866902 229 230 O
score NCT03866902 231 236 O
from NCT03866902 237 241 O
1.00 NCT03866902 242 246 B-Eq-Comparison
to NCT03866902 247 249 I-Eq-Comparison
2.99 NCT03866902 250 254 I-Eq-Comparison

- NCT03866902 258 259 O
ability NCT03866902 261 268 O
to NCT03866902 269 271 O
understand NCT03866902 272 282 O
spoken NCT03866902 283 289 O
Spanish NCT03866902 290 297 O

- NCT03866902 300 301 O
a NCT03866902 303 304 O
BMI NCT03866902 305 308 B-Observation
> NCT03866902 309 310 B-Eq-Comparison
25 NCT03866902 311 313 I-Eq-Comparison
kg NCT03866902 314 316 I-Eq-Comparison
/ NCT03866902 317 318 I-Eq-Comparison
m² NCT03866902 319 321 I-Eq-Comparison

- NCT03866902 324 325 O
residence NCT03866902 327 336 O
with NCT03866902 337 341 O
the NCT03866902 342 345 B-Family-Member___Family-Member-Type:child
child NCT03866902 346 351 I-Family-Member___Family-Member-Type:child

- NCT03866902 354 355 O
consent NCT03866902 357 364 O
to NCT03866902 365 367 O
join NCT03866902 368 372 O
the NCT03866902 373 376 O
study NCT03866902 377 382 O
and NCT03866902 383 386 O
consent NCT03866902 387 394 O
for NCT03866902 395 398 O
their NCT03866902 399 404 B-Family-Member___Family-Member-Type:child
child NCT03866902 405 410 I-Family-Member___Family-Member-Type:child
to NCT03866902 411 413 O
join NCT03866902 414 418 O
the NCT03866902 419 422 O
study NCT03866902 423 428 B-Study
. NCT03866902 429 430 O

Inclusion NCT03866902 432 441 O
criteria NCT03866902 442 450 O
for NCT03866902 451 454 O
children NCT03866902 455 463 B-Family-Member___Family-Member-Type:child
will NCT03866902 464 468 O
be NCT03866902 469 471 O
: NCT03866902 472 473 O

- NCT03866902 477 478 O
age NCT03866902 480 483 B-Age
3 NCT03866902 484 485 B-Eq-Comparison
- NCT03866902 486 487 I-Eq-Comparison
5 NCT03866902 488 489 I-Eq-Comparison
years NCT03866902 490 495 I-Eq-Comparison

- NCT03866902 498 499 O
ability NCT03866902 501 508 O
to NCT03866902 509 511 O
understand NCT03866902 512 522 O
spoken NCT03866902 523 529 O
Spanish NCT03866902 530 537 O

- NCT03866902 540 541 O
a NCT03866902 543 544 O
BMI NCT03866902 545 548 B-Observation
> NCT03866902 549 550 B-Eq-Comparison
25 NCT03866902 551 553 I-Eq-Comparison
th NCT03866902 554 556 I-Eq-Comparison
percentile NCT03866902 557 567 I-Eq-Comparison
for NCT03866902 568 571 O
age NCT03866902 572 575 B-Modifier
and NCT03866902 576 579 I-Modifier
gender NCT03866902 580 586 I-Modifier

Exclusion NCT03866902 587 596 O
criteria NCT03866902 597 605 O
for NCT03866902 606 609 O
mothers NCT03866902 610 617 B-Family-Member___Family-Member-Type:mother
will NCT03866902 618 622 O
be NCT03866902 623 625 O
: NCT03866902 626 627 O

- NCT03866902 631 632 O
heart NCT03866902 634 639 B-Condition
murmur NCT03866902 640 646 I-Condition

- NCT03866902 649 650 O
congenital NCT03866902 652 662 B-Condition
heart NCT03866902 663 668 I-Condition
disease NCT03866902 669 676 I-Condition

- NCT03866902 679 680 O
family NCT03866902 682 688 B-Family-Member
history NCT03866902 689 696 I-Family-Member
of NCT03866902 697 699 O
sudden NCT03866902 700 706 B-Condition
death NCT03866902 707 712 I-Condition

- NCT03866902 715 716 O
difficulty NCT03866902 718 728 B-Negation
exercising NCT03866902 729 739 B-Observation

- NCT03866902 742 743 O
psychological NCT03866902 745 758 B-Condition
problems NCT03866902 759 767 I-Condition

Inclusion NCT03862807 0 9 O
Criteria NCT03862807 10 18 O
: NCT03862807 19 20 O

- NCT03862807 24 25 O
Received NCT03862807 27 35 B-Eq-Comparison
liver NCT03862807 36 41 B-Procedure
transplant NCT03862807 42 52 I-Procedure
for NCT03862807 53 56 O
treatment NCT03862807 57 66 B-Procedure
of NCT03862807 67 69 O
hATTR NCT03862807 70 75 B-Modifier
amyloidosis NCT03862807 76 87 B-Condition
≥ NCT03862807 88 89 B-Eq-Comparison
12 NCT03862807 90 92 I-Eq-Comparison
months NCT03862807 93 99 I-Eq-Comparison
before NCT03862807 100 106 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03862807 107 112 B-Study
start NCT03862807 113 118 B-Eq-Comparison

- NCT03862807 121 122 O
Has NCT03862807 124 127 O
increase NCT03862807 128 136 O
in NCT03862807 137 139 O
polyneuropathy NCT03862807 140 154 B-Condition
disability NCT03862807 155 165 I-Condition
( NCT03862807 166 167 O
PND NCT03862807 168 171 B-Condition
) NCT03862807 172 173 O
score NCT03862807 174 179 O
after NCT03862807 180 185 B-Temporal-Connection___Temporal-Connection-Type-Value:after
liver NCT03862807 186 191 B-Procedure
transplant NCT03862807 192 202 I-Procedure

- NCT03862807 205 206 O
Has NCT03862807 208 211 O
received NCT03862807 212 220 B-Eq-Comparison
stable NCT03862807 221 227 O
immunosuppressive NCT03862807 228 245 B-Procedure
regimen NCT03862807 246 253 I-Procedure
with NCT03862807 254 258 B-And
≤ NCT03862807 259 260 B-Eq-Comparison
10 NCT03862807 261 263 I-Eq-Comparison
mg NCT03862807 264 266 I-Eq-Comparison
/ NCT03862807 267 268 I-Eq-Comparison
day NCT03862807 269 272 I-Eq-Comparison
of NCT03862807 273 275 O
prednisone NCT03862807 276 286 B-Drug
for NCT03862807 287 290 O
at NCT03862807 291 293 B-Eq-Comparison
least NCT03862807 294 299 I-Eq-Comparison
3 NCT03862807 300 301 I-Eq-Comparison
months NCT03862807 302 308 I-Eq-Comparison
before NCT03862807 309 315 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03862807 316 321 B-Study
start NCT03862807 322 327 B-Eq-Comparison

- NCT03862807 330 331 O
Has NCT03862807 333 336 O
Karnofsky NCT03862807 337 346 B-Observation
Performance NCT03862807 347 358 I-Observation
Status NCT03862807 359 365 I-Observation
( NCT03862807 366 367 O
KPS NCT03862807 368 371 B-Observation
) NCT03862807 372 373 O
of NCT03862807 374 376 O
≥ NCT03862807 377 378 B-Eq-Comparison
70 NCT03862807 379 381 I-Eq-Comparison
% NCT03862807 382 383 I-Eq-Comparison

- NCT03862807 387 388 O
Has NCT03862807 390 393 O
vitamin NCT03862807 394 401 B-Observation
A NCT03862807 402 403 I-Observation
level NCT03862807 404 409 I-Observation
greater NCT03862807 410 417 B-Eq-Comparison
than NCT03862807 418 422 I-Eq-Comparison
or NCT03862807 423 425 I-Eq-Comparison
equal NCT03862807 426 431 I-Eq-Comparison
to NCT03862807 432 434 I-Eq-Comparison
lower NCT03862807 435 440 I-Eq-Comparison
limit NCT03862807 441 446 I-Eq-Comparison
of NCT03862807 447 449 I-Eq-Comparison
normal NCT03862807 450 456 I-Eq-Comparison

Exclusion NCT03862807 457 466 O
Criteria NCT03862807 467 475 O
: NCT03862807 476 477 O

- NCT03862807 481 482 O
Has NCT03862807 484 487 O
previously NCT03862807 488 498 B-Eq-Comparison
received NCT03862807 499 507 I-Eq-Comparison
inotersen NCT03862807 508 517 B-Drug
or NCT03862807 518 520 B-Or
patisiran NCT03862807 521 530 B-Drug

- NCT03862807 533 534 O
Has NCT03862807 536 539 O
clinically NCT03862807 540 550 O
significant NCT03862807 551 562 O
liver NCT03862807 563 568 B-Observation
function NCT03862807 569 577 I-Observation
test NCT03862807 578 582 I-Observation
abnormalities NCT03862807 583 596 O

- NCT03862807 599 600 O
Has NCT03862807 602 605 O
known NCT03862807 606 611 O
portal NCT03862807 612 618 B-Condition
hypertension NCT03862807 619 631 I-Condition
with NCT03862807 632 636 B-And
ascites NCT03862807 637 644 B-Condition

- NCT03862807 647 648 O
Has NCT03862807 650 653 O
estimated NCT03862807 654 663 B-Observation
glomerular NCT03862807 664 674 I-Observation
filtration NCT03862807 675 685 I-Observation
rate NCT03862807 686 690 I-Observation
( NCT03862807 691 692 O
eGFR NCT03862807 693 697 B-Observation
) NCT03862807 698 699 O
≤ NCT03862807 700 701 B-Eq-Comparison
30 NCT03862807 702 704 I-Eq-Comparison
mL NCT03862807 705 707 I-Eq-Comparison
/ NCT03862807 708 709 I-Eq-Comparison
min NCT03862807 710 713 I-Eq-Comparison
/ NCT03862807 714 715 I-Eq-Comparison
1.73 NCT03862807 716 720 I-Eq-Comparison
m^2 NCT03862807 721 724 I-Eq-Comparison

- NCT03862807 728 729 O
Has NCT03862807 731 734 O
known NCT03862807 735 740 O
leptomeningeal NCT03862807 741 755 B-Modifier
amyloidosis NCT03862807 756 767 B-Condition

- NCT03862807 770 771 O
Has NCT03862807 773 776 O
infection NCT03862807 777 786 B-Condition
with NCT03862807 787 791 B-And
hepatitis NCT03862807 792 801 B-Condition
B NCT03862807 802 803 I-Condition
, NCT03862807 804 805 O
hepatitis NCT03862807 806 815 B-Condition
C NCT03862807 816 817 I-Condition
or NCT03862807 818 820 B-Or
human NCT03862807 821 826 B-Condition
immunodeficiency NCT03862807 827 843 I-Condition
virus NCT03862807 844 849 I-Condition
( NCT03862807 850 851 O
HIV NCT03862807 852 855 B-Condition
) NCT03862807 856 857 O

- NCT03862807 861 862 O
Has NCT03862807 864 867 O
New NCT03862807 868 871 B-Condition
York NCT03862807 872 876 I-Condition
Heart NCT03862807 877 882 I-Condition
Association NCT03862807 883 894 I-Condition
heart NCT03862807 895 900 I-Condition
failure NCT03862807 901 908 I-Condition
classification NCT03862807 909 923 O
of NCT03862807 924 926 O
> NCT03862807 927 928 B-Eq-Comparison
2 NCT03862807 929 930 I-Eq-Comparison

- NCT03862807 934 935 O
Is NCT03862807 937 939 O
wheelchair NCT03862807 940 950 B-Condition
bound NCT03862807 951 956 I-Condition
or NCT03862807 957 959 B-Or
bedridden NCT03862807 960 969 B-Condition

- NCT03862807 972 973 O
Has NCT03862807 975 978 O
received NCT03862807 979 987 B-Eq-Comparison
organ NCT03862807 988 993 B-Procedure
transplants NCT03862807 994 1005 I-Procedure
other NCT03862807 1006 1011 B-Exception
than NCT03862807 1012 1016 I-Exception
liver NCT03862807 1017 1022 B-Procedure
transplant NCT03862807 1023 1033 I-Procedure

- NCT03862807 1036 1037 O
Will NCT03862807 1039 1043 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862807 1044 1046 I-Assertion___Assertion-Type-Value:hypothetical
using NCT03862807 1047 1052 O
an NCT03862807 1053 1055 O
other NCT03862807 1056 1061 B-Other
tetramer NCT03862807 1062 1070 B-Procedure
stabilizer NCT03862807 1071 1081 I-Procedure
during NCT03862807 1082 1088 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03862807 1089 1092 O
study NCT03862807 1093 1098 B-Study

Inclusion NCT03860792 0 9 O
Criteria NCT03860792 10 18 O
: NCT03860792 19 20 O

- NCT03860792 24 25 O
Diagnosis NCT03860792 27 36 O
of NCT03860792 37 39 O
AD NCT03860792 40 42 B-Condition
by NCT03860792 43 45 O
current NCT03860792 46 53 O
McKhann NCT03860792 54 61 O
et NCT03860792 62 64 O
al NCT03860792 65 67 O
. NCT03860792 67 68 O
criteria NCT03860792 70 78 O

- NCT03860792 81 82 O
CDR NCT03860792 84 87 B-Observation
global NCT03860792 88 94 I-Observation
score NCT03860792 95 100 I-Observation
of NCT03860792 101 103 O
0.5 NCT03860792 104 107 B-Eq-Comparison
or NCT03860792 108 110 I-Eq-Comparison
1 NCT03860792 111 112 I-Eq-Comparison

- NCT03860792 116 117 O
Agreed NCT03860792 119 125 O
cooperation NCT03860792 126 137 O
from NCT03860792 138 142 O
an NCT03860792 143 145 O
appropriate NCT03860792 146 157 O
study NCT03860792 158 163 O
partner NCT03860792 164 171 O

- NCT03860792 174 175 O
Speaks NCT03860792 177 183 O
English NCT03860792 184 191 O
as NCT03860792 192 194 O
primary NCT03860792 195 202 O
language NCT03860792 203 211 O

- NCT03860792 214 215 O
Age NCT03860792 217 220 B-Age
50 NCT03860792 221 223 B-Eq-Comparison
to NCT03860792 224 226 I-Eq-Comparison
90 NCT03860792 227 229 I-Eq-Comparison

- NCT03860792 233 234 O
No NCT03860792 236 238 B-Negation
medication NCT03860792 239 249 B-Drug
changes NCT03860792 250 257 O
within NCT03860792 258 264 B-Eq-Comparison
the NCT03860792 265 268 I-Eq-Comparison
past NCT03860792 269 273 I-Eq-Comparison
30 NCT03860792 274 276 I-Eq-Comparison
days NCT03860792 277 281 I-Eq-Comparison

Exclusion NCT03860792 282 291 O
Criteria NCT03860792 292 300 O
: NCT03860792 301 302 O

- NCT03860792 306 307 O
Resides NCT03860792 309 316 O
in NCT03860792 317 319 O
a NCT03860792 320 321 O
nursing NCT03860792 322 329 O
home NCT03860792 330 334 O
or NCT03860792 335 337 B-Or
dementia NCT03860792 338 346 O
special NCT03860792 347 354 O
care NCT03860792 355 359 O
unit NCT03860792 360 364 O
, NCT03860792 365 366 O
or NCT03860792 367 369 B-Or
can NCT03860792 370 373 B-Negation
not NCT03860792 373 376 I-Negation
control NCT03860792 377 384 O
diet NCT03860792 385 389 B-Procedure

- NCT03860792 392 393 O
A NCT03860792 395 396 O
potentially NCT03860792 397 408 B-Assertion___Assertion-Type-Value:hypothetical
confounding NCT03860792 409 420 O
serious NCT03860792 421 428 O
medical NCT03860792 429 436 O
risk NCT03860792 437 441 B-Risk
including NCT03860792 442 451 O
insulin NCT03860792 452 459 B-Drug
- NCT03860792 460 461 O
requiring NCT03860792 462 471 B-Assertion___Assertion-Type-Value:hypothetical
diabetes NCT03860792 472 480 B-Condition
, NCT03860792 481 482 O
cancer NCT03860792 483 489 B-Condition
requiring NCT03860792 490 499 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03860792 500 512 B-Procedure
or NCT03860792 513 515 B-Or
radiation NCT03860792 516 525 B-Procedure
within NCT03860792 526 532 B-Eq-Comparison
the NCT03860792 533 536 I-Eq-Comparison
past NCT03860792 537 541 I-Eq-Comparison
5 NCT03860792 542 543 I-Eq-Comparison
years NCT03860792 544 549 I-Eq-Comparison
, NCT03860792 550 551 O
or NCT03860792 552 554 B-Or
a NCT03860792 555 556 O
recent NCT03860792 557 563 B-Eq-Comparison
cardiac NCT03860792 564 571 B-Condition
event NCT03860792 572 577 I-Condition
( NCT03860792 578 579 O
i. NCT03860792 580 582 O
e. NCT03860792 583 585 O
heart NCT03860792 587 592 B-Condition
attack NCT03860792 593 599 I-Condition
, NCT03860792 600 601 O
angioplasty NCT03860792 602 613 B-Procedure
, NCT03860792 614 615 O
etc NCT03860792 616 619 O
. NCT03860792 619 620 O
) NCT03860792 621 622 O

- NCT03860792 626 627 O
Participating NCT03860792 629 642 B-Eq-Comparison
in NCT03860792 643 645 O
another NCT03860792 646 653 B-Other
clinical NCT03860792 654 662 B-Study
trial NCT03860792 663 668 I-Study
or NCT03860792 669 671 B-Or
using NCT03860792 672 677 B-Eq-Comparison
an NCT03860792 678 680 O
investigational NCT03860792 681 696 B-Study
drug NCT03860792 697 701 B-Drug
or NCT03860792 702 704 B-Or
therapy NCT03860792 705 712 B-Procedure
within NCT03860792 713 719 B-Eq-Comparison
30 NCT03860792 720 722 I-Eq-Comparison
days NCT03860792 723 727 I-Eq-Comparison
of NCT03860792 728 730 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03860792 731 734 O
Screening NCT03860792 735 744 B-Study
Visit NCT03860792 745 750 O

- NCT03860792 753 754 O
A NCT03860792 756 757 O
history NCT03860792 758 765 B-Eq-Comparison
of NCT03860792 766 768 O
renal NCT03860792 769 774 B-Condition
stones NCT03860792 775 781 I-Condition

Inclusion NCT03860779 0 9 O
Criteria NCT03860779 10 18 O
: NCT03860779 19 20 O

- NCT03860779 24 25 O
Age NCT03860779 27 30 B-Age
above NCT03860779 31 36 B-Eq-Comparison
18 NCT03860779 37 39 I-Eq-Comparison

- NCT03860779 43 44 O
ASA NCT03860779 46 49 B-Condition
classification NCT03860779 50 64 O
I NCT03860779 65 66 B-Eq-Comparison
to NCT03860779 67 69 I-Eq-Comparison
II NCT03860779 70 72 I-Eq-Comparison

- NCT03860779 75 76 O
Indication NCT03860779 78 88 B-Indication
for NCT03860779 89 92 O
colonoscopy NCT03860779 93 104 B-Procedure
with NCT03860779 105 109 O
propofol NCT03860779 110 118 B-Drug
sedation NCT03860779 119 127 B-Procedure

- NCT03860779 130 131 O
Written NCT03860779 133 140 O
informed NCT03860779 141 149 O
consent NCT03860779 150 157 O

Exclusion NCT03860779 158 167 O
Criteria NCT03860779 168 176 O
: NCT03860779 177 178 O

- NCT03860779 182 183 O
Pregnancy NCT03860779 185 194 B-Condition

Inclusion NCT03869749 0 9 O
Criteria NCT03869749 10 18 O
: NCT03869749 19 20 O

- NCT03869749 24 25 O
two NCT03869749 27 30 B-Eq-Comparison
parents NCT03869749 31 38 B-Family-Member___Family-Member-Type:parent
in NCT03869749 39 41 O
the NCT03869749 42 45 O
home NCT03869749 46 50 O

- NCT03869749 53 54 O
an NCT03869749 56 58 O
adolescent NCT03869749 59 69 O
who NCT03869749 70 73 B-And
is NCT03869749 74 76 O
between NCT03869749 77 84 B-Eq-Comparison
14 NCT03869749 85 87 I-Eq-Comparison
and NCT03869749 88 91 I-Eq-Comparison
18 NCT03869749 92 94 I-Eq-Comparison
years NCT03869749 95 100 I-Eq-Comparison
of NCT03869749 101 103 O
age NCT03869749 104 107 B-Age

- NCT03869749 110 111 O
marital NCT03869749 113 120 B-Observation
distress NCT03869749 121 129 I-Observation

- NCT03869749 132 133 O
youth NCT03869749 135 140 O
reports NCT03869749 141 148 O
of NCT03869749 149 151 O
stress NCT03869749 152 158 B-Condition
or NCT03869749 159 161 B-Or
anxiety NCT03869749 162 169 B-Condition

Exclusion NCT03869749 170 179 O
Criteria NCT03869749 180 188 O
: NCT03869749 189 190 O

- NCT03869749 194 195 O
two NCT03869749 197 200 B-Eq-Comparison
parents NCT03869749 201 208 B-Family-Member___Family-Member-Type:parent
in NCT03869749 209 211 O
the NCT03869749 212 215 O
home NCT03869749 216 220 O
, NCT03869749 221 222 O
but NCT03869749 223 226 B-And
they NCT03869749 227 231 O
are NCT03869749 232 235 O
pursuing NCT03869749 236 244 B-Assertion___Assertion-Type-Value:intention
legal NCT03869749 245 250 B-Observation
divorce NCT03869749 251 258 I-Observation
or NCT03869749 259 261 B-Or
separation NCT03869749 262 272 B-Observation

- NCT03869749 275 276 O
parents NCT03869749 278 285 B-Family-Member___Family-Member-Type:parent
are NCT03869749 286 289 O
not NCT03869749 290 293 B-Negation
willing NCT03869749 294 301 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03869749 302 304 I-Assertion___Assertion-Type-Value:hypothetical
receive NCT03869749 305 312 O
marital NCT03869749 313 320 B-Modifier
education NCT03869749 321 330 B-Procedure
/ NCT03869749 331 332 B-Or
support NCT03869749 333 340 B-Procedure

- NCT03869749 343 344 O
adolescents NCT03869749 346 357 O
are NCT03869749 358 361 O
clinically NCT03869749 362 372 O
depressed NCT03869749 373 382 B-Condition
or NCT03869749 383 385 B-Or
report NCT03869749 386 392 O
suicidal NCT03869749 393 401 B-Condition
ideation NCT03869749 402 410 I-Condition
at NCT03869749 411 413 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03869749 414 422 B-Study

Inclusion NCT03865173 0 9 O
Criteria NCT03865173 10 18 O
: NCT03865173 19 20 O

- NCT03865173 24 25 O
Patient NCT03865173 27 34 O
being NCT03865173 35 40 O
over NCT03865173 41 45 B-Eq-Comparison
18 NCT03865173 46 48 I-Eq-Comparison
years NCT03865173 49 54 I-Eq-Comparison
of NCT03865173 55 57 O
age NCT03865173 58 61 B-Age
living NCT03865173 62 68 O
in NCT03865173 69 71 O
metropolitan NCT03865173 72 84 O
France NCT03865173 85 91 O
; NCT03865173 91 92 O

- NCT03865173 95 96 O
Patient NCT03865173 98 105 O
with NCT03865173 106 110 O
recent NCT03865173 111 117 B-Eq-Comparison
stroke NCT03865173 118 124 B-Condition
( NCT03865173 125 126 O
not NCT03865173 127 130 B-Negation
before NCT03865173 131 137 B-Eq-Comparison
2019 NCT03865173 138 142 I-Eq-Comparison
) NCT03865173 143 144 O
whose NCT03865173 145 150 O
diagnosis NCT03865173 151 160 O
confirmed NCT03865173 161 170 O
by NCT03865173 171 173 O
a NCT03865173 174 175 O
neuro NCT03865173 176 181 B-Provider
- NCT03865173 182 183 I-Provider
vascular NCT03865173 184 192 I-Provider
physician NCT03865173 193 202 I-Provider
; NCT03865173 202 203 O

- NCT03865173 206 207 O
Patient NCT03865173 209 216 O
managed NCT03865173 217 224 B-Procedure
for NCT03865173 225 228 O
stroke NCT03865173 229 235 B-Condition
in NCT03865173 236 238 O
one NCT03865173 239 242 O
of NCT03865173 243 245 O
the NCT03865173 246 249 O
13 NCT03865173 250 252 O
participating NCT03865173 253 266 O
hospitals NCT03865173 267 276 O
of NCT03865173 277 279 O
the NCT03865173 280 283 O
Aquitaine NCT03865173 284 293 O
region NCT03865173 294 300 O
; NCT03865173 300 301 O

- NCT03865173 304 305 O
Patient NCT03865173 307 314 O
giving NCT03865173 315 321 O
consent NCT03865173 322 329 O
to NCT03865173 330 332 O
participate NCT03865173 333 344 O
to NCT03865173 345 347 O
PAPASéPA NCT03865173 348 356 O
; NCT03865173 356 357 O

- NCT03865173 360 361 O
Patient NCT03865173 363 370 O
to NCT03865173 371 373 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03865173 374 376 I-Assertion___Assertion-Type-Value:hypothetical
alive NCT03865173 377 382 B-Observation
at NCT03865173 383 385 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865173 386 389 I-Temporal-Connection___Temporal-Connection-Type-Value:during
end NCT03865173 390 393 B-Eq-Comparison
of NCT03865173 394 396 O
the NCT03865173 397 400 O
acute NCT03865173 401 406 B-Modifier
management NCT03865173 407 417 I-Modifier
hospital NCT03865173 418 426 B-Encounter
stay NCT03865173 427 431 I-Encounter

Exclusion NCT03865173 432 441 O
Criteria NCT03865173 442 450 O
: NCT03865173 451 452 O

- NCT03865173 456 457 O
Patient NCT03865173 459 466 O
refuse NCT03865173 467 473 O
to NCT03865173 474 476 O
participate NCT03865173 477 488 O
to NCT03865173 489 491 O
PAPASéPA NCT03865173 492 500 O

- NCT03865173 503 504 O
Patient NCT03865173 506 513 O
died NCT03865173 514 518 B-Death
during NCT03865173 519 525 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865173 526 529 O
initial NCT03865173 530 537 B-Eq-Comparison
stay NCT03865173 538 542 B-Encounter

Inclusion NCT03868319 0 9 O
Criteria NCT03868319 10 18 O
: NCT03868319 19 20 O

- NCT03868319 24 25 O
scheduled NCT03868319 27 36 B-Eq-Comparison
for NCT03868319 37 40 O
elective NCT03868319 41 49 B-Modifier
RARC NCT03868319 50 54 B-Procedure

Exclusion NCT03868319 55 64 O
Criteria NCT03868319 65 73 O
: NCT03868319 74 75 O

- NCT03868319 79 80 O
history NCT03868319 82 89 B-Eq-Comparison
of NCT03868319 90 92 O
lung NCT03868319 93 97 B-Modifier
surgery NCT03868319 98 105 B-Procedure

- NCT03868319 108 109 O
patients NCT03868319 111 119 O
' NCT03868319 119 120 O
refusal NCT03868319 121 128 O
or NCT03868319 129 131 O
inability NCT03868319 132 141 O
to NCT03868319 142 144 O
give NCT03868319 145 149 O
informed NCT03868319 150 158 O
consent NCT03868319 159 166 O

Inclusion NCT03867994 0 9 O
Criteria NCT03867994 10 18 O
: NCT03867994 19 20 O

- NCT03867994 24 25 O
Patients NCT03867994 27 35 O
aged NCT03867994 36 40 B-Age
between NCT03867994 41 48 B-Eq-Comparison
18 NCT03867994 49 51 I-Eq-Comparison
and NCT03867994 52 55 I-Eq-Comparison
70 NCT03867994 56 58 I-Eq-Comparison
years NCT03867994 59 64 I-Eq-Comparison
. NCT03867994 65 66 O

- NCT03867994 70 71 O
Serum NCT03867994 73 78 B-Observation
creatinine NCT03867994 79 89 I-Observation
≤ NCT03867994 90 91 B-Eq-Comparison
1.5 NCT03867994 92 95 I-Eq-Comparison
mg NCT03867994 96 98 I-Eq-Comparison
/ NCT03867994 99 100 I-Eq-Comparison
dL NCT03867994 101 103 I-Eq-Comparison
. NCT03867994 104 105 O

- NCT03867994 109 110 O
Using NCT03867994 112 117 B-Eq-Comparison
a NCT03867994 118 119 O
moderate NCT03867994 120 128 B-Eq-Comparison
dose NCT03867994 129 133 O
of NCT03867994 134 136 O
atorvastatin NCT03867994 137 149 B-Drug
( NCT03867994 150 151 O
40 NCT03867994 152 154 B-Eq-Comparison
mg NCT03867994 155 157 I-Eq-Comparison
or NCT03867994 158 160 B-Or
equivalent NCT03867994 161 171 O
dose NCT03867994 172 176 O
of NCT03867994 177 179 O
other NCT03867994 180 185 B-Other
statins NCT03867994 186 193 B-Drug
) NCT03867994 194 195 O
. NCT03867994 197 198 O

- NCT03867994 202 203 O
Moderate NCT03867994 205 213 B-Eq-Comparison
to NCT03867994 214 216 I-Eq-Comparison
high NCT03867994 217 221 I-Eq-Comparison
- NCT03867994 222 223 O
risk NCT03867994 224 228 B-Risk
for NCT03867994 229 232 O
CIN NCT03867994 233 236 B-Condition
. NCT03867994 237 238 O

Exclusion NCT03867994 240 249 O
Criteria NCT03867994 250 258 O
: NCT03867994 259 260 O

- NCT03867994 264 265 O
Patients NCT03867994 267 275 O
suffering NCT03867994 276 285 B-Eq-Comparison
from NCT03867994 286 290 O
ST NCT03867994 291 293 B-Modifier
- NCT03867994 294 295 I-Modifier
segment NCT03867994 296 303 I-Modifier
elevation NCT03867994 304 313 I-Modifier
myocardial NCT03867994 314 324 B-Condition
infarction NCT03867994 325 335 I-Condition
( NCT03867994 336 337 O
STEMI NCT03867994 338 343 B-Condition
) NCT03867994 344 345 O

- NCT03867994 349 350 O
Patients NCT03867994 352 360 O
need NCT03867994 361 365 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03867994 366 369 I-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03867994 370 379 O
cardiac NCT03867994 380 387 B-Procedure
catheterization NCT03867994 388 403 I-Procedure

- NCT03867994 406 407 O
Elevated NCT03867994 409 417 O
liver NCT03867994 418 423 B-Condition
enzymes NCT03867994 424 431 I-Condition
( NCT03867994 432 433 O
Aspartate NCT03867994 434 443 B-Observation
aminotransferase NCT03867994 444 460 I-Observation
( NCT03867994 461 462 O
AST NCT03867994 463 466 B-Observation
) NCT03867994 467 468 O
and NCT03867994 469 472 B-Or
Alanine NCT03867994 473 480 B-Observation
aminotransferase NCT03867994 481 497 I-Observation
( NCT03867994 498 499 O
ALT NCT03867994 500 503 B-Observation
) NCT03867994 504 505 O
three NCT03867994 506 511 B-Eq-Comparison
times NCT03867994 512 517 I-Eq-Comparison
the NCT03867994 518 521 I-Eq-Comparison
upper NCT03867994 522 527 I-Eq-Comparison
limit NCT03867994 528 533 I-Eq-Comparison
of NCT03867994 534 536 I-Eq-Comparison
normal NCT03867994 537 543 I-Eq-Comparison
) NCT03867994 544 545 O
. NCT03867994 547 548 O

- NCT03867994 552 553 O
Active NCT03867994 555 561 B-Eq-Comparison
infection NCT03867994 562 571 B-Condition
. NCT03867994 572 573 O

- NCT03867994 577 578 O
Any NCT03867994 580 583 O
contraindication NCT03867994 584 600 B-Contraindication
to NCT03867994 601 603 O
carvedilol NCT03867994 604 614 B-Drug
, NCT03867994 615 616 O
or NCT03867994 617 619 B-Or
atorvastatin NCT03867994 620 632 B-Drug
. NCT03867994 633 634 O

- NCT03867994 638 639 O
Patients NCT03867994 641 649 O
on NCT03867994 650 652 B-Eq-Comparison
regular NCT03867994 653 660 O
use NCT03867994 661 664 O
of NCT03867994 665 667 O
vitamins NCT03867994 668 676 B-Drug
, NCT03867994 677 678 O
minerals NCT03867994 679 687 B-Drug
. NCT03867994 688 689 O

- NCT03867994 693 694 O
Using NCT03867994 696 701 B-Eq-Comparison
medication NCT03867994 702 712 B-Drug
with NCT03867994 713 717 O
antioxidant NCT03867994 718 729 B-Modifier
properties NCT03867994 730 740 I-Modifier
e. NCT03867994 741 743 O
g. NCT03867994 744 746 O
, NCT03867994 747 748 O
beta NCT03867994 749 753 B-Drug
- NCT03867994 754 755 I-Drug
carotene NCT03867994 756 764 I-Drug
, NCT03867994 765 766 O
vitamin NCT03867994 767 774 B-Drug
E NCT03867994 775 776 I-Drug
, NCT03867994 777 778 O
vitamin NCT03867994 779 786 B-Drug
C NCT03867994 787 788 I-Drug
, NCT03867994 789 790 O
selenium NCT03867994 791 799 B-Drug
, NCT03867994 800 801 O
theophylline NCT03867994 802 814 B-Drug
or NCT03867994 815 817 B-Or
N NCT03867994 818 819 B-Drug
- NCT03867994 820 821 I-Drug
acetyl NCT03867994 822 828 I-Drug
cysteine NCT03867994 829 837 I-Drug
7 NCT03867994 838 839 B-Eq-Comparison
days NCT03867994 840 844 I-Eq-Comparison
prior NCT03867994 845 850 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867994 851 853 I-Temporal-Connection___Temporal-Connection-Type-Value:before
CC NCT03867994 854 856 B-Procedure
. NCT03867994 857 858 O

- NCT03867994 862 863 O
Hemodynamically NCT03867994 865 880 B-Condition
unstable NCT03867994 881 889 O
patients NCT03867994 890 898 O
( NCT03867994 899 900 O
defined NCT03867994 901 908 O
as NCT03867994 909 911 O
abnormal NCT03867994 912 920 O
or NCT03867994 921 923 B-Or
unstable NCT03867994 924 932 O
blood NCT03867994 933 938 B-Observation
pressure NCT03867994 939 947 I-Observation
, NCT03867994 948 949 O
especially NCT03867994 950 960 O
hypotension NCT03867994 961 972 B-Condition
( NCT03867994 973 974 O
blood NCT03867994 975 980 B-Observation
pressure NCT03867994 981 989 I-Observation
less NCT03867994 990 994 B-Eq-Comparison
than NCT03867994 995 999 I-Eq-Comparison
90 NCT03867994 1000 1002 I-Eq-Comparison
/ NCT03867994 1003 1004 I-Eq-Comparison
60 NCT03867994 1005 1007 I-Eq-Comparison
mm NCT03867994 1008 1010 I-Eq-Comparison
Hg NCT03867994 1011 1013 I-Eq-Comparison
) NCT03867994 1014 1015 O
. NCT03867994 1017 1018 O

- NCT03867994 1022 1023 O
Patients NCT03867994 1025 1033 O
who NCT03867994 1034 1037 O
required NCT03867994 1038 1046 B-Assertion___Assertion-Type-Value:hypothetical
dialysis NCT03867994 1047 1055 B-Procedure
. NCT03867994 1056 1057 O

- NCT03867994 1061 1062 O
Pregnancy NCT03867994 1064 1073 B-Condition
. NCT03867994 1074 1075 O

- NCT03867994 1079 1080 O
Using NCT03867994 1082 1087 O
of NCT03867994 1088 1090 O
carvedilol NCT03867994 1091 1101 B-Drug
in NCT03867994 1102 1104 O
the NCT03867994 1105 1108 O
past NCT03867994 1109 1113 B-Eq-Comparison
three NCT03867994 1114 1119 I-Eq-Comparison
months NCT03867994 1120 1126 I-Eq-Comparison
. NCT03867994 1127 1128 O

- NCT03867994 1132 1133 O
Using NCT03867994 1135 1140 O
a NCT03867994 1141 1142 O
nephrotoxic NCT03867994 1143 1154 B-Drug
agent NCT03867994 1155 1160 I-Drug
in NCT03867994 1161 1163 O
the NCT03867994 1164 1167 O
past NCT03867994 1168 1172 B-Eq-Comparison
48 NCT03867994 1173 1175 I-Eq-Comparison
hours NCT03867994 1176 1181 I-Eq-Comparison
or NCT03867994 1182 1184 B-Or
exposure NCT03867994 1185 1193 O
to NCT03867994 1194 1196 O
a NCT03867994 1197 1198 O
contrast NCT03867994 1199 1207 B-Procedure
agent NCT03867994 1208 1213 I-Procedure
in NCT03867994 1214 1216 O
the NCT03867994 1217 1220 O
past NCT03867994 1221 1225 B-Eq-Comparison
7 NCT03867994 1226 1227 I-Eq-Comparison
days NCT03867994 1228 1232 I-Eq-Comparison
prior NCT03867994 1233 1238 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867994 1239 1241 I-Temporal-Connection___Temporal-Connection-Type-Value:before
cardiac NCT03867994 1242 1249 B-Procedure
catheterization NCT03867994 1250 1265 I-Procedure
. NCT03867994 1265 1266 O

Inclusion NCT03869775 0 9 O
Criteria NCT03869775 10 18 O
: NCT03869775 19 20 O

- NCT03869775 24 25 O
the NCT03869775 27 30 O
patient NCT03869775 31 38 O
will NCT03869775 39 43 B-Eq-Comparison
be NCT03869775 44 46 I-Eq-Comparison
operated NCT03869775 47 55 B-Procedure
with NCT03869775 56 60 O
spinal NCT03869775 61 67 B-Procedure
anesthesia NCT03869775 68 78 I-Procedure

- NCT03869775 81 82 O
over NCT03869775 84 88 B-Eq-Comparison
18 NCT03869775 89 91 I-Eq-Comparison
years NCT03869775 92 97 I-Age|Eq-Comparison

- NCT03869775 100 101 O
no NCT03869775 103 105 B-Negation
additional NCT03869775 106 116 O
disease NCT03869775 117 124 B-Condition
and NCT03869775 125 128 O
only NCT03869775 129 133 B-Exception
DM NCT03869775 134 136 B-Condition

Exclusion NCT03869775 137 146 O
Criteria NCT03869775 147 155 O
: NCT03869775 156 157 O

- NCT03869775 161 162 O
patients NCT03869775 164 172 O
with NCT03869775 173 177 O
additional NCT03869775 178 188 O
disease NCT03869775 189 196 B-Condition

- NCT03869775 199 200 O
patients NCT03869775 202 210 O
under NCT03869775 211 216 B-Eq-Comparison
18 NCT03869775 217 219 I-Eq-Comparison
years NCT03869775 220 225 I-Eq-Comparison
of NCT03869775 226 228 O
age NCT03869775 229 232 B-Age

- NCT03869775 235 236 O
patients NCT03869775 238 246 O
contraindicated NCT03869775 247 262 B-Contraindication
in NCT03869775 263 265 O
spinal NCT03869775 266 272 B-Procedure
anesthesia NCT03869775 273 283 I-Procedure

Inclusion NCT03866863 0 9 O
Criteria NCT03866863 10 18 O
: NCT03866863 19 20 O

- NCT03866863 24 25 O
All NCT03866863 27 30 O
birth NCT03866863 31 36 B-Birth
more NCT03866863 37 41 B-Eq-Comparison
than NCT03866863 42 46 I-Eq-Comparison
24 NCT03866863 47 49 I-Eq-Comparison
+ NCT03866863 50 51 I-Eq-Comparison
0 NCT03866863 52 53 I-Eq-Comparison
weeks NCT03866863 54 59 I-Eq-Comparison
of NCT03866863 60 62 B-Temporal-Connection___Temporal-Connection-Type-Value:after
amenorrhea NCT03866863 63 73 B-Condition
at NCT03866863 74 76 O
the NCT03866863 77 80 O
maternity NCT03866863 81 90 O
ward NCT03866863 91 95 O
of NCT03866863 96 98 O
the NCT03866863 99 102 O
hospital NCT03866863 103 111 O
Femme NCT03866863 112 117 O
- NCT03866863 118 119 O
Mère NCT03866863 120 124 O
- NCT03866863 125 126 O
Enfant NCT03866863 127 133 O

- NCT03866863 136 137 O
from NCT03866863 139 143 O
1 NCT03866863 144 145 B-Eq-Comparison
st NCT03866863 146 148 I-Eq-Comparison
of NCT03866863 149 151 I-Eq-Comparison
january NCT03866863 152 159 I-Eq-Comparison
2011 NCT03866863 160 164 I-Eq-Comparison
to NCT03866863 165 167 I-Eq-Comparison
31 NCT03866863 168 170 I-Eq-Comparison
december NCT03866863 171 179 I-Eq-Comparison
2017 NCT03866863 180 184 I-Eq-Comparison
. NCT03866863 184 185 O

Exclusion NCT03866863 187 196 O
Criteria NCT03866863 197 205 O
: NCT03866863 206 207 O

- NCT03866863 211 212 O
Infants NCT03866863 214 221 O
born NCT03866863 222 226 B-Birth
out NCT03866863 227 230 B-Negation
of NCT03866863 231 233 I-Negation
the NCT03866863 234 237 O
hospital NCT03866863 238 246 O
and NCT03866863 247 250 B-And
secondarily NCT03866863 251 262 B-Encounter
hospitalized NCT03866863 263 275 I-Encounter
in NCT03866863 276 278 O
the NCT03866863 279 282 O
hospital NCT03866863 283 291 O
Femme NCT03866863 292 297 O
- NCT03866863 298 299 O
Mère NCT03866863 300 304 O
- NCT03866863 305 306 O
Enfant NCT03866863 307 313 O
. NCT03866863 315 316 O

- NCT03866863 320 321 O
Multiple NCT03866863 323 331 B-Eq-Comparison
pregnancies NCT03866863 332 343 B-Condition
, NCT03866863 344 345 O

- NCT03866863 349 350 O
children NCT03866863 352 360 O
with NCT03866863 361 365 B-And
congenital NCT03866863 366 376 B-Condition
fetal NCT03866863 377 382 I-Condition
anomalies NCT03866863 383 392 I-Condition

- NCT03866863 395 396 O
pregnancies NCT03866863 398 409 B-Condition
without NCT03866863 410 417 B-Negation
first NCT03866863 418 423 B-Modifier
trimester NCT03866863 424 433 I-Modifier
ultrasound NCT03866863 434 444 B-Procedure
( NCT03866863 445 446 O
to NCT03866863 447 449 O
date NCT03866863 450 454 O
the NCT03866863 455 458 O
pregnancy NCT03866863 459 468 B-Condition
) NCT03866863 469 470 O

Inclusion NCT03868696 0 9 O
Criteria NCT03868696 10 18 O
: NCT03868696 19 20 O

- NCT03868696 24 25 O
Adults NCT03868696 27 33 O
with NCT03868696 34 38 B-And
Colles NCT03868696 39 45 B-Modifier
' NCT03868696 45 46 I-Modifier
type NCT03868696 47 51 I-Modifier
fractures NCT03868696 52 61 B-Condition
of NCT03868696 62 64 O
the NCT03868696 65 68 O
distal NCT03868696 69 75 B-Modifier
radius NCT03868696 76 82 I-Modifier
undergoing NCT03868696 83 93 B-Eq-Comparison
fracture NCT03868696 94 102 B-Procedure
manipulation NCT03868696 103 115 I-Procedure
in NCT03868696 116 118 O
the NCT03868696 119 122 O
ED NCT03868696 123 125 O

- NCT03868696 128 129 O
UDiReCT NCT03868696 131 138 O
Trial NCT03868696 139 144 O
trained NCT03868696 145 152 O
staff NCT03868696 153 158 O
available NCT03868696 159 168 O

Exclusion NCT03868696 169 178 O
Criteria NCT03868696 179 187 O
: NCT03868696 188 189 O

- NCT03868696 193 194 O
Age NCT03868696 196 199 B-Age
under NCT03868696 200 205 B-Eq-Comparison
18 NCT03868696 206 208 I-Eq-Comparison

- NCT03868696 212 213 O
Volar NCT03868696 215 220 B-Modifier
displaced NCT03868696 221 230 I-Modifier
( NCT03868696 231 232 O
Smith NCT03868696 233 238 B-Modifier
's NCT03868696 238 240 I-Modifier
) NCT03868696 241 242 O
type NCT03868696 243 247 O
fractures NCT03868696 248 257 B-Condition
( NCT03868696 258 259 O
well NCT03868696 260 264 O
established NCT03868696 265 276 O
as NCT03868696 277 279 O
being NCT03868696 280 285 O
unstable NCT03868696 286 294 O
and NCT03868696 295 298 B-And
requiring NCT03868696 299 308 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03868696 309 317 B-Procedure
treatment NCT03868696 318 327 I-Procedure
) NCT03868696 328 329 O

- NCT03868696 333 334 O
Unable NCT03868696 336 342 O
or NCT03868696 343 345 O
unwilling NCT03868696 346 355 O
to NCT03868696 356 358 O
give NCT03868696 359 363 O
informed NCT03868696 364 372 O
consent NCT03868696 373 380 O

- NCT03868696 383 384 O
Unable NCT03868696 386 392 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03868696 393 395 I-Assertion___Assertion-Type-Value:hypothetical|Negation
unwilling NCT03868696 396 405 I-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03868696 406 408 O
be NCT03868696 409 411 O
followed NCT03868696 412 420 B-Encounter
up NCT03868696 421 423 I-Encounter
( NCT03868696 424 425 O
e. NCT03868696 426 428 O
g. NCT03868696 429 431 O
orthopaedic NCT03868696 433 444 B-Provider
follow NCT03868696 445 451 B-Encounter
up NCT03868696 452 454 I-Encounter
in NCT03868696 455 457 O
another NCT03868696 458 465 B-Other
region NCT03868696 466 472 O
) NCT03868696 473 474 O

- NCT03868696 478 479 O
Major NCT03868696 481 486 O
trauma NCT03868696 487 493 B-Condition
with NCT03868696 494 498 B-And
other NCT03868696 499 504 B-Other
injuries NCT03868696 505 513 B-Condition
and NCT03868696 514 517 B-And
ISS NCT03868696 518 521 B-Observation
( NCT03868696 522 523 O
Injury NCT03868696 524 530 B-Observation
Severity NCT03868696 531 539 I-Observation
Score NCT03868696 540 545 I-Observation
) NCT03868696 546 547 O
> NCT03868696 548 549 B-Eq-Comparison
16 NCT03868696 550 552 I-Eq-Comparison

- NCT03868696 556 557 O
Urgent NCT03868696 559 565 B-Modifier
manipulation NCT03868696 566 578 B-Procedure
required NCT03868696 579 587 B-Assertion___Assertion-Type-Value:hypothetical
due NCT03868696 588 591 O
to NCT03868696 592 594 O
neurovascular NCT03868696 595 608 B-Modifier
or NCT03868696 609 611 B-Or
skin NCT03868696 612 616 B-Modifier
compromise NCT03868696 617 627 B-Condition

- NCT03868696 630 631 O
Open NCT03868696 633 637 B-Modifier
fractures NCT03868696 638 647 B-Condition
or NCT03868696 648 650 B-Or
those NCT03868696 651 656 B-Coreference
with NCT03868696 657 661 O
associated NCT03868696 662 672 O
nerve NCT03868696 673 678 B-Modifier
or NCT03868696 679 681 B-Or
tendon NCT03868696 682 688 B-Modifier
involvement NCT03868696 689 700 I-Modifier
( NCT03868696 701 702 O
affect NCT03868696 703 709 O
functional NCT03868696 710 720 O
outcome NCT03868696 721 728 O
) NCT03868696 729 730 O

- NCT03868696 734 735 O
Prisoners NCT03868696 737 746 B-Observation

Inclusion NCT03867214 0 9 O
Criteria NCT03867214 10 18 O
: NCT03867214 19 20 O

- NCT03867214 24 25 O
Adult NCT03867214 27 32 O
patients NCT03867214 33 41 O
who NCT03867214 42 45 B-And
plan NCT03867214 46 50 B-Assertion___Assertion-Type-Value:intention
to NCT03867214 51 53 I-Assertion___Assertion-Type-Value:intention
undergo NCT03867214 54 61 O
simultaneous NCT03867214 62 74 B-Modifier
primary NCT03867214 75 82 I-Modifier
total NCT03867214 83 88 B-Procedure
knee NCT03867214 89 93 I-Procedure
arthroplasty NCT03867214 94 106 I-Procedure
on NCT03867214 107 109 O
bilateral NCT03867214 110 119 B-Modifier
knee NCT03867214 120 124 I-Modifier
joint NCT03867214 125 130 I-Modifier
with NCT03867214 131 135 B-And
a NCT03867214 136 137 O
diagnosis NCT03867214 138 147 O
of NCT03867214 148 150 O
osteoarthritis NCT03867214 151 165 B-Condition
or NCT03867214 166 168 B-Or
aseptic NCT03867214 169 176 B-Condition
bone NCT03867214 177 181 I-Condition
necrosis NCT03867214 182 190 I-Condition
, NCT03867214 191 192 O
but NCT03867214 193 196 B-And
not NCT03867214 197 200 B-Negation
of NCT03867214 201 203 O
rheumatoid NCT03867214 204 214 B-Condition
arthritis NCT03867214 215 224 I-Condition
; NCT03867214 224 225 O

- NCT03867214 228 229 O
All NCT03867214 231 234 O
patients NCT03867214 235 243 O
who NCT03867214 244 247 O
have NCT03867214 248 252 O
normal NCT03867214 253 259 O
pre NCT03867214 260 263 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03867214 264 273 B-Procedure
platelet NCT03867214 274 282 B-Observation
count NCT03867214 283 288 I-Observation
, NCT03867214 289 290 O
normal NCT03867214 291 297 O
prothrombin NCT03867214 298 309 B-Observation
time NCT03867214 310 314 I-Observation
, NCT03867214 315 316 O
normal NCT03867214 317 323 O
partial NCT03867214 324 331 B-Observation
thromboplastin NCT03867214 332 346 I-Observation
time NCT03867214 347 351 I-Observation
, NCT03867214 352 353 O
and NCT03867214 354 357 B-And
normal NCT03867214 358 364 O
international NCT03867214 365 378 B-Observation
normalized NCT03867214 379 389 I-Observation
ratio NCT03867214 390 395 I-Observation
; NCT03867214 395 396 O

- NCT03867214 399 400 O
The NCT03867214 402 405 O
use NCT03867214 406 409 O
of NCT03867214 410 412 O
only NCT03867214 413 417 O
balanced NCT03867214 418 426 B-Drug
electrolyte NCT03867214 427 438 I-Drug
solutions NCT03867214 439 448 I-Drug
and NCT03867214 449 452 B-Or
/ NCT03867214 453 454 I-Or
or NCT03867214 455 457 I-Or
albumin NCT03867214 458 465 B-Observation
for NCT03867214 466 469 O
plasma NCT03867214 470 476 B-Procedure
volume NCT03867214 477 483 I-Procedure
restitution NCT03867214 484 495 I-Procedure
. NCT03867214 496 497 O

Exclusion NCT03867214 499 508 O
Criteria NCT03867214 509 517 O
: NCT03867214 518 519 O

- NCT03867214 523 524 O
Allergy NCT03867214 526 533 B-Allergy
to NCT03867214 534 536 O
tranexamic NCT03867214 537 547 B-Drug
acid NCT03867214 548 552 I-Drug
; NCT03867214 552 553 O

- NCT03867214 556 557 O
Receiving NCT03867214 559 568 B-Eq-Comparison
warfarin NCT03867214 569 577 B-Drug
or NCT03867214 578 580 B-Or
heparin NCT03867214 581 588 B-Drug
; NCT03867214 588 589 O
had NCT03867214 590 593 O
a NCT03867214 594 595 O
history NCT03867214 596 603 B-Eq-Comparison
of NCT03867214 604 606 O
hemophilia NCT03867214 607 617 B-Condition
, NCT03867214 618 619 O
deep NCT03867214 620 624 B-Condition
venous NCT03867214 625 631 I-Condition
thrombosis NCT03867214 632 642 I-Condition
, NCT03867214 643 644 O
pulmonary NCT03867214 645 654 B-Condition
embolism NCT03867214 655 663 I-Condition
, NCT03867214 664 665 O
or NCT03867214 666 668 B-Or
renal NCT03867214 669 674 B-Condition
impairment NCT03867214 675 685 I-Condition
; NCT03867214 685 686 O
or NCT03867214 687 689 B-Or
were NCT03867214 690 694 B-Eq-Comparison
pregnant NCT03867214 695 703 B-Condition
; NCT03867214 703 704 O

- NCT03867214 707 708 O
Patients NCT03867214 710 718 O
with NCT03867214 719 723 O
any NCT03867214 724 727 O
cardiovascular NCT03867214 728 742 B-Condition
problems NCT03867214 743 751 I-Condition
( NCT03867214 752 753 O
such NCT03867214 754 758 O
as NCT03867214 759 761 O
myocardiac NCT03867214 762 772 B-Condition
infarction NCT03867214 773 783 I-Condition
history NCT03867214 784 791 B-Eq-Comparison
, NCT03867214 792 793 O
atrial NCT03867214 794 800 B-Condition
fibrillation NCT03867214 801 813 I-Condition
, NCT03867214 814 815 O
angina NCT03867214 816 822 B-Condition
) NCT03867214 823 824 O
; NCT03867214 825 826 O

- NCT03867214 829 830 O
Patients NCT03867214 832 840 O
with NCT03867214 841 845 O
thromboembolic NCT03867214 846 860 B-Condition
disorders NCT03867214 861 870 I-Condition
, NCT03867214 871 872 O
or NCT03867214 873 875 B-Or
those NCT03867214 876 881 O
exhibiting NCT03867214 882 892 O
a NCT03867214 893 894 O
deteriorating NCT03867214 895 908 O
general NCT03867214 909 916 B-Condition
condition NCT03867214 917 926 I-Condition
; NCT03867214 926 927 O

- NCT03867214 930 931 O
Pre NCT03867214 933 936 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03867214 937 946 B-Procedure
anemia NCT03867214 947 953 B-Condition
( NCT03867214 954 955 O
a NCT03867214 956 957 O
hemoglobin NCT03867214 958 968 B-Observation
value NCT03867214 969 974 O
of NCT03867214 975 977 O
< NCT03867214 978 979 B-Eq-Comparison
11 NCT03867214 980 982 I-Eq-Comparison
g NCT03867214 983 984 I-Eq-Comparison
/ NCT03867214 985 986 I-Eq-Comparison
dL NCT03867214 987 989 I-Eq-Comparison
in NCT03867214 990 992 O
females NCT03867214 993 1000 O
and NCT03867214 1001 1004 B-Or
< NCT03867214 1005 1006 B-Eq-Comparison
12 NCT03867214 1007 1009 I-Eq-Comparison
g NCT03867214 1010 1011 I-Eq-Comparison
/ NCT03867214 1012 1013 I-Eq-Comparison
dL NCT03867214 1014 1016 I-Eq-Comparison
in NCT03867214 1017 1019 O
males NCT03867214 1020 1025 O
) NCT03867214 1026 1027 O
, NCT03867214 1029 1030 O
refusal NCT03867214 1031 1038 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03867214 1039 1041 O
blood NCT03867214 1042 1047 B-Procedure
products NCT03867214 1048 1056 I-Procedure
; NCT03867214 1056 1057 O

- NCT03867214 1060 1061 O
Pre NCT03867214 1063 1066 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03867214 1067 1076 B-Procedure
use NCT03867214 1077 1080 O
of NCT03867214 1081 1083 O
anticoagulant NCT03867214 1084 1097 B-Procedure
therapy NCT03867214 1098 1105 I-Procedure
within NCT03867214 1106 1112 B-Eq-Comparison
five NCT03867214 1113 1117 I-Eq-Comparison
days NCT03867214 1118 1122 I-Eq-Comparison
before NCT03867214 1123 1129 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03867214 1130 1137 B-Procedure
, NCT03867214 1138 1139 O
fibrinolytic NCT03867214 1140 1152 B-Condition
disorders NCT03867214 1153 1162 I-Condition
requiring NCT03867214 1163 1172 B-Assertion___Assertion-Type-Value:hypothetical
intraoperative NCT03867214 1173 1187 O
antifibrinolytic NCT03867214 1188 1204 B-Procedure
treatment NCT03867214 1205 1214 I-Procedure
, NCT03867214 1215 1216 O
coagulopathy NCT03867214 1217 1229 B-Condition
( NCT03867214 1230 1231 O
as NCT03867214 1232 1234 O
identified NCT03867214 1235 1245 O
by NCT03867214 1246 1248 O
a NCT03867214 1249 1250 O
pre NCT03867214 1251 1254 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03867214 1255 1264 B-Procedure
platelet NCT03867214 1265 1273 B-Observation
count NCT03867214 1274 1279 I-Observation
of NCT03867214 1280 1282 O
< NCT03867214 1283 1284 B-Eq-Comparison
150 NCT03867214 1285 1288 I-Eq-Comparison
, NCT03867214 1289 1290 I-Eq-Comparison
000 NCT03867214 1291 1294 I-Eq-Comparison
/ NCT03867214 1295 1296 I-Eq-Comparison
mm3 NCT03867214 1297 1300 I-Eq-Comparison
, NCT03867214 1301 1302 O
an NCT03867214 1303 1305 O
international NCT03867214 1306 1319 B-Observation
normalized NCT03867214 1320 1330 I-Observation
ratio NCT03867214 1331 1336 I-Observation
of NCT03867214 1337 1339 O
> NCT03867214 1340 1341 B-Eq-Comparison
1.4 NCT03867214 1342 1345 I-Eq-Comparison
, NCT03867214 1346 1347 O
or NCT03867214 1348 1350 O
a NCT03867214 1351 1352 O
prolonged NCT03867214 1353 1362 O
partial NCT03867214 1363 1370 B-Observation
thromboplastin NCT03867214 1371 1385 I-Observation
time NCT03867214 1386 1390 I-Observation
[ NCT03867214 1391 1392 O
> NCT03867214 1394 1395 B-Eq-Comparison
1.4 NCT03867214 1396 1399 I-Eq-Comparison
times NCT03867214 1400 1405 I-Eq-Comparison
normal NCT03867214 1406 1412 I-Eq-Comparison
] NCT03867214 1413 1414 O
) NCT03867214 1416 1417 O
. NCT03867214 1418 1419 O

Inclusion NCT03862378 0 9 O
Criteria NCT03862378 10 18 O
: NCT03862378 19 20 O

- NCT03862378 24 25 O
Planned NCT03862378 27 34 B-Eq-Comparison
surgery NCT03862378 35 42 B-Procedure
for NCT03862378 43 46 O
gastric NCT03862378 47 54 B-Modifier
or NCT03862378 55 57 B-Or
colorectal NCT03862378 58 68 B-Modifier
cancer NCT03862378 69 75 B-Condition
with NCT03862378 76 80 O
primary NCT03862378 81 88 B-Modifier
anastomosis NCT03862378 89 100 B-Procedure
. NCT03862378 101 102 O

- NCT03862378 106 107 O
Inform NCT03862378 109 115 O
consent NCT03862378 116 123 O
signed NCT03862378 124 130 O
before NCT03862378 131 137 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03862378 138 145 B-Procedure
. NCT03862378 146 147 O

Exclusion NCT03862378 149 158 O
Criteria NCT03862378 159 167 O
: NCT03862378 168 169 O

- NCT03862378 173 174 O
No NCT03862378 176 178 B-Negation
drainage NCT03862378 179 187 B-Procedure
tube NCT03862378 188 192 I-Procedure
placed NCT03862378 193 199 O
. NCT03862378 199 200 O

Inclusion NCT03861117 0 9 O
Criteria NCT03861117 10 18 O
: NCT03861117 19 20 O

- NCT03861117 24 25 O
Patient NCT03861117 27 34 O
18 NCT03861117 35 37 B-Eq-Comparison
years NCT03861117 38 43 I-Eq-Comparison
old NCT03861117 44 47 I-Eq-Comparison
or NCT03861117 48 50 I-Eq-Comparison
more NCT03861117 51 55 I-Eq-Comparison

- NCT03861117 58 59 O
Intubated NCT03861117 61 70 B-Procedure
and NCT03861117 71 74 B-And
ventilated NCT03861117 75 85 B-Procedure
in NCT03861117 86 88 O
intensive NCT03861117 89 98 O
care NCT03861117 99 103 O
unit NCT03861117 104 108 O
for NCT03861117 109 112 O
more NCT03861117 113 117 B-Eq-Comparison
than NCT03861117 118 122 I-Eq-Comparison
24 NCT03861117 123 125 I-Eq-Comparison
hours NCT03861117 126 131 I-Eq-Comparison

- NCT03861117 134 135 O
Patient NCT03861117 137 144 O
ready NCT03861117 145 150 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03861117 151 154 I-Assertion___Assertion-Type-Value:hypothetical
weaning NCT03861117 155 162 B-Procedure
evaluation NCT03861117 163 173 I-Procedure

- NCT03861117 176 177 O
Failure NCT03861117 179 186 O
of NCT03861117 187 189 O
a NCT03861117 190 191 O
first NCT03861117 192 197 B-Eq-Comparison
T NCT03861117 198 199 B-Modifier
- NCT03861117 200 201 I-Modifier
piece NCT03861117 202 207 I-Modifier
SBT NCT03861117 208 211 B-Procedure

Exclusion NCT03861117 212 221 O
Criteria NCT03861117 222 230 O
: NCT03861117 231 232 O

- NCT03861117 236 237 O
Chronic NCT03861117 239 246 B-Modifier
neuromuscular NCT03861117 247 260 B-Condition
disease NCT03861117 261 268 I-Condition

- NCT03861117 271 272 O
Guillain NCT03861117 274 282 B-Condition
- NCT03861117 283 284 I-Condition
Barré NCT03861117 285 290 I-Condition
Syndrome NCT03861117 291 299 I-Condition

- NCT03861117 302 303 O
Central NCT03861117 305 312 B-Condition
nervous NCT03861117 313 320 I-Condition
system NCT03861117 321 327 I-Condition
disease NCT03861117 328 335 I-Condition
with NCT03861117 336 340 B-And
consciousness NCT03861117 341 354 B-Condition
disorder NCT03861117 355 363 I-Condition

- NCT03861117 366 367 O
Tracheostomy NCT03861117 369 381 B-Procedure

- NCT03861117 384 385 O
Chronic NCT03861117 387 394 B-Modifier
disease NCT03861117 395 402 B-Condition
with NCT03861117 403 407 B-And
life NCT03861117 408 412 B-Observation
expectancy NCT03861117 413 423 I-Observation
less NCT03861117 424 428 B-Eq-Comparison
than NCT03861117 429 433 I-Eq-Comparison
1 NCT03861117 434 435 I-Eq-Comparison
year NCT03861117 436 440 I-Eq-Comparison

- NCT03861117 443 444 O
Pregnancy NCT03861117 446 455 B-Condition
, NCT03861117 456 457 O
breast NCT03861117 458 464 B-Condition
feeding NCT03861117 465 472 I-Condition

- NCT03861117 475 476 O
Withholding NCT03861117 478 489 B-Assertion___Assertion-Type-Value:hypothetical
life NCT03861117 490 494 B-Procedure
support NCT03861117 495 502 I-Procedure
regarding NCT03861117 503 512 O
a NCT03861117 513 514 O
reintubation NCT03861117 515 527 B-Procedure

- NCT03861117 530 531 O
Prisoner NCT03861117 533 541 B-Observation
or NCT03861117 542 544 B-Or
patient NCT03861117 545 552 O
interned NCT03861117 553 561 B-Encounter
in NCT03861117 562 564 O
psychiatric NCT03861117 565 576 O
hospital NCT03861117 577 585 O

- NCT03861117 588 589 O
Guardianship NCT03861117 591 603 B-Observation

- NCT03861117 606 607 O
Language NCT03861117 609 617 B-Condition
barrier NCT03861117 618 625 I-Condition

- NCT03861117 628 629 O
Lack NCT03861117 631 635 B-Negation
of NCT03861117 636 638 I-Negation
medical NCT03861117 639 646 O
insurance NCT03861117 647 656 O

- NCT03861117 659 660 O
Lack NCT03861117 662 666 O
of NCT03861117 667 669 O
the NCT03861117 670 673 O
patient NCT03861117 674 681 O
's NCT03861117 681 683 O
consent NCT03861117 684 691 O
( NCT03861117 692 693 O
or NCT03861117 694 696 O
of NCT03861117 697 699 O
the NCT03861117 700 703 O
next NCT03861117 704 708 O
of NCT03861117 709 711 O
kin NCT03861117 712 715 O
where NCT03861117 716 721 O
appropriate NCT03861117 722 733 O
) NCT03861117 734 735 O

- NCT03861117 739 740 O
Patient NCT03861117 742 749 O
under NCT03861117 750 755 O
an NCT03861117 756 758 O
exclusion NCT03861117 759 768 O
period NCT03861117 769 775 O
after NCT03861117 776 781 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03861117 782 792 O
in NCT03861117 793 795 O
another NCT03861117 796 803 B-Other
research NCT03861117 804 812 B-Study
study NCT03861117 813 818 I-Study

Inclusion NCT03866122 0 9 O
Criteria NCT03866122 10 18 O
: NCT03866122 19 20 O

- NCT03866122 24 25 O
The NCT03866122 27 30 O
subject NCT03866122 31 38 O
is NCT03866122 39 41 O
currently NCT03866122 42 51 B-Eq-Comparison
being NCT03866122 52 57 O
treated NCT03866122 58 65 B-Procedure
at NCT03866122 66 68 O
QECH NCT03866122 69 73 O
in NCT03866122 74 76 O
the NCT03866122 77 80 O
neonatal NCT03866122 81 89 B-Modifier
or NCT03866122 90 92 B-Or
KMC NCT03866122 93 96 B-Modifier
ward NCT03866122 97 101 O
. NCT03866122 102 103 O

- NCT03866122 107 108 O
Study NCT03866122 110 115 O
devices NCT03866122 116 123 O
are NCT03866122 124 127 O
available NCT03866122 128 137 O
for NCT03866122 138 141 O
use NCT03866122 142 145 O
. NCT03866122 146 147 O

- NCT03866122 151 152 O
The NCT03866122 154 157 O
subject NCT03866122 158 165 O
's NCT03866122 165 167 O
caregiver NCT03866122 168 177 B-Family-Member___Family-Member-Type:parent
has NCT03866122 178 181 O
provided NCT03866122 182 190 O
informed NCT03866122 191 199 O
consent NCT03866122 200 207 O
for NCT03866122 208 211 O
their NCT03866122 212 217 O
child NCT03866122 218 223 O
to NCT03866122 224 226 O
participate NCT03866122 227 238 O
. NCT03866122 239 240 O

Exclusion NCT03866122 242 251 O
Criteria NCT03866122 252 260 O
: NCT03866122 261 262 O

- NCT03866122 266 267 O
At NCT03866122 269 271 O
the NCT03866122 272 275 O
clinician NCT03866122 276 285 O
's NCT03866122 285 287 O
discretion NCT03866122 288 298 O
for NCT03866122 299 302 O
any NCT03866122 303 306 O
reason NCT03866122 307 313 O
including NCT03866122 314 323 O
, NCT03866122 324 325 O
but NCT03866122 326 329 O
not NCT03866122 330 333 O
limited NCT03866122 334 341 O
to NCT03866122 342 344 O
: NCT03866122 345 346 O

- NCT03866122 350 351 O
potential NCT03866122 353 362 B-Risk
for NCT03866122 363 366 O
skin NCT03866122 367 371 B-Modifier
irritation NCT03866122 372 382 B-Condition

- NCT03866122 385 386 O
Cough NCT03866122 388 393 B-Condition

- NCT03866122 396 397 O
other NCT03866122 399 404 B-Other
condition NCT03866122 405 414 B-Condition
that NCT03866122 415 419 O
may NCT03866122 420 423 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03866122 424 432 B-Negation
use NCT03866122 433 436 O
of NCT03866122 437 439 O
the NCT03866122 440 443 O
temperature NCT03866122 444 455 B-Procedure
belt NCT03866122 456 460 I-Procedure

- NCT03866122 463 464 O
concurrent NCT03866122 466 476 B-Modifier
treatments NCT03866122 477 487 B-Procedure
that NCT03866122 488 492 O
may NCT03866122 493 496 B-Assertion___Assertion-Type-Value:hypothetical
require NCT03866122 497 504 O
increased NCT03866122 505 514 O
patient NCT03866122 515 522 B-Procedure
care NCT03866122 523 527 I-Procedure

Inclusion NCT03866096 0 9 O
Criteria NCT03866096 10 18 O
: NCT03866096 19 20 O

- NCT03866096 24 25 O
Volleyball NCT03866096 27 37 B-Observation
players NCT03866096 38 45 I-Observation

- NCT03866096 48 49 O
Female NCT03866096 51 57 O

- NCT03866096 60 61 O
From NCT03866096 63 67 O
18 NCT03866096 68 70 B-Eq-Comparison
to NCT03866096 71 73 I-Eq-Comparison
25 NCT03866096 74 76 I-Eq-Comparison
years NCT03866096 77 82 I-Age|Eq-Comparison

- NCT03866096 85 86 O
With NCT03866096 88 92 O
more NCT03866096 93 97 B-Eq-Comparison
than NCT03866096 98 102 I-Eq-Comparison
one NCT03866096 103 106 I-Eq-Comparison
year NCT03866096 107 111 I-Eq-Comparison
of NCT03866096 112 114 O
sports NCT03866096 115 121 B-Observation
practice NCT03866096 122 130 I-Observation

- NCT03866096 133 134 O
Currently NCT03866096 136 145 B-Eq-Comparison
participate NCT03866096 146 157 O
in NCT03866096 158 160 O
amateur NCT03866096 161 168 O
industry NCT03866096 169 177 O
competitions NCT03866096 178 190 O

Exclusion NCT03866096 191 200 O
Criteria NCT03866096 201 209 O
: NCT03866096 210 211 O

- NCT03866096 215 216 O
Present NCT03866096 218 225 O
a NCT03866096 226 227 O
medical NCT03866096 228 235 O
diagnosis NCT03866096 236 245 O
of NCT03866096 246 248 O
musculoskeletal NCT03866096 249 264 B-Modifier
injury NCT03866096 265 271 B-Condition
at NCT03866096 272 274 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866096 275 278 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03866096 279 283 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03866096 284 286 O
beginning NCT03866096 287 296 B-Eq-Comparison
the NCT03866096 297 300 O
study NCT03866096 301 306 B-Study

- NCT03866096 309 310 O
Receive NCT03866096 312 319 B-Eq-Comparison
a NCT03866096 320 321 O
physiotherapy NCT03866096 322 335 B-Procedure
treatment NCT03866096 336 345 I-Procedure
unrelated NCT03866096 346 355 B-Negation
to NCT03866096 356 358 O
the NCT03866096 359 362 O
study NCT03866096 363 368 B-Study

- NCT03866096 371 372 O
Have NCT03866096 374 378 O
suffered NCT03866096 379 387 B-Eq-Comparison
neurological NCT03866096 388 400 B-Condition
pathology NCT03866096 401 410 I-Condition
in NCT03866096 411 413 O
the NCT03866096 414 417 O
last NCT03866096 418 422 B-Eq-Comparison
6 NCT03866096 423 424 I-Eq-Comparison
months NCT03866096 425 431 I-Eq-Comparison

- NCT03866096 434 435 O
Have NCT03866096 437 441 O
some NCT03866096 442 446 O
type NCT03866096 447 451 O
of NCT03866096 452 454 O
auditory NCT03866096 455 463 B-Modifier
or NCT03866096 464 466 B-Or
vestibular NCT03866096 467 477 B-Modifier
disorder NCT03866096 478 486 B-Condition

- NCT03866096 489 490 O
Not NCT03866096 492 495 O
signed NCT03866096 496 502 O
the NCT03866096 503 506 O
informed NCT03866096 507 515 O
consent NCT03866096 516 523 O
. NCT03866096 523 524 O

Inclusion NCT03866733 0 9 O
Criteria NCT03866733 10 18 O
: NCT03866733 19 20 O

- NCT03866733 24 25 O
elective NCT03866733 27 35 B-Modifier
cardiac NCT03866733 36 43 B-Procedure
surgery NCT03866733 44 51 I-Procedure
. NCT03866733 52 53 O

- NCT03866733 57 58 O
age NCT03866733 60 63 B-Age
18 NCT03866733 64 66 B-Eq-Comparison
- NCT03866733 67 68 I-Eq-Comparison
65 NCT03866733 69 71 I-Eq-Comparison
years NCT03866733 72 77 I-Eq-Comparison
. NCT03866733 78 79 O

- NCT03866733 83 84 O
patients NCT03866733 86 94 O
with NCT03866733 95 99 O
median NCT03866733 100 106 B-Procedure
sternotomy NCT03866733 107 117 I-Procedure
. NCT03866733 118 119 O

- NCT03866733 123 124 O
body NCT03866733 126 130 B-Observation
mass NCT03866733 131 135 I-Observation
index NCT03866733 136 141 I-Observation
< NCT03866733 142 143 B-Eq-Comparison
30 NCT03866733 144 146 I-Eq-Comparison
kg NCT03866733 147 149 I-Eq-Comparison
. NCT03866733 149 150 I-Eq-Comparison
m2 NCT03866733 151 153 I-Eq-Comparison
. NCT03866733 153 154 O

- NCT03866733 158 159 O
left NCT03866733 161 165 B-Observation
ventricular NCT03866733 166 177 I-Observation
ejection NCT03866733 178 186 I-Observation
fraction NCT03866733 187 195 I-Observation
> NCT03866733 196 197 B-Eq-Comparison
50 NCT03866733 198 200 I-Eq-Comparison
% NCT03866733 201 202 I-Eq-Comparison
. NCT03866733 204 205 O

Exclusion NCT03866733 207 216 O
Criteria NCT03866733 217 225 O
: NCT03866733 226 227 O

- NCT03866733 231 232 O
signiﬁcant NCT03866733 234 244 O
aortic NCT03866733 245 251 B-Condition
stenosis NCT03866733 252 260 I-Condition
. NCT03866733 261 262 O

- NCT03866733 266 267 O
left NCT03866733 269 273 B-Modifier
main NCT03866733 274 278 I-Modifier
coronary NCT03866733 279 287 B-Condition
artery NCT03866733 288 294 I-Condition
disease NCT03866733 295 302 I-Condition
. NCT03866733 303 304 O

- NCT03866733 308 309 O
patient NCT03866733 311 318 O
on NCT03866733 319 321 B-Eq-Comparison
anti NCT03866733 322 326 B-Drug
- NCT03866733 327 328 I-Drug
coagulants0 NCT03866733 329 340 I-Drug

- NCT03866733 343 344 O
pre NCT03866733 346 349 B-Eq-Comparison
- NCT03866733 350 351 I-Eq-Comparison
existing NCT03866733 352 360 I-Eq-Comparison
respiratory NCT03866733 361 372 B-Modifier
, NCT03866733 373 374 O
neurological NCT03866733 375 387 B-Modifier
, NCT03866733 388 389 O
or NCT03866733 390 392 B-Or
renal NCT03866733 393 398 B-Modifier
disease NCT03866733 399 406 B-Condition
. NCT03866733 407 408 O

- NCT03866733 412 413 O
CSF NCT03866733 415 418 B-Procedure
or NCT03866733 419 421 B-Or
blood NCT03866733 422 427 B-Procedure
tap NCT03866733 428 431 I-Procedure
during NCT03866733 432 438 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03866733 439 442 B-Coreference
procedure NCT03866733 443 452 I-Coreference
. NCT03866733 453 454 O

- NCT03866733 458 459 O
failure NCT03866733 461 468 B-Modifier
to NCT03866733 469 471 I-Modifier
thread NCT03866733 472 478 I-Modifier
the NCT03866733 479 482 O
catheter NCT03866733 483 491 B-Procedure
. NCT03866733 492 493 O

- NCT03866733 497 498 O
anomalies NCT03866733 500 509 B-Condition
of NCT03866733 510 512 O
vertebral NCT03866733 513 522 B-Modifier
column NCT03866733 523 529 I-Modifier
. NCT03866733 529 530 O

Inclusion NCT03869372 0 9 O
Criteria NCT03869372 10 18 O
: NCT03869372 19 20 O

- NCT03869372 24 25 O
Adults NCT03869372 27 33 O
between NCT03869372 34 41 B-Eq-Comparison
age NCT03869372 42 45 I-Eq-Comparison
18 NCT03869372 46 48 I-Eq-Comparison
and NCT03869372 49 52 I-Eq-Comparison
75 NCT03869372 53 55 I-Eq-Comparison

- NCT03869372 59 60 O
Participants NCT03869372 62 74 O
without NCT03869372 75 82 B-Negation
a NCT03869372 83 84 O
history NCT03869372 85 92 B-Eq-Comparison
of NCT03869372 93 95 O
gastrointestinal NCT03869372 96 112 B-Condition
disorders NCT03869372 113 122 I-Condition
( NCT03869372 123 124 O
control NCT03869372 125 132 O
group NCT03869372 133 138 O
) NCT03869372 139 140 O

- NCT03869372 144 145 O
Participants NCT03869372 147 159 O
with NCT03869372 160 164 O
functional NCT03869372 165 175 B-Modifier
dyspepsia NCT03869372 176 185 B-Condition
( NCT03869372 186 187 O
FD NCT03869372 188 190 O
group NCT03869372 191 196 O
) NCT03869372 197 198 O

- NCT03869372 202 203 O
Participants NCT03869372 205 217 O
with NCT03869372 218 222 O
moderate NCT03869372 223 231 B-Eq-Comparison
- NCT03869372 232 233 I-Eq-Comparison
to NCT03869372 234 236 I-Eq-Comparison
- NCT03869372 237 238 I-Eq-Comparison
severe NCT03869372 239 245 I-Eq-Comparison
irritable NCT03869372 246 255 B-Condition
bowel NCT03869372 256 261 I-Condition
syndrome NCT03869372 262 270 I-Condition
( NCT03869372 271 272 O
defined NCT03869372 273 280 O
by NCT03869372 281 283 O
IBS NCT03869372 284 287 B-Observation
symptom NCT03869372 288 295 I-Observation
severity NCT03869372 296 304 I-Observation
scores NCT03869372 305 311 I-Observation
( NCT03869372 312 313 O
IBS NCT03869372 314 317 B-Observation
- NCT03869372 318 319 I-Observation
SSS NCT03869372 320 323 I-Observation
) NCT03869372 324 325 O
greater NCT03869372 326 333 B-Eq-Comparison
than NCT03869372 334 338 I-Eq-Comparison
250 NCT03869372 339 342 I-Eq-Comparison
) NCT03869372 343 344 O
( NCT03869372 345 346 O
IBS NCT03869372 347 350 O
group NCT03869372 351 356 O
) NCT03869372 357 358 O

Exclusion NCT03869372 360 369 O
Criteria NCT03869372 370 378 O
: NCT03869372 379 380 O

- NCT03869372 384 385 O
history NCT03869372 387 394 B-Eq-Comparison
of NCT03869372 395 397 O
myocardial NCT03869372 398 408 B-Condition
infarction NCT03869372 409 419 I-Condition
, NCT03869372 420 421 O
supplemental NCT03869372 422 434 B-Procedure
oxygen NCT03869372 435 441 I-Procedure
requirement NCT03869372 442 453 O
, NCT03869372 454 455 O
or NCT03869372 456 458 B-Or
diabetes NCT03869372 459 467 B-Condition

- NCT03869372 470 471 O
history NCT03869372 473 480 B-Eq-Comparison
of NCT03869372 481 483 O
chronic NCT03869372 484 491 B-Modifier
gastrointestinal NCT03869372 492 508 B-Condition
symptoms NCT03869372 509 517 B-Assertion___Assertion-Type-Value:possible
( NCT03869372 518 519 O
for NCT03869372 520 523 O
healthy NCT03869372 524 531 O
control NCT03869372 532 539 O
population NCT03869372 540 550 O
only NCT03869372 551 555 O
) NCT03869372 556 557 O

- NCT03869372 561 562 O
history NCT03869372 564 571 B-Eq-Comparison
of NCT03869372 572 574 O
gastric NCT03869372 575 582 B-Procedure
surgery NCT03869372 583 590 I-Procedure

- NCT03869372 593 594 O
psychosis NCT03869372 596 605 B-Condition
or NCT03869372 606 608 B-Or
altered NCT03869372 609 616 B-Condition
cognitive NCT03869372 617 626 I-Condition
status NCT03869372 627 633 I-Condition

- NCT03869372 636 637 O
history NCT03869372 639 646 B-Eq-Comparison
of NCT03869372 647 649 O
head NCT03869372 650 654 B-Modifier
injury NCT03869372 655 661 B-Condition
, NCT03869372 662 663 O
metal NCT03869372 664 669 B-Condition
in NCT03869372 670 672 I-Condition
the NCT03869372 673 676 I-Condition
skull NCT03869372 677 682 I-Condition
, NCT03869372 683 684 O
stroke NCT03869372 685 691 B-Condition
, NCT03869372 692 693 O
or NCT03869372 694 696 B-Or
a NCT03869372 697 698 O
history NCT03869372 699 706 B-Eq-Comparison
of NCT03869372 707 709 O
seizures NCT03869372 710 718 B-Condition

- NCT03869372 721 722 O
implantable NCT03869372 724 735 B-Procedure
devices NCT03869372 736 743 I-Procedure
, NCT03869372 744 745 O
such NCT03869372 746 750 O
as NCT03869372 751 753 O
a NCT03869372 754 755 O
pacemaker NCT03869372 756 765 B-Procedure
or NCT03869372 766 768 B-Or
nerve NCT03869372 769 774 B-Procedure
stimulator NCT03869372 775 785 I-Procedure

- NCT03869372 788 789 O
current NCT03869372 791 798 B-Eq-Comparison
use NCT03869372 799 802 O
of NCT03869372 803 805 O
the NCT03869372 806 809 O
following NCT03869372 810 819 O
medications NCT03869372 820 831 B-Drug
or NCT03869372 832 834 B-Or
use NCT03869372 835 838 O
of NCT03869372 839 841 O
substances NCT03869372 842 852 B-Drug
which NCT03869372 853 858 O
are NCT03869372 859 862 O
known NCT03869372 863 868 O
to NCT03869372 869 871 O
lower NCT03869372 872 877 O
the NCT03869372 878 881 O
seizure NCT03869372 882 889 B-Condition
threshold NCT03869372 890 899 B-Modifier
: NCT03869372 900 901 O
amitriptyline NCT03869372 902 915 B-Drug
( NCT03869372 916 917 O
Elavil NCT03869372 918 924 B-Drug
) NCT03869372 925 926 O
, NCT03869372 928 929 O
nortriptyline NCT03869372 930 943 B-Drug
( NCT03869372 944 945 O
Pamelor NCT03869372 946 953 B-Drug
) NCT03869372 954 955 O
, NCT03869372 957 958 O
imipramine NCT03869372 959 969 B-Drug
( NCT03869372 970 971 O
Tofranil NCT03869372 972 980 B-Drug
) NCT03869372 981 982 O
, NCT03869372 984 985 O
doxepin NCT03869372 986 993 B-Drug
( NCT03869372 994 995 O
Sinequan NCT03869372 996 1004 B-Drug
) NCT03869372 1005 1006 O
, NCT03869372 1008 1009 O
clozapine NCT03869372 1010 1019 B-Drug
( NCT03869372 1020 1021 O
Clozaril NCT03869372 1022 1030 B-Drug
) NCT03869372 1031 1032 O
, NCT03869372 1034 1035 O
chlorpromazine NCT03869372 1036 1050 B-Drug
( NCT03869372 1051 1052 O
Thorazine NCT03869372 1053 1062 B-Drug
) NCT03869372 1063 1064 O
, NCT03869372 1066 1067 O
amphetamines NCT03869372 1068 1080 B-Drug
or NCT03869372 1081 1083 B-Or
methamphetamine NCT03869372 1084 1099 B-Drug
, NCT03869372 1100 1101 O
Ecstasy NCT03869372 1102 1109 B-Drug
, NCT03869372 1110 1111 O
Ketamine NCT03869372 1112 1120 B-Drug
, NCT03869372 1121 1122 O
Angel NCT03869372 1123 1128 B-Drug
Dust NCT03869372 1129 1133 I-Drug
/ NCT03869372 1134 1135 B-Or
phencyclidine NCT03869372 1136 1149 B-Drug
( NCT03869372 1150 1151 O
PCP NCT03869372 1152 1155 B-Drug
) NCT03869372 1156 1157 O
, NCT03869372 1159 1160 O
cocaine NCT03869372 1161 1168 B-Drug
, NCT03869372 1169 1170 O
or NCT03869372 1171 1173 B-Or
3 NCT03869372 1174 1175 B-Eq-Comparison
or NCT03869372 1176 1178 I-Eq-Comparison
more NCT03869372 1179 1183 I-Eq-Comparison
alcoholic NCT03869372 1184 1193 B-Drug
drinks NCT03869372 1194 1200 I-Drug
per NCT03869372 1201 1204 O
day NCT03869372 1205 1208 O

- NCT03869372 1211 1212 O
pregnancy NCT03869372 1214 1223 B-Condition

Inclusion NCT03865979 0 9 O
Criteria NCT03865979 10 18 O
: NCT03865979 19 20 O

- NCT03865979 24 25 O
Subjects NCT03865979 27 35 O
with NCT03865979 36 40 O
stroke NCT03865979 41 47 B-Condition
symptoms NCT03865979 48 56 B-Assertion___Assertion-Type-Value:possible
who NCT03865979 57 60 B-And
undergo NCT03865979 61 68 O
CT NCT03865979 69 71 B-Procedure
brain NCT03865979 72 77 I-Procedure
imaging NCT03865979 78 85 I-Procedure
. NCT03865979 86 87 O

Exclusion NCT03865979 89 98 O
Criteria NCT03865979 99 107 O
: NCT03865979 108 109 O

- NCT03865979 113 114 O
Subjects NCT03865979 116 124 O
with NCT03865979 125 129 O
poor NCT03865979 130 134 B-Modifier
or NCT03865979 135 137 B-Or
incomplete NCT03865979 138 148 B-Modifier
CT NCT03865979 149 151 B-Procedure
brain NCT03865979 152 157 I-Procedure
imaging NCT03865979 158 165 I-Procedure
. NCT03865979 165 166 O

Inclusion NCT03864497 0 9 O
Criteria NCT03864497 10 18 O
: NCT03864497 19 20 O

• NCT03864497 22 23 O
Liver NCT03864497 24 29 B-Procedure
transplantation NCT03864497 30 45 I-Procedure
candidates NCT03864497 46 56 B-Assertion___Assertion-Type-Value:hypothetical
with NCT03864497 57 61 O
one NCT03864497 62 65 O
or NCT03864497 66 68 O
more NCT03864497 69 73 O
of NCT03864497 74 76 O
the NCT03864497 77 80 O
following NCT03864497 81 90 O
: NCT03864497 91 92 O

- NCT03864497 96 97 O
inability NCT03864497 99 108 B-Negation
to NCT03864497 109 111 O
perform NCT03864497 112 119 O
> NCT03864497 120 121 B-Eq-Comparison
4 NCT03864497 122 123 I-Eq-Comparison
METs NCT03864497 124 128 B-Observation
by NCT03864497 129 131 O
history NCT03864497 132 139 B-Eq-Comparison

- NCT03864497 142 143 O
insulin NCT03864497 145 152 B-Modifier
- NCT03864497 153 154 I-Modifier
treated NCT03864497 155 162 I-Modifier
diabetes NCT03864497 163 171 B-Condition
mellitus NCT03864497 172 180 I-Condition

- NCT03864497 183 184 O
serum NCT03864497 186 191 B-Observation
creatinine NCT03864497 192 202 I-Observation
> NCT03864497 203 204 B-Eq-Comparison
152 NCT03864497 205 208 I-Eq-Comparison
μmol NCT03864497 209 213 I-Eq-Comparison
/ NCT03864497 214 215 I-Eq-Comparison
l NCT03864497 216 217 I-Eq-Comparison

- NCT03864497 220 221 O
history NCT03864497 223 230 B-Eq-Comparison
of NCT03864497 231 233 O
MI NCT03864497 234 236 B-Condition
, NCT03864497 237 238 O
PCI NCT03864497 239 242 B-Procedure
or NCT03864497 243 245 B-Or
CABG NCT03864497 246 250 B-Procedure

- NCT03864497 253 254 O
stable NCT03864497 256 262 B-Condition
angina NCT03864497 263 269 I-Condition

- NCT03864497 272 273 O
cerebrovascular NCT03864497 275 290 B-Condition
disease NCT03864497 291 298 I-Condition

- NCT03864497 301 302 O
peripheral NCT03864497 304 314 B-Condition
vascular NCT03864497 315 323 I-Condition
disease NCT03864497 324 331 I-Condition

Exclusion NCT03864497 332 341 O
Criteria NCT03864497 342 350 O
: NCT03864497 351 352 O

- NCT03864497 356 357 O
Age NCT03864497 359 362 B-Age
< NCT03864497 363 364 B-Eq-Comparison
18 NCT03864497 365 367 I-Eq-Comparison
years NCT03864497 368 373 I-Eq-Comparison

- NCT03864497 376 377 O
Pregnancy NCT03864497 379 388 B-Condition

- NCT03864497 391 392 O
Contraindication NCT03864497 394 410 B-Contraindication
to NCT03864497 411 413 O
liver NCT03864497 414 419 B-Procedure
transplantation NCT03864497 420 435 I-Procedure

Inclusion NCT03865004 0 9 O
Criteria NCT03865004 10 18 O
: NCT03865004 19 20 O
Renal NCT03865004 21 26 B-Condition
colic NCT03865004 27 32 I-Condition
patients NCT03865004 33 41 O
- NCT03865004 42 43 O

Exclusion NCT03865004 45 54 O
Criteria NCT03865004 55 63 O
: NCT03865004 64 65 O
Not NCT03865004 66 69 B-Negation
renal NCT03865004 70 75 B-Condition
colic NCT03865004 76 81 I-Condition
patients NCT03865004 82 90 O

- NCT03865004 92 93 O

Inclusion NCT03860168 0 9 O
Criteria NCT03860168 10 18 O
for NCT03860168 19 22 O
Participating NCT03860168 23 36 O
Units NCT03860168 37 42 O
: NCT03860168 43 44 O

- NCT03860168 48 49 O
Participating NCT03860168 51 64 O
PICUs NCT03860168 65 70 O
must NCT03860168 71 75 O
be NCT03860168 76 78 O
a NCT03860168 79 80 O
separate NCT03860168 81 89 O
physical NCT03860168 90 98 O
space NCT03860168 99 104 O
dedicated NCT03860168 105 114 O
to NCT03860168 115 117 O
the NCT03860168 118 121 O
care NCT03860168 122 126 O
of NCT03860168 127 129 O
critically NCT03860168 130 140 B-Condition
ill NCT03860168 141 144 I-Condition
infants NCT03860168 145 152 O
and NCT03860168 153 156 B-Or
children NCT03860168 157 165 O
, NCT03860168 166 167 O
with NCT03860168 168 172 B-And
the NCT03860168 173 176 O
ability NCT03860168 177 184 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03860168 185 187 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03860168 188 195 O
mechanical NCT03860168 196 206 B-Procedure
ventilation NCT03860168 207 218 I-Procedure
. NCT03860168 219 220 O

- NCT03860168 224 225 O
Not NCT03860168 227 230 O
implemented NCT03860168 231 242 O
a NCT03860168 243 244 O
PICU NCT03860168 245 249 O
mobility NCT03860168 250 258 O
protocol NCT03860168 259 267 O
and NCT03860168 268 271 O
would NCT03860168 272 277 O
commit NCT03860168 278 284 O
to NCT03860168 285 287 O
not NCT03860168 288 291 O
implementing NCT03860168 292 304 O
a NCT03860168 305 306 O
mobility NCT03860168 307 315 O
protocol NCT03860168 316 324 O
until NCT03860168 325 330 O
the NCT03860168 331 334 O
randomized NCT03860168 335 345 O
time NCT03860168 346 350 O
of NCT03860168 351 353 O
unit NCT03860168 354 358 O
implementation NCT03860168 359 373 O
. NCT03860168 374 375 O

Inclusion NCT03860168 377 386 O
Criteria NCT03860168 387 395 O
for NCT03860168 396 399 O
Patients NCT03860168 400 408 O
: NCT03860168 409 410 O

All NCT03860168 412 415 O
patients NCT03860168 416 424 O
admitted NCT03860168 425 433 B-Encounter
to NCT03860168 434 436 O
the NCT03860168 437 440 O
PICUs NCT03860168 441 446 O
regardless NCT03860168 447 457 O
of NCT03860168 458 460 O
length NCT03860168 461 467 O
of NCT03860168 468 470 O
stay NCT03860168 471 475 O
will NCT03860168 476 480 O
receive NCT03860168 481 488 O
the NCT03860168 489 492 O
unit NCT03860168 493 497 O
- NCT03860168 498 499 O
based NCT03860168 500 505 O
PICU NCT03860168 506 510 O
Up NCT03860168 511 513 O
! NCT03860168 513 514 O
intervention NCT03860168 515 527 B-Procedure
, NCT03860168 528 529 O
which NCT03860168 530 535 O
includes NCT03860168 536 544 O
criteria NCT03860168 545 553 O
for NCT03860168 554 557 O
no NCT03860168 558 560 B-Negation
mobilization NCT03860168 561 573 B-Procedure
based NCT03860168 574 579 O
on NCT03860168 580 582 O
specific NCT03860168 583 591 O
clinical NCT03860168 592 600 B-Condition
factors NCT03860168 601 608 I-Condition
( NCT03860168 609 610 O
i. NCT03860168 611 613 O
e. NCT03860168 614 616 O
open NCT03860168 618 622 B-Condition
chest NCT03860168 623 628 I-Condition
, NCT03860168 629 630 O
surgeon NCT03860168 631 638 B-Condition
request NCT03860168 639 646 I-Condition
) NCT03860168 647 648 O
.10 NCT03860168 649 652 O
For NCT03860168 653 656 O
inclusion NCT03860168 657 666 O
in NCT03860168 667 669 O
data NCT03860168 670 674 O
analysis NCT03860168 675 683 O
, NCT03860168 684 685 O

patients NCT03860168 687 695 O
will NCT03860168 696 700 O
be NCT03860168 701 703 O
eligible NCT03860168 704 712 O
if NCT03860168 713 715 O

- NCT03860168 718 719 O
Admitted NCT03860168 721 729 B-Encounter
to NCT03860168 730 732 O
the NCT03860168 733 736 O
participating NCT03860168 737 750 O
PICU NCT03860168 751 755 O
≥ NCT03860168 756 757 B-Eq-Comparison
3 NCT03860168 758 759 I-Eq-Comparison
days NCT03860168 760 764 I-Eq-Comparison
. NCT03860168 765 766 O

Exclusion NCT03860168 768 777 O
Criteria NCT03860168 778 786 O
for NCT03860168 787 790 O
Patients NCT03860168 791 799 O
: NCT03860168 800 801 O

- NCT03860168 805 806 O
Patients NCT03860168 808 816 O
with NCT03860168 817 821 O
an NCT03860168 822 824 O
active NCT03860168 825 831 B-Eq-Comparison
do NCT03860168 832 834 B-Observation
- NCT03860168 835 836 I-Observation
not NCT03860168 837 840 I-Observation
- NCT03860168 841 842 I-Observation
resuscitate NCT03860168 843 854 I-Observation
( NCT03860168 855 856 O
DNR NCT03860168 857 860 B-Observation
) NCT03860168 861 862 O
order NCT03860168 863 868 O
will NCT03860168 869 873 O
be NCT03860168 874 876 O
excluded NCT03860168 877 885 B-Negation
. NCT03860168 886 887 O


Inclusion NCT03869164 0 9 O
Criteria NCT03869164 10 18 O
: NCT03869164 19 20 O

1 NCT03869164 24 25 O
. NCT03869164 25 26 O
age NCT03869164 28 31 B-Age
older NCT03869164 32 37 B-Eq-Comparison
than NCT03869164 38 42 I-Eq-Comparison
60 NCT03869164 43 45 I-Eq-Comparison
years NCT03869164 46 51 I-Eq-Comparison
; NCT03869164 51 52 O

2 NCT03869164 55 56 O
. NCT03869164 56 57 O
moderate NCT03869164 59 67 B-Eq-Comparison
to NCT03869164 68 70 I-Eq-Comparison
severe NCT03869164 71 77 I-Eq-Comparison
or NCT03869164 78 80 B-Or
severe NCT03869164 81 87 O
mitral NCT03869164 88 94 B-Condition
regurgitation NCT03869164 95 108 I-Condition
; NCT03869164 108 109 O

3 NCT03869164 112 113 O
. NCT03869164 113 114 O
symptoms NCT03869164 116 124 B-Assertion___Assertion-Type-Value:possible
( NCT03869164 125 126 O
New NCT03869164 127 130 B-Condition
York NCT03869164 131 135 I-Condition
Heart NCT03869164 136 141 I-Condition
Association NCT03869164 142 153 I-Condition
[ NCT03869164 154 155 O
NYHA NCT03869164 156 160 B-Condition
] NCT03869164 161 162 O
cardiac NCT03869164 163 170 O
function NCT03869164 171 179 O
class NCT03869164 180 185 O
≥ NCT03869164 186 187 B-Eq-Comparison
2 NCT03869164 188 189 I-Eq-Comparison
) NCT03869164 190 191 O
related NCT03869164 192 199 O
to NCT03869164 200 202 O
MR NCT03869164 203 205 B-Condition
; NCT03869164 205 206 O

4 NCT03869164 209 210 O
. NCT03869164 210 211 O
the NCT03869164 213 216 O
primary NCT03869164 217 224 B-Modifier
regurgitant NCT03869164 225 236 I-Modifier
jet NCT03869164 237 240 I-Modifier
originated NCT03869164 241 251 I-Modifier
from NCT03869164 252 256 O
malcoaptation NCT03869164 257 270 B-Condition
of NCT03869164 271 273 O
the NCT03869164 274 277 O
A2 NCT03869164 278 280 B-Modifier
and NCT03869164 281 284 B-Or
P2 NCT03869164 285 287 B-Modifier
scallops NCT03869164 288 296 I-Modifier
of NCT03869164 297 299 I-Modifier
the NCT03869164 300 303 I-Modifier
mitral NCT03869164 304 310 I-Modifier
valve NCT03869164 311 316 I-Modifier
; NCT03869164 316 317 O

5 NCT03869164 320 321 O
. NCT03869164 321 322 O
high NCT03869164 324 328 O
risk NCT03869164 329 333 B-Risk
for NCT03869164 334 337 O
surgery NCT03869164 338 345 B-Procedure
according NCT03869164 346 355 O
the NCT03869164 356 359 O
MVARC NCT03869164 360 365 O
criteria NCT03869164 366 374 O
; NCT03869164 374 375 O

6 NCT03869164 378 379 O
. NCT03869164 379 380 O
providing NCT03869164 382 391 O
signed NCT03869164 392 398 O
informed NCT03869164 399 407 O
consent NCT03869164 408 415 O
. NCT03869164 416 417 O

Exclusion NCT03869164 419 428 O
Criteria NCT03869164 429 437 O
: NCT03869164 438 439 O

1 NCT03869164 443 444 O
. NCT03869164 444 445 O
acute NCT03869164 447 452 O
myocardial NCT03869164 453 463 B-Condition
infarction NCT03869164 464 474 I-Condition
in NCT03869164 475 477 O
the NCT03869164 478 481 O
prior NCT03869164 482 487 B-Eq-Comparison
4 NCT03869164 488 489 I-Eq-Comparison
weeks NCT03869164 490 495 I-Eq-Comparison
of NCT03869164 496 498 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03869164 499 502 O
intended NCT03869164 503 511 O
treatment NCT03869164 512 521 B-Procedure
; NCT03869164 521 522 O

2 NCT03869164 525 526 O
. NCT03869164 526 527 O
any NCT03869164 529 532 O
interventional NCT03869164 533 547 B-Modifier
or NCT03869164 548 550 B-Or
surgical NCT03869164 551 559 B-Modifier
cardiac NCT03869164 560 567 B-Procedure
procedure NCT03869164 568 577 I-Procedure
performed NCT03869164 578 587 O
within NCT03869164 588 594 B-Eq-Comparison
30 NCT03869164 595 597 I-Eq-Comparison
days NCT03869164 598 602 I-Eq-Comparison
prior NCT03869164 603 608 I-Eq-Comparison
; NCT03869164 608 609 O

3 NCT03869164 612 613 O
. NCT03869164 613 614 O
the NCT03869164 616 619 O
need NCT03869164 620 624 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03869164 625 628 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03869164 629 632 O
other NCT03869164 633 638 B-Other
cardiac NCT03869164 639 646 B-Procedure
surgery NCT03869164 647 654 I-Procedure
; NCT03869164 654 655 O

4 NCT03869164 658 659 O
. NCT03869164 659 660 O
echocardiographic NCT03869164 662 679 B-Procedure
evidence NCT03869164 680 688 O
of NCT03869164 689 691 O
intracardiac NCT03869164 692 704 B-Condition
mass NCT03869164 705 709 B-Modifier
, NCT03869164 710 711 O
thrombus NCT03869164 712 720 B-Modifier
, NCT03869164 721 722 O
or NCT03869164 723 725 B-Or
vegetation NCT03869164 726 736 B-Modifier
; NCT03869164 736 737 O

5 NCT03869164 740 741 O
. NCT03869164 741 742 O
life NCT03869164 744 748 B-Observation
expectancy NCT03869164 749 759 I-Observation
within NCT03869164 760 766 B-Eq-Comparison
12 NCT03869164 767 769 I-Eq-Comparison
months NCT03869164 770 776 I-Eq-Comparison
; NCT03869164 776 777 O

6 NCT03869164 780 781 O
. NCT03869164 781 782 O
moderate NCT03869164 784 792 O
or NCT03869164 793 795 B-Or
severe NCT03869164 796 802 O
aortic NCT03869164 803 809 B-Condition
stenosis NCT03869164 810 818 B-Modifier
or NCT03869164 819 821 B-Or
regurgitation NCT03869164 822 835 B-Modifier
; NCT03869164 835 836 O

7 NCT03869164 839 840 O
. NCT03869164 840 841 O
mitral NCT03869164 843 849 B-Observation
valve NCT03869164 850 855 I-Observation
orifice NCT03869164 856 863 I-Observation
area NCT03869164 864 868 I-Observation
< NCT03869164 869 870 B-Eq-Comparison
3.5 NCT03869164 871 874 I-Eq-Comparison
cm2 NCT03869164 875 878 I-Eq-Comparison
; NCT03869164 878 879 O

8 NCT03869164 882 883 O
. NCT03869164 883 884 O
untreated NCT03869164 886 895 B-Negation|Procedure
significant NCT03869164 896 907 O
coronary NCT03869164 908 916 B-Condition
stenosis NCT03869164 917 925 I-Condition
; NCT03869164 925 926 O

9 NCT03869164 929 930 O
. NCT03869164 930 931 O
history NCT03869164 933 940 B-Eq-Comparison
of NCT03869164 941 943 O
mitral NCT03869164 944 950 B-Condition
valvuloplasty NCT03869164 951 964 I-Condition
; NCT03869164 964 965 O

10 NCT03869164 967 969 O
. NCT03869164 969 970 O
Infective NCT03869164 972 981 B-Condition
endocarditis NCT03869164 982 994 I-Condition
and NCT03869164 995 998 B-Or
rheumatic NCT03869164 999 1008 B-Condition
heart NCT03869164 1009 1014 I-Condition
disease NCT03869164 1015 1022 I-Condition
; NCT03869164 1022 1023 O

11 NCT03869164 1025 1027 O
. NCT03869164 1027 1028 O
untreated NCT03869164 1030 1039 B-Negation|Procedure
cardiogenic NCT03869164 1040 1051 B-Condition
shock NCT03869164 1052 1057 I-Condition
, NCT03869164 1058 1059 O
acute NCT03869164 1060 1065 O
pulmonary NCT03869164 1066 1075 B-Condition
congestion NCT03869164 1076 1086 I-Condition
; NCT03869164 1086 1087 O

12 NCT03869164 1089 1091 O
. NCT03869164 1091 1092 O
unfavored NCT03869164 1094 1103 B-Modifier
mitral NCT03869164 1104 1110 B-Condition
valve NCT03869164 1111 1116 I-Condition
anatomy NCT03869164 1117 1124 I-Condition
that NCT03869164 1125 1129 O
may NCT03869164 1130 1133 O
preclude NCT03869164 1134 1142 B-Assertion___Assertion-Type-Value:hypothetical|Negation
device NCT03869164 1143 1149 B-Procedure
implantation NCT03869164 1150 1162 I-Procedure
including NCT03869164 1163 1172 O
: NCT03869164 1173 1174 O

calcification NCT03869164 1181 1194 B-Modifier
or NCT03869164 1195 1197 B-Or
significant NCT03869164 1198 1209 O
cleft NCT03869164 1210 1215 B-Condition
in NCT03869164 1216 1218 O
area NCT03869164 1219 1223 B-Modifier
of NCT03869164 1224 1226 I-Modifier
the NCT03869164 1227 1230 I-Modifier
A2 NCT03869164 1231 1233 I-Modifier
and NCT03869164 1234 1237 B-Or
/ NCT03869164 1238 1239 I-Or
or NCT03869164 1240 1242 I-Or
P2 NCT03869164 1243 1245 B-Modifier
scallops NCT03869164 1246 1254 I-Modifier
, NCT03869164 1255 1256 O
significant NCT03869164 1257 1268 O
regurgitation NCT03869164 1269 1282 B-Condition
beyond NCT03869164 1283 1289 B-Negation
A2 NCT03869164 1290 1292 B-Modifier
or NCT03869164 1293 1295 B-Or
P2 NCT03869164 1296 1298 B-Modifier
scallops NCT03869164 1299 1307 I-Modifier
and NCT03869164 1308 1311 B-Or
short NCT03869164 1312 1317 B-Observation
posterior NCT03869164 1318 1327 I-Observation
leaflet NCT03869164 1328 1335 I-Observation
( NCT03869164 1336 1337 O
< NCT03869164 1339 1340 B-Eq-Comparison
10 NCT03869164 1341 1343 I-Eq-Comparison
mm NCT03869164 1344 1346 O
) NCT03869164 1347 1348 O
. NCT03869164 1350 1351 O

13 NCT03869164 1354 1356 O
. NCT03869164 1356 1357 O
Other NCT03869164 1359 1364 B-Other
clinical NCT03869164 1365 1373 B-Study
trials NCT03869164 1374 1380 I-Study
that NCT03869164 1381 1385 O
the NCT03869164 1386 1389 O
subjects NCT03869164 1390 1398 O
participated NCT03869164 1399 1411 O
in NCT03869164 1412 1414 O
have NCT03869164 1415 1419 O
not NCT03869164 1420 1423 O
reached NCT03869164 1424 1431 O
the NCT03869164 1432 1435 O
end NCT03869164 1436 1439 O
point NCT03869164 1440 1445 O
. NCT03869164 1445 1446 O

Inclusion NCT03922828 0 9 O
Criteria NCT03922828 10 18 O
: NCT03922828 19 20 O

- NCT03922828 24 25 O
The NCT03922828 27 30 O
subject NCT03922828 31 38 O
must NCT03922828 39 43 O
meet NCT03922828 44 48 O
all NCT03922828 49 52 O
of NCT03922828 53 55 O
the NCT03922828 56 59 O
following NCT03922828 60 69 O
inclusion NCT03922828 70 79 O
criteria NCT03922828 80 88 O
to NCT03922828 89 91 O
participate NCT03922828 92 103 O
in NCT03922828 104 106 O
this NCT03922828 107 111 O
study NCT03922828 112 117 O
. NCT03922828 118 119 O

1 NCT03922828 128 129 O
. NCT03922828 129 130 O
Evidence NCT03922828 132 140 O
of NCT03922828 141 143 O
lung NCT03922828 144 148 B-Condition
nodule NCT03922828 149 155 I-Condition
on NCT03922828 156 158 O
chest NCT03922828 159 164 B-Procedure
radiograph NCT03922828 165 175 I-Procedure
or NCT03922828 176 178 B-Or
Computed NCT03922828 179 187 B-Procedure
Tomography NCT03922828 188 198 I-Procedure
regardless NCT03922828 199 209 O
of NCT03922828 210 212 O
underlying NCT03922828 213 223 O
aetiology NCT03922828 224 233 O

2 NCT03922828 241 242 O
. NCT03922828 242 243 O
Age NCT03922828 245 248 B-Age
> NCT03922828 249 250 B-Eq-Comparison
21 NCT03922828 251 253 I-Eq-Comparison
years NCT03922828 254 259 I-Eq-Comparison
old NCT03922828 260 263 O

3 NCT03922828 271 272 O
. NCT03922828 272 273 O
Ability NCT03922828 275 282 O
to NCT03922828 283 285 O
provide NCT03922828 286 293 O
informed NCT03922828 294 302 O
consent NCT03922828 303 310 O

Exclusion NCT03922828 311 320 O
Criteria NCT03922828 321 329 O
: NCT03922828 330 331 O

- NCT03922828 335 336 O
Subjects NCT03922828 338 346 O
who NCT03922828 347 350 O
no NCT03922828 351 353 B-Negation
radiographic NCT03922828 354 366 B-Procedure
evidence NCT03922828 367 375 O
of NCT03922828 376 378 O
lung NCT03922828 379 383 B-Condition
nodules NCT03922828 384 391 I-Condition
or NCT03922828 392 394 O
who NCT03922828 395 398 O
are NCT03922828 399 402 O
unwilling NCT03922828 403 412 O
/ NCT03922828 413 414 O
unable NCT03922828 415 421 O
to NCT03922828 422 424 O
provide NCT03922828 425 432 O
informed NCT03922828 433 441 O
consent NCT03922828 442 449 O

Inclusion NCT03926455 0 9 O
Criteria NCT03926455 10 18 O
: NCT03926455 19 20 O

- NCT03926455 24 25 O
Healthy NCT03926455 27 34 O
adult NCT03926455 35 40 O
men NCT03926455 41 44 O
or NCT03926455 45 47 B-Or
women NCT03926455 48 53 O
who NCT03926455 54 57 B-And
are NCT03926455 58 61 O
not NCT03926455 62 65 B-Negation
pregnant NCT03926455 66 74 B-Condition
or NCT03926455 75 77 O
planning NCT03926455 78 86 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926455 87 89 I-Assertion___Assertion-Type-Value:hypothetical
become NCT03926455 90 96 O
pregnant NCT03926455 97 105 B-Condition
during NCT03926455 106 112 B-Temporal-Connection___Temporal-Connection-Type-Value:during
study NCT03926455 113 118 B-Study
duration NCT03926455 119 127 O
aged NCT03926455 128 132 B-Age
18 NCT03926455 133 135 B-Eq-Comparison
to NCT03926455 136 138 I-Eq-Comparison
55 NCT03926455 139 141 O
years NCT03926455 142 147 O
. NCT03926455 148 149 O

- NCT03926455 153 154 O
Clinical NCT03926455 156 164 O
laboratory NCT03926455 165 175 B-Observation
parameters NCT03926455 176 186 I-Observation
within NCT03926455 187 193 O
normal NCT03926455 194 200 O
laboratory NCT03926455 201 211 O
limits NCT03926455 212 218 O
or NCT03926455 219 221 O
not NCT03926455 222 225 O
found NCT03926455 226 231 O
to NCT03926455 232 234 O
be NCT03926455 235 237 O
clinically NCT03926455 238 248 O
significant NCT03926455 249 260 O
by NCT03926455 261 263 O
the NCT03926455 264 267 O
PI NCT03926455 268 270 O

Exclusion NCT03926455 271 280 O
Criteria NCT03926455 281 289 O
: NCT03926455 290 291 O

- NCT03926455 295 296 O
Relevant NCT03926455 298 306 O
history NCT03926455 307 314 B-Eq-Comparison
of NCT03926455 315 317 O
physical NCT03926455 318 326 B-Modifier
or NCT03926455 327 329 B-Or
psychiatric NCT03926455 330 341 B-Modifier
illness NCT03926455 342 349 B-Condition
or NCT03926455 350 352 B-Or
medical NCT03926455 353 360 B-Condition
disorder NCT03926455 361 369 I-Condition
that NCT03926455 370 374 O
required NCT03926455 375 383 O
treatment NCT03926455 384 393 B-Procedure
. NCT03926455 394 395 O

- NCT03926455 399 400 O
Known NCT03926455 402 407 O
or NCT03926455 408 410 O
suspected NCT03926455 411 420 O
hypersensitivity NCT03926455 421 437 B-Condition
to NCT03926455 438 440 O
investigational NCT03926455 441 456 B-Study
product NCT03926455 457 464 B-Drug

- NCT03926455 467 468 O
Immunocompromised NCT03926455 470 487 B-Condition
subjects NCT03926455 488 496 O

- NCT03926455 499 500 O
Previous NCT03926455 502 510 B-Eq-Comparison
Typhoid NCT03926455 511 518 B-Procedure
vaccination NCT03926455 519 530 I-Procedure
or NCT03926455 531 533 B-Or
elevated NCT03926455 534 542 O
anti NCT03926455 543 547 B-Observation
- NCT03926455 548 549 I-Observation
Vi NCT03926455 550 552 I-Observation
antibodies NCT03926455 553 563 I-Observation
at NCT03926455 564 566 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03926455 567 576 B-Study

- NCT03926455 579 580 O
Known NCT03926455 582 587 O
history NCT03926455 588 595 B-Eq-Comparison
of NCT03926455 596 598 O
Typhoid NCT03926455 599 606 B-Condition
infection NCT03926455 607 616 I-Condition
in NCT03926455 617 619 O
the NCT03926455 620 623 O
previous NCT03926455 624 632 B-Eq-Comparison
6 NCT03926455 633 634 I-Eq-Comparison
months NCT03926455 635 641 I-Eq-Comparison

- NCT03926455 644 645 O
Positive NCT03926455 647 655 O
HIV NCT03926455 656 659 B-Condition
, NCT03926455 660 661 O
HBsAg NCT03926455 662 667 B-Condition
, NCT03926455 668 669 O
or NCT03926455 670 672 B-Or
HCV NCT03926455 673 676 B-Condition
screen NCT03926455 677 683 O

- NCT03926455 686 687 O
Any NCT03926455 689 692 O
other NCT03926455 693 698 O
condition NCT03926455 699 708 B-Condition
or NCT03926455 709 711 B-Or
abnormality NCT03926455 712 723 B-Condition
that NCT03926455 724 728 O
, NCT03926455 729 730 O
in NCT03926455 731 733 O
the NCT03926455 734 737 O
opinion NCT03926455 738 745 O
of NCT03926455 746 748 O
the NCT03926455 749 752 O
Investigator NCT03926455 753 765 O
, NCT03926455 766 767 O
may NCT03926455 768 771 B-Assertion___Assertion-Type-Value:hypothetical
compromise NCT03926455 772 782 O
the NCT03926455 783 786 O
safety NCT03926455 787 793 B-Observation
of NCT03926455 794 796 O
the NCT03926455 797 800 O
patients NCT03926455 801 809 O

Inclusion NCT03928444 0 9 O
Criteria NCT03928444 10 18 O
: NCT03928444 19 20 O

- NCT03928444 24 25 O
Clinically NCT03928444 27 37 O
diagnosed NCT03928444 38 47 O
facial NCT03928444 48 54 B-Condition
skin NCT03928444 55 59 I-Condition
aging NCT03928444 60 65 I-Condition
. NCT03928444 66 67 O

- NCT03928444 71 72 O
Glogau NCT03928444 74 80 B-Condition
photoaging NCT03928444 81 91 I-Condition
score NCT03928444 92 97 B-Eq-Comparison
II NCT03928444 98 100 I-Eq-Comparison
and NCT03928444 101 104 I-Eq-Comparison
III NCT03928444 105 108 I-Eq-Comparison
. NCT03928444 109 110 O

- NCT03928444 114 115 O
Body NCT03928444 117 121 B-Observation
mass NCT03928444 122 126 I-Observation
index NCT03928444 127 132 I-Observation
≥ NCT03928444 133 134 B-Eq-Comparison
20 NCT03928444 135 137 I-Eq-Comparison
with NCT03928444 138 142 B-And
adequate NCT03928444 143 151 O
abdominal NCT03928444 152 161 B-Modifier
or NCT03928444 162 164 B-Or
other NCT03928444 165 170 O
subcutaneous NCT03928444 171 183 B-Modifier
adipose NCT03928444 184 191 B-Observation
tissue NCT03928444 192 198 I-Observation
accessible NCT03928444 199 209 O
for NCT03928444 210 213 B-Assertion___Assertion-Type-Value:hypothetical
lipoaspiration NCT03928444 214 228 B-Procedure
. NCT03928444 229 230 O

Exclusion NCT03928444 232 241 O
Criteria NCT03928444 242 250 O
: NCT03928444 251 252 O

- NCT03928444 256 257 O
History NCT03928444 259 266 B-Eq-Comparison
of NCT03928444 267 269 O
keloid NCT03928444 270 276 B-Condition
formation NCT03928444 277 286 I-Condition
. NCT03928444 287 288 O

- NCT03928444 292 293 O
Any NCT03928444 295 298 O
coincidental NCT03928444 299 311 O
chronic NCT03928444 312 319 B-Modifier
illness NCT03928444 320 327 B-Condition
( NCT03928444 328 329 O
e. NCT03928444 330 332 O
g. NCT03928444 333 335 O
metabolic NCT03928444 337 346 B-Modifier
, NCT03928444 347 348 O
autoimmune NCT03928444 349 359 B-Modifier
or NCT03928444 360 362 B-Or
endocrinal NCT03928444 363 373 B-Modifier
) NCT03928444 374 375 O
or NCT03928444 376 378 B-Or
malignancy NCT03928444 379 389 B-Condition
. NCT03928444 390 391 O

- NCT03928444 395 396 O
Any NCT03928444 398 401 O
bleeding NCT03928444 402 410 B-Modifier
or NCT03928444 411 413 B-Or
coagulation NCT03928444 414 425 B-Modifier
disorder NCT03928444 426 434 B-Condition
or NCT03928444 435 437 B-Or
recent NCT03928444 438 444 B-Eq-Comparison
use NCT03928444 445 448 O
of NCT03928444 449 451 O
anticoagulant NCT03928444 452 465 B-Drug
therapy NCT03928444 466 473 I-Drug
. NCT03928444 474 475 O

- NCT03928444 479 480 O
Active NCT03928444 482 488 B-Eq-Comparison
infection NCT03928444 489 498 B-Condition
. NCT03928444 499 500 O

- NCT03928444 504 505 O
History NCT03928444 507 514 B-Eq-Comparison
of NCT03928444 515 517 I-Eq-Comparison
any NCT03928444 518 521 I-Eq-Comparison
previous NCT03928444 522 530 I-Eq-Comparison
aesthetic NCT03928444 531 540 B-Procedure
procedure NCT03928444 541 550 I-Procedure
on NCT03928444 551 553 O
the NCT03928444 554 557 O
face NCT03928444 558 562 B-Modifier
within NCT03928444 563 569 B-Eq-Comparison
the NCT03928444 570 573 I-Eq-Comparison
past NCT03928444 574 578 I-Eq-Comparison
6 NCT03928444 579 580 I-Eq-Comparison
months NCT03928444 581 587 I-Eq-Comparison
. NCT03928444 588 589 O

- NCT03928444 593 594 O
History NCT03928444 596 603 B-Eq-Comparison
of NCT03928444 604 606 O
intake NCT03928444 607 613 O
of NCT03928444 614 616 O
anti NCT03928444 617 621 B-Modifier
- NCT03928444 622 623 I-Modifier
aging NCT03928444 624 629 I-Modifier
systemic NCT03928444 630 638 I-Modifier
or NCT03928444 639 641 B-Or
topical NCT03928444 642 649 B-Modifier
medications NCT03928444 650 661 B-Drug
within NCT03928444 662 668 B-Eq-Comparison
the NCT03928444 669 672 I-Eq-Comparison
previous NCT03928444 673 681 I-Eq-Comparison
3 NCT03928444 682 683 I-Eq-Comparison
months NCT03928444 684 690 I-Eq-Comparison
. NCT03928444 690 691 O

Inclusion NCT03924518 0 9 O
Criteria NCT03924518 10 18 O
( NCT03924518 19 20 O
Only NCT03924518 21 25 O
patients NCT03924518 26 34 O
who NCT03924518 35 38 O
fully NCT03924518 39 44 O
meet NCT03924518 45 49 O
the NCT03924518 50 53 O
following NCT03924518 54 63 O
criteria NCT03924518 64 72 O
are NCT03924518 73 76 O
eligible NCT03924518 77 85 O
to NCT03924518 86 88 O

participate NCT03924518 89 100 O
in NCT03924518 101 103 O
the NCT03924518 104 107 O
trial NCT03924518 108 113 O
) NCT03924518 114 115 O
: NCT03924518 117 118 O

- NCT03924518 122 123 O
Meets NCT03924518 125 130 O
the NCT03924518 131 134 O
diagnostic NCT03924518 135 145 O
criteria NCT03924518 146 154 O
for NCT03924518 155 158 O
sepsis NCT03924518 159 165 B-Condition
- NCT03924518 166 167 O
3 NCT03924518 168 169 B-Eq-Comparison
developed NCT03924518 170 179 O
by NCT03924518 180 182 O
the NCT03924518 183 186 O
American NCT03924518 187 195 O
Society NCT03924518 196 203 O
of NCT03924518 204 206 O
Critical NCT03924518 207 215 O
Care NCT03924518 216 220 O
Medicine NCT03924518 221 229 O
( NCT03924518 230 231 O
SCCM NCT03924518 232 236 O
) NCT03924518 237 238 O
/ NCT03924518 240 241 O
European NCT03924518 242 250 O
Critical NCT03924518 251 259 O
Care NCT03924518 260 264 O
Medicine NCT03924518 265 273 O
Association NCT03924518 274 285 O
( NCT03924518 286 287 O
ESICM NCT03924518 288 293 O
) NCT03924518 294 295 O

- NCT03924518 299 300 O
Age NCT03924518 302 305 B-Age
≥ NCT03924518 306 307 B-Eq-Comparison
18 NCT03924518 308 310 I-Eq-Comparison
years NCT03924518 311 316 I-Eq-Comparison
old NCT03924518 317 320 O
and NCT03924518 321 324 B-And
age NCT03924518 325 328 B-Age
≤ NCT03924518 329 330 B-Eq-Comparison
80 NCT03924518 331 333 I-Eq-Comparison
years NCT03924518 334 339 O
old NCT03924518 340 343 O
. NCT03924518 344 345 O

- NCT03924518 349 350 O
Procalcitonin NCT03924518 352 365 B-Observation
≥ NCT03924518 366 367 B-Eq-Comparison
2 NCT03924518 368 369 I-Eq-Comparison
ng NCT03924518 370 372 I-Eq-Comparison
/ NCT03924518 373 374 I-Eq-Comparison
ml NCT03924518 375 377 I-Eq-Comparison

Exclusion NCT03924518 378 387 O
Criteria NCT03924518 388 396 O
: NCT03924518 397 398 O

- NCT03924518 402 403 O
Age NCT03924518 405 408 B-Age
＜ NCT03924518 409 410 B-Eq-Comparison
18 NCT03924518 411 413 I-Eq-Comparison
years NCT03924518 414 419 I-Eq-Comparison
, NCT03924518 420 421 O
or NCT03924518 422 424 B-Or
age NCT03924518 425 428 B-Age
＞ NCT03924518 429 430 B-Eq-Comparison
80 NCT03924518 431 433 I-Eq-Comparison
years NCT03924518 434 439 I-Eq-Comparison
. NCT03924518 440 441 O

- NCT03924518 445 446 O
Pregnancy NCT03924518 448 457 B-Condition
or NCT03924518 458 460 B-Or
lactating NCT03924518 461 470 B-Condition

- NCT03924518 473 474 O
A NCT03924518 476 477 O
solid NCT03924518 478 483 B-Modifier
- NCT03924518 484 485 I-Modifier
organ NCT03924518 486 491 I-Modifier
or NCT03924518 492 494 B-Or
bone NCT03924518 495 499 B-Modifier
marrow NCT03924518 500 506 I-Modifier
transplant NCT03924518 507 517 B-Procedure
patients NCT03924518 518 526 O
. NCT03924518 527 528 O

- NCT03924518 532 533 O
Patients NCT03924518 535 543 O
with NCT03924518 544 548 O
myocardial NCT03924518 549 559 B-Condition
infarction NCT03924518 560 570 I-Condition
within NCT03924518 571 577 B-Eq-Comparison
the NCT03924518 578 581 I-Eq-Comparison
past NCT03924518 582 586 I-Eq-Comparison
3 NCT03924518 587 588 I-Eq-Comparison
months NCT03924518 589 595 I-Eq-Comparison
. NCT03924518 596 597 O

- NCT03924518 601 602 O
Advanced NCT03924518 604 612 B-Condition
pulmonary NCT03924518 613 622 I-Condition
fibrosis NCT03924518 623 631 I-Condition
. NCT03924518 633 634 O

- NCT03924518 638 639 O
Patients NCT03924518 641 649 O
with NCT03924518 650 654 O
cardiopulmonary NCT03924518 655 670 B-Condition
resuscitation NCT03924518 671 684 I-Condition
before NCT03924518 685 691 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924518 692 702 B-Study
. NCT03924518 703 704 O

- NCT03924518 708 709 O
HIV NCT03924518 711 714 B-Condition
- NCT03924518 715 716 O
positive NCT03924518 717 725 O
patients NCT03924518 726 734 O
. NCT03924518 735 736 O

- NCT03924518 740 741 O
granulocyte NCT03924518 743 754 B-Condition
- NCT03924518 755 756 I-Condition
deficient NCT03924518 757 766 I-Condition
patients NCT03924518 767 775 O
. NCT03924518 776 777 O

- NCT03924518 781 782 O
blood NCT03924518 784 789 B-Modifier
/ NCT03924518 790 791 B-Or
lymphatic NCT03924518 792 801 B-Modifier
system NCT03924518 802 808 I-Modifier
tumors NCT03924518 809 815 B-Condition
are NCT03924518 816 819 O
not NCT03924518 820 823 B-Negation
remission NCT03924518 824 833 B-Modifier
. NCT03924518 834 835 O

- NCT03924518 839 840 O
patients NCT03924518 842 850 O
with NCT03924518 851 855 O
limited NCT03924518 856 863 B-Observation
care NCT03924518 864 868 I-Observation
( NCT03924518 869 870 O
lack NCT03924518 871 875 B-Negation
of NCT03924518 876 878 I-Negation
commitment NCT03924518 879 889 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924518 890 892 I-Assertion___Assertion-Type-Value:hypothetical
full NCT03924518 893 897 O
， NCT03924518 898 899 O
aggressive NCT03924518 900 910 O
life NCT03924518 911 915 B-Procedure
support NCT03924518 916 923 I-Procedure
) NCT03924518 924 925 O
. NCT03924518 927 928 O

- NCT03924518 932 933 O
patients NCT03924518 935 943 O
with NCT03924518 944 948 O
long NCT03924518 949 953 O
- NCT03924518 954 955 O
term NCT03924518 956 960 O
use NCT03924518 961 964 O
of NCT03924518 965 967 O
immunosuppressive NCT03924518 968 985 B-Drug
drugs NCT03924518 986 991 I-Drug
or NCT03924518 992 994 B-Or
with NCT03924518 995 999 O
immunodeficiency NCT03924518 1000 1016 B-Condition
. NCT03924518 1017 1018 O

- NCT03924518 1022 1023 O
patients NCT03924518 1025 1033 O
with NCT03924518 1034 1038 O
advanced NCT03924518 1039 1047 B-Condition
tumors NCT03924518 1048 1054 I-Condition
. NCT03924518 1055 1056 O

- NCT03924518 1060 1061 O
patients NCT03924518 1063 1071 O
combined NCT03924518 1072 1080 O
with NCT03924518 1081 1085 O
non NCT03924518 1086 1089 B-Negation
- NCT03924518 1090 1091 O
infectious NCT03924518 1092 1102 B-Condition
factors NCT03924518 1103 1110 I-Condition
leading NCT03924518 1111 1118 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924518 1119 1121 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03924518 1122 1125 O
death NCT03924518 1126 1131 B-Death
( NCT03924518 1132 1133 O
uncontrollable NCT03924518 1134 1148 B-Condition
major NCT03924518 1149 1154 I-Condition
bleeding NCT03924518 1155 1163 I-Condition
, NCT03924518 1164 1165 O
brain NCT03924518 1166 1171 B-Condition
hernia NCT03924518 1172 1178 B-Condition
, NCT03924518 1179 1180 O
etc NCT03924518 1181 1184 O
. NCT03924518 1184 1185 O
) NCT03924518 1186 1187 O
. NCT03924518 1189 1190 O

- NCT03924518 1194 1195 O
surgically NCT03924518 1197 1207 O
unresolved NCT03924518 1208 1218 B-Eq-Comparison
infection NCT03924518 1219 1228 B-Condition
sources NCT03924518 1229 1236 O
( NCT03924518 1237 1238 O
such NCT03924518 1239 1243 O
as NCT03924518 1244 1246 O
some NCT03924518 1247 1251 O
intraperitoneal NCT03924518 1252 1267 B-Condition
infection NCT03924518 1268 1277 I-Condition
etc NCT03924518 1278 1281 O
. NCT03924518 1281 1282 O
) NCT03924518 1283 1284 O

- NCT03924518 1288 1289 O
patients NCT03924518 1291 1299 O
allergic NCT03924518 1300 1308 B-Allergy
to NCT03924518 1309 1311 O
granisetron NCT03924518 1312 1323 O
. NCT03924518 1324 1325 O

- NCT03924518 1329 1330 O
patients NCT03924518 1332 1340 O
with NCT03924518 1341 1345 O
intestinal NCT03924518 1346 1356 B-Condition
obstruction NCT03924518 1357 1368 I-Condition
. NCT03924518 1368 1369 O

Inclusion NCT03926858 0 9 O
Criteria NCT03926858 10 18 O
: NCT03926858 19 20 O

- NCT03926858 24 25 O
18 NCT03926858 27 29 B-Eq-Comparison
years NCT03926858 30 35 I-Eq-Comparison
or NCT03926858 36 38 I-Eq-Comparison
older NCT03926858 39 44 I-Age|Eq-Comparison

- NCT03926858 47 48 O
Undergoing NCT03926858 50 60 B-Eq-Comparison
general NCT03926858 61 68 B-Modifier
or NCT03926858 69 71 B-Or
regional NCT03926858 72 80 B-Modifier
anesthesia NCT03926858 81 91 B-Procedure

- NCT03926858 94 95 O
Hospitalized NCT03926858 97 109 B-Encounter
for NCT03926858 110 113 O
at NCT03926858 114 116 B-Eq-Comparison
least NCT03926858 117 122 I-Eq-Comparison
24 NCT03926858 123 125 I-Eq-Comparison
hours NCT03926858 126 131 I-Eq-Comparison
after NCT03926858 132 137 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03926858 138 145 B-Procedure

- NCT03926858 148 149 O
Able NCT03926858 151 155 O
to NCT03926858 156 158 O
give NCT03926858 159 163 O
informed NCT03926858 164 172 O
consent NCT03926858 173 180 O

- NCT03926858 183 184 O
Able NCT03926858 186 190 O
to NCT03926858 191 193 O
read NCT03926858 194 198 O
and NCT03926858 199 202 O
write NCT03926858 203 208 O

Exclusion NCT03926858 209 218 O
Criteria NCT03926858 219 227 O
: NCT03926858 228 229 O

- NCT03926858 233 234 O
Existing NCT03926858 236 244 B-Eq-Comparison
diagnoses NCT03926858 245 254 O
of NCT03926858 255 257 O
psychiatric NCT03926858 258 269 B-Modifier
or NCT03926858 270 272 B-Or
neurologic NCT03926858 273 283 B-Modifier
pathology NCT03926858 284 293 B-Condition

- NCT03926858 296 297 O
A NCT03926858 299 300 O
history NCT03926858 301 308 B-Eq-Comparison
of NCT03926858 309 311 O
substance NCT03926858 312 321 B-Condition
abuse NCT03926858 322 327 I-Condition

- NCT03926858 330 331 O
Admitted NCT03926858 333 341 B-Encounter
to NCT03926858 342 344 O
ICU NCT03926858 345 348 O
after NCT03926858 349 354 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03926858 355 362 B-Procedure

Inclusion NCT03925389 0 9 O
Criteria NCT03925389 10 18 O
: NCT03925389 19 20 O

- NCT03925389 24 25 O
at NCT03925389 27 29 B-Eq-Comparison
least NCT03925389 30 35 I-Eq-Comparison
18 NCT03925389 36 38 I-Eq-Comparison
years NCT03925389 39 44 I-Eq-Comparison
old NCT03925389 45 48 B-Age

- NCT03925389 51 52 O
Patients NCT03925389 54 62 O
eligible NCT03925389 63 71 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925389 72 75 I-Assertion___Assertion-Type-Value:hypothetical
external NCT03925389 76 84 B-Procedure
septorhinoplasty NCT03925389 85 101 I-Procedure
: NCT03925389 102 103 O
patients NCT03925389 104 112 O
seen NCT03925389 113 117 O
in NCT03925389 118 120 O
consultation NCT03925389 121 133 O
because NCT03925389 134 141 O
of NCT03925389 142 144 O
nasal NCT03925389 145 150 B-Condition
obstruction NCT03925389 151 162 I-Condition
were NCT03925389 163 167 O
evaluated NCT03925389 168 177 B-Assertion___Assertion-Type-Value:possible
. NCT03925389 177 178 O
Patients NCT03925389 180 188 O
who NCT03925389 189 192 O
had NCT03925389 193 196 O
symptoms NCT03925389 197 205 B-Assertion___Assertion-Type-Value:possible
of NCT03925389 206 208 O
nasal NCT03925389 209 214 B-Condition
obstruction NCT03925389 215 226 I-Condition
for NCT03925389 227 230 O
at NCT03925389 231 233 B-Eq-Comparison
least NCT03925389 234 239 I-Eq-Comparison
1 NCT03925389 240 241 I-Eq-Comparison
year NCT03925389 242 246 I-Eq-Comparison
that NCT03925389 247 251 O
were NCT03925389 252 256 O
the NCT03925389 257 260 O
result NCT03925389 261 267 O
of NCT03925389 268 270 O
an NCT03925389 271 273 O
identifiable NCT03925389 274 286 O
anatomical NCT03925389 287 297 B-Condition
cause NCT03925389 298 303 I-Condition
such NCT03925389 304 308 O
as NCT03925389 309 311 O
septal NCT03925389 312 318 B-Condition
deviation NCT03925389 319 328 I-Condition
, NCT03925389 329 330 O
turbinate NCT03925389 331 340 B-Condition
hypertrophy NCT03925389 341 352 I-Condition
, NCT03925389 353 354 O
internal NCT03925389 355 363 B-Condition
valve NCT03925389 364 369 I-Condition
collapse NCT03925389 370 378 I-Condition
, NCT03925389 379 380 O
or NCT03925389 381 383 B-Or
external NCT03925389 384 392 B-Condition
valve NCT03925389 393 398 I-Condition
collapse NCT03925389 399 407 I-Condition
were NCT03925389 408 412 O
included NCT03925389 413 421 O
in NCT03925389 422 424 O
the NCT03925389 425 428 O
study NCT03925389 429 434 O
. NCT03925389 435 436 O

Exclusion NCT03925389 438 447 O
Criteria NCT03925389 448 456 O
: NCT03925389 457 458 O

- NCT03925389 462 463 O
< NCT03925389 465 466 B-Eq-Comparison
18 NCT03925389 467 469 I-Eq-Comparison
years NCT03925389 470 475 I-Age|Eq-Comparison

- NCT03925389 478 479 O
mental NCT03925389 481 487 B-Modifier
or NCT03925389 488 490 B-Or
physical NCT03925389 491 499 B-Modifier
incapacity NCT03925389 500 510 B-Condition
to NCT03925389 511 513 O
answer NCT03925389 514 520 O
the NCT03925389 521 524 O
questionnaires NCT03925389 525 539 O

- NCT03925389 542 543 O
nasal NCT03925389 545 550 B-Condition
fracture NCT03925389 551 559 I-Condition
or NCT03925389 560 562 B-Or
surgery NCT03925389 563 570 B-Procedure
in NCT03925389 571 573 O
the NCT03925389 574 577 O
past NCT03925389 578 582 B-Eq-Comparison
year NCT03925389 583 587 I-Eq-Comparison

- NCT03925389 590 591 O
nasal NCT03925389 593 598 B-Modifier
cocaine NCT03925389 599 606 B-Drug
use NCT03925389 607 610 O
in NCT03925389 611 613 O
the NCT03925389 614 617 O
past NCT03925389 618 622 B-Eq-Comparison
year NCT03925389 623 627 I-Eq-Comparison

Inclusion NCT03923920 0 9 O
Criteria NCT03923920 10 18 O
: NCT03923920 19 20 O

- NCT03923920 24 25 O
Age NCT03923920 27 30 B-Age
≥ NCT03923920 31 32 B-Eq-Comparison
50 NCT03923920 33 35 I-Eq-Comparison
years NCT03923920 36 41 I-Eq-Comparison

- NCT03923920 44 45 O
Undergoing NCT03923920 47 57 B-Eq-Comparison
surgical NCT03923920 58 66 B-Procedure
intervention NCT03923920 67 79 I-Procedure
for NCT03923920 80 83 O
non NCT03923920 84 87 B-Modifier
- NCT03923920 88 89 I-Modifier
congenital NCT03923920 90 100 I-Modifier
spinal NCT03923920 101 107 B-Condition
stenosis NCT03923920 108 116 I-Condition
and NCT03923920 117 120 B-Or
/ NCT03923920 121 122 I-Or
or NCT03923920 123 125 I-Or
spondyloarthropathy NCT03923920 126 145 B-Condition

- NCT03923920 148 149 O
Able NCT03923920 151 155 O
to NCT03923920 156 158 O
consent NCT03923920 159 166 O

Exclusion NCT03923920 167 176 O
Criteria NCT03923920 177 185 O
: NCT03923920 186 187 O

- NCT03923920 191 192 O
History NCT03923920 194 201 B-Eq-Comparison
of NCT03923920 202 204 O
congenital NCT03923920 205 215 B-Condition
spinal NCT03923920 216 222 I-Condition
stenosis NCT03923920 223 231 I-Condition
or NCT03923920 232 234 B-Or
congenital NCT03923920 235 245 B-Condition
spondyloarthropathy NCT03923920 246 265 I-Condition

Inclusion NCT03928691 0 9 O
criteria NCT03928691 10 18 O
: NCT03928691 19 20 O

pregnant NCT03928691 22 30 B-Condition
women NCT03928691 31 36 O
34 NCT03928691 37 39 B-Eq-Comparison
weeks NCT03928691 40 45 I-Eq-Comparison
or NCT03928691 46 48 I-Eq-Comparison
less NCT03928691 49 53 I-Eq-Comparison
admitted NCT03928691 54 62 B-Encounter
to NCT03928691 63 65 O
Women NCT03928691 66 71 O
's NCT03928691 71 73 O
Health NCT03928691 74 80 O
Hospital NCT03928691 81 89 O
with NCT03928691 90 94 O
a NCT03928691 95 96 O
diagnosis NCT03928691 97 106 O
of NCT03928691 107 109 O
: NCT03928691 110 111 O

- NCT03928691 115 116 O
sever NCT03928691 118 123 O
preeclampsia NCT03928691 124 136 B-Condition
. NCT03928691 136 137 O
It NCT03928691 139 141 O
is NCT03928691 142 144 O
defined NCT03928691 145 152 O
as NCT03928691 153 155 O
1 NCT03928691 156 157 O
- NCT03928691 158 159 O
blood NCT03928691 160 165 B-Observation
pressure NCT03928691 166 174 I-Observation
160 NCT03928691 175 178 B-Eq-Comparison
/ NCT03928691 179 180 I-Eq-Comparison
110 NCT03928691 181 184 I-Eq-Comparison
mmHg NCT03928691 185 189 I-Eq-Comparison
or NCT03928691 190 192 I-Eq-Comparison
more NCT03928691 193 197 I-Eq-Comparison
2 NCT03928691 198 199 O
- NCT03928691 200 201 O
proteinurea NCT03928691 202 213 B-Observation
( NCT03928691 214 215 O
+ NCT03928691 217 218 B-Eq-Comparison
3 NCT03928691 219 220 I-Eq-Comparison
or NCT03928691 221 223 I-Eq-Comparison
more NCT03928691 224 228 I-Eq-Comparison
by NCT03928691 229 231 O
dipstick NCT03928691 232 240 O
) NCT03928691 241 242 O
3 NCT03928691 243 244 B-Condition
- NCT03928691 245 246 I-Condition
HELLP NCT03928691 247 252 I-Condition
syndrome NCT03928691 253 261 I-Condition

- NCT03928691 264 265 O
threatened NCT03928691 267 277 B-Assertion___Assertion-Type-Value:possible
preterm NCT03928691 278 285 B-Condition
labour NCT03928691 286 292 I-Condition
that NCT03928691 293 297 O
will NCT03928691 298 302 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03928691 303 310 O
Magnesium NCT03928691 311 320 B-Drug
Sulphate NCT03928691 321 329 I-Drug
either NCT03928691 330 336 O
for NCT03928691 337 340 O
tocolysis NCT03928691 341 350 O
or NCT03928691 351 353 O
neuroprotection NCT03928691 354 369 O
. NCT03928691 370 371 O

Exclusion NCT03928691 373 382 O
criteria NCT03928691 383 391 O
: NCT03928691 392 393 O

- NCT03928691 396 397 O
women NCT03928691 398 403 O
with NCT03928691 404 408 B-And
more NCT03928691 409 413 B-Eq-Comparison
than NCT03928691 414 418 I-Eq-Comparison
34 NCT03928691 419 421 I-Eq-Comparison
weeks NCT03928691 422 427 I-Eq-Comparison
gestation NCT03928691 428 437 B-Observation
and NCT03928691 438 441 B-And
with NCT03928691 442 446 O
any NCT03928691 447 450 O
contraindication NCT03928691 451 467 B-Contraindication
for NCT03928691 468 471 O
Magnesium NCT03928691 472 481 B-Drug
Sulphate NCT03928691 482 490 I-Drug
intake NCT03928691 491 497 O
like NCT03928691 498 502 O
severe NCT03928691 503 509 O
renal NCT03928691 510 515 B-Condition
impairment NCT03928691 516 526 I-Condition
or NCT03928691 527 529 B-Or
myasthenia NCT03928691 530 540 B-Condition
gravis NCT03928691 541 547 I-Condition
. NCT03928691 548 549 O


Inclusion NCT03922425 0 9 O
Criteria NCT03922425 10 18 O
: NCT03922425 19 20 O

- NCT03922425 24 25 O
Age NCT03922425 27 30 B-Age
18 NCT03922425 31 33 B-Eq-Comparison
- NCT03922425 34 35 I-Eq-Comparison
65 NCT03922425 36 38 O

- NCT03922425 42 43 O
Current NCT03922425 45 52 B-Eq-Comparison
service NCT03922425 53 60 B-Encounter
users NCT03922425 61 66 I-Encounter
, NCT03922425 67 68 O
with NCT03922425 69 73 B-And
severe NCT03922425 74 80 O
and NCT03922425 81 84 B-And
enduring NCT03922425 85 93 B-Modifier
mental NCT03922425 94 100 B-Condition
disorder NCT03922425 101 109 I-Condition
, NCT03922425 110 111 O

- NCT03922425 115 116 O
Severe NCT03922425 118 124 O
Mental NCT03922425 125 131 B-Condition
Illnesses NCT03922425 132 141 I-Condition
- NCT03922425 142 143 O
bipolar NCT03922425 144 151 B-Condition
disorder NCT03922425 152 160 I-Condition
, NCT03922425 161 162 O
severe NCT03922425 163 169 B-Condition
depression NCT03922425 170 180 I-Condition
, NCT03922425 181 182 O
or NCT03922425 183 185 B-Or
schizophrenia NCT03922425 186 199 B-Condition

Exclusion NCT03922425 200 209 O
Criteria NCT03922425 210 218 O
: NCT03922425 219 220 O

- NCT03922425 224 225 O
Patients NCT03922425 227 235 O
who NCT03922425 236 239 O
do NCT03922425 240 242 O
not NCT03922425 243 246 O
consent NCT03922425 247 254 O
to NCT03922425 255 257 O
their NCT03922425 258 263 O
data NCT03922425 264 268 O
being NCT03922425 269 274 O
collected NCT03922425 275 284 O

- NCT03922425 287 288 O
Patients NCT03922425 290 298 O
with NCT03922425 299 303 O
acute NCT03922425 304 309 O
somatic NCT03922425 310 317 B-Condition
disorders NCT03922425 318 327 I-Condition

- NCT03922425 330 331 O
Patients NCT03922425 333 341 O
who NCT03922425 342 345 O
are NCT03922425 346 349 O
under NCT03922425 350 355 B-Eq-Comparison
the NCT03922425 356 359 I-Eq-Comparison
age NCT03922425 360 363 I-Eq-Comparison
of NCT03922425 364 366 I-Eq-Comparison
18 NCT03922425 367 369 I-Eq-Comparison
at NCT03922425 370 372 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922425 373 376 O
start NCT03922425 377 382 O
of NCT03922425 383 385 O
the NCT03922425 386 389 O
study NCT03922425 390 395 B-Study
. NCT03922425 395 396 O

Inclusion NCT03921892 0 9 O
Criteria NCT03921892 10 18 O
: NCT03921892 19 20 O

- NCT03921892 24 25 O
age NCT03921892 27 30 B-Age
15 NCT03921892 31 33 B-Eq-Comparison
to NCT03921892 34 36 I-Eq-Comparison
21 NCT03921892 37 39 O
, NCT03921892 40 41 O

- NCT03921892 46 47 O
be NCT03921892 49 51 O
able NCT03921892 52 56 O
to NCT03921892 57 59 O
read NCT03921892 60 64 O
and NCT03921892 65 68 O
understand NCT03921892 69 79 O
English NCT03921892 80 87 O
( NCT03921892 88 89 O
as NCT03921892 90 92 O
determined NCT03921892 93 103 O
by NCT03921892 104 106 O
having NCT03921892 107 113 O
the NCT03921892 114 117 O
individual NCT03921892 118 128 O
read NCT03921892 129 133 O
a NCT03921892 134 135 O
brief NCT03921892 136 141 O
, NCT03921892 142 143 O
eighth NCT03921892 144 150 O
grade NCT03921892 151 156 O
reading NCT03921892 157 164 O
level NCT03921892 165 170 O
paragraph NCT03921892 171 180 O
) NCT03921892 181 182 O
, NCT03921892 184 185 O

- NCT03921892 189 190 O
able NCT03921892 192 196 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921892 197 199 I-Assertion___Assertion-Type-Value:hypothetical
begin NCT03921892 200 205 O
the NCT03921892 206 209 O
intervention NCT03921892 210 222 B-Study
within NCT03921892 223 229 B-Eq-Comparison
six NCT03921892 230 233 I-Eq-Comparison
weeks NCT03921892 234 239 I-Eq-Comparison
of NCT03921892 240 242 B-Temporal-Connection___Temporal-Connection-Type-Value:after
their NCT03921892 243 248 O
infant NCT03921892 249 255 B-Family-Member___Family-Member-Type:child
's NCT03921892 255 257 I-Family-Member___Family-Member-Type:child
birth NCT03921892 258 263 B-Birth
, NCT03921892 264 265 O

- NCT03921892 269 270 O
be NCT03921892 272 274 O
able NCT03921892 275 279 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921892 280 282 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03921892 283 294 O
in NCT03921892 295 297 O
an NCT03921892 298 300 O
intervention NCT03921892 301 313 B-Study
over NCT03921892 314 318 B-Eq-Comparison
two NCT03921892 319 322 I-Eq-Comparison
weeks NCT03921892 323 328 I-Eq-Comparison
, NCT03921892 329 330 O
requiring NCT03921892 331 340 O
approximately NCT03921892 341 354 O
a NCT03921892 355 356 O
12 NCT03921892 357 359 O
- NCT03921892 360 361 O
hour NCT03921892 362 366 O
time NCT03921892 367 371 O
commitment NCT03921892 372 382 O
: NCT03921892 383 384 O
either NCT03921892 385 391 O
in NCT03921892 392 394 O
- NCT03921892 395 396 O
person NCT03921892 397 403 O
on NCT03921892 404 406 O
two NCT03921892 407 410 O
Saturdays NCT03921892 411 420 O
for NCT03921892 421 424 O
six NCT03921892 425 428 O
hours NCT03921892 429 434 O
each NCT03921892 435 439 O
, NCT03921892 440 441 O
or NCT03921892 442 444 O
a NCT03921892 445 446 O
self NCT03921892 447 451 O
- NCT03921892 452 453 O
paced NCT03921892 454 459 O
content NCT03921892 460 467 O
of NCT03921892 468 470 O
videos NCT03921892 471 477 O
and NCT03921892 478 481 O
resource NCT03921892 482 490 O
materials NCT03921892 491 500 O
over NCT03921892 501 505 O
two NCT03921892 506 509 O
weeks NCT03921892 510 515 O
, NCT03921892 516 517 O

- NCT03921892 521 522 O
own NCT03921892 524 527 O
or NCT03921892 528 530 O
have NCT03921892 531 535 O
access NCT03921892 536 542 O
to NCT03921892 543 545 O
a NCT03921892 546 547 O
device NCT03921892 548 554 O
with NCT03921892 555 559 O
internet NCT03921892 560 568 O
access NCT03921892 569 575 O
and NCT03921892 576 579 O

- NCT03921892 582 583 O
have NCT03921892 585 589 O
a NCT03921892 590 591 O
working NCT03921892 592 599 O
e NCT03921892 600 601 O
- NCT03921892 602 603 O
mail NCT03921892 604 608 O
address NCT03921892 609 616 O
. NCT03921892 617 618 O

Exclusion NCT03921892 620 629 O
Criteria NCT03921892 630 638 O
: NCT03921892 639 640 O

- NCT03921892 644 645 O
Any NCT03921892 647 650 O
condition NCT03921892 651 660 B-Condition
that NCT03921892 661 665 O
might NCT03921892 666 671 B-Assertion___Assertion-Type-Value:possible
prevent NCT03921892 672 679 B-Negation
the NCT03921892 680 683 O
father NCT03921892 684 690 B-Family-Member___Family-Member-Type:father
's NCT03921892 690 692 I-Family-Member___Family-Member-Type:father
infant NCT03921892 693 699 B-Family-Member___Family-Member-Type:child
from NCT03921892 700 704 O
reaching NCT03921892 705 713 O
normal NCT03921892 714 720 O
developmental NCT03921892 721 734 B-Observation
milestones NCT03921892 735 745 I-Observation
will NCT03921892 746 750 O
participation NCT03921892 751 764 O
, NCT03921892 765 766 O
including NCT03921892 767 776 O
congenital NCT03921892 777 787 B-Condition
malformations NCT03921892 788 801 I-Condition
or NCT03921892 802 804 B-Or
prematurity NCT03921892 805 816 B-Condition
requiring NCT03921892 817 826 O
prolonged NCT03921892 827 836 O
/ NCT03921892 837 838 O
ongoing NCT03921892 839 846 B-Eq-Comparison
infant NCT03921892 847 853 B-Family-Member___Family-Member-Type:child
hospitalization NCT03921892 854 869 B-Encounter
. NCT03921892 870 871 O


Inclusion NCT03924726 0 9 O
Criteria NCT03924726 10 18 O
: NCT03924726 19 20 O

- NCT03924726 24 25 O
Aged NCT03924726 27 31 B-Age
18 NCT03924726 32 34 B-Eq-Comparison
years NCT03924726 35 40 I-Eq-Comparison
and NCT03924726 41 44 I-Eq-Comparison
above NCT03924726 45 50 I-Eq-Comparison
at NCT03924726 51 53 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924726 54 57 I-Temporal-Connection___Temporal-Connection-Type-Value:during
start NCT03924726 58 63 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03924726 64 66 O
the NCT03924726 67 70 O
treatment NCT03924726 71 80 B-Study
. NCT03924726 81 82 O

- NCT03924726 86 87 O
Molar NCT03924726 89 94 B-Condition
relationship NCT03924726 95 107 I-Condition
either NCT03924726 108 114 O
Class NCT03924726 115 120 B-Eq-Comparison
I NCT03924726 121 122 I-Eq-Comparison
, NCT03924726 123 124 O
< NCT03924726 125 126 B-Eq-Comparison
½ NCT03924726 127 128 I-Eq-Comparison
unit NCT03924726 129 133 I-Eq-Comparison
Class NCT03924726 134 139 I-Eq-Comparison
II NCT03924726 140 142 I-Eq-Comparison
or NCT03924726 143 145 B-Or
Class NCT03924726 146 151 B-Eq-Comparison
III NCT03924726 152 155 I-Eq-Comparison
. NCT03924726 156 157 O

- NCT03924726 161 162 O
Extraction NCT03924726 164 174 B-Procedure
of NCT03924726 175 177 I-Procedure
all NCT03924726 178 181 I-Procedure
four NCT03924726 182 186 I-Procedure
first NCT03924726 187 192 I-Procedure
premolar NCT03924726 193 201 I-Procedure
teeth NCT03924726 202 207 I-Procedure
as NCT03924726 208 210 O
part NCT03924726 211 215 O
of NCT03924726 216 218 O
orthodontic NCT03924726 219 230 B-Procedure
treatment NCT03924726 231 240 I-Procedure
. NCT03924726 241 242 O

- NCT03924726 246 247 O
Maximum NCT03924726 249 256 B-Procedure
anchorage NCT03924726 257 266 I-Procedure
required NCT03924726 267 275 O
using NCT03924726 276 281 O
mini NCT03924726 282 286 B-Procedure
- NCT03924726 287 288 I-Procedure
implant NCT03924726 289 296 I-Procedure
. NCT03924726 297 298 O

- NCT03924726 302 303 O
No NCT03924726 305 307 B-Negation
systemic NCT03924726 308 316 B-Condition
disease NCT03924726 317 324 I-Condition
. NCT03924726 325 326 O

- NCT03924726 330 331 O
Good NCT03924726 333 337 O
oral NCT03924726 338 342 O
hygiene NCT03924726 343 350 O
. NCT03924726 351 352 O

- NCT03924726 356 357 O
No NCT03924726 359 361 B-Negation
periodontal NCT03924726 362 373 B-Condition
disease NCT03924726 374 381 I-Condition
. NCT03924726 382 383 O

Exclusion NCT03924726 385 394 O
Criteria NCT03924726 395 403 O
: NCT03924726 404 405 O

- NCT03924726 409 410 O
Significant NCT03924726 412 423 O
vertical NCT03924726 424 432 B-Condition
skeletal NCT03924726 433 441 I-Condition
discrepancies NCT03924726 442 455 I-Condition
. NCT03924726 456 457 O

- NCT03924726 461 462 O
Systemic NCT03924726 464 472 B-Condition
diseases NCT03924726 473 481 I-Condition
requiring NCT03924726 482 491 B-Assertion___Assertion-Type-Value:hypothetical
long NCT03924726 492 496 O
- NCT03924726 497 498 O
term NCT03924726 499 503 O
antibiotic NCT03924726 504 514 B-Drug
use NCT03924726 515 518 O
, NCT03924726 519 520 O
phenytoin NCT03924726 521 530 B-Drug
, NCT03924726 531 532 O
cyclosporin NCT03924726 533 544 B-Drug
, NCT03924726 545 546 O
anti NCT03924726 547 551 B-Drug
- NCT03924726 552 553 I-Drug
inflammatory NCT03924726 554 566 I-Drug
drugs NCT03924726 567 572 I-Drug
, NCT03924726 573 574 O
bisphosphonates NCT03924726 575 590 B-Drug
, NCT03924726 591 592 O
systemic NCT03924726 593 601 B-Drug
corticosteroids NCT03924726 602 617 I-Drug
or NCT03924726 618 620 B-Or
calcium NCT03924726 621 628 B-Drug
channel NCT03924726 629 636 I-Drug
blockers NCT03924726 637 645 I-Drug
. NCT03924726 646 647 O

- NCT03924726 651 652 O
Poor NCT03924726 654 658 B-Condition
oral NCT03924726 659 663 I-Condition
hygiene NCT03924726 664 671 I-Condition
. NCT03924726 672 673 O

- NCT03924726 677 678 O
Active NCT03924726 680 686 B-Eq-Comparison
periodontal NCT03924726 687 698 B-Condition
disease NCT03924726 699 706 I-Condition
. NCT03924726 707 708 O


Inclusion NCT03923049 0 9 O
Criteria NCT03923049 10 18 O
: NCT03923049 19 20 O

1 NCT03923049 22 23 O
. NCT03923049 23 24 O
Subjects NCT03923049 25 33 O
older NCT03923049 34 39 B-Eq-Comparison
than NCT03923049 40 44 I-Eq-Comparison
18 NCT03923049 45 47 I-Eq-Comparison
years NCT03923049 48 53 I-Eq-Comparison
of NCT03923049 54 56 O
age NCT03923049 57 60 B-Age
with NCT03923049 61 65 B-And
high NCT03923049 66 70 O
suspicion NCT03923049 71 80 B-Assertion___Assertion-Type-Value:possible
of NCT03923049 81 83 O
cardiac NCT03923049 84 91 B-Condition
sarcoidosis NCT03923049 92 103 I-Condition
and NCT03923049 104 107 B-Or
/ NCT03923049 108 109 I-Or
or NCT03923049 110 112 I-Or

biopsy NCT03923049 113 119 B-Procedure
proven NCT03923049 120 126 O
extracardiac NCT03923049 127 139 B-Condition
sarcoidosis NCT03923049 140 151 I-Condition
and NCT03923049 152 155 B-Or
/ NCT03923049 156 157 I-Or
or NCT03923049 158 160 I-Or
positive NCT03923049 161 169 O
HRS NCT03923049 170 173 B-Condition
criteria NCT03923049 174 182 O
will NCT03923049 183 187 O
be NCT03923049 188 190 O
enrolled NCT03923049 191 199 O
. NCT03923049 200 201 O

Exclusion NCT03923049 203 212 O
Criteria NCT03923049 213 221 O
: NCT03923049 222 223 O

1 NCT03923049 227 228 O
. NCT03923049 228 229 O
Coronary NCT03923049 231 239 B-Condition
artery NCT03923049 240 246 I-Condition
disease NCT03923049 247 254 I-Condition

2 NCT03923049 257 258 O
. NCT03923049 258 259 O
Insulin NCT03923049 261 268 B-Modifier
dependent NCT03923049 269 278 I-Modifier
diabetes NCT03923049 279 287 B-Condition

3 NCT03923049 290 291 O
. NCT03923049 291 292 O
Claustrophobia NCT03923049 294 308 B-Condition

4 NCT03923049 311 312 O
. NCT03923049 312 313 O
Pregnancy NCT03923049 315 324 B-Condition
/ NCT03923049 325 326 B-Or
nursing NCT03923049 327 334 B-Condition

5 NCT03923049 337 338 O
. NCT03923049 338 339 O
Presence NCT03923049 341 349 O
of NCT03923049 350 352 O
pacemaker NCT03923049 353 362 B-Procedure
or NCT03923049 363 365 B-Or
automatic NCT03923049 366 375 B-Procedure
implantable NCT03923049 376 387 I-Procedure
cardioverter NCT03923049 388 400 I-Procedure
- NCT03923049 401 402 I-Procedure
defibrillator NCT03923049 403 416 I-Procedure

6 NCT03923049 419 420 O
. NCT03923049 420 421 O
Impaired NCT03923049 423 431 B-Condition
renal NCT03923049 432 437 I-Condition
function NCT03923049 438 446 I-Condition
( NCT03923049 447 448 O
estimated NCT03923049 449 458 B-Observation
glomerular NCT03923049 459 469 I-Observation
filtration NCT03923049 470 480 I-Observation
rate NCT03923049 481 485 I-Observation
< NCT03923049 486 487 B-Eq-Comparison
45 NCT03923049 488 490 I-Eq-Comparison
ml NCT03923049 491 493 I-Eq-Comparison
/ NCT03923049 494 495 I-Eq-Comparison
min NCT03923049 496 499 I-Eq-Comparison
/ NCT03923049 500 501 I-Eq-Comparison
1.73 NCT03923049 502 506 I-Eq-Comparison
m2 NCT03923049 507 509 I-Eq-Comparison
) NCT03923049 510 511 O
will NCT03923049 512 516 O
be NCT03923049 517 519 O
excluded NCT03923049 520 528 O
. NCT03923049 529 530 O

7 NCT03923049 534 535 O
. NCT03923049 535 536 O
Inability NCT03923049 538 547 B-Negation
to NCT03923049 548 550 O
undergo NCT03923049 551 558 B-Assertion___Assertion-Type-Value:hypothetical
PET NCT03923049 559 562 B-Procedure
/ NCT03923049 563 564 B-Or
MRI NCT03923049 565 568 B-Procedure
due NCT03923049 569 572 O
to NCT03923049 573 575 O
any NCT03923049 576 579 O
other NCT03923049 580 585 O
condition NCT03923049 586 595 B-Condition
. NCT03923049 595 596 O

Inclusion NCT03920540 0 9 O
Criteria NCT03920540 10 18 O
: NCT03920540 19 20 O

- NCT03920540 24 25 O
Patients NCT03920540 27 35 O
diagnosed NCT03920540 36 45 O
with NCT03920540 46 50 O
Hunter NCT03920540 51 57 B-Condition
syndrome NCT03920540 58 66 I-Condition

- NCT03920540 69 70 O
Male NCT03920540 72 76 O
at NCT03920540 77 79 B-And
the NCT03920540 80 83 O
age NCT03920540 84 87 B-Age
of NCT03920540 88 90 O
≥ NCT03920540 91 92 B-Eq-Comparison
5 NCT03920540 93 94 I-Eq-Comparison

- NCT03920540 98 99 O
Adequate NCT03920540 101 109 O
abilities NCT03920540 110 119 O
( NCT03920540 120 121 O
including NCT03920540 122 131 O
6 NCT03920540 132 133 B-Observation
- NCT03920540 134 135 I-Observation
MWT NCT03920540 136 139 I-Observation
) NCT03920540 140 141 O
to NCT03920540 142 144 O
participate NCT03920540 145 156 O
in NCT03920540 157 159 O
this NCT03920540 160 164 O
study NCT03920540 165 170 O
in NCT03920540 171 173 O
the NCT03920540 174 177 O
opinion NCT03920540 178 185 O
of NCT03920540 186 188 O
the NCT03920540 189 192 O
investigator NCT03920540 193 205 O
. NCT03920540 206 207 O

- NCT03920540 211 212 O
Voluntarily NCT03920540 214 225 O
signed NCT03920540 226 232 O
written NCT03920540 233 240 O
informed NCT03920540 241 249 O
consent NCT03920540 250 257 O
to NCT03920540 258 260 O
participation NCT03920540 261 274 O
in NCT03920540 275 277 O
this NCT03920540 278 282 O
study NCT03920540 283 288 O

- NCT03920540 291 292 O
Consent NCT03920540 294 301 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920540 302 304 I-Assertion___Assertion-Type-Value:hypothetical
contraception NCT03920540 305 318 B-Procedure

Exclusion NCT03920540 319 328 O
Criteria NCT03920540 329 337 O
: NCT03920540 338 339 O

- NCT03920540 343 344 O
Prior NCT03920540 346 351 B-Eq-Comparison
treatment NCT03920540 352 361 B-Procedure
with NCT03920540 362 366 O
iduronate NCT03920540 367 376 B-Drug
- NCT03920540 377 378 I-Drug
2 NCT03920540 379 380 I-Drug
- NCT03920540 381 382 I-Drug
sulfatase NCT03920540 383 392 I-Drug
ERT NCT03920540 393 396 I-Drug

- NCT03920540 399 400 O
History NCT03920540 402 409 B-Eq-Comparison
of NCT03920540 410 412 O
bronchotomy NCT03920540 413 424 B-Procedure
, NCT03920540 425 426 O
bone NCT03920540 427 431 B-Procedure
marrow NCT03920540 432 438 I-Procedure
trasplanation NCT03920540 439 452 I-Procedure
, NCT03920540 453 454 O
or NCT03920540 455 457 B-Or
cord NCT03920540 458 462 B-Procedure
blood NCT03920540 463 468 I-Procedure
transplanation NCT03920540 469 483 I-Procedure
. NCT03920540 484 485 O

- NCT03920540 489 490 O
Known NCT03920540 492 497 O
hypersensitivity NCT03920540 498 514 B-Condition
reactions NCT03920540 515 524 O
to NCT03920540 525 527 O
any NCT03920540 528 531 O
of NCT03920540 532 534 O
the NCT03920540 535 538 O
components NCT03920540 539 549 O
of NCT03920540 550 552 O
the NCT03920540 553 556 O
invetigational NCT03920540 557 571 B-Study
product NCT03920540 572 579 B-Drug

- NCT03920540 582 583 O
Prior NCT03920540 585 590 B-Eq-Comparison
or NCT03920540 591 593 B-Or
planned NCT03920540 594 601 B-Eq-Comparison
administration NCT03920540 602 616 O
of NCT03920540 617 619 O
other NCT03920540 620 625 O
investigational NCT03920540 626 641 B-Study
products NCT03920540 642 650 B-Drug
within NCT03920540 651 657 B-Eq-Comparison
30 NCT03920540 658 660 I-Eq-Comparison
days NCT03920540 661 665 I-Eq-Comparison
before NCT03920540 666 672 B-Temporal-Connection___Temporal-Connection-Type-Value:before
treatment NCT03920540 673 682 B-Procedure
with NCT03920540 683 687 O
the NCT03920540 688 691 O
investigational NCT03920540 692 707 B-Study
product NCT03920540 708 715 B-Drug
in NCT03920540 716 718 O
this NCT03920540 719 723 O
study NCT03920540 724 729 O
or NCT03920540 730 732 O
duirng NCT03920540 733 739 B-Temporal-Connection___Temporal-Connection-Type-Value:during
this NCT03920540 740 744 O
study NCT03920540 745 750 B-Study
. NCT03920540 751 752 O

- NCT03920540 756 757 O
Unable NCT03920540 759 765 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03920540 766 768 O
perform NCT03920540 769 776 O
6 NCT03920540 777 778 B-Observation
- NCT03920540 779 780 I-Observation
MWT NCT03920540 781 784 I-Observation
. NCT03920540 785 786 O

- NCT03920540 790 791 O
Female NCT03920540 793 799 O

Inclusion NCT03921138 0 9 O
Criteria NCT03921138 10 18 O
: NCT03921138 19 20 O

- NCT03921138 24 25 O
patients NCT03921138 27 35 O
who NCT03921138 36 39 O
underwent NCT03921138 40 49 B-Eq-Comparison
benign NCT03921138 50 56 B-Modifier
laparoscopic NCT03921138 57 69 B-Procedure
hysterectomy NCT03921138 70 82 I-Procedure
with NCT03921138 83 87 B-And
systematic NCT03921138 88 98 B-Procedure
salpingectomy NCT03921138 99 112 I-Procedure

Exclusion NCT03921138 113 122 O
Criteria NCT03921138 123 131 O
: NCT03921138 132 133 O

- NCT03921138 137 138 O
Hysterectomy NCT03921138 140 152 B-Procedure
in NCT03921138 153 155 O
a NCT03921138 156 157 O
context NCT03921138 158 165 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
of NCT03921138 166 168 I-Temporal-Connection___Temporal-Connection-Type-Value:encounter
gynecologic NCT03921138 169 180 B-Condition
cancer NCT03921138 181 187 I-Condition

- NCT03921138 190 191 O
Hysterectomy NCT03921138 193 205 B-Procedure
not NCT03921138 206 209 B-Negation
carried NCT03921138 210 217 O
out NCT03921138 218 221 O
using NCT03921138 222 227 O
laparoscopy NCT03921138 228 239 B-Procedure

- NCT03921138 242 243 O
Fimbriated NCT03921138 245 255 B-Condition
end NCT03921138 256 259 I-Condition
missing NCT03921138 260 267 B-Modifier
or NCT03921138 268 270 B-Or
damaged NCT03921138 271 278 B-Modifier
or NCT03921138 279 281 O
impossible NCT03921138 282 292 O
for NCT03921138 293 296 O
pathologist NCT03921138 297 308 O
to NCT03921138 309 311 O
analyze NCT03921138 312 319 O

Inclusion NCT03928652 0 9 O
Criteria NCT03928652 10 18 O
: NCT03928652 19 20 O

1 NCT03928652 24 25 O
. NCT03928652 25 26 O
Colon NCT03928652 28 33 B-Modifier
or NCT03928652 34 36 B-Or
rectal NCT03928652 37 43 B-Modifier
cancer NCT03928652 44 50 B-Condition
diagnosed NCT03928652 51 60 O
by NCT03928652 61 63 O
endoscopic NCT03928652 64 74 B-Procedure
biopsy NCT03928652 75 81 I-Procedure
histopathology NCT03928652 82 96 I-Procedure
; NCT03928652 96 97 O

2 NCT03928652 100 101 O
. NCT03928652 101 102 O
Complete NCT03928652 104 112 O
sample NCT03928652 113 119 B-Observation
information NCT03928652 120 131 O
, NCT03928652 132 133 O
including NCT03928652 134 143 O
sample NCT03928652 144 150 O
number NCT03928652 151 157 O
, NCT03928652 158 159 O
gender NCT03928652 160 166 O
, NCT03928652 167 168 O
age NCT03928652 169 172 O
and NCT03928652 173 176 O
clinical NCT03928652 177 185 O
molecular NCT03928652 186 195 O
diagnostic NCT03928652 196 206 O
information NCT03928652 207 218 O
, NCT03928652 219 220 O
etc NCT03928652 221 224 O
. NCT03928652 224 225 O
; NCT03928652 226 227 O

3 NCT03928652 230 231 O
. NCT03928652 231 232 O
Sufficient NCT03928652 234 244 O
surgical NCT03928652 245 253 B-Observation
tissue NCT03928652 254 260 I-Observation
samples NCT03928652 261 268 O
are NCT03928652 269 272 O
available NCT03928652 273 282 O
for NCT03928652 283 286 B-Assertion___Assertion-Type-Value:hypothetical
testing NCT03928652 287 294 B-Observation
; NCT03928652 294 295 O

4 NCT03928652 298 299 O
. NCT03928652 299 300 O
untreated NCT03928652 302 311 B-Modifier
colon NCT03928652 312 317 B-Modifier
or NCT03928652 318 320 B-Or
rectal NCT03928652 321 327 B-Modifier
cancer NCT03928652 328 334 B-Condition
patients NCT03928652 335 343 O
; NCT03928652 343 344 O

5 NCT03928652 347 348 O
. NCT03928652 348 349 O
Patient NCT03928652 351 358 O
able NCT03928652 359 363 O
to NCT03928652 364 366 O
understand NCT03928652 367 377 O
and NCT03928652 378 381 O
sign NCT03928652 382 386 O
written NCT03928652 387 394 O
informed NCT03928652 395 403 O
consent NCT03928652 404 411 O

6 NCT03928652 414 415 O
. NCT03928652 415 416 O
No NCT03928652 418 420 B-Negation
evidence NCT03928652 421 429 O
of NCT03928652 430 432 O
distant NCT03928652 433 440 B-Condition
metastasis NCT03928652 441 451 I-Condition
( NCT03928652 452 453 O
M0 NCT03928652 454 456 O
) NCT03928652 457 458 O

Exclusion NCT03928652 460 469 O
Criteria NCT03928652 470 478 O
: NCT03928652 479 480 O

1 NCT03928652 484 485 O
. NCT03928652 485 486 O
Previously NCT03928652 488 498 B-Eq-Comparison
treated NCT03928652 499 506 B-Procedure
CRC NCT03928652 507 510 B-Condition
, NCT03928652 511 512 O
including NCT03928652 513 522 O
cytotoxic NCT03928652 523 532 B-Drug
drug NCT03928652 533 537 I-Drug
therapy NCT03928652 538 545 I-Drug
, NCT03928652 546 547 O
targeted NCT03928652 548 556 B-Procedure
drug NCT03928652 557 561 I-Procedure
therapy NCT03928652 562 569 I-Procedure
, NCT03928652 570 571 O
etc NCT03928652 572 575 O
. NCT03928652 575 576 O
; NCT03928652 577 578 O

2 NCT03928652 581 582 O
. NCT03928652 582 583 O
Other NCT03928652 585 590 O
malignant NCT03928652 591 600 B-Condition
tumors NCT03928652 601 607 I-Condition
; NCT03928652 607 608 O

3 NCT03928652 611 612 O
. NCT03928652 612 613 O
Pregnant NCT03928652 615 623 B-Condition
women NCT03928652 624 629 O
; NCT03928652 629 630 O

4 NCT03928652 633 634 O
. NCT03928652 634 635 O
Hereditary NCT03928652 637 647 B-Family-Member
colorectal NCT03928652 648 658 B-Condition
cancer NCT03928652 659 665 I-Condition
linked NCT03928652 666 672 O
to NCT03928652 673 675 O
familial NCT03928652 676 684 B-Condition
colonic NCT03928652 685 692 I-Condition
polyposis NCT03928652 693 702 I-Condition
or NCT03928652 703 705 B-Or
Lynch NCT03928652 706 711 B-Condition
syndrome NCT03928652 712 720 I-Condition

Inclusion NCT03925376 0 9 O
Criteria NCT03925376 10 18 O
: NCT03925376 19 20 O

- NCT03925376 24 25 O
Patients NCT03925376 27 35 O
undergoing NCT03925376 36 46 B-Eq-Comparison
redo NCT03925376 47 51 O
cardiac NCT03925376 52 59 B-Procedure
surgery NCT03925376 60 67 I-Procedure

Exclusion NCT03925376 68 77 O
Criteria NCT03925376 78 86 O
: NCT03925376 87 88 O

- NCT03925376 92 93 O
Age NCT03925376 95 98 B-Age
< NCT03925376 99 100 B-Eq-Comparison
18 NCT03925376 101 103 I-Eq-Comparison
years NCT03925376 104 109 I-Eq-Comparison
; NCT03925376 109 110 O

- NCT03925376 113 114 O
Patients NCT03925376 116 124 O
with NCT03925376 125 129 O
a NCT03925376 130 131 O
DNR NCT03925376 132 135 B-Observation
order NCT03925376 136 141 I-Observation
or NCT03925376 142 144 B-Or
" NCT03925376 145 146 B-Observation
do NCT03925376 146 148 I-Observation
not NCT03925376 149 152 I-Observation
escalate NCT03925376 153 161 I-Observation
care NCT03925376 162 166 I-Observation
" NCT03925376 166 167 I-Observation
order NCT03925376 168 173 I-Observation
. NCT03925376 173 174 O

Inclusion NCT03923075 0 9 O
Criteria NCT03923075 10 18 O
: NCT03923075 19 20 O

- NCT03923075 24 25 O
children NCT03923075 27 35 O
underoing NCT03923075 36 45 B-Eq-Comparison
elective NCT03923075 46 54 O
surgery NCT03923075 55 62 B-Procedure
under NCT03923075 63 68 O
general NCT03923075 69 76 B-Procedure
anaesthsia NCT03923075 77 87 I-Procedure

- NCT03923075 90 91 O
age NCT03923075 93 96 B-Age
4 NCT03923075 97 98 B-Eq-Comparison
- NCT03923075 99 100 I-Eq-Comparison
12 NCT03923075 101 103 I-Eq-Comparison
years NCT03923075 104 109 I-Eq-Comparison
old NCT03923075 110 113 O

- NCT03923075 116 117 O
ASA NCT03923075 119 122 B-Condition
I NCT03923075 123 124 B-Eq-Comparison
- NCT03923075 125 126 I-Eq-Comparison
II NCT03923075 127 129 I-Eq-Comparison

Exclusion NCT03923075 130 139 O
Criteria NCT03923075 140 148 O
: NCT03923075 149 150 O

- NCT03923075 154 155 O
patient NCT03923075 157 164 O
or NCT03923075 165 167 O
parent NCT03923075 168 174 O
refusal NCT03923075 175 182 O

- NCT03923075 185 186 O
Mallampati NCT03923075 188 198 B-Observation
score NCT03923075 199 204 I-Observation
> NCT03923075 205 206 B-Eq-Comparison
3 NCT03923075 207 208 I-Eq-Comparison

- NCT03923075 212 213 O
BMI NCT03923075 215 218 B-Observation
> NCT03923075 219 220 B-Eq-Comparison
35 NCT03923075 221 223 I-Eq-Comparison

- NCT03923075 227 228 O
severe NCT03923075 230 236 O
systemic NCT03923075 237 245 B-Modifier
cardiac NCT03923075 246 253 B-Condition
disease NCT03923075 254 261 I-Condition

- NCT03923075 264 265 O
neuromuscular NCT03923075 267 280 B-Condition
disease NCT03923075 281 288 I-Condition

- NCT03923075 291 292 O
recent NCT03923075 294 300 B-Eq-Comparison
respiratory NCT03923075 301 312 B-Condition
infection NCT03923075 313 322 I-Condition

- NCT03923075 325 326 O
drug NCT03923075 328 332 B-Drug
allergy NCT03923075 333 340 B-Allergy

Inclusion NCT03929809 0 9 O
Criteria NCT03929809 10 18 O
: NCT03929809 19 20 O

1 NCT03929809 24 25 O
. NCT03929809 25 26 O
Participants NCT03929809 28 40 O
will NCT03929809 41 45 O
be NCT03929809 46 48 O
adults NCT03929809 49 55 O
who NCT03929809 56 59 B-And
utilize NCT03929809 60 67 O
English NCT03929809 68 75 O
as NCT03929809 76 78 O
their NCT03929809 79 84 O
primary NCT03929809 85 92 O
language NCT03929809 93 101 O
. NCT03929809 102 103 O

2 NCT03929809 107 108 O
. NCT03929809 108 109 O
Unilateral NCT03929809 111 121 O
severe NCT03929809 122 128 O
to NCT03929809 129 131 O
profound NCT03929809 132 140 B-Condition
sensorineural NCT03929809 141 154 I-Condition
hearing NCT03929809 155 162 I-Condition
loss NCT03929809 163 167 I-Condition
for NCT03929809 168 171 O
a NCT03929809 172 173 O
duration NCT03929809 174 182 O
of NCT03929809 183 185 O
at NCT03929809 186 188 B-Eq-Comparison
least NCT03929809 189 194 I-Eq-Comparison
6 NCT03929809 195 196 I-Eq-Comparison
months NCT03929809 197 203 I-Eq-Comparison
( NCT03929809 204 205 O
to NCT03929809 206 208 B-Assertion___Assertion-Type-Value:hypothetical
ensure NCT03929809 209 215 I-Assertion___Assertion-Type-Value:hypothetical
stability NCT03929809 216 225 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03929809 226 228 O
hearing NCT03929809 229 236 B-Condition
loss NCT03929809 237 241 I-Condition
) NCT03929809 242 243 O
, NCT03929809 245 246 O
but NCT03929809 247 250 O
no NCT03929809 251 253 B-Eq-Comparison|Negation
greater NCT03929809 254 261 I-Eq-Comparison
than NCT03929809 262 266 I-Eq-Comparison
10 NCT03929809 267 269 I-Eq-Comparison
years NCT03929809 270 275 I-Eq-Comparison
. NCT03929809 276 277 O

3 NCT03929809 281 282 O
. NCT03929809 282 283 O
Contralateral NCT03929809 285 298 B-Condition
ear NCT03929809 299 302 I-Condition
with NCT03929809 303 307 B-And
normal NCT03929809 308 314 O
, NCT03929809 315 316 O
or NCT03929809 317 319 B-Or
near NCT03929809 320 324 O
- NCT03929809 325 326 O
normal NCT03929809 327 333 O
, NCT03929809 334 335 O
hearing NCT03929809 336 343 B-Condition
. NCT03929809 344 345 O

4 NCT03929809 349 350 O
. NCT03929809 350 351 O
Poorer NCT03929809 353 359 B-Condition
ear NCT03929809 360 363 I-Condition
( NCT03929809 364 365 O
ear NCT03929809 366 369 B-Modifier
to NCT03929809 370 372 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929809 373 375 I-Assertion___Assertion-Type-Value:hypothetical
implanted NCT03929809 376 385 B-Procedure
) NCT03929809 386 387 O
: NCT03929809 389 390 O
severe NCT03929809 391 397 O
to NCT03929809 398 400 O
profound NCT03929809 401 409 B-Condition
sensorineural NCT03929809 410 423 I-Condition
hearing NCT03929809 424 431 I-Condition
loss NCT03929809 432 436 I-Condition
, NCT03929809 437 438 O
defined NCT03929809 439 446 O
as NCT03929809 447 449 O
pure NCT03929809 450 454 B-Observation
- NCT03929809 455 456 I-Observation
tone NCT03929809 457 461 I-Observation
thresholds NCT03929809 462 472 I-Observation
70 NCT03929809 473 475 B-Eq-Comparison
dB NCT03929809 476 478 I-Eq-Comparison
HL NCT03929809 479 481 I-Eq-Comparison
or NCT03929809 482 484 I-Eq-Comparison
greater NCT03929809 485 492 I-Eq-Comparison
for NCT03929809 493 496 O
the NCT03929809 497 500 O
frequencies NCT03929809 501 512 O
500 NCT03929809 513 516 O
, NCT03929809 517 518 O
1000 NCT03929809 519 523 O
, NCT03929809 524 525 O

2000 NCT03929809 533 537 O
, NCT03929809 538 539 O
3000 NCT03929809 540 544 O
, NCT03929809 545 546 O
and NCT03929809 547 550 O
4000 NCT03929809 551 555 O
Hz NCT03929809 556 558 O
with NCT03929809 559 563 B-And
monosyllabic NCT03929809 564 576 B-Condition
word NCT03929809 577 581 I-Condition
understanding NCT03929809 582 595 I-Condition
, NCT03929809 596 597 O
as NCT03929809 598 600 O
measured NCT03929809 601 609 O
using NCT03929809 610 615 B-Eq-Comparison
the NCT03929809 616 619 O
CNC NCT03929809 620 623 B-Observation
Word NCT03929809 624 628 I-Observation
Test NCT03929809 629 633 I-Observation
at NCT03929809 634 636 O
60 NCT03929809 637 639 B-Eq-Comparison
dBA NCT03929809 640 643 I-Eq-Comparison
under NCT03929809 644 649 O
earphones NCT03929809 650 659 O
, NCT03929809 660 661 O
less NCT03929809 662 666 B-Eq-Comparison
than NCT03929809 667 671 I-Eq-Comparison
or NCT03929809 672 674 I-Eq-Comparison
equal NCT03929809 675 680 I-Eq-Comparison
to NCT03929809 681 683 I-Eq-Comparison
20 NCT03929809 684 686 I-Eq-Comparison
% NCT03929809 687 688 I-Eq-Comparison

5 NCT03929809 692 693 O
. NCT03929809 693 694 O
Better NCT03929809 696 702 B-Condition
ear NCT03929809 703 706 I-Condition
( NCT03929809 707 708 O
contralateral NCT03929809 709 722 B-Condition
ear NCT03929809 723 726 I-Condition
) NCT03929809 727 728 O
: NCT03929809 730 731 O
normal NCT03929809 732 738 O
or NCT03929809 739 741 B-Or
near NCT03929809 742 746 O
- NCT03929809 747 748 O
normal NCT03929809 749 755 O
hearing NCT03929809 756 763 B-Condition
defined NCT03929809 764 771 O
as NCT03929809 772 774 O
pure NCT03929809 775 779 B-Observation
- NCT03929809 780 781 I-Observation
tone NCT03929809 782 786 I-Observation
thresholds NCT03929809 787 797 I-Observation
no NCT03929809 798 800 B-Negation
poorer NCT03929809 801 807 B-Eq-Comparison
than NCT03929809 808 812 I-Eq-Comparison
30 NCT03929809 813 815 I-Eq-Comparison
dB NCT03929809 816 818 I-Eq-Comparison
HL NCT03929809 819 821 I-Eq-Comparison
at NCT03929809 822 824 O
250 NCT03929809 825 828 O
, NCT03929809 829 830 O
500 NCT03929809 831 834 O
, NCT03929809 835 836 O
1000 NCT03929809 837 841 O
, NCT03929809 842 843 O
2000 NCT03929809 844 848 O
, NCT03929809 849 850 O
and NCT03929809 851 854 O
3000 NCT03929809 855 859 O
Hz NCT03929809 860 862 O
and NCT03929809 863 866 B-And
no NCT03929809 867 869 B-Negation
poorer NCT03929809 870 876 B-Eq-Comparison
than NCT03929809 877 881 I-Eq-Comparison
40 NCT03929809 882 884 I-Eq-Comparison
dB NCT03929809 885 887 I-Eq-Comparison
HL NCT03929809 888 890 I-Eq-Comparison
at NCT03929809 891 893 O
4000 NCT03929809 894 898 O
Hz NCT03929809 899 901 O
with NCT03929809 902 906 B-And
monosyllabic NCT03929809 907 919 B-Condition
word NCT03929809 920 924 I-Condition
understanding NCT03929809 925 938 I-Condition
, NCT03929809 939 940 O
as NCT03929809 941 943 O
measured NCT03929809 944 952 O
using NCT03929809 953 958 B-Eq-Comparison
the NCT03929809 959 962 O
CNC NCT03929809 963 966 B-Observation
Word NCT03929809 967 971 I-Observation
Test NCT03929809 972 976 I-Observation
at NCT03929809 977 979 O
60 NCT03929809 980 982 B-Eq-Comparison
dBA NCT03929809 983 986 I-Eq-Comparison
under NCT03929809 987 992 O
earphones NCT03929809 993 1002 O
, NCT03929809 1003 1004 O
of NCT03929809 1005 1007 O
greater NCT03929809 1008 1015 B-Eq-Comparison
than NCT03929809 1016 1020 I-Eq-Comparison
or NCT03929809 1021 1023 I-Eq-Comparison
equal NCT03929809 1024 1029 I-Eq-Comparison
to NCT03929809 1030 1032 I-Eq-Comparison
85 NCT03929809 1033 1035 I-Eq-Comparison
% NCT03929809 1036 1037 I-Eq-Comparison
. NCT03929809 1039 1040 O

6 NCT03929809 1044 1045 O
. NCT03929809 1045 1046 O
Willingness NCT03929809 1048 1059 O
to NCT03929809 1060 1062 O
comply NCT03929809 1063 1069 O
with NCT03929809 1070 1074 O
all NCT03929809 1075 1078 O
study NCT03929809 1079 1084 O
requirements NCT03929809 1085 1097 O
. NCT03929809 1098 1099 O

7 NCT03929809 1103 1104 O
. NCT03929809 1104 1105 O
Patent NCT03929809 1107 1113 B-Condition
cochlea NCT03929809 1114 1121 I-Condition
and NCT03929809 1122 1125 B-And
normal NCT03929809 1126 1132 O
cochlear NCT03929809 1133 1141 B-Condition
anatomy NCT03929809 1142 1149 I-Condition
. NCT03929809 1150 1151 O

Exclusion NCT03929809 1153 1162 O
Criteria NCT03929809 1163 1171 O
: NCT03929809 1172 1173 O

1 NCT03929809 1177 1178 O
. NCT03929809 1178 1179 O
Medical NCT03929809 1181 1188 B-Modifier
or NCT03929809 1189 1191 B-Or
psychological NCT03929809 1192 1205 B-Modifier
conditions NCT03929809 1206 1216 B-Condition
that NCT03929809 1217 1221 O
contraindicate NCT03929809 1222 1236 B-Contraindication
undergoing NCT03929809 1237 1247 B-Eq-Comparison
surgery NCT03929809 1248 1255 B-Procedure
. NCT03929809 1256 1257 O

2 NCT03929809 1261 1262 O
. NCT03929809 1262 1263 O
Ossification NCT03929809 1265 1277 B-Condition
or NCT03929809 1278 1280 B-Or
any NCT03929809 1281 1284 O
other NCT03929809 1285 1290 O
cochlear NCT03929809 1291 1299 B-Condition
anomaly NCT03929809 1300 1307 I-Condition
that NCT03929809 1308 1312 O
might NCT03929809 1313 1318 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03929809 1319 1326 B-Negation
complete NCT03929809 1327 1335 O
insertion NCT03929809 1336 1345 B-Procedure
of NCT03929809 1346 1348 I-Procedure
the NCT03929809 1349 1352 I-Procedure
electrode NCT03929809 1353 1362 I-Procedure
array NCT03929809 1363 1368 I-Procedure
. NCT03929809 1369 1370 O

3 NCT03929809 1374 1375 O
. NCT03929809 1375 1376 O
Unrealistic NCT03929809 1378 1389 O
expectations NCT03929809 1390 1402 B-Assertion___Assertion-Type-Value:hypothetical
on NCT03929809 1403 1405 O
the NCT03929809 1406 1409 O
part NCT03929809 1410 1414 O
of NCT03929809 1415 1417 O
the NCT03929809 1418 1421 O
candidate NCT03929809 1422 1431 O
and NCT03929809 1432 1435 O
/ NCT03929809 1436 1437 O
or NCT03929809 1438 1440 O
candidate NCT03929809 1441 1450 O
's NCT03929809 1450 1452 O
family NCT03929809 1453 1459 O
, NCT03929809 1460 1461 O
regarding NCT03929809 1462 1471 O
the NCT03929809 1472 1475 O
possible NCT03929809 1476 1484 O
benefits NCT03929809 1485 1493 O
, NCT03929809 1494 1495 O
risks NCT03929809 1496 1501 O
, NCT03929809 1502 1503 O
and NCT03929809 1504 1507 O
limitations NCT03929809 1508 1519 O
that NCT03929809 1520 1524 O
are NCT03929809 1525 1528 O
inherent NCT03929809 1529 1537 O
to NCT03929809 1538 1540 O
the NCT03929809 1541 1544 O
surgical NCT03929809 1545 1553 B-Procedure
procedure NCT03929809 1554 1563 I-Procedure
( NCT03929809 1564 1565 O
s NCT03929809 1566 1567 O
) NCT03929809 1568 1569 O
and NCT03929809 1570 1573 B-Or
prosthetic NCT03929809 1574 1584 B-Condition
devices NCT03929809 1585 1592 I-Condition
. NCT03929809 1593 1594 O

4 NCT03929809 1598 1599 O
. NCT03929809 1599 1600 O
Unwillingness NCT03929809 1602 1615 O
or NCT03929809 1616 1618 O
inability NCT03929809 1619 1628 O
of NCT03929809 1629 1631 O
the NCT03929809 1632 1635 O
candidate NCT03929809 1636 1645 O
to NCT03929809 1646 1648 O
comply NCT03929809 1649 1655 O
with NCT03929809 1656 1660 O
all NCT03929809 1661 1664 O
investigational NCT03929809 1665 1680 O
requirements NCT03929809 1681 1693 O
. NCT03929809 1694 1695 O

5 NCT03929809 1699 1700 O
. NCT03929809 1700 1701 O
Active NCT03929809 1703 1709 B-Eq-Comparison
middle NCT03929809 1710 1716 B-Modifier
ear NCT03929809 1717 1720 I-Modifier
infection NCT03929809 1721 1730 B-Condition
. NCT03929809 1731 1732 O

6 NCT03929809 1736 1737 O
. NCT03929809 1737 1738 O
Tinnitus NCT03929809 1740 1748 B-Condition
primary NCT03929809 1749 1756 O
motivation NCT03929809 1757 1767 O
for NCT03929809 1768 1771 O
implantation NCT03929809 1772 1784 B-Procedure
. NCT03929809 1784 1785 O

Inclusion NCT03924336 0 9 O
Criteria NCT03924336 10 18 O
: NCT03924336 19 20 O

- NCT03924336 24 25 O
Stage NCT03924336 27 32 B-Eq-Comparison
III NCT03924336 33 36 I-Eq-Comparison
periodontitis NCT03924336 37 50 B-Condition
patient NCT03924336 51 58 O
having NCT03924336 59 65 B-And
at NCT03924336 66 68 B-Eq-Comparison
least NCT03924336 69 74 I-Eq-Comparison
one NCT03924336 75 78 I-Eq-Comparison
tooth NCT03924336 79 84 I-Eq-Comparison
with NCT03924336 85 89 O
2 NCT03924336 90 91 B-Modifier
- NCT03924336 92 93 I-Modifier
wall NCT03924336 94 98 I-Modifier
, NCT03924336 99 100 O
3 NCT03924336 101 102 B-Modifier
- NCT03924336 103 104 I-Modifier
wall NCT03924336 105 109 I-Modifier
, NCT03924336 110 111 O
or NCT03924336 112 114 B-Or
combined NCT03924336 115 123 O
2 NCT03924336 124 125 B-Modifier
- NCT03924336 126 127 I-Modifier
to NCT03924336 128 130 I-Modifier
3 NCT03924336 131 132 I-Modifier
- NCT03924336 133 134 I-Modifier
wall NCT03924336 135 139 I-Modifier
intraosseous NCT03924336 140 152 B-Observation
defect NCT03924336 153 159 I-Observation
≥ NCT03924336 160 161 B-Eq-Comparison
3 NCT03924336 162 163 I-Eq-Comparison
mm NCT03924336 164 166 I-Eq-Comparison
in NCT03924336 167 169 O
depth NCT03924336 170 175 O
( NCT03924336 176 177 O
assessed NCT03924336 178 186 O
by NCT03924336 187 189 O
bone NCT03924336 190 194 B-Procedure
sounding NCT03924336 195 203 I-Procedure
, NCT03924336 204 205 O
radiographic NCT03924336 206 218 B-Procedure
examination NCT03924336 219 230 I-Procedure
) NCT03924336 231 232 O
with NCT03924336 233 237 B-And
clinical NCT03924336 238 246 B-Observation
attachment NCT03924336 247 257 I-Observation
level NCT03924336 258 263 I-Observation
( NCT03924336 264 265 O
CAL NCT03924336 266 269 B-Observation
) NCT03924336 270 271 O
≥ NCT03924336 272 273 B-Eq-Comparison
5 NCT03924336 274 275 I-Eq-Comparison
mm NCT03924336 276 278 O
and NCT03924336 279 282 B-And
pocket NCT03924336 283 289 B-Observation
depth NCT03924336 290 295 I-Observation
( NCT03924336 296 297 O
PD NCT03924336 298 300 B-Observation
) NCT03924336 301 302 O
≥ NCT03924336 303 304 B-Eq-Comparison
6 NCT03924336 305 306 I-Eq-Comparison
mm NCT03924336 307 309 I-Eq-Comparison
. NCT03924336 310 311 O

- NCT03924336 315 316 O
Defect NCT03924336 318 324 B-Condition
not NCT03924336 325 328 B-Negation
extending NCT03924336 329 338 O
to NCT03924336 339 341 O
a NCT03924336 342 343 O
root NCT03924336 344 348 B-Modifier
furcation NCT03924336 349 358 I-Modifier
area NCT03924336 359 363 I-Modifier

- NCT03924336 366 367 O
Vital NCT03924336 369 374 O
teeth NCT03924336 375 380 O

- NCT03924336 383 384 O
Non NCT03924336 386 389 B-Negation
- NCT03924336 390 391 O
smokers NCT03924336 392 399 B-Condition
. NCT03924336 400 401 O

- NCT03924336 405 406 O
No NCT03924336 408 410 B-Negation
history NCT03924336 411 418 B-Eq-Comparison
of NCT03924336 419 421 O
intake NCT03924336 422 428 O
of NCT03924336 429 431 O
antibiotics NCT03924336 432 443 B-Drug
or NCT03924336 444 446 B-Or
other NCT03924336 447 452 O
medications NCT03924336 453 464 B-Drug
affecting NCT03924336 465 474 O
the NCT03924336 475 478 O
periodontium NCT03924336 479 491 B-Condition
in NCT03924336 492 494 O
the NCT03924336 495 498 O
previous NCT03924336 499 507 B-Eq-Comparison
6 NCT03924336 508 509 I-Eq-Comparison
months NCT03924336 510 516 I-Eq-Comparison
. NCT03924336 517 518 O

- NCT03924336 522 523 O
No NCT03924336 525 527 B-Negation
periodontal NCT03924336 528 539 B-Procedure
therapy NCT03924336 540 547 I-Procedure
carried NCT03924336 548 555 O
out NCT03924336 556 559 O
in NCT03924336 560 562 O
the NCT03924336 563 566 O
past NCT03924336 567 571 B-Eq-Comparison
6 NCT03924336 572 573 I-Eq-Comparison
months NCT03924336 574 580 I-Eq-Comparison
. NCT03924336 581 582 O

- NCT03924336 586 587 O
Able NCT03924336 589 593 O
to NCT03924336 594 596 O
sign NCT03924336 597 601 O
an NCT03924336 602 604 O
informed NCT03924336 605 613 O
consent NCT03924336 614 621 O
form NCT03924336 622 626 O
. NCT03924336 627 628 O

- NCT03924336 632 633 O
Patients NCT03924336 635 643 O
age NCT03924336 644 647 B-Age
between NCT03924336 648 655 B-Eq-Comparison
25 NCT03924336 656 658 I-Eq-Comparison
and NCT03924336 659 662 I-Eq-Comparison
50 NCT03924336 663 665 I-Eq-Comparison
years NCT03924336 666 671 I-Eq-Comparison
old NCT03924336 672 675 O
. NCT03924336 676 677 O

- NCT03924336 681 682 O
Patients NCT03924336 684 692 O
who NCT03924336 693 696 O
are NCT03924336 697 700 O
cooperative NCT03924336 701 712 O
, NCT03924336 713 714 O
motivated NCT03924336 715 724 O
, NCT03924336 725 726 O
and NCT03924336 727 730 O
hygiene NCT03924336 731 738 O
conscious NCT03924336 739 748 O
. NCT03924336 749 750 O

- NCT03924336 754 755 O
Systemically NCT03924336 757 769 O
free NCT03924336 770 774 O
according NCT03924336 775 784 O
to NCT03924336 785 787 O
Cornell NCT03924336 788 795 O
Medical NCT03924336 796 803 O
Index NCT03924336 804 809 O
( NCT03924336 810 811 O
Broadbent NCT03924336 812 821 O
, NCT03924336 822 823 O
1951 NCT03924336 824 828 O
) NCT03924336 829 830 O
. NCT03924336 832 833 O

Exclusion NCT03924336 835 844 O
Criteria NCT03924336 845 853 O
: NCT03924336 854 855 O

- NCT03924336 859 860 O
Pregnancy NCT03924336 862 871 B-Condition
or NCT03924336 872 874 B-Or
breast NCT03924336 875 881 B-Condition
feeding NCT03924336 882 889 I-Condition

- NCT03924336 892 893 O
The NCT03924336 895 898 O
presence NCT03924336 899 907 O
of NCT03924336 908 910 O
an NCT03924336 911 913 O
orthodontic NCT03924336 914 925 B-Condition
appliance NCT03924336 926 935 I-Condition

- NCT03924336 938 939 O
Teeth NCT03924336 941 946 B-Condition
mobility NCT03924336 947 955 I-Condition
greater NCT03924336 956 963 B-Eq-Comparison
than NCT03924336 964 968 I-Eq-Comparison
grade NCT03924336 969 974 I-Eq-Comparison
I NCT03924336 975 976 I-Eq-Comparison

Inclusion NCT03920150 0 9 O
Criteria NCT03920150 10 18 O
: NCT03920150 19 20 O

- NCT03920150 24 25 O
vitamin NCT03920150 27 34 B-Condition
D NCT03920150 35 36 I-Condition
deficiency NCT03920150 37 47 I-Condition
by NCT03920150 48 50 O
serum NCT03920150 51 56 B-Observation
level NCT03920150 57 62 I-Observation
< NCT03920150 63 64 B-Eq-Comparison
50 NCT03920150 65 67 I-Eq-Comparison
nmol NCT03920150 68 72 I-Eq-Comparison
/ NCT03920150 73 74 I-Eq-Comparison
l NCT03920150 75 76 I-Eq-Comparison

Exclusion NCT03920150 77 86 O
Criteria NCT03920150 87 95 O
: NCT03920150 96 97 O

- NCT03920150 101 102 O
hypercalcaemia NCT03920150 104 118 B-Condition

Inclusion NCT03922009 0 9 O
Criteria NCT03922009 10 18 O
: NCT03922009 19 20 O

1 NCT03922009 24 25 O
. NCT03922009 25 26 O
population NCT03922009 28 38 O
: NCT03922009 39 40 O
acceptance NCT03922009 41 51 O
of NCT03922009 52 54 O
lower NCT03922009 55 60 B-Condition
extremity NCT03922009 61 70 I-Condition
fractures NCT03922009 71 80 I-Condition
in NCT03922009 81 83 O
patients NCT03922009 84 92 O
with NCT03922009 93 97 B-And
spinal NCT03922009 98 104 B-Procedure
anesthesia NCT03922009 105 115 I-Procedure
. NCT03922009 116 117 O

2 NCT03922009 121 122 O
. NCT03922009 122 123 O
Anesthesia NCT03922009 125 135 B-Condition
classification NCT03922009 136 150 I-Condition
( NCT03922009 151 152 O
ASA NCT03922009 153 156 B-Condition
) NCT03922009 157 158 O
: NCT03922009 160 161 O
I NCT03922009 162 163 B-Eq-Comparison
- NCT03922009 164 165 I-Eq-Comparison
III NCT03922009 166 169 I-Eq-Comparison
. NCT03922009 170 171 O

3 NCT03922009 175 176 O
. NCT03922009 176 177 O
Age NCT03922009 179 182 B-Age
: NCT03922009 183 184 O
20 NCT03922009 185 187 B-Eq-Comparison
years NCT03922009 188 193 I-Eq-Comparison
old NCT03922009 194 197 I-Eq-Comparison
to NCT03922009 198 200 I-Eq-Comparison
70 NCT03922009 201 203 I-Eq-Comparison
years NCT03922009 204 209 I-Eq-Comparison
of NCT03922009 210 212 O
age NCT03922009 213 216 O
. NCT03922009 217 218 O

Exclusion NCT03922009 220 229 O
Criteria NCT03922009 230 238 O
: NCT03922009 239 240 O

1 NCT03922009 244 245 O
. NCT03922009 245 246 O
Mental NCT03922009 248 254 B-Condition
illness NCT03922009 255 262 I-Condition
and NCT03922009 263 266 B-And
taking NCT03922009 267 273 B-Eq-Comparison
related NCT03922009 274 281 O
drugs NCT03922009 282 287 B-Drug
. NCT03922009 288 289 O

2 NCT03922009 293 294 O
. NCT03922009 294 295 O
Visually NCT03922009 297 305 B-Condition
impaired NCT03922009 306 314 I-Condition
and NCT03922009 315 318 B-And
hearing NCT03922009 319 326 B-Condition
impaired NCT03922009 327 335 I-Condition
. NCT03922009 336 337 O

3 NCT03922009 341 342 O
. NCT03922009 342 343 O
Being NCT03922009 345 350 O
unable NCT03922009 351 357 B-Condition
to NCT03922009 358 360 I-Condition
communicate NCT03922009 361 372 I-Condition
or NCT03922009 373 375 B-Or
illiterate NCT03922009 376 386 B-Condition
. NCT03922009 387 388 O

4 NCT03922009 392 393 O
. NCT03922009 393 394 O
The NCT03922009 396 399 O
condition NCT03922009 400 409 B-Condition
changes NCT03922009 410 417 O
or NCT03922009 418 420 B-Or
is NCT03922009 421 423 O
critical NCT03922009 424 432 O
, NCT03922009 433 434 O
and NCT03922009 435 438 B-And
the NCT03922009 439 442 O
intensive NCT03922009 443 452 O
care NCT03922009 453 457 O
unit NCT03922009 458 462 O
is NCT03922009 463 465 O
admitted NCT03922009 466 474 B-Encounter
after NCT03922009 475 480 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03922009 481 484 O
operation NCT03922009 485 494 B-Procedure
. NCT03922009 495 496 O

5 NCT03922009 500 501 O
. NCT03922009 501 502 O
Contact NCT03922009 504 511 O
isolation NCT03922009 512 521 O
. NCT03922009 522 523 O

6 NCT03922009 527 528 O
. NCT03922009 528 529 O
Trauma NCT03922009 531 537 B-Condition
of NCT03922009 538 540 O
the NCT03922009 541 544 O
head NCT03922009 545 549 B-Modifier
and NCT03922009 550 553 B-And
wounds NCT03922009 554 560 B-Condition
on NCT03922009 561 563 O
the NCT03922009 564 567 O
head NCT03922009 568 572 B-Modifier
. NCT03922009 573 574 O

7 NCT03922009 578 579 O
. NCT03922009 579 580 O
History NCT03922009 582 589 B-Eq-Comparison
of NCT03922009 590 592 O
motion NCT03922009 593 599 B-Condition
sickness NCT03922009 600 608 I-Condition
and NCT03922009 609 612 B-Or
vertigo NCT03922009 613 620 B-Condition
. NCT03922009 620 621 O

Inclusion NCT03925766 0 9 O
Criteria NCT03925766 10 18 O
: NCT03925766 19 20 O

- NCT03925766 24 25 O
Patient NCT03925766 27 34 O
with NCT03925766 35 39 O
altered NCT03925766 40 47 B-Modifier
Roux NCT03925766 48 52 B-Procedure
en NCT03925766 53 55 I-Procedure
Y NCT03925766 56 57 I-Procedure
Gastric NCT03925766 58 65 I-Procedure
Bypass NCT03925766 66 72 I-Procedure
anatomy NCT03925766 73 80 O

Exclusion NCT03925766 81 90 O
Criteria NCT03925766 91 99 O
: NCT03925766 100 101 O

- NCT03925766 105 106 O
Patients NCT03925766 108 116 O
without NCT03925766 117 124 B-Negation
Roux NCT03925766 125 129 B-Procedure
en NCT03925766 130 132 I-Procedure
Y NCT03925766 133 134 I-Procedure
Gastric NCT03925766 135 142 I-Procedure
Bypass NCT03925766 143 149 I-Procedure
anatomy NCT03925766 150 157 O

Inclusion NCT03923465 0 9 O
Criteria NCT03923465 10 18 O
: NCT03923465 19 20 O

- NCT03923465 24 25 O
Systemically NCT03923465 27 39 B-Modifier
healthy NCT03923465 40 47 B-Condition

- NCT03923465 50 51 O
Clinical NCT03923465 53 61 O
diagnosis NCT03923465 62 71 O
of NCT03923465 72 74 O
advanced NCT03923465 75 83 O
periodontitis NCT03923465 84 97 B-Condition

- NCT03923465 100 101 O
Having NCT03923465 103 109 O
one NCT03923465 110 113 B-Eq-Comparison
isolated NCT03923465 114 122 B-Condition
intrabony NCT03923465 123 132 I-Condition
defect NCT03923465 133 139 I-Condition
with NCT03923465 140 144 O
probing NCT03923465 145 152 B-Observation
depth NCT03923465 153 158 I-Observation
( NCT03923465 159 160 O
PD NCT03923465 161 163 B-Observation
) NCT03923465 164 165 O
≥ NCT03923465 166 167 B-Eq-Comparison
7 NCT03923465 168 169 I-Eq-Comparison
mm NCT03923465 170 172 I-Eq-Comparison
, NCT03923465 173 174 O
clinical NCT03923465 175 183 B-Observation
attachment NCT03923465 184 194 I-Observation
level NCT03923465 195 200 I-Observation
( NCT03923465 201 202 O
CAL NCT03923465 203 206 B-Observation
) NCT03923465 207 208 O
≥ NCT03923465 209 210 B-Eq-Comparison
8 NCT03923465 211 212 I-Eq-Comparison
mm NCT03923465 213 215 I-Eq-Comparison
and NCT03923465 216 219 B-And
at NCT03923465 220 222 B-Eq-Comparison
least NCT03923465 223 228 I-Eq-Comparison
4 NCT03923465 229 230 I-Eq-Comparison
mm NCT03923465 231 233 I-Eq-Comparison
intrabony NCT03923465 234 243 B-Observation
component NCT03923465 244 253 I-Observation
involving NCT03923465 254 263 O
predominantly NCT03923465 264 277 O
the NCT03923465 278 281 O
interproximal NCT03923465 282 295 O
area NCT03923465 296 300 O
of NCT03923465 301 303 O
the NCT03923465 304 307 O
affected NCT03923465 308 316 O
tooth NCT03923465 317 322 O
. NCT03923465 323 324 O

- NCT03923465 328 329 O
Full NCT03923465 331 335 B-Observation
- NCT03923465 336 337 I-Observation
mouth NCT03923465 338 343 I-Observation
plaque NCT03923465 344 350 I-Observation
score NCT03923465 351 356 I-Observation
( NCT03923465 357 358 O
FMPS NCT03923465 359 363 B-Observation
) NCT03923465 364 365 O
≤ NCT03923465 366 367 B-Eq-Comparison
20 NCT03923465 368 370 I-Eq-Comparison
% NCT03923465 371 372 I-Eq-Comparison
. NCT03923465 374 375 O

- NCT03923465 379 380 O
Full NCT03923465 382 386 B-Observation
- NCT03923465 387 388 I-Observation
mouth NCT03923465 389 394 I-Observation
bleeding NCT03923465 395 403 I-Observation
score NCT03923465 404 409 I-Observation
( NCT03923465 410 411 O
FMBS NCT03923465 412 416 B-Observation
) NCT03923465 417 418 O
≤ NCT03923465 419 420 B-Eq-Comparison
20 NCT03923465 421 423 I-Eq-Comparison
% NCT03923465 424 425 I-Eq-Comparison
. NCT03923465 427 428 O

Exclusion NCT03923465 430 439 O
Criteria NCT03923465 440 448 O
: NCT03923465 449 450 O

- NCT03923465 454 455 O
Smokers NCT03923465 457 464 O

- NCT03923465 467 468 O
Patients NCT03923465 470 478 O
with NCT03923465 479 483 O
known NCT03923465 484 489 O
systemic NCT03923465 490 498 B-Modifier
diseases NCT03923465 499 507 B-Condition
such NCT03923465 508 512 O
as NCT03923465 513 515 O
diabetes NCT03923465 516 524 B-Condition
and NCT03923465 525 528 B-And
cardiovascular NCT03923465 529 543 B-Condition
diseases NCT03923465 544 552 I-Condition
or NCT03923465 553 555 B-Or
using NCT03923465 556 561 B-Eq-Comparison
medications NCT03923465 562 573 B-Drug
that NCT03923465 574 578 O
affect NCT03923465 579 585 O
periodontal NCT03923465 586 597 B-Condition
tissues NCT03923465 598 605 I-Condition
, NCT03923465 606 607 O
pregnant NCT03923465 608 616 B-Condition
or NCT03923465 617 619 B-Or
lactating NCT03923465 620 629 B-Condition
women NCT03923465 630 635 O

- NCT03923465 638 639 O
One NCT03923465 641 644 B-Condition
- NCT03923465 645 646 I-Condition
wall NCT03923465 647 651 I-Condition
intrabony NCT03923465 652 661 I-Condition
defects NCT03923465 662 669 I-Condition

- NCT03923465 672 673 O
Defects NCT03923465 675 682 B-Condition
that NCT03923465 683 687 O
involve NCT03923465 688 695 O
buccal NCT03923465 696 702 B-Modifier
and NCT03923465 703 706 B-Or
lingual NCT03923465 707 714 B-Modifier
sites NCT03923465 715 720 I-Modifier

- NCT03923465 723 724 O
Presence NCT03923465 726 734 O
of NCT03923465 735 737 O
inadequate NCT03923465 738 748 O
endodontic NCT03923465 749 759 B-Procedure
treatment NCT03923465 760 769 I-Procedure
and NCT03923465 770 773 B-Or
/ NCT03923465 774 775 I-Or
or NCT03923465 776 778 I-Or
restoration NCT03923465 779 790 B-Procedure
in NCT03923465 791 793 I-Procedure
the NCT03923465 794 797 I-Procedure
relevant NCT03923465 798 806 I-Procedure
teeth NCT03923465 807 812 I-Procedure
. NCT03923465 812 813 O

Inclusion NCT03862352 0 9 O
Criteria NCT03862352 10 18 O
: NCT03862352 19 20 O

- NCT03862352 24 25 O
Any NCT03862352 27 30 O
coronary NCT03862352 31 39 B-Procedure
artery NCT03862352 40 46 I-Procedure
perforation NCT03862352 47 58 I-Procedure
during NCT03862352 59 65 B-Temporal-Connection___Temporal-Connection-Type-Value:during
percutaneous NCT03862352 66 78 B-Procedure
coronary NCT03862352 79 87 I-Procedure
intervention NCT03862352 88 100 I-Procedure

Exclusion NCT03862352 101 110 O
Criteria NCT03862352 111 119 O
: NCT03862352 120 121 O

- NCT03862352 125 126 O
Nil NCT03862352 128 131 O

Inclusion NCT03860545 0 9 O
Criteria NCT03860545 10 18 O
: NCT03860545 19 20 O

- NCT03860545 24 25 O
a NCT03860545 27 28 O
planned NCT03860545 29 36 B-Eq-Comparison
operation NCT03860545 37 46 O
of NCT03860545 47 49 O
coronary NCT03860545 50 58 B-Procedure
artery NCT03860545 59 65 I-Procedure
bypass NCT03860545 66 72 I-Procedure
grafting NCT03860545 73 81 I-Procedure
with NCT03860545 82 86 O
the NCT03860545 87 90 O
use NCT03860545 91 94 O
of NCT03860545 95 97 O
cardiopulmonary NCT03860545 98 113 B-Procedure
bypass NCT03860545 114 120 I-Procedure

Exclusion NCT03860545 121 130 O
Criteria NCT03860545 131 139 O
: NCT03860545 140 141 O

- NCT03860545 145 146 O
emergency NCT03860545 148 157 B-Encounter
operations NCT03860545 158 168 B-Procedure
or NCT03860545 169 171 B-Or
re NCT03860545 172 174 B-Procedure
- NCT03860545 175 176 I-Procedure
operations NCT03860545 177 187 I-Procedure
; NCT03860545 187 188 O

- NCT03860545 191 192 O
a NCT03860545 194 195 O
known NCT03860545 196 201 O
pathology NCT03860545 202 211 B-Condition
of NCT03860545 212 214 I-Condition
the NCT03860545 215 218 I-Condition
urinary NCT03860545 219 226 I-Condition
tract NCT03860545 227 232 I-Condition
or NCT03860545 233 235 B-Or
renal NCT03860545 236 241 B-Condition
failure NCT03860545 242 249 I-Condition
; NCT03860545 249 250 O

- NCT03860545 253 254 O
chronic NCT03860545 256 263 B-Modifier
use NCT03860545 264 267 O
of NCT03860545 268 270 O
the NCT03860545 271 274 O
following NCT03860545 275 284 O
medications NCT03860545 285 296 B-Drug
: NCT03860545 297 298 O
iron NCT03860545 299 303 B-Drug
, NCT03860545 304 305 O
non NCT03860545 306 309 B-Drug
- NCT03860545 310 311 I-Drug
steroidal NCT03860545 312 321 I-Drug
anti NCT03860545 322 326 I-Drug
- NCT03860545 327 328 I-Drug
inflammatory NCT03860545 329 341 I-Drug
drugs NCT03860545 342 347 I-Drug
( NCT03860545 348 349 O
NSAIDs NCT03860545 350 356 B-Drug
) NCT03860545 357 358 O
, NCT03860545 360 361 O
immunosuppression NCT03860545 362 379 B-Drug
, NCT03860545 380 381 O
or NCT03860545 382 384 O
steroids NCT03860545 385 393 B-Drug
in NCT03860545 394 396 O
the NCT03860545 397 400 O
pre NCT03860545 401 404 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03860545 405 414 B-Procedure
period NCT03860545 415 421 O
; NCT03860545 421 422 O

- NCT03860545 425 426 O
polycythemia NCT03860545 428 440 B-Condition
, NCT03860545 441 442 O
porphyria NCT03860545 443 452 B-Condition
or NCT03860545 453 455 B-Or
pathological NCT03860545 456 468 B-Condition
hemoglobin NCT03860545 469 479 I-Condition
species NCT03860545 480 487 I-Condition
in NCT03860545 488 490 I-Condition
anamnesis NCT03860545 491 500 I-Condition
; NCT03860545 500 501 O

- NCT03860545 504 505 O
pre NCT03860545 507 510 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03860545 511 520 B-Procedure
signs NCT03860545 521 526 B-Assertion___Assertion-Type-Value:possible
of NCT03860545 527 529 I-Assertion___Assertion-Type-Value:possible
hepatic NCT03860545 530 537 B-Condition
failure NCT03860545 538 545 I-Condition
; NCT03860545 545 546 O

- NCT03860545 549 550 O
active NCT03860545 552 558 B-Eq-Comparison
autoimmune NCT03860545 559 569 B-Modifier
or NCT03860545 570 572 B-Or
neoplastic NCT03860545 573 583 B-Modifier
diseases NCT03860545 584 592 B-Condition
, NCT03860545 593 594 O
active NCT03860545 595 601 B-Eq-Comparison
infection NCT03860545 602 611 B-Condition
; NCT03860545 611 612 O

- NCT03860545 615 616 O
anticipated NCT03860545 618 629 B-Assertion___Assertion-Type-Value:hypothetical
significant NCT03860545 630 641 O
bleeding NCT03860545 642 650 B-Condition
( NCT03860545 651 652 O
anti NCT03860545 653 657 B-Drug
- NCT03860545 658 659 I-Drug
platelet NCT03860545 660 668 I-Drug
agents NCT03860545 669 675 I-Drug
) NCT03860545 676 677 O
, NCT03860545 679 680 O
suggesting NCT03860545 681 691 B-Assertion___Assertion-Type-Value:possible
the NCT03860545 692 695 O
use NCT03860545 696 699 O
of NCT03860545 700 702 O
blood NCT03860545 703 708 B-Drug
- NCT03860545 709 710 I-Drug
derived NCT03860545 711 718 I-Drug
products NCT03860545 719 727 I-Drug
during NCT03860545 728 734 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860545 735 738 O
operation NCT03860545 739 748 B-Procedure
and NCT03860545 749 752 O
afterward NCT03860545 753 762 O

- NCT03860545 765 766 O
acute NCT03860545 768 773 B-Condition
myocardial NCT03860545 774 784 I-Condition
infarction NCT03860545 785 795 I-Condition
after NCT03860545 796 801 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operation NCT03860545 802 811 B-Procedure

Inclusion NCT03868657 0 9 O
Criteria NCT03868657 10 18 O
: NCT03868657 19 20 O

- NCT03868657 24 25 O
Healthy NCT03868657 27 34 O
men NCT03868657 35 38 O
and NCT03868657 39 42 B-Or
women NCT03868657 43 48 O

- NCT03868657 51 52 O
Age NCT03868657 54 57 B-Age
≥ NCT03868657 58 59 B-Eq-Comparison
20 NCT03868657 60 62 I-Eq-Comparison
and NCT03868657 63 66 I-Eq-Comparison
≤ NCT03868657 67 68 I-Eq-Comparison
40 NCT03868657 69 71 I-Eq-Comparison
years NCT03868657 72 77 I-Eq-Comparison

- NCT03868657 80 81 O
BMI NCT03868657 83 86 B-Observation
≥ NCT03868657 87 88 B-Eq-Comparison
18 NCT03868657 89 91 I-Eq-Comparison
, NCT03868657 92 93 I-Eq-Comparison
5 NCT03868657 94 95 I-Eq-Comparison
and NCT03868657 96 99 I-Eq-Comparison
≤ NCT03868657 100 101 I-Eq-Comparison
27 NCT03868657 102 104 I-Eq-Comparison
, NCT03868657 105 106 I-Eq-Comparison
5 NCT03868657 107 108 I-Eq-Comparison

Exclusion NCT03868657 110 119 O
Criteria NCT03868657 120 128 O
: NCT03868657 129 130 O

- NCT03868657 134 135 O
Chronic NCT03868657 137 144 B-Condition
diseases NCT03868657 145 153 I-Condition
( NCT03868657 154 155 O
cardiac NCT03868657 156 163 B-Modifier
, NCT03868657 164 165 O
metabolic NCT03868657 166 175 B-Modifier
, NCT03868657 176 177 O
liver NCT03868657 178 183 B-Modifier
) NCT03868657 184 185 O
including NCT03868657 186 195 O
a NCT03868657 196 197 O
family NCT03868657 198 204 B-Family-Member
history NCT03868657 205 212 I-Family-Member
of NCT03868657 213 215 O
congenital NCT03868657 216 226 B-Condition
Long NCT03868657 227 231 I-Condition
QT NCT03868657 232 234 I-Condition
syndrome NCT03868657 235 243 I-Condition
. NCT03868657 244 245 O

- NCT03868657 249 250 O
QTc NCT03868657 252 255 B-Observation
values NCT03868657 256 262 O
> NCT03868657 263 264 B-Eq-Comparison
440 NCT03868657 265 268 I-Eq-Comparison
ms NCT03868657 269 271 I-Eq-Comparison
( NCT03868657 272 273 O
men NCT03868657 274 277 O
) NCT03868657 278 279 O
and NCT03868657 280 283 B-And
> NCT03868657 284 285 B-Eq-Comparison
450 NCT03868657 286 289 I-Eq-Comparison
ms NCT03868657 290 292 I-Eq-Comparison
( NCT03868657 293 294 O
women NCT03868657 295 300 O
) NCT03868657 301 302 O

- NCT03868657 306 307 O
Clinical NCT03868657 309 317 B-Modifier
important NCT03868657 318 327 I-Modifier
and NCT03868657 328 331 B-Or
/ NCT03868657 332 333 I-Or
or NCT03868657 334 336 I-Or
symptomatic NCT03868657 337 348 B-Assertion___Assertion-Type-Value:possible
bradycardia NCT03868657 349 360 B-Condition

- NCT03868657 363 364 O
Regular NCT03868657 366 373 B-Eq-Comparison
medication NCT03868657 374 384 B-Drug
( NCT03868657 385 386 O
contraceptive NCT03868657 387 400 B-Drug
pills NCT03868657 401 406 I-Drug
allowed NCT03868657 407 414 B-Exception
) NCT03868657 415 416 O

- NCT03868657 420 421 O
Pregnancy NCT03868657 423 432 B-Condition
and NCT03868657 433 436 B-Or
breastfeeding NCT03868657 437 450 B-Condition

Inclusion NCT03862391 0 9 O
Criteria NCT03862391 10 18 O
: NCT03862391 19 20 O

- NCT03862391 24 25 O
ASA NCT03862391 27 30 B-Condition
physical NCT03862391 31 39 I-Condition
status NCT03862391 40 46 I-Condition
1 NCT03862391 47 48 B-Eq-Comparison
and NCT03862391 49 52 I-Eq-Comparison
2 NCT03862391 53 54 I-Eq-Comparison
, NCT03862391 55 56 O
underwent NCT03862391 57 66 B-Eq-Comparison
gynicological NCT03862391 67 80 B-Procedure
laparotomic NCT03862391 81 92 I-Procedure
surgery NCT03862391 93 100 I-Procedure
under NCT03862391 101 106 O
general NCT03862391 107 114 B-Procedure
anesthesia NCT03862391 115 125 I-Procedure
, NCT03862391 126 127 O
followed NCT03862391 128 136 B-Encounter|Temporal-Connection___Temporal-Connection-Type-Value:after
up NCT03862391 137 139 I-Encounter
in NCT03862391 140 142 O
PACU NCT03862391 143 147 O
( NCT03862391 148 149 O
post NCT03862391 150 154 O
operative NCT03862391 155 164 O
care NCT03862391 165 169 O
unit NCT03862391 170 174 O
) NCT03862391 175 176 O

Exclusion NCT03862391 178 187 O
Criteria NCT03862391 188 196 O
: NCT03862391 197 198 O

- NCT03862391 202 203 O
ASA NCT03862391 205 208 B-Condition
3 NCT03862391 209 210 B-Eq-Comparison
or NCT03862391 211 213 I-Eq-Comparison
4 NCT03862391 214 215 I-Eq-Comparison
, NCT03862391 216 217 O
mental NCT03862391 218 224 B-Condition
retardation NCT03862391 225 236 I-Condition
, NCT03862391 237 238 O
psychiatric NCT03862391 239 250 B-Condition
disease NCT03862391 251 258 I-Condition
, NCT03862391 259 260 O
history NCT03862391 261 268 B-Eq-Comparison
of NCT03862391 269 271 O
malignant NCT03862391 272 281 B-Condition
hyperthermia NCT03862391 282 294 I-Condition
in NCT03862391 295 297 O
patient NCT03862391 298 305 B-Family-Member___Family-Member-Type:patient
or NCT03862391 306 308 B-Or
her NCT03862391 309 312 O
family NCT03862391 313 319 B-Family-Member
, NCT03862391 320 321 O
neurological NCT03862391 322 334 B-Condition
disease NCT03862391 335 342 I-Condition
, NCT03862391 343 344 O
morbid NCT03862391 345 351 B-Condition
obesity NCT03862391 352 359 I-Condition
, NCT03862391 360 361 O
history NCT03862391 362 369 B-Eq-Comparison
of NCT03862391 370 372 O
asthma NCT03862391 373 379 B-Condition
and NCT03862391 380 383 B-And
follow NCT03862391 384 390 B-Encounter
- NCT03862391 391 392 I-Encounter
up NCT03862391 393 395 I-Encounter
in NCT03862391 396 398 O
the NCT03862391 399 402 O
intensive NCT03862391 403 412 O
care NCT03862391 413 417 O
unit NCT03862391 418 422 O
. NCT03862391 422 423 O

Inclusion NCT03863925 0 9 O
Criteria NCT03863925 10 18 O
: NCT03863925 19 20 O

- NCT03863925 24 25 O
Age NCT03863925 27 30 B-Age
between NCT03863925 31 38 B-Eq-Comparison
20 NCT03863925 39 41 I-Eq-Comparison
years NCT03863925 42 47 I-Eq-Comparison
old NCT03863925 48 51 I-Eq-Comparison
and NCT03863925 52 55 I-Eq-Comparison
65 NCT03863925 56 58 I-Eq-Comparison
years NCT03863925 59 64 I-Eq-Comparison
old NCT03863925 65 68 I-Eq-Comparison

- NCT03863925 71 72 O
Diagnosis NCT03863925 74 83 O
of NCT03863925 84 86 O
major NCT03863925 87 92 B-Modifier
depressive NCT03863925 93 103 B-Condition
disorder NCT03863925 104 112 I-Condition
, NCT03863925 113 114 O
bipolar NCT03863925 115 122 B-Condition
disorder NCT03863925 123 131 I-Condition
, NCT03863925 132 133 O
and NCT03863925 134 137 B-Or
schizophrenia NCT03863925 138 151 B-Condition
, NCT03863925 152 153 O
compatible NCT03863925 154 164 O
with NCT03863925 165 169 O
SCID NCT03863925 170 174 O
for NCT03863925 175 178 O
DSM NCT03863925 179 182 O
- NCT03863925 183 184 O
5 NCT03863925 185 186 O
, NCT03863925 187 188 O
with NCT03863925 189 193 B-And
clinical NCT03863925 194 202 O
necessity NCT03863925 203 212 B-Eq-Comparison
of NCT03863925 213 215 I-Eq-Comparison
ECT NCT03863925 216 219 B-Procedure
under NCT03863925 220 225 O
a NCT03863925 226 227 O
psychiatrist NCT03863925 228 240 O
's NCT03863925 240 242 O
evaluation NCT03863925 243 253 O
and NCT03863925 254 257 O
decision NCT03863925 258 266 O

- NCT03863925 269 270 O
Patients NCT03863925 272 280 O
with NCT03863925 281 285 O
adequate NCT03863925 286 294 B-Condition
visual NCT03863925 295 301 I-Condition
acuity NCT03863925 302 308 I-Condition
and NCT03863925 309 312 B-And
auditory NCT03863925 313 321 B-Condition
acuity NCT03863925 322 328 I-Condition
without NCT03863925 329 336 O
or NCT03863925 337 339 O
with NCT03863925 340 344 O
correction NCT03863925 345 355 O

- NCT03863925 358 359 O
Patients NCT03863925 361 369 O
or NCT03863925 370 372 O
patients NCT03863925 373 381 O
' NCT03863925 381 382 O
legal NCT03863925 383 388 O
representative NCT03863925 389 403 O
signing NCT03863925 404 411 O
up NCT03863925 412 414 O
the NCT03863925 415 418 O
informed NCT03863925 419 427 O
consent NCT03863925 428 435 O

Exclusion NCT03863925 436 445 O
Criteria NCT03863925 446 454 O
: NCT03863925 455 456 O

- NCT03863925 460 461 O
Patients NCT03863925 463 471 O
already NCT03863925 472 479 O
diagnosed NCT03863925 480 489 O
with NCT03863925 490 494 O
neurocognitive NCT03863925 495 509 B-Condition
disorder NCT03863925 510 518 I-Condition

- NCT03863925 521 522 O
Patients NCT03863925 524 532 O
with NCT03863925 533 537 O
contraindications NCT03863925 538 555 B-Contraindication
to NCT03863925 556 558 O
ECT NCT03863925 559 562 B-Procedure
, NCT03863925 563 564 O
including NCT03863925 565 574 O
myocardial NCT03863925 575 585 B-Condition
infarction NCT03863925 586 596 I-Condition
, NCT03863925 597 598 O
cerebrovascular NCT03863925 599 614 B-Condition
disease NCT03863925 615 622 I-Condition
, NCT03863925 623 624 O
elevated NCT03863925 625 633 B-Condition
intracranial NCT03863925 634 646 I-Condition
pressure NCT03863925 647 655 I-Condition
, NCT03863925 656 657 O
intracranial NCT03863925 658 670 B-Condition
angiomas NCT03863925 671 679 I-Condition
, NCT03863925 680 681 O
untreated NCT03863925 682 691 B-Modifier
bony NCT03863925 692 696 B-Condition
fractures NCT03863925 697 706 I-Condition
, NCT03863925 707 708 O
cervical NCT03863925 709 717 B-Condition
spine NCT03863925 718 723 I-Condition
injury NCT03863925 724 730 I-Condition
, NCT03863925 731 732 O
pheochromocytoma NCT03863925 733 749 B-Condition
, NCT03863925 750 751 O
heart NCT03863925 752 757 B-Condition
failure NCT03863925 758 765 I-Condition
, NCT03863925 766 767 O
sever NCT03863925 768 773 O
valvular NCT03863925 774 782 B-Condition
disease NCT03863925 783 790 I-Condition
, NCT03863925 791 792 O
deep NCT03863925 793 797 B-Condition
vein NCT03863925 798 802 I-Condition
thrombosis NCT03863925 803 813 I-Condition
, NCT03863925 814 815 O
etc NCT03863925 816 819 O
. NCT03863925 820 821 O

- NCT03863925 825 826 O
Patients NCT03863925 828 836 O
with NCT03863925 837 841 O
untreated NCT03863925 842 851 B-Negation|Procedure
substance NCT03863925 852 861 B-Condition
abuse NCT03863925 862 867 I-Condition
, NCT03863925 868 869 O
including NCT03863925 870 879 O
alcohol NCT03863925 880 887 B-Drug
and NCT03863925 888 891 B-Or
illegal NCT03863925 892 899 B-Drug
drugs NCT03863925 900 905 I-Drug

- NCT03863925 908 909 O
Patients NCT03863925 911 919 O
with NCT03863925 920 924 O
unspecified NCT03863925 925 936 B-Modifier
psychiatric NCT03863925 937 948 B-Condition
disorders NCT03863925 949 958 I-Condition

- NCT03863925 961 962 O
Patients NCT03863925 964 972 O
unable NCT03863925 973 979 O
to NCT03863925 980 982 O
cooperate NCT03863925 983 992 O

Inclusion NCT03860753 0 9 O
Criteria NCT03860753 10 18 O
: NCT03860753 19 20 O

- NCT03860753 24 25 O
treatment NCT03860753 27 36 B-Procedure
- NCT03860753 37 38 O
seeking NCT03860753 39 46 B-Assertion___Assertion-Type-Value:intention
individuals NCT03860753 47 58 O
diagnosed NCT03860753 59 68 O
with NCT03860753 69 73 O
AUD NCT03860753 74 77 B-Condition
diagnostic NCT03860753 78 88 O
statistical NCT03860753 89 100 O
manual NCT03860753 101 107 O
5 NCT03860753 108 109 O
( NCT03860753 110 111 O
DSM NCT03860753 112 115 O
- NCT03860753 116 117 O
5 NCT03860753 118 119 O
) NCT03860753 120 121 O

- NCT03860753 125 126 O
fluent NCT03860753 128 134 O
in NCT03860753 135 137 O
English NCT03860753 138 145 O

- NCT03860753 148 149 O
past NCT03860753 151 155 B-Eq-Comparison
month NCT03860753 156 161 I-Eq-Comparison
excessive NCT03860753 162 171 O
alcohol NCT03860753 172 179 B-Observation
use NCT03860753 180 183 I-Observation
( NCT03860753 184 185 O
> NCT03860753 187 188 B-Eq-Comparison
7 NCT03860753 189 190 I-Eq-Comparison
drinks NCT03860753 191 197 I-Eq-Comparison
/ NCT03860753 198 199 I-Eq-Comparison
week NCT03860753 200 204 I-Eq-Comparison
for NCT03860753 205 208 O
woman NCT03860753 209 214 O
, NCT03860753 215 216 O
> NCT03860753 217 218 B-Eq-Comparison
14 NCT03860753 219 221 I-Eq-Comparison
drinks NCT03860753 222 228 I-Eq-Comparison
/ NCT03860753 229 230 I-Eq-Comparison
week NCT03860753 231 235 I-Eq-Comparison
for NCT03860753 236 239 O
men NCT03860753 240 243 O
, NCT03860753 244 245 O
> NCT03860753 246 247 O
3 NCT03860753 248 249 B-Eq-Comparison
drinks NCT03860753 250 256 I-Eq-Comparison
/ NCT03860753 257 258 I-Eq-Comparison
occasion NCT03860753 259 267 I-Eq-Comparison
for NCT03860753 268 271 O
women NCT03860753 272 277 O
> NCT03860753 278 279 B-Eq-Comparison
4 NCT03860753 280 281 I-Eq-Comparison
drinks NCT03860753 282 288 I-Eq-Comparison
/ NCT03860753 289 290 I-Eq-Comparison
occasion NCT03860753 291 299 I-Eq-Comparison
for NCT03860753 300 303 O
men NCT03860753 304 307 O
) NCT03860753 308 309 O
14 NCT03860753 310 312 O

- NCT03860753 316 317 O
baseline NCT03860753 319 327 O
Hamilton NCT03860753 328 336 B-Observation
Anxiety NCT03860753 337 344 I-Observation
Rating NCT03860753 345 351 I-Observation
Scale NCT03860753 352 357 I-Observation
( NCT03860753 358 359 O
HAM NCT03860753 360 363 B-Observation
- NCT03860753 364 365 I-Observation
A NCT03860753 366 367 I-Observation
) NCT03860753 368 369 O
or NCT03860753 370 372 B-Or
Perceived NCT03860753 373 382 B-Observation
Stress NCT03860753 383 389 I-Observation
Scale NCT03860753 390 395 I-Observation
( NCT03860753 396 397 O
PSS NCT03860753 398 401 B-Observation
) NCT03860753 402 403 O
core NCT03860753 404 408 O
indicative NCT03860753 409 419 O
of NCT03860753 420 422 O
mild NCT03860753 423 427 O
to NCT03860753 428 430 B-Or
moderate NCT03860753 431 439 O
anxiety NCT03860753 440 447 B-Condition
( NCT03860753 448 449 O
score NCT03860753 450 455 B-Eq-Comparison
8 NCT03860753 456 457 I-Eq-Comparison
to NCT03860753 458 460 I-Eq-Comparison
23 NCT03860753 461 463 I-Eq-Comparison
) NCT03860753 464 465 O
or NCT03860753 466 468 B-Or
moderate NCT03860753 469 477 O
stress NCT03860753 478 484 B-Condition
( NCT03860753 485 486 O
score NCT03860753 487 492 B-Eq-Comparison
14 NCT03860753 493 495 I-Eq-Comparison
to NCT03860753 496 498 I-Eq-Comparison
26 NCT03860753 499 501 I-Eq-Comparison
) NCT03860753 502 503 O
, NCT03860753 505 506 O
respectively NCT03860753 507 519 O

- NCT03860753 522 523 O
increase NCT03860753 525 533 O
in NCT03860753 534 536 O
alcohol NCT03860753 537 544 B-Condition
craving NCT03860753 545 552 I-Condition
following NCT03860753 553 562 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03860753 563 566 O
baseline NCT03860753 567 575 B-Study
stress NCT03860753 576 582 O
reactivity NCT03860753 583 593 O
assessment NCT03860753 594 604 O
. NCT03860753 605 606 O

Exclusion NCT03860753 608 617 O
Criteria NCT03860753 618 626 O
: NCT03860753 627 628 O

- NCT03860753 632 633 O
Individuals NCT03860753 635 646 O
will NCT03860753 647 651 O
be NCT03860753 652 654 O
excluded NCT03860753 655 663 O
for NCT03860753 664 667 O
exhibiting NCT03860753 668 678 O
severe NCT03860753 679 685 O
scores NCT03860753 686 692 O
on NCT03860753 693 695 O
the NCT03860753 696 699 O
HAM NCT03860753 700 703 B-Observation
- NCT03860753 704 705 I-Observation
A NCT03860753 706 707 I-Observation
, NCT03860753 708 709 O
PSS NCT03860753 710 713 B-Observation
, NCT03860753 714 715 O
or NCT03860753 716 718 B-Or
post NCT03860753 719 723 B-Condition
- NCT03860753 724 725 I-Condition
traumatic NCT03860753 726 735 I-Condition
( NCT03860753 736 737 O
PTSD NCT03860753 738 742 B-Condition
) NCT03860753 743 744 O
checklist NCT03860753 745 754 B-Observation
( NCT03860753 755 756 O
PCL NCT03860753 757 760 B-Observation
- NCT03860753 761 762 I-Observation
5 NCT03860753 763 764 I-Observation
) NCT03860753 765 766 O
at NCT03860753 767 769 O
the NCT03860753 770 773 O
discretion NCT03860753 774 784 O
of NCT03860753 785 787 O
the NCT03860753 788 791 O
admitting NCT03860753 792 801 O
physician NCT03860753 802 811 O

- NCT03860753 814 815 O
physical NCT03860753 817 825 O
dependence NCT03860753 826 836 B-Condition
on NCT03860753 837 839 I-Condition
alcohol NCT03860753 840 847 I-Condition
Alcohol NCT03860753 848 855 B-Observation
Use NCT03860753 856 859 I-Observation
Disorders NCT03860753 860 869 I-Observation
Inventory NCT03860753 870 879 I-Observation
( NCT03860753 880 881 O
AUDIT NCT03860753 882 887 B-Observation
) NCT03860753 888 889 O
score NCT03860753 890 895 O
indicative NCT03860753 896 906 O
of NCT03860753 907 909 O
severe NCT03860753 910 916 O
alcohol NCT03860753 917 924 B-Condition
dependence NCT03860753 925 935 I-Condition
( NCT03860753 936 937 O
≥ NCT03860753 939 940 B-Eq-Comparison
13 NCT03860753 941 943 I-Eq-Comparison
for NCT03860753 944 947 O
women NCT03860753 948 953 O
, NCT03860753 954 955 O
≥ NCT03860753 956 957 B-Eq-Comparison
15 NCT03860753 958 960 I-Eq-Comparison
for NCT03860753 961 964 O
men NCT03860753 965 968 O
) NCT03860753 969 970 O

- NCT03860753 974 975 O
greater NCT03860753 977 984 B-Eq-Comparison
than NCT03860753 985 989 I-Eq-Comparison
mild NCT03860753 990 994 O
substance NCT03860753 995 1004 B-Condition
use NCT03860753 1005 1008 I-Condition
disorder NCT03860753 1009 1017 I-Condition
on NCT03860753 1018 1020 O
drugs NCT03860753 1021 1026 B-Drug
other NCT03860753 1027 1032 B-Exception
than NCT03860753 1033 1037 I-Exception
alcohol NCT03860753 1038 1045 B-Drug
, NCT03860753 1046 1047 O
nicotine NCT03860753 1048 1056 B-Drug
, NCT03860753 1057 1058 O
and NCT03860753 1059 1062 B-And
marijuana NCT03860753 1063 1072 B-Drug

- NCT03860753 1075 1076 O
contraindications NCT03860753 1078 1095 B-Contraindication
for NCT03860753 1096 1099 O
taking NCT03860753 1100 1106 B-Eq-Comparison
pioglitazone NCT03860753 1107 1119 B-Drug
; NCT03860753 1119 1120 O
medical NCT03860753 1121 1128 O
conditions NCT03860753 1129 1139 B-Condition
contraindicating NCT03860753 1140 1156 B-Contraindication
pioglitazone NCT03860753 1157 1169 B-Drug
pharmacotherapy NCT03860753 1170 1185 O
or NCT03860753 1186 1188 B-Or
taking NCT03860753 1189 1195 B-Eq-Comparison
contraindicated NCT03860753 1196 1211 B-Contraindication
medications NCT03860753 1212 1223 B-Drug

- NCT03860753 1226 1227 O
be NCT03860753 1229 1231 O
pregnant NCT03860753 1232 1240 B-Condition
, NCT03860753 1241 1242 O
nursing NCT03860753 1243 1250 B-Condition
, NCT03860753 1251 1252 O
or NCT03860753 1253 1255 B-Or
planning NCT03860753 1256 1264 B-Assertion___Assertion-Type-Value:intention
on NCT03860753 1265 1267 O
becoming NCT03860753 1268 1276 O
pregnant NCT03860753 1277 1285 B-Condition
during NCT03860753 1286 1292 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03860753 1293 1296 O
course NCT03860753 1297 1303 O
of NCT03860753 1304 1306 O
the NCT03860753 1307 1310 O
study NCT03860753 1311 1316 B-Study

- NCT03860753 1319 1320 O
have NCT03860753 1322 1326 O
any NCT03860753 1327 1330 O
other NCT03860753 1331 1336 O
illness NCT03860753 1337 1344 B-Condition
, NCT03860753 1345 1346 O
condition NCT03860753 1347 1356 B-Condition
, NCT03860753 1357 1358 O
or NCT03860753 1359 1361 B-Or
use NCT03860753 1362 1365 O
of NCT03860753 1366 1368 O
medications NCT03860753 1369 1380 B-Drug
, NCT03860753 1381 1382 O
which NCT03860753 1383 1388 O
in NCT03860753 1389 1391 O
the NCT03860753 1392 1395 O
opinion NCT03860753 1396 1403 O
of NCT03860753 1404 1406 O
the NCT03860753 1407 1410 O
PI NCT03860753 1411 1413 O
and NCT03860753 1414 1417 O
/ NCT03860753 1418 1419 O
or NCT03860753 1420 1422 O
admitting NCT03860753 1423 1432 O
physician NCT03860753 1433 1442 O
would NCT03860753 1443 1448 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03860753 1449 1457 B-Negation
safe NCT03860753 1458 1462 B-Modifier
and NCT03860753 1463 1466 B-Or
/ NCT03860753 1467 1468 I-Or
or NCT03860753 1469 1471 I-Or
successful NCT03860753 1472 1482 B-Modifier
completion NCT03860753 1483 1493 O
of NCT03860753 1494 1496 O
the NCT03860753 1497 1500 O
study NCT03860753 1501 1506 B-Study
. NCT03860753 1507 1508 O


Inclusion NCT03867955 0 9 O
Criteria NCT03867955 10 18 O
: NCT03867955 19 20 O

- NCT03867955 24 25 O
Majors NCT03867955 27 33 O
patients NCT03867955 34 42 O

- NCT03867955 45 46 O
Score NCT03867955 48 53 O
American NCT03867955 54 62 B-Condition
Society NCT03867955 63 70 I-Condition
of NCT03867955 71 73 I-Condition
Anesthesiologists NCT03867955 74 91 I-Condition
( NCT03867955 92 93 O
ASA NCT03867955 94 97 B-Condition
) NCT03867955 98 99 O
1 NCT03867955 100 101 B-Eq-Comparison
or NCT03867955 102 104 I-Eq-Comparison
2 NCT03867955 105 106 I-Eq-Comparison

- NCT03867955 110 111 O
Managed NCT03867955 113 120 B-Encounter
in NCT03867955 121 123 O
the NCT03867955 124 127 O
operating NCT03867955 128 137 O
theater NCT03867955 138 145 O
of NCT03867955 146 148 O
the NCT03867955 149 152 O
University NCT03867955 153 163 O
Hospital NCT03867955 164 172 O
of NCT03867955 173 175 O
Saint NCT03867955 176 181 O
- NCT03867955 182 183 O
Etienne NCT03867955 184 191 O
for NCT03867955 192 195 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03867955 196 197 O
neurosurgical NCT03867955 198 211 B-Procedure
intervention NCT03867955 212 224 I-Procedure
. NCT03867955 225 226 O

Exclusion NCT03867955 228 237 O
Criteria NCT03867955 238 246 O
: NCT03867955 247 248 O

- NCT03867955 252 253 O
Single NCT03867955 255 261 B-Modifier
or NCT03867955 262 264 B-Or
bilateral NCT03867955 265 274 B-Modifier
eye NCT03867955 275 278 B-Procedure
surgery NCT03867955 279 286 I-Procedure
modifying NCT03867955 287 296 O
the NCT03867955 297 300 O
possibilities NCT03867955 301 314 O
of NCT03867955 315 317 O
variation NCT03867955 318 327 O
of NCT03867955 328 330 O
the NCT03867955 331 334 O
pupillary NCT03867955 335 344 O
diameter NCT03867955 345 353 O

- NCT03867955 356 357 O
Having NCT03867955 359 365 O
been NCT03867955 366 370 O
asleep NCT03867955 371 377 O
under NCT03867955 378 383 O
general NCT03867955 384 391 B-Procedure
anesthesia NCT03867955 392 402 I-Procedure
in NCT03867955 403 405 O
the NCT03867955 406 409 O
7 NCT03867955 410 411 B-Eq-Comparison
days NCT03867955 412 416 I-Eq-Comparison
prior NCT03867955 417 422 B-Temporal-Connection
to NCT03867955 423 425 I-Temporal-Connection
the NCT03867955 426 429 O
current NCT03867955 430 437 B-Eq-Comparison
surgery NCT03867955 438 445 B-Procedure

- NCT03867955 448 449 O
History NCT03867955 451 458 B-Eq-Comparison
of NCT03867955 459 461 O
Parkinson NCT03867955 462 471 B-Condition
's NCT03867955 471 473 I-Condition
disease NCT03867955 474 481 I-Condition
, NCT03867955 482 483 O
insulin NCT03867955 484 491 B-Modifier
- NCT03867955 492 493 I-Modifier
dependent NCT03867955 494 503 I-Modifier
or NCT03867955 504 506 B-Or
non NCT03867955 507 510 B-Modifier
- NCT03867955 511 512 I-Modifier
insulin NCT03867955 513 520 I-Modifier
- NCT03867955 521 522 I-Modifier
dependent NCT03867955 523 532 I-Modifier
diabetes NCT03867955 533 541 B-Condition
at NCT03867955 542 544 O
a NCT03867955 545 546 O
dysautonomic NCT03867955 547 559 B-Modifier
stage NCT03867955 560 565 I-Modifier
or NCT03867955 566 568 B-Or
chronic NCT03867955 569 576 B-Modifier
alcoholism NCT03867955 577 587 B-Condition
at NCT03867955 588 590 O
a NCT03867955 591 592 O
dysautonomous NCT03867955 593 606 B-Modifier
stage NCT03867955 607 612 I-Modifier

Inclusion NCT03860974 0 9 O
Criteria NCT03860974 10 18 O
: NCT03860974 19 20 O

- NCT03860974 24 25 O
undergoing NCT03860974 27 37 B-Eq-Comparison
unilateral NCT03860974 38 48 B-Modifier
or NCT03860974 49 51 B-Or
bilateral NCT03860974 52 61 B-Modifier
breast NCT03860974 62 68 B-Procedure
surgery NCT03860974 69 76 I-Procedure
with NCT03860974 77 81 B-And
at NCT03860974 82 84 B-Eq-Comparison
least NCT03860974 85 90 I-Eq-Comparison
moderate NCT03860974 91 99 I-Eq-Comparison
post NCT03860974 100 104 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03860974 105 114 B-Procedure
pain NCT03860974 115 119 B-Observation
anticipated NCT03860974 120 131 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03860974 134 135 O
analgesic NCT03860974 137 146 B-Drug
plan NCT03860974 147 151 B-Eq-Comparison
includes NCT03860974 152 160 O
a NCT03860974 161 162 O
single NCT03860974 163 169 B-Procedure
- NCT03860974 170 171 I-Procedure
injection NCT03860974 172 181 I-Procedure
peripheral NCT03860974 182 192 I-Procedure
nerve NCT03860974 193 198 I-Procedure
block NCT03860974 199 204 I-Procedure
( NCT03860974 205 206 O
s NCT03860974 207 208 O
) NCT03860974 209 210 O

- NCT03860974 214 215 O
age NCT03860974 217 220 B-Age
18 NCT03860974 221 223 B-Eq-Comparison
years NCT03860974 224 229 I-Eq-Comparison
or NCT03860974 230 232 I-Eq-Comparison
older NCT03860974 233 238 I-Eq-Comparison

Exclusion NCT03860974 239 248 O
Criteria NCT03860974 249 257 O
: NCT03860974 258 259 O

- NCT03860974 263 264 O
morbid NCT03860974 266 272 B-Condition
obesity NCT03860974 273 280 I-Condition
as NCT03860974 281 283 O
defined NCT03860974 284 291 O
by NCT03860974 292 294 O
a NCT03860974 295 296 O
body NCT03860974 297 301 B-Observation
mass NCT03860974 302 306 I-Observation
index NCT03860974 307 312 I-Observation
> NCT03860974 313 314 B-Eq-Comparison
40 NCT03860974 315 317 I-Eq-Comparison
( NCT03860974 318 319 O
BMI NCT03860974 320 323 O
= NCT03860974 324 325 O
weight NCT03860974 326 332 O
in NCT03860974 333 335 O
kg NCT03860974 336 338 O
/ NCT03860974 339 340 O
[ NCT03860974 341 342 O
height NCT03860974 343 349 O
in NCT03860974 350 352 O
meters NCT03860974 353 359 O
] NCT03860974 360 361 O
2 NCT03860974 362 363 O
) NCT03860974 364 365 O

- NCT03860974 369 370 O
renal NCT03860974 372 377 B-Condition
insufficiency NCT03860974 378 391 I-Condition
( NCT03860974 392 393 O
pre NCT03860974 394 397 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03860974 398 407 B-Procedure
creatinine NCT03860974 408 418 B-Observation
> NCT03860974 419 420 B-Eq-Comparison
1.5 NCT03860974 421 424 I-Eq-Comparison
mg NCT03860974 425 427 O
/ NCT03860974 428 429 O
dL NCT03860974 430 432 O
) NCT03860974 433 434 O

- NCT03860974 438 439 O
chronic NCT03860974 441 448 B-Modifier
opioid NCT03860974 449 455 B-Drug
use NCT03860974 456 459 O
( NCT03860974 460 461 O
daily NCT03860974 462 467 B-Eq-Comparison
use NCT03860974 468 471 O
within NCT03860974 472 478 B-Eq-Comparison
the NCT03860974 479 482 I-Eq-Comparison
2 NCT03860974 483 484 I-Eq-Comparison
weeks NCT03860974 485 490 I-Eq-Comparison
prior NCT03860974 491 496 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03860974 497 499 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03860974 500 507 B-Procedure
and NCT03860974 508 511 O
duration NCT03860974 512 520 O
of NCT03860974 521 523 O
use NCT03860974 524 527 O
> NCT03860974 528 529 B-Eq-Comparison
4 NCT03860974 530 531 I-Eq-Comparison
weeks NCT03860974 532 537 I-Eq-Comparison
) NCT03860974 538 539 O

- NCT03860974 543 544 O
history NCT03860974 546 553 B-Eq-Comparison
of NCT03860974 554 556 O
opioid NCT03860974 557 563 B-Condition
abuse NCT03860974 564 569 I-Condition

- NCT03860974 572 573 O
any NCT03860974 575 578 O
comorbidity NCT03860974 579 590 B-Condition
which NCT03860974 591 596 O
results NCT03860974 597 604 O
in NCT03860974 605 607 O
moderate NCT03860974 608 616 O
or NCT03860974 617 619 B-Or
severe NCT03860974 620 626 O
functional NCT03860974 627 637 B-Condition
limitation NCT03860974 638 648 I-Condition
inability NCT03860974 649 658 I-Condition
to NCT03860974 659 661 I-Condition
communicate NCT03860974 662 673 I-Condition
with NCT03860974 674 678 O
the NCT03860974 679 682 O
investigators NCT03860974 683 696 O
or NCT03860974 697 699 O
hospital NCT03860974 700 708 O
staff NCT03860974 709 714 O

- NCT03860974 717 718 O
pregnancy NCT03860974 720 729 B-Condition

- NCT03860974 732 733 O
planned NCT03860974 735 742 B-Eq-Comparison
regional NCT03860974 743 751 B-Drug
analgesic NCT03860974 752 761 I-Drug
with NCT03860974 762 766 B-And
perineural NCT03860974 767 777 B-Procedure
catheter NCT03860974 778 786 I-Procedure
placement NCT03860974 787 796 I-Procedure

- NCT03860974 799 800 O
incarceration NCT03860974 802 815 B-Observation


Inclusion NCT03869788 0 9 O
Criteria NCT03869788 10 18 O
: NCT03869788 19 20 O

- NCT03869788 24 25 O
vague NCT03869788 27 32 B-Modifier
gastrointestinal NCT03869788 33 49 B-Condition
disturbances NCT03869788 50 62 I-Condition
. NCT03869788 63 64 O

- NCT03869788 68 69 O
intermittent NCT03869788 71 83 B-Modifier
eosinophilia NCT03869788 84 96 B-Condition
. NCT03869788 97 98 O

- NCT03869788 102 103 O
biliary NCT03869788 105 112 B-Condition
obstruction NCT03869788 113 124 I-Condition
. NCT03869788 125 126 O

- NCT03869788 130 131 O
biliary NCT03869788 133 140 B-Condition
colic NCT03869788 141 146 I-Condition
pain NCT03869788 147 151 I-Condition
. NCT03869788 152 153 O

- NCT03869788 157 158 O
intermittent NCT03869788 160 172 B-Modifier
jaundice NCT03869788 173 181 B-Condition
. NCT03869788 182 183 O

- NCT03869788 187 188 O
right NCT03869788 190 195 B-Condition
upper NCT03869788 196 201 I-Condition
- NCT03869788 202 203 I-Condition
quadrant NCT03869788 204 212 I-Condition
abdominal NCT03869788 213 222 I-Condition
tenderness NCT03869788 223 233 I-Condition
. NCT03869788 234 235 O

Exclusion NCT03869788 237 246 O
Criteria NCT03869788 247 255 O
: NCT03869788 256 257 O

- NCT03869788 261 262 O
no NCT03869788 264 266 O
exclusion NCT03869788 267 276 O
Criteria NCT03869788 277 285 O

Inclusion NCT03862742 0 9 O
Criteria NCT03862742 10 18 O
: NCT03862742 19 20 O

- NCT03862742 24 25 O
≥ NCT03862742 27 28 B-Eq-Comparison
18 NCT03862742 29 31 I-Eq-Comparison
years NCT03862742 32 37 I-Eq-Comparison
of NCT03862742 38 40 O
age NCT03862742 41 44 B-Age

- NCT03862742 47 48 O
Own NCT03862742 50 53 O
an NCT03862742 54 56 O
iOS NCT03862742 57 60 O
or NCT03862742 61 63 O
Android NCT03862742 64 71 O
device NCT03862742 72 78 O

Exclusion NCT03862742 79 88 O
Criteria NCT03862742 89 97 O
: NCT03862742 98 99 O

- NCT03862742 103 104 O
Inability NCT03862742 106 115 O
to NCT03862742 116 118 O
give NCT03862742 119 123 O
informed NCT03862742 124 132 O
consent NCT03862742 133 140 O

- NCT03862742 143 144 O
< NCT03862742 146 147 B-Eq-Comparison
18 NCT03862742 148 150 I-Eq-Comparison
years NCT03862742 151 156 I-Eq-Comparison
of NCT03862742 157 159 O
age NCT03862742 160 163 B-Age

- NCT03862742 166 167 O
Inability NCT03862742 169 178 B-Negation
to NCT03862742 179 181 I-Negation
understand NCT03862742 182 192 I-Negation
written NCT03862742 193 200 O
English NCT03862742 201 208 O
language NCT03862742 209 217 O

- NCT03862742 220 221 O
Hypertensive NCT03862742 223 235 B-Condition
urgency NCT03862742 236 243 B-Modifier
or NCT03862742 244 246 B-Or
emergency NCT03862742 247 256 B-Modifier
as NCT03862742 257 259 O
an NCT03862742 260 262 O
admission NCT03862742 263 272 O
diagnosis NCT03862742 273 282 O

Inclusion NCT03862781 0 9 O
Criteria NCT03862781 10 18 O
: NCT03862781 19 20 O

- NCT03862781 24 25 O
Eligible NCT03862781 27 35 O
patients NCT03862781 36 44 O
are NCT03862781 45 48 O
those NCT03862781 49 54 O
over NCT03862781 55 59 B-Eq-Comparison
18 NCT03862781 60 62 I-Eq-Comparison
years NCT03862781 63 68 I-Eq-Comparison
of NCT03862781 69 71 O
age NCT03862781 72 75 B-Age
who NCT03862781 76 79 B-And
are NCT03862781 80 83 O
regularly NCT03862781 84 93 O
scheduled NCT03862781 94 103 B-Eq-Comparison
to NCT03862781 104 106 O
undergo NCT03862781 107 114 O
a NCT03862781 115 116 O
right NCT03862781 117 122 B-Procedure
hemicolectomy NCT03862781 123 136 I-Procedure
via NCT03862781 137 140 O
a NCT03862781 141 142 O
minimally NCT03862781 143 152 B-Procedure
invasive NCT03862781 153 161 I-Procedure
approach NCT03862781 162 170 I-Procedure
( NCT03862781 171 172 O
robotic NCT03862781 173 180 B-Modifier
or NCT03862781 181 183 B-Or
laparoscopic NCT03862781 184 196 B-Modifier
) NCT03862781 197 198 O
with NCT03862781 199 203 B-And
the NCT03862781 204 207 O
creation NCT03862781 208 216 O
of NCT03862781 217 219 O
an NCT03862781 220 222 O
anastomosis NCT03862781 223 234 B-Procedure
. NCT03862781 234 235 O
Right NCT03862781 237 242 B-Procedure
colectomy NCT03862781 243 252 I-Procedure
will NCT03862781 253 257 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03862781 258 260 I-Assertion___Assertion-Type-Value:hypothetical
defined NCT03862781 261 268 O
as NCT03862781 269 271 O
removal NCT03862781 272 279 B-Procedure
of NCT03862781 280 282 I-Procedure
the NCT03862781 283 286 I-Procedure
ascending NCT03862781 287 296 I-Procedure
colon NCT03862781 297 302 I-Procedure
, NCT03862781 303 304 O
ligation NCT03862781 305 313 B-Procedure
of NCT03862781 314 316 I-Procedure
the NCT03862781 317 320 I-Procedure
ileocolic NCT03862781 321 330 I-Procedure
artery NCT03862781 331 337 I-Procedure
and NCT03862781 338 341 I-Procedure
vein NCT03862781 342 346 I-Procedure
, NCT03862781 347 348 O
+ NCT03862781 349 350 O
/ NCT03862781 352 353 O
- NCT03862781 355 356 O
removal NCT03862781 357 364 B-Procedure
of NCT03862781 365 367 I-Procedure
the NCT03862781 368 371 I-Procedure
terminal NCT03862781 372 380 I-Procedure
ileum NCT03862781 381 386 I-Procedure
, NCT03862781 387 388 O
+ NCT03862781 389 390 O
/ NCT03862781 392 393 O
- NCT03862781 395 396 O
removal NCT03862781 397 404 B-Procedure
of NCT03862781 405 407 I-Procedure
the NCT03862781 408 411 I-Procedure
proximal NCT03862781 412 420 I-Procedure
transverse NCT03862781 421 431 I-Procedure
colon NCT03862781 432 437 I-Procedure
, NCT03862781 438 439 O
and NCT03862781 440 443 O
+ NCT03862781 444 445 O
/ NCT03862781 447 448 O
- NCT03862781 450 451 O
removal NCT03862781 452 459 B-Procedure
of NCT03862781 460 462 I-Procedure
the NCT03862781 463 466 I-Procedure
right NCT03862781 467 472 I-Procedure
branch NCT03862781 473 479 I-Procedure
of NCT03862781 480 482 I-Procedure
the NCT03862781 483 486 I-Procedure
middle NCT03862781 487 493 I-Procedure
colic NCT03862781 494 499 I-Procedure
artery NCT03862781 500 506 I-Procedure
and NCT03862781 507 510 I-Procedure
vein NCT03862781 511 515 I-Procedure
. NCT03862781 516 517 O

Exclusion NCT03862781 519 528 O
Criteria NCT03862781 529 537 O
: NCT03862781 538 539 O

- NCT03862781 543 544 O
Pregnant NCT03862781 546 554 B-Condition
women NCT03862781 555 560 O

- NCT03862781 563 564 O
Additional NCT03862781 566 576 O
colon NCT03862781 577 582 B-Procedure
resection NCT03862781 583 592 I-Procedure
is NCT03862781 593 595 O
planned NCT03862781 596 603 B-Eq-Comparison
( NCT03862781 604 605 O
i. NCT03862781 606 608 O
e. NCT03862781 609 611 O
left NCT03862781 613 617 B-Procedure
colectomy NCT03862781 618 627 I-Procedure
or NCT03862781 628 630 B-Or
proctectomy NCT03862781 631 642 B-Procedure
) NCT03862781 643 644 O

- NCT03862781 648 649 O
Vulnerable NCT03862781 651 661 B-Observation
populations NCT03862781 662 673 I-Observation
such NCT03862781 674 678 O
as NCT03862781 679 681 O
prisoners NCT03862781 682 691 B-Observation
or NCT03862781 692 694 O
adults NCT03862781 695 701 O
unable NCT03862781 702 708 O
to NCT03862781 709 711 O
give NCT03862781 712 716 O
consent NCT03862781 717 724 O

- NCT03862781 727 728 O
If NCT03862781 730 732 O
the NCT03862781 733 736 O
scheduled NCT03862781 737 746 O
surgery NCT03862781 747 754 B-Procedure
is NCT03862781 755 757 O
planned NCT03862781 758 765 B-Eq-Comparison
at NCT03862781 766 768 O
Butterworth NCT03862781 769 780 O
hospital NCT03862781 781 789 O
( NCT03862781 790 791 O
as NCT03862781 792 794 O
to NCT03862781 795 797 O
standardize NCT03862781 798 809 O
the NCT03862781 810 813 O
nursing NCT03862781 814 821 O
care NCT03862781 822 826 O
received NCT03862781 827 835 B-Eq-Comparison
post NCT03862781 836 840 O
operatively NCT03862781 841 852 O
) NCT03862781 853 854 O

- NCT03862781 858 859 O
Emergent NCT03862781 861 869 O
cases NCT03862781 870 875 O

Patients NCT03862781 876 884 O
will NCT03862781 885 889 O
be NCT03862781 890 892 O
excluded NCT03862781 893 901 O
from NCT03862781 902 906 O
the NCT03862781 907 910 O
study NCT03862781 911 916 O
intra NCT03862781 917 922 O
- NCT03862781 923 924 O
operatively NCT03862781 925 936 O
if NCT03862781 937 939 B-Assertion___Assertion-Type-Value:hypothetical
: NCT03862781 940 941 O

- NCT03862781 945 946 O
The NCT03862781 948 951 O
procedure NCT03862781 952 961 O
is NCT03862781 962 964 O
converted NCT03862781 965 974 O
to NCT03862781 975 977 O
an NCT03862781 978 980 O
open NCT03862781 981 985 B-Procedure
resection NCT03862781 986 995 I-Procedure

- NCT03862781 998 999 O
If NCT03862781 1001 1003 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03862781 1004 1005 O
loop NCT03862781 1006 1010 B-Procedure
ileostomy NCT03862781 1011 1020 I-Procedure
is NCT03862781 1021 1023 O
performed NCT03862781 1024 1033 O
in NCT03862781 1034 1036 B-And
addition NCT03862781 1037 1045 I-And
to NCT03862781 1046 1048 O
the NCT03862781 1049 1052 O
right NCT03862781 1053 1058 B-Procedure
colectomy NCT03862781 1059 1068 I-Procedure

Inclusion NCT03863886 0 9 O
Criteria NCT03863886 10 18 O
: NCT03863886 19 20 O

- NCT03863886 24 25 O
Adults NCT03863886 27 33 O
patients NCT03863886 34 42 O
≥ NCT03863886 43 44 B-Eq-Comparison
18 NCT03863886 45 47 I-Eq-Comparison
years NCT03863886 48 53 I-Eq-Comparison
of NCT03863886 54 56 O
age NCT03863886 57 60 B-Age
with NCT03863886 61 65 B-And
CD NCT03863886 66 68 B-Condition
with NCT03863886 69 73 B-And
at NCT03863886 74 76 O
least NCT03863886 77 82 O
colonic NCT03863886 83 90 B-Condition
involvement NCT03863886 91 102 I-Condition
, NCT03863886 103 104 O
UC NCT03863886 105 107 B-Condition
, NCT03863886 108 109 O
or NCT03863886 110 112 B-Or
non NCT03863886 113 116 B-Negation
- NCT03863886 117 118 O
IBD NCT03863886 119 122 B-Condition
controls NCT03863886 123 131 O
who NCT03863886 132 135 B-And
have NCT03863886 136 140 O
been NCT03863886 141 145 O
referred NCT03863886 146 154 B-Eq-Comparison
for NCT03863886 155 158 I-Eq-Comparison
colonoscopy NCT03863886 159 170 B-Procedure
for NCT03863886 171 174 O
clinical NCT03863886 175 183 O
reasons NCT03863886 184 191 O
. NCT03863886 191 192 O
The NCT03863886 194 197 O
clinical NCT03863886 198 206 B-Observation
reasons NCT03863886 207 214 I-Observation
may NCT03863886 215 218 O
include NCT03863886 219 226 O
colorectal NCT03863886 227 237 B-Procedure
cancer NCT03863886 238 244 I-Procedure
screening NCT03863886 245 254 I-Procedure
, NCT03863886 255 256 O
surveillance NCT03863886 257 269 B-Observation
, NCT03863886 270 271 O
diagnostic NCT03863886 272 282 O
for NCT03863886 283 286 O
CD NCT03863886 287 289 B-Condition
or NCT03863886 290 292 B-Or
UC NCT03863886 293 295 B-Condition
flare NCT03863886 296 301 O
, NCT03863886 302 303 O
or NCT03863886 304 306 B-Or
gastrointestinal NCT03863886 307 323 B-Condition
symptoms NCT03863886 324 332 B-Assertion___Assertion-Type-Value:possible
. NCT03863886 333 334 O

Exclusion NCT03863886 336 345 O
Criteria NCT03863886 346 354 O
: NCT03863886 355 356 O

- NCT03863886 360 361 O
Pregnant NCT03863886 363 371 B-Condition
patients NCT03863886 372 380 O
. NCT03863886 381 382 O

- NCT03863886 386 387 O
Patients NCT03863886 389 397 O
with NCT03863886 398 402 O
known NCT03863886 403 408 O
current NCT03863886 409 416 B-Eq-Comparison
colorectal NCT03863886 417 427 B-Modifier
cancer NCT03863886 428 434 B-Condition
, NCT03863886 435 436 O
infectious NCT03863886 437 447 B-Condition
colitis NCT03863886 448 455 I-Condition
, NCT03863886 456 457 O
diverticulitis NCT03863886 458 472 B-Condition
, NCT03863886 473 474 O
or NCT03863886 475 477 B-Or
microscopic NCT03863886 478 489 B-Condition
colitis NCT03863886 490 497 I-Condition
. NCT03863886 498 499 O

- NCT03863886 503 504 O
Patients NCT03863886 506 514 O
who NCT03863886 515 518 O
have NCT03863886 519 523 O
undergone NCT03863886 524 533 B-Eq-Comparison
surgery NCT03863886 534 541 B-Procedure
involving NCT03863886 542 551 O
the NCT03863886 552 555 O
cecum NCT03863886 556 561 B-Modifier
or NCT03863886 562 564 B-Or
rectum NCT03863886 565 571 B-Modifier
. NCT03863886 571 572 O

Inclusion NCT03866083 0 9 O
Criteria NCT03866083 10 18 O
: NCT03866083 19 20 O

- NCT03866083 23 24 O
Critically NCT03866083 25 35 O
ill NCT03866083 36 39 O
cirrhotics NCT03866083 40 50 B-Condition
with NCT03866083 51 55 B-And
early NCT03866083 56 61 B-Modifier
onset NCT03866083 62 67 I-Modifier
septic NCT03866083 68 74 B-Condition
shock NCT03866083 75 80 I-Condition
( NCT03866083 81 82 O
< NCT03866083 84 85 B-Eq-Comparison
24 NCT03866083 86 88 I-Eq-Comparison
hours NCT03866083 89 94 I-Eq-Comparison
) NCT03866083 95 96 O
with NCT03866083 97 101 B-And
norepinephrine NCT03866083 102 116 B-Drug

of NCT03866083 117 119 O
more NCT03866083 120 124 B-Eq-Comparison
than NCT03866083 125 129 I-Eq-Comparison
10 NCT03866083 130 132 I-Eq-Comparison
ug NCT03866083 133 135 O
/ NCT03866083 136 137 O
min NCT03866083 138 141 O
and NCT03866083 142 145 B-And
lactate NCT03866083 146 153 B-Observation
> NCT03866083 154 155 B-Eq-Comparison
4 NCT03866083 156 157 I-Eq-Comparison
mmol NCT03866083 158 162 I-Eq-Comparison
/ NCT03866083 163 164 I-Eq-Comparison
L NCT03866083 165 166 I-Eq-Comparison
. NCT03866083 167 168 O

Exclusion NCT03866083 170 179 O
Criteria NCT03866083 180 188 O
: NCT03866083 189 190 O

- NCT03866083 194 195 O
Patients NCT03866083 197 205 O
with NCT03866083 206 210 O
age NCT03866083 211 214 B-Age
less NCT03866083 215 219 B-Eq-Comparison
than NCT03866083 220 224 I-Eq-Comparison
18 NCT03866083 225 227 I-Eq-Comparison
years NCT03866083 228 233 I-Eq-Comparison

- NCT03866083 236 237 O
Severe NCT03866083 239 245 O
known NCT03866083 246 251 O
cardiopulmonary NCT03866083 252 267 B-Condition
disease NCT03866083 268 275 I-Condition
( NCT03866083 276 277 O
structural NCT03866083 278 288 B-Modifier
or NCT03866083 289 291 B-Or
valvular NCT03866083 292 300 B-Modifier
heart NCT03866083 301 306 B-Condition
disease NCT03866083 307 314 I-Condition
, NCT03866083 315 316 O
coronary NCT03866083 317 325 B-Condition
artery NCT03866083 326 332 I-Condition
disease NCT03866083 333 340 I-Condition
, NCT03866083 341 342 O
COPD NCT03866083 343 347 B-Condition
) NCT03866083 348 349 O

- NCT03866083 353 354 O
Severe NCT03866083 356 362 O
coagulopathy NCT03866083 363 375 B-Condition
platelets NCT03866083 376 385 B-Observation
< NCT03866083 386 387 B-Eq-Comparison
20 NCT03866083 388 390 I-Eq-Comparison
, NCT03866083 391 392 O
000 NCT03866083 393 396 O
and NCT03866083 397 400 B-And
INR NCT03866083 401 404 B-Observation
> NCT03866083 405 406 B-Eq-Comparison
5 NCT03866083 407 408 I-Eq-Comparison

- NCT03866083 412 413 O
Active NCT03866083 415 421 B-Eq-Comparison
Bleed NCT03866083 422 427 B-Condition
( NCT03866083 428 429 O
Mucosal NCT03866083 430 437 B-Modifier
or NCT03866083 438 440 B-Or
variceal NCT03866083 441 449 B-Modifier
) NCT03866083 450 451 O

- NCT03866083 455 456 O
Pregnancy NCT03866083 458 467 B-Condition

- NCT03866083 470 471 O
Chronic NCT03866083 473 480 B-Modifier
kidney NCT03866083 481 487 B-Condition
disease NCT03866083 488 495 I-Condition

- NCT03866083 498 499 O
Extremely NCT03866083 501 510 O
moribund NCT03866083 511 519 B-Death|Risk
patients NCT03866083 520 528 O
with NCT03866083 529 533 B-And
an NCT03866083 534 536 O
expected NCT03866083 537 545 O
life NCT03866083 546 550 B-Observation
expectancy NCT03866083 551 561 I-Observation
of NCT03866083 562 564 O
less NCT03866083 565 569 B-Eq-Comparison
than NCT03866083 570 574 I-Eq-Comparison
24 NCT03866083 575 577 I-Eq-Comparison
hours NCT03866083 578 583 I-Eq-Comparison

- NCT03866083 586 587 O
Failure NCT03866083 589 596 O
to NCT03866083 597 599 O
give NCT03866083 600 604 O
informed NCT03866083 605 613 O
consent NCT03866083 614 621 O
from NCT03866083 622 626 O
family NCT03866083 627 633 O
members NCT03866083 634 641 O
. NCT03866083 642 643 O

- NCT03866083 647 648 O
Hemodynamic NCT03866083 650 661 B-Condition
instability NCT03866083 662 673 I-Condition
requiring NCT03866083 674 683 O
very NCT03866083 684 688 O
high NCT03866083 689 693 O
dose NCT03866083 694 698 O
of NCT03866083 699 701 O
vasopressors NCT03866083 702 714 B-Drug
, NCT03866083 715 716 O
late NCT03866083 717 721 B-Modifier
presentation NCT03866083 722 734 I-Modifier
or NCT03866083 735 737 B-Or
spontaneous NCT03866083 738 749 B-Modifier
reversal NCT03866083 750 758 I-Modifier
of NCT03866083 759 761 O
shock NCT03866083 762 767 B-Condition

- NCT03866083 770 771 O
Patient NCT03866083 773 780 O
enrolled NCT03866083 781 789 O
in NCT03866083 790 792 O
other NCT03866083 793 798 B-Other
clinical NCT03866083 799 807 B-Study
trials NCT03866083 808 814 I-Study

Inclusion NCT03868904 0 9 O
Criteria NCT03868904 10 18 O
: NCT03868904 19 20 O

- NCT03868904 24 25 O
Participant NCT03868904 27 38 O
in NCT03868904 39 41 O
TransMedics NCT03868904 42 53 O
OCS NCT03868904 54 57 O
Lung NCT03868904 58 62 O
System NCT03868904 63 69 O
INSPIRE NCT03868904 70 77 O
trial NCT03868904 78 83 B-Study

Exclusion NCT03868904 84 93 O
Criteria NCT03868904 94 102 O
: NCT03868904 103 104 O

- NCT03868904 108 109 O
None NCT03868904 111 115 O

Inclusion NCT03866915 0 9 O
Criteria NCT03866915 10 18 O
: NCT03866915 19 20 O

- NCT03866915 24 25 O
All NCT03866915 27 30 O
patients NCT03866915 31 39 O
older NCT03866915 40 45 I-Eq-Comparison
than NCT03866915 46 50 I-Eq-Comparison
18 NCT03866915 51 53 I-Eq-Comparison
years NCT03866915 54 59 I-Eq-Comparison
undergoing NCT03866915 60 70 B-Eq-Comparison
elective NCT03866915 71 79 O
surgery NCT03866915 80 87 B-Procedure
that NCT03866915 88 92 B-And
receive NCT03866915 93 100 O
a NCT03866915 101 102 O
pre NCT03866915 103 106 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03866915 107 116 B-Coreference
visit NCT03866915 117 122 B-Encounter
by NCT03866915 123 125 O
anesthesiologists NCT03866915 126 143 B-Provider
. NCT03866915 144 145 O

Exclusion NCT03866915 147 156 O
Criteria NCT03866915 157 165 O
: NCT03866915 166 167 O

- NCT03866915 171 172 O
Patients NCT03866915 174 182 O
undergoing NCT03866915 183 193 B-Eq-Comparison
emergency NCT03866915 194 203 B-Procedure
surgery NCT03866915 204 211 I-Procedure

- NCT03866915 219 220 O
Patients NCT03866915 222 230 O
under NCT03866915 231 236 B-Eq-Comparison
18 NCT03866915 237 239 I-Eq-Comparison
years NCT03866915 240 245 I-Eq-Comparison
of NCT03866915 246 248 O
age NCT03866915 249 252 B-Age

- NCT03866915 260 261 O
Patients NCT03866915 263 271 O
who NCT03866915 272 275 O
refuse NCT03866915 276 282 O
to NCT03866915 283 285 O
participate NCT03866915 286 297 O

- NCT03866915 305 306 O
Patients NCT03866915 308 316 O
unable NCT03866915 317 323 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866915 324 326 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03866915 327 334 O
the NCT03866915 335 338 O
6 NCT03866915 339 340 B-Observation
MWT NCT03866915 341 344 I-Observation

- NCT03866915 352 353 O
Claudication NCT03866915 355 367 B-Condition
of NCT03866915 368 370 I-Condition
the NCT03866915 371 374 I-Condition
lower NCT03866915 375 380 I-Condition
extremities NCT03866915 381 392 I-Condition
and NCT03866915 393 396 B-And
inability NCT03866915 397 406 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03866915 407 409 O
maintain NCT03866915 410 418 O
a NCT03866915 419 420 O
constant NCT03866915 421 429 O
pace NCT03866915 430 434 B-Observation
of NCT03866915 435 437 I-Observation
walking NCT03866915 438 445 I-Observation
on NCT03866915 446 448 O
level NCT03866915 449 454 B-Modifier
ground NCT03866915 455 461 I-Modifier

Inclusion NCT03869398 0 9 O
Criteria NCT03869398 10 18 O
: NCT03869398 19 20 O

- NCT03869398 24 25 O
All NCT03869398 27 30 O
patients NCT03869398 31 39 O
, NCT03869398 40 41 O
age NCT03869398 42 45 B-Age
> NCT03869398 46 47 B-Eq-Comparison
18 NCT03869398 48 50 I-Eq-Comparison
, NCT03869398 51 52 O
undergoing NCT03869398 53 63 B-Eq-Comparison
total NCT03869398 64 69 B-Procedure
thyroidectomy NCT03869398 70 83 I-Procedure
are NCT03869398 84 87 O
eligible NCT03869398 88 96 O
. NCT03869398 97 98 O

Exclusion NCT03869398 100 109 O
Criteria NCT03869398 110 118 O
: NCT03869398 119 120 O

- NCT03869398 124 125 O
partial NCT03869398 127 134 B-Procedure
thyroidectomy NCT03869398 135 148 I-Procedure
, NCT03869398 149 150 O
lobectomy NCT03869398 151 160 B-Procedure
, NCT03869398 161 162 O
or NCT03869398 163 165 B-Or
concurrent NCT03869398 166 176 B-Modifier
parathyroidectomy NCT03869398 177 194 B-Procedure
. NCT03869398 194 195 O

Inclusion NCT03867968 0 9 O
Criteria NCT03867968 10 18 O
: NCT03867968 19 20 O

- NCT03867968 24 25 O
Adult NCT03867968 27 32 O
18 NCT03867968 33 35 B-Eq-Comparison
years NCT03867968 36 41 I-Eq-Comparison
old NCT03867968 42 45 I-Eq-Comparison
or NCT03867968 46 48 I-Eq-Comparison
older NCT03867968 49 54 I-Eq-Comparison

- NCT03867968 57 58 O
Have NCT03867968 60 64 O
a NCT03867968 65 66 O
child NCT03867968 67 72 B-Family-Member___Family-Member-Type:child
age NCT03867968 73 76 B-Age
3 NCT03867968 77 78 B-Eq-Comparison
- NCT03867968 79 80 I-Eq-Comparison
18 NCT03867968 81 83 O
that NCT03867968 84 88 B-And
was NCT03867968 89 92 O
hospitalized NCT03867968 93 105 B-Encounter
overnight NCT03867968 106 115 O
with NCT03867968 116 120 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03867968 121 122 O
traumatic NCT03867968 123 132 B-Condition
brain NCT03867968 133 138 I-Condition
injury NCT03867968 139 145 I-Condition
( NCT03867968 146 147 O
TBI NCT03867968 148 151 B-Condition
) NCT03867968 152 153 O
. NCT03867968 155 156 O

- NCT03867968 160 161 O
Involved NCT03867968 163 171 O
in NCT03867968 172 174 O
the NCT03867968 175 178 O
care NCT03867968 179 183 O
and NCT03867968 184 187 O
support NCT03867968 188 195 O
of NCT03867968 196 198 O
the NCT03867968 199 202 O
child NCT03867968 203 208 B-Family-Member___Family-Member-Type:child
with NCT03867968 209 213 O
the NCT03867968 214 217 O
TBI NCT03867968 218 221 B-Condition
. NCT03867968 222 223 O

- NCT03867968 227 228 O
Live NCT03867968 230 234 O
in NCT03867968 235 237 O
the NCT03867968 238 241 O
same NCT03867968 242 246 O
household NCT03867968 247 256 O
as NCT03867968 257 259 O
child NCT03867968 260 265 B-Family-Member___Family-Member-Type:child
with NCT03867968 266 270 O
a NCT03867968 271 272 O
TBI NCT03867968 273 276 B-Condition
. NCT03867968 277 278 O

- NCT03867968 282 283 O
The NCT03867968 285 288 O
child NCT03867968 289 294 B-Family-Member___Family-Member-Type:child
with NCT03867968 295 299 O
the NCT03867968 300 303 O
TBI NCT03867968 304 307 B-Condition
is NCT03867968 308 310 O
able NCT03867968 311 315 O
to NCT03867968 316 318 O
follow NCT03867968 319 325 O
simple NCT03867968 326 332 O
instructions NCT03867968 333 345 O
such NCT03867968 346 350 O
as NCT03867968 351 353 O
" NCT03867968 354 355 O
please NCT03867968 355 361 O
eat NCT03867968 362 365 O
your NCT03867968 366 370 O
toast NCT03867968 371 376 O
. NCT03867968 376 377 O
" NCT03867968 378 379 O

Exclusion NCT03867968 380 389 O
Criteria NCT03867968 390 398 O
: NCT03867968 399 400 O

- NCT03867968 404 405 O
Does NCT03867968 407 411 O
not NCT03867968 412 415 B-Negation
speak NCT03867968 416 421 O
and NCT03867968 422 425 O
read NCT03867968 426 430 O
English NCT03867968 431 438 O
. NCT03867968 439 440 O

- NCT03867968 444 445 O
Does NCT03867968 447 451 O
not NCT03867968 452 455 O
have NCT03867968 456 460 O
high NCT03867968 461 465 O
speed NCT03867968 466 471 O
Internet NCT03867968 472 480 O
access NCT03867968 481 487 O
. NCT03867968 488 489 O

- NCT03867968 493 494 O
Not NCT03867968 496 499 B-Negation
US NCT03867968 500 502 O
resident NCT03867968 503 511 O

Inclusion NCT03866486 0 9 O
Criteria NCT03866486 10 18 O
: NCT03866486 19 20 O

- NCT03866486 24 25 O
1 NCT03866486 27 28 O
. NCT03866486 28 29 O
The NCT03866486 31 34 O
patients NCT03866486 35 43 O
who NCT03866486 44 47 O
enrolled NCT03866486 48 56 O
in NCT03866486 57 59 O
the NCT03866486 60 63 O
XPL NCT03866486 64 67 O
- NCT03866486 68 69 O
IVUS NCT03866486 70 74 O
study NCT03866486 75 80 B-Study
. NCT03866486 81 82 O

- NCT03866486 86 87 O
2 NCT03866486 89 90 O
. NCT03866486 90 91 O
Provision NCT03866486 93 102 O
of NCT03866486 103 105 O
informed NCT03866486 106 114 O
consent NCT03866486 115 122 O

Exclusion NCT03866486 123 132 O
Criteria NCT03866486 133 141 O
: NCT03866486 142 143 O

- NCT03866486 147 148 O
1 NCT03866486 150 151 O
. NCT03866486 151 152 O
This NCT03866486 154 158 O
observational NCT03866486 159 172 O
study NCT03866486 173 178 B-Study
does NCT03866486 179 183 O
not NCT03866486 184 187 O
have NCT03866486 188 192 O
any NCT03866486 193 196 O
specific NCT03866486 197 205 O
exclusion NCT03866486 206 215 O
criteria NCT03866486 216 224 O
. NCT03866486 224 225 O

Inclusion NCT03868332 0 9 O
Criteria NCT03868332 10 18 O
: NCT03868332 19 20 O

Patients NCT03868332 22 30 O
who NCT03868332 31 34 O
are NCT03868332 35 38 O
diagnosed NCT03868332 39 48 O
as NCT03868332 49 51 O
ulcerative NCT03868332 52 62 B-Condition
colitis NCT03868332 63 70 I-Condition
/ NCT03868332 71 72 B-Or
Crhon NCT03868332 73 78 B-Condition
s NCT03868332 79 80 I-Condition
disease NCT03868332 81 88 I-Condition
however NCT03868332 89 96 O
in NCT03868332 97 99 O
activity NCT03868332 100 108 B-Eq-Comparison
or NCT03868332 109 111 B-Or

in NCT03868332 112 114 B-Eq-Comparison
remission NCT03868332 115 124 I-Eq-Comparison
attending NCT03868332 125 134 B-Encounter
the NCT03868332 135 138 O
the NCT03868332 139 142 O
outpatient NCT03868332 143 153 O
clinics NCT03868332 154 161 O
and NCT03868332 162 165 B-Or
inpatient NCT03868332 166 175 B-Encounter
of NCT03868332 176 178 O
gastroenterology NCT03868332 179 195 O
units NCT03868332 196 201 O

of NCT03868332 202 204 O
Internal NCT03868332 205 213 O
medicine NCT03868332 214 222 O
department NCT03868332 223 233 O

Exclusion NCT03868332 234 243 O
Criteria NCT03868332 244 252 O
: NCT03868332 253 254 O

- NCT03868332 258 259 O
Previous NCT03868332 261 269 B-Eq-Comparison
history NCT03868332 270 277 I-Eq-Comparison
of NCT03868332 278 280 O
hypertension NCT03868332 281 293 B-Condition
, NCT03868332 294 295 O
diabetes NCT03868332 296 304 B-Condition
mellitus NCT03868332 305 313 I-Condition
, NCT03868332 314 315 O
Dyslipidemia NCT03868332 316 328 B-Condition

- NCT03868332 331 332 O
Previous NCT03868332 334 342 B-Eq-Comparison
history NCT03868332 343 350 I-Eq-Comparison
of NCT03868332 351 353 O
cardiovascular NCT03868332 354 368 B-Modifier
or NCT03868332 369 371 B-Or
cerebrovascular NCT03868332 372 387 B-Modifier
events NCT03868332 388 394 B-Condition

- NCT03868332 397 398 O
Autoimmune NCT03868332 400 410 B-Modifier
, NCT03868332 411 412 O
Neoplastic NCT03868332 413 423 B-Modifier
diseases NCT03868332 424 432 B-Condition

- NCT03868332 435 436 O
Thromboembolic NCT03868332 438 452 B-Condition
diseases NCT03868332 453 461 I-Condition

Inclusion NCT03867773 0 9 O
Criteria NCT03867773 10 18 O
: NCT03867773 19 20 O

- NCT03867773 24 25 O
Male NCT03867773 27 31 O
or NCT03867773 32 34 B-Or
female NCT03867773 35 41 O
; NCT03867773 41 42 O

- NCT03867773 45 46 O
body NCT03867773 48 52 B-Observation
mass NCT03867773 53 57 I-Observation
index NCT03867773 58 63 I-Observation
( NCT03867773 64 65 O
BMI NCT03867773 66 69 B-Observation
) NCT03867773 70 71 O
between NCT03867773 72 79 B-Eq-Comparison
30.0 NCT03867773 80 84 I-Eq-Comparison
and NCT03867773 85 88 I-Eq-Comparison
49.9 NCT03867773 89 93 I-Eq-Comparison
kg NCT03867773 94 96 I-Eq-Comparison
/ NCT03867773 97 98 I-Eq-Comparison
m2 NCT03867773 99 101 I-Eq-Comparison
; NCT03867773 101 102 O

- NCT03867773 105 106 O
age NCT03867773 108 111 B-Age
between NCT03867773 112 119 B-Eq-Comparison
18 NCT03867773 120 122 I-Eq-Comparison
and NCT03867773 123 126 I-Eq-Comparison
65 NCT03867773 127 129 I-Eq-Comparison
years NCT03867773 130 135 I-Eq-Comparison
; NCT03867773 135 136 O
sedentary NCT03867773 137 146 B-Observation
( NCT03867773 147 148 O
light NCT03867773 149 154 B-Observation
exercise NCT03867773 155 163 I-Observation
less NCT03867773 164 168 B-Eq-Comparison
than NCT03867773 169 173 I-Eq-Comparison
1 NCT03867773 174 175 I-Eq-Comparison
h NCT03867773 176 177 I-Eq-Comparison
per NCT03867773 178 181 I-Eq-Comparison
week NCT03867773 182 186 I-Eq-Comparison
) NCT03867773 187 188 O
or NCT03867773 189 191 B-Or
moderately NCT03867773 192 202 B-Observation
active NCT03867773 203 209 I-Observation
( NCT03867773 210 211 O
moderate NCT03867773 212 220 B-Observation
exercise NCT03867773 221 229 I-Observation
1 NCT03867773 230 231 B-Eq-Comparison
to NCT03867773 232 234 I-Eq-Comparison
2 NCT03867773 235 236 I-Eq-Comparison
h NCT03867773 237 238 I-Eq-Comparison
per NCT03867773 239 242 I-Eq-Comparison
week NCT03867773 243 247 I-Eq-Comparison
) NCT03867773 248 249 O
; NCT03867773 250 251 O

- NCT03867773 254 255 O
weight NCT03867773 257 263 B-Observation
stable NCT03867773 264 270 O
for NCT03867773 271 274 O
> NCT03867773 275 276 B-Eq-Comparison
3 NCT03867773 277 278 I-Eq-Comparison
months NCT03867773 279 285 I-Eq-Comparison
prior NCT03867773 286 291 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03867773 292 294 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03867773 295 298 O
beginning NCT03867773 299 308 O
of NCT03867773 309 311 O
the NCT03867773 312 315 O
study NCT03867773 316 321 B-Study
( NCT03867773 322 323 O
gain NCT03867773 324 328 B-Eq-Comparison
or NCT03867773 329 331 I-Eq-Comparison
loss NCT03867773 332 336 I-Eq-Comparison
< NCT03867773 337 338 I-Eq-Comparison
4 NCT03867773 339 340 I-Eq-Comparison
kg NCT03867773 341 343 I-Eq-Comparison
) NCT03867773 344 345 O
; NCT03867773 346 347 O

- NCT03867773 350 351 O
able NCT03867773 353 357 O
to NCT03867773 358 360 O
give NCT03867773 361 365 O
written NCT03867773 366 373 O
informed NCT03867773 374 382 O
consent NCT03867773 383 390 O

Exclusion NCT03867773 391 400 O
Criteria NCT03867773 401 409 O
: NCT03867773 410 411 O

- NCT03867773 415 416 O
Smoker NCT03867773 418 424 B-Condition
; NCT03867773 424 425 O
diabetic NCT03867773 426 434 B-Condition
; NCT03867773 434 435 O

- NCT03867773 438 439 O
history NCT03867773 441 448 B-Eq-Comparison
of NCT03867773 449 451 O
alcohol NCT03867773 452 459 B-Condition
dependance NCT03867773 460 470 I-Condition
( NCT03867773 471 472 O
score NCT03867773 473 478 B-Eq-Comparison
> NCT03867773 479 480 I-Eq-Comparison
20 NCT03867773 481 483 I-Eq-Comparison
from NCT03867773 484 488 O
Alcohol NCT03867773 489 496 B-Observation
and NCT03867773 497 500 I-Observation
Health NCT03867773 501 507 I-Observation
Questionnaire NCT03867773 508 521 I-Observation
8 NCT03867773 522 523 I-Observation
) NCT03867773 524 525 O
; NCT03867773 526 527 O

- NCT03867773 530 531 O
taking NCT03867773 533 539 B-Eq-Comparison
weight NCT03867773 540 546 B-Drug
loss NCT03867773 547 551 I-Drug
medications NCT03867773 552 563 I-Drug
; NCT03867773 563 564 O

- NCT03867773 567 568 O
taking NCT03867773 570 576 B-Eq-Comparison
medication NCT03867773 577 587 B-Drug
that NCT03867773 588 592 O
requires NCT03867773 593 601 O
eating NCT03867773 602 608 B-Observation
food NCT03867773 609 613 I-Observation
before NCT03867773 614 620 B-Temporal-Connection___Temporal-Connection-Type-Value:before
( NCT03867773 621 622 O
or NCT03867773 623 625 O
with NCT03867773 626 630 O
) NCT03867773 631 632 O
the NCT03867773 633 636 B-Coreference
medication NCT03867773 637 647 I-Coreference
; NCT03867773 647 648 O
history NCT03867773 649 656 B-Eq-Comparison
of NCT03867773 657 659 O
eating NCT03867773 660 666 B-Condition
disorders NCT03867773 667 676 I-Condition
; NCT03867773 676 677 O

- NCT03867773 680 681 O
night NCT03867773 683 688 O
- NCT03867773 689 690 O
shift NCT03867773 691 696 O
workers NCT03867773 697 704 O
; NCT03867773 704 705 O

- NCT03867773 708 709 O
perimenopausal NCT03867773 711 725 B-Condition
; NCT03867773 725 726 O

- NCT03867773 729 730 O
pregnant NCT03867773 732 740 B-Condition
women NCT03867773 741 746 O

Inclusion NCT03865602 0 9 O
Criteria NCT03865602 10 18 O
: NCT03865602 19 20 O

1 NCT03865602 24 25 O
. NCT03865602 25 26 O
Admitted NCT03865602 28 36 B-Encounter
from NCT03865602 37 41 O
the NCT03865602 42 45 O
emergency NCT03865602 46 55 O
department NCT03865602 56 66 O
to NCT03865602 67 69 B-Temporal-Connection___Temporal-Connection-Type-Value:after
inpatient NCT03865602 70 79 B-Encounter
or NCT03865602 80 82 B-Or
observation NCT03865602 83 94 B-Encounter
status NCT03865602 95 101 O
at NCT03865602 102 104 O
one NCT03865602 105 108 O
of NCT03865602 109 111 O
: NCT03865602 112 113 O

Carolinas NCT03865602 120 129 O
Medical NCT03865602 130 137 O
Center NCT03865602 138 144 O
, NCT03865602 145 146 O
Carolinas NCT03865602 147 156 O
Medical NCT03865602 157 164 O
Center NCT03865602 165 171 O
- NCT03865602 172 173 O
Mercy NCT03865602 174 179 O
, NCT03865602 180 181 O
or NCT03865602 182 184 B-Or
Atrium NCT03865602 185 191 O
Health NCT03865602 192 198 O
Northeast NCT03865602 199 208 O
; NCT03865602 208 209 O

2 NCT03865602 212 213 O
. NCT03865602 213 214 O
≥ NCT03865602 216 217 B-Eq-Comparison
18 NCT03865602 218 220 I-Eq-Comparison
years NCT03865602 221 226 I-Eq-Comparison
of NCT03865602 227 229 O
age NCT03865602 230 233 B-Age
upon NCT03865602 234 238 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03865602 239 248 B-Encounter
; NCT03865602 248 249 O

3 NCT03865602 252 253 O
. NCT03865602 253 254 O
oral NCT03865602 256 260 B-Modifier
/ NCT03865602 261 262 B-Or
parenteral NCT03865602 263 273 B-Modifier
antibiotic NCT03865602 274 284 B-Drug
or NCT03865602 285 287 B-Or
bacterial NCT03865602 288 297 B-Observation
culture NCT03865602 298 305 I-Observation
order NCT03865602 306 311 O
within NCT03865602 312 318 B-Eq-Comparison
24 NCT03865602 319 321 I-Eq-Comparison
hours NCT03865602 322 327 I-Eq-Comparison
of NCT03865602 328 330 B-Temporal-Connection___Temporal-Connection-Type-Value:after
emergency NCT03865602 331 340 B-Encounter
department NCT03865602 341 351 O
presentation NCT03865602 352 364 O
and NCT03865602 365 368 O

1 NCT03865602 376 377 O
. NCT03865602 377 378 O
culture NCT03865602 380 387 B-Observation
drawn NCT03865602 388 393 O
first NCT03865602 394 399 B-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03865602 400 401 O
antibiotics NCT03865602 402 413 B-Drug
ordered NCT03865602 414 421 O
within NCT03865602 422 428 B-Eq-Comparison
48 NCT03865602 429 431 I-Eq-Comparison
hours NCT03865602 432 437 I-Eq-Comparison
or NCT03865602 438 440 B-Or

2 NCT03865602 448 449 O
. NCT03865602 449 450 O
antibiotics NCT03865602 452 463 B-Drug
ordered NCT03865602 464 471 O
first NCT03865602 472 477 B-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03865602 478 479 O
culture NCT03865602 480 487 B-Observation
ordered NCT03865602 488 495 O
within NCT03865602 496 502 B-Eq-Comparison
48 NCT03865602 503 505 I-Eq-Comparison
hours NCT03865602 506 511 I-Eq-Comparison
( NCT03865602 512 513 O
adapted NCT03865602 514 521 O
from NCT03865602 522 526 O
criteria NCT03865602 527 535 O
applied NCT03865602 536 543 O
in NCT03865602 544 546 O
development NCT03865602 547 558 O
of NCT03865602 559 561 O
the NCT03865602 562 565 O
Third NCT03865602 566 571 O
International NCT03865602 572 585 O
Consensus NCT03865602 586 595 O
Definitions NCT03865602 596 607 O
for NCT03865602 608 611 O
Sepsis NCT03865602 612 618 O
and NCT03865602 619 622 O
Septic NCT03865602 623 629 O
Shock NCT03865602 630 635 O
) NCT03865602 636 637 O

4 NCT03865602 641 642 O
. NCT03865602 642 643 O
deemed NCT03865602 645 651 O
as NCT03865602 652 654 O
high NCT03865602 655 659 B-Modifier
- NCT03865602 660 661 O
risk NCT03865602 662 666 B-Risk
for NCT03865602 667 670 O
30 NCT03865602 671 673 B-Eq-Comparison
- NCT03865602 674 675 I-Eq-Comparison
day NCT03865602 676 679 I-Eq-Comparison
readmission NCT03865602 680 691 B-Encounter
( NCT03865602 692 693 O
i. NCT03865602 694 696 O
e. NCT03865602 697 699 O
, NCT03865602 700 701 O
≥ NCT03865602 702 703 B-Eq-Comparison
20 NCT03865602 704 706 I-Eq-Comparison
% NCT03865602 707 708 I-Eq-Comparison
) NCT03865602 710 711 O
or NCT03865602 712 714 B-Or
30 NCT03865602 715 717 B-Eq-Comparison
- NCT03865602 718 719 I-Eq-Comparison
day NCT03865602 720 723 I-Eq-Comparison
mortality NCT03865602 724 733 B-Death
( NCT03865602 734 735 O
i. NCT03865602 736 738 O
e. NCT03865602 739 741 O
, NCT03865602 742 743 O
≥ NCT03865602 744 745 B-Eq-Comparison
10 NCT03865602 746 748 I-Eq-Comparison
% NCT03865602 749 750 I-Eq-Comparison
) NCT03865602 752 753 O
using NCT03865602 754 759 B-Eq-Comparison
risk NCT03865602 760 764 B-Observation
- NCT03865602 765 766 I-Observation
scoring NCT03865602 767 774 I-Observation
models NCT03865602 775 781 I-Observation

5 NCT03865602 784 785 O
. NCT03865602 785 786 O
not NCT03865602 788 791 B-Negation
discharged NCT03865602 792 802 B-Encounter
at NCT03865602 803 805 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865602 806 809 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03865602 810 814 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03865602 815 817 I-Temporal-Connection___Temporal-Connection-Type-Value:during
patient NCT03865602 818 825 B-Study
list NCT03865602 826 830 I-Study
generation NCT03865602 831 841 I-Study

Exclusion NCT03865602 842 851 O
Criteria NCT03865602 852 860 O
: NCT03865602 861 862 O

1 NCT03865602 866 867 O
. NCT03865602 867 868 O
prior NCT03865602 870 875 B-Eq-Comparison
randomization NCT03865602 876 889 O
to NCT03865602 890 892 O
either NCT03865602 893 899 O
STAR NCT03865602 900 904 O
or NCT03865602 905 907 O
usual NCT03865602 908 913 O
care NCT03865602 914 918 O
study NCT03865602 919 924 O
arms NCT03865602 925 929 O
; NCT03865602 929 930 O

2 NCT03865602 933 934 O
. NCT03865602 934 935 O
not NCT03865602 937 940 B-Negation
a NCT03865602 941 942 O
North NCT03865602 943 948 O
Carolina NCT03865602 949 957 O
resident NCT03865602 958 966 O
or NCT03865602 967 969 B-Or
residence NCT03865602 970 979 B-Modifier
> NCT03865602 980 981 B-Eq-Comparison
2.5 NCT03865602 982 985 I-Eq-Comparison
- NCT03865602 986 987 I-Eq-Comparison
hour NCT03865602 988 992 I-Eq-Comparison
drive NCT03865602 993 998 B-Observation
time NCT03865602 999 1003 I-Observation
from NCT03865602 1004 1008 O
treating NCT03865602 1009 1017 O
hospital NCT03865602 1018 1026 O
; NCT03865602 1026 1027 O

3 NCT03865602 1030 1031 O
. NCT03865602 1031 1032 O
the NCT03865602 1034 1037 O
only NCT03865602 1038 1042 O
antibiotic NCT03865602 1043 1053 B-Drug
associated NCT03865602 1054 1064 O
with NCT03865602 1065 1069 O
patient NCT03865602 1070 1077 O
is NCT03865602 1078 1080 O
administered NCT03865602 1081 1093 B-Eq-Comparison
in NCT03865602 1094 1096 O
the NCT03865602 1097 1100 O
operating NCT03865602 1101 1110 O
room NCT03865602 1111 1115 O
as NCT03865602 1116 1118 O
this NCT03865602 1119 1123 O
likely NCT03865602 1124 1130 B-Assertion___Assertion-Type-Value:possible
represents NCT03865602 1131 1141 O
pre NCT03865602 1142 1145 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03865602 1146 1147 O
operative NCT03865602 1148 1157 B-Procedure
infection NCT03865602 1158 1167 B-Condition
prophylaxis NCT03865602 1168 1179 O
and NCT03865602 1180 1183 B-And
not NCT03865602 1184 1187 B-Negation
presumed NCT03865602 1188 1196 O
infection NCT03865602 1197 1206 B-Condition
; NCT03865602 1206 1207 O

4 NCT03865602 1210 1211 O
. NCT03865602 1211 1212 O
patients NCT03865602 1214 1222 O
transferred NCT03865602 1223 1234 B-Encounter
from NCT03865602 1235 1239 O
other NCT03865602 1240 1245 O
acute NCT03865602 1246 1251 O
care NCT03865602 1252 1256 O
hospitals NCT03865602 1257 1266 O
; NCT03865602 1266 1267 O

5 NCT03865602 1270 1271 O
. NCT03865602 1271 1272 O
patients NCT03865602 1274 1282 O
with NCT03865602 1283 1287 O
a NCT03865602 1288 1289 O
change NCT03865602 1290 1296 O
in NCT03865602 1297 1299 O
code NCT03865602 1300 1304 B-Observation
status NCT03865602 1305 1311 I-Observation
( NCT03865602 1312 1313 O
i. NCT03865602 1314 1316 O
e. NCT03865602 1317 1319 O
, NCT03865602 1320 1321 O
do NCT03865602 1322 1324 B-Observation
not NCT03865602 1325 1328 I-Observation
resuscitate NCT03865602 1329 1340 I-Observation
, NCT03865602 1341 1342 O
do NCT03865602 1343 1345 B-Observation
not NCT03865602 1346 1349 I-Observation
intubate NCT03865602 1350 1358 I-Observation
) NCT03865602 1359 1360 O
within NCT03865602 1361 1367 B-Eq-Comparison
24 NCT03865602 1368 1370 I-Eq-Comparison
hours NCT03865602 1371 1376 I-Eq-Comparison
after NCT03865602 1377 1382 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03865602 1383 1392 B-Encounter
due NCT03865602 1393 1396 O
to NCT03865602 1397 1399 O
the NCT03865602 1400 1403 O
general NCT03865602 1404 1411 O
assumption NCT03865602 1412 1422 O
of NCT03865602 1423 1425 O
increased NCT03865602 1426 1435 O
risk NCT03865602 1436 1440 O
of NCT03865602 1441 1443 O
exposure NCT03865602 1444 1452 O
to NCT03865602 1453 1455 O
less NCT03865602 1456 1460 O
aggressive NCT03865602 1461 1471 O
treatment NCT03865602 1472 1481 O
; NCT03865602 1481 1482 O

6 NCT03865602 1485 1486 O
. NCT03865602 1486 1487 O
patients NCT03865602 1489 1497 O
with NCT03865602 1498 1502 O
infection NCT03865602 1503 1512 B-Condition
ruled NCT03865602 1513 1518 B-Negation
out NCT03865602 1519 1522 I-Negation
during NCT03865602 1523 1529 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03865602 1530 1533 O
index NCT03865602 1534 1539 O
hospitalization NCT03865602 1540 1555 B-Encounter
. NCT03865602 1556 1557 O


Inclusion NCT03864939 0 9 O
Criteria NCT03864939 10 18 O
: NCT03864939 19 20 O

- NCT03864939 24 25 O
patients NCT03864939 27 35 O
with NCT03864939 36 40 O
localized NCT03864939 41 50 B-Modifier
prostate NCT03864939 51 59 I-Modifier
cancer NCT03864939 60 66 B-Condition

- NCT03864939 69 70 O
indication NCT03864939 72 82 B-Indication
for NCT03864939 83 86 O
radical NCT03864939 87 94 B-Procedure
prostatectomy NCT03864939 95 108 I-Procedure

- NCT03864939 111 112 O
no NCT03864939 114 116 B-Negation
other NCT03864939 117 122 B-Other
treatment NCT03864939 123 132 B-Procedure
of NCT03864939 133 135 O
prostate NCT03864939 136 144 B-Modifier
cancer NCT03864939 145 151 B-Condition

- NCT03864939 154 155 O
availability NCT03864939 157 169 O
to NCT03864939 170 172 O
informed NCT03864939 173 181 O
consent NCT03864939 182 189 O

Exclusion NCT03864939 190 199 O
Criteria NCT03864939 200 208 O
: NCT03864939 209 210 O

- NCT03864939 214 215 O
pre NCT03864939 217 220 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03864939 221 230 B-Procedure
incontinence NCT03864939 231 243 B-Condition
( NCT03864939 244 245 O
24 NCT03864939 246 248 B-Observation
hrs NCT03864939 249 252 I-Observation
pad NCT03864939 253 256 I-Observation
- NCT03864939 257 258 I-Observation
test NCT03864939 259 263 I-Observation
) NCT03864939 264 265 O

- NCT03864939 269 270 O
pre NCT03864939 272 275 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03864939 276 285 B-Procedure
erectile NCT03864939 286 294 B-Condition
dysfunction NCT03864939 295 306 I-Condition
( NCT03864939 307 308 O
IIEF NCT03864939 309 313 B-Observation
- NCT03864939 314 315 O
5 NCT03864939 316 317 B-Eq-Comparison
< NCT03864939 318 319 I-Eq-Comparison
20 NCT03864939 320 322 I-Eq-Comparison
) NCT03864939 323 324 O

- NCT03864939 328 329 O
metastasized NCT03864939 331 343 B-Modifier
or NCT03864939 344 346 B-Or
locally NCT03864939 347 354 B-Modifier
advanced NCT03864939 355 363 I-Modifier
prostate NCT03864939 364 372 O
cancer NCT03864939 373 379 B-Condition
in NCT03864939 380 382 O
pre NCT03864939 383 386 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03864939 387 396 B-Procedure
assessment NCT03864939 397 407 B-Observation

- NCT03864939 410 411 O
previous NCT03864939 413 421 B-Eq-Comparison
radiation NCT03864939 422 431 B-Procedure
of NCT03864939 432 434 O
pelvis NCT03864939 435 441 B-Modifier

- NCT03864939 444 445 O
previous NCT03864939 447 455 B-Eq-Comparison
prostate NCT03864939 456 464 B-Modifier
cancer NCT03864939 465 471 B-Condition
therapy NCT03864939 472 479 B-Procedure

- NCT03864939 482 483 O
psychiatric NCT03864939 485 496 B-Condition
disease NCT03864939 497 504 I-Condition

- NCT03864939 507 508 O
participation NCT03864939 510 523 O
at NCT03864939 524 526 O
another NCT03864939 527 534 B-Other
study NCT03864939 535 540 B-Study

Inclusion NCT03868865 0 9 O
Criteria NCT03868865 10 18 O
: NCT03868865 19 20 O

- NCT03868865 24 25 O
curative NCT03868865 27 35 B-Condition
malignancy NCT03868865 36 46 I-Condition
( NCT03868865 47 48 O
breast NCT03868865 49 55 B-Modifier
cancer NCT03868865 56 62 B-Condition
of NCT03868865 63 65 O
TNM NCT03868865 66 69 O
( NCT03868865 70 71 O
T NCT03868865 72 73 O
: NCT03868865 74 75 O
primary NCT03868865 76 83 O
tumor NCT03868865 84 89 O
, NCT03868865 90 91 O
N NCT03868865 92 93 O
: NCT03868865 94 95 O
regional NCT03868865 96 104 O
nodes NCT03868865 105 110 O
, NCT03868865 111 112 O
M NCT03868865 113 114 O
: NCT03868865 115 116 O
metastasis NCT03868865 117 127 O
) NCT03868865 128 129 O
staging NCT03868865 130 137 B-Eq-Comparison
I NCT03868865 138 139 I-Eq-Comparison
- NCT03868865 140 141 I-Eq-Comparison
III NCT03868865 142 145 I-Eq-Comparison
) NCT03868865 146 147 O

- NCT03868865 151 152 O
receiving NCT03868865 154 163 B-Eq-Comparison
chemotherapy NCT03868865 164 176 B-Procedure

- NCT03868865 179 180 O
at NCT03868865 182 184 B-Eq-Comparison
least NCT03868865 185 190 I-Eq-Comparison
18 NCT03868865 191 193 I-Eq-Comparison
years NCT03868865 194 199 I-Eq-Comparison
old NCT03868865 200 203 B-Age

- NCT03868865 206 207 O
written NCT03868865 209 216 O
informed NCT03868865 217 225 O
consent NCT03868865 226 233 O

- NCT03868865 236 237 O
willing NCT03868865 239 246 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03868865 247 250 B-And
physically NCT03868865 251 261 O
/ NCT03868865 262 263 O
mentally NCT03868865 264 272 O
able NCT03868865 273 277 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03868865 278 280 I-Assertion___Assertion-Type-Value:hypothetical
participate NCT03868865 281 292 O
in NCT03868865 293 295 O
a NCT03868865 296 297 O
six NCT03868865 298 301 B-Eq-Comparison
hours NCT03868865 302 307 I-Eq-Comparison
day NCT03868865 308 311 I-Eq-Comparison
care NCT03868865 312 316 B-Observation
clinic NCT03868865 317 323 I-Observation
program NCT03868865 324 331 I-Observation
eleven NCT03868865 332 338 B-Eq-Comparison
times NCT03868865 339 344 I-Eq-Comparison
during NCT03868865 345 351 B-Temporal-Connection___Temporal-Connection-Type-Value:during
chemotherapy NCT03868865 352 364 B-Procedure
. NCT03868865 365 366 O

Exclusion NCT03868865 368 377 O
Criteria NCT03868865 378 386 O
: NCT03868865 387 388 O

- NCT03868865 392 393 O
insufficient NCT03868865 395 407 B-Negation
knowledge NCT03868865 408 417 O
of NCT03868865 418 420 O
the NCT03868865 421 424 O
German NCT03868865 425 431 O
language NCT03868865 432 440 O

- NCT03868865 443 444 O
physical NCT03868865 446 454 B-Modifier
or NCT03868865 455 457 B-Or
mental NCT03868865 458 464 B-Modifier
disabilities NCT03868865 465 477 B-Condition
resulting NCT03868865 478 487 O
in NCT03868865 488 490 O
ineligibility NCT03868865 491 504 O
for NCT03868865 505 508 O
participation NCT03868865 509 522 O
in NCT03868865 523 525 O
the NCT03868865 526 529 O
program NCT03868865 530 537 O
or NCT03868865 538 540 O
filling NCT03868865 541 548 O
out NCT03868865 549 552 O
the NCT03868865 553 556 O
questionnaires NCT03868865 557 571 O
. NCT03868865 572 573 O


Inclusion NCT03867565 0 9 O
Criteria NCT03867565 10 18 O
: NCT03867565 19 20 O

- NCT03867565 24 25 O
Minor NCT03867565 27 32 B-Condition
burn NCT03867565 33 37 I-Condition
, NCT03867565 38 39 O
TBSA NCT03867565 40 44 B-Observation
< NCT03867565 45 46 B-Eq-Comparison
20 NCT03867565 47 49 I-Eq-Comparison
% NCT03867565 50 51 I-Eq-Comparison

- NCT03867565 55 56 O
Age NCT03867565 58 61 B-Age
≥ NCT03867565 62 63 B-Eq-Comparison
18 NCT03867565 64 66 I-Eq-Comparison
years NCT03867565 67 72 I-Eq-Comparison
old NCT03867565 73 76 O

- NCT03867565 79 80 O
Understands NCT03867565 82 93 O
Swedish NCT03867565 94 101 O
or NCT03867565 102 104 B-Or
English NCT03867565 105 112 O
verbally NCT03867565 113 121 O
and NCT03867565 122 125 O
in NCT03867565 126 128 O
writing NCT03867565 129 136 O

- NCT03867565 139 140 O
Mentally NCT03867565 142 150 B-Condition
adequate NCT03867565 151 159 I-Condition

- NCT03867565 162 163 O
Oral NCT03867565 165 169 O
and NCT03867565 170 173 O
written NCT03867565 174 181 O
informed NCT03867565 182 190 O
consent NCT03867565 191 198 O
. NCT03867565 199 200 O

Exclusion NCT03867565 202 211 O
Criteria NCT03867565 212 220 O
: NCT03867565 221 222 O

- NCT03867565 226 227 O
Patients NCT03867565 229 237 O
deemed NCT03867565 238 244 O
not NCT03867565 245 248 O
to NCT03867565 249 251 O
be NCT03867565 252 254 O
able NCT03867565 255 259 O
to NCT03867565 260 262 O
complete NCT03867565 263 271 O
study NCT03867565 272 277 O
protocol NCT03867565 278 286 O
. NCT03867565 287 288 O

- NCT03867565 292 293 O
TBSA NCT03867565 295 299 B-Observation
< NCT03867565 300 301 B-Eq-Comparison
2 NCT03867565 302 303 I-Eq-Comparison
% NCT03867565 304 305 I-Eq-Comparison
. NCT03867565 306 307 O

Inclusion NCT03868124 0 9 O
Criteria NCT03868124 10 18 O
: NCT03868124 19 20 O

- NCT03868124 24 25 O
Diagnosed NCT03868124 27 36 O
with NCT03868124 37 41 O
open NCT03868124 42 46 B-Modifier
- NCT03868124 47 48 I-Modifier
angle NCT03868124 49 54 I-Modifier
glaucoma NCT03868124 55 63 B-Condition
or NCT03868124 64 66 B-Or
ocular NCT03868124 67 73 B-Modifier
hypertension NCT03868124 74 86 B-Condition

- NCT03868124 89 90 O
C NCT03868124 92 93 B-Observation
/ NCT03868124 94 95 I-Observation
D NCT03868124 96 97 I-Observation
ratio NCT03868124 98 103 I-Observation
≤ NCT03868124 104 105 B-Eq-Comparison
0.8 NCT03868124 106 109 I-Eq-Comparison

- NCT03868124 113 114 O
Zero NCT03868124 116 120 B-Eq-Comparison
to NCT03868124 121 123 I-Eq-Comparison
two NCT03868124 124 127 I-Eq-Comparison
pre NCT03868124 128 131 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03868124 132 141 B-Procedure
ocular NCT03868124 142 148 B-Drug
hypotensive NCT03868124 149 160 I-Drug
medications NCT03868124 161 172 I-Drug

Exclusion NCT03868124 173 182 O
Criteria NCT03868124 183 191 O
: NCT03868124 192 193 O

- NCT03868124 197 198 O
Active NCT03868124 200 206 B-Eq-Comparison
corneal NCT03868124 207 214 B-Condition
inflammation NCT03868124 215 227 I-Condition
or NCT03868124 228 230 B-Or
edema NCT03868124 231 236 B-Condition

- NCT03868124 239 240 O
Retinal NCT03868124 242 249 B-Condition
disorders NCT03868124 250 259 I-Condition
not NCT03868124 260 263 B-Exception
associated NCT03868124 264 274 O
with NCT03868124 275 279 O
glaucoma NCT03868124 280 288 B-Condition

Inclusion NCT03863717 0 9 O
Criteria NCT03863717 10 18 O
: NCT03863717 19 20 O

- NCT03863717 24 25 O
Diagnosis NCT03863717 27 36 O
of NCT03863717 37 39 O
COPD NCT03863717 40 44 B-Condition
confirmed NCT03863717 45 54 O
by NCT03863717 55 57 O
clinical NCT03863717 58 66 B-Observation
examination NCT03863717 67 78 I-Observation
and NCT03863717 79 82 B-And
a NCT03863717 83 84 O
pulmonary NCT03863717 85 94 B-Observation
function NCT03863717 95 103 I-Observation
test NCT03863717 104 108 I-Observation

- NCT03863717 111 112 O
Stable NCT03863717 114 120 O
clinical NCT03863717 121 129 B-Condition
condition NCT03863717 130 139 I-Condition
( NCT03863717 140 141 O
without NCT03863717 142 149 B-Negation
recent NCT03863717 150 156 B-Eq-Comparison
respiratory NCT03863717 157 168 B-Condition
system NCT03863717 169 175 I-Condition
infections NCT03863717 176 186 I-Condition
or NCT03863717 187 189 B-Or
any NCT03863717 190 193 O
exacerbation NCT03863717 194 206 O
of NCT03863717 207 209 O
the NCT03863717 210 213 B-Coreference
disease NCT03863717 214 221 I-Coreference
) NCT03863717 222 223 O

- NCT03863717 227 228 O
Patients NCT03863717 230 238 O
must NCT03863717 239 243 O
be NCT03863717 244 246 O
willing NCT03863717 247 254 O
to NCT03863717 255 257 O
re NCT03863717 258 260 O
evaluate NCT03863717 261 269 O
at NCT03863717 270 272 O
the NCT03863717 273 276 O
end NCT03863717 277 280 O
of NCT03863717 281 283 O
the NCT03863717 284 287 O
study NCT03863717 288 293 O

- NCT03863717 296 297 O
Patients NCT03863717 299 307 O
must NCT03863717 308 312 O
be NCT03863717 313 315 O
willing NCT03863717 316 323 O
to NCT03863717 324 326 O
give NCT03863717 327 331 O
written NCT03863717 332 339 O
consent NCT03863717 340 347 O
for NCT03863717 348 351 O
their NCT03863717 352 357 O
participation NCT03863717 358 371 O
in NCT03863717 372 374 O
the NCT03863717 375 378 O
study NCT03863717 379 384 O

Exclusion NCT03863717 385 394 O
Criteria NCT03863717 395 403 O
: NCT03863717 404 405 O

- NCT03863717 409 410 O
Age NCT03863717 412 415 B-Age
< NCT03863717 416 417 B-Eq-Comparison
18 NCT03863717 418 420 I-Eq-Comparison
years NCT03863717 421 426 I-Eq-Comparison
old NCT03863717 427 430 O

- NCT03863717 433 434 O
Unstable NCT03863717 436 444 O
cardiac NCT03863717 445 452 B-Condition
disease NCT03863717 453 460 I-Condition

- NCT03863717 463 464 O
Musculoskeletal NCT03863717 466 481 B-Modifier
and NCT03863717 482 485 B-Or
neurological NCT03863717 486 498 B-Modifier
diseases NCT03863717 499 507 B-Condition
that NCT03863717 508 512 O
could NCT03863717 513 518 O
affect NCT03863717 519 525 O
exercise NCT03863717 526 534 O
performance NCT03863717 535 546 O
or NCT03863717 547 549 O
preclude NCT03863717 550 558 O
exercise NCT03863717 559 567 O

- NCT03863717 570 571 O
Patients NCT03863717 573 581 O
of NCT03863717 582 584 O
COPD NCT03863717 585 589 B-Condition
final NCT03863717 590 595 B-Modifier
stage NCT03863717 596 601 I-Modifier
or NCT03863717 602 604 B-Or
other NCT03863717 605 610 O
serious NCT03863717 611 618 O
disease NCT03863717 619 626 B-Condition
final NCT03863717 627 632 B-Modifier
stage NCT03863717 633 638 I-Modifier

- NCT03863717 641 642 O
Significant NCT03863717 644 655 O
cognitive NCT03863717 656 665 B-Modifier
or NCT03863717 666 668 B-Or
psychiatric NCT03863717 669 680 B-Modifier
impairment NCT03863717 681 691 B-Condition
that NCT03863717 692 696 O
would NCT03863717 697 702 B-Assertion___Assertion-Type-Value:hypothetical
lead NCT03863717 703 707 O
to NCT03863717 708 710 O
an NCT03863717 711 713 O
inability NCT03863717 714 723 B-Condition
to NCT03863717 724 726 I-Condition
follow NCT03863717 727 733 I-Condition
simple NCT03863717 734 740 I-Condition
commands NCT03863717 741 749 I-Condition
in NCT03863717 750 752 O
a NCT03863717 753 754 O
group NCT03863717 755 760 O
setting NCT03863717 761 768 O

Inclusion NCT03866135 0 9 O
Criteria NCT03866135 10 18 O
: NCT03866135 19 20 O

- NCT03866135 24 25 O
Patients NCT03866135 27 35 O
diagnosed NCT03866135 36 45 O
as NCT03866135 46 48 O
AS NCT03866135 49 51 B-Condition
according NCT03866135 52 61 O
to NCT03866135 62 64 O
the NCT03866135 65 68 O
modified NCT03866135 69 77 O
New NCT03866135 78 81 O
York NCT03866135 82 86 O
diagnostic NCT03866135 87 97 O
criteria NCT03866135 98 106 O
were NCT03866135 107 111 O
included NCT03866135 112 120 O

Exclusion NCT03866135 121 130 O
Criteria NCT03866135 131 139 O
: NCT03866135 140 141 O

- NCT03866135 145 146 O
Patients NCT03866135 148 156 O
previously NCT03866135 157 167 B-Eq-Comparison
diagnosed NCT03866135 168 177 O
with NCT03866135 178 182 O
OP NCT03866135 183 185 B-Condition
, NCT03866135 186 187 O

- NCT03866135 191 192 O
Patients NCT03866135 194 202 O
previously NCT03866135 203 213 B-Eq-Comparison
treated NCT03866135 214 221 O
with NCT03866135 222 226 O
OP NCT03866135 227 229 B-Condition
, NCT03866135 230 231 O

- NCT03866135 235 236 O
Patients NCT03866135 238 246 O
with NCT03866135 247 251 B-Eq-Comparison
bone NCT03866135 252 256 B-Condition
fractures NCT03866135 257 266 I-Condition
previously NCT03866135 267 277 B-Eq-Comparison
associated NCT03866135 278 288 O
with NCT03866135 289 293 O
OP NCT03866135 294 296 B-Condition
, NCT03866135 297 298 O

- NCT03866135 302 303 O
Those NCT03866135 305 310 O
using NCT03866135 311 316 B-Eq-Comparison
drugs NCT03866135 317 322 B-Drug
that NCT03866135 323 327 O
affect NCT03866135 328 334 O
bone NCT03866135 335 339 B-Condition
metabolism NCT03866135 340 350 I-Condition
, NCT03866135 351 352 O
metabolic NCT03866135 353 362 B-Condition
bone NCT03866135 363 367 I-Condition
diseases NCT03866135 368 376 I-Condition
( NCT03866135 377 378 O
Paget NCT03866135 379 384 B-Condition
's NCT03866135 384 386 I-Condition
disease NCT03866135 387 394 I-Condition
, NCT03866135 395 396 O
osteomalacia NCT03866135 397 409 B-Condition
, NCT03866135 410 411 O
hyperparathyroidism NCT03866135 412 431 B-Condition
) NCT03866135 432 433 O
, NCT03866135 435 436 O

- NCT03866135 440 441 O
Diabetes NCT03866135 443 451 B-Condition
mellitus NCT03866135 452 460 I-Condition
, NCT03866135 461 462 O

- NCT03866135 466 467 O
Hypothyroidism NCT03866135 469 483 B-Condition
, NCT03866135 484 485 O
hyperthyroidism NCT03866135 486 501 B-Condition
, NCT03866135 502 503 O

- NCT03866135 507 508 O
Patients NCT03866135 510 518 O
with NCT03866135 519 523 O
kidney NCT03866135 524 530 B-Modifier
, NCT03866135 531 532 O
liver NCT03866135 533 538 B-Modifier
and NCT03866135 539 542 B-Or
intestinal NCT03866135 543 553 B-Modifier
diseases NCT03866135 554 562 B-Condition
, NCT03866135 563 564 O

- NCT03866135 568 569 O
Those NCT03866135 571 576 O
using NCT03866135 577 582 B-Eq-Comparison
corticosteroids NCT03866135 583 598 B-Drug


- NCT03921515 1 2 O
INCLUSION NCT03921515 4 13 O
CRITERIA NCT03921515 14 22 O
: NCT03921515 23 24 O

1 NCT03921515 33 34 O
. NCT03921515 34 35 O
Meets NCT03921515 37 42 O
one NCT03921515 43 46 O
of NCT03921515 47 49 O
the NCT03921515 50 53 O
following NCT03921515 54 63 O
: NCT03921515 64 65 O

1 NCT03921515 79 80 O
. NCT03921515 80 81 O
has NCT03921515 83 86 O
documentation NCT03921515 87 100 O
of NCT03921515 101 103 O
HIES NCT03921515 104 108 B-Condition
or NCT03921515 109 111 B-Or
CGD NCT03921515 112 115 B-Condition
( NCT03921515 116 117 O
patient NCT03921515 118 125 O
populations NCT03921515 126 137 O
) NCT03921515 138 139 O
; NCT03921515 140 141 O
or NCT03921515 142 144 B-Or

2 NCT03921515 157 158 O
. NCT03921515 158 159 O
does NCT03921515 161 165 O
not NCT03921515 166 169 B-Negation
have NCT03921515 170 174 O
clinically NCT03921515 175 185 O
apparent NCT03921515 186 194 O
evidence NCT03921515 195 203 O
of NCT03921515 204 206 O
an NCT03921515 207 209 O
immune NCT03921515 210 216 B-Condition
defect NCT03921515 217 223 I-Condition
or NCT03921515 224 226 B-Or
history NCT03921515 227 234 B-Eq-Comparison
of NCT03921515 235 237 O
invasive NCT03921515 238 246 B-Modifier
or NCT03921515 247 249 B-Or
recurrent NCT03921515 250 259 B-Modifier
S. NCT03921515 260 262 B-Organism
aureus NCT03921515 264 270 I-Organism
infections NCT03921515 271 281 B-Condition
( NCT03921515 282 283 O
healthy NCT03921515 284 291 B-Condition
volunteers NCT03921515 292 302 O
) NCT03921515 303 304 O
. NCT03921515 306 307 O

2 NCT03921515 316 317 O
. NCT03921515 317 318 O
Between NCT03921515 320 327 O
the NCT03921515 328 331 O
following NCT03921515 332 341 O
age NCT03921515 342 345 O
limits NCT03921515 346 352 O
( NCT03921515 353 354 O
inclusive NCT03921515 355 364 O
) NCT03921515 365 366 O
: NCT03921515 368 369 O

1 NCT03921515 383 384 O
. NCT03921515 384 385 O
18 NCT03921515 387 389 B-Eq-Comparison
and NCT03921515 390 393 I-Eq-Comparison
65 NCT03921515 394 396 I-Eq-Comparison
years NCT03921515 397 402 I-Eq-Comparison
old NCT03921515 403 406 B-Age
for NCT03921515 407 410 O
healthy NCT03921515 411 418 B-Condition
volunteers NCT03921515 419 429 O
; NCT03921515 429 430 O

2 NCT03921515 443 444 O
. NCT03921515 444 445 O
7 NCT03921515 447 448 B-Eq-Comparison
and NCT03921515 449 452 I-Eq-Comparison
65 NCT03921515 453 455 I-Eq-Comparison
years NCT03921515 456 461 I-Eq-Comparison
old NCT03921515 462 465 B-Age
for NCT03921515 466 469 O
patients NCT03921515 470 478 O
with NCT03921515 479 483 O
CGD NCT03921515 484 487 B-Condition
; NCT03921515 487 488 O

3 NCT03921515 501 502 O
. NCT03921515 502 503 O
18 NCT03921515 505 507 B-Eq-Comparison
and NCT03921515 508 511 I-Eq-Comparison
65 NCT03921515 512 514 I-Eq-Comparison
years NCT03921515 515 520 I-Eq-Comparison
old NCT03921515 521 524 B-Age
for NCT03921515 525 528 O
patients NCT03921515 529 537 O
with NCT03921515 538 542 O
HIES NCT03921515 543 547 B-Condition
. NCT03921515 548 549 O

3 NCT03921515 558 559 O
. NCT03921515 559 560 O
Willing NCT03921515 562 569 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921515 570 572 I-Assertion___Assertion-Type-Value:hypothetical
allow NCT03921515 573 578 B-Observation
storage NCT03921515 579 586 I-Observation
of NCT03921515 587 589 O
blood NCT03921515 590 595 B-Modifier
, NCT03921515 596 597 O
RNA NCT03921515 598 601 B-Modifier
, NCT03921515 602 603 O
bacterial NCT03921515 604 613 B-Modifier
and NCT03921515 614 617 B-Or
fungal NCT03921515 618 624 B-Modifier
cultures NCT03921515 625 633 I-Modifier
, NCT03921515 634 635 O
and NCT03921515 636 639 B-Or
other NCT03921515 640 645 O
tissue NCT03921515 646 652 B-Modifier
samples NCT03921515 653 660 I-Modifier
for NCT03921515 661 664 O
future NCT03921515 665 671 O
research NCT03921515 672 680 O
. NCT03921515 681 682 O

4 NCT03921515 691 692 O
. NCT03921515 692 693 O
Able NCT03921515 695 699 O
to NCT03921515 700 702 O
provide NCT03921515 703 710 O
informed NCT03921515 711 719 O
consent NCT03921515 720 727 O
. NCT03921515 728 729 O

EXCLUSION NCT03921515 731 740 O
CRITERIA NCT03921515 741 749 O
: NCT03921515 750 751 O

The NCT03921515 753 756 O
following NCT03921515 757 766 O
exclusion NCT03921515 767 776 O
criteria NCT03921515 777 785 O
apply NCT03921515 786 791 O
to NCT03921515 792 794 O
all NCT03921515 795 798 O
subjects NCT03921515 799 807 O
: NCT03921515 808 809 O

1 NCT03921515 813 814 O
. NCT03921515 814 815 O
For NCT03921515 817 820 O
individuals NCT03921515 821 832 O
undergoing NCT03921515 833 843 B-Eq-Comparison
blister NCT03921515 844 851 B-Modifier
or NCT03921515 852 854 B-Or
skin NCT03921515 855 859 B-Modifier
biopsy NCT03921515 860 866 B-Procedure
procedures NCT03921515 867 877 I-Procedure
, NCT03921515 878 879 O
history NCT03921515 880 887 B-Eq-Comparison
of NCT03921515 888 890 O
keloid NCT03921515 891 897 B-Condition
formation NCT03921515 898 907 I-Condition
. NCT03921515 908 909 O

2 NCT03921515 913 914 O
. NCT03921515 914 915 O
Current NCT03921515 917 924 B-Eq-Comparison
or NCT03921515 925 927 B-Or
prior NCT03921515 928 933 B-Eq-Comparison
( NCT03921515 934 935 O
within NCT03921515 936 942 B-Eq-Comparison
3 NCT03921515 943 944 I-Eq-Comparison
months NCT03921515 945 951 I-Eq-Comparison
) NCT03921515 952 953 O
anticoagulant NCT03921515 954 967 B-Modifier
or NCT03921515 968 970 B-Or
anti NCT03921515 971 975 B-Modifier
- NCT03921515 976 977 I-Modifier
platelet NCT03921515 978 986 I-Modifier
therapy NCT03921515 987 994 B-Procedure
( NCT03921515 995 996 O
other NCT03921515 997 1002 B-Exception
than NCT03921515 1003 1007 I-Exception
aspirin NCT03921515 1008 1015 B-Drug
or NCT03921515 1016 1018 B-Or
non NCT03921515 1019 1022 B-Drug
- NCT03921515 1023 1024 I-Drug
steroidal NCT03921515 1025 1034 I-Drug
anti NCT03921515 1035 1039 I-Drug
- NCT03921515 1040 1041 I-Drug
inflammatory NCT03921515 1042 1054 I-Drug
drugs NCT03921515 1055 1060 I-Drug
[ NCT03921515 1061 1062 O
NSAIDs NCT03921515 1063 1069 B-Drug
] NCT03921515 1070 1071 O
) NCT03921515 1073 1074 O
. NCT03921515 1076 1077 O

3 NCT03921515 1081 1082 O
. NCT03921515 1082 1083 O
Current NCT03921515 1085 1092 B-Eq-Comparison
or NCT03921515 1093 1095 B-Or
prior NCT03921515 1096 1101 B-Eq-Comparison
( NCT03921515 1102 1103 O
within NCT03921515 1104 1110 B-Eq-Comparison
3 NCT03921515 1111 1112 I-Eq-Comparison
months NCT03921515 1113 1119 I-Eq-Comparison
) NCT03921515 1120 1121 O
use NCT03921515 1122 1125 O
of NCT03921515 1126 1128 O
immunomodulatory NCT03921515 1129 1145 B-Drug
drugs NCT03921515 1146 1151 I-Drug
( NCT03921515 1152 1153 O
e. NCT03921515 1154 1156 O
g. NCT03921515 1157 1159 O
, NCT03921515 1160 1161 O
chemotherapy NCT03921515 1162 1174 B-Procedure
, NCT03921515 1175 1176 O
steroids NCT03921515 1177 1185 B-Drug
) NCT03921515 1186 1187 O
, NCT03921515 1189 1190 O
except NCT03921515 1191 1197 O
if NCT03921515 1198 1200 O
approved NCT03921515 1201 1209 O
by NCT03921515 1210 1212 O
the NCT03921515 1213 1216 O
principal NCT03921515 1217 1226 O
investigator NCT03921515 1227 1239 O
. NCT03921515 1240 1241 O

4 NCT03921515 1245 1246 O
. NCT03921515 1246 1247 O
Pregnancy NCT03921515 1249 1258 B-Condition
. NCT03921515 1259 1260 O

5 NCT03921515 1264 1265 O
. NCT03921515 1265 1266 O
Any NCT03921515 1268 1271 O
condition NCT03921515 1272 1281 B-Condition
that NCT03921515 1282 1286 O
, NCT03921515 1287 1288 O
in NCT03921515 1289 1291 O
the NCT03921515 1292 1295 O
opinion NCT03921515 1296 1303 O
of NCT03921515 1304 1306 O
the NCT03921515 1307 1310 O
investigator NCT03921515 1311 1323 O
, NCT03921515 1324 1325 O
contraindicates NCT03921515 1326 1341 B-Contraindication
participation NCT03921515 1342 1355 O
in NCT03921515 1356 1358 O
the NCT03921515 1359 1362 O
study NCT03921515 1363 1368 B-Study
. NCT03921515 1368 1369 O

Healthy NCT03924479 0 7 B-Observation
subjects NCT03924479 8 16 O
: NCT03924479 17 18 O
Adults NCT03924479 19 25 O
( NCT03924479 26 27 O
≥ NCT03924479 29 30 B-Eq-Comparison
21 NCT03924479 31 33 I-Eq-Comparison
years NCT03924479 34 39 I-Eq-Comparison
of NCT03924479 40 42 O
age NCT03924479 43 46 B-Age
) NCT03924479 47 48 O
in NCT03924479 49 51 O
the NCT03924479 52 55 O
absence NCT03924479 56 63 B-Negation
of NCT03924479 64 66 O
a NCT03924479 67 68 O
history NCT03924479 69 76 B-Condition
of NCT03924479 77 79 I-Condition
HFpEF NCT03924479 80 85 O
or NCT03924479 86 88 B-Or
HFrEF NCT03924479 89 94 B-Condition
, NCT03924479 95 96 O
pulmonary NCT03924479 97 106 B-Modifier
, NCT03924479 107 108 O
neurologic NCT03924479 109 119 B-Modifier
, NCT03924479 120 121 O
orthopedic NCT03924479 122 132 B-Modifier
, NCT03924479 133 134 O
or NCT03924479 135 137 B-Or
other NCT03924479 138 143 B-Modifier
diseases NCT03924479 144 152 B-Condition
affecting NCT03924479 153 162 I-Condition
the NCT03924479 163 166 I-Condition
neuromuscular NCT03924479 167 180 I-Condition
system NCT03924479 181 187 I-Condition
. NCT03924479 188 189 O

Controls NCT03924479 191 199 O
will NCT03924479 200 204 O
be NCT03924479 205 207 O
matched NCT03924479 208 215 O
for NCT03924479 216 219 O
age NCT03924479 220 223 O
and NCT03924479 224 227 O
sex NCT03924479 228 231 O
. NCT03924479 232 233 O

All NCT03924479 235 238 O
HFpEF NCT03924479 239 244 B-Condition
patients NCT03924479 245 253 O
will NCT03924479 254 258 O
be NCT03924479 259 261 O
managed NCT03924479 262 269 O
by NCT03924479 270 272 O
their NCT03924479 273 278 O
primary NCT03924479 279 286 O
care NCT03924479 287 291 O
physician NCT03924479 292 301 O
or NCT03924479 302 304 O
cardiologist NCT03924479 305 317 O
with NCT03924479 318 322 O
additional NCT03924479 323 333 O
review NCT03924479 334 340 O
and NCT03924479 341 344 O
oversight NCT03924479 345 354 O
by NCT03924479 355 357 O
Dr. NCT03924479 358 361 B-Provider
Borlaug NCT03924479 363 370 I-Provider
( NCT03924479 371 372 O
Co NCT03924479 373 375 O
- NCT03924479 376 377 O
Investigator NCT03924479 378 390 O
) NCT03924479 391 392 O
prior NCT03924479 393 398 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924479 399 401 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03924479 402 412 B-Study
to NCT03924479 413 415 O
ensure NCT03924479 416 422 O
adequacy NCT03924479 423 431 O
of NCT03924479 432 434 O
inclusion NCT03924479 435 444 O
and NCT03924479 445 448 O
exclusion NCT03924479 449 458 O
criteria NCT03924479 459 467 O
and NCT03924479 468 471 O
that NCT03924479 472 476 O
participation NCT03924479 477 490 O
in NCT03924479 491 493 O
exercise NCT03924479 494 502 O
testing NCT03924479 503 510 O
and NCT03924479 511 514 O
resistance NCT03924479 515 525 O
exercise NCT03924479 526 534 O
training NCT03924479 535 543 O
is NCT03924479 544 546 O
safe NCT03924479 547 551 O
. NCT03924479 552 553 O

Inclusion NCT03924479 555 564 O
Criteria NCT03924479 565 573 O
for NCT03924479 574 577 O
HFpEF NCT03924479 578 583 O
, NCT03924479 584 585 O
includes NCT03924479 586 594 O
: NCT03924479 595 596 O

- NCT03924479 600 601 O
Clinical NCT03924479 603 611 O
diagnosis NCT03924479 612 621 O
of NCT03924479 622 624 O
HFpEF NCT03924479 625 630 B-Condition
. NCT03924479 631 632 O

- NCT03924479 636 637 O
Patients NCT03924479 639 647 O
with NCT03924479 648 652 O
a NCT03924479 653 654 O
history NCT03924479 655 662 B-Eq-Comparison
stable NCT03924479 663 669 O
( NCT03924479 670 671 O
no NCT03924479 672 674 B-Negation
medication NCT03924479 675 685 B-Drug
changes NCT03924479 686 693 O
in NCT03924479 694 696 O
past NCT03924479 697 701 B-Eq-Comparison
6 NCT03924479 702 703 I-Eq-Comparison
weeks NCT03924479 704 709 I-Eq-Comparison
( NCT03924479 710 711 O
w NCT03924479 712 713 O
/ NCT03924479 714 715 O
duration NCT03924479 716 724 O
of NCT03924479 725 727 O
diagnosis NCT03924479 728 737 B-Coreference
> NCT03924479 738 739 B-Eq-Comparison
6 NCT03924479 740 741 I-Eq-Comparison
months NCT03924479 742 748 I-Eq-Comparison
) NCT03924479 749 750 O
. NCT03924479 752 753 O

- NCT03924479 757 758 O
New NCT03924479 760 763 B-Condition
York NCT03924479 764 768 I-Condition
Heart NCT03924479 769 774 I-Condition
Association NCT03924479 775 786 I-Condition
class NCT03924479 787 792 B-Eq-Comparison
I NCT03924479 793 794 I-Eq-Comparison
- NCT03924479 795 796 I-Eq-Comparison
III NCT03924479 797 800 I-Eq-Comparison
. NCT03924479 801 802 O

- NCT03924479 806 807 O
Current NCT03924479 809 816 B-Eq-Comparison
non NCT03924479 817 820 B-Negation
- NCT03924479 821 822 O
smokers NCT03924479 823 830 B-Condition
with NCT03924479 831 835 O
< NCT03924479 836 837 B-Eq-Comparison
15 NCT03924479 838 840 I-Eq-Comparison
pack NCT03924479 841 845 I-Eq-Comparison
year NCT03924479 846 850 I-Eq-Comparison
history NCT03924479 851 858 B-Eq-Comparison
. NCT03924479 859 860 O

- NCT03924479 864 865 O
Non NCT03924479 867 870 B-Negation
- NCT03924479 871 872 O
pregnant NCT03924479 873 881 B-Condition
women NCT03924479 882 887 O
, NCT03924479 888 889 O
and NCT03924479 890 893 B-And
individuals NCT03924479 894 905 O
who NCT03924479 906 909 O
are NCT03924479 910 913 O
able NCT03924479 914 918 B-Observation
to NCT03924479 919 921 I-Observation
exercise NCT03924479 922 930 I-Observation
( NCT03924479 931 932 O
i. NCT03924479 933 935 O
e. NCT03924479 936 938 O
without NCT03924479 940 947 B-Negation
orthopedic NCT03924479 948 958 B-Condition
limitations NCT03924479 959 970 I-Condition
or NCT03924479 971 973 B-Or
neuromuscular NCT03924479 974 987 B-Condition
disorders NCT03924479 988 997 I-Condition
) NCT03924479 998 999 O
. NCT03924479 1001 1002 O

Exclusion NCT03924479 1004 1013 O
Criteria NCT03924479 1014 1022 O
for NCT03924479 1023 1026 O
all NCT03924479 1027 1030 O
subjects NCT03924479 1031 1039 O
, NCT03924479 1040 1041 O
includes NCT03924479 1042 1050 O
: NCT03924479 1051 1052 O

- NCT03924479 1056 1057 O
history NCT03924479 1059 1066 B-Eq-Comparison
of NCT03924479 1067 1069 O
dangerous NCT03924479 1070 1079 O
arrhythmias NCT03924479 1080 1091 B-Condition

- NCT03924479 1094 1095 O
body NCT03924479 1097 1101 B-Observation
mass NCT03924479 1102 1106 I-Observation
index NCT03924479 1107 1112 I-Observation
> NCT03924479 1113 1114 B-Eq-Comparison
35 NCT03924479 1115 1117 I-Eq-Comparison
kg NCT03924479 1118 1120 I-Eq-Comparison
/ NCT03924479 1121 1122 I-Eq-Comparison
m2 NCT03924479 1123 1125 I-Eq-Comparison

- NCT03924479 1128 1129 O
current NCT03924479 1131 1138 B-Eq-Comparison
smokers NCT03924479 1139 1146 B-Condition
and NCT03924479 1147 1150 B-Or
/ NCT03924479 1151 1152 I-Or
or NCT03924479 1153 1155 I-Or
smoking NCT03924479 1156 1163 B-Observation
history NCT03924479 1164 1171 I-Observation
> NCT03924479 1172 1173 B-Eq-Comparison
15 NCT03924479 1174 1176 I-Eq-Comparison
pack NCT03924479 1177 1181 I-Eq-Comparison
years NCT03924479 1182 1187 I-Eq-Comparison

- NCT03924479 1190 1191 O
pregnant NCT03924479 1193 1201 B-Condition
women NCT03924479 1202 1207 O

- NCT03924479 1210 1211 O
uremia NCT03924479 1213 1219 B-Condition
, NCT03924479 1220 1221 O
history NCT03924479 1222 1229 B-Eq-Comparison
of NCT03924479 1230 1232 O
allergy NCT03924479 1233 1240 B-Allergy
to NCT03924479 1241 1243 O
iodides NCT03924479 1244 1251 O

- NCT03924479 1254 1255 O
impaired NCT03924479 1257 1265 B-Condition
renal NCT03924479 1266 1271 I-Condition
function NCT03924479 1272 1280 I-Condition

- NCT03924479 1283 1284 O
creatinine NCT03924479 1286 1296 B-Observation
value NCT03924479 1297 1302 O
greater NCT03924479 1303 1310 B-Eq-Comparison
than NCT03924479 1311 1315 I-Eq-Comparison
or NCT03924479 1316 1318 I-Eq-Comparison
equal NCT03924479 1319 1324 I-Eq-Comparison
to NCT03924479 1325 1327 I-Eq-Comparison
1.3 NCT03924479 1328 1331 I-Eq-Comparison
mg NCT03924479 1332 1334 I-Eq-Comparison
/ NCT03924479 1335 1336 I-Eq-Comparison
dL NCT03924479 1337 1339 I-Eq-Comparison
( NCT03924479 1340 1341 O
via NCT03924479 1342 1345 O
clinical NCT03924479 1346 1354 O
record NCT03924479 1355 1361 O
within NCT03924479 1362 1368 B-Eq-Comparison
the NCT03924479 1369 1372 I-Eq-Comparison
past NCT03924479 1373 1377 I-Eq-Comparison
6 NCT03924479 1378 1379 I-Eq-Comparison
months NCT03924479 1380 1386 I-Eq-Comparison
) NCT03924479 1387 1388 O

- NCT03924479 1392 1393 O
diagnosis NCT03924479 1395 1404 O
of NCT03924479 1405 1407 O
liver NCT03924479 1408 1413 B-Condition
disease NCT03924479 1414 1421 I-Condition

- NCT03924479 1424 1425 O
individuals NCT03924479 1427 1438 O
who NCT03924479 1439 1442 O
are NCT03924479 1443 1446 O
not NCT03924479 1447 1450 B-Negation
able NCT03924479 1451 1455 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924479 1456 1458 I-Assertion___Assertion-Type-Value:hypothetical
engage NCT03924479 1459 1465 O
in NCT03924479 1466 1468 O
exercise NCT03924479 1469 1477 B-Observation


Inclusion NCT03926520 0 9 O
Criteria NCT03926520 10 18 O
: NCT03926520 19 20 O

1 NCT03926520 24 25 O
. NCT03926520 25 26 O
Diagnosis NCT03926520 28 37 O
of NCT03926520 38 40 O
Alzheimer NCT03926520 41 50 B-Condition
's NCT03926520 50 52 I-Condition
Dementia NCT03926520 53 61 I-Condition
according NCT03926520 62 71 O
to NCT03926520 72 74 O
NIA NCT03926520 75 78 O
- NCT03926520 79 80 O
AA NCT03926520 81 83 O
Criteria NCT03926520 84 92 O
for NCT03926520 93 96 O
dementia NCT03926520 97 105 O
[ NCT03926520 106 107 O
55 NCT03926520 108 110 O
] NCT03926520 111 112 O

2 NCT03926520 116 117 O
. NCT03926520 117 118 O
MMSE NCT03926520 120 124 B-Observation
< NCT03926520 125 126 B-Eq-Comparison
15 NCT03926520 127 129 I-Eq-Comparison

3 NCT03926520 133 134 O
. NCT03926520 134 135 O
Cohen NCT03926520 137 142 B-Observation
- NCT03926520 143 144 I-Observation
Mansfield NCT03926520 145 154 I-Observation
Agitation NCT03926520 155 164 I-Observation
Inventory NCT03926520 165 174 I-Observation
Short NCT03926520 175 180 I-Observation
Version NCT03926520 181 188 I-Observation
( NCT03926520 189 190 O
CMAI NCT03926520 191 195 B-Observation
) NCT03926520 196 197 O
score NCT03926520 198 203 O
of NCT03926520 204 206 O
≥ NCT03926520 207 208 B-Eq-Comparison
4 NCT03926520 209 210 I-Eq-Comparison
on NCT03926520 211 213 O
at NCT03926520 214 216 B-Eq-Comparison
least NCT03926520 217 222 I-Eq-Comparison
one NCT03926520 223 226 I-Eq-Comparison
item NCT03926520 227 231 I-Eq-Comparison
, NCT03926520 232 233 O
a NCT03926520 234 235 O
score NCT03926520 236 241 O
of NCT03926520 242 244 O
3 NCT03926520 245 246 B-Eq-Comparison
on NCT03926520 247 249 I-Eq-Comparison
at NCT03926520 250 252 I-Eq-Comparison
least NCT03926520 253 258 I-Eq-Comparison
two NCT03926520 259 262 I-Eq-Comparison
items NCT03926520 263 268 I-Eq-Comparison
, NCT03926520 269 270 O
or NCT03926520 271 273 B-Or
a NCT03926520 274 275 O
score NCT03926520 276 281 O
of NCT03926520 282 284 O
2 NCT03926520 285 286 B-Eq-Comparison
on NCT03926520 287 289 I-Eq-Comparison
at NCT03926520 290 292 I-Eq-Comparison
least NCT03926520 293 298 I-Eq-Comparison
three NCT03926520 299 304 I-Eq-Comparison
items NCT03926520 305 310 I-Eq-Comparison
. NCT03926520 311 312 O

4 NCT03926520 316 317 O
. NCT03926520 317 318 O
At NCT03926520 320 322 B-Eq-Comparison
least NCT03926520 323 328 I-Eq-Comparison
one NCT03926520 329 332 I-Eq-Comparison
failed NCT03926520 333 339 O
pharmacological NCT03926520 340 355 B-Drug
intervention NCT03926520 356 368 O
to NCT03926520 369 371 O
manage NCT03926520 372 378 O
behavioral NCT03926520 379 389 B-Condition
symptoms NCT03926520 390 398 B-Assertion___Assertion-Type-Value:possible

5 NCT03926520 401 402 O
. NCT03926520 402 403 O
Medically NCT03926520 405 414 B-Condition
stable NCT03926520 415 421 O
for NCT03926520 422 425 B-Assertion___Assertion-Type-Value:hypothetical
safe NCT03926520 426 430 O
administration NCT03926520 431 445 O
of NCT03926520 446 448 O
ECT NCT03926520 449 452 B-Procedure
verified NCT03926520 453 461 O
by NCT03926520 462 464 O
standard NCT03926520 465 473 B-Procedure
physical NCT03926520 474 482 I-Procedure
examination NCT03926520 483 494 I-Procedure
, NCT03926520 495 496 O
urinalysis NCT03926520 497 507 B-Observation
and NCT03926520 508 511 O
serum NCT03926520 512 517 B-Observation
chemistries NCT03926520 518 529 I-Observation

6 NCT03926520 532 533 O
. NCT03926520 533 534 O
Comprehension NCT03926520 536 549 O
of NCT03926520 550 552 O
English NCT03926520 553 560 O
language NCT03926520 561 569 O

7 NCT03926520 572 573 O
. NCT03926520 573 574 O
Authorized NCT03926520 576 586 O
legal NCT03926520 587 592 O
representative NCT03926520 593 607 O
able NCT03926520 608 612 O
and NCT03926520 613 616 O
willing NCT03926520 617 624 O
to NCT03926520 625 627 O
give NCT03926520 628 632 O
informed NCT03926520 633 641 O
consent NCT03926520 642 649 O

8 NCT03926520 652 653 O
. NCT03926520 653 654 O
Age NCT03926520 656 659 B-Age
55 NCT03926520 660 662 B-Eq-Comparison
- NCT03926520 663 664 I-Eq-Comparison
89 NCT03926520 665 667 I-Eq-Comparison
years NCT03926520 668 673 I-Eq-Comparison
old NCT03926520 674 677 O
( NCT03926520 678 679 O
inclusive NCT03926520 680 689 O
) NCT03926520 690 691 O

Exclusion NCT03926520 693 702 O
Criteria NCT03926520 703 711 O
: NCT03926520 712 713 O

1 NCT03926520 717 718 O
. NCT03926520 718 719 O
Current NCT03926520 721 728 B-Eq-Comparison
diagnosis NCT03926520 729 738 O
of NCT03926520 739 741 O
co NCT03926520 742 744 B-Condition
- NCT03926520 745 746 I-Condition
morbid NCT03926520 747 753 I-Condition
delirium NCT03926520 754 762 I-Condition
, NCT03926520 763 764 O
measured NCT03926520 765 773 O
by NCT03926520 774 776 O
the NCT03926520 777 780 O
Confusion NCT03926520 781 790 B-Observation
Assessment NCT03926520 791 801 I-Observation
Measure NCT03926520 802 809 I-Observation
( NCT03926520 810 811 O
CAM NCT03926520 812 815 B-Observation
) NCT03926520 816 817 O
and NCT03926520 818 821 O
by NCT03926520 822 824 O
clinical NCT03926520 825 833 O
diagnosis NCT03926520 834 843 O

2 NCT03926520 846 847 O
. NCT03926520 847 848 O
Diagnosis NCT03926520 850 859 O
of NCT03926520 860 862 O
Non NCT03926520 863 866 B-Negation
- NCT03926520 867 868 O
AD NCT03926520 869 871 B-Condition
Dementia NCT03926520 872 880 B-Condition

3 NCT03926520 883 884 O
. NCT03926520 884 885 O
Lifetime NCT03926520 887 895 B-Eq-Comparison
or NCT03926520 896 898 B-Or
current NCT03926520 899 906 B-Eq-Comparison
diagnosis NCT03926520 907 916 O
of NCT03926520 917 919 O
Schizophrenia NCT03926520 920 933 B-Condition
, NCT03926520 934 935 O
Bipolar NCT03926520 936 943 B-Condition
Disorder NCT03926520 944 952 I-Condition
or NCT03926520 953 955 B-Or
Schizoaffective NCT03926520 956 971 B-Condition
Disorder NCT03926520 972 980 I-Condition

4 NCT03926520 983 984 O
. NCT03926520 984 985 O
Current NCT03926520 987 994 B-Eq-Comparison
episode NCT03926520 995 1002 O
of NCT03926520 1003 1005 O
Major NCT03926520 1006 1011 B-Modifier
Depressive NCT03926520 1012 1022 B-Condition
Disorder NCT03926520 1023 1031 I-Condition
( NCT03926520 1032 1033 O
MDD NCT03926520 1034 1037 B-Condition
) NCT03926520 1038 1039 O

5 NCT03926520 1043 1044 O
. NCT03926520 1044 1045 O
Active NCT03926520 1047 1053 B-Eq-Comparison
substance NCT03926520 1054 1063 B-Condition
use NCT03926520 1064 1067 I-Condition
disorder NCT03926520 1068 1076 I-Condition
within NCT03926520 1077 1083 B-Eq-Comparison
past NCT03926520 1084 1088 I-Eq-Comparison
6 NCT03926520 1089 1090 I-Eq-Comparison
months NCT03926520 1091 1097 I-Eq-Comparison

6 NCT03926520 1100 1101 O
. NCT03926520 1101 1102 O
Treatment NCT03926520 1104 1113 B-Procedure
with NCT03926520 1114 1118 O
ECT NCT03926520 1119 1122 B-Procedure
or NCT03926520 1123 1125 B-Or
other NCT03926520 1126 1131 O
neurostimulation NCT03926520 1132 1148 B-Procedure
therapies NCT03926520 1149 1158 I-Procedure
( NCT03926520 1159 1160 O
e. NCT03926520 1161 1163 O
g. NCT03926520 1164 1166 O
, NCT03926520 1167 1168 O
TMS NCT03926520 1169 1172 B-Procedure
or NCT03926520 1173 1175 O
vagal NCT03926520 1176 1181 B-Procedure
nerve NCT03926520 1182 1187 I-Procedure
stimulation NCT03926520 1188 1199 I-Procedure
) NCT03926520 1200 1201 O
within NCT03926520 1202 1208 B-Eq-Comparison
the NCT03926520 1209 1212 I-Eq-Comparison
past NCT03926520 1213 1217 I-Eq-Comparison
3 NCT03926520 1218 1219 I-Eq-Comparison
months NCT03926520 1220 1226 I-Eq-Comparison

Inclusion NCT03924492 0 9 O
Criteria NCT03924492 10 18 O
: NCT03924492 19 20 O

1 NCT03924492 24 25 O
. NCT03924492 25 26 O
Subject NCT03924492 28 35 O
has NCT03924492 36 39 O
signed NCT03924492 40 46 O
an NCT03924492 47 49 O
informed NCT03924492 50 58 O
consent NCT03924492 59 66 O
form NCT03924492 67 71 O
prior NCT03924492 72 77 B-Eq-Comparison
to NCT03924492 78 80 O
any NCT03924492 81 84 O
study NCT03924492 85 90 O
- NCT03924492 91 92 O
specific NCT03924492 93 101 O
procedures NCT03924492 102 112 O
being NCT03924492 113 118 O
performed NCT03924492 119 128 O

2 NCT03924492 131 132 O
. NCT03924492 132 133 O
Subject NCT03924492 135 142 O
is NCT03924492 143 145 O
an NCT03924492 146 148 O
ambulatory NCT03924492 149 159 B-Condition
female NCT03924492 160 166 O
at NCT03924492 167 169 B-Eq-Comparison
least NCT03924492 170 175 I-Eq-Comparison
18 NCT03924492 176 178 I-Eq-Comparison
years NCT03924492 179 184 I-Eq-Comparison
of NCT03924492 185 187 O
age NCT03924492 188 191 B-Age

3 NCT03924492 194 195 O
. NCT03924492 195 196 O
Subject NCT03924492 198 205 O
agrees NCT03924492 206 212 O
to NCT03924492 213 215 O
adhere NCT03924492 216 222 O
to NCT03924492 223 225 O
the NCT03924492 226 229 O
study NCT03924492 230 235 O
requirements NCT03924492 236 248 O

4 NCT03924492 251 252 O
. NCT03924492 252 253 O
Subject NCT03924492 255 262 O
agrees NCT03924492 263 269 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03924492 270 273 O
to NCT03924492 274 276 O
be NCT03924492 277 279 O
the NCT03924492 280 283 O
primary NCT03924492 284 291 B-Observation
caregiver NCT03924492 292 301 I-Observation
of NCT03924492 302 304 O
any NCT03924492 305 308 O
dependents NCT03924492 309 319 O
during NCT03924492 320 326 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924492 327 330 O
infusion NCT03924492 331 339 B-Procedure

5 NCT03924492 342 343 O
. NCT03924492 343 344 O
Subject NCT03924492 346 353 O
must NCT03924492 354 358 O
have NCT03924492 359 363 O
a NCT03924492 364 365 O
negative NCT03924492 366 374 O
pregnancy NCT03924492 375 384 B-Observation
test NCT03924492 385 389 I-Observation
on NCT03924492 390 392 O
Day NCT03924492 393 396 O
1 NCT03924492 397 398 O
prior NCT03924492 399 404 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924492 405 407 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03924492 408 411 O
start NCT03924492 412 417 O
of NCT03924492 418 420 O
the NCT03924492 421 424 O
ZULRESSO NCT03924492 425 433 B-Procedure
infusion NCT03924492 434 442 I-Procedure

6 NCT03924492 445 446 O
. NCT03924492 446 447 O
Subject NCT03924492 449 456 O
has NCT03924492 457 460 O
a NCT03924492 461 462 O
current NCT03924492 463 470 B-Eq-Comparison
diagnosis NCT03924492 471 480 O
of NCT03924492 481 483 O
PPD NCT03924492 484 487 B-Condition
, NCT03924492 488 489 O
as NCT03924492 490 492 O
assessed NCT03924492 493 501 O
by NCT03924492 502 504 O
the NCT03924492 505 508 O
Investigator NCT03924492 509 521 O

Exclusion NCT03924492 522 531 O
Criteria NCT03924492 532 540 O
: NCT03924492 541 542 O

1 NCT03924492 546 547 O
. NCT03924492 547 548 O
Subject NCT03924492 550 557 O
has NCT03924492 558 561 O
end NCT03924492 562 565 B-Modifier
stage NCT03924492 566 571 I-Modifier
renal NCT03924492 572 577 B-Condition
disease NCT03924492 578 585 I-Condition

2 NCT03924492 588 589 O
. NCT03924492 589 590 O
Subject NCT03924492 592 599 O
has NCT03924492 600 603 O
a NCT03924492 604 605 O
known NCT03924492 606 611 O
allergy NCT03924492 612 619 B-Allergy
to NCT03924492 620 622 O
progesterone NCT03924492 623 635 B-Drug
or NCT03924492 636 638 B-Or
allopregnanolone NCT03924492 639 655 B-Drug

Inclusion NCT03925571 0 9 O
Criteria NCT03925571 10 18 O
: NCT03925571 19 20 O

- NCT03925571 24 25 O
Majors NCT03925571 27 33 O
aged NCT03925571 34 38 B-Age
between NCT03925571 39 46 B-Eq-Comparison
18 NCT03925571 47 49 I-Eq-Comparison
and NCT03925571 50 53 I-Eq-Comparison
55 NCT03925571 54 56 I-Eq-Comparison
years NCT03925571 57 62 I-Eq-Comparison
, NCT03925571 63 64 O
with NCT03925571 65 69 O
an NCT03925571 70 72 O
appropriate NCT03925571 73 84 O
hearing NCT03925571 85 92 O
and NCT03925571 93 96 O
able NCT03925571 97 101 O
to NCT03925571 102 104 O
use NCT03925571 105 108 O
Music NCT03925571 109 114 O
- NCT03925571 115 116 O
Care NCT03925571 117 121 O
© NCT03925571 121 122 O
( NCT03925571 123 124 O
selection NCT03925571 125 134 O
of NCT03925571 135 137 O
the NCT03925571 138 141 O
playlist NCT03925571 142 150 O
via NCT03925571 151 154 O
internet NCT03925571 155 163 O
access NCT03925571 164 170 O
) NCT03925571 171 172 O
, NCT03925571 174 175 O

- NCT03925571 179 180 O
Needing NCT03925571 182 189 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03925571 190 199 B-Procedure
in NCT03925571 200 202 O
odontology NCT03925571 203 213 B-Modifier
- NCT03925571 214 215 O
periodontal NCT03925571 216 227 B-Modifier
surgery NCT03925571 228 235 B-Procedure
( NCT03925571 236 237 O
coronary NCT03925571 238 246 B-Procedure
elongation NCT03925571 247 257 I-Procedure
or NCT03925571 258 260 B-Or
sanitation NCT03925571 261 271 B-Procedure
surgery NCT03925571 272 279 I-Procedure
or NCT03925571 280 282 B-Or
muco NCT03925571 283 287 B-Procedure
- NCT03925571 288 289 I-Procedure
gingival NCT03925571 290 298 I-Procedure
surgery NCT03925571 299 306 I-Procedure
) NCT03925571 307 308 O
or NCT03925571 309 311 B-Or
implantary NCT03925571 312 322 B-Procedure
surgery NCT03925571 323 330 I-Procedure
( NCT03925571 331 332 O
placement NCT03925571 333 342 B-Procedure
of NCT03925571 343 345 I-Procedure
an NCT03925571 346 348 I-Procedure
unit NCT03925571 349 353 I-Procedure
implant NCT03925571 354 361 B-Modifier
or NCT03925571 362 364 B-Or
two NCT03925571 365 368 B-Modifier
implant NCT03925571 369 376 I-Modifier
in NCT03925571 377 379 I-Modifier
the NCT03925571 380 383 I-Modifier
same NCT03925571 384 388 I-Modifier
localization NCT03925571 389 401 I-Modifier
) NCT03925571 402 403 O
, NCT03925571 405 406 O

- NCT03925571 410 411 O
Oral NCT03925571 413 417 O
and NCT03925571 418 421 O
dated NCT03925571 422 427 O
consent NCT03925571 428 435 O
, NCT03925571 436 437 O

- NCT03925571 441 442 O
Agreeing NCT03925571 444 452 O
to NCT03925571 453 455 O
be NCT03925571 456 458 O
contacted NCT03925571 459 468 O
via NCT03925571 469 472 O
phone NCT03925571 473 478 O
at NCT03925571 479 481 O
J NCT03925571 482 483 O
+ NCT03925571 484 485 O
1 NCT03925571 486 487 O
and NCT03925571 488 491 O
to NCT03925571 492 494 O
fill NCT03925571 495 499 O
follow NCT03925571 500 506 O
- NCT03925571 507 508 O
up NCT03925571 509 511 O
study NCT03925571 512 517 O
documents NCT03925571 518 527 O
, NCT03925571 528 529 O

- NCT03925571 533 534 O
Profiting NCT03925571 536 545 O
of NCT03925571 546 548 O
social NCT03925571 549 555 O
security NCT03925571 556 564 O
or NCT03925571 565 567 O
CMU NCT03925571 568 571 O
. NCT03925571 572 573 O

Exclusion NCT03925571 575 584 O
Criteria NCT03925571 585 593 O
: NCT03925571 594 595 O

- NCT03925571 599 600 O
Patients NCT03925571 602 610 O
with NCT03925571 611 615 O
a NCT03925571 616 617 O
long NCT03925571 618 622 O
- NCT03925571 623 624 O
term NCT03925571 625 629 O
taking NCT03925571 630 636 B-Eq-Comparison
of NCT03925571 637 639 O
anxiolytic NCT03925571 640 650 B-Drug
or NCT03925571 651 653 B-Or
analgesic NCT03925571 654 663 B-Drug
, NCT03925571 664 665 O

- NCT03925571 669 670 O
Regular NCT03925571 672 679 O
consumer NCT03925571 680 688 O
of NCT03925571 689 691 O
soft NCT03925571 692 696 B-Drug
drug NCT03925571 697 701 I-Drug
( NCT03925571 702 703 O
cannabis NCT03925571 704 712 B-Drug
) NCT03925571 713 714 O
or NCT03925571 715 717 B-Or
hard NCT03925571 718 722 B-Drug
drug NCT03925571 723 727 I-Drug
( NCT03925571 728 729 O
opioid NCT03925571 730 736 B-Drug
) NCT03925571 737 738 O
, NCT03925571 740 741 O

- NCT03925571 745 746 O
Patient NCT03925571 748 755 O
with NCT03925571 756 760 O
medical NCT03925571 761 768 O
history NCT03925571 769 776 B-Eq-Comparison
of NCT03925571 777 779 O
psychiatry NCT03925571 780 790 B-Procedure
( NCT03925571 791 792 O
mental NCT03925571 793 799 B-Condition
harm NCT03925571 800 804 I-Condition
) NCT03925571 805 806 O
, NCT03925571 808 809 O
hearing NCT03925571 810 817 B-Condition
problem NCT03925571 818 825 I-Condition
, NCT03925571 826 827 O
cognitive NCT03925571 828 837 B-Modifier
and NCT03925571 838 841 B-Or
behavioural NCT03925571 842 853 B-Modifier
impairment NCT03925571 854 864 B-Condition
( NCT03925571 865 866 O
claustrophobia NCT03925571 867 881 B-Condition
) NCT03925571 882 883 O
, NCT03925571 885 886 O
sensory NCT03925571 887 894 B-Condition
disabilities NCT03925571 895 907 I-Condition
, NCT03925571 908 909 O

- NCT03925571 913 914 O
Patient NCT03925571 916 923 O
with NCT03925571 924 928 O
problems NCT03925571 929 937 O
of NCT03925571 938 940 O
hemostasis NCT03925571 941 951 B-Procedure
, NCT03925571 952 953 O

- NCT03925571 957 958 O
Majors NCT03925571 960 966 O
under NCT03925571 967 972 O
trusteeship NCT03925571 973 984 O
or NCT03925571 985 987 O
guardianship NCT03925571 988 1000 O
, NCT03925571 1001 1002 O

- NCT03925571 1006 1007 O
Pregnant NCT03925571 1009 1017 B-Condition
women NCT03925571 1018 1023 O
or NCT03925571 1024 1026 B-Or
lactating NCT03925571 1027 1036 B-Condition
, NCT03925571 1037 1038 O

- NCT03925571 1042 1043 O
Minors NCT03925571 1045 1051 O
, NCT03925571 1052 1053 O

- NCT03925571 1057 1058 O
Protected NCT03925571 1060 1069 B-Observation
person NCT03925571 1070 1076 I-Observation
, NCT03925571 1077 1078 O
deprived NCT03925571 1079 1087 O
of NCT03925571 1088 1090 O
freedom NCT03925571 1091 1098 O
or NCT03925571 1099 1101 O
under NCT03925571 1102 1107 O
justice NCT03925571 1108 1115 O
safeguard NCT03925571 1116 1125 O
, NCT03925571 1126 1127 O

- NCT03925571 1131 1132 O
Profiting NCT03925571 1134 1143 O
of NCT03925571 1144 1146 O
a NCT03925571 1147 1148 O
medical NCT03925571 1149 1156 O
help NCT03925571 1157 1161 O
from NCT03925571 1162 1166 O
government NCT03925571 1167 1177 O
( NCT03925571 1178 1179 O
AME NCT03925571 1180 1183 O
) NCT03925571 1184 1185 O
, NCT03925571 1187 1188 O

- NCT03925571 1192 1193 O
Not NCT03925571 1195 1198 O
contactable NCT03925571 1199 1210 O
after NCT03925571 1211 1216 O
care NCT03925571 1217 1221 O
, NCT03925571 1222 1223 O

- NCT03925571 1227 1228 O
Patient NCT03925571 1230 1237 O
with NCT03925571 1238 1242 O
hepatic NCT03925571 1243 1250 B-Condition
impairment NCT03925571 1251 1261 I-Condition
, NCT03925571 1262 1263 O

- NCT03925571 1267 1268 O
Patient NCT03925571 1270 1277 O
with NCT03925571 1278 1282 O
dry NCT03925571 1283 1286 B-Condition
mouth NCT03925571 1287 1292 I-Condition
, NCT03925571 1293 1294 O

- NCT03925571 1298 1299 O
Patient NCT03925571 1301 1308 O
relevant NCT03925571 1309 1317 O
a NCT03925571 1318 1319 O
suboptimal NCT03925571 1320 1330 B-Condition
hearing NCT03925571 1331 1338 I-Condition
incompatible NCT03925571 1339 1351 O
with NCT03925571 1352 1356 O
musicotherapy NCT03925571 1357 1370 O
or NCT03925571 1371 1373 O
inability NCT03925571 1374 1383 O
to NCT03925571 1384 1386 O
use NCT03925571 1387 1390 O
Music NCT03925571 1391 1396 O
- NCT03925571 1397 1398 O
care NCT03925571 1399 1403 O
® NCT03925571 1403 1404 O
. NCT03925571 1404 1405 O

Inclusion NCT03926078 0 9 O
criteria NCT03926078 10 18 O
: NCT03926078 19 20 O

- NCT03926078 24 25 O
All NCT03926078 27 30 O
patients NCT03926078 31 39 O
that NCT03926078 40 44 O
visit NCT03926078 45 50 B-Encounter
the NCT03926078 51 54 O
Zuyderland NCT03926078 55 65 O
Medical NCT03926078 66 73 O
Centre NCT03926078 74 80 O
outpatient NCT03926078 81 91 O
clinic NCT03926078 92 98 O
for NCT03926078 99 102 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
evaluation NCT03926078 103 113 B-Assertion___Assertion-Type-Value:possible
of NCT03926078 114 116 O
their NCT03926078 117 122 O
pectus NCT03926078 123 129 B-Condition
excavatum NCT03926078 130 139 I-Condition
. NCT03926078 140 141 O

- NCT03926078 145 146 O
No NCT03926078 148 150 O
age NCT03926078 151 154 O
restrictions NCT03926078 155 167 O
were NCT03926078 168 172 O
imposed NCT03926078 173 180 O
, NCT03926078 181 182 O
however NCT03926078 183 190 O
, NCT03926078 191 192 O
to NCT03926078 193 195 O
be NCT03926078 196 198 O
eligible NCT03926078 199 207 O
, NCT03926078 208 209 O
it NCT03926078 210 212 O
was NCT03926078 213 216 O
mandatory NCT03926078 217 226 O
to NCT03926078 227 229 O
be NCT03926078 230 232 O
able NCT03926078 233 237 O
to NCT03926078 238 240 O
stand NCT03926078 241 246 O
still NCT03926078 247 252 O
in NCT03926078 253 255 O
and NCT03926078 256 259 O
upright NCT03926078 260 267 O
position NCT03926078 268 276 O
for NCT03926078 277 280 O
60 NCT03926078 281 283 O
seconds NCT03926078 284 291 O
. NCT03926078 292 293 O

Exclusion NCT03926078 295 304 O
criteria NCT03926078 305 313 O
: NCT03926078 314 315 O

- NCT03926078 318 319 O
Patients NCT03926078 320 328 O
that NCT03926078 329 333 O
suffer NCT03926078 334 340 O
from NCT03926078 341 345 O
any NCT03926078 346 349 O
form NCT03926078 350 354 O
of NCT03926078 355 357 O
light NCT03926078 358 363 B-Condition
hypersensitivity NCT03926078 364 380 I-Condition
or NCT03926078 381 383 B-Or
epilepsy NCT03926078 384 392 B-Condition
were NCT03926078 393 397 O
not NCT03926078 398 401 O

considered NCT03926078 402 412 O
while NCT03926078 413 418 O
3 NCT03926078 419 420 O
D NCT03926078 421 422 O
optical NCT03926078 423 430 O
surface NCT03926078 431 438 O
images NCT03926078 439 445 O
were NCT03926078 446 450 O
acquired NCT03926078 451 459 O
with NCT03926078 460 464 O
the NCT03926078 465 468 O
use NCT03926078 469 472 O
of NCT03926078 473 475 O
structured NCT03926078 476 486 O
, NCT03926078 487 488 O

flashing NCT03926078 490 498 O
light NCT03926078 499 504 O
. NCT03926078 504 505 O

Inclusion NCT03923114 0 9 O
Criteria NCT03923114 10 18 O
: NCT03923114 19 20 O

Patients NCT03923114 22 30 O
with NCT03923114 31 35 O
treatment NCT03923114 36 45 B-Observation
response NCT03923114 46 54 I-Observation
: NCT03923114 55 56 O

- NCT03923114 60 61 O
Age NCT03923114 63 66 B-Age
≥ NCT03923114 67 68 B-Eq-Comparison
18 NCT03923114 69 71 I-Eq-Comparison
years NCT03923114 72 77 I-Eq-Comparison

- NCT03923114 80 81 O
Subject NCT03923114 83 90 O
is NCT03923114 91 93 O
diagnosed NCT03923114 94 103 O
with NCT03923114 104 108 O
type NCT03923114 109 113 B-Condition
2 NCT03923114 114 115 I-Condition
diabetes NCT03923114 116 124 I-Condition

- NCT03923114 127 128 O
Subject NCT03923114 130 137 O
showed NCT03923114 138 144 O
response NCT03923114 145 153 B-Observation
to NCT03923114 154 156 O
GLP NCT03923114 157 160 B-Procedure
- NCT03923114 161 162 I-Procedure
1 NCT03923114 163 164 I-Procedure
RA NCT03923114 165 167 I-Procedure
treatment NCT03923114 168 177 I-Procedure

- NCT03923114 180 181 O
Ability NCT03923114 183 190 O
to NCT03923114 191 193 O
sign NCT03923114 194 198 O
informed NCT03923114 199 207 O
consent NCT03923114 208 215 O

Patients NCT03923114 216 224 O
without NCT03923114 225 232 B-Negation
treatment NCT03923114 233 242 B-Observation
response NCT03923114 243 251 I-Observation
: NCT03923114 252 253 O

- NCT03923114 257 258 O
Age NCT03923114 260 263 B-Age
≥ NCT03923114 264 265 B-Eq-Comparison
18 NCT03923114 266 268 I-Eq-Comparison
years NCT03923114 269 274 I-Eq-Comparison

- NCT03923114 277 278 O
Subject NCT03923114 280 287 O
is NCT03923114 288 290 O
diagnosed NCT03923114 291 300 O
with NCT03923114 301 305 O
type NCT03923114 306 310 B-Condition
2 NCT03923114 311 312 I-Condition
diabetes NCT03923114 313 321 I-Condition

- NCT03923114 324 325 O
Subject NCT03923114 327 334 O
showed NCT03923114 335 341 O
no NCT03923114 342 344 B-Negation
response NCT03923114 345 353 B-Observation
to NCT03923114 354 356 O
GLP NCT03923114 357 360 B-Procedure
- NCT03923114 361 362 I-Procedure
1 NCT03923114 363 364 I-Procedure
RA NCT03923114 365 367 I-Procedure
treatment NCT03923114 368 377 I-Procedure

- NCT03923114 380 381 O
Ability NCT03923114 383 390 O
to NCT03923114 391 393 O
sign NCT03923114 394 398 O
informed NCT03923114 399 407 O
consent NCT03923114 408 415 O

Exclusion NCT03923114 416 425 O
Criteria NCT03923114 426 434 O
: NCT03923114 435 436 O

- NCT03923114 440 441 O
Liver NCT03923114 443 448 B-Condition
disease NCT03923114 449 456 I-Condition

- NCT03923114 459 460 O
Renal NCT03923114 462 467 B-Condition
disease NCT03923114 468 475 I-Condition

- NCT03923114 478 479 O
Pregnancy NCT03923114 481 490 B-Condition
or NCT03923114 491 493 B-Or
the NCT03923114 494 497 O
wish NCT03923114 498 502 B-Assertion___Assertion-Type-Value:intention
to NCT03923114 503 505 I-Assertion___Assertion-Type-Value:intention
become NCT03923114 506 512 O
pregnant NCT03923114 513 521 B-Condition
within NCT03923114 522 528 B-Eq-Comparison
6 NCT03923114 529 530 I-Eq-Comparison
months NCT03923114 531 537 I-Eq-Comparison
after NCT03923114 538 543 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03923114 544 547 O
study NCT03923114 548 553 B-Study

- NCT03923114 556 557 O
Breastfeeding NCT03923114 559 572 B-Condition

- NCT03923114 575 576 O
Age NCT03923114 578 581 B-Age
< NCT03923114 582 583 B-Eq-Comparison
18 NCT03923114 584 586 I-Eq-Comparison
years NCT03923114 587 592 I-Eq-Comparison

- NCT03923114 595 596 O
Pituitary NCT03923114 598 607 B-Condition
disorder NCT03923114 608 616 I-Condition

- NCT03923114 619 620 O
Inability NCT03923114 622 631 O
to NCT03923114 632 634 O
sign NCT03923114 635 639 O
informed NCT03923114 640 648 O
consent NCT03923114 649 656 O

- NCT03923114 659 660 O
Exclusion NCT03923114 662 671 O
criteria NCT03923114 672 680 O
for NCT03923114 681 684 O
MR NCT03923114 685 687 O
: NCT03923114 688 689 O

- NCT03923114 698 699 O
Fragments NCT03923114 701 710 B-Modifier
, NCT03923114 711 712 O
clips NCT03923114 713 718 B-Modifier
or NCT03923114 719 721 B-Or
devices NCT03923114 722 729 B-Modifier
in NCT03923114 730 732 O
brain NCT03923114 733 738 B-Condition
, NCT03923114 739 740 O
eyes NCT03923114 741 745 B-Modifier
, NCT03923114 746 747 O
spinal NCT03923114 748 754 B-Modifier
canal NCT03923114 755 760 I-Modifier

- NCT03923114 768 769 O
Implantable NCT03923114 771 782 B-Procedure
defibrillator NCT03923114 783 796 I-Procedure
or NCT03923114 797 799 B-Or
pacemaker NCT03923114 800 809 B-Procedure
( NCT03923114 810 811 O
wires NCT03923114 812 817 O
) NCT03923114 818 819 O

- NCT03923114 828 829 O
Mandibular NCT03923114 831 841 B-Procedure
magnetic NCT03923114 842 850 I-Procedure
implants NCT03923114 851 859 I-Procedure

- NCT03923114 867 868 O
Neurostimulator NCT03923114 870 885 B-Procedure
, NCT03923114 886 887 O
bladder NCT03923114 888 895 B-Procedure
stimulator NCT03923114 896 906 I-Procedure
, NCT03923114 907 908 O
non NCT03923114 909 912 B-Procedure
- NCT03923114 913 914 I-Procedure
removable NCT03923114 915 924 I-Procedure
insulin NCT03923114 925 932 I-Procedure
pump NCT03923114 933 937 I-Procedure

- NCT03923114 945 946 O
Metal NCT03923114 948 953 B-Procedure
tissue NCT03923114 954 960 I-Procedure
- NCT03923114 961 962 I-Procedure
expander NCT03923114 963 971 I-Procedure
in NCT03923114 972 974 I-Procedure
chest NCT03923114 975 980 I-Procedure

- NCT03923114 988 989 O
Cochlear NCT03923114 991 999 B-Procedure
implant NCT03923114 1000 1007 I-Procedure

- NCT03923114 1015 1016 O
Ossicular NCT03923114 1018 1027 B-Procedure
replacement NCT03923114 1028 1039 I-Procedure
prosthesis NCT03923114 1040 1050 I-Procedure

Inclusion NCT03921918 0 9 O
Criteria NCT03921918 10 18 O
: NCT03921918 19 20 O

1 NCT03921918 24 25 O
. NCT03921918 25 26 O
Subject NCT03921918 28 35 O
≥ NCT03921918 36 37 B-Eq-Comparison
18 NCT03921918 38 40 I-Eq-Comparison
years NCT03921918 41 46 I-Eq-Comparison
old NCT03921918 47 50 B-Age

2 NCT03921918 53 54 O
. NCT03921918 54 55 O
Infant NCT03921918 57 63 O
is NCT03921918 64 66 B-And
≥ NCT03921918 67 68 B-Eq-Comparison
1 NCT03921918 69 70 I-Eq-Comparison
and NCT03921918 71 74 B-And
≤ NCT03921918 75 76 B-Eq-Comparison
6 NCT03921918 77 78 I-Eq-Comparison
month NCT03921918 79 84 I-Eq-Comparison
old NCT03921918 85 88 B-Age

3 NCT03921918 91 92 O
. NCT03921918 92 93 O
Subject NCT03921918 95 102 O
and NCT03921918 103 106 O
baby NCT03921918 107 111 B-Family-Member___Family-Member-Type:child
are NCT03921918 112 115 O
healthy NCT03921918 116 123 B-Condition
according NCT03921918 124 133 O
to NCT03921918 134 136 O
self NCT03921918 137 141 O
- NCT03921918 142 143 O
declaration NCT03921918 144 155 O
in NCT03921918 156 158 O
the NCT03921918 159 162 O
" NCT03921918 163 164 O
Mother NCT03921918 164 170 B-Observation
and NCT03921918 171 174 I-Observation
infant NCT03921918 175 181 I-Observation
health NCT03921918 182 188 I-Observation
questionnaire NCT03921918 189 202 I-Observation
" NCT03921918 202 203 O

4 NCT03921918 206 207 O
. NCT03921918 207 208 O
Subject NCT03921918 210 217 O
is NCT03921918 218 220 O
predominantly NCT03921918 221 234 O
breastfeeding NCT03921918 235 248 B-Condition
( NCT03921918 249 250 O
80 NCT03921918 251 253 B-Eq-Comparison
% NCT03921918 254 255 I-Eq-Comparison
of NCT03921918 256 258 I-Eq-Comparison
all NCT03921918 259 262 I-Eq-Comparison
feeds NCT03921918 263 268 I-Eq-Comparison
, NCT03921918 269 270 O
i. NCT03921918 271 273 O
e. NCT03921918 274 276 O
≤ NCT03921918 278 279 B-Eq-Comparison
150 NCT03921918 280 283 I-Eq-Comparison
ml NCT03921918 284 286 I-Eq-Comparison
formula NCT03921918 287 294 I-Eq-Comparison
/ NCT03921918 295 296 I-Eq-Comparison
day NCT03921918 297 300 I-Eq-Comparison
or NCT03921918 301 303 O
equal NCT03921918 304 309 O
representative NCT03921918 310 324 O
amount NCT03921918 325 331 O
of NCT03921918 332 334 O
solid NCT03921918 335 340 O
food NCT03921918 341 345 O
) NCT03921918 346 347 O

5 NCT03921918 351 352 O
. NCT03921918 352 353 O
The NCT03921918 355 358 O
subject NCT03921918 359 366 O
agrees NCT03921918 367 373 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 374 376 I-Assertion___Assertion-Type-Value:hypothetical
pump NCT03921918 377 381 B-Observation
or NCT03921918 382 384 B-Or
feed NCT03921918 385 389 B-Observation
the NCT03921918 390 393 O
last NCT03921918 394 398 B-Eq-Comparison
time NCT03921918 399 403 I-Eq-Comparison
a NCT03921918 404 405 O
minimum NCT03921918 406 413 B-Eq-Comparison
of NCT03921918 414 416 I-Eq-Comparison
2 NCT03921918 417 418 I-Eq-Comparison
hours NCT03921918 419 424 I-Eq-Comparison
( NCT03921918 425 426 O
hr NCT03921918 427 429 O
) NCT03921918 430 431 O
before NCT03921918 432 438 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921918 439 442 O
start NCT03921918 443 448 O
of NCT03921918 449 451 O
the NCT03921918 452 455 O
pumping NCT03921918 456 463 O
session NCT03921918 464 471 O
at NCT03921918 472 474 O
the NCT03921918 475 478 O
study NCT03921918 479 484 B-Study
site NCT03921918 485 489 O

6 NCT03921918 492 493 O
. NCT03921918 493 494 O
The NCT03921918 496 499 O
subject NCT03921918 500 507 O
agrees NCT03921918 508 514 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 515 517 I-Assertion___Assertion-Type-Value:hypothetical
photographs NCT03921918 518 529 B-Observation
/ NCT03921918 530 531 I-Observation
3 NCT03921918 532 533 I-Observation
D NCT03921918 534 535 I-Observation
scan NCT03921918 536 540 I-Observation
of NCT03921918 541 543 O
the NCT03921918 544 547 O
breast NCT03921918 548 554 B-Modifier
and NCT03921918 555 558 B-Or
upper NCT03921918 559 564 B-Modifier
body NCT03921918 565 569 I-Modifier
( NCT03921918 570 571 O
no NCT03921918 572 574 B-Exception
face NCT03921918 575 579 B-Modifier
) NCT03921918 580 581 O
, NCT03921918 583 584 O

7 NCT03921918 588 589 O
. NCT03921918 589 590 O
The NCT03921918 592 595 O
subject NCT03921918 596 603 O
agrees NCT03921918 604 610 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921918 611 613 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03921918 614 615 O
video NCT03921918 616 621 B-Observation
while NCT03921918 622 627 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pumping NCT03921918 628 635 B-Observation

8 NCT03921918 638 639 O
. NCT03921918 639 640 O
The NCT03921918 642 645 O
subject NCT03921918 646 653 O
signs NCT03921918 654 659 O
the NCT03921918 660 663 O
informed NCT03921918 664 672 O
consent NCT03921918 673 680 O
documentation NCT03921918 681 694 O

9 NCT03921918 697 698 O
. NCT03921918 698 699 O
Subject NCT03921918 701 708 O
agrees NCT03921918 709 715 B-Assertion___Assertion-Type-Value:hypothetical
that NCT03921918 716 720 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03921918 721 722 O
maximum NCT03921918 723 730 B-Eq-Comparison
of NCT03921918 731 733 I-Eq-Comparison
2 NCT03921918 734 735 I-Eq-Comparison
male NCT03921918 736 740 I-Eq-Comparison
team NCT03921918 741 745 I-Eq-Comparison
members NCT03921918 746 753 I-Eq-Comparison
can NCT03921918 754 757 O
be NCT03921918 758 760 O
present NCT03921918 761 768 B-Observation
in NCT03921918 769 771 I-Observation
the NCT03921918 772 775 I-Observation
room NCT03921918 776 780 I-Observation
to NCT03921918 781 783 O
conduct NCT03921918 784 791 O
the NCT03921918 792 795 O
usability NCT03921918 796 805 O
part NCT03921918 806 810 O
of NCT03921918 811 813 O
the NCT03921918 814 817 O
study NCT03921918 818 823 O

10 NCT03921918 825 827 O
. NCT03921918 827 828 O
The NCT03921918 830 833 O
mother NCT03921918 834 840 O
accepts NCT03921918 841 848 B-Assertion___Assertion-Type-Value:hypothetical
that NCT03921918 849 853 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03921918 854 857 O
pumped NCT03921918 858 864 O
milk NCT03921918 865 869 O
in NCT03921918 870 872 O
visit NCT03921918 873 878 O
2 NCT03921918 879 880 O
must NCT03921918 881 885 O
be NCT03921918 886 888 O
donated NCT03921918 889 896 O
to NCT03921918 897 899 O
the NCT03921918 900 903 O
study NCT03921918 904 909 O
i. NCT03921918 910 912 O
e. NCT03921918 913 915 O
can NCT03921918 917 920 O
not NCT03921918 920 923 O
be NCT03921918 924 926 O
fed NCT03921918 927 930 O
to NCT03921918 931 933 O
the NCT03921918 934 937 O
baby NCT03921918 938 942 O

Exclusion NCT03921918 943 952 O
Criteria NCT03921918 953 961 O
: NCT03921918 962 963 O

1 NCT03921918 967 968 O
. NCT03921918 968 969 O
The NCT03921918 971 974 O
subject NCT03921918 975 982 O
has NCT03921918 983 986 O
a NCT03921918 987 988 O
nipple NCT03921918 989 995 B-Observation
size NCT03921918 996 1000 I-Observation
≥ NCT03921918 1001 1002 B-Eq-Comparison
21 NCT03921918 1003 1005 I-Eq-Comparison
mm NCT03921918 1006 1008 I-Eq-Comparison

2 NCT03921918 1011 1012 O
. NCT03921918 1012 1013 O
Mastitis NCT03921918 1015 1023 B-Condition
( NCT03921918 1024 1025 O
any NCT03921918 1026 1029 B-Modifier
breast NCT03921918 1030 1036 I-Modifier
within NCT03921918 1037 1043 B-Eq-Comparison
two NCT03921918 1044 1047 I-Eq-Comparison
weeks NCT03921918 1048 1053 I-Eq-Comparison
prior NCT03921918 1054 1059 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921918 1060 1062 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03921918 1063 1072 B-Study
) NCT03921918 1073 1074 O

3 NCT03921918 1078 1079 O
. NCT03921918 1079 1080 O
Engorgement NCT03921918 1082 1093 B-Condition
( NCT03921918 1094 1095 O
any NCT03921918 1096 1099 B-Modifier
breast NCT03921918 1100 1106 I-Modifier
within NCT03921918 1107 1113 B-Eq-Comparison
two NCT03921918 1114 1117 I-Eq-Comparison
weeks NCT03921918 1118 1123 I-Eq-Comparison
prior NCT03921918 1124 1129 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921918 1130 1132 I-Temporal-Connection___Temporal-Connection-Type-Value:before
enrolment NCT03921918 1133 1142 B-Study
) NCT03921918 1143 1144 O
. NCT03921918 1146 1147 O

4 NCT03921918 1151 1152 O
. NCT03921918 1152 1153 O
Case NCT03921918 1155 1159 O
of NCT03921918 1160 1162 O
current NCT03921918 1163 1170 B-Eq-Comparison
infection NCT03921918 1171 1180 B-Condition
as NCT03921918 1181 1183 O
self NCT03921918 1184 1188 O
- NCT03921918 1189 1190 O
declared NCT03921918 1191 1199 O
in NCT03921918 1200 1202 O
the NCT03921918 1203 1206 O
Mother NCT03921918 1207 1213 B-Observation
and NCT03921918 1214 1217 I-Observation
infant NCT03921918 1218 1224 I-Observation
health NCT03921918 1225 1231 I-Observation
questionnaire NCT03921918 1232 1245 I-Observation

Inclusion NCT03923699 0 9 O
Criteria NCT03923699 10 18 O
: NCT03923699 19 20 O

- NCT03923699 24 25 O
All NCT03923699 27 30 O
patients NCT03923699 31 39 O
18 NCT03923699 40 42 B-Eq-Comparison
years NCT03923699 43 48 I-Eq-Comparison
or NCT03923699 49 51 I-Eq-Comparison
older NCT03923699 52 57 I-Age|Eq-Comparison
undergoing NCT03923699 58 68 B-Eq-Comparison
surgery NCT03923699 69 76 B-Procedure
at NCT03923699 77 79 O
Barnes NCT03923699 80 86 O
Jewish NCT03923699 87 93 O
Hospital NCT03923699 94 102 O
in NCT03923699 103 105 O
St. NCT03923699 106 109 O
Louis NCT03923699 111 116 O
, NCT03923699 117 118 O
MO NCT03923699 119 121 O

Exclusion NCT03923699 122 131 O
Criteria NCT03923699 132 140 O
: NCT03923699 141 142 O

- NCT03923699 145 146 O

Inclusion NCT03920384 0 9 O
Criteria NCT03920384 10 18 O
: NCT03920384 19 20 O

- NCT03920384 24 25 O
Are NCT03920384 27 30 O
aged NCT03920384 31 35 B-Age
16 NCT03920384 36 38 B-Eq-Comparison
or NCT03920384 39 41 I-Eq-Comparison
over NCT03920384 42 46 I-Eq-Comparison

- NCT03920384 49 50 O
Are NCT03920384 52 55 O
competent NCT03920384 56 65 O
and NCT03920384 66 69 O
willing NCT03920384 70 77 O
to NCT03920384 78 80 O
provide NCT03920384 81 88 O
written NCT03920384 89 96 O
, NCT03920384 97 98 O
informed NCT03920384 99 107 O
consent NCT03920384 108 115 O

- NCT03920384 118 119 O
Are NCT03920384 121 124 O
experiencing NCT03920384 125 137 B-Eq-Comparison
delusions NCT03920384 138 147 B-Condition
( NCT03920384 148 149 O
A NCT03920384 150 151 O
score NCT03920384 152 157 B-Eq-Comparison
of NCT03920384 158 160 I-Eq-Comparison
≥ NCT03920384 161 162 I-Eq-Comparison
3 NCT03920384 163 164 I-Eq-Comparison
on NCT03920384 165 167 O
PANSS NCT03920384 168 173 B-Observation
item NCT03920384 174 178 O
P1 NCT03920384 179 181 B-Modifier
, NCT03920384 182 183 O
P5 NCT03920384 184 186 B-Modifier
or NCT03920384 187 189 B-Or
P6 NCT03920384 190 192 B-Modifier
) NCT03920384 193 194 O

Exclusion NCT03920384 196 205 O
Criteria NCT03920384 206 214 O
: NCT03920384 215 216 O

- NCT03920384 220 221 O
Significant NCT03920384 223 234 O
developmental NCT03920384 235 248 B-Condition
disability NCT03920384 249 259 I-Condition

- NCT03920384 262 263 O
Currently NCT03920384 265 274 B-Eq-Comparison
receiving NCT03920384 275 284 I-Eq-Comparison
or NCT03920384 285 287 B-Or
have NCT03920384 288 292 O
received NCT03920384 293 301 B-Eq-Comparison
CBTp NCT03920384 302 306 B-Procedure
in NCT03920384 307 309 O
the NCT03920384 310 313 O
last NCT03920384 314 318 B-Eq-Comparison
6 NCT03920384 319 320 I-Eq-Comparison
months NCT03920384 321 327 I-Eq-Comparison

- NCT03920384 330 331 O
Significant NCT03920384 333 344 O
difficulty NCT03920384 345 355 B-Negation
with NCT03920384 356 360 O
the NCT03920384 361 364 O
English NCT03920384 365 372 O
language NCT03920384 373 381 O

Inclusion NCT03925363 0 9 O
Criteria NCT03925363 10 18 O
: NCT03925363 19 20 O

- NCT03925363 24 25 O
Previous NCT03925363 27 35 B-Eq-Comparison
participants NCT03925363 36 48 O
in NCT03925363 49 51 O
healthy NCT03925363 52 59 O
aging NCT03925363 60 65 O
initiative NCT03925363 66 76 O
. NCT03925363 77 78 O

Exclusion NCT03925363 80 89 O
Criteria NCT03925363 90 98 O
: NCT03925363 99 100 O

- NCT03925363 104 105 O
Not NCT03925363 107 110 B-Negation
able NCT03925363 111 115 B-Condition
to NCT03925363 116 118 I-Condition
walk NCT03925363 119 123 I-Condition
or NCT03925363 124 126 B-Or
previous NCT03925363 127 135 B-Eq-Comparison
medical NCT03925363 136 143 O
diagnoses NCT03925363 144 153 B-Condition
that NCT03925363 154 158 O
severely NCT03925363 159 167 O
limits NCT03925363 168 174 B-Negation
the NCT03925363 175 178 O
possibility NCT03925363 179 190 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925363 191 193 O
exercise NCT03925363 194 202 B-Observation
. NCT03925363 202 203 O

Inclusion NCT03926130 0 9 O
Criteria NCT03926130 10 18 O
: NCT03926130 19 20 O

- NCT03926130 24 25 O
Diagnosis NCT03926130 27 36 O
of NCT03926130 37 39 O
CD NCT03926130 40 42 B-Condition
for NCT03926130 43 46 O
at NCT03926130 47 49 B-Eq-Comparison
least NCT03926130 50 55 I-Eq-Comparison
3 NCT03926130 56 57 I-Eq-Comparison
months NCT03926130 58 64 I-Eq-Comparison
prior NCT03926130 65 70 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926130 71 73 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926130 74 82 B-Study

- NCT03926130 85 86 O
Confirmed NCT03926130 88 97 O
diagnosis NCT03926130 98 107 O
of NCT03926130 108 110 O
moderate NCT03926130 111 119 O
to NCT03926130 120 122 B-Or
severe NCT03926130 123 129 O
CD NCT03926130 130 132 B-Condition
as NCT03926130 133 135 O
assessed NCT03926130 136 144 O
by NCT03926130 145 147 O
SF NCT03926130 148 150 B-Observation
, NCT03926130 151 152 O
AP NCT03926130 153 155 B-Observation
score NCT03926130 156 161 I-Observation
, NCT03926130 162 163 O
and NCT03926130 164 167 B-Or
SES NCT03926130 168 171 B-Observation
- NCT03926130 172 173 I-Observation
CD NCT03926130 174 176 I-Observation

- NCT03926130 179 180 O
Demonstrated NCT03926130 182 194 O
intolerance NCT03926130 195 206 B-Condition
, NCT03926130 207 208 O
loss NCT03926130 209 213 B-Condition
of NCT03926130 214 216 I-Condition
response NCT03926130 217 225 I-Condition
or NCT03926130 226 228 B-Or
inadequate NCT03926130 229 239 B-Condition
response NCT03926130 240 248 I-Condition
to NCT03926130 249 251 O
conventional NCT03926130 252 264 B-Modifier
or NCT03926130 265 267 B-Or
to NCT03926130 268 270 O
biologic NCT03926130 271 279 B-Modifier
therapy NCT03926130 280 287 B-Procedure
for NCT03926130 288 291 O
CD NCT03926130 292 294 B-Condition

- NCT03926130 297 298 O
If NCT03926130 300 302 O
female NCT03926130 303 309 O
, NCT03926130 310 311 O
subject NCT03926130 312 319 O
must NCT03926130 320 324 O
meet NCT03926130 325 329 O
the NCT03926130 330 333 O
contraception NCT03926130 334 347 B-Procedure
recommendations NCT03926130 348 363 B-Assertion___Assertion-Type-Value:hypothetical

Exclusion NCT03926130 364 373 O
Criteria NCT03926130 374 382 O
: NCT03926130 383 384 O

- NCT03926130 388 389 O
Have NCT03926130 391 395 O
a NCT03926130 396 397 O
current NCT03926130 398 405 B-Eq-Comparison
diagnosis NCT03926130 406 415 O
of NCT03926130 416 418 O
ulcerative NCT03926130 419 429 B-Condition
colitis NCT03926130 430 437 I-Condition
, NCT03926130 438 439 O
inflammatory NCT03926130 440 452 B-Condition
bowel NCT03926130 453 458 I-Condition
disease NCT03926130 459 466 I-Condition
- NCT03926130 467 468 I-Condition
unclassified NCT03926130 469 481 I-Condition
( NCT03926130 482 483 O
IBD NCT03926130 484 487 B-Condition
- NCT03926130 488 489 I-Condition
U NCT03926130 490 491 I-Condition
) NCT03926130 492 493 O
( NCT03926130 494 495 O
formerly NCT03926130 496 504 O
known NCT03926130 505 510 O
as NCT03926130 511 513 O
indeterminate NCT03926130 514 527 B-Condition
colitis NCT03926130 528 535 I-Condition
) NCT03926130 536 537 O
, NCT03926130 539 540 O
abdominal NCT03926130 541 550 B-Modifier
or NCT03926130 551 553 B-Or
perianal NCT03926130 554 562 B-Modifier
abscess NCT03926130 563 570 B-Condition
or NCT03926130 571 573 B-Or
short NCT03926130 574 579 B-Condition
bowel NCT03926130 580 585 I-Condition
syndrome NCT03926130 586 594 I-Condition

- NCT03926130 597 598 O
Have NCT03926130 600 604 O
a NCT03926130 605 606 O
stoma NCT03926130 607 612 B-Procedure
or NCT03926130 613 615 B-Or
ostomy NCT03926130 616 622 B-Procedure

- NCT03926130 625 626 O
Have NCT03926130 628 632 O
had NCT03926130 633 636 O
a NCT03926130 637 638 O
bowel NCT03926130 639 644 B-Procedure
resection NCT03926130 645 654 I-Procedure
within NCT03926130 655 661 B-Eq-Comparison
6 NCT03926130 662 663 I-Eq-Comparison
months NCT03926130 664 670 I-Eq-Comparison
, NCT03926130 671 672 O
or NCT03926130 673 675 B-Or
any NCT03926130 676 679 O
kind NCT03926130 680 684 O
of NCT03926130 685 687 O
intra NCT03926130 688 693 B-Modifier
- NCT03926130 694 695 I-Modifier
abdominal NCT03926130 696 705 I-Modifier
or NCT03926130 706 708 B-Or
extra NCT03926130 709 714 B-Modifier
abdominal NCT03926130 715 724 I-Modifier
surgery NCT03926130 725 732 B-Procedure
within NCT03926130 733 739 B-Eq-Comparison
3 NCT03926130 740 741 I-Eq-Comparison
months NCT03926130 742 748 I-Eq-Comparison
of NCT03926130 749 751 B-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926130 752 760 B-Study

- NCT03926130 763 764 O
Have NCT03926130 766 770 O
ever NCT03926130 771 775 O
received NCT03926130 776 784 B-Eq-Comparison
any NCT03926130 785 788 O
monoclonal NCT03926130 789 799 B-Procedure
antibodies NCT03926130 800 810 I-Procedure
binding NCT03926130 811 818 I-Procedure
IL NCT03926130 819 821 I-Procedure
- NCT03926130 822 823 I-Procedure
23 NCT03926130 824 826 I-Procedure

Inclusion NCT03926871 0 9 O
Criteria NCT03926871 10 18 O
: NCT03926871 19 20 O

To NCT03926871 22 24 O
Novato NCT03926871 25 31 O
workers NCT03926871 32 39 O

- NCT03926871 42 43 O
1 NCT03926871 45 46 B-Eq-Comparison
to NCT03926871 47 49 I-Eq-Comparison
2 NCT03926871 50 51 I-Eq-Comparison
days NCT03926871 52 56 I-Eq-Comparison
in NCT03926871 57 59 O
the NCT03926871 60 63 O
company NCT03926871 64 71 O

- NCT03926871 74 75 O
Not NCT03926871 77 80 O
have NCT03926871 81 85 O
previous NCT03926871 86 94 B-Eq-Comparison
experience NCT03926871 95 105 O
in NCT03926871 106 108 O
a NCT03926871 109 110 O
frigorifico NCT03926871 111 122 O
, NCT03926871 123 124 O
or NCT03926871 125 127 O
butcher NCT03926871 128 135 O
's NCT03926871 135 137 O
shop NCT03926871 138 142 O

- NCT03926871 145 146 O
Not NCT03926871 148 151 O
have NCT03926871 152 156 O
prior NCT03926871 157 162 B-Eq-Comparison
knowledge NCT03926871 163 172 O
of NCT03926871 173 175 O
the NCT03926871 176 179 O
activity NCT03926871 180 188 O
. NCT03926871 188 189 O
To NCT03926871 191 193 O
experienced NCT03926871 194 205 O
workers NCT03926871 206 213 O

- NCT03926871 216 217 O
Work NCT03926871 219 223 O
on NCT03926871 224 226 O
the NCT03926871 227 230 O
task NCT03926871 231 235 O
for NCT03926871 236 239 O
more NCT03926871 240 244 O
than NCT03926871 245 249 O
six NCT03926871 250 253 O
months NCT03926871 254 260 O

- NCT03926871 263 264 O
Be NCT03926871 266 268 O
present NCT03926871 269 276 O
in NCT03926871 277 279 O
company NCT03926871 280 287 O
during NCT03926871 288 294 O
the NCT03926871 295 298 O
study NCT03926871 299 304 B-Study
period NCT03926871 305 311 O

Exclusion NCT03926871 312 321 O
Criteria NCT03926871 322 330 O
: NCT03926871 331 332 O

For NCT03926871 334 337 O
all NCT03926871 338 341 O
workers NCT03926871 342 349 O

- NCT03926871 352 353 O
Had NCT03926871 355 358 O
already NCT03926871 359 366 O
received NCT03926871 367 375 B-Eq-Comparison
ergonomic NCT03926871 376 385 O
training NCT03926871 386 394 O
( NCT03926871 395 396 O
general NCT03926871 397 404 O
guidelines NCT03926871 405 415 O
and NCT03926871 416 419 O
postural NCT03926871 420 428 O
adjustments NCT03926871 429 440 O
) NCT03926871 441 442 O

- NCT03926871 446 447 O
Pregnant NCT03926871 449 457 B-Condition
women NCT03926871 458 463 O

- NCT03926871 466 467 O
People NCT03926871 469 475 O
with NCT03926871 476 480 O
disabilities NCT03926871 481 493 B-Condition
. NCT03926871 493 494 O

Inclusion NCT03928860 0 9 O
Criteria NCT03928860 10 18 O
: NCT03928860 19 20 O

- NCT03928860 24 25 O
Patients NCT03928860 27 35 O
with NCT03928860 36 40 O
at NCT03928860 41 43 B-Eq-Comparison
least NCT03928860 44 49 I-Eq-Comparison
3 NCT03928860 50 51 I-Eq-Comparison
months NCT03928860 52 58 I-Eq-Comparison
of NCT03928860 59 61 O
clinical NCT03928860 62 70 O
onset NCT03928860 71 76 B-Eq-Comparison
of NCT03928860 77 79 O
peripheral NCT03928860 80 90 B-Condition
vascular NCT03928860 91 99 I-Condition
disease NCT03928860 100 107 I-Condition

- NCT03928860 110 111 O
Patients NCT03928860 113 121 O
with NCT03928860 122 126 O
ABI NCT03928860 127 130 B-Observation
between NCT03928860 131 138 O
0.4 NCT03928860 139 142 O
- NCT03928860 143 144 O
1.4 NCT03928860 145 148 O

- NCT03928860 152 153 O
Patients NCT03928860 155 163 O
up NCT03928860 164 166 B-Eq-Comparison
to NCT03928860 167 169 I-Eq-Comparison
Stage NCT03928860 170 175 I-Eq-Comparison
2 NCT03928860 176 177 I-Eq-Comparison
b NCT03928860 178 179 I-Eq-Comparison
according NCT03928860 180 189 O
to NCT03928860 190 192 O
the NCT03928860 193 196 O
Fontaine NCT03928860 197 205 B-Condition
classification NCT03928860 206 220 I-Condition
system NCT03928860 221 227 I-Condition

Exclusion NCT03928860 228 237 O
Criteria NCT03928860 238 246 O
: NCT03928860 247 248 O

- NCT03928860 252 253 O
Patients NCT03928860 255 263 O
undergoing NCT03928860 264 274 B-Eq-Comparison
vascular NCT03928860 275 283 B-Modifier
or NCT03928860 284 286 B-Or
endovascular NCT03928860 287 299 B-Modifier
surgery NCT03928860 300 307 B-Procedure
in NCT03928860 308 310 O
the NCT03928860 311 314 O
last NCT03928860 315 319 B-Eq-Comparison
3 NCT03928860 320 321 I-Eq-Comparison
months NCT03928860 322 328 I-Eq-Comparison

- NCT03928860 331 332 O
Patients NCT03928860 334 342 O
with NCT03928860 343 347 O
unstable NCT03928860 348 356 B-Condition
angina NCT03928860 357 363 I-Condition

- NCT03928860 366 367 O
Patients NCT03928860 369 377 O
with NCT03928860 378 382 O
myocardial NCT03928860 383 393 B-Condition
infarction NCT03928860 394 404 I-Condition
( NCT03928860 405 406 O
MI NCT03928860 407 409 B-Condition
) NCT03928860 410 411 O

- NCT03928860 415 416 O
Patients NCT03928860 418 426 O
with NCT03928860 427 431 O
stroke NCT03928860 432 438 B-Condition

- NCT03928860 441 442 O
Patients NCT03928860 444 452 O
with NCT03928860 453 457 O
heart NCT03928860 458 463 B-Condition
failure NCT03928860 464 471 I-Condition

- NCT03928860 474 475 O
Patients NCT03928860 477 485 O
with NCT03928860 486 490 O
significant NCT03928860 491 502 O
liver NCT03928860 503 508 B-Modifier
or NCT03928860 509 511 B-Or
renal NCT03928860 512 517 B-Modifier
failure NCT03928860 518 525 B-Condition
( NCT03928860 526 527 O
ie NCT03928860 528 530 O
, NCT03928860 531 532 O
dialysis NCT03928860 533 541 B-Procedure
) NCT03928860 542 543 O

- NCT03928860 547 548 O
Acute NCT03928860 550 555 O
infectious NCT03928860 556 566 B-Condition
diseases NCT03928860 567 575 I-Condition

- NCT03928860 578 579 O
Patients NCT03928860 581 589 O
with NCT03928860 590 594 O
neoplasia NCT03928860 595 604 B-Condition

Inclusion NCT03921307 0 9 O
Criteria NCT03921307 10 18 O
: NCT03921307 19 20 O

- NCT03921307 24 25 O
Healthy NCT03921307 27 34 B-Condition
periodontal NCT03921307 35 46 I-Condition
tissue NCT03921307 47 53 I-Condition
Adequate NCT03921307 54 62 O
root NCT03921307 63 67 B-Procedure
canal NCT03921307 68 73 I-Procedure
treatment NCT03921307 74 83 I-Procedure

Exclusion NCT03921307 84 93 O
Criteria NCT03921307 94 102 O
: NCT03921307 103 104 O

- NCT03921307 108 109 O
Parafunctional NCT03921307 111 125 B-Condition
habits NCT03921307 126 132 I-Condition

Inclusion NCT03926468 0 9 O
Criteria NCT03926468 10 18 O
: NCT03926468 19 20 O

- NCT03926468 24 25 I-Or
histologically NCT03926468 27 41 O
confirmed NCT03926468 42 51 O
head NCT03926468 52 56 B-Modifier
and NCT03926468 57 60 B-Or
neck NCT03926468 61 65 B-Modifier
squamous NCT03926468 66 74 B-Condition
cell NCT03926468 75 79 I-Condition
carcinoma NCT03926468 80 89 I-Condition
( NCT03926468 90 91 O
HNSCC NCT03926468 92 97 B-Condition
) NCT03926468 98 99 O

- NCT03926468 103 104 O
WHO NCT03926468 106 109 B-Observation
performance NCT03926468 110 121 I-Observation
status NCT03926468 122 128 I-Observation
0 NCT03926468 129 130 B-Eq-Comparison
- NCT03926468 131 132 I-Eq-Comparison
2 NCT03926468 133 134 O

- NCT03926468 138 139 O
clinical NCT03926468 141 149 O
stage NCT03926468 150 155 B-Eq-Comparison
III NCT03926468 156 159 I-Eq-Comparison
patients NCT03926468 160 168 O
with NCT03926468 169 173 O
bulky NCT03926468 174 179 B-Modifier
T3 NCT03926468 180 182 I-Modifier
primary NCT03926468 183 190 I-Modifier
+ NCT03926468 191 192 B-Or
/ NCT03926468 194 195 I-Or
- NCT03926468 197 198 O
neck NCT03926468 199 203 B-Modifier
metastasis NCT03926468 204 214 B-Condition

- NCT03926468 217 218 O
all NCT03926468 220 223 O
stage NCT03926468 224 229 B-Eq-Comparison
IV NCT03926468 230 232 I-Eq-Comparison
patients NCT03926468 233 241 O

- NCT03926468 244 245 O
referral NCT03926468 247 255 O
to NCT03926468 256 258 O
definitive NCT03926468 259 269 O
radiotherapy NCT03926468 270 282 B-Procedure
or NCT03926468 283 285 B-Or
chemoradiotherapy NCT03926468 286 303 B-Procedure
or NCT03926468 304 306 B-Or
multimodality NCT03926468 307 320 B-Procedure
treatment NCT03926468 321 330 I-Procedure

Exclusion NCT03926468 331 340 O
Criteria NCT03926468 341 349 O
: NCT03926468 350 351 O

- NCT03926468 355 356 O
patients NCT03926468 358 366 O
who NCT03926468 367 370 O
are NCT03926468 371 374 O
not NCT03926468 375 378 O
able NCT03926468 379 383 O
to NCT03926468 384 386 O
sign NCT03926468 387 391 O
written NCT03926468 392 399 O
informed NCT03926468 400 408 O
consent NCT03926468 409 416 O

Inclusion NCT03923504 0 9 O
Criteria NCT03923504 10 18 O
: NCT03923504 19 20 O

- NCT03923504 24 25 O
Ability NCT03923504 27 34 O
to NCT03923504 35 37 O
read NCT03923504 38 42 O
and NCT03923504 43 46 O
understand NCT03923504 47 57 O
and NCT03923504 58 61 O
willing NCT03923504 62 69 O
to NCT03923504 70 72 O
sign NCT03923504 73 77 O
a NCT03923504 78 79 O
written NCT03923504 80 87 O
informed NCT03923504 88 96 O
consent NCT03923504 97 104 O
form NCT03923504 105 109 O
. NCT03923504 110 111 O

- NCT03923504 115 116 O
Diagnosis NCT03923504 118 127 O
of NCT03923504 128 130 O
stage NCT03923504 131 136 B-Eq-Comparison
I NCT03923504 137 138 I-Eq-Comparison
- NCT03923504 139 140 I-Eq-Comparison
IV NCT03923504 141 143 I-Eq-Comparison
non NCT03923504 144 147 B-Modifier
- NCT03923504 148 149 O
or NCT03923504 150 152 B-Or
Hodgkin NCT03923504 153 160 B-Modifier
lymphoma NCT03923504 161 169 B-Condition
and NCT03923504 170 173 B-And
expect NCT03923504 174 180 B-Assertion___Assertion-Type-Value:intention
to NCT03923504 181 183 I-Assertion___Assertion-Type-Value:intention
receive NCT03923504 184 191 O
an NCT03923504 192 194 O
anthracycline NCT03923504 195 208 B-Drug
based NCT03923504 209 214 O
chemotherapeutic NCT03923504 215 231 B-Drug
regimen NCT03923504 232 239 I-Drug
. NCT03923504 240 241 O

- NCT03923504 245 246 O
Capacity NCT03923504 248 256 B-Observation
to NCT03923504 257 259 I-Observation
walk NCT03923504 260 264 I-Observation
at NCT03923504 265 267 B-Eq-Comparison
least NCT03923504 268 273 I-Eq-Comparison
2 NCT03923504 274 275 I-Eq-Comparison
city NCT03923504 276 280 I-Eq-Comparison
blocks NCT03923504 281 287 I-Eq-Comparison
on NCT03923504 288 290 O
a NCT03923504 291 292 O
flat NCT03923504 293 297 O
surface NCT03923504 298 305 O

Exclusion NCT03923504 306 315 O
Criteria NCT03923504 316 324 O
: NCT03923504 325 326 O

- NCT03923504 330 331 O
Contraindications NCT03923504 333 350 B-Contraindication
for NCT03923504 351 354 O
MRI NCT03923504 355 358 B-Procedure

- NCT03923504 361 362 O
Contraindications NCT03923504 364 381 B-Contraindication
for NCT03923504 382 385 O
exercise NCT03923504 386 394 B-Observation
training NCT03923504 395 403 B-Modifier
or NCT03923504 404 406 B-Or
testing NCT03923504 407 414 B-Modifier

- NCT03923504 417 418 O
Active NCT03923504 420 426 B-Eq-Comparison
Pregnancy NCT03923504 427 436 B-Condition

- NCT03923504 439 440 O
Subjects NCT03923504 442 450 O
with NCT03923504 451 455 O
claustrophobia NCT03923504 456 470 B-Condition

- NCT03923504 473 474 O
Inability NCT03923504 476 485 O
to NCT03923504 486 488 O
provide NCT03923504 489 496 O
informed NCT03923504 497 505 O
consent NCT03923504 506 513 O

Inclusion NCT03924531 0 9 O
Criteria NCT03924531 10 18 O
: NCT03924531 19 20 O

- NCT03924531 24 25 O
over NCT03924531 27 31 B-Eq-Comparison
21 NCT03924531 32 34 I-Eq-Comparison
years NCT03924531 35 40 I-Eq-Comparison
of NCT03924531 41 43 O
age NCT03924531 44 47 B-Age

- NCT03924531 50 51 O
able NCT03924531 53 57 O
to NCT03924531 58 60 O
understand NCT03924531 61 71 O
and NCT03924531 72 75 O
speak NCT03924531 76 81 O
English NCT03924531 82 89 O

- NCT03924531 92 93 O
self NCT03924531 95 99 O
- NCT03924531 100 101 O
report NCT03924531 102 108 O
of NCT03924531 109 111 O
having NCT03924531 112 118 O
difficulty NCT03924531 119 129 B-Negation
with NCT03924531 130 134 O
a NCT03924531 135 136 O
healthy NCT03924531 137 144 B-Observation
diet NCT03924531 145 149 I-Observation
and NCT03924531 150 153 B-And
engaging NCT03924531 154 162 O
in NCT03924531 163 165 O
regular NCT03924531 166 173 B-Observation
physical NCT03924531 174 182 I-Observation
activity NCT03924531 183 191 I-Observation
. NCT03924531 192 193 O

Exclusion NCT03924531 195 204 O
Criteria NCT03924531 205 213 O
: NCT03924531 214 215 O

- NCT03924531 219 220 O
On NCT03924531 222 224 O
chemotherapy NCT03924531 225 237 B-Procedure
for NCT03924531 238 241 O
cancer NCT03924531 242 248 B-Procedure
treatment NCT03924531 249 258 I-Procedure

- NCT03924531 261 262 O
Current NCT03924531 264 271 B-Eq-Comparison
substance NCT03924531 272 281 B-Condition
abuse NCT03924531 282 287 I-Condition
disorder NCT03924531 288 296 I-Condition
( NCT03924531 297 298 O
i. NCT03924531 299 301 O
e. NCT03924531 302 304 O
, NCT03924531 305 306 O
drugs NCT03924531 307 312 B-Drug
, NCT03924531 313 314 O
alcohol NCT03924531 315 322 B-Drug
) NCT03924531 323 324 O
. NCT03924531 326 327 O

- NCT03924531 331 332 O
Current NCT03924531 334 341 B-Eq-Comparison
diagnoses NCT03924531 342 351 O
of NCT03924531 352 354 O
Post NCT03924531 355 359 B-Condition
- NCT03924531 360 361 I-Condition
traumatic NCT03924531 362 371 I-Condition
stress NCT03924531 372 378 I-Condition
disorders NCT03924531 379 388 I-Condition
, NCT03924531 389 390 O
severe NCT03924531 391 397 O
anxiety NCT03924531 398 405 B-Condition
, NCT03924531 406 407 O
or NCT03924531 408 410 B-Or
severe NCT03924531 411 417 O
depression NCT03924531 418 428 B-Condition
. NCT03924531 429 430 O

- NCT03924531 434 435 O
On NCT03924531 437 439 B-Eq-Comparison
hemodialysis NCT03924531 440 452 B-Procedure
. NCT03924531 453 454 O

- NCT03924531 458 459 O
Pregnant NCT03924531 461 469 B-Condition
. NCT03924531 469 470 O
( NCT03924531 472 473 O
Pregnant NCT03924531 474 482 B-Condition
women NCT03924531 483 488 O
may NCT03924531 489 492 B-Assertion___Assertion-Type-Value:hypothetical
develop NCT03924531 493 500 O
Preeclampsia NCT03924531 501 513 B-Condition
, NCT03924531 514 515 O
which NCT03924531 516 521 O
is NCT03924531 522 524 O
a NCT03924531 525 526 O
pregnancy NCT03924531 527 536 B-Condition
complication NCT03924531 537 549 I-Condition
characterized NCT03924531 550 563 O
by NCT03924531 564 566 O
high NCT03924531 567 571 B-Condition
blood NCT03924531 572 577 I-Condition
pressure NCT03924531 578 586 I-Condition
) NCT03924531 587 588 O

Inclusion NCT03922815 0 9 O
Criteria NCT03922815 10 18 O
: NCT03922815 19 20 O

- NCT03922815 24 25 O
written NCT03922815 27 34 O
consent NCT03922815 35 42 O
to NCT03922815 43 45 O
participate NCT03922815 46 57 O
in NCT03922815 58 60 O
the NCT03922815 61 64 O
study NCT03922815 65 70 O

- NCT03922815 73 74 O
written NCT03922815 76 83 O
consent NCT03922815 84 91 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922815 92 94 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03922815 95 102 B-Eq-Comparison
deep NCT03922815 103 107 B-Procedure
sedation NCT03922815 108 116 I-Procedure
for NCT03922815 117 120 O
colonoscopic NCT03922815 121 133 B-Procedure
procedure NCT03922815 134 143 I-Procedure

- NCT03922815 146 147 O
general NCT03922815 149 156 O
heath NCT03922815 157 162 O
condition NCT03922815 163 172 O
I NCT03922815 173 174 B-Eq-Comparison
- NCT03922815 175 176 I-Eq-Comparison
III NCT03922815 177 180 I-Eq-Comparison
of NCT03922815 181 183 O
American NCT03922815 184 192 B-Condition
Society NCT03922815 193 200 I-Condition
of NCT03922815 201 203 I-Condition
Anaesthesiology NCT03922815 204 219 I-Condition

Exclusion NCT03922815 220 229 O
Criteria NCT03922815 230 238 O
: NCT03922815 239 240 O

- NCT03922815 244 245 O
necessity NCT03922815 247 256 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03922815 257 259 O
administration NCT03922815 260 274 O
of NCT03922815 275 277 O
vasoactive NCT03922815 278 288 B-Drug
drugs NCT03922815 289 294 I-Drug
influencing NCT03922815 295 306 O
SPI NCT03922815 307 310 B-Procedure
monitoring NCT03922815 311 321 I-Procedure

- NCT03922815 324 325 O
pregnancy NCT03922815 327 336 B-Condition

- NCT03922815 339 340 O
anatomical NCT03922815 342 352 B-Condition
malformation NCT03922815 353 365 I-Condition
that NCT03922815 366 370 O
make NCT03922815 371 375 O
monitoring NCT03922815 376 386 B-Procedure
using NCT03922815 387 392 I-Procedure
SE NCT03922815 393 395 I-Procedure
sensor NCT03922815 396 402 I-Procedure
impossible NCT03922815 403 413 B-Assertion___Assertion-Type-Value:hypothetical|Negation

- NCT03922815 416 417 O
general NCT03922815 419 426 B-Condition
atherosclerosis NCT03922815 427 442 I-Condition
, NCT03922815 443 444 O
heart NCT03922815 445 450 B-Condition
rhythm NCT03922815 451 457 I-Condition
disturbances NCT03922815 458 470 I-Condition
impairing NCT03922815 471 480 B-Assertion___Assertion-Type-Value:hypothetical|Negation
SPI NCT03922815 481 484 B-Procedure
monitoring NCT03922815 485 495 I-Procedure

- NCT03922815 498 499 O
chronic NCT03922815 501 508 B-Modifier
medication NCT03922815 509 519 O
using NCT03922815 520 525 B-Eq-Comparison
opioid NCT03922815 526 532 B-Drug
drugs NCT03922815 533 538 I-Drug
leading NCT03922815 539 546 O
to NCT03922815 547 549 O
resistancy NCT03922815 550 560 B-Condition
to NCT03922815 561 563 I-Condition
opioids NCT03922815 564 571 I-Condition
. NCT03922815 571 572 O

Inclusion NCT03921931 0 9 O
Criteria NCT03921931 10 18 O
: NCT03921931 19 20 O

- NCT03921931 24 25 O
men NCT03921931 27 30 O
and NCT03921931 31 34 B-Or
women NCT03921931 35 40 O
aged NCT03921931 41 45 B-Age
over NCT03921931 46 50 B-Eq-Comparison
18 NCT03921931 51 53 I-Eq-Comparison
years NCT03921931 54 59 I-Eq-Comparison

- NCT03921931 62 63 O
signed NCT03921931 65 71 O
informed NCT03921931 72 80 O
consent NCT03921931 81 88 O
form NCT03921931 89 93 O

- NCT03921931 96 97 O
ametropia NCT03921931 99 108 B-Observation
below NCT03921931 109 114 B-Eq-Comparison
3 NCT03921931 115 116 I-Eq-Comparison
diopters NCT03921931 117 125 I-Eq-Comparison

- NCT03921931 128 129 O
ability NCT03921931 131 138 O
and NCT03921931 139 142 O
willingness NCT03921931 143 154 O
to NCT03921931 155 157 O
follow NCT03921931 158 164 O
instructions NCT03921931 165 177 O

for NCT03921931 178 181 O
healthy NCT03921931 182 189 B-Observation
volunteers NCT03921931 190 200 O
: NCT03921931 201 202 O

- NCT03921931 206 207 O
normal NCT03921931 209 215 O
ophthalmologic NCT03921931 216 230 B-Observation
findings NCT03921931 231 239 I-Observation

for NCT03921931 240 243 O
primary NCT03921931 244 251 B-Modifier
open NCT03921931 252 256 I-Modifier
angle NCT03921931 257 262 I-Modifier
glaucoma NCT03921931 263 271 B-Condition
patients NCT03921931 272 280 O
( NCT03921931 281 282 O
POAG NCT03921931 283 287 B-Condition
) NCT03921931 288 289 O
: NCT03921931 291 292 O

- NCT03921931 296 297 O
diagnosed NCT03921931 299 308 B-Condition
POAG NCT03921931 309 313 O

- NCT03921931 316 317 O
MD NCT03921931 319 321 B-Observation
< NCT03921931 322 323 B-Eq-Comparison
= NCT03921931 325 326 I-Eq-Comparison
10 NCT03921931 327 329 I-Eq-Comparison
dB NCT03921931 330 332 O

for NCT03921931 333 336 O
age NCT03921931 337 340 B-Modifier
- NCT03921931 341 342 I-Modifier
related NCT03921931 343 350 I-Modifier
macular NCT03921931 351 358 B-Condition
degeneration NCT03921931 359 371 I-Condition
( NCT03921931 372 373 O
AMD NCT03921931 374 377 B-Condition
) NCT03921931 378 379 O
: NCT03921931 381 382 O

- NCT03921931 386 387 O
diagnosed NCT03921931 389 398 O
dry NCT03921931 399 402 B-Modifier
AMD NCT03921931 403 406 B-Condition

- NCT03921931 409 410 O
diagnosed NCT03921931 412 421 O
stage NCT03921931 422 427 B-Eq-Comparison
II NCT03921931 428 430 I-Eq-Comparison
or NCT03921931 431 433 B-Or
stage NCT03921931 434 439 B-Eq-Comparison
III NCT03921931 440 443 I-Eq-Comparison
AMD NCT03921931 444 447 B-Condition

Exclusion NCT03921931 448 457 O
Criteria NCT03921931 458 466 O
: NCT03921931 467 468 O

- NCT03921931 472 473 O
Presence NCT03921931 475 483 O
of NCT03921931 484 486 O
any NCT03921931 487 490 O
abnormalities NCT03921931 491 504 B-Condition
preventing NCT03921931 505 515 B-Assertion___Assertion-Type-Value:hypothetical|Negation
reliable NCT03921931 516 524 O
measurements NCT03921931 525 537 B-Observation

- NCT03921931 540 541 O
Ocular NCT03921931 543 549 B-Condition
inflammation NCT03921931 550 562 I-Condition
and NCT03921931 563 566 B-Or
ocular NCT03921931 567 573 B-Condition
disease NCT03921931 574 581 I-Condition
interfering NCT03921931 582 593 O
with NCT03921931 594 598 O
the NCT03921931 599 602 O
study NCT03921931 603 608 O
aims NCT03921931 609 613 O

- NCT03921931 616 617 O
Use NCT03921931 619 622 O
of NCT03921931 623 625 O
photosensitizing NCT03921931 626 642 B-Drug
medication NCT03921931 643 653 I-Drug
( NCT03921931 654 655 O
phototoxic NCT03921931 656 666 B-Drug
drugs NCT03921931 667 672 I-Drug
, NCT03921931 673 674 O
photoallergic NCT03921931 675 688 B-Drug
drugs NCT03921931 689 694 I-Drug
) NCT03921931 695 696 O
in NCT03921931 697 699 O
the NCT03921931 700 703 O
3 NCT03921931 704 705 B-Eq-Comparison
months NCT03921931 706 712 I-Eq-Comparison
preceding NCT03921931 713 722 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921931 723 726 O
study NCT03921931 727 732 B-Study

- NCT03921931 735 736 O
Presence NCT03921931 738 746 O
of NCT03921931 747 749 O
any NCT03921931 750 753 O
condition NCT03921931 754 763 B-Condition
with NCT03921931 764 768 O
the NCT03921931 769 772 O
possibility NCT03921931 773 784 B-Assertion___Assertion-Type-Value:possible
of NCT03921931 785 787 I-Assertion___Assertion-Type-Value:possible
causing NCT03921931 788 795 O
photosensitivity NCT03921931 796 812 B-Condition
, NCT03921931 813 814 O
including NCT03921931 815 824 O
systemic NCT03921931 825 833 B-Condition
lupus NCT03921931 834 839 I-Condition
erythematosus NCT03921931 840 853 I-Condition
SLE NCT03921931 854 857 B-Condition
, NCT03921931 858 859 O
Porphyria NCT03921931 860 869 B-Condition
, NCT03921931 870 871 O
Vitiligo NCT03921931 872 880 B-Condition
, NCT03921931 881 882 O
Xeroderma NCT03921931 883 892 B-Condition
Pigmentosum NCT03921931 893 904 I-Condition
and NCT03921931 905 908 B-Or
Albinism NCT03921931 909 917 B-Condition

- NCT03921931 920 921 O
Presence NCT03921931 923 931 O
of NCT03921931 932 934 O
any NCT03921931 935 938 O
form NCT03921931 939 943 O
of NCT03921931 944 946 O
epilepsy NCT03921931 947 955 B-Condition

- NCT03921931 958 959 O
Ocular NCT03921931 961 967 B-Procedure
surgery NCT03921931 968 975 I-Procedure
in NCT03921931 976 978 O
the NCT03921931 979 982 O
3 NCT03921931 983 984 B-Eq-Comparison
months NCT03921931 985 991 I-Eq-Comparison
preceding NCT03921931 992 1001 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03921931 1002 1005 O
study NCT03921931 1006 1011 B-Study

- NCT03921931 1014 1015 O
Pregnancy NCT03921931 1017 1026 B-Condition
, NCT03921931 1027 1028 O
planned NCT03921931 1029 1036 B-Assertion___Assertion-Type-Value:intention
pregnancy NCT03921931 1037 1046 B-Condition
or NCT03921931 1047 1049 B-Or
lactating NCT03921931 1050 1059 B-Condition

- NCT03921931 1062 1063 O
Any NCT03921931 1065 1068 O
medical NCT03921931 1069 1076 O
or NCT03921931 1077 1079 O
surgical NCT03921931 1080 1088 B-Procedure
history NCT03921931 1089 1096 B-Eq-Comparison
, NCT03921931 1097 1098 O
disorder NCT03921931 1099 1107 B-Condition
or NCT03921931 1108 1110 B-Or
disease NCT03921931 1111 1118 B-Condition
such NCT03921931 1119 1123 O
as NCT03921931 1124 1126 O
acute NCT03921931 1127 1132 B-Modifier
or NCT03921931 1133 1135 B-Or
chronic NCT03921931 1136 1143 B-Modifier
severe NCT03921931 1144 1150 O
organic NCT03921931 1151 1158 B-Condition
disease NCT03921931 1159 1166 I-Condition

Inclusion NCT03926910 0 9 O
Criteria NCT03926910 10 18 O
: NCT03926910 19 20 O

- NCT03926910 24 25 O
Over NCT03926910 27 31 B-Eq-Comparison
18 NCT03926910 32 34 I-Eq-Comparison
years NCT03926910 35 40 I-Eq-Comparison
old NCT03926910 41 44 B-Age
, NCT03926910 45 46 O

- NCT03926910 50 51 O
Programmed NCT03926910 53 63 B-Eq-Comparison
for NCT03926910 64 67 O
cardiac NCT03926910 68 75 B-Procedure
surgery NCT03926910 76 83 I-Procedure
with NCT03926910 84 88 B-And
the NCT03926910 89 92 O
need NCT03926910 93 97 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03926910 98 101 I-Assertion___Assertion-Type-Value:hypothetical
invasive NCT03926910 102 110 B-Procedure
hemodynamic NCT03926910 111 122 I-Procedure
monitoring NCT03926910 123 133 I-Procedure
( NCT03926910 134 135 O
pulmonary NCT03926910 136 145 B-Procedure
artery NCT03926910 146 152 I-Procedure
catheter NCT03926910 153 161 I-Procedure
) NCT03926910 162 163 O
according NCT03926910 164 173 O
to NCT03926910 174 176 O
the NCT03926910 177 180 O
recommendations NCT03926910 181 196 O
: NCT03926910 197 198 O

- NCT03926910 207 208 O
Euroscore NCT03926910 210 219 O
with NCT03926910 220 224 O
predicted NCT03926910 225 234 B-Observation
mortality NCT03926910 235 244 I-Observation
> NCT03926910 245 246 B-Eq-Comparison
10 NCT03926910 247 249 I-Eq-Comparison
% NCT03926910 250 251 I-Eq-Comparison

- NCT03926910 260 261 O
Left NCT03926910 263 267 B-Observation
ventricular NCT03926910 268 279 I-Observation
ejection NCT03926910 280 288 I-Observation
fraction NCT03926910 289 297 I-Observation
( NCT03926910 298 299 O
LVEF NCT03926910 300 304 B-Observation
) NCT03926910 305 306 O
< NCT03926910 307 308 B-Eq-Comparison
40 NCT03926910 309 311 I-Eq-Comparison
% NCT03926910 312 313 I-Eq-Comparison

- NCT03926910 322 323 O
Left NCT03926910 325 329 B-Observation
ventricular NCT03926910 330 341 I-Observation
ejection NCT03926910 342 350 I-Observation
fraction NCT03926910 351 359 I-Observation
( NCT03926910 360 361 O
LVEF NCT03926910 362 366 B-Observation
) NCT03926910 367 368 O
< NCT03926910 369 370 B-Eq-Comparison
50 NCT03926910 371 373 I-Eq-Comparison
% NCT03926910 374 375 I-Eq-Comparison
for NCT03926910 376 379 B-And
mitral NCT03926910 380 386 B-Condition
insufficiency NCT03926910 387 400 I-Condition

- NCT03926910 408 409 O
pulmonary NCT03926910 411 420 B-Condition
artery NCT03926910 421 427 I-Condition
hypertension NCT03926910 428 440 I-Condition
( NCT03926910 441 442 O
PAH NCT03926910 443 446 B-Condition
) NCT03926910 447 448 O
> NCT03926910 450 451 B-Eq-Comparison
50 NCT03926910 452 454 I-Eq-Comparison
mmHg NCT03926910 455 459 I-Eq-Comparison

- NCT03926910 467 468 O
Tricuspid NCT03926910 470 479 B-Condition
insufficiency NCT03926910 480 493 I-Condition
> NCT03926910 494 495 B-Eq-Comparison
3.4 NCT03926910 496 499 I-Eq-Comparison
m NCT03926910 500 501 I-Eq-Comparison
/ NCT03926910 502 503 I-Eq-Comparison
s NCT03926910 504 505 I-Eq-Comparison

- NCT03926910 513 514 O
Tricuspid NCT03926910 516 525 B-Observation
annular NCT03926910 526 533 I-Observation
plane NCT03926910 534 539 I-Observation
systolic NCT03926910 540 548 I-Observation
excursion NCT03926910 549 558 I-Observation
( NCT03926910 559 560 O
TAPSE NCT03926910 561 566 B-Observation
) NCT03926910 567 568 O
< NCT03926910 569 570 B-Eq-Comparison
16 NCT03926910 571 573 I-Eq-Comparison
mm NCT03926910 574 576 I-Eq-Comparison

- NCT03926910 584 585 O
Dilatation NCT03926910 587 597 B-Condition
of NCT03926910 598 600 I-Condition
the NCT03926910 601 604 I-Condition
inferior NCT03926910 605 613 I-Condition
vena NCT03926910 614 618 I-Condition
cava NCT03926910 619 623 I-Condition
under NCT03926910 624 629 I-Condition
respiratory NCT03926910 630 641 I-Condition
collapse NCT03926910 642 650 I-Condition

- NCT03926910 653 654 O
Sinus NCT03926910 656 661 B-Condition
rhythm NCT03926910 662 668 I-Condition
in NCT03926910 669 671 O
immediate NCT03926910 672 681 O
post NCT03926910 682 686 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03926910 687 696 B-Procedure
period NCT03926910 697 703 O
, NCT03926910 704 705 O

- NCT03926910 709 710 O
Sedated NCT03926910 712 719 B-Procedure
with NCT03926910 720 724 O
mechanical NCT03926910 725 735 B-Procedure
ventilation NCT03926910 736 747 I-Procedure
, NCT03926910 748 749 O

- NCT03926910 753 754 O
Having NCT03926910 756 762 O
given NCT03926910 763 768 O
their NCT03926910 769 774 O
written NCT03926910 775 782 O
participation NCT03926910 783 796 O
consent NCT03926910 797 804 O
in NCT03926910 805 807 O
accordance NCT03926910 808 818 O
with NCT03926910 819 823 O
the NCT03926910 824 827 O
regulations NCT03926910 828 839 O
, NCT03926910 840 841 O

- NCT03926910 845 846 O
Benefiting NCT03926910 848 858 O
from NCT03926910 859 863 O
a NCT03926910 864 865 O
social NCT03926910 866 872 O
security NCT03926910 873 881 O

Exclusion NCT03926910 882 891 O
Criteria NCT03926910 892 900 O
: NCT03926910 901 902 O

- NCT03926910 906 907 O
Pregnant NCT03926910 909 917 B-Condition
or NCT03926910 918 920 B-Or
lactating NCT03926910 921 930 B-Condition
women NCT03926910 931 936 O
, NCT03926910 937 938 O

- NCT03926910 942 943 O
Patient NCT03926910 945 952 O
under NCT03926910 953 958 B-Observation
guardianship NCT03926910 959 971 I-Observation
, NCT03926910 972 973 O
Under NCT03926910 974 979 O
curatorship NCT03926910 980 991 O
or NCT03926910 992 994 O
court NCT03926910 995 1000 O
of NCT03926910 1001 1003 O
justice NCT03926910 1004 1011 O
, NCT03926910 1012 1013 O

- NCT03926910 1017 1018 O
Discomfort NCT03926910 1020 1030 B-Condition
to NCT03926910 1031 1033 I-Condition
communication NCT03926910 1034 1047 I-Condition
or NCT03926910 1048 1050 B-Or
neuropsychic NCT03926910 1051 1063 B-Condition
disorders NCT03926910 1064 1073 I-Condition
, NCT03926910 1074 1075 O
Inability NCT03926910 1076 1085 B-Negation
to NCT03926910 1086 1088 O
understand NCT03926910 1089 1099 O
, NCT03926910 1100 1101 O
to NCT03926910 1102 1104 O
read NCT03926910 1105 1109 O
or NCT03926910 1110 1112 O
to NCT03926910 1113 1115 O
write NCT03926910 1116 1121 O
the NCT03926910 1122 1125 O
French NCT03926910 1126 1132 O
language NCT03926910 1133 1141 O
, NCT03926910 1142 1143 O

- NCT03926910 1147 1148 O
Patients NCT03926910 1150 1158 O
for NCT03926910 1159 1162 O
whom NCT03926910 1163 1167 O
a NCT03926910 1168 1169 O
fluids NCT03926910 1170 1176 B-Condition
overload NCT03926910 1177 1185 I-Condition
seems NCT03926910 1186 1191 B-Assertion___Assertion-Type-Value:hypothetical
obvious NCT03926910 1192 1199 O
to NCT03926910 1200 1202 O
the NCT03926910 1203 1206 O
intensivist NCT03926910 1207 1218 O
and NCT03926910 1219 1222 B-And
for NCT03926910 1223 1226 O
whom NCT03926910 1227 1231 O
a NCT03926910 1232 1233 O
crystalloids NCT03926910 1234 1246 B-Procedure
filling NCT03926910 1247 1254 I-Procedure
would NCT03926910 1255 1260 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03926910 1261 1263 I-Assertion___Assertion-Type-Value:hypothetical
contraindicated NCT03926910 1264 1279 B-Contraindication
, NCT03926910 1280 1281 O

- NCT03926910 1285 1286 O
Patients NCT03926910 1288 1296 O
for NCT03926910 1297 1300 O
whom NCT03926910 1301 1305 O
respiratory NCT03926910 1306 1317 O
changes NCT03926910 1318 1325 O
in NCT03926910 1326 1328 O
pulse NCT03926910 1329 1334 B-Observation
pressure NCT03926910 1335 1343 I-Observation
( NCT03926910 1344 1345 O
ΔPP NCT03926910 1346 1349 B-Observation
) NCT03926910 1350 1351 O
measurement NCT03926910 1352 1363 O
is NCT03926910 1364 1366 O
not NCT03926910 1367 1370 B-Negation
validated NCT03926910 1371 1380 B-Assertion___Assertion-Type-Value:hypothetical
: NCT03926910 1381 1382 O
patients NCT03926910 1383 1391 O
with NCT03926910 1392 1396 O
spontaneous NCT03926910 1397 1408 B-Condition
ventilation NCT03926910 1409 1420 I-Condition
, NCT03926910 1421 1422 O
atrial NCT03926910 1423 1429 B-Condition
fibrillation NCT03926910 1430 1442 I-Condition
, NCT03926910 1443 1444 O
non NCT03926910 1445 1448 B-Condition
- NCT03926910 1449 1450 I-Condition
sedated NCT03926910 1451 1458 I-Condition

Inclusion NCT03925558 0 9 O
Criteria NCT03925558 10 18 O
: NCT03925558 19 20 O

- NCT03925558 23 24 O
Full NCT03925558 25 29 O
term NCT03925558 30 34 O
healthy NCT03925558 35 42 B-Condition
infant NCT03925558 43 49 O
aged NCT03925558 50 54 B-Age
3 NCT03925558 55 56 B-Eq-Comparison
- NCT03925558 57 58 I-Eq-Comparison
95 NCT03925558 59 61 O
days NCT03925558 62 66 O

Exclusion NCT03925558 67 76 O
Criteria NCT03925558 77 85 O
: NCT03925558 86 87 O

- NCT03925558 91 92 O
Prematurity NCT03925558 94 105 B-Condition

- NCT03925558 108 109 O
Low NCT03925558 111 114 O
birth NCT03925558 115 120 B-Observation
weight NCT03925558 121 127 I-Observation

- NCT03925558 130 131 O
Congenital NCT03925558 133 143 B-Condition
anomalies NCT03925558 144 153 I-Condition

- NCT03925558 156 157 O
Chronic NCT03925558 159 166 B-Condition
disease NCT03925558 167 174 I-Condition

- NCT03925558 177 178 O
Failure NCT03925558 180 187 B-Condition
to NCT03925558 188 190 I-Condition
thrive NCT03925558 191 197 I-Condition

- NCT03925558 200 201 O
Allergy NCT03925558 203 210 B-Allergy
or NCT03925558 211 213 B-Or
atopic NCT03925558 214 220 B-Condition
disease NCT03925558 221 228 I-Condition

- NCT03925558 231 232 O
Recent NCT03925558 234 240 B-Eq-Comparison
exposure NCT03925558 241 249 O
to NCT03925558 250 252 O
antibiotics NCT03925558 253 264 B-Drug

Inclusion NCT03928054 0 9 O
Criteria NCT03928054 10 18 O
: NCT03928054 19 20 O

- NCT03928054 24 25 O
Patients NCT03928054 27 35 O
with NCT03928054 36 40 O
both NCT03928054 41 45 O
sexes NCT03928054 46 51 O
from NCT03928054 52 56 O
40 NCT03928054 57 59 B-Eq-Comparison
to NCT03928054 60 62 I-Eq-Comparison
80 NCT03928054 63 65 I-Eq-Comparison
years NCT03928054 66 71 I-Eq-Comparison
old NCT03928054 72 75 B-Age

- NCT03928054 78 79 O
who NCT03928054 81 84 O
underwent NCT03928054 85 94 B-Eq-Comparison
imaging NCT03928054 95 102 B-Procedure
examination NCT03928054 103 114 I-Procedure
evidencing NCT03928054 115 125 O
grade NCT03928054 126 131 B-Eq-Comparison
II NCT03928054 132 134 I-Eq-Comparison
or NCT03928054 135 137 I-Eq-Comparison
III NCT03928054 138 141 I-Eq-Comparison
knee NCT03928054 142 146 B-Condition
osteoarthritis NCT03928054 147 161 I-Condition
according NCT03928054 162 171 O
to NCT03928054 172 174 O
the NCT03928054 175 178 O
Kellgren NCT03928054 179 187 O
and NCT03928054 188 191 O
Lawrence NCT03928054 192 200 O
classification NCT03928054 201 215 O

- NCT03928054 218 219 O
who NCT03928054 221 224 O
were NCT03928054 225 229 O
referred NCT03928054 230 238 B-Encounter
to NCT03928054 239 241 O
the NCT03928054 242 245 O
physiotherapy NCT03928054 246 259 B-Provider
service NCT03928054 260 267 I-Provider
by NCT03928054 268 270 O
a NCT03928054 271 272 O
physician NCT03928054 273 282 O
. NCT03928054 283 284 O

Exclusion NCT03928054 286 295 O
Criteria NCT03928054 296 304 O
: NCT03928054 305 306 O

- NCT03928054 310 311 O
Patients NCT03928054 313 321 O
who NCT03928054 322 325 O
are NCT03928054 326 329 O
unable NCT03928054 330 336 B-Negation
to NCT03928054 337 339 O
walk NCT03928054 340 344 B-Condition

- NCT03928054 347 348 O
with NCT03928054 350 354 O
a NCT03928054 355 356 O
history NCT03928054 357 364 B-Eq-Comparison
of NCT03928054 365 367 O
cancer NCT03928054 368 374 B-Condition

- NCT03928054 377 378 O
associated NCT03928054 380 390 O
neurological NCT03928054 391 403 B-Condition
diseases NCT03928054 404 412 I-Condition

- NCT03928054 415 416 O
morbid NCT03928054 418 424 B-Condition
obesity NCT03928054 425 432 I-Condition

Inclusion NCT03923101 0 9 O
Criteria NCT03923101 10 18 O
: NCT03923101 19 20 O

- NCT03923101 24 25 O
All NCT03923101 27 30 O
Keratoconus NCT03923101 31 42 B-Condition
patients NCT03923101 43 51 O
presenting NCT03923101 52 62 B-Encounter
in NCT03923101 63 65 O
the NCT03923101 66 69 O
department NCT03923101 70 80 O
of NCT03923101 81 83 O
ophthalmology NCT03923101 84 97 O
, NCT03923101 98 99 O
Saarland NCT03923101 100 108 O
University NCT03923101 109 119 O
Medical NCT03923101 120 127 O
Center NCT03923101 128 134 O
, NCT03923101 135 136 O
Homburg NCT03923101 137 144 O
, NCT03923101 145 146 O
Saarland NCT03923101 147 155 O
, NCT03923101 156 157 O
Germany NCT03923101 158 165 O
. NCT03923101 166 167 O

Exclusion NCT03923101 169 178 O
Criteria NCT03923101 179 187 O
: NCT03923101 188 189 O

- NCT03923101 193 194 O
Patients NCT03923101 196 204 O
without NCT03923101 205 212 B-Negation
Keratoconus NCT03923101 213 224 B-Condition
. NCT03923101 224 225 O

Inclusion NCT03926247 0 9 O
Criteria NCT03926247 10 18 O
: NCT03926247 19 20 O

- NCT03926247 24 25 O
Mexican NCT03926247 27 34 O
immigrant NCT03926247 35 44 O

- NCT03926247 47 48 O
Residing NCT03926247 50 58 O
in NCT03926247 59 61 O
Bernalillo NCT03926247 62 72 O
County NCT03926247 73 79 O
, NCT03926247 80 81 O
New NCT03926247 82 85 O
Mexico NCT03926247 86 92 O

Exclusion NCT03926247 93 102 O
Criteria NCT03926247 103 111 O
: NCT03926247 112 113 O

- NCT03926247 117 118 O
Severe NCT03926247 120 126 O
cognitive NCT03926247 127 136 B-Condition
functioning NCT03926247 137 148 I-Condition
problems NCT03926247 149 157 I-Condition

- NCT03926247 160 161 O
Imminent NCT03926247 163 171 O
suicide NCT03926247 172 179 B-Condition
risk NCT03926247 180 184 B-Risk

- NCT03926247 187 188 O
Mental NCT03926247 190 196 B-Condition
illness NCT03926247 197 204 I-Condition
that NCT03926247 205 209 O
is NCT03926247 210 212 O
so NCT03926247 213 215 O
severe NCT03926247 216 222 O
as NCT03926247 223 225 O
to NCT03926247 226 228 O
impede NCT03926247 229 235 O
participation NCT03926247 236 249 O
in NCT03926247 250 252 O
a NCT03926247 253 254 O
group NCT03926247 255 260 O
and NCT03926247 261 264 O
that NCT03926247 265 269 O
warrants NCT03926247 270 278 B-Assertion___Assertion-Type-Value:hypothetical
immediate NCT03926247 279 288 O
individual NCT03926247 289 299 O
treatment NCT03926247 300 309 B-Procedure

Inclusion NCT03921502 0 9 O
Criteria NCT03921502 10 18 O
: NCT03921502 19 20 O

- NCT03921502 24 25 O
Symptomatic NCT03921502 27 38 B-Condition
choledocholithiasis NCT03921502 39 58 I-Condition
( NCT03921502 59 60 O
choledocholithiasis NCT03921502 61 80 B-Condition
demonstrated NCT03921502 81 93 O
radiologically NCT03921502 94 108 B-Procedure
or NCT03921502 109 111 B-Or
highly NCT03921502 112 118 O
suspected NCT03921502 119 128 B-Assertion___Assertion-Type-Value:possible
by NCT03921502 129 131 O
clinical NCT03921502 132 140 O
data NCT03921502 141 145 O
( NCT03921502 146 147 O
acute NCT03921502 148 153 B-Condition
cholangitis NCT03921502 154 165 I-Condition
or NCT03921502 166 168 B-Or
obstructive NCT03921502 169 180 B-Condition
jaundice NCT03921502 181 189 I-Condition
) NCT03921502 190 191 O
, NCT03921502 193 194 O
analytical NCT03921502 195 205 O
and NCT03921502 206 209 O
imaging NCT03921502 210 217 O
according NCT03921502 218 227 O
to NCT03921502 228 230 O
the NCT03921502 231 234 O
criteria NCT03921502 235 243 O
of NCT03921502 244 246 O
high NCT03921502 247 251 O
probability NCT03921502 252 263 B-Assertion___Assertion-Type-Value:possible
of NCT03921502 264 266 O
choledocholithiasis NCT03921502 267 286 B-Condition
established NCT03921502 287 298 O
in NCT03921502 299 301 O
the NCT03921502 302 305 O
clinical NCT03921502 306 314 O
guidelines NCT03921502 315 325 O
( NCT03921502 326 327 O
ASGE NCT03921502 328 332 O
Guide NCT03921502 333 338 O
) NCT03921502 339 340 O
. NCT03921502 342 343 O

- NCT03921502 347 348 O
Discarded NCT03921502 350 359 B-Negation
for NCT03921502 360 363 O
surgical NCT03921502 364 372 B-Procedure
treatment NCT03921502 373 382 I-Procedure
due NCT03921502 383 386 O
to NCT03921502 387 389 O
age NCT03921502 390 393 B-Age
, NCT03921502 394 395 O
comorbidity NCT03921502 396 407 B-Condition
or NCT03921502 408 410 B-Or
refusal NCT03921502 411 418 B-Observation
of NCT03921502 419 421 O
the NCT03921502 422 425 O
patient NCT03921502 426 433 O
. NCT03921502 434 435 O

- NCT03921502 439 440 O
Age NCT03921502 442 445 B-Age
> NCT03921502 446 447 B-Eq-Comparison
75 NCT03921502 448 450 I-Eq-Comparison
years NCT03921502 451 456 I-Eq-Comparison

Exclusion NCT03921502 457 466 O
Criteria NCT03921502 467 475 O
: NCT03921502 476 477 O

- NCT03921502 481 482 O
Charlson NCT03921502 484 492 B-Observation
comorbidity NCT03921502 493 504 I-Observation
scale NCT03921502 505 510 I-Observation
adjusted NCT03921502 511 519 B-Modifier
to NCT03921502 520 522 I-Modifier
age NCT03921502 523 526 I-Modifier
< NCT03921502 527 528 B-Eq-Comparison
4 NCT03921502 529 530 I-Eq-Comparison
. NCT03921502 530 531 O

- NCT03921502 535 536 O
Prior NCT03921502 538 543 B-Eq-Comparison
ERCP NCT03921502 544 548 B-Procedure
. NCT03921502 549 550 O

- NCT03921502 554 555 O
Previous NCT03921502 557 565 B-Eq-Comparison
episodes NCT03921502 566 574 O
of NCT03921502 575 577 O
cholangitis NCT03921502 578 589 B-Condition
, NCT03921502 590 591 O
pancreatitis NCT03921502 592 604 B-Condition
or NCT03921502 605 607 B-Or
lithiasic NCT03921502 608 617 B-Condition
cholecystitis NCT03921502 618 631 I-Condition
. NCT03921502 632 633 O

- NCT03921502 637 638 O
Hepatobiliary NCT03921502 640 653 B-Procedure
surgery NCT03921502 654 661 I-Procedure
or NCT03921502 662 664 B-Or
previous NCT03921502 665 673 B-Eq-Comparison
superior NCT03921502 674 682 B-Condition
digestive NCT03921502 683 692 I-Condition
tract NCT03921502 693 698 I-Condition
. NCT03921502 699 700 O

- NCT03921502 704 705 O
Ascitis NCT03921502 707 714 O
. NCT03921502 715 716 O

- NCT03921502 720 721 O
Inability NCT03921502 723 732 B-Negation
to NCT03921502 733 735 O
tolerate NCT03921502 736 744 B-Assertion___Assertion-Type-Value:hypothetical
sedation NCT03921502 745 753 B-Procedure
of NCT03921502 754 756 I-Procedure
endoscopy NCT03921502 757 766 I-Procedure
, NCT03921502 767 768 O
perforation NCT03921502 769 780 B-Condition
of NCT03921502 781 783 I-Condition
the NCT03921502 784 787 I-Condition
digestive NCT03921502 788 797 I-Condition
tract NCT03921502 798 803 I-Condition
or NCT03921502 804 806 O
other NCT03921502 807 812 O
contraindication NCT03921502 813 829 B-Contraindication
to NCT03921502 830 832 O
endoscopy NCT03921502 833 842 B-Procedure
. NCT03921502 843 844 O

- NCT03921502 848 849 O
Coagulopathy NCT03921502 851 863 B-Condition
with NCT03921502 864 868 B-And
INR NCT03921502 869 872 B-Observation
( NCT03921502 873 874 O
international NCT03921502 875 888 B-Observation
normalized NCT03921502 889 899 I-Observation
ratio NCT03921502 900 905 I-Observation
) NCT03921502 906 907 O
> NCT03921502 908 909 B-Eq-Comparison
1.5 NCT03921502 910 913 I-Eq-Comparison
not NCT03921502 914 917 O
correctable NCT03921502 918 929 O
or NCT03921502 930 932 O
thrombocytopenia NCT03921502 933 949 B-Condition
< NCT03921502 950 951 B-Eq-Comparison
50000 NCT03921502 952 957 I-Eq-Comparison
/ NCT03921502 958 959 I-Eq-Comparison
mm3 NCT03921502 960 963 I-Eq-Comparison
not NCT03921502 964 967 O
correctable NCT03921502 968 979 O
. NCT03921502 980 981 O

- NCT03921502 985 986 O
Other NCT03921502 988 993 O
diagnoses NCT03921502 994 1003 B-Condition
at NCT03921502 1004 1006 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03921502 1007 1016 B-Encounter
( NCT03921502 1017 1018 O
acute NCT03921502 1019 1024 B-Condition
cholecystitis NCT03921502 1025 1038 I-Condition
, NCT03921502 1039 1040 O
acute NCT03921502 1041 1046 B-Condition
pancreatitis NCT03921502 1047 1059 I-Condition
, NCT03921502 1060 1061 O
biliopancreatic NCT03921502 1062 1077 B-Condition
neoplasia NCT03921502 1078 1087 I-Condition
) NCT03921502 1088 1089 O
. NCT03921502 1091 1092 O

- NCT03921502 1096 1097 O
Hemodynamic NCT03921502 1099 1110 B-Condition
instability NCT03921502 1111 1122 I-Condition
. NCT03921502 1123 1124 O

- NCT03921502 1128 1129 O
Urgent NCT03921502 1131 1137 B-Procedure
procedure NCT03921502 1138 1147 I-Procedure
performed NCT03921502 1148 1157 O
after NCT03921502 1158 1163 O
hours NCT03921502 1164 1169 O

- NCT03921502 1172 1173 O
No NCT03921502 1175 1177 O
availability NCT03921502 1178 1190 O
of NCT03921502 1191 1193 O
expert NCT03921502 1194 1200 O
material NCT03921502 1201 1209 O
/ NCT03921502 1210 1211 O
endoscopist NCT03921502 1212 1223 O
in NCT03921502 1224 1226 O
drainage NCT03921502 1227 1235 O
. NCT03921502 1236 1237 O

- NCT03921502 1241 1242 O
Anatomical NCT03921502 1244 1254 O
impossibility NCT03921502 1255 1268 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03921502 1269 1271 O
performing NCT03921502 1272 1282 O
biliary NCT03921502 1283 1290 B-Procedure
drainage NCT03921502 1291 1299 I-Procedure
( NCT03921502 1300 1301 O
absence NCT03921502 1302 1309 B-Negation
of NCT03921502 1310 1312 O
vesicular NCT03921502 1313 1322 B-Condition
distension NCT03921502 1323 1333 I-Condition
, NCT03921502 1334 1335 O
contact NCT03921502 1336 1343 B-Condition
between NCT03921502 1344 1351 O
gallbladder NCT03921502 1352 1363 B-Modifier
and NCT03921502 1364 1367 B-And
stomach NCT03921502 1368 1375 B-Modifier
or NCT03921502 1376 1378 B-Or
duodenum NCT03921502 1379 1387 B-Modifier
, NCT03921502 1388 1389 O
contact NCT03921502 1390 1397 B-Observation
area NCT03921502 1398 1402 I-Observation
< NCT03921502 1403 1404 B-Eq-Comparison
10 NCT03921502 1405 1407 I-Eq-Comparison
mm NCT03921502 1408 1410 I-Eq-Comparison
) NCT03921502 1411 1412 O
. NCT03921502 1414 1415 O

- NCT03921502 1419 1420 O
Baseline NCT03921502 1422 1430 O
ECOG NCT03921502 1431 1435 B-Observation
( NCT03921502 1436 1437 O
Easthern NCT03921502 1438 1446 B-Observation
Cooperative NCT03921502 1447 1458 I-Observation
Oncology NCT03921502 1459 1467 I-Observation
Group NCT03921502 1468 1473 I-Observation
) NCT03921502 1474 1475 O
> NCT03921502 1476 1477 B-Eq-Comparison
= NCT03921502 1478 1479 I-Eq-Comparison
4 NCT03921502 1480 1481 I-Eq-Comparison

- NCT03921502 1485 1486 O
Expectancy NCT03921502 1488 1498 B-Observation
of NCT03921502 1499 1501 I-Observation
survival NCT03921502 1502 1510 I-Observation
< NCT03921502 1511 1512 B-Eq-Comparison
6 NCT03921502 1513 1514 I-Eq-Comparison
months NCT03921502 1515 1521 I-Eq-Comparison
. NCT03921502 1522 1523 O

- NCT03921502 1527 1528 O
Refusal NCT03921502 1530 1537 O
to NCT03921502 1538 1540 O
participate NCT03921502 1541 1552 O
. NCT03921502 1553 1554 O

- NCT03921502 1558 1559 O
Distance NCT03921502 1561 1569 B-Observation
between NCT03921502 1570 1577 O
the NCT03921502 1578 1581 O
gallbladder NCT03921502 1582 1593 B-Modifier
and NCT03921502 1594 1597 B-And
upper NCT03921502 1598 1603 B-Modifier
digestive NCT03921502 1604 1613 I-Modifier
tract NCT03921502 1614 1619 I-Modifier
> NCT03921502 1620 1621 B-Eq-Comparison
1 NCT03921502 1622 1623 I-Eq-Comparison
cm NCT03921502 1624 1626 O
, NCT03921502 1627 1628 O
scleroatrophic NCT03921502 1629 1643 B-Condition
vesicle NCT03921502 1644 1651 I-Condition
, NCT03921502 1652 1653 O
lack NCT03921502 1654 1658 B-Negation
of NCT03921502 1659 1661 I-Negation
stable NCT03921502 1662 1668 B-Observation
acoustic NCT03921502 1669 1677 I-Observation
window NCT03921502 1678 1684 I-Observation
for NCT03921502 1685 1688 I-Observation
drainage NCT03921502 1689 1697 I-Observation

- NCT03921502 1700 1701 O
ERCP NCT03921502 1703 1707 B-Condition
failed NCT03921502 1708 1714 O
( NCT03921502 1715 1716 O
inhability NCT03921502 1717 1727 B-Negation
to NCT03921502 1728 1730 O
dain NCT03921502 1731 1735 B-Condition
common NCT03921502 1736 1742 I-Condition
bile NCT03921502 1743 1747 I-Condition
duct NCT03921502 1748 1752 I-Condition
) NCT03921502 1753 1754 O

Inclusion NCT03920813 0 9 O
Criteria NCT03920813 10 18 O
: NCT03920813 19 20 O

- NCT03920813 24 25 O
Patients NCT03920813 27 35 O
have NCT03920813 36 40 O
been NCT03920813 41 45 O
diagnosed NCT03920813 46 55 O
with NCT03920813 56 60 O
Acute NCT03920813 61 66 B-Condition
Lymphoblastic NCT03920813 67 80 I-Condition
Leukemia NCT03920813 81 89 I-Condition

- NCT03920813 92 93 O
Childhood NCT03920813 95 104 O
patients NCT03920813 105 113 O
who NCT03920813 114 117 B-And
were NCT03920813 118 122 O
undergoing NCT03920813 123 133 B-Eq-Comparison
chemotherapy NCT03920813 134 146 B-Procedure
or NCT03920813 147 149 B-Or
continuous NCT03920813 150 160 O
follow NCT03920813 161 167 B-Encounter
- NCT03920813 168 169 I-Encounter
up NCT03920813 170 172 I-Encounter
after NCT03920813 173 178 B-Temporal-Connection___Temporal-Connection-Type-Value:after
completion NCT03920813 179 189 O
of NCT03920813 190 192 O
chemotherapy NCT03920813 193 205 B-Procedure

- NCT03920813 208 209 O
Patients NCT03920813 211 219 O
received NCT03920813 220 228 B-Eq-Comparison
the NCT03920813 229 232 O
phase NCT03920813 233 238 O
of NCT03920813 239 241 O
maintenance NCT03920813 242 253 B-Procedure
therapy NCT03920813 254 261 I-Procedure
that NCT03920813 262 266 O
included NCT03920813 267 275 O
oral NCT03920813 276 280 B-Modifier
6 NCT03920813 281 282 B-Drug
- NCT03920813 283 284 I-Drug
MP NCT03920813 285 287 I-Drug
( NCT03920813 288 289 O
> NCT03920813 291 292 B-Eq-Comparison
4 NCT03920813 293 294 I-Eq-Comparison
weeks NCT03920813 295 300 I-Eq-Comparison
) NCT03920813 301 302 O
and NCT03920813 303 306 O
completion NCT03920813 307 317 O
of NCT03920813 318 320 O
≥ NCT03920813 321 322 B-Eq-Comparison
6 NCT03920813 323 324 I-Eq-Comparison
months NCT03920813 325 331 I-Eq-Comparison
according NCT03920813 332 341 O
to NCT03920813 342 344 O
the NCT03920813 345 348 O
CCLG NCT03920813 349 353 O
( NCT03920813 354 355 O
Chinese NCT03920813 356 363 O
Children NCT03920813 364 372 O
's NCT03920813 372 374 O
Leukemia NCT03920813 375 383 O
Group NCT03920813 384 389 O
) NCT03920813 390 391 O
protocol NCT03920813 392 400 O
- NCT03920813 401 402 O
ALL NCT03920813 403 406 O
2015 NCT03920813 407 411 O

Exclusion NCT03920813 413 422 O
Criteria NCT03920813 423 431 O
: NCT03920813 432 433 O

- NCT03920813 437 438 O
Patients NCT03920813 440 448 O
with NCT03920813 449 453 O
high NCT03920813 454 458 O
- NCT03920813 459 460 O
risk NCT03920813 461 465 B-Risk
ALL NCT03920813 466 469 B-Condition
( NCT03920813 470 471 O
presence NCT03920813 472 480 O
of NCT03920813 481 483 O
higher NCT03920813 484 490 B-Coreference
- NCT03920813 491 492 I-Coreference
risk NCT03920813 493 497 I-Coreference
features NCT03920813 498 506 I-Coreference
: NCT03920813 507 508 O
MRD NCT03920813 509 512 B-Observation
≥ NCT03920813 513 514 B-Eq-Comparison
1 NCT03920813 515 516 I-Eq-Comparison
% NCT03920813 517 518 O
at NCT03920813 519 521 O
46 NCT03920813 522 524 O
day NCT03920813 525 528 O
, NCT03920813 529 530 O
or NCT03920813 531 533 B-Or
age NCT03920813 534 537 B-Age
< NCT03920813 538 539 B-Eq-Comparison
6 NCT03920813 540 541 I-Eq-Comparison
month NCT03920813 542 547 I-Eq-Comparison
and NCT03920813 548 551 B-And
white NCT03920813 552 557 B-Observation
blood NCT03920813 558 563 I-Observation
cell NCT03920813 564 568 I-Observation
( NCT03920813 569 570 O
WBC NCT03920813 571 574 B-Observation
) NCT03920813 575 576 O
count NCT03920813 577 582 B-Eq-Comparison
≥ NCT03920813 583 584 I-Eq-Comparison
300 NCT03920813 585 588 I-Eq-Comparison
×109 NCT03920813 589 593 I-Eq-Comparison
/ NCT03920813 594 595 I-Eq-Comparison
L NCT03920813 596 597 I-Eq-Comparison
with NCT03920813 598 602 O
translocations NCT03920813 603 617 O
t NCT03920813 618 619 O
( NCT03920813 620 621 O
9 NCT03920813 622 623 O
; NCT03920813 624 625 O
22 NCT03920813 625 627 O
) NCT03920813 628 629 O
( NCT03920813 630 631 O
q34 NCT03920813 632 635 O
; NCT03920813 636 637 O
q11 NCT03920813 637 640 O
) NCT03920813 641 642 O
[ NCT03920813 643 644 O
BCR NCT03920813 645 648 O
- NCT03920813 649 650 O
ABL NCT03920813 651 654 O
] NCT03920813 655 656 O
, NCT03920813 658 659 O
t NCT03920813 660 661 O
( NCT03920813 662 663 O
4 NCT03920813 664 665 O
; NCT03920813 666 667 O
11 NCT03920813 667 669 O
) NCT03920813 670 671 O
( NCT03920813 672 673 O
q21 NCT03920813 674 677 O
; NCT03920813 678 679 O
q23 NCT03920813 679 682 O
) NCT03920813 683 684 O
[ NCT03920813 685 686 O
AF4 NCT03920813 687 690 O
/ NCT03920813 691 692 O
MLL NCT03920813 693 696 O
] NCT03920813 697 698 O
, NCT03920813 700 701 O
t NCT03920813 702 703 O
( NCT03920813 704 705 O
1 NCT03920813 706 707 O
; NCT03920813 708 709 O
19 NCT03920813 709 711 O
) NCT03920813 712 713 O
( NCT03920813 714 715 O
q23 NCT03920813 716 719 O
; NCT03920813 720 721 O
p13 NCT03920813 721 724 O
) NCT03920813 725 726 O
[ NCT03920813 727 728 O
E2A NCT03920813 729 732 O
- NCT03920813 733 734 O
PBX1 NCT03920813 735 739 O
] NCT03920813 740 741 O
or NCT03920813 742 744 O
other NCT03920813 745 750 O
MLL NCT03920813 751 754 O
- NCT03920813 755 756 O
rearrangements NCT03920813 757 771 O
) NCT03920813 772 773 O
were NCT03920813 774 778 O
removed NCT03920813 779 786 O

Inclusion NCT03927417 0 9 O
Criteria NCT03927417 10 18 O
: NCT03927417 19 20 O

• NCT03927417 22 23 O
Couples NCT03927417 24 31 O
with NCT03927417 32 36 O
primary NCT03927417 37 44 B-Modifier
/ NCT03927417 45 46 B-Or
secondary NCT03927417 47 56 B-Modifier
infertility NCT03927417 57 68 B-Condition
who NCT03927417 69 72 B-And
are NCT03927417 73 76 O
planned NCT03927417 77 84 B-Eq-Comparison
to NCT03927417 85 87 I-Eq-Comparison
undergo NCT03927417 88 95 I-Eq-Comparison
IVF NCT03927417 96 99 B-Procedure
/ NCT03927417 100 101 B-Or
ICSI NCT03927417 102 106 B-Procedure

treatment NCT03927417 107 116 O
in NCT03927417 117 119 O
one NCT03927417 120 123 O
of NCT03927417 124 126 O
the NCT03927417 127 130 O
above NCT03927417 131 136 O
mentioned NCT03927417 137 146 O
centers NCT03927417 147 154 O
and NCT03927417 155 158 O
who NCT03927417 159 162 O
agree NCT03927417 163 168 O
to NCT03927417 169 171 O
take NCT03927417 172 176 O
part NCT03927417 177 181 O
in NCT03927417 182 184 O
this NCT03927417 185 189 O
study NCT03927417 190 195 O
. NCT03927417 196 197 O

Exclusion NCT03927417 199 208 O
Criteria NCT03927417 209 217 O
: NCT03927417 218 219 O

- NCT03927417 223 224 O
Couples NCT03927417 226 233 O
planned NCT03927417 234 241 B-Eq-Comparison
for NCT03927417 242 245 O
oocyte NCT03927417 246 252 B-Modifier
and NCT03927417 253 256 B-Or
sperm NCT03927417 257 262 B-Modifier
donation NCT03927417 263 271 B-Observation

- NCT03927417 274 275 O
Couples NCT03927417 277 284 O
in NCT03927417 285 287 O
whom NCT03927417 288 292 O
the NCT03927417 293 296 O
female NCT03927417 297 303 O
partner NCT03927417 304 311 O
has NCT03927417 312 315 O
a NCT03927417 316 317 O
history NCT03927417 318 325 B-Eq-Comparison
of NCT03927417 326 328 O
: NCT03927417 329 330 O

- NCT03927417 334 335 O
Chemotherapy NCT03927417 337 349 B-Procedure
or NCT03927417 350 352 B-Or
radiation NCT03927417 353 362 B-Procedure
which NCT03927417 363 368 O
impacts NCT03927417 369 376 O
the NCT03927417 377 380 O
ovarian NCT03927417 381 388 O
reserve NCT03927417 389 396 O

- NCT03927417 399 400 O
Surgery NCT03927417 402 409 B-Procedure
at NCT03927417 410 412 O
the NCT03927417 413 416 O
ovaries NCT03927417 417 424 B-Modifier
/ NCT03927417 425 426 B-Or
adnex NCT03927417 427 432 B-Modifier
region NCT03927417 433 439 I-Modifier

- NCT03927417 442 443 O
Tubal NCT03927417 445 450 B-Procedure
ligation NCT03927417 451 459 I-Procedure

- NCT03927417 462 463 O
Reversal NCT03927417 465 473 B-Procedure
of NCT03927417 474 476 I-Procedure
tubal NCT03927417 477 482 I-Procedure
ligation NCT03927417 483 491 I-Procedure

- NCT03927417 494 495 O
Endometriosis NCT03927417 497 510 B-Condition

- NCT03927417 513 514 O
Couples NCT03927417 516 523 O
in NCT03927417 524 526 O
whom NCT03927417 527 531 O
the NCT03927417 532 535 O
male NCT03927417 536 540 O
partner NCT03927417 541 548 O
has NCT03927417 549 552 O
a NCT03927417 553 554 O
history NCT03927417 555 562 B-Eq-Comparison
of NCT03927417 563 565 O
: NCT03927417 566 567 O

- NCT03927417 571 572 O
Chemotherapy NCT03927417 574 586 B-Procedure
/ NCT03927417 587 588 B-Or
Radiation NCT03927417 589 598 B-Procedure
which NCT03927417 599 604 O
impacts NCT03927417 605 612 O
the NCT03927417 613 616 O
semen NCT03927417 617 622 B-Condition
result NCT03927417 623 629 O

- NCT03927417 632 633 O
Surgery NCT03927417 635 642 B-Procedure
at NCT03927417 643 645 O
the NCT03927417 646 649 O
testicles NCT03927417 650 659 B-Modifier

- NCT03927417 662 663 O
Vasectomy NCT03927417 665 674 B-Procedure

- NCT03927417 677 678 O
Surgery NCT03927417 680 687 B-Procedure
for NCT03927417 688 691 I-Procedure
reversal NCT03927417 692 700 I-Procedure
of NCT03927417 701 703 I-Procedure
vasectomy NCT03927417 704 713 I-Procedure

Inclusion NCT03928730 0 9 O
Criteria NCT03928730 10 18 O
: NCT03928730 19 20 O

- NCT03928730 24 25 O
All NCT03928730 27 30 O
with NCT03928730 31 35 O
oral NCT03928730 36 40 B-Modifier
and NCT03928730 41 44 B-Or
/ NCT03928730 45 46 I-Or
or NCT03928730 47 49 I-Or
maxillofacial NCT03928730 50 63 B-Modifier
swelling NCT03928730 64 72 B-Condition
, NCT03928730 73 74 O

Exclusion NCT03928730 76 85 O
Criteria NCT03928730 86 94 O
: NCT03928730 95 96 O

- NCT03928730 100 101 O
Any NCT03928730 103 106 O
other NCT03928730 107 112 O
swellings NCT03928730 113 122 B-Condition
that NCT03928730 123 127 O
were NCT03928730 128 132 O
caused NCT03928730 133 139 O
by NCT03928730 140 142 O
trauma NCT03928730 143 149 B-Condition
and NCT03928730 150 153 B-Or
/ NCT03928730 154 155 I-Or
or NCT03928730 156 158 I-Or
fracture NCT03928730 159 167 B-Condition
, NCT03928730 168 169 O
extended NCT03928730 170 178 B-Modifier
below NCT03928730 179 184 I-Modifier
the NCT03928730 185 188 I-Modifier
neck NCT03928730 189 193 I-Modifier
or NCT03928730 194 196 B-Or
patient NCT03928730 197 204 O
reluctant NCT03928730 205 214 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928730 215 217 I-Assertion___Assertion-Type-Value:hypothetical
undergo NCT03928730 218 225 B-Eq-Comparison
US NCT03928730 226 228 B-Procedure
were NCT03928730 229 233 O
excluded NCT03928730 234 242 B-Negation
from NCT03928730 243 247 O
the NCT03928730 248 251 O
study NCT03928730 252 257 B-Study
. NCT03928730 257 258 O

Inclusion NCT03929406 0 9 O
Criteria NCT03929406 10 18 O
: NCT03929406 19 20 O

- NCT03929406 24 25 O
Eligible NCT03929406 27 35 B-Assertion___Assertion-Type-Value:hypothetical
patients NCT03929406 36 44 O
for NCT03929406 45 48 O
deep NCT03929406 49 53 B-Procedure
brain NCT03929406 54 59 I-Procedure
stimulation NCT03929406 60 71 I-Procedure
surgery NCT03929406 72 79 I-Procedure

- NCT03929406 82 83 O
Patients NCT03929406 85 93 O
affiliated NCT03929406 94 104 O
to NCT03929406 105 107 O
social NCT03929406 108 114 O
security NCT03929406 115 123 O
or NCT03929406 124 126 O
benefiting NCT03929406 127 137 O
of NCT03929406 138 140 O
a NCT03929406 141 142 O
similar NCT03929406 143 150 O
insurance NCT03929406 151 160 O
scheme NCT03929406 161 167 O

- NCT03929406 170 171 O
Patients NCT03929406 173 181 O
having NCT03929406 182 188 O
signed NCT03929406 189 195 O
a NCT03929406 196 197 O
consent NCT03929406 198 205 O
to NCT03929406 206 208 O
participate NCT03929406 209 220 O
to NCT03929406 221 223 O
the NCT03929406 224 227 O
study NCT03929406 228 233 O

Exclusion NCT03929406 234 243 O
Criteria NCT03929406 244 252 O
: NCT03929406 253 254 O

- NCT03929406 258 259 O
Patient NCT03929406 261 268 O
not NCT03929406 269 272 B-Negation
eligible NCT03929406 273 281 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929406 282 285 O
deep NCT03929406 286 290 B-Procedure
brain NCT03929406 291 296 I-Procedure
stimulation NCT03929406 297 308 I-Procedure
surgery NCT03929406 309 316 I-Procedure

- NCT03929406 319 320 O
Pregnant NCT03929406 322 330 B-Condition
women NCT03929406 331 336 O
or NCT03929406 337 339 B-Or
nursing NCT03929406 340 347 B-Condition
mothers NCT03929406 348 355 O

- NCT03929406 358 359 O
Persons NCT03929406 361 368 O
deprived NCT03929406 369 377 B-Observation
of NCT03929406 378 380 I-Observation
liberty NCT03929406 381 388 I-Observation
by NCT03929406 389 391 O
judicial NCT03929406 392 400 O
or NCT03929406 401 403 O
administrative NCT03929406 404 418 O
decision NCT03929406 419 427 O

- NCT03929406 430 431 O
Persons NCT03929406 433 440 O
unable NCT03929406 441 447 O
to NCT03929406 448 450 O
express NCT03929406 451 458 O
their NCT03929406 459 464 O
consent NCT03929406 465 472 O
or NCT03929406 473 475 O
legally NCT03929406 476 483 B-Observation
protected NCT03929406 484 493 I-Observation

- NCT03929406 496 497 O
Persons NCT03929406 499 506 O
in NCT03929406 507 509 O
period NCT03929406 510 516 O
of NCT03929406 517 519 O
disqualification NCT03929406 520 536 O
for NCT03929406 537 540 O
another NCT03929406 541 548 B-Other
interventional NCT03929406 549 563 B-Study
research NCT03929406 564 572 O

Inclusion NCT03920436 0 9 O
Criteria NCT03920436 10 18 O
: NCT03920436 19 20 O

- NCT03920436 24 25 O
19 NCT03920436 27 29 B-Eq-Comparison
years NCT03920436 30 35 I-Eq-Comparison
and NCT03920436 36 39 I-Eq-Comparison
older NCT03920436 40 45 I-Eq-Comparison

Exclusion NCT03920436 46 55 O
Criteria NCT03920436 56 64 O
: NCT03920436 65 66 O

- NCT03920436 70 71 O
aspartate NCT03920436 73 82 B-Observation
aminotransferase NCT03920436 83 99 I-Observation
( NCT03920436 100 101 O
AST NCT03920436 102 105 B-Observation
) NCT03920436 106 107 O
or NCT03920436 108 110 B-Or
alanine NCT03920436 111 118 B-Observation
aminotransferase NCT03920436 119 135 I-Observation
( NCT03920436 136 137 O
ALT NCT03920436 138 141 B-Observation
) NCT03920436 142 143 O
more NCT03920436 144 148 B-Eq-Comparison
than NCT03920436 149 153 I-Eq-Comparison
twice NCT03920436 154 159 I-Eq-Comparison
the NCT03920436 160 163 I-Eq-Comparison
highest NCT03920436 164 171 I-Eq-Comparison
reference NCT03920436 172 181 I-Eq-Comparison
value NCT03920436 182 187 I-Eq-Comparison

- NCT03920436 190 191 O
serum NCT03920436 193 198 B-Observation
creatinine NCT03920436 199 209 I-Observation
≥ NCT03920436 210 211 B-Eq-Comparison
1.5 NCT03920436 212 215 I-Eq-Comparison
mg NCT03920436 216 218 I-Eq-Comparison
/ NCT03920436 219 220 I-Eq-Comparison
dL NCT03920436 221 223 I-Eq-Comparison
) NCT03920436 224 225 O

- NCT03920436 229 230 O
uncontrolled NCT03920436 232 244 B-Modifier
diabetes NCT03920436 245 253 B-Condition
mellitus NCT03920436 254 262 I-Condition
( NCT03920436 263 264 O
a NCT03920436 265 266 O
fasting NCT03920436 267 274 B-Observation
glucose NCT03920436 275 282 I-Observation
of NCT03920436 283 285 O
> NCT03920436 286 287 B-Eq-Comparison
160 NCT03920436 288 291 I-Eq-Comparison
mg NCT03920436 292 294 I-Eq-Comparison
/ NCT03920436 295 296 I-Eq-Comparison
dL NCT03920436 297 299 I-Eq-Comparison
) NCT03920436 300 301 O

- NCT03920436 305 306 O
uncontrolled NCT03920436 308 320 B-Modifier
hypertension NCT03920436 321 333 B-Condition
( NCT03920436 334 335 O
BP NCT03920436 336 338 B-Observation
> NCT03920436 339 340 B-Eq-Comparison
160 NCT03920436 341 344 I-Eq-Comparison
/ NCT03920436 345 346 O
100 NCT03920436 347 350 O
mmHg NCT03920436 351 355 O
) NCT03920436 356 357 O

- NCT03920436 361 362 O
severe NCT03920436 364 370 O
gastrointestinal NCT03920436 371 387 B-Condition
symptoms NCT03920436 388 396 B-Assertion___Assertion-Type-Value:possible

- NCT03920436 399 400 O
alcohol NCT03920436 402 409 B-Observation
abuser NCT03920436 410 416 I-Observation

- NCT03920436 419 420 O
pregnant NCT03920436 422 430 B-Condition
or NCT03920436 431 433 B-Or
lactating NCT03920436 434 443 B-Condition
women NCT03920436 444 449 O

- NCT03920436 452 453 O
allergic NCT03920436 455 463 B-Allergy
to NCT03920436 464 466 O
the NCT03920436 467 470 O
ingredient NCT03920436 471 481 B-Drug
involved NCT03920436 482 490 O

- NCT03920436 493 494 O
cardiocebrovascular NCT03920436 496 515 B-Condition
diseases NCT03920436 516 524 I-Condition
or NCT03920436 525 527 B-Or
any NCT03920436 528 531 O
cancer NCT03920436 532 538 B-Condition
during NCT03920436 539 545 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920436 546 549 O
six NCT03920436 550 553 B-Eq-Comparison
months NCT03920436 554 560 I-Eq-Comparison
prior NCT03920436 561 566 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920436 567 569 O
study NCT03920436 570 575 B-Study

- NCT03920436 578 579 O
smoker NCT03920436 581 587 B-Condition

Inclusion NCT03924687 0 9 O
Criteria NCT03924687 10 18 O
: NCT03924687 19 20 O

- NCT03924687 24 25 O
being NCT03924687 27 32 O
18 NCT03924687 33 35 B-Eq-Comparison
years NCT03924687 36 41 I-Eq-Comparison
of NCT03924687 42 44 I-Eq-Comparison
age NCT03924687 45 48 I-Eq-Comparison
or NCT03924687 49 51 I-Eq-Comparison
older NCT03924687 52 57 I-Eq-Comparison

- NCT03924687 60 61 O
having NCT03924687 63 69 O
suffered NCT03924687 70 78 O
from NCT03924687 79 83 O
daily NCT03924687 84 89 B-Eq-Comparison
pain NCT03924687 90 94 B-Condition
for NCT03924687 95 98 O
more NCT03924687 99 103 B-Eq-Comparison
than NCT03924687 104 108 I-Eq-Comparison
three NCT03924687 109 114 I-Eq-Comparison
months NCT03924687 115 121 I-Eq-Comparison

- NCT03924687 124 125 O
having NCT03924687 127 133 O
reading NCT03924687 134 141 O
and NCT03924687 142 145 O
writing NCT03924687 146 153 O
abilities NCT03924687 154 163 O
in NCT03924687 164 166 O
French NCT03924687 167 173 O
equivalent NCT03924687 174 184 O
or NCT03924687 185 187 O
superior NCT03924687 188 196 O
to NCT03924687 197 199 O
grade NCT03924687 200 205 O
8 NCT03924687 206 207 O

- NCT03924687 211 212 O
having NCT03924687 214 220 O
access NCT03924687 221 227 O
to NCT03924687 228 230 O
Internet NCT03924687 231 239 O
at NCT03924687 240 242 O
home NCT03924687 243 247 O
and NCT03924687 248 251 O
having NCT03924687 252 258 O
a NCT03924687 259 260 O
valid NCT03924687 261 266 O
e NCT03924687 267 268 O
- NCT03924687 269 270 O
mail NCT03924687 271 275 O
address NCT03924687 276 283 O

- NCT03924687 286 287 O
not NCT03924687 289 292 B-Negation
having NCT03924687 293 299 O
previously NCT03924687 300 310 B-Eq-Comparison
completed NCT03924687 311 320 O
an NCT03924687 321 323 O
ACT NCT03924687 324 327 B-Procedure
- NCT03924687 328 329 I-Procedure
type NCT03924687 330 334 I-Procedure
psychotherapy NCT03924687 335 348 I-Procedure
, NCT03924687 349 350 O
not NCT03924687 351 354 B-Negation
having NCT03924687 355 361 O
practiced NCT03924687 362 371 B-Observation
mindfulness NCT03924687 372 383 I-Observation
meditation NCT03924687 384 394 I-Observation
regularly NCT03924687 395 404 O
and NCT03924687 405 408 B-And
not NCT03924687 409 412 B-Negation
having NCT03924687 413 419 O
read NCT03924687 420 424 O
a NCT03924687 425 426 O
bibliotherapy NCT03924687 427 440 B-Procedure
on NCT03924687 441 443 I-Procedure
ACT NCT03924687 444 447 I-Procedure
for NCT03924687 448 451 O
pain NCT03924687 452 456 B-Condition

- NCT03924687 459 460 O
having NCT03924687 462 468 O
stable NCT03924687 469 475 O
medication NCT03924687 476 486 B-Drug
for NCT03924687 487 490 O
at NCT03924687 491 493 B-Eq-Comparison
least NCT03924687 494 499 I-Eq-Comparison
one NCT03924687 500 503 I-Eq-Comparison
month NCT03924687 504 509 I-Eq-Comparison
, NCT03924687 510 511 O
if NCT03924687 512 514 O
applicable NCT03924687 515 525 O
. NCT03924687 526 527 O

Exclusion NCT03924687 529 538 O
Criteria NCT03924687 539 547 O
: NCT03924687 548 549 O

- NCT03924687 552 553 O

Inclusion NCT03921099 0 9 O
Criteria NCT03921099 10 18 O
: NCT03921099 19 20 O

- NCT03921099 24 25 O
Adults NCT03921099 27 33 O
who NCT03921099 34 37 B-And
are NCT03921099 38 41 O
critically NCT03921099 42 52 O
ill NCT03921099 53 56 B-Condition
and NCT03921099 57 60 B-And
with NCT03921099 61 65 O
MRSA NCT03921099 66 70 B-Condition
infection NCT03921099 71 80 I-Condition
suspection NCT03921099 81 91 B-Assertion___Assertion-Type-Value:possible
. NCT03921099 92 93 O

Exclusion NCT03921099 95 104 O
Criteria NCT03921099 105 113 O
: NCT03921099 114 115 O

1 NCT03921099 119 120 O
. NCT03921099 120 121 O
Pregnancy NCT03921099 123 132 B-Condition
or NCT03921099 133 135 B-Or
breast NCT03921099 136 142 B-Condition
feeding NCT03921099 143 150 I-Condition
. NCT03921099 151 152 O

2 NCT03921099 156 157 O
. NCT03921099 157 158 O
Known NCT03921099 160 165 O
allergy NCT03921099 166 173 B-Allergy
to NCT03921099 174 176 O
either NCT03921099 177 183 O
vancomycin NCT03921099 184 194 B-Drug
or NCT03921099 195 197 B-Or
ascorbic NCT03921099 198 206 B-Drug
acid NCT03921099 207 211 I-Drug
. NCT03921099 212 213 O

3 NCT03921099 217 218 O
. NCT03921099 218 219 O
Base NCT03921099 221 225 O
line NCT03921099 226 230 O
serum NCT03921099 231 236 B-Observation
creatinine NCT03921099 237 247 I-Observation
≥ NCT03921099 248 249 B-Eq-Comparison
2 NCT03921099 250 251 I-Eq-Comparison
mg NCT03921099 252 254 O
/ NCT03921099 255 256 O
dl NCT03921099 257 259 O
. NCT03921099 260 261 O

4 NCT03921099 265 266 O
. NCT03921099 266 267 O
Patients NCT03921099 269 277 O
receiving NCT03921099 278 287 O
other NCT03921099 288 293 O
nephrotoxic NCT03921099 294 305 B-Drug
drug NCT03921099 306 310 I-Drug
( NCT03921099 311 312 O
e. NCT03921099 313 315 O
g. NCT03921099 316 318 O
, NCT03921099 319 320 O
aminoglycosides NCT03921099 321 336 B-Drug
, NCT03921099 337 338 O
amphotericin NCT03921099 339 351 B-Drug
B NCT03921099 352 353 I-Drug
, NCT03921099 354 355 O
cisplatin NCT03921099 356 365 B-Drug
or NCT03921099 366 368 B-Or
calcinurine NCT03921099 369 380 B-Drug
inhibitors NCT03921099 381 391 I-Drug
) NCT03921099 392 393 O
. NCT03921099 395 396 O

5 NCT03921099 400 401 O
. NCT03921099 401 402 O
Anticepated NCT03921099 404 415 B-Assertion___Assertion-Type-Value:hypothetical
administration NCT03921099 416 430 O
of NCT03921099 431 433 O
contrast NCT03921099 434 442 B-Drug
medium NCT03921099 443 449 I-Drug
within NCT03921099 450 456 B-Eq-Comparison
7 NCT03921099 457 458 I-Eq-Comparison
days NCT03921099 459 463 I-Eq-Comparison
. NCT03921099 464 465 O

6 NCT03921099 469 470 O
. NCT03921099 470 471 O
Patients NCT03921099 473 481 O
suffering NCT03921099 482 491 O
from NCT03921099 492 496 O
some NCT03921099 497 501 O
underlying NCT03921099 502 512 O
diseases NCT03921099 513 521 B-Condition
( NCT03921099 522 523 O
e. NCT03921099 524 526 O
g. NCT03921099 527 529 O
, NCT03921099 530 531 O
cancer NCT03921099 532 538 B-Condition
, NCT03921099 539 540 O
HIV NCT03921099 541 544 B-Condition
infection NCT03921099 545 554 I-Condition
, NCT03921099 555 556 O
systemic NCT03921099 557 565 B-Condition
lupus NCT03921099 566 571 I-Condition
erythematoses NCT03921099 572 585 I-Condition
, NCT03921099 586 587 O
or NCT03921099 588 590 B-Or
urinary NCT03921099 591 598 B-Condition
tract NCT03921099 599 604 I-Condition
stones NCT03921099 605 611 I-Condition
) NCT03921099 612 613 O
. NCT03921099 615 616 O

7 NCT03921099 620 621 O
. NCT03921099 621 622 O
Unlikelyhood NCT03921099 624 636 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03921099 637 639 O
receiving NCT03921099 640 649 O
the NCT03921099 650 653 O
study NCT03921099 654 659 O
medications NCT03921099 660 671 B-Drug
for NCT03921099 672 675 O
at NCT03921099 676 678 B-Eq-Comparison
least NCT03921099 679 684 I-Eq-Comparison
72 NCT03921099 685 687 I-Eq-Comparison
hours NCT03921099 688 693 I-Eq-Comparison

Inclusion NCT03925610 0 9 O
Criteria NCT03925610 10 18 O
: NCT03925610 19 20 O

- NCT03925610 24 25 O
Body NCT03925610 27 31 B-Observation
mass NCT03925610 32 36 I-Observation
index NCT03925610 37 42 I-Observation
( NCT03925610 43 44 O
BMI NCT03925610 45 48 B-Observation
) NCT03925610 49 50 O
equal NCT03925610 51 56 B-Eq-Comparison
or NCT03925610 57 59 I-Eq-Comparison
greater NCT03925610 60 67 I-Eq-Comparison
than NCT03925610 68 72 I-Eq-Comparison
35 NCT03925610 73 75 I-Eq-Comparison
kg NCT03925610 76 78 I-Eq-Comparison
/ NCT03925610 79 80 I-Eq-Comparison
m2 NCT03925610 81 83 I-Eq-Comparison
. NCT03925610 83 84 O

- NCT03925610 88 89 O
American NCT03925610 91 99 B-Condition
Society NCT03925610 100 107 I-Condition
of NCT03925610 108 110 I-Condition
Anesthesiologists NCT03925610 111 128 I-Condition
( NCT03925610 129 130 O
ASA NCT03925610 131 134 B-Condition
) NCT03925610 135 136 O
physical NCT03925610 137 145 O
status NCT03925610 146 152 B-Eq-Comparison
I NCT03925610 153 154 I-Eq-Comparison
- NCT03925610 155 156 I-Eq-Comparison
III NCT03925610 157 160 I-Eq-Comparison
patients NCT03925610 161 169 O
. NCT03925610 170 171 O

- NCT03925610 175 176 O
Scheduled NCT03925610 178 187 B-Eq-Comparison
to NCT03925610 188 190 I-Eq-Comparison
undergo NCT03925610 191 198 I-Eq-Comparison
laparoscopic NCT03925610 199 211 B-Procedure
roux NCT03925610 212 216 I-Procedure
- NCT03925610 217 218 I-Procedure
en NCT03925610 219 221 I-Procedure
- NCT03925610 222 223 I-Procedure
Y NCT03925610 224 225 I-Procedure
gastric NCT03925610 226 233 I-Procedure
bypass NCT03925610 234 240 I-Procedure
or NCT03925610 241 243 B-Or
gastric NCT03925610 244 251 B-Procedure
sleeve NCT03925610 252 258 I-Procedure
placement NCT03925610 259 268 I-Procedure
surgery NCT03925610 269 276 I-Procedure
for NCT03925610 277 280 O
weight NCT03925610 281 287 B-Condition
loss NCT03925610 288 292 I-Condition
. NCT03925610 293 294 O

Exclusion NCT03925610 296 305 O
Criteria NCT03925610 306 314 O
: NCT03925610 315 316 O

- NCT03925610 320 321 O
Chronic NCT03925610 323 330 B-Condition
obstructive NCT03925610 331 342 I-Condition
pulmonary NCT03925610 343 352 I-Condition
disorder NCT03925610 353 361 I-Condition
( NCT03925610 362 363 O
COPD NCT03925610 364 368 B-Condition
) NCT03925610 369 370 O
. NCT03925610 372 373 O

- NCT03925610 377 378 O
Treatment NCT03925610 380 389 B-Procedure
with NCT03925610 390 394 O
continuous NCT03925610 395 405 B-Procedure
positive NCT03925610 406 414 I-Procedure
airway NCT03925610 415 421 I-Procedure
pressure NCT03925610 422 430 I-Procedure
( NCT03925610 431 432 O
CPAP NCT03925610 433 437 B-Procedure
) NCT03925610 438 439 O
in NCT03925610 440 442 O
the NCT03925610 443 446 O
past NCT03925610 447 451 B-Eq-Comparison
three NCT03925610 452 457 I-Eq-Comparison
months NCT03925610 458 464 I-Eq-Comparison
. NCT03925610 465 466 O

- NCT03925610 470 471 O
Severe NCT03925610 473 479 O
neurological NCT03925610 480 492 B-Modifier
, NCT03925610 493 494 O
cardiopulmonary NCT03925610 495 510 B-Modifier
, NCT03925610 511 512 O
psychiatric NCT03925610 513 524 B-Modifier
, NCT03925610 525 526 O
or NCT03925610 527 529 B-Or
untreated NCT03925610 530 539 B-Modifier
thyroid NCT03925610 540 547 B-Modifier
disorder NCT03925610 548 556 B-Condition
. NCT03925610 557 558 O

- NCT03925610 562 563 O
Chronic NCT03925610 565 572 B-Condition
pain NCT03925610 573 577 I-Condition
condition NCT03925610 578 587 I-Condition
that NCT03925610 588 592 O
was NCT03925610 593 596 O
being NCT03925610 597 602 B-Eq-Comparison
treated NCT03925610 603 610 O
with NCT03925610 611 615 O
opioids NCT03925610 616 623 B-Drug
. NCT03925610 624 625 O

- NCT03925610 629 630 O
Patients NCT03925610 632 640 O
with NCT03925610 641 645 O
a NCT03925610 646 647 O
hematocrit NCT03925610 648 658 B-Observation
lower NCT03925610 659 664 B-Eq-Comparison
than NCT03925610 665 669 I-Eq-Comparison
35 NCT03925610 670 672 I-Eq-Comparison
% NCT03925610 673 674 I-Eq-Comparison
. NCT03925610 675 676 O

Inclusion NCT03921476 0 9 O
Criteria NCT03921476 10 18 O
: NCT03921476 19 20 O

Female NCT03921476 22 28 O
subjects NCT03921476 29 37 O
between NCT03921476 38 45 B-Eq-Comparison
18 NCT03921476 46 48 I-Eq-Comparison
and NCT03921476 49 52 I-Eq-Comparison
65 NCT03921476 53 55 I-Eq-Comparison
years NCT03921476 56 61 I-Eq-Comparison
of NCT03921476 62 64 O
age NCT03921476 65 68 B-Age
currently NCT03921476 69 78 B-Eq-Comparison
taking NCT03921476 79 85 B-Eq-Comparison
spironolactone NCT03921476 86 100 B-Drug
for NCT03921476 101 104 O
a NCT03921476 105 106 O
diagnosis NCT03921476 107 116 O
of NCT03921476 117 119 O
acne NCT03921476 120 124 B-Condition
vulgaris NCT03921476 125 133 I-Condition

OR NCT03921476 134 136 B-Or

Female NCT03921476 137 143 O
subjects NCT03921476 144 152 O
between NCT03921476 153 160 B-Eq-Comparison
18 NCT03921476 161 163 I-Eq-Comparison
and NCT03921476 164 167 I-Eq-Comparison
65 NCT03921476 168 170 I-Eq-Comparison
years NCT03921476 171 176 I-Eq-Comparison
of NCT03921476 177 179 O
age NCT03921476 180 183 B-Age
currently NCT03921476 184 193 B-Eq-Comparison
taking NCT03921476 194 200 B-Eq-Comparison
oral NCT03921476 201 205 B-Drug
antibiotics NCT03921476 206 217 I-Drug
for NCT03921476 218 221 O
a NCT03921476 222 223 O
diagnosis NCT03921476 224 233 O
of NCT03921476 234 236 O
acne NCT03921476 237 241 B-Condition
vulgaris NCT03921476 242 250 I-Condition

AND NCT03921476 251 254 B-And
Subjects NCT03921476 255 263 O
able NCT03921476 264 268 O
to NCT03921476 269 271 O
complete NCT03921476 272 280 O
an NCT03921476 281 283 O
online NCT03921476 284 290 O
survey NCT03921476 291 297 O
in NCT03921476 298 300 O
English NCT03921476 301 308 O

Exclusion NCT03921476 309 318 O
Criteria NCT03921476 319 327 O
: NCT03921476 328 329 O

Subjects NCT03921476 331 339 O
less NCT03921476 340 344 B-Eq-Comparison
than NCT03921476 345 349 I-Eq-Comparison
18 NCT03921476 350 352 I-Eq-Comparison
years NCT03921476 353 358 I-Eq-Comparison
of NCT03921476 359 361 O
age NCT03921476 362 365 B-Age
or NCT03921476 366 368 B-Or
older NCT03921476 369 374 B-Eq-Comparison
than NCT03921476 375 379 I-Eq-Comparison
65 NCT03921476 380 382 I-Eq-Comparison
years NCT03921476 383 388 I-Eq-Comparison
of NCT03921476 389 391 O
age NCT03921476 392 395 B-Age
Subjects NCT03921476 396 404 O
that NCT03921476 405 409 O
have NCT03921476 410 414 O
ever NCT03921476 415 419 O
been NCT03921476 420 424 O
diagnosed NCT03921476 425 434 O
with NCT03921476 435 439 O
any NCT03921476 440 443 O
mood NCT03921476 444 448 B-Condition
disorder NCT03921476 449 457 I-Condition
by NCT03921476 458 460 O
a NCT03921476 461 462 O
clinician NCT03921476 463 472 O
prior NCT03921476 473 478 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921476 479 481 O
starting NCT03921476 482 490 O
spironolactone NCT03921476 491 505 B-Drug
( NCT03921476 506 507 O
history NCT03921476 508 515 B-Eq-Comparison
of NCT03921476 516 518 O
mood NCT03921476 519 523 B-Condition
disorder NCT03921476 524 532 I-Condition
or NCT03921476 533 535 B-Or
current NCT03921476 536 543 B-Eq-Comparison
mood NCT03921476 544 548 B-Condition
disorder NCT03921476 549 557 I-Condition
) NCT03921476 558 559 O
Subjects NCT03921476 560 568 O
taking NCT03921476 569 575 B-Eq-Comparison
hormonal NCT03921476 576 584 B-Drug
contraception NCT03921476 585 598 I-Drug
( NCT03921476 599 600 O
including NCT03921476 601 610 O
but NCT03921476 611 614 O
not NCT03921476 615 618 O
limited NCT03921476 619 626 O
to NCT03921476 627 629 O
oral NCT03921476 630 634 B-Drug
contraceptive NCT03921476 635 648 I-Drug
pills NCT03921476 649 654 I-Drug
) NCT03921476 655 656 O
for NCT03921476 657 660 O
a NCT03921476 661 662 O
duration NCT03921476 663 671 O
of NCT03921476 672 674 O
less NCT03921476 675 679 B-Eq-Comparison
than NCT03921476 680 684 I-Eq-Comparison
6 NCT03921476 685 686 I-Eq-Comparison
months NCT03921476 687 693 I-Eq-Comparison
Subjects NCT03921476 694 702 O
that NCT03921476 703 707 O
have NCT03921476 708 712 O
ever NCT03921476 713 717 O
been NCT03921476 718 722 O
diagnosed NCT03921476 723 732 O
with NCT03921476 733 737 O
any NCT03921476 738 741 O
type NCT03921476 742 746 O
of NCT03921476 747 749 O
sexual NCT03921476 750 756 B-Condition
dysfunction NCT03921476 757 768 I-Condition
prior NCT03921476 769 774 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921476 775 777 O
starting NCT03921476 778 786 O
spironolactone NCT03921476 787 801 B-Drug
Subjects NCT03921476 802 810 O
not NCT03921476 811 814 B-Negation
able NCT03921476 815 819 O
to NCT03921476 820 822 O
complete NCT03921476 823 831 O
an NCT03921476 832 834 O
online NCT03921476 835 841 O
survey NCT03921476 842 848 O
in NCT03921476 849 851 O
English NCT03921476 852 859 O
Subjects NCT03921476 860 868 O
taking NCT03921476 869 875 B-Eq-Comparison
oral NCT03921476 876 880 B-Drug
isotretinoin NCT03921476 881 893 I-Drug
for NCT03921476 894 897 O
a NCT03921476 898 899 O
diagnosis NCT03921476 900 909 O
of NCT03921476 910 912 O
acne NCT03921476 913 917 B-Condition
Subjects NCT03921476 918 926 O
that NCT03921476 927 931 O
are NCT03921476 932 935 O
currently NCT03921476 936 945 B-Eq-Comparison
pregnant NCT03921476 946 954 B-Condition


Inclusion NCT03929770 0 9 O
Criteria NCT03929770 10 18 O
: NCT03929770 19 20 O

- NCT03929770 24 25 O
The NCT03929770 27 30 O
patients NCT03929770 31 39 O
who NCT03929770 40 43 O
need NCT03929770 44 48 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929770 49 51 I-Assertion___Assertion-Type-Value:hypothetical
Swan NCT03929770 52 56 B-Procedure
- NCT03929770 57 58 I-Procedure
Ganz NCT03929770 59 63 I-Procedure
catheterization NCT03929770 64 79 I-Procedure
for NCT03929770 80 83 O
heart NCT03929770 84 89 B-Procedure
surgeries NCT03929770 90 99 I-Procedure

Exclusion NCT03929770 100 109 O
Criteria NCT03929770 110 118 O
: NCT03929770 119 120 O

- NCT03929770 124 125 O
Who NCT03929770 127 130 O
does NCT03929770 131 135 O
n't NCT03929770 135 138 O
agree NCT03929770 139 144 O
to NCT03929770 145 147 O
enroll NCT03929770 148 154 O

- NCT03929770 157 158 O
Who NCT03929770 160 163 O
has NCT03929770 164 167 O
thrombus NCT03929770 168 176 B-Condition
in NCT03929770 177 179 I-Condition
the NCT03929770 180 183 I-Condition
heart NCT03929770 184 189 B-Modifier
or NCT03929770 190 192 B-Or
the NCT03929770 193 196 O
vena NCT03929770 197 201 B-Modifier
cavas NCT03929770 202 207 I-Modifier
. NCT03929770 207 208 O

Inclusion NCT03926325 0 9 O
Criteria NCT03926325 10 18 O
: NCT03926325 19 20 O

1 NCT03926325 24 25 O
. NCT03926325 25 26 O
OHCA NCT03926325 28 32 O
: NCT03926325 33 34 O
Every NCT03926325 35 40 O
patient NCT03926325 41 48 O
who NCT03926325 49 52 O
suffered NCT03926325 53 61 O
a NCT03926325 62 63 O
cardiac NCT03926325 64 71 B-Condition
arrest NCT03926325 72 78 I-Condition
that NCT03926325 79 83 O
occurred NCT03926325 84 92 O
in NCT03926325 93 95 O
any NCT03926325 96 99 O
location NCT03926325 100 108 O
other NCT03926325 109 114 B-Exception
than NCT03926325 115 119 I-Exception
a NCT03926325 120 121 O
hospital NCT03926325 122 130 O
, NCT03926325 131 132 O
and NCT03926325 133 136 B-And
was NCT03926325 137 140 O
attended NCT03926325 141 149 B-Encounter
and NCT03926325 150 153 O
/ NCT03926325 154 155 O
or NCT03926325 156 158 O
treated NCT03926325 159 166 O
by NCT03926325 167 169 O
an NCT03926325 170 172 O
EMS NCT03926325 173 176 B-Provider
. NCT03926325 177 178 O

2 NCT03926325 182 183 O
. NCT03926325 183 184 O
IHCA NCT03926325 186 190 O
: NCT03926325 191 192 O
Every NCT03926325 193 198 O
patient NCT03926325 199 206 O
who NCT03926325 207 210 O
suffered NCT03926325 211 219 O
a NCT03926325 220 221 O
cardiac NCT03926325 222 229 B-Condition
arrest NCT03926325 230 236 I-Condition
in NCT03926325 237 239 O
hospital NCT03926325 240 248 O
. NCT03926325 249 250 O

3 NCT03926325 254 255 O
. NCT03926325 255 256 O
the NCT03926325 258 261 O
representative NCT03926325 262 276 O
population NCT03926325 277 287 O
- NCT03926325 288 289 O
based NCT03926325 290 295 O
survey NCT03926325 296 302 O
: NCT03926325 303 304 O
Every NCT03926325 305 310 O
patient NCT03926325 311 318 O
who NCT03926325 319 322 O
suffered NCT03926325 323 331 O
a NCT03926325 332 333 O
cardiac NCT03926325 334 341 B-Condition
arrest NCT03926325 342 348 I-Condition
in NCT03926325 349 351 O
the NCT03926325 352 355 O
selected NCT03926325 356 364 O
cities NCT03926325 365 371 O
or NCT03926325 372 374 O
suburbs NCT03926325 375 382 O
. NCT03926325 383 384 O

Exclusion NCT03926325 386 395 O
Criteria NCT03926325 396 404 O
: NCT03926325 405 406 O

1 NCT03926325 410 411 O
. NCT03926325 411 412 O
OHCA NCT03926325 414 418 O
: NCT03926325 419 420 O
1 NCT03926325 421 422 O
) NCT03926325 423 424 O
The NCT03926325 425 428 O
out NCT03926325 429 432 B-Negation
- NCT03926325 433 434 I-Negation
of NCT03926325 435 437 I-Negation
- NCT03926325 438 439 O
hospital NCT03926325 440 448 O
cardiac NCT03926325 449 456 B-Condition
arrest NCT03926325 457 463 I-Condition
patients NCT03926325 464 472 O
who NCT03926325 473 476 O
were NCT03926325 477 481 O
taken NCT03926325 482 487 O
to NCT03926325 488 490 O
the NCT03926325 491 494 O
hospital NCT03926325 495 503 O
by NCT03926325 504 506 O
their NCT03926325 507 512 O
family NCT03926325 513 519 O
members NCT03926325 520 527 O
; NCT03926325 527 528 O
2 NCT03926325 529 530 O
) NCT03926325 531 532 O
Bystanders NCT03926325 533 543 O
suspected NCT03926325 544 553 B-Assertion___Assertion-Type-Value:possible
cardiac NCT03926325 554 561 B-Condition
arrest NCT03926325 562 568 I-Condition
, NCT03926325 569 570 O
but NCT03926325 571 574 O
the NCT03926325 575 578 O
ROSC NCT03926325 579 583 O
was NCT03926325 584 587 O
achieved NCT03926325 588 596 O
without NCT03926325 597 604 B-Negation
defibrillation NCT03926325 605 619 B-Procedure
or NCT03926325 620 622 B-Or
resuscitation NCT03926325 623 636 B-Procedure
by NCT03926325 637 639 O
EMS NCT03926325 640 643 B-Provider
. NCT03926325 644 645 O

2 NCT03926325 649 650 O
. NCT03926325 650 651 O
IHCA NCT03926325 653 657 O
: NCT03926325 658 659 O
The NCT03926325 660 663 O
patient NCT03926325 664 671 O
who NCT03926325 672 675 O
suffered NCT03926325 676 684 O
a NCT03926325 685 686 O
cardiac NCT03926325 687 694 B-Condition
arrest NCT03926325 695 701 I-Condition
that NCT03926325 702 706 O
occurred NCT03926325 707 715 O
out NCT03926325 716 719 B-Negation
- NCT03926325 720 721 I-Negation
of NCT03926325 722 724 I-Negation
- NCT03926325 725 726 O
hospital NCT03926325 727 735 O
and NCT03926325 736 739 O
then NCT03926325 740 744 B-Temporal-Connection___Temporal-Connection-Type-Value:before
transferred NCT03926325 745 756 B-Encounter
to NCT03926325 757 759 O
the NCT03926325 760 763 O
hospital NCT03926325 764 772 O
. NCT03926325 772 773 O

Inclusion NCT03924297 0 9 O
Criteria NCT03924297 10 18 O
: NCT03924297 19 20 O

- NCT03924297 24 25 O
Patients NCT03924297 27 35 O
who NCT03924297 36 39 O
have NCT03924297 40 44 O
seen NCT03924297 45 49 B-Encounter
the NCT03924297 50 53 O
study NCT03924297 54 59 O
PI NCT03924297 60 62 O
( NCT03924297 63 64 O
Remy NCT03924297 65 69 B-Provider
Coeytaux NCT03924297 70 78 I-Provider
, NCT03924297 79 80 I-Provider
MD NCT03924297 81 83 I-Provider
, NCT03924297 84 85 I-Provider
PhD NCT03924297 86 89 I-Provider
) NCT03924297 90 91 O
for NCT03924297 92 95 O
an NCT03924297 96 98 O
integrative NCT03924297 99 110 O
medicine NCT03924297 111 119 O
consultation NCT03924297 120 132 O
between NCT03924297 133 140 B-Eq-Comparison
September NCT03924297 141 150 I-Eq-Comparison
1 NCT03924297 151 152 I-Eq-Comparison
, NCT03924297 153 154 I-Eq-Comparison
2018 NCT03924297 155 159 I-Eq-Comparison
and NCT03924297 160 163 I-Eq-Comparison
April NCT03924297 164 169 I-Eq-Comparison
30 NCT03924297 170 172 I-Eq-Comparison
, NCT03924297 173 174 I-Eq-Comparison
2019 NCT03924297 175 179 I-Eq-Comparison
and NCT03924297 180 183 B-And
who NCT03924297 184 187 O
report NCT03924297 188 194 O
having NCT03924297 195 201 O
been NCT03924297 202 206 O
diagnoses NCT03924297 207 216 O
with NCT03924297 217 221 O
PTSD NCT03924297 222 226 B-Condition
or NCT03924297 227 229 B-Or
who NCT03924297 230 233 O
believe NCT03924297 234 241 O
they NCT03924297 242 246 O
may NCT03924297 247 250 B-Assertion___Assertion-Type-Value:possible
have NCT03924297 251 255 O
PTSD NCT03924297 256 260 B-Condition
or NCT03924297 261 263 B-Or
PTSD NCT03924297 264 268 B-Condition
- NCT03924297 269 270 O
related NCT03924297 271 278 O
symptoms NCT03924297 279 287 B-Assertion___Assertion-Type-Value:possible
are NCT03924297 288 291 O
eligible NCT03924297 292 300 O
to NCT03924297 301 303 O
participate NCT03924297 304 315 O
. NCT03924297 316 317 O

Exclusion NCT03924297 319 328 O
Criteria NCT03924297 329 337 O
: NCT03924297 338 339 O

- NCT03924297 343 344 O
No NCT03924297 346 348 O
exclusion NCT03924297 349 358 O
criteria NCT03924297 359 367 O

Inclusion NCT03926481 0 9 O
Criteria NCT03926481 10 18 O
: NCT03926481 19 20 O

- NCT03926481 24 25 O
English NCT03926481 27 34 O
Speaking NCT03926481 35 43 O

- NCT03926481 46 47 O
Age NCT03926481 49 52 B-Age
≥ NCT03926481 53 54 B-Eq-Comparison
65 NCT03926481 55 57 I-Eq-Comparison
years NCT03926481 58 63 I-Eq-Comparison

- NCT03926481 66 67 O
Body NCT03926481 69 73 O
Composition NCT03926481 74 85 O
Body NCT03926481 86 90 B-Observation
Fat NCT03926481 91 94 I-Observation
> NCT03926481 95 96 B-Eq-Comparison
25 NCT03926481 97 99 I-Eq-Comparison
% NCT03926481 100 101 I-Eq-Comparison
for NCT03926481 102 105 O
Men NCT03926481 106 109 O

- NCT03926481 112 113 O
Body NCT03926481 115 119 O
Composition NCT03926481 120 131 O
Body NCT03926481 132 136 B-Observation
Fat NCT03926481 137 140 I-Observation
> NCT03926481 141 142 B-Eq-Comparison
30 NCT03926481 143 145 I-Eq-Comparison
% NCT03926481 146 147 I-Eq-Comparison
for NCT03926481 148 151 O
Women NCT03926481 152 157 O

- NCT03926481 160 161 O
Participating NCT03926481 163 176 O
in NCT03926481 177 179 O
the NCT03926481 180 183 O
Dartmouth NCT03926481 184 193 O
Hitchcock NCT03926481 194 203 O
Weight NCT03926481 204 210 O
and NCT03926481 211 214 O
Wellness NCT03926481 215 223 O
Center NCT03926481 224 230 O
( NCT03926481 231 232 O
WWC NCT03926481 233 236 O
) NCT03926481 237 238 O
Healthy NCT03926481 239 246 O
Lifestyle NCT03926481 247 256 O
Program NCT03926481 257 264 O
( NCT03926481 265 266 O
HLP NCT03926481 267 270 O
) NCT03926481 271 272 O

- NCT03926481 276 277 O
Willing NCT03926481 279 286 O
and NCT03926481 287 290 O
able NCT03926481 291 295 O
to NCT03926481 296 298 O
give NCT03926481 299 303 O
informed NCT03926481 304 312 O
consent NCT03926481 313 320 O

Exclusion NCT03926481 321 330 O
Criteria NCT03926481 331 339 O
: NCT03926481 340 341 O

- NCT03926481 345 346 O
Unable NCT03926481 348 354 O
to NCT03926481 355 357 O
perform NCT03926481 358 365 O
measures NCT03926481 366 374 O

- NCT03926481 377 378 O
Individuals NCT03926481 380 391 O
unwilling NCT03926481 392 401 O
/ NCT03926481 402 403 O
unable NCT03926481 404 410 O
to NCT03926481 411 413 O
provide NCT03926481 414 421 O
consent NCT03926481 422 429 O

- NCT03926481 432 433 O
Severe NCT03926481 435 441 O
mental NCT03926481 442 448 B-Modifier
or NCT03926481 449 451 B-Or
life NCT03926481 452 456 B-Modifier
- NCT03926481 457 458 I-Modifier
threatening NCT03926481 459 470 I-Modifier
illness NCT03926481 471 478 B-Condition

- NCT03926481 481 482 O
History NCT03926481 484 491 B-Eq-Comparison
of NCT03926481 492 494 O
bariatric NCT03926481 495 504 B-Procedure
surgery NCT03926481 505 512 I-Procedure

Inclusion NCT03920033 0 9 O
Criteria NCT03920033 10 18 O
: NCT03920033 19 20 O

- NCT03920033 24 25 O
Pathologically NCT03920033 27 41 B-Procedure
confirmed NCT03920033 42 51 O
intermediate NCT03920033 52 64 O
- NCT03920033 65 66 O
or NCT03920033 67 69 B-Or
high NCT03920033 70 74 O
- NCT03920033 75 76 O
risk NCT03920033 77 81 B-Risk
prostate NCT03920033 82 90 B-Condition
cancer NCT03920033 91 97 I-Condition

- NCT03920033 100 101 O
Biochemical NCT03920033 103 114 O
recurrence NCT03920033 115 125 B-Coreference
after NCT03920033 126 131 B-Temporal-Connection___Temporal-Connection-Type-Value:after
radical NCT03920033 132 139 B-Procedure
prostatectomy NCT03920033 140 153 I-Procedure
( NCT03920033 154 155 O
Definition NCT03920033 156 166 O
: NCT03920033 167 168 O
Serial NCT03920033 169 175 O
elevation NCT03920033 176 185 O
of NCT03920033 186 188 O
PSA NCT03920033 189 192 B-Observation
over NCT03920033 193 197 B-Eq-Comparison
0.2 NCT03920033 198 201 I-Eq-Comparison
ng NCT03920033 202 204 I-Eq-Comparison
/ NCT03920033 205 206 I-Eq-Comparison
mL NCT03920033 207 209 I-Eq-Comparison
and NCT03920033 210 213 B-And
< NCT03920033 214 215 B-Eq-Comparison
= NCT03920033 217 218 I-Eq-Comparison
1.0 NCT03920033 219 222 I-Eq-Comparison
ng NCT03920033 223 225 O
/ NCT03920033 226 227 O
mL NCT03920033 228 230 O
) NCT03920033 231 232 O

- NCT03920033 236 237 O
ECOG NCT03920033 239 243 B-Observation
performance NCT03920033 244 255 I-Observation
status NCT03920033 256 262 I-Observation
0 NCT03920033 263 264 B-Eq-Comparison
- NCT03920033 265 266 I-Eq-Comparison
1 NCT03920033 267 268 O

- NCT03920033 272 273 O
Appropriate NCT03920033 275 286 O
values NCT03920033 287 293 O
of NCT03920033 294 296 O
blood NCT03920033 297 302 O
tests NCT03920033 303 308 O
within NCT03920033 309 315 B-Eq-Comparison
6 NCT03920033 316 317 I-Eq-Comparison
months NCT03920033 318 324 I-Eq-Comparison
after NCT03920033 325 330 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 331 341 B-Study
Absolute NCT03920033 342 350 B-Observation
neutrophil NCT03920033 351 361 I-Observation
count NCT03920033 362 367 I-Observation
( NCT03920033 368 369 O
ANC NCT03920033 370 373 B-Observation
) NCT03920033 374 375 O
≥ NCT03920033 376 377 B-Eq-Comparison
1500 NCT03920033 378 382 I-Eq-Comparison
cells NCT03920033 383 388 O
/ NCT03920033 389 390 O
mm3 NCT03920033 391 394 O
Platelets NCT03920033 395 404 B-Observation
≥ NCT03920033 405 406 B-Eq-Comparison
50 NCT03920033 407 409 I-Eq-Comparison
, NCT03920033 410 411 O
000 NCT03920033 412 415 O
cells NCT03920033 416 421 O
/ NCT03920033 422 423 O
mm3 NCT03920033 424 427 O
Hemoglobin NCT03920033 428 438 B-Observation
≥ NCT03920033 439 440 B-Eq-Comparison
8.0 NCT03920033 441 444 I-Eq-Comparison
g NCT03920033 445 446 I-Eq-Comparison
/ NCT03920033 447 448 I-Eq-Comparison
dl NCT03920033 449 451 I-Eq-Comparison

- NCT03920033 454 455 O
Appropriate NCT03920033 457 468 O
values NCT03920033 469 475 O
of NCT03920033 476 478 O
kidney NCT03920033 479 485 B-Observation
function NCT03920033 486 494 I-Observation
within NCT03920033 495 501 B-Eq-Comparison
6 NCT03920033 502 503 I-Eq-Comparison
months NCT03920033 504 510 I-Eq-Comparison
after NCT03920033 511 516 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 517 527 B-Study
Creatinine NCT03920033 528 538 B-Observation
< NCT03920033 539 540 B-Eq-Comparison
2.0 NCT03920033 541 544 I-Eq-Comparison
ng NCT03920033 545 547 I-Eq-Comparison
/ NCT03920033 548 549 I-Eq-Comparison
dL NCT03920033 550 552 I-Eq-Comparison

- NCT03920033 555 556 O
Appropriate NCT03920033 558 569 O
values NCT03920033 570 576 O
of NCT03920033 577 579 O
liver NCT03920033 580 585 B-Observation
function NCT03920033 586 594 I-Observation
within NCT03920033 595 601 B-Eq-Comparison
6 NCT03920033 602 603 I-Eq-Comparison
months NCT03920033 604 610 I-Eq-Comparison
after NCT03920033 611 616 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrollment NCT03920033 617 627 B-Study
total NCT03920033 628 633 B-Observation
bilirubin NCT03920033 634 643 I-Observation
< NCT03920033 644 645 B-Eq-Comparison
1.5 NCT03920033 646 649 I-Eq-Comparison
X NCT03920033 650 651 I-Eq-Comparison
maximum NCT03920033 652 659 I-Eq-Comparison
normal NCT03920033 660 666 I-Eq-Comparison
value NCT03920033 667 672 I-Eq-Comparison
alanine NCT03920033 673 680 B-Observation
aminotransferase NCT03920033 681 697 I-Observation
or NCT03920033 698 700 B-Or
aspartate NCT03920033 701 710 B-Observation
aminotransferase NCT03920033 711 727 I-Observation
< NCT03920033 728 729 B-Eq-Comparison
2.5 NCT03920033 730 733 I-Eq-Comparison
X NCT03920033 734 735 I-Eq-Comparison
maximum NCT03920033 736 743 I-Eq-Comparison
normal NCT03920033 744 750 I-Eq-Comparison
value NCT03920033 751 756 I-Eq-Comparison

Exclusion NCT03920033 757 766 O
Criteria NCT03920033 767 775 O
: NCT03920033 776 777 O

- NCT03920033 781 782 O
Clinically NCT03920033 784 794 O
gross NCT03920033 795 800 B-Condition
recurrent NCT03920033 801 810 I-Condition
tumor NCT03920033 811 816 I-Condition

- NCT03920033 819 820 O
Presence NCT03920033 822 830 B-Eq-Comparison
of NCT03920033 831 833 O
distant NCT03920033 834 841 B-Modifier
metastasis NCT03920033 842 852 B-Condition

- NCT03920033 855 856 O
Presence NCT03920033 858 866 B-Eq-Comparison
of NCT03920033 867 869 O
pelvic NCT03920033 870 876 B-Modifier
LN NCT03920033 877 879 I-Modifier
metastasis NCT03920033 880 890 B-Condition

- NCT03920033 893 894 O
History NCT03920033 896 903 B-Eq-Comparison
of NCT03920033 904 906 O
pelvic NCT03920033 907 913 B-Modifier
irradiation NCT03920033 914 925 B-Procedure

- NCT03920033 928 929 O
History NCT03920033 931 938 B-Eq-Comparison
of NCT03920033 939 941 O
cryotherapy NCT03920033 942 953 B-Procedure
or NCT03920033 954 956 B-Or
brachytherapy NCT03920033 957 970 B-Procedure
for NCT03920033 971 974 O
prostate NCT03920033 975 983 B-Modifier
cancer NCT03920033 984 990 B-Condition

- NCT03920033 993 994 O
Double NCT03920033 996 1002 B-Eq-Comparison
primary NCT03920033 1003 1010 B-Modifier
cancer NCT03920033 1011 1017 B-Condition
other NCT03920033 1018 1023 B-Exception
than NCT03920033 1024 1028 I-Exception
skin NCT03920033 1029 1033 B-Modifier
/ NCT03920033 1034 1035 B-Or
thyroid NCT03920033 1036 1043 B-Modifier
cancer NCT03920033 1044 1050 B-Condition

- NCT03920033 1053 1054 O
Combined NCT03920033 1056 1064 O
serious NCT03920033 1065 1072 O
morbidity NCT03920033 1073 1082 B-Condition


Inclusion NCT03921463 0 9 O
Criteria NCT03921463 10 18 O
: NCT03921463 19 20 O

- NCT03921463 24 25 O
1 NCT03921463 27 28 O
) NCT03921463 29 30 O
Age NCT03921463 31 34 B-Age
: NCT03921463 35 36 O
20 NCT03921463 37 39 B-Eq-Comparison
~ NCT03921463 40 41 I-Eq-Comparison
35 NCT03921463 42 44 I-Eq-Comparison
years NCT03921463 45 50 I-Eq-Comparison
old NCT03921463 51 54 O
; NCT03921463 54 55 O
2 NCT03921463 56 57 O
) NCT03921463 58 59 O
first NCT03921463 60 65 B-Eq-Comparison
parturients NCT03921463 66 77 B-Condition
registered NCT03921463 78 88 O
in NCT03921463 89 91 O
the NCT03921463 92 95 O
obstetrics NCT03921463 96 106 O
department NCT03921463 107 117 O
of NCT03921463 118 120 O
our NCT03921463 121 124 O
hospital NCT03921463 125 133 O
; NCT03921463 133 134 O
3 NCT03921463 135 136 O
) NCT03921463 137 138 O
no NCT03921463 139 141 B-Negation
medical NCT03921463 142 149 B-Condition
complications NCT03921463 150 163 I-Condition
before NCT03921463 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:before
pregnancy NCT03921463 171 180 B-Condition
, NCT03921463 181 182 O
no NCT03921463 183 185 B-Negation
UI NCT03921463 186 188 B-Condition
and NCT03921463 189 192 B-Or
POP NCT03921463 193 196 B-Condition
( NCT03921463 197 198 O
according NCT03921463 199 208 O
to NCT03921463 209 211 O
the NCT03921463 212 215 O
standard NCT03921463 216 224 B-Observation
of NCT03921463 225 227 I-Observation
POP NCT03921463 228 231 I-Observation
- NCT03921463 232 233 I-Observation
Q NCT03921463 234 235 I-Observation
stage NCT03921463 236 241 I-Observation
) NCT03921463 242 243 O
; NCT03921463 244 245 O
4 NCT03921463 246 247 O
) NCT03921463 248 249 O
no NCT03921463 250 252 B-Negation
obstetric NCT03921463 253 262 B-Condition
complications NCT03921463 263 276 I-Condition
; NCT03921463 276 277 O
5 NCT03921463 278 279 O
) NCT03921463 280 281 O
the NCT03921463 282 285 O
patients NCT03921463 286 294 O
agreed NCT03921463 295 301 O
to NCT03921463 302 304 O
conduct NCT03921463 305 312 O
the NCT03921463 313 316 O
study NCT03921463 317 322 O
and NCT03921463 323 326 O
signed NCT03921463 327 333 O
the NCT03921463 334 337 O
informed NCT03921463 338 346 O
consent NCT03921463 347 354 O
. NCT03921463 355 356 O

Exclusion NCT03921463 358 367 O
Criteria NCT03921463 368 376 O
: NCT03921463 377 378 O

- NCT03921463 382 383 O
1 NCT03921463 385 386 O
) NCT03921463 387 388 O
patients NCT03921463 389 397 O
with NCT03921463 398 402 O
uncontrolled NCT03921463 403 415 B-Modifier
epilepsy NCT03921463 416 424 B-Condition
, NCT03921463 425 426 O
central NCT03921463 427 434 B-Condition
nervous NCT03921463 435 442 I-Condition
system NCT03921463 443 449 I-Condition
diseases NCT03921463 450 458 I-Condition
or NCT03921463 459 461 B-Or
mental NCT03921463 462 468 B-Condition
disorders NCT03921463 469 478 I-Condition
, NCT03921463 479 480 O
whose NCT03921463 481 486 O
clinical NCT03921463 487 495 O
severity NCT03921463 496 504 O
shall NCT03921463 505 510 O
be NCT03921463 511 513 O
determined NCT03921463 514 524 O
by NCT03921463 525 527 O
the NCT03921463 528 531 O
researcher NCT03921463 532 542 O
to NCT03921463 543 545 O
affect NCT03921463 546 552 O
clinical NCT03921463 553 561 O
research NCT03921463 562 570 O
compliance NCT03921463 571 581 O
; NCT03921463 581 582 O
2 NCT03921463 583 584 O
) NCT03921463 585 586 O
follow NCT03921463 587 593 B-Encounter
up NCT03921463 594 596 I-Encounter
the NCT03921463 597 600 O
patients NCT03921463 601 609 O
with NCT03921463 610 614 B-Assertion___Assertion-Type-Value:hypothetical
difficulty NCT03921463 615 625 B-Negation
. NCT03921463 625 626 O

Inclusion NCT03923738 0 9 O
Criteria NCT03923738 10 18 O
: NCT03923738 19 20 O

- NCT03923738 24 25 O
Diagnosis NCT03923738 27 36 O
of NCT03923738 37 39 O
GCA NCT03923738 40 43 B-Condition
as NCT03923738 44 46 O
classified NCT03923738 47 57 O
according NCT03923738 58 67 O
to NCT03923738 68 70 O
protocol NCT03923738 71 79 O
- NCT03923738 80 81 O
specified NCT03923738 82 91 O
criteria NCT03923738 92 100 O
; NCT03923738 100 101 O

- NCT03923738 104 105 O
Participants NCT03923738 107 119 O
entering NCT03923738 120 128 B-Assertion___Assertion-Type-Value:hypothetical
Period NCT03923738 129 135 O
1 NCT03923738 136 137 O
must NCT03923738 138 142 O
be NCT03923738 143 145 O
receiving NCT03923738 146 155 B-Eq-Comparison
treatment NCT03923738 156 165 B-Procedure
with NCT03923738 166 170 O
TCZ NCT03923738 171 174 B-Drug
8 NCT03923738 175 176 B-Eq-Comparison
mg NCT03923738 177 179 I-Eq-Comparison
/ NCT03923738 180 181 I-Eq-Comparison
kg NCT03923738 182 184 I-Eq-Comparison
IV NCT03923738 185 187 I-Eq-Comparison
Q4W NCT03923738 188 191 I-Eq-Comparison
. NCT03923738 192 193 O

Exclusion NCT03923738 195 204 O
Criteria NCT03923738 205 213 O
: NCT03923738 214 215 O

- NCT03923738 219 220 O
Treatment NCT03923738 222 231 B-Procedure
with NCT03923738 232 236 O
any NCT03923738 237 240 O
other NCT03923738 241 246 B-Other
investigational NCT03923738 247 262 B-Study
agent NCT03923738 263 268 B-Drug
besides NCT03923738 269 276 B-Exception
TCZ NCT03923738 277 280 B-Drug
within NCT03923738 281 287 B-Eq-Comparison
12 NCT03923738 288 290 I-Eq-Comparison
weeks NCT03923738 291 296 I-Eq-Comparison
( NCT03923738 297 298 O
or NCT03923738 299 301 B-Or
5 NCT03923738 302 303 B-Eq-Comparison
half NCT03923738 304 308 I-Eq-Comparison
- NCT03923738 309 310 I-Eq-Comparison
lives NCT03923738 311 316 I-Eq-Comparison
of NCT03923738 317 319 O
the NCT03923738 320 323 O
investigational NCT03923738 324 339 O
drug NCT03923738 340 344 O
, NCT03923738 345 346 O
whichever NCT03923738 347 356 O
is NCT03923738 357 359 O
longer NCT03923738 360 366 O
) NCT03923738 367 368 O
prior NCT03923738 369 374 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923738 375 377 O
screening NCT03923738 378 387 B-Study
; NCT03923738 387 388 O

- NCT03923738 391 392 O
Evidence NCT03923738 394 402 O
of NCT03923738 403 405 O
serious NCT03923738 406 413 O
uncontrolled NCT03923738 414 426 B-Modifier
disease NCT03923738 427 434 B-Condition
; NCT03923738 434 435 O

- NCT03923738 438 439 O
Known NCT03923738 441 446 O
active NCT03923738 447 453 B-Eq-Comparison
current NCT03923738 454 461 I-Eq-Comparison
or NCT03923738 462 464 B-Or
history NCT03923738 465 472 B-Eq-Comparison
of NCT03923738 473 475 I-Eq-Comparison
recurrent NCT03923738 476 485 O
bacterial NCT03923738 486 495 B-Modifier
, NCT03923738 496 497 O
viral NCT03923738 498 503 B-Modifier
, NCT03923738 504 505 O
fungal NCT03923738 506 512 B-Modifier
, NCT03923738 513 514 O
mycobacterial NCT03923738 515 528 B-Modifier
, NCT03923738 529 530 O
or NCT03923738 531 533 O
other NCT03923738 534 539 O
infections NCT03923738 540 550 B-Condition
; NCT03923738 550 551 O

- NCT03923738 554 555 O
Active NCT03923738 557 563 B-Eq-Comparison
TB NCT03923738 564 566 B-Condition
requiring NCT03923738 567 576 O
treatment NCT03923738 577 586 B-Drug
within NCT03923738 587 593 B-Eq-Comparison
the NCT03923738 594 597 I-Eq-Comparison
previous NCT03923738 598 606 I-Eq-Comparison
3 NCT03923738 607 608 I-Eq-Comparison
years NCT03923738 609 614 I-Eq-Comparison
. NCT03923738 614 615 O

Inclusion NCT03923062 0 9 O
Criteria NCT03923062 10 18 O
: NCT03923062 19 20 O

- NCT03923062 24 25 O
- NCT03923062 27 28 O
Subjects NCT03923062 29 37 O
presented NCT03923062 38 47 O
with NCT03923062 48 52 O
melasma NCT03923062 53 60 B-Condition
. NCT03923062 61 62 O

- NCT03923062 66 67 O
Age NCT03923062 69 72 B-Age
20 NCT03923062 73 75 B-Eq-Comparison
- NCT03923062 76 77 I-Eq-Comparison
40 NCT03923062 78 80 I-Eq-Comparison
years NCT03923062 81 86 I-Eq-Comparison
old NCT03923062 87 90 O
. NCT03923062 91 92 O

- NCT03923062 96 97 O
Melasma NCT03923062 99 106 B-Condition
persisting NCT03923062 107 117 O
for NCT03923062 118 121 O
more NCT03923062 122 126 B-Eq-Comparison
than NCT03923062 127 131 I-Eq-Comparison
6 NCT03923062 132 133 I-Eq-Comparison
months NCT03923062 134 140 I-Eq-Comparison
that NCT03923062 141 145 O
has NCT03923062 146 149 O
failed NCT03923062 150 156 O
to NCT03923062 157 159 O
respond NCT03923062 160 167 O
to NCT03923062 168 170 O
conventional NCT03923062 171 183 B-Procedure
treatment NCT03923062 184 193 I-Procedure
with NCT03923062 194 198 O
hydroquinone NCT03923062 199 211 B-Drug
or NCT03923062 212 214 B-Or
other NCT03923062 215 220 O
topical NCT03923062 221 228 B-Drug
lightening NCT03923062 229 239 I-Drug
agents NCT03923062 240 246 I-Drug
. NCT03923062 247 248 O

Exclusion NCT03923062 250 259 O
Criteria NCT03923062 260 268 O
: NCT03923062 269 270 O

- NCT03923062 274 275 O
- NCT03923062 277 278 O
History NCT03923062 279 286 B-Eq-Comparison
of NCT03923062 287 289 O
photosensitivity NCT03923062 290 306 B-Condition
, NCT03923062 307 308 O
keloids NCT03923062 309 316 B-Condition
, NCT03923062 317 318 O
hypertrophic NCT03923062 319 331 B-Condition
scarring NCT03923062 332 340 I-Condition
and NCT03923062 341 344 B-Or
post NCT03923062 345 349 B-Condition
- NCT03923062 350 351 I-Condition
inflammatory NCT03923062 352 364 I-Condition
hyperpigmentation NCT03923062 365 382 I-Condition
. NCT03923062 383 384 O

- NCT03923062 388 389 O
Pregnancy NCT03923062 391 400 B-Condition
and NCT03923062 401 404 B-Or
lactation NCT03923062 405 414 B-Condition
. NCT03923062 415 416 O

- NCT03923062 420 421 O
Subjects NCT03923062 423 431 O
with NCT03923062 432 436 O
local NCT03923062 437 442 B-Condition
inflammatory NCT03923062 443 455 I-Condition
skin NCT03923062 456 460 I-Condition
disorder NCT03923062 461 469 I-Condition
or NCT03923062 470 472 B-Or
active NCT03923062 473 479 B-Eq-Comparison
herpes NCT03923062 480 486 B-Condition
infection NCT03923062 487 496 I-Condition
at NCT03923062 497 499 O
the NCT03923062 500 503 O
site NCT03923062 504 508 B-Modifier
of NCT03923062 509 511 O
procedure NCT03923062 512 521 B-Procedure
. NCT03923062 522 523 O

- NCT03923062 527 528 O
Subjects NCT03923062 530 538 O
with NCT03923062 539 543 O
history NCT03923062 544 551 B-Eq-Comparison
of NCT03923062 552 554 O
medical NCT03923062 555 562 B-Condition
diseases NCT03923062 563 571 I-Condition
which NCT03923062 572 577 O
contraindicate NCT03923062 578 592 B-Contraindication
cryosurgery NCT03923062 593 604 B-Procedure
such NCT03923062 605 609 O
as NCT03923062 610 612 O
; NCT03923062 612 613 O
cold NCT03923062 614 618 B-Condition
intolerance NCT03923062 619 630 I-Condition
, NCT03923062 631 632 O
cold NCT03923062 633 637 B-Condition
urticaria NCT03923062 638 647 I-Condition
, NCT03923062 648 649 O
Raynaud`s NCT03923062 650 659 B-Condition
disease NCT03923062 660 667 I-Condition
and NCT03923062 668 671 B-And
history NCT03923062 672 679 B-Eq-Comparison
of NCT03923062 680 682 O
allergic NCT03923062 683 691 B-Allergy
reactions NCT03923062 692 701 O
to NCT03923062 702 704 O
cryosurgery NCT03923062 705 716 B-Procedure
. NCT03923062 716 717 O

Inclusion NCT03928080 0 9 O
Criteria NCT03928080 10 18 O
: NCT03928080 19 20 O

- NCT03928080 24 25 O
Aged NCT03928080 27 31 B-Age
18 NCT03928080 32 34 B-Eq-Comparison
and NCT03928080 35 38 I-Eq-Comparison
above NCT03928080 39 44 I-Eq-Comparison
. NCT03928080 45 46 O

- NCT03928080 50 51 O
Having NCT03928080 53 59 O
the NCT03928080 60 63 O
ability NCT03928080 64 71 O
to NCT03928080 72 74 O
learn NCT03928080 75 80 O
the NCT03928080 81 84 O
standard NCT03928080 85 93 O
toothbrushing NCT03928080 94 107 O
method NCT03928080 108 114 O
with NCT03928080 115 119 O
artificial NCT03928080 120 130 O
intelligence NCT03928080 131 143 O
powered NCT03928080 144 151 O
toothbrush NCT03928080 152 162 O
. NCT03928080 163 164 O

- NCT03928080 168 169 O
Ability NCT03928080 171 178 O
and NCT03928080 179 182 O
willingness NCT03928080 183 194 O
to NCT03928080 195 197 O
give NCT03928080 198 202 O
written NCT03928080 203 210 O
informed NCT03928080 211 219 O
consent NCT03928080 220 227 O
. NCT03928080 228 229 O

Exclusion NCT03928080 231 240 O
Criteria NCT03928080 241 249 O
: NCT03928080 250 251 O

- NCT03928080 255 256 O
Edentulous NCT03928080 258 268 B-Condition
mouth NCT03928080 269 274 I-Condition
. NCT03928080 275 276 O

- NCT03928080 280 281 O
Pregnant NCT03928080 283 291 B-Condition
females NCT03928080 292 299 O
. NCT03928080 300 301 O

- NCT03928080 305 306 O
Having NCT03928080 308 314 O
received NCT03928080 315 323 B-Eq-Comparison
professional NCT03928080 324 336 O
periodontal NCT03928080 337 348 B-Procedure
treatment NCT03928080 349 358 I-Procedure
( NCT03928080 359 360 O
other NCT03928080 361 366 B-Exception
than NCT03928080 367 371 I-Exception
supragingival NCT03928080 372 385 B-Procedure
cleaning NCT03928080 386 394 I-Procedure
) NCT03928080 395 396 O
within NCT03928080 397 403 B-Eq-Comparison
the NCT03928080 404 407 I-Eq-Comparison
previous NCT03928080 408 416 I-Eq-Comparison
12 NCT03928080 417 419 I-Eq-Comparison
months NCT03928080 420 426 I-Eq-Comparison
. NCT03928080 427 428 O

- NCT03928080 432 433 O
Having NCT03928080 435 441 O
received NCT03928080 442 450 B-Eq-Comparison
antibiotic NCT03928080 451 461 B-Drug
medication NCT03928080 462 472 I-Drug
within NCT03928080 473 479 B-Eq-Comparison
the NCT03928080 480 483 I-Eq-Comparison
previous NCT03928080 484 492 I-Eq-Comparison
3 NCT03928080 493 494 I-Eq-Comparison
months NCT03928080 495 501 I-Eq-Comparison
. NCT03928080 501 502 O

Inclusion NCT03920423 0 9 O
Criteria NCT03920423 10 18 O
: NCT03920423 19 20 O

- NCT03920423 24 25 O
requirement NCT03920423 27 38 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920423 39 41 I-Assertion___Assertion-Type-Value:hypothetical
radial NCT03920423 42 48 B-Procedure
arterial NCT03920423 49 57 I-Procedure
catheterization NCT03920423 58 73 I-Procedure
during NCT03920423 74 80 B-Temporal-Connection___Temporal-Connection-Type-Value:during
peri NCT03920423 81 85 O
operative NCT03920423 86 95 B-Procedure
period NCT03920423 96 102 O

- NCT03920423 105 106 O
within NCT03920423 108 114 O
cardiac NCT03920423 115 122 B-Condition
- NCT03920423 123 124 I-Condition
vascular NCT03920423 125 133 I-Condition
disease NCT03920423 134 141 I-Condition

- NCT03920423 144 145 O
written NCT03920423 147 154 O
consent NCT03920423 155 162 O

Exclusion NCT03920423 163 172 O
Criteria NCT03920423 173 181 O
: NCT03920423 182 183 O

- NCT03920423 187 188 O
contraindication NCT03920423 190 206 B-Contraindication
to NCT03920423 207 209 O
radial NCT03920423 210 216 B-Procedure
arterial NCT03920423 217 225 I-Procedure
catheterization NCT03920423 226 241 I-Procedure

- NCT03920423 244 245 O
abnormal NCT03920423 247 255 B-Condition
artery NCT03920423 256 262 I-Condition
evaluated NCT03920423 263 272 O
by NCT03920423 273 275 O
ultrasonography NCT03920423 276 291 B-Procedure

Inclusion NCT03923894 0 9 O
Criteria NCT03923894 10 18 O
: NCT03923894 19 20 O

- NCT03923894 24 25 O
Adult NCT03923894 27 32 O
men NCT03923894 33 36 O
and NCT03923894 37 40 B-Or
women NCT03923894 41 46 O
over NCT03923894 47 51 B-Eq-Comparison
50 NCT03923894 52 54 I-Eq-Comparison
years NCT03923894 55 60 I-Age|Eq-Comparison

- NCT03923894 63 64 O
After NCT03923894 66 71 O
fully NCT03923894 72 77 O
hearing NCT03923894 78 85 O
and NCT03923894 86 89 O
fully NCT03923894 90 95 O
understanding NCT03923894 96 109 O
this NCT03923894 110 114 O
clinical NCT03923894 115 123 O
trials NCT03923894 124 130 O
, NCT03923894 131 132 O
those NCT03923894 133 138 O
who NCT03923894 139 142 O
agree NCT03923894 143 148 O
to NCT03923894 149 151 O
voluntarily NCT03923894 152 163 O
decide NCT03923894 164 170 O
to NCT03923894 171 173 O
participate NCT03923894 174 185 O
and NCT03923894 186 189 O
to NCT03923894 190 192 O
comply NCT03923894 193 199 O
with NCT03923894 200 204 O
the NCT03923894 205 208 O
notice NCT03923894 209 215 O

Exclusion NCT03923894 216 225 O
Criteria NCT03923894 226 234 O
: NCT03923894 235 236 O

- NCT03923894 240 241 O
If NCT03923894 243 245 O
screening NCT03923894 246 255 B-Study
shows NCT03923894 256 261 B-Temporal-Connection___Temporal-Connection-Type-Value:during
that NCT03923894 262 266 O
the NCT03923894 267 270 O
white NCT03923894 271 276 B-Observation
blood NCT03923894 277 282 I-Observation
cell NCT03923894 283 287 I-Observation
( NCT03923894 288 289 O
WBC NCT03923894 290 293 B-Observation
) NCT03923894 294 295 O
is NCT03923894 296 298 O
less NCT03923894 299 303 B-Eq-Comparison
than NCT03923894 304 308 I-Eq-Comparison
3000 NCT03923894 309 313 I-Eq-Comparison
/ NCT03923894 314 315 I-Eq-Comparison
㎕ NCT03923894 316 317 I-Eq-Comparison
or NCT03923894 318 320 B-Or
more NCT03923894 321 325 B-Eq-Comparison
than NCT03923894 326 330 I-Eq-Comparison
8000 NCT03923894 331 335 I-Eq-Comparison
/ NCT03923894 336 337 I-Eq-Comparison
㎕ NCT03923894 338 339 I-Eq-Comparison

- NCT03923894 342 343 O
Those NCT03923894 345 350 O
who NCT03923894 351 354 O
received NCT03923894 355 363 B-Eq-Comparison
influenza NCT03923894 364 373 B-Immunization
vaccination NCT03923894 374 385 I-Immunization
within NCT03923894 386 392 B-Eq-Comparison
3 NCT03923894 393 394 I-Eq-Comparison
months NCT03923894 395 401 I-Eq-Comparison
before NCT03923894 402 408 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923894 409 412 O
screening NCT03923894 413 422 B-Study

- NCT03923894 425 426 O
Those NCT03923894 428 433 O
who NCT03923894 434 437 O
have NCT03923894 438 442 O
a NCT03923894 443 444 O
body NCT03923894 445 449 B-Observation
mass NCT03923894 450 454 I-Observation
index NCT03923894 455 460 I-Observation
( NCT03923894 461 462 O
BMI NCT03923894 463 466 B-Observation
) NCT03923894 467 468 O
of NCT03923894 469 471 O
less NCT03923894 472 476 B-Eq-Comparison
than NCT03923894 477 481 I-Eq-Comparison
18.5 NCT03923894 482 486 I-Eq-Comparison
kg NCT03923894 487 489 I-Eq-Comparison
/ NCT03923894 490 491 I-Eq-Comparison
m2 NCT03923894 492 494 I-Eq-Comparison
or NCT03923894 495 497 B-Or
greater NCT03923894 498 505 B-Eq-Comparison
than NCT03923894 506 510 I-Eq-Comparison
35 NCT03923894 511 513 I-Eq-Comparison
kg NCT03923894 514 516 I-Eq-Comparison
/ NCT03923894 517 518 I-Eq-Comparison
m2 NCT03923894 519 521 I-Eq-Comparison
at NCT03923894 522 524 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03923894 525 528 O
screening NCT03923894 529 538 B-Study

- NCT03923894 541 542 O
Those NCT03923894 544 549 O
who NCT03923894 550 553 O
have NCT03923894 554 558 O
a NCT03923894 559 560 O
clinically NCT03923894 561 571 O
significant NCT03923894 572 583 O
acute NCT03923894 584 589 O
or NCT03923894 590 592 B-Or
chronic NCT03923894 593 600 B-Modifier
cardiovascular NCT03923894 601 615 B-Condition
system NCT03923894 616 622 I-Condition
, NCT03923894 623 624 O
endocrine NCT03923894 625 634 B-Condition
system NCT03923894 635 641 I-Condition
, NCT03923894 642 643 O
immune NCT03923894 644 650 B-Condition
system NCT03923894 651 657 I-Condition
, NCT03923894 658 659 O
respiratory NCT03923894 660 671 B-Condition
system NCT03923894 672 678 I-Condition
, NCT03923894 679 680 O
liver NCT03923894 681 686 B-Condition
biliary NCT03923894 687 694 I-Condition
system NCT03923894 695 701 I-Condition
, NCT03923894 702 703 O
kidney NCT03923894 704 710 B-Modifier
and NCT03923894 711 714 B-Or
urinary NCT03923894 715 722 B-Modifier
system NCT03923894 723 729 B-Condition
, NCT03923894 730 731 O
neuropsychiatry NCT03923894 732 747 B-Condition
, NCT03923894 748 749 O
musculoskeletal NCT03923894 750 765 B-Condition
system NCT03923894 766 772 I-Condition
, NCT03923894 773 774 O
inflammatory NCT03923894 775 787 B-Condition
and NCT03923894 788 791 B-Or
hematologic NCT03923894 792 803 B-Condition

- NCT03923894 806 807 O
Those NCT03923894 809 814 O
who NCT03923894 815 818 O
take NCT03923894 819 823 B-Eq-Comparison
a NCT03923894 824 825 O
medication NCT03923894 826 836 B-Drug
or NCT03923894 837 839 B-Or
health NCT03923894 840 846 B-Drug
function NCT03923894 847 855 I-Drug
food NCT03923894 856 860 I-Drug
that NCT03923894 861 865 O
affects NCT03923894 866 873 O
your NCT03923894 874 878 O
promotion NCT03923894 879 888 B-Condition
of NCT03923894 889 891 I-Condition
immunity NCT03923894 892 900 I-Condition
within NCT03923894 901 907 B-Eq-Comparison
1 NCT03923894 908 909 I-Eq-Comparison
month NCT03923894 910 915 I-Eq-Comparison
prior NCT03923894 916 921 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03923894 922 924 O
the NCT03923894 925 928 O
screening NCT03923894 929 938 B-Study

- NCT03923894 941 942 O
Those NCT03923894 944 949 O
who NCT03923894 950 953 O
have NCT03923894 954 958 O
received NCT03923894 959 967 B-Eq-Comparison
antipsychotic NCT03923894 968 981 B-Drug
medication NCT03923894 982 992 I-Drug
within NCT03923894 993 999 B-Eq-Comparison
3 NCT03923894 1000 1001 I-Eq-Comparison
months NCT03923894 1002 1008 I-Eq-Comparison
before NCT03923894 1009 1015 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923894 1016 1025 B-Study

- NCT03923894 1028 1029 O
Those NCT03923894 1031 1036 O
who NCT03923894 1037 1040 O
alcoholic NCT03923894 1041 1050 B-Modifier
or NCT03923894 1051 1053 B-Or
drug NCT03923894 1054 1058 B-Modifier
abuse NCT03923894 1059 1064 B-Condition
suspected NCT03923894 1065 1074 B-Assertion___Assertion-Type-Value:possible

- NCT03923894 1077 1078 O
Those NCT03923894 1080 1085 O
who NCT03923894 1086 1089 O
participated NCT03923894 1090 1102 B-Observation
in NCT03923894 1103 1105 I-Observation
other NCT03923894 1106 1111 I-Observation
clinical NCT03923894 1112 1120 I-Observation
trials NCT03923894 1121 1127 I-Observation
within NCT03923894 1128 1134 B-Eq-Comparison
3 NCT03923894 1135 1136 I-Eq-Comparison
months NCT03923894 1137 1143 I-Eq-Comparison
before NCT03923894 1144 1150 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03923894 1151 1160 B-Study

- NCT03923894 1163 1164 O
Laboratory NCT03923894 1166 1176 O
test NCT03923894 1177 1181 O
by NCT03923894 1182 1184 O
show NCT03923894 1185 1189 O
the NCT03923894 1190 1193 O
following NCT03923894 1194 1203 O
results NCT03923894 1204 1211 O

- NCT03923894 1219 1220 O
Aspartate NCT03923894 1222 1231 B-Observation
Transaminase NCT03923894 1232 1244 I-Observation
( NCT03923894 1245 1246 O
AST NCT03923894 1247 1250 B-Observation
) NCT03923894 1251 1252 O
, NCT03923894 1254 1255 O
Alanine NCT03923894 1256 1263 B-Observation
Transaminase NCT03923894 1264 1276 I-Observation
( NCT03923894 1277 1278 O
ALT NCT03923894 1279 1282 B-Observation
) NCT03923894 1283 1284 O
> NCT03923894 1285 1286 B-Eq-Comparison
Reference NCT03923894 1287 1296 I-Eq-Comparison
range NCT03923894 1297 1302 I-Eq-Comparison
3 NCT03923894 1303 1304 I-Eq-Comparison
times NCT03923894 1305 1310 I-Eq-Comparison
upper NCT03923894 1311 1316 I-Eq-Comparison
limit NCT03923894 1317 1322 I-Eq-Comparison

- NCT03923894 1330 1331 O
Serum NCT03923894 1333 1338 B-Observation
Creatinine NCT03923894 1339 1349 I-Observation
> NCT03923894 1350 1351 B-Eq-Comparison
2.0 NCT03923894 1352 1355 I-Eq-Comparison
mg NCT03923894 1356 1358 I-Eq-Comparison
/ NCT03923894 1359 1360 I-Eq-Comparison
dL NCT03923894 1361 1363 I-Eq-Comparison

- NCT03923894 1366 1367 O
Pregnancy NCT03923894 1369 1378 B-Condition
or NCT03923894 1379 1381 B-Or
breast NCT03923894 1382 1388 B-Condition
feeding NCT03923894 1389 1396 I-Condition

- NCT03923894 1399 1400 O
Those NCT03923894 1402 1407 O
who NCT03923894 1408 1411 O
does NCT03923894 1412 1416 B-Negation
n't NCT03923894 1416 1419 I-Negation
accept NCT03923894 1420 1426 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03923894 1427 1430 O
implementation NCT03923894 1431 1445 O
of NCT03923894 1446 1448 O
appropriate NCT03923894 1449 1460 O
contraception NCT03923894 1461 1474 B-Drug
of NCT03923894 1475 1477 O
a NCT03923894 1478 1479 O
childbearing NCT03923894 1480 1492 B-Condition
woman NCT03923894 1493 1498 O

- NCT03923894 1501 1502 O
Principal NCT03923894 1504 1513 O
Investigator NCT03923894 1514 1526 O
judged NCT03923894 1527 1533 O
inappropriate NCT03923894 1534 1547 O
for NCT03923894 1548 1551 O
participation NCT03923894 1552 1565 O
in NCT03923894 1566 1568 O
study NCT03923894 1569 1574 O
because NCT03923894 1575 1582 O
of NCT03923894 1583 1585 O
Laboratory NCT03923894 1586 1596 O
test NCT03923894 1597 1601 O
result NCT03923894 1602 1608 O
, NCT03923894 1609 1610 O
etc NCT03923894 1611 1614 O
. NCT03923894 1615 1616 O


Inclusion NCT03920345 0 9 O
Criteria NCT03920345 10 18 O
: NCT03920345 19 20 O

Subject NCT03920345 22 29 O
age NCT03920345 30 33 B-Age
18 NCT03920345 34 36 B-Eq-Comparison
- NCT03920345 37 38 I-Eq-Comparison
85 NCT03920345 39 41 I-Eq-Comparison
years NCT03920345 42 47 I-Eq-Comparison
; NCT03920345 47 48 O

- NCT03920345 51 52 O
SIJ NCT03920345 54 57 B-Condition
arthropathy NCT03920345 58 69 I-Condition
and NCT03920345 70 73 B-And
chronic NCT03920345 74 81 B-Condition
lower NCT03920345 82 87 I-Condition
back NCT03920345 88 92 I-Condition
pain NCT03920345 93 97 I-Condition
( NCT03920345 98 99 O
CLBP NCT03920345 100 104 B-Condition
) NCT03920345 105 106 O
; NCT03920345 107 108 O

- NCT03920345 111 112 O
Patient NCT03920345 114 121 O
to NCT03920345 122 124 O
undergo NCT03920345 125 132 B-Eq-Comparison
endoscopic NCT03920345 133 143 B-Procedure
electrothermic NCT03920345 144 158 I-Procedure
ablation NCT03920345 159 167 I-Procedure
of NCT03920345 168 170 B-And
spinal NCT03920345 171 177 B-Condition
levels NCT03920345 178 184 I-Condition
S1 NCT03920345 185 187 B-Eq-Comparison
- NCT03920345 188 189 I-Eq-Comparison
S3 NCT03920345 190 192 I-Eq-Comparison
. NCT03920345 192 193 O
The NCT03920345 195 198 O
L4 NCT03920345 199 201 B-Modifier
- NCT03920345 202 203 I-Modifier
L5 NCT03920345 204 206 I-Modifier
and NCT03920345 207 210 B-Or
/ NCT03920345 211 212 I-Or
or NCT03920345 213 215 I-Or
L5 NCT03920345 216 218 B-Modifier
- NCT03920345 219 220 I-Modifier
S1 NCT03920345 221 223 I-Modifier
facet NCT03920345 224 229 B-Procedure
joint NCT03920345 230 235 I-Procedure
can NCT03920345 236 239 O
be NCT03920345 240 242 O
included NCT03920345 243 251 O
in NCT03920345 252 254 O
the NCT03920345 255 258 O
ablation NCT03920345 259 267 B-Procedure
per NCT03920345 268 271 O
doctor NCT03920345 272 278 O
discretion NCT03920345 279 289 O
. NCT03920345 290 291 O

- NCT03920345 295 296 O
Correct NCT03920345 298 305 O
spinal NCT03920345 306 312 B-Condition
levels NCT03920345 313 319 I-Condition
( NCT03920345 320 321 O
ranging NCT03920345 322 329 O
L4 NCT03920345 330 332 B-Eq-Comparison
- NCT03920345 333 334 I-Eq-Comparison
S3 NCT03920345 335 337 I-Eq-Comparison
) NCT03920345 338 339 O
to NCT03920345 340 342 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03920345 343 345 I-Assertion___Assertion-Type-Value:hypothetical
treated NCT03920345 346 353 B-Procedure
have NCT03920345 354 358 O
been NCT03920345 359 363 O
confirmed NCT03920345 364 373 O
by NCT03920345 374 376 O
1 NCT03920345 377 378 O
) NCT03920345 379 380 O
diagnostic NCT03920345 381 391 B-Procedure
SIJ NCT03920345 392 395 I-Procedure
injection NCT03920345 396 405 I-Procedure
, NCT03920345 406 407 O
followed NCT03920345 408 416 B-Temporal-Connection___Temporal-Connection-Type-Value:before
by NCT03920345 417 419 O
2 NCT03920345 420 421 O
) NCT03920345 422 423 O
diagnostic NCT03920345 424 434 B-Condition
Medial NCT03920345 435 441 B-Modifier
/ NCT03920345 442 443 B-Or
Lateral NCT03920345 444 451 B-Modifier
Branch NCT03920345 452 458 O
Block NCT03920345 459 464 O
at NCT03920345 465 467 O
the NCT03920345 468 471 O
applicable NCT03920345 472 482 O
levels NCT03920345 483 489 O
. NCT03920345 490 491 O

- NCT03920345 495 496 O
The NCT03920345 498 501 O
subject NCT03920345 502 509 O
is NCT03920345 510 512 O
likely NCT03920345 513 519 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03920345 520 522 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03920345 523 529 B-Observation
standard NCT03920345 530 538 I-Observation
of NCT03920345 539 541 I-Observation
care NCT03920345 542 546 I-Observation
post NCT03920345 547 551 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03920345 552 553 O
operative NCT03920345 554 563 B-Procedure
follow NCT03920345 564 570 O
- NCT03920345 571 572 O
up NCT03920345 573 575 O
for NCT03920345 576 579 O
at NCT03920345 580 582 B-Eq-Comparison
least NCT03920345 583 588 I-Eq-Comparison
24 NCT03920345 589 591 I-Eq-Comparison
months NCT03920345 592 598 I-Eq-Comparison
. NCT03920345 599 600 O

Exclusion NCT03920345 602 611 O
Criteria NCT03920345 612 620 O
: NCT03920345 621 622 O

Patients NCT03920345 624 632 O
receiving NCT03920345 633 642 B-Eq-Comparison
additional NCT03920345 643 653 O
invasive NCT03920345 654 662 B-Procedure
back NCT03920345 663 667 I-Procedure
surgery NCT03920345 668 675 I-Procedure
after NCT03920345 676 681 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03920345 682 685 O
study NCT03920345 686 691 B-Study
treatment NCT03920345 692 701 O
. NCT03920345 702 703 O

- NCT03920345 707 708 O
Inability NCT03920345 710 719 B-Negation
to NCT03920345 720 722 B-Assertion___Assertion-Type-Value:hypothetical
complete NCT03920345 723 731 I-Assertion___Assertion-Type-Value:hypothetical
follow NCT03920345 732 738 O
- NCT03920345 739 740 O
up NCT03920345 741 743 O
visits NCT03920345 744 750 B-Encounter
or NCT03920345 751 753 O
required NCT03920345 754 762 O
questionnaires NCT03920345 763 777 O
. NCT03920345 778 779 O

- NCT03920345 783 784 O
Non NCT03920345 786 789 O
- NCT03920345 790 791 O
compliant NCT03920345 792 801 O
patients NCT03920345 802 810 O

- NCT03920345 813 814 O
Difficult NCT03920345 816 825 B-Modifier
or NCT03920345 826 828 B-Or
impossible NCT03920345 829 839 B-Modifier
communication NCT03920345 840 853 B-Condition
with NCT03920345 854 858 O
the NCT03920345 859 862 O
patient NCT03920345 863 870 O

- NCT03920345 873 874 O
Breastfeeding NCT03920345 876 889 B-Condition
, NCT03920345 890 891 O
pregnant NCT03920345 892 900 B-Condition
or NCT03920345 901 903 B-Or
patients NCT03920345 904 912 O
who NCT03920345 913 916 O
plan NCT03920345 917 921 B-Assertion___Assertion-Type-Value:intention
a NCT03920345 922 923 O
pregnancy NCT03920345 924 933 B-Condition
while NCT03920345 934 939 B-Temporal-Connection___Temporal-Connection-Type-Value:during
participating NCT03920345 940 953 O
in NCT03920345 954 956 O
the NCT03920345 957 960 O
study NCT03920345 961 966 B-Study

- NCT03920345 969 970 O
Systemic NCT03920345 972 980 B-Modifier
neurological NCT03920345 981 993 B-Condition
disorders NCT03920345 994 1003 I-Condition
with NCT03920345 1004 1008 B-And
mobility NCT03920345 1009 1017 B-Condition
limitations NCT03920345 1018 1029 I-Condition
( NCT03920345 1030 1031 O
e. NCT03920345 1032 1034 O
g. NCT03920345 1035 1037 O
advanced NCT03920345 1039 1047 O
Parkinson NCT03920345 1048 1057 B-Condition
's NCT03920345 1057 1059 I-Condition
disease NCT03920345 1060 1067 I-Condition
or NCT03920345 1068 1070 B-Or
multiple NCT03920345 1071 1079 B-Condition
sclerosis NCT03920345 1080 1089 I-Condition
) NCT03920345 1090 1091 O

- NCT03920345 1095 1096 O
Patients NCT03920345 1098 1106 O
with NCT03920345 1107 1111 O
incompatibilities NCT03920345 1112 1129 O
or NCT03920345 1130 1132 O
known NCT03920345 1133 1138 O
limitations NCT03920345 1139 1150 O
that NCT03920345 1151 1155 O
make NCT03920345 1156 1160 O
participation NCT03920345 1161 1174 O
impossible NCT03920345 1175 1185 O

- NCT03920345 1188 1189 O
Patients NCT03920345 1191 1199 O
after NCT03920345 1200 1205 O
stabilization NCT03920345 1206 1219 O
with NCT03920345 1220 1224 O
implants NCT03920345 1225 1233 B-Condition
on NCT03920345 1234 1236 O
thoracic NCT03920345 1237 1245 B-Modifier
or NCT03920345 1246 1248 B-Or
lumbar NCT03920345 1249 1255 B-Modifier
spine NCT03920345 1256 1261 I-Modifier
. NCT03920345 1262 1263 O

- NCT03920345 1267 1268 O
Inability NCT03920345 1270 1279 O
to NCT03920345 1280 1282 O
provide NCT03920345 1283 1290 O
informed NCT03920345 1291 1299 O
consent NCT03920345 1300 1307 O
without NCT03920345 1308 1315 O
a NCT03920345 1316 1317 O
legally NCT03920345 1318 1325 O
authorized NCT03920345 1326 1336 O
representative NCT03920345 1337 1351 O
. NCT03920345 1352 1353 O


Inclusion NCT03927833 0 9 O
Criteria NCT03927833 10 18 O
: NCT03927833 19 20 O

1 NCT03927833 24 25 O
. NCT03927833 25 26 O
Infants NCT03927833 28 35 B-Family-Member___Family-Member-Type:child
is NCT03927833 36 38 O
inborn NCT03927833 39 45 B-Condition

2 NCT03927833 48 49 O
. NCT03927833 49 50 O
Infant NCT03927833 52 58 B-Family-Member___Family-Member-Type:child
is NCT03927833 59 61 B-Observation
≤ NCT03927833 62 63 B-Eq-Comparison
750 NCT03927833 64 67 I-Eq-Comparison
grams NCT03927833 68 73 I-Eq-Comparison
at NCT03927833 74 76 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03927833 77 82 B-Birth
and NCT03927833 83 86 B-Or
/ NCT03927833 87 88 I-Or
or NCT03927833 89 91 I-Or
< NCT03927833 92 93 B-Eq-Comparison
27 NCT03927833 94 96 I-Eq-Comparison
weeks NCT03927833 97 102 I-Eq-Comparison
gestation NCT03927833 103 112 B-Observation
at NCT03927833 113 115 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03927833 116 121 B-Birth
by NCT03927833 122 124 O
best NCT03927833 125 129 O
OB NCT03927833 130 132 O
estimate NCT03927833 133 141 O

3 NCT03927833 144 145 O
. NCT03927833 145 146 O
Infant NCT03927833 148 154 B-Family-Member___Family-Member-Type:child
is NCT03927833 155 157 O
12 NCT03927833 158 160 B-Eq-Comparison
- NCT03927833 161 162 I-Eq-Comparison
36 NCT03927833 163 165 I-Eq-Comparison
hours NCT03927833 166 171 I-Eq-Comparison
of NCT03927833 172 174 O
age NCT03927833 175 178 B-Age
. NCT03927833 179 180 O

Exclusion NCT03927833 182 191 O
Criteria NCT03927833 192 200 O
: NCT03927833 201 202 O

1 NCT03927833 206 207 O
. NCT03927833 207 208 O
Unable NCT03927833 210 216 O
to NCT03927833 217 219 O
enroll NCT03927833 220 226 B-Assertion___Assertion-Type-Value:hypothetical
infant NCT03927833 227 233 B-Family-Member___Family-Member-Type:child
by NCT03927833 234 236 B-Eq-Comparison
36 NCT03927833 237 239 I-Eq-Comparison
hours NCT03927833 240 245 I-Eq-Comparison
of NCT03927833 246 248 O
age NCT03927833 249 252 B-Age

2 NCT03927833 255 256 O
. NCT03927833 256 257 O
Previous NCT03927833 259 267 B-Eq-Comparison
phototherapy NCT03927833 268 280 B-Procedure

3 NCT03927833 283 284 O
. NCT03927833 284 285 O
Known NCT03927833 287 292 O
hemolytic NCT03927833 293 302 B-Condition
disease NCT03927833 303 310 I-Condition

4 NCT03927833 313 314 O
. NCT03927833 314 315 O
TSB NCT03927833 317 320 B-Observation
reported NCT03927833 321 329 O
as NCT03927833 330 332 O
> NCT03927833 333 334 B-Eq-Comparison
6.0 NCT03927833 335 338 I-Eq-Comparison
mg NCT03927833 339 341 I-Eq-Comparison
/ NCT03927833 342 343 I-Eq-Comparison
dL NCT03927833 344 346 I-Eq-Comparison
before NCT03927833 347 353 B-Temporal-Connection___Temporal-Connection-Type-Value:before
12 NCT03927833 354 356 B-Eq-Comparison
hours NCT03927833 357 362 I-Eq-Comparison
age NCT03927833 363 366 B-Age

5 NCT03927833 369 370 O
. NCT03927833 370 371 O
Major NCT03927833 373 378 B-Condition
anomaly NCT03927833 379 386 I-Condition

6 NCT03927833 389 390 I-Eq-Comparison
. NCT03927833 390 391 O
Overt NCT03927833 393 398 B-Condition
nonbacterial NCT03927833 399 411 I-Condition
infection NCT03927833 412 421 I-Condition

7 NCT03927833 424 425 O
. NCT03927833 425 426 O
Infant NCT03927833 428 434 B-Family-Member___Family-Member-Type:child
is NCT03927833 435 437 O
likely NCT03927833 438 444 B-Risk
to NCT03927833 445 447 O
expire NCT03927833 448 454 B-Death
soon NCT03927833 455 459 O
: NCT03927833 460 461 O
Limiting NCT03927833 462 470 O
or NCT03927833 471 473 O
withdrawal NCT03927833 474 484 B-Negation
of NCT03927833 485 487 O
intensive NCT03927833 488 497 B-Encounter
care NCT03927833 498 502 I-Encounter
is NCT03927833 503 505 O
being NCT03927833 506 511 O
recommended NCT03927833 512 523 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03927833 524 526 O
the NCT03927833 527 530 O
parents NCT03927833 531 538 O
, NCT03927833 539 540 O
the NCT03927833 541 544 O
parents NCT03927833 545 552 O
are NCT03927833 553 556 O
requesting NCT03927833 557 567 O
withdrawal NCT03927833 568 578 O
of NCT03927833 579 581 O
care NCT03927833 582 586 O
, NCT03927833 587 588 O
or NCT03927833 589 591 O
the NCT03927833 592 595 O
pH NCT03927833 596 598 B-Observation
is NCT03927833 599 601 O
< NCT03927833 602 603 O
6.80 NCT03927833 604 608 O
or NCT03927833 609 611 B-Or
persistent NCT03927833 612 622 B-Condition
bradycardia NCT03927833 623 634 I-Condition
with NCT03927833 635 639 B-And
hypoxemia NCT03927833 640 649 B-Condition
for NCT03927833 650 653 O
> NCT03927833 654 655 B-Eq-Comparison
2 NCT03927833 656 657 I-Eq-Comparison
h. NCT03927833 658 660 O

Inclusion NCT03929822 0 9 O
Criteria NCT03929822 10 18 O
: NCT03929822 19 20 O

- NCT03929822 24 25 O
Women NCT03929822 27 32 O
called NCT03929822 33 39 O
back NCT03929822 40 44 O
from NCT03929822 45 49 O
a NCT03929822 50 51 O
screening NCT03929822 52 61 B-Procedure
mammography NCT03929822 62 73 I-Procedure
by NCT03929822 74 76 O
either NCT03929822 77 83 O
FFDM NCT03929822 84 88 B-Procedure
or NCT03929822 89 91 B-Or
tomosynthesis NCT03929822 92 105 B-Procedure
with NCT03929822 106 110 B-And
soft NCT03929822 111 115 B-Condition
tissue NCT03929822 116 122 I-Condition
abnormalities NCT03929822 123 136 I-Condition
including NCT03929822 137 146 O
masses NCT03929822 147 153 B-Condition
, NCT03929822 154 155 O
asymmetries NCT03929822 156 167 B-Condition
, NCT03929822 168 169 O
focal NCT03929822 170 175 B-Condition
asymmetries NCT03929822 176 187 I-Condition
or NCT03929822 188 190 B-Or
architectural NCT03929822 191 204 B-Condition
distortion NCT03929822 205 215 I-Condition
with NCT03929822 216 220 B-Modifier
or NCT03929822 221 223 B-Or
without NCT03929822 224 231 B-Negation
calcifications NCT03929822 232 246 B-Condition
. NCT03929822 246 247 O
Patients NCT03929822 249 257 O
will NCT03929822 258 262 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03929822 263 265 I-Assertion___Assertion-Type-Value:hypothetical
questioned NCT03929822 266 276 I-Assertion___Assertion-Type-Value:hypothetical
regarding NCT03929822 277 286 O
the NCT03929822 287 290 O
possibility NCT03929822 291 302 O
of NCT03929822 303 305 O
pregnancy NCT03929822 306 315 B-Condition
and NCT03929822 316 319 B-And
will NCT03929822 320 324 B-Assertion___Assertion-Type-Value:hypothetical
need NCT03929822 325 329 I-Assertion___Assertion-Type-Value:hypothetical
a NCT03929822 330 331 O
negative NCT03929822 332 340 O
pregnancy NCT03929822 341 350 B-Observation
test NCT03929822 351 355 I-Observation
prior NCT03929822 356 361 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03929822 362 365 O
study NCT03929822 366 371 B-Study
intervention NCT03929822 372 384 O
. NCT03929822 385 386 O

Exclusion NCT03929822 388 397 O
Criteria NCT03929822 398 406 O
: NCT03929822 407 408 O

- NCT03929822 412 413 O
Age NCT03929822 415 418 B-Age
< NCT03929822 419 420 B-Eq-Comparison
30 NCT03929822 421 423 I-Eq-Comparison
years NCT03929822 424 429 I-Eq-Comparison
old NCT03929822 430 433 O

- NCT03929822 436 437 O
Screening NCT03929822 439 448 B-Procedure
mammography NCT03929822 449 460 I-Procedure
with NCT03929822 461 465 O
only NCT03929822 466 470 O
calcifications NCT03929822 471 485 B-Condition
abnormalities NCT03929822 486 499 I-Condition

- NCT03929822 502 503 O
Male NCT03929822 505 509 O
patients NCT03929822 510 518 O

- NCT03929822 521 522 O
Pregnant NCT03929822 524 532 B-Condition
or NCT03929822 533 535 B-Or
lactating NCT03929822 536 545 B-Condition
patients NCT03929822 546 554 O

- NCT03929822 557 558 O
Patients NCT03929822 560 568 O
with NCT03929822 569 573 O
any NCT03929822 574 577 O
allergy NCT03929822 578 585 B-Allergy
to NCT03929822 586 588 O
iodinated NCT03929822 589 598 O
contrast NCT03929822 599 607 O

- NCT03929822 610 611 O
Patients NCT03929822 613 621 O
with NCT03929822 622 626 O
eGFR NCT03929822 627 631 B-Observation
< NCT03929822 632 633 B-Eq-Comparison
45 NCT03929822 634 636 I-Eq-Comparison

- NCT03929822 640 641 O
Patients NCT03929822 643 651 O
that NCT03929822 652 656 O
may NCT03929822 657 660 B-Assertion___Assertion-Type-Value:possible
be NCT03929822 661 663 O
treated NCT03929822 664 671 B-Procedure
with NCT03929822 672 676 O
radioactive NCT03929822 677 688 B-Procedure
iodine NCT03929822 689 695 I-Procedure

Inclusion NCT03924453 0 9 O
Criteria NCT03924453 10 18 O
: NCT03924453 19 20 O

1 NCT03924453 24 25 O
. NCT03924453 25 26 O
Female NCT03924453 28 34 O
( NCT03924453 35 36 O
mandatory NCT03924453 37 46 O
) NCT03924453 47 48 O

2 NCT03924453 52 53 O
. NCT03924453 53 54 O
Not NCT03924453 56 59 B-Negation
currently NCT03924453 60 69 B-Eq-Comparison
pregnant NCT03924453 70 78 B-Condition
or NCT03924453 79 81 B-Or
nursing NCT03924453 82 89 B-Condition
( NCT03924453 90 91 O
mandatory NCT03924453 92 101 O
) NCT03924453 102 103 O

3 NCT03924453 107 108 O
. NCT03924453 108 109 O
Aged NCT03924453 111 115 B-Age
21 NCT03924453 116 118 B-Eq-Comparison
- NCT03924453 119 120 I-Eq-Comparison
45 NCT03924453 121 123 O
( NCT03924453 124 125 O
advanced NCT03924453 126 134 O
age NCT03924453 135 138 O
can NCT03924453 139 142 O
hinder NCT03924453 143 149 O
hormone NCT03924453 150 157 O
levels NCT03924453 158 164 O
) NCT03924453 165 166 O

4 NCT03924453 170 171 O
. NCT03924453 171 172 O
Not NCT03924453 174 177 B-Negation
be NCT03924453 178 180 O
diagnosed NCT03924453 181 190 O
as NCT03924453 191 193 O
sub NCT03924453 194 197 B-Condition
fertile NCT03924453 198 205 I-Condition
( NCT03924453 206 207 O
infertility NCT03924453 208 219 O
causes NCT03924453 220 226 O
inconsistent NCT03924453 227 239 O
hormone NCT03924453 240 247 O
levels NCT03924453 248 254 O
) NCT03924453 255 256 O

5 NCT03924453 260 261 O
. NCT03924453 261 262 O
Not NCT03924453 264 267 B-Negation
have NCT03924453 268 272 O
used NCT03924453 273 277 O
any NCT03924453 278 281 O
form NCT03924453 282 286 O
of NCT03924453 287 289 O
hormonal NCT03924453 290 298 B-Procedure
birth NCT03924453 299 304 I-Procedure
control NCT03924453 305 312 I-Procedure
in NCT03924453 313 315 O
the NCT03924453 316 319 B-Eq-Comparison
past NCT03924453 320 324 I-Eq-Comparison
2 NCT03924453 325 326 I-Eq-Comparison
months NCT03924453 327 333 I-Eq-Comparison
( NCT03924453 334 335 O
mandatory NCT03924453 336 345 O
) NCT03924453 346 347 O

6 NCT03924453 351 352 O
. NCT03924453 352 353 O
Currently NCT03924453 355 364 B-Eq-Comparison
trying NCT03924453 365 371 B-Assertion___Assertion-Type-Value:intention
to NCT03924453 372 374 I-Assertion___Assertion-Type-Value:intention
conceive NCT03924453 375 383 B-Condition
( NCT03924453 384 385 O
ideal NCT03924453 386 391 O
but NCT03924453 392 395 O
not NCT03924453 396 399 O
required NCT03924453 400 408 O
) NCT03924453 409 410 O

7 NCT03924453 414 415 O
. NCT03924453 415 416 O
Currently NCT03924453 418 427 B-Eq-Comparison
reside NCT03924453 428 434 O
in NCT03924453 435 437 O
the NCT03924453 438 441 O
US NCT03924453 442 444 O
( NCT03924453 445 446 O
mandatory NCT03924453 447 456 O
, NCT03924453 457 458 O
this NCT03924453 459 463 O
study NCT03924453 464 469 O
is NCT03924453 470 472 O
for NCT03924453 473 476 O
US NCT03924453 477 479 O
residents NCT03924453 480 489 O
only NCT03924453 490 494 O
) NCT03924453 495 496 O

Exclusion NCT03924453 498 507 O
Criteria NCT03924453 508 516 O
: NCT03924453 517 518 O

1 NCT03924453 522 523 O
. NCT03924453 523 524 O
Male NCT03924453 526 530 O

2 NCT03924453 533 534 O
. NCT03924453 534 535 O
Pregnant NCT03924453 537 545 B-Condition

3 NCT03924453 548 549 O
. NCT03924453 549 550 O
Nursing NCT03924453 552 559 B-Condition

Inclusion NCT03921112 0 9 O
Criteria NCT03921112 10 18 O
: NCT03921112 19 20 O

- NCT03921112 24 25 O
Mechanically NCT03921112 27 39 B-Procedure
ventilated NCT03921112 40 50 I-Procedure
patients NCT03921112 51 59 O

- NCT03921112 62 63 O
ASAI NCT03921112 65 69 B-Condition
, NCT03921112 70 71 O
ASAII NCT03921112 72 77 B-Condition
, NCT03921112 78 79 O
ASAIII NCT03921112 80 86 B-Condition

Exclusion NCT03921112 87 96 O
Criteria NCT03921112 97 105 O
: NCT03921112 106 107 O

- NCT03921112 111 112 O
Patients NCT03921112 114 122 O
or NCT03921112 123 125 O
gurdians NCT03921112 126 134 O
refuse NCT03921112 135 141 O

- NCT03921112 144 145 O
Patients NCT03921112 147 155 O
with NCT03921112 156 160 O
pneumthorax NCT03921112 161 172 B-Condition

- NCT03921112 175 176 O
Patients NCT03921112 178 186 O
with NCT03921112 187 191 O
pleural NCT03921112 192 199 B-Condition
effusion NCT03921112 200 208 I-Condition

- NCT03921112 211 212 O
Patients NCT03921112 214 222 O
with NCT03921112 223 227 O
surgical NCT03921112 228 236 B-Condition
emphysema NCT03921112 237 246 I-Condition

- NCT03921112 249 250 O
Glasco NCT03921112 252 258 B-Observation
coma NCT03921112 259 263 I-Observation
score NCT03921112 264 269 B-Eq-Comparison
more NCT03921112 270 274 I-Eq-Comparison
than NCT03921112 275 279 I-Eq-Comparison
8 NCT03921112 280 281 I-Eq-Comparison

- NCT03921112 285 286 O
Patients NCT03921112 288 296 O
on NCT03921112 297 299 B-Eq-Comparison
high NCT03921112 300 304 O
inotropic NCT03921112 305 314 B-Drug
support NCT03921112 315 322 I-Drug

- NCT03921112 325 326 O
patients NCT03921112 328 336 O
with NCT03921112 337 341 O
diaphragmatic NCT03921112 342 355 B-Condition
paralysis NCT03921112 356 365 I-Condition

Inclusion NCT03928678 0 9 O
Criteria NCT03928678 10 18 O
: NCT03928678 19 20 O

- NCT03928678 24 25 O
Age NCT03928678 27 30 B-Age
≤ NCT03928678 31 32 B-Eq-Comparison
60 NCT03928678 33 35 I-Eq-Comparison
years NCT03928678 36 41 I-Eq-Comparison
, NCT03928678 42 43 O

- NCT03928678 47 48 O
Good NCT03928678 50 54 O
nutrition NCT03928678 55 64 O
, NCT03928678 65 66 O

- NCT03928678 70 71 O
No NCT03928678 73 75 B-Negation
systemic NCT03928678 76 84 B-Condition
infection NCT03928678 85 94 I-Condition
and NCT03928678 95 98 B-And

- NCT03928678 101 102 O
Elective NCT03928678 104 112 O
laparoscopic NCT03928678 113 125 B-Procedure
surgery NCT03928678 126 133 I-Procedure

Exclusion NCT03928678 134 143 O
Criteria NCT03928678 144 152 O
: NCT03928678 153 154 O

- NCT03928678 158 159 O
Age NCT03928678 161 164 B-Age
> NCT03928678 165 166 B-Eq-Comparison
75 NCT03928678 167 169 I-Eq-Comparison
years NCT03928678 170 175 I-Eq-Comparison
, NCT03928678 176 177 O

- NCT03928678 181 182 O
Malnutrition NCT03928678 184 196 B-Condition
or NCT03928678 197 199 B-Or
an NCT03928678 200 202 O
organ NCT03928678 203 208 B-Condition
system NCT03928678 209 215 I-Condition
infection NCT03928678 216 225 I-Condition

- NCT03928678 228 229 O
Associated NCT03928678 231 241 O
with NCT03928678 242 246 O
obstruction NCT03928678 247 258 B-Condition
, NCT03928678 259 260 O
bleeding NCT03928678 261 269 B-Condition
, NCT03928678 270 271 O
emergency NCT03928678 272 281 B-Procedure
surgery NCT03928678 282 289 I-Procedure
or NCT03928678 290 292 B-Or
other NCT03928678 293 298 O
surgical NCT03928678 299 307 B-Procedure
intervention NCT03928678 308 320 I-Procedure

- NCT03928678 323 324 O
Tumor NCT03928678 326 331 B-Condition
with NCT03928678 332 336 I-Condition
extensive NCT03928678 337 346 I-Condition
metastasis NCT03928678 347 357 I-Condition

- NCT03928678 360 361 O
Prior NCT03928678 363 368 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03928678 369 371 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03928678 372 379 B-Procedure
, NCT03928678 380 381 O
patient NCT03928678 382 389 O
was NCT03928678 390 393 O
fasting NCT03928678 394 401 B-Observation
, NCT03928678 402 403 O
underwent NCT03928678 404 413 B-Eq-Comparison
gastrointestinal NCT03928678 414 430 B-Procedure
decompression NCT03928678 431 444 I-Procedure
and NCT03928678 445 448 B-And
received NCT03928678 449 457 B-Eq-Comparison
nutritional NCT03928678 458 469 B-Procedure
support NCT03928678 470 477 I-Procedure

- NCT03928678 480 481 O
Previous NCT03928678 483 491 B-Eq-Comparison
history NCT03928678 492 499 I-Eq-Comparison
of NCT03928678 500 502 O
abdominal NCT03928678 503 512 B-Procedure
surgery NCT03928678 513 520 I-Procedure

- NCT03928678 523 524 O
Patient NCT03928678 526 533 O
have NCT03928678 534 538 O
previously NCT03928678 539 549 B-Eq-Comparison
undergone NCT03928678 550 559 I-Eq-Comparison
gastrostomy NCT03928678 560 571 B-Procedure

Inclusion NCT03921853 0 9 O
Criteria NCT03921853 10 18 O
: NCT03921853 19 20 O

Inclusion NCT03921853 22 31 O
Criteria NCT03921853 32 40 O
: NCT03921853 41 42 O

- NCT03921853 46 47 O
Older NCT03921853 49 54 B-Eq-Comparison
than NCT03921853 55 59 I-Eq-Comparison
18 NCT03921853 60 62 I-Eq-Comparison
and NCT03921853 63 66 O
younger NCT03921853 67 74 O
and NCT03921853 75 78 B-And
≤ NCT03921853 79 80 B-Eq-Comparison
65 NCT03921853 81 83 I-Eq-Comparison
years NCT03921853 84 89 I-Eq-Comparison
of NCT03921853 90 92 O
age NCT03921853 93 96 B-Age
. NCT03921853 97 98 O

- NCT03921853 102 103 O
With NCT03921853 105 109 O
risk NCT03921853 110 114 B-Risk
factors NCT03921853 115 122 O
to NCT03921853 123 125 O
Metabolic NCT03921853 126 135 B-Condition
syndrome NCT03921853 136 144 I-Condition

- NCT03921853 147 148 O
With NCT03921853 150 154 O
obesity NCT03921853 155 162 B-Condition
and NCT03921853 163 166 B-And
morbid NCT03921853 167 173 B-Condition
obesity NCT03921853 174 181 I-Condition
condition NCT03921853 182 191 O

- NCT03921853 194 195 O
Medical NCT03921853 197 204 O
authorization NCT03921853 205 218 O
by NCT03921853 219 221 O
a NCT03921853 222 223 O
physician NCT03921853 224 233 O
. NCT03921853 234 235 O

Exclusion NCT03921853 237 246 O
Criteria NCT03921853 247 255 O
: NCT03921853 256 257 O

- NCT03921853 261 262 O
Physical NCT03921853 264 272 B-Condition
limitations NCT03921853 273 284 I-Condition
( NCT03921853 285 286 O
e. NCT03921853 287 289 O
g. NCT03921853 290 292 O
, NCT03921853 293 294 O
restricting NCT03921853 295 306 B-Modifier
injuries NCT03921853 307 315 B-Condition
of NCT03921853 316 318 O
the NCT03921853 319 322 O
musculoskeletal NCT03921853 323 338 B-Modifier
system NCT03921853 339 345 I-Modifier
, NCT03921853 346 347 O
or NCT03921853 348 350 O
dependent NCT03921853 351 360 B-Observation
of NCT03921853 361 363 I-Observation
a NCT03921853 364 365 I-Observation
third NCT03921853 366 371 I-Observation
person NCT03921853 372 378 I-Observation
) NCT03921853 379 380 O
. NCT03921853 382 383 O

- NCT03921853 387 388 O
Exercise NCT03921853 390 398 B-Condition
- NCT03921853 399 400 I-Condition
related NCT03921853 401 408 I-Condition
dyspnoea NCT03921853 409 417 I-Condition
or NCT03921853 418 420 B-Or
respiratory NCT03921853 421 432 B-Condition
alterations NCT03921853 433 444 I-Condition
. NCT03921853 445 446 O

- NCT03921853 450 451 O
Chronic NCT03921853 453 460 B-Modifier
heart NCT03921853 461 466 B-Condition
disease NCT03921853 467 474 I-Condition
with NCT03921853 475 479 O
any NCT03921853 480 483 O
worsening NCT03921853 484 493 O
in NCT03921853 494 496 O
the NCT03921853 497 500 O
last NCT03921853 501 505 B-Eq-Comparison
month NCT03921853 506 511 I-Eq-Comparison
. NCT03921853 512 513 O

- NCT03921853 517 518 O
Adherence NCT03921853 520 529 B-Observation
rate NCT03921853 530 534 I-Observation
of NCT03921853 535 537 O
less NCT03921853 538 542 B-Eq-Comparison
than NCT03921853 543 547 I-Eq-Comparison
80 NCT03921853 548 550 I-Eq-Comparison
% NCT03921853 551 552 I-Eq-Comparison
of NCT03921853 553 555 O
the NCT03921853 556 559 O
total NCT03921853 560 565 O
interventions NCT03921853 566 579 O
. NCT03921853 579 580 O

Inclusion NCT03923088 0 9 O
Criteria NCT03923088 10 18 O
: NCT03923088 19 20 O

- NCT03923088 24 25 O
Children NCT03923088 27 35 O
: NCT03923088 36 37 O
6 NCT03923088 38 39 B-Eq-Comparison
to NCT03923088 40 42 I-Eq-Comparison
9 NCT03923088 43 44 I-Eq-Comparison
years NCT03923088 45 50 I-Eq-Comparison
old NCT03923088 51 54 B-Age
children NCT03923088 55 63 O
. NCT03923088 63 64 O
Teeth NCT03923088 66 71 O
: NCT03923088 72 73 O
tooth NCT03923088 74 79 O
requiring NCT03923088 80 89 B-Assertion___Assertion-Type-Value:hypothetical
dental NCT03923088 90 96 B-Procedure
treatment NCT03923088 97 106 I-Procedure

Exclusion NCT03923088 107 116 O
Criteria NCT03923088 117 125 O
: NCT03923088 126 127 O

- NCT03923088 131 132 O
Children NCT03923088 134 142 O
having NCT03923088 143 149 B-And
allergy NCT03923088 150 157 B-Allergy
to NCT03923088 158 160 O
local NCT03923088 161 166 B-Procedure
anaesthesia NCT03923088 167 178 I-Procedure
or NCT03923088 179 181 B-Or
systemic NCT03923088 182 190 B-Modifier
problem NCT03923088 191 198 B-Condition
. NCT03923088 198 199 O
Refusal NCT03923088 201 208 O
of NCT03923088 209 211 O
participation NCT03923088 212 225 O
Mentally NCT03923088 226 234 B-Condition
ill NCT03923088 235 238 I-Condition
or NCT03923088 239 241 B-Or
mentally NCT03923088 242 250 B-Condition
retarded NCT03923088 251 259 I-Condition
children NCT03923088 260 268 O

Inclusion NCT03921489 0 9 O
Criteria NCT03921489 10 18 O
: NCT03921489 19 20 O

- NCT03921489 24 25 O
BME NCT03921489 27 30 B-Condition
diagnosed NCT03921489 31 40 O
on NCT03921489 41 43 O
MRI NCT03921489 44 47 B-Procedure

- NCT03921489 50 51 O
Pain NCT03921489 53 57 B-Condition
to NCT03921489 58 60 O
that NCT03921489 61 65 O
area NCT03921489 66 70 B-Modifier

- NCT03921489 73 74 O
Failed NCT03921489 76 82 O
3 NCT03921489 83 84 B-Eq-Comparison
months NCT03921489 85 91 I-Eq-Comparison
of NCT03921489 92 94 O
conservative NCT03921489 95 107 B-Procedure
treatment NCT03921489 108 117 I-Procedure

Exclusion NCT03921489 118 127 O
Criteria NCT03921489 128 136 O
: NCT03921489 137 138 O

- NCT03921489 142 143 O
Patient NCT03921489 145 152 O
< NCT03921489 153 154 B-Eq-Comparison
18 NCT03921489 155 157 I-Eq-Comparison
years NCT03921489 158 163 I-Eq-Comparison
of NCT03921489 164 166 O
age NCT03921489 167 170 B-Age

- NCT03921489 173 174 O
Presence NCT03921489 176 184 O
of NCT03921489 185 187 O
osteomyelitis NCT03921489 188 201 B-Condition
of NCT03921489 202 204 O
poor NCT03921489 205 209 O
surgical NCT03921489 210 218 O
candidates NCT03921489 219 229 O
due NCT03921489 230 233 O
to NCT03921489 234 236 O
comorbidities NCT03921489 237 250 B-Condition
such NCT03921489 251 255 O
as NCT03921489 256 258 O
diabetics NCT03921489 259 268 B-Condition
with NCT03921489 269 273 B-And
an NCT03921489 274 276 O
HbA1c NCT03921489 277 282 B-Observation
of NCT03921489 283 285 O
> NCT03921489 286 287 B-Eq-Comparison
8 NCT03921489 288 289 I-Eq-Comparison
% NCT03921489 290 291 I-Eq-Comparison

- NCT03921489 295 296 O
Patient NCT03921489 298 305 O
with NCT03921489 306 310 O
previous NCT03921489 311 319 B-Eq-Comparison
foot NCT03921489 320 324 B-Modifier
and NCT03921489 325 328 B-Or
ankle NCT03921489 329 334 B-Modifier
surgeries NCT03921489 335 344 B-Procedure
that NCT03921489 345 349 O
may NCT03921489 350 353 O
interfere NCT03921489 354 363 O
with NCT03921489 364 368 O
future NCT03921489 369 375 O
outcomes NCT03921489 376 384 O

Inclusion NCT03926494 0 9 O
Criteria NCT03926494 10 18 O
: NCT03926494 19 20 O

- NCT03926494 24 25 O
All NCT03926494 27 30 O
comatose NCT03926494 31 39 B-Condition
patients NCT03926494 40 48 O
( NCT03926494 49 50 O
Glasgow NCT03926494 51 58 B-Observation
coma NCT03926494 59 63 I-Observation
score NCT03926494 64 69 I-Observation
< NCT03926494 70 71 B-Eq-Comparison
8 NCT03926494 72 73 I-Eq-Comparison
) NCT03926494 74 75 O
due NCT03926494 76 79 O
to NCT03926494 80 82 O
carbon NCT03926494 83 89 B-Condition
monoxide NCT03926494 90 98 I-Condition
poisoning NCT03926494 99 108 I-Condition
, NCT03926494 109 110 O
treated NCT03926494 111 118 O
by NCT03926494 119 121 O
hyperbaric NCT03926494 122 132 B-Procedure
oxygen NCT03926494 133 139 I-Procedure
therapy NCT03926494 140 147 I-Procedure
in NCT03926494 148 150 O
a NCT03926494 151 152 O
tertiary NCT03926494 153 161 O
hospital NCT03926494 162 170 O
in NCT03926494 171 173 O
Île NCT03926494 174 177 O
de NCT03926494 178 180 O
France NCT03926494 181 187 O
area NCT03926494 188 192 O
; NCT03926494 192 193 O

- NCT03926494 196 197 O
Aged NCT03926494 199 203 B-Age
≥ NCT03926494 204 205 B-Eq-Comparison
18 NCT03926494 206 208 I-Eq-Comparison
years NCT03926494 209 214 I-Eq-Comparison
; NCT03926494 214 215 O

- NCT03926494 218 219 O
Hospitalized NCT03926494 221 233 B-Encounter
in NCT03926494 234 236 O
hyperbaric NCT03926494 237 247 O
medicine NCT03926494 248 256 O
unity NCT03926494 257 262 O
of NCT03926494 263 265 O
Raymond NCT03926494 266 273 O
Poincaré NCT03926494 274 282 O
hospital NCT03926494 283 291 O
in NCT03926494 292 294 O
Garches NCT03926494 295 302 O
. NCT03926494 303 304 O

Exclusion NCT03926494 306 315 O
Criteria NCT03926494 316 324 O
: NCT03926494 325 326 O

- NCT03926494 330 331 O
Pregnant NCT03926494 333 341 B-Condition
woman NCT03926494 342 347 O
; NCT03926494 347 348 O

- NCT03926494 351 352 O
Patient NCT03926494 354 361 O
present NCT03926494 362 369 O
clinical NCT03926494 370 378 O
signes NCT03926494 379 385 B-Assertion___Assertion-Type-Value:possible
of NCT03926494 386 388 O
stroke NCT03926494 389 395 B-Condition
and NCT03926494 396 399 B-And
without NCT03926494 400 407 B-Negation
CO NCT03926494 408 410 B-Condition
detection NCT03926494 411 420 I-Condition
. NCT03926494 421 422 O

In NCT03926494 424 426 O
case NCT03926494 427 431 O
of NCT03926494 432 434 O
unusable NCT03926494 435 443 O
data NCT03926494 444 448 O
, NCT03926494 449 450 O
patient NCT03926494 451 458 O
will NCT03926494 459 463 O
be NCT03926494 464 466 O
excluded NCT03926494 467 475 O
from NCT03926494 476 480 O
study NCT03926494 481 486 O
. NCT03926494 486 487 O

Inclusion NCT03927638 0 9 O
Criteria NCT03927638 10 18 O
: NCT03927638 19 20 O

- NCT03927638 24 25 O
healthy NCT03927638 27 34 B-Condition
adult NCT03927638 35 40 O

Exclusion NCT03927638 41 50 O
Criteria NCT03927638 51 59 O
: NCT03927638 60 61 O

- NCT03927638 65 66 O
Have NCT03927638 68 72 O
a NCT03927638 73 74 O
history NCT03927638 75 82 B-Eq-Comparison
of NCT03927638 83 85 O
cancer NCT03927638 86 92 B-Condition
, NCT03927638 93 94 O
cardiac NCT03927638 95 102 B-Condition
issues NCT03927638 103 109 I-Condition
, NCT03927638 110 111 O
hypertension NCT03927638 112 124 B-Condition
, NCT03927638 125 126 O
pulmonary NCT03927638 127 136 B-Condition
disease NCT03927638 137 144 I-Condition
, NCT03927638 145 146 O
stroke NCT03927638 147 153 B-Condition
, NCT03927638 154 155 O
neurological NCT03927638 156 168 B-Modifier
or NCT03927638 169 171 B-Or
muscular NCT03927638 172 180 B-Modifier
dystrophy NCT03927638 181 190 B-Condition
, NCT03927638 191 192 O
uncontrolled NCT03927638 193 205 B-Modifier
diabetes NCT03927638 206 214 B-Condition
, NCT03927638 215 216 O
or NCT03927638 217 219 B-Or
any NCT03927638 220 223 O
life NCT03927638 224 228 B-Condition
threatening NCT03927638 229 240 I-Condition
chronic NCT03927638 241 248 I-Condition
conditions NCT03927638 249 259 I-Condition
. NCT03927638 260 261 O

- NCT03927638 265 266 O
Are NCT03927638 268 271 O
currently NCT03927638 272 281 B-Eq-Comparison
being NCT03927638 282 287 O
treated NCT03927638 288 295 B-Procedure
for NCT03927638 296 299 O
infectious NCT03927638 300 310 B-Condition
mononucleosis NCT03927638 311 324 I-Condition
, NCT03927638 325 326 O
hepatitis NCT03927638 327 336 B-Condition
, NCT03927638 337 338 O
pneumonia NCT03927638 339 348 B-Condition
, NCT03927638 349 350 O
or NCT03927638 351 353 B-Or
other NCT03927638 354 359 O
infectious NCT03927638 360 370 B-Condition
diseases NCT03927638 371 379 I-Condition
. NCT03927638 380 381 O

- NCT03927638 385 386 O
Are NCT03927638 388 391 O
unable NCT03927638 392 398 B-Negation
or NCT03927638 399 401 B-Or
unwilling NCT03927638 402 411 B-Negation
to NCT03927638 412 414 O
stand NCT03927638 415 420 B-Observation
in NCT03927638 421 423 I-Observation
one NCT03927638 424 427 I-Observation
position NCT03927638 428 436 I-Observation
continuously NCT03927638 437 449 O
for NCT03927638 450 453 O
15 NCT03927638 454 456 B-Eq-Comparison
- NCT03927638 457 458 I-Eq-Comparison
20 NCT03927638 459 461 I-Eq-Comparison
minutes NCT03927638 462 469 I-Eq-Comparison
at NCT03927638 470 472 O
a NCT03927638 473 474 O
time NCT03927638 475 479 O
. NCT03927638 480 481 O

- NCT03927638 485 486 O
Use NCT03927638 488 491 B-Eq-Comparison
nicotine NCT03927638 492 500 B-Drug
products NCT03927638 501 509 I-Drug
, NCT03927638 510 511 O
or NCT03927638 512 514 B-Or
non NCT03927638 515 518 B-Procedure
- NCT03927638 519 520 I-Procedure
contraceptive NCT03927638 521 534 I-Procedure
hormonal NCT03927638 535 543 I-Procedure
therapy NCT03927638 544 551 I-Procedure
( NCT03927638 552 553 O
birth NCT03927638 554 559 B-Procedure
control NCT03927638 560 567 I-Procedure
is NCT03927638 568 570 O
okay NCT03927638 571 575 B-Exception
) NCT03927638 576 577 O
. NCT03927638 579 580 O

- NCT03927638 584 585 O
Are NCT03927638 587 590 O
pregnant NCT03927638 591 599 B-Condition
or NCT03927638 600 602 B-Or
trying NCT03927638 603 609 B-Assertion___Assertion-Type-Value:intention
to NCT03927638 610 612 I-Assertion___Assertion-Type-Value:intention
become NCT03927638 613 619 O
pregnant NCT03927638 620 628 B-Condition
. NCT03927638 629 630 O

- NCT03927638 634 635 O
Are NCT03927638 637 640 O
not NCT03927638 641 644 B-Negation
between NCT03927638 645 652 B-Eq-Comparison
18 NCT03927638 653 655 I-Eq-Comparison
and NCT03927638 656 659 I-Eq-Comparison
50 NCT03927638 660 662 I-Eq-Comparison
years NCT03927638 663 668 I-Eq-Comparison
of NCT03927638 669 671 O
age NCT03927638 672 675 B-Age
. NCT03927638 675 676 O

Inclusion NCT03929198 0 9 O
Criteria NCT03929198 10 18 O
: NCT03929198 19 20 O

- NCT03929198 24 25 O
Dysfunctional NCT03929198 27 40 B-Condition
lipids NCT03929198 41 47 I-Condition
, NCT03929198 48 49 O
blood NCT03929198 50 55 B-Observation
pressure NCT03929198 56 64 I-Observation
and NCT03929198 65 68 B-And
glycemic NCT03929198 69 77 B-Condition
control NCT03929198 78 85 I-Condition
determined NCT03929198 86 96 O
at NCT03929198 97 99 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03929198 100 101 O
screening NCT03929198 102 111 B-Study
visit NCT03929198 112 117 O
: NCT03929198 118 119 O

- NCT03929198 128 129 O
Triglycerides NCT03929198 131 144 B-Observation
> NCT03929198 145 146 B-Eq-Comparison
150 NCT03929198 147 150 I-Eq-Comparison
mg NCT03929198 151 153 I-Eq-Comparison
/ NCT03929198 154 155 I-Eq-Comparison
dL NCT03929198 156 158 I-Eq-Comparison
OR NCT03929198 159 161 B-Or
HDL NCT03929198 162 165 B-Observation
< NCT03929198 166 167 B-Eq-Comparison
50 NCT03929198 168 170 I-Eq-Comparison
in NCT03929198 171 173 O
females NCT03929198 174 181 O
, NCT03929198 182 183 O
< NCT03929198 184 185 B-Eq-Comparison
40 NCT03929198 186 188 I-Eq-Comparison
mg NCT03929198 189 191 I-Eq-Comparison
/ NCT03929198 192 193 I-Eq-Comparison
dL NCT03929198 194 196 I-Eq-Comparison
in NCT03929198 197 199 O
males NCT03929198 200 205 O

- NCT03929198 213 214 O
Systolic NCT03929198 216 224 B-Observation
blood NCT03929198 225 230 I-Observation
pressure NCT03929198 231 239 I-Observation
≥ NCT03929198 240 241 B-Eq-Comparison
130 NCT03929198 242 245 I-Eq-Comparison
mmHg NCT03929198 246 250 I-Eq-Comparison
OR NCT03929198 251 253 B-Or
diastolic NCT03929198 254 263 B-Observation
blood NCT03929198 264 269 I-Observation
pressure NCT03929198 270 278 I-Observation
≥ NCT03929198 279 280 B-Eq-Comparison
80 NCT03929198 281 283 I-Eq-Comparison
mmHg NCT03929198 284 288 I-Eq-Comparison
( NCT03929198 289 290 O
or NCT03929198 291 293 B-Or
on NCT03929198 294 296 B-Eq-Comparison
hypertension NCT03929198 297 309 B-Condition
medication NCT03929198 310 320 B-Drug
) NCT03929198 321 322 O

- NCT03929198 331 332 O
HbA1c NCT03929198 334 339 B-Observation
≥ NCT03929198 340 341 B-Eq-Comparison
5.7 NCT03929198 342 345 I-Eq-Comparison
% NCT03929198 346 347 I-Eq-Comparison
or NCT03929198 348 350 I-Eq-Comparison
higher NCT03929198 351 357 I-Eq-Comparison

- NCT03929198 360 361 O
No NCT03929198 363 365 B-Negation
diagnosis NCT03929198 366 375 O
or NCT03929198 376 378 O
treatment NCT03929198 379 388 B-Procedure
for NCT03929198 389 392 O
cancer NCT03929198 393 399 B-Condition
in NCT03929198 400 402 O
the NCT03929198 403 406 O
past NCT03929198 407 411 B-Eq-Comparison
year NCT03929198 412 416 I-Eq-Comparison

- NCT03929198 419 420 O
No NCT03929198 422 424 B-Negation
diagnosis NCT03929198 425 434 O
of NCT03929198 435 437 O
mild NCT03929198 438 442 B-Condition
cognitive NCT03929198 443 452 I-Condition
impairment NCT03929198 453 463 I-Condition
or NCT03929198 464 466 B-Or
dementia NCT03929198 467 475 B-Condition
in NCT03929198 476 478 O
the NCT03929198 479 482 O
past NCT03929198 483 487 B-Eq-Comparison
year NCT03929198 488 492 I-Eq-Comparison

- NCT03929198 495 496 O
Ability NCT03929198 498 505 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929198 506 508 I-Assertion___Assertion-Type-Value:hypothetical
perform NCT03929198 509 516 O
daily NCT03929198 517 522 B-Eq-Comparison
exercise NCT03929198 523 531 B-Observation
, NCT03929198 532 533 O
including NCT03929198 534 543 O
aerobic NCT03929198 544 551 B-Observation
activity NCT03929198 552 560 I-Observation
and NCT03929198 561 564 O
resistance NCT03929198 565 575 B-Observation
exercise NCT03929198 576 584 I-Observation

- NCT03929198 587 588 O
Non NCT03929198 590 593 B-Negation
- NCT03929198 594 595 O
smoker NCT03929198 596 602 B-Condition
in NCT03929198 603 605 O
the NCT03929198 606 609 O
past NCT03929198 610 614 B-Eq-Comparison
year NCT03929198 615 619 I-Eq-Comparison

Exclusion NCT03929198 620 629 O
Criteria NCT03929198 630 638 O
: NCT03929198 639 640 O

- NCT03929198 644 645 O
Positive NCT03929198 647 655 O
exercise NCT03929198 656 664 B-Observation
stress NCT03929198 665 671 I-Observation
test NCT03929198 672 676 I-Observation

Inclusion NCT03922230 0 9 O
Criteria NCT03922230 10 18 O
: NCT03922230 19 20 O

1 NCT03922230 24 25 O
. NCT03922230 25 26 O
Diagnosis NCT03922230 28 37 O
of NCT03922230 38 40 O
esophageal NCT03922230 41 51 B-Modifier
squamous NCT03922230 52 60 B-Condition
cell NCT03922230 61 65 I-Condition
carcinoma NCT03922230 66 75 I-Condition
by NCT03922230 76 78 O
pathological NCT03922230 79 91 B-Procedure
cytology NCT03922230 92 100 I-Procedure
and NCT03922230 101 104 B-And
histology NCT03922230 105 114 B-Procedure
. NCT03922230 115 116 O

2 NCT03922230 120 121 O
. NCT03922230 121 122 O
Clinically NCT03922230 124 134 O
judged NCT03922230 135 141 O
patients NCT03922230 142 150 O
with NCT03922230 151 155 O
p0 NCT03922230 156 158 B-Modifier
~ NCT03922230 159 160 B-Or
pIV NCT03922230 161 164 B-Modifier
initial NCT03922230 165 172 B-Eq-Comparison
treatment NCT03922230 173 182 B-Procedure
. NCT03922230 182 183 O
（ NCT03922230 184 185 O
1 NCT03922230 186 187 O
Variable NCT03922230 188 196 O
risk NCT03922230 197 201 B-Risk
factors NCT03922230 202 209 O
are NCT03922230 210 213 O
overeating NCT03922230 214 224 B-Condition
food NCT03922230 225 229 O
( NCT03922230 230 231 O
habits NCT03922230 232 238 O
) NCT03922230 239 240 O
and NCT03922230 241 244 O
family NCT03922230 245 251 B-Family-Member
history NCT03922230 252 259 I-Family-Member
. NCT03922230 259 260 O
2 NCT03922230 262 263 O
Among NCT03922230 264 269 O
all NCT03922230 270 273 O
the NCT03922230 274 277 O
patients NCT03922230 278 286 O
, NCT03922230 287 288 O
the NCT03922230 289 292 O
ratio NCT03922230 293 298 O
of NCT03922230 299 301 O
male NCT03922230 302 306 O
to NCT03922230 307 309 O
female NCT03922230 310 316 O
is NCT03922230 317 319 O
3 NCT03922230 320 321 O
: NCT03922230 322 323 O
1 NCT03922230 324 325 O
, NCT03922230 326 327 O
and NCT03922230 328 331 O
the NCT03922230 332 335 O
age NCT03922230 336 339 B-Age
is NCT03922230 340 342 O
between NCT03922230 343 350 B-Eq-Comparison
50 NCT03922230 351 353 I-Eq-Comparison
and NCT03922230 354 357 I-Eq-Comparison
70 NCT03922230 358 360 I-Eq-Comparison
years NCT03922230 361 366 I-Eq-Comparison
old NCT03922230 367 370 O
. NCT03922230 370 371 O
In NCT03922230 373 375 O
addition NCT03922230 376 384 O
to NCT03922230 385 387 O
eating NCT03922230 388 394 O
too NCT03922230 395 398 O
hot NCT03922230 399 402 O
food NCT03922230 403 407 O
, NCT03922230 408 409 O
other NCT03922230 410 415 O
eating NCT03922230 416 422 O
habits NCT03922230 423 429 O
( NCT03922230 430 431 O
such NCT03922230 432 436 O
as NCT03922230 437 439 O
eating NCT03922230 440 446 O
fresh NCT03922230 447 452 O
fruits NCT03922230 453 459 O
and NCT03922230 460 463 O
vegetables NCT03922230 464 474 O
, NCT03922230 475 476 O
eating NCT03922230 477 483 O
preserved NCT03922230 484 493 O
food NCT03922230 494 498 O
, NCT03922230 499 500 O
etc NCT03922230 501 504 O
. NCT03922230 504 505 O
) NCT03922230 506 507 O
are NCT03922230 508 511 O
consistent NCT03922230 512 522 O
, NCT03922230 523 524 O
other NCT03922230 525 530 O
factors NCT03922230 531 538 B-Condition
( NCT03922230 539 540 O
such NCT03922230 541 545 O
as NCT03922230 546 548 O
BMI NCT03922230 549 552 B-Observation
, NCT03922230 553 554 O
smoking NCT03922230 555 562 B-Condition
, NCT03922230 563 564 O
drinking NCT03922230 565 573 B-Condition
, NCT03922230 574 575 O
etc NCT03922230 576 579 O
. NCT03922230 579 580 O
) NCT03922230 581 582 O
as NCT03922230 583 585 O
much NCT03922230 586 590 O
as NCT03922230 591 593 O
possible NCT03922230 594 602 O
. NCT03922230 602 603 O
3 NCT03922230 605 606 O
In NCT03922230 607 609 O
order NCT03922230 610 615 O
to NCT03922230 616 618 O
rule NCT03922230 619 623 O
out NCT03922230 624 627 O
the NCT03922230 628 631 O
interference NCT03922230 632 644 O
of NCT03922230 645 647 O
other NCT03922230 648 653 O
diseases NCT03922230 654 662 O
, NCT03922230 663 664 O
each NCT03922230 665 669 O
sample NCT03922230 670 676 O
needs NCT03922230 677 682 O
to NCT03922230 683 685 O
be NCT03922230 686 688 O
determined NCT03922230 689 699 O
to NCT03922230 700 702 O
have NCT03922230 703 707 O
no NCT03922230 708 710 B-Negation
history NCT03922230 711 718 B-Eq-Comparison
of NCT03922230 719 721 O
other NCT03922230 722 727 O
diseases NCT03922230 728 736 B-Condition
( NCT03922230 737 738 O
such NCT03922230 739 743 O
as NCT03922230 744 746 O
neurodegenerative NCT03922230 747 764 B-Condition
diseases NCT03922230 765 773 I-Condition
, NCT03922230 774 775 O
leukemia NCT03922230 776 784 B-Condition
) NCT03922230 785 786 O
. NCT03922230 787 788 O
） NCT03922230 789 790 O

3 NCT03922230 793 794 O
. NCT03922230 794 795 O
The NCT03922230 797 800 O
normal NCT03922230 801 807 O
population NCT03922230 808 818 O
comes NCT03922230 819 824 O
from NCT03922230 825 829 O
the NCT03922230 830 833 O
healthy NCT03922230 834 841 O
population NCT03922230 842 852 O
of NCT03922230 853 855 O
Nanfang NCT03922230 856 863 O
Hospital NCT03922230 864 872 O
Health NCT03922230 873 879 O
Center NCT03922230 880 886 O
of NCT03922230 887 889 O
Southern NCT03922230 890 898 O
Medical NCT03922230 899 906 O
University NCT03922230 907 917 O
. NCT03922230 918 919 O

Exclusion NCT03922230 921 930 O
Criteria NCT03922230 931 939 O
: NCT03922230 940 941 O

1 NCT03922230 945 946 O
. NCT03922230 946 947 O
Pre NCT03922230 949 952 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03922230 953 962 B-Procedure
patients NCT03922230 963 971 O
have NCT03922230 972 976 O
received NCT03922230 977 985 B-Eq-Comparison
relevant NCT03922230 986 994 O
treatment NCT03922230 995 1004 B-Procedure
, NCT03922230 1005 1006 O
such NCT03922230 1007 1011 O
as NCT03922230 1012 1014 O
radiotherapy NCT03922230 1015 1027 B-Procedure
and NCT03922230 1028 1031 O
chemotherapy NCT03922230 1032 1044 B-Procedure
; NCT03922230 1044 1045 O

2 NCT03922230 1048 1049 O
. NCT03922230 1049 1050 O
The NCT03922230 1052 1055 O
subject NCT03922230 1056 1063 O
has NCT03922230 1064 1067 O
other NCT03922230 1068 1073 O
diseases NCT03922230 1074 1082 B-Condition
, NCT03922230 1083 1084 O
such NCT03922230 1085 1089 O
as NCT03922230 1090 1092 O
tumors NCT03922230 1093 1099 B-Condition
in NCT03922230 1100 1102 O
other NCT03922230 1103 1108 O
parts NCT03922230 1109 1114 O
; NCT03922230 1114 1115 O

3 NCT03922230 1118 1119 O
. NCT03922230 1119 1120 O
Patients NCT03922230 1122 1130 O
do NCT03922230 1131 1133 O
not NCT03922230 1134 1137 O
meet NCT03922230 1138 1142 O
the NCT03922230 1143 1146 O
age NCT03922230 1147 1150 O
; NCT03922230 1150 1151 O

4 NCT03922230 1154 1155 O
. NCT03922230 1155 1156 O
There NCT03922230 1158 1163 O
is NCT03922230 1164 1166 O
no NCT03922230 1167 1169 B-Negation
guarantee NCT03922230 1170 1179 O
that NCT03922230 1180 1184 O
other NCT03922230 1185 1190 O
eating NCT03922230 1191 1197 O
habits NCT03922230 1198 1204 O
( NCT03922230 1205 1206 O
such NCT03922230 1207 1211 O
as NCT03922230 1212 1214 O
eating NCT03922230 1215 1221 O
fresh NCT03922230 1222 1227 O
fruits NCT03922230 1228 1234 O
and NCT03922230 1235 1238 O
vegetables NCT03922230 1239 1249 O
, NCT03922230 1250 1251 O
not NCT03922230 1252 1255 O
eating NCT03922230 1256 1262 O
preserved NCT03922230 1263 1272 O
foods NCT03922230 1273 1278 O
) NCT03922230 1279 1280 O
and NCT03922230 1281 1284 O
other NCT03922230 1285 1290 O
factors NCT03922230 1291 1298 B-Condition
( NCT03922230 1299 1300 O
such NCT03922230 1301 1305 O
as NCT03922230 1306 1308 O
BMI NCT03922230 1309 1312 B-Observation
, NCT03922230 1313 1314 O
smoking NCT03922230 1315 1322 B-Condition
, NCT03922230 1323 1324 O
drinking NCT03922230 1325 1333 B-Condition
, NCT03922230 1334 1335 O
etc NCT03922230 1336 1339 O
. NCT03922230 1339 1340 O
) NCT03922230 1341 1342 O
are NCT03922230 1343 1346 O
basically NCT03922230 1347 1356 O
the NCT03922230 1357 1360 O
same NCT03922230 1361 1365 O
. NCT03922230 1365 1366 O

Inclusion NCT03922542 0 9 O
Criteria NCT03922542 10 18 O
: NCT03922542 19 20 O

- NCT03922542 24 25 O
Documented NCT03922542 27 37 O
keratoconus NCT03922542 38 49 B-Condition
or NCT03922542 50 52 B-Or
ectasia NCT03922542 53 60 B-Condition
after NCT03922542 61 66 B-Temporal-Connection___Temporal-Connection-Type-Value:after
refractive NCT03922542 67 77 B-Procedure
surgery NCT03922542 78 85 I-Procedure

Exclusion NCT03922542 86 95 O
Criteria NCT03922542 96 104 O
: NCT03922542 105 106 O

- NCT03922542 110 111 O
Insufficient NCT03922542 113 125 B-Condition
corneal NCT03922542 126 133 I-Condition
thickness NCT03922542 134 143 I-Condition

- NCT03922542 146 147 O
Ocular NCT03922542 149 155 B-Condition
condition NCT03922542 156 165 I-Condition
that NCT03922542 166 170 O
may NCT03922542 171 174 B-Assertion___Assertion-Type-Value:possible
predispose NCT03922542 175 185 B-Risk
the NCT03922542 186 189 O
eye NCT03922542 190 193 B-Condition
to NCT03922542 194 196 I-Condition
complications NCT03922542 197 210 I-Condition

- NCT03922542 213 214 O
History NCT03922542 216 223 B-Eq-Comparison
of NCT03922542 224 226 O
chemical NCT03922542 227 235 B-Condition
injury NCT03922542 236 242 I-Condition
or NCT03922542 243 245 B-Or
delayed NCT03922542 246 253 B-Condition
epithelial NCT03922542 254 264 I-Condition
healing NCT03922542 265 272 I-Condition

- NCT03922542 275 276 O
Condition NCT03922542 278 287 B-Condition
that NCT03922542 288 292 O
would NCT03922542 293 298 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03922542 299 308 O
with NCT03922542 309 313 O
or NCT03922542 314 316 B-Or
prolong NCT03922542 317 324 O
epithelial NCT03922542 325 335 B-Condition
healing NCT03922542 336 343 I-Condition

- NCT03922542 346 347 O
Known NCT03922542 349 354 O
sensitivity NCT03922542 355 366 B-Condition
to NCT03922542 367 369 O
treatment NCT03922542 370 379 B-Procedure
medications NCT03922542 380 391 B-Drug

- NCT03922542 394 395 O
Pregnancy NCT03922542 397 406 B-Condition

Inclusion NCT03923660 0 9 O
Criteria NCT03923660 10 18 O
: NCT03923660 19 20 O

- NCT03923660 24 25 O
Severe NCT03923660 27 33 O
COPD NCT03923660 34 38 B-Condition
( NCT03923660 39 40 O
FEV1 NCT03923660 41 45 B-Observation
[ NCT03923660 46 47 O
forced NCT03923660 48 54 B-Observation
expiratory NCT03923660 55 65 I-Observation
volume NCT03923660 66 72 I-Observation
in NCT03923660 73 75 I-Observation
1 NCT03923660 76 77 I-Observation
second NCT03923660 78 84 I-Observation
] NCT03923660 85 86 O
/ NCT03923660 87 88 B-Or
FVC NCT03923660 89 92 B-Observation
[ NCT03923660 93 94 O
forced NCT03923660 95 101 B-Observation
vital NCT03923660 102 107 I-Observation
capacity NCT03923660 108 116 I-Observation
] NCT03923660 117 118 O
< NCT03923660 119 120 B-Eq-Comparison
70 NCT03923660 121 123 I-Eq-Comparison
% NCT03923660 124 125 I-Eq-Comparison
et NCT03923660 126 128 O
FEV1 NCT03923660 129 133 B-Observation
< NCT03923660 134 135 B-Eq-Comparison
50 NCT03923660 136 138 I-Eq-Comparison
% NCT03923660 139 140 I-Eq-Comparison
) NCT03923660 142 143 O

- NCT03923660 147 148 O
Informed NCT03923660 150 158 O
consent NCT03923660 159 166 O

- NCT03923660 169 170 O
Affiliation NCT03923660 172 183 O
to NCT03923660 184 186 O
a NCT03923660 187 188 O
social NCT03923660 189 195 O
security NCT03923660 196 204 O
scheme NCT03923660 205 211 O

Exclusion NCT03923660 212 221 O
Criteria NCT03923660 222 230 O
: NCT03923660 231 232 O

- NCT03923660 236 237 O
Effort NCT03923660 239 245 B-Procedure
oxygen NCT03923660 246 252 I-Procedure
therapy NCT03923660 253 260 I-Procedure

- NCT03923660 263 264 O
Cardiovascular NCT03923660 266 280 B-Modifier
, NCT03923660 281 282 O
neuromuscular NCT03923660 283 296 B-Modifier
or NCT03923660 297 299 B-Or
musculoskeletal NCT03923660 300 315 B-Modifier
disorders NCT03923660 316 325 B-Condition
that NCT03923660 326 330 O
can NCT03923660 331 334 O
provide NCT03923660 335 342 O
significant NCT03923660 343 354 O
dyspnea NCT03923660 355 362 B-Condition
or NCT03923660 363 365 B-Or
limit NCT03923660 366 371 O
exercise NCT03923660 372 380 B-Observation

- NCT03923660 383 384 O
Legal NCT03923660 386 391 B-Condition
incapacity NCT03923660 392 402 I-Condition

- NCT03923660 405 406 O
Low NCT03923660 408 411 O
or NCT03923660 412 414 B-Or
no NCT03923660 415 417 B-Negation
cooperation NCT03923660 418 429 B-Observation
anticipated NCT03923660 430 441 B-Assertion___Assertion-Type-Value:hypothetical

Inclusion NCT03928912 0 9 O
Criteria NCT03928912 10 18 O
: NCT03928912 19 20 O

- NCT03928912 24 25 O
The NCT03928912 27 30 O
tibial NCT03928912 31 37 B-Modifier
shaft NCT03928912 38 43 I-Modifier
fracture NCT03928912 44 52 B-Condition
was NCT03928912 53 56 O
caused NCT03928912 57 63 O
by NCT03928912 64 66 O
trauma NCT03928912 67 73 B-Condition
. NCT03928912 74 75 O

Exclusion NCT03928912 77 86 O
Criteria NCT03928912 87 95 O
: NCT03928912 96 97 O

- NCT03928912 101 102 O
The NCT03928912 104 107 O
tibial NCT03928912 108 114 B-Modifier
shaft NCT03928912 115 120 I-Modifier
fracture NCT03928912 121 129 B-Condition
was NCT03928912 130 133 O
caused NCT03928912 134 140 O
by NCT03928912 141 143 O
tumor NCT03928912 144 149 B-Condition
, NCT03928912 150 151 O
infection NCT03928912 152 161 B-Condition
and NCT03928912 162 165 O
other NCT03928912 166 171 O
reasons NCT03928912 172 179 O
. NCT03928912 179 180 O

Inclusion NCT03922581 0 9 O
Criteria NCT03922581 10 18 O
: NCT03922581 19 20 O

- NCT03922581 24 25 O
ability NCT03922581 27 34 O
to NCT03922581 35 37 O
provide NCT03922581 38 45 O
informed NCT03922581 46 54 O
consent NCT03922581 55 62 O

- NCT03922581 65 66 O
willingness NCT03922581 68 79 O
to NCT03922581 80 82 O
participate NCT03922581 83 94 O
in NCT03922581 95 97 O
study NCT03922581 98 103 O

- NCT03922581 106 107 O
self NCT03922581 109 113 O
- NCT03922581 114 115 O
identity NCT03922581 116 124 O
as NCT03922581 125 127 O
African NCT03922581 128 135 O
American NCT03922581 136 144 O

- NCT03922581 147 148 O
history NCT03922581 150 157 B-Eq-Comparison
of NCT03922581 158 160 O
childhood NCT03922581 161 170 O
and NCT03922581 171 174 B-Or
/ NCT03922581 175 176 I-Or
or NCT03922581 177 179 I-Or
adult NCT03922581 180 185 O
trauma NCT03922581 186 192 B-Condition
exposure NCT03922581 193 201 I-Condition
( NCT03922581 202 203 O
3 NCT03922581 204 205 B-Eq-Comparison
total NCT03922581 206 211 I-Eq-Comparison
criterion NCT03922581 212 221 I-Eq-Comparison
A NCT03922581 222 223 I-Eq-Comparison
traumas NCT03922581 224 231 I-Eq-Comparison
) NCT03922581 232 233 O

- NCT03922581 237 238 O
positive NCT03922581 240 248 O
PTSD NCT03922581 249 253 B-Condition
screen NCT03922581 254 260 O
( NCT03922581 261 262 O
PC NCT03922581 263 265 B-Observation
- NCT03922581 266 267 I-Observation
PTSD NCT03922581 268 272 I-Observation
≥ NCT03922581 273 274 B-Eq-Comparison
3 NCT03922581 275 276 I-Eq-Comparison
) NCT03922581 277 278 O

- NCT03922581 282 283 O
positive NCT03922581 285 293 O
MDD NCT03922581 294 297 B-Condition
screen NCT03922581 298 304 O
( NCT03922581 305 306 O
PHQ NCT03922581 307 310 B-Observation
- NCT03922581 311 312 I-Observation
9 NCT03922581 313 314 I-Observation
≥ NCT03922581 315 316 B-Eq-Comparison
5 NCT03922581 317 318 I-Eq-Comparison
) NCT03922581 319 320 O

Exclusion NCT03922581 322 331 O
Criteria NCT03922581 332 340 O
: NCT03922581 341 342 O

- NCT03922581 346 347 O
presence NCT03922581 349 357 O
of NCT03922581 358 360 O
intellectual NCT03922581 361 373 B-Condition
disability NCT03922581 374 384 I-Condition
, NCT03922581 385 386 O
bipolar NCT03922581 387 394 B-Condition
, NCT03922581 395 396 O
or NCT03922581 397 399 B-Or
psychotic NCT03922581 400 409 B-Condition
disorder NCT03922581 410 418 I-Condition

- NCT03922581 421 422 O
presence NCT03922581 424 432 O
of NCT03922581 433 435 O
current NCT03922581 436 443 B-Eq-Comparison
substance NCT03922581 444 453 B-Condition
use NCT03922581 454 457 I-Condition
disorder NCT03922581 458 466 I-Condition
( NCT03922581 467 468 O
past NCT03922581 469 473 B-Eq-Comparison
1 NCT03922581 474 475 I-Eq-Comparison
month NCT03922581 476 481 I-Eq-Comparison
; NCT03922581 481 482 O
see NCT03922581 483 486 O
cut NCT03922581 487 490 O
off NCT03922581 491 494 O
scores NCT03922581 495 501 O
in NCT03922581 502 504 O
psychological NCT03922581 505 518 O
measures NCT03922581 519 527 O
below NCT03922581 528 533 O
) NCT03922581 534 535 O

- NCT03922581 539 540 O
active NCT03922581 542 548 B-Eq-Comparison
suicidality NCT03922581 549 560 B-Condition

Inclusion NCT03920553 0 9 O
Criteria NCT03920553 10 18 O
: NCT03920553 19 20 O

- NCT03920553 24 25 O
No NCT03920553 27 29 B-Negation
systemic NCT03920553 30 38 B-Modifier
disease NCT03920553 39 46 B-Condition
, NCT03920553 47 48 O

- NCT03920553 52 53 O
the NCT03920553 55 58 O
presence NCT03920553 59 67 O
of NCT03920553 68 70 O
high NCT03920553 71 75 B-Condition
labial NCT03920553 76 82 I-Condition
frenulum NCT03920553 83 91 I-Condition
attachment NCT03920553 92 102 I-Condition
diagnosed NCT03920553 103 112 O
according NCT03920553 113 122 O
to NCT03920553 123 125 O
Mirko NCT03920553 126 131 O
et NCT03920553 132 134 O
al NCT03920553 135 137 O
. NCT03920553 137 138 O
, NCT03920553 139 140 O
- NCT03920553 141 142 O
periodontally NCT03920553 143 156 B-Observation
healthy NCT03920553 157 164 I-Observation
or NCT03920553 165 167 B-Or
a NCT03920553 168 169 O
requirement NCT03920553 170 181 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920553 182 185 I-Assertion___Assertion-Type-Value:hypothetical
periodontal NCT03920553 186 197 B-Procedure
treatment NCT03920553 198 207 I-Procedure
that NCT03920553 208 212 O
would NCT03920553 213 218 B-Assertion___Assertion-Type-Value:hypothetical
only NCT03920553 219 223 O
require NCT03920553 224 231 O
removing NCT03920553 232 240 B-Procedure
of NCT03920553 241 243 I-Procedure
dental NCT03920553 244 250 I-Procedure
plaque NCT03920553 251 257 I-Procedure
, NCT03920553 258 259 O

- NCT03920553 263 264 O
full NCT03920553 266 270 B-Observation
mouth NCT03920553 271 276 I-Observation
plaque NCT03920553 277 283 I-Observation
score NCT03920553 284 289 I-Observation
< NCT03920553 290 291 B-Eq-Comparison
15 NCT03920553 292 294 I-Eq-Comparison
% NCT03920553 295 296 I-Eq-Comparison
, NCT03920553 298 299 O
probing NCT03920553 300 307 B-Observation
pocket NCT03920553 308 314 I-Observation
depth NCT03920553 315 320 I-Observation
< NCT03920553 321 322 B-Eq-Comparison
3 NCT03920553 323 324 I-Eq-Comparison
mm NCT03920553 325 327 I-Eq-Comparison
in NCT03920553 328 330 O
all NCT03920553 331 334 O
teeth NCT03920553 335 340 O

- NCT03920553 343 344 O
no NCT03920553 346 348 B-Negation
history NCT03920553 349 356 B-Eq-Comparison
of NCT03920553 357 359 O
periodontal NCT03920553 360 371 B-Procedure
surgery NCT03920553 372 379 I-Procedure
. NCT03920553 380 381 O

Exclusion NCT03920553 383 392 O
Criteria NCT03920553 393 401 O
: NCT03920553 402 403 O

- NCT03920553 407 408 O
not NCT03920553 410 413 B-Negation
meet NCT03920553 414 418 O
the NCT03920553 419 422 O
optimal NCT03920553 423 430 O
level NCT03920553 431 436 O
of NCT03920553 437 439 O
oral NCT03920553 440 444 B-Observation
hygiene NCT03920553 445 452 I-Observation
, NCT03920553 453 454 O

- NCT03920553 458 459 O
had NCT03920553 461 464 O
any NCT03920553 465 468 O
condition NCT03920553 469 478 B-Condition
that NCT03920553 479 483 O
could NCT03920553 484 489 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920553 490 496 O
wound NCT03920553 497 502 B-Condition
healing NCT03920553 503 510 I-Condition
, NCT03920553 511 512 O

- NCT03920553 516 517 O
were NCT03920553 519 523 B-Eq-Comparison
pregnant NCT03920553 524 532 B-Condition
or NCT03920553 533 535 B-Or
lactating NCT03920553 536 545 B-Condition
, NCT03920553 546 547 O

- NCT03920553 551 552 O
were NCT03920553 554 558 B-Eq-Comparison
cigarette NCT03920553 559 568 B-Condition
smokers NCT03920553 569 576 I-Condition
or NCT03920553 577 579 B-Or
were NCT03920553 580 584 B-Eq-Comparison
takiing NCT03920553 585 592 I-Eq-Comparison
any NCT03920553 593 596 O
medication NCT03920553 597 607 B-Drug
that NCT03920553 608 612 O
might NCT03920553 613 618 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920553 619 625 O
the NCT03920553 626 629 O
outcome NCT03920553 630 637 O
of NCT03920553 638 640 O
the NCT03920553 641 644 O
study NCT03920553 645 650 B-Study
, NCT03920553 651 652 O

Inclusion NCT03926650 0 9 O
Criteria NCT03926650 10 18 O
: NCT03926650 19 20 O

- NCT03926650 24 25 O
surgery NCT03926650 27 34 B-Procedure
continues NCT03926650 35 44 O
more NCT03926650 45 49 B-Eq-Comparison
then NCT03926650 50 54 I-Eq-Comparison
1 NCT03926650 55 56 I-Eq-Comparison
hour NCT03926650 57 61 I-Eq-Comparison

- NCT03926650 64 65 O
between NCT03926650 67 74 B-Eq-Comparison
ages NCT03926650 75 79 I-Age|Eq-Comparison
18 NCT03926650 80 82 I-Eq-Comparison
- NCT03926650 83 84 I-Eq-Comparison
65 NCT03926650 85 87 I-Eq-Comparison

- NCT03926650 91 92 O
ASA NCT03926650 94 97 B-Condition
I NCT03926650 98 99 B-Eq-Comparison
, NCT03926650 100 101 I-Eq-Comparison
II NCT03926650 102 104 I-Eq-Comparison
and NCT03926650 105 108 I-Eq-Comparison
III NCT03926650 109 112 I-Eq-Comparison
patients NCT03926650 113 121 O

Exclusion NCT03926650 122 131 O
Criteria NCT03926650 132 140 O
: NCT03926650 141 142 O

- NCT03926650 146 147 O
The NCT03926650 149 152 O
patients NCT03926650 153 161 O
who NCT03926650 162 165 O
has NCT03926650 166 169 O
allergical NCT03926650 170 180 B-Allergy
reactions NCT03926650 181 190 O
of NCT03926650 191 193 O
the NCT03926650 194 197 O
drugs NCT03926650 198 203 B-Drug
used NCT03926650 204 208 O

- NCT03926650 211 212 O
neurological NCT03926650 214 226 B-Modifier
or NCT03926650 227 229 B-Or
neuromuscular NCT03926650 230 243 B-Modifier
diseases NCT03926650 244 252 B-Condition

- NCT03926650 255 256 O
the NCT03926650 258 261 O
patients NCT03926650 262 270 O
who NCT03926650 271 274 O
use NCT03926650 275 278 B-Eq-Comparison
drugs NCT03926650 279 284 B-Drug
effecting NCT03926650 285 294 O
the NCT03926650 295 298 O
neuromuscular NCT03926650 299 312 B-Condition
junction NCT03926650 313 321 I-Condition

- NCT03926650 324 325 O
pregnant NCT03926650 327 335 B-Condition
patients NCT03926650 336 344 O

- NCT03926650 347 348 O
electrolyte NCT03926650 350 361 B-Condition
disregulations NCT03926650 362 376 I-Condition

- NCT03926650 379 380 O
major NCT03926650 382 387 O
organ NCT03926650 388 393 B-Condition
failures NCT03926650 394 402 I-Condition
, NCT03926650 403 404 O
liver NCT03926650 405 410 B-Condition
failure NCT03926650 411 418 I-Condition
, NCT03926650 419 420 O
kidney NCT03926650 421 427 B-Condition
failure NCT03926650 428 435 I-Condition

- NCT03926650 438 439 O
obese NCT03926650 441 446 B-Condition
and NCT03926650 447 450 B-Or
cachectic NCT03926650 451 460 B-Condition
patients NCT03926650 461 469 O

Inclusion NCT03928899 0 9 O
Criteria NCT03928899 10 18 O
: NCT03928899 19 20 O

- NCT03928899 24 25 O
singleton NCT03928899 27 36 B-Condition
pregnant NCT03928899 37 45 I-Condition
women NCT03928899 46 51 O

- NCT03928899 54 55 O
in NCT03928899 57 59 O
vertex NCT03928899 60 66 B-Condition
presentation NCT03928899 67 79 I-Condition

- NCT03928899 82 83 O
GDM NCT03928899 85 88 B-Condition
that NCT03928899 89 93 O
is NCT03928899 94 96 O
controlled NCT03928899 97 107 O
with NCT03928899 108 112 O
only NCT03928899 113 117 O
diet NCT03928899 118 122 O
and NCT03928899 123 126 O
exercise NCT03928899 127 135 O

- NCT03928899 138 139 O
at NCT03928899 141 143 O
37 NCT03928899 144 146 B-Eq-Comparison
weeks NCT03928899 147 152 I-Eq-Comparison
0 NCT03928899 153 154 I-Eq-Comparison
days NCT03928899 155 159 I-Eq-Comparison
to NCT03928899 160 162 I-Eq-Comparison
37 NCT03928899 163 165 I-Eq-Comparison
weeks NCT03928899 166 171 I-Eq-Comparison
6 NCT03928899 172 173 I-Eq-Comparison
days NCT03928899 174 178 I-Eq-Comparison
of NCT03928899 179 181 O
gestation NCT03928899 182 191 B-Observation

- NCT03928899 194 195 O
more NCT03928899 197 201 B-Eq-Comparison
than NCT03928899 202 206 I-Eq-Comparison
18 NCT03928899 207 209 I-Eq-Comparison
years NCT03928899 210 215 I-Eq-Comparison
old NCT03928899 216 219 B-Age

- NCT03928899 222 223 O
have NCT03928899 225 229 O
no NCT03928899 230 232 B-Negation
other NCT03928899 233 238 B-Other
contraindications NCT03928899 239 256 B-Contraindication
to NCT03928899 257 259 O
vaginal NCT03928899 260 267 B-Procedure
delivery NCT03928899 268 276 I-Procedure
. NCT03928899 277 278 O

Exclusion NCT03928899 280 289 O
Criteria NCT03928899 290 298 O
: NCT03928899 299 300 O

- NCT03928899 304 305 O
prior NCT03928899 307 312 B-Eq-Comparison
caesarean NCT03928899 313 322 B-Procedure
section NCT03928899 323 330 I-Procedure
or NCT03928899 331 333 B-Or
myomectomy NCT03928899 334 344 B-Procedure

- NCT03928899 347 348 O
any NCT03928899 350 353 O
known NCT03928899 354 359 O
contraindications NCT03928899 360 377 B-Contraindication
to NCT03928899 378 380 O
vaginal NCT03928899 381 388 B-Procedure
delivery NCT03928899 389 397 I-Procedure

- NCT03928899 400 401 O
uncertain NCT03928899 403 412 B-Negation
gestational NCT03928899 413 424 B-Observation
age NCT03928899 425 428 I-Observation

- NCT03928899 431 432 O
non NCT03928899 434 437 B-Condition
reassuring NCT03928899 438 448 I-Condition
foetal NCT03928899 449 455 I-Condition
wellbeing NCT03928899 456 465 I-Condition
necessitating NCT03928899 466 479 B-Assertion___Assertion-Type-Value:hypothetical
delivery NCT03928899 480 488 B-Procedure

- NCT03928899 491 492 O
maternal NCT03928899 494 502 B-Family-Member___Family-Member-Type:mother
pregnancy NCT03928899 503 512 B-Condition
- NCT03928899 513 514 I-Condition
related NCT03928899 515 522 I-Condition
disease NCT03928899 523 530 I-Condition
necessitating NCT03928899 531 544 O
delivery NCT03928899 545 553 B-Procedure
( NCT03928899 554 555 O
any NCT03928899 556 559 O
hypertensive NCT03928899 560 572 B-Condition
disorder NCT03928899 573 581 I-Condition
, NCT03928899 582 583 O
cardiac NCT03928899 584 591 B-Condition
disease NCT03928899 592 599 I-Condition
, NCT03928899 600 601 O
renal NCT03928899 602 607 B-Condition
insufficiency NCT03928899 608 621 I-Condition
、 NCT03928899 622 623 O
immune NCT03928899 624 630 B-Condition
diseases NCT03928899 631 639 I-Condition
, NCT03928899 640 641 O
et NCT03928899 642 644 O
al NCT03928899 645 647 O
. NCT03928899 647 648 O
) NCT03928899 649 650 O

- NCT03928899 654 655 O
placenta NCT03928899 657 665 B-Condition
previa NCT03928899 666 672 B-Modifier
, NCT03928899 673 674 O
accreta NCT03928899 675 682 B-Modifier
, NCT03928899 683 684 O
vasa NCT03928899 685 689 B-Modifier
previa NCT03928899 690 696 I-Modifier

- NCT03928899 699 700 O
known NCT03928899 702 707 O
foetal NCT03928899 708 714 B-Condition
anomaly NCT03928899 715 722 I-Condition

- NCT03928899 725 726 O
negative NCT03928899 728 736 B-Negation
reproductive NCT03928899 737 749 B-Condition
history NCT03928899 750 757 I-Condition

- NCT03928899 760 761 O
ruptured NCT03928899 763 771 B-Condition
membranes NCT03928899 772 781 I-Condition
or NCT03928899 782 784 B-Or
known NCT03928899 785 790 O
oligohydramnios NCT03928899 791 806 B-Condition
( NCT03928899 807 808 O
defined NCT03928899 809 816 O
as NCT03928899 817 819 O
AFI NCT03928899 820 823 B-Observation
< NCT03928899 824 825 B-Eq-Comparison
5 NCT03928899 826 827 I-Eq-Comparison
or NCT03928899 828 830 B-Or
MVP NCT03928899 831 834 B-Observation
< NCT03928899 835 836 B-Eq-Comparison
2 NCT03928899 837 838 I-Eq-Comparison
) NCT03928899 839 840 O
before NCT03928899 841 847 B-Temporal-Connection___Temporal-Connection-Type-Value:before

37 NCT03928899 853 855 B-Eq-Comparison
weeks NCT03928899 856 861 I-Eq-Comparison
6 NCT03928899 862 863 I-Eq-Comparison
days NCT03928899 864 868 I-Eq-Comparison
of NCT03928899 869 871 O
gestation NCT03928899 872 881 B-Observation

- NCT03928899 884 885 O
fetal NCT03928899 887 892 B-Condition
growth NCT03928899 893 899 I-Condition
restriction NCT03928899 900 911 I-Condition
, NCT03928899 912 913 O
defined NCT03928899 914 921 O
as NCT03928899 922 924 O
EFW NCT03928899 925 928 B-Observation
< NCT03928899 929 930 B-Eq-Comparison
10 NCT03928899 931 933 I-Eq-Comparison
th NCT03928899 934 936 I-Eq-Comparison
percentile NCT03928899 937 947 I-Eq-Comparison

- NCT03928899 950 951 O
known NCT03928899 953 958 O
HIV NCT03928899 959 962 B-Condition
positivity NCT03928899 963 973 O
because NCT03928899 974 981 O
of NCT03928899 982 984 O
modified NCT03928899 985 993 O
delivery NCT03928899 994 1002 O
plan NCT03928899 1003 1007 O

- NCT03928899 1010 1011 O
signs NCT03928899 1013 1018 B-Assertion___Assertion-Type-Value:possible
of NCT03928899 1019 1021 O
labor NCT03928899 1022 1027 B-Condition
( NCT03928899 1028 1029 O
regular NCT03928899 1030 1037 B-Condition
painful NCT03928899 1038 1045 I-Condition
contractions NCT03928899 1046 1058 I-Condition
with NCT03928899 1059 1063 B-And
cervical NCT03928899 1064 1072 B-Condition
change NCT03928899 1073 1079 I-Condition
) NCT03928899 1080 1081 O
before NCT03928899 1082 1088 B-Temporal-Connection___Temporal-Connection-Type-Value:before
37 NCT03928899 1089 1091 B-Eq-Comparison
weeks NCT03928899 1092 1097 I-Eq-Comparison
6 NCT03928899 1098 1099 I-Eq-Comparison
days NCT03928899 1100 1104 I-Eq-Comparison
of NCT03928899 1105 1107 O
gestation NCT03928899 1108 1117 B-Observation
. NCT03928899 1117 1118 O

Inclusion NCT03923933 0 9 O
Criteria NCT03923933 10 18 O
: NCT03923933 19 20 O

- NCT03923933 24 25 O
glomerular NCT03923933 27 37 B-Observation
filtration NCT03923933 38 48 I-Observation
rate NCT03923933 49 53 I-Observation
less NCT03923933 54 58 B-Eq-Comparison
than NCT03923933 59 63 I-Eq-Comparison
30 NCT03923933 64 66 I-Eq-Comparison
ml NCT03923933 67 69 I-Eq-Comparison
/ NCT03923933 70 71 I-Eq-Comparison
min NCT03923933 72 75 I-Eq-Comparison
/ NCT03923933 76 77 I-Eq-Comparison
1.73 NCT03923933 78 82 I-Eq-Comparison
m NCT03923933 83 84 I-Eq-Comparison

- NCT03923933 87 88 O
Without NCT03923933 90 97 B-Negation
replacement NCT03923933 98 109 B-Procedure
therapy NCT03923933 110 117 I-Procedure
( NCT03923933 118 119 O
dialysis NCT03923933 120 128 B-Procedure
or NCT03923933 129 131 B-Or
hemodialysis NCT03923933 132 144 B-Procedure
) NCT03923933 145 146 O

- NCT03923933 150 151 O
Volume NCT03923933 153 159 B-Condition
overload NCT03923933 160 168 I-Condition

- NCT03923933 171 172 O
At NCT03923933 174 176 B-Eq-Comparison
least NCT03923933 177 182 I-Eq-Comparison
100 NCT03923933 183 186 I-Eq-Comparison
ml NCT03923933 187 189 I-Eq-Comparison
per NCT03923933 190 193 I-Eq-Comparison
day NCT03923933 194 197 I-Eq-Comparison
of NCT03923933 198 200 O
residual NCT03923933 201 209 B-Observation
diuresis NCT03923933 210 218 I-Observation

- NCT03923933 221 222 O
Use NCT03923933 224 227 O
of NCT03923933 228 230 O
a NCT03923933 231 232 O
loop NCT03923933 233 237 B-Drug
diuretic NCT03923933 238 246 I-Drug
for NCT03923933 247 250 O
at NCT03923933 251 253 B-Eq-Comparison
least NCT03923933 254 259 I-Eq-Comparison
one NCT03923933 260 263 I-Eq-Comparison
month NCT03923933 264 269 I-Eq-Comparison

Exclusion NCT03923933 270 279 O
Criteria NCT03923933 280 288 O
: NCT03923933 289 290 O

- NCT03923933 294 295 O
Allergies NCT03923933 297 306 B-Allergy
known NCT03923933 307 312 O
to NCT03923933 313 315 O
diuretics NCT03923933 316 325 B-Drug

- NCT03923933 328 329 O
Patients NCT03923933 331 339 O
with NCT03923933 340 344 O
severe NCT03923933 345 351 O
infections NCT03923933 352 362 B-Condition

- NCT03923933 365 366 O
Patients NCT03923933 368 376 O
with NCT03923933 377 381 O
hemodynamic NCT03923933 382 393 B-Condition
instability NCT03923933 394 405 I-Condition

- NCT03923933 408 409 O
Amputees NCT03923933 411 419 B-Condition

- NCT03923933 422 423 O
Patients NCT03923933 425 433 O
with NCT03923933 434 438 O
cognitive NCT03923933 439 448 B-Condition
impairment NCT03923933 449 459 I-Condition

- NCT03923933 462 463 O
Patients NCT03923933 465 473 O
with NCT03923933 474 478 O
acute NCT03923933 479 484 O
renal NCT03923933 485 490 B-Condition
failure NCT03923933 491 498 I-Condition

- NCT03923933 501 502 O
Patients NCT03923933 504 512 O
with NCT03923933 513 517 O
graft NCT03923933 518 523 B-Condition
loss NCT03923933 524 528 I-Condition

Inclusion NCT03922620 0 9 O
Criteria NCT03922620 10 18 O
: NCT03922620 19 20 O

1 NCT03922620 24 25 O
. NCT03922620 25 26 O
Patients NCT03922620 28 36 O
18 NCT03922620 37 39 B-Eq-Comparison
years NCT03922620 40 45 I-Eq-Comparison
of NCT03922620 46 48 I-Eq-Comparison
age NCT03922620 49 52 I-Eq-Comparison
or NCT03922620 53 55 I-Eq-Comparison
older NCT03922620 56 61 I-Eq-Comparison

2 NCT03922620 64 65 O
. NCT03922620 65 66 O
Patients NCT03922620 68 76 O
undergoing NCT03922620 77 87 B-Eq-Comparison
elective NCT03922620 88 96 O
primary NCT03922620 97 104 B-Modifier
ankle NCT03922620 105 110 I-Modifier
or NCT03922620 111 113 B-Or
hindfoot NCT03922620 114 122 B-Modifier
surgery NCT03922620 123 130 B-Procedure
( NCT03922620 131 132 O
ankle NCT03922620 133 138 B-Procedure
arthrodesis NCT03922620 139 150 I-Procedure
, NCT03922620 151 152 O
subtalar NCT03922620 153 161 B-Procedure
arthrodesis NCT03922620 162 173 I-Procedure
, NCT03922620 174 175 O
triple NCT03922620 176 182 B-Procedure
arthrodesis NCT03922620 183 194 I-Procedure
, NCT03922620 195 196 O
total NCT03922620 197 202 B-Procedure
ankle NCT03922620 203 208 I-Procedure
arthroplasty NCT03922620 209 221 I-Procedure
, NCT03922620 222 223 O
peroneal NCT03922620 224 232 B-Procedure
tendon NCT03922620 233 239 I-Procedure
debridement NCT03922620 240 251 B-Modifier
/ NCT03922620 252 253 B-Or
transfer NCT03922620 254 262 B-Modifier
, NCT03922620 263 264 O
Cavus NCT03922620 265 270 B-Procedure
Reconstruction NCT03922620 271 285 I-Procedure
, NCT03922620 286 287 O
Medial NCT03922620 288 294 B-Procedure
Displacement NCT03922620 295 307 I-Procedure
Calcaneal NCT03922620 308 317 I-Procedure
Osteotomy NCT03922620 318 327 I-Procedure
, NCT03922620 328 329 O
Dwyer NCT03922620 330 335 B-Procedure
Osteotomy NCT03922620 336 345 I-Procedure
) NCT03922620 346 347 O

Exclusion NCT03922620 349 358 O
Criteria NCT03922620 359 367 O
: NCT03922620 368 369 O

1 NCT03922620 373 374 O
. NCT03922620 374 375 O
Patients NCT03922620 377 385 O
who NCT03922620 386 389 O
are NCT03922620 390 393 O
undergoing NCT03922620 394 404 B-Eq-Comparison
revision NCT03922620 405 413 B-Procedure
surgical NCT03922620 414 422 I-Procedure
procedure NCT03922620 423 432 I-Procedure

2 NCT03922620 435 436 O
. NCT03922620 436 437 O
Patients NCT03922620 439 447 O
who NCT03922620 448 451 O
have NCT03922620 452 456 O
taken NCT03922620 457 462 O
opioid NCT03922620 463 469 B-Drug
pain NCT03922620 470 474 I-Drug
medications NCT03922620 475 486 I-Drug
in NCT03922620 487 489 O
the NCT03922620 490 493 O
past NCT03922620 494 498 B-Eq-Comparison
3 NCT03922620 499 500 I-Eq-Comparison
months NCT03922620 501 507 I-Eq-Comparison
prior NCT03922620 508 513 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922620 514 516 I-Temporal-Connection___Temporal-Connection-Type-Value:before
surgical NCT03922620 517 525 B-Procedure
procedure NCT03922620 526 535 I-Procedure

3 NCT03922620 538 539 O
. NCT03922620 539 540 O
Patients NCT03922620 542 550 O
who NCT03922620 551 554 O
have NCT03922620 555 559 O
allergies NCT03922620 560 569 B-Allergy
to NCT03922620 570 572 O
any NCT03922620 573 576 O
of NCT03922620 577 579 O
the NCT03922620 580 583 O
medications NCT03922620 584 595 B-Drug
or NCT03922620 596 598 O
components NCT03922620 599 609 O
of NCT03922620 610 612 O
medications NCT03922620 613 624 O
investigated NCT03922620 625 637 O
in NCT03922620 638 640 O
the NCT03922620 641 644 O
study NCT03922620 645 650 B-Study

4 NCT03922620 653 654 O
. NCT03922620 654 655 O
Patients NCT03922620 657 665 O
currently NCT03922620 666 675 B-Eq-Comparison
incarcerated NCT03922620 676 688 B-Observation

5 NCT03922620 691 692 O
. NCT03922620 692 693 O
Patients NCT03922620 695 703 O
who NCT03922620 704 707 O
can NCT03922620 708 711 B-Negation
not NCT03922620 711 714 I-Negation
read NCT03922620 715 719 O
and NCT03922620 720 723 O
speak NCT03922620 724 729 O
English NCT03922620 730 737 O

Inclusion NCT03922152 0 9 O
Criteria NCT03922152 10 18 O
: NCT03922152 19 20 O

- NCT03922152 24 25 O
histologically NCT03922152 27 41 O
proven NCT03922152 42 48 O
advanced NCT03922152 49 57 O
esophageal NCT03922152 58 68 B-Modifier
cancer NCT03922152 69 75 B-Condition

- NCT03922152 78 79 O
excluded NCT03922152 81 89 B-Negation
from NCT03922152 90 94 O
curative NCT03922152 95 103 B-Procedure
therapy NCT03922152 104 111 I-Procedure
because NCT03922152 112 119 O
of NCT03922152 120 122 O
disease NCT03922152 123 130 B-Coreference
stage NCT03922152 131 136 I-Coreference
and NCT03922152 137 140 B-Or
/ NCT03922152 141 142 I-Or
or NCT03922152 143 145 I-Or
presence NCT03922152 146 154 O
of NCT03922152 155 157 O
multiple NCT03922152 158 166 B-Eq-Comparison
comorbidities NCT03922152 167 180 B-Condition
and NCT03922152 181 184 B-Or
/ NCT03922152 185 186 I-Or
or NCT03922152 187 189 I-Or
poor NCT03922152 190 194 B-Condition
performance NCT03922152 195 206 I-Condition
status NCT03922152 207 213 I-Condition

- NCT03922152 216 217 O
age NCT03922152 219 222 B-Age
> NCT03922152 223 224 B-Eq-Comparison
18 NCT03922152 225 227 I-Eq-Comparison
years NCT03922152 228 233 I-Eq-Comparison

- NCT03922152 236 237 O
Eastern NCT03922152 239 246 B-Condition
Cooperative NCT03922152 247 258 I-Condition
Oncology NCT03922152 259 267 I-Condition
Group NCT03922152 268 273 I-Condition
( NCT03922152 274 275 O
ECOG NCT03922152 276 280 B-Condition
) NCT03922152 281 282 O
< NCT03922152 283 284 B-Eq-Comparison
3 NCT03922152 285 286 I-Eq-Comparison

Exclusion NCT03922152 288 297 O
Criteria NCT03922152 298 306 O
: NCT03922152 307 308 O

- NCT03922152 312 313 O
prior NCT03922152 315 320 B-Eq-Comparison
radiotherapy NCT03922152 321 333 B-Procedure
to NCT03922152 334 336 O
the NCT03922152 337 340 O
same NCT03922152 341 345 B-Modifier
region NCT03922152 346 352 I-Modifier

Inclusion NCT03929991 0 9 O
Criteria NCT03929991 10 18 O
: NCT03929991 19 20 O

- NCT03929991 24 25 O
All NCT03929991 27 30 O
pregnant NCT03929991 31 39 B-Condition
women NCT03929991 40 45 O
undergoing NCT03929991 46 56 B-Eq-Comparison
a NCT03929991 57 58 O
C NCT03929991 59 60 B-Procedure
/ NCT03929991 61 62 I-Procedure
S NCT03929991 63 64 I-Procedure
in NCT03929991 65 67 O
on NCT03929991 68 70 O
the NCT03929991 71 74 O
hospitals NCT03929991 75 84 O
during NCT03929991 85 91 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929991 92 95 O
study NCT03929991 96 101 B-Study
period NCT03929991 102 108 O
will NCT03929991 109 113 O
be NCT03929991 114 116 O
eligible NCT03929991 117 125 O
to NCT03929991 126 128 O
participate NCT03929991 129 140 O
in NCT03929991 141 143 O
this NCT03929991 144 148 O
study NCT03929991 149 154 O
. NCT03929991 155 156 O

Exclusion NCT03929991 158 167 O
Criteria NCT03929991 168 176 O
: NCT03929991 177 178 O

The NCT03929991 180 183 O
following NCT03929991 184 193 O
conditions NCT03929991 194 204 O
will NCT03929991 205 209 O
not NCT03929991 210 213 O
be NCT03929991 214 216 O
considered NCT03929991 217 227 O
as NCT03929991 228 230 O
outcome NCT03929991 231 238 O
, NCT03929991 239 240 O
unless NCT03929991 241 247 O
they NCT03929991 248 252 O
present NCT03929991 253 260 O
with NCT03929991 261 265 O

systemic NCT03929991 266 274 B-Modifier
repercussion NCT03929991 275 287 B-Condition
due NCT03929991 288 291 O
to NCT03929991 292 294 O
infection NCT03929991 295 304 B-Condition
. NCT03929991 304 305 O
For NCT03929991 307 310 O
example NCT03929991 311 318 O
: NCT03929991 319 320 O

- NCT03929991 324 325 O
Vaginosis NCT03929991 327 336 B-Condition
, NCT03929991 337 338 O
candidiasis NCT03929991 339 350 B-Condition

- NCT03929991 353 354 O
Lower NCT03929991 356 361 B-Modifier
tract NCT03929991 362 367 I-Modifier
urinary NCT03929991 368 375 I-Modifier
infection NCT03929991 376 385 B-Condition

- NCT03929991 388 389 O
Fungal NCT03929991 391 397 B-Modifier
infections NCT03929991 398 408 B-Condition
of NCT03929991 409 411 O
the NCT03929991 412 415 O
skin NCT03929991 416 420 B-Modifier
( NCT03929991 421 422 O
athlete NCT03929991 423 430 B-Condition
's NCT03929991 430 432 I-Condition
foot NCT03929991 433 437 I-Condition
, NCT03929991 438 439 O
jockitch NCT03929991 440 448 B-Condition
, NCT03929991 449 450 O
ringworm NCT03929991 451 459 B-Condition
, NCT03929991 460 461 O
and NCT03929991 462 465 O
yeast NCT03929991 466 471 B-Condition
infections NCT03929991 472 482 I-Condition
) NCT03929991 483 484 O

- NCT03929991 488 489 O
Otitis NCT03929991 491 497 B-Condition

- NCT03929991 500 501 O
Pharyngitis NCT03929991 503 514 B-Condition

- NCT03929991 517 518 O
Herpes NCT03929991 520 526 B-Condition
simplex NCT03929991 527 534 I-Condition
, NCT03929991 535 536 O
Herpes NCT03929991 537 543 B-Condition
Zoster NCT03929991 544 550 I-Condition
( NCT03929991 551 552 O
Shingles NCT03929991 553 561 B-Condition
) NCT03929991 562 563 O

- NCT03929991 567 568 O
Uncomplicated NCT03929991 570 583 B-Modifier
chronic NCT03929991 584 591 B-Condition
infection NCT03929991 592 601 I-Condition

- NCT03929991 604 605 O
Sexually NCT03929991 607 615 B-Condition
transmitted NCT03929991 616 627 I-Condition
infections NCT03929991 628 638 I-Condition
( NCT03929991 639 640 O
Gonorrhoea NCT03929991 641 651 B-Condition
, NCT03929991 652 653 O
Syphilis NCT03929991 654 662 B-Condition
, NCT03929991 663 664 O
Trichomonas NCT03929991 665 676 B-Condition
, NCT03929991 677 678 O
Chlamydia NCT03929991 679 688 B-Condition
, NCT03929991 689 690 O
Hepatitis NCT03929991 691 700 B-Condition
, NCT03929991 701 702 O
HIV NCT03929991 703 706 B-Condition
) NCT03929991 707 708 O

- NCT03929991 712 713 O
Tuberculosis NCT03929991 715 727 B-Condition

- NCT03929991 730 731 O
Bacterial NCT03929991 733 742 B-Condition
colonization NCT03929991 743 755 I-Condition
( NCT03929991 756 757 O
presence NCT03929991 758 766 O
of NCT03929991 767 769 O
microorganisms NCT03929991 770 784 B-Organism
without NCT03929991 785 792 B-Negation
clinical NCT03929991 793 801 B-Condition
signs NCT03929991 802 807 I-Condition
/ NCT03929991 808 809 I-Condition
symptoms NCT03929991 810 818 I-Condition
) NCT03929991 819 820 O

- NCT03929991 824 825 O
Known NCT03929991 827 832 O
vaginal NCT03929991 833 840 B-Modifier
, NCT03929991 841 842 O
urethral NCT03929991 843 851 B-Modifier
and NCT03929991 852 855 B-Or
/ NCT03929991 856 857 I-Or
or NCT03929991 858 860 I-Or
rectal NCT03929991 861 867 B-Modifier
GBS NCT03929991 868 871 B-Condition
colonization NCT03929991 872 884 I-Condition

- NCT03929991 887 888 O
Asymptomatic NCT03929991 890 902 B-Condition
bacteriuria NCT03929991 903 914 I-Condition

- NCT03929991 917 918 O
Known NCT03929991 920 925 O
oropharyngeal NCT03929991 926 939 B-Condition
colonization NCT03929991 940 952 I-Condition

- NCT03929991 955 956 O
Non NCT03929991 958 961 B-Modifier
- NCT03929991 962 963 I-Modifier
infectious NCT03929991 964 974 I-Modifier
hypothermia NCT03929991 975 986 B-Condition
/ NCT03929991 987 988 B-Or
hyperthermia NCT03929991 989 1001 B-Condition
( NCT03929991 1002 1003 O
e. NCT03929991 1004 1006 O
g. NCT03929991 1007 1009 O
related NCT03929991 1011 1018 O
to NCT03929991 1019 1021 O
epidural NCT03929991 1022 1030 B-Procedure
, NCT03929991 1031 1032 O
thyroid NCT03929991 1033 1040 B-Condition
storm NCT03929991 1041 1046 I-Condition
, NCT03929991 1047 1048 O
prostaglandin NCT03929991 1049 1062 B-Drug
administration NCT03929991 1063 1077 O
) NCT03929991 1078 1079 O
during NCT03929991 1080 1086 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospital NCT03929991 1087 1095 B-Encounter
stay NCT03929991 1096 1100 I-Encounter

Inclusion NCT03928457 0 9 O
Criteria NCT03928457 10 18 O
: NCT03928457 19 20 O

- NCT03928457 24 25 O
preterm NCT03928457 27 34 B-Condition
neonates NCT03928457 35 43 O
born NCT03928457 44 48 B-Birth
at NCT03928457 49 51 B-Temporal-Connection___Temporal-Connection-Type-Value:during
26 NCT03928457 52 54 B-Eq-Comparison
to NCT03928457 55 57 I-Eq-Comparison
34 NCT03928457 58 60 I-Eq-Comparison
weeks NCT03928457 61 66 I-Eq-Comparison
of NCT03928457 67 69 O
gestational NCT03928457 70 81 B-Observation
age NCT03928457 82 85 I-Observation

- NCT03928457 88 89 O
signed NCT03928457 91 97 O
written NCT03928457 98 105 O
informed NCT03928457 106 114 O
consent NCT03928457 115 122 O
form NCT03928457 123 127 O

Exclusion NCT03928457 128 137 O
Criteria NCT03928457 138 146 O
: NCT03928457 147 148 O

- NCT03928457 152 153 O
infants NCT03928457 155 162 O
infected NCT03928457 163 171 B-Condition

- NCT03928457 174 175 O
infants NCT03928457 177 184 O
suffering NCT03928457 185 194 O
from NCT03928457 195 199 O
neurological NCT03928457 200 212 B-Condition
disorders NCT03928457 213 222 I-Condition

- NCT03928457 225 226 O
serious NCT03928457 228 235 O
heart NCT03928457 236 241 B-Modifier
, NCT03928457 242 243 O
respiratory NCT03928457 244 255 B-Modifier
, NCT03928457 256 257 O
digestive NCT03928457 258 267 B-Modifier
or NCT03928457 268 270 B-Or
metabolic NCT03928457 271 280 B-Modifier
diseases NCT03928457 281 289 B-Condition

- NCT03928457 292 293 O
infants NCT03928457 295 302 O
born NCT03928457 303 307 B-Birth
from NCT03928457 308 312 O
mothers NCT03928457 313 320 B-Family-Member___Family-Member-Type:mother
aged NCT03928457 321 325 B-Age
less NCT03928457 326 330 B-Eq-Comparison
than NCT03928457 331 335 I-Eq-Comparison
18 NCT03928457 336 338 I-Eq-Comparison
years NCT03928457 339 344 I-Eq-Comparison
old NCT03928457 345 348 O
or NCT03928457 349 351 B-Or
deprived NCT03928457 352 360 B-Observation
of NCT03928457 361 363 I-Observation
their NCT03928457 364 369 I-Observation
parental NCT03928457 370 378 I-Observation
rights NCT03928457 379 385 I-Observation

- NCT03928457 388 389 O
non NCT03928457 391 394 B-Negation
covered NCT03928457 395 402 O
by NCT03928457 403 405 O
national NCT03928457 406 414 O
health NCT03928457 415 421 O
insurance NCT03928457 422 431 O

Inclusion NCT03922191 0 9 O
Criteria NCT03922191 10 18 O
: NCT03922191 19 20 O

- NCT03922191 24 25 O
post NCT03922191 27 31 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03922191 32 33 O
cardiac NCT03922191 34 41 B-Procedure
surgery NCT03922191 42 49 I-Procedure
mediastinitis NCT03922191 50 63 B-Condition

- NCT03922191 66 67 O
patients NCT03922191 69 77 O
of NCT03922191 78 80 O
the NCT03922191 81 84 O
CHU NCT03922191 85 88 O
Brugmann NCT03922191 89 97 O
( NCT03922191 98 99 O
adults NCT03922191 100 106 O
) NCT03922191 107 108 O
and NCT03922191 109 112 O
HUDERF NCT03922191 113 119 O
( NCT03922191 120 121 O
pediatric NCT03922191 122 131 O
) NCT03922191 132 133 O
Hospitals NCT03922191 134 143 O

Exclusion NCT03922191 144 153 O
Criteria NCT03922191 154 162 O
: NCT03922191 163 164 O

- NCT03922191 167 168 O
none NCT03922191 169 173 O

Inclusion NCT03929952 0 9 O
Criteria NCT03929952 10 18 O
: NCT03929952 19 20 O

- NCT03929952 24 25 O
Patient NCT03929952 27 34 O
with NCT03929952 35 39 O
a NCT03929952 40 41 O
wifi NCT03929952 42 46 O
connexion NCT03929952 47 56 O
at NCT03929952 57 59 O
home NCT03929952 60 64 O

- NCT03929952 67 68 O
Patient NCT03929952 70 77 O
with NCT03929952 78 82 O
the NCT03929952 83 86 O
ability NCT03929952 87 94 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929952 95 97 I-Assertion___Assertion-Type-Value:hypothetical
modulate NCT03929952 98 106 B-Observation
the NCT03929952 107 110 I-Observation
height NCT03929952 111 117 I-Observation
of NCT03929952 118 120 I-Observation
the NCT03929952 121 124 I-Observation
candle NCT03929952 125 131 I-Observation
by NCT03929952 132 134 O
thinking NCT03929952 135 143 O
in NCT03929952 144 146 O
the NCT03929952 147 150 O
alpha NCT03929952 151 156 B-Observation
synchrony NCT03929952 157 166 I-Observation
test NCT03929952 167 171 I-Observation
. NCT03929952 172 173 O

- NCT03929952 177 178 O
Patient NCT03929952 180 187 O
with NCT03929952 188 192 O
chronic NCT03929952 193 200 B-Condition
low NCT03929952 201 204 I-Condition
back NCT03929952 205 209 I-Condition
pain NCT03929952 210 214 I-Condition
for NCT03929952 215 218 O
more NCT03929952 219 223 B-Eq-Comparison
than NCT03929952 224 228 I-Eq-Comparison
six NCT03929952 229 232 I-Eq-Comparison
months NCT03929952 233 239 I-Eq-Comparison
with NCT03929952 240 244 B-And
a NCT03929952 245 246 O
visual NCT03929952 247 253 B-Observation
analogue NCT03929952 254 262 I-Observation
pain NCT03929952 263 267 I-Observation
scale NCT03929952 268 273 I-Observation
greater NCT03929952 274 281 B-Eq-Comparison
than NCT03929952 282 286 I-Eq-Comparison
5 NCT03929952 287 288 I-Eq-Comparison
impacting NCT03929952 289 298 O
activities NCT03929952 299 309 O
of NCT03929952 310 312 O
daily NCT03929952 313 318 O
living NCT03929952 319 325 O
, NCT03929952 326 327 O
hobbies NCT03929952 328 335 O
and NCT03929952 336 339 O
work NCT03929952 340 344 O

- NCT03929952 347 348 O
Patient NCT03929952 350 357 O
having NCT03929952 358 364 O
given NCT03929952 365 370 O
free NCT03929952 371 375 O
and NCT03929952 376 379 O
informed NCT03929952 380 388 O
consent NCT03929952 389 396 O
and NCT03929952 397 400 O
signed NCT03929952 401 407 O
consent NCT03929952 408 415 O
. NCT03929952 416 417 O

- NCT03929952 421 422 O
Affected NCT03929952 424 432 O
patient NCT03929952 433 440 O
or NCT03929952 441 443 O
beneficiary NCT03929952 444 455 O
of NCT03929952 456 458 O
a NCT03929952 459 460 O
health NCT03929952 461 467 O
insurance NCT03929952 468 477 O
plan NCT03929952 478 482 O
. NCT03929952 483 484 O

- NCT03929952 488 489 O
Patient NCT03929952 491 498 O
who NCT03929952 499 502 O
is NCT03929952 503 505 O
at NCT03929952 506 508 B-Eq-Comparison
least NCT03929952 509 514 I-Eq-Comparison
18 NCT03929952 515 517 I-Eq-Comparison
years NCT03929952 518 523 I-Eq-Comparison
old NCT03929952 524 527 B-Age
( NCT03929952 528 529 O
≥ NCT03929952 531 532 O
) NCT03929952 534 535 O
and NCT03929952 536 539 B-And
younger NCT03929952 540 547 B-Eq-Comparison
than NCT03929952 548 552 I-Eq-Comparison
75 NCT03929952 553 555 I-Eq-Comparison
years NCT03929952 556 561 I-Eq-Comparison
old NCT03929952 562 565 B-Age
( NCT03929952 566 567 O
< NCT03929952 569 570 O
) NCT03929952 572 573 O
. NCT03929952 575 576 O

Exclusion NCT03929952 578 587 O
Criteria NCT03929952 588 596 O
: NCT03929952 597 598 O

- NCT03929952 602 603 O
Pregnant NCT03929952 605 613 B-Condition
or NCT03929952 614 616 B-Or
breastfeeding NCT03929952 617 630 B-Condition
patient NCT03929952 631 638 O

- NCT03929952 641 642 O
Patient NCT03929952 644 651 O
with NCT03929952 652 656 O
a NCT03929952 657 658 O
contraindication NCT03929952 659 675 B-Contraindication
to NCT03929952 676 678 O
performing NCT03929952 679 689 O
a NCT03929952 690 691 O
fMRI NCT03929952 692 696 B-Procedure
scan NCT03929952 697 701 I-Procedure
: NCT03929952 702 703 O
ferromagnetic NCT03929952 704 717 B-Procedure
implant NCT03929952 718 725 I-Procedure
in NCT03929952 726 728 O
the NCT03929952 729 732 O
body NCT03929952 733 737 O
, NCT03929952 738 739 O
piercing NCT03929952 740 748 B-Condition
, NCT03929952 749 750 O
claustrophobia NCT03929952 751 765 B-Condition
, NCT03929952 766 767 O
unable NCT03929952 768 774 B-Condition
to NCT03929952 775 777 I-Condition
remain NCT03929952 778 784 I-Condition
in NCT03929952 785 787 I-Condition
the NCT03929952 788 791 I-Condition
scanner NCT03929952 792 799 I-Condition
stationary NCT03929952 800 810 I-Condition
for NCT03929952 811 814 O
40 NCT03929952 815 817 B-Eq-Comparison
minutes NCT03929952 818 825 I-Eq-Comparison

- NCT03929952 828 829 O
Patient NCT03929952 831 838 O
already NCT03929952 839 846 O
included NCT03929952 847 855 O
in NCT03929952 856 858 O
another NCT03929952 859 866 O
study NCT03929952 867 872 O

- NCT03929952 875 876 O
Patient NCT03929952 878 885 O
in NCT03929952 886 888 O
a NCT03929952 889 890 O
exclusion NCT03929952 891 900 O
period NCT03929952 901 907 O
determined NCT03929952 908 918 O
by NCT03929952 919 921 O
a NCT03929952 922 923 O
previous NCT03929952 924 932 B-Eq-Comparison
study NCT03929952 933 938 B-Study

- NCT03929952 941 942 O
The NCT03929952 944 947 O
subject NCT03929952 948 955 O
is NCT03929952 956 958 O
under NCT03929952 959 964 O
the NCT03929952 965 968 O
protection NCT03929952 969 979 B-Observation
of NCT03929952 980 982 I-Observation
justice NCT03929952 983 990 I-Observation
, NCT03929952 991 992 O
guardianship NCT03929952 993 1005 O
or NCT03929952 1006 1008 O
curatorship NCT03929952 1009 1020 O
. NCT03929952 1021 1022 O

- NCT03929952 1026 1027 O
The NCT03929952 1029 1032 O
subject NCT03929952 1033 1040 O
refuses NCT03929952 1041 1048 O
to NCT03929952 1049 1051 O
sign NCT03929952 1052 1056 O
the NCT03929952 1057 1060 O
consent NCT03929952 1061 1068 O
. NCT03929952 1069 1070 O

- NCT03929952 1074 1075 O
It NCT03929952 1077 1079 O
is NCT03929952 1080 1082 O
not NCT03929952 1083 1086 O
possible NCT03929952 1087 1095 O
to NCT03929952 1096 1098 O
give NCT03929952 1099 1103 O
the NCT03929952 1104 1107 O
subject NCT03929952 1108 1115 O
informed NCT03929952 1116 1124 O
information NCT03929952 1125 1136 O
. NCT03929952 1136 1137 O

Inclusion NCT03920787 0 9 O
Criteria NCT03920787 10 18 O
: NCT03920787 19 20 O

- NCT03920787 24 25 O
8 NCT03920787 27 28 B-Eq-Comparison
- NCT03920787 29 30 I-Eq-Comparison
18 NCT03920787 31 33 I-Eq-Comparison
years NCT03920787 34 39 I-Eq-Comparison
old NCT03920787 40 43 B-Age

- NCT03920787 46 47 O
overweight NCT03920787 49 59 B-Condition
or NCT03920787 60 62 B-Or
obesity NCT03920787 63 70 B-Condition

- NCT03920787 73 74 O
basal NCT03920787 76 81 B-Drug
insulin NCT03920787 82 89 I-Drug
≥ NCT03920787 90 91 B-Eq-Comparison
20 NCT03920787 92 94 I-Eq-Comparison
uU NCT03920787 95 97 I-Eq-Comparison
/ NCT03920787 98 99 I-Eq-Comparison
ml NCT03920787 100 102 I-Eq-Comparison

Exclusion NCT03920787 103 112 O
Criteria NCT03920787 113 121 O
: NCT03920787 122 123 O

- NCT03920787 127 128 O
pubertal NCT03920787 130 138 B-Condition
delay NCT03920787 139 144 I-Condition

- NCT03920787 147 148 O
hypogonadism NCT03920787 150 162 B-Condition

- NCT03920787 165 166 O
hypothyroidism NCT03920787 168 182 B-Condition
or NCT03920787 183 185 B-Or
hyperthyroidism NCT03920787 186 201 B-Condition

- NCT03920787 204 205 O
obesity NCT03920787 207 214 B-Condition
- NCT03920787 215 216 O
related NCT03920787 217 224 O
genetic NCT03920787 225 232 B-Condition
diseases NCT03920787 233 241 I-Condition

Inclusion NCT03923517 0 9 O
Criteria NCT03923517 10 18 O
: NCT03923517 19 20 O

- NCT03923517 24 25 O
informal NCT03923517 27 35 O
carer NCT03923517 36 41 O
of NCT03923517 42 44 O
a NCT03923517 45 46 O
person NCT03923517 47 53 O
with NCT03923517 54 58 O
YOD NCT03923517 59 62 B-Condition
who NCT03923517 63 66 O
has NCT03923517 67 70 O
been NCT03923517 71 75 O
diagnosed NCT03923517 76 85 O
with NCT03923517 86 90 O
either NCT03923517 91 97 O
Frontal NCT03923517 98 105 B-Condition
Temporal NCT03923517 106 114 I-Condition
Dementia NCT03923517 115 123 I-Condition
( NCT03923517 124 125 O
FTD NCT03923517 126 129 B-Condition
) NCT03923517 130 131 O
or NCT03923517 132 134 B-Or
Alzheimer NCT03923517 135 144 B-Condition
's NCT03923517 144 146 I-Condition
Disease NCT03923517 147 154 I-Condition
( NCT03923517 155 156 O
AD NCT03923517 157 159 B-Condition
) NCT03923517 160 161 O
12 NCT03923517 162 164 B-Eq-Comparison
months NCT03923517 165 171 I-Eq-Comparison
ago NCT03923517 172 175 I-Eq-Comparison
or NCT03923517 176 178 I-Eq-Comparison
less NCT03923517 179 183 I-Eq-Comparison
; NCT03923517 183 184 O

- NCT03923517 187 188 O
the NCT03923517 190 193 O
carer NCT03923517 194 199 O
has NCT03923517 200 203 O
face NCT03923517 204 208 B-Observation
- NCT03923517 209 210 I-Observation
to NCT03923517 211 213 I-Observation
- NCT03923517 214 215 I-Observation
face NCT03923517 216 220 I-Observation
contact NCT03923517 221 228 I-Observation
with NCT03923517 229 233 O
the NCT03923517 234 237 O
person NCT03923517 238 244 O
with NCT03923517 245 249 O
YOD NCT03923517 250 253 B-Condition
at NCT03923517 254 256 B-Eq-Comparison
least NCT03923517 257 262 I-Eq-Comparison
twice NCT03923517 263 268 I-Eq-Comparison
a NCT03923517 269 270 I-Eq-Comparison
weak NCT03923517 271 275 I-Eq-Comparison
; NCT03923517 275 276 O

- NCT03923517 279 280 O
the NCT03923517 282 285 O
carer NCT03923517 286 291 O
has NCT03923517 292 295 O
a NCT03923517 296 297 O
working NCT03923517 298 305 O
computer NCT03923517 306 314 O
and NCT03923517 315 318 O
internet NCT03923517 319 327 O
access NCT03923517 328 334 O
in NCT03923517 335 337 O
his NCT03923517 338 341 O
home NCT03923517 342 346 O
; NCT03923517 346 347 O

- NCT03923517 350 351 O
the NCT03923517 353 356 O
carer NCT03923517 357 362 O
is NCT03923517 363 365 O
available NCT03923517 366 375 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923517 376 379 O
the NCT03923517 380 383 O
intervention NCT03923517 384 396 B-Study
duration NCT03923517 397 405 O
of NCT03923517 406 408 O
approximately NCT03923517 409 422 O
eight NCT03923517 423 428 B-Eq-Comparison
weeks NCT03923517 429 434 I-Eq-Comparison
; NCT03923517 434 435 O

- NCT03923517 438 439 O
the NCT03923517 441 444 O
carer NCT03923517 445 450 O
is NCT03923517 451 453 O
fluent NCT03923517 454 460 O
in NCT03923517 461 463 O
German NCT03923517 464 470 O
; NCT03923517 470 471 O

- NCT03923517 474 475 O
signed NCT03923517 477 483 O
consent NCT03923517 484 491 O
form NCT03923517 492 496 O
. NCT03923517 497 498 O

Exclusion NCT03923517 500 509 O
Criteria NCT03923517 510 518 O
: NCT03923517 519 520 O

- NCT03923517 524 525 O
the NCT03923517 527 530 O
carer NCT03923517 531 536 O
has NCT03923517 537 540 O
face NCT03923517 541 545 B-Observation
- NCT03923517 546 547 I-Observation
to NCT03923517 548 550 I-Observation
- NCT03923517 551 552 I-Observation
face NCT03923517 553 557 I-Observation
contact NCT03923517 558 565 I-Observation
with NCT03923517 566 570 O
the NCT03923517 571 574 O
person NCT03923517 575 581 O
with NCT03923517 582 586 O
YOD NCT03923517 587 590 B-Condition
less NCT03923517 591 595 B-Eq-Comparison
than NCT03923517 596 600 I-Eq-Comparison
twice NCT03923517 601 606 I-Eq-Comparison
a NCT03923517 607 608 I-Eq-Comparison
week NCT03923517 609 613 I-Eq-Comparison
; NCT03923517 613 614 O

- NCT03923517 617 618 O
the NCT03923517 620 623 O
person NCT03923517 624 630 O
with NCT03923517 631 635 O
YOD NCT03923517 636 639 B-Condition
the NCT03923517 640 643 O
carer NCT03923517 644 649 O
is NCT03923517 650 652 O
caring NCT03923517 653 659 O
for NCT03923517 660 663 O
has NCT03923517 664 667 O
a NCT03923517 668 669 O
different NCT03923517 670 679 B-Other
dementia NCT03923517 680 688 B-Condition
cause NCT03923517 689 694 B-Condition
other NCT03923517 695 700 B-Exception
than NCT03923517 701 705 I-Exception
FTD NCT03923517 706 709 B-Condition
or NCT03923517 710 712 B-Or
AD NCT03923517 713 715 B-Condition
or NCT03923517 716 718 B-Or
the NCT03923517 719 722 O
diagnosis NCT03923517 723 732 B-Coreference
is NCT03923517 733 735 O
older NCT03923517 736 741 B-Eq-Comparison
than NCT03923517 742 746 I-Eq-Comparison
12 NCT03923517 747 749 I-Eq-Comparison
months NCT03923517 750 756 I-Eq-Comparison
; NCT03923517 756 757 O

- NCT03923517 760 761 O
the NCT03923517 763 766 O
carer NCT03923517 767 772 O
does NCT03923517 773 777 O
not NCT03923517 778 781 O
have NCT03923517 782 786 O
a NCT03923517 787 788 O
working NCT03923517 789 796 O
computer NCT03923517 797 805 O
and NCT03923517 806 809 O
internet NCT03923517 810 818 O
access NCT03923517 819 825 O
at NCT03923517 826 828 O
home NCT03923517 829 833 O
or NCT03923517 834 836 O
is NCT03923517 837 839 O
not NCT03923517 840 843 O
confident NCT03923517 844 853 O
to NCT03923517 854 856 O
use NCT03923517 857 860 O
them NCT03923517 861 865 O
; NCT03923517 865 866 O

- NCT03923517 869 870 O
the NCT03923517 872 875 O
carer NCT03923517 876 881 O
is NCT03923517 882 884 O
not NCT03923517 885 888 B-Negation
available NCT03923517 889 898 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03923517 899 902 O
the NCT03923517 903 906 O
approximately NCT03923517 907 920 O
eight NCT03923517 921 926 B-Eq-Comparison
week NCT03923517 927 931 I-Eq-Comparison
intervention NCT03923517 932 944 B-Study
duration NCT03923517 945 953 O
; NCT03923517 953 954 O

- NCT03923517 957 958 O
the NCT03923517 960 963 O
carer NCT03923517 964 969 O
is NCT03923517 970 972 O
not NCT03923517 973 976 B-Negation
fluent NCT03923517 977 983 O
in NCT03923517 984 986 O
German NCT03923517 987 993 O
; NCT03923517 993 994 O

- NCT03923517 997 998 O
the NCT03923517 1000 1003 O
carer NCT03923517 1004 1009 O
has NCT03923517 1010 1013 O
a NCT03923517 1014 1015 O
significant NCT03923517 1016 1027 O
health NCT03923517 1028 1034 B-Condition
problem NCT03923517 1035 1042 I-Condition
or NCT03923517 1043 1045 B-Or
disability NCT03923517 1046 1056 B-Condition
, NCT03923517 1057 1058 O
which NCT03923517 1059 1064 O
precludes NCT03923517 1065 1074 O
him NCT03923517 1075 1078 O
/ NCT03923517 1079 1080 O
her NCT03923517 1081 1084 O
from NCT03923517 1085 1089 O
participating NCT03923517 1090 1103 O
in NCT03923517 1104 1106 O
the NCT03923517 1107 1110 O
study NCT03923517 1111 1116 O
; NCT03923517 1116 1117 O

- NCT03923517 1120 1121 O
no NCT03923517 1123 1125 O
signed NCT03923517 1126 1132 O
informed NCT03923517 1133 1141 O
consent NCT03923517 1142 1149 O
. NCT03923517 1149 1150 O

Inclusion NCT03928873 0 9 O
Criteria NCT03928873 10 18 O
: NCT03928873 19 20 O

1 NCT03928873 24 25 O
. NCT03928873 25 26 O
Older NCT03928873 28 33 B-Eq-Comparison
than NCT03928873 34 38 I-Eq-Comparison
20 NCT03928873 39 41 I-Eq-Comparison
years NCT03928873 42 47 I-Eq-Comparison
of NCT03928873 48 50 O
age NCT03928873 51 54 B-Age

2 NCT03928873 57 58 O
. NCT03928873 58 59 O
Grade NCT03928873 61 66 B-Eq-Comparison
2 NCT03928873 67 68 I-Eq-Comparison
~ NCT03928873 69 70 I-Eq-Comparison
3 NCT03928873 71 72 I-Eq-Comparison
trigger NCT03928873 73 80 B-Condition
finger NCT03928873 81 87 I-Condition
based NCT03928873 88 93 O
on NCT03928873 94 96 O
the NCT03928873 97 100 O
Quinnell NCT03928873 101 109 O
classification NCT03928873 110 124 O

Exclusion NCT03928873 125 134 O
Criteria NCT03928873 135 143 O
: NCT03928873 144 145 O

1 NCT03928873 149 150 O
. NCT03928873 150 151 O
Previous NCT03928873 153 161 B-Eq-Comparison
treatment NCT03928873 162 171 B-Procedure
by NCT03928873 172 174 O
physical NCT03928873 175 183 B-Procedure
therapy NCT03928873 184 191 I-Procedure
, NCT03928873 192 193 O
local NCT03928873 194 199 B-Procedure
corticosteroid NCT03928873 200 214 I-Procedure
injection NCT03928873 215 224 I-Procedure
, NCT03928873 225 226 O
or NCT03928873 227 229 B-Or
surgical NCT03928873 230 238 O
release NCT03928873 239 246 O
for NCT03928873 247 250 O
trigger NCT03928873 251 258 B-Condition
finger NCT03928873 259 265 I-Condition
before NCT03928873 266 272 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03928873 273 276 O
study NCT03928873 277 282 B-Study

2 NCT03928873 285 286 O
. NCT03928873 286 287 O
The NCT03928873 289 292 O
presence NCT03928873 293 301 O
of NCT03928873 302 304 O
a NCT03928873 305 306 O
musculoskeletal NCT03928873 307 322 B-Condition
disease NCT03928873 323 330 I-Condition
or NCT03928873 331 333 B-Or
previous NCT03928873 334 342 B-Eq-Comparison
nerve NCT03928873 343 348 B-Condition
injuries NCT03928873 349 357 I-Condition
at NCT03928873 358 360 O
the NCT03928873 361 364 O
upper NCT03928873 365 370 B-Modifier
extremities NCT03928873 371 382 I-Modifier

3 NCT03928873 385 386 O
. NCT03928873 386 387 O
Multiple NCT03928873 389 397 B-Condition
trigger NCT03928873 398 405 I-Condition
finger NCT03928873 406 412 I-Condition
; NCT03928873 412 413 O
local NCT03928873 414 419 B-Condition
infection NCT03928873 420 429 I-Condition
; NCT03928873 429 430 O
malignancy NCT03928873 431 441 B-Condition
; NCT03928873 441 442 O
inflammatory NCT03928873 443 455 B-Condition
arthritis NCT03928873 456 465 I-Condition
; NCT03928873 465 466 O
cardiac NCT03928873 467 474 B-Condition
arrhythmia NCT03928873 475 485 I-Condition
or NCT03928873 486 488 B-Or
cardiac NCT03928873 489 496 B-Procedure
pacemaker NCT03928873 497 506 I-Procedure
; NCT03928873 506 507 O
and NCT03928873 508 511 B-Or
pregnancy NCT03928873 512 521 B-Condition
. NCT03928873 521 522 O

Inclusion NCT03922386 0 9 O
Criteria NCT03922386 10 18 O
: NCT03922386 19 20 O

1 NCT03922386 24 25 O
. NCT03922386 25 26 O
Any NCT03922386 28 31 O
subject NCT03922386 32 39 O
newly NCT03922386 40 45 O
implanted NCT03922386 46 55 O
according NCT03922386 56 65 O
to NCT03922386 66 68 O
the NCT03922386 69 72 O
most NCT03922386 73 77 O
recent NCT03922386 78 84 O
guidelines NCT03922386 85 95 O
from NCT03922386 96 100 O
the NCT03922386 101 104 O
European NCT03922386 105 113 O
Society NCT03922386 114 121 O
of NCT03922386 122 124 O
Cardiology NCT03922386 125 135 O
( NCT03922386 136 137 O
ESC NCT03922386 138 141 O
) NCT03922386 142 143 O
for NCT03922386 144 147 O
less NCT03922386 148 152 B-Eq-Comparison
than10 NCT03922386 153 159 I-Eq-Comparison
days NCT03922386 160 164 I-Eq-Comparison
with NCT03922386 165 169 O
: NCT03922386 170 171 O

- NCT03922386 180 181 O
a NCT03922386 183 184 O
Single NCT03922386 185 191 B-Modifier
Chamber NCT03922386 192 199 I-Modifier
( NCT03922386 200 201 O
SR NCT03922386 202 204 B-Modifier
) NCT03922386 205 206 O
or NCT03922386 207 209 B-Or
a NCT03922386 210 211 O
Dual NCT03922386 212 216 B-Modifier
Chamber NCT03922386 217 224 I-Modifier
( NCT03922386 225 226 O
DR NCT03922386 227 229 B-Modifier
) NCT03922386 230 231 O
pacemaker NCT03922386 232 241 B-Procedure
from NCT03922386 242 246 O
Microport NCT03922386 247 256 O
CRM NCT03922386 257 260 O
S. NCT03922386 261 263 O
r. NCT03922386 264 266 O
l NCT03922386 267 268 O
. NCT03922386 269 270 O

- NCT03922386 279 280 O
any NCT03922386 282 285 O
right NCT03922386 286 291 B-Modifier
atrial NCT03922386 292 298 I-Modifier
and NCT03922386 299 302 B-Or
/ NCT03922386 303 304 I-Or
or NCT03922386 305 307 I-Or
right NCT03922386 308 313 B-Modifier
ventricular NCT03922386 314 325 I-Modifier
XFINE NCT03922386 326 331 B-Procedure
lead NCT03922386 332 336 I-Procedure

2 NCT03922386 339 340 O
. NCT03922386 340 341 O
Have NCT03922386 343 347 O
reviewed NCT03922386 348 356 O
, NCT03922386 357 358 O
signed NCT03922386 359 365 O
and NCT03922386 366 369 O
dated NCT03922386 370 375 O
the NCT03922386 376 379 O
informed NCT03922386 380 388 O
consent NCT03922386 389 396 O

Exclusion NCT03922386 397 406 O
Criteria NCT03922386 407 415 O
: NCT03922386 416 417 O

1 NCT03922386 421 422 O
. NCT03922386 422 423 O
Included NCT03922386 425 433 O
in NCT03922386 434 436 O
another NCT03922386 437 444 B-Other
clinical NCT03922386 445 453 O
study NCT03922386 454 459 B-Study
that NCT03922386 460 464 O
could NCT03922386 465 470 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03922386 471 479 O
the NCT03922386 480 483 O
results NCT03922386 484 491 O
of NCT03922386 492 494 O
this NCT03922386 495 499 O
study NCT03922386 500 505 B-Study
such NCT03922386 506 510 O
as NCT03922386 511 513 O
studies NCT03922386 514 521 B-Study
involving NCT03922386 522 531 O
intra NCT03922386 532 537 B-Procedure
- NCT03922386 538 539 I-Procedure
cardiac NCT03922386 540 547 I-Procedure
device NCT03922386 548 554 I-Procedure

2 NCT03922386 557 558 O
. NCT03922386 558 559 O
Contraindication NCT03922386 561 577 B-Contraindication
to NCT03922386 578 580 O
a NCT03922386 581 582 O
maximum NCT03922386 583 590 B-Eq-Comparison
single NCT03922386 591 597 I-Eq-Comparison
dose NCT03922386 598 602 I-Eq-Comparison
of NCT03922386 603 605 I-Eq-Comparison
310 NCT03922386 606 609 I-Eq-Comparison
µg NCT03922386 610 612 I-Eq-Comparison
Dexamethasone NCT03922386 613 626 B-Drug
Sodium NCT03922386 627 633 I-Drug
Phosphate NCT03922386 634 643 I-Drug
( NCT03922386 644 645 O
DSP NCT03922386 646 649 B-Drug
) NCT03922386 650 651 O

3 NCT03922386 655 656 O
. NCT03922386 656 657 O
Tricuspid NCT03922386 659 668 B-Condition
valvular NCT03922386 669 677 I-Condition
disease NCT03922386 678 685 I-Condition
or NCT03922386 686 688 B-Or
tricuspid NCT03922386 689 698 B-Procedure
replacement NCT03922386 699 710 I-Procedure
heart NCT03922386 711 716 I-Procedure
valve NCT03922386 717 722 I-Procedure
( NCT03922386 723 724 O
mechanical NCT03922386 725 735 B-Modifier
or NCT03922386 736 738 B-Or
tissue NCT03922386 739 745 B-Modifier
) NCT03922386 746 747 O
only NCT03922386 748 752 O
for NCT03922386 753 756 O
subject NCT03922386 757 764 O
with NCT03922386 765 769 O
DR NCT03922386 770 772 B-Procedure
pacemaker NCT03922386 773 782 I-Procedure

4 NCT03922386 785 786 O
. NCT03922386 786 787 O
Active NCT03922386 789 795 B-Eq-Comparison
myocarditis NCT03922386 796 807 B-Condition
, NCT03922386 808 809 O
pocket NCT03922386 810 816 B-Modifier
and NCT03922386 817 820 B-Or
/ NCT03922386 821 822 I-Or
or NCT03922386 823 825 I-Or
lead NCT03922386 826 830 B-Modifier
infection NCT03922386 831 840 B-Condition

5 NCT03922386 843 844 O
. NCT03922386 844 845 O
Age NCT03922386 847 850 B-Age
less NCT03922386 851 855 B-Eq-Comparison
than NCT03922386 856 860 I-Eq-Comparison
18 NCT03922386 861 863 I-Eq-Comparison
years NCT03922386 864 869 I-Eq-Comparison
old NCT03922386 870 873 O
or NCT03922386 874 876 O
under NCT03922386 877 882 O
guardianship NCT03922386 883 895 O
or NCT03922386 896 898 O
kept NCT03922386 899 903 O
in NCT03922386 904 906 O
detention NCT03922386 907 916 O

6 NCT03922386 919 920 O
. NCT03922386 920 921 O
Life NCT03922386 923 927 B-Observation
expectancy NCT03922386 928 938 I-Observation
less NCT03922386 939 943 B-Eq-Comparison
than NCT03922386 944 948 I-Eq-Comparison
1 NCT03922386 949 950 I-Eq-Comparison
year NCT03922386 951 955 I-Eq-Comparison

7 NCT03922386 958 959 O
. NCT03922386 959 960 O
Known NCT03922386 962 967 O
pregnancy NCT03922386 968 977 B-Condition
, NCT03922386 978 979 O
women NCT03922386 980 985 O
breastfeeding NCT03922386 986 999 B-Condition
or NCT03922386 1000 1002 B-Or
in NCT03922386 1003 1005 O
childbearing NCT03922386 1006 1018 O
age NCT03922386 1019 1022 O
without NCT03922386 1023 1030 B-Negation
an NCT03922386 1031 1033 O
adequate NCT03922386 1034 1042 O
contraceptive NCT03922386 1043 1056 B-Procedure
method NCT03922386 1057 1063 I-Procedure

8 NCT03922386 1066 1067 O
. NCT03922386 1067 1068 O
Be NCT03922386 1070 1072 O
unavailable NCT03922386 1073 1084 O
for NCT03922386 1085 1088 O
the NCT03922386 1089 1092 O
scheduled NCT03922386 1093 1102 O
follow NCT03922386 1103 1109 O
- NCT03922386 1110 1111 O
up NCT03922386 1112 1114 O
associated NCT03922386 1115 1125 O
with NCT03922386 1126 1130 O
this NCT03922386 1131 1135 O
clinical NCT03922386 1136 1144 O
study NCT03922386 1145 1150 O
or NCT03922386 1151 1153 O
refusal NCT03922386 1154 1161 O
to NCT03922386 1162 1164 O
cooperate NCT03922386 1165 1174 O

Inclusion NCT03925402 0 9 O
Criteria NCT03925402 10 18 O
: NCT03925402 19 20 O

- NCT03925402 24 25 O
Adults NCT03925402 27 33 O
, NCT03925402 34 35 O
either NCT03925402 36 42 O
sex NCT03925402 43 46 O
, NCT03925402 47 48 O
ages NCT03925402 49 53 B-Age
18 NCT03925402 54 56 B-Eq-Comparison
years NCT03925402 57 62 I-Eq-Comparison
or NCT03925402 63 65 I-Eq-Comparison
above NCT03925402 66 71 I-Eq-Comparison

- NCT03925402 74 75 O
Patients NCT03925402 77 85 O
with NCT03925402 86 90 O
3 NCT03925402 91 92 B-Condition
GCRE NCT03925402 93 97 I-Condition
bacteremia NCT03925402 98 108 I-Condition

- NCT03925402 111 112 O
Patients NCT03925402 114 122 O
admitted NCT03925402 123 131 B-Encounter
to NCT03925402 132 134 O
any NCT03925402 135 138 O
of NCT03925402 139 141 O
the NCT03925402 142 145 O
study NCT03925402 146 151 O
sites NCT03925402 152 157 O

Exclusion NCT03925402 158 167 O
Criteria NCT03925402 168 176 O
: NCT03925402 177 178 O

- NCT03925402 182 183 O
Discontinuation NCT03925402 185 200 O
of NCT03925402 201 203 O
antibiotic NCT03925402 204 214 B-Drug
due NCT03925402 215 218 O
to NCT03925402 219 221 O
transition NCT03925402 222 232 B-Encounter
to NCT03925402 233 235 O
hospice NCT03925402 236 243 O
care NCT03925402 244 248 O

- NCT03925402 251 252 O
Polymicrobial NCT03925402 254 267 B-Condition
bacteremia NCT03925402 268 278 I-Condition

- NCT03925402 281 282 O
Empirical NCT03925402 284 293 B-Drug
antibiotic NCT03925402 294 304 I-Drug
after NCT03925402 305 310 B-Temporal-Connection___Temporal-Connection-Type-Value:after
24 NCT03925402 311 313 B-Eq-Comparison
hours NCT03925402 314 319 I-Eq-Comparison
of NCT03925402 320 322 I-Eq-Comparison
first NCT03925402 323 328 I-Eq-Comparison
evidence NCT03925402 329 337 O
of NCT03925402 338 340 O
bacteremia NCT03925402 341 351 B-Condition

Inclusion NCT03928132 0 9 O
Criteria NCT03928132 10 18 O
: NCT03928132 19 20 O

- NCT03928132 24 25 O
French NCT03928132 27 33 O
- NCT03928132 34 35 O
speaking NCT03928132 36 44 O
health NCT03928132 45 51 O
professionals NCT03928132 52 65 O
( NCT03928132 66 67 O
in NCT03928132 68 70 O
practice NCT03928132 71 79 O
and NCT03928132 80 83 O
in NCT03928132 84 86 O
training NCT03928132 87 95 O
) NCT03928132 96 97 O
. NCT03928132 98 99 O

Inclusion NCT03921658 0 9 O
Criteria NCT03921658 10 18 O
: NCT03921658 19 20 O

- NCT03921658 24 25 O
Age NCT03921658 27 30 B-Age
≥ NCT03921658 31 32 B-Eq-Comparison
18 NCT03921658 33 35 I-Eq-Comparison

- NCT03921658 39 40 O
Ability NCT03921658 42 49 O
to NCT03921658 50 52 O
read NCT03921658 53 57 O
and NCT03921658 58 61 O
write NCT03921658 62 67 O
in NCT03921658 68 70 O
English NCT03921658 71 78 O

- NCT03921658 81 82 O
women NCT03921658 84 89 O
with NCT03921658 90 94 B-And
newly NCT03921658 95 100 B-Eq-Comparison
diagnosed NCT03921658 101 110 O
with NCT03921658 111 115 O
ovarian NCT03921658 116 123 B-Modifier
, NCT03921658 124 125 O
primary NCT03921658 126 133 B-Modifier
peritoneal NCT03921658 134 144 I-Modifier
, NCT03921658 145 146 O
or NCT03921658 147 149 B-Or
fallopian NCT03921658 150 159 B-Modifier
tube NCT03921658 160 164 I-Modifier
cancer NCT03921658 165 171 B-Condition

- NCT03921658 174 175 O
Treatment NCT03921658 177 186 B-Procedure
plan NCT03921658 187 191 B-Assertion___Assertion-Type-Value:hypothetical
includes NCT03921658 192 200 O
chemotherapy NCT03921658 201 213 B-Procedure

- NCT03921658 216 217 O
Able NCT03921658 219 223 O
to NCT03921658 224 226 O
provide NCT03921658 227 234 O
written NCT03921658 235 242 O
voluntary NCT03921658 243 252 O
consent NCT03921658 253 260 O
before NCT03921658 261 267 O
performance NCT03921658 268 279 O
of NCT03921658 280 282 O
any NCT03921658 283 286 O
study NCT03921658 287 292 O
related NCT03921658 293 300 O
procedure NCT03921658 301 310 O
. NCT03921658 311 312 O

- NCT03921658 316 317 O
Cohort NCT03921658 319 325 O
1 NCT03921658 326 327 O
only NCT03921658 328 332 O
: NCT03921658 333 334 O
within NCT03921658 335 341 B-Eq-Comparison
2 NCT03921658 342 343 I-Eq-Comparison
years NCT03921658 344 349 I-Eq-Comparison
of NCT03921658 350 352 O
completing NCT03921658 353 363 O
initial NCT03921658 364 371 B-Eq-Comparison
chemotherapy NCT03921658 372 384 B-Procedure
treatment NCT03921658 385 394 I-Procedure

- NCT03921658 397 398 O
Cohort NCT03921658 400 406 O
2 NCT03921658 407 408 O
only NCT03921658 409 413 O
: NCT03921658 414 415 O
prior NCT03921658 416 421 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921658 422 424 O
starting NCT03921658 425 433 O
chemotherapy NCT03921658 434 446 B-Procedure

Exclusion NCT03921658 447 456 O
Criteria NCT03921658 457 465 O
: NCT03921658 466 467 O

- NCT03921658 471 472 O
Inability NCT03921658 474 483 O
to NCT03921658 484 486 O
provide NCT03921658 487 494 O
informed NCT03921658 495 503 O
written NCT03921658 504 511 O
consent NCT03921658 512 519 O

- NCT03921658 522 523 O
Previous NCT03921658 525 533 B-Eq-Comparison
exposure NCT03921658 534 542 O
to NCT03921658 543 545 O
chemotherapy NCT03921658 546 558 B-Procedure

- NCT03921658 561 562 O
Life NCT03921658 564 568 B-Observation
expectancy NCT03921658 569 579 I-Observation
< NCT03921658 580 581 B-Eq-Comparison
3 NCT03921658 582 583 I-Eq-Comparison
months NCT03921658 584 590 I-Eq-Comparison
or NCT03921658 591 593 B-Or
in NCT03921658 594 596 O
hospice NCT03921658 597 604 B-Observation
care NCT03921658 605 609 I-Observation
or NCT03921658 610 612 B-Or
nursing NCT03921658 613 620 B-Observation
home NCT03921658 621 625 I-Observation

Inclusion NCT03929562 0 9 O
Criteria NCT03929562 10 18 O
: NCT03929562 19 20 O

- NCT03929562 24 25 O
Referred NCT03929562 27 35 B-Encounter
for NCT03929562 36 39 O
elective NCT03929562 40 48 O
or NCT03929562 49 51 O
semi NCT03929562 52 56 O
- NCT03929562 57 58 O
elective NCT03929562 59 67 O
surgery NCT03929562 68 75 B-Procedure
or NCT03929562 76 78 B-Or
pre NCT03929562 79 82 B-Observation
- NCT03929562 83 84 I-Observation
operative NCT03929562 85 94 I-Observation
assessment NCT03929562 95 105 I-Observation
in NCT03929562 106 108 O
the NCT03929562 109 112 O
next NCT03929562 113 117 B-Eq-Comparison
120 NCT03929562 118 121 I-Eq-Comparison
days NCT03929562 122 126 I-Eq-Comparison

- NCT03929562 129 130 O
Meet NCT03929562 132 136 O
criteria NCT03929562 137 145 O
for NCT03929562 146 149 O
" NCT03929562 150 151 O
risky NCT03929562 151 156 B-Condition
drinking NCT03929562 157 165 I-Condition
" NCT03929562 165 166 O
as NCT03929562 167 169 O
defined NCT03929562 170 177 O
by NCT03929562 178 180 O
study NCT03929562 181 186 O
staff NCT03929562 187 192 O

Exclusion NCT03929562 193 202 O
Criteria NCT03929562 203 211 O
: NCT03929562 212 213 O

- NCT03929562 217 218 O
Displays NCT03929562 220 228 O
or NCT03929562 229 231 O
shows NCT03929562 232 237 O
evidence NCT03929562 238 246 O
of NCT03929562 247 249 O
psychotic NCT03929562 250 259 B-Condition
symptoms NCT03929562 260 268 B-Assertion___Assertion-Type-Value:possible

- NCT03929562 271 272 O
Undergoing NCT03929562 274 284 B-Eq-Comparison
surgeries NCT03929562 285 294 B-Procedure
that NCT03929562 295 299 O
commonly NCT03929562 300 308 O
require NCT03929562 309 316 O
local NCT03929562 317 322 B-Procedure
anesthesia NCT03929562 323 333 I-Procedure
only NCT03929562 334 338 O


Inclusion NCT03920397 0 9 O
Criteria NCT03920397 10 18 O
: NCT03920397 19 20 O

- NCT03920397 24 25 O
Diagnosis NCT03920397 27 36 O
of NCT03920397 37 39 O
Type NCT03920397 40 44 B-Condition
1 NCT03920397 45 46 I-Condition
Diabetes NCT03920397 47 55 I-Condition
according NCT03920397 56 65 O
to NCT03920397 66 68 O
the NCT03920397 69 72 O
American NCT03920397 73 81 O
Diabetes NCT03920397 82 90 O
Association NCT03920397 91 102 O
criteria NCT03920397 103 111 O
for NCT03920397 112 115 O
a NCT03920397 116 117 O
period NCT03920397 118 124 O
less NCT03920397 125 129 B-Eq-Comparison
than NCT03920397 130 134 I-Eq-Comparison
four NCT03920397 135 139 I-Eq-Comparison
months NCT03920397 140 146 I-Eq-Comparison
. NCT03920397 147 148 O

- NCT03920397 152 153 O
Pancreatic NCT03920397 155 165 B-Condition
Autoimmunity NCT03920397 166 178 I-Condition
( NCT03920397 179 180 O
positive NCT03920397 181 189 O
anti NCT03920397 190 194 B-Condition
- NCT03920397 195 196 I-Condition
glutamic NCT03920397 197 205 I-Condition
acid NCT03920397 206 210 I-Condition
decarboxylase NCT03920397 211 224 I-Condition
[ NCT03920397 225 226 O
GAD NCT03920397 227 230 B-Condition
] NCT03920397 231 232 O
; NCT03920397 233 234 O
and NCT03920397 235 238 B-Or
/ NCT03920397 239 240 I-Or
or NCT03920397 241 243 I-Or
Islet NCT03920397 244 249 B-Condition
antigen NCT03920397 250 257 I-Condition
2 NCT03920397 258 259 I-Condition
[ NCT03920397 260 261 O
anti NCT03920397 262 266 B-Condition
- NCT03920397 267 268 I-Condition
IA2 NCT03920397 269 272 I-Condition
] NCT03920397 273 274 O
) NCT03920397 276 277 O
. NCT03920397 279 280 O

Exclusion NCT03920397 282 291 O
Criteria NCT03920397 292 300 O
: NCT03920397 301 302 O

- NCT03920397 306 307 O
Clinical NCT03920397 309 317 O
evidence NCT03920397 318 326 O
of NCT03920397 327 329 O
malignancy NCT03920397 330 340 B-Condition
or NCT03920397 341 343 O
prior NCT03920397 344 349 B-Eq-Comparison
history NCT03920397 350 357 I-Eq-Comparison
. NCT03920397 358 359 O

- NCT03920397 363 364 O
Pregnancy NCT03920397 366 375 B-Condition
or NCT03920397 376 378 B-Or
desire NCT03920397 379 385 B-Assertion___Assertion-Type-Value:intention
to NCT03920397 386 388 I-Assertion___Assertion-Type-Value:intention
become NCT03920397 389 395 O
pregnant NCT03920397 396 404 B-Condition
within NCT03920397 405 411 B-Eq-Comparison
12 NCT03920397 412 414 I-Eq-Comparison
months NCT03920397 415 421 I-Eq-Comparison
of NCT03920397 422 424 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03920397 425 428 O
study NCT03920397 429 434 B-Study
. NCT03920397 435 436 O

- NCT03920397 440 441 O
Breastfeeding NCT03920397 443 456 B-Condition
. NCT03920397 458 459 O

- NCT03920397 463 464 O
HIV NCT03920397 466 469 B-Condition
( NCT03920397 470 471 O
+ NCT03920397 473 474 O
) NCT03920397 476 477 O
, NCT03920397 479 480 O
Hepatitis NCT03920397 481 490 B-Condition
B NCT03920397 491 492 I-Condition
( NCT03920397 493 494 O
+ NCT03920397 496 497 O
) NCT03920397 499 500 O
, NCT03920397 502 503 O
Hepatitis NCT03920397 504 513 B-Condition
C NCT03920397 514 515 I-Condition
( NCT03920397 516 517 O
+ NCT03920397 519 520 O
) NCT03920397 522 523 O
. NCT03920397 525 526 O

- NCT03920397 530 531 O
Diabetic NCT03920397 533 541 B-Condition
ketoacidosis NCT03920397 542 554 I-Condition
at NCT03920397 555 557 O
diagnosis NCT03920397 558 567 O
. NCT03920397 568 569 O

- NCT03920397 573 574 O
Glomerular NCT03920397 576 586 B-Observation
filtration NCT03920397 587 597 I-Observation
rate NCT03920397 598 602 I-Observation
less NCT03920397 603 607 B-Eq-Comparison
than NCT03920397 608 612 I-Eq-Comparison
60 NCT03920397 613 615 I-Eq-Comparison
ml NCT03920397 616 618 O
/ NCT03920397 619 620 O
min NCT03920397 621 624 O
. NCT03920397 625 626 O

- NCT03920397 630 631 O
Use NCT03920397 633 636 B-Eq-Comparison
of NCT03920397 637 639 O
immunosuppressors NCT03920397 640 657 B-Drug
or NCT03920397 658 660 B-Or
glucocorticoids NCT03920397 661 676 B-Drug
. NCT03920397 676 677 O

Inclusion NCT03922594 0 9 O
Criteria NCT03922594 10 18 O
: NCT03922594 19 20 O

- NCT03922594 24 25 O
All NCT03922594 27 30 O
infants NCT03922594 31 38 O
or NCT03922594 39 41 B-Or
fetuses NCT03922594 42 49 O
with NCT03922594 50 54 B-And
microcephaly NCT03922594 55 67 B-Condition
, NCT03922594 68 69 O
( NCT03922594 70 71 O
defined NCT03922594 72 79 O
as NCT03922594 80 82 O
head NCT03922594 83 87 B-Observation
circumference NCT03922594 88 101 I-Observation
≤ NCT03922594 102 103 O
- NCT03922594 105 106 O
3 NCT03922594 107 108 O
SD NCT03922594 109 111 O
according NCT03922594 112 121 O
to NCT03922594 122 124 O
INTERGROWTH NCT03922594 125 136 O
standards NCT03922594 137 146 O
for NCT03922594 147 150 O
gestational NCT03922594 151 162 O
age NCT03922594 163 166 O
and NCT03922594 167 170 O
sex NCT03922594 171 174 O
, NCT03922594 175 176 O
detected NCT03922594 177 185 O
during NCT03922594 186 192 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922594 193 196 O
mother NCT03922594 197 203 B-Family-Member___Family-Member-Type:mother
's NCT03922594 203 205 I-Family-Member___Family-Member-Type:mother
pregnancy NCT03922594 206 215 B-Condition
, NCT03922594 216 217 O
or NCT03922594 218 220 B-Or
at NCT03922594 221 223 O
the NCT03922594 224 227 O
end NCT03922594 228 231 O
of NCT03922594 232 234 O
the NCT03922594 235 238 O
mother NCT03922594 239 245 B-Family-Member___Family-Member-Type:mother
's NCT03922594 245 247 I-Family-Member___Family-Member-Type:mother
pregnancy NCT03922594 248 257 B-Condition
at NCT03922594 258 260 O
one NCT03922594 261 264 O
of NCT03922594 265 267 O
the NCT03922594 268 271 O
participating NCT03922594 272 285 O
maternities NCT03922594 286 297 O
) NCT03922594 298 299 O

- NCT03922594 303 304 O
and NCT03922594 306 309 O
with NCT03922594 310 314 O
abnormal NCT03922594 315 323 O
ultrasound NCT03922594 324 334 B-Procedure
and NCT03922594 335 338 B-Or
/ NCT03922594 339 340 I-Or
or NCT03922594 341 343 I-Or
clinical NCT03922594 344 352 B-Observation
examination NCT03922594 353 364 I-Observation
findings NCT03922594 365 373 I-Observation
for NCT03922594 374 377 O
newborns NCT03922594 378 386 O
. NCT03922594 387 388 O

Exclusion NCT03922594 390 399 O
Criteria NCT03922594 400 408 O
: NCT03922594 409 410 O

- NCT03922594 414 415 O
Infants NCT03922594 417 424 O
/ NCT03922594 425 426 O
fetuses NCT03922594 427 434 O
with NCT03922594 435 439 B-And
microcephaly NCT03922594 440 452 B-Condition
whose NCT03922594 453 458 O
mothers NCT03922594 459 466 B-Family-Member___Family-Member-Type:mother
are NCT03922594 467 470 O
under NCT03922594 471 476 B-Eq-Comparison
the NCT03922594 477 480 I-Eq-Comparison
age NCT03922594 481 484 I-Eq-Comparison
of NCT03922594 485 487 I-Eq-Comparison
18 NCT03922594 488 490 I-Eq-Comparison
years NCT03922594 491 496 I-Eq-Comparison
, NCT03922594 497 498 O

- NCT03922594 502 503 O
or NCT03922594 505 507 O
inability NCT03922594 508 517 O
or NCT03922594 518 520 O
refusal NCT03922594 521 528 O
of NCT03922594 529 531 O
mothers NCT03922594 532 539 O
/ NCT03922594 540 541 O
guardians NCT03922594 542 551 O
to NCT03922594 552 554 O
give NCT03922594 555 559 O
informed NCT03922594 560 568 O
consent NCT03922594 569 576 O
. NCT03922594 576 577 O

Inclusion NCT03921710 0 9 O
criteria NCT03921710 10 18 O
: NCT03921710 19 20 O

- NCT03921710 24 25 O
< NCT03921710 27 28 B-Eq-Comparison
38 NCT03921710 29 31 I-Eq-Comparison
years NCT03921710 32 37 I-Age|Eq-Comparison

- NCT03921710 40 41 O
PCOS NCT03921710 43 47 B-Condition
patients NCT03921710 48 56 O
with NCT03921710 57 61 B-And
polycystic NCT03921710 62 72 B-Condition
ovarian NCT03921710 73 80 I-Condition
morphology NCT03921710 81 91 I-Condition
: NCT03921710 92 93 O
at NCT03921710 94 96 B-Eq-Comparison
least NCT03921710 97 102 I-Eq-Comparison
25 NCT03921710 103 105 I-Eq-Comparison
follicles NCT03921710 106 115 I-Eq-Comparison|Observation
( NCT03921710 116 117 O
2 NCT03921710 118 119 O
- NCT03921710 120 121 B-Eq-Comparison
9 NCT03921710 122 123 I-Eq-Comparison
mm NCT03921710 124 126 I-Eq-Comparison
) NCT03921710 127 128 O
throughout NCT03921710 129 139 O
the NCT03921710 140 143 O
whole NCT03921710 144 149 O
ovary NCT03921710 150 155 O
and NCT03921710 156 159 O
/ NCT03921710 160 161 O
or NCT03921710 162 164 O
increased NCT03921710 165 174 O
ovarian NCT03921710 175 182 B-Observation
volume NCT03921710 183 189 I-Observation
( NCT03921710 190 191 O
> NCT03921710 193 194 B-Eq-Comparison
10 NCT03921710 195 197 I-Eq-Comparison
ml NCT03921710 198 200 O
) NCT03921710 201 202 O
( NCT03921710 203 204 O
it NCT03921710 205 207 O
is NCT03921710 208 210 O
sufficient NCT03921710 211 221 O
that NCT03921710 222 226 O
1 NCT03921710 227 228 O
ovary NCT03921710 229 234 O
fits NCT03921710 235 239 O
these NCT03921710 240 245 O
criteria NCT03921710 246 254 O
) NCT03921710 255 256 O

- NCT03921710 260 261 O
No NCT03921710 263 265 B-Negation
major NCT03921710 266 271 B-Modifier
uterine NCT03921710 272 279 B-Modifier
or NCT03921710 280 282 B-Or
ovarian NCT03921710 283 290 B-Modifier
abnormalities NCT03921710 291 304 B-Condition

Exclusion NCT03921710 305 314 O
criteria NCT03921710 315 323 O
: NCT03921710 324 325 O

- NCT03921710 329 330 O
High NCT03921710 332 336 O
( NCT03921710 337 338 O
> NCT03921710 340 341 B-Eq-Comparison
grade NCT03921710 342 347 I-Eq-Comparison
2 NCT03921710 348 349 I-Eq-Comparison
) NCT03921710 350 351 O
grade NCT03921710 352 357 O
endometriosis NCT03921710 358 371 B-Condition

- NCT03921710 374 375 O
Cases NCT03921710 377 382 O
with NCT03921710 383 387 O
extremely NCT03921710 388 397 O
poor NCT03921710 398 402 B-Condition
sperm NCT03921710 403 408 I-Condition
( NCT03921710 409 410 O
OAT NCT03921710 411 414 B-Condition
) NCT03921710 415 416 O
such NCT03921710 417 421 O
as NCT03921710 422 424 O
azoospermia NCT03921710 425 436 B-Condition
or NCT03921710 437 439 B-Or
cryptozoospermia NCT03921710 440 456 B-Condition

Inclusion NCT03920618 0 9 O
Criteria NCT03920618 10 18 O
: NCT03920618 19 20 O

1 NCT03920618 24 25 I-Eq-Comparison
. NCT03920618 25 26 O
Positive NCT03920618 28 36 O
hepatitis NCT03920618 37 46 B-Observation
b NCT03920618 47 48 I-Observation
surface NCT03920618 49 56 I-Observation
antigen NCT03920618 57 64 I-Observation
or NCT03920618 65 67 B-Or
hepatitis NCT03920618 68 77 B-Observation
b NCT03920618 78 79 I-Observation
virus NCT03920618 80 85 I-Observation
DNA NCT03920618 86 89 I-Observation
> NCT03920618 90 91 B-Eq-Comparison
0.5 NCT03920618 92 95 I-Eq-Comparison
year NCT03920618 96 100 I-Eq-Comparison
; NCT03920618 100 101 O

2 NCT03920618 104 105 O
. NCT03920618 105 106 O
Age NCT03920618 108 111 B-Age
from NCT03920618 112 116 O
18 NCT03920618 117 119 B-Eq-Comparison
to NCT03920618 120 122 I-Eq-Comparison
55 NCT03920618 123 125 I-Eq-Comparison
years NCT03920618 126 131 I-Eq-Comparison
old NCT03920618 132 135 O
; NCT03920618 135 136 O

3 NCT03920618 139 140 O
. NCT03920618 140 141 O
Serum NCT03920618 143 148 B-Observation
total NCT03920618 149 154 I-Observation
bilirubin NCT03920618 155 164 I-Observation
level NCT03920618 165 170 I-Observation
> NCT03920618 171 172 B-Eq-Comparison
10 NCT03920618 173 175 I-Eq-Comparison
times NCT03920618 176 181 I-Eq-Comparison
upper NCT03920618 182 187 I-Eq-Comparison
limit NCT03920618 188 193 I-Eq-Comparison
of NCT03920618 194 196 I-Eq-Comparison
normal NCT03920618 197 203 I-Eq-Comparison
; NCT03920618 203 204 O

4 NCT03920618 207 208 O
. NCT03920618 208 209 O
Prothrombin NCT03920618 211 222 B-Observation
time NCT03920618 223 227 I-Observation
activity NCT03920618 228 236 I-Observation
< NCT03920618 237 238 B-Eq-Comparison
40 NCT03920618 239 241 I-Eq-Comparison
% NCT03920618 242 243 O
or NCT03920618 244 246 B-Or
prothrombin NCT03920618 247 258 B-Observation
time NCT03920618 259 263 I-Observation
international NCT03920618 264 277 I-Observation
ratio NCT03920618 278 283 I-Observation
> NCT03920618 284 285 O
1.5 NCT03920618 286 289 O
； NCT03920618 290 291 O

5 NCT03920618 294 295 O
. NCT03920618 295 296 O
Do NCT03920618 298 300 O
not NCT03920618 301 304 B-Negation
receive NCT03920618 305 312 O
nucleotide NCT03920618 313 323 B-Modifier
/ NCT03920618 324 325 B-Or
nucleoside NCT03920618 326 336 B-Modifier
analogues NCT03920618 337 346 B-Procedure
treatment NCT03920618 347 356 I-Procedure
in NCT03920618 357 359 O
the NCT03920618 360 363 O
past NCT03920618 364 368 B-Eq-Comparison
half NCT03920618 369 373 I-Eq-Comparison
year NCT03920618 374 378 I-Eq-Comparison
. NCT03920618 379 380 O

Exclusion NCT03920618 382 391 O
Criteria NCT03920618 392 400 O
: NCT03920618 401 402 O

1 NCT03920618 406 407 O
. NCT03920618 407 408 O
Other NCT03920618 410 415 B-Other
active NCT03920618 416 422 B-Eq-Comparison
liver NCT03920618 423 428 B-Condition
diseases NCT03920618 429 437 I-Condition
; NCT03920618 437 438 O

2 NCT03920618 441 442 O
. NCT03920618 442 443 O
Hepatocellular NCT03920618 445 459 B-Condition
carcinoma NCT03920618 460 469 I-Condition
or NCT03920618 470 472 B-Or
other NCT03920618 473 478 B-Other
malignancy NCT03920618 479 489 B-Condition
; NCT03920618 489 490 O

3 NCT03920618 493 494 O
. NCT03920618 494 495 O
Pregnancy NCT03920618 497 506 B-Condition
or NCT03920618 507 509 B-Or
lactation NCT03920618 510 519 B-Condition
; NCT03920618 519 520 O

4 NCT03920618 523 524 O
. NCT03920618 524 525 O
Human NCT03920618 527 532 B-Condition
immunodeficiency NCT03920618 533 549 I-Condition
virus NCT03920618 550 555 I-Condition
infection NCT03920618 556 565 I-Condition
or NCT03920618 566 568 B-Or
congenital NCT03920618 569 579 B-Condition
immune NCT03920618 580 586 I-Condition
deficiency NCT03920618 587 597 I-Condition
diseases NCT03920618 598 606 I-Condition
; NCT03920618 606 607 O

5 NCT03920618 610 611 O
. NCT03920618 611 612 O
Severe NCT03920618 614 620 O
diabetes NCT03920618 621 629 B-Condition
, NCT03920618 630 631 O
autoimmune NCT03920618 632 642 B-Condition
diseases NCT03920618 643 651 I-Condition
; NCT03920618 651 652 O

6 NCT03920618 655 656 O
. NCT03920618 656 657 O
Other NCT03920618 659 664 B-Other
important NCT03920618 665 674 O
organ NCT03920618 675 680 B-Condition
dysfunctions NCT03920618 681 693 I-Condition
; NCT03920618 693 694 O

7 NCT03920618 697 698 O
. NCT03920618 698 699 O
Using NCT03920618 701 706 B-Eq-Comparison
glucocorticoid NCT03920618 707 721 B-Drug
; NCT03920618 721 722 O

8 NCT03920618 725 726 O
. NCT03920618 726 727 O
Patients NCT03920618 729 737 O
can NCT03920618 738 741 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03920618 742 745 B-Negation
follow NCT03920618 746 752 B-Encounter
- NCT03920618 753 754 I-Encounter
up NCT03920618 755 757 I-Encounter
; NCT03920618 757 758 O

9 NCT03920618 761 762 O
. NCT03920618 762 763 O
Investigator NCT03920618 765 777 O
considering NCT03920618 778 789 O
inappropriate NCT03920618 790 803 O
. NCT03920618 803 804 O

Inclusion NCT03928522 0 9 O
Criteria NCT03928522 10 18 O
: NCT03928522 19 20 O

- NCT03928522 24 25 O
Age NCT03928522 27 30 B-Age
over NCT03928522 31 35 B-Eq-Comparison
18 NCT03928522 36 38 I-Eq-Comparison

- NCT03928522 42 43 O
Total NCT03928522 45 50 B-Procedure
knee NCT03928522 51 55 I-Procedure
arthroplasty NCT03928522 56 68 I-Procedure
for NCT03928522 69 72 O
primary NCT03928522 73 80 B-Modifier
osteoarthritis NCT03928522 81 95 B-Condition
performed NCT03928522 96 105 O
by NCT03928522 106 108 O
Dr. NCT03928522 109 112 B-Provider
Rick NCT03928522 114 118 I-Provider
Wright NCT03928522 119 125 I-Provider
. NCT03928522 126 127 O

- NCT03928522 131 132 O
Primary NCT03928522 134 141 O
diagnosis NCT03928522 142 151 O
of NCT03928522 152 154 O
knee NCT03928522 155 159 B-Modifier
osteoarthritis NCT03928522 160 174 B-Condition

- NCT03928522 182 183 O
Exclusion NCT03928522 185 194 O
Criteria NCT03928522 195 203 O
: NCT03928522 204 205 O

- NCT03928522 209 210 O
Diminished NCT03928522 212 222 B-Condition
mental NCT03928522 223 229 I-Condition
capacity NCT03928522 230 238 I-Condition

- NCT03928522 241 242 O
Vancomycin NCT03928522 244 254 B-Drug
allergy NCT03928522 255 262 B-Allergy

- NCT03928522 265 266 O
Tobramycin NCT03928522 268 278 B-Drug
allergy NCT03928522 279 286 B-Allergy

- NCT03928522 289 290 O
Patient NCT03928522 292 299 O
history NCT03928522 300 307 B-Eq-Comparison
requiring NCT03928522 308 317 O
IV NCT03928522 318 320 O
administration NCT03928522 321 335 O
of NCT03928522 336 338 O
vancomycin NCT03928522 339 349 B-Drug
or NCT03928522 350 352 B-Or
tobramycin NCT03928522 353 363 B-Drug
peri NCT03928522 364 368 B-Temporal-Connection___Temporal-Connection-Type-Value:during
operatively NCT03928522 369 380 B-Procedure

- NCT03928522 383 384 O
Chronic NCT03928522 386 393 B-Modifier
kidney NCT03928522 394 400 B-Condition
disease NCT03928522 401 408 I-Condition
stage NCT03928522 409 414 B-Eq-Comparison
III NCT03928522 415 418 I-Eq-Comparison
and NCT03928522 419 422 I-Eq-Comparison
stage NCT03928522 423 428 I-Eq-Comparison
IV NCT03928522 429 431 I-Eq-Comparison

Inclusion NCT03929614 0 9 O
Criteria NCT03929614 10 18 O
: NCT03929614 19 20 O

- NCT03929614 24 25 O
AIS NCT03929614 27 30 B-Condition
. NCT03929614 31 32 O

- NCT03929614 36 37 O
10 NCT03929614 39 41 B-Eq-Comparison
- NCT03929614 42 43 I-Eq-Comparison
16 NCT03929614 44 46 I-Eq-Comparison
years NCT03929614 47 52 I-Eq-Comparison
old NCT03929614 53 56 B-Age
, NCT03929614 57 58 O
with NCT03929614 59 63 B-And
brace NCT03929614 64 69 B-Procedure
treatment NCT03929614 70 79 I-Procedure
. NCT03929614 80 81 O

- NCT03929614 85 86 O
Ability NCT03929614 88 95 O
to NCT03929614 96 98 O
read NCT03929614 99 103 O
and NCT03929614 104 107 O
understand NCT03929614 108 118 O
English NCT03929614 119 126 O
or NCT03929614 127 129 B-Or
French NCT03929614 130 136 O
. NCT03929614 137 138 O

- NCT03929614 142 143 O
Physical NCT03929614 145 153 O
and NCT03929614 154 157 O
mental NCT03929614 158 164 O
ability NCT03929614 165 172 O
to NCT03929614 173 175 O
adhere NCT03929614 176 182 O
to NCT03929614 183 185 O
bracing NCT03929614 186 193 O
protocol NCT03929614 194 202 O
. NCT03929614 203 204 O

Exclusion NCT03929614 206 215 O
Criteria NCT03929614 216 224 O
: NCT03929614 225 226 O

- NCT03929614 230 231 O
Diagnosis NCT03929614 233 242 O
of NCT03929614 243 245 O
other NCT03929614 246 251 B-Other
musculoskeletal NCT03929614 252 267 B-Modifier
or NCT03929614 268 270 B-Or
developmental NCT03929614 271 284 B-Modifier
illness NCT03929614 285 292 B-Condition
that NCT03929614 293 297 O
might NCT03929614 298 303 B-Assertion___Assertion-Type-Value:possible
be NCT03929614 304 306 I-Assertion___Assertion-Type-Value:possible
responsible NCT03929614 307 318 O
for NCT03929614 319 322 O
the NCT03929614 323 326 O
spinal NCT03929614 327 333 B-Condition
curvature NCT03929614 334 343 I-Condition
. NCT03929614 344 345 O

- NCT03929614 349 350 O
Patients NCT03929614 352 360 O
with NCT03929614 361 365 O
symptom NCT03929614 366 373 B-Assertion___Assertion-Type-Value:possible
of NCT03929614 374 376 O
a NCT03929614 377 378 O
neurological NCT03929614 379 391 B-Condition
disorder NCT03929614 392 400 I-Condition
. NCT03929614 401 402 O

- NCT03929614 406 407 O
Patients NCT03929614 409 417 O
with NCT03929614 418 422 O
any NCT03929614 423 426 O
other NCT03929614 427 432 O
disorder NCT03929614 433 441 B-Condition
of NCT03929614 442 444 I-Condition
the NCT03929614 445 448 I-Condition
musculoskeletal NCT03929614 449 464 I-Condition
system NCT03929614 465 471 I-Condition
affecting NCT03929614 472 481 O
the NCT03929614 482 485 O
lower NCT03929614 486 491 B-Modifier
limbs NCT03929614 492 497 I-Modifier
, NCT03929614 498 499 O

Inclusion NCT03926533 0 9 O
Criteria NCT03926533 10 18 O
: NCT03926533 19 20 O

- NCT03926533 24 25 O
index NCT03926533 27 32 O
ICU NCT03926533 33 36 B-Encounter
stay NCT03926533 37 41 I-Encounter
with NCT03926533 42 46 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
a NCT03926533 47 48 O
diagnosis NCT03926533 49 58 O
of NCT03926533 59 61 O
sepsis NCT03926533 62 68 B-Condition
or NCT03926533 69 71 B-Or
acute NCT03926533 72 77 O
respiratory NCT03926533 78 89 B-Condition
distress NCT03926533 90 98 I-Condition
syndrome NCT03926533 99 107 I-Condition
projected NCT03926533 108 117 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926533 118 120 O
be NCT03926533 121 123 O
discharged NCT03926533 124 134 B-Encounter
alive NCT03926533 135 140 B-Condition
as NCT03926533 141 143 O
these NCT03926533 144 149 O
patients NCT03926533 150 158 O
are NCT03926533 159 162 O
at NCT03926533 163 165 O
the NCT03926533 166 169 O
highest NCT03926533 170 177 O
risk NCT03926533 178 182 B-Risk
for NCT03926533 183 186 O
developing NCT03926533 187 197 O
PICS NCT03926533 198 202 B-Condition

Exclusion NCT03926533 203 212 O
Criteria NCT03926533 213 221 O
: NCT03926533 222 223 O

1 NCT03926533 227 228 O
. NCT03926533 228 229 O
no NCT03926533 231 233 O
access NCT03926533 234 240 O
to NCT03926533 241 243 O
computer NCT03926533 244 252 O
, NCT03926533 253 254 O
electronic NCT03926533 255 265 O
device NCT03926533 266 272 O
( NCT03926533 273 274 O
e. NCT03926533 275 277 O
g. NCT03926533 278 280 O
, NCT03926533 281 282 O
tablet NCT03926533 283 289 O
, NCT03926533 290 291 O
smartphone NCT03926533 292 302 O
) NCT03926533 303 304 O
, NCT03926533 306 307 O
and NCT03926533 308 311 O
/ NCT03926533 312 313 O
or NCT03926533 314 316 O
internet NCT03926533 317 325 O
connection NCT03926533 326 336 O
for NCT03926533 337 340 O
virtual NCT03926533 341 348 O
clinic NCT03926533 349 355 O
visit NCT03926533 356 361 O
, NCT03926533 362 363 O

2 NCT03926533 367 368 O
. NCT03926533 368 369 O
primary NCT03926533 371 378 B-Encounter
care NCT03926533 379 383 I-Encounter
received NCT03926533 384 392 B-Eq-Comparison
outside NCT03926533 393 400 B-Other
of NCT03926533 401 403 O
VUMC NCT03926533 404 408 O
network NCT03926533 409 416 O
, NCT03926533 417 418 O

3 NCT03926533 422 423 O
. NCT03926533 423 424 O
hospice NCT03926533 426 433 O
care NCT03926533 434 438 O
at NCT03926533 439 441 O
discharge NCT03926533 442 451 B-Encounter
, NCT03926533 452 453 O

4 NCT03926533 457 458 O
. NCT03926533 458 459 O
substance NCT03926533 461 470 B-Condition
abuse NCT03926533 471 476 I-Condition
or NCT03926533 477 479 B-Or
psychiatric NCT03926533 480 491 B-Condition
disorder NCT03926533 492 500 I-Condition
that NCT03926533 501 505 O
prevents NCT03926533 506 514 B-Negation
independent NCT03926533 515 526 B-Condition
living NCT03926533 527 533 I-Condition
, NCT03926533 534 535 O

5 NCT03926533 539 540 O
. NCT03926533 540 541 O
blind NCT03926533 543 548 B-Condition
, NCT03926533 549 550 O
deaf NCT03926533 551 555 B-Condition
, NCT03926533 556 557 O
unable NCT03926533 558 564 B-Negation
to NCT03926533 565 567 O
speak NCT03926533 568 573 O
English NCT03926533 574 581 O
, NCT03926533 582 583 O
or NCT03926533 584 586 O

6 NCT03926533 589 590 O
. NCT03926533 590 591 O
severe NCT03926533 593 599 B-Condition
dementia NCT03926533 600 608 I-Condition
prior NCT03926533 609 614 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926533 615 617 I-Temporal-Connection___Temporal-Connection-Type-Value:before
index NCT03926533 618 623 O
hospitalization NCT03926533 624 639 B-Encounter

Inclusion NCT03928496 0 9 O
Criteria NCT03928496 10 18 O
: NCT03928496 19 20 O

- NCT03928496 24 25 O
male NCT03928496 27 31 O
or NCT03928496 32 34 B-Or
female NCT03928496 35 41 O

- NCT03928496 44 45 O
age NCT03928496 47 50 B-Age
18 NCT03928496 51 53 B-Eq-Comparison
- NCT03928496 54 55 I-Eq-Comparison
65 NCT03928496 56 58 O

- NCT03928496 62 63 O
meets NCT03928496 65 70 O
International NCT03928496 71 84 B-Condition
Classification NCT03928496 85 99 I-Condition
Headache NCT03928496 100 108 I-Condition
Disorders NCT03928496 109 118 I-Condition
II NCT03928496 119 121 B-Eq-Comparison
( NCT03928496 122 123 O
ICHD NCT03928496 124 128 B-Condition
- NCT03928496 129 130 O
II NCT03928496 131 133 B-Eq-Comparison
) NCT03928496 134 135 O
criteria NCT03928496 136 144 O
for NCT03928496 145 148 O
post NCT03928496 149 153 B-Condition
- NCT03928496 154 155 I-Condition
traumatic NCT03928496 156 165 I-Condition
headache NCT03928496 166 174 I-Condition

- NCT03928496 177 178 O
average NCT03928496 180 187 O
pain NCT03928496 188 192 B-Observation
score NCT03928496 193 198 I-Observation
of NCT03928496 199 201 O
greater NCT03928496 202 209 B-Eq-Comparison
than NCT03928496 210 214 I-Eq-Comparison
4 NCT03928496 215 216 I-Eq-Comparison
/ NCT03928496 217 218 I-Eq-Comparison
10 NCT03928496 219 221 I-Eq-Comparison
in NCT03928496 222 224 O
severity NCT03928496 225 233 O
on NCT03928496 234 236 O
the NCT03928496 237 240 O
numerical NCT03928496 241 250 O
rating NCT03928496 251 257 O
system NCT03928496 258 264 O

- NCT03928496 267 268 O
Rancho NCT03928496 270 276 B-Observation
Los NCT03928496 277 280 I-Observation
Amigos NCT03928496 281 287 I-Observation
cognitive NCT03928496 288 297 I-Observation
scale NCT03928496 298 303 I-Observation
score NCT03928496 304 309 I-Observation
greater NCT03928496 310 317 B-Eq-Comparison
than NCT03928496 318 322 I-Eq-Comparison
seven NCT03928496 323 328 I-Eq-Comparison
. NCT03928496 329 330 O

Exclusion NCT03928496 332 341 O
Criteria NCT03928496 342 350 O
: NCT03928496 351 352 O

- NCT03928496 356 357 O
Uncontrolled NCT03928496 359 371 B-Modifier
medical NCT03928496 372 379 B-Condition
condition NCT03928496 380 389 I-Condition
other NCT03928496 390 395 B-Exception
than NCT03928496 396 400 I-Exception
PTH NCT03928496 401 404 B-Condition

- NCT03928496 407 408 O
Severe NCT03928496 410 416 O
additional NCT03928496 417 427 O
chronic NCT03928496 428 435 B-Modifier
pain NCT03928496 436 440 B-Condition
complaint NCT03928496 441 450 O
which NCT03928496 451 456 O
could NCT03928496 457 462 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03928496 463 466 B-Negation
be NCT03928496 467 469 O
distinguished NCT03928496 470 483 O
from NCT03928496 484 488 O
headache NCT03928496 489 497 B-Modifier
pain NCT03928496 498 502 B-Condition

- NCT03928496 505 506 O
pregnancy NCT03928496 508 517 B-Condition
, NCT03928496 518 519 O
breast NCT03928496 520 526 B-Condition
feeding NCT03928496 527 534 I-Condition
, NCT03928496 535 536 O

- NCT03928496 540 541 O
prior NCT03928496 543 548 B-Eq-Comparison
treatment NCT03928496 549 558 B-Procedure
with NCT03928496 559 563 O
botulinum NCT03928496 564 573 B-Drug
toxin NCT03928496 574 579 I-Drug
within NCT03928496 580 586 B-Eq-Comparison
one NCT03928496 587 590 I-Eq-Comparison
year NCT03928496 591 595 I-Eq-Comparison
of NCT03928496 596 598 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03928496 599 609 B-Study

- NCT03928496 612 613 O
current NCT03928496 615 622 B-Eq-Comparison
substance NCT03928496 623 632 B-Condition
abuse NCT03928496 633 638 I-Condition
/ NCT03928496 639 640 B-Or
dependence NCT03928496 641 651 B-Condition

- NCT03928496 654 655 O
medical NCT03928496 657 664 B-Condition
condition NCT03928496 665 674 I-Condition
that NCT03928496 675 679 O
would NCT03928496 680 685 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03928496 686 694 O
risk NCT03928496 695 699 B-Risk
of NCT03928496 700 702 O
neuromuscular NCT03928496 703 716 B-Condition
junction NCT03928496 717 725 I-Condition
blockade NCT03928496 726 734 I-Condition
with NCT03928496 735 739 O
botulinum NCT03928496 740 749 B-Drug
toxin NCT03928496 750 755 I-Drug
( NCT03928496 756 757 O
myasthenia NCT03928496 758 768 B-Condition
gravis NCT03928496 769 775 I-Condition
, NCT03928496 776 777 O
Eaton NCT03928496 778 783 B-Condition
Lambert NCT03928496 784 791 I-Condition
, NCT03928496 792 793 O
amyotrophic NCT03928496 794 805 B-Condition
lateral NCT03928496 806 813 I-Condition
sclerosis NCT03928496 814 823 I-Condition
) NCT03928496 824 825 O

- NCT03928496 829 830 O
poorly NCT03928496 832 838 O
controlled NCT03928496 839 849 O
psychiatric NCT03928496 850 861 O

- NCT03928496 864 865 O
initiation NCT03928496 867 877 O
of NCT03928496 878 880 O
a NCT03928496 881 882 O
new NCT03928496 883 886 B-Eq-Comparison
anti NCT03928496 887 891 B-Drug
- NCT03928496 892 893 I-Drug
depressant NCT03928496 894 904 I-Drug
or NCT03928496 905 907 B-Or
anti NCT03928496 908 912 B-Drug
- NCT03928496 913 914 I-Drug
seizure NCT03928496 915 922 I-Drug
medication NCT03928496 923 933 I-Drug
within NCT03928496 934 940 B-Eq-Comparison
three NCT03928496 941 946 I-Eq-Comparison
months NCT03928496 947 953 I-Eq-Comparison
of NCT03928496 954 956 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enrolling NCT03928496 957 966 O
in NCT03928496 967 969 O
study NCT03928496 970 975 B-Study

- NCT03928496 978 979 O
ongoing NCT03928496 981 988 B-Eq-Comparison
disability NCT03928496 989 999 B-Condition
or NCT03928496 1000 1002 O
litigation NCT03928496 1003 1013 O
claim NCT03928496 1014 1019 O
. NCT03928496 1019 1020 O

Inclusion NCT03925818 0 9 O
Criteria NCT03925818 10 18 O
: NCT03925818 19 20 O

- NCT03925818 23 24 O
Positive NCT03925818 25 33 O
for NCT03925818 34 37 O
H. NCT03925818 38 40 B-Organism
pylori NCT03925818 42 48 I-Organism
infection NCT03925818 49 58 B-Condition

Exclusion NCT03925818 59 68 O
Criteria NCT03925818 69 77 O
: NCT03925818 78 79 O

- NCT03925818 83 84 O
Presence NCT03925818 86 94 O
of NCT03925818 95 97 O
malignancy NCT03925818 98 108 B-Condition

- NCT03925818 111 112 O
Pregnancy NCT03925818 114 123 B-Condition
or NCT03925818 124 126 B-Or
lactation NCT03925818 127 136 B-Condition

- NCT03925818 139 140 O
Clinically NCT03925818 142 152 O
significant NCT03925818 153 164 O
diseases NCT03925818 165 173 B-Condition

- NCT03925818 176 177 O
History NCT03925818 179 186 B-Eq-Comparison
of NCT03925818 187 189 O
drug NCT03925818 190 194 B-Modifier
or NCT03925818 195 197 B-Or
alcohol NCT03925818 198 205 B-Modifier
abuse NCT03925818 206 211 B-Condition

- NCT03925818 214 215 O
Allergy NCT03925818 217 224 B-Allergy
to NCT03925818 225 227 O
pantoprazole NCT03925818 228 240 B-Drug
or NCT03925818 241 243 B-Or
to NCT03925818 244 246 O
any NCT03925818 247 250 O
component NCT03925818 251 260 B-Drug
of NCT03925818 261 263 O
regimens NCT03925818 264 272 O
used NCT03925818 273 277 O
in NCT03925818 278 280 O
the NCT03925818 281 284 O
study NCT03925818 285 290 B-Study

- NCT03925818 293 294 O
Use NCT03925818 296 299 O
of NCT03925818 300 302 O
anti NCT03925818 303 307 B-Drug
- NCT03925818 308 309 I-Drug
secretory NCT03925818 310 319 I-Drug
drugs NCT03925818 320 325 I-Drug
, NCT03925818 326 327 O
antibiotics NCT03925818 328 339 B-Drug
or NCT03925818 340 342 B-Or
probiotics NCT03925818 343 353 B-Drug
4 NCT03925818 354 355 B-Eq-Comparison
weeks NCT03925818 356 361 I-Eq-Comparison
preceding NCT03925818 362 371 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03925818 372 375 O
enrollment NCT03925818 376 386 B-Study
. NCT03925818 386 387 O

Inclusion NCT03929978 0 9 O
Criteria NCT03929978 10 18 O
: NCT03929978 19 20 O

- NCT03929978 24 25 O
Inclusion NCT03929978 27 36 O
criteria NCT03929978 37 45 O
and NCT03929978 46 49 O
justification NCT03929978 50 63 O
hereof NCT03929978 64 70 O
: NCT03929978 71 72 O

1 NCT03929978 81 82 O
. NCT03929978 82 83 O
Have NCT03929978 85 89 O
a NCT03929978 90 91 O
colostomy NCT03929978 92 101 B-Procedure
, NCT03929978 102 103 O
ileostomy NCT03929978 104 113 B-Procedure
( NCT03929978 114 115 O
jejunostomy NCT03929978 116 127 B-Procedure
) NCT03929978 128 129 O
, NCT03929978 131 132 O
loop NCT03929978 133 137 B-Procedure
stoma NCT03929978 138 143 I-Procedure
, NCT03929978 144 145 O
or NCT03929978 146 148 O
two NCT03929978 149 152 B-Eq-Comparison
stomas NCT03929978 153 159 B-Procedure
placed NCT03929978 160 166 O
closely NCT03929978 167 174 O
together NCT03929978 175 183 O

2 NCT03929978 191 192 O
. NCT03929978 192 193 O
Have NCT03929978 195 199 O
given NCT03929978 200 205 O
written NCT03929978 206 213 O
informed NCT03929978 214 222 O
consent NCT03929978 223 230 O
( NCT03929978 231 232 O
the NCT03929978 233 236 O
legal NCT03929978 237 242 O
authorized NCT03929978 243 253 O
representative NCT03929978 254 268 O
of NCT03929978 269 271 O
the NCT03929978 272 275 O
subject NCT03929978 276 283 O
) NCT03929978 284 285 O

Exclusion NCT03929978 287 296 O
Criteria NCT03929978 297 305 O
: NCT03929978 306 307 O

- NCT03929978 311 312 O
The NCT03929978 314 317 O
subjects NCT03929978 318 326 O
are NCT03929978 327 330 O
not NCT03929978 331 334 O
allowed NCT03929978 335 342 O
to NCT03929978 343 345 O
participate NCT03929978 346 357 O
in NCT03929978 358 360 O
case NCT03929978 361 365 O
they NCT03929978 366 370 O
: NCT03929978 371 372 O

Are NCT03929978 374 377 O
currently NCT03929978 378 387 B-Eq-Comparison
suffering NCT03929978 388 397 O
from NCT03929978 398 402 O
peristomal NCT03929978 403 413 B-Condition
skin NCT03929978 414 418 I-Condition
problems NCT03929978 419 427 I-Condition
i. NCT03929978 428 430 O
e. NCT03929978 431 433 O
bleeding NCT03929978 435 443 B-Condition
and NCT03929978 444 447 B-Or
/ NCT03929978 448 449 I-Or
or NCT03929978 450 452 I-Or
broken NCT03929978 453 459 B-Condition
skin NCT03929978 460 464 I-Condition

( NCT03929978 466 467 O
assessed NCT03929978 468 476 O
by NCT03929978 477 479 O
the NCT03929978 480 483 O
investigator NCT03929978 484 496 O
) NCT03929978 497 498 O

Inclusion NCT03924284 0 9 O
Criteria NCT03924284 10 18 O
: NCT03924284 19 20 O

- NCT03924284 24 25 O
Nasopharyngeal NCT03924284 27 41 B-Observation
or NCT03924284 42 44 B-Or
saliva NCT03924284 45 51 B-Observation
specimens NCT03924284 52 61 O
of NCT03924284 62 64 O
patients NCT03924284 65 73 O
in NCT03924284 74 76 O
Queen NCT03924284 77 82 O
Mary NCT03924284 83 87 O
Hospital NCT03924284 88 96 O
of NCT03924284 97 99 O
Hong NCT03924284 100 104 O
Kong NCT03924284 105 109 O

- NCT03924284 112 113 O
Tested NCT03924284 115 121 O
for NCT03924284 122 125 O
influenza NCT03924284 126 135 B-Observation
A NCT03924284 136 137 I-Observation
virus NCT03924284 138 143 I-Observation
using NCT03924284 144 149 O
a NCT03924284 150 151 O
commercially NCT03924284 152 164 O
available NCT03924284 165 174 O
assay NCT03924284 175 180 O
or NCT03924284 181 183 O
by NCT03924284 184 186 O
the NCT03924284 187 190 O
Public NCT03924284 191 197 O
Health NCT03924284 198 204 O
Laboratory NCT03924284 205 215 O
Services NCT03924284 216 224 O
Branch NCT03924284 225 231 O
in NCT03924284 232 234 O
Hong NCT03924284 235 239 O
Kong NCT03924284 240 244 O

Exclusion NCT03924284 245 254 O
Criteria NCT03924284 255 263 O
: NCT03924284 264 265 O

- NCT03924284 269 270 O
Insufficient NCT03924284 272 284 O
specimen NCT03924284 285 293 O
volume NCT03924284 294 300 O

Inclusion NCT03922178 0 9 O
Criteria NCT03922178 10 18 O
: NCT03922178 19 20 O

- NCT03922178 24 25 O
Patient NCT03922178 27 34 O
of NCT03922178 35 37 O
the NCT03922178 38 41 O
CHU NCT03922178 42 45 O
Brugmann NCT03922178 46 54 O
Hospital NCT03922178 55 63 O
receiving NCT03922178 64 73 B-Eq-Comparison
elective NCT03922178 74 82 B-Modifier
coronary NCT03922178 83 91 B-Procedure
surgery NCT03922178 92 99 I-Procedure
. NCT03922178 100 101 O

- NCT03922178 105 106 O
Patient NCT03922178 108 115 O
in NCT03922178 116 118 O
sinusal NCT03922178 119 126 B-Condition
rhythm NCT03922178 127 133 I-Condition
before NCT03922178 134 140 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03922178 141 144 O
operation NCT03922178 145 154 B-Coreference
and NCT03922178 155 158 O
during NCT03922178 159 165 O
the NCT03922178 166 169 O
collection NCT03922178 170 180 O
of NCT03922178 181 183 O
hemodynamic NCT03922178 184 195 O
data NCT03922178 196 200 O
. NCT03922178 201 202 O

- NCT03922178 206 207 O
Patients NCT03922178 209 217 O
with NCT03922178 218 222 O
conserved NCT03922178 223 232 B-Condition
left NCT03922178 233 237 I-Condition
ventricular NCT03922178 238 249 I-Condition
function NCT03922178 250 258 I-Condition
( NCT03922178 259 260 O
based NCT03922178 261 266 O
on NCT03922178 267 269 O
left NCT03922178 270 274 B-Observation
ventricular NCT03922178 275 286 I-Observation
ejection NCT03922178 287 295 I-Observation
fraction NCT03922178 296 304 I-Observation
assessed NCT03922178 305 313 O
by NCT03922178 314 316 O
pre NCT03922178 317 320 B-Temporal-Connection___Temporal-Connection-Type-Value:before
operative NCT03922178 321 330 B-Procedure
echocardiography NCT03922178 331 347 B-Procedure
and NCT03922178 348 351 O
superior NCT03922178 352 360 B-Eq-Comparison
to NCT03922178 361 363 I-Eq-Comparison
50 NCT03922178 364 366 I-Eq-Comparison
% NCT03922178 367 368 I-Eq-Comparison
) NCT03922178 370 371 O

Exclusion NCT03922178 373 382 O
Criteria NCT03922178 383 391 O
: NCT03922178 392 393 O

- NCT03922178 397 398 O
Hypertrophic NCT03922178 400 412 B-Condition
cardiomyopathy NCT03922178 413 427 I-Condition
( NCT03922178 428 429 O
diastolic NCT03922178 430 439 B-Observation
septal NCT03922178 440 446 I-Observation
thickness NCT03922178 447 456 I-Observation
> NCT03922178 457 458 B-Eq-Comparison
15 NCT03922178 459 461 I-Eq-Comparison
mm NCT03922178 462 464 I-Eq-Comparison
) NCT03922178 465 466 O

- NCT03922178 470 471 O
Heart NCT03922178 473 478 B-Condition
failure NCT03922178 479 486 I-Condition
with NCT03922178 487 491 B-And
left NCT03922178 492 496 B-Observation
ventricular NCT03922178 497 508 I-Observation
ejection NCT03922178 509 517 I-Observation
fraction NCT03922178 518 526 I-Observation
< NCT03922178 527 528 B-Eq-Comparison
50 NCT03922178 529 531 I-Eq-Comparison
% NCT03922178 532 533 I-Eq-Comparison

- NCT03922178 537 538 O
Presence NCT03922178 540 548 O
of NCT03922178 549 551 O
cardiac NCT03922178 552 559 B-Condition
valvulopathy NCT03922178 560 572 I-Condition
, NCT03922178 573 574 O
concerning NCT03922178 575 585 O
both NCT03922178 586 590 O
right NCT03922178 591 596 B-Modifier
and NCT03922178 597 600 B-And
left NCT03922178 601 605 B-Modifier
atrio NCT03922178 606 611 B-Modifier
- NCT03922178 612 613 I-Modifier
ventricular NCT03922178 614 625 I-Modifier
and NCT03922178 626 629 B-And
ventriculo NCT03922178 630 640 B-Modifier
- NCT03922178 641 642 I-Modifier
arterial NCT03922178 643 651 I-Modifier
valves NCT03922178 652 658 I-Modifier

- NCT03922178 661 662 O
Presence NCT03922178 664 672 O
of NCT03922178 673 675 O
valvular NCT03922178 676 684 B-Procedure
prosthesis NCT03922178 685 695 I-Procedure

- NCT03922178 698 699 O
Congenital NCT03922178 701 711 B-Condition
heart NCT03922178 712 717 I-Condition
disease NCT03922178 718 725 I-Condition

- NCT03922178 728 729 O
Pregnancy NCT03922178 731 740 B-Condition

- NCT03922178 743 744 O
Participation NCT03922178 746 759 O
to NCT03922178 760 762 O
another NCT03922178 763 770 B-Other
clinical NCT03922178 771 779 O
study NCT03922178 780 785 B-Study

Inclusion NCT03927014 0 9 O
Criteria NCT03927014 10 18 O
: NCT03927014 19 20 O

- NCT03927014 24 25 O
preeclampsia NCT03927014 27 39 B-Condition

- NCT03927014 42 43 O
healthy NCT03927014 45 52 B-Condition
pregnancy NCT03927014 53 62 B-Condition

Exclusion NCT03927014 63 72 O
Criteria NCT03927014 73 81 O
: NCT03927014 82 83 O

- NCT03927014 87 88 O
pregnant NCT03927014 90 98 B-Condition
women NCT03927014 99 104 O
with NCT03927014 105 109 O
any NCT03927014 110 113 O
systemic NCT03927014 114 122 B-Modifier
condition NCT03927014 123 132 B-Condition
( NCT03927014 133 134 O
such NCT03927014 135 139 O
as NCT03927014 140 142 O
chronic NCT03927014 143 150 B-Condition
hypertension NCT03927014 151 163 I-Condition
, NCT03927014 164 165 O
diabetes NCT03927014 166 174 B-Condition
mellitus NCT03927014 175 183 I-Condition
, NCT03927014 184 185 O
thyroid NCT03927014 186 193 B-Condition
diseases NCT03927014 194 202 I-Condition
, NCT03927014 203 204 O
liver NCT03927014 205 210 B-Modifier
and NCT03927014 211 214 B-Or
kidney NCT03927014 215 221 B-Modifier
diseases NCT03927014 222 230 B-Condition
) NCT03927014 231 232 O

- NCT03927014 236 237 O
women NCT03927014 239 244 O
with NCT03927014 245 249 B-And
a NCT03927014 250 251 O
history NCT03927014 252 259 B-Eq-Comparison
of NCT03927014 260 262 O
drug NCT03927014 263 267 B-Condition
use NCT03927014 268 271 I-Condition
throughout NCT03927014 272 282 B-Temporal-Connection___Temporal-Connection-Type-Value:during
pregnancy NCT03927014 283 292 B-Condition

- NCT03927014 295 296 O
history NCT03927014 298 305 B-Eq-Comparison
of NCT03927014 306 308 O
medication NCT03927014 309 319 B-Drug
for NCT03927014 320 323 O
PE NCT03927014 324 326 B-Condition
treatment NCT03927014 327 336 O
at NCT03927014 337 339 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927014 340 343 O
time NCT03927014 344 348 O
of NCT03927014 349 351 O
first NCT03927014 352 357 B-Eq-Comparison
admission NCT03927014 358 367 B-Encounter

- NCT03927014 370 371 O
patients NCT03927014 373 381 O
who NCT03927014 382 385 O
had NCT03927014 386 389 O
fetal NCT03927014 390 395 B-Condition
congenital NCT03927014 396 406 I-Condition
abnormalities NCT03927014 407 420 I-Condition
or NCT03927014 421 423 B-Or
genetic NCT03927014 424 431 B-Condition
syndromes NCT03927014 432 441 I-Condition

- NCT03927014 444 445 O
multiple NCT03927014 447 455 B-Condition
gestation NCT03927014 456 465 I-Condition

- NCT03927014 468 469 O
active NCT03927014 471 477 B-Eq-Comparison
labor NCT03927014 478 483 B-Condition

Inclusion NCT03920592 0 9 O
Criteria NCT03920592 10 18 O
: NCT03920592 19 20 O

- NCT03920592 24 25 O
All NCT03920592 27 30 O
pupils NCT03920592 31 37 O
assisting NCT03920592 38 47 O
5 NCT03920592 48 49 O
th NCT03920592 50 52 O
and NCT03920592 53 56 O
6 NCT03920592 57 58 O
th NCT03920592 59 61 O
grade NCT03920592 62 67 O
of NCT03920592 68 70 O
primary NCT03920592 71 78 O
school NCT03920592 79 85 O
( NCT03920592 86 87 O
Spain NCT03920592 88 93 O
education NCT03920592 94 103 O
system NCT03920592 104 110 O
) NCT03920592 111 112 O
of NCT03920592 113 115 O
the NCT03920592 116 119 O
" NCT03920592 120 121 O
Escola NCT03920592 121 127 O
Parc NCT03920592 128 132 O
del NCT03920592 133 136 O
Guinardó NCT03920592 137 145 O
" NCT03920592 145 146 O
school NCT03920592 147 153 O

- NCT03920592 156 157 O
Pupils NCT03920592 159 165 O
who NCT03920592 166 169 O
s NCT03920592 169 170 O
parents NCT03920592 171 178 B-Family-Member___Family-Member-Type:parent
have NCT03920592 179 183 O
read NCT03920592 184 188 O
, NCT03920592 189 190 O
understand NCT03920592 191 201 O
and NCT03920592 202 205 O
approved NCT03920592 206 214 O
the NCT03920592 215 218 O
informed NCT03920592 219 227 O
consent NCT03920592 228 235 O
of NCT03920592 236 238 O
the NCT03920592 239 242 O
study NCT03920592 243 248 O
. NCT03920592 249 250 O

Exclusion NCT03920592 252 261 O
Criteria NCT03920592 262 270 O
: NCT03920592 271 272 O

- NCT03920592 276 277 O
Pupils NCT03920592 279 285 O
whose NCT03920592 286 291 O
parents NCT03920592 292 299 B-Family-Member___Family-Member-Type:parent
have NCT03920592 300 304 O
not NCT03920592 305 308 O
approved NCT03920592 309 317 O
their NCT03920592 318 323 O
inclusion NCT03920592 324 333 O
in NCT03920592 334 336 O
the NCT03920592 337 340 O
study NCT03920592 341 346 O
. NCT03920592 346 347 O

Inclusion NCT03921840 0 9 O
Criteria NCT03921840 10 18 O
: NCT03921840 19 20 O

- NCT03921840 24 25 O
Intact NCT03921840 27 33 B-Condition
cognition NCT03921840 34 43 I-Condition

- NCT03921840 46 47 O
Poor NCT03921840 49 53 B-Condition
sleep NCT03921840 54 59 I-Condition
quality NCT03921840 60 67 I-Condition

- NCT03921840 70 71 O
Self NCT03921840 73 77 O
- NCT03921840 78 79 O
reported NCT03921840 80 88 O
presence NCT03921840 89 97 O
of NCT03921840 98 100 O
pain NCT03921840 101 105 B-Condition

- NCT03921840 108 109 O
Capacity NCT03921840 111 119 O
for NCT03921840 120 123 O
mild NCT03921840 124 128 O
to NCT03921840 129 131 B-Or
moderate NCT03921840 132 140 O
physical NCT03921840 141 149 B-Observation
activity NCT03921840 150 158 I-Observation
. NCT03921840 159 160 O

Exclusion NCT03921840 162 171 O
Criteria NCT03921840 172 180 O
: NCT03921840 181 182 O

- NCT03921840 186 187 O
Non NCT03921840 189 192 B-Negation
- NCT03921840 193 194 O
ambulatory NCT03921840 195 205 B-Condition
or NCT03921840 206 208 B-Or
have NCT03921840 209 213 O
severely NCT03921840 214 222 O
impaired NCT03921840 223 231 B-Condition
mobility NCT03921840 232 240 I-Condition
, NCT03921840 241 242 O

- NCT03921840 246 247 O
Visual NCT03921840 249 255 B-Modifier
or NCT03921840 256 258 B-Or
hearing NCT03921840 259 266 B-Modifier
impairment NCT03921840 267 277 B-Condition
that NCT03921840 278 282 O
interfered NCT03921840 283 293 O
with NCT03921840 294 298 O
assessments NCT03921840 299 310 O
, NCT03921840 311 312 O
and NCT03921840 313 316 O

- NCT03921840 319 320 O
An NCT03921840 322 324 O
acute NCT03921840 325 330 O
or NCT03921840 331 333 B-Or
a NCT03921840 334 335 O
terminal NCT03921840 336 344 B-Modifier
illness NCT03921840 345 352 B-Condition

- NCT03921840 355 356 O
Neuropathic NCT03921840 358 369 B-Modifier
pain NCT03921840 370 374 B-Condition

Inclusion NCT03929549 0 9 O
Criteria NCT03929549 10 18 O
: NCT03929549 19 20 O

- NCT03929549 24 25 O
Moderate NCT03929549 27 35 O
to NCT03929549 36 38 B-Or
severe NCT03929549 39 45 O
OSA NCT03929549 46 49 B-Condition
( NCT03929549 50 51 O
AHI NCT03929549 52 55 B-Observation
> NCT03929549 56 57 B-Eq-Comparison
15 NCT03929549 58 60 I-Eq-Comparison
) NCT03929549 61 62 O

- NCT03929549 66 67 O
Age NCT03929549 69 72 B-Age
18 NCT03929549 73 75 B-Eq-Comparison
years NCT03929549 76 81 I-Eq-Comparison
or NCT03929549 82 84 I-Eq-Comparison
older NCT03929549 85 90 I-Eq-Comparison

- NCT03929549 93 94 O
BMI NCT03929549 96 99 B-Observation
< NCT03929549 100 101 B-Eq-Comparison
40 NCT03929549 102 104 I-Eq-Comparison
, NCT03929549 105 106 O

- NCT03929549 111 112 O
Baseline NCT03929549 114 122 O
polysomnogram NCT03929549 123 136 B-Procedure
completed NCT03929549 137 146 O
within NCT03929549 147 153 B-Eq-Comparison
the NCT03929549 154 157 I-Eq-Comparison
last NCT03929549 158 162 I-Eq-Comparison
12 NCT03929549 163 165 I-Eq-Comparison
months NCT03929549 166 172 I-Eq-Comparison
with NCT03929549 173 177 B-And
no NCT03929549 178 180 O
significant NCT03929549 181 192 O
weight NCT03929549 193 199 B-Observation
changes NCT03929549 200 207 O
( NCT03929549 208 209 O
< NCT03929549 211 212 B-Eq-Comparison
10 NCT03929549 213 215 I-Eq-Comparison
lbs NCT03929549 216 219 I-Eq-Comparison
. NCT03929549 219 220 O
weight NCT03929549 222 228 O
fluctuation NCT03929549 229 240 O
) NCT03929549 241 242 O
. NCT03929549 244 245 O

- NCT03929549 249 250 O
The NCT03929549 252 255 O
baseline NCT03929549 256 264 O
sleep NCT03929549 265 270 O
study NCT03929549 271 276 O
must NCT03929549 277 281 O
be NCT03929549 282 284 O
diagnostic NCT03929549 285 295 O
with NCT03929549 296 300 O
adequate NCT03929549 301 309 O
sample NCT03929549 310 316 O

Exclusion NCT03929549 317 326 O
Criteria NCT03929549 327 335 O
: NCT03929549 336 337 O

- NCT03929549 341 342 O
BMI NCT03929549 344 347 B-Observation
≥ NCT03929549 348 349 B-Eq-Comparison
40 NCT03929549 350 352 I-Eq-Comparison

- NCT03929549 356 357 O
pregnancy NCT03929549 359 368 B-Condition

- NCT03929549 371 372 O
Central NCT03929549 374 381 B-Condition
sleep NCT03929549 382 387 I-Condition
apnea NCT03929549 388 393 I-Condition
( NCT03929549 394 395 O
CSA NCT03929549 396 399 B-Condition
) NCT03929549 400 401 O
- NCT03929549 402 403 O
5 NCT03929549 404 405 B-Eq-Comparison
or NCT03929549 406 408 I-Eq-Comparison
more NCT03929549 409 413 I-Eq-Comparison
central NCT03929549 414 421 B-Eq-Comparison|Observation
apneas NCT03929549 422 428 I-Eq-Comparison|Observation
per NCT03929549 429 432 I-Eq-Comparison
hour NCT03929549 433 437 I-Eq-Comparison

- NCT03929549 440 441 O
Psychoactive NCT03929549 443 455 B-Drug
medications NCT03929549 456 467 I-Drug
that NCT03929549 468 472 O
influence NCT03929549 473 482 O
sleep NCT03929549 483 488 B-Condition

- NCT03929549 491 492 O
Chronic NCT03929549 494 501 B-Modifier
opioid NCT03929549 502 508 B-Drug
use NCT03929549 509 512 O

- NCT03929549 515 516 O
Other NCT03929549 518 523 B-Other
sleep NCT03929549 524 529 B-Condition
disorders NCT03929549 530 539 I-Condition

- NCT03929549 542 543 O
Active NCT03929549 545 551 B-Eq-Comparison
temporomandibular NCT03929549 552 569 B-Modifier
joint NCT03929549 570 575 I-Modifier
( NCT03929549 576 577 O
TMJ NCT03929549 578 581 B-Modifier
) NCT03929549 582 583 O
Disorders NCT03929549 584 593 B-Condition

- NCT03929549 596 597 O
Fibromyalgia NCT03929549 599 611 B-Condition
with NCT03929549 612 616 B-And
significant NCT03929549 617 628 O
facial NCT03929549 629 635 B-Modifier
pain NCT03929549 636 640 B-Condition

- NCT03929549 643 644 O
Inability NCT03929549 646 655 B-Negation
to NCT03929549 656 658 O
protrude NCT03929549 659 667 B-Observation
the NCT03929549 668 671 I-Observation
mandible NCT03929549 672 680 I-Observation
beyond NCT03929549 681 687 B-Eq-Comparison
5 NCT03929549 688 689 I-Eq-Comparison
mm NCT03929549 690 692 I-Eq-Comparison

- NCT03929549 695 696 O
Inability NCT03929549 698 707 B-Negation
to NCT03929549 708 710 O
follow NCT03929549 711 717 B-Encounter
- NCT03929549 718 719 I-Encounter
up NCT03929549 720 722 I-Encounter
after NCT03929549 723 728 B-Temporal-Connection___Temporal-Connection-Type-Value:after
surgery NCT03929549 729 736 B-Procedure

- NCT03929549 739 740 O
Uncontrolled NCT03929549 742 754 B-Modifier
psychiatric NCT03929549 755 766 B-Condition
disorders NCT03929549 767 776 I-Condition

- NCT03929549 779 780 O
Dental NCT03929549 782 788 B-Condition
disorders NCT03929549 789 798 I-Condition
including NCT03929549 799 808 O
loose NCT03929549 809 814 B-Condition
teeth NCT03929549 815 820 I-Condition
and NCT03929549 821 824 B-Or
periodontal NCT03929549 825 836 B-Condition
disease NCT03929549 837 844 I-Condition

Inclusion NCT03920579 0 9 O
Criteria NCT03920579 10 18 O
: NCT03920579 19 20 O

1 NCT03920579 24 25 O
. NCT03920579 25 26 O
Healthy NCT03920579 28 35 B-Condition
volunteers NCT03920579 36 46 O
aged NCT03920579 47 51 B-Age
between NCT03920579 52 59 B-Eq-Comparison
≥ NCT03920579 60 61 I-Eq-Comparison
20 NCT03920579 62 64 I-Eq-Comparison
and NCT03920579 65 68 I-Eq-Comparison
≤ NCT03920579 69 70 I-Eq-Comparison
45 NCT03920579 71 73 I-Eq-Comparison
years NCT03920579 74 79 I-Eq-Comparison
old NCT03920579 80 83 O

2 NCT03920579 86 87 O
. NCT03920579 87 88 O
Weight NCT03920579 90 96 B-Observation
≥ NCT03920579 97 98 B-Eq-Comparison
50 NCT03920579 99 101 I-Eq-Comparison
kg NCT03920579 102 104 I-Eq-Comparison
, NCT03920579 105 106 O
with NCT03920579 107 111 O
calculated NCT03920579 112 122 O
body NCT03920579 123 127 B-Observation
mass NCT03920579 128 132 I-Observation
index NCT03920579 133 138 I-Observation
( NCT03920579 139 140 O
BMI NCT03920579 141 144 B-Observation
) NCT03920579 145 146 O
of NCT03920579 147 149 O
≥ NCT03920579 150 151 B-Eq-Comparison
18.5 NCT03920579 152 156 I-Eq-Comparison
and NCT03920579 157 160 B-And
≤ NCT03920579 161 162 B-Eq-Comparison
27.0 NCT03920579 163 167 I-Eq-Comparison
kg NCT03920579 168 170 I-Eq-Comparison
/ NCT03920579 171 172 I-Eq-Comparison
m2 NCT03920579 173 175 I-Eq-Comparison

3 NCT03920579 178 179 O
. NCT03920579 179 180 O
Those NCT03920579 182 187 O
who NCT03920579 188 191 O
have NCT03920579 192 196 O
no NCT03920579 197 199 B-Negation
congenital NCT03920579 200 210 B-Condition
chronic NCT03920579 211 218 I-Condition
disease NCT03920579 219 226 I-Condition
or NCT03920579 227 229 B-Or
chronic NCT03920579 230 237 B-Condition
disease NCT03920579 238 245 I-Condition
requiring NCT03920579 246 255 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03920579 256 265 B-Procedure
and NCT03920579 266 269 B-And
who NCT03920579 270 273 O
have NCT03920579 274 278 O
no NCT03920579 279 281 B-Negation
pathological NCT03920579 282 294 B-Condition
symptoms NCT03920579 295 303 B-Assertion___Assertion-Type-Value:possible
or NCT03920579 304 306 B-Or
findings NCT03920579 307 315 B-Modifier

4 NCT03920579 318 319 O
. NCT03920579 319 320 O
Those NCT03920579 322 327 O
who NCT03920579 328 331 O
are NCT03920579 332 335 O
judged NCT03920579 336 342 O
to NCT03920579 343 345 O
be NCT03920579 346 348 O
eligible NCT03920579 349 357 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920579 358 361 O
clinical NCT03920579 362 370 O
trials NCT03920579 371 377 O
based NCT03920579 378 383 O
on NCT03920579 384 386 O
laboratory NCT03920579 387 397 B-Observation
and NCT03920579 398 401 B-And
ECG NCT03920579 402 405 B-Observation
results NCT03920579 406 413 O
during NCT03920579 414 420 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920579 421 430 B-Study
tests NCT03920579 431 436 O

5 NCT03920579 439 440 O
. NCT03920579 440 441 O
Those NCT03920579 443 448 O
who NCT03920579 449 452 O
voluntarily NCT03920579 453 464 O
decide NCT03920579 465 471 O
to NCT03920579 472 474 O
participate NCT03920579 475 486 O
and NCT03920579 487 490 O
agree NCT03920579 491 496 O
to NCT03920579 497 499 O
comply NCT03920579 500 506 O
with NCT03920579 507 511 O
the NCT03920579 512 515 O
cautions NCT03920579 516 524 O
after NCT03920579 525 530 O
hearing NCT03920579 531 538 O
and NCT03920579 539 542 O
fully NCT03920579 543 548 O
understanding NCT03920579 549 562 O
the NCT03920579 563 566 O
detailed NCT03920579 567 575 O
description NCT03920579 576 587 O
of NCT03920579 588 590 O
this NCT03920579 591 595 O
clinical NCT03920579 596 604 O
trial NCT03920579 605 610 O

Exclusion NCT03920579 611 620 O
Criteria NCT03920579 621 629 O
: NCT03920579 630 631 O

1 NCT03920579 635 636 O
. NCT03920579 636 637 O
History NCT03920579 639 646 B-Eq-Comparison
of NCT03920579 647 649 O
presence NCT03920579 650 658 O
of NCT03920579 659 661 O
hepatobiliary NCT03920579 662 675 B-Modifier
, NCT03920579 676 677 O
renal NCT03920579 678 683 B-Modifier
, NCT03920579 684 685 O
cardiovascular NCT03920579 686 700 B-Modifier
, NCT03920579 701 702 O
endocrine NCT03920579 703 712 B-Modifier
, NCT03920579 713 714 O
respiratory NCT03920579 715 726 B-Modifier
, NCT03920579 727 728 O
gastrointestinal NCT03920579 729 745 B-Modifier
, NCT03920579 746 747 O
hematological NCT03920579 748 761 B-Modifier
, NCT03920579 762 763 O
neurologic NCT03920579 764 774 B-Modifier
, NCT03920579 775 776 O
psychiatric NCT03920579 777 788 B-Modifier
or NCT03920579 789 791 B-Or
musculoskeletal NCT03920579 792 807 B-Modifier
disorders NCT03920579 808 817 B-Condition
affecting NCT03920579 818 827 B-Assertion___Assertion-Type-Value:hypothetical
absorption NCT03920579 828 838 B-Modifier
, NCT03920579 839 840 O
distribution NCT03920579 841 853 B-Modifier
, NCT03920579 854 855 O
metabolism NCT03920579 856 866 B-Modifier
and NCT03920579 867 870 O
excretion NCT03920579 871 880 B-Modifier
of NCT03920579 881 883 O
the NCT03920579 884 887 O
drug NCT03920579 888 892 B-Drug

2 NCT03920579 895 896 O
. NCT03920579 896 897 O
Genetic NCT03920579 899 906 B-Condition
problems NCT03920579 907 915 I-Condition
such NCT03920579 916 920 O
as NCT03920579 921 923 O
galactose NCT03920579 924 933 B-Condition
intolerance NCT03920579 934 945 I-Condition
, NCT03920579 946 947 O
Lapp NCT03920579 948 952 B-Condition
lactose NCT03920579 953 960 I-Condition
deficiency NCT03920579 961 971 I-Condition
or NCT03920579 972 974 B-Or
glucose NCT03920579 975 982 B-Condition
- NCT03920579 983 984 I-Condition
galactose NCT03920579 985 994 I-Condition
malabsorption NCT03920579 995 1008 I-Condition

3 NCT03920579 1011 1012 O
. NCT03920579 1012 1013 O
Those NCT03920579 1015 1020 O
who NCT03920579 1021 1024 O
are NCT03920579 1025 1028 O
deemed NCT03920579 1029 1035 O
unfit NCT03920579 1036 1041 O
by NCT03920579 1042 1044 O
the NCT03920579 1045 1048 O
investigators NCT03920579 1049 1062 O
to NCT03920579 1063 1065 O
participate NCT03920579 1066 1077 O
in NCT03920579 1078 1080 O
the NCT03920579 1081 1084 O
clinical NCT03920579 1085 1093 O
trial NCT03920579 1094 1099 O
for NCT03920579 1100 1103 O
other NCT03920579 1104 1109 O
reasons NCT03920579 1110 1117 O
including NCT03920579 1118 1127 O
the NCT03920579 1128 1131 O
results NCT03920579 1132 1139 O
of NCT03920579 1140 1142 O
laboratory NCT03920579 1143 1153 O
tests NCT03920579 1154 1159 O

Inclusion NCT03929575 0 9 O
Criteria NCT03929575 10 18 O
: NCT03929575 19 20 O

- NCT03929575 24 25 O
Body NCT03929575 27 31 B-Observation
Mass NCT03929575 32 36 I-Observation
Index NCT03929575 37 42 I-Observation
between NCT03929575 43 50 B-Eq-Comparison
18.5 NCT03929575 51 55 I-Eq-Comparison
and NCT03929575 56 59 I-Eq-Comparison
35 NCT03929575 60 62 I-Eq-Comparison
kg NCT03929575 63 65 I-Eq-Comparison
/ NCT03929575 66 67 I-Eq-Comparison
m^2 NCT03929575 68 71 I-Eq-Comparison

- NCT03929575 75 76 O
Non NCT03929575 78 81 B-Negation
- NCT03929575 82 83 O
smoking NCT03929575 84 91 B-Condition
( NCT03929575 92 93 O
assessed NCT03929575 94 102 O
by NCT03929575 103 105 O
Health NCT03929575 106 112 B-Observation
History NCT03929575 113 120 I-Observation
Questionnaire NCT03929575 121 134 I-Observation
) NCT03929575 135 136 O

- NCT03929575 140 141 O
English NCT03929575 143 150 O
- NCT03929575 151 152 O
speaking NCT03929575 153 161 O

- NCT03929575 164 165 O
Regular NCT03929575 167 174 O
participation NCT03929575 175 188 O
in NCT03929575 189 191 O
physical NCT03929575 192 200 B-Observation
activity NCT03929575 201 209 I-Observation
( NCT03929575 210 211 O
> NCT03929575 213 214 B-Eq-Comparison
4 NCT03929575 215 216 I-Eq-Comparison
hours NCT03929575 217 222 I-Eq-Comparison
per NCT03929575 223 226 I-Eq-Comparison
week NCT03929575 227 231 I-Eq-Comparison
) NCT03929575 232 233 O

Exclusion NCT03929575 235 244 O
Criteria NCT03929575 245 253 O
: NCT03929575 254 255 O

- NCT03929575 259 260 O
Medical NCT03929575 262 269 O
conditions NCT03929575 270 280 B-Condition
that NCT03929575 281 285 O
prohibit NCT03929575 286 294 B-Negation
physical NCT03929575 295 303 B-Observation
activity NCT03929575 304 312 I-Observation
( NCT03929575 313 314 O
assessed NCT03929575 315 323 O
by NCT03929575 324 326 O
Health NCT03929575 327 333 B-Observation
History NCT03929575 334 341 I-Observation
Questionnaire NCT03929575 342 355 I-Observation
) NCT03929575 356 357 O

- NCT03929575 361 362 O
Pregnant NCT03929575 364 372 B-Condition
women NCT03929575 373 378 O
or NCT03929575 379 381 B-Or
women NCT03929575 382 387 O
expecting NCT03929575 388 397 B-Assertion___Assertion-Type-Value:intention
/ NCT03929575 398 399 B-Or
trying NCT03929575 400 406 B-Assertion___Assertion-Type-Value:intention
to NCT03929575 407 409 O
become NCT03929575 410 416 O
pregnant NCT03929575 417 425 B-Condition

- NCT03929575 428 429 O
BMI NCT03929575 431 434 B-Observation
greater NCT03929575 435 442 B-Eq-Comparison
than NCT03929575 443 447 I-Eq-Comparison
or NCT03929575 448 450 I-Eq-Comparison
equal NCT03929575 451 456 I-Eq-Comparison
to NCT03929575 457 459 I-Eq-Comparison
35 NCT03929575 460 462 I-Eq-Comparison
kg NCT03929575 463 465 I-Eq-Comparison
/ NCT03929575 466 467 I-Eq-Comparison
m^2 NCT03929575 468 471 I-Eq-Comparison

- NCT03929575 475 476 O
Current NCT03929575 478 485 B-Eq-Comparison
smoker NCT03929575 486 492 B-Condition
( NCT03929575 493 494 O
assessed NCT03929575 495 503 O
by NCT03929575 504 506 O
Health NCT03929575 507 513 B-Observation
History NCT03929575 514 521 I-Observation
Questionnaire NCT03929575 522 535 I-Observation
) NCT03929575 536 537 O

Inclusion NCT03928119 0 9 O
Criteria NCT03928119 10 18 O
: NCT03928119 19 20 O

- NCT03928119 24 25 O
ST NCT03928119 27 29 B-Condition
- NCT03928119 30 31 I-Condition
Segment NCT03928119 32 39 I-Condition
Elevation NCT03928119 40 49 I-Condition
Myocardial NCT03928119 50 60 I-Condition
Infarction NCT03928119 61 71 I-Condition
patients NCT03928119 72 80 O
within NCT03928119 81 87 B-Eq-Comparison
30 NCT03928119 88 90 I-Eq-Comparison
days NCT03928119 91 95 I-Eq-Comparison
since NCT03928119 96 101 B-Temporal-Connection___Temporal-Connection-Type-Value:after
symptoms NCT03928119 102 110 B-Assertion___Assertion-Type-Value:possible
onset NCT03928119 111 116 B-Eq-Comparison

Exclusion NCT03928119 117 126 O
Criteria NCT03928119 127 135 O
: NCT03928119 136 137 O

- NCT03928119 141 142 O
None NCT03928119 144 148 O

Inclusion NCT03923361 0 9 O
Criteria NCT03923361 10 18 O
: NCT03923361 19 20 O

- NCT03923361 24 25 O
Age NCT03923361 27 30 B-Age
18 NCT03923361 31 33 B-Eq-Comparison
- NCT03923361 34 35 I-Eq-Comparison
55 NCT03923361 36 38 O

- NCT03923361 42 43 O
Diagnosis NCT03923361 45 54 O
of NCT03923361 55 57 O
major NCT03923361 58 63 B-Modifier
depressive NCT03923361 64 74 B-Condition
disorder NCT03923361 75 83 I-Condition
or NCT03923361 84 86 B-Or
bipolar NCT03923361 87 94 B-Condition
disorder NCT03923361 95 103 I-Condition

- NCT03923361 106 107 O
Current NCT03923361 109 116 B-Eq-Comparison
moderate NCT03923361 117 125 O
- NCT03923361 126 127 O
to NCT03923361 128 130 B-Or
- NCT03923361 131 132 O
severe NCT03923361 133 139 O
depressive NCT03923361 140 150 B-Condition
episode NCT03923361 151 158 I-Condition

- NCT03923361 161 162 O
Episode NCT03923361 164 171 B-Coreference
duration NCT03923361 172 180 O
more NCT03923361 181 185 B-Eq-Comparison
than NCT03923361 186 190 I-Eq-Comparison
2 NCT03923361 191 192 I-Eq-Comparison
months NCT03923361 193 199 I-Eq-Comparison
and NCT03923361 200 203 B-And
less NCT03923361 204 208 B-Eq-Comparison
than NCT03923361 209 213 I-Eq-Comparison
5 NCT03923361 214 215 I-Eq-Comparison
years NCT03923361 216 221 I-Eq-Comparison

- NCT03923361 224 225 O
Failure NCT03923361 227 234 O
of NCT03923361 235 237 O
at NCT03923361 238 240 B-Eq-Comparison
least NCT03923361 241 246 I-Eq-Comparison
2 NCT03923361 247 248 I-Eq-Comparison
adequate NCT03923361 249 257 O
antidepressant NCT03923361 258 272 B-Drug
medication NCT03923361 273 283 I-Drug
trials NCT03923361 284 290 O
within NCT03923361 291 297 B-Eq-Comparison
the NCT03923361 298 301 I-Eq-Comparison
past NCT03923361 302 306 I-Eq-Comparison
2 NCT03923361 307 308 I-Eq-Comparison
years NCT03923361 309 314 I-Eq-Comparison

- NCT03923361 317 318 O
Body NCT03923361 320 324 B-Observation
mass NCT03923361 325 329 I-Observation
index NCT03923361 330 335 I-Observation
< NCT03923361 336 337 B-Eq-Comparison
40 NCT03923361 338 340 I-Eq-Comparison

- NCT03923361 344 345 O
16 NCT03923361 347 349 B-Observation
- NCT03923361 350 351 I-Observation
item NCT03923361 352 356 I-Observation
Quick NCT03923361 357 362 I-Observation
Inventory NCT03923361 363 372 I-Observation
of NCT03923361 373 375 I-Observation
Depressive NCT03923361 376 386 I-Observation
Symptomatology NCT03923361 387 401 I-Observation
, NCT03923361 402 403 O
self NCT03923361 404 408 O
- NCT03923361 409 410 O
rated NCT03923361 411 416 O
> NCT03923361 417 418 B-Eq-Comparison
10 NCT03923361 419 421 I-Eq-Comparison

Exclusion NCT03923361 423 432 O
Criteria NCT03923361 433 441 O
: NCT03923361 442 443 O

- NCT03923361 447 448 O
Contraindication NCT03923361 450 466 B-Contraindication
to NCT03923361 467 469 O
propofol NCT03923361 470 478 B-Drug
or NCT03923361 479 481 B-Or
midazolam NCT03923361 482 491 B-Drug

- NCT03923361 494 495 O
Daily NCT03923361 497 502 B-Eq-Comparison
use NCT03923361 503 506 O
of NCT03923361 507 509 O
benzodiazepine NCT03923361 510 524 B-Drug
, NCT03923361 525 526 O
opioid NCT03923361 527 533 B-Drug
, NCT03923361 534 535 O
ACE NCT03923361 536 539 B-Drug
inhibitor NCT03923361 540 549 I-Drug
, NCT03923361 550 551 O
or NCT03923361 552 554 B-Or
ARB NCT03923361 555 558 B-Drug
medication NCT03923361 559 569 I-Drug

- NCT03923361 572 573 O
Symptomatic NCT03923361 575 586 B-Assertion___Assertion-Type-Value:possible
coronary NCT03923361 587 595 B-Condition
artery NCT03923361 596 602 I-Condition
disease NCT03923361 603 610 I-Condition
or NCT03923361 611 613 B-Or
heart NCT03923361 614 619 B-Condition
failure NCT03923361 620 627 I-Condition

- NCT03923361 630 631 O
Poorly NCT03923361 633 639 B-Modifier
controlled NCT03923361 640 650 I-Modifier
hypertension NCT03923361 651 663 B-Condition
or NCT03923361 664 666 B-Or
diabetes NCT03923361 667 675 B-Condition

- NCT03923361 678 679 O
Abnormal NCT03923361 681 689 O
kidney NCT03923361 690 696 B-Modifier
or NCT03923361 697 699 B-Or
liver NCT03923361 700 705 B-Modifier
function NCT03923361 706 714 B-Condition

- NCT03923361 717 718 O
Pregnant NCT03923361 720 728 B-Condition
or NCT03923361 729 731 B-Or
breast NCT03923361 732 738 B-Condition
feeding NCT03923361 739 746 I-Condition

- NCT03923361 749 750 O
Traumatic NCT03923361 752 761 B-Condition
brain NCT03923361 762 767 I-Condition
injury NCT03923361 768 774 I-Condition
or NCT03923361 775 777 B-Or
significant NCT03923361 778 789 O
neurologic NCT03923361 790 800 B-Condition
signs NCT03923361 801 806 B-Assertion___Assertion-Type-Value:possible
( NCT03923361 807 808 O
past NCT03923361 809 813 B-Eq-Comparison
year NCT03923361 814 818 I-Eq-Comparison
) NCT03923361 819 820 O

- NCT03923361 824 825 O
Substance NCT03923361 827 836 B-Condition
use NCT03923361 837 840 I-Condition
disorder NCT03923361 841 849 I-Condition
( NCT03923361 850 851 O
past NCT03923361 852 856 B-Eq-Comparison
year NCT03923361 857 861 I-Eq-Comparison
) NCT03923361 862 863 O

- NCT03923361 867 868 O
Obsessive NCT03923361 870 879 B-Condition
compulsive NCT03923361 880 890 I-Condition
disorder NCT03923361 891 899 I-Condition
( NCT03923361 900 901 O
current NCT03923361 902 909 B-Eq-Comparison
) NCT03923361 910 911 O

- NCT03923361 915 916 O
Post NCT03923361 918 922 B-Condition
- NCT03923361 923 924 I-Condition
traumatic NCT03923361 925 934 I-Condition
stress NCT03923361 935 941 I-Condition
disorder NCT03923361 942 950 I-Condition
( NCT03923361 951 952 O
current NCT03923361 953 960 B-Eq-Comparison
) NCT03923361 961 962 O

- NCT03923361 966 967 O
Schizophrenia NCT03923361 969 982 B-Condition
- NCT03923361 983 984 I-Condition
spectrum NCT03923361 985 993 I-Condition
disorder NCT03923361 994 1002 I-Condition
( NCT03923361 1003 1004 O
lifetime NCT03923361 1005 1013 O
) NCT03923361 1014 1015 O

- NCT03923361 1019 1020 O
Neurocognitive NCT03923361 1022 1036 B-Condition
disorder NCT03923361 1037 1045 I-Condition
( NCT03923361 1046 1047 O
current NCT03923361 1048 1055 B-Eq-Comparison
) NCT03923361 1056 1057 O

- NCT03923361 1061 1062 O
Personality NCT03923361 1064 1075 B-Condition
disorder NCT03923361 1076 1084 I-Condition
as NCT03923361 1085 1087 O
a NCT03923361 1088 1089 O
current NCT03923361 1090 1097 B-Eq-Comparison
focus NCT03923361 1098 1103 O
of NCT03923361 1104 1106 O
treatment NCT03923361 1107 1116 B-Procedure

- NCT03923361 1119 1120 O
ECT NCT03923361 1122 1125 B-Procedure
within NCT03923361 1126 1132 B-Eq-Comparison
the NCT03923361 1133 1136 I-Eq-Comparison
past NCT03923361 1137 1141 I-Eq-Comparison
3 NCT03923361 1142 1143 I-Eq-Comparison
months NCT03923361 1144 1150 I-Eq-Comparison

- NCT03923361 1153 1154 O
Inappropriate NCT03923361 1156 1169 B-Contraindication
for NCT03923361 1170 1173 O
ECT NCT03923361 1174 1177 B-Procedure
, NCT03923361 1178 1179 O
or NCT03923361 1180 1182 B-Or
poor NCT03923361 1183 1187 O
response NCT03923361 1188 1196 O
to NCT03923361 1197 1199 O
ECT NCT03923361 1200 1203 B-Procedure
within NCT03923361 1204 1210 B-Eq-Comparison
the NCT03923361 1211 1214 I-Eq-Comparison
past NCT03923361 1215 1219 I-Eq-Comparison
5 NCT03923361 1220 1221 I-Eq-Comparison
years NCT03923361 1222 1227 I-Eq-Comparison

- NCT03923361 1230 1231 O
Incompetent NCT03923361 1233 1244 O
to NCT03923361 1245 1247 O
provide NCT03923361 1248 1255 O
consent NCT03923361 1256 1263 O

Inclusion NCT03923413 0 9 O
Criteria NCT03923413 10 18 O
: NCT03923413 19 20 O

- NCT03923413 24 25 O
Inclusion NCT03923413 27 36 O
Criteria NCT03923413 37 45 O
: NCT03923413 46 47 O
chronic NCT03923413 48 55 B-Condition
heart NCT03923413 56 61 I-Condition
failure NCT03923413 62 69 I-Condition
INTERMASC NCT03923413 70 79 B-Observation
5 NCT03923413 80 81 B-Eq-Comparison
- NCT03923413 82 83 I-Eq-Comparison
7 NCT03923413 84 85 O
or NCT03923413 86 88 B-Or

- NCT03923413 91 92 O
Patients NCT03923413 94 102 O
on NCT03923413 103 105 B-Eq-Comparison
LVAD NCT03923413 106 110 B-Procedure
support NCT03923413 111 118 I-Procedure

Exclusion NCT03923413 119 128 O
Criteria NCT03923413 129 137 O
: NCT03923413 138 139 O

- NCT03923413 143 144 O
current NCT03923413 146 153 B-Eq-Comparison
thrombembolic NCT03923413 154 167 B-Modifier
or NCT03923413 168 170 B-Or
bleeding NCT03923413 171 179 B-Modifier
event NCT03923413 180 185 B-Condition

Inclusion NCT03927885 0 9 O
Criteria NCT03927885 10 18 O
: NCT03927885 19 20 O

- NCT03927885 24 25 O
Patient NCT03927885 27 34 O
with NCT03927885 35 39 O
a NCT03927885 40 41 O
diagnosis NCT03927885 42 51 O
of NCT03927885 52 54 O
advanced NCT03927885 55 63 O
cancer NCT03927885 64 70 B-Condition
( NCT03927885 71 72 O
metastatic NCT03927885 73 83 B-Modifier
or NCT03927885 84 86 B-Or
recurrent NCT03927885 87 96 B-Modifier
incurable NCT03927885 97 106 I-Modifier
solid NCT03927885 107 112 B-Condition
tumors NCT03927885 113 119 I-Condition
) NCT03927885 120 121 O

- NCT03927885 125 126 O
Presence NCT03927885 128 136 O
of NCT03927885 137 139 O
fatigue NCT03927885 140 147 B-Condition
of NCT03927885 148 150 O
> NCT03927885 151 152 B-Eq-Comparison
= NCT03927885 154 155 I-Eq-Comparison
4 NCT03927885 156 157 I-Eq-Comparison
/ NCT03927885 158 159 I-Eq-Comparison
10 NCT03927885 160 162 I-Eq-Comparison
on NCT03927885 163 165 O
Edmonton NCT03927885 166 174 B-Observation
Symptom NCT03927885 175 182 I-Observation
Assessment NCT03927885 183 193 I-Observation
System NCT03927885 194 200 I-Observation
( NCT03927885 201 202 O
ESAS NCT03927885 203 207 B-Observation
) NCT03927885 208 209 O
Fatigue NCT03927885 210 217 O
item NCT03927885 218 222 O
( NCT03927885 223 224 O
0 NCT03927885 225 226 O
- NCT03927885 227 228 O
10 NCT03927885 229 231 O
severity NCT03927885 232 240 O
scale NCT03927885 241 246 O
) NCT03927885 247 248 O

- NCT03927885 252 253 O
Patient NCT03927885 255 262 O
should NCT03927885 263 269 O
describe NCT03927885 270 278 O
fatigue NCT03927885 279 286 B-Condition
as NCT03927885 287 289 O
being NCT03927885 290 295 O
present NCT03927885 296 303 O
for NCT03927885 304 307 O
a NCT03927885 308 309 O
minimum NCT03927885 310 317 B-Eq-Comparison
of NCT03927885 318 320 I-Eq-Comparison
2 NCT03927885 321 322 I-Eq-Comparison
weeks NCT03927885 323 328 I-Eq-Comparison
prior NCT03927885 329 334 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927885 335 337 O
screening NCT03927885 338 347 B-Study

- NCT03927885 350 351 O
Uncontrolled NCT03927885 353 365 B-Modifier
pain NCT03927885 366 370 B-Condition
; NCT03927885 370 371 O
patient NCT03927885 372 379 O
is NCT03927885 380 382 O
on NCT03927885 383 385 B-Eq-Comparison
opioids NCT03927885 386 393 B-Drug
for NCT03927885 394 397 O
the NCT03927885 398 401 O
treatment NCT03927885 402 411 B-Procedure
of NCT03927885 412 414 O
cancer NCT03927885 415 421 B-Condition
pain NCT03927885 422 426 B-Condition
, NCT03927885 427 428 O
he NCT03927885 429 431 O
/ NCT03927885 432 433 O
she NCT03927885 434 437 O
must NCT03927885 438 442 O
have NCT03927885 443 447 O
had NCT03927885 448 451 O
no NCT03927885 452 454 B-Negation
major NCT03927885 455 460 O
dose NCT03927885 461 465 O
change NCT03927885 466 472 O
( NCT03927885 473 474 O
> NCT03927885 476 477 B-Eq-Comparison
25 NCT03927885 478 480 I-Eq-Comparison
% NCT03927885 481 482 I-Eq-Comparison
) NCT03927885 484 485 O
for NCT03927885 486 489 O
at NCT03927885 490 492 B-Eq-Comparison
least NCT03927885 493 498 I-Eq-Comparison
48 NCT03927885 499 501 I-Eq-Comparison
hours NCT03927885 502 507 I-Eq-Comparison
prior NCT03927885 508 513 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03927885 514 516 O
study NCT03927885 517 522 B-Study
entry NCT03927885 523 528 O
. NCT03927885 528 529 O
Change NCT03927885 531 537 O
in NCT03927885 538 540 O
opioid NCT03927885 541 547 B-Drug
dose NCT03927885 548 552 O
after NCT03927885 553 558 B-Temporal-Connection___Temporal-Connection-Type-Value:after
study NCT03927885 559 564 B-Study
entry NCT03927885 565 570 O
is NCT03927885 571 573 O
allowed NCT03927885 574 581 B-Assertion___Assertion-Type-Value:hypothetical

- NCT03927885 584 585 O
Patient NCT03927885 587 594 O
must NCT03927885 595 599 O
be NCT03927885 600 602 O
willing NCT03927885 603 610 O
to NCT03927885 611 613 O
engage NCT03927885 614 620 O
in NCT03927885 621 623 O
telephone NCT03927885 624 633 O
follow NCT03927885 634 640 O
up NCT03927885 641 643 O
with NCT03927885 644 648 O
research NCT03927885 649 657 O
staff NCT03927885 658 663 O

- NCT03927885 666 667 O
Patient NCT03927885 669 676 O
must NCT03927885 677 681 O
have NCT03927885 682 686 O
telephone NCT03927885 687 696 O
access NCT03927885 697 703 O
to NCT03927885 704 706 O
be NCT03927885 707 709 O
contacted NCT03927885 710 719 O
by NCT03927885 720 722 O
the NCT03927885 723 726 O
research NCT03927885 727 735 O
staff NCT03927885 736 741 O

- NCT03927885 744 745 O
Hemoglobin NCT03927885 747 757 B-Observation
level NCT03927885 758 763 O
of NCT03927885 764 766 O
> NCT03927885 767 768 O
= NCT03927885 770 771 O
9 NCT03927885 772 773 I-Eq-Comparison
g NCT03927885 774 775 I-Eq-Comparison
/ NCT03927885 776 777 O
dL. NCT03927885 778 781 O
Patient NCT03927885 783 790 O
may NCT03927885 791 794 B-Assertion___Assertion-Type-Value:hypothetical
receive NCT03927885 795 802 O
packed NCT03927885 803 809 B-Procedure
red NCT03927885 810 813 I-Procedure
blood NCT03927885 814 819 I-Procedure
cell NCT03927885 820 824 I-Procedure
( NCT03927885 825 826 O
PRBC NCT03927885 827 831 B-Procedure
) NCT03927885 832 833 O
transfusion NCT03927885 834 845 B-Modifier
so NCT03927885 846 848 B-Assertion___Assertion-Type-Value:hypothetical
as NCT03927885 849 851 I-Assertion___Assertion-Type-Value:hypothetical
to NCT03927885 852 854 I-Assertion___Assertion-Type-Value:hypothetical
have NCT03927885 855 859 O
hemoglobin NCT03927885 860 870 B-Observation
level NCT03927885 871 876 O
of NCT03927885 877 879 O
> NCT03927885 880 881 O
= NCT03927885 883 884 O
9 NCT03927885 885 886 O
g NCT03927885 887 888 O
/ NCT03927885 889 890 O
dL NCT03927885 891 893 I-Eq-Comparison
so NCT03927885 894 896 O
at NCT03927885 897 899 O
participate NCT03927885 900 911 O
in NCT03927885 912 914 O
the NCT03927885 915 918 O
study NCT03927885 919 924 B-Study

Exclusion NCT03927885 925 934 O
Criteria NCT03927885 935 943 O
: NCT03927885 944 945 O

- NCT03927885 949 950 O
Surgery NCT03927885 952 959 B-Procedure
, NCT03927885 960 961 O
or NCT03927885 962 964 B-Or
pain NCT03927885 965 969 B-Procedure
relieving NCT03927885 970 979 I-Procedure
procedures NCT03927885 980 990 I-Procedure
within NCT03927885 991 997 B-Eq-Comparison
2 NCT03927885 998 999 I-Eq-Comparison
weeks NCT03927885 1000 1005 I-Eq-Comparison
of NCT03927885 1006 1008 B-Temporal-Connection___Temporal-Connection-Type-Value:after
entry NCT03927885 1009 1014 O
into NCT03927885 1015 1019 O
the NCT03927885 1020 1023 O
study NCT03927885 1024 1029 B-Study
or NCT03927885 1030 1032 B-Or
during NCT03927885 1033 1039 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927885 1040 1043 O
study NCT03927885 1044 1049 B-Study
period NCT03927885 1050 1056 O

- NCT03927885 1059 1060 O
Patients NCT03927885 1062 1070 O
with NCT03927885 1071 1075 O
history NCT03927885 1076 1083 B-Eq-Comparison
of NCT03927885 1084 1086 O
substance NCT03927885 1087 1096 B-Condition
abuse NCT03927885 1097 1102 I-Condition
( NCT03927885 1103 1104 O
Cut NCT03927885 1105 1108 B-Observation
down NCT03927885 1109 1113 I-Observation
, NCT03927885 1114 1115 I-Observation
Annoyed NCT03927885 1116 1123 I-Observation
, NCT03927885 1124 1125 I-Observation
Guilty NCT03927885 1126 1132 I-Observation
, NCT03927885 1133 1134 I-Observation
Eye NCT03927885 1135 1138 I-Observation
opener NCT03927885 1139 1145 I-Observation
[ NCT03927885 1146 1147 O
CAGE NCT03927885 1148 1152 B-Observation
] NCT03927885 1153 1154 O
> NCT03927885 1155 1156 O
= NCT03927885 1158 1159 O
2 NCT03927885 1160 1161 O
+ NCT03927885 1162 1163 O
) NCT03927885 1165 1166 O
, NCT03927885 1168 1169 O
cognitively NCT03927885 1170 1181 B-Condition
impaired NCT03927885 1182 1190 I-Condition
( NCT03927885 1191 1192 O
MD NCT03927885 1193 1195 B-Condition
Anderson NCT03927885 1196 1204 I-Condition
Symptom NCT03927885 1205 1212 I-Condition
[ NCT03927885 1213 1214 O
MDAS NCT03927885 1215 1219 B-Condition
] NCT03927885 1220 1221 O
> NCT03927885 1222 1223 B-Eq-Comparison
7 NCT03927885 1224 1225 I-Eq-Comparison
) NCT03927885 1226 1227 O

Inclusion NCT03927846 0 9 O
Criteria NCT03927846 10 18 O
: NCT03927846 19 20 O
- NCT03927846 21 22 O

1 NCT03927846 26 27 O
. NCT03927846 27 28 O
patients NCT03927846 30 38 O
at NCT03927846 39 41 O
the NCT03927846 42 45 O
primary NCT03927846 46 53 O
care NCT03927846 54 58 O
or NCT03927846 59 61 B-Or
rheumatology NCT03927846 62 74 O
clinic NCT03927846 75 81 O
with NCT03927846 82 86 B-And
daily NCT03927846 87 92 B-Eq-Comparison
pain NCT03927846 93 97 B-Condition
for NCT03927846 98 101 O
6 NCT03927846 102 103 B-Eq-Comparison
months NCT03927846 104 110 I-Eq-Comparison
or NCT03927846 111 113 I-Eq-Comparison
longer NCT03927846 114 120 I-Eq-Comparison
affecting NCT03927846 121 130 O
the NCT03927846 131 134 O
low NCT03927846 135 138 B-Modifier
back NCT03927846 139 143 I-Modifier
, NCT03927846 144 145 O
neck NCT03927846 146 150 B-Modifier
, NCT03927846 151 152 O
hip NCT03927846 153 156 B-Modifier
, NCT03927846 157 158 O
knee NCT03927846 159 163 B-Modifier
or NCT03927846 164 166 B-Or
widespread NCT03927846 167 177 B-Condition
pain NCT03927846 178 182 I-Condition
; NCT03927846 182 183 O

2 NCT03927846 186 187 O
. NCT03927846 187 188 O
at NCT03927846 190 192 B-Eq-Comparison
least NCT03927846 193 198 I-Eq-Comparison
moderate NCT03927846 199 207 I-Eq-Comparison
in NCT03927846 208 210 O
average NCT03927846 211 218 O
pain NCT03927846 219 223 B-Condition
severity NCT03927846 224 232 O
, NCT03927846 233 234 O
defined NCT03927846 235 242 O
as NCT03927846 243 245 O
a NCT03927846 246 247 O
weekly NCT03927846 248 254 O
average NCT03927846 255 262 O
pain NCT03927846 263 267 B-Observation
severity NCT03927846 268 276 I-Observation
score NCT03927846 277 282 I-Observation
of NCT03927846 283 285 O
5 NCT03927846 286 287 B-Eq-Comparison
or NCT03927846 288 290 I-Eq-Comparison
greater NCT03927846 291 298 I-Eq-Comparison
24 NCT03927846 299 301 O
; NCT03927846 302 303 O

3 NCT03927846 306 307 O
. NCT03927846 307 308 O
at NCT03927846 310 312 B-Eq-Comparison
least NCT03927846 313 318 I-Eq-Comparison
18 NCT03927846 319 321 I-Eq-Comparison
years NCT03927846 322 327 I-Eq-Comparison
of NCT03927846 328 330 O
age NCT03927846 331 334 B-Age
; NCT03927846 334 335 O

4 NCT03927846 338 339 O
. NCT03927846 339 340 O
reliable NCT03927846 342 350 O
phone NCT03927846 351 356 O
( NCT03927846 357 358 O
landline NCT03927846 359 367 O
or NCT03927846 368 370 O
cell NCT03927846 371 375 O
) NCT03927846 376 377 O
, NCT03927846 379 380 O
and NCT03927846 381 384 O

5 NCT03927846 387 388 O
. NCT03927846 388 389 O
have NCT03927846 391 395 O
home NCT03927846 396 400 O
computer NCT03927846 401 409 O
with NCT03927846 410 414 O
reliable NCT03927846 415 423 O
internet NCT03927846 424 432 O
access NCT03927846 433 439 O
. NCT03927846 440 441 O

Exclusion NCT03927846 443 452 O
Criteria NCT03927846 453 461 O
: NCT03927846 462 463 O

1 NCT03927846 467 468 O
. NCT03927846 468 469 O
planned NCT03927846 471 478 B-Eq-Comparison
elective NCT03927846 479 487 O
surgery NCT03927846 488 495 B-Procedure
during NCT03927846 496 502 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927846 503 506 O
study NCT03927846 507 512 B-Study
period NCT03927846 513 519 O
; NCT03927846 519 520 O

2 NCT03927846 523 524 O
. NCT03927846 524 525 O
very NCT03927846 527 531 O
severe NCT03927846 532 538 O
symptoms NCT03927846 539 547 B-Assertion___Assertion-Type-Value:possible
of NCT03927846 548 550 O
depression NCT03927846 551 561 B-Condition
( NCT03927846 562 563 O
i. NCT03927846 564 566 O
e. NCT03927846 567 569 O
, NCT03927846 570 571 O
PHQ8 NCT03927846 572 576 B-Observation
score NCT03927846 577 582 O
of NCT03927846 583 585 O
≥ NCT03927846 586 587 B-Eq-Comparison
20 NCT03927846 588 590 I-Eq-Comparison
) NCT03927846 591 592 O
; NCT03927846 593 594 O

3 NCT03927846 597 598 O
. NCT03927846 598 599 O
ongoing NCT03927846 601 608 O
unresolved NCT03927846 609 619 O
disability NCT03927846 620 630 O
claims NCT03927846 631 637 O
; NCT03927846 637 638 O

4 NCT03927846 641 642 O
. NCT03927846 642 643 O
inflammatory NCT03927846 645 657 B-Condition
arthritis NCT03927846 658 667 I-Condition
( NCT03927846 668 669 O
e. NCT03927846 670 672 O
g. NCT03927846 673 675 O
, NCT03927846 676 677 O
lupus NCT03927846 678 683 B-Condition
, NCT03927846 684 685 O
rheumatoid NCT03927846 686 696 B-Condition
arthritis NCT03927846 697 706 I-Condition
, NCT03927846 707 708 O
ankylosing NCT03927846 709 719 B-Condition
spondylitis NCT03927846 720 731 I-Condition
, NCT03927846 732 733 O
etc NCT03927846 734 737 O
. NCT03927846 737 738 O
) NCT03927846 739 740 O
; NCT03927846 741 742 O

5 NCT03927846 745 746 O
. NCT03927846 746 747 O
cancer NCT03927846 749 755 B-Condition
- NCT03927846 756 757 O
related NCT03927846 758 765 O
musculoskeletal NCT03927846 766 781 B-Modifier
pain NCT03927846 782 786 B-Condition
; NCT03927846 786 787 O

6 NCT03927846 790 791 O
. NCT03927846 791 792 O
history NCT03927846 794 801 B-Eq-Comparison
of NCT03927846 802 804 O
bipolar NCT03927846 805 812 B-Condition
disorder NCT03927846 813 821 I-Condition
or NCT03927846 822 824 B-Or
schizophrenia NCT03927846 825 838 B-Condition
; NCT03927846 838 839 O
and NCT03927846 840 843 O

7 NCT03927846 846 847 O
. NCT03927846 847 848 O
takes NCT03927846 850 855 B-Eq-Comparison
daily NCT03927846 856 861 B-Eq-Comparison
opioid NCT03927846 862 868 B-Drug
for NCT03927846 869 872 O
more NCT03927846 873 877 B-Eq-Comparison
than NCT03927846 878 882 I-Eq-Comparison
one NCT03927846 883 886 I-Eq-Comparison
year NCT03927846 887 891 I-Eq-Comparison
. NCT03927846 891 892 O

Inclusion NCT03920683 0 9 O
Criteria NCT03920683 10 18 O
: NCT03920683 19 20 O

- NCT03920683 24 25 O
Age NCT03920683 27 30 B-Age
≥ NCT03920683 31 32 B-Eq-Comparison
18 NCT03920683 33 35 I-Eq-Comparison
ans NCT03920683 36 39 O

- NCT03920683 42 43 O
Diabetes NCT03920683 45 53 B-Condition
mellitus NCT03920683 54 62 I-Condition
( NCT03920683 63 64 O
type NCT03920683 65 69 B-Eq-Comparison
1 NCT03920683 70 71 I-Eq-Comparison
or NCT03920683 72 74 I-Eq-Comparison
2 NCT03920683 75 76 I-Eq-Comparison
) NCT03920683 77 78 O

- NCT03920683 82 83 O
Patients NCT03920683 85 93 O
addressed NCT03920683 94 103 O
to NCT03920683 104 106 O
a NCT03920683 107 108 O
one NCT03920683 109 112 B-Eq-Comparison
- NCT03920683 113 114 I-Eq-Comparison
day NCT03920683 115 118 I-Eq-Comparison
hospitalization NCT03920683 119 134 B-Encounter
to NCT03920683 135 137 B-Temporal-Connection___Temporal-Connection-Type-Value:encounter
assess NCT03920683 138 144 O
cardiovascular NCT03920683 145 159 B-Condition
comorbidities NCT03920683 160 173 I-Condition
, NCT03920683 174 175 O
between NCT03920683 176 183 B-Eq-Comparison
January NCT03920683 184 191 I-Eq-Comparison
2014 NCT03920683 192 196 I-Eq-Comparison
and NCT03920683 197 200 I-Eq-Comparison
May NCT03920683 201 204 I-Eq-Comparison
2017 NCT03920683 205 209 I-Eq-Comparison
, NCT03920683 210 211 O
in NCT03920683 212 214 O
the NCT03920683 215 218 O
diabetes NCT03920683 219 227 O
department NCT03920683 228 238 O
, NCT03920683 239 240 O
in NCT03920683 241 243 O
the NCT03920683 244 247 O
Pitié NCT03920683 248 253 O
- NCT03920683 254 255 O
Salpêtrière NCT03920683 256 267 O
hospital NCT03920683 268 276 O

- NCT03920683 279 280 O
Coronary NCT03920683 282 290 B-Observation
artery NCT03920683 291 297 I-Observation
calcium NCT03920683 298 305 I-Observation
score NCT03920683 306 311 I-Observation
available NCT03920683 312 321 O

- NCT03920683 324 325 O
Toe NCT03920683 327 330 B-Observation
- NCT03920683 331 332 I-Observation
brachial NCT03920683 333 341 I-Observation
index NCT03920683 342 347 I-Observation
available NCT03920683 348 357 O

Exclusion NCT03920683 358 367 O
Criteria NCT03920683 368 376 O
: NCT03920683 377 378 O

- NCT03920683 382 383 O
History NCT03920683 385 392 B-Eq-Comparison
of NCT03920683 393 395 O
coronary NCT03920683 396 404 B-Condition
artery NCT03920683 405 411 I-Condition
disease NCT03920683 412 419 I-Condition

- NCT03920683 422 423 O
History NCT03920683 425 432 B-Eq-Comparison
of NCT03920683 433 435 O
Raynaud NCT03920683 436 443 B-Condition
's NCT03920683 443 445 I-Condition
syndrome NCT03920683 446 454 I-Condition

- NCT03920683 457 458 O
Opposition NCT03920683 460 470 O
of NCT03920683 471 473 O
the NCT03920683 474 477 O
patient NCT03920683 478 485 O

Inclusion NCT03929328 0 9 O
Criteria NCT03929328 10 18 O
: NCT03929328 19 20 O

- NCT03929328 24 25 O
Adult NCT03929328 27 32 O
patients NCT03929328 33 41 O
aged NCT03929328 42 46 B-Age
18 NCT03929328 47 49 B-Eq-Comparison
years NCT03929328 50 55 I-Eq-Comparison
or NCT03929328 56 58 I-Eq-Comparison
more NCT03929328 59 63 I-Eq-Comparison
, NCT03929328 64 65 O
both NCT03929328 66 70 O
gender NCT03929328 71 77 O

- NCT03929328 80 81 O
Receiving NCT03929328 83 92 B-Eq-Comparison
endotracheal NCT03929328 93 105 B-Modifier
intubation NCT03929328 106 116 B-Procedure
and NCT03929328 117 120 B-And
mechanical NCT03929328 121 131 B-Modifier
ventilation NCT03929328 132 143 B-Procedure
for NCT03929328 144 147 O
more NCT03929328 148 152 B-Eq-Comparison
than NCT03929328 153 157 I-Eq-Comparison
12 NCT03929328 158 160 I-Eq-Comparison
hours NCT03929328 161 166 I-Eq-Comparison

- NCT03929328 169 170 O
Recovery NCT03929328 172 180 O
from NCT03929328 181 185 O
the NCT03929328 186 189 O
precipitating NCT03929328 190 203 O
illness NCT03929328 204 211 B-Condition

- NCT03929328 214 215 O
Weaning NCT03929328 217 224 O
readiness NCT03929328 225 234 O
according NCT03929328 235 244 O
to NCT03929328 245 247 O
the NCT03929328 248 251 O
following NCT03929328 252 261 O
criteria NCT03929328 262 270 O
: NCT03929328 271 272 O

1 NCT03929328 281 282 O
. NCT03929328 282 283 O
Respiratory NCT03929328 285 296 O
criteria NCT03929328 297 305 O
: NCT03929328 306 307 O

1 NCT03929328 321 322 O
. NCT03929328 322 323 O
PaO2 NCT03929328 325 329 B-Observation
: NCT03929328 330 331 O
FIO2 NCT03929328 332 336 O
> NCT03929328 337 338 B-Eq-Comparison
150 NCT03929328 339 342 I-Eq-Comparison
with NCT03929328 343 347 B-And
FIO2 NCT03929328 348 352 B-Observation
≤ NCT03929328 353 354 B-Eq-Comparison
0.4 NCT03929328 355 358 I-Eq-Comparison
, NCT03929328 359 360 O
PEEP NCT03929328 361 365 B-Observation
< NCT03929328 366 367 B-Eq-Comparison
8 NCT03929328 368 369 I-Eq-Comparison
cm NCT03929328 370 372 I-Eq-Comparison
H2O NCT03929328 373 376 I-Eq-Comparison

2 NCT03929328 389 390 O
. NCT03929328 390 391 O
Arterial NCT03929328 393 401 B-Observation
pH NCT03929328 402 404 I-Observation
> NCT03929328 405 406 O
7.35 NCT03929328 407 411 O

3 NCT03929328 425 426 O
. NCT03929328 426 427 O
Rapid NCT03929328 429 434 B-Observation
shallow NCT03929328 435 442 I-Observation
breathing NCT03929328 443 452 I-Observation
index NCT03929328 453 458 I-Observation
( NCT03929328 459 460 O
RSBI NCT03929328 461 465 B-Observation
) NCT03929328 466 467 O
< NCT03929328 468 469 B-Eq-Comparison
105 NCT03929328 470 473 I-Eq-Comparison

4 NCT03929328 487 488 O
. NCT03929328 488 489 O
Maximum NCT03929328 491 498 B-Observation
inspiratory NCT03929328 499 510 I-Observation
pressure NCT03929328 511 519 I-Observation
( NCT03929328 520 521 O
MIP NCT03929328 522 525 B-Observation
) NCT03929328 526 527 O
< NCT03929328 528 529 B-Eq-Comparison
- NCT03929328 530 531 I-Eq-Comparison
20 NCT03929328 532 534 I-Eq-Comparison
cm NCT03929328 535 537 I-Eq-Comparison
H20 NCT03929328 538 541 I-Eq-Comparison

2 NCT03929328 550 551 O
. NCT03929328 551 552 O
Clinical NCT03929328 554 562 O
criteria NCT03929328 563 571 O
: NCT03929328 572 573 O

1 NCT03929328 587 588 O
. NCT03929328 588 589 O
Absence NCT03929328 591 598 B-Negation
of NCT03929328 599 601 O
electrocardiographic NCT03929328 602 622 B-Procedure
signs NCT03929328 623 628 B-Assertion___Assertion-Type-Value:possible
of NCT03929328 629 631 O
myocardial NCT03929328 632 642 B-Condition
ischemia NCT03929328 643 651 I-Condition

2 NCT03929328 664 665 O
. NCT03929328 665 666 O
No NCT03929328 668 670 B-Negation
vasoactive NCT03929328 671 681 B-Drug
drugs NCT03929328 682 687 I-Drug
, NCT03929328 688 689 O
or NCT03929328 690 692 B-Or
vital NCT03929328 693 698 B-Observation
signs NCT03929328 699 704 I-Observation
are NCT03929328 705 708 O
stable NCT03929328 709 715 O
with NCT03929328 716 720 B-And
using NCT03929328 721 726 B-Eq-Comparison
vasoactive NCT03929328 727 737 B-Drug
drugs NCT03929328 738 743 I-Drug

3 NCT03929328 756 757 O
. NCT03929328 757 758 O
Heart NCT03929328 760 765 B-Observation
rate NCT03929328 766 770 I-Observation
< NCT03929328 771 772 B-Eq-Comparison
140 NCT03929328 773 776 I-Eq-Comparison
/ NCT03929328 777 778 O
min NCT03929328 779 782 O
, NCT03929328 783 784 O

4 NCT03929328 798 799 O
. NCT03929328 799 800 O
Hemoglobin NCT03929328 802 812 B-Observation
> NCT03929328 813 814 B-Eq-Comparison
8 NCT03929328 815 816 I-Eq-Comparison
g NCT03929328 817 818 I-Eq-Comparison
/ NCT03929328 819 820 I-Eq-Comparison
dL NCT03929328 821 823 I-Eq-Comparison

5 NCT03929328 836 837 O
. NCT03929328 837 838 O
Temperature NCT03929328 840 851 B-Observation
< NCT03929328 852 853 B-Eq-Comparison
38 NCT03929328 854 856 I-Eq-Comparison
° NCT03929328 857 858 I-Eq-Comparison
C NCT03929328 858 859 I-Eq-Comparison

6 NCT03929328 872 873 O
. NCT03929328 873 874 O
No NCT03929328 876 878 B-Negation
need NCT03929328 879 883 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929328 884 887 O
sedatives NCT03929328 888 897 B-Drug
, NCT03929328 898 899 O
or NCT03929328 900 902 B-Or
mental NCT03929328 903 909 B-Condition
status NCT03929328 910 916 I-Condition
are NCT03929328 917 920 O
stable NCT03929328 921 927 O
with NCT03929328 928 932 B-And
sedatives NCT03929328 933 942 B-Drug

7 NCT03929328 955 956 I-Eq-Comparison
. NCT03929328 956 957 O
Presence NCT03929328 959 967 O
of NCT03929328 968 970 O
respiratory NCT03929328 971 982 B-Condition
stimulus NCT03929328 983 991 I-Condition
, NCT03929328 992 993 O
and NCT03929328 994 997 B-And
appropriate NCT03929328 998 1009 O
spontaneous NCT03929328 1010 1021 B-Condition
cough NCT03929328 1022 1027 I-Condition

8 NCT03929328 1040 1041 O
. NCT03929328 1041 1042 O
Absence NCT03929328 1044 1051 B-Negation
of NCT03929328 1052 1054 O
excessive NCT03929328 1055 1064 O
tracheobronchial NCT03929328 1065 1081 B-Condition
secretions NCT03929328 1082 1092 I-Condition

Exclusion NCT03929328 1093 1102 O
Criteria NCT03929328 1103 1111 O
: NCT03929328 1112 1113 O

- NCT03929328 1117 1118 O
Tracheostomy NCT03929328 1120 1132 B-Procedure
status NCT03929328 1133 1139 O

- NCT03929328 1142 1143 O
Decision NCT03929328 1145 1153 O
to NCT03929328 1154 1156 O
stop NCT03929328 1157 1161 B-Negation
life NCT03929328 1162 1166 B-Procedure
- NCT03929328 1167 1168 I-Procedure
supportive NCT03929328 1169 1179 I-Procedure
therapies NCT03929328 1180 1189 I-Procedure
before NCT03929328 1190 1196 B-Temporal-Connection___Temporal-Connection-Type-Value:before
enrollment NCT03929328 1197 1207 B-Study

Inclusion NCT03922269 0 9 O
Criteria NCT03922269 10 18 O
: NCT03922269 19 20 O

- NCT03922269 24 25 O
Participant NCT03922269 27 38 O
self NCT03922269 39 43 O
- NCT03922269 44 45 O
identifies NCT03922269 46 56 O
as NCT03922269 57 59 O
transgender NCT03922269 60 71 O
and NCT03922269 72 75 B-Or
/ NCT03922269 76 77 I-Or
or NCT03922269 78 80 I-Or
has NCT03922269 81 84 O
a NCT03922269 85 86 O
current NCT03922269 87 94 B-Eq-Comparison
gender NCT03922269 95 101 B-Condition
identity NCT03922269 102 110 I-Condition
which NCT03922269 111 116 O
differs NCT03922269 117 124 B-Negation
from NCT03922269 125 129 O
gender NCT03922269 130 136 O
assigned NCT03922269 137 145 O
at NCT03922269 146 148 B-Temporal-Connection___Temporal-Connection-Type-Value:during
birth NCT03922269 149 154 B-Birth
( NCT03922269 155 156 O
includes NCT03922269 157 165 O
all NCT03922269 166 169 O
gender NCT03922269 170 176 O
diverse NCT03922269 177 184 O
people NCT03922269 185 191 O
) NCT03922269 192 193 O

- NCT03922269 197 198 O
Age NCT03922269 200 203 B-Age
> NCT03922269 204 205 B-Eq-Comparison
18 NCT03922269 206 208 I-Eq-Comparison
years NCT03922269 209 214 I-Eq-Comparison

- NCT03922269 217 218 O
HIV NCT03922269 220 223 B-Condition
infection NCT03922269 224 233 I-Condition
diagnosis NCT03922269 234 243 O
at NCT03922269 244 246 O
any NCT03922269 247 250 O
time NCT03922269 251 255 O
before NCT03922269 256 262 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03922269 263 268 B-Study
consent NCT03922269 269 276 O

- NCT03922269 279 280 O
Having NCT03922269 282 288 O
been NCT03922269 289 293 O
prescribed NCT03922269 294 304 O
antiretroviral NCT03922269 305 319 B-Procedure
therapy NCT03922269 320 327 I-Procedure
at NCT03922269 328 330 O
any NCT03922269 331 334 O
time NCT03922269 335 339 O
( NCT03922269 340 341 O
including NCT03922269 342 351 O
people NCT03922269 352 358 O
for NCT03922269 359 362 O
who NCT03922269 363 366 O
antiretroviral NCT03922269 367 381 B-Procedure
therapy NCT03922269 382 389 I-Procedure
initiation NCT03922269 390 400 O
is NCT03922269 401 403 O
planned NCT03922269 404 411 B-Eq-Comparison
after NCT03922269 412 417 B-Temporal-Connection___Temporal-Connection-Type-Value:after
study NCT03922269 418 423 B-Study
enrolment NCT03922269 424 433 O
) NCT03922269 434 435 O

- NCT03922269 439 440 O
Willing NCT03922269 442 449 O
to NCT03922269 450 452 O
sign NCT03922269 453 457 O
an NCT03922269 458 460 O
informed NCT03922269 461 469 O
consent NCT03922269 470 477 O
and NCT03922269 478 481 O
take NCT03922269 482 486 O
part NCT03922269 487 491 O
in NCT03922269 492 494 O
the NCT03922269 495 498 O
study NCT03922269 499 504 O

Exclusion NCT03922269 505 514 O
Criteria NCT03922269 515 523 O
: NCT03922269 524 525 O

- NCT03922269 529 530 O
Age NCT03922269 532 535 B-Age
< NCT03922269 536 537 B-Eq-Comparison
18 NCT03922269 538 540 I-Eq-Comparison
years NCT03922269 541 546 I-Eq-Comparison

- NCT03922269 549 550 O
Unable NCT03922269 552 558 O
to NCT03922269 559 561 O
take NCT03922269 562 566 O
part NCT03922269 567 571 O
in NCT03922269 572 574 O
the NCT03922269 575 578 O
study NCT03922269 579 584 O
according NCT03922269 585 594 O
to NCT03922269 595 597 O
the NCT03922269 598 601 O
Investigator NCT03922269 602 614 O
opinion NCT03922269 615 622 O
( NCT03922269 623 624 O
example NCT03922269 625 632 O
: NCT03922269 633 634 O
unable NCT03922269 635 641 O
to NCT03922269 642 644 O
understand NCT03922269 645 655 O
the NCT03922269 656 659 O
study NCT03922269 660 665 O
information NCT03922269 666 677 O
leaflet NCT03922269 678 685 O
, NCT03922269 686 687 O
unable NCT03922269 688 694 O
to NCT03922269 695 697 O
provide NCT03922269 698 705 O
written NCT03922269 706 713 O
consent NCT03922269 714 721 O
, NCT03922269 722 723 O
etc NCT03922269 724 727 O
. NCT03922269 727 728 O
) NCT03922269 729 730 O

Inclusion NCT03925506 0 9 O
Criteria NCT03925506 10 18 O
: NCT03925506 19 20 O

- NCT03925506 24 25 O
Inpatient NCT03925506 27 36 B-Encounter
≥ NCT03925506 37 38 B-Eq-Comparison
18 NCT03925506 39 41 I-Eq-Comparison
y. NCT03925506 42 44 I-Eq-Comparison
o. NCT03925506 45 47 I-Eq-Comparison
who NCT03925506 49 52 B-And
are NCT03925506 53 56 O
scheduled NCT03925506 57 66 B-Eq-Comparison
elective NCT03925506 67 75 O
colonoscopy NCT03925506 76 87 B-Procedure
during NCT03925506 88 94 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03925506 95 110 B-Coreference
irrespective NCT03925506 111 123 O
of NCT03925506 124 126 O
the NCT03925506 127 130 O
indication NCT03925506 131 141 O
. NCT03925506 142 143 O

Exclusion NCT03925506 145 154 O
Criteria NCT03925506 155 163 O
: NCT03925506 164 165 O

- NCT03925506 169 170 O
Urgent NCT03925506 172 178 B-Modifier
colonoscopy NCT03925506 179 190 B-Procedure

- NCT03925506 193 194 O
Patients NCT03925506 196 204 O
who NCT03925506 205 208 O
are NCT03925506 209 212 O
not NCT03925506 213 216 B-Negation
hospitalized NCT03925506 217 229 B-Encounter
when NCT03925506 230 234 B-Temporal-Connection___Temporal-Connection-Type-Value:during
taking NCT03925506 235 241 B-Eq-Comparison
bowel NCT03925506 242 247 B-Procedure
preparation NCT03925506 248 259 I-Procedure
or NCT03925506 260 262 B-Or
when NCT03925506 263 267 O
undergoing NCT03925506 268 278 B-Eq-Comparison
colonoscopy NCT03925506 279 290 B-Procedure

Inclusion NCT03927339 0 9 O
Criteria NCT03927339 10 18 O
: NCT03927339 19 20 O

- NCT03927339 24 25 O
: NCT03927339 27 28 O
knee NCT03927339 29 33 B-Modifier
OA NCT03927339 34 36 B-Condition
with NCT03927339 37 41 B-And
obesity NCT03927339 42 49 B-Condition
; NCT03927339 49 50 O
sedentary NCT03927339 51 60 B-Condition
with NCT03927339 61 65 B-And
no NCT03927339 66 68 B-Negation
previous NCT03927339 69 77 B-Eq-Comparison
education NCT03927339 78 87 B-Observation
; NCT03927339 88 89 O
ability NCT03927339 90 97 O
to NCT03927339 98 100 O
understand NCT03927339 101 111 O
and NCT03927339 112 115 O
follow NCT03927339 116 122 O
commands NCT03927339 123 131 O
; NCT03927339 131 132 O
and NCT03927339 133 136 O
ability NCT03927339 137 144 B-Condition
to NCT03927339 145 147 I-Condition
walk NCT03927339 148 152 I-Condition
independently NCT03927339 153 166 O
. NCT03927339 167 168 O

Exclusion NCT03927339 170 179 O
Criteria NCT03927339 180 188 O
: NCT03927339 189 190 O

- NCT03927339 194 195 O
Medical NCT03927339 197 204 B-Condition
conditions NCT03927339 205 215 I-Condition
contraindicating NCT03927339 216 232 B-Contraindication
moderate NCT03927339 233 241 O
aerobic NCT03927339 242 249 B-Observation
exercising NCT03927339 250 260 I-Observation
( NCT03927339 261 262 O
as NCT03927339 263 265 O
determined NCT03927339 266 276 O
through NCT03927339 277 284 O
prescreening NCT03927339 285 297 O
questions NCT03927339 298 307 O
, NCT03927339 308 309 O
i. NCT03927339 310 312 O
e. NCT03927339 313 315 O
, NCT03927339 316 317 O
cardiac NCT03927339 318 325 B-Modifier
or NCT03927339 326 328 B-Or
coronary NCT03927339 329 337 B-Modifier
artery NCT03927339 338 344 B-Condition
disease NCT03927339 345 352 I-Condition
as NCT03927339 353 355 O
ischemic NCT03927339 356 364 B-Condition
cardiomyopathy NCT03927339 365 379 I-Condition
, NCT03927339 380 381 O
chronic NCT03927339 382 389 B-Condition
lung NCT03927339 390 394 I-Condition
disease NCT03927339 395 402 I-Condition
, NCT03927339 403 404 O
asthma NCT03927339 405 411 B-Condition
, NCT03927339 412 413 O
uncontrolled NCT03927339 414 426 B-Modifier
hypertension NCT03927339 427 439 B-Condition
) NCT03927339 440 441 O
, NCT03927339 443 444 O
inability NCT03927339 445 454 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03927339 455 457 O
exercise NCT03927339 458 466 B-Observation
via NCT03927339 467 470 I-Observation
treadmill NCT03927339 471 480 I-Observation
( NCT03927339 481 482 O
i. NCT03927339 483 485 O
e. NCT03927339 486 488 O
no NCT03927339 490 492 B-Negation
neuromuscular NCT03927339 493 506 B-Modifier
or NCT03927339 507 509 B-Or
lower NCT03927339 510 515 B-Modifier
extremity NCT03927339 516 525 I-Modifier
conditions NCT03927339 526 536 B-Condition
or NCT03927339 537 539 B-Or
any NCT03927339 540 543 O
other NCT03927339 544 549 O
medical NCT03927339 550 557 O
contraindication NCT03927339 558 574 B-Contraindication
that NCT03927339 575 579 O
could NCT03927339 580 585 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03927339 586 593 B-Negation
them NCT03927339 594 598 O
from NCT03927339 599 603 O
floor NCT03927339 604 609 B-Observation
walking NCT03927339 610 617 I-Observation
as NCT03927339 618 620 O
upset NCT03927339 621 626 O
affecting NCT03927339 627 636 O
movement NCT03927339 637 645 B-Condition
of NCT03927339 646 648 O
the NCT03927339 649 652 O
pelvic NCT03927339 653 659 B-Modifier
arch NCT03927339 660 664 I-Modifier
or NCT03927339 665 667 B-Or
pace NCT03927339 668 672 B-Modifier
, NCT03927339 673 674 O
story NCT03927339 675 680 O
of NCT03927339 681 683 O
previous NCT03927339 684 692 B-Eq-Comparison
hip NCT03927339 693 696 B-Modifier
or NCT03927339 697 699 B-Or
knee NCT03927339 700 704 B-Modifier
operating NCT03927339 705 714 B-Procedure
room NCT03927339 715 719 O
, NCT03927339 720 721 O
periarticular NCT03927339 722 735 B-Modifier
fractures NCT03927339 736 745 B-Condition
, NCT03927339 746 747 O
or NCT03927339 748 750 O
lower NCT03927339 751 756 B-Modifier
limb NCT03927339 757 761 I-Modifier
injuries NCT03927339 762 770 B-Condition
) NCT03927339 771 772 O
. NCT03927339 773 774 O
History NCT03927339 775 782 B-Eq-Comparison
of NCT03927339 783 785 O
recent NCT03927339 786 792 B-Eq-Comparison
reefer NCT03927339 793 799 B-Condition
transmission NCT03927339 800 812 I-Condition
or NCT03927339 813 815 B-Or
acute NCT03927339 816 821 O
joint NCT03927339 822 827 B-Condition
lighting NCT03927339 828 836 I-Condition
. NCT03927339 837 838 O
History NCT03927339 839 846 B-Eq-Comparison
of NCT03927339 847 849 O
recent NCT03927339 850 856 B-Eq-Comparison
joint NCT03927339 857 862 B-Procedure
injection NCT03927339 863 872 I-Procedure
( NCT03927339 873 874 O
steroid NCT03927339 875 882 B-Drug
, NCT03927339 883 884 O
hyaluronic NCT03927339 885 895 B-Drug
acid NCT03927339 896 900 I-Drug
, NCT03927339 901 902 O
etc NCT03927339 903 906 O
. NCT03927339 906 907 O
) NCT03927339 908 909 O
within NCT03927339 910 916 B-Eq-Comparison
6 NCT03927339 917 918 I-Eq-Comparison
calendar NCT03927339 919 927 I-Eq-Comparison
week NCT03927339 928 932 I-Eq-Comparison
of NCT03927339 933 935 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03927339 936 941 B-Study
. NCT03927339 941 942 O
Ingestion NCT03927339 944 953 O
of NCT03927339 954 956 O
antioxidant NCT03927339 957 968 B-Drug
supplementation NCT03927339 969 984 I-Drug
and NCT03927339 985 988 B-Or
the NCT03927339 989 992 O
use NCT03927339 993 996 O
of NCT03927339 997 999 O
psychotropic NCT03927339 1000 1012 B-Drug
agents NCT03927339 1013 1019 I-Drug
. NCT03927339 1019 1020 O

Inclusion NCT03924817 0 9 O
Criteria NCT03924817 10 18 O
: NCT03924817 19 20 O

- NCT03924817 24 25 O
Prescription NCT03924817 27 39 O
of NCT03924817 40 42 O
a NCT03924817 43 44 O
Narval NCT03924817 45 51 B-Procedure
CC NCT03924817 52 54 I-Procedure
mandibular NCT03924817 55 65 I-Procedure
advancement NCT03924817 66 77 I-Procedure
device NCT03924817 78 84 I-Procedure

- NCT03924817 87 88 O
Age NCT03924817 90 93 B-Age
≥ NCT03924817 94 95 B-Eq-Comparison
18 NCT03924817 96 98 I-Eq-Comparison
years NCT03924817 99 104 I-Eq-Comparison

- NCT03924817 107 108 O
Ability NCT03924817 110 117 O
to NCT03924817 118 120 O
understand NCT03924817 121 131 O
the NCT03924817 132 135 O
study NCT03924817 136 141 O
information NCT03924817 142 153 O
and NCT03924817 154 157 O
information NCT03924817 158 169 O
on NCT03924817 170 172 O
usage NCT03924817 173 178 O
of NCT03924817 179 181 O
personal NCT03924817 182 190 O
data NCT03924817 191 195 O

- NCT03924817 198 199 O
Signed NCT03924817 201 207 O
and NCT03924817 208 211 O
dated NCT03924817 212 217 O
informed NCT03924817 218 226 O
consent NCT03924817 227 234 O

Exclusion NCT03924817 235 244 O
Criteria NCT03924817 245 253 O
: NCT03924817 254 255 O

- NCT03924817 259 260 O
Patients NCT03924817 262 270 O
with NCT03924817 271 275 O
central NCT03924817 276 283 B-Condition
sleep NCT03924817 284 289 I-Condition
apnea NCT03924817 290 295 I-Condition
( NCT03924817 296 297 O
central NCT03924817 298 305 B-Observation
AI NCT03924817 306 308 I-Observation
> NCT03924817 309 310 B-Eq-Comparison
5 NCT03924817 311 312 I-Eq-Comparison
/ NCT03924817 313 314 I-Eq-Comparison
hour NCT03924817 315 319 I-Eq-Comparison
) NCT03924817 320 321 O

- NCT03924817 325 326 O
Patients NCT03924817 328 336 O
with NCT03924817 337 341 O
loose NCT03924817 342 347 B-Condition
teeth NCT03924817 348 353 I-Condition
and NCT03924817 354 357 B-Or
severe NCT03924817 358 364 O
parodontitis NCT03924817 365 377 B-Condition

- NCT03924817 380 381 O
Patients NCT03924817 383 391 O
with NCT03924817 392 396 O
completely NCT03924817 397 407 O
missing NCT03924817 408 415 B-Condition
teeth NCT03924817 416 421 I-Condition
or NCT03924817 422 424 B-Or
removable NCT03924817 425 434 B-Procedure
tooth NCT03924817 435 440 I-Procedure
replacement NCT03924817 441 452 I-Procedure
, NCT03924817 453 454 O
or NCT03924817 455 457 O
with NCT03924817 458 462 O
a NCT03924817 463 464 O
teeth NCT03924817 465 470 B-Condition
health NCT03924817 471 477 I-Condition
insufficient NCT03924817 478 490 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924817 491 493 O
retain NCT03924817 494 500 O
an NCT03924817 501 503 O
MAD NCT03924817 504 507 B-Procedure
Patients NCT03924817 508 516 O
with NCT03924817 517 521 O
missing NCT03924817 522 529 B-Condition
molars NCT03924817 530 536 I-Condition
Patients NCT03924817 537 545 O
with NCT03924817 546 550 O
maximum NCT03924817 551 558 B-Observation
protrusion NCT03924817 559 569 I-Observation
of NCT03924817 570 572 O
less NCT03924817 573 577 B-Eq-Comparison
than NCT03924817 578 582 I-Eq-Comparison
5 NCT03924817 583 584 I-Eq-Comparison
mm NCT03924817 585 587 I-Eq-Comparison

Inclusion NCT03928977 0 9 O
Criteria NCT03928977 10 18 O
: NCT03928977 19 20 O

- NCT03928977 24 25 O
Patient NCT03928977 27 34 O
admitted NCT03928977 35 43 O
in NCT03928977 44 46 O
for NCT03928977 47 50 O
a NCT03928977 51 52 O
transient NCT03928977 53 62 B-Condition
neurologic NCT03928977 63 73 I-Condition
deficit NCT03928977 74 81 I-Condition
and NCT03928977 82 85 B-And
suspicion NCT03928977 86 95 B-Assertion___Assertion-Type-Value:possible
of NCT03928977 96 98 O
TIA NCT03928977 99 102 B-Condition
of NCT03928977 103 105 O
carotid NCT03928977 106 113 B-Modifier
circulation NCT03928977 114 125 I-Modifier

- NCT03928977 128 129 O
Prescription NCT03928977 131 143 O
for NCT03928977 144 147 O
conventionnal NCT03928977 148 161 O
MRI NCT03928977 162 165 B-Procedure

Exclusion NCT03928977 166 175 O
Criteria NCT03928977 176 184 O
: NCT03928977 185 186 O

- NCT03928977 190 191 O
Contraindication NCT03928977 193 209 B-Contraindication
to NCT03928977 210 212 O
MRI NCT03928977 213 216 B-Procedure

- NCT03928977 219 220 O
Previous NCT03928977 222 230 B-Eq-Comparison
neurological NCT03928977 231 243 B-Condition
disease NCT03928977 244 251 I-Condition
( NCT03928977 252 253 O
with NCT03928977 254 258 B-And
lesions NCT03928977 259 266 B-Condition
) NCT03928977 267 268 O

- NCT03928977 272 273 O
Severe NCT03928977 275 281 O
psychiatric NCT03928977 282 293 B-Condition
disease NCT03928977 294 301 I-Condition

Inclusion NCT03922282 0 9 O
Criteria NCT03922282 10 18 O
: NCT03922282 19 20 O

- NCT03922282 24 25 O
Subject NCT03922282 27 34 O
who NCT03922282 35 38 O
will NCT03922282 39 43 B-Eq-Comparison
have NCT03922282 44 48 I-Eq-Comparison
thyroid NCT03922282 49 56 B-Procedure
surgery NCT03922282 57 64 I-Procedure

Exclusion NCT03922282 65 74 O
Criteria NCT03922282 75 83 O
: NCT03922282 84 85 O

- NCT03922282 89 90 O
Subject NCT03922282 92 99 O
who NCT03922282 100 103 O
underwent NCT03922282 104 113 B-Eq-Comparison
thyroid NCT03922282 114 121 B-Procedure
surgery NCT03922282 122 129 I-Procedure

- NCT03922282 132 133 O
Subject NCT03922282 135 142 O
who NCT03922282 143 146 O
underwent NCT03922282 147 156 B-Eq-Comparison
any NCT03922282 157 160 O
radiotherapy NCT03922282 161 173 B-Procedure
on NCT03922282 174 176 O
neck NCT03922282 177 181 B-Modifier

- NCT03922282 184 185 O
Subject NCT03922282 187 194 O
who NCT03922282 195 198 O
need NCT03922282 199 203 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03922282 204 206 O
neck NCT03922282 207 211 B-Modifier
dissection NCT03922282 212 222 B-Procedure

- NCT03922282 225 226 O
Subject NCT03922282 228 235 O
under NCT03922282 236 241 B-Eq-Comparison
18 NCT03922282 242 244 I-Eq-Comparison
years NCT03922282 245 250 I-Age|Eq-Comparison
or NCT03922282 251 253 B-Or
over NCT03922282 254 258 B-Eq-Comparison
70 NCT03922282 259 261 I-Eq-Comparison
years NCT03922282 262 267 I-Eq-Comparison

- NCT03922282 270 271 O
Bad NCT03922282 273 276 B-Condition
general NCT03922282 277 284 I-Condition
condition NCT03922282 285 294 I-Condition

- NCT03922282 297 298 O
High NCT03922282 300 304 O
American NCT03922282 305 313 B-Condition
Society NCT03922282 314 321 I-Condition
of NCT03922282 322 324 I-Condition
Anesthesiologists NCT03922282 325 342 I-Condition
( NCT03922282 343 344 O
ASA NCT03922282 345 348 B-Condition
) NCT03922282 349 350 O
score NCT03922282 351 356 O
( NCT03922282 357 358 O
over NCT03922282 359 363 B-Eq-Comparison
3 NCT03922282 364 365 I-Eq-Comparison
) NCT03922282 366 367 O

- NCT03922282 371 372 O
Breast NCT03922282 374 380 B-Condition
feeder NCT03922282 381 387 I-Condition
or NCT03922282 388 390 B-Or
pregnancy NCT03922282 391 400 B-Condition

- NCT03922282 403 404 O
Subject NCT03922282 406 413 O
who NCT03922282 414 417 O
disagree NCT03922282 418 426 O
to NCT03922282 427 429 O
do NCT03922282 430 432 O
this NCT03922282 433 437 O
trial NCT03922282 438 443 O

Inclusion NCT03929705 0 9 O
Criteria NCT03929705 10 18 O
: NCT03929705 19 20 O
Cohort NCT03929705 21 27 O
1 NCT03929705 28 29 O
a NCT03929705 30 31 O
and NCT03929705 32 35 O
1 NCT03929705 36 37 O
b NCT03929705 38 39 O

- NCT03929705 42 43 O
• NCT03929705 45 46 O
Must NCT03929705 47 51 O
be NCT03929705 52 54 O
at NCT03929705 55 57 B-Eq-Comparison
least NCT03929705 58 63 I-Eq-Comparison
18 NCT03929705 64 66 I-Eq-Comparison
years NCT03929705 67 72 I-Eq-Comparison
of NCT03929705 73 75 O
age NCT03929705 76 79 B-Age

- NCT03929705 87 88 O
Must NCT03929705 90 94 O
be NCT03929705 95 97 O
able NCT03929705 98 102 O
to NCT03929705 103 105 O
provide NCT03929705 106 113 O
informed NCT03929705 114 122 O
consent NCT03929705 123 130 O

- NCT03929705 138 139 O
Must NCT03929705 141 145 O
be NCT03929705 146 148 O
able NCT03929705 149 153 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929705 154 156 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929705 157 164 O
a NCT03929705 165 166 O
minimum NCT03929705 167 174 B-Eq-Comparison
of NCT03929705 175 177 I-Eq-Comparison
10 NCT03929705 178 180 I-Eq-Comparison
mL NCT03929705 181 183 I-Eq-Comparison
of NCT03929705 184 186 O
whole NCT03929705 187 192 B-Observation
blood NCT03929705 193 198 I-Observation
at NCT03929705 199 201 B-Temporal-Connection___Temporal-Connection-Type-Value:during
each NCT03929705 202 206 O
visit NCT03929705 207 212 B-Encounter
( NCT03929705 213 214 O
16 NCT03929705 215 217 B-Eq-Comparison
mL NCT03929705 218 220 I-Eq-Comparison
for NCT03929705 221 224 O
immunocompromised NCT03929705 225 242 B-Condition
i. NCT03929705 243 245 O
e. NCT03929705 246 248 O
HIV NCT03929705 250 253 B-Condition
+ NCT03929705 254 255 O
) NCT03929705 257 258 O

- NCT03929705 267 268 O
Must NCT03929705 270 274 O
be NCT03929705 275 277 O
T NCT03929705 278 279 B-Observation
- NCT03929705 280 281 I-Observation
SPOT NCT03929705 282 286 I-Observation
. NCT03929705 286 287 I-Observation
TB NCT03929705 288 290 I-Observation
positive NCT03929705 291 299 O

- NCT03929705 307 308 O
First NCT03929705 310 315 B-Eq-Comparison
visit NCT03929705 316 321 B-Encounter
suspect NCT03929705 322 329 B-Assertion___Assertion-Type-Value:possible
TB NCT03929705 330 332 B-Condition
subjects NCT03929705 333 341 O
with NCT03929705 342 346 B-And
no NCT03929705 347 349 B-Negation
prior NCT03929705 350 355 B-Eq-Comparison
history NCT03929705 356 363 I-Eq-Comparison
of NCT03929705 364 366 O
TB NCT03929705 367 369 B-Condition
diagnosis NCT03929705 370 379 O
Inclusion NCT03929705 380 389 O
Criteria NCT03929705 390 398 O
: NCT03929705 399 400 O
Cohort NCT03929705 401 407 O
2 NCT03929705 408 409 O
a NCT03929705 410 411 O
and NCT03929705 412 415 O
2 NCT03929705 416 417 O
b NCT03929705 418 419 O

- NCT03929705 427 428 O
Must NCT03929705 430 434 O
be NCT03929705 435 437 O
at NCT03929705 438 440 B-Eq-Comparison
least NCT03929705 441 446 I-Eq-Comparison
18 NCT03929705 447 449 I-Eq-Comparison
years NCT03929705 450 455 I-Eq-Comparison
of NCT03929705 456 458 O
age NCT03929705 459 462 B-Age

- NCT03929705 470 471 O
Must NCT03929705 473 477 O
be NCT03929705 478 480 O
able NCT03929705 481 485 O
to NCT03929705 486 488 O
provide NCT03929705 489 496 O
informed NCT03929705 497 505 O
consent NCT03929705 506 513 O

- NCT03929705 521 522 O
Must NCT03929705 524 528 O
be NCT03929705 529 531 O
able NCT03929705 532 536 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929705 537 539 I-Assertion___Assertion-Type-Value:hypothetical
provide NCT03929705 540 547 O
a NCT03929705 548 549 O
minimum NCT03929705 550 557 B-Eq-Comparison
of NCT03929705 558 560 I-Eq-Comparison
10 NCT03929705 561 563 I-Eq-Comparison
mL NCT03929705 564 566 I-Eq-Comparison
of NCT03929705 567 569 O
whole NCT03929705 570 575 B-Observation
blood NCT03929705 576 581 I-Observation
at NCT03929705 582 584 B-Temporal-Connection___Temporal-Connection-Type-Value:during
each NCT03929705 585 589 O
visit NCT03929705 590 595 B-Encounter
( NCT03929705 596 597 O
16 NCT03929705 598 600 B-Eq-Comparison
mL NCT03929705 601 603 I-Eq-Comparison
for NCT03929705 604 607 O
immunocompromised NCT03929705 608 625 B-Condition
i. NCT03929705 626 628 O
e. NCT03929705 629 631 O
HIV NCT03929705 633 636 B-Condition
+ NCT03929705 637 638 O
) NCT03929705 640 641 O

- NCT03929705 650 651 O
Must NCT03929705 653 657 O
be NCT03929705 658 660 O
T NCT03929705 661 662 B-Condition
- NCT03929705 663 664 I-Condition
SPOT NCT03929705 665 669 I-Condition
. NCT03929705 669 670 I-Condition
TB NCT03929705 671 673 I-Condition
positive NCT03929705 674 682 O

- NCT03929705 690 691 O
No NCT03929705 693 695 B-Negation
prior NCT03929705 696 701 B-Eq-Comparison
history NCT03929705 702 709 I-Eq-Comparison
of NCT03929705 710 712 O
TB NCT03929705 713 715 B-Condition
diagnosis NCT03929705 716 725 O

Exclusion NCT03929705 726 735 O
Criteria NCT03929705 736 744 O
: NCT03929705 745 746 O
Cohort NCT03929705 747 753 O
1 NCT03929705 754 755 O
a NCT03929705 756 757 O
and NCT03929705 758 761 O
1 NCT03929705 762 763 O
b NCT03929705 764 765 O

- NCT03929705 768 769 O
• NCT03929705 771 772 O
Negative NCT03929705 773 781 O
in NCT03929705 782 784 O
the NCT03929705 785 788 O
T NCT03929705 789 790 B-Observation
- NCT03929705 791 792 I-Observation
SPOT NCT03929705 793 797 I-Observation
. NCT03929705 797 798 I-Observation
TB NCT03929705 799 801 I-Observation
test NCT03929705 802 806 I-Observation

- NCT03929705 814 815 O
Previous NCT03929705 817 825 B-Eq-Comparison
or NCT03929705 826 828 B-Or
pre NCT03929705 829 832 B-Eq-Comparison
- NCT03929705 833 834 I-Eq-Comparison
existing NCT03929705 835 843 I-Eq-Comparison
confirmed NCT03929705 844 853 O
TB NCT03929705 854 856 B-Condition
diagnosis NCT03929705 857 866 O

- NCT03929705 874 875 O
On NCT03929705 877 879 B-Eq-Comparison
anti NCT03929705 880 884 O
- NCT03929705 885 886 O
TB NCT03929705 887 889 B-Condition
treatment NCT03929705 890 899 B-Procedure
for NCT03929705 900 903 O
more NCT03929705 904 908 B-Eq-Comparison
than NCT03929705 909 913 I-Eq-Comparison
1 NCT03929705 914 915 I-Eq-Comparison
week NCT03929705 916 920 I-Eq-Comparison
* NCT03929705 920 921 O

- NCT03929705 929 930 O
Not NCT03929705 932 935 O
meeting NCT03929705 936 943 O
inclusion NCT03929705 944 953 O
criteria NCT03929705 954 962 O
Exclusion NCT03929705 963 972 O
Criteria NCT03929705 973 981 O
: NCT03929705 982 983 O
Cohort NCT03929705 984 990 O
2 NCT03929705 991 992 O
a NCT03929705 993 994 O
and NCT03929705 995 998 O
2 NCT03929705 999 1000 O
b NCT03929705 1001 1002 O

- NCT03929705 1010 1011 O
Negative NCT03929705 1013 1021 O
T NCT03929705 1022 1023 B-Observation
- NCT03929705 1024 1025 I-Observation
SPOT NCT03929705 1026 1030 I-Observation
. NCT03929705 1030 1031 I-Observation
TB NCT03929705 1032 1034 I-Observation
test NCT03929705 1035 1039 I-Observation

- NCT03929705 1047 1048 O
Previous NCT03929705 1050 1058 B-Eq-Comparison
or NCT03929705 1059 1061 B-Or
pre NCT03929705 1062 1065 B-Eq-Comparison
- NCT03929705 1066 1067 I-Eq-Comparison
existing NCT03929705 1068 1076 I-Eq-Comparison
confirmed NCT03929705 1077 1086 O
TB NCT03929705 1087 1089 B-Condition
diagnosis NCT03929705 1090 1099 O

- NCT03929705 1107 1108 O
On NCT03929705 1110 1112 B-Eq-Comparison
anti NCT03929705 1113 1117 O
- NCT03929705 1118 1119 O
TB NCT03929705 1120 1122 B-Condition
treatment NCT03929705 1123 1132 B-Procedure

- NCT03929705 1140 1141 O
Symptoms NCT03929705 1143 1151 B-Assertion___Assertion-Type-Value:possible
of NCT03929705 1152 1154 O
active NCT03929705 1155 1161 B-Eq-Comparison
TB NCT03929705 1162 1164 B-Condition

- NCT03929705 1172 1173 O
Not NCT03929705 1175 1178 O
meeting NCT03929705 1179 1186 O
inclusion NCT03929705 1187 1196 O
criteria NCT03929705 1197 1205 O

Inclusion NCT03927066 0 9 O
Criteria NCT03927066 10 18 O
: NCT03927066 19 20 O

- NCT03927066 24 25 O
Non NCT03927066 27 30 B-Negation
- NCT03927066 31 32 O
obese NCT03927066 33 38 B-Condition
( NCT03927066 39 40 O
BMI NCT03927066 41 44 B-Observation
< NCT03927066 45 46 B-Eq-Comparison
30 NCT03927066 47 49 I-Eq-Comparison
) NCT03927066 50 51 O

- NCT03927066 55 56 O
Non NCT03927066 58 61 O
- NCT03927066 62 63 O
smokers NCT03927066 64 71 O

- NCT03927066 74 75 O
Free NCT03927066 77 81 B-Negation
of NCT03927066 82 84 I-Negation
any NCT03927066 85 88 O
systemic NCT03927066 89 97 B-Modifier
diseases NCT03927066 98 106 B-Condition
including NCT03927066 107 116 O
hypertension NCT03927066 117 129 B-Condition
, NCT03927066 130 131 O
diabetes NCT03927066 132 140 B-Condition
, NCT03927066 141 142 O
coronary NCT03927066 143 151 B-Condition
artery NCT03927066 152 158 I-Condition
disease NCT03927066 159 166 I-Condition
, NCT03927066 167 168 O
neurologic NCT03927066 169 179 B-Condition
disease NCT03927066 180 187 I-Condition
, NCT03927066 188 189 O
or NCT03927066 190 192 B-Or
any NCT03927066 193 196 O
other NCT03927066 197 202 B-Other
major NCT03927066 203 208 O
medical NCT03927066 209 216 B-Condition
co NCT03927066 217 219 I-Condition
- NCT03927066 220 221 I-Condition
morbidity NCT03927066 222 231 I-Condition

- NCT03927066 234 235 O
Women NCT03927066 237 242 O
will NCT03927066 243 247 B-Eq-Comparison
be NCT03927066 248 250 I-Eq-Comparison
either NCT03927066 251 257 O
surgically NCT03927066 258 268 B-Procedure
sterilized NCT03927066 269 279 I-Procedure
or NCT03927066 280 282 B-Or
non NCT03927066 283 286 B-Negation
- NCT03927066 287 288 O
pregnant NCT03927066 289 297 B-Condition
as NCT03927066 298 300 O
determined NCT03927066 301 311 O
by NCT03927066 312 314 O
a NCT03927066 315 316 O
urine NCT03927066 317 322 B-Observation
pregnancy NCT03927066 323 332 I-Observation
test NCT03927066 333 337 I-Observation

Inclusion NCT03925103 0 9 O
Criteria NCT03925103 10 18 O
: NCT03925103 19 20 O

- NCT03925103 24 25 O
Clinical NCT03925103 27 35 O
NSCLC NCT03925103 36 41 O
early NCT03925103 42 47 O
stage NCT03925103 48 53 O
( NCT03925103 54 55 O
stage NCT03925103 56 61 O
I NCT03925103 62 63 O
- NCT03925103 64 65 O
II NCT03925103 66 68 O
) NCT03925103 69 70 O
. NCT03925103 72 73 O

- NCT03925103 77 78 O
Both NCT03925103 80 84 O
forced NCT03925103 85 91 B-Observation
expiratory NCT03925103 92 102 I-Observation
volume NCT03925103 103 109 I-Observation
in NCT03925103 110 112 I-Observation
one NCT03925103 113 116 I-Observation
second NCT03925103 117 123 I-Observation
( NCT03925103 124 125 O
FEV1 NCT03925103 126 130 B-Observation
) NCT03925103 131 132 O
and NCT03925103 133 136 B-And
diffusion NCT03925103 137 146 B-Observation
capacity NCT03925103 147 155 I-Observation
of NCT03925103 156 158 I-Observation
carbon NCT03925103 159 165 I-Observation
monoxide NCT03925103 166 174 I-Observation
( NCT03925103 175 176 O
DLCO NCT03925103 177 181 B-Observation
) NCT03925103 182 183 O
> NCT03925103 185 186 B-Eq-Comparison
60 NCT03925103 187 189 I-Eq-Comparison
% NCT03925103 190 191 I-Eq-Comparison

- NCT03925103 195 196 O
Both NCT03925103 198 202 O
predicted NCT03925103 203 212 B-Modifier
post NCT03925103 213 217 I-Modifier
operative NCT03925103 218 227 I-Modifier
( NCT03925103 228 229 O
PPO NCT03925103 230 233 B-Modifier
) NCT03925103 234 235 O
FEV1 NCT03925103 236 240 B-Observation
and NCT03925103 241 244 B-And
PPO NCT03925103 245 248 B-Modifier
DLCO NCT03925103 249 253 B-Observation
> NCT03925103 254 255 B-Eq-Comparison
35 NCT03925103 256 258 I-Eq-Comparison
% NCT03925103 259 260 O

- NCT03925103 264 265 O
American NCT03925103 267 275 B-Condition
Society NCT03925103 276 283 I-Condition
of NCT03925103 284 286 I-Condition
Anesthesia NCT03925103 287 297 I-Condition
( NCT03925103 298 299 O
ASA NCT03925103 300 303 B-Condition
) NCT03925103 304 305 O
score NCT03925103 306 311 B-Eq-Comparison
< NCT03925103 312 313 I-Eq-Comparison
= NCT03925103 315 316 I-Eq-Comparison
2 NCT03925103 317 318 I-Eq-Comparison

- NCT03925103 322 323 O
Body NCT03925103 325 329 B-Observation
mass NCT03925103 330 334 I-Observation
index NCT03925103 335 340 I-Observation
( NCT03925103 341 342 O
BMI NCT03925103 343 346 B-Observation
) NCT03925103 347 348 O
> NCT03925103 349 350 B-Eq-Comparison
18 NCT03925103 351 353 I-Eq-Comparison
< NCT03925103 354 355 B-Eq-Comparison
28 NCT03925103 356 358 I-Eq-Comparison

Exclusion NCT03925103 360 369 O
Criteria NCT03925103 370 378 O
: NCT03925103 379 380 O

- NCT03925103 384 385 O
Clinical NCT03925103 387 395 O
NSCLC NCT03925103 396 401 B-Condition
stage NCT03925103 402 407 B-Eq-Comparison
> NCT03925103 408 409 I-Eq-Comparison
II NCT03925103 410 412 I-Eq-Comparison

- NCT03925103 415 416 O
History NCT03925103 418 425 B-Eq-Comparison
of NCT03925103 426 428 O
Neoadjuvant NCT03925103 429 440 B-Procedure
chemotherapy NCT03925103 441 453 I-Procedure
or NCT03925103 454 456 B-Or
radiotherapy NCT03925103 457 469 B-Procedure

- NCT03925103 472 473 O
Radiologic NCT03925103 475 485 B-Procedure
evidence NCT03925103 486 494 O
of NCT03925103 495 497 O
extensive NCT03925103 498 507 O
pleural NCT03925103 508 515 B-Condition
adhesions NCT03925103 516 525 I-Condition
. NCT03925103 526 527 O

- NCT03925103 531 532 O
Age NCT03925103 534 537 B-Age
< NCT03925103 538 539 B-Eq-Comparison
18 NCT03925103 540 542 I-Eq-Comparison
or NCT03925103 543 545 B-Or
> NCT03925103 546 547 B-Eq-Comparison
80 NCT03925103 548 550 I-Eq-Comparison
years NCT03925103 551 556 I-Eq-Comparison
. NCT03925103 557 558 O

- NCT03925103 562 563 O
Patients NCT03925103 565 573 O
with NCT03925103 574 578 O
previous NCT03925103 579 587 B-Eq-Comparison
pleurodesis NCT03925103 588 599 B-Procedure
or NCT03925103 600 602 B-Or
thoracotomy NCT03925103 603 614 B-Procedure
in NCT03925103 615 617 O
the NCT03925103 618 621 O
affected NCT03925103 622 630 B-Modifier
hemithorax NCT03925103 631 641 I-Modifier
. NCT03925103 642 643 O

- NCT03925103 647 648 O
Patients NCT03925103 650 658 O
who NCT03925103 659 662 O
will NCT03925103 663 667 B-Eq-Comparison
undergo NCT03925103 668 675 I-Eq-Comparison
surgical NCT03925103 676 684 B-Procedure
lung NCT03925103 685 689 I-Procedure
resection NCT03925103 690 699 I-Procedure
other NCT03925103 700 705 B-Exception
than NCT03925103 706 710 I-Exception
lobectomy NCT03925103 711 720 B-Procedure
. NCT03925103 721 722 O

- NCT03925103 726 727 O
Patients NCT03925103 729 737 O
with NCT03925103 738 742 O
severe NCT03925103 743 749 O
comorbidity NCT03925103 750 761 B-Condition
contraindicating NCT03925103 762 778 B-Contraindication
lobectomy NCT03925103 779 788 B-Procedure
. NCT03925103 789 790 O

- NCT03925103 794 795 O
Patients NCT03925103 797 805 O
refusal NCT03925103 806 813 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03925103 814 816 B-Or
noncompliance NCT03925103 817 830 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925103 831 833 O
general NCT03925103 834 841 B-Procedure
surgery NCT03925103 842 849 I-Procedure
and NCT03925103 850 853 B-Or
one NCT03925103 854 857 B-Modifier
- NCT03925103 858 859 I-Modifier
lung NCT03925103 860 864 I-Modifier
ventilation NCT03925103 865 876 B-Procedure
. NCT03925103 876 877 O

Inclusion NCT03924037 0 9 O
Criteria NCT03924037 10 18 O
: NCT03924037 19 20 O

- NCT03924037 24 25 O
American NCT03924037 27 35 O
Indian NCT03924037 36 42 O
youth NCT03924037 43 48 O
aged NCT03924037 49 53 B-Age
13 NCT03924037 54 56 B-Eq-Comparison
- NCT03924037 57 58 I-Eq-Comparison
24 NCT03924037 59 61 I-Eq-Comparison
years NCT03924037 62 67 I-Eq-Comparison
old NCT03924037 68 71 O
who NCT03924037 72 75 O
are NCT03924037 76 79 O
San NCT03924037 80 83 O
Felipe NCT03924037 84 90 O
tribal NCT03924037 91 97 O
members NCT03924037 98 105 O
living NCT03924037 106 112 O
in NCT03924037 113 115 O
the NCT03924037 116 119 O
Pueblo NCT03924037 120 126 O

- NCT03924037 129 130 O
Endorse NCT03924037 132 139 O
suicidal NCT03924037 140 148 B-Condition
ideation NCT03924037 149 157 B-Modifier
or NCT03924037 158 160 B-Or
behaviors NCT03924037 161 170 B-Modifier
on NCT03924037 171 173 O
a NCT03924037 174 175 O
universal NCT03924037 176 185 B-Procedure
screen NCT03924037 186 192 I-Procedure
by NCT03924037 193 195 O
their NCT03924037 196 201 O
primary NCT03924037 202 209 B-Provider
care NCT03924037 210 214 I-Provider
provider NCT03924037 215 223 I-Provider
. NCT03924037 224 225 O

Exclusion NCT03924037 227 236 O
Criteria NCT03924037 237 245 O
: NCT03924037 246 247 O

- NCT03924037 251 252 O
Younger NCT03924037 254 261 B-Eq-Comparison
than NCT03924037 262 266 I-Eq-Comparison
age NCT03924037 267 270 I-Eq-Comparison
of NCT03924037 271 273 I-Eq-Comparison
13 NCT03924037 274 276 I-Eq-Comparison
years NCT03924037 277 282 I-Eq-Comparison
old NCT03924037 283 286 O
or NCT03924037 287 289 B-Or

- NCT03924037 292 293 O
Older NCT03924037 295 300 B-Eq-Comparison
than NCT03924037 301 305 I-Eq-Comparison
the NCT03924037 306 309 I-Eq-Comparison
age NCT03924037 310 313 I-Eq-Comparison
of NCT03924037 314 316 I-Eq-Comparison
24 NCT03924037 317 319 I-Eq-Comparison
, NCT03924037 320 321 O

- NCT03924037 326 327 O
Not NCT03924037 329 332 B-Negation
American NCT03924037 333 341 O
Indian NCT03924037 342 348 O
, NCT03924037 349 350 O

- NCT03924037 354 355 O
Youth NCT03924037 357 362 O
who NCT03924037 363 366 B-And
do NCT03924037 367 369 O
not NCT03924037 370 373 B-Negation
receive NCT03924037 374 381 O
health NCT03924037 382 388 B-Encounter
services NCT03924037 389 397 I-Encounter
at NCT03924037 398 400 O
either NCT03924037 401 407 O
of NCT03924037 408 410 O
the NCT03924037 411 414 O
IHS NCT03924037 415 418 O
clinics NCT03924037 419 426 O
at NCT03924037 427 429 O
the NCT03924037 430 433 O
Pueblo NCT03924037 434 440 O
of NCT03924037 441 443 O
San NCT03924037 444 447 O
Felipe NCT03924037 448 454 O
, NCT03924037 455 456 O

- NCT03924037 460 461 O
Youth NCT03924037 463 468 O
who NCT03924037 469 472 B-And
screen NCT03924037 473 479 O
negative NCT03924037 480 488 O
for NCT03924037 489 492 O
suicidal NCT03924037 493 501 B-Condition
ideation NCT03924037 502 510 B-Modifier
and NCT03924037 511 514 B-Or
/ NCT03924037 515 516 I-Or
or NCT03924037 517 519 I-Or
behavior NCT03924037 520 528 B-Modifier
, NCT03924037 529 530 O

- NCT03924037 534 535 O
Refuse NCT03924037 537 543 O
to NCT03924037 544 546 O
participate NCT03924037 547 558 O
in NCT03924037 559 561 O
the NCT03924037 562 565 O
study NCT03924037 566 571 O
, NCT03924037 572 573 O
and NCT03924037 574 577 O
/ NCT03924037 578 579 O
or NCT03924037 580 582 O

- NCT03924037 585 586 O
Cognitively NCT03924037 588 599 B-Condition
unable NCT03924037 600 606 I-Condition
to NCT03924037 607 609 O
provide NCT03924037 610 617 O
informed NCT03924037 618 626 O
consent NCT03924037 627 634 O
as NCT03924037 635 637 O
demonstrated NCT03924037 638 650 O
by NCT03924037 651 653 O
a NCT03924037 654 655 O
brief NCT03924037 656 661 O
cognitive NCT03924037 662 671 B-Procedure
screen NCT03924037 672 678 I-Procedure
prior NCT03924037 679 684 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924037 685 687 O
completion NCT03924037 688 698 O
of NCT03924037 699 701 O
the NCT03924037 702 705 O
baseline NCT03924037 706 714 B-Study
interview NCT03924037 715 724 O
. NCT03924037 724 725 O

Inclusion NCT03922334 0 9 O
Criteria NCT03922334 10 18 O
: NCT03922334 19 20 O

- NCT03922334 24 25 O
Pregnant NCT03922334 27 35 B-Condition
( NCT03922334 36 37 O
any NCT03922334 38 41 O
plurality NCT03922334 42 51 O
) NCT03922334 52 53 O
delivering NCT03922334 54 64 B-Eq-Comparison
at NCT03922334 65 67 B-Eq-Comparison
or NCT03922334 68 70 I-Eq-Comparison
after NCT03922334 71 76 I-Eq-Comparison
20 NCT03922334 77 79 I-Eq-Comparison
weeks NCT03922334 80 85 I-Eq-Comparison
of NCT03922334 86 88 O
gestation NCT03922334 89 98 B-Observation
OR NCT03922334 99 101 B-Or
postpartum NCT03922334 102 112 B-Condition
( NCT03922334 113 114 O
during NCT03922334 115 121 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03922334 122 137 B-Encounter
) NCT03922334 138 139 O
, NCT03922334 141 142 O
regardless NCT03922334 143 153 O
of NCT03922334 154 156 O
perinatal NCT03922334 157 166 O
outcome NCT03922334 167 174 O

- NCT03922334 177 178 O
16 NCT03922334 180 182 B-Eq-Comparison
years NCT03922334 183 188 I-Eq-Comparison
or NCT03922334 189 191 I-Eq-Comparison
older NCT03922334 192 197 I-Age|Eq-Comparison

- NCT03922334 200 201 O
Low NCT03922334 203 206 O
- NCT03922334 207 208 O
income NCT03922334 209 215 O
socioeconomic NCT03922334 216 229 O
status NCT03922334 230 236 O
( NCT03922334 237 238 O
publicly NCT03922334 239 247 O
funded NCT03922334 248 254 O
prenatal NCT03922334 255 263 O
care NCT03922334 264 268 O
) NCT03922334 269 270 O

- NCT03922334 274 275 O
Ability NCT03922334 277 284 O
to NCT03922334 285 287 O
speak NCT03922334 288 293 O
and NCT03922334 294 297 O
read NCT03922334 298 302 O
English NCT03922334 303 310 O
or NCT03922334 311 313 B-Or
Spanish NCT03922334 314 321 O

- NCT03922334 324 325 O
Established NCT03922334 327 338 O
patient NCT03922334 339 346 O
at NCT03922334 347 349 O
the NCT03922334 350 353 O
Northwestern NCT03922334 354 366 O
Medicine NCT03922334 367 375 O
Prentice NCT03922334 376 384 O
Ambulatory NCT03922334 385 395 O
Care NCT03922334 396 400 O
clinical NCT03922334 401 409 O
site NCT03922334 410 414 O
( NCT03922334 415 416 O
at NCT03922334 417 419 B-Eq-Comparison
least NCT03922334 420 425 I-Eq-Comparison
one NCT03922334 426 429 I-Eq-Comparison
antenatal NCT03922334 430 439 O
clinical NCT03922334 440 448 O
visit NCT03922334 449 454 B-Encounter
) NCT03922334 455 456 O
. NCT03922334 458 459 O

Exclusion NCT03922334 461 470 O
Criteria NCT03922334 471 479 O
: NCT03922334 480 481 O

- NCT03922334 485 486 O
Intent NCT03922334 488 494 B-Assertion___Assertion-Type-Value:intention
to NCT03922334 495 497 O
transfer NCT03922334 498 506 B-Encounter
care NCT03922334 507 511 I-Encounter
to NCT03922334 512 514 O
an NCT03922334 515 517 O
outside NCT03922334 518 525 B-Other
institution NCT03922334 526 537 O

- NCT03922334 540 541 O
HIV NCT03922334 543 546 B-Condition
( NCT03922334 547 548 O
as NCT03922334 549 551 O
these NCT03922334 552 557 O
patients NCT03922334 558 566 O
already NCT03922334 567 574 O
receive NCT03922334 575 582 O
intensive NCT03922334 583 592 O
social NCT03922334 593 599 O
support NCT03922334 600 607 O
and NCT03922334 608 611 O
navigation NCT03922334 612 622 O
- NCT03922334 623 624 O
like NCT03922334 625 629 O
services NCT03922334 630 638 O
at NCT03922334 639 641 O
this NCT03922334 642 646 O
institution NCT03922334 647 658 O
) NCT03922334 659 660 O

Inclusion NCT03923764 0 9 O
Criteria NCT03923764 10 18 O
: NCT03923764 19 20 O

- NCT03923764 24 25 O
Diagnosed NCT03923764 27 36 O
with NCT03923764 37 41 O
COPD NCT03923764 42 46 B-Condition

- NCT03923764 49 50 O
Participating NCT03923764 52 65 O
in NCT03923764 66 68 O
ongoing NCT03923764 69 76 B-Eq-Comparison
lung NCT03923764 77 81 B-Procedure
rehabilitating NCT03923764 82 96 I-Procedure
programme NCT03923764 97 106 O
at NCT03923764 107 109 O
Hvidovre NCT03923764 110 118 O
and NCT03923764 119 122 B-Or
Bispebjerg NCT03923764 123 133 O
Hospital NCT03923764 134 142 O

- NCT03923764 145 146 O
over NCT03923764 148 152 B-Eq-Comparison
18 NCT03923764 153 155 I-Eq-Comparison
years NCT03923764 156 161 I-Age|Eq-Comparison

Exclusion NCT03923764 162 171 O
Criteria NCT03923764 172 180 O
: NCT03923764 181 182 O

- NCT03923764 186 187 O
Plasma NCT03923764 189 195 B-Observation
creatinin NCT03923764 196 205 I-Observation
over NCT03923764 206 210 B-Eq-Comparison
200 NCT03923764 211 214 I-Eq-Comparison
mikrog NCT03923764 215 221 I-Eq-Comparison
/ NCT03923764 222 223 I-Eq-Comparison
l NCT03923764 224 225 I-Eq-Comparison

- NCT03923764 228 229 O
dementia NCT03923764 231 239 B-Condition

- NCT03923764 242 243 O
unable NCT03923764 245 251 B-Negation
to NCT03923764 252 254 O
read NCT03923764 255 259 O
or NCT03923764 260 262 O
speak NCT03923764 263 268 O
danish NCT03923764 269 275 O

Inclusion NCT03925467 0 9 O
Criteria NCT03925467 10 18 O
: NCT03925467 19 20 O

Patients NCT03925467 22 30 O
meet NCT03925467 31 35 O
at NCT03925467 36 38 B-Eq-Comparison
least NCT03925467 39 44 I-Eq-Comparison
three NCT03925467 45 50 I-Eq-Comparison
out NCT03925467 51 54 B-Criteria-Count
of NCT03925467 55 57 I-Criteria-Count
the NCT03925467 58 61 I-Criteria-Count
following NCT03925467 62 71 I-Criteria-Count
six NCT03925467 72 75 B-Eq-Comparison
conditions NCT03925467 76 86 O
: NCT03925467 87 88 O

- NCT03925467 92 93 O
Any NCT03925467 95 98 O
gender NCT03925467 99 105 O
aged NCT03925467 106 110 B-Age
50 NCT03925467 111 113 B-Eq-Comparison
years NCT03925467 114 119 I-Eq-Comparison
or NCT03925467 120 122 I-Eq-Comparison
above NCT03925467 123 128 I-Eq-Comparison
; NCT03925467 128 129 O

- NCT03925467 132 133 O
Have NCT03925467 135 139 O
less NCT03925467 140 144 B-Eq-Comparison
than NCT03925467 145 149 I-Eq-Comparison
30 NCT03925467 150 152 I-Eq-Comparison
mins NCT03925467 153 157 I-Eq-Comparison
of NCT03925467 158 160 O
morning NCT03925467 161 168 B-Observation
stiffness NCT03925467 169 178 I-Observation
; NCT03925467 178 179 O

- NCT03925467 182 183 O
Crepitus NCT03925467 185 193 B-Condition
on NCT03925467 194 196 I-Condition
active NCT03925467 197 203 I-Condition
motion NCT03925467 204 210 I-Condition
; NCT03925467 210 211 O

- NCT03925467 214 215 O
Bony NCT03925467 217 221 B-Condition
tenderness NCT03925467 222 232 I-Condition
; NCT03925467 232 233 O

- NCT03925467 236 237 O
Bony NCT03925467 239 243 B-Condition
enlargement NCT03925467 244 255 I-Condition
; NCT03925467 255 256 O

- NCT03925467 259 260 O
No NCT03925467 262 264 B-Negation
palpable NCT03925467 265 273 B-Condition
warmth NCT03925467 274 280 I-Condition
. NCT03925467 281 282 O

Exclusion NCT03925467 284 293 O
Criteria NCT03925467 294 302 O
: NCT03925467 303 304 O

- NCT03925467 308 309 O
Subjects NCT03925467 311 319 O
who NCT03925467 320 323 O
are NCT03925467 324 327 O
unable NCT03925467 328 334 B-Condition
to NCT03925467 335 337 I-Condition
walk NCT03925467 338 342 I-Condition
. NCT03925467 343 344 O

- NCT03925467 348 349 O
Malignancy NCT03925467 351 361 B-Condition
, NCT03925467 362 363 O

- NCT03925467 367 368 O
Any NCT03925467 370 373 O
acute NCT03925467 374 379 O
medical NCT03925467 380 387 B-Condition
condition NCT03925467 388 397 I-Condition
, NCT03925467 398 399 O

- NCT03925467 403 404 O
Poorly NCT03925467 406 412 B-Modifier
controlled NCT03925467 413 423 I-Modifier
diabetes NCT03925467 424 432 B-Condition
or NCT03925467 433 435 B-Or
hypertension NCT03925467 436 448 B-Condition
, NCT03925467 449 450 O

- NCT03925467 454 455 O
A NCT03925467 457 458 O
motor NCT03925467 459 464 B-Modifier
or NCT03925467 465 467 B-Or
sensory NCT03925467 468 475 B-Modifier
nerve NCT03925467 476 481 B-Condition
defect NCT03925467 482 488 I-Condition
, NCT03925467 489 490 O

- NCT03925467 494 495 O
Blood NCT03925467 497 502 O
clotting NCT03925467 503 511 O
disease NCT03925467 512 519 O
, NCT03925467 520 521 O

- NCT03925467 525 526 O
Mental NCT03925467 528 534 B-Condition
illness NCT03925467 535 542 I-Condition
, NCT03925467 543 544 O

- NCT03925467 548 549 O
Dementia NCT03925467 551 559 B-Condition
, NCT03925467 560 561 O

- NCT03925467 565 566 O
Mental NCT03925467 568 574 B-Condition
retardation NCT03925467 575 586 I-Condition
or NCT03925467 587 589 O
other NCT03925467 590 595 O
abnormal NCT03925467 596 604 O
person NCT03925467 605 611 O
on NCT03925467 612 614 O
the NCT03925467 615 618 O
organic NCT03925467 619 626 O
mind NCT03925467 627 631 O
. NCT03925467 632 633 O

- NCT03925467 637 638 O
Subjects NCT03925467 640 648 O
with NCT03925467 649 653 O
intra NCT03925467 654 659 B-Modifier
- NCT03925467 660 661 I-Modifier
articular NCT03925467 662 671 I-Modifier
solid NCT03925467 672 677 I-Modifier
or NCT03925467 678 680 B-Or
hyaluronic NCT03925467 681 691 B-Modifier
acid NCT03925467 692 696 I-Modifier
injection NCT03925467 697 706 B-Procedure
in NCT03925467 707 709 O
the NCT03925467 710 713 O
past NCT03925467 714 718 B-Eq-Comparison
3 NCT03925467 719 720 I-Eq-Comparison
months NCT03925467 721 727 I-Eq-Comparison
. NCT03925467 728 729 O

- NCT03925467 733 734 O
Knee NCT03925467 736 740 B-Modifier
surgery NCT03925467 741 748 B-Procedure
, NCT03925467 749 750 O

- NCT03925467 754 755 O
Knee NCT03925467 757 761 B-Modifier
trauma NCT03925467 762 768 B-Condition
, NCT03925467 769 770 O

- NCT03925467 774 775 O
Congenital NCT03925467 777 787 B-Modifier
knee NCT03925467 788 792 I-Modifier
deformation NCT03925467 793 804 B-Condition
, NCT03925467 805 806 O

- NCT03925467 810 811 O
Severe NCT03925467 813 819 O
knee NCT03925467 820 824 B-Modifier
varus NCT03925467 825 830 B-Condition
or NCT03925467 831 833 B-Or
valgus NCT03925467 834 840 B-Condition
deformation NCT03925467 841 852 I-Condition
, NCT03925467 853 854 O

- NCT03925467 858 859 O
Endocrine NCT03925467 861 870 B-Modifier
, NCT03925467 871 872 O
metabolic NCT03925467 873 882 B-Modifier
, NCT03925467 883 884 O
infectious NCT03925467 885 895 B-Modifier
, NCT03925467 896 897 O
inflammatory NCT03925467 898 910 B-Modifier
, NCT03925467 911 912 O
secondary NCT03925467 913 922 B-Modifier
degenerative NCT03925467 923 935 I-Modifier
knee NCT03925467 936 940 I-Modifier
arthritis NCT03925467 941 950 B-Condition
caused NCT03925467 951 957 O
by NCT03925467 958 960 O
problems NCT03925467 961 969 O
with NCT03925467 970 974 O
rheumatic NCT03925467 975 984 B-Condition
immune NCT03925467 985 991 I-Condition
diseases NCT03925467 992 1000 I-Condition
. NCT03925467 1001 1002 O

- NCT03925467 1006 1007 O
Subjects NCT03925467 1009 1017 O
who NCT03925467 1018 1021 O
are NCT03925467 1022 1025 O
hypersensitive NCT03925467 1026 1040 B-Condition
to NCT03925467 1041 1043 O
needles NCT03925467 1044 1051 B-Modifier
. NCT03925467 1052 1053 O

- NCT03925467 1057 1058 O
Subjects NCT03925467 1060 1068 O
who NCT03925467 1069 1072 O
are NCT03925467 1073 1076 O
unwilling NCT03925467 1077 1086 O
to NCT03925467 1087 1089 O
cooperate NCT03925467 1090 1099 O
or NCT03925467 1100 1102 O
sign NCT03925467 1103 1107 O
the NCT03925467 1108 1111 O
subject NCT03925467 1112 1119 O
consent NCT03925467 1120 1127 O
. NCT03925467 1127 1128 O

Inclusion NCT03924180 0 9 O
Criteria NCT03924180 10 18 O
: NCT03924180 19 20 O

- NCT03924180 24 25 O
Phenylketonuric NCT03924180 27 42 B-Condition
patient NCT03924180 43 50 O
diagnosed NCT03924180 51 60 O
in NCT03924180 61 63 O
neonatal NCT03924180 64 72 B-Procedure
screening NCT03924180 73 82 I-Procedure

- NCT03924180 85 86 O
Patient NCT03924180 88 95 O
with NCT03924180 96 100 O
Phenylalaninemia NCT03924180 101 117 B-Observation
≥ NCT03924180 118 119 B-Eq-Comparison
900 NCT03924180 120 123 I-Eq-Comparison
μmol NCT03924180 124 128 I-Eq-Comparison
/ NCT03924180 129 130 I-Eq-Comparison
L NCT03924180 131 132 I-Eq-Comparison
on NCT03924180 133 135 O
blotter NCT03924180 136 143 O
made NCT03924180 144 148 O
during NCT03924180 149 155 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 156 159 O
screening NCT03924180 160 169 B-Study
period NCT03924180 170 176 O
( NCT03924180 177 178 O
or NCT03924180 179 181 B-Or
average NCT03924180 182 189 O
blotting NCT03924180 190 198 B-Coreference|Observation
results NCT03924180 199 206 I-Coreference|Observation
≥ NCT03924180 207 208 B-Eq-Comparison
900 NCT03924180 209 212 I-Eq-Comparison
μmol NCT03924180 213 217 I-Eq-Comparison
/ NCT03924180 218 219 I-Eq-Comparison
L NCT03924180 220 221 I-Eq-Comparison
if NCT03924180 222 224 O
several NCT03924180 225 232 B-Eq-Comparison
blots NCT03924180 233 238 O
made NCT03924180 239 243 O
during NCT03924180 244 250 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 251 254 O
screening NCT03924180 255 264 B-Study
period NCT03924180 265 271 O
) NCT03924180 272 273 O

- NCT03924180 277 278 O
Untreated NCT03924180 280 289 O
patient NCT03924180 290 297 O
: NCT03924180 298 299 O
not NCT03924180 300 303 B-Negation
taking NCT03924180 304 310 B-Eq-Comparison
any NCT03924180 311 314 O
amino NCT03924180 315 320 B-Drug
acid NCT03924180 321 325 I-Drug
supplement NCT03924180 326 336 I-Drug
for NCT03924180 337 340 O
his NCT03924180 341 344 O
PKU NCT03924180 345 348 B-Condition
, NCT03924180 349 350 O
regardless NCT03924180 351 361 O
of NCT03924180 362 364 O
diet NCT03924180 365 369 O

Exclusion NCT03924180 370 379 O
Criteria NCT03924180 380 388 O
: NCT03924180 389 390 O

- NCT03924180 394 395 O
Protected NCT03924180 397 406 O
patient NCT03924180 407 414 O
: NCT03924180 415 416 O
court NCT03924180 417 422 B-Condition
bail NCT03924180 423 427 I-Condition
, NCT03924180 428 429 O
curatorship NCT03924180 430 441 B-Condition
, NCT03924180 442 443 O
guardianship NCT03924180 444 456 B-Condition

- NCT03924180 459 460 O
Patient NCT03924180 462 469 O
with NCT03924180 470 474 O
concomitant NCT03924180 475 486 B-Condition
diseases NCT03924180 487 495 I-Condition
/ NCT03924180 496 497 B-Or
conditions NCT03924180 498 508 B-Condition
that NCT03924180 509 513 O
may NCT03924180 514 517 B-Assertion___Assertion-Type-Value:possible
compromise NCT03924180 518 528 O
the NCT03924180 529 532 O
study NCT03924180 533 538 B-Study
, NCT03924180 539 540 O
at NCT03924180 541 543 O
the NCT03924180 544 547 O
discretion NCT03924180 548 558 O
of NCT03924180 559 561 O
the NCT03924180 562 565 O
investigator NCT03924180 566 578 O

- NCT03924180 581 582 O
Participated NCT03924180 584 596 O
in NCT03924180 597 599 O
a NCT03924180 600 601 O
clinical NCT03924180 602 610 B-Study
trial NCT03924180 611 616 I-Study
or NCT03924180 617 619 B-Or
trial NCT03924180 620 625 B-Study
to NCT03924180 626 628 O
evaluate NCT03924180 629 637 O
PKU NCT03924180 638 641 B-Condition
foods NCT03924180 642 647 O
or NCT03924180 648 650 B-Or
treatments NCT03924180 651 661 B-Procedure
in NCT03924180 662 664 O
the NCT03924180 665 668 O
last NCT03924180 669 673 B-Eq-Comparison
7 NCT03924180 674 675 I-Eq-Comparison
days NCT03924180 676 680 I-Eq-Comparison
prior NCT03924180 681 686 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03924180 687 689 O
inclusion NCT03924180 690 699 B-Study
or NCT03924180 700 702 B-Or
planned NCT03924180 703 710 B-Eq-Comparison
during NCT03924180 711 717 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 718 721 O
next NCT03924180 722 726 B-Eq-Comparison
6 NCT03924180 727 728 I-Eq-Comparison
months NCT03924180 729 735 I-Eq-Comparison

- NCT03924180 738 739 O
Participation NCT03924180 741 754 O
in NCT03924180 755 757 O
an NCT03924180 758 760 O
interventional NCT03924180 761 775 O
study NCT03924180 776 781 B-Study
with NCT03924180 782 786 O
health NCT03924180 787 793 B-Drug
products NCT03924180 794 802 I-Drug
during NCT03924180 803 809 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03924180 810 813 O
next NCT03924180 814 818 B-Eq-Comparison
6 NCT03924180 819 820 I-Eq-Comparison
months NCT03924180 821 827 I-Eq-Comparison

- NCT03924180 830 831 O
Pregnancy NCT03924180 833 842 B-Condition
project NCT03924180 843 850 O
within NCT03924180 851 857 B-Eq-Comparison
6 NCT03924180 858 859 I-Eq-Comparison
months NCT03924180 860 866 I-Eq-Comparison
, NCT03924180 867 868 O
pre NCT03924180 869 872 B-Condition
- NCT03924180 873 874 I-Condition
conception NCT03924180 875 885 I-Condition
diet NCT03924180 886 890 I-Condition
, NCT03924180 891 892 O
pregnancy NCT03924180 893 902 B-Condition
or NCT03924180 903 905 B-Or
breastfeeding NCT03924180 906 919 B-Condition

- NCT03924180 922 923 O
Refusal NCT03924180 925 932 O
to NCT03924180 933 935 O
consume NCT03924180 936 943 O
only NCT03924180 944 948 O
validated NCT03924180 949 958 O
complements NCT03924180 959 970 O
for NCT03924180 971 974 O
the NCT03924180 975 978 O
protocol NCT03924180 979 987 O

- NCT03924180 990 991 O
Phenylketonuria NCT03924180 993 1008 B-Condition
undergoing NCT03924180 1009 1019 B-Eq-Comparison
treatment NCT03924180 1020 1029 B-Procedure
with NCT03924180 1030 1034 O
BH4 NCT03924180 1035 1038 B-Drug

- NCT03924180 1041 1042 O
Allergy NCT03924180 1044 1051 B-Allergy
to NCT03924180 1052 1054 O
the NCT03924180 1055 1058 O
product NCT03924180 1059 1066 B-Drug
under NCT03924180 1067 1072 O
study NCT03924180 1073 1078 B-Study

Inclusion NCT03921749 0 9 O
Criteria NCT03921749 10 18 O
: NCT03921749 19 20 O

- NCT03921749 24 25 O
people NCT03921749 27 33 O
aged NCT03921749 34 38 B-Age
45 NCT03921749 39 41 B-Eq-Comparison
years NCT03921749 42 47 I-Eq-Comparison
or NCT03921749 48 50 I-Eq-Comparison
more NCT03921749 51 55 I-Eq-Comparison

- NCT03921749 58 59 O
subjects NCT03921749 61 69 O
diagnosed NCT03921749 70 79 O
with NCT03921749 80 84 O
knee NCT03921749 85 89 B-Modifier
OA NCT03921749 90 92 B-Condition
according NCT03921749 93 102 O
to NCT03921749 103 105 O
the NCT03921749 106 109 O
clinical NCT03921749 110 118 O
criteria NCT03921749 119 127 O
of NCT03921749 128 130 O
the NCT03921749 131 134 O
American NCT03921749 135 143 O
College NCT03921749 144 151 O
of NCT03921749 152 154 O
Rheumatology NCT03921749 155 167 O

- NCT03921749 170 171 O
subjects NCT03921749 173 181 O
diagnosed NCT03921749 182 191 O
with NCT03921749 192 196 O
grade NCT03921749 197 202 B-Eq-Comparison
II NCT03921749 203 205 I-Eq-Comparison
or NCT03921749 206 208 I-Eq-Comparison
III NCT03921749 209 212 I-Eq-Comparison
OA NCT03921749 213 215 B-Condition
during NCT03921749 216 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
radiologicalexamination NCT03921749 223 246 B-Procedure
as NCT03921749 247 249 O
defined NCT03921749 250 257 O
by NCT03921749 258 260 O
the NCT03921749 261 264 O
radiological NCT03921749 265 277 O
classification NCT03921749 278 292 O
of NCT03921749 293 295 O
Kellgren NCT03921749 296 304 O
and NCT03921749 305 308 O
Lawrence NCT03921749 309 317 O
( NCT03921749 318 319 O
K NCT03921749 320 321 O
- NCT03921749 322 323 O
L NCT03921749 324 325 O
) NCT03921749 326 327 O
scale NCT03921749 328 333 O
for NCT03921749 334 337 O
knee NCT03921749 338 342 O
OA NCT03921749 343 345 O

- NCT03921749 348 349 O
subjects NCT03921749 351 359 O
with NCT03921749 360 364 O
tenderness NCT03921749 365 375 B-Condition
in NCT03921749 376 378 O
the NCT03921749 379 382 O
medial NCT03921749 383 389 B-Modifier
tibial NCT03921749 390 396 I-Modifier
plateau NCT03921749 397 404 I-Modifier
area NCT03921749 405 409 I-Modifier

- NCT03921749 412 413 O
subjects NCT03921749 415 423 O
who NCT03921749 424 427 O
had NCT03921749 428 431 O
pain NCT03921749 432 436 B-Condition
on NCT03921749 437 439 O
one NCT03921749 440 443 B-Modifier
side NCT03921749 444 448 I-Modifier
of NCT03921749 449 451 I-Modifier
the NCT03921749 452 455 I-Modifier
knee NCT03921749 456 460 I-Modifier
. NCT03921749 461 462 O

Exclusion NCT03921749 464 473 O
Criteria NCT03921749 474 482 O
: NCT03921749 483 484 O

- NCT03921749 488 489 O
patients NCT03921749 491 499 O
with NCT03921749 500 504 O
a NCT03921749 505 506 O
history NCT03921749 507 514 B-Eq-Comparison
of NCT03921749 515 517 O
spinal NCT03921749 518 524 B-Condition
stenosis NCT03921749 525 533 I-Condition
, NCT03921749 534 535 O
evidence NCT03921749 536 544 O
of NCT03921749 545 547 O
neurologic NCT03921749 548 558 B-Condition
disease NCT03921749 559 566 I-Condition
by NCT03921749 567 569 O
history NCT03921749 570 577 B-Eq-Comparison
or NCT03921749 578 580 O
physical NCT03921749 581 589 B-Procedure
examination NCT03921749 590 601 I-Procedure
, NCT03921749 602 603 O
or NCT03921749 604 606 B-Or
secondary NCT03921749 607 616 O
causes NCT03921749 617 623 O
of NCT03921749 624 626 O
arthritis NCT03921749 627 636 B-Condition
( NCT03921749 637 638 O
inflammatory NCT03921749 639 651 B-Modifier
or NCT03921749 652 654 B-Or
metabolic NCT03921749 655 664 B-Modifier
) NCT03921749 665 666 O

- NCT03921749 670 671 O
those NCT03921749 673 678 O
who NCT03921749 679 682 O
had NCT03921749 683 686 O
a NCT03921749 687 688 O
surgical NCT03921749 689 697 B-Procedure
intervention NCT03921749 698 710 I-Procedure
or NCT03921749 711 713 B-Or
intra NCT03921749 714 719 B-Procedure
- NCT03921749 720 721 I-Procedure
articular NCT03921749 722 731 I-Procedure
injection NCT03921749 732 741 I-Procedure
in NCT03921749 742 744 O
the NCT03921749 745 748 O
affected NCT03921749 749 757 B-Modifier
knee NCT03921749 758 762 I-Modifier
in NCT03921749 763 765 O
the NCT03921749 766 769 O
previous NCT03921749 770 778 B-Eq-Comparison
6 NCT03921749 779 780 I-Eq-Comparison
months NCT03921749 781 787 I-Eq-Comparison

- NCT03921749 790 791 O
any NCT03921749 793 796 O
contraindication NCT03921749 797 813 B-Contraindication
to NCT03921749 814 816 O
extracorporeal NCT03921749 817 831 B-Procedure
shock NCT03921749 832 837 I-Procedure
wave NCT03921749 838 842 I-Procedure
( NCT03921749 843 844 O
pregnancy NCT03921749 845 854 B-Condition
, NCT03921749 855 856 O
cancer NCT03921749 857 863 B-Condition
, NCT03921749 864 865 O
coagulation NCT03921749 866 877 B-Condition
disorders NCT03921749 878 887 I-Condition
, NCT03921749 888 889 O
inflammatory NCT03921749 890 902 B-Condition
disease NCT03921749 903 910 I-Condition
, NCT03921749 911 912 O
pacemakers NCT03921749 913 923 B-Procedure
, NCT03921749 924 925 O
or NCT03921749 926 928 O
other NCT03921749 929 934 B-Other
electronic NCT03921749 935 945 B-Procedure
implants NCT03921749 946 954 I-Procedure
) NCT03921749 955 956 O
. NCT03921749 957 958 O

Inclusion NCT03926026 0 9 O
Criteria NCT03926026 10 18 O
: NCT03926026 19 20 O

- NCT03926026 24 25 O
history NCT03926026 27 34 B-Eq-Comparison
of NCT03926026 35 37 O
blepharitis NCT03926026 38 49 B-Condition
and NCT03926026 50 53 B-And
meet NCT03926026 54 58 O
qualifying NCT03926026 59 69 O
criteria NCT03926026 70 78 O
for NCT03926026 79 82 O
an NCT03926026 83 85 O
acute NCT03926026 86 91 O
exacerbation NCT03926026 92 104 O
of NCT03926026 105 107 O
blepharitis NCT03926026 108 119 B-Condition
in NCT03926026 120 122 O
both NCT03926026 123 127 B-Modifier
eyes NCT03926026 128 132 I-Modifier
at NCT03926026 133 135 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03926026 136 145 B-Study
and NCT03926026 146 149 B-And
Baseline NCT03926026 150 158 B-Study
/ NCT03926026 159 160 O
Day NCT03926026 161 164 O
1 NCT03926026 165 166 O
Visits NCT03926026 167 173 O

- NCT03926026 176 177 O
have NCT03926026 179 183 O
a NCT03926026 184 185 O
qualifying NCT03926026 186 196 O
best NCT03926026 197 201 B-Condition
- NCT03926026 202 203 I-Condition
corrected NCT03926026 204 213 I-Condition
visual NCT03926026 214 220 I-Condition
acuity NCT03926026 221 227 I-Condition

Exclusion NCT03926026 228 237 O
Criteria NCT03926026 238 246 O
: NCT03926026 247 248 O

- NCT03926026 252 253 O
abnormality NCT03926026 255 266 B-Condition
of NCT03926026 267 269 O
the NCT03926026 270 273 O
eyelids NCT03926026 274 281 B-Modifier
or NCT03926026 282 284 B-Or
lashes NCT03926026 285 291 B-Modifier
( NCT03926026 292 293 O
other NCT03926026 294 299 B-Exception
than NCT03926026 300 304 I-Exception
blepharitis NCT03926026 305 316 B-Condition
) NCT03926026 317 318 O
, NCT03926026 320 321 O
or NCT03926026 322 324 O
previous NCT03926026 325 333 B-Eq-Comparison
eyelid NCT03926026 334 340 B-Modifier
surgery NCT03926026 341 348 B-Procedure

- NCT03926026 351 352 O
IOP NCT03926026 354 357 B-Observation
> NCT03926026 358 359 B-Eq-Comparison
21 NCT03926026 360 362 I-Eq-Comparison
mmHg NCT03926026 363 367 I-Eq-Comparison
at NCT03926026 368 370 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03926026 371 380 B-Study
or NCT03926026 381 383 B-Or
Baseline NCT03926026 384 392 B-Study
/ NCT03926026 393 394 O
Day NCT03926026 395 398 O
1 NCT03926026 399 400 O
Visits NCT03926026 401 407 O

- NCT03926026 410 411 O
use NCT03926026 413 416 O
of NCT03926026 417 419 O
steroids NCT03926026 420 428 B-Drug
in NCT03926026 429 431 O
the NCT03926026 432 435 O
past NCT03926026 436 440 B-Eq-Comparison
30 NCT03926026 441 443 I-Eq-Comparison
days NCT03926026 444 448 I-Eq-Comparison
or NCT03926026 449 451 B-Or
retinoids NCT03926026 452 461 B-Drug
in NCT03926026 462 464 O
the NCT03926026 465 468 O
past NCT03926026 469 473 B-Eq-Comparison
12 NCT03926026 474 476 I-Eq-Comparison
months NCT03926026 477 483 I-Eq-Comparison

- NCT03926026 486 487 O
uncontrolled NCT03926026 489 501 B-Modifier
systemic NCT03926026 502 510 B-Condition
disease NCT03926026 511 518 I-Condition

Inclusion NCT03929315 0 9 O
Criteria NCT03929315 10 18 O
: NCT03929315 19 20 O

- NCT03929315 24 25 O
Pediatric NCT03929315 27 36 O
residents NCT03929315 37 46 O
and NCT03929315 47 50 O
fellows NCT03929315 51 58 O
from NCT03929315 59 63 O
the NCT03929315 64 67 O
Hospital NCT03929315 68 76 O
for NCT03929315 77 80 O
Sick NCT03929315 81 85 O
Children NCT03929315 86 94 O
, NCT03929315 95 96 O
Toronto NCT03929315 97 104 O

Exclusion NCT03929315 105 114 O
Criteria NCT03929315 115 123 O
: NCT03929315 124 125 O

- NCT03929315 129 130 O
Refusal NCT03929315 132 139 O
to NCT03929315 140 142 O
participate NCT03929315 143 154 O
in NCT03929315 155 157 O
study NCT03929315 158 163 O

- NCT03929315 166 167 O
Previous NCT03929315 169 177 B-Eq-Comparison
experience NCT03929315 178 188 O
with NCT03929315 189 193 O
at NCT03929315 194 196 O
most NCT03929315 197 201 O
two NCT03929315 202 205 O
OLV NCT03929315 206 209 O
in NCT03929315 210 212 O
children NCT03929315 213 221 O

- NCT03929315 224 225 O
Previous NCT03929315 227 235 B-Eq-Comparison
experience NCT03929315 236 246 O
with NCT03929315 247 251 O
at NCT03929315 252 254 O
most NCT03929315 255 259 O
two NCT03929315 260 263 O
OLV NCT03929315 264 267 O
in NCT03929315 268 270 O
manikins NCT03929315 271 279 O

Inclusion NCT03920319 0 9 O
Criteria NCT03920319 10 18 O
: NCT03920319 19 20 O

- NCT03920319 24 25 O
Treatment NCT03920319 27 36 B-Procedure
- NCT03920319 37 38 O
seeking NCT03920319 39 46 B-Assertion___Assertion-Type-Value:intention
cigarette NCT03920319 47 56 B-Condition
smoker NCT03920319 57 63 I-Condition

- NCT03920319 66 67 O
Meet NCT03920319 69 73 O
DSM NCT03920319 74 77 O
- NCT03920319 78 79 O
IV NCT03920319 80 82 O
criteria NCT03920319 83 91 O
for NCT03920319 92 95 O
nicotine NCT03920319 96 104 B-Condition
dependence NCT03920319 105 115 I-Condition

- NCT03920319 118 119 O
Negative NCT03920319 121 129 O
result NCT03920319 130 136 O
on NCT03920319 137 139 O
urine NCT03920319 140 145 B-Observation
test NCT03920319 146 150 I-Observation
for NCT03920319 151 154 I-Observation
drug NCT03920319 155 159 I-Observation
use NCT03920319 160 163 I-Observation
during NCT03920319 164 170 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920319 171 180 B-Study

Exclusion NCT03920319 181 190 O
Criteria NCT03920319 191 199 O
: NCT03920319 200 201 O

- NCT03920319 205 206 O
History NCT03920319 208 215 B-Eq-Comparison
of NCT03920319 216 218 O
any NCT03920319 219 222 O
Axis NCT03920319 223 227 B-Eq-Comparison
I NCT03920319 228 229 I-Eq-Comparison
psychiatric NCT03920319 230 241 B-Condition
diagnosis NCT03920319 242 251 I-Condition
other NCT03920319 252 257 B-Exception
than NCT03920319 258 262 I-Exception
nicotine NCT03920319 263 271 B-Condition
dependence NCT03920319 272 282 I-Condition

- NCT03920319 285 286 O
Medical NCT03920319 288 295 B-Condition
conditions NCT03920319 296 306 I-Condition
that NCT03920319 307 311 O
might NCT03920319 312 317 B-Assertion___Assertion-Type-Value:possible
affect NCT03920319 318 324 O
brain NCT03920319 325 330 B-Condition
function NCT03920319 331 339 I-Condition

- NCT03920319 342 343 O
Current NCT03920319 345 352 B-Eq-Comparison
use NCT03920319 353 356 O
of NCT03920319 357 359 O
medications NCT03920319 360 371 B-Drug
that NCT03920319 372 376 O
could NCT03920319 377 382 B-Assertion___Assertion-Type-Value:possible
alter NCT03920319 383 388 O
brain NCT03920319 389 394 B-Condition
function NCT03920319 395 403 I-Condition

- NCT03920319 406 407 O
Pregnancy NCT03920319 409 418 B-Condition

- NCT03920319 421 422 O
Current NCT03920319 424 431 B-Eq-Comparison
illicit NCT03920319 432 439 B-Condition
drug NCT03920319 440 444 I-Condition
use NCT03920319 445 448 I-Condition
other NCT03920319 449 454 B-Exception
than NCT03920319 455 459 I-Exception
occasional NCT03920319 460 470 O
use NCT03920319 471 474 O
of NCT03920319 475 477 O
marijuana NCT03920319 478 487 B-Condition

Inclution NCT03921775 0 9 O
Criteria NCT03921775 10 18 O
: NCT03921775 19 20 O

1 NCT03921775 24 25 O
. NCT03921775 25 26 O
18 NCT03921775 28 30 B-Eq-Comparison
~ NCT03921775 31 32 I-Eq-Comparison
60 NCT03921775 33 35 I-Eq-Comparison
years NCT03921775 36 41 I-Age|Eq-Comparison
, NCT03921775 42 43 O
female NCT03921775 44 50 O
or NCT03921775 51 53 B-Or
male NCT03921775 54 58 O

2 NCT03921775 61 62 O
. NCT03921775 62 63 O
Patients NCT03921775 65 73 O
scheduled NCT03921775 74 83 B-Eq-Comparison
for NCT03921775 84 87 O
an NCT03921775 88 90 O
elective NCT03921775 91 99 B-Procedure
surgical NCT03921775 100 108 I-Procedure
procedure NCT03921775 109 118 I-Procedure
( NCT03921775 119 120 O
mechanical NCT03921775 121 131 B-Procedure
ventilation NCT03921775 132 143 I-Procedure
via NCT03921775 144 147 O
endotracheal NCT03921775 148 160 B-Procedure
tube NCT03921775 161 165 I-Procedure
) NCT03921775 166 167 O

3 NCT03921775 171 172 O
. NCT03921775 172 173 O
BMI NCT03921775 175 178 B-Observation
: NCT03921775 179 180 O
18 NCT03921775 181 183 B-Eq-Comparison
~ NCT03921775 184 185 I-Eq-Comparison
30 NCT03921775 186 188 I-Eq-Comparison
kg NCT03921775 189 191 I-Eq-Comparison
/ NCT03921775 192 193 I-Eq-Comparison
m2 NCT03921775 194 196 I-Eq-Comparison

4 NCT03921775 199 200 O
. NCT03921775 200 201 O
Patients NCT03921775 203 211 O
understand NCT03921775 212 222 O
clearly NCT03921775 223 230 O
and NCT03921775 231 234 O
participate NCT03921775 235 246 O
in NCT03921775 247 249 O
the NCT03921775 250 253 O
study NCT03921775 254 259 O
voluntarily NCT03921775 260 271 O
, NCT03921775 272 273 O
and NCT03921775 274 277 O
sign NCT03921775 278 282 O
the NCT03921775 283 286 O
informed NCT03921775 287 295 O
consent NCT03921775 296 303 O

Exclusion NCT03921775 304 313 O
criteria NCT03921775 314 322 O
: NCT03921775 323 324 O

1 NCT03921775 328 329 O
. NCT03921775 329 330 O
Patients NCT03921775 332 340 O
scheduled NCT03921775 341 350 B-Eq-Comparison
for NCT03921775 351 354 O
emergency NCT03921775 355 364 B-Procedure
surgery NCT03921775 365 372 I-Procedure

2 NCT03921775 375 376 O
. NCT03921775 376 377 O
Patients NCT03921775 379 387 O
with NCT03921775 388 392 O
a NCT03921775 393 394 O
history NCT03921775 395 402 B-Eq-Comparison
of NCT03921775 403 405 O
drug NCT03921775 406 410 B-Condition
abuse NCT03921775 411 416 I-Condition
and NCT03921775 417 420 B-Or
/ NCT03921775 421 422 I-Or
or NCT03921775 423 425 I-Or
alcohol NCT03921775 426 433 B-Condition
abuse NCT03921775 434 439 I-Condition
2 NCT03921775 440 441 B-Eq-Comparison
years NCT03921775 442 447 I-Eq-Comparison
prior NCT03921775 448 453 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921775 454 456 O
the NCT03921775 457 460 O
screening NCT03921775 461 470 B-Study
period NCT03921775 471 477 O

3 NCT03921775 480 481 O
. NCT03921775 481 482 O
One NCT03921775 484 487 O
or NCT03921775 488 490 O
more NCT03921775 491 495 O
of NCT03921775 496 498 O
the NCT03921775 499 502 O
laboratory NCT03921775 503 513 B-Observation
findings NCT03921775 514 522 I-Observation
fall NCT03921775 523 527 O
out NCT03921775 528 531 O
of NCT03921775 532 534 O
the NCT03921775 535 538 O
limitations NCT03921775 539 550 O
for NCT03921775 551 554 O
this NCT03921775 555 559 O
study NCT03921775 560 565 O
( NCT03921775 566 567 O
platelet NCT03921775 568 576 B-Observation
, NCT03921775 577 578 O
hemoglobin NCT03921775 579 589 B-Observation
, NCT03921775 590 591 O
aspartate NCT03921775 592 601 B-Observation
aminotransferase NCT03921775 602 618 I-Observation
, NCT03921775 619 620 O
etc NCT03921775 621 624 O
. NCT03921775 624 625 O
) NCT03921775 626 627 O

4 NCT03921775 631 632 O
. NCT03921775 632 633 O
Pregnant NCT03921775 635 643 B-Condition
women NCT03921775 644 649 O
or NCT03921775 650 652 B-Or
those NCT03921775 653 658 O
in NCT03921775 659 661 O
lactation NCT03921775 662 671 B-Condition
period NCT03921775 672 678 O

5 NCT03921775 681 682 O
. NCT03921775 682 683 O
Allergic NCT03921775 685 693 B-Allergy
to NCT03921775 694 696 O
drugs NCT03921775 697 702 B-Drug
used NCT03921775 703 707 O
in NCT03921775 708 710 O
the NCT03921775 711 714 O
study NCT03921775 715 720 B-Study

6 NCT03921775 723 724 O
. NCT03921775 724 725 O
Patients NCT03921775 727 735 O
with NCT03921775 736 740 O
respiratory NCT03921775 741 752 B-Condition
management NCT03921775 753 763 I-Condition
difficulties NCT03921775 764 776 I-Condition
( NCT03921775 777 778 O
Modified NCT03921775 779 787 B-Condition
Mallampati NCT03921775 788 798 I-Condition
grade NCT03921775 799 804 B-Eq-Comparison
IV NCT03921775 805 807 I-Eq-Comparison
) NCT03921775 808 809 O

7 NCT03921775 813 814 O
. NCT03921775 814 815 O
Patients NCT03921775 817 825 O
have NCT03921775 826 830 O
participated NCT03921775 831 843 O
in NCT03921775 844 846 O
other NCT03921775 847 852 B-Other
clinical NCT03921775 853 861 B-Study
trial NCT03921775 862 867 I-Study
within NCT03921775 868 874 B-Eq-Comparison
the NCT03921775 875 878 I-Eq-Comparison
3 NCT03921775 879 880 I-Eq-Comparison
months NCT03921775 881 887 I-Eq-Comparison
prior NCT03921775 888 893 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03921775 894 896 O
randomization NCT03921775 897 910 B-Study

8 NCT03921775 913 914 O
. NCT03921775 914 915 O
Any NCT03921775 917 920 O
patient NCT03921775 921 928 O
judged NCT03921775 929 935 O
by NCT03921775 936 938 O
the NCT03921775 939 942 O
Principal NCT03921775 943 952 O
Investigator NCT03921775 953 965 O
( NCT03921775 966 967 O
PI NCT03921775 968 970 O
) NCT03921775 971 972 O
or NCT03921775 973 975 O
Sub NCT03921775 976 979 O
- NCT03921775 980 981 O
Investigator NCT03921775 982 994 O
to NCT03921775 995 997 O
be NCT03921775 998 1000 O
inappropriate NCT03921775 1001 1014 O
for NCT03921775 1015 1018 O
the NCT03921775 1019 1022 O
subject NCT03921775 1023 1030 O
for NCT03921775 1031 1034 O
any NCT03921775 1035 1038 O
other NCT03921775 1039 1044 O
reason NCT03921775 1045 1051 O

Inclusion NCT03925922 0 9 O
Criteria NCT03925922 10 18 O
: NCT03925922 19 20 O

- NCT03925922 24 25 O
Nulliparous NCT03925922 27 38 B-Modifier
singleton NCT03925922 39 48 I-Modifier
pregnancy NCT03925922 49 58 B-Condition

- NCT03925922 61 62 O
gestational NCT03925922 64 75 B-Observation
age NCT03925922 76 79 I-Observation
between NCT03925922 80 87 B-Eq-Comparison
37 NCT03925922 88 90 I-Eq-Comparison
week NCT03925922 91 95 I-Eq-Comparison
and NCT03925922 96 99 I-Eq-Comparison
42 NCT03925922 100 102 I-Eq-Comparison
weeks NCT03925922 103 108 I-Eq-Comparison

- NCT03925922 111 112 O
Cephalic NCT03925922 114 122 B-Condition
presentation NCT03925922 123 135 I-Condition

- NCT03925922 138 139 O
Bishop NCT03925922 141 147 B-Observation
score NCT03925922 148 153 I-Observation
of NCT03925922 154 156 O
5 NCT03925922 157 158 B-Eq-Comparison
or NCT03925922 159 161 I-Eq-Comparison
less NCT03925922 162 166 I-Eq-Comparison

- NCT03925922 169 170 O
No NCT03925922 172 174 B-Negation
clinical NCT03925922 175 183 O
evidence NCT03925922 184 192 O
of NCT03925922 193 195 O
regular NCT03925922 196 203 B-Condition
contraction NCT03925922 204 215 I-Condition

Exclusion NCT03925922 216 225 O
Criteria NCT03925922 226 234 O
: NCT03925922 235 236 O

- NCT03925922 240 241 O
Rupture NCT03925922 243 250 B-Condition
of NCT03925922 251 253 I-Condition
membrane NCT03925922 254 262 I-Condition

- NCT03925922 265 266 O
Vaginal NCT03925922 268 275 B-Condition
bleeding NCT03925922 276 284 I-Condition

- NCT03925922 287 288 O
Any NCT03925922 290 293 O
contraindication NCT03925922 294 310 B-Contraindication
to NCT03925922 311 313 O
vaginal NCT03925922 314 321 B-Modifier
delivery NCT03925922 322 330 B-Procedure

Inclusion NCT03920696 0 9 O
Criteria NCT03920696 10 18 O
: NCT03920696 19 20 O

- NCT03920696 24 25 O
Age NCT03920696 27 30 B-Age
≥ NCT03920696 31 32 B-Eq-Comparison
18 NCT03920696 33 35 I-Eq-Comparison
years NCT03920696 36 41 I-Eq-Comparison

- NCT03920696 44 45 O
Patients NCT03920696 47 55 O
with NCT03920696 56 60 O
Pityriasis NCT03920696 61 71 B-Condition
Lichenoides NCT03920696 72 83 I-Condition
selected NCT03920696 84 92 O
from NCT03920696 93 97 O
histological NCT03920696 98 110 O
coding NCT03920696 111 117 O
OT0431 NCT03920696 118 124 O
, NCT03920696 125 126 O
seen NCT03920696 127 131 B-Encounter
at NCT03920696 132 134 O
Henri NCT03920696 135 140 O
Mondor NCT03920696 141 147 O
and NCT03920696 148 151 O
with NCT03920696 152 156 O
a NCT03920696 157 158 O
diagnosis NCT03920696 159 168 O
verified NCT03920696 169 177 O
from NCT03920696 178 182 O
medical NCT03920696 183 190 O
records NCT03920696 191 198 O
. NCT03920696 199 200 O

Exclusion NCT03920696 202 211 O
Criteria NCT03920696 212 220 O
: NCT03920696 221 222 O

- NCT03920696 226 227 O
Histological NCT03920696 229 241 O
coding NCT03920696 242 248 O
error NCT03920696 249 254 O

- NCT03920696 257 258 O
Histological NCT03920696 260 272 O
records NCT03920696 273 280 O
of NCT03920696 281 283 O
patients NCT03920696 284 292 O
in NCT03920696 293 295 O
care NCT03920696 296 300 B-Encounter
outside NCT03920696 301 308 B-Other
Henri NCT03920696 309 314 O
Mondor NCT03920696 315 321 O
( NCT03920696 322 323 O
cases NCT03920696 324 329 O
referred NCT03920696 330 338 O
for NCT03920696 339 342 O
histological NCT03920696 343 355 O
expertise NCT03920696 356 365 O
only NCT03920696 366 370 O
but NCT03920696 371 374 O
not NCT03920696 375 378 O
seen NCT03920696 379 383 O
clinically NCT03920696 384 394 O
) NCT03920696 395 396 O

- NCT03920696 400 401 O
Clinical NCT03920696 403 411 B-Condition
lesions NCT03920696 412 419 I-Condition
incompatible NCT03920696 420 432 B-Negation
with NCT03920696 433 437 O
Pityriasis NCT03920696 438 448 B-Condition
Lichenoides NCT03920696 449 460 I-Condition
according NCT03920696 461 470 O
to NCT03920696 471 473 O
classically NCT03920696 474 485 O
published NCT03920696 486 495 O
semiological NCT03920696 496 508 O
data NCT03920696 509 513 O

- NCT03920696 516 517 O
Missing NCT03920696 519 526 O
or NCT03920696 527 529 O
insufficient NCT03920696 530 542 O
medical NCT03920696 543 550 O
records NCT03920696 551 558 O
for NCT03920696 559 562 O
data NCT03920696 563 567 O
exploitation NCT03920696 568 580 O

For NCT03924427 0 3 O
more NCT03924427 4 8 O
information NCT03924427 9 20 O
regarding NCT03924427 21 30 O
Bristol NCT03924427 31 38 O
- NCT03924427 39 40 O
Myers NCT03924427 41 46 O
Squibb NCT03924427 47 53 O
Clinical NCT03924427 54 62 O
Trial NCT03924427 63 68 O
participation NCT03924427 69 82 O
, NCT03924427 83 84 O
please NCT03924427 85 91 O

visit NCT03924427 92 97 O
www NCT03924427 98 101 O
. NCT03924427 101 102 O
BMSStudyConnect NCT03924427 103 118 O
. NCT03924427 118 119 O
com NCT03924427 120 123 O

Inclusion NCT03924427 124 133 O
Criteria NCT03924427 134 142 O
: NCT03924427 143 144 O

a. NCT03924427 146 148 O
For NCT03924427 150 153 O
participants NCT03924427 154 166 O
with NCT03924427 167 171 O
plaque NCT03924427 172 178 B-Condition
psoriasis NCT03924427 179 188 I-Condition
: NCT03924427 189 190 O
i. NCT03924427 191 193 O
Stable NCT03924427 195 201 O
plaque NCT03924427 202 208 B-Condition
psoriasis NCT03924427 209 218 I-Condition
for NCT03924427 219 222 O
at NCT03924427 223 225 B-Eq-Comparison
least NCT03924427 226 231 I-Eq-Comparison
6 NCT03924427 232 233 I-Eq-Comparison
months NCT03924427 234 240 I-Eq-Comparison

ii NCT03924427 241 243 O
. NCT03924427 243 244 O
Moderate NCT03924427 246 254 B-Eq-Comparison
to NCT03924427 255 257 I-Eq-Comparison
severe NCT03924427 258 264 I-Eq-Comparison
disease NCT03924427 265 272 B-Condition|Coreference
iii NCT03924427 273 276 O
. NCT03924427 276 277 O
Candidate NCT03924427 279 288 B-Indication
for NCT03924427 289 292 O
phototherapy NCT03924427 293 305 B-Procedure
or NCT03924427 306 308 B-Or
systemic NCT03924427 309 317 B-Procedure
therapy NCT03924427 318 325 I-Procedure
b NCT03924427 326 327 O
. NCT03924427 328 329 O

Additional NCT03924427 331 341 O
protocol NCT03924427 342 350 O
- NCT03924427 351 352 O
specified NCT03924427 353 362 O
inclusion NCT03924427 363 372 O
criteria NCT03924427 373 381 O
apply NCT03924427 382 387 O
for NCT03924427 388 391 O
subjects NCT03924427 392 400 O
with NCT03924427 401 405 O
psoriatic NCT03924427 406 415 B-Condition
arthritis NCT03924427 416 425 I-Condition
, NCT03924427 426 427 O
erythrodermic NCT03924427 428 441 B-Condition
psoriasis NCT03924427 442 451 I-Condition
, NCT03924427 452 453 O
or NCT03924427 454 456 B-Or
generalized NCT03924427 457 468 B-Condition
pustular NCT03924427 469 477 I-Condition
psoriasis NCT03924427 478 487 I-Condition

Exclusion NCT03924427 488 497 O
Criteria NCT03924427 498 506 O
: NCT03924427 507 508 O

1 NCT03924427 512 513 O
. NCT03924427 513 514 O
Guttate NCT03924427 516 523 B-Modifier
, NCT03924427 524 525 O
inverse NCT03924427 526 533 B-Modifier
, NCT03924427 534 535 O
or NCT03924427 536 538 B-Or
drug NCT03924427 539 543 B-Modifier
- NCT03924427 544 545 I-Modifier
induced NCT03924427 546 553 I-Modifier
psoriasis NCT03924427 554 563 B-Condition
at NCT03924427 564 566 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03924427 567 576 B-Study
or NCT03924427 577 579 B-Or
Baseline NCT03924427 580 588 B-Study

2 NCT03924427 591 592 O
. NCT03924427 592 593 O
History NCT03924427 595 602 B-Eq-Comparison
of NCT03924427 603 605 O
recent NCT03924427 606 612 B-Eq-Comparison
infection NCT03924427 613 622 B-Condition

3 NCT03924427 625 626 O
. NCT03924427 626 627 O
Prior NCT03924427 629 634 B-Eq-Comparison
exposure NCT03924427 635 643 O
to NCT03924427 644 646 O
BMS NCT03924427 647 650 B-Drug
- NCT03924427 651 652 I-Drug
986165 NCT03924427 653 659 I-Drug
Other NCT03924427 660 665 O
protocol NCT03924427 666 674 O
defined NCT03924427 675 682 O
inclusion NCT03924427 683 692 O
/ NCT03924427 693 694 O
exclusion NCT03924427 695 704 O
criteria NCT03924427 705 713 O
could NCT03924427 714 719 O
apply NCT03924427 720 725 O


Inclusion NCT03925077 0 9 O
Criteria NCT03925077 10 18 O
: NCT03925077 19 20 O

1 NCT03925077 24 25 O
. NCT03925077 25 26 O
demonstrate NCT03925077 28 39 O
readiness NCT03925077 40 49 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925077 50 52 O
physical NCT03925077 53 61 B-Observation
activity NCT03925077 62 70 I-Observation
by NCT03925077 71 73 O
completing NCT03925077 74 84 O
the NCT03925077 85 88 O
online NCT03925077 89 95 O
Physical NCT03925077 96 104 B-Observation
Activity NCT03925077 105 113 I-Observation
Readiness NCT03925077 114 123 I-Observation
Questionnaire NCT03925077 124 137 I-Observation
( NCT03925077 138 139 O
PAR NCT03925077 140 143 B-Observation
- NCT03925077 144 145 I-Observation
Q NCT03925077 146 147 I-Observation
) NCT03925077 148 149 O
; NCT03925077 150 151 O

2 NCT03925077 154 155 O
. NCT03925077 155 156 O
have NCT03925077 158 162 O
a NCT03925077 163 164 O
SCI NCT03925077 165 168 B-Condition
resulting NCT03925077 169 178 O
in NCT03925077 179 181 O
incomplete NCT03925077 182 192 B-Modifier
or NCT03925077 193 195 B-Or
complete NCT03925077 196 204 B-Modifier
( NCT03925077 205 206 O
C5 NCT03925077 207 209 B-Eq-Comparison
and NCT03925077 210 213 I-Eq-Comparison
below NCT03925077 214 219 I-Eq-Comparison
) NCT03925077 220 221 O
paraplegia NCT03925077 222 232 B-Condition
or NCT03925077 233 235 B-Or
tetraplegia NCT03925077 236 247 B-Condition
; NCT03925077 247 248 O

3 NCT03925077 251 252 O
. NCT03925077 252 253 O
have NCT03925077 255 259 O
broadband NCT03925077 260 269 O
internet NCT03925077 270 278 O
access NCT03925077 279 285 O
; NCT03925077 285 286 O

4 NCT03925077 289 290 O
. NCT03925077 290 291 O
between NCT03925077 293 300 O
the NCT03925077 301 304 O
ages NCT03925077 305 309 B-Age
of NCT03925077 310 312 O
18 NCT03925077 313 315 B-Eq-Comparison
to NCT03925077 316 318 I-Eq-Comparison
65 NCT03925077 319 321 I-Eq-Comparison
years NCT03925077 322 327 I-Eq-Comparison
; NCT03925077 327 328 O

5 NCT03925077 331 332 O
. NCT03925077 332 333 O
have NCT03925077 335 339 O
the NCT03925077 340 343 O
ability NCT03925077 344 351 O
to NCT03925077 352 354 O
converse NCT03925077 355 363 O
and NCT03925077 364 367 O
read NCT03925077 368 372 O
English NCT03925077 373 380 O
. NCT03925077 381 382 O

Exclusion NCT03925077 384 393 O
Criteria NCT03925077 394 402 O
: NCT03925077 403 404 O

1 NCT03925077 408 409 O
. NCT03925077 409 410 O
significant NCT03925077 412 423 O
visual NCT03925077 424 430 B-Condition
impairment NCT03925077 431 441 I-Condition
that NCT03925077 442 446 O
prevents NCT03925077 447 455 B-Assertion___Assertion-Type-Value:hypothetical|Negation
seeing NCT03925077 456 462 O
a NCT03925077 463 464 O
computer NCT03925077 465 473 O
screen NCT03925077 474 480 O
to NCT03925077 481 483 O
follow NCT03925077 484 490 O
a NCT03925077 491 492 O
home NCT03925077 493 497 B-Procedure
exercise NCT03925077 498 506 I-Procedure
program NCT03925077 507 514 I-Procedure
; NCT03925077 514 515 O

2 NCT03925077 518 519 O
. NCT03925077 519 520 O
active NCT03925077 522 528 B-Eq-Comparison
pressure NCT03925077 529 537 B-Condition
ulcer NCT03925077 538 543 I-Condition
; NCT03925077 543 544 O

3 NCT03925077 547 548 O
. NCT03925077 548 549 O
any NCT03925077 551 554 O
contraindications NCT03925077 555 572 B-Contraindication
to NCT03925077 573 575 O
exercise NCT03925077 576 584 B-Observation
based NCT03925077 585 590 O
on NCT03925077 591 593 O
the NCT03925077 594 597 O
American NCT03925077 598 606 O
College NCT03925077 607 614 O
of NCT03925077 615 617 O
Sports NCT03925077 618 624 O
Medicine NCT03925077 625 633 O
guidelines NCT03925077 634 644 O
; NCT03925077 644 645 O

4 NCT03925077 648 649 O
. NCT03925077 649 650 O
significant NCT03925077 652 663 O
hearing NCT03925077 664 671 B-Condition
impairment NCT03925077 672 682 I-Condition
impeding NCT03925077 683 691 B-Assertion___Assertion-Type-Value:hypothetical|Negation
ability NCT03925077 692 699 B-Condition
to NCT03925077 700 702 I-Condition
hear NCT03925077 703 707 I-Condition
music NCT03925077 708 713 O
to NCT03925077 714 716 O
engage NCT03925077 717 723 B-Observation
in NCT03925077 724 726 I-Observation
exercise NCT03925077 727 735 I-Observation
. NCT03925077 735 736 O

Inclusion NCT03925038 0 9 O
Criteria NCT03925038 10 18 O
: NCT03925038 19 20 O

- NCT03925038 24 25 O
Patients NCT03925038 27 35 O
ages NCT03925038 36 40 B-Age
12 NCT03925038 41 43 B-Eq-Comparison
- NCT03925038 44 45 I-Eq-Comparison
100 NCT03925038 46 49 I-Eq-Comparison
years NCT03925038 50 55 I-Eq-Comparison

- NCT03925038 58 59 O
With NCT03925038 61 65 O
any NCT03925038 66 69 O
diagnosis NCT03925038 70 79 O
of NCT03925038 80 82 O
a NCT03925038 83 84 O
mood NCT03925038 85 89 B-Modifier
or NCT03925038 90 92 B-Or
anxiety NCT03925038 93 100 B-Modifier
disorder NCT03925038 101 109 B-Condition

- NCT03925038 112 113 O
Already NCT03925038 115 122 O
established NCT03925038 123 134 O
and NCT03925038 135 138 O
receiving NCT03925038 139 148 B-Eq-Comparison
care NCT03925038 149 153 B-Encounter
in NCT03925038 154 156 O
community NCT03925038 157 166 O
psychiatry NCT03925038 167 177 B-Provider
at NCT03925038 178 180 O
the NCT03925038 181 184 O
Johns NCT03925038 185 190 O
Hopkins NCT03925038 191 198 O
Bayview NCT03925038 199 206 O
Medical NCT03925038 207 214 O
Center NCT03925038 215 221 O
or NCT03925038 222 224 B-Or
at NCT03925038 225 227 O
Johns NCT03925038 228 233 O
Hopkins NCT03925038 234 241 O
Hospital NCT03925038 242 250 O
. NCT03925038 251 252 O

Exclusion NCT03925038 254 263 O
Criteria NCT03925038 264 272 O
: NCT03925038 273 274 O

- NCT03925038 278 279 O
Non NCT03925038 281 284 B-Negation
- NCT03925038 285 286 O
English NCT03925038 287 294 O
speaking NCT03925038 295 303 O

Inclusion NCT03924440 0 9 O
Criteria NCT03924440 10 18 O
: NCT03924440 19 20 O

1 NCT03924440 24 25 O
. NCT03924440 25 26 O
Female NCT03924440 28 34 O
( NCT03924440 35 36 O
mandatory NCT03924440 37 46 O
) NCT03924440 47 48 O

2 NCT03924440 52 53 O
. NCT03924440 53 54 O
Not NCT03924440 56 59 B-Negation
currently NCT03924440 60 69 B-Eq-Comparison
pregnant NCT03924440 70 78 B-Condition
or NCT03924440 79 81 B-Or
nursing NCT03924440 82 89 B-Condition
( NCT03924440 90 91 O
pregnancy NCT03924440 92 101 B-Condition
affects NCT03924440 102 109 B-Assertion___Assertion-Type-Value:hypothetical
PdG NCT03924440 110 113 B-Observation
levels NCT03924440 114 120 I-Observation
) NCT03924440 121 122 O

3 NCT03924440 126 127 O
. NCT03924440 127 128 O
Aged NCT03924440 130 134 B-Age
18 NCT03924440 135 137 B-Eq-Comparison
- NCT03924440 138 139 I-Eq-Comparison
34 NCT03924440 140 142 O
( NCT03924440 143 144 O
advanced NCT03924440 145 153 O
age NCT03924440 154 157 O
can NCT03924440 158 161 B-Assertion___Assertion-Type-Value:hypothetical
hinder NCT03924440 162 168 O
PdG NCT03924440 169 172 B-Observation
levels NCT03924440 173 179 I-Observation
) NCT03924440 180 181 O

4 NCT03924440 185 186 O
. NCT03924440 186 187 O
Cycle NCT03924440 189 194 B-Observation
length NCT03924440 195 201 I-Observation
of NCT03924440 202 204 O
26 NCT03924440 205 207 B-Eq-Comparison
- NCT03924440 208 209 I-Eq-Comparison
39 NCT03924440 210 212 I-Eq-Comparison
days NCT03924440 213 217 I-Eq-Comparison
( NCT03924440 218 219 O
long NCT03924440 220 224 B-Modifier
or NCT03924440 225 227 B-Or
short NCT03924440 228 233 B-Modifier
cycles NCT03924440 234 240 B-Observation
have NCT03924440 241 245 B-Assertion___Assertion-Type-Value:hypothetical
inconsistent NCT03924440 246 258 O
PdG NCT03924440 259 262 B-Observation
levels NCT03924440 263 269 I-Observation
) NCT03924440 270 271 O

5 NCT03924440 275 276 O
. NCT03924440 276 277 O
Currently NCT03924440 279 288 B-Eq-Comparison
use NCT03924440 289 292 O
other NCT03924440 293 298 O
fertility NCT03924440 299 308 B-Procedure
monitoring NCT03924440 309 319 I-Procedure
tools NCT03924440 320 325 I-Procedure
( NCT03924440 326 327 O
this NCT03924440 328 332 O
allows NCT03924440 333 339 O
us NCT03924440 340 342 O
to NCT03924440 343 345 O
compare NCT03924440 346 353 O
Proov NCT03924440 354 359 O
- NCT03924440 360 361 O
Ovulation NCT03924440 362 371 O
Double NCT03924440 372 378 O
Check NCT03924440 379 384 O
test NCT03924440 385 389 O
results NCT03924440 390 397 O
with NCT03924440 398 402 O
other NCT03924440 403 408 O
fertility NCT03924440 409 418 O
tracking NCT03924440 419 427 O
methods NCT03924440 428 435 O
) NCT03924440 436 437 O

Exclusion NCT03924440 439 448 O
Criteria NCT03924440 449 457 O
: NCT03924440 458 459 O

1 NCT03924440 463 464 O
. NCT03924440 464 465 O
Male NCT03924440 467 471 O

2 NCT03924440 474 475 O
. NCT03924440 475 476 O
Pregnant NCT03924440 478 486 B-Condition

3 NCT03924440 489 490 O
. NCT03924440 490 491 O
Nursing NCT03924440 493 500 B-Condition


Inclusion NCT03922958 0 9 O
Criteria NCT03922958 10 18 O
: NCT03922958 19 20 O

- NCT03922958 24 25 O
All NCT03922958 27 30 O
adults NCT03922958 31 37 O
undergoing NCT03922958 38 48 B-Eq-Comparison
cardiac NCT03922958 49 56 B-Procedure
surgery NCT03922958 57 64 I-Procedure
with NCT03922958 65 69 O
CPB NCT03922958 70 73 B-Procedure
will NCT03922958 74 78 O
be NCT03922958 79 81 O
considered NCT03922958 82 92 O
for NCT03922958 93 96 O
enrollment NCT03922958 97 107 O
. NCT03922958 108 109 O

Exclusion NCT03922958 111 120 O
Criteria NCT03922958 121 129 O
: NCT03922958 130 131 O

- NCT03922958 135 136 O
Factors NCT03922958 138 145 B-Condition
that NCT03922958 146 150 O
affect NCT03922958 151 157 O
immune NCT03922958 158 164 B-Condition
function NCT03922958 165 173 I-Condition
or NCT03922958 174 176 B-Or
AKI NCT03922958 177 180 B-Condition
assessment NCT03922958 181 191 O
are NCT03922958 192 195 O
the NCT03922958 196 199 O
basis NCT03922958 200 205 O
for NCT03922958 206 209 O
exclusion NCT03922958 210 219 O
criteria NCT03922958 220 228 O
: NCT03922958 229 230 O

- NCT03922958 239 240 O
Concurrent NCT03922958 242 252 O
disease NCT03922958 253 260 B-Condition
associated NCT03922958 261 271 O
with NCT03922958 272 276 O
immunosuppression NCT03922958 277 294 B-Condition
including NCT03922958 295 304 O
malignancy NCT03922958 305 315 B-Condition
, NCT03922958 316 317 O
chronic NCT03922958 318 325 B-Condition
infection NCT03922958 326 335 I-Condition
( NCT03922958 336 337 O
e. NCT03922958 338 340 O
g. NCT03922958 341 343 O
, NCT03922958 344 345 O
HIV NCT03922958 346 349 B-Condition
, NCT03922958 350 351 O
Hepatitis NCT03922958 352 361 B-Condition
C NCT03922958 362 363 I-Condition
) NCT03922958 364 365 O
, NCT03922958 367 368 O
organ NCT03922958 369 374 B-Procedure
transplant NCT03922958 375 385 I-Procedure
and NCT03922958 386 389 B-Or
immunosuppressant NCT03922958 390 407 B-Drug
medications NCT03922958 408 419 I-Drug

- NCT03922958 427 428 O
Documented NCT03922958 430 440 O
acute NCT03922958 441 446 B-Condition
infection NCT03922958 447 456 I-Condition
with NCT03922958 457 461 O
the NCT03922958 462 465 B-Eq-Comparison
past NCT03922958 466 470 I-Eq-Comparison
1 NCT03922958 471 472 I-Eq-Comparison
month NCT03922958 473 478 I-Eq-Comparison
( NCT03922958 479 480 O
e. NCT03922958 481 483 O
g. NCT03922958 484 486 O
, NCT03922958 487 488 O
pneumonia NCT03922958 489 498 B-Condition
, NCT03922958 499 500 O
urinary NCT03922958 501 508 B-Condition
tract NCT03922958 509 514 I-Condition
infection NCT03922958 515 524 I-Condition
) NCT03922958 525 526 O

- NCT03922958 535 536 O
Prednisone NCT03922958 538 548 B-Drug
or NCT03922958 549 551 B-Or
other NCT03922958 552 557 O
steroid NCT03922958 558 565 B-Drug
use NCT03922958 566 569 O
currently NCT03922958 570 579 B-Eq-Comparison
or NCT03922958 580 582 B-Or
within NCT03922958 583 589 B-Eq-Comparison
the NCT03922958 590 593 I-Eq-Comparison
past NCT03922958 594 598 I-Eq-Comparison
one NCT03922958 599 602 I-Eq-Comparison
month NCT03922958 603 608 I-Eq-Comparison

- NCT03922958 616 617 O
AKI NCT03922958 619 622 B-Condition
at NCT03922958 623 625 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03922958 626 629 I-Temporal-Connection___Temporal-Connection-Type-Value:during
time NCT03922958 630 634 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03922958 635 637 O
surgery NCT03922958 638 645 B-Procedure

- NCT03922958 653 654 O
ESRD NCT03922958 656 660 B-Condition
requiring NCT03922958 661 670 B-Assertion___Assertion-Type-Value:hypothetical
renal NCT03922958 671 676 B-Procedure
replacement NCT03922958 677 688 I-Procedure
therapy NCT03922958 689 696 I-Procedure

- NCT03922958 704 705 O
Estimated NCT03922958 707 716 O
GFR NCT03922958 717 720 B-Observation
< NCT03922958 721 722 B-Eq-Comparison
45 NCT03922958 723 725 I-Eq-Comparison
mL NCT03922958 726 728 I-Eq-Comparison
/ NCT03922958 729 730 I-Eq-Comparison
min NCT03922958 731 734 I-Eq-Comparison
( NCT03922958 735 736 O
as NCT03922958 737 739 O
judged NCT03922958 740 746 O
by NCT03922958 747 749 O
the NCT03922958 750 753 O
Chronic NCT03922958 754 761 O
Kidney NCT03922958 762 768 O
Disease NCT03922958 769 776 O
Epidemiology NCT03922958 777 789 O
Collaboration NCT03922958 790 803 O
( NCT03922958 804 805 O
CKD NCT03922958 806 809 O
- NCT03922958 810 811 O
EPI NCT03922958 812 815 O
) NCT03922958 816 817 O
equation NCT03922958 818 826 O

Inclusion NCT03927820 0 9 O
Criteria NCT03927820 10 18 O
: NCT03927820 19 20 O

- NCT03927820 24 25 O
Adult NCT03927820 27 32 O
patient NCT03927820 33 40 O
admitted NCT03927820 41 49 B-Encounter
to NCT03927820 50 52 O
Vanderbilt NCT03927820 53 63 O
University NCT03927820 64 74 O
Medical NCT03927820 75 82 O
Center NCT03927820 83 89 O
( NCT03927820 90 91 O
VUMC NCT03927820 92 96 O
) NCT03927820 97 98 O
( NCT03927820 99 100 O
excluding NCT03927820 101 110 B-Exception
surgery NCT03927820 111 118 B-Provider
services NCT03927820 119 127 I-Provider
) NCT03927820 128 129 O

- NCT03927820 133 134 O
on NCT03927820 136 138 B-Eq-Comparison
a NCT03927820 139 140 O
long NCT03927820 141 145 B-Drug
acting NCT03927820 146 152 I-Drug
inhaler NCT03927820 153 160 I-Drug
or NCT03927820 161 163 B-Or
prescribed NCT03927820 164 174 O
a NCT03927820 175 176 O
long NCT03927820 177 181 B-Drug
acting NCT03927820 182 188 I-Drug
inhaler NCT03927820 189 196 I-Drug
during NCT03927820 197 203 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03927820 204 213 B-Encounter
. NCT03927820 214 215 O

Exclusion NCT03927820 217 226 O
Criteria NCT03927820 227 235 O
: NCT03927820 236 237 O

- NCT03927820 241 242 O
Diagnosis NCT03927820 244 253 O
of NCT03927820 254 256 O
cystic NCT03927820 257 263 B-Condition
fibrosis NCT03927820 264 272 I-Condition

- NCT03927820 275 276 O
Diagnosis NCT03927820 278 287 O
of NCT03927820 288 290 O
graft NCT03927820 291 296 B-Condition
versus NCT03927820 297 303 I-Condition
host NCT03927820 304 308 I-Condition
disease NCT03927820 309 316 I-Condition
( NCT03927820 317 318 O
GVHD NCT03927820 319 323 B-Condition
) NCT03927820 324 325 O

- NCT03927820 329 330 O
no NCT03927820 332 334 B-Negation
medication NCT03927820 335 345 O
insurance NCT03927820 346 355 O

- NCT03927820 358 359 O
discharge NCT03927820 361 370 B-Encounter
to NCT03927820 371 373 O
any NCT03927820 374 377 O
post NCT03927820 378 382 O
- NCT03927820 383 384 O
acute NCT03927820 385 390 O
care NCT03927820 391 395 O
facility NCT03927820 396 404 O
or NCT03927820 405 407 B-Or
inpatient NCT03927820 408 417 O
hospice NCT03927820 418 425 O

- NCT03927820 428 429 O
death NCT03927820 431 436 B-Death
during NCT03927820 437 443 B-Temporal-Connection___Temporal-Connection-Type-Value:during
hospitalization NCT03927820 444 459 B-Encounter

Cystic NCT03921060 0 6 B-Condition
Fibrosis NCT03921060 7 15 I-Condition
Main NCT03921060 16 20 O
Study NCT03921060 21 26 O
Inclusion NCT03921060 27 36 O
Criteria NCT03921060 37 45 O
: NCT03921060 46 47 O

- NCT03921060 51 52 O
Must NCT03921060 54 58 O
have NCT03921060 59 63 O
CF NCT03921060 64 66 B-Condition
diagnosis NCT03921060 67 76 O
confirmed NCT03921060 77 86 O
by NCT03921060 87 89 O
sweat NCT03921060 90 95 B-Observation
test NCT03921060 96 100 I-Observation
or NCT03921060 101 103 B-Or
genotype NCT03921060 104 112 B-Procedure
analysis NCT03921060 113 121 I-Procedure

- NCT03921060 124 125 O
Subjects NCT03921060 127 135 O
( NCT03921060 136 137 O
and NCT03921060 138 141 O
parents NCT03921060 142 149 O
/ NCT03921060 150 151 O
legal NCT03921060 152 157 O
guardians NCT03921060 158 167 O
as NCT03921060 168 170 O
applicable NCT03921060 171 181 O
) NCT03921060 182 183 O
must NCT03921060 184 188 O
have NCT03921060 189 193 O
the NCT03921060 194 197 O
ability NCT03921060 198 205 O
to NCT03921060 206 208 O
read NCT03921060 209 213 O
and NCT03921060 214 217 O
write NCT03921060 218 223 O
in NCT03921060 224 226 O
English NCT03921060 227 234 O

Sub NCT03921060 235 238 O
- NCT03921060 239 240 O
study NCT03921060 241 246 O
Exclusion NCT03921060 247 256 O
Criteria NCT03921060 257 265 O
: NCT03921060 266 267 O

- NCT03921060 271 272 O
No NCT03921060 274 276 B-Negation
CF NCT03921060 277 279 B-Condition
diagnosis NCT03921060 280 289 O

- NCT03921060 292 293 O
Men NCT03921060 295 298 O
or NCT03921060 299 301 B-Or
women NCT03921060 302 307 O
without NCT03921060 308 315 B-Negation
osteoporosis NCT03921060 316 328 B-Condition

- NCT03921060 331 332 O
Less NCT03921060 334 338 B-Eq-Comparison
than NCT03921060 339 343 I-Eq-Comparison
18 NCT03921060 344 346 I-Eq-Comparison
years NCT03921060 347 352 I-Eq-Comparison
of NCT03921060 353 355 O
age NCT03921060 356 359 B-Age

- NCT03921060 362 363 O
Unwilling NCT03921060 365 374 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921060 375 377 O
return NCT03921060 378 384 O
annually NCT03921060 385 393 O
for NCT03921060 394 397 O
study NCT03921060 398 403 B-Study
visits NCT03921060 404 410 O
for NCT03921060 411 414 O
up NCT03921060 415 417 B-Eq-Comparison
to NCT03921060 418 420 I-Eq-Comparison
5 NCT03921060 421 422 I-Eq-Comparison
years NCT03921060 423 428 I-Eq-Comparison

- NCT03921060 431 432 O
Unwilling NCT03921060 434 443 B-Assertion___Assertion-Type-Value:hypothetical
and NCT03921060 444 447 B-Or
/ NCT03921060 448 449 I-Or
or NCT03921060 450 452 I-Or
medically NCT03921060 453 462 O
unable NCT03921060 463 469 B-Negation
to NCT03921060 470 472 O
take NCT03921060 473 477 O
denosumab NCT03921060 478 487 B-Drug

Inclusion NCT03928093 0 9 O
Criteria NCT03928093 10 18 O
: NCT03928093 19 20 O

- NCT03928093 24 25 O
Age NCT03928093 27 30 B-Age
: NCT03928093 31 32 O
> NCT03928093 33 34 B-Eq-Comparison
8 NCT03928093 35 36 I-Eq-Comparison
- NCT03928093 37 38 I-Eq-Comparison
40 NCT03928093 39 41 I-Eq-Comparison
years NCT03928093 42 47 I-Eq-Comparison
( NCT03928093 48 49 O
we NCT03928093 50 52 O
selected NCT03928093 53 61 O
this NCT03928093 62 66 O
range NCT03928093 67 72 O
due NCT03928093 73 76 O
to NCT03928093 77 79 O
lack NCT03928093 80 84 O
of NCT03928093 85 87 O
data NCT03928093 88 92 O
in NCT03928093 93 95 O
younger NCT03928093 96 103 O
population NCT03928093 104 114 O
and NCT03928093 115 118 O
the NCT03928093 119 122 O
difficulty NCT03928093 123 133 O
in NCT03928093 134 136 O
getting NCT03928093 137 144 O
patient NCT03928093 145 152 O
reported NCT03928093 153 161 O
outcomes NCT03928093 162 170 O
in NCT03928093 171 173 O
younger NCT03928093 174 181 O
patients NCT03928093 182 190 O
) NCT03928093 191 192 O

- NCT03928093 196 197 O
Diagnosis NCT03928093 199 208 O
of NCT03928093 209 211 O
RDEB NCT03928093 212 216 B-Condition
( NCT03928093 217 218 O
by NCT03928093 219 221 O
a NCT03928093 222 223 O
dermatologist NCT03928093 224 237 B-Provider
and NCT03928093 238 241 B-Or
/ NCT03928093 242 243 I-Or
or NCT03928093 244 246 I-Or
EB NCT03928093 247 249 B-Provider
specialist NCT03928093 250 260 I-Provider
and NCT03928093 261 264 B-Or
/ NCT03928093 265 266 I-Or
or NCT03928093 267 269 I-Or
genetic NCT03928093 270 277 B-Procedure
confirmation NCT03928093 278 290 I-Procedure
) NCT03928093 291 292 O

- NCT03928093 296 297 O
Evidence NCT03928093 299 307 O
of NCT03928093 308 310 O
neuropathy NCT03928093 311 321 B-Condition
defined NCT03928093 322 329 O
by NCT03928093 330 332 O
: NCT03928093 333 334 O
thermal NCT03928093 335 342 B-Condition
sensory NCT03928093 343 350 I-Condition
loss NCT03928093 351 355 I-Condition
( NCT03928093 356 357 O
determined NCT03928093 358 368 O
by NCT03928093 369 371 O
a NCT03928093 372 373 O
thermal NCT03928093 374 381 B-Procedure
roller NCT03928093 382 388 I-Procedure
, NCT03928093 389 390 O
ROLLTEMP2 NCT03928093 391 400 O
, NCT03928093 401 402 O
Sometic NCT03928093 403 410 O
, NCT03928093 411 412 O
Sweden NCT03928093 413 419 O
) NCT03928093 420 421 O
14 NCT03928093 422 424 O
and NCT03928093 425 428 O
> NCT03928093 429 430 B-Eq-Comparison
4 NCT03928093 431 432 I-Eq-Comparison
/ NCT03928093 433 434 I-Eq-Comparison
10 NCT03928093 435 437 I-Eq-Comparison
score NCT03928093 438 443 O
using NCT03928093 444 449 B-Eq-Comparison
a NCT03928093 450 451 O
screening NCT03928093 452 461 O
tool NCT03928093 462 466 O
for NCT03928093 467 470 O
neuropathic NCT03928093 471 482 B-Observation
pain NCT03928093 483 487 I-Observation
, NCT03928093 488 489 O
the NCT03928093 490 493 O
DN4 NCT03928093 494 497 O
questionnaire NCT03928093 498 511 O
15 NCT03928093 512 514 O

- NCT03928093 518 519 O
Pain NCT03928093 521 525 B-Observation
intensity NCT03928093 526 535 I-Observation
of NCT03928093 536 538 O
> NCT03928093 539 540 B-Eq-Comparison
4 NCT03928093 541 542 I-Eq-Comparison
/ NCT03928093 543 544 O
10 NCT03928093 545 547 O
on NCT03928093 548 550 O
a NCT03928093 551 552 O
0 NCT03928093 553 554 O
- NCT03928093 555 556 O
10 NCT03928093 557 559 O
VAS NCT03928093 560 563 O
scale NCT03928093 564 569 O
measured NCT03928093 570 578 O
daily NCT03928093 579 584 B-Eq-Comparison
( NCT03928093 585 586 O
reduced NCT03928093 587 594 O
frequency NCT03928093 595 604 O
is NCT03928093 605 607 O
also NCT03928093 608 612 O
acceptable NCT03928093 613 623 O
) NCT03928093 624 625 O
at NCT03928093 626 628 O
night NCT03928093 629 634 O
over NCT03928093 635 639 B-Eq-Comparison
2 NCT03928093 640 641 I-Eq-Comparison
weeks NCT03928093 642 647 I-Eq-Comparison

- NCT03928093 650 651 O
Itch NCT03928093 653 657 B-Observation
intensity NCT03928093 658 667 I-Observation
of NCT03928093 668 670 O
> NCT03928093 671 672 B-Eq-Comparison
4 NCT03928093 673 674 I-Eq-Comparison
/ NCT03928093 675 676 O
10 NCT03928093 677 679 O
on NCT03928093 680 682 O
a NCT03928093 683 684 O
0 NCT03928093 685 686 O
- NCT03928093 687 688 O
10 NCT03928093 689 691 O
VAS NCT03928093 692 695 O
scale NCT03928093 696 701 O
measures NCT03928093 702 710 O
daily NCT03928093 711 716 B-Eq-Comparison
( NCT03928093 717 718 O
reduced NCT03928093 719 726 O
frequency NCT03928093 727 736 O
is NCT03928093 737 739 O
also NCT03928093 740 744 O
acceptable NCT03928093 745 755 O
) NCT03928093 756 757 O
at NCT03928093 758 760 O
night NCT03928093 761 766 O
over NCT03928093 767 771 B-Eq-Comparison
2 NCT03928093 772 773 I-Eq-Comparison
weeks NCT03928093 774 779 I-Eq-Comparison

- NCT03928093 782 783 O
Consent NCT03928093 785 792 O
to NCT03928093 793 795 O
follow NCT03928093 796 802 O
with NCT03928093 803 807 O
study NCT03928093 808 813 O
procedures NCT03928093 814 824 O

Exclusion NCT03928093 825 834 O
Criteria NCT03928093 835 843 O
: NCT03928093 844 845 O

- NCT03928093 849 850 O
Intolerance NCT03928093 852 863 B-Condition
and NCT03928093 864 867 B-Or
/ NCT03928093 868 869 I-Or
or NCT03928093 870 872 I-Or
allergy NCT03928093 873 880 B-Allergy
to NCT03928093 881 883 O
Pregabalin NCT03928093 884 894 B-Drug
or NCT03928093 895 897 B-Or
gabapentin NCT03928093 898 908 B-Drug

- NCT03928093 911 912 O
Lactose NCT03928093 914 921 B-Condition
intolerance NCT03928093 922 933 I-Condition
( NCT03928093 934 935 O
placebo NCT03928093 936 943 O
capsules NCT03928093 944 952 O
contain NCT03928093 953 960 O
lactose NCT03928093 961 968 O
) NCT03928093 969 970 O

- NCT03928093 974 975 O
Pregabalin NCT03928093 977 987 B-Drug
use NCT03928093 988 991 O
within NCT03928093 992 998 B-Eq-Comparison
2 NCT03928093 999 1000 I-Eq-Comparison
weeks NCT03928093 1001 1006 I-Eq-Comparison
before NCT03928093 1007 1013 B-Temporal-Connection___Temporal-Connection-Type-Value:before
study NCT03928093 1014 1019 B-Study
enrolment NCT03928093 1020 1029 O

- NCT03928093 1032 1033 O
Ongoing NCT03928093 1035 1042 B-Eq-Comparison
treatment NCT03928093 1043 1052 B-Procedure
with NCT03928093 1053 1057 O
gabapentin NCT03928093 1058 1068 B-Drug
, NCT03928093 1069 1070 O
amitriptyline NCT03928093 1071 1084 B-Drug
, NCT03928093 1085 1086 O
duloxetine NCT03928093 1087 1097 B-Drug
, NCT03928093 1098 1099 O
nortriptyline NCT03928093 1100 1113 B-Drug
, NCT03928093 1114 1115 O
other NCT03928093 1116 1121 B-Other
tricyclics NCT03928093 1122 1132 B-Drug
or NCT03928093 1133 1135 B-Or
SNRIs NCT03928093 1136 1141 B-Drug

- NCT03928093 1144 1145 O
Medical NCT03928093 1147 1154 B-Condition
conditions NCT03928093 1155 1165 I-Condition
that NCT03928093 1166 1170 O
would NCT03928093 1171 1176 O
be NCT03928093 1177 1179 O
considered NCT03928093 1180 1190 O
as NCT03928093 1191 1193 O
contraindications NCT03928093 1194 1211 B-Contraindication
for NCT03928093 1212 1215 O
pregabalin NCT03928093 1216 1226 B-Drug
treatment NCT03928093 1227 1236 O
( NCT03928093 1237 1238 O
ischemic NCT03928093 1239 1247 B-Condition
heart NCT03928093 1248 1253 I-Condition
disease NCT03928093 1254 1261 I-Condition
, NCT03928093 1262 1263 O
cardiac NCT03928093 1264 1271 B-Condition
dysrhythmia NCT03928093 1272 1283 I-Condition
, NCT03928093 1284 1285 O
glaucoma NCT03928093 1286 1294 B-Condition
, NCT03928093 1295 1296 O
history NCT03928093 1297 1304 B-Eq-Comparison
of NCT03928093 1305 1307 O
urinary NCT03928093 1308 1315 B-Condition
retention NCT03928093 1316 1325 I-Condition
) NCT03928093 1326 1327 O

- NCT03928093 1331 1332 O
Pregnancy NCT03928093 1334 1343 B-Condition

- NCT03928093 1346 1347 O
History NCT03928093 1349 1356 B-Eq-Comparison
of NCT03928093 1357 1359 O
use NCT03928093 1360 1363 O
of NCT03928093 1364 1366 O
restrictive NCT03928093 1367 1378 B-Condition
substances NCT03928093 1379 1389 I-Condition
or NCT03928093 1390 1392 B-Or
alcohol NCT03928093 1393 1400 B-Condition
abuse NCT03928093 1401 1406 I-Condition

- NCT03928093 1409 1410 O
Allergy NCT03928093 1412 1419 B-Allergy
to NCT03928093 1420 1422 O
gelatin NCT03928093 1423 1430 O

Inclusion NCT03922347 0 9 O
Criteria NCT03922347 10 18 O
: NCT03922347 19 20 O

- NCT03922347 24 25 O
Inclusion NCT03922347 27 36 O
criteria NCT03922347 37 45 O
were NCT03922347 46 50 O
living NCT03922347 51 57 O
in NCT03922347 58 60 O
one NCT03922347 61 64 O
of NCT03922347 65 67 O
the NCT03922347 68 71 O
non NCT03922347 72 75 O
- NCT03922347 76 77 O
institutionalized NCT03922347 78 95 O
urban NCT03922347 96 101 O
or NCT03922347 102 104 B-Or
rural NCT03922347 105 110 O
residential NCT03922347 111 122 O
areas NCT03922347 123 128 O
in NCT03922347 129 131 O
one NCT03922347 132 135 O
of NCT03922347 136 138 O
the NCT03922347 139 142 O
survey NCT03922347 143 149 O
area NCT03922347 150 154 O
, NCT03922347 155 156 O
being NCT03922347 157 162 O
resident NCT03922347 163 171 O
in NCT03922347 172 174 O
the NCT03922347 175 178 O
same NCT03922347 179 183 O
address NCT03922347 184 191 B-Observation
for NCT03922347 192 195 O
at NCT03922347 196 198 B-Eq-Comparison
least NCT03922347 199 204 I-Eq-Comparison
6 NCT03922347 205 206 I-Eq-Comparison
months NCT03922347 207 213 I-Eq-Comparison
during NCT03922347 214 220 O
the NCT03922347 221 224 O
year NCT03922347 225 229 O
before NCT03922347 230 236 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03922347 237 240 O
enrolment NCT03922347 241 250 B-Study
, NCT03922347 251 252 O
age NCT03922347 253 256 B-Age
50 NCT03922347 257 259 B-Eq-Comparison
and NCT03922347 260 263 I-Eq-Comparison
over NCT03922347 264 268 I-Eq-Comparison
and NCT03922347 269 272 B-And
Iranian NCT03922347 273 280 O
nationality NCT03922347 281 292 O
. NCT03922347 292 293 O

Inclusion NCT03920020 0 9 O
Criteria NCT03920020 10 18 O
: NCT03920020 19 20 O

- NCT03920020 24 25 O
Diagnosis NCT03920020 27 36 O
of NCT03920020 37 39 O
primary NCT03920020 40 47 B-Modifier
knee NCT03920020 48 52 I-Modifier
osteoarthritis NCT03920020 53 67 B-Condition
according NCT03920020 68 77 O
to NCT03920020 78 80 O
American NCT03920020 81 89 O
College NCT03920020 90 97 O
of NCT03920020 98 100 O
Radiology NCT03920020 101 110 O

- NCT03920020 113 114 O
Being NCT03920020 116 121 O
radiographically NCT03920020 122 138 B-Condition
K NCT03920020 139 140 B-Eq-Comparison
- NCT03920020 141 142 I-Eq-Comparison
L NCT03920020 143 144 I-Eq-Comparison
grade NCT03920020 145 150 I-Eq-Comparison
2 NCT03920020 151 152 I-Eq-Comparison
- NCT03920020 153 154 I-Eq-Comparison
3 NCT03920020 155 156 I-Eq-Comparison

- NCT03920020 160 161 O
Presence NCT03920020 163 171 O
of NCT03920020 172 174 O
symptoms NCT03920020 175 183 B-Assertion___Assertion-Type-Value:possible|Coreference
for NCT03920020 184 187 O
at NCT03920020 188 190 B-Eq-Comparison
least NCT03920020 191 196 I-Eq-Comparison
3 NCT03920020 197 198 I-Eq-Comparison
months NCT03920020 199 205 I-Eq-Comparison

- NCT03920020 208 209 O
Patients NCT03920020 211 219 O
who NCT03920020 220 223 O
have NCT03920020 224 228 O
been NCT03920020 229 233 O
planned NCT03920020 234 241 B-Eq-Comparison
a NCT03920020 242 243 O
conventional NCT03920020 244 256 O
physiotherapy NCT03920020 257 270 B-Procedure
programme NCT03920020 271 280 O
because NCT03920020 281 288 O
of NCT03920020 289 291 O
knee NCT03920020 292 296 B-Modifier
osteoarthritis NCT03920020 297 311 B-Condition

- NCT03920020 314 315 O
Presence NCT03920020 317 325 O
of NCT03920020 326 328 O
functional NCT03920020 329 339 O
capacity NCT03920020 340 348 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03920020 349 352 I-Assertion___Assertion-Type-Value:hypothetical
outpatient NCT03920020 353 363 B-Procedure
physical NCT03920020 364 372 I-Procedure
therapy NCT03920020 373 380 I-Procedure

Exclusion NCT03920020 381 390 O
Criteria NCT03920020 391 399 O
: NCT03920020 400 401 O

- NCT03920020 405 406 O
Patients NCT03920020 408 416 O
with NCT03920020 417 421 O
seconder NCT03920020 422 430 B-Modifier
knee NCT03920020 431 435 I-Modifier
osteoarthritis NCT03920020 436 450 B-Condition

- NCT03920020 453 454 O
History NCT03920020 456 463 B-Eq-Comparison
of NCT03920020 464 466 O
lower NCT03920020 467 472 O
extremity NCT03920020 473 482 B-Modifier
or NCT03920020 483 485 B-Or
spine NCT03920020 486 491 B-Modifier
surgery NCT03920020 492 499 B-Procedure

- NCT03920020 502 503 O
History NCT03920020 505 512 B-Eq-Comparison
of NCT03920020 513 515 O
intraarticular NCT03920020 516 530 B-Procedure
injection NCT03920020 531 540 I-Procedure
in NCT03920020 541 543 O
last NCT03920020 544 548 B-Eq-Comparison
1 NCT03920020 549 550 I-Eq-Comparison
month NCT03920020 551 556 I-Eq-Comparison

- NCT03920020 559 560 O
Patients NCT03920020 562 570 O
with NCT03920020 571 575 O
neurological NCT03920020 576 588 B-Condition
disease NCT03920020 589 596 I-Condition
that NCT03920020 597 601 O
will NCT03920020 602 606 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03920020 607 613 O
muscle NCT03920020 614 620 B-Condition
strength NCT03920020 621 629 I-Condition
, NCT03920020 630 631 O
balance NCT03920020 632 639 B-Condition
and NCT03920020 640 643 B-Or
coordination NCT03920020 644 656 B-Condition

Inclusion NCT03925831 0 9 O
Criteria NCT03925831 10 18 O
: NCT03925831 19 20 O

Individuals NCT03925831 22 33 O
died NCT03925831 34 38 B-Death
from NCT03925831 39 43 O
cancer NCT03925831 44 50 B-Condition
between NCT03925831 51 58 B-Eq-Comparison
2008 NCT03925831 59 63 I-Eq-Comparison
and NCT03925831 64 67 I-Eq-Comparison
2017 NCT03925831 68 72 I-Eq-Comparison
. NCT03925831 72 73 O

Exclusion NCT03925831 75 84 O
Criteria NCT03925831 85 93 O
: NCT03925831 94 95 O

- NCT03925831 98 99 O

Inclusion NCT03928938 0 9 O
Criteria NCT03928938 10 18 O
: NCT03928938 19 20 O

1 NCT03928938 24 25 O
. NCT03928938 25 26 O
Signed NCT03928938 28 34 O
informed NCT03928938 35 43 O
consent NCT03928938 44 51 O

2 NCT03928938 54 55 O
. NCT03928938 55 56 O
Advanced NCT03928938 58 66 O
cancers NCT03928938 67 74 B-Condition

3 NCT03928938 77 78 O
. NCT03928938 78 79 O
Immune NCT03928938 81 87 B-Procedure
checkpoint NCT03928938 88 98 I-Procedure
inhibitor NCT03928938 99 108 I-Procedure
therapy NCT03928938 109 116 I-Procedure
initiated NCT03928938 117 126 O
within NCT03928938 127 133 O
+ NCT03928938 134 135 O
/ NCT03928938 137 138 O
- NCT03928938 140 141 O
2 NCT03928938 142 143 O
wks NCT03928938 144 147 O

4 NCT03928938 150 151 O
. NCT03928938 151 152 O
Age NCT03928938 154 157 B-Age
> NCT03928938 158 159 B-Eq-Comparison
18 NCT03928938 160 162 I-Eq-Comparison
y NCT03928938 163 164 O

5 NCT03928938 167 168 O
. NCT03928938 168 169 O
ECOG NCT03928938 171 175 B-Observation
0 NCT03928938 176 177 B-Eq-Comparison
- NCT03928938 178 179 I-Eq-Comparison
3 NCT03928938 180 181 O

6 NCT03928938 185 186 O
. NCT03928938 186 187 O
Patient NCT03928938 189 196 O
compliant NCT03928938 197 206 O
with NCT03928938 207 211 O
the NCT03928938 212 215 O
study NCT03928938 216 221 O
procedures NCT03928938 222 232 O

Exclusion NCT03928938 233 242 O
Criteria NCT03928938 243 251 O
: NCT03928938 252 253 O

1 NCT03928938 257 258 O
. NCT03928938 258 259 O
Immune NCT03928938 261 267 B-Procedure
checkpoint NCT03928938 268 278 I-Procedure
inhibitor NCT03928938 279 288 I-Procedure
therapy NCT03928938 289 296 I-Procedure
initiated NCT03928938 297 306 O
> NCT03928938 307 308 B-Eq-Comparison
2 NCT03928938 309 310 I-Eq-Comparison
wks NCT03928938 311 314 O
ago NCT03928938 315 318 B-Temporal-Connection___Temporal-Connection-Type-Value:before

2 NCT03928938 321 322 O
. NCT03928938 322 323 O
General NCT03928938 325 332 B-Condition
vulnerability NCT03928938 333 346 I-Condition
affecting NCT03928938 347 356 O
the NCT03928938 357 360 O
participation NCT03928938 361 374 O
in NCT03928938 375 377 O
the NCT03928938 378 381 O
trial NCT03928938 382 387 B-Study

3 NCT03928938 390 391 O
. NCT03928938 391 392 O
No NCT03928938 394 396 O
internet NCT03928938 397 405 O
access NCT03928938 406 412 O

Inclusion NCT03925207 0 9 O
Criteria NCT03925207 10 18 O
: NCT03925207 19 20 O

- NCT03925207 24 25 O
Patients NCT03925207 27 35 O
were NCT03925207 36 40 O
included NCT03925207 41 49 O
if NCT03925207 50 52 O
they NCT03925207 53 57 O
underwent NCT03925207 58 67 B-Eq-Comparison
orbital NCT03925207 68 75 B-Procedure
ball NCT03925207 76 80 I-Procedure
implants NCT03925207 81 89 I-Procedure
after NCT03925207 90 95 B-Temporal-Connection___Temporal-Connection-Type-Value:after
enucleation NCT03925207 96 107 B-Procedure
surgery NCT03925207 108 115 I-Procedure
by NCT03925207 116 118 O
one NCT03925207 119 122 O
ophthalmologist NCT03925207 123 138 B-Provider
surgeon NCT03925207 139 146 I-Provider
specializing NCT03925207 147 159 O
in NCT03925207 160 162 O
oculoplastic NCT03925207 163 175 B-Modifier
and NCT03925207 176 179 B-And
orbital NCT03925207 180 187 B-Modifier
surgery NCT03925207 188 195 I-Modifier
at NCT03925207 196 198 O
our NCT03925207 199 202 O
centre NCT03925207 203 209 O
. NCT03925207 210 211 O

Exclusion NCT03925207 213 222 O
Criteria NCT03925207 223 231 O
: NCT03925207 232 233 O

- NCT03925207 237 238 O
Patients NCT03925207 240 248 O
were NCT03925207 249 253 O
excluded NCT03925207 254 262 B-Negation
if NCT03925207 263 265 O
they NCT03925207 266 270 O
underwent NCT03925207 271 280 B-Eq-Comparison
other NCT03925207 281 286 B-Other
concurrent NCT03925207 287 297 O
surgical NCT03925207 298 306 B-Procedure
procedures NCT03925207 307 317 I-Procedure
, NCT03925207 318 319 O
or NCT03925207 320 322 B-Or
were NCT03925207 323 327 O
under NCT03925207 328 333 B-Eq-Comparison
18 NCT03925207 334 336 I-Eq-Comparison
yr NCT03925207 337 339 I-Eq-Comparison
of NCT03925207 340 342 O
age NCT03925207 343 346 B-Age
. NCT03925207 346 347 O

Inclusion NCT03922568 0 9 O
Criteria NCT03922568 10 18 O
: NCT03922568 19 20 O

- NCT03922568 24 25 O
Full NCT03922568 27 31 B-Modifier
Term NCT03922568 32 36 I-Modifier
Delivery NCT03922568 37 45 B-Condition

- NCT03922568 48 49 O
ICSI NCT03922568 51 55 B-Procedure
cases NCT03922568 56 61 O
using NCT03922568 62 67 B-Eq-Comparison
DGC NCT03922568 68 71 B-Procedure
for NCT03922568 72 75 I-Procedure
sperm NCT03922568 76 81 I-Procedure
selection NCT03922568 82 91 I-Procedure

- NCT03922568 94 95 O
ICSI NCT03922568 97 101 B-Procedure
cases NCT03922568 102 107 O
using NCT03922568 108 113 B-Eq-Comparison
MACS NCT03922568 114 118 B-Procedure
for NCT03922568 119 122 I-Procedure
sperm NCT03922568 123 128 I-Procedure
selection NCT03922568 129 138 I-Procedure

- NCT03922568 141 142 O
ICSI NCT03922568 144 148 B-Procedure
cases NCT03922568 149 154 O
using NCT03922568 155 160 B-Eq-Comparison
PICSI NCT03922568 161 166 B-Procedure
dishes NCT03922568 167 173 I-Procedure
for NCT03922568 174 177 I-Procedure
sperm NCT03922568 178 183 I-Procedure
selection NCT03922568 184 193 I-Procedure

- NCT03922568 196 197 O
Fresh NCT03922568 199 204 B-Procedure
blastocyst NCT03922568 205 215 I-Procedure
stage NCT03922568 216 221 I-Procedure
embryo NCT03922568 222 228 I-Procedure
transfer NCT03922568 229 237 I-Procedure
at NCT03922568 238 240 O

- NCT03922568 243 244 O
Fresh NCT03922568 246 251 B-Condition
ejaculate NCT03922568 252 261 I-Condition

Exclusion NCT03922568 262 271 O
Criteria NCT03922568 272 280 O
: NCT03922568 281 282 O

- NCT03922568 286 287 O
Frozen NCT03922568 289 295 B-Procedure
sperm NCT03922568 296 301 I-Procedure

- NCT03922568 304 305 O
Frozen NCT03922568 307 313 B-Procedure
Embryo NCT03922568 314 320 I-Procedure
transfer NCT03922568 321 329 I-Procedure

- NCT03922568 332 333 O
Fresh NCT03922568 335 340 B-Procedure
cleavage NCT03922568 341 349 I-Procedure
stage NCT03922568 350 355 I-Procedure
embryo NCT03922568 356 362 I-Procedure
transfer NCT03922568 363 371 I-Procedure

- NCT03922568 374 375 O
Vanishing NCT03922568 377 386 B-Condition
Twin NCT03922568 387 391 I-Condition
Syndrome NCT03922568 392 400 I-Condition

- NCT03922568 403 404 O
Fetal NCT03922568 406 411 B-Procedure
Reduction NCT03922568 412 421 I-Procedure

- NCT03922568 424 425 O
Preimlantation NCT03922568 427 441 O
genetically NCT03922568 442 453 B-Procedure
screened NCT03922568 454 462 I-Procedure
embryo NCT03922568 463 469 I-Procedure
transfer NCT03922568 470 478 I-Procedure

Inclusion NCT03927404 0 9 O
Criteria NCT03927404 10 18 O
: NCT03927404 19 20 O

- NCT03927404 24 25 O
1 NCT03927404 27 28 O
. NCT03927404 28 29 O
Ages NCT03927404 31 35 B-Age
of NCT03927404 36 38 O
18 NCT03927404 39 41 B-Eq-Comparison
and NCT03927404 42 45 I-Eq-Comparison
above NCT03927404 46 51 I-Eq-Comparison

- NCT03927404 54 55 O
2 NCT03927404 57 58 O
. NCT03927404 58 59 O
Unilateral NCT03927404 61 71 B-Modifier
transtibial NCT03927404 72 83 I-Modifier
or NCT03927404 84 86 B-Or
transfemoral NCT03927404 87 99 B-Modifier
amputee NCT03927404 100 107 B-Condition

- NCT03927404 110 111 O
3 NCT03927404 113 114 O
. NCT03927404 114 115 O
Ambulate NCT03927404 117 125 B-Condition
at NCT03927404 126 128 O
a NCT03927404 129 130 O
K2 NCT03927404 131 133 B-Eq-Comparison
level NCT03927404 134 139 I-Eq-Comparison
or NCT03927404 140 142 I-Eq-Comparison
higher NCT03927404 143 149 I-Eq-Comparison

- NCT03927404 152 153 O
4 NCT03927404 155 156 O
. NCT03927404 156 157 O
At NCT03927404 158 160 B-Eq-Comparison
least NCT03927404 161 166 I-Eq-Comparison
3 NCT03927404 167 168 I-Eq-Comparison
months NCT03927404 169 175 I-Eq-Comparison
post NCT03927404 176 180 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03927404 181 182 O
amputation NCT03927404 183 193 B-Procedure
per NCT03927404 194 197 O
physician NCT03927404 198 207 O
discretion NCT03927404 208 218 O

- NCT03927404 221 222 O
5 NCT03927404 224 225 O
. NCT03927404 225 226 O
Residual NCT03927404 227 235 B-Observation
limb NCT03927404 236 240 I-Observation
length NCT03927404 241 247 I-Observation
greater NCT03927404 248 255 B-Eq-Comparison
than NCT03927404 256 260 I-Eq-Comparison
6.5 NCT03927404 261 264 I-Eq-Comparison
inches NCT03927404 265 271 I-Eq-Comparison
in NCT03927404 272 274 O
length NCT03927404 275 281 O

- NCT03927404 284 285 O
6 NCT03927404 287 288 O
. NCT03927404 288 289 O
Able NCT03927404 290 294 O
to NCT03927404 295 297 O
follow NCT03927404 298 304 O
directions NCT03927404 305 315 O
and NCT03927404 316 319 O
give NCT03927404 320 324 O
informed NCT03927404 325 333 O
consent NCT03927404 334 341 O
on NCT03927404 342 344 O
their NCT03927404 345 350 O
own NCT03927404 351 354 O

- NCT03927404 357 358 O
7 NCT03927404 360 361 O
. NCT03927404 361 362 O
Must NCT03927404 363 367 O
be NCT03927404 368 370 O
able NCT03927404 371 375 B-Condition
to NCT03927404 376 378 I-Condition
ambulate NCT03927404 379 387 I-Condition
without NCT03927404 388 395 O
assistance NCT03927404 396 406 O

Exclusion NCT03927404 407 416 O
Criteria NCT03927404 417 425 O
: NCT03927404 426 427 O

- NCT03927404 431 432 O
1 NCT03927404 434 435 O
. NCT03927404 435 436 O
Conditions NCT03927404 438 448 B-Condition
that NCT03927404 449 453 O
prevent NCT03927404 454 461 B-Assertion___Assertion-Type-Value:hypothetical|Negation
wearing NCT03927404 462 469 B-Condition
a NCT03927404 470 471 I-Condition
prosthetic NCT03927404 472 482 I-Condition
socket NCT03927404 483 489 I-Condition

- NCT03927404 492 493 O
2 NCT03927404 495 496 O
. NCT03927404 496 497 O
Cognitive NCT03927404 499 508 B-Condition
deficits NCT03927404 509 517 I-Condition
or NCT03927404 518 520 B-Or
mental NCT03927404 521 527 B-Condition
health NCT03927404 528 534 I-Condition
problems NCT03927404 535 543 I-Condition
that NCT03927404 544 548 O
would NCT03927404 549 554 O
limit NCT03927404 555 560 O
ability NCT03927404 561 568 O
to NCT03927404 569 571 O
consent NCT03927404 572 579 O
and NCT03927404 580 583 O
participate NCT03927404 584 595 O
fully NCT03927404 596 601 O
in NCT03927404 602 604 O
the NCT03927404 605 608 O
study NCT03927404 609 614 O
protocol NCT03927404 615 623 O

- NCT03927404 626 627 O
3 NCT03927404 629 630 O
. NCT03927404 630 631 O
Women NCT03927404 632 637 O
who NCT03927404 638 641 B-And
are NCT03927404 642 645 O
pregnant NCT03927404 646 654 B-Condition
or NCT03927404 655 657 B-Or
who NCT03927404 658 661 O
plan NCT03927404 662 666 B-Assertion___Assertion-Type-Value:intention
to NCT03927404 667 669 I-Assertion___Assertion-Type-Value:intention
become NCT03927404 670 676 O
pregnant NCT03927404 677 685 B-Condition
in NCT03927404 686 688 O
the NCT03927404 689 692 O
near NCT03927404 693 697 B-Eq-Comparison
future NCT03927404 698 704 I-Eq-Comparison

Inclusion NCT03929367 0 9 O
Criteria NCT03929367 10 18 O
: NCT03929367 19 20 O

- NCT03929367 24 25 O
Male NCT03929367 27 31 O
or NCT03929367 32 34 B-Or
female NCT03929367 35 41 O
> NCT03929367 42 43 B-Eq-Comparison
18 NCT03929367 44 46 I-Eq-Comparison
and NCT03929367 47 50 B-And
< NCT03929367 51 52 B-Eq-Comparison
60 NCT03929367 53 55 I-Eq-Comparison
years NCT03929367 56 61 I-Eq-Comparison
of NCT03929367 62 64 O
age NCT03929367 65 68 B-Age
, NCT03929367 69 70 O
Body NCT03929367 71 75 B-Observation
Mass NCT03929367 76 80 I-Observation
Index NCT03929367 81 86 I-Observation
( NCT03929367 87 88 O
BMI NCT03929367 89 92 B-Observation
) NCT03929367 93 94 O
< NCT03929367 95 96 B-Eq-Comparison
40 NCT03929367 97 99 I-Eq-Comparison
. NCT03929367 99 100 O

- NCT03929367 104 105 O
Generally NCT03929367 107 116 O
in NCT03929367 117 119 O
good NCT03929367 120 124 B-Condition
health NCT03929367 125 131 I-Condition
as NCT03929367 132 134 O
determined NCT03929367 135 145 O
by NCT03929367 146 148 O
the NCT03929367 149 152 O
Principal NCT03929367 153 162 O
Investigator NCT03929367 163 175 O
based NCT03929367 176 181 O
on NCT03929367 182 184 O
prior NCT03929367 185 190 O
medical NCT03929367 191 198 O
history NCT03929367 199 206 O
, NCT03929367 207 208 O
American NCT03929367 209 217 B-Condition
Society NCT03929367 218 225 I-Condition
of NCT03929367 226 228 I-Condition
Anesthesiologists NCT03929367 229 246 I-Condition
physical NCT03929367 247 255 O
status NCT03929367 256 262 B-Eq-Comparison
I NCT03929367 263 264 I-Eq-Comparison
or NCT03929367 265 267 I-Eq-Comparison
II NCT03929367 268 270 I-Eq-Comparison

- NCT03929367 273 274 O
Normal NCT03929367 276 282 O
blood NCT03929367 283 288 B-Observation
pressure NCT03929367 289 297 I-Observation
( NCT03929367 298 299 O
systolic NCT03929367 300 308 B-Observation
90 NCT03929367 309 311 B-Eq-Comparison
- NCT03929367 312 313 I-Eq-Comparison
140 NCT03929367 314 317 I-Eq-Comparison
mmHg NCT03929367 318 322 I-Eq-Comparison
; NCT03929367 322 323 O
diastolic NCT03929367 324 333 B-Observation
50 NCT03929367 334 336 B-Eq-Comparison
- NCT03929367 337 338 I-Eq-Comparison
90 NCT03929367 339 341 I-Eq-Comparison
mmHg NCT03929367 342 346 I-Eq-Comparison
) NCT03929367 347 348 O
resting NCT03929367 349 356 B-Observation
heart NCT03929367 357 362 I-Observation
rate NCT03929367 363 367 I-Observation

45 NCT03929367 373 375 B-Eq-Comparison
- NCT03929367 376 377 I-Eq-Comparison
100 NCT03929367 378 381 I-Eq-Comparison
beats NCT03929367 382 387 I-Eq-Comparison
per NCT03929367 388 391 I-Eq-Comparison
minute NCT03929367 392 398 I-Eq-Comparison
) NCT03929367 399 400 O
without NCT03929367 401 408 B-Negation
medication NCT03929367 409 419 B-Drug

- NCT03929367 422 423 O
Female NCT03929367 425 431 O
subjects NCT03929367 432 440 O
of NCT03929367 441 443 O
child NCT03929367 444 449 B-Condition
- NCT03929367 450 451 I-Condition
bearing NCT03929367 452 459 I-Condition
potential NCT03929367 460 469 I-Condition
and NCT03929367 470 473 B-And
those NCT03929367 474 479 O
< NCT03929367 480 481 B-Eq-Comparison
1 NCT03929367 482 483 I-Eq-Comparison
year NCT03929367 484 488 I-Eq-Comparison
post NCT03929367 489 493 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03929367 494 495 O
menopausal NCT03929367 496 506 B-Condition
, NCT03929367 507 508 O
must NCT03929367 509 513 O
be NCT03929367 514 516 O
practicing NCT03929367 517 527 B-Eq-Comparison
highly NCT03929367 528 534 O
effective NCT03929367 535 544 O
methods NCT03929367 545 552 O
of NCT03929367 553 555 O
birth NCT03929367 556 561 B-Procedure
control NCT03929367 562 569 I-Procedure
such NCT03929367 570 574 O
as NCT03929367 575 577 O
hormonal NCT03929367 578 586 B-Procedure
methods NCT03929367 587 594 I-Procedure

Exclusion NCT03929367 595 604 O
Criteria NCT03929367 605 613 O
: NCT03929367 614 615 O

- NCT03929367 619 620 O
Hypersensitivity NCT03929367 622 638 B-Condition
, NCT03929367 639 640 O
allergy NCT03929367 641 648 B-Allergy
, NCT03929367 649 650 O
or NCT03929367 651 653 B-Or
significant NCT03929367 654 665 O
reaction NCT03929367 666 674 B-Condition
to NCT03929367 675 677 O
any NCT03929367 678 681 O
ingredient NCT03929367 682 692 O
of NCT03929367 693 695 O
Pitocin NCT03929367 696 703 B-Drug
® NCT03929367 703 704 O

- NCT03929367 707 708 O
Any NCT03929367 710 713 O
disease NCT03929367 714 721 B-Condition
, NCT03929367 722 723 O
diagnosis NCT03929367 724 733 B-Condition
, NCT03929367 734 735 O
or NCT03929367 736 738 B-Or
condition NCT03929367 739 748 B-Condition
( NCT03929367 749 750 O
medical NCT03929367 751 758 B-Modifier
or NCT03929367 759 761 B-Or
surgical NCT03929367 762 770 B-Modifier
) NCT03929367 771 772 O
that NCT03929367 773 777 O
, NCT03929367 778 779 O
in NCT03929367 780 782 O
the NCT03929367 783 786 O
opinion NCT03929367 787 794 O
of NCT03929367 795 797 O
the NCT03929367 798 801 O
Principal NCT03929367 802 811 O
Investigator NCT03929367 812 824 O
, NCT03929367 825 826 O
would NCT03929367 827 832 O
place NCT03929367 833 838 O
the NCT03929367 839 842 O
subject NCT03929367 843 850 O
at NCT03929367 851 853 O
increased NCT03929367 854 863 O
risk NCT03929367 864 868 B-Risk
( NCT03929367 869 870 O
active NCT03929367 871 877 B-Eq-Comparison
gynecologic NCT03929367 878 889 B-Condition
disease NCT03929367 890 897 I-Condition
in NCT03929367 898 900 O
which NCT03929367 901 906 O
increased NCT03929367 907 916 O
tone NCT03929367 917 921 O
would NCT03929367 922 927 O
be NCT03929367 928 930 O
detrimental NCT03929367 931 942 O
e. NCT03929367 943 945 O
g. NCT03929367 946 948 O
, NCT03929367 949 950 O
uterine NCT03929367 951 958 B-Condition
fibroids NCT03929367 959 967 I-Condition
with NCT03929367 968 972 B-And
ongoing NCT03929367 973 980 O
bleeding NCT03929367 981 989 B-Condition
) NCT03929367 990 991 O
, NCT03929367 993 994 O
compromise NCT03929367 995 1005 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03929367 1006 1009 O
subject NCT03929367 1010 1017 O
's NCT03929367 1017 1019 O
compliance NCT03929367 1020 1030 O
with NCT03929367 1031 1035 O
study NCT03929367 1036 1041 B-Study
procedures NCT03929367 1042 1052 O
, NCT03929367 1053 1054 O
or NCT03929367 1055 1057 O
compromise NCT03929367 1058 1068 O
the NCT03929367 1069 1072 O
quality NCT03929367 1073 1080 O
of NCT03929367 1081 1083 O
the NCT03929367 1084 1087 O
data NCT03929367 1088 1092 O

- NCT03929367 1095 1096 O
Women NCT03929367 1098 1103 O
who NCT03929367 1104 1107 B-And
are NCT03929367 1108 1111 O
pregnant NCT03929367 1112 1120 B-Condition
( NCT03929367 1121 1122 O
positive NCT03929367 1123 1131 O
result NCT03929367 1132 1138 O
for NCT03929367 1139 1142 O
serum NCT03929367 1143 1148 B-Observation
pregnancy NCT03929367 1149 1158 I-Observation
test NCT03929367 1159 1163 I-Observation
at NCT03929367 1164 1166 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929367 1167 1176 B-Study
visit NCT03929367 1177 1182 O
) NCT03929367 1183 1184 O
, NCT03929367 1186 1187 O
women NCT03929367 1188 1193 O
who NCT03929367 1194 1197 B-And
are NCT03929367 1198 1201 I-And
currently NCT03929367 1202 1211 B-Eq-Comparison
nursing NCT03929367 1212 1219 B-Condition
or NCT03929367 1220 1222 B-Or
lactating NCT03929367 1223 1232 B-Condition
, NCT03929367 1233 1234 O
women NCT03929367 1235 1240 O
that NCT03929367 1241 1245 B-And
have NCT03929367 1246 1250 B-Eq-Comparison
been NCT03929367 1251 1255 I-Eq-Comparison
pregnant NCT03929367 1256 1264 B-Condition
within NCT03929367 1265 1271 B-Eq-Comparison
2 NCT03929367 1272 1273 I-Eq-Comparison
years NCT03929367 1274 1279 I-Eq-Comparison

- NCT03929367 1282 1283 O
Subjects NCT03929367 1285 1293 O
with NCT03929367 1294 1298 O
neuropathy NCT03929367 1299 1309 B-Condition
, NCT03929367 1310 1311 O
chronic NCT03929367 1312 1319 B-Modifier
pain NCT03929367 1320 1324 B-Condition
, NCT03929367 1325 1326 O
diabetes NCT03929367 1327 1335 B-Condition
mellitus NCT03929367 1336 1344 I-Condition
, NCT03929367 1345 1346 O
or NCT03929367 1347 1349 B-Or
taking NCT03929367 1350 1356 B-Eq-Comparison
benzodiazepines NCT03929367 1357 1372 B-Drug
or NCT03929367 1373 1375 B-Or
pain NCT03929367 1376 1380 B-Drug
medications NCT03929367 1381 1392 I-Drug
on NCT03929367 1393 1395 O
a NCT03929367 1396 1397 O
daily NCT03929367 1398 1403 B-Eq-Comparison
basis NCT03929367 1404 1409 O
. NCT03929367 1409 1410 O

Inclusion NCT03922971 0 9 O
Criteria NCT03922971 10 18 O
: NCT03922971 19 20 O

- NCT03922971 24 25 O
Facilities NCT03922971 27 37 O
that NCT03922971 38 42 O
bill NCT03922971 43 47 O
to NCT03922971 48 50 O
fee NCT03922971 51 54 O
for NCT03922971 55 58 O
service NCT03922971 59 66 O
Medicare NCT03922971 67 75 O
for NCT03922971 76 79 O
gastrointestinal NCT03922971 80 96 B-Procedure
endoscopy NCT03922971 97 106 I-Procedure

Exclusion NCT03922971 107 116 O
Criteria NCT03922971 117 125 O
: NCT03922971 126 127 O

- NCT03922971 130 131 O

Inclusion NCT03920800 0 9 O
Criteria NCT03920800 10 18 O
: NCT03920800 19 20 O

- NCT03920800 24 25 O
Patients NCT03920800 27 35 O
followed NCT03920800 36 44 B-Encounter
within NCT03920800 45 51 O
the NCT03920800 52 55 O
CHU NCT03920800 56 59 O
Brugmann NCT03920800 60 68 O
Hospital NCT03920800 69 77 O
( NCT03920800 78 79 O
no NCT03920800 80 82 B-Negation
private NCT03920800 83 90 O
practices NCT03920800 91 100 O
) NCT03920800 101 102 O
. NCT03920800 104 105 O

- NCT03920800 109 110 O
HSIL NCT03920800 112 116 B-Condition
lesions NCT03920800 117 124 I-Condition
confirmed NCT03920800 125 134 O
by NCT03920800 135 137 O
anatomopathologic NCT03920800 138 155 O
analysis NCT03920800 156 164 O
on NCT03920800 165 167 O
cervical NCT03920800 168 176 B-Procedure
biopsies NCT03920800 177 185 I-Procedure
or NCT03920800 186 188 B-Or
cone NCT03920800 189 193 B-Observation
specimen NCT03920800 194 202 I-Observation
without NCT03920800 203 210 B-Negation
evidence NCT03920800 211 219 O
of NCT03920800 220 222 O
invasive NCT03920800 223 231 B-Condition
lesions NCT03920800 232 239 I-Condition

Exclusion NCT03920800 240 249 O
Criteria NCT03920800 250 258 O
: NCT03920800 259 260 O

- NCT03920800 264 265 O
Invasive NCT03920800 267 275 B-Condition
lesions NCT03920800 276 283 I-Condition

Inclusion NCT03927612 0 9 O
Criteria NCT03927612 10 18 O
: NCT03927612 19 20 O

- NCT03927612 24 25 O
Aged NCT03927612 27 31 B-Age
9 NCT03927612 32 33 B-Eq-Comparison
- NCT03927612 34 35 I-Eq-Comparison
12 NCT03927612 36 38 O

- NCT03927612 42 43 O
English NCT03927612 45 52 O
- NCT03927612 53 54 O
speaking NCT03927612 55 63 O

- NCT03927612 66 67 O
Meet NCT03927612 69 73 O
DSM NCT03927612 74 77 O
- NCT03927612 78 79 O
5 NCT03927612 80 81 O
criteria NCT03927612 82 90 O
for NCT03927612 91 94 O
oppositional NCT03927612 95 107 B-Condition
defiant NCT03927612 108 115 I-Condition
disorder NCT03927612 116 124 I-Condition
( NCT03927612 125 126 O
ODD NCT03927612 127 130 B-Condition
) NCT03927612 131 132 O
, NCT03927612 134 135 O
conduct NCT03927612 136 143 B-Condition
disorder NCT03927612 144 152 I-Condition
( NCT03927612 153 154 O
CD NCT03927612 155 157 B-Condition
) NCT03927612 158 159 O
, NCT03927612 161 162 O
or NCT03927612 163 165 B-Or
Other NCT03927612 166 171 B-Other
Specified NCT03927612 172 181 B-Modifier
or NCT03927612 182 184 B-Or
Unspecified NCT03927612 185 196 B-Modifier
Disruptive NCT03927612 197 207 I-Modifier
, NCT03927612 208 209 O
Impulse NCT03927612 210 217 B-Modifier
- NCT03927612 218 219 I-Modifier
Control NCT03927612 220 227 I-Modifier
, NCT03927612 228 229 O
and NCT03927612 230 233 B-Or
Conduct NCT03927612 234 241 B-Modifier
Disorder NCT03927612 242 250 B-Condition

- NCT03927612 253 254 O
Right NCT03927612 256 261 O
- NCT03927612 262 263 O
handed NCT03927612 264 270 O

- NCT03927612 273 274 O
Estimated NCT03927612 276 285 O
full NCT03927612 286 290 B-Observation
- NCT03927612 291 292 I-Observation
scale NCT03927612 293 298 I-Observation
IQ NCT03927612 299 301 I-Observation
greater NCT03927612 302 309 B-Eq-Comparison
than NCT03927612 310 314 I-Eq-Comparison
75 NCT03927612 315 317 I-Eq-Comparison

Exclusion NCT03927612 319 328 O
Criteria NCT03927612 329 337 O
: NCT03927612 338 339 O

- NCT03927612 343 344 O
Bipolar NCT03927612 346 353 B-Condition
disorder NCT03927612 354 362 I-Condition
, NCT03927612 363 364 O
any NCT03927612 365 368 O
disorder NCT03927612 369 377 B-Condition
involving NCT03927612 378 387 O
psychosis NCT03927612 388 397 B-Condition
, NCT03927612 398 399 O
pervasive NCT03927612 400 409 B-Condition
developmental NCT03927612 410 423 I-Condition
disorders NCT03927612 424 433 I-Condition
, NCT03927612 434 435 O
current NCT03927612 436 443 B-Eq-Comparison
or NCT03927612 444 446 B-Or
past NCT03927612 447 451 B-Eq-Comparison
substance NCT03927612 452 461 B-Condition
use NCT03927612 462 465 I-Condition
disorder NCT03927612 466 474 I-Condition
, NCT03927612 475 476 O
or NCT03927612 477 479 B-Or
current NCT03927612 480 487 B-Eq-Comparison
major NCT03927612 488 493 O
depressive NCT03927612 494 504 B-Condition
disorder NCT03927612 505 513 I-Condition

- NCT03927612 516 517 O
History NCT03927612 519 526 B-Eq-Comparison
of NCT03927612 527 529 O
neurological NCT03927612 530 542 B-Condition
problems NCT03927612 543 551 I-Condition
( NCT03927612 552 553 O
e. NCT03927612 554 556 O
g. NCT03927612 557 559 O
, NCT03927612 560 561 O
epilepsy NCT03927612 562 570 B-Condition
, NCT03927612 571 572 O
traumatic NCT03927612 573 582 B-Condition
brain NCT03927612 583 588 I-Condition
injury NCT03927612 589 595 I-Condition
) NCT03927612 596 597 O

- NCT03927612 601 602 O
Contraindications NCT03927612 604 621 B-Contraindication
for NCT03927612 622 625 O
MRI NCT03927612 626 629 B-Procedure

Inclusion NCT03929159 0 9 O
Criteria NCT03929159 10 18 O
: NCT03929159 19 20 O

- NCT03929159 24 25 O
Electively NCT03929159 27 37 O
scheduled NCT03929159 38 47 B-Eq-Comparison
for NCT03929159 48 51 O
surgical NCT03929159 52 60 B-Procedure
operation NCT03929159 61 70 I-Procedure
that NCT03929159 71 75 O
require NCT03929159 76 83 O
general NCT03929159 84 91 B-Procedure
anesthesia NCT03929159 92 102 I-Procedure
and NCT03929159 103 106 B-And
expected NCT03929159 107 115 B-Assertion___Assertion-Type-Value:hypothetical
duration NCT03929159 116 124 O
of NCT03929159 125 127 O
hospitalization NCT03929159 128 143 B-Encounter
of NCT03929159 144 146 O
longer NCT03929159 147 153 B-Eq-Comparison
than NCT03929159 154 158 I-Eq-Comparison
one NCT03929159 159 162 I-Eq-Comparison
day NCT03929159 163 166 I-Eq-Comparison
( NCT03929159 167 168 O
for NCT03929159 169 172 O
patients NCT03929159 173 181 O
in NCT03929159 182 184 O
Peri NCT03929159 185 189 B-Procedure
operative NCT03929159 190 199 I-Procedure
Evaluation NCT03929159 200 210 I-Procedure
& NCT03929159 211 212 I-Procedure
Management NCT03929159 213 223 I-Procedure
[ NCT03929159 224 225 O
POEM NCT03929159 226 230 B-Procedure
] NCT03929159 231 232 O
) NCT03929159 234 235 O
or NCT03929159 236 238 B-Or
high NCT03929159 239 243 O
clinical NCT03929159 244 252 O
suspicion NCT03929159 253 262 B-Assertion___Assertion-Type-Value:possible
of NCT03929159 263 265 O
sepsis NCT03929159 266 272 B-Condition
by NCT03929159 273 275 O
the NCT03929159 276 279 O
emergency NCT03929159 280 289 B-Provider
physician NCT03929159 290 299 I-Provider
( NCT03929159 300 301 O
for NCT03929159 302 305 O
patients NCT03929159 306 314 O
in NCT03929159 315 317 O
emergency NCT03929159 318 327 B-Encounter
center NCT03929159 328 334 I-Encounter
) NCT03929159 335 336 O

- NCT03929159 340 341 O
Ability NCT03929159 343 350 O
to NCT03929159 351 353 O
give NCT03929159 354 358 O
informed NCT03929159 359 367 O
consent NCT03929159 368 375 O
. NCT03929159 375 376 O
If NCT03929159 378 380 O
the NCT03929159 381 384 O
patient NCT03929159 385 392 O
is NCT03929159 393 395 O
incapacitated NCT03929159 396 409 O
and NCT03929159 410 413 O
unable NCT03929159 414 420 O
to NCT03929159 421 423 O
give NCT03929159 424 428 O
informed NCT03929159 429 437 O
consent NCT03929159 438 445 O
, NCT03929159 446 447 O
the NCT03929159 448 451 O
next NCT03929159 452 456 O
- NCT03929159 457 458 O
of NCT03929159 459 461 O
- NCT03929159 462 463 O
kin NCT03929159 464 467 O
or NCT03929159 468 470 O
a NCT03929159 471 472 O
person NCT03929159 473 479 O
who NCT03929159 480 483 O
has NCT03929159 484 487 O
the NCT03929159 488 491 O
power NCT03929159 492 497 O
of NCT03929159 498 500 O
attorney NCT03929159 501 509 O
must NCT03929159 510 514 O
be NCT03929159 515 517 O
present NCT03929159 518 525 O
for NCT03929159 526 529 O
informed NCT03929159 530 538 O
consent NCT03929159 539 546 O
. NCT03929159 547 548 O

- NCT03929159 552 553 O
For NCT03929159 555 558 O
patients NCT03929159 559 567 O
in NCT03929159 568 570 O
the NCT03929159 571 574 O
emergency NCT03929159 575 584 B-Encounter
center NCT03929159 585 591 I-Encounter
only NCT03929159 592 596 O
, NCT03929159 597 598 O
two NCT03929159 599 602 B-Eq-Comparison
or NCT03929159 603 605 I-Eq-Comparison
more NCT03929159 606 610 I-Eq-Comparison
of NCT03929159 611 613 O
the NCT03929159 614 617 B-Criteria-Count
following NCT03929159 618 627 I-Criteria-Count
SIRS NCT03929159 628 632 B-Condition
criteria NCT03929159 633 641 O
: NCT03929159 642 643 O

- NCT03929159 652 653 O
Leukocytes NCT03929159 655 665 B-Observation
> NCT03929159 666 667 B-Eq-Comparison
12 NCT03929159 668 670 I-Eq-Comparison
, NCT03929159 671 672 I-Eq-Comparison
000 NCT03929159 673 676 I-Eq-Comparison
/ NCT03929159 677 678 I-Eq-Comparison
mm^3 NCT03929159 679 683 I-Eq-Comparison
or NCT03929159 684 686 B-Or
< NCT03929159 687 688 B-Eq-Comparison
4 NCT03929159 689 690 I-Eq-Comparison
, NCT03929159 691 692 I-Eq-Comparison
000 NCT03929159 693 696 I-Eq-Comparison
/ NCT03929159 697 698 I-Eq-Comparison
mm^3 NCT03929159 699 703 I-Eq-Comparison
or NCT03929159 704 706 B-Or
> NCT03929159 707 708 B-Eq-Comparison
10 NCT03929159 709 711 I-Eq-Comparison
% NCT03929159 712 713 I-Eq-Comparison
immature NCT03929159 714 722 B-Observation
( NCT03929159 723 724 I-Observation
band NCT03929159 725 729 I-Observation
) NCT03929159 730 731 I-Observation
forms NCT03929159 732 737 I-Observation
, NCT03929159 738 739 O
provided NCT03929159 740 748 O
that NCT03929159 749 753 O
no NCT03929159 754 756 B-Negation
filgrastim NCT03929159 757 767 B-Drug
or NCT03929159 768 770 B-Or
pegfilgrastim NCT03929159 771 784 B-Drug
was NCT03929159 785 788 O
administered NCT03929159 789 801 B-Eq-Comparison
within NCT03929159 802 808 B-Eq-Comparison
30 NCT03929159 809 811 I-Eq-Comparison
days NCT03929159 812 816 I-Eq-Comparison
and NCT03929159 817 820 B-And
no NCT03929159 821 823 B-Negation
leukemia NCT03929159 824 832 B-Condition

- NCT03929159 840 841 O
Heart NCT03929159 843 848 B-Observation
rate NCT03929159 849 853 I-Observation
> NCT03929159 854 855 B-Eq-Comparison
90 NCT03929159 856 858 I-Eq-Comparison
beats NCT03929159 859 864 I-Eq-Comparison
/ NCT03929159 865 866 I-Eq-Comparison
minute NCT03929159 867 873 I-Eq-Comparison
( NCT03929159 874 875 O
min NCT03929159 876 879 O
) NCT03929159 880 881 O

- NCT03929159 890 891 O
Respiratory NCT03929159 893 904 B-Observation
rate NCT03929159 905 909 I-Observation
> NCT03929159 910 911 B-Eq-Comparison
20 NCT03929159 912 914 I-Eq-Comparison
breaths NCT03929159 915 922 I-Eq-Comparison
/ NCT03929159 923 924 I-Eq-Comparison
min NCT03929159 925 928 I-Eq-Comparison
or NCT03929159 929 931 O
partial NCT03929159 932 939 B-Observation
pressure NCT03929159 940 948 I-Observation
of NCT03929159 949 951 I-Observation
carbon NCT03929159 952 958 I-Observation
dioxide NCT03929159 959 966 I-Observation
( NCT03929159 967 968 O
CO2 NCT03929159 969 972 B-Observation
) NCT03929159 973 974 O
< NCT03929159 975 976 B-Eq-Comparison
32 NCT03929159 977 979 I-Eq-Comparison
mmHg NCT03929159 980 984 I-Eq-Comparison

- NCT03929159 992 993 O
Oral NCT03929159 995 999 B-Modifier
temperature NCT03929159 1000 1011 B-Observation
> NCT03929159 1012 1013 B-Eq-Comparison
38 NCT03929159 1014 1016 I-Eq-Comparison
degrees NCT03929159 1017 1024 I-Eq-Comparison
Celsius NCT03929159 1025 1032 I-Eq-Comparison
( NCT03929159 1033 1034 O
C NCT03929159 1035 1036 O
) NCT03929159 1037 1038 O
or NCT03929159 1039 1041 B-Or
< NCT03929159 1042 1043 B-Eq-Comparison
36 NCT03929159 1044 1046 I-Eq-Comparison
degrees NCT03929159 1047 1054 I-Eq-Comparison
C NCT03929159 1055 1056 I-Eq-Comparison
or NCT03929159 1057 1059 B-Or
axillary NCT03929159 1060 1068 B-Modifier
temperature NCT03929159 1069 1080 B-Observation
> NCT03929159 1081 1082 B-Eq-Comparison
37 NCT03929159 1083 1085 I-Eq-Comparison
degrees NCT03929159 1086 1093 I-Eq-Comparison
C NCT03929159 1094 1095 I-Eq-Comparison
or NCT03929159 1096 1098 B-Or
< NCT03929159 1099 1100 B-Eq-Comparison
35 NCT03929159 1101 1103 I-Eq-Comparison
degrees NCT03929159 1104 1111 I-Eq-Comparison
C NCT03929159 1112 1113 I-Eq-Comparison

Exclusion NCT03929159 1114 1123 O
Criteria NCT03929159 1124 1132 O
: NCT03929159 1133 1134 O

- NCT03929159 1138 1139 O
Inability NCT03929159 1141 1150 O
to NCT03929159 1151 1153 O
give NCT03929159 1154 1158 O
informed NCT03929159 1159 1167 O
consent NCT03929159 1168 1175 O
or NCT03929159 1176 1178 O
a NCT03929159 1179 1180 O
person NCT03929159 1181 1187 O
who NCT03929159 1188 1191 O
has NCT03929159 1192 1195 O
power NCT03929159 1196 1201 O
of NCT03929159 1202 1204 O
attorney NCT03929159 1205 1213 O
for NCT03929159 1214 1217 O
medical NCT03929159 1218 1225 O
decision NCT03929159 1226 1234 O
is NCT03929159 1235 1237 O
not NCT03929159 1238 1241 O
available NCT03929159 1242 1251 O

- NCT03929159 1254 1255 O
Being NCT03929159 1257 1262 B-Eq-Comparison
moribund NCT03929159 1263 1271 B-Condition
( NCT03929159 1272 1273 O
for NCT03929159 1274 1277 O
patients NCT03929159 1278 1286 O
in NCT03929159 1287 1289 O
emergency NCT03929159 1290 1299 B-Encounter
center NCT03929159 1300 1306 I-Encounter
) NCT03929159 1307 1308 O
or NCT03929159 1309 1311 O
cancellation NCT03929159 1312 1324 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03929159 1325 1327 O
surgery NCT03929159 1328 1335 B-Procedure
( NCT03929159 1336 1337 O
for NCT03929159 1338 1341 O
patients NCT03929159 1342 1350 O
in NCT03929159 1351 1353 O
POEM NCT03929159 1354 1358 B-Procedure
) NCT03929159 1359 1360 O

- NCT03929159 1364 1365 O
Active NCT03929159 1367 1373 B-Eq-Comparison
" NCT03929159 1374 1375 O
Do NCT03929159 1375 1377 B-Observation
Not NCT03929159 1378 1381 I-Observation
Resuscitate NCT03929159 1382 1393 I-Observation
" NCT03929159 1393 1394 O
or NCT03929159 1395 1397 B-Or
" NCT03929159 1398 1399 O
Do NCT03929159 1399 1401 B-Observation
Not NCT03929159 1402 1405 I-Observation
Intubate NCT03929159 1406 1414 I-Observation
" NCT03929159 1414 1415 O
order NCT03929159 1416 1421 O


Inclusion NCT03928535 0 9 O
Criteria NCT03928535 10 18 O
: NCT03928535 19 20 O

- NCT03928535 24 25 O
Clinical NCT03928535 27 35 O
diagnosis NCT03928535 36 45 O
of NCT03928535 46 48 O
AECOPD NCT03928535 49 55 B-Condition

- NCT03928535 58 59 O
Extubation NCT03928535 61 71 B-Procedure
must NCT03928535 72 76 O
be NCT03928535 77 79 O
performed NCT03928535 80 89 O
after NCT03928535 90 95 B-Temporal-Connection___Temporal-Connection-Type-Value:after
48 NCT03928535 96 98 B-Eq-Comparison
hours NCT03928535 99 104 I-Eq-Comparison
of NCT03928535 105 107 O
invasive NCT03928535 108 116 B-Modifier
ventilation NCT03928535 117 128 B-Procedure

- NCT03928535 131 132 O
Must NCT03928535 134 138 O
be NCT03928535 139 141 O
treated NCT03928535 142 149 O
sequentially NCT03928535 150 162 O
with NCT03928535 163 167 O
HFNC NCT03928535 168 172 B-Procedure
or NCT03928535 173 175 B-Or
NIV NCT03928535 176 179 B-Procedure
after NCT03928535 180 185 B-Temporal-Connection___Temporal-Connection-Type-Value:after
extubation NCT03928535 186 196 B-Procedure

- NCT03928535 199 200 O
PaCO2 NCT03928535 202 207 B-Observation
≥ NCT03928535 208 209 B-Eq-Comparison
50 NCT03928535 210 212 I-Eq-Comparison
mmHg NCT03928535 213 217 I-Eq-Comparison
when NCT03928535 218 222 B-Temporal-Connection___Temporal-Connection-Type-Value:during
extubation NCT03928535 223 233 B-Procedure

- NCT03928535 236 237 O
Positive NCT03928535 239 247 B-Observation
End NCT03928535 248 251 I-Observation
Expiratory NCT03928535 252 262 I-Observation
Pressure NCT03928535 263 271 I-Observation
( NCT03928535 272 273 O
PEEP NCT03928535 274 278 B-Observation
) NCT03928535 279 280 O
≤ NCT03928535 281 282 B-Eq-Comparison
8 NCT03928535 283 284 I-Eq-Comparison
cmH2O NCT03928535 285 290 O
( NCT03928535 291 292 O
1 NCT03928535 293 294 O
cmH2O NCT03928535 295 300 O
= NCT03928535 301 302 O
0.098 NCT03928535 303 308 O
kPa NCT03928535 309 312 O
) NCT03928535 313 314 O
when NCT03928535 315 319 B-Temporal-Connection___Temporal-Connection-Type-Value:during
extubation NCT03928535 320 330 B-Procedure

Exclusion NCT03928535 331 340 O
Criteria NCT03928535 341 349 O
: NCT03928535 350 351 O

- NCT03928535 355 356 O
Do NCT03928535 358 360 B-Observation
- NCT03928535 361 362 I-Observation
not NCT03928535 363 366 I-Observation
- NCT03928535 367 368 I-Observation
intubate NCT03928535 369 377 I-Observation

- NCT03928535 380 381 O
Tracheostomies NCT03928535 383 397 B-Procedure

- NCT03928535 400 401 O
Accidental NCT03928535 403 413 B-Modifier
extubation NCT03928535 414 424 B-Procedure

- NCT03928535 427 428 O
Self NCT03928535 430 434 B-Modifier
- NCT03928535 435 436 O
extubation NCT03928535 437 447 B-Procedure

Inclusion NCT03925987 0 9 O
Criteria NCT03925987 10 18 O
: NCT03925987 19 20 O

1 NCT03925987 24 25 O
. NCT03925987 25 26 O
DSM NCT03925987 28 31 O
- NCT03925987 32 33 O
V NCT03925987 34 35 O
diagnosis NCT03925987 36 45 O
of NCT03925987 46 48 O
an NCT03925987 49 51 O
Anxiety NCT03925987 52 59 B-Condition
disorder NCT03925987 60 68 I-Condition
( NCT03925987 69 70 O
Generalized NCT03925987 71 82 B-Condition
Anxiety NCT03925987 83 90 I-Condition
Disorder NCT03925987 91 99 I-Condition
, NCT03925987 100 101 O
Social NCT03925987 102 108 B-Condition
Anxiety NCT03925987 109 116 I-Condition
Disorder NCT03925987 117 125 I-Condition
, NCT03925987 126 127 O
Panic NCT03925987 128 133 B-Condition
Disorder NCT03925987 134 142 I-Condition
, NCT03925987 143 144 O
Agoraphobia NCT03925987 145 156 B-Condition
) NCT03925987 157 158 O

2 NCT03925987 162 163 O
. NCT03925987 163 164 O
Anxiety NCT03925987 166 173 B-Observation
Sensitivity NCT03925987 174 185 I-Observation
Index NCT03925987 186 191 I-Observation
( NCT03925987 192 193 O
ASI NCT03925987 194 197 B-Observation
- NCT03925987 198 199 I-Observation
3 NCT03925987 200 201 I-Observation
) NCT03925987 202 203 O
total NCT03925987 204 209 B-Eq-Comparison
score NCT03925987 210 215 I-Eq-Comparison
> NCT03925987 216 217 I-Eq-Comparison
29 NCT03925987 218 220 I-Eq-Comparison

3 NCT03925987 224 225 O
. NCT03925987 225 226 O
Overall NCT03925987 228 235 B-Observation
Anxiety NCT03925987 236 243 I-Observation
Severity NCT03925987 244 252 I-Observation
and NCT03925987 253 256 I-Observation
Impairment NCT03925987 257 267 I-Observation
Scale NCT03925987 268 273 I-Observation
( NCT03925987 274 275 O
OASIS NCT03925987 276 281 B-Observation
) NCT03925987 282 283 O
score NCT03925987 284 289 B-Eq-Comparison
> NCT03925987 290 291 I-Eq-Comparison
8 NCT03925987 292 293 I-Eq-Comparison

4 NCT03925987 297 298 O
. NCT03925987 298 299 O
Between NCT03925987 301 308 B-Eq-Comparison
18 NCT03925987 309 311 I-Eq-Comparison
- NCT03925987 312 313 I-Eq-Comparison
55 NCT03925987 314 316 I-Eq-Comparison
years NCT03925987 317 322 I-Eq-Comparison
of NCT03925987 323 325 O
age NCT03925987 326 329 B-Age

5 NCT03925987 332 333 O
. NCT03925987 333 334 O
Subject NCT03925987 336 343 O
must NCT03925987 344 348 O
be NCT03925987 349 351 O
" NCT03925987 352 353 O
treatment NCT03925987 353 362 B-Procedure
- NCT03925987 363 364 O
seeking NCT03925987 365 372 B-Assertion___Assertion-Type-Value:intention
" NCT03925987 372 373 O
and NCT03925987 374 377 B-And
willing NCT03925987 378 385 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925987 386 388 I-Assertion___Assertion-Type-Value:hypothetical
enroll NCT03925987 389 395 O
in NCT03925987 396 398 O
the NCT03925987 399 402 O
10 NCT03925987 403 405 B-Eq-Comparison
- NCT03925987 406 407 I-Eq-Comparison
week NCT03925987 408 412 I-Eq-Comparison
group NCT03925987 413 418 O
- NCT03925987 419 420 O
based NCT03925987 421 426 O
Exposure NCT03925987 427 435 B-Procedure
Therapy NCT03925987 436 443 I-Procedure

Exclusion NCT03925987 444 453 O
Criteria NCT03925987 454 462 O
: NCT03925987 463 464 O

1 NCT03925987 468 469 O
. NCT03925987 469 470 O
Comorbid NCT03925987 472 480 O
Bipolar NCT03925987 481 488 B-Condition
Disorder NCT03925987 489 497 I-Condition
, NCT03925987 498 499 O
Schizophrenia NCT03925987 500 513 B-Condition
, NCT03925987 514 515 O
Anorexia NCT03925987 516 524 B-Condition
or NCT03925987 525 527 B-Or
Bulimia NCT03925987 528 535 B-Condition
Nervosa NCT03925987 536 543 I-Condition
, NCT03925987 544 545 O
or NCT03925987 546 548 B-Or
Obsessive NCT03925987 549 558 B-Condition
- NCT03925987 559 560 I-Condition
Compulsive NCT03925987 561 571 I-Condition
Disorder NCT03925987 572 580 I-Condition

2 NCT03925987 583 584 O
. NCT03925987 584 585 O
Current NCT03925987 587 594 B-Eq-Comparison
Substance NCT03925987 595 604 B-Condition
Use NCT03925987 605 608 I-Condition
Disorder NCT03925987 609 617 I-Condition
> NCT03925987 618 619 B-Eq-Comparison
moderate NCT03925987 620 628 I-Eq-Comparison
( NCT03925987 629 630 O
within NCT03925987 631 637 B-Eq-Comparison
the NCT03925987 638 641 I-Eq-Comparison
past NCT03925987 642 646 I-Eq-Comparison
6 NCT03925987 647 648 I-Eq-Comparison
months NCT03925987 649 655 I-Eq-Comparison
) NCT03925987 656 657 O

3 NCT03925987 661 662 O
. NCT03925987 662 663 O
Currently NCT03925987 665 674 B-Eq-Comparison
taking NCT03925987 675 681 I-Eq-Comparison
a NCT03925987 682 683 O
psychotropic NCT03925987 684 696 B-Drug
medication NCT03925987 697 707 I-Drug

4 NCT03925987 710 711 O
. NCT03925987 711 712 O
Currently NCT03925987 714 723 B-Eq-Comparison
receiving NCT03925987 724 733 I-Eq-Comparison
psychotherapy NCT03925987 734 747 B-Procedure
/ NCT03925987 748 749 B-Or
counseling NCT03925987 750 760 B-Procedure
for NCT03925987 761 764 O
anxiety NCT03925987 765 772 B-Condition

5 NCT03925987 775 776 O
. NCT03925987 776 777 O
Currently NCT03925987 779 788 B-Eq-Comparison
being NCT03925987 789 794 O
treated NCT03925987 795 802 O
as NCT03925987 803 805 O
an NCT03925987 806 808 O
inpatient NCT03925987 809 818 B-Encounter

6 NCT03925987 821 822 O
. NCT03925987 822 823 O
Active NCT03925987 825 831 B-Eq-Comparison
suicidal NCT03925987 832 840 B-Condition
ideation NCT03925987 841 849 I-Condition
with NCT03925987 850 854 O
intent NCT03925987 855 861 B-Modifier
or NCT03925987 862 864 B-Or
plan NCT03925987 865 869 B-Modifier

7 NCT03925987 872 873 O
. NCT03925987 873 874 O
History NCT03925987 876 883 B-Eq-Comparison
of NCT03925987 884 886 O
neurological NCT03925987 887 899 B-Modifier
, NCT03925987 900 901 O
cardiovascular NCT03925987 902 916 B-Modifier
or NCT03925987 917 919 B-Or
respiratory NCT03925987 920 931 B-Modifier
problems NCT03925987 932 940 B-Condition
( NCT03925987 941 942 O
e. NCT03925987 943 945 O
g. NCT03925987 946 948 O
, NCT03925987 949 950 O
asthma NCT03925987 951 957 B-Condition
, NCT03925987 958 959 O
severe NCT03925987 960 966 O
brain NCT03925987 967 972 B-Modifier
injury NCT03925987 973 979 B-Condition
) NCT03925987 980 981 O

Inclusion NCT03928509 0 9 O
criteria NCT03928509 10 18 O
: NCT03928509 19 20 O

- NCT03928509 24 25 O
Participants NCT03928509 27 39 O
will NCT03928509 40 44 O
have NCT03928509 45 49 O
been NCT03928509 50 54 O
previously NCT03928509 55 65 B-Eq-Comparison
joined NCT03928509 66 72 O
for NCT03928509 73 76 O
a NCT03928509 77 78 O
public NCT03928509 79 85 O
health NCT03928509 86 92 O
survey NCT03928509 93 99 O
and NCT03928509 100 103 O
have NCT03928509 104 108 O
agreed NCT03928509 109 115 O
to NCT03928509 116 118 O
be NCT03928509 119 121 O
contacted NCT03928509 122 131 O
again NCT03928509 132 137 O
for NCT03928509 138 141 O
this NCT03928509 142 146 O
study NCT03928509 147 152 B-Study
; NCT03928509 153 154 O

- NCT03928509 157 158 O
Age NCT03928509 160 163 B-Age
: NCT03928509 164 165 O
18 NCT03928509 166 168 B-Eq-Comparison
years NCT03928509 169 174 I-Eq-Comparison
or NCT03928509 175 177 I-Eq-Comparison
over NCT03928509 178 182 I-Eq-Comparison
. NCT03928509 183 184 O

- NCT03928509 188 189 O
Place NCT03928509 191 196 O
of NCT03928509 197 199 O
residence NCT03928509 200 209 O
: NCT03928509 210 211 O
Sherbrooke NCT03928509 212 222 O
, NCT03928509 223 224 O
Moncton NCT03928509 225 232 O
or NCT03928509 233 235 B-Or
Saguenay NCT03928509 236 244 O
- NCT03928509 245 246 O
Lac NCT03928509 247 250 O
- NCT03928509 251 252 O
St NCT03928509 253 255 O
- NCT03928509 256 257 O
Jean NCT03928509 258 262 O
. NCT03928509 262 263 O

Inclusion NCT03924778 0 9 O
Criteria NCT03924778 10 18 O
: NCT03924778 19 20 O

- NCT03924778 24 25 O
female NCT03924778 27 33 O

- NCT03924778 36 37 O
non NCT03924778 39 42 B-Negation
- NCT03924778 43 44 O
Hispanic NCT03924778 45 53 O
, NCT03924778 54 55 O
black NCT03924778 56 61 O
or NCT03924778 62 64 B-Or
white NCT03924778 65 70 O

- NCT03924778 73 74 O
age NCT03924778 76 79 B-Age
19 NCT03924778 80 82 B-Eq-Comparison
- NCT03924778 83 84 I-Eq-Comparison
65 NCT03924778 85 87 I-Eq-Comparison
years NCT03924778 88 93 I-Eq-Comparison

- NCT03924778 96 97 O
BMI NCT03924778 99 102 B-Observation
> NCT03924778 103 104 B-Eq-Comparison
= NCT03924778 106 107 I-Eq-Comparison
30 NCT03924778 108 110 I-Eq-Comparison
kg NCT03924778 111 113 I-Eq-Comparison
/ NCT03924778 114 115 I-Eq-Comparison
m^2 NCT03924778 116 119 I-Eq-Comparison

- NCT03924778 123 124 O
able NCT03924778 126 130 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924778 131 133 I-Assertion___Assertion-Type-Value:hypothetical
visit NCT03924778 134 139 B-Encounter
Bionutrition NCT03924778 140 152 O
Unit NCT03924778 153 157 O
daily NCT03924778 158 163 B-Eq-Comparison

Exclusion NCT03924778 164 173 O
Criteria NCT03924778 174 182 O
: NCT03924778 183 184 O

- NCT03924778 188 189 O
gastrointestinal NCT03924778 191 207 B-Modifier
( NCT03924778 208 209 O
GI NCT03924778 210 212 B-Condition
) NCT03924778 213 214 O
conditions NCT03924778 215 225 B-Condition
i. NCT03924778 226 228 O
e. NCT03924778 229 231 O
, NCT03924778 232 233 O
irritable NCT03924778 234 243 B-Condition
bowel NCT03924778 244 249 I-Condition
, NCT03924778 250 251 O
diverticulitis NCT03924778 252 266 B-Condition
, NCT03924778 267 268 O
peptic NCT03924778 269 275 B-Condition
ulcers NCT03924778 276 282 I-Condition
, NCT03924778 283 284 O
Crohn NCT03924778 285 290 B-Condition
's NCT03924778 290 292 I-Condition
, NCT03924778 293 294 O
GI NCT03924778 295 297 B-Modifier
cancers NCT03924778 298 305 B-Condition
, NCT03924778 306 307 O
and NCT03924778 308 311 B-Or
adenatomous NCT03924778 312 323 B-Condition
polyps NCT03924778 324 330 I-Condition

- NCT03924778 333 334 O
antibiotic NCT03924778 336 346 B-Drug
or NCT03924778 347 349 B-Or
probiotic NCT03924778 350 359 B-Drug
use NCT03924778 360 363 O
in NCT03924778 364 366 O
the NCT03924778 367 370 O
previous NCT03924778 371 379 B-Eq-Comparison
90 NCT03924778 380 382 I-Eq-Comparison
days NCT03924778 383 387 I-Eq-Comparison

- NCT03924778 390 391 O
tobacco NCT03924778 393 400 B-Condition
use NCT03924778 401 404 I-Condition

- NCT03924778 407 408 O
heavy NCT03924778 410 415 O
alcohol NCT03924778 416 423 B-Condition
consumption NCT03924778 424 435 I-Condition

- NCT03924778 438 439 O
major NCT03924778 441 446 B-Modifier
medical NCT03924778 447 454 B-Condition
conditions NCT03924778 455 465 I-Condition
( NCT03924778 466 467 O
e. NCT03924778 468 470 O
g. NCT03924778 471 473 O
, NCT03924778 474 475 O
renal NCT03924778 476 481 B-Condition
disease NCT03924778 482 489 I-Condition
, NCT03924778 490 491 O
diabetes NCT03924778 492 500 B-Condition
, NCT03924778 501 502 O
cancer NCT03924778 503 509 B-Condition
) NCT03924778 510 511 O

Inclusion NCT03922321 0 9 O
Criteria NCT03922321 10 18 O
: NCT03922321 19 20 O

1 NCT03922321 24 25 O
. NCT03922321 25 26 O
Male NCT03922321 28 32 O
or NCT03922321 33 35 B-Or
female NCT03922321 36 42 O
≥ NCT03922321 43 44 B-Eq-Comparison
18 NCT03922321 45 47 I-Eq-Comparison
years NCT03922321 48 53 I-Eq-Comparison
of NCT03922321 54 56 O
age NCT03922321 57 60 B-Age
. NCT03922321 61 62 O

2 NCT03922321 66 67 O
. NCT03922321 67 68 O
Clinical NCT03922321 70 78 O
diagnosis NCT03922321 79 88 O
of NCT03922321 89 91 O
Graves NCT03922321 92 98 B-Condition
' NCT03922321 98 99 I-Condition
disease NCT03922321 100 107 I-Condition
with NCT03922321 108 112 B-And
hyperthyroidism NCT03922321 113 128 B-Condition
associated NCT03922321 129 139 O
with NCT03922321 140 144 O
active NCT03922321 145 151 B-Eq-Comparison
, NCT03922321 152 153 O
moderate NCT03922321 154 162 O
to NCT03922321 163 165 B-Or
severe NCT03922321 166 172 O
GO NCT03922321 173 175 B-Condition
with NCT03922321 176 180 O
a NCT03922321 181 182 O
Clinical NCT03922321 183 191 B-Observation
Activity NCT03922321 192 200 I-Observation
Score NCT03922321 201 206 I-Observation
( NCT03922321 207 208 O
CAS NCT03922321 209 212 B-Observation
) NCT03922321 213 214 O
≥ NCT03922321 215 216 B-Eq-Comparison
4 NCT03922321 217 218 I-Eq-Comparison
for NCT03922321 219 222 O
the NCT03922321 223 226 O
most NCT03922321 227 231 O
severely NCT03922321 232 240 O
affected NCT03922321 241 249 B-Modifier
eye NCT03922321 250 253 I-Modifier
at NCT03922321 254 256 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 257 266 B-Study
( NCT03922321 267 268 O
on NCT03922321 269 271 O
the NCT03922321 272 275 O
7 NCT03922321 276 277 O
- NCT03922321 278 279 O
item NCT03922321 280 284 O
scale NCT03922321 285 290 O
) NCT03922321 291 292 O
and NCT03922321 293 296 B-And
Baseline NCT03922321 297 305 B-Study
( NCT03922321 306 307 O
on NCT03922321 308 310 O
the NCT03922321 311 314 O
10 NCT03922321 315 317 O
- NCT03922321 318 319 O
item NCT03922321 320 324 O
scale NCT03922321 325 330 O
) NCT03922321 331 332 O
. NCT03922321 334 335 O

3 NCT03922321 339 340 O
. NCT03922321 340 341 O
Onset NCT03922321 343 348 B-Eq-Comparison
of NCT03922321 349 351 O
active NCT03922321 352 358 B-Eq-Comparison
GO NCT03922321 359 361 B-Condition
within NCT03922321 362 368 B-Eq-Comparison
9 NCT03922321 369 370 I-Eq-Comparison
months NCT03922321 371 377 I-Eq-Comparison
of NCT03922321 378 380 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03922321 381 390 B-Study
. NCT03922321 391 392 O

4 NCT03922321 396 397 O
. NCT03922321 397 398 O
Moderate NCT03922321 400 408 O
- NCT03922321 409 410 O
to NCT03922321 411 413 B-Or
- NCT03922321 414 415 O
severe NCT03922321 416 422 O
active NCT03922321 423 429 B-Eq-Comparison
GO NCT03922321 430 432 B-Condition
( NCT03922321 433 434 O
not NCT03922321 435 438 B-Negation
sight NCT03922321 439 444 B-Condition
- NCT03922321 445 446 I-Condition
threatening NCT03922321 447 458 I-Condition
but NCT03922321 459 462 B-And
has NCT03922321 463 466 O
an NCT03922321 467 469 O
appreciable NCT03922321 470 481 O
impact NCT03922321 482 488 O
on NCT03922321 489 491 O
daily NCT03922321 492 497 B-Observation
life NCT03922321 498 502 I-Observation
) NCT03922321 503 504 O
, NCT03922321 506 507 O
usually NCT03922321 508 515 O
associated NCT03922321 516 526 O
with NCT03922321 527 531 O
one NCT03922321 532 535 O
or NCT03922321 536 538 O
more NCT03922321 539 543 O
of NCT03922321 544 546 O
the NCT03922321 547 550 O
following NCT03922321 551 560 B-Condition
: NCT03922321 561 562 O
lid NCT03922321 563 566 B-Observation
retraction NCT03922321 567 577 I-Observation
≥ NCT03922321 578 579 B-Eq-Comparison
2 NCT03922321 580 581 I-Eq-Comparison
mm NCT03922321 582 584 I-Eq-Comparison
, NCT03922321 585 586 O
moderate NCT03922321 587 595 O
or NCT03922321 596 598 B-Or
severe NCT03922321 599 605 O
soft NCT03922321 606 610 B-Condition
tissue NCT03922321 611 617 I-Condition
involvement NCT03922321 618 629 I-Condition
, NCT03922321 630 631 O
proptosis NCT03922321 632 641 B-Observation
≥ NCT03922321 642 643 B-Eq-Comparison
3 NCT03922321 644 645 I-Eq-Comparison
mm NCT03922321 646 648 I-Eq-Comparison
above NCT03922321 649 654 I-Eq-Comparison
normal NCT03922321 655 661 I-Eq-Comparison
for NCT03922321 662 665 O
race NCT03922321 666 670 O
and NCT03922321 671 674 O
gender NCT03922321 675 681 O
, NCT03922321 682 683 O
and NCT03922321 684 687 B-Or
/ NCT03922321 688 689 I-Or
or NCT03922321 690 692 I-Or
inconstant NCT03922321 693 703 B-Modifier
or NCT03922321 704 706 B-Or
constant NCT03922321 707 715 B-Modifier
diplopia NCT03922321 716 724 B-Condition
. NCT03922321 725 726 O

5 NCT03922321 730 731 O
. NCT03922321 731 732 O
Other NCT03922321 734 739 O
, NCT03922321 740 741 O
more NCT03922321 742 746 O
specific NCT03922321 747 755 O
inclusion NCT03922321 756 765 O
criteria NCT03922321 766 774 O
are NCT03922321 775 778 O
defined NCT03922321 779 786 O
in NCT03922321 787 789 O
the NCT03922321 790 793 O
protocol NCT03922321 794 802 O

Exclusion NCT03922321 803 812 O
Criteria NCT03922321 813 821 O
: NCT03922321 822 823 O

1 NCT03922321 827 828 O
. NCT03922321 828 829 O
Use NCT03922321 831 834 O
of NCT03922321 835 837 O
any NCT03922321 838 841 O
steroid NCT03922321 842 849 B-Drug
( NCT03922321 850 851 O
intravenous NCT03922321 852 863 B-Modifier
[ NCT03922321 864 865 O
IV NCT03922321 866 868 B-Modifier
] NCT03922321 869 870 O
or NCT03922321 871 873 B-Or
oral NCT03922321 874 878 B-Modifier
) NCT03922321 879 880 O
with NCT03922321 881 885 O
a NCT03922321 886 887 O
cumulative NCT03922321 888 898 O
dose NCT03922321 899 903 O
equivalent NCT03922321 904 914 O
to NCT03922321 915 917 O
≥ NCT03922321 918 919 B-Eq-Comparison
1 NCT03922321 920 921 I-Eq-Comparison
g NCT03922321 922 923 I-Eq-Comparison
of NCT03922321 924 926 O
methylprednisolone NCT03922321 927 945 B-Drug
for NCT03922321 946 949 O
the NCT03922321 950 953 O
treatment NCT03922321 954 963 O
of NCT03922321 964 966 O
GO NCT03922321 967 969 B-Condition
within NCT03922321 970 976 B-Eq-Comparison
3 NCT03922321 977 978 I-Eq-Comparison
weeks NCT03922321 979 984 I-Eq-Comparison
prior NCT03922321 985 990 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922321 991 993 O
Screening NCT03922321 994 1003 B-Study
. NCT03922321 1004 1005 O

2 NCT03922321 1009 1010 O
. NCT03922321 1010 1011 O
Use NCT03922321 1013 1016 O
of NCT03922321 1017 1019 O
rituximab NCT03922321 1020 1029 B-Drug
, NCT03922321 1030 1031 O
tocilizumab NCT03922321 1032 1043 B-Drug
, NCT03922321 1044 1045 O
or NCT03922321 1046 1048 B-Or
any NCT03922321 1049 1052 O
monoclonal NCT03922321 1053 1063 B-Drug
antibody NCT03922321 1064 1072 I-Drug
for NCT03922321 1073 1076 O
immunomodulation NCT03922321 1077 1093 B-Condition
within NCT03922321 1094 1100 B-Eq-Comparison
the NCT03922321 1101 1104 I-Eq-Comparison
past NCT03922321 1105 1109 I-Eq-Comparison
9 NCT03922321 1110 1111 I-Eq-Comparison
months NCT03922321 1112 1118 I-Eq-Comparison
prior NCT03922321 1119 1124 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03922321 1125 1127 O
Baseline NCT03922321 1128 1136 B-Study
. NCT03922321 1137 1138 O

3 NCT03922321 1142 1143 O
. NCT03922321 1143 1144 O
Total NCT03922321 1146 1151 B-Observation
IgG NCT03922321 1152 1155 I-Observation
level NCT03922321 1156 1161 I-Observation
< NCT03922321 1162 1163 B-Eq-Comparison
6 NCT03922321 1164 1165 I-Eq-Comparison
g NCT03922321 1166 1167 I-Eq-Comparison
/ NCT03922321 1168 1169 I-Eq-Comparison
L NCT03922321 1170 1171 I-Eq-Comparison
at NCT03922321 1172 1174 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1175 1184 B-Study
. NCT03922321 1185 1186 O

4 NCT03922321 1190 1191 O
. NCT03922321 1191 1192 O
Absolute NCT03922321 1194 1202 B-Observation
neutrophil NCT03922321 1203 1213 I-Observation
count NCT03922321 1214 1219 I-Observation
< NCT03922321 1220 1221 B-Eq-Comparison
1500 NCT03922321 1222 1226 I-Eq-Comparison
cells NCT03922321 1227 1232 I-Eq-Comparison
/ NCT03922321 1233 1234 I-Eq-Comparison
mm3 NCT03922321 1235 1238 I-Eq-Comparison
at NCT03922321 1239 1241 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1242 1251 B-Study
. NCT03922321 1252 1253 O

5 NCT03922321 1257 1258 O
. NCT03922321 1258 1259 O
Participants NCT03922321 1261 1273 O
with NCT03922321 1274 1278 O
decreased NCT03922321 1279 1288 O
best NCT03922321 1289 1293 B-Condition
corrected NCT03922321 1294 1303 I-Condition
visual NCT03922321 1304 1310 I-Condition
acuity NCT03922321 1311 1317 I-Condition
due NCT03922321 1318 1321 O
to NCT03922321 1322 1324 O
optic NCT03922321 1325 1330 B-Condition
neuropathy NCT03922321 1331 1341 I-Condition
as NCT03922321 1342 1344 O
defined NCT03922321 1345 1352 O
by NCT03922321 1353 1355 O
a NCT03922321 1356 1357 O
decrease NCT03922321 1358 1366 B-Observation
in NCT03922321 1367 1369 I-Observation
vision NCT03922321 1370 1376 I-Observation
of NCT03922321 1377 1379 O
2 NCT03922321 1380 1381 B-Eq-Comparison
lines NCT03922321 1382 1387 I-Eq-Comparison
on NCT03922321 1388 1390 O
the NCT03922321 1391 1394 O
Snellen NCT03922321 1395 1402 O
chart NCT03922321 1403 1408 O
, NCT03922321 1409 1410 O
new NCT03922321 1411 1414 B-Eq-Comparison
visual NCT03922321 1415 1421 B-Condition
field NCT03922321 1422 1427 I-Condition
defect NCT03922321 1428 1434 I-Condition
, NCT03922321 1435 1436 O
or NCT03922321 1437 1439 B-Or
color NCT03922321 1440 1445 B-Condition
defect NCT03922321 1446 1452 I-Condition
secondary NCT03922321 1453 1462 O
to NCT03922321 1463 1465 O
optic NCT03922321 1466 1471 B-Condition
nerve NCT03922321 1472 1477 I-Condition
involvement NCT03922321 1478 1489 B-Modifier
within NCT03922321 1490 1496 B-Eq-Comparison
the NCT03922321 1497 1500 I-Eq-Comparison
last NCT03922321 1501 1505 I-Eq-Comparison
6 NCT03922321 1506 1507 I-Eq-Comparison
months NCT03922321 1508 1514 I-Eq-Comparison
at NCT03922321 1515 1517 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Screening NCT03922321 1518 1527 B-Study
. NCT03922321 1528 1529 O

6 NCT03922321 1533 1534 O
. NCT03922321 1534 1535 O
Previous NCT03922321 1537 1545 B-Eq-Comparison
orbital NCT03922321 1546 1553 B-Procedure
irradiation NCT03922321 1554 1565 I-Procedure
or NCT03922321 1566 1568 B-Or
surgery NCT03922321 1569 1576 B-Procedure
for NCT03922321 1577 1580 O
GO NCT03922321 1581 1583 B-Condition
. NCT03922321 1584 1585 O

7 NCT03922321 1589 1590 O
. NCT03922321 1590 1591 O
Other NCT03922321 1593 1598 O
, NCT03922321 1599 1600 O
more NCT03922321 1601 1605 O
specific NCT03922321 1606 1614 O
exclusion NCT03922321 1615 1624 O
criteria NCT03922321 1625 1633 O
are NCT03922321 1634 1637 O
defined NCT03922321 1638 1645 O
in NCT03922321 1646 1648 O
the NCT03922321 1649 1652 O
protocol NCT03922321 1653 1661 O

Inclusion NCT03926806 0 9 O
Criteria NCT03926806 10 18 O
: NCT03926806 19 20 O

- NCT03926806 24 25 O
BMI NCT03926806 27 30 B-Observation
27 NCT03926806 31 33 B-Eq-Comparison
- NCT03926806 34 35 I-Eq-Comparison
36 NCT03926806 36 38 O

- NCT03926806 42 43 O
HbA1C NCT03926806 45 50 B-Observation
< NCT03926806 51 52 B-Eq-Comparison
8.5 NCT03926806 53 56 I-Eq-Comparison
% NCT03926806 57 58 I-Eq-Comparison

- NCT03926806 62 63 O
Constant NCT03926806 65 73 O
body NCT03926806 74 78 B-Observation
weight NCT03926806 79 85 I-Observation
and NCT03926806 86 89 B-And
dietary NCT03926806 90 97 B-Observation
habits NCT03926806 98 104 I-Observation
for NCT03926806 105 108 O
the NCT03926806 109 112 O
last NCT03926806 113 117 B-Eq-Comparison
3 NCT03926806 118 119 I-Eq-Comparison
months NCT03926806 120 126 I-Eq-Comparison

- NCT03926806 129 130 O
Stable NCT03926806 132 138 O
dose NCT03926806 139 143 O
of NCT03926806 144 146 O
oral NCT03926806 147 151 B-Drug
medication NCT03926806 152 162 I-Drug
for NCT03926806 163 166 O
at NCT03926806 167 169 B-Eq-Comparison
least NCT03926806 170 175 I-Eq-Comparison
3 NCT03926806 176 177 I-Eq-Comparison
months NCT03926806 178 184 I-Eq-Comparison

- NCT03926806 187 188 O
Diagnosed NCT03926806 190 199 O
with NCT03926806 200 204 O
T2DM NCT03926806 205 209 B-Condition
for NCT03926806 210 213 O
more NCT03926806 214 218 B-Eq-Comparison
than NCT03926806 219 223 I-Eq-Comparison
1 NCT03926806 224 225 I-Eq-Comparison
year NCT03926806 226 230 I-Eq-Comparison

Exclusion NCT03926806 231 240 O
Criteria NCT03926806 241 249 O
: NCT03926806 250 251 O

- NCT03926806 255 256 O
History NCT03926806 258 265 B-Eq-Comparison
of NCT03926806 266 268 O
cardiovascular NCT03926806 269 283 B-Modifier
, NCT03926806 284 285 O
gastrointestinal NCT03926806 286 302 B-Modifier
, NCT03926806 303 304 O
renal NCT03926806 305 310 B-Modifier
and NCT03926806 311 314 B-And
endocrinological NCT03926806 315 331 B-Modifier
diseases NCT03926806 332 340 B-Condition

- NCT03926806 343 344 O
Treatment NCT03926806 346 355 O
for NCT03926806 356 359 O
weight NCT03926806 360 366 B-Condition
reduction NCT03926806 367 376 I-Condition

- NCT03926806 379 380 O
Lactose NCT03926806 382 389 B-Condition
intolerance NCT03926806 390 401 I-Condition

- NCT03926806 404 405 O
Allergies NCT03926806 407 416 B-Allergy
to NCT03926806 417 419 O
milk NCT03926806 420 424 O
and NCT03926806 425 428 B-Or
dairy NCT03926806 429 434 O
products NCT03926806 435 443 O

- NCT03926806 446 447 O
Alcohol NCT03926806 449 456 B-Observation
consumption NCT03926806 457 468 I-Observation
( NCT03926806 469 470 O
> NCT03926806 472 473 B-Eq-Comparison
2 NCT03926806 474 475 I-Eq-Comparison
drinks NCT03926806 476 482 I-Eq-Comparison
per NCT03926806 483 486 I-Eq-Comparison
day NCT03926806 487 490 I-Eq-Comparison
) NCT03926806 491 492 O

- NCT03926806 496 497 O
Intake NCT03926806 499 505 O
of NCT03926806 506 508 O
supplements NCT03926806 509 520 B-Drug

- NCT03926806 523 524 O
Receiving NCT03926806 526 535 B-Eq-Comparison
insulin NCT03926806 536 543 B-Drug

Inclusion NCT03921827 0 9 O
Criteria NCT03921827 10 18 O
: NCT03921827 19 20 O

1 NCT03921827 24 25 O
. NCT03921827 25 26 O
Patients NCT03921827 28 36 O
with NCT03921827 37 41 O
recent NCT03921827 42 48 B-Eq-Comparison
stroke NCT03921827 49 55 B-Condition
/ NCT03921827 56 57 B-Or
TIA NCT03921827 58 61 B-Condition
and NCT03921827 62 65 O
severe NCT03921827 66 72 O
stenosis NCT03921827 73 81 B-Condition
of NCT03921827 82 84 I-Condition
intracranial NCT03921827 85 97 I-Condition
ICA NCT03921827 98 101 B-Modifier
or NCT03921827 102 104 B-Or
MCA NCT03921827 105 108 B-Modifier
and NCT03921827 109 112 B-And
impaired NCT03921827 113 121 B-Condition
CVR NCT03921827 122 125 I-Condition
within NCT03921827 126 132 B-Eq-Comparison
previous NCT03921827 133 141 I-Eq-Comparison
three NCT03921827 142 147 I-Eq-Comparison
months NCT03921827 148 154 I-Eq-Comparison
but NCT03921827 155 158 B-And
not NCT03921827 159 162 B-Negation
before NCT03921827 163 169 B-Temporal-Connection___Temporal-Connection-Type-Value:before
3 NCT03921827 170 171 B-Eq-Comparison
weeks NCT03921827 172 177 I-Eq-Comparison
after NCT03921827 178 183 B-Temporal-Connection___Temporal-Connection-Type-Value:after
acute NCT03921827 184 189 O
stroke NCT03921827 190 196 B-Condition
. NCT03921827 196 197 O
This NCT03921827 199 203 O
is NCT03921827 204 206 O
to NCT03921827 207 209 O
differentiate NCT03921827 210 223 O
between NCT03921827 224 231 O
patients NCT03921827 232 240 O
with NCT03921827 241 245 O
a NCT03921827 246 247 O
long NCT03921827 248 252 B-Condition
- NCT03921827 253 254 I-Condition
standing NCT03921827 255 263 I-Condition
fixed NCT03921827 264 269 I-Condition
- NCT03921827 270 271 I-Condition
stenosis NCT03921827 272 280 I-Condition
from NCT03921827 281 285 O
patients NCT03921827 286 294 O
with NCT03921827 295 299 O
partially NCT03921827 300 309 B-Condition
recanalized NCT03921827 310 321 I-Condition
intracranial NCT03921827 322 334 I-Condition
artery NCT03921827 335 341 I-Condition
( NCT03921827 342 343 O
masquerading NCT03921827 344 356 O
as NCT03921827 357 359 O
severe NCT03921827 360 366 O
stenosis NCT03921827 367 375 B-Condition
) NCT03921827 376 377 O
. NCT03921827 379 380 O

2 NCT03921827 384 385 O
. NCT03921827 385 386 O
Age NCT03921827 388 391 B-Age
> NCT03921827 392 393 B-Eq-Comparison
21 NCT03921827 394 396 I-Eq-Comparison
years NCT03921827 397 402 I-Eq-Comparison

Exclusion NCT03921827 403 412 O
Criteria NCT03921827 413 421 O
: NCT03921827 422 423 O

1 NCT03921827 427 428 O
. NCT03921827 428 429 O
Patients NCT03921827 431 439 O
with NCT03921827 440 444 O
atrial NCT03921827 445 451 B-Condition
fibrillation NCT03921827 452 464 I-Condition
/ NCT03921827 465 466 B-Or
arrhythmias NCT03921827 467 478 B-Condition
. NCT03921827 479 480 O

2 NCT03921827 484 485 O
. NCT03921827 485 486 O
Within NCT03921827 488 494 B-Eq-Comparison
2 NCT03921827 495 496 I-Eq-Comparison
weeks NCT03921827 497 502 I-Eq-Comparison
of NCT03921827 503 505 O
cardiac NCT03921827 506 513 B-Procedure
catheterization NCT03921827 514 529 I-Procedure
or NCT03921827 530 532 B-Or
arterial NCT03921827 533 541 B-Procedure
puncture NCT03921827 542 550 I-Procedure
at NCT03921827 551 553 O
femoral NCT03921827 554 561 B-Modifier
puncture NCT03921827 562 570 I-Modifier
site NCT03921827 571 575 I-Modifier
. NCT03921827 576 577 O

3 NCT03921827 581 582 O
. NCT03921827 582 583 O
Decompensated NCT03921827 585 598 B-Modifier
heart NCT03921827 599 604 B-Condition
failure NCT03921827 605 612 I-Condition
, NCT03921827 613 614 O
usually NCT03921827 615 622 O
class NCT03921827 623 628 O
3 NCT03921827 629 630 B-Eq-Comparison
or NCT03921827 631 633 I-Eq-Comparison
4 NCT03921827 634 635 I-Eq-Comparison

4 NCT03921827 639 640 O
. NCT03921827 640 641 O
LV NCT03921827 643 645 B-Observation
EF NCT03921827 646 648 I-Observation
< NCT03921827 649 650 B-Eq-Comparison
30 NCT03921827 651 653 I-Eq-Comparison
% NCT03921827 654 655 I-Eq-Comparison

5 NCT03921827 659 660 O
. NCT03921827 660 661 O
Moderate NCT03921827 663 671 O
or NCT03921827 672 674 B-Or
severe NCT03921827 675 681 O
AR NCT03921827 682 684 B-Condition

6 NCT03921827 687 688 O
. NCT03921827 688 689 O
Persistent NCT03921827 691 701 O
and NCT03921827 702 705 B-Or
uncontrolled NCT03921827 706 718 B-Modifier
hypertension NCT03921827 719 731 B-Condition
( NCT03921827 732 733 O
BP NCT03921827 734 736 B-Observation
persistently NCT03921827 737 749 O
> NCT03921827 750 751 B-Eq-Comparison
160 NCT03921827 752 755 I-Eq-Comparison
/ NCT03921827 756 757 I-Eq-Comparison
100 NCT03921827 758 761 I-Eq-Comparison
mmHg NCT03921827 762 766 I-Eq-Comparison
) NCT03921827 767 768 O

7 NCT03921827 772 773 O
. NCT03921827 773 774 O
Bleeding NCT03921827 776 784 B-Condition
diathesis NCT03921827 785 794 I-Condition

8 NCT03921827 797 798 O
. NCT03921827 798 799 O
Active NCT03921827 801 807 B-Eq-Comparison
thrombophlebitis NCT03921827 808 824 B-Condition
/ NCT03921827 825 826 B-Or
venous NCT03921827 827 833 B-Condition
disease NCT03921827 834 841 I-Condition
of NCT03921827 842 844 O
lower NCT03921827 845 850 B-Modifier
limbs NCT03921827 851 856 I-Modifier

9 NCT03921827 859 860 O
. NCT03921827 860 861 O
Severe NCT03921827 863 869 O
lower NCT03921827 870 875 B-Modifier
extremity NCT03921827 876 885 I-Modifier
vaso NCT03921827 886 890 B-Condition
- NCT03921827 891 892 I-Condition
occlusive NCT03921827 893 902 I-Condition
disease NCT03921827 903 910 I-Condition

10 NCT03921827 912 914 O
. NCT03921827 914 915 O
Presence NCT03921827 917 925 O
of NCT03921827 926 928 O
a NCT03921827 929 930 O
documented NCT03921827 931 941 O
aortic NCT03921827 942 948 B-Condition
aneurysm NCT03921827 949 957 I-Condition
/ NCT03921827 958 959 B-Or
dissection NCT03921827 960 970 B-Procedure
requiring NCT03921827 971 980 B-Assertion___Assertion-Type-Value:hypothetical
surgical NCT03921827 981 989 B-Procedure
repair NCT03921827 990 996 I-Procedure

11 NCT03921827 998 1000 O
. NCT03921827 1000 1001 O
Pregnancy NCT03921827 1003 1012 B-Condition

Inclusion NCT03920293 0 9 O
Criteria NCT03920293 10 18 O
: NCT03920293 19 20 O

1 NCT03920293 24 25 O
. NCT03920293 25 26 O
Diagnosed NCT03920293 28 37 O
with NCT03920293 38 42 O
Myasthenia NCT03920293 43 53 B-Condition
Gravis NCT03920293 54 60 I-Condition
at NCT03920293 61 63 B-Eq-Comparison
least NCT03920293 64 69 I-Eq-Comparison
6 NCT03920293 70 71 I-Eq-Comparison
months NCT03920293 72 78 I-Eq-Comparison
( NCT03920293 79 80 O
180 NCT03920293 81 84 B-Eq-Comparison
days NCT03920293 85 89 I-Eq-Comparison
) NCT03920293 90 91 O
prior NCT03920293 92 97 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 98 100 O
the NCT03920293 101 104 O
date NCT03920293 105 109 O
of NCT03920293 110 112 O
the NCT03920293 113 116 O
Screening NCT03920293 117 126 B-Study
Visit NCT03920293 127 132 O
as NCT03920293 133 135 O
confirmed NCT03920293 136 145 O
by NCT03920293 146 148 O
specific NCT03920293 149 157 O
criteria NCT03920293 158 166 O
. NCT03920293 167 168 O

2 NCT03920293 172 173 O
. NCT03920293 173 174 O
Myasthenia NCT03920293 176 186 B-Condition
Gravis NCT03920293 187 193 I-Condition
Foundation NCT03920293 194 204 I-Condition
of NCT03920293 205 207 I-Condition
America NCT03920293 208 215 I-Condition
Clinical NCT03920293 216 224 I-Condition
Classification NCT03920293 225 239 I-Condition
Class NCT03920293 240 245 B-Eq-Comparison
II NCT03920293 246 248 I-Eq-Comparison
to NCT03920293 249 251 I-Eq-Comparison
IV NCT03920293 252 254 I-Eq-Comparison
at NCT03920293 255 257 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920293 258 267 B-Study
. NCT03920293 268 269 O

3 NCT03920293 273 274 O
. NCT03920293 274 275 O
MG NCT03920293 277 279 B-Observation
- NCT03920293 280 281 I-Observation
ADL NCT03920293 282 285 I-Observation
profile NCT03920293 286 293 O
must NCT03920293 294 298 O
be NCT03920293 299 301 O
≥ NCT03920293 302 303 B-Eq-Comparison
6 NCT03920293 304 305 I-Eq-Comparison
at NCT03920293 306 308 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03920293 309 318 B-Study
and NCT03920293 319 322 O
randomization NCT03920293 323 336 O
( NCT03920293 337 338 O
Day NCT03920293 339 342 O
1 NCT03920293 343 344 O
) NCT03920293 345 346 O
. NCT03920293 348 349 O

4 NCT03920293 353 354 O
. NCT03920293 354 355 O
Vaccinated NCT03920293 357 367 B-Immunization
against NCT03920293 368 375 O
meningococcal NCT03920293 376 389 B-Condition
infections NCT03920293 390 400 I-Condition
within NCT03920293 401 407 B-Eq-Comparison
3 NCT03920293 408 409 I-Eq-Comparison
years NCT03920293 410 415 I-Eq-Comparison
prior NCT03920293 416 421 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 422 424 I-Temporal-Connection___Temporal-Connection-Type-Value:before
, NCT03920293 425 426 O
or NCT03920293 427 429 B-Or
at NCT03920293 430 432 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03920293 433 436 O
time NCT03920293 437 441 O
of NCT03920293 442 444 O
, NCT03920293 445 446 O
initiating NCT03920293 447 457 O
study NCT03920293 458 463 B-Study
drug NCT03920293 464 468 B-Drug
to NCT03920293 469 471 O
reduce NCT03920293 472 478 O
the NCT03920293 479 482 O
risk NCT03920293 483 487 B-Risk
of NCT03920293 488 490 O
meningococcal NCT03920293 491 504 B-Modifier
infection NCT03920293 505 514 B-Condition
( NCT03920293 515 516 O
N NCT03920293 517 518 B-Organism
meningitidis NCT03920293 519 531 I-Organism
) NCT03920293 532 533 O
. NCT03920293 535 536 O

Exclusion NCT03920293 538 547 O
Criteria NCT03920293 548 556 O
: NCT03920293 557 558 O

Medical NCT03920293 560 567 B-Condition
Conditions NCT03920293 568 578 I-Condition

1 NCT03920293 581 582 O
. NCT03920293 582 583 O
Any NCT03920293 585 588 O
active NCT03920293 589 595 B-Eq-Comparison
or NCT03920293 596 598 B-Or
untreated NCT03920293 599 608 B-Modifier
thymoma NCT03920293 609 616 B-Condition
. NCT03920293 616 617 O
History NCT03920293 619 626 B-Eq-Comparison
of NCT03920293 627 629 O
thymic NCT03920293 630 636 B-Condition
carcinoma NCT03920293 637 646 I-Condition
or NCT03920293 647 649 B-Or
thymic NCT03920293 650 656 B-Condition
malignancy NCT03920293 657 667 I-Condition
unless NCT03920293 668 674 B-Exception
deemed NCT03920293 675 681 O
cured NCT03920293 682 687 O
by NCT03920293 688 690 O
adequate NCT03920293 691 699 O
treatment NCT03920293 700 709 B-Procedure
with NCT03920293 710 714 B-And
no NCT03920293 715 717 B-Negation
evidence NCT03920293 718 726 O
of NCT03920293 727 729 O
recurrence NCT03920293 730 740 B-Coreference
for NCT03920293 741 744 O
≥ NCT03920293 745 746 B-Eq-Comparison
5 NCT03920293 747 748 I-Eq-Comparison
years NCT03920293 749 754 I-Eq-Comparison
before NCT03920293 755 761 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03920293 762 771 B-Study
. NCT03920293 772 773 O

2 NCT03920293 777 778 O
. NCT03920293 778 779 O
History NCT03920293 781 788 B-Eq-Comparison
of NCT03920293 789 791 O
thymectomy NCT03920293 792 802 B-Procedure
within NCT03920293 803 809 B-Eq-Comparison
the NCT03920293 810 813 I-Eq-Comparison
12 NCT03920293 814 816 I-Eq-Comparison
months NCT03920293 817 823 I-Eq-Comparison
prior NCT03920293 824 829 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920293 830 832 O
screening NCT03920293 833 842 B-Study
. NCT03920293 843 844 O

3 NCT03920293 848 849 O
. NCT03920293 849 850 O
History NCT03920293 852 859 B-Eq-Comparison
of NCT03920293 860 862 O
N NCT03920293 863 864 B-Organism
meningitidis NCT03920293 865 877 I-Organism
infection NCT03920293 878 887 B-Condition
. NCT03920293 888 889 O

4 NCT03920293 893 894 O
. NCT03920293 894 895 O
Use NCT03920293 897 900 O
of NCT03920293 901 903 O
the NCT03920293 904 907 O
following NCT03920293 908 917 O
within NCT03920293 918 924 O
the NCT03920293 925 928 O
time NCT03920293 929 933 O
period NCT03920293 934 940 O
specified NCT03920293 941 950 O
below NCT03920293 951 956 O
: NCT03920293 957 958 O

- NCT03920293 967 968 O
IV NCT03920293 970 972 B-Drug
immunoglobulin NCT03920293 973 987 I-Drug
within NCT03920293 988 994 B-Eq-Comparison
4 NCT03920293 995 996 I-Eq-Comparison
weeks NCT03920293 997 1002 I-Eq-Comparison
of NCT03920293 1003 1005 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03920293 1006 1019 B-Study

- NCT03920293 1027 1028 O
Use NCT03920293 1030 1033 O
of NCT03920293 1034 1036 O
plasma NCT03920293 1037 1043 B-Procedure
exchange NCT03920293 1044 1052 I-Procedure
within NCT03920293 1053 1059 B-Eq-Comparison
4 NCT03920293 1060 1061 I-Eq-Comparison
weeks NCT03920293 1062 1067 I-Eq-Comparison
of NCT03920293 1068 1070 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03920293 1071 1084 B-Study

- NCT03920293 1092 1093 O
Use NCT03920293 1095 1098 O
of NCT03920293 1099 1101 O
rituximab NCT03920293 1102 1111 B-Drug
within NCT03920293 1112 1118 B-Eq-Comparison
6 NCT03920293 1119 1120 I-Eq-Comparison
months NCT03920293 1121 1127 I-Eq-Comparison
of NCT03920293 1128 1130 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03920293 1131 1140 B-Study

5 NCT03920293 1143 1144 O
. NCT03920293 1144 1145 O
Participants NCT03920293 1147 1159 O
who NCT03920293 1160 1163 O
have NCT03920293 1164 1168 O
received NCT03920293 1169 1177 O
previous NCT03920293 1178 1186 B-Eq-Comparison
treatment NCT03920293 1187 1196 B-Procedure
with NCT03920293 1197 1201 O
complement NCT03920293 1202 1212 B-Drug
inhibitors NCT03920293 1213 1223 I-Drug
( NCT03920293 1224 1225 O
for NCT03920293 1226 1229 O
example NCT03920293 1230 1237 O
, NCT03920293 1238 1239 O
eculizumab NCT03920293 1240 1250 B-Drug
) NCT03920293 1251 1252 O
. NCT03920293 1253 1254 O

Inclusion NCT03928340 0 9 O
Criteria NCT03928340 10 18 O
: NCT03928340 19 20 O

- NCT03928340 24 25 O
Diabetic NCT03928340 27 35 B-Condition
pregnant NCT03928340 36 44 B-Condition
patients NCT03928340 45 53 O
with NCT03928340 54 58 B-And
type NCT03928340 59 63 B-Condition
one NCT03928340 64 67 I-Condition
diabetes NCT03928340 68 76 I-Condition
and NCT03928340 77 80 B-And
no NCT03928340 81 83 B-Negation
other NCT03928340 84 89 B-Other
chronic NCT03928340 90 97 B-Modifier
disorders NCT03928340 98 107 B-Condition

- NCT03928340 110 111 O
Patients NCT03928340 113 121 O
on NCT03928340 122 124 B-Eq-Comparison
insulin NCT03928340 125 132 B-Drug
in NCT03928340 133 135 O
the NCT03928340 136 139 O
3 NCT03928340 140 141 B-Eq-Comparison
rd NCT03928340 142 144 I-Eq-Comparison
trimester NCT03928340 145 154 I-Eq-Comparison
of NCT03928340 155 157 O
pregnancy NCT03928340 158 167 B-Condition
( NCT03928340 168 169 O
on NCT03928340 170 172 B-Eq-Comparison
insulin NCT03928340 173 180 B-Drug
therapy NCT03928340 181 188 I-Drug
since NCT03928340 189 194 B-Temporal-Connection___Temporal-Connection-Type-Value:after
start NCT03928340 195 200 B-Eq-Comparison
of NCT03928340 201 203 O
gestation NCT03928340 204 213 B-Condition
) NCT03928340 214 215 O

- NCT03928340 219 220 O
Patients NCT03928340 222 230 O
pregnant NCT03928340 231 239 B-Condition
in NCT03928340 240 242 O
single NCT03928340 243 249 B-Modifier
living NCT03928340 250 256 I-Modifier
fetus NCT03928340 257 262 B-Family-Member___Family-Member-Type:child
with NCT03928340 263 267 O
no NCT03928340 268 270 B-Negation
apparent NCT03928340 271 279 B-Assertion___Assertion-Type-Value:possible
congenital NCT03928340 280 290 B-Condition
anomalies NCT03928340 291 300 I-Condition

- NCT03928340 303 304 O
Haemoglobin NCT03928340 306 317 B-Observation
A NCT03928340 318 319 I-Observation
1 NCT03928340 320 321 I-Observation
C NCT03928340 322 323 I-Observation
( NCT03928340 324 325 O
HbA1c NCT03928340 326 331 B-Observation
) NCT03928340 332 333 O
level NCT03928340 334 339 O
between NCT03928340 340 347 B-Eq-Comparison
7 NCT03928340 348 349 I-Eq-Comparison
% NCT03928340 350 351 I-Eq-Comparison
to NCT03928340 352 354 I-Eq-Comparison
11 NCT03928340 355 357 I-Eq-Comparison
% NCT03928340 358 359 I-Eq-Comparison

- NCT03928340 363 364 O
All NCT03928340 366 369 O
patients NCT03928340 370 378 O
have NCT03928340 379 383 O
done NCT03928340 384 388 B-Eq-Comparison
a NCT03928340 389 390 O
dating NCT03928340 391 397 O
ultrasound NCT03928340 398 408 B-Procedure
to NCT03928340 409 411 O
confirm NCT03928340 412 419 O
gestational NCT03928340 420 431 B-Observation
age NCT03928340 432 435 I-Observation
, NCT03928340 436 437 O
viability NCT03928340 438 447 O
and NCT03928340 448 451 B-And
rule NCT03928340 452 456 B-Assertion___Assertion-Type-Value:hypothetical
out NCT03928340 457 460 I-Assertion___Assertion-Type-Value:hypothetical
any NCT03928340 461 464 O
abnormality NCT03928340 465 476 B-Condition

Exclusion NCT03928340 477 486 O
Criteria NCT03928340 487 495 O
: NCT03928340 496 497 O

- NCT03928340 501 502 O
Patients NCT03928340 504 512 O
with NCT03928340 513 517 O
type NCT03928340 518 522 B-Modifier
2 NCT03928340 523 524 I-Modifier
or NCT03928340 525 527 B-Or
gestational NCT03928340 528 539 B-Modifier
diabetes NCT03928340 540 548 B-Condition

- NCT03928340 551 552 O
Patients NCT03928340 554 562 O
with NCT03928340 563 567 O
intolerance NCT03928340 568 579 B-Condition
or NCT03928340 580 582 B-Or
hypersensitivity NCT03928340 583 599 B-Condition
to NCT03928340 600 602 O
metformin NCT03928340 603 612 B-Drug

- NCT03928340 615 616 O
Patients NCT03928340 618 626 O
with NCT03928340 627 631 O
congestive NCT03928340 632 642 B-Condition
heart NCT03928340 643 648 I-Condition
failure NCT03928340 649 656 I-Condition
or NCT03928340 657 659 B-Or
a NCT03928340 660 661 O
history NCT03928340 662 669 B-Eq-Comparison
of NCT03928340 670 672 O
congestive NCT03928340 673 683 B-Condition
heart NCT03928340 684 689 I-Condition
failure NCT03928340 690 697 I-Condition

- NCT03928340 700 701 O
Patients NCT03928340 703 711 O
with NCT03928340 712 716 O
renal NCT03928340 717 722 B-Condition
insufficiency NCT03928340 723 736 I-Condition

- NCT03928340 739 740 O
Patients NCT03928340 742 750 O
having NCT03928340 751 757 O
current NCT03928340 758 765 B-Eq-Comparison
significant NCT03928340 766 777 O
gastrointestinal NCT03928340 778 794 B-Condition
problems NCT03928340 795 803 I-Condition
such NCT03928340 804 808 O
as NCT03928340 809 811 O
severe NCT03928340 812 818 O
vomiting NCT03928340 819 827 B-Condition
requiring NCT03928340 828 837 B-Assertion___Assertion-Type-Value:hypothetical
intravenous NCT03928340 838 849 B-Drug
fluids NCT03928340 850 856 I-Drug
or NCT03928340 857 859 B-Or
hospitalization NCT03928340 860 875 B-Encounter

- NCT03928340 878 879 O
Presence NCT03928340 881 889 O
of NCT03928340 890 892 O
acute NCT03928340 893 898 O
or NCT03928340 899 901 O
chronic NCT03928340 902 909 B-Modifier
metabolic NCT03928340 910 919 B-Condition
acidosis NCT03928340 920 928 I-Condition
, NCT03928340 929 930 O
including NCT03928340 931 940 O
diabetic NCT03928340 941 949 B-Condition
ketoacidosis NCT03928340 950 962 I-Condition
, NCT03928340 963 964 O
a NCT03928340 965 966 O
history NCT03928340 967 974 B-Eq-Comparison
of NCT03928340 975 977 O
diabetic NCT03928340 978 986 B-Condition
ketoacidosis NCT03928340 987 999 I-Condition
or NCT03928340 1000 1002 B-Or
history NCT03928340 1003 1010 B-Eq-Comparison
of NCT03928340 1011 1013 O
lactic NCT03928340 1014 1020 B-Condition
acidosis NCT03928340 1021 1029 I-Condition

- NCT03928340 1032 1033 O
Patients NCT03928340 1035 1043 O
with NCT03928340 1044 1048 O
liver NCT03928340 1049 1054 B-Modifier
impairment NCT03928340 1055 1065 B-Condition

- NCT03928340 1068 1069 O
Patients NCT03928340 1071 1079 O
with NCT03928340 1080 1084 O
known NCT03928340 1085 1090 O
higher NCT03928340 1091 1097 B-Modifier
order NCT03928340 1098 1103 I-Modifier
pregnancies NCT03928340 1104 1115 B-Condition
( NCT03928340 1116 1117 O
twins NCT03928340 1118 1123 B-Modifier
, NCT03928340 1124 1125 O
triplets NCT03928340 1126 1134 B-Modifier
, NCT03928340 1135 1136 O
etc NCT03928340 1137 1140 O
. NCT03928340 1140 1141 O
) NCT03928340 1142 1143 O

- NCT03928340 1147 1148 O
Patients NCT03928340 1150 1158 O
having NCT03928340 1159 1165 O
a NCT03928340 1166 1167 O
known NCT03928340 1168 1173 O
potentially NCT03928340 1174 1185 B-Assertion___Assertion-Type-Value:hypothetical
fetal NCT03928340 1186 1191 B-Condition
lethal NCT03928340 1192 1198 I-Condition
anomaly NCT03928340 1199 1206 I-Condition

Inclusion NCT03925116 0 9 O
Criteria NCT03925116 10 18 O

- NCT03925116 21 22 O
Women NCT03925116 24 29 O
at NCT03925116 30 32 O
risk NCT03925116 33 37 B-Risk
for NCT03925116 38 41 O
pregnancy NCT03925116 42 51 B-Condition

- NCT03925116 54 55 O
Women NCT03925116 57 62 O
able NCT03925116 63 67 O
to NCT03925116 68 70 O
read NCT03925116 71 75 O
and NCT03925116 76 79 O
write NCT03925116 80 85 O
in NCT03925116 86 88 O
English NCT03925116 89 96 O

Exclusion NCT03925116 97 106 O
Criteria NCT03925116 107 115 O

- NCT03925116 118 119 O
Women NCT03925116 121 126 O
who NCT03925116 127 130 B-And
have NCT03925116 131 135 O
undergone NCT03925116 136 145 B-Eq-Comparison
permanent NCT03925116 146 155 B-Procedure
sterilization NCT03925116 156 169 I-Procedure

- NCT03925116 172 173 O
Women NCT03925116 175 180 O
not NCT03925116 181 184 B-Negation
sexually NCT03925116 185 193 B-Condition
active NCT03925116 194 200 I-Condition
with NCT03925116 201 205 B-And
a NCT03925116 206 207 O
male NCT03925116 208 212 O
partner NCT03925116 213 220 B-Other

- NCT03925116 223 224 O
Women NCT03925116 226 231 O
who NCT03925116 232 235 B-And
intend NCT03925116 236 242 B-Assertion___Assertion-Type-Value:intention
to NCT03925116 243 245 I-Assertion___Assertion-Type-Value:intention
become NCT03925116 246 252 O
pregnant NCT03925116 253 261 B-Condition
in NCT03925116 262 264 O
the NCT03925116 265 268 O
next NCT03925116 269 273 B-Eq-Comparison
12 NCT03925116 274 276 I-Eq-Comparison
months NCT03925116 277 283 I-Eq-Comparison

Inclusion NCT03926351 0 9 O
Criteria NCT03926351 10 18 O
: NCT03926351 19 20 O

- NCT03926351 24 25 O
Age NCT03926351 27 30 B-Age
> NCT03926351 31 32 B-Eq-Comparison
50 NCT03926351 33 35 I-Eq-Comparison
years NCT03926351 36 41 I-Eq-Comparison

- NCT03926351 44 45 O
SCD NCT03926351 47 50 B-Condition
or NCT03926351 51 53 B-Or
MCI NCT03926351 54 57 B-Condition

- NCT03926351 60 61 O
No NCT03926351 63 65 B-Negation
evidence NCT03926351 66 74 O
of NCT03926351 75 77 O
neurodegeneration NCT03926351 78 95 B-Condition
( NCT03926351 96 97 O
i. NCT03926351 98 100 O
e. NCT03926351 101 103 O
CSF NCT03926351 105 108 B-Observation
phospho NCT03926351 109 116 I-Observation
and NCT03926351 117 120 B-Or
total NCT03926351 121 126 B-Observation
tau NCT03926351 127 130 I-Observation
- NCT03926351 131 132 I-Observation
levels NCT03926351 133 139 I-Observation
below NCT03926351 140 145 B-Eq-Comparison
cut NCT03926351 146 149 I-Eq-Comparison
- NCT03926351 150 151 I-Eq-Comparison
off NCT03926351 152 155 I-Eq-Comparison
) NCT03926351 156 157 O

- NCT03926351 161 162 O
Scandinavian NCT03926351 164 176 O
mother NCT03926351 177 183 O
tongue NCT03926351 184 190 O

- NCT03926351 193 194 O
Completed NCT03926351 196 205 O
2 NCT03926351 206 207 B-Eq-Comparison
- NCT03926351 208 209 I-Eq-Comparison
year NCT03926351 210 214 I-Eq-Comparison
follow NCT03926351 215 221 B-Encounter
- NCT03926351 222 223 I-Encounter
up NCT03926351 224 226 I-Encounter
in NCT03926351 227 229 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03926351 230 233 O
DDI NCT03926351 234 237 B-Other
- NCT03926351 238 239 O
study NCT03926351 240 245 B-Study

- NCT03926351 248 249 O
Stable NCT03926351 251 257 O
medication NCT03926351 258 268 B-Drug
for NCT03926351 269 272 O
at NCT03926351 273 275 B-Eq-Comparison
least NCT03926351 276 281 I-Eq-Comparison
3 NCT03926351 282 283 I-Eq-Comparison
months NCT03926351 284 290 I-Eq-Comparison
prior NCT03926351 291 296 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926351 297 299 O
baseline NCT03926351 300 308 B-Study
exam NCT03926351 309 313 O

Exclusion NCT03926351 314 323 O
Criteria NCT03926351 324 332 O
: NCT03926351 333 334 O

- NCT03926351 338 339 O
Dementia NCT03926351 341 349 B-Condition
( NCT03926351 350 351 O
defined NCT03926351 352 359 O
as NCT03926351 360 362 O
MMSE NCT03926351 363 367 B-Observation
< NCT03926351 368 369 B-Eq-Comparison
26 NCT03926351 370 372 I-Eq-Comparison
and NCT03926351 373 376 B-Or
/ NCT03926351 377 378 I-Eq-Comparison|Or
or NCT03926351 379 381 I-Or
CDR NCT03926351 382 385 B-Observation
> NCT03926351 386 387 O
/ NCT03926351 389 390 O
= NCT03926351 392 393 I-Eq-Comparison
1 NCT03926351 394 395 I-Eq-Comparison
) NCT03926351 396 397 O
) NCT03926351 399 400 O

- NCT03926351 404 405 O
Other NCT03926351 407 412 B-Other
dementia NCT03926351 413 421 B-Condition
giving NCT03926351 422 428 O
disease NCT03926351 429 436 O
than NCT03926351 437 441 B-Exception
AD NCT03926351 442 444 B-Condition

- NCT03926351 447 448 O
Other NCT03926351 450 455 B-Other
brain NCT03926351 456 461 B-Condition
disease NCT03926351 462 469 I-Condition

- NCT03926351 472 473 O
Significant NCT03926351 475 486 O
depression NCT03926351 487 497 B-Condition

- NCT03926351 500 501 O
Unstable NCT03926351 503 511 O
coronary NCT03926351 512 520 B-Condition
heart NCT03926351 521 526 I-Condition
disease NCT03926351 527 534 I-Condition
or NCT03926351 535 537 B-Or
heart NCT03926351 538 543 B-Condition
failure NCT03926351 544 551 I-Condition
in NCT03926351 552 554 O
need NCT03926351 555 559 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03926351 560 562 I-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03926351 563 572 B-Procedure

- NCT03926351 575 576 O
Systemic NCT03926351 578 586 B-Modifier
inflammatory NCT03926351 587 599 B-Condition
diseases NCT03926351 600 608 I-Condition

- NCT03926351 611 612 O
Somatic NCT03926351 614 621 B-Condition
disease NCT03926351 622 629 I-Condition
that NCT03926351 630 634 O
might NCT03926351 635 640 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03926351 641 647 O
cognitive NCT03926351 648 657 B-Condition
function NCT03926351 658 666 I-Condition
adversely NCT03926351 667 676 O

- NCT03926351 679 680 O
Usage NCT03926351 682 687 B-Eq-Comparison
of NCT03926351 688 690 O
anticoagulants NCT03926351 691 705 B-Drug

- NCT03926351 708 709 O
Prior NCT03926351 711 716 B-Eq-Comparison
radiation NCT03926351 717 726 B-Procedure
- NCT03926351 727 728 O
or NCT03926351 729 731 B-Or
chemo NCT03926351 732 737 B-Procedure
- NCT03926351 738 739 I-Procedure
therapy NCT03926351 740 747 I-Procedure
possibly NCT03926351 748 756 B-Assertion___Assertion-Type-Value:hypothetical
affecting NCT03926351 757 766 O
CNS NCT03926351 767 770 B-Condition

- NCT03926351 773 774 O
Relevant NCT03926351 776 784 O
cancer NCT03926351 785 791 B-Condition
or NCT03926351 792 794 O
other NCT03926351 795 800 B-Other
serious NCT03926351 801 808 O
disease NCT03926351 809 816 B-Condition
with NCT03926351 817 821 B-And
expected NCT03926351 822 830 B-Observation
survival NCT03926351 831 839 I-Observation
< NCT03926351 840 841 B-Eq-Comparison
5 NCT03926351 842 843 I-Eq-Comparison
years NCT03926351 844 849 I-Eq-Comparison

- NCT03926351 852 853 O
Fish NCT03926351 855 859 B-Drug
meal NCT03926351 860 864 I-Drug
intake NCT03926351 865 871 O
more NCT03926351 872 876 B-Eq-Comparison
than NCT03926351 877 881 I-Eq-Comparison
2 NCT03926351 882 883 I-Eq-Comparison
times NCT03926351 884 889 I-Eq-Comparison
a NCT03926351 890 891 I-Eq-Comparison
week NCT03926351 892 896 I-Eq-Comparison

- NCT03926351 899 900 O
Regularly NCT03926351 902 911 B-Eq-Comparison
intake NCT03926351 912 918 O
of NCT03926351 919 921 O
Omega NCT03926351 922 927 B-Drug
- NCT03926351 928 929 I-Drug
3 NCT03926351 930 931 I-Drug
supplements NCT03926351 932 943 I-Drug
over NCT03926351 944 948 O
the NCT03926351 949 952 O
last NCT03926351 953 957 B-Eq-Comparison
3 NCT03926351 958 959 I-Eq-Comparison
months NCT03926351 960 966 I-Eq-Comparison

Inclusion NCT03927729 0 9 O
Criteria NCT03927729 10 18 O
: NCT03927729 19 20 O

- NCT03927729 24 25 O
Conscious NCT03927729 27 36 B-Condition
patient NCT03927729 37 44 O

- NCT03927729 47 48 O
Age NCT03927729 50 53 B-Age
≥ NCT03927729 54 55 B-Eq-Comparison
18 NCT03927729 56 58 I-Eq-Comparison
years NCT03927729 59 64 I-Eq-Comparison

- NCT03927729 67 68 O
Acute NCT03927729 70 75 O
pain NCT03927729 76 80 B-Condition
of NCT03927729 81 83 O
monotraumatic NCT03927729 84 97 B-Modifier
origin NCT03927729 98 104 I-Modifier

- NCT03927729 107 108 O
Pain NCT03927729 110 114 B-Observation
> NCT03927729 115 116 B-Eq-Comparison
4 NCT03927729 117 118 I-Eq-Comparison
on NCT03927729 119 121 O
a NCT03927729 122 123 O
visual NCT03927729 124 130 O
numerical NCT03927729 131 140 O
scale NCT03927729 141 146 O

Exclusion NCT03927729 147 156 O
Criteria NCT03927729 157 165 O
: NCT03927729 166 167 O

- NCT03927729 171 172 O
State NCT03927729 174 179 B-Condition
of NCT03927729 180 182 I-Condition
shock NCT03927729 183 188 I-Condition
with NCT03927729 189 193 B-And
unstable NCT03927729 194 202 O
hemodynamics NCT03927729 203 215 B-Condition
( NCT03927729 216 217 O
PA NCT03927729 218 220 B-Observation
< NCT03927729 221 222 B-Eq-Comparison
90 NCT03927729 223 225 I-Eq-Comparison
/ NCT03927729 226 227 O
60 NCT03927729 228 230 O
) NCT03927729 231 232 O

- NCT03927729 236 237 O
Suspected NCT03927729 239 248 B-Assertion___Assertion-Type-Value:possible
or NCT03927729 249 251 O
proven NCT03927729 252 258 O
trauma NCT03927729 259 265 B-Condition
to NCT03927729 266 268 O
the NCT03927729 269 272 O
chest NCT03927729 273 278 B-Modifier
, NCT03927729 279 280 O
abdomen NCT03927729 281 288 B-Modifier
or NCT03927729 289 291 B-Or
pelvis NCT03927729 292 298 B-Modifier

- NCT03927729 301 302 O
Serious NCT03927729 304 311 O
head NCT03927729 312 316 O
trauma NCT03927729 317 323 O

- NCT03927729 326 327 O
Consciousness NCT03927729 329 342 B-Condition
disorder NCT03927729 343 351 I-Condition
with NCT03927729 352 356 B-And
Glasgow NCT03927729 357 364 B-Observation
score NCT03927729 365 370 I-Observation
< NCT03927729 371 372 B-Eq-Comparison
15 NCT03927729 373 375 I-Eq-Comparison

- NCT03927729 379 380 O
Patient NCT03927729 382 389 O
who NCT03927729 390 393 O
has NCT03927729 394 397 O
already NCT03927729 398 405 O
received NCT03927729 406 414 B-Eq-Comparison
analgesics NCT03927729 415 425 B-Drug
( NCT03927729 426 427 O
with NCT03927729 428 432 O
the NCT03927729 433 436 O
exception NCT03927729 437 446 B-Exception
of NCT03927729 447 449 O
paracetamol NCT03927729 450 461 B-Drug
) NCT03927729 462 463 O

- NCT03927729 467 468 O
Patient NCT03927729 470 477 O
receiving NCT03927729 478 487 B-Eq-Comparison
an NCT03927729 488 490 O
intravenous NCT03927729 491 502 B-Modifier
approach NCT03927729 503 511 O
for NCT03927729 512 515 O
analgesia NCT03927729 516 525 B-Drug

- NCT03927729 528 529 O
Renal NCT03927729 531 536 B-Modifier
or NCT03927729 537 539 B-Or
hepatic NCT03927729 540 547 B-Modifier
disorders NCT03927729 548 557 B-Condition
known NCT03927729 558 563 O

- NCT03927729 566 567 O
Hypersensitivity NCT03927729 569 585 B-Condition
to NCT03927729 586 588 O
fluoridated NCT03927729 589 600 B-Modifier
anesthetics NCT03927729 601 612 I-Modifier
or NCT03927729 613 615 O
history NCT03927729 616 623 B-Eq-Comparison
of NCT03927729 624 626 O
malignant NCT03927729 627 636 B-Condition
hyperthermia NCT03927729 637 649 I-Condition
in NCT03927729 650 652 O
the NCT03927729 653 656 O
patient NCT03927729 657 664 B-Family-Member___Family-Member-Type:patient
or NCT03927729 665 667 B-Or
family NCT03927729 668 674 B-Family-Member

- NCT03927729 677 678 O
Pregnant NCT03927729 680 688 B-Condition
or NCT03927729 689 691 B-Or
nursing NCT03927729 692 699 B-Condition
woman NCT03927729 700 705 O

- NCT03927729 708 709 O
Patient NCT03927729 711 718 O
under NCT03927729 719 724 O
judicial NCT03927729 725 733 B-Observation
protection NCT03927729 734 744 I-Observation

- NCT03927729 747 748 O
Non NCT03927729 750 753 B-Condition
communicating NCT03927729 754 767 I-Condition
patient NCT03927729 768 775 O
or NCT03927729 776 778 B-Or
with NCT03927729 779 783 O
difficulties NCT03927729 784 796 B-Condition
of NCT03927729 797 799 I-Condition
understanding NCT03927729 800 813 I-Condition

Exclusion NCT03927729 814 823 O
Criteria NCT03927729 824 832 O
: NCT03927729 833 834 O

- NCT03927729 838 839 O
Intravenous NCT03927729 841 852 B-Modifier
injection NCT03927729 853 862 I-Modifier
for NCT03927729 863 866 O
analgesia NCT03927729 867 876 B-Drug

Inclusion NCT03920046 0 9 O
Criteria NCT03920046 10 18 O
: NCT03920046 19 20 O

- NCT03920046 24 25 O
ASA NCT03920046 27 30 B-Condition
( NCT03920046 31 32 O
American NCT03920046 33 41 B-Condition
Society NCT03920046 42 49 I-Condition
of NCT03920046 50 52 I-Condition
Anesthesiologists NCT03920046 53 70 I-Condition
) NCT03920046 71 72 O
I NCT03920046 73 74 B-Eq-Comparison
- NCT03920046 75 76 I-Eq-Comparison
ASA NCT03920046 77 80 I-Eq-Comparison
II NCT03920046 81 83 I-Eq-Comparison
patients NCT03920046 84 92 O

- NCT03920046 95 96 O
Aged NCT03920046 98 102 B-Age
1 NCT03920046 103 104 B-Eq-Comparison
- NCT03920046 105 106 I-Eq-Comparison
18 NCT03920046 107 109 I-Eq-Comparison
Year NCT03920046 110 114 I-Eq-Comparison
old NCT03920046 115 118 O
patients NCT03920046 119 127 O

Exclusion NCT03920046 128 137 O
Criteria NCT03920046 138 146 O
: NCT03920046 147 148 O

- NCT03920046 152 153 O
Smoker NCT03920046 155 161 B-Condition
patients NCT03920046 162 170 O

Inclusion NCT03920085 0 9 O
Criteria NCT03920085 10 18 O
: NCT03920085 19 20 O

- NCT03920085 24 25 O
Participants NCT03920085 27 39 O
must NCT03920085 40 44 O
be NCT03920085 45 47 O
enrolled NCT03920085 48 56 O
in NCT03920085 57 59 O
LifeScan NCT03920085 60 68 O
Patient NCT03920085 69 76 O
Registry NCT03920085 77 85 O
. NCT03920085 86 87 O

- NCT03920085 91 92 O
Participants NCT03920085 94 106 O
must NCT03920085 107 111 O
have NCT03920085 112 116 O
read NCT03920085 117 121 O
the NCT03920085 122 125 O
Information NCT03920085 126 137 O
sheet NCT03920085 138 143 O
and NCT03920085 144 147 O
signed NCT03920085 148 154 O
an NCT03920085 155 157 O
informedconsent NCT03920085 158 173 O
form NCT03920085 174 178 O
> NCT03920085 179 180 O
prior NCT03920085 181 186 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03920085 187 189 O
study NCT03920085 190 195 B-Study
participation NCT03920085 196 209 O
. NCT03920085 210 211 O

- NCT03920085 215 216 O
Participants NCT03920085 218 230 O
must NCT03920085 231 235 O
be NCT03920085 236 238 O
16 NCT03920085 239 241 B-Eq-Comparison
years NCT03920085 242 247 I-Eq-Comparison
or NCT03920085 248 250 I-Eq-Comparison
older NCT03920085 251 256 I-Age|Eq-Comparison
. NCT03920085 257 258 O

- NCT03920085 262 263 O
Participants NCT03920085 265 277 O
must NCT03920085 278 282 O
be NCT03920085 283 285 O
diagnosed NCT03920085 286 295 O
with NCT03920085 296 300 O
Diabetes NCT03920085 301 309 B-Condition

Exclusion NCT03920085 310 319 O
Criteria NCT03920085 320 328 O
: NCT03920085 329 330 O

> NCT03920085 333 334 O
Participants NCT03920085 335 347 O
not NCT03920085 348 351 O
enrolled NCT03920085 352 360 O
in NCT03920085 361 363 O
the NCT03920085 364 367 O
LifeScan NCT03920085 368 376 O
Patient NCT03920085 377 384 O
Registry NCT03920085 385 393 O

Inclusion NCT03928223 0 9 O
Criteria NCT03928223 10 18 O
: NCT03928223 19 20 O

- NCT03928223 24 25 O
Dermatology NCT03928223 27 38 B-Provider
in NCT03928223 39 41 B-Encounter
- NCT03928223 42 43 O
and NCT03928223 44 47 B-Or
outpatients NCT03928223 48 59 B-Encounter
with NCT03928223 60 64 B-And
itch NCT03928223 65 69 B-Condition

Exclusion NCT03928223 70 79 O
Criteria NCT03928223 80 88 O
: NCT03928223 89 90 O

- NCT03928223 94 95 O
color NCT03928223 97 102 B-Condition
blindness NCT03928223 103 112 I-Condition

- NCT03928223 115 116 O
lack NCT03928223 118 122 O
of NCT03928223 123 125 O
time NCT03928223 126 130 O

- NCT03928223 133 134 O
lack NCT03928223 136 140 O
of NCT03928223 141 143 O
German NCT03928223 144 150 O
language NCT03928223 151 159 O
. NCT03928223 159 160 O

Inclusion NCT03924141 0 9 O
Criteria NCT03924141 10 18 O
: NCT03924141 19 20 O

- NCT03924141 24 25 O
Third NCT03924141 27 32 O
year NCT03924141 33 37 O
nursing NCT03924141 38 45 O
student NCT03924141 46 53 O

Exclusion NCT03924141 54 63 O
Criteria NCT03924141 64 72 O
: NCT03924141 73 74 O

- NCT03924141 78 79 O
Has NCT03924141 81 84 O
to NCT03924141 85 87 O
talk NCT03924141 88 92 O
and NCT03924141 93 96 O
understand NCT03924141 97 107 O
Norwegian NCT03924141 108 117 O

Inclusion NCT03922256 0 9 O

- NCT03922256 12 13 O
Age NCT03922256 15 18 B-Age
> NCT03922256 19 20 B-Eq-Comparison
18 NCT03922256 21 23 I-Eq-Comparison
years NCT03922256 24 29 I-Eq-Comparison
; NCT03922256 29 30 O

- NCT03922256 33 34 O
Unilateral NCT03922256 36 46 B-Modifier
fracture NCT03922256 47 55 B-Condition
of NCT03922256 56 58 O
distal NCT03922256 59 65 B-Modifier
radius NCT03922256 66 72 I-Modifier
without NCT03922256 73 80 I-Modifier
misalignment NCT03922256 81 93 I-Modifier
( NCT03922256 94 95 O
dorsal NCT03922256 96 102 B-Observation
angulation NCT03922256 103 113 I-Observation
< NCT03922256 114 115 B-Eq-Comparison
10 NCT03922256 116 118 I-Eq-Comparison
° NCT03922256 119 120 I-Eq-Comparison
, NCT03922256 121 122 O
axial NCT03922256 123 128 B-Observation
radial NCT03922256 129 135 I-Observation
shortening NCT03922256 136 146 I-Observation
< NCT03922256 147 148 B-Eq-Comparison
5 NCT03922256 149 150 I-Eq-Comparison
mm NCT03922256 151 153 I-Eq-Comparison
) NCT03922256 154 155 O
, NCT03922256 157 158 O
< NCT03922256 159 160 B-Eq-Comparison
2 NCT03922256 161 162 I-Eq-Comparison
mm NCT03922256 163 165 I-Eq-Comparison
intraarticular NCT03922256 166 180 B-Observation
stepoff NCT03922256 181 188 I-Observation
; NCT03922256 188 189 O

- NCT03922256 192 193 O
Independent NCT03922256 195 206 B-Condition
in NCT03922256 207 209 O
activities NCT03922256 210 220 O
of NCT03922256 221 223 O
daily NCT03922256 224 229 O
living NCT03922256 230 236 O
; NCT03922256 236 237 O

- NCT03922256 240 241 O
Capable NCT03922256 243 250 O
and NCT03922256 251 254 O
willing NCT03922256 255 262 O
of NCT03922256 263 265 O
signing NCT03922256 266 273 O
informed NCT03922256 274 282 O
consent NCT03922256 283 290 O
. NCT03922256 291 292 O

Exclusion NCT03922256 294 303 O

- NCT03922256 306 307 O
Children NCT03922256 309 317 O
under NCT03922256 318 323 B-Eq-Comparison
the NCT03922256 324 327 I-Eq-Comparison
age NCT03922256 328 331 I-Eq-Comparison
of NCT03922256 332 334 I-Eq-Comparison
18 NCT03922256 335 337 I-Eq-Comparison
; NCT03922256 338 339 O

- NCT03922256 342 343 O
Fracture NCT03922256 345 353 B-Condition
of NCT03922256 354 356 O
the NCT03922256 357 360 O
contralateral NCT03922256 361 374 B-Modifier
arm NCT03922256 375 378 I-Modifier
; NCT03922256 378 379 O

- NCT03922256 382 383 O
Other NCT03922256 385 390 O
fractures NCT03922256 391 400 B-Condition
of NCT03922256 401 403 O
the NCT03922256 404 407 O
ipsilateral NCT03922256 408 419 B-Modifier
arm NCT03922256 420 423 I-Modifier
; NCT03922256 423 424 O

- NCT03922256 427 428 O
Open NCT03922256 430 434 B-Modifier
fractures NCT03922256 435 444 B-Condition
; NCT03922256 444 445 O

- NCT03922256 448 449 O
Fractures NCT03922256 451 460 B-Condition
that NCT03922256 461 465 O
require NCT03922256 466 473 B-Assertion___Assertion-Type-Value:hypothetical
reduction NCT03922256 474 483 B-Procedure
. NCT03922256 483 484 O

Inclusion NCT03929471 0 9 O
Criteria NCT03929471 10 18 O
: NCT03929471 19 20 O

- NCT03929471 24 25 O
Adult NCT03929471 27 32 O
( NCT03929471 33 34 O
> NCT03929471 36 37 B-Eq-Comparison
18 NCT03929471 38 40 I-Eq-Comparison
years NCT03929471 41 46 I-Eq-Comparison
old NCT03929471 47 50 B-Age
) NCT03929471 51 52 O
outpatients NCT03929471 53 64 B-Encounter
on NCT03929471 65 67 B-Eq-Comparison
3 NCT03929471 68 69 B-Eq-Comparison
- NCT03929471 70 71 I-Eq-Comparison
4 NCT03929471 72 73 I-Eq-Comparison
times NCT03929471 74 79 I-Eq-Comparison
per NCT03929471 80 83 I-Eq-Comparison
week NCT03929471 84 88 I-Eq-Comparison
HD NCT03929471 89 91 B-Procedure
sessions NCT03929471 92 100 O
for NCT03929471 101 104 O
at NCT03929471 105 107 B-Eq-Comparison
least NCT03929471 108 113 I-Eq-Comparison
6 NCT03929471 114 115 I-Eq-Comparison
weeks NCT03929471 116 121 I-Eq-Comparison
with NCT03929471 122 126 B-And
a NCT03929471 127 128 O
life NCT03929471 129 133 B-Observation
expectancy NCT03929471 134 144 I-Observation
> NCT03929471 145 146 B-Eq-Comparison
6 NCT03929471 147 148 I-Eq-Comparison
months NCT03929471 149 155 I-Eq-Comparison
. NCT03929471 156 157 O

- NCT03929471 161 162 O
Fluid NCT03929471 164 169 B-Observation
overload NCT03929471 170 178 I-Observation
≥ NCT03929471 179 180 B-Eq-Comparison
1.1 NCT03929471 181 184 I-Eq-Comparison
L NCT03929471 185 186 I-Eq-Comparison
. NCT03929471 187 188 O

- NCT03929471 192 193 O
Medically NCT03929471 195 204 B-Condition
stable NCT03929471 205 211 O
patient NCT03929471 212 219 O
. NCT03929471 220 221 O

- NCT03929471 225 226 O
Minimum NCT03929471 228 235 B-Eq-Comparison
of NCT03929471 236 238 I-Eq-Comparison
3 NCT03929471 239 240 I-Eq-Comparison
hours NCT03929471 241 246 I-Eq-Comparison
of NCT03929471 247 249 O
dialysis NCT03929471 250 258 B-Procedure
per NCT03929471 259 262 O
session NCT03929471 263 270 B-Coreference
. NCT03929471 271 272 O

Exclusion NCT03929471 274 283 O
Criteria NCT03929471 284 292 O
: NCT03929471 293 294 O

- NCT03929471 298 299 O
Pregnancy NCT03929471 301 310 B-Condition
or NCT03929471 311 313 B-Or
lactation NCT03929471 314 323 B-Condition
. NCT03929471 324 325 O

- NCT03929471 329 330 O
Declined NCT03929471 332 340 O
informed NCT03929471 341 349 O
consent NCT03929471 350 357 O
. NCT03929471 358 359 O

- NCT03929471 368 369 O
Patients NCT03929471 371 379 O
with NCT03929471 380 384 O
cognitive NCT03929471 385 394 B-Condition
dysfunction NCT03929471 395 406 I-Condition
. NCT03929471 407 408 O

- NCT03929471 417 418 O
Severe NCT03929471 420 426 O
life NCT03929471 427 431 B-Modifier
- NCT03929471 432 433 I-Modifier
limiting NCT03929471 434 442 I-Modifier
Comorbidities NCT03929471 443 456 B-Condition
( NCT03929471 457 458 O
malignant NCT03929471 459 468 B-Condition
tumour NCT03929471 469 475 I-Condition
, NCT03929471 476 477 O
tuberculosis NCT03929471 478 490 B-Condition
, NCT03929471 491 492 O
. NCT03929471 493 494 O
. NCT03929471 495 496 O
. NCT03929471 497 498 O
. NCT03929471 499 500 O
) NCT03929471 501 502 O

- NCT03929471 511 512 O
Surgery NCT03929471 514 521 B-Procedure
within NCT03929471 522 528 B-Eq-Comparison
six NCT03929471 529 532 I-Eq-Comparison
weeks NCT03929471 533 538 I-Eq-Comparison
of NCT03929471 539 541 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03929471 542 545 O
study NCT03929471 546 551 B-Study
. NCT03929471 552 553 O

- NCT03929471 562 563 O
Nocturnal NCT03929471 565 574 B-Modifier
dialysis NCT03929471 575 583 B-Procedure
patients NCT03929471 584 592 O
. NCT03929471 593 594 O

- NCT03929471 603 604 O
Patients NCT03929471 606 614 O
expected NCT03929471 615 623 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03929471 624 626 O
receive NCT03929471 627 634 O
a NCT03929471 635 636 O
transplant NCT03929471 637 647 B-Procedure
or NCT03929471 648 650 B-Or
move NCT03929471 651 655 B-Observation
to NCT03929471 656 658 O
another NCT03929471 659 666 B-Other
center NCT03929471 667 673 O
within NCT03929471 674 680 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929471 681 684 I-Temporal-Connection___Temporal-Connection-Type-Value:during
duration NCT03929471 685 693 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03929471 694 696 O
the NCT03929471 697 700 O
study NCT03929471 701 706 B-Study
. NCT03929471 707 708 O

- NCT03929471 717 718 O
Patients NCT03929471 720 728 O
with NCT03929471 729 733 O
arteriovenous NCT03929471 734 747 B-Condition
fistula NCT03929471 748 755 I-Condition
issues NCT03929471 756 762 O
. NCT03929471 762 763 O

Inclusion NCT03922295 0 9 O
Criteria NCT03922295 10 18 O
: NCT03922295 19 20 O

- NCT03922295 24 25 O
Patients NCT03922295 27 35 O
with NCT03922295 36 40 O
chronic NCT03922295 41 48 B-Condition
suppurative NCT03922295 49 60 I-Condition
otitis NCT03922295 61 67 I-Condition
media NCT03922295 68 73 I-Condition
with NCT03922295 74 78 B-And
total NCT03922295 79 84 B-Modifier
or NCT03922295 85 87 B-Or
subtotal NCT03922295 88 96 B-Modifier
tympanic NCT03922295 97 105 B-Condition
membrane NCT03922295 106 114 I-Condition
perforation NCT03922295 115 126 I-Condition
with NCT03922295 127 131 B-And
limited NCT03922295 132 139 B-Condition
anterior NCT03922295 140 148 I-Condition
remnant NCT03922295 149 156 I-Condition
. NCT03922295 157 158 O

- NCT03922295 162 163 O
dry NCT03922295 165 168 B-Condition
perforation NCT03922295 169 180 I-Condition
for NCT03922295 181 184 O
at NCT03922295 185 187 B-Eq-Comparison
least NCT03922295 188 193 I-Eq-Comparison
3 NCT03922295 194 195 I-Eq-Comparison
months NCT03922295 196 202 I-Eq-Comparison
. NCT03922295 203 204 O

Exclusion NCT03922295 206 215 O
Criteria NCT03922295 216 224 O
: NCT03922295 225 226 O

- NCT03922295 230 231 O
Recurrent NCT03922295 233 242 B-Condition
perforation NCT03922295 243 254 I-Condition
after NCT03922295 255 260 B-Temporal-Connection___Temporal-Connection-Type-Value:during
previous NCT03922295 261 269 B-Eq-Comparison
myringoplasty NCT03922295 270 283 B-Procedure
. NCT03922295 284 285 O

- NCT03922295 289 290 O
Ossicular NCT03922295 292 301 B-Procedure
disruption NCT03922295 302 312 B-Modifier
or NCT03922295 313 315 B-Or
fixation NCT03922295 316 324 B-Modifier
. NCT03922295 325 326 O

- NCT03922295 330 331 O
immune NCT03922295 333 339 B-Condition
- NCT03922295 340 341 I-Condition
compromised NCT03922295 342 353 I-Condition
patients NCT03922295 354 362 O
including NCT03922295 363 372 O
uncontrolled NCT03922295 373 385 B-Modifier
diabetics NCT03922295 386 395 B-Condition
, NCT03922295 396 397 O
chronic NCT03922295 398 405 B-Modifier
liver NCT03922295 406 411 I-Modifier
and NCT03922295 412 415 B-Or
kidney NCT03922295 416 422 B-Modifier
diseases NCT03922295 423 431 B-Condition
. NCT03922295 431 432 O

Inclusion NCT03921944 0 9 O
Criteria NCT03921944 10 18 O
: NCT03921944 19 20 O

- NCT03921944 24 25 O
age NCT03921944 27 30 B-Age
> NCT03921944 31 32 B-Eq-Comparison
45 NCT03921944 33 35 I-Eq-Comparison
yrs NCT03921944 36 39 I-Eq-Comparison

- NCT03921944 42 43 O
primary NCT03921944 45 52 B-Modifier
diagnosis NCT03921944 53 62 O
of NCT03921944 63 65 O
osteoarthritis NCT03921944 66 80 B-Condition
of NCT03921944 81 83 O
the NCT03921944 84 87 O
shoulder NCT03921944 88 96 B-Modifier

- NCT03921944 99 100 O
total NCT03921944 102 107 B-Procedure
shoulder NCT03921944 108 116 I-Procedure
replacement NCT03921944 117 128 I-Procedure
performed NCT03921944 129 138 O
by NCT03921944 139 141 O
Dr. NCT03921944 142 145 B-Provider
Armstrong NCT03921944 147 156 I-Provider

- NCT03921944 159 160 O
administered NCT03921944 162 174 B-Eq-Comparison
a NCT03921944 175 176 O
local NCT03921944 177 182 B-Procedure
anesthetic NCT03921944 183 193 I-Procedure
mixture NCT03921944 194 201 O
and NCT03921944 202 205 B-And
not NCT03921944 206 209 B-Negation
regional NCT03921944 210 218 B-Procedure
anesthesia NCT03921944 219 229 I-Procedure

- NCT03921944 232 233 O
all NCT03921944 235 238 O
genders NCT03921944 239 246 O

- NCT03921944 249 250 O
Fluent NCT03921944 252 258 O
in NCT03921944 259 261 O
written NCT03921944 262 269 O
and NCT03921944 270 273 O
spoken NCT03921944 274 280 O
English NCT03921944 281 288 O

- NCT03921944 291 292 O
Patients NCT03921944 294 302 O
capable NCT03921944 303 310 O
of NCT03921944 311 313 O
giving NCT03921944 314 320 O
informed NCT03921944 321 329 O
consent NCT03921944 330 337 O

Exclusion NCT03921944 338 347 O
Criteria NCT03921944 348 356 O
: NCT03921944 357 358 O

- NCT03921944 362 363 O
Known NCT03921944 365 370 O
contraindications NCT03921944 371 388 B-Contraindication
to NCT03921944 389 391 O
CT NCT03921944 392 394 B-Procedure
/ NCT03921944 395 396 B-Or
EMG NCT03921944 397 400 B-Procedure

- NCT03921944 403 404 O
Inability NCT03921944 406 415 O
to NCT03921944 416 418 O
provide NCT03921944 419 426 O
informed NCT03921944 427 435 O
consent NCT03921944 436 443 O

- NCT03921944 446 447 O
History NCT03921944 449 456 B-Eq-Comparison
of NCT03921944 457 459 O
recent NCT03921944 460 466 B-Eq-Comparison
trauma NCT03921944 467 473 B-Condition
to NCT03921944 474 476 O
the NCT03921944 477 480 O
shoulder NCT03921944 481 489 B-Modifier

- NCT03921944 492 493 O
Atypical NCT03921944 495 503 B-Modifier
shoulder NCT03921944 504 512 I-Modifier
pain NCT03921944 513 517 B-Condition

- NCT03921944 520 521 O
Other NCT03921944 523 528 O
suspected NCT03921944 529 538 B-Assertion___Assertion-Type-Value:possible
shoulder NCT03921944 539 547 B-Modifier
pathology NCT03921944 548 557 B-Condition
( NCT03921944 558 559 O
i. NCT03921944 560 562 O
e. NCT03921944 563 565 O
tumor NCT03921944 567 572 B-Condition
, NCT03921944 573 574 O
infection NCT03921944 575 584 B-Condition
) NCT03921944 585 586 O

- NCT03921944 590 591 O
Pregnancy NCT03921944 593 602 B-Condition

- NCT03921944 605 606 O
Bilateral NCT03921944 608 617 B-Modifier
total NCT03921944 618 623 B-Procedure
shoulder NCT03921944 624 632 I-Procedure
arthroplasty NCT03921944 633 645 I-Procedure

Inclusion NCT03921788 0 9 O
Criteria NCT03921788 10 18 O
: NCT03921788 19 20 O

- NCT03921788 24 25 O
The NCT03921788 27 30 O
reproductive NCT03921788 31 43 B-Observation
age NCT03921788 44 47 I-Observation
of NCT03921788 48 50 O
the NCT03921788 51 54 O
woman NCT03921788 55 60 O

- NCT03921788 63 64 O
Blood NCT03921788 66 71 B-Condition
reflux NCT03921788 72 78 I-Condition
in NCT03921788 79 81 O
the NCT03921788 82 85 O
parametric NCT03921788 86 96 B-Modifier
, NCT03921788 97 98 O
uterine NCT03921788 99 106 B-Modifier
, NCT03921788 107 108 O
gonadal NCT03921788 109 116 B-Modifier
veins NCT03921788 117 122 I-Modifier

- NCT03921788 125 126 O
The NCT03921788 128 131 O
absence NCT03921788 132 139 B-Negation
of NCT03921788 140 142 O
any NCT03921788 143 146 O
concomitant NCT03921788 147 158 O
pathology NCT03921788 159 168 B-Condition
, NCT03921788 169 170 O
accompanied NCT03921788 171 182 B-And
by NCT03921788 183 185 O
chronic NCT03921788 186 193 B-Modifier
pelvic NCT03921788 194 200 B-Condition
pain NCT03921788 201 205 I-Condition

Exclusion NCT03921788 206 215 O
Criteria NCT03921788 216 224 O
: NCT03921788 225 226 O

- NCT03921788 230 231 O
The NCT03921788 233 236 O
absence NCT03921788 237 244 B-Negation
of NCT03921788 245 247 O
blood NCT03921788 248 253 B-Condition
reflux NCT03921788 254 260 I-Condition
in NCT03921788 261 263 O
in NCT03921788 264 266 O
the NCT03921788 267 270 O
parametric NCT03921788 271 281 B-Modifier
, NCT03921788 282 283 O
uterine NCT03921788 284 291 B-Modifier
, NCT03921788 292 293 O
gonadal NCT03921788 294 301 B-Modifier
veins NCT03921788 302 307 I-Modifier

- NCT03921788 310 311 O
The NCT03921788 313 316 O
presence NCT03921788 317 325 O
of NCT03921788 326 328 O
diseases NCT03921788 329 337 B-Condition
, NCT03921788 338 339 O
the NCT03921788 340 343 O
clinical NCT03921788 344 352 O
course NCT03921788 353 359 O
of NCT03921788 360 362 O
which NCT03921788 363 368 O
suggests NCT03921788 369 377 B-Assertion___Assertion-Type-Value:possible
the NCT03921788 378 381 O
presence NCT03921788 382 390 O
of NCT03921788 391 393 O
chronic NCT03921788 394 401 B-Modifier
pelvic NCT03921788 402 408 B-Condition
pain NCT03921788 409 413 I-Condition
and NCT03921788 414 417 B-And
other NCT03921788 418 423 O
varieties NCT03921788 424 433 O
of NCT03921788 434 436 O
chronic NCT03921788 437 444 B-Modifier
pain NCT03921788 445 449 B-Condition
, NCT03921788 450 451 O
including NCT03921788 452 461 O
migraine NCT03921788 462 470 B-Condition

- NCT03921788 473 474 O
Pregnancy NCT03921788 476 485 B-Condition

Inclusion NCT03929263 0 9 O
Criteria NCT03929263 10 18 O
: NCT03929263 19 20 O

- NCT03929263 24 25 O
Eligible NCT03929263 27 35 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03929263 36 39 O
fMRI NCT03929263 40 44 B-Procedure

- NCT03929263 47 48 O
Sufficient NCT03929263 50 60 O
English NCT03929263 61 68 O
fluency NCT03929263 69 76 O
to NCT03929263 77 79 O
complete NCT03929263 80 88 O
tasks NCT03929263 89 94 O

- NCT03929263 97 98 O
BMI NCT03929263 100 103 B-Observation
≦ NCT03929263 104 105 B-Eq-Comparison
40.0 NCT03929263 106 110 I-Eq-Comparison

- NCT03929263 114 115 O
Right NCT03929263 117 122 B-Condition
- NCT03929263 123 124 I-Condition
handed NCT03929263 125 131 I-Condition

- NCT03929263 134 135 O
Biological NCT03929263 137 147 B-Modifier
female NCT03929263 148 154 O

- NCT03929263 157 158 O
Co NCT03929263 160 162 B-Observation
- NCT03929263 163 164 I-Observation
residing NCT03929263 165 173 I-Observation
at NCT03929263 174 176 B-Eq-Comparison
least NCT03929263 177 182 I-Eq-Comparison
4 NCT03929263 183 184 I-Eq-Comparison
days NCT03929263 185 189 I-Eq-Comparison
/ NCT03929263 190 191 I-Eq-Comparison
week NCT03929263 192 196 I-Eq-Comparison

- NCT03929263 199 200 O
Adult NCT03929263 202 207 O
participants NCT03929263 208 220 O
: NCT03929263 221 222 O
Biological NCT03929263 223 233 O
mother NCT03929263 234 240 B-Family-Member___Family-Member-Type:mother
of NCT03929263 241 243 O
adolescent NCT03929263 244 254 O
participant NCT03929263 255 266 O

- NCT03929263 269 270 O
Adult NCT03929263 272 277 O
participants NCT03929263 278 290 O
: NCT03929263 291 292 O
Primary NCT03929263 293 300 B-Family-Member___Family-Member-Type:parent
caregiver NCT03929263 301 310 I-Family-Member___Family-Member-Type:parent
> NCT03929263 311 312 B-Eq-Comparison
50 NCT03929263 313 315 I-Eq-Comparison
% NCT03929263 316 317 I-Eq-Comparison
of NCT03929263 318 320 O
child NCT03929263 321 326 B-Family-Member___Family-Member-Type:child
's NCT03929263 326 328 O
lifespan NCT03929263 329 337 B-Observation

- NCT03929263 340 341 O
Adult NCT03929263 343 348 O
participants NCT03929263 349 361 O
: NCT03929263 362 363 O
BMI NCT03929263 364 367 B-Observation
≧ NCT03929263 368 369 B-Eq-Comparison
18.0 NCT03929263 370 374 I-Eq-Comparison

- NCT03929263 378 379 O
Adolescent NCT03929263 381 391 O
participants NCT03929263 392 404 O
: NCT03929263 405 406 O
Age NCT03929263 407 410 B-Age
13 NCT03929263 411 413 B-Eq-Comparison
- NCT03929263 414 415 I-Eq-Comparison
17 NCT03929263 416 418 I-Eq-Comparison
years NCT03929263 419 424 I-Eq-Comparison

- NCT03929263 427 428 O
Adolescent NCT03929263 430 440 O
participants NCT03929263 441 453 O
: NCT03929263 454 455 O
BMI NCT03929263 456 459 B-Observation
≧ NCT03929263 460 461 B-Eq-Comparison
16.0 NCT03929263 462 466 I-Eq-Comparison

Exclusion NCT03929263 468 477 O
Criteria NCT03929263 478 486 O
: NCT03929263 487 488 O

- NCT03929263 492 493 O
Current NCT03929263 495 502 B-Eq-Comparison
psychiatric NCT03929263 503 514 B-Condition
diagnosis NCT03929263 515 524 I-Condition

- NCT03929263 527 528 O
Medications NCT03929263 530 541 B-Drug
influencing NCT03929263 542 553 O
fMRI NCT03929263 554 558 B-Procedure

- NCT03929263 561 562 O
Medical NCT03929263 564 571 B-Condition
conditions NCT03929263 572 582 I-Condition
influencing NCT03929263 583 594 O
fMRI NCT03929263 595 599 B-Procedure

- NCT03929263 602 603 O
Alcohol NCT03929263 605 612 B-Drug
or NCT03929263 613 615 B-Or
psychoactive NCT03929263 616 628 B-Drug
drug NCT03929263 629 633 I-Drug
on NCT03929263 634 636 B-Temporal-Connection___Temporal-Connection-Type-Value:during
scan NCT03929263 637 641 B-Study
day NCT03929263 642 645 O

- NCT03929263 648 649 O
Adolescent NCT03929263 651 661 O
participants NCT03929263 662 674 O
: NCT03929263 675 676 O
Neurodevelopmental NCT03929263 677 695 B-Condition
delay NCT03929263 696 701 I-Condition

- NCT03929263 704 705 O
Adolescent NCT03929263 707 717 O
participants NCT03929263 718 730 O
: NCT03929263 731 732 O
History NCT03929263 733 740 B-Eq-Comparison
of NCT03929263 741 743 O
mood NCT03929263 744 748 B-Modifier
or NCT03929263 749 751 B-Or
psychotic NCT03929263 752 761 B-Modifier
disorder NCT03929263 762 770 B-Condition

- NCT03929263 773 774 O
Adolescent NCT03929263 776 786 O
participants NCT03929263 787 799 O
: NCT03929263 800 801 O
History NCT03929263 802 809 B-Eq-Comparison
of NCT03929263 810 812 O
obsessive NCT03929263 813 822 B-Condition
- NCT03929263 823 824 I-Condition
compulsive NCT03929263 825 835 I-Condition
disorder NCT03929263 836 844 I-Condition
( NCT03929263 845 846 O
OCD NCT03929263 847 850 B-Condition
) NCT03929263 851 852 O
or NCT03929263 853 855 B-Or
attention NCT03929263 856 865 B-Condition
- NCT03929263 866 867 I-Condition
deficit NCT03929263 868 875 I-Condition
/ NCT03929263 876 877 I-Condition
hyperactivity NCT03929263 878 891 I-Condition
disorder NCT03929263 892 900 I-Condition
( NCT03929263 901 902 O
ADHD NCT03929263 903 907 B-Condition
) NCT03929263 908 909 O

Inclusion NCT03924960 0 9 O
Criteria NCT03924960 10 18 O
: NCT03924960 19 20 O

- NCT03924960 24 25 O
Subjects NCT03924960 27 35 O
diagnosed NCT03924960 36 45 O
according NCT03924960 46 55 O
to NCT03924960 56 58 O
the NCT03924960 59 62 O
American NCT03924960 63 71 O
College NCT03924960 72 79 O
of NCT03924960 80 82 O
Rheumatology NCT03924960 83 95 O
2016 NCT03924960 96 100 O
diagnostic NCT03924960 101 111 O
criteria NCT03924960 112 120 O
for NCT03924960 121 124 O
fibromyalgia NCT03924960 125 137 B-Condition
. NCT03924960 138 139 O

Exclusion NCT03924960 141 150 O
Criteria NCT03924960 151 159 O
: NCT03924960 160 161 O

- NCT03924960 165 166 O
History NCT03924960 168 175 B-Eq-Comparison
of NCT03924960 176 178 O
comorbid NCT03924960 179 187 B-Condition
inflammatory NCT03924960 188 200 I-Condition
rheumatic NCT03924960 201 210 I-Condition
/ NCT03924960 211 212 B-Or
connective NCT03924960 213 223 B-Condition
tissue NCT03924960 224 230 I-Condition
diseases NCT03924960 231 239 I-Condition

- NCT03924960 242 243 O
History NCT03924960 245 252 B-Eq-Comparison
of NCT03924960 253 255 O
cardiovascular NCT03924960 256 270 B-Modifier
or NCT03924960 271 273 B-Or
musculoskeletal NCT03924960 274 289 B-Modifier
problems NCT03924960 290 298 B-Condition
that NCT03924960 299 303 O
could NCT03924960 304 309 B-Assertion___Assertion-Type-Value:hypothetical
prevent NCT03924960 310 317 B-Negation
them NCT03924960 318 322 O
to NCT03924960 323 325 O
participate NCT03924960 326 337 O
in NCT03924960 338 340 O
an NCT03924960 341 343 O
exercise NCT03924960 344 352 B-Procedure
program NCT03924960 353 360 I-Procedure
. NCT03924960 360 361 O

Inclusion NCT03928431 0 9 O
Criteria NCT03928431 10 18 O
: NCT03928431 19 20 O

- NCT03928431 24 25 O
Infants NCT03928431 27 34 B-Family-Member___Family-Member-Type:child
of NCT03928431 35 37 O
healthy NCT03928431 38 45 B-Condition
mothers NCT03928431 46 53 B-Family-Member___Family-Member-Type:mother
with NCT03928431 54 58 B-And
uncomplicated NCT03928431 59 72 B-Modifier
pregnancies NCT03928431 73 84 B-Condition
at NCT03928431 85 87 O
term NCT03928431 88 92 O
, NCT03928431 93 94 O
mothers NCT03928431 95 102 B-Family-Member___Family-Member-Type:mother
of NCT03928431 103 105 O
any NCT03928431 106 109 O
ethnic NCT03928431 110 116 O
or NCT03928431 117 119 O
social NCT03928431 120 126 O
background NCT03928431 127 137 O
that NCT03928431 138 142 O
can NCT03928431 143 146 O
speak NCT03928431 147 152 O
, NCT03928431 153 154 O
read NCT03928431 155 159 O
, NCT03928431 160 161 O
and NCT03928431 162 165 O
understand NCT03928431 166 176 O
Swedish NCT03928431 177 184 O
to NCT03928431 185 187 O
the NCT03928431 188 191 O
extent NCT03928431 192 198 O
that NCT03928431 199 203 O
they NCT03928431 204 208 O
can NCT03928431 209 212 O
consent NCT03928431 213 220 O
in NCT03928431 221 223 O
Swedish NCT03928431 224 231 O
. NCT03928431 231 232 O
An NCT03928431 234 236 O
additional NCT03928431 237 247 O
inclusion NCT03928431 248 257 O
criterion NCT03928431 258 267 O
for NCT03928431 268 271 O
mothers NCT03928431 272 279 O
in NCT03928431 280 282 O
the NCT03928431 283 286 O
CS NCT03928431 287 289 O
groups NCT03928431 290 296 O
is NCT03928431 297 299 O
vaginal NCT03928431 300 307 B-Observation
pH NCT03928431 308 310 I-Observation
≤ NCT03928431 311 312 B-Eq-Comparison
4 NCT03928431 313 314 I-Eq-Comparison
at NCT03928431 315 317 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928431 318 321 O
time NCT03928431 322 326 O
of NCT03928431 327 329 O
birth NCT03928431 330 335 B-Birth
. NCT03928431 336 337 O

Exclusion NCT03928431 339 348 O
Criteria NCT03928431 349 357 O
: NCT03928431 358 359 O

- NCT03928431 363 364 O
Infants NCT03928431 366 373 B-Family-Member___Family-Member-Type:child
of NCT03928431 374 376 O
mothers NCT03928431 377 384 B-Family-Member___Family-Member-Type:mother
with NCT03928431 385 389 O
pre NCT03928431 390 393 B-Condition
- NCT03928431 394 395 I-Condition
eclampsia NCT03928431 396 405 I-Condition
or NCT03928431 406 408 B-Or
complicated NCT03928431 409 420 B-Modifier
pregnancies NCT03928431 421 432 B-Condition
, NCT03928431 433 434 O
mothers NCT03928431 435 442 B-Family-Member___Family-Member-Type:mother
< NCT03928431 443 444 B-Eq-Comparison
18 NCT03928431 445 447 I-Eq-Comparison
years NCT03928431 448 453 I-Eq-Comparison
or NCT03928431 454 456 B-Or
> NCT03928431 457 458 B-Eq-Comparison
40 NCT03928431 459 461 I-Eq-Comparison
years NCT03928431 462 467 I-Eq-Comparison
of NCT03928431 468 470 O
age NCT03928431 471 474 B-Age
, NCT03928431 475 476 O
genital NCT03928431 477 484 B-Condition
herpes NCT03928431 485 491 I-Condition
simplex NCT03928431 492 499 I-Condition
, NCT03928431 500 501 O
genital NCT03928431 502 509 B-Condition
warts NCT03928431 510 515 I-Condition
, NCT03928431 516 517 O
HIV NCT03928431 518 521 B-Condition
, NCT03928431 522 523 O
Hepatitis NCT03928431 524 533 B-Condition
B NCT03928431 534 535 I-Condition
or NCT03928431 536 538 B-Or
complications NCT03928431 539 552 B-Condition
during NCT03928431 553 559 B-Temporal-Connection___Temporal-Connection-Type-Value:during
delivery NCT03928431 560 568 B-Condition
, NCT03928431 569 570 O
infants NCT03928431 571 578 B-Family-Member___Family-Member-Type:child
delivered NCT03928431 579 588 O
prior NCT03928431 589 594 B-Eq-Comparison
to NCT03928431 595 597 I-Eq-Comparison
37 NCT03928431 598 600 I-Eq-Comparison
weeks NCT03928431 601 606 I-Eq-Comparison
of NCT03928431 607 609 O
gestation NCT03928431 610 619 B-Observation
. NCT03928431 619 620 O
Additional NCT03928431 622 632 O
exclusion NCT03928431 633 642 O
criteria NCT03928431 643 651 O
for NCT03928431 652 655 O
mothers NCT03928431 656 663 O
in NCT03928431 664 666 O
the NCT03928431 667 670 O
CS NCT03928431 671 673 O
group NCT03928431 674 679 O
: NCT03928431 680 681 O
Mothers NCT03928431 682 689 B-Family-Member___Family-Member-Type:mother
positive NCT03928431 690 698 O
to NCT03928431 699 701 O
Group NCT03928431 702 707 B-Condition
B NCT03928431 708 709 I-Condition
Streptococcus NCT03928431 710 723 I-Condition
, NCT03928431 724 725 O
Group NCT03928431 726 731 B-Condition
A NCT03928431 732 733 I-Condition
Streptococcus NCT03928431 734 747 I-Condition
, NCT03928431 748 749 O
bacterial NCT03928431 750 759 B-Condition
vaginosis NCT03928431 760 769 I-Condition
, NCT03928431 770 771 O
vaginal NCT03928431 772 779 B-Observation
pH NCT03928431 780 782 I-Observation
> NCT03928431 783 784 B-Eq-Comparison
4 NCT03928431 785 786 I-Eq-Comparison
at NCT03928431 787 789 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928431 790 793 O
time NCT03928431 794 798 O
of NCT03928431 799 801 O
birth NCT03928431 802 807 B-Birth
. NCT03928431 807 808 O
Mothers NCT03928431 810 817 B-Family-Member___Family-Member-Type:mother
with NCT03928431 818 822 O
fecal NCT03928431 823 828 O
samples NCT03928431 829 836 B-Observation
positive NCT03928431 837 845 O
for NCT03928431 846 849 O
Salmonella NCT03928431 850 860 B-Organism
, NCT03928431 861 862 O
Shigella NCT03928431 863 871 B-Organism
, NCT03928431 872 873 O
Campylobacter NCT03928431 874 887 B-Organism
or NCT03928431 888 890 B-Or
Yersinia NCT03928431 891 899 B-Organism
. NCT03928431 899 900 O

Inclusion NCT03925129 0 9 O
Criteria NCT03925129 10 18 O
: NCT03925129 19 20 O

- NCT03925129 24 25 O
Patients NCT03925129 27 35 O
seeking NCT03925129 36 43 B-Assertion___Assertion-Type-Value:intention
medication NCT03925129 44 54 B-Drug
abortion NCT03925129 55 63 B-Procedure
with NCT03925129 64 68 O
a NCT03925129 69 70 O
definite NCT03925129 71 79 B-Modifier
, NCT03925129 80 81 O
singleton NCT03925129 82 91 B-Modifier
, NCT03925129 92 93 O
intrauterine NCT03925129 94 106 B-Modifier
pregnancy NCT03925129 107 116 B-Condition
( NCT03925129 117 118 O
IUP NCT03925129 119 122 B-Condition
) NCT03925129 123 124 O
< NCT03925129 125 126 B-Eq-Comparison
70 NCT03925129 127 129 I-Eq-Comparison
days NCT03925129 130 134 I-Eq-Comparison
' NCT03925129 134 135 O
gestation NCT03925129 136 145 B-Observation
on NCT03925129 146 148 O
ultrasound NCT03925129 149 159 B-Procedure

- NCT03925129 162 163 O
Rapid NCT03925129 165 170 B-Observation
Estimate NCT03925129 171 179 I-Observation
of NCT03925129 180 182 I-Observation
Adult NCT03925129 183 188 I-Observation
Literacy NCT03925129 189 197 I-Observation
in NCT03925129 198 200 I-Observation
Medicine NCT03925129 201 209 I-Observation
- NCT03925129 210 211 I-Observation
Short NCT03925129 212 217 I-Observation
Form NCT03925129 218 222 I-Observation
( NCT03925129 223 224 O
REALM NCT03925129 225 230 B-Observation
- NCT03925129 231 232 I-Observation
SF NCT03925129 233 235 I-Observation
) NCT03925129 236 237 O
22 NCT03925129 238 240 O
score NCT03925129 241 246 B-Eq-Comparison
> NCT03925129 247 248 I-Eq-Comparison
4 NCT03925129 249 250 I-Eq-Comparison

- NCT03925129 254 255 O
Age NCT03925129 257 260 B-Age
equal NCT03925129 261 266 B-Eq-Comparison
to NCT03925129 267 269 I-Eq-Comparison
or NCT03925129 270 272 I-Eq-Comparison
greater NCT03925129 273 280 I-Eq-Comparison
than NCT03925129 281 285 I-Eq-Comparison
18 NCT03925129 286 288 I-Eq-Comparison
years NCT03925129 289 294 I-Eq-Comparison

- NCT03925129 297 298 O
Provide NCT03925129 300 307 O
informed NCT03925129 308 316 O
consent NCT03925129 317 324 O
to NCT03925129 325 327 O
participate NCT03925129 328 339 O

- NCT03925129 342 343 O
Willing NCT03925129 345 352 O
to NCT03925129 353 355 O
adhere NCT03925129 356 362 O
to NCT03925129 363 365 O
study NCT03925129 366 371 O
procedures NCT03925129 372 382 O
, NCT03925129 383 384 O
including NCT03925129 385 394 O
access NCT03925129 395 401 O
to NCT03925129 402 404 O
a NCT03925129 405 406 O
smart NCT03925129 407 412 O
phone NCT03925129 413 418 O
, NCT03925129 419 420 O
ability NCT03925129 421 428 O
to NCT03925129 429 431 O
receive NCT03925129 432 439 O
text NCT03925129 440 444 O
messages NCT03925129 445 453 O
and NCT03925129 454 457 O
answer NCT03925129 458 464 O
online NCT03925129 465 471 O
surveys NCT03925129 472 479 O
on NCT03925129 480 482 O
smart NCT03925129 483 488 O
phone NCT03925129 489 494 O

Exclusion NCT03925129 495 504 O
Criteria NCT03925129 505 513 O
: NCT03925129 514 515 O

- NCT03925129 519 520 O
Contraindication NCT03925129 522 538 B-Contraindication
to NCT03925129 539 541 O
medication NCT03925129 542 552 B-Drug
abortion NCT03925129 553 561 B-Procedure

- NCT03925129 564 565 O
Allergy NCT03925129 567 574 B-Allergy
to NCT03925129 575 577 O
mifepristone NCT03925129 578 590 B-Drug
or NCT03925129 591 593 B-Or
misoprostol NCT03925129 594 605 B-Drug

- NCT03925129 608 609 O
Contraindication NCT03925129 611 627 B-Contraindication
or NCT03925129 628 630 B-Or
allergy NCT03925129 631 638 B-Allergy
to NCT03925129 639 641 O
ibuprofen NCT03925129 642 651 B-Drug

- NCT03925129 654 655 O
History NCT03925129 657 664 B-Eq-Comparison
of NCT03925129 665 667 O
cardiac NCT03925129 668 675 B-Condition
arrhythmia NCT03925129 676 686 I-Condition

- NCT03925129 689 690 O
Presence NCT03925129 692 700 O
of NCT03925129 701 703 O
an NCT03925129 704 706 O
implantable NCT03925129 707 718 B-Procedure
device NCT03925129 719 725 I-Procedure
with NCT03925129 726 730 O
electrical NCT03925129 731 741 B-Modifier
discharge NCT03925129 742 751 I-Modifier
, NCT03925129 752 753 O
i. NCT03925129 754 756 O
e. NCT03925129 757 759 O
cardiac NCT03925129 761 768 B-Procedure
pacemaker NCT03925129 769 778 I-Procedure

- NCT03925129 781 782 O
History NCT03925129 784 791 B-Eq-Comparison
of NCT03925129 792 794 O
chronic NCT03925129 795 802 B-Modifier
pain NCT03925129 803 807 B-Condition
disorder NCT03925129 808 816 I-Condition

- NCT03925129 819 820 O
Any NCT03925129 822 825 O
opioid NCT03925129 826 832 B-Drug
use NCT03925129 833 836 O
during NCT03925129 837 843 B-Temporal-Connection___Temporal-Connection-Type-Value:during
previous NCT03925129 844 852 B-Eq-Comparison
30 NCT03925129 853 855 I-Eq-Comparison
days NCT03925129 856 860 I-Eq-Comparison

- NCT03925129 863 864 O
Current NCT03925129 866 873 B-Eq-Comparison
or NCT03925129 874 876 B-Or
prior NCT03925129 877 882 B-Eq-Comparison
use NCT03925129 883 886 O
of NCT03925129 887 889 O
TENS NCT03925129 890 894 B-Procedure

- NCT03925129 897 898 O
BMI NCT03925129 900 903 B-Observation
> NCT03925129 904 905 B-Eq-Comparison
30 NCT03925129 906 908 I-Eq-Comparison

Inclusion NCT03925883 0 9 O
Criteria NCT03925883 10 18 O
: NCT03925883 19 20 O

- NCT03925883 24 25 O
Positive NCT03925883 27 35 O
FIT NCT03925883 36 39 B-Observation
test NCT03925883 40 44 I-Observation

Exclusion NCT03925883 45 54 O
Criteria NCT03925883 55 63 O
: NCT03925883 64 65 O

- NCT03925883 69 70 O
Prior NCT03925883 72 77 B-Eq-Comparison
colorectal NCT03925883 78 88 B-Modifier
cancer NCT03925883 89 95 B-Condition

- NCT03925883 98 99 O
Dialysis NCT03925883 101 109 B-Procedure
patient NCT03925883 110 117 O

Inclusion NCT03920904 0 9 O
Criteria NCT03920904 10 18 O
: NCT03920904 19 20 O

- NCT03920904 24 25 O
ASA NCT03920904 27 30 B-Condition
l NCT03920904 31 32 B-Eq-Comparison
- NCT03920904 33 34 I-Eq-Comparison
lll NCT03920904 35 38 I-Eq-Comparison

- NCT03920904 41 42 O
Undergoing NCT03920904 44 54 B-Eq-Comparison
sternotomy NCT03920904 55 65 B-Procedure
for NCT03920904 66 69 O
cardiac NCT03920904 70 77 B-Procedure
surgery NCT03920904 78 85 I-Procedure
under NCT03920904 86 91 O
a NCT03920904 92 93 O
PIFB NCT03920904 94 98 B-Procedure
and NCT03920904 99 102 B-And
general NCT03920904 103 110 B-Procedure
anesthesia NCT03920904 111 121 I-Procedure

Exclusion NCT03920904 122 131 O
Criteria NCT03920904 132 140 O
: NCT03920904 141 142 O

- NCT03920904 146 147 O
Patient NCT03920904 149 156 O
's NCT03920904 156 158 O
refusal NCT03920904 159 166 O
or NCT03920904 167 169 O
inability NCT03920904 170 179 O
to NCT03920904 180 182 O
consent NCT03920904 183 190 O

- NCT03920904 193 194 O
Allergy NCT03920904 196 203 B-Allergy
, NCT03920904 204 205 O
hypersensibility NCT03920904 206 222 B-Condition
or NCT03920904 223 225 B-Or
resistance NCT03920904 226 236 B-Condition
to NCT03920904 237 239 O
local NCT03920904 240 245 B-Procedure
anesthetic NCT03920904 246 256 I-Procedure

- NCT03920904 259 260 O
Contraindication NCT03920904 262 278 B-Contraindication
to NCT03920904 279 281 O
regional NCT03920904 282 290 B-Procedure
anesthesia NCT03920904 291 301 I-Procedure
: NCT03920904 302 303 O
infection NCT03920904 304 313 B-Condition
in NCT03920904 314 316 O
the NCT03920904 317 320 O
designated NCT03920904 321 331 O
area NCT03920904 332 336 O
, NCT03920904 337 338 O
severe NCT03920904 339 345 O
congenital NCT03920904 346 356 B-Modifier
coagulopathy NCT03920904 357 369 B-Condition
or NCT03920904 370 372 O
inadequate NCT03920904 373 383 B-Negation
hemostasis NCT03920904 384 394 B-Procedure
before NCT03920904 395 401 B-Temporal-Connection___Temporal-Connection-Type-Value:before
PIFB NCT03920904 402 406 B-Procedure

- NCT03920904 409 410 O
Severe NCT03920904 412 418 O
hepatic NCT03920904 419 426 B-Modifier
( NCT03920904 427 428 O
Child NCT03920904 429 434 O
B NCT03920904 435 436 B-Modifier
and NCT03920904 437 440 B-Or
C NCT03920904 441 442 B-Modifier
) NCT03920904 443 444 O
or NCT03920904 445 447 B-Or
renal NCT03920904 448 453 B-Modifier
insufficiency NCT03920904 454 467 B-Condition
( NCT03920904 468 469 O
GFR NCT03920904 470 473 B-Eq-Comparison|Observation
< NCT03920904 474 475 I-Eq-Comparison
30 NCT03920904 476 478 I-Eq-Comparison
mL NCT03920904 479 481 I-Eq-Comparison
/ NCT03920904 482 483 I-Eq-Comparison
min NCT03920904 484 487 I-Eq-Comparison
) NCT03920904 488 489 O

Inclusion NCT03922685 0 9 O
Criteria NCT03922685 10 18 O
: NCT03922685 19 20 O

- NCT03922685 24 25 O
postmenopausal NCT03922685 27 41 B-Condition

- NCT03922685 44 45 O
normal NCT03922685 47 53 O
blood NCT03922685 54 59 B-Observation
glucose NCT03922685 60 67 I-Observation

- NCT03922685 70 71 O
no NCT03922685 73 75 B-Negation
cholesterol NCT03922685 76 87 B-Condition
medication NCT03922685 88 98 B-Drug

- NCT03922685 101 102 O
age NCT03922685 104 107 B-Age
between NCT03922685 108 115 B-Eq-Comparison
50 NCT03922685 116 118 I-Eq-Comparison
an NCT03922685 119 121 I-Eq-Comparison
65 NCT03922685 122 124 I-Eq-Comparison
years NCT03922685 125 130 I-Eq-Comparison

- NCT03922685 133 134 O
overweight NCT03922685 136 146 B-Condition
but NCT03922685 147 150 B-And
not NCT03922685 151 154 B-Negation
obese NCT03922685 155 160 B-Condition

- NCT03922685 163 164 O
BMI NCT03922685 166 169 B-Observation
between NCT03922685 170 177 B-Eq-Comparison
25 NCT03922685 178 180 I-Eq-Comparison
and NCT03922685 181 184 I-Eq-Comparison
30 NCT03922685 185 187 I-Eq-Comparison
kg NCT03922685 188 190 I-Eq-Comparison
/ NCT03922685 191 192 I-Eq-Comparison
m2 NCT03922685 193 195 I-Eq-Comparison

- NCT03922685 198 199 O
weight NCT03922685 201 207 B-Observation
- NCT03922685 208 209 O
stable NCT03922685 210 216 O
during NCT03922685 217 223 B-Temporal-Connection___Temporal-Connection-Type-Value:during
past NCT03922685 224 228 B-Eq-Comparison
6 NCT03922685 229 230 I-Eq-Comparison
months NCT03922685 231 237 I-Eq-Comparison

- NCT03922685 240 241 O
exercise NCT03922685 243 251 B-Observation
less NCT03922685 252 256 B-Eq-Comparison
than NCT03922685 257 261 I-Eq-Comparison
20 NCT03922685 262 264 I-Eq-Comparison
minutes NCT03922685 265 272 I-Eq-Comparison
three NCT03922685 273 278 B-Eq-Comparison
times NCT03922685 279 284 I-Eq-Comparison
a NCT03922685 285 286 I-Eq-Comparison
week NCT03922685 287 291 I-Eq-Comparison

Exclusion NCT03922685 292 301 O
Criteria NCT03922685 302 310 O
: NCT03922685 311 312 O

- NCT03922685 316 317 O
metabolic NCT03922685 319 328 B-Condition
disease NCT03922685 329 336 I-Condition
other NCT03922685 337 342 B-Exception
than NCT03922685 343 347 I-Exception
hormonally NCT03922685 348 358 B-Modifier
- NCT03922685 359 360 I-Modifier
corrected NCT03922685 361 370 I-Modifier
hypothyroidism NCT03922685 371 385 B-Condition

- NCT03922685 388 389 O
musculo NCT03922685 391 398 B-Condition
- NCT03922685 399 400 I-Condition
skeletal NCT03922685 401 409 I-Condition
disability NCT03922685 410 420 I-Condition
that NCT03922685 421 425 O
would NCT03922685 426 431 B-Assertion___Assertion-Type-Value:hypothetical
preclude NCT03922685 432 440 B-Negation
exercise NCT03922685 441 449 B-Observation

- NCT03922685 452 453 O
smoker NCT03922685 455 461 B-Condition

- NCT03922685 464 465 O
do NCT03922685 467 469 O
not NCT03922685 470 473 O
meet NCT03922685 474 478 O
inclusion NCT03922685 479 488 O
criteria NCT03922685 489 497 O

Inclusion NCT03921398 0 9 O
Criteria NCT03921398 10 18 O
( NCT03921398 19 20 O
ESRD NCT03921398 21 25 B-Condition
group NCT03921398 26 31 O
) NCT03921398 32 33 O
: NCT03921398 35 36 O

- NCT03921398 40 41 O
Age NCT03921398 43 46 B-Age
≥ NCT03921398 47 48 B-Eq-Comparison
18 NCT03921398 49 51 I-Eq-Comparison
years NCT03921398 52 57 I-Eq-Comparison
, NCT03921398 58 59 O

- NCT03921398 63 64 O
History NCT03921398 66 73 B-Eq-Comparison
of NCT03921398 74 76 O
biopsy NCT03921398 77 83 O
- NCT03921398 84 85 O
proven NCT03921398 86 92 O
lupus NCT03921398 93 98 B-Condition
nephritis NCT03921398 99 108 I-Condition

- NCT03921398 111 112 O
All NCT03921398 114 117 O
classes NCT03921398 118 125 O
of NCT03921398 126 128 O
lupus NCT03921398 129 134 B-Condition
nephritis NCT03921398 135 144 I-Condition

- NCT03921398 147 148 O
Written NCT03921398 150 157 O
informed NCT03921398 158 166 O
consent NCT03921398 167 174 O

- NCT03921398 177 178 O
Affiliation NCT03921398 180 191 O
to NCT03921398 192 194 O
a NCT03921398 195 196 O
social NCT03921398 197 203 O
security NCT03921398 204 212 O
regime NCT03921398 213 219 O

Exclusion NCT03921398 220 229 O
Criteria NCT03921398 230 238 O
( NCT03921398 239 240 O
ESRD NCT03921398 241 245 B-Condition
group NCT03921398 246 251 O
) NCT03921398 252 253 O
: NCT03921398 255 256 O

- NCT03921398 260 261 O
Past NCT03921398 263 267 B-Eq-Comparison
- NCT03921398 268 269 I-Eq-Comparison
history NCT03921398 270 277 I-Eq-Comparison
of NCT03921398 278 280 O
kidney NCT03921398 281 287 B-Modifier
transplantation NCT03921398 288 303 B-Procedure

- NCT03921398 306 307 O
Active NCT03921398 309 315 B-Eq-Comparison
infection NCT03921398 316 325 B-Condition

- NCT03921398 328 329 O
Active NCT03921398 331 337 B-Eq-Comparison
allergy NCT03921398 338 345 B-Allergy
( NCT03921398 346 347 O
such NCT03921398 348 352 O
as NCT03921398 353 355 O
hay NCT03921398 356 359 B-Condition
fever NCT03921398 360 365 I-Condition
) NCT03921398 366 367 O

- NCT03921398 371 372 O
Pregnant NCT03921398 374 382 B-Condition
or NCT03921398 383 385 B-Or
breastfeeding NCT03921398 386 399 B-Condition
women NCT03921398 400 405 O

- NCT03921398 408 409 O
Protected NCT03921398 411 420 O
adults NCT03921398 421 427 O
( NCT03921398 428 429 O
individuals NCT03921398 430 441 O
under NCT03921398 442 447 B-Observation
guardianship NCT03921398 448 460 I-Observation
by NCT03921398 461 463 O
court NCT03921398 464 469 O
order NCT03921398 470 475 O
) NCT03921398 476 477 O

Inclusion NCT03921398 479 488 O
criteria NCT03921398 489 497 O
( NCT03921398 498 499 O
non NCT03921398 500 503 B-Negation
ESRD NCT03921398 504 508 B-Condition
group NCT03921398 509 514 O
) NCT03921398 515 516 O
: NCT03921398 518 519 O

- NCT03921398 523 524 O
Age NCT03921398 526 529 B-Age
≥ NCT03921398 530 531 B-Eq-Comparison
18 NCT03921398 532 534 I-Eq-Comparison
years NCT03921398 535 540 I-Eq-Comparison
, NCT03921398 541 542 O

- NCT03921398 546 547 O
Biopsy NCT03921398 549 555 B-Procedure
proven NCT03921398 556 562 O
ACTIVE NCT03921398 563 569 B-Eq-Comparison
lupus NCT03921398 570 575 B-Condition
nephritis NCT03921398 576 585 I-Condition

- NCT03921398 588 589 O
First NCT03921398 591 596 B-Eq-Comparison
event NCT03921398 597 602 O
of NCT03921398 603 605 O
lupus NCT03921398 606 611 B-Condition
nephritis NCT03921398 612 621 I-Condition

- NCT03921398 624 625 O
No NCT03921398 627 629 B-Negation
immunosuppressive NCT03921398 630 647 B-Procedure
therapy NCT03921398 648 655 I-Procedure
( NCT03921398 656 657 O
including NCT03921398 658 667 O
corticosteroids NCT03921398 668 683 B-Drug
) NCT03921398 684 685 O

- NCT03921398 689 690 O
Written NCT03921398 692 699 O
informed NCT03921398 700 708 O
consent NCT03921398 709 716 O

- NCT03921398 719 720 O
Affiliation NCT03921398 722 733 O
to NCT03921398 734 736 O
a NCT03921398 737 738 O
social NCT03921398 739 745 O
security NCT03921398 746 754 O
regime NCT03921398 755 761 O

Exclusion NCT03921398 762 771 O
criteria NCT03921398 772 780 O
( NCT03921398 781 782 O
non NCT03921398 783 786 B-Negation
ESRD NCT03921398 787 791 B-Condition
group NCT03921398 792 797 O
) NCT03921398 798 799 O
: NCT03921398 800 801 O

- NCT03921398 805 806 O
Immunosuppressive NCT03921398 808 825 B-Procedure
treatment NCT03921398 826 835 I-Procedure

- NCT03921398 838 839 O
Relapse NCT03921398 841 848 B-Condition
of NCT03921398 849 851 O
lupus NCT03921398 852 857 B-Condition
nephritis NCT03921398 858 867 I-Condition
under NCT03921398 868 873 B-Temporal-Connection___Temporal-Connection-Type-Value:during
treatment NCT03921398 874 883 B-Procedure

- NCT03921398 886 887 O
Pregnant NCT03921398 889 897 B-Condition
or NCT03921398 898 900 B-Or
breastfeeding NCT03921398 901 914 B-Condition
women NCT03921398 915 920 O

- NCT03921398 923 924 O
Protected NCT03921398 926 935 B-Observation
adults NCT03921398 936 942 O
( NCT03921398 943 944 O
individuals NCT03921398 945 956 O
under NCT03921398 957 962 B-Observation
guardianship NCT03921398 963 975 I-Observation
by NCT03921398 976 978 O
court NCT03921398 979 984 O
order NCT03921398 985 990 O
) NCT03921398 991 992 O

Inclusion NCT03927924 0 9 O
Criteria NCT03927924 10 18 O
: NCT03927924 19 20 O

- NCT03927924 24 25 O
Visible NCT03927924 27 34 B-Condition
index NCT03927924 35 40 I-Condition
lesion NCT03927924 41 47 I-Condition
( NCT03927924 48 49 O
s NCT03927924 50 51 O
) NCT03927924 52 53 O
on NCT03927924 54 56 O
MRI NCT03927924 57 60 B-Procedure

- NCT03927924 63 64 O
Index NCT03927924 66 71 B-Observation
lesion NCT03927924 72 78 I-Observation
( NCT03927924 79 80 O
s NCT03927924 81 82 O
) NCT03927924 83 84 O
greater NCT03927924 85 92 B-Eq-Comparison
than NCT03927924 93 97 I-Eq-Comparison
0.5 NCT03927924 98 101 I-Eq-Comparison
cm3 NCT03927924 102 105 I-Eq-Comparison

- NCT03927924 108 109 O
Found NCT03927924 111 116 O
to NCT03927924 117 119 O
have NCT03927924 120 124 O
localized NCT03927924 125 134 B-Modifier
low NCT03927924 135 138 O
- NCT03927924 139 140 O
risk NCT03927924 141 145 B-Risk
or NCT03927924 146 148 B-Or
intermediate NCT03927924 149 161 O
- NCT03927924 162 163 O
risk NCT03927924 164 168 B-Risk
prostate NCT03927924 169 177 B-Condition
cancer NCT03927924 178 184 I-Condition
after NCT03927924 185 190 B-Temporal-Connection___Temporal-Connection-Type-Value:after
MRI NCT03927924 191 194 B-Procedure
- NCT03927924 195 196 I-Procedure
USG NCT03927924 197 200 I-Procedure
fusion NCT03927924 201 207 I-Procedure
targeted NCT03927924 208 216 I-Procedure
biopsy NCT03927924 217 223 I-Procedure
and NCT03927924 224 227 B-Or
saturation NCT03927924 228 238 B-Procedure
biopsy NCT03927924 239 245 I-Procedure
: NCT03927924 246 247 O

1 NCT03927924 256 257 O
. NCT03927924 257 258 O
Clinical NCT03927924 260 268 O
tumour NCT03927924 269 275 B-Condition
stage NCT03927924 276 281 B-Eq-Comparison
T2 NCT03927924 282 284 I-Eq-Comparison
, NCT03927924 285 286 O
or NCT03927924 287 289 B-Or

2 NCT03927924 297 298 O
. NCT03927924 298 299 O
Gleason NCT03927924 301 308 B-Observation
score NCT03927924 309 314 I-Observation
7 NCT03927924 315 316 B-Eq-Comparison
, NCT03927924 317 318 O
or NCT03927924 319 321 B-Or

3 NCT03927924 329 330 O
. NCT03927924 330 331 O
PSA NCT03927924 333 336 B-Observation
20 NCT03927924 337 339 B-Eq-Comparison
ng NCT03927924 340 342 I-Eq-Comparison
/ NCT03927924 343 344 I-Eq-Comparison
ml NCT03927924 345 347 I-Eq-Comparison

Exclusion NCT03927924 348 357 O
Criteria NCT03927924 358 366 O
: NCT03927924 367 368 O

- NCT03927924 372 373 O
Prostate NCT03927924 375 383 B-Observation
size NCT03927924 384 388 I-Observation
larger NCT03927924 389 395 B-Eq-Comparison
than NCT03927924 396 400 I-Eq-Comparison
50 NCT03927924 401 403 I-Eq-Comparison
ml NCT03927924 404 406 I-Eq-Comparison

- NCT03927924 409 410 O
Patients NCT03927924 412 420 O
unfit NCT03927924 421 426 B-Contraindication
for NCT03927924 427 430 O
contrast NCT03927924 431 439 B-Procedure
MRI NCT03927924 440 443 I-Procedure
exam NCT03927924 444 448 O

- NCT03927924 451 452 O
Patients NCT03927924 454 462 O
with NCT03927924 463 467 O
previous NCT03927924 468 476 B-Eq-Comparison
treatment NCT03927924 477 486 B-Procedure
of NCT03927924 487 489 O
prostate NCT03927924 490 498 B-Modifier
cancer NCT03927924 499 505 B-Condition

- NCT03927924 508 509 O
Patients NCT03927924 511 519 O
with NCT03927924 520 524 O
previous NCT03927924 525 533 B-Eq-Comparison
surgery NCT03927924 534 541 B-Procedure
on NCT03927924 542 544 O
the NCT03927924 545 548 O
prostate NCT03927924 549 557 B-Modifier

- NCT03927924 560 561 O
Patients NCT03927924 563 571 O
with NCT03927924 572 576 O
active NCT03927924 577 583 B-Eq-Comparison
urinary NCT03927924 584 591 B-Modifier
tract NCT03927924 592 597 I-Modifier
infection NCT03927924 598 607 B-Condition

- NCT03927924 610 611 O
Patients NCT03927924 613 621 O
with NCT03927924 622 626 O
bladder NCT03927924 627 634 B-Condition
pathology NCT03927924 635 644 I-Condition
including NCT03927924 645 654 O
bladder NCT03927924 655 662 B-Condition
stone NCT03927924 663 668 I-Condition
and NCT03927924 669 672 B-Or
bladder NCT03927924 673 680 B-Modifier
cancer NCT03927924 681 687 B-Condition

- NCT03927924 690 691 O
Patients NCT03927924 693 701 O
with NCT03927924 702 706 O
urethral NCT03927924 707 715 B-Condition
stricture NCT03927924 716 725 I-Condition

- NCT03927924 728 729 O
Patients NCT03927924 731 739 O
with NCT03927924 740 744 O
neurogenic NCT03927924 745 755 B-Condition
bladder NCT03927924 756 763 I-Condition
and NCT03927924 764 767 B-Or
/ NCT03927924 768 769 I-Or
or NCT03927924 770 772 I-Or
sphincter NCT03927924 773 782 B-Condition
abnormalities NCT03927924 783 796 I-Condition

- NCT03927924 799 800 O
Fail NCT03927924 802 806 O
to NCT03927924 807 809 O
give NCT03927924 810 814 O
informed NCT03927924 815 823 O
consent NCT03927924 824 831 O

Inclusion NCT03928418 0 9 O
Criteria NCT03928418 10 18 O
: NCT03928418 19 20 O

- NCT03928418 24 25 O
Age NCT03928418 27 30 B-Age
18 NCT03928418 31 33 B-Eq-Comparison
years NCT03928418 34 39 I-Eq-Comparison
and NCT03928418 40 43 I-Eq-Comparison
older NCT03928418 44 49 I-Eq-Comparison
; NCT03928418 49 50 O

- NCT03928418 53 54 O
HIV NCT03928418 56 59 B-Condition
positive NCT03928418 60 68 O
; NCT03928418 68 69 O

- NCT03928418 72 73 O
On NCT03928418 75 77 B-Eq-Comparison
ART NCT03928418 78 81 B-Procedure
for NCT03928418 82 85 O
at NCT03928418 86 88 B-Eq-Comparison
least NCT03928418 89 94 I-Eq-Comparison
six NCT03928418 95 98 I-Eq-Comparison
months NCT03928418 99 105 I-Eq-Comparison
; NCT03928418 105 106 O

- NCT03928418 109 110 O
Reported NCT03928418 112 120 O
alcohol NCT03928418 121 128 B-Drug
use NCT03928418 129 132 O
in NCT03928418 133 135 O
the NCT03928418 136 139 O
prior NCT03928418 140 145 B-Eq-Comparison
year NCT03928418 146 150 I-Eq-Comparison
at NCT03928418 151 153 O
clinic NCT03928418 154 160 O
entry NCT03928418 161 166 O
; NCT03928418 166 167 O

- NCT03928418 170 171 O
Fluency NCT03928418 173 180 O
in NCT03928418 181 183 O
Runyakole NCT03928418 184 193 O
; NCT03928418 193 194 O

- NCT03928418 197 198 O
Living NCT03928418 200 206 O
within NCT03928418 207 213 B-Eq-Comparison
two NCT03928418 214 217 I-Eq-Comparison
hours NCT03928418 218 223 I-Eq-Comparison
travel NCT03928418 224 230 B-Observation
time NCT03928418 231 235 I-Observation
from NCT03928418 236 240 O
the NCT03928418 241 244 O
clinic NCT03928418 245 251 O
; NCT03928418 251 252 O

- NCT03928418 255 256 O
Owning NCT03928418 258 264 O
or NCT03928418 265 267 O
having NCT03928418 268 274 O
daily NCT03928418 275 280 O
access NCT03928418 281 287 O
to NCT03928418 288 290 O
a NCT03928418 291 292 O
cell NCT03928418 293 297 O
phone NCT03928418 298 303 O
; NCT03928418 303 304 O

- NCT03928418 307 308 O
Screening NCT03928418 310 319 O
positive NCT03928418 320 328 O
on NCT03928418 329 331 O
the NCT03928418 332 335 O
AUDIT NCT03928418 336 341 B-Observation
- NCT03928418 342 343 I-Observation
C NCT03928418 344 345 I-Observation

Exclusion NCT03928418 346 355 O
Criteria NCT03928418 356 364 O
: NCT03928418 365 366 O

- NCT03928418 370 371 O
Plans NCT03928418 373 378 B-Assertion___Assertion-Type-Value:intention
to NCT03928418 379 381 O
move NCT03928418 382 386 B-Observation
out NCT03928418 387 390 I-Observation
of NCT03928418 391 393 O
the NCT03928418 394 397 O
catchment NCT03928418 398 407 O
area NCT03928418 408 412 O
within NCT03928418 413 419 B-Eq-Comparison
6 NCT03928418 420 421 I-Eq-Comparison
months NCT03928418 422 428 I-Eq-Comparison
; NCT03928418 428 429 O

- NCT03928418 432 433 O
Unable NCT03928418 435 441 O
to NCT03928418 442 444 O
provide NCT03928418 445 452 O
informed NCT03928418 453 461 O
consent NCT03928418 462 469 O
. NCT03928418 470 471 O

- NCT03928418 475 476 O
Participation NCT03928418 478 491 O
in NCT03928418 492 494 O
another NCT03928418 495 502 B-Other
research NCT03928418 503 511 O
study NCT03928418 512 517 B-Study
. NCT03928418 517 518 O

Inclusion NCT03924544 0 9 O
Criteria NCT03924544 10 18 O
: NCT03924544 19 20 O

- NCT03924544 24 25 O
Primary NCT03924544 27 34 B-Modifier
Open NCT03924544 35 39 I-Modifier
Angle NCT03924544 40 45 I-Modifier
Glaucoma NCT03924544 46 54 B-Condition

Exclusion NCT03924544 55 64 O
Criteria NCT03924544 65 73 O
: NCT03924544 74 75 O

- NCT03924544 79 80 O
Secondary NCT03924544 82 91 B-Modifier
Glaucoma NCT03924544 92 100 B-Condition
, NCT03924544 101 102 O
Closed NCT03924544 103 109 B-Modifier
angle NCT03924544 110 115 I-Modifier
glaucoma NCT03924544 116 124 B-Condition

Inclusion NCT03924791 0 9 O
Criteria NCT03924791 10 18 O
: NCT03924791 19 20 O

- NCT03924791 24 25 O
Diagnosed NCT03924791 27 36 O
with NCT03924791 37 41 O
sciatica NCT03924791 42 50 B-Condition
by NCT03924791 51 53 O
GP NCT03924791 54 56 B-Provider

- NCT03924791 59 60 O
NRS NCT03924791 62 65 B-Observation
leg NCT03924791 66 69 I-Observation
pain NCT03924791 70 74 I-Observation
of NCT03924791 75 77 O
6 NCT03924791 78 79 B-Eq-Comparison
or NCT03924791 80 82 I-Eq-Comparison
more NCT03924791 83 87 I-Eq-Comparison
on NCT03924791 88 90 O
a NCT03924791 91 92 O
10 NCT03924791 93 95 O
- NCT03924791 96 97 O
point NCT03924791 98 103 O
NRS NCT03924791 104 107 O
scale NCT03924791 108 113 O

- NCT03924791 116 117 O
Minimum NCT03924791 119 126 O
duration NCT03924791 127 135 O
of NCT03924791 136 138 O
symptoms NCT03924791 139 147 B-Assertion___Assertion-Type-Value:possible|Coreference
of NCT03924791 148 150 O
3 NCT03924791 151 152 B-Eq-Comparison
weeks NCT03924791 153 158 I-Eq-Comparison
and NCT03924791 159 162 O
maximum NCT03924791 163 170 B-Eq-Comparison
duration NCT03924791 171 179 I-Eq-Comparison
of NCT03924791 180 182 I-Eq-Comparison
8 NCT03924791 183 184 I-Eq-Comparison
weeks NCT03924791 185 190 I-Eq-Comparison

Exclusion NCT03924791 191 200 O
Criteria NCT03924791 201 209 O
: NCT03924791 210 211 O

- NCT03924791 215 216 O
Age NCT03924791 218 221 B-Age
under NCT03924791 222 227 B-Eq-Comparison
18 NCT03924791 228 230 I-Eq-Comparison
years NCT03924791 231 236 I-Eq-Comparison

- NCT03924791 239 240 O
Condition NCT03924791 242 251 B-Condition
preventing NCT03924791 252 262 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03924791 263 265 O
receive NCT03924791 266 273 O
transforaminal NCT03924791 274 288 B-Modifier
epidural NCT03924791 289 297 B-Procedure
injection NCT03924791 298 307 I-Procedure

- NCT03924791 310 311 O
Severe NCT03924791 313 319 O
scoliosis NCT03924791 320 329 B-Condition

- NCT03924791 332 333 O
Transforaminal NCT03924791 335 349 B-Modifier
epidural NCT03924791 350 358 B-Procedure
injection NCT03924791 359 368 I-Procedure
received NCT03924791 369 377 B-Eq-Comparison
in NCT03924791 378 380 I-Eq-Comparison
6 NCT03924791 381 382 I-Eq-Comparison
months NCT03924791 383 389 I-Eq-Comparison
before NCT03924791 390 396 B-Temporal-Connection___Temporal-Connection-Type-Value:before
randomization NCT03924791 397 410 B-Study
date NCT03924791 411 415 O

- NCT03924791 418 419 O
Surgery NCT03924791 421 428 B-Procedure
for NCT03924791 429 432 O
sciatica NCT03924791 433 441 B-Condition
at NCT03924791 442 444 O
the NCT03924791 445 448 O
same NCT03924791 449 453 B-Modifier
level NCT03924791 454 459 I-Modifier

- NCT03924791 462 463 O
Surgery NCT03924791 465 472 B-Procedure
for NCT03924791 473 476 O
sciatica NCT03924791 477 485 B-Condition
at NCT03924791 486 488 O
another NCT03924791 489 496 B-Modifier
level NCT03924791 497 502 I-Modifier
within NCT03924791 503 509 B-Eq-Comparison
one NCT03924791 510 513 I-Eq-Comparison
year NCT03924791 514 518 I-Eq-Comparison
before NCT03924791 519 525 B-Temporal-Connection___Temporal-Connection-Type-Value:before
inclusion NCT03924791 526 535 B-Study

- NCT03924791 538 539 O
Pregnancy NCT03924791 541 550 B-Condition

Inclusion NCT03929289 0 9 O
Criteria NCT03929289 10 18 O
: NCT03929289 19 20 O

- NCT03929289 24 25 O
Male NCT03929289 27 31 O
or NCT03929289 32 34 B-Or
female NCT03929289 35 41 O

- NCT03929289 44 45 O
Aged NCT03929289 47 51 B-Age
18 NCT03929289 52 54 B-Eq-Comparison
to NCT03929289 55 57 I-Eq-Comparison
35 NCT03929289 58 60 I-Eq-Comparison
years NCT03929289 61 66 I-Eq-Comparison
old NCT03929289 67 70 O

- NCT03929289 73 74 O
Signed NCT03929289 76 82 O
written NCT03929289 83 90 O
informed NCT03929289 91 99 O
consent NCT03929289 100 107 O

- NCT03929289 110 111 O
Insurance NCT03929289 113 122 O
coverage NCT03929289 123 131 O

Exclusion NCT03929289 132 141 O
Criteria NCT03929289 142 150 O
: NCT03929289 151 152 O

- NCT03929289 156 157 O
Neurological NCT03929289 159 171 B-Modifier
or NCT03929289 172 174 B-Or
psychiatric NCT03929289 175 186 B-Modifier
or NCT03929289 187 189 B-Or
ophthalmological NCT03929289 190 206 B-Modifier
disorder NCT03929289 207 215 B-Condition

- NCT03929289 218 219 O
Non NCT03929289 221 224 B-Negation
- NCT03929289 225 226 O
stabilized NCT03929289 227 237 O
medical NCT03929289 238 245 B-Condition
condition NCT03929289 246 255 I-Condition

- NCT03929289 258 259 O
Ongoing NCT03929289 261 268 B-Eq-Comparison
treatment NCT03929289 269 278 B-Procedure
with NCT03929289 279 283 O
drugs NCT03929289 284 289 B-Drug
that NCT03929289 290 294 O
affect NCT03929289 295 301 O
the NCT03929289 302 305 O
central NCT03929289 306 313 B-Condition
nervous NCT03929289 314 321 I-Condition
system NCT03929289 322 328 I-Condition

- NCT03929289 336 337 O
Uncorrected NCT03929289 339 350 B-Modifier
visual NCT03929289 351 357 B-Condition
inadequacy NCT03929289 358 368 I-Condition

- NCT03929289 376 377 O
No NCT03929289 379 381 B-Negation
fluency NCT03929289 382 389 O
in NCT03929289 390 392 O
French NCT03929289 393 399 O
reading NCT03929289 400 407 O

- NCT03929289 415 416 O
Pregnant NCT03929289 418 426 B-Condition
and NCT03929289 427 430 B-Or
/ NCT03929289 431 432 I-Or
or NCT03929289 433 435 I-Or
breastfeeding NCT03929289 436 449 B-Condition
woman NCT03929289 450 455 O
, NCT03929289 456 457 O
this NCT03929289 458 462 O
exclusion NCT03929289 463 472 O
criterion NCT03929289 473 482 O
will NCT03929289 483 487 O
be NCT03929289 488 490 O
sought NCT03929289 491 497 O
by NCT03929289 498 500 O
questioning NCT03929289 501 512 O
the NCT03929289 513 516 O
subject NCT03929289 517 524 O

- NCT03929289 532 533 O
Subject NCT03929289 535 542 O
commonly NCT03929289 543 551 O
in NCT03929289 552 554 O
care NCT03929289 555 559 O
in NCT03929289 560 562 O
a NCT03929289 563 564 O
health NCT03929289 565 571 O
or NCT03929289 572 574 O
social NCT03929289 575 581 O
facility NCT03929289 582 590 O
for NCT03929289 591 594 O
purposes NCT03929289 595 603 O
other NCT03929289 604 609 O
than NCT03929289 610 614 O
that NCT03929289 615 619 O
of NCT03929289 620 622 O
research NCT03929289 623 631 O

- NCT03929289 639 640 O
Subject NCT03929289 642 649 O
under NCT03929289 650 655 B-Observation
guardianship NCT03929289 656 668 I-Observation

- NCT03929289 676 677 O
Subject NCT03929289 679 686 O
deprived NCT03929289 687 695 B-Observation
of NCT03929289 696 698 I-Observation
liberty NCT03929289 699 706 I-Observation
by NCT03929289 707 709 O
a NCT03929289 710 711 O
judicial NCT03929289 712 720 O
or NCT03929289 721 723 O
administrative NCT03929289 724 738 O
decision NCT03929289 739 747 O

- NCT03929289 755 756 O
Incompatibility NCT03929289 758 773 B-Contraindication
with NCT03929289 774 778 O
the NCT03929289 779 782 O
Magnetic NCT03929289 783 791 B-Procedure
Resonance NCT03929289 792 801 I-Procedure
Imaging NCT03929289 802 809 I-Procedure
( NCT03929289 810 811 O
MRI NCT03929289 812 815 B-Procedure
) NCT03929289 816 817 O
examination NCT03929289 818 829 O
determined NCT03929289 830 840 O
by NCT03929289 841 843 O
answering NCT03929289 844 853 O
the NCT03929289 854 857 O
following NCT03929289 858 867 O
questions NCT03929289 868 877 O
: NCT03929289 878 879 O

- NCT03929289 883 884 O
Carrier NCT03929289 886 893 O
of NCT03929289 894 896 O
a NCT03929289 897 898 O
neurological NCT03929289 899 911 B-Procedure
stimulator NCT03929289 912 922 I-Procedure
, NCT03929289 923 924 O
cardiac NCT03929289 925 932 B-Condition
( NCT03929289 933 934 O
battery NCT03929289 935 942 B-Modifier
) NCT03929289 943 944 O
or NCT03929289 945 947 B-Or
defibrillator NCT03929289 948 961 B-Procedure

- NCT03929289 964 965 O
Carrier NCT03929289 967 974 O
of NCT03929289 975 977 O
a NCT03929289 978 979 O
cardiac NCT03929289 980 987 B-Modifier
prosthesis NCT03929289 988 998 B-Procedure
( NCT03929289 999 1000 O
valve NCT03929289 1001 1006 B-Procedure
, NCT03929289 1007 1008 O
stent NCT03929289 1009 1014 B-Procedure
. NCT03929289 1015 1016 O
. NCT03929289 1017 1018 O
. NCT03929289 1019 1020 O
) NCT03929289 1021 1022 O
or NCT03929289 1023 1025 B-Or
vascular NCT03929289 1026 1034 B-Modifier

- NCT03929289 1037 1038 O
Holder NCT03929289 1040 1046 O
of NCT03929289 1047 1049 O
intracranial NCT03929289 1050 1062 B-Procedure
clips NCT03929289 1063 1068 B-Modifier
or NCT03929289 1069 1071 B-Or
clamps NCT03929289 1072 1078 B-Modifier
( NCT03929289 1079 1080 O
staples NCT03929289 1081 1088 B-Procedure
) NCT03929289 1089 1090 O

- NCT03929289 1094 1095 O
Carrier NCT03929289 1097 1104 O
of NCT03929289 1105 1107 O
a NCT03929289 1108 1109 O
cerebrospinal NCT03929289 1110 1123 B-Procedure
fluid NCT03929289 1124 1129 I-Procedure
bypass NCT03929289 1130 1136 I-Procedure

- NCT03929289 1139 1140 O
Presence NCT03929289 1142 1150 O
of NCT03929289 1151 1153 O
metal NCT03929289 1154 1159 B-Procedure
chips NCT03929289 1160 1165 I-Procedure
in NCT03929289 1166 1168 B-Modifier
the NCT03929289 1169 1172 I-Modifier
eyes NCT03929289 1173 1177 I-Modifier

- NCT03929289 1180 1181 O
Metal NCT03929289 1183 1188 B-Procedure
prosthesis NCT03929289 1189 1199 I-Procedure
carrier NCT03929289 1200 1207 O
( NCT03929289 1208 1209 O
teeth NCT03929289 1210 1215 B-Modifier
, NCT03929289 1216 1217 O
knees NCT03929289 1218 1223 B-Modifier
) NCT03929289 1224 1225 O

- NCT03929289 1229 1230 O
Pump NCT03929289 1232 1236 B-Procedure
carrier NCT03929289 1237 1244 I-Procedure
or NCT03929289 1245 1247 B-Or
infusion NCT03929289 1248 1256 B-Procedure
system NCT03929289 1257 1263 I-Procedure

- NCT03929289 1266 1267 O
Presence NCT03929289 1269 1277 O
of NCT03929289 1278 1280 O
metal NCT03929289 1281 1286 B-Procedure
tattoo NCT03929289 1287 1293 I-Procedure
near NCT03929289 1294 1298 B-Modifier
the NCT03929289 1299 1302 I-Modifier
head NCT03929289 1303 1307 I-Modifier

- NCT03929289 1310 1311 O
Presence NCT03929289 1313 1321 O
of NCT03929289 1322 1324 O
permanent NCT03929289 1325 1334 B-Procedure
makeup NCT03929289 1335 1341 I-Procedure

- NCT03929289 1344 1345 O
Claustrophobia NCT03929289 1347 1361 B-Condition
or NCT03929289 1362 1364 B-Or
respiratory NCT03929289 1365 1376 B-Condition
disorders NCT03929289 1377 1386 I-Condition

Inclusion NCT03928197 0 9 O
Criteria NCT03928197 10 18 O
: NCT03928197 19 20 O

- NCT03928197 24 25 O
Age NCT03928197 27 30 B-Age
between NCT03928197 31 38 B-Eq-Comparison
25 NCT03928197 39 41 I-Eq-Comparison
years NCT03928197 42 47 I-Eq-Comparison
and NCT03928197 48 51 I-Eq-Comparison
60 NCT03928197 52 54 I-Eq-Comparison
years NCT03928197 55 60 I-Eq-Comparison

- NCT03928197 63 64 O
For NCT03928197 66 69 O
the NCT03928197 70 73 O
volunteers NCT03928197 74 84 O
with NCT03928197 85 89 O
venous NCT03928197 90 96 B-Condition
insuffiency NCT03928197 97 108 I-Condition
: NCT03928197 109 110 O
clearly NCT03928197 111 118 B-Modifier
visual NCT03928197 119 125 I-Modifier
venous NCT03928197 126 132 B-Condition
insufficiency NCT03928197 133 146 I-Condition
( NCT03928197 147 148 O
CEAP NCT03928197 149 153 B-Condition
1 NCT03928197 154 155 B-Eq-Comparison
and NCT03928197 156 159 I-Eq-Comparison
2 NCT03928197 160 161 I-Eq-Comparison
) NCT03928197 162 163 O

- NCT03928197 167 168 O
BMI NCT03928197 170 173 B-Observation
between NCT03928197 174 181 B-Eq-Comparison
24 NCT03928197 182 184 I-Eq-Comparison
and NCT03928197 185 188 I-Eq-Comparison
30 NCT03928197 189 191 I-Eq-Comparison

Exclusion NCT03928197 193 202 O
Criteria NCT03928197 203 211 O
: NCT03928197 212 213 O

- NCT03928197 217 218 O
Volunteers NCT03928197 220 230 O
using NCT03928197 231 236 B-Eq-Comparison
medication NCT03928197 237 247 B-Drug
( NCT03928197 248 249 O
exception NCT03928197 250 259 B-Exception
for NCT03928197 260 263 O
contraception NCT03928197 264 277 B-Drug
) NCT03928197 278 279 O

- NCT03928197 283 284 O
Volunteers NCT03928197 286 296 O
having NCT03928197 297 303 B-Eq-Comparison
comorbidities NCT03928197 304 317 B-Condition

- NCT03928197 320 321 O
Pregnant NCT03928197 323 331 B-Condition
women NCT03928197 332 337 O

- NCT03928197 340 341 O
Women NCT03928197 343 348 O
who NCT03928197 349 352 B-And
menstruate NCT03928197 353 363 B-Condition
on NCT03928197 364 366 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928197 367 370 O
test NCT03928197 371 375 B-Study
date NCT03928197 376 380 I-Study

- NCT03928197 383 384 O
Volunteers NCT03928197 386 396 O
with NCT03928197 397 401 O
an NCT03928197 402 404 O
implanted NCT03928197 405 414 B-Procedure
elektronical NCT03928197 415 427 I-Procedure
device NCT03928197 428 434 I-Procedure
( NCT03928197 435 436 O
IPG NCT03928197 437 440 B-Procedure
, NCT03928197 441 442 O
Pacemaker NCT03928197 443 452 B-Procedure
) NCT03928197 453 454 O


Inclusion NCT03922451 0 9 O
Criteria NCT03922451 10 18 O
: NCT03922451 19 20 O

- NCT03922451 24 25 O
supported NCT03922451 27 36 B-Eq-Comparison
on NCT03922451 37 39 O
ECMO NCT03922451 40 44 B-Procedure

- NCT03922451 47 48 O
receive NCT03922451 50 57 B-Eq-Comparison
piperacillin NCT03922451 58 70 B-Drug
- NCT03922451 71 72 I-Drug
tazobactam NCT03922451 73 83 I-Drug
or NCT03922451 84 86 B-Or
cefazolin NCT03922451 87 96 B-Drug
as NCT03922451 97 99 O
part NCT03922451 100 104 O
of NCT03922451 105 107 O
routine NCT03922451 108 115 B-Procedure
care NCT03922451 116 120 I-Procedure
or NCT03922451 121 123 B-Or
infection NCT03922451 124 133 B-Procedure
management NCT03922451 134 144 I-Procedure

Exclusion NCT03922451 145 154 O
Criteria NCT03922451 155 163 O
: NCT03922451 164 165 O

- NCT03922451 169 170 O
> NCT03922451 172 173 B-Eq-Comparison
= NCT03922451 175 176 I-Eq-Comparison
18 NCT03922451 177 179 I-Eq-Comparison
years NCT03922451 180 185 I-Age|Eq-Comparison

- NCT03922451 188 189 O
No NCT03922451 191 193 O
Consent NCT03922451 194 201 O
provided NCT03922451 202 210 O

Key NCT03926637 0 3 O
Inclusion NCT03926637 4 13 O
Criteria NCT03926637 14 22 O
: NCT03926637 23 24 O

- NCT03926637 28 29 O
Ability NCT03926637 31 38 O
to NCT03926637 39 41 O
understand NCT03926637 42 52 O
the NCT03926637 53 56 O
purpose NCT03926637 57 64 O
and NCT03926637 65 68 O
risks NCT03926637 69 74 O
of NCT03926637 75 77 O
the NCT03926637 78 81 O
study NCT03926637 82 87 O
and NCT03926637 88 91 O
provide NCT03926637 92 99 O
signed NCT03926637 100 106 O
and NCT03926637 107 110 O
dated NCT03926637 111 116 O
informed NCT03926637 117 125 O
consent NCT03926637 126 133 O
and NCT03926637 134 137 O
authorization NCT03926637 138 151 O
to NCT03926637 152 154 O
use NCT03926637 155 158 O
confidential NCT03926637 159 171 O
health NCT03926637 172 178 O
information NCT03926637 179 190 O
in NCT03926637 191 193 O
accordance NCT03926637 194 204 O
with NCT03926637 205 209 O
applicable NCT03926637 210 220 O
participant NCT03926637 221 232 O
privacy NCT03926637 233 240 O
regulations NCT03926637 241 252 O

- NCT03926637 255 256 O
Diagnosis NCT03926637 258 267 O
of NCT03926637 268 270 O
MS NCT03926637 271 273 B-Condition
, NCT03926637 274 275 O
including NCT03926637 276 285 O
Clinically NCT03926637 286 296 B-Condition
Isolated NCT03926637 297 305 I-Condition
Syndrome NCT03926637 306 314 I-Condition

- NCT03926637 317 318 O
Ability NCT03926637 320 327 O
to NCT03926637 328 330 O
understand NCT03926637 331 341 O
the NCT03926637 342 345 O
audio NCT03926637 346 351 O
and NCT03926637 352 355 O
visual NCT03926637 356 362 O
instructions NCT03926637 363 375 O
for NCT03926637 376 379 O
the NCT03926637 380 383 O
test NCT03926637 384 388 O
modules NCT03926637 389 396 O

- NCT03926637 399 400 O
Visual NCT03926637 402 408 B-Condition
function NCT03926637 409 417 I-Condition
, NCT03926637 418 419 O
based NCT03926637 420 425 O
on NCT03926637 426 428 O
the NCT03926637 429 432 O
investigator NCT03926637 433 445 O
's NCT03926637 445 447 O
clinical NCT03926637 448 456 O
judgement NCT03926637 457 466 O
that NCT03926637 467 471 O
does NCT03926637 472 476 O
not NCT03926637 477 480 B-Negation
preclude NCT03926637 481 489 O
an NCT03926637 490 492 O
ability NCT03926637 493 500 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926637 501 503 I-Assertion___Assertion-Type-Value:hypothetical
interact NCT03926637 504 512 O
with NCT03926637 513 517 O
the NCT03926637 518 521 O
Multiple NCT03926637 522 530 B-Observation
Sclerosis NCT03926637 531 540 I-Observation
Performance NCT03926637 541 552 I-Observation
Test NCT03926637 553 557 I-Observation
( NCT03926637 558 559 O
MSPT NCT03926637 560 564 B-Observation
) NCT03926637 565 566 O
. NCT03926637 568 569 O

Key NCT03926637 571 574 O
Exclusion NCT03926637 575 584 O
Criteria NCT03926637 585 593 O
: NCT03926637 594 595 O

- NCT03926637 599 600 O
Unable NCT03926637 602 608 O
or NCT03926637 609 611 O
unwilling NCT03926637 612 621 O
to NCT03926637 622 624 O
provide NCT03926637 625 632 O
informed NCT03926637 633 641 O
consent NCT03926637 642 649 O

- NCT03926637 652 653 O
Participants NCT03926637 655 667 O
younger NCT03926637 668 675 B-Eq-Comparison
than NCT03926637 676 680 I-Eq-Comparison
18 NCT03926637 681 683 I-Eq-Comparison
years NCT03926637 684 689 I-Eq-Comparison
of NCT03926637 690 692 O
age NCT03926637 693 696 B-Age
, NCT03926637 697 698 O
unless NCT03926637 699 705 O
their NCT03926637 706 711 O
parent NCT03926637 712 718 O
or NCT03926637 719 721 O
legal NCT03926637 722 727 O
guardian NCT03926637 728 736 O
provides NCT03926637 737 745 O
the NCT03926637 746 749 O
required NCT03926637 750 758 O
signed NCT03926637 759 765 O
and NCT03926637 766 769 O
dated NCT03926637 770 775 O
informed NCT03926637 776 784 O
consent NCT03926637 785 792 O
and NCT03926637 793 796 O
authorization NCT03926637 797 810 O
to NCT03926637 811 813 O
use NCT03926637 814 817 O
confidential NCT03926637 818 830 O
health NCT03926637 831 837 O
information NCT03926637 838 849 O
and NCT03926637 850 853 O
the NCT03926637 854 857 O
participant NCT03926637 858 869 O
provides NCT03926637 870 878 O
assent NCT03926637 879 885 O
in NCT03926637 886 888 O
accordance NCT03926637 889 899 O
with NCT03926637 900 904 O
national NCT03926637 905 913 O
and NCT03926637 914 917 O
local NCT03926637 918 923 O
subject NCT03926637 924 931 O
privacy NCT03926637 932 939 O
regulations NCT03926637 940 951 O

NOTE NCT03926637 952 956 O
: NCT03926637 957 958 O
Other NCT03926637 959 964 O
protocol NCT03926637 965 973 O
defined NCT03926637 974 981 O
Inclusion NCT03926637 982 991 O
/ NCT03926637 992 993 O
Exclusion NCT03926637 994 1003 O
criteria NCT03926637 1004 1012 O
may NCT03926637 1013 1016 O
apply NCT03926637 1017 1022 O
. NCT03926637 1022 1023 O

Inclusion NCT03929510 0 9 O
Criteria NCT03929510 10 18 O
: NCT03929510 19 20 O

- NCT03929510 24 25 O
Male NCT03929510 27 31 O
participants NCT03929510 32 44 O
who NCT03929510 45 48 B-And
are NCT03929510 49 52 O
healthy NCT03929510 53 60 B-Condition
as NCT03929510 61 63 O
determined NCT03929510 64 74 O
by NCT03929510 75 77 O
medical NCT03929510 78 85 B-Procedure
evaluation NCT03929510 86 96 I-Procedure
including NCT03929510 97 106 O
a NCT03929510 107 108 O
detailed NCT03929510 109 117 O
medical NCT03929510 118 125 O
history NCT03929510 126 133 O
, NCT03929510 134 135 O
full NCT03929510 136 140 B-Modifier
physical NCT03929510 141 149 B-Procedure
examination NCT03929510 150 161 I-Procedure
, NCT03929510 162 163 O
including NCT03929510 164 173 O
blood NCT03929510 174 179 B-Observation
pressure NCT03929510 180 188 I-Observation
( NCT03929510 189 190 O
BP NCT03929510 191 193 B-Observation
) NCT03929510 194 195 O
and NCT03929510 196 199 B-And
pulse NCT03929510 200 205 B-Observation
rate NCT03929510 206 210 I-Observation
( NCT03929510 211 212 O
PR NCT03929510 213 215 B-Observation
) NCT03929510 216 217 O
measurement NCT03929510 218 229 O
, NCT03929510 230 231 O
12 NCT03929510 232 234 B-Procedure
lead NCT03929510 235 239 I-Procedure
ECG NCT03929510 240 243 I-Procedure
, NCT03929510 244 245 O
and NCT03929510 246 249 O
clinical NCT03929510 250 258 O
laboratory NCT03929510 259 269 B-Observation
tests NCT03929510 270 275 I-Observation
. NCT03929510 276 277 O

- NCT03929510 281 282 O
Body NCT03929510 284 288 B-Observation
mass NCT03929510 289 293 I-Observation
index NCT03929510 294 299 I-Observation
( NCT03929510 300 301 O
BMI NCT03929510 302 305 B-Observation
) NCT03929510 306 307 O
of NCT03929510 308 310 O
17.5 NCT03929510 311 315 B-Eq-Comparison
to NCT03929510 316 318 I-Eq-Comparison
30.5 NCT03929510 319 323 I-Eq-Comparison
kg NCT03929510 324 326 I-Eq-Comparison
/ NCT03929510 327 328 I-Eq-Comparison
m2 NCT03929510 329 331 I-Eq-Comparison
; NCT03929510 331 332 O
and NCT03929510 333 336 O
a NCT03929510 337 338 O
total NCT03929510 339 344 O
body NCT03929510 345 349 B-Observation
weight NCT03929510 350 356 I-Observation
> NCT03929510 357 358 B-Eq-Comparison
50 NCT03929510 359 361 I-Eq-Comparison
kg NCT03929510 362 364 I-Eq-Comparison
( NCT03929510 365 366 O
110 NCT03929510 367 370 B-Eq-Comparison
lb NCT03929510 371 373 I-Eq-Comparison
) NCT03929510 374 375 O
. NCT03929510 377 378 O

Exclusion NCT03929510 380 389 O
Criteria NCT03929510 390 398 O
: NCT03929510 399 400 O

- NCT03929510 404 405 O
Known NCT03929510 407 412 O
immunodeficiency NCT03929510 413 429 B-Condition
disorder NCT03929510 430 438 I-Condition
, NCT03929510 439 440 O
including NCT03929510 441 450 O
positive NCT03929510 451 459 O
serology NCT03929510 460 468 O
for NCT03929510 469 472 O
human NCT03929510 473 478 B-Condition
immunodeficiency NCT03929510 479 495 I-Condition
virus NCT03929510 496 501 I-Condition
( NCT03929510 502 503 O
HIV NCT03929510 504 507 B-Condition
) NCT03929510 508 509 O
at NCT03929510 510 512 B-Temporal-Connection___Temporal-Connection-Type-Value:during
screening NCT03929510 513 522 B-Study
, NCT03929510 523 524 O
or NCT03929510 525 527 B-Or
a NCT03929510 528 529 O
first NCT03929510 530 535 B-Modifier
degree NCT03929510 536 542 I-Modifier
relative NCT03929510 543 551 B-Family-Member
with NCT03929510 552 556 O
a NCT03929510 557 558 O
hereditary NCT03929510 559 569 B-Modifier
immunodeficiency NCT03929510 570 586 B-Condition
. NCT03929510 587 588 O

- NCT03929510 592 593 O
Infection NCT03929510 595 604 B-Condition
with NCT03929510 605 609 I-Condition
hepatitis NCT03929510 610 619 I-Condition
B NCT03929510 620 621 I-Condition
or NCT03929510 622 624 B-Or
hepatitis NCT03929510 625 634 B-Condition
C NCT03929510 635 636 I-Condition
viruses NCT03929510 637 644 I-Condition
. NCT03929510 645 646 O

- NCT03929510 650 651 O
Participants NCT03929510 653 665 O
with NCT03929510 666 670 O
selected NCT03929510 671 679 O
acute NCT03929510 680 685 O
or NCT03929510 686 688 O
chronic NCT03929510 689 696 B-Condition
infections NCT03929510 697 707 I-Condition
or NCT03929510 708 710 B-Or
infection NCT03929510 711 720 B-Condition
history NCT03929510 721 728 B-Eq-Comparison
. NCT03929510 729 730 O

- NCT03929510 734 735 O
Participants NCT03929510 737 749 O
have NCT03929510 750 754 O
a NCT03929510 755 756 O
known NCT03929510 757 762 O
present NCT03929510 763 770 B-Eq-Comparison
or NCT03929510 771 773 B-Or
a NCT03929510 774 775 O
history NCT03929510 776 783 B-Eq-Comparison
of NCT03929510 784 786 O
malignancy NCT03929510 787 797 B-Condition
other NCT03929510 798 803 B-Exception
than NCT03929510 804 808 I-Exception
a NCT03929510 809 810 O
successfully NCT03929510 811 823 O
treated NCT03929510 824 831 B-Procedure
or NCT03929510 832 834 B-Or
excised NCT03929510 835 842 B-Procedure
non NCT03929510 843 846 B-Modifier
metastatic NCT03929510 847 857 I-Modifier
basal NCT03929510 858 863 I-Modifier
cell NCT03929510 864 868 I-Modifier
or NCT03929510 869 871 B-Or
squamous NCT03929510 872 880 B-Modifier
cell NCT03929510 881 885 I-Modifier
cancer NCT03929510 886 892 B-Condition
of NCT03929510 893 895 O
the NCT03929510 896 899 O
skin NCT03929510 900 904 B-Modifier
. NCT03929510 905 906 O

- NCT03929510 910 911 O
History NCT03929510 913 920 B-Eq-Comparison
of NCT03929510 921 923 O
alcohol NCT03929510 924 931 B-Condition
abuse NCT03929510 932 937 I-Condition
or NCT03929510 938 940 B-Or
binge NCT03929510 941 946 B-Condition
drinking NCT03929510 947 955 I-Condition
and NCT03929510 956 959 B-Or
/ NCT03929510 960 961 I-Or
or NCT03929510 962 964 I-Or
any NCT03929510 965 968 O
other NCT03929510 969 974 B-Other
illicit NCT03929510 975 982 B-Condition
drug NCT03929510 983 987 I-Condition
use NCT03929510 988 991 I-Condition
or NCT03929510 992 994 B-Or
dependence NCT03929510 995 1005 B-Condition
within NCT03929510 1006 1012 B-Eq-Comparison
6 NCT03929510 1013 1014 I-Eq-Comparison
months NCT03929510 1015 1021 I-Eq-Comparison
of NCT03929510 1022 1024 B-Temporal-Connection___Temporal-Connection-Type-Value:before
Screening NCT03929510 1025 1034 B-Study
. NCT03929510 1035 1036 O

- NCT03929510 1040 1041 O
Use NCT03929510 1043 1046 O
of NCT03929510 1047 1049 O
tobacco NCT03929510 1050 1057 B-Drug
/ NCT03929510 1058 1059 B-Or
nicotine NCT03929510 1060 1068 B-Drug
containing NCT03929510 1069 1079 O
products NCT03929510 1080 1088 O
within NCT03929510 1089 1095 B-Eq-Comparison
3 NCT03929510 1096 1097 I-Eq-Comparison
months NCT03929510 1098 1104 I-Eq-Comparison
prior NCT03929510 1105 1110 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03929510 1111 1113 O
dosing NCT03929510 1114 1120 O
or NCT03929510 1121 1123 O
positive NCT03929510 1124 1132 O
urine NCT03929510 1133 1138 B-Observation
cotinine NCT03929510 1139 1147 I-Observation
test NCT03929510 1148 1152 I-Observation
. NCT03929510 1152 1153 O

Inclusion NCT03924752 0 9 O
Criteria NCT03924752 10 18 O
: NCT03924752 19 20 O

- NCT03924752 24 25 O
Between NCT03924752 27 34 B-Eq-Comparison
18 NCT03924752 35 37 I-Eq-Comparison
- NCT03924752 38 39 I-Eq-Comparison
85 NCT03924752 40 42 I-Eq-Comparison
years NCT03924752 43 48 I-Eq-Comparison
of NCT03924752 49 51 O
age NCT03924752 52 55 B-Age

- NCT03924752 58 59 O
Subjects NCT03924752 61 69 O
should NCT03924752 70 76 O
be NCT03924752 77 79 O
capable NCT03924752 80 87 B-Condition
of NCT03924752 88 90 I-Condition
walking NCT03924752 91 98 B-Modifier
, NCT03924752 99 100 O
ascending NCT03924752 101 110 B-Modifier
/ NCT03924752 111 112 I-Modifier
descending NCT03924752 113 123 I-Modifier
stairs NCT03924752 124 130 I-Modifier
and NCT03924752 131 134 O
ramps NCT03924752 135 140 O
with NCT03924752 141 145 B-And
full NCT03924752 146 150 B-Condition
capability NCT03924752 151 161 I-Condition
in NCT03924752 162 164 I-Condition
lower NCT03924752 165 170 I-Condition
extremity NCT03924752 171 180 I-Condition
passive NCT03924752 181 188 I-Condition
range NCT03924752 189 194 I-Condition
of NCT03924752 195 197 I-Condition
motion NCT03924752 198 204 I-Condition
( NCT03924752 205 206 O
knee NCT03924752 207 211 B-Observation
flexion NCT03924752 212 219 I-Observation
contracture NCT03924752 220 231 I-Observation
of NCT03924752 232 234 O
> NCT03924752 235 236 B-Eq-Comparison
10 NCT03924752 237 239 I-Eq-Comparison
degrees NCT03924752 240 247 I-Eq-Comparison
, NCT03924752 248 249 O
knee NCT03924752 250 254 B-Observation
flexion NCT03924752 255 262 I-Observation
ROM NCT03924752 263 266 I-Observation
< NCT03924752 267 268 B-Eq-Comparison
90 NCT03924752 269 271 I-Eq-Comparison
degrees NCT03924752 272 279 I-Eq-Comparison
, NCT03924752 280 281 O
hip NCT03924752 282 285 B-Observation
flexion NCT03924752 286 293 I-Observation
contracture NCT03924752 294 305 I-Observation
< NCT03924752 306 307 B-Eq-Comparison
25 NCT03924752 308 310 I-Eq-Comparison
degrees NCT03924752 311 318 I-Eq-Comparison
, NCT03924752 319 320 O
and NCT03924752 321 324 B-And
ankle NCT03924752 325 330 B-Observation
plantar NCT03924752 331 338 I-Observation
flexion NCT03924752 339 346 I-Observation
contracture NCT03924752 347 358 I-Observation
of NCT03924752 359 361 O
> NCT03924752 362 363 B-Eq-Comparison
15 NCT03924752 364 366 I-Eq-Comparison
degrees NCT03924752 367 374 I-Eq-Comparison
) NCT03924752 375 376 O
. NCT03924752 378 379 O

- NCT03924752 383 384 O
Subjects NCT03924752 386 394 O
must NCT03924752 395 399 O
be NCT03924752 400 402 O
able NCT03924752 403 407 B-Condition
to NCT03924752 408 410 I-Condition
walk NCT03924752 411 415 I-Condition
for NCT03924752 416 419 O
at NCT03924752 420 422 B-Eq-Comparison
least NCT03924752 423 428 I-Eq-Comparison
5 NCT03924752 429 430 I-Eq-Comparison
minutes NCT03924752 431 438 I-Eq-Comparison
and NCT03924752 439 442 B-And
willing NCT03924752 443 450 O
and NCT03924752 451 454 O
able NCT03924752 455 459 B-Condition
to NCT03924752 460 462 I-Condition
participate NCT03924752 463 474 I-Condition
over NCT03924752 475 479 O
a NCT03924752 480 481 O
1 NCT03924752 482 483 B-Eq-Comparison
- NCT03924752 484 485 I-Eq-Comparison
6 NCT03924752 486 487 I-Eq-Comparison
hours NCT03924752 488 493 I-Eq-Comparison
experiment NCT03924752 494 504 O
with NCT03924752 505 509 O
breaks NCT03924752 510 516 O
and NCT03924752 517 520 O
rest NCT03924752 521 525 O
enforced NCT03924752 526 534 O
regularly NCT03924752 535 544 O
and NCT03924752 545 548 O
as NCT03924752 549 551 O
needed NCT03924752 552 558 O
. NCT03924752 559 560 O

- NCT03924752 564 565 O
Subjects NCT03924752 567 575 O
must NCT03924752 576 580 O
be NCT03924752 581 583 O
able NCT03924752 584 588 B-Condition
to NCT03924752 589 591 I-Condition
transfer NCT03924752 592 600 I-Condition
( NCT03924752 601 602 O
sit NCT03924752 603 606 B-Condition
- NCT03924752 607 608 I-Condition
to NCT03924752 609 611 I-Condition
- NCT03924752 612 613 I-Condition
stand NCT03924752 614 619 I-Condition
and NCT03924752 620 623 B-And
stand NCT03924752 624 629 B-Condition
- NCT03924752 630 631 I-Condition
to NCT03924752 632 634 I-Condition
- NCT03924752 635 636 I-Condition
sit NCT03924752 637 640 I-Condition
) NCT03924752 641 642 O
with NCT03924752 643 647 O
no NCT03924752 648 650 O
external NCT03924752 651 659 O
support NCT03924752 660 667 O
( NCT03924752 668 669 O
arm NCT03924752 670 673 O
rests NCT03924752 674 679 O
OK NCT03924752 680 682 O
) NCT03924752 683 684 O
and NCT03924752 685 688 O
to NCT03924752 689 691 O
ambulate NCT03924752 692 700 B-Condition
over NCT03924752 701 705 B-Modifier
small NCT03924752 706 711 I-Modifier
slopes NCT03924752 712 718 I-Modifier
( NCT03924752 719 720 O
3 NCT03924752 721 722 B-Eq-Comparison
degrees NCT03924752 723 730 I-Eq-Comparison
) NCT03924752 731 732 O
and NCT03924752 733 736 B-And
a NCT03924752 737 738 O
few NCT03924752 739 742 O
steps NCT03924752 743 748 B-Modifier
( NCT03924752 749 750 O
6 NCT03924752 751 752 B-Eq-Comparison
steps NCT03924752 753 758 I-Eq-Comparison
) NCT03924752 759 760 O
. NCT03924752 762 763 O

Exclusion NCT03924752 765 774 O
Criteria NCT03924752 775 783 O
: NCT03924752 784 785 O

- NCT03924752 789 790 O
History NCT03924752 792 799 B-Eq-Comparison
of NCT03924752 800 802 O
neurological NCT03924752 803 815 B-Condition
injury NCT03924752 816 822 I-Condition
, NCT03924752 823 824 O
gait NCT03924752 825 829 B-Condition
pathology NCT03924752 830 839 I-Condition
, NCT03924752 840 841 O
or NCT03924752 842 844 B-Or
cardiovascular NCT03924752 845 859 B-Condition
condition NCT03924752 860 869 I-Condition
that NCT03924752 870 874 O
would NCT03924752 875 880 B-Assertion___Assertion-Type-Value:hypothetical
limit NCT03924752 881 886 O
your NCT03924752 887 891 O
ability NCT03924752 892 899 B-Condition
to NCT03924752 900 902 I-Condition
ambulate NCT03924752 903 911 I-Condition
for NCT03924752 912 915 O
multiple NCT03924752 916 924 B-Eq-Comparison
hours NCT03924752 925 930 I-Eq-Comparison
. NCT03924752 930 931 O

Inclusion NCT03929276 0 9 O
Criteria NCT03929276 10 18 O
: NCT03929276 19 20 O

- NCT03929276 24 25 O
Subjects NCT03929276 27 35 O
with NCT03929276 36 40 O
adhesive NCT03929276 41 49 B-Condition
capsulitis NCT03929276 50 60 I-Condition
diagnosis NCT03929276 61 70 O
by NCT03929276 71 73 O
physical NCT03929276 74 82 B-Procedure
examination NCT03929276 83 94 I-Procedure
( NCT03929276 95 96 O
Compared NCT03929276 97 105 O
with NCT03929276 106 110 O
intact NCT03929276 111 117 O
side NCT03929276 118 122 O
, NCT03929276 123 124 O
there NCT03929276 125 130 O
is NCT03929276 131 133 O
more NCT03929276 134 138 B-Eq-Comparison
than NCT03929276 139 143 I-Eq-Comparison
25 NCT03929276 144 146 I-Eq-Comparison
% NCT03929276 147 148 I-Eq-Comparison
limitation NCT03929276 149 159 O
in NCT03929276 160 162 O
at NCT03929276 163 165 B-Eq-Comparison
least NCT03929276 166 171 I-Eq-Comparison
two NCT03929276 172 175 I-Eq-Comparison
directions NCT03929276 176 186 I-Eq-Comparison
of NCT03929276 187 189 O
shoulder NCT03929276 190 198 B-Observation
range NCT03929276 199 204 I-Observation
of NCT03929276 205 207 I-Observation
motion NCT03929276 208 214 I-Observation
) NCT03929276 215 216 O

- NCT03929276 220 221 O
Subjects NCT03929276 223 231 O
have NCT03929276 232 236 O
complaints NCT03929276 237 247 B-Condition
for NCT03929276 248 251 O
at NCT03929276 252 254 B-Eq-Comparison
least NCT03929276 255 260 I-Eq-Comparison
1 NCT03929276 261 262 I-Eq-Comparison
month NCT03929276 263 268 I-Eq-Comparison

- NCT03929276 271 272 O
No NCT03929276 274 276 B-Negation
pregnancy NCT03929276 277 286 B-Condition
/ NCT03929276 287 288 B-Or
breastfeeding NCT03929276 289 302 B-Condition

Exclusion NCT03929276 303 312 O
Criteria NCT03929276 313 321 O
: NCT03929276 322 323 O

- NCT03929276 327 328 O
History NCT03929276 330 337 B-Eq-Comparison
of NCT03929276 338 340 O
bilateral NCT03929276 341 350 B-Modifier
adhesive NCT03929276 351 359 B-Condition
capsulitis NCT03929276 360 370 I-Condition

- NCT03929276 373 374 O
History NCT03929276 376 383 B-Eq-Comparison
of NCT03929276 384 386 O
shoulder NCT03929276 387 395 B-Modifier
trauma NCT03929276 396 402 B-Condition
, NCT03929276 403 404 O
fracture NCT03929276 405 413 B-Condition
, NCT03929276 414 415 O
shoulder NCT03929276 416 424 B-Procedure
shoulder NCT03929276 425 433 I-Procedure
surgery NCT03929276 434 441 I-Procedure
, NCT03929276 442 443 O
calcific NCT03929276 444 452 B-Condition
tendinopathy NCT03929276 453 465 I-Condition
, NCT03929276 466 467 O
glenohumeral NCT03929276 468 480 B-Condition
osteoarthritis NCT03929276 481 495 I-Condition
, NCT03929276 496 497 O
inflammatory NCT03929276 498 510 B-Condition
rheumatic NCT03929276 511 520 I-Condition
diseases NCT03929276 521 529 I-Condition
, NCT03929276 530 531 O
tumor NCT03929276 532 537 B-Condition
, NCT03929276 538 539 O
infection NCT03929276 540 549 B-Condition

- NCT03929276 552 553 O
History NCT03929276 555 562 B-Eq-Comparison
of NCT03929276 563 565 O
corticosteroid NCT03929276 566 580 B-Drug
injection NCT03929276 581 590 O
in NCT03929276 591 593 O
the NCT03929276 594 597 O
shoulder NCT03929276 598 606 B-Modifier
during NCT03929276 607 613 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03929276 614 617 O
last NCT03929276 618 622 B-Eq-Comparison
3 NCT03929276 623 624 I-Eq-Comparison
months NCT03929276 625 631 I-Eq-Comparison

- NCT03929276 634 635 O
History NCT03929276 637 644 B-Eq-Comparison
of NCT03929276 645 647 O
recent NCT03929276 648 654 B-Eq-Comparison
lung NCT03929276 655 659 B-Modifier
, NCT03929276 660 661 O
breast NCT03929276 662 668 B-Modifier
or NCT03929276 669 671 B-Or
bypass NCT03929276 672 678 B-Modifier
surgery NCT03929276 679 686 B-Procedure

- NCT03929276 689 690 O
History NCT03929276 692 699 B-Eq-Comparison
of NCT03929276 700 702 O
cervical NCT03929276 703 711 B-Condition
radiculopathy NCT03929276 712 725 I-Condition
/ NCT03929276 726 727 B-Or
brachial NCT03929276 728 736 B-Condition
plexus NCT03929276 737 743 I-Condition
lesion NCT03929276 744 750 I-Condition

- NCT03929276 753 754 O
History NCT03929276 756 763 B-Eq-Comparison
of NCT03929276 764 766 O
neuromuscular NCT03929276 767 780 B-Condition
disease NCT03929276 781 788 I-Condition

- NCT03929276 791 792 O
History NCT03929276 794 801 B-Eq-Comparison
of NCT03929276 802 804 O
physical NCT03929276 805 813 B-Procedure
therapy NCT03929276 814 821 I-Procedure
program NCT03929276 822 829 O
for NCT03929276 830 833 O
the NCT03929276 834 837 O
same NCT03929276 838 842 B-Modifier
shoulder NCT03929276 843 851 I-Modifier
in NCT03929276 852 854 O
the NCT03929276 855 858 O
last NCT03929276 859 863 B-Eq-Comparison
6 NCT03929276 864 865 I-Eq-Comparison
months NCT03929276 866 872 I-Eq-Comparison

Inclusion NCT03921164 0 9 O
Criteria NCT03921164 10 18 O
: NCT03921164 19 20 O

- NCT03921164 24 25 O
Patients NCT03921164 27 35 O
> NCT03921164 36 37 B-Eq-Comparison
18 NCT03921164 38 40 I-Eq-Comparison
years NCT03921164 41 46 I-Age|Eq-Comparison
, NCT03921164 47 48 O
scheduled NCT03921164 49 58 B-Eq-Comparison
for NCT03921164 59 62 O
an NCT03921164 63 65 O
elective NCT03921164 66 74 B-Procedure
interventional NCT03921164 75 89 B-Procedure
neuroradiology NCT03921164 90 104 I-Procedure
procedure NCT03921164 105 114 I-Procedure
under NCT03921164 115 120 O
general NCT03921164 121 128 B-Procedure
anesthesia NCT03921164 129 139 I-Procedure
requiring NCT03921164 140 149 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03921164 150 151 O
continuous NCT03921164 152 162 O
monitoring NCT03921164 163 173 O
of NCT03921164 174 176 O
mean NCT03921164 177 181 B-Observation
arterial NCT03921164 182 190 I-Observation
pressure NCT03921164 191 199 I-Observation
and NCT03921164 200 203 B-And
cardiac NCT03921164 204 211 B-Observation
output NCT03921164 212 218 I-Observation
. NCT03921164 219 220 O

Exclusion NCT03921164 222 231 O
Criteria NCT03921164 232 240 O
: NCT03921164 241 242 O

- NCT03921164 246 247 O
age NCT03921164 249 252 B-Age
< NCT03921164 253 254 B-Eq-Comparison
18 NCT03921164 255 257 I-Eq-Comparison
years NCT03921164 258 263 I-Eq-Comparison

- NCT03921164 266 267 O
Patient NCT03921164 269 276 O
who NCT03921164 277 280 O
has NCT03921164 281 284 O
not NCT03921164 285 288 O
signed NCT03921164 289 295 O
the NCT03921164 296 299 O
consent NCT03921164 300 307 O

- NCT03921164 310 311 O
Pregnant NCT03921164 313 321 B-Condition
woman NCT03921164 322 327 O

- NCT03921164 330 331 O
Patient NCT03921164 333 340 O
under NCT03921164 341 346 O
judicial NCT03921164 347 355 B-Observation
protection NCT03921164 356 366 I-Observation

- NCT03921164 369 370 O
Patient NCT03921164 372 379 O
without NCT03921164 380 387 O
affiliation NCT03921164 388 399 O
to NCT03921164 400 402 O
a NCT03921164 403 404 O
social NCT03921164 405 411 O
security NCT03921164 412 420 O
scheme NCT03921164 421 427 O

Inclusion NCT03928626 0 9 O
Criteria NCT03928626 10 18 O
: NCT03928626 19 20 O

1 NCT03928626 24 25 O
. NCT03928626 25 26 O
Adults NCT03928626 28 34 O
ages NCT03928626 35 39 B-Age
18 NCT03928626 40 42 B-Eq-Comparison
- NCT03928626 43 44 I-Eq-Comparison
25 NCT03928626 45 47 O

2 NCT03928626 51 52 O
. NCT03928626 52 53 O
Capability NCT03928626 55 65 O
of NCT03928626 66 68 O
performing NCT03928626 69 79 O
the NCT03928626 80 83 O
experimental NCT03928626 84 96 O
tasks NCT03928626 97 102 O
( NCT03928626 103 104 O
e. NCT03928626 105 107 O
g. NCT03928626 108 110 O
, NCT03928626 111 112 O
can NCT03928626 113 116 O
read NCT03928626 117 121 O
, NCT03928626 122 123 O
able NCT03928626 124 128 O
to NCT03928626 129 131 O
use NCT03928626 132 135 O
computers NCT03928626 136 145 O
) NCT03928626 146 147 O

3 NCT03928626 151 152 O
. NCT03928626 152 153 O
Native NCT03928626 155 161 O
or NCT03928626 162 164 O
fluent NCT03928626 165 171 O
speaker NCT03928626 172 179 O
of NCT03928626 180 182 O
English NCT03928626 183 190 O

4 NCT03928626 193 194 O
. NCT03928626 194 195 O
Provides NCT03928626 197 205 O
informed NCT03928626 206 214 O
consent NCT03928626 215 222 O

5 NCT03928626 225 226 O
. NCT03928626 226 227 O
Normal NCT03928626 229 235 O
or NCT03928626 236 238 B-Or
corrected NCT03928626 239 248 O
- NCT03928626 249 250 O
to NCT03928626 251 253 O
- NCT03928626 254 255 O
normal NCT03928626 256 262 O
vision NCT03928626 263 269 B-Condition

6 NCT03928626 272 273 O
. NCT03928626 273 274 O
Willing NCT03928626 276 283 O
to NCT03928626 284 286 O
commit NCT03928626 287 293 O
to NCT03928626 294 296 O
the NCT03928626 297 300 O
full NCT03928626 301 305 O
length NCT03928626 306 312 O
of NCT03928626 313 315 O
the NCT03928626 316 319 O
protocol NCT03928626 320 328 O

7 NCT03928626 331 332 O
. NCT03928626 332 333 O
Heavy NCT03928626 335 340 B-Condition
drinking NCT03928626 341 349 I-Condition
or NCT03928626 350 352 B-Or
binge NCT03928626 353 358 B-Condition
- NCT03928626 359 360 I-Condition
drinking NCT03928626 361 369 I-Condition

Exclusion NCT03928626 370 379 O
Criteria NCT03928626 380 388 O
. NCT03928626 389 390 O

1 NCT03928626 394 395 O
. NCT03928626 395 396 O
Present NCT03928626 398 405 B-Eq-Comparison
DSM NCT03928626 406 409 B-Condition
disorders NCT03928626 410 419 I-Condition
, NCT03928626 420 421 O
apart NCT03928626 422 427 B-Exception
from NCT03928626 428 432 I-Exception
alcohol NCT03928626 433 440 B-Condition
use NCT03928626 441 444 I-Condition
disorders NCT03928626 445 454 I-Condition

2 NCT03928626 457 458 O
. NCT03928626 458 459 O
Reports NCT03928626 461 468 O
of NCT03928626 469 471 O
neurological NCT03928626 472 484 B-Modifier
or NCT03928626 485 487 B-Or
systemic NCT03928626 488 496 B-Modifier
disorders NCT03928626 497 506 B-Condition
that NCT03928626 507 511 O
can NCT03928626 512 515 B-Assertion___Assertion-Type-Value:hypothetical
cause NCT03928626 516 521 O
cognitive NCT03928626 522 531 B-Condition
impairment NCT03928626 532 542 I-Condition

3 NCT03928626 545 546 O
. NCT03928626 546 547 O
Minor NCT03928626 549 554 O
cognitive NCT03928626 555 564 B-Condition
impairment NCT03928626 565 575 I-Condition
evidenced NCT03928626 576 585 O
by NCT03928626 586 588 O
an NCT03928626 589 591 O
inability NCT03928626 592 601 B-Condition
to NCT03928626 602 604 I-Condition
correctly NCT03928626 605 614 I-Condition
understand NCT03928626 615 625 I-Condition
study NCT03928626 626 631 B-Study
information NCT03928626 632 643 O

4 NCT03928626 646 647 O
. NCT03928626 647 648 O
Reports NCT03928626 650 657 O
entirely NCT03928626 658 666 O
no NCT03928626 667 669 B-Negation
interest NCT03928626 670 678 B-Assertion___Assertion-Type-Value:intention
in NCT03928626 679 681 O
reducing NCT03928626 682 690 O
the NCT03928626 691 694 O
amount NCT03928626 695 701 O
of NCT03928626 702 704 O
drinking NCT03928626 705 713 B-Condition
( NCT03928626 714 715 O
Alcohol NCT03928626 716 723 B-Observation
Contemplation NCT03928626 724 737 I-Observation
Ladder NCT03928626 738 744 I-Observation
score NCT03928626 745 750 I-Observation
of NCT03928626 751 753 O
9 NCT03928626 754 755 B-Eq-Comparison
or NCT03928626 756 758 I-Eq-Comparison
10 NCT03928626 759 761 I-Eq-Comparison
) NCT03928626 762 763 O
. NCT03928626 764 765 O

Inclusion NCT03926780 0 9 O
Criteria NCT03926780 10 18 O
: NCT03926780 19 20 O

- NCT03926780 24 25 O
Evidence NCT03926780 27 35 O
of NCT03926780 36 38 O
LV NCT03926780 39 41 B-Condition
thrombus NCT03926780 42 50 I-Condition
as NCT03926780 51 53 O
assessed NCT03926780 54 62 O
by NCT03926780 63 65 O
trans NCT03926780 66 71 B-Procedure
- NCT03926780 72 73 I-Procedure
thoracic NCT03926780 74 82 I-Procedure
echocardiography NCT03926780 83 99 I-Procedure
( NCT03926780 100 101 O
TTE NCT03926780 102 105 B-Procedure
) NCT03926780 106 107 O
. NCT03926780 109 110 O

Exclusion NCT03926780 112 121 O
Criteria NCT03926780 122 130 O
: NCT03926780 131 132 O

- NCT03926780 136 137 O
Creatinine NCT03926780 139 149 B-Observation
clearance NCT03926780 150 159 I-Observation
less NCT03926780 160 164 B-Eq-Comparison
than NCT03926780 165 169 I-Eq-Comparison
50 NCT03926780 170 172 I-Eq-Comparison
ml NCT03926780 173 175 I-Eq-Comparison
/ NCT03926780 176 177 I-Eq-Comparison
min NCT03926780 178 181 I-Eq-Comparison
. NCT03926780 181 182 O

Inclusion NCT03922243 0 9 O
Criteria NCT03922243 10 18 O
: NCT03922243 19 20 O

- NCT03922243 24 25 O
Dental NCT03922243 27 33 B-Procedure
treatment NCT03922243 34 43 I-Procedure
performed NCT03922243 44 53 O
in NCT03922243 54 56 O
the NCT03922243 57 60 O
time NCT03922243 61 65 O
frame NCT03922243 66 71 O

Exclusion NCT03922243 72 81 O
Criteria NCT03922243 82 90 O
: NCT03922243 91 92 O

- NCT03922243 96 97 O
Dental NCT03922243 99 105 B-Procedure
treatment NCT03922243 106 115 I-Procedure
not NCT03922243 116 119 B-Negation
performed NCT03922243 120 129 O

Inclusion NCT03920332 0 9 O
Criteria NCT03920332 10 18 O
: NCT03920332 19 20 O

- NCT03920332 24 25 O
Inherited NCT03920332 27 36 B-Condition
fibrinogen NCT03920332 37 47 I-Condition
disorders NCT03920332 48 57 I-Condition
( NCT03920332 58 59 O
hypofibrinogenemia NCT03920332 60 78 B-Condition
, NCT03920332 79 80 O
dysfibrinogenemia NCT03920332 81 98 B-Condition
, NCT03920332 99 100 O
hypodysfibrinogenemia NCT03920332 101 122 B-Condition
) NCT03920332 123 124 O

- NCT03920332 128 129 O
At NCT03920332 131 133 B-Eq-Comparison
lest NCT03920332 134 138 I-Eq-Comparison
one NCT03920332 139 142 I-Eq-Comparison
past NCT03920332 143 147 I-Eq-Comparison
pregnancy NCT03920332 148 157 B-Condition

- NCT03920332 160 161 O
Adult NCT03920332 163 168 O

Exclusion NCT03920332 169 178 O
Criteria NCT03920332 179 187 O
: NCT03920332 188 189 O

- NCT03920332 193 194 O
No NCT03920332 196 198 B-Negation
past NCT03920332 199 203 B-Eq-Comparison
pregnancy NCT03920332 204 213 B-Condition

- NCT03920332 216 217 O
Not NCT03920332 219 222 B-Negation
confirmed NCT03920332 223 232 O
fibrinogen NCT03920332 233 243 B-Condition
disorder NCT03920332 244 252 I-Condition

Inclusion NCT03929458 0 9 O
Criteria NCT03929458 10 18 O
: NCT03929458 19 20 O

- NCT03929458 24 25 O
Both NCT03929458 27 31 O
sexes NCT03929458 32 37 O
aged NCT03929458 38 42 B-Age
between NCT03929458 43 50 O
20 NCT03929458 51 53 B-Eq-Comparison
- NCT03929458 54 55 I-Eq-Comparison
90 NCT03929458 56 58 I-Eq-Comparison
years NCT03929458 59 64 I-Eq-Comparison
. NCT03929458 65 66 O

- NCT03929458 70 71 O
Received NCT03929458 73 81 B-Eq-Comparison
stable NCT03929458 82 88 O
hemodialysis NCT03929458 89 101 B-Procedure
at NCT03929458 102 104 B-Eq-Comparison
least NCT03929458 105 110 I-Eq-Comparison
3 NCT03929458 111 112 I-Eq-Comparison
months NCT03929458 113 119 I-Eq-Comparison
. NCT03929458 120 121 O

- NCT03929458 125 126 O
Written NCT03929458 128 135 O
informed NCT03929458 136 144 O
consent NCT03929458 145 152 O
. NCT03929458 153 154 O

Exclusion NCT03929458 156 165 O
Criteria NCT03929458 166 174 O
: NCT03929458 175 176 O

- NCT03929458 180 181 O
patients NCT03929458 183 191 O
with NCT03929458 192 196 O
severe NCT03929458 197 203 O
infections NCT03929458 204 214 B-Condition
, NCT03929458 215 216 O
severe NCT03929458 217 223 O
heart NCT03929458 224 229 B-Condition
disease NCT03929458 230 237 I-Condition
and NCT03929458 238 241 B-Or
liver NCT03929458 242 247 B-Condition
disease NCT03929458 248 255 I-Condition
, NCT03929458 256 257 O
malignancy NCT03929458 258 268 B-Condition
, NCT03929458 269 270 O
autoimmune NCT03929458 271 281 B-Condition
disorders NCT03929458 282 291 I-Condition
, NCT03929458 292 293 O
severe NCT03929458 294 300 B-Condition
malnutrition NCT03929458 301 313 I-Condition
, NCT03929458 314 315 O
or NCT03929458 316 318 O
clinical NCT03929458 319 327 O
conditions NCT03929458 328 338 B-Condition
requiring NCT03929458 339 348 B-Assertion___Assertion-Type-Value:hypothetical
oral NCT03929458 349 353 B-Drug
nutrition NCT03929458 354 363 I-Drug
supplements NCT03929458 364 375 I-Drug
; NCT03929458 375 376 O

- NCT03929458 379 380 O
Inability NCT03929458 382 391 O
to NCT03929458 392 394 O
follow NCT03929458 395 401 O
protocol NCT03929458 402 410 O
. NCT03929458 411 412 O

- NCT03929458 416 417 O
Pregnancy NCT03929458 419 428 B-Condition
or NCT03929458 429 431 B-Or
wishing NCT03929458 432 439 B-Assertion___Assertion-Type-Value:intention
/ NCT03929458 440 441 B-Or
trying NCT03929458 442 448 B-Assertion___Assertion-Type-Value:intention
to NCT03929458 449 451 O
get NCT03929458 452 455 O
pregnant NCT03929458 456 464 B-Condition

Inclusion NCT03921762 0 9 O
Criteria NCT03921762 10 18 O
: NCT03921762 19 20 O

- NCT03921762 24 25 O
> NCT03921762 27 28 B-Eq-Comparison
50 NCT03921762 29 31 I-Eq-Comparison
years NCT03921762 32 37 I-Eq-Comparison
old NCT03921762 38 41 B-Age

- NCT03921762 44 45 O
Bilateral NCT03921762 47 56 B-Modifier
age NCT03921762 57 60 I-Modifier
- NCT03921762 61 62 I-Modifier
related NCT03921762 63 70 I-Modifier
cataract NCT03921762 71 79 B-Condition

- NCT03921762 82 83 O
Qualify NCT03921762 85 92 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03921762 93 96 I-Assertion___Assertion-Type-Value:hypothetical
bilateral NCT03921762 97 106 B-Procedure
implantation NCT03921762 107 119 I-Procedure
within NCT03921762 120 126 B-Eq-Comparison
1 NCT03921762 127 128 I-Eq-Comparison
month NCT03921762 129 134 I-Eq-Comparison

- NCT03921762 137 138 O
No NCT03921762 140 142 B-Negation
previous NCT03921762 143 151 B-Eq-Comparison
refractive NCT03921762 152 162 B-Modifier
or NCT03921762 163 165 B-Or
ocular NCT03921762 166 172 B-Modifier
surgery NCT03921762 173 180 B-Procedure

- NCT03921762 183 184 O
Available NCT03921762 186 195 O
IOL NCT03921762 196 199 B-Observation
dioptre NCT03921762 200 207 I-Observation
range NCT03921762 208 213 I-Observation
: NCT03921762 214 215 O
18 NCT03921762 216 218 B-Eq-Comparison
to NCT03921762 219 221 I-Eq-Comparison
27 NCT03921762 222 224 I-Eq-Comparison
D NCT03921762 225 226 I-Eq-Comparison

- NCT03921762 229 230 O
Expected NCT03921762 232 240 B-Assertion___Assertion-Type-Value:hypothetical
post NCT03921762 241 245 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03921762 246 255 B-Procedure
astigmatism NCT03921762 256 267 B-Observation
≤ NCT03921762 268 269 B-Eq-Comparison
0.75 NCT03921762 270 274 I-Eq-Comparison
D NCT03921762 275 276 I-Eq-Comparison

Exclusion NCT03921762 277 286 O
Criteria NCT03921762 287 295 O
: NCT03921762 296 297 O

- NCT03921762 301 302 O
Pupil NCT03921762 304 309 B-Observation
> NCT03921762 310 311 B-Eq-Comparison
4 NCT03921762 312 313 I-Eq-Comparison
mm NCT03921762 314 316 I-Eq-Comparison

- NCT03921762 319 320 O
Occupation NCT03921762 322 332 O
requiring NCT03921762 333 342 O
night NCT03921762 343 348 O
- NCT03921762 349 350 O
time NCT03921762 351 355 O
driving NCT03921762 356 363 O
or NCT03921762 364 366 O
any NCT03921762 367 370 O
occupation NCT03921762 371 381 O
incompatible NCT03921762 382 394 O
with NCT03921762 395 399 O
multifocality NCT03921762 400 413 O

- NCT03921762 416 417 O
Acute NCT03921762 419 424 O
or NCT03921762 425 427 B-Or
chronic NCT03921762 428 435 B-Modifier
disease NCT03921762 436 443 B-Condition
or NCT03921762 444 446 B-Or
illness NCT03921762 447 454 B-Condition
that NCT03921762 455 459 O
would NCT03921762 460 465 B-Assertion___Assertion-Type-Value:hypothetical
increase NCT03921762 466 474 O
risk NCT03921762 475 479 B-Risk
or NCT03921762 480 482 B-Or
confound NCT03921762 483 491 O
study NCT03921762 492 497 B-Study
results NCT03921762 498 505 O
[ NCT03921762 506 507 O
e. NCT03921762 508 510 O
g. NCT03921762 511 513 O
diabetes NCT03921762 515 523 B-Condition
mellitus NCT03921762 524 532 I-Condition
( NCT03921762 533 534 O
with NCT03921762 535 539 B-And
retinopathy NCT03921762 540 551 B-Condition
) NCT03921762 552 553 O
, NCT03921762 555 556 O
immunocompromised NCT03921762 557 574 B-Condition
, NCT03921762 575 576 O
glaucoma NCT03921762 577 585 B-Condition
, NCT03921762 586 587 O
epiretinal NCT03921762 588 598 B-Condition
membrane NCT03921762 599 607 I-Condition
, NCT03921762 608 609 O
cornea NCT03921762 610 616 B-Condition
guttata NCT03921762 617 624 I-Condition
, NCT03921762 625 626 O
etc NCT03921762 627 630 O
… NCT03921762 630 631 O
. NCT03921762 631 632 O
] NCT03921762 633 634 O
found NCT03921762 635 640 O
to NCT03921762 641 643 O
be NCT03921762 644 646 O
relevant NCT03921762 647 655 O
by NCT03921762 656 658 O
the NCT03921762 659 662 O
investigators NCT03921762 663 676 O

- NCT03921762 679 680 O
Amblyopia NCT03921762 682 691 B-Condition
, NCT03921762 692 693 O
strabismus NCT03921762 694 704 B-Condition

- NCT03921762 707 708 O
Extremely NCT03921762 710 719 O
shallow NCT03921762 720 727 B-Condition
anterior NCT03921762 728 736 I-Condition
chamber NCT03921762 737 744 I-Condition

- NCT03921762 747 748 O
Capsule NCT03921762 750 757 B-Modifier
or NCT03921762 758 760 B-Or
zonular NCT03921762 761 768 B-Modifier
abnormalities NCT03921762 769 782 B-Condition
that NCT03921762 783 787 O
may NCT03921762 788 791 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03921762 792 798 O
post NCT03921762 799 803 B-Temporal-Connection___Temporal-Connection-Type-Value:after
operative NCT03921762 804 813 B-Procedure
centration NCT03921762 814 824 B-Modifier
or NCT03921762 825 827 B-Or
tilt NCT03921762 828 832 B-Modifier
of NCT03921762 833 835 O
the NCT03921762 836 839 O
lens NCT03921762 840 844 B-Condition
( NCT03921762 845 846 O
e. NCT03921762 847 849 O
g. NCT03921762 850 852 O
pseudoexfoliation NCT03921762 854 871 B-Condition
syndrome NCT03921762 872 880 I-Condition
, NCT03921762 881 882 O
uveitis NCT03921762 883 890 B-Condition
, NCT03921762 891 892 O
Marfan NCT03921762 893 899 B-Condition
's NCT03921762 899 901 I-Condition
syndrome NCT03921762 902 910 I-Condition
) NCT03921762 911 912 O

- NCT03921762 916 917 O
Pupil NCT03921762 919 924 B-Condition
abnormalities NCT03921762 925 938 I-Condition
( NCT03921762 939 940 O
non NCT03921762 941 944 B-Condition
- NCT03921762 945 946 I-Condition
reactive NCT03921762 947 955 I-Condition
, NCT03921762 956 957 O
tonic NCT03921762 958 963 B-Condition
pupils NCT03921762 964 970 I-Condition
, NCT03921762 971 972 O
abnormally NCT03921762 973 983 B-Condition
shaped NCT03921762 984 990 I-Condition
pupils NCT03921762 991 997 I-Condition
or NCT03921762 998 1000 B-Or
pupils NCT03921762 1001 1007 B-Condition
that NCT03921762 1008 1012 I-Condition
do NCT03921762 1013 1015 I-Condition
not NCT03921762 1016 1019 I-Condition
dilate NCT03921762 1020 1026 I-Condition
under NCT03921762 1027 1032 B-Modifier
mesopic NCT03921762 1033 1040 I-Modifier
/ NCT03921762 1041 1042 I-Modifier
scotopic NCT03921762 1043 1051 I-Modifier
conditions NCT03921762 1052 1062 I-Modifier
) NCT03921762 1063 1064 O

- NCT03921762 1068 1069 O
Instability NCT03921762 1071 1082 O
to NCT03921762 1083 1085 O
place NCT03921762 1086 1091 B-Procedure
the NCT03921762 1092 1095 I-Procedure
intraocular NCT03921762 1096 1107 I-Procedure
lens NCT03921762 1108 1112 I-Procedure
safely NCT03921762 1113 1119 O
at NCT03921762 1120 1122 O
the NCT03921762 1123 1126 O
location NCT03921762 1127 1135 O
planned NCT03921762 1136 1143 O

- NCT03921762 1146 1147 O
Pregnancy NCT03921762 1149 1158 B-Condition
( NCT03921762 1159 1160 O
pregnancy NCT03921762 1161 1170 B-Observation
test NCT03921762 1171 1175 I-Observation
will NCT03921762 1176 1180 B-Eq-Comparison
be NCT03921762 1181 1183 I-Eq-Comparison
taken NCT03921762 1184 1189 O
pre NCT03921762 1190 1193 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03921762 1194 1195 O
operatively NCT03921762 1196 1207 B-Procedure
in NCT03921762 1208 1210 O
women NCT03921762 1211 1216 O
of NCT03921762 1217 1219 B-And
reproductive NCT03921762 1220 1232 B-Condition
age NCT03921762 1233 1236 I-Condition
) NCT03921762 1237 1238 O

Inclusion NCT03925909 0 9 O
Criteria NCT03925909 10 18 O
: NCT03925909 19 20 O

- NCT03925909 24 25 O
30 NCT03925909 27 29 B-Eq-Comparison
- NCT03925909 30 31 I-Eq-Comparison
60 NCT03925909 32 34 I-Eq-Comparison
years NCT03925909 35 40 I-Age|Eq-Comparison

- NCT03925909 43 44 O
Increased NCT03925909 46 55 O
fasting NCT03925909 56 63 B-Observation
blood NCT03925909 64 69 I-Observation
glucose NCT03925909 70 77 I-Observation
from NCT03925909 78 82 O
6.1 NCT03925909 83 86 B-Eq-Comparison
to NCT03925909 87 89 I-Eq-Comparison
7.0 NCT03925909 90 93 I-Eq-Comparison
mmol NCT03925909 94 98 I-Eq-Comparison
/ NCT03925909 99 100 I-Eq-Comparison
L NCT03925909 101 102 I-Eq-Comparison
or NCT03925909 103 105 B-Or
, NCT03925909 106 107 O

- NCT03925909 111 112 O
Decreased NCT03925909 114 123 O
glucose NCT03925909 124 131 B-Observation
tolerance NCT03925909 132 141 I-Observation
of NCT03925909 142 144 O
7 NCT03925909 145 146 B-Eq-Comparison
, NCT03925909 147 148 I-Eq-Comparison
8 NCT03925909 149 150 I-Eq-Comparison
to NCT03925909 151 153 I-Eq-Comparison
11.1 NCT03925909 154 158 I-Eq-Comparison
mmol NCT03925909 159 163 I-Eq-Comparison
/ NCT03925909 164 165 I-Eq-Comparison
L NCT03925909 166 167 I-Eq-Comparison
or NCT03925909 168 170 B-Or
, NCT03925909 171 172 O

- NCT03925909 176 177 O
Glycated NCT03925909 179 187 B-Modifier
hemoglobin NCT03925909 188 198 B-Observation
with NCT03925909 199 203 O
values NCT03925909 204 210 O
between NCT03925909 211 218 B-Eq-Comparison
5.7 NCT03925909 219 222 I-Eq-Comparison
and NCT03925909 223 226 I-Eq-Comparison
6.4 NCT03925909 227 230 I-Eq-Comparison
% NCT03925909 231 232 I-Eq-Comparison

Exclusion NCT03925909 234 243 O
Criteria NCT03925909 244 252 O
: NCT03925909 253 254 O

- NCT03925909 258 259 O
Use NCT03925909 261 264 B-Eq-Comparison
hypoglycemic NCT03925909 265 277 B-Drug
, NCT03925909 278 279 O
hypolipidemic NCT03925909 280 293 B-Drug
drugs NCT03925909 294 299 O
, NCT03925909 300 301 O

- NCT03925909 305 306 O
Use NCT03925909 308 311 B-Eq-Comparison
dietary NCT03925909 312 319 B-Drug
supplements NCT03925909 320 331 I-Drug
( NCT03925909 332 333 O
vitamins NCT03925909 334 342 B-Drug
, NCT03925909 343 344 O
minerals NCT03925909 345 353 B-Drug
, NCT03925909 354 355 O
bioflavonoids NCT03925909 356 369 B-Drug
, NCT03925909 370 371 O
prebiotics NCT03925909 372 382 B-Drug
, NCT03925909 383 384 O
probiotics NCT03925909 385 395 B-Drug
or NCT03925909 396 398 O
other NCT03925909 399 404 B-Other
bioactive NCT03925909 405 414 B-Drug
compounds NCT03925909 415 424 I-Drug
) NCT03925909 425 426 O
, NCT03925909 428 429 O

- NCT03925909 433 434 O
Exercise NCT03925909 436 444 B-Condition
intensely NCT03925909 445 454 O
( NCT03925909 455 456 O
more NCT03925909 457 461 B-Eq-Comparison
than NCT03925909 462 466 I-Eq-Comparison
10 NCT03925909 467 469 I-Eq-Comparison
hours NCT03925909 470 475 I-Eq-Comparison
per NCT03925909 476 479 I-Eq-Comparison
week NCT03925909 480 484 I-Eq-Comparison
) NCT03925909 485 486 O

- NCT03925909 490 491 O
History NCT03925909 493 500 B-Eq-Comparison
of NCT03925909 501 503 O
cardiovascular NCT03925909 504 518 B-Condition
diseases NCT03925909 519 527 I-Condition
, NCT03925909 528 529 O
diabetes NCT03925909 530 538 B-Condition
mellitus NCT03925909 539 547 I-Condition
, NCT03925909 548 549 O
liver NCT03925909 550 555 B-Modifier
and NCT03925909 556 559 B-Or
kidney NCT03925909 560 566 B-Modifier
disease NCT03925909 567 574 B-Condition
. NCT03925909 574 575 O

Inclusion NCT03928587 0 9 O
Criteria NCT03928587 10 18 O
: NCT03928587 19 20 O

1 NCT03928587 24 25 O
. NCT03928587 25 26 O
Healthy NCT03928587 28 35 B-Condition
children NCT03928587 36 44 O
with NCT03928587 45 49 B-And
absence NCT03928587 50 57 B-Negation
of NCT03928587 58 60 I-Negation
severe NCT03928587 61 67 O
chronic NCT03928587 68 75 B-Modifier
disease NCT03928587 76 83 B-Condition

2 NCT03928587 86 87 O
. NCT03928587 87 88 O
Age NCT03928587 90 93 B-Age
5 NCT03928587 94 95 B-Eq-Comparison
- NCT03928587 96 97 I-Eq-Comparison
8 NCT03928587 98 99 I-Eq-Comparison
years NCT03928587 100 105 I-Eq-Comparison
, NCT03928587 106 107 O
both NCT03928587 108 112 O
inclusive NCT03928587 113 122 O
, NCT03928587 123 124 O
at NCT03928587 125 127 O
inclusion NCT03928587 128 137 O

3 NCT03928587 140 141 O
. NCT03928587 141 142 O
Ability NCT03928587 144 151 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928587 152 154 I-Assertion___Assertion-Type-Value:hypothetical
cooperate NCT03928587 155 164 O
at NCT03928587 165 167 O
dental NCT03928587 168 174 B-Procedure
examination NCT03928587 175 186 I-Procedure

4 NCT03928587 189 190 O
. NCT03928587 190 191 O
Ability NCT03928587 193 200 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03928587 201 203 I-Assertion___Assertion-Type-Value:hypothetical
cooperate NCT03928587 204 213 O
to NCT03928587 214 216 O
a NCT03928587 217 218 O
daily NCT03928587 219 224 B-Eq-Comparison
intake NCT03928587 225 231 O
of NCT03928587 232 234 O
a NCT03928587 235 236 O
lozenge NCT03928587 237 244 B-Drug

5 NCT03928587 247 248 O
. NCT03928587 248 249 O
Parents NCT03928587 251 258 O
/ NCT03928587 259 260 O
legal NCT03928587 261 266 O
guarding NCT03928587 267 275 O
provided NCT03928587 276 284 O
voluntary NCT03928587 285 294 O
written NCT03928587 295 302 O
informed NCT03928587 303 311 O
consent NCT03928587 312 319 O

Exclusion NCT03928587 320 329 O
Criteria NCT03928587 330 338 O
: NCT03928587 339 340 O

1 NCT03928587 344 345 O
. NCT03928587 345 346 O
Children NCT03928587 348 356 O
with NCT03928587 357 361 B-And
severe NCT03928587 362 368 O
medical NCT03928587 369 376 B-Condition
conditions NCT03928587 377 387 I-Condition

2 NCT03928587 390 391 O
. NCT03928587 391 392 O
Mentally NCT03928587 394 402 B-Modifier
or NCT03928587 403 405 B-Or
physically NCT03928587 406 416 B-Modifier
disabled NCT03928587 417 425 B-Condition
children NCT03928587 426 434 O

3 NCT03928587 437 438 O
. NCT03928587 438 439 O
Children NCT03928587 441 449 O
of NCT03928587 450 452 O
parents NCT03928587 453 460 B-Family-Member___Family-Member-Type:parent
with NCT03928587 461 465 O
language NCT03928587 466 474 O
barriers NCT03928587 475 483 O
and NCT03928587 484 487 O
not NCT03928587 488 491 O
able NCT03928587 492 496 O
to NCT03928587 497 499 O
give NCT03928587 500 504 O
written NCT03928587 505 512 O
informed NCT03928587 513 521 O
consent NCT03928587 522 529 O

Inclusion NCT03923439 0 9 O
Criteria NCT03923439 10 18 O
: NCT03923439 19 20 O

- NCT03923439 24 25 O
Patients NCT03923439 27 35 O
older NCT03923439 36 41 B-Eq-Comparison
than NCT03923439 42 46 I-Eq-Comparison
18 NCT03923439 47 49 I-Eq-Comparison
years NCT03923439 50 55 I-Eq-Comparison
old NCT03923439 56 59 B-Age

- NCT03923439 62 63 O
Cerebral NCT03923439 65 73 B-Condition
infarct NCT03923439 74 81 I-Condition
within NCT03923439 82 88 O
the NCT03923439 89 92 O
anterior NCT03923439 93 101 B-Modifier
circulation NCT03923439 102 113 I-Modifier
due NCT03923439 114 117 O
to NCT03923439 118 120 O
occlusion NCT03923439 121 130 B-Condition
of NCT03923439 131 133 I-Condition
intracranial NCT03923439 134 146 I-Condition
carotid NCT03923439 147 154 I-Condition
artery NCT03923439 155 161 I-Condition
or NCT03923439 162 164 O
proximal NCT03923439 165 173 B-Modifier
( NCT03923439 174 175 O
M1 NCT03923439 176 178 B-Eq-Comparison
) NCT03923439 179 180 O
MCA NCT03923439 181 184 B-Condition
. NCT03923439 185 186 O

- NCT03923439 190 191 O
With NCT03923439 193 197 O
acute NCT03923439 198 203 O
MRI NCT03923439 204 207 B-Procedure
performed NCT03923439 208 217 O
within NCT03923439 218 224 B-Eq-Comparison
the NCT03923439 225 228 I-Eq-Comparison
first NCT03923439 229 234 I-Eq-Comparison
24 NCT03923439 235 237 I-Eq-Comparison
h NCT03923439 238 239 I-Eq-Comparison
and NCT03923439 240 243 B-And
showing NCT03923439 244 251 O
significant NCT03923439 252 263 O
penumbra NCT03923439 264 272 B-Condition
defined NCT03923439 273 280 O
as NCT03923439 281 283 O
ratio NCT03923439 284 289 B-Observation
between NCT03923439 290 297 I-Observation
the NCT03923439 298 301 I-Observation
volumes NCT03923439 302 309 I-Observation
of NCT03923439 310 312 O
critically NCT03923439 313 323 O
hypoperfused NCT03923439 324 336 B-Modifier
tissue NCT03923439 337 343 I-Modifier
( NCT03923439 344 345 O
defined NCT03923439 346 353 O
by NCT03923439 354 356 O
Tmax NCT03923439 357 361 B-Observation
> NCT03923439 362 363 B-Eq-Comparison
6 NCT03923439 364 365 I-Eq-Comparison
s NCT03923439 366 367 O
) NCT03923439 368 369 O
and NCT03923439 370 373 B-And
the NCT03923439 374 377 O
ischemic NCT03923439 378 386 B-Modifier
core NCT03923439 387 391 I-Modifier
( NCT03923439 392 393 O
defined NCT03923439 394 401 O
by NCT03923439 402 404 O
ADC NCT03923439 405 408 B-Observation
< NCT03923439 409 410 B-Eq-Comparison
600 NCT03923439 411 414 I-Eq-Comparison
× NCT03923439 415 416 O
10 NCT03923439 417 419 B-Eq-Comparison
- NCT03923439 420 421 I-Eq-Comparison
6 NCT03923439 422 423 I-Eq-Comparison
mm2 NCT03923439 424 427 I-Eq-Comparison
/ NCT03923439 428 429 I-Eq-Comparison
s NCT03923439 430 431 I-Eq-Comparison
) NCT03923439 432 433 O
of NCT03923439 434 436 O
1.8 NCT03923439 437 440 B-Eq-Comparison
or NCT03923439 441 443 I-Eq-Comparison
more NCT03923439 444 448 I-Eq-Comparison
, NCT03923439 449 450 O
with NCT03923439 451 455 O
an NCT03923439 456 458 O
absolute NCT03923439 459 467 B-Observation
difference NCT03923439 468 478 I-Observation
of NCT03923439 479 481 O
15 NCT03923439 482 484 B-Eq-Comparison
mL NCT03923439 485 487 I-Eq-Comparison
or NCT03923439 488 490 I-Eq-Comparison
more NCT03923439 491 495 I-Eq-Comparison
and NCT03923439 496 499 B-And
ischemic NCT03923439 500 508 B-Observation
core NCT03923439 509 513 I-Observation
volume NCT03923439 514 520 I-Observation
of NCT03923439 521 523 O
less NCT03923439 524 528 B-Eq-Comparison
than NCT03923439 529 533 I-Eq-Comparison
70 NCT03923439 534 536 I-Eq-Comparison
mL NCT03923439 537 539 I-Eq-Comparison
. NCT03923439 540 541 O

- NCT03923439 545 546 O
Successful NCT03923439 548 558 O
recanalization NCT03923439 559 573 B-Procedure
( NCT03923439 574 575 O
TICI NCT03923439 576 580 B-Condition
2 NCT03923439 581 582 B-Eq-Comparison
b NCT03923439 583 584 I-Eq-Comparison
- NCT03923439 585 586 I-Eq-Comparison
3 NCT03923439 587 588 I-Eq-Comparison
) NCT03923439 589 590 O
by NCT03923439 591 593 O
thrombectomy NCT03923439 594 606 B-Procedure
alone NCT03923439 607 612 B-Modifier
or NCT03923439 613 615 B-Or
in NCT03923439 616 618 O
combination NCT03923439 619 630 O
with NCT03923439 631 635 O
IV NCT03923439 636 638 B-Modifier
thrombolysis NCT03923439 639 651 B-Procedure
( NCT03923439 652 653 O
if NCT03923439 654 656 O
within NCT03923439 657 663 B-Eq-Comparison
the NCT03923439 664 667 I-Eq-Comparison
first NCT03923439 668 673 I-Eq-Comparison
4.5 NCT03923439 674 677 I-Eq-Comparison
h NCT03923439 678 679 I-Eq-Comparison
) NCT03923439 680 681 O
. NCT03923439 683 684 O

- NCT03923439 688 689 O
Patient NCT03923439 691 698 O
/ NCT03923439 699 700 O
Legally NCT03923439 701 708 O
Authorized NCT03923439 709 719 O
Representative NCT03923439 720 734 O
has NCT03923439 735 738 O
signed NCT03923439 739 745 O
the NCT03923439 746 749 O
Informed NCT03923439 750 758 O
Consent NCT03923439 759 766 O
form NCT03923439 767 771 O
. NCT03923439 772 773 O

Exclusion NCT03923439 775 784 O
Criteria NCT03923439 785 793 O
: NCT03923439 794 795 O

- NCT03923439 799 800 O
History NCT03923439 802 809 B-Eq-Comparison
of NCT03923439 810 812 O
symptomatic NCT03923439 813 824 B-Assertion___Assertion-Type-Value:possible
cerebral NCT03923439 825 833 B-Condition
infarct NCT03923439 834 841 I-Condition
with NCT03923439 842 846 B-And
functional NCT03923439 847 857 B-Condition
deficit NCT03923439 858 865 I-Condition
( NCT03923439 866 867 O
pre NCT03923439 868 871 B-Temporal-Connection___Temporal-Connection-Type-Value:before
- NCT03923439 872 873 O
stroke NCT03923439 874 880 B-Condition
modified NCT03923439 881 889 B-Observation
Rankin NCT03923439 890 896 I-Observation
Scale NCT03923439 897 902 I-Observation
score NCT03923439 903 908 B-Eq-Comparison
≥ NCT03923439 909 910 I-Eq-Comparison
1 NCT03923439 911 912 I-Eq-Comparison
) NCT03923439 913 914 O
to NCT03923439 915 917 B-Assertion___Assertion-Type-Value:hypothetical
measure NCT03923439 918 925 I-Assertion___Assertion-Type-Value:hypothetical
the NCT03923439 926 929 O
impact NCT03923439 930 936 O
of NCT03923439 937 939 O
the NCT03923439 940 943 O
infarct NCT03923439 944 951 B-Condition
and NCT03923439 952 955 B-And
selective NCT03923439 956 965 B-Condition
neuronal NCT03923439 966 974 I-Condition
loss NCT03923439 975 979 I-Condition
on NCT03923439 980 982 O
long NCT03923439 983 987 O
- NCT03923439 988 989 O
term NCT03923439 990 994 O
outcome NCT03923439 995 1002 O
without NCT03923439 1003 1010 O
being NCT03923439 1011 1016 O
biased NCT03923439 1017 1023 O
by NCT03923439 1024 1026 O
pre NCT03923439 1027 1030 O
- NCT03923439 1031 1032 O
existing NCT03923439 1033 1041 O
deficits NCT03923439 1042 1050 O
. NCT03923439 1051 1052 O

- NCT03923439 1056 1057 O
History NCT03923439 1059 1066 B-Eq-Comparison
of NCT03923439 1067 1069 O
severe NCT03923439 1070 1076 O
cognitive NCT03923439 1077 1086 B-Condition
impairment NCT03923439 1087 1097 I-Condition
( NCT03923439 1098 1099 O
dementia NCT03923439 1100 1108 B-Condition
) NCT03923439 1109 1110 O
or NCT03923439 1111 1113 O
DSMIV NCT03923439 1114 1119 B-Eq-Comparison
axis NCT03923439 1120 1124 I-Eq-Comparison
1 NCT03923439 1125 1126 I-Eq-Comparison
psychiatric NCT03923439 1127 1138 B-Condition
disorders NCT03923439 1139 1148 I-Condition
that NCT03923439 1149 1153 O
would NCT03923439 1154 1159 B-Assertion___Assertion-Type-Value:hypothetical
confound NCT03923439 1160 1168 O
the NCT03923439 1169 1172 O
neurological NCT03923439 1173 1185 B-Procedure
evaluations NCT03923439 1186 1197 I-Procedure
. NCT03923439 1198 1199 O

- NCT03923439 1203 1204 O
Pregnant NCT03923439 1206 1214 B-Condition
or NCT03923439 1215 1217 B-Or
breast NCT03923439 1218 1224 B-Condition
- NCT03923439 1225 1226 I-Condition
feeding NCT03923439 1227 1234 I-Condition
women NCT03923439 1235 1240 O
. NCT03923439 1241 1242 O

- NCT03923439 1246 1247 O
Contraindications NCT03923439 1249 1266 B-Contraindication
to NCT03923439 1267 1269 O
MRI NCT03923439 1270 1273 B-Procedure
. NCT03923439 1273 1274 O

Inclusion NCT03925844 0 9 O
Criteria NCT03925844 10 18 O
: NCT03925844 19 20 O

- NCT03925844 24 25 O
population NCT03925844 27 37 O
aged NCT03925844 38 42 B-Age
55 NCT03925844 43 45 B-Eq-Comparison
to NCT03925844 46 48 I-Eq-Comparison
74 NCT03925844 49 51 I-Eq-Comparison
years NCT03925844 52 57 I-Eq-Comparison
from NCT03925844 58 62 O
NEDICES NCT03925844 63 70 O
2 NCT03925844 71 72 O
study NCT03925844 73 78 B-Study

- NCT03925844 81 82 O
to NCT03925844 84 86 O
have NCT03925844 87 91 O
signed NCT03925844 92 98 O
informed NCT03925844 99 107 O
consent NCT03925844 108 115 O

- NCT03925844 118 119 O
to NCT03925844 121 123 O
have NCT03925844 124 128 O
done NCT03925844 129 133 B-Eq-Comparison
the NCT03925844 134 137 O
neuropsicological NCT03925844 138 155 B-Procedure
assessment NCT03925844 156 166 I-Procedure

Exclusion NCT03925844 167 176 O
Criteria NCT03925844 177 185 O
: NCT03925844 186 187 O

- NCT03925844 191 192 O
to NCT03925844 194 196 O
have NCT03925844 197 201 O
a NCT03925844 202 203 O
dementia NCT03925844 204 212 B-Condition
diagnosis NCT03925844 213 222 O
at NCT03925844 223 225 B-Temporal-Connection___Temporal-Connection-Type-Value:during
baseline NCT03925844 226 234 B-Study
. NCT03925844 234 235 O

Inclusion NCT03928145 0 9 O
Criteria NCT03928145 10 18 O
: NCT03928145 19 20 O

- NCT03928145 24 25 O
Adults NCT03928145 27 33 O
( NCT03928145 34 35 O
age NCT03928145 36 39 B-Age
30 NCT03928145 40 42 B-Eq-Comparison
to NCT03928145 43 45 I-Eq-Comparison
75 NCT03928145 46 48 I-Eq-Comparison
years NCT03928145 49 54 I-Eq-Comparison
) NCT03928145 55 56 O
. NCT03928145 58 59 O

- NCT03928145 63 64 O
Diagnosis NCT03928145 66 75 O
of NCT03928145 76 78 O
primary NCT03928145 79 86 B-Condition
hypertension NCT03928145 87 99 I-Condition
based NCT03928145 100 105 O
on NCT03928145 106 108 O
ABPM NCT03928145 109 113 B-Procedure
( NCT03928145 114 115 O
mean NCT03928145 116 120 B-Eq-Comparison
24 NCT03928145 121 123 I-Eq-Comparison
- NCT03928145 124 125 I-Eq-Comparison
h NCT03928145 126 127 I-Eq-Comparison
systolic NCT03928145 128 136 B-Observation
BP NCT03928145 137 139 I-Observation
≥ NCT03928145 140 141 B-Eq-Comparison
130 NCT03928145 142 145 I-Eq-Comparison
mmHg NCT03928145 146 150 I-Eq-Comparison
or NCT03928145 151 153 B-Or
mean NCT03928145 154 158 B-Eq-Comparison
24 NCT03928145 159 161 I-Eq-Comparison
- NCT03928145 162 163 I-Eq-Comparison
h NCT03928145 164 165 I-Eq-Comparison
diastolic NCT03928145 166 175 B-Observation
BP NCT03928145 176 178 I-Observation
≥ NCT03928145 179 180 B-Eq-Comparison
80 NCT03928145 181 183 I-Eq-Comparison
mmHg NCT03928145 184 188 I-Eq-Comparison
) NCT03928145 189 190 O
. NCT03928145 192 193 O

- NCT03928145 197 198 O
No NCT03928145 200 202 B-Negation
current NCT03928145 203 210 B-Eq-Comparison
use NCT03928145 211 214 O
of NCT03928145 215 217 O
antihypertensive NCT03928145 218 234 B-Drug
medication NCT03928145 235 245 I-Drug
. NCT03928145 246 247 O

Exclusion NCT03928145 249 258 O
Criteria NCT03928145 259 267 O
: NCT03928145 268 269 O

- NCT03928145 273 274 O
Low NCT03928145 276 279 O
life NCT03928145 280 284 B-Observation
expectancy NCT03928145 285 295 I-Observation
. NCT03928145 296 297 O

- NCT03928145 301 302 O
Other NCT03928145 304 309 B-Other
indications NCT03928145 310 321 B-Indication
for NCT03928145 322 325 O
the NCT03928145 326 329 O
use NCT03928145 330 333 O
of NCT03928145 334 336 O
diuretics NCT03928145 337 346 B-Drug
. NCT03928145 347 348 O

- NCT03928145 352 353 O
Intolerance NCT03928145 355 366 B-Condition
or NCT03928145 367 369 B-Or
contraindications NCT03928145 370 387 B-Contraindication
to NCT03928145 388 390 O
the NCT03928145 391 394 O
study NCT03928145 395 400 B-Study
drugs NCT03928145 401 406 B-Drug
. NCT03928145 407 408 O

- NCT03928145 412 413 O
Cardiovascular NCT03928145 415 429 B-Condition
disease NCT03928145 430 437 I-Condition
( NCT03928145 438 439 O
heart NCT03928145 440 445 B-Condition
failure NCT03928145 446 453 I-Condition
, NCT03928145 454 455 O
myocardial NCT03928145 456 466 B-Condition
infarction NCT03928145 467 477 I-Condition
or NCT03928145 478 480 B-Or
stroke NCT03928145 481 487 B-Condition
) NCT03928145 488 489 O
. NCT03928145 491 492 O

- NCT03928145 496 497 O
Secondary NCT03928145 499 508 B-Modifier
hypertension NCT03928145 509 521 B-Condition
. NCT03928145 522 523 O

- NCT03928145 527 528 O
Chronic NCT03928145 530 537 B-Modifier
kidney NCT03928145 538 544 I-Modifier
disease NCT03928145 545 552 B-Condition
and NCT03928145 553 556 B-Or
/ NCT03928145 557 558 I-Or
or NCT03928145 559 561 I-Or
abnormal NCT03928145 562 570 O
renal NCT03928145 571 576 B-Modifier
function NCT03928145 577 585 B-Condition
( NCT03928145 586 587 O
creatinine NCT03928145 588 598 B-Observation
> NCT03928145 599 600 B-Eq-Comparison
1.5 NCT03928145 601 604 I-Eq-Comparison
mg NCT03928145 605 607 I-Eq-Comparison
/ NCT03928145 608 609 I-Eq-Comparison
dL NCT03928145 610 612 I-Eq-Comparison
) NCT03928145 613 614 O
. NCT03928145 616 617 O

- NCT03928145 621 622 O
Hyperkalemia NCT03928145 624 636 B-Condition
( NCT03928145 637 638 O
serum NCT03928145 639 644 B-Observation
potassium NCT03928145 645 654 I-Observation
> NCT03928145 655 656 B-Eq-Comparison
5.5 NCT03928145 657 660 I-Eq-Comparison
mEq NCT03928145 661 664 I-Eq-Comparison
/ NCT03928145 665 666 I-Eq-Comparison
L NCT03928145 667 668 I-Eq-Comparison
) NCT03928145 669 670 O
. NCT03928145 672 673 O

- NCT03928145 677 678 O
Gout NCT03928145 680 684 B-Condition
. NCT03928145 685 686 O

- NCT03928145 690 691 O
Previous NCT03928145 693 701 B-Eq-Comparison
antihypertensive NCT03928145 702 718 B-Drug
treatment NCT03928145 719 728 B-Procedure
with NCT03928145 729 733 O
more NCT03928145 734 738 B-Eq-Comparison
than NCT03928145 739 743 I-Eq-Comparison
one NCT03928145 744 747 I-Eq-Comparison
drug NCT03928145 748 752 B-Drug
. NCT03928145 753 754 O

- NCT03928145 758 759 O
Systolic NCT03928145 761 769 B-Observation
blood NCT03928145 770 775 I-Observation
pressure NCT03928145 776 784 I-Observation
≥ NCT03928145 785 786 B-Eq-Comparison
160 NCT03928145 787 790 I-Eq-Comparison
mmHg NCT03928145 791 795 I-Eq-Comparison
or NCT03928145 796 798 B-Or
diastolic NCT03928145 799 808 B-Observation
blood NCT03928145 809 814 I-Observation
pressure NCT03928145 815 823 I-Observation
≥ NCT03928145 824 825 B-Eq-Comparison
100 NCT03928145 826 829 I-Eq-Comparison
mmHg NCT03928145 830 834 I-Eq-Comparison
measured NCT03928145 835 843 O
through NCT03928145 844 851 O
office NCT03928145 852 858 O
blood NCT03928145 859 864 O
pressure NCT03928145 865 873 O
. NCT03928145 874 875 O

- NCT03928145 879 880 O
Pregnancy NCT03928145 882 891 B-Condition
or NCT03928145 892 894 B-Or
prospective NCT03928145 895 906 B-Assertion___Assertion-Type-Value:intention
pregnancy NCT03928145 907 916 B-Condition
during NCT03928145 917 923 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928145 924 927 O
study NCT03928145 928 933 B-Study
. NCT03928145 934 935 O

- NCT03928145 939 940 O
Lactating NCT03928145 942 951 B-Condition
women NCT03928145 952 957 O
. NCT03928145 957 958 O

Inclusion NCT03922737 0 9 O
Criteria NCT03922737 10 18 O
: NCT03922737 19 20 O

1 NCT03922737 22 23 O
. NCT03922737 23 24 O
Subjects NCT03922737 26 34 O
over NCT03922737 35 39 B-Eq-Comparison
18 NCT03922737 40 42 I-Eq-Comparison
and NCT03922737 43 46 B-And
under NCT03922737 47 52 B-Eq-Comparison
75 NCT03922737 53 55 I-Eq-Comparison
years NCT03922737 56 61 I-Eq-Comparison
of NCT03922737 62 64 O
age NCT03922737 65 68 B-Age
undergoing NCT03922737 69 79 B-Eq-Comparison
elective NCT03922737 80 88 O
primary NCT03922737 89 96 B-Modifier
orthopaedic NCT03922737 97 108 B-Procedure
surgery NCT03922737 109 116 I-Procedure
at NCT03922737 117 119 O
Thomas NCT03922737 120 126 O
Jefferson NCT03922737 127 136 O
University NCT03922737 137 147 O
Hospital NCT03922737 148 156 O
, NCT03922737 157 158 O
Rothman NCT03922737 159 166 O
Orthopaedic NCT03922737 167 178 O
Specialty NCT03922737 179 188 O
Hospital NCT03922737 189 197 O
or NCT03922737 198 200 B-Or
Methodist NCT03922737 201 210 O
Hospital NCT03922737 211 219 O
who NCT03922737 220 223 O
have NCT03922737 224 228 O
the NCT03922737 229 232 O
capability NCT03922737 233 243 O
to NCT03922737 244 246 O
utilize NCT03922737 247 254 O
a NCT03922737 255 256 O
telecommunications NCT03922737 257 275 O
platform NCT03922737 276 284 O
( NCT03922737 285 286 O
computer NCT03922737 287 295 O
, NCT03922737 296 297 O
tablet NCT03922737 298 304 O
or NCT03922737 305 307 O
similar NCT03922737 308 315 O
device NCT03922737 316 322 O
at NCT03922737 323 325 O
home NCT03922737 326 330 O
with NCT03922737 331 335 O
a NCT03922737 336 337 O
webcam NCT03922737 338 344 O
, NCT03922737 345 346 O
microphone NCT03922737 347 357 O
and NCT03922737 358 361 O
access NCT03922737 362 368 O
to NCT03922737 369 371 O
high NCT03922737 372 376 O
- NCT03922737 377 378 O
speed NCT03922737 379 384 O
internet NCT03922737 385 393 O
) NCT03922737 394 395 O
. NCT03922737 397 398 O

Exclusion NCT03922737 400 409 O
Criteria NCT03922737 410 418 O
: NCT03922737 419 420 O

1 NCT03922737 424 425 O
. NCT03922737 425 426 O
Subjects NCT03922737 428 436 O
who NCT03922737 437 440 O
are NCT03922737 441 444 O
unable NCT03922737 445 451 O
to NCT03922737 452 454 O
access NCT03922737 455 461 O
the NCT03922737 462 465 O
telemedicine NCT03922737 466 478 O
platform NCT03922737 479 487 O
or NCT03922737 488 490 O
who NCT03922737 491 494 O
are NCT03922737 495 498 O
uncomfortable NCT03922737 499 512 O
with NCT03922737 513 517 O
following NCT03922737 518 527 O
up NCT03922737 528 530 O
in NCT03922737 531 533 O
this NCT03922737 534 538 O
fashion NCT03922737 539 546 O

2 NCT03922737 549 550 O
. NCT03922737 550 551 O
Subjects NCT03922737 553 561 O
who NCT03922737 562 565 O
are NCT03922737 566 569 O
unable NCT03922737 570 576 O
or NCT03922737 577 579 O
unwilling NCT03922737 580 589 O
to NCT03922737 590 592 O
provide NCT03922737 593 600 O
post NCT03922737 601 605 B-Temporal-Connection___Temporal-Connection-Type-Value:after
- NCT03922737 606 607 O
operative NCT03922737 608 617 B-Procedure
radiographs NCT03922737 618 629 O
electronically NCT03922737 630 644 O
or NCT03922737 645 647 O
who NCT03922737 648 651 O
are NCT03922737 652 655 O
unable NCT03922737 656 662 O
or NCT03922737 663 665 O
unwilling NCT03922737 666 675 O
to NCT03922737 676 678 O
obtain NCT03922737 679 685 O
them NCT03922737 686 690 O

3 NCT03922737 693 694 O
. NCT03922737 694 695 O
Subjects NCT03922737 697 705 O
with NCT03922737 706 710 O
workman NCT03922737 711 718 O
's NCT03922737 718 720 O
compensation NCT03922737 721 733 O
or NCT03922737 734 736 O
automotive NCT03922737 737 747 O
claims NCT03922737 748 754 O
or NCT03922737 755 757 O
other NCT03922737 758 763 O
ongoing NCT03922737 764 771 O
litigation NCT03922737 772 782 O

4 NCT03922737 785 786 O
. NCT03922737 786 787 O
Subjects NCT03922737 789 797 O
that NCT03922737 798 802 O
are NCT03922737 803 806 O
unable NCT03922737 807 813 O
or NCT03922737 814 816 O
unwilling NCT03922737 817 826 O
to NCT03922737 827 829 O
consent NCT03922737 830 837 O
for NCT03922737 838 841 O
enrollment NCT03922737 842 852 O

5 NCT03922737 855 856 O
. NCT03922737 856 857 O
Patients NCT03922737 859 867 O
under NCT03922737 868 873 B-Eq-Comparison
the NCT03922737 874 877 I-Eq-Comparison
age NCT03922737 878 881 I-Age|Eq-Comparison
of NCT03922737 882 884 I-Eq-Comparison
18 NCT03922737 885 887 I-Eq-Comparison
years NCT03922737 888 893 I-Eq-Comparison

6 NCT03922737 896 897 O
. NCT03922737 897 898 O
Pregnant NCT03922737 900 908 B-Condition
or NCT03922737 909 911 B-Or
breastfeeding NCT03922737 912 925 B-Condition
women NCT03922737 926 931 O

7 NCT03922737 934 935 O
. NCT03922737 935 936 O
Patients NCT03922737 938 946 O
undergoing NCT03922737 947 957 B-Eq-Comparison
surgery NCT03922737 958 965 B-Procedure
for NCT03922737 966 969 O
tumor NCT03922737 970 975 B-Condition
, NCT03922737 976 977 O
trauma NCT03922737 978 984 B-Condition
or NCT03922737 985 987 B-Or
infection NCT03922737 988 997 B-Condition
or NCT03922737 998 1000 O
who NCT03922737 1001 1004 O
require NCT03922737 1005 1012 O
revision NCT03922737 1013 1021 O
or NCT03922737 1022 1024 O
staged NCT03922737 1025 1031 O
procedures NCT03922737 1032 1042 O

8 NCT03922737 1045 1046 O
. NCT03922737 1046 1047 O
Patients NCT03922737 1049 1057 O
without NCT03922737 1058 1065 B-Negation
English NCT03922737 1066 1073 O
- NCT03922737 1074 1075 O
language NCT03922737 1076 1084 O
proficiency NCT03922737 1085 1096 O

9 NCT03922737 1099 1100 O
. NCT03922737 1100 1101 O
Patients NCT03922737 1103 1111 O
with NCT03922737 1112 1116 O
unforeseen NCT03922737 1117 1127 B-Assertion___Assertion-Type-Value:hypothetical
intra NCT03922737 1128 1133 B-Temporal-Connection___Temporal-Connection-Type-Value:during
- NCT03922737 1134 1135 O
operative NCT03922737 1136 1145 B-Procedure
or NCT03922737 1146 1148 B-Or
peri NCT03922737 1149 1153 B-Temporal-Connection___Temporal-Connection-Type-Value:during
operative NCT03922737 1154 1163 B-Procedure
complications NCT03922737 1164 1177 B-Condition


Inclusion NCT03925064 0 9 O
Criteria NCT03925064 10 18 O
: NCT03925064 19 20 O

- NCT03925064 24 25 O
18 NCT03925064 27 29 B-Eq-Comparison
- NCT03925064 30 31 I-Eq-Comparison
40 NCT03925064 32 34 I-Eq-Comparison
years NCT03925064 35 40 I-Eq-Comparison
old NCT03925064 41 44 B-Age
pregnant NCT03925064 45 53 B-Condition
women NCT03925064 54 59 O

Exclusion NCT03925064 60 69 O
Criteria NCT03925064 70 78 O
: NCT03925064 79 80 O

- NCT03925064 84 85 O
fetal NCT03925064 87 92 B-Condition
cardiac NCT03925064 93 100 I-Condition
anomalies NCT03925064 101 110 I-Condition

- NCT03925064 113 114 O
multiple NCT03925064 116 124 B-Condition
gestations NCT03925064 125 135 I-Condition

Inclusion NCT03921216 0 9 O
Criteria NCT03921216 10 18 O
: NCT03921216 19 20 O

Diabetic NCT03921216 22 30 B-Condition
nephropathy NCT03921216 31 42 I-Condition
, NCT03921216 43 44 O
because NCT03921216 45 52 O
of NCT03921216 53 55 O
type NCT03921216 56 60 B-Condition
2 NCT03921216 61 62 I-Condition
diabetes NCT03921216 63 71 I-Condition
, NCT03921216 72 73 O
undergoing NCT03921216 74 84 B-Eq-Comparison
hemodialysis NCT03921216 85 97 B-Procedure
and NCT03921216 98 101 B-And
subjects NCT03921216 102 110 O
with NCT03921216 111 115 O
chronic NCT03921216 116 123 B-Modifier
kidney NCT03921216 124 130 B-Condition
disease NCT03921216 131 138 I-Condition
of NCT03921216 139 141 O
other NCT03921216 142 147 B-Other
causes NCT03921216 148 154 B-Condition
undergoing NCT03921216 155 165 B-Eq-Comparison
hemodialysis NCT03921216 166 178 B-Procedure
. NCT03921216 179 180 O

Exclusion NCT03921216 182 191 O
Criteria NCT03921216 192 200 O
: NCT03921216 201 202 O

- NCT03921216 206 207 O
Active NCT03921216 209 215 B-Eq-Comparison
infection NCT03921216 216 225 B-Condition
that NCT03921216 226 230 O
increases NCT03921216 231 240 O
the NCT03921216 241 244 O
risk NCT03921216 245 249 B-Risk
of NCT03921216 250 252 O
secondary NCT03921216 253 262 B-Condition
infection NCT03921216 263 272 I-Condition
in NCT03921216 273 275 O
the NCT03921216 276 279 O
skin NCT03921216 280 284 B-Modifier
where NCT03921216 285 290 B-And
the NCT03921216 291 294 O
vesicles NCT03921216 295 303 B-Condition
containing NCT03921216 304 314 I-Condition
interstitial NCT03921216 315 327 I-Condition
fluid NCT03921216 328 333 I-Condition
have NCT03921216 334 338 O
been NCT03921216 339 343 O
emptied NCT03921216 344 351 B-Modifier
of NCT03921216 352 354 I-Modifier
interstitial NCT03921216 355 367 I-Modifier
fluid NCT03921216 368 373 I-Modifier
with NCT03921216 374 378 O
a NCT03921216 379 380 O
fine NCT03921216 381 385 B-Procedure
needle NCT03921216 386 392 I-Procedure
and NCT03921216 393 396 B-And
the NCT03921216 397 400 O
bladder NCT03921216 401 408 B-Condition
roof NCT03921216 409 413 I-Condition
is NCT03921216 414 416 O
intact NCT03921216 417 423 B-Modifier
. NCT03921216 424 425 O

- NCT03921216 429 430 O
Treatment NCT03921216 432 441 B-Procedure
with NCT03921216 442 446 O
Warfarin NCT03921216 447 455 B-Drug
due NCT03921216 456 459 O
to NCT03921216 460 462 O
increased NCT03921216 463 472 O
risk NCT03921216 473 477 B-Risk
of NCT03921216 478 480 O
Calciphylaxis NCT03921216 481 494 B-Condition
( NCT03921216 495 496 O
calcific NCT03921216 497 505 B-Condition
uremic NCT03921216 506 512 I-Condition
arteriolopathy NCT03921216 513 527 I-Condition
, NCT03921216 528 529 O
CUA NCT03921216 530 533 B-Condition
) NCT03921216 534 535 O


Inclusion NCT03924622 0 9 O
Criteria NCT03924622 10 18 O
: NCT03924622 19 20 O

- NCT03924622 24 25 O
Men NCT03924622 27 30 O
and NCT03924622 31 34 B-Or
women NCT03924622 35 40 O

- NCT03924622 43 44 O
Age NCT03924622 46 49 B-Age
18 NCT03924622 50 52 B-Eq-Comparison
to NCT03924622 53 55 I-Eq-Comparison
55 NCT03924622 56 58 I-Eq-Comparison

- NCT03924622 62 63 O
Meet NCT03924622 65 69 O
the NCT03924622 70 73 O
physical NCT03924622 74 82 O
standards NCT03924622 83 92 O
for NCT03924622 93 96 O
military NCT03924622 97 105 O
personnel NCT03924622 106 115 O

- NCT03924622 118 119 O
Weigh NCT03924622 121 126 B-Observation
less NCT03924622 127 131 B-Eq-Comparison
than NCT03924622 132 136 I-Eq-Comparison
250 NCT03924622 137 140 I-Eq-Comparison
pounds NCT03924622 141 147 I-Eq-Comparison

- NCT03924622 150 151 O
Be NCT03924622 153 155 O
able NCT03924622 156 160 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924622 161 163 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03924622 164 170 O
in NCT03924622 171 173 O
the NCT03924622 174 177 O
study NCT03924622 178 183 B-Study
position NCT03924622 184 192 B-Observation
for NCT03924622 193 196 O
the NCT03924622 197 200 O
duration NCT03924622 201 209 B-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03924622 210 212 O
the NCT03924622 213 216 O
study NCT03924622 217 222 B-Study
. NCT03924622 223 224 O

Exclusion NCT03924622 226 235 O
Criteria NCT03924622 236 244 O

- NCT03924622 247 248 O
Previous NCT03924622 250 258 B-Eq-Comparison
injuries NCT03924622 259 267 B-Condition
to NCT03924622 268 270 O
sacrum NCT03924622 271 277 B-Modifier
/ NCT03924622 278 279 B-Or
buttocks NCT03924622 280 288 B-Modifier
with NCT03924622 289 293 B-Modifier
scarring NCT03924622 294 302 I-Modifier

- NCT03924622 305 306 O
History NCT03924622 308 315 B-Eq-Comparison
of NCT03924622 316 318 O
pressure NCT03924622 319 327 B-Modifier
injuries NCT03924622 328 336 B-Condition

- NCT03924622 339 340 O
Cardiovascular NCT03924622 342 356 B-Condition
disease NCT03924622 357 364 I-Condition

- NCT03924622 367 368 O
Neurological NCT03924622 370 382 B-Condition
disease NCT03924622 383 390 I-Condition
that NCT03924622 391 395 O
would NCT03924622 396 401 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03924622 402 408 O
vascular NCT03924622 409 417 B-Modifier
response NCT03924622 418 426 B-Condition

- NCT03924622 429 430 O
Diabetes NCT03924622 432 440 B-Condition

- NCT03924622 443 444 O
History NCT03924622 446 453 B-Eq-Comparison
of NCT03924622 454 456 O
malignancy NCT03924622 457 467 B-Condition

- NCT03924622 470 471 O
Current NCT03924622 473 480 B-Eq-Comparison
skin NCT03924622 481 485 B-Condition
condition NCT03924622 486 495 I-Condition
( NCT03924622 496 497 O
e. NCT03924622 498 500 O
g. NCT03924622 501 503 O
, NCT03924622 504 505 O
eczema NCT03924622 506 512 B-Condition
or NCT03924622 513 515 B-Or
psoriasis NCT03924622 516 525 B-Condition
) NCT03924622 526 527 O

- NCT03924622 531 532 O
Current NCT03924622 534 541 B-Eq-Comparison
neck NCT03924622 542 546 B-Modifier
/ NCT03924622 547 548 B-Or
back NCT03924622 549 553 B-Modifier
pain NCT03924622 554 558 B-Condition
or NCT03924622 559 561 B-Or
history NCT03924622 562 569 B-Eq-Comparison
of NCT03924622 570 572 O
chronic NCT03924622 573 580 B-Modifier
neck NCT03924622 581 585 B-Modifier
/ NCT03924622 586 587 B-Or
back NCT03924622 588 592 B-Modifier
pain NCT03924622 593 597 B-Condition

- NCT03924622 600 601 O
Known NCT03924622 603 608 O
vertebral NCT03924622 609 618 B-Modifier
/ NCT03924622 619 620 B-Or
spinal NCT03924622 621 627 B-Modifier
cord NCT03924622 628 632 I-Modifier
disease NCT03924622 633 640 B-Condition
/ NCT03924622 641 642 B-Or
injury NCT03924622 643 649 B-Condition
( NCT03924622 650 651 O
scoliosis NCT03924622 652 661 B-Condition
, NCT03924622 662 663 O
kyphosis NCT03924622 664 672 B-Condition
, NCT03924622 673 674 O
or NCT03924622 675 677 B-Or
lordosis NCT03924622 678 686 B-Condition
) NCT03924622 687 688 O

- NCT03924622 692 693 O
Self NCT03924622 695 699 B-Modifier
- NCT03924622 700 701 I-Modifier
reported NCT03924622 702 710 I-Modifier
pregnancy NCT03924622 711 720 B-Condition

- NCT03924622 723 724 O
Concern NCT03924622 726 733 O
about NCT03924622 734 739 O
ability NCT03924622 740 747 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03924622 748 750 I-Assertion___Assertion-Type-Value:hypothetical
remain NCT03924622 751 757 B-Observation
in NCT03924622 758 760 O
the NCT03924622 761 764 O
vacuum NCT03924622 765 771 B-Modifier
spine NCT03924622 772 777 I-Modifier
board NCT03924622 778 783 I-Modifier
for NCT03924622 784 787 O
120 NCT03924622 788 791 B-Eq-Comparison
minutes NCT03924622 792 799 I-Eq-Comparison

Inclusion NCT03925272 0 9 O
Criteria NCT03925272 10 18 O
: NCT03925272 19 20 O

- NCT03925272 24 25 O
unprotected NCT03925272 27 38 B-Modifier
adults NCT03925272 39 45 O
with NCT03925272 46 50 O
social NCT03925272 51 57 O
security NCT03925272 58 66 O
who NCT03925272 67 70 O
have NCT03925272 71 75 O
attested NCT03925272 76 84 O
their NCT03925272 85 90 O
consent NCT03925272 91 98 O
after NCT03925272 99 104 O
receiving NCT03925272 105 114 O
any NCT03925272 115 118 O
relevant NCT03925272 119 127 O
information NCT03925272 128 139 O
about NCT03925272 140 145 O
the NCT03925272 146 149 O
study NCT03925272 150 155 O

- NCT03925272 158 159 O
subjects NCT03925272 161 169 O
whose NCT03925272 170 175 O
ethno NCT03925272 176 181 O
- NCT03925272 182 183 O
geographical NCT03925272 184 196 O
origin NCT03925272 197 203 O
of NCT03925272 204 206 O
both NCT03925272 207 211 O
parents NCT03925272 212 219 B-Family-Member___Family-Member-Type:parent
is NCT03925272 220 222 O
known NCT03925272 223 228 O

- NCT03925272 231 232 O
subjects NCT03925272 234 242 O
for NCT03925272 243 246 O
whom NCT03925272 247 251 O
data NCT03925272 252 256 O
on NCT03925272 257 259 O
principal NCT03925272 260 269 B-Modifier
vaccinations NCT03925272 270 282 B-Immunization
( NCT03925272 283 284 O
diphtheria NCT03925272 285 295 B-Condition
, NCT03925272 296 297 O
tetanus NCT03925272 298 305 B-Condition
, NCT03925272 306 307 O
poliomyelitis NCT03925272 308 321 B-Condition
, NCT03925272 322 323 O
hepatitis NCT03925272 324 333 B-Condition
B NCT03925272 334 335 I-Condition
, NCT03925272 336 337 O
possibly NCT03925272 338 346 B-Assertion___Assertion-Type-Value:hypothetical
tuberculosis NCT03925272 347 359 B-Condition
) NCT03925272 360 361 O
are NCT03925272 362 365 O
documented NCT03925272 366 376 O

- NCT03925272 379 380 O
subjects NCT03925272 382 390 O
who NCT03925272 391 394 O
consented NCT03925272 395 404 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03925272 405 407 I-Assertion___Assertion-Type-Value:hypothetical
carry NCT03925272 408 413 O
out NCT03925272 414 417 O
serological NCT03925272 418 429 B-Observation
tests NCT03925272 430 435 I-Observation
HIV NCT03925272 436 439 B-Condition
, NCT03925272 440 441 O
HCV NCT03925272 442 445 B-Condition
, NCT03925272 446 447 O
HBV NCT03925272 448 451 B-Condition

Exclusion NCT03925272 452 461 O
Criteria NCT03925272 462 470 O
: NCT03925272 471 472 O

- NCT03925272 476 477 O
Any NCT03925272 479 482 O
conditions NCT03925272 483 493 B-Condition
that NCT03925272 494 498 O
would NCT03925272 499 504 B-Assertion___Assertion-Type-Value:hypothetical
not NCT03925272 505 508 B-Negation
allow NCT03925272 509 514 O
participation NCT03925272 515 528 O
in NCT03925272 529 531 O
the NCT03925272 532 535 O
present NCT03925272 536 543 O
study NCT03925272 544 549 B-Study
, NCT03925272 550 551 O
on NCT03925272 552 554 O
the NCT03925272 555 558 O
opinion NCT03925272 559 566 O
of NCT03925272 567 569 O
the NCT03925272 570 573 O
investigator NCT03925272 574 586 O
( NCT03925272 587 588 O
documenting NCT03925272 589 600 O
) NCT03925272 601 602 O
, NCT03925272 604 605 O
ie NCT03925272 606 608 O
any NCT03925272 609 612 O
acute NCT03925272 613 618 O
or NCT03925272 619 621 B-Or
chronic NCT03925272 622 629 B-Modifier
pathology NCT03925272 630 639 B-Condition
that NCT03925272 640 644 O
may NCT03925272 645 648 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03925272 649 658 O
with NCT03925272 659 663 O
the NCT03925272 664 667 O
immune NCT03925272 668 674 B-Condition
system NCT03925272 675 681 I-Condition
, NCT03925272 682 683 O
such NCT03925272 684 688 O
as NCT03925272 689 691 O
progressive NCT03925272 692 703 B-Modifier
or NCT03925272 704 706 B-Or
chronic NCT03925272 707 714 B-Modifier
pathology NCT03925272 715 724 B-Condition
severe NCT03925272 725 731 O
or NCT03925272 732 734 B-Or
uncontrolled NCT03925272 735 747 B-Modifier
by NCT03925272 748 750 O
current NCT03925272 751 758 B-Eq-Comparison
treatments NCT03925272 759 769 B-Procedure
or NCT03925272 770 772 B-Or
a NCT03925272 773 774 O
pathology NCT03925272 775 784 B-Condition
requiring NCT03925272 785 794 B-Assertion___Assertion-Type-Value:hypothetical
the NCT03925272 795 798 O
administration NCT03925272 799 813 O
of NCT03925272 814 816 O
immune NCT03925272 817 823 B-Drug
impact NCT03925272 824 830 I-Drug
drugs NCT03925272 831 836 I-Drug
: NCT03925272 837 838 O
long NCT03925272 839 843 B-Modifier
- NCT03925272 844 845 I-Modifier
term NCT03925272 846 850 I-Modifier
anti NCT03925272 851 855 B-Drug
- NCT03925272 856 857 I-Drug
inflammatory NCT03925272 858 870 I-Drug
, NCT03925272 871 872 O
immunosuppressive NCT03925272 873 890 B-Drug
, NCT03925272 891 892 O
etc NCT03925272 893 896 O

- NCT03925272 899 900 O
Pregnant NCT03925272 902 910 B-Condition
or NCT03925272 911 913 B-Or
lactating NCT03925272 914 923 B-Condition
women NCT03925272 924 929 O

- NCT03925272 932 933 O
For NCT03925272 935 938 O
the NCT03925272 939 942 O
realization NCT03925272 943 954 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03925272 955 957 I-Assertion___Assertion-Type-Value:hypothetical
skin NCT03925272 958 962 B-Modifier
biopsies NCT03925272 963 971 B-Procedure
: NCT03925272 972 973 O
allergy NCT03925272 974 981 B-Allergy
to NCT03925272 982 984 O
local NCT03925272 985 990 B-Drug
anesthetics NCT03925272 991 1002 I-Drug
, NCT03925272 1003 1004 O
cardiac NCT03925272 1005 1012 B-Condition
valvulopathy NCT03925272 1013 1025 I-Condition

- NCT03925272 1028 1029 O
For NCT03925272 1031 1034 O
the NCT03925272 1035 1038 O
realization NCT03925272 1039 1050 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03925272 1051 1053 I-Assertion___Assertion-Type-Value:hypothetical
Tubertest NCT03925272 1054 1063 B-Observation
: NCT03925272 1064 1065 O
Subject NCT03925272 1066 1073 O
presenting NCT03925272 1074 1084 O
a NCT03925272 1085 1086 O
contraindication NCT03925272 1087 1103 B-Contraindication
to NCT03925272 1104 1106 O
tuberculin NCT03925272 1107 1117 B-Drug

Inclusion NCT03928756 0 9 O
Criteria NCT03928756 10 18 O
: NCT03928756 19 20 O

1 NCT03928756 24 25 O
. NCT03928756 25 26 O
Have NCT03928756 28 32 O
an NCT03928756 33 35 O
iPhone NCT03928756 36 42 O
smartphone NCT03928756 43 53 O
on NCT03928756 54 56 O
which NCT03928756 57 62 O
the NCT03928756 63 66 O
app NCT03928756 67 70 O
can NCT03928756 71 74 O
be NCT03928756 75 77 O
downloaded NCT03928756 78 88 O

2 NCT03928756 91 92 O
. NCT03928756 92 93 O
Self NCT03928756 95 99 O
- NCT03928756 100 101 O
reported NCT03928756 102 110 O
past NCT03928756 111 115 B-Eq-Comparison
- NCT03928756 116 117 I-Eq-Comparison
month NCT03928756 118 123 I-Eq-Comparison
binge NCT03928756 124 129 B-Condition
drinking NCT03928756 130 138 I-Condition
( NCT03928756 139 140 O
4 NCT03928756 141 142 B-Eq-Comparison
/ NCT03928756 143 144 I-Eq-Comparison
5 NCT03928756 145 146 I-Eq-Comparison
or NCT03928756 147 149 I-Eq-Comparison
more NCT03928756 150 154 I-Eq-Comparison
drinks NCT03928756 155 161 B-Observation
on NCT03928756 162 164 O
one NCT03928756 165 168 B-Eq-Comparison
occasion NCT03928756 169 177 I-Eq-Comparison
, NCT03928756 178 179 O
tailored NCT03928756 180 188 O
by NCT03928756 189 191 O
sex NCT03928756 192 195 B-Condition
) NCT03928756 196 197 O
OR NCT03928756 198 200 B-Or
any NCT03928756 201 204 O
past NCT03928756 205 209 B-Eq-Comparison
- NCT03928756 210 211 I-Eq-Comparison
month NCT03928756 212 217 I-Eq-Comparison
marijuana NCT03928756 218 227 B-Condition
use NCT03928756 228 231 I-Condition
without NCT03928756 232 239 B-Negation
a NCT03928756 240 241 O
medical NCT03928756 242 249 B-Observation
marijuana NCT03928756 250 259 I-Observation
card NCT03928756 260 264 I-Observation

3 NCT03928756 267 268 O
. NCT03928756 268 269 O
Meet NCT03928756 271 275 O
study NCT03928756 276 281 O
verification NCT03928756 282 294 O
criteria NCT03928756 295 303 O
( NCT03928756 304 305 O
i. NCT03928756 306 308 O
e. NCT03928756 309 311 O
, NCT03928756 312 313 O
use NCT03928756 314 317 O
of NCT03928756 318 320 O
CAPTCHA NCT03928756 321 328 O
, NCT03928756 329 330 O
IP NCT03928756 331 333 O
address NCT03928756 334 341 O
checks NCT03928756 342 348 O
, NCT03928756 349 350 O
social NCT03928756 351 357 O
media NCT03928756 358 363 O
checks NCT03928756 364 370 O
) NCT03928756 371 372 O
. NCT03928756 374 375 O

Exclusion NCT03928756 377 386 O
Criteria NCT03928756 387 395 O
: NCT03928756 396 397 O

1 NCT03928756 399 400 O
. NCT03928756 400 401 O
Unable NCT03928756 403 409 B-Negation
to NCT03928756 410 412 O
understand NCT03928756 413 423 O
English NCT03928756 424 431 O

Inclusion NCT03928795 0 9 O
Criteria NCT03928795 10 18 O
: NCT03928795 19 20 O

- NCT03928795 24 25 O
Monofetal NCT03928795 27 36 B-Modifier
pregnancy NCT03928795 37 46 B-Condition

- NCT03928795 49 50 O
Age NCT03928795 52 55 B-Age
over NCT03928795 56 60 B-Eq-Comparison
18 NCT03928795 61 63 I-Eq-Comparison
years NCT03928795 64 69 I-Eq-Comparison
old NCT03928795 70 73 O

- NCT03928795 76 77 O
Term NCT03928795 79 83 B-Condition
Pregnancy NCT03928795 84 93 I-Condition
≥ NCT03928795 94 95 B-Eq-Comparison
37 NCT03928795 96 98 I-Eq-Comparison
SA NCT03928795 99 101 I-Eq-Comparison

- NCT03928795 104 105 O
Indication NCT03928795 107 117 B-Indication
for NCT03928795 118 121 O
Elective NCT03928795 122 130 B-Modifier
caesarean NCT03928795 131 140 B-Procedure
section NCT03928795 141 148 I-Procedure

Exclusion NCT03928795 149 158 O
Criteria NCT03928795 159 167 O
: NCT03928795 168 169 O

- NCT03928795 173 174 O
- NCT03928795 176 177 O
Fetal NCT03928795 178 183 B-Modifier
pathology NCT03928795 184 193 B-Condition
known NCT03928795 194 199 O
prenatally NCT03928795 200 210 O
like NCT03928795 211 215 O
intrauterine NCT03928795 216 228 B-Modifier
severe NCT03928795 229 235 O
growth NCT03928795 236 242 B-Condition
retardation NCT03928795 243 254 I-Condition
with NCT03928795 255 259 B-And
Doppler NCT03928795 260 267 B-Condition
abnormalities NCT03928795 268 281 O
, NCT03928795 282 283 O
fetal NCT03928795 284 289 B-Modifier
malformation NCT03928795 290 302 B-Condition
or NCT03928795 303 305 B-Or
a NCT03928795 306 307 O
known NCT03928795 308 313 O
fetal NCT03928795 314 319 B-Modifier
genetic NCT03928795 320 327 B-Condition
defect NCT03928795 328 334 I-Condition
. NCT03928795 335 336 O

- NCT03928795 340 341 O
Anomaly NCT03928795 343 350 B-Condition
of NCT03928795 351 353 O
placental NCT03928795 354 363 B-Modifier
adhesion NCT03928795 364 372 I-Modifier
. NCT03928795 373 374 O

- NCT03928795 378 379 O
Caesarean NCT03928795 381 390 B-Procedure
in NCT03928795 391 393 B-Temporal-Connection___Temporal-Connection-Type-Value:during
a NCT03928795 394 395 I-Temporal-Connection___Temporal-Connection-Type-Value:during
context NCT03928795 396 403 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928795 404 406 O
medical NCT03928795 407 414 B-Modifier
or NCT03928795 415 417 B-Or
obstetric NCT03928795 418 427 B-Modifier
emergency NCT03928795 428 437 B-Observation
. NCT03928795 438 439 O

- NCT03928795 443 444 O
Caesarean NCT03928795 446 455 B-Procedure
section NCT03928795 456 463 I-Procedure
performed NCT03928795 464 473 O
under NCT03928795 474 479 O
general NCT03928795 480 487 B-Procedure
anesthesia NCT03928795 488 498 I-Procedure
following NCT03928795 499 508 B-Temporal-Connection___Temporal-Connection-Type-Value:after
failure NCT03928795 509 516 O
of NCT03928795 517 519 O
locoregional NCT03928795 520 532 B-Modifier
anesthesia NCT03928795 533 543 B-Procedure
. NCT03928795 544 545 O

- NCT03928795 549 550 O
Refusal NCT03928795 552 559 O
of NCT03928795 560 562 O
the NCT03928795 563 566 O
woman NCT03928795 567 572 O
to NCT03928795 573 575 O
participate NCT03928795 576 587 O
in NCT03928795 588 590 O
the NCT03928795 591 594 O
study NCT03928795 595 600 B-Study
. NCT03928795 601 602 O

- NCT03928795 606 607 O
Impossibility NCT03928795 609 622 B-Assertion___Assertion-Type-Value:hypothetical|Negation
or NCT03928795 623 625 B-Or
failure NCT03928795 626 633 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03928795 634 636 O
study NCT03928795 637 642 O
the NCT03928795 643 646 O
neonatal NCT03928795 647 655 B-Modifier
acid NCT03928795 656 660 B-Observation
- NCT03928795 661 662 I-Observation
base NCT03928795 663 667 I-Observation
balance NCT03928795 668 675 I-Observation
on NCT03928795 676 678 O
the NCT03928795 679 682 O
umbilical NCT03928795 683 692 B-Modifier
cord NCT03928795 693 697 I-Modifier
. NCT03928795 697 698 O

Inclusion NCT03924024 0 9 O
Criteria NCT03924024 10 18 O
: NCT03924024 19 20 O

- NCT03924024 24 25 O
Male NCT03924024 27 31 O
or NCT03924024 32 34 B-Or
female NCT03924024 35 41 O
, NCT03924024 42 43 O
18 NCT03924024 44 46 B-Eq-Comparison
to NCT03924024 47 49 I-Eq-Comparison
65 NCT03924024 50 52 I-Eq-Comparison
years NCT03924024 53 58 I-Eq-Comparison
of NCT03924024 59 61 O
age NCT03924024 62 65 B-Age
. NCT03924024 66 67 O

- NCT03924024 71 72 O
Able NCT03924024 74 78 O
to NCT03924024 79 81 O
provide NCT03924024 82 89 O
informed NCT03924024 90 98 O
consent NCT03924024 99 106 O
. NCT03924024 107 108 O

- NCT03924024 112 113 O
Present NCT03924024 115 122 B-Encounter
to NCT03924024 123 125 O
Stanford NCT03924024 126 134 O
Emergency NCT03924024 135 144 O
Department NCT03924024 145 155 O
as NCT03924024 156 158 O
a NCT03924024 159 160 O
trauma NCT03924024 161 167 B-Condition
with NCT03924024 168 172 B-And
a NCT03924024 173 174 O
major NCT03924024 175 180 B-Modifier
operative NCT03924024 181 190 I-Modifier
lower NCT03924024 191 196 I-Modifier
extremity NCT03924024 197 206 I-Modifier
injury NCT03924024 207 213 B-Condition

- NCT03924024 216 217 O
Glasgow NCT03924024 219 226 B-Observation
coma NCT03924024 227 231 I-Observation
scale NCT03924024 232 237 I-Observation
of NCT03924024 238 240 O
15 NCT03924024 241 243 B-Eq-Comparison
within NCT03924024 244 250 B-Eq-Comparison
24 NCT03924024 251 253 I-Eq-Comparison
hours NCT03924024 254 259 I-Eq-Comparison
after NCT03924024 260 265 B-Temporal-Connection___Temporal-Connection-Type-Value:after
admission NCT03924024 266 275 B-Encounter
or NCT03924024 276 278 B-Or
extubation NCT03924024 279 289 B-Procedure

- NCT03924024 292 293 O
Negative NCT03924024 295 303 O
urinary NCT03924024 304 311 B-Observation
toxicology NCT03924024 312 322 I-Observation
screen NCT03924024 323 329 B-Modifier
for NCT03924024 330 333 I-Modifier
illicit NCT03924024 334 341 I-Modifier
substances NCT03924024 342 352 I-Modifier
; NCT03924024 352 353 O

- NCT03924024 356 357 O
Negative NCT03924024 359 367 O
pregnancy NCT03924024 368 377 B-Condition
test NCT03924024 378 382 O
if NCT03924024 383 385 O
female NCT03924024 386 392 O
and NCT03924024 393 396 B-And
less NCT03924024 397 401 B-Eq-Comparison
then NCT03924024 402 406 I-Eq-Comparison
60 NCT03924024 407 409 I-Eq-Comparison
y NCT03924024 410 411 I-Eq-Comparison
/ NCT03924024 412 413 I-Eq-Comparison
o NCT03924024 414 415 I-Age|Eq-Comparison
; NCT03924024 415 416 O

- NCT03924024 419 420 O
No NCT03924024 422 424 B-Negation
suspicion NCT03924024 425 434 B-Assertion___Assertion-Type-Value:possible
for NCT03924024 435 438 O
a NCT03924024 439 440 O
head NCT03924024 441 445 B-Modifier
injury NCT03924024 446 452 B-Condition
and NCT03924024 453 456 B-Or
/ NCT03924024 457 458 I-Or
or NCT03924024 459 461 I-Or
negative NCT03924024 462 470 O
head NCT03924024 471 475 B-Modifier
CT NCT03924024 476 478 B-Procedure
scan NCT03924024 479 483 I-Procedure
for NCT03924024 484 487 O
intracranial NCT03924024 488 500 B-Condition
hemorrhage NCT03924024 501 511 I-Condition
or NCT03924024 512 514 B-Or
injury NCT03924024 515 521 B-Condition
based NCT03924024 522 527 O
on NCT03924024 528 530 O
standard NCT03924024 531 539 O
of NCT03924024 540 542 O
care NCT03924024 543 547 O

- NCT03924024 550 551 O
No NCT03924024 553 555 B-Negation
history NCT03924024 556 563 B-Eq-Comparison
of NCT03924024 564 566 O
seizure NCT03924024 567 574 B-Condition
disorder NCT03924024 575 583 I-Condition
or NCT03924024 584 586 B-Or
other NCT03924024 587 592 B-Other
neurological NCT03924024 593 605 B-Condition
disorders NCT03924024 606 615 I-Condition
. NCT03924024 616 617 O

- NCT03924024 621 622 O
All NCT03924024 624 627 O
patients NCT03924024 628 636 O
included NCT03924024 637 645 O
must NCT03924024 646 650 O
screen NCT03924024 651 657 O
positive NCT03924024 658 666 O
for NCT03924024 667 670 O
PHQ NCT03924024 671 674 B-Observation
- NCT03924024 675 676 I-Observation
9 NCT03924024 677 678 I-Observation
score NCT03924024 679 684 B-Eq-Comparison
> NCT03924024 685 686 I-Eq-Comparison
4 NCT03924024 687 688 I-Eq-Comparison
( NCT03924024 689 690 O
positive NCT03924024 691 699 O
symptoms NCT03924024 700 708 B-Assertion___Assertion-Type-Value:possible
of NCT03924024 709 711 O
depression NCT03924024 712 722 B-Condition
) NCT03924024 723 724 O
and NCT03924024 725 728 B-And
CES NCT03924024 729 732 B-Observation
- NCT03924024 733 734 I-Observation
T NCT03924024 735 736 I-Observation
score NCT03924024 737 742 B-Eq-Comparison
< NCT03924024 743 744 I-Eq-Comparison
36 NCT03924024 745 747 I-Eq-Comparison
( NCT03924024 748 749 O
poor NCT03924024 750 754 B-Condition
coping NCT03924024 755 761 I-Condition
self NCT03924024 762 766 I-Condition
- NCT03924024 767 768 I-Condition
efficacy NCT03924024 769 777 I-Condition
) NCT03924024 778 779 O
. NCT03924024 781 782 O

Exclusion NCT03924024 784 793 O
Criteria NCT03924024 794 802 O
: NCT03924024 803 804 O

- NCT03924024 808 809 O
Incarceration NCT03924024 811 824 B-Observation
, NCT03924024 825 826 O

- NCT03924024 830 831 O
Pregnant NCT03924024 833 841 B-Condition
females NCT03924024 842 849 O
, NCT03924024 850 851 O

- NCT03924024 855 856 O
Prior NCT03924024 858 863 B-Eq-Comparison
psychotic NCT03924024 864 873 B-Condition
disorder NCT03924024 874 882 I-Condition
, NCT03924024 883 884 O

- NCT03924024 888 889 O
Current NCT03924024 891 898 B-Eq-Comparison
use NCT03924024 899 902 I-Eq-Comparison
of NCT03924024 903 905 O
anti NCT03924024 906 910 B-Drug
- NCT03924024 911 912 I-Drug
depressant NCT03924024 913 923 I-Drug
or NCT03924024 924 926 B-Or
anti NCT03924024 927 931 B-Drug
- NCT03924024 932 933 I-Drug
psychotic NCT03924024 934 943 I-Drug
medications NCT03924024 944 955 I-Drug
, NCT03924024 956 957 O

- NCT03924024 961 962 O
Prior NCT03924024 964 969 B-Eq-Comparison
- NCT03924024 970 971 O
admission NCT03924024 972 981 B-Encounter
opioid NCT03924024 982 988 B-Condition
use NCT03924024 989 992 I-Condition
within NCT03924024 993 999 B-Eq-Comparison
30 NCT03924024 1000 1002 I-Eq-Comparison
days NCT03924024 1003 1007 I-Eq-Comparison
( NCT03924024 1008 1009 O
patients NCT03924024 1010 1018 O
will NCT03924024 1019 1023 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03924024 1024 1026 I-Assertion___Assertion-Type-Value:hypothetical
screened NCT03924024 1027 1035 O
for NCT03924024 1036 1039 O
recent NCT03924024 1040 1046 B-Eq-Comparison
prescription NCT03924024 1047 1059 O
opioid NCT03924024 1060 1066 B-Drug
use NCT03924024 1067 1070 O
using NCT03924024 1071 1076 O
the NCT03924024 1077 1080 O
CURES NCT03924024 1081 1086 B-Observation
report NCT03924024 1087 1093 O
) NCT03924024 1094 1095 O
, NCT03924024 1097 1098 O

- NCT03924024 1102 1103 O
Heavy NCT03924024 1105 1110 O
alcohol NCT03924024 1111 1118 B-Condition
use NCT03924024 1119 1122 I-Condition
, NCT03924024 1123 1124 O

- NCT03924024 1128 1129 O
Lesional NCT03924024 1131 1139 B-Modifier
neurological NCT03924024 1140 1152 B-Condition
disorder NCT03924024 1153 1161 I-Condition
or NCT03924024 1162 1164 B-Or
brain NCT03924024 1165 1170 B-Modifier
implant NCT03924024 1171 1178 B-Procedure
or NCT03924024 1179 1181 B-Or
intracranial NCT03924024 1182 1194 B-Condition
ferromagnetic NCT03924024 1195 1208 I-Condition
material NCT03924024 1209 1217 I-Condition
, NCT03924024 1218 1219 O

- NCT03924024 1223 1224 O
Seizure NCT03924024 1226 1233 B-Condition
disorder NCT03924024 1234 1242 I-Condition

Inclusion NCT03926169 0 9 O
Criteria NCT03926169 10 18 O
: NCT03926169 19 20 O

- NCT03926169 24 25 O
Participant NCT03926169 27 38 O
with NCT03926169 39 43 O
moderate NCT03926169 44 52 B-Eq-Comparison
to NCT03926169 53 55 I-Eq-Comparison
severe NCT03926169 56 62 I-Eq-Comparison
Hidradenitis NCT03926169 63 75 B-Condition
Suppurativa NCT03926169 76 87 I-Condition
( NCT03926169 88 89 O
HS NCT03926169 90 92 B-Condition
) NCT03926169 93 94 O
for NCT03926169 95 98 O
at NCT03926169 99 101 B-Eq-Comparison
least NCT03926169 102 107 I-Eq-Comparison
one NCT03926169 108 111 I-Eq-Comparison
year NCT03926169 112 116 I-Eq-Comparison
prior NCT03926169 117 122 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 123 125 I-Temporal-Connection___Temporal-Connection-Type-Value:before
Baseline NCT03926169 126 134 B-Study
visit NCT03926169 135 140 O
. NCT03926169 141 142 O

- NCT03926169 146 147 O
HS NCT03926169 149 151 B-Condition
lesions NCT03926169 152 159 I-Condition
present NCT03926169 160 167 O
in NCT03926169 168 170 O
at NCT03926169 171 173 B-Eq-Comparison
least NCT03926169 174 179 I-Eq-Comparison
two NCT03926169 180 183 I-Eq-Comparison
distinct NCT03926169 184 192 I-Eq-Comparison
anatomical NCT03926169 193 203 I-Eq-Comparison
areas NCT03926169 204 209 I-Eq-Comparison
. NCT03926169 210 211 O

- NCT03926169 215 216 O
Draining NCT03926169 218 226 B-Observation
fistula NCT03926169 227 234 I-Observation
count NCT03926169 235 240 I-Observation
of NCT03926169 241 243 O
< NCT03926169 244 245 B-Eq-Comparison
= NCT03926169 247 248 I-Eq-Comparison
20 NCT03926169 249 251 I-Eq-Comparison
at NCT03926169 252 254 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Baseline NCT03926169 255 263 B-Study
visit NCT03926169 264 269 O
. NCT03926169 270 271 O

- NCT03926169 275 276 O
Total NCT03926169 278 283 O
abscesses NCT03926169 284 293 B-Observation
and NCT03926169 294 297 I-Observation
nodule NCT03926169 298 304 I-Observation
count NCT03926169 305 310 I-Observation
( NCT03926169 311 312 O
AN NCT03926169 313 315 B-Observation
count NCT03926169 316 321 I-Observation
) NCT03926169 322 323 O
of NCT03926169 324 326 O
> NCT03926169 327 328 B-Eq-Comparison
= NCT03926169 330 331 O
5 NCT03926169 332 333 I-Eq-Comparison
at NCT03926169 334 336 B-Temporal-Connection___Temporal-Connection-Type-Value:during
Baseline NCT03926169 337 345 B-Study
visit NCT03926169 346 351 O
. NCT03926169 352 353 O

- NCT03926169 357 358 O
Participants NCT03926169 360 372 O
are NCT03926169 373 376 O
required NCT03926169 377 385 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926169 386 388 I-Assertion___Assertion-Type-Value:hypothetical
use NCT03926169 389 392 O
a NCT03926169 393 394 O
daily NCT03926169 395 400 B-Eq-Comparison
antiseptic NCT03926169 401 411 B-Procedure
wash NCT03926169 412 416 I-Procedure
on NCT03926169 417 419 O
their NCT03926169 420 425 O
HS NCT03926169 426 428 B-Condition
lesions NCT03926169 429 436 I-Condition
. NCT03926169 438 439 O

- NCT03926169 443 444 O
Participant NCT03926169 446 457 O
must NCT03926169 458 462 O
have NCT03926169 463 467 O
a NCT03926169 468 469 O
history NCT03926169 470 477 B-Eq-Comparison
of NCT03926169 478 480 O
inadequate NCT03926169 481 491 B-Condition
response NCT03926169 492 500 I-Condition
or NCT03926169 501 503 B-Or
intolerance NCT03926169 504 515 B-Condition
to NCT03926169 516 518 O
an NCT03926169 519 521 O
adequate NCT03926169 522 530 O
trial NCT03926169 531 536 O
of NCT03926169 537 539 O
oral NCT03926169 540 544 B-Drug
antibiotics NCT03926169 545 556 I-Drug
for NCT03926169 557 560 O
treatment NCT03926169 561 570 B-Procedure
of NCT03926169 571 573 O
HS NCT03926169 574 576 B-Condition
. NCT03926169 577 578 O

Exclusion NCT03926169 580 589 O
Criteria NCT03926169 590 598 O
: NCT03926169 599 600 O

- NCT03926169 604 605 O
Participant NCT03926169 607 618 O
has NCT03926169 619 622 O
a NCT03926169 623 624 O
history NCT03926169 625 632 B-Eq-Comparison
of NCT03926169 633 635 O
active NCT03926169 636 642 B-Eq-Comparison
skin NCT03926169 643 647 B-Condition
disease NCT03926169 648 655 I-Condition
other NCT03926169 656 661 B-Exception
than NCT03926169 662 666 I-Exception
HS NCT03926169 667 669 B-Condition
that NCT03926169 670 674 O
could NCT03926169 675 680 B-Assertion___Assertion-Type-Value:hypothetical
interfere NCT03926169 681 690 O
with NCT03926169 691 695 O
the NCT03926169 696 699 O
assessment NCT03926169 700 710 B-Procedure
of NCT03926169 711 713 O
HS NCT03926169 714 716 B-Condition
. NCT03926169 717 718 O

- NCT03926169 722 723 O
Participant NCT03926169 725 736 O
has NCT03926169 737 740 O
active NCT03926169 741 747 B-Eq-Comparison
tuberculosis NCT03926169 748 760 B-Condition
( NCT03926169 761 762 O
TB NCT03926169 763 765 B-Condition
) NCT03926169 766 767 O
or NCT03926169 768 770 B-Or
concurrent NCT03926169 771 781 O
treatment NCT03926169 782 791 B-Procedure
for NCT03926169 792 795 O
latent NCT03926169 796 802 B-Modifier
TB NCT03926169 803 805 B-Condition
or NCT03926169 806 808 B-Or
evidence NCT03926169 809 817 O
of NCT03926169 818 820 O
hepatitis NCT03926169 821 830 B-Condition
B NCT03926169 831 832 I-Condition
virus NCT03926169 833 838 I-Condition
( NCT03926169 839 840 O
HBV NCT03926169 841 844 B-Condition
) NCT03926169 845 846 O
or NCT03926169 847 849 B-Or
hepatitis NCT03926169 850 859 B-Condition
C NCT03926169 860 861 I-Condition
virus NCT03926169 862 867 I-Condition
( NCT03926169 868 869 O
HCV NCT03926169 870 873 B-Condition
) NCT03926169 874 875 O
or NCT03926169 876 878 B-Or
human NCT03926169 879 884 B-Condition
immuno NCT03926169 885 891 I-Condition
deficiency NCT03926169 892 902 I-Condition
virus NCT03926169 903 908 I-Condition
( NCT03926169 909 910 O
HIV NCT03926169 911 914 B-Condition
) NCT03926169 915 916 O
infection NCT03926169 917 926 B-Condition
. NCT03926169 927 928 O

- NCT03926169 932 933 O
Participant NCT03926169 935 946 O
has NCT03926169 947 950 O
prior NCT03926169 951 956 B-Eq-Comparison
exposure NCT03926169 957 965 O
to NCT03926169 966 968 O
anti NCT03926169 969 973 O
- NCT03926169 974 975 O
interleukin NCT03926169 976 987 B-Condition
- NCT03926169 988 989 I-Condition
1 NCT03926169 990 991 I-Condition
( NCT03926169 992 993 O
anti NCT03926169 994 998 O
- NCT03926169 999 1000 O
IL NCT03926169 1001 1003 B-Condition
- NCT03926169 1004 1005 I-Condition
1 NCT03926169 1006 1007 I-Condition
) NCT03926169 1008 1009 O
treatment NCT03926169 1010 1019 B-Procedure
within NCT03926169 1020 1026 B-Eq-Comparison
3 NCT03926169 1027 1028 I-Eq-Comparison
months NCT03926169 1029 1035 I-Eq-Comparison
or NCT03926169 1036 1038 B-Or
5 NCT03926169 1039 1040 B-Eq-Comparison
half NCT03926169 1041 1045 I-Eq-Comparison
- NCT03926169 1046 1047 I-Eq-Comparison
lives NCT03926169 1048 1053 I-Eq-Comparison
, NCT03926169 1054 1055 O
whichever NCT03926169 1056 1065 O
is NCT03926169 1066 1068 O
longer NCT03926169 1069 1075 O
, NCT03926169 1076 1077 O
prior NCT03926169 1078 1083 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1084 1086 I-Temporal-Connection___Temporal-Connection-Type-Value:before
baseline NCT03926169 1087 1095 B-Study
. NCT03926169 1096 1097 O

- NCT03926169 1101 1102 O
Participant NCT03926169 1104 1115 O
has NCT03926169 1116 1119 O
received NCT03926169 1120 1128 B-Eq-Comparison
prescription NCT03926169 1129 1141 O
topical NCT03926169 1142 1149 B-Drug
therapies NCT03926169 1150 1159 I-Drug
( NCT03926169 1160 1161 O
including NCT03926169 1162 1171 O
topical NCT03926169 1172 1179 B-Drug
antibiotics NCT03926169 1180 1191 I-Drug
) NCT03926169 1192 1193 O
within NCT03926169 1194 1200 B-Eq-Comparison
14 NCT03926169 1201 1203 I-Eq-Comparison
days NCT03926169 1204 1208 I-Eq-Comparison
prior NCT03926169 1209 1214 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1215 1217 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926169 1218 1221 O
Baseline NCT03926169 1222 1230 B-Study
visit NCT03926169 1231 1236 O
. NCT03926169 1237 1238 O

- NCT03926169 1242 1243 O
Participant NCT03926169 1245 1256 O
has NCT03926169 1257 1260 O
received NCT03926169 1261 1269 B-Eq-Comparison
systemic NCT03926169 1270 1278 B-Modifier
non NCT03926169 1279 1282 B-Procedure
- NCT03926169 1283 1284 I-Procedure
biologic NCT03926169 1285 1293 I-Procedure
therapies NCT03926169 1294 1303 I-Procedure
that NCT03926169 1304 1308 O
can NCT03926169 1309 1312 O
also NCT03926169 1313 1317 O
be NCT03926169 1318 1320 O
used NCT03926169 1321 1325 O
to NCT03926169 1326 1328 O
treat NCT03926169 1329 1334 O
HS NCT03926169 1335 1337 B-Condition
within NCT03926169 1338 1344 B-Eq-Comparison
4 NCT03926169 1345 1346 I-Eq-Comparison
weeks NCT03926169 1347 1352 I-Eq-Comparison
prior NCT03926169 1353 1358 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1359 1361 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926169 1362 1365 O
Baseline NCT03926169 1366 1374 B-Study
visit NCT03926169 1375 1380 O
. NCT03926169 1381 1382 O

- NCT03926169 1386 1387 O
Participant NCT03926169 1389 1400 O
has NCT03926169 1401 1404 O
received NCT03926169 1405 1413 B-Eq-Comparison
any NCT03926169 1414 1417 O
systemic NCT03926169 1418 1426 B-Modifier
( NCT03926169 1427 1428 O
including NCT03926169 1429 1438 O
oral NCT03926169 1439 1443 B-Modifier
) NCT03926169 1444 1445 O
antibiotic NCT03926169 1446 1456 B-Drug
treatment NCT03926169 1457 1466 B-Procedure
within NCT03926169 1467 1473 B-Eq-Comparison
4 NCT03926169 1474 1475 I-Eq-Comparison
weeks NCT03926169 1476 1481 I-Eq-Comparison
prior NCT03926169 1482 1487 B-Temporal-Connection___Temporal-Connection-Type-Value:before
to NCT03926169 1488 1490 I-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03926169 1491 1494 O
Baseline NCT03926169 1495 1503 B-Study
visit NCT03926169 1504 1509 O
. NCT03926169 1509 1510 O

Inclusion NCT03921606 0 9 O
Criteria NCT03921606 10 18 O
: NCT03921606 19 20 O

- NCT03921606 24 25 O
aged NCT03921606 27 31 B-Age
18 NCT03921606 32 34 B-Eq-Comparison
years NCT03921606 35 40 I-Eq-Comparison
or NCT03921606 41 43 I-Eq-Comparison
above NCT03921606 44 49 I-Eq-Comparison
, NCT03921606 50 51 O

- NCT03921606 55 56 O
able NCT03921606 58 62 O
to NCT03921606 63 65 O
speak NCT03921606 66 71 O
Cantonese NCT03921606 72 81 O
and NCT03921606 82 85 B-Or
read NCT03921606 86 90 O
Chinese NCT03921606 91 98 O

- NCT03921606 101 102 O
do NCT03921606 104 106 O
not NCT03921606 107 110 B-Negation
intend NCT03921606 111 117 B-Assertion___Assertion-Type-Value:intention
to NCT03921606 118 120 I-Assertion___Assertion-Type-Value:intention
quit NCT03921606 121 125 B-Condition
smoking NCT03921606 126 133 I-Condition
( NCT03921606 134 135 O
pre NCT03921606 136 139 B-Condition
- NCT03921606 140 141 I-Condition
contemplation NCT03921606 142 155 I-Condition
stage NCT03921606 156 161 I-Condition
) NCT03921606 162 163 O
, NCT03921606 165 166 O
but NCT03921606 167 170 B-And
are NCT03921606 171 174 O
willing NCT03921606 175 182 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921606 183 185 I-Assertion___Assertion-Type-Value:hypothetical
promote NCT03921606 186 193 O
their NCT03921606 194 199 O
health NCT03921606 200 206 B-Condition

- NCT03921606 209 210 O
use NCT03921606 212 215 O
a NCT03921606 216 217 O
smartphone NCT03921606 218 228 O
and NCT03921606 229 232 O
can NCT03921606 233 236 O
use NCT03921606 237 240 O
an NCT03921606 241 243 O
instant NCT03921606 244 251 O
messaging NCT03921606 252 261 O
tool NCT03921606 262 266 O
( NCT03921606 267 268 O
e. NCT03921606 269 271 O
g. NCT03921606 272 274 O
, NCT03921606 275 276 O
WhatsApp NCT03921606 277 285 O
/ NCT03921606 286 287 O
WeChat NCT03921606 288 294 O
) NCT03921606 295 296 O

- NCT03921606 300 301 O
willing NCT03921606 303 310 O
to NCT03921606 311 313 O
receive NCT03921606 314 321 O
health NCT03921606 322 328 O
promotion NCT03921606 329 338 O
advice NCT03921606 339 345 O
and NCT03921606 346 349 O
interact NCT03921606 350 358 O
with NCT03921606 359 363 O
our NCT03921606 364 367 O
interventionist NCT03921606 368 383 O
via NCT03921606 384 387 O
WhatsApp NCT03921606 388 396 O
/ NCT03921606 397 398 O
WeChat NCT03921606 399 405 O
on NCT03921606 406 408 O
a NCT03921606 409 410 O
smartphone NCT03921606 411 421 O
throughout NCT03921606 422 432 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921606 433 436 O
study NCT03921606 437 442 B-Study
period NCT03921606 443 449 O

Exclusion NCT03921606 450 459 O
Criteria NCT03921606 460 468 O
: NCT03921606 469 470 O

- NCT03921606 474 475 O
inability NCT03921606 477 486 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921606 487 489 O
give NCT03921606 490 494 O
informed NCT03921606 495 503 O
consent NCT03921606 504 511 O
or NCT03921606 512 514 O
participate NCT03921606 515 526 O
in NCT03921606 527 529 O
our NCT03921606 530 533 O
intervention NCT03921606 534 546 B-Procedure
due NCT03921606 547 550 O
to NCT03921606 551 553 O
impaired NCT03921606 554 562 B-Condition
mental NCT03921606 563 569 I-Condition
status NCT03921606 570 576 I-Condition
, NCT03921606 577 578 O
cognitive NCT03921606 579 588 B-Condition
impairment NCT03921606 589 599 I-Condition
or NCT03921606 600 602 O
communication NCT03921606 603 616 B-Condition
barriers NCT03921606 617 625 I-Condition

- NCT03921606 628 629 O
participate NCT03921606 631 642 O
in NCT03921606 643 645 O
another NCT03921606 646 653 B-Other
smoking NCT03921606 654 661 B-Procedure
cessation NCT03921606 662 671 I-Procedure
programme NCT03921606 672 681 O
or NCT03921606 682 684 O
service NCT03921606 685 692 O

Inclusion NCT03924232 0 9 O
Criteria NCT03924232 10 18 O
: NCT03924232 19 20 O

- NCT03924232 24 25 O
All NCT03924232 27 30 O
patients NCT03924232 31 39 O
aged NCT03924232 40 44 B-Age
18 NCT03924232 45 47 B-Eq-Comparison
or NCT03924232 48 50 I-Eq-Comparison
older NCT03924232 51 56 I-Eq-Comparison
and NCT03924232 57 60 B-And
with NCT03924232 61 65 O
a NCT03924232 66 67 O
recent NCT03924232 68 74 B-Eq-Comparison
( NCT03924232 75 76 O
< NCT03924232 78 79 B-Eq-Comparison
48 NCT03924232 80 82 I-Eq-Comparison
h NCT03924232 83 84 I-Eq-Comparison
) NCT03924232 85 86 O
ICU NCT03924232 87 90 B-Encounter
entry NCT03924232 91 96 I-Encounter
requiring NCT03924232 97 106 O
mechanical NCT03924232 107 117 B-Procedure
ventilation NCT03924232 118 129 I-Procedure
for NCT03924232 130 133 O
at NCT03924232 134 136 B-Eq-Comparison
least NCT03924232 137 142 I-Eq-Comparison
3 NCT03924232 143 144 I-Eq-Comparison
days NCT03924232 145 149 I-Eq-Comparison
will NCT03924232 150 154 O
be NCT03924232 155 157 O
considered NCT03924232 158 168 O
for NCT03924232 169 172 O
enrolment NCT03924232 173 182 O

Exclusion NCT03924232 183 192 O
Criteria NCT03924232 193 201 O
: NCT03924232 202 203 O

- NCT03924232 207 208 O
not NCT03924232 210 213 B-Negation
intubated NCT03924232 214 223 B-Procedure
patients NCT03924232 224 232 O

- NCT03924232 235 236 O
patients NCT03924232 238 246 O
with NCT03924232 247 251 O
an NCT03924232 252 254 O
ICU NCT03924232 255 258 B-Encounter
prevision NCT03924232 259 268 I-Encounter
of NCT03924232 269 271 I-Encounter
stay NCT03924232 272 276 I-Encounter
less NCT03924232 277 281 B-Eq-Comparison
than NCT03924232 282 286 I-Eq-Comparison
3 NCT03924232 287 288 I-Eq-Comparison
days NCT03924232 289 293 I-Eq-Comparison

Inclusion NCT03925662 0 9 O
Criteria NCT03925662 10 18 O
: NCT03925662 19 20 O

- NCT03925662 24 25 O
Colorectal NCT03925662 27 37 B-Modifier
cancer NCT03925662 38 44 B-Condition
stage NCT03925662 45 50 B-Eq-Comparison
4 NCT03925662 51 52 I-Eq-Comparison
. NCT03925662 52 53 O

Exclusion NCT03925662 55 64 O
Criteria NCT03925662 65 73 O
: NCT03925662 74 75 O

- NCT03925662 79 80 O
Agranulocytosis NCT03925662 82 97 B-Condition

- NCT03925662 100 101 O
Pregnancy NCT03925662 103 112 B-Condition

- NCT03925662 115 116 O
Allergy NCT03925662 118 125 B-Allergy
to NCT03925662 126 128 O
mebendazole NCT03925662 129 140 B-Drug
. NCT03925662 140 141 O

Inclusion NCT03924583 0 9 O
Criteria NCT03924583 10 18 O
: NCT03924583 19 20 O

- NCT03924583 24 25 O
central NCT03924583 27 34 B-Procedure
venous NCT03924583 35 41 I-Procedure
catheter NCT03924583 42 50 I-Procedure
more NCT03924583 51 55 B-Eq-Comparison
than NCT03924583 56 60 I-Eq-Comparison
48 NCT03924583 61 63 I-Eq-Comparison
hours NCT03924583 64 69 I-Eq-Comparison
in NCT03924583 70 72 B-Modifier
situ NCT03924583 73 77 I-Modifier

- NCT03924583 80 81 O
consent NCT03924583 83 90 O
of NCT03924583 91 93 O
a NCT03924583 94 95 O
patient NCT03924583 96 103 O

Exclusion NCT03924583 104 113 O
Criteria NCT03924583 114 122 O
: NCT03924583 123 124 O

- NCT03924583 128 129 O
technical NCT03924583 131 140 B-Assertion___Assertion-Type-Value:hypothetical
difficulties NCT03924583 141 153 I-Assertion___Assertion-Type-Value:hypothetical
of NCT03924583 154 156 O
ultrasound NCT03924583 157 167 B-Procedure
machine NCT03924583 168 175 I-Procedure

- NCT03924583 178 179 O
unfavorable NCT03924583 181 192 O
local NCT03924583 193 198 O
findings NCT03924583 199 207 B-Condition
- NCT03924583 208 209 O
inflammation NCT03924583 210 222 B-Condition
of NCT03924583 223 225 I-Condition
skin NCT03924583 226 230 I-Condition
, NCT03924583 231 232 O
excoriation NCT03924583 233 244 B-Condition
etc NCT03924583 245 248 O
. NCT03924583 248 249 O

Inclusion NCT03925688 0 9 O
Criteria NCT03925688 10 18 O
: NCT03925688 19 20 O

- NCT03925688 24 25 O
Have NCT03925688 27 31 O
a NCT03925688 32 33 O
previous NCT03925688 34 42 B-Eq-Comparison
history NCT03925688 43 50 I-Eq-Comparison
of NCT03925688 51 53 O
elbow NCT03925688 54 59 B-Modifier
joint NCT03925688 60 65 I-Modifier
fracture NCT03925688 66 74 B-Condition
or NCT03925688 75 77 B-Or
dislocation NCT03925688 78 89 B-Condition
that NCT03925688 90 94 O
conform NCT03925688 95 102 O
to NCT03925688 103 105 O
its NCT03925688 106 109 O
manifestations NCT03925688 110 124 O
and NCT03925688 125 128 O
signs NCT03925688 129 134 O
. NCT03925688 134 135 O
And NCT03925688 137 140 O
it NCT03925688 141 143 O
is NCT03925688 144 146 O
diagnosed NCT03925688 147 156 B-Coreference
by NCT03925688 157 159 O
X NCT03925688 160 161 B-Procedure
- NCT03925688 162 163 I-Procedure
ray NCT03925688 164 167 I-Procedure
test NCT03925688 168 172 I-Procedure
. NCT03925688 172 173 O
HO NCT03925688 175 177 O
must NCT03925688 178 182 O
accord NCT03925688 183 189 O
with NCT03925688 190 194 O
the NCT03925688 195 198 O
relative NCT03925688 199 207 O
diagnostic NCT03925688 208 218 O
criteria5 NCT03925688 219 228 O
and NCT03925688 229 232 O
have NCT03925688 233 237 O
imaging NCT03925688 238 245 B-Procedure
evidences NCT03925688 246 255 O
of NCT03925688 256 258 O
heterotopic NCT03925688 259 270 B-Condition
ossification NCT03925688 271 283 I-Condition
. NCT03925688 284 285 O

- NCT03925688 289 290 O
Have NCT03925688 292 296 O
complete NCT03925688 297 305 O
clinical NCT03925688 306 314 O
and NCT03925688 315 318 O
imaging NCT03925688 319 326 B-Procedure
dates NCT03925688 327 332 O
. NCT03925688 333 334 O

- NCT03925688 338 339 O
The NCT03925688 341 344 O
age NCT03925688 345 348 B-Age
＞ NCT03925688 349 350 B-Eq-Comparison
18 NCT03925688 351 353 I-Eq-Comparison
and NCT03925688 354 357 O
no NCT03925688 358 360 O
gender NCT03925688 361 367 O
limitation NCT03925688 368 378 O
. NCT03925688 379 380 O

- NCT03925688 384 385 O
The NCT03925688 387 390 O
patient NCT03925688 391 398 O
is NCT03925688 399 401 O
being NCT03925688 402 407 O
a NCT03925688 408 409 O
relatively NCT03925688 410 420 O
stable NCT03925688 421 427 O
physical NCT03925688 428 436 B-Modifier
and NCT03925688 437 440 B-And
mental NCT03925688 441 447 B-Modifier
state NCT03925688 448 453 B-Condition
without NCT03925688 454 461 B-Negation
acute NCT03925688 462 467 O
injection NCT03925688 468 477 B-Procedure
or NCT03925688 478 480 B-Or
diseases NCT03925688 481 489 B-Condition
. NCT03925688 490 491 O

Exclusion NCT03925688 493 502 O
Criteria NCT03925688 503 511 O
: NCT03925688 512 513 O

- NCT03925688 517 518 O
Have NCT03925688 520 524 O
a NCT03925688 525 526 O
history NCT03925688 527 534 B-Eq-Comparison
of NCT03925688 535 537 O
diabetes NCT03925688 538 546 B-Condition
mellitus NCT03925688 547 555 I-Condition
or NCT03925688 556 558 B-Or
impaired NCT03925688 559 567 B-Condition
blood NCT03925688 568 573 I-Condition
glucose NCT03925688 574 581 I-Condition
, NCT03925688 582 583 O
metabolic NCT03925688 584 593 B-Condition
syndrome NCT03925688 594 602 I-Condition
and NCT03925688 603 606 B-Or
gout NCT03925688 607 611 B-Condition
or NCT03925688 612 614 B-Or
renal NCT03925688 615 620 B-Modifier
dysfunction NCT03925688 621 632 B-Condition
( NCT03925688 633 634 O
creatinine NCT03925688 635 645 B-Observation
≥ NCT03925688 646 647 B-Eq-Comparison
1.5 NCT03925688 648 651 I-Eq-Comparison
mg NCT03925688 652 654 I-Eq-Comparison
/ NCT03925688 655 656 I-Eq-Comparison
dL NCT03925688 657 659 I-Eq-Comparison
) NCT03925688 660 661 O
that NCT03925688 662 666 O
apparently NCT03925688 667 677 B-Assertion___Assertion-Type-Value:possible
influence NCT03925688 678 687 O
glucose NCT03925688 688 695 B-Modifier
, NCT03925688 696 697 O
lipid NCT03925688 698 703 B-Modifier
and NCT03925688 704 707 B-Or
protein NCT03925688 708 715 B-Modifier
metabolic NCT03925688 716 725 B-Condition
of NCT03925688 726 728 O
the NCT03925688 729 732 O
body NCT03925688 733 737 B-Modifier
. NCT03925688 738 739 O

- NCT03925688 743 744 O
Have NCT03925688 746 750 O
a NCT03925688 751 752 O
history NCT03925688 753 760 B-Eq-Comparison
of NCT03925688 761 763 O
taking NCT03925688 764 770 O
drugs NCT03925688 771 776 B-Drug
that NCT03925688 777 781 O
can NCT03925688 782 785 O
influence NCT03925688 786 795 O
uric NCT03925688 796 800 B-Condition
acid NCT03925688 801 805 I-Condition
metabolic NCT03925688 806 815 I-Condition
including NCT03925688 816 825 O
gout NCT03925688 826 830 B-Condition
suppressant NCT03925688 831 842 B-Drug
, NCT03925688 843 844 O
diuretic NCT03925688 845 853 B-Drug
, NCT03925688 854 855 O
small NCT03925688 856 861 O
- NCT03925688 862 863 O
dose NCT03925688 864 868 O
aspirin NCT03925688 869 876 B-Drug
( NCT03925688 877 878 O
75 NCT03925688 879 881 B-Eq-Comparison
~ NCT03925688 882 883 I-Eq-Comparison
300 NCT03925688 884 887 I-Eq-Comparison
mg NCT03925688 888 890 I-Eq-Comparison
/ NCT03925688 891 892 I-Eq-Comparison
d NCT03925688 893 894 I-Eq-Comparison
) NCT03925688 895 896 O
or NCT03925688 897 899 B-Or
large NCT03925688 900 905 O
- NCT03925688 906 907 O
dose NCT03925688 908 912 O
aspirin NCT03925688 913 920 B-Drug
( NCT03925688 921 922 O
＞ NCT03925688 924 925 B-Eq-Comparison
3 NCT03925688 926 927 I-Eq-Comparison
g NCT03925688 928 929 I-Eq-Comparison
/ NCT03925688 930 931 I-Eq-Comparison
d NCT03925688 932 933 I-Eq-Comparison
) NCT03925688 934 935 O
, NCT03925688 937 938 O
anti NCT03925688 939 943 O
- NCT03925688 944 945 O
tuberculosis NCT03925688 946 958 B-Condition
drugs NCT03925688 959 964 B-Drug
, NCT03925688 965 966 O
immunosuppressor NCT03925688 967 983 B-Drug
, NCT03925688 984 985 O
nicotinic NCT03925688 986 995 B-Drug
acid NCT03925688 996 1000 I-Drug
and NCT03925688 1001 1004 O
anti NCT03925688 1005 1009 O
- NCT03925688 1010 1011 O
tumor NCT03925688 1012 1017 B-Condition
drugs NCT03925688 1018 1023 B-Drug
such NCT03925688 1024 1028 O
as NCT03925688 1029 1031 O
cyclophosphamide NCT03925688 1032 1048 B-Drug
and NCT03925688 1049 1052 O
so NCT03925688 1053 1055 O
on NCT03925688 1056 1058 O
. NCT03925688 1058 1059 O

Inclusion NCT03924596 0 9 O
Criteria NCT03924596 10 18 O
: NCT03924596 19 20 O

- NCT03924596 24 25 O
Participants NCT03924596 27 39 O
with NCT03924596 40 44 O
renal NCT03924596 45 50 B-Observation
stones NCT03924596 51 57 I-Observation
equal NCT03924596 58 63 B-Eq-Comparison
or NCT03924596 64 66 I-Eq-Comparison
less NCT03924596 67 71 I-Eq-Comparison
than NCT03924596 72 76 I-Eq-Comparison
10 NCT03924596 77 79 I-Eq-Comparison
mm NCT03924596 80 82 I-Eq-Comparison
in NCT03924596 83 85 O
size NCT03924596 86 90 O

Exclusion NCT03924596 91 100 O
Criteria NCT03924596 101 109 O
: NCT03924596 110 111 O

- NCT03924596 115 116 O
Participants NCT03924596 118 130 O
with NCT03924596 131 135 O
renal NCT03924596 136 141 B-Condition
pathology NCT03924596 142 151 I-Condition
( NCT03924596 152 153 O
Renal NCT03924596 154 159 B-Modifier
anomalies NCT03924596 160 169 B-Condition
, NCT03924596 170 171 O
multiple NCT03924596 172 180 B-Modifier
renal NCT03924596 181 186 I-Modifier
cysts NCT03924596 187 192 B-Condition
, NCT03924596 193 194 O
renal NCT03924596 195 200 B-Modifier
tumors NCT03924596 201 207 B-Condition
) NCT03924596 208 209 O

- NCT03924596 213 214 O
Participants NCT03924596 216 228 O
with NCT03924596 229 233 O
comorbidities NCT03924596 234 247 B-Condition
( NCT03924596 248 249 O
DM NCT03924596 250 252 B-Condition
, NCT03924596 253 254 O
CKD NCT03924596 255 258 B-Condition
) NCT03924596 259 260 O

Key NCT03921411 0 3 O
Inclusion NCT03921411 4 13 O
Criteria NCT03921411 14 22 O

- NCT03921411 25 26 O
Male NCT03921411 28 32 O
or NCT03921411 33 35 B-Or
female NCT03921411 36 42 O
subjects NCT03921411 43 51 O
≥ NCT03921411 52 53 B-Eq-Comparison
12 NCT03921411 54 56 I-Eq-Comparison
to NCT03921411 57 59 I-Eq-Comparison
< NCT03921411 60 61 I-Eq-Comparison
18 NCT03921411 62 64 I-Eq-Comparison
years NCT03921411 65 70 I-Eq-Comparison
of NCT03921411 71 73 O
age NCT03921411 74 77 B-Age

- NCT03921411 80 81 O
Chronic NCT03921411 83 90 B-Modifier
AD NCT03921411 91 93 B-Condition
that NCT03921411 94 98 O
has NCT03921411 99 102 O
been NCT03921411 103 107 O
documented NCT03921411 108 118 O
for NCT03921411 119 122 O
at NCT03921411 123 125 B-Eq-Comparison
least NCT03921411 126 131 I-Eq-Comparison
2 NCT03921411 132 133 I-Eq-Comparison
years NCT03921411 134 139 I-Eq-Comparison

- NCT03921411 142 143 O
Eczema NCT03921411 145 151 B-Observation
Area NCT03921411 152 156 I-Observation
and NCT03921411 157 160 I-Observation
Severity NCT03921411 161 169 I-Observation
Index NCT03921411 170 175 I-Observation
( NCT03921411 176 177 O
EASI NCT03921411 178 182 B-Observation
) NCT03921411 183 184 O
score NCT03921411 185 190 O
≥ NCT03921411 191 192 B-Eq-Comparison
16 NCT03921411 193 195 I-Eq-Comparison

- NCT03921411 199 200 O
IGA NCT03921411 202 205 B-Observation
score NCT03921411 206 211 O
≥ NCT03921411 212 213 B-Eq-Comparison
3 NCT03921411 214 215 I-Eq-Comparison

- NCT03921411 219 220 O
AD NCT03921411 222 224 B-Observation
involvement NCT03921411 225 236 I-Observation
≥ NCT03921411 237 238 B-Eq-Comparison
10 NCT03921411 239 241 I-Eq-Comparison
% NCT03921411 242 243 I-Eq-Comparison
of NCT03921411 244 246 I-Eq-Comparison
Body NCT03921411 247 251 I-Eq-Comparison
Surface NCT03921411 252 259 I-Eq-Comparison
Area NCT03921411 260 264 I-Eq-Comparison
( NCT03921411 265 266 O
BSA NCT03921411 267 270 O
) NCT03921411 271 272 O

- NCT03921411 276 277 O
Documented NCT03921411 279 289 O
recent NCT03921411 290 296 B-Eq-Comparison
history NCT03921411 297 304 B-Eq-Comparison
of NCT03921411 305 307 O
inadequate NCT03921411 308 318 O
response NCT03921411 319 327 O
to NCT03921411 328 330 O
topical NCT03921411 331 338 B-Drug
medications NCT03921411 339 350 I-Drug

- NCT03921411 353 354 O
Women NCT03921411 356 361 O
of NCT03921411 362 364 O
childbearing NCT03921411 365 377 B-Condition
potential NCT03921411 378 387 B-Assertion___Assertion-Type-Value:hypothetical
must NCT03921411 388 392 O
agree NCT03921411 393 398 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03921411 399 401 I-Assertion___Assertion-Type-Value:hypothetical
be NCT03921411 402 404 O
strictly NCT03921411 405 413 O
abstinent NCT03921411 414 423 B-Condition
or NCT03921411 424 426 B-Or
to NCT03921411 427 429 O
use NCT03921411 430 433 O
an NCT03921411 434 436 O
effective NCT03921411 437 446 O
and NCT03921411 447 450 O
approved NCT03921411 451 459 O
method NCT03921411 460 466 O
of NCT03921411 467 469 O
contraception NCT03921411 470 483 B-Procedure
throughout NCT03921411 484 494 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921411 495 498 O
study NCT03921411 499 504 B-Study
and NCT03921411 505 508 B-And
for NCT03921411 509 512 O
12 NCT03921411 513 515 B-Eq-Comparison
weeks NCT03921411 516 521 I-Eq-Comparison
after NCT03921411 522 527 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03921411 528 531 O
last NCT03921411 532 536 B-Eq-Comparison
study NCT03921411 537 542 B-Study
drug NCT03921411 543 547 B-Procedure
injection NCT03921411 548 557 I-Procedure
. NCT03921411 558 559 O

Key NCT03921411 561 564 O
Exclusion NCT03921411 565 574 O
Criteria NCT03921411 575 583 O

- NCT03921411 586 587 O
Body NCT03921411 589 593 B-Observation
weight NCT03921411 594 600 I-Observation
< NCT03921411 601 602 B-Eq-Comparison
30 NCT03921411 603 605 I-Eq-Comparison
kg NCT03921411 606 608 I-Eq-Comparison

- NCT03921411 611 612 O
Cutaneous NCT03921411 614 623 B-Modifier
infection NCT03921411 624 633 B-Condition
within NCT03921411 634 640 B-Eq-Comparison
1 NCT03921411 641 642 I-Eq-Comparison
week NCT03921411 643 647 I-Eq-Comparison
or NCT03921411 648 650 B-Or
any NCT03921411 651 654 O
infection NCT03921411 655 664 B-Condition
requiring NCT03921411 665 674 B-Assertion___Assertion-Type-Value:hypothetical
treatment NCT03921411 675 684 B-Procedure
with NCT03921411 685 689 O
oral NCT03921411 690 694 B-Modifier
or NCT03921411 695 697 B-Or
parenteral NCT03921411 698 708 B-Modifier
antibiotics NCT03921411 709 720 B-Procedure
, NCT03921411 721 722 O
antivirals NCT03921411 723 733 B-Drug
, NCT03921411 734 735 O
antiparasitics NCT03921411 736 750 B-Drug
, NCT03921411 751 752 O
or NCT03921411 753 755 B-Or
antifungals NCT03921411 756 767 B-Drug
within NCT03921411 768 774 B-Eq-Comparison
1 NCT03921411 775 776 I-Eq-Comparison
week NCT03921411 777 781 I-Eq-Comparison

- NCT03921411 784 785 O
History NCT03921411 787 794 B-Eq-Comparison
of NCT03921411 795 797 O
hypersensitivity NCT03921411 798 814 B-Condition
( NCT03921411 815 816 O
including NCT03921411 817 826 O
anaphylaxis NCT03921411 827 838 B-Condition
) NCT03921411 839 840 O
to NCT03921411 841 843 O
an NCT03921411 844 846 O
immunoglobulin NCT03921411 847 861 B-Drug
product NCT03921411 862 869 I-Drug
( NCT03921411 870 871 O
plasma NCT03921411 872 878 B-Modifier
- NCT03921411 879 880 I-Modifier
derived NCT03921411 881 888 I-Modifier
or NCT03921411 889 891 B-Or
recombinant NCT03921411 892 903 B-Modifier
, NCT03921411 904 905 O
eg NCT03921411 906 908 O
, NCT03921411 909 910 O
monoclonal NCT03921411 911 921 B-Drug
antibody NCT03921411 922 930 I-Drug
) NCT03921411 931 932 O

- NCT03921411 936 937 O
Any NCT03921411 939 942 O
clinically NCT03921411 943 953 O
significant NCT03921411 954 965 O
issue NCT03921411 966 971 B-Condition
, NCT03921411 972 973 O
based NCT03921411 974 979 O
investigator NCT03921411 980 992 O
judgement NCT03921411 993 1002 O

Inclusion NCT03924804 0 9 O
Criteria NCT03924804 10 18 O
: NCT03924804 19 20 O

- NCT03924804 24 25 O
1 NCT03924804 27 28 O
. NCT03924804 28 29 O
ethnic NCT03924804 31 37 O
Chinese NCT03924804 38 45 O
; NCT03924804 45 46 O

- NCT03924804 49 50 O
2 NCT03924804 52 53 O
. NCT03924804 53 54 O
age NCT03924804 56 59 B-Age
, NCT03924804 60 61 O
18 NCT03924804 62 64 B-Eq-Comparison
to NCT03924804 65 67 I-Eq-Comparison
65 NCT03924804 68 70 I-Eq-Comparison
years NCT03924804 71 76 I-Eq-Comparison
old NCT03924804 77 80 O
; NCT03924804 80 81 O

- NCT03924804 84 85 O
3 NCT03924804 87 88 O
. NCT03924804 88 89 O
American NCT03924804 91 99 B-Condition
Society NCT03924804 100 107 I-Condition
of NCT03924804 108 110 I-Condition
Anaesthesiologists NCT03924804 111 129 I-Condition
( NCT03924804 130 131 O
ASA NCT03924804 132 135 B-Condition
) NCT03924804 136 137 O
physical NCT03924804 138 146 O
status NCT03924804 147 153 O
I NCT03924804 154 155 B-Eq-Comparison
or NCT03924804 156 158 I-Eq-Comparison
II NCT03924804 159 161 I-Eq-Comparison
; NCT03924804 161 162 O

- NCT03924804 165 166 O
4 NCT03924804 168 169 O
. NCT03924804 169 170 O
Daytime NCT03924804 172 179 O
patients NCT03924804 180 188 O
scheduled NCT03924804 189 198 B-Eq-Comparison
for NCT03924804 199 202 O
general NCT03924804 203 210 B-Procedure
anesthesia NCT03924804 211 221 I-Procedure

Exclusion NCT03924804 222 231 O
Criteria NCT03924804 232 240 O
: NCT03924804 241 242 O

- NCT03924804 246 247 O
Patients NCT03924804 249 257 O
unwilling NCT03924804 258 267 O
to NCT03924804 268 270 O
cooperate NCT03924804 271 280 O
with NCT03924804 281 285 O
the NCT03924804 286 289 O
experiment NCT03924804 290 300 O

- NCT03924804 303 304 O
Body NCT03924804 306 310 B-Observation
mass NCT03924804 311 315 I-Observation
index NCT03924804 316 321 I-Observation
exceeding NCT03924804 322 331 B-Eq-Comparison
30 NCT03924804 332 334 I-Eq-Comparison
kg NCT03924804 335 337 I-Eq-Comparison
/ NCT03924804 338 339 I-Eq-Comparison
m2 NCT03924804 340 342 I-Eq-Comparison
; NCT03924804 342 343 O

- NCT03924804 346 347 O
Patients NCT03924804 349 357 O
with NCT03924804 358 362 O
a NCT03924804 363 364 O
history NCT03924804 365 372 B-Eq-Comparison
of NCT03924804 373 375 O
heart NCT03924804 376 381 B-Modifier
, NCT03924804 382 383 O
liver NCT03924804 384 389 B-Modifier
and NCT03924804 390 393 B-Or
Renal NCT03924804 394 399 B-Modifier
failure NCT03924804 400 407 B-Condition
, NCT03924804 408 409 O
hypertension NCT03924804 410 422 B-Condition
, NCT03924804 423 424 O
diabetes NCT03924804 425 433 B-Condition
mellitus NCT03924804 434 442 I-Condition
or NCT03924804 443 445 B-Or
arteriosclerosis NCT03924804 446 462 B-Condition
; NCT03924804 462 463 O
and NCT03924804 464 467 B-Or
any NCT03924804 468 471 O
allergy NCT03924804 472 479 B-Allergy
to NCT03924804 480 482 O
drugs NCT03924804 483 488 B-Drug
used NCT03924804 489 493 O
in NCT03924804 494 496 O
the NCT03924804 497 500 O
study NCT03924804 501 506 B-Study
. NCT03924804 507 508 O

- NCT03924804 512 513 O
Patients NCT03924804 515 523 O
with NCT03924804 524 528 O
the NCT03924804 529 532 O
urinary NCT03924804 533 540 B-Condition
diseases NCT03924804 541 549 I-Condition
, NCT03924804 550 551 O
such NCT03924804 552 556 O
as NCT03924804 557 559 O
kidney NCT03924804 560 566 B-Condition
, NCT03924804 567 568 O
ureteral NCT03924804 569 577 B-Condition
calculi NCT03924804 578 585 I-Condition
and NCT03924804 586 589 B-Or
tumors NCT03924804 590 596 B-Condition
, NCT03924804 597 598 O
prostatic NCT03924804 599 608 B-Condition
hypertrophy NCT03924804 609 620 I-Condition
. NCT03924804 620 621 O

Inclusion NCT03926975 0 9 O
Criteria NCT03926975 10 18 O
: NCT03926975 19 20 O

- NCT03926975 24 25 O
young NCT03926975 27 32 O
, NCT03926975 33 34 O
normal NCT03926975 35 41 O
individuals NCT03926975 42 53 O

Exclusion NCT03926975 54 63 O
Criteria NCT03926975 64 72 O
: NCT03926975 73 74 O

- NCT03926975 78 79 O
IOP NCT03926975 81 84 B-Observation
> NCT03926975 85 86 B-Eq-Comparison
20 NCT03926975 87 89 I-Eq-Comparison
mm NCT03926975 90 92 I-Eq-Comparison
in NCT03926975 93 95 O
either NCT03926975 96 102 B-Modifier
eye NCT03926975 103 106 I-Modifier
, NCT03926975 107 108 O
and NCT03926975 109 112 O
h NCT03926975 113 114 B-Eq-Comparison
/ NCT03926975 115 116 I-Eq-Comparison
o NCT03926975 117 118 I-Eq-Comparison
ocular NCT03926975 119 125 B-Condition
hypertension NCT03926975 126 138 I-Condition
, NCT03926975 139 140 O
glaucoma NCT03926975 141 149 B-Condition
, NCT03926975 150 151 O
or NCT03926975 152 154 B-Or
ocular NCT03926975 155 161 B-Modifier
surgery NCT03926975 162 169 B-Procedure
that NCT03926975 170 174 O
can NCT03926975 175 178 B-Assertion___Assertion-Type-Value:hypothetical
affect NCT03926975 179 185 O
IOP NCT03926975 186 189 B-Observation
. NCT03926975 190 191 O

- NCT03926975 195 196 O
h NCT03926975 198 199 B-Eq-Comparison
/ NCT03926975 200 201 I-Eq-Comparison
o NCT03926975 202 203 I-Eq-Comparison
scleral NCT03926975 204 211 B-Condition
lens NCT03926975 212 216 I-Condition
wear NCT03926975 217 221 O
or NCT03926975 222 224 B-Or
current NCT03926975 225 232 B-Eq-Comparison
scleral NCT03926975 233 240 B-Condition
lens NCT03926975 241 245 I-Condition
wear NCT03926975 246 250 O

Inclusion NCT03925298 0 9 O
Criteria NCT03925298 10 18 O
: NCT03925298 19 20 O

- NCT03925298 24 25 O
Participants NCT03925298 27 39 O
were NCT03925298 40 44 O
eligible NCT03925298 45 53 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925298 54 57 I-Assertion___Assertion-Type-Value:hypothetical
inclusion NCT03925298 58 67 O
in NCT03925298 68 70 O
the NCT03925298 71 74 O
study NCT03925298 75 80 B-Study
if NCT03925298 81 83 O
they NCT03925298 84 88 O
had NCT03925298 89 92 O
evidence NCT03925298 93 101 O
suggesting NCT03925298 102 112 B-Assertion___Assertion-Type-Value:possible
acute NCT03925298 113 118 O
ischemic NCT03925298 119 127 B-Condition
stroke NCT03925298 128 134 I-Condition
that NCT03925298 135 139 O
lasted NCT03925298 140 146 O
for NCT03925298 147 150 O
≤ NCT03925298 151 152 B-Eq-Comparison
4.5 NCT03925298 153 156 I-Eq-Comparison
hours NCT03925298 157 162 I-Eq-Comparison
. NCT03925298 164 165 O

- NCT03925298 169 170 O
Those NCT03925298 172 177 O
Participants NCT03925298 178 190 O
were NCT03925298 191 195 O
treated NCT03925298 196 203 B-Procedure
with NCT03925298 204 208 O
intravenous NCT03925298 209 220 B-Modifier
thrombolytic NCT03925298 221 233 B-Procedure
therapy NCT03925298 234 241 I-Procedure
( NCT03925298 242 243 O
( NCT03925298 245 246 O
recombinant NCT03925298 247 258 B-Drug
tissue NCT03925298 259 265 I-Drug
plasminogen NCT03925298 266 277 I-Drug
activator NCT03925298 278 287 I-Drug
( NCT03925298 288 289 O
rt NCT03925298 290 292 B-Drug
- NCT03925298 293 294 I-Drug
PA NCT03925298 295 297 I-Drug
) NCT03925298 298 299 O
) NCT03925298 301 302 O
. NCT03925298 304 305 O

Exclusion NCT03925298 307 316 O
Criteria NCT03925298 317 325 O
: NCT03925298 326 327 O

- NCT03925298 331 332 O
Those NCT03925298 334 339 O
who NCT03925298 340 343 O
had NCT03925298 344 347 B-Eq-Comparison
hemorrhagic NCT03925298 348 359 B-Condition
stroke NCT03925298 360 366 I-Condition

- NCT03925298 369 370 O
participants NCT03925298 372 384 O
presented NCT03925298 385 394 O
with NCT03925298 395 399 O
acute NCT03925298 400 405 B-Condition
myocardial NCT03925298 406 416 I-Condition
infarction NCT03925298 417 427 I-Condition
, NCT03925298 428 429 O
cerebrovascular NCT03925298 430 445 B-Condition
stroke NCT03925298 446 452 I-Condition
in NCT03925298 453 455 O
the NCT03925298 456 459 O
previous NCT03925298 460 468 B-Eq-Comparison
three NCT03925298 469 474 I-Eq-Comparison
months NCT03925298 475 481 I-Eq-Comparison
. NCT03925298 482 483 O

- NCT03925298 487 488 O
serious NCT03925298 490 497 O
head NCT03925298 498 502 B-Modifier
trauma NCT03925298 503 509 B-Condition
in NCT03925298 510 512 O
the NCT03925298 513 516 O
previous NCT03925298 517 525 B-Eq-Comparison
three NCT03925298 526 531 I-Eq-Comparison
months NCT03925298 532 538 I-Eq-Comparison
. NCT03925298 539 540 O

- NCT03925298 544 545 O
urinary NCT03925298 547 554 B-Modifier
tract NCT03925298 555 560 I-Modifier
, NCT03925298 561 562 O
lung NCT03925298 563 567 B-Modifier
, NCT03925298 568 569 O
or NCT03925298 570 572 B-Or
gastrointestinal NCT03925298 573 589 B-Modifier
hemorrhage NCT03925298 590 600 B-Condition
within NCT03925298 601 607 B-Eq-Comparison
the NCT03925298 608 611 I-Eq-Comparison
three NCT03925298 612 617 I-Eq-Comparison
weeks NCT03925298 618 623 I-Eq-Comparison
. NCT03925298 624 625 O

- NCT03925298 629 630 O
serious NCT03925298 632 639 O
trauma NCT03925298 640 646 B-Condition
or NCT03925298 647 649 B-Or
major NCT03925298 650 655 B-Modifier
surgery NCT03925298 656 663 B-Procedure
within NCT03925298 664 670 B-Eq-Comparison
the NCT03925298 671 674 I-Eq-Comparison
previous NCT03925298 675 683 I-Eq-Comparison
two NCT03925298 684 687 I-Eq-Comparison
weeks NCT03925298 688 693 I-Eq-Comparison
. NCT03925298 694 695 O

- NCT03925298 699 700 O
lumbar NCT03925298 702 708 B-Modifier
or NCT03925298 709 711 B-Or
arterial NCT03925298 712 720 B-Modifier
puncture NCT03925298 721 729 B-Condition
at NCT03925298 730 732 O
a NCT03925298 733 734 O
non NCT03925298 735 738 B-Modifier
- NCT03925298 739 740 I-Modifier
compressible NCT03925298 741 753 I-Modifier
site NCT03925298 754 758 I-Modifier
within NCT03925298 759 765 B-Eq-Comparison
one NCT03925298 766 769 I-Eq-Comparison
week NCT03925298 770 774 I-Eq-Comparison
. NCT03925298 775 776 O

- NCT03925298 780 781 O
those NCT03925298 783 788 O
received NCT03925298 789 797 B-Eq-Comparison
heparin NCT03925298 798 805 B-Drug
within NCT03925298 806 812 B-Eq-Comparison
48 NCT03925298 813 815 I-Eq-Comparison
hours NCT03925298 816 821 I-Eq-Comparison
, NCT03925298 822 823 O
resulting NCT03925298 824 833 O
in NCT03925298 834 836 O
an NCT03925298 837 839 O
activated NCT03925298 840 849 B-Observation
partial NCT03925298 850 857 I-Observation
thromboplastin NCT03925298 858 872 I-Observation
time NCT03925298 873 877 I-Observation
greater NCT03925298 878 885 B-Eq-Comparison
than NCT03925298 886 890 I-Eq-Comparison
the NCT03925298 891 894 I-Eq-Comparison
upper NCT03925298 895 900 I-Eq-Comparison
limit NCT03925298 901 906 I-Eq-Comparison
of NCT03925298 907 909 I-Eq-Comparison
normal NCT03925298 910 916 I-Eq-Comparison
. NCT03925298 917 918 O

- NCT03925298 922 923 O
systolic NCT03925298 925 933 B-Observation
pressure NCT03925298 934 942 I-Observation
> NCT03925298 943 944 B-Eq-Comparison
185 NCT03925298 945 948 I-Eq-Comparison
mmHg NCT03925298 949 953 I-Eq-Comparison
or NCT03925298 954 956 B-Or
diastolic NCT03925298 957 966 B-Observation
pressure NCT03925298 967 975 I-Observation
> NCT03925298 976 977 B-Eq-Comparison
110 NCT03925298 978 981 I-Eq-Comparison
mmHg NCT03925298 982 986 I-Eq-Comparison
. NCT03925298 987 988 O

- NCT03925298 992 993 O
blood NCT03925298 995 1000 B-Observation
glucose NCT03925298 1001 1008 I-Observation
< NCT03925298 1009 1010 B-Eq-Comparison
50 NCT03925298 1011 1013 I-Eq-Comparison
or NCT03925298 1014 1016 B-Or
> NCT03925298 1017 1018 B-Eq-Comparison
400 NCT03925298 1019 1022 I-Eq-Comparison
mg NCT03925298 1023 1025 I-Eq-Comparison
/ NCT03925298 1026 1027 I-Eq-Comparison
dL NCT03925298 1028 1030 I-Eq-Comparison
. NCT03925298 1031 1032 O

- NCT03925298 1036 1037 O
current NCT03925298 1039 1046 B-Eq-Comparison
use NCT03925298 1047 1050 I-Eq-Comparison
of NCT03925298 1051 1053 O
anticoagulants NCT03925298 1054 1068 B-Drug
with NCT03925298 1069 1073 B-And
an NCT03925298 1074 1076 O
International NCT03925298 1077 1090 B-Observation
Normalized NCT03925298 1091 1101 I-Observation
Ratio NCT03925298 1102 1107 I-Observation
> NCT03925298 1108 1109 B-Eq-Comparison
1.7 NCT03925298 1110 1113 I-Eq-Comparison
or NCT03925298 1114 1116 B-Or
prothrombin NCT03925298 1117 1128 B-Observation
time NCT03925298 1129 1133 I-Observation
> NCT03925298 1134 1135 B-Eq-Comparison
15 NCT03925298 1136 1138 I-Eq-Comparison
sec NCT03925298 1139 1142 I-Eq-Comparison
; NCT03925298 1142 1143 O
platelet NCT03925298 1144 1152 B-Observation
count NCT03925298 1153 1158 I-Observation
< NCT03925298 1159 1160 B-Eq-Comparison
100 NCT03925298 1161 1164 I-Eq-Comparison
, NCT03925298 1165 1166 I-Eq-Comparison
000 NCT03925298 1167 1170 I-Eq-Comparison
/ NCT03925298 1171 1172 I-Eq-Comparison
mm3 NCT03925298 1173 1176 I-Eq-Comparison
. NCT03925298 1176 1177 O

- NCT03925298 1181 1182 O
pregnancy NCT03925298 1184 1193 B-Condition
; NCT03925298 1193 1194 O
serious NCT03925298 1195 1202 O
heart NCT03925298 1203 1208 B-Modifier
, NCT03925298 1209 1210 O
lung NCT03925298 1211 1215 B-Modifier
, NCT03925298 1216 1217 O
kidney NCT03925298 1218 1224 B-Modifier
or NCT03925298 1225 1227 B-Or
other NCT03925298 1228 1233 B-Other
organ NCT03925298 1234 1239 B-Modifier
dysfunction NCT03925298 1240 1251 B-Condition
. NCT03925298 1252 1253 O

- NCT03925298 1257 1258 O
allergy NCT03925298 1260 1267 B-Allergy
to NCT03925298 1268 1270 O
active NCT03925298 1271 1277 O
ingredients NCT03925298 1278 1289 O
of NCT03925298 1290 1292 O
rt NCT03925298 1293 1295 B-Drug
- NCT03925298 1296 1297 I-Drug
PA NCT03925298 1298 1300 I-Drug
; NCT03925298 1300 1301 O
patients NCT03925298 1302 1310 O
with NCT03925298 1311 1315 O
> NCT03925298 1316 1317 B-Eq-Comparison
4.5 NCT03925298 1318 1321 I-Eq-Comparison
hours NCT03925298 1322 1327 I-Eq-Comparison
from NCT03925298 1328 1332 B-Temporal-Connection___Temporal-Connection-Type-Value:after
the NCT03925298 1333 1336 O
last NCT03925298 1337 1341 B-Eq-Comparison
time NCT03925298 1342 1346 I-Eq-Comparison
known NCT03925298 1347 1352 O
to NCT03925298 1353 1355 O
be NCT03925298 1356 1358 O
asymptomatic NCT03925298 1359 1371 B-Condition
. NCT03925298 1372 1373 O

- NCT03925298 1377 1378 O
those NCT03925298 1380 1385 O
in NCT03925298 1386 1388 O
whom NCT03925298 1389 1393 O
troponin NCT03925298 1394 1402 B-Observation
was NCT03925298 1403 1406 O
not NCT03925298 1407 1410 B-Negation
measured NCT03925298 1411 1419 O
at NCT03925298 1420 1422 B-Temporal-Connection___Temporal-Connection-Type-Value:during
admission NCT03925298 1423 1432 B-Encounter
were NCT03925298 1433 1437 O
excluded NCT03925298 1438 1446 B-Negation
from NCT03925298 1447 1451 O
the NCT03925298 1452 1455 O
study NCT03925298 1456 1461 B-Study

Inclusion NCT03928964 0 9 O
criteria NCT03928964 10 18 O
: NCT03928964 19 20 O

1 NCT03928964 24 25 O
. NCT03928964 25 26 O
Patients NCT03928964 28 36 O
with NCT03928964 37 41 O
locally NCT03928964 42 49 B-Modifier
advanced NCT03928964 50 58 I-Modifier
or NCT03928964 59 61 B-Or
metastatic NCT03928964 62 72 B-Modifier
renal NCT03928964 73 78 I-Modifier
cell NCT03928964 79 83 I-Modifier
carcinoma NCT03928964 84 93 B-Condition

2 NCT03928964 96 97 O
. NCT03928964 97 98 O
Whose NCT03928964 100 105 O
first NCT03928964 106 111 B-Procedure
- NCT03928964 112 113 I-Procedure
line NCT03928964 114 118 I-Procedure
treatment NCT03928964 119 128 I-Procedure
included NCT03928964 129 137 O
at NCT03928964 138 140 B-Eq-Comparison
least NCT03928964 141 146 I-Eq-Comparison
one NCT03928964 147 150 I-Eq-Comparison
anti NCT03928964 151 155 B-Drug
- NCT03928964 156 157 I-Drug
angiogenic NCT03928964 158 168 I-Drug
agent NCT03928964 169 174 I-Drug
( NCT03928964 175 176 O
tyrosine NCT03928964 177 185 B-Drug
kinase NCT03928964 186 192 I-Drug
inhibitor NCT03928964 193 202 I-Drug
or NCT03928964 203 205 O
monoclonal NCT03928964 206 216 B-Drug
antibodies NCT03928964 217 227 I-Drug
) NCT03928964 228 229 O
and NCT03928964 230 233 B-Or
/ NCT03928964 234 235 I-Or
or NCT03928964 236 238 I-Or
an NCT03928964 239 241 O
mTOR NCT03928964 242 246 B-Drug
inhibitor NCT03928964 247 256 I-Drug
; NCT03928964 256 257 O

3 NCT03928964 260 261 O
. NCT03928964 261 262 O
Whatever NCT03928964 264 272 O
was NCT03928964 273 276 O
the NCT03928964 277 280 O
overall NCT03928964 281 288 O
ECOG NCT03928964 289 293 B-Observation
- NCT03928964 294 295 I-Observation
PS NCT03928964 296 298 I-Observation
score NCT03928964 299 304 O
( NCT03928964 305 306 O
Eastern NCT03928964 307 314 B-Observation
Cooperative NCT03928964 315 326 I-Observation
Oncology NCT03928964 327 335 I-Observation
Group NCT03928964 336 341 I-Observation
Performance NCT03928964 342 353 I-Observation
Status NCT03928964 354 360 I-Observation
) NCT03928964 361 362 O
at NCT03928964 363 365 B-Temporal-Connection___Temporal-Connection-Type-Value:during
treatment NCT03928964 366 375 B-Procedure
initiation NCT03928964 376 386 B-Eq-Comparison
time NCT03928964 387 391 O

4 NCT03928964 394 395 O
. NCT03928964 395 396 O
With NCT03928964 398 402 O
first NCT03928964 403 408 B-Procedure
- NCT03928964 409 410 I-Procedure
line NCT03928964 411 415 I-Procedure
treatment NCT03928964 416 425 I-Procedure
carried NCT03928964 426 433 B-Eq-Comparison
out NCT03928964 434 437 I-Eq-Comparison
between NCT03928964 438 445 B-Eq-Comparison
2007 NCT03928964 446 450 I-Eq-Comparison
and NCT03928964 451 454 I-Eq-Comparison
June NCT03928964 455 459 I-Eq-Comparison
2016 NCT03928964 460 464 I-Eq-Comparison
. NCT03928964 464 465 O

Exclusion NCT03928964 467 476 O
criteria NCT03928964 477 485 O
: NCT03928964 486 487 O

1 NCT03928964 491 492 O
. NCT03928964 492 493 O
Patient NCT03928964 495 502 O
previously NCT03928964 503 513 B-Eq-Comparison
treated NCT03928964 514 521 B-Procedure
with NCT03928964 522 526 O
only NCT03928964 527 531 O
one NCT03928964 532 535 B-Eq-Comparison
cytokine NCT03928964 536 544 B-Drug
( NCT03928964 545 546 O
Interferon NCT03928964 547 557 B-Drug
α2 NCT03928964 558 560 I-Drug
a NCT03928964 561 562 I-Drug
, NCT03928964 563 564 O
high NCT03928964 565 569 O
- NCT03928964 570 571 O
dose NCT03928964 572 576 O
interleukin NCT03928964 577 588 B-Drug
- NCT03928964 589 590 I-Drug
2 NCT03928964 591 592 I-Drug
) NCT03928964 593 594 O

2 NCT03928964 598 599 O
. NCT03928964 599 600 O
Refusal NCT03928964 602 609 O
of NCT03928964 610 612 O
processing NCT03928964 613 623 O
of NCT03928964 624 626 O
personal NCT03928964 627 635 O
data NCT03928964 636 640 O

Inclusion NCT03926949 0 9 O
Criteria NCT03926949 10 18 O
: NCT03926949 19 20 O

1 NCT03926949 24 25 O
. NCT03926949 25 26 O
Patients NCT03926949 28 36 O
18 NCT03926949 37 39 B-Eq-Comparison
years NCT03926949 40 45 I-Eq-Comparison
of NCT03926949 46 48 I-Eq-Comparison
age NCT03926949 49 52 I-Eq-Comparison
or NCT03926949 53 55 I-Eq-Comparison
older NCT03926949 56 61 I-Eq-Comparison

2 NCT03926949 64 65 O
. NCT03926949 65 66 O
Patients NCT03926949 68 76 O
screened NCT03926949 77 85 O
at NCT03926949 86 88 O
risk NCT03926949 89 93 B-Risk
of NCT03926949 94 96 O
malnutrition NCT03926949 97 109 B-Condition
by NCT03926949 110 112 O
Canadian NCT03926949 113 121 B-Observation
Nutrition NCT03926949 122 131 I-Observation
Screening NCT03926949 132 141 I-Observation
Tool NCT03926949 142 146 I-Observation
( NCT03926949 147 148 O
CNST NCT03926949 149 153 B-Observation
) NCT03926949 154 155 O
and NCT03926949 156 159 B-And
identified NCT03926949 160 170 O
as NCT03926949 171 173 O
malnourished NCT03926949 174 186 B-Condition
by NCT03926949 187 189 O
subjective NCT03926949 190 200 B-Procedure
global NCT03926949 201 207 I-Procedure
assessment NCT03926949 208 218 I-Procedure
( NCT03926949 219 220 O
SGA NCT03926949 221 224 B-Procedure
) NCT03926949 225 226 O
B NCT03926949 227 228 B-Modifier
or NCT03926949 229 231 B-Or
C NCT03926949 232 233 B-Modifier

Exclusion NCT03926949 234 243 O
Criteria NCT03926949 244 252 O
: NCT03926949 253 254 O

1 NCT03926949 258 259 O
. NCT03926949 259 260 O
Patients NCT03926949 262 270 O
undergoing NCT03926949 271 281 B-Eq-Comparison
minor NCT03926949 282 287 B-Modifier
or NCT03926949 288 290 B-Or
laparoscopic NCT03926949 291 303 B-Modifier
surgery NCT03926949 304 311 B-Procedure

2 NCT03926949 314 315 O
. NCT03926949 315 316 O
Pregnancy NCT03926949 318 327 B-Condition

3 NCT03926949 330 331 O
. NCT03926949 331 332 O
Patients NCT03926949 334 342 O
with NCT03926949 343 347 O
severe NCT03926949 348 354 O
systemic NCT03926949 355 363 B-Modifier
diseases NCT03926949 364 372 B-Condition
defined NCT03926949 373 380 O
by NCT03926949 381 383 O
American NCT03926949 384 392 B-Condition
Society NCT03926949 393 400 I-Condition
of NCT03926949 401 403 I-Condition
Anesthesiologists NCT03926949 404 421 I-Condition
( NCT03926949 422 423 O
ASA NCT03926949 424 427 B-Condition
) NCT03926949 428 429 O
classification NCT03926949 430 444 B-Eq-Comparison
III NCT03926949 445 448 I-Eq-Comparison
to NCT03926949 449 451 I-Eq-Comparison
V NCT03926949 452 453 I-Eq-Comparison

4 NCT03926949 456 457 O
. NCT03926949 457 458 O
Patients NCT03926949 460 468 O
with NCT03926949 469 473 O
diabetes NCT03926949 474 482 B-Condition
mellitus NCT03926949 483 491 I-Condition

5 NCT03926949 494 495 O
. NCT03926949 495 496 O
Patients NCT03926949 498 506 O
with NCT03926949 507 511 O
planned NCT03926949 512 519 B-Eq-Comparison
palliative NCT03926949 520 530 B-Procedure
treatment NCT03926949 531 540 I-Procedure

Inclusion NCT03921983 0 9 O
Criteria NCT03921983 10 18 O
: NCT03921983 19 20 O

- NCT03921983 24 25 O
COPD NCT03921983 27 31 B-Condition
diagnostic NCT03921983 32 42 O

- NCT03921983 45 46 O
Both NCT03921983 48 52 O
sex NCT03921983 53 56 O

- NCT03921983 59 60 O
18 NCT03921983 62 64 B-Eq-Comparison
< NCT03921983 65 66 I-Eq-Comparison
Age NCT03921983 67 70 B-Age
< NCT03921983 71 72 B-Eq-Comparison
80 NCT03921983 73 75 I-Eq-Comparison
years NCT03921983 76 81 I-Eq-Comparison
old NCT03921983 82 85 O

- NCT03921983 88 89 O
LTOT NCT03921983 91 95 B-Condition
- NCT03921983 96 97 O
group NCT03921983 98 103 O
: NCT03921983 104 105 O
PaO2 NCT03921983 106 110 B-Observation
≥ NCT03921983 111 112 B-Eq-Comparison
65 NCT03921983 113 115 I-Eq-Comparison
mmHg NCT03921983 116 120 I-Eq-Comparison
and NCT03921983 121 124 B-And
SaO2 NCT03921983 125 129 B-Observation
≥ NCT03921983 130 131 B-Eq-Comparison
92 NCT03921983 132 134 I-Eq-Comparison
% NCT03921983 135 136 I-Eq-Comparison

- NCT03921983 140 141 O
LTOT NCT03921983 143 147 B-Condition
+ NCT03921983 148 149 O
group NCT03921983 150 155 O
: NCT03921983 156 157 O
long NCT03921983 158 162 B-Modifier
term NCT03921983 163 167 I-Modifier
oxygenotherapy NCT03921983 168 182 B-Procedure
prescribed NCT03921983 183 193 O
for NCT03921983 194 197 O
more NCT03921983 198 202 B-Eq-Comparison
than NCT03921983 203 207 I-Eq-Comparison
3 NCT03921983 208 209 I-Eq-Comparison
months NCT03921983 210 216 I-Eq-Comparison
, NCT03921983 217 218 O
with NCT03921983 219 223 O
daily NCT03921983 224 229 B-Eq-Comparison
use NCT03921983 230 233 I-Eq-Comparison
between NCT03921983 234 241 I-Eq-Comparison
12 NCT03921983 242 244 I-Eq-Comparison
and NCT03921983 245 248 I-Eq-Comparison
15 NCT03921983 249 251 I-Eq-Comparison
hours NCT03921983 252 257 I-Eq-Comparison
. NCT03921983 258 259 O

Patients NCT03921983 261 269 O
in NCT03921983 270 272 O
both NCT03921983 273 277 O
groups NCT03921983 278 284 O
will NCT03921983 285 289 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03921983 290 292 I-Assertion___Assertion-Type-Value:hypothetical
matched NCT03921983 293 300 O
for NCT03921983 301 304 O
age NCT03921983 305 308 B-Age
( NCT03921983 309 310 O
± NCT03921983 312 313 B-Eq-Comparison
5 NCT03921983 314 315 I-Eq-Comparison
years NCT03921983 316 321 I-Eq-Comparison
) NCT03921983 322 323 O
, NCT03921983 325 326 O
sex NCT03921983 327 330 O
and NCT03921983 331 334 B-And
physical NCT03921983 335 343 B-Observation
activity NCT03921983 344 352 I-Observation

estimated NCT03921983 353 362 O
by NCT03921983 363 365 O
GPAQ NCT03921983 366 370 B-Observation
questionnaire NCT03921983 371 384 I-Observation
( NCT03921983 385 386 O
± NCT03921983 388 389 B-Eq-Comparison
15 NCT03921983 390 392 I-Eq-Comparison
% NCT03921983 393 394 I-Eq-Comparison
Mets NCT03921983 395 399 I-Eq-Comparison
. NCT03921983 399 400 I-Eq-Comparison
min NCT03921983 401 404 I-Eq-Comparison
/ NCT03921983 405 406 I-Eq-Comparison
week NCT03921983 407 411 I-Eq-Comparison
) NCT03921983 412 413 O
. NCT03921983 415 416 O

Exclusion NCT03921983 418 427 O
Criteria NCT03921983 428 436 O
: NCT03921983 437 438 O

- NCT03921983 442 443 O
Recent NCT03921983 445 451 B-Eq-Comparison
cardiorespiratory NCT03921983 452 469 B-Condition
exacerbation NCT03921983 470 482 I-Condition
( NCT03921983 483 484 O
< NCT03921983 486 487 B-Eq-Comparison
6 NCT03921983 488 489 I-Eq-Comparison
weeks NCT03921983 490 495 I-Eq-Comparison
) NCT03921983 496 497 O
. NCT03921983 499 500 O

- NCT03921983 504 505 O
Pulmonary NCT03921983 507 516 B-Procedure
rehabilitation NCT03921983 517 531 I-Procedure
program NCT03921983 532 539 O
during NCT03921983 540 546 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03921983 547 550 O
last NCT03921983 551 555 B-Eq-Comparison
2 NCT03921983 556 557 I-Eq-Comparison
months NCT03921983 558 564 I-Eq-Comparison

- NCT03921983 567 568 O
Continuous NCT03921983 570 580 B-Eq-Comparison
LTOT NCT03921983 581 585 B-Procedure
( NCT03921983 586 587 O
24 NCT03921983 588 590 B-Eq-Comparison
hours NCT03921983 591 596 I-Eq-Comparison
) NCT03921983 597 598 O
or NCT03921983 599 601 B-Or
deambulation NCT03921983 602 614 B-Modifier
O2 NCT03921983 615 617 B-Procedure
therapy NCT03921983 618 625 I-Procedure
alone NCT03921983 626 631 O

- NCT03921983 634 635 O
Anticoagulant NCT03921983 637 650 O
drugs NCT03921983 651 656 O

- NCT03921983 659 660 O
Hematocrit NCT03921983 662 672 B-Observation
outside NCT03921983 673 680 O
the NCT03921983 681 684 O
normal NCT03921983 685 691 O
range NCT03921983 692 697 O
( NCT03921983 698 699 O
35 NCT03921983 700 702 B-Eq-Comparison
- NCT03921983 703 704 I-Eq-Comparison
50 NCT03921983 705 707 I-Eq-Comparison
% NCT03921983 708 709 I-Eq-Comparison
) NCT03921983 711 712 O

Inclusion NCT03922087 0 9 O
Criteria NCT03922087 10 18 O
: NCT03922087 19 20 O

- NCT03922087 24 25 O
Pregnant NCT03922087 27 35 B-Condition
women NCT03922087 36 41 O
who NCT03922087 42 45 B-And
have NCT03922087 46 50 O
plan NCT03922087 51 55 B-Assertion___Assertion-Type-Value:intention
to NCT03922087 56 58 I-Assertion___Assertion-Type-Value:intention
delivery NCT03922087 59 67 B-Condition
and NCT03922087 68 71 O
participate NCT03922087 72 83 O
in NCT03922087 84 86 O
child NCT03922087 87 92 O
care NCT03922087 93 97 O
in NCT03922087 98 100 O
Huizhou NCT03922087 101 108 O
hospital NCT03922087 109 117 O
; NCT03922087 117 118 O

- NCT03922087 121 122 O
Pregnant NCT03922087 124 132 B-Condition
women NCT03922087 133 138 O
who NCT03922087 139 142 B-And
have NCT03922087 143 147 O
resided NCT03922087 148 155 B-Observation
in NCT03922087 156 158 O
Huizhou NCT03922087 159 166 O
for NCT03922087 167 170 O
at NCT03922087 171 173 B-Eq-Comparison
least NCT03922087 174 179 I-Eq-Comparison
3 NCT03922087 180 181 I-Eq-Comparison
years NCT03922087 182 187 I-Eq-Comparison
; NCT03922087 187 188 O

- NCT03922087 191 192 O
Pregnant NCT03922087 194 202 B-Condition
women NCT03922087 203 208 O
who NCT03922087 209 212 B-And
are NCT03922087 213 216 O
consent NCT03922087 217 224 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03922087 225 228 I-Assertion___Assertion-Type-Value:hypothetical
specimens NCT03922087 229 238 O
and NCT03922087 239 242 O
data NCT03922087 243 247 O
collection NCT03922087 248 258 O
and NCT03922087 259 262 O
follow NCT03922087 263 269 B-Encounter
- NCT03922087 270 271 I-Encounter
ups NCT03922087 272 275 I-Encounter
for NCT03922087 276 279 O
both NCT03922087 280 284 O
mother NCT03922087 285 291 B-Family-Member___Family-Member-Type:mother
and NCT03922087 292 295 B-And
infant NCT03922087 296 302 B-Family-Member___Family-Member-Type:child
. NCT03922087 303 304 O

Exclusion NCT03922087 306 315 O
Criteria NCT03922087 316 324 O
: NCT03922087 325 326 O

- NCT03922087 330 331 O
Pregnant NCT03922087 333 341 B-Condition
women NCT03922087 342 347 O
who NCT03922087 348 351 B-And
are NCT03922087 352 355 O
with NCT03922087 356 360 O
gestational NCT03922087 361 372 B-Observation
age NCT03922087 373 376 I-Observation
more NCT03922087 377 381 B-Eq-Comparison
than NCT03922087 382 386 I-Eq-Comparison
24 NCT03922087 387 389 I-Eq-Comparison
weeks NCT03922087 390 395 I-Eq-Comparison
; NCT03922087 396 397 O

- NCT03922087 400 401 O
Pregnant NCT03922087 403 411 B-Condition
women NCT03922087 412 417 O
who NCT03922087 418 421 O
refuse NCT03922087 422 428 O
to NCT03922087 429 431 O
participate NCT03922087 432 443 O
or NCT03922087 444 446 O
be NCT03922087 447 449 O
unwilling NCT03922087 450 459 O
to NCT03922087 460 462 O
sign NCT03922087 463 467 O
informed NCT03922087 468 476 O
consent NCT03922087 477 484 O
; NCT03922087 484 485 O

- NCT03922087 488 489 O
Pregnant NCT03922087 491 499 B-Condition
women NCT03922087 500 505 O
who NCT03922087 506 509 B-And
are NCT03922087 510 513 O
mentally NCT03922087 514 522 B-Condition
incapacitated NCT03922087 523 536 I-Condition
and NCT03922087 537 540 O
need NCT03922087 541 545 O
guardians NCT03922087 546 555 O
. NCT03922087 555 556 O

Inclusion NCT03923400 0 9 O
Criteria NCT03923400 10 18 O
: NCT03923400 19 20 O

- NCT03923400 24 25 O
Any NCT03923400 27 30 O
kind NCT03923400 31 35 O
of NCT03923400 36 38 O
primary NCT03923400 39 46 B-Modifier
mesenchymal NCT03923400 47 58 B-Condition
tumor NCT03923400 59 64 I-Condition
of NCT03923400 65 67 O
the NCT03923400 68 71 O
gastrointestinal NCT03923400 72 88 B-Modifier
tract NCT03923400 89 94 I-Modifier
with NCT03923400 95 99 O
a NCT03923400 100 101 O
histomorphological NCT03923400 102 120 B-Modifier
and NCT03923400 121 124 B-Or
immunohistochemical NCT03923400 125 144 B-Modifier
( NCT03923400 145 146 O
CD117 NCT03923400 147 152 B-Condition
( NCT03923400 153 154 O
+ NCT03923400 156 157 O
) NCT03923400 159 160 O
and NCT03923400 161 164 B-Or
/ NCT03923400 165 166 I-Or
or NCT03923400 167 169 I-Or
DOG1 NCT03923400 170 174 B-Condition
( NCT03923400 175 176 O
+ NCT03923400 178 179 O
) NCT03923400 181 182 O
) NCT03923400 184 185 O
profile NCT03923400 186 193 B-Condition
consistent NCT03923400 194 204 O
with NCT03923400 205 209 O
GIST NCT03923400 210 214 B-Condition
. NCT03923400 215 216 O

Exclusion NCT03923400 218 227 O
Criteria NCT03923400 228 236 O
: NCT03923400 237 238 O

- NCT03923400 241 242 O

Inclusion NCT03921203 0 9 O
Criteria NCT03921203 10 18 O
: NCT03921203 19 20 O

- NCT03921203 24 25 O
Over NCT03921203 27 31 B-Eq-Comparison
18 NCT03921203 32 34 I-Eq-Comparison
years NCT03921203 35 40 I-Age|Eq-Comparison
. NCT03921203 41 42 O

- NCT03921203 46 47 O
For NCT03921203 49 52 O
the NCT03921203 53 56 O
T2D NCT03921203 57 60 B-Condition
study NCT03921203 61 66 O
group NCT03921203 67 72 O
: NCT03921203 73 74 O
Diagnosed NCT03921203 75 84 O
with NCT03921203 85 89 O
type NCT03921203 90 94 B-Condition
2 NCT03921203 95 96 I-Condition
diabetes NCT03921203 97 105 I-Condition
. NCT03921203 106 107 O

Exclusion NCT03921203 109 118 O
Criteria NCT03921203 119 127 O
: NCT03921203 128 129 O

For NCT03921203 131 134 O
subjects NCT03921203 135 143 O
with NCT03921203 144 148 O
type NCT03921203 149 153 B-Condition
2 NCT03921203 154 155 I-Condition
diabetes NCT03921203 156 164 I-Condition
: NCT03921203 165 166 O

- NCT03921203 170 171 O
Systemic NCT03921203 173 181 B-Modifier
inflammatory NCT03921203 182 194 B-Condition
disease NCT03921203 195 202 I-Condition
that NCT03921203 203 207 O
requires NCT03921203 208 216 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 217 223 B-Eq-Comparison
treatment NCT03921203 224 233 B-Procedure

- NCT03921203 236 237 O
Thyroid NCT03921203 239 246 B-Condition
disease NCT03921203 247 254 I-Condition
that NCT03921203 255 259 O
requires NCT03921203 260 268 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 269 275 B-Eq-Comparison
treatment NCT03921203 276 285 B-Procedure

- NCT03921203 288 289 O
Skin NCT03921203 291 295 B-Condition
disease NCT03921203 296 303 I-Condition
that NCT03921203 304 308 O
requires NCT03921203 309 317 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 318 324 B-Eq-Comparison
treatment NCT03921203 325 334 B-Procedure
and NCT03921203 335 338 B-And
causes NCT03921203 339 345 O
significant NCT03921203 346 357 O
changes NCT03921203 358 365 B-Condition
in NCT03921203 366 368 I-Condition
the NCT03921203 369 372 I-Condition
area NCT03921203 373 377 I-Condition
of NCT03921203 378 380 I-Condition
the NCT03921203 381 384 I-Condition
skin NCT03921203 385 389 I-Condition
that NCT03921203 390 394 O
is NCT03921203 395 397 O
to NCT03921203 398 400 O
be NCT03921203 401 403 O
investigated NCT03921203 404 416 O

- NCT03921203 419 420 O
Treatment NCT03921203 422 431 B-Procedure
with NCT03921203 432 436 O
oral NCT03921203 437 441 B-Drug
glucocorticoids NCT03921203 442 457 I-Drug

- NCT03921203 460 461 O
Levels NCT03921203 463 469 O
of NCT03921203 470 472 O
SR NCT03921203 473 475 B-Observation
, NCT03921203 476 477 O
TSH NCT03921203 478 481 B-Observation
, NCT03921203 482 483 O
T4 NCT03921203 484 486 B-Observation
or NCT03921203 487 489 B-Or
Hemoglobin NCT03921203 490 500 B-Observation
in NCT03921203 501 503 O
the NCT03921203 504 507 O
blood NCT03921203 508 513 O
pronouncedly NCT03921203 514 526 O
outside NCT03921203 527 534 O
the NCT03921203 535 538 O
reference NCT03921203 539 548 O
range NCT03921203 549 554 O

- NCT03921203 557 558 O
Pregnancy NCT03921203 560 569 B-Condition

For NCT03921203 570 573 O
healthy NCT03921203 574 581 O
controls NCT03921203 582 590 O
: NCT03921203 591 592 O

- NCT03921203 596 597 O
Registered NCT03921203 599 609 O
disease NCT03921203 610 617 B-Condition
in NCT03921203 618 620 O
the NCT03921203 621 624 O
health NCT03921203 625 631 O
declaration NCT03921203 632 643 O
that NCT03921203 644 648 O
requires NCT03921203 649 657 B-Assertion___Assertion-Type-Value:hypothetical
continuous NCT03921203 658 668 B-Eq-Comparison
systemic NCT03921203 669 677 B-Modifier
treatment NCT03921203 678 687 B-Procedure
. NCT03921203 687 688 O
Exception NCT03921203 690 699 B-Exception
to NCT03921203 700 702 O
the NCT03921203 703 706 O
above NCT03921203 707 712 O
: NCT03921203 713 714 O
well NCT03921203 715 719 O
controlled NCT03921203 720 730 B-Modifier
hypertension NCT03921203 731 743 B-Condition
in NCT03921203 744 746 O
which NCT03921203 747 752 O
case NCT03921203 753 757 O
the NCT03921203 758 761 O
subject NCT03921203 762 769 O
should NCT03921203 770 776 O
not NCT03921203 777 780 B-Negation
have NCT03921203 781 785 O
treatment NCT03921203 786 795 B-Procedure
with NCT03921203 796 800 O
more NCT03921203 801 805 B-Eq-Comparison
than NCT03921203 806 810 I-Eq-Comparison
one NCT03921203 811 814 I-Eq-Comparison
antihypertensive NCT03921203 815 831 B-Drug
drug NCT03921203 832 836 I-Drug
, NCT03921203 837 838 O
the NCT03921203 839 842 O
drug NCT03921203 843 847 B-Coreference
must NCT03921203 848 852 O
not NCT03921203 853 856 B-Negation
be NCT03921203 857 859 O
an NCT03921203 860 862 O
alpha NCT03921203 863 868 B-Drug
- NCT03921203 869 870 I-Drug
blocker NCT03921203 871 878 I-Drug
or NCT03921203 879 881 B-Or
beta NCT03921203 882 886 B-Drug
- NCT03921203 887 888 I-Drug
blocker NCT03921203 889 896 I-Drug
or NCT03921203 897 899 B-Or
thiazide NCT03921203 900 908 B-Drug
diuretic NCT03921203 909 917 I-Drug

- NCT03921203 920 921 O
Skin NCT03921203 923 927 B-Condition
disease NCT03921203 928 935 I-Condition
that NCT03921203 936 940 O
requires NCT03921203 941 949 B-Assertion___Assertion-Type-Value:hypothetical
active NCT03921203 950 956 B-Eq-Comparison
treatment NCT03921203 957 966 B-Procedure
and NCT03921203 967 970 B-And
causes NCT03921203 971 977 O
significant NCT03921203 978 989 O
changes NCT03921203 990 997 B-Condition
in NCT03921203 998 1000 I-Condition
the NCT03921203 1001 1004 I-Condition
area NCT03921203 1005 1009 I-Condition
of NCT03921203 1010 1012 I-Condition
the NCT03921203 1013 1016 I-Condition
skin NCT03921203 1017 1021 I-Condition
that NCT03921203 1022 1026 O
is NCT03921203 1027 1029 O
to NCT03921203 1030 1032 O
be NCT03921203 1033 1035 O
investigated NCT03921203 1036 1048 O

- NCT03921203 1051 1052 O
Blood NCT03921203 1054 1059 B-Observation
pressure NCT03921203 1060 1068 I-Observation
pronouncedly NCT03921203 1069 1081 O
above NCT03921203 1082 1087 B-Eq-Comparison
140 NCT03921203 1088 1091 I-Eq-Comparison
/ NCT03921203 1092 1093 I-Eq-Comparison
90 NCT03921203 1094 1096 I-Eq-Comparison

- NCT03921203 1100 1101 O
Blood NCT03921203 1103 1108 B-Observation
test NCT03921203 1109 1113 I-Observation
results NCT03921203 1114 1121 O
pronouncedly NCT03921203 1122 1134 O
outside NCT03921203 1135 1142 O
the NCT03921203 1143 1146 O
reference NCT03921203 1147 1156 O
range NCT03921203 1157 1162 O

- NCT03921203 1165 1166 O
Pregnancy NCT03921203 1168 1177 B-Condition

Inclusion NCT03929887 0 9 O
Criteria NCT03929887 10 18 O
: NCT03929887 19 20 O

- NCT03929887 24 25 O
Diagnosis NCT03929887 27 36 O
of NCT03929887 37 39 O
glomerulonephritis NCT03929887 40 58 B-Condition
( NCT03929887 59 60 O
MCD NCT03929887 61 64 B-Condition
, NCT03929887 65 66 O
FSGS NCT03929887 67 71 B-Condition
, NCT03929887 72 73 O
MN NCT03929887 74 76 B-Condition
, NCT03929887 77 78 O
IgAN NCT03929887 79 83 B-Condition
, NCT03929887 84 85 O
RPGN NCT03929887 86 90 B-Condition
, NCT03929887 91 92 O
lupus NCT03929887 93 98 B-Condition
nephritis NCT03929887 99 108 I-Condition
and NCT03929887 109 112 O
etc NCT03929887 113 116 O
. NCT03929887 116 117 O
) NCT03929887 118 119 O
on NCT03929887 120 122 O
first NCT03929887 123 128 B-Eq-Comparison
diagnostic NCT03929887 129 139 O
kidney NCT03929887 140 146 B-Modifier
biopsy NCT03929887 147 153 B-Procedure
, NCT03929887 154 155 O
as NCT03929887 156 158 O
per NCT03929887 159 162 O
specified NCT03929887 163 172 O
pathology NCT03929887 173 182 O
definitions NCT03929887 183 194 O

- NCT03929887 197 198 O
First NCT03929887 200 205 B-Eq-Comparison
diagnostic NCT03929887 206 216 O
kidney NCT03929887 217 223 B-Modifier
biopsy NCT03929887 224 230 B-Procedure
since NCT03929887 231 236 B-Eq-Comparison
2010 NCT03929887 237 241 I-Eq-Comparison

- NCT03929887 245 246 O
Willingness NCT03929887 248 259 O
to NCT03929887 260 262 O
comply NCT03929887 263 269 O
with NCT03929887 270 274 O
study NCT03929887 275 280 O
requirements NCT03929887 281 293 O
, NCT03929887 294 295 O
including NCT03929887 296 305 O
intention NCT03929887 306 315 O
to NCT03929887 316 318 O
fully NCT03929887 319 324 O
participate NCT03929887 325 336 O
in NCT03929887 337 339 O
protocol NCT03929887 340 348 O
- NCT03929887 349 350 O
specified NCT03929887 351 360 O
follow NCT03929887 361 367 O
- NCT03929887 368 369 O
up NCT03929887 370 372 O
at NCT03929887 373 375 O
a NCT03929887 376 377 O
clinical NCT03929887 378 386 O
study NCT03929887 387 392 O
site NCT03929887 393 397 O

- NCT03929887 400 401 O
Informed NCT03929887 403 411 O
consent NCT03929887 412 419 O
and NCT03929887 420 423 O
, NCT03929887 424 425 O
where NCT03929887 426 431 O
age NCT03929887 432 435 O
appropriate NCT03929887 436 447 O
, NCT03929887 448 449 O
informed NCT03929887 450 458 O
assent NCT03929887 459 465 O
( NCT03929887 466 467 O
clinical NCT03929887 468 476 O
data NCT03929887 477 481 O
, NCT03929887 482 483 O
human NCT03929887 484 489 O
derived NCT03929887 490 497 O
materials NCT03929887 498 507 O
including NCT03929887 508 517 O
genomic NCT03929887 518 525 O
data NCT03929887 526 530 O
) NCT03929887 531 532 O

Exclusion NCT03929887 534 543 O
Criteria NCT03929887 544 552 O
: NCT03929887 553 554 O

- NCT03929887 558 559 O
Unwillingness NCT03929887 561 574 O
to NCT03929887 575 577 O
give NCT03929887 578 582 O
informed NCT03929887 583 591 O
consent NCT03929887 592 599 O

- NCT03929887 602 603 O
Not NCT03929887 605 608 B-Negation
enough NCT03929887 609 615 B-Assertion___Assertion-Type-Value:hypothetical|Modifier
kidney NCT03929887 616 622 B-Observation
tissue NCT03929887 623 629 I-Observation
to NCT03929887 630 632 O
confirm NCT03929887 633 640 O
a NCT03929887 641 642 O
diagnosis NCT03929887 643 652 O
( NCT03929887 653 654 O
adequate NCT03929887 655 663 O
tissue NCT03929887 664 670 O
: NCT03929887 671 672 O
more NCT03929887 673 677 B-Eq-Comparison
than NCT03929887 678 682 I-Eq-Comparison
2 NCT03929887 683 684 I-Eq-Comparison
cores NCT03929887 685 690 I-Eq-Comparison
of NCT03929887 691 693 O
kidney NCT03929887 694 700 B-Observation
tissues NCT03929887 701 708 I-Observation
( NCT03929887 709 710 O
10 NCT03929887 711 713 B-Eq-Comparison
x NCT03929887 714 715 I-Eq-Comparison
1.2 NCT03929887 716 719 I-Eq-Comparison
mm NCT03929887 720 722 I-Eq-Comparison
) NCT03929887 723 724 O
including NCT03929887 725 734 O
over NCT03929887 735 739 B-Eq-Comparison
10 NCT03929887 740 742 I-Eq-Comparison
- NCT03929887 743 744 I-Eq-Comparison
15 NCT03929887 745 747 I-Eq-Comparison
glomerulus NCT03929887 748 758 I-Eq-Comparison
each NCT03929887 759 763 O
) NCT03929887 764 765 O

Inclusion NCT03926546 0 9 O
Criteria NCT03926546 10 18 O
: NCT03926546 19 20 O

- NCT03926546 24 25 O
Participants NCT03926546 27 39 O
must NCT03926546 40 44 O
be NCT03926546 45 47 O
adults NCT03926546 48 54 O
18 NCT03926546 55 57 B-Eq-Comparison
years NCT03926546 58 63 I-Eq-Comparison
or NCT03926546 64 66 I-Eq-Comparison
older NCT03926546 67 72 I-Eq-Comparison
. NCT03926546 73 74 O

- NCT03926546 78 79 O
Participants NCT03926546 81 93 O
must NCT03926546 94 98 O
have NCT03926546 99 103 O
the NCT03926546 104 107 O
capacity NCT03926546 108 116 O
and NCT03926546 117 120 O
ability NCT03926546 121 128 O
to NCT03926546 129 131 O
give NCT03926546 132 136 O
informed NCT03926546 137 145 O
consent NCT03926546 146 153 O
. NCT03926546 154 155 O

- NCT03926546 159 160 O
Participants NCT03926546 162 174 O
have NCT03926546 175 179 O
been NCT03926546 180 184 O
given NCT03926546 185 190 B-Eq-Comparison
an NCT03926546 191 193 O
assessment NCT03926546 194 204 B-Procedure
and NCT03926546 205 208 B-And
received NCT03926546 209 217 B-Eq-Comparison
a NCT03926546 218 219 O
diagnosis NCT03926546 220 229 O
of NCT03926546 230 232 O
OCD NCT03926546 233 236 B-Condition
. NCT03926546 237 238 O

- NCT03926546 242 243 O
Participants NCT03926546 245 257 O
must NCT03926546 258 262 O
speak NCT03926546 263 268 O
English NCT03926546 269 276 O
. NCT03926546 277 278 O

- NCT03926546 282 283 O
Participants NCT03926546 285 297 O
must NCT03926546 298 302 O
be NCT03926546 303 305 O
able NCT03926546 306 310 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03926546 311 313 I-Assertion___Assertion-Type-Value:hypothetical
physically NCT03926546 314 324 O
attend NCT03926546 325 331 O
treatment NCT03926546 332 341 B-Procedure
. NCT03926546 342 343 O

Exclusion NCT03926546 345 354 O
Criteria NCT03926546 355 363 O
: NCT03926546 364 365 O

- NCT03926546 369 370 O
Prisoners NCT03926546 372 381 B-Observation
or NCT03926546 382 384 B-Or
any NCT03926546 385 388 O
other NCT03926546 389 394 B-Other
high NCT03926546 395 399 O
- NCT03926546 400 401 O
risk NCT03926546 402 406 B-Risk
population NCT03926546 407 417 O
group NCT03926546 418 423 O
. NCT03926546 424 425 O

- NCT03926546 429 430 O
experiencing NCT03926546 432 444 O
active NCT03926546 445 451 B-Eq-Comparison
psychosis NCT03926546 452 461 B-Condition

- NCT03926546 464 465 O
experiencing NCT03926546 467 479 O
active NCT03926546 480 486 B-Eq-Comparison
substance NCT03926546 487 496 B-Condition
abuse NCT03926546 497 502 I-Condition
disorder NCT03926546 503 511 I-Condition

- NCT03926546 514 515 O
experiencing NCT03926546 517 529 O
active NCT03926546 530 536 B-Eq-Comparison
suicidality NCT03926546 537 548 B-Condition

Inclusion NCT03926234 0 9 O
Criteria NCT03926234 10 18 O
: NCT03926234 19 20 O

- NCT03926234 24 25 O
Patients NCT03926234 27 35 O
, NCT03926234 36 37 O
older NCT03926234 38 43 B-Eq-Comparison
than NCT03926234 44 48 I-Eq-Comparison
14 NCT03926234 49 51 I-Eq-Comparison
years NCT03926234 52 57 I-Age|Eq-Comparison
and NCT03926234 58 61 B-And
admitted NCT03926234 62 70 B-Encounter
to NCT03926234 71 73 O
the NCT03926234 74 77 O
ED NCT03926234 78 80 O
, NCT03926234 81 82 O
were NCT03926234 83 87 O
eligible NCT03926234 88 96 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03926234 97 100 I-Assertion___Assertion-Type-Value:hypothetical
this NCT03926234 101 105 O
study NCT03926234 106 111 B-Study
. NCT03926234 112 113 O

Exclusion NCT03926234 115 124 O
Criteria NCT03926234 125 133 O
: NCT03926234 134 135 O

- NCT03926234 139 140 O
Gynecologic NCT03926234 142 153 B-Modifier
and NCT03926234 154 157 B-Or
obstetric NCT03926234 158 167 B-Modifier
emergencies NCT03926234 168 179 B-Condition

- NCT03926234 182 183 O
Patients NCT03926234 185 193 O
, NCT03926234 194 195 O
who NCT03926234 196 199 O
left NCT03926234 200 204 B-Observation
against NCT03926234 205 212 I-Observation
medical NCT03926234 213 220 I-Observation
advice NCT03926234 221 227 I-Observation
or NCT03926234 228 230 O
had NCT03926234 231 234 O
n't NCT03926234 234 237 O
been NCT03926234 238 242 O
aided NCT03926234 243 248 O
by NCT03926234 249 251 O
a NCT03926234 252 253 O
doctor NCT03926234 254 260 O

Inclusion NCT03927664 0 9 O
Criteria NCT03927664 10 18 O

- NCT03927664 21 22 O
Patients NCT03927664 24 32 O
diagnosed NCT03927664 33 42 O
with NCT03927664 43 47 O
peritoneal NCT03927664 48 58 B-Condition
tuberculosis NCT03927664 59 71 I-Condition

- NCT03927664 74 75 O
Patients NCT03927664 77 85 O
who NCT03927664 86 89 O
have NCT03927664 90 94 O
undergone NCT03927664 95 104 B-Eq-Comparison
a NCT03927664 105 106 O
computed NCT03927664 107 115 B-Procedure
tomographic NCT03927664 116 127 I-Procedure
examination NCT03927664 128 139 I-Procedure

Exclusion NCT03927664 140 149 O
Criteria NCT03927664 150 158 O
: NCT03927664 159 160 O

- NCT03927664 164 165 O
Age NCT03927664 167 170 B-Age
< NCT03927664 171 172 B-Eq-Comparison
12 NCT03927664 173 175 I-Eq-Comparison

- NCT03927664 179 180 O
Unclear NCT03927664 182 189 O
diagnosis NCT03927664 190 199 O

- NCT03927664 202 203 O
More NCT03927664 205 209 B-Eq-Comparison
than NCT03927664 210 214 I-Eq-Comparison
one NCT03927664 215 218 I-Eq-Comparison
etiology NCT03927664 219 227 B-Condition
for NCT03927664 228 231 O
ascites NCT03927664 232 239 B-Condition

- NCT03927664 242 243 O
Not NCT03927664 245 248 O
willing NCT03927664 249 256 O
for NCT03927664 257 260 O
consent NCT03927664 261 268 O

Inclusion NCT03926208 0 9 O
Criteria NCT03926208 10 18 O
: NCT03926208 19 20 O

1 NCT03926208 24 25 O
. NCT03926208 25 26 O
≥ NCT03926208 28 29 B-Eq-Comparison
18 NCT03926208 30 32 I-Eq-Comparison
years NCT03926208 33 38 I-Eq-Comparison
of NCT03926208 39 41 O
age NCT03926208 42 45 B-Age

2 NCT03926208 48 49 O
. NCT03926208 49 50 O
Patient NCT03926208 52 59 O
requires NCT03926208 60 68 B-Assertion___Assertion-Type-Value:hypothetical
a NCT03926208 69 70 O
foot NCT03926208 71 75 B-Modifier
or NCT03926208 76 78 B-Or
ankle NCT03926208 79 84 B-Modifier
operative NCT03926208 85 94 B-Procedure
procedure NCT03926208 95 104 I-Procedure

3 NCT03926208 107 108 O
. NCT03926208 108 109 O
Patient NCT03926208 111 118 O
provides NCT03926208 119 127 O
informed NCT03926208 128 136 O
consent NCT03926208 137 144 O

Exclusion NCT03926208 145 154 O
Criteria NCT03926208 155 163 O
: NCT03926208 164 165 O

1 NCT03926208 169 170 O
. NCT03926208 170 171 O
Patient NCT03926208 173 180 O
refuses NCT03926208 181 188 O

2 NCT03926208 191 192 O
. NCT03926208 192 193 O
Patient NCT03926208 195 202 O
is NCT03926208 203 205 O
incarcerated NCT03926208 206 218 B-Observation
, NCT03926208 219 220 O
incapacitated NCT03926208 221 234 B-Condition
, NCT03926208 235 236 O
or NCT03926208 237 239 O
otherwise NCT03926208 240 249 O
unable NCT03926208 250 256 O
to NCT03926208 257 259 O
provide NCT03926208 260 267 O
appropriate NCT03926208 268 279 O
informed NCT03926208 280 288 O
consent NCT03926208 289 296 O

Inclusion NCT03921567 0 9 O
Criteria NCT03921567 10 18 O
: NCT03921567 19 20 O

- NCT03921567 24 25 O
Age NCT03921567 27 30 B-Age
of NCT03921567 31 33 O
both NCT03921567 34 38 O
genders NCT03921567 39 46 O
from NCT03921567 47 51 O
18 NCT03921567 52 54 B-Eq-Comparison
to NCT03921567 55 57 I-Eq-Comparison
75 NCT03921567 58 60 I-Eq-Comparison
years NCT03921567 61 66 I-Eq-Comparison

- NCT03921567 69 70 O
ASA NCT03921567 72 75 B-Condition
physiological NCT03921567 76 89 O
status NCT03921567 90 96 O
I NCT03921567 97 98 B-Eq-Comparison
- NCT03921567 99 100 I-Eq-Comparison
III NCT03921567 101 104 I-Eq-Comparison

- NCT03921567 107 108 O
Participation NCT03921567 110 123 O
in NCT03921567 124 126 O
abdominal NCT03921567 127 136 B-Modifier
, NCT03921567 137 138 O
orthopedic NCT03921567 139 149 B-Modifier
, NCT03921567 150 151 O
laparoscopical NCT03921567 152 166 B-Modifier
, NCT03921567 167 168 O
gynecological NCT03921567 169 182 B-Modifier
and NCT03921567 183 186 B-Or
urological NCT03921567 187 197 B-Modifier
interventions NCT03921567 198 211 B-Study
. NCT03921567 212 213 O

Exclusion NCT03921567 215 224 O
Criteria NCT03921567 225 233 O
: NCT03921567 234 235 O

- NCT03921567 239 240 O
Patient NCT03921567 242 249 O
rejection NCT03921567 250 259 O

- NCT03921567 262 263 O
History NCT03921567 265 272 B-Eq-Comparison
of NCT03921567 273 275 O
chronic NCT03921567 276 283 B-Modifier
opioid NCT03921567 284 290 B-Drug
intake NCT03921567 291 297 O

- NCT03921567 300 301 O
History NCT03921567 303 310 B-Eq-Comparison
of NCT03921567 311 313 O
renal NCT03921567 314 319 B-Modifier
, NCT03921567 320 321 O
hepatic NCT03921567 322 329 B-Modifier
or NCT03921567 330 332 B-Or
psychiatric NCT03921567 333 344 B-Modifier
disorders NCT03921567 345 354 B-Condition

- NCT03921567 357 358 O
Heart NCT03921567 360 365 B-Condition
failure NCT03921567 366 373 I-Condition
, NCT03921567 374 375 O

- NCT03921567 379 380 O
Organ NCT03921567 382 387 B-Procedure
transplant NCT03921567 388 398 I-Procedure
history NCT03921567 399 406 B-Eq-Comparison
, NCT03921567 407 408 O

- NCT03921567 412 413 O
Lidocaine NCT03921567 415 424 B-Drug
allergy NCT03921567 425 432 B-Allergy

- NCT03921567 435 436 O
Family NCT03921567 438 444 B-Family-Member
history NCT03921567 445 452 I-Family-Member
of NCT03921567 453 455 O
malignant NCT03921567 456 465 B-Condition
hyperthermia NCT03921567 466 478 I-Condition

Inclusion NCT03925701 0 9 O
Criteria NCT03925701 10 18 O
: NCT03925701 19 20 O

- NCT03925701 24 25 O
NAFLD NCT03925701 27 32 B-Condition
and NCT03925701 33 36 O
type NCT03925701 37 41 B-Condition
2 NCT03925701 42 43 I-Condition
DM NCT03925701 44 46 I-Condition

Exclusion NCT03925701 47 56 O
Criteria NCT03925701 57 65 O
: NCT03925701 66 67 O

- NCT03925701 71 72 O
Viral NCT03925701 74 79 B-Condition
hepatitis NCT03925701 80 89 I-Condition
. NCT03925701 90 91 O

- NCT03925701 95 96 O
Child NCT03925701 98 103 O
score NCT03925701 104 109 O
more NCT03925701 110 114 B-Eq-Comparison
than NCT03925701 115 119 I-Eq-Comparison
6 NCT03925701 120 121 I-Eq-Comparison
. NCT03925701 121 122 O

- NCT03925701 126 127 O
renal NCT03925701 129 134 B-Modifier
impairment NCT03925701 135 145 B-Condition
. NCT03925701 145 146 O

Inclusion NCT03926585 0 9 O
Criteria NCT03926585 10 18 O
: NCT03926585 19 20 O

- NCT03926585 24 25 O
Patients NCT03926585 27 35 O
admitted NCT03926585 36 44 B-Encounter
to NCT03926585 45 47 O
the NCT03926585 48 51 O
department NCT03926585 52 62 O
of NCT03926585 63 65 O
endocrinology NCT03926585 66 79 B-Provider
with NCT03926585 80 84 B-And
the NCT03926585 85 88 O
diagnose NCT03926585 89 97 O
hypothyroidism NCT03926585 98 112 B-Condition
because NCT03926585 113 120 O
of NCT03926585 121 123 O
persistent NCT03926585 124 134 B-Modifier
hypothyroid NCT03926585 135 146 B-Condition
symptoms NCT03926585 147 155 B-Assertion___Assertion-Type-Value:possible
despite NCT03926585 156 163 B-And
treatment NCT03926585 164 173 B-Procedure
with NCT03926585 174 178 O
L NCT03926585 179 180 B-Drug
- NCT03926585 181 182 I-Drug
thyroxine NCT03926585 183 192 I-Drug
mono NCT03926585 193 197 B-Procedure
- NCT03926585 198 199 I-Procedure
therapy NCT03926585 200 207 I-Procedure
and NCT03926585 208 211 B-And
normal NCT03926585 212 218 O
and NCT03926585 219 222 B-And
stable NCT03926585 223 229 O
TSH NCT03926585 230 233 B-Observation
( NCT03926585 234 235 O
for NCT03926585 236 239 O
at NCT03926585 240 242 B-Eq-Comparison
least NCT03926585 243 248 I-Eq-Comparison
6 NCT03926585 249 250 I-Eq-Comparison
months NCT03926585 251 257 I-Eq-Comparison
) NCT03926585 258 259 O
. NCT03926585 261 262 O

- NCT03926585 266 267 O
Started NCT03926585 269 276 O
in NCT03926585 277 279 O
combination NCT03926585 280 291 B-Procedure
therapy NCT03926585 292 299 I-Procedure
with NCT03926585 300 304 O
L NCT03926585 305 306 B-Drug
- NCT03926585 307 308 I-Drug
thyroxine NCT03926585 309 318 I-Drug
and NCT03926585 319 322 B-And
Liothyronine NCT03926585 323 335 B-Drug
in NCT03926585 336 338 O
an NCT03926585 339 341 O
approximately NCT03926585 342 355 O
17 NCT03926585 356 358 B-Eq-Comparison
/ NCT03926585 359 360 I-Eq-Comparison
1 NCT03926585 361 362 I-Eq-Comparison
ratio NCT03926585 363 368 I-Eq-Comparison

- NCT03926585 371 372 O
Exclusion NCT03926585 374 383 B-Negation
of NCT03926585 384 386 O
an NCT03926585 387 389 O
alternative NCT03926585 390 401 B-Other
explanation NCT03926585 402 413 B-Condition
for NCT03926585 414 417 O
persistent NCT03926585 418 428 B-Modifier
hypothyroid NCT03926585 429 440 B-Condition
symptoms NCT03926585 441 449 B-Assertion___Assertion-Type-Value:possible

Exclusion NCT03926585 450 459 O
Criteria NCT03926585 460 468 O
: NCT03926585 469 470 O

- NCT03926585 474 475 O
Initiation NCT03926585 477 487 B-Eq-Comparison
of NCT03926585 488 490 O
L NCT03926585 491 492 B-Drug
- NCT03926585 493 494 I-Drug
thyroxine NCT03926585 495 504 I-Drug
treatment NCT03926585 505 514 B-Procedure
in NCT03926585 515 517 O
patients NCT03926585 518 526 O
with NCT03926585 527 531 B-And
s NCT03926585 532 533 B-Observation
- NCT03926585 534 535 I-Observation
TSH NCT03926585 536 539 I-Observation
below NCT03926585 540 545 B-Eq-Comparison
upper NCT03926585 546 551 I-Eq-Comparison
normal NCT03926585 552 558 I-Eq-Comparison
limit NCT03926585 559 564 I-Eq-Comparison
( NCT03926585 565 566 O
with NCT03926585 567 571 O
assay NCT03926585 572 577 O
in NCT03926585 578 580 O
current NCT03926585 581 588 O
use NCT03926585 589 592 O
, NCT03926585 593 594 O
that NCT03926585 595 599 O
is NCT03926585 600 602 O
TSH NCT03926585 603 606 B-Observation
< NCT03926585 607 608 B-Eq-Comparison
4 NCT03926585 609 610 I-Eq-Comparison
mU NCT03926585 611 613 I-Eq-Comparison
/ NCT03926585 614 615 I-Eq-Comparison
L NCT03926585 616 617 I-Eq-Comparison
) NCT03926585 618 619 O

- NCT03926585 623 624 O
Ongoing NCT03926585 626 633 B-Eq-Comparison
pregnancy NCT03926585 634 643 B-Condition

- NCT03926585 646 647 O
Age NCT03926585 649 652 B-Age
below NCT03926585 653 658 B-Eq-Comparison
18 NCT03926585 659 661 I-Eq-Comparison
years NCT03926585 662 667 I-Eq-Comparison
or NCT03926585 668 670 B-Or
above NCT03926585 671 676 B-Eq-Comparison
80 NCT03926585 677 679 I-Eq-Comparison
years NCT03926585 680 685 I-Eq-Comparison
. NCT03926585 686 687 O

- NCT03926585 691 692 O
Patients NCT03926585 694 702 O
who NCT03926585 703 706 O
do NCT03926585 707 709 O
not NCT03926585 710 713 O
read NCT03926585 714 718 O
and NCT03926585 719 722 O
understand NCT03926585 723 733 O
information NCT03926585 734 745 O
material NCT03926585 746 754 O
given NCT03926585 755 760 O

- NCT03926585 763 764 O
Patients NCT03926585 766 774 O
who NCT03926585 775 778 O
are NCT03926585 779 782 O
not NCT03926585 783 786 O
competent NCT03926585 787 796 O
to NCT03926585 797 799 O
give NCT03926585 800 804 O
informed NCT03926585 805 813 O
consent NCT03926585 814 821 O


Inclusion NCT03928769 0 9 O
Criteria NCT03928769 10 18 O
: NCT03928769 19 20 O

- NCT03928769 24 25 O
Male NCT03928769 27 31 O
or NCT03928769 32 34 B-Or
female NCT03928769 35 41 O
≥ NCT03928769 42 43 B-Eq-Comparison
18 NCT03928769 44 46 I-Eq-Comparison
years NCT03928769 47 52 I-Age|Eq-Comparison

- NCT03928769 55 56 O
Patient NCT03928769 58 65 O
for NCT03928769 66 69 O
whom NCT03928769 70 74 O
a NCT03928769 75 76 O
vascular NCT03928769 77 85 B-Modifier
surgery NCT03928769 86 93 B-Procedure
is NCT03928769 94 96 O
programmed NCT03928769 97 107 B-Eq-Comparison
, NCT03928769 108 109 O
and NCT03928769 110 113 B-And
whose NCT03928769 114 119 O
nature NCT03928769 120 126 O
allows NCT03928769 127 133 B-Assertion___Assertion-Type-Value:hypothetical
obtaining NCT03928769 134 143 O
of NCT03928769 144 146 O
arterial NCT03928769 147 155 B-Condition
segment NCT03928769 156 163 I-Condition
without NCT03928769 164 171 B-Negation
any NCT03928769 172 175 O
harm NCT03928769 176 180 O
for NCT03928769 181 184 O
the NCT03928769 185 188 O
health NCT03928769 189 195 B-Condition
of NCT03928769 196 198 O
the NCT03928769 199 202 O
patient NCT03928769 203 210 O

- NCT03928769 213 214 O
Patient NCT03928769 216 223 O
for NCT03928769 224 227 O
whom NCT03928769 228 232 O
a NCT03928769 233 234 O
blood NCT03928769 235 240 B-Observation
sample NCT03928769 241 247 I-Observation
is NCT03928769 248 250 O
planned NCT03928769 251 258 B-Eq-Comparison
on NCT03928769 259 261 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03928769 262 265 I-Temporal-Connection___Temporal-Connection-Type-Value:during
day NCT03928769 266 269 I-Temporal-Connection___Temporal-Connection-Type-Value:during
of NCT03928769 270 272 O
the NCT03928769 273 276 O
procedure NCT03928769 277 286 B-Procedure

- NCT03928769 289 290 O
Person NCT03928769 292 298 O
who NCT03928769 299 302 O
has NCT03928769 303 306 O
received NCT03928769 307 315 O
complete NCT03928769 316 324 O
information NCT03928769 325 336 O
on NCT03928769 337 339 O
the NCT03928769 340 343 O
organization NCT03928769 344 356 O
of NCT03928769 357 359 O
the NCT03928769 360 363 O
research NCT03928769 364 372 O
and NCT03928769 373 376 O
who NCT03928769 377 380 O
has NCT03928769 381 384 O
not NCT03928769 385 388 O
objected NCT03928769 389 397 O
to NCT03928769 398 400 O
his NCT03928769 401 404 O
participation NCT03928769 405 418 O
and NCT03928769 419 422 O
the NCT03928769 423 426 O
exploitation NCT03928769 427 439 O
of NCT03928769 440 442 O
his NCT03928769 443 446 O
data NCT03928769 447 451 O

- NCT03928769 454 455 O
Compulsory NCT03928769 457 467 O
affiliation NCT03928769 468 479 O
to NCT03928769 480 482 O
social NCT03928769 483 489 O
security NCT03928769 490 498 O

Exclusion NCT03928769 499 508 O
Criteria NCT03928769 509 517 O
: NCT03928769 518 519 O

- NCT03928769 523 524 O
Patient NCT03928769 526 533 O
who NCT03928769 534 537 O
has NCT03928769 538 541 O
previously NCT03928769 542 552 B-Eq-Comparison
undergone NCT03928769 553 562 I-Eq-Comparison
radiotherapy NCT03928769 563 575 B-Procedure
at NCT03928769 576 578 O
the NCT03928769 579 582 O
sampling NCT03928769 583 591 B-Modifier
site NCT03928769 592 596 I-Modifier

- NCT03928769 599 600 O
Patient NCT03928769 602 609 O
with NCT03928769 610 614 O
cancer NCT03928769 615 621 B-Condition
at NCT03928769 622 624 O
the NCT03928769 625 628 O
sampling NCT03928769 629 637 B-Modifier
site NCT03928769 638 642 I-Modifier

Inclusion NCT03925259 0 9 O
Criteria NCT03925259 10 18 O
: NCT03925259 19 20 O

- NCT03925259 24 25 O
Long NCT03925259 27 31 B-Modifier
term NCT03925259 32 36 I-Modifier
physical NCT03925259 37 45 B-Condition
health NCT03925259 46 52 I-Condition
condition NCT03925259 53 62 I-Condition
and NCT03925259 63 66 B-Or
comorbid NCT03925259 67 75 B-Condition
mental NCT03925259 76 82 I-Condition
health NCT03925259 83 89 I-Condition
problem NCT03925259 90 97 I-Condition

- NCT03925259 100 101 O
Age NCT03925259 103 106 B-Age
16 NCT03925259 107 109 B-Eq-Comparison
+ NCT03925259 110 111 I-Eq-Comparison

- NCT03925259 115 116 O
Referred NCT03925259 118 126 B-Encounter
to NCT03925259 127 129 O
a NCT03925259 130 131 O
psychological NCT03925259 132 145 B-Provider
therapies NCT03925259 146 155 I-Provider
service NCT03925259 156 163 I-Provider

Exclusion NCT03925259 164 173 O
Criteria NCT03925259 174 182 O
: NCT03925259 183 184 O

- NCT03925259 188 189 O
Diagnosis NCT03925259 191 200 O
of NCT03925259 201 203 O
' NCT03925259 204 205 O
medically NCT03925259 205 214 B-Condition
unexplained NCT03925259 215 226 I-Condition
symptoms NCT03925259 227 235 I-Condition
' NCT03925259 235 236 O
including NCT03925259 237 246 O
somatoform NCT03925259 247 257 B-Condition
disorders NCT03925259 258 267 I-Condition
( NCT03925259 268 269 O
e. NCT03925259 270 272 O
g. NCT03925259 273 275 O
pain NCT03925259 277 281 B-Condition
disorder NCT03925259 282 290 I-Condition
, NCT03925259 291 292 O
conversion NCT03925259 293 303 B-Condition
disorder NCT03925259 304 312 I-Condition
, NCT03925259 313 314 O
body NCT03925259 315 319 B-Condition
dysmorphic NCT03925259 320 330 I-Condition
disorder NCT03925259 331 339 I-Condition
, NCT03925259 340 341 O
hypochondriasis NCT03925259 342 357 B-Condition
) NCT03925259 358 359 O
and NCT03925259 360 363 O
functional NCT03925259 364 374 B-Condition
somatic NCT03925259 375 382 I-Condition
syndromes NCT03925259 383 392 I-Condition
( NCT03925259 393 394 O
e. NCT03925259 395 397 O
g. NCT03925259 398 400 O
irritable NCT03925259 402 411 B-Condition
bowel NCT03925259 412 417 I-Condition
syndrome NCT03925259 418 426 I-Condition
, NCT03925259 427 428 O
chronic NCT03925259 429 436 B-Condition
fatigue NCT03925259 437 444 I-Condition
syndrome NCT03925259 445 453 I-Condition
, NCT03925259 454 455 O
fibromyalgia NCT03925259 456 468 B-Condition
, NCT03925259 469 470 O
non NCT03925259 471 474 B-Modifier
- NCT03925259 475 476 I-Modifier
cardiac NCT03925259 477 484 I-Modifier
chest NCT03925259 485 490 I-Modifier
pain NCT03925259 491 495 B-Condition
, NCT03925259 496 497 O
non NCT03925259 498 501 B-Condition
- NCT03925259 502 503 I-Condition
epileptic NCT03925259 504 513 I-Condition
seizures NCT03925259 514 522 I-Condition
) NCT03925259 523 524 O

- NCT03925259 528 529 O
Mental NCT03925259 531 537 B-Condition
health NCT03925259 538 544 I-Condition
diagnoses NCT03925259 545 554 O
in NCT03925259 555 557 B-Or
addition NCT03925259 558 566 I-Or
to NCT03925259 567 569 I-Or
anxiety NCT03925259 570 577 B-Condition
or NCT03925259 578 580 B-Or
depression NCT03925259 581 591 B-Condition
( NCT03925259 592 593 O
e. NCT03925259 594 596 O
g. NCT03925259 597 599 O
personality NCT03925259 601 612 B-Condition
disorder NCT03925259 613 621 I-Condition
, NCT03925259 622 623 O
bipolar NCT03925259 624 631 B-Condition
disorder NCT03925259 632 640 I-Condition
or NCT03925259 641 643 B-Or
psychosis NCT03925259 644 653 B-Condition
) NCT03925259 654 655 O

- NCT03925259 659 660 O
Currently NCT03925259 662 671 B-Eq-Comparison
accesses NCT03925259 672 680 B-Encounter
secondary NCT03925259 681 690 O
care NCT03925259 691 695 O
mental NCT03925259 696 702 B-Provider
health NCT03925259 703 709 I-Provider
services NCT03925259 710 718 I-Provider

- NCT03925259 721 722 O
Significant NCT03925259 724 735 O
current NCT03925259 736 743 B-Eq-Comparison
suicidal NCT03925259 744 752 B-Condition
risk NCT03925259 753 757 B-Risk

- NCT03925259 760 761 O
Current NCT03925259 763 770 B-Eq-Comparison
substance NCT03925259 771 780 B-Condition
misuse NCT03925259 781 787 I-Condition

- NCT03925259 790 791 O
Previous NCT03925259 793 801 B-Eq-Comparison
contact NCT03925259 802 809 B-Encounter
with NCT03925259 810 814 O
mental NCT03925259 815 821 B-Provider
health NCT03925259 822 828 I-Provider
services NCT03925259 829 837 I-Provider
( NCT03925259 838 839 O
defined NCT03925259 840 847 O
as NCT03925259 848 850 O
two NCT03925259 851 854 B-Eq-Comparison
or NCT03925259 855 857 I-Eq-Comparison
more NCT03925259 858 862 I-Eq-Comparison
prior NCT03925259 863 868 B-Eq-Comparison
episodes NCT03925259 869 877 O
of NCT03925259 878 880 O
service NCT03925259 881 888 B-Encounter
contact NCT03925259 889 896 I-Encounter
without NCT03925259 897 904 B-Negation
significant NCT03925259 905 916 O
change NCT03925259 917 923 O
) NCT03925259 924 925 O

- NCT03925259 929 930 O
Inpatient NCT03925259 932 941 B-Encounter
admission NCT03925259 942 951 I-Encounter
for NCT03925259 952 955 O
mental NCT03925259 956 962 B-Condition
health NCT03925259 963 969 I-Condition
difficulties NCT03925259 970 982 I-Condition
within NCT03925259 983 989 B-Eq-Comparison
the NCT03925259 990 993 I-Eq-Comparison
last NCT03925259 994 998 I-Eq-Comparison
five NCT03925259 999 1003 I-Eq-Comparison
years NCT03925259 1004 1009 I-Eq-Comparison

- NCT03925259 1012 1013 O
History NCT03925259 1015 1022 B-Eq-Comparison
of NCT03925259 1023 1025 O
self NCT03925259 1026 1030 B-Condition
- NCT03925259 1031 1032 I-Condition
injury NCT03925259 1033 1039 I-Condition

- NCT03925259 1042 1043 O
A NCT03925259 1045 1046 O
stated NCT03925259 1047 1053 O
reluctance NCT03925259 1054 1064 B-Assertion___Assertion-Type-Value:hypothetical|Negation
to NCT03925259 1065 1067 O
engage NCT03925259 1068 1074 O
in NCT03925259 1075 1077 O
psychotherapy NCT03925259 1078 1091 B-Procedure
. NCT03925259 1091 1092 O

Inclusion NCT03927300 0 9 O
Criteria NCT03927300 10 18 O
: NCT03927300 19 20 O

- NCT03927300 24 25 O
Adult NCT03927300 27 32 O
patients NCT03927300 33 41 O
( NCT03927300 42 43 O
≥ NCT03927300 45 46 B-Eq-Comparison
18 NCT03927300 47 49 I-Eq-Comparison
years NCT03927300 50 55 I-Eq-Comparison
) NCT03927300 56 57 O
with NCT03927300 58 62 O
no NCT03927300 63 65 O
age NCT03927300 66 69 O
limit NCT03927300 70 75 O
; NCT03927300 75 76 O

- NCT03927300 79 80 O
Patients NCT03927300 82 90 O
receiving NCT03927300 91 100 B-Eq-Comparison
peritoneal NCT03927300 101 111 B-Procedure
dialysis NCT03927300 112 120 I-Procedure
on NCT03927300 121 123 O
the NCT03927300 124 127 O
investigation NCT03927300 128 141 O
center NCT03927300 142 148 O
between NCT03927300 149 156 B-Eq-Comparison
2012 NCT03927300 157 161 I-Eq-Comparison
and NCT03927300 162 165 I-Eq-Comparison
2014 NCT03927300 166 170 I-Eq-Comparison
( NCT03927300 171 172 O
Group1 NCT03927300 173 179 O
) NCT03927300 180 181 O
and NCT03927300 182 185 B-And
between NCT03927300 186 193 B-Eq-Comparison
2016 NCT03927300 194 198 I-Eq-Comparison
and NCT03927300 199 202 I-Eq-Comparison
2018 NCT03927300 203 207 I-Eq-Comparison
( NCT03927300 208 209 O
Group NCT03927300 210 215 O
2 NCT03927300 216 217 O
) NCT03927300 218 219 O
; NCT03927300 220 221 O

- NCT03927300 224 225 O
Patient NCT03927300 227 234 O
information NCT03927300 235 246 O
in NCT03927300 247 249 O
this NCT03927300 250 254 O
retrospective NCT03927300 255 268 O
study NCT03927300 269 274 B-Study
; NCT03927300 274 275 O

Exclusion NCT03927300 276 285 O
Criteria NCT03927300 286 294 O
: NCT03927300 295 296 O

- NCT03927300 300 301 O
Patients NCT03927300 303 311 O
who NCT03927300 312 315 O
have NCT03927300 316 320 O
started NCT03927300 321 328 B-Eq-Comparison
a NCT03927300 329 330 O
peritoneal NCT03927300 331 341 B-Procedure
dialysis NCT03927300 342 350 I-Procedure
program NCT03927300 351 358 O
before NCT03927300 359 365 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03927300 366 369 O
periods NCT03927300 370 377 O
of NCT03927300 378 380 O
investigation NCT03927300 381 394 B-Study
; NCT03927300 394 395 O

- NCT03927300 398 399 O
Patients NCT03927300 401 409 O
who NCT03927300 410 413 O
have NCT03927300 414 418 O
been NCT03927300 419 423 O
equipped NCT03927300 424 432 O
with NCT03927300 433 437 O
apTeleCare NCT03927300 438 448 B-Procedure
during NCT03927300 449 455 B-Temporal-Connection___Temporal-Connection-Type-Value:during
the NCT03927300 456 459 O
dialysis NCT03927300 460 468 B-Procedure
program NCT03927300 469 476 O
; NCT03927300 476 477 O

- NCT03927300 480 481 O
Subject NCT03927300 483 490 O
under NCT03927300 491 496 B-Observation
guardianship NCT03927300 497 509 I-Observation
, NCT03927300 510 511 O
curators NCT03927300 512 520 O
or NCT03927300 521 523 O
safeguard NCT03927300 524 533 O
of NCT03927300 534 536 O
justice NCT03927300 537 544 O
; NCT03927300 544 545 O

- NCT03927300 548 549 O
Patient NCT03927300 551 558 O
not NCT03927300 559 562 O
affiliated NCT03927300 563 573 O
to NCT03927300 574 576 O
a NCT03927300 577 578 O
French NCT03927300 579 585 O
social NCT03927300 586 592 O
protection NCT03927300 593 603 O
; NCT03927300 603 604 O


Inclusion NCT03924609 0 9 O
Criteria NCT03924609 10 18 O
: NCT03924609 19 20 O

A. NCT03924609 22 24 O
Histologically NCT03924609 26 40 B-Procedure
proven NCT03924609 41 47 O
breast NCT03924609 48 54 B-Modifier
cancer NCT03924609 55 61 B-Condition
confirmed NCT03924609 62 71 O
by NCT03924609 72 74 O
biopsy NCT03924609 75 81 B-Procedure
or NCT03924609 82 84 B-Or
pathological NCT03924609 85 97 B-Procedure
examination NCT03924609 98 109 I-Procedure
of NCT03924609 110 112 O
the NCT03924609 113 116 O
resected NCT03924609 117 125 B-Modifier
tumor NCT03924609 126 131 B-Condition
. NCT03924609 132 133 O

B. NCT03924609 135 137 O
Histologically NCT03924609 139 153 B-Procedure
confirmed NCT03924609 154 163 O
breast NCT03924609 164 170 B-Modifier
cancer NCT03924609 171 177 B-Condition
patients NCT03924609 178 186 O
, NCT03924609 187 188 O
fulfilling NCT03924609 189 199 O
any NCT03924609 200 203 O
of NCT03924609 204 206 O
the NCT03924609 207 210 B-Criteria-Count
following NCT03924609 211 220 I-Criteria-Count
: NCT03924609 221 222 O

1 NCT03924609 226 227 O
. NCT03924609 227 228 O
Multiple NCT03924609 230 238 B-Eq-Comparison
bone NCT03924609 239 243 B-Modifier
metastases NCT03924609 244 254 B-Condition
indicated NCT03924609 255 264 O
by NCT03924609 265 267 O
bone NCT03924609 268 272 B-Procedure
scan NCT03924609 273 277 I-Procedure

2 NCT03924609 280 281 O
. NCT03924609 281 282 O
Bone NCT03924609 284 288 B-Procedure
scan NCT03924609 289 293 I-Procedure
positive NCT03924609 294 302 O
, NCT03924609 303 304 O
and NCT03924609 305 308 B-And
proven NCT03924609 309 315 O
by NCT03924609 316 318 O
other NCT03924609 319 324 B-Other
imaging NCT03924609 325 332 B-Procedure
examinations NCT03924609 333 345 I-Procedure
, NCT03924609 346 347 O
including NCT03924609 348 357 O
computed NCT03924609 358 366 B-Procedure
tomography NCT03924609 367 377 I-Procedure
( NCT03924609 378 379 O
CT NCT03924609 380 382 B-Procedure
) NCT03924609 383 384 O
, NCT03924609 386 387 O
magnetic NCT03924609 388 396 B-Procedure
resonance NCT03924609 397 406 I-Procedure
imaging NCT03924609 407 414 I-Procedure
( NCT03924609 415 416 O
MRI NCT03924609 417 420 B-Procedure
) NCT03924609 421 422 O
and NCT03924609 423 426 B-Or
X NCT03924609 427 428 B-Procedure
- NCT03924609 429 430 I-Procedure
ray NCT03924609 431 434 I-Procedure
. NCT03924609 435 436 O

3 NCT03924609 440 441 O
. NCT03924609 441 442 O
Bone NCT03924609 444 448 B-Procedure
scan NCT03924609 449 453 I-Procedure
positive NCT03924609 454 462 O
, NCT03924609 463 464 O
with NCT03924609 465 469 B-And
clinical NCT03924609 470 478 O
symptoms NCT03924609 479 487 B-Condition
, NCT03924609 488 489 O
including NCT03924609 490 499 O
bone NCT03924609 500 504 B-Modifier
pain NCT03924609 505 509 B-Condition
, NCT03924609 510 511 O
pathologic NCT03924609 512 522 B-Condition
fracture NCT03924609 523 531 I-Condition
, NCT03924609 532 533 O
spinal NCT03924609 534 540 B-Condition
cord NCT03924609 541 545 I-Condition
compression NCT03924609 546 557 I-Condition
and NCT03924609 558 561 O
so NCT03924609 562 564 O
on NCT03924609 565 567 O
. NCT03924609 568 569 O

4 NCT03924609 573 574 O
. NCT03924609 574 575 O
Bone NCT03924609 577 581 B-Modifier
metastases NCT03924609 582 592 B-Condition
indicated NCT03924609 593 602 O
by NCT03924609 603 605 O
PET NCT03924609 606 609 B-Procedure
- NCT03924609 610 611 I-Procedure
CT NCT03924609 612 614 I-Procedure

5 NCT03924609 617 618 O
. NCT03924609 618 619 O
Histologically NCT03924609 621 635 B-Procedure
proven NCT03924609 636 642 O
bone NCT03924609 643 647 B-Modifier
metastases NCT03924609 648 658 B-Condition

Exclusion NCT03924609 659 668 O
Criteria NCT03924609 669 677 O
: NCT03924609 678 679 O

A. NCT03924609 681 683 O
No NCT03924609 685 687 B-Negation
bone NCT03924609 688 692 B-Modifier
metastases NCT03924609 693 703 B-Condition
confirmed NCT03924609 704 713 O
by NCT03924609 714 716 O
pathological NCT03924609 717 729 B-Procedure
examination NCT03924609 730 741 I-Procedure

B. NCT03924609 743 745 O
Bone NCT03924609 747 751 B-Modifier
metastases NCT03924609 752 762 B-Condition
secondary NCT03924609 763 772 O
to NCT03924609 773 775 O
other NCT03924609 776 781 B-Other
malignant NCT03924609 782 791 B-Condition
tumor NCT03924609 792 797 I-Condition
other NCT03924609 798 803 B-Exception
than NCT03924609 804 808 I-Exception
breast NCT03924609 809 815 B-Modifier
cancer NCT03924609 816 822 B-Condition

C. NCT03924609 824 826 O
Secondary NCT03924609 828 837 B-Modifier
primary NCT03924609 838 845 I-Modifier
tumor NCT03924609 846 851 B-Condition


Inclusion NCT03926793 0 9 O
Criteria NCT03926793 10 18 O
: NCT03926793 19 20 O

1 NCT03926793 24 25 O
. NCT03926793 25 26 O
Adult NCT03926793 28 33 O
( NCT03926793 34 35 O
males NCT03926793 36 41 O
and NCT03926793 42 45 B-Or
females NCT03926793 46 53 O
) NCT03926793 54 55 O
aged NCT03926793 56 60 B-Age
18 NCT03926793 61 63 B-Eq-Comparison
to NCT03926793 64 66 I-Eq-Comparison
75 NCT03926793 67 69 I-Eq-Comparison
years NCT03926793 70 75 I-Eq-Comparison
( NCT03926793 76 77 O
inclusive NCT03926793 78 87 O
) NCT03926793 88 89 O
with NCT03926793 90 94 B-And
pulmonary NCT03926793 95 104 B-Condition
arterial NCT03926793 105 113 I-Condition
hypertension NCT03926793 114 126 I-Condition
( NCT03926793 127 128 O
PAH NCT03926793 129 132 B-Condition
) NCT03926793 133 134 O

2 NCT03926793 138 139 O
. NCT03926793 139 140 O
A NCT03926793 142 143 O
current NCT03926793 144 151 B-Eq-Comparison
diagnosis NCT03926793 152 161 O
of NCT03926793 162 164 O
symptomatic NCT03926793 165 176 B-Assertion___Assertion-Type-Value:possible
PAH NCT03926793 177 180 B-Condition
classified NCT03926793 181 191 O
by NCT03926793 192 194 O
one NCT03926793 195 198 B-Eq-Comparison
of NCT03926793 199 201 O
the NCT03926793 202 205 B-Criteria-Count
following NCT03926793 206 215 I-Criteria-Count
: NCT03926793 216 217 O

1 NCT03926793 226 227 O
. NCT03926793 227 228 O
Idiopathic NCT03926793 230 240 B-Condition
( NCT03926793 241 242 O
IPAH NCT03926793 243 247 B-Condition
) NCT03926793 248 249 O
or NCT03926793 250 252 B-Or
heritable NCT03926793 253 262 B-Modifier
pulmonary NCT03926793 263 272 B-Condition
arterial NCT03926793 273 281 I-Condition
hypertension NCT03926793 282 294 I-Condition
( NCT03926793 295 296 O
HPAH NCT03926793 297 301 B-Condition
) NCT03926793 302 303 O

2 NCT03926793 312 313 O
. NCT03926793 313 314 O
PAH NCT03926793 316 319 B-Condition
associated NCT03926793 320 330 O
with NCT03926793 331 335 O
one NCT03926793 336 339 B-Eq-Comparison
of NCT03926793 340 342 O
the NCT03926793 343 346 B-Criteria-Count
following NCT03926793 347 356 I-Criteria-Count
connective NCT03926793 357 367 B-Condition
tissue NCT03926793 368 374 I-Condition
diseases NCT03926793 375 383 I-Condition
( NCT03926793 384 385 O
CTDs NCT03926793 386 390 B-Condition
) NCT03926793 391 392 O
: NCT03926793 394 395 O

limited NCT03926793 407 414 B-Condition
scleroderma NCT03926793 415 426 I-Condition
, NCT03926793 427 428 O
mixed NCT03926793 429 434 B-Condition
connective NCT03926793 435 445 I-Condition
tissue NCT03926793 446 452 I-Condition
disease NCT03926793 453 460 I-Condition
or NCT03926793 461 463 B-Or
overlap NCT03926793 464 471 B-Condition
syndrome NCT03926793 472 480 I-Condition
, NCT03926793 481 482 O
or NCT03926793 483 485 B-Or
systemic NCT03926793 486 494 B-Modifier
lupus NCT03926793 495 500 B-Condition
erythematosus NCT03926793 501 514 I-Condition

3 NCT03926793 522 523 O
. NCT03926793 523 524 O
PAH NCT03926793 526 529 B-Condition
associated NCT03926793 530 540 O
with NCT03926793 541 545 O
anorexigen NCT03926793 546 556 B-Drug
or NCT03926793 557 559 B-Or
methamphetamine NCT03926793 560 575 B-Drug
use NCT03926793 576 579 O

3 NCT03926793 582 583 O
. NCT03926793 583 584 O
World NCT03926793 586 591 B-Condition
Health NCT03926793 592 598 I-Condition
Organization NCT03926793 599 611 I-Condition
( NCT03926793 612 613 O
WHO NCT03926793 614 617 B-Condition
) NCT03926793 618 619 O
/ NCT03926793 621 622 B-Or
New NCT03926793 623 626 B-Condition
York NCT03926793 627 631 I-Condition
Heart NCT03926793 632 637 I-Condition
Association NCT03926793 638 649 I-Condition
( NCT03926793 650 651 O
NYHA NCT03926793 652 656 B-Condition
) NCT03926793 657 658 O
functional NCT03926793 659 669 O
class NCT03926793 670 675 B-Eq-Comparison
II NCT03926793 676 678 I-Eq-Comparison
- NCT03926793 679 680 I-Eq-Comparison
IV NCT03926793 681 683 I-Eq-Comparison
symptomatology NCT03926793 684 698 O

Exclusion NCT03926793 699 708 O
Criteria NCT03926793 709 717 O
: NCT03926793 718 719 O

1 NCT03926793 723 724 O
. NCT03926793 724 725 O
Clinically NCT03926793 727 737 O
significant NCT03926793 738 749 O
systemic NCT03926793 750 758 B-Condition
hypertension NCT03926793 759 771 I-Condition
or NCT03926793 772 774 B-Or
hypotension NCT03926793 775 786 B-Condition

2 NCT03926793 789 790 O
. NCT03926793 790 791 O
History NCT03926793 793 800 B-Eq-Comparison
of NCT03926793 801 803 O
left NCT03926793 804 808 B-Modifier
- NCT03926793 809 810 I-Modifier
sided NCT03926793 811 816 I-Modifier
heart NCT03926793 817 822 B-Condition
disease NCT03926793 823 830 I-Condition
and NCT03926793 831 834 B-Or
/ NCT03926793 835 836 I-Or
or NCT03926793 837 839 I-Or
clinically NCT03926793 840 850 O
significant NCT03926793 851 862 O
cardiac NCT03926793 863 870 B-Condition
disease NCT03926793 871 878 I-Condition

3 NCT03926793 881 882 O
. NCT03926793 882 883 O
History NCT03926793 885 892 B-Eq-Comparison
of NCT03926793 893 895 O
decompensated NCT03926793 896 909 B-Modifier
right NCT03926793 910 915 B-Condition
heart NCT03926793 916 921 I-Condition
failure NCT03926793 922 929 I-Condition
within NCT03926793 930 936 B-Eq-Comparison
30 NCT03926793 937 939 I-Eq-Comparison
days NCT03926793 940 944 I-Eq-Comparison
of NCT03926793 945 947 B-Temporal-Connection___Temporal-Connection-Type-Value:before
screening NCT03926793 948 957 B-Study
( NCT03926793 958 959 O
e. NCT03926793 960 962 O
g. NCT03926793 963 965 O
, NCT03926793 966 967 O
hospitalization NCT03926793 968 983 B-Encounter
for NCT03926793 984 987 O
PAH NCT03926793 988 991 B-Condition
or NCT03926793 992 994 B-Or
the NCT03926793 995 998 O
need NCT03926793 999 1003 O
to NCT03926793 1004 1006 O
add NCT03926793 1007 1010 O
an NCT03926793 1011 1013 O
additional NCT03926793 1014 1024 B-Other
PAH NCT03926793 1025 1028 B-Condition
medication NCT03926793 1029 1039 B-Drug
) NCT03926793 1040 1041 O

Inclusion NCT03928782 0 9 O
Criteria NCT03928782 10 18 O
: NCT03928782 19 20 O

- NCT03928782 24 25 O
subjects NCT03928782 27 35 O
who NCT03928782 36 39 O
suffer NCT03928782 40 46 O
from NCT03928782 47 51 O
acute NCT03928782 52 57 O
leukemic NCT03928782 58 66 B-Condition
subjects NCT03928782 67 75 O
who NCT03928782 76 79 O
accept NCT03928782 80 86 B-Assertion___Assertion-Type-Value:hypothetical
chemotherapy NCT03928782 87 99 B-Procedure
within NCT03928782 100 106 B-Eq-Comparison
one NCT03928782 107 110 I-Eq-Comparison
month NCT03928782 111 116 I-Eq-Comparison
and NCT03928782 117 120 B-And
will NCT03928782 121 125 B-Assertion___Assertion-Type-Value:hypothetical
be NCT03928782 126 128 I-Assertion___Assertion-Type-Value:hypothetical
pretreated NCT03928782 129 139 B-Procedure
by NCT03928782 140 142 O
whole NCT03928782 143 148 B-Procedure
- NCT03928782 149 150 I-Procedure
body NCT03928782 151 155 I-Procedure
irradiation NCT03928782 156 167 I-Procedure
peripheral NCT03928782 168 178 B-Modifier
blood NCT03928782 179 184 I-Modifier
cells NCT03928782 185 190 I-Modifier
of NCT03928782 191 193 O
subjects NCT03928782 194 202 O
are NCT03928782 203 206 O
approximate NCT03928782 207 218 O
to NCT03928782 219 221 O
those NCT03928782 222 227 O
of NCT03928782 228 230 O
healthy NCT03928782 231 238 O
person NCT03928782 239 245 O
aged NCT03928782 246 250 B-Age
between NCT03928782 251 258 B-Eq-Comparison
18 NCT03928782 259 261 I-Eq-Comparison
and NCT03928782 262 265 I-Eq-Comparison
50 NCT03928782 266 268 I-Eq-Comparison
years NCT03928782 269 274 I-Eq-Comparison
old NCT03928782 275 278 O
subjects NCT03928782 279 287 O
who NCT03928782 288 291 O
are NCT03928782 292 295 O
competent NCT03928782 296 305 O
to NCT03928782 306 308 O
give NCT03928782 309 313 O
written NCT03928782 314 321 O
informed NCT03928782 322 330 O
consent NCT03928782 331 338 O
subjects NCT03928782 339 347 O
without NCT03928782 348 355 O
other NCT03928782 356 361 O
systemic NCT03928782 362 370 O
diseases NCT03928782 371 379 O

Exclusion NCT03928782 380 389 O
Criteria NCT03928782 390 398 O
: NCT03928782 399 400 O

- NCT03928782 404 405 O
subjects NCT03928782 407 415 O
who NCT03928782 416 419 O
suffer NCT03928782 420 426 O
from NCT03928782 427 431 O
serious NCT03928782 432 439 O
other NCT03928782 440 445 B-Other
systemic NCT03928782 446 454 B-Modifier
diseases NCT03928782 455 463 B-Condition
subjects NCT03928782 464 472 O
who NCT03928782 473 476 O
are NCT03928782 477 480 O
unwilling NCT03928782 481 490 O
or NCT03928782 491 493 O
unable NCT03928782 494 500 O
to NCT03928782 501 503 O
cooperate NCT03928782 504 513 O
with NCT03928782 514 518 O
this NCT03928782 519 523 O
clinical NCT03928782 524 532 O
study NCT03928782 533 538 B-Study
other NCT03928782 539 544 O
serious NCT03928782 545 552 O
cases NCT03928782 553 558 B-Condition
that NCT03928782 559 563 O
probably NCT03928782 564 572 B-Assertion___Assertion-Type-Value:hypothetical
hinder NCT03928782 573 579 O
this NCT03928782 580 584 O
clinical NCT03928782 585 593 O
study NCT03928782 594 599 B-Study

Inclusion NCT03925675 0 9 O
Criteria NCT03925675 10 18 O
: NCT03925675 19 20 O

1 NCT03925675 24 25 O
. NCT03925675 25 26 O
Patients NCT03925675 28 36 O
evaluated NCT03925675 37 46 B-Assertion___Assertion-Type-Value:hypothetical
for NCT03925675 47 50 I-Assertion___Assertion-Type-Value:hypothetical
residual NCT03925675 51 59 B-Modifier
or NCT03925675 60 62 B-Or
recurrent NCT03925675 63 72 B-Modifier
gliomas NCT03925675 73 80 B-Condition
after NCT03925675 81 86 B-Temporal-Connection___Temporal-Connection-Type-Value:after
initial NCT03925675 87 94 B-Eq-Comparison
tumor NCT03925675 95 100 B-Condition
surgery NCT03925675 101 108 B-Procedure
, NCT03925675 109 110 O
external NCT03925675 111 119 B-Procedure
beam NCT03925675 120 124 I-Procedure
radiation NCT03925675 125 134 I-Procedure
and NCT03925675 135 138 B-Or
/ NCT03925675 139 140 I-Or
or NCT03925675 141 143 I-Or
chemotherapy NCT03925675 144 156 B-Procedure
with NCT03925675 157 161 O
temozolamide NCT03925675 162 174 B-Drug
. NCT03925675 175 176 O

2 NCT03925675 180 181 O
. NCT03925675 181 182 O
Male NCT03925675 184 188 O
and NCT03925675 189 192 B-Or
female NCT03925675 193 199 O

3 NCT03925675 202 203 O
. NCT03925675 203 204 O
Ages NCT03925675 206 210 B-Age
18 NCT03925675 211 213 B-Eq-Comparison
to NCT03925675 214 216 I-Eq-Comparison
70 NCT03925675 217 219 I-Eq-Comparison

Exclusion NCT03925675 221 230 O
Criteria NCT03925675 231 239 O
: NCT03925675 240 241 O

1 NCT03925675 245 246 O
. NCT03925675 246 247 O
Patient NCT03925675 249 256 O
diagnosis NCT03925675 257 266 O
with NCT03925675 267 271 O
glioma NCT03925675 272 278 B-Condition
but NCT03925675 279 282 O
before NCT03925675 283 289 B-Temporal-Connection___Temporal-Connection-Type-Value:before
surgery NCT03925675 290 297 B-Procedure
, NCT03925675 298 299 O
external NCT03925675 300 308 B-Procedure
beam NCT03925675 309 313 I-Procedure
radiation NCT03925675 314 323 I-Procedure
and NCT03925675 324 327 B-Or
/ NCT03925675 328 329 I-Or
or NCT03925675 330 332 I-Or
chemotherapy NCT03925675 333 345 B-Procedure
with NCT03925675 346 350 O
temozolamide NCT03925675 351 363 B-Drug
. NCT03925675 364 365 O

2 NCT03925675 369 370 O
. NCT03925675 370 371 O
Women NCT03925675 373 378 O
who NCT03925675 379 382 O
were NCT03925675 383 387 B-Eq-Comparison
pregnant NCT03925675 388 396 B-Condition
, NCT03925675 397 398 O
breast NCT03925675 399 405 B-Condition
feeding NCT03925675 406 413 I-Condition
, NCT03925675 414 415 O
or NCT03925675 416 418 B-Or
possibly NCT03925675 419 427 B-Assertion___Assertion-Type-Value:possible
pregnant NCT03925675 428 436 B-Condition
. NCT03925675 437 438 O

3 NCT03925675 442 443 O
. NCT03925675 443 444 O
Patients NCT03925675 446 454 O
with NCT03925675 455 459 O
hepatic NCT03925675 460 467 B-Modifier
or NCT03925675 468 470 B-Or
renal NCT03925675 471 476 B-Modifier
dysfunction NCT03925675 477 488 B-Condition
. NCT03925675 489 490 O

4 NCT03925675 494 495 O
. NCT03925675 495 496 O
Patients NCT03925675 498 506 O
with NCT03925675 507 511 O
MRI NCT03925675 512 515 B-Procedure
contraindications NCT03925675 516 533 B-Contraindication
( NCT03925675 534 535 O
i. NCT03925675 536 538 O
e. NCT03925675 539 541 O
pacemakers NCT03925675 543 553 B-Procedure
, NCT03925675 554 555 O
non NCT03925675 556 559 B-Procedure
- NCT03925675 560 561 I-Procedure
MR NCT03925675 562 564 I-Procedure
compatible NCT03925675 565 575 I-Procedure
devices NCT03925675 576 583 I-Procedure
) NCT03925675 584 585 O
. NCT03925675 587 588 O

5 NCT03925675 592 593 O
. NCT03925675 593 594 O
Patients NCT03925675 596 604 O
with NCT03925675 605 609 O
a NCT03925675 610 611 O
history NCT03925675 612 619 B-Eq-Comparison
of NCT03925675 620 622 O
drug NCT03925675 623 627 B-Drug
hypersensitivity NCT03925675 628 644 B-Condition
to NCT03925675 645 647 O
18 NCT03925675 648 650 B-Drug
F NCT03925675 651 652 I-Drug
- NCT03925675 653 654 I-Drug
Fluciclovine NCT03925675 655 667 I-Drug
. NCT03925675 667 668 O

Inclusion NCT03920917 0 9 O
Criteria NCT03920917 10 18 O
: NCT03920917 19 20 O

- NCT03920917 24 25 O
1 NCT03920917 27 28 O
. NCT03920917 28 29 O
Patient NCT03920917 31 38 O
with NCT03920917 39 43 O
paroxysmal NCT03920917 44 54 B-Condition
atrial NCT03920917 55 61 I-Condition
fibrillation NCT03920917 62 74 I-Condition
who NCT03920917 75 78 B-And
is NCT03920917 79 81 O
scheduled NCT03920917 82 91 B-Eq-Comparison
for NCT03920917 92 95 O
ablation NCT03920917 96 104 B-Procedure
procedure NCT03920917 105 114 I-Procedure
and NCT03920917 115 118 B-And
≥ NCT03920917 119 120 B-Eq-Comparison
20 NCT03920917 121 123 I-Eq-Comparison
and NCT03920917 124 127 B-And
≤ NCT03920917 128 129 B-Eq-Comparison
80 NCT03920917 130 132 I-Eq-Comparison
years NCT03920917 133 138 I-Eq-Comparison
of NCT03920917 139 141 O
age NCT03920917 142 145 B-Age

- NCT03920917 148 149 O
2 NCT03920917 151 152 O
. NCT03920917 152 153 O
Left NCT03920917 155 159 B-Observation
atrium NCT03920917 160 166 I-Observation
size NCT03920917 167 171 I-Observation
< NCT03920917 172 173 B-Eq-Comparison
45 NCT03920917 174 176 I-Eq-Comparison
mm NCT03920917 177 179 I-Eq-Comparison

- NCT03920917 182 183 O
3 NCT03920917 185 186 O
. NCT03920917 186 187 O
paroxysmal NCT03920917 189 199 B-Condition
atrial NCT03920917 200 206 I-Condition
fibrillation NCT03920917 207 219 I-Condition
that NCT03920917 220 224 O
is NCT03920917 225 227 O
recurrence NCT03920917 228 238 O
during NCT03920917 239 245 B-Temporal-Connection___Temporal-Connection-Type-Value:during
antiarrhythmic NCT03920917 246 260 B-Drug
drug NCT03920917 261 265 I-Drug
treatment NCT03920917 266 275 B-Procedure
or NCT03920917 276 278 B-Or
is NCT03920917 279 281 O
not NCT03920917 282 285 B-Negation
able NCT03920917 286 290 O
to NCT03920917 291 293 O
use NCT03920917 294 297 O
an NCT03920917 298 300 O
antiarrhythmic NCT03920917 301 315 B-Drug
drug NCT03920917 316 320 I-Drug
. NCT03920917 321 322 O

- NCT03920917 326 327 O
4 NCT03920917 329 330 O
. NCT03920917 330 331 O
Patient NCT03920917 333 340 O
who NCT03920917 341 344 O
is NCT03920917 345 347 O
indicated NCT03920917 348 357 B-Indication
for NCT03920917 358 361 O
anticoagulation NCT03920917 362 377 B-Procedure
therapy NCT03920917 378 385 I-Procedure
( NCT03920917 386 387 O
for NCT03920917 388 391 O
prevention NCT03920917 392 402 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920917 403 405 O
cerebral NCT03920917 406 414 B-Condition
infarction NCT03920917 415 425 I-Condition
) NCT03920917 426 427 O

Exclusion NCT03920917 429 438 O
Criteria NCT03920917 439 447 O
: NCT03920917 448 449 O

- NCT03920917 453 454 O
1 NCT03920917 456 457 O
. NCT03920917 457 458 O
Patients NCT03920917 460 468 O
with NCT03920917 469 473 O
persistent NCT03920917 474 484 B-Modifier
or NCT03920917 485 487 B-Or
permanent NCT03920917 488 497 B-Modifier
atrial NCT03920917 498 504 B-Condition
fibrillation NCT03920917 505 517 I-Condition

- NCT03920917 520 521 O
2 NCT03920917 523 524 O
. NCT03920917 524 525 O
Atrial NCT03920917 527 533 B-Condition
fibrillation NCT03920917 534 546 I-Condition
associated NCT03920917 547 557 O
with NCT03920917 558 562 O
severe NCT03920917 563 569 O
cardiac NCT03920917 570 577 B-Condition
malformation NCT03920917 578 590 I-Condition
or NCT03920917 591 593 B-Or
a NCT03920917 594 595 O
structural NCT03920917 596 606 B-Modifier
heart NCT03920917 607 612 B-Condition
disease NCT03920917 613 620 I-Condition
that NCT03920917 621 625 O
is NCT03920917 626 628 O
hemodynamically NCT03920917 629 644 B-Modifier
affected NCT03920917 645 653 O

- NCT03920917 656 657 O
3 NCT03920917 659 660 O
. NCT03920917 660 661 O
Patients NCT03920917 663 671 O
with NCT03920917 672 676 O
severe NCT03920917 677 683 O
renal NCT03920917 684 689 B-Condition
impairment NCT03920917 690 700 I-Condition
or NCT03920917 701 703 B-Or
CT NCT03920917 704 706 B-Procedure
imaging NCT03920917 707 714 I-Procedure
difficulty NCT03920917 715 725 O
using NCT03920917 726 731 O
contrast NCT03920917 732 740 B-Procedure
media NCT03920917 741 746 I-Procedure

- NCT03920917 749 750 O
4 NCT03920917 752 753 O
. NCT03920917 753 754 O
Patients NCT03920917 756 764 O
with NCT03920917 765 769 O
a NCT03920917 770 771 O
past NCT03920917 772 776 B-Eq-Comparison
history NCT03920917 777 784 I-Eq-Comparison
of NCT03920917 785 787 O
radiofrequency NCT03920917 788 802 B-Procedure
ablation NCT03920917 803 811 I-Procedure
for NCT03920917 812 815 O
atrial NCT03920917 816 822 B-Condition
fibrillation NCT03920917 823 835 I-Condition
or NCT03920917 836 838 B-Or
other NCT03920917 839 844 B-Other
cardiac NCT03920917 845 852 B-Procedure
surgery NCT03920917 853 860 I-Procedure

- NCT03920917 863 864 O
5 NCT03920917 866 867 O
. NCT03920917 867 868 O
Patients NCT03920917 870 878 O
with NCT03920917 879 883 O
active NCT03920917 884 890 B-Eq-Comparison
internal NCT03920917 891 899 B-Condition
bleeding NCT03920917 900 908 I-Condition

- NCT03920917 911 912 O
6 NCT03920917 914 915 O
. NCT03920917 915 916 O
Patients NCT03920917 918 926 O
with NCT03920917 927 931 O
contraindications NCT03920917 932 949 B-Contraindication
for NCT03920917 950 953 O
anticoagulation NCT03920917 954 969 B-Procedure
therapy NCT03920917 970 977 I-Procedure
( NCT03920917 978 979 O
for NCT03920917 980 983 O
prevention NCT03920917 984 994 B-Assertion___Assertion-Type-Value:hypothetical
of NCT03920917 995 997 O
cerebral NCT03920917 998 1006 B-Condition
infarction NCT03920917 1007 1017 I-Condition
) NCT03920917 1018 1019 O
and NCT03920917 1020 1023 B-And
antiarrhythmic NCT03920917 1024 1038 B-Drug
drugs NCT03920917 1039 1044 I-Drug

- NCT03920917 1047 1048 O
7 NCT03920917 1050 1051 O
. NCT03920917 1051 1052 O
Patients NCT03920917 1054 1062 O
with NCT03920917 1063 1067 O
valvular NCT03920917 1068 1076 B-Modifier
atrial NCT03920917 1077 1083 B-Condition
fibrillation NCT03920917 1084 1096 I-Condition
( NCT03920917 1097 1098 O
mitral NCT03920917 1099 1105 B-Condition
stenosis NCT03920917 1106 1114 I-Condition
> NCT03920917 1115 1116 B-Eq-Comparison
grade NCT03920917 1117 1122 I-Eq-Comparison
2 NCT03920917 1123 1124 I-Eq-Comparison
, NCT03920917 1125 1126 O
mechanical NCT03920917 1127 1137 B-Procedure
valve NCT03920917 1138 1143 I-Procedure
, NCT03920917 1144 1145 O
mitral NCT03920917 1146 1152 B-Procedure
valvuloplasty NCT03920917 1153 1166 I-Procedure
) NCT03920917 1167 1168 O

- NCT03920917 1172 1173 O
8 NCT03920917 1175 1176 O
. NCT03920917 1176 1177 O
Patients NCT03920917 1179 1187 O
with NCT03920917 1188 1192 O
a NCT03920917 1193 1194 O
severe NCT03920917 1195 1201 O
comorbid NCT03920917 1202 1210 B-Condition
disease NCT03920917 1211 1218 I-Condition

- NCT03920917 1221 1222 O
9 NCT03920917 1224 1225 O
. NCT03920917 1225 1226 O
Expected NCT03920917 1228 1236 B-Observation
survival NCT03920917 1237 1245 I-Observation
< NCT03920917 1246 1247 B-Eq-Comparison
1 NCT03920917 1248 1249 I-Eq-Comparison
year NCT03920917 1250 1254 I-Eq-Comparison

- NCT03920917 1257 1258 O
10 NCT03920917 1260 1262 O
. NCT03920917 1262 1263 O
Drug NCT03920917 1265 1269 B-Condition
addicts NCT03920917 1270 1277 I-Condition
or NCT03920917 1278 1280 B-Or
alcoholics NCT03920917 1281 1291 B-Condition

- NCT03920917 1294 1295 O
11 NCT03920917 1297 1299 O
. NCT03920917 1299 1300 O
Patients NCT03920917 1302 1310 O
who NCT03920917 1311 1314 O
can NCT03920917 1315 1318 O
not NCT03920917 1318 1321 O
read NCT03920917 1322 1326 O
the NCT03920917 1327 1330 O
consent NCT03920917 1331 1338 O
form NCT03920917 1339 1343 O
( NCT03920917 1344 1345 O
illiterates NCT03920917 1346 1357 B-Condition
, NCT03920917 1358 1359 O
foreigners NCT03920917 1360 1370 O
, NCT03920917 1371 1372 O
etc NCT03920917 1373 1376 O
. NCT03920917 1376 1377 O
) NCT03920917 1378 1379 O

- NCT03920917 1383 1384 O
12 NCT03920917 1386 1388 O
. NCT03920917 1388 1389 O
Other NCT03920917 1391 1396 O
patients NCT03920917 1397 1405 O
who NCT03920917 1406 1409 O
are NCT03920917 1410 1413 O
judged NCT03920917 1414 1420 O
by NCT03920917 1421 1423 O
the NCT03920917 1424 1427 O
principal NCT03920917 1428 1437 O
or NCT03920917 1438 1440 O
sub NCT03920917 1441 1444 O
- NCT03920917 1445 1446 O
investigator NCT03920917 1447 1459 O
to NCT03920917 1460 1462 O
be NCT03920917 1463 1465 O
ineligible NCT03920917 1466 1476 O
for NCT03920917 1477 1480 O
participation NCT03920917 1481 1494 O
in NCT03920917 1495 1497 O
this NCT03920917 1498 1502 O
clinical NCT03920917 1503 1511 O
study NCT03920917 1512 1517 B-Study

Inclusion NCT03923205 0 9 O
Criteria NCT03923205 10 18 O
: NCT03923205 19 20 O

Healthy NCT03923205 22 29 B-Condition
and NCT03923205 30 33 B-And
T2D NCT03923205 34 37 B-Condition
( NCT03923205 38 39 O
controlled NCT03923205 40 50 O
by NCT03923205 51 53 O
diet NCT03923205 54 58 B-Procedure
and NCT03923205 59 62 B-And
lifestyle NCT03923205 63 72 B-Observation
or NCT03923205 73 75 B-Or
metformin NCT03923205 76 85 B-Drug
) NCT03923205 86 87 O
volunteers NCT03923205 88 98 O
; NCT03923205 98 99 O
Age NCT03923205 100 103 B-Age
18 NCT03923205 104 106 B-Eq-Comparison
+ NCT03923205 107 108 I-Eq-Comparison
; NCT03923205 109 110 O
males NCT03923205 111 116 O
and NCT03923205 117 120 B-Or
females NCT03923205 121 128 O
. NCT03923205 128 129 O

Exclusion NCT03923205 132 141 O
Criteria NCT03923205 142 150 O
: NCT03923205 151 152 O

For NCT03923205 154 157 O
the NCT03923205 158 161 O
healthy NCT03923205 162 169 B-Condition
group NCT03923205 170 175 O
: NCT03923205 176 177 O

- NCT03923205 181 182 O
taking NCT03923205 184 190 B-Eq-Comparison
prescribed NCT03923205 191 201 O
medication NCT03923205 202 212 B-Drug

- NCT03923205 215 216 O
HbA1c NCT03923205 218 223 B-Observation
above NCT03923205 224 229 B-Eq-Comparison
48 NCT03923205 230 232 I-Eq-Comparison
mmol NCT03923205 233 237 I-Eq-Comparison
/ NCT03923205 238 239 I-Eq-Comparison
mol NCT03923205 240 243 I-Eq-Comparison
( NCT03923205 244 245 O
or NCT03923205 246 248 B-Or
6.5 NCT03923205 249 252 B-Eq-Comparison
% NCT03923205 253 254 I-Eq-Comparison
) NCT03923205 256 257 O

- NCT03923205 261 262 O
pregnant NCT03923205 264 272 B-Condition
or NCT03923205 273 275 B-Or
breastfeeding NCT03923205 276 289 B-Condition

- NCT03923205 292 293 O
blood NCT03923205 295 300 B-Observation
donation NCT03923205 301 309 I-Observation
in NCT03923205 310 312 O
the NCT03923205 313 316 O
last NCT03923205 317 321 B-Eq-Comparison
three NCT03923205 322 327 I-Eq-Comparison
months NCT03923205 328 334 I-Eq-Comparison

- NCT03923205 337 338 O
unable NCT03923205 340 346 O
to NCT03923205 347 349 O
give NCT03923205 350 354 O
written NCT03923205 355 362 O
informed NCT03923205 363 371 O
consent NCT03923205 372 379 O

- NCT03923205 382 383 O
eating NCT03923205 385 391 B-Condition
disorders NCT03923205 392 401 I-Condition
such NCT03923205 402 406 O
as NCT03923205 407 409 O
anorexia NCT03923205 410 418 B-Condition
, NCT03923205 419 420 O
bulimia NCT03923205 421 428 B-Condition
, NCT03923205 429 430 O
binge NCT03923205 431 436 B-Condition
eating NCT03923205 437 443 I-Condition
or NCT03923205 444 446 B-Or
night NCT03923205 447 452 B-Condition
eating NCT03923205 453 459 I-Condition
syndrome NCT03923205 460 468 I-Condition
. NCT03923205 469 470 O

- NCT03923205 474 475 O
significant NCT03923205 477 488 O
health NCT03923205 489 495 B-Condition
issue NCT03923205 496 501 I-Condition

- NCT03923205 504 505 O
taking NCT03923205 507 513 B-Eq-Comparison
vitamin NCT03923205 514 521 B-Drug
or NCT03923205 522 524 B-Or
mineral NCT03923205 525 532 B-Drug
supplements NCT03923205 533 544 I-Drug
( NCT03923205 545 546 O
unless NCT03923205 547 553 B-Exception
they NCT03923205 554 558 O
agree NCT03923205 559 564 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923205 565 567 I-Assertion___Assertion-Type-Value:hypothetical
discontinue NCT03923205 568 579 B-Negation
supplementation NCT03923205 580 595 B-Drug
2 NCT03923205 596 597 B-Eq-Comparison
weeks NCT03923205 598 603 I-Eq-Comparison
or NCT03923205 604 606 I-Eq-Comparison
more NCT03923205 607 611 I-Eq-Comparison
before NCT03923205 612 618 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923205 619 622 O
start NCT03923205 623 628 O
of NCT03923205 629 631 O
the NCT03923205 632 635 O
study NCT03923205 636 641 B-Study
) NCT03923205 642 643 O

- NCT03923205 647 648 O
Food NCT03923205 650 654 O
allergies NCT03923205 655 664 B-Allergy
/ NCT03923205 665 666 B-Or
intolerances NCT03923205 667 679 B-Condition

For NCT03923205 680 683 O
the NCT03923205 684 687 O
T2D NCT03923205 688 691 B-Condition
groups NCT03923205 692 698 O
: NCT03923205 699 700 O

- NCT03923205 704 705 O
T2D NCT03923205 707 710 B-Condition
controlled NCT03923205 711 721 O
by NCT03923205 722 724 O
medication NCT03923205 725 735 B-Drug
other NCT03923205 736 741 B-Exception
than NCT03923205 742 746 I-Exception
metformin NCT03923205 747 756 B-Drug

- NCT03923205 759 760 O
pregnant NCT03923205 762 770 B-Condition
or NCT03923205 771 773 B-Or
breastfeeding NCT03923205 774 787 B-Condition

- NCT03923205 790 791 O
blood NCT03923205 793 798 B-Observation
donation NCT03923205 799 807 I-Observation
in NCT03923205 808 810 O
the NCT03923205 811 814 O
last NCT03923205 815 819 B-Eq-Comparison
three NCT03923205 820 825 I-Eq-Comparison
months NCT03923205 826 832 I-Eq-Comparison

- NCT03923205 835 836 O
unable NCT03923205 838 844 O
to NCT03923205 845 847 O
give NCT03923205 848 852 O
written NCT03923205 853 860 O
informed NCT03923205 861 869 O
consent NCT03923205 870 877 O

- NCT03923205 880 881 O
eating NCT03923205 883 889 B-Condition
disorders NCT03923205 890 899 I-Condition
such NCT03923205 900 904 O
as NCT03923205 905 907 O
anorexia NCT03923205 908 916 B-Condition
, NCT03923205 917 918 O
bulimia NCT03923205 919 926 B-Condition
, NCT03923205 927 928 O
binge NCT03923205 929 934 B-Condition
eating NCT03923205 935 941 I-Condition
or NCT03923205 942 944 B-Or
night NCT03923205 945 950 B-Condition
eating NCT03923205 951 957 I-Condition
syndrome NCT03923205 958 966 I-Condition
. NCT03923205 967 968 O

- NCT03923205 972 973 O
any NCT03923205 975 978 O
other NCT03923205 979 984 O
significant NCT03923205 985 996 O
health NCT03923205 997 1003 B-Condition
issue NCT03923205 1004 1009 I-Condition
other NCT03923205 1010 1015 B-Exception
than NCT03923205 1016 1020 I-Exception
T2D NCT03923205 1021 1024 B-Condition

- NCT03923205 1027 1028 O
taking NCT03923205 1030 1036 B-Eq-Comparison
vitamin NCT03923205 1037 1044 B-Drug
or NCT03923205 1045 1047 B-Or
mineral NCT03923205 1048 1055 B-Drug
supplements NCT03923205 1056 1067 I-Drug
( NCT03923205 1068 1069 O
unless NCT03923205 1070 1076 B-Exception
they NCT03923205 1077 1081 I-Exception
agree NCT03923205 1082 1087 B-Assertion___Assertion-Type-Value:hypothetical
to NCT03923205 1088 1090 I-Assertion___Assertion-Type-Value:hypothetical
discontinue NCT03923205 1091 1102 B-Negation
supplementation NCT03923205 1103 1118 B-Drug
2 NCT03923205 1119 1120 B-Eq-Comparison
weeks NCT03923205 1121 1126 I-Eq-Comparison
before NCT03923205 1127 1133 B-Temporal-Connection___Temporal-Connection-Type-Value:before
the NCT03923205 1134 1137 O
start NCT03923205 1138 1143 O
of NCT03923205 1144 1146 O
the NCT03923205 1147 1150 O
study NCT03923205 1151 1156 B-Study
) NCT03923205 1157 1158 O

- NCT03923205 1162 1163 O
food NCT03923205 1165 1169 O
allergies NCT03923205 1170 1179 B-Allergy
/ NCT03923205 1180 1181 B-Or
intolerances NCT03923205 1182 1194 B-Condition


Inclusion NCT03924973 0 9 O
Criteria NCT03924973 10 18 O
: NCT03924973 19 20 O

- NCT03924973 24 25 O
Inclusion NCT03924973 27 36 O
in NCT03924973 37 39 O
the NCT03924973 40 43 O
initial NCT03924973 44 51 O
IDEA NCT03924973 52 56 O
trail NCT03924973 57 62 O

- NCT03924973 65 66 O
Requiring NCT03924973 68 77 B-Assertion___Assertion-Type-Value:hypothetical
less NCT03924973 78 82 B-Eq-Comparison
than NCT03924973 83 87 I-Eq-Comparison
40 NCT03924973 88 90 I-Eq-Comparison
minutes NCT03924973 91 98 I-Eq-Comparison
travel NCT03924973 99 105 B-Observation
to NCT03924973 106 108 O
the NCT03924973 109 112 O
assessment NCT03924973 113 123 O
center NCT03924973 124 130 O

Exclusion NCT03924973 131 140 O
Criteria NCT03924973 141 149 O
: NCT03924973 150 151 O

- NCT03924973 155 156 O
Impossibility NCT03924973 158 171 B-Assertion___Assertion-Type-Value:hypothetical|Negation
of NCT03924973 172 174 O
coming NCT03924973 175 181 B-Observation
in NCT03924973 182 184 I-Observation
for NCT03924973 185 188 O
assessment NCT03924973 189 199 B-Procedure

- NCT03924973 202 203 O
Exclusion NCT03924973 205 214 O
from NCT03924973 215 219 O
IDEA NCT03924973 220 224 O

